[{"orgOrder":0,"company":"Pulmatrix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$100.2 million","upfrontCash":"$7.2 million","newsHeadline":"Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PUR1800","moa":"p38 MAP kinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pulmatrix \/ Johnson & Johnson Enterprise Innovation","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Antabio","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Pseudomonas elastase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Antabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Antabio \/ CARB-X","highestDevelopmentStatusID":"1","companyTruncated":"Antabio \/ .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,800.0 million","upfrontCash":"$2,800.0 million","newsHeadline":"Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"BeiGene","amount2":2.7999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.7999999999999998,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Balance Medical","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues NexoBrid\u2019s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Balance Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Balance Medical \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"Balance Me.."},{"orgOrder":0,"company":"Indivior","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Drinabant","moa":"CB1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indivior \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"$3.0 million","newsHeadline":"Leap, BeiGene Ink Exclusive Antibody Alliance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Black Diamond Therapeutics readies IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mutabilis","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ Novo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Mutabilis .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"$9.0 million","newsHeadline":"GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Apollomics","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,550.0 million","upfrontCash":"$50.0 million","newsHeadline":"Merck Establishes Strategic Oncology Collaboration with Taiho and Astex","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Taiho Pharmaceutical","amount2":2.5499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5499999999999998,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle & NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion & Other Forms of Traumatic Brain Injury.","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"NorthShore University HealthSystem","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NorthShore.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"$2.2 million","newsHeadline":"NanoViricides Receives Cash Infusion of $2.25 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"URUGUAY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"NV-HHV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"NanoViricides \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The alliance is aimed at co-developing a combination therapy of YS-ON-001\/002 and Tavo-201\/203 for cancer treatment.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tavo-201","moa":"CD4+ T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tavotek Biotherapeutics \/ Yisheng Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Bi.."},{"orgOrder":0,"company":"University of California","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"iPSC CAR NK cells","moa":"Chimeric antigen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"PUR1800","moa":"p38 MAP kinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pulmatrix \/ Nocion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Curis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies \\n-","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Onvatilimab","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuNext Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmuNext Inc \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"ImmuNext I.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Research Collaboration With CSL Behring","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$20.0 million","newsHeadline":"Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle\u00ae Immuno-oncology Candidate, BT7401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"BT7401","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Shanghai Miracogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugate linker","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Shanghai Miracogen","highestDevelopmentStatusID":"1","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma, Biosolution to market CartiLife in South Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mundipharma \/ Biosolution Co. Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"BioIntervene","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"MPM backs new biotech in the hunt for non-opioid painkiller","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"BIO-205","moa":"A3AR","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioIntervene","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"BioIntervene \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"BioInterve.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tarsus Pharmaceuticals Raises $60 Million in Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"TP-03","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Topical","sponsorNew":"Tarsus Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"PeriphaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Candel Therapeutics acquires next-generation herpes drug development platform and manufacturing expertise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"rQNestin34.5","moa":"ICP34.5 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ PeriphaGen, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TG01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"OSP-101","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Altavant Sciences \/ Altavant Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Xencor","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Gilead Enter License Agreement for Use of XmAb\u00ae Antibody Technologies in Investigational Agents for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GS-9722","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ G.."},{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara Partners with Galderma in Advancing Modeling and Simulation Technology to Attain FDA Approval of AKLIEF\u00ae Topical Acne Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Certara","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Certara \/ .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF\/MEK Inhibitor CH5126766","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CHO-DG44","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"Undisclosed","newsHeadline":"Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"AT-100","moa":"IL-8","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Airway Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Icosabutate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Kitov Pharma","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"$13.5 million","newsHeadline":"Kitov Pharma Announces Closing of FameWave Acquisition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Kitov Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"China\\'s Adagene bags $69M to advance lead immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series D Financing","leadProduct":"Adg106","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ General Atlantic","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerebral Therapeutics Completes $35 Million Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Sodium Valproate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral T.."},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"$15.0 million","newsHeadline":"Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"BNZ-1","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Bioniz Therapeutics \/ Almirall, S.A","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz The.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibody","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Almirall, S.A","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Monoclonal Antibody","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"23andMe \/ Almirall, S.A","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunic Exercises Option to License Daiichi\u2019s IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IMU-856","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Immunic","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta, Daewoong Form Immunotherapy JV","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen inks next Commercial GlymaxX\u00ae License with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GlymaxX","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec and BMS Expand IPSC Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Induced pluripotent stem cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Evotec","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Evotec \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Vickers Venture Partners","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emergex completes \u00a38.4m Series A vaccines funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Set-point vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ Vickers Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Pfenex","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL\u00ae, containing CRM197 produced in Pfenex Expression Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"CRM197","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfenex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfenex \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Pfenex \/ S.."},{"orgOrder":0,"company":"Rockefeller University","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Elipovimab","moa":"gp41","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Rockefeller University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rockefeller University \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Rockefelle.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$71.5 million","upfrontCash":"Undisclosed","newsHeadline":"Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Eganelisib","moa":"PI3K-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ BVF Partners L.P","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Enleofen Bio Pte","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"SINGAPORE","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Enx108A","moa":"IL-11","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Enleofen Bio Pte","amount2":1,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Enleofen Bio Pte \/ Boehringer Ingelheim","highestDevelopmentStatusID":"5","companyTruncated":"Enleofen B.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Centyrins","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":1.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"$143.2 million","upfrontCash":"$11.1 million","newsHeadline":"Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA receptor A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acacia Pharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.14000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals N.V.","highestDevelopmentStatusID":"10","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"JSP191","moa":"CD117","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Jasper Therapeutics \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Matinas BioPharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"MAT9001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ BTIG","highestDevelopmentStatusID":"5","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptinyx Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"ArTara Therapeutics","sponsor":"Proteon Therapeutics","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"Undisclosed","newsHeadline":"ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Penicillin G Potassium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ArTara Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"ArTara Therapeutics \/ Proteon Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ArTara The.."},{"orgOrder":0,"company":"Sapphire Biotech","sponsor":"AXIM Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXIM\u00ae Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-like molecules","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapphire Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapphire Biotech \/ AXIM Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"Sapphire B.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$507.0 million","upfrontCash":"$15.0 million","newsHeadline":"eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"eIF4E","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Effector Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Genethon","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genethon strengthens its collaboration with Sarepta Therapeutics for the development of the gene therapy product GNT0004 in Duchenne muscular dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"GNT0004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genethon \/ Sarepta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tucidinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$417.0 million","upfrontCash":"$45.0 million","newsHeadline":"Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0.41999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Alderaan Biotechnology","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"French Biotech Raises \u20ac19M to Hit Phase I with Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alderaan Biotechnology","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Alderaan Biotechnology \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alderaan B.."},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Oxalate","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Novome Bio.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Alta Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tyra Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"BW Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BW Therapeutics Announces Opening Of Series A Round And Strategic Partnering Initiatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BW Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BW Therape.."},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"NeoTCR-T cell","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"PACT Pharma \/ Vida Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharm.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Gemphire Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Pharmaceuticals to Focus on Advancing Clinical Stage Pipeline for Neurodegenerative Diseases lead drug candidate, lead drug candidate,","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Merger","leadProduct":"NB-01","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Teoxane SA","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teoxane SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teoxane SA \/ Revance Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teoxane SA.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nektar Therapeutics \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","amount":"$62.8 million","upfrontCash":"$11.4 million","newsHeadline":"China licence agreement for Feraccru\/Accrufer","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield The.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Knight Partners With Debiopharm for the Commercialization of Trelstar\u00ae in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Eyevensys","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyevensys Closes $30M Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"EYS606","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyevensys","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Eyevensys \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"Eyevensys .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Nestl\u00e9 Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Nestle Health Science","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"PB2452","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"NBE Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"NBE-Therapeutics Closes USD 22M Series C Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"NBE-002","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NBE Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"NBE Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"6","companyTruncated":"NBE Therap.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Lilly Announces Agreement to Acquire Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amunix","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,540.0 million","upfrontCash":"$40.0 million","newsHeadline":"Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Polypeptides","moa":"scFvs","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Amunix","amount2":1.54,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.54,"dosageForm":"","sponsorNew":"Amunix \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"Amunix \/ R.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance\u00ae (palbociclib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"ZW25","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IOV-3001","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Biose","sponsor":"Biomica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"BMC121","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biose","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biose \/ Biomica","highestDevelopmentStatusID":"4","companyTruncated":"Biose \/ Bi.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Oncologie","pharmaFlowCategory":"D","amount":"$306.0 million","upfrontCash":"$4.0 million","newsHeadline":"Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mereo BioPharma Group","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Secures $25 Million Series A Funding","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"T cells therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$587.5 million","upfrontCash":"$17.5 million","newsHeadline":"Kyverna Therapeutics Enters into Strategic Collaboration with Gilead Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"T cells therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.58999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Qiagen","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qiagen \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Qiagen \/ A.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Enters into OmniAb\u00ae Platform License Agreement with Pandion Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Mazindol","moa":"MAO transporter","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Adare Pharma Solutions \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Adare Phar.."},{"orgOrder":0,"company":"Crestone","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of Novel Antibiotic to Treat NTM Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"MmpL3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crestone \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer\u2019s Disease in Collaboration With University of Pennsylvania","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Pennsylvania \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Respiratory syncytial virus vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codagenix","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Codagenix \/ Adjuvant Capital","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$750.0 million","newsHeadline":"MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"MorphoSys \/ Incyte","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","amount":"$331.0 million","upfrontCash":"$3.0 million","newsHeadline":"Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer\u2019s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.33000000000000002,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Axsome Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coherus Acquires Commercial Rights for Avastin\u00ae Biosimilar in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Coherus BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$710.0 million","upfrontCash":"$75.0 million","newsHeadline":"Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer\u2019s Disease and Parkinson\u2019s Disease from Pfizer Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"PF-05251749","moa":"CK1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.70999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Apotex Inc","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox\u00ae (deferiprone)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Inc \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics to license certain TALEN technology from Cellectis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tumor infiltrating lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"NCK AS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ NCK A\/S.","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"KinoPharma","sponsor":"Aska Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASKA Pharmaceutical Co., Ltd. and KinoPharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"RKP00156","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KinoPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KinoPharma \/ ASKA Pharmaceutical Co.","highestDevelopmentStatusID":"6","companyTruncated":"KinoPharma.."},{"orgOrder":0,"company":"TAXIS Pharmaceuticals","sponsor":"Boston University","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"$3.2 million","newsHeadline":"TAXIS Pharmaceuticals Announces CARB-X Award of $3.2 Million, With Potential for an Additional $11.4 Million, to Develop Efflux Pump Inhibitors (EPIs), a New Drug Class to Defeat Multi-Drug Resistant Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"TXA709","moa":"Efflux pump","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TAXIS Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"TAXIS Pharmaceuticals \/ Boston University","highestDevelopmentStatusID":"6","companyTruncated":"TAXIS Phar.."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic\u00ae in India","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Rockwell Medical \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clinigen signs agreement with Iovance Biotherapeutics to supply Proleukin\u00ae (aldesleukin) for use in Tumor Infiltrating Lymphocyte (TIL) Clinical R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ ProBioGen AG","highestDevelopmentStatusID":"1","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"George Washington University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"George Washington University","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"George Washington University \/ Hoth Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"George Was.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"$60.0 million","newsHeadline":"Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalton Expands Cannabinoids Capabilities","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dalton Pharma Services","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Dalton Pharma Services \/ Health Canada","highestDevelopmentStatusID":"12","companyTruncated":"Dalton Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Bayer enter into acquisition agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Koate DVI","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ WuXi Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"Phage Therapy Firm APT Lands DoD Contract for Antibiotic Alternative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Phage-based therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Bonus BioGroup","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharm.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"ArQule","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of ArQule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"ARQ 531","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ArQule","amount2":2.7000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2.7000000000000002,"dosageForm":"Oral","sponsorNew":"ArQule \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"ArQule \/ M.."},{"orgOrder":0,"company":"Evotec","sponsor":"OncoResponse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Just \u2013 Evotec Biologics announces product development and manufacturing agreement with OncoResponse","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"OR2805","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ OncoResponse","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ O.."},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"$67.0 million","newsHeadline":"BioNTech to acquire Neon to strengthen global leadership position in T cell therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"NEO-STC-01","moa":"RAS neoantigen","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Neon Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Neon Thera.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx\u00ae Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT\u2122 (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"AgilVax","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"AgilVax Announces Expansion of Series A-1 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Monoclonal antibody-based therapy","moa":"SLC7A11\/xCT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AgilVax","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"AgilVax \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AgilVax \/ .."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"TB Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pretomanid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ TB Alliance","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revolution Med shoots for $100M+ IPO \u2014 and divulges some secrets about that Warp Drive buyout","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"Vociprotafib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"China Medical System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus inks pact with China Medical System to market Desidustat in Greater China","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ China Medical System","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Seekyo","sponsor":"French Tech Seed","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"BIOTECH START-UP SEEKYO RAISES \u20ac800K WITH LEVERAGE FROM FRENCH TECH SEED FUND","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"SKY01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seekyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seekyo \/ French Tech Seed","highestDevelopmentStatusID":"4","companyTruncated":"Seekyo \/ F.."},{"orgOrder":0,"company":"Betagenon","sponsor":"Ivy Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"China-Based Ivy Capital Invests in Betagenon\\'s Clinical Stage AMPK Activator Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"O304","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Betagenon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betagenon \/ Ivy Capital","highestDevelopmentStatusID":"8","companyTruncated":"Betagenon .."},{"orgOrder":0,"company":"Contract Sales Organization","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Triethanolamine Salicylate","moa":"COX-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Contract Sales Organization","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Contract Sales Organization \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Contract S.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Rumpus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Rumpus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"Ncardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cardiomyocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ncardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ncardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Ncardia \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seattle Genetics Achieves Milestone Following European Commission Approval of Roche\u2019s Polivy\u00ae (Polatuzumab Vedotin)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ R.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Roche Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma to Focus Commercial Efforts on Talicia\u00ae and Aemcolo\u00ae; Discontinuing Promotion of Legacy Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Xellia Pharmaceuticals ApS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen\u00ae (phenylephrine HCl) Co-Promotion Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Phenylephrine HCl","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$12.2 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer, Novo-backed German biotech banks \u20ac11M in liver regeneration push","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Mapk4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"HepaRegeniX","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"HepaRegeniX \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"1","companyTruncated":"HepaRegeni.."},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Galacto-oligosaccharide","moa":"Lactase enzyme","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pha.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Won & Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics raises funds from 2 Korean firms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Supernova 1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Won & Partners","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$200.0 million","newsHeadline":"PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Apexian Pharmaceuticals","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"APX3330","moa":"Ref-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Apexian Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apexian Pharmaceuticals \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Apexian Ph.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$279.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces Pricing of $279.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"ZW25","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Zymeworks \/ J.P. Morgan Securities","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar PMJ","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuneering Raises $20 Million in Oversubscribed Series A Funding","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"KRAS","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0.02,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Boxcar PMJ","highestDevelopmentStatusID":"1","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"IGL Pharma","sponsor":"Q2Earth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Samarium Sm-153","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"IGL Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGL Pharma \/ Q2Earth","highestDevelopmentStatusID":"1","companyTruncated":"IGL Pharma.."},{"orgOrder":0,"company":"Skysong Innovations","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXIM\u00ae Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SBI-183","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Skysong Innovations","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skysong Innovations \/ Sapphire Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Skysong In.."},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab Announces 2019 Net Sales Figures for DARZALEX\u00ae (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ J.."},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","amount":"$22.2 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*line Pharma Raises \u20ac20 Million in Series B Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"PDC lung01","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"PDC*line Pharma \/ Korean Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line P.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellicum Enters Asset Purchase Agreement with MD Anderson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Ro","sponsor":"Greenstone LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer\u2019s Greenstone and Digital Men\u2019s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra\u00ae (sildenafil citrate)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ro","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ro \/ Greenstone","highestDevelopmentStatusID":"12","companyTruncated":"Ro \/ Green.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Metoclopramide","moa":"5-HT4 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Ridinilazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Summit Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Ionctura","sponsor":"INKEF Capital","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"IOA-244","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ionctura \/ INKEF Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Teva Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergan keeps Linzess generics out until 2029 with Teva settlement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase?C","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen Astellas Biopharma to Become a Wholly Owned Amgen Affiliate","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"DemeRx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DemeRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DemeRx \/ ATAI Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"DemeRx \/ A.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ ASTRAZENECA","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT\u00ae\/ALOXI\u00ae and AKYNZEO\u00ae in Russia and CIS region","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"Neurokinin 1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Berlin Chemie","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Berlin Chemie \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"Berlin Che.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","amount":"$390.0 million","upfrontCash":"$350.0 million","newsHeadline":"AstraZeneca divests rights to established hypertension medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Divestment","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.39000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.39000000000000001,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Atnahs Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Synthorx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi announced today the successful completion of its acquisition of Synthorx, Inc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"THOR-707","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthorx","amount2":2.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5,"dosageForm":"","sponsorNew":"Synthorx \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Synthorx \/.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TILT-123","moa":"TNF-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Biotheus","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Bill & Melinda Gates Medical Research Institute","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M72\/AS01E","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Medical Research Institute","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Medical Research Institute \/ GlaxoSmithKline","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Mel.."},{"orgOrder":0,"company":"National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program to Oversee Trials of the FGFR Inhibitor Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Comprehensive Cancer Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"8","companyTruncated":"National C.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata\\'s Bacteriophage Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$17.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vascular Therapies Completes Upsized $17.3 Million Private Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"T lymphocyte","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular T.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BioLexis Pte. Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ BioLexis Pte. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Cell Therapies","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kymriah\u00ae To Be Manufactured at Cell Therapies Pty Ltd, Marking Australia\u2019s First On-Shore Commercial Production of CAR T therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Cell Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cell Therapies \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Cell Thera.."},{"orgOrder":0,"company":"BravoVax","sponsor":"GeoVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BravoVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BravoVax \/ GeoVax","highestDevelopmentStatusID":"1","companyTruncated":"BravoVax \/.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX\u00ae (cabozantinib) for Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"$343.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytRx Corporation","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"6","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Parkinson\u2019s Foundation","sponsor":"Zelira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelira Therapeutics collaborates with Parkinson\\'s Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-based Product","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Parkinson\u2019s Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parkinson\u2019s Foundation \/ Zelira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Parkinson\u2019.."},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"TLY012","moa":"DR5","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Theraly Fibrosis","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Theraly Fibrosis \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Theraly Fi.."},{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Locust Walk","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locust Walk \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Locust Wal.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$201.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Announces Successful IPO by Black Diamond Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Minister of Economy and Research","pharmaFlowCategory":"D","amount":"$16.4 million","upfrontCash":"Undisclosed","newsHeadline":"iTeos Therapeutics Awarded \u20ac15 Million in Non-Dilutive Funding by the Walloon Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Minister of Economy and Research","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JT to market CORECTIM in Japan to treat atopic dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Phar.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Expands Partnership with Rocket Pharmaceuticals for Childhood Disorder Treatment","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"RP-L201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Lonza","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Bryan, Garnier & Co","pharmaFlowCategory":"D","amount":"$19.3 million","upfrontCash":"Undisclosed","newsHeadline":"GeNeuro Announces Successful \u20ac17.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Private Placement","leadProduct":"Temelimab","moa":"HERV-W","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"GeNeuro","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"GeNeuro \/ Bryan, Garnier & Co","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$330.0 million","newsHeadline":"Sandoz completes acquisition of Aspen\u2019s Japanese operations, strengthening its position in world\u2019s third largest market for generics and off-patent medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.44,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.44,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Onc-392","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Na\u00efve Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itacitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acura Pharmaceuticals Provides an Update on the Development of LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Acura Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Acura Phar.."},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem reports positive ALS cell therapy results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AstroRx","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-210","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202\/MOR202 in Multiple Myeloma in Mainland China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme reports positive arimoclomol data from open-label phase 2\/3 extension in Niemann-Pick disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RHB-106","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3773274","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA\u2019s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HBV immunogen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b\/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fisogatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T\u2122 in Patients with Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3006","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"IN10018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Escape Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ESB1609","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Escape Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escape Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR\u2122 Therapy for Relapsed or Refractory T-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GC027","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Phosphate","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Th.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dibuprenorphine-ethyl-ether","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS and University of Saskatchewan Partner to Conduct Cannabinoid-Based Research on Possible Treatment of Brain Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabis derivatives","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Significant Progress on LAM-001 and LAM-004 Programs","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis climbs as its drug beats Alexion's Soliris in phase 3","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Locus Biosciences initiates world\\'s first controlled clinical trial for a CRISPR enhanced bacteriophage therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Locus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"Invectys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"INVAC-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Commences Phase 1 trial with AGEN1223","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AGEN1223","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Suzhou Connect Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201 \\nD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Connect Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Suzhou Connect Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Con.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Astellas' sNDA for Expanded Indication of MYCAMINE for Invasive Candidiasis in Children Less Than 4 Months of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Micafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topical Ocular Formulation of Aerpio Pharmaceutical\u2019s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125\/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"PellePharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Patidegib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PellePharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PellePharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PellePharm.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota\u00ae Therapy for the Prevention of Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ETX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b\/2a Clinical Trial in Allogeneic HCT Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribaxamase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promethera\u00ae Announces Initiation of Phase 2b DHELIVER Study of HepaStem\u2122 in Patients with Acute-on-Chronic Liver Failure (ACLF)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HepaStem","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Promethera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promethera.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp\\'s Ability to Treat Severe Fungal Infections in the Hospital Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis ligelizumab (QGE031) more effective than Xolair\u00ae at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MBT5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1\/2a Dry Eye Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALY688","moa":"Adiponectin receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allysta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Ph.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-007","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Healios K.K","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, CA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HLCM051","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Healios K.K \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Healios K..."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac\u00ae Meets Primary and Secondary Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sci-B-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Provides PR001 Program Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GEM103","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1\/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DTX301","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces First Patient Dosed in the REPAIR-MS Clinical Trial for the Treatment of Multiple Sclerosis with Lead Nanocatalytic Therapeutic, CNM-Au8","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich\u2019s ataxia (FA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RXC007","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis and AffaMed Therapeutics\u2019 Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 Trial","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Pleural Effusions (MPE)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SCB-313","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Staphylococcus epidermidis strain","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MV-012-968","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Presents Results From An Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pressurised Metered Dose Inhaler","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Bio\u2019s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences and Boston Children\\'s Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE196","moa":"PKC","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics releases interim study data validating the safety of its ketamine depression drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"Staphylococcus Aureus","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Announces Strategic Priorities and Expected Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"RAR-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-6231","moa":"PD-L1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I\/II trial in AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous dendritic cell vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genome & Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1244","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Dova Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Dova Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dova Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dova Pharm.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura\u00ae in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Celerion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson\u2019s Disease and Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NPT520-34","moa":"SLC22A8","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neuropore Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neuropore Therapies \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Neuropore .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics\\' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society\\'s Groundbreaking Beat Aml(R) Master Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Receives IND Clearance for Phase 1b\/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan\/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS\u00ae (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tagraxofusp","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Desethyloxybutynin","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Disintegrating Tablet","sponsorNew":"Neos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neos Thera.."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r\/r AML and MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYAD-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PBCAR269A","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ACN00177","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NT-814","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kandy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Chikungunya virus-like particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-715","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita\u00ae (burosumab) for Tumor-Induced Osteomalacia (TIO)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Head-to-Head Phase 3 Data Show SKYRIZI\u2122 (risankizumab) Superior to Cosentyx\u00ae (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS\u00ae (ravulizumab) in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosomal protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenetic Biosciences (XBIO) Announces Publication of Data from Partner\\'s Phase 1\/2 Study Evaluating Program Leveraging Polyxen Platform Technology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SHP656","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Xenetic Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xenetic Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xenetic Bi.."},{"orgOrder":0,"company":"Kannalife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company\u2019s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KLS-13019","moa":"mNCX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kannalife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kannalife \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kannalife .."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL201","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in critical limb ischaemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYP-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Provides Update on One-Year ARDS Study Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem cell therapy","moa":"T cell","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613\u00ae? (devimistat) for Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda\u00ae in NSCLC Patients Progressing on Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with Cellectis\u2019 New Allogeneic UCART123 Product Candidate for Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"UCART123","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS\u2122 (KPI-121 0.25%) for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology\u2019s Rubraca\u00ae (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CART-TnMUC1-01","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb\u2019s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm\u00ae Phase 2a Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"buccal film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidea Technologies Utilizes GenScript\\'s Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SNP-7\/8a","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avidea Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidea Technologies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avidea Tec.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Granted Fast Track Designation for NanoFlu in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant quadrivalent seasonal influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New small molecule to treat Alzheimer\\'s disease and Dravet syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GNE-0723","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hanmi Pharma to develop innovative drugs for rare diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HM15211","moa":"Glucagon\/GIP\/GLP-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringes","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Copper histidinate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Neuroptika","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NRO-1","moa":"Semaphorin-3A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuroptika \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika.."},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics announces that a common LAM-002 mechanism in cancer and neurodegenerative diseases shows antitumor activity in the clinic and hope for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"PIKfyve kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kintai Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kintai Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintai The.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Gains 29% In 5 Days, FLX475 Phase 2 Data Due In Q2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"FLX475","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Theranexus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theranexus Announces The Clinical Results Of Its Phase Ib Study Demonstrating The Extended Pharmacological Profile Of Its Drug\\n Candidate Thn201 Compared To Donepezil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Theranexus","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theranexus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theranexus.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest rockets on promising pancreatic cancer data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Arena Pharmaceuticals\\' APD418 for Development in Decompensated Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"APD418","moa":"ADRB3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"OncoTartis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Research Collaboration Reveals Promising Drug Candidate for Treatment of Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-82","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoTartis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"OncoTartis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoTartis.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BTX-A51","moa":"CK1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"A3AR","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umbralisib Developer Seeks FDA Approval In Marginal Zone Lymphoma and Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech\u2019s $220K Equity Investment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-EGFR antibodies","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RMC-4630","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NV-HHV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-200","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TenNor Therapeutics Received FDA Orphan Drug Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TNP-2092","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TenNor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TenNor The.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir\\'s Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-711","moa":"Cathepsin K","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza regulatory submission granted Priority Review in US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J pushes to expand Imbruvica label after clinical success","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Antimicrobial therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999 \\nS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OBI-999","moa":"Globo H glycolipid antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Presents Positive Data from Pilot Intranasal Human Abuse Study of Its Investigational Abuse Deterrent Stimulant, ADAIR, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Regorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Evoke Pharma\u2019s NDA Resubmission for Gimoti\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"5-HT4 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Announces the Initiation of a Phase 1b\/2 Clinical Trial of CPI-613\u00ae (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven\\'s Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"JZP-258","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT\/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmac.."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LB Pharmaceuticals Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintai Therapeutics Advances Anti-Obesity Agent KTX-0200 into IND-Enabling Studies Following Positive Preclinical Data Demonstrating Sustained Weight Loss and Improved Health Markers","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KTX-0200","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintai Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kintai The.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Neurotrope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer\\'s Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"Inhibitor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itraconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibitor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibitor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibitor .."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rovatirelin","moa":"Thyrotropin releasing hormone receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Kissei Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pha.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK\u2122 (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cad-1883","moa":"Calcium-sensitive potassium ion channel PAM","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BTRX-140","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BlackThorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn.."},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HLS Therapeutics Files New Drug Submission for PERSERIS\u00ae in Canada","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therap.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-702","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TNX-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent to Support DiaMedica Trial Using GPEx Technology","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DM199","moa":"Kallikrein-1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalent Pharma Solutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"LipoMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LipoMedix Announces Publication of Positive Phase 1 Data for Promitil\u00ae (PL-MLP) in Research Journal Investigational New Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Promitil","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix .."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia\/Lymphoma at Two Upcoming Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobomarsen","moa":"miR-155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"gossamer bio announces data presentation at the 2020 crohn\u2019s & colitis congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer\\'s regorafenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CS1001","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen\u2019s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC22","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO Announces Result from Phase III Clinical Study Evaluating Opdivo\u00ae (Nivolumab)\\nin Patients with Platinum-Refractory Advanced or Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DB-020","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The First Patient Included in Australia in Isofol\\'s Phase 3 AGENT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn\u2019s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro models","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Announces Positive Topline Results of AKP01 Phase III Clinical Study Using Calcipotriol Spray Against Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces Formal Acceptance of CNM-Au8 for HEALEY ALS Platform Trial as Center Receives FDA Approval to Proceed","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Asparagine, L-","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Awarded Cannabis Research License from Health Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid-based Product","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Takes Delivery of GMP AAGP\u00ae PKX-001 Dedicated for Phase 1 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PKX-001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene downgrades late-stage study of PARP inhibitor in gastric cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"GABA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GABA Therapeutics commences phase I study of Etifoxine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Etifoxine","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GABA Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"GABA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GABA Thera.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\\'s checkpoint inhibitor fails pivotal urothelial cancer trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces PDUFA Date for Intravenous Meloxicam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Influenza Challenge Study Published in Lancet Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"H1 influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology Presents Data on LONSURF\u00ae (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Trifluridine","moa":"DNA nucleic acid","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero to expand ongoing Phase IIa trial of AKR-001 for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b\/2a Study of Hyleukin-7\u2122 (NT-I7) and KEYTRUDA\u00ae (Pembrolizumab) in Relapsed\/Refractory Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NT-I7","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ficlatuzumab","moa":"HGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX\u00ae2-73 (blarcamesine) Phase 2 Parkinson\u2019s Disease Dementia (PDD) Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka announces positive top-line results from clinical trials in Japan of\\nfremanezumab as a prophylactic treatment for migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson\\'s Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PD01","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ .."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DNV3837","moa":"DNA topoisomerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SA.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Completes Enrollment in Anti-GBM","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology Platform At ASCO-GI Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"1st clinical trial kicks off to test antibody-drug combination for HIV treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"CD24 binding site","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF617","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI\u00ae for the Treatment of Prostate Cancer in Collaboration with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow\u2019s Feet Lines Published in Dermatologic Surgery","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene epoxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Blueberry Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CD24Fc","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer\\'s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antianxiety and Antidepressant Effects from a Single Dose of Psychedelic Drug Persist Years Later in Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NYU Grossman School of Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NYU Grossman School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Grossm.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OX401","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Update to Parkinson\u2019s Disease Program SLS-007","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte\\'s skin disease drug meets main goal in late-stage study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Present Positive Interim Data on Appili Therapeutics\u2019 ATI-1701 Biodefense Program at 2020 ASM Biothreats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leronlimab Under Evaluation for Potential Treatment of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"Leukotriene receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Multiple neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer nixes multiple Bavencio tests in recent clinical program dump","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PF 04518600","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrevus Receives FDA Qualified Infectious Disease Product (QIDP) Designation for the Treatment of Cystic Fibrosis Pulmonary Exacerbations","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Fusidate","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"National Institutes of Health Clinical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First human trial of monoclonal antibody to prevent malaria opens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mAb CIS43LS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health Clinical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health Clinical Center \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ronopterin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA\u2122 for Treatment of Relapsed Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International and Prevacus Provide Development Update on its Potential Concussion and Nieman Picks Drug Candidates","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals Granted Orphan Designation in Europe for Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"EHP-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Emerald He.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Dosing of First Patient in CSPC\u2019s Chinese Study Evaluating COPIKTRA\u00ae (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ACTR707","moa":"T cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Unum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Unum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Unum Thera.."},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GNOS-PV02","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos The.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation for GLPG1690 in systemic sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Inarigivir","moa":"INFs","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tnx-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itraconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olipudase alfa","moa":"SMPD1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics\\' GMI-1359","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GMI-1359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company\u2019s Lead Investigational Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CVL-936","moa":"D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces FDA Acceptance of IND Application for FS120","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"FS120","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"MLL1-Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-134","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"QR-421a","moa":"USH2A protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-246","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir has received notices of allowance in the EU and Japan for MIV-818 patent applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"D6PV","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia T.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"10153627","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Seattle Genetics\u2019 Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP issues positive opinions for both bempedoic acid and the bempedoic acid \/ ezetimibe fixed dose combination tablet as treatments for hypercholesterolaemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex drops VX-961 to continue search for perfect pain drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"VX-961","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TPST-1495","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Forma Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 1701963","moa":"SOS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boehringer Ingelheim GmbH \/ FORMA Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Lilly Completes Acquisition of Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$50.0 million","newsHeadline":"GSK pays $50M for 2 solid tumor cell therapies from Immatics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Allogeneic T-cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Immatics \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$473.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aimmune Announces $200 Million Equity Investment by Nestle","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis hypogaea) Allergen-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Science","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$437.6 million","upfrontCash":"$27.6 million","newsHeadline":"Cellectis and Servier Expand Collaboration on UCART19 Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Cellectis \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Xencor","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","amount":"$395.0 million","upfrontCash":"$10.0 million","newsHeadline":"Aimmune Licenses Worldwide Rights to Xencor\u2019s XmAb\u00ae7195","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0.40000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Xencor \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ A.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"$375.0 million","newsHeadline":"Assertio Announces Sale of NUCYNTA\u00ae Franchise to Collegium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Tapentadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0.38,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Assertio Therapeutics \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$363.3 million","upfrontCash":"$3.3 million","newsHeadline":"Oncodesign and Servier Reach a Key First Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"LRRK2 kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign","amount2":0.35999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"$5.0 million","newsHeadline":"Five Prime Grabs $5M lifeline in Seattle Genetics ADC deal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Five Prime Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Seattle Genetics","highestDevelopmentStatusID":"1","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Closing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Passage Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Therapy Developer Passage Bio Files for $125M IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"PBGM01","moa":"Beta-galactosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Passage Bio \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme A\/S","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALX raises $105M for midphase trials of CD47 cancer drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series C Financing","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Vivo Capital","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Moleculin Biotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"CANbridge Pharmaceuticals Completes US$98 Million Series D Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series D Financing","leadProduct":"Idursulfase beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spruce Biosciences Raises $88 Million in Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"NEA-founded Imara pitches mid-stage alternative for $86M IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Un.."},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"$60.0 million","newsHeadline":"Valneva Announces New $85 Million Financing Arrangement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$82.3 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Proposed $75 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$67.1 million","upfrontCash":"$5.1 million","newsHeadline":"VALBIOTIS inks Strategic Partnership With NESTL\u00c9 HEALTH SCIENCE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alladapt Immunotherapeutics Secures $60 Million in Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series C Financing","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Alladapt Immunotherapeutics \/ Gurnet Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$56.8 million","upfrontCash":"Undisclosed","newsHeadline":"Kezar Announces Closing of $56.8 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Elanco","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$55.0 million","newsHeadline":"Elanco Signs Agreement with Merck Animal Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Diclazuril","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elanco","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Elanco \/ Merck Animal Health","highestDevelopmentStatusID":"12","companyTruncated":"Elanco \/ M.."},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Announces \u00a327.5 M Extended Series A Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OMass Therapeutics \/ Syncona","highestDevelopmentStatusID":"1","companyTruncated":"OMass Ther.."},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series C Financing","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"NeoTX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Ther.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$22.0 million","newsHeadline":"BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Corbus Pharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Lenabasum","moa":"CB2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sonoma bags $40M to push Tregs for autoimmune, neuro diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"Treg therapy","moa":"T cell","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Bio.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$30.0 million","newsHeadline":"Sirtex Medical closes Strategic Transaction with OncoSec Medical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Sirtex","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azafaros Completes EUR 25 Million Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Azafaros","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Forbion","highestDevelopmentStatusID":"1","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Closes First $25 Million Securities Purchase Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tocagen and Forte Biosciences Announce Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ ","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","amount":"$22.1? million","upfrontCash":"Undisclosed","newsHeadline":"Cerecor and Aevi Genomic Medicine Complete Merger","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genom.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$21.7 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma Announces \u20ac18 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"MaaT Pharma \/ SymBiosis","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"PentixaPharm","sponsor":"ELSA Eckert Life Science Accelerator","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"PENTIXAPHARM Secures \u20ac 15 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"PentixaPharm \/ ELSA Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPha.."},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"$15.1 million","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Enters into Collaboration","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Gut microbiome based therapeutics","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MRM Health","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"MRM Health \/ DuPont","highestDevelopmentStatusID":"1","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"$2.0 million","newsHeadline":"Ocumension inks $14M deal with EyePoint Pharma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Wanbury Limited","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Folic Acid","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Wanbury Limited","amount2":0.01,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Wanbury Limited \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Wanbury Li.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Finnish Funding Agency for Innovation","pharmaFlowCategory":"D","amount":"$10.9 million","upfrontCash":"$1.2 million","newsHeadline":"Valo Therapeutics Announces New Funding for Immuno-Oncology Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"PeptiCRAd","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Finnish Funding Agency for Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Pricing of Equity Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Financing","leadProduct":"ATI-2307","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aduro Biotech Announces Milestone Achieved under Merck Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"MK-5890","moa":"CD27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chinook Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"$6.0 million","newsHeadline":"Can-Fite Granted Patent Allowance for Namodenoson in South Korea","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Chong Kun Dang Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"$5.2 million","newsHeadline":"CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Catheter Lock Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Stony Brook University","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Stony Brook University gets $4.2 million NCI grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Stony Brook University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stony Brook University \/ National Cancer Institute","highestDevelopmentStatusID":"2","companyTruncated":"Stony Broo.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Therapeutics to Receive $1.0 Million Milestone Payment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Eurofarma Laboratorios SA","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Bodor Laboratories","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$1.0 million","newsHeadline":"Brickell Biotech Announces Settlement of Dispute with Bodor Labs","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Bodor Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Bodor Laboratories \/ Brickell Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Bodor Labo.."},{"orgOrder":0,"company":"Novan","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Receives Phase 2 NIH Federal Grant of $1.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"WH602","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Novan \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ Na.."},{"orgOrder":0,"company":"Equinox Science","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.0 million","newsHeadline":"EyePoint Pharmaceuticals inks License Agreement with Equinox Science","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Equinox Science","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Equinox Science \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Equinox Sc.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Scandion Oncology receives DKK 5 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"SCO-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Innovation Fund Denmark","highestDevelopmentStatusID":"8","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plex Pharmaceuticals Awarded $600,000 Phase I NIH SBIR Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Plex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plex Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Plex Pharm.."},{"orgOrder":0,"company":"University College London","sponsor":"Cure Parkinson\u2019s Trust","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"UCL researchers test cough syrup drug for Parkinson\u2019s","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Ambroxol","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University College London","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"University College London \/ Cure Parkinson\u2019s Trust","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio, Inc. Awarded $500,000 Grant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Neuropore Therapies Receives $500,000 Grant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"NPT1220-312","moa":"TLR2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuropore Therapies \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore .."},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vietnam\u2019s Vingroup funds three coronavirus research projects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"VIETNAM","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vabiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vabiotech \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Vabiotech .."},{"orgOrder":0,"company":"Salzman Group","sponsor":"Kalytera Therapeutics","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Kalytera Announces New Payments Agreement with the Salzman Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Salzman Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Salzman Group \/ Kalytera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Salzman Gr.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"University of California, Irvine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics to Collaborate with University of California","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Neural stem cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ University of California, Irvine","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"AffyXell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta and Daewoong collaborate with AffyXell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ AffyXell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Seraph Research Institute","sponsor":"Enochian BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enochian Biosciences Acquires Exclusive License for Novel HVB B Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"ENOB-HB-01","moa":"HBV polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seraph Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seraph Research Institute \/ Enochian Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Seraph Res.."},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Navrogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Navrogen and Levena collaborate to Develop Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody drug conjugates","moa":"HIO","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Levena Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Levena Biopharma \/ Navrogen","highestDevelopmentStatusID":"4","companyTruncated":"Levena Bio.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma and Solarvest Enhance Commitment to CBD Research Project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Solarvest BioEnergy","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theratechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theratechnologies Ink Agreements with General Hospital Massachusetts","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Theratechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyowa Kirin Terminates ASACOL\u00ae deal with Zeria Pharmaceutical","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zeria Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Zeria Phar.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioxytran Seeking Partners for Late Stage Treatment of Coronavirus","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"BXT-25","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Diamyd enters agreement to facilitate transition of manufacturing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne strikes agreement with CoreRx","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ J.."},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curis and Aurigene Announce Amendment of Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Aurigene Discovery Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Curis \/ Au.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trefoil Selects AGC Biologics as Lead Manufacturer of TTHX1114","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"AGC Biologics \/ Trefoil Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Certara","sponsor":"Arvinas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arvinas picks Certara for Its Targeted Protein Degradation Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Proteolysis targeting chimera","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Certara","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Certara \/ Arvinas","highestDevelopmentStatusID":"1","companyTruncated":"Certara \/ .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla Medpro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Medpro Gets Distribution and Marketing Rights for Seroquel","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Cipla Medpro","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$761.0 million","upfrontCash":"$37.0 million","newsHeadline":"KalVista Pharma Provides Update on Diabetic Macular Edema Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Termination","leadProduct":"KVD001","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0.76000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.76000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"KalVista Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"J & J collaborates with U.S. Department of Health & Human Services","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Janssen Pharmaceutical K.K.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nippon Shinyaku inks new agreement for prostate cancer treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Nippon Shinyaku","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Nippon Shinyaku \/ Janssen Pharmaceutical K.K.","highestDevelopmentStatusID":"12","companyTruncated":"Nippon Shi.."},{"orgOrder":0,"company":"MAbSilico solutions","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Partners with MAbSilico","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"T-lymphocytes","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAbSilico solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MAbSilico solutions \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"MAbSilico .."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syros Announces $60 Million Loan Facility with Oxford Finance LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Vitiprints","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LakePharma and NJ Bio to streamline antibody-drug conjugate services","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vitiprints","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitiprints \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Vitiprints.."},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fib.."},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Norgine \/ Faes Farma S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ .."},{"orgOrder":0,"company":"myTomorrows","sponsor":"AiCuris Anti-infective Cures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AiCuris collaborates with myTomorrows","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Pritelivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"myTomorrows","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"myTomorrows \/ AiCuris Anti-infective Cures","highestDevelopmentStatusID":"8","companyTruncated":"myTomorrow.."},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novimmune unit nabs Takeda milestone payment for hemophilia work","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Light Chain Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Light Chain Bioscience \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Light Chai.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi joins forces with U.S. Department of Health for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"SARS vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ B.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vision Center Network of America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals and Vision Center Network Ink Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vision Center Network of America","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"GenesisCare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxopharm Alliance With GenesisCare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Idronoxil","moa":"PMET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ GenesisCare","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Vectans Pharma","sponsor":"m8 Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"m8 Pharmaceuticals and Vectans Pharma Enter Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Miconazole","moa":"CYP50","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vectans Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vectans Pharma \/ m8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Vectans Ph.."},{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evgen and Rochester University partner to advance SFX-01 trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"SFX-01","moa":"Nrf2","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Acquires Manufacturing Assets for Radioprotectant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Royal DSM \/ Humanetics Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Premier ProvideGx Program Partners with Pfizer","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"IBUTILIDE FUMARATE","moa":"hREG","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"ProMab Biotechnologies","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences and ProMab Biotechnologies Inks Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"CB-011","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProMab Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMab Biotechnologies \/ Caribou Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"ProMab Bio.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"GRCBDS","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erytech Pharma Announces Strategic Supply Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Eryaspase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GRCBDS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GRCBDS \/ Erytech Pharma","highestDevelopmentStatusID":"10","companyTruncated":"GRCBDS \/ E.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vifor Pharma and Fresenius Kabi create joint venture in China","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied DNA and Takis Biotech partner on coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Applied DNA","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"Tianjin University","sponsor":"Beroni Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Group teams up with Tianjin University for COVID-19 treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Nanobased antibody therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tianjin University \/ Beroni Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Un.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover and GSK Announce Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 S-Trimer","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"4","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Drug developer PolyPid to file for Wall Street IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Doxycycline","moa":"MMP7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Virology laboratory, U.S","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"Defensin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virology laboratory, U.S","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virology laboratory, U.S \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Virology l.."},{"orgOrder":0,"company":"Viatris","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beximco To Distribute Mylan Product Portfolio In Bangladesh","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Beximco Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear\u00ae in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aciclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Medivir \/ Shijiazhuang Yuanmai Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$94.6 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Closing of Full Exercise of Underwriters\u2019 Option","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Human Immune Globulin","moa":"Phagocytosis","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"GSK","sponsor":"Suir Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STADA becomes a major Consumer Healthcare player by acquiring 15 well-established GSK brands","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Troxerutin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ STADA AG","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ STAD.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Paratek Announces License Grant to Almirall for SEYSARA\u00ae (sarecycline) for Greater China Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"$3.2 million","newsHeadline":"Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ .."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Flerie Invest AB","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"KAHR Medical Raises $18 Million in Private Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Atezolizumab","moa":"SIRP alpha\/41BBL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Kahr Medical \/ Flerie Invest AB","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Peptilogics Announces CARB-X Funding to Accelerate Development of First-in-Class Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"DNDi","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"LXE408","moa":"Proteasome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DNDi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"DNDi \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"DNDi \/ Nov.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and FUJI YAKUHIN Conclude License Agreement","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Urate transporter","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fuji Yakuhin \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuh.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Announces Pricing of $10 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcus Biosciences and Taiho Pharmaceutical Announce Taiho\u2019s Exercise of an Exclusive License to Zimberelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AB154","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic .."},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Xerys Funds","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced BioDesign Raises Additional \u20ac9 Million From Xerys Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"ABD-3001","moa":"ALDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Advanced BioDesign","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Advanced BioDesign \/ Xerys Funds","highestDevelopmentStatusID":"4","companyTruncated":"Advanced B.."},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Research Collaboration with Southern Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Live modified horsepox virus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Southern R.."},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda buys PvP in $330M deal to bag a 2nd celiac drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0.33000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"PvP Biologics \/ Takeda","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biolog.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma Pharma to commercialise Glenmark Pharma\u2019s new nasal spray Ryaltris in US","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Domainex","sponsor":"LUNAC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Protease","url1":"","url2":"","graph1":"Hematology","graph2":"Discovery","graph3":"Domainex","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domainex \/ LUNAC Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,720.0 million","upfrontCash":"$350.0 million","newsHeadline":"Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"ST-501","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":2.7200000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.7200000000000002,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"University of Hawai'i at Manoa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Filovirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ University of Hawai\\'i at Manoa","highestDevelopmentStatusID":"1","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Abigo Medical AB","sponsor":"Essity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Dialkylcarbamoylchloride","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Abigo Medical AB","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Abigo Medical AB \/ Essity","highestDevelopmentStatusID":"12","companyTruncated":"Abigo Medi.."},{"orgOrder":0,"company":"MAKScientific","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MAKScientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAKScientific \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"MAKScienti.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$30.0 million","newsHeadline":"Medexus expands US product portfolio by acquiring hematology asset IXINITY","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Recombinant coagulation factor IX","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Private Placement","leadProduct":"Defactinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"HMBD-002","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mycenax Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mycenax Biotech \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Mycenax Bi.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Announces Publishes Two Manuscripts on Bempegaldesleukin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INS1007","moa":"DPP-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces Study of Unituxin\u00ae (dinutuximab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"United The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Review Supplemental New Drug Application for RECARBRIO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Imipenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Publishes Patient Benefit Results From A Pilot Clinical Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3106","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Updates on Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva to Present Results from its Phase IIa Odiparcil Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Odiparcil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Announces FDA Grant of Rolling Review of Neutrolin\u00ae NDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Catheter Lock Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes 50% Patient Enrollment in Phase III RA Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Gains Japanese Dusquetide Patent Allowance in Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dusquetide","moa":"p62 protein","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Successfully Completes of Phase 1 AML Trial of Annamycin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Pharma Receives Issue Notification for a U.S. Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Immunitor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunitor publishes interim results from Phase III trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hepcortespenlisimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunitor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunitor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunitor .."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Presents Clinical Data from its Phase 1\/1b CPI-818 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-818","moa":"Il-2 induced T-cell Kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Receives Formulation Patent Extending NCX 470 U.S","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCIB1 Investigational New Drug (IND) application approved","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SCIB1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Receives Fast Track Designation by U.S. FDA for ANAVEX\u00ae2-73","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharma Achieves Patient Screening Target for Zygel","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Receives FDA Breakthrough Therapy for Apabetalone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon, Exscientia begin study of AI based OCD drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Rebiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rebiotix Completes Enrollment for Pivotal Phase 3 Trial of RBX2660","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Advances GMI-1359 Program With Patent Issuance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GMI-1359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Doses First Patient in USA in its Phase 1b\/2a Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Selects AGC Biologics as Lead Manufacturer of TTHX1114","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\\'s IRL790 Receives New Name `mesdopetam\\'","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emtora Presents Phase Ib Data in Low Grade Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emtora Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Bio.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Initiates Expanded Access Program for Tafasitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon Announce current Status of BLA Review of FYB201","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces First Patients Treated in Separate Phase 1b","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AKST4290","moa":"CCR3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alkahest","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Present TACTI-002 Interim Data at German Cancer Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Desmetramadol is G-Protein Biased Opioid Receptor Agonist: Syntrix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Desmetramadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Syntrix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syntrix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Syntrix Ph.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Announces Publication of Abstracts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec\u2019s INS-3001 Reduces Cardiovascular Calcification","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INS-3001","moa":"Vascular calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Inositec AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inositec AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inositec A.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Reports Interim Clinical Data on ARO-APOC3 and ARO-ANG3","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u2122 Meets Primary and Key Secondary Endpoints","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences to Present KSI-301 Phase 1b Clinical Study Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID-sponsored Trial of M-001 Validates Previous Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"M-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector Announces FDA Fast Track Designation Granted to AL101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Gets FDA Clearance of IND Application for BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Completes Patient Enrollment in Roluperidone Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Topline Data from Positive Phase 1 Trial with THR-687","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foamix Announces Publication of Phase 3 Studies Evaluating FMX103","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pha.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Receives Orphan Drug Designation for Amyotrophic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Gets PDUFA Date Extension for NDA of Avapritinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SUNFISH Pivotal Results for Risdiplam Demonstrate Meaningful Benefit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PIC1-dPEG24","moa":"Complement C1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Provides Positive Update on Clinical Study of OpRegen\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cell","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ROR1 CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Presents Updated Data from MERECA Trial of Ilixadencel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Announces Positive Top-line Results from Trial of FINTEPLA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Gest U.S. FDA Acceptance of BLA for DAXI","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharma Gets IND Authorization for its Multiple Myeloma Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Publication Relating To Design Of Galactic-Hf","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data for SRK-015","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Prepared to Advance GOVX-B11 HIV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GOVX-B11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents Vopratelimab Predictive Biomarker Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"ICOS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Provides SB206 Program and Business Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Announces DSMB has Confirmed Initial Safety of GEN-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Commences Phase 3 Trial of AD04","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi brain-penetrant BTK inhibitor meets primary endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Topline Results for Solanezumab from DIAN-TU Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Solanezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche experimental drug flops in early Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review for Kite\u2019s KTE-X19 BLA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KTE-X19","moa":"CD19","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Significant Progress of SACT-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Further Positive Data For Its ALS-4","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"S-Trimer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides Topline Results From Gantenerumab Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Receives Authorization from FDA To Begin Trial for INO-3107","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Elorac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elorac to Present Naloxone Lotion Phase III Study Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elorac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Elorac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elorac \/ N.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle, Astellas Announce Updated Results from PADCEV\u2122 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits to U.S. FDA for New DARZALEX\u00ae Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix Presents Key Clinical Data of Pegunigalsidase Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Progresses in Prophylactic Vaccines Modality with CMV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Patient Enrolled in mRNA-3704 Phase II","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-3704","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Gets Fast Track Designation By U.S. FDA NBTXR3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Seurat Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seurat Therapeutics Shows Novel Mechanisms from Rat Migraine Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Insulin-Like-Growth-Factor-I 21-40","moa":"IGF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seurat Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seurat Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seurat The.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring\u2019s Plinabulin Activates Adaptive and Innate Immune System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Avalglucosidase Alfa, a Potential New Therapy for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AKST4290","moa":"CXCR3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Decision to Discontinue AB-452","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Unveils Results from Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Updated Phase II Savolitinib \/ Imfinzi\u00ae Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven anxiety treatment fails late-stage study, shares fall 16%","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics Announces Discovery of Gene Targets to PD-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CT-1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Safety, Efficacy and Durability Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Walter Reed Army Institute of Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Army Inches Closer To Develop Zika And Dengue Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MZ4","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Walter Reed Army Institute of Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walter Reed Army Institute of Research \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Walter Ree.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz to initiate phase III clinical trial of centhaquine","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STP705 Gets Orphan Drug Designation By US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Reports Topline Results from Two Pivotal Clinical Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T3D Begins Enrollment in PIONEER Phase 2 Trial of T3D-959","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"T3D-959 Sodium","moa":"PPAR delta\/gamma","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therap.."},{"orgOrder":0,"company":"DaVolterra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Da Volterra Reports Positive Top-line Results from DAV132 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DAV132","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DaVolterra","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"DaVolterra \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DaVolterra.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics and Natera To Collaborate for ELI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces MET Inhibitor Capmatinib (INC280), the First Potential Treatment for METex14 Mutated Advanced Non-small Cell Lung Cancer, Granted Priority FDA Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants New Drug Application and Priority Review for Ripretinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Initiate Trial for Novel Delivery Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Reports Early Completion of Patient Enrollment in TLC590 Phase II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allena Pharmaceuticals Announces Streamlined Design for URIROX-2","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Reloxaliase","moa":"Oxalate","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pha.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Receives the EMA PRIME Designation for Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"T lymphocyte","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preliminary, Preclinical Data","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Anandamide","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Initiates First-in-Human Study of ATI-2173","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"HBV polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Review of NDA for Oral ASTX727 or oral C-DEC Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XTANDI Improves Overall Survival in Phase III PROSPER Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PRIVIGEN Granted Orphan-Drug Designation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RGLS4326","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Angiopoietin-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga\u00ae-Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Riptide Bioscience Announces Discovery of Novel Immune Checkpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Riptide Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Riptide Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Riptide Bi.."},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX.."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay\u00ae for Treatment up to 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuMentis Therapeutics Inc to Focus on Developing New Therapy to Treat High Value Neurodevelopmental and Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"EM-036","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"EuMentis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EuMentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EuMentis T.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Announces Presentations on JR-141 and JR-162 at the 16th Annual WORLDSymposium 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"JR-141","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Data Presentations at the Congress of the European Crohn\u2019s and Colitis Organisation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces Publication of Olutasidenib\u2019s Molecular Design and Potential Utility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Updated Survival Data in Phase 1\/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-PSA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b\/2 Clinical Trial of Ciforadenant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scynexis completes patient enrollment for women\u2019s health phase 3 study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Provides Regulatory Update For COR388 Development Program In Alzheimer\u2019S Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Soligenix \\\"Fast Track\\\" Designation for RiVax\u00ae in the Prevention of Ricin Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ricin toxin","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polatuzumab Vedotin Achieved Primary Endpoint in the Japanese study for Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Publication of Phase 1b\/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx Announces IRB Approval to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Interim Data from STARDUST Study Show 2\/3rd of Patients Achieved Clinical Remission After Two Doses of STELARA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Anaprazole sodium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sihuan Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sihuan Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Active Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the ?4?7 Integrin","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Advances Development of CAN04 Through Successful Production Scale Up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nidanilimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Reveals 1-year Data for Novel Subcutaneous Formulation of Infliximab in Crohn\u2019s disease and Ulcerative colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indications of Tecentriq and Avastin for the Treatment of Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Latest Data for LENVIMA\u00ae in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recardio Completes Interim Analysis of Phase 2 in AMI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb announces updated results from phase 3 CheckMate -214 study of Opdivo plus Yervoy versus sunitinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis\\' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC40","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Reveals Data In Renal Cell Carcinoma From an Ongoing Trial Of Sitravatinib In Combination With Nivolumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zelira Therapeutics Meets Primary Endpoints for Phase (1b\/2a) Medicinal Cannabis Trial for Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ZLT-101","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Zelira Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zelira The.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The First Patient Included in Japan in Isofol\\'s Phase 3 AGENT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1220","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces Results From Study to Evaluate Efficacy of Elamipretide","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo\u00ae in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabiralizumab","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrevus Receives FDA Orphan Drug Designation for ARV-1801 (sodium fusidate)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Fusidate","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmac.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology\u2019s ALX148 Receives Two Fast Track Designations from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces First Subject Treated in Phase 1\/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SNP3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Defensin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation for Retrotope\u2019s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta\u2019s Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"Leukotriene receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts BioCryst\u2019s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Initiates Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion gets approval to add new sites to Phase II trial of SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China approves first anti-viral drug against coronavirus Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Favilavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang H.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Huntington\\'s disease drug, RG6042 gets Japanese orphan drug designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tominersen","moa":"mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Aurigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurigene announces dose administration in first patient study for phase II study of psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AUR101","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurigene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV\u2122 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"FGF-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Reveals Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics to Discuss Novel Lymph Node Vaccine Targeting Seven Key mKRAS Mutations at RAS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1?I in a Model of Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine Kinase 1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Bioch.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Genentech\u2019s Tecentriq Monotherapy as First-line Treatment of Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Fibrotic Activity of Hepion Pharmaceuticals\u2019 CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"resTORbio Announces Interim Results for Phase 1b\/2a Trial of RTB101 in Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RTB101","moa":"TORC1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals\\' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Provides Update Regarding ZIMHI","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CoImmune Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CMN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Kowa Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kowa Achieves Goal Of Randomizing 10,000 Patients Into Landmark \\\"PROMINENT\\\" Cardiovascular Outcomes Study Of K-877 (Pemafibrate)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemafibrate","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Research Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Research Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Resea.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS: Second patient treated in the Phase I study, NZ-DTX-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National C.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation and Rare Pediatric Disease Designation for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Results from Phase 2 Study of Investigational Therapy Nemolizumab for Moderate to Severe Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-456","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Completes Enrollment in its Phase I\/II Trial to Evaluate Trappsol\u00ae Cyclo\u2122 for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac for Advanced Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-Survivac","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Study of CAPLYTA\u2122 (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science announces positive top-line Phase 2B\/3 results for oral masitinib in progressive forms of multiple sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"NoNO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nerinetide","moa":"PSD-95","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NoNO","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NoNO \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NoNO \/ Not.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed With Artery Infusion of Transgene\u2019s Oncolytic Virus TG6002 for Colorectal Cancer With Liver Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TG6002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrahepatic Artery Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Positive Clinical Data in Ongoing Phase 1\/2 ADXS-503 Trial in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3773274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces Phase 1\/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb\\'s Opdivo\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PH10","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breath Therapeutics, a Zambon Company, Initiates BOSTON-3 and BOSTON-4, Two Additional Clinical Studies for the Treatment of Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals\\' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor announces progress of the Phase III immuno-oncology program with balixafortide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DYV-700","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dyve Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosc.."},{"orgOrder":0,"company":"Mannin Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mannin Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mannin Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Res.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM9161","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed .."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise aims to develop coronavirus vaccine and drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech announces new direction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"ReNeuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReNeuron Announces Positive Long-term Data in Retinal Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"hRPC stem cell","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"ReNeuron","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReNeuron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ReNeuron \/.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Approval for the Phase Ib\/II Clinical Trial of APG-1387 in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-1387","moa":"Apoptosis protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA accepts GSK\\'s sNDA for Zejula for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"Il-2 mutein","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Announces Research Publication Showing Markedly Enhanced Pain Relief of Second Pipeline Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATB-352","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants \u2018breakthrough\u2019 status to antibiotic alternative as ContraFect rushes to join fight against superbug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Presents Updated Phase 1b\/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AU-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Conditioning Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-117","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CD24Fc","moa":"G\/10-associated SHP1 signaling","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fosun Kite\u2019s New Drug Application (NDA) Filing For Axicabtagene Ciloleucel Accepted For Review By China NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Kite Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Kite.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study of Aldafermin in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX\u00ae2-73 (blarcamesine) in Multiple Sclerosis (MS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces INCREASE Study Of Tyvaso\u00ae Meets Primary And All Secondary Endpoints","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering ATI-2173","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"HBV polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Regulatory Path Forward for TLANDO\u2122 Resubmission","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Enhances its Intellectual Property Estate for CBP-307","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Announces Breakthrough Data from DeCidE1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019 Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant quadrivalent seasonal influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefepime","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Allecra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Th.."},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CDNF","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral infusion","sponsorNew":"Herantis Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Herantis P.."},{"orgOrder":0,"company":"Excel Diagnostics and Nuclear Oncology Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excel Nuclear Oncology Center initiates the first Lu-177 DOTATOC PRRT clinical trial for the PUT-Neuroendocrine Tumors, in U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu-DOTATOC","moa":"SSTR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Excel Diagnostics and Nuclear Oncology Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excel Diagnostics and Nuclear Oncology Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Excel Diag.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab","moa":"IRS1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol-Myers Squibb Advances CytomX Therapeutics\u2019 Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986249","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3K? Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"IOA-244","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Completion of Enrollment in its Extension Protocol to the Phase I Trial to Evaluate Trappsol Cyclo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Includes First Patient in U.S. Phase 1\/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ABX196","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod in FSHD","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Completes Enrollment of Subjects in AXA1665-002 Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Pyoderma Gangraenosum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MRT5005","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel\u2122 in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ZYN002","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APEIRON\u2019s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"APN01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R\/R AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 mAB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM9167","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Inflazome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inflazome\u2019s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Somalix","moa":"NLRP3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for Sternal Wound Infection Post-cardiac Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Debiopharm\\'s Novel Chemo-Radio Sensitizer Debio 1143","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide in Combination With Anti-PD-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine\u2019s 36th Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"OX401","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fifth and Final Site Announced for BrainStorm\u2019s Progressive Multiple Sclerosis Phase 2 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors cell","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1\/2 ADXS-503 Trial in NSCLC at I\/O 360\u00b0 Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NI006","moa":"Transthyretin amyloid","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Presents Blinded Interim Data from the VISIONARY-MS Phase 2 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nonprofit drug development company starts GoFundMe for emergency funds to treat coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"EIDD-2801","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innov.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"BGB-3245","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics Initiates Phase 1\/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage rethinks SAGE-217 program after phase 3 failure","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara to present at Transplantation & Cellular Therapy 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead starts 2 late-stage studies for coronavirus drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa gets RMAT designation for new CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CD30 CAR-T","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA in Combination with Low-Dose Cytarabine in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYA Bioscience International\u00ae Announces the Successful Completion of Phase 1 Trial of HBI-3000","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulcardine sulfate","moa":"Fast sodium current","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Respivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Respivant Sciences Supports International Rare Disease Day Through Awareness Activities","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Cromoglicate","moa":"Mast Cell","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Respivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Respivant .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Presents Preclinical Results for GB-401","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GB-401","moa":"ADRB","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP Opinion","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hanmi\u2019s anti-NASH drug candidate set to become \u2018game changer\u2019 in global pharmaceutical market","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringes","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Beijing Advaccine Biotechnology","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beijing Advaccine Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beijing Advaccine Biotechnology \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Ad.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Celularity ","highestDevelopmentStatusID":"1","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"CureVac","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"$8.3 million","newsHeadline":"CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"CureVac \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Pharmaceuticals Starts Clinical Trial of Anti-viral Drug\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Galidesivir","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"nCoV nanoviricide drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Tongji University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Hospital to Develop mRNA Vaccine Targeting the 2019-nCoV in 40 Days","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tongji University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Uni.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Announces Expanded Collaboration with HHS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibodie","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Pasteur Institute","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","amount":"$0.3 million ","upfrontCash":"Undisclosed","newsHeadline":"Pasteur Institute receives grant for Research on epidemiological characteristics and severe acute respiratory syndrome coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pasteur Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasteur Institute \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Pasteur In.."},{"orgOrder":0,"company":"CSL","sponsor":"University of Queensland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Collaborates With University of Queensland for Treatment of COVID-19 \n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Squalene API","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"CSL \/ Univ.."},{"orgOrder":0,"company":"Advent","sponsor":"The Jenner Institute, Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Advent","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Advent \/ The Jenner Institute, Oxford University","highestDevelopmentStatusID":"6","companyTruncated":"Advent \/ T.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International","highestDevelopmentStatusID":"1","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Kansas State University Research Foundation","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma licences coronavirus drug candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kansas State University Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University Research Foundation \/ Cocrystal Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Kansas Sta.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Beijing ZhonghuaInvestment Fund Management","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"$1.0 million","newsHeadline":"Chinese companies contract Generex for Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management","highestDevelopmentStatusID":"1","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"iBio","sponsor":"CC-Pharming","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Plant derived vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ CC-Pharming","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ CC-.."},{"orgOrder":0,"company":"GSK","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":""},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM for organ failure in COVID-19 Patients ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tongji Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tongji Hospital \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tongji Hos.."},{"orgOrder":0,"company":"Bone Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation\n","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"rhNELL-1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biolo.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese official says Fujifilm\u2019s Favipiravir could treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Toyama Chemical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China approves use of Roche arthritis drug for some Covid-19 patients\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla ready with repurposed HIV drug to combat coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiwan firm teams up with US to develop Covid-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigen Vaccine Biologics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"AntiCancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Methioninase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer.."},{"orgOrder":0,"company":"Tulane University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tulane University launches new, primate-based coronavirus research program for vaccine aid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tulane University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tulane University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tulane Uni.."},{"orgOrder":0,"company":"Forty Seven","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$4,900.0 million","upfrontCash":"$4,900.0 million","newsHeadline":"Gilead to Acquire Forty Seven for $4.9 Billion\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Magrolimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forty Seven","amount2":4.9000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":4.9000000000000004,"dosageForm":"","sponsorNew":"Forty Seven \/ Gilead ","highestDevelopmentStatusID":"8","companyTruncated":"Forty Seve.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"STCube ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and STCube Enter into Development and Manufacturing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"STT-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ STCube ","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Takeda Ventures","pharmaFlowCategory":"D","amount":"$100.5 million","upfrontCash":"Undisclosed","newsHeadline":"Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"XTX201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Takeda Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"ITM","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ITM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ITM \/ Endocyte ","highestDevelopmentStatusID":"10","companyTruncated":"ITM \/ Endo.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA\u2122 Vaccine Candidates Designed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Applied DNA Sciences ","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"Immunocore","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunocore Secures $130 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"MAGE-A4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunocore \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Chemical Co Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$90.0 million","newsHeadline":"Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka ","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda agrees to divest select OTC and Non core assets in Latin America to Hypera Pharma for $825 million USD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipidio Pharmaceuticals Launches with First Close of Series A Financing","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Ph.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Bexotegrast","moa":"AlphaVbeta1 integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Novartis ","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"NanoSurface Biomedical Awarded $1.9M in Funding from NIH","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Human iPSC-derived cardiac tissues","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoSurface Biomedical \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurfac.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Rockefeller University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.7 million","newsHeadline":"Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"10-1074","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Rockefeller University","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian angel investors","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian angel investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Ph.."},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Beijing Shenogen Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DI-LEU16-IL2","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alopexx Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Beijing Shenogen Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Alopexx On.."},{"orgOrder":0,"company":"Amunix","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amunix Raises $73 Million in Series A Financing Led by Omega Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Amunix \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ O.."},{"orgOrder":0,"company":"Moffitt Cancer Center ","sponsor":"DeMelle","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DeMelle OncoPharma Licenses Clinical-Stage Technology from Moffitt Cancer Center for New Targeted Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Farnesyl-Di-Methyl-Chromanol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center ","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moffitt Cancer Center \/ DeMelle","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Ca.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$94.0 million","upfrontCash":"Undisclosed","newsHeadline":"Royalty pharma acquires royalties on Entyvio from Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Massachusetts General Hospital","amount2":0.089999999999999997,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Miami Miller School of Medicine","sponsor":"Heat Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heat Biologics Announces Research Collaboration with University of Miami ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"gp-96 based COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Miami Miller School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miami Miller School of Medicine \/ Heat Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Miami Mill.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Iliad Research and Trading","pharmaFlowCategory":"D","amount":"$0.4 million ","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Iliad Research and Trading","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONO and Nichi-Iko Enter into Licensing Agreement and Technical Collaboration for Limaprost Alfadex Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alfadex","moa":"PGE2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier Canada","pharmaFlowCategory":"D","amount":"$410.0 million ","upfrontCash":"$27.6 million","newsHeadline":"Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Cellectis \/ Servier ","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","amount":"$25.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Linaprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Ph.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"$84.0 million","newsHeadline":"Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"EP1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Abbhi Investments","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Abbhi Investments","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Therapeutics and Shionogi Announce Expanded Alliance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Zatolmilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi ","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics wants a $58M IPO\n","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Hong Kong Teson Pharma","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$3.0 million","newsHeadline":"Correvio Partners with Hong Kong Teson Pharma Limited","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Correvio Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Correvio Pharma \/ Hong Kong Teson Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Correvio P.."},{"orgOrder":0,"company":"Heartseed","sponsor":"Itochu Chemical Frontier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Allogeneic iPSC-derived cardiomyocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Heartseed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Itochu Chemical Frontier","highestDevelopmentStatusID":"6","companyTruncated":"Heartseed .."},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma and Cytovance Biologics Announce Collaboration for the treatment of coronavirus infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"OXS-3550","moa":"CD16","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cytovance Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Cytovance .."},{"orgOrder":0,"company":"Novavax","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Signs Development and Manufacturing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Emergent BioSolutions","highestDevelopmentStatusID":"6","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"J&J partner Legend plans IPO to fund CAR-T pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"$1,080.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Pellino protein","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":1.0800000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Atomwise \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"China's GenFleet banks $58M for cancer, autoimmune pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta receptor 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ 3SBio ","highestDevelopmentStatusID":"5","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio files for $50 million offering amid Covid-19 vaccine hunt","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"XOMA","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus Cadila inks licensing pact with XOMA Corp","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Interleukin-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Zydus Cadila","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Zyd.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"European Health Authorities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie Partnering with Global Authorities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ European Health Authorities","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Menlo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Merger","leadProduct":"Serlopitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foamix Pharmaceuticals \/ Menlo Therapeutics ","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pha.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1\/2 oncology biotech Zentalis Pharmaceuticals files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"The Australian Research and Development Tax Incentive","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Receives $850,000 from The Australian R&D Tax Incentive Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ The Australian Research and Development Tax Incentive","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ IDEAYA Biosciences ","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Res.."},{"orgOrder":0,"company":"GSK","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Angelini Pharma Acquires ThermaCare\u00ae From GSK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Ange.."},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burke Therapeutics, LLC Signs Exclusive US Marketing and Supply Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Burke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Burke Ther.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Venture Partners","pharmaFlowCategory":"D","amount":"$78.5 million","upfrontCash":"Undisclosed","newsHeadline":"Silverback Therapeutics Raises $78.5 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Silverback Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund ","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.02,"dosageForm":"","sponsorNew":"Biosight \/ Israel Biotech Fund ","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.3 million","newsHeadline":"Nicox to Receive \u20ac15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces $102 Million Series C Financing\n","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Lilly to Co-develop Antibody Therapies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly ","highestDevelopmentStatusID":"1","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Context Therapeutics ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tyligand Bioscience and Context Therapeutics Sign Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyligand Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyligand Bioscience \/ Context Therapeutics ","highestDevelopmentStatusID":"8","companyTruncated":"Tyligand B.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces $2.75 Million Registered Direct Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $75 Million Series B+ Venture Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Nona Biosciences \/ SK Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Psagot Investment House","pharmaFlowCategory":"D","amount":"$43.7 million","upfrontCash":"Undisclosed","newsHeadline":"Protalix BioTherapeutics Announces $43.7 Million in Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Pegunigalsidase alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Protalix BioTherapeutics \/ Psagot Investment House","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelluna Immunotherapy collaborates with Karolinska Institutet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"TCR based Natural Killer cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Karolinska Institutet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Institutet \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"2","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"EXUMA Biotech","sponsor":"MSD Partners","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"F1 Oncology Changes Name To EXUMA Biotech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"CAR-T cells therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"EXUMA Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EXUMA Biotech \/ MSD Partners","highestDevelopmentStatusID":"1","companyTruncated":"EXUMA Biot.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.2 million","upfrontCash":"Undisclosed","newsHeadline":"A biotech tests Wall Street's roiled waters and comes away with a $75M IPO haul","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Un.."},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen and Vir Biotechnology to Collaborate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ V.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India, Novavax to develop and commercialise malaria vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M vaccine adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kuur Therapeutics Launches to Develop and Commercialize \u201cOff-the-shelf\u201d CAR-NKT Cell Therapies\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"CMD-501","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kuur Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson ","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israe.."},{"orgOrder":0,"company":"Lewis Katz School of Medicine","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lewis Katz School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lewis Katz School of Medicine \/ Can-Fite","highestDevelopmentStatusID":"4","companyTruncated":"Lewis Katz.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"siRNAs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"University of Saskatchewan","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Saskatoon research lab gets $200,000 to find COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Saskatchewan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Saskatchewan \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 consortium","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Aprinoia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Anti-tau monoclonal antibody","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Aprinoia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$26.9 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Merger","leadProduct":"Gabapentin","moa":"CaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assertio Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"The Peter Doherty Institute","sponsor":"Jack Ma Foundation","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Doherty Institute awarded AU$3.2 million to accelerate a vaccine for COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Peter Doherty Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Peter Doherty Institute \/ Jack Ma Foundation","highestDevelopmentStatusID":"1","companyTruncated":"The Peter .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics and Duke-NUS Medical School Partner to develop a coronavirus (COVID-19) vaccine using STARR Technology\u2122\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Starr RNA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School ","highestDevelopmentStatusID":"2","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"University of Texas Medical Branch","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Texas Medical Branch","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Texas Medical Branch \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Bill & Melinda Gates Foundation ","pharmaFlowCategory":"D","amount":"$5.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Measles vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaxxas \/ Bill & Melinda Gates Foundation ","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ B.."},{"orgOrder":0,"company":"Ribomic","sponsor":"AJU Pharma","pharmaFlowCategory":"D","amount":"$6.0 million ","upfrontCash":"Undisclosed","newsHeadline":"RIBOMIC Enters License Agreement with AJU Pharma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RBM-007","moa":"FGF-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ AJU Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"$45.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Eureka Therapeutics Completes $45 Million Series E Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Canada Pension Plan Investment Board ","pharmaFlowCategory":"D","amount":"$80.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sigilon Therapeutics Announces $80.3 Million Series B Financing to Advance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"SIG-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board ","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$21.4 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OSE-127","moa":"IL-7R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Bloom Science","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"The ALS Association Awards Bloom Science for Novel Microbiota-based Therapies\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"BL-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloom Science \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Scie.."},{"orgOrder":0,"company":"Immatics","sponsor":"Arya Sciences Acquisition Corp","pharmaFlowCategory":"D","amount":"$252.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces Business Combination with Arya Sciences Acquisition Corp\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"T cell immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Immatics \/ Arya Sciences Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Griffith University","sponsor":"Luina Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luina Bio, Griffith University team up to develop coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Griffith University \/ Luina Bio","highestDevelopmentStatusID":"1","companyTruncated":"Griffith U.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$5.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Binimetinib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ IDEAYA Biosciences ","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"NewCo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FORMA Therapeutics Announces Divestiture of Select Hit Discovery Capabilities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"FT-4202","moa":"RBC pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ NewCo","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Meridian IT","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Partners With Meridian IT to Fast Track Drug Manufacturing for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meridian IT","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meridian IT \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Meridian I.."},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$43.0 million","newsHeadline":"Kindred Biosciences Announces Mirataz\u00ae (mirtazapine transdermal ointment) Transaction","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Kindred Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals PLC","highestDevelopmentStatusID":"12","companyTruncated":"Kindred Bi.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$180.0 million ","upfrontCash":"$135.0 million ","newsHeadline":"BioNTech and Fosun to Develop mRNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0.17999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"BioNTech \/ Fosun Pharma ","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Institute of Chemical Technology","sponsor":"Lasa Supergenerics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lasa partners with ICT to develop Favipiravir therapy for COVID 19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Chemical Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Institute of Chemical Technology \/ Lasa SuperGenerics","highestDevelopmentStatusID":"1","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Binex","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genexine, Binex to co-develop coronavirus vaccine GX-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Binex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Binex \/ Genexine","highestDevelopmentStatusID":"1","companyTruncated":"Binex \/ Ge.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer, BioNTech to Co-Develop Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Institute of Microbiology of the Chinese Academy of Sciences ","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences Announces Co-Development Agreement with IMCAS ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Microbiology of the Chinese Academy of Sciences ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institute of Microbiology of the Chinese Academy of Sciences \/ Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Bismuth Subsalicylate","moa":"COX","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$289.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinese cancer drugs developer InnoCare raises US$289 million after Hong Kong IPO is nearly 300 times oversubscribed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"Heme polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ U.S. Government","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"NineteenGale Therapeutics","sponsor":"Cyclica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Cannabinoid-based product","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NineteenGale Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NineteenGale Therapeutics \/ Cyclica","highestDevelopmentStatusID":"1","companyTruncated":"NineteenGa.."},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.9 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI collaborates with Institut Pasteur to develop COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institut Pasteur \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"Institut P.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax partners with UGA researcher on Covid-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ EpiVax ","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Generex Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Li-Key peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Generex Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ G.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"RoosterBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RoosterBio, Senti Biosciences Partner on Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human mesenchymal stem\/stromal cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ RoosterBio","highestDevelopmentStatusID":"1","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Nice & Green S.A","pharmaFlowCategory":"D","amount":"$21.2 million","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Moberg Pharma \/ Nice & Green S.A","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Biological E","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Daptomycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biological E \/ Sandoz ","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Agreement to Joint Development for a Self-Assembling Vaccine (SAV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Self-assembling vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$0.2 million","newsHeadline":"CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ CNS Pharmaceuticals ","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"BELLUS Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"adMare BioInnovations \/ Bellus Health ","highestDevelopmentStatusID":"8","companyTruncated":"adMare Bio.."},{"orgOrder":0,"company":"Ubix Therapeutics","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NT-I7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ubix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ubix Therapeutics \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Ubix Thera.."},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Oxurion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"LUXEMBOURG","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ocriplasmin","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Inceptua Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inceptua Group \/ Oxurion ","highestDevelopmentStatusID":"12","companyTruncated":"Inceptua G.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$105.1 million ","upfrontCash":"Undisclosed","newsHeadline":"AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer\u2122 Tau Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"ACI3024","moa":"Tau aggregates","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AC Immune","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Lipigon ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Antisense oligonucleotide therapies","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Lipigon ","highestDevelopmentStatusID":"1","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas ","pharmaFlowCategory":"D","amount":"$1,600.0 million","upfrontCash":"$80.0 million","newsHeadline":"CytomX Therapeutics and Astellas Announce Strategic Collaboration ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"T-cell bispecific antibodies","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CytomX Therapeutics","amount2":1.6000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6000000000000001,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Astellas ","highestDevelopmentStatusID":"2","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Immunotherapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil) for COVID-19 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cascade Chemistry","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cascade Chemistry \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Cascade Ch.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GDA-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Phase 2a Study of Cancer Vaccine Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Progression-Free Survival ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces Completed Enrollment in the ONCOS-102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"GMCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Announces First Participant Trial of Wholly-Owned Lymphedema LYT-100","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Genentech\u2019s Esbriet pirfenidone","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sihuan Announces Clinical Research of Favipiravir, Co-Developed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pha.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Biomarker Data Showing EDP1815","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unum Implements Strategic Restructuring to Prioritize Efforts on BOXR1030","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BOXR1030","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Unum Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Unum Thera.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Troxacitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomic Therapeutics Announces Completion of Pre-IND Meeting with US FDA for ITI-1001, a Vaccine for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1\/2 Study of ARO-HSD ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-HSD","moa":"HSD17B13","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals Receives Fast Track Designation from US FDA for EHP-101 in the Treatment of Systemic Sclerosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EHP-101","moa":"PPAR gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Emerald He.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient in treatment for RhoVac's clinical phase II study in Finland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001V","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial ","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OTX-TKI","moa":"TYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAX BioPharma Announces Key Update to its Liver Fibrosis Program ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxy210","moa":"TGF beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MAX BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"MAX BioPha.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Preclinical Data For AMG 594 Presented At The Keystone Symposium On Heart Failure. ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 594","moa":"Cardiac Troponin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient treated with CRISPR medicine in phase 1\/2 trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AGN-151587","moa":"CEP290","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in AVITA Medical\u2019s Pivotal Study Evaluating RECELL\u00ae System for Pediatric Scald Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous regenerative epidermal cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medi.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda begins development of COVID-19 plasma therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TAK-888","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505 ","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Announces Allowance of New European Patent Covering Seclidemstat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Reldesemtiv","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MetaBlok","moa":"DPEP1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Receives Orphan Drug Designation for Umbralisib ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Eleusis","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eleusis Announces Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Eleusis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Eleusis \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Eleusis \/ .."},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ZM-H1505R","moa":"Capsid fromation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shanghai Zhimeng Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"HDP","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Expands Patent Portfolio for its Novel Versamune\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"CD8 positive T lymphocyte stimulant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals completes enrollment in registrational trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Grindeks AS","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grindeks has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"LATVIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyl-GBB","moa":"GBBH","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Grindeks AS","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grindeks AS \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Grindeks A.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Debio 0123","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynacure Announces First Patient Dosed in Phase 1 \/ 2 'UNITE-CNM' Study of DYN101","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DYN101","moa":"Dynamin 2 expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Proof Of Concept Trial In PNH Patients With Oral Factor D Inhibitor, BCX9930","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces First Patient Treated In Third And Final Dose Cohort Of Actimab-A Clag-M ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Announces Issuance of U.S. Patent for Use of PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Trial of Ionis Huntington\u2019s Disease Drug Halted After Side Effects","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA antisense","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"AJ Vaccines","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AJ Vaccines To Develop Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AJ Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AJ Vaccines \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"AJ Vaccine.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck & WEHI discover novel class of Candidate Anti Malaria Agents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WM382","moa":"Plasmepsins IX\/X","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study shows Nilvadipine slows early-stage Alzheimer\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nilvadipine","moa":"L-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roskamp Institute \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp In.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GEMoaB Announces First Patient Apheresed in a Phase IA Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"UniCAR-T-CD123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEMoaB \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Clearances for Three Phase Ib\/II Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare presents positive 48-week data from phase III study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharma Announces Significant Results in STRIDE 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE-083","moa":"GDF8","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA announce Rare Pediatric Disease Designation for Trofinetide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Neuraly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NLY01","moa":"GLP1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ .."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen, Tracon discontinue development of eye drug after mid-stage trial failure","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Carotuximab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Santen Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Reports Preliminary Data from Phase II Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Signs Agreement with the FDA on its Planned Pivotal Phase 3 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IPH5201","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixazomib Citrate","moa":"Proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Troxacitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Plans to Develop MN-166 (ibudilast)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Defensin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable ","highestDevelopmentStatusID":"5","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment With Gilead\u2019s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vesatolimod","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Receives FDA Fast Track Designation For DARE-BV1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Developing TZLS-501 as Treatment for Coronavirus Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Interim Clinical Data Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Updates On STARS Study FDA Interaction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarizotan","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"MedDay Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedDay Reports Top-Line Data from Phase III Trial \u201cSPI2\u201d","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Biotin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"MedDay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MedDay Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"MedDay Pha.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Durable Virus Control of SHIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"N-803","moa":"IL-15","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Presents 96-week DISCOVER Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announce ASN008 Achieves Positive Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ASN008","moa":"NaV Channel","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Asana BioSciences \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Provides Update on Opaganib (Yeliva\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH\/NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma announces new data on ex-vivo FC21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgrastim","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA grants Fast Track designation to Jardiance\u00ae\r\n","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progress of the Small Sample Clinical Trial of Ganovo\u00ae and Ritonavir Combination Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Danoprevir","moa":"NS3\/4A protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable ","highestDevelopmentStatusID":"11","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attacking drug-resistant tumors with Sierra\u2019s struggling CHK1 blocker","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SRA737","moa":"Chk1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and EMD Serono bail on study of avelumab in head and neck cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Johns Hopkins Center for Health Security","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential universal flu vaccine shows efficacy in clinical trial\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Flu-v vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johns Hopkins Center for Health Security","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johns Hopkins Center for Health Security \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem and Charit\u00e9 University of Medicine Berlin Join Forces Targeting COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for Coronavirus Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-HIG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Engage Therapeutics reports positive results from Phase 2 study of Staccato alprazolam for epileptic seizures\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Alprazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Engage The.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemarituzumab","moa":"FGFR2B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Lattice Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Amniotic fluid supplement","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lattice Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lattice Biologics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Lattice Bi.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen\u2019s Lenzilumab as a Potential Therapeutic for Lung Damage Arising From Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Beroni Group","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beroni Group Advances Research and Development of Medical Solution for Coronavirus (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beroni Group \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Gro.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon launches antiviral programme focused on Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-101","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Biotron","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotron\u2019s Compound BIT036 as an antiviral for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cinnamoylguanidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biotron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biotron \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Biotron \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Therapeutics Initiates Infectious Disease Programs\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"XPhyto \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ N.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt explores iNO as potential Covid-19 therapy\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Therapeutic agent against Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nascent Biotech \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmuneMed tests new drug candidate VSF on COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Virus suppressing factor","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuneMed, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneMed, Inc \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneMed,.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cansino Biologics and Institute Of Biotechnology, Academy Of Military Medical Sciences Developing Novel Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Gain Trial in Alzheimer\u2019s Disease Has Reached Enrollment Milestone of 300 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cediranib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research Institute","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH clinical trial of investigational vaccine for COVID-19 begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kaiser Permanente Washington Health Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kaiser Permanente Washington Health Research Institute \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Kaiser Per.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma to Present Late Breaking Abstract at the AAT-AD\/PD Conference (Advances in Alzheimer's and Parkinson's Therapies)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the FDA for Voclosporin","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pilot testing of potential COVID-19 vaccine progresses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stemirna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stemirna Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Stemirna T.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiator Pharma reports positive data from IPED2015 Phase IIa trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IPED2015","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Initiator Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Initiator .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Berotralstat (BCX7353) Significantly Reduced Use of Acute On-Demand Medicine in HAE Patients in APeX-2","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces Acceptance of sNDA Submission of ZEJULA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1\/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Celavet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA\u2019s Center for Veterinary Medicine ","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OK100 stem cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celavet","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celavet \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celavet \/ .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson says no evidence HIV drug works against coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Darunavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar reports positive results for Aplidin\u00ae against coronavirus HCoV-229E\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"VEGFA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Greffex","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greffex completes COVID-19 vaccine, prepares for FDA animal testing\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Greffex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Greffex \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Greffex \/ .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome in COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-Corona (COVID-19) IgG product","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Completes Rolling Submission of New Drug Application to the FDA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces Important Advances in Novel COVID-19 Antibody Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Virus neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet publishes papers from studies of Takeda\u2019s dengue vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TAK-003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SignPath Pharma to Focus on Coronavirus Disease (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"PPAR gamma","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SignPath Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SignPath Pharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"SignPath P.."},{"orgOrder":0,"company":"Avivagen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avivagen Accelerates Plans for Commercial Launch of Its OxC-Beta\u2122 Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Beta Carotene","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avivagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avivagen \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Avivagen \/.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epinephrine Nasal Spray Demonstrates Bioequivalent Exposure","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Safely Completes Expanded Dosing of METABLOK","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva announces completion of patient visits for Phase IIb clinical study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces Publication of Positive TAVO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Leverages its Novel Glycan Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbohydrate binding modules","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pneumagen \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellenkos, Focuses on the Development of Cell-theray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CK0801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces First Patient Dosed in Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Reports Positive Study Results for ET-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences\u2019 ALPN-101 Receives FDA Orphan Drug Designations","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"VIB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIB achieves important milestone in the development of a COVID-19 drug\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody-based drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VIB \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Not .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie\/Roche\u2019s Venclexta fails in confirmatory AML trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Walter Reed Army Institute of Research","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Storied Army institute developing COVID-19 diagnostic test, vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Walter Reed Army Institute of Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walter Reed Army Institute of Research \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Walter Ree.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB provides an update on Phase 2b padsevonil safety and efficacy study in epilepsy (ARISE)\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Padsevonil","moa":"GABA receptor A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage to run 3 new studies to save once-failed depression drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposa\n","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhejiang Hisun Pharmaceutical Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang H.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WEG232","moa":"Substance P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharma Publishes Phase 2 Study Data in Major Peer-reviewed Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis announces NEJM publication of three pivotal trials ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody for COVID-19 Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Binimetinib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Initiates Phase III Clinical Trial of Actemra in Hospitalized Patients With Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Fusogenix DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Receives Orphan Drug Designation From FDA for DCR-A1AT ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in COVID-19 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eusa Pharma \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for SARS-CoV-2 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ii-Key peptide vaccine","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generex Biotechnology \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"20vPnC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alstr\u00f6m Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nelipepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen to start trial of SNG001 in COVID-19 imminently","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharnext Receives Promising Innovative Medicine Designation for PXT3003 ","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 ","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sunitinib","moa":"FLT3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Novotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novotech Wins Cro Contract For Komipharm Coronavirus Covid-19 Clinical Trial In South Korea\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Panaphix","moa":"Cytokine","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novotech \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie\u2019s HIV drug combo shows no benefit in Covid-19 trial\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Leads Coronavirus Vaccine Charge","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QED Therapeutics begins patient dosing in ph3 and ph 2 trials of Infigratinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"QED Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"QED Therap.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Dupixent rival makes the grade in phase 3\u2014again","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Accelerates Completion Of Advance-1 Phase 2\/3 Trial Of Axs-05 In Alzheimer's Disease Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics To Announce Baseline Characteristics From Galactic-Hf During ACC.20\/WCC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BX001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Aqualung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"5","companyTruncated":"Aqualung T.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Develops STI-4398 For Potential Prevention And Treatment Of SARS-COV-2 Coronavirus Disease (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan\u2122 Esophageal Implant","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cellspan Esophageal Implant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Not Applicable ","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Ap.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's CanSino pushes coronavirus vaccine into clinical testing as Moderna kicks off trial\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CanSino Biologics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BARDA: Athersys\u2019 Cell Therapy \u201cHighly Relevant\u201d for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"iBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iBio Developing Proprietary COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 Virus-Like Particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Not.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared IND for IMS001 ","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IMS001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IRL752","moa":"5-HT7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migrain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib\/II Clinical Study ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical development plans for SCO-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SCO-101","moa":"VRAC complex","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese Center for Drug Evaluation (CDE) Cleared Taletrectinib IND ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Inc. Announces Positive Safety Profile of Its Drug Trappsol\u00ae Cyclo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLN-1474","moa":"Integrin Alpha5beta1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VTP-800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"PATH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Funded Nipah virus vaccine candidate first to reach Phase 1 clinical trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"HeV-sG-V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PATH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PATH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PATH \/ Not.."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Developing New Drug for Pulmonary Fibrosis Caused by COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoclonal Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Decheng Capital","pharmaFlowCategory":"D","amount":"$123.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Decheng Capital","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Interleukin 2","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Aegis Capital Corp","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FAZ053","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Laekna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Private Placement","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and DKSH partner to bring key biosimilar to Asia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"IVIX","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ovoca Bio plc: Acquisition of Remaining Minority Shareholding in IVIX LLC","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"RUSSIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"IVIX","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"IVIX \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"IVIX \/ Ovo.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Debio 0228","moa":"CA IX","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"3B Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ Debiopharm","highestDevelopmentStatusID":"2","companyTruncated":"3B Pharmac.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"MedinCell Receives $ 6.4 Million Grant From Unitaid to Fight Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Avectas","sponsor":"Vycellix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for Cell & Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"VY-M","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avectas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avectas \/ Vycellix","highestDevelopmentStatusID":"1","companyTruncated":"Avectas \/ .."},{"orgOrder":0,"company":"Regenacy Pharmaceuticals","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regenacy Pharmaceuticals Raises $30 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"Ricolinostat","moa":"HDAC6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Regenacy Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Regenacy Pharmaceuticals \/ Cobro Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Regenacy P.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Gen Sign Distribution Agreement ","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Gen","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Xencor","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend\u2122 XmAb\u00ae Antibody Technology in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Xencor \/ V.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Alector","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-SIRP-alpha antibody","moa":"SIRP alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Alector","highestDevelopmentStatusID":"4","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"SkylineDx","sponsor":"BioInvent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SkylineDx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SkylineDx \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"SkylineDx .."},{"orgOrder":0,"company":"ViralClear Pharmaceuticals","sponsor":"NeuroClear","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Merimepodib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ViralClear Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ViralClear Pharmaceuticals \/ NeuroClear","highestDevelopmentStatusID":"1","companyTruncated":"ViralClear.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Castle Creek Biosciences Announces $75 Million Investment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"10","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ JDRF T1D","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"SutroVax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series D Financing","leadProduct":"SVX-24","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SutroVax","amount2":0.11,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"SutroVax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"SutroVax \/.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$10.0 million","newsHeadline":"CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"mRNA-mediated protein replacement therapies","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"ReCode Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"1","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Akers Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Coronvirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Akers Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Premas Bio.."},{"orgOrder":0,"company":"iBio","sponsor":"AzarGen Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Supporting AzarGen Biotechnologies\u2019 Development of a Rituximab Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ AzarGen Biotechnologies","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Aza.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ T.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Minnesota \/ Rising Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$3.5 million","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi\u00ae Sprinkle","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diurnal Group","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Kitasato Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.5 million","newsHeadline":"Daiichi Sankyo, Kitasato Pharma to terminate sales cooperation for Influenza HA Vaccine \u201cDaiichi Sankyo\u201d in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Vaccine","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Influenza HA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Kitasato Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AmMax Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 820","moa":"CSF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ AmMax Bio","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"TJD5","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"University of Alabama","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Alabama","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Alabama \/ Altimmune","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19 and Landmark Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Retinamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isoprene Pharmaceuticals \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene P.."},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"Aptorum","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"SACT-COV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Covar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Covar Pharmaceuticals \/ Aptorum Group","highestDevelopmentStatusID":"1","companyTruncated":"Covar Phar.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"AM-Pharma Increases Funding To \u20ac163m For Phase-Iii Trial Of Recap In Sa-Aki","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Ilofotase alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"CureDuchenne Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Oligonucleotide linked antibody","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ CureDuchenne Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"National Research Council of Canada","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Collaboration with the National Research Council of Canada to Develop Pan-Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Pan-coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Research Council of Canada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Research Council of Canada \/ VBI Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"National R.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor for Coronavirus Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee's Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Lee's Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Ildong to collaborate with development projects on INDiGO platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"IDG-16177","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Ildong","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ I.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces up to $16.5 Million in Equity Financing Agreements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Keystone Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"$40.0 million","newsHeadline":"Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Karolinska Institutet","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"Coalition for Epidemic Preparedness Innovations","sponsor":"U.K Government","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"UK boosts support for CEPI to spur COVID-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Coalition for Epidemic Preparedness Innovations","amount2":0.27000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Coalition for Epidemic Preparedness Innovations \/ U.K Government","highestDevelopmentStatusID":"1","companyTruncated":"Coalition .."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"8","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Novavax","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent Biosolutions Signs Development And Manufacturing Agreement With Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Recombinant vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emergent BioSolutions \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$50.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Oncology biotech Ayala Pharmaceuticals files for a $50 million IPO\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pentagon Strikes Deal With Biotech Firm to Make Coronavirus Drug Available to Troops\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019 NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant hemagglutinin protein nanoparticle influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"OncoQuest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"Mucin-16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoQuest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoQuest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoQuest .."},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"eTheRNA immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"eTheRNA immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"eTheRNA im.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Ready to Ship AAGP\u00ae to the University of Alberta for the Continuation of Phase 1 Human Trials","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-629","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data for SRK-015 at the Muscular Dystrophy Association Clinical and Scientific Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"LB1148","moa":"Serine protease","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Initiation of Investigator-Sponsored Phase 1\/2 Study of AVB-500","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Clinical Candidate Apabetalone Featured As A Potential Covid-19 Treatment In Recent Publication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1\/2 Study (O-12-M1)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SCO-101","moa":"VRAC complex","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Receives FDA Fast Track Designation for Niemann-Pick Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Receives Fast Track Designation for IPI-549 in Combination with the Checkpoint Inhibitor Opdivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Danoprevir","moa":"NS3\/4A protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS announces positive preclinical data for NanoZolid\u00ae-TLR9 agonist project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NZ-TLR9","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vopec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vopec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vopec Phar.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China clears Taletrectinib IND, issues clinical trial authorizations","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology to test COVID-19 antibody 'in the summer'","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Technologies Receives Rare Pediatric Disease Designation from FDA for OT-58","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-58","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orphan Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Tec.."},{"orgOrder":0,"company":"Inflazome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Periodic Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Inzomelid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Telacebec","moa":"Cytochrome bc1 complex","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qurient","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation to AlloVir\u2019s Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief therapeutics and NeuroRx File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-OD031","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"APR Applied Pharma Research","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"APR Applied Pharma Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"APR Applie.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed ","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-CB1 antagonist analogues","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyripharm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vyripharm .."},{"orgOrder":0,"company":"EpiVax Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-PD-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EpiVax Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax Onc.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-305","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"BioDuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Nanobody","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioDuro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioDuro \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BioDuro \/ .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex binder","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Transtympanic Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Bio-Pharm Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"JBPOS0101","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Bio-Pharm Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bio-Pharm Solutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Pharm .."},{"orgOrder":0,"company":"National Tsing Hua University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan focuses on BNCT for cancer treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed ","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Boron Neutron Capture Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Tsing Hua University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Tsing Hua University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National T.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Positive Preliminary Phase 1a\/1b Clinical Trial Results for AB-729","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Translate Bio Provides MRT5005 Program Updates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MRT5005","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Composition of Matter Patent in China Expands ONC201\u2019s Global Coverage","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Provides Update on Impact of COVID-19","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Submits New Drug Application for ISTURISA\u00ae in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharma Publishes study in Antimicrobial Agents and Chemotherapy Journal showing Positive Preclinical Results for Mino-Lok","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BDC-1001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan and Lupin Announce Positive CHMP Opinion for Nepexto\u00ae, Biosimilar Etanercept","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenScript ProBio Congratulates XlifeSciences on the Start of TAEST16001 Early Phase Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue L.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"HGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck reports headline results from phase IIa AMBLED study of foliglurax in Parkinson\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor type 4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Submits Phase III Protocol Synopsis to FDA for Lenzilumab for Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA\u00ae (ozanimod)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP backs Sanofi\u2019s myeloma drug Sarclisa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Genentech\u2019s New Drug Application for Xofluza for the Treatment of Influenza in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Relapsed\/Refractory B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals\u2019 Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease\r\n","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces American College Of Cardiology Presentation Of Positive Phase 3 Evinacumab Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen jumps into COVID-19 arena with polyclonal antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant anti-coronavirus 19 hyperimmune gammaglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACC: Bayer, Merck's vericiguat leads meeting with phase 3 data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome reports late-stage depression trial defeat, shares wilt","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupropion Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SEL120","moa":"CDK8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics Launches Program to Evaluate ST266 in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-471","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals To Move Forward With A PCS499 Phase 3 Trial After A Successful FDA Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PCS499","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Outcomes Of Mesoblast\u2019s Cell Therapy In End-Stage Ischemic Heart Failure Presented","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Revascor","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Transendocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Receives Orphan Drug Designation from FDA for Toripalimab-Axitinib Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar delays CB4211 Phase 1b Study for NASH and Obesity","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CB4211","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilonacept","moa":"IL-1 beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Patient Dosing in Phase 2a DME Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck announces phase IIa study results of Lu AG06466 in adults with Tourette Syndrome\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Sagimet's Lead Candidate TVB-2640 to be Presented at EASL ILC 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Announces Positive New Data Validating the INTASYL Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ME-401","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces Favorable Topline Results From Investigative Formulation of Rifaximin SSD IR","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Immediate Release Soluble Solid Dispersion Tablet","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"miRNA-125b","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Horizon Discovery Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Discovery Group \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Horizon Di.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Mimetogen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavilermide","moa":"TrkA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mimetogen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mimetogen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mimetogen .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for ADCETRIS in Combination with Cyclophosphamide, Doxorubicin and Prednisone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application for Anti-BCMA CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BNC375","moa":"Nicotinic alpha-7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Positive Findings From an Interim Analysis in the Phase 1\/2 trial of QR-421","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"QR-421a","moa":"USH2A protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002\/RG7935) in Parkinson's Disease to be Presented at AAT-AD\/PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocardia Announces Positive DSMB Recommendation To Continue Phase 3 Pivotal CardiAMP Heart Failure Study As Planned","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Provides Comment on Impact of Vascepa\u00ae Patent Litigation on MAT9001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Announces the Selection of PRTX007 for COVID-19 and Oncology Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts IND Application for CRISPR\/Cas9-Based Sickle Cell Disease Therapeutic Candidate","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OTQ923","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Announces Arthur DeCillis, MD as Acting Chief Medical Officer to Support CBX-12\u2019s Entry into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Exatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Commencement of Retreatment of Patient Under GTB-3550 TriKE therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"HMPL-453","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Study Data for Gilead\u2019s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GS-6207","moa":"HIV capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Launches Novel I-Cell\u2122 COVID-19 Cellular Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-6991","moa":"Spike protein S1 domain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Biocad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOCAD started working on mRNA vaccine against coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-COV-2 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Biocad","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocad \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Biocad \/ N.."},{"orgOrder":0,"company":"Open Orphan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open Orphan\u2019s Cathal Friel on firm\u2019s \u201cmilestone\u201d human coronavirus challenge study (ORPH)\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OC43 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Open Orphan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Open Orphan \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Open Orpha.."},{"orgOrder":0,"company":"Fillmed Laboratories","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescita Signs Exclusive Distribution Agreement with FILLMED","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Fillmed Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fillmed Laboratories \/ Crescita Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fillmed La.."},{"orgOrder":0,"company":"Murdoch Children\u2019s Research Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Murdoch Children\u2019s Research Institute to trial preventative vaccine for COVID-19 healthcare workers\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Murdoch Children\u2019s Research Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Murdoch Children\u2019s Research Institute \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Murdoch Ch.."},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Neuronasal","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Neuronasal.."},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oblato Biotech Company Acquires Hearing Loss Drug","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ .."},{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anges to develop coronavirus vaccine with Osaka University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ No.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila looks to expedite Covid-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Initiation of Coronavirus Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codagenix partners Serum Institute of India on Covid-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Live-attenuated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Codagenix ","highestDevelopmentStatusID":"1","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 hyperimmune globulin therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise introduces PolyTope mAb therapy to tackle coronavirus pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Medicago","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Announces Production of a Viable Vaccine Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Virus-Like Particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicago \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medical firms accelerate coronavirus vaccine research, clinical trials expected in late April","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Kangtai Biological Products \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shenzhen K.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib emerges as potential treatment for new coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amarillo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as Defense Against Coronavirus\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon-alpha","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Amarillo Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amarillo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Amarillo B.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cell exosomes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Novacell","sponsor":"AD Korea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novacell, AD Korea Corona 19 treatment joint development MOU","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Heptameric peptide FPR2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novacell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novacell \/ AD Korea","highestDevelopmentStatusID":"4","companyTruncated":"Novacell \/.."},{"orgOrder":0,"company":"Texas A&M University System laboratories","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Announces Advancement of COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"IBIO-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Texas A&M University System laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Texas A&M University System laboratories \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Texas A&M .."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generation Bio and Vir Biotechnology Ink Research Pact to Leverage Scalable Non-Viral Gene Therapy Platform for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generation Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generation Bio \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Generation.."},{"orgOrder":0,"company":"The University of Hong Kong","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI partners with HKU for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Hong Kong","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Hong Kong \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Fudan University","sponsor":"RNACure Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Towards an effective mRNA vaccine against 2019-nCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fudan University \/ RNACure Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Fudan Univ.."},{"orgOrder":0,"company":"International Vaccine Institute","sponsor":"Sumagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sumagen teams up with IVI to develop COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Viral vaccine vector","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"International Vaccine Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"International Vaccine Institute \/ Sumagen","highestDevelopmentStatusID":"4","companyTruncated":"Internatio.."},{"orgOrder":0,"company":"Cellivery","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellivery, iCP-NI 'Corona 19' Primate Treatment Efficacy Verification Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"iCP-NI","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellivery","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellivery \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellivery .."},{"orgOrder":0,"company":"ISR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISR Starts Vaccine Development For Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Corona vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISR","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISR \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ISR \/ Not .."},{"orgOrder":0,"company":"Distributed Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Doctor Featured In Netflix's Pandemic Believes He Has Found A 'Cure' For Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibodies","moa":"S-protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Distributed Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Distributed Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Distribute.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Drug Development Update From Nanoviricides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside A Startup\u2019s Pivot To Have AI Fight Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"HONG KONG","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"G+FLAS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G+FLAS Life Sciences Readying Animal Testing Of Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunogenic recombinant vaccine","moa":"S-protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"G+FLAS Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"G+FLAS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"G+FLAS Lif.."},{"orgOrder":0,"company":"ReiThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"After The USA And Australia, The First Pre-Clinical Animal Tests Are Also Carried Out In Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Max Planck Institute for Infection Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"German Scientists Test TB Vaccine Against Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VPM1002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Planck Institute for Infection Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Max Planck Institute for Infection Biology \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Study To Look At Using Gout Drug To Prevent Lung Complications And Deaths From Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Qilu Hospital of Shandong University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bevacizumab For The Treatment Of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Qilu Hospital of Shandong University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qilu Hospital of Shandong University \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Qilu Hospi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Trials Asthma Drug Alvesco To Fight COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Statement On SOLIRIS\u00ae (Eculizumab) And COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"Melatonin receptor type 1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated With GENOSYL\u00ae DS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VERO Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VERO Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"VERO Biote.."},{"orgOrder":0,"company":"German Primate Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japanese Encephalitis Drug May Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Primate Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"German Primate Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"German Pri.."},{"orgOrder":0,"company":"University of Tokyo ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nafamostat Inhibits SARS-Cov-2 Infection, Preventing COVID-19 Transmission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Tokyo ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Tokyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemvax & Kael Expands GV1001 Patent To Cover COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tertomotide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GemVax & KAEL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GemVax & K.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Submits Letter Of Intent For A Clinical Trial Application For A Phase II Study In Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"C21","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Viennese Biotech Company Panoptes Pharma Gmbh Has A Promising Active Ingredient Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PP-OO1","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panoptes Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panoptes Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panoptes P.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel tests coronavirus vaccine prototype on rodents at defense lab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Ridgeback ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emory's DRIVE, Ridgeback partnering for drug vs coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"EIDD-2801","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Drug Innovation Ventures at Emory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Ridgeback ","highestDevelopmentStatusID":"4","companyTruncated":"Drug Innov.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pandion Raises $80 Million Series B to Advance Autoimmune Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novellus \/ Citius","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"MindMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Acquires Exclusive License to Eight Clinical Trials of LSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Basel","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Basel \/ MindMed","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Ethris","sponsor":"Neurimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurimmune and Ethris Enter Collaboration to Rapidly Develop Inhaled mRNA-based Antibody Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NI007","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Neurimmune","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ N.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Holdings Announces Merger Closing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"Atexakin Alfa","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Seikagaku","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Diclofenac conjugated sodium hyaluronate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seikagaku \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku .."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"iTeos Therapeutics Closes $125 Million Series B2 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"$20.0 million","newsHeadline":"Paratek Pharmaceuticals Announces Initiation of Funding from BARDA ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0.28999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.28999999999999998,"dosageForm":"Oral","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"HK Tainuo","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"$10.0 million","newsHeadline":"Flexion Therapeutics Announces ZILRETTA\u00ae License Agreement and Provides Business Update Amid Coronavirus Pandemic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Omadacycline","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Flexion Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0.040000000000000001,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ HK Tainuo","highestDevelopmentStatusID":"12","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"$67.5 million","upfrontCash":"$52.5 million","newsHeadline":"AZ licences Movantik rights to RedHill","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.070000000000000007,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Diamond Light Source","sponsor":"Exscientia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exscientia forms UK-US partnership to screen possible Covid-19 drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Anti-viral drugs","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Diamond Light Source","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamond Light Source \/ Exscientia","highestDevelopmentStatusID":"1","companyTruncated":"Diamond Li.."},{"orgOrder":0,"company":"Soleo Health","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleo Health Selected by Grifols as Limited Drug Distribution Partner for XEMBIFY\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Immune globulin human-klhw","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Grifols","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Heal.."},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Neuroscience Announces $70 Million Series A Financing to Advance First Autologous Neuron Replacement Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"ANPD001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aspen Neuroscience","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Aspen Neuroscience \/ OrbiMed","highestDevelopmentStatusID":"5","companyTruncated":"Aspen Neur.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Human neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Adaptive Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Biotechnologies \/ Amgen","highestDevelopmentStatusID":"2","companyTruncated":"Adaptive B.."},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":2.2999999999999998,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmac.."},{"orgOrder":0,"company":"Curzion Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$45.0 million","newsHeadline":"Horizon Therapeutics Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"HZN-825","moa":"LyLPAR1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Curzion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curzion Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Curzion Ph.."},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Voltron Therapeutics Enters into Sponsored Research Agreement with The Vaccine & Immunotherapy Center for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaccine and Immunotherapy Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vaccine an.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$54.6 million","upfrontCash":"Undisclosed","newsHeadline":"Dynacure Announces \u20ac50M ($55M) Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series C Financing","leadProduct":"DYN101","moa":"Dynamin 2 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Dynacure \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Savara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Savara Obtains Global Rights to Develop and Commercialize Apulmiq","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Grifols International \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"University of Wisconsin\u2013Madison","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UW\u2013Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CoroFlu vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Wisconsin\u2013Madison","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Wisconsin\u2013Madison \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BCMA antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Kite","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$14.5 million","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Partners with U.S. Government to Expedite Development of Plasma-Derived Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"COVID-Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$165.2 million","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Announces Pricing Of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"RemeGen Completes USD $100 Million Plus in Funding\n","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"BioArdis","sponsor":"Shenogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BIO-1262","moa":"FGFR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BioArdis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArdis \/ Shenogen","highestDevelopmentStatusID":"10","companyTruncated":"BioArdis \/.."},{"orgOrder":0,"company":"XBiotech","sponsor":"BioBridge Global","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Human antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ BioBridge Global","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Oncology Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Kalos's Anti-Cancer Drug in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KTH-222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalos Therapeutics \/ Oncology Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Ther.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":" BARDA","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA, Department Of Defense, And SAb Biotherapeutics To Partner To Develop A Novel COVID-19 Therapeutic\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK and Vir Biotechnology enter collaboration to find coronavirus solutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-viral antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vir Biotechnology","amount2":0.25,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"1","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,538.0 million","upfrontCash":"$38.0 million","newsHeadline":"Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":1.54,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.54,"dosageForm":"","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Gen.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Shenzhen Smoore Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech and Shenzhen Smoore Technology Enter Agreement to Research Utilizing Smoore Inhalation Delivery Device","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aim ImmunoTech \/ Shenzhen Smoore Technology","highestDevelopmentStatusID":"4","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"$6.6 million","newsHeadline":"Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onxeo","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Onxeo \/ Acrotech Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Onxeo \/ Ac.."},{"orgOrder":0,"company":"Suzhou Ribo","sponsor":"Capital Venture Capital Fund ","pharmaFlowCategory":"D","amount":"$66.0 million","upfrontCash":"Undisclosed","newsHeadline":"Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series C Financing","leadProduct":"RB-RQ007","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Suzhou Ribo","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Suzhou Ribo \/ Capital Venture Capital Fund ","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou Rib.."},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$14.5 million","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Announces the National Cancer Institute\u2019s Award of $14.54M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Pa.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"U.S. Food & Drug Administration ","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"$0.5 million","newsHeadline":"Timber Pharmaceuticals Announces Award of Second Tranche of FDA Orphan Products Clinical Trials Grant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ U.S. Food & Drug Administration ","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"PCORI","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"DCRI To Trial Hydroxychloroquine To Prevent Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ PCORI","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clini.."},{"orgOrder":0,"company":"GB Sciences","sponsor":"Wellcana Plus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GB Sciences Completes and Achieves Milestone in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Cannabinoid-containing complex","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GB Sciences \/ Wellcana Plus","highestDevelopmentStatusID":"4","companyTruncated":"GB Science.."},{"orgOrder":0,"company":"GSK","sponsor":"Xiamen Innovax Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK allies with Innovax for COVID-19 vaccine R&D project","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"AS03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Xiamen Innovax Biotech ","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Xiam.."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trovagene Announces Acceptance of P 1b\/2 KRAS-Mutated Metastatic Colorectal Cancer Trial Abstract at the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Regeneron Launch Second Kevzara Trial Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fibroblast cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces First Patient Dosed in Phase 1b\/2 Trial of ZW25","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ZW25","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu)-lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech Announces Results Of Phase 1 Clinical Trial Of Anti-EGFR Monoclonal Antibody Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HLX07","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Pharmaceuticals Delays Recruitment In Donesta Phase III Clinical Programme","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt and Novoteris Receive Clearance from to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I\/II Clinical Study of ONC201 Begins in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to study the effect of interferon beta-1a in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"FINLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Clinical Trial of Tedopi OSE Immunotherapeutics Announces Positive Top-Line Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fda Accepts Mesoblast\u2019s Biologics Licence Application For Ryoncil\u2122 And Agrees To Priority Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento forms alliance for preclinical testing of Covid-19 drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda receives CHMP positive opinion for ADCETRIS in combination with CHP in the treatment large-scale anaplastic lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Announces Two Phase 3 Randomised Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Receives Data Supporting Brilacidin\u2019s Direct Inhibition of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional patients treated in LIDDS clinical study NZ-DTX-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV- Pembrolizumab Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b\/2a Clinical Trial of AB-2004 for Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"APN01","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn seeks approval to trial leronlimab for severe Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genfit says Covid-19 may not significantly delay NASH trial readout","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces the Initiation of ODYSSEY for Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Describes Mechanism of Action for T?4 in Corneal Wound Healing and Regeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces IND and Investigator-Initiated Studies of AT-001 in Critical COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momenta Provides Corporate Update Amid COVID-19 Pandemic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofranergene obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Therapeutics Team Publishes Article On The Positive Clinical Study Results For Ot-101 Against Recalcitrant Resistant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Emergency IND Use of Humanigen's Lenzilumab For Compassionate Use In COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ENU200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ennaid Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ennaid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ennaid The.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma Today Presented Key Preclinical Data on its Novel Cognitive Enhancer at the AAT-AD\/PD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar has submitted a Phase II clinical trial of Aplidin for the treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"eEF1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sialidase L","moa":"Sialic acid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ansun Biopharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biop.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Completes Phase-3 Clinical Study Of A Billion-Dollar Asthma Generic\n","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Fast Track Designation from FDA for Zimura\u00ae for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD\/PD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AADvac1","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection\/Injectable","sponsorNew":"Axon Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuro.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 of coronavirus vaccine human trials may begin in spring, Moderna chairman says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s portfolio company Umecrine Cognition announces results from a phase 2a clinical study of golexanolone","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"resTORbio Announces Delay of its Ongoing Phase 1b\/2a trial of RTB101 ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RTB101","moa":"TORC1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GC007g","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Filing of FDA Pre-IND Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clues to COVID-19 coronavirus\u2019s vulnerability emerge from an antibody against SARS\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation Of Two-Centre Compassionate Study Involving Namilumab In The Treatment Of Rapidly Worsening COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Namilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Izana Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bios.."},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hope Biosciences Receives FDA Approval to Commence First Stem Cell Clinical Trial for Protection Against COVID-19\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Adipose-derived mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hope Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosc.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Rutgers Cancer Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial For Drug Combination To Treat Coronavirus Is Fast-Tracked By Rutgers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved ","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rutgers Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Ca.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRIEF-Synact Pharma Applies For Patent For Ap1189 Within Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AP1189","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SynAct Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SynAct Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SynAct Pha.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Provides COVID-19 Business Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces ASCENT Study to be Stopped for Compelling Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Serlopitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menlo Ther.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Celebrates Migraine PhIII Win, Shifting Eyes Toward A Pair Of Q4 Submissions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"LFB","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LFB Announces FDA Approval of SEVENFACT for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LFB \/ HEMA Biologics","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ HEMA.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"OxThera AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact\u00ae in Patients With Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxalobacter formigenes","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"OxThera AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OxThera AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OxThera AB.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boston Biomedical Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-3654","moa":"PIM kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COM902","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma Presents Data Demonstrating Comparable Pharmacokinetic and Pharmacodynamic Effects of Intranasal Epinephrine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Bryn Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces European Commission Approval of the NUSTENDI Tablet for Hypercholesterolemia and Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Clinical Progress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer\u2019s Trial Screening Data Links High Amyloid Levels With Early Stage Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Solanezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intelgenx Announces Adjusted Versafilm\u00ae Business Strategy, Next Steps For Rizaport\u00ae Versafilm\u00ae Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio Pharma confirms Type B Meeting date with FDA on HCC01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Investigational New Drug Application Amendment for HST 001","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Yiviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Yiviva","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiviva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yiviva \/ N.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated Marzeptacog Alfa","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Positive Results In Dose-Finding Pediatric Study Of Macimorelin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Premas Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Premas Bio.."},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide\r\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Livoletide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Millendo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Millendo T.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-H0731","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Providence Cancer Institute","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Tavokinogene Telseplasmid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Providence Cancer Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Cancer Institute \/ OncoSec","highestDevelopmentStatusID":"6","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Biology to Launch COVID-19 Drug Discovery Platform based on Breakthrough Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Androgens","moa":"TMPRSS2 expression","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan BioScience Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Nolasiban","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Yuyuan BioScience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Y.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Myring\u2122 in Italy, the Third Biggest Worldwide Market","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Farmitalia ","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Acquires Commercial Rights for Oral Contraceptive Zoely \n","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Theramex ","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"TherapeuticsMD ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Afaxys Enter Into Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved ","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Afaxys Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Afaxys Pharma \/ TherapeuticsMD ","highestDevelopmentStatusID":"12","companyTruncated":"Afaxys Pha.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Gets 88% One-Year Response Rate with Relugolix ","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Polysulfated glycosaminoglycan","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Regulatory Submission for Tanezumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Reports Safety Results from KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Symphogen \/ Servier ","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen .."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics, Pharmabcine Partner to Develop & Manufacture PMC-402 Pipeline to Treat Oncology And Neovascular Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"PMC-402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ PharmAbcine ","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Advent Life Sciences","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Amphista Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Advent Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"GAIA Vaccine Foundation","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"EPV-CoV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GAIA Vaccine Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GAIA Vaccine Foundation \/ EpiVax","highestDevelopmentStatusID":"4","companyTruncated":"GAIA Vacci.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Medison","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Cove","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC\u2122 ODT","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cove","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Cove \/ Biohaven","highestDevelopmentStatusID":"12","companyTruncated":"Cove \/ Bio.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.7 million","upfrontCash":"Undisclosed","newsHeadline":"Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Prostate Cancer Clinical Trial Consortium","sponsor":"CellCentric","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellcentric Signs Deal for Clinical Trial Expansion into the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"CCS1477","moa":"p300\/CBP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prostate Cancer Clinical Trial Consortium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prostate Cancer Clinical Trial Consortium \/ CellCentric","highestDevelopmentStatusID":"7","companyTruncated":"Prostate C.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"University of Georgia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Announces R&D Collaboration with the University of Georgia for a Universal Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ University of Georgia","highestDevelopmentStatusID":"1","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Cardiothoracic Surgical Trials Network","sponsor":"Mesoblast","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Partners With The Cardiothoracic Surgical Trials Network","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiothoracic Surgical Trials Network","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiothoracic Surgical Trials Network \/ Mesoblast Limited","highestDevelopmentStatusID":"9","companyTruncated":"Cardiothor.."},{"orgOrder":0,"company":"Celularity","sponsor":"Lung Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Lung Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"EpiVax \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ I.."},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Korean firm invests $2M in SuperTrans Medical","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans.."},{"orgOrder":0,"company":"Infectious Disease Research Institute","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"IBIO-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Infectious Disease Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infectious Disease Research Institute \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Infectious.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"$362.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Inks $362M Deal To Boost Vir's COVID-19 Antibody Output","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Viroclinics Biosciences","sponsor":"University of Queensland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"International Partnership Progresses UQ COVID-19 Vaccine Project","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Viroclinics Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viroclinics Biosciences \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"Viroclinic.."},{"orgOrder":0,"company":"East China Normal University","sponsor":"ImmuneCyte Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ThermoGenesis Announces Its ImmuneCyte Joint Venture Acquires Key Technologies to Develop Therapeutics for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Monoclonal antibody drug conjugates","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"East China Normal University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"East China Normal University \/ ImmuneCyte Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"East China.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo, Mitsubishi UFJ Capital & Nagoya Institute of Technology Collaborate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"GtCCR4","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Seagull Biosolutions","sponsor":"The Union science and technology ministry\n of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Active virosome vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seagull Biosolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seagull Biosolutions \/ The Union science and technology ministry\n of India","highestDevelopmentStatusID":"1","companyTruncated":"Seagull Bi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$30.0 million","newsHeadline":"Zai Lab Targets Blood Cancers In Deal With Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"REGN1979","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly Begins Clinical Testing of Therapies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Macromoltek","sponsor":"Cytovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics and Macromoltek to Develop Dual-Acting Natural Killer Immunotherapy Against SARS Cov2 (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Natural killer immunotherapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macromoltek","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Macromoltek \/ Cytovia","highestDevelopmentStatusID":"1","companyTruncated":"Macromolte.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ CSL Behring","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"University of Illinois","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals Inc. and The University of Illinois Announce Partnership to Identify Novel Antivirals Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antiviral drugs","moa":"Cathepsin-L","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Illinois","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Illinois \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Increases Focus on Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Biopharma Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Grants Merck Patent For CRISPR-Chrom Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Lamellar Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lamellasome COVID-19 therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lamellar Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lamellar Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lamellar B.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200 ","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-200","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupus Therapeutics Developing a Study Focused On Lupus Patients And COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Ther.."},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Pyruvate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EmphyCorp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"EmphyCorp .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Approval for the Phase Ib\/II Clinical Study of Bcl-2 Inhibitor APG-2575","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Completes Rolling Submission of New Drug Application to the U.S.FDA and Submits Marketing Authorization Application","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous adipose-derived regenerative cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Provides Update on Development Projects CAN04 and CAN10","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading BioSciences Sees Potential for Its Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Operational and Financial Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Pipeline Progress Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BT1718","moa":"MMP-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Update in Response to COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of PBCAR20A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer\u2019s and Parkinson\u2019s Therapies AAT-AD\/PD\u2122 Focus Meeting 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FS120","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves BRAFTOVI in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LUNAR-COV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma Files First Investigational New Drug Application with The U.S. FDA for Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"K-NK002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial of Hydroxychloroquine, a Potential Therapy For COVID-19, Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Provides an Update on Oral Paclitaxel FDA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Provides Statement Regarding COVID-19 Pandemic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Advances Battle Against Covid-19 On Multiple Fronts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm Announces the Start of a Phase II Clinical Trial of its Influenza Antiviral Drug \"Avigan\u00ae Tablet\" for COVID-19 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"University of Utah Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Utah Health and Intermountain Healthcare Launch Two COVID-19 Clinical Trials to Test Effectiveness of Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Utah Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Utah Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Commences Next Phase of VNLG-152 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Axon Neuroscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axon Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axon Neuro.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo Plus Yervoy\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FirstWave Bio to Initiate Phase 2a\/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Highlights Positive Impacts of Centhaquine on COVID-19 Patients.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Galidesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"EicOsis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EC5026","moa":"sEH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EicOsis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ .."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PHA121 Shows Clinically Relevant Activity in a Translational in Vivo Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Business Update Related to COVID-19 Pandemic","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 \u201cHELP Study\u201d of Levosimendan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of the American Academy of Neurology Publishes ProMIS Neurosciences\u2019 Abstracts on Novel Antibody Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chromocell Makes Chromovert Technology and Novel Compounds Available to Support COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ENaC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1\/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Acceptance of XOSPATA\u00ae (gilteritinib) for Regulatory Review in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Updates Corporate Progress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinciguat","moa":"sGC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MAP2K1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Starts Ph III Trial of Actemra for COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Sesderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesderma Labs Produces Lactyferrin to Counter the COVID-19 Strain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Genistein","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sesderma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesderma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sesderma \/.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes to Collect COVID-19 Patient Plasma, Research Antibodies Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasma therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Phase III ADAURA Trial will be Unblinded Early After Overwhelming Efficacy in the Adjuvant Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Swissx Labs AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissx Labs Calls for Trials of Anti-Viral Naja Venom Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Naja Venom","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Swissx Labs AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Swissx Labs AG \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Swissx Lab.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell to Present TruUCAR\u2122 GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GC027","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Announces Closing of Enrollment in its Phase 1b\/2a NASH Trial ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"ProLynx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidivarin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EIDD-2801","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Independent Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARV-110","moa":"Androgen receptor degradation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Biology to License Intellectual Property Rights to a Novel Cannabinoid Based Therapy Under Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ATG-019","moa":"PAK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Bcl-2 antisense oligonucleotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"Siglec-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Receives IND Approval for its HIV Drug ASC09F","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC09","moa":"HIV protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"HBG 1\/2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Kerecis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Evaluating Kerecis Omega3 Viruxide Spray for the Treatment of COVID-19 Patient\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ICELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega3 Viruxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerecis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kerecis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerecis \/ .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Joins Battle Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Coronavirus Vaccine Designed to Meet a Global Demand\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Coravax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Thomas Jefferson University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thomas Jefferson University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Thomas Jef.."},{"orgOrder":0,"company":"Fiocruz research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fiocruz Investigates the Action of Anti-Retrovirals Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BRAZIL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atazanavir","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fiocruz research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fiocruz research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fiocruz re.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 \n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse\u00ae Inhaled Nitric Oxide Therapy\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Antiviral Drug Heading Into Clinical Trials Offers Hope For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EIDD-2801","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Investigating Potential COVID-19 Treatment\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Ossianix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ossianix is Responding to the COVID-19 Pandemic by Developing Therapeutic Single Domain VNAR Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VNAR antibodies","moa":"Transferrin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ossianix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tarveda Therapeutics Provides Update on Proposed Merger with Organovo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Locnartecan","moa":"Topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Organovo","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Griffith University","sponsor":"Indian Immunologicals Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"India, Australia Partner to Develop Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Live Attenuated SARS \u2013 CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Griffith University \/ Indian Immunologicals Limited","highestDevelopmentStatusID":"1","companyTruncated":"Griffith U.."},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Montreal Heart Institute (MHI) Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NYU Grossman School of Medicine Partners with Montreal Heart Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NYU Grossman School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Grossman School of Medicine \/ Montreal Heart Institute (MHI) Research Center","highestDevelopmentStatusID":"10","companyTruncated":"NYU Grossm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Circassia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Circassia To Terminate AstraZeneca Deal And Transfer Assets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol Powder","sponsorNew":"AstraZeneca \/ Circassia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Abandons Deal for Takeda's Tachosil Surgical Patch","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Human fibrinogen","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.40000000000000002,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Morningside Venture","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Termination","leadProduct":"RX-5902","moa":"Phosphorylated-p68","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Rexahn Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Sets Back Review Date for Roche\u2019s SMA Drug by 3 Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s UQ Covid-19 Vaccine Candidate Advances to Preclinical Tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Begins Efforts to Identify Antibodies Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Antibodies that Modulate TGF-\u03b2 Activation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-181","moa":"TGF-beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Academia Sinica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan\u2019s Academia Sinica Finds Powerful Inhibitor to Fight Wuhan Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Academia Sinica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Academia Sinica \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Academia S.."},{"orgOrder":0,"company":"Shanghai Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese Scientists Determine COVID-19 Protease Structure for Quickened Drug Identification","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shanghai Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shanghai I.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Fast-Tracks Phase 1 Testing of Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation Board","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene\u2019s Tislelizumab gets Chinese Approval to Treat Locally Advanced\/metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Investigational New Drug Application For Mesoblast To Use Remestemcel-L In Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Ziphius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziphius Therapeutics Announces Acceleration of mRNA Based Vaccine Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ZIP-1642","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ziphius Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ziphius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ziphius Th.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$682.5 million","upfrontCash":"$100.0 million","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ME-401","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"S-protein COVID-19 antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"HaNK","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Institut Pasteur Korea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Launches COVID-19 Program in Collaboration With Institut Pasteur Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Union Therapeutics \/ Institut Pasteur Korea","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Tamir Biotechnology","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Ranpirnase","moa":"tRNA hydrolytic enzyme","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Tamir Biotechnology","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Tamir Biotechnology \/ Orgenesis","highestDevelopmentStatusID":"7","companyTruncated":"Tamir Biot.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gates, GV Chip into $45M Round for CNS biotech Cerevance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CVN424","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Anti-viral drugs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ AIkido Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Applied BioMath","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath Announces Collaboration with OncoMyx Therapeutics for Systems Pharmacology Modeling in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Myxoma virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied BioMath \/ OncoMyx Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galapagos and Ryvu Announce Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"POLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Galapagos NV","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Athersys","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$50.1 million","upfrontCash":"Undisclosed","newsHeadline":"Athersys Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"MultiStem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Athersys \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"1","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Halix BV","sponsor":"University\u2019s Jenner Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HALIX Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Halix BV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ University\u2019s Jenner Institute","highestDevelopmentStatusID":"7","companyTruncated":"Halix BV \/.."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ginkgo Bioworks","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ginkgo Bioworks \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Ori Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ori Biotech, Achilles Therapeutics Partner to Test Novel Cell Therapy Manufacturing Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Tumour-derived T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Therapeutics \/ Ori Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jenner Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Jenner Institute","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$40.0 million","newsHeadline":"LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FB825","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0.56999999999999995,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Intravenous Infusion","sponsorNew":"Oneness Biotech \/ LEO Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Bi.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck, Samsung Join Newly Crowded Market for Herceptin Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"University of Ottawa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ University of Ottawa","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FairJourney Biologics and Iontas Announce Partnership in Search for SARS-CoV-2 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Iontas \/ F.."},{"orgOrder":0,"company":"Northwell Health","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia\n","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Northwell Health \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Northwell .."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pulmatrix and Sensory Cloud Announce Partnership to Develop Potential Nasal Prophylactic and Anticontagion Product for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters into Partnership with Medison Pharma to Distribute NURTEC\u2122 ODT In Israel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Advances Therapeutic for COVID-19 in Partnership with Department of Defense and BARDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","amount":"$407.3 million","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"VAP-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leo Pharma \/ Kubota Vision Inc","highestDevelopmentStatusID":"2","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 Mutant KRAS Targeting Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National C.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Sinovac Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Soligenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CoVaccine HT","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BTG Specialty Pharmaceuticals \/ Soligenix","highestDevelopmentStatusID":"1","companyTruncated":"BTG Specia.."},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$139.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Closing of $139.4 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.14000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"NB-01","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Dilafor AB","sponsor":"Liverpool University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dilafor Initiates Collaboration with Liverpool University to Study the Effect of Tafoxiparin on SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Tafoxiparin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dilafor AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dilafor AB \/ Liverpool University","highestDevelopmentStatusID":"4","companyTruncated":"Dilafor AB.."},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"V-Capital","pharmaFlowCategory":"D","amount":"$25.4 million","upfrontCash":"Undisclosed","newsHeadline":"V-Capital Leads $25M New Round In Ocular Drug Developer Cloudbreak Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CBT-001","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Cloudbreak Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Cloudbreak Therapeutics \/ V-Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cloudbreak.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clinical Stage Oncology Biotech Lantern Pharma Files for a $29 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Irofulven","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$483.0 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA Promises $483M to Shepherd COVID-19 Vaccine To Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Edesa Biotech","pharmaFlowCategory":"D","amount":"$372.0 million","upfrontCash":"Undisclosed","newsHeadline":"Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NI-0101","moa":"TLR4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Light Chain Bioscience","amount2":0.37,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.37,"dosageForm":"","sponsorNew":"Light Chain Bioscience \/ Edesa Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Light Chai.."},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CB Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"1","companyTruncated":"CB Therape.."},{"orgOrder":0,"company":"OntoChem","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antiviral drugs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OntoChem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OntoChem \/ Anixa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"OntoChem \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Cue Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Kitov Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho Co, Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$6.4 million","newsHeadline":"Biofrontera AG Enters Into Exclusive License Agreement with Maruho Co., Ltd.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho Co, Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Biotech ORIC Pharmaceuticals Sets Terms for $75 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Bell Potter Securities","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paradigm Biopharmaceuticals has Significant Clarity on Development Pathway for Zilusol","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Pentosan Polysulfate Sodium","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Paradigm Biopharmaceuticals \/ Bell Potter Securities","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerus Expands BARDA Funding by Additional $14M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Intercept treated Red Blood Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corp.."},{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Delpharm Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Delpharm Group \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Delpharm G.."},{"orgOrder":0,"company":"SIRS Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIRS Therapeutics to Develop FX06 for Treatment Of ARDS in COVID-19 Patients in Collaboration with F4 Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"FX06","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIRS Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIRS Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"1","companyTruncated":"SIRS Thera.."},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody recruiting molecule","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Green Cross Lab Cell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Green Cross Lab Cell \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Green Cros.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zegocractin","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Data Shows Improvement In Covid-19 With Redhill\u2019s Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Begins Clinical Study in Canada Evaluating Virazole in Combo with Standard of Care Therapy for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribavirin","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiverse Investment Fund Announces Portfolio Company\u2019s Commencement of Clinical Trials to Treat ARDS Caused by Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic umbilical cord-derived mesenchymal stromal cell","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Orbsen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orbsen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orbsen The.."},{"orgOrder":0,"company":"Ligandal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligandal Proposes \u2018Antidote\u2019 to COVID-19 Using Robot-like Peptide Scaffolds\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligandal","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ligandal \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ligandal \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Initiates CALAVI Clinical Trial With Calquence Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"MLL1-Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Reports Promising Progress in Phase I\/lla Trial of Lead Program BI-1206 in Combination with Rituximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RBN-2397","moa":"PARP7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON to Present Latest Clinical Data From the NOX-A12 \/ Keytruda\u00ae Combination Trial in Colorectal and Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 for the Treatment of Duchenne and Becker Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Epirium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Epirium \/ .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-629","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grid Therapeutics Announces FDA Approval of IND Application for GT103","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GT103","moa":"CFH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Thera.."},{"orgOrder":0,"company":"LifeMax Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LifeMax Receives Fast Track Designation For LM-030 for the Treatment of Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LM-030","moa":"KLK7\/ELA2","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LifeMax Laboratories","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"LifeMax Laboratories \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"LifeMax La.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1893","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"KD Pharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"KD Pharma Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KD Pharma Group \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"KD Pharma .."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MBT2","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of Cgvhd","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin alpha4\/beta1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Gets FDA Approval to Study Multistem Therapy for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Healios K.K","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HLCM051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Healios K..."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Submits New Drug Application for E4\/DRSP to the FDA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to RemeGen's Telitacicept as a Treatment for Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Synthon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthon Biopharmaceuticals Relaunches as Byondis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"(vic-) trastuzumab duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Synthon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synthon Ph.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Receives FDA Orphan Drug Designation for FT-4202 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AG013","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Mouth Rinse","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA Ships COVID-19 LinearDNA\u2122 Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Clinical Trial of HBM916","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Drug Designation for TransCon\u2122 hGH as Treatment for Growth Hormone Deficiency in the US","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Advances Cell Line Development for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1\/2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Initiation of Humanigen\u2019s Phase III Study of Lenzilumab in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PPP003","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion Highlights Potential Role Of Inflammatory Lipid Modulator Prostaglandin E2 In COVID-19 Disease And Proposes Potential Treatment Pathway With Sonlicromanol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Leronlimab in Phase 2b\/3 Trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ansun Biopharma Enrolls First Patient in Proof of Concept Trial of DAS181 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sialidase L","moa":"Sialic acid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biop.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SMC Accepts Janssen\u2019s Ulcerative Colitis Drug Stelara for NHS Use","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"Il-12","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax\u2122\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Announces PV-10\u00ae Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterin to Conduct a Randomized Phase 1\/2a Study in Hospitalized Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COV-ENT-1","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterin \/ .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Initiation of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi\u00ae) as a Treatment for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Launching Brukinsa Trial In Later-Stage COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Present Phase 2 Detailed Results of its Brain-Penetrant BTK Inhibitor in Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MD Anderson Research Freeze Stops Production of Bellicum Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"18-Methoxycoronaridine","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"TissueTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. Food and Drug Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TTAX02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"TissueTech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TissueTech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"TissueTech.."},{"orgOrder":0,"company":"SciTech Development","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciTech Development, LLC Submits COVID-19 Treatment with Proven Antiviral Activity to U.S. Health & Human Services (HHS)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SciTech Development","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SciTech De.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphamab Oncology Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN-EB3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FS118","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Laboratory Test Results of RYANODEX Against Coronavirus SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med's Surufatinib Bags US Fast Track Designations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma to Develop COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Astodrimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus On Go to Start U.S. Studies of CAR T Candidate for ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO1","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New COVID-19 Clinical Trial Supported by Octapharma USA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH AFRICA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Initiates Project to Test RT001 in an Animal Model of Lung Damage to Protect Against COVID-19 Impact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RT001","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"Ionising radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Receives its 4th FDA Orphan Drug Designation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari\u00ae Priority Review Request","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1\/2A Study of AFM24","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Preps Phase 3 Study of Ultomiris in Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS' Opdivo-Yervoy Combo Helps Mesothelioma Patients Live Longer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Lands PhIII Kidney Cancer Win With Bristol Myers in Their Hunt For $4 Billion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"University of Southampton","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Researchers to Trial Covid-19 Vaccine and Plasma Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Southampton","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Southampton \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from FDA for Initiating Clinical Trials for its Novel Monoclonal Antibody TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Anti-Cancer Microbiome Therapeutic Receives FDA IND Clearance in Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genome & Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NW Bio to Discuss Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia's Rival to Merck's Insomnia Drug Clears Phase 3 Test","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Announces Clearance of IND to Initiate Phase I\/II Study for First-in-Class PRGN-2009 AdenoVerse\u2122 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY 1905254","moa":"ILDR2 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Updates Clinical Development and Operations Activities During the COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Begins Phase II COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx-4DP0004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology to Discuss Clinical Data from Investigator-initiated RAF\/MEK and FAK Combination Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First COVID-19 Patient Treated Using Stemedica Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ischemic-tolerant mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemedica Cell Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Stemedica .."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon\u2122 PTH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis and Partner Announce Enrollment Completion of Global Phase 3 GENERATION HD1 Study for Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tominersen","moa":"HTT protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoldenBiotech Antroquinonol Selected as Potential Drug in Global Solicitation of Covid-19 Pneumonia Treament Projects\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"Nrf -2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"Yale University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"$100,000 Gift Speeds Exploration of Sobetirome as COVID-19 Treatment\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sobetirome","moa":"TRb1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Yale University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yale University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yale Unive.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces Coronavirus Vaccine Program\nTargeting At-Risk Elderly ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Alpha4Beta1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA and EMA Accept Applications for Roche\u2019s OCREVUS (Ocrelizumab) shorter 2-hour infusion time","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Porton Biopharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Biopharma Limited Licenses Erwinase\u00ae to Clinigen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Porton Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Solution","sponsorNew":"Porton Biopharma \/ Clinigen","highestDevelopmentStatusID":"12","companyTruncated":"Porton Bio.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce, a California Based Biotech Company With a Mission to Solve the Opioid Crisis, Exploring a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Upamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ NIAID","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio Gets Grant to Partner with IVI and KNIH for Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$190.0 million","newsHeadline":"Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RNA targeted small molecule","moa":"RNA","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Arrakis Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Arrakis Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Arrakis Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"FSIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI\u00ae and SYMDEKO\u00ae for Eligible Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Lumacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ FSIO","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo taps Mogrify for off-the-shelf CAR-Treg project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CAR-Treg cell therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mogrify \/ Sangamo","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ .."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antigen peptides","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Targovax ","highestDevelopmentStatusID":"1","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Liechti Laboratory","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed in Collaboration with Liechti Laboratory Develops LSD Neutralizer Technology to Shorten and Stop LSD Trips\n","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Liechti Laboratory","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Liechti Laboratory \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Liechti La.."},{"orgOrder":0,"company":"Ewha Womans University ","sponsor":"SOM Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOM Biotech Announces the In Vitro Confirmation of Three Drug Candidates for COVID-19 in Collaboration with the Ewha Womans University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ewha Womans University ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ewha Womans University \/ SOM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Ewha Woman.."},{"orgOrder":0,"company":"Linical","sponsor":"Alpha Cognition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linical and Alpha Cognition Announce Strategic Partnership to Position Alpha-1062 for Approval in the U.S and Japan Alzheimer's Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Alpha-1062","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Linical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linical \/ Alpha Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Linical \/ .."},{"orgOrder":0,"company":"MigVax","sponsor":"OurCrowd ","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Financing","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MigVax \/ OurCrowd ","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ O.."},{"orgOrder":0,"company":"oNKo-innate","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"oNKo-innate","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"oNKo-innate \/ Gilead","highestDevelopmentStatusID":"2","companyTruncated":"oNKo-innat.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Children\u2019s Research Holdings","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReAlta Life Sciences Closes $14 Million Series A2 Financing to Support Transition into a Clinical Organization","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"RLS-0071","moa":"Complement","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Children\u2019s Research Holdings","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viravaxx AG, Medical University of Vienna launch project for an integrated platform for immune diagnosis and vaccination for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical Un.."},{"orgOrder":0,"company":"Pathogen and Microbiome Institute ","sponsor":"Oncology Venture","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture to Test Activity of Its PARP Inhibitor, 2X-121, as a Potential Therapy for Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Stenoparib","moa":"PARP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pathogen and Microbiome Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pathogen and Microbiome Institute \/ Oncology Venture","highestDevelopmentStatusID":"4","companyTruncated":"Pathogen a.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"$698.0 million","upfrontCash":"$20.0 million","newsHeadline":"Oasmia Receives Upfront Payment of 20 M USD from Elevar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Memgen","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MEM-288","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memgen \/ Moffitt Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memgen \/ M.."},{"orgOrder":0,"company":"Population Health Research Institute ","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Population Health Research Institute \/ Bayer ","highestDevelopmentStatusID":"10","companyTruncated":"Population.."},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"$25.0 million","newsHeadline":"Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NV-5138","moa":"mTORC1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Navitor Pharmaceuticals","amount2":0.47999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Oral","sponsorNew":"Navitor Pharmaceuticals \/ Supernus","highestDevelopmentStatusID":"6","companyTruncated":"Navitor Ph.."},{"orgOrder":0,"company":"Bugworks","sponsor":"University of Tokyo Edge Capital","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bugworks Raises US$7.5M From a Global Investment Syndicate to Combat the Global Challenge Posed by Deadly Bacterial Superbugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"GYROX-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Bugworks \/ University of Tokyo Edge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/.."},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Ablexis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 S1 antibodies","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Berkeley Lights","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Berkeley Lights \/ Ablexis","highestDevelopmentStatusID":"4","companyTruncated":"Berkeley L.."},{"orgOrder":0,"company":"Cara Care","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cara Care Announces Collaboration With Consumer Healthcare Business Unit of Sanofi Germany for Digestive Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Hyoscine Butyl Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cara Care","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cara Care \/ Sanofi ","highestDevelopmentStatusID":"12","companyTruncated":"Cara Care .."},{"orgOrder":0,"company":"QIMR Berghofer Medical Research Institute","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute ink License Agreement on Novel Bispecific Target Combinations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"EMB-01","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"QIMR Berghofer Medical Research Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QIMR Berghofer Medical Research Institute \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"QIMR Bergh.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$27.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices to Adapt Veroplex\u00ae Cell Platform for Rapid Response to Viral Threats for Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"OncoQuest","sponsor":"Dual Industrial","pharmaFlowCategory":"D","amount":"$375 million","upfrontCash":"Undisclosed","newsHeadline":"Dual Industrial to Buy OncoQuest's immunotherapy Drug Portfolio and Commit to fund Oregovomab Phase 3 Clinical Trial ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Oregovomab","moa":"Mucin-16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"OncoQuest \/ Dual Industrial","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest .."},{"orgOrder":0,"company":"Affinivax","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"MAPS Pneumococcal vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Affinivax","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Affinivax \/ Viking Global Investors","highestDevelopmentStatusID":"8","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"BrainVectis","sponsor":"AskBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"BV-CYP01","moa":"CYP46A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BrainVectis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BrainVectis \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"BrainVecti.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bio Launches Stock Purchase Agreement for $15M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Intravaginal","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"CMIC Holdings","sponsor":"FUJIFILM Toyama Chemical ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMIC Group Supports Clinical Trials and Manufacturing of Influenza Antiviral Drug \u201cAvigan\u00ae Tablet\u201d ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CMIC Holdings","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CMIC Holdings \/ FUJIFILM Toyama Chemical ","highestDevelopmentStatusID":"10","companyTruncated":"CMIC Holdi.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"TLR9","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Valneva SE","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI\u2122 (eptinezumab-jjmr) ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Orsini Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"University Hospital Institute ","sponsor":"Pharnext","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharnext, UHI to Evaluate Repurposed Drugs Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University Hospital Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Institute \/ Pharnext","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"ProThera Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProThera Biologics and Takeda Enter Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Plasma-derived Inter-alpha Inhibitor Proteins therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ProThera Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProThera Biologics \/ Takeda ","highestDevelopmentStatusID":"4","companyTruncated":"ProThera B.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Altium Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $15 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Altium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"HLB","pharmaFlowCategory":"D","amount":"$61.3 million","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics Announces Close of $61.3M Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Dendritic cell vaccine therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ HLB","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$15.4 Million","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Secures Financing of up to \u20ac 14.2 Million Through Convertible Bonds From Atlas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Emapticap pegol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"TME Pharma \/ Atlas Special Opportunities","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"EcoR1 Capital ","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Accent Therapeutics nabs $63M for RNA cancer push","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"METTL3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Accent Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ EcoR1 Capital ","highestDevelopmentStatusID":"1","companyTruncated":"Accent The.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","amount":"$11.0 million ","upfrontCash":"$10.0 million","newsHeadline":"Menlo Therapeutics and Cutia Therapeutics ink License Agreement for AMZEEQ\u2122 and Approved Topical Minocycline Products in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Foamix Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Foamix Pha.."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hansoh Pharma and NiKang Therapeutics Enter into a Partnership for a Novel Treatment for Anti-Viral Diseases in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NKT-1992","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ Jiangsu Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORIC pulls off $120M Wall Street debut, eclipsing $86M goal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Senhwa Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Senhwa Biosciences, NIH to develop COVID-19 drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Senhwa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Rasna Therapeutics","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"$0.1 million","newsHeadline":"Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D from Rasna Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Dactinomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rasna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rasna Therapeutics \/ Tiziana Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rasna Ther.."},{"orgOrder":0,"company":"Akshaya Bio","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovance Biologics and Akshaya Bio Collaborate to Develop Therapeutics for Treatment of Coronavirus and Hepatitis B Virus Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Akshaya Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akshaya Bio \/ Cytovance Biologics ","highestDevelopmentStatusID":"6","companyTruncated":"Akshaya Bi.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$31.6 million","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals Closes of $31.6 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Apamistamab-I-131","moa":"BC8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"State of North Dakota ","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise Awarded Grant Focused on Coronavirus and Other Emerging Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Monocloncal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ State of North Dakota ","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRACON Retains Global Rights to TRC253 Following Completion of a Phase 1\/2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TRC253","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Johnson & Johnson Innovative Medicine \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ReiThera","sponsor":"Univercells","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Adenoviral vector-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"The University of Dundee","sponsor":"Insmed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brensocatib to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Brensocatib","moa":"DPP-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Dundee","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The University of Dundee \/ Insmed Incorporated ","highestDevelopmentStatusID":"1","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Institute for Systems Biology","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck joins Seattle Effort to Uncover COVID-19's Molecular Works","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute for Systems Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institute for Systems Biology \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rome Therapeutics debuts with $50M and Rosana Kapeller as CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Rome Thera.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$100.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Aeglea BioTherapeutics Announces Proposed Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","amount":"$35.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Announces Proposed Public Offering Of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Polyclonal IgG Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 polyclonal immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Kedrion Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kamada \/ K.."},{"orgOrder":0,"company":"Crestone","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crestone, Inc. Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to Treat H. pylori Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"CRS3123","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crestone \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"CSHL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Lonodelestat","moa":"Human neutrophil elastase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ CSHL","highestDevelopmentStatusID":"1","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Secures up to $25 Million in Convertible Note Financing","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Genpharm Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC\u2122 ODT in the Middle East","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Genpharm Services","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Lausanne University Hospital","sponsor":"Prokarium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prokarium Signs an Exclusive Option Agreement with the Lausanne University Hospital for the Treatment of Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Salmonella Typhi Ty21a","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lausanne University Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Lausanne University Hospital \/ Prokarium","highestDevelopmentStatusID":"4","companyTruncated":"Lausanne U.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Closes $2.0 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VBI Vaccines","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"10","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Imperial College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechn & Imperial College London collaborate to produce saRNA for COVID-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Self-amplifying RNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TriLink BioTechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"TriLink Bi.."},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$34.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim VC backs Actym Therapeutics for $34 million Series A Financing ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Salmonella Typhimurium Attenuated Cancer Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Actym Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Actym Ther.."},{"orgOrder":0,"company":"NYC Health + Hospitals\/Metropolitan","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atossa Therapeutics Contracts with NYC Health + Hospitals\/Metropolitan for COVID-19 HOPE Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYC Health + Hospitals\/Metropolitan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NYC Health + Hospitals\/Metropolitan \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NYC Health.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Announces COVID-19 Vaccine Development Partnership With Clover Biopharmaceuticals\u2019 Australian Subsidiary","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 S-Trimer","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pha.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Vocimagene amiretrorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epivax and Entos Pharmaceuticals to develop DNA-based vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Fusogenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ E.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"GARDP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Cefepime","moa":"Peptidoglycan synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"VenatoRx Pharmaceuticals \/ GARDP","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"4","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$530.0 million ","upfrontCash":"$300.0 million","newsHeadline":"Supernus to Acquire CNS Portfolio from US WorldMeds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"US WorldMeds","amount2":0.53000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CAD-9303","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.040000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"resTORbio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ resTORbio","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Taps Almac in Neurodegenerative Drug Discovery Deal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"DUBs","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune\u00ae-Based Anti-Cancer Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"PDS0103","moa":"Mucin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ PDS Biotechnology Corporation","highestDevelopmentStatusID":"4","companyTruncated":"National C.."},{"orgOrder":0,"company":"Atreca","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"IgM antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ B.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$101.3 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$308.0 million","upfrontCash":"$130.0 million","newsHeadline":"Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"VLA15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.31,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"BioAge Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho\u2019s Phase 1 HIF-PH Inhibitor to Treat Aging","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BGE-117","moa":"HIF-PHI","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taisho Pharmaceutical \/ BioAge Labs","highestDevelopmentStatusID":"6","companyTruncated":"Taisho Pha.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.1 million","newsHeadline":"PharmaMar Inks Pact with Immedica Pharma to market lurbinectedin in Eastern Europe and Other Territories ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Immedica Pharma AB","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Trio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"TRIObody drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Trio Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"CTGF","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Bixink Therapeutics","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX\u00ae (neratinib) in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Bixink Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Prometrika","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometrika and Karyopharm Partner in Global COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Prometrika","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prometrika \/ Karyopharm","highestDevelopmentStatusID":"8","companyTruncated":"Prometrika.."},{"orgOrder":0,"company":"Wistar Institute","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wistar and Batavia Collaborate to Manufacture Rubella Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"RA 27\/3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Wistar Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wistar Institute \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Wistar Ins.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaccitech and Oxford University Enter Partnership with AstraZeneca To develop and Distribute COVID-19 vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Vaccitech","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mallinckrodt to Fund Nitric Oxide Therapy Trial in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Massachusetts General Hospital \/ Mallinckrodt","highestDevelopmentStatusID":"1","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"$3.0 million","newsHeadline":"Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Mycenax Biotech","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"Mycenax Biotech \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Mycenax Bi.."},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovate Biopharmaceuticals and RDD Pharma Merge to Form 9 Meters Biopharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate B.."},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclacel Pharmaceuticals Inks Collaboration With University of Edinburgh to Study CDK Inhibitors in COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Expands Existing License Agreement with Luxna Biotech Inc ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antisense oligonucleotide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Aligos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biot.."},{"orgOrder":0,"company":"University of Maryland","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antiviral drugs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Maryland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Maryland \/ AIkido Pharma","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Xortx Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus \/ COVID-19 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ XORTX Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch + Lomb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE\u2122 Commercial Partnership with Bausch Health","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Bausch + Lomb","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Sino Biological","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax and Sino Biological Establish Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant proteins","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sino Biological","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sino Biological \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"Sino Biolo.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"The Department of Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ The Department of Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Georgia\u2019s Covid-19 vaccine shows promise in test models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"Viral spike glycoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Another PhIII win in hand, Cara aims straight for priority review of 'breakthrough' pruritus drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces First Patient Dosed in Phase 1b\/2a Study of Anti-FcRn Batoclimab to Treat Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Circularity Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New COVID-19 Clinical Trial Announced To Treat over 90% Of Patients With Underlying Medical Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Deoxyhemoglobin vasodilator","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Circularity Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Circularity Healthcare \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Circularit.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Anandamide","moa":"Complement C3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals Announces US FDA Grants 67Cu-SARTATE\u2122 Orphan Drug Designation for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"67Cu-Sartate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioG.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NB-02","moa":"AChE","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Announces Results from Three Analyses of Hizentra\u00ae in Primary Immunodeficiency (PI)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Locnartecan","moa":"HSP90","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity of a Potent and Selective Inhibitor of CBP\/p300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-6876","moa":"CBP\/p300","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scynexis' New Antifungal Delivers in Yeast Infection Phase 3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-7110","moa":"TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel Lupus Drug Leads","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TXR-711","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asarina Pharma Reports Topline Results from Phase Iib Study in PMDD","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Ph.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic's IMU-838 Demonstrate Preclinical Activity Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial to Treat Patients with Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Marrow-Infiltrating lymphocytes","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WindMIL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Th.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Submits New Drug Application to the FDA for Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Phase 1\/2b Study of ARQ-252 in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcinonacog alfa","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Reports Encouraging Results from Use of RUCONEST\u00ae in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Conestat alfa","moa":"C1 esterase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acquist Therapeutics Expands Patent Portfolio for Novel Small Molecules, Receives Fourth U.S. Composition Patent","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ACQT1127","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Acquist Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acquist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Acquist Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kymriah\u00ae Receives FDA Regenerative Medicine Advanced Therapy Designation in Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Data Showing Jakavi\u00ae (Ruxolitinib) More Effective Than Best Available Therapy in Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data in Hand, Ono\/Takeda to Seek 1st-Line RCC Nod for Opdivo\/Cabometyx Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"AntiCancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AntiCancer Inc. Establishes Subsidiary CoronaCure to Develop Its Novel Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Methioninase","moa":"Methionine","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Tot Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Tot Biopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tot Biopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tot Biopha.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Provides Update on its Antibody Therapy for COVID-19 and also Human Brain Cancer Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nascent Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b\/3 Multinational Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Thera.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Gains Accelerated US Approval for Trodelvy in Previously-Treated Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Presents New Data from the GARNET Study Revealing Potential of Dostarlimab to Treat Recurrent or Advanced Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Agastiya Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agastiya Biotech Proceeding with Drug Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB001","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Agastiya Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agastiya Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Agastiya B.."},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarck Announces, Phase 2a Clinical Trial Results of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO-11006","moa":"MARCKS protein","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Acquist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Th.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Highlight Clinical Data on Vitrakvi\u00ae (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY2416964","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Trial of Metablok to Stop Lung and Kidney Inflammation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS119","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Publication Evaluating Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial of CPI-613\u00ae ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX\u00ae2-73 (blarcamesine) in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Presentation of New Phase IIIb ANJESO\u2122 Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Publication of Comprehensive Review of Oliceridine Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"University Hospitals Geneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swiss Hospitals Launch Drug Trial to Prevent Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospitals Geneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University Hospitals Geneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals\u2019 Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Lynparza shows further promise in prostate cancer study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane\u00ae (Ranibizumab) Biosimilar Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Xbrane Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Bio.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics, Voltron Therapeutics & HaloVax Announce Selection of First of Virus Targeting Peptides in Development of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Self-Assembling Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Three New Phexxi\u2122 or Presentation at 2020 ACOG","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Announces That Data Safety Monitoring Board Validates NOX-A12 Dose Escalation in Phase 1\/2 Brain Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from the Second Phase III SAkuraStar Study for Chugai\u2019s Satralizumab in Neuromyelitis Optica Spectrum Disorder ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Initiate ESCAPE, Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharma receives South Korean regulatory approval to begin phase 2 COVID-19 study of Ifenprodil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Tecentriq, on top of targeted drugs, stalls melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MD Anderson and Ipsen Advance New Therapy with Potential Benefit for Underserved Patients with Lung and Ovarian Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IPN60090","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Pads Case for Convenient Keytruda Dosing with New Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Pits Fast-Rising Farxiga Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"NEC Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEC Publishes Design Blueprints for SARS-Cov-2 Vaccines Using its Artificial Intelligence Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NEC Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NEC Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NEC Corpor.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi, Regeneron Tout Libtayo's First Lung Cancer Win","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Syndax data broach 'undruggable' leukemia mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"MLL1-Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Green Valley to Start US Trials of Algae-Based Alzheimer\u2019s Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium oligomannate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Green Valley Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Green Vall.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tecentriq\/Xtandi Combo Fails to Show OS Benefit, Halting Roche's PD-L1 Push into Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202\/MOR202 in r\/r Multiple Myeloma in Mainland China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Phosphate","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Th.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 ","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin peptide conjugate","moa":"Sortilin receptor 1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301 for Post-Operative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Funapide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat ARDS in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Romark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romark Initiates Phase 3 Clinical Trials Of NT-300 For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Romark \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ N.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-104","moa":"Liver X receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biopharma Starts Clinical Trials on Possible Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"High affinity immunoglobulin gamma Fc receptor I","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Biopharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Biopharma .."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medici.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE\u00ae Technology For Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Present Data from Study Highlighting Clinical Activity of RAF\/MEK and FAK Combination in KRAS Mutant Tumors ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PN-1007","moa":"MAG IgM","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polyneuron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1b\/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer Presented at the AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"Sema4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg\/30mL (1mg\/mL) Multiple Dose Vial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib for Treatment of NSCLC Patients ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN217","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Givinostat","moa":"HDAC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Italfarmaco S.p.A","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Italfarmac.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics Gets Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells to Treat Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR-BCMA T cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Gets Spanish Medicines Agency Authorization for APLICOV-PC Clinical Trial With Aplidin\u00ae for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"eEF1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Ltd Announces Positive Anti-Viral Activity for Novel Glycan Approach in Preventing Coronavirus (COVID-19) Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbohydrate binding modules","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pneumagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Part 2 of FIREFISH Shows Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide Significantly Improved Clinical Outcome in Patients with Acute Cerebral Ischemic Stroke When Compared to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NC-MSCs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Trial of Libtayo\u00ae as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A new FDA Fast Track designation for Zambon","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Epsilogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOv18 IgE","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epsilogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen .."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-533","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2\/3 Trial in Alzheimer\u2019s Disease Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Therapeutics to Support Development of a Pan - Coronavirus Vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19-adenovirus vector-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio's Bemcentinib to Be Fast-tracked as Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CRX100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Results from Phase 3 VOYAGER Trial of Avapritinib vs Regorafenib in Advanced Gastrointestinal Stromal Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Plans COVID-19 Testing for Ilaris","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-456","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FS222","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics to Present New Preclinical Data from Its CRISPR\/Cas9 Programs at the American Society of Gene and Cell Therapy Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Allows Trial to Proceed for Retrotope\u2019s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR\u2122 Technology at the ASGCT Virtual 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-605","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1\/2 trial of COVID-19 vaccine candidates in Germany","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AE37 Peptide","moa":"Helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter baumannii","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-7072","moa":"Protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KBP Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"R-Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cromos Pharma Supports R-Pharm to Initiate Global Program to Test Two of its Leading Candidates in Patients with Severe COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olokizumab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"R-Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"R-Pharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"R-Pharm \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Positive Phase II TACTI-002 Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Avdoralimab Phase Ii Clinical Trial in Covid-19 Patients with Severe Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avdoralimab","moa":"C5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Initiates Phase 2 Study of BXCL701 in Combination with PD-1 Inhibitor to Treat Emergent Neuroendocrine Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Reports Analysis from Phase 1b Geographic Atrophy Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiTAA-specific T cells","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces First Patient Enrolled in AEROSURF\u00ae Bridging Study for the Treatment of Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Drug Designation to Amylyx Pharmaceuticals\u2019 AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Defibrotide Sodium","moa":"Plasminogen","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MGD013","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Troxacitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sprint Bioscience Publishes Scientific Study With New Positive Data from the Vps34 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SB02024","moa":"Vps34","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sprint Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bio.."},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Bioch.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Publishes Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Receives Approval to Conduct Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis ","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Initiates IND-Enabling Activities For EDIT-201, An Allogeneic NK Cell Medicine For The Treatment Of Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark to conduct trials in India for potential COVID-19 drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compelling Data on Mechanism of Action for GlycoMimetics\u2019 Late-stage Clinical Candidate Uproleselan Published in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion Biotechnology Successfully Completes Phase I Clinical Study of 0b-002h Topical Gel for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"0B-002","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calcimedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical Covid-19 Pneumonia on High-Flow Oxygen Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CM4620-IE","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology\u2019s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Initiates Same Day Dosing Clinical Trial for ROLONTIS\u00ae (eflapegrastim)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson\u2019s and Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NEO-PTC-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neon Thera.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b\/3 NASH-RX Protocol in NASH Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America To Present Data from its Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILC Seeks \u00a34m to Help Advance COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alpha 14","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ILC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILC Therap.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan intends to screen NVN1000 against viruses including SARS-CoV-2\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus explores the biologicals route to treat novel Coronavirus\nwith long-acting Interferon alpha-2b","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon alpha-2b","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular partners Launch Anti-COVID-19 Therapeutic Program Bolstering DARPin Proteins Multi-Target Binding to Neutralize SARS-CoV-2 Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DARPin","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Kicks Off COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"T cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Indian Institute of Science ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IISc, start-up developing vaccine for Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"Viral spike glycoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Indian Institute of Science ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Institute of Science \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indian Ins.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics and Servier to Present Results from Phase 1 Alpha Study of Allo-501 Allocar T\u2122 Therapy ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-501","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Sanofi Provide Update on U.S. Phase 2\/3 Adaptive-Designed Trial Of Kevzara\u00ae (Sarilumab) In Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ThermoGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody drug candidate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ThermoGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ThermoGenesis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ThermoGene.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen delays Alzheimer's drug filing plans, shares fall\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition, Inc. Receives FDA\/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha-1062","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Arthritis Drug Tocilizumab Shows Promise in Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Royal Melbourne Hospital ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Researchers Launch ASCOT Study for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Royal Melbourne Hospital ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Royal Melbourne Hospital \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Royal Melb.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biontech And Pfizer to Commence First Clinical Trial of Covid-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis\n","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Viriom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Elsulfavirine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viriom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ N.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announced Results of Interim Analysis for RECOVERY Study of Tonmya ","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$270.4 million ","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across Indications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Curadev Pharma Private Limited","amount2":0.27000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Curadev Pharma Private Limited \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"Curadev Ph.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cstone Submits New Drug Application for the Targeted Therapy Avapritinib In Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptvac Signs Agreement with AGC Biologics to Develop & Produce COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 capsid-Virus Like Particle vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ AdaptVac","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Raises $80M to Take Magic Mushroom Drug Toward Phase 3","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Compass Pathways \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19 Related Delays in RhoVac AB Ongoing Phase IIb-study are Expected to be Managed With Existing Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin to Host Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kalos Therapeutics Announces Progress in Covid-19 Preventative & Therapeutic Approaches","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KTH-222","moa":"Mapk","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Ther.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Gets NMPA Acceptance of its New Drug Application in Mainland China for Avapritinib in Two Gastrointestinal Stromal Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces U.S. FDA Filing Acceptance of New Drug Application for Terlipressin to Treat Hepatorenal Syndrome Type 1","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health to Present Somatrogon Phase 3 Pediatric Trial Results at ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics to Present a Manufacturing Update at the virtual 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Clonal neoantigen T cells","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Enrollment for the INSIGHT-004 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002\/RG7935) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Announces First Subject Dosed In Phase 1 Study of TD-0903","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Underway to Examine the Planned Use of BTG Pharmaceutical's Voraxaze\u00ae with Methotrexate in CNS Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specia.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Pharma Provides Update on Its Phase 1\/2a Clinical Trial of RXC004","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RXC004","moa":"Porcupine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSig Subsidiary ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR\u2019s Zotatifi Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zotatifin","moa":"eIF4A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Results of Phase 3 Clinical Trial of DEXTENZA\u00ae for the Treatment of Ocular Itching in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Grants Positive Opinion for Janssen Pharmaceutical's DARZALEX\u00ae Subcutaneous Formulation for Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Presents Session on Repurposing Niclosamide for COVID-19 Treatment at AAPS Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Limited Begins Enrollment of Phase 2\/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna\u2019s Vaccine (mRNA-1273) Against Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Group \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$459.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Announces Closing Of Public Offering Of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0.46000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ValiRx \/ Undisclosed ","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ U.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$175.6 million","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Gets Funding for Drug Discovery Technology That Identifies Antibodies for Potential Use in drugs to treat and prevent COVID-19.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.17999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"AbCellera \/ Government of Canada","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$677.0 million","upfrontCash":"$677.0 million","newsHeadline":"Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Menarini ","highestDevelopmentStatusID":"12","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Transgene","sponsor":"Vaxxel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxel Buys Transgene\u2019s Cell Line to Develop New Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"DuckCelt-T17","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Vaxxel","highestDevelopmentStatusID":"1","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Noachis Terra","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 Vaccine Candidate Utilizing \u201cSpike Protein\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"TerraCoV2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noachis Terra","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noachis Terra \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Noachis Te.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Arcturus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Intralytix","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Shigella bacteriophage therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intralytix \/ NIAID","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marinomed Receives FFG Funding to Research SARS-Cov-2 Therapy Based On Carragelose\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Carragelose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Marinomed Biotech \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Collaborates with Mabpharm On Development and Commercialization of Ace-Mab\u2122 to Potentially Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/.."},{"orgOrder":0,"company":"Nuritas","sponsor":"Advanced Computing in Europe","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuritas Leverages AI Platform to Identify Therapeutic Peptides for the Treatment of COVID-19\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Peptides","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nuritas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuritas \/ Advanced Computing in Europe","highestDevelopmentStatusID":"2","companyTruncated":"Nuritas \/ .."},{"orgOrder":0,"company":"Kansas State University Research Foundation","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation for Coronavirus Antiviral Compounds\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antiviral drugs","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kansas State University Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University Research Foundation \/ Cocrystal Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kansas Sta.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital After NDA Filing for Potential New ADHD Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"KemPharm \/ Gurnet Point Capital ","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Signs Manufacturing Agreement With US Cell Therapy Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kubota Vision Completes Enrollment in the Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre receives Positive CHMP Opinion for BRAFTOVI\u00ae in Combination with Cetuximab for Treatment of BRAFV600E-mutant Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UC San Diego to Assess Hypertension Drug Ramipril for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ramipril","moa":"ACE","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar\u2019s Abstract for ATS 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MBT2","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Bristol Myers Squibb\u2019s Application for CC-486 for Maintenance Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Re-purposes Ifenprodil Drug Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec\u00ae (secnidazole) for the Treatment of Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Oxford and Sound Pharmaceuticals Complete Phase 2 Bipolar Disorder Study with SPI-1005","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HQP1351","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics to Present at Maxim Group\u2019s Infectious Disease Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2307","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS\u2122 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan in Patients With Rett Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarizotan","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Receives Priority Medicines Designation from European Medicines Agency for Sotatercept in Pulmonary Arterial Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"SIRPalpha-CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INS-3001","moa":"Vascular calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inositec AG \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inositec A.."},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TC-210","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Thera.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia IND Application for CAN04 Approved by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nidanilimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Biosciences Launches With an Ambitious Strategy to Address Life-threatening Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CMTX-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"CARE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARE Conducting Clinical Trials For Primary & Secondary Prophylaxis to Reduce COVID-19 Hospitalization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imiquimod","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARE \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Not.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data from Assembly Biosciences\u2019 Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-M201","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Laboratories Announces Successful Completion of Pre-IND Meeting with FDA on Sildenafil Oral Spray to Treat Erectile Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Upcoming Presentations on MDNA55 at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI\u2019s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine to Treat Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Presents GB0139 Preclinical and Clinical Data on Anti-Fibrotic Activity as Online Experimental Biology 2020 Poster","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Interim Results from an Open-Label Extension Study of Antolimab in Eosinophilic Gastritis and\/or Eosinophilic Duodenitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Antolimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Expert Review of Data Supports the Potential of XF-73 to Address Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"EvergreenHealth ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EvergreenHealth Prepares for 2nd Arm of Clinical Trial After Getting Promising Results for Remdesivir as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EvergreenHealth ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EvergreenHealth \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EvergreenH.."},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant triple antigen vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Premas Bio.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of California to Assess Whether Hypertension Drug May Reduce COVID-19 Severity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam, Vir Plan Year-End Trial of New Rnai COVID-19 Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-2703","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces That ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Utrecht University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Utrecht University, Erasmus Medical Center and Harbour BioMed Report Discovery of Antibody that Blocks Novel Coronavirus Infection in Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Human monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Utrecht University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Utrecht University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Utrecht Un.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BXT-10","moa":"Galectin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi, Eli Lilly Agree to Co-develop JS016 Antibodies Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"JS016","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Viriom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom Initiates Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VM1500A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Viriom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ N.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma BAGS MHRA Nod for Covd-19 Trial in Record Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces FDA Release of IND Order for Ntx-001, A New Approach For Treating Patients With Peripheral Nerve Injuries","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts IND Application of ATyr Pharma on Phase 2 Study For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"Neuropilin-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"University of Colorado Denver","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Colorado Doctors Test Anti-blood Clot Treatment on COVID-19 Patients, Optimistic About Results So Far","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Alteplase","moa":"Plasminogen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Colorado Denver","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Colorado Denver \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak to Present New Preclinical Data on EngEx therapeutic candidates at the American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EngEx therapeutic candidates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential New Antiretroviral drug Developed at UNMC for HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiretroviral drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Nebraska Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Nebraska Medical Center \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Announces Final Clinical Safety And Efficacy Data From Illuminate-204 Trial In Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Factor IIa","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laboratori Derivati Organici \/ Cerus DMCC","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Details Early Responses to Tils in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation in EU for MIV-818 to Treat Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First novel COVID-19 vaccine candidate commences animal testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Government of United Kingdom","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imperial College London gets UK funding for Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Self-amplifying RNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imperial College London","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imperial College London \/ Government of United Kingdom","highestDevelopmentStatusID":"4","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"University City Science Center inks partnership with CSL Behring","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Chemokine-derived antifibrotic peptides","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Pittsburgh To Begin Work on Novel Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine Candidate Shows Immune Response in Early Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PittCoVacc","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"University of Pittsburgh \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Eli Lilly Announce NMPA Acceptance of Supplemental New Drug Application for Sintilimab in Combination with ALIMTA and Platinum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements with Genfa Medica","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Genfa Medica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"Genfa Medi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Imophoron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imophoron Develops COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imophoron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imophoron \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Imophoron .."},{"orgOrder":0,"company":"Censa Pharmaceuticals","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","amount":"$366.0 million","upfrontCash":"$10.0 million","newsHeadline":"PTC Therapeutics to Acquire Censa Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Sepiapterin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Censa Pharmaceuticals","amount2":0.37,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Censa Pharmaceuticals \/ PTC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Censa Phar.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Uncloaks with $60M to Target the Innate immune System","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-1B","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Dr. Daniel Carter","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Using Novel Nanoparticle Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NSP-10 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Predictive Oncology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Predictive Oncology \/ Dr. Daniel Carter","highestDevelopmentStatusID":"6","companyTruncated":"Predictive.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Inks Manufacturing Deal with Faron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bausch + Lomb Licenses Exclusive Rights from STADA and Xbrane to a Biosimilar Candidate for Lucentis in the United States and Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"CaaMTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaaMTech Collaborates With National Institutes of Health to Research Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ CaaMTech","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$5.0 million","newsHeadline":"BetterLife Pharma Enters into a Licensing Agreement with Altum Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AntiCovir","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Mediolanum Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mediolanum Farmaceutici Acquires the French Company ElsaLys Biotech to Develop Next Generation Immuno-oncology Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Inolimomab","moa":"IL-2 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ElsaLys Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElsaLys Biotech \/ Mediolanum Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"ElsaLys Bi.."},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"ZYUS Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Collaborates with USask\u2019s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Plant based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIDO-InterVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VIDO-InterVac \/ ZYUS Life Sciences ","highestDevelopmentStatusID":"1","companyTruncated":"VIDO-Inter.."},{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AI VIVO Seeks Collaboration Partners to Progress Top-ranked COVID-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ .."},{"orgOrder":0,"company":"Iontas","sponsor":"Inotrem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets with Inotrem","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"TREM-1","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ Inotrem","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ I.."},{"orgOrder":0,"company":"Defence Materials Technology Centre","sponsor":"Certara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Chloroquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Defence Materials Technology Centre","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Defence Materials Technology Centre \/ Certara","highestDevelopmentStatusID":"11","companyTruncated":"Defence Ma.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth of Pennsylvania","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Noveome Biotherapeutics Receives $4 Million Grant From Commonwealth of Pennsylvania","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"University of Alberta","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Inks Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TNX-1810","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Alberta","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Alberta \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"jCyte","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","amount":"$252.0 million","upfrontCash":"$50.0 million ","newsHeadline":"jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Santen Pharmaceutical","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"jCell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0.25,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.25,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Santen Pharmaceutical ","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Sa.."},{"orgOrder":0,"company":"Mount Sinai Health System","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento ventures into COVID-19 with Mount Sinai antibody pact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVI-SHIELD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mount Sinai Health System","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mount Sinai Health System \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mount Sina.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"NYIP","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Announces Capital Increase of \u20ac 5.5 Million by Private Placement to Further Develop Its Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Private Placement","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ NYIP","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"IDBiologics","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IDBiologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDBiologics \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"2","companyTruncated":"IDBiologic.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ONCOlogues","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Fortress Biotech ","highestDevelopmentStatusID":"1","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Cities","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Third Rock-backed biotech Pliant Therapeutics files for an $86 million IPO","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Cities","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Themis Collaborates with ABL Europe to Manufacture its SARS-Cov-2 Vaccine Candidate in France","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ Themis","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$85.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $85.3 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical\u2019s Favipiravir ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujifilm Toyama Chemical \/ Appili Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Megapharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Megapharm","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$45.0 million","newsHeadline":"Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0.40999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"National Center for Advancing Translational Sciences","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Emetine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Center for Advancing Translational Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Center for Advancing Translational Sciences \/ Acer ","highestDevelopmentStatusID":"9","companyTruncated":"National C.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Business Finland","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Faron receives grant from Business Finland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Faron Pharmaceuticals \/ Business Finland","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inhibitory Effect of Innovation Pharmaceuticals\u2019 Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Terminated Distribution and Commercialization Agreement of its SYMJEPI Products with Sandoz","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Epinephrine","moa":"Adrenergic alpha\/beta","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Sandoz ","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI with US WorldMeds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Stabilitech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"Stabilitech Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"OraPro-COVID-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stabilitech Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Stabilitech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Stabilitec.."},{"orgOrder":0,"company":"DongWha Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DongWha Pharm to Kick Off Trials for Virus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DW2008","moa":"TIGIT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DongWha Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DongWha Pharm \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"DongWha Ph.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis, Incyte will Test Jakafi in 2nd COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG's Leukemia Combo Clears Phase 3, Aims for 2020 Filing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Propeller Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 asthma triple heads CHMP\u2019s latest meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Propeller Health","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ANT3310","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ .."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I\/II Peritoneal Trial is Accepted at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LPCN 1148","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BT5528","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Te.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Starts Phase II Study of ArtemiC to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ArtemiC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the ECCMID Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Positive Clinical Results from VERU-111 Phase 1b\/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of Oral Tebipenem HBr vs Intravenous Ertapenem for Complicated UTI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia in Adult Patients on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Organicell Flow","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Composition of Matter Patent Allowance Extends Protection for Berotralstat in U.S. Market by Four Years to 2039","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Announces Publication of ANG-3777 Phase 2 Results in the Scientific Journal Transplantation","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck\u2019s RECARBRIO Vs Piperacillin and Tazobactam in HABP\/VABP ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imipenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyvyt (Sintilimab Injection) Combined with Gemzar (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Top-Line Results From Otezla\u00ae (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Actemra studies against COVID-19 could be done this month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at the ASCO20 Virtual Scientific Program Reflects Genentech\u2019s Commitment to Accelerating Progress in Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-305","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OpRegen","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric AutoAntibody Receptor T cells","moa":"B Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Rebiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rebiotix and Ferring Announce World\u2019s First Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics studies Aviptadil for Covid-19-related ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Mainz University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Potential Active Substances Against Coronavirus by Running Supercomputer Simulations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Simeprevir","moa":"HCV proteases\/NS3-4A serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mainz University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mainz University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mainz Univ.."},{"orgOrder":0,"company":"Translational Genomics Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atovaquone","moa":"Cytochrome b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Translational Genomics Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Genomics Research Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Translatio.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-EGFR antibodies","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Saposin C-dioleoylphosphatidylserine","moa":"Spingomyelinase catalysis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pha.."},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sj\u00f6gren's Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharm.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HTD1801","moa":"Lipid","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits SNDA for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2+ Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals & Laurus Labs to Support Phase 2 Clinical Trial of Hydroxychloroquine for COVID-19 Prophylaxis in Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK to Test Experimental Drug to Treat Pneumonia from COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Otilimab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1\/2 Trial of Lead Candidate ST101 in Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PARI Nebulizer Used in New Study with Pulmotect's Inhaled PUL-042 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"Lundquist Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Sponsored COVID-19 Clinical Trial Begins at The Lundquist Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lundquist Institute \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Gets Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CM4620-IE","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data At The ASCO20 Virtual Scientific Program Reflects Roche\u2019s Commitment to Accelerating Progress in Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Dosing of First Patient in Phase 1\/2 Trial of RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Announces Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Columbia University Irving Medical Center ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hydroxychloroquine Fails to Show Benefit In Covid-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Columbia University Irving Medical Center ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Columbia University Irving Medical Center \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Keck Medicine ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keck Medicine to Launch Clinical Trial for Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Keck Medicine ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Keck Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Keck Medic.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai, A*STAR to Develop Therapeutic Ab Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Synthetic human antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers at LSTM Demonstrate a Novel Way to Treat Snakebite","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimercaprol","moa":"Heavy metal","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Liverpool School of Tropical Medicine","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liverpool School of Tropical Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Liverpool .."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives U.S. FDA Approval for Retevmo\u2122 (selpercatinib), the First Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fexuprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda to Begin Trial Against Virus in Summer with Global Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasma-derived therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio to Present Updated Results from Pivotal Phase 2 Karmma Study Of Ide-Cel In Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents Positive Additional Results From A Phase 2a Study Of Golexanolone","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Umecrine Cognition \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine C.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Novant Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novant Health Initiates Phase 2b\/3 Trial with CytoDyn\u2019s Leronlimab for Severely and Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Novant Health","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gastric-Cancer Drug Designated Breakthrough by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics Announces Topline Results from the BRIDGE Phase III Open-Label Trial of Pegunigalsidase Alfa in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genfit Delivers Latest NASH Drug Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Hong Kong Baptist University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide drug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hong Kong Baptist University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hong Kong Baptist University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hong Kong .."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Pharma Highlights Results from Recent Clinical Reports and Studies on use of Interferon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion\u2122 for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Radium-223","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triple Drug Combination Shows Promise in Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Hong Kong","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"University of Hong Kong \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Reports Continued Progress Advancing HS-110","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Successful Completion of Immuno-Oncology Study Safety Phase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc\u2019s INB03 Inhibits Cell Migration, Tumor Growth in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INB03","moa":"TNF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"TolerogenixX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MIC-Lx","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TolerogenixX","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TolerogenixX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tolerogeni.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Filing of IND for Phase 2\/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Introduces 3-in-1 Inhaler Therapy for COPD in India, Promising Reduction in Risk of Severe Attacks and Improvement in Lung Function","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV for Endogenous Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Successful Type B Meeting with FDA for Pivotal Study of Envafolimab in Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Chronic Pruritus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Receives US FDA IND Approval to Initiate Phase 1b\/2a Trial of HST 001 in Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Tiburio Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiburio Announces Publication of Preclinical TBR-760 Data in Non-Functioning Pituitary Adenoma in Journal of the Endocrine Society","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TBR-760","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tiburio Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tiburio Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiburio In.."},{"orgOrder":0,"company":"HJB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HJB & Mabspace Biosciences' Develop, Mfg Agreement for Novel Humanized Claudin1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized Claudin18.2 monoclonal antibody","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HJB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Not .."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen's Swiss Facility Ready to Help Boost Aducanumab Rollout","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Eyes 'Early Summer' Start for Phase 3 COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fox Chase Researchers Examine Role of Pembrolizumab in Treating Patients With Metastatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fox Chase Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fox Chase .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac\u2019s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PiCoVacc","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AVA-Trap","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces First Quarter 2020 Financial Results and Provides Corporate Update ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-2901","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Waterloo developing DNA-based COVID-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Waterloo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of Waterloo \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Verndari","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19 Vaccine with Patch Delivery Technology Enters Preclinical Testing at Uc Davis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VaxiPatch COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dermal Patch","sponsorNew":"Verndari \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/.."},{"orgOrder":0,"company":"Rochester Clinical Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical trials for COVID-19 vaccine to begin in Rochester","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rochester Clinical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rochester Clinical Research \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Rochester .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three Research Sites to Lead Clinical Trial of I-Mab\u2019s of TJM2 to Counter COVID-19\u2019s Deadly Cytokine Storm\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Houston Researchers Test Lung Inhalant That Could Protect Healthcare Workers From COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar announces the initiation of a study of lurbinectedin in combination with immunotherapy ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar, Jazz Pharma Announce FDA Acceptance and Priority Review of NDA for Lurbinectedin in Relapsed Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rafael Pharmaceuticals Announces Collaboration to Evaluate the Effects of CPI-613\u00ae in Combination with Azacitidine and Venetoclax","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$8.3 million ","upfrontCash":"Undisclosed","newsHeadline":"Weill Cornell Medicine secured funding HIV and HPV Prevention","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Recombinant Human Papillomavirus 9-valent Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Weill Cornell Medicine","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Weill Cornell Medicine \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Weill Corn.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento and Smartpharm to collaborate to develop novel gene-encoded antibody vaccine intended to protect against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Gene encoded antibody vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SmartPharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SmartPharm Therapeutics \/ Sorrento","highestDevelopmentStatusID":"1","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"DiNAQOR AG","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DiNA-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DiNAQOR AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DiNAQOR AG \/ BioMarin Pharmaceutical ","highestDevelopmentStatusID":"5","companyTruncated":"DiNAQOR AG.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Unveils New Strategic Plan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics to Present New Data on GeneRide\u2122 Platform and Next Generation Capsid Development Program at ASGCT 2020\r\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"SUO-CTC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery Brings Bladder Cancer Patients Hope","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nadofaragene firadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"SUO-CTC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"SUO-CTC \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SUO-CTC \/ .."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Biosciences to Present on Gene Circuit-Based Therapies at the 2020 ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SENTI-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA offers CRISPR, Vertex drug program VIP status for its comeback play","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"University of Texas Medical Branch","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"U.S., Chinese institutions work on vaccine against new coronavirus, says expert","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ University of Texas Medical Branch","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"These Texas doctors are working on a vaccine for the coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"AlloVir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlloVir, Baylor ally to develop COVID-19 T-cell therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College Researchers Study BCG Vaccine for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Kings College London","sponsor":"Epsilogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Licences Experimental Ige Antibody from KCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MOv18 IgE","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kings College London","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ Epsilogen","highestDevelopmentStatusID":"6","companyTruncated":"Kings Coll.."},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New study identifies drugs that are safe to use in COVID-19 treatment\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kings College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings Coll.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion\u2019s SEP-363856 for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ulotaront","moa":"TAAR1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$510.0 million","upfrontCash":"$60.0 million","newsHeadline":"Esperion Announces Agreement with Otsuka Pharmaceutical for Development and\r\nCommercialization of NEXLETOL and NEXLIZET\u2122 Tablets in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"ATP synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayurvedic Drug Zingivir-H Gets Approval for Clinical Trial to Treat COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Undisclosed","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Zingivir-H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pankajakas.."},{"orgOrder":0,"company":"MIGAL Research Institute","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Researchers Near Covid-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MIGAL Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MIGAL Research Institute \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"MIGAL Rese.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Regains Global Rights to Brazikumab From Allergan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"NanoTx Therapeutics","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"$137.2 million","upfrontCash":"$0.4 million","newsHeadline":"Plus Therapeutics Announces Closing of Agreement to License Novel Oncology Platform with NanoTx Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoTx Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"NanoTx Therapeutics \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NanoTx The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Dose First Participants in The U.S. As Part of Global Covid-19 mRNA Vaccine Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Initiation of Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-181","moa":"TGF-beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CB5064 analogs","moa":"Apelin receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Neurokinin 1 receptor positive mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takis Vaccines Neutralize SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flagship-Backed Evelo Biosciences Joins Covid-19 Hunt With Proposal for Bacteria Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data of Gencaro for Atrial Fibrillation in Heart Failure Featured in Three Presentations at 2020 Heart Rhythm Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EAACI 2020 Annual Congress Has Accepted AB Science's Phase 3 Study Results with Masitinib in Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Clears Pluristem\u2019s IND Application for Phase II COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"CaroGen","sponsor":"Yale University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaroGen and Yale Scientists Team to Develop a COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 recombinant vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CaroGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CaroGen \/ Yale University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"CaroGen \/ .."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"iPSC-derived CAR-NK cells immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":3.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.1000000000000001,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Symvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Symvivo to Start Safety Analysis of a COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"bacTRL-Spike","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ .."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring\u2122 in Switzerland","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Gynial","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citi and Jefferies","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cancer Biotech Ayala Pharmaceuticals Prices Upsized US IPO at $15 midpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Citi and Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$388.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Inks $388M Deal With CEPI to Fund Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0.39000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"Novavax \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$17.2 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio Receives CEPI Funding to Expand Manufacturing of COVID-19 DNA Vaccine INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Adimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adimmune May Start COVID-19 Vaccine Clinical Trials in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimmune \/.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces Initiation of Clinical Program Targeting Soluble TNF to Prevent Complications of Cytokine Storm Caused by COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IC14","moa":"CD14","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Implicit Bioscience \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Implicit B.."},{"orgOrder":0,"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Enters into an Option Agreement with IRICoR and University of Montreal for A Discovery-stage Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ University of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Un.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Coronavirus Vaccine Trial Starts In Philadelphia, Kansas City","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Maastricht University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Maastricht University","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Montreal Heart Institute Colcorona Receives Grant from the COVID-19 Therapeutics Accelerator to Study Cheap, Readily Available Drug","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi to Start a Clinical Study to Evaluate Whether Anakinra and Emapalumab May Relieve Complications Associated with Severe COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Cardiff University","sponsor":"Ervaxx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"T cells clone","moa":"MHC-I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cardiff University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff University \/ Ervaxx","highestDevelopmentStatusID":"1","companyTruncated":"Cardiff Un.."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Skyhawk Therapeutics Expands its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Stimunity","sponsor":"Portage Biotech","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Portage Makes Additional Investment in Stimunity S.A.S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"STI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Stimunity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Stimunity \/ Portage Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Stimunity .."},{"orgOrder":0,"company":"Cipla","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Inks Voluntary Licensing Agreements With Multiple Companies for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Gi.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$15.0 million","newsHeadline":"Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease Product Candidate GB004","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aerpio Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Aerpio Pharmaceuticals \/ Gossamer","highestDevelopmentStatusID":"6","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Singota Solutions Collaborates with Noveome Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Singota Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Singota Solutions \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Singota So.."},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"TKS1","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Travecta Therapeutics Secures $15 Million in Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"TVT-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Travecta Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Travecta Therapeutics \/ TKS1","highestDevelopmentStatusID":"1","companyTruncated":"Travecta T.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Animal Health to Acquire U.S. Rights to SENTINEL\u00ae Brand of Combination Parasiticides for Companion Animals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Milbemycin Oxime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virbac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virbac \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Virbac \/ M.."},{"orgOrder":0,"company":"Alivexis","sponsor":"SBI Investments","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Modulus Discovery Closes $25.5M USD Series B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alivexis","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Alivexis \/ SBI Investments","highestDevelopmentStatusID":"2","companyTruncated":"Alivexis \/.."},{"orgOrder":0,"company":"Abveris","sponsor":"Nkarta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse\u00ae on the Berkeley Lights Beacon\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Abveris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abveris \/ Nkarta","highestDevelopmentStatusID":"2","companyTruncated":"Abveris \/ .."},{"orgOrder":0,"company":"Manhattan BioSolutions","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"$0.1 million","newsHeadline":"Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manhattan BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Manhattan BioSolutions \/ Nascent Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Manhattan .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Gree Group","pharmaFlowCategory":"D","amount":"$232.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintor Pharmaceutical Raises $1.8b IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Oral","sponsorNew":"Kintor Pharmaceutical \/ Gree Group","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Neovii","sponsor":"Tel Aviv University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TAU and Neovii Team Up to Develop Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neovii","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neovii \/ Tel Aviv University","highestDevelopmentStatusID":"1","companyTruncated":"Neovii \/ T.."},{"orgOrder":0,"company":"Exyte","sponsor":"Univercells","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exyte \/ Univercells Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Exyte \/ Un.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"PoC Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cardiff Oncology Ink Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff Oncology \/ PoC Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"QurAlis Nabs $42M Funding Round for ALS, Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Stem cell therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"QurAlis \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ennaid Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ENU200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Ennaid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"ReiThera","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$215.5 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA Provides the Sabin Vaccine Institute With an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ChAd3-SUDV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReiThera","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"ReiThera \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$73.3 million","upfrontCash":"Undisclosed","newsHeadline":"Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Oasis Capital","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Oasis Capital","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"Creapharm","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Enters into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Trial Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Creapharm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Creapharm \/ AzurRx","highestDevelopmentStatusID":"8","companyTruncated":"Creapharm .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0.089999999999999997,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Danish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rigshospitalet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rigshospitalet \/ Innovation Fund Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Rigshospit.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ALM301","moa":"Akt kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$153.0 million","upfrontCash":"Undisclosed","newsHeadline":"TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Legend Biotech Aims for $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Immunai","sponsor":"Viola Group","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunai Raises $20M with an Immunology Focus","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"CAR-T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunai","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Immunai \/ Viola Group","highestDevelopmentStatusID":"1","companyTruncated":"Immunai \/ .."},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Flu Lab","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Greenlight Biosciences Raises $17M Financing Round to Accelerate Large-Scale Manufacturing of Future COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Financing","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GreenLight Biosciences","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ Flu Lab","highestDevelopmentStatusID":"1","companyTruncated":"GreenLight.."},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Exvastat Wins 3.6m Euro Grant For COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"PTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Closing of $98.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Baillie Gifford","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Halozyme To Receive $15 Million Milestone Payment From Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Moksha8","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tak-733","moa":"MEK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Recursion","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Enters License Pact for its Antibody Engineering Technologies with Eli Lilly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$81.3 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SQZ Biotech Snags $65M To Push Cancer Vaccine, Break Into Infectious Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series D Financing","leadProduct":"Atezolizumab","moa":"CD8 T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Temasek","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$1,437.5 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna Plans to Raise $1.25 Billion in a Secondary Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":1.4399999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.4399999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Neurotrope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Neurotrope","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals Announces Merger Closing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Park West Asset Management","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Aspirin","moa":"COX","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Liquid Capsule","sponsorNew":"PLX Pharma \/ Park West Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"MD Anderson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics and MD Anderson Enter a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT in Rare Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ MD Anderson","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Chelexa Biosciences","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antimicrobial therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Chelexa Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chelexa Biosciences \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chelexa Bi.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clovis Oncology Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Clovis Oncology \/ J. P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$60.1 million","upfrontCash":"Undisclosed","newsHeadline":"Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters\u2019 Option","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0.059999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Axcella Health \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Panobinostat lactate","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ H.C. Wainwright","highestDevelopmentStatusID":"6","companyTruncated":"Midatech P.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintor Pharmaceuticals Completes $240 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rallybio Scores $145M, Unveils Lead Rare Disease Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"RLYB211","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rallybio \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Five Leaf Labs","sponsor":"Cannaworx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Phytocannabinoid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Five Leaf Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Five Leaf Labs \/ Cannaworx","highestDevelopmentStatusID":"12","companyTruncated":"Five Leaf .."},{"orgOrder":0,"company":"HintMD","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"DaxibotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"HintMD","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HintMD \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"HintMD \/ R.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"DLA Piper","pharmaFlowCategory":"D","amount":"$483.3 million","upfrontCash":"Undisclosed","newsHeadline":"DLA Piper Advises Immunomedics in its US$483 Million Follow-On Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Immunomedics \/ DLA Piper","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Abnova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmajet and Abnova Partner to Develop and Deliver COVID-19 Mrna Vaccine Using Needle-Free Injection Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection\n","sponsorNew":"PharmaJet \/ Abnova","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Therapix Biosciences","sponsor":"Evero","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Therapix Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapix Biosciences \/ Evero","highestDevelopmentStatusID":"8","companyTruncated":"Therapix B.."},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Ospemifene","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Duchesnay","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duchesnay \/ Plushcare","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay .."},{"orgOrder":0,"company":"Vibalogics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vibalogics Announces Collaboration to Provide Additional Clinical Trial Material for COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vibalogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vibalogics \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Vibalogics.."},{"orgOrder":0,"company":"Genocea","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GEN-003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Shionogi","highestDevelopmentStatusID":"1","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Cue Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"Undisclosed","newsHeadline":"With Bucks From Pfizer Added To Their New Round, Amplyx Steers a Tricky Course Through PhII and a Global Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Deactivated rabies vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Thomas Jefferson University","highestDevelopmentStatusID":"4","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn and Mexican NIH to Assess Leronlimab for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"National I.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"IL-6 Signalling Pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter and Eliza Hall Institute of Medical Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IQVIA \/ Walter and Eliza Hall Institute of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Wa.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$341.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Successfully Completes the Offering of New Shares Thereby Securing Funding for the Company\u2019s Growth Plan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Aprocitentan","moa":"Endothelin receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0.34000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617 in Combination with KEYTRUDA in Solid Tumor Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assertio Completed Merger with Zyla Life Sciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Diclofenac Potassium","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assertio Therapeutics \/ Assertio Holdings","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"Celonic","sponsor":"Airway Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Airway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for Coronavirus","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Celonic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Celonic \/ .."},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kindred Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kindred Biosciences \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Kindred Bi.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Laidlaw & Company","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CanSino, Precision NanoSystems to co-develop COVID-19 RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 mRNA-LNP vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ CanSino Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SR One fuels HotSpot's $65M B round to fund allosteric R&D","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PKC theta","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Plasmid DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Takara Bio","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Synlogic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synlogic Announces Termination of AbbVie Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Synthetic Biotic medicines","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Mizuho Securities USA LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Mizuho Securities USA LLC","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and NDA Acceptance for BTK Inhibitor BRUKINSA\u2122 (zanubrutinib) in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medison Pharma \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"Celularity","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kleo Pharmaceuticals and Celularity Team-up to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody recruiting molecule","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Advantech Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Advantech Capital","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medexus Provides an Update on the IXINITY\u00ae Acquisition and its Overall Business in the COVID-19 Environment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Recombinant coagulation factor IX","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","amount":"$20.2 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sinapultide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Windtree Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Lyophilized Powder","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"4","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Valence Life Sciences","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Valence Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Funding Secured For UK Clinical Trial in Children With Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Vincristine Sulfate","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Birmingham \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellect Biotechnology's ApoGraft\u2122 to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ApoGraft treated stem cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellect Biotechnology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cellect Bi.."},{"orgOrder":0,"company":"Purdue University","sponsor":"Gibson Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gibson Oncology Expands its Scientific Advisory Board for Novel Oncology cMYC Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Azaindenoisoquinolines","moa":"cMYC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Purdue University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purdue University \/ Gibson Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Purdue Uni.."},{"orgOrder":0,"company":"Romanian National Institute of Infectious Diseases","sponsor":"CervoMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diffusion Pharma and Romanian National Institute of Infectious Diseases Join Hands to Expand Clinical Trial Program of TSC for COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"ROMANIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Romanian National Institute of Infectious Diseases","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Romanian National Institute of Infectious Diseases \/ Diffusion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Romanian N.."},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Acquired Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Abivertinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Thera.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$231.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK Partners with Samsung Biologics to Secure Additional Manufacturing Capacity for Innovative Biopharmaceutical Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Belimumab","moa":"TNFSF13B","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Biologics","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Biologics \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Millicent Pharma Limited","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"$20.0 million","newsHeadline":"AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa\u00ae to Millicent Pharma for up to $125 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Divestment","leadProduct":"Prasterone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Hormone","amount2New":0.13,"dosageForm":"Intravaginal","sponsorNew":"AMAG Pharmaceuticals \/ Millicent Pharma Limited","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rigel Looking for Collaboration with Research Institutes to Investigate Potential Of TAVALISSE to Treat Severe COVID-19 Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Henlius Biotech Says Entered Cooperation Agreement With Sanyou Biopharmaceuticals & Shanghai Zj Bio-Tech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Antibody drug conjugate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Bio.."},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese Scientist Unite Together to Tackle With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"CAStem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Chinese Academy of Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinese Academy of Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chinese Ac.."},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Zhifei Longcom Biopharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zhifei Inks Exclusive CAS Tie-Up to Make First Vaccine for New Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chinese Academy of Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Chinese Ac.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Korea\u2019s SK Bioscience Gets $3.6 M Funding from Gates Foundation for COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$225.5 million","upfrontCash":"$10.0 million","newsHeadline":"Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"ABY-035","moa":"IL-17","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series D Financing","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib for COVID-19 Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrthoTrophix Presents More Evidence on TPX-100 for Disease Modification in Knee Osteoarthritis in a New Abstract Published in a Journal","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"OrthoTrophix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTroph.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Sarclisa Cuts Death Risk In Mutiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Initiates Phase 3 Clinical Trials on Favipiravir to Check Efficacy on COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipal's Clinical Trials Using Arthritis Drug Tocilizumab Get Nod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences to Start P2 Trial Of Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"YD Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YD Life Science Proves Efficacy Of Diabetic Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"YD Life Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Sc.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport\u00ae Achieved High Levels of Satisfaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AbobotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces the Approval of TUKYSA in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel to Treat Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Reports Progress on CRISPR\/Cas9 AML Cancer Therapy Using Cell Engineering Process at the 23rd ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Announces New Data Validating and Enhancing its PM21 K-NK-Cell Platform Presented Today at the ASGCT Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"K-NK002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Recommends Wider Compassionate Use of Remdesivir in Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Files PCT Patent Application for Neuroprotection in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Stanford Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stanford Medicine Researchers Trial Interferon-Lambda for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon-lambda","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Stanford Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stanford Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Stanford M.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results for Two Comparative Studies for AVT02, a Proposed Biosimilar to HUMIRA\u00ae (Adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna's Potential Coronavirus Vaccine Gains FDA's 'Fast Track' Status","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Launches Covid-19 Trial to Study Drugs for Elderly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Expects to Launch Clinical Trials Of Covid-19 Vaccine in July","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Assessing Use of Tick Molecule for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Evasins","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1\/2 Clinical Trial in China for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TJD5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pracinostat","moa":"pan-HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Polynoma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polynoma Presenting Final Analysis of MAVIS Phase III Part B1 Data of Its Investigational Melanoma Vaccine, Seviprotimut-L, at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Showcases Oncology Pipeline At ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Receives First Regulatory Approval from BfArM to Initiate a Phase 2 Clinical Trial of IMU-838, in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF and ChemRar Announce First Interim Results of Clinical Trials of Favipiravir Drug's Effectiveness in Coronavirus Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Provides Updates for Pivotal BREATHE Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Betterlife Pharma Announces Interferon Alpha-2b Covid-19 News Regarding its Emergence as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BXQ-350","moa":"Spingomyelinase catalysis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pha.."},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbor Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for AR19","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Phar.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC41","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYVYT ORIENT-2 Study Met its Primary Endpoint in the Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion Ditches Once-Rejected ADHD, Binge Eating Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasotraline","moa":"MAO transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Macrogenics Chief Scott Koenig Details the Upbeat Cancer Drug Data from 2 Programs That Drove a Big Spike in their Share Price","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MGD013","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BT5528","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Shares Initial Data from FORWARD II Testing Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarveda Therapeutics Reports Complete Data from Phase 1 Portion of Phase 1\/2a Study of PEN-866 to be Presented at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Locnartecan","moa":"HSP90","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb\u00ae20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb20717","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo + Yervoy Improves Overall Survival vs. Chemotherapy Alone in First-Line Metastatic Non-Small Cell Lung Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DM199","moa":"KLK1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Publication Describing Underlying Biology Behind Sotatercept\u2019s Potential as a Novel Therapy in PAH","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scimount Announces FDA Approval of SMP-100's IND Application for the Treatment of Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Xiling Lab \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines to Present Data Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea to Present Long-term Follow-up Data from GEN-009 Neoantigen Vaccine at Virtual ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced CKD at ASCO 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex to Present Results from CLASSICAL-Lung Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"SEMA4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"NaPi2b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Inks Agreement with FDA on Resubmission of the Application for HETLIOZ to Treat Patients with Smith-Magenis Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Gets FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"DCprime","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCprime Extends International Roll-out of DCP-001 Into the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"DCprime","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DCprime \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DCprime \/ .."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oasmia Announces Outcome of Strategic Review to Deliver Long-Term, Profitable Growth as a Specialty Pharma Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Genkyotex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genkyotex Receives Approval From the French Medicines Agency (ANSM) to Initiate a Phase 1 Clinical Study With High-dose Setanaxib","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Genkyotex","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genkyotex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genkyotex .."},{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIB7734","moa":"IL-7","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viela Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio .."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReGenTree Announces Efficacy Results of the Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Veloce BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halodine\u00ae Nasal and Oral Antiseptics Show Rapid Antiviral Activity Against SARS-CoV-2 (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veloce BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veloce BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Veloce Bio.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves ADCETRIS for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"SIRPalpha-CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Suspension","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Initiates Clinical Trial to Evaluate Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The AIDS Clinical Trials Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The AIDS Clinical Trials Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The AIDS C.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc To Develop Emergency and Conventional Covid-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Announces Abstracts Regarding Phase 1\/2 Study of SEL120 and SEL24\/MEN1703 Accepted for Presentation at 25th EHA Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS16","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intracoronary Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaxCyte to Present Poster Presentation on MCY-M11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 004","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CLR 131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Provides Updates on BLU-5937","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oasmia Pharmaceutical Announces Poster Presentation at American Society of Clinical Oncology 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda China Announces ADCETRIS\u00ae (Brentuximab Vedotin) ss Approved for the Treatment of Adult Patients with CD30-Positive Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immupharma\u2019s Efforts in the Fight Against Covid-19 with Lupuzor\u2122 and Ureka","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IPP-201101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuPharma.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics to Present First Efficacy & Safety Data From Its Lead Program CBX-12 and Data From CBX-13 at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Alphale-Exatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Data to be Presented at the EHA25 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy Between Merimepodib and Remdesivir Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Helix BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helix BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Helix BioP.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF231","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Shares FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Presentation of Positive Clinical Data for Envafolimab in MSI-H\/dMMR Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1\/2 ADXS-503 Trial in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for Presentation at 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"T-Cell mediated immune response","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r\/r DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pevonedistat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Reports Provides Update on Cytisinicline Development Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"Nicotinic receptor alpha4\/beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Says Coronavirus Treatment Trial Using Recovered Patients' Blood Could Start in July","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TAK-888","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397 - and its Discovery Platform at AACR 2020 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RBN-2397","moa":"PARP7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Upcoming Poster Presentation of Phase 1\/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HFB301001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"U3-1402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure to Present Clinical Data at AACR 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents New Preclinical Data Demonstrating Potential of EngEx\u2122 Engineered Exosomes to Drive New Class of Molecular Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"exoVACC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Pre-IND Submission to USFDA for Piclidenoson to Treat COVID-19 Infected Patients with Moderate-to-Severe Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Develops SARS-COV-2 Neutralising Affimer Reagents with Therapeutic Potential for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-COV-2 Neutralising Affimers","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Present Preclinical Data Demonstrating BT-001\u2019s Powerful Activity Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Syntekabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"STB-C017","moa":"Indoleamine 2,3-dioxygenase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syntekabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Presentations on TLANDO\u2122 at AUA Virtual Experience 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vividion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming AACR Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"UniCAR-T-CD123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEMoaB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ N.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Provides Update on Pivotal Phase 3 FLASH Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ\/11 Tumors and Preclinical MAT2A Synthetic Lethality Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE196","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-3526","moa":"MCL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"VSY Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Drug to Treat COVID-19, TR-C 19 is Now Ready for Human Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TR-C 19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VSY Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VSY Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VSY Biotec.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271 at AACR Virtual Annual Meeting II 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA2271","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IMGN151","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon Announces Update On Biosimilar Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer\u2019s Disease Does Not Meet Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"ICOS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T\u2122 at the AACR Virtual Annual Meeting II in June 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Presents Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells to Develop Engineered Cell Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals to Present Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1 beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the 25th EHA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ME-401","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BI1029539","moa":"Microsomal prostaglandin E synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Gesynta Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gesynta Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gesynta Ph.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Consortium Develops COVID-19 Vaccine for Human Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brinton Pharmato Launch Favipiravir, a Promising Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brinton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brinton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Brinton Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Data Show Moderna Covid-19 Vaccine Generates Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Seeks Ethics Approval for Covid-19 Trials in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCLA Researchers to Study Prostate Cancer Drug for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Degarelix Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Study finds Convalescent Plasma Safe for Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mayo Clinic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clini.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viiv HIV Prevention Trial Stopped Early on Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Bevespi Aerosphere approved in China for patients with COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Hong Kong Baptist University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HKBU Discovers New Treatment for Nasopharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"HONG KONG","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-Epstein-Barr virus drug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hong Kong Baptist University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hong Kong Baptist University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Hong Kong .."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi to Develop Prophylactic Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Prophylactic recombinant protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion Pharma's Udenafil Improved Ventricular Function Measured by Myocardial Performance Index in adolescents with SVHD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Udenafil","moa":"PDE5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIPAC Oncology Announces Presentation of Data from Phase 1\/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"LIPAC Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Onco.."},{"orgOrder":0,"company":"Mercaptor Discoveries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mercaptor Discoveries Uses its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Capton based drug","moa":"COX-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mercaptor Discoveries","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mercaptor Discoveries \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mercaptor .."},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in JHL's Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biolo.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Tobacco Files Supplemental New Drug Application for Use of Riona to Treat Adult Patients with Iron Deficiency Anemia in Japan","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC\u2122 ODT with 25 Presentations on the 2020 AAN Virtual Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Amivantamab","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics Receives IND Clearance from the US FDA for CT041 CLDN18.2-CAR-T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized anti-claudin18.2 autologous Chimeric Antigen Receptor T Cells","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Abcore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcore Announces a Panel of Patent Pending Functional Single Domain Antibodies for Use as Therapeutic Candidates for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Single domain antibodies","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Abcore","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abcore \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Abcore \/ N.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BM-Allo.MSC","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals to Support Global Clinical Trial Conducted by the CROWN Collaborative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Chloroquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Reports Additional Findings from Successful Phase II NASH Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva\u2019s Latest Research on Odiparcil\u2019s Mechanism of Action Published in Leading Peer-Reviewed Scientific Journal PLOS ONE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Odiparcil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Positive Feedback from The EMA on its Pivotal Trial Design for Trappsol Cyclo for Niemann-Pick Disease Type C1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CCX140","moa":"CCR2 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears the IND Application to Enable the Phase II Trial of ViralClear\u2019s Merimepodib to Treat Advanced COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triphase Accelerator and Catalent Biologics Share Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TRPH-222","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Triphase Accelerator \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triphase A.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson to Share Information on Clinical Data to be Presented at the ASCO and the Janssen Oncology Strategy and Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Teclistamab","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Doses First Chinese Patient in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durlobactam","moa":"Beta-lactamases A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Provides Recent Updates From Phase 3 SPIRIT 2 and Phase 3 SPIRIT 1 study in women with endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liproca Phase II b Study Results Indicate Cancer Control","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mgb-BP-3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopha.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Establishes Independent Data Monitoring Committee for Pivotal Phase 3 REGAL Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HIV Prevention Trials Network Finds Cabotegravir Linked With Prevention of HIV Infection in Cisgender Men and Transgender Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces Enrollment of First Patient in ESCAPE: a Phase II Clinical Trial With Vafidemstat In Severely Ill COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Outcomes of Recardio's Dutogliptin Published in the British Journal of Pharmacology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patients in Pivotal JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Highlights Findings in Abstract Accepted at OARSI 2020 and Published in Osteoarthritis and Cartilage","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results From the ProCID Study of Efficacy and Safety of 3 Different Dosages of Panzyga in Patients with CIDP Presented at AAN 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Normal Human Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"TASK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Africa BCG Booster Trials Seek Low-Cost Weapon Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TASK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"TASK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TASK \/ Not.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Tecentriq nabs solo OK in first-line lung cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy for Treatment of Progeria and Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-1454","moa":"PK M1\/M2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 and EAN Virtual Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Presentation of Update on Phase 1\/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Expands Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus \/ COVID-19 Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA\u2122 to Reverse Cancer Resistance to PARPi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Its Joint Venture, Aleor Dermaceuticals Receives USFDA Approval for Clobetasol Propionate Shampoo, 0.05%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRIEF-Dynavax Says Intend To Provide Update On Early-Stage Collaborations Regarding Potential Development Of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 adjuvanted vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Publication of TIBSOVO\u00ae Phase 3 Data in The Lancet Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals\u2019 Brilacidin Reduces Viral Titer of SARS-CoV-2 by 75 percent After Only 1 Hour of Preincubation In Vitro Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Salinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"St. Elizabeth Healthcare Partners with CTI and Pulmotect Becoming First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals' CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CRV431","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Receives FDA IND Authorization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm Shares Fall After Report Avigan Not Showing Clear Efficacy in Some Coronavirus Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioG.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Presentations on REBLOZYL at ASCO 2020 and EHA 2020 Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept-aamt","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NRP2 Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa\u00ae (Idebenone) in Duchenne Muscular Dystrophy (DMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO as a Treatment for Patients with Multiple Myeloma After","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OBI-3424","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Normal Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics\u2019 Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-1612","moa":"HSP90","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FT538","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brensocatib","moa":"DPP-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug AT-H201","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-coronavirus drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Doses First Patient In Pivotal Phase 3 Respect Trial Of Rezafungin In Patients Undergoing Allogeneic Blood And Marrow Transplantation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Progenabiome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenabiome Begins Hydroxychloroquine Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Progenabiome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Progenabio.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PneumoBlast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Completes Pre-IND Meeting with FDA on Epoladerm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107\/HyLeukin-7\u2122 in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 ASCP Virtual Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATL1102","moa":"CD49d","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Clears Appili Therapeutics\u2019 Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Trial to Investigate the Effects of VASCEPA\u00ae (icosapent ethyl) in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellect Biotechnology Plans to Examine Therapeutic Effects of Stem Cells to Reduce Pulmonary Manifestations Caused by COVID-19 Infection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ApoGraft","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cellect Biotechnology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellect Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellect Bi.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study of BioAegis\u2019 Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat + Exemestane in HR+, HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Alethia Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-16B5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alethia Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alethia Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alethia Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR at ASCP 2020 Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences\u2019 KBP-5074 Appears Well Tolerated in a single dose PK Study in severe CKD patients with and without hemodialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitovant Biopharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitovant Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitovant.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Antolimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Strongly Recommends CalciMedica to Move to a Blinded Placebo-controlled Trial with Auxora\u2122 in Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montefiore and Albert Einstein College Are First to Test A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaLead Pharma to Conduct Clinical Trials for Repurposed Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NLP21","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovaLead Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead P.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Group Receives FDA Approval for Ferriprox\u00ae (deferiprone) twice-a-day tablets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deferiprone","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics To Present Data on Multiple Immunomodulation Approaches with KRYSTEXXA at the EULAR 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Kancera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kancera Applies for a Phase II Study with KAND567 in COVID-19 Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KAND567","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kancera","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kancera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Announces Presentations During Upcoming Scientific Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX\u00ae3-71 (AF710B)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AF710B","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bozitinib","moa":"c-MET Type 1b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion Announces U.S. FDA Approval of KYNMOBI Sublingual Film for the Treatment of Parkinson\u2019s Disease OFF Episodes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Reports Additional Safety Data of Satralizumab in NMOSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin+Nivolumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Takeda\u2019s ALUNBRIG as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Shares Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First human trial of COVID-19 Vaccine from CanSino Biologic finds its Safe and Induces Rapid Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adenovirus vector based SARS-CoV-2 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's COVID-19 Vaccine Enters Phase 2\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Beijing Institute of Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First COVID-19 Vaccine Human Trial Finds ft is Safe, Induces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Beijing Institute of Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Beijing Institute of Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing In.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo, Sarah Cannon Research Institute begin phase 1 trial of DS-6157 in patients with advanced gastrointestinal stromal tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DS-6157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces FDA Acceptance of NDA for the Dasiglucagon Hypopal rescue Pen for Treatment of Severe Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Provides Update on COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme\u2019s Arimoclomol Receives US Fast Track Designation in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Announces U.S. FDA Acceptance of IND Application to Conduct Phase 1\/2 Clinical Trial of NT219 in Variety of Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NT219","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics to Present Interim Clinical Data for TriTAC\u00ae HPN424 at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN424","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Samumed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samumed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Samumed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samumed \/ .."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi\u2019s Regulatory Submission for Pegfilgrastim Biosimilar Accepted for Review By EMA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle\u00ae in Canada","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Finds Over 80% Of Patients with Spasticity And Cervical Dystonia Treated With Botulinum Toxin-A Experience Symptom Recurrence","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novalead to Start Trial on Anti- Parasitic Drug for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"NovaLead Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead P.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Submits IND Application with U.S. FDA for Multinational Phase 2b\/3 Human Study to Evaluate Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deltyba\u00ae (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Delamanid","moa":"H37Rv","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Outcomes Using RYONCIL in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Novaremed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaremed Submits IND to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI939","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Is Beginning Clinical Trials Of Its Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NVX\u2011CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo Linked With Survival of 85% of Newly Diagnosed Glioblastoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac\u00b4s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"ImmunSYS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunSYS Announces Upcoming Presentation at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cryosurgical tumor cell lysis","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunSYS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunSYS \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunSYS \/.."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Birmingham to Launch CATALYST Trial for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Birmingham \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Aarhus University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers IN Denmark Testing if Senicapoc Drug Can Reduce Lung Damage In Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Senicapoc","moa":"Intermediate conductance calcium-activated potassium channel protein 4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aarhus University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aarhus University \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aarhus Uni.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves First Covid-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Inactivated COVID-19 Vaccine Enters 2nd-Phase Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Massachusetts Eye and Ear and Massachusetts General Hospital Advancing Novel Experimental Gene-based COVID-19 Vaccine, AAVCOVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Massachusetts General Hospital \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"OncoGenerix USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncogen Researchers Propose Personalized Vaccinomics Strategy for the Novel China Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OncoGenerix USA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoGenerix USA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoGeneri.."},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trials For SARS-Cov-2 Vaccine Set to Start September","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"German Center for Infection Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"German Cen.."},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Development of a New Antiviral Agent Against SARS-Cov-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RHCDS-13b","moa":"Alpha-ketoamide protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"German Center for Infection Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"German Cen.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BPI-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Flow Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flow Pharma Announces Start of Pre-Clinical Efficacy Study for FlowVax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FlowVax COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Flow Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flow Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flow Pharm.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Approval of Veklury\u00ae (remdesivir) in Japan for Patients With Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Postponds Intercept's NDA Application Meeting for Obeticholic Acid","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOBI Announces Results From Pivotal Phase 2\/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOBI's Anakinra Found to Decrease Covid-19 Symptoms in a Small Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Shares Preclinical Efficacy Data on Telotristat Ethyl\u2019s Antiproliferative Effects Against Various Cancer Cell Lines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX to Present Data at the American Society of Clinical Oncology Virtual Scientific Program Featuring its Novel Probody Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTI-622","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LPCN 1144","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ENOB-HV-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Purdue University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Purdue-Developed Nanomaterial Significantly Enhances Potential COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Purdue University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purdue University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Purdue Uni.."},{"orgOrder":0,"company":"Osel Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osel\u2019s LACTIN-V Phase 2b Bacterial Vaginosis Study Published in the New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lactin-V","moa":"Hydrogen Peroxide","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osel Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Osel Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osel Pharm.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARAMIS Phase III Data to be Presented at ASCO 2020 Reveals Nubeqa Linked with Improved Overall Survival in Non-Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma to Present New Efficacy Data for Monalizumab in Combination with Cetuximab in Head and Neck cancer at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med to Highlight Clinical Data on Lead Products at the Upcoming ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Gets Priority FDA Review for Sutimlimab Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"Complement C1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Announces New Clinical Data Published on Menopur\u00ae in a Predicted High Responder Population","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Menotropins","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates to Present New Data on its Engineered Toxin Bodies at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MT-6402","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Pharmaceuticals Reports Harmful Association of Gucocorticoids in Interferon Beta-1a Treated Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19: AIIMS Bhopal Claims Good Results in Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mycobacterium w","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Cadila Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repurposed Drug Helps Obese Mice Lose Weight, Improve Metabolic Function","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Aging \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Phase 3 Trial of Ranibizumab Biosimilar Candidate, SB11 to Treat Namd Meets Primary Endpoints","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nellone Therapeutics Files Provisional Patent Application for NELL1 to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NELL1","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NellOne Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NellOne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NellOne Th.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Begins Phase 1b\/2 Study of HTX-034 to Treat Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Virginia Commonwealth University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virginia Commonwealth University \/ Hoth Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Virginia C.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Highlights Scientific Innovation and Advances in its Growing Oncology Portfolio at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Frozen Liquid","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme and GACI Global Initiate Study to Understand Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics to Present Preclinical Data from Lead ImmunoTAC Candidate, SBT6050, at Upcoming ASCO and AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera's Qinlock Becomes the First Drug to get FDA Approval for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STI-1499, a Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability to Completely Inhibit In Vitro Virus Infection In Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Delcath Systems Prices $22M Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Melphalan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.02,"dosageForm":"","sponsorNew":"Delcath Systems \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Optune\u00ae for the Treatment of Newly Diagnosed and Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Optune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"K S Kim International","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MGC Signs Multi-Country Distribution Agreement for Anti-Infective Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ArtemiC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"K S Kim International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"K S Kim International \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"K S Kim In.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammatory Disease Biotech Applied Molecular Transport Files for a $100 Million IPO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$494.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody fragment-based therapeutics","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0.48999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"CDR Life \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoMab and University Hospital Aachen to Start a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoMab Technology \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Te.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$31.3 million","upfrontCash":"Undisclosed","newsHeadline":"Orion Receives Total of EUR 28 Mllion Milestones From Bayer For Sales of Darolutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Tybourne Capital Management","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Tybourne Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Bags $60m to Change Cancer Care and Acquires Takeda\u2019s Rights to Develop and Commercialize DAY101 Worldwide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Day One Biopharmaceuticals \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"M-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Key Oncologics Have Signed an Exclusive Agreement to Commercialize Yondelis\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas' PROTAC\u00ae Protein Degrader ARV-110 Shows Promise in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ARV-110","moa":"Androgen receptor degradation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Oakwood Laboratories","sponsor":"Flow Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flow Pharma Announces Strategic Partnership with Oakwood Labs for GMP Manufacturing of FlowVax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"FlowVax COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oakwood Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oakwood Laboratories \/ Flow Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Oakwood La.."},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"VSV\u2206G-SARS-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Batavia Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Batavia Bioscience \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Batavia Bi.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals Enters into Cooperation with Guangzhou\u2019s Sun Yat-sen University to Develop a Treatment for SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antisense oligonucleotides","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"Proteona","sponsor":"Flinders University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Proteona\u2019s ESCAPE\u2122 platform selected for SARS-CoV-2 vaccine characterization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Proteona","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteona \/ Flinders University","highestDevelopmentStatusID":"1","companyTruncated":"Proteona \/.."},{"orgOrder":0,"company":"Adjuvance Technologies","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adjuvance Technologies Announces NIH Funding for COVID-19 Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"TQL1055","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adjuvance Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adjuvance Technologies \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Adjuvance .."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals Presents Edasalonexent, A Potential Foundational Therapy For Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minoryx Therapeutics Doses First Patient With Leriglitazone In Registration-Enabling Cald Nexus Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leriglitazone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Minoryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for Its Progranulin Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha-602","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's CAR-T Shows 100% Response Rate In Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"JNJ-4528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Final Guidance Backs Pfizer's Lorviqua","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorlatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Revives Eritorian as a Possible COVID-19 Treatment, Plans to Launch an International Collaborative Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Eritoran","moa":"TLR4\/MD-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA + LENVIMA Investigational Combination Therapy & HALAVEN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics to Report Results from Phase 1\/2 Trial with MultiTAA-Specific T Cell Therapy in Pancreatic Adenocarcinoma at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiTAA-Specific T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Showcase Oncology Portfolio and Innovative Pipeline at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Society of Clinical Oncology Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed\/Refractory Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-501","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with DMD Treated with Lead Candidate CAP-1002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s First Semaglutide Obesity Trial Hits The Mark","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"HHMI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial to Test Treatment that Targets Overactive Immune Response to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HHMI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HHMI \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HHMI \/ Not.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia's Mavacamten Met Primary and Secondary Endpoints in Phase 3 EXPLORER Clinical Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Amphista Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$525.0million","upfrontCash":"$10.0 million","newsHeadline":"ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vanderbilt University","amount2":0.53000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Vanderbilt University \/ ACADIA Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's ENHERTU\u00ae Granted Orphan Drug Designation in the U.S. for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Poxel","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","amount":"$19.4 million","upfrontCash":"Undisclosed","newsHeadline":"Poxel Successfully Raises \u20ac17.7 Million in a Capital Increase","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Poxel \/ JMP Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ JM.."},{"orgOrder":0,"company":"George Mason University","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Signs Agreement with George Mason Univeristy for Highly Pathogenic RNA Virus Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Set-point vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"George Mason University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"George Mason University \/ Emergex","highestDevelopmentStatusID":"1","companyTruncated":"George Mas.."},{"orgOrder":0,"company":"Purdue University","sponsor":"Gibson Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gibson Oncology Gains Commercial Rights to New Anti-Cancer Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Azaindenoisoquinolines","moa":"cMYC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Purdue University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purdue University \/ Gibson Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Purdue Uni.."},{"orgOrder":0,"company":"University of Montreal","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene, IRICoR and Universit\u00e9 de Montr\u00e9al Sign Collaboration and Exclusive Licensing Option on Novel Cancer Antigens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"T Cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Montreal","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Montreal \/ Medigene AG","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"UCI Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCI Health launches therapeutic clinical trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UCI Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCI Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCI Health.."},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Licenses Patent Rights for bacterial Vaccine Development","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae vaccine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude C.."},{"orgOrder":0,"company":"UCI Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCI Health to Initiate Drug Clinical Trial to Treat Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"UCI Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCI Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"UCI Health.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody-Based therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Epacadostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Epacadostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"AmideBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Orphan Drug Designation to Amidebio's Glucagon Analog for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-G023","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"AmideBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Therapeutics Becomes a Wholly Owned Subsidiary of Shionogi","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Zatolmilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ridgeback Biotherapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$3,065 million","upfrontCash":"$65.0 million","newsHeadline":"Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Repare Therapeutics","amount2":3.0699999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.0699999999999998,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"NanoViricides Completes $10.2 Million Registered Direct Offering Funds to Accelerate COVID-19 Drug Program and HerpeCide Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"NV-HHV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"NanoViricides \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"SeraNovo","sponsor":"Carna Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SeraNovo Enters into a Second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna\u2019s Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"SeraNovo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SeraNovo \/ Carna Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"SeraNovo \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Hutchison China MediTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Hutchison China MediTech Limited","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Alvaxa Biosciences","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Nanobodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alvaxa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvaxa Biosciences \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Alvaxa Bio.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$175.0 million","newsHeadline":"Gilead Sciences and Arcus Biosciences Ink Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AB154","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Yimiao Shenzhou Pharmaceutical","sponsor":"EdiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boya Series and Yimiao China Announced that They will Jointly Develop Allogeneic CAR-T Therapy For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Allogeneic CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yimiao Shenzhou Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yimiao Shenzhou Pharmaceutical \/ EdiGene","highestDevelopmentStatusID":"1","companyTruncated":"Yimiao She.."},{"orgOrder":0,"company":"AbCellera","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"AbCellera \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Brill International S.L","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe for its Microdacyn60\u00ae Eye Care","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sonoma Pharmaceuticals \/ Brill International S.L","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pha.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures LLC","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures LLC","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Shanghai Cell Therapy Group","sponsor":"Baize Plan Fund","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Cell Therapy Group Ink Collaboration with USC to Improve Ex Vivo Expansion of Hematopoietic Stem Cells for Clinical Applications","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Hematopoietic stem cells","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai Cell Therapy Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Cell Therapy Group \/ Baize Plan Fund","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai C.."},{"orgOrder":0,"company":"Conatus Pharmaceuticals","sponsor":"Histogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Conatus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Conatus Pharmaceuticals \/ Histogen","highestDevelopmentStatusID":"6","companyTruncated":"Conatus Ph.."},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"$76.0 million","newsHeadline":"Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Correvio Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Correvio P.."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"Nuformix","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VistaGen and Nuformix agree to develop cocrystalline forms of AV-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"4-Chlorokynurenine","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuformix \/ VistaGen","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/.."},{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$17.1 million","upfrontCash":"Undisclosed","newsHeadline":"Microbion Gets $17.1 M from CARB-X and Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0.02,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for I-SPY COVID Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Methamphetamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University Hospital Basel","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SYN-020","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Synthetic Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Cowen","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo and Syneos Health\u00ae Form Strategic Coalition for Development of Daiichi Sankyo\u2019s ADC Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"University of Toronto","sponsor":"Virna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SARS-CoV-2 neutralizing antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Toronto \/ Virna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck, Baylor College of Medicine Extend Collaboration to Advance Manufacturing Platform to Fight COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"WP1244","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaxxas","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaxxas \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Vaxxas \/ M.."},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis The.."},{"orgOrder":0,"company":"Southwest Research Institute","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"SwRI Awarded $1.9 Million Contract to Develop Treatment for COVID-19 in Collaboration with DOD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Antiviral drug therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southwest Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Southwest Research Institute \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Southwest .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Norton Heart & Vascular Institute in Louisvill","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Immune globulin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Norton Heart & Vascular Institute in Louisvill","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the NIH for the Treatment of Patients with Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck\u2019s KEYTRUDA\u00ae for Certain Late-Stage Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ RefleXion Medical","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Medac","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Enters Marketing Agreement For Biosimilar Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medac","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medac \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Fr.."},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck to Acquire Themis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Themis Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Themis Bioscience \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Themis Bio.."},{"orgOrder":0,"company":"CordenPharma","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Extends Lipid Supply For Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CordenPharma \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"CordenPhar.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$0.2 million","newsHeadline":"CNS Provides Update on Development Agreement for WP1122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pneumagen Announces \u00a34m Fundraising and Commits to Clinical Trial Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Carbohydrate binding modules","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Zafgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Merger","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Larimar Therapeutics \/ Zafgen","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and Sernova to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Recombinant pluripotent stem cell-derived pancreatic islet beta cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Oncology Biotech Repare Therapeutics Files for a $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"RP-3500","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Stempeutics","sponsor":"Novumcella","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stempeutics Inks Pact with Novumcella for Development Co-Operation of Stempeucel to Treat CLI Due to Buerger\u2019s Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bone marrow-derived allogeneic mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Stempeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stempeutics \/ Novumcella","highestDevelopmentStatusID":"12","companyTruncated":"Stempeutic.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ Astrazeneca","highestDevelopmentStatusID":"9","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"The National Cancer Center Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Establishes Illuminox\u2122 Alliance Institutes to Accelerate Development of Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"ASP-1929","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ The National Cancer Center Japan","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Oncoprex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Marinus Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Genexine","sponsor":"PT Kalbe Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kalbe to Start COVID-19 Vaccine Trial with S. Korean Pharma Firm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ PT Kalbe Farma","highestDevelopmentStatusID":"4","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Arrevus","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Arrevus Receives Dual Awards from NIH and Department of Defense for Development of ARV-1502","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ARV-1502","moa":"DnaK protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrevus \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Icagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$274.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Icagen\u2019s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Icagen","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Icagen \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Icagen \/ R.."},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ V.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen\u2019s Novel Wnt Activating Antibodies","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Wnt Activating Antibodies","moa":"WNT signalling pathway","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Announces Positive Topline Phase 3 ADAPT Trial Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark to Commence Another New Phase 3 Clinical Trial on a Combination of Two Anti-Viral Drugs Favipiravir and Umifenovir for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emgality\u00ae Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Announces Dosing of First Patient with Fourth Immtac\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IMC-F106C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Adds to Its Trove of Positive Data for Multiple Myeloma Contender as Rivals Continue to Command the Spotlight","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Shows Survival Benefit In HR+\/HER2 Advanced Breast Cancer With Consistent Results In Patients With More Aggressive Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen to Start Trial of SNG001 in COVID-19 Imminently","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Presents Data from Phase 1 Study of MSB2311 in Pre-treated Advanced Solid Tumors and Select Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MSB2311","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remdesivir Preliminary Results From NIAID Trial Published","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize Enrolls First Patient In Phase II Trial of Nitric Oxide Releasing Solution for Prevention and to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Provides Update on Coronavirus Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves VESIcare LS\u2122 (solifenacin succinate) Oral Suspension for Pediatric Patients","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaled Suspension","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Methadone","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Releases CBN Preclinical Results in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Publication of Data from Ongoing COMBAT\/KEYNOTE-202 Clinical Trial in Nature Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Kantum Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-1801","moa":"P2Y14 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kantum Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kantum Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kantum Pha.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Announces Rare Pediatric Disease Designation for ATR-12 for the Treatment of Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ N.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review Fresenius Kabi\u2019s BLA Submission for Pegfilgrastim Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Launch of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b\/2 Study of ALRN-6924","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves New Pediatric Formulation of SIRTURO\u00ae (bedaquiline) as Part of Combination Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bedaquiline","moa":"ATP synthase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with IBS-D","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review of Nucala for Patients with Hypereosinophilic Syndrome","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Covered Status for AMZEEQ\u00ae (minocycline) topical foam, 4%, on Additional Commercial Formulary","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Ther.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-3434","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Organicell Flow","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aqualung Therapeutics Gets NIH Approval to Advance to IND-Enabling Studies for Development of Novel Antibody for ARDS and the Critically Ill","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung T.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal P.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Announces New Recommendations for Rubraca\u00ae (rucaparib) Tablets in Updated NCCN Guidelines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Clinical Data to be Presented at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TLY012","moa":"DR5","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Theraly Fibrosis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theraly Fibrosis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theraly Fi.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present at Jefferies Virtual Global Healthcare Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NDX-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Further Broadens Drug Development Capabilities with Addition of R\u00f3is\u00edn Armstrong, PhD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Tests Diabetes Drug Farxiga for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche initiates Phase III Clinical Trial of Actemra\/RoActemra Plus Remdesivir in Hospitalised Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Advances LYT-100 for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces FDA Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Treatment of KRAS-Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Lyon Sud Hospital Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avelumab Appears to be Effective in Preventing Relapse in Women With GTT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lyon Sud Hospital Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyon Sud Hospital Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyon Sud H.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Reports Positive Phase 3 BOSTON Data at the American Society of Clinical Oncology 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora\u2122 in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dactolisib","moa":"TORC1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals Receives Positive CHMP Opinion For HEPCLUDEX\u00ae (bulevirtide)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"HDV receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MYR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"MedStar Washington Hospital Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Development of Drug Resistance in Colon Cancer Patients Contributed to Failure of Oxaliplatin-based HIPEC PRODIGE 7 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MedStar Washington Hospital Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MedStar Washington Hospital Center \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedStar Wa.."},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AMV564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Updated Results of ENHANCE 1, Investigating HALAVEN plus KEYTRUDA in Patients with Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Eribulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"JNJ-4528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib in Advanced NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Presents Findings from Clinical Studies Evaluating TP-1287 and TP-3654 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-1287","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE\u00ae (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1\/2 Study of GB1275","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GB1275","moa":"CD11b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Response and Translational Data from DeCidE1, Phase 2 Study of DPX-Survivac Immunotherapy in Advanced Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD8+ T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Presents Data from Phase 1b\/2 Study of Rebastinib and Paclitaxel Combo in Advanced Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rebastinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO for Preventive Treatment for Hereditary Angioedema Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Reports Results from Exploratory Analyses of HER2CLIMB for TUKYSA in Brain Metastases Patients With HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Alteogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-P7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alteogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IO-202","moa":"LILRB4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Talaris\u2019 Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics Presents Data Supporting Clinical Activity of SBT6050 as a Single Agent and in Combination with Trastuzumab for HER2-Expressing Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead's Magrolimab and Azacitidine Combo Shows Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta\u00ae (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig\u00ae for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Phase 1b\/2 DEDUCTIVE Study of FOTIVDA in Combination with IMFINZI Advances to Phase 2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Receives Positive CHMP Opinion for Janssen\u2019s Investigational Preventive Ebola Vaccine Regimen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion to Present Results from Multiple Preclinical and Health Economic Studies at the American Transplant Congress Virtual Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treos Bio Reports Positive Final Results of Phase I\/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PolyPEPI1018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Treos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Final Results of GENUINE Phase 3 Study Testing Ublituximab + Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"Siglec-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-0046","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Announces New Data Related To Its K-NK Cell Therapy Platform Presented today at the ASCO 2020 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTI-622","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Announces Approval of the REVocan Study by Regulatory Authorities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Highlights Updated Envafolimab Results in MSI-H\/dMMR Colorectal Cancer and Results from Clinical Trial of Opdivo and Yervoy Combination Therapy in Undifferentiated Pleomorphic Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiTAA-Specific T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show First-Line Triplet Regimen of Pembrolizumab, Herzuma\u00ae and Chemotherapy are Effective in Treatment of HER2+ Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"American Society of Clinical Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAPUR Study Shows Encouraging Results for Olaparib in BRCA-Mutated Advanced Prostate and Pancreatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"American Society of Clinical Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"American Society of Clinical Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American S.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics to Present Additional Data at ASCO Showing Clinical Benefit from ONC201 for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelcitoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Zhongnan Hospital of Wuhan University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Effects of Dipyridamole on COVID-19 Patients With Coagulation Dysfunction 2 Coagulation Dysfunction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dipyridamole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhongnan Hospital of Wuhan University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhongnan Hospital of Wuhan University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhongnan H.."},{"orgOrder":0,"company":"Apeptico","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APEPTICO supplies SOLNATIDE Investigational Medicinal Product to the Medical University Vienna for the assessment of efficacy in COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Solnatide","moa":"Sodium channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeptico","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apeptico \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Submits BLA to U.S. Food and Drug Administration for Pegunigalsidase Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MesenCure","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioG.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Launches ENHERTU\u00ae in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Evofem Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"1","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Vaxine","sponsor":"Medytox","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxine and Medytox partner on Covid-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVAX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxine \/ Medytox Inc","highestDevelopmentStatusID":"4","companyTruncated":"Vaxine \/ M.."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KPC34","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkido Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkido Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alkido Pha.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Report Positive Topline Results from the NORA Phase 3 Study of ZEJULA\u00ae as Maintenance Therapy Platinum-sensitive, Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-002","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XTANDI\u00ae (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GC027","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Plus Tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Poster Presentations at EULAR 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Evofem Biosciences' Phexxi\u2122 (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therap.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1\/2a Trial Part A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"OrPro Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrPro Therapeutics Advances a New Inhalation Treatment Approach for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP100S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OrPro Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OrPro Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OrPro Ther.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology Announces Presentation of Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at 2020 ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR\u2019s Tomivosertib Shows Positive Phase 2 Results in Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"Mapk 1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan Approves Gilead's Remdesivir to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Lilly to Collaborate with Duke Clinical Research Institute on a Trial Examining Jardiance's Effects Following an Acute Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ Boehringer Ingelheim","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clini.."},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"rVSV\u0394G-SARS-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BAR.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"CLBS12","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Completes $100 Million Series C Financing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Antibody-Oligonucleotide Conjugates","moa":"DMPK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Avidity Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"ADX-914","moa":"IL-7R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ T.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Initiates Phase 1\/2 Study of APL-9 in Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-9","moa":"Complement C3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Announces Start of Clinical Trial to Evaluate Leukine in Respiratory Illness in Patients with COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"ProSciento","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nimacimab","moa":"CB1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Skye Bioscience \/ ProSciento","highestDevelopmentStatusID":"8","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL\u2011CEBPA in Combination with Sorafenib in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"CCAAT\/-binding protein alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Releases Takeda From Commitment to Divest Shire\u2019s Pipeline Compound SHP647","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin Cell adhesion molecule-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation to Present Clinical Trial Results at the Annual Meeting of the American Society for Radiation Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Files Patent for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Hana Pharm","sponsor":"Bold Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics Executes Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hana Pharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hana Pharm \/ Bold Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hana Pharm.."},{"orgOrder":0,"company":"Chimeron Bio","sponsor":"Mason University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chimeron Bio and George Mason University Partner to Develop a Coronavirus Vaccine using ChaESARTM Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Self-amplifying RNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chimeron Bio \/ Mason University","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron B.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","amount":"$3.0 milion","upfrontCash":"$2.0 milion","newsHeadline":"Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$20.0 million","newsHeadline":"SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"SPARC \/ Sun Pharma","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Su.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Together with Partner Astellas, Reports Final Prosper Results Show Xtandi Extends Overall Survival In Men With Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Montefiore Health System","sponsor":"NIH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montefiore Health System","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Montefiore Health System \/ NIH","highestDevelopmentStatusID":"10","companyTruncated":"Montefiore.."},{"orgOrder":0,"company":"McMaster University","sponsor":"Ceapro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Yeast beta-glucans","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"McMaster University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"McMaster University \/ Ceapro","highestDevelopmentStatusID":"4","companyTruncated":"McMaster U.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Receives Positive CHMP Opinion For A Third Nintedanib Indication In Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion to Extend Invokana Indication to Reflect Improved Renal Outcomes in Diabetic Kidney and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napp Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharm.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Unveils Interim Data from OPTIC Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Translational Data Supports DPX-Survivac Mechanism of Action","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-Survivac","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Reports Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"saRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Harvard Stem Cell Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Muscular Dystrophy Collaboration Aims to Correct Muscle Stem Cells\u2019 DNA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CRISPR\/Cas9 genome","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Harvard Stem Cell Institute","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Stem Cell Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Harvard St.."},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis, NHS England team up in 'world-first' access agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"NHS Englan.."},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Viral vector gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vigene Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vigene Bioscience \/ ASC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vigene Bio.."},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"OMNI nuclease","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Emendo Biotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"1","companyTruncated":"Emendo Bio.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"MUt transgene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Axovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Announces Positive 12 Month Data on Axo-Lenti-PD and Provide Updates on Gene Therapy Pipeline Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Axovant","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axovant \/ .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1\/2 Clinical Trials in Achromatopsia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Adeno-associated virus-based gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-ANGPTL3-LRx","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GJB2 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-102","moa":"Gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKI2S","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Ophthalmic gene therapy company launches with \u00a32.5m seed cash","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikarovec \/ UKI2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Results from URO-902 Phase 1 Trials","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Clinical Data Presentation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Reveals First Patient Dosed in Phase 1 AAV Gene Therapy Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NAN-101","moa":"PP1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex to Focus Its Clinical Efforts on Oncoprex with Osimertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Erlotinib","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"FerGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FerGene to Present Bladder Cancer Data at 2020 ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nadofaragene firadenovec","moa":"INF alpha 2b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"FerGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"FerGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FerGene \/ .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Presents Initial Data for Cystinosis Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Provides Update on FDA Review of LB-001 NDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Provides Research Update for CTX120","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline presents data on its AAV-based gene therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics\u2019 PR001 Gets Orphan Drug Designation By FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"REN001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Completes Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1\/2 Clinical Trial for X-Linked Retinitis Pigmentosa","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AGTC-501","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI\u2019s 15th Annual Huntington\u2019s Disease Therapeutics Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Akouos","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akouos Closes $105 Million Series B Financing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.11,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Akouos \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ P.."},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HORAMA Signs Exclusive License Agreement with Leiden University Medical Center","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1 gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leiden University Medical Center \/ Horama SA","highestDevelopmentStatusID":"1","companyTruncated":"Leiden Uni.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Partners with Vanderbilt University Medical Center for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Synthetic genes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"The Invus Group","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Closes $170 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"Cell and gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"ElevateBio \/ The Invus Group","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV\u00ae Technology Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gene Therapy-AAV8","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Ultragenyx","highestDevelopmentStatusID":"1","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,080.0 million","upfrontCash":"$60.0 million","newsHeadline":"Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Small interfering RNA","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":2.0800000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.0800000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Announces Investigational New Drug Application Active for PR006","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson\u2019s Disease with GBA1 mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Gene Therapy Publishes Preclinical Data of Ocugen\u2019s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NR2E3-AAV","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 Phase III Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NG-641","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Akamis Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline receives Orphan Drug Designation from the European Commission","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer to Host Free Webinar on Pfizer\u2019s Advancement to Phase III Gene Therapy Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Peer-Reviewed Publication Of HMI-102 Investigational Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Advances RNAi Approaches to Target Highly Conserved Regions of Coronavirus RNAs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNAs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion\u2019s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Provides Initial Observations From PHYOX 3 Trial of Nedosiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics to Present at AAT-AD\/PD Focus Meeting 2020: Advances in Alzheimer\u2019s and Parkinson\u2019s Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sofinnova Telethon Fund Backs Naldini's Gene Therapy Biotech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire .."},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"CureDuchenne Ventures","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Non-viral gene therapy","moa":"Dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Myosana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myosana Therapeutics \/ CureDuchenne Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Myosana Th.."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Pharmaceuticals and Affinia Therapeutics Set Up Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"AAV capsid-gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affinia Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"PBM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Announce $30 Million Seed Financing and Strategic Partnership with the UT Southwestern Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"TGTX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Taysha Gene Therapies","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ PBM Capital","highestDevelopmentStatusID":"5","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$17.3 million","upfrontCash":"Undisclosed","newsHeadline":"Genespire Secures \u20ac16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire .."},{"orgOrder":0,"company":"UT Southwestern","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Inks an Unrivaled Alliance with the UT Southwestern Gene Therapy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"AAV gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"UT Southwestern","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UT Southwestern \/ Taysha Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwe.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson\u2019s Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobra Biologics successfully completes key milestone in CombiGene\u2019s epilepsy project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Gene-modified cellular therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-C","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TissueGene-C","moa":"Chondrocytes","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Kolon TissueGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Tiss.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I\/II Trial of GS030","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GS030","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Receives Advanced Therapy Medicinal Product Classification from EMA for MB-107 Lentiviral Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Announces Additional Positive Long-Term and Interim Phase I\/Iia Trial Update for RGX-314 for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces Upcoming Oral and Poster Presentations at the American Society of Gene and Cell Therapy Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the ASGCT 23rd Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"$125.0 million","newsHeadline":"Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ultragenyx Pharmaceutical","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Daiichi Sankyo","highestDevelopmentStatusID":"3","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"KT-A112","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kriya Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Kriya Therapeutics \/ QVT","highestDevelopmentStatusID":"1","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"SR-Tiget","sponsor":"Genespire","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genespire and SR-Tiget Announce Alliance for the Development of Transformative Gene Therapies for Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"MicroRNA-regulated lentiviral vectors","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SR-Tiget","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SR-Tiget \/ Genespire","highestDevelopmentStatusID":"1","companyTruncated":"SR-Tiget \/.."},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"siRNAs","moa":"MSUT2 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"DTx Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DTx Pharma \/ Alzheimer's Association","highestDevelopmentStatusID":"4","companyTruncated":"DTx Pharma.."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Affinia Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Facial Pain Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AAV vectors","moa":"Ligand gated ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coda Biotherapeutics \/ Facial Pain Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Coda Bioth.."},{"orgOrder":0,"company":"Hitachi Chemicals","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma ink Clinical and Commercial Manufacturing Pact with Bluebird Bio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemicals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hitachi Chemicals \/ Bluebird bio","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Ch.."},{"orgOrder":0,"company":"Axplora","sponsor":"Lysogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep and Lysogene Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"LYS-GM101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Axplora","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axplora \/ Lysogene","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ .."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio and UNC Team Up to Develop Angelman Syndrome Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AAV gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Toshiba Corporation","sponsor":"Shinshu University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shinshu University, Toshiba Develop Tumor-Tropic Liposome Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Liposome vector based gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Toshiba Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toshiba Corporation \/ Shinshu University","highestDevelopmentStatusID":"1","companyTruncated":"Toshiba Co.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Teams With Mass. Eye & Ear to Join Coronavirus Vaccine Chase","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AAVCOVID","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Phoenix Nest","sponsor":"Cure Sanfilippo Foundation","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Cure Sanfilippo Grants $380,000 to Type C Gene Therapy Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"AAV-TT","moa":"HGSNAT gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Phoenix Nest","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phoenix Nest \/ Cure Sanfilippo Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Ne.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAVrh8-HexA\/HexB","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Provides Update regarding SGT-001 Phase I\/II Clinical Hold on IGNITE DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics's Preclinical Data reveal In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TANGO antisense oligonucleotides","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Demonstrates FORCE\u2122 Platform\u2019s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FORCE-M23D","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd ASGCT Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Synthetic AAV capsids Proteins","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Thera.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Presents Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PBKR03","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection\n","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1\/2 Study of DTX301 Gene Therapy OTC Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DTX301","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Presents Data on MGTA-145 at The Annual Meeting of American Society of Gene and Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Self-delivering RNAi compounds","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Shares Positive Interim Results from Phase 1\/2 Trial of KB105 in TGM1-related Autosomal Recessive Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KB105","moa":"Transglutaminase 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s New Phase 1b Results of Gene Therapy in Ambulatory Boys with DMD Support Advancement into Pivotal Phase 3 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avexis Receives EC Approval and Activates \u201cDay One\u201d Access Program for Zolgensma\u00ae, the only Gene Therapy for Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"3 Hemophilia B Patients Report Uniqure's AMT-060 Gene Therapy Gave Them Normalcy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV5-hFIX","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gene Therapy Shows Promise in Mouse Model of Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ETX101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Shares Positive Preclinical Data With Scientific Evidence for its Ongoing Clinical Program in X-Linked Retinitis Pigmentosa Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Wins Conditional EU Approval for Gene Therapy Zolgensma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec-xioi","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Agrees to Phase 1 Trial of ET3, Gene Therapy for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ET3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Expression Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Expression Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Expression.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides 4 Years of Clinical Data from Ongoing Phase 1\/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO\u2122 and Its Electroporation Gene Delivery System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Passage Bio","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Passage Bio Adds More Programs, Tech and Time to UPENN Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"University of Pennsylvania \/ Passage Bio","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Provides Update on Preclinical Experiment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VXL-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Tel Aviv Medical Center","sponsor":"Vaxil Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxil Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Peptide based COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tel Aviv Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tel Aviv Medical Center \/ Vaxil bio","highestDevelopmentStatusID":"4","companyTruncated":"Tel Aviv M.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Tel Aviv Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Tel Aviv Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Reports New Responses in Esophagogastric Junction, Lung, and Head and Neck Cancers Using its SPEAR T-cells Targeting MAGE-A4","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Therapeutics Provides Clinical Update on its Allogeneic Platforms ADP-A2M4CD8, ADP-A2M4 and ADP-A2AFP at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$897.5 million","upfrontCash":"$50.0 million","newsHeadline":"Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"T cell based therapy","moa":"T-cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adaptimmune Therapeutics","amount2":0.90000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Opinion for Orphan Drug Designation for ADP-A2M4 in EU for Treatment of Soft Tissue Sarcoma from EMA' Committee","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Clover Biopharmaceuticals Announce Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 S-Trimer","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"JAB-3068","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Jacobio","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"REGENERON","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$70.0 million","newsHeadline":"Regeneron and Intellia Therapeutics Expand Collaboration to Develop Crispr\/Cas9-Based Treatments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"CRISPR\/Cas9 based gene therapy","moa":"Factor IX gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ REGENERON","highestDevelopmentStatusID":"4","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences and Merck Announce Collaboration to Explore Promising New Composition Treatment for Head and Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Immune-activating antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Biotheus","highestDevelopmentStatusID":"1","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Ragon Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC\u2122 Vaccine Platform in SARS-CoV-2 and HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"exoVACC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Ragon Institute","highestDevelopmentStatusID":"2","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"Undisclosed","newsHeadline":"Processa Pharmaceuticals Has Entered into an Agreement with Aposense, to License in the Next Generation Irinotecan Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$35.6 million","upfrontCash":"Undisclosed","newsHeadline":"Kaleido Biosciences Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"KB109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA Biopharma Announces $9.4 Million Registered Direct Offering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0.01,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Secures $50 Million Credit Facility","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Live modified horsepox virus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"ImStem Biotechnology","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent for Investigational MSC Candidate IMS001 for COVID-19 and ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImStem Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImStem Biotechnology \/ AgeX","highestDevelopmentStatusID":"1","companyTruncated":"ImStem Bio.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Personalis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarepta Therapeutics \/ Personalis","highestDevelopmentStatusID":"1","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"MigVax","sponsor":"OurCrowd","pharmaFlowCategory":"D","amount":"$100.0 Million","upfrontCash":"Undisclosed","newsHeadline":"OurCrowd Launches $100 Million Pandemic Innovation Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"MigVax-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MigVax \/ OurCrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ O.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Trevena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Trevena","highestDevelopmentStatusID":"6","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc and EpiVax Team up in Development of COVID-19 Emerging Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"OMV-peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ I.."},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Hillhouse","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hillhouse Leads $160M Round for Chinese Antibody Maker Genor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Genolimzumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genor Biopharma","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Genor Biopharma \/ Hillhouse","highestDevelopmentStatusID":"8","companyTruncated":"Genor Biop.."},{"orgOrder":0,"company":"Edith Wolfson Medical Center","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis\u2019 Proprietary POCare Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Tumor infiltrating lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Edith Wolfson Medical Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edith Wolfson Medical Center \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Edith Wolf.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel\u00ae and Seroquel XR\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Alvogen Korea","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"NodThera","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"NodThera Announces Close of $55 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"NodThera","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"NodThera \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"Shorla Nabs $8.3M to Bring Improved Cancer Meds to the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"SH-105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shorla Oncology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Shorla Oncology \/ Seroba Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Exeltis Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Exeltis Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Selects AGC Biologics to Manufacture Matrix-M\u2122 Adjuvant for Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Katana Pharmaceuticals","sponsor":"March of Dimes","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Katana Pharmaceuticals Gets $1.05 M Grant to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Non-opioid drug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Katana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Katana Pharmaceuticals \/ March of Dimes","highestDevelopmentStatusID":"1","companyTruncated":"Katana Pha.."},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Distributed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Distributed Bio Partners With Mediar Therapeutics, Inc.","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Mediar Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Distributed Bio","highestDevelopmentStatusID":"2","companyTruncated":"Mediar The.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Paracetamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Aqualung Therapeutics Gets $2.3 M NIH Fast-Track Award To Develop Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"ALT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung T.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune\u2122 Immune Boosting Data in Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Concept Life Sciences","sponsor":"AstronauTx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Astrocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Concept Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Concept Life Sciences \/ AstronauTx","highestDevelopmentStatusID":"2","companyTruncated":"Concept Li.."},{"orgOrder":0,"company":"American Porphyria Foundation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"American Porphyria Foundation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Porphyria Foundation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"American P.."},{"orgOrder":0,"company":"Duchenne research","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"$1M Gene Therapy Research Grant Launched by PPMD, Duchenne UK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"DMD gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Duchenne research","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duchenne research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Duchenne r.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","amount":"$62.5 million","upfrontCash":"Undisclosed","newsHeadline":"Prilenia Therapeutics Raises $62.5M to Fund Late Stage Trials In HD and ALS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Morningside Venture","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"AntiCovir","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Sulopenem","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athira Pharma Closes $85 Million Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"NDX-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Perceptive Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1\/2 Clinical Trial of INOVIO's INO-4800 in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Seoul National University Hospital \/ INOVIO","highestDevelopmentStatusID":"6","companyTruncated":"Seoul Nati.."},{"orgOrder":0,"company":"Leidos","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Microbially derived peptides","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leidos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leidos \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Leidos \/ T.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"U.S FDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aldeyra Therapeutics Reaches Agreement with the US FDA for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ U.S FDA","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Completes the Acquisition of Symphogen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Symphogen \/ Sevier","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mereo BioPharma Announces Completion of $70 Million Private Placement and Plans to Develop Etigilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Private Placement","leadProduct":"Etigilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Janchor Partners","pharmaFlowCategory":"D","amount":"$310.0 million","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Completes US$310 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Everest Medicines","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Janchor Partners","highestDevelopmentStatusID":"1","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"CSL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$270\u202c.0 million","upfrontCash":"$125.0 million","newsHeadline":"UCB Acquires Engage Therapeutics for Staccato\u00ae Alprazolam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.27000000000000002,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ UCB","highestDevelopmentStatusID":"10","companyTruncated":"Engage The.."},{"orgOrder":0,"company":"VIVEbiotech","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VIVEbiotech Collaborates with Xyphos Biosciences for Clinical Development Support Of Convertible CAR-T\u2122 Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"convertible CAR-T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"VIVEbiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VIVEbiotech \/ Xyphos Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"VIVEbiotec.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Receives Financing Commitment of up to CHF 20 Million from Fund Managed by Highbridge Capital Management","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Reading Scientific Services","sponsor":"Ethypharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Fentanyl","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reading Scientific Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reading Scientific Services \/ Ethypharm","highestDevelopmentStatusID":"1","companyTruncated":"Reading Sc.."},{"orgOrder":0,"company":"PolyPeptide Group","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PolyPeptide Group Partners with Novavax on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PolyPeptide Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolyPeptide Group \/ Novavax","highestDevelopmentStatusID":"6","companyTruncated":"PolyPeptid.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Join Hands to Develop Antibody Therapy to Prevent and Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AbbVie","highestDevelopmentStatusID":"1","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"DLA Piper","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"Undisclosed","newsHeadline":"DLA Piper Advises Iovance Biotherapeutics in its US$604 million Common Stock Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Lifileucel","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ DLA Piper","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus Venture\nPartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Columbus Venture\nPartners","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Espero BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Espero BioPharma, Inc. Expands Collaboration Effort for Tecarfarin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin K","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Espero BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Espero BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Espero Bio.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$98.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cullinan Oncology Completes $98.5 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"VK-2019","moa":"EBNA1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Novavax","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Gets US Defense Funding For Its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Novavax \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Surgical Infection Biotech PolyPid Refiles for a $58 Million IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Akouos","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing loss biotech Akouos files for a $100 million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.10000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akouos \/ BofA Securities","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ B.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda","pharmaFlowCategory":"D","amount":"$227.0 million","upfrontCash":"$5.0 million","newsHeadline":"LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug Conjugate Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"LCB73","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Iksuda","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"National Centre for Research and Development","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ryvu Therapeutics to Receive NCRD Grant to Develop Targeted Immuno-Oncology Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"SEL120","moa":"CDK8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ National Centre for Research and Development","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Plexxikon","sponsor":"Novellus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexxikon \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon .."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$14.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bharat Bio Consortium Gets $14m Grant for Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"BBV87","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bharat Biotech","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bharat Biotech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Scandion Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Scandion Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Delos Psyche Research Group","sponsor":"New Wave Holdings Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Wave Holdings Corp Provides Funding for LSD Research Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delos Psyche Research Group","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delos Psyche Research Group \/ New Wave Holdings Corp","highestDevelopmentStatusID":"1","companyTruncated":"Delos Psyc.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GCAR Selects DelMar Pharmas' VAL-083 to Participate in GBM AGILE Study In Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Brown University Award of $3.4M includes funds for IND and First Clinical Trial of ONC212","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown Univ.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Rottapharm Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.3 million","newsHeadline":"Rottapharm Biotech and Takis Enter an Agreement for the Co-Development of the Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-eVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Rottapharm Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"GE Healthcare Inc","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Covigenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GE Healthcare Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GE Healthcare Inc \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"GE Healthc.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$25.0 million","newsHeadline":"Revance and Mylan to Advance Development Program for Biosimilar to BOTOX\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OnabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Mylan","highestDevelopmentStatusID":"1","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Begins First Human Tests of an Antibody Drug Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Korea's Celltrion Aims to Start In-Human COVID-19 Drug Trial in July","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 antiviral antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum's Future Looks Uncertain, After Lead Antibiotic Fails Consecutive Pivotal Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Submits NDA to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Plans Covid-19 Clinical Trial Program Launch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Taltz Outpaces Novartis' Cosentyx with 4th FDA Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe's NSAID Alternative Curbs Arthritis Pain in Phase 2","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences\u2019 Roluperidone Fails In Phase III Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma to Trial Nafamostat for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"ChemRar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Grants Temporary Approval for Avifavir to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ChemRar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ChemRar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChemRar \/ .."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Announces Positive Results From OCEAN Study Between Melflufen & Pomalidomide In Patients With RRMM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Results From INSIGHT-004 Phase I study Of EFTI In Combo With Avelumabto Treat Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen to Discontinue Phase 3 oGVHD Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RNA Gene Therapy Seen to Effectively Treat Hemophilia A Mouse Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FVIII mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seattle Children\u2019s Research Institute \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seattle Ch.."},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivet\u2019s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VTX-803","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Ther.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-129","moa":"CFTR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces Submission of Request for Final Approval of Brixadi\u2122 for the Treatment of Opioid Use Disorder in the US","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Initiates Rolling Submission Of New Drug Application For Arimoclomol With FDA in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Longeveron Mesenchymal Stem Cells","moa":"VEGF","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces U.S. Availability of DAYVIGO\u00ae (lemborexant) CIV, a New Treatment Option for Adults With Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Gets FDA Clearance of IND Application for Phase 1\/2 Triple Combination Study of COM701 with Opdivo and TIGIT Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SYNB1891","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives Chinese Regulatory Approval to Begin Seamless Phase 2\/3 Clinical Trial of HBM9161 in Graves\u2019 Ophthalmopathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Gets FDA Acceptance for Filing of an NDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO-11006","moa":"MARCKS protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biomarck Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck P.."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Shionogi\u2019s sNDA with Priority Review for FETROJA\u00ae for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OpRegen RPE Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Vault Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Vaccine Development Underway by Vault Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vault Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vault Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vault Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXIM\u00ae Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SPX-1009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biote.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Announces Completion of ReveraGen\u2019s Long-Term Extension Study with Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum\u2019s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Gets U.S. FDA Acceptance of Biologics License Application for Danyelza\u2122 in Neuroblastoma for Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellenkos Gets FDA Clearance to Initiate Phase 1 Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells for COVID-19 Associated ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cord Blood-Derived T-Regulatory Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Launches Clinical Trial of T-COVIDTM, Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"T-COVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ\u2122 (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Reports Interim Results from Phase 1b\/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"E-EDV-D682","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnGeneIC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok\u00ae Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk To Present New Data at the 80th Annual American Diabetes Association Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the American Academy of Dermatology Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announces Topline Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gusacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia in Patients with Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announces First European Launch of Isturisa\u00ae (osilodrostat)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and NeuroRx Enrolls First Patients with RLF- 100 in Phase 2b\/3 Clinical Trial in Patients with COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Issued European Patent for Method of Treating Alzheimer\u2019s Disease with ANVS401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Ther.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety and Efficacy Results from Part I of MATINS Study Presented in Poster at ASCO20 Virtual","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Stem cell gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Reports Data From and Planned Continuation of the ILLUMINATE-206 Trial for Micro-Satellite Stable Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Sarclisa\u00ae (isatuximab) for Adults with Relapsed And Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarclisa Combination Therapy Demonstrated Superior Progression Free Survival and Clinically Meaningful Depth of Response In Relapsed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Begins Enrollment in Phase 1b\/2a Trial of HST 001 to Treat Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Complexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CXA-10","moa":"Nrf2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Complexa","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complexa \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1\/2 Study of HPK1 Inhibitor, CFI-402411","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-402411","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Gets Approval for BRUKINSA in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia and Two more Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Provides Status Update in the Portfolio Projects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax\u00ae-L for Glioblastoma Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Invited to Present Seclidemstat Data at Pediatric Oncology Subcommittee of the FDA Advisory Committee Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Memgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memgen Announces Research to Be Presented at 2020 American Association of Cancer Research (AACR) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MEM-288","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memgen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Memgen \/ N.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NurOwn","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alize Pharma 3 Announces Rebranding to Amolyt Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alize\u0301 Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pha.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Jay Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jay Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Jay Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jay Pharma.."},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings Coll.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer with Intra-Arterial Gemcitabine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-arterial","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Presents New Data Across Continuum of Care from its Broad Renal Portfolio at ERA-EDTA 2020 Virtual Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New First-in-Class Phase 3 TREMFYA\u00ae (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel to Present Four Posters Highlighting IRAK1\/4 Inhibitor at the EULAR 2020 E-Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibafloxacin","moa":"IL-1 receptor-associated Kinase-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Files Pre-CTA Meeting Request with Health Canada and Update on IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centres","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FOL-005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follicum A.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Publication Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Provides Data Update from MISSION Study of KZR-616","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Shares New Data for Olumiant\u00ae in Rheumatoid Arthritis and Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented on KRYSTEXXA Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Publication of the Phase 1 Clinical Trial Results for ATI-450","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"Mapk2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Initiates Patient Recruitment for AK002 Registrational Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Presented at EULAR and ERA-EDTA Congresses","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to Test One-Dose Antibiotic for the Prevention of Maternal and Infant Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Advances IV SB 11285 Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Expands into Italy and Broadens its Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Carrageenan API","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Throat Sprays","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Provides Updates Regarding Phase 2b Study of PTI-125","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune\u2019s Ongoing Registration-Directed Clinical Trials with RP1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RP1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Announces Positive Data From Clinical Study with ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports Veyonda\u2019s Potential in Late-Stage Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF\/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-30x","moa":"BAFF","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Concludes Successful Meeting with EMA for Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Identifies Potent SARS-CoV-2-Neutralizing Antibodies From the Blood of Recovered COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2-neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elixirgen Therapeutics Concludes pre-IND Meeting with FDA for its COVID-19 Vaccine Candidate EXG-5003","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Gets Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b\/3 ANAVEX\u00ae2-73","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Announces Important Updates on AAVance Phase 2\/3 Clinical Trial with LYS-SAF302 in MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento COVIDTRAP\u2122(STI-4398) Demonstrates in Preclinical Studies its Ability to Completely Inhibit SARS-CoV-2 Viral Infection In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair\u00ae Breezhaler\u00ae (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Imipenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication of Results From Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViralClear adds St. David's HealthCare in Austin to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CD45-ADC","moa":"CD45","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Vericiguat for Marketing Authorization in the EU and Japan for the Treatment Of Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamas Announces FDA Filing Acceptance of sNDA to Modify Indication Statement for Gocovri","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pha.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts PharmaEssentia\u2019s Application for Ropeginterferon Alfa-2b to Treat Polythycemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Phase IIb\/III Study in Parkinson's disease to Target Good ON","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio for EULAR 2020 E-Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Submission to Expand Clinical Sites in European AML Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Reports Weight Loss of 14.9% (16.9% if taken as intended) in STEP 1 trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyneuron\u2019s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PN-1007","moa":"IgM","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polyneuron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Publications in Peer-Reviewed Journals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta to Share Clinical Update from SRP-9003 Gene Therapy Trial for Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9003","moa":"Gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Initiates Phase II clinical Trial on AQCH, A Phytopharmaceutical Drug, As Potential Treatment for COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aqueous extract of Cocculus Hirsutus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO\u00ae (lanadelumab) in Reducing Hereditary Angioedema Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Hosts Virtual R&D Event Providing Updates on Clinical Programmes in Oncology and COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FOIPAN\u00ae Tablets, a Protease Enzyme Inhibitor, ONO Has Started Clinical Studies for Novel Coronavirus Infection (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Proteinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine Trial Data Being Presented at Virtual EHA Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex\u2019s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"AiCuris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiCuris Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir to Treat HSV Infections in Immunocompromised Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritelivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leukavir, an Antiviral Agent for Bukwang Pharm, Confirmed the Effect on New Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Clevudine","moa":"Protein P","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Ph.."},{"orgOrder":0,"company":"University Hospitals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UH to Launch Clinical Trial in the Fight to Protect Clinicians Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetylpyridinium Chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospitals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospitals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beech Tree Labs is Developing a Potential Antiviral Therapy to Fight COVID-19 Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Thimerosal","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beech Tree Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sublingual Drop","sponsorNew":"Beech Tree Labs \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Beech Tree.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant factor H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial To Treat Patients With Suspected or Confirmed Covid-19 Diagnosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals Announces that the US FDA Grants Rare Pediatric Disease Designation to 67Cu-SARTATE to Treat Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Virginia Tech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virginia Tech Drug Researcher Develops \u2018Fat Burning\u2019 Molecule That has Implications for Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BAM 15","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Virginia Tech","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virginia Tech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"SanBio","sponsor":"Ocumension","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"$6.0 million","newsHeadline":"Sanbio and Ocumension Ink Pact For Research, Development of Innovative Stem Cell Therapies for Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"SB623","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SanBio","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SanBio \/ Ocumension","highestDevelopmentStatusID":"4","companyTruncated":"SanBio \/ O.."},{"orgOrder":0,"company":"Promedior","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$390.0 million","newsHeadline":"Promedior Announces Completion of Acquisition by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"PRM-151","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Promedior","amount2":1.3999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Promedior \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Promedior .."},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuPharma provides an update on the Avion Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Rigerimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ImmuPharma \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Duchenne UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catabasis Pharmaceuticals \/ Duchenne UK","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Catabasis Pharmaceuticals \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics Completes $30 Million Series C Financing","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Achillion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$930.0 million","upfrontCash":"$930.0 million","newsHeadline":"Alexion Completes Acquisition of Achillion","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Achillion","amount2":0.93000000000000005,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.93000000000000005,"dosageForm":"Oral","sponsorNew":"Achillion \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Achillion .."},{"orgOrder":0,"company":"Histogen","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$135.1 million","upfrontCash":"Undisclosed","newsHeadline":"Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Histogen","amount2":0.14000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Quench Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Quench Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Quench Bio \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Quench Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Ningbo NewBay Medical Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ningbo NewBay Medical Technology Co., Ltd. Announces a License Agreement with Genentech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GDC-0570","moa":"Pan-PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Ningbo NewBay Medical Technology","highestDevelopmentStatusID":"4","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Transcell Oncologics","sponsor":"L2P Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"L2P Research (Former AJES Life Sciences, LLC) and Transcell Oncologics, LLC Announce Partnership to Provide High Quality Hu-CB-CD34 and Hu-PBMC to Generate Humanized Mouse Models for Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Trans HSC (CD34+)","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Transcell Oncologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcell Oncologics \/ L2P Research","highestDevelopmentStatusID":"4","companyTruncated":"Transcell .."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"SK Holdings, Heritas Capital, SEEDS Enterprise","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Closes Extended Series B Funding Round of $25M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"HMBD-001","moa":"HER3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ SK Holdings, Heritas Capital, SEEDS Enterprise","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotec.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Citigroup Global Markets","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sweden's Calliditas Seeks $75M IPO Haul to Bring Its Oral Steroid to Patients with an Orphan Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.080000000000000002,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0.080000000000000002,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Citigroup Global Markets","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.089999999999999997,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0.089999999999999997,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$190.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Forge Therapeutics, Inc","amount2":0.19,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Forge Therapeutics, Inc \/ Roche","highestDevelopmentStatusID":"4","companyTruncated":"Forge Ther.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$882.0 million","upfrontCash":"$44.0 million","newsHeadline":"Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Protein therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0.88,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"$0.4 million","newsHeadline":"Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Trypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford\u2019s Potential New Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Proteona","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Neutralizing antibody therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Proteona","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi To Present Oncology Strategy, Provide Update On Portfolio And Emerging Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofranergene obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-3745","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America Receives FDA Clearance of IND for Phase I\/2a Trial of SNK01 in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced\/Metastatic HER2- or EGFR- Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"iBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iBio Announces Second COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBIO-201","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"iBio \/ Not.."},{"orgOrder":0,"company":"Rigenerand","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigenerand Receives Regulatory Approval for Gene Therapy Production","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RR001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rigenerand","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rigenerand \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rigenerand.."},{"orgOrder":0,"company":"Baylx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAYLX,INC. Received US FDA Clearance of IND Application for Cord Tissue Mesenchymal Stem Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BX-U001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Baylx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ No.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Receives Positive CHMP Opinion for Janssen\u2019s Investigational Preventive Ebola Vaccine Regimen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Doses First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in RA Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Anvisa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anvisa Publishes Clinical Study Of Potential Vaccine Against Covid-19 Authorized","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BRAZIL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anvisa","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anvisa \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anvisa \/ N.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Showcases Positive 1-Year Data and Budget Impact Analysis for Novel Subcutaneous Formulation of Infliximab for RA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Follica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Male Androgenetic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follica","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Follica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follica \/ .."},{"orgOrder":0,"company":"Dimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Remap-Cap Platform Trial Protocol to Include Dmx-200 in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DMX-200","moa":"CCR2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Dimerix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dimerix \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Dimerix \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Preliminary Results of the Anti-PD-1\/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI318","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Devotes New York Facility To COVID-19 Cocktail Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bionomics Announces Financing Led by Apeiron Investment Group Ltd","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Liquid Suspension","sponsorNew":"Bionomics \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Partners with Inventage to Expand Long-Acting Injection Biz","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Inventage Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventage Lab \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Inventage .."},{"orgOrder":0,"company":"Octapharma","sponsor":"University of California San Diego School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ University of California San Diego School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Introduces GEN-011, a Transformational T cell Therapy Designed to Improve on Current Limitations of TIL Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI310","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Receives Marketing Authorization for Lyfaquin\u2122 (centhaquine) from Indian Regulatory Agency","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology to Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"HSBC","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Nanobiotix Secures \u20ac10M in Non-Dilutive Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Nanobiotix","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ HSBC","highestDevelopmentStatusID":"9","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Microbiotica","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbiotica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microbiotica \/ Cancer Research UK","highestDevelopmentStatusID":"1","companyTruncated":"Microbioti.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Vaccines Manufacturing and Innovation Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Vaccines Manufacturing and Innovation Centre","highestDevelopmentStatusID":"9","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"HitGen","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Evotec SE","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ E.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$46.7 million","upfrontCash":"Undisclosed","newsHeadline":"Kezar Announces Pricing of a Public Offering of $46.7 Million of Common Stock and Pre-Funded Warrants","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$75.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cognition Therapeutics Gets $75.8 M NIA Grant for Phase 2 Study of CT1812 in Collaboration with the Alzheimer\u2019s Clinical Trials Consortium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"CT1812","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Returns Rights to Gene Therapies to Oxford Biomedica","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"$220.0 million","newsHeadline":"Royalty Pharma Acquires Partial Royalty Interest On Prevymis\u2122 (Letermovir) From Aicuris Anti-Infective Cures Gmbh","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AiCuris","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"","sponsorNew":"AiCuris \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AiCuris \/ .."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Docetaxel","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Behring to Acquire Biotech Company Vitaeris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"IL-6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Vitaeris","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vitaeris \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"Vitaeris \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University of Tokyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Tokyo, RIKEN, Nichi-Iko & Daiichi Sankyo Ink Collaborative R&D on Nafamostat Inhalation Formulation to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ The University of Tokyo","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Agreement with Aerami Therapeutics Inc","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Imatinib Mesylate","moa":"PTK","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Aerami","highestDevelopmentStatusID":"5","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,230\u202c.0 million","upfrontCash":"$20.0 million","newsHeadline":"Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"RNA interference","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":1.23,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.23,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"LAXAI Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LAXAI Life Sciences \/ Laxai Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"LAXAI Life.."},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prime Therapeutics and EMD Serono Ink Value-Based Agreement on MAVENCLAD\u00ae (Cladribine) Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"12","companyTruncated":"Prime Ther.."},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CANbridge Pharmaceuticals Enters Into Rare Disease Gene Therapy Research Agreement With UMass Medical School","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Massachusetts Medical School","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Massachusetts Medical School \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"ABX-002","moa":"TR-Beta","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autobahn Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"IGY Life Sciences","sponsor":"MMS Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"IgY-110","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IGY Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"IGY Life Sciences \/ MMS Holdings","highestDevelopmentStatusID":"4","companyTruncated":"IGY Life S.."},{"orgOrder":0,"company":"Staidson Biopharma","sponsor":"Pivotal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Staidson and Pivotal are Collaborating in the Conduct of a Clinical Trial in Europe in Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"BDB-001","moa":"C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Staidson Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Staidson Biopharma \/ Pivotal","highestDevelopmentStatusID":"8","companyTruncated":"Staidson B.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ SAKK","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$308.0 million","upfrontCash":"$130.0 million","newsHeadline":"Valneva Announces HSR Clearance for Lyme Vaccine Collaboration with Pfizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.31,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Sass & Larsen ApS","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Acquires Full Control of Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Dovitinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncology Venture","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ Sass & Larsen ApS","highestDevelopmentStatusID":"10","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phase 2 Clinical Trial of LSD for \"Suicide Headaches\" Begins Treating Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supernus Completes Acquisition of CNS Portfolio from US WorldMeds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"US WorldMeds","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strategic Distribution Between Bayer Animal Health and Bioiberica in the International Companion Animal Health Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bioiberica","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Ceek Womens Health","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Marketing Agreement With Ceek for Women's Health Products to Improve OB\/GYN and Patient Exam Experience","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ceek Womens Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceek Womens Health \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Ceek Women.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lyvgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lyvgen Announces Clinical Trial Collaboration With MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"LVGN6051","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Lyvgen","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar\u00ae for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Triptorelin Pamoate","moa":"GnRH analog","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Verity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"UbiVac","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"BMS-986178","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"UbiVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UbiVac \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"UbiVac \/ B.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$10.0 million","newsHeadline":"Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkmate Pharmaceuticals Secures $85 Million in Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"Vidutolimod","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Longitude Capital","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"NeuroPharma","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group to Acquire NeuroPharm Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NeuroPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroPharma \/ Mydecine","highestDevelopmentStatusID":"1","companyTruncated":"NeuroPharm.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Refana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Refana","highestDevelopmentStatusID":"4","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"Adgero Biopharmaceuticals","sponsor":"Minakem (formerly Delmar Chemicals)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adgero Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adgero Biopharmaceuticals \/ DelMar","highestDevelopmentStatusID":"8","companyTruncated":"Adgero Bio.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmabcine Execute an Agreement with Thermo Fisher for the Development and Manufacturing Of Pmc-309","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"PMC-309","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ PharmAbcine","highestDevelopmentStatusID":"4","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$677.0 million","upfrontCash":"$677.0 million","newsHeadline":"Menarini Group Completes Acquisition of Stemline Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Tanabe Research Laboratories","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Masked antibody drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tanabe Research Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tanabe Research Laboratories \/ Adagene","highestDevelopmentStatusID":"1","companyTruncated":"Tanabe Res.."},{"orgOrder":0,"company":"Greene Street Pharmaceuticals","sponsor":"VerdePharmHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VerdePharmHealth Signs Exclusive Partnership Agreement with Greene Street Pharmaceuticals for Cannabidiol Transdermal Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Greene Street Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Greene Street Pharmaceuticals \/ VerdePharmHealth","highestDevelopmentStatusID":"4","companyTruncated":"Greene Str.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$25.0 Million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics, Today Announced the Completion of a US$100 Million Series B Round Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"JWCAR029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"JW Therapeutics \/ CR-CP Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$725.0 million","newsHeadline":"Novo Nordisk to Acquire Corvidia Therapeutics to Expand Cardiovascular Presence","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Ziltivekimab","moa":"IL-6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corvidia Therapeutics","amount2":2.1000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Corvidia T.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University of Louisville","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville to Develop AS1411 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ University of Louisville","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institute of Health","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chrysalis BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chrysalis BioTherapeutics \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chrysalis .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Institut of Butantan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Inactivated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Institut of Butantan","highestDevelopmentStatusID":"4","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Collaborations on Dupixent\u00ae (dupilumab) Highlighted During Sanofi R&D Investor Event","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Tumor-infiltrating Treg","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Egle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Egle Thera.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"AntiCovir","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca ties up with Emergent BioSolutions to Make COVID-19 Vaccine in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Emergent BioSolutions","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Partners with Anthos Therapeutics for Thrombosis Treatment","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene-editing therapies","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Stanford University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Acquires Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumes License of TNX-1900","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Oxytocin","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Stanford University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Stanford U.."},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Naari","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Intas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intas Pharmaceuticals \/ Naari","highestDevelopmentStatusID":"12","companyTruncated":"Intas Phar.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CpG-STAT3siRNA","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Scopus BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"U.S. Regional Biocontainment Laboratory","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharma Collaborating with Regional Biocontainment Lab on Grant Application to Study Brilacidin as Pan-Coronavirus Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"U.S. Regional Biocontainment Laboratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"U.S. Regional Biocontainment Laboratory \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"U.S. Regio.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Tibelia\u00ae in Liechtenstein and Switzerland","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"Sulphatase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"LSP","pharmaFlowCategory":"D","amount":"$38.1 million","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA Nabs \u20ac34M For mRNA Vaccine Including COVID-19 Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"SARS-CoV-2 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"eTheRNA immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"eTheRNA immunotherapies \/ LSP","highestDevelopmentStatusID":"1","companyTruncated":"eTheRNA im.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shattuck Labs Announces Closing of $118 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"SL-172154","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Redmile Group","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forte Biosciences, Inc. Announces Closing of Merger With Tocagen","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Tocagen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"$278.0 million","upfrontCash":"$266.0 million","newsHeadline":"Takeda to Divest Select APAC Assets to Celltrion for $278M","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Celltrion","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mapi Pharma, Mylan Expand MS Alliance","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"Schreiner MediPharm","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva Partners with Schreiner MediPharm for Novel Adrenaline Injector Label","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Schreiner MediPharm","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Prefilled Syringe for Injection","sponsorNew":"Schreiner MediPharm \/ TEVA","highestDevelopmentStatusID":"12","companyTruncated":"Schreiner .."},{"orgOrder":0,"company":"Atum Bio","sponsor":"Phylex BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATUM and Phylex BioSciences Collaborate to Accelerate the Development of a Universal SARS Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"VLP based coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atum Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atum Bio \/ Phylex BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Atum Bio \/.."},{"orgOrder":0,"company":"Vernalis","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Vernalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$130.4 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"CDX-3379","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","amount":"$71.1 million","upfrontCash":"Undisclosed","newsHeadline":"Vedanta Biosciences Announces Series C Financing and Data from Two Phase 1 Studies of VE202","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"Champignon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Champignon Identifies Synthetic Ketamine and Psilocybin\/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dalriada Drug Discovery","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dalriada Drug Discovery \/ Champignon","highestDevelopmentStatusID":"4","companyTruncated":"Dalriada D.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"academia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advancing our Discovery of Novel Coronavirus-Neutralising Antibodies Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ academia","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Autotelic BIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Announces Achievement of Milestone Under Licensing of OT-101\/IL-2 Combination to Autotelic BIO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Autotelic BIO","highestDevelopmentStatusID":"4","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry of Science and Innovation","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Initiates a New Project to Explore the Efficacy of Vafidemstat in the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Spanish Ministry of Science and Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Magenta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Magenta's Technology Attracts Another Gene Therapy Developer Beam Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"MGTA-117","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beam Therapeutics \/ Magenta Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted at ENDO 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE397","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ' Calquence Showed Promising Clinical Improvement in Majority of Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine from China's Sinopharm Clears Animal Tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BBIBP-CorV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Serums to assess sepsis drug Ulinastatin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Urinastatin","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Serums & Vaccines ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Ser.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex to Present at the MoneyShow June Virtual Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oncoprex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"13-cis-RAMBA Retinamides","moa":"MNK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brensocatib","moa":"DPP-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces \u201cAtuzaginstat\u201d Selected as First-in-Class Nonproprietary Name for COR388","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Completes Patient Enrollment for Long-Term Safety Study of Tapinarof in Adult Patients with Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTherapeutix Announces Orphan Drug Designation Granted by FDA for ATX01 in Erythromelalgia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amitriptyline","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Announces Plans to Seek Expanded Labeling for Oxbryta\u00ae (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ardelyx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces a Phase 2 Study Result of tenapanor (KHK7791) for Hemodialysis Patients with Hyperphosphatemia in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Kirin \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) Multiple-Dose Vial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno's Drug Misses Key Goal in Prader-Willi Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Participation in ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Completes Enrollment of Low-Dose Cohort in Phase 1\/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I Patients with GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASI Pharmaceuticals Announces Submission of Clinical Trial Application to Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CID-103","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CASI Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of PBCAR269A for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-35","moa":"TNFRSF25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the EULAR E-Congress 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28\/ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ENOB-HV-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-001 for the Treatment of Diabetic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironshore to Present a Dose Conversion Poster at the 2020 American Society of Clinical Psychopharmacology Virtual Scientific Poster Session","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Ironshore Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironshore .."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentation of Phase 1\/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcinonacog alfa","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Starts Enrolment in Pamrevlumab Trial for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"CTGF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Finds Niclosamide Effective Against Covid-19 in Animal Tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis and FDA QIDP Designation for Multiple Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olorofim","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BT051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Th.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON\u2122 Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-CLEC-1 monoclonal antibody","moa":"CLEC-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK begins US test of experimental drug for pneumonia caused by COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Otilimab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac\u00ae in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Powder for Suspension","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 510","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Amgen","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Dosing of First Patient in a Phase 1\/2 Study of Selinexor in Combination with Standard of Care Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Announces Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody\u2122 ISAC Technology and its Lead Development Candidate, BDC-1001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BDC-1001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Gets FDA Clearance for CALVID-1 Trial in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring\u2019s PROTECTIVE-2 Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor announces oral presentation of the first phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson to Begin Human Trials for Coronavirus Vaccine in Late July, Earlier than Expected","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2\/3 Study with Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DMT310","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Receives Rare Pediatric Disease Designation for RZ358","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"University of Florida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UF Health researchers developing COVID-19 vaccine using gene therapy technique","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Florida \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Tychan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Temasek-backed Tychan to Start Human Trials Next Week for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TY027","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tychan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tychan \/ N.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science to Present Results from AB8939 Preclinical Program in Acute Myeloid Leukemia at EHA 2020 Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AB8939","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform and Bifunctional Therapy Targeting PD-1 and IL-7 For Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BiCKI-IL-7","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Opdivo for the Treatment of Patients with Advanced ESCC After Prior Fluoropyrimidine- and Platinum-based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABBV-3373","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharnext Provides Regulatory and Clinical Update on PXT3003 Phase III Study for the Treatment of Charcot-Marie-Tooth Type 1A","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca to Showcase Leadership in Treating Type 2 Diabetes and Cardiorenal Complications at ADA 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Initiate CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Starts Production of its Hyperimmune Immunoglobulin as a Potential Passive Immune Therapy Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 hyperimmune globulin therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Launches Trials of COVID-19 Antibody \u201cCocktail\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Pfizer\u2019s Oncology Supportive Care Biosimilar, NYVEPRIA\u2122 (pegfilgrastim-apgf)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Starts Clinical Trial Evaluating Leukine\u00ae in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab to Treat Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and Therapeutics","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Starts Large-Scale Trial of Tirzepatide In Diabetic Heart Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World's First iLDC Enabling ADC Drug Receives IND Clearance by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GQ1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Th.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Provides Update on Preliminary Data for Bomedemstat at the 2020 Virtual EHA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Reports Data from Pivotal Phase 2 Clinical Trial and Phase 1\/2 Combination Clinical Trial of Loncastuximab Tesirine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent \u03b1- and \u03b2-Thalassemia in Phase 2 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pivotal Data Demonstrate Superiority of Apellis\u2019 Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO1","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents Updated Data on Novel CD20xCD3 Bispecific Cancer Immunotherapy Glofitamab In Heavily Pre-Treated Non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Glofitamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Infection (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KTX-201","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech files provisional patent application for Ampligen as treatment for COVID-19 induced fatigue","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATL1102","moa":"CD49d","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense .."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Advances the BIV201 Clinical Program and Prefilled Syringe","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Continuous Infusion","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s ML Bio Solutions Dosed First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b\/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Trial for Paltusotine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a\/1b Study of TSC in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents New Late-Breaking Data Showing SKYRIZI Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX\u00ae at 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara\u00ae at Week 16 in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Dermira Present New Positive Lebrikizumab Phase 2b Clinical Data","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"ZZ Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZZ Biotech Announces FDA Fast Track Designation for Stroke Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"3K3A-APC","moa":"Tissue plasminogen","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ZZ Biotech","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZZ Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ZZ Biotech.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for Potential Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Presents Early Phase 1a\/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Presents Results From French Phase Ib\/II Clinical Trial of APR-246 and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixazomib Citrate","moa":"Proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1701","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Results from 2 New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AU-011","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Betibeglogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TJ-CD4B","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Reports Findings From Janssen's Phase 3 Andromeda Study Evaluating Daratumumab Utilizing ENHANZE In Light-Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VENCLEXTA\u00ae\/VENCLYXTO Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Na\u00efve Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AHS Posters for Lundbeck\u2019s VYEPTI in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"University of Sydney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Clot-Busting Drug Holds Hope for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-clotting drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Sydney","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Sydney \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda\u00ae in NSCLC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational, Once-Weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-Daily Insulin Glargine U100 In Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Clinical and Non-Clinical Evidence for Dasiglucagon Rescue Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-7110","moa":"TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Presents Data on Simplici-T1 Study Supporting the Role of TTP399 as an Oral Adjunctive Therapy for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Darinaparsin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Solasia Pharma KK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Solasia Pharma KK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Solasia Ph.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio to Announce Zimura\u00ae 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momenta Clears a PhII Hurdle on Nipo But One Big Rival Remains Well in the Lead in this Packed Field","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves ViiV Healthcare\u2019s Tivicay to treat HIV in children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Four Patients Given Higher AXO-Lenti-PD Dose in Gene Therapy Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dapagliflozin May Help Reduce Onset of Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domp\u00e9 Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ladarixin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"Cirius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics' MSDC-0602K Improved Insulin Handling","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MSDC-0602K","moa":"Mitochondrial pyruvate carrier","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Cirius Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cirius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cirius The.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 AHS Virtual Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Emerging Oncology Pipeline Highlighted at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt to Present Phase 3 StrataGraft\u00ae Regenerative Skin Tissue Clinical Trial Results","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"StrataGraft skin tissue","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Completion of Enrollment in the PEGASUS Trial of AMX0035 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Present Results from Head-to-Head PK Comparison Study of Jivi\u00ae Vs Adynovate\u00ae in Late-Breaker Presentation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Antihemophilic factor recombinant PEGylated-aucl","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder for Solution for Intravenous","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Reports Notice of Allowance for a US Patent Application Covering Use of Thykamine for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Thylakoid extract","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces ALPN-202 Poster Presentation at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Extends Clinical Development Program for Finerenone with Phase III trial in Heart Failure and Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives FDA Orphan Drug Designation for NT-I7 for the Treatment of Progressive Multifocal Leukoencephalopathy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Micro\u2122 Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Diasome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diasome Reports Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diasome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diasome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Diasome Ph.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imperial to Begin First Human Trials of New COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Provides Clinical Trial Status Update","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ402","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Data Continues to Show Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed\/Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ManKind Presents Positive Original Analyses of Afrezza\u00ae Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Pharmaceuticals Reports Results of the Mars study, a Phase 2a Study of the Efficacy and Safety of TP-03 to Treat Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-03","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PolyPEPI-SCoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Treos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Pharma Submits Application for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi\u00ae for Pediatric Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva\u2019s Lanifibranor Meets Primary & Key Secondary Endpoints in the Phase IIb NATIVE Clinical Trial In Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicure \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on Clinical Trials and Development Programs","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Full Commercial Launch of ANJESO\u2122 and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Start of AT-007 Pediatric Galactosemia Study; Releases Additional 40mg\/kg Data from Adult Galactosemia Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcinonacog alfa","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion Announces Health Canada Approval of KYNMOBI\u2122 Soluble Film for the Treatment of Parkinson\u2019s Disease OFF Episodes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Receives FDA IND Clearance to Initiate a Phase 1\/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T\u00ae for HER2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Files IND Application for GEN-011, a T cell Therapy Designed to Improve on Current Limitations of TIL Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present New Preclinical Data on IL-15 Superagonist, SO-C101, at the 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cy.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, \u201cHyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HyLeukin-7","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"CN Bio","sponsor":"Cambridge University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"CN Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CN Bio \/ Cambridge University","highestDevelopmentStatusID":"1","companyTruncated":"CN Bio \/ C.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG.APV-527","moa":"5T4 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma Publishes Positive Results from Its Intranasal Epinephrine Preclinical Study Program In Three Peer-Reviewed Scientific Journals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bryn Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$55.0 million","newsHeadline":"Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Spinal Muscular Atrophy (SMA)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Launches PhIII JAK Study, Aiming for the First Drug to Lower Mortality in Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"British Heart Foundation","sponsor":"Imperial College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"British Heart Foundation Researchers to Test Promising Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"British Heart Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"British Heart Foundation \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"British He.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayo Clinic Study of Humanigen\u2019s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Dosses First Patient with FT596","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FT516","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta's SRP-9003 Gene Therapy for LGMD2E Shows Benefits After 1 Year","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9003","moa":"Gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Grants Orphan Drug Designation to Nippon Shinyaku's viltolarsen (NS-065\/NCNP-01)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shi.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Reports Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"L.E.A.F. Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"L.E.A.F. Pharmaceuticals Lead Investigational Product for Lung and Colorectal Cancers, LEAF-1401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gamma L-pentaglutamated pemetrexed","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"L.E.A.F. Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"L.E.A.F. Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"L.E.A.F. P.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$822.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals Emerges from Pandemic Delays with Pitch for $822M IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.81999999999999995,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.81999999999999995,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA\u2122 for the Middle East and North Africa region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces License to Commercialize Tempol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tempol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Matrix Biomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matrix Biomed \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Matrix Bio.."},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCLA Receives Nearly $14 million from NIH to Investigate Gene Therapy to Combat HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"UCLA \/ National Institution of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ Nat.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi To Present Phase 3 Results of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-BN-WEV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharma Advances Pivotal Phase 3 Clinical Trials in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn announces FDA acceptance of IND application for TAS0953\/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HM06","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to present growth opportunities and development strategy for Dupixent\u00ae (dupilumab) in type 2 inflammatory diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Presents Preliminary Phase 1 Results of ALX148 in Combination with Rituximab in Relapsed or Refractory Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"SIRPalpha-CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in\nMolecular Genetics and Metabolism Reports","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Show Near Elimination of Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1\/2 Clinical Study of bluebird bio\u2019s LentiGlobin\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of ADHD in Adult Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Centanafadine","moa":"Serotonin uptake","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"International Vaccine Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO, IVI to Start Ph 1\/2 Trials of COVID-19 Vaccine in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ International Vaccine Institute","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Spicona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Partners with Spicona for COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"VLP based COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Spicona","highestDevelopmentStatusID":"1","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lycia uncloaks with $50M to Tackle Protein Degradation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Lysosome targeting chimeras","moa":"Apolipoprotein-E4","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Ther.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$3,900.0 million","upfrontCash":"$750.0 million","newsHeadline":"AbbVie and Genmab Announce Broad Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":3.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.8999999999999999,"dosageForm":"","sponsorNew":"Genmab \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"BioNTech","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$112.3 million","upfrontCash":"Undisclosed","newsHeadline":"European Investment Bank to provide BioNTech with up to \u20ac100 M in debt financing for COVID-19 vaccine development and manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.11,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Develops \u201cChange History\u201d for its Clinical Trial Product for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CypCaps","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer with TAVO\u2122 and KEYTRUDA\u00ae Plus Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Izana Bioscience\u2019s Drug Enters UK Covid-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Namilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Izana Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bios.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Ona Therapeutics","sponsor":"Fund+","pharmaFlowCategory":"D","amount":"$33.6 million","upfrontCash":"Undisclosed","newsHeadline":"Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ona Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ona Therapeutics \/ Fund+","highestDevelopmentStatusID":"4","companyTruncated":"Ona Therap.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Perceptive Advisors and Cobro Ventures","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Transcription factor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Perceptive Advisors and Cobro Ventures","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Pluristyx","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"ESI human embryonic stem cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Pluristyx","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluristyx \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pluristyx .."},{"orgOrder":0,"company":"Ichor Medical Systems","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation Delivery Technology for ITI-1001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ichor Medical Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ichor Medical Systems \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichor Medi.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,015.0 million","upfrontCash":"$120.0 million","newsHeadline":"Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"TAK-831","moa":"DAAO","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":2.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":2.02,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Raises $75 Million in Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"4D-310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Lifeline Ventures","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"TILT-123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$100.0 million","newsHeadline":"Glaxosmithkline Pens $120M Upfront Cancer Pact with Ideaya","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GlaxoSmithKline","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Valneva","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Inactivated polio vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Batavia Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Saiba AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saiba AG and AGC Biologics Enter COVID-19 Vaccine Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Virus-like particle vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Saiba AG","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Gets $15 Million Award from the U.S. DoD to Develop Bacteriophage Therapy to Treat S. aureus Bacteremia Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"AP-SA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Iodine-131 apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LGC Group GB \/ OliX Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group .."},{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NTC \/ Taro Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Taro.."},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent.."},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics to Treat Fibrosis and Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"LASN01","moa":"IL-11 receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lassen Therapeutics \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"Lassen The.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$44.6 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix and Southern Research to Study Immune Responses to Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"TNX-1800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Southern Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Southern R.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lightspeed Venture","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orca Bio Raises $192m to Support Cell Therapies Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series D Financing","leadProduct":"TRGFT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Orca Bio \/ Lightspeed Venture","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Farmacore Biotechnology","sponsor":"MCTIC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotech and Farmacore Partner to Develop Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"PDS0204","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Farmacore Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Farmacore Biotechnology \/ MCTIC","highestDevelopmentStatusID":"4","companyTruncated":"Farmacore .."},{"orgOrder":0,"company":"Cipla","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche Pharma India Expands Partnership with Cipla to Improve Access to Key Oncology Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Ro.."},{"orgOrder":0,"company":"Entero Healthcare Solutions","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche Pharma India Partners with Entero Healthcare Solutions to Improve Access to Nephrology Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Entero Healthcare Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Entero Healthcare Solutions \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Entero Hea.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$95.7 million","upfrontCash":"Undisclosed","newsHeadline":"Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Sirnaomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics and Precision NanoSystems Have Formed a Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Precision NanoSystems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ Sirnaomics","highestDevelopmentStatusID":"8","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"ISA Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ ISA Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO\u00ae, the First and Only Single-Dose Treatment for Acute Otitis Externa","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Oton.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Raises $32 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rexahn and Ocuphire Enter into Definitive Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Rexahn","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$13.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"MVA-BN Filo vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of Themis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Themis Bioscience \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bio.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$865\u202c.0 million","upfrontCash":"$60.0 million","newsHeadline":"Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ALPN-101","moa":"ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.87,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.87,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Renovion","sponsor":"White Rock Capital Management","pharmaFlowCategory":"D","amount":"$8.1 million","upfrontCash":"Undisclosed","newsHeadline":"Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"Approved","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"ARINA-1","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Renovion","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Renovion \/ White Rock Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Achilles Vaccines","sponsor":"The EU Malaria Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Malaria vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Achilles Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Vaccines \/ The EU Malaria Fund","highestDevelopmentStatusID":"1","companyTruncated":"Achilles V.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical oncology biotech Nkarta files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pha.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent to Partner with ViralClear for Oral COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ BioSig Technologies","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kaiser Permanente Joins Forces with Civica Rx to Improve Availability and\nAffordability of Essential Generic Medications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaiser Permanente Washington Health Research \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Kaiser Per.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Halozyme to Receive $10 Million Milestone Payment From Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"$35.0 million","newsHeadline":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vizient \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ .."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Minerva Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44 CAR T cells","moa":"MUC1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tanner Pharma \/ Tasman Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pha.."},{"orgOrder":0,"company":"Orgenesis","sponsor":"Leidos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Ranpirnase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orgenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orgenesis \/ Leidos","highestDevelopmentStatusID":"4","companyTruncated":"Orgenesis .."},{"orgOrder":0,"company":"Intravacc","sponsor":"Wageningen Bioveterinary Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Partners With Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Intravacc \/ Wageningen Bioveterinary Research","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology biotech Poseida Therapeutics refiles for a $115 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"P-BCMA-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Poseida Therapeutics, Inc","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi\u2019s Investigational Enzyme Replacement Therapy Improves Critical Manifestations of Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak to Present New Preclinical Data on exoASO\u2122-STAT6 and exoASO-C\/EBP\u03b2 at the AACR 2020 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Serum Institute to Play Pivotal Role in COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VPM1002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Singapore Scientists to Start Human Trials of COVID-19 Vaccine in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Duke-NUS Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duke-NUS Medical School \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Duke-NUS M.."},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Pharmaceutical to Repurpose Targeted Oncology Drug as COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CWP291","moa":"Wnt\/Beta-Catenin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JW Pharmaceutical Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JW Pharmaceutical Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"JW Pharmac.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces the Initiation of a Phase 2\/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Emvododstat","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Reveals a New Bispecific Antibody Technology Platform at BIO Digital 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Confirmatory In Vitro Analysis of WP1122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex\u2122 Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oncoprex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Vyome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyome Therapeutics Announces Positive Results in Phase 2 Trial of VB-1953 for Moderate to Severe Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-1953","moa":"TLR\/MD2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Vyome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vyome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyome Ther.."},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senju Pharmaceutical Launches New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SENJU PHAR.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABY-035","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Treatment for Adult Onset Still\u2019s Disease, a Severe and Rare Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX\u00ae2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionic Sight Doses First Patient in a Phase 1\/2 Trial of a New Investigational Treatment for Blindness caused by Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BS01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sig.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Presents NURTEC Clinical and Pharmacoeconomic Data at the American Headache Society Virtual Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Published Phase I\/II Clinical Trial Results of Ilixadencel in Gastrointestinal Stromal Tumors in Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Dosed First Patient in Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for Chronic Hep B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-1387","moa":"Apoptosis protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Enrolled First Patient in Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of M.S","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology to Highlight Rubraca\u00ae (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucitanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer\u2019s Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases: Isturisa\u00ae (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives FDA Fast Track Designation for ONIVYDE as a First-Line Combination Treatment for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1\/2A Study of AFM24","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Verzenio Shows up Ibrance, Hitting its Goal in Early Breast Cancer After Pfizer's Drug Faltered","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides Additional Data from Ongoing Phase 1\/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Bio.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"AriBio","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio Announces Completion of Enrollment in Phase 2 Alzheimer\u2019s Study with AR1001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"CREB pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ S.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"Mapk2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Completes Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides Clinical Update on ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Reports Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II\/III Trial of IFX-1 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presented Results from Preclinical Studies of TNX-1700 in a Poster at the AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TNX-1700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Pfizer\u2019s Steglatrotm Meets Primary Endpoint in VERTIS CV Trial for Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ertugliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients in Italian Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Announce Updated Phase 1\/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events in 3e13 Vg\/Kg Cohort After Sb-525 Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Receives Rare Pediatric Disease Designation From U.S.FDA for Nedosiran for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ Monotherapy Results in Skin Clearance and Itch in First Phase 3 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-c165","moa":"RTK transmembrane receptor ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals to Discuss APEX\u2122 in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HQP1351","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 S-Trimer vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s IPATential150 Study Testing Ipatasertib in Combination With Abiraterone & Prednisone\/Prednisolone Met Its Co-Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipatasertib","moa":"Serine\/threonine-protein kinase AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Initiates the LIFT Study, a Phase 2a Clinical Trial of TERN-101 for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK\u2122 (tazemetostat) for Relapsed\/Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Prevention Pharmaceuticals Submits EU Marketing Authorization Application for CPP-1X\/sul to Treat Familial Adenomatous Polyposis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences, Inc. Announces Issuance of New U.S. Patent","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY\u00ae (fremanezumab-vfrm) Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of XP-3924 in Adults with Type 1 DM","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pramlintide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SEA-TGT","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Host Scientific Seminar on Promising Preclinical Data from HPK1 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen\u00ae for the Treatment of Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Announces Long-Term Efficacy and Safety Data for Fitusiran from Interim Analysis of Phase 2 Extension Study in Hemophilia A and B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Givosiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology\u2019s Virtual Heart Failure Association Discoveries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Danicamtiv","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in A Phase 1b\/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI362","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Successfully Completes AM833 Phase 2 Trial and Phase 1 Combination Trial with AM833 and Semaglutide in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fleroxacin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA for the Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Status to Chi-Med\u2019s Fruquintinib for Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH stops clinical trial of hydroxychloroquine to treat adults hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Discontinues Hydroxychloroquine Clinical Trial Based on Slow Enrollment, Remains Committed to Pandemic Research Efforts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"University of South Australia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breakthrough Discovery to Transform Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of South Australia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of South Australia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces that V114 Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche, BioNTech Post 'Low' Response Rate in Cancer Vaccine Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces Priority Review and FDA Acceptance of NDA for Once-Daily, Oral Relugolix for Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences announces EDP1815 to advance into phase 2\/3 TACTIC-E COVID-19 trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ambrisentan","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 634","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABM-1310","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Colvis Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alkermes Plc \/ Colvis Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dendritic Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TXR-311","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-804","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JBI-802","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Reports News Preclinical Data Suggesting Synergy Between STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1\/2a Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Reports New Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FS222","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Data from Four Preclinical XmAb\u00ae 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb30819","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-104","moa":"Liver X receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-019","moa":"MerTK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents New Data Reinforcing Galectin-9 as a Compelling Therapeutic Target and Biomarker for a Range of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LYT-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NMBS-1","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics to Present Preclinical Data on SBT6050","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS\u00ae (eflapegrastim) at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EMB-01","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Bio.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BT5528","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Completes Patient Enrollment Into the AUDREY Phase 2\/3 Clinical Trial of Voclosporin Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1701","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Presentation of Data on Genentech\u2019s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed\u2019s ROCK\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Shasqi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shasqi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma's Drug Candidate VP01 Demonstrates Potential for Significant Benefit in Severe Pulmonary Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac Receives Approval in Sweden to Start Clinical Phase IIb Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MRG-229","moa":"miR-29","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dracen Announces Two DRP-104 Presentations at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pha.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo\u00ae in Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1592","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-35","moa":"TNFRSF25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces the Initiation of a Phase 1\/2a Study of Rigosertib Plus Nivolumab for KRAS+ Lung Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-819","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JTX-1811","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MGC018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AFP TCR T Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates\u2019 Presentations at the American Association of Cancer Research AACR Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MT-5111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon and GMP to Proceed to Clinical Development of OT-101 and Artemisin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"SINTX Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sintx Technologies Announces Sars-Cov-2 Testing Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Silicon Nitride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SINTX Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SINTX Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SINTX Tech.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid\u201019 Infection in Psoriasis Patients Treated with Cyclosporin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Pennsylvania \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galecto to merge with onetime Celgene partner PharmAkea","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"PAT-1251","moa":"LOXL2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ PharmAkea","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody\u2122 Platform","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Hypoimmunogenic cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$72.5 million","newsHeadline":"Sarepta and Codiak BioSciences to develop rare disease therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Linnaeus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ITM","sponsor":"POINT Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ITM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ITM \/ POINT Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"ITM \/ POIN.."},{"orgOrder":0,"company":"Frontier Scientific","sponsor":"Renibus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frontier Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Frontier Scientific \/ Renibus Therapuetics","highestDevelopmentStatusID":"8","companyTruncated":"Frontier S.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Olivia Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Private Placement","leadProduct":"CTX-471","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Olivia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$35.0 million","newsHeadline":"AsclepiX Therapeutics Announces $35 Million Series A Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"AXT107","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX T.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replicate Bioscience and Immunomic Therapeutics Form Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RBI-5000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Replicate Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$450.0 million","newsHeadline":"CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Quest Products","sponsor":"Quest Products, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quest Products, LLC. Acquires Summit Pharmaceuticals \/ Alliance Labs, Including Enemeez\u00ae and DocuSol\u00ae Brands","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Docusate Potassium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Quest Products","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quest Products \/ Quest Products, LLC","highestDevelopmentStatusID":"12","companyTruncated":"Quest Prod.."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Simcha debuts with $25M to advance custom-built IL-18 for cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"ST-067","moa":"IL-18","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"7","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Toleranzia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Bio and Toleranzia Enter Orphan Drug Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"3P Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3P Biopharmaceuticals \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3P Biophar.."},{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Edge Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edge Pharma \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Edge Pharm.."},{"orgOrder":0,"company":"Enterome","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","amount":"$52.6 Million","upfrontCash":"Undisclosed","newsHeadline":"Enterome Completes \u20ac46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"EO2401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ SymBiosis, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied Biology in Collaboration with Corpometria Institute to Launch AntiAndrogen Clinical Study for the Treatment of COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals Set to Make Historic IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"NaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.80000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"EDP1815","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Evelo Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals And Indegene Enter Into Probuphine\u00ae Co-Promotion Partnership","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"12","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis .."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics Signs Drug Development Deal with Merck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Yumanity Therapeutics","amount2":0.5,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$414.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Deliveries of Oral TPOXX\u00ae to HHS Valued at Approximately $32 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1\/2 oncology biotech iTeos Therapeutics files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics to Receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Immunotherapy","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ PharmAbcine","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Development Agreement - Autoimmune Disease Treatments","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"IBM Watson Health","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution to help Support clinical COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"IBIO-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IBM Watson Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IBM Watson Health \/ iBio Inc.","highestDevelopmentStatusID":"4","companyTruncated":"IBM Watson.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Brain Tumor Society","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Brain Tumor Society","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelluna Collaborates with Lion TCR to Develop TCR-NK Cell Therapies to Treat Virally Induced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"TCR based Natural Killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zelluna Immunotherapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelluna Immunotherapy \/ Lion TCR","highestDevelopmentStatusID":"1","companyTruncated":"Zelluna Im.."},{"orgOrder":0,"company":"Aldevron","sponsor":"Alaunos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aldevron Announces Agreement with Ziopharm Oncology for neoGMP\u00ae Production of Sleeping Beauty Plasmid DNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"DNA plasmids","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aldevron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldevron \/ Ziopharm Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Aldevron \/.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$69.3 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Raises Approximately EUR 61.81 Million in Successful Initial Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Sotalol Hydrochloride","moa":"hREG","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Health Ministry","pharmaFlowCategory":"D","amount":"$127.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil, AstraZeneca Sign $127 Million Deal To Produce Experimental COVID-19 Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"AstraZeneca \/ Brazilian Health Ministry","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"EverInsight Therapeutics","pharmaFlowCategory":"D","amount":"$177.0 million","upfrontCash":"$5.0 million","newsHeadline":"VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ EverInsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burning Rock and CStone Pharmaceuticals reached a strategic collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Burning Rock Dx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Burning Rock Dx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Burning Ro.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Goldfinch Bio Secures $100 Million in Series B Financing","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Eventide Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Freeline Closes Major $120M Funding Round","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$42.6 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices Gets $42.6M DoD Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Anti-botulinum neurotoxin monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Corporation Receives $10 Million Through Warrant Exercises","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Interleukin 2","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"University of Natural Resources","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avalon GloboCare to Develop Intranasal and Oral Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"S-layer COVID vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Avalon GloboCare \/ University of Natural Resources","highestDevelopmentStatusID":"1","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"PainReform","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Extended Release Solution","sponsorNew":"PainReform \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"PainReform.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"National Health Service (NHS)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Successful Eloctaq Bid Should Widen Access to the Drug in the UK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Efmoroctocog alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ National Health Service (NHS)","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acceleron Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0.45000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Acceleron Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3,881.0 million\u202c","upfrontCash":"$16.0 million","newsHeadline":"Alteogen Enters into a Global License Agreement with a Top Ten Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ALT-B4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":3.8799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.8799999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"$425.0 million","newsHeadline":"Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK\u2019s MHRA renews EAMS Scientific Opinion for Santhera\u2019s Idebenone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vecabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunesis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunesis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breztri Aerosphere Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Enrols First Patient in Pamrevlumab\u2019s Covid-19 Trial in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"CTGF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines begins patient dosing in phase1 trial of RMC-4630 in combo with pembrolizumab to treat solid tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GL0034","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Released Research Data of \"FAK inhibitor IN10018 Overcomes Drug Resistance of KRAS G12C Inhibition\" at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"REN001","moa":"PPAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methadone","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PL8177","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Receives USAN Approval for \"zelenoleucel\" as Nonproprietary Name for MT-401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zelenoleucel","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Polynoma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/.."},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OPL-002","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oppilan Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oppilan Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oppilan Ph.."},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564 at the AACR 2020 Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMV564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena .."},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Bioch.."},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Bioresearch Announces Issuance of U.S. Patent on its Prodrug Stimulant PRX-P4-003","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PRX-P4-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Praxis Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Pha.."},{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RubrYc Therapeutics To Present at AACR Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-003","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RubrYc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc The.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"Leukotriene receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Phase 2 Study of Arimoclomol In Gaucher Disease Demonstrates Marked Improvements in Key Clinical Markers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces First Patient Dosed in Phase 2 Trial With Long-Acting GLP-1\/Glucagon Dual Agonist in Obesity\/Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 456906","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Nobilis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug\/Device Combination for Treatment of Panic Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Xenon","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Nobilis Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nobilis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nobilis Th.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Receives First Patent Approval for ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1017","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene Enters Phase I Clinical Development with its TCR-T Immunotherapy MDG1021 in Hematological Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MDG1021","moa":"Antigen HA-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Final Data from Phase I PK\/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Doses First Patient in Phase 1 Clinical Trial of KD033","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KD033","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Doses First Patient in Phase 2 BRACELET-1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TYME-18","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Pirbright Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Studies at BBSRC-funded Pirbright Institute demonstrate two doses of Oxford University's COVID-19 vaccine boosts immune response in pigs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pirbright Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pirbright Institute \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pirbright .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces Initial European Trial Sites Activated in AEROSURF\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces OCD Proof Of Concept Phase 2\/3 Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Expands Clinical Pipeline to Evaluate NurOwn\u00ae for AZ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Positive Pharmacokinetic (PK) \/ (PD) Study Results for PXL770","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IM Therapeutics Announces First Patient Dosed in Ph1 Study IMT-002","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMT-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMole.."},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grid Therapeutics Announces Enrollment of First Patient in Ph1 Study of GT103","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GT103","moa":"CFH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Thera.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Initiates First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Severe Symptoms of Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"M5049","moa":"TLR7\/8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Erlotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-H2158","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTX-080","moa":"HLA-G","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tizona Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tizona The.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"The Lundquist Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unique Clinical Trial Investigates a New Treatment Approach for Fatal \u2018Childhood Alzheimer\u2019s\u2019 and Continues Despite COVID-19 Pandemic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"The Lundquist Institute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Lundquist Institute \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"The Lundqu.."},{"orgOrder":0,"company":"University of Wisconsin School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UW\u2013Madison and UW Health quickly launch a number of COVID-19 clinical trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Wisconsin School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Wisconsin School of Medicine \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BC007","moa":"Coronavirus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Berlin Cures","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Berlin Cures \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Berlin Cur.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Announces Plans to Seek Regulatory Approval for Oxbryta\u00ae (voxelotor) to Treat Sickle Cell Patients in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HST5040","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Reports Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferrous Gluconate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Appoints Chief Medical Consultant in Charge of COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nascent Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CCX559","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"University of the Witwatersrand","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial of Oxford COVID-19 Vaccine in South Africa Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ox1Cov-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of the Witwatersrand","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of the Witwatersrand \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Gets Ethics Approval for Lfenprodil\u2019s Covid-19 Trial in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"UC San Francisco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Researchers Trial Azithromycin to Treat Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UC San Francisco","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"UC San Francisco \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UC San Fra.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Secures Positive CHMP Opinion for Aybintio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Completes Enrollment in Phase 3 DOM-INNATE Trial of SGX942 to Treat Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dusquetide","moa":"p62 protein","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus for Advanced Malignant PEComa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports COVID-19 Trial Program to Commence in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DR-18","moa":"Il-18","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Submission of Biologics License Application for TransCon\u2122 hGH in Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Announces Positive Data from Phase 1\/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AIV001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Bio.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox\u00ae in Primary Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OPC1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Receives FDA Response on Pre-Investigational New Drug Application for its Induced Mesenchymal Stem Cells","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"iPSC-derived MSCs","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Celltex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltex Therapeutics Receives FDA Approval: Phase II Clinical Trial Using Mesenchymal Stem Cells for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous adipose-derived stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Celltex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celltex Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pexidartinib","moa":"Stem Cell growth factor receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives positive CHMP opinion for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"Il-12","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfenex Announces Positive European CHMP Opinion for PF708","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ N.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BO-112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bifikafusp alfa","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Begins Patient Dosing in Phase 1b\/2 Trial of NT-I7 in Combo with Keytruda to Treat r\/r Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoiet.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montreal Heart Institute Announces COLCORONA Trial in Patients COVID-19 Passes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech Announces Investigator Sponsored Ph 2 Trial Pelareorep","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOBiome Reports Successful Clinical Trials in Pruritus Associated with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"B244","moa":"IL-4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Th.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Meeting with US FDA Provides Development Pathway for ATH434","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SFA Therapeutics Announces FDA Approval To Begin IND Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SFA002","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"SFA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SFA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SFA Therap.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEEL Therapeutics Announces Possible New Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Neutrophil targeting peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PEEL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Thera.."},{"orgOrder":0,"company":"ChemRar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data of Avifavir to Become Available to International Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ChemRar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ChemRar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChemRar \/ .."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces CHMP Recommendation of Translarna Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granules for Oral Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Cytocom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Phase 2 Trial of CYTO-201 in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CYTO-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Final Data Analysis from Phase II NASH Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CAS 7632-00-0","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NuvOx Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"NuvOx Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NuvOx Phar.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VITRAC Therapeutics Initiated Global Clinical Development of VIC-1911, licensed from Taiho Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VIC-1911","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VITRAC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC The.."},{"orgOrder":0,"company":"GoLiver Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoLiver Therapeutics Receives Scientific Advice from EMA on its Clinical Development and Biomanufacturing Strategy for Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cell therapy products","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"GoLiver Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GoLiver Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GoLiver Th.."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X\/sul for Treatment of Familial Adenomatous Polyposis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima\u00ae SC","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Provides Regulatory Update on VP-102","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"REVIMMUNE INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin-7","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"REVIMMUNE INC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"REVIMMUNE INC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"REVIMMUNE .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Announces Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives Approval for COVID-19 Phase 2\/3 Study with Opaganib in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consultation with FDA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I\/II Study in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI214","moa":"PDE1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Endari\u00ae Marketing Authorization from the Israeli Ministry of Health","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AVA-001","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Short-Acting Selective \u03b21 Blocker, Onoact\u00ae for Intravenous Infusion 50mg\/150mg Approved","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Announces FDA Allowance of IND for Phase 1a\/b Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel\u2122 (CBD Gel) in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Clinical Benefit From use of Lopinavir-Ritonavir in Hospitalised COVID-19 Patients Studied in RECOVERY, Reports University of Oxford Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Submission of IND with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Amniox Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTAX01","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase III","graph3":"Amniox Medical","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amniox Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amniox Med.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b\/3 Trial of Belapectin","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Provides Pipeline Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Stem Cell-Based Application for BeyondSpring\u2019s Plinabulin Presented at ISSCR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion Announces Submission of NDA for its Orphan Drug Udenafil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Udenafil","moa":"PDE5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MAP2K1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation (ODD) for Prestige BioPharma\u2019s PBP1510 Anti-PAUF Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PBP1510","moa":"PAUF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Cambridge University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cambridge Launches Fast-Turnaround Experimental Drug Trial to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge University \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge .."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Launches Cipremi the only U.S. FDA Approved Emergency Use Authorisation (EUA) Treatment for Patients with Severe COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Announces the Approval and Launch of First Generic \u2018COVIFOR\u2019 (Remdesivir) in India for the Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hetero Drugs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hetero Drugs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hetero Dru.."},{"orgOrder":0,"company":"Vascular BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR Peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vascular BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vascular BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vascular B.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Quadrivalent Influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Presents New Preclinical Data on CAN04 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nidanilimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CAL1 vaccinia virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"AIMM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIMM Therapeutics Presents Preclinical Data on its Four Oncology Therapies at AACR\u2019s Annual Meeting Session on Antibody Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AT1412","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AIMM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AIMM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AIMM Thera.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data for PRGN-3005 UltraCAR-T\u00ae Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BeiGene","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifirafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces First Patient Enrolled in Sanofi\u2019s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Tecentriq in Combination With Chemotherapy Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO\u2122 (fosfomycin) for injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosfomycin Sodium","moa":"UDP-N-acetylglucosamine 1-carboxyvinyltransferase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMGN151","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Presents Biomarker Identification Strategies for Investigational Agents Alvocidib and TP-1287 at AACR Meeting II 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-1287","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Gamalei National Research Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia to Begin Clinical Trials of Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gamalei National Research Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamalei National Research Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gamalei Na.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Announces FDA Approval Of Updated Label For Seysara\u00ae (Sarecycline) Tablets","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Metastatic or Unresectable Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Completes Rolling Submission of New Drug Application for Umbralisib as a Treatment for Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Announces FDA Clearance of its IND Application for HB-202\/201 Clinical Trial to Treat HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Renibus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cascade Chemistry Selected to Produce Active Pharmaceutical Ingredient for Clinical Trial Supplies of COVID-19 Investigational Drug RBT-9","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cascade Chemistry","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cascade Chemistry \/ Renibus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cascade Ch.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Announces New Agreement With Cystic Fibrosis Foundation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"4D-710","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"4D Molecular Therapeutics","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Oncologie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bavituximab","moa":"Phosphatidylserine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie .."},{"orgOrder":0,"company":"Nagourney Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Identification of Alpelisib (BYL 719) as a Potential Treatment for Endometrial Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpelisib","moa":"PI3K p110-alpha subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nagourney Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nagourney Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nagourney .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Patent Issuances Covering AXA1665","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar Heathcare","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Accepts Bio-Thera Solutions\u2019 Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Amunix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ N.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentation of Preclinical Data for TransCon IL-2 \u03b2\/\u03b3 at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon IL-2 \u03b2\/\u03b3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"PP-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Primary Peptides \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Pe.."},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Qingdao Primedicine Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qingdao Primedicine Pharmaceutical Co. Ltd and Primary Peptides Inc. Announce Exclusive China Partnership","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PP-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Primary Peptides \/ Qingdao Primedicine Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Pe.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Morningside","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Raises $30 Million in Series B Funding","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Morningside","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","amount":"$93.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bolt Biotherapeutics nabs $93.5M to Push Provenge Inventor's New Idea Deeper in the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"BDC-1001","moa":"TLR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Carmine Therapeutics","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Partners up with Carmine Therapeutics to Develop and Market Rare Disease Candidates","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"RBCEV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0.90000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Carmine Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"$407.5 million","upfrontCash":"$10.0 million","newsHeadline":"Hansa Biopharma Inks Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0.40999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"CF PharmTech","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series F Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CF PharmTech","amount2":0.050000000000000003,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Aerosol","sponsorNew":"CF PharmTech \/ BioTrack Capital","highestDevelopmentStatusID":"1","companyTruncated":"CF PharmTe.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib + Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ex.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Ridgeback Bio","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpicentRx and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RRx-001","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"EpicentRx \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Chiasma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"ANX005","moa":"C1q","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Annexon Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Redmile Group","highestDevelopmentStatusID":"7","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Crestone","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$18.2 million","upfrontCash":"Undisclosed","newsHeadline":"Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CRS0540","moa":"PolC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Crestone \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"ChemRar","sponsor":"Russian Direct Investment Fund (RDIF)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and ChemRar Exceed Target Production of Avifavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ChemRar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ChemRar \/ Russian Direct Investment Fund (RDIF)","highestDevelopmentStatusID":"12","companyTruncated":"ChemRar \/ .."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$14.5 million","newsHeadline":"Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion Completes Acquisition of Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Intravacc","sponsor":"CimCure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc, CimCure Partner on Cancer, COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ CimCure","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Lysogene","sponsor":"Weizmann Institute of Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lysogene Enters Research Pact with Weizmann Institute of Science to Develop New AAV Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AAV gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lysogene \/ Weizmann Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"CureVac","sponsor":"Tesla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Tesla","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"DePuy Synthes Sales Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ DePuy Synthes Sales Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics' New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"MultiTAA-Specific T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Coalition for Adaptive Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai to Investigate Eritoran in REMAP-COVID Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Eritoran","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ The Global Coalition for Adaptive Research","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Th.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Seltorexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Minerva Neurosciences \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Shionogi","sponsor":"StemRIM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shionogi Signs New Contract with StemRIM Toward Investigator-initiated Clinical Study Implementation of S-005151","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Redasemtide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ StemRIM","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Raises $15m and Expands its Relationship with Pfizer","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"USP30","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Massachusetts Eye and Ear","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen Joins Harvard in Gene Therapy Pact to Fight Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AAV gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Massachusetts Eye and Ear","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ M.."},{"orgOrder":0,"company":"Novavax","sponsor":"Operation Warp Speed","pharmaFlowCategory":"D","amount":"$1,600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax, maker of a Covid-19 vaccine, is backed by Operation Warp Speed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"NVX\u2011CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":1.6000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.6000000000000001,"dosageForm":"","sponsorNew":"Novavax \/ Operation Warp Speed","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Micro-cap Oncology Biotech Sun BioPharma Files for a $12 Million Nasdaq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rare Disease Biotech Inozyme Pharma Files for an $86 million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Oncology Biotech Nkarta Sets Terms for $150 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"CureVac","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Nets EU Funding to Ramp up Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ European Investment Bank","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"SciLifeLab","sponsor":"Medivir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and SciLifeLab Partner to Identify Covid-19 Drug Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"SARS CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SciLifeLab","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciLifeLab \/ Medivir","highestDevelopmentStatusID":"2","companyTruncated":"SciLifeLab.."},{"orgOrder":0,"company":"Kiq","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","amount":"$104.4 million","upfrontCash":"Undisclosed","newsHeadline":"Unum Therapeutics Inc. Announces Acquisition of Kiq LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"PLX9486","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiq","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Kiq \/ Unum Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kiq \/ Unum.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Fluconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Collaborates with MSD to Evaluate APG-115 in Combo with Keytruda in Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NK cell Engager Therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"Calcium dependent Cardiac Troponin C","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"WEP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA\u00ae (lefamulin)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ WEP","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lineage Cell Therapeutics Announces Extension of OpRegen\u00ae Development Grant From Israel Innovation Authority","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Retinal pigment epithelium cell transplant therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Morphic Extend Drug Discovery Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Morphic Therapeutic","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ M.."},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"89bio Announces Proposed Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Bo.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Shionogi","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Asenapine Maleate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"LTS - Lohmann Therapie Systeme \/ LIVZON","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohm.."},{"orgOrder":0,"company":"American Regent","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Announces Execution of Agreement with American Regent for Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Regent \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"American R.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra to Commercialize Myring In France, Poland And UK","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Starts Regn-Cov2 Phase 3 Covid-19 Prevention Trial In Collaboration With National Institute of Allergy and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"DynPort","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immune Regulation and DynPort to Trial Covid-19 Drug Candidate","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"ILR201104","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ DynPort","highestDevelopmentStatusID":"4","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"$3.0 million","newsHeadline":"Entasis Therapeutics Awarded Contract from National Institutes of Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"ETX0462","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Receives US Orphan-Drug Designation for ISA101b in HPV16-Positive Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Presents Phase I\/II Data Testing Onivyde as an Investigational First-Line Combination Treatment for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Selection of T-VIVA-19\u2122 as Targeted Protein Vaccine Candidate for SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"T-VIVA-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"Nrf -2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"MetVital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MetVital Gets FDA Fast Track Designation of Enol-Oxaloacetate for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Enol-oxaloacetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MetVital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MetVital \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MetVital \/.."},{"orgOrder":0,"company":"NeurAegis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeurAegis Announces Publication of Preclinical Animal Data Supporting Calpain-2 as a Promising Therapeutic Target for Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Calpain-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeurAegis","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeurAegis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeurAegis .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Submits NDA to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Pharmaceuticals Announces European Commission Approval of Invokana\u00ae (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napp Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharm.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces European Commission Approval for Janssen\u2019s Preventive Ebola Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Moves Forward with Clinical Development of Neihulizumab in Steroid-Refractory Acute Graft-Vs-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FUROSCIX\u00ae NDA Resubmission","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences to Present Clinical Data from Phase 1\/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Doses First Patient in EXCELLENCE Phase 2\/3 Clinical Trial of ANAVEX\u00ae2-73 (Blarcamesine) in Patients with Rett Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV for Endogenous Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces All CONTROL Study Sites Open and Enrolling Patients with Moderate to Severe Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Submitted Marketing Authorization Application to the EMA for Setmelanotide in POMC and LEPR Deficiency Obesities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Starts Patient Recruitment in Phase 2 Safety & Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan BioScience Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ObsEva \/ Yuyuan BioScience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Y.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Whole brain radiation therapy","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rhythm Rare Pediatric Disease Designation for Rare Obesities Drug","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Seeks US FDA Approval to Initiate Phase 1 Study of SYN-020 Intestinal Alkaline Phosphatase","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Tropical Infectious Diseases Research and Education Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIDREC Laboratory Studies Confirm the Effectiveness of BETADINE\u00ae Gargle and Mouthwash Against COVID-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"MALAYSIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tropical Infectious Diseases Research and Education Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gargle And Mouthwash","sponsorNew":"Tropical Infectious Diseases Research and Education Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tropical I.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Sanofi Provide Update on Kevzara\u00ae (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"HIV-1 attachment","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO\u2122 (remimazolam injection)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medici.."},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emcure Pharma Launches Generic Drug for Hyperphosphatemia in Chronic Kidney Disease Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pha.."},{"orgOrder":0,"company":"Anivive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anivive Initiates Two Pre-Clinical Studies of Investigational Antiviral GC376 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GC376","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anivive","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anivive \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anivive \/ .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare to Present New Data on Long-Acting Regimens for HIV Prevention and Treatment, Alongside Extensive Insights into the Evolving Needs of People Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib\/II Trial of MEN1611 in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1611","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Na\u00efve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Study of MRx-4DP0004 in Patients Hospitalized with COVID-19 Open for Enrolment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx-4DP0004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus\u2019 Vaccine for COVID-19 (ZyCoV-D) Successfully Completes Preclinical\nDevelopment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viiv Healthcare Presents Positive Data from First-Ever Implementation Research Study on How Best to Integrate an Investigational Once-Monthly Injectable HIV Treatment In US Healthcare Practices","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Discontinues Hydroxychloroquine and Lopinavir\/Ritonavir Treatment Arms for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis SA Says Melani-01 Trial has been Placed on Clinical Hold By U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"UCARTCS1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"EspeRare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EspeRare Gets FDA Breakthrough Therapy Designation for ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ER-004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"EspeRare","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces U.S FDA has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Additional Safety & Efficacy Data for Islatravir in Combination with Doravirine in Adults with HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Decision by the Investigator to Reduce the Number of Patients in the Ongoing Phase II Trial Evaluating lanifibranor in Type 2 Diabetes Patients with Non-Alcoholic Fatty Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Nyrada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nyrada Reveals Encouraging Cholesterol-Lowering Drug Study Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NYX-PCSK9i","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nyrada","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nyrada \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nyrada \/ N.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Treats First Cancer Patients in Part B of Phase I\/II trial of MRx0518 in Combination with Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Presents Additional Data on Relugolix Combination Therapy in Women with Uterine Fibroids and Ovulation Inhibition Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Limited Announces Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Celixir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celixir Provides Update on Ongoing Clinical Programme with Lead Therapeutic Candidate CLXR-001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"iMP cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celixir","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celixir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celixir \/ .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong to Conduct Phase 1 trial of Covid-19 Treatment in Indonesia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DWP710","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX\u00ae3-71 (AF710B)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AF710B","moa":"S1R\/Muscarinic acetylcholine receptor M1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Positive Top-Line Results from Phase 1\/2 Clinical Trial of OTO-313 in Patients with Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"LSU Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LSU Health New Orleans Discovers New Class of Safer Analgesics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"LSU Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LSU Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LSU Health.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on OTIVIDEX\u00ae Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Positive Opinion from the Paediatric Committee of the EMA on the Agreement of a Paediatric Investigation Plan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune to Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NasoVAX","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Gene Therapies","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Poseida Therapeutics, Inc","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"University of St Andrews","sponsor":"ILC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ILC Therapeutics Announces Research Partnership with University of St Andrews to Fight Against COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Alfacyte","moa":"INF alpha 14","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of St Andrews","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of St Andrews \/ ILC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai\u2019s Equfina receives South Korean marketing approval to treat Parkinson\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AL002","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Announces First Patient Enrolled in Clinical Study Conducted at The Ohio State University in R\/R AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Completes Submission of NDA Seeking Approval of Casimersen for Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Casimersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Develops New Phase IIa Alzheimer\u2019s Trial Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Clears New Class of Anaemia Therapy from Bristol Myers Squibb","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Develops India\u2019s First DCGI-Approved Vaccine Candidate, Gets Nod for Human Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"ReNeuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReNeuron Announces Further Positive Data in Retinal Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Human retinal progenitor cell therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReNeuron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces MET Inhibitor Tabrecta\u2122 Approved in Japan for Advanced Non-Small Cell Lung Cancer with METex14","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces First Patient Dosed in Second Zimura\u00ae Phase 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsca\u00aeApproved in Japan for Additional Indication of Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolvaptan","moa":"V2R","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Millmount Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rybelsus\u00ae approved in Japan for the treatment of type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication in PNAS Unveils Molecular Pathway Required for Influenza Virus Replication with Large Potential as an Antiviral Drug Target","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-002","moa":"MEK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data presented at ISTH Virtual Congress highlights Sanofi\u2019s commitment to advancing treatments for people with rare blood disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Antihemophilic Factor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Global Virus Network","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Virus Network Suggests Oral Polio Vaccine May Provide Temporary Protection Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oral poliovirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Global Virus Network","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Global Virus Network \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Vir.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analysts hail Akero's Midphase NASH Data as Best in Class","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces Anti-COVID-19 Product Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OPN-019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"RCSI University of Medicine and Health Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Irish Researchers Test Alpha-1-Antitrypsin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha-1-antitrypsin","moa":"Alpha-1 antiproteinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RCSI University of Medicine and Health Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RCSI University of Medicine and Health Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RCSI Unive.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MV-014-210","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Submits a CTA for a Phase I\/IIa trial of BI-1808","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1B","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Radiolabelled MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar","highestDevelopmentStatusID":"1","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Enrolls First Patient in the Second Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breast Cancer Drug Capivasertib Enters Major Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"The Institute of Cancer Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Status to NeuroRx\u2019s Covid-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"SFA005","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Discovery","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Melior Discovery \/ SFA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Melior Dis.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Dosed in Phase 1 Clinical Study with VTP-300 Immunotherapeutic to Treat Chronically Infected Hepatitis B Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VTP-300","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Enrolls First Patient in Phase I\/IIa Trial of BI-1206 in Combination With KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4\/DRSP in the US","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imperial College London Begins Dosing in Covid-19 Vaccine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"IgNova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgNova Files Patent Application on Antibody Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IgY antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IgNova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IgNova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IgNova \/ N.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Reports IMBRUVICA\u00ae (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenstr\u00f6m's Macroglobulinemia (WM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9 Treatment in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Research Highlights Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Completion of Initial Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Gene and Cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sana Biotechnology","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA\u00ae 3PSP Smart Device","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","amount":"$59.0\u202c million","upfrontCash":"$43.0 million","newsHeadline":"La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"IBM Watson Health","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution for Phase II Clinical Trial of OT-101 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IBM Watson Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IBM Watson Health \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IBM Watson.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Holdings Raises $100.0 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Canadian Institutes of Health Research (CIHR)","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Entos Pharmaceuticals Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Fusogenix DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Canadian Institutes of Health Research (CIHR)","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$23.1 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Termination","leadProduct":"Sucrose Acetate Isobutyrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Durect Corporation","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Durect Corporation \/ Gilead Sciences, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"STC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Life Sciences Announces Agreement STC Biologics for GMP Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"TZLS-501","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Tiziana Life Sciences \/ STC Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$139.0 million","newsHeadline":"Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0.25,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"BioNTech \/ Temasek","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Smerud Medical Research","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Out-Licenses Clinical Assets to Smerud","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Oncology Venture \/ Smerud Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"University of Oslo","sponsor":"BioArctic AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"NORWAY","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Apolipoprotein E","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"University of Oslo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oslo \/ BioArctic","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ G1 Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Expansion of Reimbursement Agreement With NHS England","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NHS England \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NHS Englan.."},{"orgOrder":0,"company":"Bioasis","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","amount":"$141.0 million","upfrontCash":"$3.0 million","newsHeadline":"Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Transcend-peptide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bioasis","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Bioasis \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"Bioasis \/ .."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pandion Therapeutics Raises $75 million IPO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Medicago","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Candidate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CoVLP vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Medicago","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Medi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Announces Manufacturing and Supply Agreement for Barda And U.S. DOD For Regn-Cov2 Anti-Viral Antibody Cocktaill","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor","highestDevelopmentStatusID":"8","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices Wins Three Department of Defense Awards Totaling More Than $16 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ology Bioservices","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APEIRON Biologics and MaxCyte Enter Into Clinical and Commercial Licensing Agreement for APN401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ APEIRON","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Osivax","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"OVX836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Osivax \/ European Innovation Council","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ E.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"CytoAgents Receives Funding to Accelerate COVID-19 Clinical Trials for Cytokine Storm Treatment From Richard King Mellon Foundation","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Gesynta raises SEK 190M in Round Led by Hadean Ventures to Accelerate Development of First-in-Class mPGES-1 Inhibitor GS-248","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"GS-248","moa":"mPGES-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Gesynta Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Ph.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntelGenx \/ Cybin Corp","highestDevelopmentStatusID":"1","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Multi-specific antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vor Biopharma Closes $110 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VOR33","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vor Biopharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Quantitative Medicine","sponsor":"Predictive Oncology","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology Completes Acquisition of Quantitative Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Quantitative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quantitative Medicine \/ Predictive Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Quantitati.."},{"orgOrder":0,"company":"Biothera Pharmaceuticals","sponsor":"HiberCell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Imprime PGG","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biothera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biothera Pharmaceuticals \/ HiberCell","highestDevelopmentStatusID":"8","companyTruncated":"Biothera P.."},{"orgOrder":0,"company":"AlloVir","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon, AlloVir Gun for $100M IPOs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AlloVir \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn\u00ae Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$66.0 million","newsHeadline":"CEPI to Invest $66 Million to Boost Clover's COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"S-Trimer COVID vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA\u00ae for the Treatment of Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Bentley University","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$6,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"$6.5 billion in NIH Funding for Foundational Research Enabled Emergency Use Authorization of Remdesivir for Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bentley University","amount2":6.5,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":6.5,"dosageForm":"Intravenous Injection","sponsorNew":"Bentley University \/ Ntional Institute of Health","highestDevelopmentStatusID":"12","companyTruncated":"Bentley Un.."},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Plakous Therapeutics Awarded $1.7 Million Fast-Track SBIR Grant from NIH to Develop Therapies for Necrotizing Enterocolitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plakous Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Th.."},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"EDIT-301","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Grou.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"$25.0 million","newsHeadline":"Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"T Cell Engaging Bispecific Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ X.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Taiba","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$36.6 million","upfrontCash":"Undisclosed","newsHeadline":"VarmX Raises \u20ac32 Million to Develop Innovative Reversal Agent for the Treatment of Bleeding in Patients on Oral Anticoagulants","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VMX-COO1","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0.040000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ys.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"T20K","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Professor Rikard Holmdahl","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Var2 Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VAR2 Pharmaceuticals Wins MilliporeSigma\u2019s Advance Biotech Grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"rVAR2 Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Var2 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Var2 Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Var2 Pharm.."},{"orgOrder":0,"company":"SGS Life Sciences","sponsor":"Biophytis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophytis and SGS Partner to Test Sarconeos in Covid-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"SGS Life Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SGS Life Sciences \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"SGS Life S.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Thermo Fisher Signs CDx Agreement with Chugai Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead axes $445M Precision Biosciences Gene Therapy Hep B Pact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Termination","leadProduct":"HBV gene therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Moderna","highestDevelopmentStatusID":"10","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"TQS-168","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tranquis Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis T.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$891.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces New Multispecific Antibody Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0.89000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"","sponsorNew":"Zymeworks \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Kreos Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenSight Biologics Obtains a \u20ac7m Non-Dilutive Loan and Renegotiates the Bond Agreement With Kreos Capital Extending Runway to Mid-2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenSight Biologics \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"DynPort Vaccine Company","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DynPort Vaccine Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"DynPort Vaccine Company \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"DynPort Va.."},{"orgOrder":0,"company":"MolMed","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"OTL-200","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MolMed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MolMed \/ Orchard Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ O.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration for COVID-19 Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Hyperimmune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces XHANCE Co-Promotion Agreement with Kal\u00e9o","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"KALEO INC","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC .."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda Teams up with Twist Bioscience to Boost Biologics R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Natco Pharma's Canadian Unit Signs Pact with Celgene for Cancer Treatment Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Natco Pharma \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"OcuMension Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"5","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Kures","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Takes on Opioid Crisis by Acquiring Kures to Develop Novel Therapeutics for Opioid Abuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"KUR-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Kures","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kures \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kures \/ AT.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Times Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B\u00ae Hepatitis B Vaccine to Customers Throughout Oahu","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Hepatitis B Vaccine (Recombinant) Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Times Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","amount":"$102.8 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Ardigen","sponsor":"CVC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ardigen, CVC Collaborate to Develop SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ardigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ardigen \/ CVC","highestDevelopmentStatusID":"3","companyTruncated":"Ardigen \/ .."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Expands Partnership With Ultragenyx To Provide Dojolvi\u2122 (triheptanoin)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Triheptanoin","moa":"Triglyceride","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plex Pharmaceuticals Awarded $1.6 Million in Grant Funding from NIH to Advance Eye Drop Therapy for Cataracts","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Plex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Plex Pharmaceuticals \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plex Pharm.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Jefferies","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Expands Collaboration with Roche Evaluating TrodelvyTM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Excivion","sponsor":"CPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CPI Partners with Excivion to Optimise and Scale up Production of Safe and Effective Zika Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Zika-HX antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Excivion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excivion \/ CPI","highestDevelopmentStatusID":"1","companyTruncated":"Excivion \/.."},{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Licenses Canadian Rights to Ametop\u2122 Gel from Alliance Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetracaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alliance Pharmaceutical Company","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alliance Pharmaceutical Company \/ Valeo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Alliance P.."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"2X Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Acquires Full Ownership of its PARP Inhibitor (2X-121) Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Stenoparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ 2X Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Enters Industry-Academia-Government Joint Research Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"E6742","moa":"TLR7\/8","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Un.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Antimicrobial Resistance Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Closes Deal with Merck KGaA, Darmstadt to Receive Cetuximab for Production of its ASP-1929 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Premier Inc. ProvideGx\u2122 Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Therapeutics to Fund Observational Studies of Artemisinin in Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Reports superior efficacy of long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Launch In-House Developed New Anti-insomnia Drug in Japan","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Johns Hopkins University Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cord blood derived T-regulatory cell therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johns Hopkins University Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johns Hopkins University Hospital \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"jCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"jCyte Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic human retinal progenitor cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ No.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Gets IRB Approval for Phase II trial of ANVS401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Evaluates Monoclonal Antibody in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Garadacimab","moa":"Factor XIIa","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ILB-202","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ILIAS Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILIAS Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILIAS Biol.."},{"orgOrder":0,"company":"Sinomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinomed Completes Enrollment in PIONEER-III pivotal US & Japanese Trial of the BuMA Supreme Coronary DES","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinomed \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ .."},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evive Biotech meets Promising Results at Global Ph III Trial for Neutropenia Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efbemalenograstim alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biot.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Neurogene\u2019s Gene Therapy for the Treatment of CLN5 Batten Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-based engineered transgene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSIR Seeks Regulatory Nod for Clinical Trials Using Combination of Antivirals and HDTs Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LAXAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life.."},{"orgOrder":0,"company":"Biophytis","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Receives IND Clearance for COVA, a Phase 2\/3 Clinical Trial with Sarconeos for Treatment of COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ SGS","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CYT-0851","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Dosing Initiation in 2nd Phase 1 Trial with INM-755","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"TALLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TA-A001","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"TALLC","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"TALLC \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TALLC \/ No.."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Biosciences Published data in eBioMedicine Validates Novel Scientific Approach That Disarms Bacterial Defenses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL\u2122 Study in RDEB after COVID-19 Related Pause","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Talaris Therapeutics\u2019 IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Initiates Phase 1\/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ANG-3777","moa":"HGF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Publish New Results in Journal of Alzheimer's Disease Support Masitinib\u2019s Potential Mode of Action in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Seaver Autism Center for Research and Treatment","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seaver Autism Center For Research and Treatment at Mount Sinai Launches First Drug Trial for ADNP Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seaver Autism Center for Research and Treatment","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seaver Autism Center for Research and Treatment \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaver Aut.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Awarded U.S. Composition of Matter Patent Covering Engineered Bacterial Strains for Treating Skin Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Staphylococcus epidermidis","moa":"SPINK5 gene","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ N.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Submits Publication on StemVacs\u2122 Preclinical Data Supporting COVID-19 Indication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dendritic Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection\n","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"In Vitro Testing of Innovation Pharmaceuticals\u2019 Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Files IND for International Phase 1b\/2b COVID-19 Clinical Program With TSC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX\u00ae Intranasal Antiviral Protection Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenava","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Publishes of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"CD73","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Resumes CB4211 Phase 1b Clinical Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CB4211","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex\u2122-exatecan), a Novel Treatment for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alphalex-exatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces Simultaneous Regulatory Approvals by U.S. FDA and Health Canada of INQOVI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Doses First DIPG Patient in Phase 1\/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics' TXA127 to be Tested in Multiple Clinical Trials for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PTC857","moa":"15-LOX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARCLISA\u2122 (isatuximab for injection) Now Available in Canada for Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"University of Liverpool","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial Platform Launched to Accelerate COVID-19 Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Liverpool","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Liverpool \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Nod for Lynparza in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Erasmus University Medical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stem Cell Gene Therapy Restores Glycogen Levels, Aids Movement in Mouse Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hematopoietic Stem Cell Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erasmus University Medical Center","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasmus University Medical Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Erasmus Un.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Data Support Catalyst Biosciences\u2019 Potential Hemophilia B Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FIX-Gene Therapy","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gargle And Mouthwash","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data to be Presented at ISTH Virtual Congress Highlights Sobi's Commitment to Advancing Rare Haematology Treatments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"rFVIIIFc-VWF-XTEN","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Announces Publication of Research Demonstrating the Impact of the Novel Treatment, Arina-1 on Mucus Transport in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Reports Positive Results of Preclinical Study of KB-0742","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's BRILINTA Gets FDA Priority Review for the Reduction of Subsequent Stroke Acute Ischemic Stroke Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergy Therapeutics Announces Invalidation of the Birch MATA MPL Phase III Primary Endpoint Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tree MATA MPL","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Th.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Gets Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JS InnoPharm Announces First Patient Dosed with JSI-1187","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"JSI-1187","moa":"ERK1\/2 Mapk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"JS InnoPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPha.."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal\/Provincial\/Territorial Public Drug Plan Formularies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Announces Initiation of Phase 1\/2 Clinical Trial of NT219 in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NT219","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Grifols International","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Availability of TAVLESSE\u00ae (Fostamatinib Disodium Hexahydrate) in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Grifols S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients with Delirium and Agitation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Maruho\u2019s Phase III Study with Chugai\u2019s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Clinical Drug Candidate IRL752 Published in JPET","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IRL752","moa":"5-HT7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces the Latest Findings of Its Vaborem\u2122 and Quofenix\u2122 Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Delafloxacin","moa":"Topoisomerse 4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq for Acquired Blepharoptosis (Droopy Eyelid) in Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-H2158","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Brown University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug treatment Could Improve Effectiveness of Immunotherapy for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Navtemadlin","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brown University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Brown Univ.."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for Major Depressive and Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Duloxetine Hydrochloride","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in Animal Model Advances NanoViricides\u2019 SARS-CoV-2 Therapeutics Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"APN","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cormedix inc. Reports Submission of Defencath\u2122 New Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Aichi Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aichi Cancer Center, NEC study Advanced Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neoantigen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aichi Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aichi Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Aichi Canc.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indapta Therapeutics Provides Updates on Its G-NK cell Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic G-NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TerraCoV2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Atox Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atox Bio Announces Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial in Necrotizing Soft Tissue Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Reltecimod","moa":"CD28","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atox Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces Updated Indication for Dysport\u00ae (abobotulinumtoxinA) for the Treatment of Spasticity in Children","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm's Avigan Inconclusive in COVID-19 Patients in Japan Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s Phoenix Tissue Repair to Highlight Interim Phase 1\/2 Study Data","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FT819","moa":"CAR19 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CS02","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Lab.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Lab Gets USFDA Nod for Baclofen Tablets; Stock Ends Higher","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pankajakasthuri Announces Promising Interim Results for ZingiVir\u2013H Among COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Undisclosed","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zingivir-H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakas.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon\u2019s Breakthrough Drug Itolizumab Receives DCGI Nod for its\nUse in Moderate to Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7-day Levofloxacin\/Dexamethasone Eye Drops as Effective as Standard Treatment After Cataract Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Authorization for Individual Patient Expanded Access Protocol for the use of Tradipitant for Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Presents New Haemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen's ALS Therapy Bags US Orphan Status","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse\u00ae Inhaled Nitric Oxide Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AVA-001","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension\/Switch Study of Investigational Once-Nightly FT218","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amendments to ProtoKinetix AAGP\u00ae Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1\/2b Study Evaluating ARQ-252 in Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All Patients Have Completed their 15-month Visits in the European Phase IIb Trial with the Diabetes Vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing ARDS due to COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience AB (publ) Interim Report January-June 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-280","moa":"Arginase-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel\u2019s Clinical Stage CDK2\/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1\/2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"S15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and Haemostasis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1\/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SPK-8011","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"Queensland University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s Queensland University Begins Covid-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Queensland University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Queensland University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Queensland.."},{"orgOrder":0,"company":"Sechenov University Center for Clinical Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian University Completes Clinical Trials of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sechenov University Center for Clinical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for the Preparation of an Intramuscular Solution","sponsorNew":"Sechenov University Center for Clinical Research \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sechenov U.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients with Chronic Kidney Disease and T2D","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces U.S. FDA Acceptance of Biologics License Application for Tralokinumab for Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia May Start Phase III Tial of COVID-19 Vaccine in Mid-August: RIA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac Lyo","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ExeGi \/ No.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces that the United Kingdom\u2019s MHRA Grants Early Access to Lumasiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Phase IIIb Study Reinforces Safety Profile of Genentech\u2019s Hemlibra (emicizumab-kxwh) in People With Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immodulon Announces that IMM-101 will be Evaluated in World-First, Prophylactic Immuneboosting Strategy for COVID-19 in Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IMM-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Immodulon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immodulon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immodulon .."},{"orgOrder":0,"company":"Archivel Farma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Archivel Farma\u2019s RUTI Vaccine to Start a Clinical Trial to Increase the Immunity of Healthcare Professionals Exposed to the Risk of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RUTI vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archivel Farma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Archivel Farma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Archivel F.."},{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucero Therapeutics Announces Promising Covid-19 Virus Laboratory Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pixatimod","moa":"Spike protein S1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zucero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zucero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zucero The.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"CSIRO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceutical's RECCE\u00ae Compounds Selected by CSIRO\/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Recce 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"ICMR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ICMR Partners with Bharat Biotech to Launch COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ ICMR","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pracinostat","moa":"pan-HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Helsinn Group","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma Gets E.C Approval for Extended Invokana\u00ae (Canagliflozin) Indication to Cover Diabetic KD in Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring's IDELVION\u00ae Becomes First and Only Factor IX Therapy with 21-Day Prophylactic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Albutrepenonacog Alfa","moa":"Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty\u00ae for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil\u2019s Regulator Approves Trial of Sinovac\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second PhIII Study for Idorsia's Sleep Drug Returns Positive Results","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ\u00ae Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Final Data From its Phase IIa Clinical Trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Completes Patient Dosing in Cohort 4 of OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm to Partner with Dr Reddy's to Sell Avigan Overseas as Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Toyama Chemical \/ Dr Reddy's","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co., LLC","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces a \u20ac 6.1 Million Capital Increase Through Private Placement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Biophytis \/ H.C. Wainwright & Co., LLC","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson\u2019s Lead COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Animal Health Acquires US Rights to Sentinel Flavor Tabs & Sentinel From Virbac","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Milbemycin Oxime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virbac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virbac \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Virbac \/ M.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"2 Months After Launch, QurAlis Nabs Early ALS Compounds from Eli Lilly","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Citryll","sponsor":"BOM Brabant Ventures","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citryll Completes \u20ac 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Traps","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Citryll \/ BOM Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ .."},{"orgOrder":0,"company":"Revitope Oncology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Taps Revitope for Next-Gen Anticancer Bispecifics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Immunotherapy compound","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Revitope Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revitope Oncology \/ Junshi Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Revitope O.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CK-274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0.45000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ RTW Investments","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Educell","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis Enters Collaboration Agreement with Educell","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Educell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Educell \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Educell \/ .."},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lamassu Pharma Receives Prestigious $1.5 Million NIH SBIRP Grant to Support Further Development of its Novel Therapy for Acute Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"RABI-767","moa":"Lipase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novocure Announces Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"Tumor growth","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Novocure","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied Biology and Kintor to Collaborate on the Use of Proxalutamide for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptors","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinical Trials","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"RNA based therapies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Versameb","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/.."},{"orgOrder":0,"company":"Vivasc Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vivasc Therapeutics Receives NIH Phase I STTR Grant to Utilize Novel Cardiac Targeting Peptides for Targeted Delivery of Amiodarone","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CTP-Amio","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Vivasc Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivasc Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Vivasc The.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sterling Pharma Solutions \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Sterling P.."},{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Nurx Expand Access to ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Nurx","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravaginal Ring","sponsorNew":"Nurx \/ TherapeuticMD","highestDevelopmentStatusID":"12","companyTruncated":"Nurx \/ The.."},{"orgOrder":0,"company":"GSK","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Licenses Gene Therapy Technology from GSK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OTL-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Orchard Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Orch.."},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hackensack Meridian Partners with Merck for Covid-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hackensack Meridian CDI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hackensack Meridian CDI \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Hackensack.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relay Passes the Baton from Private to Public Biotech for $400M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"RLY-1971","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Kronos Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bischofberger's Kronos Buys SYK Inhibitors from Gilead","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Entospletinib","moa":"SYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Kronos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Imvax","sponsor":"HP WILD Holding AG","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imvax Raises $112M to Advance Brain Cancer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ HP WILD Holding AG","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ HP.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Assigned US License for BYFAVO\u2122 (remimazolam) by Cosmo Pharmaceuticals NV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Invetx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Invetx","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncorus Announces Collaboration with Merck to Evaluate the Combination of Oncorus\u2019 ONCR-177 with Merck\u2019s KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ONCR-177","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Oncorus","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Tetravalent bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Merck KGaA","highestDevelopmentStatusID":"4","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Virometix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"V-306","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virometix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Virometix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Virometix .."},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Leiden University Medical Center","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leiden University Medical Center \/ Mydecine","highestDevelopmentStatusID":"4","companyTruncated":"Leiden Uni.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes Metropole","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Covepit","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes Metropole","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Soleus Capital","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioAtla Rakes in $72.5M Series D, Advancing Research for pH-Detecting Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series D Financing","leadProduct":"CAB-AXL-ADC","moa":"AXL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"BioAtla \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari\u00ae for Diverticulosis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner In.."},{"orgOrder":0,"company":"Path BioAnalytics","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE\u00ae Compounds in Expanded SARS-CoV-2 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Recce 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Path BioAnalytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Path BioAnalytics \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Path BioAn.."},{"orgOrder":0,"company":"GSK","sponsor":"Foundation Consumer Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Consumer Healthcare to Add Seven Over-the-Counter Brands to Expanding Portfolio of Healthcare Products","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Brompheniramine Maleate","moa":"H1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Foundation Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Foun.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inozyme Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Inozyme Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"PicnicHealth","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche, Genentech Employ PicnicHealth to Tap into MS Patient Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"PicnicHealth","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PicnicHealth \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"PicnicHeal.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Closes Series B Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Pharmapark","sponsor":"Pharmapark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Partners with Pharmapark to Market BAT2506 in Russia and other CIS Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pharmapark","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmapark \/ Pharmapark","highestDevelopmentStatusID":"6","companyTruncated":"Pharmapark.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$183.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson\u2019s Disease Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Bayer Announce Co-Promotion Agreement for Respiratory Treatments Clenil and Foster in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Beclomethasone Dipropionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Group \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO\u00ae (selinexor) Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Karyopharm Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Aceso Life Science Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Promethera Plans to Form Joint Venture to Conduct Research and Develop Cell-Based and Biological Therapies to Treat Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"HepaStem","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Promethera Biosciences \/ Aceso Life Science Holding","highestDevelopmentStatusID":"8","companyTruncated":"Promethera.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix to Focus on Precision Medicine Approaches for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Participation in AMR Action Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Antimicrobial Resistance Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"NewG Lab","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"AnHeart Therapeutics Announces License Agreement with NewG Lab for Taletrectinib Rights in Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ NewG Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$40.0 million","newsHeadline":"Assembly Biosciences and BeiGene Announce License and Collaboration Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ABI-H0731","moa":"Core protein allosteric","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0.54000000000000004,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Consonance Capital Management","pharmaFlowCategory":"D","amount":"$43.0 million","upfrontCash":"Undisclosed","newsHeadline":"Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"MT-3724","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Molecular Templates \/ Consonance Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$650.0 million","newsHeadline":"Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.65000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.65000000000000002,"dosageForm":"Oral","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Asili Research Alliance","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Artemisinin","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asili Research Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asili Research Alliance \/ Mateon","highestDevelopmentStatusID":"4","companyTruncated":"Asili Rese.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$18.9 million","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Syracuse Biopharma","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics\u2019 Solid Tumor Technology in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"HONG KONG","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"T-cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Syracuse Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syracuse Biopharma \/ JW Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Syracuse B.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,680.0 million","upfrontCash":"$775.0 million","newsHeadline":"Roche Signs up to $1.7bn Cancer Drug Deal with Blueprint Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":1.6799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.6799999999999999,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$986.0 million","upfrontCash":"$20.4 million","newsHeadline":"Kiadis Licenses Previously Undisclosed Pre-Clinical K-NK-cell Programs to Sanofi, with Total Potential Deal Value of \u20ac875 Million, Plus Royalties","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Isatuximab-irfc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0.98999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.98999999999999999,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Vizient","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Vizient","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Establishes Manufacturing Network in Preparation for Its Ph 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"LP-300","moa":"ALK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Fairhaven Pharmaceuticals","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program for Eosinophilic-Driven Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"OXE receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Fairhaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fairhaven Pharmaceuticals \/ Liminal BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Fairhaven .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1\/2 Gene Therapy Biotech Freeline Therapeutics Files for a $100 million US IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"FHI Clinical","sponsor":"Leidos Biomedical Research, Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FHI Clinical Inc. Providing Clinical Operations Services for ACTT-1 Trial of Remdesivir for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"FHI Clinical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"FHI Clinical \/ Leidos Biomedical Research, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"FHI Clinic.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1068.5 million","upfrontCash":"$72.3 million","newsHeadline":"Basilea Reports Launch of Antifungal Cresemba\u00ae (isavuconazole) in Taiwan, Triggering the Second Milestone Payment Related to Asia-Pacific","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":1.0700000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.0700000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Curia","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViralClear, Curia Enter COVID-19 Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curia \/ Biosig","highestDevelopmentStatusID":"8","companyTruncated":"Curia \/ Bi.."},{"orgOrder":0,"company":"Rosalind Franklin Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Researchers Engineer Antibodies from llamas Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanobodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rosalind Franklin Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rosalind Franklin Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rosalind F.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces FDA Advisory Committee Votes in Favour of Positive Benefit\/Risk Profile for Belantamab Mafodotin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Hermann-Texas Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Hermann-Texas Medical Center","highestDevelopmentStatusID":"5","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Announces Clearance for Investigational New Drug Application of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Medicago","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Inflazome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation for Inflazome\u2019s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inzomelid","moa":"NLRP3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Immutep","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces United States Patent Grant for IMP701 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Intravenous Infusion","sponsorNew":"Immutep \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-3061","moa":"Kv7.2\/7.3 potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Exosome-mediated RNAi","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s QED Therapeutics Doses First Child in Phase 2 Trial of the Investigational Medicine Infigratinib in Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Manuscript Describes How TLC\u2019s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit in Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenstr\u00f6m Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Plant-based COVID-19 antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President of Clinical Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Starts Human Trials of ZyCoV-D, its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Hebrew University of Jerusalem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hebrew U: Drug Could Turn Covid-19 Into Common Cold","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenofibrate","moa":"PPAR alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hebrew University of Jerusalem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hebrew University of Jerusalem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hebrew Uni.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Rensselaer Polytechnic Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Researchers Say Heparin May Neutralise Covid-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rensselaer Polytechnic Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rensselaer Polytechnic Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rensselaer.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ Unveils Detailed Data from THALES Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilteritinib Becomes First NICE-Approved Oral Therapy for Relapsed or Refractory Acute Myeloid Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Santa Lucia Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Study Funded by the Alzheimer's Drug Discovery Foundation Finds Dopamine Therapy Improves Cognitive Function in Mild-to-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rotigotine","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Santa Lucia Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Santa Lucia Foundation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santa Luci.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma Reports Positive Data from octagam\u00ae Usage in Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Third Nintedanib Indication in Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RBM-007","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ribomic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation AT-301","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxaquin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SA.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2\/3 Study in the CHEST Journal","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis\u2019 ARQ-151 for Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Galt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Galt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galt Pharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's FARXIGA Granted Fast Track Designation for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Centivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centivax Antibody Effective in Reducing COVID-19 Lung Damage, Virus Levels and Symptoms in Immunocompromised Hamsters","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centivax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Centivax \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s New Drug Application for Vericiguat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Filing Of Protocol For ENVASARC Pivotal Trial With The FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b\/3 Human Study of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI\u00ae for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives Approval for Phase 2\/3 COVID-19 Study in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR-T Therapy","moa":"CD3 complex","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for Front-Line Treatment of TP53 Mutant AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J eyes September for Late-Stage Study of Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilonacept","moa":"IL-1 beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora \u00ae Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Data Showing Auxora\u2122 Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Advances Phospho-Tau Alzheimer\u2019s Vaccine in Phase 1b\/2a Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Biotech AG Announces that Carragelose\u00ae has the Potential to Reduce the Risk of an Infection with SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Carrageenan API","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Throat Sprays","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Provides IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Ph 2 GNAQ\/11 Basket Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE196","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Ume\u00e5 University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swedish Trial to Assess Prostate Cancer Drug for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ume\u00e5 University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ume\u00e5 University \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ume\u00e5 Unive.."},{"orgOrder":0,"company":"Russian Defence Ministry","sponsor":"National Research Center for Epidemiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia finds Covid-19 Vaccine Candidate is Safe in Initial Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Russian Defence Ministry","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Defence Ministry \/ National Research Center for Epidemiology","highestDevelopmentStatusID":"1","companyTruncated":"Russian De.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment, Dosing Underway in Sanfilippo Type A and B Trials of Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ABO-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Dosed First Patient in Pivotal Ph 2 Portion of LOTIS 3 Trial of Loncastuximab Tesirine in Combination With Ibrutinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Launches Human Clinical Trial of Potential COVID-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 antiviral antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA and Takis Report Positive Preclinical Results from LineaDNA\u2122 Vaccine Candidates for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LineaDNA vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"G42 Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World\u2019s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ G42 Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Gives the Go-Ahead for Human Trials of BioNTech's COVID Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine AZD1222 Showed Robust Immune Responses in all Participants in Phase I\/II Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Starts Human Trial of its Anti-COVID Vaccine at PGI Rohtak: Minister Vij","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV2\/5-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Cancer Research UK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flagship Cancer Research UK Precision Medicine Trial Highlights the Need for a New Approach in Treating Genomically Complicated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD4547","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Birmingham \/ Cancer Research UK","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer\u2019s Disease Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IW-6463","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx Touts Upbeat Readout from a Small PhII Study for Lead Antifungal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Shares Soar on COVID-19 Treatment, but Caveats Abound","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Supplemental New Drug Application of ACADIA Pharmaceutical's NUPLAZID\u00ae to Treat Dementia-Related Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identify a New Drug Target for Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Vitronectin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sanford Bu.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 Related Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals\u2019 Brilacidin Inhibits COVID-19 by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Biosceinces Provides Clinical Updates on Its Neoantigen Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Karyopharm\u2019s Supplemental New Drug Application for XPOVIO\u00ae for Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Vyriad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Vyriad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vyriad \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyriad \/ N.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Announces Positive Results from Phase 1 Clinical Trials of LBS-008","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo\u00ae (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanifit to Start New Clinical Development Program of SNF472 in End Stage Kidney Disease Patients with Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GMcSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Pharmaceuticals Reports Positive Phase 3 Study Results for TRIKAFTA\u00ae in People Ages 12 and Older With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Starts CONTACT-03 Ph 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 as a Potential Treatment for Scalp Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Initiates Phase 2 Clinical Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Completion of Patient Enrolment into First Cohort of Phase 2 Study FIDES-01 With Derazantinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University of Alabama","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Doses First Patient in Recurrent Glioblastoma Investigator Sponsored Ph I\/II Study Assessing Selective AXL Inhibitor Bemcentinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ University of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imperial College Advances Covid-19 Vaccine into Next Phase","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabis derived compounds","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyfaquin\u00ae, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"LintonPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LintonPharm Gets Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Catumaxomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"LintonPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"LintonPharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LintonPhar.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Completes Rolling Submission of New Drug Application to U.S. FDA for Arimoclomol for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces a New Publication \u201cApoptotic Cell Therapy for Cytokine Storm Associated with Acute Severe Sepsis\u201d in Cell Death & Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abicipar Pegol","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Ph 2\/3 Trial of RLF-100 for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA\u00ae (tafenoquine) for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT BIO\u2019s COVID-19 Vaccine Candidate HDT-301 Induces Neutralizing Antibody Responses After a Single Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HDT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"IDBiologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDBiologics Announces Nature Publication Highlighting Preclinical Results of Ultra-Potent Monoclonal Antibodies Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IDB003","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IDBiologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDBiologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IDBiologic.."},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasopharm Announces Last Patient Last Visit in NOSTRA III Traumatic Brain Injury Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ronopterin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm .."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Doses First Patient in Phase 2b\/3 COVID-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camargo Client Chiasma Receives FDA Approval for Novel Somatostatin Analog for Long-Term Maintenance Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Receives FDA IND Clearance for COVA Testing Sarconeos for the Treatment of Patients with COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Completion of all Dosing in NurOwn\u00ae Phase 3 Clinical Trial in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Commission has Granted Orphan Medicinal Product Designation in the EU for Medivir's MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boryung Pharmaceutical Announces Superior Results for Plitidepsin (Aplidin\u00ae) Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"Protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ PharmaMar","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Ph.."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Publishes PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharma Announces Positive Results from Phase I\/II ARROW Trial of Pralsetinib in Chinese Patients with RET-Fusion NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Abliva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abliva receives positive FDA feedback on its KL1333 development plant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KL1333","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Abliva","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Abliva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Abliva \/ N.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai\u2019s Hemlibra in Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"VelosBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$137.0 million","upfrontCash":"Undisclosed","newsHeadline":"VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VLS-101","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"VelosBio \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"Kansas State University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Live Replicating Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kansas State University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kansas Sta.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Molecular Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin\u00ae Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"MP0420","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"GHO Capital","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"NCX 470","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ GHO Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$305.0 million","newsHeadline":"Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"DNA plasmids","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ CombiGene AB","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soundny Presents a New Drug-based Alternative in Fight Against Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hubei Soundny Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soun.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Publishes in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sorafenib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from FDA for Treatment of Sonic Hedgehog Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE for Treatment of Patients with Refractory MAC Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liposome Inhalation Suspension","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Reduces Workforce to Focus on Development of PDK1 inhibitor, SNS-510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SNS-510","moa":"PDK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunesis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma Canada Announces that Nova Scotia has Added the Company's Treatment for Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma-Pharma Announces Submission for Their Botulinum Toxin to Treat Glabellar (frown) Lines to the German Authority BfArM","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Croma-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Phar.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn\u2019s Leronlimab Prevents Transmission of SHIV in Macaque Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Photodynamic drug","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Begins Patient Enrollment in Phase 1 Trial of ANAVEX3-71 to Treat Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AF710B","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Presentations on Phase I and Phase I\/II Trials using Trappsol\u00ae Cyclo\u2122 Intravenously to Treat Patients with Niemann-Pick Disease Type C1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Publishes Data Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within B7 Superfamily","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Administer ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Coated Formulation","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Final Results from Phase 1\/2 Study of Tofersen for a Genetic Form of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Advances HBV Candidate EDP-514 in Phase I Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-514","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"panCELLa","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"panCELLa Receives Research and Development Support for Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Human embryonic stem cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"panCELLa","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"panCELLa \/ NRC IRAP","highestDevelopmentStatusID":"3","companyTruncated":"panCELLa \/.."},{"orgOrder":0,"company":"Antengene","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avance Clinical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Avance Clinical \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avance Cli.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenzing Acquisition and Reviva Pharmaceuticals Announce Execution of Definitive Agreement and Plan of Merger","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Aisling Capital","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Seribantumab","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Aisling Capital","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Selva Therapeutics Announces $3 Million Series A Financing to Advance a Novel Broad Spectrum Antiviral for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"SLV213","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Selva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Selva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Selva Ther.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"ImaginAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ ImaginAb","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"AdaptVac","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$4.6 million","newsHeadline":"Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CLP based Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AdaptVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AdaptVac \/ Bavarian Nordic","highestDevelopmentStatusID":"4","companyTruncated":"AdaptVac \/.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"South Korea's SK Bioscience in Deal with AstraZeneca on Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Acentrus Specialty","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx\u00ae (neratinib) to Health Systems and Hospitals in the Acentrus Network","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Acentrus Specialty","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"European Cooperative Group","sponsor":"Groupe Francophone","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des My\u00e9lodysplasies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"European Cooperative Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"European Cooperative Group \/ Groupe Francophone","highestDevelopmentStatusID":"8","companyTruncated":"European C.."},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panaxia's Agreement with International Pharma Neuraxpharm is Finalized","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Cannabis products","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuraxpharm \/ Panaxia","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxphar.."},{"orgOrder":0,"company":"University of Louisville","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Louisville","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Louisville \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces $54 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Olema Oncology \/ BVF Partners L.P","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"X-Chem","sponsor":"Orexia Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem Announces Achievement of Milestone In Orexia Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"X-Chem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Orexia Limited","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ O.."},{"orgOrder":0,"company":"Vesigen Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vesigen Therapeutics Launches with USD 28.5 Million Series A Investment Led by Leaps by Bayer and Morningside Ventures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"ARMMs based cell and gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vesigen Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vesigen Therapeutics \/ Bayer","highestDevelopmentStatusID":"3","companyTruncated":"Vesigen Th.."},{"orgOrder":0,"company":"Synaffix","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of Collaboration with ADC Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody-drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Synaffix \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genocea Announces Private Placement Financing of Up to $80 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series D Financing","leadProduct":"ETX101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Encoded Therapeutics \/ GV","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"University of Connecticut","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ovid and UConn Enter Strategic Research Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Gaboxadol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ University of Connecticut","highestDevelopmentStatusID":"1","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding from NIAID to Test Drug in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Humanetics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pha.."},{"orgOrder":0,"company":"SarcoMed","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Protalix BioTherapeutics Inks Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Alidornase alfa","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SarcoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SarcoMed \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SarcoMed \/.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$3.0 million","newsHeadline":"Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini Group","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$30.0 million","newsHeadline":"AMAG Pharmaceuticals and Norgine B.V. Ink Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0.28999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Norgine B.V","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"NCCN Oncology Research Program","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program to Get Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression Together with Taiho Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NCCN Oncology Research Program","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NCCN Oncology Research Program \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"NCCN Oncol.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces $60 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"ALPN-101","moa":"ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"EpiPharm","sponsor":"CalciMedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CM5480","moa":"CARC channel","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiPharm \/ CalciMedica","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento to Acquire SmartPharm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"STI-1499","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SmartPharm Therapeutics \/ Sorrento","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"National Institute of Neurological Disorders","sponsor":"MetVital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MetVital Joins National Institute of Neurological Disorders and Stroke (part of the NIH) in the Epilepsy Therapy Screening Program (ETSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Enol-oxaloacetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute of Neurological Disorders","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Neurological Disorders \/ MetVital","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Interferon a2b","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ Betterlife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Israeli Ministry of Health","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Department of Biotechnology Provides seed Funding for Gennova Biopharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"HGCO19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aurinia Closes US$200 Million Public Offering of Common Shares","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Global Stem Cell Technology","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Acquires GST to Strengthen its Stem Cell Capabilities in Animal Health","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Mesenchymal stem cell therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Global Stem Cell Technology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Global Stem Cell Technology \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"Global Ste.."},{"orgOrder":0,"company":"Humanigen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"National Institutes of Health Selects Humanigen\u2019s Lenzilumab for its COVID-19 Big Effect Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea\u00ae (paclitaxel micellar)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"$12.0 million","newsHeadline":"AMAG Pharmaceuticals Completes Divestment of Women\u2019s Health Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Palatin Technologies \/ AMAG","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Kobe University","sponsor":"Lynk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals Ink Licensing Agreements with Kobe University and RIKEN Research Institute to develop RAS inhibitors with a New MOA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kobe University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kobe University \/ Lynk Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kobe Unive.."},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics and Cyclica Collaborate to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclica \/ Cerevel Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ .."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"$44.2 million","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Non-beta-lactam antibiotic","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VenatoRx Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VenatoRx Pharmaceuticals \/ NIAID","highestDevelopmentStatusID":"2","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.6 million","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma Announces Completion of $5.6 Million Bridge Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"GTB-3550","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"CorMedix","sponsor":"SunTrust Robinson Humphrey","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CorMedix Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ SunTrust Robinson Humphrey","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tvardi\u2019s TTI-101 Receives $5 Million in Grant Funding to Support Clinical Trials and Translational Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Enters Into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion to Acquire Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$63,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":63,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":63,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants fast track status to Hanmi\u2019s investigational fatty liver med","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Pre-filled Syringes","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Begins Human Trials of its First Homegrown Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Indian Council of Medical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Council of Medical Research \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Indian Cou.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm to Begin Clinical Trials Testing Avigan in COVID-19 Patients in Kuwait","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Doses Patients in Phase 1\/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"XC001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Lilly at Alzheimer's Association International Conference 2020\u00ae (AAIC\u00ae 2020) to Showcase Clinical Advances in Alzheimer's Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Repair Activator Cibinetide Shows Potential for Efficacy in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Araim Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Araim Phar.."},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2B Study of ColonaryConcepts\u2019 Novel Colonoscopy Prep Confirms Excellent Efficacy & Safety Higher Patient Preference Over Standard Prep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Macrogol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ColonaryConcepts \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryCo.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino Vaccine Produces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Pharma completes pharmacokinetic bridging study of NASH drug candidate ASC40","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Publishes Data in Blood Highlighting Proof-of-Concept to Enhance Potency of Anti-CD38 Antibodies with Kiadis\u2019 K-NK004","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isatuximab-irfc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Starts IND Enabling Studies for its Second D-PUFA Drug Candidate, Targeting the Treatment of AMD and Related Retinal Pathologies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DHA","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data on Pipeline Assets In the Area of Alzheimer\u2019s Disease and Dementia at The AAIC 2020 Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces FDA Approval of Wynzora\u00ae Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Triplet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triplet Therapeutics Selects Clinical Candidate for Novel Treatment of Repeat Expansion Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TTX-3360","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Triplet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Triplet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Triplet Th.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial of CPI-613\u00ae for Relapsed or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Provides Clinical Updates on its Phase III Critical Limb Ischemia (CLI) Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Receives FDA Authorization for Transfer of Investigational New Drug (IND) Application for its Sodium Nitrite Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ICER Publishes Evidence Report on Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b\/2a Clinical Trial in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NM-002","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Provides Clarification Regarding Trial of SNG001 in Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Commercial Product Using Antares Pharma\u2019s Multi-Dose Pen Platform Launches in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 Mutation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Initiates Phase 1\/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies In Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IMM-124E","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Doses First Patient in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 to Treat Hematologic Malignancies in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupus Research Alliance Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoiet.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Starts Patient Dosing in the LIFT Study, a Phase 2a Clinical Trial of TERN-101 in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Approves Dexamethasone as Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Nichi-Iko Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nichi-Iko .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u2122 (upadacitinib) Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces REACH3 Trial of Ruxolitinib in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Initiates Phase 1\/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PIPE-505","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobomarsen","moa":"miR-155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Gets Breakthrough Therapy Designation for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Granted Access to PRIME Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Upcoming Data Presentations at the Alzheimer\u2019s Association International Conference 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Publication Of Preclinical Data Supporting Rigosertib\u2019s Mechanism Of Action As A Targeted Anticancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Receives EMA Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn\u00ae derived Exosome-Based Treatment for COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"QBS10072S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quadriga BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quadriga BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quadriga B.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts All Clinical Holds on CymaBay Therapeutics' Seladelpar","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACRO Biomedical to Conduct Trials on Acellular Cornea Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ACRO Biomedical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biome.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Begins Early Study of BB-301 Gene Therapy for OPMD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Gets Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Receives Notice of US Patent Issuance for PT-112 as Therapeutic Agent for Treatment of Bone or Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Bags CHMP Positive Opinion for Expanded Use of IMBRUVICA\u00ae in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaginal Ring to Reduce the Risk of HIV Infection for Women in non-EU Countries with High Disease Burden","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapivirine","moa":"Reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"International Partnership for Microbicides \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Internatio.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi will File for a Re-Examination of Emapalumab in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca COPD Drug Finally Gets OK From FDA, inching closer to GSK leader","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA\u00ae (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dana-Farber to Offer First CAR T-cell Therapy for Mantle cell Lymphoma Following FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dana-Farber Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Present Data at Virtual 2020 Alzheimer\u2019s Association International Conference Highlighting Comprehensive Approach to treat AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Oral Presentation Of Phase 1 Data For 4-1bb\/Her2 Bispecific Prs-343 At ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics to Announce Interim Data from Phase 1\/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TC-210","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Thera.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Submits Marketing Authorization Application to European Medicines Agency for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Shows Positive Phase 3b Results Against Cosentyx","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Adakveo\u00ae Receives Positive CHMP Opinion for the Prevention of Recurrent Vaso-Occlusive Crises in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Crizanlizumab","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Cipla","sponsor":"Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Regulatory Approval for Launch of Ciplenza (Favipiravir 200 mg) in India to Treat Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cipla \/ Indian Institute of Chemical Technology","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ In.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liposome Inhalation Suspension","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF\u2122 (HTX-011) for the Management of Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Preclinical Results Generated with Sareum\u2019s TYK2\/JAK1 Inhibitors in a Disease Model of Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to Start a Mass of Large Clinical Trials for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiviral monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Kite\u2019s Tecartus\u2122, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"PolarityTE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE\u2122 Diabetic Foot Ulcer Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SkinTE","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Undisclosed","graph3":"PolarityTE","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolarityTE \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"PolarityTE.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med starts Phase I Hematological Malignancies Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HMPL-306","moa":"Isocitrate dehydrogenase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII Seeks Approval to Trial Oxford Covid-19 Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Reports Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Choose Lead Mrna Vaccine Candidate Against Covid-19 And Commence Pivotal Phase 2\/3 Global Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BIONTECH","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic's First Patient Enrolled in Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Boston University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Famotidine Doesn\u2019t Work as a COVID-19 Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Famotidine","moa":"H2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boston Uni.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Perflutren","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"AxoProtego Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EQ-6","moa":"HSP90","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AxoProtego Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AxoProtego Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AxoProtego.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Publishes Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FDA Acceptance of FUROSCIX\u00ae New Drug Application Resubmission","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-110","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Announces Receipt of IND Clearance to Conduct Window-of-Opportunity Trial of NT-I7 (efineptakin alfa) in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharma Gets FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade to Treat Types of Metastatic\/Unresectable Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"BCL11A gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Reports New Data of OPT-302 in Diabetic Macular Edema at the 2020 Annual Meeting of the American Society of Retina Specialists","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma Provides Update on its Phase 2b Clinical Study of XF-73","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Doses First COVID-19 Patient in the ATTRACT Study in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CypCaps","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DalCor Announces Dal-GenE Trial Continues with Final Data Expected in the First Half of 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"DalCor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharma Announces that Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid to Present Phase 2 Results of D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ethanol","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present More Clinical Data from STEADFAST Study of Azeliragon at the Alzheimer's Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CAS 603148-36-3","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R\/M Adenoid Cystic Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b\/2b COVID-19 Clinical Program with TSC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"jCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic human retinal progenitor cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ No.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Submits Application For Rigosertib To Participate In Federally Funded Human Studies In COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Formation of Scientific Advisory Board","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CD377","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Versamune-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COLCORONA Trial Researchers Announce Increased U.S. Enrollment Options for this At-Home Study for Newly Diagnosed Patients\u00ad\u00ad\u00ad with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priority Review Granted to BeiGene\u2019s New Drug Application of Pamiparib in Ovarian Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Announces First Brain Cancer Patient From Second Dose Cohort Reaches 4 Weeks of Treatment With NOX-A12 Combined With Radiotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Multiple Molecules tat Shut Down SARS-Cov-2 Polymerase Reaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofosbuvir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Entera Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Health Announces Approval of COVID-19 Clinical Trial using EnteraGam in Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bovine plasma derived immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entera Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Entera Hea.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Fibroblast Based Cell Therapy Candidate Shown to\nReduce Lung Scarring in Aggressive Animal Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PneumoBlast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"EXACT Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.9 million","upfrontCash":"Undisclosed","newsHeadline":"EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"ACT associated Chemotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EXACT Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EXACT Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EXACT Ther.."},{"orgOrder":0,"company":"Sanofi","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ M.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"ImmuneOncia Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics, ImmuneOncia Enter Into Manufacturing Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"IMC-002","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ ImmuneOncia","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge Biotherapeutics Becomes BaseLaunch's First Asia Pacific Partner","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch.."},{"orgOrder":0,"company":"NuGenerex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"NuGenerex Immuno-Oncology Closes $50 Million Financing Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"AE37 Peptide","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NuGenerex","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"NuGenerex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuGenerex .."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO\u00ae (tedizolid phosphate) in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Tedizolid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adagio Therapeutics Launches With $50M Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Neutralizing Monoclonal Antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Invivyd","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett and Cediprof Announce Exclusive Distribution Agreement for An Approved Levothyroxine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"EP4 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Exalys Therapeutics","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Exalys Therapeutics \/ Catalys Pacific","highestDevelopmentStatusID":"1","companyTruncated":"Exalys The.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"AT-GAA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amicus Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Intellia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"RevCAR-T 1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEMoaB \/ Intellia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GEMoaB \/ I.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.K Governement","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ U.K Governement","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kedrion Biopharma forms Partnership with Columbia University Irving Medical Center to Support Development of New IgG Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Anti-COVID IgG therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kedrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kedrion \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$22.1 million","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DSE Healthcare's VANQUISH Introduces Digital Headache Brand Pain Reliever For Modern Day Headaches","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"DSE Healthcare Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DSE Healthcare Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DSE Health.."},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PreveCeutical Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeuti.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of mRNA-1273","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"DSG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DSG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DSG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DSG \/ Not .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India to Apply for Local Trials on Oxford's Vaccine by August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Announces Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for Adjunctive Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abivertinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioniz Announces Positive Efficacy and Safety Data for BNZ-1 from Interim Analysis of Phase 1\/2 Study in Cutaneous T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BNZ-1","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioniz Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz The.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA, Takis Announce Positive Preclinical Results from LineaDNA Vaccine Candidates for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LineaDNA vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takis Biotech \/ Applied DNA Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar has Filed Lurbinectedin for Temporary Marketing Authorisation with the Swiss Agency for Therapeutic Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech, Inc. (2696 HK) \u2013 Expecting five NDA Approvals Within Two Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HLX71","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.0 billion","upfrontCash":"Undisclosed","newsHeadline":"Merck to Focus on Key Growth Pillars Through Spinoff of Women\u2019s Health, Trusted Legacy Brands and Biosimilars Products into New Company","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Committee Backs Terlipressin Approval for HRS-1","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's DUPIXENT Receives Positive Recommendation from INESSS for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi\u2122 in Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Announces the First Patient Visit in the International Phase II\/III REVERSE-IT Clinical Study on TOTUM-63","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives USFDA SANDA Approval for Doxycycline Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Publishes Data from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XENLETA\u00ae (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shield Therapeutics PT20 Paper Publication","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric oxide adipate","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Shield Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shield The.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Early Breast Cancer Drug Now Approved in Malaysia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus gets Mexican Regulatory Approval to Conduct Trials of Pegylated IFN Alfa-2b, PegiHep in Patients COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"BANNER LIFE SCIENCES LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Banner Life Sciences Announces Commercial Launch of BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BANNER LIFE SCIENCES LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"BANNER LIFE SCIENCES LLC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BANNER LIF.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"U.K Government","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Innovate UK Awards Epsilogen Further Funding for Ovarian Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Mov18 IgE","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovate Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovate Biopharmaceuticals \/ U.K Government","highestDevelopmentStatusID":"6","companyTruncated":"Innovate B.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forge Debuts with $40M and Tim Miller at the Helm","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"FBX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRBM to Collaborate with MSD to Develop Peptides Against Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IRBM","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRBM \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Mer.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$40.0 million","newsHeadline":"Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Solute carrier","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":1.04,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Tubulis","sponsor":"BioMedPartners","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Tubulis Raises \u20ac10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"TUB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Tubulis \/ BioMedPartners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo & Gustave Roussy Collaborate for Oncology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gustave Roussy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gustave Roussy \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Gustave Ro.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"UNION therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Announces Acquisition of PDE4i Compound Class from LEO Pharma with Oral Lead Candidate (orismilast) in Phase 2","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Orismilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leo Pharma \/ UNION therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Centus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centus Bio.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals opens SARTATE\u2122 neuroblastoma clinical trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"AbSci","sponsor":"Alpha Cancer Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cancer Technologies to License AbSci's SoluPro Strain for the Expression of Alpha-Fetoprotein","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-fetoprotein","moa":"Alpha Fetoprotein receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AbSci","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbSci \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"AbSci \/ Al.."},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"T3 Pharma Raises 25M CHF to Advance Bacterial Cancer Therapy Through Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"T3P-Y058-739","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"T3 Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"T3 Pharma .."},{"orgOrder":0,"company":"Novavax","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ FUJIFILM Diosynth Biotechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Galapagos Gets Positive EU CHMP Opinion For Jyseleca\u00ae For The Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Starts Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Vector State Virology Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocad discussing potential COVID-19 vaccine production in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vesicular stomatitis virus-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vector State Virology Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vector State Virology Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vector Sta.."},{"orgOrder":0,"company":"Staten Biotechnology","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Staten Biotechnology, In Collaboration with Novo Nordisk, Starts Dosing of Anti-ApoC3 Antibody SST-5058 in First-in-Human Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SST-5058","moa":"apoC3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Staten Biotechnology","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Staten Biotechnology \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Staten Bio.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Medigen Partner to Develop Adjuvanted Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 adjuvanted vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"Rutgers University","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Gut-Microbiome","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rutgers University \/ DuPont","highestDevelopmentStatusID":"2","companyTruncated":"Rutgers Un.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ U.S Government","highestDevelopmentStatusID":"6","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"TTX-080","moa":"HLA-G","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":1.55,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.55,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Tizona The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$421.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amgen Doubles Down on BeiGene Collaboration, Investing $421M More","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumos Pharma Announces Sale of Priority Review Voucher","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Live Ebola Zaire Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lumos Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Lumos Pharma \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Starts Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KB109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-S6-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Completes Enrollment in Controlled Ph 2 Trial of Relacorilant + Nab-Paclitaxel to Treat Metastatic Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ElsaLys Biotech Submits Biologics License Application to FDA for LEUKOTAC for the treatment of graft-versus-host disease in adult patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inolimomab","moa":"IL-2 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ElsaLys Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElsaLys Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ElsaLys Bi.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vita Therapeutics Receives Orphan Drug Designation from FDA for New Novel Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"VTA-110","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vita Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vita Thera.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem to Initiate Phase IIa Study of Nangibotide for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nangibotide","moa":"TREM-1 pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Say Newly Identified Antibodies can Neutralise SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Updates Plan for Retinitis Pigmentosa Gene Therapy Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine\/Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LEAPS COVID 19 conjugate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Authorised Uses of Cancer Medicine Yondelis Unchanged Following Review of New Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer's Gene Therapy BAY 2599023 Showing Steady FVIII Activity, Safety in Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY2599023","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Ultragenyx Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Russian Ministry of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia to Vaccinate Medics for Coronavirus in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Ministry of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Ministry of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Russian Mi.."},{"orgOrder":0,"company":"China's military-backed research unit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Covid-19 vaccine candidate shows some promise in animal tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"China's military-backed research unit","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"China's military-backed research unit \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"China's mi.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"RIVOPHARM SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Launches Mexiletine HCl Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lannett Company, Inc. \/ Rivopharm SA","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Novocure\u2019s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tumor Treating Fields","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus and Duke-NUS to Trial Covid-19 Vaccine in Singapore","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent's BI-1206 Could Improve Treatment In several cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Dana Solutions","sponsor":"Curi Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curi Bio Acquires Dana Solutions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Human iPSC-derived cardiomyocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dana Solutions","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dana Solutions \/ Curi Bio","highestDevelopmentStatusID":"2","companyTruncated":"Dana Solut.."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Start of Phase II Trial of LAM-002A (apilimod dimesylate) for Treatment of COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"Il-12","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Drops Hep B Antiviral as Late-Stage Pipeline Tests Largely on Track' Despite COVID-19 Disruption","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6217","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Favorable PhIII data for Roche\u2019s Port Delivery System with ranibizumab for neovascular ARMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sobi And Selecta Announce Closing of Previously Announced Strategic Licensing Agreement For Sel-212","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces $110 Million Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.11,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Eventide Asset Management","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Launches Bright Peak Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"IL-2 conjugates","moa":"CD25 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Pea.."},{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$13.3 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"IMM-BCP-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Immunome","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Viva Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Schr\u00f6dinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Viva Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"TRN-000632","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Terns Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Raises \u20ac28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Ph.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and Lilly to Collaborate in Commercializing Elunate\u00ae in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ A.."},{"orgOrder":0,"company":"MolMed","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC to Complete the Acquisition of MolMed on July 31, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Zalmoxis","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MolMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MolMed \/ AGC Biologics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ A.."},{"orgOrder":0,"company":"Sera Labs","sponsor":"CURE Pharmaceutical","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"$20.0 million","newsHeadline":"CURE Pharmaceutical to Acquire Sera Labs in a $20 Million Transaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sera Labs","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0.040000000000000001,"dosageForm":"Topical Cream","sponsorNew":"Sera Labs \/ CURE Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sera Labs .."},{"orgOrder":0,"company":"Sanofi","sponsor":"UK government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi\/GSK Sign Deal with UK Gov for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ UK government","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dalton Pharma Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dalton Pharma Services \/ VIDO-InterVac","highestDevelopmentStatusID":"1","companyTruncated":"Dalton Pha.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kodiak, Lonza Sign Long-Term Manufacturing Contract","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Lonza Group \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.9 million","newsHeadline":"Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis\u00ae U.S. Licensing Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ophthalmology Pharmaceutical and IACTA Pharmaceuticals Sign New Licensing Agreement for Dry Eye Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Phar.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Announces Pricing of Public Offering of Common Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Essa Pharma \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SARM1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","amount":"$89.0 million","upfrontCash":"$25.0 million","newsHeadline":"Santen and RVL Pharmaceuticals Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0.089999999999999997,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harmony Biosciences Files for a $100 million IPO","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"TrialSpark","sponsor":"resTORbio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio and TrialSpark Collaborate to Investigate RTB-101 for COVID-19 on the Project Covalence Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"RTB-101","moa":"TORC1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TrialSpark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TrialSpark \/ resTORbio","highestDevelopmentStatusID":"10","companyTruncated":"TrialSpark.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"MSD Partners","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioTheryX Announces $35 Million Series D Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series D Financing","leadProduct":"BTX-A51","moa":"Multi-Kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ MSD Partners","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"TrueBinding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Chinese Hamster Ovary K1 cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Horizon Discovery Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Discovery Group \/ TrueBinding","highestDevelopmentStatusID":"3","companyTruncated":"Horizon Di.."},{"orgOrder":0,"company":"BioMed Valley Discoveries","sponsor":"Strata Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Ulixertinib","moa":"MAP kinase ERK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioMed Valley Discoveries","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BioMed Valley Discoveries \/ Strata Oncology","highestDevelopmentStatusID":"8","companyTruncated":"BioMed Val.."},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Opus","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trobix Bio Completed Series A Funding by a Leading Japanese\/Singapore Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"TBX101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trobix Bio \/ Chartered Opus","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio.."},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"TGL-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Res.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sunesis Announces Pricing of $12 Million Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"SNS-510","moa":"PDK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sunesis Pharmaceuticals \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AMG 890","moa":"Apolipoprotein A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omega Therapeutics Advances Controllable Epigenomic Programming Platform to Deliver a Pipeline of Novel Therapeutics with $85M in Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ .."},{"orgOrder":0,"company":"Poxel","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"$21.3 million","upfrontCash":"Undisclosed","newsHeadline":"Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ Su.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech, Regeneron join forces in I-O battle against melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"BNT111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$250.9 million","upfrontCash":"Undisclosed","newsHeadline":"Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"Tau and Alpha-synuclein vectorized antibody","moa":"Mapk tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0.25,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"PIPE","pharmaFlowCategory":"D","amount":"$445.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevel to Raise $445M in Merger with Blank-Check Company","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ PIPE","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$795.0 million","upfrontCash":"$75.0 million","newsHeadline":"Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"AAV based gene regulation therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0.80000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Life Science Partners","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vico Therapeutics Raises $31 Million in Series A Financing Round","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Antisense OligoNucleotides","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Life Science Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vico Thera.."},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide .."},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tanner Pharma Group and Domp\u00e9 Initiate Distribution Partnership for Oxervate\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Cenegermin","moa":"TrkA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tanner Pharma \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pha.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"TerSera","pharmaFlowCategory":"D","amount":"$224.0 million","upfrontCash":"$159.0 million","newsHeadline":"Lexicon Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For The Sale Of Xermelo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ TerSera","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"U.S Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Land $2.1 Billion Deal With U.S. For Covid-19 Vaccine Development And 100 Million Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":2.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Sanofi \/ U.S Department of Health and Human Services","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$276.2 million","upfrontCash":"Undisclosed","newsHeadline":"Allovir Raises $276M IPO to Run Broad Cell Therapy Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR105","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0.28000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Emery Pharma","sponsor":"Halodine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halodine Engages Emery Pharma for Next Generation Development of Oral and Nasal Antiseptics Active Against SARS-CoV-2 (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Povidone-Iodine","moa":"Inflammatory mediator","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emery Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Emery Pharma \/ Halodine","highestDevelopmentStatusID":"1","companyTruncated":"Emery Phar.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$12.0 million","newsHeadline":"Sesen Bio Signs Exclusive License Agreement with Qilu Pharmaceutical for the Development and Commercialization of Vicineum\u2122 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sesen Bio \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ European Union","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ E.."},{"orgOrder":0,"company":"Xencor","sponsor":"MorphoSys","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi\u00ae (tafasitamab-cxix) in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Xencor","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"Xencor \/ M.."},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immodulon, Champalimaud Foundation Team Up on \u2018Difficult To Treat\u2019 Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"IMM-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immodulon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immodulon Therapeutics \/ Champalimaud Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Immodulon .."},{"orgOrder":0,"company":"Wuxi Shuangliang Biotechnology","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Enter Into a Research Collaboration with Wuxi Shuangliang Biotechnology to Study a Combination Therapy to Treat NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"C-005","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wuxi Shuangliang Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wuxi Shuangliang Biotechnology \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Wuxi Shuan.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"OB-002","moa":"CCR5 pathway","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"4","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VistaGen Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Axovant Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Executes Licensing Agreement with Isoprene Pharmaceuticals of VNLG-152 for Treatment of Dermatological Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"BioCorRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Irisys to Manufacture BioCorRx's Opioid Use Disorder Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"IRISYS, LLC \/ BioCorRx","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"Wockhardt","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt snags Covid-19 Vaccine Manufacturing Deal From the UK Govt","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ UK Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector\u00ae Platform for Next Generation CAR-T Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Lentiviral vector","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"LUMICKS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CAR-NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ LUMICKS","highestDevelopmentStatusID":"4","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Announces Manufacturing Agreement With Vigene Biosciences For AdCOVID\u2122, Its Single Dose Intranasal Vaccine Candidate For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vigene Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Vigene Bioscience \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Vigene Bio.."},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics\u2019 First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"SIT Laboratorio Farmaceutico","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIT Laboratorio Farmaceutico Acquires LOPRESSOR\u00ae, ICAZ\u00ae and MIOREL\u00ae from Daiichi Sankyo France","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Metoprolol Tartrate","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ SIT Laboratorio Farmaceutico","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","amount":"$259.0 million","upfrontCash":"$5.0 million","newsHeadline":"TriSalus Life Sciences Acquires Dynavax\u2019s SD-101 Oncology Program in Purchase Agreement for up to $250 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"SD-101","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.26000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ TriSalus Life Scineces","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OTO-6XX","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHA.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$57.2 million","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"T Cell surface glycoprotein CD3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"CAT-5571","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$27.1 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"ExeVir Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Human trials of second Russian Covid-19 vaccine to start July 27: TASS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Launches Chlorzoxazone Tablet in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"Intermediate conductance calcium-activated potassium channel protein 4","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Adastra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adastra Pharmaceuticals to Present at LifeSci Partners' Summer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zotiraciclib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adastra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adastra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adastra Ph.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HST5040","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces U.S. FDA Clearance of First Investigational New Drug Application for RLS-0071","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RLS-0071","moa":"Inflammatory cascade","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 S1 Antibody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for the Treatment of Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Reports Positive Results From the Phase III LINC-3 Study of Isturisa\u00ae (osilodrostat) for the Treatment of Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Data Presentations at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of HER2 Mutated Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR\/ErbB2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"PPAR gamma","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Third Pivotal Phase 3 Study Shows RINVOQ Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Gets Positive Opinion on Orphan Drug Designation Received from the EMA for CTI-1601","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Wake Forest Institute for Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Cell-Based Gene Therapy Approach to Better Treat Patients with Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cell-based gene therapy","moa":"Factor VIII transgene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wake Forest Institute for Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wake Forest Institute for Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wake Fores.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Breast cancer vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Gets Breakthrough Therapy Designation for MK-6482 to Treat Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-6482","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DIMERIX\u2019s DMX-200 Posts Strong Results in Kidney Disease Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Propagermanium","moa":"CCR2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Dimerix","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dimerix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dimerix \/ .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Announces Dosing of First Patient in Phase 1\/2 Clinical Trial of RP-3500","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-3500","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Reports Results from Its Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation of Nebulized Solution","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Topline Data from SER-109 Phase 3 Study in Recurrent C. Difficile Infection Expected in August 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CiVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent\/Metastatic Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Together with Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MRG-110","moa":"MicroRNA-92a","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing\u2019s Syndrome of Adrenal Origin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ivy Brain Tumor Center and QED Therapeutics Announce Dosing of First Patient in a Phase 0\/2 Trial of Infigratinib in Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Apogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Asunercept","moa":"Apoptosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339 for Acute Myeloid Leukemia and Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-5339","moa":"VCP\/p97","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleave Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cleave The.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Phase 3 REFALS Trial Evaluating Oral Levosimendan in Treatment of ALS Patients Did Not Reach its Pre-Specified Endpoints","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE-3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi\u00ae \u2018Atalante at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Beremagene geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Receives Orphan Drug Designation From for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"HPV6","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL758","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"S. Korea's Green Cross seeks phase 2 trials of COVID-19 plasma drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GC5131A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Green Cross Lab Cell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Green Cross Lab Cell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cros.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for ansuvimab Ebola Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ansuvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Receives FDA Approval to Initiate 'EXIT-COVID-19,' a Phase II Investigational New Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bone marrow-derived extracellular vesicle and exosome product","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India Gets Approval to Start Human Trials for Oxford Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Announces Publication of Explore Covid-19 Translational Study Findings In Nature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avdoralimab","moa":"C5aR1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Reports Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Status to Regulus Therapeutics' Treatment for Common Type of PKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RGLS4326","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics Announces Start of Phase 2 Trial of Peptide Drug TXA127 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samus Therapeutics Presents Phase 1 PU-AD Study Data at AAIC 2020 Advancing the Company's Platform for Treating Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PU-AD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Ther.."},{"orgOrder":0,"company":"Helixmith","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1\/2a Trial of Gene Therapy Engensis for CMT1A Begins in Korea","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Donaperminogene seltoplasmid","moa":"HGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helixmith \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith .."},{"orgOrder":0,"company":"Tychan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Study Demonstrates Safety and Efficacy of mAb to Treat Yellow Fever","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TY014","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tychan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tychan \/ N.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics\u2019 Aviptadil gets US FDA Expanded Access Protocol to Treat Respiratory Failure in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Crashes Out of KRAS Race as it Ditches Phase 1 Effort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinopharm to Test Potential COVID-19 Vaccine in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J Begins First Trial of Covid-19 Vaccine After Positive Preclinical Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Dumps ex-Achillion C3G Program After Seeing Phase 2 Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck, via Themis Starts New COVID-19 Trial with V591","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"V591","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-176 for Seasonal Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Provides Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives MHRA Approval to Initiate Phase I Trial of Potential COVID-19 Antiviral Antibody Treatment, CT-P59, in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201 for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL758","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Denali Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ D.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and Bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Files Japan NDA for Preventive Treatment of Migraines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets Breakthrough Therapy Designation for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pevonedistat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Waverley Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Waverley Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Waverley Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Waverley P.."},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Made-in-Singapore Cancer Drug ETC-159 Advances Further In Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ETC-159","moa":"Wnt Signalling Pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Duke-NUS Medical School","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duke-NUS Medical School \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Duke-NUS M.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MCA-derived mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG\/KG Level","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SIRP\u03b1-IgG1 Fc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AGT103-T","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Gene Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"American G.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Files IND Application for Phase 2\/3 COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharmaceuticals Files IND to Test SPI-1005 in Phase 2 COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gan & Lee Pharmaceuticals Initiates First-in Human Phase 1 Clinical Trial for New Anti-tumor Drug GLR2007","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GLR2007","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha1\/beta1\/gamma2","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Aytu BioScience","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Aytu BioScience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioSc.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Presents New Phase IIIb ANJESO\u00ae Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study (\"Study II\") Progress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves STELARA for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Reduced Respiratory Syncytial Virus Infections Requiring Medical Care in Healthy Premature Infants in Phase 2b Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents the Latest Data from the Phase 2b Open-Label Extension Study of BAN2401 at AAIC 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Initiates Global Phase 2\/3 Study for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Two US Regulatory Milestones for KEYTRUDA\u00ae (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha37","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea To Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine Gen-009 In Combination With Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisinicline Analogs","moa":"Nicotinic receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinity\u2019s COVID-19 Antibodies Ready for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BIOQUAL \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ .."},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOQUAL Publishes in Nature of Non-Human Primate Preclinical Viral Challenge Study of Single-shot Ad26 vaccine protects against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BIOQUAL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"BIOQUAL \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BIOQUAL \/ .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim\u2019s EMPEROR-Reduced phase II trial of empagliflozin in adults with heart failure meets primary endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynacure Gets Rare Pediatric Disease Designation from U.S. FDA for DYN101 for Myotubular and Centronuclear Myopathies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dynamin 101","moa":"Dynamin 2 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynacure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives Piqray\u00ae approval in Europe \u2013 the first and only targeted medicine for HR+\/HER2- advanced breast cancer with a PIK3CA mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Monjuvi in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals Completes Phase 1\/2 Clinical Trial Notification of JR-171 for mucopolysaccharidosis type I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Backs Mercks's Bavencio Combo for Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Drug SCO-101 Potentiates the Effect of Chemotherapy in the First Cohort in Chemo-Resistant Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Endovion","moa":"Chloride channel","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2\/3 Trial of RLF-100 for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenicriviroc Sulfone","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47\/PD-L1 Bispecific Antibody in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI322","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pimavanserin Reduces Dementia-Related Psychosis Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"TB Alliance","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"IQWiG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide in Prostate Cancer: Indication of Considerable Added Benefit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IQWiG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQWiG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IQWiG \/ No.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-TDP-43 antibody","moa":"TAR DNA binding protein 43","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces First Patients Enrolled in HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits CTA Application In UK To Start Phase 1 Trial Of ALN-HSD To Treat NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALN-HSD","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Neutrolis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps For Patients With Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NTR-441","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neutrolis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neutrolis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Neutrolis .."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Sonoran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonoran Biosciences Announces Qualified Infectious Disease Product Designation Granted by FDA for SBG003","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tobramycin","moa":"70s ribosome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sonoran Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonoran Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonoran Bi.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Completes Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AVOVA-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Publication of LPCN 1144 Liver Fat Study (\"LFS\") Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Announces First Patient Dosed in Phase 1b\/2a Study of Tsquinimod Use in Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Receives EU Approval for First-Line Systemic Treatment in Pediatric Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for BCX9930 in PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Drugs in Dermatology Publishes Results from Phase 1\/2a Trial of Arcutis\u2019 ARQ-151 for the Treatment of Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Granted Fast Track Designation from FDA for D-PLEX\u2081\u2080\u2080 for Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Cerecor","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-006","moa":"mTOR 1\/2 complex","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecor \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Personalized Stem Cells","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner: Personalized Stem Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adipose-derived MSCs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Personalized Stem Cells","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Personalized Stem Cells \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Personaliz.."},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx\u00ae Phase 1\/2a Clinical Trial in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Human astrocytes","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ\u00ae (tasimelteon) in the Treatment of Smith-Magenis Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Usona Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Usona Institute Publishes Breakthrough Development in Scalable Psilocybin Synthesis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Usona Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Inst.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Reports Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen to Host Investor Conference Call to Discuss NIH\u2019s Selection of Lenzilumab for Big Effect Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amrta Karuna","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Vopec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Vopec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Vopec Phar.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Gets Positive Opinion on Orphan Drug Designation Received from the EMA for CUTX-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly starts late-stage study of COVID-19 drug in nursing homes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic's Lead MS Drug Hits Primary and Key Secondary Endpoints in PhII, But Questions Remain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Themis Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mv-Sars-Cov-2 Vaccine Candidate: A New Partnership Between Institut Pasteur, Cepi, Th\u00e9mis And Msd","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MV-SARS-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Institut Pasteur","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institut Pasteur \/ Th\u00e9mis","highestDevelopmentStatusID":"4","companyTruncated":"Institut P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 Ilaris [Canakinumab] Unexpectedly Slashes Need For Joint Replacements From Osteoarthritis In Key Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ono Reports Positive Phase III Data for Opdivo Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":2,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":6,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ ASTRAZENECA","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"BioNTech","sponsor":"U.S. government","pharmaFlowCategory":"D","amount":"$1,950.0 million","upfrontCash":"Undisclosed","newsHeadline":"US signs $1.95bn deal for Pfizer and BioNTech\u2019s Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":1.95,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.95,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ U.S. government","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$147.1 million","newsHeadline":"GSK and CureVac Announce Strategic mRNA Technology Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CV7301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"CureVac \/ Glaxosmithkline","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$870.0 million","upfrontCash":"$10.0 million","newsHeadline":"Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Efinopegdutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0.87,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.87,"dosageForm":"","sponsorNew":"Hanmi Pharmaceutical \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"IMV","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ NRC .."},{"orgOrder":0,"company":"resTORbio","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Dactolisib","moa":"TORC1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Premier Inc. ProvideGx\u00ae Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole\/Trimethoprim","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"Dihydropteroate synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset P.."},{"orgOrder":0,"company":"Transgene","sponsor":"Tasly BioPharmaceuticals","pharmaFlowCategory":"D","amount":"$22.2 million","upfrontCash":"Undisclosed","newsHeadline":"Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Tasly BioPharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Partner Therapeutics Announces $35 Million Deal with U.S. DOD for Advanced Development and Emergency Use of Leukine for COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Sargramostim","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Partner Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expansion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ BARDA","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Gero","sponsor":"Bulba Ventures","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Gero, a Singapore-based Biotech Startup raises $2.2M in Series A Funding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"SINGAPORE","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Gero","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gero \/ Bulba Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Gero \/ Bul.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Suzhou GenHouse","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"HBI-2376","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Suzhou GenHouse","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Suzhou GenHouse \/ HUYA Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou Gen.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"EverInsight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ EverInsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"National Yang-Ming University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vyripharm and the National Yang-Ming University Signed a MOU to Develop VYR-206 for Neurological Disorders Outcomes Following Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"VYR-206","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyripharm Biopharmaceuticals \/ National Yang-Ming University","highestDevelopmentStatusID":"3","companyTruncated":"Vyripharm .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal Antibodies biosimilar","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Teva","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"TSHA-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 With National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx .."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Seismic Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Seismic Bio","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adicet Bio Receives $10 Million Product Development Milestone From Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"ADI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adicet Bio \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Synthetic Lethality","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Synthetic Lethality","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Announces Successful USD $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycu","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"UWM Research Foundation","sponsor":"RespireRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KRM-II-81","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"UWM Research Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UWM Research Foundation \/ RespireRx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"UWM Resear.."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"BostonGene","sponsor":"The Weinstock Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BostonGene Announces Scientific Collaboration with Leading Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BostonGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"BostonGene \/ The Weinstock Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"BostonGene.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","amount":"$40.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SON-081","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and Serum Institute of India Announce Development and Commercial Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"LTL Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTL Pharma to Take Over Sanofi\u2019s Diregura in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ LTL Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ L.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer, BioNTech Ink Deal To Supply Canada With Potential Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Government of Canada","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Matterhorn Biosciences","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Launches Matterhorn Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Matterhorn Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Matterhorn Biosciences \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Matterhorn.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"ForDoz","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Gets Exclusive Rights to Market and Distribute 2 Complex Injectable Assets from ForDoz Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ForDoz","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ForDoz \/ Lupin","highestDevelopmentStatusID":"1","companyTruncated":"ForDoz \/ L.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Simcere","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$14.0 million","newsHeadline":"G1, Simcere to bring new cancer therapy in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trilaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Simcere","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna, Evotec Form Strategic Antisense Alliance","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Antisense oligonucleotide therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$1,525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":1.53,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.53,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ U.S. Government","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"W. L. Gore & Associates","sponsor":"ViaCyte Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Stem cell-derived pancreatic islet cell progenitors","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"W. L. Gore & Associates","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"W. L. Gore & Associates \/ ViaCyte","highestDevelopmentStatusID":"4","companyTruncated":"W. L. Gore.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"U.S. Department Of Defense","pharmaFlowCategory":"D","amount":"$35.6 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ U.S. Department Of Defense","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Belantamab mafodotin-blmf","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Seagen \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ G.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Osimertinib Mesylate","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ARC Therapeutics","sponsor":"Eshelman Ventures","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARC Therapeutics Launches to Develop Novel CDK Inhibitors for the Treatment of Advanced and Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ARC Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ARC Therapeutics \/ Eshelman Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ARC Therap.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Phage-based therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$11.5 million","newsHeadline":"Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$560.0 million","newsHeadline":"Biogen and Denali to Collaborate on LRRK2 Program for Parkinson\u2019s Disease and TV Platform-Enabled Programs for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm.."},{"orgOrder":0,"company":"Veristat","sponsor":"PreveCeutical Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veristat","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Veristat \/ PreveCeutical","highestDevelopmentStatusID":"4","companyTruncated":"Veristat \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$90.0 million","newsHeadline":"Editas Medicine Regains Full Global Rights to Ocular Medicines","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"EDIT-101","moa":"CEP290","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Cato Research","sponsor":"JanOne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Cato Research","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cato Research \/ JanOne","highestDevelopmentStatusID":"5","companyTruncated":"Cato Resea.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"MidCap Financial Trust","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ MidCap Financial Trust","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Eversana","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Eversana \/ Zosano","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Mucokinetica","sponsor":"Covistat","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mucokinetica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mucokinetica \/ Covistat","highestDevelopmentStatusID":"1","companyTruncated":"Mucokineti.."},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"IOV-3001","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avid Bioservices","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avid Biose.."},{"orgOrder":0,"company":"Athenex","sponsor":"Sagard Healthcare Royalty Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Sagard Healthcare Royalty Partners","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"RA Capital Incubator","pharmaFlowCategory":"D","amount":"$72.6 million","upfrontCash":"Undisclosed","newsHeadline":"Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Disease-Modifying Pulmonary Arterial Hypertension Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0.070000000000000007,"dosageForm":"Inhalation","sponsorNew":"Aerovate Therapeutics \/ RA Capital Incubator","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"T-knife","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"T-knife Completes \u20ac66 Million Series AFinancing to Develop Next-Generation T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Humanized T-cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"T-knife","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"T-knife \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Pfizer Inc \/ Gilead Scinces","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SII, Gavi and BMGF Collaborate to Boost Access to COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Gavi","highestDevelopmentStatusID":"8","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biohaven and Royalty Pharma Announce Funding Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Zavegepant","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Japan in Deals with AstraZeneca, Novavax for COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UK's Hikma Making Gilead's COVID-19 Drug Remdesivir to Increase Supply","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Gilead Sciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"CTT1403","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Targeted Technology \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Tar.."},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Amarin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amarin Supports Investigator-Initiated Trial at Kaiser","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaiser Permanente Washington Health Research \/ AMARIN","highestDevelopmentStatusID":"11","companyTruncated":"Kaiser Per.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Ministry of Health, Labour and Welfare of Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Selected as Provider for Japanese Government\u2019s \u201cEmergent Initiative to Build Production Capacity for COVID-19 Vaccines (First Round)\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Ministry of Health, Labour and Welfare of Japan","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Government of Switzerland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Swiss Government Signs Agreement with Moderna for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Government of Switzerland","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"MODAG","sponsor":"The Michael J. Fox Foundation for Parkinson's Research.","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"MODAG Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Anle138b","moa":"Alpha synuclein protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ The Michael J. Fox Foundation for Parkinson's Research.","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Th.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XORTX Partners with Mount Sinai\u2019s Icahn School of Medicine on US-based Clinical Trial in COVID-19","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"MTEC","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for Treatment of ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ MTEC","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Celularity","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Celularity Announces the Activation of First California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Gentbio","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Inks Licensing Agreement with Seattle Children\u2019s Research Institute to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Engineered Regulatory T cell therapy","moa":"T cell","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seattle Children\u2019s Research Institute","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Seattle Children\u2019s Research Institute \/ Gentbio","highestDevelopmentStatusID":"3","companyTruncated":"Seattle Ch.."},{"orgOrder":0,"company":"Gavi","sponsor":"Bill and Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gavi Gets $150 million Funding From Bill & Melinda Gates Foundation to Support Collaboration With SII","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gavi","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Gavi \/ Bill and Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Gavi \/ Bil.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Independently Confirms and Extends Laboratory Findings and Expands Safety Profile of ATH434","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019s Covid-19 Vaccine Yields Positive Data in Phase I Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long Journey for DBV Peanut Patch Ends in Rejection by FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly initiates trial of neutralising antibody against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Singapore-MIT Alliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Singapore develops potential antibody treatment for yellow fever","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TY014","moa":"Viral envelope protein epitope","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Singapore-MIT Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Singapore-MIT Alliance \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Singapore-.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces First Two Patients Treated in Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila's COVID-19 Vaccine Candidate found Safe in Early-Stage Human Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Starts the Phase 2 PORT Study Comparing Peripheral Versus Central Administration of Melflufen and Dexamethasone in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Enrolls First Patient in Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucitanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Clovis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Gets U.S. FDA Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sisunatovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReViral \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Moderna Investigational COVID-19 Vaccine Shows Promise in Mouse Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S CIMZIA is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces NDA for Ripretinib Granted Priority Review by China\u2019s NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Mundipharma's Tinostamustine in EU for Very Rare form of Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tinostamustine","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANA Therapeutics Announces U.S. FDA Clearance Of IND Application To Initiate Clinical Trial Of Niclosamide In COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"T-2143","moa":"pan-PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tarveda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-047","moa":"Alk2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 In Vitro Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Aspacytarabine to Treat Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves GSK\u2019s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Fingolimod Capsules, 0.5 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"IMAC Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IMAC Holdings","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IMAC Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IMAC Holdi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives EC approval for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Beroni Group","sponsor":"Tianjin University in China","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"nanobody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beroni Group \/ Tianjin University in China","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Gro.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin, Concord, Receive US FDA Approval for Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Audentes is Developing AT845 for the Treatment of Pompe Disease.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AT845","moa":"GAA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes T.."},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indoco Remedies Gets USFDA Nod for Schizophrenia, Bipolar Disorder Treatment Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Rem.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Introduces Higher Strength (400 mg) of FabiFlu\u00ae to Reduce Pill Burden of COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zenara Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenara Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zenara Pha.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amilo-5MER","moa":"Serum Amyloid A","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galmed Pharmaceuticals \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune\u2122 Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diabetologia Publishes Results Highlighting Efficacy of the Diabetes Vaccine Diamyd\u00ae in Genetically Defined Subgroups of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Levo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levo Therapeutics Announces Top-line Results from Phase 3 CARE-PWS Study of LV-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Levo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Levo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Levo Thera.."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX\u00ae2-73 (blarcamesine) for Alzheimer\u2019s Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rodatristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Formally Accepts PharmaCyte Biotech\u2019s Drug Master File for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck Discontinues Phase II Proof of Concept Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lu AF11167","moa":"PDE10A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Positive Oral Data on New RECCE\u00ae 435 Against Helicobacter Pylori in Animal Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RECCE 435","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of First Patient in 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Griffith University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Aussie Drug Signals Breakthrough for Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DpC","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Griffith University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Griffith University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Griffith U.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Reports Clinical Eesults on OPTIC-X","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaled Powder in Capsule","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"Medicinova","sponsor":"UCLA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN\u2011166 (ibudilast) in Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals Receives Marketing Approval for NERLYNX\u00ae (neratinib) in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Provides Update on Phase III Study of Tecentriq in Combination with Paclitaxel for People with Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mountain Valley MD Announces Successful Complexation of Ivermectin Drug in Quicksome(TM) Oral Strip and Commencement of Pre-Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain V.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals\u2019 Firdapse\u00ae (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Secures Permanent J-Code (J1738) for ANJESO\u00ae from Centers for Medicare and Medicaid Services","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Achieves Target Enrollment of 500 Patients in Phase 3 AVENGER 500 Trial of CPI-613 for Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma\u2019s Phase 2\/3 COVID-19 Study Approved in Mexico","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Initiates Ph2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R\/R FL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu)-lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Labs Receives US FDA Approval to Market Generic Detrol Tablets","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolterodine Tartrate","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Gets Positive CHMP Opinion for Avapritinib to Treat Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio Farma Begins Human Trials of Coronavirus Vaccine in Indonesia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio Farma \/ Sinovac Biotech Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces NEJM Publication of Phase III ASCLEPIOS Trials Demonstrating Superior Efficacy of Ofatumumab in Patients with Relapsing Multiple Sclerosis\n\nNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficac","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces That OmniAb-derived CS1001 Phase 3 Trial Met the Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces FDA Approval of Evrysdi for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces First Patient Dosed in a Phase 1b\/2 Study of FGF401 in Combination with Pembrolizumab for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Roblitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Acceptance for Regulatory Review of Pfizer\u2019s Marketing Authorization Application for Antifungal Isavuconazole in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Activation of Investigational New Drug for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy\u2011Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield\u2122, a Single Dose Intranasal Anthrax Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NasoShield","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Nanyang Technological University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u200bNTU Singapore Develops Peptide that Makes Drug-Resistant Bacteria Sensitive to Antibiotics Again","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CSM5-K5","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Nanyang Technological University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanyang Technological University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanyang Te.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo Plus Yervoy Shows S Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Lampit\u00ae (nifurtimox) for the Treatment of Chagas Disease in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nifurtimox","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Reports Second Quarter 2020 Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Ther.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET\u2122 Immunotherapy Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DF-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IsoTherapeutics Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"2","companyTruncated":"IsoTherape.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","amount":"$381.0 million","upfrontCash":"$70.0 million","newsHeadline":"Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA\u00ae (duvelisib) Rights to Secura Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Verastem Oncology","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.38,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"12","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis\u00ae in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Expands Partnership with Novavax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"AnHeart Announces Entry into Series A+ Equity Financing Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"KALEO INC","sponsor":"pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kal\u00e9o and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT\u00ae Auto-Injector","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"KALEO INC","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"KALEO INC \/ pan Canadian Pharmaceutical Alliance","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC .."},{"orgOrder":0,"company":"CureVac","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Proposed Initial Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pieris and Lilly Ink Clinical Trial Collaboration to Evaluate Combination of Prs-343 with Ramucirumab and Paclitaxel In Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces $115M Financing to Ramp Up Muscle Disease Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Antibody-oligonucleotide conjugates","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$516.0 million","upfrontCash":"$438.0 million","newsHeadline":"Ligand to Acquire Pfenex Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0.52000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ L.."},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$875.0 million","upfrontCash":"$425.0 million","newsHeadline":"Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"NT-814","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0.88,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.88,"dosageForm":"Capsule","sponsorNew":"Kandy Therapeutics \/ Bayer Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Ther.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$25.9 million","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Scioto Biosciences Receives Series B Investment from Genome & Company","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"SB-121","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Bio.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Announces Closing of $23 Million Public Offering of Common Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"DM199","moa":"Kallikrein-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"DiaMedica Therapeutics \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Government","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil's Bolsonaro Orders $360 million to Be Set Aside for AstraZeneca Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Brazilian Government","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$3,680.0 million","upfrontCash":"$3,680","newsHeadline":"Sanofi to acquire Principia Biopharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":3.6800000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.6800000000000002,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$377.0 million","upfrontCash":"Undisclosed","newsHeadline":"Redx Signs Out Licensing Agreement With Astrazeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RXC006","moa":"Porcupine","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.38,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Redx Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Swiss Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin\u00ae Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"MP0420","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Swiss Government","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$187.0 million","upfrontCash":"Undisclosed","newsHeadline":"MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0.19,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","amount":"$113.5 million","upfrontCash":"Undisclosed","newsHeadline":"Verrica Pharmaceuticals Licenses LTX-315 from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lytix Biopharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Lytix Biop.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces CAR-T Agreement with University of Pennsylvania","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pennsylvania \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Sapphire Biotech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sapphire Biotech Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"SPX-1009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapphire Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sapphire Biotech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Sapphire B.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia and Arctic Vision Ink License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Arctic Vision","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$60.8 million","upfrontCash":"Undisclosed","newsHeadline":"F2G Raises $61M for Late-Phase Antifungal R&D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Olorofim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"F2G Limited \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Celleron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celleron Therapeutics Enters Into a Iicense Agreement with Roche to Improve the Lives of Patients Living with Tenosynovial Giant Cell Tumour","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Emactuzumab","moa":"CSF-1R positive macrophages depleter","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Celleron","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Perrigo Acquires Market-Leading OTC Self-Care Brands In Eastern Europe From Sanofi","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ P.."},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Me.."},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"NTN Buzztime","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Merger","leadProduct":"Cyclophosphamide","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn I.."},{"orgOrder":0,"company":"Genkyotex","sponsor":"Genkyotex","pharmaFlowCategory":"D","amount":"$37.7 million","upfrontCash":"Undisclosed","newsHeadline":"Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Setanaxib","moa":"NOX4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genkyotex","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Genkyotex \/ Calliditas","highestDevelopmentStatusID":"8","companyTruncated":"Genkyotex .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax, SK bioscience Collaborate for COVID-19 Vax Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Beroni Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Group Collaborates with Genscript Biotech Corporation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Nanobodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GenScript Biotech Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ Beroni Group","highestDevelopmentStatusID":"4","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"PR600","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Isofol Enters Licensing Agreement with Solasia to Develop and Commercialize Arfolitixorin in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Isofol Medical \/ Solasia","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"QBiotics Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Tigilanol Tiglate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ QBiotics","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"MicuRx Announces CARB-X US$7.78 Million Financing for Development of MRX-8","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"MRX-8","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"MicuRx Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MicuRx Pharmaceuticals \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"MicuRx Pha.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"J&J Strikes Covid Vaccine Supply Deal with Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mexico Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca will Work with Mexico, Argentina on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Mexico Government","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novavax","sponsor":"Government of United Kingdom","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax\u2019 COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Government of United Kingdom","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canadian Biotech JN Nova Pharma Inc. Partners with the Government of Canada to Develop Therapeutic Platform for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"KG2019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JN Nova Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JN Nova Pharma \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"JN Nova Ph.."},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Onc.."},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moffitt Cancer Center \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Ca.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Receives Eur 1.0 Million to Advance Ongoing JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"$3.0 million","newsHeadline":"Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$6,295.0 million","upfrontCash":"$125.0 million","newsHeadline":"Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":6.2999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6.2999999999999998,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$635.8 million","upfrontCash":"$43.3 milllion","newsHeadline":"Bayer and Hua Medicine Announce Commercialization Agreement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0.64000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.64000000000000001,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medici.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tango Therapeutics Announces $50 Million Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Dermin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ Dermin","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Union Therapeutics","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Union Therapeutics Option Agreement to Acquire Worldwide Exclusive License for Covid-19 Technologies Developed By TFF Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TFF Pharmaceuticals","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ UNION therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG and Northway Biotechpharma Collaborate Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"MTX-COVAB","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Northway Biotechpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ Memo Therapeutics AG","highestDevelopmentStatusID":"2","companyTruncated":"Northway B.."},{"orgOrder":0,"company":"Attwill Medical Solutions","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Attwill Medical Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Attwill Medical Solutions \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Attwill Me.."},{"orgOrder":0,"company":"McKesson","sponsor":"Centers for Disease Control","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McKesson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McKesson \/ Centers for Disease Control","highestDevelopmentStatusID":"1","companyTruncated":"McKesson \/.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Diosynth Biotechnologies Expands Its Partnership with Novavax to Manufacture Covid-19 Vaccine Candidate at its Billingham Site","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Coronavirus Immunotherapy Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Mono & Bi-specific antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Respirent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Signs Agreement with Respirent Pharmaceuticals for Exclusive Distributor Of Generic Flovent\u00ae Diskus\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lannett Company, Inc. \/ Respirent Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Open Orphan","sponsor":"Codagenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Open Orphan Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"CodaVax-COVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Open Orphan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Open Orphan \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Open Orpha.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase 3 Trial Testing Topical Gene Therapy B-VEC Now Enrolling DEB Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Beremagene geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Ofev\u00ae Data in Patients with Chronic Fibrosing ILDs Available During American Thoracic Society Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Investigator-Initiated Trial at Kaiser Permanente to Study VASCEPA\u00ae in Reducing Viral Upper Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Release Clinical Trial Data of Sintilimab in Combination with ALIMTA and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Publishes Data on New Recombinant Hyperimmune Drug GIGA-2050 as COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AG019","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr.Reddy\u2019S Launches Generic Version of Ciprodex","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinopharm Starts Phase III Trial of COVID-19 Vaccine in Bahrain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury\u00ae (Remdesivir) for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX Administered in Suprachoroidal Space","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb\/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UB-421","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"iBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iBio Provides Update on IBIO-201 COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IBIO-201","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"iBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"iBio \/ Not.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces U.S. FDA Filing Acceptance of BLA for StrataGraft\u00ae Regenerative Skin Tissue for Deep Partial-thickness Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"StrataGraft skin tissue","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Receives Fourth FDA Orphan Drug Designation for OCU400 Gene Therapy to Treat PDE6B Gene Mutation-Associated Retinal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Novocellbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocellbio in Korea Confirms NOVO-NK\u2019s Promising Antiviral Effects Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NOVO-NK","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novocellbio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novocellbio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novocellbi.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Launches Ontruzant in Brazil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Initiated Dosing of its COVID-19 STARR\u2122 mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1\/2 study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces Enrolment of First Patient in Multinational Clinical Trial for the Treatment of COVID-19 with RUCONEST\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Conestat alfa","moa":"C1 esterase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Announces SUNRISE Phase 1\/2 Clinical Design for LB-001 to Treat Methylmalonic Acidemia in Pediatric Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Appili Therapeutics to Expand its Phase 2 Trial of Favipiravir for Prevention of COVID-19 at U.S. Long-Term Care Facilities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces FDA Approval of OLINVYK\u2122 (oliceridine) injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Purified Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA\u2019s CHMP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 for Treatment of Allergic Reactions Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio's Etokimab Provides More Disappointing Results, Raising Questions About Compound's Future","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Etokimab","moa":"Interleukin-33","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in RhoVac's Clinical Phase IIb Study in the USA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Romark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Romark \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ N.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Announces FDA Orphan Drug Designation for CLN7 Batten Disease Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-based engineered transgene","moa":"CLN7 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China National Medical Products Administration Approves Gilead's Truvada\u00ae for HIV Pre-Exposure Prophylaxis (PrEP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Dosing Phase 1\/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation of Nebulized Solution","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CheckMate -577 Evaluating Opdivo as Adjuvant Therapy for Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOQUAL Announces Publication in NEJM of Non-Human Primate Preclinical Viral Challenge Study of an mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BIOQUAL \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Launches Phase 3 Trial for COVID-19 Vaccine in Indonesia, Reports Phase 2 Details","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Emerald Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Emerald Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emerald Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Emerald Bi.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Management Changes","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Pharmaceuticals Welcomes Aziz Mottiwala as Chief Commercial Officer and Relocates to Larger Irvine Headquarters","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-03","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. FDA Acceptance of BLA for Pegunigalsidase Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum\u2019s losmapimod Fails Interim Analysis in Muscle Wasting Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotech to Begin Mid-to-Late Stage Study of Covid-19 Drug Candidate In August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"India Globalization Capital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Initiation of IGC\u2019s Cannabinoid Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"India Globalization Capital","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"India Globalization Capital \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"India Glob.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Reports Positive Interim Data From First Patient Cohort in Phase 2 Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for \"Methods of Administering 3,4-Diaminopyridine\"","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Provides Clinical Trial Update on Zevtera","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ceftobiprole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Deflazacort","moa":"CTGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Pharmaceuticals Provides Clinical and Business Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Update Regarding FPI-1434 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"[225Ac]-FPI-1434","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sustained-Release Oral Formulation","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate Designated Promising Innovative Medicine (PIM) by the UK\u2019s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma\u2019s Novel Antibiotic Asset XF-73 Clears Safety Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SYD1875","moa":"5T4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Kymab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KY1005","moa":"OX40L","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kymab \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ No.."},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saillant Therapeutics to Develop Generic Virus Inhibiting Therapy Based on Activation of a Cellular Master Regulator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saillant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant T.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Institute of Allergy and Infectious Diseases Started Enrolling in Clinical Trials Of Monoclonal Antibodies To Prevent Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AGT103-T","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Gene Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"American G.."},{"orgOrder":0,"company":"MANA RBM","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential Enhancement of Prostate Cancer Treatment Options: First Patient Randomized in Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MANA RBM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MANA RBM \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MANA RBM \/.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1\/2a Study Arm Evaluating VB10.NEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Vaccibody AS","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Evinacumab BLA for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"SIRP alpha\/41BBL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"LivaNova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Autonomic regulation therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"LivaNova","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LivaNova \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"LivaNova \/.."},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces TUKYSA\u00ae (tucatinib) Approved Within Months for All Countries Participating in FDA\u2019s Project Orbis Initiative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of BLD-2660 in Treating Patients with COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BLD-2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma's VILTEPSO injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON to Present Data From the NOX-A12 \/ Keytruda\u00ae Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Resumes Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Designation for TransCon\u2122 CNP for the Treatment of Achondroplasia in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon CNP","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KCP506","moa":"nAchR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Dosed First Patient with ST101 in Phase 1\/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate Pharma Confirms Path Forward with FDA to Develop Combination Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kiora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiora Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiora Phar.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elusys Therapeutics Receives Health Canada Approval For Anthim\u00ae For The Treatment Of Inhalation Anthrax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elusys The.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PneumoBlast","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Starts Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced\/Metastatic Triple Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-400945","moa":"PLK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Reports End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study of Nomacopanfor for Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-310","moa":"GLA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope Therapeutics Starts Phase II Programme Evaluating Its Gene Therapy, GT005, for Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT\u00ae (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"ChemDiv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ChemDiv","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChemDiv \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ChemDiv \/ .."},{"orgOrder":0,"company":"Antengene","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Therapeutic Goods Administration Approves First Phase I Trial of ATG-017 for Advanced Solid Tumors and Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATG-017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing ARDS due to COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Reports that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinopharm Shares Phase 2 Data On Inactivated Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Minnesota Trials Stem Cell Therapy for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Minnesota \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Presents Phase 3 Data for Solosec\u00ae (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral Granules","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer\u2019s Disease Has Reached Enrollment Milestone of 500 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Gets FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Marginal Zone Lymphoma and Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Dosed First Patient in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daridorexant Phase 3 Results In Insomnia to be Presented at Sleep 2020","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm\u2019S IAP Antagonist Significantly Improves Overall Survival Of High-Risk Head & Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Patent Granted Covering INmune Bio\u2019s XPro1595","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Receives USFA Tentative Approval for Antifungal Medication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Enspryng for Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Begins Plonmarlimab Dosing In Rheumatoid Arthritis Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Plonmarlimab","moa":"GM-CSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"7\u00d721 CAR-T cells","moa":"IL-7 expression","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unity Biotechnology Announces 12-Week Data From Ubx0101 Phase 2 Clinical Study In Patients With Painful Osteoarthritis Of The Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u2018AeroNabs\u2019 Promise Powerful, Inhalable Protection Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanobodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Unveils Publication of QINLOCK Phase 1 Study Results in Gastrointestinal Stromal Tumor in Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech\u2019S Kb407 Granted Orphan Drug Designation by The FDA to Treat Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KB407","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Balticgruppen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Balticgruppen Bio Starts Bridging Pharmacokinetic & Safety Clinical Trial of a Novel Solid Pharmaceutical Composition of AMPK Activator O304","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Balticgruppen Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Balticgruppen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Balticgrup.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First Trastuzumab Biosimilar Approved by NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ETD002","moa":"TMEM16A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics sNDA Application For Tyvaso \u00ae For Pulmonary Hypertension Associated with Interstitial Lung Disease Accepted by U.S. FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin to Present New Study Evaluating VASCEPA in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Announces FDA Approval of NARCAN\u00ae (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Published Data Supporting First Wave of Disease-Modifying Alzheimer\u2019s Treatments with Aducanumab, Gantenerumab, BAN2401 and ALZ-801","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces FDA Clearance of ENVASARC Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Axcella\u2019s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Neuroptika","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NRO-1","moa":"Semaphorin-3A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuroptika \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi for the Treatment of Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"GNI Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydronidone","moa":"TGF beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GNI Group","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GNI Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GNI Group .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio to Present Data from Elivaldogene Autotemcel Gene Therapy Trial for Cerebral Adrenoleukodystrophy EBMT Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MAU868","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Will Attempt to Use Leronlimab During Bone Marrow Transplant for 5 HIV Patients Who also have Cancer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Dosed First Patient in Phase I\/II Study of First-in-Class PRGN-2009 AdenoVerse\u2122 Immunotherapy to Treat HPV-associated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19 related ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Bill & Melinda Gates Medical Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 to treat Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"CAT-5571","moa":"Autophagy","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catabasis Pharmaceuticals \/ Bill & Melinda Gates Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Lens Pharma Expands Its Scientific Advisory Board","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mediprint Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mediprint .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ\u2019s Fasenra Study Confirms Robust Efficacy in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MYR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Aims to Make 1 Billion Doses of COVID-19 Vaccine Candidate in 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Inhaled Use IND for RLF-100 (Aviptadil) to Treat Patients With Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics Holdings","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkem Labs launches Alfluenza for Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alkem Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkem Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkem Labo.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharmaceuticals Launches Favipiravir Under Brand name 'BDFAVI' at Rs 63 per Tablet in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND\u2122 Phase 3 open-label, safety trial of STS101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Japan Confirms Daridorexant Dose Response in Japanese Patients with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, COVID-19 Preventive Vaccine, GX-19, clinical 1\/2 Phase Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Starts the First Study with Melflufen Outside Multiple Myeloma and Enrolls First Patient in Phase 1\/2 AL Amyloidosis Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Gets FDA Approval of an Expanded Indication for Dovato (dolutegravir\/lamivudine)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Expedited Review to Biogen's Alzheimer's Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Health Canada Approval of DARZALEX\u00ae* SC for the Treatment of Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Highly active anti-retroviral therapy","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BLD-2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces That Lead program Zenocutuzumab Remains on Track for Zenocutuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pankajakasthuri Declares Final Clinical Trials of ZingiVir-H as Adjunct Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Undisclosed","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Zingivir-H","moa":"RNA-dependent DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakas.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$433.5 million","upfrontCash":"$25.0 million","newsHeadline":"AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0.42999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Government of Singapore","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Singapore Will Get First Claim to Any Successful Arcturus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Government of Singapore","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Avoro Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"PMV Pharma Raises $70M for Tumor Suppressor Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"p53 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PMV Pharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"PMV Pharma \/ Avoro Capital","highestDevelopmentStatusID":"2","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurasic Therapeutic Launched to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Acid-sensing ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Neurasic Therapeutic","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurasic Therapeutic \/ McGill University","highestDevelopmentStatusID":"2","companyTruncated":"Neurasic T.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Shanghai Pharma","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Intratumoral Oncolytic Virus Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"oHSV-1","moa":"IL 12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Shanghai Pharma","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Mirikizumab Superior to Cosentyx\u00ae (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Tsinghua University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tsinghua University, 3rd People\u2019s Hospital of Shenzhen and Brii Biosciences Enter Partnership to Develop Antibodies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BRII-196","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ Tsinghua University","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"TransThera Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"TransThera Biosciences \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"TransThera.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta and LG Chem Life Sciences Expand Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"AVA6000","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"AV-001","moa":"Angiopoietin 1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$200.0 million","newsHeadline":"Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Foundation for Angelman Syndrome Therapeutics","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Foundation for Angelman Syndrome Therapeutics and Lixte Biotechnology Collaborate to Support the Preclinical Study of LB-100","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"LB-100","moa":"Protein phosphatase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Foundation for Angelman Syndrome Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse\u00ae Available to LEMS Patients in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"KYE Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"KYE Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"KYE Pharma.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Israeli Ministry of Health","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Therapure Biomanufacturing","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapure Signs Manufacturing Deal with VBI Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"VBI-2901","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapure Biomanufacturing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapure Biomanufacturing \/ VBI Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Therapure .."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"NIH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharm Abcine Executes of a Material Cooperative Research and Development Agreement with NIH to Evaluate Efficacy of P-403 to Treat SCLS","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"PMC-403","moa":"Tie2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$6,500.0 million","upfrontCash":"$6,500.0 million","newsHeadline":"Momenta Enters Definitive Agreement with Johnson & Johnson","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"Medlight SA","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Announces Acquisition of Medlight SA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Medlight SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medlight SA \/ Rakuten Medical","highestDevelopmentStatusID":"10","companyTruncated":"Medlight S.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$106.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Minakem (formerly Delmar Chemicals)","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$19.6 million","upfrontCash":"Undisclosed","newsHeadline":"DelMar Announces $19.6 Million Private Placement Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Minakem (formerly Delmar Chemicals)","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Minakem (formerly Delmar Chemicals) \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minakem (f.."},{"orgOrder":0,"company":"Dualogics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"IgG-like bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Dualogics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dualogics \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Dualogics .."},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Novavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Cipla","sponsor":"Stempeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla and Stempeutics Collaborate for Launch of\nStempeucel\u00ae, First \u2018Made in India\u2019 Cell Therapy to\nTreat Critical Limb Ischemia (CLI)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Bone marrow-derived allogeneic mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Stempeutics","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ St.."},{"orgOrder":0,"company":"Evotec","sponsor":"Centogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Centogene Expand Collaboration into Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Induced pluripotent stem cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ CENTOGENE","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ C.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ Monopar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"Pharmaceutics International","sponsor":"Humanetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation and Pharmaceutics International Announce Partnership in Support of BIO 300 Clinical Trials in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmaceutics International","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pharmaceutics International \/ Humanetics Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pharmaceut.."},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Biose.."},{"orgOrder":0,"company":"GID BIO","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Gid Bio Wins Funding from Richard King Mellon Foundation to Study Regenerative Medicine to Treat Severe Respiratory Distress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Autologous stromal vascular fraction cell therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"GID BIO","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GID BIO \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"1","companyTruncated":"GID BIO \/ .."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Proteostasis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Proteostasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kronos Bio Announces $155 Million Private Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Jefferies LLC","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vantage Outsourcing","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vantage Outsourcing","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series C Financing","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.12,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin\u00ae (Bevacizumab) Biosimilar BAT1706 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MC2 Therapeutics Announces Collaboration with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA\u00ae Cream, in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health.."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Terra Magnum Capital Partners","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"RV1730","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Terra Magnum Capital Partners","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune .."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Prevention and Research Institute\nof Texas","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"IMGS-001","moa":"PD1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ImmunoGenesis \/ Cancer Prevention and Research Institute\nof Texas","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Confirms Advanced Discussions with EU to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":2.2999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":2.2999999999999998,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Blackstone Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kiadis collaborates with premier Dutch institutions to apply K-NK-cell technology for the development of a novel COVID-19 therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"K-NK-ID101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Treatment benefits from Tradipitant in COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Announces New Research Showing Veyonda\u00ae Cancer Survival Rates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-HIF2","moa":"HIF2-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"QBECO SSI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Granted FDA Priority Review for Less-Frequent, Fixed-Dose Use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD\/NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Yeast beta-glucans","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ N.."},{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sentien Biotechnologies Announces Open IND in Phase 1\/2 Trial of SBI-101 for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sentien Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sentien Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sentien Bi.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Doses First Subject in Phase 1 Proof of Concept Study of Oligonucleotide Drug Candidate ALG-010133","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Therapy Combination Effective for Patients with Advanced Cholangiocarcinoma and Braf Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan Brings Critical Access to the M.S Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study of Aldafermin in Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARMA Cell Therapies\u2122 Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Reports Publication of COVID-19 Data and Initiation of Clinical Trial of Auxora\u2122 in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Reports Positive Data from Phase I Trial of RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RSVDG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azur Rx Launches Option 2 Cystic Fibrosis Trialinn Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio\u2019s Lymph Node Targeting Covid-19 Vaccine Candidate Induces Up To 25-Fold More T Cells Over Benchmark Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-005","moa":"T cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac\u00ae Abstracts Accepted for Oral and Poster Presentations at EASL 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Third-generation hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Data Presentations at the EASL Digital International Liver Congress\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-305","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Reveals Preclinical Data from COBRA\u2122 Program, MVC-280, at Virtual Cell Engager Summit 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of AVIGAN\u00ae (Favipiravir) in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Institute of Technology on Immunobiologicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex and Bio-Manguinhos\/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Yellow fever vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ Institute of Technology on Immunobiologicals","highestDevelopmentStatusID":"4","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"AmideBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Rare Pediatric Disease Designation to Amide Bio's Glucagon Analog for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-G023","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"AmideBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics to Present Data from Phase 2 Study of VK2809 in Non-Alcoholic Fatty Liver Disease Patients with Elevated LDL-Cholesterol","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VK2809","moa":"TR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMU-856","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hackensack Meridian Health Observational Study Identifies Drug that Improves Survival in Sickest COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hackensack Meridian CDI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hackensack Meridian CDI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NW Bio Announces Completion of Further Data Gathering For Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Initiates Phase 2 Study to Evaluate Clinical and Immunologic Activity of ALKS 4230 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Announces First Participant Vaccinated in Phase 3 Clinical Trials of Its 5-in-1, Meningitis Abcwy Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Men ABCWY vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Receives Health Canada Approval for Dupixent to Treat Severe Chronic Rhinosinusitis with Nasal Polyposis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Z Factor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Z Factor Doses First Subject with ZF874, a Potential Disease-Modifying Treatment for Alpha-1-Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ZF874","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Z Factor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor \/.."},{"orgOrder":0,"company":"Nuformix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NXP004","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuformix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Trial Suggests that Amzell\u2019s New Topical Treatment (AMZ001) for the Treatment of Knee Osteoarthritis Symptoms Is Effective","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Amzell B.V","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amzell B.V \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amzell B.V.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Provides Update on COVID-19 Clinical Trial Activities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virtual FDA Advisory Committee Meeting to Review Alkermes' New Drug Application for ALKS 3831 in Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for Additional Indication of Kadcyla for Adjuvant Therapy of HER2-Positive Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab Emtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in Japan for the Treatment of Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene\u2019s CLN7 Gene Therapy Granted FDA Orphan Drug Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Resamirigene bilparvovec","moa":"MTM1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Audentes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes T.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with MDR HIV-1 infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UB-421","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Announces Results from the Next Evaluable Chemo-Resistant Colorectal Cancer Patient Treated with SCO-101 and Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Endovion","moa":"Chloride channel","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutic Doses First Patient in Phase 1\/2 Clinical Trial of 4D-125 for the Treatment of X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-125","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"HK inno.N","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hk Inno.N Publishes P3 Trial Results of Drug on Gastric Ulcers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"HK inno.N","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HK inno.N .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on Phase III Study Evaluating Investigational Spartalizumab in Combination with Tafinlar\u00ae + Mekinist\u00ae in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Freeze-Dried Formulation","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"CHOP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEEL Therapeutics Developing Cancer Drug from Plant Toxin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SN22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PEEL Therapeutics \/ CHOP","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Thera.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Appoints Candidate Drug in the Tumorad Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tumorad-Lu177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (RX) ) at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Presentst Positive Results of the Conduct Study at Two Leading Medical Conferences","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Initiates Phase 2 Portion of Phase 1\/2 Clinical Trial of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"ReiThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study with First Healthy Volunteer Dosed in Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Receives Rare Pediatric Disease Designation For EDIT-301 For The Treatment Of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics Completes Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of EBMT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Submitts Supplemental New Drug Application to U.S. FDA for CABOMETYX\u00ae in Combination With Opdivo\u00ae for Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Gelatin Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec\u2019s RAMQ List of Medications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals' Covid-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-Sars-Co V-2 Activity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name \u2018sumifilam\u2019 by USAN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Announces an Investigator-Initiated Study of DSUVIA\u00ae in Orthopedic Patients in the Perioperative Setting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai Life Sciences Launches Empath Bio to Treat Post-Traumatic Stress Disorder with Novel Mdma Product","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Reports that Clinical Trial with Remygen[\u00ae] is Expanded to Evaluate Prevention of Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces AGGRASTAT\u00ae Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicure","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/.."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adlai Nortye Doses First Patient in Phase 1b Clinical Trial of AN0025 in Combination with Merck's KEYTRUDA for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AN0025","moa":"EP4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adlai Nortye \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Granted a Patent on Methods and Use of Anti-Il-6\/il-6 Receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and Other Pulmonary Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Announces Poster Presentation at the European Congress of Endocrinology Virtual Annual Meeting","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Receives Two New Approvals in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 and Kymriah in Relapsed\/Refractory Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-527","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odonate Therapeutics Announces Positive Top-line Results from CONTESSA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed For The Global Phase 3 Study Of Oral Edaravone For ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma Files Natural Product License with Health Canada for Bioflavonoid Formulation, Hesperco","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hesperidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valeo Pharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lentivirus-Hematopoietic Stem Cell","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Expression Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Expression Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Expression.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"26S proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-2026","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Ingenza","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ingenza Meets a Key Milestone in the Deployment of Novel Cost-Effective Covid-19 Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ingenza","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ingenza \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ingenza \/ .."},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabies Immune Globulin [Human]","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ K.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Fast Track Disease Designation from U.S. FDA for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Initiate Phase 4 Respond Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kimera\u00ae Labs Files First FDA Investigational New Drug (IND) Application Using XoGlo\u00ae for Treatment of ARDS Secondary to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell- Derived Exosomes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kimera Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kimera Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kimera Lab.."},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeting Endothelial Barrier Function in Critically Ill Covid-19 Patients: Adrecizumab Shows Beneficial Effects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"ExCellThera","sponsor":"IRICoR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRICoR Makes Additional Investment in ExCellThera","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExCellThera \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's Empagliflozin Meets Primary Endpoint in Reducing Risk of Cardiovascular Death or Hospitalization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Provides Update on Phase III Studies of Etrolizumab In People with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"Beta-7 integrin Ligand binding","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino to Start Phase III Trial of COVID-19 Vaccine in Saudi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Federal Biomedical Agency of Russia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian Drug Given Patent for Dalargin for the Treatment of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Leitragin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Federal Biomedical Agency of Russia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Federal Biomedical Agency of Russia \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Federal Bi.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Analysis of Real-World Data Confirms Sequential Gilotrif\u00ae Followed By Osimertinib Imporved Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Afatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Report Promising Phase I\/Ii Data of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162b1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Xolair (Omalizumab) Prefilled Syringe for Self-Administration Across All Indications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutic Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibiotic","moa":"Staphylococcal biofilm formation","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Pd-1\/Ctla-4 Bi-Specific Antibody (Ak104) of Akeso Granted FDA Fast Track Designation For Recurrent And Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AK104","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Resumes the Phase 3 Clinical Trials Investigating Concizumab (Anti-Tfpi Mab) In Haemophilia A and B With or without Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Advisory Committee Votes in Favor of Ryoncil for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Wockhardt","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"India's Wockhardt Strikes Deal to Supply COVID-19 Vaccines to UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ U.S Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chrysalis BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chrysalis BioTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chrysalis .."},{"orgOrder":0,"company":"Biological E","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biological E Inks Agreement with Janssen Pharmaceutica NV for Coronavirus Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biological E \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Biological E","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baylor College of Medicine and Biological E ink Licensing Agreement to Develop Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Covid 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Biological E","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review for OS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofranergene obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novateur Study Points Toward Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Zileuton","moa":"5-LOX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Formulation","sponsorNew":"Novateur Ventures \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur V.."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carisma Therapeutics Enters Into Scientific Research AND Licensing Agreement with Nyu Langone Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Vpx Lentiviral Vector","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NYU Langone Health \/ CARISMA Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langon.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Diaprost","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diaprost AB Acquires Rights to use of PSA Antibodies from Memorial Sloan Kettering Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"h5A10","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Diaprost","highestDevelopmentStatusID":"4","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Therapyx","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Intravacc and Therapyx Jointly Develop the World's First Prophylactic Gonorrhea Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"NGoXIM","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapyx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapyx \/ Intravacc","highestDevelopmentStatusID":"4","companyTruncated":"Therapyx \/.."},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"EI1071","moa":"CSF1R","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Alzheimer's Association","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron I.."},{"orgOrder":0,"company":"CerSci Therapeutics","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$939.5 million","upfrontCash":"Undisclosed","newsHeadline":"ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"ACP-044","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"CerSci Therapeutics","amount2":0.93999999999999995,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.93999999999999995,"dosageForm":"Oral","sponsorNew":"CerSci Therapeutics \/ ACADIA Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"CerSci The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Amsterdam Pharma Acquires Obicetrapib from Amgen","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"CohBar","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"CB4211","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"CohBar \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ R.."},{"orgOrder":0,"company":"ReViral","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReViral Raises $44 Million in Series C Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series C Financing","leadProduct":"Sisunatovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"ReViral \/ CR-CP Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Premier","sponsor":"Baudax Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Premier","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Baudax Bio","highestDevelopmentStatusID":"12","companyTruncated":"Premier \/ .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Bio Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Bio Farma","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Contrafect Announces Funding Agreement with the Cystic Fibrosis Foundation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$100.0 million","newsHeadline":"Morphic Announces that Abbvie Exercises License Option to \u0391v\u03b26 Integrin Inhibitor Program, Including Morf-720, for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MORF-720","moa":"Alpha5Beta6 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Morphic Therapeutic","amount2":0.12,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"EpiVax","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"EPV-CoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ EpiVax Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ E.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kinnate Biopharma Closes $98 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kinnate Biopharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Propeller Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propeller Health Enters Japan with Digital Health Sensor for New Enerzair\u00ae and Atectura\u00ae Breezhaler\u00ae Asthma Medications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Propeller Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Propeller Health \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Propeller .."},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"IVMED-80","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ N.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M1231","moa":"MUC1-EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"U.S Department of Defense","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ U.S Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ivy Brain Tumor Center and Vivace Therapeutics Collaborate to Test Targeted Agent in Glioblastoma and Meningioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"VT-01","moa":"TEAD palmitoylation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivace Therapeutics \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"4","companyTruncated":"Vivace The.."},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ G.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Novit LP","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP With $1.0 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Novit LP","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Singlomics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DXP-593","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Singlomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Singlomics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Singlomics.."},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"TAC01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Triumvira Immunologics \/ Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira .."},{"orgOrder":0,"company":"Sarah Cannon","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"CAR T-Cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sarah Cannon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarah Cannon \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sarah Cann.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Odonate Therapeutics Announces Public Offering of Shares of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Harvard University","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Harvard University","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Harvard University \/ AbbVie","highestDevelopmentStatusID":"1","companyTruncated":"Harvard Un.."},{"orgOrder":0,"company":"Scancell","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scancell Led Consortium Awarded Funding by Innovate UK to Progress Second Generation Covid-19 Vaccine Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Covid 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scancell \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"Avid Bioservices","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antiviral antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mapp Biopharmaceutical \/ Avid Bioservices","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Bioph.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"U.S. Army Contracting Command","pharmaFlowCategory":"D","amount":"$106.3 million","upfrontCash":"$53.1 million","newsHeadline":"U.S. Army Contracting Command Awards Ology Bioservices Contract to Reserve Production Capacity IN Support of Operation Warp Speed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Ology Bioservices \/ U.S. Army Contracting Command","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"SymBiosis II, LLC","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clene Nanomedicine Raises Series D Financing of $42.5 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series D Financing","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ SymBiosis II, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ADX10061","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"2","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"UK Research and Innovation","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccitech Receives Government Grant for Covid-19 Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ UK Research and Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Vitanova Biomedical","sponsor":"National Science Foundation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Vitanova Biomedical Awarded Competitive Grant from the National Science Foundation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"VNBp-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vitanova Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vitanova Biomedical \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Vitanova B.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"TRACON Pharmaceuticals Announces $5.0 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Exeltis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intelgenx and Exeltis Healthcare S.L. Expand Rizaport\u00ae Commercialization Agreement to Include the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"IntelGenx \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Natera","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Natera Enters Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natera \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ M.."},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"T3D Therapeutics Receives a Research Award from the Alzheimer\u2019s Association Part the Cloud-Gates Partnership Grant Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"T3D-959 Sodium","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Alzheimer's Association","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therap.."},{"orgOrder":0,"company":"Elion Oncology","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","amount":"$103.1 million","upfrontCash":"$88.0 million","newsHeadline":"Processa Pharmaceutical Enters Licensing Agreement with Elion Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"DPD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elion Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Elion Oncology \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elion Onco.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$490.0 million","upfrontCash":"$30.0 million","newsHeadline":"PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi\u2122 (risdiplam)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Jacobson Pharma","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobson Pharma Collaborates with Fosun Pharma Group to Supply BioNTech SE\u2019s COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jacobson Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jacobson Pharma \/ Fosun Pharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Jacobson P.."},{"orgOrder":0,"company":"Planet Biotechnology","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACE2-Fc","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Planet Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Planet Biotechnology \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Planet Bio.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fibromyalgia biotech Virios Therapeutics files for a $35 million IPO","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ U.."},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$50.1 million","upfrontCash":"$29.5 million","newsHeadline":"Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"AUT00206","moa":"Kv3 potassium channel","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Autifony Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Autifony Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Autifony T.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$1,930.0 million","upfrontCash":"$1,930.0 million","newsHeadline":"Nestl\u00e9 to Acquire Aimmune Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":1.9299999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.9299999999999999,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Nestl\u00e9","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$357.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leo Pharma Sells Portfolio of Four Products to Cheplapharm","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leo Pharma \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Seneca Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seneca Therapeutics, Inc. Licenses Tumor Endothelial Marker 8 (TEM8) to Enable Better Patient Selection for SVV-001 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Seneca Valley virus-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beximco Pharma and Serum Institute of India Announce Intention to Cooperate on A Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Beximco Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Alcami","sponsor":"Trevena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alcami Providing Commercial Manufacturing for Trevena\u2019s Recently FDA Approved OLINVYK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alcami","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alcami \/ Trevena","highestDevelopmentStatusID":"12","companyTruncated":"Alcami \/ T.."},{"orgOrder":0,"company":"ForwardVue","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ForwardVue Pharma Secures Funding to Advance Pre-Clinical Development Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Caroboxyamidotriazole","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ForwardVue","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ForwardVue \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ForwardVue.."},{"orgOrder":0,"company":"HitGen","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Almirall Announce Achievement of Milestoneinn their Strategic Collaboration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ A.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Fosun Pharma to Supply 10 Million Doses of BioNTech\u2019s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"$4.3 million","newsHeadline":"PDL BioPharma Announces Sale of Kybella\u00ae, Zalviso\u00ae and Coflex\u00ae Royalties to SWK Holdings Corporation","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"PDL BioPharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PDL BioPharma \/ SWK Holdings Corporation","highestDevelopmentStatusID":"12","companyTruncated":"PDL BioPha.."},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"$8.1 million","newsHeadline":"SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"BOXR1030","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Unum Therapeutics \/ SOTIO","highestDevelopmentStatusID":"4","companyTruncated":"Unum Thera.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRISYS, LLC \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$17.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Closed $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Antiviral therapy","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"University of Cambridge","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cambridge University Aims for Autumn Trials of Coronavirus Vaccine After Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"DIOS-CoVax2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cambridge","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Cambridge \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Selects Syneos Health as Commercialization Partner to Launch Daridorexant in the United States","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Galidesivir","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX-100","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ASX-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bi.."},{"orgOrder":0,"company":"Verndari","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verndari, Inc. Announces Funding from U.S. Government Agency BARDA to Accelerate Development of VaxiPatch\u2122 Dermal Patch Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"VaxiPatch","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verndari \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Union Therapeutics A\/s Completes Dosing of Healthy Volunteers with UNI911 (inhaled Niclosamide) for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO\u2122 (lemborexant) CIV, at the SLEEP 2020 Virtual Conference","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Filing of NDA for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Application to FDA for RINVOQ\u2122 (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Provides FDA Update on IND Filing for Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"University of Kentucky","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanders-Brown Study Leads to Potential for a New Treatment Approach to Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AL002","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kentucky","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Kentucky \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress\u2122","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cilofexor","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen to Present Results from Move, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (fop), at Asbmr 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand OmniAb\u00ae Partner Immunovant Announced Positive Topline Results from Phase 2a Trial of IMVT-1401 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Bonac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bonac to Begin Human Clinical Tests for Covid-19 Drug in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNC-1322","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bonac \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonac \/ No.."},{"orgOrder":0,"company":"Bolder BioTechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolder BioTechnology Announces Positive Preclinical Data for Use of BBT-032 to Inhibit Growth of the SARS-CoV-2 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BBT-032","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bolder BioTechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolder BioTechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bolder Bio.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma Provides Development Update on Spl7013 Nasal Spray for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Astodrimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical patch","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric AutoAntibody Receptor T cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KB301","moa":"COL3A1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine\u00ae (rhuGM-CSF, sargramostim) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Positioned to Launch Prestige Aesthetics Portfolio with the RHA\u00ae Collection of Dermal Fillers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics and NYSCF File Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"iPSC CAR-NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) NDA for Duchenne Muscular Dystrophy Amenable to Skipping Exon 45","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Casimersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mind Med Announces First-Ever Clinical Trial Combining MDMA and LSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves CYSTADROPS\u00ae 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cysteamine Hydrochloride","moa":"Cystine reducing agent","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Altimmune","sponsor":"University of Alabama","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ University of Alabama","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Mitotech","sponsor":"Essex Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 \u2013 a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Essex Bio","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 ELEKTRA Study of Soticlestat Meets Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ovid Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents the Clinical Project Portfolio at Virtual R & D Day August 27, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida sinks as FDA rejection raises prospect of new trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Translate Bio, Sanofi Covid-19 Vaccine Candidate Produces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Melbourne\u2019s Walter and Eliza Hall Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melbourne\u2019s Walter and Eliza Hall Institute's Coronavirus Antibody Therapy Aims for Trial in Early 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody therapy","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melbourne\u2019s Walter and Eliza Hall Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Melbourne\u2019s Walter and Eliza Hall Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Melbourne\u2019.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives Korean MFDS Approval to Initiate Phase I Trial of COVID-19 Antiviral Antibody Treatment Candidate, CT-P59, in Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at ACIP Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-2901","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME\u2019s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bile Salts","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha\u00ae (evolocumab) Efficacy In High-Risk Patient Populations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b\/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BGE-175","moa":"Prostaglandin D2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for the Prevention and Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L401","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Announces First Commercial Launch of VAFSEO\u2122 (vadadustat tablets)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm\u2019s New Generation Radionuclide Therapy Advances Into Clinical Research in the Fight Against Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Minigastrin-Lu177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience: Encouraging Interim Safety Data in Ator-1017 Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1017","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrolment Initiated in World's First Rct with Sirolimus Coated Balloon for the Treatment of Below-the-Knee (btk) Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-1387","moa":"Apoptosis protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Starts a Phase 2 Study at the Moffitt Cancer Center to Evaluate Combination of TAVO plus OPDIVO\u00ae as Neoadjuvant Therapy for Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Provides Update on a Phase 2 Trial of an RTGel\u2122 Hydrogel Formulation and BOTOX\u00ae Combo for Overactive Bladder and Urinary Incontinence","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Orphan Drug Designation and Rare Pediatric Disease Designation for TSHA-101 for GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TSHA-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex\u2019s Kaftrio Approved for Use in Europe and Made Accessible on the NHS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Northwestern University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Drug Combo Attacks Breast Cancer Brain Metastases in Mice","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Molibresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Northwestern University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Northwestern University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Northweste.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Receives FDA Approval for Winlevi\u00ae (clascoterone Cream 1%)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Conditional Approval for Hansa's Idefirix[tm] (imlifidase) in Highly Sensitized Kidney Transplant Patients in the European Union","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Pharma Launches Enspryng Subcutaneous Injection 120 Mg Syringe for Prevention of Relapses of NMOSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trishula Therapeutics Established to Advance Novel TTX-030, an Anti-CD39 Antibody, Being Evaluated in Phase 1\/1B Study in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ttx-030","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trishula Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trishula T.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole in Acute Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Publishes Preclinical Data in Hepatology Showing the Potential of Imm Tav\u00ae Bispecific Molecules to Cure Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMC-I109V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Phase III DAPA-CKD Trial Paradigm-Shifting Data to Be Presented at ESC 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Non-Clinical Research Results of Chugai\u2019s Switch Antibody STA551 Published in Cancer Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STA551","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Data Presentation on ALT-801","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-801","moa":"GCGR\/GLP-1R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Doses First Patient in Phase 2 IRENE Study of Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital ILC 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference in October","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Comprehensive Clinical Benefit Data from Part a Of Combination Trial of M Rx051 and Keytruda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg) from NORSE 1","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"Premas Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akers, Premas Note Positive Proof-Of-Concept Data of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PRAK-03202 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Akers Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Akers Biosciences \/ Premas Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Akers Bios.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Queensland's Covid-19 Vaccine Shows Effectiveness in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at EBMT 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Expands Cohorts in Ongoing Phase 1 Study of Oral CFI-402257, in Patients with Breast Cancer and Additional Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-402257","moa":"Tyrosine threonine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital EASL 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KB174","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces First Patient Dosed in Phase 2 Study of Oral AMT-101 in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The \n Digital ILC 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Present New Data from the Interim Analysis of Regenerate Show that Oca Helped Patients with Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella\u2019s Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ammendments to ProtoKinetix AAGP\u00ae Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos to Present Nonclinical Data for All Components of Chronic Hep B Combination Therapy at EASL Digital International Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Publishes Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA\u2122 in Advanced Solid Tumors in the British Journal of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava\u2122 to Treat Complicated Intra-Abdominal Infections in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois Chicago","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Human Trials Suggest Uic-Developed Breast Cancer Drug Is Safe, Effective","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TTC-352","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ University of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncolo.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Presents Promising Phase 2A Data for Chronic Hepatitis B Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GSK3228836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead and Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"JNJ-3989","moa":"HBV gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Filing of NDA for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Vericiguat for Marketing Authorization in China for the Treatment of Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data from Assembly Biosciences\u2019 HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Core protein allosteric","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune\u2122 and Minocycline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Therapeutics Presents Promising Data from Phase 1 Trial with ADP-A2 Afpinn Liver Cancer at the International Liver Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics LP Announces Initiation of Expanded Access Protocol for Ebola Treatment Ansuvimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ansuvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Provides Regulatory Update for TLANDO\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Pharmaceuticals Launches Cadalimab\u2122 (Adalimumab biosimilar) for India","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMB-115","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NILEMDO\u00ae Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac's Coronavirus Vaccine Candidate Approved for Emergency Use in China- Source","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review of Melflufen for Patients with Triple-Class Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital ILC 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actelion P.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Investigational Antiviral Veklury\u00ae (Remdesivir) Receives FDA Emergency Use Authorization for Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BA-1049","moa":"Rho-associated protein kinase 2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Improves Survivalinn Kidney Disease Patients Study Shows","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R\/R ENKTL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Can-Fite to Commence Phase II Study of Piclidenoson COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis New Analysis Shows High Consistency in Lowering LDL-C in Individual Response with Investigational Inclisiran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents Positive New Phase 1\/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at the ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Kannalife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kannalife, Inc. Receives Patent Grants for KLS-13019 in Additional European Territories","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KLS-13019","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kannalife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kannalife \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kannalife .."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology and Gsk Start Phase 2\/3 Study of Covid-19 Antibody Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Multitope Peptide-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Expands Development of Covid-19 Vaccine Azd1222 Into Us Phase III Clinical Trial Across All Adult Age Groups","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae Reduced the Combined Relative Risk of Cardiovascular Death and Hospitalization for Heart Failure by 25% in Adults with and Without Diabetes Who Had Heart Failure with Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Gene Therapy Shows Sustained Benefit in Rare Metabolic Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Glaxo Smith Kline's Blenrep for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Kaken Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"GtreeBNT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture GtreeBNT Expects to Complete Phase 3 Dry Eye Trial in November 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"GtreeBNT \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Announces Initiation of Phase 1 Clinical Trial of SL-172154 (SIRP\u03b1-Fc-CD40L) for the Treatment of Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SL-172154","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the HFSA Annual Scientific Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-207","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SPR720","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"VelosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VLS-101","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VelosBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Investigational New Drug Application for OMS906 Cleared by FDA","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"MBL-associated serine protease","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Metyrapone","moa":"CYP450","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embera NeuroTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Embera Neu.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-015","moa":"IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Provention.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation for BCX9930 in PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission Potential of Acute Kidney Injury Emerging as a Serious Consequence of COVID-19","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmascience Reiterates Its Support to the Montreal Heart Institute's Colchicine Repurposing Research Studies in Cardiovascular Medicine and Covid-19","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-1688","moa":"15-Hydroxyprostaglandin dehydrogenase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Results of the Phase 1\/2 Clinical Study of PCSK9 Antibody Tafolecimab at the ESC Annual Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves XARACOLL\u00ae (bupivacaine HCl) Implant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"Allied Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allied Corp. Strengthens IP and Pharma Strategy by Filing Provisional Patent for ALID-10 and ALID-11","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALID-10","moa":"CB receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allied Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Cor.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astex Pharmaceuticals Announces That Tolinapant Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis proteins","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study at Digital ILC 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Alfa 2A","moa":"Interferon alpha\/beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Data on UCB's Vimpat\u00ae CV in Primary Generalized Tonic-Clonic Seizures Published in Journal of Neurology, Neurosurgery & Psychiatry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears SPI\u2019s Ebselen for Phase II COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's Covid-19 Vaccine Selected by Japanese Drug Discovery Body","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presents Phase 3 Sci-B-Vac\u00ae Data at EASL 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Third-generation hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer\u2019s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BARHEMSYS\u00ae (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of PONV","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Hercules Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hercules' AHR Inhibitor Hp163 Blocks Viral Replicationinn Zika Infection and Potentially in Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"HP163","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hercules Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hercules Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hercules P.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn\u00ae Mechanism in ALS, Progressive MS and Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Alternative Research Associates","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organicell Partnered With Alternative Research Associates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alternative Research Associates","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alternative Research Associates \/ Organicell","highestDevelopmentStatusID":"7","companyTruncated":"Alternativ.."},{"orgOrder":0,"company":"Kentucky BioProcessing","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bat Working on Potential Covid-19 Vaccine Through Us Bio-Tech Subsidiary","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kentucky BioProcessing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kentucky BioProcessing \/ ","highestDevelopmentStatusID":"4","companyTruncated":"Kentucky B.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Approves Human Trials for Potential Johnson & Johnson Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CombiGene","sponsor":"Cobra Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobra Biologics Completes Production of Master Cell Banks for CombiGene\u2019s Epilepsy Gene Therapy Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CombiGene","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CombiGene \/ Cobra Biologics","highestDevelopmentStatusID":"4","companyTruncated":"CombiGene .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Highmark Forges Outcomes-Based Contract with UCB for Anti-Inflammatory Drug CIMZIA\u00ae (certolizumab pegol)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Highmark","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Highmark \/.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech: Publication of Case Report Series from the Phase I Study in Bile Duct Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$337.0 million","upfrontCash":"Undisclosed","newsHeadline":"Medtronic Announces a $337 Million Product Investment from Blackstone Life Sciences to Expand Development of Future Diabetes Technologies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0.34000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BOS-580","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"WestRiver Management","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"LMN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Lumen Bioscience \/ WestRiver Management","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"ImmProNano","sponsor":"Emergex Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Vaccines Forms US Subsidiary by Acquisition of Laboratories, Technology and Assets of US-Based T Cell Specialist Biotech ImmProNano","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Set-point vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmProNano","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmProNano \/ Emergex Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"ImmProNano.."},{"orgOrder":0,"company":"Cornell University","sponsor":"reVision Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"reVision Therapeutics, Inc. Announces License with Cornell to Develop Treatment for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"REV-0100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Cornell University","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cornell University \/ reVision Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cornell Un.."},{"orgOrder":0,"company":"H&T Presspart","sponsor":"Bilim Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bilim Pharmaceuticals, H&T Presspart and Hovione Technology Unveil Collaboration for New Asthma Product: Ventofor Combi Fix","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"H&T Presspart","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Dry Powder Inhaler","sponsorNew":"H&T Presspart \/ Bilim Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"H&T Pressp.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Avomeen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Dar\u00e9\u2019s Novel Pipeline of Women\u2019s Health Programs","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Ferrous Gluconate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Dar\u00e9 Bioscience \/ Avomeen","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$805.0 million","upfrontCash":"$85.0 million","newsHeadline":"Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jounce Therapeutics","amount2":0.81000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.81000000000000005,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program, with Taiho Oncology, to Explore New Research into Oral Medication Targeting Tumor Suppression Genes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"1","companyTruncated":"The Nation.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$64.9 million","upfrontCash":"$19.4 million","newsHeadline":"Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Oxford Biomedica","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Flaskworks","sponsor":"Northwest Biotherapeutics","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"$1.6 million","newsHeadline":"Northwest Biotherapeutics Acquires Flaskworks","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Flaskworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Flaskworks \/ Northwest Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Flaskworks.."},{"orgOrder":0,"company":"AskBio","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"AskBio Awarded \u00a32m Scottish Enterprise R&D Grant to Help Reduce Barriers to Mainstream Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"AAV2\/8LSPhGAA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Scottish Enterprise","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ S.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sun BioPharma, Inc. Closes $10.5 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sun BioPharma \/ Craig-Hallum Capital Group","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"SternAegis Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ SternAegis Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Australian Government Department of Industry, Science, Energy and Resources","pharmaFlowCategory":"D","amount":"$0.02 million","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Receives Entrepreneurs\u2019 Programme Innovation Connections Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Recce 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Australian Government Department of Industry, Science, Energy and Resources","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Mitochondria therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"LUCA Science","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"LUCA Science \/ Axil Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Scien.."},{"orgOrder":0,"company":"Binex","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Signs a CMO Contract with Binex so Binex Can Produce Olinvacimab at Its New 5,000 L Production Line","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Binex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Binex \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Binex \/ Ph.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"$19.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Announces the Closing of Its Acquisition of SmartPharm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"STI-2020dna","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"Fred Hutchinson Cancer Research Center","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Therapy Research for Hiv Awarded $14.6 Million Nih Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Research Center","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Fred Hutchinson Cancer Research Center \/ National Institute of Health","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutch.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.01,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Santhera","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orca Bio and Lyell Immunopharma Announce Research Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Pocono Coated Product","sponsor":"Nutriband","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Acquires Transdermal and Health Product Manufacturing Business","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Opioid based transdermal medications","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Pocono Coated Product","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Pocono Coated Product \/ Nutriband","highestDevelopmentStatusID":"1","companyTruncated":"Pocono Coa.."},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management and Research Company LLC","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"SHINE Technologies","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SHINE Technologies \/ Fidelity Management and Research Company LLC","highestDevelopmentStatusID":"1","companyTruncated":"SHINE Tech.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Option Care Health Selected as a Limited Distribution Provider of VILTEPSO\u2122 Injection for Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Option Care Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Option Car.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Protein Degrader Biotech Kymera Therapeutics Files for A $100 Million Ipo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Boxer Capital","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rain Therapeutics Closes $63 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"RAIN-32","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Rain Oncology \/ Boxer Capital","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Curia","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curia \/ Tryp Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Curia \/ Tr.."},{"orgOrder":0,"company":"Hibiskus BioPharma","sponsor":"Lodo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lodo Therapeutics Acquires Hibiskus Biopharma AND Licenses Rights to Novel Proteasome Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"TIR-199","moa":"Syrbactin proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hibiskus BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hibiskus BioPharma \/ Lodo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hibiskus B.."},{"orgOrder":0,"company":"CannaGlobal Wellness","sponsor":"Sansero Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CannaGlobal, Sansero Life Sciences and Rise Wellness Complete Merger, Announce Formation of CannaGlobal Wellness","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CannaGlobal Wellness","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CannaGlobal Wellness \/ Sansero Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CannaGloba.."},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb\u00ae Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Vibecotamab","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ MD Anderson","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ M.."},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMTA and Pharnext Enter Biomarker Research Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Ma.."},{"orgOrder":0,"company":"Curia","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curia \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Curia \/ As.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-AML specific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","amount":"$418.0 million","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Hillhouse Capital Group","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,940.0 million","upfrontCash":"$180.0 million","newsHeadline":"AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":1.9399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.9399999999999999,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Fosun Pharma, Sinopharm Group Sign Deal to Supply BioNTech Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Shanghai Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"CureVac","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","amount":"$297.8 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0.29999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"CureVac \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Government Exercises Option To Purchase Additional RAPIVAB\u00ae from BioCryst for Delivery to Strategic National Stockpile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Relation Therapeutics Teams up With Mila in Coalition to Identify Covid-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Relation Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Relation T.."},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"InxMed \/ Ennovation Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ E.."},{"orgOrder":0,"company":"University of Wisconsin","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Wisconsin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Wisconsin \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"State of Pennsylvania","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ State of Pennsylvania","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Tumbles on Possible FDA Approval Delay of Omaveloxolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces that the First Phase I Clinical Study of Anti-Il-23 Monoclonal Antibody Ibi112 Has Been Administered to A Subject","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI112","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITI Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-1000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Announces Publication Describing Preclinical Profile of ATI-2173","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strengthened Patent Protection for Arfolitixorin in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo phase 3 ELDERCARE AF study of anticoagulant, edoxaban in non-valvular atrial fibrillation & high bleeding risk meets primary endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nocion Therapeutics Advances to Clinical Stage and Expands Leadership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-1175","moa":"Sodium channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nocion Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nocion The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Onureg\u00ae, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Launch for Novo's New Diabetes Pill","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisatracurium Besylate","moa":"Nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio and Quantum Leap Doses First Patients with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare Collaborative","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Radboud University","sponsor":"Hellenic Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elderly People Protected Against Respiratory Infections by Bcg Vaccine Reveals Radboud University Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"NETHERLANDS","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Radboud University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Radboud University \/ Hellenic Institute","highestDevelopmentStatusID":"11","companyTruncated":"Radboud Un.."},{"orgOrder":0,"company":"Universities of Liverpool","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identify Promising New ALS Drug Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Universities of Liverpool","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Universities of Liverpool \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Universiti.."},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clear Creek Bio Doses First Patient in Clinical Study of Brequinar in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brequinar","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clear Creek Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clear Creek Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clear Cree.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor\u2122 for Immune Mediated Complications in COVID19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Fujita Health University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elixirgen Therapeutics Planning to Begin Phase I\/II Clinical Trials of Its Covid-19 Vaccine Candidate Exg-5003 at Fujita Health University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Fujita Health University","highestDevelopmentStatusID":"4","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Vertex\u2019s Supplemental New Drug Applications for TRIKAFTA\u00ae , SYMDEKO\u00ae and KALYDECO\u00ae for Additional CFTR Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Successfully Completes Multiple Dose Toxicity and Toxicokinetic Studies Of ALT-801 For The Treatment Of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-801","moa":"GCGR\/GLP-1R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical's Analysis of Prevention Trials and Intralymphatic Pilot Trial with the Diabetes Vaccine Diamyd\u00ae Support a Positive Trend in Genetically Defined Subgroups of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC Bio Publishes GATHER1 Phase 3 Clinical Trial Results for Zimura\u00ae in Geographic Atrophy Secondary to Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer\u2019s and Parkinson\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Provides Update on Tradipitant Development Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in the EU for the Treatment of Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx\u2019s Neuron-Protecting Drug Slows ALS Decline in Nejm Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents New Data on Efficacy of MS Treatment Ocrevus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MS Virtual 2020 Meeting, Furthering Innovation in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CiVax","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Oral Presentation of Phase 1b Combination Study of PT-112 Plus Avelumab at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia in CKD Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Libtayo\u00ae (cemiplimab) Pivotal Data in Advanced Non-Small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at Esmo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu) lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANVISA Authorizes Domp\u00e9's REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Reparixin","moa":"IL-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Nejm Publication of Pivotal Study of Tabrecta\u2122 in Patients with ME Tex14 Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Ionis Pharmaceuticals' Study Results Evaluating Ionis Antisense Therapy in Treatment of Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IONIS-PKK-LRx","moa":"Prekallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Cansino Kicks Off Phase III Vaccine Clinical Trials in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of 50th Patient in Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Issued Key Patent on Combination Platform Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HS-130","moa":"T-Cell mediated immune response","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmabcine Is Presenting on Olinivacimab Plus Pembrolizuamb Study at the KSMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek\u00ae National Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides to Present COVID-19 Drug Update at The LD 500 Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Announces Initiation of Patient Dosing in TWT-101, a Phase 1\/2 Study CFI-402411, in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-402411","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in \u2018Blood\u2019","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott\u2019s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Pulmonem","sponsor":"McGill University Health Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New COVID-19 Drug Therapy Developed by Canadian Biotech Start-up Headed for Phase III Clinical Trial Sponsored by the RI-MUHC Fran\u00e7ais","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmonem \/ McGill University Health Centre","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/.."},{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xellia Pharmaceuticals expands approved doses of VANCO READY\u2122 (Ready-to-use Premixed Vancomycin bags)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Xellia Pharmaceuticals ApS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellia Pharmaceuticals ApS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xellia Pha.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Orphan Drug Designation for MB-107 to Treat X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents Data from Clinical Phase 2a Study at AALSD International Liver Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Umecrine Cognition \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine C.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pioglitazone","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on U.S. Development Program for the Subcutaneous Formulation of ENTYVIO\u00ae for Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corning Jerry's Bispecific Antibody Kn046 Was Granted Orphan Drug Designation by the Us FDA for the Treatment of Thymic Epithelial Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces that Janssen\u2019s COVID-19 Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for NTM Lung Infection in People Living With Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Additional Doses of Trulicity\u00ae (dulaglutide) for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mexico Eyes October Start for Gamaleya Research Institute of Epidemiology and Microbiology's Phase 3 Trials of Russian Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX\u00ae to Treat HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Reports Long-Lasting Two-Year Efficacy and Safety Data from ABX464 Ulcerative Colitis Phase 2a Maintenance Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RLY-4008","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"BANNER LIFE SCIENCES LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Banner Life Sciences Announces BAFIERTAM for Relapsing Forms of Multiple Sclerosis, is Now Available in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BANNER LIFE SCIENCES LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"BANNER LIFE SCIENCES LLC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BANNER LIF.."},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CeleCor Announces Publication of Positive Clinical Results of RUC-4 (zalanfiban) for Subcutaneous Point-of-Care STEMI Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RUC-4","moa":"GPIIb\/IIIa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CeleCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Th.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune\u2122 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara\u00ae (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Announces Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-MARV-VLP vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Neumentum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumentum Announces Two Poster Presentations for Novel Non-opioid, Non-NSAID Analgesic Drug Candidate at PAINWeek 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTM-006","moa":"A3AR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces US Drug Manufacturing Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"FGF21","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich\u2019s Ataxia at AAN","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA Granted Marketing Approval for SULINNO\u00ae (Adalimumab Injection) in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma Launches Phase 3 Superiority Study for Pediatric Acute-onset Neuropsychiatric Syndrome","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Immune globulin, human - ifas","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lianhua Qingwen Receives First International Approval for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lianhua Qingwen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pha.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concept Medical Announces Enrolment of Index Patient in the Crucial Transform -1 RCT Using Magic Touch Sirolimus Coated Balloon for Small Coronary Vessels","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 1 Gene Therapy Study in Ireland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BIIB078","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Completes Enrollment for Intravenous Covid-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite Submits Supplemental Biologics License Application to U.S. FDA for Yescarta\u00ae in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Completes the Extended Enrollment for the Pivotal Phase 3 Ocean Study in Relapsed Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Positive Biomarker Data Demonstrating Proof of Mechanism in Mitazalimab Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at ESE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca to Begin Phase 1\/2 Clinical Trials of Coronavirus Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces FDA Approval of Gavreto for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Pfizer Receive Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2\/3 Trial for COVID-19 Vaccine Candidate BNT162b2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Provides Update on Kevzara\u00ae (sarilumab) Phase 3 Trial in Severe and Critically Ill Covid-19 Patients Outside the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medtronic Announces FDA Approval for Minimed\u2122 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Provides Updated Guidance on Its Clinical Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viela Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio .."},{"orgOrder":0,"company":"Syntekabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntekabio Found Repurposable Covid-19 Drug Candidates Stronger than Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syntekabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma\u2019s BCL-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 2\/3 Neurodegeneration Biotech Athira Pharma Files for a $100 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Goldman Sachs","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nell One Therapeutics Secures Key Patent to Revolutionize Large-Scale Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NV1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NellOne Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NellOne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NellOne Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Lademirsen","moa":"miR-21","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Government of Canada","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0.5,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Engitix Therapeutics \/ Takeda Pharmaceutical Company","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational Novel Stamp Inhibitor Asciminib (ABL001) Meets Primary Endpoint of Phase III Chronic Myeloid Leukemia Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Washington University School of Medicine's Experimental Nasal Vaccine Protects Upper and Lower Respiratory Tracts Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAd-SARS-CoV-2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Washington University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Novavax","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax to Supply 76M Doses of COVID-19 Vax to Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Government of Canada","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Carlyle","pharmaFlowCategory":"D","amount":"$260.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"JK07","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.26000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN S.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"SporeGen\u00ae Announces Collaboration with Destiny Pharma Supported by an Innovate UK grant award for a Preventative Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"SPOR-COV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai to Take Over Manufacturing and Marketing Approval for Equfina\u00ae 50 Mg Tablets (safinamide Mesilate)INn Japan from Meiji Seika Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Receives US NIH\/NIAID Contract to Develop Enterovirus D68 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Inactivated EV D68 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Biotech Prelude Guns for $100 M IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"PRT543","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astex Pharmaceuticals and MD Anderson Collaborate to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Astex","highestDevelopmentStatusID":"1","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Biopharma","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta\u00ae (voxelotor) in Six Middle Eastern Countries","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biopharma \/ Global Blood Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biopharma .."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inversago Pharma Closes US$35 M Series B Financing Round and Expands Board of Directors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"$10.0 million","newsHeadline":"Redx Announces New Research Collaboration with Jazz Pharmaceuticals to Discover and Develop Two Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Redx Pharma","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galmed and Ascletis Subsidiary Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Aramchol","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Galmed","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Exscientia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huadong Medicine and Exscientia Enter Co-Development Partnership to Accelerate Oncology Drug Discovery Through Artificial Intelligence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Hangzhou Z.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and Biontech to Potentially Supply the EU with 200 Million Doses of mRNA-Based Vaccine Candidate Against SARS-Cov-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ European Union","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnGes Anoounces Collaboration Agreement with Brickell Biotech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Brickell Biotech","highestDevelopmentStatusID":"7","companyTruncated":"AnGes \/ Br.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"HM Capital","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Onco Immune, Inc. Raises $56 Million Series B Financing for Novel Cancerandd Covid-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"MK-7110","moa":"CD24","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ HM Capital","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to Purchase Agreement with Oasis Capital, LLC","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Bioclinica","sponsor":"Direct Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioclinica Partners with Direct Biologics to Provide Interactive Response Technology (IRT) Solution for COVID-19 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bioclinica","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioclinica \/ Direct Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Bioclinica.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"$7.0 million","newsHeadline":"Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$21,000.0 million","upfrontCash":"$15,000.0 million","newsHeadline":"Gilead Sciences to Acquire Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":21,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":21,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Valneva","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord Healthcare Enters Exclusive Distribution Agreement with Molteni Farmaceutici for First Buprenorphine Implant Approved in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Myotonic Dystrophy Clinical Research Network","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AOC 1001","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai and Takeda Ink Clinical Collaboration for Global Phase III Studies for the Combination Therapy with Multiple Tumor Types in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CMAB Biopharma Inc","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Afuresertib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CMAB Biopharma Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CMAB Biopharma Inc \/ Laekna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CMAB Bioph.."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Wu Capital","pharmaFlowCategory":"D","amount":"$91.5 million","upfrontCash":"Undisclosed","newsHeadline":"Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"RNA editing therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Korro Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Korro Bio \/ Wu Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"Casma Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Casma Therapeutics Announces $50 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TRPML1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Casma Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Casma Therapeutics \/ The Column Group","highestDevelopmentStatusID":"4","companyTruncated":"Casma Ther.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"CAP ALTER PHARMA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapidly","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ CAP ALTER PHARMA","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied Biology in Collaboration with Corpometria Institute to Launch ANDROCOV TRIAL for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BRAZIL","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"Steroid 5-alpha reductase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometri.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"National Institute of Allergy and Infectious Diseases.","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"HDT BIO Receives NIH Contract to Advance Novel RNA\/LION\u2122 COVID-19 Vaccine Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"HDT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ National Institute of Allergy and Infectious Diseases.","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoBrain Checkpoint Awarded Alzheimer\u2019s Association Grant to Support Phase II Trial Investigating Novel Immunotherapeutic Approach to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrai.."},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Bluestem Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"CSF-1","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Bluestem Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pha.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Biodesix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Regains Full Global Rights to Ficlatuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cetuximab","moa":"HGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aveo Oncology \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Anelixis Therapeutics","sponsor":"Novus Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novus Therapeutics Announces Acquisition of Anelixis Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"AT-1501","moa":"CD40","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anelixis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anelixis Therapeutics \/ Novus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Anelixis T.."},{"orgOrder":0,"company":"ABL Bio","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Announces a Global Strategic Partnership with ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ABL Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ABL Bio \/ .."},{"orgOrder":0,"company":"Attralus","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Attralus \/ venBio Partners","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Saptagir Laboratories","sponsor":"Jubilant Generics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saptagir Labs Signs Manufacturing Deal with Jubilant Generics for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Saptagir Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Saptagir Laboratories \/ Jubilant Generics","highestDevelopmentStatusID":"12","companyTruncated":"Saptagir L.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Partners with Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemorrhage","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Neogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Neo-Antigen TCR Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Neo-Antigen T Cell Receptor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Neogene \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$4,200.0 million","upfrontCash":"$600.0 million","newsHeadline":"Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":4.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":4.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics and Janssen to Evaluate Nirogacestat in Combination with Teclistamab for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Escape Bio","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Escape Bio Closes $73 Million to Advance Clinical Development of Precision Neurology Medicines for Genetic Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"ESB1609","moa":"S1P5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Escape Bio","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Escape Bio \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurodegeneration Biotech Athira Pharma Sets Terms for $160 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.16,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.16,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Tracer","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tracer to Support Akston Biosciences\u2019 Phase 1 Clinical Study of AKS-452, an Innovative Anti-Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tracer","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tracer \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Tracer \/ A.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Nebraska Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNMC, COVAXX Sign Agreement Paving Way for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ University of Nebraska Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spy Biotech and Serum Institute of India Announce Dosed First Subjects in \nPhase I\/II Trial of a Novel Virus-Like Particle Vaccine Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Virus-like-particle vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Serum Institute of India","highestDevelopmentStatusID":"7","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 PTH and Hypoparathyroidism at ASBMR 2020 Virtual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Initiates Pilot Study with PMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PGI Rohtak to Start Phase-2 Trial of Bharat Biotech's COVAXIN","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Zion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zion Pharma Announces Initiation of Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-A-1041","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharm.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in China Enrolled in Clinical Phase 3 Study NefIgArd with Lead Candidate Nefecon","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement on Astra Zeneca Oxford SARS-CO V-2 Vaccine, AZD1222, Covid-19 Vaccine Trials Temporary Pause","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Refractory or Unexplained Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Submits Marketing Authorisation Application to the EMA for TransCon\u2122 hGH for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Humantakinogene hadenovec","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Launches Development of Drug-Free Nasal Spray for Protection Against Airborne Pathogens and Allergens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CIBMTR Completes Enrollment in Yescarta\u00ae Long-Term Post-Marketing Safety Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Center for International Blood and Marrow Transplant Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for International Blood and Marrow Transplant Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Center for.."},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipac Oncology Announces Completion of Phase 2a Clinical Trial of LiPainin Patients with Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"LIPAC Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Onco.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health: Enrollment Completed for Phase 3 wearABLe Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Trabsdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Publication of Independent Research on Kevetrin, the Company\u2019s p53 Drug Candidate, in Oncology Reports","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Kevetrin","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma\u2019s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics to Accelerate ARQ-151 into Phase 3 Trials for Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data in Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Athena Bioscience's New Drug Application (NDA) for QDOLO\u2122 (tramadol hydrochloride) Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Athena Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Athena Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Bio.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 to Advance in Oncology and Rare Disease Indications","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces U.S. Commercial Launch of Phexxi\u2122, the First and Only Non-Hormonal, Prescription Contraceptive Vaginal Gel","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Announces Positive Results on CorVax\u2122 in In-Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CorVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Completes Enrollment in Rescue-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis with CNM-Au8","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces Topline Results from its Phase 3 ADAPT-PO Trial of Tebipenem HBr in Complicated UTI and Acute Pyelonephritis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Showcase New Data from Evolving Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Regorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences Announces FDA Clearance of its IND for CB-010","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Initiates Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From a Phase 1 Trial With Transgene\u2019s Oncolytic Virus TG6002","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271 to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA2271","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in Phase 1\/2 Triple Combination Study\nof COM701 with Bristol Myers Squibb\u2019s Opdivo\u00ae and Anti-TIGIT\nAntibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Announces Positive Data from Analysis of Trial in COPD Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science to Present Results from Its AB07015 Study in Severe Asthma at the Annual European Respiratory Society International Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune Regulation Ltd Receives Notice of Allowance for New U.S. Patent for Its Novel Protein \"1805\" with Anti-Inflammatory Properties","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IRL201805","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Gets Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin for Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces Resubmission of Biologics License Application to USFDA for Ryplazim\u00ae (plasminogen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India to Halt Trial of the Astrazeneca Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Fast Track Designation from USFDA for PBCAR269A for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMPIO Reports Positive Results For Ampion Treatment in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Regenxbio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical\u2019s Licensing Partner REGENXBIO Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector\u00ae for Suprachoroidal Delivery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ REGENXBIO","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Initiate Phase 1\/2 Clinical Trial of Covid-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Orphan Drug Designation by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GLR2007","moa":"CDK-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart\u2019s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMRYT Announces Positive Top Line Results from Pivotal Phase 3 \"ease\" Trial of Filsuvez\u00ae in Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Expands Its M.S Portfolio with Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenebrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Trials of Sinovac Covid-19 Vaccine Show Promising Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose\n(SLS-005)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Provides Update on IMA204 ACTengine\u00ae Cell Therapy Program Targeting the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA204","moa":"COL6A3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dosing Underway for Diffusion Pharma's Lead Asset in Early-Stage COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial of FINTEPLA\u00ae in Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Oral Zavegepant Receives Authorization to Proceed from FDA and Achieves First in Human Dosing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces NMPA Approval of ZEJULA\u00ae for First-Line Maintenance Treatment of Ovarian Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Completion of ANAVEX\u00ae2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum DIsorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Fasenra Met Both Co-Primary Endpoints of Reduced Nasal Polyp Size and Blockage in the Ostro Phase III Trial","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Positive Final Results from Phase 1\/2a Study of BIVV001 in People with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rFVIIIFc-VWF-XTEN","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s ENSPRYNG (satralizumab) Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS\u2019 Multidisciplinary NET Medical Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tidutamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Data for NUBEQA\u00ae Plus Androgen Deprivation Therapy for Men with Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Propose Expansion of Pivotal Covid-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Receives UK MHRA Approval to Resume Covid-19 Vaccine AZD1222 Clinical Trials in UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Dupixent\u00ae (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis By FDA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck (Finally) Starts a Clinical Trial of its Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"V591","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio to Announce Topline Results from Phase 1b\/2a Study of BIO89-100 in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Presents Phase 2B\/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Showcases Commitment to Patient-Centric Advances in Oncology with Record Number of Abstracts to Be Presented at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Dosed First Patient in Phase 3 Clinical Trial of Dextenza\u00ae for Post-Surgical Ocular Inflammation and Pain in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I\/IIa EVICTION Trial for ICT01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ICT01","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NaQuinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medi.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen To Present New Insights at ASBMR For Potential Treatment of Ultra-Rare Disease Fibrodysplasia Ossificans Progressiva, Including Global Phase III MOVE Trial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces First Patient Dosed in Phase I\/II Trial of Bicycle\u00ae Toxin Conjugate BT8009 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BT8009","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich Biosciences to Present Safety and Efficacy Data of Nabiximols in MS-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Greenwich Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Announces FDA Acceptance for Filing of NDA for Epsolay\u00ae for the Treatment of Inflammatory Lesions of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbor Presents Data from Pivotal Study of AR19 to Resist Physical Manipulation form Nonmedical Misuse or Abuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Phar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Activ Initiative Launches Adaptive Clinical Trials of Blood-Clotting Treatments for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"NaviFUS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaviFUS Launches Clinical Trial of a Combination FUS-Bevacizumab Therapy in rGBM Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces that BioComo\u2019s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Phase 3 Study for TRIKAFTA\u00ae in Children Ages 6-11 Years With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Advances Novel Bi-specific TRAILR2\/CDH17 Antibody to Phase 1 Clinical Trial for Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 905711","moa":"TRAILR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Receives Fast Track Designation for TERN-201 as a Treatment for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's REYVOW\u2122 (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Application Seeking USFDA Approval of DARZALEX FASPRO\u2122 for the Treatment of Patients with Light Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS\u00ae in Patients with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term 3 Year Data on an Investigational Gene Therapy for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurocrine Biosciences \/ Voyager Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Positive Results of Phase 1a Study of ATA188 in MS Patients with Sustained Disability","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Prevention Pharmaceuticals Publishes Landmark Phase 3 Clinical Trial Data for Treatment of Familial Adenomatous Polyposis in NEJM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at ASBMR 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-012","moa":"ACVR2A","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Its First Complex Injectable Approval from USFDA for Doxorubicin Hydrochloride Liposome Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liposomal Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LB Pharmaceuticals Inc Announces Results of LB-102 Phase 1 First-in-Human Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI\u2019s Platform-Derived Hypothesis For COVID-19 Treatment Validated In US NIAID Randomised Control Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunity Pharma Announces Promising Interim Results of its Phase 1\/2a Study with IPL344 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IPL344","moa":"Akt signaling pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity P.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase IIb Topline Results Demonstrate a Significant Treatment Effect of Diamyd\u00ae in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Once Daily Dosing Option for NITYR (nitisinone) Tablets for HT-1 Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitisinone","moa":"HPDD","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's Phase II Trial Results Demonstrated Improvement in Cognition with BI 425809 in Adult Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 425809","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indoco Receives USFDA Approval for Apixaban Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Rem.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Positive Topline Results from the First Phase III Trial of Beovu\u00ae Vs Aflibercept in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Angiopoietin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA\u00ae in Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Announces Registration of HONEDRA\u00ae Trademark and New Patent in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS12","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Transfusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinuvel Progresses Innovative DNA Repair Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Clinuvel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Clinuvel P.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual SRNT-E Virtual Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes in Usage or Dosage for Anticoagulant Edoxaban","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's ILB\u00ae Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextrans","moa":"MMP","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recovery Covid-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identified GC376 and Boceprevir Can Inhibit SARS-Co V-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Boceprevir","moa":"HCV proteases\/NS3-4A serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chinese Academy of Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chinese Academy of Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chinese Ac.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Plans to Initiate a Phase 2 Clinical Trial with Rabeximod in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Descartes 30","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Nanobody that May Prevent Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ty1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Karolinska Institutet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Institutet \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Experimental Covid-19 Vaccine Prevents Severe Disease in Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VSV-SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$239.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Pharmaceuticals Raises $239 Million And Partners With Bayer","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"REC-994","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0.23999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Latest Clinical Research Evaluating VASCEPA\u00ae in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Announces Start of Trial to Evaluate the New Esprit\u2122 BTK Drug-Eluting Resorbable Scaffold","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck\u2019s Commitment to Advancing Cancer Research and Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive MS at MSVirtual2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Dosed First Patient in Oxurion\u2019s Phase II Trial Using a Novel Bicycle\u00ae-based Plasma Kallikrein Inhibitor for DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Further Positive Data on ALS-4 Against MRSA Wound Infection and MRSA Bacteraemia Against Linezolid and Vancomycin Respectively in In Vivo Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Enrolls First Patient in COVA, Phase 2\/3 Clinical Trial with Sarconeos for the Treatment of COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Ponce De Leon Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Reveals Longevity Benefits of Calcium Alpha-Ketoglutarate in Scientific Journal Cell Metabolism","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Alpha-Ketoglutarate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ponce De Leon Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ponce De Leon Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ponce De L.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Initiates Rolling Submission of an NDA for Maralixibat for Cholestatic Pruritus in Patients with Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chong Kun Dang Proceeds to Phase 2 Trial in Russia to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Research UK and AstraZeneca\u2019s New Antibody Maturation Technique Yields High-Affinity Arginase 2 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"C0021158","moa":"Arginase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition I Limited","pharmaFlowCategory":"D","amount":"$542.5 million","upfrontCash":"$25.0 million","newsHeadline":"Clene Nanomedicine, Inc. to Go Public Through Merger with Tottenham Acquisition I Limited","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.54000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.54000000000000004,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition I Limited","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanford Health Is First in Nation to Dose Patient with Promising Novel Therapeutic Candidate for Covid-19, SAB-185","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science New Independent Research Reveals that Masitinib Has Direct Anti-Viral Activity Against the SARS-CoV-2 Virus in Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen to Discontinue Pimodivir Influenza Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimodivir","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"University of Chicago Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U Chicago Medicine Begins Clinical Trial Testing the Efficacy of Antibody Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Chicago Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Chicago Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janone Confirms Stability Data of JAN101 Development Batch and Prepares for Commercial GMP Production to Support the Upcoming Pad and Potential Covid-19 Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$146.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Plasma-based therapies","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Alkahest","amount2":0.14999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Alkahest \/ Grifols","highestDevelopmentStatusID":"2","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus Under New Partnership with the University of Adelaide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Transcutaneous","sponsorNew":"University of Adelaide \/ Enesi Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"$232.0 million","upfrontCash":"$20.0 million","newsHeadline":"Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Ovid Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Taw Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ema Begins Review of Taw Pharma's Dexamethasone Taw for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Taw Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taw Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Taw Pharma.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Commences Patient Dosing in Relief-DPN-1 Phase 2 Clinical Study of LX9211 for Diabetic Peripheral Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Discontinues Development of BI 467335 for Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 1467335","moa":"AOC3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 phase III IRIDIUM study shows high-dose once-daily Enerzair Breezhaler reduces severe asthma exacerbation rates","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Tolimidone","moa":"Lyn kinase","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pha.."},{"orgOrder":0,"company":"Viralgen","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viralgen \/ Axovant Gene Therapie","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/.."},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Croma Establishes New Joint Venture in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Croma-Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Croma-Pharma \/ China National Biotech Group","highestDevelopmentStatusID":"12","companyTruncated":"Croma-Phar.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"International Pharmaceutical Development Consortium to Partner With PharmaJet for Delivery of COVID-19 DNA Vaccine, GX-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Pascal Biosciences","sponsor":"SORSE Technology","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Biotech Company Pascal Biosciences and SORSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-based therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pascal Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pascal Biosciences \/ SORSE Technology","highestDevelopmentStatusID":"6","companyTruncated":"Pascal Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"8","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"BioNTech","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","amount":"$438.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech to Receive up to \u20ac375M in Funding from German Federal Ministry of Education and Research to Support BNT162","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0.44,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.44,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and Dr. Reddy\u2019s to Cooperate on Clinical Trials and Supply of 100 million Doses of Sputnik V Vaccine to India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Direct Investment Fund \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"BB Pureos Bioventures","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of $64 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"ICT01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ BB Pureos Bioventures","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Systems Oncology","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$370.0 million","upfrontCash":"$25.0 million","newsHeadline":"Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ErSO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Systems Oncology","amount2":0.37,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Systems Oncology \/ Bayer Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Systems On.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CART Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AMP-CD19","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Novo Ventures","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Novo Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Japanese Government","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Japan Commits $165 Million to WHO's Global Coronavirus Vaccine Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"World Health Organization \/ Japanese Government","highestDevelopmentStatusID":"1","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$25.0 million","newsHeadline":"Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$455.0 million","upfrontCash":"$75.0 million","newsHeadline":"Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"LNP based mRNA Therapeutics","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Vertex","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"$69.2 million","upfrontCash":"$5.2 million","newsHeadline":"Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"WJ1075","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wigen Biomedicine Technology","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Wigen Biomedicine Technology \/ Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Wigen Biom.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Corza","pharmaFlowCategory":"D","amount":"$427.0 million","upfrontCash":"427.0 million","newsHeadline":"Takeda to Divest TachoSil\u00ae to Corza Health for \u20ac350 Million","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Human Fibrinogen","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.42999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Corza","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$562.0 million","upfrontCash":"$562.0 million","newsHeadline":"Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.56000000000000005,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ National Institute of Health","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Children\u2019s Oncology Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Collaboration with Children\u2019s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Children\u2019s Oncology Group","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Dogma Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Acquires Dogma Therapeutics\u2019 PCSK9 Inhibitor Programme","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dogma Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dogma Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Dogma Ther.."},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"$27.0 million","newsHeadline":"Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RZL 012","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Fosun Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Raziel The.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI1701963","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"BI 1701963","moa":"SOS1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Canaan Partners","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"STK-012","moa":"Interleukin-2 partial","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Synthekine \/ Canaan Partners","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Proniras","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Tezampanel","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Proniras","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Proniras \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"1","companyTruncated":"Proniras \/.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Graphite Bio Launches with $45 Million Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Graphite Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech to Acquire GMP Manufacturing Site of Novartis to Expand COVID-19 Vaccine Production Capacity in First Half 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"LY-CoV-555","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Servier Expand CART Oncology Development Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"CAR T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Huntington Study Group","sponsor":"Prilenia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huntington Study Group Announces a Partnership with Prilenia Therapeutics to Conduct a Global Phase 3 Clinical Study of Pridopidine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Huntington Study Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Huntington Study Group \/ Prilenia Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Huntington.."},{"orgOrder":0,"company":"Humanigen","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol \u201cHGEN\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"XW10172","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"XWPharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"XWPharma \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"XWPharma \/.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne\u00aeCDx and FoundationOne\u00aeLiquid CDx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Adimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan\u2019s Leading Covid-19 Vaccine Produced by Adimmune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eden Biologics \/ Adimmune","highestDevelopmentStatusID":"1","companyTruncated":"Eden Biolo.."},{"orgOrder":0,"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Will Provide Up To 300 Million Doses of COVID-19 Vaccine to the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ European Union","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ E.."},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes a Deal with Teva to Market Teriparatide","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"Valneva","sponsor":"U.K. Government","pharmaFlowCategory":"D","amount":"$1,611.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":1.6100000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.6100000000000001,"dosageForm":"","sponsorNew":"Valneva \/ U.K. Government","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"List Biological Laboratories","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"AP-003","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"List Biological Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"List Biological Laboratories \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"List Biolo.."},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australia Invests $6M in New COVID-19 Vaccine Projects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Melbourne","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Melbourne \/ Medical Research Future Fund","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Inflazome","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$441.9 million","newsHeadline":"Inflazome Announces its Acquisition by Roche","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Inzomelid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Roche","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$10.0 million","newsHeadline":"Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Op.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$42.2 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"VBI-2900","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$53.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immune Regulation Limited raises \u00a340.6 million \/ $53.4 million Series B Equity Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"IRL201805","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Revolo Biotherapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Novellus","sponsor":"Pontifax","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novellus Closes $57M Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novellus","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Novellus \/ Pontifax","highestDevelopmentStatusID":"7","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bristol Myers Squibb Completes Acquisition of Forbius","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ .."},{"orgOrder":0,"company":"City of Hope","sponsor":"Chimeric","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CART Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CLTX-CAR T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Chimeric","highestDevelopmentStatusID":"6","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Announces Strategic Plan to Divest its Legacy Businesses","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ U.."},{"orgOrder":0,"company":"Enzolytics","sponsor":"BioClonetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Merger","leadProduct":"Anti-HIV recombinant monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enzolytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzolytics \/ BioClonetics","highestDevelopmentStatusID":"1","companyTruncated":"Enzolytics.."},{"orgOrder":0,"company":"Histogen","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"HST-003","moa":"Hyaline cartilage","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0.38,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Bio.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J Unit to Start Mid-Stage Covid-19 Vaccine Trials in Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Vector virology institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Completes Early Trials of Second Potential Covid-19 Vaccine - IFAX","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EpiVacCorona","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vector virology institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vector virology institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vector vir.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ\u00ae Gene Therapy for Leber Hereditary Optic Neuropathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CRV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vac.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology to Present Futibatinib (TAS-120) Data in Advanced Intrahepatic Cholangiocarcinoma at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces AB-729 90 mg Single-Dose in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME\u2019s Phase II Prostate Cancer Study of SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in Investigational New Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Bristol Myers Squibb\u2019s Type II Variation Application for Opdivo Plus Yervoy for First-line Treatment of Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Magrolimab Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces FDA Acceptance for Filing of its NDA of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Filovirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto\u2019s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for BPX-01 and BPX-04","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Investor Day Features Significant Number of Pipeline Advances for Covid-19 Programs and Across Numerous Therapeutic Areas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-07304814","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to Jardiance\u00ae (empagliflozin) to Improve Outcomes following a Heart Attack","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial Tests Common Diabetes Drug to Enhance Brain Function in Childhood Brain Cancer Survivors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian C.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Receives Fast Track Designation from FDA for Its Novel Glioblastoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Approves Label Update for HYQVIA\u00ae Expanding its Use to a Broader Group of Patients with Secondary Immunodeficiencies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Corino Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corino Therapeutics Announces Presentation of New Clinical Research Finding at the XVII International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolcapone","moa":"COMT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Corino Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corino Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corino The.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Launches Novel Antibiotic Fetcroja in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Begins Patient Dosing in Phase 2 Study of Patritumab Deruxtecan to Treat Advanced\/Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Gets DCGI Nod to Resume Clinical Trial of Oxford AstraZeneca COVID-19 Vaccine Candidate in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Arimoclomol for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Proof of Concept Data for Neutralizing Antibody LY-CoV555 in the COVID-19 Outpatient Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Announce Data from Preclinical Studies of mRNA-Based Vaccine Candidate Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Institute of Cancer Research's Test if Combining Two Precision Medicines Can Treat Drug-Resistant Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Granted Pediatric Disease Designation for OXi-4503","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Trials Evaluating ARQ-151 as a Treatment for Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Theris Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theris Medical Launches Patient Enrollment for \u201cOrphan Drug\u201d Clinical Trial to Help African-Americans Suffering from Sickle Cell Ulcers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deferoxamine Mesylate","moa":"Fe","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Theris Medical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Theris Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theris Med.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication of Results of Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipapkinogen sovacivec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Merck KGaA","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle AVM Biotechnology Announces Second IND for AVM0703","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Genelux","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant\/Refractory Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Genelux \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Highlights Start of Recruitment Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of Multinational 2b\/3 Human Study of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Unveils Clinical Follow-Up Results of 'Abincio'","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Presentation of Updated Phase 1\/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IO-202","moa":"LILRB4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Presents Promising Interim Results from Ongoing Phase 1b\/2 Trial of Cavrotolimod at Virtual KOL Event Today","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma\u2019s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pitt Scientists Discover Tiny Antibody Component That is Highly Effective in Preventing and Treating SARS-CoV-2 Infection in Animal Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ab8","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PBFT02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals launches HEPCLUDEX\u00ae in Germany, France and Austria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bulevirtide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MYR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Support Strong Clinical Profile of Vitrakvi\u00ae for Adult and Pediatric Patients with TRK Fusion Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Larotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin\u00ae at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Presents Clinical Data From Phase 1\/2 NOX-A12 \/ Keytruda\u00ae Combination Trial in Colorectal and Pancreatic Cancer at the ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Presents Data from Rebastinib at the European Society for Medical Oncology (ESMO) Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rebastinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Presents Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent and Trademark Office Allows Reven\u2019s Patent Application to Issue as a New Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Recruitment Starts for the International PRO-SID study Evaluating Panzyga\u00ae for Primary Prophylaxis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Immune globulin, human - ifas","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1\/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX\u00ae (furosemide) for subcutaneous administration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb\u2019s Yervoy\u00ae in a Phase 2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Virometix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"V-306","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virometix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virometix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Virometix .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives Korean MFDS Approval to Initiate Phase II\/III Pivotal Trial of CT-P59","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CLN-081","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Begins Patient Dosing in Europe for Phase I\/II DIAMOND-01 Trial of SEL24\/MEN1703 to Treat AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini Group","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 Neutralizing Antibody in COVID-19 Positive Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brainstorm Announces Grant of a New Japanese Patent for NurOwn\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories Launches Over-the-Counter Eye Allergy Drop, the Store-Brand\nEquivalent of Pataday\u00ae, in US","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna to Seek Limited Emergency Use of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces NIH\/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac\u2019s Coronavac\u2122, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I\/II Clinical Trial in Adolescents and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray for COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"GreenLight Clinical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ GreenLight Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Sweden","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210\/TJ210 in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1611","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AMTX-100","moa":"SRTFs","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx The.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the ERS International Congress 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the AAN Science Committee as Featured Presentation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Cebina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEBINA Reports Positive Findings on the Potency of Azelastine, a Widely Used Anti-Histamine, as Anti-Covid-19 Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Azelastine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cebina","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cebina \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cebina \/ N.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces the FDA Clearance of Investigational New Drug Application for ALVR109 for the Treatment of High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Presents Data Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Presents Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity for Resistant EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-945","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EP-7041","moa":"Factor XIa","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera P.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze\u00ae In Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Presents 2-Year Landmark Data from Combination Therapy Trial of PV-10\u00ae and KEYTRUDA\u00ae for Checkpoint-Na\u00efve Advanced Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Efficacy and Safety Results of its CLEPSIDRA Trial with Iadademstat in ED-SCLC Patients at ESMO-2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at European Association for the Study of Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At AHA Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Presents Additional Data on AUTO3 in DLBCL During the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen's Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline\u00ae Autogel\u00ae Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 months","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Shows Interim Results from Registration-Enabling Trial of Cosibelimab in Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Pivotal Data for Libtayo\u00ae (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CEL-4000","moa":"Il-17 alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi's Orfadin\u00ae (nitisinone) Receives Positive Opinion from CHMP for Treatment of AKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitisinone","moa":"HPDD","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"MEDIMETRIKS PHARMS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medimetriks' MM36 (difamilast) Atopic Dermatitis Development Program Streamlined Following FDA Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"MEDIMETRIKS PHARMS","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"MEDIMETRIKS PHARMS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"MEDIMETRIK.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Presents Results in HER2 Exon 20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Results from Evaluation of Cytisinicline Vs Chantix\u00ae in 5-HT3 Receptor Binding Assay Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Merck KGaA","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Oncologie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bavituximab","moa":"Phosphatidylserine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to Junshi\u2019s Toripalimab to Treat Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Receives CHMP Positive Opinion Recommending Approval of Zejula (niraparib) as First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Presents Data from QINLOCK Program in Patients with Gastrointestinal Stromal Tumor at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Reports Early Data from Phase 1\/2 Clinical Trial of SNS-301 Pembrolizumab Combo in Advanced Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for Recurrent\/Metastatic Adenoid Cystic Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent\/Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Improving Results from INSIGHT-004 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Data on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Plus Yervoy Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab for the Treatment of Advanced Squamous Cell Carcinoma of Anal Canal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives Positive CHMP Opinion for Tecentriq in Combination with Avastin for the Treatment of Most Common form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven\u00ae at Esmo Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eribulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedic's Trodelvy\u2122 Encouraging Early-Stage Clinical Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira Receives Positive CHMP Opinion for EXPAREL\u00ae for Postsurgical Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Highlight Therapeutics Announces Second Collaboration with MSD to Evaluate Combination of BO-112 and Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"BO-112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ Highlight Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1,030.0 million","upfrontCash":"$30.0 million","newsHeadline":"Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Recursion Pharma","amount2":1.03,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"VLA2001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"SanBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SanBio Announces Additional Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SB623","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SanBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ N.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Government of Australia","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australia Secures Onshore Manufacturing Deal for Two Covid-19 Vaccines Developed By Oxford\/AstraZeneca and University of Queensland\/CSL","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":1.7,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.7,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Government of Australia","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exosome Biotech Codiak Bio Sciences Refiles for a $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"exoSTING","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino Phase 3 Covid-19 Vaccine Trialinn Pakistan Expected to Begin This Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Abigail Wexner Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FDA Approves Abigail Wexner Research Institute's IND for A Covid-19 Clinical Trial with Off-the-Shelf K-NK Cells Using Kiadis\u2019 Platforms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"K-NK-cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Abigail Wexner Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abigail Wexner Research Institute \/ Kiadis","highestDevelopmentStatusID":"5","companyTruncated":"Abigail We.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Approves Safety Label Update for Novartis Beovu\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Show Early Treatment with Mayzent\u00ae Show Benefits in Cognitive Performance in Patients with Secondary Progressive MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Siponimod fumarate","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Janssen Pharmaceutical's TREMFYA\u00ae, a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"National Institute of Immunology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NII\u2019s Covid-19 Vaccine Candidate Exhibits Positive Results in Immunogenicity Study on Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Immunology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Immunology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Foscarbidopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx\u00ae Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO\u2122 for Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"Taurus Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Ligand Expands Omniab\u00ae Antibody Discovery Platform Through the Acquisitions of Taurus Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Taurus Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Taurus Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Taurus Bio.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Achieved with Ziritaxestat in Novesa Trial in Systemic Sclerosis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Xcella Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Expands Omni AB\u00ae Antibody Discovery Platform Through the Acquisitions of XCella Biosciences and Taurus Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcella Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Xcella Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Xcella Bio.."},{"orgOrder":0,"company":"Valneva","sponsor":"US Government","pharmaFlowCategory":"D","amount":"$166.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces New Ixiaro\u00ae Supply Contract with the US Government Worth up to $166 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Inactivated aluminum-adjuvanted JE vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ US Government","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at 2020 ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","amount":"$77.5 million","upfrontCash":"Undisclosed","newsHeadline":"Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1\/1b Clinical Trial Of EP547","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"EP547","moa":"MRGPRX4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Sanofi Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SPARC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SPARC \/ Tripoint Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"SPARC \/ Tr.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OnKure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Binimetinib","moa":"Class I HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ OnKure","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"T-knife","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"T-cell receptor-based cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"T-knife","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"T-knife \/ Catalent","highestDevelopmentStatusID":"1","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Precision Oncology Biotech PMV Pharmaceuticals Sets Terms for $125 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"PC14586","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Goldman Sachs","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$766.4 million","upfrontCash":"Undisclosed","newsHeadline":"Zai Lab Announces Pricing of Hong Kong Secondary Listing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0.77000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.77000000000000002,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ J.P. Morgan Securities","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Impilo Therapeutics","sponsor":"Cend Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cend Therapeutics Announces Acquisition of Impilo Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Impilo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Impilo Therapeutics \/ Cend Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Impilo The.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stevanato Group And Bexson Biomedical Announce Collaboration To Develop A Customized Wearable Ketamine Delivery Device","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Stevanato Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stevanato Group \/ Bexson Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Stevanato .."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"$150.0 million","newsHeadline":"MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.90000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Expands Partnership with Samsung Biologics for PMC-403","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100\u2122 and Selection of Commercial Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and SpringWorks Therapeutics Collaborate to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpringWorks Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Canadian Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Canadian Government","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"SymBio Pharmaceuticals","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"$12.5 million","newsHeadline":"Eagle Pharmaceuticals\u2019 Licensing Partner, SymBio, Gets Approval of TREAKISYM Ready-To-Dilute Formulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"U.S. Army","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Awarded U.S. Army Contract for DSUVIA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ U.S. Army","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Beyond Celiac","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beyond Celiac Partners with Provention Bio on Phase 2 Clinical Trial for Promising Celiac Disease Therapeutic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Beyond Celiac","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beyond Celiac \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Cel.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech Inks Licensing Deal with Washington University School of Medicine to advance COVID-19 Intranasal Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Covid 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Washington University School of Medicine \/ Bharat Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Freeline Announces Supply Agreement for Haemophilia B Program With Thermo Fisher Scientific","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Freeline Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thermo Fisher Scientific \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Announces Inks Pact with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fox Chase Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fox Chase Cancer Center \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Fox Chase .."},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta The.."},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nutcracker Therapeutics Radies $60M Series B Financing for an mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"mRNA therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Nutcracker Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vivet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet\u2019s Investigational Gene Therapy for Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"VTX-801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Vivet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0.20000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IAG, Image Analysis Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IAG, Image Analysis Group \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"IAG, Image.."},{"orgOrder":0,"company":"Sixfold Bioscience","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sixfold Bioscience and Medicines Discovery Catapult Awarded Innovate Uk Grant to Pursue Ground-Breaking Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sixfold Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sixfold Bioscience \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Sixfold Bi.."},{"orgOrder":0,"company":"Hovione","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury\u00ae for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Modified Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hovione","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hovione \/ Ligand","highestDevelopmentStatusID":"12","companyTruncated":"Hovione \/ .."},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immetas Therapeutics Announces Series A Financing for its Research on Inflammation Pathways in Aging and Develop Anti-Inflammatory Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Bi-specific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Immetas Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Th.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"oHSV-1","moa":"IL 12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"InSysBio","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InSys Bio Announces Its Collaboration with Genmab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"GEN1042","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InSysBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InSysBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"InSysBio \/.."},{"orgOrder":0,"company":"KYAN Therapeutics","sponsor":"Georgetown University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KYAN-001","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KYAN Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KYAN Therapeutics \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"KYAN Thera.."},{"orgOrder":0,"company":"Libra Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"Libra Therapeutics Launches with $29 Million Series A to Develop Novel Therapeutics for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Libra Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Libra Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"2","companyTruncated":"Libra Ther.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kanaph Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"KNP-301","moa":"C3b","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Biologics \/ Kanaph Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"UMass Medical School","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UMass Medical School and Johns Hopkins Team up For COVID Plasma Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Anti- SARS-CoV-2 Plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"UMass Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UMass Medical School \/ Johns Hopkins University","highestDevelopmentStatusID":"8","companyTruncated":"UMass Medi.."},{"orgOrder":0,"company":"GSK","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Sign Agreements with the Government of Canada to Supply up To 72 Million Doses of Adjuvanted Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Government of Canada","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Gove.."},{"orgOrder":0,"company":"BioVie","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioVie Announces Closing of Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"Continuous Infusion","sponsorNew":"BioVie \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ T.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira Funds","pharmaFlowCategory":"D","amount":"$1,880.0 million","upfrontCash":"Undisclosed","newsHeadline":"Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neuraxpharm","amount2":1.8799999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8799999999999999,"dosageForm":"Oral prefilled syringe","sponsorNew":"Neuraxpharm \/ Permira Funds","highestDevelopmentStatusID":"12","companyTruncated":"Neuraxphar.."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas, University of Pittsburgh Enter Research Collaboration for Dry Age-Related Macular Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA and Pfizer Expand Clinical Trial Collaboration to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Darovasertib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ IDEAYA Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"USAMRDC","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Awarded Federal Grant to Rapidly Develop Nanobody-based Covid-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Camelid antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lumen Bioscience \/ USAMRDC","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Jupiter Orphan Announces Federal Grant to ADVANCE JOTROL\u2122 to Phase I Clinical Trial for Alzheimer's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Or.."},{"orgOrder":0,"company":"AbCellera","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IgM antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ IGM Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opthea Files for a $150 Million US IPO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ U.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Sets Terms for $30 million IPO","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GRAM Partners with Johnson & Johnson on Manufacturing in Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grand River Aseptic Manufacturing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grand River Aseptic Manufacturing \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Grand Rive.."},{"orgOrder":0,"company":"Galecto","sponsor":"Soleus Capital","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Portfolio Company Galecto Raises USD 64 Million to Accelerate Development of Clinical Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"LB Pharmaceuticals Inc Secures $10.0 Million in Additional Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"N-methyl amisulpride","moa":"Dopamine","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics preparing $100M IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"MyoKardia","pharmaFlowCategory":"D","amount":"$465.0 million","upfrontCash":"$12.5 million","newsHeadline":"MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fulcrum Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Fulcrum Therapeutics \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MyoKardia Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Opdivo\u00ae and CABOMETYX\u00ae Combo Shows Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Trial Data Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA\u00ae Plus LENVIMA\u00ae in Seven Different Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Abemaciclib Improves OS In Combination With Tamoxifen In HR-Positive, HER2-Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Reports No Improvement In Survival With Avelumab Added To CRT In Locally Advanced SCCHN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy\u2122 in Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisinopril","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pha.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MGD019","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Shanghai SIMR Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai SIMR Biotechnology's First Patient Successfully Dosed with the Candidate Drug SR419 for Peripheral Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SR419","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai SIMR Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Shanghai SIMR Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai S.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Release Biomarker Results of TYVYT\u00ae, ALIMTA\u00aeand Platinum Chemotherapy Combo as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Release Phase 3 Results of TYVYT\u00ae, GEMZAR\u00aeand Platinum Chemotherapy Combo as First-Line Treatment for Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algiax Pharmaceuticals Enrolles First Patient in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AP-325","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pha.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Submits BLA to the U.S FDA for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Opdivo Shows Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Lynparza Recommended for Approval in the EU by CHMP for Brca-Mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Metastatic Cervical Cancer at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ G.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae Doubled Five-Year Survival Rate Versus Chemotherapy in Some Patients With Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's ESMO Presentation Shows Libtayo\u00ae Monotherapy Increases Overall Survival in First-Line Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IH201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Highlights Stage IV M1C Patient Outcome from Combination Therapy Trial of PV-10\u00ae and KEYTRUDA\u00ae for Checkpoint-Na\u00efve Advanced Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Gets Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Beximco Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beximco Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beximco Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gene Signatures and Tumour Microenvironments were Identified that Associate with Nivolumab Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Calcilytix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calcilytix Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Calcilytix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calcilytix.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Reports Final OS Data from Phase 3 ClarIDHy Study of TIBSOVO\u00ae in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the at the EORTC-NCI-AACR Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin-Madison","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ University of Wisconsin-Madison","highestDevelopmentStatusID":"6","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H\/dMMR Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"HanX Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"ARK5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onconova Therapeutics \/ HanX Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CRN04777","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Announces Publication of Results from SJX-653 Proof-of-Mechanism Study in The Journal of Clinical Endocrinology & Metabolism","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics and BeiGene Dosed First Patient in Study of DKN-01 and Tislelizumab Combo for Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Provides Update on Progress on BLA for Ryplazim\u00ae(plasminogen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presents Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed\/Refractory Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TK216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Launches Two Digital Inhalers in the U.S., AirDuo\u00ae Digihaler\u00ae (fluticasone propionate and salmeterol) Inhalation Powder","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Pharma Speeds Up Developing Covid-19 Plasma Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyper-immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves INREBIC\u00ae (fedratinib), First New Treatment in Nearly a Decade for Patients Living with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fedratinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Butalbital, Acetaminophen, and Caffeine Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali Receives Highest Rating of any CDK4\/6 Inhibitor on the ESMO Magnitude of Clinical Benefit Scale","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo Sowed Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae Plus Chemotherapy Reduced Risk of Death by 27% as First-Line Treatment for Locally Advanced Esophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi\u00ae in NSCLC at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Micreos Initiates Clinical Trial to Evaluate World\u2019s First Endolysin-Drug as a Therapy for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"XZ.700","moa":"Cell wall","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Hu.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society of Medical Oncology Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG To Present Discovery\/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinoma Treated With BPM 31510-IV","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Phase III EMPACTA Study Showed Actemra Reduced Odds of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Astellas Announce PADCEV\u00ae (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ A.."},{"orgOrder":0,"company":"The Chumakov Federal Scientific Center","sponsor":"Vektor State Research Center of Virology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ministry of Health Allows Human Trials of Another Vaccine Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Whole-virion vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Chumakov Federal Scientific Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Chumakov Federal Scientific Center \/ Vektor State Research Center of Virology","highestDevelopmentStatusID":"1","companyTruncated":"The Chumak.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verzenio\u00ae Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and Bluebird Bio Gets U.S. FDA Priority for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ bluebird bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Afimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Epeleuton","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Afimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Erasmus University Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces 50% Enrollment in Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Biology and Corpometria Institute Receive National IRB Approval to Study a Potential Breakthrough Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXIM\u00ae Biotechnologies Gets Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SBI-183","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biote.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Aflibercept Injection (EyleaTM) for Intravitreal use Receives DCGI Approval for Diabetic Macular Edema Indication","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio\u2019s Lenti Globin\u2122 for Sickle Cell Disease Gene Therapy (bb1111) Granted PRIME Designation by European Medicines Agency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Approves RedHill Biopharma\u2019s Phase 2\/3 COVID-19 Study with Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Holds a Company Briefing on the Development of New Drug Candidates for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BBT-401","moa":"Pellino-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Rectal","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Gets CHMP Nod for MenQuadfi\u00ae for Active Immunization Against Invasive Meningococcal ACWY Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Meningococcal (Groups A, C, Y, W) Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Sanofi's Supemtek\u00ae for the Prevention of Influenza in Adults Aged 18 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Quadrivalent recombinant influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Presents Clinical Trial Data at The Retina Society 2020 and Reports XIPERE\u2122 Data in Diabetic Macular Edema in Ophthalmology Retina","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics and Vertex Pharmaceuticals' CTX001\u2122 Gets PRIME Designation Granted by the EMA for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271, Company Advances Second Cardiac Myosin Inhibitor","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3772271","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Receives Positive Opinion from EMA\u2019S CHMP on Use of Antiepileptic Agent Fycompa\u00ae in Pediatric Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Emmecell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EO2002","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Emmecell","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emmecell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Emmecell \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces First Patient Dosed in Phase 2a Trial of Sibofimloc in Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sibofimloc","moa":"E coli fimH protein blocker","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Supplemental New Drug Application for Pfizer\u2019s XALKORI\u00ae for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Crizotinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized in Sobi's Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm's Anti-Influenza drug Avigan\u00ae Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"Geneva Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geneva Biotech Announces SARS-CoV-2 Antiviral Pipeline Based on Ground-Breaking Discovery Published in Science Magazine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Geneva Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Geneva Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Geneva Bio.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Announces FDA Acceptance of Gen-011 IND Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals Gets Australian TGA Approval for Epidyolex for Seizures in Patients with Two Rare Forms of Childhood-Onset Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 in Patients with Myelodysplastic Syndromes\/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"JSP191","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MGA012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Publication of Flotetuzumab Interim Phase 1\/2 Clinical Trial Results in Blood","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Therapeutics\u2019 Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova's COVID-19 Vaccine Induces Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 Using BC-PIV Vector Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BC-PIV vaccine","moa":"SARS-CoV-2 S1 antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio's MB-207 Gets Orphan Drug Designation to Treat X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-207","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis to Present Significant Corporate and Clinical Development Progress at Upcoming Biotech and Ophthalmology Conferences","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Rutgers University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rutgers University's New Smart Drug Delivery System May Help Treatment for Neurological Disorders","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rutgers University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers Un.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Reports Positive Results of Phase 1B Trial of Resiniferatoxin Epidural in Cancer Patients with Intractable Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virginia Commonwealth University Study Shows the Experimental Drug AR-12 Could be a Promising COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-12","moa":"PDK-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virginia Commonwealth University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Virginia Commonwealth University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia C.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces the Launch of ILUMYA\u00ae (tildrakizumab) for Treatment of Plaque Psoriasis in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tildrakizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Switching to Novo Nordisk's Investigational Insulin Icodec Found to be Efficacious in People with Type 2 Diabetes in Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"TPG Capital IP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ellodi Pharmaceuticals \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Trulicity\u00ae, Now Indicated as an Adjunct to Diet, Exercise, and Standard of Care Therapy to Reduce Risk of Stroke in T2DM","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Top-Line Results of Phase 2 SIGNAL Study in Huntington\u2019s Disease Support Potential for Cognitive Benefit of Pepinemab","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSig Subsidiary ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Semorinemab","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"American CryoStem Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Cryo Stem Announces: FDA Has Cleared Its Investigational New Drug (IND) for Post-Concussion Syndrome for PhaseII Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"American CryoStem Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American CryoStem Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"American C.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Files Clinical Trial Notification for Phase 3 Trial of TransCon\u2122 hGH for Pediatric Growth Hormone Deficiency in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Durect Corporation Doses First Patient in Phase 2 Safety & Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Dermatology Publishes Results from Verrica\u2019s Two \n Pivotal Phase III CAMP (Cantharidin Application in Molluscum \n Patients) Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Launches First-in-human Clinical Trial for ONC-392","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Onc-392","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Successfully completes Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetravalent recombinant chimeric Dengue vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th EASD Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the \nWMS 2020 Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Achieves Important Regulatory Milestone for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada approves Merck\u2019s etanercept biosimilar for new indications","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Program To Investigate The Safety And Pharmacokinetics Of VALTOCO\u00ae (Diazepam Nasal Spray) In Children Aged 2 To 5","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Submits Request for Emergency Use Authorization for RLF-100\u2122 for Patients with Critical Covid-19 and Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Completes Dosing of First Cohort in Phase 1\/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Expands Clinical Trials to Test Convalescent Plasma Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Presents Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month \n Mercury 3 Clinical Trial in Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Starts KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Telaglenastat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from USFDA for Dimethyl Fumarate Delayed-Release Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 S-Trimer vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SPIRO-2101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spirovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant .."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenScript ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TAEST16001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ GenScript","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue L.."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo to Present Qwo\u2122 (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals Announces Publication of Clinical Data from the Phase I\/Ib study of Tenalisib in Patients with Relapsed\/Refractory T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenalisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Innova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innova Therapeutics Receives Rare Pediatric Disease Designation from the FDA for IVT-8086 for the Treatment of Osteosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IVT-8086","moa":"SFRP2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innova The.."},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MLE-301","moa":"NK3R","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo T.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the \n Journal Cell","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports High Response Rates with CAN04 Combination Therapy in Nsclc and Presents Next Development Steps","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharm Announces Positive High-Level Data from Investigator-Initiated Phase 2 Trial with Imlifidase to Treat Anti-GBM Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gavorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Grants Marketing Authorization for Gilead's Jyseleca\u00ae for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics to Present Data from its USP1 Inhibitor Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KSQ-4279","moa":"USP1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Promising Data of Apeiron's APN01 (rhsACE2) to Treat COVID-19 in Named Patient Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Alunacedase alfa","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer\u2019s Disease Has Exceeded Study Enrollment Target of 570 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ANK-700","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-GTX-501","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health & Menarini Group Provide Elacestrant Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini Group","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-504","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Grants Market Authorization to Polivy\u2122 (polatuzumab vedotin) for the Treatment of Adult Patients with Relapsed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Revises the Development Plan for Rabeximod","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"TNF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Begins Patient Dosing in PHEARLESS Phase 1\/2 Study of BMN 307 to Treat Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Posts Interim Results from Phase 1\/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Japanese Approval for Additional Indication of Tecentriq and Avastin to Treat Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Glaxosmithkline's Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant\u2122 (diazepam) Buccal Film for Management of Seizure Clusters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II\/III COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Kaken Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Kaken Pharmaceuticals \/ Brickell Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Kaken Phar.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pha.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Files For Expedited Review Of AD04 with The FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UniQure Gets Recommendations from Data Safety Monitoring Board of Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Stereotaxic Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab at 2020 CSCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's ENHERTU\u00ae Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ono Pharmaceutical's Opdivo and Yervoy Combination Therapy Approved in Japan to Expand Use for the Treatment of MSI-High Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"GlycoMimetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Expands ArtemiC\u2122 Phase II Clinical Trial on COVID-19 Patients in Israel and India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent's TYVYT\u00ae in Combination with BYVASDA\u00ae in ORIENT-32 Study Met Its Primary Endpoints","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OLX10010","moa":"CTGF","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Presents Data at NAMS Showing SJX-653 Exhibits Potent NK3 Antagonist Profile Across Nonclinical and Initial Clinical Studies in Men and Postmenopausal Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NYX-2925","moa":"NMDA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVISTAT, a Subsidiary of Ensysce Biosciences Is Commencing Phase 1 Study of Novel COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"TMPRSS2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals Presents Information on Edasalonexent at the Virtual 25th International Congress of the World Muscle Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Receives Orphan Drug Designation from the EMA for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Completes Final Patient Treatment in AUDREY Phase 2\/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves HAEGARDA\u00ae for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version of Biogen IDEC Inc.'s Tecfidera\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica's itMSC Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ischemic-tolerant mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemedica Cell Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Stemedica .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 \/ 3 Trial of COVID-19 Vaccine Candidate INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Receives Orphan Drug and Fast Track Designations from the U.S FDA for Elezanumab for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Elezanumab","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion; Intravenous","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda-1a","moa":"Type III IFN receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell\u2122 Universal Donor Stem Cell Therapy for Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Receives Clinical Trial Application Approval for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Presents Data from Intranasal COVID-19 Vaccine and Therapeutic Programs \u2013 AdCOVID\u2122 and T-COVID\u2122 at the World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of a Clinical Trial in Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SCO-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ena Respiratory Announces an Extension of its Series A and Positive COVID-19 Ferret Challenge Study Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"INNA-051","moa":"TLR2\/TLR6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics\u2019 Zynrelef Receives European Marketing Approval to Treat Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taro Pharmaceutical Launches Generic Deferiprone in U.S","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deferiprone","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharm.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Danicamtiv","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia's Mavacamten Treatment Significantly Reduced Biomarkers of Cardiac Injury In Hypertrophic Cardiomyopathy Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for 69th ACC Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Koligo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Koligo Therapeutics to Develop Personalized Cell Therapy for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-PC-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Koligo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Koligo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Koligo The.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MAN-19","moa":"Tie2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$757.2 million","upfrontCash":"$310.4 million","newsHeadline":"Divestment of Aspen\u2019s European Thrombosis Business to Mylan and Withdrawal of Cautionary","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.76000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.76000000000000001,"dosageForm":"","sponsorNew":"Aspen Pharmacare Holdings \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"PT00114","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Protagenic Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protagenic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Protagenic.."},{"orgOrder":0,"company":"Imunon","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imunon \/ Lincoln Park Capital","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ L.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Rituximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics's Study Results Show 79% of Patients Achieved Complete Response Using KRYSTEXXA\u00ae with Methotrexate","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"REMD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript Biotech Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ REMD","highestDevelopmentStatusID":"3","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Lonza Group","sponsor":"LamKap Bio Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"NILK-2301","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ LamKap Bio Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Panolos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"PB101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Panolos","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"University of Montana","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$33.4 million","upfrontCash":"Undisclosed","newsHeadline":"University of Montana Receives $33.4 million for Development and Clinical Trials of Opioid Vaccines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Opioid vaccines","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"University of Montana","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"University of Montana \/ National Institute of Health","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Sialidase-Fc","moa":"Sialoglycan","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Palleon Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palleon Pharmaceuticals \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Papyrus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"PYTX-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Papyrus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Reports Data From Study 211 Supporting 24 Mg As the Appropriate Starting Dose for Lenvima to treat Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Presents Data from Phase 1 Clinical Study of Dubermatinib in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"LiberaTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u200bSingapore Start-Up, LiberaTx, Plans Clinical Trial of a Single Daily Pill Replacing Multiple Pills for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"LiberaTx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LiberaTx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LiberaTx \/.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Announces Second Novel Drug Candidate from Its Multi-Target Drug Discovery Collaboration with Pfizer has Started Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":1.8899999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.8899999999999999,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","amount":"$83.7 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Issues Statement Regarding Orphazyme\u2019s Global Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ CytRx","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$144.0 million","upfrontCash":"$77.0 million","newsHeadline":"Locus Biosciences Signs Contract with BARDA to Advance $144 Million Precision Medicine Program to Develop LBP-EC01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Locus Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Out-Licensed Taigexyn\u00ae to Luminarie Canada for Canada, Australia and New Zealand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"TaiGen Biotechnology \/ Luminarie","highestDevelopmentStatusID":"12","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Koligo Therapeutics","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Autologous pancreatic islets cells","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Koligo Therapeutics","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Koligo Therapeutics \/ Orgenesis","highestDevelopmentStatusID":"12","companyTruncated":"Koligo The.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100\u2122 (aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharm-Olam Selected as a CRO for Department of Defense Support to Operation Warp Speed Vaccine Trials, Partnering with Geneva Foundation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharm-Olam \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam.."},{"orgOrder":0,"company":"Progreso y Salud Foundation","sponsor":"Amarna Therapeutics","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Amarna Announces Research Join Hands with Progreso y Salud Foundation for Testing MS Gene Therapy Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"SV40 vector based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Progreso y Salud Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Progreso y Salud Foundation \/ Amarna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Progreso y.."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Drugs for Neglected Disease Initiative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"CpG-D35","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Drugs for Neglected Disease Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"FightMND","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"M102","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Th.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Engineered hematopoietic stem cell","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Arbor Biotechnologies, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vor Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$480.0 million","upfrontCash":"Undisclosed","newsHeadline":"CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"ABEC","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute Selects ABEC for Large-Scale, Single-Use COVID-19 Vaccine Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ABEC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ABEC \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"ABEC \/ Ser.."},{"orgOrder":0,"company":"Invetx","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Antibody therapeutics","moa":"GPCR","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Invetx","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Invetx \/ Casdin Capital","highestDevelopmentStatusID":"2","companyTruncated":"Invetx \/ C.."},{"orgOrder":0,"company":"DSG","sponsor":"Reven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reven Selects\u200c E-Clinical Services\u200c Provider\u200c DSG for Clinical Data Management Services","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DSG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DSG \/ Reven","highestDevelopmentStatusID":"6","companyTruncated":"DSG \/ Reve.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","amount":"$381.0 million","upfrontCash":"$70.0 million","newsHeadline":"Verastem Oncology Announces Closing of COPIKTRA\u00ae (duvelisib) Sale to Secura Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Verastem Oncology","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.38,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"12","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Synairgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synairgen and Clinigen Sign Managed Access Program Agreement with SNG001 for Treatment of Hospitalised Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Clinigen Group \/ SYNAIRGEN","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$77.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Therapeutics raises $77 million to go after \u2018undruggable\u2019 diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Applied BioMath","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath, LLC Announces Collaboration with Cullinan Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"CLN-049","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied BioMath \/ Cullinan Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"CNCT19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Juventas Cell Therapy \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Juventas C.."},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Ph.."},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevation Oncology and US Oncology Research Ink Collaboration in Support of Phase 2 CRESTONE Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Seribantumab","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"US Oncology Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"US Oncology Network \/ Elevation Oncology","highestDevelopmentStatusID":"8","companyTruncated":"US Oncolog.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Accord healthcare","pharmaFlowCategory":"D","amount":"$565.0 million","upfrontCash":"$27.0 million","newsHeadline":"Henlius Granted Exclusive Development and Commercialisation Rights of HLX02 in the US and Canada to Accord","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0.56999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ ACCORD HEALTHCARE","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","amount":"$49.3 million","upfrontCash":"$30.8 million","newsHeadline":"HLS Therapeutics Acquires Portfolio of Four Royalty Interest, Gains Takeda's Obizur","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Porcine recombinant Factor VIII","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ HLS Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Exactis Innovation","sponsor":"Sermonix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Lasofoxifene","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exactis Innovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exactis Innovation \/ Sermonix","highestDevelopmentStatusID":"8","companyTruncated":"Exactis In.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LogicBio Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Kreos","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"$5.9 million","newsHeadline":"Kiadis Announces the Placement of \u20ac5 Million Convertible Bonds with Kreos","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Financing","leadProduct":"K-NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sanofi \/ Kreos","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ K.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSig Technologies \/ Sorrento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute to Produce up to Additional 100 mn COVID-19 Vaccine Doses for India and LMIC in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"VLP Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Signs Manufacturing Contract with VLP Therapeutics for Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm holding \/ VLP Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carmot Therapeutics Closes $47 Million Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"CT-868","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"R4D Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"PneumoBlast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ R4D Biotech","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recipharm AB \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"University of Louisville","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AS1411-GNP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Louisville","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Louisville \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$5.0 million","newsHeadline":"Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna\u00ae in U.S.","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Hormone","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Antares Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$715.0 million","upfrontCash":"$200.0 million","newsHeadline":"Vaccibody Enters into Worldwide License and Collaboration Agreement with Genentech to Develop Individualized Neoantigen Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"VB10.NEO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0.71999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$647.0 million","upfrontCash":"$647.0 million","newsHeadline":"Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.65000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radius Health Divests RAD 140 Program to Ellipses Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Georgetown University","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Georgetown University \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics and Pfizer Join Hands to Evaluate Nirogacestat and PF\u201006863135 Combo in Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Lysosomal Therapeutics","sponsor":"BIAL","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson's Disease Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"LTI-291","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lysosomal Therapeutics","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"Lysosomal Therapeutics \/ BIAL","highestDevelopmentStatusID":"6","companyTruncated":"Lysosomal .."},{"orgOrder":0,"company":"Safi Biosolutions","sponsor":"iBio","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming\u00ae System","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Blood cell therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Safi Biosolutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Safi Biosolutions \/ iBio","highestDevelopmentStatusID":"1","companyTruncated":"Safi Bioso.."},{"orgOrder":0,"company":"The University of Manchester","sponsor":"Avrobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lentiviral gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"The University of Manchester","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Manchester \/ Avrobio","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$13,100.0 million","upfrontCash":"$13,100.0 million","newsHeadline":"Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":13.1,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":13.1,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"ViroVax","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech to Use ViroVax\u2019s Adjuvant for Longer-Lasting Immunity by Covaxin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Alhydroxiquim-II","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViroVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViroVax \/ Bharat Biotech","highestDevelopmentStatusID":"8","companyTruncated":"ViroVax \/ .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Gets FDA Acceptance of IND Application for a Phase 2 Clinical Trial of KL4 Surfactant in Acute Lung Injury in Adults with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diperoxochloric Acid","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved","graph3":"Centaur Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Centaur Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centaur Ph.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma and Origin Biosciences Gets FDA Acceptance Of Its New Drug Application For Fosdenopterin For The Treatment Of MoCD Type A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharma Reports Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-15512","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences Dosed First Patient in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR\/Cas9-Based Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma to Submit NDA for Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharma Gets FDA Approval of Orphan Drug ALKINDI\u00ae SPRINKLE as Replacement Therapy in Children with Adrenocortical Insufficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits NDA for UPTRAVI\u00ae Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prelude Therapeutics Doses First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for Relapsed\/Refractory Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PRT1419","moa":"Mcl-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Gets Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy to Treat Advanced TNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves REBLOZYL\u00ae (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Organicell Expanded Access To Treat COVID-19 Patients With ZofinTM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR-NKT Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kuur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company\u2019s Lead Peripheral CB1 Blocker","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Initiates the First Clinical Trial of its Covid-19 \n Prevention Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Publication in NEJM of Interim Results From Phase 1 Study of its mRNA Vaccine Against COVID-19 in Older Age Group","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Doses First Patient in Clinical Study of Microbiome Metabolic Therapy KB295 to treat Mild to Moderate Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KB295","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ZT-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara The.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of 100 Patients in Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I\/II Clinical Study of ART27.13","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ART27.13","moa":"CB receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Update for its HST-002 Dermal Filler Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HST-002","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OLX301A","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces First Dosing with Toledo Compound GLPG3970 in Psoriasis Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GLPG3970","moa":"TOL2\/3","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Plans to Complete Phase 3 RELIEF Study of TNX-102 SL to Manage Fibromyalgia Based on Results of Interim Analysis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz\u00ae Immunotherapy Product in Rheumatoid Arthritis Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmCelz","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Field Trip Psychedelics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Field Trip Psychedelics Successfully Synthesizes GLP, Results From Initial Preclinical Testing for FT-104, its First Molecule in Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-104","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Psychedelics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Field Trip Psychedelics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1096","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Mesdopetam IND Accepted by the US FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Zolgensma\u00ae Demonstrate Therapeutic Benefit, Including Increased Motor Function and Milestone Achievement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zosano Pharma Receives Preliminary FDA Communication on Qtrypta\u2122 NDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zosano Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Baylx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylx Receives US FDA Clearance of Covid-19 IND Application for Umbilical Cord Tissue Mesenchymal Stem Cells Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Human umbilical cord tissue mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baylx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ No.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson\u2019s Treatment of NASH at AASLD 2020 Virtual Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences\u2019 Phase 2b Clinical Results in Alzheimer\u2019s Selected as Late-Breaking News at CTAD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Melanoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Pasteur launches Tetraxim, the first full-dose DTaP booster vaccine in India for preschoolers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DTaP-IPV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta to Present Preliminary Phase I\/II Clinical Data on Temferon\u2122 in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Temferon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin in Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorcaserin HCl","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Provides Soticlestat (OV935\/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Doses First Patients in Two Phase II Clinical Studies of Batoclimab to Treat Myasthenia Gravis and Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Therapeutics Announces Data Presentation at the American Society of Nephrology Kidney Week 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Continues Progress and Expansion of Clinical Development Program for RGX-121 to Treat Mucopolysaccharidosis Type II (MPS II)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-121","moa":"IDS gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS Announces Data on Liproca Depot from Open Label Extension Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"xCures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"xCures launches compassionate use programme for ulixertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"xCures","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"xCures \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"xCures \/ N.."},{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Discover Small Molecule that Targets, Destroys RNA Sequence of Virus that Causes COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"C5-RIBOTAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Sanofi's Regulatory Submission for Avalglucosidase Alfa for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for Primary Hyperoxaluria Type 1 in Children Aged 6","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi and Selecta Biosciences Announce Topline Data of SEL-212 From the Phase 2 COMPARE Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Treatment for Alexander Disease Receives Orphan Drug Designation from U.S. FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst\u2019s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-na\u00efve PNH Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IGM-8444","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinderfarms Announces the Launch of Kinderlyte\u00ae Sleep and Immunity","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Kinderfarms","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinderfarms \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kinderfarm.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical's SIMPONI ARIA\u00ae Approved by the U.S. FDA for Active Polyarticular Juvenile Idiopathic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Golimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centus Biotherapeutics Receives European Marketing Authorization for Equidacent\u00ae, Biosimilar Avastin\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Centus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Centus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centus Bio.."},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study by Irvine School of Medicine finds Antidepressant Drug Effective in Treating \"Lazy Eye\" in Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Irvine School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine Sch.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated D-serine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Oral Solution","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord-UK Launches Pelgraz\u00ae Pre-filled Injector and Patient App, Supporting Patients to Self-Inject at Home","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Regulatory Submission for Avalglucosidase Alfa, a Potentially new Standard of Care Enzyme Replacement Therapy for Pompe disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Granted Breakthrough Therapy Designation in US for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine to Present New Data from MET409 Program in NASH at AASLD\u2019s The Liver Meeting Digital Experience\u2122","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Launches TrilynX - A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx-99 an Experimental Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AGLE-102","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aegle Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aegle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aegle Ther.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olorinab","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Doses First Patient in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces ZILXI\u2122 (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cinacalcet Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"CiVi Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CiVi Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CiVi Bioph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teneobio Reports US FDA Clearance of its IND Application for TNB-486 and the Initiation of Phase I Clinical Studies for B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TNB-486","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Starts Patient Dosing for the LIFT-AD Study, a Phase 2\/3 Clinical Trial to Evaluate ATH-1017 for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces First Patient Dosed in Multicenter Phase 1\/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Relmapirazin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Completes Scientific Advice Meeting with EMA for a Pivotal Phase III Study of Nomacopan to treat Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data from the Company\u2019s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals' Three Abstracts Accepted by The Liver Meeting Digital Experience, including Data on Phase 3 MAESTRO-NAFLD-1 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$11.7 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces a \u20ac 10 Million Capital Increase Through Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Private Placement","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Biophytis \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Medicure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicure Announces an Agreement with Reliance Life Sciences for the Marketing Rights of a Cardiovascular Biosimilar","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Reliance Life Sciences Private Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reliance Life Sciences Private Limited \/ Medicure","highestDevelopmentStatusID":"1","companyTruncated":"Reliance L.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b\/3 Clinical Trial Design Based On FDA Written Guidance","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Ministry of Health and Welfare, Taiwan","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Vaxxinity \/ Ministry of Health and Welfare, Taiwan","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"JPMorgan Chase Bank","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.16,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$62.5 million","upfrontCash":"$41.0 million","newsHeadline":"Lexicon Pharmaceuticals Reaches Agreements To Exchange Convertible Notes, Reduce Outstanding Indebtedness","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Liechti Lab","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Liechti Lab","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liechti Lab \/ MindMed","highestDevelopmentStatusID":"6","companyTruncated":"Liechti La.."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Minoryx Therapeutics and Sperogenix Therapeutics Sign License Pact to Develop and Commercialize Leriglitazone in Mainland China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Minoryx Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Brain Trust Accelerator Fund II","pharmaFlowCategory":"D","amount":"$8.8 million","upfrontCash":"Undisclosed","newsHeadline":"NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Brain Trust Accelerator Fund II","highestDevelopmentStatusID":"6","companyTruncated":"NeuroThera.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"CMB International","pharmaFlowCategory":"D","amount":"$142.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Raised 142 Million Dollars (USD) in Support of Project Integrum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"Human antibodies","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Biocytogen \/ CMB International","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune\u2019s SACCOVID\u2122 (CD24Fc) Exhibits Superb Therapeutic Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-7110","moa":"CD24","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-003","moa":"TLR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NMT-cP12","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix .."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"REX Health Ventures","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rediscovery Life Sciences Completes $4.5M Series B Financing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rediscovery Life Sciences \/ REX Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Rediscover.."},{"orgOrder":0,"company":"Palladio Zannini Industrie","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Palladio Completes $20 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Zannini Industrie","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Palladio Zannini Industrie \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Z.."},{"orgOrder":0,"company":"Genelux","sponsor":"Woodward Diversified Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genelux Announces Closing of a Strategic Financing Transaction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Genelux \/ Woodward Diversified Capital","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"InventisBio","sponsor":"GL Ventures","pharmaFlowCategory":"D","amount":"$147.0 million","upfrontCash":"Undisclosed","newsHeadline":"InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"D-0502","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InventisBio","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"InventisBio \/ GL Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InventisBi.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicine Files for a $100 million IPO","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"MEDUNIK CANADA","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M\u00e9dunik Canada's Ruzurgi\u00ae Now Available to Canadian Lambert-Eaton Myasthenic Syndrome Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"MEDUNIK CANADA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MEDUNIK CANADA \/ Jacobus Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MEDUNIK CA.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Biopharmaceuticals has Clear Path Towards Zilosul\u00ae OA Phase 3 Clinical Trial and Product Registration in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IONTAS and FairJourney Biologics Discover SARS-CoV2 Neutralizing Antibodies with Picomolar Potency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV2 neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ F.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Xeljanz approved by the FDA for the treatment of children with arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Fosaprepitant for Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosaprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncology Venture\u2019s Novel PARP Inhibitor Stenoparib Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oncology Venture","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"Peking University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Isolates Potent Neutralizing Abs Against Sars-Co V-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BD-368-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Peking University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peking University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Peking Uni.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$300.0 million","newsHeadline":"Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 \r\n Antitrypsin-Associated Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.04,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$96.8 milion","newsHeadline":"Enterprise Therapeutics\u2019 TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"ETD002","moa":"TMEM16A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Roche","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$222.7 million","upfrontCash":"Undisclosed","newsHeadline":"Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0.22,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.22,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE\u00ae Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Zoic Capital","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"HDT Bio Announces Completion of Seed Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"HDT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Zoic Capital","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Engineered Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$526.7 million","upfrontCash":"$58.6 million","newsHeadline":"Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M6495","moa":"ADAMTS5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Merck & Co","amount2":0.53000000000000003,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TG4050","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene.."},{"orgOrder":0,"company":"Sansero Life Sciences","sponsor":"University of Toronto","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sansero Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sansero Life Sciences \/ University of Toronto","highestDevelopmentStatusID":"4","companyTruncated":"Sansero Li.."},{"orgOrder":0,"company":"Kao Corporation","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Lead Optimization trial for Soil-transmitted\n helminths Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Cry5B protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kao Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kao Corporation \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Kao Corpor.."},{"orgOrder":0,"company":"MILLENNIUM PHARMS","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Hit Identification trial for Malaria\n Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MILLENNIUM PHARMS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MILLENNIUM PHARMS \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"MILLENNIUM.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.07 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Hit Identification trial for Chagas disease,\n Leishmaniasis Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"$2,830.0 million","upfrontCash":"$175.0 million","newsHeadline":"Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":2.8300000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.8300000000000001,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Bridgebio Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Ther.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recipharm Signs Agreement with Arcturus Therapeutics to Support the Manufacture of LUNAR[\u00ae]-COV19 (ARCT-021) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Arcturus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$200.0 million","newsHeadline":"Innovent Announces Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma Announces Expanded TriKe(tm) Partnership with Cytovance Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance .."},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Mustang Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mustang Bio Licenses LentiBOOST\u2122 Technology from SIRION Biotech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MB-207","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sirion Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirion Biotech \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sirion Bio.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Talaris Therapeutics Closes $115 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dyno Therapeutics Join Hands With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"AAV vectors based gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":1.8,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Thera.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aro Collaboration with Ionis Advances with Option Exercise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ASO-Centyrin drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$71.5 million","upfrontCash":"Undisclosed","newsHeadline":"A2 Biotherapeutics Closes $71.5M Series B To Begin Clinical Development Of Its Potentially Transformative Selective Tumor Cell Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Tmod-engineered T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"A2 Biotherapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ The Column Group","highestDevelopmentStatusID":"2","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRISYS LLC Signs a Third Contract with TFF Pharma to Produce Medication to Treat Lung Conditions, Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IRISYS, LLC \/ TFF Pharma","highestDevelopmentStatusID":"1","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"D","amount":"$149.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rhizen Pharmaceuticals and Curon Biopharmaceutical Limited Announce an Exclusive License Agreement to Develop and Commercialize Tenalisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tenalisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Curon Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage\u2122 Platform Targeting Multiple Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"SNS-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sensei Biotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Cambrian Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Urovant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunovion Pharmaceuticals \/ Urovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Luminera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel","sponsorNew":"Luminera \/ Innovative Luminera","highestDevelopmentStatusID":"12","companyTruncated":"Luminera \/.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$560.0 million","newsHeadline":"Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.3 million","newsHeadline":"OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Th\u00e9a to Develop siRNA Therapeutics for Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OLX301A","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"The European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury\u00ae (remdesivir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Gilead Sciences \/ The European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$6,500.0 million","upfrontCash":"$6,500.0 million","newsHeadline":"Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"BioNTech","sponsor":"New Zealand government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ New Zealand government","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamada Provides Update on 2021 GLASSIA Supply to Takeda","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Alpha1-Proteinase Inhibitor (Human)","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ T.."},{"orgOrder":0,"company":"Janpix","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janpix Announces $10 Million Series B Financing to Advance STAT Protein Degrader Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Janpix","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Janpix \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Janpix \/ M.."},{"orgOrder":0,"company":"Federation Bio","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Human gut microbiome","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Federation Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Federation Bio \/ Horizons Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Federation.."},{"orgOrder":0,"company":"Rentschler Biopharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Joining forces against SARS-CoV-2, Rentschler Biopharma contributes to manufacturing of COVID-19 mRNA vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rentschler Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rentschler Biopharma \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Rentschler.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Government of Brazil","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil's Sao Paulo Signs Agreement with Sinovac for COVID Vaccine Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Government of Brazil","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Geron","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geron Secures up to $75M Non-Dilutive Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ He.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CD19-CAR-T cells","moa":"4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Receives FDA Fast Track Designation For Duchenne Muscular Dystrophy Investigational Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lovastatin Lactone","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canada joins countries in real-time AstraZeneca COVID vaccine review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia to begin Phase III trials of second COVID-19 vaccine in Nov-Dec: TASS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Germany Approves Third Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-SARS-2-S vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IDT Biologika GmbH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDT Biologika GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IDT Biolog.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMGN632","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients At The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin and MEI Pharma Dosed First Patient in Japanese Pivotal Phase 2 Study of Zandelisib for Indolent B-cell non-Hodgkin's Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Initiates Phase 1\/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AIV001","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Bio.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Publication Of Manuscript Detailing Baseline Characteristics Of Galactic-HF inEuropean Journal Of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Confirms that REGN-COV2 Antibody Cocktail Provided to \n President Trump Under Compassionate Use Request","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Resveratrol","moa":"Angiogenesis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Or.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCurity Pharma Gets Issuance of European Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cerium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCurity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Announces EMA Acceptance of Marketing Authorization Application for Elivaldogene Autotemcel Gene Therapy for Cerebral Adrenoleukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial of Zeposia\u00ae in Ulcerative Colitis at UEG Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces Lenzilumab in COVID-19 Program Updates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA\u00ae and ATRIPLA\u00ae Tablets in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at HFSA Annual Scientific Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS\u2019 Multidisciplinary NET Medical Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tidutamab","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech\u2019s Investigational New Drug Application Placed on Hold by the U. S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the U.S for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsius Pharma Achieves Positive Results In Proof Of Concept Study For TRS01 Targeting Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results Evaluating The Effect Of Kaneka Nutrients' Ubiquinol On Endothelial Function Published In Nutrients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kaneka Nutrients","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaneka Nutrients \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Nut.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces EC Approval of CRYSVITA\u00ae for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Eyevensys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EYS611","moa":"Human transferrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyevensys","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eyevensys \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys .."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS\u00ae T Cell Therapy in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ET140203","moa":"Alpha fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Canada Announces Availability of Aermony RespiClick\u2122, an Innovative New Device for the Treatment of Bronchial Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odonate Therapeutics Results of CONTESSA in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented at the 2020 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1\/2 Trial in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AO-176","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncol.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa\u00ae in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals\u2019 results of the phase IIb study with cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB (publ) Announces Next Safety and Enrollment Update for Phase Ib\/II ILIAD Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ACN00177","moa":"Homocysteine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobomarsen","moa":"miR-155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva to Present the Results of its NATIVE Phase IIb Clinical Trial with Lanifibranor in NASH The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline's ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer Fran\u00e7ais","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer\u2019s Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G \/ IC-MPGN and ALS, Rare Diseases with High Unmet Need","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Presentation of Positive Results from Phase 2 Trial of OCS-01 in Patients with DME at EURETINA 2020 Virtual","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation to CARsgen\u2019s CT041 CLDN18.2 CAR-T Cells to Treat Gastric and Gastroesophageal Junction Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized anti-claudin18.2 autologous Chimeric Antigen Receptor T Cells","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Dimethyl Fumarate Delayed-Release Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Provides Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Breezhaler\u00ae Approval in the European Union as a Treatment for Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Approval in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder for Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes that Enerzair\u00ae Breezhaler\u00ae has Been Recommended for Approval in the E.U for treating Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's seeks DCGI nod to conduct phase-3 clinical trial of Russian COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel for Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis and Biogen Announce EMA Filing Acceptance OF SB11, a Proposed Biosimilar Referencing Lucentis\u00ae (RANIBIZUMAB)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories to submit a revised protocol for conducting clinical trials of Russian COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology and GSK Announce Global Expansion to Phase 3 of COMET-ICE Study Evaluating VIR-7831 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune First Patient Dosed in NexImmune Phase 1\/2 Clinical Trial of NEXI-002 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acacia Pharma Announces BYFAVO its Newly Approved Product for Procedural Sedation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Elorac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elorac Biotherapeutics Announces Amendment to Naloxone Lotion Phase III Study For Increased Access to Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elorac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Elorac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elorac \/ N.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Taiwan Liposome Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Doses First Patient in Phase 1 Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 'Long Haulers' in the AMP-511 ME\/CFS Clinical Trial of Ampligen","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Rega Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1096","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Rega Institute","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Broadly Supports Oragenics\u2019 Pre-IND Development Program for its SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Terra CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Shows Reduction of Mortality and Potent Therapeutic Activity of Anti-COVID-19 DARPin\u00ae Candidates in Advanced COVID-19 Disease Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MP0420","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Gets Rare Pediatric Disease Designation from U.S. FDA for TK216 for Treatment of Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TK216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium\u00ae, December 9 \u2013 11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces Clinical Trial Site Expansion in its Multi-Center Phase 1\/2 Actimab-A Venetoclax Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"AbFero Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abfero Announces PK Study Results For SP-420 in\n Transfusional Iron Overload -- Proceeds With\n PHASE 1-2 Trial Of Iron Chelator","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SP-420","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbFero Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbFero Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AbFero Pha.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GP2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet To Present Data From Phase 2 Fascinate-1 Trial Of TVB-2640 in NASH at AASLD\u2019S the Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Dosed First Patient in Greater China in the Global Phase 2\/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO\u2122 and Its Gene Delivery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KB109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Institute of Cancer Research's New Drug Targeting High-Risk Children\u2019s Cancer is Ready for Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"N-Myc","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Cyclacel","highestDevelopmentStatusID":"6","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Dosed First Patient in Phase 2 Trial of CVL-865 for the Treatment of Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CVL-865","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates a Combined Phase I\/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NMD670","moa":"ClC-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Expands its Phase II COVID-19 European Clinical \n Trial to Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Phase II Results Underpin GemVax Decision to Apply for Expanded Access IND for GV1001 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tertomotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & K.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA\u00ae Collection During the ASDS Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILC Therapeutics Announces \u2018Significant\u2019 COVID-19 Drug Breakthrough","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IFN Alpha-14","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILC Therap.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1\/2a MONARCH Study for Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo Plus Chemotherapy Improves Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces Two Lancet Oncology Publications on TAZVERIK\u00ae (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals to Publish Results From Phase 1b Study of Waldenstrom's Macroglobulinemia in H1, 2021 - (Fidelity via NewsPoints Desk)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Salicyn-30","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-548","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs\u2019 Nivatrotamab for the Treatment of Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivatrotamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics\u2019 COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Bristol Myers Squibb's ZEPOSIA, an Oral Treatment for Relapsing Remitting Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Gets Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences\u2019 CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-280","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Gets IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Liquid Oral Suspension","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics' Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-0022","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb to Host Virtual Investor Event Focusing on Phase 3 True North Trial of Zeposia\u00ae in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Provides Regulatory Update On VY-HTT01 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Cytokinetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Cytokinetics","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Announces Topline Phase 3 Data of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Receives Complete Response Letter From FDA For Obeticholic Acid For the Treatment OF Fibrosis Due To NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Positive Results from Phase II BHT-II-002 Trial of Blautix in Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Announces Expects to Complete Enrollment on its SP-102 (SEMDEXA\u2122) Phase 3 Pivotal Trial Program in 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SP-102","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia a Gene Therapy Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Completes Patient Dosing in Phase 1b\/2a Trial of HST-001 to Treat Androgenic Alopecia in Men","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"HST-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results of National Institute of Allergy and Infectious Diseases\u2019 ACTT-1 Trial Published in NEJM Expand Clinical Benefits of Veklury\u00ae for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cerecin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin\u2019s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tricaprylin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerecin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerecin \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces NDA for CAMCEVI\u2122 42MG Accepted for Review by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Evaluating KRYSTEXXA\u00ae With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Announces First COVID-19 Patient Treated in Veyonda\u00ae Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Topline Phase 1 Clinical Trial Results of OTX-CSI","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthrax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elusys The.."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Allowance for Sareum\u2019s SDC-1802 TYK2\/JAK1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Gets FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ezogabine","moa":"KCNQ","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Revs up for Xolair Biosimilar\u2019s Phase 3 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Neuropharma Presents Data from Pivotal Phase 3 Registration Study of INP104 for the Treatment of Acute Migraine at 2020 Migraine Trust Virtual Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All patients included in Follicum\u2019s Phase II Study with FOL-005 for Stimulation of Hair Growth","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FOL-005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follicum A.."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L19TNF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu) lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Phase I\/II Study of a New Gene Therapy for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OTQ923","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"BSP Pharmaceuticals S.p.A","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ BSP Pharmaceuticals S.p.A","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patients Enrolled in Rigel's NIH\/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics to Present Data from its Positive PRISM3 Trial of CP101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Aurigene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis and Aurigene Announce Promising Preclinical Data to Be Presented at the ENA Symposium Back Development of a Novel CDK7 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AUR102","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Aurigene","highestDevelopmentStatusID":"4","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SARS-CoV-2 Vaccine Candidate BNT162b2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark's Antiviral Combination for Moderate COVID-19 Shows no Clinical Benefit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with Tp-1454 IN Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"PK M1\/M2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-3434","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Gets FDA Rare Pediatric Disease Designation for Givinostat in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Givinostat","moa":"HDAC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfa.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Received European Medicines Agency (EMA) PRIME Designation for Iptacopan (LNP) in C3 Glomerulopathy (C3G)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Penelope-B Trial of Ibrance\u00ae (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav\u2122 Oral Solution for Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"University of Exeter Medical School","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Study Tests if BCG Vaccine Protects Against COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Exeter Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Exeter Medical School \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Begins Phase 1 Trial of Niclosamide as COVID-19 Drug in Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA\u00ae (Rituximab Injection) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi\u2019s Phase III JUPITER-02 Study of Toripalimab and Gemcitabine Combo to Treat Recurrent Nasopharyngeal Carcinoma Meets Endpoints","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Farmalider SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo Laboratories, Inc. Acquires International Rights to Sildenafil Oral Spray for the Treatment of Erectile Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Farmalider","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Olema Oncology \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive NICE Recommendation for Rizmoic\u00ae (naldemedine) for OIC","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Naldemedine Tosylate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sandoz B2B \/ Shionogi","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Inks Financing Transaction Pact Involving the Sale of Royalty Rights Related to Future Mytesi Revenue Stream for $5 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces EU Decision for Expanded Use of IMBRUVICA\u00ae in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12\u2122 for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"exoIL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO\u2122 in Patients with Advanced RET-Mutant Medullary Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Blueprint Medicines \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Announces FDA Approval of Fetroja\u00ae for Hospital-Acquired Bacterial Pneumonia AND Ventilator-Associated Bacterial Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women's & Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Mitochondrial therapy","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Scien.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$76.9 million","upfrontCash":"$7.4 million","newsHeadline":"Vedanta Biosciences Awarded Up to $76.9 Million from BARDA to Advance the Development of VE303","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Institute of Cancer Research's New Drug Targeting DNA Repair Shows Promise in Range of Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY1895344","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Receives Complete Response Letter From the FDA for its BLA for Steroid-Refractory Acute Graft Versus Host Disease in Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Initiates Patient Dosing in Phase 1\/2 Clinical Trial of exoSTING\u2122 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"exoSTING","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Imvaq Therapeutics","sponsor":"Hanne Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"MQ710","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Imvaq Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Imvaq Therapeutics \/ Hanne Capital","highestDevelopmentStatusID":"4","companyTruncated":"Imvaq Ther.."},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"The Pirbright Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enesi Pharma's ImplaVax\u00ae-Enabled Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PRRSV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Enesi Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enesi Pharma Limited \/ The Pirbright Institute","highestDevelopmentStatusID":"2","companyTruncated":"Enesi Phar.."},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$516.0 million","upfrontCash":"$438.0 million","newsHeadline":"Ligand Completes Acquisition of Pfenex Inc","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0.52000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Pfenex \/ Ligand","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ L.."},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aegle Therapeutics Announces Award of Grant by U.S. DOD Congressionally Directed Medical Research Programs for Development of AGLE-102","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"AGLE-102","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aegle Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aegle Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Aegle Ther.."},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and IGAN Biosciences Collaborate to Study ImmTOR\u2122 Immune Tolerance Platform in Combination with IgA Protease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosc.."},{"orgOrder":0,"company":"Vincera Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vincera Pharma Announces Exclusive License Agreement with Bayer for Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VIP152","moa":"PTEFb","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincera Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincera Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vincera Ph.."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Launches to Transform the Treatment of Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"suPAR","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Walden Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Walden Biosciences \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"Federal Emergency Management Agency","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Federal Emergency Management Agency","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Federal Emergency Management Agency \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Federal Em.."},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for ARDS in COVID","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NC-iMSCs therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"Celiac Disease Foundation","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celiac Disease Foundation Partners with Provention Bio on Its Phase 2b Study of Celiac Disease Therapeutic PRV-015","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celiac Disease Foundation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celiac Disease Foundation \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Celiac Dis.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces EC Approval of Agreement to Supply 200 Million Doses of Janssen\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Vinnova","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oblique Therapeutics Together with Collaborators at Sahlgrenska University Hospital and Karolinska Institutet Granted 5MSEK by Vinnova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"\u03b1SARS-CoV-2 antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Vinnova","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Th.."},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Abveris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abveris Announces Antibody Discovery Agreement with Immunitas Using the Berkeley Lights Beacon\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Berkeley Lights","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Berkeley Lights \/ Abveris","highestDevelopmentStatusID":"2","companyTruncated":"Berkeley L.."},{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almirall \/ University of Dundee","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"VirTrial","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Announces VirTrial, as Clinical Trial Patient Monitoring Partner","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"AP-003","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VirTrial","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"VirTrial \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VirTrial \/.."},{"orgOrder":0,"company":"Kineta","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"KCP-506","moa":"nAchR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ G.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Commonwealth of Australia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Finalises Agreement to Supply 51 Million Doses of UQ Covid-19 Vaccine Candidate to Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"V451","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Commonwealth of Australia","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fibrosis Biotech Galecto Files for a $100 Million IPO","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STADA Expands Specialty Footprint Through Acquisition of Innovative Therapy for Treating Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lobsor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lobsor Pharmaceuticals \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Lobsor Pha.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$632.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Announces Capital Increase to Prepare for the Launch of Daridorexant and Further Fund Its Diversified Pipeline","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0.63,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.63,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Adds Israel Rights to Movantik\u00ae From AstraZeneca","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"$125.0 million","newsHeadline":"Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KDT-3594","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Affamed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pha.."},{"orgOrder":0,"company":"Mid-Atlantic BioTherapeutics","sponsor":"Connectyx Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Connectyx Technologies Holdings Group Announces Agreement with Mid-Atlantic BioTherapeutics for Treatment of Symptomatic Rabies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"IMT504","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mid-Atlantic BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mid-Atlantic BioTherapeutics \/ Connectyx Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Mid-Atlant.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Cam Capital","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-List to Nasdaq","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Private Placement","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Cam Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Completes Drawdown from \u20ac25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS\u00ae and BYFAVO\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$486.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's COVID-19 Long-Acting AntiBody Combination AZD7442 Rapidly Advances into Phase III Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0.48999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Governemnt of Mexico","pharmaFlowCategory":"D","amount":"$159.8 million","upfrontCash":"Undisclosed","newsHeadline":"Mexico Makes Nearly $160 Million Down Payment for COVAX Vaccine Plan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.16,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"World Health Organization \/ Governemnt of Mexico","highestDevelopmentStatusID":"1","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Priothera","sponsor":"Fountain Healthcare","pharmaFlowCategory":"D","amount":"$35.4 million","upfrontCash":"Undisclosed","newsHeadline":"Priothera Closes \u20ac30 Million Series A Financing to Develop Highly Promising Therapies for Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Mocravimod","moa":"S1PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Priothera \/ Fountain Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch Health","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$10.0 million","newsHeadline":"Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"EdiGene","sponsor":"3H Health Investment","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ET-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"EdiGene","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"EdiGene \/ 3H Health Investment","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chord Therapeutics Launches with USD 16 million Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Ther.."},{"orgOrder":0,"company":"University of Houston","sponsor":"AuraVax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AuraVax Therapeutics Enters into Exclusive License Option Agreement with the University of Houston for Intranasal Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Houston","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Houston \/ AuraVax Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sidero Bioscience Announces Agreement with SRS Life Sciences for Commercialization of BioFe for Iron Deficiency","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bio.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Sickle Cell Disease Association of America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Sickle Cell Disease Association of America","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Regains RSV Vaccine Programme from Merck","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1172","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Hunan Warrant Chiral Pharmaceutical","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hunan Warrant Chiral Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hunan Warrant Chiral Pharmaceutical \/ CytoDyn","highestDevelopmentStatusID":"10","companyTruncated":"Hunan Warr.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Knopp Biosciences NIH-Funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Kv7.2\/Kv7.3 cellular potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Knopp Biosciences LLC","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Knopp Biosciences LLC \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"miR-21","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Novellus","sponsor":"NoveCite","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"$5.0 million","newsHeadline":"Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Induced Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Novellus \/ NoveCite","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Co-Leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"PTPA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rappta Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rappta Therapeutics \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Rappta The.."},{"orgOrder":0,"company":"University of Goettingen","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Goettingen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Goettingen \/ Iksuda Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Immuneel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuneel, HCB and IDIBAPS Enter into a Collaboration and Licensing Agreement for CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Autologous T-cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hospital Clinic of Barcelona","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hospital Clinic of Barcelona \/ Immuneel Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hospital C.."},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KindredBio Expands Manufacturing Agreement with Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Centaur Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centaur Pharmaceuticals \/ Vaxart","highestDevelopmentStatusID":"6","companyTruncated":"Centaur Ph.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Israel's Redhill Biopharma Signs Manufacturing Deal for Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Polyphor","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$18.4 million","upfrontCash":"Undisclosed","newsHeadline":"Polyphor Receives CARB-X Award of up to USD 18.44 Million to Support Development of New Antibiotic Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Thanatin-derivative antibiotic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Polyphor \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"EverInsight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AffaMed Therapeutics Announces Merger with EverInsight Therapeutics and Appoints Dayao Zhao, M.D., Ph.D. as CEO","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ EverInsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Takara Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Takara Bio","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Nimbus Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$57.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cedilla Therapeutics Announces $57.6 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cedilla Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Th.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Neogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Neogene","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"Foundation to Fight H-ABC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation to Fight H-ABC, University of Massachusetts Medical School and Yale University Initiate Gene Therapy Study Targeting Cure for Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AAV-based gene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"University of Massachusetts Medical School","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Massachusetts Medical School \/ Foundation to Fight H-ABC","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$506.0 million","upfrontCash":"$47.0 million","newsHeadline":"SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.51000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Filaggrin","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ L.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides Signs \u20ac 40 Million Loan Agreement with the EIB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ European Investment Bank","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Earns $1.9 Million Associated with Two Partner Developments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rez.."},{"orgOrder":0,"company":"Lactiga","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"LCTG-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lactiga \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ .."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"FS Development Corp","pharmaFlowCategory":"D","amount":"$216.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"GEM103","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0.22,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.22,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ FS Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Greenteaspoon","sponsor":"PanTheryx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PanTheryx Acquires Goodgut\u00ae and Preliva\u00ae Brands from Greenteaspoon Inc.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Prebiotics","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Greenteaspoon","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Greenteaspoon \/ PanTheryx","highestDevelopmentStatusID":"12","companyTruncated":"Greenteasp.."},{"orgOrder":0,"company":"Enzolytics","sponsor":"BioClonetics Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Anti-HIV recombinant monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enzolytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzolytics \/ BioClonetics Immunotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Enzolytics.."},{"orgOrder":0,"company":"Yale Cancer Center","sponsor":"Alliance for Cancer Gene Therapy","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Yale Cancer Center Receives ACGT Grant To Advance Strategies For Treating Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"MAEGI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yale Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yale Cancer Center \/ Alliance for Cancer Gene Therapy","highestDevelopmentStatusID":"1","companyTruncated":"Yale Cance.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.19,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Orion Corporation \/ Tenax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar signs an agreement with Jazz Pharmaceuticals for lurbinectedin in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The National Comprehensive Cancer Network \/ Puma Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"The Nation.."},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Announces Closing of $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptorum","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antengene signs MoU with WuXi Biologics to advance development of innovative oncology medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Initiates Post-Exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Human Trials of Russian Covid-19 Vaccine Abroad, in UAE, Have Launched","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"oNKord","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Receives Complete Response Letter from USFDA for IV Tramadol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex a Wholly Owned Subsidiary of Ascletis Pharma Received US IND Approval for its NASH Drug Candidate ASC42","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Glasgow Research Details Promising Precision Medicine Approach in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Glasgow","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Glasgow \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-GTX-501","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Safety and Efficacy of Subcutaneous Entyvio Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Pooled Efficacy Data for Derazantinib in iCCA Patients with FGFR2 Gene Mutations and Amplifications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces that the Oncos-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Targovax \/ Astrazeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"With the Priority Review Underway at FDA, Oncopeptides Moves Forward with Intent to File for Conditional Approval of Melflufen with EMA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical Present STELARA\u00ae Five-Year Results from Long-term Extension Study of Clinical Response and Remission in Patients with Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's TREMFYA\u00ae Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab-cwvz) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces FDA Orphan Drug Designation of Trodelvy\u2122 for Adult and Pediatric Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Phase III FIDELIO-DKD Study Presented at the American Society of Nephrology (ASN)\u2019s Kidney Week 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SNS-510","moa":"PDPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunesis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Mirikizumab Shows Improved Symptom and Reduces Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured at EORTC-NCI-AACR Annual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Oxular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OXU-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxular \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ N.."},{"orgOrder":0,"company":"Altimmune","sponsor":"UAB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID\u2122 Intranasal COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ UAB","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines to Present Interim Data from Phase 1b\/2 Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor to be Presented at ASN's Kidney Week 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders for Development of Oxbryta\u00ae Tablets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FR104","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Interim Results from Phase 1\/2 Study Fides-02 Exploring Derazantinib in Patients with Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Biopharma Receives Positive EMA Opinion on Orphan Designation for PBP1510 for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PBP1510","moa":"PAUF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Announce Efficacy Data from Patients Treated with RLF-100\u2122 Under the U.S. FDA Expanded Access Protocol Authorization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Pharmaceuticals' Dupixent\u00ae Reduced Severe Asthma Attacks in Children","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Injects First Patient with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ UNIV TX MD ANDERSON","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Buntanetap","moa":"APP","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis' Inhaled Antisense Medicine Demonstrates Potential as a Novel Treatment for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IONIS-ENAC-2.5Rx","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid\u2019s Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Funapide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Osmotica's Upneeq\u2122 for Acquired Ptosis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Dosed First Patient in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA\u00ae for Treatment of Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix\u2122 Intranasal Antiviral Protection Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Announces FDA Acceptance of IND Application for NUV-422 for Treatment of Patients with High-grade Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NUV-422","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Radiation therapy","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Initiates Rolling Submission of NDA for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure gets abstract on the NeuroRestore platform against Alzheimer's accepted for poster presentation at CTAD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Institutes of Health Launches its ACTIV-5 \u201cBig Effect Trial\u201d Evaluating Humanigen\u2019s Lenzilumab\u2122 as Potential COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VAC2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoAgents Launches Clinical Trials for GP1681, Treatment of COVID-19 Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"Curia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BryoLogyx Announces Completion of World\u2019s First GMP Synthesis of Bryostatin-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ Albany Molecular Research Inc.","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aliqopa\u2122 (copanlisib) in Combination With Rituximab Meets Primary Endpoint in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Copanlisib","moa":"PI3K p110-alpha subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics Expands IP Portfolio With Additional Patents for ONC201 and ONC212","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC212","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Intends to Submit a Registration Application in Europe in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD\/NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Apogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Asunercept","moa":"CD95","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Publication of Preclinical Data Supporting Advancement of PBGM01 into Clinic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics\u2019 Allogeneic Cell Therapy Product, Allob, Shows 90% Fusion Rate at 24 Months in Phase II A Studyinn Lumbar Spinal Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLOB","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Introduces NINDANIB for the Treatment of Pulmonary Fibrosis in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva\u2019s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Announces Publication of Two Studies in the Lancet Infectious Diseases Highlighting the Efficacy and Safety of Fetroja\u00ae For the Treatment of Infections Due To Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Positive Findings on MN-001 in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Initiates Pre-Clinical Study in New Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MUC1-SP-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PC14586","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Reports Positive Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Enrollment of Next Two Patients in Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Stereotaxic Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Announces Presentation of Phase 1 Clinical Data for Lead Precision Kidney Therapeutic Candidate, Gfb-887","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Ministry of Health Authorizes Initiation of Enlivex's Phase II Clinical Trial of Allocetra in COVID-19 Severe and Critical Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuGenerex Immuno-Oncology Publishes Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AE37 Peptide","moa":"Helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science' Results from Masitinib Study AB07015 in Severe Asthma Have Been Selected at an American Thoracic Society symposium Symposium","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparc Reports Positive Top-Line Results of Phase 3 Clinical Trial of SDN-037","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SDN-037","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TregGraft","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Approves Second Covid-19 Vaccine After Preliminary Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EpiVacCorona","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Announces Data Lock of Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio\u2019s Expanded Phase 2 Study of Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"University of Notre Dame","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advancement of Anticancer Compounds for B Cell Cancer Therapy Targeting a Cellular Stress Response Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"B-I09","moa":"IRE-1 RNAse","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Wistar Institute \/ University of Notre Dame","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LN-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Announces Upcoming Data Presentations at Virtual SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nelonemdaz","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GNT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Abstract for CI-8993 Accepted for Presentation at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ICT01","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astex and Otsuka Announce Results of Phase 3 ASTRAL-2 and ASTRAL-3 Studies of Guadecitabine in Patients with Previously Treated AML and Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Guadecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Data from the Phase 1 Study of XmAb\u00ae20717 and Three Research Programs at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb20717","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BT7480","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VX-814","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cell therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Qihan Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qihan Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Qihan Biot.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-102 as a Treatment for Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TSHA-102","moa":"MECP2 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's New First-in-Class Phase 3 Data Demonstrate TREMFYA Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KVD824","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces Positive Interim, Zuranolone Safety and Tolerability Data from SHORELINE Study in Patients with MDD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Thomas Jefferson University","highestDevelopmentStatusID":"5","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARISE-3 Phase 3 Trial Completion Expected by End of 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX For The Treatment Of Cataplexy In Adult Patients With Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC\u2122 ODT For The Preventive Treatment Of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh10-h.SGSH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes Phase 1 Trial of ImmunityBio\u2019s Novel COVID-19 Vaccine Candidate hAd5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Positive Results from Phase 2 Clinical Trial Evaluating ANAVEX\u00ae2-73 in Parkinson\u2019s Disease Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shasqi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Announces Pipeline Programs Targeting Validated and Classically \u201cUndruggable\u201d Disease-Causing Proteins","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANVISA Authorizes Sorrento Therapeutics\u2019 Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Abivertinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recipharm\u2019s Proprietary Molecule Erdosteine has been Positively Tested As Part of COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Erdosteine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recipharm AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Three Presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Presentation of Preclinical Data on AFM13-Targeted NK Cells at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT311","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"ALV-304","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alivio Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Alivio The.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Dexcom","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Dexcom Team Up on New Program to Help Improve Diabetes Management","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dexcom","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dexcom \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Dexcom \/ E.."},{"orgOrder":0,"company":"NuGenerex","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"NuGenerex Closes Licensing & Distribution Agreement with Bintai Kinden to Advance Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NuGenerex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NuGenerex \/ Bintai Kinden","highestDevelopmentStatusID":"1","companyTruncated":"NuGenerex .."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamond Supports GenSight Biologics in LUMEVOQ MAA Submission","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Requests Emergency Approval for COVID-19 Therapy Given to Trump","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KB301","moa":"COL3A1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions\u2019 COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-105","moa":"PSCA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS119","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NBI-921352","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Zydus Cadila","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus launches India\u2019s first pressurized Metered Dose Inhaler for patients suffering from Chronic Obstructive Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Cadila","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zydus Cadila \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Cadi.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera to Discontinue Phase 3 SIDEROS Study and Development of\n Puldysa\u00ae in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Phase 2b\/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TaiGen Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Quest Products","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces Agreement For a Fundraising of Approximately $50 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quest Products","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Quest Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quest Prod.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biontech and Pfizer Initiate Rolling Submission to European Medicines Agency For Sars-Cov-2 Vaccine Candidate BNT162B2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Next-generation Wet AMD Therapy Beovu\u00ae, Now Available in Canada, Receives Positive Recommendation from CADTH Drug Expert Committee","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$15.0 million","newsHeadline":"Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"CRISPR based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0.41999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed\/Refractory AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients with Crohn\u2019s Disease AND Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meabco Gets $5.9 M US Government Contract to Advance Its Bp-C2 Compound for Cutaneous Radiation Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Meabco \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ N.."},{"orgOrder":0,"company":"Dren Bio","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dren Bio Announces a $60M Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"DR-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dren Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Dren Bio \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dren Bio \/.."},{"orgOrder":0,"company":"Essex Biotechnology","sponsor":"Henlius","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$10.0 million","newsHeadline":"Essex and Henlius Ink Global Co-Development and License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Essex Biotechnology","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Essex Biotechnology \/ Henlius","highestDevelopmentStatusID":"10","companyTruncated":"Essex Biot.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Connectyx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Connectyx","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"AnGes","sponsor":"Er-Kim","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene\u00ae in Turkey","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Beperminogene Perplasmid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Er-Kim","highestDevelopmentStatusID":"12","companyTruncated":"AnGes \/ Er.."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia Executes Agreement with GCAR To Commence GBM Agile Pivotal Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Paxalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Global Coalition for Adaptive Research \/ Kazia","highestDevelopmentStatusID":"8","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$100.0 million","newsHeadline":"Vifor Pharma and Cara Therapeutics Sign US License Agreement for IV Korsuva\u2122* to Treat Dialysis Patients with Pruritus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"BioEleven","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Partners with BioEleven for Cancer Immunotherapy Development and Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"BN-101A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ BioEleven","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland BioLabs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Noroxymorphone analogs","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ .."},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Biologics Receives Grant to Enable an Antibody Product for the Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Anti-SARS-CoV-2 antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","amount":"$305.0 million","upfrontCash":"$40.0 million","newsHeadline":"ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Immunogen \/ Huadong Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Sesen Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio Ink Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharma Distribution Services for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cardinal Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardinal Health \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Cardinal H.."},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-Beta for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Akron Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Akron Biot.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$50.0 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Genomics \/ qilu pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.11,"dosageForm":"","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"RGN-259","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Disarm Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,360.0 million","upfrontCash":"$135.0 million","newsHeadline":"Lilly Announces Agreement to Acquire Disarm Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"SARM1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Disarm Therapeutics","amount2":1.3600000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.3600000000000001,"dosageForm":"","sponsorNew":"Disarm Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Disarm The.."},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Thera.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz Canada","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amryt and Swixx Sign Distribution Deal for Lojuxta","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Swixx BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Swixx BioPharma \/ Amryt","highestDevelopmentStatusID":"12","companyTruncated":"Swixx BioP.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$28.6 million","upfrontCash":"Undisclosed","newsHeadline":"EIB Provides Immunic With up to \u20ac24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Nevakar","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nevakar and Zhaoke Ophthalmology Enter into Licensing Agreement for NVK-002 (Atropine to Treat Progression of Myopia in Children)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Zhaoke Ophthalmology \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Oph.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Credit Suisse","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuno-Oncology Biotech Compass Therapeutics Files for a $50 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Credit Suisse","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Cevec","sponsor":"Rznomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec and Rznomics Sign License Agreement for THE Use of CAP\u00ae Technology inManufacturing of Adenoviral Vectors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RCA-free adenoviral vectors","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cevec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ Rznomics","highestDevelopmentStatusID":"1","companyTruncated":"Cevec \/ Rz.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Enters into a License Agreement for Chugai\u2019s Antibody Engineering Technologies with Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Circuit Clinical","sponsor":"Intrommune Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intrommune Therapeutics Strikes Deal with Circuit Clinical\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Circuit Clinical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circuit Clinical \/ Intrommune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Circuit Cl.."},{"orgOrder":0,"company":"Regenerative Care Network","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin\u2122 for Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Regenerative Care Network","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenerative Care Network \/ Organicell","highestDevelopmentStatusID":"5","companyTruncated":"Regenerati.."},{"orgOrder":0,"company":"NKMax","sponsor":"Affimed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"AFM24","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NKMax \/ Affimed","highestDevelopmentStatusID":"4","companyTruncated":"NKMax \/ Af.."},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Parexel Biotech Collaborates with Synairgen on Pivotal Phase III Trial for Study of Inhaled COVID-19 Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Parexel Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Bi.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma and University Of Georgia Team Up To Develop A New Anti-Coronavirus Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"SBFM-PL4","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Symvivo","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Symvivo Corporation Receives Funding for COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"bacTRL-Spike vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EU Signs Supply Deal with J&J on Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"InCarda Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"InCarda Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"The University Of Colorado Anschutz Medical Campus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma and The University Of Colorado Anschutz Medical Campus Collaborate To Advance Medicines For Genetically Driven Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lubrizol Expands Partnership with the Population Council","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Segesterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lubrizol Life Science Health","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lubrizol Life Science Health \/ Population Council","highestDevelopmentStatusID":"1","companyTruncated":"Lubrizol L.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Broad Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"PARG","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Broad Institute","highestDevelopmentStatusID":"2","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals Awarded an NIH Grant to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"131-I Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharma Signs a License Agreement with Diurnal for the Registration and Commercialization of Alkindi\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ EffRx","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech Ink 2nd Collaboration with Roche to Evaluate NT-I7 in Combination with PD-L1 Checkpoint Inhibitor in First-line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"F. Hoffmann-La Roche \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"University of Sydney","sponsor":"Medicinova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 in Chemotherapy-Induced Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"University of Sydney","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Sydney \/ MediciNova","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"IAVI","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 neutralising monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAVI \/ Merck KGaA","highestDevelopmentStatusID":"2","companyTruncated":"IAVI \/ Mer.."},{"orgOrder":0,"company":"ProteoNic","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant protein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ Immunomedics","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic .."},{"orgOrder":0,"company":"Lassogen","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lassogen Raises Seed Round to Develop Novel Therapeutics for Challenging Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"LAS-103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lassogen \/ Playground Global","highestDevelopmentStatusID":"4","companyTruncated":"Lassogen \/.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent to Present Data on BI-1808, an Anti-TNFR2 Antibody, at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Writes Off Ulcerative Colitis Portion of Etrolizumab Program, Days After Dissecting Phase III Setback","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"Beta-7 integrin Ligand binding","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Antibody Cocktail REGN-EB3 (INMAZEB\u00ae) Is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atoltivimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Sarclisa Bags NICE Recommendation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to RedHill\u2019s RHB-204 to Treat Nontuberculous Mycobacteria Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives US FDA Approval to Market Fingolimod Capsules & Verapamil HCl Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files a New Drug Application for Risdiplam as the First Oral Drug for Spinal Muscular Atrophy in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solidarity Therapeutics Trial Produces Conclusive Evidence on the Effectiveness of Repurposed Drugs for COVID-19 in Record Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ W.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Castle Creek Biosciences Announces First Patient Dosed in Phase 1\/2 Clinical Trial of FCX-013 Gene Therapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FCX-013","moa":"MMP-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Castle Creek Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genomic Study of 6000 NCI-MATCH Cancer Patients Leads to New Clinical Trial Benchmarks","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Afatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ECOG-ACRIN.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Plans Phase III Trial of Cancer Drug for COVID-19, Shares Jump","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm Filed an Application for Partial Changes to the Manufacturing and Marketing Approval Matters of Anti-Influenza Drug Avigan\u00ae Tablet in Japan to Include Additional Indication for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Beijing Institute of Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Vaccine Candidate from China's CNBG Shows Promise in Human Test","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BBIBP-CorV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Beijing Institute of Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beijing Institute of Biological Products \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beijing In.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Respira to Present Clinical Data on RT234-PAH Patient-Controlled Treatment to Acutely Improve Episodic Symptoms in PAH Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vardenafil Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Respira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics to Present New Tyvaso\u00ae Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda-1a","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Gummy Company Secures The First (IND) Gummy Drug Approval From FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seattle Gummy \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gu.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Gets Clearance of IND Application to Initiate Phase 1b\/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Publication of CENTAUR Survival Data Showing Statistically Significant Survival Benefit of AMX0035 for People with ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European CHMP Adopts Positive Opinion for Kite\u2019s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharmaceuticals Announces Data Presentations for CMP-001 at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Meabco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BP-C2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meabco \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ N.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Flotetuzumab Publication in Blood Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with ASD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Publishes Paper in Journal of Clinical Oncology Demonstrating Relevance of Iadademstat in Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics to Present Esophagogastric Cancer Data at SITC 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis to Present Data from Ongoing ADXS-503 Phase 1\/2 Clinical Trial at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen's APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zonisamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company\u2019s Abemaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Sermonix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix P.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-9","moa":"Complement C3 inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Antisense Medicine Being Evaluated in an investigator-Initiated Clinical Study of COVID-19 Patients in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IONIS-PKK-LRx","moa":"Prekallikrein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarkers Associated With Clinical Response in Patients With r\/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented by IMV at the Upcoming SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion Biotechnology Successfully Completes Phase 1 Clinical Trial of a First-in-Class Precision Engineered Ligand Analog for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OB-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Transfers OS Therapies' IND Application OST-HER2 (Listeria monocytogenes) to OS Therapies in Record Time","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OST-HER2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Seek Approval for Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Receives Positive CHMP Opinion on PALFORZIA\u00ae for the Treatment of Patients with Peanut Allergy in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Study Aims to Identify Promising COVID-19 Treatments for Larger Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Accepts Eisai\u2019s sNDA for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures, Paediatric Indication for Partial Onset Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's VENCLEXTA\u00ae (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Regeneron's Dupixent\u00ae (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents 3-years Survival Data for KEYTRUDA\u00ae in Combination With Chemotherapy and Updated Phase 1\/2 Data for MK-1308 and KEYTRUDA Combo in Advanced Non\u2011Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone furoate","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 OMS906 Data Presented at Complement-based Drug Development Summit","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy\u2122 for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Libmeldy","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion for Leqvio\u00ae, a Potential First-in-Class siRNA for the Treatment of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the ESID 2020 Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Pharma India will Launch Calquence in India on Oct 21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MRT5500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"5","companyTruncated":"Sanofi \/ T.."},{"orgOrder":0,"company":"VelosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VLS-101","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VelosBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Submitts Investigational New Drug Application to FDA for the Second Drug Candidate from the PDC Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OPD5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-MOSPD2 monoclonal antibodies","moa":"MOSPD2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval from USFDA for Tofacitinib Extended-Release Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European CHMP Adopts Positive Opinion for Kite\u2019s KTE-X19 for THE Treatment of Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Immune checkpoint inhibitor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OncoMyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Th.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ\u2122 (upadacitinib) in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released by Astellas Pharma at the ASN Kidney Week 2020 Reimagined","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"AmacaThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmacaThera to Commence Phase 1 Clinical Trial for Non-Opioid, Post-Operative Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-143","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AmacaThera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmacaThera \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AmacaThera.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Reaches 50% Treated Patients in Ongoing JTA-004 Phase III Pivotal Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals\u2019 Lead Compound CPI-613\u00ae\ufe0f for Patients With Pancreatic Cancer in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777 for the Treatment of Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Abpro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ABP 300","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Abpro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abpro \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Abpro \/ No.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Announces Upcoming Scientific Presentations at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Announces Late-Breaking Presentation of CM-101 First Evidence of Anti-Fibrotic Activity in NAFLD Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Montanide ISA 51VG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Treos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Receives Ethics Approval to Start Phase I\/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE\u00ae 327 on Chronic Burn Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Recce 327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Midatech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Midatech P.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 for Cryptococcal Meningitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Bristol Myers Squibb's Priority Review Applications for OPDIVO\u00ae in Combination with CABOMETYX\u00ae in Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b\/2 study for Etigilimab (Anti-TIGIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Forxiga Recommended for Approval in the EU by CHMP for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"World Health Organization","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead's remdesivir has 'little or no effect' on COVID-19 recovery or mortality: WHO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ World Health Organization","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 Mayzent Receives Approval from the Scottish Medicines Consortium as the First Recommended Treatment in Scotland for Patients Living with Secondary Progressive Multiple Sclerosis (SPMS) with Active Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Siponimod fumarate","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"AskBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmTOR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Asklepios BioPharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Receives FDA Fast Track Designation in MPS VI for its Clinical-Stage Asset Odiparci","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Odiparcil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NGM707","moa":"ILT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology to Present Preclinical Data on OP-1250, Lead Program in Breast Cancer, at ENA 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Presents Positive Efficacy and Biomarker Data from mCRPC Trial Showing Ability of Onvansertib to Overcome Zytiga\u00ae Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the AACR Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-VISTA antibodies","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav\u2122 Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"NeuClone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuClone Announces Positive Results from Phase I Study of Stelara\u00ae (ustekinumab) Biosimilar Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"NeuClone","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuClone \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuClone \/.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Updates Progress of Human Clinical Trial with Tacrolimus Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces Activation of First Clinical Site in Phase 2 Study of NTX-001 for the Treatment of Nerve Repair","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinovac Vaccine is Safe, Brazil Institute Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Butantan Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Butantan I.."},{"orgOrder":0,"company":"Chumakov Federal Scientific Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia\u2019s Chumakov Center Begins Clinical Trials of its COVID-19 Vaccine in St. Petersburg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chumakov Federal Scientific Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chumakov Federal Scientific Center \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Chumakov F.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Presents Positive Clinical Data on Maternal and Older Adults RSV Candidate Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GSK3888550A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Ethacrynic Acid Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ethacrynic Acid","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priority Review Granted to Ascentage Pharma's NDA for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the IDSA IDWeek Conference 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces Publication of Study in Immunity Highlighting the Discovery of Novel T Cell Targets in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"T Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio B.."},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gusacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives US FDA Orphan Drug Designation for branaplam (LMI070) in Huntington\u2019s disease (HD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Branaplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Receives Orphan Drug Designation from EC for Leniolisib for the Treatment of Activated Phosphoinositide 3-Kinase Delta Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leniolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Actemra May Curb Covid Deaths in Critical Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"IncellDx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IncellDx to Study Maraviroc in a COVID-19 Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Maraviroc","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IncellDx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IncellDx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IncellDx \/.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-400945","moa":"PLK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Tagrisso Granted Priority Review in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b\/3 COVID-19 Registrational Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Launches Nintib to Treat Idiopathic Pulmonary Fibrosis, in Continuation of its Fight Against Rare Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Fast Track Designation to Astellas Pharma's ASP0367\/MA-0211","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASP0367","moa":"PARP delta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Brigham and Women\u2019s Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brigham and Women\u2019s Hospital's Study Shows Rheumatoid Arthritis Drug Tocilizumab Advances as a COVID Treatment, as Other Regimens Fall Back","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brigham and Women\u2019s Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brigham and Women\u2019s Hospital \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brigham an.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110\u2122 in Relapsed or Refractory CD19+ B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX110","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma to Present Amphetamine Extended-Release Tablet Data at the American Academy of Child and Adolescent Psychiatry Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Plecanatide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Announce Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV\u00ae in Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"RayzeBio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"RayzeBio \/ venBio Partners","highestDevelopmentStatusID":"1","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device Mirena\u00ae 52 mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Sterile Inserter","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PCI Biotech: Preclinical Research Collaboration with Big Pharma Ended","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"AavantiBio","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"AavantiBio Launches with $107 Million Series A Financing Perceptive Advisors Including Sarepta Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"AavantiBio \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio.."},{"orgOrder":0,"company":"Arixa Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arixa Pharmaceuticals Announces Acquisition by Pfizer\u2019s Hospital Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"ARX-1796","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arixa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arixa Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Arixa Phar.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Receives \u20ac2 million Milestone from Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1055","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Th.."},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Biotech","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"$3.0 million","newsHeadline":"Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ketorolac Trometamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Nuance Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum .."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$350.0 million","newsHeadline":"Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"AZR-MD-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Azura Ophthalmics \/ OrbiMed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Longwood Fund","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Engineer B cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Be Biopharma \/ Longwood Fund","highestDevelopmentStatusID":"1","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","amount":"$517.0 million","upfrontCash":"$90.0 million","newsHeadline":"Retrophin Announces Agreement to Acquire Orphan Technologies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0.52000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Orphan Technologies \/ Retrophin","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Tec.."},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Announces Further Uk Government Funding for Further Development of A Novel Ig E Antibody Cancer Immunotherapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"EPS 201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Epsilogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epsilogen \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Epsilogen .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Antibody-targeted Amanitin-Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ Heidelberg Pharma","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Jefferies and Piper Sandler","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares\n and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Jefferies and Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Rotating Boulder Fund","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics Sealed US$105M Series D Financing to Fund RNAi Therapeutics for Cancers, Fibrotic Diseases and Viral Infections Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series D Financing","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Sirnaomics \/ Rotating Boulder Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Aerogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$21,000.0 million","upfrontCash":"$15,000.0 million","newsHeadline":"Gilead Sciences Completes Acquisition of Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":21,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":21,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entos Pharmaceuticals Awarded Funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Covigenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Entos Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ NRC IRAP","highestDevelopmentStatusID":"6","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$18.2 million","upfrontCash":"Undisclosed","newsHeadline":"Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Orbus Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Voronoi","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","amount":"$621.0 million","upfrontCash":"$5.0 million","newsHeadline":"Oric Pharma Teams up With Korean firm to Expand Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ORIC-114","moa":"Irreversible EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voronoi","amount2":0.62,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.62,"dosageForm":"Oral","sponsorNew":"Voronoi \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Voronoi \/ .."},{"orgOrder":0,"company":"Carelink","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Partners with Chinese Pharmaceutical Company Carelink in Deploying Anti-influenza Drug Avigan\u00ae Tablets in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carelink","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Carelink \/ Fujifilm","highestDevelopmentStatusID":"10","companyTruncated":"Carelink \/.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"$295.0 million","upfrontCash":"$40.0 million","newsHeadline":"Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"SGT-001","moa":"Dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.29999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"PAO Group","sponsor":"Undiaclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PAO Group \/ Undiaclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group .."},{"orgOrder":0,"company":"hVIVO","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"$13.1 million","newsHeadline":"UK Government Invests in Human Challenge Trials for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"hVIVO","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"hVIVO \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"hVIVO \/ UK.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Surrozen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"$1.0 million","newsHeadline":"Surrozen Awarded NIH Grant to Support Development of SZN-043","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Announces Three Additional Clinical Centers to Recruit Patients for NOX-A12 Brain Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson Establishes new $50M+ Biotech Fund to Choose the Next Promising Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Cancer therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund.."},{"orgOrder":0,"company":"George Mason University NCBID","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"ARDS-003","moa":"CB2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"George Mason University NCBID","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"George Mason University NCBID \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"4","companyTruncated":"George Mas.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa\u00ae Mucoadhesive Delivery Technology for Dronabinol","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IntelGenx \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$4,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"Bayer Acquires Asklepios Bio Pharmaceutical to Broaden Innovation Base in Cell and Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"AAV2\/8LSPhGAA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Bayer","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceutical Developer Vallon Pharmaceuticals Files for a $17 million IPO","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vallon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$35.0 million","newsHeadline":"Jazz Pharmaceuticals Acquires Spring Works Therapeutics' Faah Inhibitor Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0.40999999999999998,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Tumor Biotech SQZ Biotechnologies Sets Terms for $75 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GEO-CM01","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ GeoVax","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"USAMRIID","sponsor":"Vaxil Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxil Enters Into a Cooperative Research and Development Agreement With USAMRIID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"CorVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"USAMRIID","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"USAMRIID \/ Vaxil","highestDevelopmentStatusID":"4","companyTruncated":"USAMRIID \/.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,340.0 million","upfrontCash":"$1,175.0 million","newsHeadline":"Anaptysbio and Glaxosmithkline Amend Strategic Immuno-Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":1.3400000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3400000000000001,"dosageForm":"","sponsorNew":"AnaptysBio \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Ministry of Public Health of Qatar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Ministry of Public Health of Qatar","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"ISOThrive Awarded $800K Virginia Catalyst Grant to address major unmet need in gastroesophageal reflux disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Maltosyl-isomaltooligosaccharide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regenxbio to Receive $80.0 Million Milestone Payment from Novartis Ag","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"NAV AAV9 vector","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Regenxbio","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncolytics Biotech\u00ae Collaborates with Roche and AIO to Initiate a Phase 1\/2 Gastrointestinal Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Oncolytics Biotech","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"$5.0 million","newsHeadline":"BioInvent Licenses Anti-Fc\u03b3RllB Antibody BI-1206 to CASI Pharmaceuticals for Greater China Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$150.0 million","newsHeadline":"CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: Sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":1.3,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ EQRx","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"University of California","sponsor":"Releviate Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RLVT-9-01","moa":"MMP-9","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Releviate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"European Medicines Agency","pharmaFlowCategory":"D","amount":"$207.8 million","upfrontCash":"Undisclosed","newsHeadline":"Arvelle Announces Closing of Final Tranche of Series A Financing Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ European Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese Rare Disease Player inks First Deal Around Narcolepsy Drug Wakix After Grabbing $80M to Build an Ecosystem","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harmony Biosciences \/ Citrine Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Immutep","sponsor":"University Hospital Pilsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces the Start of an Investigator-Initiated\n Phase II Study in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ University Hospital Pilsen","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 \u201cVIOLET Studies\u201d for Oteseconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPS\u2122 Vaccine for Streptococcus pneumoniae at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASP3772","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Dosed First Patient in the Phase 1\/2 GRECO-1 Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GC4711","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Presentation of Tapinarof Pivotal Phase 3 PSOARING Data at Fall Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1\/2 Inhibitor, at the 32nd EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASN007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Offers Insights on Treatment with KRYSTEXXA\u00ae Among Kidney Transplant Patients for the Management of Uncontrolled Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Allergy and Clinical Immunology Publishes Results from BioCryst\u2019s APeX-2 Pivotal Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STORM Therapeutics Selects First-in-Class Clinical Candidate Targeting METTL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"STC-15","moa":"METTL3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Storm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DS-1055","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Focuses on ATOR-1017 and Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olorofim","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Anti-Epileptic Drug Vimpat[\u00ae] (lacosamide) Receives EU CHMP Positive Opinion for Primary Generalised Tonic-Clonic Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Continued Positive Findings From First-Ever Implementation Science Study on Integrating an Investigational Once-Monthly Injectable HIV Treatment into US Healthcare Practices","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive New Findings from Two Studies of its Investigational, Long-Acting Regimen of Cabotegravir and Rilpivirine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with ENIGMA in the NEJM","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ J.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseases 2020 Virtual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danish Biotech UNION Therapeutics A\/S Adds Program to Prevent COVID-19 With Intranasal Delivery of Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefepime","moa":"Peptidoglycan synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"VenatoRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics & Pivotal Advance into a Phase IIa Trial to Examine Gastro-Intestinal Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BO-112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Pivotal","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Gets Fast Track Designation by the FDA to Ublituximab in Combination with Umbralisib for Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Presents New Data on VIR-2482 at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Secures New European Patent for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Provides Clinical Trial Updates for Haduvio\u2122","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zosano Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Presenting New Data on NUZYRA\u00ae (Omadacycline) at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxeia Biopharmaceuticals, Inc. Announces Initiation Of Phase 2 Trial For OXE103 For The Treatment Of Concussions","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Ghrelin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxeia Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biop.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Pfizer\u2019s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at Idweek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Gets CDSCO Nod to Conduct Phase III Covid-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Novel COVID-19 Vaccine Candidate hAd5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Receives US FDA Approval for Generic Ofirmev Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Gilead\u2019s Antiviral Veklury\u00ae (remdesivir) for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SOM Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotec.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis' Third Novel Antisense Medicine for ALS, its First Designed to Treat a Broad ALS Population, Begins Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ION541","moa":"Ataxin 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Vycellix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NK Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Vycellix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vycellix \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vycellix \/.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents New Interim Data From PHYOX\u21223 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients with Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Interim Data from First Cohort of Patients in Pilot Phase 1\/2 Clinical Trial of GC4419 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ansun Biopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ansun Biopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ansun Biop.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces European Medicines Agency (EMA) has Granted Orphan Drug Designation for Iptacopan (LNP023) in IgA Nephropathy (IgAN)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dovitinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Sumitomo Chemical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Chemical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Chemical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo C.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Designation for TransCon\u2122 PTH for Treatment of Hypoparathyroidism in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's and Lilly's New Jardiance\u00ae Findings Showed Improved Cardio-Renal Outcomes in Adults with Heart Failure with Reduced Ejection Fraction Regardless of CKD status","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Provides Pemziviptadil (PB1046) Program Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Accelerates Arimoclomol Pre-Launch Activities and Updates Financial Outlook for 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Nevakar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-To-Use Vials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ephedrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nevakar","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of Tenapanor at ASN's Kidney Week 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm\u2019s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"TrippBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrippBio Completes Enrollment in a Proof of Concept Trial Evaluating the Efficacy of TD213 in Treating Patients with Confirmed COVID-19 Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TD213","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TrippBio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112 in Metastatic Castration Resistant Prostate Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the ASN Kidney Week 2020 Reimagined","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Publishes Data Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRP\u03b1 BI 765063","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OSE-172","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Receives Notice of Intent to Grant a New Patent Enhancing THE Protection IN Europe of Asidna\u2122 Combined with Parp Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanifit Presents New Data for SNF472 in Treatment of Vascular Calcification at ASN Kidney Week 2020","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces U.S. FDA Approval for Enstilar\u00ae (Calcipotriene and Betamethasone Dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-Term Use in Plaque Psoriasis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Pharmaceuticals Wins FDA Approval of Its IND Application for Treatment of COVID-19 With Rejuveinix (RJX)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flublok Vaccine Given Authorisation for Temporary Supply in the UK to Meet Public Health Need","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Flublok Quadrivalent","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd\n EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes Researchers Find Effective COVID-19 \u2018Cytokine Storm\u2019 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia's European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Announces Enrollment of First Patient in Phase Ib\/II Study Revocan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the ASHG 2020 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gavorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to CKD in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Positive Top-Line Olutasidenib Data From A Planned Interim Analysis Of A Registrational Phase 2 Clinical Trial In AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (Dupilumab) Late-Breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis - First US Patient Enrolled in COVA, a Multinational\n Phase 2\/3 Clinical Trial with Sarconeos (BIO101) for the\n Treatment of COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh10-h.SGSH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce Positive Interim Phase 1\/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Dosed First Patient with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"Tie2 activator\/Vascular endothelial protein tyrosine phosphatase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CB5138 Analog peptides","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Beat AML, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beat AML, LLC Study in Nature Medicine Shows Superior Outcomes for Patients in The Leukemia & Lymphoma Society's Paradigm-Shifting Beat AML Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"CD200","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beat AML, LLC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beat AML, LLC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beat AML, .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa's New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at ACR Convergence","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Announces FDA Orphan Drug Designation For TRC102 In Malignant Glioma, Including Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis\u2019 ADXS-503 Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1\/2 Lung Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Flatley Discovery Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vatiquinone","moa":"15-LOX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Flatley Discovery Lab","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flatley Discovery Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Flatley Di.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Publication Shortlists Resverlogix's Apabetalone for Its Potential Covid-19 Effectiveness Including Reducing Cytokine Storms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"University of Maryland School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Maryland School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Initiates Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at ASCAT Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib for Cholangiocarcinoma Fran\u00e7ais","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOi Receives FDA Approval to Begin the Trial on its New Drug NOviricid to Treat COVID 19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Nitric Oxide Innovations \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxi.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP\u00ae Biomarker Patents","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dovitinib","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke and Eversana Announce Commercial Launch of Gimoti\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Antitumor Activity of Tipifarnib in Combination with PI3K\u03b1 Inhibitor in Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SHR0302","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone B.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Announces U.S. FDA Filing Acceptance of NDA for Cyclosporine Topical Ophthalmic Emulsion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viral Clear Halts Its Phase 2 Hospitalized Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Seribantumab","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Allakos' Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Shows Improvement in HF Patients Measured by Exercise Outcomes and Cardiac Function","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Presents Preclinical Data on Anti-Angiogenic Activity of Derazantinib at ENA 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Promising Interim Phase II Data of Potential First-in-Class Oral Therapy Iptacopan in Rare Renal Disease C3 Glomerulopathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel to Start COVID-19 Vaccine Human Trials on Nov. 1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntrix Completes Initial SX-682 Dosing in Broad Phase 1\/2 Cancer Trial Campaign","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SX-682","moa":"CXCR1\/CXCR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syntrix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Ph.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Data Revealing Novel Mechanistic Attributes for PT-112 at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer\u2019s Abrocitinib","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DHA-dFdC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkido Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkido Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alkido Pha.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at EADV Virtual Congress October 29","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Dosed First Patient in ASPEN-02","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Global Coalition for Adaptive Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"KYE Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KYE Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KYE Pharma.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANA Therapeutics Begins Phase 2\/3 Clinical Trial of Proprietary Oral Niclosamide Formulation to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics to Present at TSX Life Sciences Investor Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event \"COVID-19 Therapeutics in Development\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Enhertu Granted Priority Review in the US for the Treatment of HER2-Positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Forxiga Cardiovascular Outcomes Benefit Approved in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuronasal \/ ATAI","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genome & Company Announces First Patient Dosed in Phase 1\/1b Study of GEN-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioArctic\u2019s Partner Eisai to Present Latest Data on BAN2401 at CTAD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTA Approval of BioInvent\u2019s BI-1808, a First-in-Class Anti-TNFR2 Antibody, Sets Stage for Phase I\/IIa Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 764198","moa":"TRPC6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals to Share New Reproductive Medicine Data at ASRM 2020 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Menotropins","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Draft Guidance Recommends Eli Lilly's Galcanezumab for Preventing Migraines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Versantis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versantis Receives FDA Rare Pediatric Disease Designation for VS-01 for the Treatment of Urea Cycle Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-01","moa":"Ammonia clearance","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Versantis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Versantis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versantis .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Dosed in Appili Therapeutics\u2019 Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Advances Leadership in Renal Disease with More Than 80 Abstracts at ASN Kidney Week 2020 Reimagined","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamada Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 IgG Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Israeli Health Authorities","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ I.."},{"orgOrder":0,"company":"University of Alberta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Alberta Study Shows Targeted Delivery of Anti-Inflammatory Therapy Shows Promise in Slowing Progression of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Belnacasan","moa":"Caspase-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Alberta","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Alberta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces Positive Top-Line Phase 3 Results for Oral Masitinib in Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"University Medical Center Utrecht","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University Medical Center Utrecht Study Shows that Crushed Prasugrel Prehospital Fails to Improve STEMI Reperfusion vs. Integral Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Medical Center Utrecht","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Medical Center Utrecht \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"University.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$22.5 Million","upfrontCash":"$14.0 million","newsHeadline":"Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"SNSP003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Anagram Therapeutics \/ CF Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Th.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Dinona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Inks Development Partnership with Dinona for Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"DNP-019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Dinona","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"SparingVision","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$51.9 million","upfrontCash":"Undisclosed","newsHeadline":"SparingVision Raises \u20ac44.5 Million and Appoints St\u00e9phane Boissel\n as Chief Executive Officer","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ 4BIO Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$592.3 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Successfully Completes Capital Increase with Gross Proceeds of CHF 535.5 Million","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0.58999999999999997,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.63,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Amerimmune","sponsor":"Histogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Histogen and Amerimmune Enter into a Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Emricasan","moa":"Caspase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Amerimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amerimmune \/ Histogen","highestDevelopmentStatusID":"5","companyTruncated":"Amerimmune.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Miragen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viridian Therapeutics \/ miRagen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"$150.0 million","newsHeadline":"Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0.28000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Acquisition","pharmaFlowCategory":"D","amount":"$850.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"NUV-422","moa":"CDK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0.84999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Panacea Acquisition","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"FHD-286","moa":"Allosteric ATPase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Foghorn Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"4","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50 M Payment from Astrazeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"NKG2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"ImStem Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ ImStem Biotechnology","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus\u2019s Novel Anti-TIGIT Antibody, Plus Imfinzi\u00ae in Stage III NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Insitro","amount2":2.1000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Insitro \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Insitro \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Gavi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Axplora","sponsor":"Sensorion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AAV vectors","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axplora","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axplora \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Axplora \/ .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$1,245.0 million","upfrontCash":"$250.0 million","newsHeadline":"Sobi and Apellis Enter Collaboration for Global Co-Development and Ex-Us Commercialisation of Systemic Pegcetacoplan in Rare Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":1.25,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.25,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"CAM Capital","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Announces $27.4 Million Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ CAM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for Ramucirumab in the Ongoing Fides-03 Study with Derazantinib in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"LianBio","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$310.0 million","upfrontCash":"Undisclosed","newsHeadline":"LianBio Announces $310 Million Crossover Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0.31,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.31,"dosageForm":"Capsule","sponsorNew":"LianBio \/ RA Capital","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","amount":"$149.0 million","upfrontCash":"$50.0 million","newsHeadline":"Santen and Aerie Conclude Exclusive License Agreement for Rhopressa\u00ae and Rocklatan\u00ae in Japan and Several Other Asian Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Teams Up with Merck to Pair Keytruda with a Next-Gen IL-2 Candidate from the Synthorx Buyout","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"THOR-707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Government of Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Government of Japan","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"JT Pharmaceuticals","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"JT-09","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"JT Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JT Pharmaceuticals \/ Titan Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"JT Pharmac.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Tadekinig alfa","moa":"IL-18","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$517.0 million","upfrontCash":"$37.0 million","newsHeadline":"XOMA Earns $25 Million Milestone Payment as Anti-TGF\u03b2 Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Gemcitabine Hydrochloride","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0.52000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Nov.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Multiple Myeloma Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical Development of Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Allogeneic G-NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Prokarium","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prokarium Closes $21M Series B Financing Round and Strengthens Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Vesibax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Prokarium \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"CellCentric","sponsor":"Morningside Venture Investments","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"CellCentric Raises $33m to Broaden Clinical Trials of its First-in-Class p300\/CBP Inhibitor, CCS1477","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"CCS1477","moa":"Acetyltransferases p300\/CBP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Morningside Venture Investments","highestDevelopmentStatusID":"7","companyTruncated":"CellCentri.."},{"orgOrder":0,"company":"OncoBeta","sponsor":"NanoMab Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoMab and OncoBeta Outline the Pathway to a Strategic Alliance and Supply Agreement Focused on the Secure Supply of Rhenium-188","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Rhenium-188","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"OncoBeta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoBeta \/ NanoMab","highestDevelopmentStatusID":"1","companyTruncated":"OncoBeta \/.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$11.3 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"DOD Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ology Bioservices","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ADX-914","moa":"IL-7R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oscine","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Acquisition of Oscine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Glial progenitor cell therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oscine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oscine \/ Sana Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Oscine \/ S.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Bill & Melinda Gates Foundation and Open Philanthropy","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"IVX-411","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Icosavax \/ Bill & Melinda Gates Foundation and Open Philanthropy","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"$12.0 million","newsHeadline":"Ocular Therapeutix\u2122 and Affamed Therapeutics Announce License Agreement and Collaboration for Dextenza\u00ae AND Otx-Tic IN Asia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ AffaMed Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Rugen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Ce.."},{"orgOrder":0,"company":"Genmab","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Camidanlumab tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ ADC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced Chemotherapy Technologies, Inc. Announces $5.5M Series A Financing Round led by Khosla Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"ACT-IOP-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Advanced Chemotherapy Technologies","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Advanced C.."},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"EPIM-001","moa":"IL-2R beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpis Biopharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Elpis Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Elpis Biop.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics and Horizon Therapeutics plc Expand Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AGC Biologics \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"University of Campinas","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BRAZIL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Campinas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Campinas \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$40.0 million","newsHeadline":"Fochon Pharmaceuticals Announces Licensing Agreement with Eli Lilly and Company for Novel Selective BCL-2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tufts Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tufts Medical Center \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Tufts Medi.."},{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synedgen Receives Supplemental NEI Funding To Identify Lead Development Candidate for Ocular Mustard Gas Injury Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Synedgen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synedgen \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"Synedgen \/.."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"EIB Provides Minoryx with up to \u20ac25 Million to Support Development of Breakthrough Therapies in Orphan Neurodegenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Leriglitazone","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Minoryx Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Biotechnology Industry Research Assistance Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Partners with Department of Biotechnology - BIRAC for Sputnik V Vaccine Clinical Trials in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Biotechnology Industry Research Assistance Council","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Mebias Discovery","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$7.1 million","upfrontCash":"Undisclosed","newsHeadline":"Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for Prevention of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"MEB-1170","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mebias Discovery","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Mebias Discovery \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Mebias Dis.."},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Aptar Pharma \/ Opiant Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Phar.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan for Anti-CGRP Antibody Galcanezumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$990.0 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"PN-235","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"Undisclosed","newsHeadline":"miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Miragen Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"Miragen Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"5","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of Debcoemagene Autoficel (D-Fi) Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant\u2019s Pivotal Phase 3 PSOARING Data for Tapinarof Cream in Adults with Plaque Psoriasis Selected at the 29th EADV Virtual Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Plans to Complete Phase 3 Trial of Sputnik V Covid Vaccine by March End","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dracen Pharmaceutical\u2019s DRP-104 Granted U.S. FDA Fast Track Designation for the treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data for Lilly's Bamlanivimab (LY-CoV555) in COVID-19 Outpatients Published in New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX\u00ae in Combination with OPDIVO\u00ae for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Presents Data from Its PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Interim Data from Pilot Phase 1\/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope's First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I\/II FOCUS Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna on Track to Report Late-Stage COVID-19 Vaccine Data Next Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC206","moa":"D2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Late-Stage Coronavirus Vaccine Trial is Near Complete Enrollment with 42,000 Volunteers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"GBA1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington\u2019s Disease in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial of CPI-613\u00ae (Devimistat) for Relapsed or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic\u2122 Oncology Product Candidate for HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's Shionogi Readies COVID-19 Vaccine for December Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipapkinogen sovacivec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, Starts Phase II Clinical Study HEART","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellodi Pharmaceuticals Presents Phase 2b Data at ACG 2020 on the Safety and Efficacy of Maintenance Treatment Following Induction of Remission in Eosinophilic Esophagitis with APT-1011","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Orally Disintegrating Tablet","sponsorNew":"Ellodi Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pha.."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Olatec Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Convalescent Plasma Misses the Mark in Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Council of Medical Research \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indian Cou.."},{"orgOrder":0,"company":"reVision Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"reVision Therapeutics Announces US FDA Grant of Rare Pediatric Disease and Orphan-Drug Designation for REV-0100 for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REV-0100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"reVision Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"reVision Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"reVision T.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BBP-589","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It\u2019s ERSG Library In Two Leading Journals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expected Therapeutic Dose Levels Achieved in Phase I Study with ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyl dendrimer","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"iVeena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iVeena Announces Positive Topline Results; IVMED-80 Advancing to Phase 3 Clinical Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IVMED-80","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"iVeena \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ N.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces FDA Approval of EYSUVIS\u2122 for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Provides Important Update on its Australian Clinical Study Design","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MeiraGTx to Present Data from Ongoing Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa at AAO 2020 Virtual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV2\/5-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JadiCell\u2122 Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double Blind FDA Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts For Priority Review LIBTAYO\u00ae (cemiplimab-RWLC) For Advanced Non-Small Cell Lung Cancer With PD-L1 Expression Of \u226550%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Kangtai Starts Mid-Stage Trial of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Kangtai Biological Products \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen K.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Tecentriq in Combination with Avastin Approved in China for People with the Most Common form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Clover Applies for Philippines COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 S-Trimer vaccine","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at EADV 2020 Confirm Lilly's Taltz\u00aeDemonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Announces Approval for Ph 1 Trial of Bladder Cancer Drug in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-1501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocontrolled","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Approves GlaxoSmithKline's Zejula as a First-Line Monotherapy Maintenance Treatment in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 spike protein plasmid DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces that Independent Monitoring Committee Recommends Halting REGN-COV2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Announces Interim BPX-601 Data and Corporate Restructuring","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Completed the Phase 2b Trial with Ziltivekimab in Cardiovascular Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Reports Results of Phase 2b Dose-Finding Study with Delgocitinib cream in Patients with Mild-to-Severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia During Late-Breaking Session at EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligomerix to Present at Clinical Trials on Alzheimer\u2019s Disease Conference & Life Sciences Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces First Patient Dosed in NIH ACTIV-5\/Big Effect Trial Evaluating Lenzilumab\u2122 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-15512","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SXC-2023","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promentis .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira\u00ae in Moderate-to-Severe Psoriasis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaBios and Orion Publish Scientific Article Describing Novel Cardiac Compound","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ORM-11372","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AnaBios","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnaBios \/ Orion","highestDevelopmentStatusID":"4","companyTruncated":"AnaBios \/ .."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children \u22652 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Announces Commercial Launch of XARACOLL\u00ae (bupivacaine HCI) Implant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Field Trip Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Field Trip Health Ltd. Provides Update on FT-104, Its Next Generation Psychedelic Molecule in Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-104","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Field Trip Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complete Data from Connect Biopharma's Phase 1b Study of CBP-201 Demonstrate Improvement in Patient Quality of Life and Atopic Dermatitis Symptoms","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with Terlipressin","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Avillion's Phase 2 Trial of Sonelokinab in Chronic Psoriasis Presented in Late-Breaking News Session at EADV 2020 meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonelokinab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avillion LLP \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avillion L.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ\u2122 (upadacitinib) in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"George Mason University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals and George Mason University Announce Public Release of Laboratory Testing Results on Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ George Mason University","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics to Present New Data from ARQ-151 Clinical Program at Three Global Dermatology Conferences","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Doses First Subject in Phase 1 Proof-of-Concept Study of ALG-000184 for Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 Trials of Tavapadon for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Trial for Hypertrophic Scars","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OLX10010","moa":"CTGF","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Sickle Cell Medicine Adakveo\u00ae approved in Europe to Prevent Recurrent Vaso-Occlusive Crises","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Crizanlizumab","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Data for Tralokinumab on Pooled Safety, S. Aureus Colonization Reduction and Impact on Vaccine Response Rates","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Announces First Patient Dosed in Phase1\uff0f2 Global Clinical Trial of JR-171 for MPS I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Green Light From DSMB to Continue its Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT\u2122 Glioblastoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IN-001","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Insignis Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"5","companyTruncated":"Insignis T.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek\u00ae 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present Study Update and Preliminary Data of Phase 2 Elevage Study Evaluating Azeliragon","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CAS 603148-36-3","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4\/8","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces Positive Results from Phase 3 Trial of Filsuvez\u00ae in Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at EADV","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies of Taletrectinib in ROS1+ NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Doses First Patient in Phase 1\/2 Clinical Trial for HB-202\/HB-201 Alternating Vector Therapy to Treat HPV16-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New PBC and NASH Data to be Presented at AASLD\u2019s The Liver Meeting Digital Experience\u2122","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IM Therapeutics Launches Phase 1b Trial of Lead Drug IMT-002 in Autoimmunity; Announces Positive Safety Data of Phase 1a Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyldopa","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therape.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte\u2019s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Improvements in Patient's Quality of Life Assessments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento's COVI-AMG\u2122 Neutralizing Antibody Intranasal Administration Prevented COVID-19 Disease Progression in Infected Hamsters","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVI-AMG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"PellePharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Patidegib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"PellePharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PellePharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm.."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor Completes Recruitment in Phase III Trial of Balixafortide in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffyImmune Enrolls First Patient in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AIC100","moa":"ICAM-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AffyImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Efficacy and Safety in Patients as Young as Six Years with Moderate-To-Severe Atopic Dermatitis Further Reinforced by New Analyses Presented at EADV","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCLA Begins Recruitment For Phase 3 Of The Oxford University - AstraZeneca COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Oxford Biomedica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson\u2019s Disease R&D Day on October 30, 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Oxford Biomedica","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoinvent Advances Radspherin[\u00ae] to Third Dose Level in Ongoing Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 SITC Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MSIDS Research Foundation Study Finds That Leprosy Drugs Provide Potential Cure for Chronic Lyme Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MSIDS Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Rese.."},{"orgOrder":0,"company":"Cerecin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecin's Tricaprilin Receives ODD in the Treatment of Infantile Spasms","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tricaprylin","moa":"Ketone body","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerecin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerecin \/ .."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OSE-230","moa":"ChemR23","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants HAE Patients Early Access to BioCryst\u2019s Berotralstat in United Kingdom","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Receives Orphan Drug Designation from the European Commission for AVR\u2011RD\u201101, an Investigational Gene Therapy for Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA\u2122 for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline's Nucala Filings Accepted by European Medicines Agency for Three Additional Eosinophil-Driven Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets Tentative US FDA Approval for Dapagliflozin Tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.2 million","upfrontCash":"Undisclosed","newsHeadline":"Kazia Therapeutics Completes $25.2 Million Capital Raising","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorises Restart of the Covid-19 AstraZeneca's Azd1222 Vaccine US Phase III Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$231.0 million","upfrontCash":"$22.0 million","newsHeadline":"Molecular Partners Announces Collaboration with Novartis to Develop two DARPin\u00ae Therapies Designed for Potential use Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MP0420","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0.23000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Article on RhoVac's Phase I\/II Study to be Published in November","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS' NanoZolid-TLR9 Agonist Demonstrates Strong and Durable Preclinical Anti-Tumoral Effect","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NZ-TLR9","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces Clinical Collaboration to Evaluate\r\n OP-1250 in Combination with Advanced Breast Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Novartis","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"SpyBiotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"VLPs based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3P Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3P Biopharmaceuticals \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"3P Biophar.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Report SRF388 Preclinical Data at the Upcoming International Cytokine and Interferon Society\u2019s Cytokines 2020 Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Effector\u2019s Zotatifin (EFT226) Downregulates Key Oncogenic Driver Proteins Providing Single Agent Activity and Key Combination Opportunities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zotatifin","moa":"eIF4A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tetraphase Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu-omburtamab-DTPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergy Therapeutics Announces Start of Innovative Exploratory Field Study to Evaluate Efficacy and Safety of Grass MATA MPL","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Grass MATA MPL","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Th.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Completes Enrollment in Phase 1\/2b Study Evaluating ARQ-252 in Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals' CDR132 Demonstrates Improvement of Heart Function in Chronic Heart Failure Model","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Approval for the Phase Ib\/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"U.S. government","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly Announces Agreement with U.S. Government to Supply 300,000 vials of LY-CoV555 in an Effort to Fight COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Bamlanivimab","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0.38,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.38,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ U.S. government","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","amount":"$353.5 million","upfrontCash":"$10.0 million","newsHeadline":"CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"LCB71","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Dosed First Patient in Phase 2 Dose-Expansion Portion of Study Evaluating DSP-7888 in Patients with Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ombipepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNB Vesper begins GPP-Baladol clinical trials in COVID-19 patients at BJ Medical College & Sasoon General Hospital Pune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GPP-Baladol","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PNB Vesper \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper.."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$3,600.0 million","upfrontCash":"$600.0 million","newsHeadline":"Seagen Announces Closing of $1.0 Billion Stock Sale to Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab vedotin","moa":"LIV-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":3.6000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.6000000000000001,"dosageForm":"Intravenous infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"$14.2 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics, Catalent Ink Pact to Streamline Production of Allogeneic Cell Therapy Product, ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"ALLOB","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Shandong Boan Biological Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Shandong Boan Biological Technology","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU (Fam-Trastuzumab Deruxtecan-NXKI) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Amnio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amnio Technology Starts Phase 2 Clinical Trial to Evaluate PalinGen\u00ae Flow for the Treatment of Venous Stasis and Diabetic Ulcers","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PalinGen Flow","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amnio Technology","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amnio Technology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amnio Tech.."},{"orgOrder":0,"company":"National Center for Global Health and Medicine","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Joins Industry-Academia-Government for the Development of Drug Discovery for Covid-19 Utilizing Eritoran and E6011","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Eritoran","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Center for Global Health and Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Center for Global Health and Medicine \/ Eisai","highestDevelopmentStatusID":"4","companyTruncated":"National C.."},{"orgOrder":0,"company":"BioAtla","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioatla and Beigene Revise Global Development and Commercialization Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"BA3071","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Checkpoint Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Checkpoint Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"$5.0 million","newsHeadline":"Addex Receives Additional $2.8 Million from Indivior and Extends Gabab Pam Research Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA-B","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0.33000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior PLC","highestDevelopmentStatusID":"2","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$575.0 million","newsHeadline":"Royalty Pharma Acquires Additional Royalty Interest from the Cystic Fibrosis Foundation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cystic Fibrosis Foundation","amount2":0.65000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Cystic Fibrosis Foundation \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cystic Fib.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Perrigo Completes Acquisition Of Market-Leading OTC Self-Care Brands In Eastern Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ P.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Ships First Medicine in Collaboration with Civica Rx to Supply Us Hospitals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Pantoprazole Sodium","moa":"H\/K ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sandoz B2B \/ Civica Rx","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$328.0 million","upfrontCash":"$69.5 million","newsHeadline":"CEPI Extends Partnership With Clover Biopharmaceuticals to Fund COVID-19 Vaccine Candidate Through Global Phase 2\/3 Study to Licensure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 S-Trimer vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0.33000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Augmenta Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals and Augmenta Bioworks Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Human-derived monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Augmenta Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$4.0 million","newsHeadline":"CURE Pharmaceutical Closes $10 Million Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Cure Pharmaceutical \/ Axiom Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharm.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"CB-280","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Molteni Farmaceutici","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharma Completes Debt Settlement with Molteni and Horizon; Acquisition of JT-09","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"JT-09","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Molteni Farmaceutici","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Molteni Farmaceutici \/ Titan Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Molteni Fa.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Implements Reorganization and Secures Financing to Advance Vamorolone to Pivotal Read-out in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"PALADIN LABS","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$103.0 million","newsHeadline":"Isofol Announces Licensing Agreement for Paladin Labs Inc. To Commercialize Arfolitixorin in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Isofol Medical \/ Paladin Labs","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"XOMA","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$1.2 million","newsHeadline":"XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group\u2013Bioasis Strategic Alliance","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Enzyme replacement therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"XOMA","amount2":0.14999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"XOMA \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Chi.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","amount":"$186.0 million","upfrontCash":"Undisclosed","newsHeadline":"CARsgen Therapeutics Closes a $186 M Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series C Financing","leadProduct":"CT053","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Loyal Valley Capital","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Amphilix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eurofins Discovery Collaborates with Swiss Biotech Amphilix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eurofins Discovery \/ Amphilix","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins D.."},{"orgOrder":0,"company":"Humanigen","sponsor":"KPM Tech","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$6.0 million","newsHeadline":"Humanigen Executes Licensing Agreement for Lenzilumab\u2122 in COVID-19 with KPM Tech\/Telcon RF Pharmaceutical for South Korea and the Philippines ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ KPM Tech","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurodegenerative Disease Biotech Inhibikase Therapeutics Lowers Proposed Deal Size by 40% Ahead of $15 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.13,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Novavax","sponsor":"Government of Australia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and Commonwealth of Australia Announce Agreement in Principle for Acquisition of Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Government of Australia","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"VelosBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,750.0 million","upfrontCash":"$2,750.0 million","newsHeadline":"Merck to Acquire VelosBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"VLS-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Felix Biotechnology","pharmaFlowCategory":"D","amount":"$281.0 million","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bacteriophage based biotherapeutics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Felix Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","amount":"$15.3 million","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG Raises CHF 14 Million in a Series B Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series B Financing","leadProduct":"MTX-COVAB","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"8","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Decides on fully Guaranteed Rights Issue of Approximately SEK 150 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"$0.1 million","newsHeadline":"Crescita Announces Licensing Agreement for Pliaglis\u00ae in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Juyou Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$380.8 million","upfrontCash":"$29.7 million","newsHeadline":"OncoArendi and Galapagos Enter Into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OATD-01","moa":"AMCase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"OncoArendi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"OncoArendi Therapeutics \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"OncoArendi.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$29.7 million","newsHeadline":"Outlook Therapeutics Secures $10 Million in Additional Working Capital","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group","pharmaFlowCategory":"D","amount":"$11.7 million","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics Draws Down the Second Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Negma Group","highestDevelopmentStatusID":"12","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Om Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Om Pharma and Astrazeneca Enter Into Strategic Collaboration to Expand Presence in Respiratory and Immunology Fields in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Bacterial Lysates","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Om Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Om Pharma \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Om Pharma .."},{"orgOrder":0,"company":"Flamma SpA","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flamma, Gilead Continue Mfg. Partnership for Veklury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Flamma SpA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Flamma SpA \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Flamma SpA.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Inks Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK\u00ae in a Multi-Regional Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Medison Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Polar Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces Closing of Private Placement of $50 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Private Placement","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Summit Biosciences \/ Polar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Summit Bio.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$715.0 million","upfrontCash":"$200.0 million","newsHeadline":"Vaccibody Announces the Closing of the Worldwide License and Collaboration Agreement with Genentech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"VB10.NEO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epizyme \/ Pharmakon Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Ping An Capital","pharmaFlowCategory":"D","amount":"$124.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apollomics, Inc. Closes $124 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series C Financing","leadProduct":"APL-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apollomics Inc \/ Ping An Capital","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"STA Pharmaceutical","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"STA Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"STA Pharmaceutical \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"STA Pharma.."},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Termination","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Curia","sponsor":"Cassiopea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia Named Exclusive API Supplier for Recently Approved Acne Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Curia \/ Cassiopea","highestDevelopmentStatusID":"12","companyTruncated":"Curia \/ Ca.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"miR-21","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Florence Healthcare","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Signs eTMF Partner to Help Accelerate AP-003 Clinical Trial Operations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Interferon Alfa-2B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Florence Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Florence Healthcare \/ BetterLife Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Florence H.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stealth BioTherapeutics Announces Development Financing To Advance Elamipretide Clinical Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals Collaborates with AstraZeneca to Develop and Commercialize Next-Gen Radiopharmaceuticals and Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Radioactive labelled-antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel Starts Human Trials on Covid-19 Vaccine as Schools Slowly Reopen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"rVSV-SARS-CoV-2-S vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Announces Multiple IND Application Submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Gets FDA IND Approval for Phase-1 Trial of PD1-Vaxx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces Outcome of AUDREY\u2122 Clinical Trial in Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus Infection Accepted for Presentation at The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Interferon lambda receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm's Phase 3 SEAL Study Meets Primary Endpoint in Patients with Unresectable Dedifferentiated Liposarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"enGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"enGene Gets FDA Clearance of IND Application for EG-70","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EG-70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"enGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"enGene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"enGene \/ N.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Completes Rolling Submission of the BLA for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Further Expands Patent Portfolio for TIGIT Inhibitor COM902 with Composition of Matter Patent in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Enrols 200 Patients in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VFMCRP and ChemoCentryx Announce European Medicines Agency has Accepted to Review the Marketing Authorization Application for avacopan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"oral","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the AASLD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Enrolled First Patient in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-1501","moa":"CD40","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Zatolmilast","moa":"PDE4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Tetra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Therapeutics to Present Update on Regenerative Treatments for Corneal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU\u00ae Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics to Present Poster on the Use of Novel Hepatocyte Targeted Hydroxyl Dendrimer Therapeutic at The Liver Meeting 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyl dendrimer","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Clearance by the US FDA of Phase II Clinical Trial Using Orelabrutinib for the Treatment of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented at AASLD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FPA157","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Doses First Patient in its Phase 2b Registration Clinical Trial of Trodelvy for Breast Cancer Treatment in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Receives Pre-IND Response from FDA on COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals COVID-19 Abstract Selected for \u201cHot Topic\u201d Oral Session at the 2020 SITC Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia to Deliver Late-breaking Poster Presentation at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiple Abstracts Highlighting Assembly Biosciences\u2019 Hepatitis B Core Inhibitor Development Programs Accepted at the 2020 AASLD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Core protein allosteric","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo\u2019s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio To Present Data From Phase 1b\/2a Study of BIO89-100 In NASH at AASLD\u2019s The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics to Present Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seal Rock Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SRT-015","moa":"ASK1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seal Rock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' KISQALI\u00ae (ribociclib) UPs Overall Survival in Pre- and Perimenopausal Women with HR+\/HER2- Advanced Breast Cancer Fran\u00e7ais","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus to Present PBC and NASH Clinical Trial Data of Saroglitazar Mg at AASLD Event","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR alpha\/gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomic Therapeutics to Present at The Society for Immunotherapy of Cancer\u2019s (SITC) 35th Anniversary Annual Meeting & Pre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming ASH Annual Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Doses First COVID-19 Patient with iNKT Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces PLOS ONE\u2019s Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen\u2019s Positive Role in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 in Chronic Plaque Psoriasis and Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA\u00ae Concomitantly Used with the Immunomodulator Mycophenolate Mofetil","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Symvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Healthy Volunteer Dosed in Symvivo's Phase 1 Clinical Trial of bacTRL-Spike\u2122, an Oral COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"bacTRL-Spike vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s TACTI-002 Data to be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves Roche\u2019s Tecentriq in Combination with Avastin for the Treatment of People with the Most Common Form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces CTLA Approval by China NMPA for Phase 3 Registration Trial of Trodelvy\u2122 for Metastatic Breast Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Phase IV Study Showed Superior Tolerability and Efficacy of Aimovig\u00ae Compared to Topiramate in Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Erenumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Amgen","highestDevelopmentStatusID":"11","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin\u2122 Peanut by European Medicines Agency","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"epicutaneous patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Begins Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"T Cell surface glycoprotein CD3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs' Phase I Trial Results Evaluating UV1 in Non-Small Cell Lung Cancer Published in Frontiers in Immunology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"P-PSMA-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Additional Acceptance of Two Late-Breaking Abstracts at the AASLD The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"film-coated tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Allows Johnson & Johnson to Resume Trial of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saillant Therapeutics Reports Proof of Concept of its Treatment in Heart Failure showing Functional Reversal and Myocardial Rejuvenation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ST02","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saillant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis and Akcea Announce That Pfizer has Initiated a Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Reports Positive Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-005 Z-PODS","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac\u00ae for Intratumoral Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics, Inc. to Present at the 10th Annual Traumatic Brain Injury Conference (Virtual), November 2-4, 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Deucravacitinib Demonstrated Superiority to Placebo and Otezla\u00ae in Pivotal Phase 3 Psoriasis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Doses First Patient with Camidanlumab Tesirine in Combination with Pembrolizumab in Phase 1b Clinical Trial in Selected Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Reviews Recent Portfolio Progress and Reports Third Quarter 2020 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Libmeldy","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer\u2019s Disease Agitation at CTAD Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Provides Update on its ONWARD(TM) Pivotal Phase 3 Trial of AD04 for Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Fosun to End BioNTech's COVID-19 Vaccine Trial, Seek Approval for Another","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled-Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Gets Approval for its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-1202","moa":"MetAP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Green Valley Pharmaceutical is Set to Enroll First US Patient In its Alzheimer Disease Drug Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Vall.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex to Present CRISPR\/Cas9 Gene-Editing Therapy CTX001\u2122 Data for Severe Hemoglobinopathies at the 62nd ASH Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT\u00ae to Be Presented at the ESMO ASIA Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Axatilimab","moa":"CSF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cladribine","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Two Oral Presentations Featuring Data and Findings from Phase 3 SIERRA Trial of Iomab-B at the 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Oral Presentation at the 62nd American Society of Hematology Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaEssentia to Present Long-Term Data on Ropeginterferon Alfa-2b in Polycythemia Vera at Virtual ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at 2020 ASH Virtual Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Bio.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at the ASH Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibecotamab","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-413","moa":"IRAK4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the ASH 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"APTO-253","moa":"Myc","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces XPOVIO\u00ae (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd ASH Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TregGraft","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with Palbociclib (IBRANCE\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Telaglenastat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune to Highlight Preliminary Results from Phase 1\/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Fortress Biotech \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant Announces Updated Data to be Presented in Oral Presentation of ARU-1801 Data at the 62nd ASH Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Presents Promising New Clinical and Preclinical Data on Anti-Fc\u03b3RllB Antibody, BI-1206, at the ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"Fc?RllB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd ASH Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Affimed","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Affimed \/ Gilead","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces REBLOZYL\u00ae Virtual Presentations at the 62nd American Society of Hematology Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek\u00ae 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Shows Early Synovitis Reduction in Patients with Psoriatic Arthritis in First-Of-Its-Kind Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved in the EU as 1st-line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in the EU for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HMPL-689","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves Vertex's KALYDECO\u00ae as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Continuation of RLF-100\u2122 Trial for Treatment of COVID-19 Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces Upcoming Presentations for Ryplazim\u00ae (plasminogen) at the 62nd ASH Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Loxo-305","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncol.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology\/Oncology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daunorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CYAD-211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting\u00ae","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin\u2019s Lymphoma at 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IGM-2323","moa":"CD20 x CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announced Presentation of New Clinical Data from Phase 1b Study of NKTR-358","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GDA-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cy.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed\/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-647","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova AB Announces Study Design for First Clinical Study with the Oligomer-Specific Therapeutic Vaccine ALZ-101 at a Scientific Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALZ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"All India Institutes of Medical Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIIMS Find Ivermectin Prophylaxis Reduces Infection in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"All India Institutes of Medical Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"All India Institutes of Medical Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"All India .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Confirms Its Agreement with the U.S. FDA Regarding BLA Submission for LentiGlobin\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharmaceuticals Gets New Patent for Dual Function HDAC Molecules for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Shenzhen China Resources Gosun Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Approval of Antibiotic Zevtera\u00ae in China to Treat Community-Acquired Pneumonia and Hospital-Acquired Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ceftobiprole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Basilea Pharmaceutica \/ Shenzhen China Resources Gosun Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab\u2122 in Patients Hospitalized with COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Issues Positive Final Appraisal Determination for AbbVie\u2019s RINVOQ in Severe Active Rheumatoid Arthritis (RA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Presents Efficacy and Safety Data for Potential COVID-19 Treatment Candidate CT-P59 in Patients with Mild Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Data on BRUKINSA\u00ae (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pevonedistat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma to Host Virtual KOL Event Reviewing New Data Presented at the Society for Immunotherapy of Cancer Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Presents an Update and Baseline Data from the Phase 2\/3 GAIN Trial of Atuzaginstat at CTAD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces Multiple ADCETRIS\u00ae (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Present Updated Preclinical Data From HPK1 Inhibitor Program in Scientific Seminar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inravenoys infusion","sponsorNew":"Legend Biotech \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Investigational Data Highlighting LENVIMA\u00ae Based Combination Therapy in Patients With Renal Cell Carcinoma at IKCS 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces All Patients Showed Clinical and Sustained Cure in Ph2A Open-Label Trial of Ibezapolstat Against C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology to Report Momelotinib Long-term Overall Survival Data in Oral Presentation at ASH 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea to Host Investor Call Highlighting New GEN-009 Clinical and Immunogenicity Data to be Presented at Virtual SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recovery Trial Data Monitoring Committee Recommends Continuing Evaluation of Regn-COV2 in all Hospitalized Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brilinta Approved in the US to Reduce the Risk of Stroke in Patients with an Acute Ischaemic Stroke or High-Risk Transient Ischaemic Attack","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on CAN-COVID Trial in Hospitalized Patients with Covid-19 Pneumonia and Cytokine Release Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT, its Multi-Target and Long-Lasting Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MBX-2982","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT Peptide to Treat Complications from Covid-19","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"XenoTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Xeno-Skin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"XenoTherapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XenoTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XenoTherap.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Doses First Patient with Relapsed\/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1\/2 Clinical Trial of RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-CVX1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intranasal spray","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs to Present Poster on Gamma Delta T Cell Engager, GADLEN\u2122, Platform at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon to Present 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn\u2019s Disease, and Ulcerative Colitis with Allocetra Immunotherapy","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra","moa":"Immunotolerance","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual Scientific Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare to Present Clinical Data of Orelabrutinib at the Upcoming 62nd Annual Meeting of ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioniz Announces Oral Presentation at ASH 2020 of Positive Clinical Data of BNZ-1 for the Treatment of Refractory Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BNZ-1","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioniz Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz The.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Sarepta Therapeutics \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Interim Results from Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"DCprime","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCprime to Present Interim Clinical Data of ADVANCE II Trial in Oral Presentation at ASH 2020 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"DCprime","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DCprime \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DCprime \/ .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submitts a Type II Variation Application to the EMA for Use Of Subcutaneous DARZALEX\u00ae in Patients with Light-Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ J.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharma Completes Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Schr\u00f6dinger to Present Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Receives Permission to Conduct Phase 3 Clinical Trials for Covid Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Data From Imago BioSciences\u2019 Phase 2b Study of Bomedemstat for Treatment of Myelofibrosis to Be Presented at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics' New OTL-201 Clinical Data in Sanfilippo Syndrome Type A Accepted for Oral Presentation at 62nd ASH Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces Upcoming Data Presentations at ASH Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"PolyActiva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poly Activa Completes Initial Clinical Trial with Latanoprost FASR Ocular Implant Delivering Glaucoma Treatment to Patients Over a Six-Month Period","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Latanoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC\u2122 Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Apolipoprotein A-I [human]","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fexuprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Astellas Pharma\u2019s Xtandi to Treat Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft capsules","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Aims to Bring Non-U.S. Vaccine Data Before the FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Dosing Hold in Fitusiran Trials Initiated by Sanofi Genzyme to Investigate New Adverse Events","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Givosiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila to Test ZyCoV-D on 30,000 Patients in Phase-3 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Alvocidib at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives EC Approval for Opdivo (nivolumab) Plus Yervoy with Two Cycles of Chemotherapy for Lung Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Phase 3 Study Results for XELJANZ \u00ae in Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company\u2019s Oral Drug Delivery System in Targeting the Colon","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Sedor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand\u2019s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT\u2122 to treat Status Epilepticus in Adult and Pediatric Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosphenytoin Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sedor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedor Phar.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, to Share New Data at American Academy of Ophthalmology (AAO) 2020 Virtual","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Data from ADVOCATE Phase III Trial in ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex to Present Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX\u00ae2-73 in Parkinson\u2019s Disease Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Presentation of Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma to Present Results From the Phase III ProDERM Study at the ACR Convergence 2020 Virtual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-301","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GB1275","moa":"CD11b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Positive Topline Results from Pivotal Ph 3 NefIgArd Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series D Financing","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Partners with GPCR to Develop Burixafor & Taigexyn\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Burixafor","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"TaiGen Biotechnology \/ GPCR Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Vertex Ventures","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inmagene Biopharmaceuticals closed $21 Million Series B Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series B Financing","leadProduct":"IMG-20","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Vertex Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"PRA023","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0.13,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Eventide Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$30.0 million","newsHeadline":"Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ANG-3777","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0.34000000000000002,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Affimed","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","amount":"$2,060.0 million","upfrontCash":"$60.0 million","newsHeadline":"Affimed and Roivant Sciences Ink Licensing Agreement to Develop and Commercialize Novel Innate Cell Engagers for Multiple Cancer Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"AFM32","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":2.0600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0600000000000001,"dosageForm":"","sponsorNew":"Affimed \/ Roivant Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","amount":"$711.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.70999999999999996,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"Merck & Co \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuno-Oncology Biotech Compass Therapeutics Sets Terms for $50 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Stargazer Pharmaceuticals","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stargazer Pharmaceuticals Announces $57 Million Series A Financing and Start of a Phase 2a Study of STG-001 in Stargardt Disease Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"STG-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stargazer Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Stargazer Pharmaceuticals \/ Novo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Stargazer .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONO and Bristol Myers Squibb Enter Patent License Agreement with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ono Pharmaceutical \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Croda Inc.","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Croda Strikes Deal with Pfizer to Supply COVID-19 Vaccine Additives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Croda Inc.","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Croda Inc. \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Croda Inc..."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AC Immune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune\u2019s Anti-TDP-43 Antibodies into Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Anti-TDP-43 antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ AC Immune","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Handl therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB Acquires Handl Therapeutics BV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"AAV-mediated gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Handl therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Handl therapeutics \/ UCB","highestDevelopmentStatusID":"4","companyTruncated":"Handl ther.."},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"AAV-mediated gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Lacerta Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lacerta Therapeutics \/ UCB","highestDevelopmentStatusID":"2","companyTruncated":"Lacerta Th.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Xencor","highestDevelopmentStatusID":"1","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"American College of Cardiology","sponsor":"MyoKardia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MyoKardia and American College of Cardiology and PINNACLE\/Veradigm Join Hands to Launch Patient Registry of Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American College of Cardiology","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"American College of Cardiology \/ MyoKardia","highestDevelopmentStatusID":"10","companyTruncated":"American C.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Completes $28.5 M Convertible Note Financing to Help Expedite Successful COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Vapogenix","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vapogenix Awarded $1.5M Phase II SBIR Grant to Develop Groundbreaking Topical Therapy for Painful Inflammatory Conditions","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Sevoflurane","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Vapogenix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Vapogenix .."},{"orgOrder":0,"company":"CoImmune","sponsor":"FIDIM Group","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"CoImmune Announces Closing of $45 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"CMN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CoImmune","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"CoImmune \/ FIDIM Group","highestDevelopmentStatusID":"8","companyTruncated":"CoImmune \/.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Tumor Biotech Silverback Therapeutics Files for a $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"SBT6050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Neuraly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"NLY01","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pennsylvania \/ Neuraly","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series B Financing","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Google Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige Biopharma and Teva Israel Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Tibet Rhodiola Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"China's Rhodiola Set to Sell and Test Russia's Sputnik-V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tibet Rhodiola Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tibet Rhodiola Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tibet Rhod.."},{"orgOrder":0,"company":"Inipharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Inipharm","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inipharm \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Inipharm \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Singapore Economic Development Board","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"$45.0 million","newsHeadline":"Arcturus Announces Positive Interim ARCT-021 Phase 1\/2 Study Results, and Up to $220M in Additional Financial Commitments from Singapore","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Singapore Economic Development Board","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Bridge Medicines","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Medicines","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bridge Medicines \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Med.."},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","amount":"$22.4 million","upfrontCash":"Undisclosed","newsHeadline":"Synendos Therapeutics Raises CHF 20 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"SYT-510","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Synendos Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"4","companyTruncated":"Synendos T.."},{"orgOrder":0,"company":"OneThree Biotech","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"JBI-802","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OneThree Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OneThree Biotech \/ Jubilant Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OneThree B.."},{"orgOrder":0,"company":"PhoreMost","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"LentiVector based gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ Oxford Biomedica","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost .."},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho and Lung Therapeutics Enter into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"LTI-01","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lung Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Lung Thera.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"$584.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Merger","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Urovant Sciences","amount2":0.57999999999999996,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","amount":"$517.0 million","upfrontCash":"$90.0 million","newsHeadline":"Retrophin Completes Acquisition of Orphan Technologies, OT-58 Strengthens Pipeline of Therapies Targeting Rare Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0.52000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Orphan Technologies \/ Retrophin","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Tec.."},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"MyMD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Merger","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Akers Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akers Biosciences \/ MyMD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Akers Bios.."},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"P014","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Kira Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Kira Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"3","companyTruncated":"Kira Pharm.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Government of Isreal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Israel Signs Deal with Pfizer for Potential Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Government of Isreal","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pluristyx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pluristyx to Support Development of Kiadis\u2019 K-NK Cell COVID-19 Therapy Funded by $9.5 Million From BioFabUSA Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"K-NK-ID101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Pluristyx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluristyx \/ Kiadis","highestDevelopmentStatusID":"5","companyTruncated":"Pluristyx .."},{"orgOrder":0,"company":"Sanaria","sponsor":"EU Malaria Fund","pharmaFlowCategory":"D","amount":"$15.7 million","upfrontCash":"Undisclosed","newsHeadline":"EU Malaria Fund: Sanaria Receives Substantial Investment Into its Proprietary Malaria Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"PfSPZ Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanaria","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sanaria \/ EU Malaria Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sanaria \/ .."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Five Prime Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Bemarituzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics Announces Partnership with Elevatebio to Expand TC-210 Manufacturing Capacity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"TC-210","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ TCR\u00b2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"National Ataxia Foundation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"National Ataxia Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Ataxia Foundation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"National A.."},{"orgOrder":0,"company":"Xiromed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xiromed LLC Launches Gemmily\u2122, First-to-Market Generic to Taytulla\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Xiromed","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Xiromed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xiromed \/ .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th CTAD Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Phase 1 Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Receives USFDA Tentative Approval for Palbociclib\n Capsules, 75 mg, 100 mg, and 125 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AMV564","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena .."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Neuropharma Announces FDA Submission of New Drug Application For INP104 For The Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Concludes Pre-Clinical Study on Human Biopsies in Preparation for FDA Pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre Initiates a \"First in Human\" Clinical Trial for An Innovative Monoclonal Antibody (W0180)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical's New XARELTO\u00ae Peripheral Artery Disease Data from EXPLORER Clinical Research Program to be Unveiled at AHA Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics To Present at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Presents First Clinical Data for AMG 757 at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 757","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL in a Single Therapeutic For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to AMO Pharma for AMO-02 for Treatment of Congenital Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"oral suspension","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRP\u03b1 Antibody Programs At The 2020 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"APX601","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Neutralizing Antibody Bamlanivimab Receives FDA Emergency Use Authorization forthee Treatment of Recently Diagnosed Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Discontinue KEYNOTE-598 Trial in Certain Patients With Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces Results of Phase 2 Trial of Daxibotulinumtoxin A for Injection in Plantar Fasciitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BDB001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seven and .."},{"orgOrder":0,"company":"Transgene","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b\/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipapkinogen sovacivec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Transgene \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Presents Preclinical Data at SITC 2020 Demonstrating Significant Improvement in Tumor Growth Inhibition and Overall Survival Through a Combination of E7777 (Denileukin Diftitox) and an Immune Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-PD-1 agent","moa":"Interleukin-2 receptor binding agent","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eisai","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Last Patient Completes Final Study Visit in PEGASUS Trial of AMX0035 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Presents New MARIO-1 Phase 1\/1b Clinical Data at The SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infinity Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istari Oncology Presents Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-PD-1 agent","moa":"CD155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Istari Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Istari Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Istari Onc.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Presents Additional Data from Phase 1\/2 Clinical Trial of SNS-301 at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer\u2019s (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Data from Multiple Preclinical XmAb\u00ae Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoNano Announces Positive Preclinical Data for ONM-400 Tumor Specific IL-2 Delivery at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ONM-400","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncoNano Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoMyx Announces Presentation of Preclinical Efficacy Data of Novel Oncolytic Immunotherapy at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Myxoma virotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Th.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA\u00ae (Dinutuximab Beta) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"solution for infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Showing Safety and Efficacy of Deucravacitinib in Patients with Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces Investigational Injectable Cabotegravir is Superior to Oral Standard of Care for HIV Prevention in Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"ViiV Healthcare \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with Galapagos' GLPG3667 in Psoriasis Patient Phase 1b Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GLPG3667","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Announces Publication of a Study Evaluating Montelukast\u2019s Effect on Neurological Aging","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"buccal film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data Being Presented at SITC Underscore Promising Combinations of Affimed\u2019s AFM13 and Cytokine-Activated NK Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b\/3 Clinical-Stage Lead Product Candidate Validive\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"mucobuccal tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Phase II TACTI-002 Study Reports Encouraging Data at SITC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"DNAtrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DNAtrix Announces Multiple Data Presentations, Including Late-Breaking Phase 2 CAPTIVE Data at the Society for Neuro-oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"DNAtrix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral injection","sponsorNew":"DNAtrix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DNAtrix \/ .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Showcases New Data Across Cardiovascular Portfolio at AHA Scientific Sessions 2020: A Virtual Experience","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Olpasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces American College of Rheumatology Convergence 2020 Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Presents New Data From Two MRx0518 Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV\u2019s T Cell Therapy Shows 86% Objective Response Rate in Combination with Keytruda\u00ae in PD-L1 Positive Patients with r\/r DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb20717","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic\u2122 Clinical Oncology Program, RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FOIPAN\u00ae Tablets, a Protease Enzyme Inhibitor, Started Clinical Study in Patients with Novel Coronavirus Infection (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Proteinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 SITC Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AO-176","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncol.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARMA Cell Therapies\u2122 to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer\u2019s 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Merus","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MCLA-145","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Merus \/ Incyte","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ In.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Therapeutics Announce Two Confirmed Responses and Five Out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LN-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NKX019","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics to Present Preclinical Data for IO-108 at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IO-108","moa":"LILRB2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"immediate release tablet","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vigeo Therapeutics to Present New Phase 1\/2 VT1021 Dose Escalation and Expansion Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"VT1021","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vigeo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vigeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigeo Ther.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent and Transgene Present Data on Next Generation Oncolytic Virus BT-001 at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Announces That Data Safety Monitoring Board Validates Further NOX-A12 Dose Escalation in Phase 1\/2 Brain Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-668","moa":"IL4I1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed Enrollment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Doses First Patient in Landmark CRISPR\/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYA Bioscience International Presents Positive Data On HBI-8000 at Society for Immunotherapy of Cancer Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"oral","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Expands Planned Phase 1\/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-AAV-GM2","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim\u00ae(Plasminogen) BLA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presented Latest Data Regarding Drug Candidate BAN2401 at CTAD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AP1189","moa":"Il-6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"SynAct Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"suspension","sponsorNew":"SynAct Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SynAct Pha.."},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Marrow-Infiltrating Lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WindMIL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Th.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharmaceuticals Presents Updated Clinical Data with CMP-001 at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces First Healthy Volunteers Dosed in Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"COVI-AMG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BT7480","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Upcoming Poster Presentations at AASLD The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pioglitazone","moa":"Mitochondrial pyruvate carrier","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1\/2 Lung Cancer Trial at the 2020 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repertoire Immune Medicines Presents First Clinical Data on PRIME IL-15 Cell Therapy in Advanced Metastatic Cancers at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PRIME IL-15 cell therapy","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Formycon","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon and Bioeq Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Formycon \/ Bioeq","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents Preclinical Data Showing Potential of engEx\u2122 Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"exoIL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1908","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Expects FDA Decision on Covid-19 Vaccine Trial Start This Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Announces Positive Phase 1 Results for Its Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AS03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Suspends Covid-19 Vaccine Trial Due to Serious Adverse Event","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APL-1702 International Multicenter Phase III Clinical Trial of the First Patient in Asia Hong","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-1702","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r\/r B-ALL Treatment at 2020 ASH Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CTA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Bioheng Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Bi.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Reports that Hydroxychloroquine Does Not Benefit Adults Hospitalized With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Successfully Submitted an NDA for Ivosidenib in Singapore, for IDH1-mutated Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"CStone Pharmaceuticals \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"FGFR2B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Farmacore Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune\u00ae-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Farmacore","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer\u2019s SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotech Presents Preclinical Data for SQZ APC and AAC Cellular Vaccine Platforms at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613\u00ae (Devimistat) for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AGT103-T","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Gene Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"American G.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle Technology Achieved in Phase 1\/2 Study of ETV:IDS in Hunter Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Announces AU-011 Data From Phase 1b\/2 Clinical Trial Selected for Late Breaking Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AU-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IO-202","moa":"LILRB4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of AMT-101 for Inflammatory Diseases in The Journal of Immunology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"XTX201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BDC-1001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the AHA Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Apolipoprotein A-I [human]","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen\u2019s Totect\u00ae Receives FDA Approval for New Indication to Treat Incidence and Severity of Cardiomyopathy Associated with Doxorubicin in Women with Metastatic Breast Cancer","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexrazoxane","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affibody Announces Initiation of Confirmatory Phase 2 Trial of ABY-035 in Psoriatic Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ABY-035","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group of COVID-19 Patients With Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Files Patent Application to Extend Exclusivity of Rabeximod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"TNF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Phase I Data from ACTolog\u00ae Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b\/3 COVID-19 Human Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1\/2 Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies to Highlight Data on Viaskin\u2122 Peanut Treatment Delivery and Patient Experience at ACAAI 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Genexine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine and NeoImmuneTech Announce Data Release for their Phase 1b\/2 Study of GX-I7\/NT-I7 and KEYTRUDA\u00ae in Patients With Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENVIMA\u00ae Plus KEYTRUDA\u00ae Improved Progression-Free Survival in Patients With Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII\u2122","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Marketing Application for Gilead's Filgotinib for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Launch Doptelet\u00ae (Avatrombopag) in Europe","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion's NEXLETOL\u00aeTablets Highlighted at AHA 2020 with Presentations Showing Significant LDL-C Reduction in Phase 3 Study Subgroups","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ZT-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Zucara Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zucara The.."},{"orgOrder":0,"company":"Sagent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagent Pharmaceuticals Launches Phase 2 Trial to Evaluate Camostat Mesilate for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Proteinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sagent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagent Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinopharm Says Data 'Better Than Expected\" From Unit's COVID-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamaleya Institute Confirms 1st Interim Data Analysis of the Sputnik V Vaccine Against Covid-19 Phase III Clinical Trials Show 92% Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mountain Valley MD Files Patent to Protect Science Achievement in Solubilization of Ivermectin Without Organic Solvents in Treatment of COVID-19 and Other Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mountain Valley MD","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mountain V.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating GT005, in Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1\/2a Clinical Study of OpRegen\u00ae Cell Therapy for Dry Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Revive Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"6","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Pharma Reports Positive Results Regarding the Clinical Safety and Preclinical Efficacy of Its COVID-19 Drug Candidate Rejuveinix","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1\/2 Study in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Encouraging Preliminary Results from Antiviral Screening Program at The Doherty Institute Evaluating RECCE\u00ae 327 Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Recce 327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed\/Refractory Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TK216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix To Present Data At AASLD's The Liver Meeting Digital Experience","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Immediate release tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-205","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angiocrine Bioscience \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-2099","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Interim Analysis of Clinical Outcomes After 135 Patients Results in Recommendation to Continue Mesoblast's Remestemcel-L Phase 3 Trial in COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program at XTOS Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Letaplimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"UB-621","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual thin film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer\u2019s (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ICT01","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Successfully Completes Phase II Clinical Trials with Pegylated Interferon Alpha2b in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegylated Interferon alpha-2b","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Calquence Approved in the EU for the Treatment of Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil's National Health Surveillance Agency Authorizes Resumption of the Phase III Clinical Trial of CoronaVac\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at AAO 2020 Virtual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"oral solution","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Human anti-VISTA antibodies","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO\u2122\/ DARZALEX\u00ae Subcutaneous Formulation Utilizing ENHANZE\u00ae Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma Announces Amikacin Approval in CANADA and U.S. Launch of Ethacrynate Sodium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"liposome inhalation suspension","sponsorNew":"Valeo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KAHR Announces First Patient Dosed in Phase 1\/2 Clinical Trial of DSP107","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"SIRP alpha\/41BBL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"Zhaoke","sponsor":"Nevakar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Zhaoke \/ Nevakar Inc","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke \/ N.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology's 1st Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 and OPDIVO\u00ae Combo in Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Oteseconazole to Treat Recurrent Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasomune Announces FDA Allowance of IND Application For AV-001 for the Treatment of Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasculotide","moa":"Tie2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Enrolls First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilofotase alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronasal, Inc. Announces Completion of Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Receives Approval to Start Clinical PhaseII Trial with ACD856 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EPCAM ProTriTAC\u2122 Program at 35th SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharma Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Start of Huntington\u2019s Disease Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Publication of XPOVIO\u00ae (Selinexor) Phase 3 BOSTON Study Results in The Lancet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Medicinova","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Presentation of Positive Findings on MN-001 in Acute Liver Injury Model at The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on FDA Advisory Committee\u2019s Meeting on Aducanumab in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics Hauls in $300M IPO Just as Liso-Cel-Inspired CAR-T Nears the Finish Line in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Relmacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JW Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Reports Third Quarter 2020 Financial Results Provides Updates on Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Ten Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH's to Present Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia at the ASH 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV's T Cell Therapy in Combination With Merck's Keytruda\u00ae in Patients With r\/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis' ASH Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R\/R Adult B-ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"UCART22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Eusa Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b\/2 TiNivo Study in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Aveo Oncology \/ EUSA Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Government of Bangladesh","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bangladesh Signs Deal with India for 30 Million Doses of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Government of Bangladesh","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership with Catalent","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"TSHA-118","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Catalent","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Specialised Therapeutics Asia Inks Deal with Deciphera Pharmaceuticals for Gastrointestinal Stromal Tumours (GIST) Drug Launch","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Aditum Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Aditum Bio to Advance mGlu5 NAM Clinical Program for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"3-Chloro-5-[6-(5-Fluoropyridin-2-Yl)pyrimidin-4-Yl]benzonitrile","moa":"mGluR5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Aditum Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Reports European Medicines Agency Accepts Biogen\u2019s Aducanumab Marketing Authorization Application for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Provides Update on the Garetosmab Phase 2 LUMINA-1 Trial in Fibrodysplasia Ossificans Progressiva (FOP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Garetosmab","moa":"Activin A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the ACG 2020 Annual Scientific Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris Announces Pricing of $12 Million Public Offering","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Barclays","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cancer Biotech IN8bio Postpones $75 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"INB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"IN8bio \/ Barclays","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ B.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"C4 Therapeutics Reports Termination of its EGFR Drug Pact with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Roche","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chronic Disease Biotech Sigilon Therapeutics Files for a $100 Million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"SIG-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Olema Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces Clinical Trial Agreement to Evaluate OP-1250 in Combination with IBRANCE\u00ae in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Olema Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$2,458.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson and U.S. Department of Health & Human Services Expand Agreement to Support Next Phase of COVID-19 Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":2.46,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":2.46,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Ocuphire Pharma Announces Expansion of Global Patents for Nyxol\u00ae and $1.7 Million NIH Grants for APX3330 Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Door Pharmaceuticals","sponsor":"Assembly Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assembly Biosciences and Door Pharmaceuticals Ink Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Live microbial biotherapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Door Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Door Pharmaceuticals \/ Assembly Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Door Pharm.."},{"orgOrder":0,"company":"CureVac","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"European Commission Announces that It will Authorize the Agreement with CureVac for the Supply of up to 405M Doses of CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-based vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"$10.0 million","newsHeadline":"BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Seed Therapeutics","amount2":0.80000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Seed Thera.."},{"orgOrder":0,"company":"Lead Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$328.2 million","upfrontCash":"$12.1 million","newsHeadline":"Lead Pharma Inks Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Lead Pharma","amount2":0.33000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Lead Pharma \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Lead Pharm.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$647.0 million","upfrontCash":"$647.0 million","newsHeadline":"Covis Group Completes Acquisition of AMAG Pharmaceuticals","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Covis Group","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"OncoZenge","sponsor":"Baltic Sea Foundation","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"OncoZenge Secures Approximately SEK 70 Million in Financing Ahead of spin-off and separate listing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"OncoZenge","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"OncoZenge \/ Baltic Sea Foundation","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge .."},{"orgOrder":0,"company":"XOMA","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Mezagitamab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"XOMA","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"XOMA \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Tak.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris' Quillivant XR in Israel","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"United Kingdom Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ United Kingdom Government","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$13,100.0 million","upfrontCash":"$13,100.0 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company\u2019s Leading Cardiovascular Franchise","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":13.1,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":13.1,"dosageForm":"","sponsorNew":"MyoKardia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and STADA Sign Agreement to Commercialize Yondelis\u00ae (trabectedin) in the MENA Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncternal Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"ReveraGen Gets $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"ReveraGen BioPharma \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen .."},{"orgOrder":0,"company":"CDG Care","sponsor":"Cerecor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Alpha-D-Galactose","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CDG Care","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CDG Care \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"CDG Care \/.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$5.0 million","newsHeadline":"Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Li-Key-SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Generex Biotechnology","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Generex Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series C Financing","leadProduct":"PHA-022121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pharvaris","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pharvaris \/ Viking Global Investors","highestDevelopmentStatusID":"6","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"Undisclosed","newsHeadline":"Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"VivoCAR T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Trianni","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"$90.0 million","newsHeadline":"AbCellera Expands Technology Stack with Acquisition of Trianni for $90 Million","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Human antibodies","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Trianni","amount2":0.089999999999999997,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Trianni \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Trianni \/ .."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Farallon Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imago BioSciences Raises $80 Million in Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series C Financing","leadProduct":"Bomedemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Imago BioSciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Imago BioSciences \/ Farallon Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"CNCT19","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Juventas Cell Therapy","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Juventas Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juventas C.."},{"orgOrder":0,"company":"Mannkind","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"$45.0 million","newsHeadline":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Mannkind \/ United Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Soft Bones","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soft Bones Awards its 2020 Grant to Sanford Burnham Prebys Researcher to Promote Gene Therapy Advancements in Hypophosphatasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Tissue non-specific alkaline phosphatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Soft Bones","highestDevelopmentStatusID":"4","companyTruncated":"Sanford Bu.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Collaborate to Study Nintedanib for Fibrosing ILD after COVID-19 infection","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Nintedanib Esylate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Icahn School of Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics raises \u20ac37M in Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"Emactuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SynOx Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"SynOx Therapeutics \/ HealthCap","highestDevelopmentStatusID":"6","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Avrobio \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VFMCRP and Fresenius Kabi Expand Collaboration in Nephrology in China with Veltassa\u00ae Agreement","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Patiromer","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,355.0 million","upfrontCash":"$50.0 million","newsHeadline":"Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-L","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":1.3600000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.3600000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$555.0 million","upfrontCash":"$100.0 million","newsHeadline":"Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0.56000000000000005,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"GI Innovation","sponsor":"Agilent Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agilent Announces MOU to Collaborate with GI Innovation for Biomarker Profiling in Phase 1\/2 Study of Cancer Immunotherapy GI-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"GI-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GI Innovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GI Innovation \/ Agilent Technologies","highestDevelopmentStatusID":"7","companyTruncated":"GI Innovat.."},{"orgOrder":0,"company":"Bach Biosciences","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and Bach Biosciences Announce Licensing and Partnership for canSEEK\u2122 Pan-Cancer Targeting Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PNT2004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bach Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bach Biosciences \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Bach Biosc.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Announces Collaboration with the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ BriaCell","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Agenus","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"An Agenus-Discovered First-in-Class ILT4 Antibody, MK-4830, Enters Phase 2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"MK-4830","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ M.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Vesalius Biocapital III","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"CatalYm Raises EUR50 Million to Advance GDF-15 Antibody into Clinical Trials for Checkpoint-Inhibitor Refractory Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Series B Financing","leadProduct":"CTL-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CatalYm","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"CatalYm \/ Vesalius Biocapital III","highestDevelopmentStatusID":"4","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"HitGen","sponsor":"Guangzhou Baiyunshan Pharmaceutical Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.8 million","newsHeadline":"HitGen Licenses Its Trk\/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"HG030","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Guangzhou Baiyunshan Pharmaceutical Holdings","highestDevelopmentStatusID":"4","companyTruncated":"HitGen \/ G.."},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Life Sciences Announces Collaboration with Parexel Biotech to Conduct Phase 1b\/2 Clinical Trial in Patients with Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Parexel Biotech","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parexel Biotech \/ Tiziana Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Parexel Bi.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Rocket Pharma Gets Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"RP-L401","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Announces Strategic Manufacturing Partnership with Lilly to Accelerate Delivery of COVID-19 Antibody Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Zymeworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks and ALX Oncology Collaborate to Study Zanidatamab with ALX148 in Patients with Advanced HER2\u2011Expressing Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"ALX148","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALX Oncology \/ Zymeworks","highestDevelopmentStatusID":"1","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"CoImmune","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"CoImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CoImmune \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CoImmune \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA issues Complete Response Letter for Sutimlimab, an Investigational Treatment for Hemolysis in Adults with Cold Agglutinin Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"Complement C1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Reports Final Results from the Phase 3 HELP Study\u2122 Open-Label Extension Support TAKHZYRO\u00ae Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedemas","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"pre-filled syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19:\u2009Bharat Biotech Begins Phase 3 Trials of Covaxin in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Indian Council of Medical Research","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief, Neuro Rx Announce Enrollment of 150 Patientsinn Phase 2b\/3 Trial of RLF-100 for Critical Covid-19 with Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Provides Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac CEO Eyes Covid-19 Vaccine Approval in Third Quarter of 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Switzerland Starts 'Rolling Review' of Moderna Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma's AFFIRM-AHF Study Show Ferinject\u00ae Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension at the 2020 AHA Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALN-AGT","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT8230","moa":"TLR8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Presents Additional Positive Data from Phase 2a BALANCED Study Showing Potential of Efruxifermin as a Foundational NASH Monotherapy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presents Phase 3 Sci-B-Vac\u00ae Data at The Liver Meeting\u00ae 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Third-generation hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human complement Factor H","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda\u00ae in the European Union","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Pomalidomide Capsules (Generic for Pomalyst\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pomalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma Limited","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Novartis Analyses for Investigational Inclisiran Shows Consistently Effective and Sustained LDL-C Reduction at Month 17","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising New Data for Ionis' Antisense Medicine Targeting PCSK9 Presented at American Heart Association Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ION449","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"MeiraGTx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV2\/5-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ MeiraGTx","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Real-World Data and Post-Hoc Analysis of Novartis Beovu\u00ae Pivotal Trials Presented at AAO 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Expected to Apply for Approval of Covid-19 Vaccine Next Fall","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present Data from its Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Unveils Final Results of Phase 3 Clinical Trial for SB11","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The IND Application Of Henlius Daratumumab Biosimilar Accepted By NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"soft capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Presents Phase 2b Data on Linerixibat for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Linerixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association\u2019s Scientific Sessions 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Presents Updated Clinical Data from Positive Phase 1b\/2a Study of BIO89-100 in NASH at AASLD\u2019s The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TXR-611","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich Biosciences to Present Data From 3 Studies of Nabiximols in Multiple Sclerosis Related Spasticity at the AAPM&R Annual Assembly","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Greenwich Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeGi Pharma Announces FDA Orphan Drug Designation for EXE-346 Live Biotherapeutic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EXE-346","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ExeGi \/ No.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Durect Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621 in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Highlights Results from its Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angelini Pharma and Sunovion Pharmaceutical Europe Receive EMA Approval for Latuda for the Treatment of Adolescent Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Sunovion Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Angelini P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Roche\u2019s Phesgo for HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Presents Data Showing Sustained Attack Rate Reductions and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from RhoVac's Clinical Phase I\/II Study Published in Journal of ImmunoTherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Presents Data on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Gets Breakthrough Therapy Designation for Investigational, Long-Acting Cabotegravir for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Initiates Second Global Phase 3 Clinical Trial of its Janssen COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces Initiation of Phase 2\/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Emvododstat","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Gets U.S. FDA IND Clearance for Phase 2 Study of NT-I7 and Atezolizumab Combo in First-line Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Presented NASH Phase II Namodenoson Data at the American Association for the Study of Liver Diseases Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna\u2019s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Gets Positive CHMP Opinion for Use of Pradaxa\u00ae to Treat venous thromboembolic events in Newsborns and Adults","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from the Interim Analysis of Intercept Pharmaceuticals' REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Gets Approval of Protocol Design to Study Microdoses of LSD For Adult ADHD In Phase 2a Trial from Swiss and Dutch Health Authorities","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"intravitreal implant","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Abpro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Abpro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abpro \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Abpro \/ No.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD\u2019s 2020 Liver Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-020572","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Gets Study May Proceed Letter from US FDA to Start Phase 1 Trial of JTX-8064 Targeting the LILRB2\/ILT4 Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SRT-015","moa":"ASK1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seal Rock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock .."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces Data from a Multicenter Post HOC Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Results of the Phase I Clinical Trial of IBI302 for Neovascular Age-Related Macular Degeneration at 2020 AAO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI302","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Announces FDA Filing Acceptance of Supplemental New Drug Application for Solosec\u00ae for the Treatment of Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral granules","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta\u2019s Temferon\u2122 Shows Controlled and Targeted Interferon Expression in Preliminary Phase I\/II Clinical Data in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Temferon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant for Treatment of Preterm Labor","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"oral","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech: European Patent for Treatment of Bile Duct Cancer with the FimaChem Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calypso Biotech Doses First Patient First Phase 1 Cohort with Anti-IL-15 Monoclonal Antibody CALY-002 to Treat Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CALY-002","moa":"IL-15","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Calypso Biotech SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Bi.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Recruits the First Patient in the Phase II Proof-of-Concept Study in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Starts Phase 2 Segment of its Phase 2\/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of mRNA COVID-19 Vaccine by Moderna Biotech Spain, S.L","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 to Treat Elevated Lipoprotein at American Heart Association 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SLN360","moa":"LPA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b\/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3773274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"tablet","sponsorNew":"Cytokinetics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Biological E","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biological E. Limited Starts Phase I\/II Clinical Trial of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biological E \/ Dynavax Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant Receives Orphan Designation from European Medicines Agency for Gene Therapy ARU-1801 for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 to Treat Chronic Hepatitis B at AASLD\u2019s The Liver Meeting 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1\/2 Clinical Trial of FLX475 in Multiple Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FLX475","moa":"CCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Heart Failure Drug Succeeds but Slightly Higher Death Rate Seen - Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Amgen","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine to Present the Final Data of Phase IIa rGBM Trial at SNO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Publishes Positive Phase I Shigella Conjugate Vaccine Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SF2a-TT15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Institut Pasteur","highestDevelopmentStatusID":"8","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene's RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met its Primary Endpoint of Overall Survival at Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Topline Results from NurOwn\u00ae Phase 3 ALS Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding ZIMHI","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu Biopharmaceuticals Initiates Phase Ib\/IIa Clinical Trial of KPG-818 in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Bio.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Type III IFN receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB's VIMPAT\u00ae CV Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric use for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2\/3 Study in Symptomatic COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Upamostat","moa":"serine protease S1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"TrippBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrippBio Reports Results from Investigator-Initiated Clinical Trial of TD213 for the Treatment of Mild to Moderate COVID-19 Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TD213","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TrippBio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Precigen","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Doses First Patients with UltraCAR-T\u00ae Cells in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept in Patients with Moderate-to-Severe Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health's LUMIFY\u00ae and BESIVANCE\u00ae Eye Drops Preserved With Benzalkonium Chloride Completly Inactivats SARS-CoV-2","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Eye Drops","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Abzyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abzyme Files Patent Application for pH-Dependent Anti-CD3 Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-hCD3 antibodies","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abzyme Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abzyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abzyme The.."},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palladio Biosciences Doses First Patient With Lixivaptan in The ALERT Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio B.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Trial in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Valproate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral T.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complete and Durable Responses Observed in UroGen Pharma's OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Announces New Clinical Trial to Investigate Niagen\u00ae and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Presents FIDELIO-DKD Phase III Study Cardiovascular Subgroup Analysis of Patients With Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterium-stabilized R-pioglitazone","moa":"Mitochondrial pyruvate carrier","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Starts Phase 1 Clinical Study for REVTx\u201199 for Respiratory Viral Infection, Including COVID\u201119","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"REVTx\u201199","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces FDA Granted Orphan Drug Designation for AMX0035 for the Treatment of Wolfram Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Presents New OpRegen\u00ae Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelium cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma Submits Supplemental New Drug Applications for VAZALORE\u2122 325 mg and 81 mg to U.S. Food and Drug Administration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Gets Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Yeast recombinant lipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fox Chase Offering First CAR T Therapy Approved for Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fox Chase Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Fox Chase Cancer Center \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Fox Chase .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety and Efficacy Signals In Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"EicOsis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EicOsis Successfully Completes Phase 1a Clinical Trial of EC5026","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"EC5026","moa":"sEH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EicOsis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's DUPIXENT\u00ae (Dupilumab Injection) Now Approved by Health Canada for Patients with Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Provides Update on PRAX-114 IND Submission for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HLS Therapeutics Announces Health Canada Approval of PERSERIS\u00ae for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"HLS Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Injectable Suspension","sponsorNew":"HLS Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HLS Therap.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo's Once-Weekly Semaglutide 2.0 mg Shows Superior Reduction in HbA1c vs Once-Weekly Semaglutide 1.0 mg in Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech to Present AWARE-1 Data and Updates on Phase 2 BRACELET-1 and IRENE Trials at the San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis\u2019 Product Candidate UCARTCS1 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"UCARTCS1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"infusion","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Positive Results from Phase 2\/3 CAPELLA Trial of Lenacapavir in Heavily Treatment-Experienced People Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2\/3 COVID-19 Study with Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma and Gets Breakthrough Therapy Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"DAY101","moa":"pan-RAF kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces that the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to Humira\u00ae (Adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Teva","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covis Group Announces Data for Ciraparantag Published in Blood, the Journal of the American Society of Hematology","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Covis Phar.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at ASH to Reinforce Breadth of Novartis Hematology Portfolio Across Multiple Blood Cancers and Serious Hematologic Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Presents Safety and Efficacy Results of Rivoceranib in Combination with Nivolumab at the 2020 CTOS Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 SNO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"GH Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GH Research Completes Phase 1 Clinical Study with GH001 in Healthy Volunteers and Updates on Further Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"GH Research","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"inhalation","sponsorNew":"GH Research \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GH Researc.."},{"orgOrder":0,"company":"F4 Pharma","sponsor":"Assistance Publique Hopitaux de Paris","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F4 Pharma Starts Clinical Trial with FX06 in Frace to Treat Most Severely Affected Covid-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"FX06","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F4 Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F4 Pharma \/ Assistance Publique Hopitaux de Paris","highestDevelopmentStatusID":"8","companyTruncated":"F4 Pharma .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline and MMV Present Positive Data on Treatment for Plasmodium Vivax Malaria in Children from 6 Months up to 15 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives US Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Update on Omburtamab in DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"124I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Two Presentations at WORLD Symposium 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"AskBio","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic AcidemiaGene therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmTOR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AskBio \/ S.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IH201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Tract Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACT Therapeutics Receives Orphan-Drug Designation for TRK-001 from the U.S. Food and Drug Administration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TRK-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Tract Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tract Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tract Ther.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B at the 62nd Annual Meeting of the American Society of Hematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TNB-383B","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Completes Enrollment of the Phase III Study of Polihexanide 0.08% for the Treatment of Acanthamoeba Keratitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Receives Orphan Drug Designation From EC for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Presentation of Data from Phase I Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Oculos Development Services","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol\u00ae for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Oculos Development Services","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Announces Positive Interim Data from ReSPECT\u2122 Phase 1 Clinical Trial in Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from MD Anderson Cancer Center Phase 2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal Article Reviews Phoenix's Oleandrin\u2019s Antiviral Activity Against \u2018Enveloped\u2019 Viruses, Including Sars-Cov2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Oleandrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phoenix Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phoenix Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Bi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-200","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-S6-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Gains Approval For OXLUMO In European Union For Treatment Of Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NorthSea Therapeutics Doses First Patient in Phase 1 Trial of SEFA-1024 in Dyslipidemia and Further Expands its Clinical Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SEFA-1024","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"NorthSea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"OBI-833","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"GBA1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Affimed","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Publishes Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD\u2019s KEYTRUDA\u00ae in Blood","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Affimed \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"University of Oxford","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford University Breakthrough on Global COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"University.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present New Investigational Data on LENVIMA\u00ae (lenvatinib) in Thyroid Cancer and Osteosarcoma at ESMO Asia 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Key Regulatory Designations to PTC Therapeutics\u2019 PTC596 to Treat Two Rare Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Unesbulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts for Review Samsung Bioepis & Biogen\u2019s BLA for SB1, a Proposed Biosimilar Referencing Lucentis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's COVID-19 Vaccine Shows Midphase Efficay in Old Age People","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces the Approval of XGEVA\u00ae in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clear Creek Bio Doses First Patient in Phase 2 Outpatient Study of Brequinar to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Brequinar","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clear Creek Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Clear Creek Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clear Cree.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Biotech Plans Clinical Trial with Carragelose Nasal Spray to Investigate Prevention of COVID-19 in Frontline Healthcare Staff","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Carrageenan API","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"throat sprays","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA confirms December 4 2020 for Type \u2018A\u2019 Meeting to Discuss Guidance on ImmuPharma's Forthcoming International Phase 3 Trial of Lupuzor\u2122","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"IPP-201101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma.."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycostem Initiates Phase I\/IIa (Pivotal) Trial to Evaluate the Safety and Efficacy of oNKord\u00ae in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"oNKord","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CT053","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Presents Clinical Results of INO-5401 + INO-9012 in Combination with Libtayo to Treat Newly Diagnosed Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Shares Topline Data from Partner\u2019s Pivotal Phase 3 Study of VASCEPA\u00ae (Icosapent Ethyl) in Mainland China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Edding Pharm","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edding Pharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Edding Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Imfinzi approved in the US for less-frequent, fixed-dose use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002Trial to Evaluate Ability of BP1002","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BP1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts ADC Therapeutics' BLA, Grants Priority Review for Loncastuximab Tesirine for Relapsed\/Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces FDA Approval of Zokinvy\u2122 for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Groupe Persavita","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Persavita is Preparing for a Clinical Trial to Test its Experimental Natural Health Product in Covid-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Groupe Persavita","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Groupe Persavita \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Per.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChariotMS to Test Mavenclad in SPMS, PPMS Patients With Little Ability to Walk","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Queen Mary University of London \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission approves Supemtek\u00ae for the prevention of influenza in adults aged 18 years and older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Quadrivalent recombinant influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From SOLOIST and SCORED Outcomes Studies Presented at the AHA Scientific Sessions and Published in the NEJM","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to BTK Inhibitor, Rilzabrutinib to Treat Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVersys Announces First Subjects Dosed in Ph 1 Clinical Trial of BV100","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifabutin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Conclude Phase 3 Study of Covid-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"University of Florida","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Florida \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevar Therapeutics and Taiba Middle East FZ LLC Partner to Commercialize Apealea\u00ae in the Middle East and North Africa Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiba Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Taiba Heal.."},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"ValiRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValiRx PLC Signs an Agreement with Kalos Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"KTH222","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kalos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalos Therapeutics \/ ValiRx","highestDevelopmentStatusID":"4","companyTruncated":"Kalos Ther.."},{"orgOrder":0,"company":"BlueWillow Biologics","sponsor":"Medigen Vaccine Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigen, BlueWillow Collaborate to Develop SARS-CoV-2 Intranasal Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"S-2P-NE-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BlueWillow Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueWillow Biologics \/ Medigen","highestDevelopmentStatusID":"4","companyTruncated":"BlueWillow.."},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"12","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"COVAX Advance Market Commitment","sponsor":"Gates Foundation","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gates Foundation Adds $70 Million More Funding for COVID Vaccines for Poor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"COVAX Advance Market Commitment","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"COVAX Advance Market Commitment \/ Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"COVAX Adva.."},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"CODA Biotherapeutics Receives Grant from the NIH to Help Advance its Next-Generation Gene Therapy-Mediated Chemogenetic Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Funding","leadProduct":"AAV Vector based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coda Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Coda Bioth.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Starts VERSATILE-002 Phase 2 Trial of PDS0101-KEYTRUDA\u00ae in Recurrent\/Metastatic Head and Neck Cancer Together with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Clinical Trial Updates on Sotatercept in Pulmonary Arterial Hypertension at the 2020 AHA Scientific Sessions","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cleveland Clinic Research Shows that Melatonin is a Promising Candidate for Prevention and Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma to Release Updated Clinical Results of HQP1351 in Drug-Resistant Chronic Myeloid Leukemia at the ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Provides Regulatory Update on PRAX-114 Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents at the SITC 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Initiates Phase 1 Clinical Trial for SB16, Proposed Biosimilar to Prolia (Denosumab)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Receives Positive FDA Feedback to Advance Its Lead Drug Candidate Lanifibranor Into Pivotal Phase III in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"film-coated tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Medikine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medikine to Present Breakthrough Discoveries of Peptide-Based Agonists of IL-7 and IL-2\/15 Receptors at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MDK-271","moa":"IL-7 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medikine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medikine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medikine \/.."},{"orgOrder":0,"company":"Immunophotonics","sponsor":"Swiss Group for Clinical Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"N-dihydrogalactochitosan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunophotonics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Immunophotonics \/ Swiss Group for Clinical Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Immunophot.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Fujitsu","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Japan's Fujitsu, Mizuho, PeptiDream to Establish Joint Venture to Develop COVID-19 Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Fujitsu","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"AzurRx BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Asymchem Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Asymchem Laboratories \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Asymchem L.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Conjugated Estrogens","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aspen Pharmacare Holdings \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma Announces Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjogren's Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharm.."},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BTG Specialty Pharmaceuticals Reports Initial Study Results Show Feasibility of Outpatient Methotrexate Administration with Planned-Use Voraxaze\u00ae During Covid-19 Pandemic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specia.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Unveils Details on New HSC Gene Therapy Research Programs as Part of R&D Investor Event","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-204","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals to Present at The Liver Meeting Digital Experience(TM) 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"softgel capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selva Therapeutics Announces First Dosing in Phase 1 Clinical Study of SLV213, a Potential Oral Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"SLV213","moa":"Cathepsin L","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Selva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Ther.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Presents New Preclinical Data on ATA3271 to Treat Solid Tumors, at the 35th SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA3271","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Britain Starts Accelerated Review for AstraZeneca's Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"ISD-017","moa":"STING pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISD Immunotech \/ Biogen Inc","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immuno.."},{"orgOrder":0,"company":"Charit\u00e9 Universit\u00e4tsmedizin","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charit\u00e9 - Universit\u00e4tsmedizin Berlin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Charit\u00e9 Universit\u00e4tsmedizin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charit\u00e9 Universit\u00e4tsmedizin \/ Actimed Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charit\u00e9 Un.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"The Progeria Research Foundation","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Divestment","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"MARATHON PHARMS","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI\u2122 Monetization","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.089999999999999997,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Marathon","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generex and NuGenerex Li-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Distribution & Licensing Option","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generex Biotechnology \/ Bintai Kinden","highestDevelopmentStatusID":"4","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Argenx","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Argenx Enters Into Agreement To Acquire Priority Review Voucher","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ a.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO\u2122 (pralsetinib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"oral","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Mitacs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Minaris Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Deal for MB-107 Lentiviral Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mustang Bio \/ Minaris Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"CureVac","sponsor":"Wacker Chemie AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac and WACKER Sign Manufacturing Contract for CureVac\u2019s COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Wacker","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Cytokinetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG594 from Amgen","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Cytokinetics","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teneobio Announces Poseida\u2019s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CAR-T therapies","moa":"scFv","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AbbVie Inc","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Teneobio","highestDevelopmentStatusID":"4","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Series C Financing","leadProduct":"R-Ketamine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.13,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"CAR-NK cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,755.0 million","upfrontCash":"$55.0 million","newsHeadline":"Schr\u00f6dinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":2.7599999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Schrodinger \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$425.0 million","newsHeadline":"Merck to Acquire OncoImmune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"MK-7110","moa":"SIGLEC10","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.42999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense for Advanced Development","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Anti-COVID-19 Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense for Advanced Development","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Evox Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evox Therapeutics Announces Launch of Strategic Collaboration with the University of Oxford","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Exosome-based therapeutics","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Evox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces Expansion of TACTI-002 Collaboration Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ambrx Closes $200 million in Crossover Financing to Advance its Clinical and Preclinical Pipeline of Precision Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"ARX788","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Ambrx Inc \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Pharmsynthez","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO, Pharmsynthez and IBCh Sign Covid-19 Antibody Development Deal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pharmsynthez","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmsynthez \/ HiFiBiO","highestDevelopmentStatusID":"6","companyTruncated":"Pharmsynth.."},{"orgOrder":0,"company":"Elevian","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elevian Announces $15 Million Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"rGDF11","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Elevian","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Elevian \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Elevian \/ .."},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"US Navy","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vivacelle Bio Receives $5.3M from the US Navy to Study VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"VBI-S","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Vivacelle Bio \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle .."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"IGEA Clinical Biophysics","sponsor":"OncoSec Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Announces Exclusive License Agreement for Cliniporator\u00ae Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CORVax12","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IGEA Clinical Biophysics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGEA Clinical Biophysics \/ OncoSec Medical","highestDevelopmentStatusID":"6","companyTruncated":"IGEA Clini.."},{"orgOrder":0,"company":"Almac Group","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Almac Group Works to Enable Efficient Manufacturing of Remdesivir in Response to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Almac Group \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"12","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$300.0 million","newsHeadline":"Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.04,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent and Cantargia Sign Manufacturing Agreement for Monoclonal Antibody CAN10","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1RAP","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Cantargia","highestDevelopmentStatusID":"4","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$3,125.0 million","upfrontCash":"$1,525.0 million","newsHeadline":"Biogen and Sage Therapeutics Join Hands to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":3.1299999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":3.1299999999999999,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"DARPA","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"DARPA and JPEO Award Contract to SmartPharm to Develope Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"STI-2020","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SmartPharm Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"SmartPharm Therapeutics \/ DARPA","highestDevelopmentStatusID":"7","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Merger","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domp\u00e9 and The FarmaMondo Group Enter Agreement to Distribute Oxervate in Russia and Other CIS Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Cenegermin","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"FarmaMondo","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"FarmaMondo \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"FarmaMondo.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark to Sell Select Anti-Allergy Brands to Dr Reddy\u2019s in Russia, Ukraine, Kazakhstan and Uzbekistan for its \u201cRyaltris\u201d Launch","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr Reddy\u2019s Lab","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Agreement with Kinaset Therapeutics Inc. to Support the Development of VR588 to Treat Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VR588","moa":"JAK","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kinaset Therapeutics \/ Vectura","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Th.."},{"orgOrder":0,"company":"Duchesnay","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Population Council and Duchesnay Announce New International License Agreement for ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Segesterone Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Duchesnay","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravaginal ring","sponsorNew":"Duchesnay \/ Population Council","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay .."},{"orgOrder":0,"company":"University of Michigan","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Inks Agreement with University of Michigan to Obtain an Exclusive License for a MDM2 Degrader Using PROTAC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MDM2 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"University of Michigan","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Michigan \/ Ascentage Pharma","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Spotlight Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Series A Financing","leadProduct":"CRISPR ribonucleoproteins","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spotlight Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Spotlight Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Spotlight .."},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Eisai Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Wren Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wren Therapeutics \/ Eisai","highestDevelopmentStatusID":"3","companyTruncated":"Wren Thera.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences Announces Licensing Agreement for scFvs Targeting CD371 to Enable Development of Allogeneic Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Anti-CD371 scFvs based cell therapy","moa":"CD371","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Caribou Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Premier","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProvideGx\u00ae Partners with Fresenius Kabi to Help Stabilize Supply of Heparin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Premier","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Premier \/ .."},{"orgOrder":0,"company":"Gyeonggido Business and Science Accelerator","sponsor":"CINECA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EU and South Korean Research Organisations Sign an Agreement to Work Together on the Development of a Covid-19 Treatment Using Raloxifene","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Gyeonggido Business and Science Accelerator","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gyeonggido Business and Science Accelerator \/ CINECA","highestDevelopmentStatusID":"1","companyTruncated":"Gyeonggido.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Adva-27a","moa":"Topoisomerase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Qiagen","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-Associated Squamous cell Carcinoma of the Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"BNT113","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qiagen \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Qiagen \/ B.."},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Creation of a Research Partnership Between Pierre Fabre and Y-Biologics to Develop New Immunotherapies Based on Monoclonal Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Y-Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"2","companyTruncated":"Y-Biologic.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ionis Announces third Investigational Antisense Medicine to treat Nonalcoholic Steatohepatitis (NASH) Enters Development","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ION455","moa":"PNPLA3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Ionis Pharmaceuticals","amount2":0.33000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"amfAR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ amfAR","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Symvivo","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Symvivo Corporation Announces Research Collaboration With Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Plasmid DNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Symvivo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Janssen","highestDevelopmentStatusID":"4","companyTruncated":"Symvivo \/ .."},{"orgOrder":0,"company":"Tempus","sponsor":"Novellus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempus \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Tempus \/ N.."},{"orgOrder":0,"company":"Domainex","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"APN431","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Domainex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domainex \/ APEIRON Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/.."},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Egle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Egle Thera.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Geneventiv Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GENV HEM","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ Geneventiv Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"3S Bio Inc","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"3SBio Inc. Received Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"3S Bio Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"3S Bio Inc \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"3S Bio Inc.."},{"orgOrder":0,"company":"AB Science","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EIB Supports AB Science in its COVID-19 Development Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX\u00ae to Treat Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Covaxx Announces $2.8 Billion in Advance Purchase Commitments to Deliver More than 140 Million Vaccine Doses to Emerging Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vaxxinity","amount2":2.7999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":2.7999999999999998,"dosageForm":"","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$359.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Offers to Acquire Kiadis, A Clinical-Stage Company Developing Cell-Based Immunotherapy Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Isatuximab-irfc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,720.0 million","upfrontCash":"$125.0 million","newsHeadline":"Sangamo Announces Closing of Biogen Collaboration Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sangamo Therapeutics","amount2":2.7200000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.7200000000000002,"dosageForm":"Intravenous infusion","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Gets Approvals for Two Phase Ib\/II Clinical Studies of APG-2575 to Treat Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent\u2019s Product SULINNO\u2019s New Indication Approved by NMPA China, For Patients with Polyarticular Juvenile Idiopathic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron\u2019s Casirivimab and Imdevimab Antibody Cocktail for Covid-19 Is First Combination Therapy to Receive FDA Emergency Use Authorization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sotira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arizona BioTech Company Successfully Completes Pre-Clinical Testing for Vaccine Alternative to Prevent COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KEPTIDE COVID","moa":"ACE2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sotira","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Sotira \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotira \/ N.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces Dosing of First Subject in Phase 1\/2 Clinical Trial for INO-3107","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel and Medison Announce Health Canada Approval of TAVALISSE\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Comprehensive Cancer Network\u00ae Adds INQOVI\u00ae Tablets to its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"tablet","sponsorNew":"Taiho Oncology \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Completes Pre-IND Meeting With FDA to Establish Clinical Development Program for NRL-4 in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar 1 Mania in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NRL-4","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Reports Recently Published Data on Favipiravir as Treatment for Mild to Moderate Covid-19 Shows Significant Improvement in No Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 as a Potential Treatment for Scalp and Body Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Silicon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silicon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silicon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silicon Th.."},{"orgOrder":0,"company":"Brainever","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainEver Receives FDA Orphan Drug Designation for BREN-02, for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human homeoprotein Engrailed 1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Brainever","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brainever \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Brainever .."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"TB202-3","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ennaid Therapeutics Discovers Orally Deliverable Generic COVID-19 Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Drospirenone","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ennaid Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ennaid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ennaid The.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Announces Second Publication and Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Submits Applications for Licensure of V114 for Use in Adults to the U.S. FDA and European Medicines Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin\u00ae Therapeutic Candidate MP0420","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse\u00ae for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Starts Phase 3 Study of RSV Maternal Candidate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore's Tebentafusp Hits Main Goal of Late-Stage Uveal Melanoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioShin Enrolls First Patient Into an Asia-Pacific Regional Multi-Center Phase III Trial of Rimegepant For the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Biohaven","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4\/6 Inhibitor ON 123300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evgen Pharma Recruits First Patient in STAR Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulforaphane","moa":"Nrf2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Phar.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Announces Positive Results of the Two Japanese Registration Studies with Clazosentan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Triple monoamine reuptake","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma's AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AB201","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves NK-Mediated Tumor Cell Killing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"N-803","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constellation Pharmaceuticals to Host Analyst \/ Investor Event to Discuss Update of MANIFEST Trial for CPI-0610 Presented at ASH Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm to Present NurOwn\u00ae Phase 3 Clinical Trial Results at 31st International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharma Doses First Patient in Phase 1\/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PC14586","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces COVID-19 Vaccine Clinical Development Progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope Initiates Phase 1 Clinical Trial to Test Its First SARS-CoV-2 Investigational Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Announces First Patient Dosed in Phase 2 Clinical Trial with AD109, Lead Candidate for Treatment of Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aroxybutynin","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Cato Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Clears Appili Therapeutics for New Phase 3 Clinical Trial to Evaluate Avigan Tablets in the Prevention of COVID-19 in Exposed Individuals in the Community","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Appili Therapeutics \/ CATO Research","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives E.C Approval for Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Genentech","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Shionogi & Co","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the EMA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"3-antigen hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Enapotamab Vedotin Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Enapotamab Vedotin","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"NaviFUS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaviFUS Highlights Clinical Trial Data and Device Capabilities at Virtual International Focused Ultrasound Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia\u2019s Sputnik COVID-19 Vaccine Has 91.4% Efficacy After 28 days, New Interim Data Show","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of GM2 Gangliosidosis With PLX-300","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-300","moa":"PPAR alpha","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Initiates Phase 3 Trial of Oral Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Starts Second Phase 3 Study For NOV03 For Dry Eye Disease Associated With Meibomian Gland Dysfunction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Reports Lokelma Label Update Approved in China for Patients with Hyperkalaemia on Chronic Haemodialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Provides Update on Omaveloxolone Program for Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals to Host Fireside Chat with Analysts to Discuss 2021 Outlook for its Lead Programs and Novel mAb Discovery Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Tolmar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolmar Publishes FENSOLVI \u00ae for Injectable Suspension Safety and Efficacy Data in Journal of Clinical Endocrinology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tolmar","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tolmar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ N.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Colorectal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"extended release Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QuadraMune\u2122 Synergizes with Metformin to Stimulate Anti-Viral Defenses in Pilot Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Demonstrates Encouraging Survival Data for ONCOS-102 in Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron to Treat Irritable Bowel Syndrome Pain","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Fosun Pharma Announce the Start of a Phase 2 Clinical Trial of Lead mRNA COVID-19 Vaccine BNT162b2 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Receives USFDA Tentative Approval for Testosterone Gel, 1.62% (20.25 mg\/1.25 gm actuation).","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Defers Approval of Revance Therapeutics' DaxibotulinumtoxinA for Injection in Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Completes Enrolment for Global Phase II Clinical Trial with Covid-19 Treatment Candidate CT-P59","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Gets Approval for Phase I\/II Clinical Trial of ATG-016, in Mainland China for the Treatment of Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Antengene \/ Karyopharm Therapeutic","highestDevelopmentStatusID":"7","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Updates Regulatory and Clinical Trial Events","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Submission Of Investigational New Drug Application For AdCOVID\u2122 A Single-Dose Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"nasal spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Reports Fourth Iteration of COVID-19 Treatment Trial Underway","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Approval of EVRENZO\u00ae in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Haoma Medica Completes First-in-Human Trial for NaQuinate","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NaQuinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Application for Merck's Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Eisai","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie, Eisai Receives Approval for Additional Indication of Humira to Treat Pyoderma Gangrenosum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eisai \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ab.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Oxford to Investigate Inhaled Corticosteroids as a Possible Treatment for Covid-19 in National Principle Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Oxford to Investigate Colchicine as a Possible Treatment for COVID-19 in the RECOVERY trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"tablet","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on OTIVIDEX\u00ae and OTO-313 Programs","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"FerGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FerGene Reports Landmark Study in Non-Muscle Invasive Bladder Cancer Testing Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Published in The Lancet Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Nadofaragene firadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"FerGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"FerGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FerGene \/ .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Gets FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Completes Target Enrollment in the INTRIGUE Phase 3 Study of QINLOCK\u00ae in Patients with Second-Line Gastrointestinal Stromal Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Eprenetapopt","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergy Publishes Results from BioCryst\u2019s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Labs Receives ANDA Approval for Atenolol and Chlorthalidone Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atenolol","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Axatilimab","moa":"CSF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Expands Phase 2 Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"EvviVax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LinearDNA COVID-19 vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Applied DNA Sciences Inc \/ EvviVax","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing an EUA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Y-mAbs\u2019 DANYELZA\u00ae (naxitamab-gqgk) for the Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Dupixent\u00ae Approved by EC As First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabometyx Scores Japanese Approval for Unresectable Hepatocellular Carcinoma Patients Following Systemic Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Submits Its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Drug for Neglected Diseases initiative","sponsor":"Inserm-ANRS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Largest Clinical Trial to Test the Efficacy and Safety of Treatments in 2,000 to 3,000 Mild to Moderate COVID-19 Patients in Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Drug for Neglected Diseases initiative","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Drug for Neglected Diseases initiative \/ Inserm-ANRS","highestDevelopmentStatusID":"10","companyTruncated":"Drug for N.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Pharma Completes Acquisition of Bone Therapeutics\u2019 Cell Therapy Manufacturing Subsidiary Skeletal Cell Therapy Support","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"ALLOB","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Catalent Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","amount":"$124.0 million","upfrontCash":"$8.0 million","newsHeadline":"Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Leuprolide Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Foresee Pharmaceuticals \/ GenScience Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Survival Among Elderly Patients Could Be Improved by Arthritis Drug, Shows Imperial College London Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"tablet","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Navire Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio and Navire Pharma Doses First Patient in Phase 1 Trial of BBP-398 for RAS and Receptor Tyrosine Kinase Mutation Driven Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BBP-398","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Navire Pharma","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Completes Enrolment into Second Safety Cohort of Follicular Lymphoma Patients in Archer-1 Phase 1b Betalutin\u00ae\/Rituximab Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Sagimet Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Pharma, a Wholly Owned Company of Ascletis Pharma Completed Patient Enrollment in ASC40 (TVB-2640) Phase 2 NASH Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Sagimet Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID\u2122 its Single-Dose Intranasal Vaccine Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV to Present Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Immutep","sponsor":"Australian Ethical","pharmaFlowCategory":"D","amount":"$22.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Immutep \/ Australian Ethical","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Pharma and Weill Cornell Medicine Collaborate To Start Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Weill Cornell Medicine \/ Biohaven Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Weill Corn.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recipharm Announces Signature of letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine Candidate (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Moderna","highestDevelopmentStatusID":"10","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$6,910.0 million","upfrontCash":"$30.0 million","newsHeadline":"Merck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artios Pharma Limited","amount2":6.9100000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6.9100000000000001,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$55.0 million","newsHeadline":"AbbVie and Frontier Medicines Ink Global Partnership to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":1.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Frontier Medicine \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$320.0 million","newsHeadline":"AstraZeneca's Crestor to be Divested to Gr\u00fcnenthal in Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Divestment","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Gr\u00fcnenthal","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Hemera Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"HMR59","moa":"CD59","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hemera Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Hemera Biosciences \/ Janssen","highestDevelopmentStatusID":"8","companyTruncated":"Hemera Bio.."},{"orgOrder":0,"company":"BioClonetics Immunotherapeutics","sponsor":"Enzolytics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics, Inc","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Merger","leadProduct":"Anti-HIV recombinant monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioClonetics Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioClonetics Immunotherapeutics \/ Enzolytics","highestDevelopmentStatusID":"4","companyTruncated":"BioCloneti.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$30.0 million","newsHeadline":"Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE\u00ae Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Halozyme Therapeutics","amount2":0.19,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.19,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"Noema Pharma raises CHF54 Million in Series A Financing Round Led By Sofinnova Partners and Polaris Partners","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"NOE-101","moa":"mGluR5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Noema Pharma \/ Sofinnova Partners","highestDevelopmentStatusID":"8","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"TAC-001","moa":"TLR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tallac Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"7","companyTruncated":"Tallac The.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$39,000.0 million","upfrontCash":"$13,300.0 million","newsHeadline":"AstraZeneca To Acquire Alexion, Accelerating the Company's Strategic and Financial Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":39,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":39,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca PLC","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly Announces Agreement to Acquire Prevail Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"GBA1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"NBE Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,435.6 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"NBE-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NBE Therapeutics","amount2":1.4399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.4399999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"NBE Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"NBE Therap.."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,762.0 million","upfrontCash":"$1,400.0 million","newsHeadline":"Gilead Sciences to Acquire MYR GmbH","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Bulevirtide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MYR Pharmaceuticals \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,555.0 million","upfrontCash":"$55.0 million","newsHeadline":"Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":2.5600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5600000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Chrysalis BioTherapeutics","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Chrysalis BioTherapeutics \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Chrysalis .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"3W Fund Management","pharmaFlowCategory":"D","amount":"$43.0 million","upfrontCash":"Undisclosed","newsHeadline":"Canbridge Pharmaceuticals Completes $43 Million Series E Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Series E Financing","leadProduct":"Idursulfase beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ 3W Fund Management","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Vipergen","sponsor":"Casma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vipergen \/ Casma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$29.5 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma Announces Series B Extension and Final Closing with Total of \u20ac25 Million ($29.5 Million)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"enema","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Viatris","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Groundbreaking Agreement Reduces by 75% the Cost of HIV Treatment for Children in Low-and Middle-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$37.2 million","upfrontCash":"Undisclosed","newsHeadline":"OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"OLX101A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Kyowa Kirin Sign License Agreement to Strengthen Their Presence in Asia Pacific\u2019s Rare Disease Therapy Area","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Topical","sponsorNew":"Helsinn Advanced Synthesis \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Amring Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amring Pharmaceuticals Inc. Acquires LYSTEDA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Amring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Israel Biotech Fund","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Fluasterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"SteroTherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"SteroTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"SteroThera.."},{"orgOrder":0,"company":"The University of Calgary","sponsor":"Therapix Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"THX-160","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"The University of Calgary","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Calgary \/ Therapix Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$540.0 million","newsHeadline":"Endo Completes Acquisition of BioSpecifics","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"BioSpecifics","amount2":0.54000000000000004,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"Injection","sponsorNew":"BioSpecifics \/ Endo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"BioSpecifi.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"1","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"Rubedo Life Sciences","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rubedo Lif.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"GP2 Peptide","moa":"HER2\/Neu protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intradermal injection","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for 7 Additional Essential Medications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Vizient","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vizient \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Vizient \/ .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Tubulis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tubulis Partners with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"TUB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Tubulis","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Regent Pacific","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Regent Pacific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cutaneous spray","sponsorNew":"Regent Pacific \/ Wanbang Pharmaceutical Marketing and Distribution","highestDevelopmentStatusID":"12","companyTruncated":"Regent Pac.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Sara\u2019s Cure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rafael Pharmaceuticals Partners with Sara\u2019s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613 Hydroxychloroquine combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Devimistat","moa":"TCA cycle","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Sara\u2019s Cure","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"iBio","sponsor":"ATB Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Selected to Produce ATB Therapeutics\u2019 Bioengineered Antibody-Toxin Fusion Proteins","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Atbody-st-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ ATB Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"iBio \/ ATB.."},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$29.5 million","upfrontCash":"$10.0 million","newsHeadline":"Exelixis In-Licenses Aurigene\u2019s CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Trial in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"XL102","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aurigene","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Aurigene \/.."},{"orgOrder":0,"company":"United Health Group","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and UnitedHealth Group Partner on Pragmatic Study of Neutralizing Antibody Bamlanivimab (LY-CoV555) for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"United Health Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United Health Group \/ Lilly","highestDevelopmentStatusID":"12","companyTruncated":"United Hea.."},{"orgOrder":0,"company":"Tevard Biosciences","sponsor":"Zogenix","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"$10.0 million","newsHeadline":"Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"tRNA-based gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Tevard Biosciences","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Tevard Biosciences \/ Zogenix","highestDevelopmentStatusID":"3","companyTruncated":"Tevard Bio.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Funding","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0.5,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Sentinel Oncology","sponsor":"PharmaEngine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"SOL-578","moa":"Chk1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sentinel Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sentinel Oncology \/ PharmaEngine","highestDevelopmentStatusID":"4","companyTruncated":"Sentinel O.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-mAbs Therapeutics, Takeda Ink Exclusive License and Distribution Agreement for DANYELZA and Omburtamab in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"Takeda Pharmaceutical \/ Y-mAbs","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","amount":"$18.1 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Raises \u20ac15 million in Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Private Placement","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ HBM Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Sareum","sponsor":"UKRI","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Sareum Formally Awarded Grant Funding from the UK Government (UKRI) to Explore Potential of SDC-1801","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"SDC-1801","moa":"JAK1\/TYK2 kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ UKRI","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ U.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","amount":"$263.5 million","upfrontCash":"Undisclosed","newsHeadline":"Richter Announces the Acquisition of Janssen\u2019s Evra\u00ae Transdermal Contraceptive Patch Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Norelgestromin","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0.26000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.26000000000000001,"dosageForm":"Transdermal patch","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"$12.0 million","newsHeadline":"Syros Acquires Clinical-Stage Drug Candidate from Orsenix for Acute Promyelocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orsenix","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Orsenix \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ .."},{"orgOrder":0,"company":"AbCellera","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","amount":"$357.0 million","upfrontCash":"Undisclosed","newsHeadline":"AI drug Discovery Platform AbCellera Sets terms for $357 Million IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"Bamlanivimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"AbCellera \/ BMO Capital Markets","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"$60.0 million","newsHeadline":"Bayer and Atara Biotherapeutics Enter Strategic Collaboration for next Generation, Mesothelin-Targeted CAR-T Cell Therapies for solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ATA3271","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Atara Biotherapeutics","amount2":0.67000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Rev1 Ventures","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Basking Biosciences, Inc. Completes $5.4M Seed Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"DTRI-031","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Basking Biosciences","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Basking Biosciences \/ Rev1 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Basking Bi.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$125.0 million","newsHeadline":"BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.33000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"BioCryst Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"3D Medicines","pharmaFlowCategory":"D","amount":"$202.0 million","upfrontCash":"$7.5 million","newsHeadline":"SELLAS Life Sciences and 3D Medicines Ink License Agreement to Develop and Commercialize of Galinpepimut-S and GPS+ in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ 3D Medicines","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Orexo","sponsor":"Accord healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV\u00ae in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Accord","highestDevelopmentStatusID":"12","companyTruncated":"Orexo \/ Ac.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"$5.0 million","newsHeadline":"Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Nabriva","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$458.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Ink Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Aligos Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Therapy Developer 4D Molecular Therapeutics Sets Terms for $100 million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"4D-125","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Xencor","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$50.0 million","newsHeadline":"Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"B7-H3 x CD28 bispecific antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Janssen","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ J.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Roivant Unveils Targeted Protein Degradation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Roivant Sciences","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Roivant Sciences \/ SK Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Initium Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Through Strategic Collaboration with GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Drug Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody-based therapeutics","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ Initium Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into RenMab\u2122\/RenLite\u2122 Licensing Agreement with Xencor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Human antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Xencor","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$634.0 million","upfrontCash":"$56.0 million","newsHeadline":"KaliVir Immunotherapeutics and Astellas Ink Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"VET2-L2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KaliVir Immunotherapeutics","amount2":0.63,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.63,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Astellas","highestDevelopmentStatusID":"4","companyTruncated":"KaliVir Im.."},{"orgOrder":0,"company":"Proxygen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proxygen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proxygen \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Proxygen \/.."},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","amount":"$15.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Signs Definitive Agreement To Acquire Adelia Therapeutics As Part Of Its Commitment To Strategic Growth","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Ketamine analogs","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Adelia Therapeutics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Adelia Therapeutics \/ CYBIN","highestDevelopmentStatusID":"3","companyTruncated":"Adelia The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ionis Announces Astra Zeneca's Initiation of Phase 2b Clinical Study of Its Antisense Medicine Targeting PCSK9 to Lower LDL-Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"AZD8233","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx Rare\u00ae Pharmacy Chosen as Partner by Alnylam for OXLUMO to Treat Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PANTHERx Rare Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amzell to Begin Phase 3 Trial of AMZ002 to Treat Infantile Epileptic Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"AMZ002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Amzell B.V","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amzell B.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amzell B.V.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM\u2013002 (S-oxprenolol) for Treating Cancer Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxprenolol","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, Takeda and UCB Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets DGCI Nod for Phase 3 Clinical Trials with Biological Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios' Phase 3 ACTIVATE Trial of Mitapivat Met Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca\u2122 in Combination with Doxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces the Initiation of a Rolling Submission for its Single-dose Janssen COVID-19 Vaccine Candidate with Health Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ispen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Gets FDA Fast Track Designation for Irinotecan Liposome Injection as a Second Line Monotherapy Treatment for small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ispen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ispen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ispen \/ No.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Penicillamine Tablets USP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Penicillamine","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Take Major Step Toward Angelman Syndrome Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ Asklepios Biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Event","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia's Helix Biotherapeutic Delivery System Used In CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Data from NuCana's Phase Ib Study of Acelarin plus Cisplatin Published Online Ahead of Print in The Oncologist","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Tentative Approval for Axitinib Tablets, 1 mg and 5 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Aphios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphios Granted US Patent for Combination Therapeutic to Treat Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aphios","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aphios \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aphios \/ N.."},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Licenses XEOMIN\u00ae (incobotulinumtoxinA) for Adult Patients With Sialorrhea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharm.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Inc. Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CodaVax-RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Starts Rolling Biologic License Application to the U.S. FDA for AT-GAA in Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cipaglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Completes Patient Enrolment into Phase 1 trial of Betalutin\u00ae in Diffuse Large B Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE-1334","moa":"TGF beta-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Expands ReSPECT\u2122 Clinical Trial to MD Anderson Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Plus Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AGLE-177","moa":"Homocysteine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ABX-002","moa":"TR-Beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Autobahn Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Initiates Phase 2 NASH Trial of Oral Insulin","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Gets FDA Fast Track Designation for Subcutaneous MarzAA to Treat Episodic Bleeding in Hemophilia A or B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio\u2019s Phase I Study for Inhaled Ampion Advances to Completing Enrollment of Covid-19 Patients with Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Allomek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants AlloMek Orphan Designation for CIP-137401, Treatment of Neurofibromatosis Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CIP-137401","moa":"MEK kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allomek \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ .."},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BT051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Th.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Completes 9-Month Stability Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Metavant Sciences","sponsor":"Sumitomo Pharma Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Provides Update on Metavant Partnership with Imeglimin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Metavant Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metavant Sciences \/ Sumitomo Dainippon","highestDevelopmentStatusID":"10","companyTruncated":"Metavant S.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. FDA for the Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Appili Therapeutics\u2019 Phase 3 Clinical Trial of Avigan\u00ae Tablets for the Treatment of COVID-19 in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's and RDIF Commence Clinical Trials for Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"9","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Xolair\u00ae (Omalizumab) for Adults with Nasal Polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Starts Rolling Submission of BLA to U.S. FDA for Ublituximab and Umbralisib Combo to treat Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Announces Dosing of First Patient IN Phase I\/II Trial of Rgx-111 for THE Treatment of Mucopolysaccharidosis Type I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-111","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Completes Patient Enrollment in phase 2b\/3 Study of Ifenprodil to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Final Approval for Metolazone Tablets USP 2.5 mg, 5 mg, and 10 mg","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Metolazone","moa":"Sodium-chloride cotransporter","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Janssen\u2019s TREMFYA\u00ae\u25bc (Guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Initiation of the Global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in Patients with Familial Chylomicronemia Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"GLPG1205","moa":"GPR84","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"hard gelatin capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Of New Drug Application For BridgeBio Pharma And QED's Infigratinib For The Treatment Of Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"QRA-244","moa":"Kv7.2\/7.3 ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Advances Development Program for Multiple System Atrophy Based on the Key Role of c-Abl Kinase in MSA Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"IkT-148x","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation of First UniCAR Cellular Immunotherapy Study in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"UniCAR-T-PSMA","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ N.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex to Present at the Benzinga Global Small Cap Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Xeruborbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qpex Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Bioph.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV\u2019s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Hard-to-Treat Advanced Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Demonstrates Growing Leadership in Breast Cancer at SABCS with Data From Its Innovative Medicines and Robust Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Camizestrant","moa":"Selective oestrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Seeks Approval of Amivantamab to Treat Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Gets Rare Pediatric Disease and Orphan Drug Designations for TSHA-103 to Treat Epilepsy in SLC6A1 Haploinsufficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"TSHA-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Axial Therapeutics Phase 1b\/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics's Antibody Against Sars-Cov-2 Shows Potent Therapeutic and Prophylactic Activity in Advanced Covid-19 Disease Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"MTX-COVAB","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resolve Therapeutics Publishes Positive Sjogren\u2019s Syndrome Clinical Trial Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"RSLV-132","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resolve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Th.."},{"orgOrder":0,"company":"reMYND","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReMynd Commences First-in-Human Trial of ReS19-T Alzheimer\u2019s Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis restoration","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"reMYND \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ N.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Fibrinogen","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Korea Daewoong Pharma eyes Phase II trials of coronavirus drug, shares jump","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Presents Phase 2 Tebentafusp Clinical Results at ESMO Immuno-Oncology Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Rezolute\u2019s IND Application for RZ402","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ402","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"ImprimisRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study on Patented Non-Opioid MKO Melt\u00ae Reported in Leading Peer-Reviewed Anesthesia Journal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"ImprimisRx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Sublingual Troche","sponsorNew":"ImprimisRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ImprimisRx.."},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Submits NDAs for XPOVIO\u00ae (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics\u2019 Uproleselan in Combination With Venetoclax\/HMA Shown to Break Chemoresistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"E-selectin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Teclistamab","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA\u00ae-Based Regimen as Fixed Duration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite's Yescarta\u00ae Is First CAR T-cell Therapy to Show High Response Rates in a Pivotal Indolent Non-Hodgkin Lymphoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS and Bluebird Bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed\/Refractory Multiple Myeloma at ASH 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Bluebird Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta\u00ae in ZUMA-1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme\u2019s Phase 2\/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer\u2019s Disease Successfully Advances Past Interim Analysis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Pharmaceutical's TAK-620 Meets Primary Endpoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Maribavir","moa":"BGLF4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin's New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO\u00ae Responders with Specific Subtypes of Cutaneous T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mogamulizumab","moa":"CCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's BCMAxCD3 Bispecific Antibody Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN5458","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA\u00ae\/VENCLYXTO\u00ae in Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's IMBRUVICA\u00ae Plus VENCLEXTA\u00ae\/VENCLYXTO\u00ae Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Janssen","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's APOLLO Study Show Clinically Meaningful Response with DARZALEX FASPRO\u00ae Regimen After First Relapse in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loxo Oncology at Lilly Announces Updated Data from the Phase 1\/2 BRUIN Clinical Trial for LOXO-305","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Loxo-305","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncol.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's Phase 1b\/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Center for Advanced Research and Education","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Center for Advanced Research and Education","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for US FDA Regulatory Approval of Once-Weekly Semaglutide 2.4 mg For Weight Management","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approved IND for Alligator Bioscience's CD40-Targeting Antibody Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio's Investigational LentiGlobin\u2122 Gene Therapy Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"LentiGlobin Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605 at the 62nd Meeting of the American Society of Hematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-605","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Calquence Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals Presents Preclinical Data on KPMW135 Showing Increased Anti-Tumor Activity Compared to Rituximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"KPMW135","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents Data Evaluating Potential of Liso-cel Across Leukemia and Lymphomas at ASH 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine to Present New Interim Data From its Ongoing mTNBC trial at SABCS 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics' Boltbody\u2122 ISAC Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BDC-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's ANDROMEDA Study Show Hematologic Response for DARZALEX FASPRO\u00ae in Newly Diagnosed Light Chain (AL) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at ASH Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Influenza A (H5N1) monovalent vaccine, adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents New Robust Phase II Iadademstat Efficacy Data in AML at ASH-2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"TNB-383B","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Meets Primary Endpoint for Phase 2b Study of KBP-5074 in Treatment of Uncontrolled High BP in Advanced CKD Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"tablet","sponsorNew":"KBP Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five-Year Data on Ropeginterferon Alfa-2b Illustrate Durable Response at Five Years in People With Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Approves Clinical Trials for Chinese COVID-19 Vaccine Ad5-Ncov - Ifax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral spray","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's New data Reinforces the Benefit\/risk Profile of Fixed-Duration Polivy Plus Bendamustine and Mab Thera\/rituxaninn Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Follow-Up Phase III Data Reinforce the Long-Term Benefit of Roche\u2019s Hemlibra for People with Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Meet Patient Enrollment Target in Phase 2b\/3 Trial of RLF-100 for Critical COVID-19 with Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2\/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 Shows Promising Anti-Tumor Activity and Favorable Tolerability","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06863135","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Corporation's VASCEPA\u00ae (Icosapent Ethyl)-Related Scientific Findings to Be Presented at National Lipid Association (NLA) Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus announces Phase I trials of ZYIL1, a novel oral small molecule NLRP3 Inflammasome Inhibitor","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ZYIL1","moa":"NLRP3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Presents New Data from phase 2 ANCHOR Combination Study in Multiple Myeloma at American Society of Hematology Meeting ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Presents Data at ASH Showing the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed\/Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential \u2013Inclacumab and GBT021601","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclacumab","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio's Ongoing Orca-T Trial Shows Significantly Improved Improved 12-Month Graft Versus Host Disease Free and Relapse-Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"TregGraft","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Presents Highlights from ASH and Corporate Update Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Demonstrate Long-Term Benefit of IMBRUVICA\u00ae (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces Multiple ADCETRIS\u00ae (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Georgia State University Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Drug Blocks SARS-CoV-2 Transmission, Georgia State Biomedical Sciences Researchers Find","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Georgia State University Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Georgia State University Institute \/ Merck","highestDevelopmentStatusID":"9","companyTruncated":"Georgia St.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAR T-Cell Therapy Found Highly Effective in Patients with High-Risk Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New DARZALEX\u00ae (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR\u00ae AML-001 Study of Onureg in Adults with Acute Myeloid Leukemia in First Remission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents Clinical Proof-of-Concept Data Supporting the Potential of FT-4202 to Treat Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Allos Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allos Pharma Secures Exclusive License on Arbaclofen in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Baclofen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seaside Therapeutics \/ Allos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Th.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Presents Preclinical Data of Phage Targeting Klebsiella Pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reaches 50% Enrollment in IXINITY\u00ae Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant coagulation factor IX","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces New and Broad Versamune\u00ae Platform Patent Claims","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sentien Biotechnologies Announces First Subject Dosed in Phase 1\/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sentien Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sentien Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sentien Bi.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion Shares Progress of Sonlicromanol Development Programme at Mitochondrial Medicine 2020 Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves MenQuadfi\u00ae for Individuals 12 Months of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Meningococcal (Groups A, C, Y, W) Conjugate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Polyphor","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic murepavadin to Treat Pseudomonas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Murepavadin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Polyphor \/ CF Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"Yangtze River Pharmaceutical Group","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Yangtze River Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yangtze River Pharmaceutical Group \/ Alvotech","highestDevelopmentStatusID":"1","companyTruncated":"Yangtze Ri.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb\u00ae Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Ligand Pharmaceuticals \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Termination of Bridge Biotherapeutics's Collaboration and License Agreement with Boehringer Ingelheim","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Termination","leadProduct":"BBT-877","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Phase 3 Results of TYVYT\u00ae and BYVASDA\u00ae Combo as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GemVax & Kael Reports Further Positive Data from GV1001 Phase II Alzheimer's Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tertomotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & K.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharmaceuticals Announces the Results of GEMSTONE-302","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Alzprotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ezeprogind","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzprotect","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzprotect \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzprotect.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Doses First Participant in Phase 3 Marstacimab Study for People with Severe Hemophilia A and B with or Without Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Financing","leadProduct":"RNA processing targeted therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Remix Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Remix Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"1","companyTruncated":"Remix Ther.."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$181.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuance Pharma Closes Series D Financing","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Series D Financing","leadProduct":"Polysaccharide iron complex","moa":"CIAO2B","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Nuance Pharma \/ RTW Investments","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"VGL101","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vigil Neuroscience","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Vigil Neuroscience \/ Atlas Venture","highestDevelopmentStatusID":"5","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Announces Completion of the Emisphere Technologies Acquisition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Emisphere Technologies","amount2":1.8,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Emisphere .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $126.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Halix BV","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/.."},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"PepGen Raises $45M Series A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"Cell-penetrating peptides conjugates","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"PepGen","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"PepGen \/ R.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Novo Ventures","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"REN001","moa":"PPAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Novo Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Labor Dr. Merk","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Modified Oncolytic virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Labor Dr. Merk","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Labor Dr. Merk \/ Boehringer Ingelheim","highestDevelopmentStatusID":"1","companyTruncated":"Labor Dr. .."},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescendo Biologics Expands its Ongoing Collaboration with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Humabody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Crescendo Biologics Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crescendo Biologics Ltd \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Crescendo .."},{"orgOrder":0,"company":"Biological E","sponsor":"Biological E","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BE Signs Exclusive License Agreement for Covid-19 Vaccine with US Based OSIF","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Attenuated recombinant measles viruses","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biological E \/ Biological E","highestDevelopmentStatusID":"4","companyTruncated":"Biological.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop an anti-CD39 Antibody for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Arcus Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forma Therapeutics Launches Proposed Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"FT-4202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Curexsys GmbH","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sartorius and Evotec Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Exosomes","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Curexsys GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curexsys GmbH \/ Evotec","highestDevelopmentStatusID":"1","companyTruncated":"Curexsys G.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"ARCT-021","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics Raises $69 Million Series E To Advance Clinical Trials And Manufacturing Of Robotic Pill","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Series E Financing","leadProduct":"Teriparatide","moa":"PTH 34 N-terminal amino acid","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Enteric-coated Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","amount":"$12.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"CYR-064","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.01,"dosageForm":"Intranasal spray","sponsorNew":"Cyrano Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano The.."},{"orgOrder":0,"company":"Faze Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Faze Medicines","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Faze Medicines \/ Third Rock Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Faze Medic.."},{"orgOrder":0,"company":"BioAtla","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Tumor Biotech Bio Atla Sets Terms for $150 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"CAB-AXL-ADC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"BioAtla \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai in-Licenses Antibody Cocktail for COVID-19 from Roche","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Chugai","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ampio Enters Into Collaborative Research Agreements to Explore Additional Clinical Indications for Its Immunomodulatory Drug, Ampion","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals Receives First Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Jiangsu Wuzhong Pharmaceutical Group","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Endostatin","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Wuzhong Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Wuzhong Pharmaceutical Group \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Wu.."},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Huons CO., LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"LIPAC Oncology \/ Huons","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Onco.."},{"orgOrder":0,"company":"Pacific Pediatric Neuro-Oncology Consortium","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ONC-201","moa":"Dopamine","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pacific Pediatric Neuro-Oncology Consortium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pacific Pe.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"CG Oncology Closes $47 Million Series D Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series D Financing","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravesical Injection","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Exscientia Receives $4.2M Grant From Gates Foundation to Identify New Targets and Leads for Malaria, TB, and Non-Hormonal Contraception","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","amount":"$44.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Neos Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioScience","highestDevelopmentStatusID":"12","companyTruncated":"Neos Thera.."},{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"CaaMTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Tryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"UMass Dartmouth","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UMass Dartmouth \/ CaaMTech","highestDevelopmentStatusID":"2","companyTruncated":"UMass Dart.."},{"orgOrder":0,"company":"NorthShore University","sponsor":"Johns Hopkins","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthShore Joins Fight Against COVID-19 with Convalescent Plasma Trials for Close Contact Exposed and Newly Diagnosed Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Convalescent blood plasma therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NorthShore University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthShore University \/ Johns Hopkins","highestDevelopmentStatusID":"8","companyTruncated":"NorthShore.."},{"orgOrder":0,"company":"KindredBio","sponsor":"Elanco","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"$0.5 million","newsHeadline":"Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"KIND-030","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"KindredBio","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"KindredBio \/ Elanco Animal Health Incorporated","highestDevelopmentStatusID":"10","companyTruncated":"KindredBio.."},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir Strengthens Its Business Development Possibilities Through a Renegotiated Agreement with Tetra Logic Regarding Birinapant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Birinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TetraLogic Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"6","companyTruncated":"TetraLogic.."},{"orgOrder":0,"company":"InveniAI","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"InveniAI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InveniAI \/ Kyowa Kirin","highestDevelopmentStatusID":"2","companyTruncated":"InveniAI \/.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Receive Milestone Payment From Neotx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ Neotx","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Verseau Therapeutics","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Guojian Selects Verseau's VSIG4-Targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-VSIG4 antibodies","moa":"VSIG4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Verseau Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verseau Therapeutics \/ 3SBio","highestDevelopmentStatusID":"4","companyTruncated":"Verseau Th.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing Acquisition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reviva Pharmaceuticals and Tenzing Acquisition Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Kalypso Wellness Centers","sponsor":"Eleusis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eleusis Launches Clinical Development of Psychedelic Infusion Therapies for Major Depressive Disorder and Acquires Kalypso Wellness Centers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"ELE-Psilo+","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Kalypso Wellness Centers","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kalypso Wellness Centers \/ Eleusis","highestDevelopmentStatusID":"6","companyTruncated":"Kalypso We.."},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaBlock Enters Strategic Partnership with Ascentage Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"HQP1351","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaBlock Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaBlock Sciences \/ Ascentage Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaBloc.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Extend Collaboration to Develop \u2018Next Generation\u2019 Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$795.0 million","upfrontCash":"$75.0 million","newsHeadline":"Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"GDC-6036","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.80000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.80000000000000004,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Locanabio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel Rnatargeted Gene Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"C9orf2 -ALS","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Locanabio","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Locanabio \/ Vida Ventures LLC","highestDevelopmentStatusID":"2","companyTruncated":"Locanabio .."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ABBV-47D11","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Nona Biosciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Indivior","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$8.1 million","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Indivior","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues Global Expansion with Distribution Agreement for in United Arab Emirates with Ghassan Aboud Group","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Insightec","sponsor":"SonALAsense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SonALAsense Pioneers Sonodynamic Therapy Enters Into a Collaboration and License Agreement With Insightec","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Insightec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insightec \/ SonALAsense","highestDevelopmentStatusID":"7","companyTruncated":"Insightec .."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Unicycive Therapeutics Acquires Renazorb from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in CKD Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Dioxycarbonate","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Allarity Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Al.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Lind Global Asset Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Lind Global Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"MinervaX","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"MinervaX Raises Upsized USD 57M Series B To Advance Its Novel Group B Streptococcus vAccine Through Mid-Stage Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"GBS-NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ Sanofi Ventures","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Renews Deal with Who to Fight Tropical Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Fexinidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"World Health Organization","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clarity Pharmaceuticals Closes $25m Capital Raising","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"EmendoBio Gene Editing Company Acquired by AnGes, Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"EMD-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Emendo Biotherapeutics","amount2":0.25,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"4","companyTruncated":"Emendo Bio.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Defense Advanced Research Projects Agency","pharmaFlowCategory":"D","amount":"$37.6 million","upfrontCash":"Undisclosed","newsHeadline":"INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb\u00ae) Candidates to Treat COVID-19 with Funding from DARPA and the DoD JPEO-CBRND","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Funding","leadProduct":"DNA-encoded monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Defense Advanced Research Projects Agency","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$193.8 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca\u00ae (Filgotinib)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Galapagos","amount2":0.19,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Westport Bio","sponsor":"Greenwich LifeSciences","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"GP2 Peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Westport Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Westport Bio \/ Greenwich LifeSciences","highestDevelopmentStatusID":"4","companyTruncated":"Westport B.."},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BERG Deepens Research Collaboration With AdventHealth To Advance Aging, Metabolism and Nash Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Nanosuspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anchiano Therapeutics, Inc \/ Chemomab","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano T.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lonza Group \/ Aurinia","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Faran","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$12.1 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Faran","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.7 million","upfrontCash":"Undisclosed","newsHeadline":"Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Immuron","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuron SARS-CoV-2 Research Agreement with Monash University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"IMM-124E","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$509.7 million","upfrontCash":"Undisclosed","newsHeadline":"Chordia and Ono Pharmaceutical Enter into Exclusive License Agreement on CTX-177, a MALT1 Inhibitor, and Other Related Compounds","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"CTX-177","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chordia Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Chordia Th.."},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 in Patients Undergoing Head & Neck Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"ALM-488","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alume Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Alume Bios.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"EspeRare","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The EspeRare Foundation and Pierre Fabre Join Forces to Develop and Market a Pioneering Treatment for XLHED","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ER-004","moa":"Endogenous EDA protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"EspeRare","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-amniotic injection","sponsorNew":"EspeRare \/ Pierre Fabre group","highestDevelopmentStatusID":"6","companyTruncated":"EspeRare \/.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1001.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janux Therapeutics Announces Collaboration with Merck to Develop Novel Drug Candidates for Immuno-Oncology using T Cell Engager Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Tumor Activated T Cell Engager","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Janux Therapeutics","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Cadent Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$770.0 million","upfrontCash":"$210.0 million","newsHeadline":"Novartis Builds on Commitment to Addressing Need in Neuropsychiatric Disorders with Cadent Therapeutics Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"MIJ821","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cadent Therapeutics","amount2":0.77000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.77000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"Cadent Therapeutics \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Cadent The.."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$815.0 million","upfrontCash":"$85.0 million","newsHeadline":"Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SRF813","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Surface Oncology","amount2":0.81999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.81999999999999995,"dosageForm":"","sponsorNew":"Surface Oncology \/ GlaxoSmithKline","highestDevelopmentStatusID":"5","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Healthcare Royalty","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE\u00ae and MOVANTIK\u00ae Royalties for $150 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Antihemophilic Factor (Recombinant), PEGylated","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Nektar Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Healthcare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's AZD1222 Oxford Phase III Trials Interim Analysis Results Published in The LANCET","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Irlab Strengthens Patent Protection for Phase IIb\/III Drug Candidate Mesdopetam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Adalimumab Biosimilar Approved by NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Reports Positive Top Line Data from the Attract Clinical Study in Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Reports 67% ORR in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"H3 Biomedicine Presents Data Update on H3B-6545 at San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"H3B-6545","moa":"Selective estrogen receptor covalent","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"H3 Biomedicine Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H3 Biomedicine Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"H3 Biomedi.."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Advances Phase 2 Clinical Trial of SJX\u2011653 for Menopausal Hot Flashes","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX\u2011653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"OPC1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-5051","moa":"Dystrophin expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's AnGes Begins Phase 2\/3 Clinical Trial Of DNA-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AG0302-COVID19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AnGes \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ No.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen's Sotorasib Grabs Breakthrough Therapy Designation For Advanced Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational STAMP Inhibitor Asciminib (ABL001) Shows Superior Mmr Rate to Bosulif\u00ae* in Chronic Myeloid Leukemia Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Receives US FDA Approval for Generic Precedex","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R\/R Adult B-ALL at the ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Reports Positive Topline Results with GLPG1205 in IPF Patients in Pinta Proof-Of-Concept Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GLPG1205","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech To Begin Trial of Intranasal Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2\/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mount Sinai Researchers Advance a Universal Influenza Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AS03","moa":"Hemagglutinin-neuraminidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icahn School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icahn School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icahn Scho.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Granted Fast Track Designation by the USFDA for Saroglitazar in the Treatment of Patients with Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Receives Regulatory Approval to Initiate a Clinical Phase 2 Study with Rabeximod in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Bio-absorbable Film","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upadacitinib Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-VISTA antibodies","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"ApolloBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16\/18","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ ApolloBio","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"inhalation solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Demonstrates Nearly Five Years Median Overall Survival in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Significantly Reduced A1 Candd Body Weightinn People with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data for Bluebird Bio\u2019s beti-cel Gene Therapy Show Patients Across Ages and \u03b2-thalassemia Genotypes Achieve Transfusion Independence","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Betibeglogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Doses First Patient in Phase 3 Registration Asian Study of Trodelvy\u2122 in HER2 Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review Biologics License Application for Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine for 18 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Continues to Demonstrate Durable Responses with New Data from Destiny-Breast01 in HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Enspryng Becomes First Approved Medicine for Nmosd in Taiwan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at ASCO Gastrointestinal Cancers Virtual Annual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"FGFR2B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals to Present Positive Functional and Survival Data and New Predictive Modeling Results from CENTAUR Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gennova Biopharmaceuticals Granted Conditional Permission for Human Clinical Trial of Its Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HGCO19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PRX004","moa":"TTR protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Files Patent Application for New Formulation of ART27.13","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ART27.13","moa":"CB1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"solid dosage formulation","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Commences Dosing In Phase 1 Clinical Trial Of ALT-801","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-801","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Therapeutics Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Reports Clinical Progress Across All Four Tritac\u00ae Pipeline Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN424","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Highlights TUKYSA\u00ae (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Grabs Breakthrough Therapy Designation for Repotrectinib in Treatment of ROS1+ Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Oracle Cancer Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Target Thyroid Cancer with Triple Threat Drug Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Institute of Cancer Research \/ Oracle Cancer Trust","highestDevelopmentStatusID":"4","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"European Myeloma Network","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Research & Development Reports Subcutaneous Daratumumab Extends Progression-Free Survival in Relapsed, Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ European Myeloma Network","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Neumentum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumentum to Present New Data for Drug Candidate NTM-001 at the 2020 ASHP Midyear Clinical Meeting and Exhibition","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum .."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure\u2019s Enrolls First Patient in Global Phase 3 TRIDENT Trial of Optune\u00ae Concurrent with Radiation Therapy for Glioblastoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Temozolomide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Presents Results from First Combination Trial of ENHERTU\u00ae and Immune Checkpoint Inhibitor in Patients with HER2+ Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi and Apellis Report Positive Top-Line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Apellis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Files for Japan Approval for Alzheimer's Drug Developed with Eisai","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Discloses Third Oncology Development Candidate, NGM438","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"NGM438","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Presents Final Phase 2 Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib at SABCS 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Full Data Set of Oncopeptides Phase 2 Horizon Study in Multiple Myeloma Published in the Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents Exploratory Data from the Phase III I MVIGOR010 Studyinn Early Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Enrolls First Patient in Phase 1\/2 Clinical Trial for BPX-603","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zanidatamab Clinical Data Selected for Oral Presentation at the ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"NovoCodex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Presents Phase 1 Trial Data Update and Phase 2\/3 Clinical Trial in Progress for Lead Program ARX788","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ARX788","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Ambrx Inc \/ NovoCodex","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO Submits Supplemental Application for Approval for Opdivo\u00ae to Expand the Use in Recurrent Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara Provides Pipeline and Business Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"inhalation powder","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy\u00ae in Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"softgel capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Resume Dosing in Fitusiran Clinical Studies in the U.S","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Givosiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Initiates Multi-Dose Portion Of Phase 1 Trial Of FPI-1434 In Patients With Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"[225Ac]-FPI-1434","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European CHMP Adopts Positive Opinion for HEPLISAV-B\u00ae, Dynavax's Two Dose Adult Hepatitis B Adjuvanted Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Hepatitis B Vaccine (Recombinant), Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"CSL","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Queensland and CSL Provides Update on UQ COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"v451","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Stalicla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STALICLA Translates its Novel Precision Medicine Approach into Clinical Development with First Patient in Phase 1b Trial of STP1","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"STP1","moa":"pan-PDE","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Stalicla \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO\u2122 and Its Gene Electrotransfer Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Delay Their Adjuvanted Recombinant Protein-Based Covid-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adjuvanted recombinant protein-based COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Doses First Patient in Oncolytic Immunotherapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"CG Oncology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"The Himalaya Drug Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Himalaya Drug Company Clinical Trial of Herbal Immunomodulators Proves Its Role as Adjuvant Treatment for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Guduchi","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Himalaya Drug Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Himalaya Drug Company \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"The Himala.."},{"orgOrder":0,"company":"University of Antwerp","sponsor":"Fidec Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Antwerp Identifies a Vaccine that Demonstrates Efficacy Against Mutated Polio Strain in Phase II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"nOPV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"University of Antwerp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Antwerp \/ Fidec Corporation","highestDevelopmentStatusID":"12","companyTruncated":"University.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck's KEYTRUDA\u00ae Plus LENVIMA\u00ae Combination Demonstrated Statistically Significant Improvement in Overall Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharma Receives FDA Fast Track Designation for CPI-613\u00ae for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants Dosed in Phase 2\/3 Study of COVID-19 Vaccine Candidate in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"23-Valent Pneumococcal Polysaccharide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Final Approval for Asenapine Sublingual Tablets, 5 mg and 10 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Announce Publication of Results from Landmark Phase 3 Trial of BNT162 B2 Covid-19 Vaccine Candidate in the NEJM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives EU Approval for Leqvio\u00ae* (Inclisiran)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Announce Updated Phase 1\/2 Results of Hemophilia A Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pfizer Inc \/ Sangamo","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Proxalutamide's COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ National Institute of Health","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAVENCIO\u00ae Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"EMD Serono \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approvals of AbbVie's RINVOQ\u2122 for Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results of CONTESSA Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Grabs Positive CHMP Opinion for Inrebic for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Fedratinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Grabs Positive CHMP Opinion for SPRAVATO for the Rapid Reduction of Depressive Symptoms for Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo\u2122 for Severe Hypoglycaemia Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae as First-Line Treatment in Adult Patients With Mismatch Repair Deficient Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QurAlis' QRA-244 Demonstrates up to 20-Fold Increase in Potency and Reduction in Side Effects Compared to Retigabine in Preclinical Models","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"QRA-244","moa":"Kv7.2\/7.3 ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Tychan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"TY027","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ N.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled-Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venetoclax Plus Navitoclax Shows Promise for Paediatric Acute Lymphoblastic Leukaemia, Lymphoblastic Lymphoma: Presented at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Jude Children \/ Abbvie","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude C.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RECOVERY Trial Finds No Benefit from Azithromycin in Patients Hospitalised with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix, Serum Institute to Begin U.K Trials of Nasal Covid-19 Vaccine in January","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"COVI-VAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal drops","sponsorNew":"Codagenix \/ Serum Institute","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on RUXCOVID Study of Ruxolitinib for Hospitalized Patients with Covid-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Commences Global Pivotal Phase 2b\/3 Trial for COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Doses First Patient in Phase 2 Pivotal Trial of IBI310 Combined with TYVYT For the Treatment of Second-Line Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI310","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC\u00ae Protein Degraders ARV-471 and ARV-110","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ARV-471","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42\uff0can FXR Agonist","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Amitriptyline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's TROPION-Lung05 Phase 2 Trial of DS-1062a Initiated in Patients with Advanced NSCLC with Actionable Genomic Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm for Endocrine Resistant Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Selective androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Nasal aerosol","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Initiates Phase 3 Clinical Trial for SB16, Proposed Biosimilar to Prolia (Denosumab)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"NSP-15","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Anticipates DSMB Feedback on Interim Data from Pivotal Phase 3 CardiAMP Heart Failure Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences's Positive Topline Cholangiocarcinoma Data Abstract Accepted by 2021 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences' CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Reports Updated Data From Phase 1\/2 B-AMAZE Trial in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Verbrinacogene setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor Commences First Patient Dosing in AT278 PhI Clinical Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ultra-concentrated Rapid Acting Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"S. Korea's Nafabeltan gets clinical approval for COVID-19 treatment in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun .."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"GPH101","moa":"Hemoglobin beta chain","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMAG Files Submission in Response To the FDA\u2019s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Receives EU CHMP Positive Opinion for Biosimilar Adalimumab, CT-P17","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts New Drug Application for Review, for Takeda\u2019s TAK-721 for the Treatment of Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Positive Topline Results From Second Phase III trial of Beovu\u00ae in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Amarin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HLS Therapeutics Reports Positive Data from Covid-19 Outpatient Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HLS Therapeutics \/ Amarin Corporation","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therap.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF Confirms Sputnik V COVID Vaccine\u2019s Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Direct Investment Fund \/ Gamaleya Research Institute of Epidemiology and Microbiology","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Open Orphan","sponsor":"Codagenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open Orphan Receoves MHRA Approval for Nasal COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"COVI-VAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Open Orphan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Open Orphan \/ Codagenix","highestDevelopmentStatusID":"6","companyTruncated":"Open Orpha.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Beijing Institute of Biological Product","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UAE Ministry of Health and Prevention Announces Official Registration of Inactivated Covid-19 Vaccine Used in #4 Humanity Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Beijing Institute of Biological Product","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"National Human Genome Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sio Gene Therapies Posts Positive PhI\/II Data in Rare Pediatric Disease, the First Readout Since Its Name Change","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ National Human Genome Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Announces FDA Approval Of Klisyri\u00ae (Tirbanibulin), A New Innovative Topical Treatment for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Grabs Breakthrough Therapy Designation for IO102 and IO103 in Combination with Anti-PD-1 in Unresectable\/ Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ecopipam","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bio.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Begins Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in KRAS Mutant Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Defactinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Provides Latest Clinical Developments at Virtual R&D Update Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"Mucin-16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma Starts a Phase III Clinical Study for Denosumab Injection (LY01011) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Kentucky BioProcessing","sponsor":"British American Tobacco","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAT Progresses COVID-19 Candidate Vaccine Into Phase I Human Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-COVID-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kentucky BioProcessing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kentucky BioProcessing \/ British American Tobacco","highestDevelopmentStatusID":"7","companyTruncated":"Kentucky B.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Pivotal, Phase 3 Trial for SECUADO\u00ae (asenapine) Published in Journal of Clinical Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Phar.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Recommended for Approval in the EU by CHMP for Less-Frequent, Fixed-Dose Use in Unresectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone has Filed an IND in the US with Rabeximod Following Positive Feed-Back from Pre-Ind Meeting with the FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"Multiple cytokine","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's Phase 2\/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves AbbVie's VENCLEXTA in Combination with Azacitidine Or Low Dose Cytarabine for Untreated Aml Fran\u00e7ais","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT\u2122 Glioblastoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Enrolls First Patient In Phase 2 Trial of Pitolisant For Excessive Daytime Sleepiness In Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Fera Pharmaceuticals, LLC","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential COVID-19 Adjuvant Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Naproxcinod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fera Pharmaceuticals, LLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fera Pharmaceuticals, LLC \/ Nicox","highestDevelopmentStatusID":"1","companyTruncated":"Fera Pharm.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Ramelteon Tablets","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ramelteon","moa":"Melatonin receptor 1","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"BOL Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kindeva and BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"BOL-DP-o-04","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kindeva Drug Delivery","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kindeva Drug Delivery \/ BOL Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Kindeva Dr.."},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Emisphere Technologies and Obtain Ownership of the Eligen\u00ae SNAC Oral Delivery Technology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Emisphere Technologies","amount2":1.8,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Emisphere .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$12,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Merger","leadProduct":"Amlodipine","moa":"L-Type VGCC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":12,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":12,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,800.0 million","newsHeadline":"Servier to Acquire Agios Pharmaceuticals\u2019 Oncology Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Vorasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2,"dosageForm":"Oral","sponsorNew":"Agios Pharmaceuticals \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"$7.5 million","newsHeadline":"Exelixis In-Licenses Iconic Therapeutics\u2019 Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned NDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"XB002","moa":"Tissue Factor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Iconic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Iconic Therapeutics \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Iconic The.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Therapeutics Announces Merck Opt-In of TriNKET\u2122 Immunotherapy Candidate for Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"DF1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"ViGeneron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership For Next-Generation Ophthalmic Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"VG901","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"WuXi Biologics \/ ViGeneron","highestDevelopmentStatusID":"5","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Expands Partnership With Alnylam\u00ae Pharmaceuticals as a Limited Distribution Partner For OXLUMO\u2122 (lumasiran)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"EyeCRO","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InMed Licenses MiDROPS\u00ae Delivery Technology from EyeCRO to Deliver Therapeutic Cannabinoids","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"EyeCRO","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"EyeCRO \/ InMed","highestDevelopmentStatusID":"4","companyTruncated":"EyeCRO \/ I.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adjuvanted COVID-19 S-Trimer vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Glaxosmithkline","highestDevelopmentStatusID":"9","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Data Raise Hopes for COVID-19 Vaccine Durability","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Extended Release Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$10.0 million","newsHeadline":"Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"QP50ESO5RA","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0.38,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Biohaven","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and Fuji Pharma Extend Biosimilar Partnership in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Neurogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurogene Closes $115 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"AAV-based gene therapy","moa":"CLN5","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurogene","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Neurogene \/ EcoR1 Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exo Therapeutics Launches with $25 Million Series A Financing to Unlock Intractable Drug Targets with Exosites","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Exo Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Exo Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"2","companyTruncated":"Exo Therap.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Pontifax Medison Debt Financing","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"Hypericin","moa":"LSD 5B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Pontifax Medison Debt Financing","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"SAR439483","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"YAP-TEAD transcription activity","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vivace Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vivace The.."},{"orgOrder":0,"company":"Christian Social Services Commission","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Biologics Signs an MoU with CSSC in Tanzania for Mission 10 Cents","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Peptide","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Rh-insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Christian Social Services Commission","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Christian Social Services Commission \/ Biocon Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Christian .."},{"orgOrder":0,"company":"Overland ADCT BioPharma","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Overland ADCT BioPharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Overland ADCT BioPharma \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Overland A.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Aurinia Collaborates with Otsuka Pharmaceutical to Develop and Commercialize Voclosporin in EU and Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Fortovia Therapeutics","sponsor":"Galt Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galt Pharmaceuticals\u00ae Acquires Oravig\u00ae (Miconazole Buccal Tablets 50mg) from Fortovia Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Miconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fortovia Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fortovia Therapeutics \/ Galt Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Fortovia T.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"AC BioScience","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Pharmaceuticals Enters Data Collaboration with AC Bioscience","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"LX2931","moa":"S1P lyase","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ AC Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Th\u00e9a Open Innovation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ripple Therapeutics \/ Th\u00e9a Open Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Ripple The.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BlackRock Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ BlackRock Fund","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Biological E","sponsor":"International Finance Corporation","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"IFC Supports Biological E to Expand Access to Low-Cost Vaccines in Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biological E","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Biological E \/ International Finance Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"$304.0 million","upfrontCash":"$50.0 million","newsHeadline":"Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0.29999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Ultragenyx","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Teijin Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teijin Pharma \/ TransThera Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Teijin Pha.."},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prime Therapeutics and Takeda Agree to Outcomes-Based Arrangement for Hemophilia A Treatment ADVATE\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Antihemophilic factor recombinant","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Prime Therapeutics \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Prime Ther.."},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"InnoBation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript and InnoBation Enter into the Agreement for CAR-T therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"IBC 101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenScript Biotech Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ InnoBation","highestDevelopmentStatusID":"1","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"RNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Imperial College London \/ Enesi Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gracell Biotechnologies Files for a $100 Million US IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"GC012F","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Gracell Biotechnologies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN\u00ae Royalty with SWK Holdings Corporation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA\u00ae and Omburtamab in Eastern Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Y-mAbs Therapeutics \/ Swixx","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Ethypharm","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Ethypharm","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Ethypharm \/ Medexus","highestDevelopmentStatusID":"12","companyTruncated":"Ethypharm .."},{"orgOrder":0,"company":"Columbia University","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Novan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Catalent Pharma Solutions \/ Novan","highestDevelopmentStatusID":"5","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"European Biomedical Research Institute of Salerno","sponsor":"European Biomedical Research Institute of Salerno","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"9 Meters Biopharma Announces Agreement with EBRIS to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"European Biomedical Research Institute of Salerno","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"European Biomedical Research Institute of Salerno \/ European Biomedical Research Institute of Salerno","highestDevelopmentStatusID":"6","companyTruncated":"European B.."},{"orgOrder":0,"company":"Iconovo","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iconovo Signs Agreement for Development of Inhaled Oxytocin in ICOone For Maternal Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Iconovo","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Monash University","highestDevelopmentStatusID":"1","companyTruncated":"Iconovo \/ .."},{"orgOrder":0,"company":"Uniquest","sponsor":"Alterity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alterity and UniQuest to Reverse Bacterial Resistance to Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"PBT2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Uniquest","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Uniquest \/ Alterity Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Uniquest \/.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Announces LOI to Acquire PharmaTher\u2019s Psilocybin Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"MAO","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaTher \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Presight Capital","pharmaFlowCategory":"D","amount":"$35.4 million","upfrontCash":"Undisclosed","newsHeadline":"Peptilogics Closes $35.4 Million Series B Financing to Further Advance Proprietary Computational Peptide Drug Design and Discovery Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Irrigation solution","sponsorNew":"Peptilogics \/ Presight Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.0 million","newsHeadline":"Miravo Healthcare Ireland Enters into Suvexx\u00ae License and Supply Agreement with Orion Corporation for Select EU Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Naproxen Sodium","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Miravo Healthcare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Miravo Hea.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hasten","pharmaFlowCategory":"D","amount":"$322.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Divestment","leadProduct":"Urapidil Hydrochloride","moa":"AR Alpha1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.32000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Hasten","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"BCG","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$44.0 million","newsHeadline":"Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPR35","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0.47999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ GlaxoSmithKline","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Atomwise","sponsor":"FutuRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atomwise and FutuRx Launch A2i Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ FutuRx","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocugen and Bharat Biotech to Co-Develop COVAXIN\u2122, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke\u00ae in Israel and the Palestinian Authority","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"HitGen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Announces License Agreement with Merck to Access Compounds for Potential Development of A Novel Class of Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ M.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Healthcare Royalty Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$200.0 million","newsHeadline":"Regenxbio Announces Agreement to Monetize Portion of Zolgensma\u00ae Royalties for $200 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Onasemnogene abeparvovec-xioi","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Healthcare Royalty Management","highestDevelopmentStatusID":"12","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma Group LTD","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Financing","leadProduct":"Ixabepilone","moa":"Microtubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"injection","sponsorNew":"Allarity Therapeutics \/ Negma Group LTD","highestDevelopmentStatusID":"12","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","amount":"$46.9 million","upfrontCash":"Undisclosed","newsHeadline":"ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"University of Geneva","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology Expanding the Use of TNX-1900","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Geneva","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Geneva \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ajinomoto Bio-Pharma \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"Princeton University","sponsor":"Barer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SHMT","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Princeton University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Princeton University \/ Barer Institute","highestDevelopmentStatusID":"2","companyTruncated":"Princeton .."},{"orgOrder":0,"company":"Advanced Neural Dynamics","sponsor":"Neuropathix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Hydroxylated Sulfamides derivatives","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Advanced Neural Dynamics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Advanced Neural Dynamics \/ Neuropathix","highestDevelopmentStatusID":"1","companyTruncated":"Advanced N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"MK-7110","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"Intavenous infusion","sponsorNew":"Merck & Co \/ U.S. Government","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"FP-025","moa":"MMP-12","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Foresee Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Yumanity Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A2 Biotherapeutics Enters Into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Tmod-based cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"A2 Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"$8.0 million","newsHeadline":"SWK Holdings\u2019 Subsidiary, Enteris Biopharma, Receives Second Milestone Payment from Cara Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Bi.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris\u2122 Nasal Spray in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Glenmark Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Signs Second Agreement for $6 Million Non-Dilutive Financing Transaction","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Financing","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Soligenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"CiVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea\u00ae (Paclitaxel Micellar) in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Inceptua Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Inceptua Group \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Inceptua G.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$231.0 million","upfrontCash":"$20.0 million","newsHeadline":"Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"AIVITA Biomedical Closes $25 Million Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Closes Non-Brokered Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Private Placement","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","amount":"$31.9 million","upfrontCash":"Undisclosed","newsHeadline":"Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.029999999999999999,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$294.5 million","upfrontCash":"Undisclosed","newsHeadline":"Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Cream","sponsorNew":"Cellenkos \/ Incyte","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Lygenesis","sponsor":"Juvenescence","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"LYG-LIV0001","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lygenesis","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Lygenesis \/ Juvenescence","highestDevelopmentStatusID":"8","companyTruncated":"Lygenesis .."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QU Biologics Receives Funding for COVID-19 Prevention\/Treatment Research with Qu\u2019s Novel Immunotherapy Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"QBKPN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Vertice Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MannKind and Vertice to Co-Promote Thyquidity\u2122 (levothyroxine sodium) Oral Solution","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mannkind \/ Vertice","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"ER-004","moa":"Endogenous EDA protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-amniotic injection","sponsorNew":"AGC Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,240.0 million","upfrontCash":"$40.0 million","newsHeadline":"Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Skyhawk Therapeutics","amount2":2.2400000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.2400000000000002,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Vertex","highestDevelopmentStatusID":"3","companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Medicines Development for Global Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 634","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Medicines Development for Global Health","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"VHH antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Epsilon Molecular Engineering","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"2","companyTruncated":"Epsilon Mo.."},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Merger","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Adrestia Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,150.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration for Five Projects","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Adrestia Therapeutics","amount2":1.1499999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.1499999999999999,"dosageForm":"","sponsorNew":"Adrestia Therapeutics \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Adrestia T.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Poseida Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poseida Therapeutics and TScan Therapeutics Collaborate to Explore Developing Allogeneic T Cell Receptor Therapies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Allogeneic TCR-T cell therapies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Poseida Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly To Begin Pragmatic Study of Neutralizing Antibody Bamlanivimab for Covid-19 in New Mexico","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Supplemental New Drug Application for Takeda\u2019s ICLUSIG\u00ae (ponatinib) for Chronic-Phase CML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ponatinib","moa":"ABL1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peripheral NOP Agonist Addressing Chronic Peripheral Neuropathic Pain Enters Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grunenthal \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics to Present Phase 2 Results of HTD1801 in NASH Patients Co-Morbid with Type 2 Diabetes at NASH Summit","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's NILEMDO Tablet and Its Combination With Ezetimibe NUSTENDI Tablet Approved in Switzerland","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"film-coated tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk To Enter Phase 3 Development in Alzheimer\u2019s Disease with Oral Semaglutide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Phase 1\/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Iptacopan Receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces FDA Approval of MARGENZA\u2122 for Patients with Pretreated Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Positive FDA Advisory Committee Recommendation For Use of Entresto\u00ae To Treat Patients With HFpEF","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Results of Cohort B of its Phase 1\/2a Clinical Trial of AstroRx\u00ae for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Human astrocytes","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HemoShear Therapeutics\u2019 HST5040 Receives U.S. Orphan Drug Designations for Treatment of Methylmalonic Acidemia and Propionic Acidemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HST5040","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral liquid","sponsorNew":"HemoShear Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Tangdu Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoadjuvant Camrelizumab Plus Chemo Improves Response Rates in Locally Advanced NSCLC: Presented at ESMO Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Camrelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tangdu Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tangdu Hospital \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tangdu Hos.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX\u2081\u2080\u2080 for the Prevention of Post-Abdominal Surgery Incisional Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"extended release Sterile powder for paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves GSK\u2019s BENLYSTA As the First Medicine for Adult Patients with Active Lupus Nephritis in the US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Belimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Provides Regulatory Update for IV Tramadol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces Its First Phase 3 COVID-19 Vaccine Trial ENSEMBLE is Fully Enrolled","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biological E","sponsor":"Bayer college of medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Biological E. to Start Vaccine Late-Stage Trials in April","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biological E \/ Bayer college of medicine","highestDevelopmentStatusID":"7","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results IN Non-Hospitalized Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Update on COVID-19 ARDS Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Applies for Covid-19 Vaccine Approval in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech\u2019s Covid-19 Vaccine Shows No Serious Adverse Effects in Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s Tecartus Gets Conditional Marketing Authorization for Relapsed or Refractory Mantle Cell Lymphoma in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma Enrolles First Patient in Phase 3 Clinical Trial Investigating Siltuximab in Hospitalised Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Final Results from Phase 2a COMBAT\/KEYNOTE-202 Study of Motixafortide in Second Line Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Launches Generic Advair Diskus\u00ae Following FDA Approval","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampion Demonstrates Safety in Covid-19 Patients AND Initiates Global Clinical Trial for Intravenous Ampion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions Files IND for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell\u00ae","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT for Advanced Systemic Mastocytosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's Phase 2\/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for Complement Dysregulation Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CAN106","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Novaremed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1 For Treatment of Painful Diabetic Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s sBLA for KEYTRUDA\u00ae Plus Chemotherapy for Esophageal and Gastroesophageal Junction Cancer Gets FDA Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Supplemental New Drug Application for Takeda\u2019s ICLUSIG\u00ae for Adult Patients with Resistant or Intolerant Chronic-Phase CML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ponatinib","moa":"ABL1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunological Analysis of Phase IIb Trial with Diamyd\u00ae Show Differences Between Genetically Defined Patient Groups","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Oxybutynin Chloride Tablets","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxybutynin Hydrochloride","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Complete Response Letter from U.S. FDA for Inclisiran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Roxadustat in Anaemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BRII-196","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Analysis of Recardio's Phase II Clinical Trial Published in European Heart Journal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for Niemann Pick Disease Types A and B With PLX-300","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-300","moa":"PPAR alpha","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai's Osteoporosis Agent Edirol Obtains Regulatory Approval in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Completes Enrolment of First Cohort of Patients in Phase I Clinical Trial of Checkpoint Immunotherapy Candidate PD1-VAXX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Cologne University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"DZIF-10c","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Cologne University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Submits New Drug Application to U.S FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosight Receives Orphan Medicinal Product Designation from EMA for Aspacytarabine for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update On Assessment of Marketing Authorisation Application For Moderna\u2019s mRNA-1273 COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Covid-19 Therapeutics to Be Evaluated in Large Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Provides Updates on NC318 Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"Siglec-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Positive Top-Line Results from Phase 1\/2 Clinical Trial of OTO-413 in Patients with Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Brain-Derived Neurotrophic Factor","moa":"BDNF","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"SIG-005","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VFMCRP and Chemocentryx Provide Topline Results from Accolade Trial of Avacopan in C3 Glomerulopathy Including Improved EGFR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"MT-5111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' XOSPATA\u00ae, Azacitidine Combo Did Not Meet Endpoint in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology\u2019s Rubraca\u00ae Met The Primary Endpoint In The ARIEL4 Randomized Phase 3 Treatment Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China CanSinoBIO's COVID-19 Vaccine Trials Recruit Over 20,000 People","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"CureVac","sponsor":"University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain enriched proteolytic enzymes","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12\u2122 for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"exoIL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX\u00ae Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in the Us for the Adjuvant Treatment of Patients with Early-Stage EGFR-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces the Marketing Authorisation of the first Complete Long-Acting Injectable HIV Treatment in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Murepavadin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Faricimab Meets Primary Endpoint in Two Global Phase III Studies for Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces FDA Approval of ORGOVYX\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Starts Rolling Submission of a BLA to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioeclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CRX100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse.."},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lumosa Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lumosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lumosa The.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Enrolls the First Patient in the phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Rufinamide Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rufinamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca gets DCGI Nod for Asthma Drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Provides Update on Galidesivir Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Galidesivir","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Positive Results from Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alstr\u00f6m Syndromes","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"MODAG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson\u00b4s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Anle138b","moa":"Alpha synuclein protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ No.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Submission of Clinical Trial Application for AVA6000 Pro-Doxorubixin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"FAP activated doxorubicin prodrug","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABIONYX Initiates a Phase 2a Clinical Trial with CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Ph.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs ASA Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Cancer stem Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Receive CTA Approval for Phase 1\/2a Trial of Oncolytic Virus BT-001 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent International","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on SOURCE Phase III Trial for Tezepelumab in Patients with Severe, Oral Corticosteroid-Dependent Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of NIH-Sponsored ACTIV-3 Trial Published","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC41","moa":"TR-Beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz\u00ae Stroke Regenerative Activity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmCelz","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moffitt Researchers Discover Potential New Drug Target to Treat Cutaneous T Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SATB1 expression","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moffitt Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moffitt Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moffitt Ca.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019s Antidepressant Drug LY03005 Completes Primary Endpoint Observation for a Phase III Clinical Trial in China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ansofaxine Hydrochloride","moa":"Serotonin-norepinephrine-dopamine triple reuptake","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Provides Update On NBIb-1817 (VY-AADC) Gene Therapy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"Vaccine Formulation Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIDO\u2019s COVID-19 Vaccine Receives Health Canada Clinical Trial Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"COVAC-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VIDO-InterVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VIDO-InterVac \/ Vaccine Formulation Institute","highestDevelopmentStatusID":"4","companyTruncated":"VIDO-Inter.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Completes Recruitment and Patient Treatment in JTA-004 Pivotal Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXIN\u2122 Clinical Trials cross 13,000 Subjects, the half Way Mark and Forges Ahead, India\u2019s Largest Phase III Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Completes Manufacturing Scale-Up for Production of REQORSA\u2122 for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results Show that C21 Can Become an Important Complement to COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"SunTrap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"LeSoleil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SunTrap","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SunTrap \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SunTrap \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Submitted Data for Vaccine Approval, UK's Hancock Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMBRUVICA\u00ae (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenstr\u00f6m's Macroglobulinemia (WM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's, Global Response Aid, and Appili Therapeutics announce the filing of an application for REEQONUS\u2122 Tablets for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Appili Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Receives US FDA \u2018Study May Proceed\u2019 Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pidnarulex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Conbercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Ka.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA Granted New Indication Approvals for SULINNO\u00ae for Pediatric Plaque Psoriasis and Non-infectious Uveitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Seeks Approval from CDSCO Panel to Modify Remdesivir Composition to Reduce Renal Toxicity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"INO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Institute Says Corona Vac Efficacy Above 50%, but Delays Full Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"INO","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"INO \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"INO \/ Not .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Seeks Govt Nod to Start Phase-III Clinical Trials of Covid-19 Vaccine ZyCoVD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mountain Valley MD Files for Acceleration of Patent Examination for Solubilized Ivermectin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain V.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakuten Medical Enrolls First Patient in the U.S. For ASP-1929 in Combination with Anti-PD1 Therapy, for Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-001","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argentina has Registered the Sputnik V Vaccine Based on Russian Clinical Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ The Gamaleya National Center Of Epidemiology And Microbiology","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Receives IND Clearance from the U.S. FDA for ALLO-715 in Combination with Nirogacestat in R\/R Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-715","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Provides an Update On Its Investigational New Drug Application For A Phase 1 AdCOVID\u2122 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"nasal spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Providence Therapeutics COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Nangibotide","moa":"TREM-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Treatment for Ebola Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ansuvimab-zykl","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Govt Board: Data on Efficacy of Covid-19 Drug Candidate Avigan Is Inconclusive","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Aimmune's PALFORZIA\u00ae As First-Ever Treatment for Peanut Allergy in the EU","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder in capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces the Marketing Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eprenetapopt","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LORBRENA\u00ae (Lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Submits Cta Application for Mitazalimab Phase II Study OPTIMIZE-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the NMPA Granted New Indication Approval for BYVASDA\u00ae for the Treatment of Adult Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Meloxicam Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (Olaparib) Receives Three New Approvals in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Presents Results of SOR007 Phase 1\/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Japanese approval For Humanized anti-PD-L1 Monoclonal Antibody, Tecentriq To Treat Unresectable Advanced\/Recurrent NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Provides Regulatory Update on Arimoclomol for NPC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Submits New Drug Application to U.S. FDA for KORSUVA\u2122 Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for EU Regulatory Approval of Once-Weekly Semaglutide 2.0 mg For the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Shenyang Tonglian Medicines Co.,Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shenyang Tonglian's Carrimycin Gets FDA Approval for International, Multi-country Phase III Trial for the treatment of severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Carrimycin","moa":"mTOR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenyang Tonglian Medicines Co.,Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Shenyang Tonglian Medicines Co.,Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang T.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Provides Update on Usamriid and Oral Experiments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"MUC1-SP-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Secures United States Patent for Eftilagimod Alpha IN Combination with a PD-1 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Reports Update on COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin fixed Dose Combination, at an Affordable Price for T2 Dminn India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Remogliflozin Etabonate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell's Zofin\u2122 Featured in Two National Publications Examining Potential Therapies for COVID-19 Long-Haulers","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olatec Therapeutics\u2019 Dapansutrile Prevents the Inflammatory Response, Restores Cognitive and Behavioral Deficits in Mouse Model of AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Olatec Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"3B Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Submits IND for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ 3B Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion's Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Pan-Cyclophilin A","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"softgel capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Announces the Approval of Saroglitazar Mg for Non-Alcoholic Fatty Liver Disease in India","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Statement on Opdivo (Nivolumab) Small Cell Lung Cancer U.S. Indication","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Resamirigene bilparvovec","moa":"MTM1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes T.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharma Gets USFDA Nod for Erectile Dysfunction Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics to Advance ARCT-032 as a Development Candidate for Cystic Fibrosis Lung Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-032","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia's Sputnik Vaccine Applies for Phase 3 Study in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Reports Positive Initial Phase 1 Data for exoIL-12\u2122 Showing Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"exoIL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon\u2019s Global Study for OT-101\/ Tgf-\u0392 Inhibitor Against Covid-19 Enrolls and Treats Its First Patient","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Begins Multinational Phase 2 Clinical Trial Of HepTcellTM, A Novel Immunotherapeutic For The Treatment Of Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HepTcell","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xspray Pharma Reports Positive Results From a Study with Dasatinib During Omeprazole Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasatinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pha.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Stock Plunges After FDA Rejects Covid-19 Emergency Approval","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update On Rolling Review of Astra Zeneca\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetirizine","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"ophthalmic solution","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Announces New Us Patent for Zubsolv\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum\u2122 and Has Requested Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update On the Recently Acquired NTCD-M3 Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"NTCD-M3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with Mydcombi Targeting 80 Million Patient in the U.S. Annually","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tropicamide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Biotest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotest AG: Biotest Treats First Covid-19 Patient with Trimodulin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Trimodulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biotest","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biotest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ .."},{"orgOrder":0,"company":"GeneOne Life Science, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2nd Phase Clinical Trial of S. Korean Drug Firm's Covid-19 Treatment Candidate Approved in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"GLS-1027","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeneOne Life Science, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"GeneOne Life Science, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeneOne Li.."},{"orgOrder":0,"company":"Abpro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abpro Starts Phase 2\/3 Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abpro \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ No.."},{"orgOrder":0,"company":"SIWA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIWA Therapeutics To Participate in September Investor Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SIWA 318H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIWA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIWA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"SIWA Thera.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"LSNME\/SW1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Johns Hopkins University","highestDevelopmentStatusID":"4","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Announces Successful Preclinical Results of Invisimask\u2122 Human Antibody Nasal Spray Against Sars-Cov-2 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"InvisiMask","moa":"SARS-CoV-2 S1 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Announces Selection of COVID-19 Vaccine Candidate, SN14","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"SN14","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO and GeneOne Life Science Report Positive Phase 1\/2a Clinical Data With DNA Vaccine INO-4700 for MERS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GLS-5300","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Xenothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XAV-19: Validation of the First Dose of Anti-Covid Treatment of Xenothera and Continuation of the Polycor Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"XAV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xenothera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xenothera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenothera .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s COVID-19 Vaccine Authorised for Emergency Supply in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"University of Cologne","sponsor":"Apogenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19: Targeted Treatment Trial Launched in Vienna","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR9","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Cologne","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Cologne \/ Apogenix","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Byondis","sponsor":"Syneos Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Intends to Bag Commercialisation Partner for Breast Cancer ADC by 2H21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab duocarmazine","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Th\u00e9a Open Innovation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"Ripple Therapeutics \/ Th\u00e9a Open Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Ripple The.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$4,200.0 million","upfrontCash":"$650.0 million","newsHeadline":"Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":4.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":4.2000000000000002,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol Reaches 440 Patients in Global Phase III Agent Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Receives Fast Track Designation from the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trixeo Aerosphere Approved in the EU for Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Begins Program to Assess Covid-19 Vaccines Combinations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Gamaleya Research Institute of Epidemiology and Microbiology","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Provides Update on Odronextamab Clinical Trials in B-Cell Non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Odronextamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Seeks Japanese Expanded Indication Approval for Prasugrel HCl for Prevention of Recurrence of Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Initiates NurOwn Expanded Access Programme for ALS Patients Who Meet Specific Eligibility Criteria","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Dana Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Biological E","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Partners with Biological E To Advance Development and Manufacture of Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Biological E","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Biological E \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"University College London Hospitals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCLH Doses First Patient in the World in Covid-19 Antibody Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University College London Hospitals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University College London Hospitals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$161.5 million","upfrontCash":"$7.0 million","newsHeadline":"Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen\u2019s Discovery Technology to Target Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Trial of Novavax Investigational COVID-19 Vaccine Opens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"$3.7 million","newsHeadline":"MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGC Pharmaceuticals \/ Malta Enerprises","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ADM03820","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ology Bioservices","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ology Bioservices \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","amount":"$15.75 million","upfrontCash":"Undisclosed","newsHeadline":"CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Adelia Therapeutics","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Adelia Therapeutics \/ CYBIN","highestDevelopmentStatusID":"12","companyTruncated":"Adelia The.."},{"orgOrder":0,"company":"Neuron23","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","amount":"$33.5 million","upfrontCash":"Undisclosed","newsHeadline":"Neuron23\u2122 Closes $113.5 Million Series A And B Financing Led By Westlake Village BioPartners, Kleiner Perkins, And Redmile Group","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Neuron23 \/ Westlake Village BioPartners","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/.."},{"orgOrder":0,"company":"Neuron23","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neuron23\u2122 $113.5 Million Series A And B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Neuron23 \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India launches India\u2019s First Fully Indigenously Developed Pneumococcal Vaccine, 'PNEUMOSIL'","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"10-Valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Canaccord Genuity Corp","pharmaFlowCategory":"D","amount":"$62.8 million","upfrontCash":"Undisclosed","newsHeadline":"MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Financing","leadProduct":"LSD","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Canaccord Genuity Corp","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adapalene","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene's Partner, Karyopharm has Received FDA Approval of XPOVIO\u00ae for Patients with Multiple Myeloma After At Least One Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform Finland Reports First Dosing of Nanoformed Drug Successfully Accomplished","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral immediate release","sponsorNew":"Nanoform \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax\u2019s Covid-19 Phase 2b\/3 miR-AGE Trial with ABX464 Declared Research National Priority by the French Government\u2019s Clinical Trial Council","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Receives \u20ac5.2 M in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Funding","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cancer biotech Sensei Biotherapeutics files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"HAAH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intradermal Injection","sponsorNew":"Sensei Biotherapeutics \/ Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Relaxera Pharmazeutische","sponsor":"CBL- Chemical and Biopharmaceutical Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human Relaxin-2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Partnership","leadProduct":"Relaxin-2 protein, human","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relaxera Pharmazeutische","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relaxera Pharmazeutische \/ CBL Patras","highestDevelopmentStatusID":"8","companyTruncated":"Relaxera P.."},{"orgOrder":0,"company":"CohBar","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"CB5064 Analogs","moa":"Apelin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"$960.0 million","newsHeadline":"Angelini Pharma Acquires Arvelle Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.95999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.95999999999999996,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","amount":"$15.7 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$3,290.0 million","upfrontCash":"$125.0 million","newsHeadline":"Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Termination","leadProduct":"HTL0018318","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":3.29,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.29,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"IK-930","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Omega Funds","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Adamas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamas Completes Acquisition of OSMOLEX ER\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Adamas","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Y-Biologics","sponsor":"3D Medicines","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"$2.0 million","newsHeadline":"3D Medicines Signed License Agreement with Y-Biologics on the Co-development of Next-generation T Cell Bispecific Engager","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Y-Biologics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Y-Biologics \/ 3D Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Y-Biologic.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"IPH6101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"LakePharma","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akston Biosciences and LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LakePharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"LakePharma \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"LakePharma.."},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LA.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Global Health Investment Advisors","pharmaFlowCategory":"D","amount":"$9.1 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"intranasal spray","sponsorNew":"Revelation Biosciences \/ Global Health Investment Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Qpex Biopharma Strengthens Leadership Team and Provides Update on BARDA Award for Portfolio of Drugs for Antimicrobial Resistance (AMR)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Xeruborbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"Qpex Biopharma \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Bioph.."},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Radius Health","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"Radius Health, Inc. Announces Acquisition of Orphan Disease Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.070000000000000007,"dosageForm":"oral solution","sponsorNew":"Benuvia Therapeutics \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Th.."},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"MT-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Myeloid Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Myeloid Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"4","companyTruncated":"Myeloid Th.."},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Greater China and Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TG01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ IOVaxis","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","amount":"$72.2 million","upfrontCash":"Undisclosed","newsHeadline":"Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"CPV-101","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn","highestDevelopmentStatusID":"4","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV - joint press release","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evommune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Ribometrix","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$25.0 million","newsHeadline":"Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"RNA-Targeted Therapeutics","moa":"RNA","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ribometrix","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Ribometrix \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Ribometrix.."},{"orgOrder":0,"company":"ViGeneron","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViGeneron Signs Global Collaboration Agreement for Ophthalmic Gene Therapy Development","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"VG801","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron .."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"$75.0 million","newsHeadline":"Argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0.17999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Z.."},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$70.0 million","newsHeadline":"ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Next-generation T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio.."},{"orgOrder":0,"company":"Cristal Therapeutics","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cristal Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cristal Therapeutics \/ Intravacc","highestDevelopmentStatusID":"3","companyTruncated":"Cristal Th.."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Atezolizumab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kleo Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Kleo Pharmaceuticals \/ Biohaven","highestDevelopmentStatusID":"4","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of CAR-T and CAR-NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"CAR-T therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Karolinska Institutet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Institutet \/ Oncternal Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"LX1004","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Mass General Brigham Ventures","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abcuro Raises $42 Million in Series A-1 Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"ABC008","moa":"KLRG1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Abcuro, Inc","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Abcuro, Inc \/ Mass General Brigham Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"WTX-124","moa":"Interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$239.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Adjuvance Technologies","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Terra CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adjuvance Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adjuvance Technologies \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Adjuvance .."},{"orgOrder":0,"company":"Alteogen","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"$6.0 million","newsHeadline":"Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled Hybrozyme\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"ALT-B4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Symbiosis II","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Symbiosis II","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Taladegib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Endeavor Biomedicines \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Winhealth Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"AC-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"TWi Biotechnology \/ Winhealth Pharma","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotec.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"ANA Therapeutics \/ Neurobo Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"University Health Network","sponsor":"Avicanna","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Advances Pharmaceutical Epilepsy Program With Collaboration With the University Health Network","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University Health Network","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Health Network \/ Avicanna","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"GX Acquisition","sponsor":"Celularity","pharmaFlowCategory":"D","amount":"$372.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Merger","leadProduct":"CYNK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GX Acquisition","amount2":0.37,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"","sponsorNew":"GX Acquisition \/ Celularity","highestDevelopmentStatusID":"5","companyTruncated":"GX Acquisi.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Sequoia China","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"VISEN Pharmaceuticals Closes $150 Million Series B Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Visen Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Sequoia China","highestDevelopmentStatusID":"12","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Cellares","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellares Adds PACT Pharma to its Early Access Partnership Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"NeoTCR-P1 T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PACT Pharma \/ Cellares","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharm.."},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Metalloenzyme-targeted medicines","moa":"Metalloenzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Blacksmith Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith.."},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Integral Molecular and Optimeos Partner to Deliver Long-acting Therapeutic Antibodies Using Nanoparticle Formulation Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Long-acting Therapeutic antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"sustain delivery formulation","sponsorNew":"Integral Molecular \/ Optimeos","highestDevelopmentStatusID":"3","companyTruncated":"Integral M.."},{"orgOrder":0,"company":"Pharmaleads","sponsor":"IACTA Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"IC 800","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Pharmaleads","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pharmaleads \/ IACTA","highestDevelopmentStatusID":"5","companyTruncated":"Pharmalead.."},{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Raises $6.8 million Series A Round Co-Led by Epidarex Capital and Taiho Ventures to Advance Viral Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Oncolytic viral therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Theolytics \/ Epidarex Capital","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics.."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiCE Molecules Announces $80 Million Series C Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"DICE Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Affinivax","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","amount":"$226.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Announces $226 Million Series C Financing to Advance its Pipeline of Novel MAPS\u2122 Vaccines Targeting Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"ASP3772","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0.23000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Rock Springs Capital","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Cevec","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec Announces New License Agreement for Its Aav Manufacturing Technology Elevecta\u00ae IN Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Bi.."},{"orgOrder":0,"company":"Mana Therapeutics","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"MANA Therapeutics Launches with $35 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"MANA-312","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mana Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Mana Therapeutics \/ Cobro Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Mana Thera.."},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIRION Biotech GmbH Licensed Its LentiBOOST\u2122 Transduction Technology to Cellectis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic CAR T-cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sirion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ Cellectis","highestDevelopmentStatusID":"3","companyTruncated":"Sirion Bio.."},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Rick Klausner","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"LifeMine Therapeutics Announces $50 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ Rick Klausner","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine T.."},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ University of Texas MD Anderson","highestDevelopmentStatusID":"3","companyTruncated":"Xencor \/ U.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biomea Fusion Raises $56 Million to Bring First Irreversible Menin Inhibitor into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"BMF-219","moa":"Irreversible menin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biomea Fusion","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"oral","sponsorNew":"Biomea Fusion \/ Cormorant Asset Management","highestDevelopmentStatusID":"5","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Aulos","sponsor":"ATPGroup","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Monoclonal antibody","moa":"IL?2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aulos","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Aulos \/ ATP","highestDevelopmentStatusID":"4","companyTruncated":"Aulos \/ AT.."},{"orgOrder":0,"company":"Daavlin","sponsor":"Soligenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daavlin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Daavlin \/ Soligenix","highestDevelopmentStatusID":"10","companyTruncated":"Daavlin \/ .."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alkido Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkido Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alkido Pha.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Chronic Hepatitis B Virus Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Selgantolimod","moa":"TLR8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vir Biotechnology \/ Gilead","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Simtra BioPharma Solutions","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Simtra BioPharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Simtra BioPharma Solutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Simtra Bio.."},{"orgOrder":0,"company":"Immunocore","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunocore Announces Closing of $75.0 Million Series C Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ BlackRock","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"EQRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.5,"dosageForm":"intravenous infusion","sponsorNew":"EQRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Und.."},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atalanta Therapeutics Announces Strategic Collaborations with Biogen, Genentech to Develop RNAi Therapeutics for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"RNAi therapeutics","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Atalanta Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atalanta Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Atalanta T.."},{"orgOrder":0,"company":"Eversana","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eversana \/ Humanigen","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchison China MediTech","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Inmagene","highestDevelopmentStatusID":"4","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"EpiPharm","sponsor":"CycloLab Cyclodextrin Research and Development Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclolab and EpiPharma Form Joint Venture Company Targetrin Therapeutics to Develop Conjugated Cyclodextrin Peptide Drugs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Conjugated cyclodextrin-peptide therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiPharm \/ Cyclolab","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces $10 Million Bought Deal Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"IRISYS, LLC Awarded $850,000 NIH Contract for the Formulation of Drinabant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Drinabant","moa":"CB1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRISYS, LLC \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Streamlines Agreement on Anti-Fc\u03b3 Rll B Antibody, BI-1206, Ahead of Phase I\/II Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"Fc?RllB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BioInvent \/ Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amneal to Acquire Substantially all of Kashiv Specialty Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"K102","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"1","companyTruncated":"Kashiv Spe.."},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,060.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration to Discover Novel Shared Antigens for Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":1.0600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.0600000000000001,"dosageForm":"","sponsorNew":"Enara Bio \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio .."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Announces $30 Million Financing to Advance Proprietary ImmunoPhage\u2122 Platform and Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"Aspartyl beta hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"injection","sponsorNew":"Sensei Biotherapeutics \/ Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"mRNA-based therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Intratumoral Injection","sponsorNew":"Strand Therapeutics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Strand The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"$650.0 million","newsHeadline":"BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":2.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Affimed","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affimed Announces \u20ac25 Million Debt Financing Agreement with Silicon Valley Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Affimed \/ Silicon Valley Bank","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","amount":"$35.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$224.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"EB005","moa":"Microbiome","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Eligo Bioscience","amount2":0.22,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.22,"dosageForm":"Topical","sponsorNew":"Eligo Bioscience \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Eligo Bios.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Successfully Completes $11.5 Million Capital Increase","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"Dipraglurant","moa":"mGlu5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"KSQ Therapeutics And Takeda Enter Broad Strategic Collaboration To Research, Develop And Commercialize Novel Immuno-Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"KSQ-4279","moa":"USP1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KSQ Therapeutics","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.7,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Recognify Life Sciences","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"RL-007","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Recognify Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Recognify Life Sciences \/ Atai Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Recognify .."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET\u2122 Immunotherapy Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"DF1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"oral","sponsorNew":"Essa Pharma \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$125.0 million","newsHeadline":"Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"BND-22","moa":"ILT2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1299999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biol.."},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Amgen","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Thera.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Capricor Collaborates with Lonza for the Development of CAP-1002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Capricor","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"HBM Healthcare Investment","pharmaFlowCategory":"D","amount":"$153.9 million","upfrontCash":"Undisclosed","newsHeadline":"IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ HBM Healthcare Investment","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Serometrix","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ESPERION Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Serometrix","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serometrix \/ ESPERION","highestDevelopmentStatusID":"4","companyTruncated":"Serometrix.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Meridian Medical Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meridian Medical Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"Meridian M.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Receives Milestone Payment from Merck","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"IBSA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IBSA Reacquires Commercial Rights to the Flector\u00ae Brand in the US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Diclofenac Epolamine","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Pfizer Inc \/ IBSA","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"PAION UK LTD","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"$22.5 million","newsHeadline":"La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA\u2122 (Angiotensin II) and XERAVA\u2122 (Eravacycline) in Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Angiotensin II","moa":"AT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"La Jolla Pharmaceutical","amount2":0.13,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"La Jolla Pharmaceutical \/ PAION AG","highestDevelopmentStatusID":"12","companyTruncated":"La Jolla P.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$196.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Completes $196M (\u20ac160M) Series A Funding for Comprehensive Phase 3 Development Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.20000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Morningside Ventures","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation To Provide Increased Funding for ELX-02 Global Phase 2 Clinical Trial Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ CF Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Poxel","sponsor":"Metavant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poxel Regains Imeglimin Rights From Metavant","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Termination","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Metavant","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ Me.."},{"orgOrder":0,"company":"Chiome Bioscience","sponsor":"Henlius","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies Targeting Human TROP2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"LIV-2008","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Chiome Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chiome Bioscience \/ Henlius","highestDevelopmentStatusID":"4","companyTruncated":"Chiome Bio.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"HT-001","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Charles River Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Inks Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Apalutamide","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Essa Pharma \/ Janssen","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Pennsylvania University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Reports Risankizumab Significantly Improves Clinical Remission in Two Phase 3 Induction Studies with Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Pennsylvania University","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Celid Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celid, \"Corona 19 Vaccine AdCLD-CoV19, the First Clinical Trial Subject to be Administered\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AdCLD-CoV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celid Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celid Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celid Biot.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on Status of Contingent Value Rights","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Grants Conditional Market Approval for Sinopharm CNBG\u2019S COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Begins Multinational Phase 2 Clinical Trial Of HepTcellTM, A Novel Immunotherapeutic For The Treatment Of Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HepTcell","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo\u2122 to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Approvals from the DCGI to Start Phase III Clinical Trial of ZyCoV-D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Telaglenastat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum, Bharat Biotech Vaccines Get Restricted Use Approval from DCGI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Expects to Begin Late-Stage Covid-19 Vaccine Study in Second Quarter","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efficacy and Safety of the Moderna's mRNA-1273 SARS-CoV-2 Vaccine Gets Published in NEJM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Tibet Rhodiola Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stemirna COVID-19 Vaccine Candidate Obtains Clinical Trial Approval in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemirna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stemirna Therapeutics \/ Rhodiola Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Stemirna T.."},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Provides Pipeline and Business Update","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"MLE-301","moa":"NK3R","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo T.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sci PLC - Completion of Foralumab Clinical Trial in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"T Cell surface glycoprotein CD3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE\u00ae (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation Suspension","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and sNDA for Myrbetriq Tablets","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Mirabegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16\/18","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Publishes Positive SER-287 Phase 1B Ulcerative Colitis Study Results in Journal Gastroenterology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Submits New Drug Application for Next-Gen Oral Testosterone Replacement Therapy for Hypogonadism in Males","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide as a Treatment For Cardiomyopathy In Barth Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Microtubule associated protein 2","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Darovasertib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to Test Combination Monoclonal Antibody Therapy for Mild\/moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Stero Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stero Biotechs Supports an Exploratory Study of CBD-Based Treatment for COVID-19 Severe Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Stero Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Stero Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stero Biot.."},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue\u2122","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Cure Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharm.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma Completes Phase 2b Clinical Trial of XF-73 Patient Recruitment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AsclepiX Therapeutics Doses First Patient in Phase 1\/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AXT107","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX T.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Vaccine 78% Effective in Brazil Trial, Experts Call for More Details","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Recommends COVID-19 Vaccine Moderna for Authorisation in the EU Share","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche, Sanofi's Arthritis Drugs Effective in Improving Survival in Sickest COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Completes Volunteer Enrollment for Phase 3 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UAE Starts Trials of Russia's Sputnik V Coronavirus Vaccine as Cases Rise","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Positive Topline Results from its Third Phase 3 Clinical Trial of Oteseconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue \u201cLong Hauler\u201d Patient Dosed with Ampligen","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Announces Successful Proof of Concept Data for CERC-002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon \u2122 CNP in Achondroplasia (ACH) in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon CNP","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Oregon Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-1111","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Oregon Health","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative Approval for Empagliflozin and Metformin Hydrochloride ER Tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Enrollment and Financing of Covid-19 Cohort in Phase III Revival Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arthritis Drugs May Reduce Mortality and Time in ICU for Sickest Covid Patients- Reports Imperial College","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Risankizumab Improves Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"In Vitro Studies Shows Pfizer and Biontech Covid-19 Vaccine Elicits Antibodies that Neutralize U.K. and South African Variants of SARS-COV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sunitinib","moa":"FLT3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SAGE-319","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in Rho Vac's Clinical Phase IIb Study in United Kingdom","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Montanide ISA 51","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Provides Business Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaEssentia Initiates Pivotal Trial of Ropeginterferon alfa-2b to Treat Essential Thrombocythemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA for INV-101 for the Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Standigm","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Standigm","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Standigm \/ SK Chemicals","highestDevelopmentStatusID":"4","companyTruncated":"Standigm \/.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Ophthalmics Previews Important Clinical Progress in 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Formally Granted for Sareum\u2019s SDC-1802 TYK2\/JAK1 Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SDC-1802","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Creighton University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study identifies Repurposed Drug with Potential to Protect Hearing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Creighton University School of Medicine","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creighton University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creighton .."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Therapeutics A\/S Receives FDA Approval for IND of Oral Next-Gen PDE4-Inhibitor for investigation in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Orismilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Oyagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyagen, Inc. Publishes Study On Its OYA1 As A \"Highly Effective\" Experimental Drug Candidate For Treating Infections By The Ebola Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sangivamycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oyagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oyagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oyagen \/ N.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Pharma Completes phase 2 trial of COVID-19 plasma Therapy Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyper-immunoglobulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol\u00ae for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Starts Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmCelz\u00ae Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and MedinCell Announce Results for Registration Trial of Extended-Release Subcutaneous Injectable Risperidone for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ MedinCell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"IDT Biologika GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine Developed by German Research Group Fails in Early Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"MVA-SARS-2-S vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"German Center for Infection Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"German Center for Infection Research \/ IDT biologika","highestDevelopmentStatusID":"6","companyTruncated":"German Cen.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA\u00ae (darolutamide) Prescribing Information","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 2b ICONA Interim Results for Icosabutate in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosabutate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics Publishes Preclinical Results Showing Neuroprotective Properties of ST266 Require Full Complement of Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs at the 39th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-721","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech\u2019s \u2018COVAXIN\u2122\u2019 Emergency Use Authorization Approval by DCGI-CDSCO, MoH&FW","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JB Chemicals Gets USFDA Nod for Generic Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Loratadine","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"J.B.Chemic.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"LYS-GM101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Affirms Initiation of Phase 2\/3 Trial of Inhaled RLF-100\u2122 (aviptadil; Zyesami\u2122) in Severe Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalational","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada-Approved COVID-19 Treatment Drug Rejected by British Columbia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces First Patient Treated in Respond Study Evaluating Benefit of Spinraza\u00ae in Patients Treated with Zolgensma\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"WuXi STA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Orelabrutinib Included in Priority Review by NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ WuXi STA","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix and Serum Institute of India Initiate Dosing in Phase 1 Trial of COVI-VAC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Live-attenuated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal drops","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Commences Dosing in its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalational","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Presents MIV-818 Data at ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Data on LENVIMA\u00ae Monotherapy and in Combination with KEYTRUDA\u00ae in Multiple Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Supplemental New Drug Application for Jardiance\u00ae (empagliflozin) for Adults with Heart Failure with Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Biologics License Application for V114","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"OX2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OX2 Therapeutics Reports New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"hP1A8","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OX2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OX2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OX2 Therap.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Quemliclustat","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Arcus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Reports that Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics Provides Update on TEPEZZA\u00ae (teprotumumab-trbw) Supply and New KRYSTEXXA\u00ae (pegloticase injection) Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Errant Gene Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Errant Gene Therapeutics Pushing Clinical Trial of Potentially Curative Treatment for Beta-Thalassemia and Eventually Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous CD34+ cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Errant Gene Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Errant Gene Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Errant Gen.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclanda","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Outlines Upcoming Clinical Milestones","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SYNB1618","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CK-3773274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Initiates Phase 2 Trial of Oral KORSUVA\u2122 for the Treatment of Pruritus in Patients with Notalgia Paresthetica","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Selects Formulation for Continuous Subcutaneous Lenalidomide Delivery System for CLL Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Chronic HF","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"INCB001158","moa":"Aarginase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Incyte Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announces USFDA Approval of Metformin Hydrochloride ER Tablets USP, 500 mg and 1000 mg","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Provides Update on Phase 3 Study of ULTOMIRIS\u00ae (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Combination Treatment for Methamphetamine Use Disorder Shows Promise in NIH Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review to New Drug Application for Finerenone to Treat Patients with Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize's Covid-Busting Nasal Spray Begins UK Trials January 11th","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor\u2019s Preliminary Result of COVID-19 Trial in Female Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present Data Showing Tecentriq and Avastin Combo Substantially Improves Overall Survival in People with Common Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA Acceptance of a sNDA for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Receives EU Marketing Authorisation for the First-Ever Dispersible-Tablet Formulation of Dolutegravir, Tivicay","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dispersible tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Gets Positive Response from FDA on Sufficiency of One Phase 3 Trial for Filing of NDA for the Use of Ganaxolone in CDD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos\u2019 iDose\u00ae TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intraocular implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces Publication of Results from LUMEVOQ\u00ae RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Grants Approval for the Registrational Phase 1\/2 Clinical Study for GC007g","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"GC007g","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Servier","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology and Servier To Present Data on LONSURF\u00aeat 2021 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Trifluridine","moa":"Nucleic acid","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Servier","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen's Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Achieves Major Manufacturing Milestone for REQORSA\u2122 Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo\u2019s Continued Commitment in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Phase III Clinical Study of AJM300 for Treatment of Ulcerative Colitis Conducted in Japan (AJM300\/CT3 Study)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Carotegrast Methyl","moa":"Alpha4 integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ EA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pha.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream as a Potential Treatment for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sitaxentan","moa":"Endothelin Receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Seeks UK MHRA Marketing Approval for Chronocort to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Receives European Orphan Drug Designation for ALS Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patient in ALLOB Phase IIb Tibial Fracture Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Osteoblastic Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apabetalone\u2019s Positive Effect on Hospitalized Patients Involving Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Xalkori\u00ae (Crizotinib) Approved by FDA for ALK-Positive Anaplastic Large Cell Lymphoma IN Children and Young Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Crizotinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Announces Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport\u00ae in Five Therapeutic Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"PEGASUS LABORATORIES INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants First Conditional Approval Under Expanded Authority to Pegasus Laboratories' Drug for Seizures in Dogs with Idiopathic Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Bromide","moa":"Adenosine kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PEGASUS LABORATORIES INC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Chewable tablet","sponsorNew":"PEGASUS LABORATORIES INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PEGASUS LA.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Study of Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in NEJM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Serum Institute Expects WHO Emergency Approval for AstraZeneca Shot Soon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pressurized metered-dose inhaler","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Organogenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu\u00ae for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic suspension allograft","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Organogenesis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogene.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals\u2019 Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Daratumumab Biosimilar Received IND Approval from NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol To Present Gene Expression Results from the Completed Phase I\/IIa ISO-CC-005 Studyat ASCO-GI 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biot.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Provides Update on Generic Advair Diskus\u00ae Launch","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"University of New Hampshire","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNH Researchers Discover New Inhibitor Drug Combination for Rare Form of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"JQ-1","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of New Hampshire","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of New Hampshire \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's Darzalex Faspro\u00ae Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in the EU for Less-Frequent, Fixed-Dose Use in Unresectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT \u201cBasket\u201d Trial at ASCO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zanidatamab Data Highlight Durable Antitumor Activity in HER2\u2011Expressing Biliary Tract and Gastroesophageal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime Therapeutics Presents Results of Phase 2 FIGHT Trial at ASCO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"FGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Announces Data Sowing Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"VERVE-101","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rifamycin","moa":"DdRP","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"DiosCURE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"DIOS-202","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DiosCURE Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DiosCURE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"DiosCURE T.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA\u00ae to Oxycodone at the 2021 NANS Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Aesthetics and Allergan to Present 16 Neurotoxin Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin Gets Central Drugs Authority Panel Approval for Restricted Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Doses First Patient in Cohort 2 of Redwood-HCM Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CK-274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX\u00ae2-73 in People with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Amended Agreement with Spero Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Ixaka","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$55.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ixaka (Formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"Rexmyelocel-T","moa":"Angiogenesis","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ixaka","amount2":0.059999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"intra-arterial catheter","sponsorNew":"Ixaka \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ixaka \/ Un.."},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"TenNor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TenNor Therapeutics \/ Janssen","highestDevelopmentStatusID":"3","companyTruncated":"TenNor The.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aruvant Chooses Lonza to Manufacture ARU-1801","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Aruvant","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Aavnergene","sponsor":"Neurophth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"AAV capsids-gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Aavnergene","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aavnergene \/ Neurophth","highestDevelopmentStatusID":"3","companyTruncated":"Aavnergene.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Etana Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA\u00ae in Indonesia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Etana Biotechnologies","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"ConserV Bioscience","sponsor":"Lawrence Livermore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ConserV and Lawrence Livermore National Laboratory to collaborate on coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ConserV Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"injection","sponsorNew":"ConserV Bioscience \/ Lawrence Livermore","highestDevelopmentStatusID":"4","companyTruncated":"ConserV Bi.."},{"orgOrder":0,"company":"Slate Bio","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"IL233","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Slate Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Slate Bio \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Slate Bio .."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Lipidor and Cannassure Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based on Lipidor's AKVANO\u00ae Technology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$94.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"VERVE-101","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous infusion","sponsorNew":"Verve Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"5","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"LifeArc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metrion Biosciences and LifeArc Further Extend Neuroscience-focused Ion Channel Drug Discovery Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Potassium ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Metrion Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metrion Biosciences \/ LifeArc","highestDevelopmentStatusID":"2","companyTruncated":"Metrion Bi.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Sirtex","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria monocytogene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Abingworth LLP","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Abingworth LLP","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Consortium Including ElsaLys Biotech and Novadiscovery Awarded \u20ac3.35 Million by Bpifrance to Advance Inolimomab in Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Inolimomab","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ElsaLys Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous perfusion","sponsorNew":"ElsaLys Biotech \/ Bpifrance","highestDevelopmentStatusID":"12","companyTruncated":"ElsaLys Bi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Genpharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous CD34+ cell enriched HSPC","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dispersion for infusion","sponsorNew":"Orchard Therapeutics \/ GenPharm","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Myst Therapeutics","sponsor":"Turnstone Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turnstone Biologics Acquires Novel Cell Therapy Platform Developer, Myst Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Tumor infiltrating lymphocyte therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Myst Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myst Therapeutics \/ Turnstone","highestDevelopmentStatusID":"1","companyTruncated":"Myst Thera.."},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Octapharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akron Signs Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum Derived from Octaplas\u00ae for Cell Therapy Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Virally inactivated human AB serum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Akron Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Octapharma","highestDevelopmentStatusID":"1","companyTruncated":"Akron Biot.."},{"orgOrder":0,"company":"Advita","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"Relief Sings Binding Term Sheet To Acquire All Shares of AdVita to Expand the Scope of Development of Aviptadil Inhaled Formulation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Advita","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Advita \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Advita \/ R.."},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Immunotech Biopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"HERV-E TCR transduced CD8+\/CD34+ enriched T cells","moa":"HERV-E","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"T-Cure Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"infusion","sponsorNew":"T-Cure Bioscience \/ Immunotech Biopharm","highestDevelopmentStatusID":"6","companyTruncated":"T-Cure Bio.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Commits for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","amount":"$117.0 million","upfrontCash":"$7.0 million","newsHeadline":"TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"TR009","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Trigr \/ Elpiscience Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ El.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$262.2 million","upfrontCash":"Undisclosed","newsHeadline":"Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"saRNA therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"VECT-HORUS","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$14.5 million","upfrontCash":"Undisclosed","newsHeadline":"VECT-HORUS Completes Its \u20ac12 Million Fund-Raising Operation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series D Financing","leadProduct":"Nucleic acid based therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VECT-HORUS","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"VECT-HORUS \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VECT-HORUS.."},{"orgOrder":0,"company":"reMYND","sponsor":"Korys Investments","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"reMYND extends Series B funding to EUR 24 million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series B Financing","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis restoration","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"reMYND \/ Korys Investments","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ K.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProvideGx\u00ae Partners with Pfizer Inc. to Secure the Supply of Five Essential Medications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Labetalol Hydrochloride","moa":"ADRB1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Pfizer Inc \/ ProvideGx","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Canaccord Genuity Corp.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Mydecine \/ Canaccord Genuity Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix Announces $14.0 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$13.4 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Vaxess","sponsor":"National Science Foundation","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"mRNA-based COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaxess","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxess \/ National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vaxess \/ N.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly Completes Acquisition of Prevail Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"GBA1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Continuus Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$69.3 million","upfrontCash":"Undisclosed","newsHeadline":"Continuus Pharmaceuticals Secures $69.3 Million Government Contract to Manufacture Critical Medicines in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Continuus Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Continuus Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Continuus .."},{"orgOrder":0,"company":"Precigen","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$112.5 million","upfrontCash":"Undisclosed","newsHeadline":"Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"AG019","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0.11,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Precigen \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Pharma, Taisho Pharma Terminate Co-Marketing Agreement for Edirol to Treat Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Termination","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Taisho Pha.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen Licenses GlymaxX\u00ae Technology to AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Afucosylated antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ AbbVie","highestDevelopmentStatusID":"1","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Shionogi","sponsor":"BioAge Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shionogi and BioAge Conclude a License Agreement Aimed at Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Asapiprant","moa":"DP1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Shionogi \/ BioAge","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing Disorder Biotech Decibel Therapeutics Files for a $75 Million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Barclays","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Kinnear Pharmaceuticals","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for Anti-Infective","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"CSA-131","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kinnear Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kinnear Pharmaceuticals \/ CF Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Kinnear Ph.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"NASA","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ NASA","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Pharmadrug Production GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaDrug Enters Definitive Agreement to Acquire Sairiyo Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Cepharanthine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sairiyo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sairiyo Therapeutics \/ PharmaDrug","highestDevelopmentStatusID":"1","companyTruncated":"Sairiyo Th.."},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"Medical Research Council (U.K)","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Aclipse Therapeutics Announces $2.2 Million Grant from UK\u2019s Medical Research Council for Development of M102","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"M102","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ Medical Research Council (U.K)","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Th.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Lenzilumab\u2122","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Emergent BioSolutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$1.0 million","newsHeadline":"Relief Therapeutics and Acer Therapeutics Ink Option Agreement for Exclusivity to Negotiate a Collaboration and License Deal for ACER-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"immediate-release Powder","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Valneva","sponsor":"Instituto Butantan","pharmaFlowCategory":"D","amount":"$23.4 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Instituto Butantan","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Omnix Medical","sponsor":"EIC Accelerator Programme","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omnix Medical Wins \u20ac10.8M in EIC Accelerator Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"OMN6","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Omnix Medical","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Omnix Medical \/ EIC Accelerator Programme","highestDevelopmentStatusID":"5","companyTruncated":"Omnix Medi.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Nirogy therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Nirogy Therapeutics Launches with $16.5 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nirogy therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Nirogy therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nirogy the.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"TScan Therapeutics Announces $100 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"TSC-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Senda Biosciences","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Senda Biosciences and Nestl\u00e9 Health Science Enter into an Option Agreement for Senda's Intersystems Biology-Based Metabolic Health Products","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Nutritional therapies","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Senda Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senda Biosciences \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"4","companyTruncated":"Senda Bios.."},{"orgOrder":0,"company":"Care Access Research","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Care Access Research Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Care Access Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Care Acces.."},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scopus BioPharma Announces Pricing of $9 Million Follow-On Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"CO-sTiRNA","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scopus Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Scopus Biopharma \/ The Benchmark Company","highestDevelopmentStatusID":"5","companyTruncated":"Scopus Bio.."},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Wren Therapeutics Announces Financing of \u00a312.4 Million (c. $17.0 Million)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Wren Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Wren Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"2","companyTruncated":"Wren Thera.."},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quercis Pharma Licenses Key Patents for Thromboembolism Platform Across Cancer and Covid-19 Indications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Isoquercitrin","moa":"sP-selectin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beth Israel Deaconess Medical Center \/ Quercis Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Beth Israe.."},{"orgOrder":0,"company":"Elasmogen","sponsor":"University of Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elasmogen Announces Panel of Novel Anti-Covid-19 Therapeutic Candidates Identified Through Collaboration with U.S. Research Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elasmogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Elasmogen \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Elasmogen .."},{"orgOrder":0,"company":"Aji Bio Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Lenzilumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Aji Bio Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Aji Bio Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Aji Bio Ph.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"NeuBase Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"NT0200","moa":"DMPK protein degradation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ NeuBase Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine","pharmaFlowCategory":"D","amount":"$13.2 million","upfrontCash":"$0.5 million","newsHeadline":"Citrine Medicine Announces Strategic Partnership with Diurnal To Bring Alkindi\u00ae To China For Use In Pediatric Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Citrine","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvalent Launches with $50M Series A Financing to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"NUV-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvalent","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Nuvalent \/ Deerfield Management","highestDevelopmentStatusID":"5","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Quellis Biosciences Inc","sponsor":"Catabasis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals Announces Acquisition Of Quellis Biosciences Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"QLS-215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quellis Biosciences Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Quellis Bi.."},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xuanzhu Biopharm Acquires Combio Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"KM257","moa":"HER2D4","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pha.."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,866.0 million","upfrontCash":"$30.0 million","newsHeadline":"Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration with Merck to Develop Candidate CAR-NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artiva Biotherapeutics","amount2":1.8700000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8700000000000001,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"Evozyne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evozyne and Takeda Announce Strategic Collaboration and License Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Synthetic proteins","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Evozyne","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evozyne \/ Takeda","highestDevelopmentStatusID":"3","companyTruncated":"Evozyne \/ .."},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centre for Human Drug Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Centre for Human Drug Research \/ AIM ImmunoTech","highestDevelopmentStatusID":"4","companyTruncated":"Centre for.."},{"orgOrder":0,"company":"Recordati","sponsor":"Tolmar","pharmaFlowCategory":"D","amount":"$168.6 million","upfrontCash":"$42.1 million","newsHeadline":"Recordati: License Obtained for the Commercialization of Eligard in Europe and Other Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Recordati","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recordati \/ Tolmar International","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Funding","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Nevakar","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nevakar and Th\u00e9a Enter into Licensing Agreement for the Commercialization of NVK-002 in Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nevakar","amount2":0.14000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Nevakar \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"10","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of \u20ac35m","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Roche Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Ph.."},{"orgOrder":0,"company":"Novaremed","sponsor":"GEM Global Yield","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Novaremed \/ GEM Global Yield","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"University of Maryland","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of Maryland","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Maryland \/ Mydecine Innovations","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Launches Generic Icatibant in U.S for Angioedema, Strategically Enhancing Injectables Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Slayback P.."},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Expands Research Collaboration with Weill Cornell Medicine to Continue Advancement of HT-003 for Acne Treatment Research","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"TLR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Corn.."},{"orgOrder":0,"company":"Asahi Kasei Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$20.0 million","newsHeadline":"Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AK1780","moa":"P2X7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Asahi Kasei Pharma","amount2":0.40999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Asahi Kasei Pharma \/ Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Asahi Kase.."},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Theratechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Announces Sterile Fill\/Finish Program with Theratechnologies Inc. for TH1902 Peptide-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Docetaxel-TH19P01 conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Piramal Pharma Solutions \/ Theratechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Ph.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Next Generation Manufacturing Canada","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Providence Therapeutics Welcomes Funding from NGen to Bolster COVID-19 Vaccine Manufacturing Capacity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Funding","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Providence Therapeutics \/ Next Generation Manufacturing Canada","highestDevelopmentStatusID":"8","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Medolife","sponsor":"Ministry of Environment of The Dominican Republic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medolife Submits Applications Of Their Scorpion Venom To Help Fight Against Cancer And COVID-19 With The FDA In The Dominican Republic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Scorpion venom","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medolife","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medolife \/ Ministry of Environment of The Dominican Republic","highestDevelopmentStatusID":"1","companyTruncated":"Medolife \/.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte\u2019s Lead Compound LB-100 to Treat Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chulalongkorn University to Start Human Trials for its Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ChulaCov19 mRNA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Chulalongkorn University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chulalongkorn University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chulalongk.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Positive Gastric Adenocarcinomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Globe Biotech Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Globe Biotech's BANCOVID Elicits Neutralizing Antibody and Balanced Cellular Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"D614G variant LNP-encapsulated mRNA","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Globe Biotech Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Globe Biotech Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Globe Biot.."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols To Begin Clinical Trial To Evaluate Plasma-derived COVID-19 Drug - Quick Facts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 polyclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yuhan\u2019s Lung Cancer Treatment Lazertinib Wins Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lazertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Yuhan Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuhan Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yuhan Corp.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Presents Positive Efficacy Data of Dostarlimab in Mismatch Repair-Deficient Solid Cancers at ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hanmi Pharmaceutical Expects U.S. FDA Approval for 2 New Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Uniao Quimica Farmaceutica Nacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazilian Approval of Sputnik V Vaccine Delayed by Missing Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Uniao Quimica Farmaceutica Nacional","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniao Quimica Farmaceutica Nacional \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniao Quim.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Group Announces Positive top-line Efficacy and Safety Data From Global Phase II\/III trial of COVID-19 Treatment Candidate CT-P59","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tecartus wins NICE Recommendation for Mantle cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"EdiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves EdiGene\u2019s IND Application of CRISPR\/Cas 9 Gene-Editing Therapy, ET-01 to Treat Transfusion Dependent \u00df-Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ET-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"EdiGene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EdiGene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"STP705","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"ImmunoFlex","sponsor":"Chemistree","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemistree Investee ImmunoFlex Receives Health Canada Approval For Flex 10 Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ImmunoFlex","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoFlex \/ Chemistree","highestDevelopmentStatusID":"12","companyTruncated":"ImmunoFlex.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Hosting KOL Symposium and Pipeline Update Aramchol Phase 3 Trial for Non-Alcoholic Steatohepatitis and Liver Fibrosis Amilo-5MER","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Completes Enrollment of First Phase 3 Study for NOV03 (Perfluorohexyloctane)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"GC019F","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Provides Update On Phase 2\/3 Trial And Alzheimer's Disease Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Bendamustine","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Genkyotex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genkyotex SA, a subsidiary of Calliditas Therapeutics Announced Positive Phase 1 Results in High-Dose Setanaxib Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Setanaxib","moa":"NOX1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genkyotex","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genkyotex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genkyotex .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Firmicute species bacterial spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Encapsulated purified suspension","sponsorNew":"Seres Therapeutics \/ Nestle","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Gets Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 to Treat Epilepsy Caused by SLC13A5 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV9-based gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I\/IIa Trial of BT-001 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra tumoral","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGA Grants Additional Provisional Determination for Novavax's COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Partial Clinical Hold Pieris Pharmaceuticals' Prs-343 Phase 1 Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PRS-343","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces U.S. FDA Approval of VERQUVO\u00ae (Vericiguat)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous CD34+ cell","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intracoronary","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"University of Dundee","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evgen Pharma Provides Patient Recruitment Update in STAR-COVID 19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulforaphane","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ University of Dundee","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Phar.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expert Panel Recommends Phase 1 Trial of Bharat Biotech's Nasal Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Veru","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Nature Medicine Publication on Enobosarm in Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4\/6 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"University of Adelaide","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Adelaide \/ Veru","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating VP-102 in Molluscum and External Genital Warts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Reports FDA Clinical Hold for Planned Phase 1\/2 Trial of HST-003 for Knee Cartilage Regeneration","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"HST-003","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO\u00ae in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"STI-2020","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"R-Pharm","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azerbaijan issues Permit to Conduct World\u2019s First Clinical Trials of Vaccine Combination, Sputnik V and COVID-19 Vaccine AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"R-Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"R-Pharm \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"R-Pharm \/ .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Gets Notice of Allowance for New Patent Covering Combination of MN-166 and Riluzole for Amyotrophic Lateral Sclerosis in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Receives DMC Recommendation for Starting Recruitment for Part 2 of its Phase 2-3 COVA Study in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100 at HonorHealth Research Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CRX100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for intravenous infusion","sponsorNew":"BioEclipse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Gets Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients with Resected Esophageal or GE Juction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mapi Pharma Engages PRA Health Sciences as CRO for Phase III Multiple Sclerosis Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ PRA Health Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Research Against Covid-19 Launched IN France with Debiopharm\u2019s Antiviral Alisporivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Alisporivir","moa":"Cyclophilin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemincare Initiates Phase I Clinical Trial of anti-SARS-CoV-2 Neutralizing Antibody JMB2002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"JMB-2002","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine Extended-Release Tablet in Adults with ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Extended-release tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Files for Regulatory Approval in the US of Once-Weekly Semaglutide 2.0 Mg for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Gets EU Approval Doptelet\u00ae (Avatrombopag) for treatment of ITP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-Star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"FS118","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Prevotella histicola strain","moa":"IL-6","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Transgene","sponsor":"NEC Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (Myvac\u00ae Platform)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ NEC","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Application for Opdivo\u00ae Chemotherapy Combo for Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ONCOtherapeutics \/ Incyte","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherap.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA accepts Precision BioSciences\u2019 IND application for PBCAR19B to treat r\/r non-Hodgkin lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Prevented COVID-19 at Nursing Homes in the BLAZE-2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Roche\u2019s Esbriet (Pirfenidone) for Unclassifiable Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"TGF beta","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"film-coated tablet","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces FDA Approval of Cabenuva (Cabotegravir, Rilpivirine)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Injectable Suspension","sponsorNew":"ViiV Healthcare \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 1\/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-919","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Bharat Biotech Seeks Bangladesh Trial for COVID Vaccine Approved at Home","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"International Centre for Diarrhoeal Disease Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Internatio.."},{"orgOrder":0,"company":"REMD Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REMD Biotherapeutics Completes Enrollment AND Announces Top-Line Results of A Phase 2 Clinical Study of Volagidemab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Volagidemab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"REMD Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"REMD Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"REMD Bioth.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech: 13,000 Volunteers Administered 2nd Dose of Covaxin in phase-3 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces that the Phase II Ulcerative Colitis Study of GSK2831781 Has Been Discontinued","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"IMP731","moa":"LAG3 Cell","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immu.."},{"orgOrder":0,"company":"University of Texas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"University of Texas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"University of Texas \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO Receives a Manufacturing and Marketing Approval of Adlumiz\u00ae, a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Anamorelin HCl","moa":"Ghrelin receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Manufacturing and Marketing Approval in Japan for ALUNBRIG\u00ae ALK Fusion Gene-positive Unresectable Advanced Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turn Therapeutics Receives Authorization to Commence Human Trial for COVID-19 Therapeutic Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Petrolatum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Turn Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Turn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Turn Thera.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian Direct Investment Fund Reports that Ministry of Health of the UAE Has Approved the Use of Sputnik V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies' CAPLYTA\u00ae Open-Label Safety Switching Study in Schizophrenia Published in the Journal, Schizophrenia Research","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evgen Pharma Announces Positive Pre-Clinical Data in Glioma for Lead Asset SFX-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulforaphane","moa":"SHP2 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Phar.."},{"orgOrder":0,"company":"EuBiologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of 'EuCorVac-19' in Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EuCorVac-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EuBiologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"EuBiologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EuBiologic.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Therapeutics Presents Positive Data From its Phase 2b Clinical Study of DMT310 for the Treatment of Moderate to Severe Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"DMT310","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Presentation at the Reimagine Health Research Symposium Features Platform Technology and Four Antiviral Case Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CC-31244","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Receives European Commission Approval of ELZONRIS, for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tagraxofusp","moa":"IL-3 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Pharma Announces Marketing Approval for Hunterase ICV Injection 15 mg for Mucopolysaccharidosis Type II","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Idursulfase beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform's Clinical Study Indicates Positive Interim Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanoform \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Aurinia Pharmaceuticals\u2019 LUPKYNIS\u2122 (Voclosporin) for Adult Patients with Active Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Bristol Myers Squibb' OPDIVO\u00ae in Combination with CABOMETYX as First-line Treatment for Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous solution","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech's COVID-19 Shot Safe, Produced Immune Response in Early Human Trial - The Lancet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Approves Use of CoronaVac Doses Partly Manufactured Locally","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Receives Japanese Approval for Yescarta To Treat Relapsed\/Refractory Large B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Receives USFDA Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Full-Dose Blood Thinners Decreased Need for Life Support and Improved Outcome in Hospitalized COVID-19 Patients- NIH Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"National I.."},{"orgOrder":0,"company":"Caplin Point Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Point Labs Gets USFDA Nod for Anticoagulant Injection","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Argatroban","moa":"Thrombin","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Caplin Point Laboratories Limited","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caplin Point Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Poi.."},{"orgOrder":0,"company":"Neuvogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuvogen Announces Next Generation Cancer Vaccine Strategy to Transform How Solid Tumors are Treated","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Neuvogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuvogen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Neuvogen \/.."},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"XT-150","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Ther.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Says Remdesivir Likely to be Effective Against New COVID-19 Strains","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from USFDA for Liothyronine Sodium Tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Liothyronine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme\u2019s Arimoclomol Expected to Be Used with Zavesca After Likely FDA Approval in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Discontinues Development of SARS-CoV-2\/COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"V591","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Calquence Met Primary Efficacy Endpoint in Head-To Head Trial Against Ibrutinib in Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Faricimab Meets Primary Endpoint in Two Global Phase III Studies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PRINCIPLE Trial Finds Antibiotics Azithromycin and Doxycycline Not Generally Effective Treatments for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Sevelamer Carbonate Tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Reports Positive Interim Data with REGEN-COV\u2122 Antibody Cocktail Used as Passive Vaccine to Prevent Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Junshi Biosciences' Toripalimab Fast Track Designation for Mucosal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Fragile X Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Demonstrates Synaptogenix's Bryostatin Normalizes Autistic Spectrum Behaviors in Mice","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Fragile X Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"YH001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases: Carbaglu\u00ae Tablets 200mg Gets Approval for A New Indication","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Carglumic Acid","moa":"CPS1","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EB05","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minoryx Presents Topline Results from Phase 2\/3 \u201cADVANCE\u201d Study Showing Significant Clinical Benefit of Leriglitazone in Adrenomyeloneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Leriglitazone","moa":"PPAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minoryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"E.C Approves KEYTRUDA\u00ae for Treatment of Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Has Enrolled First Patient in a Phase I\/IIa Trial of BI-1808 For the Treatment of Solid Tumors and CTCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics to Test Activity of Stenoparib, as a Potential Therapy for New Highly Infectious Strain B.1.1.7 of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Suggests ASLAN Pharmaceutical's ASLAN003 Has the Potential to Be the Best-In-Class DHODH Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Farudodstat","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Adds Two New Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Yeast recombinant lipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Uttroside B","moa":"Mapk","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Symbicort Turbuhaler approved in China as an Anti-Inflammatory Reliever in Mild Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Receives \"Study May Proceed\" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic PDAC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents Interim Findings from Phase 2a Trial of Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"UPMC Hillman Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals\u2019 Lead Immunotherapy ISA101b with Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ UPMC Hillman Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Secures U.S. Patent for Codon-Deoptimized RSV Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CodaVax-RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline to Present Data at the 2021 European Association for Haemophilia and Allied Disorders and the 17th Annual WORLDSymposium\u2122 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Verbrinacogene setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Umbilical cord generated dendritic cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Highlight Data From an Open-Label Phase 2 Study of the Treatment of Upper Facial Lines With DaxibotulinumtoxinA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"UCSF QBI","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCSF QBI and Icahn School of Medicine at Mount Sinai Scientists Report New Preclinical Data on Plitidepsin for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"VEGF\/VEGFR-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"UCSF QBI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCSF QBI \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"UCSF QBI \/.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong To Start Phase 3 Trial of COVID-19 Preventive","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Camostat","moa":"TMPRSS2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Low-Dose Aspirin May Improve Pregnancy Chances for Women with One or Two Prior Miscarriages-NIH Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National I.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus' Desidustat Shows Efficacy and Safety in Treating Hypoxia in Hospitalized COVID-19 Patients in Mexico","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Desidustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma\u2019s Redesca\u2122 Receives Positive Recommendation for Public Reimbursement in Quebec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Stealth cell","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173 in Patients with Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Ursodiol Capsules","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ursodeoxycholic Acid","moa":"AKR1C2","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of Xeljanz\u00ae in Rheumatoid Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Bio's Ongoing Phase 1 Trial of VIR-3434 Data for Chronic Hepatitis B Virus Infection shows Reduction in Hepatitis B Surface Antigen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-3434","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGB Biopharma Announces End-of-Phase 2 Meeting with FDA for MGB-BP-3 as a Treatment for Clostridioides Difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Mgb-BP-3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopha.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Strengthens IP Rights for Overdose Rescue Drug OX124","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EU101","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ National OncoVenture","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Comments on ARISE-3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 \/ OST31-164-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AOST2121","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics Receives Orphan Drug Designation for Gene Therapy of Blindness","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"VMCO-I","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves AbbVie's RINVOQ\u2122 (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"TAblet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax\u2019s CpG 1018 Doses First Participant in Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Global Response Aid FZCO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s and GRA Announce Avigan Pivotal Studies Update Study for Hospitalized Moderate to Severe Cases in Kuwait Terminated","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Global Response Aid FZCO","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"12-Month Data from Surmodics\u2019 TRANSCEND Trial Presented at LINC 2021 Event","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 spike protein plasmid DNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoSec Immunotherapies \/ National Institute Health","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Immunoforge","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PF1801","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immunoforge","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunoforge \/ PhaseBio","highestDevelopmentStatusID":"6","companyTruncated":"Immunoforg.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Serum Applies to Conduct Local Trial for Novavax Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts GBT\u2019s Marketing Authorization Application for Oxbryta\u00ae for Hemolytic Anemia in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Mundipharma's Rezafungin in EU for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Applies for COVID-19 Vaccine's Regulatory Approval in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Peer Review journal Science Confirms the Potent Activity of PharmaMar's Plitidepsin Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"eEF1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Receives Positive CHMP Opinion for NEXPOVIO\u00ae (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"GLR2007","moa":"CDK-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals\u2019 Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion for Kesimpta\u00ae, A Self-Administered Treatment for Adult Patients with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Receives Positive Chmp Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Ovoca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Ovoca Bio's Phase II Study - BP-101","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BP-101","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Ovoca Bio","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Ovoca Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovoca Bio .."},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"CLR 131","moa":"DNA damage","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"BieGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Auristatin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BieGene","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Phase I\/IIa Data Suggest BI-1206 Restores Activity of Rituximab in Relapsed non-Hodgkin's Lymphoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BI-1206","moa":"Fc?RllB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (Alphalex\u2122-Exatecan)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Frontotemporal Dementia with Granulin Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PBFT02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Application Submitted to PMDA in Japan for OPKO Health's Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum AB Reports that All Patients Have Completed Treatment With FOL-005 in the Phase II Study Against Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"FOL-005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follicum A.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Advanced Lung Cancer after Platinum-Based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"CStone Pharmaceuticals \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Evotec","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evotec Starts Clinical Development of Chikungunya Antibody Together with NIAID and Leading Academic Research Organisation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EVT894","moa":"Chikungunya viral protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Evotec \/ National Institute Health","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical Reports New Amivantamab Data from CHRYSALIS Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan and ENHERTU\u00ae Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Presents Data from Phase 1b\/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ S.K Biopharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed's Batoclimab Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Data on LENVIMA\u00ae Based Combination Therapies in Renal Cell Carcinoma at the 2021 Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents Results From Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA\u00ae in Combination With Ipilimumab Vs KEYTRUDA Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion Receives EMA Agreement on its Paediatric Investigation Plan for Sonlicromanol","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Genomics Launches Phase III Pivotal REFRESH Study in Resistant Hypertension with Once-a-day Formulation of Firibastat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants Promising Innovative Medicine Designation to Sanofi\u2019s Nirsevimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc\u2019s Sabin-IPV Vaccine Eupolio Receives WHO Prequalification to Treat Poliomyelitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sabin-inactivated polio vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acacia Pharma Launches BYFAVO in the U.S for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 30 Minutes or Less","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized powder","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta Enters License Agreement with POINT Biopharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pro-doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Avacta Group \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Nanoform","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and Herantis sign Biologics Proof of Concept Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Cerebral Dopamine Neurotrophic Factor","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral infusion","sponsorNew":"Herantis Pharma \/ Nanoform","highestDevelopmentStatusID":"7","companyTruncated":"Herantis P.."},{"orgOrder":0,"company":"Asahi Kasei Finechem","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea\u2019s Partner Asahi Kasei Pharma Completes Patient Enrolment in Phase 3 Study with Antifungal Isavuconazole (Cresemba\u00ae) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Asahi Kasei Finechem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asahi Kasei Finechem \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"Asahi Kase.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"PRAX-222","moa":"SCN2A gene","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"CYT-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Public Offering","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$3,900.0 million","upfrontCash":"$750.0 million","newsHeadline":"Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":3.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.8999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","amount":"$352.5 million","upfrontCash":"$1.0 million","newsHeadline":"IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"SMAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho and Astex Extend Strategic Oncology Collaboration with MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Taiho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies and UT Southwestern Medical Center Launch Innovation Fund to Accelerate Advancement of AAV Gene Therapies for CNS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"TSHA-112","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"UT Southwestern Medical Center","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UT Southwestern Medical Center \/ Taysha Gene Therapies","highestDevelopmentStatusID":"2","companyTruncated":"UT Southwe.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Invests $25 Million in Trillium Therapeutics Through the Pfizer Breakthrough Growth Initiative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"TTI-622","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Invests $60 million in Homology Medicines Through the Pfizer Breakthrough Growth Initiative","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Financing","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda\u00ae in China) for Non-Pancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-high non-small cell lung cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Publishes Review in Drug Discovery on Mechanism of Action and Transformative Potential of ABX464 for Inflammatory Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"CanProbe","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lutetium\u2013177 Octreotate","moa":"SSRT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CanProbe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CanProbe \/ POINT Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"CanProbe \/.."},{"orgOrder":0,"company":"Cybin","sponsor":"Adelia Therapeutics","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Tryptamine derivatives","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Adelia","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ Ad.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","amount":"$271.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO) in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0.27000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Aadi Bioscience \/ EOC Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Receives FDA Guidance for Development of RLS 103, Designed for the Treatment of Acute Panic Attack","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"A3AR","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Powder for inhalation","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"HPN217","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Petrovax","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese COVID-19 Vaccine Ad5-Ncov Shows High Antibody Levels at Russian Trial -Ifax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Petrovax \/ CanSino Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/.."},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$3,005.0 million","upfrontCash":"$3,005.0 million","newsHeadline":"Horizon Therapeutics to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":3.0099999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":3.0099999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio .."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$785.0 million","upfrontCash":"$30.0 million","newsHeadline":"Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone\u2019s Vaccine Platform Technology for HIV Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"HIV-specific therapeutic vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gritstone bio","amount2":0.79000000000000004,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.79000000000000004,"dosageForm":"","sponsorNew":"Gritstone bio \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Metrion Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metrion Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"Metrion Bi.."},{"orgOrder":0,"company":"Catalyst Clinical Research","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalyst Clinical Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Catalyst Clinical Research \/ Moleculin","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst C.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Announces Closing of $4.4 Million in Series A-1 Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intranasal spray","sponsorNew":"Revelation Biosciences \/ National Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$11.0 million","newsHeadline":"Exelixis and Adagene Ink Collaboration to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$99.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"TLR9","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ CEPI","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"UK-Based Cancer Biotech Immunocore Sets Terms for $200 Million Us IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cell Therapy Biotech Vor Biopharma Sets Terms for $150 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Engineered hematopoietic stem cell therapy","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vor Biopharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Vor Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"5","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Walter Reed Army Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noveome Biotherapeutics and Walter Reed Army Institute of Research to Study Noveome\u2019s Lead Product Candidate ST266 in Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Noveome Biotherapeutics \/ Walter Reed Army Institute","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Acquires NeuroCycle Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Engrail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Engrail Therapeutics \/ Engrail Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin\u2122 in the US Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"Exonate","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exonate Announces the Initiation of Phase Ib\/II Clinical Trial for Diabetic Macular Oedema, as Part of its Collaboration with Janssen","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Exonate \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Antengene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"ATG-022","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Antengene","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$148.3 million","upfrontCash":"$16.3 million","newsHeadline":"Ribon Therapeutics Inks License Agreement with Ono Pharmaceutical for RBN-2397","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"RBN-2397","moa":"PARP7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Krystal Biotech Announces Pricing of Upsized $125 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Beremagene geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Noetic Psychedelic Fund","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Bexson Biomedical Raises $4.8 Million In Oversubscribed Series A","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bexson Biomedical \/ Noetic Psychedelic Fund","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Bio.."},{"orgOrder":0,"company":"JanOne","sponsor":"A.G.P.\/Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"JanOne Announces Closing of $6.0 Million Common Stock Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"JanOne \/ A.G.P.\/Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ A.."},{"orgOrder":0,"company":"University of British Columbia","sponsor":"MYND Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Columbia on Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"University of British Columbia \/ MYND Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$15.3 million","upfrontCash":"Undisclosed","newsHeadline":"Evgen Pharma Announces Placing and Open Offer to raise up to \u00a311 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Sulforaphane","moa":"SHP2 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Phar.."},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medexus and Medac Enter Into a License Agreement for Treosulfan, in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"powder for solution for infusion","sponsorNew":"Medac \/ Medexus Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Me.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology Inks Clinical Supply Deal with Regeneron for Phase 1\/2 Trial Evaluating THIO in Sequential Administration with Libtayo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ MAIA Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7,200.0 million","upfrontCash":"$7,200.0 million","newsHeadline":"Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":7.2000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":7.2000000000000002,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK and CureVac To Develop Next Generation mRNA COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0.17999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Signs Exclusive License Agreement with University of Georgia for Covid-19 Compounds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"SBFM-PL4","moa":"PLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"GMS Ventures","pharmaFlowCategory":"D","amount":"$41.6 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics\u2019 Recent Financing Secures Funding to Support ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg) Through Planned BLA Submission","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Funding","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ GMS Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.12,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$194.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Tumor Biotech Bolt Biotherapeutics Increases Deal Size by 29% Ahead of $194 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Intravenous Infusion","sponsorNew":"Bolt Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cell Therapy Biotech Longeveron Sets Terms for $25 Million IPO","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Lomecel-B","moa":"VEGF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longeveron","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"intravenous infusion","sponsorNew":"Longeveron \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Catalent Pharma Solutions \/ Decibel","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Enters into Outsourcing Agreement to Manufacture AstraZeneca COVID-19 Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Equillium","sponsor":"Decheng Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Equillium Announces Closing of $30 Million Registered Direct Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Equillium \/ Decheng Capital","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces $150 Million Strategic Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Autologous CD34+ cell enriched HSPC","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dispersion for infusion","sponsorNew":"Orchard Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Avid Bioservices","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Avid Bioservices \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Avid Biose.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$133.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"Aspartyl beta hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"injection","sponsorNew":"Sensei Biotherapeutics \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Mutabilis","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"Carb-X Is Funding Mutabilis to Develop New Class of Antibacterials for Infections Caused by Carbapenem-Resistant Enterobacterales Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Funding","leadProduct":"EBL-1463","moa":"PBP2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mutabilis","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Mutabilis .."},{"orgOrder":0,"company":"Abzena Ltd","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"$13.3 million","upfrontCash":"Undisclosed","newsHeadline":"Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome\u2019s COVID-19 Antibody Based Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Abzena Ltd","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Abzena Ltd \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Abzena Ltd.."},{"orgOrder":0,"company":"The Rockefeller University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Anitoby Combination for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"C-135-LS","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"The Rockefeller University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"The Rockefeller University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"The Rockef.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Trizell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Macrophage-based advanced cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Trizell","highestDevelopmentStatusID":"6","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Merck Group","sponsor":"4D Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Longevity Acquisition Corporation Inks 4D pharma Clinical Trial Collaboration for Locally Advanced or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck Group \/ 4D pharma","highestDevelopmentStatusID":"12","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Relmacabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ JW Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Apotex Inc","sponsor":"ProvideGx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProvideGx\u00ae Partners with Apotex to Stabilize Supply of Three Vital Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Cefazolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"injection","sponsorNew":"Apotex Inc \/ ProvideGx","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc.."},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Linperlisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yingli Pharmaceutical","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Y.."},{"orgOrder":0,"company":"CollPlant","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"$14.0 million","newsHeadline":"CollPlant Inks Global Commercialization Deal with Allergan Aesthetics for rhCollagen in Dermal and Soft Tissue Filler Products","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"rhCollagen","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"CollPlant","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"CollPlant \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"CollPlant .."},{"orgOrder":0,"company":"Neurgain Technologies","sponsor":"Lineagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"OPC1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Neurgain Technologies","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Neurgain Technologies \/ Lineage","highestDevelopmentStatusID":"7","companyTruncated":"Neurgain T.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"DBTX","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing Disorder Biotech Decibel Therapeutics Sets Terms for $100 Million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ DBTX","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Charles River Laboratories, Inc \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Agencja Bada\u0144 Medycznych","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Moleculin Biotech \/ Agencja Bada\u0144 Medycznych","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Drug Farm","sponsor":"BioVeda China Fund","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Drug Farm Closes $56M USD Financing for Advancement of Lead Hepatitis B Drug into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Financing","leadProduct":"DF-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Drug Farm","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Drug Farm \/ BioVeda China Fund","highestDevelopmentStatusID":"5","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes Deal with AstraZeneca for European Rights to CRESTOR\u2122 (Rosuvastatin)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Gr\u00fcnenthal","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Seraxis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seraxis Announced Closing of $40M Series C Financing Round","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"SR-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Seraxis","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Seraxis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Seraxis \/ .."},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"EO1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edison Oncology \/ Apollomics","highestDevelopmentStatusID":"7","companyTruncated":"Edison Onc.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$340.0 million","upfrontCash":"$40.0 million","newsHeadline":"AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"CAR-T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caribou Biosciences","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ AbbVie","highestDevelopmentStatusID":"3","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapeutic Solutions Acquires Stem Cell Therapy That has Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Umbilical cord derived mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"immediate-release tablet","sponsorNew":"Day One Biopharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Notch Therapeutics","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"iPSC-derived T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Notch Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Notch Therapeutics \/ Allogene Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Notch Ther.."},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ L.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","amount":"$830.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Merger","leadProduct":"NUV-422","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0.82999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.82999999999999996,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Panacea","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Medivir","sponsor":"Ubiquigent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir Enters Into Licensing Agreement with Ubiquigent for Preclinical Program USP7","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medivir \/ Ubiquigent","highestDevelopmentStatusID":"4","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Famar Health Care Services Madrid","sponsor":"Medicom Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicom Healthcare Ltd Announces the Signing of an Asset Purchase Agreement of BIMATOPROST 0.3 mg\/mL, 3ml","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Famar Health Care Services Madrid","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Famar Health Care Services Madrid \/ Medicom Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Famar Heal.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Bionomics \/ Apeiron","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$193.5 million","upfrontCash":"Undisclosed","newsHeadline":"KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0.19,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.19,"dosageForm":"tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Venture","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced Chemotherapy Technologies, Inc. Announces $2.5M Series A Investment by Spectrum Financial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Gemcitabine","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Venture","highestDevelopmentStatusID":"8","companyTruncated":"Advanced C.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Suvretta Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"HST5040","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"solution","sponsorNew":"HemoShear Therapeutics \/ Suvretta Capital","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Stealth BioTherapeutics Announces Pricing Of $4.7 Million Registered Direct Offering Of American Depositary Shares","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Elamipretide","moa":"Microtubule associated protein 2","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Johns Hopkins University School of Medicine","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Research Agreement with Johns Hopkins University School of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Johns Hopkins University School of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johns Hopkins University School of Medicine \/ Panbela","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.20000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK to Sell Cephalosporin Antibiotics Business to Sandoz","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Divestment","leadProduct":"Cefuroxime Axetil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0.5,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Sand.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pipeline Therapeutics Completes $80 Million Series C Financing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"PIPE-505","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Franklin Templeton","highestDevelopmentStatusID":"7","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Ensoma","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First \u201cOff-the-shelf\u201d Genomic Medicines","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Engenious vectors","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ensoma","amount2":0.070000000000000007,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Ensoma \/ 5AM Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ 5.."},{"orgOrder":0,"company":"French National Institute of Health and Medical Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharma Licenses Technology for Treating Prader-Willi Syndrome from the French National Institute of Health and Medical Research","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"French National Institute of Health and Medical Research","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"French National Institute of Health and Medical Research \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"French Nat.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Negma","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Ixabepilone","moa":"Microtubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Allarity Therapeutics \/ Negma","highestDevelopmentStatusID":"12","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"CYT-0851","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"oral","sponsorNew":"Cyteir Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Ascletis Pharma","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sagimet Biosciences Raises $80 Million in Crossover Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Financing","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Ascletis","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.11,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.11,"dosageForm":"Vaginal insert","sponsorNew":"TherapeuticsMD \/ Cantor","highestDevelopmentStatusID":"12","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Infinity Announces Pricing of $80 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,370.0 million","upfrontCash":"$70.0 million","newsHeadline":"Molecular Templates Inks Collaboration With Bristol Myers Squibb to Discover and Develop Next Generation Engineered Toxin Bodies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Molecular Templates","amount2":1.3700000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3700000000000001,"dosageForm":"","sponsorNew":"Molecular Templates \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Oragenics","sponsor":"A.G.P.\/Alliance Global Partners","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Oragenics \/ A.G.P.\/Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$20.0 million","newsHeadline":"Antibe Therapeutics Announces Strategic Licensing Deal in China with Nuance Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"UOFG Announces Research Collaboration with Lilly to Discover Potential New Drug Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"University of Glasgow","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"University of Glasgow \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Biomunex Pharmaceutical","sponsor":"Onward Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Onward Therapeutics and Biomunex Ink Worldwide Exclusive License and Co-development Deal to a Bispecific Antibody for Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Bispecific antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomunex Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomunex Pharmaceutical \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biomunex P.."},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Funding","leadProduct":"Neuregulin-4-based therapy","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avexegen Therapeutics \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen T.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Cetirizine","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"ophthalmic solution","sponsorNew":"Nicox SA \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Enters a Loan Agreement of up to \u20ac25 Million with the European Investment Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Tedopi","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"1","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke Department of Medicine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aker BioMarine Enters Into Research Collaboration for Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Universit\u00e9 de Sherbrooke Department of Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Universit\u00e9 de Sherbrooke Department of Medicine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Universit\u00e9.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"$775.0 million","upfrontCash":"$15.0 million","newsHeadline":"Cytovia Therapeutics and Cellectis Partner to Develop TALEN\u00ae Gene-Edited iPSC-Derived Natural Killer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"CYT-150","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0.78000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"Cellectis \/ Cytovia","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$18.0 million","newsHeadline":"Almirall and MC2 Therapeutics Ink Collaboration for European Rights to Wynzora\u00ae Cream for Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces $75 Million Financing with Highbridge Capital Management","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Financing","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Highbridge Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$23.7 million","upfrontCash":"Undisclosed","newsHeadline":"Gt Biopharma Announces Closing of $23.7 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"GTB-3550 TriKE","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"GT Biopharma \/ Roth Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"EmpathBio","sponsor":"Bionomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Joint Feasibility Assessment of Bionomics' BNC210 and EmpathBio's MDMA Derivative EMP-01 Treatment Regimen for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"EmpathBio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"EmpathBio \/ Bionomics","highestDevelopmentStatusID":"4","companyTruncated":"EmpathBio .."},{"orgOrder":0,"company":"Merck Group","sponsor":"4D Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"4D Pharma Inks Clinical Trial Collaboration with Merck KGA & Pfizer to Evaluate MRx05IN in Combo with Bavencio to Treat Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck Group \/ 4D pharma","highestDevelopmentStatusID":"4","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Hangzhou Chance Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aerami The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Arch Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Oncology to Collaborate with Merck on Phase 1\/2 Trial of AO-176 in Combination with KEYTRUDA\u00ae in Patients with Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"AO-176","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Arch Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Softigel Procaps","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Engages Procaps for Development and Production of CannAmide\u2122 and its SCI-110 Product Candidate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Softigel Procaps","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Softigel Procaps \/ SciSparc","highestDevelopmentStatusID":"8","companyTruncated":"Softigel P.."},{"orgOrder":0,"company":"MindShift Compounds","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MindShift Compounds","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindShift Compounds \/ MindMed","highestDevelopmentStatusID":"4","companyTruncated":"MindShift .."},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Niclosamide","moa":"SARS-CoV-2 spike protein 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PPD","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"immediate-release Capsule","sponsorNew":"PPD \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"PPD \/ Azur.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Deuterated D-serine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for oral solution","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's CanSino Says Gets Green Light to Continue Phase III Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Application for Zeposia for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. FDA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints of its Phase 3 ENSEMBLE Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor\u2019s GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GT20029","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA in Certain Patients With Relapsed or Refractory Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Restart of Pediatric Galactosemia Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AT-007","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of ARQ-151 in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix's CEO to Present Update on COVI-VAC During New York Academy of Sciences Event, \"Quest for a COVID-19 Vaccine\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"COVI-VAC","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Therapeutic Efficacy of StemVacs Derived Exosomes in Regression of Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"StemVacs Derived Exosomes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its JT-09 Proneura\u00ae Development Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"JT-09","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Titan Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From Phase II study ATTRACT in Patients with COVID-19 Published Online: Vicore Pharma Holding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"C21","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in a Peer Reviewd Journal Provides Human Data Confirming Potential of Inflammasome's Proprietary Compounds for AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Kamuvudines","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inflammaso.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of Regeneron REGN-COV2 Antibody Combination (Casirivimab \/ Imdevimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AbCellera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Treatment with Lilly's LY-CoV555 and LY-CoV016 Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ AbCellera Biologics","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"ATL Cell growth","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz\u00ae Therapeutic Activity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"HGF-1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT \u201cThe Spirit Molecule\u201d","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Indication BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Indication BioScience","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indication BioScience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indication.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Seeks Thai Approval for COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Reports U.S. FDA Approval of POSIMIR\u00ae For Post-Surgical Pain Reduction for up to 72 Hrs After Arthroscopic Subacromial Decompression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Th.."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GEM103","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine AstraZeneca Confirms 100% Protection Against Severe Disease, Hospitalisation and Death","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Sogroya Moves Closer Towards EU Approval","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives Approval in the UK for Xarelto to Treat Children With Venous Thromboembolism (VTE) and to Prevent VTE Recurrence","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Study Shows Hyaluronan is Effective in Treating Chronic Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"AIIMS","sponsor":"CSIR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIIMS Researchers Find Ayurvedic-Allopathic Combo BGR-34 & Glibenclamide in Controlling Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BGR-34","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AIIMS","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AIIMS \/ CSIR","highestDevelopmentStatusID":"12","companyTruncated":"AIIMS \/ CS.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"United Biomedical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXX Announces Initiation of Phase 2 Clinical Trials in Taiwan of UB-612 Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ United Biomedical","highestDevelopmentStatusID":"9","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford Coronavirus Vaccine Shows Sustained Protection of 76% During the 3-month Interval Until the Second Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Reports Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared Otezla","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s is Pleased to Share that Sputnik V Showed Strong Efficacy, Immunogenicity and Safety Results in the Interim Phase-3 Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gamaleya Research Institute","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA alpha-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended release","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of ADVA-27A in Canada until 2033","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GEM-difluorinated C-glycoside derivative of Podophyllotoxin","moa":"Topoisomerase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Receives Rare Pediatric Disease Designation from U.S. FDA for CHK-336 for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CHK-336","moa":"LDH-A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-001","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group plc - Chronocort\u00ae Phase 3 and Safety Extension Study Results Published in JCEM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Provides Update On NBIb-1817 (VY-AADC) Gene Therapy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"NeurMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"17\u03b1-ethynyl-androst-5-ene-3,7,17-triol","moa":"Mapk3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeurMedix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix .."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Update on Cell Therapy Product Development and 2021 Milestones","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences\u2019 Simufilam Improves Cognition and Behavior in Alzheimer\u2019s Disease in Interim Analysis of Open-label Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dihydrohonokiol-B","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pressurized metered dose inhaler","sponsorNew":"Verona Pharma \/ Iqvia","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Suramin","moa":"P2Y2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Exonate","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exonate Announces the Initiation of Phase Ib\/II Clinical Trial for Diabetic Macular Oedema, As Part of its Collaboration with Janssen","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Exonate","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Exonate \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exonate \/ .."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Scripps Research","sponsor":"IAVI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First-in-Human Clinical Trial Confirms Novel HIV Vaccine Approach Developed by IAVI and Scripps Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AS01B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Heart Failure Drug Forxiga Now Approved in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive P2 Results for Reistone's JAK Inhibitor Demonstrate Significant Improvement in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SHR0302","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reistone Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone B.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CV8102","moa":"TLR7\/8\/RIG-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Completes Enrollment in Pivotal P2 Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Camidanlumab tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CPI-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Reports Positive Phase 1 Results for Exo Il-12\u2122 Confirming Local Pharmacology for Trial in Cutaneous T Cell Lymphoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"exoIL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies\u2019 Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment Of Sortilin-Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel to Present an Update from its Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Initiates Expanded Access Protocol for Oxbryta\u00ae (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"Hemoglobin subunit alpha","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual WORLDSymposium\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing\u2019s Disease (CRN04894) Advances into P1 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CRN04894","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Urology Focus Has Accepted a Scientific Article Describing LIDDS Phase IIb Study Results with Liproca\u00ae Depot","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Confirms U.S. Patent Term Extension for Ibrance\u00ae (Palbociclib) until March 2027","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics\u2019 SARS CoV-2 Vaccine Shows >25 Fold Higher T Cell Responses Than Benchmark Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ELI-005","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 \u2013 December 31, 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral drop","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"SPR720","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Initiates Phase 2\/3 Study of Inhaled ZYESAMI\u2122 for Severe COVID-19 with UCI Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"National Immunisation Schedule Evaluation Consortium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World's First COVID-19 Vaccine Alternating Dose Study Launches in UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Immunisation Schedule Evaluation Consortium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Immunisation Schedule Evaluation Consortium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National I.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"iNKT cell therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces FDA Accelerated Approval of UKONIQ\u2122 (Umbralisib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TG Therapeutics \/ Rhizen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized anti-CD117 monoclonal antibody","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Libtayo as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab-rwlc","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Provides Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab as 1st-line treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics to Host Call to Review Results from its Study of Translarna in Nonsense Mutation Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 inactivated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives FDA Breakthrough Therapy Designations for Investigational STAMP Inhibitor Asciminib (ABL001) in Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Orelabrutinib in Combination with R-CHOP as First-Line Therapy for Mantle Cell Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present at Medical Dermatology Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-tumoral","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Oragenics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CoV-2 S-2P","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoldenBiotech\u2019s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"RAS","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"IM156","moa":"Protein Complex 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"ImmunoMet","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoMet .."},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Galapagos \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and Seagen Submit BLA for Tisotumab Vedotin to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ S.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"GRB2 adaptor protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford University Extends COVID-19 Vaccine Study to Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"University.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STADA Launches Novel Parkinson\u2019s Therapy in Germany and Austria","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Showing Clinically Significant Responses Across All Endpoints","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's SPRAVATO Authorised in Europe for Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in Plato\u00ae Gene Therapy Platform Phase 2 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Reports 1st Patient Dosed in Phase III Pivotal Trial of IBI310 Combined with TYVYT for First-line Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears IND Application for Passage Bio\u2019s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PBKR03","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Breast Cancer Treatment Approved in Scotland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bisindole","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Reports Initial Phase 2b\/3 Study Results of ZYESAMI in Patients with Respiratory Failure due to Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Submits NDA to Manufacture and Market Darvadstrocel In Japan for Complex Perianal Fistulas in Adult Patients with Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Darvadstrocel","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Presents Results of Phase 3 Study of Omidubicel in Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Therapeutics Begins Second Phase 2 \u201cSTORM\u201d Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MED\u2122 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"T19","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/.."},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Provides Update on Vascepa\u00ae (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Edding","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ E.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Tavaborole Topical Solution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical solution","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib for Relapsed or Refractory Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CA-4948","moa":"IRAK4 kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol\u00ae Cyclo\u2122, at WORLDSymposium 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Evolve Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolve Biologics\u00ae Completes Phase III Adult and Pediatric Trials for Plasmacap\u2122 Ig (Intravenous Immunoglobulin)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Evolve Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evolve Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolve Bio.."},{"orgOrder":0,"company":"UCLA Jonsson Comprehensive Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination \u201cBreakthrough\u201d Gives Longest-Ever Survival in Patients with Nonresectable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UCLA Jonsson Comprehensive Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"UCLA Jonsson Comprehensive Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCLA Jonss.."},{"orgOrder":0,"company":"Taiga Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiga Treats First Cancer Patient in TBX-3400-003 Clinical Trial in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"TBX-3400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Taiga Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Taiga Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiga Biot.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis to Host Investor Briefing to Discuss Data Presented at the ASCO's 2021 Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Results from Phase 3 ACIS Study for Prostate Cancer Patients Treated with Apalutamide and Abiraterone Acetate Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Advances Lacutamab Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Commenced Dosing with its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accure Therapeutics Publishes Pivotal Preclinical Efficacy Study in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"IPR-179","moa":"MMP","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Accure Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Accure The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's BOTOX\u00ae (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP25","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Clindamycin Phosphate Gel USP, 1%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives Both Rare Pediatric Disease and Orphan Drug Designations for the Treatment of Krabbe Disease With PLX-300","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PLX-300","moa":"TFEB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ONM-501","moa":"STING protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoNano Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variants","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GEM103","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem\u00ae Female Infertility\/Ovarian Failure Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"OvaStem","moa":"T Cell","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Provides Update on Current Clinical Trial: Decision to Hold Administration of SBP-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Peripheral Arterial Disease in Patients with End-stage Kidney Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for JR-141 for the Treatment of Mucopolysaccharidosis Type II (Hunter Syndrome)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"JR-141","moa":"Transferrin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals Receives FDA IND Clearance to Initiate Global P3 Trial of JR-141 for Mucopolysaccharidosis Type II (Hunter Syndrome)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"JR-141","moa":"Transferrin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b\/3 COVID-19 Study Protocol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"VO659","moa":"RNA","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vico Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vico Thera.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports +Ve Topline Results from P2 Study FIDES-01 for Derazantinib in FGFR2 Gene Fusion +ve Patients with Bile Duct Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus\u2019 AT-GAA Shows Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cipaglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for Autosomal Dominant PKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RGLS4326","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Announces First Patient Dosed In Its Atopic Dermatitis Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BEN-2293","moa":"Trk","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical ointment","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tocilizumab Cuts Death Rate in Severe COVID-19, Study Finds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Regeneron's First-in-Class Evkeeza\u2122 (evinacumab-Dgnb) for Patients with Ultra-Rare Inherited Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune\u2019s Alzheimer\u2019s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b\/2a Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Maribavir","moa":"BGLF4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Receives FDA Clearance of Investigational New Drug Application to Initiate the Gene Therapy Clinical Trial in the US with LYS-GM101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh.10 expressing beta-galactosidase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Faricimab Is the First Investigational Injectable Eye Drug to Extend Time Between Treatments up to Four Months","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 17th Annual WORLDSymposium\u2122 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"M011","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therap.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Presents Data from Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Phar.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Libtayo Data Showing Extended Overall Survival in Advanced Non-small Cell Lung Cancer with PD-L1 Expression of \u226550%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab-rwlc","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Derazantinib\/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding part of FIDES-02 Study in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Receives EC Approval of Ogluo\u2122 for Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucagon","moa":"Glucagon receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of mRNA COVID-19 Vaccine by Moderna Biotech Spain, S.L","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single Injection of Mesoblasts' Rexlemestrocel-L + Hyaluronic Acid Carrier Lowers Pain for at Least 2 Years in Degenerative Disc Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Initiates PHYOX\u21224 Trial of Nedosiran for Primary Hyperoxaluria Type 3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010\/LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics to Present New Data for Rezafungin AND Influenza AVCS at the 21 St ICHS Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Announce Submission of Two sBLAs to the U.S. FDA for PADCEV\u00aein Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Semaglutide Injection Effective in Weight Loss Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNB Vesper Completes Phase 2 of Clinical Trials of GPP-Baladol on COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GPP-Baladol","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PNB Vesper \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces FDA Orphan Drug Designation Granted to Iadademstat for Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Reports Positive Three-Month Data from Phase 1\/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"EU101","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eutilex Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eutilex Inc \/ Samsung Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Eutilex In.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves Seagen\u2019s TUKYSA\u00ae for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics to Host Key Opinion Leader Event to Highlight BXCL501 as a Treatment for Agitation and Opioid Withdrawal Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Orally dissolving thin film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Four Potential COVID-19 Therapeutics Enter Phase 2\/3 Testing in NIH ACTIV-2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"National I.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Reports New Positive Phase 1\/2 Interim Data on Abeona\u2019s ABO-102 Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"scAAV9.U1a.hSGSH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real-World Setting Study Shows Velphoro Effective in CKD-HP Management","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"SunTrap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"LeSoleil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SunTrap","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SunTrap \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SunTrap \/ .."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Receives EC Approval for the First High Concentration, Low-Volume and Citrate-Free Biosimilar Adalimumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck's KEYTRUDA Plus LENVIMA Shows Superior Progression-Free Survival Vs Sunitinib in Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Exelixis","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Highlights Positive Results for CABOMETYX in Metastatic Papillary Renal Cell Carcinoma in SWOG S1500\/PAPMET Study at ASCO GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ NIH","highestDevelopmentStatusID":"8","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Rescindo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Rescindo\u2019s Treatment for Kabuki Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RSC-57","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Rescindo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rescindo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rescindo T.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Authorized to Launch HEART for TOTUM-070 to treat High Blood LDL-Cholesterol Levels","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Orvacabtagene autoleucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Presents Positive Cholangiocarcinoma Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theramex Launches Livogiva\u00ae, a New Teriparatide Pre-Filled Pen for the Treatment of Severe Osteoporosis London","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Libmeldy","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gesynta Pharma Initiates Phase II study Of Its First-in-Class Drug Candidate GS248 in Patients with Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"GS-248","moa":"mPGES-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"Gesynta Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Ph.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz\u00ae Regenerative Immunotherapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureGenetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Cure Genetics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cure Genetics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Cure Genet.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ALS-4","moa":"Staphyloxathin synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Wistar Institute \/ Jubilant Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"$60.0 million","newsHeadline":"Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Seltorexant","moa":"Selective orexin-2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0.16,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Erdal","sponsor":"ActoPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erdal Can Alkoclar to Renew Antiviral License for ActoPharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Flavonol glycoside analouges","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Erdal","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erdal \/ ActoPharma","highestDevelopmentStatusID":"1","companyTruncated":"Erdal \/ Ac.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Darigabat","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"PH Precision Med","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"PH Precision Med","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"PH Precision Med \/ Tenax Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PH Precisi.."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces the Publication of Preclinical Data on NurOwn\u00ae Derived Exosome-Based Treatment for COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intratracheal","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Dosed First Patient in Phase 1 Clinical Trial Evaluating FT-7051 Metastatic Castration-resistant Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"FT-7051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Announces Completion of Recruitment Into its Phase II Home-Based COVID-19 Study of Inhaled Interferon Beta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"University of Cambridge","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gene Therapy Study for Monogenic Blindness Fails to Meet Endpoint","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"University of Cambridge","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"University of Cambridge \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Tenalisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Enrolls First Patient in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$76.5 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pulmatrix Announces Closing of $40 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Itraconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"dry powder for inhalation","sponsorNew":"Pulmatrix \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Lumira Ventures","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Lumira Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Announces Closing of US$4.5 Million Private Placement","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Biomunex Pharmaceutical","sponsor":"Onward Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Bispecific Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"BMX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomunex Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomunex Pharmaceutical \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biomunex P.."},{"orgOrder":0,"company":"Fiona Stanley Hospital","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1\/2 Clinical Trial of RECCE\u00ae 327 on Chronic Burn Wounds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Recce 327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fiona Stanley Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical spray","sponsorNew":"Fiona Stanley Hospital \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fiona Stan.."},{"orgOrder":0,"company":"Athersys","sponsor":"Healios K.K","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athersys Announces Cooperation Agreement With HEALIOS K.K.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"MultiStem","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ HEALIOS","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kadmon Announces Closing of $240 Million Convertible Senior Notes Offering Including Full Exercise of $40 Million Over-Allotment Option","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.23999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ C.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Awards Up to $2.17 Million to Beyond Air\u00ae to Develop Portable NTM Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Funding","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"inhalation","sponsorNew":"Beyond Air \/ CF Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"$125.0 million","newsHeadline":"Lilly and Rigel Enter Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"R552","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0.95999999999999996,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.95999999999999996,"dosageForm":"Oral","sponsorNew":"Rigel Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"BITT","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$125.6 million","upfrontCash":"Undisclosed","newsHeadline":"Boston Immune Technologies and Therapeutics and BeiGene Enter into an Option and License Agreement to Develop Novel TNFR2 Antagonists","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"BITR2101","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"BITT \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Bei.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$845.0 million","upfrontCash":"$225.0 million","newsHeadline":"GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0.84999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis and the Gates Foundation Collaborate to Discover and Develop an Accessible in Vivo Gene Therapy for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Braavos Investment Advisers","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech Raises $32.5M in Series A Funding and Appoints Lutz B. Giebel as Chairman","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SpyBiotech","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"SpyBiotech \/ Braavos Investment Advisers","highestDevelopmentStatusID":"4","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Acquires Unique Psilocybin Assets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"MAO","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"PharmaTher \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"PPD","sponsor":"US Army","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PPD Awarded US Army Study to Help Develop Post-Traumatic Stress Disorder Drugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"PPD","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PPD \/ US Army","highestDevelopmentStatusID":"1","companyTruncated":"PPD \/ US A.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"Undisclosed","newsHeadline":"Infinity Announces Closing of $92 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Piper Sandler & Co","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"$10.0 million","newsHeadline":"SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vyera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Vyera Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Vyera Phar.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"neoX Biotech","sponsor":"Sky9 Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"neoX Biotech closes US$30 million Series A round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"neoX Biotech","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"neoX Biotech \/ Sky9 Capital","highestDevelopmentStatusID":"3","companyTruncated":"neoX Biote.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nektar Announces Agreement for Phase 2\/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Merck & Co \/ Nektar Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$75.9 million","upfrontCash":"Undisclosed","newsHeadline":"Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"MT-3724","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Molecular Templates","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$23.5 million","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Proposed Capital Raising by Way of a Placing of New Ordinary Shares and Provides Update on Early Launch of BARHEMSYS\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Acacia Pharma \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals for Newly-Approved LUPKYNIS\u2122 Softgels","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Towa Pharmaceutical Enter Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Physiomics","sponsor":"ValiRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValiRx plc Extension of Collaboration Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"VAL201","moa":"Androgen activated SRC kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Physiomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Physiomics \/ ValiRx","highestDevelopmentStatusID":"7","companyTruncated":"Physiomics.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Secures a Total of $73 Million in Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"AMP CpG","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"LYFE Capital","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Secures US$37 Million Series B Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"XW003","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ LYFE Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"HEC Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HEC Group \/ Lannett","highestDevelopmentStatusID":"1","companyTruncated":"HEC Group .."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ayala Pharmaceuticals Announces $25 Million Strategic Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Financing","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Dalton Pharma Services","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dalton Pharma Services \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dalton Pha.."},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$27.0 million","newsHeadline":"KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genexine","amount2":1.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ KGBio","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alexion Pharmaceuticals \/ Arcturus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Minaris","sponsor":"MaxiVAX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing\nPartnership for MVX-ONCO-2 Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"MVX-ONCO-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Minaris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Minaris \/ MaxiVAX","highestDevelopmentStatusID":"8","companyTruncated":"Minaris \/ .."},{"orgOrder":0,"company":"Halix BV","sponsor":"NovalGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noval Gen Enters Strategic Partnership with Halix B.V. to Manufacture Clinical Trial Materials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"NVG-111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Halix BV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Halix BV \/ NovalGen","highestDevelopmentStatusID":"6","companyTruncated":"Halix BV \/.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma, Athena Bioscience Enter Exclusive License Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tris Pharma Inc \/ Athena Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies and Piper Sandler","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"Anti-androgens therapy","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Jefferies and Piper Sandler","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Compugen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Compugen","highestDevelopmentStatusID":"6","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Orexia Therapeutics","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Spin-Off Company Orexia Therapeutics Merged Into Newly Created Centessa Pharmaceuticals","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Orexia Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orexia Therapeutics \/ Centessa","highestDevelopmentStatusID":"4","companyTruncated":"Orexia The.."},{"orgOrder":0,"company":"Ciitizen","sponsor":"Praxis Precision Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"PRAX-562","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ciitizen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ciitizen \/ Praxis Precision Medicines","highestDevelopmentStatusID":"6","companyTruncated":"Ciitizen \/.."},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Cend Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"CEND-1","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qilu Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Qilu Pharmaceutical \/ Cend Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Qilu Pharm.."},{"orgOrder":0,"company":"Bial","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix\u00ae Expanding Neurology Footprint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Termination","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Eis.."},{"orgOrder":0,"company":"EMERCell","sponsor":"Onward Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EMERCell Signs Strategic Partnership with Onward Therapeutics for the Development of its NK Cell Therapy Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Bispecific antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EMERCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EMERCell \/ Onward Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EMERCell \/.."},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma Transfers TriKE\u2122 Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"GTB-3550 TriKE","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance .."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Huadong Pharmaceutical","pharmaFlowCategory":"D","amount":"$293.0 million","upfrontCash":"$6.0 million","newsHeadline":"Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"PRV-3279","moa":"CD32B","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Provention Bio","amount2":0.28999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Provention Bio \/ Huadong","highestDevelopmentStatusID":"6","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pimasertib","moa":"MEK 1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Merck Group \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National C.."},{"orgOrder":0,"company":"The Israeli Medical Center for Alzheimer's","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"The Israeli Medical Center for Alzheimer's","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Israeli Medical Center for Alzheimer's \/ SciSparc","highestDevelopmentStatusID":"8","companyTruncated":"The Israel.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teon Therapeutics Completes $30 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Beijing Tide Pharmaceutical","sponsor":"Graviton","pharmaFlowCategory":"D","amount":"$517.5 million","upfrontCash":"Undisclosed","newsHeadline":"Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TDI01","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Beijing Tide Pharmaceutical","amount2":0.52000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Beijing Tide Pharmaceutical \/ Graviton","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Ti.."},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$17.6 million","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Private Placement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Predictive Oncology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Predictive.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,850.0 million","upfrontCash":"$1,850.0 million","newsHeadline":"Merck to Acquire Pandion Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"IL-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.8500000000000001,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Merger","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"XTX202","moa":"Tumor-selective IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Rock Springs Capital","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Logos Capital","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline\nof Precision Oncology and Immunology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Kepa1-Nrf2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Vividion Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Vividion Therapeutics \/ Logos Capital","highestDevelopmentStatusID":"2","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"YishengBio","sponsor":"Oceanpine","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"YSJA rabies vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"YishengBio","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"YishengBio \/ Oceanpine","highestDevelopmentStatusID":"12","companyTruncated":"YishengBio.."},{"orgOrder":0,"company":"Cullgen","sponsor":"3E Bioventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"CG001419","moa":"TRK protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cullgen \/ 3E Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ .."},{"orgOrder":0,"company":"Lysarc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed\/Refractory B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lysarc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Lysarc \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"Lysarc \/ D.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Cybrexa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Cybrexa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"Cyprium Therapeutics and Sentynl Therapeutics Sign Development and Asset Purchase Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Th.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$50.0 million","newsHeadline":"Puma Biotechnology and Pierre Fabre Amend NERLYNX\u00ae License Agreement to Include Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Cellarity","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$123.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cellarity","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Cellarity \/ BlackRock","highestDevelopmentStatusID":"2","companyTruncated":"Cellarity .."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artiva Raises $120M in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Canbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate Nerlynx\u00ae License Agreement AND Settle Arbitration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Termination","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Canbridge Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"HT-KIT","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"LISCure Biosciences Successfully Raises $21 million in Series B Funding","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"LB-P8","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and Takeda Finalize License Agreement for Novavax\u2019 COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1\/2 Trial in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sybleu","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Pharma Signs Licensing Deal with Sybleu to market a Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AQ4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sybleu","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sybleu \/ Oncology Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Sybleu \/ O.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":1.25,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"XNK Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XNK Therapeutics Partners with Karolinska Institutet on Phase II Study in Patients with Multiple Myeloma with Support from Sanofi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous NK cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Karolinska Institutet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Karolinska Institutet \/ XNK Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Pharmidea","sponsor":"Lidds","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lidds and Pharmidea Signs Manufacturing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"NZ-TLR9","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pharmidea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pharmidea \/ LIDDS","highestDevelopmentStatusID":"4","companyTruncated":"Pharmidea .."},{"orgOrder":0,"company":"PureForm","sponsor":"Enveric","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PureForm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureForm \/ Enveric","highestDevelopmentStatusID":"4","companyTruncated":"PureForm \/.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nektar Announces Collaboration with SFJ Pharmaceuticals\u00ae for Bempegaldesleukin in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"intravenous infusion","sponsorNew":"Nektar Therapeutics \/ SFJ","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Microbion","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"Microbion Corporation Receives Additional Funding Support from the Cystic Fibrosis Foundation to Speed Advancement of Inhaled Pravibismane","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Funding","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"inhalation","sponsorNew":"Microbion \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Research Bridge Partners","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Financing","leadProduct":"Salicylic Acid","moa":"COX-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asalyxa Bio \/ Research Bridge Partners","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bi.."},{"orgOrder":0,"company":"Merus","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,660.0 million","upfrontCash":"$40.0 million","newsHeadline":"Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Bispecific antibody therapies","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Merus","amount2":1.6599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6599999999999999,"dosageForm":"","sponsorNew":"Merus \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Merus \/ El.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 trial Evaluating Bamlanivimab (LY-CoV555) With VIR-7831","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imcyse Enters into Research Collaboration and License Agreement for its Imotope\u2122 Technology with Pfizer in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Imcyse","amount2":0.17999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"injection","sponsorNew":"Imcyse \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Imcyse \/ P.."},{"orgOrder":0,"company":"Kymab","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,450.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"OX40L","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":1.45,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.45,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kymab \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ Sa.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Starts Phase III RSV Candidate Vaccine Programme for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AS01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGA Provisionally Approves AstraZeneca's COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20 for the Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo and AstraZeneca ENHERTU\u00ae Authorised in the UK for the Treatment of Her2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Viventia Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Viventia Bio","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"InteRNA Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Te.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Alfred E Tiefenbacher GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Posaconazole Delayed-Release Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed release tablet","sponsorNew":"Lupin Ltd \/ AET Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird bio Announces Temporary Suspension on Phase 1\/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"HGB-206","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Entresto\u00ae Granted Expanded Indication in Chronic Heart Failure by FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOBI's Kineret\u00ae (anakinra) Approved in Russia for the Treatment of CAPS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Cytocom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opoid mu\/kappa\/delta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cytocom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ .."},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Signature Cord Prime\u2122 Receives IND Approval from FDA for Phase 1 Study in Patients with Symptomatic Osteoarthritis of the Knee.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Micronized umbilical cord tissue","moa":"Cell growth","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Signature Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Signature Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Signature .."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharma's in-Vivo Study Concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Drug Candidate for Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CNM-ZnAg","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forge Biologics Gets FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Krabbe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"FBX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Forge Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Commence Global Clinical Trial to Evaluate Covid-19 Vaccine in Pregnant Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BIONTECH","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm's Avigan Shows No Significant Benefit on Covid-19 Mortality: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Approves the Start of the Phase III NEPTUNO Trial with PharmaMar's Aplidin\u00ae (Plitidepsin) for the Treatment of Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"VEGF\/VEGFR-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Initiates Pivotal Phase 2 Magnetismm-3 Trial of Bcma-Cd3 Bispecific Antibody Elranatamab (pf-06863135) in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tirzepatide Significantly Reduced A1C and body Weight in People with Type 2 Diabetes in Two Phase 3 Trials From Lilly's SURPASS Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NICHD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Funds Study to Evaluate Remdesivir for Covid-19 in Pregnancy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ NICHD","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Reports Start of the Second Stage of the FITE19 Phase 2\/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Emvododstat","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World\u2019s First Covid-19 Human Challenge Study Call for Volunteers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data from PSOARING 3 Support Long-Term Use of Tapinarof Cream in Adults with Plaque Psoriasis, with Durable and Remittive Benefits","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study of Prostate Cancer-Specific Therapeutic Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"TENDU vaccine","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of IBDs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-003","moa":"TLR2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"AskBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR\u2122 in Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"SEL-399","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Askbio","highestDevelopmentStatusID":"6","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Recurrent GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Humantakinogene hadenovec","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Efanesoctocog Alfa Granted FDA Fast Track Designation for treatment of hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Efanesoctocog alfa","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Bioverativ","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ B.."},{"orgOrder":0,"company":"Inspyr Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inspyr Therapeutics Further Strengthens Global Intellectual Property","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"RT-AR001","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inspyr Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Inspyr Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inspyr The.."},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thailand\u2019s Second Locally-Made Vaccine Set to Enter Human Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"THAILAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChulaCov19 mRNA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Chulalongkorn University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chulalongkorn University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chulalongk.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"ICON Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ ICON Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Ingenew Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma's Hesperco\u2122 Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hesperidin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valeo Pharma \/ Ingenew Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Shows Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Mutant Strain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Show Multiple Sclerosis Patients and Nurses Prefer Kesimpta\u00ae (ofatumumab) Sensoready\u00ae Autoinjector Pen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"IDMC","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDMC Concludes that OlympiA Trial of Lynparza Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"IDMC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IDMC \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"IDMC \/ Ast.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"SLN360","moa":"Lipoprotein","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Medpace","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"National Pediatric Cancer Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Completes Dose-Escalation Stage of Phase 1\/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ National Pediatric Cancer Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NDMA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces FDA Clearance of AdCOVID\u2122 IND Application","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psychobiotic PS128 Consumption Shows Benefits to Parkinson's Symptoms in New Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bened Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bened Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bened Biom.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"FAP-Activated Doxorubicin prodrug","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Droxidopa Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Labs Gets USFDA Approval for Apremilast Tablets","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces Submission to WHO for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Faricimab, 1st Injectable Eye Medicine to Extend Time Between Treatments up To 4 Months in Two Leading Causes of Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Reports Topline Results from Two Phase 3 Pivotal Global Trials of Fezolinetant for Vasomotor Symptoms in Postmenopausal Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL-C","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore\u2019s Tebentafusp Granted Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets USFDA Nod for Generic Droxidopa Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perception Neuroscience's PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Perception Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Perception.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Activated allogeneic dendritic cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces High-Level FDA Feedback on NurOwn\u00ae ALS Clinical Development Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX\u00ae in Patients with M\u00e9ni\u00e8re's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Chumakov Centre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Approves Its Third Covid-19 Vaccine, COVIVAC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CoviVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chumakov Centre","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Chumakov Centre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chumakov C.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHLW Grants Orphan Drug Designation in Japan to Eisai's Novel Fgf Receptor Selective Tyrosine Kinase Inhibitor E7090","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"E7090","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark\u2019s Ryaltris\u00ae- Innovative Single Nasal Spray Ready to Market in Russia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Positive Data from Can-Fite\u2019s Liver Cancer Phase II Clinical Study with Namodenoson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Continued Survival Benefit in Targovax\u2019s ONCOS-102 Trial in Mesothelioma at the 21-Month Follow-Up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The BCMA CAR-T Co-developed by Innovent and IASO was Granted Breakthrough Therapy Designation by the NMPA for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI326","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ IASO","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Submits Supplemental New Drug Application for Otezla\u00ae (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2nd Phase 3 Induction Study Confirms AbbVie's Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Descartes-11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Completes Patients' Recruitment for Proxalutamide's COVID-19 Hospitalised Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Presents Preclinical Data on Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kochi Firm PNB Vesper Life Completes Phase 2 Clinical Trial of Covid Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GPP-Baladol","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PNB Vesper \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNI91103, Developed By UNION therapeutics A\/S, Selected as First Agent for Prophylactic Covid-19 \"protect-V\" Study in High-Risk Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"inhalation","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Provides Update on Ongoing Clinical Programs with Givinostat in Oral Presentation at XVIII International Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Givinostat","moa":"HDAC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Italfarmaco S.p.A","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Italfarmaco S.p.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Italfarmac.."},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"VP-001","moa":"PRPF31","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PYC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PYC Therap.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Approves Toripalimab in Patients with Recurrent\/Metastatic Nasopharyngeal Carcinoma Who Faild at Least Two Lines of Systemic Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zosano Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"MediWound","sponsor":"Soroka Medical Cente","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"MWPC005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Soroka Medical Cente","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amyris Reports Pre-Clinical Data For COVID-19 RNA Vaccine Platform With Advantaged Manufacturing, Storage And Distribution Characteristics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Amyris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amyris \/ Infectious Disease Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amyris \/ I.."},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yale-led Clinical Trial Offers Hope for COVID Patients and a Path Forward for Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Yale School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yale School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Yale Schoo.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tempol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Bristol Myers Squibb\u2019s Breyanzi (lisocabtagene maraleucel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynavax Announces European Commission Marketing Authorization for HEPLISAV B\u00ae, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hepatitis B Vaccine (Recombinant) Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Pharma Science Arm Gets American Drug Regulator's Nod for Pain Relieving Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Performs Phase I Studies for FDA Approval of Vibegron","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Altasciences Company Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altascienc.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Reports Preclinical Data on Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UPDATE 1-EU Drug Watchdog to Weigh in On Extended Use for Remdesivir by Summer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Gets Orphan Medicinal Product Designation for OCU400, to Treat Both Retinitis Pigmentosa and Leber Congenital Amaurosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monoclonal Antibodies Against MERS Coronavirus Show Promise in Phase 1 NIH-Sponsored Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"REGN3048","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial to File Fast Track Application for AD04 with the FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Pfizer\u2019s Application for Tico Vac\u2122 (TICK-Borne Encephalitis Vaccine)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Tick-Borne Encephalitis Virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of Celltrion Antibody Regdanvimab for Covid-19 Share","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South African Phase IIIb study of J&J\u2019s Single-Jab Covid-19 Vaccine Enrols 18,000 Participants in First Week","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thailand Approves Sinovac Vaccine Ahead of National Rollout","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Accepts the Application for Conditional Marketing Authorization of CanSinoBIO\u2019s COVID-19 Vaccine ConvideciaTM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Evaluating Use of Veklury in Covid-19 Patients Not Requiring Supplemental Oxygen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announces Approval of Acetaminophen, Aspirin and Caffeine Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets USFDA Nod for Antidepressant Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Nortriptyline","moa":"Sodium-dependent noradrenaline transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Reports that IDMC Found Clear Efficacy for REGEN-COV\u2122 (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUMIRA\u00ae (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data from PTC Therapeutics' FIREFISH Study of Evrysdi in Infants with Type 1 Spinal Muscular Atrophy Published in The NEJM","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Results from Bluebird Bio's Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva as an HIV Treatment for Use Every 2-Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verity Pharmaceuticals Reports that Bladder Cancer Drug Shortage Resolved with Health Canada Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin: Strain Russian BCG-I","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Verity Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pha.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib\u2019s Antiviral Activity Against New Variants of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Locus Biosciences Completes First-Of-Its-Kind Controlled Clinical Trial for CRISPR-Enhanced Bacteriophage Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Locus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Presents Promising Preclinical Findings on DB-OTO Designed to Provide Hearing to Individuals with Otoferlin Mutations","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech\u2019s Subsidiary, NV Hemispherx, Gets Orphan Medicinal Product Designation by the EMA for Ampligen to Treat Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera Submits Study Report of Pharmacokinetics Study to FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efficacy and Safety Data from Solid Biosciences\u2019 IGNITE DMD Phase I\/II Trial to be Presented at the MDA Clinical & Scientific Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Results Evaluating Its Investigational Monoclonal Antibody, Otilimab, for Hospitalised Adult Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Otilimab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After revealing its CD12 Trial Data for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Discontinues Development of SARS-CoV-2\/COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"MK-7110","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intavenous infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Oral Treatment for Spinal Muscular Atrophy (SMA) Developed by Genentech Recommended For EMA Approval","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Issues Advice on Use of REGN-COV2 Antibody Combination (Casirivimab \/ Imdevimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics\u2019 Promising Treatment for Covid-19 Enters Clinical Trials in Israeli Medical Centers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Angiotensin (1-7)","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Pfizer\u2019s Marketing Authorization Application for Its 20-valent Pneumococcal Conjugate Vaccine for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"20vPnC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives Positive CHMP Opinion for Cabometyx\u00ae in Combination With Opdivo\u00ae as First-line Treatment for Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Br.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives Approval for Generic Version of Ortho Evra\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Norelgestromin","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Transdermal patch","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity to Present at the 7th International Congress of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZyVersa Therapeutics' to Present at the 3rd Annual Chronic Kidney Disease Drug Development Summit Being Held Virtually March 2-4, 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"IC 100","moa":"ASC","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARPAC Clinical Trial of Leukine in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Sarclisa in Combination with Carfilzomib and Dexamethasone for Relapsed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Soft gel capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida Provides Update on FDA Interactions","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Request for EUA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences and Arbutus Biopharma Starts Phase 2 Clinical Trial of Triple Combination Therapy for Chronic Hepatitis B Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Beigene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces FDA Approval of AMONDYS 45\u2122 (casimersen) Injection for the Treatment of DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Casimersen","moa":"Exon 45","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emgality (Galcanezumab) Now Approved for Use in Canada for the Treatment of Episodic Cluster Headache","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boan Biotech Completes First Patient Dosing in Phase \u2162 Clinical Trial for LY09004, Multiple R&D Projects Under Intensive Development","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canagliflozin (TA-7284) has Been Approved in Taiwan For Diabetic Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Gains EU Label Update for First-Of-Its-Kind Maximise Data in Axial Manifestations of Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Receives Positive CHMP Opinion for ORLADEYO\u2122 Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD\u00ae-treated RMS Patients Mount Protective Antibody Response to Common Vaccines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"PT AIVITA Biomedika","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AV-COVID-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aivita Biomedical \/ PT AIVITA Biomedika","highestDevelopmentStatusID":"7","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Initiates Phase 2a Trial of BGE-117 in Elderly Patients with Unexplained Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BGE-117","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"R\u00e9nibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stero Biotechs Report Initial Results in the Exploratory Study it Supports of CBD-Based Treatment for Covid-19 Severe Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Stero Biotechs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"Stero Biotechs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stero Biot.."},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dociparstat sodium","moa":"HMGB1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant\u2122 (diazepam) Buccal Film Following FDA Feedback","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD\u2122 Phase 3 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Mirdametinib","moa":"MEK 1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"capsule","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA\u00ae for up to ~3.5 Years","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis hypogaea allergen powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral powder in capsules","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PAS-nomacopan","moa":"Leukotriene B4","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID\u2122 -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind's Investigational New Drug Approved for NASH Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"XW003","moa":"Glucagon secretion","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sciwind Biosciences \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Data from Octapharma's NuProtect Study Published in Immunogenicity of Nuwiq in Previously Untreated Critical Haemophilia A Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Simoctocog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Capecitabine Tablets, USP in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed-Release Orally Disintegrating Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Published Data from Phase 1\/2 Clinical Trial in Acquired Sensorineural Hearing Loss Patients Receiving FX-322","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Launches Epilepsy Treatment Drug Brivaracetam in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Human immune globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall U.S. Launches Klisyri\u00ae (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Updates on Phase 1\/2 Clinical Trials of Novavax\u2019 and Moderna\u2019s COVID-19 Vaccine Candidates in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-019","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Moderna","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm To Restart Clinical Trial of Avigan to Treat Covid-19: Media","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Clears Pfizer-BioNTech Coronavirus Vaccine for Emergency Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\/BioNTech Vaccine Appears Effective Against Mutation in New Coronavirus Variants -Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701 for the Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"UX701","moa":"ATP7B copper transport","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford\/AstraZeneca COVID Shot Less Effective Against South African Variant: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Tigermed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tigermed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/.."},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"JAG101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Gene Therapy \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gen.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's initiates process for Emergency Use Authorization of Sputnik V","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharma Launches Generic Sunitinib Oral Capsules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sunitinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmacosmos' Monoferric\u00ae (Ferric Derisomaltose) Injection is Approved by the US FDA for the Treatment of Iron Deficiency Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Derisomaltose","moa":"Iron","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Pharmacosmos AS","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmacosmos AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmacosm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Ligelizumab (QGE031) Receives FDA Breakthrough Therapy Designation for Patients with Chronic Spontaneous Urticaria (CSU)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Cevec","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec and Carisma Therapeutics Sign License Agreement for the Use of Cap\u00ae Technology in Anti-Tumor Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CAR-macrophage immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ Carisma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Ca.."},{"orgOrder":0,"company":"Camargo Pharmaceutical","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"HT-001","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Camargo Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Camargo Pharmaceutical \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Camargo Ph.."},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Eikonizo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The McQuade Center for Strategic Research and Development and Eikonizo Ink Deal to Develop Treatments for Patients with Rare Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"HDAC6","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Ce.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Receives FDA Approval for Restylane\u00ae Defyne for Chin Augmentation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Group Gets the European Marketing Authorisation for Trimbow","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pressurised metered dose inhaler","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$150.0 million","newsHeadline":"Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences\u2019 PD-1, toripalimab, in United States and Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus BioSciences","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apollomics and Iterion Announce Exclusive Collaboration and License Deal to Develop and Commercialize Tegavivint in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Apollomics","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Bamlanivimab (LY-CoV555) Administered with Etesevimab (LY-CoV016) Receives FDA Emergency use Authorization for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"FogPharma","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"FogPharma\u00ae Announces $107 Million Series C Financing to Advance Direct \u03b2-Catenin Antagonist and Universal Druggability\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series C Financing","leadProduct":"Helicon peptides-based therapeutics","moa":"Beta catenin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"FogPharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"FogPharma \/ venBio Partners","highestDevelopmentStatusID":"4","companyTruncated":"FogPharma .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Altaris Capital Partners","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"$1,500.0 million","newsHeadline":"Perrigo To Sell Generic Drugs Business for $1.55 Billion","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Divestment","leadProduct":"Adapalene","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":1.55,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":1.55,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Altaris Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"UC Berkeley","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"Undisclosed","newsHeadline":"Weill Neurohub Joins with Genentech, Roche to Advance Neuroscience Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"UC Berkeley","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"UC Berkeley \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"UC Berkele.."},{"orgOrder":0,"company":"MEDILINK PHARMACHEM","sponsor":"Apricot Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Antibody-drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MEDILINK PHARMACHEM","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"MEDILINK PHARMACHEM \/ Apricot Capital","highestDevelopmentStatusID":"4","companyTruncated":"MEDILINK P.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"$4.0 million","newsHeadline":"Kazia Licenses Cantrixil, a Clinical-Stage, First-in-Class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cantrixil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Kazia Therapeutics \/ Oasmia","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Evotec","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Chinook Therapeutics Enter Into Strategic Collaboration to Discover and Develop Novel Precision Medicines for CKD","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Chinook Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ C.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Harvard University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harvard University and Kyowa Kirin Enter Strategic Research Alliance","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ Harvard University","highestDevelopmentStatusID":"2","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"SalioGen Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Non-viral gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SalioGen Therapeutics","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"SalioGen Therapeutics \/ PBM Capital","highestDevelopmentStatusID":"4","companyTruncated":"SalioGen T.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$106.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series C Financing","leadProduct":"AAV-gene therapy","moa":"MYBPC3 Gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Tenaya Therapeutics","amount2":0.11,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Cipla","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Cipla \/ Alvotech","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Al.."},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Artizan Bioscience","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Artizan Bioscience \/ Hatteras Venture","highestDevelopmentStatusID":"4","companyTruncated":"Artizan Bi.."},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","amount":"$17.8 million","upfrontCash":"Undisclosed","newsHeadline":"Oscotec and Beactica Therapeutics Announce License and Collaboration Agreement to Develop New Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"LSD1 allosteric","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"CARISMA Therapeutics Completes Series B Financing Totaling $59 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"DTx Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Completes $100M Series B Financing to Advance its FALCON\u2122 Platform and Pipeline of RNA Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"RNA-based therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"DTx Pharma \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma.."},{"orgOrder":0,"company":"University College London","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"AS1411-GNP","moa":"Nucleolin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University College London","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"University College London \/ Qualigen","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Therapeutics and Scilex Holding Ink Agreement with Aardvark Therapeutics to Acquire Its ARD-301","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Aardvark Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aardvark T.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adverum Biotechnologies \/ LEXEO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinese Inflammatory Disease Biotech Connect Biopharma Files for a $100 Million US IPO","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"WestPark Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Biotech Transcode Therapeutics files for a $30 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"TTX-MC138","moa":"microRNA-10b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"injection","sponsorNew":"TransCode Therapeutics \/ WestPark Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","amount":"$4.1 million","upfrontCash":"Undisclosed","newsHeadline":"Lixte Biotechnology Announces $4.19 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starton Therapeutics and Haisco Pharmaceutical Ink Licensing Agreement to Develop & Commercialize STAR-OLZ for Nausea and Vomiting in China","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Olanzapine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"transdermal patch","sponsorNew":"Starton Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Collaborate with Merck and Maverick Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Presage Biosciences \/ LabCorp Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Presage Bi.."},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"MTK-458","moa":"PINK1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mitokinin \/ AbbVie","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin .."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Avalon GloboCare","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates using T Cell Engager (TRACTr) Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"TROP2-TRACTr based therapeutics","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Avalon Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Completes US$110\/A$138 Million Financing Led by US Strategic Investor Group","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0.11,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.11,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Statement on Collaboration with Merck","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Lygenesis","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Merger","leadProduct":"LYG-LIV0001","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lygenesis","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lygenesis \/ AgeX Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lygenesis .."},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicines","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ SERB","highestDevelopmentStatusID":"12","companyTruncated":"BTG Specia.."},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK and Teon Therapeutics Advance New First-in-Class Cancer Drug Into Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teon Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Teon Thera.."},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Private Placement","leadProduct":"MT-1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Navidea Biopharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Navidea Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Navidea Bi.."},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Beyond Batten Disease Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Miglustat","moa":"GCS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Beyond Batten Disease Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Actelion P.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"University of Kansas","sponsor":"PharmaTher","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"iGluRs","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kansas","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Kansas \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"LianBio","sponsor":"ReViral","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"$14.0 million","newsHeadline":"ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Sisunatovir","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"LianBio \/ ReViral","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Farallon Capital Management","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series C Financing","leadProduct":"CB-010","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Farallon Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Mabion SA","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mabion Announces Agreement with Novavax for Large-Scale Vaccine Manufacturing Feasibility Assessment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mabion SA \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA .."},{"orgOrder":0,"company":"Oxular","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxular Raises $37 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Oxular","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Sustained-release Suprachoroidal Injection","sponsorNew":"Oxular \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"Oxular \/ F.."},{"orgOrder":0,"company":"ConserV Bioscience","sponsor":"eTheRNA immunotherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ConserV Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ConserV Bioscience \/ eTheRNA","highestDevelopmentStatusID":"4","companyTruncated":"ConserV Bi.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":1.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"Intravenous infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amryt and Medison Pharma Sign Distribution Agreement for Myalepta\u00ae (metreleptin) in Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Metreleptin","moa":"Leptin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Injection","sponsorNew":"Medison Pharma \/ Amryt","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"$5.5 million","newsHeadline":"Cleave Therapeutics Licenses First-in-Class VCP\/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CB-5339 Tosylate","moa":"p97","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave The.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Iontas","sponsor":"Quellis Biosciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Engineered Treg cell therapy product","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ Quell","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ Q.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Pricing of Initial Public Offering ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1 Biotech Prometheus Biosciences Sets Terms for $125 Million IPO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.13,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"PsiVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsiVac and Lonza Enter a Strategic Agreement for the Process Development and cGMP Manufacturing of Ixovex-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Ixovex-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lonza Group \/ PsiVac","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Winhealth Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Winhealth Pharma and Merz Collaborate on Hepa-Merz\u00ae to benefit patients with liver disease in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"L-Ornithine L-aspartate","moa":"Ammonia detoxification","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"concentrate for solution for infusion","sponsorNew":"Merz Pharma \/ Winhealth Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharm.."},{"orgOrder":0,"company":"Wugen","sponsor":"Alpha Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Memory NK Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wugen \/ Alpha Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Wugen \/ Al.."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"TAK-186","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Maverick Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$121.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.12,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Biolojic Design \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic D.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"venBio","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"OPL-002","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Spray dried dispersion","sponsorNew":"Ventyx Biosciences \/ venBio","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baxter BioPharma Solutions and Moderna Announce Agreement for Fill\/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Baxter Healthcare Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baxter Healthcare Corporation \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Baxter Hea.."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Loyal Valley Capital","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Novitium Pharma LLC","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$372.5 million","upfrontCash":"$89.5 million","newsHeadline":"ANI Pharmaceuticals to Acquire Novitium Pharma, Strengthening R&D Engine and Expanding Generics and CDMO Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Aciclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novitium Pharma LLC","amount2":0.37,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.37,"dosageForm":"oral suspension","sponsorNew":"Novitium Pharma LLC \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novitium P.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grifols Reinforces Its Innovation Strategy After Completing the Acquisition of Gigagen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Grifols","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Evonik","sponsor":"Cassava Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik and Cassava Sciences Join Forces to Fight Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evonik \/ Cassava Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Evonik \/ C.."},{"orgOrder":0,"company":"Affinivax","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Receives CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS\u2122 Vaccine Candidate into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Staphylococcus aureus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Affinivax \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Jubilant Cadista Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jubilant HollisterStier, Eli Lilly Enter COVID-19 Treatment Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Jubilant Cadista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jubilant Cadista Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Jubilant C.."},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Peptide based-pan Coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmunoScape","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoScape \/ Valo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImmunoScap.."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"Undisclosed","newsHeadline":"AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"AGMB-101","moa":"MET","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"AgomAb Therapeutics N.V","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"AgomAb Therapeutics N.V \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"VBI-2905","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VBI Vaccines","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"VBI Vaccines \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Biodextris","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Enters Into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"BDX100","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biodextris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biodextris \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Biodextris.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Cowen and Piper Sandler","pharmaFlowCategory":"D","amount":"$56.2 million","upfrontCash":"Undisclosed","newsHeadline":"Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"intravenous infusion","sponsorNew":"Jounce Therapeutics \/ Cowen and Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Ezogabine","moa":"KCNQ","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"HighCape Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cybrexa Therapeutics Closes $25 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybrexa Therapeutics \/ HighCape Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Shanghai Haohai Biological Technology","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eirion Therapeutics Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Topical Liniment","sponsorNew":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology","highestDevelopmentStatusID":"8","companyTruncated":"Eirion The.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Genome & Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genome and Company Ink 2nd Clinical Trial Collaboration and Supply Agreement with Merck KGA and Pfizer for Immuno-Oncology Microbiome Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Merck Group \/ Genome","highestDevelopmentStatusID":"6","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo EU","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Inks $5 M Non-dilutive Financing Involving Sale of Royalty Rights of Mytesi COVID-related Indication Revenue Stream","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Crofelemer","moa":"CFTR\/CaCC","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"delayed-release tablet","sponsorNew":"Jaguar Health \/ Napo","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"BITT","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT\u2019s Lead TNFR2 Oncology Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Boston Immune Technologies and Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopha.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento and Mount Sinai Health System Ink License Agreement for Development of Potent Antibody For UK and South Africa COVID-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Neutralizing antibody cocktail","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Mount Sinai Health System","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Ohio State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX to Collaborate with The Ohio State University to Generate Animal Data for AgeX\u2019s BAT Cell Therapy Candidate for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"AgeX-BAT1","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Dutch Government","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"InteRNA Technologies Awarded \u20ac 2.7M Clinical Innovation Credit from Dutch Government","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"InteRNA Technologies \/ Dutch Government","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Te.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Announces $80 Million Loan Facility from Hercules Capital","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Biovectra Inc","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Biovectra Inc","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biovectra Inc \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biovectra .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"The Ministry of Science, Technology and Innovation of Brazil","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotech Announces That its COVID-19 Vaccine Consortium Received Funding from The MCTI for PDS0203","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"PDS0203","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ The Ministry of Science, Technology and Innovation of Brazil","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Tivozanib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"capsule","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$26.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Expand Partnership to Develop Vaccine Against Covid-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$86.8 million","upfrontCash":"Undisclosed","newsHeadline":"Contrafect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurelis Announces Close Of $114 Million Series D Financing Round To Advance Neuroscience Focus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Series D Financing","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.11,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Cormorant Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"IRICoR","sponsor":"Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRICoR, UdeM, IRIC and Valence Discovery collaborate to design novel drug candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"IRICoR","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRICoR \/ Universit\u00e9 de Montr\u00e9al","highestDevelopmentStatusID":"3","companyTruncated":"IRICoR \/ U.."},{"orgOrder":0,"company":"Diverse Biotech","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol-conjugate therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Diverse Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diverse Biotech \/ Enveric Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Diverse Bi.."},{"orgOrder":0,"company":"Delonix Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Synthetic vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Delonix Bioworks","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Delonix Bioworks \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Delonix Bi.."},{"orgOrder":0,"company":"Complix","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Complix Signs Agreement with I-Mab to Develop Cell Penetrating Alphabodies against 2 Intracellular Immuno-oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Cell penetrating alphabodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Complix \/ I-Mab","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ .."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"BCA101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicara Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bicara Therapeutics \/ Biocon","highestDevelopmentStatusID":"7","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$3,005.0 million","upfrontCash":"$3,005.0 million","newsHeadline":"Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":3.0099999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":3.0099999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Viela Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology to Regain Ex-North American Rights to AV-203","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Termination","leadProduct":"AV-203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ AVEO Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Avoro Capital Advisors","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series C Financing","leadProduct":"Molecular glues","moa":"Protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Avoro Capital Advisors","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0.19,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.19,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ SVB Leerink","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genevant Sciences Announces Global Collaboration with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"LNP based nucleic acid therapeutics","moa":"Hepatic stellate Cell","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Genevant Sciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Genevant Sciences \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA OPDIVO Combo in IO Relapsed Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Tivozanib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"capsule","sponsorNew":"Aveo Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$45.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"intravenous infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Cormorant Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano T.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biovaxys Inks Agreement With WuXi Biologics to Synthesize Proteins for Its Sars-CoV-2 Vaccine and Covid-T\u2122 Immunodiagnostic Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"SARS-CoV-2 s-protein based vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ BioVaxys Technology","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Spinal Muscular Atrophy Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SMA Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Collaboration is Focused on Advancing Clinical Development and Commercialization of the Oncolytic Virus-Based cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous mesenchymal stem cells infected oncolytic virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas \/ Orgenesis","highestDevelopmentStatusID":"6","companyTruncated":"Hospital I.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex\u00ae (Mazindol)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pathios Therapeutics Receives \u00a3350K Funding Reward From Innovate UK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pathios Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Pathios Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"2","companyTruncated":"Pathios Th.."},{"orgOrder":0,"company":"SciSparc","sponsor":"The Sheba Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc to Commence a Pre-Clinical Study Using its SCI-210 Cannabidiol Based Treatment for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ The Sheba Fund","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Epoladerm(TM)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Diclofenac Epolamine","moa":"COX-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"metered-dose spray film","sponsorNew":"Charles River Laboratories, Inc \/ Virpax","highestDevelopmentStatusID":"4","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"IQVIA","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IQVIA \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ Ja.."},{"orgOrder":0,"company":"Hammersmith Medicines Research","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hammersmith Medicines Research","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Hammersmith Medicines Research \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hammersmit.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Has Planned Trials of its Vaccine that will Include Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridgebio Pharma and Affiliate Origin Biosciences Announce fda Approval of Nulibry","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47\/PD-L1 Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI322","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"QureBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2\/PD-L1 Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Q-1802","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"QureBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QureBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"QureBio \/ .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics Receives EMA Orphan Medicinal Product Designation for CT041 CLDN18.2 CAR T Cells for Gastric Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CT041","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline\u2019s IMITREX\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Sumatriptan","moa":"5-HT1B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotech's Shares Routed After the FDA Demands New Trial, Raises Safety and Endpoint Issues in Surprise CRL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterin to Present at Chardan's Virtual 3rd Annual Microbiome Medicines Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ENT-01","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ .."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on KEYTRUDA\u00ae (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Have Enrolled First Patient in Phase I\/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"TissueTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TissueTech Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug TTBT01","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TTBT01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TissueTech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TissueTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TissueTech.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Submits Supplemental New Drug Application to FDA for TIBSOVO for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals, Inc. Submits NDA for Company\u2019s Lead Program: Bardoxolone in Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accure Therapeutics Enrols First Patient in Phase II Clinical Trial on Acute Optic Neuritis with Lead Candidate ACT-01","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ACT-01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Accure Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Accure The.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ANX007","moa":"C1q","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Submits NDA for Clazosentan to Japanese PMDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"Endothelin A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Oncorena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Orellanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncorena \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Receives Orphan Drug Designation from the European Commission for AVR\u2011RD\u201104, an Investigational Gene Therapy for Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Hematopoietic stem cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"KB407","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kissei Pharmaceutical Reports Submission of New Drug Application for Avacopan (CCX168), a Complement C5a Receptor Inhibitor, in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"C5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Olorinab","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Luvadaxistat","moa":"DAAO","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"ApolloBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces Positive Results from REVEAL 1 Evaluating VGX-3100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ ApolloBio","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"CMAB Biopharma Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ CMAB Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo\u00ae (Lemborexant) in Hong Kong","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Organon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FOR-6219","moa":"HSD17B1","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Organon \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company\u2019s Strategic Vision Call","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PIPE-307","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences to Present at Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GP2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope President to Deliver Talk on Gene Therapy for Retinal Diseases at Association for Ocular Pharmacology and Therapeutics Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"vMCO-010","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Selects Product Candidate for Clinical Trial with First in Class COVID-19 Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ISA106","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Reports Positive Results in Phase IIa Clinical Study in ALS and Patent Allowance in the USA for PrimeC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"VP-001","moa":"PRPF31","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PYC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PYC Therap.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Gets FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody for Treatment of Multiple Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"STI-6643","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Presents Preclinical Data that Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight & Pivotal start Phase IIA Melanoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BO-112","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Expands its anti-GM-CSF Patent Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare to Present New Data on Long-Acting Regimens for HIV Prevention and Treatment, Alongside Pipeline Advances at CROI 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"Integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Janssen Research and Development","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Pan-Coronavirus Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NV-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO\u2122 (berotralstat)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"INB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"IXICO","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IXICO Selected by Cyclerion for New Alzheimer's Disease Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"CY6463","moa":"sGC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IXICO","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IXICO \/ Cyclerion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"IXICO \/ Cy.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Study to Investigate the High Potency of Cymerus\u2122 MSCs","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"ObvioHealth","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObvioHealth, RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial for Highest Level of At-home Patient Monitoring to Date","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Upamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ObvioHealth","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObvioHealth \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"ObvioHealt.."},{"orgOrder":0,"company":"Numinus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update Fran\u00e7ais","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Numinus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Numinus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Numinus \/ .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARPAC Clinical Trial of Leukine\u00ae in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Opinions: EMA Refuses Asthma Label Expansion for GSK\u2019s Copd Drug Trelegy Ellipta","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Penicillamine Tablets USP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Penicillamine","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NGM120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2B ECO-Reset Study for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Provides Regulatory Update on sNDA for Pimavanserin for Hallucinations and Delusions Associated with Dementia-Related Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"Selective serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Launch of First Generic Version of AZOPT 1%, used to Treat High Pressure Inside the Eye, in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Brinzolamide","moa":"CA2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of Alinia\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"Pyruvate synthase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem Granted a Patent in Israel for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Human pluripotent stem cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huyabio International AND Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese NDA for Efinaconazole as Jublia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Efinaconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Receives Positive Opinion on the Agreement of a Paediatric Investigation Plan for Trappsol Cyclo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, Ensovibep, in NIH-Sponsored ACTIV-3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PRINCIPLE Covid-19 Treatments Trial Widens to Under 50s and Adds Colchicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen's BLINCYTO Prolonged Event-Free Survival In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WellmarkerBio Receives Approval for Phase I Clinical Trial from the Australian Therapeutic Goods Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"WM-S1-030","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Wellmarker Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wellmarker Bio \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"Wellmarker.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Dosed First Patient in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma's JV Aleor Dermaceuticals Gets American Regulator Nod for Testosterone Gel","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Testosterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Review of Regdanvimab for COVID-19 to Support National Decisions on Early Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Says Tirzepatide Achieved Superior A1C and Body Weight Reductions Across all Three Doses Compared to Injectable Semaglutide in T2D","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Gets Tentative American Health Regulator Nod for Apremilast Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Med.."},{"orgOrder":0,"company":"Elastrin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop New Technology Capable of Reversing Tissue and Organ Calcification","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Elastrin Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elastrin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Elastrin T.."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Conducts Phase I Study of Rls-0071 in Acute Lung Damage from Covid-19 Pneumonia in Normal Healthy Volunteers","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Altasciences Company Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altascienc.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Adds University of Wisconsin as Second Site in Ongoing Phase 1\/2 Clinical Trial of GTB-3550 TriKE","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GTB-3550 TriKE","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Novel Once-Daily Capsule AZSTARYS","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Celerion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prometheus Biosciences \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Akelos","sponsor":"Weill Cornell Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akelos Inc.'s Lead Compound Achieves Preclinical Safety Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"AKE-1018","moa":"HCN1 channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Akelos","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akelos \/ Weill Cornell Medicin","highestDevelopmentStatusID":"4","companyTruncated":"Akelos \/ W.."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of the Sputnik V COVID-19 Vaccine Share","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Expands Approval of Pfizer\u2019s Lorbrena\u00ae as First-Line Treatment for Alk-Positive Metastatic Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Reports Primary Endpoint for THE Ongoing Filgotinib Manta AND Manta-Ray Safety Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OFEV Receives Positive Recommendation from CADTH and INESSS for the Treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"FGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma\u2019s LUM-201 Therapy Published in Journal of the Endocrine Society","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Provides Update on Clinical Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP50","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaled dry powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TwoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel CKD Treatment Candidates","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TXR-1208","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Provides Update on APL-9 for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"APL-9","moa":"Complement C3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Dupixent\u00ae (Dupilumab) for Review in Children with Moderate-to-Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"GlycoMimetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics\u2019 Uproleselan for the Treatment of AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NVD-003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Novadip Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Novadip Bi.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCH Publishes Paper Showing Pre-Clinical Efficacy of AB569 Against Multi-Drug Resistant Acinetobacter Baumannii and Acinetobacter spp","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Acidified nitrite","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NCX 470","moa":"sGC","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA\u00ae in Europe for the Treatment of Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ixabepilone","moa":"Microtubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Publishes data of ABX464 Induction and Long-Term Maintenance Phase 2a Ulcerative Colitis Study in 'Gastroenterology'","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Orally dissolving thin film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Triple monoamine reuptake","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Provides Update on ImmCelz\u00ae FDA Application","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"HGF-1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dialectic Therapeutics Gets FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DT2216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dialectic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic .."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"Tie2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous solution","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TerSera Presents Data on cetirizine HCL Injection for Hypersensitivity Infusion Reactions in Breast Cancer and Other Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TerSera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Th.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD\/PD\u2122 2021, Including Lecanemab (BAN2401) Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biktarvy\u00ae Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Na\u00efve Adults in Four-Year Data Presented at CROI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma\u2019s Phase 2 Clinical Trial of Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivimed Labs Gets Approval from Uzbekistan Govt for Two Products","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Vivimed Labs","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivimed Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vivimed La.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (Generic for Afinitor\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkahest to Present Positive Data from Phase 2 Clinical Trial at the 15th International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GRF6021","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Alkahest \/ Grifols","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"AltruBio","sponsor":"AbGenomics B.V","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio\u2019s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"AltruBio \/ AbGenomics B.V","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaptysbio Reports Imsidolimab Poplar Phase 2 Clinical Trial in Moderate-To-Severe Palmoplantar Pustulosis Did Not Meet Primary Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radhoud University Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Radhoud University Medical","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"CMAB Biopharma Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMAB Congratulates Junshi Biosciences on NMPA Approval of Application for Clinical Trial of its PD-1\/TGF-\u03b2 Bifunctional Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"JS201","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ CMAB Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of a COVID-19 Therapeutic Molnupiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn\u2019s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge with Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"EHP-101","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald He.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Yescarta\u00ae for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Covid-19 Vaccination Roll-out Causes Delay to RhoVac's Phase IIb Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oncotelic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon\u2019s Update on C001 - Global Study for Ot-101 Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mateon Therapeutics \/ Oncotelic","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents Results from Phase 1 Trial of Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show NEXTSTELLIS\u00ae Has Selective Impact On Endocrine Markers Compared With Common Combined Oral Contraceptives","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Drospirenone","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\/BioNTech COVID-19 Vaccine Neutralizes Brazil variant in Lab Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study IN Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement on NIH Starting Enrollment for Third Trial of Blood Clotting Treatments for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns to Present on VAP-1 and FXR at NASH-TAG Conference 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-101","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"TissueTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TissueTech Gets FDA Clearance to Proceed with Phase 1 Clinical Study using New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved Amniotic Membrane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"TissueTech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"TissueTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TissueTech.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Selected to Present TOTUM-854\u2019s Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TOTUM-854","moa":"NOS","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ University of Avignon","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Data for Long-Acting Cabotegravir and rilpivirine for Hiv Showing Continued Virologic Suppression to 96 Weeks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Janssen Research and Development","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Gives Update on Phase III Study of Canakinumab and Chemotherapy Combo as 2nd or 3rd-Line Treatment in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Bamlanivimab and Etesevimab Together Reduced Hospitalizations and Death in Phase 3 Trial for Early Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aveo Gets FDA Nod for Fotivda in Third-Line Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tivozanib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Alar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alar Pharm.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Jiangsu Alphamab Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Jiangsu Alphamab Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"DemeRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1\/2a Study as First Clinical Trial in Opioid Use Disorder in the UK","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"DemeRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"DemeRx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DemeRx \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Valneva","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Valneva","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Tentative Approval to Generic Version of Symbicort","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Viatris \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Orca Therapeutics","sponsor":"CMX Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Therapeutics to Start Highest Dose in Treatment-Na\u00efve Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ORCA-010","moa":"CD8 positive T lymphocyte stimulant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Orca Therapeutics \/ CMX Research","highestDevelopmentStatusID":"7","companyTruncated":"Orca Thera.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DM199","moa":"KLK1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BGB-15025","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN106","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Wuxi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolimidone","moa":"Lyn kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pha.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive Proof-of-Concept Findings for GSK3640254","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GSK3640254","moa":"Maturation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s Therapeutic Goods Administration (TGA) Approves Feraccru\u00ae to Treat Iron Deficiency With or Without Anaemia in Adults","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Maltol","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Shield Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shield The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Approval for Kymriah by Health Sciences Authority as Singapore\u2019s First Commercially Approved CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Submits Application to Start New Clinical Trial Investigating Antibody CAN04 and FOLFIRINOX in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Provides Updated Findings from Reported Case of AML in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lentiglobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yumanity Therapeutics\u2019 YTX-7739 Demonstrates Prevention of Motor Function Deficits in a Parkinson\u2019s Disease Mouse Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Sunitinib","moa":"FLT3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MET642","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents vafidemstat 12-month Clinical Data From its Phase IIa Trials ETHERAL and REIMAGINE-AD in Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"EB01","moa":"sPLA2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021 to Showcase Clinical Advances in AD Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti alpha-synuclein antibody","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Secures Second United States Patent Grant for Eftilagimod Alpha in Combination with A PD-1 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Cancer Drug Retsevmo Gets UK Approval for Multiple Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Northwestern University","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A First-in-Human Phase 0 Clinical Study of RNA Interference\u2013Based Spherical Nucleic Acids in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NU-0129","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Northwestern University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Northwestern University \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Northweste.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1\/2 Clinical Trial for VX-880","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Expands Phase II Trial of TG4001 in Combination With Avelumab Vs Avelumab Monotherapy in HPV16-positive Anogenital Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tipapkinogen sovacivec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Merck KGaA","highestDevelopmentStatusID":"8","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GMI-1359","moa":"E-selectin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics\u2019 Rivelin-CLO Patch for Treatment of Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Transmucosal","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Thera.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of Eli Lilly Antibodies Bamlanivimab and Etesevimab for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NUV-422","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen\u2019s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PH10","moa":"Chemosensory receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b\/3 COVID-19 Trial of Ifenprodil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Bioventus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS\u2122 (PTP-001) for the Treatment of Knee OA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PTP-001","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Bioventus","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bioventus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioventus .."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GEM-difluorinated C-glycoside derivative of Podophyllotoxin","moa":"Topoisomerase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Receives PDUFA Date for KYZATREX\u00ae NDA for Treatment of Hypogonadism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron\u2019s Lomecel-B\u2122 Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lomecel-B","moa":"VEGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Submits New Drug Application for Enfortumab Vedotin in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitazalimab Synergizes with Chemotherapy - Alligator Bioscience Presents New Preclinical Data at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Receives Approval to Begin Phase 1b Trials of NOUS-PEV, a Novel Personalized Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NOUS-PEV","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn\u2019s Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 Days; Enrollment to be Completed This Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Biotech AG Enrolls First Patients in Phase II Clinical Trial of Tacrosolv to Treat Allergic Rhinoconjunctivitis (Hay Fever)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Spectrum Pharmaceuticals\u2019 Poziotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"IMU-131","moa":"HER2\/NEU receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Pan-Cyclophilin A","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Softgel capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Begins Dosing with ALG-010133, in First Cohort of Chronic Hepatitis B Patients in a Phase 1 Proof-of-Concept Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarus Therapeutics Seeks to Initiate Clinical Trial of TT-10 (A2AR antagonist) in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-10","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Ther.."},{"orgOrder":0,"company":"Natera","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natera and Genentech Initiate Phase III Trial Using Signatera as a Companion Diagnostic for Atezolizumab in Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Natera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Natera \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Natera \/ G.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ N.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MRTX9768","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Preclinical Data on ZN-c3 and the Company\u2019s EGFR inhibitor, ZN-e4, Will be Presented as Poster Presentations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ZN-c3","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FLX475","moa":"CCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus to Present New Clinical Data on AGEN1181 at AACR 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lipid Nanoparticles","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AELIX Has Presented Positive Results from the Clinical Study AELIX-002 at the 2021 Conference on Retroviruses and Opportunistic Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vesatolimod","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aelix Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aelix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aelix Ther.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Viriom","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom and Chromis Publish Results of a Post-Marketing Clinical Study in 940 COVID-19 Patients Confirming Efficacy of Avifavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viriom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viriom \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"Viriom \/ R.."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melinta Therapeutics Nabs FDA Nod for More Convenient Rework of Antibiotic Orbactiv","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Oritavancin","moa":"Peptidoglycan precursor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio initiate Phase 1\/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MRT5500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Bio\u2019s long, troubled slog through the clinic yields promising early data. Can it win back trust?","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TD139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Reports that Phase 3 Trial of Libtayo Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab-rwlc","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exclusive: U.S. Green Light for AstraZeneca Vaccine Could Come in April, Independent Monitors Assessing Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Zolgensma Data Shows Age-Appropriate Development when Used Early, Real-World Benefit in Older Children","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Subgroup Analysis from Phase 3 Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Maribavir","moa":"UL97 protein kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Pharma: DSMB Confirms Safety and Validates Recruitment of Last Patients in Final High-Dose Cohort of NOX-A12","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai\u2019s Anti-Cancer Agent LENVIMA Receives Orphan Drug Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"PurGenesis Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine\u2122 in Mild to Moderate AD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Thykamine","moa":"Cytokine","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Devonian Health Group \/ PurGenesis Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK initiate new Phase 2 Study of Their Adjuvanted Recombinant Protein-Based Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Adjuvanted recombinant protein-based COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise Announces Data from Preclinical Study of TATX-03 PolyTope\u2122 Monoclonal Antibody Cocktail Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-\u03b2 Agonist ASC41 for NASH","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC41","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Rhizen Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharma Announces that Umbralisib Received US FDA Accelerated Approval for Relapsed or Refractory MZL & FL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TG Therapeutics \/ Rhizen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noven Submits New Drug Application for Investigational Dextroamphetamine Transdermal System for ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Noven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noven Phar.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update On IGC\u2019s Phase 1 Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"P-BCMA-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Poseida Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Xiamen University","sponsor":"Yiling Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Progress in Study on Mechanism of Lianhua Qingwen Capsules for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lianhua Qingwen","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Xiamen University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xiamen University \/ Yiling Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Xiamen Uni.."},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series B Financing","leadProduct":"Imotope","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Imcyse","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imcyse \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Imcyse \/ P.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$95.4 million","upfrontCash":"Undisclosed","newsHeadline":"Evox Therapeutics Completes \u00a369.2 Million Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"EVX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ .."},{"orgOrder":0,"company":"Oxford Drug Discovery","sponsor":"Exscientia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exscientia and the University of Oxford Announce Partnership to Develop Treatments for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Oxford Drug Discovery","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Drug Discovery \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Dru.."},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ L.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson and Mirati Therapeutics Announce Kras Strategic Research AND Development Collaboration IN Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GL Ventures","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Series C Financing","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ GL Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"AAV capsid-gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sirion Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sirion Bio.."},{"orgOrder":0,"company":"Bio-Techne","sponsor":"Luminary Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Techne And Luminary Therapeutics Sign License Agreement For Use Of Bio-Techne\u2019s TcBuster\u2122 to Develop CAR-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"LMY-920","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Techne","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Techne \/ Luminary Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Techne.."},{"orgOrder":0,"company":"Qiagen","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO and QIAGEN Expand Collaboration To Develop Next Generation Sequencing Companion Diagnostic for VGX-3100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Qiagen \/ INOVIO","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ I.."},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda To Receive a Manufacturing Technology Transfer from Novavax for TAK-019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-919","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"Perception and Otsuka Enter Collaboration and Licensing Deal for Depression Drug Candidate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Perception Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Perception.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie in Talks to Sell $5 Billion Women's Drugs Portfolio","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Divestment","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"transdermal","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"HT-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cincinnati","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Cincinnati \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","amount":"$353.0 million","upfrontCash":"Undisclosed","newsHeadline":"GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanofi","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Sanofi \/ Global Blood Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Amathus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amathus Therapeutics Signs Strategic Collaboration with Merck to Develop Treatments for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Chaperone","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Amathus Therapeutics","amount2":0.5,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Amathus Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Amathus Th.."},{"orgOrder":0,"company":"Anchiano Therapeutics, Inc","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chemomab Completes Merger with Anchiano Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Merger","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Anchiano Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Anchiano Therapeutics, Inc \/ Chemomab","highestDevelopmentStatusID":"8","companyTruncated":"Anchiano T.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Completes Second Round of a US$100 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","year":"2021","type":"Private Placement","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Baxter Healthcare SA","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Announces Close of US$50 million \/ EUR42 million Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"VHH72-Fc antibody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ExeVir Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"ExeVir Bio \/ VIB","highestDevelopmentStatusID":"5","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Ridgeback Capital Investments","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taiwan's Acepodia Closes Series B with the Promise of Conjugating Antibodies and Off-the-Shelf NK Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"ACE1702","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Ridgeback Capital Investments","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm and Sana Biotechnology Enter Cell Therapy Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"iPSC-Derived Cell Therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm holding \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopha.."},{"orgOrder":0,"company":"Biocentriq","sponsor":"Tevogen Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tevogen Bio Announces Partnership With BioCentriq to Enhance Tevogen\u2019s Development Capacity of Its Targeted T Cell Therapy For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Purified Cytotoxic CD8+ T Lymphocytes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Biocentriq","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biocentriq \/ Tevogen Bio","highestDevelopmentStatusID":"5","companyTruncated":"Biocentriq.."},{"orgOrder":0,"company":"DZNE","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dzne and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"DZNE","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DZNE \/ EISAI","highestDevelopmentStatusID":"2","companyTruncated":"DZNE \/ EIS.."},{"orgOrder":0,"company":"StrideBio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$81.5 million","upfrontCash":"Undisclosed","newsHeadline":"StrideBio Announces Closing of $81.5M Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"STRX-310","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"StrideBio","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"StrideBio \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio .."},{"orgOrder":0,"company":"Lieber Institute for Brain Development","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"COMT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lieber Institute for Brain Development","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lieber Institute for Brain Development \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Lieber Ins.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma","pharmaFlowCategory":"D","amount":"$42.7 million","upfrontCash":"$2.2 million","newsHeadline":"Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Ewopharma","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Rivastigmine Multi-Day Transdermal Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Rivastigmine","moa":"AChE\/BChE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Luye Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Immutep","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz in-Licenses Authorized Generic of Respiratory Medicine Proventil\u00ae HFA Inhalation Aerosol from Kindeva Drug Delivery","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kindeva Drug Delivery","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation aerosol","sponsorNew":"Kindeva Drug Delivery \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Kindeva Dr.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"M&G Investment Management","pharmaFlowCategory":"D","amount":"$168.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ M&G Investment Management","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"$69.5 million","upfrontCash":"$11.5 million","newsHeadline":"Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical for VP-102","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals\u2019 Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer\u00ae (TMB-002) in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AFT Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"AFT Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AFT Pharma.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"Intravenous infusion","sponsorNew":"Solid Biosciences \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$2,420.0 million","upfrontCash":"$120.0 million","newsHeadline":"Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Huntingtin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anima Medical Centre","amount2":2.4199999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.4199999999999999,"dosageForm":"","sponsorNew":"Anima Medical Centre \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Anima Medi.."},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and University of Hong Kong Expand Partnership to Develop Intranasal COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Hong Kong","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Hong Kong \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Deuterated tryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Orally disintegrating tablet","sponsorNew":"Catalent Pharma Solutions \/ Cybin","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"YuanBio Venture Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Tavo111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tavotek Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Tavotek Biotherapeutics \/ YuanBio Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tavotek Bi.."},{"orgOrder":0,"company":"Virchow Group","sponsor":"The Russian Direct Investment Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF Partners with Virchow Biotech for Production of Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virchow Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Virchow Group \/ The Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"Virchow Gr.."},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"Consortium Led by etheRna Immunotherapies Awarded Eu Commission Tiger Grant of Eur 6.9 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"mRNA cancer vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"eTheRNA immunotherapies","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"eTheRNA immunotherapies \/ European Commission","highestDevelopmentStatusID":"7","companyTruncated":"eTheRNA im.."},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"China Merchants Bank International","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series C Financing","leadProduct":"FIT-013a","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ China Merchants Bank International","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Bio.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","amount":"$41.9 million","upfrontCash":"Undisclosed","newsHeadline":"XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"AdVEGFXC1","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead and Novo Nordisk Expand NASH Clinical Collaboration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica","pharmaFlowCategory":"D","amount":"$151.5 million","upfrontCash":"$21.5 million","newsHeadline":"Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech\u2019s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"PMN310","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"$10.0 million","newsHeadline":"Relief and Acer Therapeutics Sign Collaboration for Worldwide Development and Commercialization of ACER-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Powder","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","amount":"$228.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Genetic Disease Biotech Design Therapeutics Sets Terms for $228 Million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Gene targeted chimeras","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Design Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Design Therapeutics \/ Renaissance Capital","highestDevelopmentStatusID":"2","companyTruncated":"Design The.."},{"orgOrder":0,"company":"UC San Diego","sponsor":"MatriSys Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MatriSys Expands Licensing Agreement with UCSD School of Medicine to Develop Acne Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"MSB-3163","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"UC San Diego \/ MatriSys Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"UC San Die.."},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Alpha Radio Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aktis Oncology","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Aktis Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"2","companyTruncated":"Aktis Onco.."},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"GSK3903371","moa":"Interleukin-1 Receptor Modulator","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boston Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pha.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Collaboration with Merck KGaA and Pfizer to Evaluate XL092 and Avelumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dutch Cancer Biotech Lava Therapeutics Sets Terms for $101 Million US IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Gamma-delta bsTCE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Nuvothera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Omega-3","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"DS Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"DS Biopharma \/ Nuvothera","highestDevelopmentStatusID":"12","companyTruncated":"DS Biophar.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Shanghai Haini Pharmaceutical","pharmaFlowCategory":"D","amount":"$3,240.0 million","upfrontCash":"$6.0 million","newsHeadline":"Daewoong Pharmaceutical Signs Agreement to Export Fexuprazan, A New Drug for Gastroesophageal Reflux Disease, to China","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"Proton pump","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":3.2400000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":3.2400000000000002,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Shanghai Haini Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cancer Biotech Instil Bio Raises Deal Size by 25% Ahead of $312 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"ITIL-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Renaissance Capital","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ikena Oncology Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"IK-930","moa":"Transcription Factor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Jefferies","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Continues Streamlining of Established Products with Sale of Anti-Inflammatory Drugs to Fidia Farmaceutici","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Divestment","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Fidia Farmaceutici","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ F.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Acidified nitrite","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cincinnati","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"University of Cincinnati \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"UC San Diego","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Enters Into Research Agreement with UCSD for TD-0148A Behavioural Pharmacology Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"oral","sponsorNew":"UC San Diego \/ BetterLife","highestDevelopmentStatusID":"4","companyTruncated":"UC San Die.."},{"orgOrder":0,"company":"Step Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Step Pharma Raises Funds Through Series B Round to Advance Cancer Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"STP938","moa":"CTPS1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Step Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Step Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Step Pharm.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apnimed Closes Series B Financing to Advance Once-Daily Oral Medication for Obstructive Sleep Apnea (OSA)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Aroxybutynin","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0.029999999999999999,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Morningside Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Exothera","sponsor":"CyanVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CyanVac Selects Exothera for the Development and GMP Manufacturing of Its Covid-19 Intranasal Vaccine Candidate for Phase III Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"CVXGA1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exothera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Exothera \/ CyanVac","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Forbion\u2019s Growth Opportunities Fund","pharmaFlowCategory":"D","amount":"$148.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series C Financing","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Forbion\u2019s Growth Opportunities Fund","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Amplicore","sponsor":"Photon Fund","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"AM3101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amplicore","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amplicore \/ Photon Fund","highestDevelopmentStatusID":"4","companyTruncated":"Amplicore .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces Closing of $30.0 Million Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Istaroxime","moa":"SERCA2a","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Oppenheimer & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.5 million","upfrontCash":"Undisclosed","newsHeadline":"Achilles Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"ATL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Jubilant Generics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jubilant, Novavax Enter COVID-19 Vaccine Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jubilant Generics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jubilant Generics \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Jubilant G.."},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"PY265","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Biologics Inc \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biol.."},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS\u00ae (Tagraxofusp) in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tagraxofusp","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Nippon Shinyaku","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Menarini Group","highestDevelopmentStatusID":"12","companyTruncated":"Nippon Shi.."},{"orgOrder":0,"company":"itheranostics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Expands Targeted Radioligand Therapy Pipeline with in-License for Compounds Targeting Fibroblast Activation Protein (FAP)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"FAPI-46 Targeted Radioligand Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"itheranostics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"itheranostics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"itheranost.."},{"orgOrder":0,"company":"Rodeo Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$721.0 million","upfrontCash":"$55.0 million","newsHeadline":"Amgen to Acquire Rodeo Therapeutics Corporation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"15-PGDH","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Rodeo Therapeutics","amount2":0.71999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"Oral","sponsorNew":"Rodeo Therapeutics \/ Amgen","highestDevelopmentStatusID":"4","companyTruncated":"Rodeo Ther.."},{"orgOrder":0,"company":"Celonic","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celonic and Curevac Announce Agreement to Manufacture Over 100 Million Doses of Curevac\u2019s Covid-19 Vaccine Candidate, CVNCOV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"mRNA vaccines","moa":"T Cell activatior","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celonic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Celonic \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Celonic \/ .."},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$8.0 million","newsHeadline":"ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"IgG4 monoclonal antibody","moa":"CD47-SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOncia Therapeutics, Inc","amount2":0.46999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"ImmuneOncia Therapeutics, Inc \/ 3D Medicines","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnci.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Arix Bioscience Plc","pharmaFlowCategory":"D","amount":"$152.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"PYX-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Arix Bioscience","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omega Therapeutics to Advance Pipeline and Platform Development with $126 Million in Additional Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"OTX-2002","moa":"Myc expression","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Nanoform","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (\"PoC\") Agreement for Two Ophthalmic Drug Candidates","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"NPI-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanoform \/ Nacuity Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Lake Bleu Capital","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"AffaMed Therapeutics \/ Lake Bleu Capital","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"IO-202","moa":"LILRB4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$856.0 million","upfrontCash":"$196.0 million","newsHeadline":"Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Termination","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0.85999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.85999999999999999,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite: Summary of Existing Out-Licensing Deals with Potential Milestone Payments of Up To Approximately $130 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.13,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"InDex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InDex Pharmaceuticals Enters Agreement with Parexel Biotech for Phase III Clinical Study of Cobitolimod for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Parexel Biotech \/ InDex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Bi.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"QED Therapeutics","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bridgebio Pharma\u2019s Affiliate Qed Therapeutics and Helsinn Group Announce Strategic Collaboration for Infigratinib in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ QED Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"GC012F","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Biologics Inc \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Biol.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Avoro Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scribe Therapeutics Raises $100M Series B Financing to Further Develop \u201cCRISPR by Design\u201d Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Avoro Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$116.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entrada Therapeutics Announces Closing of $116 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Oligonucleotide antibody","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Rakovina Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"EO2000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Edison Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edison Oncology \/ Rakovina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Edison Onc.."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Luminous Ventures","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Treos Bio Announces $14 Million Convertible Loan Note Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"PolyPEPI-1018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Treos Bio","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Treos Bio \/ Luminous Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"4SC AG","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","amount":"$17.2 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"4SC AG","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"4SC AG \/ Immunic","highestDevelopmentStatusID":"8","companyTruncated":"4SC AG \/ I.."},{"orgOrder":0,"company":"Cipla","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Cipla \/ SI.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Ottawa Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Ottawa Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"CareDx","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CareDx Supports Vir Biotechnology\u2019s Clinical Trial Recruitment Efforts for COMET-ICE","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CareDx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CareDx \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CareDx \/ V.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"The Queen's University of Belfast","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"PharmaTher \/ The Queen's University of Belfast","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"AllianThera Biopharma","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AllianThera Biopharma Comes out Of Stealth and Collaborates on AI with Insilico Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"AllianThera Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AllianThera Biopharma \/ Insilico","highestDevelopmentStatusID":"1","companyTruncated":"AllianTher.."},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Advanced Biofuels","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Norbaeocystin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PsyBio Therapeutics \/ Advanced Biofuels","highestDevelopmentStatusID":"6","companyTruncated":"PsyBio The.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hansa Biopharma Enters Preclinical Research Collaboration with Argenx","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ argenx BV","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"CARB-X Is Funding University of Oxford\u2019s Jenner Institute to Develop a New Vaccine to Prevent Gonorrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Funding","leadProduct":"dmGC_0817560","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Oxford","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"University of Oxford \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"NanoSmart Pharmaceuticals","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals for Initial Phases of IND-Enabling Activities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Dactinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"NanoSmart Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoSmart Pharmaceuticals \/ Oncology Pharma","highestDevelopmentStatusID":"2","companyTruncated":"NanoSmart .."},{"orgOrder":0,"company":"Rokote Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rokote Lab\u2019s COVID-19 Nasal Vaccine on Financing Fence Before Phase I Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"FINLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Rokote Lab","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Rokote Lab \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Rokote Lab.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm's NOXCOVID Trial Advances to Final Stage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from the Second Year of Evrysdi Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Seeks US FDA Approval for Nefecon to Treat Primary IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Arcagy Gineco","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics, ARCAGY-GINECO Initiate Phase 2 TEDOVA Trial of Tedopi in Combo with Keytruda to Treat Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Arcagy Gineco","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives US FDA Approval for Potassium chloride for Oral Solution","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants Dosed in Phase 2\/3 Study of COVID-19 Vaccine Candidate in Pediatric Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Medicago","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago and GSK Start Phase 3 Trial of Adjuvanted Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Bio Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in 2E14 vg\/kg Cohort","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson's TREMFYA Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Clinical Trial Confirms SaNOtize\u2019s Breakthrough Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna\u2019s Next Generation COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1283","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Extension of Review for sNDA of Upadacitinib for Adults with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Reports Positive Data From Ongoing Phase 1\/2 Trial of RTX-240 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion IN Covid-19 Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pep-Therapy and Institut Curie Granted Approval from Ansm to Start First-in-Human Clinical Trial of Pep-010 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PEP-010","moa":"Caspase-9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"PEP-Therapy \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therap.."},{"orgOrder":0,"company":"Hovione","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hovione Completes its Phase 2 Clinical Trial of the First Minocycline Ophthalmic","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Hovione \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hovione \/ .."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Highlights Publication of Wakix\u00ae (Pitolisant) Efficacy Data in Sleep Medicine","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio\u00ae at St. Gallen Virtual Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine\u00ae Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"IMA201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology\u2019s PBI-06150 Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Oleandrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phoenix Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phoenix Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TNX-1800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Announces Commercial Availability of Bronchitol Inhalation Powder for Improvement in Pulmonary Function in Cystic Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mannitol API","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"CHIESI USA INC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for inhalation","sponsorNew":"CHIESI USA INC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CHIESI USA.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin's InVascepa Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark Reduce-It\u00ae Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Obesity Increases Covid Death Rate 10X, ERX Pharmaceuticals Novel Approach & Research Could Be Gamechanger","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ERX-1000","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Oral pill","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEXLETOL\u00ae (Bempedoic Acid) Tablet, Ezetimibe and Atorvastatin Combination Lowered Bad Cholesterol by 60.5% vs. Placebo in Phase 2 Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Results from the Phase 3 DEVENT Study of Jakafi in Patients with COVID-19 Associated ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts BMS\u2019s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENVIMA Plus KEYTRUDA Improved Progression-Free Survival Versus Chemotherapy in Advanced Endometrial Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Ellipses Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resistance-Busting ICR Drug Enters Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"EP0042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Institute of Cancer Research \/ Ellipses Pharma","highestDevelopmentStatusID":"7","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Precigen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse\u2122 Immunotherapy for Recurrent Respiratory Papillomatosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Drug Delivery System Receives US FDA Approval for Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DBPR115","moa":"Cancer Cell membrane protein-phosphatidyl serine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Health Research Institutes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Health Research Institutes \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National H.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces U.S. FDA Approval of PONVORY, an Oral Treatment for Adults with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Calcilytix Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Proof-Of-Concept Data Of Encaleret In ADH1 At The Endocrine Society\u2019s 2021 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Calcilytix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta\u2019s SRP-9003 for Limb-Girdle Muscular Dystrophy Type 2E Shows Functional Improvements 2 Years After Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"SRP-9003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol receives Recommendation from iDSMB To Complete the Global Phase III AGENT Study for Market Registration as Planned with 440 Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Sylentis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sylentis, PharmaMar Group, Initiates a Phase I Clinical Trial with SYL1801 For Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"SYL18001","moa":"Notch-regulated ankyrin repeat protein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Sylentis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Sylentis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sylentis \/.."},{"orgOrder":0,"company":"Peptomyc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptomyc\u2019s OMO-103, Has Obtained Approval for First-in-Human Phase I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Omomyc","moa":"Myc","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peptomyc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Peptomyc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Peptomyc \/.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"CR2O","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ CR2O","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"GSK","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Starts the First Phase 3 Study With a Long-Acting Anti-IL-5 Treatment for Patients with Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GSK3511294","moa":"IL-5","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Iqvia","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Iqvi.."},{"orgOrder":0,"company":"PainReform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PainReform Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"PainReform \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PainReform.."},{"orgOrder":0,"company":"Mitsubishi Chemical Holdings Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Chemical Holdings Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Chemical Holdings Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' KISQALI (Ribociclib) Product Monograph in Canada Now Includes MONALEESA-3 Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Doses First Participants in TCOM Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Bolus","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"ImmunogenX","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunogenX and Mayo Clinic Successfully Complete the CeliacShield Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Announces Results from Illuminate-301 Trial of Tilsotolimod + Ipilimumab in Anti-PD-1 Refractory Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino\u2019s Covid-19 Vaccine Receives Approval in Hungary for Emergency Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces FDA Approval of ARCALYST \u00ae (rilonacept) for Recurrent Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Rilonacept","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"KM Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's KM Biologics Begins Clinical Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"KD-414","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KM Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"KM Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KM Biologi.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase III Study Shows Roche\u2019s Tecentriq Helped People with Early Lung Cancer Live Longer without Their Disease Returning","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Diltiazem Hydrochloride","moa":"L-Type VGCC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Phase 1\/2 Clinical Trial for mRNA COVID19 vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DS-5670","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Drug Prevents Heart Failure in Mouse Models","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MCB-613","moa":"Steroid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Trial Shows Regen-Cov Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Provides Update on Tominersen Programme in Manifest Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA antisense","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Ionis","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed's ARIKAYCE Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liposome inhalation suspension","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma's Phase 1 Trial Shows Clinical Benefit of Pacritinib for the Prevention of Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"TYK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Issues Update on ARISE-3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol receives Notice that Clinical Use Patent in Europe for Drug Candidate Arfolitixorin Will Be Approved","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ F.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Starts Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging, a Key Cause of Morbidity and Mortality in Older Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Asapiprant","moa":"DP1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioAge Labs \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase III Study Shows Genentech\u2019s Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst\u2019s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen\u2019s Poster at the ADAA 2021 conference Differentiates PH94B\u2019s Mechanism of Action from Highly-Addictive Benzodiazepines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiasma Presents Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial of MYCAPSSA for Acromegaly at ENDO 2021","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Approval to Pembrolizumab for the Treatment of Advanced Esophageal or GEJ Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Receives Green Light from FDA on Investigational New Drug Application for CBX-12 (alphalex\u2122-exatecan)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta\u00ae (metreleptin)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Metreleptin","moa":"Leptin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Injection","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b\/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Completes Pre-IND Meeting with FDA: Clearing Path to Phase 1 Clinical Study for STAR-LLD Continuous Infusion","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Futura Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Futura Medical Receives US FDA Agreement for Confirmatory Clinical study, FM71 for MED3000","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MED3000","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Futura Medical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Futura Med.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Xylonix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"010DS-Zn","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xylonix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xylonix \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Xylonix \/ .."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Oxford to Study Nasal Administration of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives CRL From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA\u00ae in High-Risk Early-Stage TNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Receives Refusal to File Letter for Once-Weekly Semaglutide 2.0 mg For the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against Sars-Cov-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PF-07321332","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSinoBIO Gets China Nod For inhaled COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac COVID-19 Vaccine Appears Safe, Triggers Antibodies in Trial in Children: Researcher","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Advises Against Use of Ivermectin for the Prevention or Treatment of Covid-19 Outside Randomised Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok\u00ae at Benzinga Biotech Small Cap Conference on March 25","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA\u2019s Approved Dual Concurrent Protocol","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ANK-700","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"InteRNA Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Te.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen\u00ae for Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical\u2019s CRV431","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Pan-Cyclophilin A","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Softgel capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Submits NDA for NK1 Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms Associated with Cancer Chemotherapy","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Fosnetupitant Chloride","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TD139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Presents Additional Analysis of Phase 1b\/2a NASH Study at the Annual ENDO 2021 Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumos Pharma's Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB\u00ae for Treatment of Acid-Related Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NCX 470","moa":"sGC","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn\u00ae as a Treatment for Progressive MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib Recommended for Breakthrough Therapy Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Receives FDA IND Clearance for EO2463, an 'OncoMimic' based Immunotherapy Targeting Liquid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"EO2463","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives Australian TGA Approval for TRIKAFTA to Treat People With Cystic Fibrosis Ages 12 Years and Older with F508del Mutation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Phase Ib\/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"CG Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Participation in Global Phase III Clinical Trial For CG0070, a Drug for Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Kissei Pharmaceutical \/ CG Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pha.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Publishes Vafidemstat First-in-Human Clinical Trial Manuscript in CNS Drugs Journal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REN001 Granted Fast Track Designation by FDA for Patients with Primary Mitochondrial Myopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"REN001","moa":"PPAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UPLIZNA Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"EirGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"EG12014","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EirGenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"EirGenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EirGenix \/.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Hoag Memorial Hospital Presbyterian","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces RELATIVITY-047 Meets Primary Endpoint of Progression-Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride in Water for Injection","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1\/2 Trial from Intravenous Trappsol\u00ae Cyclo\u2122 in Rare Disease Niemann-Pick Type C1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Initiates Phase 2 Clinical Trial of BRIMOCHOL for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for XTANDI\u2122 (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft capsules","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Targeted Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ARDS-003","moa":"CB2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetra BioPharma \/ Targeted Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for KAFTRIO in Combination With Ivacaftor for Cystic Fibrosis With At Least One F508del Mutation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolls in Horizon's FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA and Methotrexate to Treat Uncontrolled Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based QIVc in the 2018\/19 U.S. Influenza Season","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dipivefrin","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral sublingual film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Cambridge Biomedical Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cambridge Leads National Drug Trial to Prevent Deaths After Covid-19 Patients Leave Hospital","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cambridge Biomedical Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge Biomedical Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge .."},{"orgOrder":0,"company":"Kineta","sponsor":"Wellcome Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"LHF-535","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Kineta \/ Wellcome Trust","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ W.."},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE\u2122","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dehydrated human amniotic membrane allograft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Te.."},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Wellbeing Drug Material for Cancer Cachexia Shows Efficacy","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BST204","moa":"IL-6","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Green Cross Well-being \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cros.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Gets CTA Approval to Start Phase I\/II Study to Evaluate the Safety, Dosing and Clinical Activity of ANV419 in Solid Tumors Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ANV419","moa":"Selective interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"Aptabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptabio To Initiate Phase II Oral Covid-19 Therapy Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"APX-115","moa":"NADPH oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aptabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptabio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptabio \/ .."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"AV-001","moa":"Tie2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Receives Conditional Marketing Authorization from EC for NEXPOVIO and Dexamethasone Combo for Relapsed and or Refractory ML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Reports Positive Topline Phase 2 Study Results of Its Novel Antisense Treatment for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"IONIS-PKK-LRx","moa":"Prekallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for MSI-H Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR\u2011210 in Oral Presentation at COSM 2021 Virtual","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Gets Positive CHMP Opinion for PONVORY for the Treatment of Relapsing MS With Active Disease Defined by Clinical or Imaging Features","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Expands MEND Clinical Trial in Covid-19 and Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CYP-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Announces ZYESAMI Met the Primary Endpoint of Its Phase 2b\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Mesh nebulizer","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2\/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FP-025","moa":"MMP-12","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Announces Topline Results from Pivotal Trial of Arimoclomol for Inclusion Body Myositis (IBM)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Provides Update on Phase 1b\/2a PRECISION-HD Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"WVE-120102","moa":"SNP3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Covis Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Covis Phar.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives EU Approval for Kesimpta\u00ae (Ofatumumab)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Evrysdi Approved by European Commission as First and Only at Home Treatment for Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucose","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Reports That Lenzilumab\u2122 Improves Survival Without Need for Mechanical Ventilation in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"AntiCancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patent Allowed for AntiCancer's Oral Methioninase Which Targets Cancer, Covid-19, Diabetes, Obesity and Aging","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Methioninase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AntiCancer","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AntiCancer.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulized for inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Lung02 Phase 2 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Psirenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psirenity Granted Approval to Conduct Jamaica\u2019s First Psilocybin Clinical Trial to Help Manage Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psirenity","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Psirenity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Psirenity .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approvals Strengthen Octapharma USA Pediatric Critical Care Product Portfolio","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Human fibrinogen","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Enrolls First Patient in PORTICO, a Phase IIb Clinical Trial With Vafidemstat in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"CB4211","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Kanghong Pharma Hits Limit Down as France Stops Trials of Ophthalmic Drug","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Conbercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Ka.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Receives European Commission (ec) Approval for Vazkepa to Reduce Cardiovascular Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Enrolls First Patient IN Phase 2\/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Announces FDA Acceptance of Ind for At-100 IN Preterm Infants at Risk for Bronchopulmonary Dysplasia (bpd)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"rhSP-D","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intratracheal","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Complix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cell-Penetrating Alphabodies","moa":"MCL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Complix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Complix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Complix \/ .."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONTOZRY\u00ae (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Submits NDA for Vadadustat to Treat Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RP-6306","moa":"CCNE1-SL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent for PV-10\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Four Patients In Bionic Sight\u2019s Optogenetic Gene Therapy Trial Are Able To Detect Light And Motion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BS01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sig.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial of CPI-613\u00ae for Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology\u2019s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics\u2019 Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Biom Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biom Therapeutics Receives Orphan Drug Status for BIO017 from the U.S. FDA for the treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"BIO017","moa":"TRPV1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Biom Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biom Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biom Thera.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and ABL Bio Gets US FDA Approval to Start Phase 1 Trial of Bispecific Antibody TJ-CD4B\/ABL111 in Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ABL111","moa":"CD137 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai: EMA Accepts the MAA for Two Additional Indications of Anti Cancer Agent Lenvatinib and Pembrolizumab Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GemVax's Highly Promising Phase II Alzheimer's Disease Clinical Trial Results Published in Prestigious Alzheimer's Research & Therapy' journal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tertomotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & K.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Issues Positive Recommendation for Use of Kineret to Treat Still\u2019s Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics To Start Dravet Syndrome Therapy Trial in UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Sponsored Trial Finds Eylea Injection Reduced Vision-Threatening Complications by 68% After Two Years in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces the FDA Allowed Treatment for a Secondary Progressive Multiple Sclerosis Patient for the Nasal Administration of Foralumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Initiates Phase 3 Clinical Trial for MT-7117","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dersimelagon","moa":"MC1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Enteric capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Provides An Update on the Expected Timelines for the Read-Out of its Masitinib Phase 3 study (AB12003)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b\/3 Clinical Trial of ANAVEX\u00ae2-73","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Ascendis Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Ascendis Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Receives Positive CHMP Opinion for Subcutaneous Formulation of Infliximab, Remsima\u00ae SC","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"HT-003","moa":"TLR2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Reprocell","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reprocell \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Reprocell .."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Johnson & Johnson Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Quark Venture LP","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Announces $21 Million Series D Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series D Financing","leadProduct":"Auxora","moa":"CRAC channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Quark Venture LP","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Formosa Laboratories","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sosei Heptares","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Sosei Heptares \/ Formosa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces Dosing of First Patient IN Phase 2 Trial of MT-401 IN Acute Myeloid Leukemia Following Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Zelenoleucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech to Start Phase-1 Trials of Covid-19 Intranasal Vaccine in Feb-March","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Provides Regulatory Update on sNDA for Pimavanserin for Hallucinations and Delusions Associated with Dementia-Related Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"HitGen","sponsor":"UPPTHERA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and UPPTHERA Enter Into Drug Discovery Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ UPPTHERA","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ U.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1\/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminum phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"$579.4 million","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals Announces Closing Of Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.57999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Ipsen \/ Fusion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fu.."},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Kyorin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyorin Pharmaceutical \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Kyorin Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$392.0 million","upfrontCash":"$342.0 million","newsHeadline":"Royalty Pharma Acquires Royalty Interest in Cabozantinib from GSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Divestment","leadProduct":"Cabozantinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0.39000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0.39000000000000001,"dosageForm":"Tablet","sponsorNew":"GSK \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Roya.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":1.25,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.25,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Zikani Therapeutics","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.6 million","upfrontCash":"Undisclosed","newsHeadline":"Eloxx Pharmaceuticals Acquires Zikani Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Eukaroyotic ribosomal selective glycoside","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zikani Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zikani Therapeutics \/ Eloxx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zikani The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Journey Medical Corporation Enters into a Definitive Agreement with Dermira to Acquire QBREXZA\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Eli Lilly \/ Journey Medical Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,800.0 million","newsHeadline":"Servier Completes Acquisition of Agios Pharmaceuticals\u2019 Oncology Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Ivosidenib","moa":"Isocitrate dehydrogenase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Servier","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA Alkylation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Johns Hopkins University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johns Hopkins University \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ European Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Manus Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Manus Bio Awarded Additional Funding To Support Its Artemisinin Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Funding","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Manus Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Manus Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Manus Bio .."},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Merger","leadProduct":"Abivertinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Thera.."},{"orgOrder":0,"company":"TOA EIYO","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and TOA EIYO Announce Termination of Distribution Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Termination","leadProduct":"Isosorbide Dinitrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"TOA EIYO","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"White Transluscence tape","sponsorNew":"TOA EIYO \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"TOA EIYO \/.."},{"orgOrder":0,"company":"Hadassah","sponsor":"MyBiotics Pharma Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Gut microbiome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hadassah","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hadassah \/ MyBiotics","highestDevelopmentStatusID":"4","companyTruncated":"Hadassah \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Oxiconazole Nitrate","moa":"Ergosterol biosynthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sandoz B2B \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$152.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pyxis Follows Pfizer Alliance With $152m Fundraising for Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"PYX-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyxis Oncology","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"Leronlimab","moa":"CCR5 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Columbia University","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for Early Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"ADXS-504","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Advaxis","highestDevelopmentStatusID":"5","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Alkido Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkido Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alkido Pha.."},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamada Announces Amendment to GLASSIA\u00ae License Agreement with Takeda","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Human Alpha 1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhaler","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ T.."},{"orgOrder":0,"company":"Icosavax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV\/hMPV Vaccine Candidate Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"Stabilized prefusion F antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Biomm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"Tregs migration","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Akamis Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"NG-641","moa":"AP\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Bristol Myers Squibb \/ PsiOxus Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,320.0 million","upfrontCash":"$20.0 million","newsHeadline":"Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Radioligand Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artios Pharma Limited","amount2":1.3200000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Novartis","highestDevelopmentStatusID":"3","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alkermes Plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alkermes Inks Clinical Trial Collaboration With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA in Patients Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Nemvaleukin alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Alkermes","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AB Science","sponsor":"University of Chicago","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AB Science Collaborates with University of Chicago to Conduct Research for Treatment of Covid-19 with Masitinib and Other AB Science Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Masitinib Mesylate","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ University of Chicago","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.5 million","upfrontCash":"Undisclosed","newsHeadline":"Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Public Offering","leadProduct":"Neoantigen Reactive T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Humanized antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"N-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Antisense oligonucleotide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"$180.0 million","newsHeadline":"Royalty Pharma Acquires Oxlumo\u2122 Royalty Interest from Dicerna for up to $240 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"HO-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dicerna Pharmaceuticals","amount2":0.23999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$590.0 million","upfrontCash":"$10.0 million","newsHeadline":"KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS\u2122","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Serdexmethylphenidate","moa":"Dopamine\/Norepinephrine level","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.58999999999999997,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.58999999999999997,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Baring Private Equity Asia","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hutchmed Announces US$100 Million Equity Investment by Baring Private Equity Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"c-MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Baring Private Equity Asia","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$30.0 million","newsHeadline":"Biogen and Bio-Thera Announce License Agreement for Proposed Biosimilar to Treat Moderate to Severe Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"BAT1806","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"ValenzaBio Advances Pipeline of Antibody Therapeutics Toward Clinical Development for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"CD19-targeting mAb","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"ValenzaBio","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"ValenzaBio \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"ValenzaBio.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$22.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bionomics Successfully Completes A$22.9 million Equity Raise","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Liquid suspension","sponsorNew":"Bionomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Celcuity","pharmaFlowCategory":"D","amount":"$340.0 million","upfrontCash":"$5.0 million","newsHeadline":"Celcuity Announces Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Gedatolisib","moa":"PI3K\/mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Celcuity","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"City of Hope Enters Licensing Agreements with CytoImmune Therapeutics to Develop Portfolio of Chimeric Antigen Receptor-NK Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune.."},{"orgOrder":0,"company":"Tidal","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$160.0 million","newsHeadline":"Sanofi Acquires Tidal Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tidal","amount2":0.46999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Tidal \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Tidal \/ Sa.."},{"orgOrder":0,"company":"Kymab","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,450.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Sanofi Completes Kymab Acquisition","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":1.45,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.45,"dosageForm":"","sponsorNew":"Kymab \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ Sa.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,850.0 million","upfrontCash":"$1,850.0 million","newsHeadline":"Merck Completes Acquisition of Pandion Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"PT101","moa":"CD25","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":1.8500000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.8500000000000001,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Enters into Clinical Collaboration with GlaxoSmithKline to Evaluate ZN-c3, in Combination with Niraparib","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Niraparib tosylate","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ Zent.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antios Therapeutics Raises $96 Million in a Series B Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"ATI-2173","moa":"Active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunOs Therapeutics Receives Public Funding from Eurostars and Innosuisse for a Novel Antibody to Treat Inflammatory Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Funding","leadProduct":"OCi mAb","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ImmunOs Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunOs Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"ImmunOs Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"TILT Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of TILT-123 in Combination with Keytruda for Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$139.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Gene Therapy Closes $139 Million Series B Funding Co-Led by Eli Lilly and Company and Deerfield Management","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"JAG101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Jaguar Gene Therapy \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gen.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"BCTG Acquisition Corp","pharmaFlowCategory":"D","amount":"$353.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"TNG908","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ BCTG Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","amount":"$134.7 million","upfrontCash":"$2.7 million","newsHeadline":"Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Oxprenolol","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0.13,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Faraday Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"THE-630","moa":"pan-variant KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Foresite Capital","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"GH Research Announces Closing of $125 Million Oversubscribed Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.13,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.13,"dosageForm":"inhalation","sponsorNew":"GH Research \/ RA Capital","highestDevelopmentStatusID":"8","companyTruncated":"GH Researc.."},{"orgOrder":0,"company":"FairJourney Biologics","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FairJourney Biologics Enters Next-Generation Antibody Discovery Collaboration with Argenx","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"FairJourney Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FairJourney Biologics \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"FairJourne.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$24.8 million","upfrontCash":"$5.5 million","newsHeadline":"Taysha Gene Therapies Acquires Exclusive Worldwide Rights to TSHA-120 for the Treatment of Giant Axonal Neuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"NovaQuest","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Financing","leadProduct":"Tavapadon","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ NovaQuest","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denovo Biopharma \/ Aytu BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"Agtc","sponsor":"TeamedOn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TeamedOn and AGTC Announce a Licensing Agreement Advancing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV2tYF-CB-hRS1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ TeamedOn","highestDevelopmentStatusID":"1","companyTruncated":"Agtc \/ Tea.."},{"orgOrder":0,"company":"Arcellx","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series C Financing","leadProduct":"CART-ddBCMA","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Arcellx \/ Samsara BioCapital","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"Lonza Group","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr\u2019s Anti-NRP2 Antibody ATYR2810","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"ATYR2810","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Alchemab","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alchemab Completes \u00a360m Series A funding To Advance Novel Antibody Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Alchemab \/ RA Capital Management","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO\u2122 (berotralstat) for Prophylactic Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Factor Bioscience","sponsor":"Brooklyn ImmunoTherapeutics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brooklyn Acquires License for mRNA Technology Platform from Factor Bioscience to Treate Multiple Cancers and Blood Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Factor Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Factor Bioscience \/ Brooklyn ImmunoTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Factor Bio.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Consonance-HFW","pharmaFlowCategory":"D","amount":"$212.0 million","upfrontCash":"$92.0 million","newsHeadline":"Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination Focused on Wnt Biology and Tissue Regeneration","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Merger","leadProduct":"SZN-1326","moa":"Lrp6","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0.20999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Surrozen \/ Consonance-HFW","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cilastatin","moa":"DPEP1","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Telara Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telara Pharma \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"Telara Pha.."},{"orgOrder":0,"company":"Rumpus Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumpus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumpus Therapeutics \/ Aytu BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Rumpus The.."},{"orgOrder":0,"company":"Mestex AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Acquires Mestex and its Phase-III-Ready Investigational Medicine MTX-071 to Treat Pain Associated with Osteoarthritis of the Knee","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Mestex AG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Mestex AG \/ Grunenthal","highestDevelopmentStatusID":"8","companyTruncated":"Mestex AG .."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Pharmapark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Bevacizumab Biosimilar in Russia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Prestige BioPharma Pte Ltd \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"$3.1 million","upfrontCash":"Undisclosed","newsHeadline":"Sound Pharmaceuticals to Launch NIH-Funded Covid-19 Oral Therapeutic Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Funding","leadProduct":"Ebselen","moa":"Glutathione peroxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirum Pharmaceuticals Ink License Agreement for Vivet\u2019s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"VTX-803","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Ther.."},{"orgOrder":0,"company":"PPD","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Niclosamide","moa":"Wnt signaling","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"PPD","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"oral immediate-release tablet","sponsorNew":"PPD \/ AzurRx BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"PPD \/ Azur.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Gets China NMPA CTA Approval to Evaluate Trodelvy\u00ae in a Phase 2 Basket Trial for a Variety of Cancers TROP-2 Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Sanofi's Sarclisa in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Submits ANDA For Generic ADVAIR DISKUS\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Results of Acceleron's Pulsar Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Taltz Approved by Health Canada for the Treatment of Pediatric Patients with Moderate- to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Add-on Therapy for Patients with Genetic form of Severely High Cholesterol","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Alirocumab","moa":"PCSK9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"NR082","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Extension of Review for sNDA of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Grifols International","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Announces Topline Data From NIAID Phase 3 ITAC Trial of Hyperimmune Globulins as A Treatment for Hospitalized Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Grifols International \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of COVID-19 Hyperimmune Globulin Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Takeda Pharmaceutical \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Preclinical Data for CK-3773274 to Be Presented at the American Chemical Society Spring 2021 Virtual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CK-3773274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Announces FDA Approval of Qelbree\u2122 (SPN-812) for the Treatment of ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces Top-Line Results from its Phase 1\/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Plasma-derived hyperimmune globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PXS-6302","moa":"Pan-LOX","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Pharmaxis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Evaluating Moderna COVID-19 Variant Vaccine Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273.351","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"JMB2002","moa":"Spike glycoproteins of mutant viruse","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyondspring Submits New Drug Application to FDA and China NMPA for Plinabulin and G-CSF Combination for Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIRALEZE\u2122 Now Launched by Lloyds Pharmacy in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Astodrimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Makes Two Revisions to Moderna COVID-19 Vaccine Emergency Use Authorization to Help Increase the Number of Vaccine Doses Available","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Secura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Secura Bio's COPIKTRA\u00ae Receives Positive CHMP Opinion for the Treatment of Relapsed and Refractory CLL and Refractory FL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Secura Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Secura Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Secura Bio.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KIDCARES10, First Patient Enrolled in Pediatric PI Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Kedrion IVIG","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kedrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"ROCK 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Codebase","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codebase Ventures Receives Positive Technical Study Results for Hydroxychloroquine Patch Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Codebase","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codebase \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codebase \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ\u2122 in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Gets China NMPA New Drug Approval of AYVAKIT for Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Reports Data From Its Phase 1b Clinical Trial Of NasoShield\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Adenovirus-vectored anthrax vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Seeks DCGI Approval for the Use of Pegylated Interferon Alpha-2b in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegylated Interferon Alpha-2b","moa":"INF alpha receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Initiates Phase 3 Trial of Novel Antisense Medicine to Treat Leading Cause of Juvenile-Onset ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ION363","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates to Assume Full Rights To TAK-169 Including Taking Control of Clinical Development from Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-169","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Molecular Templates \/ Takeda","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Penn Study Uncovers Possible COVID-19 Drugs \u2014 Including Several That are Already FDA-Approved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dacomitinib","moa":"ErbB1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 1\/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018\u2122 Adjuvant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-702","moa":"Adenosine A2B receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Teon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Teon Thera.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"CogState","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with PD Dementia and Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"NYX-458","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ CogState","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Enters Clinical Stage with AZ-3102, An Oral Small Molecule Being Developed for Rare Neurogenetic Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"University of Louisville","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maxwell Biosciences \/ University of Louisville","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Bi.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Published Peer-Reviewed Data Shows AbCellera's Bamlanivimab\u2019s High Potency Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Gets Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PBKR03","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharma Completes Interim Safety Data Review of Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ARDS-003","moa":"CB2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1\/2 Trial Begins for Daiichi Sankyo\u2019s DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Published in Arthritis & Rheumatology Show Higher Response Rates of Horizon's KRYSTEXXA with the Immunomodulator Mycophenolate Mofetil","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Horizon Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peer Reviewed Research Paper Reports that ProtoKinetix's AAGP\u00ae Enhanced Stem Cell Vision Restoration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada has Initiated a Safety Review On Xeljanz and Xeljanz XR (Tofacitinib), Used to Treat Arthritis and Ulcerative Colitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Reports Positive Top-Line Results From the TOPAZ Phase 2 Clinical Trial of Apitegromab in Patients With Type 2 and Type 3 SMA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte Communicate Review Extension of sNDA for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals\u2019 Study Shows Ampion Inhibits a Key Inflammatory Pathway in Covid-19 and Lupus Nephritis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces Initiation of Phase 1\/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BBT-176","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Study of Intranasal Administration of Ampligen for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience Leads in the Repurposing of Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalational","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bi.."},{"orgOrder":0,"company":"MitoImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MitoImmune Gets FDA Clearance of IND Application for MIT-001 for CCRT Patients with Head and Neck Cancer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MIT-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"MitoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MitoImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MitoImmune.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Reports, DESTINY-CRC02 Phase 2 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Announces USFDA Approval For First Generic for Ibrutinib Capsules, 70 mg and Gets Eligibility for 180-Day Exclusivity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"RTK","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte Announce Results from the Phase 3 COV-BARRIER Study of Baricitinib in Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazilian Health Regulator Anvisa Authorizes Trials for GSK-Medicago COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Regulatory Update Regarding BLA of Teplizumab For Patients at Risk of Getting Clinical Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"APX3330","moa":"Ref-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Eprenetapopt","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Announces its Joint Venture Aleor Dermaceuticals Receives USFDA Tentative Approval for Efinaconazole Topical Solution, 10%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Efinaconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical solution","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Blood Therapeutics' Oxbryta Significantly Improves Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Launches BRUKINSA\u00ae (Zanubrutinib) in Canada for Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MP1032","moa":"Macrophage","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"MetrioPharm","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MetrioPharm \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MetrioPhar.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI to Treat Relapsing-Remitting Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Provides Clinical Development Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Sanofi's Sutimlimab Pivotal Trial for People with Cold Agglutinin Disease Published in New England Journal of Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Claritas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric oxide releasing compound","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Claritas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Claritas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Claritas P.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia\u2122 in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications for SKYRIZI\u00ae (Risankizumab) in Psoriatic Arthritis to FDA and EMA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Covid-19 Treatment Guidelines Strongly Recommend Use of Regen-Cov\u2122 in Outpatients at High Risk of Clinical Progression","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety Monitoring Committee Recommends 7 MBq as Clinical Dose for Radspherin in RAD-18-002 Phase 1 Trial for Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"NMBS-2","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer, BioNTech Seek U.S. Emergency Nod for Covid-19 Vaccine in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA Shows Superior Disease-Free Survival as Adjuvant Therapy in Patients With Renal Cell Carcinoma After Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Gets European and UK Licence for Kesimpta","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen to Highlight Data from Novel Targeted Therapies at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Bilayer tablet","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nammi Therapeutics Unveils Two Novel Immunotherapies at AACR Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"QXL138AM","moa":"CD138","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nammi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nammi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nammi Ther.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the ACS Spring 2021 Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido\u00ae Label Expansion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Synthorx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Late-Breaking Clinical Data Validate Not-Alpha Profile of THOR-707 (SAR444245), Sanofi\u2019s Novel Investigational IL-2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"THOR-707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Synthorx","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data with ImCheck\u2019s ICT01 to be Presented at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized anti-Butyrophilin 3A monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Identifies New Role of BioAegis\u2019 \u2018Inflammation Regulator\u2019 Gelsolin Relevant for a Range of Inflammatory Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data of GP2 Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"GP2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pexidartinib","moa":"CSF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharma Presents Positive in Vivo Data Showing Strong Tumor Control for The Intratumoral Delivery of Intasyl\u2122 Rnai Targeting Pd-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Reports Preclinical Data Shwing Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Voruciclib","moa":"CDK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"GMI-1757","moa":"E-selectin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Reports that Aliqopa and rituximab Combo Increases Progression-Free Survival in Relapsed Indolent non-Hodgkin's Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Copanlisib","moa":"PI3K p110-alpha subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tachyon Presents Promising Preclinical Data on its First-in-Class pan-KDM4 Epigenetic Regulator, TACH101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tachyon Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Te.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"SO-N102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Starts Phase 3 Trial of Roflumilast Cream as a Potential Treatment for Atopic Dermatitis in Patients Aged Between 2-5 Years","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last Patient Completes Marinomed Biotech AG\u2019s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CB 2782-PEG","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Catalyst Biosciences \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Initiates Global Phase 1\/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TPX-0131","moa":"Anaplastic lymphoma kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Says CardiolRx Safe and Well Tolerated in Phase I Study of Oral Cannabidiol Formulation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Receives Tentative Approval for Ibrutinib Tablets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Highlights Data for Sl-9258 in An Acquired Resistance Model and Expanded Preclinical Data from the Gadlen\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"SL-9258","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed Regen-Cov Reduced Progression to Symptomatic Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Approves Junshi Biosciences' Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Provides an Update on ZIMHI\u2122","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Reports Results of Review by DSMB for its Phase 2\/3 Trials of ANAVEX\u00ae2-73 in Patients with Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Saint Luke's Health System","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Provides Update on the DARE-19 Phase III trial for Farxiga in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Saint Luke's Health System","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Accelerates Early Oncology Pipeline Across Key Strategic Scientific Platforms at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AZD5305","moa":"PARP1 selective","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Announces FDA Acceptance of Ind for AT-100\u2019s Second Indication IN Severe Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"rhSP-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intratracheal","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma\u2019s Phase 2\/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Presents Initial Preclinical Results From PRMT5 Inhibitor in MTAP-Deleted Cancer Models at AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Open IND with FDA for Bullous Pemphigoid Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in 2nd- or 3rd-Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HGCO19 Vaccine Candidate: Gennova Starts Enrolment for Phase 1\/2 Human Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Trial of Anti-CD14 Antibody to Treat Covid-19 Respiratory Disease Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"IC14","moa":"CD14","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant and Pfizer Dosed First Participant in Phase 3 Serene Study of Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Myovant","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Begins Patient Dosing in Phase II trial of ATG-008 To Treat Advanced Solid Tumors with Specific Genetic Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Onatasertib","moa":"mTORC1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics\u2019 Belapectin, Anti-PD-1 Therapy Combo Enhances Tumor Response, Reports Journal for ImmunoTherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase 3 XTEND-Kids Study with Efanesoctocog Alfa in Children with Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Efanesoctocog alfa","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV to Present at Wet AMD and DME Drug Development Summit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BI 456906","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Doses First Cancer Patient with iNKT Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic iNKT cell therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharma\u2019s Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"MitoChem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MitoChem Therapeutics Granted FDA Orphan Drug Designation for Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MC16","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MitoChem Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MitoChem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"MitoChem T.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO Submits Supplemental Application for Approval for Opdivo\u00ae (Nivolumab) to Expand the Use for Cancer of Unknown Primary in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Completes Induction Treatment of Last Patient in ABX464 Phase 2b Clinical Study in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Imperial Collage London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magic Mushroom Compound Performs as Well as Antidepressant in Small Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Imperial Collage London","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imperial Collage London \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics To Present Phase 2 Data at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BO-112","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed\u2019s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PsiOxus and Bluebird Bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-EGFR CAR-T therapy","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akamis Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ BluebirdBio","highestDevelopmentStatusID":"5","companyTruncated":"Akamis Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in China for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGA Grants Provisional Determination to Glaxo SmithKline Australia Pty Ltd for COVID-19 Monoclonal Antibody Treatment - Sotrovimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna\u2019s Covid-19 Variant Vaccines Boost Neutralising Titers in Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273.351","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Gets Approval for Import of Russia\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Accelerated Approval to Trodelvy\u00ae for the Treatment of Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ATR-002","moa":"MEK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap concludes Icatibant Portion of I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Presents Phase 2 Data of Rivelin-CLO at 2021 AAOM Virtual Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Transmucosal","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Thera.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Discontinue Development of MK-7110 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MK-7110","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qlaris Bio Enrolls First Patient in Phase 1\/2 Studies of QLS-101 in Patients with Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"QLS-101","moa":"KATP Channel","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Qlaris Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Closes Enrollment in Trial Comparing COVID-19 Treatment Regimens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elsalys Confirms The Renew of Its Cohort Atu in France and Compassionate Use Programs Submissions in Several Other Countries for Inolimomab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Inolimomab","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ElsaLys Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous perfusion","sponsorNew":"ElsaLys Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ElsaLys Bi.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Deflazacort","moa":"CTGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ART27.13","moa":"CB1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Solid dosage formulation","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae and SOLTI Achieve Primary Endpoint in AWARE-1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Presents New Data on Retevmo in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Loxo Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic COVID-19 Infections with Subcutaneous Administration of Regen-COV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Statement on Phase 3 Veklury\u00ae (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Accepted for Use Within NHS Scotland for Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Presented Preclinical Data Showing Potent Synergistic Effect of ATG-010 and ATG-008 Combo for Treatment of Triple-Hit DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives FDA Approval of Xolair\u00ae (Omalizumab) Self-Injection with Prefilled Syringe Across All Indications for Appropriate Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Tolmar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolmar Publishes Study on the Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tolmar","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"In situ gel","sponsorNew":"Tolmar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ N.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-001","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Presents The Non-Clinical data of PMC-309 at AACR 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PMC-309","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer, Starts Phase II Trial With Registrational Intent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Berzosertib","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Reveals Positive TOTUM\u2022854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TOTUM\u2022854","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ University of Avignon","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Confirms Safety of Tegavivint After Completion of Enrollment in Phase 1\/2a Expansion Study for Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tegavivint","moa":"Nuclear beta catenin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-Paclitaxel in the Treatment of mTNBC at AACR 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Lindis Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Catumaxomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lindis Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal infusion","sponsorNew":"Lindis Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lindis Bio.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Deuterated tryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Orally disintegrating tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Begins Dosing with Capsid Assembly Modulator Drug Candidate, ALG-000184","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Presents Data at AACR Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Files Septic Shock Treatment Patent for Veyonda\u00ae","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Gets EC Approval for Opdivo, Cabometyx Combo as First-Line Treatment for Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Provides Global Regulatory Update on Amx0035 for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Approved C5 Complement Inhibitor Recommended by NICE for NHS Use","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ideaya Doses First Patient in Solid Tumour Treatment Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Romark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romark\u2019s Investigational Covid-19 Drug Lowers Disease Progression in Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"PFOR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Romark \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ N.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Novavax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford University Expands Com-Cov2 Dose-Mixing Study with Novavax\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"University of Oxford \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"GL Mountrose Investment Two","pharmaFlowCategory":"D","amount":"$169.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Divestment","leadProduct":"Savolitinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ GL Mountrose Investment Two","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cerecor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Human Monoclonal Antibody","moa":"LIGHT","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Cerecor","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Inc. Enters into an Agreement for Enerzair\u00ae Breezhaler\u00ae and Atectura\u00ae Breezhaler\u00ae in Canada","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Valeo","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Seagen","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pieris Announces Amendment of Existing Collaboration with Seagen to Evaluate Cinrebafusp Alfa in Combination with Tukysa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Cinrebafusp alfa","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ P.."},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Tempest Therapeutics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tempest and Millendo Announce Proposed Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Merger","leadProduct":"TPST-1495","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Tempest","highestDevelopmentStatusID":"6","companyTruncated":"Millendo T.."},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Lassen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lassen Therapeutics Collaborates with Cedars Sinai to Study the Role of IL-11 Signaling and Inhibition in Lung Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"LASN01","moa":"IL-11 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cedars-Sinai","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cedars-Sinai \/ Lassen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cedars-Sin.."},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bright Peak Therapeutics and Ajinomoto Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Immunocytokines","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bright Peak Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ajinomoto","highestDevelopmentStatusID":"1","companyTruncated":"Bright Pea.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Corporation Prices Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Positive Result of Phase III Study with Radioligand Therapy 177Lu-PSMA-617 in Patients with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to 9 Months HET Obesity on Setmelanotide","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG To Conduct Phase Two Trial For Treatment Of Deadly Glioblastoma Multiforme [GBM]","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM\u2019s n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamas Publishes New Data Analyses Demonstrating GOCOVRI Treatment More Than Doubled ON Time Without Dyskinesia in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Phase 1 Trial for Nafamostat Inhalation Formulation (DS-2319) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine endopeptidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Confirms Release of 60-Day Findings from Phase 2b\/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Mesh nebulizer","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Shiyu Capital","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"OnQuality Pharmaceuticals Announces Closing of $35 Million Series A and A+ Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Series A Financing","leadProduct":"OQL011","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Shiyu Capital","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Varian Biopharmaceuticals","sponsor":"Healthtech Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healthtech Solutions, Inc. Announces Contract To Acquire Varian Biopharmaceuticals, A Precision Oncology Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"VAR-101","moa":"PKC-iota","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Varian Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Varian Biopharmaceuticals \/ Healthtech Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Varian Bio.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Announces $55.0 Million At-the-Market Private Placement Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Abingworth","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"SemaThera Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Semaphorin-3A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SemaThera Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SemaThera Inc \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"SemaThera .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aura Biosciences Announces Oversubscribed $80 Million Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"Belzupacap sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Matrix Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONK Therapeutics Strengthens its Cell Therapy Manufacturing Process with License for EBV-LCL Feeder Cell Line from NIH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ONKT101","moa":"CCR7 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"National I.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Funding","leadProduct":"Mitomycin","moa":"DNA Alkylation","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.080000000000000002,"dosageForm":"Pyelocalyceal solution","sponsorNew":"UroGen Pharma \/ RTW Investments","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Upamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ ","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces FDA Approval of Zegalogue injection, for the Treatment of Severe Hypoglycemia in People with Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Tolmar","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Returns Rights to EligardTM in Europe, Middle East, CIS, and Asia to Tolmar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Tolmar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tolmar \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ A.."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TB Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TB Alliance \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Announces Termination of Co-promotion Agreement with Viatris for Lipitor\u00ae Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Termination","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Announces a Research Collaboration with Actinium for Molecular Targeted Radiotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Actinium-225 based therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Astellas","highestDevelopmentStatusID":"4","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Harvard University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Harvard Establish Strategic Research Alliance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Harvard University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harvard University \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"Harvard Un.."},{"orgOrder":0,"company":"Nanna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$98.5 million","upfrontCash":"$17.0 million","newsHeadline":"Astellas Announces Acquisition of Nanna","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nanna Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nanna Therapeutics \/ Astellas","highestDevelopmentStatusID":"3","companyTruncated":"Nanna Ther.."},{"orgOrder":0,"company":"Gifu University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gifu University and Astellas establish a Research Course on Phage Biologics, Aimed at Creating New Treatments for Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Next-generation phage therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gifu University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gifu University \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"Gifu Unive.."},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$3,000.0 million","upfrontCash":"$3,000.0 million","newsHeadline":"Astellas Completes Acquisition of Audentes Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Resamirigene bilparvovec","moa":"MTM1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":3,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":3,"dosageForm":"","sponsorNew":"Audentes Therapeutics \/ Astellas","highestDevelopmentStatusID":"7","companyTruncated":"Audentes T.."},{"orgOrder":0,"company":"Viatris","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Viatris Announce Termination of Co-promotion Agreement for Celecox\u00ae Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Termination","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas\u2019 XOSPATA Receives Conditional Approval by China\u2019s NMPA for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen To Presentation Data from PADCEV Trial in Urothelial Cancer Patients Who Were Ineligible for Cisplatin Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas, Seagen Report Phase 3 Trial Data Showing Survival Benefits of PADCEV in Previously Treated Advanced Urothelial Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Garners New Indication & New Product Formulation Approvals From U.S. FDA for Children with Neurogenic Detrusor Overactivity (NDO)","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Mirabegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas\u2019 XOSPATA Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed\/Refractory AML with a FLT3 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Announce U.S. FDA Acceptance of Two sBLAs for PADCEV in Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas, Seagen Report Updated Data from Two Trials of PADCEV Advanced Urothelial Cancer Patients Not Eligible for Cisplatin Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan\u2019s Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas\u2019 XTANDITM (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seattle Gets FDA Breakthrough Therapy Designation for PADCEV and Pembrolizumab Combo in First-Line Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seattle Genetics","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Astellas Announce Updated Results from Phase 1b\/2 PADCEV, Pembrolizumab Combination Trial in Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seattle Genetics","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Submits sNDA for Approval of Evrenzo for the Treatment of CKD Associated Anemia in Non-Dialysis Dependent Patients in Japan","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leucovorin","moa":"Claudin 18.2 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$1.25 million","newsHeadline":"Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Servier \/ Precision BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Peptron","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"PAb001-ADC","moa":"MUC1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Peptron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peptron \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Peptron \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Cytokine derivative therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sutro Biopharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amgen Successfully Completes Acquisition Of Five Prime Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Bemarituzumab","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":1.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"Intravenous infusion","sponsorNew":"Five Prime Therapeutics \/ Amgen","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Immunitas Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza and Immunitas Therapeutics Announce Manufacturing Agreement to Rapidly Advance Lead Program to the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"IMT-009","moa":"CD161","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Biologics Inc \/ Immunitas Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biol.."},{"orgOrder":0,"company":"Invivyd","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$336.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series C Financing","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0.34000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"The University of Texas MD","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"pan-KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The University of Texas MD \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Agtc","sponsor":"SparingVision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGTC licenses Promoter Technology to SparingVision SAS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ SparingVision","highestDevelopmentStatusID":"5","companyTruncated":"Agtc \/ Spa.."},{"orgOrder":0,"company":"Oyagen","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Inks Exclusive Licensing Agreement with OyaGen to Develop Antiviral SARS-CoV-2 Inhibitor, TNX-3500, for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Sangivamycin Hydrochloride","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oyagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oyagen \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Oyagen \/ T.."},{"orgOrder":0,"company":"Evotec","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"$366.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Enters Partnership with Kazia Therapeutics for Clinical Development of EVT801","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"EVT801","moa":"VEGFR 3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evotec","amount2":0.37,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Evotec \/ Kazia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ K.."},{"orgOrder":0,"company":"Phico Therapeutics","sponsor":"Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator","pharmaFlowCategory":"D","amount":"$18.2 million","upfrontCash":"Undisclosed","newsHeadline":"Phico Therapeutics Awarded up to $18.2 Million USD CARB-X Funding to Advance SASPject Antibacterial Therapy Through Phase 1 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Funding","leadProduct":"SASPject PT3.9","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Phico Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Phico Therapeutics \/ Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator","highestDevelopmentStatusID":"4","companyTruncated":"Phico Ther.."},{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Elektrofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elektrofi \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Elektrofi .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"$2.0 million","newsHeadline":"Lineage Announces License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lineage Cell Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Immunomic","highestDevelopmentStatusID":"1","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Yale University","sponsor":"D&D Pharmatech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"D&D Pharmatech Announces Sponsored Research Agreement with Yale University for the Treatment of Brain Cancer and Other CNS Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"VEGFC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Yale University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yale University \/ D&D Pharmatech","highestDevelopmentStatusID":"4","companyTruncated":"Yale Unive.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Noble Capital Markets","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"OS Therapies Completes $6 Million Series A Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Attenuted Listeria monocytogene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"OS Therapies \/ Noble Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$26.6 million","upfrontCash":"Undisclosed","newsHeadline":"Synendos Therapeutics Expands Series A to CHF 24 Million with New Investment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"SYT-510","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Synendos Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Synendos Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Synendos T.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$900.0 million","newsHeadline":"Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for CTX001\u2122 in Sickle Cell Disease and Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":1.1000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Intravenous infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Rezolute","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ SLR Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"GAMUT Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"SPVN20","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GAMUT Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"GAMUT Therapeutics \/ SparingVision","highestDevelopmentStatusID":"4","companyTruncated":"GAMUT Ther.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"EC-18","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzychem Lifesciences Corporation \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$14.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rinri Therapeutics Raises \u00a310M from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"Stem cell therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0.01,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rinri Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Ther.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PSMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ BVF Partners L.P","highestDevelopmentStatusID":"4","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zai Lab Announces Proposed Public Offering of American Depositary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0.75,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.75,"dosageForm":"Tablet","sponsorNew":"Zai Lab \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"CordenPharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolo Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture \u20181104 for Eosinophilic Esophagitis and Allergic Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"CordenPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Lyophilised powder for intravenous","sponsorNew":"CordenPharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CordenPhar.."},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Vertex","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$75.0 million","newsHeadline":"Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Obsidian Therapeutics","amount2":1.3,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.3,"dosageForm":"","sponsorNew":"Obsidian Therapeutics \/ Vertex","highestDevelopmentStatusID":"3","companyTruncated":"Obsidian T.."},{"orgOrder":0,"company":"CMAX","sponsor":"Claritas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Nitric oxide-releasing compound","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"CMAX","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CMAX \/ Claritas","highestDevelopmentStatusID":"4","companyTruncated":"CMAX \/ Cla.."},{"orgOrder":0,"company":"Intratus","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"INT-11P001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Intratus","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intratus \/ Glaukos","highestDevelopmentStatusID":"8","companyTruncated":"Intratus \/.."},{"orgOrder":0,"company":"Yale University","sponsor":"Aptorum","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Yale University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yale University \/ Aptorum","highestDevelopmentStatusID":"4","companyTruncated":"Yale Unive.."},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Allosteric phosphatase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Anavo Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Ther.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Expands Partnership with Rocket Pharmaceuticals","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"AGC Biologics \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Seed Health","sponsor":"The Craftory","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"SEED synbiotic","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seed Health","amount2":0.040000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Seed Health \/ The Craftory","highestDevelopmentStatusID":"8","companyTruncated":"Seed Healt.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Samil Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Biosplice \/ Samil Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Italian Angels for Growth","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"PEP-Therapy Raises \u20ac2.75 Million in Series A Financing to Advance Its Lead Candidate, PEP-010, Into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"PEP-Therapy \/ Italian Angels for Growth","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therap.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"$168.0 million","newsHeadline":"Knight Therapeutics to Acquire Regional Rights to Exelon\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.17999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Kartos Therapeutics","sponsor":"Illumina","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"KRT-232","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kartos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kartos Therapeutics \/ Illumina","highestDevelopmentStatusID":"9","companyTruncated":"Kartos The.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics & TG Expand Collaboration for Large Scale Mfg of Ublituximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samsung Biologics \/ TG Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"CT-0508","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"University of Minnesota","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Minnesota \/ CARISMA Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","amount":"$363.0 million","upfrontCash":"$10.0 million","newsHeadline":"Pieris Pharmaceuticals and Boston Pharmaceuticals Ink Exclusive Worldwide Product License for PRS-342","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"PRS-342","moa":"4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pieris Pharmaceuticals","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Pieris Pharmaceuticals \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Miami University Broaden","sponsor":"PsyBio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsyBio and Miami University Broaden Partnership for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Miami University Broaden","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miami University Broaden \/ PsyBio","highestDevelopmentStatusID":"4","companyTruncated":"Miami Univ.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"OS Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria monocytogene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$393.6 million","upfrontCash":"$8.5 million","newsHeadline":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"FR104","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0.39000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$30.0 million","newsHeadline":"Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":1.1299999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.1299999999999999,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Bristol Myers Squibb to Extend Their Targeted Protein Degradation Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein degradation","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"Asher Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"AB248","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ Asher Bio","highestDevelopmentStatusID":"5","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Palisade Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leading BioSciences Closes Merger with Seneca Biopharma and Set to Begin Trading on Nasdaq as PALI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Merger","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Seneca Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","amount":"$3360.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioVie Acquires Biopharma Assets from Privately Held NeurMedix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"17\u03b1-ethynyl-androst-5-ene-3,7,17-triol","moa":"Mapk3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":3.3599999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.3599999999999999,"dosageForm":"Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix .."},{"orgOrder":0,"company":"Shasqi","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shasqi Awarded Prestigious Direct-to-Phase-2 Small Business Innovation Research Grant by National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Funding","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"$591.0 million","upfrontCash":"$10.0 million","newsHeadline":"LogicBio Therapeutics Ink Collaboration with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0.58999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"Intravenous infusion","sponsorNew":"LogicBio Therapeutics \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arch Oncology Secures $105 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series C Financing","leadProduct":"AO-176","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intravenous Injection","sponsorNew":"Arch Oncology \/ Eventide Asset Management","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncol.."},{"orgOrder":0,"company":"Blue Water Acquisition Corporation","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","amount":"$379.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Acquisition Corporation Announces Merger Agreement with Clarus Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Merger","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Blue Water Acquisition Corporation","amount2":0.38,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.38,"dosageForm":"Capsule","sponsorNew":"Blue Water Acquisition Corporation \/ Clarus Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zuellig Pharma Partners with Moderna to Supply Moderna\u2019s Covid-19 Vaccine in Asia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boundless Bio Raises Oversubscribed $105 M Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against ecDNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"ecDNA-directed therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Boundless Bio","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Boundless Bio \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Acquires Amplyx Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Allen Institute","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Allen Institute","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allen Institute \/ BioMarin","highestDevelopmentStatusID":"1","companyTruncated":"Allen Inst.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AavantiBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Psychedelic drug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biot.."},{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma\u00ae Announces Acquisition of Park Therapeutics \u2013 Pain Company with First-in-class, Phase III-Ready New Chemical Entity (NCE)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Park Thera.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alcon Inc","pharmaFlowCategory":"D","amount":"$355.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Brinzolamide","moa":"CA2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.35999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.35999999999999999,"dosageForm":"Ophthalmic suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alcon","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Adcendo","sponsor":"Novo Seeds","pharmaFlowCategory":"D","amount":"$62.2 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Antibody drug conjugate","moa":"uPARAP","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adcendo","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Adcendo \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Adcendo \/ .."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Public Offering","leadProduct":"WTX-124","moa":"Interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma Announces Exclusive Agreement with AFT Pharmaceuticals for Injectable Non-Opioid Pain Medication Combogesic\u00ae IV in the US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AFT Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AFT Pharmaceuticals \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"AFT Pharma.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Public Offering","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"SLN501","moa":"Complement C3","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":2.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.02,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Mallinckrodt","highestDevelopmentStatusID":"5","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Inks Collaborates with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Darolutamide","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma and Zylo Enter Into Joint Venture Agreement to Focus on the Development of Ketamine using ZTI\u2019s Z-pod\u2122 Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zylo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sustained Transdermal","sponsorNew":"Zylo Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zylo Thera.."},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"CBC Group","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adcentrx Complete $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Antibody drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adcentrx Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Adcentrx Therapeutics \/ CBC Group","highestDevelopmentStatusID":"1","companyTruncated":"Adcentrx T.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Sirnaomics","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"STP702","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Sirnaomics \/ Sirnaomics","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"D-alanyl-D-alanine carboxypeptidase DacB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Melinta Therapeutics \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$11.0 million","newsHeadline":"Mirum Pharmaceuticals and CANbridge Pharmaceuticals Ink Licensing Agreement for Maralixibat in Greater China for Rare Liver Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Oral solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Resbiotic","sponsor":"Timberline Holdings","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"ResBiotic Raises $3M Seed Round and Announces Leadership Team","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Financing","leadProduct":"Probiotic","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Resbiotic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Resbiotic \/ Timberline Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Resbiotic .."},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Precirix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precirix Partners with Evergreen to Expand North American Clinical Trial Supply","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"131-Iodine conjugated anti-HER2 sdAb 2Rs15d","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evergreen Theragnostics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Evergreen Theragnostics \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Evergreen .."},{"orgOrder":0,"company":"Biophytis","sponsor":"BPI","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Receives \u20ac980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Funding","leadProduct":"BIO201","moa":"PPAR alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ BPI","highestDevelopmentStatusID":"4","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Versiti","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Versiti to Coordinate NIH Trials of Blood Thinners to Improve Care for COVID-19 Patients at Risk for Blood Clots","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Versiti","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Versiti \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Versiti \/ .."},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$7.5 million","newsHeadline":"Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Divestment","leadProduct":"Testosterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Aytu BioPharma \/ Acerus Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPh.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$490.0 million","upfrontCash":"$30.0 million","newsHeadline":"PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"9 Meters Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"9 Meters Biopharma Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"NM-002","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Duke Clinical Research Institute","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Duke Clinical Research Institute \/ 9 Meters Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Duke Clini.."},{"orgOrder":0,"company":"Foundation for Prader-Willi Research","sponsor":"Saniona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saniona Annonces Partnership with Foundation for Prader-Willi Research to Support its Prader-Willi Syndrome Clinical Trial with Tesomet","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"Tesofensine","moa":"Triple monoamine reuptake","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Foundation for Prader-Willi Research","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation for Prader-Willi Research \/ Saniona","highestDevelopmentStatusID":"8","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Announces Clinical Trial Collaboration with MSD for the Phase II Study in mTNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharma, Eli Lilly accelerate antibody therapies in Greater China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody therapies","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$620.0 million","upfrontCash":"$90.0 million","newsHeadline":"Capsida Biotherapeutics Debuts with $140 Million of Capital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsida","amount2":0.62,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.62,"dosageForm":"","sponsorNew":"Capsida \/ AbbVie","highestDevelopmentStatusID":"3","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Denk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI for COVID-19 Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NRx Pharmaceuticals \/ Denk Pharma","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s OCREVUS Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford University Expands Com-Cov2 Dose-Mixing Study with Novavax\u2019s Covid-19 Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Looking to Cement Its Lead in packed MS market, Roche's Ocrevus Uncorks New Data in Early-Stage Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bold Therapeutics' BOLD-100 Effective In Vitro Against COVID-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BOLD-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Revumenib","moa":"Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Analyzes Interhospital Transport of Newborns Using VERO Biotech's GENOSYL Delivery System for Delivery of Inhaled NO","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"VERO Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VERO Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VERO Biote.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Experimental Antiviral for COVID-19 Effective in Hamster Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"National I.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Grows Presence in China with The Approval of Tecfidera for The Treatment of Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in M.S","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Reports Darovasertib's Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Darovasertib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Kesimpta data Showed Reduction in Disability Progression Independent of Relapse Activity in Newly Diagnosed Patients with RMS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chipscreen Received a Phase 1b\/2 Clinical Trial of Chiauranib\/CS2164 IND Clearance from the US Food and Drug Administration (FDA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Chiauranib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prostate Cancer Study to Be Initiated at Uppsala University Hospital with Nano Zolid Technology\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Momenta Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Showcases Phase 2 Nipocalimab Data in Adults with Generalized Myasthenia Gravis at the 2021 ANN","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Momenta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA Oral Solution on Dravet Syndrome Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Integrated Data and Follow-up Outcomes From Two TEPEZZA Pivotal Trials Published in The Lancet Diabetes & Endocrinology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data for UPLIZNA\u00ae (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"CTGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Is Starting Clinical Trials of A Covid Vaccine that Can Be Inhaled","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Submits Application for Conditional Marketing Authorization of Melflufen in the EU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Jubilant Pharmova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Pharmova Arm Completes Studies Using Novel Oral Formulation of Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Jubilant Pharmova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Pharmova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Requests Revocation of EUA doe Bamlanivimab Alone in the U.S to Complete Transition to Bamlanivimab and Etesevimab Together","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viewpoint Molecular Targeting (TM) Presents Positive Preclinical Results of VMT01 at the 10th World Congress of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"VMT01","moa":"MC-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viewpoint Molecular Targeting","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viewpoint Molecular Targeting \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viewpoint .."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in Nature Shows F-Star\u2019s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nerve cell therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Steriles Receives Final USFDA Approval for Milrinone Lactate Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Milrinone Lactate","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Ste.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darzalex SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Chimeric Antigen Receptor-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil's Health Regulator Greenlights Trials of New Chinese Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALK Gains Paediatric Approval for Its Ragweed Slit-Tablet in the USA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Short Ragweed Pollen Allergen Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CA-4948","moa":"IRAK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Has Determined the Starting Dose for the Next Part of the Phase Ib Study with MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Advances Research in Spinal Muscular Atrophy with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Receives IND Clearance from the U.S. FDA for ALLO-605 for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ALLO-605","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates 97.6% Efficacy According to Analysis of Data from 3.8 Million Vaccinated Persons in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"Tregs migration","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at AAD Virtual Meeting Experience","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Trichomylin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Reports Data on Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Start a Potential Registrational Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fosun Submits Trial Data of Foreign Covid-19 Vaccine for State Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PRX004","moa":"TTR protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Gives Go-Ahead for XBiotech\u2019s Candidate Therapy for Phase I\/II Double-blind Placebo Controlled Study in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AACR 2021-ImmVira Presents the Preclinical Study Results of MVR-T3011 Via Intravenous Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MVR-T3011","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces Submission of Tyvaso DPI\u2122 New Drug Application to FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry powder for inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Corp's VASCEPA Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Zilucoplan Shows no Relevant Effect in Immune-Mediated Necrotizing Myopathy (IMNM)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk to Initiate Phase 3a Development in Obesity With Oral Semaglutide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biot.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apabetalone\u2019s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiple Abstracts from Incyte\u2019s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD824","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax\u2019s MMS019 Reduced Nasal and Brain Viral Load in Animal Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MMS019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ABX-002","moa":"TR-Beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Autobahn Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Initiates Pivotal Clinical Study of Novel Antisense Medicine to Treat Patients with Alexander Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ION373","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"FGFR2B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Large Clinical Trial to Study Repurposed Drugs to Treat Covid-19 Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Resumes Launch Of Generic Version Of GlaxoSmithKline's Advair Diskus In U.S","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Betaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Betaliq Initiates Enrollment of Phase 2 Clinical Trial For The Treatment of Glaucoma or Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BTQ-1901-A","moa":"Beta","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic suspension","sponsorNew":"Betaliq \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ .."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Two Ibrexafungerp Posters at the 2021 ACOG Annual Clinical and Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"MAO","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Presents Analysis Examining Real-World Data on ALS Patient Disease Progression Milestones","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol\u00ae Cyclo\u2122 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Gives Update on Phase 3 ACIS Study in Prostate Cancer Treated with ERLEADA, ZYTIGA Plus Prednisone Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals Gets EC Approval for EPIDYOLEX for the Treatment of Seizures Linked with Tuberous Sclerosis Complex","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sermonix Project With Huntsman Cancer Institute Researcher to Investigate Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sermonix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sermonix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sermonix P.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono's Evobrutinib, First and Only BTK Inhibitor to Reduce a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Translational Research In Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Translatio.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Prevotella histicola strain","moa":"IL-6","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CB4211","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Group Receives European Marketing Authorization for Trimbow\u00ae Inhalation Powder for the Treatment of Moderate to Severe COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pressurized metered-dose inhaler","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Genomics To Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Mount Sinai Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mount Sinai Hospital in New York Joins RhoVac's Phase IIb Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mount Sinai Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mount Sinai Hospital \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mount Sina.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1\/TGF-\u03b2 Antibody TST005","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TST005","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Statement on NEJM of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves GSK\u2019s Checkpoint Inhibitor Jemperli for Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-L1 checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Steriles Gets US FDA Approval for Generic Bloxiverz Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Milrinone Lactate","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Ste.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vortioxetine Significantly Improves Overall Functioning in A Global Real-World Study in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin reuptake","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak\u2019s exoSTING Preclinical Development Data for Solid Tumors Published in Nature Research Publication, Communications Biology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CDK-002","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of Therapeutics for Severely Ill Hospitalized Covid-19 Patients Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"National I.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Pharma launches Benralizumab (Fasenra) for asthma patients; Stock skyrockets 11%","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome Patients Treated with FINTEPLA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Completes Enrollment for its Expanded Access Trial to Treat COVID-19 Patients with Zofin\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alladapt Commences Phase 1\/2 Clinical Trial in Food Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic enzymes enriched in bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH\u2019s ACTIV-2 Phase 2\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"SAB Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Triple monoamine reuptake","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patents for Nicox\u2019s Latanoprostene Bunod, Commercialized as VYZULTA\u00ae, Eligible for Patent Term Extension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor- Update on the Company's Phase III Clinical Trial of Drug Candidate AKP02 for Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yumanity Therapeutics\u2019 YTX-7739 Achieved Target Engagement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"scAAV8OTC","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Expands its Phase II COVID-19 Study to Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Monopteros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopteros Therapeutics Initiates Clinical Trial to Reprogram Regulatory T Cells in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MPT-0118","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopteros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopteros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopteros.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Gets Emergency Nod for Pegylated Interferon ALPHA-2b, \u2018Virafin\u2019 for Covid-19 Treatment in Adult","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegylated Interferon alpha-2b","moa":"INF alpha receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\"The New England Journal of Medicine\" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's OLUMIANT Improves Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VOLTAIRE-X Phase III Data in Patients with Moderate-to-Severe Chronic Plaque Psoriasis Support Interchangeability Application","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical's TREMFYA Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Dupixent Analyses Reinforce Long-term Safety and Efficacy Profile in Atopic Dermatitis as Young as 6 Years","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Gets +Ve CHMP Opinion for VENCLYXTO as a Combination Regimen for Adult Patients with Newly Diagnosed AML Ineligible for Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Novavax","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ University of Oxford","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Receives Positive CHMP Opinion of Adtralza\u00ae (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharma Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Eczema Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Showing Superiority of Deucravacitinib Vs Placebo and Otezla","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives +Ve CHMP Opinion for Onureg as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Gusacitinib at AAD VMX","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gusacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo for High-Grade Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces FDA Approval of ZYNLONTA\u2122 (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces FDA Approval of ZYNLONTA\u2122 (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Submits NDA in Japan for Filgotinib for Ulcerative Colitis with An Inadequate Response to Conventional Therapies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pressurized metered-dose inhaler","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis to Initiate SMART Phase 3b Global Study of Zolgensma in Children up to 21 kg, Building on Real-World Experience","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Taltz Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Vs Seven Other Biologics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Reports Results from Phase 3 Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel for Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress\u2122 2021 (EASL)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"FASN","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at AAD 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Steriles Receives USFDA Approval for Prochlorperazine Edisylate Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Prochlorperazine Edisylate","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Ste.."},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gland Pharma Receives Approval for Generic Foscarnet Sodium Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Foscarnet Sodium","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHAR.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Begins Patient Dosing in Phase 2 Study of Rigosertib to Treat RDEB-Associated Locally Advanced\/Metastatic SCC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Apex Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Laboratories Gets Approval for CleVira as Covid Supportive Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Andrographis paniculata","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Apex Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apex Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apex Labor.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Demonstrated Protection Against Respiratory Syncytial Virus Disease in Healthy Infants in Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Biocon","sponsor":"Viatris","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ V.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Storm Therapeutics Publishes Data in Nature Showing its METTL3 Inhibitor Drug Is Effective as a New Therapeutic Strategy Against AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"STM2457","moa":"METTL3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Storm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Launches a New Research Program to Develop a Melanoma Treatment Drug Candidate for FDA Approval Track","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HyBryte\u2122 Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark's Ryaltris Nasal Spray Now Approved in Europe for the First Line Treatment of Allergic Rhinitis in Patients over 12 Years of Age","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intraparenchymal infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sunitinib analog","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Completes Successful Pre-IND Meeting with the FDA for its TRS02 Program of Back-of-the-Eye Blinding Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TRS02","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Seeks Approval for Covid Drug Candidate Molnupiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"5-HT1A\/2A\/2B\/7 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Reports Progress in Phase 3 Trial of COVID-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"A*STAR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Duke-NUS Medical School's Newly-Discovered Molecule Provides Dual Protection Against Vascular Inflammation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"SINGAPORE","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Cytochrome C oxidase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Duke-NUS Medical School","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duke-NUS Medical School \/ A*STAR","highestDevelopmentStatusID":"2","companyTruncated":"Duke-NUS M.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selumetinib Gets EU Recommendation as the First Medicine for Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MEK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Recommended for Approval in the EU by CHMP For the Adjuvant Treatment of Patients with Early-Stage Egfr-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zosano Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Medicago","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada to Start Real-Time Review of Medicago COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Two-Years Follow-up Data from ETNA-AF-Europe Reaffirms Benefit of LIXIANA\u00ae (Edoxaban) in People with Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Chugai\u2019s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Reports Clinical Findings that Supports DaxibotulinumtoxinA\u2019s 24-Week Long Duration Profile Across Multiple Female Age Cohorts","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"SQZ-PBMC-HPV","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive in Vivo Results with AFFiRiS\u2019 mAB C6-17 to Treat Huntington\u2019s Disease to be Presented at the 16th HD Therapeutics Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"mAB C6-17","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Affiris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affiris \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Affiris \/ .."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-Ocular in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Progesterone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Hormone","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Meets All Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Launches Global Access Program for FINTEPLA\u00ae (Fenfluramine) Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"STING pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021 Annual Virtual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillhurst Biopharmaceuticals Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of HBI-002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hillhurst Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst .."},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Rebonuputemcel","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Intradiscal injection","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals to Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics to Present at 4th Global NASH Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"STI-3031","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Mount Sinai School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepatitis C Drugs Combined with Remdesivir Show Strong Effectiveness Against Covid-19, Study Finds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Simeprevir","moa":"SARS-CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mount Sinai School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mount Sinai School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mount Sina.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PYX-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noven to Present Pivotal Study Results for Investigational Dextroamphetamine Transdermal System for Pediatric ADHD Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Noven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noven Phar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial of Existing Antibiotic for Treating Staphylococcus Aureus Bacteremia Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dalbavancin","moa":"D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Elicera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicera Therapeutics Files a Patent Application for the Development of the Next Generation Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ELC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicera Th.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ITIL-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Signature Biologics\u2122 Research & Development Staff Published Advanced Findings on COVID-19 and hUC Mesenchymal Stem Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Human umbilical cord derived mesenchymal stem cells","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Signature Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Signature Biologics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Signature .."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for Clinical Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion\u2122 in Osteoarthritis and COVID-19","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Announce PRIME Designation Granted by the EMA to CTX001\u2122 for Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets FDA Priority Review for NDA for Mobocertinib as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Doses First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in R\/R Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRUKINSA Found Superior to Ibrutinib in a Interim Analysis in a Trial for Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Evaluating Use of Olumiant in Hospitalised COVID-19 Patients Requiring Supplemental Oxygen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Drops BCMA Drug After Seeing Early Clinical Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MEDI2228","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Announces Topline Results From KARE Phase 2 Dose-Ranging Trial in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Begins Patient Dosing in Phase 2 Trial of IBI302 to Treat Neovascular Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI302","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance to Present Clinical Data for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Analysis from Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delix Therapeutics Publishes Study Demonstrating Therapeutic Potential for a Psychedelic Analog--Without Hallucinogenic Effects","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AAZ","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Concludes Cenicriviroc Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenicriviroc","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present Clinical Updates for SRF388 and SRF617","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27 antibody","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Doses First Subject in Phase 1 Study of XmAb\u00ae564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"XmAb-27564","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in CARE-HK in HF to Evaluate Role of Veltassa\u00ae (Patiromer) in Enabling RAASi Treatment","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Nefecon, for Patients with IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Pharma Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma and Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 for ABCC6 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarus Therapeutics Seeks To Initiate Clinical Trial of TT-4 (A2BR Antagonist) in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Ther.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharma Surpasses 50 Percent Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed\/Refractory B Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"NKX019","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered hematopoietic stem cell therapy","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T\u2122 Therapy Program in R\/R Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ALLO-501","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CiVax","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris' Ph 1 LUT014 Data for Skin Toxicities Linked with Treatment of Colorectal Cancer with EGFR Inhibitors Published in Cancer Discovery","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"LUT-014","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Lutris Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pha.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Icon Plc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The 24-Month Follow-Up of DIAGNODE-2 With the Diabetes Vaccine Diamyd\u00ae Will be Presented in Early July","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant human glutamic acid decarboxylase","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ ICON","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok\u00ae Phase 3 Trial-Related Webinar","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Okogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okogen Reports Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"OKG-0301","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Okogen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Okogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Okogen \/ N.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics To Present a Dovitinib-DRP\u00ae e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dovitinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Safety Shot \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bexson Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Bio.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Eukaroyotic ribosomal selective glycoside","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics Expands The Connection Study to Include Infants with a Birth Weight Below 750 Grams","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral drop","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo\u00ae (Glucagon) Injection for the Treatment of Severe Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented by AKL Research and Development Advances Understanding of Biological Effects of APPA to Protect Against Joint Damage","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AKL4","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AKL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therap.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ilaris\u00ae Receives Health Canada Approval as First of Its Kind Treatment for Rare, Inflammatory Disorder, Adult-Onset Still's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports New Preclinical Data for COVID-19 Vaccine Confirming Potential for Broad Protection against SARS-CoV2 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene Has HER-Vaxx Phase 1B Data Published in Prestigious Clinical Cancer Research Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"IMU-131","moa":"HER2\/NEU receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 Ophthalmic Solution for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AVX012","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine in High-risk Non-hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s Phase III Psoriasis Study Achieves 75% Enrollment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAVENCIO Receives Reimbursement Recommendation from pCODR and INESSS for the Maintenance Treatment of Patients with Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune to Present at Upcoming Scientific Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in Humans","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PLX-R18","moa":"PPi\/Adenosine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review BMS\u2019 Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope Opens Phase 2 Clinical Trial to Test If Intake of Mushroom-Powder Tablets Could Slow the Progression of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"White Button Mushroom Extract","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Gets SEC Approval for Phase 3 Trials of Sputnik V","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Bio.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate\/Severe COVID-19 ARDS, Reports Mesoblast","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Fera Pharmaceuticals, LLC","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Updates on Fera Pharmaceuticals\u2019 Continuing Evaluation of Naproxcinod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Naproxcinod","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fera Pharmaceuticals, LLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fera Pharmaceuticals, LLC \/ Nicox","highestDevelopmentStatusID":"4","companyTruncated":"Fera Pharm.."},{"orgOrder":0,"company":"SOLA Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOLA Biosciences Presented Positive ALS Animal Efficacy Data of SOL-257","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"SOL-257","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SOLA Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SOLA Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SOLA Biosc.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Receives EC Approval of ORLADEYO, First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"PRAX-562","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Praxis Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY\u00ae in the EU to Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Confirms the Stability and Potency of a Novel Formulation of Liquid Levothyroxine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"IBSA Institut Biochimique","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Solution","sponsorNew":"IBSA Institut Biochimique \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IBSA Insti.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Data on Positive Outcome and Sustained Response of Oral Ibrexafungerp in Difficult-to-Treat Vaginal Yeast Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Presents Data Evaluating INOmax, for Inhalation in Neonates with Pulmonary Hypertension at PAS 2021 Virtual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Efficacy Data Reinforces NEXTSTELLIS\u00ae Benefits Across Patient Populations","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Drospirenone","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech: First US Patient Enrolled in the Fima Chem Pivotal RELEASE Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics to Share Clinical Update for 30 mg\/kg arm of MOMENTUM Study for SRP-5051","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"SRP-5051","moa":"Dystrophin expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva SA Presents Posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Gets EC Approval for KAFTRIO in Combo with Ivacaftor to Treat Cystic Fibrosis With At Least One F508del Mutation in the CFTR gene","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International and FDA Reaches Agreement on Trial Design for First Stem Cell Clinical Trial in Chronic Traumatic Encephalopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Stem Cells Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pvsripo","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Istari Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Istari Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Istari Onc.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"DKN-01","moa":"Dickkopf-1 activity","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Positive Data Against Streptococcus Pneumoniae Sinusitis Infection in Animal Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Starts Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Methadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Submits NDA to U.S. FDA and China NMPA for Plinabulin and G-CSF Combo for Prevention of Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GEF-H1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Celon Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celon Pharma Announces CPL\u2019280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CPL\u2019280","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Celon Labs","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celon Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celon Labs.."},{"orgOrder":0,"company":"AEGIS Ltd. Cyprus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aegis Life Announces Start of Phase 1\/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"VAX-001","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AEGIS Ltd. Cyprus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEGIS Ltd. Cyprus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AEGIS Ltd..."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The EASL 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR signalling","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceuticals Sucessfully Dosed First Batch of Patients for Acne Vulgaris Phase I\/II Clinical Trial of Pyrilutamide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moffitt Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moffitt Cancer Center \/ Anixa Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Moffitt Ca.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Taltz\u00ae (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Center Groningen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Doses First Patient with Next-Gen Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ University Medical Center Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J\u2019s Covid Vaccine Remains Paused as Cdc Advisers Seek Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Therapeutics Closes $100 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"NLRP3","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ BVF Partners L.P","highestDevelopmentStatusID":"2","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Drug Regulator Asks Dr.Reddy's For More Data on Sputnik V Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Demonstrates In Vitro Activity of DeltEx DRI CAR-T Cells Against Glioblastoma Multiforme at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"DeltEx DRI Chlorotoxin CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Data Showing LUPKYNIS Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Merck Group","sponsor":"NKMax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NKMax, Merck Expand Clinical Collaboration to Include Phase I\/IIa Trial of SNK01 in Combo With Erbitux To Treat L Metastatic NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous natural killer cells","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ NKMax","highestDevelopmentStatusID":"7","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Institut Pasteur Korea","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Institut Pasteur Korea & Genexine Sign MOU for Global Clinical Trials for the COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"GX-19N","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Institut Pasteur Korea","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Institut Pasteur Korea \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Institut P.."},{"orgOrder":0,"company":"AltruBio","sponsor":"aMoon","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Altrubio Raises $63 Million Series A Round to Continue Its Company Transformation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AltruBio","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ aMoon","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Achieves Fast Track Designation From US FDA For Efti In First Line Recurrent\/Metastatic Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite Submits Supplemental Biologics License Application to U.S. FDA for Tecartus to Treat Relapsed\/Refractory Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Gets Patent for Additional Dims Compounds Granted in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford-AstraZeneca Paediatric Vaccine Trial Halted Amid Blood Clot Concerns","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Publishes Data Shwoing Potential of Pan-RGD Integrin Antagonists to Improve the Treatment of Diabetic Retinopathy and Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics to Present Research at the National Kidney Foundation\u2019s 2021 Spring Clinical Meetings","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"DM199","moa":"Kallikrein-1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$780.0 million","upfrontCash":"$27.0 million","newsHeadline":"Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize Avcs for The Prevention and Treatment of Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0.78000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Janssen","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Termination of Vaccine Business Alliance with Sanofi in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Termination","leadProduct":"Bordetella pertussis protective antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Daiichi Sankyo \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Kahr Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"TIGITxPD1 fusion protein","moa":"IgG1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kahr Medical \/ KAHR","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"Iconovo","sponsor":"Immune System Regulation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ISR Signs Agreement with Iconovo for Development of Inhaled Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Adjuvanted SARS-CoV-2 spike proteins","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iconovo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Iconovo \/ Immune System Regulation","highestDevelopmentStatusID":"4","companyTruncated":"Iconovo \/ .."},{"orgOrder":0,"company":"Evotec","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Enters Agreement with Takeda Pharma to Discover & Develop RNA Targeting Small Molecule Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Evotec \/ Takeda","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ T.."},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"Filgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kashiv Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv Specialty Pharmaceuticals \/ Amneal","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Spe.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Alembic Global Holding SA Receives USFDA Final Approval for Treprostinil Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for inhalation","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repertoire Immune Medicines to Present Data from Autologous T Cell Therapy in Advanced or Metastatic Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"RPTR-147","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Simcah Management","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah Management","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series A Financing","leadProduct":"Platelet-based freeze-dried hemostatic agent","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0.02,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellphire Therapeutics \/ Simcah Management","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire .."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology To Present Phase 2 Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at Virtual AACR Annual Meeting 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Showcase Phase 3 Results Evaluating DaxibotulinumtoxinA for Injection for Cervical Dystonia at the 2021 AAN Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Gets USFDA Approval for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units\/gram and 1 mg\/gram","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Nystatin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech to Initiate Trials of Booster Dose of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Phase 3 ITAC Trial Evaluating Immunoglobulins to Treat Hospitalized Patients with Covid-19 Fails to Meet Endpoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical AB Fully Recruited Patients in Clinical Trial with Diamyd\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical To Present at Upcoming Scientific Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the Design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DIAGNODE-2 Results and Meta-Analysis with Diamyd\u00ae to Be Presented at Diabetes Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Athenex","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$70.0 million","newsHeadline":"Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Intravenous infusion","sponsorNew":"Kuur Therapeutics \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Core One Labs Completes Milestone Acquisition of Akome Biotech","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biot.."},{"orgOrder":0,"company":"Oculis","sponsor":"BVCF Management","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oculis Announces an Oversubscribed US$57 million Series C Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.059999999999999998,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ BVCF Management","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ B.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"$1.0 million","newsHeadline":"Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Interleukin 6","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Hosts Organon Investor Day Outlining New Company\u2019s Vision, Focus and Business Model for Sustained Growth","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Skin Implant","sponsorNew":"Merck & Co \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gyroscope Therapeutics Postpones Initial Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys and BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"BVX-0918A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio Elpida","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Elpida \/ BioVaxys","highestDevelopmentStatusID":"4","companyTruncated":"Bio Elpida.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Terminates $450M+ Cytokinetics Pact","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Termination","leadProduct":"Reldesemtiv","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Astellas","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Merck Group","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics Licensed Tri-Specific Nanobody\u00ae Sonelokimab from Merck KGaA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"Il-17 alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck Group \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"William Harvey Research Institute","sponsor":"Cyxone AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"World Leading Rheumatology Authority Professor Costantino Pitzalis Collaborates with Cyxone on Rabeximod Phase 2b Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"William Harvey Research Institute","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"William Harvey Research Institute \/ Cyxone","highestDevelopmentStatusID":"8","companyTruncated":"William Ha.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of California","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ University of California","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Enzyvant","sponsor":"Aceragen","pharmaFlowCategory":"D","amount":"$226.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aceragen Launches with Acquisition of Enzyvant\u2018s Investigational Therapy for Farber Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Recombinant human acid ceramidase","moa":"Acid ceramidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enzyvant","amount2":0.23000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Enzyvant \/ Aceragen","highestDevelopmentStatusID":"5","companyTruncated":"Enzyvant \/.."},{"orgOrder":0,"company":"GamaMabs Pharma","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma\u2019s Humanized Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Murlentamab","moa":"AMHR2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GamaMabs Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"GamaMabs Pharma \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"GamaMabs P.."},{"orgOrder":0,"company":"Esteve Huayi Pharmaceutical","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Esteve and Kowa Pharmaceuticals America Enter into an Exclusive License and Commercialization Agreement for Rights to E-58425","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Esteve Huayi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esteve Huayi Pharmaceutical \/ Kowa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Esteve Hua.."},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"$2,050.0 million","upfrontCash":"$450.0 million","newsHeadline":"UniQure Announces Closing of Commercialization and License Agreement With CSL Behring","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":2.0499999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"Intravenous infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinia Therapeutics Closes $110 Million Series B Financing","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series B Financing","leadProduct":"AAV-based gene therapies","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Affinia Therapeutics","amount2":0.11,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Affinia Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7,200.0 million","upfrontCash":"$7,200.0 million","newsHeadline":"Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":7.2000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":7.2000000000000002,"dosageForm":"Oral solution","sponsorNew":"GW Pharmaceutical \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Alchemab","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alchemab to Collaborate with AstraZeneca on Prostate Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/.."},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI-Powered Gene Therapy Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"AAV based-gene therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Thera.."},{"orgOrder":0,"company":"Stanford Medical","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Partners with Stanford on Immunology research","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Stanford Medical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stanford Medical \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Stanford M.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Biopharmaceuticals Files for $100M IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Immediate-release tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Esker Therapeutics Launches to Transform the Treatment of Autoimmune Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"ESK-001","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Alumis","amount2":0.070000000000000007,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ F.."},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Osimertinib Mesylate","moa":"TUSC2 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Chiasma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Amryt Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Nicox SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nicox Partners with Laboratorios Grin to Bring ZERVIATE to Mexico","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Cetirizine","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Lupin Ltd \/ Nicox","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Albert Einstein Israelite Hospital","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Reaches Agreement with Albert Einstein Israelite Hospital in Brazil to Conduct Two COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"BRAZIL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"Tregs migration","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Albert Einstein Israelite Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Albert Einstein Israelite Hospital \/ CytoDyn","highestDevelopmentStatusID":"8","companyTruncated":"Albert Ein.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"DanCann Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tetra BioPharma \/ DanCann Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Grace","sponsor":"Acasti Pharma","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"$64.0 million","newsHeadline":"Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Nimodipine","moa":"Voltage-gated L-type calcium channel subunit beta-4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Grace","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous infusion","sponsorNew":"Grace \/ Acasti Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Grace \/ Ac.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Amplitude Healthcare Acquisition Corporation","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$180.0 million","newsHeadline":"Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Merger","leadProduct":"Humanized anti-CD117 monoclonal antibody","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.38,"dosageForm":"Intravenous infusion","sponsorNew":"Jasper Therapeutics \/ Amplitude Healthcare Acquisition Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Talaris Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Cryopreserved allogeneic stem cell therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Announces Closing of $40 Million Bought Deal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Inspira","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"IPA-001","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Inspira","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"APL-1202","moa":"MetAP2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Asieris","highestDevelopmentStatusID":"4","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Buzzard Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Biopharmaceuticals and Buzzard Pharmaceuticals Start a Collaboration to Develop a New Treatment to Combat Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Isunakinra","moa":"IL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"3P Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"3P Biopharmaceuticals \/ Buzzard Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"3P Biophar.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Oculis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oculis Selects AGC Biologics\u2019 Heidelberg Facility to Manufacture OCS-02","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"OCS-02","moa":"TNF-alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"AGC Biologics \/ Oculis","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Enters into Voluntary Licensing Agreement with Lilly to Expand Access for COVID-19 Treatment in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Signs Voluntary Licensing Agreement with Eli Lilly for Expanding Access to Baricitinib in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prothena Announces Achievement of $60 Million Milestone From Roche","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"URAT1","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Fortress Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuh.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Checkmate Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod in Combination with Libtayo","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Cemiplimab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Checkmate Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Testosterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amneal Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunological Disease Biotech Vera Therapeutics Sets Terms for $65 Million IPO","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Syngene International Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syngene International Limited \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Syngene In.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$25.0 million","newsHeadline":"Lilly and MiNA Therapeutics Announce saRNA Research Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":1.25,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.25,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$40.8 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series B Financing","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Capsigen","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$1,307.0 million","upfrontCash":"$15.0 million","newsHeadline":"Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"AAV capsids based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsigen","amount2":1.3100000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.3100000000000001,"dosageForm":"","sponsorNew":"Capsigen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Capsigen \/.."},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$162.5 million","upfrontCash":"Undisclosed","newsHeadline":"Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Autologous anti-BCMA CAR-T therapy","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ .."},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"CTX-009","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Trigr \/ Compass Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Co.."},{"orgOrder":0,"company":"TMS","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$353.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"TMS-007","moa":"Plasminogen","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TMS","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Inravenous infusion","sponsorNew":"TMS \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"TMS \/ Biog.."},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nexturn Bio Inc. Decided to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using miRNA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"miRNA based therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Th.."},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"Vivacitas Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Silatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IAG, Image Analysis Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IAG, Image Analysis Group \/ Vivacitas Oncology","highestDevelopmentStatusID":"8","companyTruncated":"IAG, Image.."},{"orgOrder":0,"company":"XOMA","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Cetrelimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Janssen Biotech","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Jan.."},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"NPH-022","moa":"Epoxyeicosatrienoic acid","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Nephraegis Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nephraegis Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Nephraegis.."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"RNA Engineered Allogeneic Human Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"TT-20","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tellus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tellus Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Tellus The.."},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"NDI-5033","moa":"AMPK","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NephroDI Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI T.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dana-Farber Receives $50 million Funding to Study Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectis and Sanofi Partner on Alemtuzumab as Lymphodepletion Agent for Allogeneic CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Alemtuzumab","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Cellectis","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ C.."},{"orgOrder":0,"company":"SpliSense","sponsor":"Biotel Limited","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"SpliSense Secures $28.5 Million in Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series B Financing","leadProduct":"SPL84-23","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SpliSense","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"SpliSense \/ Biotel Limited","highestDevelopmentStatusID":"5","companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Rinri Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rinri Therapeutics Secures Innovate UK Funding Grant for \u00a33.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Stem cell therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Rinri Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rinri Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Rinri Ther.."},{"orgOrder":0,"company":"Interline Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"Undisclosed","newsHeadline":"Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Interline Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Interline Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"4","companyTruncated":"Interline .."},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Transcription factor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Flare Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Flare Ther.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Macleods Pharmaceuticals Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"Tregs migration","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Macleods Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"OrbiMed Asia Partners","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"KIN-2787","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ OrbiMed Asia Partners","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Autobahn Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"ABX-003","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Autobahn Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Polish National Center for Research and Development","pharmaFlowCategory":"D","amount":"$6.7 million","upfrontCash":"Undisclosed","newsHeadline":"WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous infusion","sponsorNew":"WPD Pharmaceuticals \/ Polish National Center for Research and Development","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AUM Biosciences enters in a Strategic Collaboration with Handok and CMG Pharm to develop CHC2014","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"CHC2014","moa":"Pan-TRK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"HANDOK \/ AUM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ A.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Alzheimer's Biotech Alzamend Neuro Files for a $12 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Kinase Inhibitors for Treatment-Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series B Financing","leadProduct":"NVL-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Nuvalent \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"SiteOne Therapeutics Announces $1.73M Grant from NIH\/NHLBI and Adds Respiratory Advisory Team","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SiteOne Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Th.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic suspension","sponsorNew":"Kala Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"PIP-2","moa":"Peroxiredoxin 6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peroxitech Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech.."},{"orgOrder":0,"company":"Shifa Biomedical","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shifa Launches with Seed Financing to Develop Orally Bioavailable Drugs for the Treatment of Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"P-21","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Shifa Biomedical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shifa Biomedical \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Shifa Biom.."},{"orgOrder":0,"company":"ActualEyes","sponsor":"Arctic Vision","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arctic Vision Announces Exclusive Licensing Agreement With ActualEyes to Develop and Commercialize Cell Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Rho-associated kinase-Human corneal endothelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ActualEyes","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"ActualEyes \/ Arctic Vision","highestDevelopmentStatusID":"4","companyTruncated":"ActualEyes.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$91.2 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Prices Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.089999999999999997,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Quercis Pharma","sponsor":"FDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Isoquercitrin","moa":"PDI","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quercis Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quercis Pharma \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Quercis Ph.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Opts-in to join Exelixis with Ongoing Development of Cabometyx\u00ae For People Living with a Form of Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Progenity","sponsor":"Crohn\u2019s & Colitis Foundation IBD Ventures Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Progenity Receives Funding from Crohn\u2019s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Crohn\u2019s & Colitis Foundation IBD Ventures Fund","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Faron Secures U.S. Rights to Patent Related to Traumakine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"CD73","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"$20.0 million","newsHeadline":"NANOBIOTIX Partners With LianBio to Develop and Commercialize NBTXR3 Across Tumor Types and Therapeutic Combinations in Asian Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ LIANBIO","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"IQVIA","sponsor":"ProtoKinetix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProtoKinetix and IQVIA Partner to Support Development of AAGP Product in the Treatment of Ocular Conditions","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Antiaging Glycopeptide","moa":"S-opsin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"IQVIA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IQVIA \/ ProtoKinetix","highestDevelopmentStatusID":"4","companyTruncated":"IQVIA \/ Pr.."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Greater Bay Area Homeland Development Fund","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elpiscience Announces the Completion of $105 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"ES002","moa":"CD39 ATPase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Elpiscience \/ Greater Bay Area Homeland Development Fund","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$338.0 million","upfrontCash":"$65.0 million","newsHeadline":"Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.34000000000000002,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives Emergency Use Authorisation in India for Its Investigational Antibody Cocktail Used in the Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Amgen's Supplemental New Drug Application For Otezla\u00ae (Apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI and Tremelimumab With Chemotherapy Shows Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-514","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Receives FDA Clearance of Investigational New Drug Application for LYN-014","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Levomethadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single Dose Vaccine, Sputnik Light, Authorized for Use in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"KIN-2787","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD CV Outcomes Study in Chronic Kidney Disease and T2D Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Australasian Leukaemia and Lymphoma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for APL Confirm Bioequivalence of Oral and IV Formulations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Australasian Leukaemia and Lymphoma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Australasian Leukaemia and Lymphoma Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Australasi.."},{"orgOrder":0,"company":"Nemysis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Chinese Patent for IHAT, the Novel Iron Nanoparticulate Supplement for Iron Deficiency (ID) and Iron Deficiency With Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"Iron","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Nemysis","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nemysis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nemysis \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Reports Positive Phase II Data for Next-Gen DMD Therapy SRP-5051","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SRP-5051","moa":"Dystrophin expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Begins Phase III trial of Biosimilar Targeting Wet AMD Drug Eylea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Morphine Sulfate","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NATCO Receives Emergency Use Approval for Baricitinib Tablets For Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Reports Acute Safety Data from the First Dose Cohort in DesCAARTes Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"DSG3-CAART","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Australian TGA Approves Key Label Updates to Buvidal\u00ae for Treatment of Opioid Dependence","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Tsai Laboratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"NFX-179","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tsai Laboratory","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Tsai Laboratory \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tsai Labor.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Finds that Vortioxetine Helps Patients with MDD and Comorbid Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin reuptake","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Receives US FDA Clearance of IND Application for its Next-Generation PSMA Theranostic Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"IM156","moa":"Protein Complex 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ImmunoMet","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoMet \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoMet .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"LY3853113","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Eli lilly","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"jCyte","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"jCyte Identifies Retinitis Pigmentosa Patients Most Likely to Respond in Planned Pivotal Study with jCell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Retinal Progenitor Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Ca.."},{"orgOrder":0,"company":"IQVIA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IQVIA\u2019s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"IQVIA","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IQVIA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IQVIA \/ No.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity Against Other Coronaviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Broad Efficacy and Improved Safety Profile of HyBryte Presented at Society for Investigative Dermatology Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Maps Laboratories Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS\u2019 Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Maps Laboratories Private Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Maps Laboratories Private Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Maps Labor.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV (casirivimab with imdevimab) and Dupixent (dupilumab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Clinical Investigators Provide Encore Presentation of Data from the Company\u2019s Ongoing XLRP and Achromatopsia Phase 1\/2 Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RP-6306","moa":"PKMYT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis At The 2021 SID Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Telazorlimab","moa":"OX40","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ichnos Sciences \/ Glenmark pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Licensee Bausch + Lomb Launches VYZULTA (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the ATS 2021 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Hellenic Institute for the Study of Sepsis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi and Hellenic Institute for the Study of Sepsis: Anakinra Improved Overall Clinical Outcomes by 64% in Hospitalised Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of COVID-19 Vaccine (Vero Cell) Inactivated","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Vero Cell","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea Completes Patient Randomization for its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from 10 Stage 4 Cancer Patients Treated with CytoDyn's Leronlimab will be Basis for Pre-Breakthrough Therapy Designation Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data and Other Research Results Regarding VASCEPA to Be Presented at the ACC 70th Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Hypertrophic Cardiomyopathy at Upcoming ACC Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Star Compounds for GBA1 Parkinson\u2019s Disease & Related \u03b1-synucleopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT Bio, Gennova Biopharmaceuticals Announce First Healthy Volunteers Dosed in Phase I\/II Trials Of Unique COVID-19 RNA Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Tecentriq Approved by EC As a First-Line Monotherapy Treatment for Type of Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Nemera","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nemera\u2019s Preservative-Free Multi-Dose Eyedropper Approved in Brazil for Ach\u00e9\u2019s NSAID\u2019s and Dry Eye Formulations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nemera","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Nemera \/ Ache","highestDevelopmentStatusID":"12","companyTruncated":"Nemera \/ A.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives European Approval for Expanded Use of Benlysta to Treat Adult Patients with Active Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Belimumab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Files for Patent Waiver Rights for Baricitinib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Sterling Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics\u2019 ZYNLONTA Added to National Comprehensive Cancer Network\u00ae Clinical Practice Guidelines in Oncology for B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab tesirine-lpyl","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Sterling Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Gets a Notice of Intention to Grant for a New Patent on Combination of MN-166 and Riluzole for ALS in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's Injectafer\u00ae Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Gets Orphan Drug Designation for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Completes Patient Enrollment in Phase 2 PORT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TILT-123","moa":"TNF-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics to Present at the Benzinga Global Small Cap Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Replimune","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still\u2019s Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AEVI-007","moa":"IL-18","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity to Present at New York Academy of Sciences\u2019 Frontiers in Cancer Immunotherapy 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"T20K","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Pharmaceuticals Begins Saturn-2, Second Pivotal Phase 3 Trial on Safety and Efficacy of TP-03 for Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lotilaner","moa":"Chloride channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Core One Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Core One Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Oral Strip","sponsorNew":"Core One Labs \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Core One L.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Medicines Regulator Issues its First Authorisation Under Project Orbis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA IND Approval Leads to Breakthrough Testing of Veyonda in First-Line Sarcoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences\u2019 Covistat Subsidiary \u201cAt Home Coronavirus Pill\u201d Commencing to Phase 2 Clinical Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nafamostat","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Trevena","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Trevena \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Gets Priority Review From FDA for KEYTRUDA + LENVIMA for Advanced Renal Cell Carcinoma and for Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Results in Patients with Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Bionical Emas","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionical Emas Launches Expanded Access Program for JZP458 - A Recombinant Erwinia Asparaginase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Asparaginase Erwinia chrysanthemi","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Bionical Emas","highestDevelopmentStatusID":"9","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Bolus","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Receives FDA Clearance of IND Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Reports Partial Response in Ongoing Phase 1 Monotherapy Study of CUE-101 in Patients with HPV+ Recurrent Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2 variant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resuscitative Effect of Centhaquine (Lyfaquin\u00ae) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-DOTA-rosopatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives Positive CHMP Opinion for the Self-Administration of CRYSVITA to Treat X-Linked Hypophosphataemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"The Institute of Cancer Research \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF\u2122 (HTX-011) for the Management of Postoperative Pain for up to 72 Hours","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, AstraZeneca Strengthen Case for Approval of Tezepelumab in Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck's Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in High-Risk Early-Stage Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mexico to Start Late-Stage Clinical Trial for China's mRNA COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Walvax Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Bio.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Gets Nod for Phase 2\/3 Clinical Trials of Covaxin on 2 to 18-Year-Olds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 3 Libtayo\u00ae (cemiplimab) Results in Advanced Cervical Cancer Presented at Esmo Virtual Plenary","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"DSP-0038","moa":"5-HT1A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Sumitomo Dainippon Pharma Co., Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Allay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Ther.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Says \u2018No\u2019 to Pfizer\u2019s Vyndaqel for Rare Heart Condition","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafamidis","moa":"Transthyretin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Nod for BMS\u2019 Opdivo in Advanced Oesophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CV2CoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"4","companyTruncated":"GSK \/ Cure.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts GC Pharma\u2019s Biologics License Application for Immune Globulin 'GC5107'","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GC5107","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CTX001 For Severe Hemoglobinopathies at EHA2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at EHA 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America to Present Analysis of Real-World Claims Data for Patients Treated With RADICAVA at EHA 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia at EHA 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches to Improve Survival in Cancer and Blood Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib and Zanubrutinib Combo at EHA 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy for HLA-Matched Donor Kidney Transplants","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PsyBio Increases Intellectual Property Portfolio with Filing of Novel Genetic Optimization Pathways for Psychedelic Medication Biosynthesis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PsyBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PsyBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PsyBio The.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xilio Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"XTX101","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Presents Trial Design of Global Phase 3 PHOENIX Study of AMX0035 in ALS at the ENCALS 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Completes Enrollment in VEGA-1 Phase 2 Trial on Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Gets UK Approval of ORLADEYO (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics to Present New Data on AUTO1 in r\/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AUTO1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Evolus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aesthetic Surgery Journal Publishes Long Term Safety and Efficacy Data of Jeuveau for the Treatment of Moderate to Severe Frown Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ D.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"4D-150","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4802","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Presents New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 3 Libtayo (Cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"KER-050","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics TXA127 For COVID-19 To Enter NIH-Funded Clinical Trial At 60 Sites Around The U.S","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Angiotensin-(1-7)","moa":"ARAS pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Constant Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Receives First FDA Approval and Prepares for Launch of Zegalogue (Dasiglucagon) Injection","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Legend Biotech \/ Janssen Research & Development","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From Incyte\u2019s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma launches Hydralazine Hydrochloride Injection, USP, 20mg\/mL, in the US, Through its US Affiliate, Hikma Pharmaceuticals USA Inc.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydralazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte and MorphoSys Doses First Patient in Phase 3 frontMIND Study on Tafasitamab Combo as Treatment for Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Topline Results From Phase 2\/3 Gene Therapy Study for XLRP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cotoretigene toliparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Betibeglogene autotemcel","moa":"Alpha\/Beta globulin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Osmol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"OSM-0205","moa":"IntraCellular calcium","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Osmol Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osmol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Osmol Ther.."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for Wet AMD Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Aflibercept","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in May and June","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharma Files Form 10-Q; Patient Enrollment in Phase 2 Clinical Trial of Brilacidin for COVID-19 Tops 70 Percent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at DDW 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR At ASRA's 46th Annual Spring Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AEVI-002","moa":"LIGHT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"IMA402","moa":"T cell engaging receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"GRP78","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efficacy Of Repatha\u00ae (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Evolocumab","moa":"PCSK9","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"VERVE-101","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Receives Approval in Pakistan for the Use of Zofin\u2122 for Compassionate Grounds for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived microRNAs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron to Host Conference Call and Webcast to Review Trial Updates, Preclinical Presentations on Sotatercept in PAH at the ATS 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"TGF-beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data Demonstrate Potential of Codiak\u2019s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Targeting Technologies and University of Antwerp Begin Study of TDURA Diagnostic to Detect Response to Colon Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"99mTc-Duramycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Molecular Targeting Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Targeting Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio\u2019s TVGN-489 Demonstrates Strong Anti-Viral Activity in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GENFIT Provides Pipeline Update and Launch of New Clinical Programs","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"Pyruvate synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"OTL-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioArctic Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AD1503","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Reports Positive Topline Phase 1 Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CTI-1601","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samus Therapeutics Receives IND Clearance from FDA for PU-AD for the Treatment of Recurrent Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Icapamespib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Ther.."},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alume Biosciences Granted FDA Fast Track Designation Of ALM-488 For Surgical Nerve Visualization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ALM-488","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alume Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Alume Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alume Bios.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV5-gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Phase I\/II Glioblastoma Data at ASGCT Show Temferon\u2122 Delivered Tumor-Focused Interferon Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Hematopoietic stem progenitor cell immuno-gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from Preclinical Study of KER-012 in PAH at the American Thoracic Society International Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"KER-012","moa":"ACVR2A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz\u00ae IND for Stroke Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"HGF-1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Analysis Available During ATS 2021 Supports Long-Term Treatment with Ofev in Systemic Sclerosis-Associated Interstitial Lung Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Eyes Clinical Trial of Hearing Loss Gene Therapy","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"JAB-21822","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NT0200","moa":"DMPK protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuBase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Th.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves LUMAKRAS\u2122 (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Qiagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Qiagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Qiagen \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Pauses Enrolment for Trial Evaluating Anti-Bcma Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Reports Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Pancreatic Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ NantKwest","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Bintrafusp Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Merck Group","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential COVID-19 Treatment Identified in UCLA-Led Lab Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Berzosertib","moa":"Protein kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ UCLA","highestDevelopmentStatusID":"1","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Berzosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starpharma Signs DEP\u00ae ADC Research Agreement with MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Dendrimer based antibody drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,070.0 million","upfrontCash":"$224.4 million","newsHeadline":"Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":1.0700000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.0700000000000001,"dosageForm":"Oral solution","sponsorNew":"Debiopharm \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Discontinues Two Feladilimab Trials in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Feladilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Merc.."},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avillion's Positive Phase 2 Trial of Tri-Specific Nanobody\u00ae Sonelokimab (M1095) in Chronic Psoriasis Published in The Lancet","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avillion LLP \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Avillion L.."},{"orgOrder":0,"company":"Adaptate Biotherapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptate Biotherapeutics Raises $18 Million in Series A2 Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Financing","leadProduct":"ADT-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptate Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Adaptate Biotherapeutics \/ Abingworth","highestDevelopmentStatusID":"4","companyTruncated":"Adaptate B.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hetero Drugs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hetero Enters Into a Voluntary Licensing Agreement with MSD for the Manufacturing and Distribution of \u2018Molnupiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Hetero Drugs","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Healthcare's Hepatitis C Drug Gets Approval for Emergency Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegylated Interferon Alpha-2b","moa":"INF alpha receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Phar.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentia Medical Sciences and Neurocrine Biosciences Enter into Strategic Collaboration to Discover Novel CRF Peptides","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Astressin B","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sentia Medical Science","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sentia Med.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to the EMA Seeking Approval of BCMA CAR-T Therapy Ciltacabtagene Autoleucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Humira Gets Approval In Canada for Treatment of Pediatric Patients With Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Enspryng Leads Latest CHMP Recommendations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Azathioprine","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Corat Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Hospitalized COVID-19 Patient Treated with the Antibody Drug Candidate COR-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"COR-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Corat Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Corat Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corat Ther.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GLOBAL Sarcoma Therapy Now Approved for Australian Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Commave Therapeutics","pharmaFlowCategory":"D","amount":"$590.0 million","upfrontCash":"Undisclosed","newsHeadline":"KemPharm Receives $10M Milestone Payment for FDA Approval of AZSTARYS Per License Agreement with Affiliate of Gurnet Point Capital","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.58999999999999997,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.58999999999999997,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Commave Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lecanemab (BAN2401) Phase 2b Study in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research & Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Clears NeoTX\u2019s IND Application for Phase 2 Trial of Naptumomab Estafenatox to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoTX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Ther.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Advita","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief and AdVita to Begin Inhaled RLF-100 Trial for Covid-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Mesh nebulizer","sponsorNew":"Relief Therapeutics \/ AdVita Lifescience","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Iconovo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iconovo Extends Agreement with Amneal for Generic Symbicort to Cover Key Markets U.S. and China, as Well as Nordic Sales Rights","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Amneal Pharmaceuticals \/ Iconovo","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"AazeinTX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AdMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"NEO6860","moa":"TRPV1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"adMare BioInnovations","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"adMare BioInnovations \/ AazeinTX","highestDevelopmentStatusID":"4","companyTruncated":"adMare Bio.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Vertex","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$160.0 million","newsHeadline":"Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Deutivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Vertex","highestDevelopmentStatusID":"8","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases for SPR206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"$20.0 million","newsHeadline":"Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Merger","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Antengene","pharmaFlowCategory":"D","amount":"$255.0 million","upfrontCash":"Undisclosed","newsHeadline":"Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CB-708","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Calithera Biosciences","amount2":0.26000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Antengene","highestDevelopmentStatusID":"4","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Thin Film Strip","sponsorNew":"LTS - Lohmann Therapie Systeme \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohm.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"BioMed X","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioMed X Institute and Merck Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioMed X","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioMed X \/ Merck KGA","highestDevelopmentStatusID":"2","companyTruncated":"BioMed X \/.."},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Octagon Capital","pharmaFlowCategory":"D","amount":"$77.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Octagon Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sparrow Pharmaceuticals Secures $50 Million Series A Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Refuge Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"RB-340","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Refuge Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chime Biologics \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biol.."},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,560.0 million","upfrontCash":"$200.0 million","newsHeadline":"Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus\u2019 Anti-TIGIT Bispecific Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.5600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Bristol Myers","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Upgrades Financial Guidance for Supply Agreement With AstraZeneca for Manufacture of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"S.Korea's Genexine Signs COVID-19 Vaccine Candidate Manufacturing Deal with Hanmi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"GX-19N","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hanmi Pharmaceutical \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Earns $10 Million Option Exercise Fee","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"ARO-JNJ1","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$171.2 million","upfrontCash":"Undisclosed","newsHeadline":"CanSino Unit Gets USD171.2 Million to Build Covid-19 Vaccine Production Line","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience Raises US$125 Million in Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"HMBD-001","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeneQuantum Raises Hundreds of Millions RMB in Series C Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"GQ1001","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GeneQuantum Healthcare \/ China Life Private Equity Investment","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mestag Therapeutics Announces Collaboration with Janssen","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mestag Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mestag Therapeutics \/ Janssen","highestDevelopmentStatusID":"3","companyTruncated":"Mestag The.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,375.0 million","upfrontCash":"$50.0 million","newsHeadline":"Exscientia Announces Multi-Target, AI-Driven Drug Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":1.3799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3799999999999999,"dosageForm":"","sponsorNew":"Exscientia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Western New England University","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Western New England University and Quercis Pharma Sign Exclusive Worldwide License Agreements","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Zafirlukast","moa":"Thiol isomerase","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Western New England University","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Western New England University \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Western Ne.."},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Anti-CD38 Monoclonal Antibodies Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"VyGen-Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VyGen-Bio \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VyGen-Bio .."},{"orgOrder":0,"company":"RenBio","sponsor":"Ruentex Group","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"RenBio Completes $24 Million Series A Financing and Licenses Novel SARS-CoV-2 Bispecific Antibody from Columbia University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"RB-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RenBio","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"RenBio \/ Ruentex Group","highestDevelopmentStatusID":"4","companyTruncated":"RenBio \/ R.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$17.6 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Iconovo","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Iconovo and Respiratorius Sign Agreement for Development of Inhalation Product to Treat COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"RES030-085","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Iconovo","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iconovo \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Iconovo \/ .."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Avalon Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cancer Biotech Janux Therapeutics Files for $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"PSMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Janux Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Avalon Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Closing of $50 Million Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ H.C. Wainwright","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Announced the Closing of US$11M in Seed Financing","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pha.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma in Stock and CVR Transaction","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Dichlorphenamide","moa":"CA","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Centessa Announces Pricing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.33000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.33000000000000002,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Intermediate Capital Group","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eliem Raises $60M to Take Neuro Programs to Series of Data Drops","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series B Financing","leadProduct":"ETX-810","moa":"PPAR alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Intermediate Capital Group","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dicerna Announces Boehringer Ingelheim\u2019s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"DCR-LIV2","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pediatric Oncology Biotech Day One Biopharma Sets Terms for $126 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Immediate-release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$210.1 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI and SK Bioscience Expand Partnership to Advance Multiple COVID-19 Variant Vaccines and Scale-Up Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Brooklyn I.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Enveric Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OPKO Health Reports Transfer of Licensed Rights to RAYALDEE\u00ae in Japan to Vifor","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Vifor","highestDevelopmentStatusID":"12","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"MolGenie","sponsor":"OntoChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MolGenie","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MolGenie \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"MolGenie \/.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech, Fosun Pharma Entering Into Term Sheet in Relation to Formation of a Joint Venture","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recro Enters Development Agreement With Astex Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ Astex","highestDevelopmentStatusID":"10","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Ethypharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethypharm Reinforces its Late-Stage R&D Pipeline with a Novel Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Samsung Biologics \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Vitamin K2","moa":"SXR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"NattoPharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis","highestDevelopmentStatusID":"12","companyTruncated":"NattoPharm.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"J. Wood Capital Advisors LLC","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Heron Therapeutics Announces $150 Million Convertible Debt Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ J. Wood Capital Advisors LLC","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"AcuraStem","sponsor":"U.S Department of Defense","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"AcuraStem Awarded $1M DOD Grant to Advance AS-202 Drug Development Candidate for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"AS-202","moa":"PIKfyve","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AcuraStem \/ U.S Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem .."},{"orgOrder":0,"company":"Xencor","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend\u2122 XmAb\u00ae Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"C-135-LS","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xencor \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Xencor \/ B.."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$5.0 million","newsHeadline":"Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Recombinant AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Univercells","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"COVI-VAC","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Codagenix \/ Univercells","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"NiKang Therapeutics Announces Completion of $200 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"MediSynergics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Ketamine Derivatives","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ MediSynergics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Locust Walk","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Merger","leadProduct":"Tomivosertib","moa":"MNK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Locust Walk","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Prestige Consumer Healthcare","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$230.0 million","newsHeadline":"Akorn Announces Agreement to Sell its Consumer Health Business to Prestige Consumer Healthcare","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Divestment","leadProduct":"Sodium Carboxymethylcellulose","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Phar.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"HCW Files for $50M IPO to Trial Fusion Protein in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"HCW9218","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series C Financing","leadProduct":"PC945","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Inhalation","sponsorNew":"Pulmocide \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Acquires Rights to Trademarks of Three Diabetes Drug Brands in India from AstraZeneca","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Immediate-release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"USAMRDC","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled \"Muco-trapping\" Antibody for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"IN-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inhalon Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Inhalon Biopharma \/ USAMRDC","highestDevelopmentStatusID":"4","companyTruncated":"Inhalon Bi.."},{"orgOrder":0,"company":"Senator Richard Lugar Research Institute","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharma to Develope COVID-19 Medicines and Vaccines in Central Europe in Collaboration with the Lugar Institute and Cromos Pharma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Senator Richard Lugar Research Institute","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Senator Richard Lugar Research Institute \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Senator Ri.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS\u00ae (linaclotide) 72 mcg Dosage Strength","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase-C","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Teva","highestDevelopmentStatusID":"12","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"$168.0 million","newsHeadline":"Knight Therapeutics Announces Closing of Previously Announced Acquisition and Exclusive License to Exelon\u00ae in Canada and Latin America","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"AChE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.17999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"KAHR Receives Investment from Cancer Focus Fund to Support Phase 1\/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Azacytidine","moa":"CD47x41BB","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kahr Medical","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ Cancer Focus Fund","highestDevelopmentStatusID":"5","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"ST101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Sapience Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National C.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Bavarian Nordic","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Life Sciences Partners with Portugal\u2019s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Trichomylin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Aureuspharma","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Walter and Eliza Hall Institute of Medical Research","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells from Australia\u2019s WEHI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"NK cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Walter and Eliza Hall Institute of Medical Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walter and Eliza Hall Institute of Medical Research \/ ONK Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Walter and.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Alexander Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Micro-cap Antibiotic Biotech Acurx Pharmaceuticals Files and Sets Terms for a $15 Million IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Alexander Capital","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"ValiRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KTH222 Evaluation Agreement Concluded","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Termination","leadProduct":"KTH222","moa":"Mapk","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kalos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalos Therapeutics \/ ValiRx","highestDevelopmentStatusID":"4","companyTruncated":"Kalos Ther.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annovis Bio, Inc. Announces Closing of $50 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Disc medicine","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0.20000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Disc Medicine","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$266.7 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Editing Biotech Verve Therapeutics Files for a $100 Million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Public Offering","leadProduct":"VERVE-101","moa":"PCSK9 gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Aldevron","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aldevron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aldevron \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Aldevron \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Secondary Analysis of Galactic-HF Presented in Late Breaking Clinical Trial Session at ACC 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Publish Statement on CytoDyn's Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101) at ACC 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ninerafaxstat","moa":"Partial fatty acid oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pha.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved m-ceNK cells","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"The American College of Cardiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finerenone May Delay Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease, Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"The American College of Cardiology","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The American College of Cardiology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"The Americ.."},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advicenne Receives Positive Feedback from the US FDA on Phase III Study Protocol for its Treatment of dRTA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne .."},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Weill Cornell Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AIC100","moa":"ICAM-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AffyImmune Therapeutics \/ Weill Medical College of Cornell University","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SRP-9001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Roche Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yumanity Therapeutics\u2019 R&D Day Reviews Near-Term Value Drivers and Pipeline-Generating Discovery Engine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Reports FDA Clearance of Ind Application for KIN-2787","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"KIN-2787","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented at ATS Meeting Reinforces the Potential of an Oral Drug Combination Therapy for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Suggests Convalescent Plasma May Improve Survival with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pirfenidone Reduces Scar Tissue in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"TGF beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ National Institute for Health Research","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's XARELTO + Aspirin Reduces Total Ischemic Events in Peripheral Artery Disease Patients After Lower-Extremity Revascularization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MTX-COVAB","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Serum Institute of India","highestDevelopmentStatusID":"4","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's REGEN-COV\u2122 Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Data at ATS 2021 Show Dupixent\u00ae (Dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"BDTX-189","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience\u2019s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REDUCE-IT\u00ae Heart Failure Analyses by VASCEPA\u00ae Driven Serum EPA Levels Suggest Potential Benefit in New Heart Failure in At-Risk Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin Effectively Neutralises All Key Emerging Variants, Says Study Published in Oxford Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan\u00ae\/Reeqonus\u2122 Trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpiVax Identifies T cell Epitopes critical to Robust T cell Immune Response in SARS-CoV-2 , Results Published in NPJ Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"EPV-CoV19","moa":"SARS-CoV-2 spike N-terminal","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ N.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT1A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Gets IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Starts first Phase 3 Clinical Trial with Delgocitinib Cream in Adult Patients with Moderate-To-Severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma to Present Additional Data from Phase II Study of Blautix for Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics\u2019 SRP-9001 Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta\u2019s Commercial Process Material","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"Micro-dystrophin protein production","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Ziltivekimab Hits Primary Endpoint in CKD Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ziltivekimab","moa":"Il-6","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol\u00ae, Including for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MET642","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071 to Include Three Multiple-Ascending Dose Cohorts","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested With Ivectosol\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain V.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma to Present New Phase 1 Data on AZP-3601 and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform's Final Clinical Results Confirm Value Proposition to the Pharma Industry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Immediate-release Tablet","sponsorNew":"Nanoform \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"State University of New York","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Island Pharmaceuticals Granted Key Patent for ISLA-101 in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ISLA-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Island Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Island Pharmaceuticals \/ State University of New York","highestDevelopmentStatusID":"8","companyTruncated":"Island Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS\u2019 Opdivo Wins FDA Approval for Resected Esophageal or GEJ Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Topline Results from PNEU-DIRECTION and PNEU-PLAN Phase 3 Pediatric Studies for V114","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS' Six-and-a-Half-Year Outcomes for Opdivo in Combination with Yervoy Continue to Demonstrate Durable Long-Term Survival Benefits","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen and Astellas Announce Updated Results from Two Trials of PADCEV in Patients with Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"TGF-beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Presents Interim Results from Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotatercept","moa":"TGF-beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1\/2 Study of Valoctocogene Roxaparvovec","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pluripotent stem cell-derived mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Regulator Backs Extending Approval for Remdesivir for Another Year","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Reports +Ve Topline Results from Phase 3 Trial of Tislelizumab, Chemotherapy Combo for Recurrent\/Metastatic Nasopharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Leucadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leucadia Pharmaceuticals Launches Calcitonin Salmon Injection","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Calcitonin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Leucadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leucadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leucadia P.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Dong-A Socio Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Achieves all Primary and Key Secondary Study Outcomes Against Insulin Glargine in Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia to Present AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS in Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recardio Completes Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Therapeutics to Provide Interim Results of Phase 3 Mercury Study of MDR-101 Cell Therapy in Living Donor Kidney Transplants","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Receives Orphan Drug Designation for its Most Advanced Gene Therapy Product for Genetic Hypertrophic Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Hosts Research and Development Day on Proprietary Ion Channel Drug Discovery Engine and Pipeline Programs","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved m-ceNK cells","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Mid America Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EXPLORER-HCM Trial Finds Health Improvements with Mavacamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mid America Heart Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mid America Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mid Americ.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics\u2019 XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"XT-150","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Ther.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous cell Carcinoma Published","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Remetinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altavant Sciences Reports Rodatristat Ethyl PK\/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Rodatristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiasma to Present Encore and New Data from MPOWERED Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA to Present Phase 1 Anti-Tumor Activity Data On HB-201 and HB-202 For the Treatment of Advanced HPV16+ Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"GammaDelta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GDX012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GammaDelta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GammaDelta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GammaDelta.."},{"orgOrder":0,"company":"NovalGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovalGen Presents Data at American Society of Clinical Oncology for novel ROR1xCD3 Bispecific Antibody for Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"NVG-111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NovalGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NovalGen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NovalGen \/.."},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharm-Olam is Now Enrolling UK Volunteers into a Pivotal Phase III COVID-19 Vaccine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA2001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pharm-Olam \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics and Boehringer Ingelheim Present Phase 1 Results with SIRP\u03b1 Inhibitor BI 765063 in Advanced Solid Tumors at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"OSE-172","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single-Dose Sputnik Light Vaccine Approved for Use in Nicaragua","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Showcase Data from Its Transformative Oncology Pipeline at 2021 ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Receives Positive CHMP Opinion for Bylvay\u2122 (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Announces Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rybrevant Gets FDA Approval as the First Targeted Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMBRUVICA Based Combination Regimen First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Janssen Research & Development,","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J's Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Amcenestrant Data Featured at ASCO Support its Potential to Become a New Endocrine Backbone Therapy for ER+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM's Aldafermin Becomes Latest NASH Failure as it Misses Mark in Phase IIB","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldafermin","moa":"FGF19 protein","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"SHIRE LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review of Maribavir for Post-Transplant Recipients With Cytomegalovirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Maribavir","moa":"Phosphotransferase pUL97","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Shire","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Receives Positive CHMP Opinion for Klisyri\u00ae\u25bc (Tirbanibulin), An Innovative Topical Treatment for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Gets Positive CHMP Opinion for SKYSONA\u2122 Gene Therapy for Patients Below 18 Years of Age with Early Cerebral Adrenoleukodystrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Prama Gets Positive CHMP Opinion for Setmelanotide for Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd\u00ae Phase IIb trial results published in Diabetes Care","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GAD65-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043 at 2021 Digestive Disease Week Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SZN-1326","moa":"Fzd5\/8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ\u00ae (Upadacitinib) in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's SKYRIZI Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 \u2013 Inhalable Liposome Formulations of Antiviral Drugs for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ISPM21","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Presents New Data at Digestive Disease Week\u00ae on Zeposia Highlighting Safety Profile in Patients with Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives USFDA Approval for Icatibant Injection, 30 mg\/3 mL (10 mg\/mL) Single-Dose Prefilled Syringe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Centocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves PONVORYTM for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Centocor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centocor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centocor \/.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"TGF beta","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Surges 20%, Hits New High on USFDA Nod for Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Launches \u2018Ujvira\u2019 to Treat Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab Emtansine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong, First-in-Class PRS-Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Shows Promising Result in Early Stage Clinical Test","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy for Certain Esophageal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and\/or Eosinophilic Duodenitis (EG\/EoD) is Highly Underdiagnosed","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Bio Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at European Congress of Endocrinology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"More Than a Third of Surveyed IBS-C Patient's Symptoms Worsened During COVID-19 According Findings Presented by Ironwood Pharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase-C","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Allergan","highestDevelopmentStatusID":"12","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PN-232","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Janssen Research & Development","highestDevelopmentStatusID":"6","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Approval of Moderna\u2019s COVID-19 Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-919","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Gufic Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gufic Biosciences Gets Nod to Manufacture and Market Liposomal Amphotericin B Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gufic Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gufic Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gufic Bios.."},{"orgOrder":0,"company":"Sinovant Sciences","sponsor":"Nabriva Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with CABP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovant Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovant Sciences \/ Nabriva Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Sinovant S.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Larimar Therapeutics \/ Veristat, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Receives Positive CHMP Opinion for RYEQO\u00ae (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Re-Initiates Path to IND for PMN310 with Producer Cell Line Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive CHMP Opinion for Bayer\u2019s New Symptomatic Chronic Heart Failure Treatment Vericiguat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion for Jardiance\u00ae (Empagliflozin) for the treatment of Adults with Heart Failure with Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for Essential Thrombocythemia and Myelofibrosis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MSN Labs Launch Indigenous Drug Posaconazole to Treat Black Fungus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MSN Labora.."},{"orgOrder":0,"company":"GenEros BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenEros BioPharma\u2019s Clinflamozyde Approved for Clinical Trials for COVID-19 in the US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Clinflamozyde","moa":"STAT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GenEros BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenEros BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GenEros Bi.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Firmicute species bacterial spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Microbiota-based live biotherapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Gets Brazilian ANVISA\u2019s Clearance for Phase II Covid-19 Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Adipose-derived mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Centocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen\u2019s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Teclistamab","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Centocor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centocor \/.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics to Present Preclinical Data Using SORT-LNP\u2122 and RNA Platforms to Rescue CFTR Function","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RNA-based therapy","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Clinical Data About Axcella\u2019s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Designation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"BI 425809","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (Cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spain's PharmaMar Says Covid-19 Treatment Drug Shows Clinical Efficacy in Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"VEGF\/VEGFR-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Prosit Sole Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PSP001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Prosit Sole Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prosit Sole Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prosit Sol.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax\u2019s ABX464 shows \u2018Impressive\u2019 Efficacy in Severe Ulcerative Colitis Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves Venclyxto-Based Combo for Adults with Newly Diagnosed Acute Myeloid Leukaemia Who Are Ineligible for Intensive Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Report Top-line Results from the Phase 3 PRINCE Study of EMPAVELI\u2122 (Pegcetacoplan) in Treatment-Na\u00efve Patients with PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a \u2018Universal Boost\u2019 in Vaccinated Subjects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Bioventus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PTP-001","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Bioventus","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bioventus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioventus .."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma\u2019s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GEM-difluorinated C-glycoside derivative of Podophyllotoxin","moa":"Topoisomerase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-release Powder","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Commences Phase 1b\/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Biopharmaceuticals Receives US FDA Feedback on IND Application for PPS in Knee OA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MSN Lab Begins Phase III Clinical Trial of Molnupiravir Capsules for Covid Treatment in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MSN Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MSN Labora.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib for Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion's NDA for its Orphan Drug Udenafil for Single Ventricle Heart Disease (\"SVHD\") has been Accepted for Filing by the FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Udenafil","moa":"PDE5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Initiate Global Phase 3 Clinical Efficacy Study of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 recombinant protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Biomm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ No.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of CoVepiT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UniQure Announces Positive Recommendation to Advance Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Low Doses of Inhalable 'nanobody' Fights Off Covid in Hamsters","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nanobody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"The University of Pittsburgh School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Resubmits Once-Weekly Semaglutide 2.0 mg For the Treatment of Type 2 Diabetes for US Regulatory Approval","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISD Immunotech Granted US and EU Patents for Novel Severe Systemic Lupus Erythematosus (SLE) Therapy Candidate ISD017","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ISD017","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"ISD Immunotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISD Immunotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ISD Immuno.."},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Provides Results from Key Study for Its Targeted Therapeutics Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXIM\u00ae Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"SPX-1009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biote.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613\u00ae (Devimistat)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2\/3 Clinical Trial for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Saint Louis University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Demonstrates Strong Neutralization Of South African Variant In Preclinical Study Of Intranasal AdCOVID\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Altimmune \/ Saint Louis University","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ZT-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara The.."},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Pramlintide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adocia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ N.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical T1D","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Aragon Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERLEADA Patient-Reported Outcomes in Metastatic Castration-Sensitive Prostate Cancer Shows Maintenance of Health-Related Quality of Life","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Aragon Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ubrogepant","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's Data Shows Improvement in Hematologic Complete Response with DARZALEX FASPRO\u00ae in Newly Diagnosed Light Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Gelesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Gelesis Presents Findings on Plenity\u00ae-Induced Weight Loss at the AACE 2021 Annual Virtual Meeting","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GS100","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Gelesis","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gelesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gelesis \/ .."},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent and Transgene Receive IND Approval from the U.S. FDA for BT-001, A Novel Oncolytic Virus for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences to Host Virtual MISSION Phase 1b Data Update Call at EULAR 2021 on June 2, 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Enrollment Reaches 90 Percent in Innovation Pharma\u2019s Phase 2 Clinical Trial of Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarus Therapeutics Receives Clearance from the FDA to Initiate Clinical Trial of TT-4 (A2BR Antagonist) in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-4","moa":"Adenosine A2B receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tarus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tarus Ther.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharma Launches the First Generic RUCAPARIB to Treat Advanced Ovarian and Prostate Cancers in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos to Present Data on Rheumatoid Arthritis at the Upcoming European League Against Rheumatism (EULAR) Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Provides Update on NDA Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19: Zydus Seeks DCGI Nod to Undertake Clinical Trials for Monoclonal Antibodies Cocktail","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Covimabs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo and Yervoy Combination Therapy Approved in Japan for First-line Treatment of Unresectable Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFFiRiS: Positive Phase 1 Results with Immunotherapies Targeting PCSK9 to Treat Hypercholesterolemia Published Peer Reviewed Journal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"AT04A","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Affiris","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Fezagepras","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO\u201921 Virtual Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4Beta7 Integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac\u2019s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b\/3 Efficacy Readout in Variant-rich Environment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CV07050101","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of the COLCORONA Study Published in The Lancet Respiratory Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharma Resubmits NDA For Pedmark","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO\u2122 in Multiple Myeloma as a First-Line Maintenance Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixazomib Citrate","moa":"Proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech Receives Orphan Drug Designation in South Korea for Fimaporfin in the Treatment of Bile Duct Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"H\u00e4mophilie-Zentrum Rhein Main","sponsor":"Octapharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MOTIVATE (MOdern Treatment of Inhibitor-Positive Patients with Haemophilia A) Enrolls First Patient in the US","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Simoctocog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"H\u00e4mophilie-Zentrum Rhein Main","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma","highestDevelopmentStatusID":"12","companyTruncated":"H\u00e4mophilie.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Got Full Approval to Conduct Phase I\/II Study of RVU120 in Patients with Advanced Solid Tumors in Poland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Bajaj Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bajaj Healthcare Launches Posaconazole API for Treatment of Black Fungus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bajaj Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bajaj Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bajaj Heal.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Penn Researchers Discover Drug that Blocks Multiple SARS-CoV-2 Variants in Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"diABZI","moa":"STING","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Pennsylvania \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nextstellis\u00ae Receives FDA Marketing Exclusivity and Phase III Data Published","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Drospirenone","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Mithra Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports One Year Results of Phase III MERLIN Study Evaluating BEOVU\u00ae Every Four Week Dosing and Provides Update on BEOVU Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in the EU for the Adjuvant Treatment of Patients with Early-Stage Egfr-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Approves Johnson & Johnson\u2019s Single-Dose Covid Vaccine for Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J's Multiple Myeloma Car-T Scores FDA Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Legend Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"EQRx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EQRx \/ Cstone","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Cst.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Nurtec\u00ae ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Gets its First GI Drug Approval, and it Comes from A Longtime Celgene MS Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alebund Pharmaceuticals Raises $60 million in Series B Financing Round","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series B Financing","leadProduct":"Solnatide","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Alebund Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Alebund Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alebund Ph.."},{"orgOrder":0,"company":"3M Company","sponsor":"IDRI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"3M-052","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"3M Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"3M Company \/ IDRI","highestDevelopmentStatusID":"4","companyTruncated":"3M Company.."},{"orgOrder":0,"company":"Appia Bio","sponsor":"8VC","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appia Bio Launches with $52 Million Series A Financing and Establishes Scientific Advisory Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Series A Financing","leadProduct":"CAR-iNKT","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Appia Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Appia Bio \/ 8VC","highestDevelopmentStatusID":"2","companyTruncated":"Appia Bio .."},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"OncoTEX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoTEX and Sterling Pharma Solutions Sign Clinical Manufacturing Agreement for the Development of Novel Treatment Against Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Oxaliplatin","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sterling Pharma Solutions \/ OncoTEX","highestDevelopmentStatusID":"4","companyTruncated":"Sterling P.."},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"UCB0599","moa":"Alpha synuclein misfolding","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuropore Therapies","amount2":0.46000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Neuropore Therapies \/ UCB Biopharma SRL","highestDevelopmentStatusID":"8","companyTruncated":"Neuropore .."},{"orgOrder":0,"company":"Qiagen","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qiagen \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ M.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Private Placement","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ECI Pharmaceuticals LLC Signs Agreement to Be Exclusive U.S. Distributor of Generic Cialis\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Qilu Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Qilu Pharm.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children 6 Months Through <4 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"C5aR receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives EUA in India for Its Investigational Antibody Cocktail (Casirivimab and Imdevimab) Used in the Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (Sotrovimab) for the Early Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Centocor","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Seeks EU Approval for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-Cel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Centocor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centocor \/ Legend Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Centocor \/.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VILTEPSO (viltolarsen) Injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Initiates Phase 1 Clinical Trial of GFB-024 for Patients with Severe Insulin Resistant Diabetic Nephropathy (DN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"GFB-024","moa":"CB1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ertapenem Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b\/3 COVID Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA 2B","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Enrols First UK Participant in Phase 3 Investigational Gene Therapy Study for Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ema Starts Evaluating Use of Olumiant in Hospitalised Covid-19 Patients Requiring Supplemental Oxygen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor Recruiting Melas Syndrome Patients for Phase 1 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Citrulline","moa":"Atherogenic","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$400.0 million","newsHeadline":"Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"KHK4083","moa":"OX40","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":1.25,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"MorphoSys","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"$1,700.0 million","newsHeadline":"Morphosys to Buy Constellation in $1.7B Deal, Aided by Unusual Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.7,"dosageForm":"Tablet","sponsorNew":"Constellation Pharmaceuticals \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"Breast International Group","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Partnering with Leading Academic Cooperative Groups to Study Amcenestrant in the Adjuvant Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Breast International Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breast International Group \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Breast Int.."},{"orgOrder":0,"company":"Aptamer Group","sponsor":"PinotBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"FL-118-based Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aptamer Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptamer Group \/ PinotBio","highestDevelopmentStatusID":"2","companyTruncated":"Aptamer Gr.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kahr Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"DSP502","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ KAHR Medical","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"US Naval Medical Research Center","sponsor":"Henry Jackson Foundation","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Centivax and U.S. Naval Medical Research Center Announce Strategic Partnership to Initiate Clinical Development of a Broad-Spectrum Injectable For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"SARS-CoV-2 Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"US Naval Medical Research Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"US Naval Medical Research Center \/ Henry Jackson Foundation","highestDevelopmentStatusID":"4","companyTruncated":"US Naval M.."},{"orgOrder":0,"company":"Otonomy","sponsor":"ALK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALK Acquires OTIPRIO\u00ae (Ciprofloxacin Otic Suspension), Broadening Treatment Solutions for Healthcare Providers and Patients","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Otonomy \/ ALK","highestDevelopmentStatusID":"12","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Abivertinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Thera.."},{"orgOrder":0,"company":"University of Singapore","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"MNPR-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Singapore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Singapore \/ Monopar","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Ocugen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocugen Expands COVAXIN\u2122 Commercialization Rights to Include Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Ocugen","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"ATLAS PHARMS LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxxon Announces Manufacturing of NOX-A12 Drug Substance and Issuance of Convertible Bonds Under Financing Agreement With Atlas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Atlas","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"SipNose","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement for SipNose Cribriform Targeted Device","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ST266","moa":"SIRT1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SipNose","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"SipNose \/ Noveome","highestDevelopmentStatusID":"6","companyTruncated":"SipNose \/ .."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Agreement with Thermo Fisher Scientific for Fill\/Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Thermo Fisher Scientific \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Immutep","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Enters Into a New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ Immutep","highestDevelopmentStatusID":"5","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"$1.0 million","newsHeadline":"Diurnal Triggers $1.25m in Milestone Payments from Citrine Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"TSRL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ TSRL","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"M1231","moa":"MUC1-EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Kineta","sponsor":"Cheongbo Industrial","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"KVA12.1","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kineta \/ Cheongbo Industrial","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ C.."},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Nexturn Bio","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Nexturn Bio Inc. Acquired a 50% Stake in Ros Vivo Therapeutics, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"miRNA Based Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RosVivo Therapeutics \/ Nexturn Bio","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Th.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$147.0 million","upfrontCash":"$12.0 million","newsHeadline":"Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement for LYR-210","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.14999999999999999,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Proteros","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$73.3 million","upfrontCash":"Undisclosed","newsHeadline":"Proteros to Receive Research Funding AND Milestone Payments Plus Royalties","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proteros","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Proteros \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Proteros \/.."},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lonza Biologics Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Biologics Inc \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Lonza Biol.."},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ajax Raises $40 M To Develop Novel Small Molecules Targeting Cytokine Signaling Pathways for Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Cytokine signaling pathways","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ajax Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ajax Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ajax Thera.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"$880.0 million","upfrontCash":"$10.0 million","newsHeadline":"Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody-based Conjugate Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bolt Biotherapeutics","amount2":0.88,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"3","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma and Ferring Pharmaceuticals Enter Into Licensing Agreement for Introducing CARITEC\u00ae in India","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HAVN Life Completes Acquisition of Clinical Stage IP for Development of Cluster Headache Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ HAVN Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Neoletix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio and Neoletix Signed a Letter of Intent on Clinical and Commercial Production of Recombinant Human Coagulation Factor Viii","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Recombinant Human Coagulation Factor VIII","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GenScript ProBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ Neoletix","highestDevelopmentStatusID":"4","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$598.0 million","upfrontCash":"$55.0 million","newsHeadline":"Heartseed and Novo Nordisk Enter Into Global Collaboration and Licence Agreement for Stem Cell-Based Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Allogeneic iPSC-derived Cardiomyocytes","moa":"Angiogenic factors secretion","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Heartseed","amount2":0.59999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Heartseed .."},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Lee Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSIR-IICT Licenses Process Knowhow for Synthesis of 2-Deoxy-D-Glucose to Lee Pharma Ltd.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"2-Deoxy-D-Glucose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sachet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Lee Pharma","highestDevelopmentStatusID":"1","companyTruncated":"CSIR-India.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"US Government","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Announces Supply Agreement with U.S. Government for Molnupiravir for Treatment of Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":1.2,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":1.2,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ US Government","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Marc Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSIR-CDRI Signs Agreement with Marc Labs to Develop Drug for Heart Attack and Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"S007-867","moa":"Collagen induced aggregation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Marc Laboratories","highestDevelopmentStatusID":"5","companyTruncated":"CSIR-India.."},{"orgOrder":0,"company":"Resilience","sponsor":"AavantiBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AavantiBio and Resilience Announce Strategic Collaboration for Gene Therapy Development and Manufacturing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Resilience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resilience \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Resilience.."},{"orgOrder":0,"company":"Stellanova Therapeutics","sponsor":"Sporos Bioventures","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"Undisclosed","newsHeadline":"Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Stellanova Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Stellanova Therapeutics \/ Sporos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"Stellanova.."},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Termination","leadProduct":"Cusatuzumab","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Janssen-Cilag","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Janssen-Cilag \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Janssen-Ci.."},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series D Financing","leadProduct":"Encapsulated Pancreatic Islet Precursor Cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"ViaCyte Inc","amount2":0.12,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.12,"dosageForm":"Implant","sponsorNew":"ViaCyte Inc \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ViaCyte In.."},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"BPT-143","moa":"IL-2 receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ RA Capital","highestDevelopmentStatusID":"5","companyTruncated":"Bright Pea.."},{"orgOrder":0,"company":"Exelead","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelead Inks deal to Manufacture Lipid Nanoparticles for Pfizer\/bio N Tech Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Exelead","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Exelead \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Exelead \/ .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","amount":"$219.0 million","upfrontCash":"$40.0 million","newsHeadline":"Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0.22,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"UB-TT170","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ SoftBank Vision","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Medison Pharma Partner to Commercialize Moderna\u2019s COVID-19 Vaccine Across Central Eastern Europe and Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurogastrx \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastr.."},{"orgOrder":0,"company":"Novogene","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird and Novogene Enter Into Strategic Partnership to Expand Precision Medicine Testing NRG1-Fusion Driven Cancers in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"HMBD-001","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novogene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novogene \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Novogene \/.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Successfully Closed of \u00a32.5m Extended Seed B Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$8.0 million","newsHeadline":"SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Bi.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Regenerative Medicine Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding From Regenerative Medicine Minnesota to Study New Drug for Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Regenerative Medicine Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks and Seagen Team UP in Multiple Myeloma; Merck and Eisai Build out Keytruda\/Lenvima Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SpringWorks Therapeutics \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Innovative Molecules","sponsor":"Life Sciences Partners","pharmaFlowCategory":"D","amount":"$23.7 million","upfrontCash":"Undisclosed","newsHeadline":"Innovative Molecules Raises \u20ac20 Million Series A Equity Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"IM-250","moa":"Helicase-primase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovative Molecules","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Innovative Molecules \/ Life Sciences Partners","highestDevelopmentStatusID":"4","companyTruncated":"Innovative.."},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Study Itolizumab in Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Oxford University","highestDevelopmentStatusID":"4","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Supriya Lifescience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Supriya Lifescience \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Supriya Li.."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Drogsan Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic in Turkey","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rockwell Medical \/ Drogsan Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Join Hands with Mayo Clinic and Gets FDA Clearance for First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Ipilimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Mayo Clinic \/ Sorrento","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clini.."},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"17\u03b1-ethynyl-androst-5-ene-3,7,17-triol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.3599999999999999,"dosageForm":"Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix .."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$805.0 million","upfrontCash":"$85.0 million","newsHeadline":"Jounce Achieves First Milestone in a License Agreement with Gilead Sciences and FDA Clearance of IND Application for Anti-CCR8 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0.81000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.81000000000000005,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Brandon Capital","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"INNA-051","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Brandon Capital","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"D","amount":"$585.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Praliciguat","moa":"sGC","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.58999999999999997,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Announces Entry Into \u201cLetter-of-Intent\u201d for the Acquisition of Armesocarb by Adhera Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Armesocarb","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pha.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dermavant Announces $200 Million of Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0.20000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Marathon Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Mirae Asset Capital","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iksuda Therapeutics Closes $47 Million Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"IKS03","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Iksuda Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Iksuda Therapeutics \/ Mirae Asset Capital","highestDevelopmentStatusID":"4","companyTruncated":"Iksuda The.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Kingswood Capital Markets","pharmaFlowCategory":"D","amount":"$31.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Kingswood Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Trinity College Dublin","sponsor":"ONK Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"ONKT103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Trinity College Dublin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trinity College Dublin \/ ONK Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Trinity Co.."},{"orgOrder":0,"company":"Kojin Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Ferroptosis-based Drug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kojin Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kojin Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"Kojin Ther.."},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$267.0 million","upfrontCash":"$17.0 million","newsHeadline":"Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"TMEM175","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Caraway Therapeutics \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Th.."},{"orgOrder":0,"company":"SATT Conectus","sponsor":"Lysogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"FXS01","moa":"DGKk","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SATT Conectus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SATT Conectus \/ Lysogene","highestDevelopmentStatusID":"4","companyTruncated":"SATT Conec.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Blue Ocean & Pharnext Announce the Signing of a Financing Agreement for up to 81 Million Euros","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Alpha Blue Ocean","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$107.5 million","upfrontCash":"Undisclosed","newsHeadline":"Synthekine Announces $107.5 Million Oversubscribed Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"STK-012","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Synthekine \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kurome Therapeutics Closes $15 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IRAK1\/4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kurome Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Kurome Therapeutics \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Kurome The.."},{"orgOrder":0,"company":"Onchilles Pharma","sponsor":"University of Chicago","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Onchilles Pharma Raises $7 Million Series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Onchilles Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Onchilles Pharma \/ University of Chicago","highestDevelopmentStatusID":"4","companyTruncated":"Onchilles .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna\u2019s COVID-19 Vaccine in Saudi Arabia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Heartseed","sponsor":"UTokyo Innovation Platform","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series C Financing","leadProduct":"Allogeneic iPSC-derived Cardiomyocytes","moa":"Angiogenic factors secretion","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Heartseed","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ UTokyo Innovation Platform","highestDevelopmentStatusID":"6","companyTruncated":"Heartseed .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Collaborates with Bristol Myers Squibb to Evaluate XL092 Immuno-oncology Therapies Combo in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Insmed","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiba Middle East Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE in the Countries of GCC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liposome Inhalation Suspension","sponsorNew":"Insmed \/ taiba Middle East FZ","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ t.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Mirae Asset Financial Group","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series D Financing","leadProduct":"HFB200301","moa":"Anti-TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Mirae Asset Financial Group","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"VectorY","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$36.7 million","upfrontCash":"Undisclosed","newsHeadline":"VectorY Raises \u20ac31 Million in Seed Financing to Develop Next-Generation Gene Therapies Aimed at Muscular and CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Vectorized Antibodies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VectorY \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alentis Therapeutics Raises USD 67 Million in Series B Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"ALE.F02","moa":"Claudin-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Morningside Venture","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Magenta Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Magenta Partner to Distribute Moderna\u2019s COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Magenta Partners","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"University of Florida","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoMyx Gets Exclusive Option to License IP Rights for Myxoma Virus Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"OM301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"University of Florida","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Florida \/ OncoMyx","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"The Virginia Catalyst","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"ReAlta Life Sciences Receives $3.2M Grant from Virginia Catalyst to Accelerate Trial for the Treatment of Acute Lung Injury Due to COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ The Virginia Catalyst","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ALX Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology to Collaborate with Lilly to Evaluate ALX148 + CYRAMZA, Trastuzumab, and Paclitaxel in Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ ALX Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities LLC","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix Announces $12.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Inks Supply Deal for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AGC Biologics \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolo Enters into Partnership Agreement with Northway Biotech to Manufacture its Novel Binding Immunoglobulin Protein, \u20181805","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"\u20181805","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Northway Biotechpharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Northway Biotechpharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Northway B.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi XDC and LegoChem Ink ADC Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"LCB14","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Modus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Modus Therapeutics Partners with Imperial College London on Malaria Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Sevuparin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imperial College London \/ Modus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"IAVI","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAVI \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ CEP.."},{"orgOrder":0,"company":"Thirona Bio","sponsor":"Mannkind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"FBM5712","moa":"ALK-5 kinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Thirona Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Thirona Bio \/ MannKind","highestDevelopmentStatusID":"4","companyTruncated":"Thirona Bi.."},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alcyone Therapeutics Launches to Advance Next-Generation Gene Therapies for CNS Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"ACTX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Alcyone Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alcyone Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"4","companyTruncated":"Alcyone Th.."},{"orgOrder":0,"company":"Tribune Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tribune Therapeutics Launches to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"CCN2","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Tribune Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tribune Therapeutics \/ HEALTHCAPS INDIA LTD","highestDevelopmentStatusID":"4","companyTruncated":"Tribune Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Halts Venglustat Clinical Programme in ADPKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Venglustat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Ipsen\u2019s Nda for Ultra-Rare Genetic Disorder Drug","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DMD study in Vamorolone Reports Positive Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Validates Sinovac COVID-19 Vaccine for Emergency Use and Issues Interim Policy Recommendations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Gets Indian Emergency Use Nod for Covid-19 Antibody Drug Combination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Merck's first and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Diphtheria Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces a Voluntary Hold in the Clinical Studies of Masitinib Worldwide","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS drug Opdivo Lands FDA Approval for Gastro Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teclistamab","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives European Commission Approval for Opdivo + Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Accelerated Approval for ADUHELM\u2122 as the First and Only Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Reports New Data for NBTXR3 in Combination with Anti-Pd-1 Showing Local or Distant Tumor Regression in 76.9%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Presents Positive One-Year Data for the First High-Concentration and Citrate-Free Biosimilar Adalimumab Yuflyma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay (odevixibat) in PFIC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The First Hormone Replacement Therapy for Hypoparathyroidism in China Obtains IND Approval for Phase III Clinical Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope's Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MCO-010","moa":"MCO gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope Physicians and Scientists Present New Immunotherapy Research at ASCO Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teclistamab","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion\u2019s AI-powered Vaccine Platform RAVEN for SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Stops Three Late-Stage Studies of Beovu Eye Drug Citing Patient Safety","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ IQVIA Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Clinically Relevant Improvement in Median Overall Survival Data in Final Analysis of Pivotal NETTER-1 Study With Targeted Radioligand Therapy Lutathera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lutetium Lu 177 dotatate","moa":"SSRT2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of Brovana\u00ae in the United States","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Showcases CGRP-Antagonist Franchise Data Including Nurtec\u00ae ODT, Now Approved to Treat and Prevent Migraine Attacks","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives USFDA Tentative Approval For Osimertinib Tablets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-KIT","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Expands VERSATILE-002 study of PDS0101 and KEYTRUDA in Advanced Head & Neck Cancer to Include Patients Who Have Failed Prior Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways and Kings College London Publish Cognition Results from COMP360 Psilocybin Study in Healthy Volunteers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexmarilimab Results Published in CCR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bexmarilimab","moa":"CLEVER-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-721","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-721","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Reports Positive Interim Results in Dermatitis Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"EB01","moa":"sPLA2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"QBiotics Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tigilanol Tiglate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"QBiotics Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"QBiotics Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"QBiotics G.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Results of the BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent Commented in Journal, Blood","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CT103A","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anifrolumab Showed Early and Sustained Treatment Benefit for Patients with Systemic Lupus Erythematosus in the TULIP Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial shows Benefits of Targeted Drug Against Early-Stage Breast Cancer with Inherited BRCA Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Institute of Cancer Research \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis 177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival for Men with Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents Data from CheckMate -648 of Opdivo Plus Chemotherapy and Opdivo Plus Yervoy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys and Bioproduction Partner Bio Elpida Begin Construction of GMP Facility to Produce Clinical Supply","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BVX-0918A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized IgG2 Agonistic Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PEC-01 Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"ViaCyte Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"ViaCyte Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ViaCyte In.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from UCB's Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-KIT","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Dilafor Presents Positive Results from A Phase 2b Study of Tafoxiparin","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafoxiparin","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Launches Clinical Trial of Universal Influenza Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"VRC-FLUMOS0111-00-VP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Receives Orphan Drug Designation from the EMA for Elamipretide for the Treatment of Barth Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group plc - Diurnal receives European Commission approval for Efmody\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi at EHA Virtual Congress 2021: Focus on Results in Pnh and Treatment for ITP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Submits NDA to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Launches Estradiol Valerate Injection, USP","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Estradiol Valerate","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive FDA Meetings Enable Neuren to Proceed with INDs for Three Phase 2 Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NNZ-2591","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neuren Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuren Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuren Pha.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Analysis Evaluating Continuous RINVOQ\u00ae Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ in Patients with Rheumatoid Arthritis to be Presented at EULAR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Receives Conditional Marketing Authorization in the UK for NEXPOVIO in Combination with Dexamethasone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AKL's Investigational Osteoarthritis Drug APPA Reduces Senescence and Reactive Oxygen Species Production","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CAS 498-02-2","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AKL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therap.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OLUMIANT\u00ae Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist Securities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Inc. Expands Phase I\/IIa Clinical Trial With Additional Study Site","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics\u2019 INT230-6 Effective as Either Monotherapy or in Combination with Checkpoint Inhibitors in R\/R Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BI 456906","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Presents Positive One-Year Data for the First High-Concentration Biosimilar Adalimumab, YuflymaTM in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Submits NDA to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen\u2019s Lumakras Secures FDA Nod For NSCLC with KRAS G12C Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine to Present at the BIO Digital International Convention 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira will Present the U.S. Clinical Phase I Study Results of MVR-T3011 Via Intratumoral Administration at ASCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"T3011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas\u2019 Novel High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HD-MAP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ N.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics Plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kymriah\u00ae Pivotal Trial Demonstrates Strong Response Rates and A Remarkable Safety Profile in R\/R Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik Light Vaccine Demonstrates 78.6-83.7% Efficacy Among the Elderly in Argentina","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Elected to Present Diamyd\u00ae Meta-Analysis Results at the EASD Diabetes Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ALPN-303","moa":"B Cell cytokine","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis PREVENT Data Show Cosentyx\u00ae Helps Patients Realize Early and Lasting Relief in Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Results Show Patients with Crohn's Disease Receiving Risankizumab Achieved Clinical Remission at 1 Year","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay (odevixibat) in PFIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced ESCC at ASCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Ortho Regenerative Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Regenerative Technologies Receives Clinical Hold Letter from The U.S. FDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ORTHO-R","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Ortho Regenerative Technologies","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ortho Regenerative Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ortho Rege.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"SP Accure Labs Pvt. Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SP Accure Labs Launches Drug Amphotericin-B-Emulsion for Mucormycosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SP Accure Labs Pvt. Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"SP Accure Labs Pvt. Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SP Accure .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s PD-1 Inhibitor Jemperli Approved in the Uk","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-L1 checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"CSIR-Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Clinical Trial of Niclosamide Drug for Treatment of Covid-19 Patients Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LAXAI Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"LAXAI Life Sciences \/ CSIR","highestDevelopmentStatusID":"8","companyTruncated":"LAXAI Life.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and \u03b2-Thalassemia Studies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HGB-206","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Showed Fewer Incidences of Atrial Fibrillation versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian Direct Investment Fund: Single-Dose Sputnik Light Vaccine aPproved for Use in the Republic of the Congo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Launches Remsima Sc, the World's First Subcutaneous Formulation of Infliximab in Canada, for Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Crestone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CRS3123","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Crestone","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Crestone \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Application for Clinical Trials of the Second Indication of its Fully Human CD19\/CD22 Dual-targeted CAR-T Drug Accepted","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19\/CD22","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Presents Positive Tab-cel\u00ae Long-Term Overall Survival Data for EBV-Driven Post-Transplant Lymphoproliferative Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex and Walmart Launch Tru Niagen\u00ae in 3,800 Walmart Stores Across the United States","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Agendia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agendia\u2019s MammaPrint\u00ae Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Letrozole","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agendia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Agendia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agendia \/ .."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GM CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2\/7.3 as a Therapeutic Target in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"QRA-244","moa":"Kv7.2\/7.3 ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506, a Proposed Biosimilar of Simponi (Golimumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Golimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Strengthens Global IP Protection for its Novel Invir.IO\u2122 Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Genetically modified Vaccinia virus Copenhagen","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences to Present Updated Phase 1b\/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-179","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ VBI Vaccines","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at IASP World Congress","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Data Presented at DDW 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac for Mucinous Cystic Neoplasms of the Pancreas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"MigVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MigVax\u2019s COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MigVax-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MigVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MigVax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MigVax \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Reports Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Publishes Detailing the Mechanism of Action of PDE7 In Nicotine Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"OMS527","moa":"PDE7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Mogamulizumab","moa":"CCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Launches Trial for ANJ900 to Treat T2D Patients with Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharm.."},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Analysis Supports GOCOVRI for Motor Complications for People With PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pha.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem Reports Interim Futility Analysis for Its Phase IIB ASTONISH Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nangibotide","moa":"TREM-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Report HIV Pipeline with Opening of a Phase 1 \u2018HIV Cure Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Antiretroviral therapy","moa":"IL-15","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Nalmefene HCI Injection","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose TR","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Study Results Show IMBRUVICA\u00ae (ibrutinib)-Based Combination Regimen Shows Superior Progression-Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago\u2019s Bomedemstat Shows Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 SMA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents New Phase 1 Data on Etavopivat at 26th European Hematology Association Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Bio.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl\u00ae (luspatercept-aamt) in NTD Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Presents Preclinical Data Using SORT-LNP and RNA Platforms to Rescue CFTR Function","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"RCT223","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TNF-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Presents the First Real-World Data for Truxima (Biosimilar Rituximab) in Patients with Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longer-Term Data for Kite\u2019s Yescarta in Relapsed or Refractory Follicular Lymphoma ShowsSubstantial Survival Improvement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Doses First Subjects in Phase I Trial for Novel Cystic Fibrosis Therapy ETD001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ETD001","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity to Present at The Keystone Symposia Precision Oncology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K-gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BX005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"MASP-2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Study Show Combination Regimen Based on IMBRUVICA as a Fixed Duration Oral Treatment Shows Superior Progression-Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Veracyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte\u2019s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veracyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veracyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veracyte \/.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte's Updated Data for Ruxolitinib Cream Accepted for Presentation at RAD2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Provides Update on NYX-783 Development Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NYX 783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Reaches Primary Completion Date in Its Switching Study for AVT02","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Journal of the AMA Publishes Data on Efficacy of VYEPTI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"PulmoSIM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PulmoSIM Therapeutics Granted Orphan Drug Designation for PT001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PT001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"PulmoSIM Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PulmoSIM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PulmoSIM T.."},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical to Present at H.C. Wainwright 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cure Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Cure Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cure Pharm.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-HANK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"N-803","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data from ImmunoPrecise\u2019s Drug Pipeline to be Presented During the BIO International Partnering Event","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TATX-21","moa":"LDL uptake","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC42","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAPTIVATE Study Shows an IMBRUVICA Plus VENCLEXTA\/VENCLYXTO Chemotherapy-Free Combination Has Potential to Provide Remission in CLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approval of Aducanumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurimmune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurimmune \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"A&G Pharmaceutical","sponsor":"Precision Antibody","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Identification of An Internalizing Cancer Target for Novel Antibody Drug Conjugate by A&G Pharmaceutical and Precision Antibody Researchers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Antibody Drug Conjugate","moa":"PTGFRN","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"A&G Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"A&G Pharmaceutical \/ Precision Antibody","highestDevelopmentStatusID":"4","companyTruncated":"A&G Pharma.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Presents Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax in CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Fight Trial Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In FGFR2b+ Gastric, Gastroesophageal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"FGFR2B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO in Patients with IDH Mutant Low-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Coordination Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Coordination Pharmaceuticals IND Approval for CPI-300, a Novel Antitumor Nanomedicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bupropion Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Coordination Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coordination Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Coordinati.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Receives Regulatory Approval to Start Clinical Trial Investigating Nadunolimab and Folfirinox in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Receives FDA Fast Track Designation For Bemcentinib \/ Anti-PD-(L)1 Combination In NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CT103A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ IASO Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH and in Hepatic Impairment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Calcium","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai To Present Latest Data Of Lemborexant At 35th Annual Sleep Meeting (SLEEP2021)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"AUM LifeTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM LifeTech Present Preclinical Data on Lung Cancer, PD, and HIV at BIO Digital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Anitisense Oligonucleotides","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM LifeTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM LifeTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM LifeTe.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates 94.3% Efficacy and High Safety Profile During the Vaccination Campaign in Bahrain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lancet Publishes Results of Phase 3 Study Program Evaluating Upadacitinib in AD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax\u2019s ONCOS-102 Mesothelioma 24-month Data Shows Class-leading Median Overall Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBMG' Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"C-CAR066","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Presents New Analysis Showing Clinical Impact Of WAKIX","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yingli Pharma to Present on the Phase 2 Clinical Trial of Linperlisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Linperlisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Y.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte\u2122 in CTCL from the European Medicines Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics to Present at 2021 BIO Digital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide (PMZ-1620), a First-in-Class Investigational Product, Shows Promise to Slow Down the Progression of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"SpliSense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SPL23-ASO","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SpliSense","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SpliSense \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bergenbio Presents Encouraging Updated Preliminary Data From Phase II Study In Relapsed Aml Patients At Eha Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"OxThera AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OxThera reports Results from Phase 3 ePHex Study with Oxabact in Primary Hyperoxaluria Patients with Maintained Kidney Function","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oxalobacter formigenes","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"OxThera AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OxThera AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OxThera AB.."},{"orgOrder":0,"company":"Taiko Pharmaceutical","sponsor":"Kitasato University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Chlorine Dioxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taiko Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Aqueous Solution","sponsorNew":"Taiko Pharmaceutical \/ Kitasato University","highestDevelopmentStatusID":"1","companyTruncated":"Taiko Phar.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momelotinib Oral Presentation at EHA Demonstrates Association Between Transfusion Independence and Improved Overall Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"LPCN 1154","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Releases Presentations of ONCOS-102 Mesothelioma 24-Month Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Axon Drugs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Aging Publishes Phase II Results for AADvac1, a First-in-Man Alzheimer's Tau Vaccine Developed by Axon Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AADvac1","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Drugs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Axon Drugs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Drugs.."},{"orgOrder":0,"company":"European Hematology Association","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Survival Benefit Established With Daratumumab Plus Lenalidomide and Dexamethasone in Elderly Patients with Transplant-ineligible NDMM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"European Hematology Association","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"European Hematology Association \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"European H.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira Completed the First Dosing for Phase II of MVR-T3011 (Intratumoral Injection) in the U.S. and China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"T3011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Dosed First Obese Subject in A Phase 2 Clinical Trial of IBI362","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI362","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braeburn Resubmits New Drug Application for BRIXADI","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GAL-201","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Galimedix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galimedix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galimedix .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety Data Highlighting Low Rates of Adverse Events with Iomab-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Methadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Ampion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampion \/ N.."},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Presents Preclinical Data Showing Gut Microbiome Modulation via Delivery of CRISPR Nuclease Impacts Disease Progression","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"EB003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eligo Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bios.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Will Share TRULANCE (Plecanatide) Data At The 2021 AANP National Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Plecanatide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acura Pharmaceuticals Provides Development Update on LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Phar.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Confirms NDA for Oleogel-S10 Will not Require an Advisory Committee Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Presents Pre-clinical Data on CFT8919 at Keystone Symposium on Targeted Protein Degradation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CFT8919","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Completes Treatment of First Cohort in Phase 1 Trial with Gamma Delta T-Cell Therapy in Newly Diagnosed Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"INB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ NIH","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Publishes Preclinical Data on Novel Off-the-Shelf Natural Killer Cell Therapy, ACE1702","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAPLYTA\u00ae (Lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and Phase 2\/3 Eosinophilic Esophagitis Trials of Lirentelimab","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Receives IND Clearance from the FDA for CLN-049","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CLN-049","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Shares Jump 35% Ahead of Data on Endoxifen in Breast Cancer Surgery Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Phase 1 HB-200 Data Show Unprecedented T cell","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Outlines Next Steps for the Development of Mavrilimumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents BION-1301 Interim Phase 1\/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science is Providing a Summary of the Live Webcast Held on June 3, 2021 Following the Voluntary Hold in the Clinical Studies of Masitinib","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"PDGFRA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Th.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"KT-413","moa":"IRAKIMiD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Adaptive Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adaptive Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adaptive B.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Qu Biologics\u2019 Crohn\u2019s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"QBECO SSI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"MNK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress EASL 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia to Present New Phase 3 Data on Daridorexant in Insomnia at Sleep 2021","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HC-5404","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Presents PROLONG Phase 2A Proof-of-Concept Data on Ebopiprant for the Treatment of Spontaneous Preterm Labor","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION Confirms Institutional Review Board Approval and Submission of the IND Application to FDA to Start Phase 2 Study Evaluating THR-687","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Showcase New Data at the EASL International Liver Congress 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Hosting Investor Webinar with Corporate Updates and KOL and Patient Advocate Presentations on M. abscessus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"aNRP2-14","moa":"Sema3F\/NRP2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Plans Clinical Trial for EDSIVO (celiprolol) Following Type B FDA Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Equillium \/ Biocon Limited","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"STI-2099","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the EHA2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"KER-050","moa":"Activin receptor type IIA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Presents New Data on Obe-Cel in r\/r Indolent B Cell Lymphomas and Gives an Update of Obe-Cel in R\/R Adult","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Obecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Presents Data Supporting the Initiation of the EDIT-301 Phase 1\/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Busulfan","moa":"CD34+ gene","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Supporting the Potential Use of Oxbryta in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at EHA 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Mendus","sponsor":"VU University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mendus \/ VU University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ V.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Ptacopan (LNP023) Shows Benefit as Monotherapy in Treatment-Na\u00efve Patients with Paroxysmal Nocturnal Hemoglobinuria","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Oncoheroes Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dovitinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Oncoheroes Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX 2-73 and ANAVEX 3-71 Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"MUHC Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III North American Clinical Trial for COVID-19 Treatment begins after FDA & Health Canada approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MUHC Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MUHC Foundation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MUHC Found.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech\u2019s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight for Late-Stage Clinical Trials of LB1148","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET\u2122 To Treat Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Initiates Expansion of Phase 1\/2 Clinical Trial for OTO-413 in Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Brain-Derived Neurotrophic Factor","moa":"BDNF","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Data at EAN 2021 Showcase Significant Impact of Therapies Across Diverse Neuroscience Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences Reports Positive Data From phase I Study of NVD-001 For Spinal Fusion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NVD-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Novadip Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novadip Bi.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Presents Updated Data Demonstrating Promising Efficacy and Safety of Lisaftoclax in R\/R, CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent \u03b1- and \u03b2-Thalassemia at EHA2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Naratuximab Emtansine","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria and SYNB8802 for Enteric Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SYNB1934","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UTILITY Therapeutics Preparing NDA Submission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pivmecillinam","moa":"PBP1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UTILITY therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UTILITY th.."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Launches Drug to Treat Black Fungus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gastro-Resistant Tablet","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSIR in Partnership with Laxai Life Sciences has received Regulatory Approval to Begin Clinical Trials on Covid-19 Patients with Colchicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Laxai Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"CSIR-India.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Launches Tiogiva\u00ae, Becoming One of the First Companies in the Uk to Launch a Bioequivalent Version of Tiotropium Bromide","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder Inhaler","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Alchem International Private Ltd","sponsor":"AIIMS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIIMS Patna Confirms efficacy of AlchemLife\u2019s Phytorelief a Natural Anti-Viral for Mild to Moderate Covid-19 Cases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Curcuminoid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alchem International Private Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Lozenges","sponsorNew":"Alchem International Private Ltd \/ AIIMS","highestDevelopmentStatusID":"1","companyTruncated":"Alchem Int.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech\u2019s partner Ocugen to seek full approval for Covaxin in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"06-2021-InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophore seeks DCGI Emergency Use Approval of Aviptadil for Covid-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore I.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA for THR-687","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Roche Data for Evrysdi Show Improved Motor Function in Pre-Symptomatic Babies After One Year","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DELYTACT\u00ae Oncolytic Virus G47\u2206 Approved in Japan for Treatment of Patients with Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teserpaturev","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Stereotactic Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files New Drug Application in Japan for Faricimab for Diabetic Macular Edema and Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh.10 expressing beta-galactosidase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo\u2019s Valemetostat Data Shows Promising Durable Tumor Response in Patients with Relapsed\/Refractory PTCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Gives Approval to Amivantamab-Vmjw in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Announces Positive Topline Results of Pivotal Phase III TULIP\u00ae Study in Patients With HER2-Positive Unresectable Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab Duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer to Test COVID-19 Vaccine in Larger Group of Children Below 12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Report Data from Phase 3 COSMIC-311 Pivotal Trial in Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ex.."},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences Reports pOsitive Data from Phase I Study of NVD-001 for Spinal Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NVD-001","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Provides Update on New Phase 3 Study Results of IMBRUVICA\u00ae (ibrutinib)-Based Combination Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pivotal Data at EHA 2021 reinforces Sutimlimab as A First-in-Class Investigational C1s Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"C1-activated hemolysis","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Bioverativ","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces U.S. FDA Approval for TRIKAFTA\u00ae in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen to Pursue a BLA path in the US for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argentina Issues Emergency Approval to China's Single-Dose Cansino Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Stroke Patient Treated with Afamelanotide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Clinuvel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clinuvel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clinuvel P.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and \u03b2-Thalassemia Studies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Betibeglogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces New Interim Analysis Phase II Data for Iptacopan in Rare Kidney Disease C3 Glomerulopathy (C3G)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 (Semaglutide 2.4 mg), the First and Only Once-Weekly Glp-1 Therapy for Weight Management, Approved in the US","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi\u00ae) in Chronic Graft-Versus-Host Disease (GVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Biogen","sponsor":"NightstaRx Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Timrepigene emparvovec","moa":"Human choroideremia gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ NightstaRx Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Reports Positive Top-Line Results from Phase 2 a Lift Study of Fxr Agonist TERN-101 in Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-101","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Highlights Recent Progress in Three Phase 3 Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Oncopeptides\u00b4 PEPAXTO\u00ae (Melphalan Flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"DCC-3116","moa":"ULK kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis to Unveil New Data at ASCO and EHA From Its Robust Portfolio, Including Overall Survival in Prostate and Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"TNO155","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ERAS-601","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces Initiation of Its Phase 1\/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AMP CpG","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"HavaH Therapeutics","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"D","amount":"$11.2 million","upfrontCash":"$0.5 million","newsHeadline":"Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"HavaH Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Implant","sponsorNew":"HavaH Therapeutics \/ Clarus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"HavaH Ther.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Merger","leadProduct":"Cycloserine","moa":"d-Ala-d-Ala ligase A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NRx Pharmaceuticals \/ NeuroRx","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Nipro Glass","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca, Nipro Sign COVID-19 Vaccine Deal for Supply in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nipro Glass","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nipro Glass \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Nipro Glas.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANDA Approval from USFDA for Unichem\u2019s Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Centocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX SC Formulation for New Indications in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Centocor","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centocor \/.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Funding","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Provides Recent Updates of CUE-101 Phase 1 Dose Escalation Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Deerfield Partners","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Deerfield Partners","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$18.0 million","newsHeadline":"Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement for Omilancor and NX-13","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.22,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ LianBio","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Highlights the Cabometyx Thyroid Cancer Phase 3 Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Talquetamab","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Anti-inflammatory drug","moa":"IL-22","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alivio Therapeutics \/ PureTech","highestDevelopmentStatusID":"4","companyTruncated":"Alivio The.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$1,455.0 million","upfrontCash":"$55.0 million","newsHeadline":"MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibody-based Therapy","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MacroGenics","amount2":1.46,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.46,"dosageForm":"","sponsorNew":"MacroGenics \/ Zai Lab","highestDevelopmentStatusID":"4","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$104.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Launches Hong Kong Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Fruquintinib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Aldevron","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aruvant Partners with Aldevron to Provide Key Plasmid Raw Materials Used to Manufacture Pipeline Products","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aldevron","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aldevron \/ Aruvant","highestDevelopmentStatusID":"7","companyTruncated":"Aldevron \/.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"aMoon","pharmaFlowCategory":"D","amount":"$46.5 million","upfrontCash":"Undisclosed","newsHeadline":"KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Atezolizumab","moa":"CD47x41BB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Kahr Medical \/ aMoon","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Funding","leadProduct":"Ketamine Hydrochloride","moa":"iGluRs","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience and Novo Nordisk Collaborate to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lumen Bioscience \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"$45.0 million","newsHeadline":"Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Binimetinib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$132.2 million","upfrontCash":"Undisclosed","newsHeadline":"Protagonist closes $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Rusfertide","moa":"Iron homeostasis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Neurelis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"BA-1049","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Neurelis","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone B.."},{"orgOrder":0,"company":"Public Health Vaccines","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Public Health Vaccines Awarded Options Under Advanced Development Contract From BARDA to Develop Vaccine Against Marburg Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"rVSV\u2206G-MARV (Angola) GP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Public Health Vaccines","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Public Health Vaccines \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Public Hea.."},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"CellPoint","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CellPoint and Lonza Enter Strategic Collaboration to Deliver CAR-T Cells to Patients at Point-of-Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"CAR-T Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lonza Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Biologics Inc \/ CellPoint","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Biol.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Aggrega Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M8 Pharmaceuticals and UCB Partner for Central Nervous System and Respiratory Portfolio in Mexico","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Piracetam","moa":"Ach receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Ph.."},{"orgOrder":0,"company":"Abcam plc","sponsor":"Pionyr","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"PY314","moa":"TREM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Abcam plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abcam plc \/ Pionyr","highestDevelopmentStatusID":"6","companyTruncated":"Abcam plc .."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"$20.0 million","newsHeadline":"Alfasigma Buys Back its European License for Bentracimab from PhaseBio","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.25,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"$40.0 million","newsHeadline":"ViiV Healthcare and Halozyme Collaborate for ENHANZE\u00ae Drug Delivery Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Halozyme Therapeutics \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"TNB-383B","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Alexander Capital L.P.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acurx Pharmaceuticals, Inc. Announces Pricing of $15 Million Underwritten Initial Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Alexander Capital L.P.","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Gavi","highestDevelopmentStatusID":"9","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Clover","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Cannex Scientific","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cannex Scientific Announces Agreement to Advance Commercialization of FDA-Regulated Cannabinoid Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Cannabinoid Therapies","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cannex Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cannex Scientific \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Cannex Sci.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Health Sciences Antigua","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Thin Film","sponsorNew":"Revive Therapeutics \/ University of Health Sciences Antigua","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$2,075.0 million","upfrontCash":"$625.0 million","newsHeadline":"GSK Pays Up Big for Rights To TIGIT-Targeted Cancer Immunotherapy from Iteos","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iteos Therapeutics","amount2":2.0800000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0800000000000001,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ GlaxoSmithKline","highestDevelopmentStatusID":"6","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Mnemo Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mnemo Banks $90M to Tackle Barriers in CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mnemo Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Mnemo Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Mnemo Ther.."},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Apollo Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"4","companyTruncated":"Apollo The.."},{"orgOrder":0,"company":"Everads Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Everads Therapy","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Everads Therapy \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Everads Th.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"CROSSJECT: License agreement in the United States and Canada with Eton Pharmaceuticals for ZENEO\u00ae Hydrocortisone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","amount":"$51.7 million","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotechnology Closes Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Novan","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Announces Pricing of $40 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ca.."},{"orgOrder":0,"company":"Icon Plc","sponsor":"Evergreen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evergreen Therapeutics Announces Agreement with ICON to Conduct Phase II Clinical Trial for COVID-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"EG-009A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icon Plc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Icon Plc \/ Evergreen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Icon Plc \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Global WholeHealth Partners Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 2nd COVID-19 Vaccine - The Pfizer-BioNTech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Global WholeHealth Partners Corp","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma GmbH","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360\u2122 Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"PR600","moa":"TNF","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Imunon","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ S.."},{"orgOrder":0,"company":"NextCure","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"NAMRU-3","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"STI-2020","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ NAMRU-3","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"vTv Therapeutics and Cantex Pharmaceuticals Enter Strategic Licensing Agreement Dvelopm and commercialise Azeliragon for Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"vTv Therapeutics \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"UCB Ventures","pharmaFlowCategory":"D","amount":"$41.5 million","upfrontCash":"Undisclosed","newsHeadline":"Neurona Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurona Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ UCB Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Corlieve Therapeutics","sponsor":"Uniqure","pharmaFlowCategory":"D","amount":"$106.2 million","upfrontCash":"$54.6 million","newsHeadline":"uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"AMT-260","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Corlieve Therapeutics","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Corlieve Therapeutics \/ uniQure","highestDevelopmentStatusID":"4","companyTruncated":"Corlieve T.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pacira BioSciences Signs Exparel Distribution Agreement With Eurofarma in Latin America","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anavex Life Sciences Announces $50 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"FHI Clinical","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"FHI Clinical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"FHI Clinical \/ Tiziana","highestDevelopmentStatusID":"6","companyTruncated":"FHI Clinic.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$110.0 million","newsHeadline":"Osmotica Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Divestment","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Journey Medical Corporation Enters into an Agreement with Dr. Reddy\u2019s Laboratories to Develop DFD-29 for the Treatment of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Cenexi","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cenexi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cenexi \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cenexi \/ O.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"$50.0 million","newsHeadline":"Apellis and Beam Therapeutics Enter Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Beam Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravitreal Injection","sponsorNew":"Beam Therapeutics \/ Apellis","highestDevelopmentStatusID":"3","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Bioasis","sponsor":"Oxyrane","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Enzyme Replacement Therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioasis \/ Oxyrane","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ .."},{"orgOrder":0,"company":"Olimmune","sponsor":"Scopus Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"OLIM-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Olimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olimmune \/ Scopus BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Olimmune \/.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"XBiotech Announces Receipt of $75 Million from Sale of Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Divestment","leadProduct":"Bermekimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"XBiotech","amount2":0.75,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.75,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAegis Awarded BARDA Contract to Advance Development of Gelsolin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbutus and Antios Therapeutics Announce Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 Hep B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Antios Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Allied Corp","sponsor":"HAVN Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex\u2122 RX","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Allied Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allied Corp \/ HAVN Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Allied Cor.."},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Signs Non-Binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Baymedica","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Baymedica \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Baymedica .."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA\u00ae (omadacycline) Valued at ~$38 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Funding","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $10.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"SAMDC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 in Patients with Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Ibudilast","moa":"IL-1 beta","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"DyDo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse\u00ae in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ DyDo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$650.0 million","newsHeadline":"Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai\u2019s MORAb-202 Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Eribulin","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":3.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.1000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Br.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$14.4 million","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise Option for Gross Proceeds of $14.4 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Spartan Capital Securities","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"AM-Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma to Prepare for the Commercial Launch Acute Kidney Disease Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBI Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KBI Biopharma \/ AM-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"KBI Biopha.."},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Allogeneic Cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shoreline Biosciences","amount2":2.2999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2999999999999998,"dosageForm":"","sponsorNew":"Shoreline Biosciences \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"Shoreline .."},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Catalyst Health Ventures","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin beta-1 chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Catalyst Health Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Th.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Advantech Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoNano Medicine Raises ~$50 Million in Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"ONM-501","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoNano Medicine","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"OncoNano Medicine \/ Advantech Capital","highestDevelopmentStatusID":"4","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pinteon Therapeutics Announces $3M Award from Advanced Technology International to Support Phase 1 Study of PNT001","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Th.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Amasa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Amasa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Debuts With $47 Million Series A Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Aceclidine Hydrochloride","moa":"AchE","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"LENZ Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group and Nextech","pharmaFlowCategory":"D","amount":"$66.0 million","upfrontCash":"Undisclosed","newsHeadline":"Circle Pharma Raises $66 Million in Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cyclin A","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Circle Pharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Circle Pharma \/ The Column Group and Nextech","highestDevelopmentStatusID":"2","companyTruncated":"Circle Pha.."},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"RNA Therapies","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ochre Bio","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ochre Bio \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ochre Bio .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead and Horizon Collaborate to Develop RNAi Therapeutic","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"ARO-XDH","moa":"Xanthine dehydrogenase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Lux Capital","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bio.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Big Cypress Acquisition Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Merger","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Big Cypress Acquisition Corp","highestDevelopmentStatusID":"9","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Iksuda Therapeutics Expand License Agreement for Development of Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"LegoChem Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"Netcapital","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phoenix PharmaLabs Successfully Completes Second Oversubscribed Netcapital Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"PPL-138","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phoenix Pharmalabs \/ Netcapital","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Ph.."},{"orgOrder":0,"company":"Vital Therapeutics & Formulations Pvt Ltd","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"VTA-100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vital Therapeutics & Formulations Pvt Ltd","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vital Therapeutics & Formulations Pvt Ltd \/ Cambrian Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Vital Ther.."},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"IMM Investment","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"ORM-5029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ IMM Investment","highestDevelopmentStatusID":"6","companyTruncated":"Orum Thera.."},{"orgOrder":0,"company":"Glycomine","sponsor":"ImmuneID","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"GLM101","moa":"Mannose-1-phosphate","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Glycomine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycomine \/ ImmuneID","highestDevelopmentStatusID":"4","companyTruncated":"Glycomine .."},{"orgOrder":0,"company":"ImmuneID","sponsor":"Alta Partners","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"ImmuneID","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"ImmuneID \/ Alta Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmuneID \/.."},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aleta Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Aleta Biot.."},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Raises $52M in Oversubscribed Series A Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"mRNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"4","companyTruncated":"Strand The.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Slate Path Capital","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series B Financing","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Slate Path Capital","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$135.0 million","newsHeadline":"Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vividion Therapeutics \/ Roche","highestDevelopmentStatusID":"4","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"Gliknik","sponsor":"First In Ventures","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"Undisclosed","newsHeadline":"Gliknik Inc. Raises $11.5 Million in Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series C Financing","leadProduct":"Biropepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gliknik","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Gliknik \/ First In Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gliknik \/ .."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"AIG Investments","pharmaFlowCategory":"D","amount":"$60.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lyndra Therapeutics Completes $60.5 Million Series C Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Series C Financing","leadProduct":"Risperidone","moa":"5-HT2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Extended Release Capsule","sponsorNew":"Lyndra Therapeutics \/ AIG Investments","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"AIFA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO\u00ae, SYMKEVI\u00ae and ORKAMBI\u00ae and KALYDECO\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Vertex Pharmaceuticals \/ AIFA","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Anova Pharma","sponsor":"NeOnc Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anova Partners with NeOnc Technologies to Bring NEO100 to Patients With IDH1 Mutated Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Perillyl Alcohol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anova Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Anova Pharma \/ NeOnc Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Anova Phar.."},{"orgOrder":0,"company":"Alvogen","sponsor":"AZTIQ PHARMA","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aztiq Buys 17% Stake in Alvogen US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Lisinopril","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alvogen","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Alvogen \/ Aztiq","highestDevelopmentStatusID":"12","companyTruncated":"Alvogen \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aragen Announces Expansion of Research Agreement with Boehringer Ingelheim","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Everolimus","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aragen Life Sciences \/ Boehringer Ingelheim","highestDevelopmentStatusID":"8","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"IMA402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ KBI Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent\u2019s Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Innovent","highestDevelopmentStatusID":"4","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Mosaic Biosciences","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocular Therapeutix\u2122 and Mosaic Biosciences Ink Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Complement","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Mosaic Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mosaic Biosciences \/ Ocular Therapeutix","highestDevelopmentStatusID":"2","companyTruncated":"Mosaic Bio.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"FS Development Corp. II","pharmaFlowCategory":"D","amount":"$276.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pardes Biosciences and FS Development Corp. II Announce Merger Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Merger","leadProduct":"PBI-0451","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0.28000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Pardes Biosciences \/ FS Development Corp. II","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"SomaLogic","sponsor":"Ixaka","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"AntigenxCD3 Bispecific Aptamers","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SomaLogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SomaLogic \/ Ixaka","highestDevelopmentStatusID":"4","companyTruncated":"SomaLogic .."},{"orgOrder":0,"company":"Adtech Pharma","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ault Global Holdings Announces Agreement to Acquire up to 40% of Adtech Pharma, Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Nabilone","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Adtech Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Adtech Pharma \/ Ault Global Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Adtech Pha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"French Health Authorities for the cystic fibrosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces National Reimbursement Agreement in France for KAFTRIO\u00ae for Eligible Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"Vertex Pharmaceuticals \/ French Health Authorities for the cystic fibrosis","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Croma-Pharma","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Croma Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","amount":"$16.6 million","upfrontCash":"Undisclosed","newsHeadline":"Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"VLX-1005","moa":"12-LOX","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Veralox Therapeutics","amount2":0.02,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Veralox Therapeutics \/ Hatteras Venture","highestDevelopmentStatusID":"6","companyTruncated":"Veralox Th.."},{"orgOrder":0,"company":"University of Chicago","sponsor":"InFlectis BioScience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InFlectis BioScience Licenses Rights to a Potential New Class of Therapies for Demyelinating Diseases from The University of Chicago","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Chicago \/ InFlectis BioScience","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Prometic Biotherapeutic","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Prometic Biotherapeutic","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Lyophilized Powder for Reconstitution","sponsorNew":"Prometic Biotherapeutic \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Prometic B.."},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$72.2 million","upfrontCash":"$23.3 million","newsHeadline":"Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Amino Acids Mixture","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"APR Applied Pharma Research","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Controlled-release Granule","sponsorNew":"APR Applied Pharma Research \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"APR Applie.."},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Autologous Treg Cell Therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Abata Ther.."},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"GT-2108","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Giiant pharma \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pha.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carmot to Receive Royalty Payments Upon Sales of Amgen\u2019s FDA Approved First-in-class KRAS G12C Inhibitor, LUMAKRAS\u2122 (sotorasib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Carmot Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"Carmot Therapeutics \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"CincyTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eikonoklastes Closes Oversubscribed Series A Financing, Helping to Advance Immunotherapies Toward Clinical Trial Stage","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"L-ICON3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eikonoklastes Therapeutics \/ CincyTech","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklas.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Five Pharma Majors Collaborate for Clinical Trial of Oral Anti-Viral Drug Molnupiravir to Treat Mild Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Cipla","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$82.1 million","upfrontCash":"Undisclosed","newsHeadline":"Immutep Secures Commitments for A$60 Million Through a Two-Tranche Institutional Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Announces Rare Disease Ophthalmology Product Candidate Portfolio Update and Termination of Roche Collaboration and License","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Termination","leadProduct":"4D-110","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ 4D Molecular Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oblique Therapeutics and Targovax Enter Collaboration to Target Mutant Ras Cancers by Combining Their Oncos and Abiprot\u2122 Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oblique Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Targovax","highestDevelopmentStatusID":"4","companyTruncated":"Oblique Th.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lupin Ltd","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Lupin Ltd \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Broad Institute of MIT","sponsor":"Anji Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"ANJ810","moa":"MCL1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Broad Institute of MIT","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Broad Institute of MIT \/ Anji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Broad Inst.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax to Use Envelta\u2122 IND Enabling Study Results for Two Additional Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Enkephalin","moa":"Delta opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medsenic Partners With Phebra for the Clinical Development of the Oral Form of Arscimed\u00ae for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/.."},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Settles generic Revlimid Patent Litigation in US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Lenalidomide","moa":"Cereblon","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Celgene Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Celgene Co.."},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Gets FDA Nod for Strata Graft Thermal Burn Treatment","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cultured Keratinocytes Dermal Fibroblasts Murine Collagen-dsat","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Receives USFDA Final Approval for Testosterone Topical Solution USP, 30 mg Per Pump Actuation","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Testosterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Laboratories Announces Commercial Launch of 2DG","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"2-Deoxy-D-Glucose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Mannkind","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI\u2122 with NDA Acceptance from the FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"United Therapeutics \/ Mannkind","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Doses Second Patient of Phase 1\/2 MARVEL-1 Clinical Trial for Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Gosuranemab","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Phase 2 TROPIC-I Clinical Study will be First to Use Total Control Primary Endpoint in Superiority Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher to Present at The H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on AEDD TRIALS XVI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nerve Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at PPMD 2021 Virtual Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TPX0022","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin\u2019s Development Program in Anti-cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine and Its Partners to Present Data at the EASL International Liver Congress\u2122 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MET642","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AT-007","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Pol\u03b8 Polymerase Inhibitor in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Polymerase theta helicase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Artios Pharma Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intrommune Therapeutics to Present at BIO Digital 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Toothpaste","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ETX0282","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Commences Patient Enrollment in TransportNPC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan\u00ae\/Reeqonus\u2122 for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Monash University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monash University\u2019s New Antibiotic Against Superbugs Starts US Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"QPX9003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Monash University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monash University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monash Uni.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sisunatovir","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ReViral \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Reports Positive Data of Efgartigimod in Myasthenia Gravis Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"CureVac","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Provides Update on Phase 2b\/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Tofacitinib Lowers Mortality in Covid-19 Pneumonia Trial in Brazil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage-Biogen\u2019s Zuranolone Meets Primary Goal in Phase III MDD Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality\u00ae with Every-Other-Day Nurtec\u00ae ODT","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Timrepigene Emparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE\u2122 Phase I Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus to Present Additional Data from its ADPKD Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"RGLS4326","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Report Top-Line Results From Phase 2 Study of Nezulcitinib","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nezulcitinib","moa":"JAK","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vibativ\u00ae Helps Treat Secondary Bacterial Infections In COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Telavancin Hydrochloride","moa":"Peptidoglycan cross-linking","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Lecanemab in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics, Inc. Commences Phase 1 Clinical Study of ST266 Application for Infectious Disease (including COVID-19)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PPeptide-conjugated Ketamine","moa":"Glutamate receptor allosteic","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AIkido Pharm \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pha.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"RSLV-132","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Resolve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Th.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits New Drug Application to U.S. FDA for XARELTO\u00ae (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evrysdi\u2122 Approved in Japan for the Treatment of Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version Of Sunovion Pharmaceuticals, Inc.'s Brovana\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results Add to Body of Evidence Confirming EMFLAZA\u00ae's Benefit Over Prednisone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Donanemab Receives U.S. FDA's Breakthrough Therapy Designation for Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First CAR-T Cell Therapy Approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Kite Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Kite.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's SURPASS-2 Results Published in The New England Journal of Medicine Show Tirzepatide Achieved Superior A1 C","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Douglas CDMO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Isotretinoin Capsules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Douglas Pharmaceuticals Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for EVRENZO\u2122 (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Gets Positive CHMP Opinion in Europe for Vosoritide for Children with Achondroplasia from Age 2 Until Growth Plates Close","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma To Present Progress And Innovations In DMT-Assisted Therapy For The Treatment Of Depression At Upcoming Conferences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"HistoIndex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tropifexor","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HistoIndex","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"HistoIndex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HistoIndex.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Atopic Dermatitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae Approved by the European Commission as the First Immunotherapy Indicated for Advanced Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab-rwlc","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta's Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"VISTA","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Broadens the Development of Nadunolimab in Three Forms of Cancer and Submits Application for Phase I\/II Trial CESTAFOUR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nadunolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Bovine Intestinal Alkaline Phosphatase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the NORD for Zokinvy\u00ae (lonafarnib)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upadacitinib (RINVOQ\u00ae) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Receives FDA Fast Track Designation for LION-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"LION-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed\/Refractory Acute Leukemias","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"Menin-MLL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Randomized Trial of Leukine\u00ae (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupilumab SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's SURPASS-1 Results Published in The Lancet Show Tirzepatide's Superior A1 Candd Body Weight Reductions Versus Placebo","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intranasal COVID-19 vAccine Demonstrates Single-Dose Efficacy in Preclinical Studies Achievement of Phase 1 Clinical Milestone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"COVI-VAC","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in COM701\/Opdivo\u00ae (nivolumab) Phase 1b Cohort Expansion Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Demonstrates Potential for MIMEDX Purion\u00ae Processed Dehydrated Human Amnion \/ Chorion Membrane","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF beta1","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ N.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos to Present Phase 1 Safety and Pharmacokinetic Data for STOPS\u2122 Molecule Drug Candidate ALG-010133 and Chronic Hep B Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"KT-413","moa":"IRAKIMiD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1\/3 Degrader for the Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CFT7455","moa":"IKZF1\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"DAY101","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept to Present New NASH and PBC Data at the Digital International Liver Congress\u2122 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress\u2122 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals to Present at World Microbe Forum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"R327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto\u2019s GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olitigaltin","moa":"Galectin-3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celon Pharma Files for Approval of Phase II Trial of CPL\u2019280, a Second Generation GPR40 Agonist, in Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CPL\u2019280","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Celon Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celon Phar.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BP1003","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera Provides Update on Clinical Developments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide-donating Prostaglandin Analog","moa":"sGC","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress\u2122 EASL 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Medolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts COVID-19 Clinical Study and Advises on Next Steps for Pre-IND Filing by Medolife Rx","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Caribbean Blue Scorpion Extract","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medolife","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medolife \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Medolife \/.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Commercial Launch Update for BREXAFEMME\u00ae (ibrexafungerp tablets)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Provides Regulatory and Development Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau\u00ae in Patients with Skin of Color","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Resubmits New Drug Application for Libervant\u2122 (diazepam) Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive\u00ae Trial at MASCC\/ISOO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Reports Data from its Ongoing Phase 1\/2 Achromatopsia Clinical Trials Showing Biologic Activity against Mutations in ACHM B3 Gene","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"CNGB3 gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi: Libtayo\u00ae Approved by the European Commission for First-Line Treatment of Advanced Non-Small Cell Lung CanceR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs\u2019 177Lu-Omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion by EMA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-omburtamab-DTPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Licensee Bausch + Lomb Receives Approval for VYZULTA\u00ae (latanoprostene bunod ophthalmic solution), 0.024% in UAE","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for EVRENZO\u2122 (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ\u2122","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613 from its Multicenter, Randomized Phase 1b\/2 Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Reports Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1\/2 Study of Galinpepimut-S Combined with Keytruda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605 for the Treatment of Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ALLO-605","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation for LX2006 for Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea\u2019s AT-527 Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Publishes Results of ALLOB Phase I\/IIa Study for the Treatment of Delayed-Union Fractures in Stem Cell Research & Therapy","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Osteoblastic Cells","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I\/IIa Clinical Trial of NMD670","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NMD670","moa":"ClC-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PepGNP-Dengue","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Emergex Vaccines Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire\u2019s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Bolus","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethics Approval for Cynata\u2019s Clinical Trial in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Initiates Phase 1 Clinical Trial of SAN711","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma to Present Data on Glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Glepaglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"HPP737","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"OK-101","moa":"Chemerin receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613\u00ae (Devimistat) for Treatment of Biliary Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Development of BioVie\u2019s NE3107 Asset Featured by the American Diabetes Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"17\u03b1-ethynyl-androst-5-ene-3,7,17-triol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cend Therapeutics\u2019 CEND-1 Granted Fast Track Designation for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CEND-1","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals files a US provisional patent for a new generation of natural product-based derivatives","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Receives FDA Clearance of IND Application for CLN-619","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CLN-619","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"LN-145","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Prexasertib","moa":"CHK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acrivon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Th.."},{"orgOrder":0,"company":"Adocia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Adocia","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adocia \/ N.."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rockwell Files Pre-IND Meeting Request with FDA for its Clinical Trial of FPC for Iron Deficiency Anemia in Patients Receiving Home Infusion","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational 2.0 mg Dose of Ozempic\u00ae (Semaglutide) Demonstrates Superior Reductions in Blood Sugar vs Ozempic\u00ae 1.0 Mg","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Completes COMP360 Psilocybin Therapy Administration for 216 Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s ENSPRYNG Approved by European Commission as First and Only At-Home Subcutaneous Treatment for NMOSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for Episodic Bleeding in Factor VII Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Marzeptacog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Provides an Update on the Phase 1\/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Rigosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Presents 36-Month Data Supporting Durable Response to Arimoclomol During Parseghian Scientific Conference for Npc Research","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced HER2 Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical to Initiate Market Launch of Bentrio\u2122 Nasal Spray in Germany","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Shows Positive Topline Results in RSV Phase 2\/3 MEDLEY Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Welcomes the Decision that Nice Will Revisit Their Appraisal of the Innovative Systemic Treatment, POTELIGEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Mogamulizumab","moa":"CCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Pushes Back Ascendis' Pdufa for Long-Acting Hormone Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Bionaut Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bionaut Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionaut Labs \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Bionaut La.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BHV3100","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sosei Group Corporation \/ Biohaven Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Analysis Shows Superiority of Zanubrutinib Over Ibrutinib for Relapsed\/Refractory CLL, SLL: Presented at EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Histopathology Data from ImmunoPrecise's Polytope \u2122 Program Confirm Reduction in Lung Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TATX-03a","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines to Present at Upcoming Scientific Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan\u00ae\/Reeqonus\u2122 for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NYX 783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Presents Updated ZYNLONTA Clinical Data at 16th Annual International Conference on Malignant Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine-lpyl","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives European Commission Approval for Onureg\u00ae (Azacitidine Tablets) as Frontline Oral Maintenance Therapy for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting PK\/PD Data at the 2021 European Academy of Neurology Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance Approved in Europe for the Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present More Than 70 Abstracts At The International Liver Congress\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bulevertide","moa":"Sodium\/bile acid cotransporter","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Biopharma\u2019s PBP1510, Receives Approval for Clinical Trial in France","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PBP1510","moa":"PAUF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New data Supporting the sAfety and Efficacy Profile of AJOVY","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo to Present at the 2021 NPC Patient","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Notes Orphazyme\u2019s Regulatory Update from the FDA on Arimoclomol","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Safety Data on Treatment of Breastfeeding Mothers with COPAXONE\u00ae (glatiramer acetate) Who Are Living with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daratumumab Subcutaneous Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Grace Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grace Science Receives U.S. FDA Orphan Drug Designation for GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV9 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Grace Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grace Science \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Grace Scie.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Bio Study Uncovers Major Breakthrough in Understanding and Treating Respiratory Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Biovanta","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Lozenges","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Begins Patient Dosing in ESTRELLA Phase 2 Trial of Belcesiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Belcesiran","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage\u2019s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Transplant Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma to revise DIAMOND Study, readout expected in H2 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences and VBI Vaccines Present Data from the Complete Phase 1b \/ 2a Study of BRII-179 in Patients with Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-179","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin \u00ae From Merz","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"Ach","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teijin Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Teijin Pharma \/ Merz Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teijin Pha.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity against Metastatic, PDL1-High Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-721","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize Obtains Health Canada Approval to Begin Enrolment for Phase III Trials for COVID-19 Anti-Viral Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Microbiotica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbiotica\u2019s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MB097","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Microbiotica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Microbiotica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbioti.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-HSD","moa":"HSD17B13","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Presents Preclinical Data on Once-Weekly Oral Buprenorphine Treatment, LYN-013, in Development for Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended release Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the ILC 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmot Therapeutics Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Receives FDA Approval for Verkazia 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Pivotal Trial of once wEekly Exenatide in Adolescents Aged 10\u201317 Shows Benefit for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents New Data at ESHRE 2021 Supporting the Use of Rekovelle (follitropin delta) for Individualized Fertility Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Follitropin","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Glycomine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycomine\u2019s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GLM101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Glycomine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycomine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Glycomine .."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Receives Positive EMA Opinion on Orphan Drug Designation for Pridopidine in Als","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Pill for Postpartum Depression Shows Promise in Clinical Trial Led by the Feinstein Institutes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update: PharmaJet Needle-free COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant DNA Vaccine","moa":"SARS-CoV-2 S1 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Comments on Orphazyme\u2019s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Infectious Diseases Published Data from Sinovac\u2019s Phase I\/II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"Tregs","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ\u00ae Efficacy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenadogene Nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedanta Biosciences Presents New Data from Phase 1 Study of VE202 at the International Human Microbiome Consortium Congress 2021 (IHMC)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA\u00ae (vibegron) for Patients with Overactive Bladder","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives EC Approval for Opdivo+Yervoy for Mismatch Repair Deficient or Microsatellite Instability in High Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Empagliflozin Lowers risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with T2D","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac\u00ae Platform)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tauopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Pinteon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pinteon Th.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI\u2019s Multikine\u00ae Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit in Head and Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences and SpringWorks Dose First Patient in Expanded Phase 1\/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies wins legal battle against French firm for paracetamol patent","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXIN: News Reports on Submitting Phase-3 Data to WHO Is Incorrect, Says Bharat Biotech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech's Covaxin Gets SEC Approval on Its Phase 3 Trials Efficacy Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories launches Icosapent Ethyl Capsules in US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Submitts Covaxin's Phase III Trial Data to DCGI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to Inno Care\u2019s Pan-FGFR Inhibitor, Gunagratinib to Treat Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Gunagratinib","moa":"Selective pan-FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives US FDA Approval to Market Generic Renagel Tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics to Submit NDA to US FDA for AXS-14 for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Esreboxetine Succinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MKP10241","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines\u2019 Rare Blood Disease Drug Avapritinib Receives Us FDA Approval","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Begins Patient Dosing in Phase 3 Trial of Ociperlimab in Combo with Tislelizumab to Treat Metastatic NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ociperlimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Launches Justoza to Treat Diabetes, Heart Failure & CKD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Bio Receives French Ansm Approval for Phase 1\/2a Trial of PBP1510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"PBP1510","moa":"PAUF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation to Bioheng Biotech\u2019s CTD401 to Treat T-All","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CTD401","moa":"CD7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bioheng Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioheng Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioheng Bi.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Biotech Begins Patient Dosing in Phase 1B\/2 TRIAL OF Annamycin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"PNB Vesper","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNB Vesper gets DCGI Nod to Begin Phase III Trials For PNB 001\/GPP-Balacovin for Covid-19 treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"GPP-Baladol","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PNB Vesper","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PNB Vesper \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PNB Vesper.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Status To Targovax ONCOS-102 to Treat Refractory Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai\u2019s Tazverik Gets Japanese Marketing Approval to Treat r\/r EZH2 Gene Mutation-Positive Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Adroit Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adroit Biomed Launches Immunity Enhancing Tablets, Glutone MD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Setria Glutathione","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Adroit Biomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Orally Dissolving Effervescent Tablet","sponsorNew":"Adroit Biomed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adroit Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based Flu Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ T.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Zolgensma data Demonstrate Age-Appropriate Development when Used Presymptomatically","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze\u2122 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (recombinant)-rywn","moa":"Asparagine synthetase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hutchmed Announces Savolitinib Approved in China for Patients with Lung Cancer with Met Exon 14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ HUTCHMED","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Eisai Update for the Alzheimer\u2019s Disease Community","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-TIGIT Domvanalimab-Based Combinations Showed Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Actemra\/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in Hospitalised Adults and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S.FDA for Patients with Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Final Data from Phase 2b\/3 Trial of CVnCoV, Demonstrates Protection in Age Group of 18 to 60","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"University of Cambridge","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cambridge Study Spots Antimalarial, Arthritis Drugs for COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Proguanil","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cambridge","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Cambridge \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics\u2019 Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte and MorphoSys Report Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for R\/R Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CVL-871","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences and Coherus Announce Toripalimab in Combination with Chemotherapy Met Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Biopharma Gets Nod for Sputnik Phase-3 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Bio.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NUPLAZID\u00ae (Pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Cellerys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Signs Deal that Could Lead to Acquisition of Zurich Start-Up Cellerys","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"CLS12311","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cellerys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellerys \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Cellerys \/.."},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Nordic Capital","pharmaFlowCategory":"D","amount":"$846.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nordic Capital Acquires Advanz Pharma for $846 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Advanz Pharma","amount2":0.84999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.84999999999999998,"dosageForm":"Powder for Concentrate for Solution for Infusion\n","sponsorNew":"Advanz Pharma \/ Nordic Capital","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pha.."},{"orgOrder":0,"company":"Noria Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Doubles Down on Radiotherapy with Acquisitions of 2 Tiny Biotech Players Built Around Research from Cornell","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Actinium-225 Labeled Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Noria Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noria Therapeutics \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Noria Ther.."},{"orgOrder":0,"company":"PSMA Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Acquires Noria and PSMA Therapeutics to Expand Portfolio in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Actinium-225 Labeled Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PSMA Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PSMA Therapeutics \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"PSMA Thera.."},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Sequoia Capital","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"China's Stemirna Raises About $200 Mln to Fund Covid-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"mRNA Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemirna Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Stemirna Therapeutics \/ Sequoia Capital","highestDevelopmentStatusID":"5","companyTruncated":"Stemirna T.."},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Shouyao","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaBlock Sciences Partners with Shouyao Holdings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"SY-707","moa":"ALK\/FAK\/IGF1R multi-target kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"PharmaBlock Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaBlock Sciences \/ Shouyao","highestDevelopmentStatusID":"9","companyTruncated":"PharmaBloc.."},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Contezolid","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MicuRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MicuRx Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Bolsters Case for Skyrizi in Crohn's with Phase III Maintenance Data","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces FDA Approval of LYBALVI\u2122 for the Treatment of Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Research Reveals that New IgM Antibodies Administered Intranasally to Fight Covid-19 More Potent than Commonly Used Ones","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered IgM Antibody Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Receives NMPA Acceptance of its First Indication IND Application for CT120, a Fully Human CD19\/CD22 Dual-Targeting CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19\/CD22","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck to Showcase New VYEPTI\u00ae (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA (Zanubrutinib) and Tislelizumab at EHA2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Reports New Data for BCMA CAR-T, Cilta-Cel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3b Psoriatic Arthritis Data Show First-in-Class TREMFYA Achieved Robust Joint Symptom Improvement and Complete Skin Clearance","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates at ASCO and EHA Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Capsida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CRISPR Therapeutics \/ Capsida Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"$30.0 million","newsHeadline":"Indivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading Asset","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0.13,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farm.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Betibeglogene Autotemcel (beti-cel) One-Time Gene Therapy for \u03b2-Thalassemia Continues to Demonstrate Durable Efficacy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Betibeglogene autotemcel","moa":"Alpha\/Beta globulin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Triastek","sponsor":"Matrix Partners China","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Triastek Completes its Series B Financing with a Value of USD 50 Million, Co-Financed by Matrix Partners China and CPE","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series B Financing","leadProduct":"T19","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Triastek","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Delayed-release Tablet","sponsorNew":"Triastek \/ Matrix Partners China","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"UniCAR-T-CD123","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ U.."},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"regRNAs Therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CAMP4 Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"4","companyTruncated":"CAMP4 Ther.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$63.8 million","upfrontCash":"Undisclosed","newsHeadline":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Nuevocor","sponsor":"EVX Ventures","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuevocor Closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Nuevocor \/ EVX Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/.."},{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"ArriVent Biopharma Launches With Up to $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Arrivent","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"12","companyTruncated":"Arrivent \/.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"$175.0 million","newsHeadline":"Seres Therapeutics, Nestl\u00e9 Health Science Announce SER-109 Co-Commercialization License Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"$700.0 million","newsHeadline":"GSK and Alector Announce Global Collaboration in Immuno-Neurology for Two Clinical Stage Monoclonal Antibodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"AL001","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":2.2000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Rotating Boulder Fund","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics Secures $105 Million Series E Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series E Financing","leadProduct":"Cotsiranib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intralesional Injection","sponsorNew":"Sirnaomics \/ Rotating Boulder Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$83.1 million","upfrontCash":"Undisclosed","newsHeadline":"Lipidor AB Licence Agreement Grants Menarini Group Exclusive Rights to Two New Psoriasis Drug Candidates for Potential Value of MEUR 70","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0.080000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.080000000000000002,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Menarini Group company","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo Biopharma In-Licenses Late-Stage Alzheimer's Disease Asset from Lundbeck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Idalopirdine","moa":"5-HT6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Private Placement","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Flugen","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"FluGen Awarded US DoD Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"M2SR","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intranasal","sponsorNew":"Flugen \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ U.."},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-Biologics and Pierre Fabre Sign an Exclusive License Agreement in the Field Of Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Human Antibody-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Y-Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"1","companyTruncated":"Y-Biologic.."},{"orgOrder":0,"company":"InveniAI","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InveniAI \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Laekna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Biological E","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ Biological E","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Usher III Initiative","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Usher III Initiative Receives $1M Grant from Foundation Fighting Blindness to Advance Novel Treatment for Usher Syndrome Type 3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"BF844","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Usher III Initiative","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Usher III Initiative \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Usher III .."},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Expands Series A Financing and Welcomes M Ventures as a New Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Oncolytic Viral Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theolytics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics.."},{"orgOrder":0,"company":"Muna Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings Launches Muna Therapeutics with US$ 73M Series A","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Progranulin pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Muna Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Muna Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Muna Thera.."},{"orgOrder":0,"company":"Edge Pharma","sponsor":"Evio Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EVIO, Inc. Enters Into Letter of Intent to Acquire Leading Edge Pharms, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Cannabis Sativa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Edge Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Edge Pharma \/ EVIO Labs","highestDevelopmentStatusID":"12","companyTruncated":"Edge Pharm.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Clionix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Strontium Chloride, Sr-89","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Clionix","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Amniotics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"Amniotics Raises SEK 60 Million in First North IPO to Advance Lead Candidate PulmoStem\u2122 Into Clinic","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"PulmoStem","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Amniotics","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Amniotics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amniotics .."},{"orgOrder":0,"company":"Cincinnati Children's Hospital Medical Center","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Inks Exclusive, Global License Agreement of Novel Vaccine Platform from Cincinnati Children's Hospital Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cincinnati Children's Hospital Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cincinnati Children's Hospital Medical Center \/ Blue Water Vaccines","highestDevelopmentStatusID":"3","companyTruncated":"Cincinnati.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$45.0 million","newsHeadline":"Ionis Enters Exclusive Licensing Agreement with Bicycle Therapeutics Aimed at Further Advancing LICA Technology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"TfR1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Ionis","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Ghent University","sponsor":"eTheRNA immunotherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA Immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"mRNA-based Immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ghent University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ghent University \/ eTheRNA immunotherapies","highestDevelopmentStatusID":"1","companyTruncated":"Ghent Univ.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.6 million","upfrontCash":"Undisclosed","newsHeadline":"Kintor Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for COVID-19 in India and Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"$30.0 million","newsHeadline":"Ascentage Pharma and Innovent Biologics Reach Multifaceted Strategic Agreement to Market Olverembatinib (HQP1351) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Aguettant","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Enters into Licensing Agreement for DZUVEO\u00ae in Europe and In-licensing Agreement for Two Products in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0.059999999999999998,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Laboratoire Aguettant","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Protomer Technologies","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly Announces Acquisition of Protomer Technologies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Glucose Responsive Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Protomer Technologies","amount2":1,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Protomer Technologies \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Protomer T.."},{"orgOrder":0,"company":"Banner Alzheimer's Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Banner Alzheimer's Institute Collaborate on Planned Phase 3 Prevention Trial of Donanemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Banner Alzheimer's Institute","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Banner Alzheimer's Institute \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Banner Alz.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"IntoCell","sponsor":"Cellectar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Phospholipid Drug Conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"IntoCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IntoCell \/ Cellectar","highestDevelopmentStatusID":"1","companyTruncated":"IntoCell \/.."},{"orgOrder":0,"company":"PAQ Therapeutics","sponsor":"Sherpa Healthcare","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"PAQ Therapeutics Launches with $30 Million Series A to Develop Novel Therapies through Autophagy-Dependent Degradation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Autophagosome-tethering Compound Based Therapy","moa":"Ubiquitin-proteosome pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"PAQ Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"PAQ Therapeutics \/ Sherpa Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"PAQ Therap.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures Up to \u20ac16 Million Loan Financing from the European Investment Bank","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Pharming","pharmaFlowCategory":"D","amount":"$211.5 million","upfrontCash":"$17.5 million","newsHeadline":"Orchard Therapeutics and Pharming Group Collaborate to Develop and Commercialize Ex Vivo Autologous HSC Gene Therapy for Genetic Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous Hematopoietic Stem Cell Gene Therapy","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Pharming Group","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$206.0 million","upfrontCash":"Undisclosed","newsHeadline":"NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"NGM621","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0.20999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Tavapadon","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0.34999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Raises \u20ac5.0m Following Its Successful Initial Public Offering on Euronext Growth Paris\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","amount":"$19.2 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment Under ZERVIATE\u00ae Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Cetirizine","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nicox SA","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbutus and Vaccitech Collaborate to Evaluate AB-729, in Combination VTP-300 for Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Barinthus Biotherapeutics \/ Arbutus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,560.0 million","upfrontCash":"$200.0 million","newsHeadline":"Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":1.5600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5600000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Biosight","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$50.0 million","newsHeadline":"Advaxis and Biosight Announce Entry into Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Merger","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Biosight","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Codexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$6.0 million","newsHeadline":"Codexis Earns Milestone Payment from GlaxoSmithKline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codexis","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Codexis \/ GlaxoSmithKline","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Ischemix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ischemix Receives US DoD Funding of $2.9M to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"CMX-2043","moa":"Akt phosphorylation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ischemix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ischemix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ischemix \/.."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Reset Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reset Pharmaceuticals Inks Worldwide License Agreement with NYU Langone Health for IP and Data on Psilocybin and Related Psychedelics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NYU Langone Health \/ Reset Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langon.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oxford Finance LLC","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"University Medical Center of Johannes Gutenberg University Mainz","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA Biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ University Medical Center of Johannes Gutenberg University Mainz","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Altesa Biosciences","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Vapendavir","moa":"Capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Altesa Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ A.."},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","amount":"$27.8 million","upfrontCash":"Undisclosed","newsHeadline":"NeRRe Therapeutics Raises \u00a320 Million in a Series B2 Financing Round","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series B Financing","leadProduct":"Orvepitant Maleate","moa":"NK-1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NeRRe Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"NeRRe Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"NeRRe Ther.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ensysce Biosciences Receives NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"PF614","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Ensysce Biosciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Ensysce Biosciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$12.0 million","newsHeadline":"F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0.31,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$29.6 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Gets \u20ac10M Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Tedopi","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Me.."},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$100.0 million","newsHeadline":"Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena\u2019s ATTR Amyloidosis Programme","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":1.2,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.2,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$937.5 million","upfrontCash":"$125.0 million","newsHeadline":"Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib For the Treatment of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0.93999999999999995,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.93999999999999995,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"CAMP4 Therapeutics","pharmaFlowCategory":"D","amount":"$93.5 million","upfrontCash":"Undisclosed","newsHeadline":"OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SCN1A gene","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"OPKO Health","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"OPKO Health \/ CAMP4 Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Evrys Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"SIRT-2 protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evrys Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Evrys Bio \/ US Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evrys Bio .."},{"orgOrder":0,"company":"ExCellThera","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ExCellThera and Astellas Enter into a License for the Use of Molecule UM171 in the Field of Pluripotent Stem Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"UM171-based PSC-derived Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExCellThera \/ Astellas","highestDevelopmentStatusID":"4","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"CDX-0159","moa":"KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0.25,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.25,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Farudodstat","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ASLAN Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Reloxaliase","moa":"Oxalate","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pha.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces First Commercial Sale of ORPATHYS\u00ae in China, Triggering a US$25 million Milestone Payment from AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Savolitinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Decheng Capital","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series B Financing","leadProduct":"RNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Decheng Capital","highestDevelopmentStatusID":"2","companyTruncated":"Shape Ther.."},{"orgOrder":0,"company":"Kuros Biosciences","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Acquires Royalty and Milestone Interest in Checkmate\u2019s Vidutolimod (CMP-001) from Kuros Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Nivolumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kuros Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"Kuros Biosciences \/ XOMA Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kuros Bios.."},{"orgOrder":0,"company":"Zendal","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spanish Pharmaceutical Company Zendal and IAVI Partner to Advance the Tuberculosis Vaccine Candidate MTBVAC Into Efficacy Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Live Attenuated Mycobacterium Tuberculosis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zendal","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zendal \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Zendal \/ I.."},{"orgOrder":0,"company":"Indian Institute of Science","sponsor":"Ignite Life Science Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ignite Life Science Foundation Awards its First Grant for Developing mRNA Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Indian Institute of Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Institute of Science \/ Ignite Life Science Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Indian Ins.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Equity Investment from Lilly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"RNA-based Medicines","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Takara Bio","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takara Bio Enters into a License and Supply Agreement of RetroNectin\u00ae with BioNTech Cell & Gene Therapies GmbH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"BNT211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Takara Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takara Bio \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Takara Bio.."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Tetherex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetherex Pharmaceuticals Ink Licensing Deal with Mayo Clinic for Development of a Novel Single-Cycle Adenovirus Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Single-Cycle Adenovirus Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Mayo Clinic \/ Tetherex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clini.."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"University of Hong Kong","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arctic Vision Joins Forces with the University of Hong Kong to Discover and Develop Novel Neuroprotective Therapies Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"ARVN601","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctic Vision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arctic Vision \/ University of Hong Kong","highestDevelopmentStatusID":"4","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor Provides Update on the Phase III Fortress Study of Balixafortide in Patients with Advanced HER2 Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discussion of Results of CEL-SCI\u2019s Phase 3 Trial Is Now Available","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pauses ARO-ENaC Phase 1\/2 Clinical Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart, Lispro, and Glargine Presented at the American Diabetes Association\u2019s Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"Gadeta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with Gadeta's Gamma Delta TCR Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Gamma delta T-cell receptor based immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gadeta \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ N.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2\/3 Clinical Trial for its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b \/ 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"GRP78","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Receives CRL to Biologics License Application for Teplizumab for Delay of Clinical Type 1 Diabetes in At-Risk Individuals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Dosed First Patient in Part 2 of a Registrational Study of SLS-002 for Acute Suicidal Ideation in Major Depressive Disorder Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen\/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi to Present Data at the ISTH 2021 Within Rare Haematology Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftrenonacog Alfa","moa":"Coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (Perfluorohexyloctane)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for Small Molecule GPR65 Inhibitor in Human PDX Cancer Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PTT-3196","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pathios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Th.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharma Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"IDG16177","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ildong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ildong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ildong Pha.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VILTEPSO\u00ae (Viltolarsen) Injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma to Present Its Continued Dedication to Improving Lives of People with Hemophilia and Von Willebrand Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Simoctocog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Starts Emergency Use Training and Extension of Phase 2\/3 Inhaled ZYESAM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakuten Medical Publishes Data from Phase I study of RM-1929 Photoimmunotherapy in Recurrent Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab-conjugated IRDye 700DX","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Shares Updated Results from the Phase 3 OCEAN Study Based upon Further Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Venetoclax Has Shown Progression-Free Survival in Patients With Chronic Lymphocytic Leukemia After 3 Years of Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Risanchizumab Achieves Clinical Remission and Endoscopic Response within 12 Weeks in Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Vaccine Demonstrates a High Level of Safety in the Vaccination Course","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clean Interim Safety Review of RhoVac's Clinical Phase IIb Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Vaccine Elicits High IGG Antibodies and Neutralizing Antibodies Titers, Reports Argentina Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"GT20029","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Petros Completes Pilot Label Comprehension Study to Initiate Process for Stendra\u00ae Prescription Erectile Dysfunction Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Receives Approval to Extend Dose Escalation in Phase 1\/2 European Clinical Trial Evaluating Annamycin for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Kedrion IVIG","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kedrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New TAVALISSE\u00ae Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"American Association of Kidney Patients","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Impact Statement: FDA Approval of Kerendia to Help Slow Kidney Disease and Failure Associated with Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ American Association of Kidney Patients","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Clinical Data on 4D-110","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"4D-110","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Roche","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Presents at the American Diabetes Association\u2019s 81st Scientific Sessions","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG\u2122 Based Skin Care Products","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Avicanna \/ Bio-Gate","highestDevelopmentStatusID":"6","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Iontas","sponsor":"F-star Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IONTAS Collaboration with F-star Enters Oncology Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"FS222","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ F-star","highestDevelopmentStatusID":"6","companyTruncated":"Iontas \/ F.."},{"orgOrder":0,"company":"Labcorp","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Labcorp Launches Companion Diagnostic for Amgen\u2019s Newly-approved Lung Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Labcorp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Labcorp \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Labcorp \/ .."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foundation Medicine's FoundationOne\u00aeCDx Gets Approval as a Companion Diagnostic for ALUNBRIG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Dose Escalation Label Update for Puma Biotechnology\u2019s NERLYNX\u00ae in HER2+ Early Stage and Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Adlon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Supplemental New Drug Application for Adhansia XR\u00ae (methylphenidate HCl) Extended-Release Capsules CII","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Sodium-dependent dopamine transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adlon Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adlon Ther.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Sorafenib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ Gennova Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Human Alkaline Phosphatase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara\u00ae (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Provides Progress Update on Product Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"MMS019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"QLS-215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VRG101","moa":"PIKfyve","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Biomarck Clinical and Preclinical Studies of BIO-11006 in ARDS to be Presented at the 2021 ARDS Drug Development Summit","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BIO-11006","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomarck Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck P.."},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"EMB-02","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Bio.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia\u2019s Phase 3 Huntington\u2019s Disease Clinical Trial Achieves 50% Enrollment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Positive Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s KERENDIA\u00ae (Finerenone) Receives U.S. FDA Approval","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from the Phase 3 HELP Study\u2122 Evaluating TAKHZYRO to be Presented at EAACI","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune to Present New Two-Year Treatment Satisfaction Data","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Regular Approval and Expands Indication for PADCEV","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas Pharma Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ A.."},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Presents Data on BT051 at ECCO \u201821","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BT051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Th.."},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ASP3772","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia: FDA Grants Orphan Drug Designation for Pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present New Data at IAS 2021 Demonstrating the Company\u2019s Commitment to Advancing Innovation in HIV Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Results from Phase 2\/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"TYA-11631","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OpRegen\u00ae Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the AAIC 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN106","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foundation Medicine Expands Indication for FoundationOne\u00aeLiquid CDx to be Used as a Companion Diagnostic for TABRECTA\u00ae (Capmatinib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Genentech\u2019s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ulodesine","moa":"PNPase","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Laevoroc Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laevoroc Oncology \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Laevoroc O.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"HSV1-TGM1","moa":"Transglutaminase 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORLADEYO\u2122 (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I\/IIa Study in Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ATL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Filing of HUTCHMED\u2019s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"George Medicines Initiates Two Phase III Trials of Triple Combination Candidate to Treat Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Telmisartan","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"George Med.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"CB 4332","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen\u2019s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Showing 77.8% Protection Against Overall Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present New Data at the ISTH 2021 Congress Highlighting Long-Standing Commitment to Advancing Haemophilia A Standard of Care","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advicenne Receives MHRA Approval to Market Sibnayal\u2122 (ADV7103) in the UK for the Treatment of DRTA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne .."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Dovitinib","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st ECCMID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Whole-virus Inactivated Adjuvanted SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Provides Status Update of its Clinical Naptumomab Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"5T4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ NeoTX therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease at ECCO 2021 Virtual Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin For Treatment of the Knee Pain in Osteoarthritis Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Giredestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translatio.."},{"orgOrder":0,"company":"Opthea","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea\u2019s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Phase 3 ONWARD\u2122 Trial Meets its Screening Target and Nears Enrollment Completion","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avdoralimab","moa":"C5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Initiates Phase 1\/2 Clinical Trial of NC762 for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"NC762","moa":"B7-H4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1\/2a Data on July 8","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healthy Extracts Introduces Breakthrough Nutraceutical Formulation, Ultimate Brain Nutrients ACTIVATE\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Spearmint Extract","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Ex.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics' Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Medolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Caribbean Blue Scorpion Ptides Derived Extract","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medolife","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medolife \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medolife \/.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Updated ADUHELM\u2122 Prescribing Information to Emphasize Population Studied in Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HIV Cure Program Releases Initial Clinical Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AGT103-T","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Gene Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"American G.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Mupadolimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics to Present Interim Data from Phase 1\/2 Study of ETV:IDS for the Potential Treatment of Hunter Syndrome at MPS 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Starts Phase 2 Trial for Combination of VIR-2218 and VIR-3434 as Functional Cure Regimen for Chronic Hep B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Achieves Second Development Milestone from 3D Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AVB-S6-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Provides Update on Its Planned Phase 3 Clinical Trial in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Roche\u2019s Hemlibra Reinforce Safety Profile in People with Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Provides Update on the Progress of Clinical Studies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"JTA-004","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Soliqua\u00ae Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on KEYTRUDA\u00ae (Pembrolizumab) Indication in Third-Line Gastric Cancer in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Gets EC Approval for Opdivo+Yervoy for Mismatch Repair Deficient High Metastatic Colorectal Cancer After Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files New Drug Application in Japan for Antibody Cocktail Casirivimab and Imdevimab for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Concludes Final Analysisfor COVAXIN\u00ae Efficacy from Phase 3 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII Gets CDSCO Committee Nod to Conduct Clinical Trial of Reduced Inactivated Salk Polio Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Salk Polio Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Call for Expression of Intent to Participate as a Study Site for India-UK RECOVERY","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Cou.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Applies to the DCGI for EUA to Launch ZyCoV-D, the World\u2019s First Plasmid DNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Labs Denied Approval for Final Trial of Russian-Made Sputnik Light","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals announces USFDA Final Approval for Nitrofurantoin Capsules, USP (Macrocrystals), 25 mg, 50 mg and 100 mg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitrofurantoin","moa":"30S Ribosomal S10","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark to Conduct Phase III Trial Nasal Spray Meant to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"American Diabetes Association","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Use Of Sotagliflozin Provides Benefits For People With Type 2 Diabetes With Chronic Kidney Disease Or Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American Diabetes Association","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"American Diabetes Association \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"American D.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma's Drug Candidate Opaganib Shows Inhibitory Effect Against Covid-19 Variants in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab Lenalidomide Combo for R\/R DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise\u2019s Drug Pipeline to be Presented at BIO International Partnering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"TATX-21","moa":"LDL uptake","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akome Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biot.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"MRT5400","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ T.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Set for India Launch with SII as Mfg Partner","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Rancho Santa Fe Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ataciguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Rancho Santa Fe Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alter Pharma group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alter Pharma group \/ Hyloris","highestDevelopmentStatusID":"12","companyTruncated":"Alter Phar.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Announces Positive Top-Line Results from Global Phase III Trial of Regdanvimab (CT-P59)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 D614G","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pamrevlumab Included in Pancreatic Cancer Action Network\u2019s Adaptive Clinical Trial Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"CTGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen\u2019s Aimovig Gets Japanese Marketing Approval for Suppression of Onset of Migraine Attacks in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Erenumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Submits New Drug Application to U.S. FDA for Lenacapavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves Aubagio as the first oral MS Therapy for First-Line Treatment of Children and Adolescents Living with Relapsing-Remitting MS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Public Offering","leadProduct":"ACU193","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"VUB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA and VUB Expand Strategic Collaboration to Engineer Next Generation mRNA Therapeutics with TetraMix\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"TetraMix-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"eTheRNA immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"eTheRNA immunotherapies \/ VUB","highestDevelopmentStatusID":"1","companyTruncated":"eTheRNA im.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$3,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream and Takeda Expand Collaborative Research and License Agreement to Develop Peptide Drug Conjugates for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Peptide-drug Conjugates","moa":"TfR1","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"PeptiDream","amount2":3.5,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.5,"dosageForm":"","sponsorNew":"PeptiDream \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"ABBV-CLS-579","moa":"PTPN2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calico Life Sciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Calico Lif.."},{"orgOrder":0,"company":"Teneobio","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"$900.0 million","newsHeadline":"Amgen to Acquire Privately Held Teneobio for $900 Million in Cash with Future Contingent Milestone Payments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Teneobio","amount2":2.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5,"dosageForm":"Intravenous Injection","sponsorNew":"Teneobio \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Teneobio \/.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Closing of $45.0 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the NIH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National C.."},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Anaxago","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"PEP-Therapy Extends Series-A Financing, Raising a Total of \u20ac5.4 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Anaxago","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therap.."},{"orgOrder":0,"company":"NIMIUM Therapeutics","sponsor":"Paraza Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NIMIUM and Paraza Pharma form Partnership to Treat Cardiometabolic Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"NIMIUM Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NIMIUM Therapeutics \/ Paraza Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NIMIUM The.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Health~Holland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISA Pharmaceuticals, in Partnership with Erasmus MC, is Awarded TKI Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"ISA104","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Health~Holland","highestDevelopmentStatusID":"4","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Mithra CDMO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ExeVir and Mithra Announce Manufacturing Collaboration for Innovative Covid-19 Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"llama-derived VHH-Fc Antibody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mithra Pharmaceuticals \/ Mithra","highestDevelopmentStatusID":"7","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"$15.0 million","newsHeadline":"Relmada Therapeutics Announces the Acquisition of Novel Psilocybin and Derivates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Methadone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Relmada Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Relmada Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kineta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kineta and Samsung Biologics Announce Development and Manufacturing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"KVA12.1","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Kineta","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rivus Pharmaceuticals Launches with $35 Million Series A Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"HU6","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ Longitude Capital","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Phar.."},{"orgOrder":0,"company":"Pharming","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharming Signs Agreement with NewBridge for the Commercialization of RUCONEST","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Conestat Alfa","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Injection","sponsorNew":"Pharming \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"$24.0 million","newsHeadline":"Calliditas Therapeutics and STADA Partner to Register and Commercialize Specialty Therapy for IgA Nephropathy in Europe","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0.12,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ STADA Arzneimittel AG","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"Coave Therapeutics Closes $39 million Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series B Financing","leadProduct":"CTx-PDE6b","moa":"PDE6b gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Subretinal Injection","sponsorNew":"Coave Therapeutics \/ Seroba Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"BBP-398","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ BridgeBio","highestDevelopmentStatusID":"5","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Meiji Seika Pharma \/ Intas","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"Kalthera","sponsor":"ImmPACT Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmPACT Merger with Kalthera to Progress Next-Generation CAR Therapies Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Merger","leadProduct":"CAR T-cell Therapy","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kalthera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalthera \/ ImmPACT Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kalthera \/.."},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo US$ 55M Series A Generation Therapeutics for BleedingThrombosis Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Monoclonal-bispecific Antibody-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Hemab Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Hemab Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Hemab Ther.."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Norgine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine Enter Agreement to Commercialise DFMO in Independent States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"US WorldMeds \/ Norgine","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"$45.0 million","newsHeadline":"Sun Pharma, Cassiopea Signing of License and Supply Agreements for Winlevi\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0.23999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LISCure Biosciences How License Agreement ,Stock Purchase Agreement Mayo Clinic","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"LB-P8","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Intech Biopharm Ltd","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intec Announces $30 Million Private Placement Ahead of Decoy Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Private Placement","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Intech Biopharm Ltd","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Intech Biopharm Ltd \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Intech Bio.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Collaborate with Regeneron to Research, Develop & Commercialise","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Harrow Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"AMP-100","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"SINTETICA SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"SINTETICA SA \/ Harrow Health","highestDevelopmentStatusID":"10","companyTruncated":"SINTETICA .."},{"orgOrder":0,"company":"Cornell University","sponsor":"Bridge Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge License Agreement with Cornell University for UBR5 Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"UBR5","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cornell University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cornell University \/ Bridge Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Cornell Un.."},{"orgOrder":0,"company":"The Valens Company","sponsor":"Harvest One Cannabis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Valens Agreement Manufacture and Distribute Leading Infused Topical Brand","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"The Valens Company","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Harvest One Cannabis","highestDevelopmentStatusID":"12","companyTruncated":"The Valens.."},{"orgOrder":0,"company":"Complix","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Alphabody Therapeutics","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Complix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Complix \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Complix \/ .."},{"orgOrder":0,"company":"Respirent Pharmaceuticals","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LANNETT Expands Respiratory Pipeline, Signs Exclusive Commercialization","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Tiotropium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Respirent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Respirent Pharmaceuticals \/ Lannett","highestDevelopmentStatusID":"12","companyTruncated":"Respirent .."},{"orgOrder":0,"company":"IN8bio","sponsor":"B. Riley Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IN8bio Launches Proposed Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Genetically Modified Autologous Gamma-delta T Cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ B. Riley Securities","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ B.."},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$2,070.0 million","upfrontCash":"$70.0 million","newsHeadline":"Lilly and Kumquat Biosciences Discover and Develop Novel Small Molecules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kumquat Biosciences","amount2":2.0699999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0699999999999998,"dosageForm":"","sponsorNew":"Kumquat Biosciences \/ Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Kumquat Bi.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$162.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Partner Jazz Pharmaceuticals Launches RYLAZE\u2122 (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Asparaginase Erwinia Chrysanthemi (recombinant)-rywn","moa":"Asparagine synthetase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Macomics","sponsor":"Caribou Property Limited","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"Macomics Macrophage-based Drug Discovery Company, Secures \u00a34.24m Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Macrophage-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Macomics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Macomics \/ Caribou Property Limited","highestDevelopmentStatusID":"2","companyTruncated":"Macomics \/.."},{"orgOrder":0,"company":"Celularity","sponsor":"GX Acquisition Corp","pharmaFlowCategory":"D","amount":"$138.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Merger","leadProduct":"Human Placental Hematopoietic Stem Cell Derived Natural Killer Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ GX Acquisition Corp","highestDevelopmentStatusID":"6","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"LX2022","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ LEXEO Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer,BioNTech Collaborate with Biovac to Manufacture, Distribute COVID-19 Vaccine Doses within Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Biovac Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Biovac Institute \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"The Biovac.."},{"orgOrder":0,"company":"Leyden Labs","sponsor":"Nanopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanopharm and Leyden Labs Ink Deal to Develop Intranasal Spray Product for Prophylactic Use Against Known and New Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Leyden Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Leyden Labs \/ Nanopharm","highestDevelopmentStatusID":"4","companyTruncated":"Leyden Lab.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Yeast Recombinant Lipase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Brickell Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brickell Biotech Closing of $8.05 Million Bought Deal Offering , Including Full Exercise","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Brickell Biotech","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Topical gel","sponsorNew":"Brickell Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Brickell B.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharma , Medison Pharma Partner to Commercialize IMCIVREE in Israel","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$2,050.0 million","upfrontCash":"$650.0 million","newsHeadline":"Arvinas & Pfizer Global Collaboration to Develop and Commercialize PROTAC\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"ARV-471","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":2.0499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$316.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics Public Offering Full Exercise of Underwriter Additional Shares","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0.32000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.32000000000000001,"dosageForm":"Film-coated Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Annexon Autoimmune Franchise 3RD Anti-C1q Product Candidate Strategic Expansion","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"ANX009","moa":"C1q","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharma, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acura Pharmaceuticals and AD Pharma Amend License to LIMITx\u2122 LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharma, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Acura Phar.."},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces Additional License Agreement for Tirbanibulin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allarity and Lantern Enter Agreement Future Clinical Development of Irofulven","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Irofulven","moa":"DNA adduct","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Allarity Therapeutics \/ Lantern Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Tech Transfer and Licensing Agreement SA Rubic Consortium Aim Develop","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Rubic Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Glycotope","sponsor":"Byondis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Byondis , Glycotope Enter Platform Access Agreement Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ Byondis","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope .."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$153.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artios $153 Million (\u00a3110 Million) Series C Financing Led by Omega Funds and TCG X","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Artios Pharma Limited","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atai to Create Innaris Bio to Develop a More Effective Nasal Delivery Method","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Queensland \/ atai Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crinetics $15.0 Million Private Placement with Frazier Healthcare Partners","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Private Placement","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIGA with Oxford University Support Expanded Access Protocol for Use of TPOXX","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Addex and Indivior Extend Collaboration on GABAB Positive Allosteric Modulator","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"INDV-1000","moa":"GABA B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","amount":"$14.2 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda and Frazier Healthcare Partners Collaborate to Launch HilleVax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Norovirus Bivalent GI.1\/GII.4 VLP Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Frazier Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ALK","sponsor":"Grandpharma","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALK and Grandpharma Team Up to Market the First Adrenaline Autoinjector in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Epinephrine Bitartrate","moa":"Adrenergic receptor alpha-1A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ALK","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"ALK \/ Grandpharma","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Gran.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals Ink License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo\u00ae in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Tetris Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"PFM Health Sciences","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Turnstone Biologics Raises $80 Million Series D Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series D Financing","leadProduct":"Engineered Oncolytic Vaccinia Virus","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intratumoral Injection","sponsorNew":"Turnstone Biologics \/ PFM Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"Q-State Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Q-State Biosciences Awarded NIH Grant for the Development of ASO Therapies Targeting Cancer Pain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Funding","leadProduct":"Antisense Oligonucleotide Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Q-State Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q-State Biosciences \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"Q-State Bi.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Closes $135M Series C Financing Led by Viking Global Investors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Series C Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.14000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Lygenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and LyGenesis Terminate Merger Negotiations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Termination","leadProduct":"AGEX-VASC1","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ LyGenesis","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acorda Therapeutics Announces Agreement to Commercialize INBRIJA\u00ae in Spain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Synaffix","pharmaFlowCategory":"D","amount":"$246.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"PRO1184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"ProfoundBio \/ Synaffix","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"Seppic","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akston Biosciences Announces Commercial Supply Agreement of Seppic\u2019s Adjuvant to Formulate Akston COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Engineered SARS-CoV-2-RBD-Fc Fusion Protein Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Seppic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Seppic \/ Akston Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Seppic \/ A.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"affiliates of Magnetar Capital","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series D Financing","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ affiliates of Magnetar Capital","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ GT Apeiron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing Antibody Treatment to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Biocon Biologics","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"ObsEva","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ebopiprant","moa":"F2 alpha receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":1,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":1,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Organon","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ O.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"GC Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Mirum Pharmaceuticals and GC Pharma Ink Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ GC Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Athyrium Capital Management","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Funding","leadProduct":"Neratinib","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Athyrium Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"University of Massachusetts","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASC Therapeutics Partnership With University of Massachusetts Medical School","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"University of Massachusetts","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Massachusetts \/ ASC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$60.0 million","newsHeadline":"Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"RIST4721","moa":"CXCR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Th.."},{"orgOrder":0,"company":"BAKX Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$852.0 million","upfrontCash":"$14.5 million","newsHeadline":"Ipsen Strengthens Its Phase Oncology Portfolio Through Exclusive Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"BKX-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BAKX Therapeutics","amount2":0.84999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"Oral","sponsorNew":"BAKX Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"BAKX Thera.."},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Enters Into Agreement with the National Research Council of Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alnylam and PeptiDream Enter into Collaboration Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Peptide-siRNA Conjugates","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.2000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"PeptiDream \/ Alnylam","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Kortuc","sponsor":"AXA Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KORTUC Inc. Closes Financing from AXA Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Hydrogen Peroxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kortuc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Kortuc \/ AXA Japan","highestDevelopmentStatusID":"8","companyTruncated":"Kortuc \/ A.."},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Announces Execution of License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Armesocarb","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pha.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Neopharm Labs Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UroGen Pharma Announces License and Supply Agreement with Neopharm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Neopharm","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Deep Genomics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deep Genomics Raises $180M in Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series C Financing","leadProduct":"RNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Deep Genomics","amount2":0.17999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Deep Genomics \/ SoftBank Vision Fund","highestDevelopmentStatusID":"3","companyTruncated":"Deep Genom.."},{"orgOrder":0,"company":"University of Bonn","sponsor":"University of Bonn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DiosCURE Announces Exclusive Worldwide License Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"DIOS-203","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Bonn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Bonn \/ University of Bonn","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Genoa Ventures","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Human Induced Pluripotent Stem Cells","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Stemson Therapeutics \/ Genoa Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Th.."},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Erasca Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Oral","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ J.."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Castle Creek, Eliem and Adagio file for IPOs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"ETX-810","moa":"PPAR alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Suvratoxumab","moa":"Staphylococcus aureus alpha toxin binding","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intradermal Injection","sponsorNew":"AstraZeneca \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$39,000.0 million","upfrontCash":"$13,300.0 million","newsHeadline":"Acquisition of Alexion Completed","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":39,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":39,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Candel Nets Downsized $72M IPO to Advance Cancer-Killing Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$165.7 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvalent Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"NVL-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Momentum Capital Markets","pharmaFlowCategory":"D","amount":"$166.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Series D Financing","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rakuten Medical","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Momentum Capital Markets","highestDevelopmentStatusID":"12","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"$20.0 million","newsHeadline":"Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Mitochondrial Cell Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Minovia Therapeutics","amount2":0.41999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Minovia Therapeutics \/ Astellas","highestDevelopmentStatusID":"1","companyTruncated":"Minovia Th.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Baker Bros","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Termination","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0.23000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Baker Bros","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"GentiBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GentiBio, Forge Biologics Ink Development and Manufacturing Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forge Biologics \/ GentiBio","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Curtana Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curtana Pharmaceuticals Signs Development and Manufacturing Agreement with Catalent for Brain Cancer Drug CT-179","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"CT-179","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Curtana Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Aldevron","sponsor":"AavantiBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Partnership","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Aldevron","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aldevron \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Aldevron \/.."},{"orgOrder":0,"company":"Indian Defence Research and Development Organisation","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BDR Pharma Inks License Agreement with DRDO to Produce COVID-19 Drug 2-DG","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"2-Deoxy-D-Glucose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Indian Defence Research and Development Organisation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Indian Defence Research and Development Organisation \/ BDR Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Indian Def.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Unity Biotechnology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing Senolytic Drug Candidate UBX1325","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ascentage Pharma \/ UNITY Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Guide Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beam Therapeutics Announces Acquisition of Guide Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Guide Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guide Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Guide Ther.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"$39.0 million","newsHeadline":"Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Settlement of Movantik\u00ae Patent Litigation with Apotex","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Apotex","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand\u2019s Partner Merck Receives FDA Approval for Vaxneuvance\u2122 for Prevention of Invasive Pneumococcal Disease Caused by 15 Serotypes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intramuscular Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MOLCURE Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ MOLCURE Inc","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Pharma Enters 2nd Collaboration With MSD to Evaluate NOX-A12 in Combination With KEYTRUDA\u00aein a Phase 2 Pancreatic Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Merck Sharp & Dohme Corp","highestDevelopmentStatusID":"8","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basis for BioVie\u2019s Phase 3 Clinical Trial of NE3107 in Treatment of Alzheimer\u2019s Disease Published in Neurodegenerative Disease Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"17\u03b1-ethynyl-androst-5-ene-3,7,17-triol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Limited to Present Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Marzeptacog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"FT516","moa":"hnCD16 Fc receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena to Present Data from Two of its Alzheimer\u2019s Disease Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PRX012","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura- Dose in Healthy Volunteer for Next Gen Autotaxin Inhibitor IOA-289","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"IOA-289","moa":"Autotaxin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant - European Commission Approval for RYEQO Treatment ofUterine Fibroid","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Starts Dosing in Phase 1b\/2a FOCUS-C9 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Stereopure antisense oligonucleotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"CV Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CV Sciences and University of California Publish Study of Cannabidiol Efficacy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"CV Science","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"CV Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CV Science.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RECCE\u00ae 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"R327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences\u2019 CAReS Study on July 28, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ART27.13","moa":"GPCR","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Solid Dosage Formulation","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer\u2019s Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Product FINTEPLA\u00ae (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment Outcomes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Expand Psychedelic Patent with Filing of U.S. Patent Application Novel Ketamine Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Expands Portfolio Novel Molecules Filing New Patent MDMALike Compound","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Thrixopelma pruriens venom peptide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Receive Orphan Drug Designation, INZ-701 from EMA Treatment of ABCC6 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Discovery of T Cell Targets for COVID19 CellMediated Therapy Infectious Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"TCR-T cell therapies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion to Present CTD CY6463 Phase 2a Study in Participants with Alzheimer","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"CY6463","moa":"sGC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Abstract Results from its Phase 3 AB09004 Study on Alzheimer Disease Selected","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis \/ Bladder Pain Syndrome at the AUA Conference","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"Muscarinic M1\/M2\/M3 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical","graph3":"Trigone Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Trigone Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trigone Ph.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Phase 2B Lorecivivint Clinically Meaningful to Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Report that PP2 a Inhibitor Lb-100 Combined Another Investigational Agent","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Nature Communications Publication of New MCLA-145","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"MCLA-145","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation New In Vitro Data Supporting Broad-Spectrum Antiviral Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma FDA Acceptance of IND Application for ATRS-1902","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"RenovaCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovaCare Update Clinical Trial for the SkinGun, CellMist System Wound Healing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tissue-specific pluripotent cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray Suspension","sponsorNew":"RenovaCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Doses First Patient COVID19 Phase 1b Clinical Trial as a HostTargeted","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"eIF4A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Anti-Viral Patent Granted in USA for RECCE\u00ae Anti-Infectives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"R327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Kernal Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kernal Enter Development Phase Reaching Milestone for it 1st mRNACancer Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-Based Cancer therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kernal Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kernal Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kernal Bio.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Journal Cellular Signaling Oral Ref1 Inhibitor APX3330 Phase 2 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"APX3330","moa":"Ref-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landos Phase 2 Data of Omilancor in Ulcerative Colitisr Oral Presentation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Omilancor","moa":"LANCL2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Interim Analysis of Phase 3 of TNX-102 SL the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Present Data from ADUHELM and Alzheimer\u2019s Disease Portfolio AAIC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lee\u2019s 1st Patient Dosed Socazolimab, Licensed From Sorrento Treatment Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health Plans for Global PraderWilli Syndrome Pivotal Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Nutrapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"RPI-78M","moa":"Ach receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nutrapharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nutrapharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutrapharm.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Clinical Trial EB101 Pivotal VIITAL Study Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigilon Preclinical Data International Symposium on MPS and Related Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"SIG-005","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Positive Interim Data from Phase 1\/2 Study with ETV:IDS (DNL310)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus New Saturn-1 Pivotal Data, Titan Prevalence Study Results at ASCRS 2021","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lotilaner","moa":"Chloride channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Positive Initial Phase CERC-002 in Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AEVI-002","moa":"LIGHT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufila","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Upcoming Phase 2 Alzheimer\u2019s Disease Clinical Trial and New Phase 1b AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Health Commence Human Trials Evaluate AT-1501 in Kidney Transplantation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AT-1501","moa":"CD40","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Announces Publication of Data Evaluating AAV Vectors the Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ImmTOR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Initiation of U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena's 1st Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum Review Data Safety Monitoring Board for Phase Ib Part of ILIAD Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Activated allogeneic dendritic cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Gets U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea\u2019s Partner Asahi Kasei Pharma Prepares NDA Filing for the Marketing Authorization of Isavuconazole in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Gets FDA Clearance Investigational NDA for Lanraplenib for Treatment of Patient with Leukemia AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis, Zai Lab Enrollment ATTACK Phase 3 Clinical Trial Sulbactam-Durlobactam","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entasis Therapeutics \/ Zai Lab Limited","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics New Data for Rezafungin at the (ISHAM) Asia Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundi Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Project Evaluating Novel PI3K\u03b4-inhibitor IOA-244 in Lymphoma to be Co-Funded by Innosuisse","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Altum Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Cat\u00f3lica de Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Altum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"UX053","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma 1st Subject Randomized in SUMMIT\u2122, a Phase 3 Efficacy Trial of STS101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Upifitamab Rilsodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ IQVIA Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance by NMPA of\n Supplemental New Drug Application for Toripalimab Plus\n Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Masitinib Study AB09004 in Mild to Moderate Alzheimer\u2019s Disease Presented at\n AAIC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Celsion\u2019s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Augmenta Bioworks","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data on AUG-3387","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AUG-3387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Augmenta Bioworks","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Augmenta Bioworks \/ TFF Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Augmenta B.."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data for Roche\u2019s Evrysdi Published in New England Journal of Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte Provide Update on sNDA for Baricitinib","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo's Flagship Pharmaceutical Pipeline Asset OX124 Enters Pivotal Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Receives European Commission approval of Klisyri\u00ae\u25bc (tirbanibulin) for Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YishengBio PIKA Recombinant COVID-19 Vaccine Gets Phase I Trial IND Clearance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PIKA Recombinant COVID-19 Vaccine","moa":"TLR-3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Receives FDA Fast Track Designation for DA01","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"DA01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope's Patient Dosed in Phase 2b clinical trial of Optogenetic Gene therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"MCO-010","moa":"MCO gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in Phase 1\/2 COM701, Opdivo\u00ae and BMS-986207 Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Presents Evidence ZYESAMI\u2122 (aviptadil) Helps Prevent \"Cytokine Storm\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Aronora","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aronora Reports Positive Topline Data From Phase 2 Study of AB023","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Xisomab 3G3","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Aronora","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aronora \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aronora \/ .."},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Line Albuvirtide-Based 2-Drug Regimen Non-Inferior to 3-Drug Standard Therapy: Presented at IAS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Albuvirtide","moa":"HIV-1 fusion","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frontier Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Frontier B.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Phase III Clinical Trial ASC40 Combined Bevacizumab Treatment Patients Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III Study CONCLUDE With Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Oral Presentation ISTH Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1\/2 Study of Valoctocogene Roxaparvovec","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VLP COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Data on Lecanemab to be Presented at Alzheimer's Association International Conference (AAIC)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venetoclax (VENCLEXTA\u00ae) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NCCN Newly Approv Rylaze Clinical Practice Oncology Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (recombinant)-rywn","moa":"Asparagine synthetase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne as Trial Manager for Phase 2b Study of JAN101 Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sustained Release Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI\u2122 (aviptadil) in Nation of Georgia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DALVANCE FDA Approval Acute Bacterial Skin Structure Infections in Pediatric","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Dalbavancin","moa":"D-Ala-D-Ala moiety of NAM\/NAG peptide subunits of peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent 1st Patient Dosed Phase 1 Study of IBI321 with Advanced Malignant Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI321","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laekna Therapeutics Will Present Two Clinical Study Results in ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"LAE001","moa":"CYP17","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laekna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Laekna The.."},{"orgOrder":0,"company":"Fidia Farmaceutici Spa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fidia FDA Orphan Drug Designation for ONCOFID\u00ae-P for Malignant Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"CD44","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fidia Farmaceutici Spa","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Fidia Farmaceutici Spa \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fidia Farm.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics to Present at the ESMO 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Positive Results of Further Bryostatin Trial Analyses AAIC 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PMC-403","moa":"Tie2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis 149 Patient Positive Interim Results of Phase IIb Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals to Present at Aspen Lung Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Successful Completion of Pre-IND Meeting with the FDA for KVA12.1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"KVA12.1","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Methadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gr\u00fcnenthal's Glucocorticoid Receptor Modulator Enters Clinical Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grunenthal \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris and Biocon Biologic Announce Approval for First Interchangeable Biosimilar Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Granted Orphan Drug Designation for TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"TST001","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Significant Survival and Developmental Milestones SMA Patient Treated Evrysdi\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Actinium-225-Vofatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication of Results from HOPE Trial for ZYNRELEF\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides AB Announces Regulatory update from US Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Commences Cu-64\/Cu-67 SAR-bisPSMA Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ZT-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara The.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Eccogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ECC0509","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Eccogene","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eccogene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"GT20029","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"BiArctic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BiArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VO659","moa":"RNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vico Thera.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic gamma delta T cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VX-548","moa":"Selective NaV1.8","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Sabin strain based Inactivated Polio Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Genentech\u2019s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Data From Second Dovato (dolutegravir\/lamivudine) Switch Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives Approval for Generic TobraDex\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selva to Present Preclinical Data at ASV 2021 on Therapeutic Oral Dosing of SLV213 for COVID-19 Protected Lungs from SARS-CoV-2-Induced Damage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"SLV213","moa":"Cathepsin L","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Selva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Ther.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Receives EC Approval for SKYSONA\u2122 Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant von Willebrand Factor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Flatiron Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flatiron Health Real-World Data Support FDA Approval of New Dosing Regimen for ERBITUX\u00ae (Cetuximab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Flatiron Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Flatiron Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Flatiron H.."},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"McMaster University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rapid Dose Therapeutics and McMaster University Enter Next Stage of COVID-19 QuickStrip\u2122 Vaccine Research Ahead of Schedule","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Rapid Dose Therapeutics \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ADX-2191 to Treat Primary Vitreoretinal Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating Investigational Oral Islatravir for HIV-1 Prevention at IAS 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BYDUREON BCise Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Announces First Patient Dosed in Phase I\/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"JAB-21822","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"NYU Langone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Combination of Experimental Drug Classes Shown to Extend Survival in Mice with Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"SHP099","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NYU Langone","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NYU Langone \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NYU Langon.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"In3Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN3BIO Gains Approval for Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IN01","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"In3Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ N.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Effective Against Lung Cancers Caused by Common Genetic Error","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"NYU Grossman School of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NYU Grossman School of Medicine \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"NYU Grossm.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AL002","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen\u2019s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme to Present New Data at AAIC 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-287","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves KEYTRUDA\u00ae Plus LENVIMA\u00ae Combination for Patients With Certain Types of Advanced Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Results from the Acadia's Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REZUROCK\u2122 Tablets Approved to Treat Adult and Pediatric Patients 12 Years and Older With Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Presents New Data Showing Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IM Therapeutics Reports Positive Results in Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Methyldopa","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therape.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VERQUVO\u00ae (Vericiguat) Approved in the European Union","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves KEYTRUDA\u00ae for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligomerix to Present at Alzheimer's Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"OLX-07010","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura\u00ae Ahead of Schedule","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios' Clinical Sites Gets Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA \u201cFast Track\u201d Review Designated for Oral IMC-1","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Infection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u2019 MYMD-1 Shows Commonality in Comparative Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio\u2019s Novel Immunotherapy NANT Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin hydrochloride","moa":"IL-15 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra\u2019s Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Levomethadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Commences Phase 2 Component of Phase 1\/2 EXACT Study of XC001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AdVEGFXC1","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Doses First Patient in U.S.-Based Phase 1 Clinical Trial of OTX-TKI","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Preliminary Results of Cohort C of QUILT 88","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data for Genentech\u2019s Evrysdi (Risdiplam) Published in New England Journal of Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Gets FDA \u201cStudy May Proceed\u201d Letter for AL001 for Dementia in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient with HER2-Ve+ Breast Cancer Dosed with Zanidatamab Tukysa Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation to Takeda\u2019s Investigational TAK-994","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-994","moa":"Orexin receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Start Phase 3 Development Program for New Once-Daily Triple Combo Regimen","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Deutivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Apic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apic Bio gets FDA Fast Track Designation for APB-102 for Patients with SOD1 ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"APB-102","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Reports Positive Results from Phase 2 Study of Oral Obicetrapib","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M6P Therapeutics Presented Data on M041","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"M041","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therap.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Begins Patient Dosing in Phase 1 Study of IBI319 to Treat Advanced Malignant Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI319","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Supported Study Shows Emergency Department-Administered, High-Dose Buprenorphine May Enhance Opioid Use Disorder Treatment Outcomes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National I.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Begins Patient Dosing in Phase 2 MARCH Study of Combination of VIR-2218 & VIR-3434 For Chronic HBV infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Five Studies of Phase 3 ASCEND Programme of Daprodustat for Patients with Anaemia Due To CKD Meets Primary Endpoints","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA\u2019s CRDA Committee Votes Against Approval Of AstraZeneca\u2019s Roxadustat to Treat Anaemia in Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Begins Patient Dosing in Phase 2 Study of STP705","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta\/COX-2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Begins Patient Dosing in Phase I Trial of TST005","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"TST005","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen, Ionis Pharma\u2019s Phase 1b Study of BIIB080\/IONIS-MAPTRx","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BIIB080","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ I.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Focus Covid-19 Therapy Research on Development of Alteplase","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Alteplase","moa":"Tissue plasminogen","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Suspends Clinical Trials of Bharat Biotech's Covaxin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Authorized Use of REGEN-COV\u2122 (Casirivimab and Imdevimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"SYNB1934","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides Update Regarding RINVOQ\u00ae (Upadacitinib)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Meeting to Petros Pharma Discuss Label Expansion of Drug STENDRA\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharma Awarded New Patent for Selective Inhibitors for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"XOMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Granted Orphan Drug Designation XOMA\u2019s Licensed anti-TGF\u03b2 Asset NIS793","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Not.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc\u2019s Inactivated Polio Vaccine, Out Licensed to Sinovac, Receives Market Authorization in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"sIPV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intravacc \/ Sinovac","highestDevelopmentStatusID":"10","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces U.S. FDA Approval of VAXNEUVANCE for Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Above","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab MEDLEY Phase II\/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Granted a New US Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Bio Doses First Patient in Phase 1 Allogeneic CAR T Trial of PBCAR19B Immune Evading Stealth Cell for R\/R Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Anti-CD19 CAR T Cells","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Pharma Launches Triazole Antifungal Drug Posaconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Cadila Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University Hospital Southampton","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ University Hospital Southampton","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic to Host Virtual R&D Day Today to Provide an Update on IMU-935","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"IMU-935","moa":"ROR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"SAR439483","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab Granted Priority Review By U.S. FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"EirGen Pharma","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"$65.0 million","newsHeadline":"Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Acquisition","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"EirGen Pharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"EirGen Pharma \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EirGen Pha.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologous Treg Cell Therapy, for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Expanded Treg Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,500.0 million","newsHeadline":"Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Kepa1-Nrf2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Vividion Therapeutics \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"Vivacitas Oncology","sponsor":"DSS Biomedical International","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Silatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Vivacitas Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vivacitas Oncology \/ DSS Biomedical International","highestDevelopmentStatusID":"8","companyTruncated":"Vivacitas .."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Abingworth","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Horizon Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Human Monoclonal Antibody","moa":"LIGHT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Horizon Technology","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autolus and Moderna Sign Option and License Agreement for Access to Proprietary Targeting Technology from Autolus","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Autolus Therapeutics \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zentera Therapeutics Announces Closing of $75 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"ZN-c3","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Receives $200 Million Strategic Investment from Roivant Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.20000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Roivant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"T-knife","sponsor":"Fidelity Management & Research Company, LLC","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"TK-8001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"T-knife \/ Fidelity Management & Research Company, LLC","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$3,200.0 million","upfrontCash":"$3,200.0 million","newsHeadline":"Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology Across Vaccines and Therapeutics Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":3.2000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":3.2000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$6.0 million","newsHeadline":"BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB\u2122 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech Completes Acquisition of Kite\u2019s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Autogene Cevumeran","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Calpain 3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Abigail We.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"$222.3 million","upfrontCash":"$17.5 million","newsHeadline":"Oyster Point Pharma Ink Exclusive License Agreement with Ji Xing Pharmaceuticals for OC-01 and OC-02","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0.22,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Bioresearch Awarded $2.9 Million Fast-Track SBIR Grant for Development of Novel Therapy for Apathy in Alzheimer\u2019s Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"PRX-P4-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bio.."},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$112.5 million","upfrontCash":"Undisclosed","newsHeadline":"PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"EDO51","moa":"Exon 51 inclusion","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PepGen","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"PepGen \/ R.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant\u2122 Related Capital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Dartmouth College","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ifenprodil Tartrate","moa":"GluN2B-NMDA receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dartmouth College","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dartmouth College \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dartmouth .."},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"PP-001","moa":"DHODH","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Kiora Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Kiora Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Kiora Phar.."},{"orgOrder":0,"company":"Mannkind","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI\u2122 (aviptadil) Inhaler for Respiratory Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"Mannkind \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Flerie Invest","pharmaFlowCategory":"D","amount":"$23.6 million","upfrontCash":"Undisclosed","newsHeadline":"EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"EP395","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Flerie Invest","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Ph.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix and Merck to Commence Pan-Cancer Clinical Combination Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"177Lu-rosopatamab","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck Group \/ Telix","highestDevelopmentStatusID":"4","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"$277.0 million","upfrontCash":"$4.0 million","newsHeadline":"Sprint Bioscience Licenses the Cancer Drug Program Vps34 to Deciphera Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"SB02024","moa":"Vps34","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Sprint Bioscience \/ Deciphera","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bio.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Recombinant Bovine Intestinal Alkaline Phosphatase","moa":"Intestinal alkaline phosphatase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Synthetic Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Stand Up To Cancer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jazz Pharmaceuticals \/ Stand Up To Cancer","highestDevelopmentStatusID":"1","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"isoSolutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Strontium Chloride, Sr-89","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ isoSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"La Jolla Institute","sponsor":"Cytocom","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"TLR","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"La Jolla Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"La Jolla Institute \/ Cytocom","highestDevelopmentStatusID":"3","companyTruncated":"La Jolla I.."},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Sen-Jam Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners With Duke-NUS Medical School for a Phase 2 Trial for a New COVID 19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"SJP-002C","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Duke-NUS Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duke-NUS Medical School \/ Sen-Jam Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Duke-NUS M.."},{"orgOrder":0,"company":"TetraLogic","sponsor":"Medivir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir Strengthens the Business Development Potential of Remetinostat Through Renegotiated Multi-Party Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Remetinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TetraLogic \/ Medivir","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic.."},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$158.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sierra Oncology Provides Update to Momelotinib Development Timeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Momelotinib","moa":"JAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undi.."},{"orgOrder":0,"company":"AustinPx","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DisperSol and Catalent Collaborate to Establish KinetiSol\u00ae Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Deferasirox","moa":"Iron","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"AustinPx","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AustinPx \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"AustinPx \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Vingroup","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.0 million","newsHeadline":"Arcturus Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Investigational mRNA Vaccines for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Vingroup","highestDevelopmentStatusID":"10","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SaNOtize Inks Agreement with Glenmark to Commercialize Nitric Oxide Nasal Spray for COVID-19 Treatmeninin Indiandnd Other Asian Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Nitric Oxide","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Glenmark","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"SNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":1.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.02,"dosageForm":"","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Tottori University","sponsor":"GC Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Pharma and Tottori University Enter Research Collaboration and License Agreement for Development of GM1 Gangliosidosis Chaperone Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Chaperone Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Tottori University","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tottori University \/ GC Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Tottori Un.."},{"orgOrder":0,"company":"Eyevensys","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyevensys Raises $12M in a Series B Plus Funding Round","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"EYS809","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyevensys","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Eyevensys \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys .."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics Announces Agreement with Northwestern University for Commercial Rights to their IND for Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"NNV1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable for Melanoma and Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"mRNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Strand The.."},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$265.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sonoma Raises $265M in an Oversubscribed Series B Financing Towards a Cell Therapy for Autoimmune and Other Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"SBT-77-7101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sonoma Biotherapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sonoma Bio.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ault Global Holdings Announces Additional Investment in Alzamend Under an INDA for AL001 for Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Ault Global Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Kyowa Kirin","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Extends Series A Financing to $64 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Tachyon Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-\u03b2 Superfamily Member for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"TACH204","moa":"LEFTY1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Tachyon","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Momelotinib","moa":"JAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Sierra Oncology","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"TTX-MC138","moa":"microRNA-10b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Syros Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"EQRx","sponsor":"CM Life Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Merger","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2,"dosageForm":"Tablet","sponsorNew":"EQRx \/ CM Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ CM .."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"CypCaps","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Qiagen","sponsor":"OncXerna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN and OncXerna Therapeutics Sign Diagnostic Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qiagen \/ OncXerna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Qiagen \/ O.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$17.8 million","upfrontCash":"Undisclosed","newsHeadline":"Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-TB Combo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"OPC-167832","moa":"DprE1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Otsuka Pharmaceutical","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammasome to Develop Dual Sustained-Release HIV Prevention Implant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sustained-release Implant","sponsorNew":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Inflammaso.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Global Fund II, LP","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Secures $3.5 Million in Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Lind Global Fund II, LP","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Eagle Announces Licensing Agreement with AOP Orphan for Landiolol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AOP Orphan","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AOP Orphan \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AOP Orphan.."},{"orgOrder":0,"company":"OtiTopic","sponsor":"Philip Morris International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Acquires Inhaled Drug Specialist OtiTopic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"OtiTopic","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"OtiTopic \/ Philip Morris","highestDevelopmentStatusID":"1","companyTruncated":"OtiTopic \/.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission and AbbVie deal in Alzheimer\u2019s and Parkinson Reaches Next Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DUBs enzyme","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Mission Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Sydnexis","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Sydnexis \/ Visionary Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/.."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"LSP","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Visus Secures $20 Million in Additional Financing Led by New Investor LSP","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ LSP","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced Chemotherapy Technologies, Inc. Awarded $4 Million NIH Grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Gemcitabine","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Chemotherapy Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced Chemotherapy Technologies \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Advanced C.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Schrodinger","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics and Schr\u00f6dinger Collaborate to Discover Novel Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Schr\u00f6dinger","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Seagen","pharmaFlowCategory":"D","amount":"$2,600.0 million","upfrontCash":"$200.0 million","newsHeadline":"Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Disitamab Vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":2.6000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.6000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$30.0 million","newsHeadline":"Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.14999999999999999,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$10.0 million","newsHeadline":"Rgenta Therapeutics Enters into a Collaboration with Lundbeck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Rgenta Therapeutics \/ Lundbeck","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta The.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$338.0 million","upfrontCash":"Undisclosed","newsHeadline":"Schr\u00f6dinger and Zai Lab Announce a Global R&D Collaboration in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Schrodinger \/ Zai Lab","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Appia Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$875.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"HSC-derived CAR iNKT-cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Appia Bio","amount2":0.88,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Appia Bio \/ Kite","highestDevelopmentStatusID":"3","companyTruncated":"Appia Bio .."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Molecular Partners to Regain Global Rights to Abicipar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Abicipar Pegol","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Molecular Partners \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"LQT Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"LQT Therapeutics Announces Closing of US$19M Series A Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SGK1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"LQT Therapeutics","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"LQT Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"5","companyTruncated":"LQT Therap.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"FIN-524","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Imbrium Therapeutics","pharmaFlowCategory":"D","amount":"$59.5 million","upfrontCash":"Undisclosed","newsHeadline":"PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503\/IMB-150 for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"IMB-150","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0.059999999999999998,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Imbrium Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"GentiBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$157.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"Engineered Regulatory T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"GentiBio","amount2":0.16,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"GentiBio \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"GentiBio \/.."},{"orgOrder":0,"company":"Imugene","sponsor":"Celularity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Imugene and Celularity Ink Partnership Deal to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination fors Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"CF33-CD19 Oncolytic Virus","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Celularity","highestDevelopmentStatusID":"4","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Chula Vaccine Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechnologies\u00ae Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chula VRC Bangkok","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"ChulaCov19 mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TriLink BioTechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"TriLink BioTechnologies \/ Chula Vaccine Research Center","highestDevelopmentStatusID":"6","companyTruncated":"TriLink Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Provides Update on U.S. FDA Review of Abrocitinib and Xeljanz\u00ae Filings","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"The University of Kansas","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ The University of Kansas","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International Completes IND-enabling Studies, Submits Investigator\u2019s Brochure for Phase 1 Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CUPID Study of Telix\u2019s Targeted Alpha Therapy Candidate for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"64Cu-DOTA-TLX592","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Presenting at Two Conferences in August","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity\u2019s Stenoparib, Shows Additional Pre-Clinical Antiviral Activity Against New Variants of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Receives Orphan Drug Designation from the FDA for Sotigalimab (APX005M) for the Treatment of Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b\/3 Validive\u00ae VOICE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Study Shows Roche's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radboud University Medical Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Initial Results from First-in-Human Trial of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Radboud University Medical Centre","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics, Inc. Doses First Patient in A Phase I Clinical Trial of APL-102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"APL-102","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals\u2019 CRN04894, Shows Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CRN04894","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"SL-172154","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA2001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Gamma Delta T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Present Data from ReSPECT\u2122-GBM Trial at the American Association of Neurological Surgeons 2021 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo\u2122) for Systemic Lupus Erythematosus (SLE)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"LUT-014","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Lutris Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pha.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-ALZ","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV\u2122 to Prevent SARS-CoV-2 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Dermatology Publishes Data Showing RINVOQ\u00ae Achieved Superiority Versus DUPIXENT\u00ae for Primary and All Ranked Secondary Endpoints","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Parexel Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PXS-5505","moa":"Pan-LOX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Gelation Capsule","sponsorNew":"Pharmaxis \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"Akeso","sponsor":"Sino Biopharmaceutical Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Penpulimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Sino Biopharmaceutical Limited","highestDevelopmentStatusID":"12","companyTruncated":"Akeso \/ Si.."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PXS-5505","moa":"Pan-LOX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Gelation Capsule","sponsorNew":"Pharmaxis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Medivir's MIV-818 Phase 1b Study to be Presented at the ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Receives FDA Fast Track Designation for Setanaxib in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Setanaxib","moa":"NOX1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma To Present At Canaccord Genuity's Annual Growth Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals ReceivesMHRA Approval for EPIDYOLEX\u00ae for Seizures Associated with Tuberous Sclerosis Complex","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Completes Enrollment of Second Phase 3 Study for CyclASol\u00ae for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in a Phase III study with QUTENZA\u00ae in Post-Surgical Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Capsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas P.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Irofulven","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Positive Interim Analysis from Phase 2\/3 Study of its GM-CSF Antibody Plonmarlimab for Severe COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Plonmarlimab","moa":"GM-CSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Calcium","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corporation Durezol\u00ae (Difluprednate Ophthalmic Emulsion 0.05%)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Lebrikizumab Improved Skin Clearance and Itch in People with Moderate-To-Severe Atopic Dermatitis in Two Phase 3 Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BI 853520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Reports Topline Ganaxolone Phase 2 Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives Patent for EMERPHED\u00ae Ready-To-Use Ephedrine Sulfate Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets US FDA Tentative Marketing Nod for Lenalidomide Capsules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics to Present First Clinical Data on Samuraciclib at the European Society for Medical Oncology (ESMO) Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Reports Phase 1b Study Results of IBI362 in Chinese Participants with Obesity Published in EClinicalMedicine by the Lancet","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI362","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Held Investigator Meeting and Initiated Phase IIa Clinical Trial of Claudin18.2 Monoclonal Antibody TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taffix\u00ae Regains Marketing Approval in Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2\/3 Clinical Trial for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Sun Yat-sen University","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Positive Results from Phase III Trials of Beovu\u00ae in Diabetic Macular Edema, Including Dosing Intervals up To 16 Weeks","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CV2CoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"4","companyTruncated":"GSK \/ Cure.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Oral Antiviral Drug for Covid-19 Reviewed by Health Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"National Institute for Health Research","sponsor":"Manchester University NHS Foundation Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pirfenidone Could Offer \u2018viable\u2019 Heart Failure Treatment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"National Institute for Health Research","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute for Health Research \/ Manchester University NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Genentech\u2019s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China\u2019s National Medical Products Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"5","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Biotherapeutics\u2019 World\u2019s First Fully Human CD19\/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab-fnia","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the Move Virtual Scientific Conference","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based Molecular Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Advances ACTIV-5\/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2\/3 Study for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"9","companyTruncated":"National I.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer\u2019s Disease and Related Tauopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"OLX07010","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives EC Approval for Opdivo as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Risuteganib","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Op.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune\u2019s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA\u00ae Safety and Efficacy Increased Over Time in Patients with Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell to Present at the BTIG Virtual Biotechnology Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Submits NDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Provides Clinical Update for Otenaproxesul","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Reports Positive Top-Line Results From PHYOX\u21222 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Veristat Inc","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results from the Longest Hereditary Angioedema Study Support the Sustained Safety and Efficacy of TAKHZYRO\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Provides Interim Results from Ongoing Phase 1b\/2 Clinical Trial of Cavrotolimod (AST-008)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae Prolonged Recurrence-Free Survival vs Placebo in Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxxon Updates On Current Clinical Programs Assessing nox-a12 in Brain and Pancreal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quanterix Simoa\u00ae Technology Powers Breakthrough Alzheimer\u2019s Disease Research Presented by Eli Lilly and Company at AAIC 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Quanterix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Quanterix .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Improved Progression-Free Survival in DESTINY-Breast03 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo Company","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Vutrisiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals to Commence Clinical Trials for Oral COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"VLP COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyMD Pharmaceuticals \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"Tregs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoAgents\u2019 Phase 1 Trials Show \u201cCytokine Release Syndrome\u201d Drug Candidate Safe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytoAgents \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Gives Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium EQUALISES Study of Itolizumab in Lupus Erythematosus, Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Biocon Limited","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Reported the Discovery of a SARS-CoV-2 Neutralizing Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"2F8","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Achieves Milestones Supporting Analysis of REVERSE-IT Phase 3 Trial","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Confirms Advantage of Combination LuPSMA Therapy in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets Final Approval from USFDA for OCD Treatment Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkem Laboratories Launches Ibuprofen, Famotidine Tablets in US Market","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alkem Laboratories","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkem Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkem Labo.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Adds Fifth Vaccine to its Arsenal, Johnson & Johnson's Single Dose Covid Shot Gets Emergency Nod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Gets Nod for Phase 2\/3 Trials of Intranasal Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Medicinal Product Status to Epygenix Therapeutics\u2019 EPX-200 to Treat Dravet syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lorcaserin HCl","moa":"5-HT signaling pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hummingbird Bioscience gets UK MHRA Approval to Initiate Phase 1 Trial of HMBD-001 in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HMBD-001","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Korean MFDS Approves Antengene\u2019s NDA for Selinexor in Combo with Dexamethasone to Treat r\/r Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Status to Moderna\u2019s Respiratory Syncytial Virus Vaccine, mRNA-1345","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers\u2019 Subsidiary Celgene Receives US FDA Approval for HDAC Inhibitor, Istodax to Treat Peripheral T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Romidepsin","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boston Begins Enrollment in HI-PEITHO Trial for EkoSonic Endovascular System for Treatment of Pulmonary Embolism","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Boston Scientific","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston Scientific \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Boston Sci.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioShin Gets China NMPA Nod to Begin Clinical Trial of New Glutamate Modulator","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Status to Calliditas\u2019 Setanaxib for PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Setanaxib","moa":"NOX1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee Recommends Orphan Drug Designation for Akouos\u2019 AK-OTOF","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Begins Patient Dosing in Phase I AVA6000 Trial of Doxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"FAP Activated Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent\u2019s Phase 3 CREDIT-2 Study of IBI306 Meets Primary Endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Seeks More Trial Data on Astrazeneca\u2019s NDA for Roxadustat for CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Positive Results from Phase 2\/3 Study of Plonmarlimab to Treat CRS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Plonmarlimab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivet Therapeutics\u2019 VTX-801 Gets FDA Fast Track Designation for Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"VTX-801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivet Therapeutics \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Ther.."},{"orgOrder":0,"company":"MedAlliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedAlliance Completes Patient Enrollment in PRISTINE Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MedAlliance","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"MedAlliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MedAllianc.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Receives CTA Approval by China NMPA for Phase 3 Trial of Xeravanfor for Community-Acquired Bacterial Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Wants Partner to Sell Nedosiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Gets FDA Agreement Under SPA for GATHER2 Phase 3 Zimura\u00ae Trial in Geographic Atrophy Secondary to AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disitamab Vedotin Has Become the First Adc Drug Created and Developed by A China Biopharma to Receive Marketing Approval!","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Disitamab Vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Positive Topline Results of Redwood-HCM","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spark Therapeutics\u2019 SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1\/2 Gene Therapy Study in Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"SPK-8011","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"scAAV9.U1a.hSGSH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Presents Data Supporting NE3107 in the Treatment of Alzheimer\u2019s Disease at 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"NLC Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2\/3 Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tollovir","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Todos Medical \/ NLC Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS\u00ae in Patients with MET Amplified Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Gets Pediatric Disease Designation Orphan Drug Designation for LX1004","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"LX1004","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Gets U.S. FDA Orphan Drug Designation for Lisavanbulin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lisavanbulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Affiris","sponsor":"AC Immune","pharmaFlowCategory":"D","amount":"$100.8 million","upfrontCash":"$5.0 million","newsHeadline":"AC Immune Acquires AFFiRiS\u2019 Specific Active Immunotherapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"PD01","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ AC Immune","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech to Acquire Kite\u2019s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Autogene Cevumeran","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Last Patient Out for Phase 2\/3 COVID-19 Study of Oral Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Receives Approval for European Dossier","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Presents Preclinical Data on Alzheimer Disease Candidates at the AAIC Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"ALZ-201","moa":"Amyloid beta 42 aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alzinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alzinova \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa\u00ae in Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ HLS Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Integrated","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Beckley Psytech Completes Oversubscribed $80m (\u00a358m) Fundraise to Develop Portfolio of Psychedelic Medicine Breakthroughs","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0.080000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Beckley Psytech \/ Integrated","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Golden Mountain Partners","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic and Golden Mountain Partners Forming a Joint Venture for IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Golden Mountain Partners","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arctic Vision Expands License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include Asean Countries & India","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$134.2 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Awarded Additional USD 4.3 Million by BARDA to Support Phase 3 Development of Ceftobiprole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.13,"dosageForm":"Powder for Concentrate for Solution for Infusion\n","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adding Multimedia Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Invenra","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$487.5 million","upfrontCash":"$17.0 million","newsHeadline":"Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Multi-specific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0.48999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"Invenra \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ .."},{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gracell Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Immune Cell Therapies","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"FutureGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FutureGen \/ Gracell Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"FutureGen .."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HDT Bio Announces Agreement With Korea\u2019s Quratis to Co-Develop Innovative COVID-19 Vaccine in Asia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ Quratis Inc","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","amount":"$117.5 million","upfrontCash":"$35.0 million","newsHeadline":"Incyte and Innocare Announce Collaboration and License Agreement for Tafasitamab in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Incyte Corporation \/ InnoCare","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Silicon Valley Bank","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Thunderbolt","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.7 million","newsHeadline":"Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-Related Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"AUR200","moa":"B-Cell activating factor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Thunderbolt","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thunderbolt \/ Aurinia","highestDevelopmentStatusID":"5","companyTruncated":"Thunderbol.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$20.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Self-amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Gritstone bio \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Cellectar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, Now Known as Iopofosine I-131","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Iopofosine I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evergreen Theragnostics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Evergreen Theragnostics \/ Cellectar Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen .."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop and Promote High Payload Dry Powder Inhaler","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Mannitol API","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Inhaler Powder","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"Puerto Rico Science Technology and Research Trust","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Mushroom Ganoderma Lucidum Compounds","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Puerto Rico Science Technology and Research Trust","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Puerto Rico Science Technology and Research Trust \/ Revive Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Puerto Ric.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"DMT310","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$50.0 million","newsHeadline":"Bristol Myers Squibb Exercises Option to Develop Exscientia\u2019s AI-Designed, Immune-Modulating Drug Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Exscientia","amount2":1.2,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Exscientia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Tumor-targeted protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ranok Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ranok Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ranok Ther.."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vigil Neuroscience Completes Series B Financing to Advance Pipeline of Microglia-targeted Medicines to Treat Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"VGL101","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Vida Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jnana Therapeutics Closes $50 Million Series B Financing To Advance Lead PKU Program and Small Molecule Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"SLC6A19","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jnana Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Agent Capital","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Drug Development Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"IMT-009","moa":"CD161","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunitas Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Immunitas Therapeutics \/ Agent Capital","highestDevelopmentStatusID":"4","companyTruncated":"Immunitas .."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Orion Pharma","pharmaFlowCategory":"D","amount":"$552.8 million","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alligator Bioscience","amount2":0.55000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.1 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"GSK","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Woodward Pharma Services LLC Acquires LOVAZA(R) Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Woodward Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Wood.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"Wakamoto Pharmaceutical","sponsor":"Harrow Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wakamoto Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Wakamoto Pharmaceutical \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Wakamoto P.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","amount":"$13.1 million","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Zelenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.1 million","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Announces $30 Million Private Placement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Private Placement","leadProduct":"Cycloserine","moa":"d-Ala-d-Ala ligase A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"VyGen-Bio","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"CD38-GEAR-NK","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"VyGen-Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VyGen-Bio \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"VyGen-Bio .."},{"orgOrder":0,"company":"Alloplex Biotherapeutics","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical and Hanall Biopharma invest US $ 1 million in Alloplex Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Suplexa Therapeutic Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alloplex Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alloplex Biotherapeutics \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Alloplex B.."},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche and KeChow Reach a Cooperation Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Vemurafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Kechow Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Kechow Pharma \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai K.."},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,635.0 million","upfrontCash":"$35.0 million","newsHeadline":"Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"LYTAC-based Therapeutics","moa":"Lysosomal targeting chimera","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":1.6399999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.6399999999999999,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Ther.."},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Tsing Song Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"IONOVA Life Science Announces New Financing Round of USD $100 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"INV-1120","moa":"EP4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Ionova Life Science \/ Tsing Song Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Lif.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals Announced the completion of Series B financing of $50 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"LNK01002","moa":"Triple kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Lynk Pharmaceuticals \/ Lilly Asia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy\u2122 (epinephrine nasal spray)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Series D Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0.059999999999999998,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Signs Five-Year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Genpharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Albireo and Genpharm Announce Agreement to Commercialize Bylvay\u2122 (odevixibat) in Saudi Arabia and the Gulf Region","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Genpharm","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Cellectar","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Iopofosine I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cellectar \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Shaare Zedek Scientific Ltd.","sponsor":"Greater Cannabis Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shaare Zedek Scientific Ltd.","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shaare Zedek Scientific Ltd. \/ Greater Cannabis Company","highestDevelopmentStatusID":"1","companyTruncated":"Shaare Zed.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Yuma Regional Medical Center","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces $5.2M Investment by The Yuma Regional Medical Center","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Yuma Regional Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Vitality","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Cannabosides","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Vitality","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vitality \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vitality \/.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Angiogenesis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation for Beta Glucan and Avenanthramides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Beta Glucan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Angiogenesis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ A.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"The Texas A&M University System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"MPI8","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sorrento Therapeutics \/ The Texas A&M University System","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HMNC Brain Health and Develco Pharma Partner to Initiate Ketamine Study Targeting Treatment-Resistant Depression (TRD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Prolonged-release","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain.."},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Melior Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adhera Inks Exclusive License Agreement with Melior Pharmaceuticals for MLR-1023","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adhera Therapeutics \/ Melior Pharmaceuticals I","highestDevelopmentStatusID":"6","companyTruncated":"Adhera The.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","amount":"$20.1 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"ProMIS Neurosciences \/ Leede Jones Gable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Constellation Alpha Holdings","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"$170.0 million","newsHeadline":"Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Merger","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0.25,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.25,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Constellation Alpha Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Merger","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aadi Bioscience \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Sixth Element Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Sixth Element Capital","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Stanford Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAdaptives Collaboration with Stanford Professor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Boswellia Serata","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioAdaptives","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAdaptives \/ Stanford Medical Center","highestDevelopmentStatusID":"12","companyTruncated":"BioAdaptiv.."},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"NIA","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer\u2019s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"ImmunoBrain Checkpoint","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ImmunoBrain Checkpoint \/ NIA","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoBrai.."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Enters Into Research Collaboration with Leading Cancer Institute to Evaluate Nirogacestat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix and Merck to Commence Pan-Cancer Clinical Combination Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"177Lu-rosopatamab","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Telix","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt and Jemincare Partner for Novel Respiratory Antibiotic Nafithromycin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Nafithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wockhardt \/ Jiangxi Jemincare Group Company","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Closing of $3.5 Million Funding Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ H.C. Wainwright","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik .."},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"McQuade Center for Strategic Research and Development Enters Collaboration with Ach\u00e9 to Treat General Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ MSRD","highestDevelopmentStatusID":"4","companyTruncated":"Ache Labor.."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiCE Molecules Announces $60 Million Series C-1 Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series C Financing","leadProduct":"S011806","moa":"IL-17","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"DICE Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series C Financing","leadProduct":"XT-150","moa":"IL-10v","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intrathecal Injection","sponsorNew":"Xalud Therapeutics \/ PBM Capital","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Ther.."},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Arbor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity","highestDevelopmentStatusID":"12","companyTruncated":"Arbor Phar.."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$303.0 million","newsHeadline":"Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Genevant Sciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genevant Sciences \/ Takeda","highestDevelopmentStatusID":"1","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$2,260.0 million","upfrontCash":"$2,260.0 million","newsHeadline":"Pfizer to Acquire Trillium Therapeutics Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Maplirpacept","moa":"SIRP alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":2.2599999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2599999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Lucid-201","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lucid Psycheceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lucid Psycheceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lucid Psyc.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"Encapsulated Live Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Combioxin","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b\/3, Novel First-in-Class Antitoxin Agent CAL02","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CAL02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Combioxin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Combioxin \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Combioxin .."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"DNA chain","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"TumorGen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TumorGen Receives $390K NCI Grant to Counter Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TumorGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TumorGen \/ National Cancer Institute","highestDevelopmentStatusID":"3","companyTruncated":"TumorGen \/.."},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline for Gastrointestinal Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Fexuprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Neurogastrx","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neurogastr.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$20.0 million","newsHeadline":"Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Petra Acquisition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences, Inc. to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Merger","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Interferon-Induced Protein-10","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Drop Solution","sponsorNew":"Revelation Biosciences \/ Petra Acquisition","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Pangu Capital","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"EI-1071","moa":"CSF1R","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Pangu Capital","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron I.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Carlsbad","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tyra Biosciences Wants to Bank $100 M for an IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Public Offering","leadProduct":"TYRA-300","moa":"FGFR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Carlsbad","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$3,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shape Therapeutics Enters Into a Strategic Research Collaboration With Roche to Advance Breakthrough AAV-Based RNA Editing Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":3,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Shape Ther.."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Inkef Capital","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardior Raises \u20ac64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"CDR132L","moa":"miRNA-132","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cardior Pharmaceuticals \/ Inkef Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"NovaRock Biotherapeutics","sponsor":"Flame Biosciences","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"$7.5 million","newsHeadline":"Nova Rock Biotherapeutics Announces Exclusive License Agreement and Strategic Partnership with Flame Bio Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"NBL-015","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NovaRock Biotherapeutics","amount2":0.64000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"NovaRock Biotherapeutics \/ Flame Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"NovaRock B.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Tesaro","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"FDA Grants Accelerated Approval of Jemperli (Dostarlimab-gxly) for DMMR Recurrent or Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ TESARO","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$6.0 million","newsHeadline":"Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"AUR300","moa":"M2 macrophages dysregulation","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Riptide Bioscience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Riptide Bioscience \/ Aurinia","highestDevelopmentStatusID":"5","companyTruncated":"Riptide Bi.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Financing","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to InxMed's IN10018","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"IN10018","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Applies for IND Number from the US Food and Drug Administration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Safety Shot \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Experimental Drug that Boosts Immunotherapy Shows Promise in Bladder Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CV2CoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"4","companyTruncated":"GSK \/ Cure.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anticancer Agent \u201cTazverik\u00ae Tablets 200mg\u201d (Tazemetostat Hydrobromide) Launched In Japan For EZH2 Gene Mutation-Positive Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative U.S. FDA Approval for Brivaracetam Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Unveils Positive Interim Data for Sparsentan in Phase III IG a Nephropathy Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Almirall","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lebrikizumab Significantly Improved Skin Clearance and Itch in People with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical\u2019s Pivotal Study of the RECELL\u00ae System for Vitiligo Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Regenerative Epidermal Suspension","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Avita Medical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avita Medi.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Receives Favorable Recommendation From Data Monitoring Committee on BIO101 in COVA Study in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2\ua7f7 Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-721","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex to Commence Phase IIb Trial of Cell Therapy for Covid-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Clinical Research Evaluating VASCEPA\u00ae\/VAZKEPA in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Immunicom","sponsor":"Acibadem University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicom Continues Successful Immunopheresis\u00ae Clinical Trial in Advanced, Non-Small Cell Lung Cancer Treatment with Acibadem University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunicom","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Immunicom \/ Acibadem University","highestDevelopmentStatusID":"12","companyTruncated":"Immunicom .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ICP-332","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept\u2019s NASH Drug May Need Time to Meet Sky-high Sales Predictions if Approved","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s WELIREG\u2122 (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Belzutifan","moa":"HIF2-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taffix\u00ae Regains Marketing Approval in Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"MHRA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Combined Paracetamol and Ibuprofen Medicine Approved for General Sale","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Reckitt Benckiser","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reckitt Benckiser \/ MHRA","highestDevelopmentStatusID":"12","companyTruncated":"Reckitt Be.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Ticovac\u2122, Pfizer\u2019s Tick-Borne Encephalitis (TBE) Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Tick-Borne Encephalitis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suven Life Sciences Announces Phase 3 Clinical Trial of SUVN-502 for Treatment of Agitation and Aggression in Alzheimer\u2019s Type Dementias","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Masupirdine","moa":"5-HT6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Prepares to Apply for EUA for its FDA Phase III COVID-19 Stem Cell Therapy JadiCell\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Carbamazepine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New 30 Patient Study Of AOBiome's New Shelf-Stable Formulation Of Its Ammonia Oxidizing Bacteria (AOB) Shows Reduction Of Itch Levels","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ammonia Oxidizing Bacteria","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Th.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets Tentative Approval from USFDA for Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Jardiance\u00ae (empagliflozin) to Treat Adults Living with Heart Failure with Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspirin to be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NHS England \/ University of Manchester","highestDevelopmentStatusID":"8","companyTruncated":"NHS Englan.."},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Integral Molecular's Extensive Collection of SARS-CoV-2 Reporter Virus Variants Supports the Clinical Development of Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 Pseudotyped Reporter Virus Particles","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Integral Molecular","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Integral M.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ABI-4334","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives FDA Accelerated Approval for Jemperli for Mismatch Repair-Deficient (d Mmr) Recurrent or Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Secures New Approval in China for Cosentyx\u00ae (Secukinumab) in Pediatric Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol-Myers Squibb Gets Interim Relief in Patent Litigation Against Micro Labs on Anticoagulant Drug Apixaban","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Begins Patient Dosing in Phase 1\/2 Study of mRNA-3705 For Methylmalonic Acidemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-3705","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in American Society of Gene & Cell Therapy\u2019s Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CT125A","moa":"CD5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs to Advance a Phase II Clinical Trial on DMT for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes\u2122 Trial in Patients with mPV","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Completes Largest Ever Dry Eye Disease Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Gel","sponsorNew":"Zhaoke Ophthalmology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Oph.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for UB-421 Monotherapy and in Combination with Chidamide Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Chidamide","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Reports Topline Outcomes on a Phase II Trial That Evaluated Brexpiprazole for The Treatment of Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Orally-disintegrating Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives EC Approval for First-in-Class EVRENZO for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives EC Approval for Abecma (Idecabtagene Vicleucel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dispersion for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Gilead\u2019s Marketing Authorization Application for Lenacapavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals conducts PK Study with Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch of UPASITA\u00ae IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sanwa Kaga.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharma Provides Positive Safety Update On Zyesami in NIH sponsored ACTIV-3 Critical Care Phase 3 Study in Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Receives Complete Response Letter from FDA for Vicineum\u2122 (oportuzumab monatox-qqrs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Protein Filovirus Vaccines Aluminum-Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Monoclonal Antibody Treatment for COVID-19 Approved for Use in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives EUA from DCGI for ZyCoV-D, the Only Needle-Free COVID Vaccine in the World","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Reaches Full Enrollment Target for ONWARD\u2122 Phase 3 Trial of AD04 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Amyris","sponsor":"Infectious Disease Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amyris Achieves Promising in-vivo Results for Intranasal RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"RNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Amyris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Amyris \/ Infectious Disease Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amyris \/ I.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Combination Between AstraZeneca and The First Component of Sputnik V Vaccine (Sputnik Light) Demonstrates High Immunogenicity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"The American College of Medical Toxicology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American College of Medical Toxicology Reports Data on Adverse Effects and Toxicity from Unapproved Use of Ivermectin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivermectin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The American College of Medical Toxicology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The American College of Medical Toxicology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The Americ.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRAFTOVI\u00ae Capsule, a BRAF Inhibitor, Approved in South Korea for Treatment of Advanced or Recurrent BRAFV600E-Mutant Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation\u2019s BIO 300 Receives Fast Track Designation from FDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Orphazyme\u2019s Published Results From Its Phase 2\/3 Trial of Arimoclomol in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ME3183","moa":"PDE4","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Provides Progress Update on Phase 2 Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD824","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review BMS\u2019 Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer-BioNTech COVID-19 Vaccine COMIRNATY\u00ae Receives Full U.S. FDA Approval for Individuals 16 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Phase I Clinical Trial Reveals Anti-Inflammatory Response in Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Idronoxil","moa":"TANK-binding kinase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"TSHA-105","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Receives Two New Approvals in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Empagliflozin is the First Therapy to Show Significant Improvement in Heart Failure Outcomes in Adults with Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Support the Use Of LIXIANA \u00ae (edoxaban) In Complex Populations of Patients with Atrial Fibrillation (AF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Demonstrate the Benefits of Early Use of UPTRAVI in Delaying Disease Progression in a Broad Population of Patients with PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results From Pfizer\u2019s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnov-Therapeutics Completes Recruitment of KT-110 Phase 2 Clinical Trial in Alcohol Dependence Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov The.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present 18 Abstracts, Including One Late-Breaker, on AJOVY\u00ae Injection at the International Headache Society and European Headache","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Orphan Drug Approval: Octapharma\u2019s Octagam\u00ae 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand\u2019s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for Recurrent or Refractory Classical Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Zimberelimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gloria Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gloria Biosciences \/ Ligand","highestDevelopmentStatusID":"12","companyTruncated":"Gloria Bio.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Bio Corp","highestDevelopmentStatusID":"7","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XEOMIN\u00ae (incobotulinumtoxinA) Receives European Approval for the Treatment of Chronic Sialorrhea in Children","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Merz Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Pharm.."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica B.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"CypCaps","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"NK-1\/NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Wins Vasopressin Patent Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Updated Indication for Merck\u2019s KEYTRUDA for Treatment of Certain Patients With Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Persica Pharmaceuticals has Completed the First Stage of Its Clinical Trial on Unique Injectable PP353, To Treat Chronic Lower Back Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PP353","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Persica Ph.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Publishes Positive Initial Results of SOFUSA\u00ae Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"NGM831","moa":"ILT3 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solaris Pharma Receives Approval for First Generic Version of Clindagel\u00ae (clindamycin phosphate EQ 1%)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Solaris Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Solaris Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Solaris Ph.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon\u2019s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Reports Data from REDUCE-IT\u00ae Showing VASCEPA\u00ae\/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"DMT\/5-MeO-DMT Analog","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmoheal\u2122\/ Artiveda\u2122 Is Clinically Active Against Mild and Moderate Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharma Reaches Enrollment Goal in Late-Stage Trial for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Phase Ib\/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) for Scalp and Body Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) Against Delta Variant of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruitment of the Smallest Infants in the Connection Study Paused","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions\u2019 COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ NIH","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Balstilimab Monotherapy Data Published in Gynecologic Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PBI-0451","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pardes Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Receives Orphan Drug Designation for FINTEPLA\u00ae (Fenfluramine) in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma Inc.\u2019s VAZALORE\u2122 Now on Shelves; National Media Campaign Launches Today","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"Beta Tubulin Polymerisation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Montreal Heart Institute \/ Pendopharm","highestDevelopmentStatusID":"12","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Extended-Release Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofranergene Obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Important Overall Survival and Quality-Of-Life Results Across Solid Tumor Portfolio, Among Other Key Data at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem\u00ae Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Giredestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Translational Research In Oncology \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translatio.."},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF\u2122 Shown to Reduce Symptom Duration by 61% and Frequency by 39%","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ultimate Brain Nutrients RELIEF","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Ex.."},{"orgOrder":0,"company":"iCAD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iCAD\u2019s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Xoft Brain IORT","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"iCAD","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iCAD \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"iCAD \/ Not.."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Initiates Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA\u00ae\/VAZKEPA and Eicosapentaenoic Acid Presented at ESC Congress 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Johnpro Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HebaBiz Biotech's Anti-Cancer Drug Candidate Under Development Siroquine (JP001) has been Approved for IND Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Siroquine","moa":"Dual autophagy","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"HebaBiz Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HebaBiz Biotech \/ Johnpro Biotech","highestDevelopmentStatusID":"9","companyTruncated":"HebaBiz Bi.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AS1411","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Enters Phase I Clinical Study on Alcohol Hangover Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"SPJ-001","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Participants in High Dose BriLife\u2122 Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"AOC 1001","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Strengthens the Clinical Development Organization in Preparation of the Start of the Phase III study CONCLUDE with Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Astodrimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Clarity's Cu-64\/Cu-67 SAR-bisPSMA Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Bolus Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laekna Therapeutics Gets China NMPA Nod to Begin Phase Ib\/III Study of Afuresertib in Combo with Fulvestrant for HR+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Afuresertib","moa":"Pan-AKT","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laekna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna The.."},{"orgOrder":0,"company":"Aria Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aria Pharmaceuticals Presents In Vivo Data Showing Two Treatment Candidates Showed Efficacy & Tolerability in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"TRX-1002","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Aria Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aria Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aria Pharm.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Brain and Cognition Discovery Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific to Start Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Braxia Scientific \/ Brain and Cognition Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data At ESC Congress 2021 Shows Repatha\u00ae Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Files INDA with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"iPSC-Derived Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Dupixent\u00ae Pivotal Trial Meets All the Endpoints Becoming First Biologic Medicine to Reduce Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PXS-6302","moa":"Pan-LOX","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Pharmaxis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Humanis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Affron\u00ae Saffron Study Shows a Quick Effect on Sleep at Low Dosage","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Saffron","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Humanis","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humanis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Humanis \/ .."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Genhouse Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HBI-2376","moa":"SHP2 Allosteric","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Genhouse Bio","highestDevelopmentStatusID":"5","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"P-PSMA-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Comments on Non-Infringement Ruling in VASOSTRICT\u00ae Patent Litigation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Seeks Nod for Trial of Single-Dose Vaccine on Adolescents in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVI and BBIL Launch Global Chikungunya Vaccine Phase II\/III trial in Costa Rica","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reliance Life Sciences Seeks Approval for Phase I trial of its Covid Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Protein Based Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Reliance Life Sciences Private Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reliance Life Sciences Private Limited \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Reliance L.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Droxidopa Capsules, 100mg, 200mg, and 300mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor alpha-1A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA accepts BeiGene\u2019s sBLA for Tislelizumab in Combo with Chemotherapy to Treat Recurrent or Metastatic Nasopharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Merck Group","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Discontinue Phase II INTR@PID BTC 055 Study of Bintrafusp Alfa in Combo with Gemcitabine Plus Cisplatin for Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Bintrafusp Alfa","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck Group \/ GlaxoSmithKline","highestDevelopmentStatusID":"9","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca PROVENT Phase III Pre-Exposure Prophylaxis Trial Of AZD7442 to Treat Covid-19 Meets Primary Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts for Priority Review Bristol Myers\u2019 sBLA for Orencia for Prevention of Acute Graft versus Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Xeljanz Receives European Marketing Approval to Treat Active Jia & Juvenile Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives Two US Patents Covering Opaganib For Ebola virus & RHB-104 for Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys\u2019 Partner Incyte Gets Marketing Approval from Health Canada for Minjuvi and Lenalidomide Combo to Treat Relapsed\/Refractory DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marksans Pharma Gets US FDA Approval for Tylenol ER Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis partner Takeda & Ono Receive Japanese Approval for Cabometyx in Combo with Opdivo To Treat Unresectable or Metastatic RCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Bayer\u2019s sNDA for Mirena to Prevent Pregnancy for Up to Seven Years","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Sterile Inserter","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Phase III FoCus Trial of ALXN1840 to Treat Wilson Disease Meets Primary Endpoints Showing Improvement in Copper Mobilisation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reliance Life Sciences Receives CDSCO Panel\u2019s Nod for Phase I Study of Its Recombinant Protein-Based Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Protein-based Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Reliance Life Sciences Private Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reliance Life Sciences Private Limited \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Reliance L.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2018s Keytruda Receives Japanese Approval to Treat Patients with HER2-Negative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Pharma Receives European Marketing Approval for Voxzogo to Treat Children with Achondroplasia from Age 2 until Growth Plates Close","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Receives Brazil's ANVISA Approval to Begin NNOVATE Phase 2\/3 Trial of INO-4800 to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Introduces Single-Dose Formulation of Carbetocin for Prevention of Postpartum Haemorrhage in India","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Vaginal Injection","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Begins Patient Dosing in US Trial of LYS-GM101 to Treat GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh.10 Expressing Beta-galactosidase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Epygenix\u2019s IND Application to Initiate Clinical Trial for EPX-100 to Treat Lennox-Gastaut Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Labs Receives US FDA Approval for Generic Librax","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Chlordiazepoxide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation to Polaryx Therapeutics\u2019 PLX-200 to Treat GM2 Gangliosidoses","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemfibrozil","moa":"PPAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis phase III ORION Leqvio Analyses Show Effective and Sustained LDL-C Reduction in Two Sub-Populations of Patients with ASCVD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis (\"NASH\") Resolution Regulatory Endpoint in Phase 2 LiFT Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's XARELTO + Aspirin Gets FDA Nod to Include Peripheral Artery Disease Patients Who Have Undergone Lower-Extremity Revascularization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Global WholeHealth","sponsor":"Nunzia Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First COVID-19 Vaccine Which Can Be Distributed by Global WholeHealth Partners Corp as US Anticipates Considerable Uptick","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Global WholeHealth","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Global WholeHealth \/ Nunzia Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Global Who.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on CHAMPION-ALS Phase III trial of Ultomiris in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Announces that U.S. FDA and EMA Accept Biologics License Application and Marketing Authorization Application for Tebentafusp","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments for its Phase 3 Studies of Simufilam for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Immutep","sponsor":"Eoc Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Chinese Partner, EOC Pharma, Expands Efti Trial Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ EOC Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives EC Approval for First-in-Class EVRENZO for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell\u2122 Chronic Traumatic Encephalopathy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Receives FDA Clearance to Start Phase III Pivotal Registration Trial for JadiCell","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Report Positive Data from Phase 3 Study of TIBSOVO Azacitidine Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Approaches the Potential Approval and Commercial Launch of Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Gets China NMPA Approval to Begin Phase II Trial of ASC40 for Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Eisai\u2019s Fycompa as Monotherapy for Partial-Onset Seizures in Patients with Epilepsy 4 Years of Age and Older","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Pharma Gets China NMPA Nod to Begin Phase II Trial of Orelabrutinib","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Robotic Pill Developer Rani Therapeutics Nets $73M IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"SSTR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Breakthrough Therapy Status to Junshi and Coherus\u2019 Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives US FDA Approval for Mesalamine ER Capsules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesalazine","moa":"COX","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofranergene Obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 For the Treatment of Melanoma and Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pre-Clinical Data on Hookipa\u2019s Arenaviral Immunotherapeutic in Melanoma Published in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"SARS-CoV-2 spike protein 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.089999999999999997,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Disc medicine \/ OrbiMed","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Felix Biotechnology","sponsor":"The National Science Foundation","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Felix Biotechnology Awarded Competitive Grant from the National Science Foundation to Power Phage Engineering Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Engineering Bacteriophage","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Felix Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Felix Biotechnology \/ The National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Felix Biot.."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gene Quantum and Brigh Gene Sign Agreement for Development of Antibody Immune Agonist Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"GQ1007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ BrighGene Biomedical","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Synimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gen Script Pro Bio Enters Into an Agreement with Synimmune for The Manufacture of Its Innovative Antibody Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Flysyn","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenScript ProBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenScript ProBio \/ Synimmune","highestDevelopmentStatusID":"7","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Windgap Medical","sponsor":"Taiwania Capital","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taiwania Capital Joins Pool of Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Company, Windgap Medical, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Windgap Medical","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Injection for Pre-filled Pen","sponsorNew":"Windgap Medical \/ Taiwania Capital","highestDevelopmentStatusID":"1","companyTruncated":"Windgap Me.."},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"National Cancer Institute (NCI) Awards Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Mnk1\/2 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Isoprene Pharmaceuticals \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene P.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$40.0 million","newsHeadline":"Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Oncology Immunotherapy (E7777) for Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Denileukin Diftitox","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","amount":"$21.5 million","upfrontCash":"Undisclosed","newsHeadline":"EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"EBX-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnteroBiotix","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"1","companyTruncated":"EnteroBiot.."},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recombinant Covid-19 Vaccine (Adenovirus Vector) Licensed for Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AZD1222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"Shenzhen Kangtai Biological Products \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen K.."},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Platinum International Health Care Fund","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Haema Logi X Raises $10 Million to Advance Multiple Myeloma Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HaemaLogiX","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"HaemaLogiX \/ Platinum International Health Care Fund","highestDevelopmentStatusID":"8","companyTruncated":"HaemaLogiX.."},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion's Exclusive Botulinum API Manufacturer","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"HTL Biotechnology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Liniment","sponsorNew":"HTL Biotechnology \/ Eirion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"HTL Biotec.."},{"orgOrder":0,"company":"Octarine Bio","sponsor":"Clerkenwell Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Danish Synthetic Biology and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Octarine Bio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Octarine Bio \/ Clerkenwell Health","highestDevelopmentStatusID":"4","companyTruncated":"Octarine B.."},{"orgOrder":0,"company":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huadong Medicine and Insilico Medicine Enter Co-Development Partnership to Advance Oncology Drug Discovery by Hitting Undruggable Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Hangzhou H.."},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic to Acquire Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Autotelic Bio \/ Oncotelic","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic .."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, for Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$34.7 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Government Exercises Option to Purchase Additional RAPIVAB\u00ae (peramivir injection) from BioCryst for Delivery to National Stockpile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RadioMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"RadioMedix \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"RadioMedix.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic CAR-T Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Precision BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Albireo Sells Priority Review Voucher (PRV) for $105 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$1,775.0 million","upfrontCash":"$50.0 million","newsHeadline":"Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"NBI-921352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":1.78,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"IL-2 Mutein","moa":"IL-2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyrus Biotechnology \/ Selecta Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biot.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Erasca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Encorafenib Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Erasca","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"IntroSpect Digital Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeutic Approach in Patients Receiving Ketamine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"IntroSpect Digital Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IntroSpect Digital Therapeutics \/ atai","highestDevelopmentStatusID":"8","companyTruncated":"IntroSpect.."},{"orgOrder":0,"company":"Codexis","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Codexis \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"BioDelivery Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioDelivery Sciences International Completes Acquisition of ELYXYB\u2122 for Acute Migraine Treatment in the U.S. and Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ BioDelivery Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Medical College of Wisconsin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Medical College of Wisconsin","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Arctic Vision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Clearside Biomedical Expands XIPERE\u2122 License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Arctic Vision","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"SaponiQx","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Saponin-based Adjuvanted Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SaponiQx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SaponiQx \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"SaponiQx \/.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"Asher Bio Closes $108 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"AB248","moa":"IL-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Bial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson\u2019s Disease OFF Episodes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Harrow Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Harrow Health","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Sentinel Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The McQuade Center for Strategic Research and Development Enters Agreement with Sentinel Oncology to Develop Breakthrough Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"SOL784","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Ce.."},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Asset Management","pharmaFlowCategory":"D","amount":"$13.7 million","upfrontCash":"Undisclosed","newsHeadline":"Locate Bio Closes \u00a310 million Funding Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"rhBMP-2","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Locate Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Controlled Release Spinal Fusion","sponsorNew":"Locate Bio \/ Mercia Asset Management","highestDevelopmentStatusID":"1","companyTruncated":"Locate Bio.."},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADARx Raises $75 Million to Advance Growing Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"Oligonucleotide-based Therapeutics","moa":"RNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ADARx Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ADARx Pharmaceuticals \/ SR One Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"ADARx Phar.."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ POINT","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"The Texas A&M University System","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics and The Texas A&M University System Enter Licensing Agreement for Elesclomol in Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Elesclomol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"The Texas A&M University System","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"The Texas A&M University System \/ Engrail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Texas .."},{"orgOrder":0,"company":"HilleVax","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"HilleVax \/ Frazier Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exscientia Enters $70M Collaboration to Develop Antiviral Therapeutics Against Coronavirus and Other Viruses With Pandemic Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$710.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0.70999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"iECURE","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"Endonuclease-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"iECURE","amount2":0.050000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"iECURE \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ V.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"NRx Pharmaceuticals \/ IQVIA","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"TetraGenetics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"TetraGenetics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TetraGenetics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"TetraGenet.."},{"orgOrder":0,"company":"Walking Fish Therapeutics","sponsor":"Emerson Collective","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"Engineered B-cells Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Walking Fish Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Walking Fish Therapeutics \/ Emerson Collective","highestDevelopmentStatusID":"4","companyTruncated":"Walking Fi.."},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nimble Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Incyte","highestDevelopmentStatusID":"2","companyTruncated":"Nimble The.."},{"orgOrder":0,"company":"AlivaMab","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Antibody-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AlivaMab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlivaMab \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AlivaMab \/.."},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","amount":"$77.0 million","upfrontCash":"Undisclosed","newsHeadline":"ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ Sanofi Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Rome Thera.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces $91 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Private Placement","leadProduct":"ALPN-303","moa":"Dual B Cell cytokine ant","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"Sodium ion channel","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Ther.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"PBGENE-PCSK9","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TB Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Lupin Limited","highestDevelopmentStatusID":"12","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$3,300.0 million","upfrontCash":"$150.0 million","newsHeadline":"Adaptimmune Enters Into a Collaboration with Genentech to Research, Develop, Commercialize Cancer-Targeted Allogeneic T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Allogeneic T-cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adaptimmune Therapeutics","amount2":3.2999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.2999999999999998,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$50.0 million","newsHeadline":"ProQR Announces Axiomer\u00ae RNA Editing Licensing and Research Collaboration with Lilly","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Editing Oligonucleotides","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":1.3,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.3,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IRAK4\/TrkA","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Evommune","amount2":0.080000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Evommune \/ Andera Partners","highestDevelopmentStatusID":"2","companyTruncated":"Evommune \/.."},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"LYTAC-based Therapeutics","moa":"Lysosomal targeting chimera","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Redmile Group","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Ther.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"D1 Capital Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lexeo Therapeutics Closes $100 Million Series B Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"LX2006","moa":"FXN gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ D1 Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Drug Discovery Platform Exscientia Files for A $100 Million US IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"EXS21546","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Powder for Oral Suspension","sponsorNew":"Exscientia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"$229.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azurrx Biopharma Announces Acquisition of First Wave Bio and Its Proprietary Niclosamide Formulations Targeting Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ AzurRx","highestDevelopmentStatusID":"7","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vanqua Bio Launches with $85 Million Series B Financing and A Mission to Vanquish Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Vanqua Bio \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio.."},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"3H Health Investment","pharmaFlowCategory":"D","amount":"$54.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alebund Pharmaceuticals Raises $54.5 Million in Series B+ Financing Round to Fuel Development of Renal Disease Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"AP-302","moa":"MASP-2","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alebund Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Alebund Pharmaceuticals \/ 3H Health Investment","highestDevelopmentStatusID":"5","companyTruncated":"Alebund Ph.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$100.0 million","newsHeadline":"Everest Medicines Enters into Comprehensive Agreement with Providence Therapeutics to Advance mRNA Vaccines and Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ Everest","highestDevelopmentStatusID":"8","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Valneva","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Dynavax Provides Update on its COVID-19 Collaboration with Valneva","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Termination","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Dynavax","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"U.S. government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV\u2122 (casirivimab and imdevimab) Antibody Cocktail","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Casirivimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ U.S. government","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Nanoscope Awarded $1.5M Phase 2B SBIR Grant to Advance Ambient Light Activatable Opsin Gene Therapy to Restore Vision for AMD Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"MCO-010","moa":"MCO gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ National Eye Institute","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"TF Capital","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"CYT-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ TF Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$3,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":3.2000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":3.2000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Leader Medical","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"$1.0 million","newsHeadline":"LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"OPK88003","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"OPKO Health","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ LeaderMed Health","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"MiHKAL GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Psychedelic Compound","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ MiHKAL GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx\u2019s Graduation to Toronto Stock Exchange","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IntelGenx \/ atai","highestDevelopmentStatusID":"4","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Institute for Life Changing Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and The Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"mRNA-3351","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Institute for Life Changing Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Dis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0.19,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"NeuExcell therapeutics \/ Spark","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell .."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Institutional Review Board","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of its Recently Initiated Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Sublingual Chewing Gum","sponsorNew":"Tauriga Sciences \/ Institutional Review Board","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"Vipergen","sponsor":"PhoreMost","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vipergen Establishes Research Partnership with Phore Most Focused on Dna Encoded Library (DEL)-Based Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vipergen \/ PhoreMost","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Strengthens Pipeline by Entering Into Agreement for Biosimilar Bevacizumab, a Key Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Sandoz","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,750.0 million","upfrontCash":"$370.0 million","newsHeadline":"AbbVie and REGENXBIO Announce Eye Care Collaboration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":1.75,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.75,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Termination","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"CytoLynx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$400.0 million","newsHeadline":"Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture to Advance NK Cell Therapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"CYT-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ CytoLynx","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from NIH\/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit's AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AQV-1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aquavit Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aquavit Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquavit Ph.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Will Share RELISTOR\u00ae (Methylnaltrexone Bromide) Data At PAINWeek 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health Companies","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Provides Regulatory Update from US Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Launches Multrys\u2122 (trace elements injection 4*, USP)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zinc","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Receives HREC Clearance for Phase II Trial of Olinvacimab and Pembrolizumab in mTNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis to Host ATTR Symposium Highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Eplontersen","moa":"TTR protein","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Astrazeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Expands Nadunolimab Development in Non-Squamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo\u00ae (cemiplimab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Presents Tyvaso DPI\u2122 BREEZE Clinical Data At The European Respiratory Society International Congress 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Soin Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Status to Soin Therapeutics for Low Dose Naltrexone (LDN) to Treat Complex Regional Pain Syndrome (CRPS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soin Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soin Neuro.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Claims Approval of Autoleucel Relmacabtagen Injection in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Autoleucel Relmacabtagen","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Jardiance Breakthrough Therapy Designation for Heart Failure with Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences to Present New INGREZZA\u00ae (valbenazine) and ONGENTYS\u00ae (opicapone) Data at the MDS Virtual Congress 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of Investigational Epcoritamab (DuoBody\u00ae-CD3xCD20) Published in The Lancet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Awarded Three Patents For Its Novel Compounds and Methods","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer\u2019s Patients Treated with INmune Bio\u2019s XPro\u2122 Show Reduction in CSF Phospho-Tau and Evidence of Remyelination","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International Approved to Start Human Trial to Treat Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Stellate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stellate Therapeutics Publishes Positive Results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"STL-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Stellate Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stellate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Stellate T.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Doses First Patients in Phase 2\/3 Clinical Trial for Tempol in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Genetically Modified AFP\u1d9c\u00b3\u00b3\u00b2T Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Clinical Data from Editas Medicine\u2019s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at a Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta\u00ae (voxelotor) for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Medicine Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-tumoural Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its Drugs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech\u2019s Natrunix\u2122 Anti-Cancer Therapy in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen for Post-COVID-19 Cognitive Dysfunction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at IASLC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"HC-5404","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Neumentum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumentum Presents Latest Data on NTM-006, a Novel Non-Opioid, Non-NSAID Analgesic Drug Candidate, at PAINWeek 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NTM-006","moa":"A3AR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PP-001","moa":"DHODH","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Kiora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Kiora Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiora Phar.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS\u00ae and TAGRISSO\u00ae Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MSP-1014","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VOR33 Granted U.S. FDA Fast Track Designation for AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel\u2122 in Children and Adolescents with ASD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Provides Update on Phase 3 Study Evaluating Rilzabrutinib for the Treatment of Pemphigus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA\u00ae (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Provides an Update on Its Product Portfolio, Following the FDA Acceptance of New Drug Application for the Product mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Teva","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pevonedistat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants BRUKINSA\u00ae (Zanubrutinib) Approval in Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine Clinical Trial in People With Autoimmune Disease Starts at Feinstein Institutes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA (pembrolizumab) Approved in China in Combination With Chemotherapy for Esophageal or Gastroesophageal Junction Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Versantis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versantis Receives U.S. FDA Orphan Drug Designation for VS-01","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VS-01","moa":"Ammonia clearance","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Versantis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Versantis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versantis .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA\u00ae (teprotumumab-trbw) for Chronic Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodegradable Mucoadhesive Patch","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-TNF\u03b1 Antibody","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"AFYX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AFYX Thera.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"INV-202","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Giredestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Starts New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized Anti-CD117 Monoclonal Antibody","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"COR588","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS' Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Completes the Technology Transfer of its Investigational COVID-19 T Cell Therapy, Achieves Major Milestone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Begins a Phase 1 Clinical Trial with INV-202, A New Generation Peripheral Action CB1 Blocker","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"INV-202","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stallergenes Greer Receives Market Approval in Austria for Its Sublingual Allergen Immunotherapy Tablet for Household Mite Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"House Dust Mite Allergen Extracts","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Stallergenes Greer","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Stallergen.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Empagliflozin Receives Breakthrough Therapy Designation in U.S. for Heart Failure with Preserved Ejection Fraction (HFpEF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptive Phage Therapeutics Publishes a Case Study of a Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a Child","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Phage-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fixed-Dose Combination of Albuterol and Budesonide Showed benefits for Asthma Patients in MANDALA and DENALI Phase III Trials","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Avillion","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Research on SINOVAC\u2019s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USPTO Grants ONK Therapeutics\u2019 Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ONKT102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therap.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for R\/R T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LB1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics to Present Data from its Phase 1\/1b Clinical Trial of SBT6050 at the ESMO 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Presents Positive Ambulatory Blood Pressure Data on GEMTESA\u00ae (vibegron) 75 mg","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits MAA to the European Medicines Agency for Investigational Vutrisiran for Hereditary ATTR Amyloidosis with Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Cytel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recent Fluvoxamine COVID Benefits Discovered Using Cytel-Designed Platform Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluvoxamine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cytel","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytel \/ No.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Mirati Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope Trial Tests a New COVID-19 Vaccine in Immunocompromised Bone Marrow Transplant and Cell Therapy Patients With Blood Cancers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the HFSA Annual Scientific Meeting 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte: Data on Ruxolitinib Cream will be Presented at Virtual Congress of the European Academy of Dermatology and Venereology EADV 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s EXKIVITY\u2122 Approved by U.S. FDA as the First Oral Therapy Designed for Patients with EGFR Exon20 Insertion+ NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Highlights New Clinical Data on its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From Clinical Trial Continues to Demonstrate a Single Administration of OpRegen\u00ae Can Provide Anatomical and Functional Improvements","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SAGE-718","moa":"NMDA receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NUBEQA\u00ae (darolutamide) Impact on Local Symptoms Evaluated in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Extended-Release Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Regulatory Approval from MHRA for Phase 1\/2a Combination Study with MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Gets IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Labs Launches Generic Revlimid Capsules in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"Cereblon","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharma Gets CDSCO Approval to Import its Nanoparticle Micellar Formulation, CimetrA for Testing to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Curcumin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Starts Phase III Clinical Development Program OASIS with Elinzanetant","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"NK-1\/NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck, Ridgeback Begin Phase 3 MOVe-AHEAD Study of Molnupiravir for Prevention of Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Initiates Phase 3 Renoir Trial of Single Dose RSV Vaccine Candidate, RSVpreF in Adults Ages 60 Years or Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to Novartis\u2019 LNA043 for Treatment for Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Canakinumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Articular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Accepts CStone\u2019s NDA for Sugemalimab to Treat Unresectable Stage III NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Clears Arctic Vision\u2019s IND Application for Phase III study of ARVN003 to Treat Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Arm Receives US FDA Approval for Sitagliptin Base","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present new Oncology Data at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Giredestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Gets US patent for Tedopi, a Combination of Neoepitopes to treat NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tedopi","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Seeks US FDA nod to Begin Phase 1\/2 trial of TransCon IL-2 \u00df\/? to Treat Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon IL-2 \u03b2\/\u03b3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets US FDA Tentative Marketing Nod for Brexpiprazole Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sec Seeks More Data for Approval of Two-Dose Regimen of Cadila\u2019s Covid-19 Vaccine ZyCov-D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK to Present New Data in Oncology Pipeline and Portfolio at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Cibinqo Receives UK MHRA Marketing Approval to Treat Adults and Adolescents with Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Begins Patient Dosing Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with HR Gene Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pidnarulex","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biological E's Corbevax Gets Nod for Phase 2\/3 Trials on Those aged 5-18","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Gets DGCI Approval for Generic Version of Tocilizumab for Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hetero Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hetero Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hetero Bio.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"AIIMS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIIMS Delhi to Conduct Phase 2 of Bharat Biotech's Nasal Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ AIIMS","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 \/ LYTENAVA\u2122 at EURETINA Virtual 2021 Medical Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Expands Phase 2b\/3 VOICE Clinical Trial to Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Mucobuccal Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Presents Preclinical Data on its FGFR Inhibitor Candidate at JCA-AACR Precision Cancer Medicine International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"KIN-3248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Data from Hepion Pharmaceuticals\u2019 Phase 2a \u2018AMBITION\u2019 Trial Further Strengthens CRV431 Clinical Profile","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia to Present Data from Preclinical and Phase 1 Studies of ACE1702 at the European Society for Medical Oncology 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Results of CHOICE-01 Study on Coherus' and Junshi Biosciences\u2019 Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmocide\u2019s Lead Drug Candidate Opelconazole Granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Opelconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide .."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21\u02e2\u1d57","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nimodipine","moa":"Voltage-gated L-type calcium channel subunit beta-4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SRP-9001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Doses First Patient in MDNA11 Phase 1\/2 ABILITY Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"WTX-124","moa":"Interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex CEO Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington\u2019s Disease Network Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision Receives FDA Clearance of IND for Phase 1\/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"EBT-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Plans to Start Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRASG12C","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LABP-104","moa":"LANCL2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemincare Group Has Completed the Phase I Clinical Trial of its anti-SARS-CoV-2 Neutralizing Antibody JMB2002","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"JMB2002","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jemincare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in the Journal EClinicalMedicine on the Efficacy of the \"Sputnik Light\" Vaccine Among the Elderly in Argentina","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Presents Phase 3 OCEAN Study Results at the IMW Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDUFA Goal Date Extension for Nefecon NDA in the U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2\/3 Study in Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ecopipam","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bio.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CytoTIL15","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Obsidian Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Obsidian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Obsidian T.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes BLA Resubmission","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"TearClear","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Latanoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"TearClear \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals' AR-15512\n Achieved Statistical Significance in Phase 2b Clinical Study for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AR-15512","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences Shares Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ABI-H2158","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Halts Study of Iscalimab in Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Corticosteroid","moa":"CD40","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Ultomiris Approved for Use on Children in EU","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Resamirigene Bilparvovec","moa":"MTM1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Agnafit Bidco","pharmaFlowCategory":"D","amount":"$8,000.0 million","upfrontCash":"$8,000.0 million","newsHeadline":"Statement by The Board of Directors of Swedish Orphan Biovitrum AB in Relation to The Public Cash Offer by Advent and GIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Efmoroctocog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":8,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":8,"dosageForm":"Powder and Solvent for Solution for Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Sinovent","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"$561.0 million","upfrontCash":"$12.0 million","newsHeadline":"Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"XNW1011","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Sinovent","amount2":0.56000000000000005,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"Capsule","sponsorNew":"Sinovent \/ Everest","highestDevelopmentStatusID":"4","companyTruncated":"Sinovent \/.."},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"LaNova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asymchem and LaNova Medicines Enter into Partnership Agreement, Expanding Biological Capabilities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Antibody-drug Conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Asymchem Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asymchem Laboratories \/ LaNova","highestDevelopmentStatusID":"1","companyTruncated":"Asymchem L.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$87.3 million","upfrontCash":"$11.6 million","newsHeadline":"Coave Therapeutics and Th\u00e9a Open Innovation Sign Exclusive Licensing, Co-Development and Commercialization Agreement for Europe For CTx-PDE6b, A Novel Gene Therapy Candidate in Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CTx-PDE6b","moa":"PDE6B gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravitreal","sponsorNew":"Coave Therapeutics \/ Th\u00e9a","highestDevelopmentStatusID":"7","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Announces Closing of MagicMed Industries Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Psychedelic Derivative Compound","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Enveric","highestDevelopmentStatusID":"3","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Faes Farma","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and FAES Farma Enter Into Exclusive Licensing Agreement for The Commercialisation of Bilastine Tablets In The US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Bilastine","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Faes Farma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Faes Farma.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Rosalind Franklin University of Medicine and Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rosalind Franklin University Collaborates with Aptinyx to Research New Therapeutics for Brain Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Rosalind Franklin University of Medicine and Science","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"University Medical Center Goettingen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ University Medical Center Goettingen","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"U.S. National Institute of Neurological Disease and Stroke","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ U.S. National Institute of Neurological Disease and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$267.0 million","upfrontCash":"$20.0 million","newsHeadline":"UNION therapeutics and Innovent Biologics Enter Into Strategic Collaboration and License Agreement for Orismilast, a Next-Generation PDE4 Inhibitor for Inflammatory Dermatology Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Orismilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.27000000000000002,"dosageForm":"Oral","sponsorNew":"Union Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected by Sanofi as a Limited Distribution Partner for Nexviazyme\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Avalglucosidase Alfa-ngpt","moa":"Enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"GtreeBNT","sponsor":"HLB Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RegeneRx Licensee Acquired by Korean Biopharmaceutical Group","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"GtreeBNT \/ HLB Group","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/.."},{"orgOrder":0,"company":"Corium","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Corium Secures $235 Million in Debt Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ H.."},{"orgOrder":0,"company":"Remedium","sponsor":"Tufts University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium Bio Announces Research Agreement with a Leading Rheumatology Laboratory","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"RMD 1101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Remedium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedium \/ Tufts University","highestDevelopmentStatusID":"4","companyTruncated":"Remedium \/.."},{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","amount":"$40.8 million","upfrontCash":"$0.4 million","newsHeadline":"Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"McGill University","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"McGill University \/ Clarus","highestDevelopmentStatusID":"2","companyTruncated":"McGill Uni.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Sectoral Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Hainan Poly Pharm","sponsor":"Imunon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion\u2019s DNA-based Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"DNA-based COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hainan Poly Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Hainan Poly Pharm \/ Celsion","highestDevelopmentStatusID":"4","companyTruncated":"Hainan Pol.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Over-encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"180 Life Sciences \/ Celltrion Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn\u2019s Disease with the Icahn School of Medicine at Mount Sinai","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Omilancor","moa":"LANCL2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Landos Biopharma \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"The Charcot\u2013Marie\u2013Tooth Association","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ The Charcot\u2013Marie\u2013Tooth Association","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kabuki Syndrome Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oryzon Announces $1 Million Grant From Kabuki Syndrome Philanthropists to Support a Precision Medicine Phase I\/II Trial With Vafidemstat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Kabuki Syndrome Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Richard E. Uihlein","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Belapectin","moa":"Galectin 3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Galectin Therapeutics \/ Richard E. Uihlein","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CinFina Pharma In-Licenses Obesity Portfolio","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"RD Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"OPGx-001","moa":"LCA5 gene mutation","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Opus Genetics \/ RD Fund","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"BioNTech","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"BioNTech \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"TNX-1800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Columbia University","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danish Ministry of Health","pharmaFlowCategory":"D","amount":"$124.4 million","upfrontCash":"$12.4 million","newsHeadline":"Bavarian Nordic\u2019s COVID-19 Funding Agreement with the Danish Ministry of Health Receives Final Approval from Parliament","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Intramuscular","sponsorNew":"Bavarian Nordic \/ Danish Ministry of Health","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Implant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Signs Research Partnership with Implant Therapeutics to Access Induced Pluripotent Stem Cells (iPSC)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"iPSC Derived MSCs","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Implant Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virpax \u00ae Pharmaceuticals Announces Closing of a $ 40 Million Public Offering of Common Stock","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"Diclofenac","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Topical Spray Film","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"SciClone","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tarveda Therapeutics and SciClone Pharmaceuticals Expand Partnership by Entering into a License Agreement for HSP90-PI3K Miniature Drug Conjugates in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"PI3K Miniature Drug Conjugates","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tarveda Therapeutics \/ SciClone","highestDevelopmentStatusID":"4","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"BWXT Medical Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ BWXT Medical Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ K2 HealthVentures","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"IASO Bio","sponsor":"CDH Baifu","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series C Financing","leadProduct":"RD126","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"IASO Bio \/ CDH Baifu","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan\u00ae\/Reeqonus\u2122 for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ FUJIFILM Toyama Chemical","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Attillaps Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"AchE","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glaukos \/ Attillaps Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Lucid-201","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lucid Psycheceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Lucid Psycheceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lucid Psyc.."},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Hexagon Bio \/ Nextech Invest","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bi.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Northwestern University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Temelimab","moa":"HERV-W envelope","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GeNeuro \/ Northwestern University","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Inserm","sponsor":"T.H.A.C.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T.H.A.C Announces the Acquisition of an International Patent on Its Drug Candidate ALF-5755 For the Early Treatment of Type 2 Diabetes Mellitus and Relative to the Gut Microbiota Composition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"ALF-5755","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Inserm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inserm \/ T.H.A.C.","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ T.."},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"BVX-0918A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio Elpida","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio Elpida \/ BioVaxys Technology","highestDevelopmentStatusID":"4","companyTruncated":"Bio Elpida.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"SOLTI Innovative Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Announces Collaboration On HARMONIA, a Phase III, Head-To-Head Trial Evaluating Kisqali\u00ae vs. Ibrance\u00ae* in Patients with Hr+\/her2- Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ SOLTI Innovative Cancer Research","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRAS\u2122 (sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Amgen","highestDevelopmentStatusID":"7","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"World-first Agreement Between Novartis and the NHS Enables Broad and Rapid Access to First-in-Class Cholesterol-Lowering Medicine Leqvio\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"NHS Englan.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$22.0 million","newsHeadline":"GenFleet and Innovent Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"GFH925","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$55.0 million","newsHeadline":"Vifor Pharma and Travere Therapeutics Announce Licensing Agreement for The Commercialization of Sparsentan in Europe, Australia and New Zealand","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0.19,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Anjarium Biosciences","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"DNA-based Gene Vectors","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Anjarium Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Anjarium Biosciences \/ Abingworth","highestDevelopmentStatusID":"1","companyTruncated":"Anjarium B.."},{"orgOrder":0,"company":"Elevian","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elevian Raises $40 Million Series A to Advance Treatments for Stroke Recovery and Age-Related Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"rGDF11","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Elevian","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Elevian \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Elevian \/ .."},{"orgOrder":0,"company":"Gubra","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$253.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gubra ApS and Bayer AG Collaborate to Develop Next Generation Cardiorenal Treatments","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gubra","amount2":0.25,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Gubra \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Ba.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series B Financing","leadProduct":"VTX958","moa":"Allosteric TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Surveyor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"The University of Chicago","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bankrolled by Pfizer and Bayer, Pyxis Files For $100M IPO To Take Cancer Drugs Into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"PYX-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pyxis Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ The University of Chicago","highestDevelopmentStatusID":"5","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"858 Therapeutics Launches with Proven Team and $60 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"858 Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"858 Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"858 Therap.."},{"orgOrder":0,"company":"GenEdit","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"Genetic Medicine Encapsulated Polymeric Nanoparticles","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"GenEdit","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"GenEdit \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"GenEdit \/ .."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"ARTIS Ventures","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"DLX-1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ ARTIS Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Tianjin Tiancheng Pharma. Co., Ltd.","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$1,281.5 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patients\u2019 Access to Plasma Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"BT524","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tianjin Tiancheng Pharma. Co., Ltd.","amount2":1.28,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.28,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianjin Tiancheng Pharma. Co., Ltd. \/ Grifols","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Ti.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$11,500.0 million","upfrontCash":"$11,500.0 million","newsHeadline":"Merck to Acquire Acceleron Pharma Inc","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"TGF-beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":11.5,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Arctos Medical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Acquires Arctos Medical, Expanding Optogenetics Portfolio to Bring Gene Therapies to Patients with Severe Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Optogenetics-based AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Arctos Medical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arctos Medical \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Arctos Med.."},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astra Zeneca to Fully Acquire Caelum Biosciences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0.5,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.5,"dosageForm":"Sterile Solution","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Bio.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Bispecific Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Everest Medicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"The Translational Health Science and Technology Institute","sponsor":"Nanogen Pharmaceutical Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Translational Health Science and Technology Institute (THSTI) Signs Memorandum of Understanding (MoU) with The Nanogen Pharmaceutical Biotechnology JSC, Vietnam","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Nanocovax","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Translational Health Science and Technology Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Translational Health Science and Technology Institute \/ Nanogen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"The Transl.."},{"orgOrder":0,"company":"Mycrodose Therapeutics","sponsor":"HAVN Life","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mycrodose Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mycrodose Therapeutics \/ HAVN Life","highestDevelopmentStatusID":"1","companyTruncated":"Mycrodose .."},{"orgOrder":0,"company":"Leeds University","sponsor":"ChemomAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Leeds University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leeds University \/ Chemomab Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Leeds Univ.."},{"orgOrder":0,"company":"Abexxa Biologics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abexxa Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abexxa Biologics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Abexxa Bio.."},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"AskGene Pharma Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Single-domain Antibody","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"GenScript ProBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ AskGene","highestDevelopmentStatusID":"2","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Care Access Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Care Access and Eli Lilly and Company Partner to Increase Diversity Within Oncology Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"CDK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Care Access Research \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Care Acces.."},{"orgOrder":0,"company":"AiPharma","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AiPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiPharma \/ Appili","highestDevelopmentStatusID":"11","companyTruncated":"AiPharma \/.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"AstraZeneca-CICC Fund","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"C-CAR039","moa":"CD19\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund","highestDevelopmentStatusID":"6","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Senti Bio Awarded Funding from National Cancer Institute (NCI) to Support Development of Logic Gated Allogeneic CAR-NK Cell Therapy SENTI-202 to Treat Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"University of Virginia School of Medicine","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Adenosine Analogs","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of Virginia School of Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Virginia School of Medicine \/ Adial Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"IntelGenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx and Aquestive Therapeutics Partner with Leading Men\u2019s Health Company to Market Tadalafil Oral Films in the U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Oak Bay Biosciences","sponsor":"FrontFundr","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oak Bay Biosciences Inc. Opens Equity Raise With Goal of Bringing First Treatment for Inherited Blindness to the Global Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Complement","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oak Bay Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oak Bay Biosciences \/ FrontFundr","highestDevelopmentStatusID":"4","companyTruncated":"Oak Bay Bi.."},{"orgOrder":0,"company":"GigaGen","sponsor":"ProteoNic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GigaGen Licenses ProteoNic\u2019s 2G UNicTM Technology Platform for High Yield Production of GigaGen\u2019s Mono- and Polyclonal Antibody Drug Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ ProteoNic","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners\u00ae for Up to $125 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Financing","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.13,"dosageForm":"Film-coated Tablet","sponsorNew":"Spero Therapeutics \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"hVIVO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Aim ImmunoTech \/ hVIVO","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"AnaBios","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"NIH\/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain States","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"ANB-504","moa":"Dual sodium channels","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AnaBios","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnaBios \/ NIH","highestDevelopmentStatusID":"5","companyTruncated":"AnaBios \/ .."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Amring Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amring Pharmaceuticals Inc. Licenses LYSTEDA to Pierre Fabre for Mexican Market","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pierre Fabre \/ Amring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck KGaA, Darmstadt, Germany Announces Mutual Decision to End Bintrafusp Alfa Agreement with GSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Termination","leadProduct":"Bintrafusp Alfa","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$31.2 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Bacteriophage Therapies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$270.0 million","newsHeadline":"Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Ulotaront","moa":"TAAR1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0.89000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.89000000000000001,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Pabinafusp Alfa","moa":"Transferrin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$602.0 million","upfrontCash":"$152.0 million","newsHeadline":"Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.59999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0.5,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"PD-L1 XT","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Nanomerics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Virpax Pharmaceuticals \/ Nanomerics","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"1910 Genetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"1910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"1910 Genetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"1910 Genetics \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"1910 Genet.."},{"orgOrder":0,"company":"Carbon Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carbon Health Unveils Carbon for Research, a Clinical Trial Research Program to Drive Healthcare Advancements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carbon Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carbon Health \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Carbon Hea.."},{"orgOrder":0,"company":"Psyence","sponsor":"Pure Extracts Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A Joint Venture Sealed between Psyence Group and Pure Extracts: Psychedelic Medicinal Mushroom Extracts in Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psyence \/ Pure Extracts Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Starts Global Phase 2\/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PF-07321332","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"LifeCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LifeCell\u2019s Mesocel Gets Nod for Clinical Trial from DCGI; Therapy to Treat Patients with Moderate to Severe COVID 19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LifeCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LifeCell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LifeCell \/.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group launches Efmody in UK to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Positive Health-Related Quality of Life Data for 177Lu-PSMA-617 radioligand Therapy in Patients with Advanced Prostate Cancer at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRP\u03b1 Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"OSE-172","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its New Generation of Compounds Are Significantly More Effective than FDA-Approved Topical Ad Drug Crisaborole","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Nrf2","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Kt-3000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924\u2019s Best-in-Class Potential as a Chemoprotective Agent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics to Present Data at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"FS120","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Presents Preliminary Findings from Ongoing Phase 1a\/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NGM120","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ITIL-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Presents Dovitinib Survival Data from DRP\u00ae Screened RCC Patients at ESMO 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dovitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA\u00ae in Aggressive Forms of Prostate Cancer at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals\u2019 Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CRN04777","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL BIOSCIENCES: Phase II\/III clinical trial for NFL-101 For Smoking Cessation Approved in France","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I\/O In Vivo Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GRP78","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CNP-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharm.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"RAS","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LUMAKRAS\u2122 (Sotorasib) Combined With Vectibix\u00ae (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision Receives FDA Clearance of IND for Phase 1\/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"EBT-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix to Advance Synthetic Hypericin Development in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to Camurus\u2019 CAM2029 to Treat Polycystic Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Octreotide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with Fgfr2 Fusion-Positive iCCA at ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends VUMERITY\u00ae (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Diroximel fumarate","moa":"Nicotinic alpha 10 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Presents Preliminary Patient Response Data from the Phase I\/IIa EVICTION Trial with ICT01 at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized anti-Butyrophilin 3A Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Leadership to Present at Five Scientific Events in September","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives Positive CHMP Opinion For Gavreto\u00ae (pralsetinib) For the Treatment of Adults With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Gold Nanocrystals","moa":"Cellular energy production","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' and Pfizer's XTANDI\u00ae (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VILTEPSO\u00ae (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Starts Dosing of First COVID-19 Patients in The Global Phase 3 Trial ATTRACT-3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS \u2265 5","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Results from Phase 1b\/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA\u00ae (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DS-7300","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monalizumab Data from COAST Trial Presented at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Monalizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ\u00ae) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius will Release 4 Oral Presentations of 2 Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar HLX04","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Henlius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Henlius \/ .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CT041","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on RYBREVANT\u00ae (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tastuzumab Duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESMO Late-breaking Data Show Libtayo\u00ae (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA\u00ae in Combination with TUOYI\u00ae in the Treatment of Advanced Neuroendocrine Carcinoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Presents Data From Phase 1\/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Eprenetapopt","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I\/II Clinical Trial of SGT-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Receives Complete Response Letter from The FDA Identifying Deficiencies at A Facility of A Contract Manufacturer for Its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase III Data Support the Benefit of Roche\u2019s Tecentriq in Early-Stage Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA\u00ae in Advanced Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presented Positive Final Results of Tedopi\u00ae Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tedopi","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE\u00ae (setmelanotide) For the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alstr\u00f6m Syndromes","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Presents Data at The European Society for Medical Oncology (ESMO) Congress 2021 Demonstrating a Reduction in Circulating Tumor Dna (ct Dna) While on Tebentafusp Is Associated with Overall Survival in The Phase 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"EDO51","moa":"Exon 51 inclusion","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents New Kisqali\u00ae Data Showing Longest Median Overall Survival Ever Reported in HR+\/HER2- Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triumvira Immunologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI\u00ae) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Lincoln Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lincoln Pharma Plans to Launch Cephalosporin Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cephalexin Hydrochloride","moa":"PBP3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lincoln Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lincoln Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lincoln Ph.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Clindamycin Phosphate Foam, 1%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STRIDE Data Show Translarna\u2122 Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL BIOSCIENCES: Approval for Its Patent to Be Granted in The United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Scopus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DUET-02","moa":"CpG-STAT3 Antisense","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Scopus Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scopus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scopus Bio.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Dupixent\u00ae (dupilumab) Data in Patients as Young as 6 Years Old with Moderate-To-Severe Atopic Dermatitis to Be Presented At WCPD and EADV","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ELI-005","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science receives Health Canada Approval Letter to Commence Phase I\/II trial of AB8939 In the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AB8939","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Versamune-TARP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Pontificia Universidad Catolica de Chile","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile","highestDevelopmentStatusID":"8","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"GluN2B-NMDA receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences Provides Scientific Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redpin Therapeutics Receives Four Additional US Patents","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV-based Engineered Ion Channel Gene","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Redpin Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Redpin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Redpin The.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized In TRS4VISION Phase-III Clinical Trial In Patients With Active Non-Infectious Anterior Uveitis Including Patients With Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Accepts for Priority Review Vertex Pharma\u2019s sNDA for PrKalydeco To Treat Cystic Fibrosis in Patients from 4 Months to 18 Years of Age","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Receives Clearance from Brazil\u2019s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg\/week)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed\/Refractory Unresectable or Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart\u202fTo Present at Upcoming Vaccine Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 Therapeutic Program Heading to Clinical Trial in Early 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MAN-19","moa":"Tie2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Mannin Research Inc","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Vesselon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Preclinical Study Reports 658% Increase in STING Agonist to Tumor When Used in Combination with Vesselon's Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Imagent encapsulated MSA-1","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Vesselon","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Endo International","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First and Only Generic Version of Chantix\u00ae (varenicline) Tablets in the United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Par Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Par Pharmaceutical \/ Endo International","highestDevelopmentStatusID":"12","companyTruncated":"Par Pharma.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2\/3 SPECTRA Trial Dominated by Variants of Concern and Interest","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"5QB0T2IUN0","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NV-Cov-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA\u00ae (lurbinectedin) Approved in Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Specialised Therapeutics \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Obtains SARS Coronavirus Patent for C21 in The USA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Receives Approval from The EMA's Paediatric Committee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Application for Cadonilimab (PD-1\/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Quad-NIV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Cytovation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I\/IIa CICILIA Trial Which Now Moves to Expansion Phase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila gets US FDA Marketing Approval for Apremilast Tablets","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharma Launches Biapenem to Treat Intra-Abdominal, Lower Respiratory or Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Biapenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injection","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Therapeutics to Present Data at IDWeek 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Presenting New Data for NUZYRA\u00ae (omadacycline) at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Initiates Phase 1\/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tamoxifen Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LN-145","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Orally Dissolving Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I\/II Clinical Trial of SGT-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen to Present Phase 2a\/2b Efficacy and New Safety Data with Vamorolone at Forthcoming Conferences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents New Data at World Muscle Society (WMS) 2021 Highlighting New Advances for People Living with Rare Neuromuscular Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.Micro-dystrophin","moa":"Micro-dystrophin protein production","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olyx to Present Liver Disease Treatment and Base Technology at OTS Conference in 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"OLX702A","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Opko Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Granted European Patent for ONCOS-102 in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA\/CD3 Bispecific Antibody at World Bispecific Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BA1202","moa":"CEA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SRP-5051","moa":"Dystrophin pre-mRNA exon 51","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fully Human Anti-TNF\u03b1 Monoclonal Antibody HUMIRA\u00ae Obtains Additional Approval for High-Dose Regimen of Ulcerative Colitis in Adult Patients and for New Regimen in Pediatric Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO\u00ae (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Verzenio\u00ae (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed and Liechti Lab Provide Results From Their Psilocybin R&d Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT1A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healthy Extracts Begins New Clinical Trial to Investigate Ability of UBN RELIEF\u2122 to Naturally Alleviate Migraine Symptoms and Improve Cognitive Function","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Marigold Extract","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Ex.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca and Sputnik Light Covid Vaccines Show Antibody Growth in Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Brazil\u2019s ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces KEYTRUDA\u00ae (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Repatha\u00ae (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Griffith University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope and Griffith University Researchers Use Novel Method to Block HIV in Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ZPAMt","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Griffith University","highestDevelopmentStatusID":"4","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1\/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Phased European Launch of Klisyri\u00ae (tirbanibulin) for the Treatment of Actinic Keratosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX\u2122, to Treat Systemic Inflammatory Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"CinnaGen Co","sponsor":"Vaxine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Advax-SM","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CinnaGen Co \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen C.."},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Anticoagulant Treatment of COVID-19 Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Premier Inc","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2\/3 COVA Study With Sarconeos (BIO101) in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion\u2019s Monoclonal Antibody Treatment For COVID-19, Regdanvimab (CT-P59) Becomes the First Authorized COVID-19 Treatment Approved from The Korean Ministry of Food and Drug Safety (MFDS)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR\/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vixotrigine","moa":"NaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer-BioNTech COVID-19 Vaccine COMIRNATY\u00ae Receives Full Health Canada Approval for Individuals 12 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinopharm's COVID Booster Reverses Antibody Decline, Enhances Cell-Based Responses - Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ETX0462","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Stock Jumps 47% on Positive DKN-01 + Tislelizumab Data in Gastroesophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia P.."},{"orgOrder":0,"company":"Novavax","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Is Reviewing the Authorisation Extension for A Third Dose of The COVID-19 Vaccines from Pfizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Is Reviewing the Authorisation Extension for A Third Dose of The COVID-19 Vaccines from Pfizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Elasomeran mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cereno Scientific Obtains IND Acceptance from FDA to Start Phase II Study with Drug Candidate CS1 in PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CS1","moa":"HDAC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cereno Scientific","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cereno Scientific \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cereno Sci.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Pauses Start of DIAGNODE-3 In the US Pending Clarification on Study Drug","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives CHMP Positive Opinions Recommending Approval of Nucala (mepolizumab) in Three Additional Eosinophil-Driven Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics Announces Positive Interim Results from Ongoing Phase 1\/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Thera.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives Positive CHMP Opinion for BRUKINSA\u00ae (Zanubrutinib) for the Treatment of Adults with Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb\u2019s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin\/Docetaxel Combination versus Docetaxel Alone in 2nd\/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncolo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination Shows Promise in Treatment-Resistant Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"The Institute of Cancer Research \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Flugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Naobios Manufactures FluGen Inc\u2019s M2SR Influenza Vaccine Candidate for Upcoming Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"M2SR","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Flugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ N.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RP7214","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI\u00ae (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Will Leverage IND and Use FDA Pre-Review for Covid-19 Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces the Acceptance of its US FDA Investigational New Drug Application (IND) for Lead Candidate, ALPHA-1062 for Mild to Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare To Present Key Data that Provides Further Support for The Use of 2-Drug Regimens, Including Long-Term Efficacy, Alongside New Insights Into Living With HIV at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"HPP737","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Crysvita\u00ae (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"ZENOAQ","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indication of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ZENOAQ","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZENOAQ \/ Chugai","highestDevelopmentStatusID":"12","companyTruncated":"ZENOAQ \/ C.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Zogenix","sponsor":"PPD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Submits Supplemental New Drug Application for FINTEPLA\u00ae (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ PPD","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1\/2 Trials at the Fourteenth International Symposium on Retinal Degeneration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sunitinib","moa":"FLT3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Alphalex-exatecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRM Health Receives CTA Approval for Phase 1b\/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MH002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-0159","moa":"KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Marzeptacog Alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Receives Regulatory Authorization to Commence a Second Phase 2 Covid-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Orbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Phosphorylated HexaAcyl Disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal drop","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI\u2122 (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to ViiV Healthcare\u2019s New Drug Application For Cabotegravir Long-Acting for Prevention Of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC\u2122 RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"DCR-A1203","moa":"ALDH2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cycle Pharmaceuticals Launches SAJAZIRTM (icatibant) Injection, A New Treatment Option in Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Crisaborole","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Mayne Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Three Additional Strengths Of Isotretinoin Capsules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Mayne Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With \u03b2-thalassemia Who Require Regular Red Blood Cell Transfusions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/Beta globulin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD824","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants BRUKINSA\u00ae (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Release Phase 3 Results of TYVYT\u00ae (Sintilimab Injection) in Combination with GEMZAR\u00ae (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Lilly's ERBITUX\u00ae (cetuximab) Label with Combination of BRAFTOVI\u00ae (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Will Share RELISTOR\u00ae (Methylnaltrexone Bromide) Data At The American Society For Pain Management Nursing (ASPMN) 31st National Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New REGEN-COV\u2122 (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Aurora Cannabis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurora Cannabis Launches its First Medical CBD Product in Uruguay","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurora Cannabis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oil","sponsorNew":"Aurora Cannabis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurora Can.."},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals Receives Study May Proceed Letter from FDA for a Phase 1b\/2 Clinical Trial of BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Saposin C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bexion Pha.."},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NNI-362","moa":"Allosteric p70S6 kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronasce.."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cumberland Pharmaceuticals Launches RediTrex\u00ae Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Prefilled Syringe","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Showcases Recent Data in Relapsing Multiple Sclerosis at the 2021 European Committee for Treatment and Research in Multiple Sclerosis Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO to Present Three Posters at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New BIMZELX (bimekizumab) Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at The 30th European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cell-based Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approved IND Submitted by Pharmazz, Inc. to Initiate a Phase III Clinical Trial of Centhaquine in Patients with Hypovolemic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LISCure Biosciences Received Clinical Approval for Two Microbiome Programs Targeting Autoimmune Disease And NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LB-P8","moa":"Tissue necrosis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LISCure Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Asceneuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ASN120290","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asceneuron \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI\u00ae) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Receives Approval to Start the First Clinical Study with The Oligomer-Specific ALZ-101 Vaccine in Patients with Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ALZ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OLUMIANT\u00ae Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Led to Greater Improvements in Liver Fat Content Compared to Insulin Degludec in Adults with Type 2 Diabetes In SURPASS-3 MRI Sub-Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Discover Previously Unknown Role of BioAegis\u2019 Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All Endpoints Met in Hepion Pharmaceuticals\u2019 Drug-Drug Interaction Study with CRV431","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Pan-Cyclophilin A","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present Updates from Phase 2\/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"KB407","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pha.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"KB295","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek\u2122 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I\/II Clinical Trial of SGT-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 \u2013 October 2, 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"KB-0742","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Cancer Research UK Cancer Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MRT-048","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Cancer Research UK Cancer Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"KIN-2787","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New, Late-Breaking Data At EADV Highlights Emerging Clinical Profile of Amlitelimab (formerly KY1005) In Adults with Inadequately Controlled Moderate-To-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"OX40L","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New FINTEPLA\u00ae (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRASG12C","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II\/III Trial Shows Ronapreve\u2122 (casirivimab and imdevimab) Significantly Reduces Viral Load Within Seven Days of Treatment in Patients Hospitalised With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Results for the Six Months ended 30 June 2021 - Barhemsys\u00ae and Byfavo\u00ae Launches Continue to Achieve Strong Hospital Formulary Adoption","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Next recruitment milestone reached in IBT\u2019s Phase III Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Drop","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pha.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents Comprehensive Data from Five Trials of The RBX2660 Demonstrating Uniform Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Evidation Health","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evidation Study Shows Digital Intervention Increases Flu Vaccination Rates Among People With Diabetes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evidation Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evidation Health \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Evidation .."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Notice of Approval for a New US Patent Broadening the Use of Arsenic Trioxide to Treat the Relapsing-Remitting Form of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"TSHA-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising New OpRegen\u00ae Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm To Present Update From GDF-15 Targeting First-in-Human I\/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CTL-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics to Present Initial Data from the Phase 1\/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"BT5528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients\u2019 Immunological System to Combat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AL002","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Showcases New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof in Patients with Plaque Psoriasis at the 30th EADV Virtual Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present 8 Abstracts on AJOVY\u00ae (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ONM-501","moa":"STING protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"OncoNano Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents New Adtralza\u00ae (tralokinumab) Data Following Long-Term Continuous Treatment At EADV 30th Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Show Achieving Complete Control of Chronic Spontaneous Urticaria (CSU) Improves Overall Quality of Life, as Reported by Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Lilly's ERBITUX\u00ae (cetuximab) Label with Combination of BRAFTOVI\u00ae (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Gets Marketing Approval for Ryaltris in 13 EU, UK Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Receives Regulatory Authorization to Commence a Second Phase 2 Covid Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Show Rapid and Effective Disease Activity Control with Remibrutinib (lou064) in Patients with Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Remibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nexodyn Acid-oxidizing Solution","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray Solution","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze\u00ae in The US","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Ohara Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ohara Phar.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta\u00ae in Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Health Canada Approves its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Elasomeran mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Trudhesa\u2122 (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis to Present New Findings of Enerzair Breezhaler, Highlighting its Digital Companion at ERS Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"old Sano","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi & Regeneron to Present Dupixent Efficacy and Quality of Life Data in Asthma Patients Across Multiple Age Groups at 2021 ERS Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"old Sano","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"old Sano \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"old Sano \/.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Receives US FDA Approval for Metrogel Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces Clinical Trial Application of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC42","moa":"HBsAg","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Caplin Steriles","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caplin Steriles Gets USFDA Nod for Labetalol Hydrochloride Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Labetalol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Caplin Steriles","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Caplin Steriles \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Caplin Ste.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Begins Patient Dosing in phase 2 Trial of IBI362 to Treat Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"LY3305677","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharma Launches Cabozantinib to Treat Metastatic Medullary Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Generic Duexis Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates 94.8% Efficacy Against COVID During the Vaccination Campaign in San Marino","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Introduces Three New Movantik Data Analyzes at PAINWeek 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The U.S. FDA Approves the First Product Candidate GCC19CART of Stancel Biotechnology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"GCC19CART","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovative Cellular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"AL101","moa":"Gamma secretase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$20.0 million","newsHeadline":"Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0.14000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Intrarticular Injection","sponsorNew":"Biosplice \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Journey Colab","sponsor":"MBX Capital","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Journey Colab Secures $12 M Series A Funding for Phase 1 Trial of Mescaline H Cl (jour-001) for Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Series A Financing","leadProduct":"Mescaline","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Journey Colab","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Journey Colab \/ MBX Capital","highestDevelopmentStatusID":"4","companyTruncated":"Journey Co.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Issued For DEP\u00ae Cabazitaxel Nanoparticle","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Tubulin alpha-4A chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel Ex Vivo Engineered Cell Therapies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Ex-vivo Engineered Cell Therapies","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Arbor Biotechnologies, Inc","amount2":1.2,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe\u00ae Safety Switch","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Cellular Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Canter","highestDevelopmentStatusID":"1","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY\u00ae (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2,100.0 million","newsHeadline":"Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Ulipristal Acetate","moa":"Progesterone receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"HRA Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HRA Pharma \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"HRA Pharma.."},{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humedix Closes Strategic Investment in US-based Kineta to Boost CMO Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ .."},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Naronapride","moa":"5-HT4 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion .."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"USAMRDC","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"LMN-301","moa":"ACE2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lumen Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lumen Bioscience \/ USAMRDC","highestDevelopmentStatusID":"5","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dexa Medica","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Powder for Injection","sponsorNew":"Dexa Medica \/ Debiopharm","highestDevelopmentStatusID":"12","companyTruncated":"Dexa Medic.."},{"orgOrder":0,"company":"Enzolytics","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Anti-HIV Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enzolytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzolytics \/ Samsung Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Enzolytics.."},{"orgOrder":0,"company":"Tolmar","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Tolmar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tolmar \/ Sanofi Canada","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ S.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its \u03b2-catenin antagonist peptide (BCAP) Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Beta catenin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"MUSC Foundation for Research Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TP-2021","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development","highestDevelopmentStatusID":"4","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BioNova Pharmaceuticals","pharmaFlowCategory":"D","amount":"$204.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Intravenous","sponsorNew":"Sutro Biopharma \/ BioNova Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"IDG Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series C Financing","leadProduct":"XW003","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sciwind Biosciences","amount2":0.070000000000000007,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ IDG Capital","highestDevelopmentStatusID":"4","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Keystone Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Kainos Medicine","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"KM10544","moa":"IRAK4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kainos Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kainos Medicine \/ Emmaus","highestDevelopmentStatusID":"4","companyTruncated":"Kainos Med.."},{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Centers","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ketamine Wellness Centers Partners with Veterans Affairs (VA) Community Care Network to Provide Free Ketamine Treatments to Veterans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delic Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delic Corp \/ Ketamine Wellness Centers","highestDevelopmentStatusID":"1","companyTruncated":"Delic Corp.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"SerpinPC","moa":"Protein C","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0.29999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Oberland Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,124.0 million","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Selecta Biosciences","amount2":1.1200000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.1200000000000001,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Autotelic Bio","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic Acquires Fast to Market Late-Stage Drug Candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autotelic Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Autotelic Bio \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Autotelic .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Southern Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"TNX-1800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Southern Research","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Financing","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Beijing Wonner Biotech","sponsor":"Shineco","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shineco, Inc. Intends to Acquire Biotechnology Company to Jointly Develop Rapid-acting Antidepressant Natural Innovative Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"SNG","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Beijing Wonner Biotech","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Beijing Wonner Biotech \/ Shineco","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Wo.."},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Gro.."},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$150.0 million","newsHeadline":"Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.5,"dosageForm":"Sterile Solution","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Bio.."},{"orgOrder":0,"company":"Eurobio Scientific","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"AGN-231868","moa":"Chemokine","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eurobio Scientific","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Eurobio Scientific \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Eurobio Sc.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Athyrium Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Athyrium Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Outpace Bio","sponsor":"Century Therapeutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Engineered iPSC-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outpace Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Outpace Bio \/ Century Therapeutic","highestDevelopmentStatusID":"3","companyTruncated":"Outpace Bi.."},{"orgOrder":0,"company":"ScalmiBio","sponsor":"ALX Oncology","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"$6.5 million","newsHeadline":"ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ScalmiBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ScalmiBio \/ ALX Oncology Holdings","highestDevelopmentStatusID":"1","companyTruncated":"ScalmiBio .."},{"orgOrder":0,"company":"Evotec","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Pasithea Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ P.."},{"orgOrder":0,"company":"GSK","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Completes Acquisition of GSK\u2019s Cephalosporin Business, Reinforcing Leading Global Position in Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Cefuroxime Axetil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Sand.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$143.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinCor Pharma Raises $143 Million in Series B Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ General Atlantic","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,580.0 million","upfrontCash":"$20.0 million","newsHeadline":"Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.5800000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5800000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Fosun Pharma Sign Exclusive License and Distribution Agreements For Aloxi\u00ae, Akynzeo\u00ae Oral, NEPA IV and Anamorelin in Mainland China, Hong Kong SAR and Macau SAR","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Palonosetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Helsinn","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"CombiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CG01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spark Therapeutics, Inc \/ CombiGene AB","highestDevelopmentStatusID":"4","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"$15.0 million","newsHeadline":"Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay\u2122 (Odevixibat) in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$456.5 million","upfrontCash":"$6.5 million","newsHeadline":"Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"siRNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"OliX Pharmaceutical","amount2":0.46000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"BX005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Maruho Co. Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"BiomX \/ Ma.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Emerges with Largest Clinical-Stage Precision Psychiatry Pipeline and $40 Million in Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.040000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$365.0 million","upfrontCash":"$45.0 million","newsHeadline":"Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel\u00ae)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0.37,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.37,"dosageForm":"Intravenous","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$230.0 million","newsHeadline":"MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody\u00ae Sonelokimab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Atlas Antibodies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T-Cure Bioscience, Inc. and Atlas Antibodies AB Enter a Collaboration Agreement for the Development, Manufacture, and Supply of CT83 (KK-LC-1) Monoclonal Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"820TCR","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"T-Cure Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"T-Cure Bioscience \/ Atlas Antibodies","highestDevelopmentStatusID":"4","companyTruncated":"T-Cure Bio.."},{"orgOrder":0,"company":"Sinclair Research","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"AnQlar","moa":"ACE2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sinclair Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sinclair Research \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sinclair R.."},{"orgOrder":0,"company":"AavantiBio","sponsor":"University of Florida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AavantiBio Furthers Strategic Partnership with University of Florida to Research and Develop Next Generation Gene Therapy Capsids","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"AAV-based Capsid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AavantiBio \/ University of Florida","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio.."},{"orgOrder":0,"company":"Rectify Pharma","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Positive functional","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rectify Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Rectify Pharma \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Rectify Ph.."},{"orgOrder":0,"company":"Abalos Therapeutics","sponsor":"Seventure Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Arenavirus-based Drug Candidates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abalos Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Abalos Therapeutics \/ Seventure Partners","highestDevelopmentStatusID":"5","companyTruncated":"Abalos The.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities Inc.","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Closing of Public Offering of $7,000,220","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Public Offering","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$17.0 million","newsHeadline":"Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"ADAR1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Storm Therapeutics \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"TCRyption Inc","sponsor":"Treadwell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Autologous TCR-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TCRyption Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TCRyption Inc \/ Treadwell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"TCRyption .."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax's CpG 1018 Adjuvant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dynavax Technologies \/ US Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"EPI-7386","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Caris Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Programme Grant From MJFF","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"USP30","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$37.1 million","upfrontCash":"Undisclosed","newsHeadline":"Micreos Secures \u20ac32 Million for Its Endolysin-Based Platform as Sustainable Alternative to Antibiotics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"XZ.700","moa":"Cell wall","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Hu.."},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Gro.."},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exo Therapeutics Raises $78 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Exo Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Exo Therapeutics \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Exo Therap.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$630.0 million","upfrontCash":"$30.0 million","newsHeadline":"Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACER\u1d40\u1d39 AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AAV Capsids","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Voyager Therapeutics, Inc","amount2":0.63,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.63,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"ORI Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"AIC100","moa":"ICAM-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AffyImmune Therapeutics \/ ORI Capital","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune.."},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Non-viral Based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intergalactic Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Intergalactic Therapeutics \/ ATP","highestDevelopmentStatusID":"2","companyTruncated":"Intergalac.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$3,600.0 million","upfrontCash":"$45.0 million","newsHeadline":"Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"P-FVIII-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Poseida Therapeutics, Inc","amount2":3.6000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":3.6000000000000001,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tentarix Biotherapeutics Emerges with $50 Million Series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Antibody-based Multifunctional Therapeutic","moa":"IL2R gamma receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix B.."},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"TLR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic Imm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"$279.0 million","upfrontCash":"$9.0 million","newsHeadline":"Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"iPSC-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bristol Myers Squibb","amount2":0.28000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"$0.2 million","newsHeadline":"Hemogenyx Pharmaceuticals Announces CDX Licence Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CDX bi-specific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Financing","leadProduct":"THIO-101","moa":"Telomerase stress","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Athos Service","pharmaFlowCategory":"D","amount":"$75.8 million","upfrontCash":"Undisclosed","newsHeadline":"iOmx Therapeutics Raises EUR 65 Million in Series B Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"IMT-07","moa":"SIK3 kinase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"iOmx Therapeutics \/ Athos Service","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Thera.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Forge Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Forge Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Sapreme technologies","sponsor":"Aglaia Oncology Funds","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"SPT001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapreme technologies","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sapreme technologies \/ Aglaia Oncology Funds","highestDevelopmentStatusID":"4","companyTruncated":"Sapreme te.."},{"orgOrder":0,"company":"Imophoron","sponsor":"Science Creates Ventures","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Collaborative COVID-19 Lockdown Effort Delivers Major Boost for Vaccine Innovation in Bristol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"ADDomer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imophoron","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intranasal","sponsorNew":"Imophoron \/ Science Creates Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Imophoron .."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Group Purchasing Organizations","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Group Purchasing Organizations","highestDevelopmentStatusID":"12","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Hunterian Medicine","sponsor":"Inscripta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hunterian Medicine\u00ae Licenses Inscripta\u2019s MAD7\u2122 Nuclease to Advance Gene Editing Research and Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"MAD7 Nuclease","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Hunterian Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hunterian Medicine \/ Inscripta","highestDevelopmentStatusID":"1","companyTruncated":"Hunterian .."},{"orgOrder":0,"company":"Aurigene","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"XL114","moa":"CBM","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aurigene","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Aurigene \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Aurigene \/.."},{"orgOrder":0,"company":"Flightpath Biosciences","sponsor":"Northeastern University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flightpath Licenses the First Antibiotic that Selectively Kills Lyme Disease Spirochetes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"FP-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Flightpath Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flightpath Biosciences \/ Northeastern University","highestDevelopmentStatusID":"5","companyTruncated":"Flightpath.."},{"orgOrder":0,"company":"Cipla","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla to sell Eli Lilly's Insulin Products Humalog, Trulicity in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cipla \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ El.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ Pacira","highestDevelopmentStatusID":"12","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Announces Bristol Myers Squibb opt-in of EVT8683 As the First Programme from iPSC-Based Neurodegeneration Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.1 million","newsHeadline":"Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Milrinone","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Baker Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Baker Institute \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baker Inst.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"National Cancer Institute Selects ImmunityBio\u2019s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"N-803","moa":"IL-15 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ National Cancer Institute","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage and Biogen\u2019s Depression Drug Iffy on Efficacy Despite Dosing, Safety Upside","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse\u00ae for LEMS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Present Phase II TACTI-002 Data at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus to Present AGEN1181 Clinical Data at SITC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"DYNE-251","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TENDU Vaccine","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Following Completion of The Initial Phase of The Ongoing Trial in The US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets Permission to Conduct Phase III Trial for Two-Dose Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083\/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMG 451","moa":"OX40","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the First Patient Dosed in the Phase I\/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI351","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everolimus 10mg (Afinitor) Launched","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"N-Methyl Amisulpride","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"LB Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BOS-580","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Boston Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boston Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Boston Pha.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Receives FDA Authorization to Start Clinical Development Program of Masitinib in Mast Cell Activation Syndrome (MCAS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure\u2019s Alzheimer Project Has Initiated the Next Clinical Phase I Study With ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces Completion of Patient Enrollment For DIVERSITY Phase 3 Study with Filgotinib in Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Submits FDA Application for First Dispersible Single Tablet Regimen Containing Dolutegravir (DTG) For Children Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present New Data On OCREVUS In Multiple Sclerosis and ENSPRYNG In Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA\u00ae (Lefamulin)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Presents New Data from The SELECTION Phase 3 Program at The United European Gastroenterology Week (UEGW) 2021 Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoZolid\u00ae-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NanoZolid-Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect\u2019s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"Interferon-Induced Protein-10","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Drop","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Na\u00efve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results of Clinical Trial Comparing Coherus\u2019 Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis\u00ae (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Sc","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NLC-V-01","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Norgine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data in The European Heart Journal Show Ciraparantag Reverses the Anticoagulant Activity of Apixaban and Rivaroxaban in Elderly Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Covis Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Covis Pharma \/ Norgine B.V.","highestDevelopmentStatusID":"8","companyTruncated":"Covis Phar.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA\u2122) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Presents Positive Phase 2a Data With SOM3355 at the 34thECNP Congress 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SOM3355","moa":"VMAT2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SOM Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotec.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"Micro-dystrophin protein production","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Kite\u2019s Tecartus\u00ae as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Appello Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appello Pharmaceuticals Begins Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AP-472","moa":"Metabotropic glutamate receptor type 4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Appello Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appello Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Appello Ph.."},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nanoparticle Encapsulating PDC-E2","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cour Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharm.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Reports Further Analysis of Phase 2\/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA\u00ae (ustekinumab) in Older Patients Across Approved Indications","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NV-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac Presents 3-Year Follow-Up Results of The Phase I\/II Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"NovaBiotics Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NP339","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NovaBiotics Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovaBiotics Ltd \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NovaBiotic.."},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EmphyCorp Inc. Non-Steroidal N115 Nasal Spray Completed Phase III Clinical Trial for COVID-19, Long COVID-19 (Long Haulers), and Pulmonary Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Pyruvate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"EmphyCorp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp .."},{"orgOrder":0,"company":"Cintex","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cintex Services, LLC and Senores Pharmaceuticals, Inc. Launch Chlorzoxazone Tablets USP, 250 mg in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Cintex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cintex \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cintex \/ S.."},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"DehydraTECH-Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Pouch","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bi.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SZN-1326","moa":"Lrp6","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics to Host Virtual Event Highlighting CTX110\u2122 Clinical Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CTX110","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B\u2019s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Leadership to Present at Seven Scientific and Industry Events in October","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent To Present Preclinical Data On BT-001 Oncolytic Virus At SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-Tumoral","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Boan Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boan Biotech\u2019s New ADCC-Enhanced Anti-Claudin 18.2 Antibody Drug BA1105 Approved for Clinical Trials in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BA1105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Boan Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boan Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Boan Biote.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma's Talicia\u00ae added to Medi-Cal Contract Drug List with No Prior Authorization Requirements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Forbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forbion Portfolio Company Covicept Therapeutics Initiates a Phase 2 Clinical Trial Of PJS-539 For the Treatment of Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PJS-539","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Forbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ .."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on TAK-994 Clinical Program","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TAK-994","moa":"Orexin receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Journal of Urology Publishes Results of UroGen Pharma\u2019s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC).","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for The Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PEP-010","moa":"Caspase9\/PP2A interaction","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therap.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b \u2018X-TOLE\u2019 Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UTILITY Therapeutics to Present Data at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pivmecillinam","moa":"PBP1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"UTILITY therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UTILITY th.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Presentations of its Supportive Phase 3 Clinical Study (ultraVIOLET) Evaluating the Safety and Efficacy of Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) and Susceptibility Testing ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Expands its Generic Formulations Portfolio with the Launch of Everolimus Tablets in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Gets DCGI Nod to Conduct Phase III Trials for Two-Dose Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NVL-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PH-894","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presents Preclinical Data on Its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Alpha CD27 mab","moa":"Anti-CD27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Upadacitinib (RINVOQ\u00ae) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's RINVOQ\u00ae (Upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"PolarityTE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolarityTE Provides Update on Investigational New Drug Application","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SkinTE","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"PolarityTE","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolarityTE \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PolarityTE.."},{"orgOrder":0,"company":"Second Genome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SG-3-0020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Second Genome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Gen.."},{"orgOrder":0,"company":"MinervaX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MinervaX Provides Clinical and Leadership Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"GBS-NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"MinervaX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces FDA and EMA Filing Acceptances of Beovu\u00ae for Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis To Present Broad Range of Portfolio Data At ECTRIMS, Reinforcing Long-Standing Commitment to People Living with Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kesimpta\u00ae (ofatumumab) Data at ECTRIMS Highlights Preservation of Ig G Levels and Safety Experience Over Extended Exposure (~3.5 Years) in People Living with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data for EDP-235, Enanta\u2019s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-235","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ABC008","moa":"KLRG1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Abcuro, Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abcuro, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin beta-1 chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Th.."},{"orgOrder":0,"company":"Precirix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precirix Dosed First Patients in Phase I\/II Clinical Study Evaluating CAM-H2 in HER2-Positive Metastatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cam-H2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Inc. Receives Notification From the PCT That Its International Patent Application Has Been Published (Publication No. WO2021\/188612)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Sublingual Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA Antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives Authorization to Initiate Phase 1\/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Reports Data from Phase 2\/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura\u2122) in Patients With Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Elasomeran mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scancell","sponsor":"University of Cape Town Lung Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in COVIDITY Phase 1 Clinical Trial In South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SCOV1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scancell \/ University of Cape Town Lung Institute","highestDevelopmentStatusID":"6","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart\u2009Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"ALX Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks And ALX Oncology Announce First Patient Dosed In Phase 1b\/2 Clinical Trial Of Zanidatamab And Evorpacept (ALX148) In Patients With Advanced HER2-Expressing Breast Cancer And Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Evorpacept","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ ALX Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Carmustine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Effector Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ALLO-501A","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"LAVA-051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Kratom Extract","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924\u2019s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Nationwide Children\u2019s Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals and Nationwide Children\u2019s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs\u2019 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-omburtamab-DTPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"KIN-2787","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"MRT-048","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Amunix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ N.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IK-930","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2\/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrospective Analysis of Pooled Results from Three Studies Shows COSELA\u2122 (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Elzovantinib","moa":"MET\/SRC\/CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals to Present Virology and Early Clinical Data at the ISIRV-WHO Virtual Conference 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CVL-871","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi: Positive Results from The First Study of High-Dose Influenza Vaccine With a COVID-19 mRNA Booster Support Co-Administration Recommendations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Influenza Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data Reinforcing Promising Safety and Efficacy Profile of Brain-Penetrant Tolebrutinib Presented at ECTRIMS 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolebrutinib","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1\/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"DCC-3116","moa":"ULK kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM20324","moa":"Interleukin-38","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"FT-7051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTX-009 (ABL001\/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CTX-009","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tachyon Presents TACH101 Data at the 2021 AACR-NCI-EORTC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tachyon Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tachyon Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tachyon Te.."},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program for Advanced Solid Tumors or Lymphomas at AACR-NCI-EORTC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"E7766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"H3 Biomedicine Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"H3 Biomedicine Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"H3 Biomedi.."},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gland Pharma Receives Tentative Approval for Sugammadex Injection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sugammadex Sodium","moa":"Sugammadex?rocuronium chelating complex","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHAR.."},{"orgOrder":0,"company":"Enzyvant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzyvant Receives FDA Approval for RETHYMIC\u00ae (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Processed Thymus Tissue-agdc","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Enzyvant","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzyvant \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Enzyvant \/.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval From USFDA for Adapalene and Benzoyl Peroxide Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Adapalene","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Application Seeking U.S. FDA Approval of STELARA\u00ae (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Merus","sponsor":"Chiltern International Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Petosemtamab","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merus \/ Chiltern International","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Ch.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Center for Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ONCT-534","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Center for Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Launches Tavulus\u00ae for COPD Treatment in Spain, Becoming One of The First Companies to Launch a Bioequivalent Version of The Dry Powder Inhaler","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder Inhaler","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces BRUKINSA\u00ae (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1\/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"4D-125","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Presents Positive Initial Data from Phase Ii Altitude\u2122 Trial of RGX-314 for The Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Announces the Results of MODIFY, a Phase 3 Study of Lucerastat in Fabry disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lucerastat","moa":"GCS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Hard Gelatin Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rusfertide","moa":"Iron homeostasis","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 Targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CTL-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Announces Several Patents Granted by USPTO, Strengthening the Company\u2019s Intellectual Property Position in Ingestible Therapeutics Technologies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-020572","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Presents Preclinical Data on Synergy Between Derazantinib and Paclitaxel in Gastric Tumor Models At ANE Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION - Positive Phase 2 Part A THR-149 Data Shared at The America Society of Retinal Specialists (ASRS) Annual Scientific Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA\u00ae (tafenoquine) for Treatment of Mild-Moderate Covid-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110\u2122 in Relapsed or Refractory CD19+ B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CTX110","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HyBryte\u2122 FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Reports Positive Data on ImmCelz\u2122 Immunotherapy Product","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic Fluid Derived Stem Cells","moa":"HGF-1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Screening to Resume in IntelGenx\u2019s \u2018BUENA\u2019 Montelukast VersaFilm\u00ae Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI\u00ae (Cenobamate Tablets) CV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Sc.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u2019 Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Medolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medolife Rx Reports 257% Increase in Efficacy of Ibuprofen Through Proprietary Polarization Method, Looks to Expand Into Other APIs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Medolife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Medolife \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medolife \/.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"GPH101","moa":"Hemoglobin beta chain","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present at 12th Annual World ADC Digital Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ARC-01","moa":"CD79","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV\u00ae (Enfortumab Vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Files an International Patent Application Covering Psychedelic Delivery Methods","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CYB004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"kt-3000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN\u237a2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Expands CMC and Clinical Teams","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apeiron Biologics Begins Phase 1 Trial to Treat Covid-19 with Inhaled APN01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Alunacedase Alfa","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalational","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biological E Seeks DCGI's Nod for Phase-3 Trial of Corbevax as Booster Dose in Those Vaccinated with Covishield or Covaxin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intas launches the World's First SB-100mg Itraconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Itraconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Intas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intas Phar.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces World\u2019s First Gene Editing Clinical Trial for PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"HMI-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"RGLS8429","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI\u2122 (Aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Planning to Trial Oral COVID Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SJP-002C","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"Sofie Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"[68Ga]FAPI-46","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sofie Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sofie Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sofie Bios.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients\u201490% of Patients Have Exceeded Historical Survival Rates to Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin Hydrochloride","moa":"IL-15 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA\u00ae (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Real-World MAVENCLAD\u00ae Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM\u25bc (Ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Safety Data on Treatment with COPAXONE\u00ae (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Agilent Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Verzenio\u00ae (abemaciclib) as the First and Only CDK4\/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Agilent","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN\u00ae to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Four-Year Data Show Roche's ENSPRYNG Significantly Reduces Debilitating Relapses in People with Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Gazyvaro Shorter 90-Minute Infusion Time Approved in Europe for People with Previously Treated or Untreated Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Obinutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2 Antibody Drug Conjugate (TROP-2 ADC) for Multiple Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SKB264","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Selective androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Biosciences to Present New Data for the ImmTOR\u2122 platform at the ESGCT 28th Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ImmTOR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Safety and Efficacy Data of Vafidemstat from The Phase II SATEEN Trial in Multiple Sclerosis At ECTRIMS-2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"DYNE-251","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP1867","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Smart Immune Receives IRB Approval For Phase 1\/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcell\u2122) for AML and ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic T Cell Progenitors","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b\/3 Clinical Trial of ANAVEX\u00ae2-73 in Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1\/2a Human Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at ECTRIMS 2021 Highlight Biogen\u2019s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Provides Corporate Update Following Type A Meeting with FDA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"APL-1202","moa":"MetAP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asieris Pharmaceuticals \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pindolol","moa":"Beta-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data up to 8-years for Roche\u2019s OCREVUS (Ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New SARCLISA\u00ae (Isatuximab for Injection) Combination Now Approved by Health Canada for Adults with Relapsed and\/or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2\/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone Covid-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR\u2122 mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD\u2019S The Liver Meeting\u00ae 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx\u2019s VAZALORE Specifically Indicated for Secondary Prevention","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid-Filled Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics to Present New Real-World Experience Data for JATENZO\u00ae (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Augmenta Bioworks","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aug-3387","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder For Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Augmenta Bioworks","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity\u00ae Genetic Testing Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Viridian Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R Antibody for The Treatment Of Thyroid Eye Disease, to the U.S. Food and Drug Administration","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viridian Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian S.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2a","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Seribantumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents \u22652 to <18 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generation Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli\u00ae (Pegcetacoplan) for the Treatment of PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Tremelimumab Significantly Improved Overall Survival In HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension For Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rapid Advancement of Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AK120","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene to Present Data of Its PD-L1\/4-1BB Bispecific Antibody ATG-101 and ERK1\/2 Inhibitor ATG-017 at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Manufacturing Commences on Adhera\u2019s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Armesocarb","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adhera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adhera The.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPSYNVI\u00ae (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Macitentan","moa":"Endothelin-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Showcase New Data at AASLD The Liver Meeting\u00ae 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New 4-Year Data Show Genentech\u2019s Enspryng (Satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety Results from Large Real-World Safety Study in Combined Oral Contraception Published","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nomegestrol Acetate","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension For Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (Ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for RYBREVANT\u00ae (Amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Clinical Trial Data of NurOwn\u00ae in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts REGEN-COV\u00ae (Casirivimab and Imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00aePartner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adlai Nortye \/ Oncolytics Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Medivir","sponsor":"Rheos Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Joint Patent Application For MALT1 Inhibitors Published","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medivir \/ Rheos Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (Pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS \u22651)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Iodide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Faraday Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Faraday Ph.."},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Adocia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adocia\u2019s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone\u00ae Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Tonghua Dongbao Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Adocia","highestDevelopmentStatusID":"6","companyTruncated":"Tonghua Do.."},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451\/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMG 451","moa":"OX40","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Granted Breakthrough Therapy Designation in US For Patients With HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"NICE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Recommends First Treatment in Two Decades for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Crizanlizumab","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NICE","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NICE \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NICE \/ Not.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196\/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of Evusheld (Tixagevimab and Cilgavimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin\u00ae Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Corticotropin","moa":"ACTH","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Cirmtuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncternal Therapeutics \/ Celularity","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Comet Therapeutics","sponsor":"VectivBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VectivBio Announces Closing of Comet Therapeutics Acquisition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"VB-1197","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Comet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Comet Therapeutics \/ VectivBio Holding","highestDevelopmentStatusID":"4","companyTruncated":"Comet Ther.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Shares Jump 12% After Highlighting Promising Data from Uproleselan Leukemia Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"INNA-051","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Frazier Life Sciences Public Fund","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone Announces Private Placement Financing of $55.0 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Private Placement","leadProduct":"Self-amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Gritstone bio \/ Frazier Life Sciences Public Fund","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vincerx Pharma Announces $50 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Private Placement","leadProduct":"VIP152","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Deerfield Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"GSK","sponsor":"U.S. government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DeSantis Says Florida Acquired Glaxosmithkline Monoclonals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"GSK \/ U.S. government","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ U.S..."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Narcotic","amount2New":0.01,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Stifel","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Regulatory Timeline for Review of MAA in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","amount":"$72.3 million","upfrontCash":"$7.5 million","newsHeadline":"Basilea\u2019s Partner Asahi Kasei Pharma Filed New Drug Application For the Marketing Authorization of Isavuconazole in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Partnership","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"ARYA Sciences","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$50.0 million","newsHeadline":"Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: \u201cCaritas Therapeutics\u201d","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.59999999999999998,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ ARYA Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Viela Bio","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammatory Disease Biotech Ventyx Biosciences Files for A $100 Million IPO","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"VTX958","moa":"Allosteric TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Viela Bio","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Three-Year Switch Data for Dovato (dolutegravir\/lamivudine) Confirming Long-Term, Non-Inferior Efficacy with No Virologic Failure versus Continuation of Taf-Based Regimens of At Least Three Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Announces Successful Completion Of Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetravalent Recombinant Chimeric Dengue Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI112","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"MYCO-003","moa":"Serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Concludes Study on COVID Drug Favipiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Wave Life Sciences and Takeda Amend CNS Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"WVE-004","moa":"C9orf72 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Antares Pharma","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$11.0 million","newsHeadline":"Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO\u00ae in U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Antares Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Dextromethorphan","moa":"NMDA receptor subunit epsilon 1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Calithera Biosciences","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$10.0 million","newsHeadline":"Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Sapanisertib","moa":"TORC1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Takeda Pharmaceutical","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Calithera Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Tebentafusp","moa":"gp100","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$446.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"METTL3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Accent The.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Kedrion","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Lyophilized Powder For Injection","sponsorNew":"Kedrion \/ Kedrion Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Locus Biosciences Secures Financing of up to $25 Million from Hercules Capital","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Engineered Bacteriophage","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Locus Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Locus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"3","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"ATI-2173","moa":"Active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Antios Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CareDx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CareDx \/ E.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Reprocell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Extends Partnership Agreement with REPROCELL","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"HT-003","moa":"TLR2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Reprocell","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"InflaRx","sponsor":"German Federal Government","pharmaFlowCategory":"D","amount":"$50.7 million","upfrontCash":"Undisclosed","newsHeadline":"InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ German Federal Government","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Clovis Oncology \/ ITM Isotope technologies","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"FSD Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Lucid-PSYCH","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Covar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Covar Pharmaceuticals \/ FSD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Covar Phar.."},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"DS Asset Management","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"D&D Pharmatech Raises $51M in Series C Financing to Advance Potential Disease-Modifying Treatments for Neurodegenerative, Fibrotic, and Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series C Financing","leadProduct":"DD01","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"D&D Pharmatech","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"D&D Pharmatech \/ DS Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"D&D Pharma.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"Debio 1453","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Oncolys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Announces the Decision of the Termination of Exclusive License Agreement on OBP-301 (Telomelysin), Oncolytic Viral Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Termination","leadProduct":"Pembrolizumab","moa":"Telomerase reverse transcriptase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Oncolys","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax\u00ae-enabled Flu Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Recombinant Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enesi Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Enesi Pharma Limited \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enesi Phar.."},{"orgOrder":0,"company":"Pharmaron","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"OLX703A","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pharmaron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmaron \/ OliX Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaron .."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,367.5 million","upfrontCash":"$17.5 million","newsHeadline":"F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tetravalent Bispecific Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"F-star Therapeutics","amount2":1.3700000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3700000000000001,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Janssen","highestDevelopmentStatusID":"2","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Ab Magnitude Ventures Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Ab Magnitude Ventures Group","highestDevelopmentStatusID":"2","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Cytoreason","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoReason Collaborates with Merck KGaA, Darmstadt, Germany, on Cancer Immunotherapy Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytoreason \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ The Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Immunoglobulin G Protease","moa":"Neutralizing antibodies","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Genovis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genovis \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genovis \/ .."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"U.S. Food & Drug Administration","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ U.S. Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Specialised Therapeutics \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"$2.0 million","newsHeadline":"Luoxin Pharmaceutical Signs Licensing Agreement With Austria-based Marinomed Biotech AG for Budesolv\u00ae Budesonide Nasal Spray","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Marinomed Biotech","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Nasal Spray","sponsorNew":"Marinomed Biotech \/ Shandong Luoxin Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Signs New Initial Agreement With BioNTech To Support Fill and Finish of The mRNA Pfizer-BioNTech COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"CR Double-Crane Pharmaceuticals Co., Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand\u2019s BEPro Technology\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"BEPro-enabled COVID-19 antiviral","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ligand Pharmaceuticals \/ Double-Crane Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Mablink Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergence Therapeutics \/ Mablink Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Emergence .."},{"orgOrder":0,"company":"Tiumbio","sponsor":"Oncodesign","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Nanocyclix Drug Candidates","moa":"kinase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Tiumbio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiumbio \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Tiumbio \/ .."},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"LSP","pharmaFlowCategory":"D","amount":"$46.4 million","upfrontCash":"Undisclosed","newsHeadline":"Egle Therapeutics Raises 40 Million \u20ac Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"T-regulatory Cells Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Egle Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ LSP","highestDevelopmentStatusID":"4","companyTruncated":"Egle Thera.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Acino Pharma","pharmaFlowCategory":"D","amount":"$119.4 million","upfrontCash":"Undisclosed","newsHeadline":"Acino Acquires Selected Aspen Brands in South Africa","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.12,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Aspen Pharmacare Holdings \/ Acino","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$82.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cedilla Therapeutics Completes $82.6M Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Cedilla Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Th.."},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CICC Capital","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"CASI Pharmaceuti\u00ad\u00ad\u00adcals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series C Financing","leadProduct":"CNCT19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Juventas Cell Therapy","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Juventas Cell Therapy \/ CICC Capital","highestDevelopmentStatusID":"8","companyTruncated":"Juventas C.."},{"orgOrder":0,"company":"Resilia Pharmaceuticals","sponsor":"Pelle Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Resilia Pharmaceuticals Acquires License to Commercialize Solace\u2122 Eczema Cream in the United States","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Resilia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Resilia Pharmaceuticals \/ Pelle Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Resilia Ph.."},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Mabylon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Human Auto-antibodies","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"SciNeuro Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciNeuro Pharmaceuticals \/ Mabylon","highestDevelopmentStatusID":"3","companyTruncated":"SciNeuro P.."},{"orgOrder":0,"company":"Nippon Kayaku","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Darinaparsin","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nippon Kayaku","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nippon Kayaku \/ Solasia Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Nippon Kay.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$250.0 million","newsHeadline":"AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ Sagard Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Scriptr","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CANbridge Pharmaceuticals Enters into Exclusive Worldwide Research Collaboration and Licensing Agreement with Scriptr Global for Stitchr\u2122 RNA Assembly Technology to Develop Gene Therapy Product Targeting Dystrophinopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scriptr","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scriptr \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Scriptr \/ .."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Destum Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Phosphorylated HexaAcyl Disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Drop","sponsorNew":"Revelation Biosciences \/ Destum Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo\u00ae and Yervoy\u00ae in Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Gavocabtagene Autoleucel","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ TCR2 Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","amount":"$18.4 million","upfrontCash":"Undisclosed","newsHeadline":"OncoNano Announces $18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"ONM-501","moa":"STING protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoNano Medicine","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral","sponsorNew":"OncoNano Medicine \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"4","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Pharmaceuticals Enters Collaboration Agreement with Merck","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xeris Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quanta Therapeutics Announces Oversubscribed $60 Million Series C Financing to Advance Novel RAS-targeting Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Quanta Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"4","companyTruncated":"Quanta The.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aragen Life Sciences \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo\u00ae for Eligible Patients With Multi-Drug Resistant HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Ibalisumab","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Italian Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ubiquigent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ubiquigent Extends and Expands Drug Discovery Collaboration With Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Ubiquigent Limited","highestDevelopmentStatusID":"3","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD8 Treg Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Mozart Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Mozart Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Mozart The.."},{"orgOrder":0,"company":"Curacle","sponsor":"Th\u00e9a Open Innovation","pharmaFlowCategory":"D","amount":"$2,163.5 million","upfrontCash":"$6.0 million","newsHeadline":"CURACLE and Th\u00e9a Announce Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"CU06","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Curacle","amount2":2.1600000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":2.1600000000000001,"dosageForm":"Capsule","sponsorNew":"Curacle \/ Th\u00e9a Open Innovation","highestDevelopmentStatusID":"6","companyTruncated":"Curacle \/ .."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silo Pharma \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"Cryostem","sponsor":"Rheos Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1\u2011Targeted Therapeutics for Graft-versus-Host-Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"RHX-317","moa":"MALT1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cryostem","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cryostem \/ Rheos","highestDevelopmentStatusID":"5","companyTruncated":"Cryostem \/.."},{"orgOrder":0,"company":"Biomica","sponsor":"Rambam Health Care Campus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomica & Rambam Health Care Campus Sign Agreement for Clinical Trial of Biomica's Microbiome-Based Immuno-Oncology Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Rambam Health Care Campus","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Novitium Pharma LLC","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Carglumic Acid","moa":"CPS1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Novitium Pharma LLC","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novitium Pharma LLC \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novitium P.."},{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palette Life Sciences Secures Loan Facility for Up to $40 Million with Silicon Valley Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Palette Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palette Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":"12","companyTruncated":"Palette Li.."},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"U.S. Army Medical Research Acquisition Activity","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"IC 800","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"IACTA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"IACTA Pharmaceuticals \/ U.S. Army Medical Research Acquisition Activity","highestDevelopmentStatusID":"4","companyTruncated":"IACTA Phar.."},{"orgOrder":0,"company":"Origo Biopharma","sponsor":"AgomAb Therapeutics N.V","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agomab Therapeutics to Acquire Origo Biopharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"ORG-129","moa":"TGF-beta","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Origo Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Origo Biopharma \/ Agomab","highestDevelopmentStatusID":"6","companyTruncated":"Origo Biop.."},{"orgOrder":0,"company":"Kinectrics","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Ytterbium-176","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kinectrics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinectrics \/ POINT Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kinectrics.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Lipidor Submits New Patent Application and Expands Collaboration with Cannassure Using Lipidor's AKVANO\u00ae Technology for Medicinal Cannabis Products","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"Enkephalin","moa":"MAO transporter","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Societal CDMO \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Albert Einstein College of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orange Grove Bio, AlleyCorp and Alexandria Venture Investments Establish Partnership with Albert Einstein College of Medicine to Support Development of Novel Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orange Grove Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Albert Einstein College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Orange Gro.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"LNP-based RNA Therapy","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence\u2019s mRNAi GOLD\u2122 Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Teneobio","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"$900.0 million","newsHeadline":"Amgen Successfully Completes Acquisition Of Teneobio, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Teneobio","amount2":2.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5,"dosageForm":"Intravenous Injection","sponsorNew":"Teneobio \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Teneobio \/.."},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$691.0 million","upfrontCash":"$41.0 million","newsHeadline":"Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"In-vivo Gene-editing Therapies","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Mammoth Biosciences","amount2":0.68999999999999995,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"Mammoth Biosciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mammoth Bi.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR\/Cas9 Technology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"SPVN50","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ SparingVision","highestDevelopmentStatusID":"2","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"The Medici.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Funding","leadProduct":"Antiviral drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Antisense Oligonucleotides","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Secarna","highestDevelopmentStatusID":"3","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA\u00ae (Pembrolizumab) for Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"HMBD-002","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Alcami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Alcami Corporation","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Longbow Immunotherapy","sponsor":"Versiti Blood Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Longbow Immunotherapy Launches ReACT, A Novel CAR-T Platform Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"CAR-T cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Longbow Immunotherapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longbow Immunotherapy \/ Versiti Blood Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Longbow Im.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National University Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"ADG106","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ National University Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"HistoIndex","sponsor":"Galecto","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"GB2064","moa":"LOXL2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HistoIndex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HistoIndex \/ Galecto","highestDevelopmentStatusID":"8","companyTruncated":"HistoIndex.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kedrion enters into Agreement with Liminal BioSciences","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Kedrion","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibody Treatment For MIS-C Works by Depleting Inflammatory Immune Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Immuno Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Labs Launches Copy of BI Drug; Move May Lead to Legal Battle","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"PAO Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PAOG to Launch Second CBD Nutraceutical Product Later This Week Further Ramping Up 2021 Revenue Potential","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"PAO Group","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"PAO Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PAO Group .."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"HMI-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"UX701","moa":"ATP7B copper transport","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Completes Submission of Manufacturing Data for Tesomet Capsules To U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Triple monoamine reuptake","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BX001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progress Update on Tyvaso DPI\u2122 New Drug Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder For Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Granted Orphan Drug Designation by the FDA for SOM3355","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"SOM3355","moa":"VMAT2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SOM Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotec.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AOC 1001","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Shanghai Public Health Clinical Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"UB-621","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United BioPharma \/ Shanghai Public Health Clinical Centre","highestDevelopmentStatusID":"6","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"APG-5918","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABX464 Shows Excellent Long-Term Efficacy Data in Abivax's Phase 2b Maintenance Trial in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ADX-097","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present STP705, the Company's Lead Drug Candidate, for the Treatment of Cutaneous Squamous Cell Carcinoma in situ, at the 2021 Fall Clinical Dermatology Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Launches Study to Evaluate AXL inhibitor AB-329 in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AB-329","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ I.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Receives FDA Approval for ZIMHI","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Over-Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1\/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Non-competitive autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Clears Xilio Therapeutics\u2019 IND Application for XTX202 to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"XTX202","moa":"Tumor-selective IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Labs Receives US FDA Approval for Generic Revlimid","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biological E Seeks DCGI Nod for Phase-3 Trial for Booster Dose Vaccine Corbevax for Fully Vaccinated People","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"4-L-[131I] iodo-phenylalanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"OSE-279","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Ambulero","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambulero\u2019s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AMB-301","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ambulero","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ambulero \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ambulero \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Inc. to Present Pre-Clinical Data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"OCU410","moa":"RAR Related Orphan Receptor A gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia\/Lymphoma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tucidinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Ortho Dermatologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health Companies","highestDevelopmentStatusID":"12","companyTruncated":"Ortho Derm.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANANDA Scientific\u2019s Liquid Structure\u2122 Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Sci.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV\u2013WHO Virtual Conference 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-235","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tirzepatide Results Published in The Lancet Show Superior A1C and Body Weight Reductions Compared to Insulin Glargine in Adults with Type 2 Diabetes with Increased Cardiovascular Risk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways is Granted New US Patent for Crystalline Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"DMT310","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Reports Positive Data From Phase III Acinetobacter Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Results for PHYOX\u21224, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics to Present Preclinical Data from mRNA-based Program for Cystic Fibrosis at Upcoming Virtual 2021 North American Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based antibody","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Seraph Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Announces the Successful Completion of an FDA pre-IND For a Potential Cure For HIV: The Second Pre-IND in 1 Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ENOB-HV-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Seraph Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Approval of Dupixent\u00ae (Dupilumab) to Include Children Aged 6 to 11 Years with Moderate-To-Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes the Results of The NATIVE Phase IIb Clinical Trial with Lanifibranor in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Gamma-delta T Cells in Science Translational Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized anti-Butyrophilin 3A Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data from Editas Medicine\u2019s Ongoing Phase 1\/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy At Virtual Congress Of The European Society Of Gene And Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"GBA1 Gene Replacement Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air\u00ae Reports Positive Interim Results for LungFit\u00ae GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-3001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open-label Study of COMP360 Psilocybin Therapy for Depression in Cancer Patients Demonstrates Feasibility of Simultaneous Psilocybin Administration in Small Groups","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Numinus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Numinus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numinus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Numinus \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn\u00ae Aos for Hard-To-Heal Ulcers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nexodyn Acid-oxidizing Solution","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray Solution","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Healx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healx Receives Ind and Orphan Drug Designation for Fragile X Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"HLX-0201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Healx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Healx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Healx \/ No.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\"House Rules\" Delivers Strong Initial Results and Drives Phexxi Growth","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lactic Acid","moa":"pH level","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Present Data Demonstrating Successful Inhibition of Covid19 Viral Variants with Ensovibep at The 2021 ISIRV-WHO Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dinitrophenyl Modified S-spike Protein of SARS-CoV-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Felzartamab","moa":"CD38","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"STAT-205","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Statera Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Statera Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tegavivint","moa":"TBL1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Gets Interim Injunction Against Dr. Reddy\u2019s Labs, MSN Labs Against Copies of Anti-Diabetes Drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics to Present at the 6th Biennial Canadian Cancer Research Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Kt-3000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CB-280","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Forms Steering Committee for Phase 2a PASSPORT Clinical Trial to Evaluate FW-ICI-AC in Cancer Patients with Immune Checkpoint Inhibitor-Associated Colitis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"reMYND","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"reMYND\u2019s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer\u2019s, Has Moved to MAD phase After Demonstrating Strong Safety In SAD Phase","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"RES19-T","moa":"Calcium dyshomeostasis restoration","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"reMYND","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"reMYND \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"reMYND \/ N.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Phase 2 Clinical Study of \u20181104 in Allergic Disease in the UK","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder For Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approval Of Mixing and Matching of COVID Booster Shots By FDA is yet Another Confirmation of Efficacy of Vaccine Cocktail Approach Pioneered by The Russian Sputnik V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior to Present New Data on Opioid Use Disorder at CSAM-SMCA 2021 Scientific Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA\u00ae (Teprotumumab-trbw) for Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"S-217622","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Presents Long-Term Switch Data Reinforcing Biktarvy\u00ae as a Treatment Option for a Broad Range of People Living With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Currax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Currax Pharmaceuticals Granted Type C Meeting with FDA Regarding its Phase 3 Study to Evaluate the Safety and Efficacy of CX-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Currax","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Currax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine\/Islatravir for the Treatment of People with HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Peter MacCallum Cancer Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa\u2019s Pidnarulex to Combined With Pfizer\u2019s Talazoparib in a Clinical Trial for the Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pidnarulex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Axalbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AX-8","moa":"TRPM8","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Axalbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Notice Regarding the Progress of Phase 2\/3 Clinical Trial for New Formulation of COVID-19 Recombinant Protein-based Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"S-268019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatas","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Bovine Intestinal Alkaline Phosphatase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery of ceDNA and mRNA at the European Society of Gene and Cell Therapy 2021 Annual Virtual Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Closed-ended DNA","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Generation Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Neoantigen Reactive T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso is Rapidly Advancing the Clinical Study of The PD-1\/CTLA-4 Bispecific Antibody Cadonilimab Combined With TIGIT Monoclonal Antibody for The Teratment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AK127","moa":"TIGT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adtralza\u00ae (Tralokinumab) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Issues Voluntary Nationwide Recall of CUBICIN\u00ae (Daptomycin for Injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Daptomycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Susvimo, a First-Of-Its-Kind Therapeutic Approach for Neovascular or \u201cWet\u201d Age-Related Macular Degeneration (nAMD)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Vigabatrin for Oral Solution USP, 500mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Top-Line Results for CANOPY-1 Phase III Study Support Further Evaluation of Canakinumab in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Dupixent\u00ae (Dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO's Advisory Group Set to Meet on October 26 to Decide on Covaxin EUL Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA\u00ae (Pembrolizumab) Plus LENVIMA\u00ae (Lenvatinib) in Two Different Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE\u2122 (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"Sodium-dependent serotonin transporter negative","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1\/GIP Agonists at ObesityWeek 2021","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Neurodon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curative Potential for Diabetes, Alzheimer\u2019s and Parkinson\u2019s Seen in Research Data Highlighted at Neurodon\u2019s 2nd Annual Scientific Advisory Board Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NDC-0009","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Neurodon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurodon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurodon \/.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today\u2019s Virtual R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"GDA-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite CEO to Present Namodenoson\u2019s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes the First Company to Launch Remogliflozin + Vildagliptin + Metformin Fixed Dose Combination, at An Affordable Price for Adults with Type 2 Diabetes in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Remogliflozin Etabonate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Priority Review by US FDA and Filing Acceptance By EMA for Kymriah\u00ae To Treat Patients with Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio to Present New Sub-Analysis from Phase 1b\/2a NASH Study of BIO89-100 at AASLD\u2019s The Liver Meeting 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TEV 47948","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1\/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1\/2 Clinical Trial in Patients with Choroideremia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"4D-310","moa":"GLA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Epinephrine Prodrug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"S011806","moa":"IL-17","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and\/or Eosinophilic Duodenitis with Systematic Evaluation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Begin Phase 1\/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-C3","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lancet's EClinicalMedicine Publishes Phase 2 Data On C21 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Will Feature New Data At The American College Of Gastroenterology\u00ae 2021 Annual Scientific Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch health","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson\u2019s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax\/BSK01, Company\u2019s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BSK01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA\u00ae (Pegloticase Injection) with Methotrexate","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliPass \/ .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Attenuted Listeria Monocytogene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Receives Ethics Approval to Start Phase I Intravenous Clinical Trial of RECCE\u00ae 327","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"R327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives U.S. Orphan Drug Designation for Alvelestat in the Treatment of Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Present New ORLADEYO\u00ae (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"HGF","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"VXA-CoV2-1.1-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for Endari\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nova Mentis Life Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nova Mentis Life Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nova Menti.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces FDA Approval of TAVNEOS\u2122 (Avacopan) in ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Announces Expansion of Translarna\u2122 Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ataluren","moa":"80s ribosome","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2a","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"Mucin-16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Enrolls Phase 1a\/1b Clinical Trial of BHV-1100, Lead Asset from its ARM\u2122 (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Cytokine Induced Memory-Like NK Cell","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biohaven Pharmaceuticals \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cleveland Clinic Launches First-of-its-Kind Preventive Breast Cancer Vaccine Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Anixa Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics to Present Data on its INDUKINE\u2122 Product Candidates at the Society for Immunotherapy of Cancer Annual Meetin","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"WTX-124","moa":"Interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZSTARYS\u00ae, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present New Data from Comprehensive Finerenone Clinical Trial Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Gabaeron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GABAeron Presents Promising Preclinical Data on Stem Cell-Based Therapy for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Human IPSC Derived Interneuron Progenitors","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Gabaeron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gabaeron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gabaeron \/.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion of Enrollment in Phase III Comparative Study for Investigational Regenerative Cellular Medicine (gMSC\u00ae1) for Knee Chondrogenesis Using Allogeneic 3D Artificial Tissue of MSC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Gingival Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Multi-modular Engineered Treg Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quell Ther.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Cochlear Limited","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Dilafor Recruits First Patient to Phase 2a Study of Tafoxiparin in Women Diagnosed with Preeclampsia","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafoxiparin","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Synagile","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with the DopaFuse\u00ae Delivery System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solaris Pharma Receives FDA Approval for Generic Metrogel-Vaginal\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Solaris Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Solaris Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Solaris Ph.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech to Launch Novel Candidate Therapy for Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CAR90972","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Holdings Provides Update on Rafael Pharmaceuticals\u2019 Two Phase 3 Trials of CPI-613\u00ae (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Verzenio\u00ae (Abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive Interim Data Showing Vocabria (Cabotegravir) and Rekambys (Rilpivirine) Can Be Implemented Successfully in A Variety of European Healthcare Settings","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Says Trying to Find Marketing Partner, or Open to Possible Sale of Specialty Drug Solosec","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral Granules","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Optimus Pharma","sponsor":"JSS Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Optimus Pharma Seeks Approval to Produce Generic Merck COVID-19 Pill","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Optimus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Optimus Pharma \/ JSS Research","highestDevelopmentStatusID":"10","companyTruncated":"Optimus Ph.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Novartis Scemblix\u00ae (Asciminib), With Novel Mechanism of Action for The Treatment of Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Significant ADHD Symptom Improvement with 30-Minute Onset and 13-Hour Duration of Efficacy Delivered by Once-Daily Corium Product AZSTARYS\u00ae (Serdexmethylphenidate and Dexmethylphenidate) in Children Ages 6 to 12 Years","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Recruited Into Alzinova's Phase 1b Clinical Study with The Oligomer-Specific ALZ-101 Vaccine Against Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ALZ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma Inc. Provides VAZALORE Launch Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid-Filled Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy\u00ae in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Patent Office Maintained Bayer Patent on The Once-Daily Administration of Rivaroxaban (Xarelto\u2122)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of \u20181104 in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Lyophilised Powder For Intravenous","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Hetero Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco and Hetero Awaiting Market Authorization from DCGI on Molnupiravir After Submitting Phase-3 Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Hetero","highestDevelopmentStatusID":"10","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Provides Regulatory Update Following Type A Meeting with FDA on Arimoclomol in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics to Present \u201cConquering Pneumonia and Systemic Inflammation with a Human Protein,\u201d at the MACRO Trends Investor Conference in Belgium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000\/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1\/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Cyltezo\u00ae (Adalimumab-adbm) as First Interchangeable Biosimilar with Humira\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Receive First U.S. FDA Emergency Use Authorization of a Covid-19 Vaccine in Children Ages 5 Through 11 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Development Progress of mRNA COVID19 Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"REC-2282","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"REC-4881","moa":"MEK1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves VUITY\u2122 (Pilocarpine HCI Ophthalmic Solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Cariprazine (VRAYLAR\u00ae) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI\u00ae) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces ABBV-951 (Foslevodopa\/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa\/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ancora Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TNB-486","moa":"CD19xCD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Ancora Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma, MSN Labs Seek DCGI Nod for Phase-III Trials of Merck's Molnupiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Rhoshan Pharmaceuticals","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$0.7 million","newsHeadline":"Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Aspirin","moa":"COX","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Rhoshan Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous","sponsorNew":"Rhoshan Pharmaceuticals \/ Hyloris","highestDevelopmentStatusID":"1","companyTruncated":"Rhoshan Ph.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Pharmapark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara\u00ae Biosimil","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Pharmapark","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"EyeGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechnologies\u00ae Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"EG-COVID mRNA COVID-19 vaccine","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TriLink BioTechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ EyeGene","highestDevelopmentStatusID":"5","companyTruncated":"TriLink Bi.."},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$450.0 million","newsHeadline":"Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pha.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Neumora therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Amgen","highestDevelopmentStatusID":"2","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"Sanofi to Acquire Kadmon to Further Strengthen Growth of Transplant Business","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":1.8999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":1.8999999999999999,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Bio Presents Positive Phase 3 Data on BRII-196\/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MSN Labs Launches Generic Cangrelor, a New Drug for PCI To Reduce Risk of MI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MSN Labora.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Expands LANCER, a Phase II\/III Trial of CardiolRx\u2122, into Brazil, Mexico, and Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Autogene Cevumeran","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation (ODD) to AlloVir\u2019s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca to Transfer Global Rights For Eklira and Duaklir to Covis Pharma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.27000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.27000000000000002,"dosageForm":"Inhalation Powder","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$151.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Public Offering","leadProduct":"VTX002","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.14999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Collaborates with Columbia University & Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BridgeBio Pharma \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"University of Georgia","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"PDS0202","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"University of Georgia \/ PDS Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Mustang Bio \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and Almirall Enter an Exclusive Licensing Agreement to Market Finjuve in the Middle East and North Africa Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Almirall \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Hopstem Biotechnology","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"HOPSTEM Completed 40 Million USD Series B Financing, to Develop Safe, Effective and Affordable iPSC Cell Therapies for Global Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"hNPC01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hopstem Biotechnology","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Hopstem Biotechnology \/ Lilly Asia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Hopstem Bi.."},{"orgOrder":0,"company":"Antiva Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antiva Biosciences Closes $31 Million Series D Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series D Financing","leadProduct":"ABI-2280","moa":"HPV replication","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antiva Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Antiva Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"Antiva Bio.."},{"orgOrder":0,"company":"Dunad Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,324.0 million","upfrontCash":"$24.0 million","newsHeadline":"Dunad Therapeutics Enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dunad Therapeutics","amount2":1.3200000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3200000000000001,"dosageForm":"Oral","sponsorNew":"Dunad Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Dunad Ther.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"AB-729","moa":"Active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Burning Rock Dx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in Both US And China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"IMP9064","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IMPACT Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"IMPACT Therapeutics, Inc \/ Burning Rock Biotech Limited","highestDevelopmentStatusID":"5","companyTruncated":"IMPACT The.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher Holdings Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Clade Therapeutics","sponsor":"Syncona Ltd.","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"Induced Pluripotent Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Clade Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Clade Therapeutics \/ Syncona Ltd.","highestDevelopmentStatusID":"2","companyTruncated":"Clade Ther.."},{"orgOrder":0,"company":"Koneksa","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Koneksa Broadens Multi-Year CNS Research Collaboration with Sanofi","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Tolebrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Koneksa","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Koneksa \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Koneksa \/ .."},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biond Biologics Announces Closing of $15 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series C Financing","leadProduct":"BND-22","moa":"ILT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous","sponsorNew":"Biond Biologics \/ Deep Insight","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biol.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Sands Capital","pharmaFlowCategory":"D","amount":"$43.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prilenia Closes Oversubscribed $43 Million in Series B Financing Round","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Sands Capital","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hims & Hers Health, Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Hims & Hers Health, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$517.0 million","upfrontCash":"$37.0 million","newsHeadline":"XOMA Earns $35 Million Milestone Payment as Anti-TGF\u03b2 Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Gemcitabine","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0.52000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Nov.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Padagis","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Aciclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Padagis","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"reMYND","sponsor":"National Institute of Neurological Disorders","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) Begin Collaboration on Epilepsy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"ReS3-T","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"reMYND","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"reMYND \/ National Institute of Neurological Disorders","highestDevelopmentStatusID":"4","companyTruncated":"reMYND \/ N.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Aptose Biosciences","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"$12.5 million","newsHeadline":"Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"HM43239","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"Oral","sponsorNew":"Hanmi Pharmaceutical \/ Aptose Biosciences Inc","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Digitalis Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"NSAA-protein Therapeutics","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"GRO Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"GRO Biosciences \/ Digitalis Ventures","highestDevelopmentStatusID":"1","companyTruncated":"GRO Biosci.."},{"orgOrder":0,"company":"Asembia","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support Services","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"L-Glutamine","moa":"NAD redox potential","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Asembia","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Asembia \/ Emmaus Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Asembia \/ .."},{"orgOrder":0,"company":"University of L'Aquila","sponsor":"SiSaf Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SiSaf Exercises Its Option Under Licencing Agreement on Gene Therapy for Rare Bone Disease and Announces Progress on Ind Enabling Studies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"SIS-101-ADO","moa":"CLCN7 gene mutation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"University of L'Aquila","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"University of L'Aquila \/ SiSaf Ltd","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"Specialty Process Labs","sponsor":"Letco Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Letco Medical, LLC Partners with Specialty Process Labs to Distribute US-Manufactured Thyroid USP","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Thyroid","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Specialty Process Labs","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder Extract","sponsorNew":"Specialty Process Labs \/ Letco Medical","highestDevelopmentStatusID":"12","companyTruncated":"Specialty .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Integral Molecular","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"AstraZeneca \/ Integral Molecular","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"GlycoEra","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"Glycoengineered Therapeutics","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GlycoEra","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Dosage Strength\/Form","sponsorNew":"GlycoEra \/ 5AM Ventures","highestDevelopmentStatusID":"3","companyTruncated":"GlycoEra \/.."},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","amount":"$495.0 million","upfrontCash":"$20.0 million","newsHeadline":"Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Nanoparticle Encapsulating PDC-E2","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0.5,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.5,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Cour Pharmaceuticals \/ Ironwood","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharm.."},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pioneering Medicines, an Initiative of Flagship Pioneering, Establishes First-of-its-Kind Partnership with Cystic Fibrosis Foundation to Develop Breakthrough Treatments for CF","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Flagship Pioneering \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Flagship P.."},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"DEKA Research & Development","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"DEKA Research & Development \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"DEKA Resea.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"Arch Ventures","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"bit.bio Raises in Excess of $100 Million in First Close of Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"Human iPSC-derived Glutamatergic Neurons","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bit Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bit Bio \/ Arch Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Suzhou Alphamab Co","sponsor":"Ascletis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Suzhou Alphamab Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Suzhou Alphamab Co \/ Ascletis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Alp.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Kukbo Co. Ltd.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Private Placement","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Kukbo Co. Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Kings College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marengo Therapeutics and King\u2019s College London Advance ImmunoOncology Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"STAR0602","moa":"TCR-V beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Marengo Therapeutics \/ King\u2019s College","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Th.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Versamune-TARP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"PDS Biotechnology \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AFT Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"AFT Pharmaceuticals \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"AFT Pharma.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gyroscope Therapeutics Announces Sanofi Investment of Up to $60 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4\/6 Inhibitor IBRANCE\u00ae (Palbociclib) in Metastatic ER+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Allderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Enters Into Collaboration with Allderma for Launch in Scandinavia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moberg Pharma \/ Allderma","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.16,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Ionetix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ IONETIX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Athenex","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Allogeneic NKT Cell Therapy","moa":"Mutated p53","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Athenex \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,750.0 million","upfrontCash":"$370.0 million","newsHeadline":"REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":1.75,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.75,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"EdiGene","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Short Engineered ADAR-recruiting RNAs","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"EdiGene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"EdiGene \/ University of Wisconsin\u2013Madison","highestDevelopmentStatusID":"2","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Termination","leadProduct":"Canerpaturev","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Takara Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Takara Bio.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"Nuclease Therapies","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":0.22,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.22,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Arbor Biotechnologies, Inc \/ Temasek","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"OcuTerra Raises $35 Million Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"OTT166","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Eye Drop","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra T.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$187.0 million","upfrontCash":"$35.0 million","newsHeadline":"Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Xanomeline","moa":"Muscarinic M1\/M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.19,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Zai Lab Limited","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"mRNA-based CAR-T Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Strand Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Strand Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Strand The.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$615.0 million","upfrontCash":"$25.0 million","newsHeadline":"Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"BLU-945","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0.62,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.62,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Zai Lab Limited","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Off-the-shelf Gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Asgard Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Asgard Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Asgard The.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.6 million","newsHeadline":"Acorda Therapeutics Announces Agreement to Commercialize INBRIJA\u00ae in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"The Autism Impact Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yamo Pharmaceuticals \/ The Autism Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharm.."},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$605.0 million","upfrontCash":"$15.0 million","newsHeadline":"Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Genetically Engineered Microbial Medicines","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.60999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.60999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Novome Biotechnologies \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Novome Bio.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Leiden University Medical Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ex-vivo Lentiviral Gene Therapies","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Leiden University Medical Centre","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Inventprise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"IVT-25","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inventprise","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Inventprise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inventpris.."},{"orgOrder":0,"company":"4E Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"Texas Based 4E Therapeutics Awarded National Institutes of Health Research Grant to Develop Non-Opioid Treatment for Pain to End Addiction","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"4ET1103","moa":"MNK receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"4E Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"4E Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"4E Therape.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax Advances Envelta\u2122 Development with NCATS Under CRADA Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Enkephalin","moa":"Delta opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Bacthera","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Firmicute Species Bacterial Spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bacthera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bacthera \/ Seres Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bacthera \/.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"DYN101","moa":"Dynamin 2 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Nippon Shinyaku","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Oxford Finance LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Achilles Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Secarna Pharma \/ Achilles Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$75.0 million","newsHeadline":"Organon to Acquire Forendo Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"Prexasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Acrivon Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Th.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shasqi Raises $50 Million to Expand Click Chemistry Platform Beyond Injectable Tumors and Accelerate Lead Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shasqi","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Arcus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Shasqi \/ A.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Massachusetts Eye and Ear and Harvard Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"OPGx-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Opus Genetics \/ Massachusetts Eye and Ear and Harvard Medical School","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Genpharm","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin\u2019s Lead Asset, QRX003","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Genpharm","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Genpharm \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Genpharm \/.."},{"orgOrder":0,"company":"Gaeta Therapeutics","sponsor":"Oncorus","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"$0.2 million","newsHeadline":"Oncorus Announces Exclusive Licensing Agreement with Gaeta Therapeutics Ltd. for Use of Locally Delivered Interleukin-12 (IL-12) via Oncolytic Viral Expression in Combination with Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Interleukin-12 Expressing Oncolytic Virus","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gaeta Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Gaeta Therapeutics \/ Oncorus","highestDevelopmentStatusID":"1","companyTruncated":"Gaeta Ther.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Reaches Programme Designations in Neuroscience Collaboration With Bristol Myers Squibb","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"EVT8683","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Evotec","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Borealis Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ankyra Therapeutics Announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. as Chief Medical Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"ANK-101","moa":"Cytokines","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intratumoral","sponsorNew":"Ankyra Therapeutics \/ Borealis Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Fusogenix-formulated Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Entos Pharmaceuticals \/ BioMarin","highestDevelopmentStatusID":"1","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Lowell Therapeutics","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lowell Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lowell Therapeutics \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Lowell The.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Kala Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"KPI-012","moa":"Protease","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kala Pharmaceuticals \/ Kala Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (Palbociclib) for Planned Phase 3 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Gedatolisib","moa":"Pan-PI3K class I","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Celcuity \/ Pfizer","highestDevelopmentStatusID":"5","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"IRBM","sponsor":"Antios Therapeutics","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IRBM","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Dosage Strength\/Form","sponsorNew":"IRBM \/ Antios Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IRBM \/ Ant.."},{"orgOrder":0,"company":"Tolmar","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tolmar","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tolmar \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ E.."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tricida Raises $42 Million in Registered Direct Equity Financing","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0.040000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 3 Data of mdc-IRM, First Product Based On MedinCell\u2019s Technology, Shows Significant Improvements in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Risperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0.12,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"In-vivo Gene Editing Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Full Exercise of Underwriters\u2019 Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 MillionV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone Life Sciences to Invest up to $250 Million in Autolus Therapeutics to Develop Obe-cel in Adult Acute Lymphoblastic Leukemia (ALL) and Advance Broader Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Autolus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mirati Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,240.0 million","upfrontCash":"$500.0 million","newsHeadline":"Biohaven And Pfizer Enter Strategic Collaboration For The Commercialization of Rimegepant Outside The United States","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":1.24,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.24,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Compugen","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$89.7 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxinity Announces Pricing of Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"UB-311","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$181.5 million","upfrontCash":"Undisclosed","newsHeadline":"Entrada Therapeutics Announces Closing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Entrada Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirati Therapeutics to Collaborate with Sanofi on Phase 1\/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Atreca","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ATRC-501","moa":"CSP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Atreca \/ Bill & Melinda Gates Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ B.."},{"orgOrder":0,"company":"Ivy Brain Tumor Center","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ivy Brain Tumor Center Collaborates with GSK on New Phase 0 Clinical Trial to Evaluate Niraparib in Patients with Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ivy Brain Tumor Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ivy Brain Tumor Center \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ivy Brain .."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Mitapivat","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centogene \/ Agios","highestDevelopmentStatusID":"10","companyTruncated":"Centogene .."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Purisys LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I\/II (a) Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"CNBX Pharmaceuticals \/ Purisys","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Plecoid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"Oncoheroes Biosciences Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncoheroes Biosciences Inc. Out-licences Volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Volasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Notable Labs \/ Oncoheroes Biosciences Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Cyclica","sponsor":"Structural Genomics Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key Component in Proteasomal Degradation, With a Novel Ligand to Support Targeted Therapeutics Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"DCAF1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Cyclica \/ Structural Genomics Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ .."},{"orgOrder":0,"company":"4E Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Texas Based 4E Therapeutics Awarded National Institutes of Health Research Grant to Develop Non-Opioid Treatment for Pain to End Addiction","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"4ET1103","moa":"MNK receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"4E Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"4E Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"4E Therape.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Avrobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Humanized Anti-CD117 Monoclonal Antibody","moa":"CD117","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ AVROBIO","highestDevelopmentStatusID":"4","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting\u2122 2021, Hosted by the AASLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Thrombolytic Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thrombolytic Science Granted US Patent on Novel Clot Dissolving Therapy, Complementing Patent Protection in Europe, Japan, China, Hong Kong, Mexico & CIS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Mutant pro-urokinase","moa":"Plasminogen","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Thrombolytic Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thrombolytic Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Thrombolyt.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek\u00ae 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences, Inc. Receives Notice of Publication from the U.S. Patent and Trademark Office","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix In Active Discussions With The Kingdom of Morocco\u2019s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two New Studies Demonstrate In Vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Micronized Dehydrated Human Amnion Chorion Membrane","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MiMedx \/ N.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex to Present at the Virtual Huntington\u2019s Study Group Meeting on November 4-6, 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CB-280","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes\u2122 Trial in Patients with mPV","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TR 009","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXON Neuroscience Presented Results from its Phase II Clinical Trial Showing Multifold Therapeutic Effect of its Vaccine-Induced Antibodies at Eurotau 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AADvac1","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Axon Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuro.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck Reports Positive Results For Vyepti[\u00ae] (Eptinezumab) From the DELIVER Study in Patients with Migraine and Prior Preventive Treatment Failures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Iconovo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Granted ICOone\u00ae Patent in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Iconovo","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"Iconovo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iconovo \/ .."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Core protein allosteric","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"MIE-101","moa":"TLR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Mosaic ImmunoEngineering \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic Imm.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New LIVMARLI\u2122 (Maralixibat) Data to be Showcased at AASLD The Liver Meeting\u00ae 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medi.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon\u2019s Commitment to Improving Outcomes for People Living with Uncontrolled Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Gelesis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Is Pleased to Note Publication in Nature\u2019s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GS100","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Gelesis","highestDevelopmentStatusID":"12","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ricin Toxin Vaccine","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents New INGREZZA\u00ae (valbenazine) Data at Psych Congress 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Novatek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novatek Seeks EUA after its Oral TQ Formula Significantly improved Total Symptom Burden in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of COVID-19 Patients in the Outpatient Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymoquinone","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novatek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Enteric-Coated Capsule","sponsorNew":"Novatek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novatek Ph.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1\/GIP Agonists at ObesityWeek\u00ae 2021","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Comprehensive Phase 3 Data Show First-in-Class TREMFYA\u00ae (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1\/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Eisai Inc","sponsor":"PRISM BioLab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The CREB-Binding Protein (CBP)\/\u03b2-Catenin Inhibitor E7386, Co-Created By Eisai and PRISM BioLab, Achieved the Clinical POC (Proof of Concept)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"E7386","moa":"CBP\/beta catenin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ PRISM BioLab","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc .."},{"orgOrder":0,"company":"Biocad","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of An Original Russian Drug for The Treatment of Lung Cancer Starts in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BCD-100","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Biocad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocad \/ Shanghai Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ S.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia to Advance Cenerimod Into Phase 3 Development for Treatment of Patients with Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cenerimod","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I\/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"RP12146","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rhizen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ZF874","moa":"A1AT gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s Findings on Cannabis Compound\u2019s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD\u2019s The Liver Meeting\u00ae 2021 Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PD-1\/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant\/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AK112","moa":"PD-1\/VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Onatasertib","moa":"mTORC1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 First-in-Class TREMFYA\u00ae (Guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delhi HC Restrains Generic Pharma Firms from Making, Selling Patent Drug of Novartis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Data on GENFIT\u2019s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting\u00ae","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Pinnacle Clinical Research","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pinnacle Clinical Research, PLLC Participating in RESPONSE, a Global Phase 3 Clinical Research Study Evaluating an Investigational Therapy for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Pinnacle Clinical Research","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pinnacle Clinical Research \/ CymaBay Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pinnacle C.."},{"orgOrder":0,"company":"Texas Liver Institute","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Texas Liver Institute Participating in RESPONSE, a Global Phase 3 Clinical Research Study Evaluating an Investigational Therapy for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Texas Liver Institute","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Texas Liver Institute \/ CymaBay Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Texas Live.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arthrosi Presents AR882 Posters at ACR 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AR882","moa":"URAT1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Arthrosi Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arthrosi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arthrosi T.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Initiates Phase II Program with \u201cExtra Strength\u201d Dose for Extended Duration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Nova Mentis Orphan Drug Application","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nova Mentis Life Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nova Mentis Life Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nova Menti.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BTX-1188","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore\u2019s C21 Reduces Long-Term Lung Injury After COVID-19 in the ATTRACT Phase 2 Extension Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Issues Notice of Compliance (NOC) for Jardiance\u00ae (Empagliflozin) For the Treatment of Heart Failure with Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Initiates Pivotal Phase 3 Clinical Study of Olezarsen in Patients with Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olezarsen","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GT90001","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"GeneVentiv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the Treatment of Hemophilia A or B With or Without Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GENV HEM","moa":"Factor Va","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneVentiv Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GeneVentiv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneVentiv.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech\u2019s COVAXIN\u00ae Authorized for Emergency Use by the World Health Organization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin Shelf Life Now Extended upto 12 Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LUMYKRAS\u00ae (Sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Ends Rolling Review of The Antibodies Bamlanivimab and Etesevimab For COVID-19 Following Withdrawal by Lilly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OMass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"OMass Ther.."},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis and Nestl\u00e9 Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"6","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways to Launch Phase II Trial of COMP360 Psilocybin Therapy for Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pha.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by as Much as 10% Compared to Baseline.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"INT230-6","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents New Data Supporting the Development of Golexanolone as A Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of Antara\u00ae in the United States","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenofibrate","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lentiviral gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"An Open, Non-Randomised, Phase 1\/2 Trial on The Safety, Tolerability, and Immunogenicity of Single-Dose Vaccine \u201cSputnik Light\u201d For Prevention of Coronavirus Infection in Healthy Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from ImmunoGenesis' Lead Programs to be Presented at Society for Immunotherapy of Cancer (SITC) Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Data from BION-1301 Phase 1\/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data At ASH Spotlight Novartis Recently Approved Scemblix\u00ae, Next-Generation CAR-T Platform and Expanding Hematology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences\u2019 Lead Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor to Present New Platform and Preclinical Data at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CD33 CAR-T cells","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum to Present Data Update on Phase II ADVANCE II at Annual American Society of Hematology Meeting (ASH)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS\/LM Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus to Participate in Webcast Hosted by William Blair to Discuss AGEN1181 Clinical Data from SITC 2021 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains TD-0148A In Vitro Pharmacology Data Confirming its Activity in Key Receptors Implicated in Depression and Neuropathic Pain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents PHYOX\u21222 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from PROTECT Trial Evaluating KRYSTEXXA\u00ae (Pegloticase Injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza\u00ae and Venclexta\u00ae in Relapsed\/Refractory Acute Myeloid Leukemia at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"More than 35 Abstracts from Incyte\u2019s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition for Treatment of Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medi.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GDA-501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS\u2019 Multidisciplinary NET Medical Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tidutamab","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Introduces Second Phase III Trial, COMPOSE, with n.c.a. 177Lu-edotreotide for Neuroendocrine Tumors at NANETS Annual Symposium 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"No-carrier-added Lutetium-177 edotreotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI\u00ae (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spirovant Presents Preclinical Data Showing SP-101 Restores CF Transmembrane Conductance Regulator Function at the 2021 North American Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SP-101","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spirovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Birinapant Clinical Study Initiated By IGM Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Birinapant","moa":"SMAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"REGN5458","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Achieves Significant Clinical Progress for UltraCAR-T\u00ae and AdenoVerse\u2122 Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PRGN-3006","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Enrols First Patient to EVT801 Phase I Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"EVT801","moa":"VEGFR 3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Menarini","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Receives FDA Orphan Drug Designation for SEL24\/MEN1703, a first in class, dual PIM\/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Menarini \/ Ryvu Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Versameb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versameb to Present Novel Data on Its Lead Asset, VMB-100 at 9th International mRNA Health Conference","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VMB-100","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/.."},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TT-00420","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TransThera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TransThera.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OS Therapies Receives Rare Pediatric Disease Designation (RDD) in Osteosarcoma for OST-HER2 (Listeria monocytogenes)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ADXS31-164","moa":"ERBB 2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"CareDx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ CareDx","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces Preliminary Phase 1\/2 Data Showing Tolerability and Sustained Elevated \u03b1-Gal A Enzyme Activity in Patients With Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Isaralgagene Civaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CAR-NKT Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Continuous Infusion","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BI-1206","moa":"Fc?RllB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Receives IND Clearance to Initiate Phase 1\/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Advaccine Biopharmaceuticals Suzhou Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Novel Covid-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2\/3 EPIC-HR Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"GSK","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Phase III Efficacy and Safety Data for Daprodustat in Patients with Anaemia Due to Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ ","highestDevelopmentStatusID":"12","companyTruncated":""},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First And Only Randomized, Double-blind, Head-to-head Study Comparing Aimovig\u00ae (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Erenumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Delcath Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hepatic Injection","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer\u2019s Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Mesenchymal Stem Cells","moa":"Vascular endothelial growth factor activator","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"6","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO\u00ae (berotralstat)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ABC008","moa":"KLRG1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Abcuro, Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Key Rheumatology Data at ACR Convergence 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA\u00ae in Clinical Practice in the U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder In Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1\/CD137 Bispecific Antibody) in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IBI319","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae Shows Consistent Cardio-Renal Benefits in Adults with Heart Failure with Left Ventricular Ejection Fraction Over 40% Regardless of Chronic Kidney Disease Status","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly and Company","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Analyses Show That a Single Dose of REGEN-COV\u00ae (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Bugworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bugworks Research Begins First in Human Phase 1 Study of BWC0977 to Treat Critical Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BWC0977","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bugworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"KER-012","moa":"Modified ActRII Ligand Trapper","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TPST-1495","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company\u2019s Sharpened Clinical Development Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"KIO-101","moa":"DHODH","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Kiora Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kiora Phar.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Research Evaluating VASCEPA\u00ae\/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neurona Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received previously","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"Tregs migration","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Clinical Expansion Positions Lead PI3K\u03b4 Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Finlay Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venezuela Begins Vaccinating 2-Year-Old Children with Cuban Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CUBA","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"FINLAY-FR-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Finlay Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Finlay Institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Finlay Ins.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NUCALA (Mepolizumab) The First and Only Anti-Il-5 Add-On Treatment Approved in Canada that Targets Eosinophilic Inflammation in Adults with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte\u2122 in CTCL in the United Kingdom","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Janssen","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ADX-097","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Showcases Biology, Genetic and Clinical Programs at ASN Kidney Week Demonstrating Leadership in Precision Medicines for Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hybrid Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"L-Type VGCC","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Petros Pharmaceuticals \/ Hybrid Medical","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Profounda Pharmaceuticals","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Profounda Orphan Drug Designation Approval for treatment of Treatment of Invasive Candidiasis with Miltefosine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Miltefosine","moa":"Cytochrome c oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Profounda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Profounda Pharmaceuticals \/ Knight Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Profounda .."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DIAN-TU Selects Lecanemab As Background Anti-Amyloid Therapy In Clinical Trial Evaluating Investigational Therapy Targeting Tau For Dominantly Inherited Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck Launches a Phase II Study for Potential New Treatment of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lu AF82422","moa":"Alpha synuclein protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Tentative Approval for Liquidia\u2019s YUTREPIA\u2122 (Treprostinil) Inhalation Powder","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Presents New Subgroup Analysis of Prespecified Pooled Analysis of Phase III Studies for KERENDIA\u00ae (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without SGLT2i Use at Baseline","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Published on ABBV-0805 in Neurobiology of Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ABBV-0805","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Telaglenastat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI\u00ae) in Psoriatic Arthritis at ACR Convergence 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presented Updated Interim Phase 1\/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed\/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TK216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-\u03b2 agonist TERN-501","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-501","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Advances HB-200 Program to Phase 2 and Prioritizes Oncology Portfolio Based on Clinical Data Updates Across Its Novel Arenaviral Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"HB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Invariant Natural Killer T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"OncoC4","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoC4, Inc. Reports Phase Ia Data on Safety and Clinical Activities of ONC-392 (Nextgen Anti-CTLA-4) Monotherapy for Stage IV Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Onc-392","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ N.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer\u2019s Disease (CTAD) Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect\u2019s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PRX-P4-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bio.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bulevirtide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bi-Sialidase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Apobiologix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Apobiologix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Apobiologix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apobiologi.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2\u2011Positive Gastroesophageal Adenocarcinoma (GEA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"HER2 biparatopic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nova Mentis Files Genetic Neuroinflammatory Disease Patent","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nova Mentis Life Science \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Menti.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer's Disease (CTAD) Conference and Society for Neuroscience Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"OLX-07010","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TerSera\u00ae Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo\u00ae (telotristat ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"TerSera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"TerSera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TerSera Th.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ\u00ae (Upadacitinib) Among Patients with Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Df1001","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CST-103","moa":"ADRB2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CuraSen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Th.."},{"orgOrder":0,"company":"Imvax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ No.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced\/Metastatic Non-small Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intra-Arterial","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"US Biotest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac\u00ae to Standard of Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin beta-1 chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"NanOlogy \/ US Biotest","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"RepliCel","sponsor":"Innovacell Biotechnologie","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RepliCel\u2019s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cultured, Autologous Hair Follicle Cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"RepliCel","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"RepliCel \/ Innovacell Biotechnologie","highestDevelopmentStatusID":"6","companyTruncated":"RepliCel \/.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis to be Presented at the American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ABL111","moa":"CD137 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Obsidian Therapeutics to Present In Vivo Anti-Tumor Efficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CytoTIL15","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Obsidian Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Obsidian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Obsidian T.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent and Transgene to Present Preclinical Data on BT-001 Oncolytic Virus At SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-Tumoral","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OLUMIANT\u00ae Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"University of Rochester","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PXS-5505","moa":"Pan-LOX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Gelation Capsule","sponsorNew":"Pharmaxis \/ University of Rochester","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Positive Phase III Results for Cosentyx\u00ae in Children with Active Enthesitis-Related Arthritis (ERA) And Juvenile Psoriatic Arthritis (JPsA) at ACR 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2\/3 AIS Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"DM199","moa":"KLK1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pvsripo","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Istari Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Istari Onc.."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-Tumoral","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preliminary Results Show SINOVAC\u2019s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 Virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives US FDA Approval to Market Glycopyrrolate Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"M1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in Mild-to-Moderate Alzheimer\u2019s Disease at CTAD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Receives Request for Emergency Use of CanSino Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"PathAI, inc","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PathAI And Novo Nordisk Present AI-Powered Scoring Showing Significant Reduction of Fibrosis Following Semaglutide Treatment in Patients With NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"PathAI, inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PathAI, inc \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"PathAI, in.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"AmyriAD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Company AmyriAD Steps into the Light with Phase III Symptom Relief Drug for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AD101","moa":"Calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AmyriAD \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ .."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CV8102","moa":"TLR7\/8\/RIG-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Aphios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphios Granted Chinese Patent for Novel Bryoid to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Protein kinase C","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Aphios","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aphios \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aphios \/ N.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication Of Data On SFX-01 In Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sulforaphane","moa":"SHP2 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Phar.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Aflibercept For Regulatory Approval in the EU and Japan for Retinopathy of Prematurity in Premature Babies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Announces Initiation of Phase 1\/2 Clinical Trial to Study Tegavivint in Pediatric Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tegavivint","moa":"TBL1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CT103A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u2122 Recommended for Approval for The Treatment of Obesity by The European Regulatory Authorities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Afamitresgene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rockwell Medical Submits Investigational New Drug Application with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Gamma Delta T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Viroclinics Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics\u2019 Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Allarity Therapeutics \/ Viroclinics","highestDevelopmentStatusID":"4","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Supplemental New Drug Application and Grants Priority Review for Jardiance\u00ae For Adults with Heart Failure Independent of Left Ventricular Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNOC Study in Childhood Brain Cancer Enrols First Patient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gmax's GMA106, Second Generation Obesity\/T2DM\/NASH mAb Gives First in Human Dose","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GMA106","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gmax Biopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Bioph.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme\u2019s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer\u2019s Disease and P. Gingivalis Infection in Phase 2\/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Volasertib","moa":"PLK-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Notable Labs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Met in COMET-TAIL Phase III Trial Evaluating Intramuscular Administration of Sotrovimab for Early Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Activity of AGEN1181 Demonstrated Across Nine Treatment-Resistant Cancers at SITC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AGN1181","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leqvio\u00ae* (Inclisiran) Reduced LDL-C in People who Are Overweight or Obese","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Provides Promising Updated Patient Response Data from the Phase I\/IIa EVICTION Trial with ICT01 at SITC Meeting 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized anti-Butyrophilin 3A Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Recommendation for Use of TAVNEOS\u2122 (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients\u2019 T Cell Immune Function When Administered Prior to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Presents Compelling Preclinical Data on its Clinical Stage Autotaxin Inhibitor IOA-289 at SITC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IOA-289","moa":"Autotaxin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Presents New Data at AASLD The Liver Meeting\u2122 Highlighting the Progress of its HBV Core Inhibitor Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ABI-4334","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae Digital Experience 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting\u00ae 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Positive CHMP Opinion for TransCon\u2122 hGH for Patients with Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting\u00ae Digital Experience 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-101","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Presents Positive Preclinical Data from PD-1\/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-585","moa":"ILT4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Therapeutics Presents New PALFORZIA\u00ae [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Real-World Data Show High Rate of Patient Adherence to TEPEZZA\u00ae (teprotumumab-trbw) for Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Belcesiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for KAFTRIO\u00ae (Ivacaftor\/Tezacaftor\/Elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-514","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination Helps Children with Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National C.."},{"orgOrder":0,"company":"American Heart Association","sponsor":"Janssen Scientific Affairs","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heart Failure Symptoms Improved with A Type 2 Diabetes Medicine in Fully Remote Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"American Heart Association","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"American Heart Association \/ Janssen Scientific Affairs","highestDevelopmentStatusID":"10","companyTruncated":"American H.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CLRs","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Presents New Data from Phase 1b\/2a NASH Study Showing BIO89-100 Reduces Spleen Volume","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TEV 47948","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon\u2019s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose Control Across the Full Range of Kidney Function in New Analysis of Clinical Data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 \/ LYTENAVA\u2122 (Bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Highlights Actimab-A Combined with CD47 Immunotherapy Results in Upregulation of Calreticulin Leading to Enhanced Phagocytosis in AML at the Society for Immunotherapy for Cancer (SITC) Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Presents First Ever Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors at the Society for Immunotherapy for Cancer (SITC) Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Irofulven","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presentation Today at The Liver Meeting\u00ae 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion\u2019s Monoclonal Antibody Treatment Regdanvimab, Approved by the European Commission for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Regdanvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Zilebesiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data Show Positive Correlation Between ADUHELM\u2122 Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO\u00ae (Vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Antibody Based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"SARS-CoV-2 inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEMPS Authorizes Phase IIb Clinical Trial of HIPRA Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Messenger RNA Based Covid Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laboratorios HIPRA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios HIPRA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"R&D Milestone: HebaBiz Biotech's Application for Phase III clinical trial in China for Clevudine (L-FMAU), An Anti-Hepatitis B Virus Drug Candidate Under Development Has Been Approved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Clevudine","moa":"HBV DNA chain replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HebaBiz Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"HebaBiz Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"HebaBiz Bi.."},{"orgOrder":0,"company":"AT Research Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Contraceptive by AT Research Partners Promises Efficacy, Access and Safety for Women Using Nanotechnology","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Halogenated Fullerene Nanoparticle","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"AT Research Partners","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AT Research Partners \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AT Researc.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Temozolomide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Reports Subgroup Data from REDUCE-IT\u00ae Highlighting Benefits of VASCEPA\u00ae\/VAZKEPA (Icosapent Ethyl) in Patients with Prior Peripheral Artery Disease (PAD) Presented in Rapid Fire Oral Session Presentation at the American Heart Association Scientific ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jyseleca\u00ae\u25bc(Filgotinib) Approved in The European Union for The Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics\u2019 INT230-6 (PORT-1) at November Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"T-knife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TK-8001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"T-knife \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OpRegen\u00ae Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Extends Clinical Development Program for Finerenone With Phase III Study in Children and Adolescents with Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"MimiVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"M57-KLH","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MimiVax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Milvexian","moa":"Factor XIa","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics co-Founder and President to Present at World Orphan Drug Congress Europe 2021, Nov. 17, in Barcelona, Spain","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"MCO-010","moa":"MCO gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Authorizes Booster Dose of Moderna\u2019s COVID-19 Vaccine in Individuals 18 Years of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Elasomeran mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Lecanemab Presented at The CTAD Alzheimer Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Versantis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VS-01","moa":"Ammonia clearance","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versantis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis .."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Announces First Patient Dosed in Phase 2 Clinical Trial of RXC004 in Patients with Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Denosumab","moa":"Porcupine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"EspeRare","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre and The Espe Rare Foundation Start The EDELIFE Clinical Trial of A Prenatal Treatment for A Rare Genetic Disease, XLHED","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ER004","moa":"TNF receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"EspeRare","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Pierre Fabre group","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/.."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IMGS-001","moa":"PD1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"NV-Cov-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"JNJ-3989","moa":"HBV gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunOs Therapeutics\u00b4 Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"iosH2","moa":"LILRB1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImmunOs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunOs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunOs Th.."},{"orgOrder":0,"company":"Cytovation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with CyPep-1 in Combination with KEYTRUDA\u00ae in Cytovation's Ph I\/IIa CICILIA Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma to Initiate Phase 3 Study of Imlifidase to Treat Anti-Glomerular Basement Membrane (anti-GBM) dIsease After Successful Pre-Ind Meeting With U.S. FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravesical","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Reports Positive Data in Phase II Dyslipidemia Trial\u00a0","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Begins Dosing in Phase I\/II Solid Tumours Therapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"NDI-101150","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Wins Prestigious Prix Galien USA Award for Oxbryta\u00ae (voxelotor)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V And Sputnik Light Vaccines Authorized in Cambodia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies to Highlight New Long-term Data From REALISE Trial at ACAAI 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement: Updates to Mirati Therapeutics Executive Leadership Team","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin\u2122 Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Corticotropin","moa":"ACTH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"2Seventy Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dispersion for Infusion","sponsorNew":"2Seventy Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unity Biotechnology Announces Improvement In Visual Acuity Sustained Through 24 Weeks Following Single Dose Of Ubx1325 In Phase 1 Study Of Patients With Advanced Vascular Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson\u2019s Disease; Company Plans to Advance Program to Phase 2","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Semorinemab","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Oncorus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ONCR-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncorus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ingtratumoral Injection","sponsorNew":"Oncorus \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Oncorus \/ .."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Invariant Natural Killer T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Presents Final Phase 1b\/2 Data for its First Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jakob Lindberg Appointed CEO of Oncopeptides","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Announces Interim Results From the MISSION Phase 2 Trial in Patients with Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Announces FDA Approval of TYRVAYA\u2122 (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"DNL343","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Microtubuli formation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer\u2019s Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Reports that its U.S. Collaboration Partner\u2019s Emergency Use Authorization Request for ZYESAMI\u00ae\/RLF-100\u2122 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by the U.S. Food & Drug Administration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Axplora","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teriflunomide \u2013 API and Licensing Agreements for Tablets Available","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Axplora","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axplora \/ Breckenridge","highestDevelopmentStatusID":"12","companyTruncated":"Axplora \/ .."},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Menashe Bar-Eli","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"NT219","moa":"IRS1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Purple Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purple Biotech \/ Menashe Bar-Eli","highestDevelopmentStatusID":"1","companyTruncated":"Purple Bio.."},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cardurion Pharmaceutical","amount2":0.29999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Cardurion .."},{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Chinalink Asia Holdings","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson\u2019s Disease and Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Immediate Release Tablet","sponsorNew":"Chase Therapeutics \/ Chinalink Asia Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Chase Ther.."},{"orgOrder":0,"company":"PAO Group","sponsor":"CBD pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PAOG Entertains Partnership To Accelerate Development Of CBD Pharmaceutical Treatment For $14 Billion COPD Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid Extract","sponsorNew":"PAO Group \/ CBD pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Reports Two Publications of Positive Data On Nexodyn\u00ae AOS For Hard-To-Heal Ulcers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Nexodyn Acid-oxidizing Solution","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray Solution","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Apogenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"CAN008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Apogenix","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer, CureVac Terminate COVID-19 Shot Production Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Termination","leadProduct":"CVnCoV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"AUM Biosciences Announces Closing of $27 Million in a \"Series A\" Round of Funding to Advance Its Clinical Stage Pipeline of Precision and Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"AUM001","moa":"MNK","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"AUM Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AUM Biosciences \/ SPRIM Global investments","highestDevelopmentStatusID":"1","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HCmed Reaches Milestone in Immunoglobin Combination Product Development with CSL Behring","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Human Plasma-derived Polyvalent Immunoglobulin G","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CSL Behring \/ HCmed Innovations","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (Dupilumab) Is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in This Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed With PVSRIPO in Istari Oncology\u2019s LUMINOS-103 Phase 1\/2 Bladder Cancer Sub-Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pvsripo","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Istari Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Istari Onc.."},{"orgOrder":0,"company":"Isotopia","sponsor":"Seibersdorf Labor GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"No-carrier-added Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotopia \/ Seibersdorf Labor GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting\u00ae Digital Experience 2021","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"TERN-101","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Granted Authorization from The French Health Authority (ANSM) to Initiate a Study of AB8939 in the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"AB8939","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Enrolls First Patient in The US in PORTICO, a Phase IIb Clinical Trial with Vafidemstat in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bright Peak Therapeutics Licenses Rights to Livzon\u2019s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pha.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$1,027.5 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"LCB20A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"Dosage Strength\/Form","sponsorNew":"LegoChem Biosciences \/ SOTIO","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Gavi","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Medicines Patent Pool \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"The Medici.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"AyurMaya","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"Izokibep","moa":"IL-17A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0.25,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acelyrin \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Funding","leadProduct":"Tizanidine HCl","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Delpor","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"Delpor \/ N.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"Dosage Strength\/Form","sponsorNew":"HemoShear Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Dendreon Pharmaceuticals, Inc","sponsor":"Grant Hill","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dendreon Pharmaceuticals Partners with Grant Hill to Help Men Start Strong with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Sipuleucel-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dendreon Pharmaceuticals, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Dendreon Pharmaceuticals, Inc \/ Grant Hill","highestDevelopmentStatusID":"12","companyTruncated":"Dendreon P.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Leidos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers of Immunology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Malaria Vaccine","moa":"CSP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"EpiVax \/ Leidos","highestDevelopmentStatusID":"2","companyTruncated":"EpiVax \/ L.."},{"orgOrder":0,"company":"Abintus Bio","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"In Vivo CAR-X Products","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abintus Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Abintus Bio \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Abintus Bi.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"GuardRX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Ebola DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ GuardRX","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Diverchim S.A.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences: Agreement Signed with Diverchim to Manufacture Its Active Ingredients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Diverchim","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Protego Biopharma","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Unfolded Protein Response","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Protego Biopharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Protego Biopharma \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Protego Bi.."},{"orgOrder":0,"company":"Imugene","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Avelumab","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Imugene \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytovia and Cellectis Expand Their TALEN\u00ae Gene-Edited iNK Partnership to Enable Broader Collaboration in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Gene-edited iPSC-derived NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0.82999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.82999999999999996,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Beyond Air","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Beyond Air\u00ae Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer\u2122 Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Private Placement","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Beyond Cancer \/ Beyond Air, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Can.."},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces Closing of $46.0 Million Public Offering of Common Stock","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.050000000000000003,"dosageForm":"Intranasal","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Myung In Pharm Co. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"NLC Pharma","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Todos Medical Announces Tollovid\u00ae Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Plant Extracts","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ NLC Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$397.4 million","upfrontCash":"Undisclosed","newsHeadline":"Clover and CEPI Expand Partnership for COVID-19 Vaccine Candidate to Include Evaluation as a Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"SCB-2019","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0.40000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$3,300.0 million","upfrontCash":"$3,300.0 million","newsHeadline":"Novo Nordisk to Acquire Dicerna","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"DCR-NOVO1","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dicerna Pharmaceuticals","amount2":3.2999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":3.2999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Dicerna Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Queen\u2019s University of Belfast","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Continues to Strengthen Early Oncology Pipeline With Queen\u2019s University Belfast Collaboration and Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Queen\u2019s University of Belfast","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Queen\u2019s University of Belfast \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Queen\u2019s Un.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Sino Biopharmaceutical Limited","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"Undisclosed","newsHeadline":"Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"CFI-400945","moa":"PLK4 Inhibitor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Sino Biopharmaceutical Limited","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Genelux","sponsor":"ELIAS Animal Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genelux Announces Exclusive Out-Licensing Agreement with ELIAS Animal Health for V-VET1, a Proprietary Oncolytic Vaccinia Virus Treatment for Pets with Various Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"V-VET1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Genelux \/ ELIAS Animal Health","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"$2,450.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio\u2019s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"BBP-954","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":2.4500000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.4500000000000002,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Helsinn","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Tempus","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Tempus \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ A.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Spanish government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Reimbursement Agreement in Spain for KAFTRIO\u00ae (ivacaftor\/tezacaftor\/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Spanish government","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen and Guggenheim Securities","pharmaFlowCategory":"D","amount":"$115.4 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.12,"dosageForm":"Intravitreal Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen and Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Announce Strategic Partnership and Exclusive Licensing Agreement on Anti-CTLA-4 Monoclonal Antibody CS1002 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"CS1002","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Intravenous","sponsorNew":"CStone Pharmaceuticals \/ Jiangsu Hengrui Pharmaceuticals Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Kreos Capital","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Abveris","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$10.0 million","newsHeadline":"Twist Bioscience Acquires Abveris to Complement Antibody Capabilities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abveris","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Abveris \/ Twist Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Abveris \/ .."},{"orgOrder":0,"company":"EQRx","sponsor":"Abdul Latif Jameel Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Aumolertinib","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Abdul Latif Jameel Health","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Abd.."},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institutes of Aging","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"Undisclosed","newsHeadline":"The Institute for Molecular Medicine has Received a Total $7.7M From NIH to Develop a First-of-its-Kind Vaccine Targeting Both Hallmarks of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"Duvax","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"The Institute for Molecular Medicine \/ National Institutes of Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Kamada","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$95.0 million","newsHeadline":"Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Cytomegalovirus Immune Globulin [Human]","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Saol therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous","sponsorNew":"Saol therapeutics \/ Kamada Ltd.","highestDevelopmentStatusID":"12","companyTruncated":"Saol thera.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"OMERS Capital Market","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Adds $350 Million in New Financing with Royalty Pharma and\u00a0OMERS Capital Markets","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ OMERS Capital Market","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$925.0 million","upfrontCash":"$30.0 million","newsHeadline":"Nykode Therapeutics (formerly Vaccibody*) Enters Into Multi-Target License and Collaboration Agreement with Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Neoantigen Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nykode Therapeutics","amount2":0.93000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.93000000000000005,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Nykode Therapeutics \/ Regeneron","highestDevelopmentStatusID":"6","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"177Lu-EBTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"iX Biopharma","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$9.0 million","newsHeadline":"Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"iX Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Wafer","sponsorNew":"iX Biopharma \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"iX Biophar.."},{"orgOrder":0,"company":"InveniAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"InveniAI","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"InveniAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"InveniAI \/.."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Desjardins Capital Markets","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2021","year":"2021","type":"Private Placement","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Valeo Pharma","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Desjardins Capital Markets","highestDevelopmentStatusID":"12","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$450.0 million","newsHeadline":"Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pha.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"EF Hutton","pharmaFlowCategory":"D","amount":"$30.4 million","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pasithea Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Pasithea Therapeutics \/ EF Hutton","highestDevelopmentStatusID":"1","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Belgian Nuclear Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lu-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Point Biopharma \/ Belgian Nuclear Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$156.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0.16,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.16,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Ther.."},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Ming Bioventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Help Therapeutics Completes Series C Financing of 25 Million Dollars","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series C Financing","leadProduct":"iPSC-derived Cardiomyocyte","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Help Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Help Therapeutics \/ Ming Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"Help Thera.."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"HotSpot Therapeutics \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces $1 Billion Deal Expansion with Mersana","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"XMT-1592","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Synaffix","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaffix \/ Mersana Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ablaze Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ablaze Pharma \/ Vivo Capital","highestDevelopmentStatusID":"12","companyTruncated":"Ablaze Pha.."},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Chaperone-mediated protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ranok Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ranok Therapeutics \/ Pfizer Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Ranok Ther.."},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Funding","leadProduct":"Iduronate Sulfatase","moa":"Enzyme Replacement","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immusoft Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Immusoft Corporation \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Immusoft C.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences\u2019 Anti-TIGIT Program in Japan and Certain Territories in Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"NLC Pharma","sponsor":"Todos Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"NLC-V-01","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NLC Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"NLC Pharma \/ Todos Medical","highestDevelopmentStatusID":"8","companyTruncated":"NLC Pharma.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter\u2019s Option to Purchase Additional Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Sciwind Biosciences Co.","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Terragenx","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Terragenx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Terragenx \/ Novo Integrated Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Terragenx .."},{"orgOrder":0,"company":"MicroDoz Therapy Inc.","sponsor":"Love Pharma","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Love Pharma\u2019s Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MicroDoz Therapy Inc.","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infused Oral Strip","sponsorNew":"MicroDoz Therapy Inc. \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"MicroDoz T.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr\u2019s Lead Therapeutic Candidate ATYR1923","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"ATYR1923","moa":"Neuropilin-2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ aTyr Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for\u00a0COVID-19 Vaccine and Cancer Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"EnGeneIC Dream Vector","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnGeneIC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"EnGeneIC \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"EnGeneIC \/.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"St. Baldrick\u2019s Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Partners with St. Baldrick\u2019s Foundation to Research and Develop New Treatments for Childhood Bone Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Funding","leadProduct":"Kt-3000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Rakovina Therapeutics \/ St. Baldrick\u2019s Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Cellevolve","sponsor":"Acclaimed Investors","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellevolve Launches with Acclaimed Investors and Pivotal Manufacturing Partnership, Focused on Accelerating the Commercialization of Novel Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellevolve","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Cellevolve \/ Acclaimed Investors","highestDevelopmentStatusID":"1","companyTruncated":"Cellevolve.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"HTL0016878","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":2.7000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":2.7000000000000002,"dosageForm":"Oral Solution","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Baidu Research","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Baidu Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Baidu Research \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Baidu Rese.."},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"IDG Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allorion Therapeutics Announces $40 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allorion Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Allorion Therapeutics \/ IDG Capital","highestDevelopmentStatusID":"4","companyTruncated":"Allorion T.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Ribonexus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aglaia Therapeutics Becomes Ribonexus and Signs Exclusive License Agreement with Pierre Fabre on Small Molecules Targeting eIF4A, an Innovative Target in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"K01401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Pierre Fabre \/ Ribonexus","highestDevelopmentStatusID":"4","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Pierre Fabre \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$725.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0.72999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Genomma Lab","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oramed Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Genomma Lab","highestDevelopmentStatusID":"4","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lysogene Secures a \u20ac4.3 Million Non-dilutive Financing From Bpifrance to Support Its Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"LYS-GM101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"Lysogene \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"LoQus23 Therapeutics Exits Stealth with \u00a311.5 Million Seed Financing From the Dementia Discovery Fund and Novartis Venture Fund","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"LoQus23 Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LoQus23 Therapeutics \/ Dementia Discovery Fund","highestDevelopmentStatusID":"2","companyTruncated":"LoQus23 Th.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters Collaborative Agreement with Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody Medicines","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Confo Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Gets New Patent for Cobitolimod Granted in Canada","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces New PDUFA Date for Mavacamten","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Receives FDA Approval for VOXZOGO\u2122 (Vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the \"Best of The Liver Meeting's Summary\" by AASLD Review Committee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC42","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Gannex Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gannex Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gannex Pha.."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"UC San Diego School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ UC San Diego School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta To Present Updated Phase I\/II Data At Upcoming Scientific Congresses SNO AND ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Hematopoietic Stem Progenitor Cell Immuno-gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Features FDA-Approved XIPERE\u2122 in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA\u00ae\/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Reports Positive Initial Data for exoSTING\u2122 Phase 1\/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CDK-002","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presented New Translational Data on Tedopi\u00ae and Preclinical Data on PD-1\/IL-7 Bifunctional Program BiCKI\u00ae-IL-7","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Phase III Results for Arpraziquantel as Part of its Schistosomiasis Elimination Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arpraziquantel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"B244","moa":"IL-4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD8601 EPICCURE Phase II Trial Demonstrated Safety and Tolerability in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AZD8601","moa":"VEGF A expression","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AstraZeneca \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Fentanyl","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Its Joint Venture Aleor Dermaceuticals Receives USFDA Final Approval for Mupirocin Cream USP, 2%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mupirocin","moa":"Isoleucine-tRNA ligase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Alembic Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LOKELMA\u00ae Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graphite Bio Enrolls First Patient in Phase 1\/2 Clinical Trial of GPH101 for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GPH101","moa":"Hemoglobin beta chain","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Amitriptyline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in the U.S. Phase I Trial for ASC43F Only Half a Month after IND Approval by the U.S. FDA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ASC41","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gannex Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pha.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NURTEC\u00ae ODT Approved In Kuwait For Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Files Two International Patent Applications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IMG-007","moa":"OX40","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI\u00ae (Risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Launches Tipanat Tabs in India to Treat Advanced Colorectal and Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Trifluridine","moa":"Nucleic acid","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Gets 180-Day Exclusivity for Nelarabine Injection, Announces Final Approval From USFDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Nelarabine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Nucala (Mepolizumab) in Three Additional Eosinophil-Driven Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"DNA synthesis","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spark Therapeutics Updated SPK-8011 Data from Phase 1\/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SPK-8011","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cirtuvivint","moa":"CLK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"NB1000S","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novome Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novome Bio.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Vall d\u2019Hebr\u00f3n Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial With Vafidemstat in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Vall d\u2019Hebr\u00f3n Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Regulatory Review of Aducanumab in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co., Ltd.","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ELX-02","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Beta Glucan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ N.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Receives U.S. Food and Drug Administration (FDA) Authorization to Resume Patient Enrolment in The Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I\/IIa Breast Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Longeveron\u2019s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Bone Marrow-Derived Medicinal Signaling Cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Files Patent Suit Against Glenmark","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emgality\u00ae Versus Nurtec\u00ae ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Biohaven","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA\u00ae (Guselkumab) in Adults With Moderately to Severely Active Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New analyses of the Comprehensive Finerenone Clinical Trial Program Reinforces Renal and Cardiovascular Benefits in Patients With CKD and T2D, Independent of Baseline Therapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"City of Hope","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope Opens Oncolytic Virus Clinical Trial for Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"City of Hope \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics to Present Data for Novel Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VENT-01","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ventus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Second Genome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Genome Presents Preclinical Data at Crohn\u2019s & Colitis Foundation\u2019s\u00ae IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SG-5-00455","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Second Genome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Gen.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AP-SA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Provides Brilacidin Program Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Roche\u2019s Gavreto (Pralsetinib) For the Treatment of Adults With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives Approval for Difluprednate Ophthalmic Emulsion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bulevirtide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA\/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (Bevacizumab Biosimilar Injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Showcases Progress From the DREAMM Clinical Trial Programme in Multiple Myeloma at the 2021 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Belantamab Mafodotin-blmf","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Announces JNJ-75220795 in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"JNJ-75220795","moa":"PNPLA3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IO-202","moa":"LILRB4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA\u00ae (Inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BGB-23339","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Receives European Commission Approval of QINLOCK\u00ae for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Granted New Composition of Matter Patent for Its TGF-\u00df Trap Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AdAPT-001","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Doses First Participants in Altitude Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Bolus","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Seeks DCGI Approval for Novel Oral Pill to Treat Anaemia in Kidney Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Desidustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals announces USFDA Final Approval for Formoterol Fumarate Inhalation Solution, 20 mcg\/2 ml per Unit-Dose Vial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Completes Patient Recruitment For MANGROVE Phase 2 Trial With GLPG2737 in Polycystic Kidney Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GLPG2737","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Pulmonem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising COVID-19 Therapeutic Drug to start\u00a0Phase 3 Clinical Trial in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmonem \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/.."},{"orgOrder":0,"company":"Codexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis Presents Pre-Clinical Data Highlighting its Programs in Homocystinuria and Maple Syrup Urine Disease at ICIEM 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-6512","moa":"Enzyme Replacement","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Codexis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Evaluating Data on Booster Dose of COVID-19 Vaccine Janssen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s LIVTENCITY (Maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Maribavir","moa":"CMV pUL97 kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval of Zeposia (Ozanimod) For Use in Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Submits IND for US Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME\u00ae\u00a0(Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Granted Fifth US Patent for Crystalline Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS\u00ae and TAGRISSO\u00ae Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol Medical AB (PUBL) Receives FDA Fast Track Designation For Arfolitixorin in Advanced Colorectal Cancer (mCRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Variant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VARIANT Receives European Orphan Drug Designation for its Gene Therapy Product Candidate, VAR002, for the Treatment of Both Leber Congenital Amaurosis and Cone-Rod Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VAR002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Variant","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Variant \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Variant \/ .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Receives IND Clearance by NMPA for KX-826\u2019s Pivotal Study to Treat Male Alopecia Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Enrols First Patient in The Phase III Study CONCLUDE With Cobitolimod in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharma\u2019s Byannli Receives European Approval for Maintenance Treatment of Schizophrenia in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Biotheraputics' CT120 Granted Orphan Drug Designation by the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CT120","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"IDOR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover\u2019s COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ IDOR","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Cancer Agent Herceptin Approved for Additional Indication of Salivary Gland Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma Releases Positive DEP\u00ae phase 2 Interim Results in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Tubulin alpha-4A chain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"HMPL-523","moa":"SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN\u2122 (BBV152)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback\u2019s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Notes New Data on BriLife\u00ae COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Recombinant Vesicular Stomatitis Virus \u0394G","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KEYTRUDA\u00ae (Pembrolizumab) Plus LENVIMA\u00ae (Lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb\u2019s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SERB Receives Positive CHMP Opinion for Voraxaze\u00ae (Glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Serb","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serb \/ BTG.."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ABM-1310","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Novel Anti PD-L1\/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"HLX301","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KEYTRUDA\u00ae (Pembrolizumab) Plus LENVIMA\u00ae (Lenvatinib) for Patients With Certain Types of Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (Olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA\u00ae (Olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Japan Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (Pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Japan Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Begins First Human Trial of AI-Designed Fibrosis Drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ISM001-055","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech\u2019s Partner NeoTX at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Active Biotech \/ NeoTX","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Pan-Cyclophilin A","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo Reports Interim Data from ACTIVATE Phase 1b\/2 Study of Etigilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Granted New Japanese Patent for KETABET\u2122 (Ketamine Combination Formulation), Strengthening Global Patent Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Reports that None of the Mutations Present in SARS-CoV-2 Variant, Omicron, are Associated with Escape from ADG20 Neutralization In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caldolor Now FDA Approved For Pre-Operative Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"ICURE PHARM, INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icure Acquires Drug Product Approval for World\u2019s First Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"ICURE PHARM, INC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"ICURE PHARM, INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ICURE PHAR.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Treatment for Rare Blood Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK2V617F","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philippines Approves Emergency Use of Novavax's COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (Pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Authorizes Use of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine) in Children 5 to 11 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Henan Normal University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China-Developed Oral COVID-19 Drug Expected to Be Approved for Market Use in December","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Azvudine","moa":"Reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Henan Normal University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Henan Normal University \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Henan Norm.."},{"orgOrder":0,"company":"Calroy Health Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calroy Health Sciences Awarded U.S. Patent for Vulnerable Plaque Stabilization and Regression","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Rhamnan Sulfate","moa":"Thrombin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Calroy Health Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calroy Health Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calroy Hea.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces that Pfizer Reports Topline Results from Phase 2b Clinical Study of Vupanorsen","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree LLC","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) For Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Perception Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"GEO-CM02","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Presentations from the Company\u2019s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Shanghai Zhijiang Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bispecific Antibody Drug Against Covid-19 Jointly Developed By Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals Appearing at China International Import Expo (CIIE)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SYZJ001","moa":"SARS-CoV-2 virus protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shanghai Zhijiang Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Shanghai Zhijiang Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK\u2122 in Patients with Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI\u00ae (Aviptadil) Treated Patients Previously Administered Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Expects To Receive Complete Response Letter From The Fda For Its New Drug Application For Pedmark\u2122 To Prevent Ototoxicity Associated With Cisplatin In Pediatric Patients With Localized, Non-Metastatic, Solid Tumors","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Provides Regulatory Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ \/ HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone\u2019s Self-Amplifying mRNA COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Self-Amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Gritstone bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces First Patient Enrolled In Phase 1B Study Of SER-155, An Investigational Microbiome Therapeutic To Reduce The Risk Of Antibiotic-Resistant Bacterial Infections And Graft-Versus-Host Disease (GvHD)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"SER-155","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Launching IBSRELA Second Quarter of 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"MedRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Investigational New Drug Application Submitted for MRX-7MLL","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Memantine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"MedRx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"MedRx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MedRx \/ No.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals announces USFDA Tentative Approval for Dabigatran Etexilate Capsules, 150 mg.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Prothrombin","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ReCOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"ReCOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis Program at 2021 North American Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Termination","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Supreme Council of the Arab-African Economy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Supreme Council of the Arab-African Economy","highestDevelopmentStatusID":"9","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Cellenkos","sponsor":"BVCF Management Ltd","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellenkos\u00ae Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series A Financing","leadProduct":"CK0802","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ BVCF Management Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Monash University","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World-First Psilocybin Clinical Trial in The Treatment of Generalised Anxiety Disorder Receives Ethics Approval","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Monash University","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Monash University \/ Incannex Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Monash Uni.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium Receives March 11, 2022 PDUFA Date for New Drug Application for ADLARITY\u00ae Patch (Donepezil Transdermal System) for Treatment of Patients with Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beximco Pharma Introduces World's First Generic Molnupiravir, an Oral Antiviral Drug For COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Beximco Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beximco Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beximco Ph.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0.20000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi to Acquire Origimm Biotechnology in First Move to Treat Acne with Vaccine-Based Immunotherapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"ORI-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"3E Bioventures Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITabMed Completes Series A-Round Financing After Spin-off","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"A-319","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tianweiyuanhe Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianweiyuanhe Biomedical \/ 3E Bioventures Capital","highestDevelopmentStatusID":"6","companyTruncated":"Tianweiyua.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"zPREDICTA","sponsor":"Predictive Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology Acquires zPREDICTA, Inc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"zPREDICTA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"zPREDICTA \/ Predictive Oncology","highestDevelopmentStatusID":"4","companyTruncated":"zPREDICTA .."},{"orgOrder":0,"company":"Longeveron","sponsor":"EF Hutton","pharmaFlowCategory":"D","amount":"$20.5 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Bone Marrow-Derived Medicinal Signaling Cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Longeveron","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ EF Hutton","highestDevelopmentStatusID":"12","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"AviadoBio\u2122 Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"AVB-PGRN","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ New Enterprise Associates","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$1,618.0 million","upfrontCash":"$18.0 million","newsHeadline":"Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"AAV Capsids","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":1.6200000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.6200000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Dyno Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Thera.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trefoil Therapeutics Announces Third Tranche of $28 Million Series A Financing Based on Achievement of Clinical Trial Objectives","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"Engineered FGF-1","moa":"Corneal endothelial Cell proliferation acivator","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bayer Invests \u20ac100 million in Sustainable Health Products to Advance Company\u2019s 2030 Sustainability Commitments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Financing","leadProduct":"Aspirin","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bayer AG","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Hudson Institute of Medical Research","sponsor":"Noxopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA Vaccine","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hudson Institute of Medical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Hudson Institute of Medical Research \/ Noxopharm","highestDevelopmentStatusID":"2","companyTruncated":"Hudson Ins.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Notable and CicloMed Initiate Phase 1B\/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Fosciclopirox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"7","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"C4 holding BV","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"Amarna Therapeutics Secures Additional \u20ac5 ($5.7) Million to Advance Its Transformative Gene Therapy Platform Towards Clinical Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Financing","leadProduct":"AMA005","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Amarna Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Amarna Therapeutics \/ C4 holding BV","highestDevelopmentStatusID":"5","companyTruncated":"Amarna The.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series C Financing","leadProduct":"ACE1831","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Acepodia","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"4","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","amount":"$316.5 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Secures \u20ac280m of Funding to Expand and Advance Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Financing","leadProduct":"Pembrolizumab","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous","sponsorNew":"Sotio \/ PPF Group","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ PP.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities LLC","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Petros Pharmaceuticals Announces Closing of $10 Million Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Cardinal Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clarity and Cardinal Health Enter into Agreement for Targeted Copper Theranostics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"67Cu-labelled MeCOSar-Tyr3-octreotate","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Osteoblastic Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE\u00ae and Addition of SULANDA\u00ae in the National Reimbursement Drug List in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon Platform for Automated Manufacturing of Personalised CAR T-Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Autologous CAR-T Cells","moa":"NKG2D receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clarus Therapeutics Announces $15 Million Private Placement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","amount":"$20.3 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*Line Pharma Raises \u20ac17.5 Million ($20.3M) In Series B2 Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series B Financing","leadProduct":"PDC*lung01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Dosage Strength\/Form","sponsorNew":"PDC*line Pharma \/ Korea Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line P.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"RareStone","pharmaFlowCategory":"D","amount":"$75.5 million","upfrontCash":"$12.0 million","newsHeadline":"Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (Setmelanotide) in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ RareStone","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"MTS Securities","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellicum Announces Positive Interim Data from Phase 1\/2 GoCAR-T\u00ae Studies, Secures $35 Million Private Placement Equity Financing Priced at Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ MTS Securities","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$25.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone Bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"SAM Covid-19 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gritstone bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Gritstone bio \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Scynexis","sponsor":"FDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ FDA","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"IQVIA","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ ASLAN Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ AS.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","amount":"$168.0 million","upfrontCash":"$88.0 million","newsHeadline":"Aerie Concludes Exclusive License Agreement With Santen for Rhopressa\u00ae and Rocklatan\u00ae in Europe and Several Other Regions","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Opelconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Pulmocide \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide .."},{"orgOrder":0,"company":"Biomm","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Biomm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biomm \/ Lupin","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Lu.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","amount":"$847.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recordati to Acquire Eusa Pharma (UK) Ltd, A Global Specialty Pharmaceutical Company Focused on Rare and Niche Oncology Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eusa Pharma","amount2":0.84999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"12","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Ltd Partners with Tabuk Pharmaceuticals to Commercialise Its Speciality Generic Medicines in the Middle East","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Insulin Glargine","moa":"Insulin receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tabuk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Pen Injection","sponsorNew":"Tabuk Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Tabuk Phar.."},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"FoxWayne Enterprises","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Merger","leadProduct":"Imatinib Mesylate","moa":"ABL1 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerami Therapeutics \/ FoxWayne Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Aerami The.."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Delix Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Aegis Capital Corp.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clarus Therapeutics Announces Closing of Approximately $15 Million Private Placement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"UNICEF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNICEF Signs Supply Agreement for Clover COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"SCB-2019","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ UNICEF","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Proteros","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Arbutus Biopharma \/ Proteros","highestDevelopmentStatusID":"2","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","amount":"$98.3 million","upfrontCash":"Undisclosed","newsHeadline":"Emergence Therapeutics Raises \u20ac87 million Series A Financing to Advance Nectin-4 ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"ETx-22","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Emergence Therapeutics \/ Pontifax Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Emergence .."},{"orgOrder":0,"company":"Mycotopia Therapies","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mycotopia and Ei.Ventures Sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million Transaction, And Will Apply To List Shares On NASDAQ","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mycotopia Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Mycotopia Therapies \/ Ei.Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mycotopia .."},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Sotio \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Me.."},{"orgOrder":0,"company":"Avistone Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avistone Pharmaceuticals Secures $200 Million Strategic Investment From Vivo Capital, Bain Capital and Primavera Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avistone Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Avistone Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"1","companyTruncated":"Avistone P.."},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Lumira Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series B Financing","leadProduct":"OM1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous","sponsorNew":"OncoMyx Therapeutics \/ Lumira Ventures","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Th.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Anti-CSP IgM Antibodies","moa":"CSP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"IGM Biosciences \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$610.0 million","upfrontCash":"$76.5 million","newsHeadline":"Continued Strong Cresemba\u00ae (Isavuconazole) Sales by Pfizer Trigger USD 10 Million Sales Milestone Payment to Basilea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0.60999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Valneva","sponsor":"Kingdom of Bahrain","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Kingdom of Bahrain","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ .."},{"orgOrder":0,"company":"Qiagen","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qiagen \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ D.."},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$5.0 million","newsHeadline":"SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Bi.."},{"orgOrder":0,"company":"Bloom Science","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bloom Science Raises USD $12 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"BL-001","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bloom Science \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Scie.."},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Richter and Hikma Sign Exclusive Commercialisation and License Agreement for Denosumab in the US, a Proposed Biosimilar Referencing Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gedeon Richter \/ Hikma","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Ric.."},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"TOS-358","moa":"PI3K alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medi.."},{"orgOrder":0,"company":"Define Biotech","sponsor":"ABVC BioPharma","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Beta Glucan","moa":"Beta glucan receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Define Biotech","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Define Biotech \/ ABVC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Define Bio.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kreos Capital","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Restructures Kreos Capital Bond Financing Agreement and Raises \u20ac15 Million in Private Placement ","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$152.0 million","upfrontCash":"$117.0 million","newsHeadline":"Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Incyte","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"$50.0 million","newsHeadline":"Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Regor Therapeutics","amount2":1.55,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":1.55,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Regor Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Regor Ther.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Gavi","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Partnership for Accelerating Cancer Therapies","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Partnership for Accelerating Cancer Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Partnership for Accelerating Cancer Therapies \/ Candel Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Partnershi.."},{"orgOrder":0,"company":"Biosion","sponsor":"OBI Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"BSI04702","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biosion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Biosion \/ OBI Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Biosion \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$6,700.0 million","upfrontCash":"$6,700.0 million","newsHeadline":"Pfizer to Acquire Arena Pharmaceuticals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":6.7000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":6.7000000000000002,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Partners with Affinivax to Develop a Novel COVID-19 Vaccine to Target Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Affinivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"2","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$23.6 million","newsHeadline":"Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class Il-1 RAP Antagonist Monoclonal Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ichnos Sciences \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$12.5 million","newsHeadline":"Vaccitech Acquires Avidea Technologies to Expand Product Pipeline and Strengthen Scientific Leadership in Immunotherapies and Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"SNAPvax Cancer Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avidea Technologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous","sponsorNew":"Avidea Technologies \/ Vaccitech plc","highestDevelopmentStatusID":"5","companyTruncated":"Avidea Tec.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$190.5 million","upfrontCash":"$20.0 million","newsHeadline":"Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"KER-050","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Hansoh","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"$40.0 million","newsHeadline":"Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"GalNAc-RNAi","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0.29999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Qilu Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca\u2019s Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$920.0 million","upfrontCash":"$150.0 million","newsHeadline":"Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics\u2019 TCR Bispecific Program IMA401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"IMA401","moa":"MAGEA4\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.92000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.92000000000000004,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$100.0 million","newsHeadline":"Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Financing","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.20000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Myrtelle","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myrtelle Announces Exclusive Worldwide Gene Therapy Licensing Agreement for Canavan Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV-Olig001-ASPA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Myrtelle \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/.."},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$77.4 million","upfrontCash":"$4.7 million","newsHeadline":"Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intratumoral","sponsorNew":"VCN Biosciences \/ Grifols","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosci.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Assertio Holdings","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"$18.0 million","newsHeadline":"Assertio Holdings, Inc. Announces the Acquisition of Otrexup\u00ae (Methotrexate) a Drug Device Combination from Antares Pharma, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Antares Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Assertio Holdings","highestDevelopmentStatusID":"12","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Orpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Orpharm","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"180 Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"HMGB1","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"University of Oxford \/ 180 Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"NTC","sponsor":"I-MED","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NTC and I-MED Pharma Form Strategic Partnership to Bring the Leading HA-Based Dry Eye Ointment to The United States Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NTC","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"NTC \/ I-MED","highestDevelopmentStatusID":"12","companyTruncated":"NTC \/ I-ME.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"SH-879","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Wellcome","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige BioPharma and Dr. Reddy\u2019s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prestige BioPharma Pte Ltd \/ Dr. Reddy\u2019s","highestDevelopmentStatusID":"10","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerogen and CanSinoBIO Agree on Landmark Development and Commercial Supply Partnership for World\u2019s First Inhaled Covid-19 Vaccine Delivery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Convidecia","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aerogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aerogen \/ CanSinoBIO","highestDevelopmentStatusID":"12","companyTruncated":"Aerogen \/ .."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swiss Federal Funding","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Covab 36","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Memo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Memo Therapeutics \/ Swiss Federal Funding","highestDevelopmentStatusID":"4","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Swiss Federal Office of Public Health","pharmaFlowCategory":"D","amount":"$7.3 million","upfrontCash":"Undisclosed","newsHeadline":"Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Temelimab","moa":"HERV-W envelope","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"GeNeuro \/ Swiss Federal Office of Public Health","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biofontera Inc. Announces Closing of $15 million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Biofrontera \/ Wellcome","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"CYAD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ F.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"H.C. Wainwright & Co. ","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Esperion Announces Pricing of $225 Million Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ H.C. Wainwright & Co. ","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$12,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Recursion Pharma","amount2":12.15,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":12.15,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Roche ","highestDevelopmentStatusID":"3","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"$40.0 million","newsHeadline":"Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Cisplatin","moa":"HER2 biparatopic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0.42999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$11,700.0 million","upfrontCash":"$11,700.0 million","newsHeadline":"CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":11.699999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":11.699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$300.0 million","newsHeadline":"Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn\u2019s Proprietary Gene Traffic Control\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.38,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Foghorn Therapeutics \/ Loxo Oncology","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"GBT Announces Pricing of Upsized Offering of $300.0 Million of Convertible Senior Notes","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Legend Biotech Corporation Announces Proposed Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"R-Ketamine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Metastatic Breast Cancer ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,355.0 million","upfrontCash":"$50.0 million","newsHeadline":"Novartis Terminates Remestemcel-L Development Agreement with Mesoblast","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2021","year":"2021","type":"Termination","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":1.3500000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.3500000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp I","pharmaFlowCategory":"D","amount":"$1,640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (\u201cSPAC\u201d) Enter into Letter of Intent for Proposed Business Combination","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":1.6399999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":1.6399999999999999,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp I","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica In License and Supply Deals With Novartis and Arcellx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oxford Biomedica \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology ","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"A197","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Topical","sponsorNew":"Aramis Biosciences \/ Safar Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Bio.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Provides Regulatory Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA\u00ae for Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI\u2122","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Presents Updated Data from RESCUE-ALS Phase 2 Study at 4th Annual ALS ONE Research Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Gold Nanocrystals","moa":"Cellular energy production","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Corp.Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Nodular Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RTX-T1D","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Entolimod","moa":"TLR5","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Statera Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Statera Biopharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PUL-042","moa":"TLR 9 Agonist","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"GM-CSF","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 activation\/HSV-1 replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYABIO International Receives Regulatory Approval for Hiyasta\u00ae Monotherapy of Peripheral T-Cell Lymphoma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Marks Enrollment Milestone in Dermatitis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"EB01","moa":"sPLA2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Seeks DCGI's Approval for Covishield as Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Monalizumab","moa":"NKG2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Hepagene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"HPG1860","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepagene Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepagene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepagene T.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARASENS Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets\u2019 Channelchek Virtual Roadshow","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1\/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals\u2019 Novel Drug Candidate Demonstrates Significant Anti-inflammatory and Anti-fibrotic Activity in Multi-organ Fibrosis Preclinical Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"EHP-101","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald He.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Announces FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CAR T Gene Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Comments on COV-Boost Clinical Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol Medical AB (PUBL) Will Not Reach 300 PFS Events in t\r\nthe AGENT Study with Current Censoring Rules Based on FDA Decision","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Scientists Discover New B Cell that Tempers Autoimmunity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"I27-Breg","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Eye Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National E.."},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adrenomed Receives Positive EMA Scientific Advice for Further Clinical Development of Adrecizumab in Septic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adrecizumab","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Significantly Increased Overall Survival in Patients with Advanced Hormone-Sensitive Prostate Cancer - the Main Endpoint of the ARASENS Study was Achieved","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IGM-2323","moa":"CD20 x CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG116","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo\u00ae for Patients Living With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibalisumab","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Presents Promising Clinical Data on SRF617 at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Provides Recruitment Update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Follow-Up Information on Oxford University and the Company\u2019s Successful Dupuytren\u2019s Phase 2b Clinical Trial Results","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Nodular Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sustaine Release Tablet","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched In Bromelain","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"MCLA-145","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1\/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nivolumab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and\/or Myocardial Ischemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1\/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol\u00ae Cyclo\u2122 for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atamyo Therapeutics Obtains First Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-100, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I\/R9","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ATA-100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Atamyo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atamyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Atamyo The.."},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer\u2019s Disease and Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Kamuvudine Derivative","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Inflammaso.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Submits New Drug Application for Poziotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector to Present at 3rd Targeted Radiopharmaceutical Summit 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"LY3305677","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT\u00ae (Avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I\/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upadacitinib (RINVOQ\u00ae) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 with New Data Underscoring Ambition to Redefine Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (Pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (?12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Shows GSK-Vir Drug Works Against All Omicron Mutations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains High Efficacy Regardless of Lower Respiratory Tract Disease Severity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Seasonal Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Revalesio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Clinical Data on Revalesio\u2019s RNS60 Presented at 32nd International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RNS60","moa":"IntraCellular signaling","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Provide Update on Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Pfizer\u2019s XELJANZ\u00ae (Tofacitinib) for the Treatment of Active Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Additional Phase 2\/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Announce Updated Phase 1\/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s Cibinqo\u00ae (Abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius' Phase 3 Clinical Study of Novel PD-1 Inhibitor Serplulimab for the Treatment of First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Meets Primary Study Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S to Host Virtual R&D Program Update on December 14","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Resiquimod","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra Articular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech: Update on Regulatory Interactions for the RELEASE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"FS222","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present at Upcoming Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Interleukin-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VIP152","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech Reports Promising Interim Efficacy Analysis in Phase 1b\/2a Clinical Study in Chronic HBV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actemra\/RoActemra Approved by the European Commission to Treat Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CODA Biotherapeutics' Chemogenetic Gene Therapy Platform Can Control Focal Seizures In Vivo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV Vector Based Gene Therapy","moa":"Ligand gated ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Coda Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Coda Bioth.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld (Formerly AZD7442) Long-Acting Antibody Combination Authorised for Emergency Use in the US for Pre-Exposure Prophylaxis (Prevention) of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VUITY\u2122 (Pilocarpine HCI Ophthalmic Solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u00ae (Upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Bone Marrow-Derived Medicinal Signaling Cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"HER2 biparatopic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn\u2019s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"NeurOp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"NP10679","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NeurOp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeurOp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeurOp \/ N.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longest Follow-Up Data on Trastuzumab Biosimilar Presented at 2021 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Positive Phase 3 Dupixent\u00ae (Dupilumab) Results in Children with Moderate-To-Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Kisqali\u00ae Data Shows Consistent Overall Survival Benefit Across Genomic and Clinical Subtypes of Interest in HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Initiates Patient Recruitment for a Phase 1\/2a Trial of Innate Cell Engager AFM24 in Combination with Roche\u2019s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Bio Announces Amubarvimab\/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sahpra Approval of Booster Dosing with the Pfizer (COMIRNATY\u00ae) COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1010","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Chosen by XORTX Therapeutics, Inc. to Conduct Pharmacokinetic Bridging Study XRX-OXY-101 in Support of Developing New Therapies for Progressive Kidney Disease and Acute Kidney Injury","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Altasciences","highestDevelopmentStatusID":"4","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Additional Analyses Further Reinforce Ground-Breaking Efficacy in Patients with HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix\u00ae for IBS-C and IBS-D at Gastro 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"XW003","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Another Clean Interim Safety Review of RhoVac's Clinical Phase IIb Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Announces EPICS-IIITM Phase 2(b)\/3 Adaptive Pivotal Clinical Trial of Saroglitazar Mg in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Saroglitazar magnesium","moa":"PPAR alpha\/gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Lanreotide Injection","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Venlafaxine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus to Begin Phase II (a) Clinical Trial of ZYIL1, a Novel Oral NLRP3 Inflammasome Inhibitor in Patients with CryopyrinAssociated Periodic Syndrome (CAPS) in Australia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ZYIL1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval From USFDA for Cariprazine Capsules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ALG-055009","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech\u2019s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed to Host VirtualInvestor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Presents\u00a0Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IOA-289","moa":"Autotaxin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Shows No Dose-limiting Toxicity and Reduced T-regs in Solid Tumor Study of PI3K? Inhibitor IOA-244 Presented at ESMO-IO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI\u00ae and BriLife COVID-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech\u2019s Novel Anti-TIGIT Tiragolumab Plus Tecentriq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT\u00ae ? (Amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Vamifeport","moa":"Ferroportin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trodelvy\u00ae Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Presents New Melflufen Data at The Annual American Society of Hematology Meeting ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indication of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Applauds U.S. House of Representatives for Passing ACT for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Expanded Treg Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Highlight Efficacy of Piqray\u00ae in HR+\/HER2- Metastatic Breast Cancer With a PIK3CA Driver Mutation Immediately Post-CDK4\/6i","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Alpelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from The Phase II CITYSCAPE Trial Show Encouraging Results with Roche\u2019s Novel Anti-TIGIT Tiragolumab Plus Tecentriq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod\u00a0\u00a0","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT Bio Partner Quratis Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio\u2019s RNA COVID-19 Vaccine in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Quratis","highestDevelopmentStatusID":"6","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia\/Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Study Led by City of Hope Shows First-in-Class Cancer Immunotherapy Achieves High Rate of Remission in Patients With a Type of Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Receives FDA Approval for New SCULPTRA\u00ae Label, Offering More Options to Aesthetic Partners","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Talquetamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"HGB-206","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel\u00ae at the 63rd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ\u00ae Injections at 2-Year Follow-Up of REFLECT Phase III Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenadogene Nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Teclistamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based Approach to Treating Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medi.."},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Ph.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CAT-248","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19\/CD20 CAR-T Cell Therapy for Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"C-CAR039","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021\u00a0ASH\u00a0Annual\u00a0Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"HMPL-523","moa":"SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"HM43239","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ORIC-533","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspaveli\u00ae\/Empaveli\u2122 (Pegcetacoplan) Demonstrated Sustained Normalisation of Clinical Measures in a Broad PNH Patient Population","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi ","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CPI-818","moa":"ITK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Presenting New Bylvay\u2122 (Odevixibat) Data at NASPGHAN 2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON at ASH-2021: Iadademstat 36-Month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CLN-081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 3 Dupixent\u00ae (Dupilumab) Data in Children 6 Months to 5 Years with Moderate-To-Severe Atopic Dermatitis Featured in RAD 2021 Late-Breaking Session","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia to Further Characterize Lucerastat for The Treatment of Fabry Disease by Continuing the Open-Label Extension of the Phase 3 MODIFY Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lucerastat","moa":"GCS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Hard Gelatin Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Data from Phase III HAVEN 6 Study Demonstrate Favourable Safety and Efficacy Profile of Roche\u2019s Hemlibra in People with Moderate or Mild Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"City of Hope Researchers Help Find Improved Treatment Options for Patients With Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"City of Hope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASH 2021 | Ascentage Pharma Releases Long-Term Clinical Data of Olverembatinib (HQP1351) in Oral Presentation Demonstrating Efficacy and Safety","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in the MIV-818 Combination Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IMU-935","moa":"ROR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Issuance of U.S. Patent No. 11,197,906 Covering OKYO Pharma\u2019s Drug Candidate OK-101 for Use to Treat Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"OK-101","moa":"Chemerin receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Provides Pipeline Update for TriTAC Clinical Programs and T Cell Engager Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"HPN328","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Phase II\/III Clinical Trial Launched for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic\u2019s Dr. Anthony Maida to Present at 2nd Annual TGF-? for Immuno-Oncology Drug Development Summit in January 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People with Previously Untreated Aggressive Form of Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From Two Phase 3 Studies Demonstrating Fitusiran Significantly Reduced Bleeds in People with Hemophilia A or B, with or without Inhibitors, Were Featured at ASH\u2019s Plenary and Late-Breaking Sessions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Givosiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Receives Orphan Drug Designation from European Commission for Atrasentan for Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"iCAD","sponsor":"Xoft Brain","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"iCAD","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"iCAD \/ Xoft Brain","highestDevelopmentStatusID":"8","companyTruncated":"iCAD \/ Xof.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual \nMeeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Eprenetapopt","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes\u2122 Trial in Patients with Mucosal Pemphigus Vulgaris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant ","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Generation Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAR T-cell Therapy Found Equivalent to Standard of Care as Second-line Treatment for Aggressive non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Announces Tilsotolimod Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Announce Positive Preliminary Booster Data for Their COVID-19 Vaccine Candidate and Continuation of Phase 3 Trial per Independent Monitoring Board Recommendation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Extends COVID-19 Phase 2 Study with Oral Antiviral LAU-7b that has Showed 100% Reduction in the Risk of Progression onto Mechanical Ventilation and Death","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Confo Therapeutics Expands Patent Estate for ConfoBody\u00ae-Based GPCR Screening Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"VarmX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in First-in-Human Trial for VarmX\u2019s Anticoagulant Reversal Agent, VMX-C001","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VMX-C001","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"VarmX","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VarmX \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VarmX \/ No.."},{"orgOrder":0,"company":"MYND Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MYND Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MYND Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MYND Life .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review for Spesolimab for The Treatment of Flares in Patients with Generalized Pustular Psoriasis (GPP), A Rare, Life-Threatening Skin Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Spesolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ABL111","moa":"CD137 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"NUV-422","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Mitotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/.."},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Folic-acid Functionalized C\\'Dot-Drug-Conjugate","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida On.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Tasquinimod Data Presented at ASH 2021 Available on Active Biotech\u2019s Website","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS\u2019 Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)\/ FLORetina Symposia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine\u2019s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Gold Nanocrystals","moa":"Cellular energy production","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Suggest COVAXIN\u2122 (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl\u00ae (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kolon TissueGene To Expand Indications For TG-C","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"TissueGene-C","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra Articular Injection","sponsorNew":"Kolon TissueGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Tiss.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO\u00ae for the Treatment of Advanced Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Grunenthal","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA\u2019s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb\u2019s Breyanzi (Lisocabtagene Maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results\n12\/11\/2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xevudy (Sotrovimab) Granted Marketing Authorisation by The European Commission for the Early Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Bamlanivimab with Etesevimab Authorized as The First and Only Neutralizing Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Accelerates Development of Nebulised Cocktail Therapy (CT-P63 in combination with CT-P59) Using Its Antibody Platform to Tackle New COVID-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CT-P63","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides Update on RINVOQ\u00ae (Upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VX-147","moa":"ApoL1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Pharmaceuticals Receives Complete Response Letter From The FDA For Plinabulin New Drug Application For Prevention Of Chemotherapy-Induced Neutropenia (CIN)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofontera Obtains Notice of Allowance For US Patent on Innovative Illumination Protocol","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b\/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Humanized Anti-CD117 Monoclonal Antibody","moa":"CD117","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Withdrawal of EMA Marketing Authorization for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angoin and Vifor Pharma Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac-Surgery Associated with Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Terevalefim","moa":"HGF","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz\u00ae + BF-RhodoLED\u00ae in Moderate-to-Severe Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IGM-2323","moa":"CD20 x CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 \/ 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T\u2122 Cell Therapy in Relapsed\/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ALLO-647","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xbrane Has Initiated Development of Two New Biosimilar Candidates, Building an Oncology Biosimilar Portfolio Targeting \u20ac23B in Annual Reference Product Sales","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xbrane Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xbrane Biopharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Xbrane Bio.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Reports Reduction in In-Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG20","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BB21217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"2Seventy Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces Nurtec ODT Receives First Global Approval Outside the U.S. for Prevention of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1\/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pegtibatinase","moa":"CBS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Calliditas Therapeutics Accelerated Approval of TARPEYO\u2122 (Budesonide) to Reduce Proteinuria in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Delayed-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b\/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BEAM-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed \/ Refractory DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"FT516","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners\u2019 Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI\u00ae and BriLife COVID-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Israel Institute for Biological Research \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Xencor","sponsor":"Zenas BioPharma","pharmaFlowCategory":"D","amount":"$480.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Obexelimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Xencor","amount2":0.47999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Zenas BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Z.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"SIM0417","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica","highestDevelopmentStatusID":"4","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"CMG-SDIC Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series C Financing","leadProduct":"rAAV-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Neurophth Therapeutics \/ CMG-SDIC Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Initiates Phase 3 Clinical Program of Donidalorsen in Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Donidalorsen Sodium","moa":"Prekallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP-721","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BNT111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY\u00ae in Children 5 to under 12 Years of Age in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Ncardia","sponsor":"Kiniciti","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"iPSC-based Allogenic Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ncardia","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ncardia \/ Kiniciti","highestDevelopmentStatusID":"4","companyTruncated":"Ncardia \/ .."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Elivaldogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ CytRx Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Aluminum hydroxide","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Presents New Non-Clinical Data for TransCon\u2122 TLR7\/8 Agonist Oncology Program at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-targeted CRISPR-Cas9","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"INSTI - ULA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Exavir Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Exavir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Exavir The.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Covid vaccine: Bio E May submit Corbevax Trial Data This Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Completes Recruitment in Its International Phase 3 SPRINTER Study of SNG001 in Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics\u2019 Uproleselan for the Treatment of AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TenNor Reports Positive Results of TNP-2092 Capsule for the Treatment of Liver Cirrhosis Hyperammonemia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"TNP-2092","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TenNor The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$3,585.0 million","upfrontCash":"$200.0 million","newsHeadline":"AstraZeneca and Ionis Sign Deal to Develop and Commercialise Eplontersen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":3.5899999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.5899999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$119.6 million","upfrontCash":"Undisclosed","newsHeadline":"Anaveon to raise CHF 110 million in oversubscribed Series B financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series B Financing","leadProduct":"ANV419","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"Novadiscovery","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novadiscovery Expands Janssen Collaboration by Implementing its JINKO\u00ae Clinical Trial Simulation Platform for The Development of Lung Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Novadiscovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Novadiscovery \/ Janssen","highestDevelopmentStatusID":"2","companyTruncated":"Novadiscov.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$1,560.0 million","upfrontCash":"$25.0 million","newsHeadline":"Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Protein-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":1.5600000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.5600000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Alpine Immune Sciences \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Genfit","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$583.0 million","upfrontCash":"$137.7 million","newsHeadline":"Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0.57999999999999996,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ I.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Cerebral","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Twist Bioscience \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics Secures $98 Million in New Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Verge Genomics \/ BlackRock","highestDevelopmentStatusID":"3","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"Bioqube Ventures","sponsor":"Metrion Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metrion Biosciences and Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Kv1.3 potassium ion channel","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Bioqube Ventures","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Bioqube Ventures \/ Metrion","highestDevelopmentStatusID":"2","companyTruncated":"Bioqube Ve.."},{"orgOrder":0,"company":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital\u2019s Center for the Neuroscience of Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Psychedelic Compounds","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Massachusetts General Hospital Center for the Neuroscience of Psychedelics \/ atai","highestDevelopmentStatusID":"2","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Emotional Brain BV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Freya Pharma Solutions to Acquire All IP From Emotional Brain, Giving Opportunities to Further Examine Pharmaceutical Therapies for Female Sexual Interest\/Arousal Disorder in A Double Blind, Randomized Phase 3 Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"PDE5A","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Freya Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Freya Pharma \/ Emotional Brain BV","highestDevelopmentStatusID":"8","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Advances IMP761 Manufacturing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"IMP761","moa":"LAG-3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Northway Biotechpharma \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Northway B.."},{"orgOrder":0,"company":"BCI Pharma","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BCI Pharma Enters Into Strategic Partnership with Mithra to Identify Novel Therapy for Endometriosis and Cancer in Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CSF1R kinase","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"BCI Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"BCI Pharma \/ Mithra","highestDevelopmentStatusID":"4","companyTruncated":"BCI Pharma.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vera Therapeutics","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"$5.0 million","newsHeadline":"Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"MAU868","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous","sponsorNew":"Pfizer Inc \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"$0.5 million","newsHeadline":"Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Protein-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Dyadic International, Inc \/ Janssen","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Genfit","sponsor":"Genoscience Pharma","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"On heels of Global Strategic Partnership Announced Today, GENFIT Acquires Rights to Novel Asset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"GNS561","moa":"PPT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Genfit \/ Genoscience Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ G.."},{"orgOrder":0,"company":"Vaneltix Pharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"$6.7 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Vaneltix Pharma","amount2":0.01,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Prefilled Syringe","sponsorNew":"Vaneltix Pharma \/ Hyloris","highestDevelopmentStatusID":"8","companyTruncated":"Vaneltix P.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"$50.0 million","newsHeadline":"Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen\u00ae RPE Cell Therapy for the Treatment of Ocular Disorders","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.67000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$2,895.0 million","upfrontCash":"$300.0 million","newsHeadline":"BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene\u2019s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Ociperlimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":2.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.8999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARMGO Pharma Raises $35 Million to Progress Clinical Studies of Lead Molecule ARM210 in Cardiac and Skeletal Muscle Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"ARMGO Pharma \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Phar.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Dynamics Special Purpose Corp","pharmaFlowCategory":"D","amount":"$601.0 million","upfrontCash":"Undisclosed","newsHeadline":"Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"SENTI-202","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Senti Biosciences \/ Dynamics Special Purpose Corp","highestDevelopmentStatusID":"5","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantCapital","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Financing","leadProduct":"hAd5 S+N","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ImmunityBio","amount2":0.46999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ NantCapital","highestDevelopmentStatusID":"7","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Chord Ther.."},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Terra CoV-2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha-2A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,225.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Sanofi to Acquire Amunix Immuno-Oncology Pipeline with Next Generation Conditionally Activated Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":1.23,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.23,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ S.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"VBL Therapeutics Selected for \u20ac17.5 Million of Funding from Horizon Europe EIC Accelerator Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Ofranergene Obadenovec","moa":"Angiogenic\/vascular","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous","sponsorNew":"VBL Therapeutics \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"PharmaTher","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"LTS - Lohmann Therapie Systeme \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohm.."},{"orgOrder":0,"company":"WHO","sponsor":"Government of Belgium","pharmaFlowCategory":"D","amount":"$9.1 million","upfrontCash":"Undisclosed","newsHeadline":"Belgium and WHO Sign New Agreement to Increase Global Equitable Access to Essential Health Products and Technologies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WHO","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"WHO \/ Government of Belgium","highestDevelopmentStatusID":"1","companyTruncated":"WHO \/ Gove.."},{"orgOrder":0,"company":"Ambys Medicines","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"Allogenic Liver-cell Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ambys Medicines","amount2":0.050000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Ambys Medicines \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ambys Medi.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$257.5 million","upfrontCash":"$10.0 million","newsHeadline":"Ligand and GSK Expand Global Collaboration and License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.26000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"VaxAlta","sponsor":"Scandinavian Biopharma","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"VaxAlta Inc. Announces License Agreement With Scandinavian Biopharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Campylobacter Jejuni Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxAlta","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"VaxAlta \/ Scandinavian Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"VaxAlta \/ .."},{"orgOrder":0,"company":"Chroma Dermatology","sponsor":"DermBiont","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Ruboxistaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Chroma Dermatology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chroma Dermatology \/ DermBiont","highestDevelopmentStatusID":"6","companyTruncated":"Chroma Der.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"FS Development Corp. II","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Merger","leadProduct":"PBI- 0451","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pardes Biosciences \/ FS Development Corp. II","highestDevelopmentStatusID":"6","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"ANSTO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"No-carrier-added Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Isotope Technologies Munich \/ ANSTO","highestDevelopmentStatusID":"12","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$277.5 million","upfrontCash":"$75.0 million","newsHeadline":"Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO\u00ae (Selinexor) in Europe and Other Key Global Territories","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.28000000000000003,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"The Valens Company","sponsor":"PMI Mexico","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Valens Company Announces Two Strategic Agreements with PMI Mexico","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"The Valens Company","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"The Valens Company \/ PMI Mexico","highestDevelopmentStatusID":"1","companyTruncated":"The Valens.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"PRC Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Hypoxic Cultured Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ PRC Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heat Biologics Announces Planned Acquisition of Elusys Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Elusys The.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"The Lind Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Financing","leadProduct":"ATI-2307","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Appili Therapeutics \/ The Lind Partners","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Aerogen","pharmaFlowCategory":"D","amount":"$212.5 million","upfrontCash":"$20.0 million","newsHeadline":"Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AP-002","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nuance Pharma","amount2":0.20999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Inhalation","sponsorNew":"Nuance Pharma \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-PHARM","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pha.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$800.0 million","newsHeadline":"Novartis to Acquire Gyroscope Therapeutics, Adding a One-Time Gene Therapy that Could Transform Care for Geographic Atrophy, a Leading Cause of Blindness","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"GT005","moa":"CFI","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":1.5,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.5,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Enzene Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Prefilled Syringe","sponsorNew":"Enzene Biosciences \/ Theramex","highestDevelopmentStatusID":"1","companyTruncated":"Enzene Bio.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"HTL0016878","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":2.7000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":2.7000000000000002,"dosageForm":"Oral Solution","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Financing","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ SLR Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Eczac\u0131ba\u015f\u0131 Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Licensing and Commercialization Agreement With Eczacibasi for Lurbinectedin in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Eczac\u0131ba\u015f\u0131 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","amount":"$385.0 million","upfrontCash":"$40.0 million","newsHeadline":"Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.39000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Tasly Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$3,585.0 million","upfrontCash":"$200.0 million","newsHeadline":"Ionis and AstraZeneca Close Deal to Develop and Commercialize Eplontersen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":3.5899999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.5899999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Oravax Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyMD Pharmaceuticals \/ Oravax Medical","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Public Offering","leadProduct":"COVID-19 Nanosized Antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Anc80L65","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Affinia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Lumbar Puncture","sponsorNew":"Affinia Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"4","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Dovitinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Talem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Talem Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"2","companyTruncated":"Talem Ther.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$729.5 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Receives USD 10 Million Milestone Payment Related to Approval of Antifungal Cresemba\u00ae (Isavuconazole) in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0.72999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Oncorena","sponsor":"Linc AB","pharmaFlowCategory":"D","amount":"$17.7 million","upfrontCash":"Undisclosed","newsHeadline":"Oncorena Secures Financing of the Company's Continued Development of Orellanine, a Potential Breakthrough Therapy for Advanced Renal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Financing","leadProduct":"Orellanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Linc AB","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,975.0 million","upfrontCash":"$175.0 million","newsHeadline":"Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":1.98,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.98,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"McMaster University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rapid Dose Therapeutics and McMaster University Provide Update on COVID-19 Vaccine Research Collaboration with Orally Dissolvable QuickStrip\u2122 Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapid Dose Therapeutics \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose.."},{"orgOrder":0,"company":"Rapid Dose Therapeutics","sponsor":"Natural Sciences and Engineering Research Council of Canada","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rapid Dose Therapeutics and McMaster University\u2019s COVID-19 Vaccine Study Receives NSERC Research and Development Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Funding","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rapid Dose Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapid Dose Therapeutics \/ Natural Sciences and Engineering Research Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Rapid Dose.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India and Novavax Receive Emergency Use Authorization in India for COVOVAX\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Emergency Use Authorisation (EUA) to Launch Oral Anti-Viral Drug Cipmolnu\u00ae (Molnupiravir 200mg) in India for Treatment of Adult Patients With COVID-19, with SpO2>93% And with High Risk of Disease Progression Including Hospitalization or Dea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Gets DCGI Nod for Molnupiravir, to Launch Soon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Clinical Update on First Patients in Phase I\/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENVIMA\u00ae (Lenvatinib) Plus KEYTRUDA\u00ae (Pembrolizumab) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in IPH6101\/SAR443579 Phase 1\/2 Clinical Trial in Various Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IPH6101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVT02 Approved for Use in European Union","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Debio 0123","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Trial of SHR8058 Eye Drops (Perfluorohexyloctane) Conducted by Jiangsu Hengrui Pharmaceuticals in The People\u2019s Republic of China Shows Statistically Significant Topline Results","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Invios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"invIOs Goes Live with Unique Cell Therapy Platform and Clinical-Stage Immuno-Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"APN401","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Invios \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ N.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the Phase 4 Confirmatory Study of ADUHELM\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enalare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Th.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Orphan Drug Designation From US FDA for ZY-19489, A Novel Compound to Treat Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ZY-19489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Submits Phase 3 Data to Health Canada for Its Plant-Based COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AS03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Glaxosmith Kline","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Issues Advice for Potential Early Use of Pfizer\u2019s Novel COVID-19 Oral Antiviral Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-Acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Independent FDA Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results for BIMZELX[\u00ae]\u25bc(Bimekizumab) in Phase 3 Ankylosing Spondylitis Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the Development of Oral COVID-19 Drug Candidate AT-527 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Atea","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Doses First Patient in Phase 1\/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Kansas Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Gamma Delta T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IN8bio \/ University of Kansas Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ U.."},{"orgOrder":0,"company":"Old Dominion University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ODU Team Leads Study into Potential Role of Gas Plasma in Overcoming Cancer Therapy Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Trident Cold Atmospheric Plasma","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Old Dominion University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Old Dominion University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Old Domini.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TEZSPIRE (Tezepelumab) Approved in the US for Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"XT-150","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Index Knee Injection","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TEPMETKO\u00ae (Tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Receive Positive CHMP Opinion for PADCEV\u2122 (Enfortumab Vedotin) in Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-CD27 Monoclonal Antibody","moa":"Anti-CD27","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta\u00ae (Voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Tauriga Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tauriga Sc.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT\u2019s Oxbryta\u00ae (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse\u00ae for Treatment of Pulmonary Hypertension Associated with Sarcoidosis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Miromatrix Submits Pre-IND Request to the FDA for Its External Liver Assist Product to Treat Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"United The.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai Co.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Regulatory Submission for Aducanumab in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co.","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Australia in ATG-101 First-in-Human Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Adopts a Positive CHMP Opinion for Pfizer\u2019s and OPKO\u2019s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine 'COVOVAX","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides an Update on Phase III Ligelizumab (QGE031) Studies in Chronic Spontaneous Urticaria (CSU)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma Reports Positive Outcome of The Phase-IIIb DIAMOND Trial of Veltassa","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"AriBio","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Potential of PDE5 Inhibitors, Such as AriBio\u2019s AR1001, the Lead Clinical Candidate for Alzheimer\u2019s Disease, Confirmed in a Recent Independent Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"PDE5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Cleveland Clinic Genomic Medicine Institute","highestDevelopmentStatusID":"8","companyTruncated":"AriBio \/ C.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ALN-APP","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"5","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liver Cancer Patient Treated with Can-Fite\u2019s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Swiss PharmaCan","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swiss Pharmacan's Supplement Authorized for Immediate Clinical Study to Confirm Effectiveness Against Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Swiss PharmaCan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Swiss PharmaCan \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Swiss Phar.."},{"orgOrder":0,"company":"Stelis Biopharma","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stelis Biopharma Gets CDSCO Nod to Export 50 Million Doses of Sputnik Light Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Stelis Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Stelis Biopharma \/ RDIF","highestDevelopmentStatusID":"12","companyTruncated":"Stelis Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saphnelo Recommended for Approval in The EU by CHMP for The Treatment of Patients with Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company\u2019s NDA for Libervant\u2122 (diazepam) Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"ATONCO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"89Zr-DFO-girentuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Telix Pharmaceuticals \/ ATONCO","highestDevelopmentStatusID":"6","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences Prevails in BELBUCA\u00ae ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Provides Update on Investigational Viaskin\u2122 Peanut","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Epicutaneous Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"KIN-2787","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Avicanna","sponsor":"Harrington Wellness","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna and Harrington Wellness Launch re+PLAY\u2122 Branded CBD Topicals Products in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical","sponsorNew":"Avicanna \/ Harrington Wellness","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Provides Pemziviptadil (PB1046) Program Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT1A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Novaremed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaremed\u2019s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in UroGen Pharma\u2019s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PKMYT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Submits New Drug Application for FINTEPLA\u00ae (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Lebrikizumab Demonstrated Significant Skin Improvement and Itch Relief when Combined with Topical Corticosteroids in People with Atopic Dermatitis in Third Phase 3 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-Acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Studies from Oxford and Washington Universities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Regulatory Submission Accepted Under FDA Priority Review in The US for Adults with Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Comments on FDA Approval of Leqvio\u00ae, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9 mRNA RNAi Inhibitor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand\u2019s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly\u00ae) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ligand Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Traditional Chinese Medicine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Receives FDA Approval for The Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Intermountain Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intermountain Healthcare Researchers Play Key Role in New Study Finding Antiviral Drug is Effective in Preventing Severe Illness in COVID Patients When Given Early","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Intermountain Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Intermountain Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intermount.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Arcutis Biotherapeutics\u2019 New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Dovitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma\u2019s COVID-19 Oral and Intranasal\/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan\u2019s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains Under Review","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Otezla\u00ae (Apremilast) for The Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Lung 04 Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical receives IND approval for US trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"Lion TCR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"LioCyx-M004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lion TCR","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lion TCR \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lion TCR \/.."},{"orgOrder":0,"company":"Biocon","sponsor":"Equillium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biocon \/ Equillium","highestDevelopmentStatusID":"6","companyTruncated":"Biocon \/ E.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative Approval from U.S. FDA for Azilsartan Medoxomil Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Azilsartan","moa":"Angiotensin II receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin Gets Nod for Use in Kids Above 12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Notice Regarding the Initiation of a Global Phase 3 Clinical Trial for COVID-19 Recombinant Protein-based Vaccine, S-268019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"S-268019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback\u2019s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indications of Refractory Pemphigus Vulgaris and Pemphigus Foliaceus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Zenyaku Kogyo","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Zenyaku Ko.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Alzheimer\u2019s Disease Therapy Lecanemab Granted FDA Fast Track Designation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KEYTRUDA\u00ae (Pembrolizumab) Plus LENVIMA\u00ae (Lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion of Patient Enrollment in Phase II Clinical Trial of Gumokimab (IL-17 a Monoclonal Antibody, AK111) for The Treatment of Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Gumokimab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma announces FDA approval of Adbry\u2122 (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Plans to Launch Molnupiravir Capsules This Week for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia\/Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Triple monoamine reuptake","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Virus-like Particle Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Wins Court Decisions on Sanofi Appeals of Lantus\u00ae Patent Invalidations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Teclistamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Enrolls First Patient in U.S. Randomized, Controlled Pivotal Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1\/2 Sarcoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational\u00a0Treatment of Pediatric Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"STAT-201","moa":"Opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Statera Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Successfully Treats \u201cNo Option\u201d Patients with its JadiCell\u2122 Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"BioCorRx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"Societal CDMO \/ BioCorRx","highestDevelopmentStatusID":"6","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Immunolight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruiting Patients for Phase 1 Trial of the X-PACT System in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Methoxsalen","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunolight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Immunolight \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunoligh.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA\u00ae (Lumateperone) for the Treatment of Bipolar Depression in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK MHRA Awards Innovation Passport to Lysogene\u2019s Gene Therapy, LYS-GM101 to Treat GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"AAVrh.10 Expressing beta-galactosidase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Submits Biologics License Application for Proposed Biosimilar Trastuzumab to US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sandoz B2B \/ EirGenix","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BREXAFEMME\u00ae (Ibrexafungerp Tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Orencia\u00ae (Abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron\u2019s Next Generation Monoclonal Antibodies are Active Against All Known Variants of Concern, Including Both Omicron and Delta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Provides Update on APTO-253 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"APTO-253","moa":"Myc","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Seeks Nod for Phase-3 Trials of Intranasal COVID-19 Vaccine as Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin's Shelf Life Extended to 12 Months from Date of Manufacture","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXIN\u00ae for Children: Study Demonstrates Robust Safety and Immunogenicity in 2-18 Volunteers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Initial Findings From the Phase 1b\/2 Study of IMGN632 in Combination With Vidaza\u00ae and Venclexta\u00ae in Relapsed\/Refractory Acute Myeloid Leukemia at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta\u00ae Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical and Real-World Data Support Use of DARZALEX\u00ae (Daratumumab) in Patients with Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Presents Data from Pacritinib Program at the 63rd American Society of Hematology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Molecular Partners \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for \u03b2-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/Beta globulin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces T-Charge\u2122, Next-Generation CAR-T Platform with First-In-Human Data At ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ibrutinib","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ATA2271","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody\u00ae and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ADG153","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CYNK-101","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves XBiotech\u2019s IND in Rheumatology","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"XB2001","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Epinephrine Prodrug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"OSE-127","moa":"Il-7 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives FDA Approval for Vasopressin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Samsung Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Samsung Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$772.0 million","upfrontCash":"$30.0 million","newsHeadline":"Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"LBL-007","moa":"LAG3 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0.77000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.77000000000000002,"dosageForm":"Injection","sponsorNew":"Leads Biolabs \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biol.."},{"orgOrder":0,"company":"Organon","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$75.0 million","newsHeadline":"Organon Completes Acquisition of Forendo Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"FOR-6219","moa":"HSD17B1","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Organon","amount2":0.94999999999999996,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Organon \/ Organon","highestDevelopmentStatusID":"6","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and AstraZeneca Expand Strategic Manufacturing Partnership to Include COVID-19 and Cancer Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Samsung Biologics","amount2":0.38,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.38,"dosageForm":"Intramuscular Injection","sponsorNew":"Samsung Biologics \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","amount":"$15.2 million","upfrontCash":"Undisclosed","newsHeadline":"Numab and 3SBio\u2019s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"ND021","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Guojian Pharmaceutical","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Numab Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine G.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$580.0 million","upfrontCash":"$20.0 million","newsHeadline":"Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"DARPin-conjugated Radioligand Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Molecular Partners","amount2":0.57999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"Intratumoral","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas and Pfizer Announce PROTAC\u00ae Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"ARV-471","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Initiates a Phase 2b Dose-Ranging Clinical Trial With an Oral H4R Antagonist in Adult Patients With Moderate-to-Severe Atopic Dermatitis (AD)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"LEO 152020","moa":"H4R","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial on Alzheimer\u2019s Patients Indicates Positive Safety and Tolerability Data for IGC\u2019s THC-Based Investigational New Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$125.0 million","newsHeadline":"Omeros Announces Agreement to Sell OMIDRIA\u00ae Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Omeros","amount2":1,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":1,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"12","companyTruncated":"Omeros \/ R.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$2,220.0 million","upfrontCash":"$2,220.0 million","newsHeadline":"Pfizer Completes Acquisition of Trillium Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Maplirpacept","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":2.2200000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2200000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Merck","pharmaFlowCategory":"D","amount":"$11,500.0 million","upfrontCash":"$11,500.0 million","newsHeadline":"Merck Completes Acquisition of Acceleron Pharma Inc.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Sotatercept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":11.5,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":11.5,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Acceleron Pharma \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Montes Archimedes Acquisition Corporation","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Merger","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0.20000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"Topical Cream","sponsorNew":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$2,025.0 million","upfrontCash":"$1,425.0 million","newsHeadline":"MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"MorphoSys","amount2":2.0299999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.0299999999999998,"dosageForm":"","sponsorNew":"MorphoSys \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Rivaara Labs","sponsor":"GC Cell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Cell Inks First Licensing Agreement for Immuncell-LC\u00ae With Rivaara Immune Private Limited in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Autologous T-cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rivaara Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Rivaara Labs \/ GC Cell","highestDevelopmentStatusID":"12","companyTruncated":"Rivaara La.."},{"orgOrder":0,"company":"Amyris","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amyris and ImmunityBio Complete Joint Venture for Next Generation COVID-19 RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"hAd5 S+N","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Amyris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amyris \/ ImmunityBio","highestDevelopmentStatusID":"7","companyTruncated":"Amyris \/ I.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"$419.5 million","upfrontCash":"$4.5 million","newsHeadline":"Genmab and Synaffix Enter into License Agreement for ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Synaffix \/ Genmab","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"NaNotics LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NaNotics to Collaborate with Mayo Clinic on Nanomedicine Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"NaNot-antibody","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mayo Clinic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mayo Clinic \/ NaNotics LLC","highestDevelopmentStatusID":"4","companyTruncated":"Mayo Clini.."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Ray-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ 4BIO Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therap.."},{"orgOrder":0,"company":"BiomX","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CFF Supporting Phase 1\/2 Trial of Phage Therapy for P. aeruginosa Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"BiomX \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Cy.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumberland Pharmaceuticals Acquires Sancuso\u00ae From Kyowa Kirin North America","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Granisetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kyowa Kirin \/ Cumberland Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.27000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.27000000000000002,"dosageForm":"Inhalation Powder","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"MDimune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PCI Biotech and MDimune Announce Research Collaboration Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PCI Biotech \/ MDimune Inc.","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"SalioGen Therapeutics","sponsor":"GordonMD Global","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene CodingTM \u2013 A New Category of Genetic Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SalioGen Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"SalioGen Therapeutics \/ GordonMD Global","highestDevelopmentStatusID":"4","companyTruncated":"SalioGen T.."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$116.0 million","upfrontCash":"Undisclosed","newsHeadline":"Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline of RNA Editing Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Korro Bio \/ Eventide Asset Management","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","amount":"$21.5 million","upfrontCash":"Undisclosed","newsHeadline":"ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"ONKT102","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therap.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"NiKang Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2\u03b1 Inhibitor, and FOTIVDA\u00ae (Tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ NiKang Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"PLG0301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peptilogics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"The McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ The McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Acquires Saol Therapeutics\u2019 Baclofen Franchise","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Saol therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Saol therapeutics \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Saol thera.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Xicheng Jinrui Equity Investment Fund","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atom Bioscience Raises $45 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic Diseases","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series C Financing","leadProduct":"ABP-671","moa":"Urate transporter protein","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0.050000000000000003,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Xicheng Jinrui Equity Investment Fund","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.0 million","newsHeadline":"RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia\u00ae for the United Arab Emirates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$50.0 million","newsHeadline":"Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Nucleic acid-based Therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"University of Helsinki","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics Acquires University of Helsinki\u00b4s Technology that Capitalizes on Pre-Existing Immunity Acquired via Childhood Vaccination Programs to Potentiate the Efficacy of Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"PeptiCRAd-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Helsinki","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Helsinki \/ Valo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"MD Infusions","sponsor":"Front Door Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Front Door Health Launches Joint Venture with MD Infusions to Deliver Novel In-home Ketamine Treatment for Addiction and Mental Health Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MD Infusions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Infusions \/ Front Door Health","highestDevelopmentStatusID":"1","companyTruncated":"MD Infusio.."},{"orgOrder":0,"company":"SRI International","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SRI International Announces Collaboration Agreement with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"SRI International","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SRI International \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"3","companyTruncated":"SRI Intern.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Dutch Leiden University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Partners Dutch Leiden University Medical Center to Begin Phase I\/II Study of New Intranasal Corona Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Nanovac","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Intravacc \/ Dutch Leiden University Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Eversana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"OWP Pharmaceuticals \/ EVERSANA","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"Biorchestra","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antisense Oligonucleotides","moa":"microRNAs","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Biorchestra","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorchestra \/ SK Biopharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Biorchestr.."},{"orgOrder":0,"company":"Alumis","sponsor":"AyurMaya","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Esker Therapeutics Announces Name Change to Alumis and Completion of $200 Million Series B Financing to Advance Precision Medicines for Autoimmune Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"ESK-001","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Alumis","amount2":0.20000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Alumis \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Alumis \/ A.."},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"XB002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iconic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Iconic Therapeutics \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Iconic The.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$5.0 million","newsHeadline":"2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"MegaTAL mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"2Seventy Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"French Multidisciplinary Consortium ARPEGE Awarded Public Funding of Close To \u20ac9 Million to Fight Antibiotic Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"ANT3310","moa":"Serine beta-lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous","sponsorNew":"Antabio \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ .."},{"orgOrder":0,"company":"AbSci","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$610.0 million","newsHeadline":"Absci Announces Research Collaboration with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Enzyme","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"AbSci","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbSci \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"AbSci \/ Me.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0.45000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Warden Bio","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"AAV-mediated Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Warden Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Warden Bio \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Warden Bio.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"Epetraborole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AN2 Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coherus BioSciences Secures Credit Financing with Pharmakon Advisors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Pharmakon Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"KU Leuven","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"BHV-2100","moa":"TRPM3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"KU Leuven","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KU Leuven \/ Biohaven","highestDevelopmentStatusID":"4","companyTruncated":"KU Leuven .."},{"orgOrder":0,"company":"GSK","sponsor":"US Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorised for The Early Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ US Government","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ US G.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"MZE001","moa":"GYS1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0.19,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and HotSpot Therapeutics Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","amount":"$204.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CT103A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Sana Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$35.0 million","newsHeadline":"Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"JS006","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO\u00ae in Puerto Rico","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Testosterone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Verity Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Gel","sponsorNew":"Verity Pharmaceuticals Inc \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Verity Pha.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF) to Support UB-312 Vaccine Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"UB-312","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"EsoCap","sponsor":"Upadia Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EsoCap and Upadia Sign Exclusive Licensing Agreement Combining Eso Cap Technology with Upadia Antibodies for The Treatment of Barrett\u2019s Esophagus","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"EsoCap","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Upadia Holding","highestDevelopmentStatusID":"4","companyTruncated":"EsoCap \/ U.."},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"Agile Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agile Therapeutics and Afaxys Partner to Expand Access to Twirla\u00ae (Levonorgestrel and Ethinyl Estradiol) Transdermal System","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Afaxys Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Afaxys Pharma \/ Agile Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Afaxys Pha.."},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BigHat Biosciences Completes First Stage of Research Collaboration with Amgen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BigHat Biosciences \/ Amgen","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Bio.."},{"orgOrder":0,"company":"Quris","sponsor":"Welltech Ventures","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quris Closes $28 Million in Seed Funding From Top Institutional Investors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quris","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Quris \/ Welltech Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Quris \/ We.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Oligonucleotide Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Aligos Therapeutics","amount2":1.3799999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":1.3799999999999999,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Antion Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR\u2122 Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Antion Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$6.7 million","newsHeadline":"Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"NBI-921352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$75.0 million","newsHeadline":"AstraZeneca and Scorpion Therapeutics Enter Agreement to Discover, Develop and Commercialise Novel Cancer Treatments Against \u2018Undruggable\u2019 Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Bi.."},{"orgOrder":0,"company":"DeuteRx","sponsor":"Salarius Pharmaceuticals","pharmaFlowCategory":"D","amount":"$220.5 million","upfrontCash":"$1.5 million","newsHeadline":"Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Deuterium-stabilized S-avadomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"DeuteRx","amount2":0.22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"DeuteRx \/ Salarius","highestDevelopmentStatusID":"4","companyTruncated":"DeuteRx \/ .."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"$20.0 million","newsHeadline":"VYNE Therapeutics Divests Topical Minocycline Assets","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Journey Medical Corporation","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Hana Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"BOLD-100","moa":"GRP78","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Bold Therapeutics \/ Hana Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Vaccinal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vir Biotechnology","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Avicanna","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Knopp Biosciences LLC \/ Avicanna","highestDevelopmentStatusID":"12","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Gemcitabine","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Targovax \/ Innovation Norway","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"PR600","moa":"TNF","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Genocea","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genocea Biosciences Provides Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Cancer Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,240.0 million","upfrontCash":"$500.0 million","newsHeadline":"Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":1.24,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.24,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Adaptate Biotherapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (\u03b3\u03b4) T Cell Engager Therapies Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"ADT-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptate Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptate Biotherapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Adaptate B.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$193.6 million","upfrontCash":"Undisclosed","newsHeadline":"CinCor Pharma Announces Pricing of Initial Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.19,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"The University of Texas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"188RNL-BAM","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ The University of Texas","highestDevelopmentStatusID":"4","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Psychedelic-derived Therapeutic","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"1","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Erase PTSD","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Erase PTSD","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Irofulven","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Asymchem Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"AUM601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Asymchem","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"KYV-201","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Kyverna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx\u2019s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"CDX bi-specific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Selexis","highestDevelopmentStatusID":"4","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Lysogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Termination","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Sarepta Therapeutics \/ Lysogene","highestDevelopmentStatusID":"9","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Accuredit Therapeutics","sponsor":"N1 Life","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"N1-109","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Accuredit Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Accuredit Therapeutics \/ N1 Life","highestDevelopmentStatusID":"4","companyTruncated":"Accuredit .."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"MSN Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals Settles HETLIOZ\u00ae Patent Litigation with MSN","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ MSN Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Macquarie University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Government Grant to Apply NanoCelle\u00ae to an RNA Nasal Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medlab Clinical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medlab Clinical \/ Macquarie University","highestDevelopmentStatusID":"4","companyTruncated":"Medlab Cli.."},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CB Therapeutics and atai Life Sciences Launch TryptageniX to Sustainably Supply and Develop Clinically Relevant Compounds to Tackle the Growing Mental Health Crisis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"CB Therapeutics \/ atai Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CB Therape.."},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Covis Enters Promotion and Distribution Agreement for Two Respiratory Medicines, Seebri\u00ae Breezhaler\u00ae and Ultibro\u00ae Breezhaler\u00ae, in Canada","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic M2\/M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Covis Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder for Capsule","sponsorNew":"Covis Pharma \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Covis Phar.."},{"orgOrder":0,"company":"Elicera Therapeutics","sponsor":"Immunicum AB","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"$0.2 million","newsHeadline":"Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ad5PTD","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elicera Therapeutics \/ Immunicum AB","highestDevelopmentStatusID":"4","companyTruncated":"Elicera Th.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novavax \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week : Report","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces U.S. Court of Appeals for the Federal Circuit (CAFC) Upholds Validity of GILENYA\u00ae (Fingolimod) Dosage Regimen Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ALE.F02","moa":"Claudin-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives U.S. FDA Fast Track Designation for REQORSA\u2122 Immunogene Therapy in Combination with Keytruda\u00ae for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"Poly kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Reprioritizes Pipeline Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck's Anti- Covid Pill 'Molflu' 5-Day Course to Cost \u20b9 1,400 In India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Study Proves Capsule Material is Not Toxic for Encapsulated Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia and\/or Established Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First Generic Version of CUVPOSA\u00ae (glycopyrrolate) Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"Ach receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer Therapy Induced Skin Toxicity that Met Expectations","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"OQL011","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dusquetide","moa":"Innate defense","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"8-Methoxycoronaridine Hydrochloride","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive EMA Opinion for the Use of Teysuno in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegafur","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Nordic Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nordic Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Pha.."},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entod Pharma to Launch Generic Molnupiravir Under Brand Molentod in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Entod Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Entod Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Entod Phar.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"APN-850271","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington\u2019s Disease Following Six-Month Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Potassium ATP channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Ethics Board Approves Amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRASG12C","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-L-opsin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda\u00ae and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Sema4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences Achieves Successful Completion of Part A of MultipleAscending Dose (MAD)\/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nafamstat Mesylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMP360 Psilocybin Study of 89 Healthy Participants Published in Journal of Psychopharmacology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"VRDN-002","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Authorized Generic of Narcan\u00ae (Naloxone Hydrochloride) Nasal Spray 4 mg in US to Help Reverse Opioid Overdose, Expanding Access During Surge in Overdose Deaths","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Decitabine and Cedazuridine (ASTX727) Granted Orphan Drug Designation (ODD) by the European Commission for the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK life Science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Carisbamate","moa":"MAP2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Sc.."},{"orgOrder":0,"company":"Akeso","sponsor":"Dawnrays Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadonilimab (PD-1\/CTLA-4 Bispecific Antibody) in Combination with VEGFR-2 Monoclonal Antibody Obtained Approval to Initiate Phase Ib\/II Clinical Trial for Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"AK109","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Dawnrays Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Da.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Launches COVID-19 Drug Molnupiravir in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosight Reports Final Primary Endpoint Data from Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL\u00ae System for Soft-Tissue Reconstruction","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Regenerative Epidermal Suspension","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Avita Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avita Medi.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"23ME-00610","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics\u2019 Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO\u00ae (nivolumab) in Ongoing Phase 1\/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Halting Further Development of STOPS\u2122 Drug Candidate, ALG-010133","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"MDGN-002","moa":"LIGHT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"FIN-211","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-938","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR0602","moa":"TCR-V beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Th.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Highlights Strategic Priorities for 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin\u00ae in R\/R Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Suramin","moa":"P2Y2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Provides Update on Clinical Pipeline Progress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Dynacure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"DYN101","moa":"Dynamin 2 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dynacure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Announces FDA Clearance of IND for JBI-802, a Novel Dual LSD1 and HDAC6 Inhibitor, for treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-802","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Molnupiravir Under the Brand Name Molnulup for the Treatment of COVID-19 in Adults in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin reputake","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXIN\u00ae (BBV152) Booster Dose Study Shows Promising Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laekna Therapeutics and Innovent Biologics obtain IND Approval for Combination Therapy in Patients With Specific Types of Solid Tumors Who Have Been Refractory to Treatment With Pd-1\/pd-l1 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Afuresertib","moa":"Pan-AKT kinase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna The.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BEAM-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KAFTRIO\u00ae (ivacaftor\/tezacaftor\/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Life Science Alliance Journal Publishes Results of Plitidepsin in Patients With Covid-19, Which Includes Additional Data on Its Antiviral Activity Against Delta and Omicron Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"VEGF\/VEGFR-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"MSD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy\u00ae in Combination with KEYTRUDA\u00ae (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nanoparticle Encapsulating PDC-E2","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cour Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharm.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"NUV-422","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Macrogol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ MERIDIAN MEDICAL TECHNOLOGIES","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Human Immune Monitoring Center at Stanford University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX\u00ae3-71","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"AF710B","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Harvard University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Harvard University","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"5-HT1A\/2A\/2B\/7 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion Completes Enrolment in KHENERGYZE Phase IIb Trial Evaluating Sonlicromanol in Adult Patients With MELAS Spectrum Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single Dose of Mesoblast\u2019s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"SAR442720","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Medolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Caribbean Blue Scorpion Peptides Derived Extract","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medolife","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medolife \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medolife \/.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Presents Updated Clinical Data from Ongoing Phase 1\/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"CD34+ gene","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio\u2122 Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results of Pfizer\u2019s Phase 3 Study Exploring Coadministration of PREVNAR 20\u2122 With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT162b2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhittya Genesis Medicine Starts Parkinson\u2019s Disease Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zhittya Genesis Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Zhittya Genesis Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhittya Ge.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Potassium ATP channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CRN04894","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Phase 3 Ocean Study Published in the Lancet Haematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"C-CAR039","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 1 Study Of Its Mrna Epstein-barr Virus (Ebv) Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1189","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI\u00ae (durvalumab) and LYNPARZA\u00ae (olaparib) Data at ASCO GI and GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor The.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Shares Updated Corporate Presentation","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives European Approval for TransCon\u2122 hGH for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase Alfa","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Receives European Patent on Drug Composition to Treat Travelers\u2019 Diarrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-124E","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2\/3 Study in Severely Ill Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Pfizer\u2019s CIBINQO\u00ae (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Announces Positive Top-Line Results from Donesta\u00ae Phase 3 Studies in Menopausal Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Estetrol","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Specialty S.A. (Switzerland) Receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris\u2122 Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and ","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Oregon State University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oregon State Research Shows Hemp Compounds Prevent Coronavirus From Entering Human Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oregon State University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oregon Sta.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Receives USFDA Approval of Quviviq (Daridorexant) 25 and 50 Mg for the Treatment of Adults with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA\u00ae (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Psychedelic Therapy","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"DNL919","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMCY-0098","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Imcyse","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imcyse \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imcyse \/ N.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Provide Preliminary Update on Phase 1\/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Provides Regulatory Update on Galactosemia Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"T Cell-Enhanced Self-Amplifying mRNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology\u2019s LB-100 Reported to Convert Immunologically Unresponsive (\u201cCold\u201d) Tumors to Immunologically Responsive (\u201cHot\u201d) Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"Protein phosphatase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI\u00ae Phase 4 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Revefenacin","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"Poly kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Announces First Parkinson\u2019s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-312","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG20","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Polynoma","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polynoma Receives Special Protocol Assessment (SPA) Agreement from the U.S. FDA for a Pivotal Phase 3 Clinical Study of Seviprotimut-L, a Melanoma Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces U.S. FDA Approval of Recorlev (Levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Atropine","moa":"mAChRs","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Teligent, Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Teligent, Inc \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Teligent, .."},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EraCal Therapeutics Enters into Research Collaboration with Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ionis' Partner to Evaluate Tominersen for Huntington's Disease in New Phase 2 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Tominersen","moa":"Huntingtin mRNA antisense","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Human-derived Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Neurimmune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurimmune \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Phokam Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascletis Announces the Signing of a Purchase Agreement for Ritonavir Tablets with Phokam Pharmaceutical Import-Export Co., Ltd in Laos","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Ritonavir","moa":"CYP450 A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Phokam Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Divestment","leadProduct":"Amlodipine","moa":"L-Type VGCC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Cosette Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Amagma Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Amagma Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amagma Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amagma The.."},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engitix Announces $54m Series A Financing and a Strategic Collaboration with Domp\u00e9 Farmaceutici Using Exscalate\u2019s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Engitix Therapeutics \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Th.."},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Faeth Therapeutics Raises $20M to Advance Precision Nutrition Platform as A New Modality in Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Serabelisb","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Faeth Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Faeth Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Faeth Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"United Nations Children\u2019s Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ United Nations Children\u2019s Fund","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Leyden Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leyden Labs Licenses Pan-Influenza Antibody from Janssen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CR9114","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Leyden Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Danish Cancer Society Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ The Danish Cancer Society Research Center","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"MabGenesis","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with MabGenesis to Discover & Develop Novel Monoclonal Antibodies in Canine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"MabGenesis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MabGenesis \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"MabGenesis.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$59.7 million","upfrontCash":"Undisclosed","newsHeadline":"Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Tebipenem Pivoxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Spero Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SiteOne Therapeutics Announces Collaboration and License Agreement with Vertex Pharmaceuticals to Advance NaV1.7 Inhibitors for the Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"ST-2427","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SiteOne Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Th.."},{"orgOrder":0,"company":"Eleusis","sponsor":"Silver Spike Acquisition Corp","pharmaFlowCategory":"D","amount":"$446.0 million","upfrontCash":"Undisclosed","newsHeadline":"Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Merger","leadProduct":"ELE-Psilo","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Eleusis","amount2":0.45000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Eleusis \/ Silver Spike Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Eleusis \/ .."},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$111.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed\/Refractory B-cell Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"CD19-CD20 bi-specific CAR-T Cell Therapy","moa":"CD19\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmPACT Bio","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ venBio Partners","highestDevelopmentStatusID":"6","companyTruncated":"ImmPACT Bi.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience Initiates Sponsored Research Agreement With University of Pennsylvania Led by Dr Gregory Beatty","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"5-fluorouracil","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Natco Pharma Signs Pact With MPP to Sell Molnupiravir Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson and Yingli Pharma Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Linperlisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ MD Anderson","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Y.."},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophore Receives Sub-License From MPP to Manufacture and Market Molnupiravir for Covid Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"Biophore I.."},{"orgOrder":0,"company":"EdiGene","sponsor":"Haihe Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"ET-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"EdiGene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EdiGene \/ Haihe Laboratory","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleo Health Selected as Limited Distribution Partner for VYVGART\u2122","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Argenx SE","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Heal.."},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytovation Raises $20 Million in Series a Financing Round to Advance Clinical Development of CyPep-1, a First-In-Class Targeted Tumor Membrane Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRA (Avanafil) to the United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Indivior","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Combat Stress","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Combat Stress","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous","sponsorNew":"Atara Biotherapeutics \/ FUJIFILM Diosynth Biotechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Concentric Analgesics Announces Completion of $20 Million Financing and Appoints Two New Board Members as it Prepares to Initiate Registration-Enabling Phase 3 Studies for Vocacapsaicin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Vocacapsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concentric.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Medical University of South Carolina","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Medical University of South Carolina","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation to Continue Advancement of TRPML1 Agonists for GBA-Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"TRPML1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caraway Therapeutics \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Th.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Artisan Industries Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Cell Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Artisan Development Labs Inc.","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"VectorY","sponsor":"Wageningen University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wageningen University & Research and VectorY to Jointly Develop Novel Production Technologies for Safer and More Affordable Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Baculovirus-based AAV Vector","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ Wageningen University","highestDevelopmentStatusID":"1","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"SBI Investment Co","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Raises $2Million (\u00a5200M Yen) in Seed Funding Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Disulfide Rich Peptides","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ SBI Investment Co","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Tec.."},{"orgOrder":0,"company":"Xiamen Biotime Biotechnology","sponsor":"Adlai Nortye","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AN4005","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xiamen Biotime Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xiamen Biotime Biotechnology \/ Adlai Nortye Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Bio.."},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"PMI21","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ionetix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionetix \/ Precision Molecular","highestDevelopmentStatusID":"5","companyTruncated":"Ionetix \/ .."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"KYV-101","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Kyverna Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Northpond Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"CellCentric","sponsor":"BrightEdge","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CellCentric Secures Investment from The American Cancer Society\u2019s Impact Venture Capital Fund","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Inobrodib","moa":"p300\/CBP bromodomain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CellCentric \/ BrightEdge","highestDevelopmentStatusID":"7","companyTruncated":"CellCentri.."},{"orgOrder":0,"company":"Akome Biotech","sponsor":"University of Barcelona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Core One Labs\u2019 Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Thin Film Strip","sponsorNew":"Akome Biotech \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biot.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Expands Its Commercialization Partnership With Syneos Health for Daridorexant in Europe and Canada","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Syneos Health \/ Idorsia Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Institution of Biomedical Academic Research","sponsor":"genOway","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genoway Grants the Leading UK Academic Research Funder a Non-Exclusive License For CRISPR\/CAS9 Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Institution of Biomedical Academic Research","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institution of Biomedical Academic Research \/ genOway","highestDevelopmentStatusID":"4","companyTruncated":"Institutio.."},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Neurelis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aculys Pharma Signed an Exclusive Licensing Agreement with Neurelis, Inc. for The Development and Commercialization of VALTOCO\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aculys Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Aculys Pharma \/ Neurelis","highestDevelopmentStatusID":"12","companyTruncated":"Aculys Pha.."},{"orgOrder":0,"company":"Sanzyme","sponsor":"J.B.Chemicals & Pharmaceuticals","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"JB Chemicals To Acquire Brands from Sanzyme For Rs, 628 Crore","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Lacticacid Bacillus","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanzyme","amount2":0.080000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Sanzyme \/ JB Chemicals","highestDevelopmentStatusID":"12","companyTruncated":"Sanzyme \/ .."},{"orgOrder":0,"company":"Ostentus Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ostentus Therapeutics, Inc., and City of Hope to Initiate Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Plant-derived OST Compounds","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ostentus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ostentus Therapeutics \/ City of Hope","highestDevelopmentStatusID":"4","companyTruncated":"Ostentus T.."},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Promotional Agreement with Exeltis on SOLOSEC\u00ae (secnidazole) Expanding Access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Exeltis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral Granules","sponsorNew":"Exeltis \/ Lupin Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Exeltis \/ .."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"SDIC Venture Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ractigen Therapeutics Closes an Additional $30 Million in Series A+ Funding to Push Development of Its RNAa Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"RAG-06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ractigen Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ SDIC Venture Capital","highestDevelopmentStatusID":"5","companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Psychedelics-based Therapeutic","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Dalriada Drug Discovery","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dalriada Drug Discovery \/ atai Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Dalriada D.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Ocugen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Liminal BioSciences \/ Ocugen","highestDevelopmentStatusID":"12","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1\/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"ST-067","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"7","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Th\u00e9a to Acquire Branded Ophthalmic Products from Akorn, Expanding Th\u00e9a\u2019s Presence into the U.S. Eye Care Industry","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Akorn Pharmaceuticals \/ Th\u00e9a","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Phar.."},{"orgOrder":0,"company":"HanBio Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"HanBio Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"HanBio Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"4","companyTruncated":"HanBio The.."},{"orgOrder":0,"company":"Novavax","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Israeli Ministry of Health","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"AUP-16","moa":"FGF-2","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Aurealis Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aurealis Therapeutics \/ Xbiome","highestDevelopmentStatusID":"7","companyTruncated":"Aurealis T.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Pneumagen Raises \u00a33.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Financing","leadProduct":"Neumifil","moa":"Sialic acid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intranasal","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Designs for Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ChromaDex and Designs for Health Partner for New Product Development on Niagen","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Designs for Health","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"GSK","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"GSK \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Jeff.."},{"orgOrder":0,"company":"Gandeeva Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gandeeva Raises $40M in Series A Funding to Develop Novel Therapies Based on Precision Imaging of Protein-Drug Interactions","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Precision Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gandeeva Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Gandeeva Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Gandeeva T.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Announces that Sio Gene Therapies Intends to Cease the License Agreement for Gene Therapy Programme in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Receives a \u20ac4 Million Milestone Payment from AbbVie for Cedirogant Phase IIb Initiation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Cedirogant","moa":"ROR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"AR-701","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Epizyme Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Cancer Research Technology Ltd.","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Pepscan Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals Announces Research Collaboration With Pepscan To Develop Peptide-Based Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Peptide-based Radiopharmaceutical","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Pepscan Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion for Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pneumococcal 20-valent Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Moleac","sponsor":"National University Hospital Singapore","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroAiD(TM)II Holds Promise as a Safe Add-on Therapy to Standard Alzheimer Disease Symptomatic Treatments and May Have a Disease Modifying Effect by Delaying Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"MLC901","moa":"Cholinesterase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Moleac","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Moleac \/ National University Hospital Singapore","highestDevelopmentStatusID":"8","companyTruncated":"Moleac \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review Libtayo\u00ae (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXIN\u00ae (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VFMCRP Receives EU Approval for Tavneos\u00ae for the Treatment of ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Receives Japanese PMDA Approval of PIVLAZ (clazosentan sodium) 150 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"ET receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Connection Study Continues After Pre-scheduled Data Monitoring Committee (DMC) Review","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science has been Granted Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbus Therapeutics\u2019 Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Delta Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Delta Health","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumakras\u00ae (Sotorasib) Receives Approval in Japan for Patients With KRAS G12C-mutated Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan\u00ae Ophthalmic Solution in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fer.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"NR082","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates Strong Protection Against Omicron Variant, With Over 2 Times Higher Virus Neutralizing Activity Compared to the Pfizer Vaccine According to a Unique Independent Comparative Study Conducted by the Spallanzani Institute in Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva\u2019s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio\u2122 to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tachyon Presents New Data Supporting the Development of TACH101, a Novel KDM4 Inhibitor, as a Potential Therapy for Gastrointestinal Cancers at the 2022 ASCO-GI Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tachyon Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tachyon Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tachyon Te.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I\/II Trial of MRx-4DP0004","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"MRx-4DP0004","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Pivotal Phase 3 KEYNOTE-775\/Study 309 Trial of KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in IntelGenx\u2019s Resumed \u2018BUENA\u2019 Montelukast VersaFilm\u00ae Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Presents Three Posters for Tivozanib\/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"TD-0148A","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson\u2019s Disease (PD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor Commences US phase I Clinical Trial of AT247 Ultra-rapid Insulin in Combination With an Insulin Pump","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Fast Acting Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Provides Enrollment Update on Multi-Indication Phase 1\/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora\u2122 in Patients with Critical COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Doses First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA in China in Cataract Surgery Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"12","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENTOD Pharmaceuticals Introduces a Saffron based Eye Care Product in India to Promote Visual Performance","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Saffron Extract","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Entod Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Entod Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Entod Phar.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"WHO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Recommends Reduced Dose Pfizer COVID Vaccine for Under 12s","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"WHO","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WHO \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"WHO \/ Not .."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm\u2122 for Chronic Pain Associated with Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray Film","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altascienc.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn\u2019s and Colitis Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"KB295","moa":"Microbiome","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"AO-176","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncol.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results for BIMZELX[\u00ae]\u25bc(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b\/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"VK0214","moa":"TR-Beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Eplontersen Receives Orphan Drug Designation From U.S. FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data on NT-I7 Published in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ\u00ae Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenadogene Nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Ipsen\u2019s Sohonos (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Irofulven","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech: Update on the RELEASE trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide from a Transdermal Patch in an In Vivo Nonclinical Study with STAR-LLD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics\u2019 Novel Bifunctional Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ University of Minnesota","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Updated Interim Results for iCCA patients with FGFR2 Mutations and Amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Derazantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Clinical Hold on Atuzaginstat\u2019s Investigational New Drug Application","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Merus","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Provides Update on Parsaclisib and MCLA-145","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Merus","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melanoma Research Alliance Statement on FDA Approval of Tebentafusp, the First Drug for Treating Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Incheon National University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incheon National University Scientists Review Progress in Promising Anticancer Compounds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BODIPY-based MOC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Incheon National University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Incheon National University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Incheon Na.."},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoPass's Intradermal Delivery Platform Used in Emergex's Next-Generation COVID-19 Vaccination Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"LD PepGNP-SARSCoV2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoPass Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ Emergex","highestDevelopmentStatusID":"6","companyTruncated":"NanoPass T.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BTX-1188","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in ProstACT Program for Prostate Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-rosopatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA\u00ae in First Line Patients with HPV+ Recurrent\/Metastatic Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-020572-401","moa":"TR-Beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals\u2019 Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b\/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Sema4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silencing a Faulty Gene May Uncover Clues to Rare Forms Of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ION363","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ NIH","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg\/6.25 mg, 5 mg\/6.25 mg, and 10 mg\/6.25 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bisoprolol Fumarate","moa":"ADRB1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Launches PrCEQUA\u2122 (Cyclosporine Ophthalmic Solution 0.09% w\/v), the First Dry Eye Treatment with Nanomicellar (NCELL\u2122) technology*, in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai Co","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of \u03b2-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"TSHA-101","moa":"HEXA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data Show Potential for Use of Genprex\u2019s ONCOPREX\u00ae Nanoparticle Delivery System in Treating Colon Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"FAS DNA plasmid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Avrobio","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO to Present New Data from Phase 1\/2 Clinical Trial in Cystinosis at WORLDSymposium\u2122 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Evorpacept","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Union Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ UNION Therapeutics A\/S","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Olitigaltin","moa":"Galectin-3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Metronidazole Vaginal Gel,0.75%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Metronidazole","moa":"DNA synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces Oleogel-S10 EMA Regulatory Update","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"eOD-GT8 60mer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion to Expand Jardiance (empagliflozin) Indication Based on Unprecedented Benefit in Adult Heart Failure Patients With Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback\u2019s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTB001, Bioheng Auto CAR - T Product, Received Orphan Drug Designation (ODD) from the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CTB001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Bi.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines' AYVAKYT\u00ae (Avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Galapagos","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JYSELECA\u00ae (Filgotinib) Licensed for The Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis in Great Britain","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta\u00ae Showing Prophylactic Steroid Use Improves Management of Cytokine Release Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/Beta globulin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee\u00ae (Insulin Glargine Injection), 100 units\/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Statement on Zydelig\u00ae U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Idelalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides U.S. and Japan Regulatory Update for Gefapixant","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specic Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives Full U.S. FDA Approval for COVID19 Vaccine Spikevax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Sanofi Provide Regulatory Update on Libtayo\u00ae (Cemiplimab-RWLC) in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Dupixent\u00ae (dupilumab) For Children Aged 6 to 11 Years With Severe Asthma With Type 2 Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Bispecific Antibody Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Teclistamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"MZE001","moa":"GYS1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"GeneDx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Taysha Gene Therapies \/ GeneDx","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex External Research Program (CERP\u2122) Celebrates 100 Peer-Reviewed Published Studies on Niagen\u00ae and Other Ingredients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"NM8074","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"DNA Based Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium\u2122 on Lysosomal Diseases, MPS-1 and MPS-6","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"SIG-005","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Presenting New Data and Updates on APX3330 and Nyxol\u00ae Clinical Programs at Virtual Investor R&D Day","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"APX3330","moa":"Ref-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Ionis","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-251","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"KIN-3248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1\/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"XTX202","moa":"Tumor-selective IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in The US \u2013 No Intent to Market in The US at This Time","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan\u2019s MHLW Approves Pfizer and OPKO\u2019s NGENLA\u00ae (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"Poly kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Provides Updates on Trudhesa\u2122 Launch and Recent Business Highlights","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ORIC-114","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT\u2019s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"VLP Therapeutics","sponsor":"Nobelpharma","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"VLP Therapeutics Raises $21M Series A-1 For Cancer Treatment Vaccine, Infectious Diseases Vaccine R&D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Series A Financing","leadProduct":"VLPM01","moa":"CSP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VLP Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intramuscular","sponsorNew":"VLP Therapeutics \/ Nobelpharma","highestDevelopmentStatusID":"6","companyTruncated":"VLP Therap.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","amount":"$215.5 million","upfrontCash":"$12.5 million","newsHeadline":"Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"OV350","moa":"KCC2 transporter","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.22,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"AstraZeneca \/ Ovid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","amount":"$124.0 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Alastin Skincare","sponsor":"Galderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galderma Successfully Completes Acquisition of ALASTIN Skincare","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Herbal Extract","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alastin Skincare","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alastin Skincare \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Alastin Sk.."},{"orgOrder":0,"company":"Alastin Skincare","sponsor":"Galderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galderma to Acquire Award-Winning ALASTIN Skincare\u00ae Enhancing its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Herbal Extract","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alastin Skincare","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Alastin Skincare \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Alastin Sk.."},{"orgOrder":0,"company":"Intrance Medical System","sponsor":"Erik Selin","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directors","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Intrance Medical System","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Intrance Medical System \/ Erik Selin","highestDevelopmentStatusID":"5","companyTruncated":"Intrance M.."},{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advicenne Announces Commercialization Agreement With FrostPharma AB for Sibnayal\u2122 in the Nordic region","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Potassium Citrate","moa":"Calcium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ FrostPharma AB","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$225.0 million","newsHeadline":"Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Shingles Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioNTech","amount2":0.42999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pediatric Brain Tumor Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa\u2019s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senhwa Biosciences \/ Pediatric Brain Tumor Consortium","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s VYNDAQEL\u00ae\/VYNDAMAX\u00ae Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafamidis Meglumine","moa":"Transthyretin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"V2R","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eagle Pharmaceuticals \/ Par Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Xediton Sign Exclusive License and Distribution Agreement for TRUSELTIQ\u2122 (Infigratinib) in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Xediton","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"TTC Oncology Launches Equity Crowdfunding Campaign on WeFunder to Support Funding of Phase 2 Clinical Trials for Breast Cancer With $100,000 Initial Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"TTC-352","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ University of Illinois","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncolo.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Yumanity\u2019s Approach to Neurodegenerative Diseases Validated by Two External Collaborations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Funding","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CD22-directed CAR T cell Therapy","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"PostEra","sponsor":"Breyer Capital","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"PostEra Closes $24M in New Financing to Advance Drug Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Antiviral Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"PostEra \/ Breyer Capital","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ SANOFI","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T\u2122 Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-501A","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch of Tilray\u2019s Fast-Acting Oral Strips Highlights Commitment to Medical Cannabis Innovation and Patient Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Tilray","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ A.."},{"orgOrder":0,"company":"Intima Bioscience","sponsor":"MaxCyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CISH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intima Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intima Bioscience \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Intima Bio.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1,250.0 million","newsHeadline":"GSK Announces Settlement Between ViiV Healthcare and Gilead Sciences, Inc. Resolving Litigation Relating to Biktarvy and ViiV\u2019s Dolutegravir Patents and Entry Into a Patent Licence Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Genentech","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$30.0 million","newsHeadline":"Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Lenalidomide","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Ethris","sponsor":"Laureus Capital","pharmaFlowCategory":"D","amount":"$26.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"ETH47","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Laureus Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ L.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Abcam plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"VHH Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Abcam","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio\u00ae in Phase 3 ENABLAR-2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Abemaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli.."},{"orgOrder":0,"company":"GenEdit","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"GenEdit","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenEdit \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GenEdit \/ .."},{"orgOrder":0,"company":"Biosana Pharma","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair\u00ae (Omalizumab)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Biosana Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biosana Pharma \/ Alvotech Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Biosana Ph.."},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Juvena Therapeutics Awarded Highly Competitive CIRM Grant To Advance Lead Program, JUV-161, To Treat Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"JUV-161","moa":"Myogenesis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Juvena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Juvena Therapeutics \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Juvena The.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hildred Capital Management, LLC, Bourne Partners Strategic Capital and The Emerson Group Launch Carlin Consumer Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Carlin Consumer Health","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar\u00ae In South Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Debiopharm","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"The Canadian Neuromuscular Disease Registry","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"The Canadian Neuromuscular Disease Registry","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Canadian Neuromuscular Disease Registry \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"The Canadi.."},{"orgOrder":0,"company":"Argonaut Manufacturing Services","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"n-Lorem Foundation Partners with Argonaut to Manufacture ASO Medicines for Patients with Nano-rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotides","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Argonaut Manufacturing Services","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Argonaut Manufacturing Services \/ n-Lorem Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Argonaut M.."},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Evolution Research Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Vocacapsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Evolution Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Concentric.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Public Offering","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"NHS England","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ NHS England","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Social Capital Suvretta Holdings Corp. III","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProKidney \/ Social Capital Suvretta Holdings Corp. III","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Nano Precision Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Nano Precision Medical","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Med.."},{"orgOrder":0,"company":"Eighteen Fifty-Nine","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"1859 Inc. Launches with $40 Million Series A to Industrialize New Medicine Discovery by Combining Artificial Intelligence and Empirical Screening Data at Scale","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Eighteen Fifty-Nine","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Eighteen Fifty-Nine \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Eighteen F.."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"Taladegib","moa":"PTCH1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Ally Bridge Group","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Vocacapsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ University of Rochester Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Concentric.."},{"orgOrder":0,"company":"Ortho Regenerative Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ortho Regenerative Technologies Enters Into A Material Transfer Agreement With A Global Strategic Medical Company For Its Ortho-R Rotator Cuff Tear Repair Phase I\/II U.S. Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Chitosan-PRP","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Ortho Regenerative Technologies","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ortho Regenerative Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ortho Rege.."},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"$8.0 million","newsHeadline":"Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA\u00ae (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Xbrane Biopharma \/ Biogen Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Bio.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Oak Hill Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oak Hill Bio Launches With Pipeline and Senior Leadership From Takeda","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"OHB-607","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Oak Hill Bio","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Evotec","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Enters iPSC-Based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.28999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurodegenerative Disease Biotech Vigil Neuroscience Files For a $100 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurodegenerative Disease Biotech Vigil Neuroscience Sets Terms for $112 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Celmatix","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Partner Celmatix Achieves Milestone For PCOS Drug Programme","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/.."},{"orgOrder":0,"company":"Oncorena","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorena Initiates the Phase I-II Clinical Trial with Orellanine in Advanced Kidney Cancer Patients at Karolinska University Hospital in Sweden","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Orellanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorena \/ Karolinska University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Gets USFDA Approval to Market Clarithromycin Tablets in America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Trial for Booster Vaccination of mRNA Vaccine Against COVID-19 (DS-5670) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANAVEX\u00ae2-73 (Blarcamesine) AVATAR Phase 3 Trial Met Primary and Secondary Efficacy Endpoints","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEMPS Authorizes Phase III Clinical Trial of the Hipra\u2019s Vaccine Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Protein Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laboratorios HIPRA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios HIPRA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Completes Enrollment for Phase 2b\/3 PRISM Study in Chronic Pruritus in PN","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ University College London","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera AG Announces Progress of Phase III Study for the Treatment of sBCC with Ameluz","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"Ferrochelatase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Liver Institute Northwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liver Institute Northwest Participating in RESPONSE, a Global Phase 3 Clinical Research Study Evaluating an Investigational Therapy for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Liver Institute Northwest","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Liver Institute Northwest \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liver Inst.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2\/3 Smoking Cessation Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Johns Hopkins University","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Receives USFDA Tentative Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fesoterodine","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KVD900","moa":"Protease","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M6P Therapeutics to Participate in Key Event Highlights at WORLDSymposium\u2122 2022 and Present Preclinical Data Across Multiple Lysosomal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"M041","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therap.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"SEFA-6179","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"NorthSea Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"THE-630","moa":"pan-variant KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1\/2 Gastrointestinal Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"SRW Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading Cellular Senescence Scientist Works With SRW on the Development of Cel3 Renewal","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fisetin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SRW Laboratories","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRW Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SRW Labora.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"VIP236","moa":"Alpha5Beta3 Integrin Ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Vifor Fresenius Medical Care Renal Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAYALDEE\u00ae Launched in Germany by OPKO Health\u2019s Licensee, VFMCRP","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Vifor Fresenius Medical Care Renal Pharma","highestDevelopmentStatusID":"12","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi\u00ae is No Longer Valid","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Hooke Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Hooke Laboratories","highestDevelopmentStatusID":"2","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of Sovateltide (PMZ-1620) in Hypoxic-ischemic Encephalopathy in Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals Receives the WORLDSymposium\u2122 New Treatment Award for IZCARGO\u00ae (Pabinafusp Alfa)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pabinafusp Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"EuBiologics","sponsor":"Korea Institute of Science and Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"EuCorVac-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EuBiologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"EuBiologics \/ Korea Institute of Science and Technology","highestDevelopmentStatusID":"7","companyTruncated":"EuBiologic.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADCETRIS\u00ae Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ T.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze\u2122 (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday\/Wednesday\/Friday Dosing Schedule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn","moa":"Asparagine synthetase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Received Approval From ANVISA (Brazil) To Give Access To Sarconeos (BIO101) To Hospitalized Covid-19 Patients Through An Expanded Access Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Will Discontinue Phase II Development Candidate Eliapixant","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Eliapixant","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Evotec","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA\/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"FT536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Phase Ib\/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HMPL-453","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B \u2013 Data Presented at EAHAD 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics' Antibody Patent Granted","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Monoclonal Antibody","moa":"TIM-3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of \u20181805 in Autoimmune Diseases in the United Kingdom","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"\u20181805","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Provides Supplemental Information on ANAVEX\u00ae2-73 AVATAR Phase 3 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V vaccine Granted Full Permanent Approval in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Reports Positive Top-Line CAN106 Phase 1 Data Receives Approval to Treat Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Phase 1b\/2 Trial in China Results Suggest Complete Blockade of Complement Function CAN106 Safe and Well-Tolerated","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Complement C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Medical Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10 Expressing Beta-galactosidase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Haemnet","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HMB-001","moa":"Factor VIIa","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hemab Therapeutics \/ Haemnet","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Ther.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Investigating Possible Increased Risk of Death With Lymphoma Medicine Ukoniq (umbralisib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare to Present New Long-term Findings From its Innovative 2-Drug and Long-acting Hiv Medicines Portfolio at CROI 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanopass\u2019s Intradermal Injection Platform Proven to Sustain COVID-19 Vaccine Antibodies Using 1\/15 of The Dose Reports Chinese Institute Of Medical Biology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NanoPass Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ YNC Medical","highestDevelopmentStatusID":"1","companyTruncated":"NanoPass T.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Study May Proceed letter for Clarity\u2019s Cu-64 SAR-bisPSMA trial in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"PET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science to Present on its Amyotrophic Lateral Sclerosis (ALS) Development Program at the 2022 ALS Drug Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2\/3 Study of Tempol for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX104C","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio\u2019s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Varsity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Novobiocin Sodium","moa":"Polymerase theta helicase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Varsity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Varsity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Varsity Ph.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVAnc80-antiVEGF Vector","moa":"VEGF","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intracochlear","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-037","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Submits Investigational New Drug (IND) Application to Initiate a Global Phase III Clinical Trial Evaluating an Inhaled COVID-19 Antibody Cocktail Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-P63","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"VGL101","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover\u2019s Final SPECTRA Phase 2\/3 Clinical Trial Efficacy Data Is Published in The Lancet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Acuitas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"mRNA-LNP Based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ .."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"$45.0 million","newsHeadline":"Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"In-vivo Engineered CAR Monocyte Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Carisma Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"LCB14","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Iksuda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iksuda Therapeutics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Iksuda The.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Trial Results Showed Spesolimab Significantly Improved Signs and Symptoms of Flare in Rare, Life-threatening Skin Disease, Generalized Pustular Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Spesolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis and Molecular Partners Report Positive Topline Data from Phase 2 study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Lumykras\u00ae (Sotorasib) for Patients with Kras G12c-mutated Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1644","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IAVI \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Mod.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"$11.0 million","newsHeadline":"Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody\u00ae Novel Masked Antibody-Drug Conjugate Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"ADG126","moa":"CTLA4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Affiris","sponsor":"Frontier Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AFFiRiS and Frontier Biotechnologies Announce License Agreement for AFFITOPE\u00aeAT04, an Active Immunotherapy Targeting PCSK9 to Treat Hypercholesterolemia, in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Affitope AT04","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Affiris","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Frontier Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ .."},{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Macromolecules","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therap.."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$5.0 million","newsHeadline":"2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"MegaTAL mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genevant Sciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Genevant Sciences \/ 2seventy bio","highestDevelopmentStatusID":"1","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Inactivated NDV-HXP-S COVID-19 Vaccine Induces a Significantly Higher Ratio of Neutralizing to Non-Neutralizing Antibodies in Humans as Compared to mRNA Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"CpG1018","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Icahn School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Icahn School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Icahn Scho.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"C\/EBP-alpha protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Bayer","highestDevelopmentStatusID":"8","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (\u201cXSCID\u201d) in Previously Transplanted Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Skyepharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Skyepharma","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Metronidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"EdiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ex-vivo Engineered Cell Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Arbor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Pharmaceuticals \/ EdiGene","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Phar.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"177Lu-rosopatamab","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Eckert & Ziegler Strahlen","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"SEngine Precision Medicine","sponsor":"Oncodesign","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"SEngine Precision Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SEngine Precision Medicine \/ Oncodesign","highestDevelopmentStatusID":"2","companyTruncated":"SEngine Pr.."},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Awarded NIH Grant","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Siolta The.."},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seismic Therapeutic","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Seismic Therapeutic \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seismic Th.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"SoftBank Vision Fund 2","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Therapeutics Closes $140 Million Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series C Financing","leadProduct":"VENT-01","moa":"NLRP3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ SoftBank Vision Fund 2","highestDevelopmentStatusID":"4","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"EdiGene","sponsor":"Neukio Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"iPSC-CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EdiGene \/ Neukio Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"Orthox","sponsor":"Parkwalk","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix\u2122 Product Platform","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"Fibroin","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Orthox","amount2":0.01,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Orthox \/ Parkwalk","highestDevelopmentStatusID":"1","companyTruncated":"Orthox \/ P.."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"EF Hutton","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Public Offering","leadProduct":"STAT-201","moa":"Opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Statera Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Statera Biopharma \/ EF Hutton","highestDevelopmentStatusID":"10","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"Cytiva","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"n-Lorem Foundation Partners with Cytiva to Bring Individualized ASO Medicines to Patients with Nano-rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Cytiva","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytiva \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Cytiva \/ n.."},{"orgOrder":0,"company":"Argobio","sponsor":"Oncode Bridge Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncode Institute and ArgoBio Launch Laigo Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Argobio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Argobio \/ Oncode Bridge Fund","highestDevelopmentStatusID":"3","companyTruncated":"Argobio \/ .."},{"orgOrder":0,"company":"Cytovation","sponsor":"Recurrent Respiratory Papillomatosis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovation Collaborates with Recurrent Respiratory Papillomatosis Foundation to Expand Its Clinical Investigations of CyPep-1 Into Rare Neoplastic Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cytovation \/ Recurrent Respiratory Papillomatosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nippon Shinyaku and Capricor Therapeutics enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in US","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Allogeneic Cardiosphere-derived Cell Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Capricor Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shi.."},{"orgOrder":0,"company":"Excelra","sponsor":"X-Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem and Excelra's GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Excelra","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excelra \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$720.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lilly Will Supply Up To 600,000 Doses of Bebtelovimab to U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0.71999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"Intravenous","sponsorNew":"Eli Lilly \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva Strategic Opportunities LLC","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities LLC","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"G-NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Arkuda Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arkuda Therapeutics Raises $64 Million Series B Financing To Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Arkuda Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Arkuda Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"Arkuda The.."},{"orgOrder":0,"company":"MediWound","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$211.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin synthesis","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0.20999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Topical","sponsorNew":"MediWound \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Announces Pricing of an Upsized $250 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Twist Bioscience \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Theramex","sponsor":"ObsEva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Announces Licensing Agreement with ObsEva for the Commercialisation of Linzagolix for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theramex \/ ObsEva SA","highestDevelopmentStatusID":"10","companyTruncated":"Theramex \/.."},{"orgOrder":0,"company":"Chengdu Yousino Biotechnology","sponsor":"Matrix Partners","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ucello Therapeutics Completes US$25 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"AT19","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Chengdu Yousino Biotechnology","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Chengdu Yousino Biotechnology \/ Matrix Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chengdu Yo.."},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healis Therapeutics Acquires Ownership of Key Botulinum Toxin Patent","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"SNAP25","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Healis Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Healis The.."},{"orgOrder":0,"company":"Awakened Biosciences","sponsor":"Core One Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Core One Labs Completes Strategic Acquisition of Awakened Biosciences and its Game-Changing Provisional Patents","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Awakened Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Thin Film Strip","sponsorNew":"Awakened Biosciences \/ Core One Labs Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Awakened B.."},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix and SHINE Partner for Lutetium-177 Supply","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"177Lu-rosopatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SHINE Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SHINE Technologies \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SHINE Tech.."},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Qu.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"University of Maryland School of Medicine\u2019s Institute of Human Virology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, Expanding Its DispersinB\u00ae Applications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"DispersinB","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Biofilm","sponsorNew":"Kane Biotech \/ University of Maryland School of Medicine\u2019s Institute of Human Virology","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Oncode Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Enters Into Global Patent License Agreement with Oncode Institute for Tasquinimod in Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Oncode Institute","highestDevelopmentStatusID":"4","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"QBREXZA\u00ae (Rapifort\u00ae Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Journey Medical Corporation","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Maruho Co","highestDevelopmentStatusID":"12","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Maruho Co","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"QBREXZA\u00ae (Rapifort\u00ae Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Eli Lilly \/ Maruho Co","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Medis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medis \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Medis \/ Lu.."},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Drug Innovation Ventures at Emory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Global Viral Threats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"ALT-2023","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altesa Biosciences \/ Drug Innovation Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Bio.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis India Limited Extends Access to Its Medicines in India by Signing Exclusive Sales and Distribution Agreement With Dr. Reddy\u2019s Laboratories","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Diclofenac","moa":"COX-1\/COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sustained Release Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Theramex","sponsor":"Endoceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Australia Enters Partnership With Endoceutics For Intrarosa\u00ae For The Treatment Of Postmenopausal Vulvovaginal Atrophy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Prasterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Pessary","sponsorNew":"Theramex \/ Endoceutics","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Mucoadesive Tablet","sponsorNew":"Avicanna \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Teclison","sponsor":"W.T.T. Investment","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Teclison Completes $5.9 Million Capital Raise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Financing","leadProduct":"TEC-001","moa":"Hypoxia","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Teclison","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Teclison \/ W.T.T. Investment","highestDevelopmentStatusID":"8","companyTruncated":"Teclison \/.."},{"orgOrder":0,"company":"Amunix","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Completes Acquisition of Amunix","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"AMX-818","moa":"Dysregulated protease","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ S.."},{"orgOrder":0,"company":"Celeris Therapeutics","sponsor":"Pace Ventures Enigma","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"CelerisTx Announces $4.4m Financing to Advance Pipeline of Novel Proximity Inducing Compound","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Celeris Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celeris Therapeutics \/ Pace Ventures Enigma","highestDevelopmentStatusID":"2","companyTruncated":"Celeris Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Gets DCGI Nod for Single-Shot Sputnik Light Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ RDIF","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer\n","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol\u00ae Cyclo\u2122, at WORLDSymposium 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS\u00ae T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ET140203","moa":"Alpha fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Aphios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphios Granted US Patent For Combination HIV Latency Nanoparticles Towards an HIV Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"APH-0812","moa":"PKC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aphios","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aphios \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aphios \/ N.."},{"orgOrder":0,"company":"Immunome","sponsor":"Boston University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome\u2019s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM20184","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Boston University","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Red Blood Cell-encapsulated Arginine Deiminase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Toothpaste","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Concludes Type A Meeting with FDA Related to MydCombi\u2122 NDA Resubmission","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tropicamide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PBI-0451","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pardes Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit\/Hyperactivity Disorder (ADHD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HU6","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Phar.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Launches Managed Access Program for Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase 3 Data for KEYTRUDA\u00ae (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion and Otsuka Initiate Phase 3 Clinical Development of Non-Racemic Amisulpride for the Treatment of People with Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Generium JSC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch of Generium\u2019s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis\u2019 Ninth Commercial Product","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"KBI Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"KBI Biopharma \/ Generium JSC","highestDevelopmentStatusID":"12","companyTruncated":"KBI Biopha.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Clinical Trial Confirms SaNOtize\u2019s Breakthrough Treatment is 99% Effective Against COVID-19; Receives Regulatory Approval in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"SaNOtize \/ Glenmark Pharmaceuticals Limited","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Sirtex Medical","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres\u00ae Y-90 resin microspheres in China from the National Medical Products Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Yttrium Radioisotopes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sirtex Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirtex Medical \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"12","companyTruncated":"Sirtex Med.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Jena University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Well Begun And Half Done! - SIRONA Randomized Trial Achieves Fifty Percent Enrollment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Jena University Hospital","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olipudase alfa Shown to Provide Sustained Improvement Across Multiple Clinical Manifestations of ASMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Olipudase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Enjaymo\u2122 (sutimlimab-jome), First Treatment for Use in Patients With Cold Agglutinin Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"Complement C1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNtech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Statement on First Administration of its COVID-19 Vaccine in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Bebtelovimab Receives Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eli Lilly \/ AbCellera Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio (Nasdaq: PALI) To Announce Adhesions Clinical Data At SAGES 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Top-Line Results from Phase 2\/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick disease type C in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Announced the Start of a Phase I Clinical Trial for Evaluation of the Safety, Tolerability and Anti-Tumor Activity of the Company's SiRNA (Small Interfering RNA) Drug Candidate, STP707 With Intravenous (IV) Administration in the United States. ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"STP707","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's First Homegrown mRNA COVID-19 Vaccine Currently Under Final Clinical Trial Stages: Govt","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Statement on Sintilimab Oncologic Drugs Advisory Committee (ODAC) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives U.S. FDA Fast Track Designation for Asundexian Stroke Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Asundexian","moa":"Factor XIa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Two-year Data for Roche\u2019s Vabysmo and Susvimo Reinforce Potential to Maintain Vision with Fewer Treatments for People with Two Leading Causes of Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Famotidine Cinical Trial Shows Reduction in Covid-19 Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Famotidine","moa":"PLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"MZE001","moa":"GYS1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Reports Favorable Preclinical Safety Data for Envelta\u2122 for the Treatment of Acute and Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Enkephalin","moa":"Delta opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso's NGF Monoclonal Antibody (AK115) Approved To Initiate Clinical Trial In Pain (Including Cancer Pain)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AK115","moa":"NGF","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore's AIR Study Interim Analysis Suggests that C21 Improves Lung Function in IPF Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio to Present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"DeltEx DRI Chlorotoxin CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Xencor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ Xencor","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China\u2019s National Medical Products Administration Approves Benlysta (belimumab) for Adult Patients with Active Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Belimumab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"WHO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement on Miltefosine - Potential Ocular disorders in Patients Treated with Miltefosine for Post-Kala-azar Dermal leishmaniasis (PKDL)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Miltefosine","moa":"Cytochrome-c oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"WHO","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"WHO \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"WHO \/ Not .."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-Cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Legend Brett Favre and Odyssey Health, Inc. Involved with Human Trials of First Drug Treatment for Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA Cancer Vaccine","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regen BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioP.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AbCellera","sponsor":"Vaccine Research Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Vaccine Research Center","highestDevelopmentStatusID":"8","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury\u00ae (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium\u2122 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"M011","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"M6P Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therap.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CT103A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COPAXONE\u00ae Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces VCN Biosciences\u2019 VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Abraxane","moa":"Hyaluronidase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Synthetic Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosci.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from Phase 2b\/3 Trial of Ritlecitinib in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC kinase","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo\u00ae (nivolumab) in Combination with CABOMETYX\u00ae (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Medicine Publishes Full Results from Axial Therapeutics\u2019 Phase 1b\/2a Clinical Trial in Autism Spectrum Disorder (ASD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Review Article in ESC\u2019s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition\u2019s Role in Reducing Cardiovascular Disease Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"NRC Human Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JN Nova Pharma and NRC Human Health Group Partnership to Move Pan-COVID19 Therapeutic into Clinical Development, their lead therapeutic product JN2019 neutralizes the SARS-CoV-2 variants of concern (VOCs), including Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"JN2019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JN Nova Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JN Nova Pharma \/ NRC Human Health","highestDevelopmentStatusID":"4","companyTruncated":"JN Nova Ph.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium\u2122 Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumakras\u00ae (Sotorasib) Shows Encouraging And Clinically Meaningful Anticancer Activity In Patients With Kras G12c-Mutated Advanced Pancreatic Cancer In Codebreak 100 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey Demonstrating Oncodermatology Unmet Need at ASCO GU","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"OQL011","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Shanghai Public Health Clinical Center","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai Public Health Clinical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Hypodermic Injection","sponsorNew":"Shanghai Public Health Clinical Center \/ Ascletis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai P.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA\u00ae (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tivozanib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Provides Update on CTI-1601 Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Larimar Therapeutics \/ Veristat, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PBI-0451","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pardes Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acura Pharmaceuticals Provides Development Update on LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Phar.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New ERLEADA\u00ae (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Apalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves JUV\u00c9DERM\u00ae VOLBELLA\u00ae XC For Undereye Hollows","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AT845","moa":"GAA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biktarvy\u00ae Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Na\u00efve Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-care in 1st-line Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veklury\u00ae (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only LongActing HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Dupixent\u00ae (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Dupixent\u00ae (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Grants Prequalification of Actemra\/RoActemra for Patients with Severe or Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexviazyme\u00ae (Avalglucosidase Alfa) Shows Sustained Improvements in Respiratory Function and Mobility in Patients With Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Avalglucosidase Alfa-ngpt","moa":"Enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[\u00ae] (brivaracetam) and VIMPAT[\u00ae] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"PRT120","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prota Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Ther.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme to Present Additional Data on Arimoclomol\u2019s Mechanism of Action During 2022 Annual WORLDSymposium\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HSB-510","moa":"HDAC6\/PI3K-delta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Plexium","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amgen and Plexium Announce Multi-Year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Plexium \/ Amgen","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ .."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Generic of Restasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Anakuria","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"AT-20494","moa":"mTORC1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anakuria","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Anakuria \/ Janssen","highestDevelopmentStatusID":"4","companyTruncated":"Anakuria \/.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Modelsat the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Association for Research in Otolaryngology","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas is Awarded Grant from the NIH to Fund Early Clinical Trial of ASP8062 to Investigate Potential Novel Therapeutic for Opioid Crisis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Positive Results from Cosentyx Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Presents Interim Data from its Phase 1\/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"VB517","moa":"c-KIT","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty No.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"EF Hutton","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"TC Biopharm Announces Closing of $17.5 Million Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Public Offering","leadProduct":"TCB 008-001","moa":"Cytokine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ EF Hutton","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Greehey Children's Cancer Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"PTGR1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$10.0 million","newsHeadline":"HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Arenavirus-based Vector","moa":"CD8+ T Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.40999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"SpliceBio","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$56.6 million","upfrontCash":"Undisclosed","newsHeadline":"SpliceBio Raises EUR 50M in Oversubscribed Series A Financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"ABCA4 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SpliceBio","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SpliceBio \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"SpliceBio .."},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"THB001","moa":"KIT","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Third Harmonic Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Third Harm.."},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP Targeted Therapies for Immunological Diseases and Cancer","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"ELA026","moa":"SIRP","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Electra Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Electra Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Electra Th.."},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Pure MHC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoScape Inks Licensing Deal with Pure MHC to Advance Development of Novel TCR-Based Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"TCR-T Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoScape \/ Pure MHC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScap.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Organon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organon Acquires Contraceptive Products, Marvelon\u00ae and Mercilon\u00ae, in the People\u2019s Republic of China, Including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Desogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"PerkinElmer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PerkinElmer\u2019s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirion Biotech","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirion Biotech \/ PerkinElmer","highestDevelopmentStatusID":"4","companyTruncated":"Sirion Bio.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","amount":"$588.4 million","upfrontCash":"Undisclosed","newsHeadline":"ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Lutetium-177-edotreotide","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","amount":"$40.2 million","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series B Financing","leadProduct":"MTX-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Swisscanto","highestDevelopmentStatusID":"6","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Closing of $10 Million Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Public Offering","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"AvantGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adcentrx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adcentrx Therapeutics \/ AvantGen","highestDevelopmentStatusID":"2","companyTruncated":"Adcentrx T.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","amount":"$588.4 million","upfrontCash":"Undisclosed","newsHeadline":"ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater China Area","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lutetium-177-edotreotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Neopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy\u00ae in Combination With KEYTRUDA\u00ae in First-Line Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand Its Biologics Offering in the US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Microbiome Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arranta Bio \/ Recipharm","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bi.."},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$75.0 million","newsHeadline":"Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Arrakis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrakis Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Arrakis Th.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Announces Collaboration with Alnylam to Explore Targeted Therapy to Restore Liver Function","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"siRNA-based Targeted Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"$93.0 million","upfrontCash":"$30.0 million","newsHeadline":"Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza\u00ae (Evinacumab) Outside the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Ultragenyx","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$60.0 million","newsHeadline":"Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"BIIB115","moa":"SMN protein synthesis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Eisai","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, A Splicing Modulator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"H3B-8800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Roivant Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Ro.."},{"orgOrder":0,"company":"GigaMune","sponsor":"Champions Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"T-cell Therapy","moa":"T-cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GigaMune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaMune \/ Champions Oncology","highestDevelopmentStatusID":"3","companyTruncated":"GigaMune \/.."},{"orgOrder":0,"company":"Dante Labs","sponsor":"The Renato Dulbecco Foundation","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dante Labs Partnering with The Renato Dulbecco Foundation to Advance Personalized Medicines for Cancer, COVID-19 and Rare Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Pronectines Nanoantibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dante Labs","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Dante Labs \/ The Renato Dulbecco Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Dante Labs.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"LB1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA\u00ae (teprotumumab-trbw) Comparable with Clinical Trial Observations","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Starts Phase 3 Study With Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenretinide","moa":"RAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals\u2019 Research Presentations at WORLDSymposium\u2122 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pabinafusp Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriOri BioTech Inc. Granted Patent for Topical Formulation of Rofecoxib","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriOri Bio.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabometyx\u00ae in Combination With Opdivo\u00ae Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-up in the Phase III CheckMate -9ER trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Shimadzu","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakuten Medical and Shimadzu Enroll First Patient in the U.S. Clinical Trial of Photoimmunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ASP-1929 Photoimmunotherapy","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Shimadzu","highestDevelopmentStatusID":"8","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized in Pivotal TRANSFORM Study with Setanaxib","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Setanaxib","moa":"NOX1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2\/neu Positive Gastric and Gastroesophageal Junction Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CYNK-101","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Qualigen Therapeutics\u2019 Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"TD-0148A","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Regencell Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regencell Bioscience\u2019s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"RGCA-CV01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regencell Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Regencell Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regencell .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead\u2019s Investigational HIV-1 Capsid Inhibitor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kato Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kato Wins FDA Approval for Human Studies of Drug for Retinal Disorders","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Liposome-loaded urea compound","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kato Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kato Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kato Pharm.."},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nova Mentis Life Science \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Menti.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"STP707","moa":"TGF beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"The National Institutes of Biomedical Innovation, Health and Nutrition","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The National Institutes of Biomedical Innovation, Health and Nutrition","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The National Institutes of Biomedical Innovation, Health and Nutrition \/ Shionogi & Co., Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"The Nation.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune ACI-35.030 Phase 1b\/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer\u2019s Vaccine in Highdose Cohort","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb\u2019s Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID\u00ae (pimavanserin) to Treat Alzheimer\u2019s Disease Psychosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Topline Results from Meteoric-HF","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and OPKO\u2019s Once-Weekly NGENLA\u2122 (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Approves Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 20-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces FDA Approval of PYRUKYND\u00ae (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides Updates on Progress in Gene Therapy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Veklury\u00ae (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ATA2271","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Newly Published Network Meta-Analysis (NMA) Found TREMFYA\u00ae (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"H. Lundbeck A\/S","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application for REXULTI\u00ae (brexpiprazole) to Treat Schizophrenia in Pediatric Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Holdings","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ H. Lundbeck A\/S","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Hol.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"P-PSMA-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Zelenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Second Indication for SKYRIZI\u00ae (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves RINVOQ\u00ae (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Applications for Upadacitinib (RINVOQ\u00ae) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire\u2122 (tezepelumab-Ekko) Now Available in The United States for The Treatment of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Announce Initial Results of PADCEV\u00ae (enfortumab vedotin-ejfv) in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab EMA Regulatory Submission Accepted Under Accelerated Assessment for RSV Protection in All Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saphnelo Approved in The EU for The Treatment of Moderate to Severe Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Anifrolumab-fnia","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Reduced Risk of Death By 20% in 1st-Line Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Vaxzevria Data Further Support Its Use as Third Dose Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Raises Peak Sales for Nubeqa to Exceed Three Billion Euro Amid Positive Phase III ARASENS Trial Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Plus Androgen Deprivation Therapy and Docetaxel Significantly Increases Overall Survival in Patients With Metastatic Hormone-sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"DA01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"DA01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Positive Phase 3 DUPIXENT\u00ae (DUPILUMAB) Trial Confirms Significant Improvements for Patients With Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Regeneron Provide Regulatory Update on Libtayo\u00ae (Cemiplimab-rwlc) in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIMZELX[\u00ae] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Top-Line Results for BIMZELX[\u00ae]\u25bc(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Pivotal Phase 3 Study 309\/KEYNOTE-775 Trial of LENVIMA\u00ae (lenvatinib) Plus KEYTRUDA\u00ae (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Enrolled in Phase II\/III Study of Eisai\u2019s Anti-Mtbr Tau Antibody E2814 For Dominantly Inherited Alzheimer's Disease (DIAD), Conducted By DIAN-TU","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"E2814","moa":"MTBR-tau","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updates on OLUMIANT\u00ae (baricitinib) Phase 3 Lupus Program And FDA Review for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Announces First Patient Dosed in Phase 3 Global Clinical Trial of JR-141 for Treatment of MPS II (Hunter Syndrome)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pabinafusp Alfa","moa":"Transferrin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Provides Update on Phase Iii RSV Maternal Vaccine Candidate Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVPreF3 OA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Ongoing Dupixent\u00ae (Dupilumab) Chronic Spontaneous Urticaria Phase 3 Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO\u00ae (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alofisel\u00ae\u25bc (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Darvadstrocel","moa":"IFN gamma","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"High Infliximab Trough Levels Are Associated With Low Risk of Relapse When Switching to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease, Suggests New Data Presented at ECCO 2022 Virtual Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Pharmaceutical Receives U.S. FDA Fast Track Designation for DZD4205 (Golidocitinib) for the Treatment of Refractory or Relapsed Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Golidocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Codiak\u2019s exoASO\u2122-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"STAT6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO\u2019s European Lung Cancer Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"MHC II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from an Ongoing Phase I\/II CYPIDES Trial of ODM-208 Presented at ASCO-GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fludrocortisone","moa":"CYP11A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Synairgen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topline Results From Phase 3 SPRINTER trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Receives Authorisation to Initiate New Study in France to Evaluate Nidlegy\u2122 in Several Nonmelanoma Skin Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech's Covaxin Gets Nod for Human Trials in the US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients With HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbevax Receives EUA For 12-18 Age Group","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Expands Its mRNA Pipeline with Three New Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1608","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Majority of Adults with Moderately to Severely Active Crohn\u2019s Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA\u00ae (guselkumab)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA\u00ae (guselkumab) at 12 Weeks","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Vers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Submitted Request U.S. Food and Drug Administration For Waiver of The Requirements On DMT310 Acne Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"DMT310","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kairos Pharma Announces FDA Clearance of Investigational New Drug (IND) for ENV105 for the Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Apalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kairos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pha.."},{"orgOrder":0,"company":"Neurocentria","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb\/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults with ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Threonic Acid Magnesium Salt","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Neurocentria","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Sustained Release Formulation","sponsorNew":"Neurocentria \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurocentr.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KSP-1007","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitovant Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitovant Biopharma \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sumitovant.."},{"orgOrder":0,"company":"ZielBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZielBio Announces First Patient Dosed in Phase 1\/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB131","moa":"CSP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ZielBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ .."},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Pergamum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Recruited to Promore Pharma's Clinical Trial Regarding Scarring According to Plan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensereptide","moa":"PAI-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Promore Pharma \/ Pergamum AB","highestDevelopmentStatusID":"8","companyTruncated":"Promore Ph.."},{"orgOrder":0,"company":"Brains Bioceutical","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brains Bioceutical Initiates Clinical Trial Agreement To Tackle Opioid Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Brains Bioceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Brains Bioceutical \/ Icahn School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Brains Bio.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Reports Remarks by Israel Institute for Biological Research On the Future of The BriLife\u2122 Covid-19 Investigational Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Gets 180 Days Shared Exclusivity For Roflumilast Tablets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2\/3 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like Behavior","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"4-ethylphenol Sulfate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN-RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Providence Therapeutics Announces $2.118 Million USD in Funding to Support Process Development and Validation of The PTX-COVID19-B Program, Which Targets High Quality mRNA COVID-19 Vaccine to Low-To Middle-Income Countries at Affordable Prices","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Funding","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Providence Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Thermo Fisher Scientific \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$29.1 million","newsHeadline":"BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"TCR Immunotherapy","moa":"T-cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Honeywell","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Honeywell Teams With AstraZeneca To Develop Next-Generation Respiratory Inhalers That Use Near-Zero Global Warming Potential Propellant","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Honeywell","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pressurised Metered-dose Inhaler","sponsorNew":"Honeywell \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Honeywell .."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HighTide Therapeutics Announces End-of-Phase 2 Meeting with FDA and Agreement to Proceed to Phase 3 for HTD1801 for the Treatment of PSC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pressurised Metered-dose Inhaler","sponsorNew":"HighTide Therapeutics \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Actinium-225 Conjugated Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ AVEO Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"RosVivo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RosVivo Therapeutics, Inc. Signed a Material Transfer Agreement (MTA) for First-In-Class Diabetes Treatment With Eli Lilly and Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"RSVI-301","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"RosVivo Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RosVivo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"RosVivo Th.."},{"orgOrder":0,"company":"TargED Biopharmaceuticals","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$43.7 million","upfrontCash":"Undisclosed","newsHeadline":"TargED Biopharmaceuticals Raises EUR 39 Million in Series A Financing to Bring Groundbreaking Thrombolytic Treatment to Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"Microlyse","moa":"ULVWF","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"TargED Biopharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"TargED Biopharmaceuticals \/ Andera Partners","highestDevelopmentStatusID":"4","companyTruncated":"TargED Bio.."},{"orgOrder":0,"company":"Sabal Therapeutics","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sabal Therapeutics Announces Sales and Marketing Agreement to Promote Athena Bioscience Cardiovascular Product Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sabal Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Sabal Therapeutics \/ Athena Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Sabal Ther.."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Lidds","sponsor":"Nice & Green","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"LIDDS Secures Financing of Up To 40.8 MSEK to Create Foundation for New Partnerships Based on The NanoZolid\u00ae Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Financing","leadProduct":"2-Hydroxyflutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Depot Injection","sponsorNew":"Lidds \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ Ni.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Emergex Awarded \u00a3490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Synthetic T-cell Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Emergex Vaccines Holding \/ Department of Health and Social Care","highestDevelopmentStatusID":"2","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$25.0 million","newsHeadline":"Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Thermo Fisher Scientific \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Plexium","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"IKZF2 transcription factor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Plexium \/ BVF Partners","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"AVT16","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"University of Jaen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propanc Biopharma\u2019s Joint Research Partnership with the Universities of Ja\u00e9n and Granada Enters 13th Year","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ University of Jaen","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Asofarma Central America and Caribbean","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asofarma Central America And The Caribbean, Through Its Headquarters Adium, Reaches An Important Agreement With Moderna Inc. To Collaborate In The Distribution And Marketing Of Vaccines Against Covid 19 In The Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Asofarma Central America and Caribbean","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Asofarma Central America and Caribbean \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Asofarma C.."},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Binnopharm Group Enters Into Agreement to Acquire Two Anti-Bacterial Brands From Dr. Reddy\u2019s in the Russia & CIS Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Binnopharm Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Binnopharm Group \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Binnopharm.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"TRPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"FP-045","moa":"ALDH2","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foresee Pharmaceuticals \/ TRPharm","highestDevelopmentStatusID":"7","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"hC Bioscience","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"hC Bioscience Announces $24 Million Series A Financing to Develop Innovative Pipeline of Protein-Editing Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"tRNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"hC Bioscience","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"hC Bioscience \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"hC Bioscie.."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","amount":"$251.1 million","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0.25,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Panacea Biotec","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Repirinast","moa":"Mast cell","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"GliaPharm","sponsor":"Wyss Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"GliaPharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GliaPharm \/ Wyss Center","highestDevelopmentStatusID":"3","companyTruncated":"GliaPharm .."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Pricing of $10.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"iosBio","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Iosbio Receives UK Grant to Develop Oral Vaccine Against Nipah Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iosBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iosBio \/ Department of Health and Social Care","highestDevelopmentStatusID":"1","companyTruncated":"iosBio \/ D.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), From Bristol Myers Squibb","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Taldefgrobep Alfa","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Biohaven Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Privo Technologies","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Privo Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Privo Technologies \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Privo Tech.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"University of Arizona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program by Signing a Collaboration Agreement with The University of Arizona","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"SBFM-PL4","moa":"PLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ University of Arizona","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Texas Children\u2019s Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpicentRx and Texas Children\u2019s Cancer Center Announce the Initiation of a Phase 1 Clinical Trial with RRx-001 for Pediatric CNS Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"RRx-001","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpicentRx \/ Texas Children\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Adium Pharma","sponsor":"Adium Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Adium Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adium Pharma \/ Adium Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Adium Phar.."},{"orgOrder":0,"company":"SEAL Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Santhera Signs Gene Therapy Agreement with SEAL Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Laminin alpha-2 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SEAL Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SEAL Therapeutics \/ Santhera","highestDevelopmentStatusID":"4","companyTruncated":"SEAL Thera.."},{"orgOrder":0,"company":"Serenity LLC","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"$6.0 million","newsHeadline":"Acerus Announces Definitive Agreement to Acquire Serenity LLC and The Global Rights To NOCTIVA\u2122","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Serenity LLC","amount2":0.02,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Hormone","amount2New":0.02,"dosageForm":"","sponsorNew":"Serenity LLC \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serenity L.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Sanwa Kagaku Kenkyusho","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$13.0 million","newsHeadline":"Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter Into Exclusive Licensing Agreement for The Development and Commercialization of Paltusotine in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Sanwa Kagaku Kenkyusho Co.","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Serotiny","sponsor":"Tessera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serotiny and Tessera Therapeutics Enter Into Collaboration to Engineer and Optimize Programmable Gene Writer Proteins","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Serotiny","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serotiny \/ Tessera Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Serotiny \/.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Leading Academic Medical Centers in Promising Novel Oral COVID-19 Therapeutic Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"COPD Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"INNA-051","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"ENA Respiratory \/ COPD Foundation","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Parexel and n-Lorem Foundation Partner to Support Development of New Investigational Therapies for Nano-rare Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Parexel Biotech","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parexel Biotech \/ n-Lorem","highestDevelopmentStatusID":"2","companyTruncated":"Parexel Bi.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"MRx0005","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Enrolls First Patient in Phase 2\/3 Sinusitis Trial of Nurtec\u00ae ODT","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s New Treatment Kerendia\u00ae (finerenone) Approved in EU for Adult Patients With Chronic Kidney Disease Associated With Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Lenalidomide in 19 Countries Across Europe, Expanding Access to Essential Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World\u2019s First Clinical Trial for DMT-assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Columbia University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University\u2019s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RenovoRx \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Mitsubishi Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Corporation Life Sciences Granted New US Patent for \"Composition Containing Glutathione as an Active Ingredient for Improvement or Prevention of Non-Alcoholic Fatty Liver\"","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Glutathione","moa":"Glutathione peroxidase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Mitsubishi Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicara Therapeutics Initiates Dose Expansion Arm of Phase 1\/1b Clinical Study of BCA101 in Disease-Specific Cohorts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"BCA101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Supplemental New Drug Application to U.S. FDA for Cariprazine (VRAYLAR\u00ae) for the Adjunctive Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Provides a Regulatory Update on Terlipressin","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Emeriti Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Takes Major Step Towards a Clinical Platform Company Targeting AT2R \u2013 New Molecule Ready for Phase 1","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"C106","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Emeriti Bio","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4Beta7 Integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9930","moa":"Factor D","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Progenity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO\u201922","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Progenity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Progenity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Progenity .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Granted New Patent for NCX 4251 in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Provides Update on Bexmarilimab Development Program Ahead of R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexmarilimab","moa":"CLEVER-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Top-Line Results from its initial Phase 2b\/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK to Seek Regulatory Authorization for Covid19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"AS03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2\/3 Clinical Trial With Gene Therapy LYS-SAF302 For the Treatment of MPSIIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Nalmefene HCl Injection, 2mg\/2mL (1mg\/1mL) for the Treatment of Known or Suspected Opioid Overdose with Natural or Synthetic Opioids","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jnana Therapeutics To Advance JNT-517 As Development Candidate And Potential First-In-Class Oral Treatment For PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"JNT-517","moa":"SLC6A19","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Doses First Participants in Phase 1\/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 PALADIN Study with ILUVIEN\u00c2\u00ae Published in Peer-Reviewed Journal Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Completes KP1077 Pre-IND Meeting Process with FDA","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Announces the Completion of A Second Interim Analysis of Its Phase III Clinical Program with Nidlegy for The Treatment of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ\u00ae) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ Abbvie","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO\u00ae (berotralstat)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Institute of Genetics and Cancer","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP900","moa":"YES1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Institute of Genetics and Cancer","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK\u00ae) in Patients with Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ S.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New MAVENCLAD\u00ae Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QUVIVIQ (daridorexant) Recommended for Approval in Europe as a New Treatment for Adults With Insomnia Disorder","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biontech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Will Host a Live Webcast on February 28, 2022 to Provide Details on the Masitinib Filing in the Treatment Als in Canada and to Provide an Update on Its Clinical Program in All Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"TYK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Doses First Subject in a Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Amarin","sponsor":"MedStar Health Research Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Publication Highlights VASCEPA\u00ae (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ MedStar Health Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ M.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Anti-CD19 UCAR-T","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"GC012F","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Jardiance\u00ae (Empagliflozin) to Treat Adults With Heart Failure Regardless of Left Ventricular Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Launches Global Clinical Trials for AI-based Sarcopenia Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"OC514","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross .."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Highlights Ongoing Phase 1\/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Cohort 2 SARTATE\u2122 Neuroblastoma Therapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"64Cu-labelled MeCOSar-Tyr3-octreotate","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamifant (Emapalumab) Recommended for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX\u00ae (relugolix) for the Treatment of Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kapruvia Receives Positive CHMP Opinion for the Treatment of Moderate-to-severe Pruritus in Hemodialysis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago and GSK Announce the Approval by Health Canada of Covifenz\u00ae, an Adjuvanted Plant-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Adjuvanted Plant-based Virus-like Particle","moa":"SARS?CoV?2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Further Reinforce Efficacy of Tezspire\u2122 (Tezepelumab-ekko) in a Broad Population of Severe Asthma Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII Seeks Permission for Phase-3 Study of COVID Vaccine Covovax as Booster Dose in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent\u00ae (Dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Celyad","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ MSD","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ M.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis (FSGS)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review Pfizer\u2019s Supplemental Application for ABRILADA\u2122 (adalimumab-afzb) Interchangeability","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac\u2122, Pfizer\u2019s Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Inactivated Tick-Borne Encephalitis Virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Provides Further Update on Phase Iii RSV Maternal Vaccine Candidate Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"RSV MAT Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational Crispr Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-causing Protein","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent\u00ae (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Sanofi Provide Update on Ongoing Dupixent\u00ae (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Tolebrutinib Data Demonstrated Superior Brain Penetration and Potency","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolebrutinib","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Phase 4 Data Support TAKHZYRO\u00ae (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Beverly Hills","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beverly Hills MD Celebrates Their Best Selling Product, Dermal Repair Complex, Achieving over 1500 Reviews","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyl Sulfone","moa":"DHT","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Beverly Hills","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beverly Hills \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beverly Hi.."},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-0200","moa":"mRNA splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Th.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience's Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Genialis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Selects Genialis ResponderID\u2122 for Clinical Optimization Study of INBRX-109","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Inhibrx \/ Genialis","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-2925","moa":"NMDA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glucophage\u00ae Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"MSC-NTF Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Correcting and Replacing GC Pharma Receives Complete Response Letter From the U.S. FDA For 'GC5107'","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Approves OXBRYTA\u00ae (voxelotor), First Treatment Approved in the EU to Target the Cause of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides Update Regarding SKYRIZI\u00ae (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Seeks New Indication for IMBRUVICA\u00ae (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Extends Clinical Development Program for Finerenone With Phase II Study Investigating the Initial Combination Therapy with Empagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb\u2019s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression \u22651%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENVIMA\u00ae (lenvatinib) Plus KEYTRUDA\u00ae (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cormedix Inc. Announces Resubmission Of New Drug Application For DefenCath","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Telisotuzumab Vedotin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Studies Showing Roche\u2019s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments Up to Four Months","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lenvima\u00ae\uff08Lenvatinib) in Combination With Keytruda\u00ae\uff08Pembrolizumab\uff09Approved in Taiwan for the First-line Treatment of Patients With Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC\u00ae (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral Granules","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Biopharma Asked to Submit More Data on Sputnik Light","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hetero Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Hetero Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hetero Bio.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Radium-224","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"Undisclosed","newsHeadline":"Xcellbio Announces $27.5 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Bios.."},{"orgOrder":0,"company":"Ceptur Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Series A Financing","leadProduct":"Oligonucleotide-based RNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ceptur Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Ceptur Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ceptur The.."},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Qu.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Silicon Valley Bank","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acura Pharmaceuticals and AD Pharma Amend License to LIMITx\u2122 LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Phar.."},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quanterix Announces New Agreements with Lilly to Advance Alzheimer\u2019s Disease Diagnosis and Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix .."},{"orgOrder":0,"company":"NextRNA Therapeutics","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Non-coding RNA-directed Medicine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"NextRNA Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"NextRNA Therapeutics \/ Cobro Ventures","highestDevelopmentStatusID":"3","companyTruncated":"NextRNA Th.."},{"orgOrder":0,"company":"Alchemee","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taro Completes Acquisition of Alchemee","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alchemee","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Alchemee \/ Taro Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Alchemee \/.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Affinivax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$65.0 million","newsHeadline":"Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax\u2019s MAPS\u2122 Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"24-valent Streptococcus Pneumoniae Vaccine","moa":"B-Cell antibody","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Astellas Pharma \/ Affinivax","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$760.0 million","upfrontCash":"$30.0 million","newsHeadline":"AstraZeneca and Neurimmune Close Exclusive Global Collaboration and Licence Agreement to Develop and Commercialise NI006","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin amyloid","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0.76000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"Epsilogen","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","amount":"$41.2 million","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Announces Completion of Oversubscribed \u00a330.75 Million ($41.20 Million) Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"MOv18 IgE","moa":"FR alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ Novartis Venture Fund","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen .."},{"orgOrder":0,"company":"Lausanne University Hospital","sponsor":"Prokarium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Salmonella Typhi Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lausanne University Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lausanne University Hospital \/ Prokarium","highestDevelopmentStatusID":"4","companyTruncated":"Lausanne U.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Successfully Raises Eur >10 Million From Leading Us And European Healthcare Investors In A Private Equity Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Bank Degroof Petercam","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Riluzole","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Aquestive Therapeutics \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Aston Sci","sponsor":"Timefolio Asset","pharmaFlowCategory":"D","amount":"$22.7 million","upfrontCash":"Undisclosed","newsHeadline":"Aston Sci. Raises USD 22.7 Million Series C Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aston Sci","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intradermal Injection","sponsorNew":"Aston Sci \/ Timefolio Asset","highestDevelopmentStatusID":"8","companyTruncated":"Aston Sci .."},{"orgOrder":0,"company":"Alivexis","sponsor":"Green Coinvest Investment Limited","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"Modulus Discovery Closes $20.4M USD Series C","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Series C Financing","leadProduct":"MOD-A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Alivexis","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Alivexis \/ Green Coinvest Investment Limited","highestDevelopmentStatusID":"3","companyTruncated":"Alivexis \/.."},{"orgOrder":0,"company":"ArrePath","sponsor":"Venture Fund","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Anti-infective Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"ArrePath","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ArrePath \/ Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"ArrePath \/.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incannex Healthcare \/ Monash University","highestDevelopmentStatusID":"8","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Group and Bridgebio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in The U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ BridgeBio Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Revitalist Lifestyle and Wellness","sponsor":"PharmaTher","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revitalist Lifestyle and Wellness","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Revitalist Lifestyle and Wellness \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revitalist.."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Ray-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Ray Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therap.."},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"DaVita Venture Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Upacicalcet Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ DaVita Venture Group","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys P.."},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Milagro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Cure Pharmaceutical \/ Milagro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharm.."},{"orgOrder":0,"company":"Spexis","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Spexis Achieves First CARB-X Milestone for Its Thanatin Derivatives Program and Receives Funding of up to USD 1.9 Million to Initiate Lead Optimization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"POL7306","moa":"LPS transport pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spexis \/ CARB-X","highestDevelopmentStatusID":"2","companyTruncated":"Spexis \/ C.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Guokang Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela\u00ae In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Melphalan","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CASI Pharmaceuticals \/ Guokang Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Receives a US$15 Million Milestone From AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS\u00ae in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Savolitinib","moa":"c-MET receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Versameb Announce GMP Manufacturing Supply Agreement","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"VMB-100","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Versameb","highestDevelopmentStatusID":"4","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"Medicines Discovery Catapult","sponsor":"Alchemab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alchemab Extends Partnership with Medicines Discovery Catapult to Bolster Collaborative Approach to Tackle Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Human Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Medicines Discovery Catapult","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicines Discovery Catapult \/ Alchemab","highestDevelopmentStatusID":"2","companyTruncated":"Medicines .."},{"orgOrder":0,"company":"Microbiotica","sponsor":"Flerie Invest","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Microbiotica Raises \u00a350m ($67m) to Advance Pipeline of Microbiome-based Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"MB097","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Microbiotica","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Microbiotica \/ Flerie Invest","highestDevelopmentStatusID":"4","companyTruncated":"Microbioti.."},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"WuXi AppTec","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"WuXi AppTe.."},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"QS-21 Stimulon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acer Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Successfully Closes EUR >10 Million in Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"UCB Completes Acquisition of Zogenix, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":1.8999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Elixirgen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"ZSCAN4-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taisho Pharmaceutical \/ Elixirgen Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Taisho Pha.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genome and Company Announces Clinical Trial Collaboration with MSD to Evaluate 'GEN-001' in Combination of KEYTRUDA\u00ae (pembrolizumab) in Phase 2 Clinical Trial in Biliary Tract Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genome & Company \/ MSD","highestDevelopmentStatusID":"5","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Aevisbio","sponsor":"KB investment","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"AevisBio Publishes Data with NIH Demonstrating Novel Immunomodulatory Imide Drug Reduces Neuroinflammation and Prevents Cognitive Impairment in Alzheimer\u2019s Disease Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"3,6\u2019-dithiopomalidomide","moa":"TNF alpha","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aevisbio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aevisbio \/ KB investment","highestDevelopmentStatusID":"5","companyTruncated":"Aevisbio \/.."},{"orgOrder":0,"company":"Novotech","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Novotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Novotech \/ Skye Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Novotech \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Upamostat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 CLOVER Trial for Pfizer\u2019s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PF-06425090","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CP101","moa":"Microbiome diversity","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Enobosarm","moa":"Selective androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Developmental Therapeutics Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Developmental Therapeutics Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Th.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MuSK-CAART","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces First Patient Dosed in Phase 1\/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma Inc. to Present at Oppenheimer & Co\u2019s 32nd Annual Healthcare Conference on March 15, 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid-Filled Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives Approval to Commercialize ELUNATE\u00ae in Macau","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetirizine","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Imiquimod","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Miravo Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Miravo Healthcare\u2122 Announces the Canadian Commercial Launch of Blexten\u00ae for Patients 4 Years of Age and Older*","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aralez Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aralez Pharmaceuticals \/ Miravo Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Aralez Pha.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO\u00ae for the Treatment of Advanced Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"GDF-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u2122 (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae Provided a Significant Clinical Benefit in Adults Stabilized in Hospital Following Acute Heart Failure in Empulse Phase III Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Sage Chemical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harm Reduction Therapeutics Announces That Its Naloxone Nasal Spray Met Its Primary Endpoints in a Phase 1 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Sage Chemical","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Trupharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TruPharma, LLC Announces Approval and Launch of Apomorphine Hydrochloride Cartridges, 30 mg\/3 mL (10 mg\/mL), the First Generic Version of APOKYN\u00ae Cartridges","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trupharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Trupharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trupharma .."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long Term Study Confirms Efficacy of Isa Pharmaceuticals' T-cell Activating Immunotherapy in Combination With Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Generic Medication in US Market","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio\u2019s Scaled m-ceNK Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Inbakicept","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi\u00ae (ropeginterferon alfa-2b-njft) for the Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK2V617F","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"XT-150","moa":"IL-10","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Ther.."},{"orgOrder":0,"company":"PanTheryx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TruBiotics\u00ae Grows Its Family: New Baby Drops Feature Clinically Researched Probiotic Strain BB-12\u00ae Shown to Reduce Excessive Infant Crying and Fussing, and Increase Sleep Duration","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bifidobacterium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"PanTheryx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Drop","sponsorNew":"PanTheryx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PanTheryx .."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Announces Positive Topline Results For XARACOLL\u00ae (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"BlueWillow Biologics","sponsor":"Medigen Vaccine Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueWillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal COVID-19 Booster Candidate in Pre-clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BW-1019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BlueWillow Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"BlueWillow Biologics \/ Medigen Vaccine Biologics","highestDevelopmentStatusID":"4","companyTruncated":"BlueWillow.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson\u2019s Disease (PD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion\u2122 Targeting Severe Osteoarthritis of the Knee (OAK)","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intra-Articular Injection","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod\u2122 Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tmod CEA CAR T Cell Therapy","moa":"Carcinoembryonic antigen","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"A2 Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLT Announces New Clinical Studies that Shed Light on the Non-Stimulant Thermogenic Benefits of Slendacor\u00ae Weight Management Complex","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Curcumin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"PLT Health Solutions","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PLT Health Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLT Health.."},{"orgOrder":0,"company":"Mind Cure Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MC-808","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mind Cure Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Cure Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Cure .."},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elgan Pharma Announces Positive Results from its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elgan Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Phar.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redcloud Bio Announces FDA Acceptance Of Ind Application For Next-Generation EGFR Inhibitor H002 In Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"H002","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedCloud Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud B.."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-9199","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"University of Sheffield","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Delayed Clearance Parathyroid Hormone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aeterna Zentaris \/ University of Sheffield","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Synthetic Cannabinoid","moa":"CB1","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Solid Dosage Formulation","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Further Strengthens FIRDAPSE\u00c2\u00ae U.S. Patent Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio Announces Positive Phase 2 Results Demonstrating Proof-of-Concept for the Novel Local Delivery of AMB-05X in Patients with Tenosynovial Giant Cell Tumor (TGCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AMB-05X","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"HPN217","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexeo Therapeutics Announces Positive Initial Data from Ongoing Phase 1\/2 Clinical Trial of AAV-Based Gene Therapy Candidate LX1001 In Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hAPOE2","moa":"Apolipoprotein E 2\/3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Announces Start of TPOXX\u00ae Post-Exposure Prophylactic (\u201cPEP\u201d) Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Statera Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Statera Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2\/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Evorpacept","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces 750th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX\u2081\u2080\u2080 in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barr\u00e9 Syndrome and Huntington\u2019s Disease at AAN 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elucida Oncology to Present at Two Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Folic-acid Functionalized C\\'Dot-Drug-Conjugate","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida On.."},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legal Delta-9 THC Gummies Launched By ExhaleWell.com","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Exhale Wellness","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Exhale Wellness \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exhale Wel.."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AgenT-797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"HDAC10","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intraprostatic Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TNG908","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Imprime PGG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Imprime PGG","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"Axl tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics\u00ae Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Waiver in China Opens Door to 2022 Registration Filing for ALK's Dust Mite Allergy Tablet","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"House Dust Mite Allergen Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Inspirevax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ Inspirevax","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Health Canada Approval for BRUKINSA\u00ae (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan With the Aim of Obtaining Early Approval for Investigational Anti-amyloid Beta Protofibril Antibody Lecanemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai Inc \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc .."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athena Bioscience Announces Launch of Nexiclon\u2122 XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Athena Bioscience","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Athena Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Bio.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Extension of U.S. FDA BLA\/sNDA PDUFA Date for Ublituximab Plus UKONIQ\u00ae (U2) to Treat Patients with CLL and SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroGenesis and Hadassah Medical Center Report Positive NF-L Biomarker Results from a Phase 2 Study in Progressive Multiple Sclerosis Treated with NG-01 Cells Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NeuroGenesis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Hadassah Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"NeuroGenes.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mocravimod","moa":"S1PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promis Neurosciences\u2019 PMN310 Antibody Demonstrates Significant Cognitive Benefit In a Mouse Model of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BMS-9896415","moa":"IL-12 fusion protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dragonfly Therapeutics \/ BMS","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida to Participate in Cowen 42nd Annual Health Care Conference","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"ABL1 gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder For Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"Axl tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"PolyActiva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Latanoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Sustained Release Ocular Implant","sponsorNew":"PolyActiva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva.."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Significantly Protected Infants Against RSV Disease in Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Onco360","sponsor":"CTI BioPharma Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VONJO\u2122 (pacritinib) Now Approved for the Treatment of Adults with Intermediate or High-Risk Primary or Secondary Myelofibrosis with a Platelet Count Below 50 x 109\/L","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onco360 \/ CTI BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences' Real World Data on Endari\u00ae Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Aravax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravax Opens IND for PVX108 Phase 2 Trials and Strengthens Sab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PVX108","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aravax","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Aravax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aravax \/ N.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix To Present New Long-term Data on FINTEPLA\u00c2\u00ae (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Launch of a First Generic Version of Revlimid\u00ae (lenalidomide capsules), in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae (Empagliflozin) Becomes the First and Only Approved Treatment in Europe for Adults With Symptomatic Chronic Heart Failure Regardless of Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Two Presentations at the 27th International Conference on Advances in Critical Care Nephrology","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1\/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"Ataxia-Telangiectasia","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"SanBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vandefitemcel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SanBio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ N.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-930","moa":"Transcriptional enhanced associate domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Biotech Completes Recruitment for Phase 1\/2a Clinical Trial for EVX-02","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"EVX-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"HPN328","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Ben-Gurion University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Provides Update on Research Activities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"P-Esbp Conjugated Doxorubicin","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Ben-Gurion University","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"TLC BioSciences","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"TLC BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TLC BioSci.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"PD-L1\/CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO\u00ae (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Provides an Update on Its COVAXIN\u2122 Pediatric (2-18) Emergency Use Authorization (EUA) Request","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Hmaxi-K","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Recalls Inderal- LA (Propranolol Hydrochloride) Capsules Due to a Nitrosamine Impurity","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Significantly Protected Infants Against RSV Disease in Phase III MELODY Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on SNG001 in The ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 Activity Against Delta and Omicron variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA\u00ae (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatibility Issues","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency (EMA) Accepts Marketing Authorisation Application for Daprodustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Peer-reviewed Safety and Tolerability Data Further Strengthens Kesimpta\u2019s (Ofatumumab) Favorable Benefit-risk Profile in Patients With Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Opdivo\u00ae (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Obinutuzumab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku Co., Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recursion Provides Updated Guidance on Clinical Trial Starts","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"REC-3599","moa":"PKC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Tempus","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KIN004","moa":"CDK12","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Tempus","highestDevelopmentStatusID":"5","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Signet","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Signet Healthcare Partners","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharm.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Endpoint Health","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols Signs Global Collaboration Agreement with Endpoint Health to Develop and Commercialize Antithrombin III for Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Antithrombin III","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Grifols International","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Grifols International \/ Endpoint Health","highestDevelopmentStatusID":"4","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Harvard University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cantex Licenses Intellectual Property from Harvard University to Develop Repurposed Drug Identified by Wyss Institute to Treat Inflammatory Lung Diseases Including COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"IL-6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cantex Pharmaceuticals \/ Harvard University","highestDevelopmentStatusID":"6","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"HitGen","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Has Successfully Completed a Three-Year Collaboration With MTPC to Discover Novel Hit Compounds for Multiple Drug Targets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Mitsubishi Tanabe Pharma Corporation","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ M.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Temozolomide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"BI 1015550","moa":"PDE4B","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Receives Positive CHMP Opinion for Kimmtrak\u00ae (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Initiates its Phase 1a\/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"HC-7366-K","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Immediate Releasse Capsule","sponsorNew":"HiberCell \/ Covance","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Mitotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech CSO to Present at Mitochondria-Targeted Drug Development Summit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Institute of Materia Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Herbs that Protect the Heart: Bilobalide Reduces Cardiac Damage in Myocardial Ischemia, Says New Study in Journal of Pharmaceutical Analysis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bilobalide","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Institute of Materia Medica","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institute of Materia Medica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Institute .."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$39.6 million","upfrontCash":"Undisclosed","newsHeadline":"NMD Pharma Raises \u20ac35 Million in a New Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Financing","leadProduct":"NMD670","moa":"ClC-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NMD PHARMA","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Vaximm AG","sponsor":"NEC OncoImmunity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Necvax Neo 1","moa":"Cytotoxic T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaximm AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaximm AG \/ NEC OncoImmunity","highestDevelopmentStatusID":"4","companyTruncated":"Vaximm AG .."},{"orgOrder":0,"company":"Serenity Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Serenity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Hormone","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Serenity Pharmaceuticals \/ Acerus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serenity P.."},{"orgOrder":0,"company":"Brain Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Expands Its Business in Southeast Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Brain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oromucosal Solution","sponsorNew":"Brain Therapeutics \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Brain Ther.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo\u00ae (cemiplimab) Combination in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Creyon Bio","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"Oligonucleotide-based Medicine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Creyon Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Creyon Bio \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Creyon Bio.."},{"orgOrder":0,"company":"TRexBio","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"TRB-051","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"TRexBio","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TRexBio \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"TRexBio \/ .."},{"orgOrder":0,"company":"GlycoMantra","sponsor":"University of Maryland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"University of Maryland, Baltimore (UMB) Grants GlycoMantra Exclusive License to Advance the Company's Therapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"GM300","moa":"Galectin-3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GlycoMantra","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GlycoMantra \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"GlycoMantr.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma\u2019s NULIBRY\u2122 (Fosdenopterin)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Fosdenopterin","moa":"Molybdenum cofactor synthesis","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$99.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma's US subsidiary acquires Galderma's companies in US, Japan & Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Topical Solution","sponsorNew":"Galderma \/ Taro Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"University of Montreal Hospital Research Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ University of Montreal Hospital Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Nevakar","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nevakar Announces Closing Of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nevakar","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Nevakar \/ Oxford Finance LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"eGenesis","sponsor":"University of Miami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"HuCo Islet Cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"eGenesis \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/.."},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cincinnati Children\u2019s Hospital Medical Center and Orange Grove Bio Establish Collaboration to Develop and Commercialize Novel Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Orange Gro.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Runway Growth Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Relmapirazin","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Runway Growth Capital","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"HM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osteal Therapeutics Closes an Oversubscribed $30 Million Series B Financing to Advance Platform Therapy for Treatment of Musculoskeletal Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ HM Capital","highestDevelopmentStatusID":"8","companyTruncated":"Osteal The.."},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Th\u00e9a Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akorn Announces Completion of the Sale of its Branded Ophthalmic Products to Th\u00e9a Pharma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Tafluprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Akorn Pharmaceuticals \/ Th\u00e9a Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Phar.."},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"225Ac\u2212Rosopatamab","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Convergent Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Convergent Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"Convergent.."},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"DecentraNet","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Ropocamptide","moa":"Hepatitis B virus membrane","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maxwell Biosciences \/ DecentraNet","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Bi.."},{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HTL Announces Its Incubator's Equity Investment In GelMEDIX, An Early-Stage Biotech Aiming At Revolutionizing Ocular And Regenerative Therapies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Hydrogel Implant","sponsorNew":"GelMEDIX \/ HTL","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Portfolio Limited","pharmaFlowCategory":"D","amount":"$26.1 million","upfrontCash":"Undisclosed","newsHeadline":"Freeline Announces $26.1 Million Registered Direct Offering of American Depositary Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Portfolio Limited","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Ciloa","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ciloa Secures \u20ac5 Million for the Development of Its New Generation of Biomedicines and Vaccines Using Exosomes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"Exosomes-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ciloa","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ciloa \/ Bpifrance","highestDevelopmentStatusID":"1","companyTruncated":"Ciloa \/ Bp.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Twist Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gedeon Richter","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gedeon Richter \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Gedeon Ric.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Signs Initial Agreement With Carisma Therapeutics For The Manufacturing of HER 2 Targeted CAR-M Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"CT-0508","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pyramid Biosciences and Caris Life Sciences Announce MI Trials Collaboration for Clinical Trial Matching in Support of Study for Patients with NTRK Fusion Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"PBI-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pyramid Bio \/ Caris","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bi.."},{"orgOrder":0,"company":"Centurion BioPharma","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Merger","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Centurion BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Centurion BioPharma \/ CytRx Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Centurion .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Acquisition of A Portfolio of Novel CNS Therapeutics from Concert Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Terran Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"University of Michigan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"OncoArendi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoArendi Therapeutics \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"OncoArendi.."},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Completes Acquisition of VCN Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Gemcitabine","moa":"Hyaluronidase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Synthetic Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosci.."},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Dingxin Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Impact Therapeutics Announces Completion of Series D1 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series D Financing","leadProduct":"Senaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IMPACT Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Dingxin Capital","highestDevelopmentStatusID":"10","companyTruncated":"IMPACT The.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"University of Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catamaran Bio Expands Collaboration for CAR-NK Cell Engineering with the University of Minnesota and Secures an Exclusive Patent License to Next Generation Manufacturing Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ University of Minnesota","highestDevelopmentStatusID":"2","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"LYFE Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediLink Therapeutics Closes US$70 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"Antibody-Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MediLink Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ LYFE Capital","highestDevelopmentStatusID":"4","companyTruncated":"MediLink T.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Darovasertib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Pfizer Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen and Eisai Amend Collaboration Agreements on Alzheimer\u2019s Disease Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India and GreenLight Biosciences Multitarget Licensing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"GreenLight Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"GreenLight.."},{"orgOrder":0,"company":"NexImmune","sponsor":"The Laura and Isaac Perlmutter Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Melanoma Research Collaboration with NYU Langone\u2019s Perlmutter Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Neoantigen-specific CD8+ T Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ The Laura and Isaac Perlmutter Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Cedars-Sinai Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cedars-Sinai Medical Center and AIkido Pharma Inc. to Codevelop Novel Immuno-Oncology Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"AIkido Pharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AIkido Pharm \/ Cedars-Sinai Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"AIkido Pha.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Massachusetts Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Biologic Medicine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Massachusetts Institute of Technology","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Arena","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$6,700.0 million","upfrontCash":"$6,700.0 million","newsHeadline":"Pfizer Completes Acquisition of Arena Pharmaceuticals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Arena","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arena \/ Pfizer Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Arena \/ Pf.."},{"orgOrder":0,"company":"DepYmed","sponsor":"Monash Biomedicine Discovery Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors Against a Novel Intracellular Checkpoint in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"PTP1B","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"DepYmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"DepYmed \/ Monash Biomedicine Discovery Institute","highestDevelopmentStatusID":"4","companyTruncated":"DepYmed \/ .."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data of Prestige Biopharma\u2019s First-in-Class Pancreatic Cancer Treatment, PBP1510, Presented in ESMO TAT 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PAUF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline\u00ae Autogel\u00ae\/Somatuline\u00ae Depot (lanreotide)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Preclinical Data on Anti-cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BAL0891","moa":"Threonine tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present New Evrysdi Data at MDA 2022 and Highlight Expanding Neuromuscular Disease Portfolioular Disease Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Seeks Approval of a New Indication for IMBRUVICA\u00ae (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of Neuroendocrine Tumors at Annual ENETS Conference 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac\u00ae platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TG4050","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ORM-5029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Thera.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1\/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Schr\u00f6dinger To Present New Preclinical Data From Its Wee1 Inhibitor Program At AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Preclinical Data from XmAb\u00ae Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"XmAb306","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CDK12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AB521","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arcus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences to Present Preclinical Data Highlighting AU\u2011011\u2019s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalacan","moa":"Heparan sulfate proteoglycans","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GTAEXS-617","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Xentria","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xentria to Present Initial Findings from Preclinical Study of XTMAB-16 at ATS 2022 International Conference","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"XTMAB-16","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Xentria","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xentria \/ .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Muscular Dystrophy Association","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Muscular Dystrophy Association","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caraway Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"TRPML1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Caraway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Th.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1\/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"E-602","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Trial of COR588","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"COR588","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody\u00ae-CD3xCD20) in Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Grossman School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Ananda Scientific \/ NYU Grossman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Sci.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s Phase III Psoriasis Study Data Expected Q2 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer\u2019s Disease at AD\/PD and NDDS Scientific Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Statement on Availability of its COVID-19 Vaccine in New Zealand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals' JV Gets USFDA Final Nod for Anti-Fungal Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nystatin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Initiates Phase 2\/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"JZP815","moa":"Fibrosarcoma","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-894","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"YH001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eucure Biopharma \/ Biocytogen","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Labs Granted Phase 2a Clinical Trial Application Approval by Health Canada for Treatment of PTSD in Veterans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Announces Positive Phase 1b\/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-005 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics to Present Phase 1\/1b Clinical Data at the Upcoming AD\/PD\u2122 Alzheimer's & Parkinson's Diseases Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antisense Therapeutics to Present Poster at World\u2019s Largest NMD Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ATL1102","moa":"CD49d antisense","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense .."},{"orgOrder":0,"company":"In3Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Approves Phase I\/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IN01","moa":"EGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"In3Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"In3Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"In3Bio \/ N.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Stimunity","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Virus Like Particles","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Stimunity","highestDevelopmentStatusID":"4","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"SEMA4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PRT3645","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SL-9258","moa":"TIGIT checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CFT8634","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Initiation of Phase 1\/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"DNL593","moa":"Progranulin protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children\u2019s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-101","moa":"IL-13 alpha-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Running for Research \u2013 Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody Drug Conjugate","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Announces First Patient Dosed in the Phase 1\/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Frontier Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon\u2122 in Unmethylated Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Temferon","moa":"INF alpha 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Votucalis","moa":"H1\/H2\/H3\/H4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha 2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA55","moa":"Interleukin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRP\u00ce\u00b1 Inhibitor BI 765063 in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"OSE-172","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC\u2122 Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CTG","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Design Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Design Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Design The.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura to Present Preclinical Data on its Clinical Stage Autotaxin Inhibitor, IOA-289, at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IOA-289","moa":"Autotaxin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma\u2019s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"7HP349","moa":"VLA-4\/LFA-1 allosteric","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"Irreversible menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics\u00ae Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Fibrosarcoma kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG138","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GRT-C903","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio\u2019s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KB-0742","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Cancer to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LYL797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics Announces End-of-Phase 2 Meeting with FDA and Agreement to Proceed to Phase 3 for HTD1801 for the Treatment of PSC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Berberine Ursodeoxycholate","moa":"Lipid","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighTide Therapeutics \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Antengene","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces XPOVIO\u00ae Approved by the TGA in Australia for the Treatment of Relapsed and\/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Karyopharm","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"OP-1250","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TNG908","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VIP152","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX130","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LN-145","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MCLA-129","moa":"EGFR\/Tyrosine protein kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CD 70 CAR NK Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BP1003","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BDC-2034","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VB10.16","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Class I HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"6","companyTruncated":"OnKure The.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CFT7455","moa":"IKZF1\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM707","moa":"ILT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ORIC-533","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ZN-c3","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces the Publication of Data From an Investigator-Initiated Study of NUZYRA\u00ae (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium Complex","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Oral KORSUVA\u2122 (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO\u00ae in Pediatric Patients Following Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol\u00ae for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE\u00ae 327","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Recce 327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofranergene Obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Innovaderm Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Innovaderm Research","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"VPS4A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid to Deliver Poster Presentation at SAGES 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Extended Release Sterile Powder For Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces Successful Bioavailability Study for Mycapssa\u00ae (octreotide capsules)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"MiroBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MB272","moa":"BTLA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiroBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech to Present at 32nd Annual Oppenheimer Healthcare Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IO-108","moa":"LILRB2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriOri BioTech Inc. Granted Patent for Topical Formulation of Vioxx","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BriOri Bio.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPA Updates On Investigational New Drug (IND) Enabling Program for PolyTope\u00ae TATX-03","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TATX-03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"FogPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FogPharma Announces Selection of Clinical Development Candidate Directly Targeting \u03b2-Catenin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"FOG-001","moa":"TCF-1\/beta-catenin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FogPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma .."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics to Participate in Upcoming Investor Conferences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon Pharmaceuticals to Present Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bi-Sialidase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Imvax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous GBM Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imvax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imvax \/ No.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV to Showcase its DPX\u00ae Delivery Technology in Two Presentations at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Sachets","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DERMAdoctor Launches New HA Serum to Expand Calm Cool + Corrected Product Line","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Serum","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Therapeutics Announces Publication of AACR Abstract Demonstrating Systemic Anti-Tumor Immune Response in Syngeneic Pancreatic Murine Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Seneca Valley Virus-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seneca Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seneca Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seneca The.."},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Morning side VENTURE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morningside Ventures Launches Adiso Therapeutics to Advance Novel Therapies for Inflammatory Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Single Strain Live Biotherapeutic Products","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Adiso Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adiso Therapeutics \/ Morning side VENTURE","highestDevelopmentStatusID":"8","companyTruncated":"Adiso Ther.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Sachets","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Presented Safety \/ Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics to Present Preclinical Data of BBT-207 at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BBT-207","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE\u00ae Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tri-specific NK-cell Engager","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TJ-C64B","moa":"4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Announces Upcoming Presentation of Biomarker Analysis from Patients in MATINS Trial at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexmarilimab","moa":"CLEVER-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Phase 1b Data Demonstrating Clinical Proof-ofConcept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCurity Pharmaceuticals Inc. ('BioCurity' or \u2018Company\u2019) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cerium Oxide","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioCurity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity .."},{"orgOrder":0,"company":"Specifica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Specifica Is Pleased to Announce the United States Patent and Trademark Office Has Granted Two Patents to Specifica for Its Innovative Generation 3 Antibody Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Specifica","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Specifica \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Specifica .."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows It Produced Robust Antibodies and T Cells Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GeoVax Labs \/ City of Hope","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PIPE-307","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ONM-501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"OncoNano Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCurity Pharmaceuticals Inc. ('BioCurity' or \u2018Company\u2019) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiation Using the Company\u2019s Cerium Oxide Nanoparticles","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cerium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioCurity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity .."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Confo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gan & Lee Pharmaceuticals Begins First-In-Human Trial in the U.S. for Investigational Drug, GZR18","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Glucagon-like Peptide-1 Analogue","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-1044","moa":"PADI4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC channel","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Observes Substantial Reduction in AHI in Preliminary Results of Clinical Trial Assessing IHL-42x in Patients With OSA; Proceeds to Pivotal Studies","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-316","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Institute of Cancer Research in London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Institute of Cancer Research in London","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asher Bio to Showcase Continued Progress with Lead Program AB248 and Growing Pipeline of Precisely-Targeted Immunotherapies at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AB248","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Resubmits Biologics License Application for DaxibotulinumtoxinA for Injection for Glabellar Lines to the FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Collaboration Partner Bayer Submits Applications in The U.S. and EU for Additional Indication of Darolutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Coated Tablet","sponsorNew":"Bayer AG \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID\u00ae (pimavanserin) for the Treatment of Alzheimer\u2019s Disease Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"Selective serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cefepime","moa":"Peptidoglycan synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Acetate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Positive Phase 3 Atogepant (QULIPTA\u2122) Data for the Preventive Treatment of Chronic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Clinical Hold on Immunome\u2019s IMM-BCP-01 IND Application for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 virus protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Positive Results from Capricor Therapeutics\u2019 Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest lecanemab Data to be Presented at The AD\/PD\u2122 Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Provides Regulatory Update on its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved in the US as Adjuvant Treatment for Patients With Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant to Present New Data from the Phase 3 PSOARING 3 Long-Term Extension Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"A3AR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Result of the Phase 3 Study for Prestige BioPharma\u2019s Herceptin Biosimilar, HD201(Tuznue\u00ae), Published in JAMA Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Present New Research at the International Conference on Alzheimer's and Parkinson's Diseases (AD\/PD 2022)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Oral Solution","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Isoamyl Nitrite","moa":"ANP receptor 1","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID Researchers Launch Trial to Study Allergic Reactions to Covid-19 mRNA Vaccine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Themis Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Themis Gets Drug Controller\u2019s Nod to Launch Inosine Pranobex a Novel Medicine to Treat Covid19, A Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Inosine Pranobex","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Themis Medicare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Themis Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Themis Med.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Selective myostatin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Again Demonstrate Age-appropriate Development When Zolgensma Is Used Presymptomatically, and Post-hoc Data Reveal Sma Type 1 Patients Could Speak, Swallow and Maintain Airway Protection","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-0231.F","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NeuBase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Th.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Phase 3 PaTHway Trial of TransCon\u2122 PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"RCSI University of Medicine and Health Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RCSI Clinical Trial Reveals New Treatment Option For COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Alpha-1-antitrypsin","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"RCSI University of Medicine and Health Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RCSI University of Medicine and Health Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RCSI Unive.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Gets US FDA Tentative Nod for Macitentan Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Macitentan","moa":"Endothelin Receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gennova Biopharma Submits Final Vaccine Trial Data to Regulator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Provides Update on Phase 2 study Evaluating Amcenestrant in ER+\/HER2- Advanced or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura\u2122) for the Treatment of Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Fasenra in Chronic Rhinosinusitis with Nasal Polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Bristol Myers Squibb \/ Nektar","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RG6501 (OpRegen\u00ae) Full Phase 1\/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme to Present New GAIN Trial Data at AD\/PD 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: Namodenoson\u2019s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Namodenoson","moa":"A3AR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R\/R CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KROS-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kairos Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kairos Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kairos Pha.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium Receives FDA Approval of ADLARITY\u00ae (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"OncoTEX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoTEX Issued New U.S. Patent for Ovarian Cancer-Fighting Drug OxaliTEX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxaliplatin Pt(IV) Prodrug","moa":"Mutant p53","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"OncoTEX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoTEX \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"OncoTEX \/ .."},{"orgOrder":0,"company":"Wesana Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Wesana Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wesana Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Wesana Hea.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL Study of EB-101 in RDEB","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer's Disease at AD\/PD 2022 Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves LYNPARZA\u00ae (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BG505 MD39.3 mRNA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specic Bivalent Booster Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publication of Novartis Kisqali\u00ae Data Shows Longest Median Overall Survival Ever Reported in HR+\/HER2- Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efanesoctocog Alfa Met Primary and Key Secondary Endpoints in Pivotal Study in Hemophilia a, Demonstrating Superiority to Prior Factor Prophylaxis Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present Long-term Outcomes for Lumakras\u00ae (Sotorasib) in Kras G12c-mutated NSCLC at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Present New Research at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD 2022)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Applications in The U.S. and EU for Additional Indication of Nubeqa\u2122 (darolutamide)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EISAI to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets At the AD\/PD\u2122 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Bioarctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector to Present New AL001 Data at AD\/PD\u2122 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AL001","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Announces First Patient Dosed in Phase 1\/2 Acclaim-1 Clinical Trial of REQORSA\u2122 Immunogene Therapy in Combination with Tagrisso\u00ae to Treat Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech and Biofabri Partner to Develop, Manufacture and Distribute a Novel TB Vaccine, MTBVAC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biofabri \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/.."},{"orgOrder":0,"company":"VGXI","sponsor":"Geneos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"GT-30","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VGXI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VGXI \/ Geneos Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"VGXI \/ Gen.."},{"orgOrder":0,"company":"Biomay","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomay Cooperates with BioNTech to Supply DNA Template for COVID-19 mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biomay","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomay \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Biomay \/ B.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Richter-Helm BioLogics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inovio Expands Manufacturing of Covid-19 DNA Vaccine INO-4800 With New Funding From CEPI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"ANL Bio","sponsor":"Biovian","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANLBIO Selected Biovian for Manufacturing of AAV-based product for The Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"ANL-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ANL Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ANL Bio \/ Biovian","highestDevelopmentStatusID":"4","companyTruncated":"ANL Bio \/ .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Providence Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Providence Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Symrise","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Avenanthramides","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Ceapro \/ Symrise","highestDevelopmentStatusID":"12","companyTruncated":"Ceapro \/ S.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Announces \u20ac300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Subcutaneous Solution","sponsorNew":"Sanofi \/ Blackstone","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ B.."},{"orgOrder":0,"company":"Imugene","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"HER-Vaxx","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Phillips - Medisize","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline\u00ae Autogel\u00ae \/ Somatuline\u00ae Depot (lanreotide) Designed to Improve Patient Experience","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Phillips-Medisize","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ph.."},{"orgOrder":0,"company":"Seagen","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Seagen \/ S.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$987.5 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"PN-235","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.98999999999999999,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Precirix","sponsor":"INKEF Capital","pharmaFlowCategory":"D","amount":"$87.8 million","upfrontCash":"Undisclosed","newsHeadline":"Precirix Raises EUR 80m in Series B to Advance Its Pipeline of Precision Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"Cam-H2","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous","sponsorNew":"Precirix \/ INKEF Capital","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/.."},{"orgOrder":0,"company":"KayoThera","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KayoThera","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"KayoThera \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"2","companyTruncated":"KayoThera .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"AXA1125","moa":"Mitochondrial dysfunction","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Axcella Health","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"225Ac-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clovis Oncology \/ Evergreen Theragnostics","highestDevelopmentStatusID":"1","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Antiviral Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Scripps Research","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Cantrixil","moa":"Selective mitochondrial electron transfer","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal","sponsorNew":"Oasmia Pharmaceutical \/ Lonza","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Qu Biologics Closes USD$12M Equity Financing","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Qbeco","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Saniona","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Advances to Next Stage","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Saniona","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Saniona \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp","pharmaFlowCategory":"D","amount":"$1,640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":1.6399999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":1.6399999999999999,"dosageForm":"Prefilled Syringe For Epidural","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$50.0 million","newsHeadline":"Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Oaktree Capital","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Enzyme Therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Revel Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Revel Pharmaceuticals \/ Kizoo Technology Capital","highestDevelopmentStatusID":"2","companyTruncated":"Revel Phar.."},{"orgOrder":0,"company":"Centogene","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Centogene Announces Expansion of Data Access and Collaboration Agreement With Pfizer","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Centogene","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centogene \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Centogene .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY\u00ae (donepezil transdermal system)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Donepezil","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"KemPharm \/ Corium","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Todos Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"NLC-V-01","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Todos Medical","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Claris Ventures","pharmaFlowCategory":"D","amount":"$18.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kither Biotech Raises \u20ac18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"KIT2014","moa":"cAMP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"Kither Biotech \/ Claris Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Kither Bio.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Portfolio Limited","pharmaFlowCategory":"D","amount":"$26.1 million","upfrontCash":"Undisclosed","newsHeadline":"Freeline Closes $26.1 Million Registered Direct Offering of American Depositary Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Syncona Portfolio Limited","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University of Louisville Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"RAS-F Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ University of Louisville Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Caring Cross","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enochian BioSciences \/ Caring Cross","highestDevelopmentStatusID":"7","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Chimeron Bio","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chimeron Bio Enters Into an Agreement With the NIAID, a Federal Agency, for Pre-clinical Assessment of Its Self-Amplifying COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV2 antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chimeron Bio \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron B.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Athyrium Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Athyrium Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"RNAGENE Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ RNAGENE Inc.","highestDevelopmentStatusID":"2","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"35 Generic Manufacturers Sign Agreements With MPP to Produce Low-Cost, Generic Versions of Pfizer's Oral COVID-19 Treatment Nirmatrelvir in Combination with Ritonavir for Supply in 95 Low- and Middle-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Medicines Patent Pool \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"The Medici.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Kukbo Co.","pharmaFlowCategory":"D","amount":"$7.1 million","upfrontCash":"$1.5 million","newsHeadline":"RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Kukbo Co.","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"The Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Preventive Vaccine for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"AV-1959D","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"The Institute for Molecular Medicine","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"The Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"SU2C Catalyst","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stand Up To Cancer Announces $1 Million Donation From Zentalis Pharmaceuticals To Fund Targeted Cancer Therapy Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"ZN-c3","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ SU2C Catalyst","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Biolexis","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biolexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biolexis \/ Akston Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Biolexis \/.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"HMP Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HMP Partners Invests in Tevogen Bio\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ HMP Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prellis Biologics Announces Collaboration with Sanofi","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Bi.."},{"orgOrder":0,"company":"Spotlight Therapeutics","sponsor":"GordonMD Global","pharmaFlowCategory":"D","amount":"$36.5 million","upfrontCash":"Undisclosed","newsHeadline":"Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"TAGE Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spotlight Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Spotlight Therapeutics \/ GordonMD Global","highestDevelopmentStatusID":"4","companyTruncated":"Spotlight .."},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"TCR T-cell Therapy","moa":"KRAS G12V","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Affini-T Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T T.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Indigenous Critical Infrastructure Fund Canada","pharmaFlowCategory":"D","amount":"$36.3 million","upfrontCash":"Undisclosed","newsHeadline":"ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Arginine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"Recombinant Human Plasma Gelsolin","moa":"Actin-calcium binding","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals and Simcere Announced Strategic Commercialization Partnership upon Novel JAK1 Inhibitor LNK01001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"LNK01001","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"USAMRIID","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Recombinant Vesicular Stomatitis Virus SARS Cov-2 Glycoprotein","moa":"SARS-CoV-2 S glycoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Powder","sponsorNew":"TFF Pharmaceuticals \/ USAMRIID","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"Allogeneic Cell Replacement Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Transcenta Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo\u00ae in Patients with Locally Advanced or Metastatic Gastric \/ Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Nivolumab","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Transcenta","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Neuromagen Pharma","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"AGS-499","moa":"Telomerase reverse transcriptase","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuromagen Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Neuromagen Pharma \/ Israel Innovation Authority","highestDevelopmentStatusID":"4","companyTruncated":"Neuromagen.."},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"The Conrad Prebys Foundation","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"n-Lorem Foundation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"n-Lorem Foundation \/ The Conrad Prebys Foundation","highestDevelopmentStatusID":"2","companyTruncated":"n-Lorem Fo.."},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AllianceRx Walgreens Prime Relaunches Exclusive Partnership for the Distribution of Cystaran\u00ae (cysteamine ophthalmic solution) 0.44%","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Cysteamine Hydrochloride","moa":"Glutathione synthase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Leadiant Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Leadiant Biosciences \/ AllianceRx Walgreens","highestDevelopmentStatusID":"12","companyTruncated":"Leadiant B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Australian Federal Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Finalizes Strategic Partnership with Australian Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Australian Federal Government","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Yarrow Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$115.0 million","newsHeadline":"ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Antisense Oligonucleotide Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Yarrow Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health Companies","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Op.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$987.5 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"PN-235","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.98999999999999999,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO's Complement Portfolio in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"CB 2782-PEG","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalyst Biosciences \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BO-112","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval From USFDA for Colestipol Hydrochloride Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Colestipol","moa":"Bile acid reabsorption","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Genentech\u2019s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae Phase III EMPA-KIDNEY trial, Will Stop Early Due to Clear Positive Efficacy in People With Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical Scientific Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Microtubule associated protein 2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alcohol Hangover Treatments and the Classification for Treating Hangovers as a Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Naproxen","moa":"COX-1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q Biomed Announces Publication of Research Showing Augmented Efficacy of Its Drug Candidate Uttroside-b Against Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Uttroside B","moa":"Mapk","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oligon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligon to Present Three Abstracts at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oligon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oligon \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Oligon \/ N.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag\u2122 (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u00ae (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Launches New Phase III Study to Reconcile Mixed Fibromyalgia Data","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TERN-201","moa":"VAP-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VRDN-002","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"OSE-279","moa":"Programmed death receptor-1 \/ Interleukin 7 stimulator","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cyprium Therapeutics \/ Fortress","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Th.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Research Evaluating VASCEPA\u00ae (Icosapent Ethyl) to be Presented at the American College of Cardiology's 71st Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces FDA Approval of IND for FRIDA, a Phase Ib Trial With Iadademstat in R\/R AML FLT3mut+ Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Uniqure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pardes Biosciences to Present at the International Conference On Antiviral Research 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PBI-0451","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pardes Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablets","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer\u2019s Disease at the 2022 AD\/PD\u2122 Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Omicron mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO's Breast Cancer Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA\u2122) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Prefilled Syringe For Epidural","sponsorNew":"Scilex Pharmaceuticals \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Invea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Invea Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Invea Ther.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces Positive Results on CMND-100 trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Scisparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pb-IFN-\u03b12b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alladapt Announces Initiation of Encore Open-Label Extension Study for its Harmony Phase 1\/2 Study of ADP101 for Treatment of Food Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CLN-081","moa":"Irreversible EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Korean Intellectual Property Office","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Korean Intellectual Property Office","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces Peer-Reviewed Publication of ADUHELM\u00ae Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO\u00ae (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Allied Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allied Corp Files for Full Psilocybin Patent for Psilonex Rx Pharmaceutical","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allied Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Cor.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK Engager Multispecific Antibodies at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CYT-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"WTX-124","moa":"Interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Nucro-Technics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Nucro-Technics","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"APX3330","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces Positive Long-Term Data from Phase 1\/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"Lysosomal alpha-glucosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces FDA Clearance to Proceed with Phase 1b\/2 Trial of Anti-CTLA-4 ADG126 SAFEbody\u00ae in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG126","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen\u00ae for the Treatment of Locally Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Phase 3 Data Show ADUHELM\u00ae Continues to Reduce Underlying Pathologies of Alzheimer's Disease in Patients Treated for More Than Two Years","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Vigonvita Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VV116","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Vigonvita Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD\/PD 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Roche's Evrysdi (Risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Cellectis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Investigational New Drug Application (IND) Allowed to Proceed for TALEN\u00ae-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IOV-4001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Cellectis","highestDevelopmentStatusID":"5","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TCX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexa-acyl Disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dovitinib","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"ExCellThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excellthera Announces New Data to Be Presented at the EBMT 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ExCellThera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Moves into Boston's Seaport District and Provides Update on Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-002","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"INNA-051","moa":"TLR2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intra-nasal","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson's and Alzheimer's Disease at the AD\/PD 2022 Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Nine Data Presentations at AD\/PD\u2122 2022 - International Conference on Alzheimer's and Parkinson's Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"EDO51","moa":"Exon 51 inclusion","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"23ME-00610","moa":"CD200R1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AU-007","moa":"Interleukin 2 blocker","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Announces Presentation at the European Lung Cancer Congress (ELCC) 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Provides New GAIN Trial Data at AD\/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer\u2019s Population","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVUSHELD\u2122 Long-acting Antibody Combination Retains Neutralizing Activity Against Omicron Variants Including Ba.2 in New Independent Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Washington University School","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ABP-671","moa":"Urate transporter protein","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"Ixaka","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle in vivo Gene Delivery Technology With Any Cargo in Any Therapeutic Area","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lentivirus Based CAR T-cell Therapy","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ixaka","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ixaka \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ixaka \/ No.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship To Clinical Outcomes And Dosing Regimens - Presented at AD\/PD\u2122 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces The FDA Approval And Launch Of an Ab Rated Generic Version Of Tobradex\u00ae Ophthalmic Suspension","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tobramycin","moa":"70s ribosome","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LMN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cali Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Injection","sponsorNew":"Cali Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cali Biosc.."},{"orgOrder":0,"company":"Evommune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"EVO101","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Evommune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Medicines Evaluation Unit","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PUR1800","moa":"p38 MAP kinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pulmatrix \/ Medicines Evaluation Unit","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Presents TriKE\u00ae Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GTB-5550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces U.S. Fda Approval For Otc Use Of Nasonex\u00ae 24hr Allergy","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Perrigo Company plc \/ Organon LLC","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China CDE Approved First Universal CAR-T IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CTA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Bi.."},{"orgOrder":0,"company":"Seton Pharmaceuticals","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. Launch Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg\/325 mg\/40 mg in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Seton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seton Pharmaceuticals \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Seton Phar.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Approval of ZYNRELEF\u00ae by Health Canada for the Management of Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"CB receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD\/PD 2022)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Shows Positive Preliminary Results of Flibanserin in Breast Cancer Patients Suffering from Low Libido","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sprout Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sprout Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sprout Pha.."},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CSF-1","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pha.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD\/PD\u2122 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QRL-201","moa":"STMN2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Business Update on ASC10, an Oral Double Prodrug Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10-A","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Melanoma Research Alliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melanoma Research Alliance Statement on FDA Approval of Relatlimab + Nivolumab for Treatment of Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Melanoma Research Alliance","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Melanoma Research Alliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Melanoma R.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Purdue Pharma L.P. to Provide Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal in Emergency Medicine Settings","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Opens a New Clinical Psychedelic Research Facility","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Update on SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet partner Immunomic Therapeutics Initiates Clinical Trial of DNA Vaccine for Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen Announces First Patient Dosed in Phase 1\/2 Trial of WU-CART-007 for the Treatment of Patients with R\/R T-ALL\/LBL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"WU-CART-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Announces Dosing of First Participant With Metabolic Syndrome in Phase 1B Clinical Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet\n","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA\u00ae (zanubrutinib) for the Treatment of Waldenstr\u00f6m's Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Medison","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Initiate Phase 1\/2a Study of ARO-RAGE for Treatment of Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"iRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer for Inhalation","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"Methyltransferase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC Biopharm Updates Intellectual Property Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"cyclophosphamide","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA\u00ae (Niraparib) at Society of Gynecologic Oncology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"KCL Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regen BioPharma \/ KCL Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioP.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ H.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Provides a Regulatory Update on EMA Process for Nefecon","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Announces the Publication of a GMP Process for a Semi-synthetic Shigella Glycoconjugate Vaccine Candidate From Institut Pasteur","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SF2a-TT15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Institut Pasteur","highestDevelopmentStatusID":"8","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides NATPARA Regulatory Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Parathyroid Hormone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CHS-006","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Duet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scopus BioPharma's Subsidiary Duet BioTherapeutics to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CpG-STAT3siRNA","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Duet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Duet BioTh.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"VCN Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Theriva Biologics \/ VCN bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology's Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Xcovery","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensartinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Xcovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xcovery \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Xcovery \/ .."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Trofinetide","moa":"Cytokine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Ifosamide Prodrug","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KSQ-4279","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL\u2122 PF for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics\u2019 Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-147","moa":"ApoL1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS\u2122 in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Letermovir","moa":"Tripartite terminase subunit 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lung Therapeutics Announces Successful Completion of Phase 1a Clinical Trial of LTI-03 in Healthy Volunteers","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Caveolin-1-scaffolding Protein-derived Peptide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Lung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder Inhaler","sponsorNew":"Lung Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lung Thera.."},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ECP Pharma Developing Innovative Drug Products For Neurological and Central Nervous System Diseases","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ECP-101","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ECP Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Advances Development of Glioblastoma Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"4-L-[131] Iodo-phenylalanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Announces FDA IND Clearance for PT199, a Next Generation Monoclonal Antibody Against Human CD73","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PT199","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Baush Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Derm.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech Successfully Completes Safety and Biocompatibility Studies for DispersinB Wound Gel in Preparation for Human Clinical Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"DispersinB","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nimodipine","moa":"Calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lucinactant","moa":"Cell menbrane permeability","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intratracheal Liquid","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Galveston National Laboratory","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Galveston National Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Announces First Patient Dosed in Phase 1\/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD\/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1\/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ZN-D5","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Announces Withdrawal of European Marketing Authorisation Application for Arimoclomol for the Treatment of Niemann-pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) in Combination with LYNPARZA\u00ae (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SAGE-718","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S\u2011217622","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensitrelvir","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The AIDS Clinical Trials Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The AIDS Clinical Trials Group \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"The AIDS C.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover\u2019s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"D5-KRM-II-81","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Immutep","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Leramilimab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women\u2019s Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shasqi to Present on SQ3370 and CAPAC\u2122 Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shasqi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"Wesana Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wesana Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Hea.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents \u226512 to <18 in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Viatris","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort\u00ae Inhalation Aerosol, Breyna\u2122 (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Viatris \/ Kindeva","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Lacosamide Tablets Usp, 50 Mg, 100 Mg, 150 Mg and 200 Mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Announces FDA Approval of ZTALMY\u00ae (ganaxolone) for CDKL5 Deciency Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces New Otezla (Apremilast) Data at AAD Congress 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca\u2019s Antibody Combination, Evusheld (Tixagevimab Co-packaged With Cilgavimab) Authorised for Use in Great Britain for Pre-exposure Prophylaxis (Prevention) of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients With Germline Brca-mutated High-risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Application in the EU for an Extension of the Indication of Finerenone to Include Early Stages of Chronic Kidney Disease Associated With Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"MyoKardia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology\u2019s 71st Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae (empagliflozin) Phase III EMPA-KIDNEY trial Will Stop Early Due to Clear Positive Efficacy in People With Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK to Demonstrate Its Commitment to Improving Outcomes for Patients With Gynaecologic Cancer at the 2022 SGO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Patients With MSI\u2011H\/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2- Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1230","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Peer-reviewed Research Shows No Increased Risk of Serious Covid-19 Infections in Kesimpta\u00ae (Ofatumumab)-treated Adults With Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Voluntary Nationwide Recall of Lots of ACCURETIC\u2122 (quinapril HCl\/hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and quinapril HCl\/hydrochlorothiazide Tablets Due to N-Nitroso- Quinapril Content","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Quinapril","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"$553.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Buys a Majority Stake In mAbxience","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mabxience","amount2":0.55000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Fresenius","highestDevelopmentStatusID":"12","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces that Its IND Application for the Phase II Combination Trial With Lanifibranor and Empagliflozin in Patients With NASH and T2D Has Been Accepted by the FDA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Announces Update for Phase 3 Biliary Tract Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosifloxuridine Nafalbenamide","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoImmune to Present New Preclinical Data Highlighting Potential of Novel TRACK-NK Cell Therapies as Treatments for both Solid Tumors and Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CYTO NK-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1\/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"Ataxia-Telangiectasia","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel Chemotherapy-Induced Diarrhea Therapeutic, at AACR","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"OQL051","moa":"CDK-4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA to Present New Preclinical, Translational, and Clinical Biomarker Data at AACR Further Supporting the Potential of Arenaviral Platform in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"NuclixBio Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NuclixBio Announces a Collaborative Research Agreement with PharmAbcine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ NuclixBio Inc.","highestDevelopmentStatusID":"2","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Oslo University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Oslo University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CLN-049","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Valneva","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","amount":"$27.2 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Awarded Up to \u00a320 Million by Scottish Enterprise to Advance Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Funding","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Scottish Enterprise","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merz Strengthens Partnership With Start-up Vensica and Invests up to $3 million","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"IncobotulinumtoxinA","moa":"SNAP25","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Vensica Therapeutics","amount2":0.02,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Vensica Therapeutics \/ Merz Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vensica Th.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$350.0 million","newsHeadline":"Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0.65000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$70.0 million","newsHeadline":"LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine T.."},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"NVIDIA Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Building a New Generation AI Engine and Jointly Accelerating World-Class Innovative Drug Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Regor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regor Therapeutics \/ NVIDIA Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Regor Ther.."},{"orgOrder":0,"company":"Newport Pharmaceuticals","sponsor":"WellSpring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wellspring Ophthalmics Announces Acquisition of Novel Cyclosporine Dry Eye Therapy Patent Portfolio from Newport Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Newport Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Newport Pharmaceuticals \/ Wellspring Ophthalmics","highestDevelopmentStatusID":"4","companyTruncated":"Newport Ph.."},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Cyclosporin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Cyclica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclica \/ Arctoris","highestDevelopmentStatusID":"2","companyTruncated":"Cyclica \/ .."},{"orgOrder":0,"company":"Vaxxas","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxas \/ The University of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ T.."},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Executive Officer","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"OCE-205","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ocelot Bio \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio.."},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"GT-30","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Geneos Therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Geneos The.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"University of the Witwatersrand","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol\u00ae Cyclo\u2122 to Expand Pipeline","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclo Therapeutics \/ University of the Witwatersrand","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Young Pharmaceuticals","sponsor":"Lactobio A\/S","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Young Pharmaceuticals Announces Exclusive North America Distribution Partnership With Lactobio For BAK Probiotic Skincare","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"LB356R","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Young Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Young Pharmaceuticals \/ Lactobio A\/S","highestDevelopmentStatusID":"12","companyTruncated":"Young Phar.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ EQRx","highestDevelopmentStatusID":"4","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$25.0 million","newsHeadline":"Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE\u00ae Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Recombinant Human Hyaluronidase PH20 Enzyme","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Halozyme Therapeutics","amount2":0.19,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Chugai","highestDevelopmentStatusID":"1","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"APIRx","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incannex to Acquire APIRx Pharmaceuticals USA, LLC","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Tetrahydrocannabivarin","moa":"CBR","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"APIRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"APIRx \/ Incannex","highestDevelopmentStatusID":"4","companyTruncated":"APIRx \/ In.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Society","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Signs Definitive Collaboration Agreement for The Development of A Pipeline of Innovative Nanosized Antibody (NanoAb) Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Society","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0.5,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.5,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Harm Reduction Therapeutics to Receive Additional Funding for the Development of its Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma after Bankruptcy Court Approval","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elysium Health\u2122 Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Micronutrient-based Dietary Supplement","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Elysium Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elysium Health \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Elysium He.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Australian Pharmaceutical Benefits Scheme","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Australian Pharmaceutical Benefits Scheme","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Innovent and Lilly Expand Strategic Partnership in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Ramucirumab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Trinity College Dublin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"ART26.12","moa":"Fatty acid binding protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Trinity College Dublin","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$53.0 million","newsHeadline":"Axsome Therapeutics to Acquire Sunosi\u00ae from Jazz Pharmaceuticals, Expanding Axsome\u2019s Leadership in Neuroscience","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"$182.4 million","upfrontCash":"$78.5 million","newsHeadline":"Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Veritaz Healthcare","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aurobindo Pharma Buys Veritaz for Rs 171 Crore to Enter Domestic Formulation Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Veritaz Healthcare","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"","sponsorNew":"Veritaz Healthcare \/ Aurobindo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Veritaz He.."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Freya Pharma Solutions Secures US$8.5 Million Enabling the Start of A Pivotal Phase 3 Trial with Lybrido Against Female Sexual Interest\/Arousal Disorder (FSIAD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"PDE-5","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Freya Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Long Zone Holdings Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-2307","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Long Zone Holdings Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Sodium\/potassium\/chloride cotransporter","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Italian Institute of Technology","highestDevelopmentStatusID":"2","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Viscogliosi Bros.","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spine BioPharma Completes Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"SB-01","moa":"TGF beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intradiscal injection","sponsorNew":"Spine BioPharma \/ Viscogliosi Bros.","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioP.."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Sirnaomics","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"RIM730","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RNAimmune","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"RNAimmune \/ Sirnaomics Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune .."},{"orgOrder":0,"company":"Optifye Therapeutics","sponsor":"DelSiTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Optifye Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optifye Therapeutics \/ DelSiTech Ltd","highestDevelopmentStatusID":"4","companyTruncated":"Optifye Th.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$30.0 million","newsHeadline":"VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.20000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"GAS6-AXL binding","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aravive \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Vyant Bio","sponsor":"OrganoTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vyant Bio and Organo Therapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Vyant Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyant Bio \/ OrganoTherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vyant Bio .."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"MMP13","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"SteroTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SteroTherapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"SteroThera.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$276.6 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Iktos","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Iktos","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Ono Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ On.."},{"orgOrder":0,"company":"Geron","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"Imetelstat","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Geron \/ Stifel","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ St.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ SELLAS","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Boxer Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"INX-315","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Boxer Capital","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix B.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$815.0 million","upfrontCash":"$85.0 million","newsHeadline":"Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0.81999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.81999999999999995,"dosageForm":"","sponsorNew":"Surface Oncology \/ GlaxoSmithKline","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$15.0 million","newsHeadline":"Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, An Affiliate of CBC Group","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"D","amount":"$192.5 million","upfrontCash":"$10.0 million","newsHeadline":"Organon Enters into Global License Agreement to Commercialize Dar\u00e9 Bioscience\u2019s XACIATO\u2122 (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.19,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Dare Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Copernicus Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$21.4 million","upfrontCash":"Undisclosed","newsHeadline":"Northeastern University and Copernicus Therapeutics, Inc. Awarded $14.7 Million NIDA\/NIH Grant to Develop a Gene Therapy Approach for Treating Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"DNA Nanoparticle-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Copernicus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Copernicus Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Copernicus.."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tabuk And Cumberland Partner To Bring Innovative Antibiotic With Life-Saving Potential To Middle East","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cumberland Pharmaceuticals \/ Tabuk","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Vaxine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19\/Influenza Combo Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Covax-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Vaxine Pty Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Funding","leadProduct":"ELX-02","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Angiocrine Bioscience Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of AB-205 in Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) and Completion of Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series B Financing","leadProduct":"AB-205","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Angiocrine Bioscience \/ Cobro Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Sinopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab\/Romlusevimab Combination, in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Sinopharm","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Lantheus Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantheus Holding \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Lantheus H.."},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Barth Syndrome Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Barth Syndrome Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Bio.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"ZN-c3","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Caris Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"Undisclosed","newsHeadline":"UPDATE: Hyloris Launches Equity Offering by Means of a Private Placement Via an Accelerated Bookbuild Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"ABX Advanced Biochemical Compounds","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"D","amount":"$172.0 million","upfrontCash":"$12.0 million","newsHeadline":"Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. of - Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ABX Advanced Biochemical Compounds","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"ABX Advanced Biochemical Compounds \/ Endocyte Inc","highestDevelopmentStatusID":"12","companyTruncated":"ABX Advanc.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma to Introduce Its Version of Vortioxetine in India Under an Exclusive Patent License from Lundbeck","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Th.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,024.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"SLN501","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":2.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.02,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Mallinckrodt","highestDevelopmentStatusID":"5","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viiv Healthcare Announces Label Update for Its Long-acting HIV Treatment, Cabenuva (Cabotegravir, Rilpivirine), to Be Initiated With or Without an Oral Lead-in Period","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS \u22651)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces its COVID-19 Vaccine Phase 2\/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma Announces Positive Interim Results from the Phase I\/II Study of the Combination of MRx0518 and KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4D Pharma \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Pluvicto\u2122 Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Ribomic","sponsor":"Midwest Eye Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RBM-007","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ribomic \/ Midwest Eye Institute","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Virtuoso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bispecific Antibody","moa":"CD38\/ICAM-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Virtuoso Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virtuoso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virtuoso T.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Announces Mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II Enrolling at 900 \u00b5g\/kg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride Trihydrate","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"The Centre for Mental Health Research and Innovation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ The Centre for Mental Health Research and Innovation","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH 34 N-terminal amino acid","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy DonorDerived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-605","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on CALLA Phase III trial Of Concurrent Use of Imfinzi and Chemoradiotherapy in Locally Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"H1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces Label Update for Its Long-acting Hiv Treatment, Cabenuva (Cabotegravir, Rilpivirine), to Be Initiated With or Without an Oral Lead-in Period","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Pifzer","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Temozolomide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Stalicla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"STP1","moa":"PDE","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stalicla \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mescaline","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen to Present at the Innate Killer Summit 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Carbidopa","moa":"DOPA decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Initiate Phase 1\/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-MUC5AC","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Ph.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma to Present Clinical Data Abstracts for ILUMYA\u00ae (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tildrakizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial Collaboration for Cu-64 SAR-bisPSMA in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"67Cu SAR-bisPSMA","moa":"PET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK life Science to Present Latest XCOPRI\u00ae (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Sc.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca\u00ae (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"DNA adduct formation","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Adlai Nortye","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncolytics Biotech \/ Adlai Nortye","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-\u03b1 with TLR3 Agonist Rintatolimod, (Ampligen\u00ae), Accepted for Poster Presentation by Roswell P","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology's (AAD) 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Publication of TACTI-002 Abstract at ESMO's European Lung Cancer Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"MHC II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Johns Hopkins Psychedelic Research Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Johns Hopkins Psychedelic Research Group","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Orcosa","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orcosa Comments on Positive Results of NYU Langone\u2019s Phase 1\/2 Clinical Trial Utilizing ORAVEXX","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Orcosa","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orcosa \/ NYU Langone Health","highestDevelopmentStatusID":"7","companyTruncated":"Orcosa \/ N.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi\u00ae) for the Treatment of Acute and Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Completes Purchase of FDA Phase III JadiCell Stem Cell Investigational New Drug Application from University of Miami","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion Recommending CARVYKTI\u00ae (Ciltacabtagene Autoleucel) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry\u2122 (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"Ionising radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines' AYVAKYT\u00ae (avapritinib) Receives European Commission Approval for the Treatment of Adults with Advanced Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA\u00ae (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatm","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Cassiopea","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Presents Phase 3 Data for WINLEVI\u00ae (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Cassiopea","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Roche's Polivy Combination for People with Previously Untreated Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Spotlights Key Findings in Presentations at AD\/PD\u2122 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion For Kymriah\u00ae CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV & BIVIGAM from 24 to 36 Months","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"FcRs","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ADMA Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn\u2019s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis\u2019 Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl\u00ae (luspatercept-aamt) Supplemental Biologics License Application","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO\u00ae at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tretinoin","moa":"RAR beta\/gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite to Present at Dermatology Drug Development Summit Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CAN106 Phase 1b\/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura\u2122) in Patients With Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-488","moa":"JH2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be Presented at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC61","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT\u00ae 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-breaking Phase 3 Data at AAD 2022 Show Dupixent\u00ae (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1\/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PRX012","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Gamma Delta T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nevakar","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"12","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris\u00ae I.V. Infusion 235mg in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosnetupitant Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jyseleca\u00ae Approved in Japan for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenpozyme\u00ae (olipudase alfa), Approved in Japan, First and Only Approved Therapy Indicated to Treat Acid Sphingomyelinase Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olipudase Alfa","moa":"SMPD1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM\u2022070, Against Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Totum\u2022070","moa":"Lipid metabolism","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN108 New Drug Application\/Orphan Drug Registration (NDA\/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces First Patient Dosed in Phase 3 \u2018ARES\u2019 Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell: Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s TAKHZYRO\u00ae (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Biorasi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Selects Premier Regenerative Medicine CRO Biorasi to Initiate and Run Phase III FDA Registration Clinical Trial for JadiCell\u2122 Universal Donor Adult Stem Cell Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen Biostimulators and Liquid Neuromodulators at AMWC 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Syneos Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"Ach","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b\/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PIPE-307","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Spesolimab Data Show Clinically Significant Improvement in Patients With Generalized Pustular Psoriasis (GPP) Flares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Spesolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maruho Obtained Regulatory Approval for Mitchga, the First Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ C.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives Approval In Japan For Kerendia\u2122 (Finerenone), A New Treatment For Adults With Chronic Kidney Disease And Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarlige\u00ae Tablets Approved in Japan for Treatment of Patients with Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirogabalin Besylate","moa":"CaV1\/CaV2 Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Perjeta and Herceptin for Additional Indication of HER2-Positive Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"HER2\/Neu receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ozempic\u00ae 2.0 mg Approved in the US for the Treatment of Type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Announces Endari\u00ae To Be Added to the Florida Medicaid Preferred Drug List","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"Glutathione","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1\/2 Study of DSP-5336 in Patients with Acute Leukemia With and Without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"DSP-5336","moa":"Menin and mixed-lineage leukemia interaction","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase level","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RJx-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rejuvenate Biomed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity's US-Based Cu-64 SAR-bisPSMA Trial in Prostate Cancer Opens for Recruitment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"67Cu-SAR-bisPSMA","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Cytonus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytonus Therapeutics to Present Preclinical Data for Cargocyte\u2122 CA-IL-12 for Treating Immune Checkpoint Inhibitor-Resistant Late Stage Metastatic Cancers at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CA-IL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytonus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytonus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytonus Th.."},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and\/or Ophthalmologic Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Abionyx Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abionyx Ph.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Progranulin","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present Data From Cardiovascular Portfolio Including Late-breaking Presentations From Fidelity (Kerendia\u2122) and First Phase 2b Data From Pacific Study Program for Oral Factor XIa Inhibitor (Asundexian)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces Dosing of First Patient in Phase 1\/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TX200","moa":"HLA-A2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Noxopharm by US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Sphingosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1\/2a Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CYB003","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX- 629","moa":"RASP","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Zalifrelimab","moa":"TLR7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announce Publication in The Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming Efficacy and Safety of ISTURISA\u00ae (osilodrostat) in Patients With Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TSHA-102","moa":"MECP2 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-235","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Corium","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium To Present at Academy of Managed Care Pharmacy: Fast-Acting AZSTARYS\u00ae (serdexmethylphenidate and dexmethylphenidate) Significantly Improves Attention and Behavior in Children Aged 6 to 12 Years With ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ G.."},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RIST4721","moa":"CXCR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Th.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Partner Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"4","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Loki Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loki Therapeutics Announces Publication in Science Translational Medicine Demonstrating Potential of AWAKE-LM-TT as a Treatment for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AWAKE-LM-TT","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Loki Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Loki Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Loki Thera.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE\u00ae (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Clearside Biomedical","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar\u00ae Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Corticotropin","moa":"Melanocortin receptor 2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Gadeta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GDT002","moa":"Gamma Delta T cell","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gadeta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gadeta \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gadeta \/ N.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosing of Claudin18.2\/CD3 Bispecific Antibody IBI389 in Phase 1a\/1b Clinical Trial for Advanced Solid Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI389","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Submits Final Protocol for ADUHELM\u00ae (aducanumab-avwa) Phase 4 ENVISION Trial to FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kither Biotech Announces Publication of New Data in Science Translational Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"KIT2014","moa":"cAMP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kither Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kither Bio.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ELX-02","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CRN04777","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"OncoTEX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoTEX Receives Notice of Allowance for Patent in Korea Regarding Ovarian Cancer-Fighting Drug OxaliTEX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoTEX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoTEX \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoTEX \/ .."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Kt-3000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Osanetant","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"SCI-160","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-8371","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"TNF 1A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE\u00ae 327","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Nerx Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NERx-20-04","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nerx Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nerx Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nerx Biosc.."},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NNI-362","moa":"Allosteric p70S6 kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronasce.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Genetically Modified HSV Type 1","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ad Hoc Announcement Pursuant to Art. 53 LR Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Updated Preclinical Data at Vaccines Summit Boston 2022 on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine, Demonstrating It Induces Potent Cross-Reactive Cellular and Humoral Immunity to SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-005","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Completes Enrollment in Phase 1b\/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ARZC-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Artizan Bioscience","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artizan Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artizan Bi.."},{"orgOrder":0,"company":"Palette Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palette Life Sciences Receives Favorable Post Approval Study Results for Solesta","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Palette Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palette Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palette Li.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Lipocine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma Announces FDA Approval Of TLANDO, an Oral Treatment for Testosterone Replacement Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antares Pharma \/ Lipocine","highestDevelopmentStatusID":"12","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol\u00ae in the Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PBKR03","moa":"Galactosylceramidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"Hyaluronidase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva\u00ae in Second-line Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cstone Announces First Patient Enrollment in the U.S. In the Phase 1 Clinical Trial of CS5001, a Potential Global Best-in-class ROR1-targeting ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CS5001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Halia Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Halia Ther.."},{"orgOrder":0,"company":"AllianceRx Walgreens Prime","sponsor":"Duquesne University School of Pharmacy","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AllianceRx Walgreens Prime Studies Use of Ocaliva\u00ae in the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"AllianceRx Walgreens Prime","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AllianceRx Walgreens Prime \/ Duquesne University School of Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"AllianceRx.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Clevudine Monophosphate Prp","moa":"Active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TST005","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Improves Manufacturing Process of ALZ-101 to Meet Phase 2 Requirements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ALZ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/.."},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merz Aesthetics to Showcase New Data at the 20th Aesthetics & Anti-Aging Medicine World Congress 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Incobotulinumtoxin A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Merz Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merz Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merz Aesth.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"TILT-123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AC0176","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Pharma Files Submission to Health Canada for The Marketing Authorization of Methotrexate Autoinjector for Treating Rheumatoid Arthritis in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"Folic acid","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Nordic Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Pha.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears ReAlta Life Sciences\u2019 Phase 2 STAR Trial of RLS-0071 in Neonates with Hypoxic-Ischemic Encephalopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RLS-0071","moa":"Complement","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"QPX9003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qpex Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Bioph.."},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concentric Analgesics Announces Positive Results from Pilot Phase 2 Clinical Trial of Vocacapsaicin in Open Laparotomy for Repair of Abdominal Ventral Hernia","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vocacapsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Concentric Analgesics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Concentric.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in a Phase 1 Study in Australia Evaluating BAT6026, an Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, an Anti-PD-1 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BAT1308","moa":"OX40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Initiation of Phase 1\/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM831","moa":"ILT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI Naloxone Product","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Through a New Mechanism","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CVN424","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD), Suggesting Antidepressant Efficacy and Showing Placebo-Level Dissociative Side Effects in Phase 2 Oral Prolonged-Release Ketamine (KET01) ","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain.."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary Progressive Forms of Multiple Sclerosis at the American Academy of Neurology (AAN) 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Provides Update on Clinical-Stage and Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Humanized Anti-CD117 Monoclonal Antibody","moa":"CD117","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Files IND with US FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"ValenzaBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment of Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonigutamab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"ValenzaBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ValenzaBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ValenzaBio.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akston Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis Finds UPLIZNA\u00ae (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating \u201cExtra-Strength\u201d Dose of Jeuveau\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"University of Zurich","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gnubiotics Sciences SA to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"GCX","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Gnubiotics Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gnubiotics Sciences \/ University of Zurich","highestDevelopmentStatusID":"5","companyTruncated":"Gnubiotics.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology\u2019s Rubraca\u00ae (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Authorised to Initiate First Clinical Trial for Lead DUB Program, MTX652, in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MTX652","moa":"USP30","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Announces the Launch of Selenious Acid Injection, USP in a 12 mcg\/2 mL Single-Dose Vial.","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Selenious Acid","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord BioPharma Announces U.S. Launch for CAMCEVI\u2122 (Leuprolide) Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase I Clinical Trial of CB06","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CB06","moa":"TLR8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Zhimeng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI\u00ae (aviptadil) When Given by Mouth Inhalation in Critically Ill Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"rhSP-D","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Aesthetics Brings Data, Innovation & Industry Expertise to the 2022 Aesthetic and Anti-aging Medicine World Congress (AMWC)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ondexxya Approved in Japan for Reversal of Acute Major Bleeds in Patients on Factor Xa Inhibitors","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Andexanet Alfa","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics Announces Initiation of Phase 1b\/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the Lung","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"RBN-2397","moa":"PARP7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-1607","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Brigham and Women's Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"miR-155","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regulus Therapeutics \/ Brigham and Women's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BIIB078","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-acting Antibody Combination Approved in the EU for Pre-exposure Prophylaxis (Prevention) of COVID-19 in a Broad Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's Ministry of Health, Labour and Welfare Accepts Bristol Myers Squibb\u2019s Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present Data From Cardiovascular Portfolio Including Late-breaking Presentations From FIDELITY (Kerendia\u2122) and First Phase 2b Data From Pacific Study Program for Oral Factor XIa Inhibitor (asundexian)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Vabysmo, the First Bispecific Antibody in Ophthalmology, for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Announcement About an Approval for Additional Indication of Jyseleca\u00ae, JAK Inhibitor, for the Treatment of Moderate to Severe Ulcerative Colitis With Inadequate Response to Conventional Therapies approval of Additional Indication Based on Phase IIb\/III Se","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgotinib","moa":"RTK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces U.S.FDA Approval of Triumeq PD, the First Dispersible Single Tablet Regimen Containing Dolutegravir, a Once-daily Treatment for Children Living With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Pluvicto\u2122 Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA Positive Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PSMA-617","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces European Commission Approval of Beovu\u00ae for People Living with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Receives Complete Response Letter from U.S. FDA for Vadadustat for the Treatment of Anemia associated with Chronic Kidney Disease in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Akebia Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Obtains Approval in Japan for SAMTASU\u00ae for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolvaptan Sodium Phosphate","moa":"V2 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves FINTEPLA\u00ae (fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New UCB Data Analysis Adds to Demonstrated Efficacy of Romosozumab to Reduce the Risk of Fractures","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Romosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-548","moa":"Selective NaV1.8","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS\u2122 in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Letermovir","moa":"Tripartite terminase subunit 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Pre-exposure Prophylaxis (Prevention) of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Participation in Two Booster Studies Using its COVID19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authoriza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Adintrevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Erlotinib","moa":"HSPg96","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"ATEM Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Triumvira Immunologics Completes Extension of Series A Financing, for Total Round of Approximately $100 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Triumvira Immunologics \/ ATEM Capital","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira .."},{"orgOrder":0,"company":"Nanomerics","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax Pharmaceuticals Expands AnQlar\u2122 Development and Commercialization Rights Through Worldwide Licensing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AnQlar","moa":"ACE","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Nanomerics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanomerics \/ Virpax","highestDevelopmentStatusID":"5","companyTruncated":"Nanomerics.."},{"orgOrder":0,"company":"LinKinVax","sponsor":"GTP Bioways","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LinKinVax Announces a Collaboration With GTP Bioways for the Development and Production of Its Second-generation Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Covid-19 Anti-CD40.COV2 Vaccine","moa":"CD40","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LinKinVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LinKinVax \/ GTP Bioways","highestDevelopmentStatusID":"4","companyTruncated":"LinKinVax .."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"$604.0 million","newsHeadline":"Collegium Completes the Acquisition of BDSI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Engineered Human Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akron Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Vor Bio","highestDevelopmentStatusID":"7","companyTruncated":"Akron Biot.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ABL111","moa":"Claudin 18.2 x 4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immvira's Breakthrough Intravenous Oncolytic Virus Product MVR-T3011 IV Completed First Dosing In Phase I Clinical Trial In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"MVR-T3011","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Polyclonal Antibody Therapeutic","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Ossium Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ossium Health Announces FDA Clearance of its Investigational New Drug Application for Treatment of Perianal Fistulizing Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Ossium Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ossium Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ossium Hea.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Agtc","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"AGTC Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Public Offering","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Agtc \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Can.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Covid 19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Exothera","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rokote Laboratories Selects Exothera For GMP Manufacturing of Its Second-\u200bgeneration Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"FINCoVac 2.0","moa":"SARS-CoV-2-viral spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exothera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Exothera \/ Rokote Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Controlled-release Tablet","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Aravive","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Batiraxcept","moa":"GAS6-AXL binding","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous","sponsorNew":"Aravive \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dr Reddy's Buys Novartis Cardiovascular Brand Cidmus in India for Rs 456 Crore","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.059999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Film-Coated Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Dr. Reddy's","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-Biofilm Technology for Life-Threatening Bacterial Infections","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"CMTX-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Biofilm","sponsorNew":"Clarametyx Biosciences \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"Antibiotic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous","sponsorNew":"Adaptive Phage Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series C Financing","leadProduct":"Taniborbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VenatoRx Pharmaceuticals \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Sciensus Rare","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sciensus Rare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sciensus Rare \/ MGC Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sciensus R.."},{"orgOrder":0,"company":"Vipergen","sponsor":"Theseus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vipergen \/ Theseus Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viridian Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Dragon Overseas","pharmaFlowCategory":"D","amount":"$77.6 million","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncotelic Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Oncotelic Therapeutics \/ Dragon Overseas","highestDevelopmentStatusID":"4","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Institute of Diabetes and Digestive Kidney Disease","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703\u2019s Potential to Reverse Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AVM Biotechnology \/ National Institute of Diabetes and Digestive Kidney Disease","highestDevelopmentStatusID":"4","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Finance Announces the Closing of a $75 Million Credit Facility With Fusion Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"111In-FPI-1547","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ Oxford Finance","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Cellvera","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cellvera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cellvera \/ Aditxt","highestDevelopmentStatusID":"12","companyTruncated":"Cellvera \/.."},{"orgOrder":0,"company":"ViGeneron","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViGeneron Signs Gene Therapy Strategic Collaboration and Option Agreement with Regeneron for One Inherited Retinal Disease Target","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"VG801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViGeneron \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron .."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Termination","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Agenus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,850.0 million","upfrontCash":"$150.0 million","newsHeadline":"Agenus CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"AGEN2373","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":1.8500000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8500000000000001,"dosageForm":"Intravenous","sponsorNew":"Agenus \/ Gilead","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ G.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Komodo Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Komodo Health","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Expands its Derma-Cosmetics Brand Pura H&W Into the European Union Through a Partnership with Bio-Gate AG","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Avicanna \/ Bio-Gate AG","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Kansas State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas State University to Develop Live-Virus Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"TNX-2300","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Kansas State University","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Oncorus","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"ONCR-021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Oncorus \/ K2 HealthVentures","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ .."},{"orgOrder":0,"company":"Jagdale Industries","sponsor":"Bharat Serums & Vaccines ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Serums and Vaccines Acquires Key Women Health Brand Tidilan from Jagdale Industries","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Isoxsuprine Hydrochloride","moa":"ADRB2","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Jagdale Industries","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jagdale Industries \/ Bharat Serums and Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Jagdale In.."},{"orgOrder":0,"company":"New American Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL\u00ae (metoprolol succinate) From New American Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Metoprolol Succinate","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"New American Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"New American Therapeutics \/ Melinta","highestDevelopmentStatusID":"12","companyTruncated":"New Americ.."},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Tegmine Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Tegmine Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Ther.."},{"orgOrder":0,"company":"Oragenics","sponsor":"National Research Council of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Extends Collaboration to Develop Vaccines Against Future Variants of Coronaviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Oragenics \/ National Research Council of Canada","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Kynos Therapeutics Emerges from Stealth with \u00a39 Million Financing and Phase 1-ready KMO Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"KMO","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Kynos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Kynos Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kynos Ther.."},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series A Financing","leadProduct":"RNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rona Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ Lilly Asia Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rona Thera.."},{"orgOrder":0,"company":"HitGen","sponsor":"Uppthera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and UPPTHERA Extend PROTAC Research Collaboration After Hit Finding Success on Undruggable Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Uppthera","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ U.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"ATCC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Yellow Fever Booster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ ATCC","highestDevelopmentStatusID":"4","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Kreos Capital VI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Doxycycline","moa":"MMP13","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder For Paste","sponsorNew":"PolyPid \/ Kreos Capital VI","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Completes Acquisition of Brands from Anglo-French","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Nicotinamide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Anglo-French Drugs and industries","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Anglo-Fren.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$25.0 million","newsHeadline":"Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"HBM7022","moa":"CLDN18.2\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MediSix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ MediSix","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Granite Point Capital","pharmaFlowCategory":"D","amount":"$9.7 million","upfrontCash":"Undisclosed","newsHeadline":"Receptor Life Sciences Secures $9.7 Million Financing to Advance RLS103 (Inhaled Dry Powder CBD) into Clinical Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Inhaled Dry Powder","sponsorNew":"Receptor Life Sciences \/ Granite Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Elastrin Therapeutics","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kizoo Portfolio Company Elastrin Therapeutics Inc. Closes $10M Funding Round","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"ELT-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastrin Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Elastrin Therapeutics \/ Kizoo Technology Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elastrin T.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Narcotic","amount2New":0.059999999999999998,"dosageForm":"Extended-Release Tablet","sponsorNew":"Trevi Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Sequence Bio","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Sequence Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sequence Bio \/ LEO Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sequence B.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Microbiome Based Product","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Microba Life Sciences \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Microba Li.."},{"orgOrder":0,"company":"China Resources Pharmaceutical Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"China Resources Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"China Resources Pharmaceutical Group \/ Everest","highestDevelopmentStatusID":"8","companyTruncated":"China Reso.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Berenberg","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Successfully Raises EUR 15.0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Private Placement","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Berenberg","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Foresee Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI\u2122 (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Subcutaneous Injection\n","sponsorNew":"Accord healthcare \/ Foresee Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Allergy Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"VLP-Based Peanut Allergy Vaccine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AGC Biologics \/ Allergy Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","amount":"$111.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lytix Biopharma Receives Milestone Payment From Verrica Pharmaceuticals Inc. Triggered by First Patient Dosed With LTX-315","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"Tumor Cell lysis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biop.."},{"orgOrder":0,"company":"Atreca","sponsor":"Zymeworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atreca Announces Expansion of Preclinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ATRC-301","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Zymeworks","highestDevelopmentStatusID":"5","companyTruncated":"Atreca \/ Z.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Medidata","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Nanoliposome-based Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$9.3 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI to Co-fund Vaxxinity's Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"MediCane Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Medical Cannabis Product","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ MediCane Health","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI And Moderna Partner to Tackle Broad Global Health Priorities Using Mrna for Vaccines and Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"eOD-GT8 60mer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ IAVI","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Sisunatovir","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.53000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"ReViral \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Axantia Group","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intas and Axantia Sign an Exclusive License and Supply Agreement for Ranibizumab Biosimilar in the Middle East","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Axantia Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Axantia Group \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Axantia Gr.."},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces Positive Data from Phase II\/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AC0682","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present New Analyses of AJOVY\u00ae (fremanezumab-vfrm) Injection and AUSTEDO\u00ae (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JNJ-73763989","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ANEB-001","moa":"CBR","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO\u2122 (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate (ONTOZRY\u00ae), for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults, Is Now Available in the Netherlands","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini P.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Asceneuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer's and Parkinson's Disease Models","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ASN90","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO\u00ae (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Presents Updated Data on Retevmo\u00ae (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Zhongze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ZZ6398","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Zhongze Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhongze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhongze Th.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations on FSHD at the American Academy of Neurology's Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PRAX-944","moa":"T type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1\/2 Clinical Trial for Chronic Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces First Patient Dosed in Phase 1\/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV at CIS 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"FcRs","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review to Roche\u2019s Actemra\/RoActemra For the Treatment Of COVID-19 in Hospitalised Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suspension of Supply of COVID-19 Vaccine (COVAXIN\u00ae)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"New York Heart Association","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ New York Heart Association","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta\u00ae Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Dupixent\u00ae (Dupilumab) for Priority Review in Patients Aged 12 Years and Older With Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Presents Positive Results From First Phase 2b Trial on Safety of Asundexian in Patients With Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Asundexian","moa":"Factor XIa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ\u00ae TAC Platform\u2019s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RBC-derived Engineered Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Finerenone on the Risk Reduction of Cardiovascular and Renal Outcomes in Patients With a Combination of Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Healios K.K","sponsor":"Athersys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem\u00ae Clinical Programs in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"Tregs","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healios K.K","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Athersys","highestDevelopmentStatusID":"10","companyTruncated":"Healios K..."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review to Genentech\u2019s Actemra for the Treatment of COVID-19 in Hospitalized Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DIAMOND trial: Veltassa\u00ae Enables Patients to Achieve Long-term Potassium Control and Optimized RAASi Therapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Nihon Medi-Physics","sponsor":"Cyclotron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nihon Medi-Physics Attains World's First Manufacturing of Actinium-225 with Cyclotron on Production Scale for Investigational Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225 PET","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nihon Medi-Physics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nihon Medi-Physics \/ Cyclotron","highestDevelopmentStatusID":"1","companyTruncated":"Nihon Medi.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"STP707","moa":"COX-2","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Three Poster Presentations At The 2022 Annual Meeting Of The American Academy Of Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA\u00ae (edaravone) at 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T\u00ae in Patients with Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PRGN-3006","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trishula Therapeutics Announces Oral Presentation on TTX-030 Anti-CD39 Antibody at American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ttx-030","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trishula Therapeutics \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Trishula T.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces US Launch of IBSRELA\u00ae, a New First-in-Class Treatment for IBS-C in Adults","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Nobelpharma's HYFTOR\u2122 (sirolimus topical gel) 0.2%","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Nobelpharma America","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Nobelpharma America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nobelpharm.."},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D1\/D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"NeuroDerm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceuticals Will Present the Latest Research Data on Prokalutamide and C-MYC Degrader at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI306","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva\u00ae in Mantle Cell Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ART0380","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artios Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ENOB-HV-21","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Expands Zolgensma Manufacturing Capacity With Approval of Multi-product North Carolina Facility","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1\/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2tYF-PR1.7-hCNGB3","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART\u00ae (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"4D-710","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BPT-143","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bright Pea.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"KPI-012","moa":"Protease","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elucida Oncology's Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Folic-acid Functionalized C\\'Dot-Drug-Conjugate","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elucida Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elucida Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elucida On.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Participate in Upcoming April Women's Health Medical Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NLC-V-01","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Highlights INKmune Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics\u2122 EDSIVO (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1\/2 Clinical Proof-of-Concept Study in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Announces Transition in Clinical Leadership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"MNK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-097558","moa":"SARS-CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Welcomes New Guidelines for the Management of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1\/2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Positive Preliminary Data from Phase 1\/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Positive Update to Ongoing Phase 1b\/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"WVE-004","moa":"C9orf72 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF\/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH-1020","moa":"HGF\/MET","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KIMMTRAK\u00ae (tebentafusp) For the Treatment of Unresectable or Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Announces FDA Clearance of IND Application for STAR-OLZ TDS for the Treatment of CINV","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JS006","moa":"CD112R","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1\/2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Launches Generic Methylprednisolone Sodium Succinate for Injection in US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylprednisolone Sodium Succinate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Genprex","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Announces the Opening for Enrollment of its Phase 1\/2 Acclaim-2 Clinical Trial of REQORSA\u2122 Immunogene Therapy in Combination With Keytruda\u00ae to Treat Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bond Biosciences Announces First Dosing of Sentinel Patients in a Phase Ia\/b Clinical Trial for a Novel Therapy to Treat Patients with Hemochromatosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BBI-001","moa":"Iron absorption","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bond Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosc.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in Phase 2 Trial of Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces New Data and Progress of VBI-2900, VBI\u2019s eVLP Coronavirus Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VBI-2905","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Vaxess","sponsor":"GC Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxess Announces Production of The First GMP Batch of MIMIX\u2122 Technology Vaccine Patches for an Upcoming Phase 1 Seasonal Influenza Clinical Trial; Clinical Entry Expected This Summer Based on a Successful February Pre-CTA Meeting With Health Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VX103","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxess","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Controlled Release Microneedle Patch","sponsorNew":"Vaxess \/ GC Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Vaxess \/ G.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Therapeutics\u2019 Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA\u2019s Autism Action Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC60","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Approval of Pemazyre\u00ae (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Key Data Results of the Phase III Global Multicenter Clinical Trial of Prokluamide in the Treatment of Non-Hospitalized COVID-19 Patients with Mild and Moderate Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY\u2122 (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Granted NASH Patent in Europe","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bisphosphocin","moa":"Cell membrane","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Lakewood-Amedex","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Lakewood-Amedex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lakewood-A.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves Novartis Vijoice\u00ae (alpelisib) as First and Only Treatment for Select Patients With PIK3CA-Related Overgrowth Spectrum (PROS)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Alpelisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"XMT-1660","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Brigham and Women\u2019s Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Brigham and Women\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase\u00ae Provides Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravesical Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"De-TIL-0255","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces FDA Approval of IGALMI\u2122 (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ME3183","moa":"PDE4","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Ph.."},{"orgOrder":0,"company":"Medikine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medikine to Highlight Preclinical Data on its Lead Program MDK-703, an IL-7 Mimetic, at the 2022 Annual Meeting of the American Association for Cancer Research (AACR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MDK-703","moa":"Interleukin-7R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medikine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Launches Tru Niagen\u00ae Immune, Further Expanding Innovative Product Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces the Publication of Tyvaso DPI\u2122 BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder For Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (Dupilumab) Approved by European Commission for Children Aged 6 to 11 Years With Severe Asthma With Type 2 Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Bened Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lactobacillus Plantarum","moa":"Dopamine","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bened Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bened Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bened Biom.."},{"orgOrder":0,"company":"BiOneCure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiOneCure Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for BIO-106, a Novel TROP2 ADC for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BIO-106","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BiOneCure Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiOneCure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiOneCure .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I\/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"iOmx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OMX-0407","moa":"SIK3","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"iOmx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"iOmx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"iOmx Thera.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"L-asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 43rd Annual Meeting and the Genetic Metabolic Dieticians International Conference 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegtibatinase","moa":"CBS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ M.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Toothpaste","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5HT-2A receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Merzee\u00ae Capsules in the United States","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"Sperm penetration","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Slayback Pharma \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Slayback P.."},{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ArkBio Announces Positive Results of Phase 3 Study with Ziresovir in Infants and Children Hospitalized with Respiratory Syncytial Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ziresovir","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ark Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ark Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ark Biosci.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Demonstrating Tvardi\u2019s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to Be Presented at the 2022 Annual Meeting of the American Association for Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Centre Groningen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Doses First Volunteers in Phase II\/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akston Biosciences \/ University Medical Centre Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Interleukin-2 partial","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"STK-002","moa":"Optic atrophy 1 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Dystrogen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dystrophin Expressing Chimeric Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dystrogen Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dystrogen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dystrogen .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Clayton Pharmaceuticals","sponsor":"Vista Pharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clayton Pharmaceuticals and VistaPharm (a Vertice company) Receive FDA Approval for Sucralfate Oral Suspension","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sucralfate","moa":"Pepsin A5","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Clayton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clayton Pharmaceuticals \/ Vista Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Clayton Ph.."},{"orgOrder":0,"company":"Avet Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avet Pharmaceuticals Announces Approval and Launch of Propofol Injectable Emulsion, USP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Propofol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avet Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avet Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avet Pharm.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MEN1309","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari\u00ae in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Pharmaceuticals Will Present Scientific Data At The Society Of Hospital Medicine Converge 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"RedCloud Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redcloud Bio To Present Preclinical Data Of Next-Generation EGFR TKI H002 At Annual Meeting Of American Association Of Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"H002","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RedCloud Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedCloud Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RedCloud B.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec\u00ae ODT Therapy: A Real-World Administrative Claims Analysis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pathalys Pharma Announces Phase 3 Program for Upacicalcet","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys P.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OBI-3424","moa":"AKR1C3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Second Part of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile Infections to Be Extended to Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SA.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Presentation of a Scientific Abstract at the Next International Conference on Fatty Liver","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Briacell Advances Preparatory Work for New Bria-ots\u2122 Breast Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b\/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agile Therapeutics\u00ae Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Ther.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ANX007","moa":"C1q","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VERVE-101","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen To Present At ATS 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RBC-loaded Enzyme","moa":"Enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-Omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SAGE-718","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma\u2019s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GEM-difluorinated C-glycoside Derivative of Podophyllotoxin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Demonstrated Sustained Improvements in Functional Activities and Quality of Life in Adults With Generalised Myasthenia Gravis Through 60 Weeks","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD8233 Reduced Low-density Lipoprotein Cholesterol Levels by 73% in Patients With High-risk Hypercholesterolemia in ETESIAN Phase IIb Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xareno Study Revealed Xarelto\u2122 Was Associated With Net Clinical Benefit and a Reduced Risk of Kidney Failure Compared to Vitamin K Antagonists","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression \u22651%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Health Canada Approval of RYBREVANT\u00ae (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World Health Organization Updated Emergency Use Listing Recommends Johnson & Johnson COVID-19 Vaccine for Booster Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Intramuscular Suspension","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Intramuscular Suspension","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension For Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Anti-PD-1 Tislelizumab Accepted by EMA for Regulatory Review in Esophageal and Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents New Four-year Data on Efficacy and Safety of Kesimpta\u00ae (Ofatumumab) in People Living With Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Roche\u2019s Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"CYTOO","sponsor":"Astellas Gene Therapies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CYTOO\u2019S Partner Astellas Gene Therapies to Present Results of An AGT\/ CYTOO Collaboration on Clinical Candidate Selection to Treat Dmd at The 2 Nd Gene Therapy for Muscular Disorders Summit","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CYTOO","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CYTOO \/ Astellas Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"CYTOO \/ As.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BMND07","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA Biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"$27.5 million","newsHeadline":"Novan Acquires EPI Health, a Specialty Dermatology Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health.."},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"DT-216","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Design The.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CLN-081","moa":"Irreversible EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life to Present at the American Association for Cancer Research 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"CDR404","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CDR Life \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Receives FDA Study May Proceed Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX1\/COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Hester Biosciences","sponsor":"BIRAC","pharmaFlowCategory":"D","amount":"$7.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hester Biosciences Gets Rs 60 Crore Grant from Govt to Make Covaxin Drug Substance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hester Biosciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Hester Biosciences \/ BIRAC","highestDevelopmentStatusID":"12","companyTruncated":"Hester Bio.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"LNC-based mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"1","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Italian Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Autigen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autigen Announces Collaboration with Boehringer Ingelheim to Discover and Develop Novel Treatments for Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Autigen","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autigen \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Autigen \/ .."},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem and the Crohn\u2019s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of A New Therapeutic Approach in Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"TREM-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Opthalamic Solution","sponsorNew":"LENZ Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$15.0 million","newsHeadline":"LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Aceclidine Hydrochloride","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.11,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.11,"dosageForm":"Opthalamic Solution","sponsorNew":"LENZ Therapeutics \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"EdiGene","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EdiGene \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"CDR Life","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"CDR-Life Announces $76 Million Raised in Series A Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series A Financing","leadProduct":"CDR404","moa":"Cytotoxic T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CDR Life","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"CDR Life \/ Jeito Capital","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Blumentech S.L.","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences and Blumentech S.L. Announce the Acquisition of a Patent Portfolio Covering the Groundbreaking Discoveries of Prominent Psychedelics Researcher Dr. Jordi Riba","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Blumentech S.L.","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blumentech S.L. \/ Terran Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Blumentech.."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$6.0 million","newsHeadline":"Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Entolimod","moa":"TLR5","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Statera Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Statera Biopharma \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"WestPark Capital","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ WestPark Capital","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"ATL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Gesval S.A.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Gesval S.A.","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures EUR 5 Million Financing","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"WuXi Advanced Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chimeric Enters Strategic Manufacturing Partnership With WuXi Advanced Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"CLTX CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Chimeric Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Chimeric Therapeutics \/ WuXi Advanced Therapies","highestDevelopmentStatusID":"6","companyTruncated":"Chimeric T.."},{"orgOrder":0,"company":"Bioasis","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Enters Into Research Collaboration With Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioasis \/ Janssen","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ .."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"National Resilience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"OPGx-001","moa":"LCA5 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Opus Genetics \/ National Resilience","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series D Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$8.6 million","upfrontCash":"Undisclosed","newsHeadline":"Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","amount":"$100.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics Announces Closing of $100.5 Million Private Placement","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Private Placement","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Immedica","pharmaFlowCategory":"D","amount":"$452.0 million","upfrontCash":"$35.0 million","newsHeadline":"Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Immedica","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Private Placement","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Acuta Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Private Placement","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Albumedix","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Albumedix and Valneva Expand Collaboration to Include Newly Approved Inactivated COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Albumedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Albumedix \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"Albumedix .."},{"orgOrder":0,"company":"Oncode-PACT","sponsor":"National Growth Fund","pharmaFlowCategory":"D","amount":"$353.6 million","upfrontCash":"Undisclosed","newsHeadline":"Growth Fund Invests 325 Million Euros in Oncode-PACT To Accelerate the Development of Cancer Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncode-PACT","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Oncode-PACT \/ National Growth Fund","highestDevelopmentStatusID":"4","companyTruncated":"Oncode-PAC.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Generic of Symbicort to Treat Asthma and COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biological E to Get mRNA Technology from WHO to Make COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Neuro-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Drug From Neuro-Bio Effective in a Mouse Model of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NBP14","moa":"Nicotinic alpha-7 allosteric receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuro-Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuro-Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neuro-Bio .."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"GGV Capital","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ensem Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Ensem Therapeutics \/ GGV Capital","highestDevelopmentStatusID":"2","companyTruncated":"Ensem Ther.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Azenosertib","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumakras\u00ae (Sotorasib) Codebreak 100 Study Shows Two-year Overall Survival of 32.5% in Patients With Kras G12c-mutated Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapivirine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"Johnson & Johnson \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipelukast","moa":"PDE3\/4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Presents Positive Preliminary Phase 1\/2 Data for First-in-Class CAR-T Program BNT211 at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CLDN6 CAR-T","moa":"CLDN6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed\/Refractory to Venetoclax in Ongoing Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Statement on the Centers for Medicare and Medicaid Services\u2019 National Coverage Determination With Coverage With Evidence Development for Monoclonal Antibodies Directed Against Amyloid for The Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GTAEXS-617","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NTX-801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravescial","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera Presents Data on T Cell Engager Platform at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Data from Multiple Preclinical XmAb\u00ae Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"XmAb306","moa":"IL-15 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"CDK12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoMyx Presents New Data at AACR 2022 Demonstrating Multi-Armed Myxoma Virus Coordinates Tumor-Killing by Activating Innate and Adaptive Immune Responses","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OM1","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoMyx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoMyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OncoMyx Th.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT\u2011179, a HER2-targeted Allogeneic CAR-NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon Presents Preclinical Data on Lead Program E-602 and Novel Bifunctional PD-L1-Targeted Sialidase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"E-602","moa":"Sialoglycan","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asher Bio to Present New Preclinical Data Demonstrating Differentiated Profile of AB248, its Lead Cis-targeted IL-2 Immunotherapy, at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AB248","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Imvax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Imvax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ No.."},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EPIM-001","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpis Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elpis Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpis Biop.."},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphagen Pharmaceuticals Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class Steroidogenic Factor 1 Inhibitor, for the Treatment of Leydig Cell Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OR-449","moa":"NR5A1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen P.."},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein Degrader, ORM-5029, Degrading GSPT1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ORM-5029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Orum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Orum Thera.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IO-108","moa":"LILRB2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"OncoOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ON203","moa":"MIF","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoOne","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoOne \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoOne \/ .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"Ataxia-Telangiectasia","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TG4050","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"University of Heidelberg","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca\u00ae (Rucaparib) at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Clovis Oncology \/ University of Heidelberg","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152\u2019s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NKT2152","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene to Present Clinical Results and Biomarker Data on cc in Solid Tumors at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kowa To Discontinue K-877 (Pemafibrate) \"Prominent\" Cardiovascular Outcomes Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemafibrate","moa":"PPAR alpha","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Kowa Pharmaceuticals America","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Pharm.."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Allosteric Therapy","moa":"Cbl","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TP-1287","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK\u2122 Cell Engagers at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CYT-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-0508","moa":"T Cell checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-894","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Reaction Biology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Adavosertib","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Reaction Biology","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JZP815","moa":"Fibrosarcoma","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Second Genome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SG-3-06686","moa":"CXCR3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Second Genome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Gen.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BTM-3566","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bantam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pha.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TPX-100: OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TPX-100","moa":"Type II collagen","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"OrthoTrophix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTroph.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin Booster Enhances Antibody Response Against Covid Variants Including Omicron: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen\u00ae for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Cancer Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Can.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces Resubmission of FUROSCIX New Drug Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Affimed","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Presents Updated Clinical Data from Phase 1\/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Affimed \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"UCART20x22","moa":"CD20\/CD22","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Fibrosarcoma kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Yiviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906\u2019s Immunomodulatory Mechanisms in Combination with Immune Checkpoint or CAR T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Yiviva","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yiviva \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yiviva \/ N.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SL-9258","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Presentation of New Data from MM1636 Phase 1\/2 Clinical Trial Presented at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CD 70 CAR NK Cells","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nab-Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG138","moa":"HER2\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Polatuzumab-monomethyl auristatin E","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress Platform at the 2022 AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TCX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Presents Encouraging Initial Data from GEN-011 Phase 1\/2a Trial at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"KB-0742","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PYX-106","moa":"Siglec-15-mediated","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb\/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PTEFb\/CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"VPS4A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-8371","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I\/IIa EVICTION Trial at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ICT01","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-253","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-TT170","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IOA-289","moa":"Autotoxin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Afamitresgene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AGEN1571","moa":"ILT4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MCLA-129","moa":"EGFR\/Tyrosine protein kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Class I HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OnKure The.."},{"orgOrder":0,"company":"Oncorus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ONCR-021","moa":"ICAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncorus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ .."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448\/GSK4428859A, at the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"Irreversible menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1\/2 Clinical Trial of CFT7455, a Novel IKZF1\/3 Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CFT7455","moa":"IKZF1\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE Molecules at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Pauses Enrollment in BCX9930 Clinical Trials","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA19","moa":"PD-1 inhibitor\/IL-2 super","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA413","moa":"IL-4\/IL-13 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Publication of ADXS-PSA Data in The Oncologist","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AK127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"T-knife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TK-2504","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"T-knife \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Presentation of SADA Technology at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GD-2 SADA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM707","moa":"ILT2\/ILT4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody\u00ae-CD3xCD20) From Phase 1\/2 Trial in Patients with Relapsed\/Refractory Large B-cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Abbvie","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS\u00ae (bevacizumab-maly)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA\u00ae (vibegron) 75 mg at 2022 American Urological Association Annual Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"hMaxi-K","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intradetrusor Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a\/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves PADCEV\u2122 (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ONM-501","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"OncoNano Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"SyneuRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir\u00ae (SNB01)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentarlandir","moa":"DAAO","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SyneuRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SyneuRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SyneuRx \/ .."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravesical","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VAC2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Demonstrates NT-I7\u2019s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BI 853520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment Developed by CHOP Researchers Prevents Hypoglycemia in Children with Hyperinsulinism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Avexitide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Children's Hospital of Philadelphia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Children's.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ISM025","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BOTOX\u00ae Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer's disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OLINVYK Data Selected as President's Choice Abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GRT-C903","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Gritstone bio \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ORIC-533","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at the 2022 Synuclein Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Data from the Phase 1\/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company\u2019s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MGTA-117","moa":"CD117 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants Dosed in Phase 1\/2 Study With mRNA1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1020","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Brimonidine Tartrate\/timolol Maleate Eyedrop in Us for Patients With Ocular Hypertension, Expanding Leading Ophthalmic Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sandoz B2B \/ ","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"kt-4000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the\u00c2 Society for Inherited Metabolic Disorders Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Publication of Peer-Reviewed Paper, Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"IO Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IO102-IO103","moa":"Indoleamine 2,3-dioxygenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ IO Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Provides Update on its Phase 2\/3 Study of COVAXIN (BBV152)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Covid 19 DNA Vaccine,","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces Poster Presentation at American Association for Cancer Research:","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine Prodrug","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CHK-336","moa":"LDH-A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProKidney Confirms Phase 3 program for Autologous Kidney Cell Therapy REACT","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides Progress on Advancement of Ampligen Clinical Development Program for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare Bioscience Initiates Phase 1\/2 Clinical Study of DARE-HRT1","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Progesterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor Announces Oral Presentation at Attd 2022 of Phase I Clinical Trial of AT278 Ultra-Concentrated Ultra-Rapid Acting Insulin for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ultra-Concentrated Rapid Acting Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Mesenchymal Cell","moa":"NK-1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ University of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Provides Update for Phase 1\/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-6402","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover To Present at World Vaccine Congress Washington 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Announces Molecular Targets of CT-01 Program Developing TPD Therapy for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Captor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor The.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated with Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA (lefamulin) in Adult Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT6555","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Azenosertib","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL BIOSCIENCES: Notice of Allowance of Its Patent In China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tobacco Leaf Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"SNAP25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Aquaporin-4 protein","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ATYR2810","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Completes Dosing in Altitude Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"Passive oxygen diffusion","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Bolus","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GTB-5550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Cysteine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"INB03","moa":"DN-TNFs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND (mitapivat) for Adults with Pyruvate Kinase Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Imunon","sponsor":"Medidata","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Medidata","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ M.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer's Symposium; International Frailty and Sarcopenia Research Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lomecel-B","moa":"IL-10","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b\/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin 3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and\/or Invasive Candidiasis at ECCMID 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 1\/2 Study Results of Rilzabrutinib in People With Immune Thrombocytopenia Published in the New England Journal of Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Caplet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ASN004","moa":"5T4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tularemia Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Extends Review of Biologics License Application for REGEN-COV\u00ae (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Casirivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"XL114","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY\u00ae (ganaxolone) Phase 3 Marigold Trial Results","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Appoints Susan Flint as Vice President of Clinical Operations, Patrick Kesslak, PhD, as Vice President of Clinical Development & Medical Affairs, and Erwan de Naurois as Vice President of Finance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NCCN Guidelines\u00ae Recommend VONJO\u2122 (pacritinib) for the Treatment of Myeloproliferative Neoplasms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx's Late-Stage Clinical Trial Reaches New Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Publishes Preclinical Results of PD-1\/LAG-3 Bi-specific Antibody\uff08AK129\uff09at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AK129","moa":"PD-1\/LAG-3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"AB521","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arcus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Navitoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives Approval for Precision Oncology Treatment Vitrakvi\u2122 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Larotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial Approval in China Supports Global Development Strategy for TauRx\u2019s Oral Tau Aggregation Inhibitor","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TRx-237-801","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants Dosed in Phase 1\/2 Study with mRNA-1020 and mRNA-1030 Seasonal Inuenza Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1020","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Early Clinical Data for Unique KRASG12C Inhibitor at American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JDQ443","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE\u00ae for the Management of Moderate to Severe Pain Associated with Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer\u2019s LORBRENA\u00ae (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lorlatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAKHZYRO\u00ae (lanadelumab) Open Label Phase 3 Study Met its Objectives in Children Ages 2 to <12 Years of Age with Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital Sucrase-Isomaltase Deficiency (CSID) Patients on Sucraid\u00ae (sacrosidase) Oral Solution","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"QOL Medical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Optum Frontier Therapies","highestDevelopmentStatusID":"12","companyTruncated":"QOL Medica.."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokines","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Ankyra Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"AMB302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"4","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"TCR-mimic Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$375.0 million","newsHeadline":"Hikma Completes Acquisition of Custopharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm.."},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$111.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"SION-638","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Sionna The.."},{"orgOrder":0,"company":"Labcorp","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Labcorp Enhances Cell and Gene Therapy Development Support Through Collaboration With Xcell Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Labcorp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Labcorp \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Labcorp \/ .."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Comera Life Sciences \/ Intas","highestDevelopmentStatusID":"12","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson\u2019s Research to Support Development of Its TLR2 Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"NPT1220-478","moa":"TLR2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuropore Therapies \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore .."},{"orgOrder":0,"company":"Microviable Therapeutics","sponsor":"Inmunomet Intolerancia y Disbiosis SL","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company\u00b4s Microbiota-Derived Biotherapeutic Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"MVT-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microviable Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL","highestDevelopmentStatusID":"4","companyTruncated":"Microviabl.."},{"orgOrder":0,"company":"Fathom Pharma","sponsor":"Consegna Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Consegna Pharma Acquires Fathom Pharma to Strengthen Initiatives that Address the Opioid Crisis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"FP01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Fathom Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fathom Pharma \/ Consegna Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fathom Pha.."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Bull Horn Holdings Corp.","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Merger","leadProduct":"Anti-CD38 Monoclonal Antibody","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ Bull Horn Holdings Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Th.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.13,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.13,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Psyence","sponsor":"Filament Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Filament Health Corp.","highestDevelopmentStatusID":"5","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SpringWorks Therapeutics \/ Regeneron","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Private Placement","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heat Biologics (NightHawk Biosciences) Completes Acquisition of Elusys Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Elusys Therapeutics \/ Heat Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Elusys The.."},{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VantAI \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ B.."},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Licensing Deal with Sanofi for Two Late-Stage CNS Pipeline Assets ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Tolebrutinib","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Terran Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Terran Biosciences \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Terran Bio.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"CDI-988","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Octantbio","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"Chaperon Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Octantbio","amount2":0.080000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Octantbio \/ Catalio Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Octantbio .."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$755.0 million","upfrontCash":"$80.0 million","newsHeadline":"AbbVie Terminates Collaboration with BioArctic on alpha-Synuclein Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Termination","leadProduct":"ABBV-0805","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BioArctic AB","amount2":0.76000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Savara","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Molgramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Spray","sponsorNew":"Savara \/ Silicon Valley Bank","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ S.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncomatryx Announces a \u20ac15 Million Capital Increase to Conduct Clinical Trials Against the Tumor Micro-environment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"OMTX705","moa":"Fibroblast activation alpha protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncomatryx","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Oncomatryx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oncomatryx.."},{"orgOrder":0,"company":"Immuron","sponsor":"Medical Technology Enterprise Consortium","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuron New MTEC Project Proposal Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Bovine Colostrum","moa":"Enterotoxigenic Escherichia coli","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Medical Technology Enterprise Consortium","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Custopharm","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$375.0 million","newsHeadline":"Hikma Strengthens US Injectables Business Through Acquisition of Custopharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Custopharm","amount2":0.42999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Custopharm \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Custopharm.."},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs Drug","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Partners with Clinilabs Drug Development Corporation for Phase 1\/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Cybin \/ Clinilabs Drug","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cl.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$250.0 million","newsHeadline":"Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Checkmate Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"Engineered B Cell Medicine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Be Biopharma \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Aerium Therapeutics","sponsor":"Lausanne University Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaVentures Advises Lausanne Hospital (CHUV) and EPFL on Their Collaboration and Founding of Aerium Therapeutics to Develop Their Highly Potent SARS-CoV-2 Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"SARS-CoV-2 Monocloncal Antibody","moa":"SARS-CoV-2 virus","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aerium Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aerium Therapeutics \/ Lausanne University Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Aerium The.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Receives Reimbursement for VAZKEPA\u00ae in Sweden","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Cyanvac","sponsor":"Blue Lake Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CyanVac and Blue Lake Biotechnology Announce FDA Clearance of IND Application for BLB-201 Intranasal RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"BLB-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cyanvac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyanvac \/ Blue Lake Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Cyanvac \/ .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viiv Healthcare Announces US FDA Approval of Triumeq PD, the First Dispersible Single Tablet Regimen Containing Dolutegravir, a Once-daily Treatment for Children Living With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Abacavir","moa":"HIV integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Publishes Preclinical Results of PD-1\/CD73 Bi-specific Antibody?AK131?at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AK131","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Publishes Preclinical Results of TIGIT monoclonal antibody?AK127?at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AK127","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Presents Compelling Data From the Phase I\/II Study of ANV419 During the AACR Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ANV419","moa":"Selective interleukin-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Accelerated Approval for Immunomedics\u2019 Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME\u00ae (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Collaboration Partner Bayer Submits Application for Additional Indication of Darolutamide in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Mynvax","sponsor":"Indian Institute of Science","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's 'Warm' Vaccine Candidate Effective Against Delta, Omicron Variants in Mice: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mynvax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mynvax \/ Indian Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Mynvax \/ I.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SIM0417","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Top-line Results From Phase 3 Study of ABP 654, Biosimilar Candidate to Stelara\u00ae (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LMN-201","moa":"Bacterial Cell Wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Novavax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Approval of Nuvaxovid\u00ae COVID-19 Vaccine for Primary and Booster Immunization in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ACP-044","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Therapeutics, Inc. to Present at the World Vaccine Congress in Washington, DC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Seneca Valley Virus-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seneca Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Seneca Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seneca The.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"KIN-3248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air to Participate in Three Upcoming Medical Conferences","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Spray","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"26-kDa","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug to Present at the 2022 ASCRS Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GB-501","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastromal Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covovax for 7-12-Year-Olds: Panel Seeks More Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and MedinCell Receive Complete Response Letter for TV-46000\/mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Medincell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Accepts New Drug Application for Daprodustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Announces Third ANDA Approval and The 4th U.S. Approval for the Alter Pharma Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"AchE","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Milla Pharmaceuticals \/ Alter Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Milla Phar.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA\u00ae in Dry and Wet Overactive Bladder Populations","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology Founder and CSO to Present Company Information and Clinical Trial Progress at Life Science Innovation Northwest","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Announces Completion of IND Submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RBM-007","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ribomic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Ifosamide Prodrug","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Hesperos","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hesperos Shows Potential for In Vitro Approach to Replace Conventional Animal Efficacy Studies for Rare Neuromuscular Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SAR445088","moa":"Complement C1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Hesperos","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hesperos \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hesperos \/.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Neuraly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NLY01","moa":"GLP1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ .."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BGE-105","moa":"Apelin receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Granted CMG901 Fast Track Designation For Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer Which Have Relapsed and\/or Are Refractory to Approved Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CMG901","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Bi.."},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Lacosamide Tablets, USP (generic version of Vimpat\u00ae) Manufactured by MSN Laboratories Private Limited","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSN Laboratories \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MSN Labora.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant to Participate in Multiple Conferences This Spring","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi\u00ae from Evofem's Phase 3 AMPOWER Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN-RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics to Present New Data for JATENZO (testosterone undecanoate) at the Androgen Society 4th Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Announces Dosing of First Patient in Phase 1\/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Telparevir","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyclacel Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"HANDOK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CHC2014","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Handok","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT6 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"NextCure","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NC525","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NextCure \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold (migalastat), Strengthening Patent Protection Through 2038","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nanoliposome-based Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVUSHELD\u2122 Significantly Protected Against Symptomatic COVID-19 for At Least Six Months in PROVENT Phase III trial in High-Risk Populations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Netarsudil","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP450","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed-Release Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MDL-101","moa":"Laminin alpha-1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Modalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Th.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PKMYT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IO-106","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Endevica Bio\u2019s Lead Compound, TCMCB07, Published in \u201cACS Pharmacology & Translational Science\u201d Suggest a Platform Approach for Producing Drug-Like Peptides","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica B.."},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selva Announces Preclinical Data Confirming SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SLV213","moa":"Cathepsin L","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Selva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Selva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Selva Ther.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease-2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPA\u2019s Advanced PolyTope\u00ae TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TATX-03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Monopteros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopteros Therapeutics Announces Two Presentations at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer (SITC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MPT-0118","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopteros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Monopteros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopteros.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Partners with Oncology Development Expert to Advance LADR Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GM-CSF","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Dragon Boat Pharmaceutical","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanyou Bio Congratulates Dragon Boat Pharmaceutical on the Approval of Clinical Trials of anti-CLDN18.2 Antibody Drug BC008","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BC008","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dragon Boat Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragon Boat Pharmaceutical \/ Sanyou Biopharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Dragon Boa.."},{"orgOrder":0,"company":"Aggrega Pharma","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Penicillamine Capsules, USP (generic for Cuprimine\u00ae)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Penicillamine","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aggrega Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aggrega Pharma \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aggrega Ph.."},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics to Present at the Raymond James LILRB\/ILT Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BND-22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biol.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva\u00ae in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"exoVACC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Publication of MN-166 (ibudilast) Data Regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Plant Extract","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces First Patient Dosed in Pivotal Phase 2\/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"CTGF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenti-virus Based Hematopoietic Stem Progenitor Cell Immuno-gene Therapy","moa":"IL alpha-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Brain-Derived Neurotrophic Factor","moa":"BDNF","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"Multi-TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress of the European Association of Dermato-Oncology (EADO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexmarilimab","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Miglustat Capsules (generic for Zavesca\u00ae)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Miglustat","moa":"Glucosylceramide synthase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI\u00ae (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA\u00ae for Plastic Surgery Procedures at The Aesthetic Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin to Present at Eyecelerator@ American Society of Cataract and Refractive Surgery (ASCRS) 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PL9643","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 AGILE Data of TIBSOVO\u00ae (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Announces Launch of Erythromycin Lactobionate for Injection, USP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Erythromycin Lactobionate","moa":"Protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qpex Biopharma Announces Presentation of Clinical Data for Ultra-Broad Spectrum \u03b2-lactamase Inhibitor Xeruborbactam and the Lipopeptide QPX9003 at ECCMID 2022 Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Xeruborbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qpex Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Bioph.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tvardi Therapeutics\u2019 TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides Summary of Ampligen\u00ae Data Supporting Synergistic Potential with Checkpoint Blockade Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GCC19CART","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Navicixizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OncXerna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncXerna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OncXerna T.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Multivalent COVID-19 DNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera Launches New Patient-Focused Websites for Ameluz\u00ae and Xepi\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"FXS01","moa":"Diacylglycerol kinase kappa","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion for Filsuvez for the Treatment of Dystrophic and Junctional EB","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Regulatory Submission for Aducanumab in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir\u2019s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Tentative Approval of its ANDA for Dabigatran Etexilate Capsules (generic for Pradaxa\u00ae)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol Announces Start of Study Data Analysis of Phase III AGENT Study in Advanced Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta\u00ae) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY\u2122 (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Maribavir","moa":"CMV pUL97 kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Conditional Approval of Roche\u2019s Potential First-in-class Bispecific Antibody Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Significantly Protected Against Symptomatic COVID-19 For at Least Six Months in PROVENT Phase III Trial in High-Risk Populations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Application in China for Additional Indication of Darolutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Roche\u2019s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.211","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novoseven\u00ae Recommended for Approval for the Treatment of Severe Postpartum Haemorrhage by the European Medicines Agency","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Coagulation cascade","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL\u00ae (Quinapril HCl) Due to N-Nitroso-Quinapril Content","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Quinapril","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezurock\u00ae (Belumosudil) Patient-reported Outcomes Correlated With Clinical Response in Chronic Graft-versus Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Grants Marketing Authorization for TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Inc. Receives FDA Approval of Erythromycin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Erythromycin Lactobionate","moa":"Protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Cyan Bio","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adge Pharmaceuticals Partners with Cyan Bio of Korea to Advance Treatments for Rare Pediatric Diseases in Asian Countries","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyan Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyan Bio \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cyan Bio \/.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Signs RenMab\u2122\/RenLite\u2122 Licensing Agreement with BeiGene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Deaconess Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"ViGeneron","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViGeneron Announces Follow-On Collaboration with Daiichi Sankyo to Develop a Novel Gene Therapy for Prevalent Eye Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"vgAAV.GL","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViGeneron \/ Daiichi Sankyo Company","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron .."},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Aluminium hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nkarta Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nkarta Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"EntreChem","sponsor":"AI Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"AIT-102","moa":"SWI\/SNF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EntreChem","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EntreChem \/ AI Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EntreChem .."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"STI-001","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Portage Biotech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"SpineThera","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpineThera Awarded $5 Million Grant from Department of Defense","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Epidural Injection","sponsorNew":"SpineThera \/ Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Laboratoires DELBERT","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Laboratoires DELBERT is Proud to Announce the Acquisition From Sanofi of TERALITHE 250 mg, Divisible Tablet and TERALITHE LP 400 mg, Prolonged-Release Tablet and Continues to Engage for Maintaining Access For Patients to MITM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Lithium Carbonate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Laboratoires DELBERT","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ L.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Ray-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therap.."},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody\u00ae in Switzerland","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EffRx Pharmaceuticals \/ Diurnal Group","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Phar.."},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Pavilion Capital","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"mRNA COVID Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RVAC Medicines","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"RVAC Medicines \/ Pavilion Capital","highestDevelopmentStatusID":"4","companyTruncated":"RVAC Medic.."},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioEclipse Therapeutics\u2122 Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"CRX100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse.."},{"orgOrder":0,"company":"Apertura Gene Therapy","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Apertura Gene Therapy","amount2":0.070000000000000007,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Apertura Gene Therapy \/ Deerfield Management Company","highestDevelopmentStatusID":"2","companyTruncated":"Apertura G.."},{"orgOrder":0,"company":"NemaLife","sponsor":"University of California","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NemaLife and UC Davis Enter Into a Research Partnership to Test the Therapeutic Potential of Several Novel Psychoplastogens Developed in David E. Olson's Lab","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"Psychoplastogen","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NemaLife","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NemaLife \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"NemaLife \/.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Azenosertib","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Isleworth Healthcare Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to Fight Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Merger","leadProduct":"Flex-NK Cell Engager","moa":"GPC3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Isleworth Healthcare Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Delta Crystallon","sponsor":"Serenity Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serenity Bioworks Acquires DC-TAB for Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Recombinant Human HspB5","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Delta Crystallon","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delta Crystallon \/ Serenity Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Delta Crys.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Huadong Medicine Investment Holding","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"Dendrimer N-acetyl-cysteine","moa":"IKK beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Huadong Medicine Investment Holding","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Huadong Medicine","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ashvattha Therapeutics Announces $69 Million in Series B Financing and up to $45M Exclusive License Agreement with Huadong to Advance Hydroxyl Dendrimer-Based Precision Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dendrimer N-acetyl-cysteine","moa":"IKK beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Huadong Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"$20.0 million","newsHeadline":"Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Flex-NK Cell Engager","moa":"GPC3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0.82999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.82999999999999996,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"$44.5 million","upfrontCash":"Undisclosed","newsHeadline":"Catalent Acquires Commercial-Scale Cell Therapy Development and Manufacturing Facility in Princeton, New Jersey, from Erytech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Eryaspase","moa":"Asparagine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Catalent","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"ImmVira","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmVira Enters Clinical Development in Combination Therapy of MVR-T3011 IT and MEK inhibitor in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Cobimetinib","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ GC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ .."},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Inhalation","sponsorNew":"OMass Therapeutics \/ GV","highestDevelopmentStatusID":"2","companyTruncated":"OMass Ther.."},{"orgOrder":0,"company":"Plexium","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$565.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plexium \/ AbbVie","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$250.0 million","newsHeadline":"Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Monalizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Maruho","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Vimseltinib","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Digital Power Lending","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Financing","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Digital Power Lending","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Alta Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer Precision Targeted Genetic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Series A Financing","leadProduct":"LVV-based CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kelonia Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Kelonia Therapeutics \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Kelonia Th.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Advanced Therapies and A*STAR Announce Partnership to Advance Cell and Gene Therapy in The Asia-Pacific Region","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"University of L\u2019Aquila","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ University of L\u2019Aquila","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"CMAX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Skye Bioscience \/ CMAX Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"ObsEva \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ T.."},{"orgOrder":0,"company":"XBiotech","sponsor":"The French National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I\/II\/III Clinical Study for Natrunix\u2122 in Combination with Trifluridine\/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Tipiracil","moa":"Il-1 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ The French National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Tuberculosis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILiAD Biotechnologies \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"INV-1120","moa":"EP4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionova Life Science \/ MSD","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Lif.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Columbia University Irving Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center\u2019s Herbert Irving Comprehensive Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Adoptive Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ Columbia University Irving Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$23.6 million","newsHeadline":"AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.28999999999999998,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer Precision Targeted Genetic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"LVV-based GeneTherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Kelonia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kelonia Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"1","companyTruncated":"Kelonia Th.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$350.0 million","newsHeadline":"Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech for BCMA CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0.65000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion for Tabrecta\u00ae for Patients with METex14 Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT\u2122 and CIBMTR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for leniolisib from UK MHRA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA A receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Expands Intellectual Property Estate for Valtoco\u00ae, a Patient-centric Nasal Spray for Acute Treatment of Episodes of Frequent Seizure Activity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners to Regain Global Rights for MP0310 from Amgen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MP0310","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PN-943","moa":"Alpha4beta7 integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Immediate-release Tablet","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ALTA-2530","moa":"IL-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Antares Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves TLANDO\u00ae (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Antares Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minimal Side Effects and Short Recovery Time Reported for DSUVIA\u00ae-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b\/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mocravimod","moa":"S1PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Priothera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Avexitide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Iodine-131 Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novaliq \/ Bausch + Lomb","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cairo Laboratory","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT\u2122 and CIBMTR\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NKTR-255","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Cairo Laboratory","highestDevelopmentStatusID":"4","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pha.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Orca-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (\u201cTandem\u201d) Meetings of ASTCT and CIBMTR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic CD19 CAR-NKT Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Photoreceptor Neural Cell","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Engineered Human Stem Cell Therapy","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air\u00ae Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Spray","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-9167","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"WVE-004","moa":"C9orf72 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022\u2122, the Annual Event of the American Association of Immunologists","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"AQP4","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Oral Solution","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces Publication in Nature Cancer on Petosemtamab\u2019s (MCLA-158) Unique Mechanism of Action","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Petosemtamab","moa":"GPCR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb\u00ae Technology for Complex Membrane Antigen Expression to Enable Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Poxvirus-based Antibody","moa":"SEMA4D","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Extended-release Powder for Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Doses First Subjects in Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus\u2019 CAR T cell therapy, obe-cel, for the treatment of adult B-ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air\u00ae Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Galderma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA\u00ae (lumateperone) for Specific Patient Populations","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ETX-810","moa":"PPAR alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex Announces IND Approval for Phase 1 Clinical Trial of LEM-S401, siRNA Gene Therapeutics With Nano-Drug Delivery Platform DegradaBALL\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LEM-S401","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lemonex Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bi.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative\u2122 Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ARX788","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ambrx Inc \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"N-803","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"400 Patients Have Been Enrolled in AM-Pharma\u2019s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and\/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"CEP290 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Upcoming Clinical Presentations at ARVO 2022 Medical Meeting and MODLive! 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"APX3330","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Olitigaltin","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Dry Powder","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PRX012","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"OncoC4","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoC4 Announces Fast Track Designation Granted by the U.S. FDA for ONC-392 Monotherapy in PD(L)1-Resistant NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Onc-392","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ N.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofranergene Obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"SO-N102","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Results from Respiratory Physiology Study of Head-toHead Comparison of OLINVYK\u00ae and IV Morphine in Elderly\/Overweight Subjects","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH\u00ae (tenapanor)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VITRAC Therapeutics Initiates a Phase 1\/2 Clinical Trial with the Aurora Kinase A inhibitor VIC-1911 in GVHD Prophylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Aurora kinase A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota Medical School","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC The.."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Provides Regulatory Update and Initiation of Clinical Program in Non-CF Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Successfully Completes Initial Preclinical Studies for VRP324","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Personalis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion to Utilize Personalis\u2019 ImmunoID NeXT Platform\u00ae to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Personalis","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Doses First Subject in Phase I\/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"THIO-103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JANX007","moa":"PSMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-term Health Outcomes Using Simulation Model of Investigational Lecanemab in Patients With Early Alzheimer\u2019s Disease Published in a Peer-reviewed Journal, Neurology and Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta protein A4","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Fervent Pharmaceuticals","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fervent Pharmaceuticals commences virtual at home Phase 2 Clinical Trial of a Peri- and Post-Menopausal Therapy for Treating Hot Flashes and Night Sweats","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"FP-101","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Fervent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fervent Pharmaceuticals \/ Iqvia","highestDevelopmentStatusID":"8","companyTruncated":"Fervent Ph.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoural","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Halobetasol","moa":"Corticosteroid hormone receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc. Doses First Patient in Phase I\/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Clevudine Monophosphate Prodrug","moa":"Nucleotide active site polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CFI-400945","moa":"PLK4 Inhibitor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope's Vision Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as part of ARVO Annual Meeting in Denver","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"MCO-010","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Teneligliptin Hydrobromide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bergenbio Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients \u2013 Primary Efficacy Endpoint Met","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio\u2019s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AVB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for Pedmark\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Tislelizumab Plus Chemotherapy Significantly Improved Overall Survival as First-line Treatment for Advanced Esophageal Cancer in Phase III Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"PTK erbB-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Research Published in Science Advances Demonstrates Repertoire Immune Medicines\u2019 Cell-Tethering Technology Delivers Potent Interleukin-12 Directly to Solid Tumors Potentially Improving Effectiveness of Cellular Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RPTR-168","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Zydus Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Presents Partner Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"PharmaJet \/ Zydus","highestDevelopmentStatusID":"10","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aulos Bioscience Announces Presentation on First-in-Human Phase 1\/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Announces Annals of Neurology Publication Featuring Biomarker Data in ALS Patients Treated with Tregs Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"COYA 101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Inspirna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride Trihydrate","moa":"SLC6A8\/CKB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Genexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexa\u00ae Launches the First Ever Clean Acetaminophen Pain Relief Products for Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genexa","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genexa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genexa \/ N.."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tazarotene","moa":"RAR-alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Ortho Dermatologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Ortho Derm.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Seribantumab","moa":"ERBB3 protein expression","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Initiates Phase 3 Trial of Pitolisant in Adult Patients With Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ANB032","moa":"BTLA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Oncocyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of Determaio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncocyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Oncocyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncocyte \/.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30\/CD16A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"HER2\/HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AL101","moa":"Gamma secretase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PC14586","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CLN-081","moa":"Irreversible EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American So","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institutes Of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Data Analyses Showing Ibrexafungerp's Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR T Cell Product Candidate, for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-605","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma to Present New Analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GB-401","moa":"ADRB","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Sustained-Release Intravitreal Implant","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9250","moa":"Alk2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tremelimumab Accepted Under Priority Review in the US for Patients With Unresectable Liver Cancer in Combination With Imfinzi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tremelimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veklury\u00ae (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Shares Top-Line Results from Phase 2\/3 EPIC-PEP Study of PAXLOVID\u2122 for Post-Exposure Prophylactic Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biohaven\u2019s Vydura\u00ae (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Human dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Delivered up to 22.5% Weight Loss in Adults with Obesity or Overweight in SURMOUNT-1","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces its COVID-19 Vaccine Phase 2\/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advisory - Apotex Recalls Apo-Acyclovir Tablets Due to a Nitrosamine Impurity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aciclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fer.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u00ae (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"PRAX-222","moa":"SCN2A gene","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kapruvia\u00ae Approved by European Commission for the Treatment of Moderate-to-severe Pruritus in Hemodialysis Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Alzinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzinova Announces Positive Safety Review and Continuation of its Phase 1b study in Alzheimer's disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ALZ-101","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Recommendation of the Data and Safety Monitoring Board to Continue the Phase 2 Study Evaluating Masitinib in Combination With Isoquercetin in Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"Stem Cell growth factor receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Publishes Phase II MERECA Trial Results of Ilixadencel in Kidney Cancer in European Urology Open Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"Cytotoxic CD8 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"CT5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Three-Year Data for Genentech\u2019s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Valbiotis","sponsor":"INAF","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces the First Visit of the First Patient in the TOTUM\u202263 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestl\u00e9 Health Science","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Totum-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ INAF","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and SK bioscience's COVID Vaccine Submitted for S.Korea Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GBP510","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ralinepag","moa":"IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Berberine Ursodeoxycholate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Delpor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delpor Announces First Subjects Dosed in Phase 1 Clinical Trial of Once or Twice-Yearly Naltrexone Implant for Opioid Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delpor","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delpor \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma Patients Selected for Poster Discussion at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"GM-CSF","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Highlights Rubraca\u00ae (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-401","moa":"PKP2 gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Mycovia Pharmaceuticals\u2019 VIVJOA\u2122 (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"14 alpha demethylase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b \u201cFORTRESS\u201d Clinical Trial for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV\u2019s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Chimera Bioengineering","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimera Appoints New CEO, Wins AFCR BRACE Award, and Accelerates towards the Clinic with TME-Modifying CAR-T Therapies for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"CBIO-007","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Chimera Bioengineering","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chimera Bioengineering \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chimera Bi.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Presentation of KSI-301 Phase 2b\/3 Study Data in wet AMD at Upcoming Research Conferences","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Alpha-Lactalbumin Vaccine","moa":"Mullerian hormone receptor II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M1\/M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"PLA2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Reports Interim Results from the Open-Label part of the ARMOR study with Aramchol Showing Robust Fibrosis Improvement Across Multimodality Histological Assessment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lytix Biopharma to Present at the American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoural Injection","sponsorNew":"Lytix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biop.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Blosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transcenta Holding \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Nodular Injection","sponsorNew":"180 Life Sciences \/ University of Oxford","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces European Commission Approval for ORGOVYX\u00ae (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA A receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Preclinical Data on the AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy for Solid Tumors at the 2022 Keystone Symposia: Emerging Cellular Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphiphile-peptide Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OCU410","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO (testosterone undecanoate)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"UCART123","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Humanized anti-CD117 Monoclonal Antibody","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OPGx-002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Opus Genetics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Nevakar","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nevakar","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Prefilled Injection","sponsorNew":"Nevakar \/ Par Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1\/2 TRIDENT-1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor Presents Full Data From Positive Phase I Clinical Trial of AT278 Ultra-concentrated Ultra-rapid Acting Insulin for Diabetes at ATTD Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ultra-Concentrated Rapid Acting Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-930","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Receives FDA's IND Clearance for OX40 Antagonist","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"IMG-007","moa":"OX40","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Presents Positive Data From Lantern Phase 2 Study Of LYR-210 For Treatment Of Chronic Rhinosinusitis At COSM 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Sustained Topical Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"EQRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EQRx \/ Not.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-312","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Results From Two Open Label Extension Studies of Repatha\u00ae (Evolocumab)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in The US for Adults with Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Granted Breakthrough Therapy Designation in The US for Patients with HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Camzyos\u2122 (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Several New Studies Presented at ECCMID 2022 Confirm Veklury\u00ae (Remdesivir) Activity in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Decient Mismatch Repair (dMMR) Tumors in Five Dierent Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS \u22651)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-weekly Insulin Icodec Demonstrates Superior Reduction in HBA1c Vs Insulin Degludec in People With Type 2 Diabetes in Onwards 2 Phase 3A Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Three-year Data for Roche\u2019s Evrysdi (Risdiplam) Show Long-term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-715","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Immune Therapeutics","pharmaFlowCategory":"D","amount":"$402.0 million","upfrontCash":"$2.0 million","newsHeadline":"Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Naltrexone Hydrochloride","moa":"TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Statera Biopharma","amount2":0.40000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Capsule","sponsorNew":"Statera Biopharma \/ Immune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Statera Bi.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Series A Financing","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced Atthe-Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$300.0 million","newsHeadline":"Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"DF7001","moa":"5T4 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Virica Biotech","sponsor":"Innovation, Science and Economic Development Canada","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Virica Biotech Announces Collaboration with the Government of Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Re-engineered AAV-LPL","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Virica Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virica Biotech \/ Innovation, Science and Economic Development Canada","highestDevelopmentStatusID":"1","companyTruncated":"Virica Bio.."},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Gabapentin","moa":"CaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Nevakar","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"8","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Allinaire Therapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Acquires Pioneering Therapeutic Monoclonal Antibodies Portfolio Against EMAP II as Potential Treatment For PAH","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Anti-EMAP II Monoclonal Antibody","moa":"EMAP-II","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Allinaire Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allinaire Therapeutics \/ Chiesi Farmaceutici","highestDevelopmentStatusID":"4","companyTruncated":"Allinaire .."},{"orgOrder":0,"company":"Intravacc","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Signs an Exclusive License Agreement with Zhifei Lvzhu Biopharmaceutical to Commercialize Avacc 3 - an OMV Based Whooping Cough Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Avacc-3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Intravacc \/ Beijing Zhifei Lvzhu Biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"HTX-001","moa":"IncRNA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HAYA Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Thera.."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"SARS-CoV2 protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Storm Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"3","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"Empirico","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Antibody-based Therapy","moa":"GPCR","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Empirico","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Empirico \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Empirico \/.."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$15.0 million","newsHeadline":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"NKT2152","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NiKang Therapeutics","amount2":0.22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.22,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"7","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Benchmark Company","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Belite Bio Announces Closing of $36 Million Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"BIOKEY","sponsor":"NeuCen BioMed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"CEN501","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"BIOKEY","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Strip","sponsorNew":"BIOKEY \/ NeuCen BioMed","highestDevelopmentStatusID":"8","companyTruncated":"BIOKEY \/ N.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Juniper Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Juniper Biologics Signs Exclusive License Agreement with Helsinn for Infigratinib (INN) For the Emerging Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Juniper Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate's Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"1","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rezolute, Inc. Announces Closing of Registered Direct Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Morgan Stanley & Co.","pharmaFlowCategory":"D","amount":"$260.0 million","upfrontCash":"$100.0 million","newsHeadline":"Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0.26000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Morgan Stanley & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Rubio Laboratories","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo Acquires Bandol Sildenafil Spray, Currently Marketed In Spain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Rubio Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Rubio Laboratories \/ Aspargo Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Rubio Labo.."},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"TYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Betta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Betta Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Betta Phar.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scribe Therapeutics Expands Collaboration With Biogen to Second Target","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"CRISPR-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Biogen Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Tikomed","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TIKOMED and IQVIA Announce a Strategic Collaboration for The Development of TIKOMED's Lead Drug Platform Candidate ILB","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"ILB","moa":"TGF beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma and Cannvalate Enter Into Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.8 million","newsHeadline":"Orion Enters Into Exclusive Agreement with Jemincare for Novel Non-Opioid Drug Candidate for The Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Orion","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"AUM001","moa":"MNK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$405.0 million","newsHeadline":"Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $405MM Upfront and an Additional $45MM in Contingent Payments","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO (tedizolid phosphate) in the U.S. Through the End of 2026","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Tedizolid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"InfectoPharm Drugs and Consilium \/ Societal","highestDevelopmentStatusID":"12","companyTruncated":"InfectoPha.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Atezolizumab","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Engimmune Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"D","amount":"$16.7 million","upfrontCash":"Undisclosed","newsHeadline":"Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-cell Receptor Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"T-cell Receptor Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Engimmune Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Extended-release Capsule","sponsorNew":"Engimmune Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"2","companyTruncated":"Engimmune .."},{"orgOrder":0,"company":"Illumina","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina and Deerfield Management Partner to Accelerate Drug Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"Illumina \/ Deerfield Management","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$6,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Engineered IgM Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1500000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HempStreet Announces Partnership with MGC Pharma to Revolutionise Global Phytomedicine Sector","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Hempstreet \/ MGC Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CANbridge Pharmaceuticals Enters into Rare Disease Gene Therapy Research Agreement with UMass Medical School","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"AAV9-mediated Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kennedy Krieger Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Kennedy Krieger Institute","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,352.0 million","upfrontCash":"$18.4 million","newsHeadline":"Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRP\u00b1 Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"OSE-172","moa":"SIRP alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":1.3500000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3500000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Tubulis","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Andera Partners Supports Tubulis in a \u20ac60 Million Series B Financing to Accelerate the Development of its ADCs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series B Financing","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tubulis \/ Andera Partners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK Tech","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"Polpharma","sponsor":"MS Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioeq, the Polpharma Biologics Group Joint Venture Company and MS Pharma Sign Exclusive Agreement for Ranibizumab in MENA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"$25.0 million","newsHeadline":"Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"LaNova Medicines","amount2":0.22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Turning Point Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"LaNova Med.."},{"orgOrder":0,"company":"Asceneuron","sponsor":"The Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson's Disease Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"ASN51","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asceneuron \/ The Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces Update on Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Private Placement","leadProduct":"DispersinB","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Marc Edwards","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Financing","leadProduct":"HTX-001","moa":"IncRNA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"HAYA Therapeutics","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"HAYA Therapeutics \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"HAYA Thera.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Public Offering","leadProduct":"Immune Globulin (Human)","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Dosage Strength\/Form","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Public Offering","leadProduct":"Immune Globulin (Human)","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"ADMA Biologics \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Octavius Pharma Pvt. Ltd","sponsor":"Senta Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crampsal Cream (Pain Relief Cream) \u2013 Launched in Sudan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Menthol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Octavius Pharma Pvt. Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Octavius Pharma Pvt. Ltd \/ Senta Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Octavius P.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA\u00ae (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KPI-012","moa":"Protease","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S to Present New Endocrinology Results at Four Medical Meetings in May","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces FD Approval of Cuvrior\u2122 for the Treatment of Adult Patients With Stable Wilson\u2019s Disease Who Are De-coppered and Tolerant to Penicillamine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA A receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID\u00ae (pimavanserin) for the Treatment of Alzheimer\u2019s Disease Psychosis Scheduled for June 17, 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"Selective serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGENE-PH1","moa":"HO-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"STK-002","moa":"Optic atrophy 1 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CERo Therapeutics\u2019 Multifunctional CER T Cells Synergize with Standard-of-Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CER T-cell Therapy","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CERo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CERo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CERo Thera.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-179","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Engineered AAV Capsids","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"26S proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gordon Robert Alton, PhD Joins BriOri BioTech as COO to Develop Patented Topical Formulation of Vioxx\u00ae Providing Those Suffering with Osteoarthritis a Long Lasting Non-Opioid Option for Pain Relief","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriOri Bio.."},{"orgOrder":0,"company":"Ingenia Therapeutics","sponsor":"Mosaic Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ingenia Therapeutics & Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IGT-427","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ingenia Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ingenia Therapeutics \/ Mosaic Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Ingenia Th.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Biorasi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell\u2122 Universal Donor Stem Cell Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Pro-inflammatory protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax to Highlight Preclinical Data from COVID-19 MAPS\u2122 Vaccine Development Program at IMMUNOLOGY 2022\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"24-Valent Pneumococcal Vaccine","moa":"B-Cell antibody","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, Targeting Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen\u2019s Verkazia\u00ae (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s CEO to Present Namodenoson\u2019s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Namodenoson","moa":"A3AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin\u00ae in Combination with the PARP-inhibitor Olaparib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-NNV003","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Locanabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Locanabio to Present New Preclinical Data Demonstrating Application of CORRECTx\u2122 Platform for Treating Amyotrophic Lateral Sclerosis at American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Hexanucleotide","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Locanabio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Locanabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Locanabio .."},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orna Therapeutics to Present Novel, First-in-Class Circular RNA Data at Upcoming ASGCT 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ORN-101","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orna Thera.."},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedere Bio II to Present Two Abstracts at the ASGCT 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"Vedere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio.."},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alcyone Announces Two Oral Presentations on its Gene Therapy Platforms at the 25th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV9-IGHMBP2 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Alcyone Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alcyone Th.."},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XNK Therapeutics Gets Abstract on ACP-001 Selected for Presentation at EHA2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ACP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XNK Therap.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Patent Application Filed for Cervical Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BVX-0918C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ Procare Health","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ALTA-2530","moa":"IL-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"5-HT1A\/2A\/2B\/7 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curium\u2019s Phase 3 ECLIPSE Trial Starts Enrolling Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PSMA-I&T","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US .."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MAU868","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex, Texas Children\u2019s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed\/Refractory High Risk Neuroblastoma at the ASG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-200-A02","moa":"MHC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"miRNA-based AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Codexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVrh10-Based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Magna Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"mbIL-15 TCR-T Cell Therapy","moa":"KRAS\/P53\/EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SEL-302","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"NY-ESO-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Century Therapeutics to Present at the ASGCT 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CNTY-102","moa":"CD19\/CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Century Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-VV100","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DSG3-CAART","moa":"DSG3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-0231.F","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuBase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Th.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Luxeptinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled-release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio to Present Data from Gene Circuit-Engineered Allogeneic CAR-NK Cell Therapy Pipeline at Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous anti-VEGF wet AMD and DME Candidate at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"D-4517.2","moa":"VEGFR\/PDGFR tyrosine kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD\u2122 IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-9199","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1\/2 trial for the Treatment of Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"T-cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DNL788","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SZN-413","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-311","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1\/2 ABILITY Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA11","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces Presentations at ARVO 2022 Annual Meeting and ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia\u2019s Precision Genome Engineering Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-6001","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel\u2122 in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox at ARVO 2022: Presentation of Clinical Phase 2 results on NCX 4251 And New Non-clinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comp360 Psilocybin Therapy Shows Potential in Exploratory Open-label Studies for Anorexia Nervosa And Severe Treatment-resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Provides Additional Information Regarding the New Drug Application for mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Suspension for Injection","sponsorNew":"MedinCell \/ TEVA","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Cellics Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellics Therapeutics Receives First IND Allowance by FDA for Its Innovative Cellular Nanoparticle (CNP) Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cellics Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellics Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellics Th.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dazodalibep","moa":"CD40","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform From Its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RG6501 (OpRegen\u00ae) Phase 1\/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Retinal Pigment Epithelial Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis\u2019 Partner Ipsen Receives European Commission Approval for CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Ex.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Publishes Results from a Phase 1\/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Azacytidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"DepYmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"PTP1B","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DepYmed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ .."},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"A166","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Levena Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Levena Bio.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"L-Type VGCC","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-107","moa":"IL-2RG","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR T-cell Therapy","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The US Food and Drug Administration (FDA) Accepts a New Supplemental Marketing Authorization Application for the Additional Indication for Darolutamide and Grants It Expedited Processing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VB-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver\u00e2\u20ac\u2122s International","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid 2 protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KCNQ potassium channel","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hAPOE2","moa":"Apolipoprotein E 2\/3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer\u00e2\u20ac\u2122s Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha 2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Lumbar Intrathecal Infusion","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akouos to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Receives FDA Fast Track Designation For LBS-008","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based HER2 Antibody","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Seeks DCGI Nod for Phase 2\/3 Covaxin Booster Trial Among Two to 18-year-old","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gland Pharma Launches Generic Cancer Treatment Drug in US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"26S proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHAR.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII Lowers Price of Each Dose of Covovax Jab From Rs 900 to Rs 225","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Receives Final USFDA Approval for Cold Sore Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Docosanol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Garvan Institute of Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microba Accelerates Cancer Program With New Leads","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Microba Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Microba Life Sciences \/ Garvan Institute of Medical Research","highestDevelopmentStatusID":"2","companyTruncated":"Microba Li.."},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio Co., Ltd. Announces the Successful Completion of Their End of Phase 2 Meeting With the USFDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"PDE5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ N.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphera\u2019s MesoPher Cell Therapy Demonstrates Favourable Safety and Promising Survival in a Phase II Clinical Trial in Resected Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MesoPher Dendritic Cell Therapy","moa":"Mature dendritic cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amphera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Amphera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amphera \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Protein COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase II Renal Cancer Theranostics Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-Girentuximab","moa":"CA IX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BPL Receives Orphan Drug Marketing Authorization for Coagadex\u00ae in Mexico","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Coagulation Factor X (Human)","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bio Products Laboratory","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Products Laboratory \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bio Produc.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T\u03b24 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GT90001","moa":"Angiogenesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"ILYA Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clearance of IND for First-in-class ILP100-topical Immunotherapy Treatment of Surgical Wounds in Patients With Prediabetes, Diabetes and Obesity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Emilimogene Sigulactibac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILYA Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"ILYA Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILYA Pharm.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"SOLTI-Innovative Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ SOLTI-Innovative Cancer Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Presentation of NurOwn\u00ae Exosome Preclinical Data at ISCT 2022 San Francisco Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MSC-NTF Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Announces Publication in PNAS: Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OPGx-001","moa":"LCA5 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Opus Genetics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Heterologous Booster Trial of Inactivated, COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zelenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-VV100","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Presents New and Significant Data from the AIPAC Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive 18-Month Data from Ongoing Phase 1\/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Progresses to Higher Dosing Cohort in Temferon Phase 1\/2a Clinical Trial in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Temferon","moa":"INF alpha 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Receives Fast Track Designation for HM43239 in Relapsed\/Refractory AML Patients and FLT3 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tuspetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Novartis Data Demonstrate Only Kisqali\u00ae Offers More Life in the First-line Setting for Postmenopausal Hr+\/her2- Advanced Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults With Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in the US for Patients With HER2-positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces European Commission Approval of Jakavi\u00ae (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART\u00ae (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Peripheral chemosensory neuron","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"Dll4-Notch1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elpiscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aulos Bioscience Initiates Phase 1\/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Bi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces CYB003 Poster to be Presented at the \u2018From Research to Reality\u2019 Global Summit on Psychedelic-Assisted Therapies and Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Medicago","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Adjuvanted Plant-based Virus-like Particle","moa":"SARS?CoV?2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Met Primary Endpoint in DELIVER Phase III trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients With Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GDA-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioarctic Receives New Drug Substance Patent in the US for ABBV-0805 Against Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ABBV-0805","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1\u2122 Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From Novel, Exploratory Analysis of Intermittent Valtoco\u00ae (Diazepam Nasal Spray) Civ Use Indicates More Than Two-fold Increase in Mean Interval Between Seizure Clusters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Aesthetics to Introduce New Clinical Study of Qwo\u00ae (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Abelacimab","moa":"Factor XI","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Expands Synthetic Lethality Portfolio With Nomination Of A Preclinical Candidate Targeting MAT2A For The Treatment Of MTAP-deleted Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hearing Loss Company Acousia Therapeutics: First Patient With Age-related Hearing Loss Treated With ACOU085","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ACOU085","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acousia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Th.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNBX Pharmaceuticals Granted Patent in Hong Kong","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Announces Pre-clinical and Clinical Results of Sunvozertinib (DZD9008) Published in Cancer Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Ther.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Newsoara","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"KIRS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Presented Interim Results of LBS-008 Phase 1b\/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed to Supply Rare Cannabinoids to Radicle Science's Radicle Energy Study to Assess the Health Effects of THCV","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabivarin","moa":"CBR","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"12","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AT-007","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Nanoemulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OPT-302","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ .."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Opens Enrollment for Patients in Their COVID Therapy Phase 2 Clinical Trial in Nepal and Engages With Strategic Investor for Worldwide Distribution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK Tech","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altavant Sciences Presents Data Showing Potential For Combination Of Rodatristat Ethyl And Ambrisentan In Model Of Pulmonary Arterial Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rodatristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Alvelestat","moa":"Leucocyte elastase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Provides Update on ASCO AFM13-104 Oral Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Adoptive NK-cell Therapy","moa":"CD30\/CD16A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Merit Seen in Including Paxlovid in Covid Treatment: ICMR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"SARS-CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ ICMR","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kymriah\u00ae Receives EC Approval as First Car-t Cell Therapy for Adults With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives European Commission Approval for Jakavi\u00ae to Be the First Post-steroid Treatment for Acute and Chronic Graft-versus-host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on Production of Radioligand Therapy Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium Lu 177 dotatate","moa":"SSRT2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE\u00ae (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[\u00ae]\u25bc(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Provides Updates on Phase 1\/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV9-Based Gene Therapy","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"ChemR23","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Hetero Drugs","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer's \"Game-Changing\" COVID-19 pill, Paxlovid, Gets India\u2019s DCGI Nod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Pfizer Inc \/ Hetero labs","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anifrolumab Showed Early and Sustained Treatment Benefit for Patients With Systemic Lupus Erythematosus in the TULIP Clinical Trial Programme And Planing to Conduct Phase III Study for Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Cugene","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$48.5 million","newsHeadline":"AbbVie and Cugene Announce Collaboration in Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"CUG252","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cugene","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cugene \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Cugene \/ A.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Juvise Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less than One Month","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Anastrozole","moa":"Aromatase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AiPing Pharmaceutical Inc","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ECI Pharmaceuticals LLC Enters into Exclusive U.S. Distribution Agreement for Ibuprofen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Agreement","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AiPing Pharmaceutical Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AiPing Pha.."},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"PENAO","moa":"AdNT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene P.."},{"orgOrder":0,"company":"Curia","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by Curia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curia \/ BryoLogyx","highestDevelopmentStatusID":"5","companyTruncated":"Curia \/ Br.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upadacitinib (RINVOQ) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa\/Foslevodopa) for the Treatment of Advanced Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase-C","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Fermenta Biotech Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fermenta Biotech Licenses Its Proprietary Enzymatic Technology for Manufacturing Molnupiravir to Aurigene Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurigene Pharmaceutical Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ Fermenta Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Aurigene P.."},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GARDP, Dr. Reddy\u2019s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access Through Collaborative Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurigene Pharmaceutical Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Aurigene P.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GARDP, Dr. Reddy\u2019s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access Through Collaborative Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"InxMed","sponsor":"Hyfinity Investments","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series B Financing","leadProduct":"Cobimetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"InxMed \/ Hyfinity Investments","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ H.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Comera Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"BioGenCell","sponsor":"Marius Nacht","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioGenCell, Developer of A Unique Platform for Treating Microvascular Disease, Has Completed a $16 Million Seed Round Led by Private Investor Marius Nacht","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"BGC101","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"BioGenCell \/ Marius Nacht","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell.."},{"orgOrder":0,"company":"Arvinas","sponsor":"GNS Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Arvinas \/ GNS Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Granisetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cumberland Pharmaceuticals \/ Verity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"OPKO Health","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OPKO Health","amount2":0.29999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Inhalation","sponsorNew":"OPKO Health \/ OPKO","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aadi Bioscience \/ Foundation Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Accord healthcare","pharmaFlowCategory":"D","amount":"$140.5 million","upfrontCash":"$50.0 million","newsHeadline":"Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX\u00ae for Advanced Hormone-Sensitive Prostate Cancer in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Inhalation","sponsorNew":"Myovant Sciences \/ Accord Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB331","moa":"Matriptase-2","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Rallybio Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Lophora","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines With Research Collaboration and Strengthening of Relationship With Lophora ApS","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"LPH-5","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lophora","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lophora \/ Beckley Psytech Limited","highestDevelopmentStatusID":"4","companyTruncated":"Lophora \/ .."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Panacea Venture","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Therapeutics Raises $42m Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"DT-9081","moa":"EP4R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Inhalation","sponsorNew":"Domain Therapeutics \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"Panag Pharma","sponsor":"True North Cannabis Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Panag Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Panag Pharma \/ True North Cannabis Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Panag Phar.."},{"orgOrder":0,"company":"Genascence","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Genascence \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Genascence.."},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"T1D Antigen-specific Nanoparticle","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Clearmind Medicine \/ SciSparc Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Neuramedy","sponsor":"Bioasis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis and Neuramedy Enter into Research Collaboration and License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Tomaralimab","moa":"TLR2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuramedy","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neuramedy \/ Bioasis","highestDevelopmentStatusID":"4","companyTruncated":"Neuramedy .."},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"Protein-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nuvig Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Inhalation","sponsorNew":"Nuvig Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Nuvig Ther.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biopas Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA\u00ae in Latin America","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"MAO","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Biopas Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Zhaoke Ophthalmology","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"$15.0 million","newsHeadline":"Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL\u2122 PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Carbachol","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Inhalation","sponsorNew":"Visus Therapeutics \/ Zhaoke Ophthalmology","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Sound Pharmaceuticals' NIH Grant For a Novel Oral COVID-19 Treatment Increases to $4.2M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Ebselen","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sound Pharmaceuticals \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$40.6 million","upfrontCash":"Undisclosed","newsHeadline":"Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Inhalation","sponsorNew":"Belite Bio \/ The Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Emerald Health Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Skye Bioscience \/ Emerald","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Expanded License Agreement with St. Jude Children's Research Hospital for Novel Bacterial Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"BWV-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Blue Water Vaccines \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"5","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) Through Partnership with Pharmacy Services Provider","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Lay Sciences","sponsor":"Statera Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Avian Antibody","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lay Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lay Sciences \/ Statera Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Lay Scienc.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Monrol","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monrol is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix\u2019s Phase III ZIRCON Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"177Lu-DOTA-girentuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Telix Pharmaceuticals \/ Monrol","highestDevelopmentStatusID":"8","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"King\u2019s College London","sponsor":"Compass Pathways","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"COMPASS Pathways To Fund Study of COMP360 Psilocybin in Autistic Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"King\u2019s College London","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"King\u2019s College London \/ COMPASS Pathways","highestDevelopmentStatusID":"4","companyTruncated":"King\u2019s Col.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"AnGes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy\u00ae (lonafarnib) in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Eiger BioPharmaceuticals \/ AnGes","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Selah Therapeutics","sponsor":"Juvenescence","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Juvenescence and the Buck Institute for Research on Aging launch Selah Therapeutics, Targeting Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Ketone-based Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Selah Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Selah Therapeutics \/ Juvenescence","highestDevelopmentStatusID":"1","companyTruncated":"Selah Ther.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"$405.0 million","upfrontCash":"$275.0 million","newsHeadline":"Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081\/TAS6417 and Taiho\u2019s Acquisition of Cullinan Pearl","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Inhalation","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Baili Pharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 Bispecific Antibody, in Combination with Tagrisso\u00ae in Patients with Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Osimertinib Mesylate","moa":"EGFR \/ HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Baili Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Baili Pharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Baili Phar.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Termination","leadProduct":"Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Bavarian Nordic","highestDevelopmentStatusID":"4","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Flagship Pioneering Announce a Strategic Collaboration to Create a Portfolio of Transformational Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Flagship Pioneering \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Flagship P.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,895.0 million","upfrontCash":"$198.0 million","newsHeadline":"Announcement of Termination of Global License Agreements for Renal Anemia Treatment with Akebia Therapeutics, Inc.","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":1.8999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka","highestDevelopmentStatusID":"10","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Nortec Quimica","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nortec Qu\u00edmica Receives License From The Medicines Patent Pool (MPP) to Produce API Nirmatrelvir for Innovative Oral Treatment Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nortec Quimica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nortec Quimica \/ The Medicines Patent Pool","highestDevelopmentStatusID":"9","companyTruncated":"Nortec Qui.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Nirsevimab Data Analyses Reinforce Efficacy Against RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bit.bio Launches Huntington\u2019s Disease Human Cell Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Positive Interim Results From Its Phase 2 trial with VB10.16 in Combination With Immune Checkpoint Inhibitor Atezolizumab in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation of Positive Results From the ACTIMIS Phase 1b\/2a Study in Stroke at ESOC 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell\u2122 Universal Donor Adult Stem Cells","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elpiscience Announces FDA IND Clearance of ES014, a First-in-Class Anti-CD39xTGF-\u03b2 Bispecific Antibody for Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ES014","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elpiscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week\u00ae 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase-C","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Ambys Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambys Medicines to Present New Data on Liver Cell Replacement Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AMI-918","moa":"Hepatocyte Cell","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ambys Medicines","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ambys Medicines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ambys Medi.."},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medi.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BAT7104","moa":"PD-1\/PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theramex Launches Non-hormonal Femarelle\u00ae on the 12th of May","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Flaxeed","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Announces Selection Of Trispecific Antibody Isb 2001 As Next Clinical Candidate For Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ISB 2001","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab\/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Nanovo","sponsor":"BGN Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Mental Care Develops Treatment for Post-Traumatic Stress Disorder Based on Psychedelic Drugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Nanovo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Nanovo \/ BGN Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Nanovo \/ B.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Enara Bio","sponsor":"Monash University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"MR1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Enara Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enara Bio \/ Monash University","highestDevelopmentStatusID":"2","companyTruncated":"Enara Bio .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CLINUVEL Progresses Vitiligo Treatment Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Clinuvel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinuvel P.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2a Study Results in Binge Eating Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ACT-539313","moa":"OX1R","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PRAX-944","moa":"T type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics to Present New Data for JATENZO\u00ae (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Announces Successful Toxicology Data Published in \"Toxicologic Pathology\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"LianBio","sponsor":"MyoKardia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"LianBio \/ MyoKardia","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte to Provide Human Acellular Vessels\u2122 (HAVs\u2122) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"Vascular Cell","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imago BioSciences \/ University of Washington School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer\u00e2\u20ac\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics Proprietary Exosome Engineering Platform with New Data on Exosome Targeting and In Vivo Distribution","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody-loaded Exosomes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I\/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ATL001","moa":"T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Editing Oligonucleotides","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Announcement on Early Termination of GV-971 Global Multi-Center Phase III Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oligomannate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Green Valley Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Green Vall.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TriSalus Life Sciences \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announces Multiple Scientific Abstracts to Be Highlighted at American Association of Clinical Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Neogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-125","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead\u2122 Programs at the TIDES USA 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"STP122G","moa":"Factor XI expression","url1":"","url2":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac AB Announces Database Lock in Its Phase IIb Trial of Onilcamotide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shoreline Biosciences To Present Two Posters On Ink Cell Platform At 19th Meeting Of The Society For Natural Immunity (NK2022)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"iPSC-NK Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shoreline Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shoreline Biosciences \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Shoreline .."},{"orgOrder":0,"company":"Arcellx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ACLX-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcellx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics to Announce Updated Data from its Phase 1 Study of BBT-176 in Advanced Non-Small Cell Lung Cancer in an Oral Presentation at IASLC 2022 World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BBT-176","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CT041","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Talazoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Iodide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Faraday Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Faraday Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Faraday Ph.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1\/2a Clinical Trial for EVX-02","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EVX-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA401","moa":"MAGEA4\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Lilly and Incyte's OLUMIANT\u00ae (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"Lysosomal alpha-glucosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ABX1100","moa":"CD71 centyrin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel\u2122 to the FDA in Second Half of 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ALEXIS-PRO-1","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Neumifil","moa":"Sialic acid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pneumagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CB03","moa":"KCNQ2\/3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Zhimeng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acousia Therapeutics to Present Its First-in-class Hearing Loss Treatment Program With ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ACOU085","moa":"KCNQ potassium channel","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acousia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Th.."},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"On Target Laboratories, Inc. Announces Presentation of the Results from the ELUCIDATE Phase 3 Trial for CYTALUX\u2122 (pafolacianine) injection for Intraoperative Molecular Imaging of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pafolacianine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"On Target Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"On Target .."},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuvivo Begins Manufacturing of NP001 for Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NP001","moa":"Macrophage","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ .."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RGLS8429","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spine BioPharma Initiating U.S. Phase 3 Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SB-01","moa":"TGF beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Spine BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intradiscal injection","sponsorNew":"Spine BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spine BioP.."},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1\/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myeloid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Th.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astex Announces that the Phase 3 ASCERTAIN - Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial\u2019s Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Announces Full Results From the Logics Study of Recorlev\u00ae and Presentation of New Burden of Illness in Cushing\u2019s Syndrome Data at AACE Annual Meeting May 12-14","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Cytonus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytonus Therapeutics to Present Cargocyte\u2122 Drug-Delivery Data at the ASGCT 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CA-IL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytonus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytonus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytonus Th.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akston Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys to Present New Data on Pelabresib and Monjuvi\u00ae (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio to Present New Clinical Data on Orca-T at the European Hematology Association 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Orca-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"KIR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell\u2122 for Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Addition of Multiple XPOVIO\u00ae Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches First Generic Pirfenidone in US for Patients With Idiopathic Pulmonary Fibrosis, Growing Its Respiratory Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"CYP1A2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces XPOVIO\u00ae (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"PLA2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AUTO4","moa":"TRBC1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130\u00e2\u201e\u00a2 for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX130","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children\u2019s Hospital Medical Center (CCHMC) Using CURE\u2019s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Tran","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vitamin D3","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Cure Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Cure Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cure Pharm.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1\/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data at ASCO and EHA Showcase Latest Oncology Research and Innovation, Including in Breast and Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT D816V","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Entospletinib","moa":"Syk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN\u00c2\u00ae Use for IOP Outcomes","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RNA-Based Medicine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shape Ther.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"AIM Biologicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Autoimmunity Modifying Biologicals","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeterna Zentaris \/ AIM Biologicals","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Initiation of Phase 1\/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM438","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"Th1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OTO-825","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Immunotherapeutics Starts Phase 2 trial of The Nanobody\u00ae Sonelokimab in Patients with Moderate-to-Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SP-3164","moa":"Cereblon","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV) Therapeutics at TIDES USA 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GT-02329","moa":"GCase level","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Kt-3000","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS\u00ae (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms\u2019 Tumor 1 (WT1) - expressing cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-102","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Announces Presentations at Digestive Disease Week\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Blue Knight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENA Respiratory Selected for BLUE KNIGHT\u2122 to Accelerate Development of Pan-Antiviral Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"INNA-051","moa":"TLR2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ENA Respiratory \/ Blue Knight","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bezafibrate","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha\/beta tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn To Present Data at Upcoming AMMF's 2022 European Cholangiocarcinoma Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Announces US Patent Grant for CA4P and OXI4503 Combination With Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"Tubulin polymerisation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Lilly's Mounjaro\u2122 (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences\u00ae Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Hmaxi-K","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III LINC 3 Study Demonstrates That ISTURISA\u00ae (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA Alkylation","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Announces New Data from the Phase I\/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Golidocitnib","moa":"JAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces XPOVIO\u00ae (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycostem Announces New Data Presentation at EHA 2022 Congress Highlighting Early Safety and Clinical Course of oNKord\u00ae in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Ex-vivo Generated NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"Lanier Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lanier Biotherapeutics to Present Seminal LNR125 Publication at American Thoracic Society Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"LNR125","moa":"IL-25","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lanier Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lanier Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lanier Bio.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Launches Drug for Treating Bad Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Launches Antibody Drug for Breast Cancer in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus to Launch OxemiaTM (Desidustat) a Breakthrough Treatment for Anemia in Patients Suffering From Chronic Kidney Disease (CKD)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Desidustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal\u2122) and announces Leadership Changes to support Commercialisation","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne .."},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lu-177-PSMA-I&T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CURIUM US LLC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CURIUM US .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer\u2019s Disease Under the Accelerated Approval Pathway","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-initiated Clinical Trial of Ultrahigh-dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylcobalamin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"[Ad Hoc Announcement Pursuant to Art. 53 LR] Roche Reports Interim Results for Phase III SKYSCRAPER-01 Study in Pd-L1-high Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on U.S. FDA Review of Biologics License Application (BLA) for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Selects Kindeva Drug Delivery as Development Partner for Diclofenac pMDI Commercialization","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX1\/COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virpax Pharmaceuticals \/ Kindeva","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives USFDA Approval to Market Generic Pregabalin Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Suzhou Porton Biologics","sponsor":"Guizhou Sinorda Biomedicine Co. Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biopharma and Proton Bio Announce Strategic Cooperation to Accelerate the Development of Solid Tumor Cell Therapy Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Partnership","leadProduct":"SND002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Suzhou Porton Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Porton Biologics \/ Guizhou Sinorda Biomedicine Co. Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Por.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics Group Announces that Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) For Biosimilar Ranibizumab to The U.S. Food and Drug Administration (FDA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxilio Signs a Significant Service Contract with Quotient Sciences to Support the Formulation Development of NXP-001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Evonik","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evonik \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Evonik \/ B.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Reinforces Presence in Poland with The Acquisition of Glenmark\u2019s CNS Product Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Lamotrigine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Acquires Market-Leading Buccolam\u00ae For Emergency Treatment of Epileptic Children","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Takeda Pharmaceutical \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Panaxia","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Enters the Advanced Medical Cannabis Market in Germany with A Collaboration with Panaxia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabis-based Product","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Panaxia","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panaxia \/ Neuraxpharm Group","highestDevelopmentStatusID":"1","companyTruncated":"Panaxia \/ .."},{"orgOrder":0,"company":"Zambon Switzerland","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Newron and Zambon Sign Agreement for Potentially Pivotal Study with Safinamide in Parkinson\u2019s Disease Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zambon Switzerland","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zambon Switzerland \/ Newron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Zambon Swi.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"$15.0 million","newsHeadline":"Vectura Earns $11m Milestone as Hikma Receives US FDA Approval for Generic Advair Diskus\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Vectura Ltd","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Enterin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"How Creative Chemistry and Collaboration Synthesized a Better Drug Strategy For Enterin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"ENT-01","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer CentreOne","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer CentreOne \/ Enterin","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Cen.."},{"orgOrder":0,"company":"Almirall","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Expands Italian Product Portfolio with A Well-Established Brand From Almirall","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Almirall \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo Announces Successful DCP Closure for Icatibant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ A.."},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Laboratorium Ofichem B.V","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Entheon Biomedical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Ofichem Laboratorium","highestDevelopmentStatusID":"7","companyTruncated":"Entheon Bi.."},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraxpharm Launches First Product in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neuraxpharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oromucosal","sponsorNew":"Neuraxpharm \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Neuraxphar.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Acetaminophen Analog","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb\u00ae in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Ab-Biotics","sponsor":"Zambon Group SpA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19. A Probiotic Formula Reduces Symptom Duration and Viral Load, Increases Antibodies, and Improves Remission Rate Among Patients With Mild Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"KABP022","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ab-Biotics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ab-Biotics \/ Zambon","highestDevelopmentStatusID":"1","companyTruncated":"Ab-Biotics.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase 3 PROMIS-I Study of CMS I-neb\u00ae in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vectura Highlights Update Made by Hikma on Launch of Generic Advair Diskus\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Status Update on VR315 (US)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Vectura Ltd \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QVM149 Receives Regulatory Approval in Europe and Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Vectura Ltd \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Effik","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer CenterOne\u2019s Enviero\u00ae Receives First EU Authorization As Part of ESTIMA\u00ae (progesterone) Product Approval","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Progesterone","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pfizer CentreOne","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer CentreOne \/ Effik","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Cen.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Secures a Euro 50 Million Credit Facility From the European Investment Bank","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"Lanifibranor","moa":"PPAR alpha","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"SOM Biotech","sponsor":"University of Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOM Biotech Signs Licensing Agreement With the University of Minnesota","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SOM Biotech \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotec.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"KemPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$12.8 million","newsHeadline":"KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Arimoclomol","moa":"HSP","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ KemPharm","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Valneva","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Receives Notice of European Commission's Intent to Terminate COVID-19 Vaccine Purchase Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$225.0 million","newsHeadline":"Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA\u00ae (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.33000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$480.0 million","upfrontCash":"$100.0 million","newsHeadline":"Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Olorofim","moa":"Pyrimidine biosynthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0.47999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.47999999999999998,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Shionogi & Co.","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"AffyXell","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AffyXell Expands its Strategic Partnership With GenScript ProBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Genetically Modified Mesenchymal Stem Cells Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"AffyXell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AffyXell \/ GenScript ProBio","highestDevelopmentStatusID":"1","companyTruncated":"AffyXell \/.."},{"orgOrder":0,"company":"RQ Biotechnology Ltd","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LifeArc Co-Founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"SARS-CoV-2 Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RQ Biotechnology Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RQ Biotechnology Ltd \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"RQ Biotech.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Achieves Third Milestone in Its AI-enabled Drug Discovery Collaboration With AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Kallyope","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Kallyope","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kallyope \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"OK-101","moa":"ChemR23","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo\u00ae (cemiplimab) in KRAS-Driven Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Elicio Therapeutics \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Overnight Marketed Equity Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimble Therapeutics Announces Achievement of Development Milestones From Multiple Partnered Programs Connected to a Strategic Large Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble The.."},{"orgOrder":0,"company":"Osivax","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"OVX836","moa":"Nucleoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Private Placement","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Vivera Pharmaceuticals","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vivera Partners with NINDS of NIH to Identify Potential Stuttering Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"VVRA\u2013TM 008","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Vivera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivera Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Vivera Pha.."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"University of Pittsburgh","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"CAR-T Cell Therapy","moa":"mSA2 affinity-enhanced biotin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Th.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series B Financing","leadProduct":"SBT101","moa":"ALDP expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Th.."},{"orgOrder":0,"company":"LUCA Science","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science and Kyowa Kirin Announce Joint Research Agreement on Mitochondrial Disease Treatment With Novel Mitochondria Modality","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Mitochondrial-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"LUCA Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LUCA Science \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Scien.."},{"orgOrder":0,"company":"PostEra","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"PostEra Spearheads AI-Driven Drug Discovery Collaboration to Develop Antiviral Therapeutics with Initial $68M in NIH Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"PostEra","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Pill","sponsorNew":"PostEra \/ National Institutes of Health","highestDevelopmentStatusID":"3","companyTruncated":"PostEra \/ .."},{"orgOrder":0,"company":"Quantitative Biosciences Institute","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$67.5 million","upfrontCash":"Undisclosed","newsHeadline":"UCSF QBI and QCRG Awarded Initial $67.5 Million from NIAID\/NIH to Develop Novel Therapies Against Viruses with Pandemic Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Quantitative Biosciences Institute","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Quantitative Biosciences Institute \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"3","companyTruncated":"Quantitati.."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Artis Ventures","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Locus Biosciences Announces $35 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series B Financing","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Locus Biosciences \/ Artis Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Alberta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Sangivamycin Hydrochloride","moa":"Wnt\/Beta-Catenin signaling pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Inceptor Bio","sponsor":"Kineticos Ventures","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inceptor Bio Announces $37 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"M83-based CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inceptor Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inceptor Bio \/ Kineticos Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Inceptor B.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Proposed Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler & Co","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Acuitas","sponsor":"Myeloid Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"MT-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acuitas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Myeloid Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Acuitas \/ .."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"OK-101","moa":"ChemR23","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Instituto Butantan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ Instituto Butantan","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Medical College of Wisconsin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate's Adenosine Compounds as Potential Treatments for Diabetes and NASH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Adenosine Analog","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Medical College of Wisconsin","highestDevelopmentStatusID":"4","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Maryland Board of Public Works","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Maryland Board of Public Works","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"ABL Europe","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABL and Odimma Therapeutics Enter Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"ODI-2001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odimma Therapeutics \/ ABL Europe","highestDevelopmentStatusID":"4","companyTruncated":"Odimma The.."},{"orgOrder":0,"company":"PepGen","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PepGen Announces Pricing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon 51 skipping oligonucleotide","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ B.."},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Medtronic Completes Acquisition of Intersect ENT","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"NF-?B","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Intersect ENT","amount2":1.1000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Intersect ENT \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Intersect .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Live Modified Vaccinia Virus Ankara","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Athenex","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol Plus KEYTRUDA\u00ae (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"LNP-encapsulated mRNA Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol For Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Commercial Availability of XPOVIO\u00ae (Selinexor), for the Treatment of Relapsed\/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GQ1005","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarclisa\u00ae (Isatuximab) Combination Provides Unprecedented Median Progression Free Survival in Patients With Relapsed Multiple Myeloma Receiving a Proteasome Inhibitor Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio to Present 11 Abstracts at Upcoming American Society of Gene and Cell Therapy\u2019s 25th Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NAN-101","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura to Present at ASCO Encouraging Phase Ib Refractory Uveal Melanoma Data for First Semi-Allosteric PI3K\u03b4 inhibitor, IOA-244","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Roginolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC618","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ASC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therap.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV9-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO\u00ae, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine Models for Novel Gene Therapy in Maple Syrup Urine Disease at the 25th ASGCT Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ASC Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ASC Therapeutics \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"ASC Therap.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy\/Ventilation-free Survival and Reduced Occurrence of First Hospitalization","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"RootPath","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RootPath to Present at the Upcoming American Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"InfiniTIL","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RootPath","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RootPath \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RootPath \/.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"JAG101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Gene Therapy \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gen.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGENE-PH1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GPH102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Presents ZYNRELEF\u00ae Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-894","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Affinia Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affinia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"Caring Cross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caring Cross to Present Two Posters at the American Society of Gene & Cell Therapy Annual Meeting 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Anti-HIV DuoCAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Caring Cross","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caring Cross \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Caring Cro.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I\/II Bexmarilimab Combination Study in Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"STAB1 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OBI-999","moa":"Globo H","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ADP-TILIL7","moa":"Il-7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AGTC-501","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Presented at the American Heart Association's Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Acyl-CoA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"National Institutes on Drug Abuse","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KRM-II-81","moa":"GABA A receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ National Institutes on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC\u2122 Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CFT8634","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Codexis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CDX-6316","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-101","moa":"DMPK gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces FDA Acceptance of FUROSCIX New Drug Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VCAP-102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62 at the 24th European Congress of Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"LASN01","moa":"IL-11","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lassen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lassen The.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces New Findings Highlighting Potential of ProAir\u00ae Digihaler\u00ae (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada\u2019s AJOVY\u00ae (fremanezumab), for the Preventive Treatment of Migraine in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Preclinical Data Supports Clinical Advancement of First AAV-Based Gene Therapy for Adrenomyeloneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SBT101","moa":"ALDP expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Th.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma Presents Late Breaking Abstract from Phase I\/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MRx-4DP0004","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Reports Positive Data From Phase 1\/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"CTNS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SIM0417","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar\u00ae Gel (Repository Corticotropin Injection) Presented at the American Thoracic Society Annual International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Corticotropin","moa":"MC-2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix to Present at the Cell Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Model Medicines","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Model Medicines Announces AI-Discovered Oral Antiviral Therapeutic, MDL-001, Has Demonstrated Potential Best-In-Class Combination of Viral Load Reduction, Symptom Reduction, Activity Against SARS-CoV-2 Variants and Pan Antiviral Activity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MDL-001","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Model Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Model Medicines \/ Icahn School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Model Medi.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Pre-IND Meeting with US FDA for IHL-42X for Obstructive Sleep Apnoea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Capsida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAP-001","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Capsida","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Capsida \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Updates Business and Clinical Development Strategy to Better Leverage Aramchol's Anti-Fibrotic Effects","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aramchol","moa":"Acyl-CoA desaturase 1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air Presents Positive Study Update from the At-Home LungFit GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PDL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lee Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lee Pharma \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Lee Pharma.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Abivertinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovative Cellular Therapeutics (ICT) to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GCC19CART","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative.."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EBT-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell \"Off-the-Shelf\" Induced Pluripotent Stem Cell Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DeltEx DRI Chlorotoxin CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"engEx-AAV","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"LNP-based mRNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Biotech Acquisition Company","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Biotech Acquisition Company","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Undertaking PRP Manufacturing & Development for Human Use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Regencell Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RGCA-CV01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Regencell Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Regencell Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regencell .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"QLS-101","moa":"Potassium channel","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio.."},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Successful Completion of Phase I Study for Lead Asset EP395","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EP395","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Ph.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-03","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1\/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"XC001","moa":"VEGF gene producer","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Clinical Update on AAVance Phase 2\/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Cytovation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Cytovation's IND Application For Phase II Combination Studies of CyPep-1, a First-In-Class Targeted Tumor Membrane Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Capsida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV9-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Capsida","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capsida \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces XPOVIO\u00ae Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101\/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"FR104","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Veloxis Pharmaceuticals \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Ph.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Experience Survey Reported Positive Findings for GIMOTI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio Highlights Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells in Three Presentations at ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nimodipine","moa":"Calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVTX-002","moa":"LIGHT","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor to Host KOL Webinar on the Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ultra-Concentrated Rapid Acting Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA (pembrolizumab) as First-Line Treatment in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-101","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo\u00ae (nivolumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"TCR-T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-103","moa":"Phenylalanine ammonia lyase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Analysis Shows No Evidence of Increased Risk of Cardiovascular Events or Mortality with Roxadustat Compared with Erythropoiesis-Stimulating Agents (ESAs) at 59th ERA Congress 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Gets CDSCO Nod for Jardiance to Treat for New Heart Failure Indication","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Lab To Approach Regulator for Sputnik Light as Universal Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"rAd26","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TAC-001","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tallac Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tallac The.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio\u2122 at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group and Radius Health, Inc. Announce Publication of Elacestrant Pivotal Phase 3 EMERALD Clinical Trial Data in The Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Updates on Phase III Study of AKP02 In Treatment of Psoriasis - Half of Patients Now Recruited","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Calcitriol receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adiso Therapeutics' ADS024 Selected for Oral Presentation at 2022 Digestive Disease Week Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Single Strain Live Biotherapeutic Product","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adiso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Ther.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome to Present World First Clinical Data With EO2401, Its First-In-Class Off-The-Shelf OncoMimics\u2122 Therapeutic Cancer Vaccine, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EO2463","moa":"B-Cell activating factor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Provides Update on Ongoing Review of Tesofensine in Mexico","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tesofensine","moa":"MAO reuptake","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GIGA-564","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-107","moa":"IL-2RG","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Xenpozyme\u00ae (Olipudase Alfa), the First and Only Treatment for ASMD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Olipudase Alfa","moa":"SMPD1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Segesterone Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"TherapeuticsMD \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (\u226512 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Famotidine","moa":"H2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO\u00ae (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini Group","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Lilly and Incyte's OLUMIANT\u00ae (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS\u00ae by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Curcumin","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx (secukinumab) Receives Positive CHMP Opinion for Expanded Use in Childhood Arthritic Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sunitinib","moa":"TYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear at the American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"TLR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol\u00ae Eye Drops for Night Vision Disturbances","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-200-A02","moa":"MHC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics' TRACER Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VCAP-102","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas, With a Fresh Approval for Tarpeyo in Hand, Launches IgA Kidney Disease Education Campaign","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Delayed-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SER-109","moa":"Intestinal gut microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim\u2019s Latest Investigational Treatment Slowed Lung Function Decline in People Living with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BI 1015550","moa":"PDE4B","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences\u00ae Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMG-004","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zenas BioPharma \/ Viridian Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioP.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Granted Key NASH Patent in Israel","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Developing a Novel Class of Potent NLRP3 Inhibitors With Distinct Structural and Pharmacologic Properties for Inflammatory and Age-Related Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"NLRP3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized in Phase 2 Trial in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Setanaxib","moa":"NOX1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate, First Company to Validate Significant Quality of Life Improvements Compared with Standard Care","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PRT120","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Prota Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prota Ther.."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sifi Receives Favorable Feedback From the US FDA on Akantior\u00ae for the Treatment of Acanthamoeba Keratitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder For Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-\u03b1 Targeted Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT2004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"\u0394TRACCAR\u0394B2MHLAE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Plan to Submit Avasopasem NDA by Year End","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH-1019","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Imugene","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imugene And City Of Hope Announce First Patient Dosed In Phase 1 Trial To Test Cancer-Killing Oncolytic Virus Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CF33-hNIS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imugene \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Amazentis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure\u2122) Improves Muscle Strength and Exercise Performance in Middle Aged Adults","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Urolithin A","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amazentis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amazentis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amazentis .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"ILT7","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"University of Nebraska Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Nebraska Medical Center and ANANDA Scientific Announce FDA Approval of the IND for a Clinical TrialExploring Treatment for Post-Traumatic Stress Disorder (PTSD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ University of Nebraska Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Sci.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huyabio International Announces Completion Of HBI-3000 Phase 1 Trial And Fda Approval To Proceed With Dose Escalation In Phase 2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulcardine Sulfate","moa":"Ion Channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Alpha1-Proteinase Inhibitor","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathalamic","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-5948","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences presents at the 2022 Neuro4D International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1\/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Phage-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pradigastat","moa":"DGAT1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anji Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anji Pharm.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Publication in Molecular Therapy of ARCUS\u00ae In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Gene Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veloxis Pharmaceuticals Announces Dosing of the First Participant in a Phase I Study of VEL-101, a Novel Investigational Drug for Kidney Transplant Immunosuppression","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VEL-101","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Veloxis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Veloxis Pharmaceuticals \/ Asahi Kasei","highestDevelopmentStatusID":"6","companyTruncated":"Veloxis Ph.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Pharmaceuticals To Share New Data At Digestive Disease Week\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch health","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Texas Heart Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Texas Heart Institute","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Presents Updated Interim DesCAARTes Trial Phase 1 Data at the ASGCT 25th Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric Auto Antibody Receptor T Cells","moa":"EC 1\/2\/3\/4","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-938","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida Announces Administrative Stop of the VALOR-CKD Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Independent Committee to Conduct Investigation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma to Launch First-In-Class Oral Lipid-Lowering Drug in India","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACL","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present Key Data Across Oncology Portfolio Showcasing Significant Advances in Cancer Care At 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform\u2019s Potential Utility for the Treatment of Bile Duct Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"Allosteric tyrosine kinase 2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zolunicant Hydrochloride","moa":"nAChR Alpha3Beta4","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedere Bio II Presents Positive New Data Supporting Its Proprietary Platform at the 25th Annual ASGCT Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV Based Capsid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vedere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Results From the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-301","moa":"HDAC6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Receives Positive CHMP Opinion for Upstaza\u2122 for the Treatment of AADC Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"AADC gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BBI-02","moa":"DYRK1A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson's Disease and Movement Disorders Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CLBS201","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces First Patient Dosed in the Phase I\/II SWATCH Study of XPOVIO\u00ae (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Kingdom First to Grant Licence for Teva\u2019s Ophthalmology Biosimilar Ongavia (ranibizumab)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Bioeq","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"XMT-2056","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Marnetegragene Autotemcel","moa":"Gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-012","moa":"SMAD 2\/3","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and\/or Refractory AML and MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present New Kerendia\u2122 (finerenone) Data from Comprehensive Clinical Trial Program in Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verquvo\u2122 (vericiguat) Approved in China to Treat Patients with Chronic Heart Failure and Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"EA Pharma","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u201cMOVICOL\u00ae HD\u201d Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Macrogol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"EA Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"EA Pharma \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"EA Pharma .."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1\/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show TREMFYA\u00ae (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"IAVI","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"eOD-GT8 60mer mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IAVI \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Mod.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evkeeza\u00ae (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Dupixent\u00ae (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Filing of Marketing Authorization Application for Valneva\u2019s Inactivated COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Patheon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX\u00ae (tecovirimat)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SIGA Technologies \/ Patheon Pharmaceuticals Inc.","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"Tregs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma to Launch Brillo\u00ae, a First-In-Class Oral Lipid-Lowering Drug in India","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Complement C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir\u00ae Digihaler\u00ae (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$9.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocugen, Inc. to Commercialize COVAXIN in Mexico, Rights Now Encompassing All of North America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep's Efti in Combination with MSD's Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"MHC II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EORTC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ EORTC","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,407.0 million","upfrontCash":"$47.0 million","newsHeadline":"China\u2019s Kelun Pharma Jumps on Licensing New Cancer Drug to Holland\u2019s Merck Sharp & Dohme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Macromolecule-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Kelun Pharmaceutical","amount2":1.4099999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.4099999999999999,"dosageForm":"","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Merck & Co.","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Ke.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Edenbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent to Supply Edenbridge Pharmaceuticals with a Patient-Focused Fast-Dissolve Zydis\u00ae Formulation of Glycopyrrolate Intended for Use as Adjunctive Therapy in the Treatment of Patients with Peptic Ulcer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve Zydis\u00ae Formulation for Cannabidiol as an Anesthesia Premedication","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ JOS Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna\u2019s COVID-19 Vaccine and Clinical Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna","highestDevelopmentStatusID":"12","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"$60.0 million","newsHeadline":"Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Termination","leadProduct":"ATA2271","moa":"Mesothelin protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0.67000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Olpha","sponsor":"Not Applicable","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JSC Olainfarm & Adalvo to Launch a New Urology Product in 17 Countries In 2022-2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Furazidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Olpha","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olpha \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Olpha \/ No.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre and EORTC Open a Large Phase III Clinical Study in The Adjuvant Setting of Stage IIB-C Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Silvanols","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silvanols Puts Special Emphasis on A Research-Based and Developed Agent to Strengthen the Body\u2019s Defence Abilities During This Viral Season \u2013 Go Immune Strong","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Olea Europea Extract","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Silvanols","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Silvanols \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Silvanols .."},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Lorraine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silvanols Launches the First Combined Product in Latvia with The Innovative Ingredient Lactium\u00ae \u2013 Against Everyday Stress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Crocus Sativus","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Silvanols","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Silvanols \/ University of Lorraine","highestDevelopmentStatusID":"12","companyTruncated":"Silvanols .."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and Bayer Expand Development Program for Darolutamide in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nubeqa\u00ae (darolutamide) Receives EU Approval as A New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Plus Androgen Deprivation Therapy Significantly Increased Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Granted for Darolutamide in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Fermion Oy","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fermion's Long Term Customer G1 Therapeutics Received FDA Approval For COSELA\u2122 (Trilaciclib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fermion Oy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fermion Oy \/ G1 therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fermion Oy.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Announces Global Launch of Teriflunomide Making Multiple Sclerosis Therapy More Affordable and Better Available Worldwide","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis Medicine Teriflunomide in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Epilepsy Medicine Lacosamide in Australia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Antihistamine Bilastine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn\u00ae Manufacturing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"MSC-NTF Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Announces Selection of AAGP\u00ae Candidate Formulations for Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-Aging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProtoKinetix \/ Catalent","highestDevelopmentStatusID":"4","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU\u00ae Sprinkle (Deferasirox Granules)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Deferasirox","moa":"Iron","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granule","sponsorNew":"Aucta Pharmaceuticals \/ Oakrum Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Phar.."},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Partners Group","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"Undisclosed","newsHeadline":"Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":1.8999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Pharmathen SA \/ Partners Group","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Agreement Expands Collaboration Between Ondosis and Tiefenbacher Group","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiefenbacher Group \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion and the Blood Service launch Collaboration to Develop New CAR T-cell Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ CuraTeQ Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Bioiberica","sponsor":"ByHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Partnership With ByHealth in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Undenatured Type II Collagen","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ ByHealth","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica.."},{"orgOrder":0,"company":"Bioiberica","sponsor":"Apsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioiberica and Apsen Reinforce Partnership with New Holistic Mobility Product\u2013Motilex HA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Apsen","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica.."},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 Health Science Partners with Bioiberica to Deliver Innovative Nutrition in Joint Health and Mobility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Hea.."},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Reveals Bioiberica's Dermial\u00ae Delivers Superior Benefits for Skin Health","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica.."},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Further Validates Bioiberica\u2019s B-2cool\u00ae Native Type II Collagen as Trusted Source for Holistic Mobility Solutions","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"chondroitin sulphate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica.."},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioiberica Rebrands Its Range of Nutraceutical Ingredients for Healthcare","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica.."},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratorios Ordesa Incorporates B-2cool\u00ae, Bioiberica\u2019s Native Type II Collagen, in Its New Colnatur\u00ae Forte","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Harpagophytum Procumbens Extract","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica.."},{"orgOrder":0,"company":"Satiogen","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.8 million","newsHeadline":"Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Satiogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Satiogen \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Satiogen \/.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Alcon Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$60.0 million","newsHeadline":"Alcon to Acquire EYSUVIS Adding to Its Ophthalmic Eye Drop Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Kala Pharmaceuticals \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"ZZ Biotech","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"ZZ Biotech\u2019s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"3K3A-Activated Protein C","moa":"APC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ZZ Biotech","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"ZZ Biotech \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"8","companyTruncated":"ZZ Biotech.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Beijing Tianshi Tongda Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Casi Pharmaceuticals Enteres Into Sublicense Agreement with Tianshi Pharmaceuticals for Anti-CD38 Monoclonal Antibody (MAB) CID-103 in Autoimmune Field","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CID-103","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Beijing Tianshi Tongda Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Announces Pricing of a $105 Million Public Offering","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"Lysine-targeted Covalent Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Terremoto Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Terremoto Biosciences \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"Terremoto .."},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Altesa BioSciences Recognizes Co-Founder and Partner for Major NIH Research Grant to Discover New Antiviral Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Altesa Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Altesa Biosciences \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"Altesa Bio.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"KB Investment","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"OLX10010","moa":"CTGF","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"OliX Pharmaceutical \/ KB Investment","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Sequoia","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Sequoia","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amytrx Therapeutics Raises $18M For New Therapeutic Interventions of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"AMTX-100","moa":"NF-kB","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx The.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$79.2 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"EDP1815","moa":"TLR2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Allocetra-OTS","moa":"Macrophage homeostasis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"$60.0 million","newsHeadline":"Catalyst Biosciences Sells Complement Portfolio for $60 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"CB 2782-PEG","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Catalyst Biosciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Closing of Public Offering of $4,500,000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"NovoMedix","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NovoMedix Receives Research Grant from the National Institutes of Health (NIH) to Advance NMX1 in TBNC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"NMX1","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NovoMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovoMedix \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"NovoMedix .."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1\/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"NRG Therapeutics Announces \u00a32.68M Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"mPTP","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NRG Therapeutics \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therap.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Signs Definitive Subscription Agreement for A Maximum of EUR 5M Convertible Bonds Facility With ABO","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.01,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Metropolitan AntiViral Drug Accelerator","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$65.1 million","upfrontCash":"Undisclosed","newsHeadline":"Academia, Pharma Team up to Discover New Drugs in Fight Against SARS-CoV-2, Viruses of the Future","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Metropolitan AntiViral Drug Accelerator","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Metropolit.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$250.0 million","newsHeadline":"Regeneron Completes Acquisition of Checkmate Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Checkmate Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"Injectable\/Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Regeneron","highestDevelopmentStatusID":"9","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"JanOne","sponsor":"SPYR Technologies","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"$13.5 million","newsHeadline":"JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Sustained-Release","sponsorNew":"JanOne \/ SPYR Technologies","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ S.."},{"orgOrder":0,"company":"MiMedx","sponsor":"U.S. Army Medical Research and Development","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Dehydrated Human Amnion Chorion Membrane","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ U.S. Army Medical Research and Development","highestDevelopmentStatusID":"1","companyTruncated":"MiMedx \/ U.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Financing","leadProduct":"SENTI-202","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer\u2019s DNA Vaccine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"DNA-based Vaccine","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Institute for Molecular Medicine","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka's Moizerto\u00ae Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Completes Acquisition of Dry Powder Inhaler Spray Drying, Capsule Manufacturing, and Packaging Capabilities from Acorda Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag\u00ae Bioconjugation Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"XB010","moa":"5T4 oncofetal antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Catalent","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Laboratories to Commercialise Novel Molecule Tegoprazan in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Tegoprazan","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"HK inno.N","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"HK inno.N \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"HK inno.N .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Completes Kiadis Acquisition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Acquisition","leadProduct":"K-NK002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"ZM008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zumutor Biologics \/ Catalent","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Bi.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"Folate analog metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent Supports Rapid Development and Supply of Nocion Therapeutics\u2019 Clinical Trial Materials for Acute and Chronic Cough Using Blow-Fill-Seal Technology","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-1175","moa":"Sodium channel","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"Nocion The.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent Biologics and Humanigen to Present a Case Study on Accelerated Scale Up of a Monoclonal Antibody to Treat COVID-19 at BioProcess International Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Catalent","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent Announces Supplying Blueprint Medicines\u2019 Precision Therapy AYVAKIT\u2122 (avapritinib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo and Catalent Announce FDA Approval of Perrigo\u2019s AB-rated Generic Version of ProAir\u00ae HFA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Perrigo Company plc \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Fexinidazole as The First All-Oral Treatment for Sleeping Sickness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Fexinidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Second Indication of Sarclisa\u00ae (isatuximab) for Relapsed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Nexviazyme\u00ae (avalglucosidase alfa-ngpt), an Important New Treatment Option for Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Avalglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Announces Results of CHMP Re-Examination of the New Active Substance status for Avalglucosidase alfa, a Potential New Standard of Care for The Treatment of Pompe disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Avalglucosidase Alfa","moa":"Enzyme","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Regulatory Submission for Olipudase Alfa, the First Potential Therapy for ASMD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Olipudase Alfa","moa":"SMPD1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the First-to-Market Launch of an AB Rated Generic Version Of Zomig\u00ae Nasal Spray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Padagis","sponsor":"Ayana Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Doxil\u00ae (Doxorubicin Liposome Injection)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Padagis \/ Ayana Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the Re-Launch of Over-The-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve\u00ae in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"PG G\/H synthase 1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Genencell","sponsor":"Ordi Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genencell Signs Accord With UAE Partner to Distribute Covid-19 Pills","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"ES16001","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Genencell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Genencell \/ Ordi Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Genencell .."},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"VET-ROG1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KaliVir Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"KaliVir Im.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Immunocore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Tebentafusp-tebn","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medison Pharma \/ Immunocore Holdings","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"RSBT-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTher.."},{"orgOrder":0,"company":"Queensland University of Technology","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"VCAM-1","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Queensland University of Technology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Queensland University of Technology \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Queensland.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Lupagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"UB-VV100","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Lupagen","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechnologies, Part of Maravai LifeSciences, Announces Cooperative Agreement With Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"mRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"TriLink Bi.."},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Ellipses Pharma Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"SRB22","moa":"HER-3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SunRock Biopharma \/ Ellipses Pharma Limited","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Bi.."},{"orgOrder":0,"company":"Excelra","sponsor":"HotSpot Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Excelra","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excelra \/ HotSpot Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ .."},{"orgOrder":0,"company":"CPDC Centre for Probe Development and Commercialization","sponsor":"CellBion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Centre for Probe Development and Commercialization Expands Into Asia and Executes a Development, Manufacturing, and Clinical Supply Agreement For 177Lu-PSMA (DGUL) With South Korea-based CellBion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Lu-177-PSMA-D GUL","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CPDC Centre for Probe Development and Commercialization","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CPDC Centre for Probe Development and Commercialization \/ CellBion","highestDevelopmentStatusID":"8","companyTruncated":"CPDC Centr.."},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"Ionetix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"177Lu-PSMA-I&T","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Convergent Therapeutics \/ Ionetix","highestDevelopmentStatusID":"7","companyTruncated":"Convergent.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"CC Biotechnology Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"PharmaTher \/ CC Biotechnology Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"PharmEnable","sponsor":"Denali Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmEnable Announces Multi-Target Collaboration with Denali Therapeutics in Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"PharmEnable","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmEnable \/ Denali Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"PharmEnabl.."},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"HK inno.N","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ILIAS Biologics Signed An MOU with HK inno.N For Joint Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Exosome-loaded Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ILIAS Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILIAS Biologics \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"ILIAS Biol.."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"xCures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"Taladegib","moa":"Hedgehog signaling pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ xCures","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I\/ONTAK, into a New Standalone Publicly Traded Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Divestment","leadProduct":"Denileukin Diftitox","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Undisclosed \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Agenus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Agenus","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Fidelity Management & Research","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Drugs for the Treatment of Orphan Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Series B Financing","leadProduct":"RIST4721","moa":"CXCR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Fidelity Management & Research","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Th.."},{"orgOrder":0,"company":"Institute for Molecular Medicine","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer\u2019s DNA Vaccine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"Beta-amyloid Vaccine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Institute for Molecular Medicine","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Institute for Molecular Medicine \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Novocure","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA\u00ae (pembrolizumab) in Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novocure \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces Additional Licensing Agreements for Tirbanibulin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Athenex","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces U.S. Launch of Klisyri\u00ae and Licensing of Additional Territories for Tirbanibulin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ PharmaEssentia","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Intersect ENT","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Medtronic to Acquire Intersect ENT","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Corticosteroid","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Intersect ENT","amount2":1.1000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Intersect ENT \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Intersect .."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Announces Pricing of Public Offering of Ordinary Shares and Warrants to Purchase Ordinary Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aruna Bio Advances Therapeutic Development for Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Funding","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$433.2 million","upfrontCash":"$7.3 million","newsHeadline":"Up to \u20ac414 Million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A Inhibitor Programme","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.42999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"C4X Discovery \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discov.."},{"orgOrder":0,"company":"Factor Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Factor Bioscience to Deliver Four Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based iPSC-derived Macrophage","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Factor Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Factor Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Factor Bio.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell) at ASGCT 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic T-cell Progenitor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GLSI-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Modra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Phar.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 3 Study with Aprocitentan Demonstrates Significant Antihypertensive Efficacy in Patients with Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aprocitentan","moa":"Endothelin Receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona's Clinical Trial in Hypothalamic Obesity Published in Scientific Journal","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica to Present at the ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BMC128","moa":"Immune checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexson Biomedical to Present at Arrowhead Publishers' 2nd Annual Psychedelic Therapeutics & Drug Development Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Bexson Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Bio.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents New INGREZZA\u00ae (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO\u00ae (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and\/or Peripheral Artery Disease (PAD)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR\u00ae) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b\/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AP-SA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezagepras","moa":"GPR84","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Filovirus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Dermavant's VTAMA (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind's Technosphere Inhalation Platform Utilized in FDA-Approved Tyvaso DPI","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Neuronascent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NNI-351","moa":"DYRK kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neuronascent","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuronascent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasce.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA in Coronary Microvascular Dysfunction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CLBS16","moa":"Angiogenesis","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"DepYmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DPM-1001","moa":"PTP1B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DepYmed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ .."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi\u00ae in Immuno-Oncology at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OSE2101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation\u00c2 at the European Society of Cardiology Heart Failure Meeting in Madrid","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-99b","moa":"CCR3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces First Patients Dosed in Phase 1b\/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma's Phase 3 Height Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference, May 23-25, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HCW9218","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort at 4,000mg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Pathways Presents Largest Ever Study of Psilocybin Therapy, at American Psychiatric Association Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AMP-Peptide Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX\u00e2\u201a\u0081\u00e2\u201a\u20ac\u00e2\u201a\u20ac at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces FDA Approval of Tyvaso DPI","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I\/II Clinical Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Kanyos Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Positive Data from Phase 1 ACED Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Kanyos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Presents New Long-Term AUSTEDO\u00ae (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Immunome","sponsor":"Fox Chase Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Fox Chase Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-1002","moa":"SIRP alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Navidea Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Navidea Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Navidea Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Aims to Transform Cancer Care with Practice-Changing Data at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ\u00ae) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Ocugen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin's Clinical Trials Can Resume In US as FDA Lifts Hold","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bharat Biotech \/ Ocugen","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics Granted U.S. Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company\u2019s Intellectual Property Position in Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase IV","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"EVX-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics, Inc. Receives Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Necrotizing Enterocolitis in Neonates","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AVX012","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Docosanol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosette Pharma \/ Alembic Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"Genuv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SNR1611","moa":"MEK1\/2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ No.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Presents Data at DDW 2022 on IBSRELA\u00ae (tenapanor), a First-In-Class Treatment for IBS-C in Adults","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA\u00ae (guselkumab) and Long-Term Safety Profile for STELARA\u00ae (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week\u00ae 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Second Genome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SG-5-00455","moa":"PAI-1\/PAI-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Second Genome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Second Genome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Second Gen.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TVT-004","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Travecta Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Travecta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Travecta T.."},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Lake Biotechnology Announces FDA Fast Track Designation for BLB-201 Intranasal RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BLB-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Blue Lake Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blue Lake Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Blue Lake .."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Vigonvita Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VV116","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Vigonvita Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals CPI-613 (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week (DDW) 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SZN-1326","moa":"Wnt signalling pathway","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"BDD Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ BDD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Taladegib","moa":"Hedgehog pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week\u00ae (DDW) 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IW-3300","moa":"Guanylate cyclase-C","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OVX836","moa":"Nucleoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Presents New Talicia\u00ae Data Analyses at DDW 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Growlab Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Growlab\u2122 Pharmaceuticals Achieved High Remission on Clinical Trials of Comacadine\u00ae for Treatment of Diabetes Mellitus","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Growlab Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Growlab Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Growlab Ph.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Initiates Phase 1 Evaluation of Intranasal Vaccine CoviLiv\u2122 for Use as COVID-19 Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Covi-vac","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS (omburtamab) for the Treatment of Neuroblastoma for Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HBM7008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evox Therapeutics Presents Progress Across its Deliverex\u2122Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody-loaded Exosomes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TCX-101","moa":"HA-1 T Cell Receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI\u00ae (aviptadil) in Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ NIH","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac\u00ae platform) at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TG4050","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO\u00ae in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"TLR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pionyr Immunotherapeutics\u2019 Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TREM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Imm.."},{"orgOrder":0,"company":"Inspirna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride Trihydrate","moa":"SLC6A8\/CKB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inspirna \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/.."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aulos Bioscience Presents Poster on Phase 1\/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"PTK erbB-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb\u00ae104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From the Ongoing Radspherin\u00ae RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients to Be Presented at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Radspherin","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Merck & Co. Inc","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Phase 2 PILOT Study of Bristol Myers Squibb\u2019s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ S.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I\/II Clinical Trial at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BT7480","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2\u2011Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 signal","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen: ASCO 2022: New Cabometyx\u00ae Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vapendavir","moa":"Capsid binding","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Bio.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono to Present Latest Research From Oncology Portfolio at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EMD Serono \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Presents 100 Years of Clinical Evidence for \u201cNovel\u201d Enzyme Therapeutic Approach to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tvardi Therapeutics\u2019 TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine\u2122 Positive Phase 2 Clinical Trial Results in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"SP-624","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo Bio.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Bio.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Treatment of Depression and Anxiety in Alzheimer\u2019s Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"FT-7051","moa":"CBP\/p300","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Incyte\u2019s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u00ae (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymoangioblast-derived Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX-097","moa":"Complement activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MEN1309","moa":"CD205","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ\u00ae) in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR\/MSI-H Solid Tumors, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lytix Biopharma AS Announces that an Abstract on LTX-315 in Combination With Adoptive Cell Therapy Is Selected for a Poster Presentation at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lytix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biop.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-0508","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Seribantumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Showcases How Amgen Is Advancing All Angles Of Cancer Care Through Innovative Oncology Portfolio And Pipeline At Asco 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces U.S. FDA Approval For Omeprazole Magnesium Delayed-Release Mini Capsules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion to Present New Preclinical Data Showing BMF-219's Strong Activity in Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"Covalent menin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS\/NRAS Activity of IMM-1-104","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Announces Upcoming Presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"NovalGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovalGen announces compelling data from the Phase 1\/2 Study of NVG-111 at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NVG-111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovalGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"AXL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hookipa to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202\/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Glaxosmithkline","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1\/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zotatifin","moa":"eIF4A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1\/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alaunos Therapeutics \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b\/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib's Differentiated Inhibitory and Improved Safety Profile in Preclinical Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PC14586","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PMV Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"University of Iowa Holden Comprehensive Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Checkmate Pharmaceuticals \/ University of Iowa Holden Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1\/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from SOTIO's Phase 1\/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HPN328","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"KIRS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1\/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RTX-224","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces that Health Canada Has Started the Review of New Drug Submission for Masitinib in The Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG126","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"VEGFR 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"HER2\/HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BBP-671","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"Galectin 3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics' Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"RAS-F","moa":"Pan-RAS","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CEND-1","moa":"Alpha V integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Cend Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CX-904","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GCC19CART","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1\/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda\u00c2\u00ae in Patients with WT1+ Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Two Opdivo\u00ae (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"LintonPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Catumaxomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"LintonPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LintonPharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LintonPhar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA\u2122 (pegfilgrastim-pbbk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"Hematopoietic Cell","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006\/r in mCRPC Patients at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Modra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Phar.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-221","moa":"IgE receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inxmed IN10018 at ASCO 2022 Demonstrates Robust Efficacy in Patients With Platinum-resistant Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"IN10018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Novartis Kymriah\u00ae CAR-T Cell Therapy for Adult Patients With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"JAB-21822","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris to Present a Study Protocol of APL-1202 in Combination With Beigene's Tislelizumab as Neoadjuvant Therapy (NAC) for Muscle Invasive Bladder Cancer (MIBC) Patients at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"APL-1202","moa":"MetAP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GPRC5D-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2\/3 Clinical Trial for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo\u00ae (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BDC-1001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-002","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NLC-V-01","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Cialis\u00ae Rx-to-OTC Switch Actual Use Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through 15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Confirms Vaccines and Related Biological Products Advisory Committee Review of Novavax\u2019 COVID-19 Vaccine on June 7, 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"AskGene Pharma Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ASKG712","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AffaMed Therapeutics \/ AskGene Pharma","highestDevelopmentStatusID":"6","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Shanghai Jiao Tong University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TST003","moa":"BMP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Shanghai Jiao Tong University","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Announces FDA Approval of TWYNEO\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"GALDERMA LABS LP","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Cream","sponsorNew":"GALDERMA LABS LP \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GALDERMA L.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"TGF beta-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"PAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PAI Life Sciences Doses First Healthy Volunteer in Schistosomiasis Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GLA-SE Adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PAI Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PAI Life S.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Initiates Phase 1 Clinical Study of MTX-005 Against BK Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MTX-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Avillion LLP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts New Drug Application Filed by Avillion for Astra Zeneca's PT027 For the As-Needed Treatment or Prevention of Symptoms in Asthma Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Avillion LLP","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"Avillion LLP \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Avillion L.."},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera Receives Fast Track Designation for Mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Mocravimod","moa":"S1PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Priothera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Statistically Greater Improvements in Clinical Outcomes with Subcutaneous Infliximab, Compared to Intravenous Infliximab, in Patients With Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Introduces New Generic for the Treatment of Non-Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"DHFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius SE & Co. KGaA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"OMTX705","moa":"Alpha Fibroblast activation","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncomatryx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncomatryx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncomatryx.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Files Investigational New Drug Application (\u201cIND\u201d) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Submits IND Application to FDA for its Phase 1\/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society\u2019s Annual Meeting, ENDO 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GFB-024","moa":"CB1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"JANX007","moa":"PSMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Seagen Inc","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauRx's LUCIDITY trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces Presentations at SLEEP 2022","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Greenfire Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenfire Bio to Update Progress on Phase 1 Clinical Trial for SIK2\/SIK3 Inhibitor, GRN-300, In Ovarian Cancer at The Asco Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"GRN-300","moa":"SIK2\/SIK3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Greenfire Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Greenfire Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Greenfire .."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Udenafil","moa":"PDE5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"QureBio Ltd.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Q-1802","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"QureBio Ltd.","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QureBio Ltd. \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"QureBio Lt.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Topline Phase 2 Data For Investigational Olpasiran In Adults With Elevated Lipoprotein(a)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Olpasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis To Highlight Valtoco (Diazepam Nasal Spray) CIV Development Program Updates At 16th Eilat Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VILTEPSO\u00ae (viltolarsen) Injection: Long-Term Efficacy and Safety Data Published in the Journal of Neuromuscular Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftansomatropin Alfa","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Results from AENEAS Study of Hansoh Pharma's Ameile\u00ae Published in Top International Academic Journal JCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aumolertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pha.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psyence Taps Another Pharma Exec to Drive its Clinical Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psyence \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Fuji Yakuhin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dotinurad","moa":"URAT1","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fortress Biotech \/ Fuji Yakuhin","highestDevelopmentStatusID":"12","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1\/2 Study of GRANITE and Trial in Progress Poster at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CLN-081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1\/GLP-2 Dual Agonist Dapiglutide","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX\u2081\u2080\u2080 for Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BND-22","moa":"ILT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biond Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biol.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Affibody","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene and Affibody Announce IND Clearance for Izokibep (IMG-020) For the Treatment of Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17 A receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Affibody AB","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Athenex","sponsor":"Almirall","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces U.S. Launch of Klisyri\u00ae and Licensing of Additional Territories for Tirbanibulin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triphase Accelerator and Catalent Biologics Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222 in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CAT-02-106","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triphase Accelerator \/ Catalent","highestDevelopmentStatusID":"6","companyTruncated":"Triphase A.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces First Patient Dosed in ADORING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"BX005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Ma.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Completes Pre-IND meeting with the U.S. Food & Drug Administration for JW-100 in the Treatment of Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Unveils Latest Research Advances Demonstrating Strength of Its Portfolio and Pipeline at ASCO and EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Belantamab Mafodotin-blmf","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants Conditional Approval of CARVYKTI\u00ae (Ciltacabtagene Autoleucel), Janssen\u2019s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch in Japan of SAMTASU\u00ae for IV Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolvaptan Sodium Phosphate","moa":"V2 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Otsuka Holdings","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Otsuka Holdings \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Hol.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod\u2019s Potentially Best-in-Class Profile in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Granted FDA Fast Track Designation for Ervogastat\/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ervogastat","moa":"DGAT2","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Dupixent\u00ae (dupilumab) for Priority Review in Adults with Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pivotal Data Demonstrate Clinical Benefit of Roche\u2019s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Glofitamab","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda and Seagen to Highlight ADCETRIS\u00ae Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data at the 2022 ASCO Annual Meeting Highlight Roche\u2019s Continued Commitment to Innovation in Oncology and Personalised Healthcare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Glofitamab","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"European Myeloma Network","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29\/XPORT-MM-031 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ European Myeloma Network","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Reports Top-Line CRN04894 MAD Results from Phase 1 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"CRN04894","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KIN-3248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma (NHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott to Release Elecare\u00ae Amino Acid-Based Formulas to Help Meet Critical Patient Need","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Amino Acid-Based Therapeutic","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI\u00ae) in Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxzevria Approved in the EU as Third Dose Booster Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Support Renal and Cardiovascular Benefits of Kerendia\u2122 (Finerenone) in Patients With and Without History of Left Ventricular Hypertrophy and Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Large Xarelto\u2122 Studies Support Effectiveness of Dual Pathway Inhibition in Patients with Coronary Artery Disease And\/or Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"DA01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Tecentriq Obtains Regulatory Approval as the First Immunotherapy in Japan for Adjuvant Treatment of Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Launches Vabysmo Intravitreal Injection 120 mg\/mL for the Treatment of Age-related Macular Degeneration Associated with Subfoveal Choroidal Neovascularization and Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"VEGF A\/Ang-2 inhibitor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Showcases Bold Leadership in Oncology with Survival Improvements for Certain Patients with Cancer at ASCO and EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Development Progress of mRNA COVID19 Vaccine (DS-5670) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylcobalamin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Contributes to The Science of Cancer Medicine at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Farletuzumab Ecteribulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ Br.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Pharma Announces European Commission Approval of Adtralza\u00ae (Tralokinumab) as the First and Only Treatment Specifically Targeting Il-13 for Adults With Moderate-to-severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ahmedabad-Based Zydus Gets USFDA Approval to Market Generic Acne Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adapalene","moa":"RAR-beta","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hofseth BioCare Announces Global Innovation Partnership with Catalent to Develop Delayed-Release Formulation of OmeGo\u00ae Fish Oil","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Catalent Pharma Solutions \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Egis Pharmaceuticals PLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.7 million","newsHeadline":"Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Crescita Therapeutics \/ Egis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"National Institute of Pharmacy and Nutrition","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Egis Favipiravir Drug Licenced for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Egis Pharmaceuticals PLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition","highestDevelopmentStatusID":"12","companyTruncated":"Egis Pharm.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT\u00ae (vasopressin injection, USP) Vials in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg\/mL, Single-Dose Vial in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"Adrenergic alpha\/beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Launches Minoxidil for Women Following First-Ever Approval in India for The Treatment of Female Pattern Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Albendazole","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sapropterin Hydrochloride","moa":"PAH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluphenazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"GABA transaminase","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the Re-Launch of Over-The-Counter Famotidine Tablets USP, 10 mg and 20 mg, Store-Brand Equivalent of Pepcid AC\u00ae in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Famotidine","moa":"H2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim\u00ae in the U.S. Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pyrimethamine","moa":"DHFR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s and RDIF Receive Approval to Conduct Clinical Trial for Sputnik V Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2-viral spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gamaleya National Research Institute of Epidemiology and Microbiology","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sapropterin Hydrochloride","moa":"PAH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Announces the Launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, The Store Brand Version of Voltaren\u00ae Arthritis Pain in the U.S. Market","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"COX","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Redyx in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg\/5 mL (50 mg\/mL) per Single-dose Syringe in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Penicillamine Capsules USP, 250 mg in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Penicillamine","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Received Approval of XEGLYZE\u2122 (abametapir) Lotion, 0.74%, in the U.S.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abametapir","moa":"Metalloproteinase","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, The Store Brand Version of Nicorette\u00ae Lozenges in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nicotine","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Abiraterone Acetate Tablets USP, 250 mg in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Partners With FUJIFILM and Global Response Aid for Avigan\u00ae (favipiravir), A Potential Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Healiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SMITH & NEPHEW INC","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SMITH & NEPHEW INC \/ Healiva","highestDevelopmentStatusID":"8","companyTruncated":"SMITH & NE.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$47.5 million","upfrontCash":"Undisclosed","newsHeadline":"Concert Pharmaceuticals Announces Pricing of Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Concert Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"GSK","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"SNP318","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"GSK \/ SciN.."},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"MycoMedica Life Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"MycoMedica Life Sciences \/ Obvious Ventures","highestDevelopmentStatusID":"1","companyTruncated":"MycoMedica.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Directed Issue and Private Placement Corresponding to Approx. 6.6 % of Existing Share Capital","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"TTX-MC138","moa":"miR-10b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"CDI-873","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"G42 Investments","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$12.5 million","newsHeadline":"vTv Therapeutics Announces Investment by And Entry Into Collaboration and License Agreement with Affiliates of G42 Healthcare","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ G42 Investments","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series B Financing","leadProduct":"OLX07010","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"Upstream","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"UPB-101","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Upstream","amount2":0.20000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Upstream \/ OrbiMed","highestDevelopmentStatusID":"4","companyTruncated":"Upstream \/.."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Sequoia China","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"PRO1184","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"ProfoundBio \/ Sequoia China","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clearmind Medicine \/ SciSparc Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Arvinas","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine Announces Strategic Collaboration with Arvinas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Bavdegalutamide","moa":"PROTAC protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","amount":"$30.3 million","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Raises \u00a53.86 Billion ($30.3 Million) in Oversubscribed Series B Financing","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series B Financing","leadProduct":"Mitochondrial-based Therapy","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"LUCA Science \/ Fast Track Initiative","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Scien.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"BHR Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series D Financing","leadProduct":"ISM001-55","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Insilico Medicine \/ BHR Partners","highestDevelopmentStatusID":"6","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Argenx","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ M.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"$26.0 million","newsHeadline":"Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Kineta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Merger","leadProduct":"KVA12.1","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Code Bio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Code Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Code Bio \/ Northpond Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Code Bio \/.."},{"orgOrder":0,"company":"Soleo Health","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleo Health Named a Limited Drug Distribution Partner by Mitsubishi Tanabe Pharma America for RADICAVA ORS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Soleo Health \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Heal.."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Curie Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"n.c.a. Ac-225 Conjugated Therapeutic","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Curie Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"Microbion","sponsor":"US Navy","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"COYA 101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Johns Hopkins University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Johns Hopkins University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Immatics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Gamma-delta T Cell Adoptive Cell Therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Immatics","highestDevelopmentStatusID":"2","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aptar Pharma \/ Opiant Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Phar.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics, Inc. Announces Closing of $8.5 Million Registered Direct Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Anagenex","sponsor":"Catalio","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anagenex Closes $30 Million Series A Round led by Catalio to Advance Small Molecule Drug Discovery with a Novel, Directed Evolution Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0.029999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Anagenex \/ Catalio","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ABL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coave Therapeutics and ABL Enter Into Strategic Collaboration to Develop Gene Therapy Manufacturing Processes and Create Joint Capabilities for Process Development of AAV-Based Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"CTx-GBA1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coave Therapeutics \/ ABL","highestDevelopmentStatusID":"4","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"OnCusp Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OnCusp Therapeutics and Multitude Therapeutics Enter into an Ex-China Licensing Agreement for a Potentially Highly Differentiated CDH6-Targeting Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CUSP06","moa":"CDH6","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Multitude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Multitude Therapeutics \/ OnCusp Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Multitude .."},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Acquires DMT Clinical Study from Entheon Biomedical","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"Serotonin receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entheon Biomedical \/ Cybin","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Bi.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImaginAb and Roche Have Entered a Clinical Trial Supply Agreement for Provision of Atezolizumab (Tecentriq\u00ae)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"Frame Cancer Therapeutics","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"$33.3 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"mRNA Cancer Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Frame Cancer Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Frame Cancer Therapeutics \/ CureVac","highestDevelopmentStatusID":"3","companyTruncated":"Frame Canc.."},{"orgOrder":0,"company":"Aurigene","sponsor":"Olema Oncology","pharmaFlowCategory":"D","amount":"$438.0 million","upfrontCash":"$8.0 million","newsHeadline":"Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Aurigene \/ Olema","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferring Announces New Collaboration for Development of Olamkicept","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Olamkicept","moa":"Il-6","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ferring Pharmaceuticals \/ I-Mab","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Genuv","sponsor":"Nanocarry Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Brain Barrier","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"GNUV201","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genuv","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genuv \/ Nanocarry Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Genuv \/ Na.."},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Op.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"$182.4 million","upfrontCash":"$78.5 million","newsHeadline":"Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Amisulpride","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Acacia Pharma \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin America","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ BioCryst","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharm.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"Bendamustine","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Niowave","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"[225Ac]-FPI-1434","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Niowave","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Niowave \/ Fusion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Niowave \/ .."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asher Bio Announces Clinical Trial Collaboration with Merck to Evaluate AB248 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"AB248","moa":"IL2 Signalling Pathway","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunocore Announces Clinical Trial Collaboration with Sanofi to Evaluate Sanofi's Product Candidate SAR444245, Non-Alpha Il-2, in Combination With KIMMTRAK In Patients with Metastatic Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"SAR444245","moa":"Il-2 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen\u00ae into Mainland China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sinopharm \/ ChromaDex","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"$50.0 million","newsHeadline":"Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"IPH5201","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"ReViral","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Completes Acquisition of ReViral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Sisunatovir","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.53000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"ReViral \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Synklino","sponsor":"The Danish Growth Fund","pharmaFlowCategory":"D","amount":"$31.8 million","upfrontCash":"Undisclosed","newsHeadline":"Synklino Completes Series A Raise of EUR 29.8 Million to Advance Clinical Trials of Its Drug Candidate for The Treatment of Cytomegalovirus (CMV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"SYN002","moa":"US28","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Synklino","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Synklino \/ The Danish Growth Fund","highestDevelopmentStatusID":"4","companyTruncated":"Synklino \/.."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at the American Society for Cell and Gene Therapy 25th Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Dupixent\u00ae (Dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years With Moderate-to-severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Onatasertib","moa":"TORC1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Epizyme","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces TAZVERIK Approved to be Used in Hainan Pilot Zone in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Epizyme","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Epizyme","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G\/GEJ Cancer at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camber Pharma Launches Generic Pepcid\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Famotidine","moa":"H2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Camber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Camber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camber Pha.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Prednisolone","moa":"HSD-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703 Against Solid Tumors and Blood Cancers at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF\/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ALPN-303","moa":"BAFF\/APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"SynDevRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 1b\/2 Clinical Research Study with SynDevRx Drug Evexomostat (SDX-7320) Announced for Triple-Negative Breast Cancer Patients with Baseline Insulin Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eribulin","moa":"MetAP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SynDevRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SynDevRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SynDevRx \/.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA\u00ae (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches LYVISPAH\u00ae (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SER-155","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1\/2 Study of NK Cell Therapy Candidate GDA-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NAM-expanded Allogeneic NK Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin\u00ae in R\/R FL as a Result of Continuing Slow Recruitment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMP Pharma, Inc Announces that Norliqva\u00ae, the First and Only FDA-approved Liquid Solution of Amlodipine, is Now Available","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Amlodipine Besylate","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositis Agent in Locally Advanced Head and Neck Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AEF0117","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Indivior \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS\u00ae (edaravone), an Oral Treatment for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Translational Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neotx Announces Successful First Stage Completion of Its Phase 2a Clinical Trial of Naptumomab Estafenatox (Nap), in Combination With Docetaxel in Advanced Non-small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NeoTX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoTX Therapeutics \/ Translational Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"NeoTX Ther.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"For Suspension","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TPX-100: OrthoTrophix Presents the Latest Clinical Data at BIO 2022","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TPX-100","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OrthoTrophix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTroph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Patients Treated with First-in-Class TREMFYA\u00ae (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elucida Oncology to Present Trials in Progress Poster for Phase 1\/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FR at 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Folic-acid Functionalized C\\'Dot-Drug-Conjugate","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida On.."},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cangrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CHIESI USA INC","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CHIESI USA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CHIESI USA.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613 (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Stanford University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics to Present Initial Phase 1\/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Data on Zygel at the American Society of Clinical Psychopharmacology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"AmyriAD","sponsor":"Societal CDMO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer's Disease Treatment, AD101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AmyriAD \/ Societal CDMO","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peer-Reviewed Post Hoc Analysis Shows Jeuveau\u00ae is Highly Effective for Millennials by All Measures and at All Time Points Assessed","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Clinically Meaningful Improvements for Investigational Oral Pharmacologic Treatment AD504 in People With Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Provides Update on ANJ900 Pivotal Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharm.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data on Lemborexant at the 36th Annual Sleep 2022 Meeting","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Provides an Update on the Phase 1b\/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Launches EPSOLAY\u00ae Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Sci.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta\u00ae CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADCETRIS\u00ae (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX10010","moa":"CTGF","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Data Demonstrating LUPKYNIS\u00ae (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR\/ERA Recommendations","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1\/1b Trial of Lead Bifunctional Program, BCA101, at the American Society of Clinical Oncology 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BCA101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Announces Positive Results From Phase 2 Clinical Trial Investigating the Effect of IHL-42x for Treatment of Obstructive Sleep Apnoea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Presents Positive Final Data From Phase Ii Study Of Paxalisib In Newly Diagnosed Glioblastoma At Asco Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Affibody","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC., Affibody AB and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Affibody AB","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"National Comprehensive Cancer Network","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and Adjuvant Temozolomide Met its Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bavituximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OncXerna Therapeutics \/ National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna T.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Evorpacept Clinical Program Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Achieves Primary Objectives of Onwards 1 and 6 Trials With Once-weekly Insulin Icodec Demonstrating Superior Reduction in Hba1c Vs Insulin Glargine U100 in Onwards 1","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnKure Therapeutics Announces First Patient Dosed in the Phase 1b\/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Class I HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OnKure The.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Transgene","sponsor":"IUCT-Oncopole","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presented Additional Phase I Data with TG4050 (myvac\u00ae platform) at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TG4050","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transgene \/ IUCT-Oncopole","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bendamustine","moa":"Monocarboxylate transporter","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adjuvant Treatment With Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tecartus\u00ae Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT \u2018Basket\u2019 Trial of Neratinib at the ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"PTK erbB-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel\u00ae European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"EBV","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta\u00ae CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Announces Presentations On DCVax\u00ae-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax\u00ae-L Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dendritic Cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH925","moa":"KRAS G12C covalent","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Farletuzumab Ecteribulin","moa":"FR alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's SURMOUNT-1 Results Published in the New England Journal of Medicine Show Tirzepatide Achieved Between 16.0% and 22.5% Weight Loss in Adults With Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IRAK4 kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hookipa Announces Positive Phase 1 Data and Phase 2 Plans for HB-200 Program for the Treatment of Advanced Head and Neck Cancers at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"HB-200","moa":"KRAS G12C covalent","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MAU868","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219\u2019s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rare Eye Disease Gene Therapy Lacks Efficacy in NIH-funded Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"scAAV2-P1ND4v2","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK\u00ae) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Tissue factor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ S.."},{"orgOrder":0,"company":"Onco360","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORGOVYX\u00ae (relugolix) Now Available from Onco360 for the Treatment of Adult Patients with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Myovant Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GM-CSF","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology\u2019s Rubraca\u00ae (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 \u00b1 Defactinib in Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Mounjaro\u2122 (tirzepatide) injection for The Treatment of Adults with Type 2 Diabetes Presented at the American Diabetes Association's\u00ae 82nd Scientific Sessions\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group and Radius Health, Inc. Present a Subgroup Analysis From the Elacestrant Pivotal Phase 3 EMERALD Clinical Trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Linnaeus Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CT041","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Presents Post-Hoc Analysis Of Wakix\u00ae (Pitolisant) Pivotal Data In Adults With High Burden Of Narcolepsy Symptoms","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech's Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Presents Proof-Of-Concept Immune Response Data and First Clinical Data From Phase 1\/2 Trial With EO2401, a First-In-Class OncoMimics\u2122 Therapeutic Cancer Vaccine for Glioblastoma, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"EO2401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I\/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT's Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and\/or Nivolumab in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Portage Biotech \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Health Canada has Authorized ORLADEYO (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Presentation of Final Positive Phase 1b\/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib\/II Trial of EMB-01 in Combination with Tagrisso\u00ae for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"FIT-013a","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"EpimAb Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EpimAb Bio.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ENX-101","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Engrail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Presents Encouraging Interim Results for Evenamide in Patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer\u2019s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Phase 2 study of Mazdutid\uff08IBI362) in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"MedAlliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in SELUTION SLR IDE BTK Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MedAlliance","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MedAlliance \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"MedAllianc.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Scemblix\u00ae, With Novel Mechanism of Action, Shows Superior, Long-Term Efficacy and Consistent Tolerability in 96-Week Follow-Up of Chronic Myeloid Leukemia Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA\u00ae (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Innovation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Receives Supportive Scientific Advice from The Paul Ehrlich Institute (PEI) for COVID-19 NanoAb Development Plans Including First-In-Human Phase 1\/2a safety and efficacy clinical trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 NanoAb","moa":"SARS-CoV-2 virus","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces Commercial Launch of TLANDO\u2122, an Oral Treatment for Testosterone Replacement Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Halozyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Presents Positive Data from Phase 2\/3 Trial of Rylaze\u00ae (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn","moa":"Asparagine synthetase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PC14586","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PMV Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ab Science Today Announced Publication of Results From Its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-reviewed Journal of Asthma and Allergy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO (berotralstat) by Swissmedic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Merck","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Two Oral Presentations Highlighting the Potential for TransCon PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Observed Safety Profile Supports Bilateral Dosing of ProKidney's REACT-007 Update","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AUM001","moa":"MNK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxyl Dendrimer Based Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in The VALIANT Phase 3 Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Positive Results from Study of KETABET for Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME\u00ae (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Second Phase 2 Add-On Ketamine Trial in Treatment-Resistant Depression (TRD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HMNC Brain Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Presents New Immunogenicity Data on Human Acellular Vessels\u2122 (HAVs\u2122)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress\u2122 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa\u00ae (oral octreotide) at ENDO 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deflazacort","moa":"CTGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada Approve KIMMTRAK\u00ae (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives Positive Opinion in Europe for Dysport\u00ae in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP25","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTx\u2019s ATX01 Granted Fast Track Designation by FDA for Chemotherapy-Induced Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Amitriptyline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Inaxaplin","moa":"APOL1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I\/II Trial of Bicycle\u00ae Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BT5528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ATI-1428","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics Announces Peer Reviewed Publication of First-in-Human Clinical Trial of PT-112 in The Lancet's eClinicalMedicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT\u2122 in Recurrent Cutaneous SCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces FDA Orphan Drug Designation Granted to Iadademstat for Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Receives Institutional Review Board Approval for its Phase 1\/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a Tool in the Fight to Eradicate Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Real-World Data Evaluating AJOVY\u00ae (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck to Present Data on VYEPTI\u00ae (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stada and Alvotech Broaden European Patients\u2019 Options by Launching Hukyndra\u00ae High-concentration, Citrate-free Adalimumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Demonstrates AbbVie's VENCLYXTO\u00ae\/VENCLEXTA\u00ae Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Approval of Trodelvy\u00ae in China for Second-Line Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Cyanvac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CyanVac Announces Data from Preclinical Studies of Intranasal PIV5-based COVID-19 Vaccine Candidate CVXGA1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PIV5-SARS CoV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cyanvac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyanvac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyanvac \/ .."},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AMTX-100","moa":"NF-kB","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx The.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Announces Seven Abstracts Accepted for Presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"HT-ALZ","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec\u00ae ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"[225Ac]-FPI-1434","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics to Present New Data for JATENZO (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ETX0462","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Pharmaceuticals to Present Trudhesa Data at the 64th Annual Meeting of the American Headache Society","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabivarin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InMed Pharmaceuticals \/ BayMedica","highestDevelopmentStatusID":"1","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exavir Therapeutics Announces Publication of Preclinical Data for Ultra-long-acting Dolutegravir Prodrug XVIR-120","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Prodrug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exavir Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Exavir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Exavir The.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's 64th Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Activated Allogeneic Dendritic Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (voxelotor) in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Entospletinib","moa":"Syk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab), A Proposed Biosimilar to Soliris, at the European Hematology Association (EHA) Congress 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Slips as It Changes Endpoint for Trial in Aim to Greatly Broaden Ayvakit Label","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62 at the Endocrine Society (ENDO) 2022 Annual Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura\u00ae in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Complement factor C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI\u00ae (aviptadil)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New IMBRUVICA\u00ae (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Abbvie","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Daratumumab","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics Presents Antitumor Activity of Its Cd38-targeting FLEX-NK\u2122 Cell Engager Antibody at EHA 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CYT-338","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Un.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Na\u00efve Myelofibrosis Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Navitoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Karolinska Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Karolinska Institute","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 virus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GTB-7550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb\/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VIP152","moa":"PTEFb\/CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CY6463","moa":"sGC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-050","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidubicel","moa":"CD34","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Withdraws Supplemental Biologics License Application (sBLA) for Reblozyl\u00ae (luspatercept-aamt) for Non-transfusion Dependent (NTD) Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Riabni\u2122 (Rituximab-Arrx), A Biosimilar To Rituxan\u00ae (Rituximab), For Adults With Moderate To Severe Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tilray Medical Launches Sleep-Oriented CBN Night Oil for Medical Cannabis Patients in Canada","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Tilray","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oil","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ N.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Data at EULAR 2022 Demonstrate Deucravacitinib Significantly Improved Disease Activity in Phase 2 PAISLEY Study in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LB1908","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fludrocortisone Acetate","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Renovacor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"BAG3 Gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor .."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"University of Alabama","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics\u2019 Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ University of Alabama","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegavivint","moa":"Nuclear beta catenin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-2174","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Calcium","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CODA Biotherapeutics Announces New Preclinical Data From Epilepsy Program Showing Significant Correlation Between Gene Expression and Efficacy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coda Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Coda Bioth.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Receives FDA Clearance of Investigational New Drug Application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax\u2122-RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CodaVax-RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Colchicine","moa":"pH","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dyve Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosc.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Reports Day 26 Update For Case Study #4","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Plant Extracts","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-333","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"A166","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sichuan Kelun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sichuan Kelun Pharmaceutical \/ Levena Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Ke.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"PLX Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ANX005","moa":"C1q","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"STAT3 protein","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"ADRB1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Samsung Bioepis\u2019 BYOOVIZ\u2122 (ranibizumab-nuna) Launches in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TQS-168","moa":"PGC-1a","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis T.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"Tregs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"VectorY","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectorY Presents New Pre-clinical data at the European Network for the Cure of ALS (ENCALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-VecTabs","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed\/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J INTS BIO 4th Generation EGFR TKI (JIN-A02) US FDA Phase 1\/2 IND submission completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"JIN-A02","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio.."},{"orgOrder":0,"company":"eTiraRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EtiraRx's Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ERX-41","moa":"LIPA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"eTiraRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"eTiraRx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"eTiraRx \/ .."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NTAGI May Soon Review Efficacy Data of India's First Intranasal Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"US Oncology Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US Oncology Network \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"US Oncolog.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro to Present at the 12th Annual LD Micro Invitational","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Naveris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Naveris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Naveris \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Naveris \/ .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Unesbulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Presentation of A Scientific Abstract at The 82nd Scientific Sessions of The American Diabetes Association","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"SARS-CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Biogen","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Bio-Thera Solutions","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ B.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ Assay as a Standard for MRD Assessment Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptive Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive B.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces New Data at the Macula Society's 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Helsinn's Oncology Pipeline Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vepafestinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-GI.1.NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces Upcoming Scientific Conference Presentations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Shows Effectiveness of Merakris Wound Care Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merakris Therapeutics \/ University of Texas Medical Branch","highestDevelopmentStatusID":"8","companyTruncated":"Merakris T.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cstone and Pfizer Announce NMPA Approval of Sugemalimab in Patients With Unresectable Stage III Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approval of Lymphoma Medicine Ukoniq (Umbralisib) Is Withdrawn Due to Safety Concerns","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Data for Janssen\u2019s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CG Oncology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Nucleai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Naratuximab Emtansine","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nucleai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nucleai \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nucleai \/ .."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR\/MSI-H Solid Tumors, at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody\u00ae Program at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LB101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Presents New Data from VX-880 Phase 1\/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RP-2000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-097558","moa":"SARS-CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ALN-APP","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Lilly and Incyte's OLUMIANT\u00ae (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Statement on The Out-Licensing Agreement for Investigational Sonelokimab (M1095)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Epicatechin","moa":"Mitochondrial protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Piramal Pharma Solutions \/ Epirium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Ph.."},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Ph.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"BDC-1001","moa":"HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Piramal","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Piramal Pharma Solutions Announces Sterile Fill\/Finish Program with Theratechnologies Inc. for TH1902 Peptide-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Agreement","leadProduct":"TH1902","moa":"Sortilin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Piramal","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"$73.0 million","newsHeadline":"Organon Enters into Global License Agreement to Commercialize Henlius\u2019 Investigational Perjeta\u00ae (Pertuzumab) and Prolia\u00ae\/Xgeva\u00ae (Denosumab) Biosimilar Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"D. E. Shaw Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$535.0 million","upfrontCash":"$60.0 million","newsHeadline":"D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"DES-7114","moa":"Kv1.3 channel","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"D. E. Shaw Research","amount2":0.54000000000000004,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"D. E. Shaw Research \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"D. E. Shaw.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$30.0 million","newsHeadline":"Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Taiwan Liposome Company","amount2":0.14000000000000001,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Steroid","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Taiwan Liposome Company \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Immunogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"OBT227","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ ImmunoGen","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Op.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"BWX Technologies","sponsor":"TRIUMF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRIUMF and BWXT Medical Execute Agreement for Manufacture of Ac-225 Based Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"n.c.a Ac-225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BWX Technologies \/ TRIUMF","highestDevelopmentStatusID":"1","companyTruncated":"BWX Techno.."},{"orgOrder":0,"company":"Open Book Extracts","sponsor":"Biopharmaceutical Research Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Open Book Extracts & Biopharmaceutical Research Company Establish Research & Development Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Open Book Extracts","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Open Book Extracts \/ Biopharmaceutical Research Company","highestDevelopmentStatusID":"1","companyTruncated":"Open Book .."},{"orgOrder":0,"company":"VectivBio","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company, a Sorrento Company, Enters Into an Agreement for An Exclusive License With ROMEG Therapeutics, LLC, For the Right to Commercialize Gloperba, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults, in the US","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"RxOMEG Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Solution","sponsorNew":"RxOMEG Therapeutics \/ Scilex Holding","highestDevelopmentStatusID":"12","companyTruncated":"RxOMEG The.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Health Emergency Preparedness and Response Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Health Emergency Preparedness and Response Authority","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Clinton Health Access Initiative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Cefiderocol","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shionogi \/ Clinton Health Access Initiative","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Trutino Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"ODC-IL2","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Trutino Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trutino Biosciences \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Trutino Bi.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Ksana Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beckley Psytech Announces Partnership With Ksana Health, Building on Digital Strategy to Deliver Optimised Patient Outcomes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Ksana Health","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Earlybird","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series C Financing","leadProduct":"ICT01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ImCheck Therapeutics \/ Earlybird","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi\u00ae (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Lenalidomide","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Announces Public Offering of Units","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Carnegie Mellon University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carnegie Mellon Exosome Engineering Tech Licensed to Coya Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Treg-derived Exosomes","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Carnegie Mellon University","highestDevelopmentStatusID":"1","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Hong Kong Winhealth Pharma Group","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Hong Kong Winhealth Pharma Group","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hong Kong Winhealth Pharma Group \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Hong Kong .."},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series B Financing","leadProduct":"NPI-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Ph.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"AFNT-111","moa":"KRAS G12V","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Affini-T Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Pembrolizumab","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$37.5 million","newsHeadline":"Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Civica Rx","sponsor":"GeneSys Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Financing","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Civica Rx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Civica Rx \/ GeneSys Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Civica Rx .."},{"orgOrder":0,"company":"Humanigen","sponsor":"PCI Pharma Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ PCI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$172.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Invectys","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invectys, MD Anderson And CTMC Announce Strategic Collaboration For Car T Cell Therapy Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"HLA-G\/CAR-T Cell Therapy","moa":"HLA-G","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ MD Anderson","highestDevelopmentStatusID":"5","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"Lenire Biosciences","sponsor":"University College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"VSN16R","moa":"KCa channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lenire Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lenire Biosciences \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"Lenire Bio.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"PLN-1474","moa":"Integrin Alpha5beta1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Cresence","sponsor":"Bioasis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"CRES101","moa":"M2 polarization","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Cresence","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cresence \/ Bioasis","highestDevelopmentStatusID":"5","companyTruncated":"Cresence \/.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$25.0 million","newsHeadline":"Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$205.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scholar Rock Announces $205 Million Registered Direct Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0.20999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"JATT Acquisition Corp","sponsor":"Zura Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$65.0 million","newsHeadline":"JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Merger","leadProduct":"ZB-168","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"JATT Acquisition Corp","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JATT Acquisition Corp \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"JATT Acqui.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1068.5 million","upfrontCash":"$72.3 million","newsHeadline":"Cresemba\u00ae Sales in Asia Pacific Region Trigger Sales Milestone Payment to Basilea from Pfizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":1.0700000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.0700000000000001,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"HealthCap","pharmaFlowCategory":"D","amount":"$26.4 million","upfrontCash":"Undisclosed","newsHeadline":"Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"Satoreotide Tetraxetan","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ariceum Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Solution For Injection","sponsorNew":"Ariceum Therapeutics \/ HealthCap","highestDevelopmentStatusID":"7","companyTruncated":"Ariceum Th.."},{"orgOrder":0,"company":"Crossject","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agreement with BARDA on ZENEO\u00ae Midazolam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.059999999999999998,"dosageForm":"Intramuscular injection","sponsorNew":"Crossject \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"MetasTx","sponsor":"J-Star Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MetasTx LLC Raises Funds, Engages J-STAR Research as Manufacturing Partner, and Advances Phase One Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"IPA-3","moa":"PAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MetasTx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MetasTx \/ J-STAR Research","highestDevelopmentStatusID":"4","companyTruncated":"MetasTx \/ .."},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Enters a Drug Discovery Collaboration with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Janssen","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ J.."},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Nanoparticle-based DNA Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral M.."},{"orgOrder":0,"company":"Phase Genomics","sponsor":"Bill and Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"With New Funding, Phase Genomics Seeks to Eliminate One of Biology\u2019s Biggest Blind Spots","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Phage Therapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Phase Genomics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Phase Genomics \/ Bill and Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Phase Geno.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"VLA15","moa":"OspA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"225 Ac-conjugated PSMA","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ratio Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ratio Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Ratio Ther.."},{"orgOrder":0,"company":"xFOREST Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otsuka Enters Collaboration with xFOREST Therapeutics on RNA Structure- \nTargeted Drug Discovery Covering Multiple Diseases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"xFOREST Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"xFOREST Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"xFOREST Th.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Esteve Launches INBRIJA\u00ae in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"Decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Centogene and Agios Expand Partnership for Clinical Development of PYRUKYND (mitapivat) to Treat Children With Rare Blood Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centogene \/ Agios","highestDevelopmentStatusID":"10","companyTruncated":"Centogene .."},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Cannabichromene","moa":"TRPA1","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Baymedica","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Baymedica \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Baymedica .."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR Mimic CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"SIFI","sponsor":"Durbin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sifi Announces EMA Validation Of Its Marketing Authorisation Application For Akantior For The Treatment Of Acanthamoeba Keratitis And The Opening Of An Early Access Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"SIFI \/ Durbin","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Dur.."},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-712","moa":"CLK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Chordia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chordia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chordia Th.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-018","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa's Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pidnarulex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OriCell Reports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at American Society of Clinical Oncology (ASCO) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OriCAR-017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OriCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"MRM Health","sponsor":"University Hospital of Vall d\u2019Hebron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"9-Strain Live Bacterial Consortia Therapeutic","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ University Hospital of Vall d\u2019Hebron","highestDevelopmentStatusID":"4","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"VEGFR 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Icatolimab","moa":"BTLA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Provides Key Strategic Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VIP152","moa":"PTEFb\/CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CCX559","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treosulfan Pivotal Study Results Published","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-6402","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ABI-H3733","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OV329","moa":"GABA-AT","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Vaccitech","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Dose\u2011Ranging Clinical Trial Results of CTP\u2011543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"ECP Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ECP Pharma\u2019s Path Forward Clearer After FDA\u2019s Response To Pre-IND Submission On Its Neurological, CNS Diseases Drug Products","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ECP-101","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"ECP Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ECP Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ECP Pharma.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Presented Clinical Data Supporting Seizure Cluster Interval Analysis At The Epilepsy Foundation Pipeline Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK\/ALK\/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society\u00ae (AHS) Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"TargImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TargImmune Announces Successful Completion of GLP\/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TAR001","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TargImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TargImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TargImmune.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus to Present Seven Scientific Posters at EASL International Liver Congress 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Todos Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Plant Extracts","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ 3CL Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Participates in the Kinin 2022 Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PHVS416","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Clearmind medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Presentations at ENDO 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY\u20112 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TERN-101","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Present New Data at the EASL International Liver Congress\u2122 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL\u2019s International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Announces Presentations During The International Liver Congress\u2122 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PBML04","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"5","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Alberta","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"FRAXA Research Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex\u2019s Publication Supports Clinical Biomarker for ANAVEX\u00ae2-73 in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Anavex Life Sciences \/ FRAXA Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for BioCryst\u2019s ALK-2 Inhibitor, BCX9250","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BCX9250","moa":"Alk2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"9vHPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announces Several Scientific Abstracts to Be Presented at the Upcoming Endo Society Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Presentation of Additional Phase 2 Data on Denifanstat Identifying a Predictive Metabolic Signature in NASH Patients at EASL\u2019s International Liver Congress (ILC) 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Denifanstat","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"PathAI, inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PathAI To Present Three Abstracts at International Liver Congress 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"PathAI, inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PathAI, inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PathAI, in.."},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SBT115301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Bio.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-297","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Enanta Pharmaceuticals \/ PRA Health Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences to Present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"XW003","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Bio Elpida","sponsor":"Biovaxys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BVX-0918","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bio Elpida","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio Elpida \/ BioVaxys Technology Corp","highestDevelopmentStatusID":"5","companyTruncated":"Bio Elpida.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TP-3654","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gennova Closes in On Nod for mRNA Vax Developed in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib\u2019s Potential for the Treatment of PAH","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Seralutinib","moa":"PDGFR\/ CSF1R\/ c-KIT","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent Supports U.S. Launch of Phathom Pharmaceuticals\u2019 New Products Following Regulatory Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Study Published in Epilepsia, a World-class Journal Dedicated to Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Isotopia","sponsor":"CPDC Centre for Probe Development and Commercialization","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"No-Carrier-Added Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Isotopia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotopia \/ CPDC Centre for Probe Development and Commercialization","highestDevelopmentStatusID":"1","companyTruncated":"Isotopia \/.."},{"orgOrder":0,"company":"ResVita Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ResVita Bio Receives Rare Pediatric Disease Designation for RVB-001 as a Treatment for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RVB-001","moa":"Proteolysis","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"ResVita Bio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ResVita Bio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ResVita Bi.."},{"orgOrder":0,"company":"Biorchestra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIORCHESTRA, Presenting Lead Candidate BMD-001 for Alzheimer's disease and Drug Delivery System Technology at the 2022 BIO International Convention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BMD-001","moa":"MiR-485-3p","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Biorchestra \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestr.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"LPS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"T Cell surface glycoprotein CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Pivotal Phase III Data for Its Respiratory Syncytial Virus (RSV) Vaccine Candidate for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AS01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Presentations at Upcoming Hematology Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant Announces Data Presentation at European Hematology Association 2022 Hybrid Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GRT-R910","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Venthera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BBP-681","moa":"PI3K","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"BridgeBio Pharma \/ Venthera","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-5948","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Gets USFDA Nod for Cancer Treatment Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dasatinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy\u00ae in Heavily Pre-treated HR+\/HER2- Metastatic Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Everest Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pozelimab","moa":"C5 complement","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CEND-1","moa":"Alpha V integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody\u00ae-CD3xCD20) in Patients with Relapsed\/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Granted US Patents Directed To CNS And Liver Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Dodecanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company's Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Provides Update on NASH Regulatory Timeline","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Announces Submission of Clinical Trial Application for Belgium Phase 3 study of LBS-008","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"Alpha\/Beta globulin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ\u00ae) in Patients with Axial Spondyloarthritis at EULAR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Head-To-Head Data Show Vectibix\u00ae (panitumumab) Demonstrated Superior Overall Survival Compared to Bevacizumab in Combination with Chemotherapy in Japanese Patients with Wild-Type Ras Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Panitumumab","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Demonstrates Pipeline and Portfolio Strength Across Malignant and Rare Haematological Diseases at EHA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukaemia With 90% of Patients Surviving Five Years in Elevate-tn Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Abatacept","moa":"GMP-AMP synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae (Empagliflozin) Decreased Relative Risk of Hospitalization for Heart Failure by 50% Versus Dpp-4 Inhibitors and by 30% Versus Glp-1 Receptor Agonists in Adults With Type 2 Diabetes in Real-world Evidence Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Award-peds Trial Investigating Use of Trulicity\u00ae (Dulaglutide) in Youth and Adolescents With Type 2 Diabetes Showed Superiority in A1C Reduction Vs Placebo","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trodelvy\u00ae Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+\/HER2- Metastatic Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces US FDA Approval of Priorix for the Prevention of Measles, Mumps and Rubella in Individuals 12 Months of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Live Measles, Mumps and Rubella Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI\u2122 (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 SHINE Results Show IMBRUVICA\u00ae (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback Announce New Data For Investigational LAGEVRIO\u2122 (molnupiravir) From Phase 3 MOVe-OUT Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Favezelimab","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Inuenza Vaccine Candidate (mRNA-1010)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1010","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Tafinlar\u00ae (Dabrafenib) + Mekinist\u00ae (Trametinib) Demonstrates Unprecedented Efficacy in Pediatric Patients With BRAF V600 Low-grade Gliomas in Phase II\/III Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Novartis Data Show Piqray\u00ae Effectiveness Across Key Biomarkers in Patients With Hr+\/her2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Alpelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New CDK4\/6I Data at Asco Reinforce Novartis Kisqali\u00ae as Only Drug in Class With Consistently Proven Overall Survival Benefit in Hr+\/her2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch in Japan of Moizerto\u00ae Ointment, a Treatment for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Elranatamab","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Roche\u2019s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Roche\u2019s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi, a Leader in Immune-mediated Rare Blood Disorders, to Present Latest Data at EHA 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001\u2122 at the 2022 Annual European Hematology Association (EHA) Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and\/or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"9","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analysis of Pooled Data from TEPEZZA\u00ae (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OR-449","moa":"SF-1\/ NR5A1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orphagen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen P.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody\u00ae-CD3xCD20) in Relapsed\/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT\u2122-LYM Trial of CTX130\u2122 in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX130","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versanis Presents Data Demonstrating Bimagrumab Treatment Leads to Substantial Fat Mass Loss Coupled with Lean Mass Gain in Diabetic and Non-Diabetic Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis B.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk a\/s: Sogroya\u00ae Data Show Potential as Once-weekly Treatment in Children Living With Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Perelman School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Five-year Kymriah\u00ae Data Show Durable Remission and Long-term Survival Maintained in Children and Young Adults With Advanced B-cell ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Perelman School of Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"9","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu Announces First Patient Dosed in the US Phase IIa Clinical Trial of NeoMIDES\u2122 Molecular Glue KPG-818 in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"KPG-818","moa":"CRL4-CRBN","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Bio.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA\u2122 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Etana","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Etana Jointly Announce the Approval of Bevagen\u00ae (Bevacizumab Biosimilar) by the Indonesian Food and Drugs Authority (BPOM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Etana","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"QXL138AM","moa":"CD138","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nammi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nammi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nammi Ther.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domp\u00e9 Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Reparixin","moa":"IL-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"Amivas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMIVAS Ireland Ltd. Receives Authorisation from the Medicines & Healthcare Products Regulatory Agency (MHRA) to Market Artesunate Amivas (artesunate) in U.K. for Initial Treatment of Severe Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Artesunate","moa":"Malaria protein EXP-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Amivas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amivas \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amivas \/ N.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RGLS8429","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Avexitide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec\u00ae ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Treatment for Angelman Syndrome Receives Orphan Drug and Rare Pediatric Disease Designations From U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ION582","moa":"UB3EA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Curocell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curocell Announced Impressive CR Rate in Phase 1 Study With Anbal-cel, the Next Generation Cd19 Car-t Integrated Ovis\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Anbalcabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Curocell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curocell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curocell \/.."},{"orgOrder":0,"company":"Vitalunga","sponsor":"Hebrew University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Startup Vitalunga Creates Novel Oral Drug to Enable Disease-free Aging; Pre-clinical Studies Expected to Begin in Near Future","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Vitalunga","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitalunga \/ Hebrew University","highestDevelopmentStatusID":"2","companyTruncated":"Vitalunga .."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruna Bio Announces Issuance Of A New Composition Of Matter Patent Covering Neural Exosomes In Japan","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RKER-012","moa":"TGF-beta","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP900","moa":"YES1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SZN-043","moa":"Wnt signalling pathway","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1\/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Autoimmunity Modifying Biologicals","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Clinical Site Initiation for the Company\u2019s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bendamustine","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces FDA Approval of AMVUTTRA\u2122 (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals to Showcase LIVMARLI\u00ae (maralixibat) Data at EASL and ESPGHAN Annual Congresses","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ALPHA-0702","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"BeiGene","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces BRUKINSA\u2122 (zanubrutinib) Is Approved in 50 Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drugmakers Seem to Be in No Hurry to Launch Covid Antiviral Pill Paxlovid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation Botulinumtoxina (Relabotulinumtoxina) for the Treatment of Glabellar Lines (Frown) and Lateral Canthal Lines (Crow\u2019s Feet)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"Ach","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute \u201cLong\u201d COVID with Respiratory Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"JIN-A02","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication Showing ZYNRELEF\u00ae as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Will Report Positive Phase 1b Trial Results on Its Hbv Capsid Inhibitor Zm-h1505r in the Upcoming International Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ZM-H1505R","moa":"HBV capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Zhimeng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huyabio International Announces Initiation Of Hbi-3000 Phase 2 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulcardine Sulfate","moa":"Multi-Ion Channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Completes Dosing in Phase 1 Trial of Universal Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CodaVax-H1N1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covis Pharma Provides Update on FDA Public Hearing for Makena","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Covis Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Covis Phar.."},{"orgOrder":0,"company":"Pike Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pike Therapeutics Announces Positive Pharmacokinetic Animal Study Results and Unexpected Benefits for its Proprietary Weekly CBD Continuous Transdermal Delivery Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Pike Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Pike Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pike Thera.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nimodipine","moa":"Calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Doses First Patient with SCB-219M in Phase 1 Trial for Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SCB-219M","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect's Direct Lytic Agents (DLAs) to Address MRSA Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK in Post-Operative Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"EsoCap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esocap Holds a Multidisciplinary Advisory Board Meeting on Barrett's Esophagus","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Reports Additional Data on PAXLOVID\u2122 Supporting Upcoming New Drug Application Submission to U.S. FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-rhPSMA-10.1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Blue Earth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tremeau Receives May Proceed Notification From FDA For Phase III Program in Acute Migraine For TRM-201 (Rofecoxib)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Ph.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII\u2019s Cervical Cancer Vaccine: SEC to Review HPV Jab Trial Data Today","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetravalent HPV Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RADICAVA ORS\u00ae (edaravone) Now Available in the U.S. for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184, a Novel NEK7\/NLRP3 Inhibitor","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"HT-6184","moa":"NEK7","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Ther.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2\/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PT886","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-413","moa":"IRAKIMiD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Presentations at the International Liver Congress 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Announces Approval of GIMOTI to Florida State Medicaid Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA (nusinersen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177-edotreotide","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"ClearB Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CLB-3000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ClearB Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ClearB Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ClearB The.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announces Positive Data From Phase III Linc 4, Phase III Linc 3, and Illustrate ISTURISA\u00ae Studies Presented at ENDO 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Progranulin","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis at Keystone Symposia Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LASN01","moa":"IL-11","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lassen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lassen The.."},{"orgOrder":0,"company":"Prothione","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamic Acid","moa":"Glutathione peroxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Prothione","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prothione \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothione .."},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astrocyte Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte .."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CK0804","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phexxi\u00ae Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore announces first human dosed with novel ATRAG, C106","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"C106","moa":"Angiotensin II receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE recommends use of Hansa Biopharma's Idefirix\u00ae (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bit.bio Presents Data at ISSCR Demonstrating Their Platform Capability to Create Any Human Cell","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-201","moa":"MYBPC3 Gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TREM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Imm.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cornerstone Pharmaceuticals Announces Published Data on CPI-613\u00ae (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism \u2013 UPDATE","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-VV100","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Presents Data on Combination Therapy with INB03\u2122 on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"INB03","moa":"TNF alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Galecto","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"Galectin 3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Roche","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1\/2a Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Reldesemtiv","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Terminates Dipraglurant Phase 2b\/3 Study in Patients with Dyskinesia Associated with Parkinson\u2019s Disease due to Slow Recruitment Rate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"mGlu5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Danone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Infant Formula Update: June 17, 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Iron","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Danone","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Danone \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Danone \/ N.."},{"orgOrder":0,"company":"Brand Institute","sponsor":"Myovant Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for European Commission Approved Treatment for Advanced Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Brand Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brand Institute \/ Myovant Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Brand Inst.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Theramex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces European Commission Marketing Authorization for Yselty\u00ae (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ T.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CY6463","moa":"sGC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress\u2122 on June 25, 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solasia Pharma: DARVIAS\u00ae Injection 135mg (Generic Name: DARINAPARSIN \/Development Code: SP-02) Approved in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Darinaparsin","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Solasia Pharma KK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Solasia Pharma KK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Solasia Ph.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech's Covid-19 Nasal Vaccine Phase IIITrials Completed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"AOP Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi\u00ae (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AOP Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"AOP Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AOP Health.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Announce the Approval of TYVYT\u00ae (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces Results Of 2022 AGM","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna\u2122 (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ataluren","moa":"80s ribosome","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix to Share New Data from XIFAXAN\u00ae (Rifaximin) Clinical Research at EASL's International Liver Congress\u2122 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"XB2001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi-GSK Next-generation Covid-19 Booster Delivers Strong Immune Response Against Variants of Concern, Including Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Protein-Based COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla and DNDi Launch Child-Friendly 4-in-1 Antiretroviral Treatment for Young Children Living with HIV in South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Abacavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Positive Interim Results from RegistrationEnabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Provides Update on The Phase 3 Program for Its Covid-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE\u00ae (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SKYRIZI\u00ae (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Application for Proposed Biosimilar Adalimumab\u2019s High Concentration Formulation Accepted by EMA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eplontersen Met Co-primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III trial For Hereditary Transthyretin-mediated Amyloid Polyneuropathy (ATTRv-PN)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rivaroxaban (Xarelto\u2122) Approved in Japan for Patients With Peripheral Artery Disease (Pad) After Revascularisation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Hemlibra for Additional Indication of Acquired Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Partial Change Approval for Neutrogin and Avastin Based on Public Knowledge-based Applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenograstim","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention of Recurrence of Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Zenyaku Kogyo","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Zenyaku Ko.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Therapy for Stage IB (\u22654 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Nature Medicine Publication of Zolgensma Data Demonstrating Age-appropriate Milestones When Treating Children With SMA Presymptomatically","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of schizophrenia in Adult Patients Stabilised with Aripiprazole","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Syringe","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY\u00ae Subcutaneous Injection 225 mg for Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Banner Alzheimer\u2019s Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche provides update on Alzheimer\u2019s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Banner Alzheimer\u2019s Institute","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"EXS-21546","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"UX111","moa":"AAV9 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Enteric Capsule","sponsorNew":"Tenax Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biovaxys \/ Hospices Civils de Lyon","highestDevelopmentStatusID":"5","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"Jawaharlal Nehru Centre for Advanced Scientific Research","sponsor":"India Globalization Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGC Acquires Exclusive Rights for a Potential Alzheimer\u2019s Drug Development Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"TGR-63","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Jawaharlal Nehru Centre for Advanced Scientific Research","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jawaharlal Nehru Centre for Advanced Scientific Research \/ India Globalization Capital","highestDevelopmentStatusID":"4","companyTruncated":"Jawaharlal.."},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Genistein","moa":"PTK","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Vanquish Group","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo Expands Beyond Spain Into Latin America, Disrupting Erectile Dysfunction (ED) Market With Oral Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Vanquish Group","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Vanquish Group \/ Aspargo Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Vanquish G.."},{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"CBR","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cronos Group \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Gro.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Juntendo University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Juntendo University","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX\u00ae (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"HGF IgG1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ AVEO Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Alpha-5 integrin","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Alpha-5 Integrin Monoclonal Antibody","moa":"Alpha V integrin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha-5 integrin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha-5 integrin \/ Pasithea Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpha-5 in.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Centre for Addiction and Mental Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Centre for Addiction and Mental Health","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Biocept Inc","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocept Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocept Inc \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Biocept In.."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"Affilogic","sponsor":"Apellis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"APL-1030","moa":"Complement C3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Affilogic","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affilogic \/ Apellis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Affilogic .."},{"orgOrder":0,"company":"Biocartis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocartis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocartis \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Biocartis .."},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Molecure To Regain Worldwide Rights to Dual Chitinase Inhibitor OATD-01","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"OATD-01","moa":"Chitinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Molecure","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"Molecure \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Pfizer Announce Closing of Equity Investment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"VLA15","moa":"OspA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"$9.3 million","upfrontCash":"Undisclosed","newsHeadline":"Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"$405.0 million","upfrontCash":"$275.0 million","newsHeadline":"Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081\/TAS6417","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"invoX","pharmaFlowCategory":"D","amount":"$161.0 million","upfrontCash":"$161.0 million","newsHeadline":"invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"FS118","moa":"PD-L1\/LAG-3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ invoX","highestDevelopmentStatusID":"7","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Ziphius Vaccines","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"ZIP-1642","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ziphius Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ziphius Vaccines \/ Charles River Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Ziphius Va.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Sale of Hospital Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Eton Pharmaceuticals \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Biopharmaceuticals Forged Strategic Partnership with Dragon Sail Pharmaceutical to Upgrade Integrated Innovative Antibody Drug R&D","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Bio.."},{"orgOrder":0,"company":"Chimerix","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","amount":"$25.3 million","upfrontCash":"Undisclosed","newsHeadline":"Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$512.5 million","upfrontCash":"$90.0 million","newsHeadline":"Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Immunostimulatory Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sutro Biopharma","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Biocodex","sponsor":"PANTHERx Rare Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx Rare Announces Partnership with Biocodex for the Distribution of DIACOMIT\u00ae (stiripentol) for the Treatment of Seizures Associated with Dravet Syndrome in Patients 2 Years of Age and Older Taking Clobazam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Stiripentol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biocodex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ PANTHERx Rare","highestDevelopmentStatusID":"12","companyTruncated":"Biocodex \/.."},{"orgOrder":0,"company":"BIOKEY","sponsor":"Rgene Corporation","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"RGC-1501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BIOKEY","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BIOKEY \/ Rgene Corporation","highestDevelopmentStatusID":"4","companyTruncated":"BIOKEY \/ R.."},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging\/Anti-Wrinkle Compound for Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"TFC-1326","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"WuXi AppTec","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Sirona Biochem","highestDevelopmentStatusID":"4","companyTruncated":"WuXi AppTe.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Sapien Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Sapien Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group Partners with Geocann to Leverage VESIsorb Delivery Technology for Faster Absorption","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Gro.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Announces Pricing of Public Offering of Units","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"BT-001","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Kovina Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kovina Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Kovina The.."},{"orgOrder":0,"company":"Scohia Pharma","sponsor":"Kuria Therapeutics","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"KTX-101","moa":"Nrf2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Scohia Pharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Scohia Pharma \/ Kuria Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Scohia Pha.."},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Acc-225","moa":"Ionising radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BWX Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BWX Technologies \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"BWX Techno.."},{"orgOrder":0,"company":"Wockhardt","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Pharmaceuticals Inc., USA Continues to Expand Its Over-The-Counter (OTC) Portfolio With the Acquisition of Approved ANDAs From Wockhardt Limited","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Famotidine","moa":"H2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Wockhardt","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wockhardt \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced N.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Niraparib","moa":"Polymerase theta helicase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0.95999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$94.5 million","upfrontCash":"Undisclosed","newsHeadline":"89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Bo.."},{"orgOrder":0,"company":"Optimi Health","sponsor":"SABI Mind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ SABI Mind","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Hea.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell and CAR-NK Cell Therapies for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"IPSC-derived CAR NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ ONO Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"VeriSIM","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VeriSIM Life Enters into Collaboration Agreement with Mayo Clinic to Jointly Advance Drug Discovery and Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"VeriSIM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VeriSIM \/ Mayo Clinic","highestDevelopmentStatusID":"3","companyTruncated":"VeriSIM \/ .."},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Lynx1 Capital Management","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Series C Financing","leadProduct":"Sodium Valproate","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Lynx1 Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral T.."},{"orgOrder":0,"company":"Maxima Pharmaceuticals","sponsor":"Medisca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medisca Acquires all IP assets of Maxima Pharmaceuticals Including the DIFFUSIMAX\u00ae Brand","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Pluronic Lecithin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maxima Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maxima Pharmaceuticals \/ Medisca","highestDevelopmentStatusID":"12","companyTruncated":"Maxima Pha.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","amount":"$196.5 million","upfrontCash":"Undisclosed","newsHeadline":"Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Bifunctional HER2-Sialidase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"BiomX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Engineered Phage Therapy","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"BiomX \/ Bo.."},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Generian Pharmaceuticals","amount2":0.17999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Generian Pharmaceuticals \/ Mitobridge","highestDevelopmentStatusID":"3","companyTruncated":"Generian P.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Harvard Medical School","highestDevelopmentStatusID":"2","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series B Financing","leadProduct":"MB272","moa":"BTLA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MiroBio \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ .."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Series B Financing","leadProduct":"SORT LNP-based DNAI1 mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Aerosol","sponsorNew":"ReCode Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,895.0 million","upfrontCash":"$198.0 million","newsHeadline":"Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":1.8999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$10.0 million","newsHeadline":"Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Financing","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.02,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Synaffix","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"$5.0 million","newsHeadline":"Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Private Placement","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ New Enterprise Associates","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$192.5 million","upfrontCash":"$10.0 million","newsHeadline":"Dare Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Vaxart","sponsor":"hVIVO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxart Announces Agreement with hVIVO to Develop World's First Human Omicron Challenge Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ hVIVO Services Limited","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ h.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"VHH Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Public Offering","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Renews License Triggering Payment to Avacta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"PD-L1 XT","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Osivax","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ B.."},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Eversana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord Bio and EVERSANA Announce Partnership to Support the Launch of CAMCEVI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Accord BioPharma \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Accord Bio.."},{"orgOrder":0,"company":"Ermium Therapeutics","sponsor":"Kurma Partners","pharmaFlowCategory":"D","amount":"$12.8 million","upfrontCash":"Undisclosed","newsHeadline":"Ermium Therapeutics Extends Its Initial \u20ac6.3 M Funding to \u20ac12.3 M","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"CXCR4","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ermium Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ermium Therapeutics \/ Kurma Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ermium The.."},{"orgOrder":0,"company":"Canntab Therapeutics","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Canntab Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Canntab Therapeutics \/ MediPharm Labs","highestDevelopmentStatusID":"12","companyTruncated":"Canntab Th.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"OncoBeta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avion Medical Skin Centres to Offer Innovative Treatment for Non-Melanoma Skin Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Rhenium-188","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Avion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Paste","sponsorNew":"Avion Pharmaceuticals \/ OncoBeta","highestDevelopmentStatusID":"12","companyTruncated":"Avion Phar.."},{"orgOrder":0,"company":"Drugs for Neglected Diseases initiative","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"Wellcome Renews Partnership With DNDi to Develop New Generation Drugs to Treat Leishmaniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"LXE408","moa":"Proteasome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Drugs for Neglected Diseases initiative","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Drugs for Neglected Diseases initiative \/ Wellcome","highestDevelopmentStatusID":"8","companyTruncated":"Drugs for .."},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-1500","moa":"CD40L","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China\u2019s NMPA for YUTIQ\u00ae for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents Positive Results from Phase 1\/2 Study Evaluating V116, the Company\u2019s Investigational Pneumococcal Conjugate Vaccine for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO\u00ae (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BioLexa","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics Based on its Proprietary GalAhead\u2122 Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"STP122G","moa":"Factor XI expression","url1":"","url2":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin\u00ae in R\/R Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceruvia Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Li.."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Febrile Neutropenia in Cancer Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase II Study Data for ARAKODA\u00ae (tafenoquine) in Patients with Mild-Moderate COVID-19 Disease Published by New Microbes and New Infections; Larger Studies Planned to Confirm ARAKODA Accelerates Clinical Recovery in Mild-Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AddaVax","moa":"Mullerian hormone receptor II","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RGLS8429","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH\u00ae NDA Tentatively Scheduled for November 16, 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics' PT217 Receives Orphan Drug Designation for Small Cell Lung Cancer from the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PT217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NVL-520","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-189","moa":"SHP2 Allosteric","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Phase 3 PROpel Trial of LYNPARZA\u00ae (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Purdue Pharma Introduces Nalmefene HCl Injection, 2mg\/2mL (1mg\/1mL) in the U.S. for the Treatment of Known or Suspected Overdose with Natural or Synthetic Opioids","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma Aesthetics Canada Launches Saypha\u00ae VOLUME PLUS","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Hyaluronic acid","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Hugel","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hugel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hugel \/ No.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA\u00ae for Patients with First-Line Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"COR803","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tranquis Therapeutics Granted FDA Orphan Drug Designation for TQS-168 for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TQS-168","moa":"PGC-1a","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis T.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Affinivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AFX3772","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Affinivax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medsenic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals' NUZYRA Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces FDA Clearance of IND for NXP800","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Teclison","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with Unresectable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirapazamine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Teclison","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teclison \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Teclison \/.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel (HAV) for Repair of Vascular Trauma Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"Vascular Cell","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces PBC Data Presentations at The International Liver Congress\u2122 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Talazoparib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Duchesnay","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Duchesnay Announces the Launch of Vablys (dequalinium chloride vaginal tablets), an Antiseptic and Anti-Infective Treatment for Bacterial Vaginosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dequalinium Chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Duchesnay","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Duchesnay \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay .."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Phase Ib NMIBC Clinical Study Published","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Tafinlar + Mekinist Receives FDA Approval for First Tumor-Agnostic Indication for BRAF V600E Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Radius Health \/ Menarini Group","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"SK Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Efficacy and Safety Data of XCOPRI\u00ae (cenobamate tablets) CV Published in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Life Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Life Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Life Sc.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ZT-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara The.."},{"orgOrder":0,"company":"Flugen","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluzone HD IIV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flugen \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ U.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress\u2122 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TERN-101","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"INT301","moa":"Allergen Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"Irreversible menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CY6463","moa":"sGC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healthy Extracts\u2019 WHITNEY JOHNS ACTIVE\u2122 Clinically Proven to Enhance Physical Performance by Increasing Nitric Oxide by 73% and Oxygen Consumption by 24%","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"choline","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Ex.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL\u2019s International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ABI-H3733","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Brahm Segal Appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Launches IMCIVREE\u00ae (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RTX-T1D","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE\u00ae 327","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BBP-812","moa":"ASPA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces ORLADEYO\u00ae (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces Data From Secondary Analyses of the CHELATE Trial for Maintenance Patients With Wilson\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech's VTP-300 Induced Sustained Reductions of Surface Antigen in Patients With Chronic Hepatitis B Both as a Monotherapy and in Combination With a Single Low Dose of Anti-PD-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cethrin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"BioAxone BioSciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"BioAxone BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAxone B.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s CSO Hails Dostarlimab\u2019s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CLS-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Positive New Clinical Findings Evaluating VIVJOA\u2122 (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Uniqure Announces Update on Low-Dose Cohort in Phase I\/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Lucius Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VTX-067","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voltron Therapeutics \/ Lucius Partners","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Th.."},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bantam Pharmaceutical and Collaborators to Present New Data in Support of its Clinical Candidate BTM-3566 at Third AACR International Meeting - Advances in Malignant Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BTM-3566","moa":"HRI Kinase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bantam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bantam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bantam Pha.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Leaders Presentation at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"225Ac-IPN-1087","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX-097","moa":"Complement activity","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Initiates Phase 1b\/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt to Present Data on Terlipressin in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed\/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Mivavotinib","moa":"Syk kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Soroka University Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Treg-derived Exosomes","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProKidney Corroborates the Mechanism of Action of REACT with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Filsuvez\u00ae for the treatment of Dystrophic and Junctional EB","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Birch Bark Extract","moa":"Keratinocytes","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"University of Miami Miller School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ University of Miami Miller School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Releases Preliminary Data From IRB-Waived Tollovid Market Research Study in Acute and Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Plant Extracts","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics to Host KOL event on Monday, June 27, to Discuss Therapies in wet Age-Related Macular Degeneration and Potential Advantages of KIN001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Selonabant","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma Aesthetics Canada Ltd. Receives Canadian Market Authorization for Letybo (LetibotulinumtoxinA for Injection) for the Treatment of Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LetibotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Hugel","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hugel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hugel \/ No.."},{"orgOrder":0,"company":"Novaremed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USA FDA Grants Fast Track Designation to ReAlta Life Sciences\u2019 Lead Compound RLS-0071 for the Treatment of Hypoxic-Ischemic Encephalopathy In Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RLS-0071","moa":"Complement","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment With Hepcludex\u00ae (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Amring Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Timolol Maleate","moa":"ADRB","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Amring Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amring Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amring Pha.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"DermBiont","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SM-020","moa":"AKT","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Begins Multinational Phase 2 Clinical trial for DWN12088, a New Drug for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bold Therapeutics BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"GRP78 upregulation pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Regeneron","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences to Present at the H.C.wainwright 1st Annual Mental Health Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tobacco Leaf Protein","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ART26.12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Presentations at the International Liver Congress\u2122 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PLN-74809","moa":"Alpha5Beta1\/Alpha5Beta6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona\u2019s Preclinical Candidate SAN903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SAN903","moa":"KCa3.1","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ University of Arhus","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Approval for Additional Formulation of Antifungal Cresemba\u00ae (Isavuconazole) in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA\u00ae (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Biolexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II\/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akston Biosciences \/ Biolexis","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harrow Health Announces Launch of IOPIDINE\u00ae 1% and MAXITROL\u00ae in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ N.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CF602","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (\u226512 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Versantis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versantis Presents New VS-01 Data at The International Liver Congress 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VS-01","moa":"Ammonia clearance","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Versantis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Versantis .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Presents New Data at The International Liver Congress\u2122 of the European Association for the Study of the Liver (EASL)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Volixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Recommended for Approval in the EU by CHMP for Patients with HER2-Positive Metastatic Breast Cancer Treated with a Prior anti-HER2-based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NTAGI to Review Trial Data on SII's qHPV Vaccine Against Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Announce Positive Progress for BT-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BT-001","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Givinostat","moa":"HDAC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"The Italfarmaco Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfa.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Upadacitinib (RINVOQ\u00ae) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Announce the Approval of TYVYT\u00ae (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AT845","moa":"GAA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ATI-2173","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Presentation of Positive Phase 2b Data for Chronic Hepatitis B Treatment at the EASL International Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bepirovirsen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL\u2019s International Liver Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"HBsAg expression","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress\u2122 2022 and Provides AB-836 Clinical Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Announces the Presentation of Initial Data from the Phase 1 ImmTAV\u00ae trial for Chronic Hepatitis B at the EASL International Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IMC-I109V","moa":"T Cell receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NUV-422","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients With Alzheimer\u2019s Dementia Treated With Brexpiprazole","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TST004","moa":"MASP2","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Brand Institute","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for European Commission Authorized Vaccine for the Prevention of Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brand Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brand Institute \/ VBI vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Brand Inst.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA\u2122) to Support Label Expansion for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"WTX101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Positive Phase III Results From JUNIPERA Study Supporting Cosentyx\u00ae As a Potential Treatment in a JIA Population at EULAR 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Lift of Partial Clinical Trial Hold and Plans to Initiate a New, Pivotal Phase 3 Study of Intrathecal OAV-101 in Older Patients With SMA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"OAV-101","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AV7909","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen to Present at Upcoming Industry Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea's Positive Results of PIII ERADICATE Study with Ceftobiprole in SAB","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexviadyme\u00ae (avalglucosidase alfa) Approved by European Commission as a Potential New Standard of Care for the treatment of Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Avalglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenpozyme\u00ae (olipudase alfa) Approved by European Commission as First and Only treatment for ASMD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olipudase Alfa","moa":"SMPD1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Database Lock for the ONWARD\u2122 Phase 3 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Bio Presents Positive PC Results of ART26.12 in Chemotherapy-Induced Pain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ART26.12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613\u00ae (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2\/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ORF-229","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b study of PDE10A inhibitor gemlapodect (NOE-105) in Childhood Onset Fluency Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemlapodect","moa":"PDE10A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-1300","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alk Begins Clinical Trial of Its SLIT-tablet for the Treatment of Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Xenikos B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard\u00ae in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ricin Toxin A Conjugated Monoclonal Antibodies","moa":"CD3\/CD7","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Xenikos B.V","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xenikos B.V \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenikos B..."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Announces Presentation of Additional Positive Data for its Next Generation Pertussis Vaccine at the 13th International Bordetella Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Receives FDA IND Clearance for its Phase 1\/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SBT101","moa":"ALDP expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Th.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Dosing of the First Two Patients in Phase 1b\/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fazirsiran","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Prestige Biopharma\u2019s IND for Phase 1\/2a trial of First-in-Class Pancreatic Cancer Treatment, PBP1510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PAUF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allowing Corbevax as Booster For those Vaccinated with Covishield, Covaxin Likely to be Considered by NTAGI today","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for IMBRUVICA\u00ae (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Pepscan","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pepscan\u2019s Personalized Neoantigen Peptide Pools in Phase I trial \u201cPneoVCA with Pembro in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pepscan","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pepscan \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Pepscan \/ .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration\/ Functional Cure of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Updates on Ongoing NDA Submission for Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Reports Positive Topline Results from PII Trial of Pegozafermin in SHTG","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air's LungFit PH Receives FDA Approval for Hypoxic Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 1\/1b Results for VLP Vaccine Candidate IVX-121 Against RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces UK MHRA Marketing Authorization for Yselty\u00ae (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CY6463","moa":"Soluble guanylyl cyclase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"LPS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Hosts Sunosi\u00ae Investor Update Virtual Event Today with Key Opinion Leaders","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Cytochrome A3","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1\/1b Trial of RMC-6236","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MH002","moa":"Microbiome","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cantharidin","moa":"PP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$261.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck For M1069 Clinical Development in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/A2BR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Domain Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Reports the U.S. FDA Accepted Its Investigational New Drug (IND) Application for TCMCB07, a Melanocortin\u20104 Antagonist Peptide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica B.."},{"orgOrder":0,"company":"Inspirna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride Trihydrate","moa":"SLC6A8\/CKB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inspirna \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VTAMA\u00ae (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"Sodium-dependent noradrenaline transporter","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"3-Antigen HBV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Schr\u00f6dinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SGR-1505","moa":"MALT1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"XC001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s CAR T-cell Therapy Yescarta\u00ae Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces IND Clearance by FDA for Novel EED Inhibitor APG-5918","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"APG-5918","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"CanariaBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanariaBio Announces Milestone Achievement of 50% Patient Enrollment in Its Phase III FLORA-5 Clinical Study of Its Lead Product Oregovomab in Front-Line Advanced Ovarian Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"CA-125 IgC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CanariaBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CanariaBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanariaBio.."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announced Its Application for EMA Scientific Advice on its Phase 3 Clinical Trial to Confirm Efficacy of Lybrido in Women Suffering From FSIAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA\u00ae (edaravone)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso\u2019s Cadonilimab (PD-1\/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Reports Positive Results from the Ph2b\/3 PRISM Trial of Haduvio\u2122 in the Treatment of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data from the Clinical Phase I MAD study with AlzeCure's Alzheimer's Project NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Will Supply an Additional 150,000 Doses of Bebtelovimab to U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bebtelovimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Spherix Global Insights","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Nephrologists Lead the Way with Adoption of Astellas\/FibroGen\u2019s HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Spherix Global Insights","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spherix Global Insights \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Spherix Gl.."},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Announces Publication of Positive Efficacy Data With Sitoiganap in Patients With Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoiet.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CD4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates ROSELLA \u2013 A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Volixibat","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"APX3330","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Initiates PIII of LB1148 in Postoperative Return of Bowel Function","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health Completes Safety Evaluation of Cohort II for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Updates on PI Trial of ADXS-504 for Early Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ADXS-504","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Columbia University Irving Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Initiates Dosing in PI Trial of exoASO-STAT6 with Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"STAT6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines to Present on its Gene Editing and Therapy Programs for PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel\u2122 (HAV\u2122) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"Vascular Cell","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Istaroxime","moa":"Sodium\/potassium-transporting ATPase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Initiates Phase 2\/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Results from PI Stage of GRECO-1 Trial of Rucosopasem","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucosopasem","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Provides Update for Vilobelimab in Pyoderma Gangrenosum and COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"C5a","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Positive Topline PI Data for VTX2735","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VTX2735","moa":"NLRP3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AN2 Therapeutics Initiates Pivotal Phase 2\/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Shows Unprecedented Activity for Botensilimab\/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT Bio\u2019s COVID-19 Vaccine Wins Regulatory Approval in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Axalbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axalbion Announces Positive Findings from PII Study in Chronic Cough with AX-8","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AX-8","moa":"TRPM8","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Axalbion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Axalbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axalbion \/.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Begins Dosing with RLS103 in PIb\/IIa Study in Anxiety","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine-lpyl","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"National Institute for Biomedical Imaging and Bioengineering","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-EB-TATE","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"STX-721","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Grant of Prime Eligibility From the European Medicines Agency for Its Rsv Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN-RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"American Regent","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Launches a New Vial Presentation","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylene Blue","moa":"Methemoglobin","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"American Regent \/ Provepharm Life Solution","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"RIST4721","moa":"CXCR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Th.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics\u2019 PT886 Granted Orphan Drug Designation for the Treatment of Pancreatic Cancer by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PT886","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"SAN711","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implantable Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides Vitargus\u00ae Update","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-1607","moa":"Cbl","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"REN001","moa":"PARP delta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. to Host FUROSCIX\u00ae (furosemide) 80mg\/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces First Patient Enrolled for the Company\u2019s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NLC-V-01","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING\u2122 and exoIL-12\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CDK-002","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Tx to Present New Data for PALFORZIA at the EAACI","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Arachis Hypogaea","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH\/NIAID Locks ACTIV-5\/BET-B Database","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Late-Stage Study of LYT-100 in IPF and Advances LYT-200","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Receives FDA FTD for Belzupacap Sarotalocan (AU-011)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Xenikos B.V","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard\u00ae in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ricin Toxin A Conjugated Monoclonal Antibodies","moa":"CD3\/CD7","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veloxis Pharmaceuticals \/ Xenikos","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Ph.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"GB Sciences","sponsor":"University of Lethbridge","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabis-based Therapeutics","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GB Sciences \/ University of Lethbridge","highestDevelopmentStatusID":"4","companyTruncated":"GB Science.."},{"orgOrder":0,"company":"GB Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GB Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GB Science.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO\u2122 (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Celiprolol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues a Positive Opinion Recommending Full Approval of Oncopeptides Pepaxti in Eu for Patients With Triple Class Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Bristol Myers Squibb\u2019s CAR T Cell Therapy Breyanzi\u00ae for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Gene Therapy to Treat Severe Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover\u2019s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCGI Approves Indigenous MRNA Covid Jab for Emergency Use in 18 Yrs & Above","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Significantly Improved Pathologic Complete Response in Aegean Phase III Trial in Resectable Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Submits Fezolinetant New Drug Application to U.S. FDA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients With Germline BRCA-mutated Her2-Negative High-risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilisation From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tiomolibdate Choline","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kerendia\u2122 (Finerenone) Approved in China for the Treatment of Adults With Chronic Kidney Disease Associated With Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Patent Office Grants Patent Related to TECFIDERA\u00ae (Dimethyl Fumarate)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Supplemental New Drug Application Submitted in Japan for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GSK","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi-GSK First to Report a Successful Efficacy Study Against Omicron with COVID-19 Beta-Containing Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"GSK4353001A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Sano.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Talquetamab","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDC\u2019s ACIP Unanimously Votes to Provisionally Recommend Use of Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Bivalent Booster mRNA1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion for Scemblix\u00ae, a Novel Treatment for Adult Patients With Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Novartis Extension Phase Data Show Nearly 80% of RMS Patients Treated With Kesimpta\u00ae (Ofatumumab) Had No Evidence of Disease Activity (Neda-3)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genmab","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosentyx\u00ae (Secukinumab) Receives Expanded Approvals in EU for Use in Childhood Arthritic Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives European Commission Approval for Tabrecta\u00ae for the Treatment of METex14 Skipping Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Plans to Petition the U.S. Court of Appeals for the Federal Circuit for Further Review to Uphold Validity of the Gilenya\u00ae (fingolimod) Dosing Regimen Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients With Alzheimer's Dementia Treated With Brexpiprazole","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brepocitinib","moa":"TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Roivant Sciences \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EYLEA\u00ae (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Enrollment of Phase III Tolebrutinib Trials Paused in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolebrutinib","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-930","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI\u00ae (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VLA2001 Becomes the First Covid-19 Vaccine to Receive a Standard Marketing Authorization in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USPTO Issues Patent Covering Use of XPro\u2122 for Treatment of CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Wellcome","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Renews Commitment to Neglected Tropical Disease and Malaria Elimination, Investing USD 250 Million Over Five Years to Research and Develop New Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"LXE408","moa":"Proteasome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Wellcome","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces Development of A Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Toolgen","sponsor":"mCureX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"TGT-101","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Toolgen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toolgen \/ mCureX","highestDevelopmentStatusID":"2","companyTruncated":"Toolgen \/ .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Sixth Street","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$250.0 million","newsHeadline":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Sixth Street","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$340.0 million","upfrontCash":"$175.0 million","newsHeadline":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Blueprint Medicines \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"CellPoint","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$234.7 million","upfrontCash":"$130.4 million","newsHeadline":"Galapagos to Acquire CellPoint And AboundBio to Accelerate Access to Next-Generation Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"CD19 CAR-T Cell Therapy","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellPoint","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"CellPoint \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"CellPoint .."},{"orgOrder":0,"company":"Abound Bio","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Galapagos to Acquire CellPoint And AboundBio to Accelerate Access to Next-Generation Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"CD19 CAR-T Cell Therapy","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abound Bio","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Abound Bio \/ Galapagos","highestDevelopmentStatusID":"7","companyTruncated":"Abound Bio.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces Second dose Escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"FAP Activated Doxorubicin Prodrug","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$900.0 million","newsHeadline":"Regeneron Completes Purchase of Sanofi's Stake in Libtayo\u00ae (cemiplimab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":1.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$405.0 million","newsHeadline":"Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva for PBC Outside the U.S.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Divestment","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Intercept Pharmaceuticals \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Molecular Biology Institute of Parana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Vaccines Signs Heads of Terms for A Collaboration with Molecular Biology Institute of Parana (IBMP) in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8+ T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergex Vaccines Holding \/ Molecular Biology Institute of Parana","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"GSK Completes Acquisition of Sierra Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":1.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":""},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"AAV-Based Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Mogrify","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mogrify \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Mogrify \/ .."},{"orgOrder":0,"company":"EditForce","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"$145.7 million","upfrontCash":"Undisclosed","newsHeadline":"EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"PPR Proteins-Based Therapeutic","moa":"RNA","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"EditForce","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"EditForce \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"EditForce .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Announces Closing of Public Offering of Units","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Urovant Sciences and Pierre Fabre M\u00e9dicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"University of Wisconsin\u2013Madison","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Bria-Pros","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ University of Wisconsin\u2013Madison","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Announces Research Collaboration with University of Michigan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"suPAR","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Walden Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"1","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox Preparedness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Live Nonreplicating Smallpox and Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Intravacc","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"DZNE and Intravacc Awarded EU Funding to Develop Vaccine Against Genetic ALS Variant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Polyglycine alanine","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ European Union","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-Drug Conjugate Based Therapeutic","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Innorna","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Innorna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innorna \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Innorna \/ .."},{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"$21.0 million","newsHeadline":"Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"PORT-6","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarus Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tarus Therapeutics \/ Portage Biotech Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Tarus Ther.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Hande Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Hande Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kamada Announces $11.4 Million International VARIZIG Procurement Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Varicella Zoster Immune Globulin (Human)","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ U.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga Treatment for Ebola","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Ansuvimab-zykl","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ridgeback Biotherapeutics \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Burke Neurological Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Burke Neurological Institute Receives a $45 Million NIH Grant to Study a Vitamin B1 Precursor for Treatment of Alzheimer\u2019s Disease in Multi-center Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Funding","leadProduct":"Benfotiamine","moa":"Transketolase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Burke Neurological Institute","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Burke Neurological Institute \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Burke Neur.."},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$5.0 million","newsHeadline":"Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"EN1001","moa":"TNFR1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Enosi Therapeutics","amount2":0.11,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Enosi Therapeutics \/ Danuo Science Group","highestDevelopmentStatusID":"4","companyTruncated":"Enosi Ther.."},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"Swiss Innovation Agency","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Gnubiotics Sciences Announces Funding from the Swiss Innovation Agency to Accelerate Development of Glycopeptide Mediated Immunotherapies Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"GNU201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Gnubiotics Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gnubiotics Sciences \/ Swiss Innovation Agency","highestDevelopmentStatusID":"4","companyTruncated":"Gnubiotics.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Carleton University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Carleton University","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs New Three Year Agreement with AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Merger","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Syros","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Terumo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$30.0 million","newsHeadline":"Orchestra BioMed Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchestra Biomed \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra .."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Private Placement","leadProduct":"Tamibarotene","moa":"RAR alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Syros Pharmaceuticals \/ Flagship Pioneering","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Kedalion Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Transform Patient Experience","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Lifitegrast","moa":"LFA-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kedalion Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kedalion Therapeutics \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Kedalion T.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$26.6 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Public Offering","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Piper Sandler & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"VectorY","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VTx-002","moa":"TDP-43 aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s TAKHZYRO Shows Positive Results in the Prevention of HAE Attack","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Declines Emergency Use Authorization for Zyesami\u00ae (Aviptadil) for Subgroup of Patients With Critical Covid-19 at Immediate Risk of Death From Respiratory Failure Despite Treatment With Approved Therapy, Including Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"EspeRare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre and the EspeRare Foundation Administer Investigational Treatment to First Patient in EDELIFE Clinical Trial for Rare Genetic Disease, XLHED","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ER004","moa":"Utero protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pierre Fabre \/ EspeRare foundation","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Vast Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vast Therapeutics Presents Promising Preclinical Results for Novel Treatment for NTM Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"MD3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vast Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Vast Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vast Thera.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI\u00ae (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX10212","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the Registration of Maxigesic IV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO (berotralstat)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allergen Extract","moa":"IL-4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Stallergenes Greer","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Stallergenes Greer \/ ","highestDevelopmentStatusID":"12","companyTruncated":"Stallergen.."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA\u00ae (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 TK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Merck & Co. Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Pioglitazone","moa":"AMPK","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo\u2019s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma Shares New Data at ISTH 2022 in Its Mission to Meet the Challenges Faced by People With Bleeding Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OCTA12","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aneurotech Receives Positive Feedback From the FDA for Its Pivotal Phase IIIb Development Programme for ANT-01 as an Adjunctive Anti-depression Drug for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pipamperone","moa":"5-HT2A\/D4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ANeuroTech \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The U.S. FDA Accepts and Grants Priority Review for EISAI\u2019s Biologics License Application of Lecanemab for Early Alzheimer\u2019s Disease Under the Accelerated Approval Pathway","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1\/2 Clinical Trial for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Selonabant","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Sollievo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sollievo Pharmaceuticals, Inc. Announces a Breakthrough in Intramuscular Sedation of Agitated and Violent Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Avizafone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sollievo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular injection","sponsorNew":"Sollievo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sollievo P.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa\u2019s Dual Protective Mechanism","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"A2AR","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s CEO Comments On The 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1\/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"iRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IMG-007","moa":"OX40","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Roche's Lunsumio for People With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Discontinuation of the Phase 1\/2 Study of its Antibody- OBI 888 To Focus on Other Priority Cancer Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OBI-888","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2\/3 RINGSIDE Trial of AL102 in Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Arrivent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Arrivent \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin in 3L R and R Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Junshi","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generics of MSD Diabetes Pill Set to Flood Market as Patent Expires","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Sun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"TSB Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Announces Commercial Launch of its Amubarvimab\/Romlusevimab Combination Therapy for COVID-19 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brii Biosciences \/ TSB Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Announces Scientific Data on XIPERE\u00ae (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-490","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Announces Clinical Hold of its Phase 2\/3 ReMEDy2 Clinical Trial for DM199","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"DM199","moa":"Kallikrein-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic EBV T-cell","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caraway Therapeutics to Participate in William Blair Biotech Focus Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"TRPML1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caraway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Th.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subacromial injection","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PBI-200","moa":"TRK kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pyramid Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyramid Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Pyramid Bi.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Spexis","sponsor":"University of Michigan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spexis' CXCR4 Inhibitor Balixafortide Demonstrates Synergistic Efficacy in Combination With Docetaxel in a Metastatic Prostate Cancer Preclinical Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ U.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacmilimab","moa":"CD166","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed\/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sapanisertib","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AMP-CpG","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-301","moa":"HDAC6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Sheba Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I\/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Sheba Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cend Therapeutics Announces Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CEND-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Eyenovia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Arctic Vision \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-005","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Topline Results for Intralymphatic Diamyd\u00ae in Patients With LADA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coagulant Therapeutics Announces Publication of In Vivo Data Demonstrating Safety and Efficacy of CT-001 for the Management of Acute Bleeding","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"Factor VII","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant .."},{"orgOrder":0,"company":"Sunho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SunHo Announces First Patient Dosed in Phase 1\/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IAP0971","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sunho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sunho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sunho Phar.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Taldefgrobep Alfa","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Screening of the First Patient in LEGEND, a Phase IIa Combination Trial With Lanifibranor and Empagliflozin in Patients With NASH and T2D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR alpha","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels in the Treatment of Vascular Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Abstract Accepted for Presentation at the Alzheimer's Association International Conference (AAIC)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Birch Bark Extract","moa":"Transient receptor potential channel","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Positive Data in Fibrosis Due to NASH From a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-529","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Filament Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Filament Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Filament Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Filament H.."},{"orgOrder":0,"company":"Amazentis","sponsor":"Scripps Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Shows Urolithin A (Mitopure\u00ae) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Urolithin A","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amazentis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amazentis \/ Scripps Research","highestDevelopmentStatusID":"4","companyTruncated":"Amazentis .."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Announces Publication in Science Advances on the Validation of Human Derived Organoids as a Predictable and Translatable Preclinical Model in Kidney Disease for the Evaluation of Therapeutic Drug Candidates","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRPC5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Nuvaxovid COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVHSC16","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"N, N-dimethyltryptamine Pamoate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALK Spotlights the Impact of Respiratory Allergies on Children at EAACI Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Prophylactic Treatment with VONVENDI\u00ae [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Announces Submission of Clinical Trial Registration for China Phase 3 Study of LBS-008","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord's SONDELBAY\u00ae (teriparatide) is Given Green Light by CHMP","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH1R","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives European Commission Approval for its Pegfilgrastim Biosimilar Stimufend\u00ae - Fresenius Kabi Global","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"NC318","moa":"Siglec-15 \/LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Plus Androgen Deprivation Therapy and Docetaxel Demonstrates Consistent Overall Survival Benefits Across Various Patient Segments in Metastatic Hormone-sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Themis Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCGI Approved Themis Medicare\u2019s Viralex Effective Against Covid-19, Viral Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Inosine Pranobex","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Themis Medicare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Themis Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Themis Med.."},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven\u2019s Troriluzole and Vigeo\u2019S VT1021 in GBM AGILE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VT1021","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Vigeo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vigeo Therapeutics \/ Biohaven","highestDevelopmentStatusID":"9","companyTruncated":"Vigeo Ther.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces Presentations at DDW 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"Biofrontera Inc. Announces Closing of $9.4 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"Ferrochelatase","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxilio OXL001 Formulation Optimisation and Clinical Trial Preparation Contract with Quotient Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"OXL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Evotec","sponsor":"Sernova Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Sernova Announce Exclusive Strategic Partnership For iPSC-based Beta Cell Replacement Therapy to Advance a 'functional Cure' for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Beta Cell Replacement Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evotec \/ Sernova Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ S.."},{"orgOrder":0,"company":"Endpoint Health","sponsor":"Mayfield","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endpoint Health Raises $52 Million in Financing to Expand and Progress Precision Immunology Pipeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Financing","leadProduct":"Antithrombin III","moa":"Thrombin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Endpoint Health","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Endpoint Health \/ Mayfield","highestDevelopmentStatusID":"4","companyTruncated":"Endpoint H.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vyluma and Laboratoires Thea Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Atropine","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ L.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody\u00ae Drug Discovery and Development Technology in Rare Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Financing","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data Demonstrate Two of Vaxart's COVID-19 Vaccine Candidates Protect Against Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company, a Sorrento Company, Announces Continued Growth in ZTlido in Managed Health Care Plans","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma To Present Data Update for the Phase 1b\/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Precision Autoimmune Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Casi Pharmaceuticals Announces Its Partner, Precision Autoimmune Therapeutics Co., Ltd Has Completed First-Round Financing of $21 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"CID-103","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precision Autoimmune Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Precision Autoimmune Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nurix Therapeutics Announces $40 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"ViaCyte Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$320.0 million","newsHeadline":"Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"VC-02","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"ViaCyte Inc","amount2":0.32000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Implant","sponsorNew":"ViaCyte Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"ViaCyte In.."},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Lahey Hospital & Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"ATH-63","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Athos Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athos Therapeutics \/ Lahey Hospital & Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Athos Ther.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Glycotope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Glycotope GmbH","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Sulopenem Etzadroxil","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innoviva Completes Acquisition of Entasis Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"Acinetobacter baumannii enzyme","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Inspirna","sponsor":"Sands Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inspirna Raises $50 Million in Series D Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Series D Financing","leadProduct":"Irinotecan Hydrochloride Trihydrate","moa":"SLC6A8\/CKB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Inspirna \/ Sands Capital","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/.."},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innoviva to Acquire La Jolla Pharmaceutical Company","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Angiotensin II receptor type 1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"La Jolla Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"12","companyTruncated":"La Jolla P.."},{"orgOrder":0,"company":"Entheon Biomedical","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Entheon Biomedical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entheon Biomedical \/ Cybin IRL Limited","highestDevelopmentStatusID":"6","companyTruncated":"Entheon Bi.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"EpicentRx Awarded Grant from The Michael J. Fox Foundation to Evaluate Therapeutic Potential of RRx-001 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"EpicentRx \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Akanda Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF\u2122, a Potential Multimillion Dollar Prescription Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Akanda Corp","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Agtc","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGTC Announces Pricing of $10 Million Underwritten Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agtc \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ H.C.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$290.0 million","newsHeadline":"Orion and MSD Announce Global Collaboration for The Development and Commercialisation Of ODM-208, An Investigational Steroid Synthesis Inhibitor for The Treatment of Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Fludrocortisone","moa":"CYP11A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ MSD","highestDevelopmentStatusID":"7","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"CQDM","sponsor":"Quebec Breast Cancer Foundation","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"CQDM, the Quebec Breast Cancer Foundation and Theratechnologies Fund Close To $2 Million for Research Project to Validate the Anti-Metastatic Potential of TH1902 At The Universite du Quebec Montreal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CQDM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CQDM \/ Quebec Breast Cancer Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CQDM \/ Que.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"LR19023","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Verapamil PM and Verelan SR Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Verapamil Hydrochloride","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Societal CDMO \/ Lannett Company","highestDevelopmentStatusID":"12","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Renovacor","sponsor":"University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"DSG2 gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Renovacor \/ University of Utah\u2019s Nora Eccles Harrison Cardiovascular Research and Training Institute","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor .."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Bascom Palmer Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Bascom Palmer Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Peptilogics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Biotechnology \/ Peptilogics","highestDevelopmentStatusID":"3","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$153.0 million","upfrontCash":"Undisclosed","newsHeadline":"BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0.14999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gossamer Bio Announces $120 Million Private Placement Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Private Placement","leadProduct":"Seralutinib","moa":"PDGFR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0.12,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Series B Financing","leadProduct":"ORG-129","moa":"ALK-5","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"Optimi Health","sponsor":"Bloom Psychedelic Therapy and Research Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Optimi Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Bloom Psychedelic Therapy and Research Centre","highestDevelopmentStatusID":"6","companyTruncated":"Optimi Hea.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"GHRF","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$506.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Acquires Testosterone Treatment Nebido\u2122 From Bayer","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Bayer AG","amount2":0.51000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.51000000000000001,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"$15.0 million","newsHeadline":"SK Biopharmaceuticals, Eurofarma Enter into Licensing Agreement for Cenobamate in Latin America","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Eurofarma","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Codexis","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID (Nirmatrelvir Tablets;Ritonavir Tablets)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Codexis \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita (burosumab) for $500 Million to OMERS Capital Markets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Divestment","leadProduct":"Burosumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Ultragenyx Pharmaceutical","amount2":0.5,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.5,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Alpha-5 integrin","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Awarded a Drug Development Research Grant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"PAT 103","moa":"Alpha V\/beta I integrin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Alpha-5 integrin","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Oregon Health & Science University","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"AAV-based Gene Therapy","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CytoDyn","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"CytoDyn \/ Oregon Health & Science University","highestDevelopmentStatusID":"4","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"DAAN Bio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ DAAN Bio Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Pharmacyclics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$14.0 million","newsHeadline":"COSELA\u00ae (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Simcere","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jnana Therapeutics to Present Preclinical Data for its PKU Program at the 2022 National PKU Alliance (NPKUA) Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"JNT-517","moa":"SLC6A19","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE\u00ae Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Abbvie","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Enoblituzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Hannover Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Hannover Medical School","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Technologies Receives Approval from UK for Tecovirimat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI\u2122-100 Advancing it Closer to First-in-Human Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-100","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aditxt \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ N.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2 Gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Data for Concizumab Show 86% Reduction in Treated Bleeds in Haemophilia a or B With Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Data Demonstrate Once-weekly Efanesoctocog Alfa Provides Superior Bleed Protection Compared to Prior Factor Prophylaxis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCG Cell Therapy Announces U.S FDA Clearance of Investigational New Drug Application for SCG101, SCG's Novel TCR-T Cell Therapy For Hepatitis B-related Liver Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"SCG101","moa":"HBsAg","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SCG Cell Therapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCG Cell Therapy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SCG Cell T.."},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CDL200","moa":"Bacterial Cell Wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"iNtRON Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Bio.."},{"orgOrder":0,"company":"Brand Institute","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Attention Deficit Hyperactivity Disorder (ADHD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Brand Institute","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Brand Institute \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Brand Inst.."},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris Pharma Receives Notice of Allowance for Key U.S. Patent Application Covering Lead Compound, LUT014, a Novel B-Raf Inhibitor","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"LUT-014","moa":"EGFR","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lutris Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lutris Pha.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"LPCN 2101","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rexlemestrocel-L to be Highlighted at Maxim's Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Folia Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Presentation of DCCR Data at the 11th International Prader-Willi Syndrome Organisation Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Folia Health","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Biotherapeutics Reports Positive Results From Proof-of-Concept Trial for First Investigational Compound","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"RSBT-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTher.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Initial Data from its U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-204-C07","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Repirinast","moa":"Mast cell","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Phase III Haven 6 Study Reinforce Favourable Safety and Efficacy Profile of Roche's Hemlibra in People With Moderate or Mild Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA\u00ae in Combination with Rituximab in Global Phase 3 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NTAGI Likely to Discuss Soon Data of India's First mRNA Vaccine Against COV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance Into Phase 3 Clinical Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IONIS-FB-LRx","moa":"Complement factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fesoterodine","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of BBT-176 at the World Conference of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BBT-176","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phexxi\u00ae Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I\/ONTAK (Denileukin Diftitox) for the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"Il-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces New H. Pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coagulant Therapeutics Presents Data for Severe Postpartum Hemorrhage Clinical Candidate, CT-001, at International Society for Thrombosis and Haemostasis Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"Factor VIIa","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant .."},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ronopterin","moa":"iNOS","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO at the 2022 WCLC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1\/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs' Announces Clearance of IND for GD2-SADA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-101","moa":"Mutant DMPK gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Sapu Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Announces Presentation of P001- OT-101 Phase 1\/2 Trial in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Sapu Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ\u00ae APCs and Effective CD8 T Cell Activation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD8 T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BT7480","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Therapeutics Initiates Phase 2b\/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Zatolmilast","moa":"PDE4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tetra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating \u201cExtra-Strength\u201d Dose of Jeuveau","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histopathology Data of Preclinical Repeated Dose Toxicity Study and Ex Vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA\u2019s PolyTope\u00ae TATX-03, a Synergistic Antibody Cocktail against SARS\u2011CoV\u20112","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TATX-03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs Drug Development Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinilabs Drug Development Corporation Begins Enrollment for Phase 1\/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Clinilabs Drug Development Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cl.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Regulator Approves Country's First Indigenously Developed HPV by Serum Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic EBV T-cell","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Receives Preliminary Topline Data From NIH\/NIAID Study of Lenzilumab in ACTIV-5\/BET-B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NVL-655","moa":"ALK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Index Pharmaceuticals Gets New Patent for Cobitolimod Granted in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for the treatment of Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sapanisertib","moa":"TORC1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Provides Strategic Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BMS-986249","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (Dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age With Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica B.."},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Lucid Psycheceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lucid Psycheceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lucid Psyc.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor \u03b1 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BAT8006","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-05","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Phase 3 Study in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Samarium-153 DOTMP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QSAM Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosc.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic PLX-PAD Cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2002","moa":"Myc expression","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Massachusetts General Hospital's Vaccine and Immunotherapy Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VTX-067","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voltron Therapeutics \/ Massachusetts General Hospital's Vaccine and Immunotherapy Center","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Th.."},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"SWK Holdings","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enteris Biopharma Inc \/ SWK Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Bi.."},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allos Pharma Inc. Presents New Positive Data Analyses at the 18th NFXF International Fragile X Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Arbaclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allos Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allos Phar.."},{"orgOrder":0,"company":"Inbiomotion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Shows That Selection of Breast Cancer Patients for Adjuvant Bisphosphonate Therapy Based on Inbiomotion's MAFTEST\u00ae Reduces the Risk of Death in Comparison With Current Clinical Guidance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Clodronate Disodium","moa":"Bone resorption factor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inbiomotion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inbiomotion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inbiomotio.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NEXI-003","moa":"CD3\/CD4","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Frontier Science Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eight-year Data From APHINITY Study Show Roche's Perjeta-based Regimen Continues to Reduce the Risk of Disease Returning for People With HER2-positive Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Frontier Science Foundation","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-99b","moa":"CCR3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at Controlled Release Society 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Two-year Data Confirm Roche\u2019s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics Provides Update on Ridinilazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbS polymerization","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0202","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1.1-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Emergent BioSolutions","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ E.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Receives Orphan Drug Designation from the FDA for Mycapssa (Oral Octreotide) for the Treatment of Carcinoid Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"George Clinical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"HSF-1 pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ George Clinical","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAdaptives, Inc. Launching Next Generation Products for Natural Health Practitioners","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Boswellia Serata","moa":"COX2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioAdaptives","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAdaptives \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioAdaptiv.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel-TH19P01 Conjugate","moa":"Sortilin receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmceuticals","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"LG203003","moa":"DGAT2","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LG Chem","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Creative Bio-Peptides","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data Demonstrate Potential of Creative Bio-Peptides\u2019 Multi-Chemokine Receptor Antagonist RAP-103 to Provide Opioid Sparing Post-Surgical Pain Relief and Treatment for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"RAP-103","moa":"CXCR4","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Creative Bio-Peptides","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Creative Bio-Peptides \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Creative B.."},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Two-Year Data Confirm Genentech\u2019s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic\u2122, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimesna","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces FDA Approval of Beovu\u00ae for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Receives CHMP Positive Opinion for Biosimilar Bevacizumab, Vegzelma\u2122 (CT-P16)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA CHMP Recommends Grant of Marketing Authorization of Insulin Aspart Biosimilars","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics\u2019 Partner Receives Approval for Human Insulin for IV Infusion","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Baxter Healthcare Corporation","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Biocon Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Baxter Hea.."},{"orgOrder":0,"company":"LFB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Cevenfacta to Control Bleeding Episodes in Patients With Congenital Haemophilia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Beta","moa":"Factor VII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ Not .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Eli Lilly's Migraine Medication Rayvow","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA CHMP Recommends Grant of Marketing Authorization of Ranibizumab Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Midas Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Midas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Midas Phar.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA\u2122 TRIPLE PAK\u2122 (Vonoprazan, Amoxicillin, Clarithromycin) and VOQUEZNA\u2122 DUAL PAK\u2122 (Vonoprazan, Amoxicillin) for the Treatment of H. pylori Infection in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA1215","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1215","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Signicantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4\/5 Compared To Currently Authorized Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mim8 Phase 1 & 2 Data Demonstrates Potential as Once Monthly Treatment for People With Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Mim8","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Introducing New B240 Tablets Effortless Way to Consume a Unique Ingredient for Maintenance of Physical Condition","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lactiplantibacillus Pentosus ONRICb0240","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion, USP (Containing Benzyl Alcohol), Due To The Potential Presence of Visible Particulate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Propofol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hospira, Inc.","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Hospira, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hospira, I.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY\u00ae For Adolescents 12 through 15 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Phase III Haven 6 Study Reinforce Favourable Safety and Efficacy Profile of Roche\u2019s Hemlibra in People With Moderate or Mild Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fitusiran Prophylaxis Reduced Bleeds by 61% in People With Hemophilia a or B, With or Without Inhibitors, Compared to Prior Factor or Bypassing Agent Prophylaxis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Givosiran","moa":"Antithrombin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Places Focus on Personalized Care and Innovation for Bleeding Disorders at ISTH 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Analysis of Japanese Phase III Clinical Trial of Hemlibra for Acquired Hemophilia A (AGEHA Study) Presented at ISTH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GLSI-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces FDA Accelerated Approval of VONJO\u2122 (Pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2\/IRAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Reduced the Risk of Disease Progression or Death by 50% Vs. Chemotherapy in Patients With HER2-low Metastatic Breast Cancer With HR-positive and HR-negative Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"DelSiTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.2 million","newsHeadline":"Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Sustained-Release","sponsorNew":"IVERIC bio \/ DelSiTech","highestDevelopmentStatusID":"10","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Announces Approval to Proceed with Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE\u00ae (Palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Data of InnoCare\u2019s Orelabrutinib for the Treatment of SLE Presented at LBA Session of EULAR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Alladapt Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altasciences Continues Manufacturing Expansion in Philadelphia With Client\u2011Dedicated Building Project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Altasciences Company Inc \/ Alladapt Immunotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Altascienc.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Endo Ventures Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Endo Ventures Limited","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"KaliVir Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ KaliVir Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$153.0 million","upfrontCash":"Undisclosed","newsHeadline":"BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0.14999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Immunocore","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunocore Announces $140 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Private Placement","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunocore \/ RTW Investments","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Therapeutics Expands XENLETA (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Lefamulin Acetate","moa":"Peptidyl transferase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nabriva Therapeutics \/ Er-Kim","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Purespring Therapeutics And SwanBio Therapeutics Announce Licensing Agreement for Use of FunSel Screening Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Purespring Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Purespring.."},{"orgOrder":0,"company":"GSK","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK Welcomes Agreement with The Government of Canada for The Provision of Pandemic and Seasonal Influenza Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"AS03-adjuvanted H1N1 Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Government of Canada","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Gove.."},{"orgOrder":0,"company":"TSB Therapeutics","sponsor":"China Resources Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab\/Romlusevimab Combination, in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TSB Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TSB Therapeutics \/ China Resources Pharmaceutical Commercial Group","highestDevelopmentStatusID":"12","companyTruncated":"TSB Therap.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"PMV Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"PC14586","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ PMV Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury\u00ae (Remdesivir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Series B Financing","leadProduct":"Antisense Oligonucleotide Therapeutic","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"CAMP4 Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"5","companyTruncated":"CAMP4 Ther.."},{"orgOrder":0,"company":"Transpire Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transpire Bio Announces Agreement with Recipharm for The Development of An Inhaled Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"TRB-1","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Transpire Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Transpire Bio \/ Recipharm","highestDevelopmentStatusID":"4","companyTruncated":"Transpire .."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp.","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"Cholesterol efflux","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected as Limited Distribution Partner for Amvuttra\u2122 (vutrisiran)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Vutrisiran","moa":"TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Ei.Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$48.0 million","upfrontCash":"Undisclosed","newsHeadline":"Auron Therapeutics Announces $48 Million Series A Financing to Drive Novel Oncology Pipeline Leveraging a Machine Learning, Multi-Omics-Based Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Auron Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Auron Ther.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"$1.0 million","newsHeadline":"F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"F-star Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$466.0 million","upfrontCash":"$60.0 million","newsHeadline":"Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"In-vivo Gene Editing Medicines","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Verve Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artizan Biosciences Announces Multi-Year Research Collaboration with the University Medical Center Utrecht and Microviable Therapeutics SL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artizan Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artizan Bioscience \/ University Medical Center Utrecht","highestDevelopmentStatusID":"3","companyTruncated":"Artizan Bi.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Baylor College of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"177Lu-DOTA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Novaremed","sponsor":"NeuroFront Therapeutics","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"Novaremed \/ NeuroFront Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Silverback Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silverback Therapeutics and ARS Pharmaceuticals Announce Merger","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Silverback Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"George Medicines Advances Triple Combination Candidate GMRx4 Into Phase II Clinical Development for First-Line Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Med.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$442.2 million","upfrontCash":"Undisclosed","newsHeadline":"Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"IPH6401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Optimizes Statistical Analysis and Introduces Interim Analysis in The Ongoing ALLOB Phase IIb Study for High-Risk Tibial Fractures","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces Discontinuation for Developing KW-6356","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"KW-6356","moa":"A2AR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGF\u03b21 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"LTBP-TGF beta 1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Escend Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ES-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Escend Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escend Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Escend Pha.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"HMPL-A83","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura\u00ae at American Society of Retina Specialists Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Scientists Published Results of Study Showing Pruxelutamide's Inhibitory Effects on Acute Lung Injury and Its Molecular Mechanism of Anti-Inflammatory Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Trehalose API","moa":"TFEB","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-0390, an Investigational Emopamil-binding Protein (EBP) Inhibitor for the Treatment of Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"DSP-0390","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"OliPass","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ .."},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azurity Pharmaceuticals, Inc. Announces FDA Approval of Zonisade\u2122 (Zonisamide Oral Suspension)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Ph.."},{"orgOrder":0,"company":"Byondis","sponsor":"Medac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Medac","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR Study, Reports Disease-Modifying Profile for Short Term DSR and Provides Business Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Alfapump DSR Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sequana Medical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Me.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Abbvie","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"GeneTx Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1\/2 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ GeneTx","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals to Announce Topline Results of ONWARD Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Ring Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Ring Thera.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Inactivated Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces U.S. FDA Approval of Opzelura\u2122 (ruxolitinib) Cream for the Treatment of Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Trofinetide","moa":"Cytokine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell\u2122 Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Publishes an Article in Transplantation and Cellular Therapy, Unveiling High Response Rate and Corticosteroid Sparing With Arsenic Trioxide-based First-line Therapy in cGvHD after allo-HSCT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"T\/B Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medsenic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTHR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ETX-155","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eliem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces FDA Approval of ZONISADE (Zonisamide Oral Suspension)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eton Pharmaceuticals \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VK0214","moa":"TR beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Reports 5 Years\u2019 Data Showing Sustained Efficacy and Safety Following One-time Treatment With LUMEVOQ","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenadogene Nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LB Announces Publication of Phase 1 Clinical Study of LB-102","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"N-Methyl Amisulpride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"CureVac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Presents Latest Research Showing Benefits of Needle-free at mRNA-Based Therapeutics Summit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CV7201 mRNA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaJet \/ CureVac","highestDevelopmentStatusID":"6","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS\u00ae(celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharm.."},{"orgOrder":0,"company":"Medikine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"MDK-703","moa":"IL-7R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medikine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CypCaps","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaCyte Biotech \/ Heidelberg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R\/R T-ALL\/LBL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"WU-CART-007","moa":"CD7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CRD-740","moa":"PDE9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion .."},{"orgOrder":0,"company":"Creative Bio-Peptides","sponsor":"The Center for Substance Abuse Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAP-103 Inhibits Opioid-derived Dependence, Withdrawal and Respiratory Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"RAP-103","moa":"Chemokine receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Creative Bio-Peptides","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Bio-Peptides \/ The Center for Substance Abuse Research","highestDevelopmentStatusID":"4","companyTruncated":"Creative B.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Reports Positive Phase 1 Data for HY-004, a Proprietary Tranexamic Acid Oral Mouth Rinse for Bleeding Related to Dental Procedures","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Positive Preliminary Data from Phase 1\/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"INZ-701","moa":"PPi\/Adenosine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ IQVIA Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ofranergene Obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Synthetic Cannabinoid","moa":"CB1 receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"Exosome release","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Sigma-2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Announces Presentation of Preclinical Data on the HAV\u00e2\u201e\u00a2 in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8\u00ae for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"HSF-1 pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Submission to European Medicines Agency","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"MKS Enterprise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MKS Enterprise LLC Voluntary Recalls of Dose Vital VIP Vital Honey Due to Presence of Undeclared Tadalafil","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Caviar","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MKS Enterprise","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sachet\n","sponsorNew":"MKS Enterprise \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MKS Enterp.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"p5RHH\/mRNA Complex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Topline Results For Onward\u2122 Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira's Intravenous Administered oHSV MVR-T3011 IV Demonstrated Promising Clinical Biological Activities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HyBryte\u2122 Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"YP-P10","moa":"Cytokines\/Cheokines","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharm.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Quality of Life Data for Valtoco\u00ae (Diazepam Nasal Spray) Civ in the Treatment of Seizure Clusters Published in Epilepsy & Behavior","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upstaza\u2122 Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"The Progeria Research Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Receives European Approval for Zokinvy\u00ae (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Progeria Research Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis B.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Eltanexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Assembly Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Assembly Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HilleVax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen As Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-free and Overall Survival Over Previously Published Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Dialco Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectral Medical Provides Update on Tigris Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectral Medical \/ Dialco Medical","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1\/2 Trial for the Treatment of Gaucher Disease in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN103","moa":"Glucocerebrosidase enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"LiberoThera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BCG005","moa":"CCR 8","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ LiberoThera","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Publication of Adbry\u2122 (tralokinumab-ldrm) Efficacy Data in Moderate-to-Severe Atopic Dermatitis in American Journal of Clinical Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"O-(3,5-Dichlorophenyl)hydroxylamine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Receives FDA \u201cStudy May Proceed\u201d Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"RHX-317","moa":"MALT 1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rheos Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rheos Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rheos Medi.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Siolta The.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Updates Phase 1 Timeline","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"SBI-100 OE","moa":"CB1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covaxin Third Jab Boosts Antibody Response Against Several Covid Strains: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Wellspring Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellspring Ophthalmics Announces Receiving Its Second Patent for Novel Cyclosporine Dry Eye Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Wellspring Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Wellspring Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wellspring.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Supplemental Biologics License Application Accepted by US FDA for Biosimilar Hyrimoz (adalimumab-adaz) High Concentration Formulation (HCF)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior AntiHER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Goods Administration Grants Provisional Approval for Moderna\u2019s COVID-19 Vaccine in Children Aged Six Months to Five Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA\u00ae for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Crizotinib","moa":"ALK receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum\u2122 in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ \/ HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OP-1250","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dalcetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pha.."},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Alabama at Birmingham","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Issued European Patent Broadens IN8bio\u2019s Drug Resistant Immunotherapy (DRI) Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"INB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ University of Alabama at Birmingham","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ U.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Positive Long-Term Data on Freeline\u2019s Gene Therapy Candidate FLT180a for People with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ University College London","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Vicebio","sponsor":"Medicxi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicebio Launched by Medicxi to Advance the Molecular Clamp Technology and Develop Next Generation RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VXB-211","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vicebio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicebio \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Vicebio \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"REC-4881","moa":"MEK1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City\u2019s Early Access Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Innovaderm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Innovaderm","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"CBSET","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CypCaps","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaCyte Biotech \/ CBSET","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TX200","moa":"HLA-A2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cultured Epidermal Autograft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Vericel Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vericel Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vericel Co.."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"DC-806","moa":"IL-17","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"cKIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"Alpha-5 beta-1\/alpha-5 beta-6 integrin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Health Canada","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"QBKPN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Health Canada","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Liquidia Corporation \/ United Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"MC4R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces European Commission Grants Approval of Kinpeygo\u00ae for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Releases Promising Data of Ivonescimab (PD-1\/VEGF BsAbs, AK112) for Advanced NSCLC at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announces Oral Presentation Featuring Promising Clinical Data Of Cadonilimab (PD-1\/CTLA-4 BsAbs, AK104) For The First-line Treatment Of R\/M Cervical Cancer At ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI110","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae Decreased Relative Risk of Hospitalization for Heart Failure by 50% Versus DPP-4 Inhibitors and by 30% Versus GLP-1 Receptor Agonists in Adults With Type 2 Diabetes in Real-world Evidence Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Reports Encouraging Top-line Results of the Phase 1b\/2 Clinical Trial With GX-I7 (efineptakin alfa) in Refractory or Recurrent (R\/R) Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1\/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Zotatifin","moa":"eIF4A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Jantibody Inc","sponsor":"H-CYTE","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Jantibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jantibody Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jantibody Inc \/ H-CYTE","highestDevelopmentStatusID":"4","companyTruncated":"Jantibody .."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund LTV","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Raises $4.2 Million in Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGlu5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund LTV","highestDevelopmentStatusID":"9","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Replay Bio","sponsor":"KKR","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Replay Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Replay Bio \/ KKR","highestDevelopmentStatusID":"1","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Rona Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"siRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Rona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"ERS Genomics","sponsor":"Lepton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR\/Cas9 License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"miRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ERS Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ERS Genomics \/ Lepton Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ERS Genomi.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Merger","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"CinPax","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$6.0 million","newsHeadline":"vTv Therapeutics Announces Investment by CinRx Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Cadisegliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ CinPax","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI\u00ae to include Japan, Australia, New Zealand, Brazil, Mexico and Russia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lotus Acquires Cialis\u00ae (Tadalafil) in Taiwan From Lilly","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioMarin Sells Priority Review Voucher for $110 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","year":"2022","type":"Divestment","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"Injectable\/Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.23999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale up Genomic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"RBI-1000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Precision NanoSystems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Strm.Bio","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"STRM.BIO Receives $2.1 Million SBIR Grant to Advance Extracellular Vesicle Technology for Non-Viral, In Vivo Delivery of Gene Therapies","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"EV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Strm.Bio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Strm.Bio \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Strm.Bio \/.."},{"orgOrder":0,"company":"University of Helsinki","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"EUROPE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"PeptiCRAd","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"University of Helsinki","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Helsinki \/ Valo Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,660.0 million","upfrontCash":"$60.0 million","newsHeadline":"Sutro Biopharma Achieves \u201cFirst in Human\u201d Milestone in Cytokine Derivatives Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"MK-1484","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":1.6599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6599999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Sutro Biopharma \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Armistice Master Fund Ltd.","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Completes $4.2 Million Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Dipraglurant","moa":"mGlu5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Armistice Master Fund Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Vetter Pharma-Fertigung GmbH & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics Signs Development and Manufacturing Agreement With Vetter Pharma International GmbH","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Vetter Pharma International","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Collaborates with the CMT Research Foundation in the US","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HDAC6","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ CMT Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ K2 HealthVentures","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector\u00ae Platform for CAR-T Therapy","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Soleo Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleo Health Selected by Novartis as Limited Drug Distribution Partner for Administration of LEQVIO","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Soleo Health","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Heal.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carmot Therapeutics Closes $160 Million Series D Financing to Advance Clinical Pipeline of Novel Incretin Receptor Modulators","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Series D Financing","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0.16,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Financing","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS and the SEA Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Excellgene","pharmaFlowCategory":"D","amount":"$19.3 million","upfrontCash":"Undisclosed","newsHeadline":"Developing a Variant-Proof SARS-CoV-2 Vaccine: a CEPI-funded ExcellGene Partnership with Bharat Biotech and the University of Sydney","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bharat Biotech","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Excellgene","highestDevelopmentStatusID":"4","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Its Breakthrough Leukocyte-Targeting Anti-Inflammatory Human Peptides","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NF-kB","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx The.."},{"orgOrder":0,"company":"EUROAPI","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CDMO: EUROAPI Supports Sanofi\u2019s mRNA Vaccine Platform with The Development of Lipid Nanoparticles","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EUROAPI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EUROAPI \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"EUROAPI \/ .."},{"orgOrder":0,"company":"AbCellera","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Lapam Capital","pharmaFlowCategory":"D","amount":"$38.5 million","upfrontCash":"Undisclosed","newsHeadline":"BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemoproteomics Platform and First-in-Class Oncology Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"BridGene Biosciences \/ Lapam Capital","highestDevelopmentStatusID":"4","companyTruncated":"BridGene B.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"University of Miami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZyVersa Therapeutics and University of Miami Awarded a Grant from The Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation with IC 100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Funding","leadProduct":"IC 100","moa":"ASC","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ZyVersa Therapeutics, Inc \/ University of Miami","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Melinta Therapeutics \/ Cidara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Announces Proposed Public Offering Of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"National Institute for Health and Care Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium\/Cognitive Deficit in a Jointly Funded Program Wi","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Funding","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"180 Life Sciences \/ National Institute for Health and Care Research","highestDevelopmentStatusID":"4","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Patient Enrolled in Merakris-Sponsored VA Clinical Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Human Amniotic Fluid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris T.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$120.0 million","newsHeadline":"Takeda Terminated Its TAK-605 Collaboration with Turnstone Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Termination","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turnstone Biologics","amount2":1.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Turnstone Biologics \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"SEngine Precision Medicine","sponsor":"Washington Research Foundation","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"SEngine Precision Medicine Closes Series A Bringing Total Financing To $19M Enabling Continued Advancement of Personalized Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"SEngine Precision Medicine","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"SEngine Precision Medicine \/ Washington Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SEngine Pr.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Kenya Medical Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"TNX-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Kenya Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Organon","sponsor":"Cirqle Biomedical","pharmaFlowCategory":"D","amount":"$370.0 million","upfrontCash":"$10.0 million","newsHeadline":"Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Mushroom-Derived Biopolymer","moa":"Cervical mucus","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Organon","amount2":0.37,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Organon \/ Cirqle Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Vicinitas Therapeutics","sponsor":"16z","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"WEE1 kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vicinitas Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Vicinitas Therapeutics \/ 16z","highestDevelopmentStatusID":"3","companyTruncated":"Vicinitas .."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"MigVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"MigVax-101","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ MigVax","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer\u2019s Disease Treatment, AD101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ AmyriAD","highestDevelopmentStatusID":"8","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA\u00ae in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Societal CDMO \/ InfectoPharm","highestDevelopmentStatusID":"12","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"BioCina","sponsor":"Australian Government Department of Industry","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"Bio Cina Awarded Grant to Advance RNA Vaccines and Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2022","year":"2022","type":"Funding","leadProduct":"RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioCina","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"BioCina \/ Australian Government Department of Industry","highestDevelopmentStatusID":"2","companyTruncated":"BioCina \/ .."},{"orgOrder":0,"company":"Hovione","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"JX08","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Hovione","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hovione \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hovione \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$126.6 million","upfrontCash":"Undisclosed","newsHeadline":"AlloVir Announces $126.6 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Kite","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"ASC618","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Charles River Laboratories, Inc \/ ASC Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Novasenta","sponsor":"UPMC Enterprises","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Series A Financing","leadProduct":"NST0023","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novasenta","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novasenta \/ UPMC Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"Novasenta .."},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NIH, GreenLight Biosciences to Collaborate On COVID-19 Vaccine Development for New Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GreenLight Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"GreenLight.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"REVTx-99b","moa":"CCR3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in The First-To-File ANDA For the Private Label Version of Lumify in The U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback P.."},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kyowa Pharmaceutical Industry","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Phar.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"AMG 193","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Amgen Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Athena Pharmaceutiques","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Athena Pharmaceutiques Acquires Bisoprolol + Aspirin Capsules Dossier and Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Bisoprolol Fumarate","moa":"ADRB1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Undisclosed \/ ATHENA Pharmaceutiques","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s CAR T-cell Therapy Tecartus\u00ae Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r\/r ALL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Vutrisiran Sodium","moa":"TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion Recommending Veklury\u00ae (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces Positive CHMP Opinion for LUPKYNIS\u00ae (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TJ033721","moa":"Claudin 18.2 x 4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Announces Publication of Study Results Highlighting the Efficacy and Safety of DYANAVEL\u00ae XR (amphetamine) Tablets for the Treatment of the Symptoms of ADHD in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet Receives CTAs Approval for Two Phase II Combination Studies of TGF-\u03b2 R1 Inhibitor (GFH018) with PD-1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH018","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-99b","moa":"CCR3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"MDbio Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MDbio Starts Clinical Trials for Pharmaceutical-Grade Products That Target Sleeplessness, Stress and Pain","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabis Sativa Oil","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"MDbio Wellness","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MDbio Wellness \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MDbio Well.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Roche\u2019s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGF A\/Ang-2 inhibitor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Polpharma \/ Sandoz","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma's Partner Breckenridge Gets FDA Nod for Prostate Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Microtubule","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbevax Under WHO's Detailed Review for Emergency Use Listing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Genuine Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China to Allow Use of Genuine Biotech's HIV Drug in COVID Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Azvudine","moa":"Reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genuine Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuine Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genuine Bi.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D\u00ae 24 Hr in the U.S. Market","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Recommended for Approval in The EU by CHMP For the Treatment of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present the Latest Lecanemab Data, Including Aria-e and Subcutaneous Formulation, and Other Alzheimer's Disease Research at the Alzheimer's Association International Conference (AAIC) 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"B.More","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"B.More Submits FDA Investigational New Drug Application for Psilocybin Alcohol Use Disorder Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"B.More \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nobelpharma America Debuts New Product, HYFTOR\u2122 (sirolimus topical gel) 0.2%, at the 2022 World TSC Conference","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Nobelpharma America","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nobelpharm.."},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sling Therapeutics Initiates Enrollment in Phase 2b LIDS Clinical Trial Evaluating Linsitinib in Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Linsitinib","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sling Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Ther.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Allergan","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Lepu Biopharma","sponsor":"Hanx Biopharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-PD-1 Monoclonal Antibody Puyouheng\u2122 (HX-008, Pucotenlimab injection) Co-developed by Lepu Biopharma and Hanx Biopharmaceuticals Was Approved for Marketing in China by NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pucotenlimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Lepu Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lepu Biopharma \/ Hanx Biopharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Lepu Bioph.."},{"orgOrder":0,"company":"LFB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LFB Announces the Approval of CEVENFACTA\u00ae (eptacog beta) in the European Union","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Eptacog Beta","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LFB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ Not .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Beigene","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"LineaRx","sponsor":"EvviVax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA Biotherapeutics Subsidiary LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA\u2122 Platform as a Unique Approach to Veterinary DNA Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"LinearDNA SARS-CoV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LineaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LineaRx \/ EvviVax","highestDevelopmentStatusID":"4","companyTruncated":"LineaRx \/ .."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel (HAV) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-411","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts HOOKIPA's Investigational New Drug Application for HB-300 For the Treatment of Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"HB-300","moa":"PAP\/PSA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Announces Enrolment of 214 Patients in the Nidlegy\u2122 Phase III European Clinical Trial For the Treatment of Locally Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF\/MET receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY (fosdenopterin) for the Treatment of MoCD Type A","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the Midwest Surgical Association 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Expands Ready-to-Administer Portfolio with Glycopyrrolate Injection, USP Simplist\u00ae Prefilled Syringe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"Ach","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius SE & Co. KGaA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Biogen\u2019s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ I.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab\/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4\/5 and BA.2.12.1 Subvariants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Survivin mRNA-Based Vaccine","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regen BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioP.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Oklahoma Medical Research Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q Biomed Announces Publication of Pre-clinical Research Showing Superior Safety and Efficacy Against Current First Line Therapy of Its Drug Candidate Uttroside-B for Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Uttroside B","moa":"Mapk","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Oklahoma Medical Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Expanded Approval of Nuvaxovid\u2122 COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT\u00ae and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANANDA Scientific Announces First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Sci.."},{"orgOrder":0,"company":"Biomica","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Neumentum","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuance Pharma Announces the Completion of Dosing for All NTM-001 Phase 1 Clinical Study Participants in HKU Clinical Trials Centre","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nuance Pharma \/ Neumentum","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Domp\u00e9's AI Platform for Drug Design","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AISA Pharma Announces Positive Data Safety Monitoring Board Review of First Phase 2 Data of Profervia\u00ae to treat Raynaud\u2019s Disease in Scleroderma Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilnidipine","moa":"Calcium channel","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aisa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharm.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTHR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm\/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"REN001","moa":"PARP delta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn I.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Completes Dosing in OASIS Phase 1\/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford Biomedica Initiates New Project With Orchard Therapeutics Utilising LentiStable\u2122 Technology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OTL-203","moa":"IDUA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Orchard Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ US Naval Medical Research Center","highestDevelopmentStatusID":"5","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Publication of Positive Phase 3 Data Evaluating VIVJOA\u2122 (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) in NEJM Evidence","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ-801 (Valiltramiprosate) Oral Tablet at 2022 Alzheimer\u2019s Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces the U.S. Launch of the First Generic Version of THIOLA\u00ae (tiopronin) Tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patent Grant to Strengthen Small Pharma\u2019s DMT Patent Strategy With Injectable Formulation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Reviewing Data on Sabizabulin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"AKSO Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AKSO Announces Publication of Preclinical Data Demonstrating Engineered Soluble BCMA Decoy Receptor AB001 Effectively Inhibits Multiple Myeloma and Diffuse Large B Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AB001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AKSO Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AKSO Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AKSO Bioph.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Live Attenuated COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"COR588","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"BerGenBio ASA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"AXL receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ BerGenBio","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Step Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Step Pharma Progresses into Oncology Clinical Trials with STP938, the World\u2019s Most Advanced CTPS1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STP938","moa":"CTPS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Step Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharm.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11\u2019s Single Agent Anti-Cancer Activity in the Phase 1\/2 ABILITY Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company\u2019s Drug Candidate for the Treatment of Postherpetic Neuralgia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present at 2022 Alzheimer\u2019s Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"CD34+ gene","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athena\u2019s First Market Authorization in Brazil with Ondansetron ODT","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Athena Pharmaceutiques","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Pha.."},{"orgOrder":0,"company":"Zenara pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenara Pharma to Launch Generic Paxlovid Soon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zenara pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zenara pharma \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Zenara pha.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Positive Topline Results From Phase 2b Clinical Study of Fesomersen, a Potential Novel Anti-thrombotic Treatment","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fesomersen","moa":"Factor XI","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Bayer","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Salix Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Provides Update Following Oral Order in XIFAXAN\u00ae Patent Litigation","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ Salix","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Curia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in the ENLIGHTEN Biomarker-Guided Global Clinical Trial of DB104 (Liafensine) for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Liafensine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Albany Molecular Research","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharma Initiates Enrollment in Pivotal Phase 3 Clinical Trial of SPI-1005 For the Treatment of Hearing Loss and Tinnitus in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"KP104","moa":"Complement system","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharm.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-411","moa":"SARS-CoV-2 virus protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation, a Novel Approach for the Differentiation and Expansion of Induced Pluripotent Stem Cells to Generate Cytotoxic Innate Lympho","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-VV100","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Trogarzo\u00ae Data at AIDS 2022 Shows Potential for Improved Treatment Regimens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibalizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen\u00ae for the Treatment of Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO\u00ae (testosterone undecanoate)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated\u00ae Nomacopan That Support the Potential to Advance Research Toward IND\/IMPD for Clinical Trials in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"PAS-Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"CY6463","moa":"Soluble guanylyl cyclase","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Kings College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Launches Phase II Clinical Trial of Psilocybin Therapy in Anorexia Nervosa","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ King\u2019s College London","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Present Data from Ongoing ReSPECT\u2122 Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TRV045","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sareum Submits Clinical Trial Authorisation Application to UK MHRA for Development of TYK2\/JAK1 Inhibitor SDC-1801 and Provides an Operational Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"SDC-1801","moa":"TYK2\/JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biktarvy\u00ae Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"NervGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NervGen Pharma\u2019s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NVG-291-R","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NervGen Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NervGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NervGen Ph.."},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1\/2 Study for Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"TAC-001","moa":"TLR9 agonist\/CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tallac Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tallac The.."},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"CytoImmune.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY\u00ae (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bacillus Calmette Guerin","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg\/20 mcg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Belimumab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare to Present New Data From Innovative HIV treatment and Prevention Portfolio at AIDS 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces New Data at AIDS 2022 from Unblinded Phase of HPTN 084 Study in Women in sub Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-acting for PrEP over daily, oral TDF\/FTC tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI\u00ae (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Achieves Primary Objectives of ONWARDS 3 and 4 Trials With Once-weekly Insulin Icodec Demonstrating Superior Reduction in HbA1c Vs Insulin Degludec in ONWARDS 3","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"siRNA-Based Therapeutic","moa":"CIDEB gene","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Advances VX-548 in Acute and Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-548","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm\/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen and Astellas Announce Positive Topline Results For PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ A.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC epsilon","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"LNK01004","moa":"kinase","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"ACM Biolabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"As part of 'Operation Nasal Vaccine' to Counter COVID-19 spread, ACM-001 Booster Vaccine Administered to First Subject in Phase 1 Safety and Immunogenicity Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ACM-001","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ACM Biolabs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ACM Biolabs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ACM Biolab.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte\u2122 for the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u00ae (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1\/JAK3","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer\u2019s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces ALBRIOZA is Now Available in Canada for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Omeros\u2019 MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OMS906","moa":"MASP-3","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive Five-year Data at AIDS 2022, Demonstrating the Durability of Fostemsavir in People Living With HIV Who Are Heavily Treatment-experienced","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"gp120","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-235","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ\u00ae) in Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves RINVOQ\u00ae (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Recommended for Approval in the EU by CHMP for the Treatment of Adults with Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Alexion","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biolo.."},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eden Biologics\u2019 Leading Biosimilar Program Receives Phase 3 Approval in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biolo.."},{"orgOrder":0,"company":"SyneuRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir\u00ae (SNB01)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentarlandir","moa":"TMPRSS2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SyneuRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SyneuRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SyneuRx \/ .."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Announces First Entire Clinical Alzheimer\u2019s Gene Pathway Data of ANAVEX\u00ae2-73 at AAIC 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma 1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATHENA\u2019s First Launch in Russia with Levocetirizine ODT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Athena Pharmaceutiques","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Dispersible","sponsorNew":"Athena Pharmaceutiques \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Pha.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy Candidate Into Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"HTL0039732","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Cancer Research UK","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica to Present at the Microbiome Connect Europe 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD117","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Incannex Healthcare \/ Curia Global","highestDevelopmentStatusID":"4","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Medac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycostem and Medac Enter Into License, Manufacturing, Supply and Commercialization Agreement for Glycostem's Lead Product - oNKord","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Medac GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series B Financing","leadProduct":"Ori-C101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OriCell Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"OriCell Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"GluBio Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"GluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GluBio Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"GluBio Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"GluBio The.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","amount":"$89.0 million","upfrontCash":"$15.0 million","newsHeadline":"Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AVTX-002","moa":"LIGHT","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"Avalo Therapeutics \/ Apollo Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Yale University","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare Capital Management","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$7.8 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"7 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Funding","leadProduct":"7HP349","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology Announces Closing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Sylvester Comprehensive Cancer Center","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$9.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sylvester Researchers Receive $9.5 Million Grant to Study Esophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sylvester Comprehensive Cancer Center","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sylvester Comprehensive Cancer Center \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Sylvester .."},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Segesterone Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"TherapeuticsMD \/ Rubric Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris\u2019 Commercialization Partner for Ogluo, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tetris Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Arecor Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tetris Pha.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$133.0 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series B Financing","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0.13,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Structure Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Divestment","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Enterome","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.7 million","newsHeadline":"Enterome Signs Major Strategic R&D Collaboration with Nestl\u00e9 Health Science to Develop and Commercialize New AllerMimics\u2122 and EndoMimics\u2122 Immunotherapies for Food Allergies and Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"EB1010","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"4","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cortexyme Announces Agreement to Acquire Novosteo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"NOV004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Cortexyme","highestDevelopmentStatusID":"5","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cortexyme Successfully Completes Acquisition of Novosteo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"NOV004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Cortexyme","highestDevelopmentStatusID":"5","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"$2.0 million","newsHeadline":"Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Olutasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"The Menarini Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ The Menarini Group","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Adalvo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo Acquires Its First Branded Product, Onsolis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"Undisclosed \/ Adalvo","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"IDRx","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series A Financing","leadProduct":"IDRX-42","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"IDRx \/ Andreessen Horowitz","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ And.."},{"orgOrder":0,"company":"Sironax","sponsor":"Gaorong Capital","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sironax Announces Closing of $200 Million Series B Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series B Financing","leadProduct":"SIR0365","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sironax","amount2":0.20000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Sironax \/ Gaorong Capital","highestDevelopmentStatusID":"7","companyTruncated":"Sironax \/ .."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"KALEO INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Enters Into License Agreement with Kal\u00e9o for The Canadian Rights to Allerject\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valeo Pharma \/ Kaleo Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"VolitionRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ VolitionRx","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$112.5 million","upfrontCash":"$2.6 million","newsHeadline":"PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX\u2081\u2080\u2080 in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ ADVANZ PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Curia","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"srRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Curia \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Re.."},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Founding Partners","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Visiox Pharma Announces Close of $7M Seed Round","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Visiox Pharma \/ Founding Partners","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pha.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Kintara Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Raises $30 Million From Insiders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"TNX-1300","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpectrumX Partners With Leading UK Specials Group to Accelerate Production of Anti-Pathogenic Drug for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX .."},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$405.0 million","upfrontCash":"$405.0 million","newsHeadline":"Gilead Sciences to Acquire MiroBio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ .."},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Thorne HealthTech Announces Two-Year Collaboration with AstraZeneca on Disease Discovery System to Advance Novel Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Thorne HealthTech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thorne HealthTech \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Thorne Hea.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Padagis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma and Padagis Sign Agreement For MOB-015 in Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Padagis Israel Agencies Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"RVL Pharmaceuticals","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Private Placement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenoceptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"RVL Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"RVL Pharmaceuticals \/ Athyrium Capital","highestDevelopmentStatusID":"12","companyTruncated":"RVL Pharma.."},{"orgOrder":0,"company":"Entourage Health","sponsor":"Irwin Naturals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Entourage Health Signs Exclusive Licensing Agreement with Irwin Naturals to Produce and Distribute its Cannabis Products in Canada","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Entourage Health","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Entourage Health \/ Irwin Naturals","highestDevelopmentStatusID":"12","companyTruncated":"Entourage .."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Adds Three New Customers, Signing Agreements to Provide CDMO Services Supporting Clinical Development of Several Novel Therapeutic Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$305.6 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Innovent Biologics Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Tusamitamab Ravtansine","moa":"CEACAM5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"BNT313","moa":"CD27","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Genmab \/ B.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sosei Heptares\u2019 Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"HTL-0016878","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":2.7000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":2.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Morningside Venture Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Epigenetic Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Epigenic Therapeutics \/ Morningside Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic T.."},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"$205.0 million","newsHeadline":"AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Termination","leadProduct":"AL003","moa":"CD33","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0.23000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Abbvie","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1\/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1\/PD-L1 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Laekna","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenas BioPharma Obtains IND Approval in China for Phase 1\/2 Study of ZB001 for the Treatment of Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Zenas BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zenas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zenas BioP.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"CDK2\/CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Cabazitaxel Intravenous Solution (Generic for Jevtana Kit\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Microtubule","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Tavanta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tavanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tavanta Th.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 \"EVOGUARD\" Trial Evaluating Phexxi\u00ae for the Prevention of Chlamydia and Gonorrhea in Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AP-SA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio to Participate on Alzheimer's Association International Conference Panel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"VEGF receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Eccogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eccogene Announces US IND Approval for THR\u03b2 Agonist ECC4703","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ECC4703","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Eccogene","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eccogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eccogene \/.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Nordic Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"N3pE amyloid","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Provides Progress Update on GBM Agile Pivotal Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed\/Refractory Follicular Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"Methyltransferase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband Receives Notice of Allowance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Enrolls First Patient in Phase 1\/2a Trial of BI-1607 in HER2 Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BI-1607","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"UCART20x22","moa":"CD20\/CD22","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME\u00ae (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-247","moa":"Nucleolin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AGEN1571","moa":"ILT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exhale Wellness Expands Its Product Line With The Launch Of Delta 9 Gummies & Drops","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Exhale Wellness","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Exhale Wellness \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exhale Wel.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-311","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Presentation at Alzheimer\u2019s Association International Conference\u00ae 2022 (AAIC\u00ae) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cantharidin","moa":"PP2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC\u00ae Candidate IMC-F106C Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IMC-F106C","moa":"PRAME","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology\u2019s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Evorpacept","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"KB407","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40L","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-488","moa":"TK2\/JH2 allosteric","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Monalizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Astrazeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Publishes Results from a Phase 1\/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Graminex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graminex, L.L.C. Completes Clinical Trial with Graminex Flower Pollen Extract Focusing on Women\u2019s Urinary Incontinence with Positive Results.","therapeuticArea":"Urology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Graminex G63 Flower Pollen Extract","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Undisclosed","graph3":"Graminex","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Graminex \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Graminex \/.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Reports Positive Topline Results for Second CTP\u2011543 Phase 3 Clinical Trial in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics to Participate in \u201cDrug Development in Pulmonary Medicine\u201d Panel Discussion at 2022 BTIG Biotechnology Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last patient completed follow-up period in Phase II\/III study of Amphera\u2019s MesoPher cell therapy in mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"MesoPher","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Amphera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amphera \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amphera \/ .."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AVX012","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Therapeutics Provides ETX-810 Program Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ETX-018810","moa":"PPAR alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eliem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Expects Regulator's Nod for Intranasal COVID-19 vaccine in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dovitinib","moa":"Pan-TKI","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ReCOV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1\/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Enrolls Patients in the MARINA\u2122 Open-Label Extension Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AOC 1001","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics' Anti-CD47 Antibody Patent Granted in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PT886","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde\u00ae in Second-Line Monotherapy for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"OTT166","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra T.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca\u2019s Effects on Trauma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Unlimited Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Unlimited Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Unlimited .."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Orca-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Presentation of Topline Results from Two Studies Evaluating VIVJOA\u2122 (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC) at the 2022 IDSOG Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BAT8009","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Paromomycin","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Detailed Data From the Phase II Crenezumab Alzheimer\u2019s Prevention Initiative Study in Autosomal Dominant Alzheimer\u2019s Disease Presented at AAIC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Coherus\u2019 CIMERLI\u2122 (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis\u00ae for All Five Indications, with 12 Months of Interchangeability Exclusivity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Polpharma","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF\/MET receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"APIE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"APIE Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"APIE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"APIE Thera.."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Receives FDA Approval of KYZATREX\u2122, an Oral Testosterone Replacement Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CLBS201","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Fucose","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avalo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIPR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patent Issued to HCW Biologics for Foundational Platform Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"HCW9302","moa":"Tregs","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HCW Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chime Biologics Received Commercial Manufacturing License Indicating the Kick-off into the Era of Commercial Production","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pucotenlimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chime Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chime Biol.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS LI","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RGX-121","moa":"IDS gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of APOE4 Genotype on Aria-E Incidence at The Alzheimer's Association International Conference (AAIC) 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"PhorMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phormed Announces ARDS Study Results","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"12-O-Tetradecanoylphorbol-13-acetate","moa":"IL-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"PhorMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PhorMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PhorMed \/ .."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc. Announces US FDA Clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, For Treatment of Solid Tumors With Brain Metastases and Primary Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"JBI-778","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"LNK01004","moa":"kinase","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProfoundBio Receives FDA \"Study May Proceed\" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRO1184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProfoundBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"ST Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STP0404","moa":"HIV-1 allosteric integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ST Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ST Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ST Pharma .."},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte\u2122 Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AVB-001","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avenge Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IC 100","moa":"ASC","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Provides Regulatory Updates on its Development Programs","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"University of Kansas Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxeia Announces Positive Interim Results of Phase 2 Trial For OXE103 For the Treatment of Concussions","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Ghrelin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biop.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"113 Anti-tau Antibody","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer\u2019s Patients at the Alzheimer's Association International Conference 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF\/MET receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-1558","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Macrophage homeostasis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Wisconsin Medical Cyclotron & Radiopharmacy","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613\u00ae (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Lipoic acid","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Medical College of Wisconsin","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-13","moa":"NLRX1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol\u00ae for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"RAR alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IM-101","moa":"Completent C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"ImmunAbs","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunAbs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunAbs \/.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Enters Final Stage of Clinical Development for New Gout Drug","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tigulixostat","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Civica Rx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CivicaScript Announces Launch of its First Product, Creating Significant Patient Savings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Civica Rx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Civica Rx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Civica Rx .."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Acebutolol Hydrochloride","moa":"ADRB1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GLSI-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ET140203","moa":"Alpha fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde\u00ae in Second-Line Monotherapy for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Me.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval From USFDA for type 2 Diabetes Tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Phar.."},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Gets USFDA Nod for Ivermectin Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivermectin","moa":"Chloride channel","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zydus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Phar.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandin synthesis","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"26S proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Initiation of Phase 2b\/3 Hummingbird\u2122 Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION therapeutics Announces Enrollment of the First Patient in ADESOS Phase 2b Study of Orismilast MR Tablet in Patients With Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Orismilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical and Lundbeck Present Positive Results Showing Reduced Agitation in Patients With Alzheimer\u2019s Dementia Treated With Brexpiprazole at the 2022 Alzheimer's Association International Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Children\u2019s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"iPSC-derived Allogeneic Immune Therapies","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BX003","moa":"Klebsiella pneumoniae","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Denifanstat","moa":"FASN","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves IMBRUVICA\u00ae (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces FDA Clearance of IND for MT-601, the Six-Antigen Targeted T Cell Therapy For the Treatment of Relapsed\/Refractory Non-hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-601","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer\u2019s Disease Processes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Sigma-2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Oregon Health & Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Oregon Health & Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemlapodect","moa":"PDE10A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CRN04894","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"The ALS Association","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics\u2019 Completed ALS Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirasemtiv","moa":"Troponin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ The ALS Association","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer to Discontinue Development Program for PF-07265803 for LMNA-Related Dilated Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Emprumapimod","moa":"p38 alpha MAP kinase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Declines to Approve Expanded Use of Acadia's Antipsychotic Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Innovation in Targeted Protein Degradation with Debut of Protein Degrader DKY709 at American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"DKY709","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics Announces EMA Acceptance of Marketing Authorization Application for Proposed Biosimilar Natalizumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Polpharma \/ Sandoz","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-221","moa":"IgE production","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics Reports Promising Interim Data From Combination Study of Paxalisib With Radiotherapy in Treatment of Brain Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence\u00ae (Acalabrutinib) Tablet Formulation Approved in the US Across Current Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"C5252","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC61","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves JUV\u00c9DERM\u00ae VOLUX\u2122 XC for Improvement of Jawline Definition","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":" \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":" \/ Not App.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in the US as the First HER2-Directed Therapy for Patients With HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE\u00ae, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined With PD-1 Inhibitor Libtayo\u00ae (Cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (MCRPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PSMA\/CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STELARA\u00ae (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed\/refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Shows WNT974 In Combination With Spartalizumab Well Tolerated for Advanced Solid Tumor Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WNT974","moa":"Porcupine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives FDA Fast Track Designation for Sabatolimab (MBG453) in Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"TIM-3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces T-Charge\u2122, Next-Generation CAR-T Platform with First-in-Human Data at ASH 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"PHE885","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lp(a) Horizon Achieves 50% Enrollment in Trial to Assess the Safety and Efficacy of Pelacarsen in Reducing Recurrent Cardiovascular Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pelacarsen","moa":"Apolipoprotein A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MMV Awards Project of the Year 2019 to Novartis for the Discovery of INE963","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"INE963","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Abbvie","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves RADICAVA ORS\u00ae (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Data of InnoCare\u2019s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"$32.5 million","newsHeadline":"Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Clearside Biomedical \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Indivior","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill\u00ae Platform Advancement and Clinical Pipeline Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Parathyroid Hormone (1-34)","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer\u2019s Disease Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oligomerix \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptar Pharma Acquires Worldwide License for Orbital\u2122 High Payload Dry Powder Inhaler","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Pharmaxis","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Pharmaxis .."},{"orgOrder":0,"company":"Medsenic","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Bone Therapeutics to Broaden and Derisk Therapeutic Portfolio by Acquiring Majority Participation in Medsenic","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Medsenic","amount2":0.01,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Medsenic \/ Bone Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Medsenic \/.."},{"orgOrder":0,"company":"Starpharma","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starpharma Signs New DEP Agreement With MSD","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ MSD","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Develops New Human Tissue-Based Model of Rare Liver Disease Under Research Collaboration with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava in Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Eravacycline","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ TTY Biopharm","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.25,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caladrius Biosciences\u2019 Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"CEND-1","moa":"Alpha V integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Private Placement","leadProduct":"BWV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"MDNA11","moa":"IL2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Medicenna Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Helocyte","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Funding","leadProduct":"CMV-modified Vaccinia Ankara Vaccine","moa":"pp65 protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Helocyte \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/.."},{"orgOrder":0,"company":"Athenex","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Athenex \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"TRON Group","sponsor":"Nanopharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"MALAYSIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Merger","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TRON Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRON Group \/ Nanopharmaceutics","highestDevelopmentStatusID":"10","companyTruncated":"TRON Group.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Celesta Capital","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series C Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Celesta Capital","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Bi.."},{"orgOrder":0,"company":"Evotec","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Just- Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"ALPN-303","moa":"BAFF\/APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evotec \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ A.."},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic\/-Prophylactic for COVID-19-Induced Lung Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"PGX-YBG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ M.."},{"orgOrder":0,"company":"TeneoTwo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,265.0 million","upfrontCash":"$100.0 million","newsHeadline":"Astra Zeneca Completes Acquisition of TeneoTwo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD19\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TeneoTwo","amount2":1.27,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.27,"dosageForm":"Injectable\/Injection","sponsorNew":"TeneoTwo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"TeneoTwo \/.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann & Co.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley & Co","pharmaFlowCategory":"D","amount":"$254.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.25,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley & Co","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"RayzeBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Peptide-radioisotope Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ RayzeBio","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$455.0 million","upfrontCash":"$280.0 million","newsHeadline":"Gilead to Acquire Remaining Worldwide Rights of Trodelvy\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0.46000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Short Wave Pharma","sponsor":"The Sheba Center for Eating Disorders","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Short Wave Pharma Signs Clinical Trial Agreement with The Sheba Research Fund and The Sheba Center for Eating Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Short Wave Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Short Wave Pharma \/ The Sheba Center for Eating Disorders","highestDevelopmentStatusID":"7","companyTruncated":"Short Wave.."},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aytu BioPharma \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPh.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Owl Rock","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADC Therapeutics \/ Owl Rock","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Resilience","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Resilience Announces Collaboration to Manufacture and Deliver Biotherapeutics for Rare and Complex Conditions","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Resilience","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resilience \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Resilience.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS\u2122 Selected Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"HFB200301","moa":"TNFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"GABA B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Identifies Second Target to Treat NASH for Takeda","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Additional Indication of NUBEQA\u00ae (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cstone Presents Updated Results of a Registrational Study of Sugemalimab in Patients With stage III NSCLC via Oral Presentation at WCLC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A\/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI324","moa":"VEGF-A\/Ang-2 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IMG-004","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ HUTCHMED","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Reports Positive Interim Results from Phase 1c\/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Participation in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Presents New Tarlatamab Clinical Data at WCLC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tarlatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (MPRO) Small Molecule Inhibitor, Laying Foundation for The Treatment of Acute and Long Covid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Bofutrelvir","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontier Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Frontier B.."},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Healthcare's Memorial Health University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ondine Biomedical Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylene Blue","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ondine Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Ondine Bio.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment to Help Retinal Disease Patients Maintain or Gain Vision","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/ binding protein beta inhibitor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Porustobart","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"OspA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Verona Pharma \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Inc. Announces Regulatory and Manufacturing Updates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex, Inc.\u2019s Phase 2 \u201cSIGNAL\u201d Study to Evaluate Pepinemab Antibody in Huntington\u2019s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"LPS","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Panavance Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panavance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panavance .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma to Host Investor Education Event, \u201cUnderstanding the PNT2002 Phase 3 SPLASH Trial Control Arm\u201d","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lu-177-PSMA-I&T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Announce that TAGRISSO\u00ae Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and\/or Amplification in SAVANNAH Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Presents Newly Available Data on Vepafestinib at IASCLC 2022 World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Vepafestinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"SpectrumX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpectrumX Confirms Scientific Advice Meeting With MHRA, Proposed Timeline for Human Clinical Trials for Ground-Breaking Medicine SPX-001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX .."},{"orgOrder":0,"company":"Guardant Health","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Guardant Health and Blueprint Medicines Present Real-world Data Identifying EGFR C797x Mutation as Most Common Resistance Mechanism to Osimertinib Therapy at IASCLC 2022 World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Guardant Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Guardant Health \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Guardant H.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"JAK1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative Announces Termination of the Cyclosporine Treatment Arm for Critically Ill COVID-19 Patients in the I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Upstream","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"UPB-101","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Upstream \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Upstream \/.."},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fore Biotherapeutics to Present Phase 1\/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"FORE8394","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fore Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Bioth.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor Granted European Patents Protecting Proprietary Formulations of High Concentration Humira\u00ae Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbevax Approved as Precaution Dose for Adults Vaccinated With Covaxin, Covishield","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BECOV2D","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1\/2 Study of NK Cell Therapy Candidate GDA-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NAM-expanded Allogeneic NK Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ABX1100","moa":"Glycogen synthase 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2seventy bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Picankibart","moa":"IL23p19 subunit","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Onternabez","moa":"CB2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Arbele","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ARB202","moa":"CDH17","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbele \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ N.."},{"orgOrder":0,"company":"Psilera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psilera's New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5HT-1A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psilera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ .."},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peel Therapeutics Initiates Clinical Trial of PEEL-224 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SN22","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PEEL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PEEL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PEEL Thera.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optimi Health Unveils Canada\u2019s First Natural Therapeutic Psilocybin Product For Approved Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Optimi Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Optimi Hea.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Launches ZORYVE\u2122 (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Announces \u201cBreakthrough Article\u201d Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-251","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY\u00ae (fosdenopterin) for the Treatment of MoCD Type A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutic","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artios initiates Phase 2 study of Pol\u03b8 Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ART4215","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Artios Pharma Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA\/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CPT-6281","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Captor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Captor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Captor The.."},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bi.."},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropocamptide","moa":"Keratinocyte","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Promore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Ph.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group\u2019s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+\/HER2- Advanced or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Alvogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company\u2019s Proposed Generic to Xifaxan\u00ae for IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ .."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GLSI-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullgen Announces Chinese NMPA Allowance of Investigational New Drug Application of TRK Degrader to Begin Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CG001419","moa":"TRK protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullgen \/ .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches 4 New Generic Products, Including Vasopressin Single-dose","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recbio Announces Phase III Trial Progress of Recombinant HPV 9-valent Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Nine-valent HPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND\u00ae (mitapivat) in Non-transfusion-dependent \u03b1- and \u03b2-Thalassemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-204","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PAS002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA\u00ae (lefamulin) in Adult Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"Peptidyl transferase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces European Commission Approval of VYVGART\u2122 (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PBFT02","moa":"AAV1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces Leading Publication Revealing an Immune Mechanism of Action Driving Anti-tumor Activity of Adenovirus Vectored Vaccines and Anti-PD1 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9 gene","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Cure Rare","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cure Rare Disease Receives FDA Approval to Administer First-in-Human CRISPR Therapeutic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CRD-TMH-001","moa":"Dystrophin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Cure Rare","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cure Rare \/ Charles River Laboratories","highestDevelopmentStatusID":"5","companyTruncated":"Cure Rare .."},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regen BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioP.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Recommendation Expands Patient Eligibility for AbbVie\u2019s Ozurdex (dexamethasone 0.7mg intravitreal implant) in Diabetic Macular Oedema (DMO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SYNB2081","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Results from Phase 3 ENHANCE-2 Trial Supporting Use of Nebulized Ensifentrine for Maintenance of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3\/PDE4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Sanofi","sponsor":"NIHR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIHR and Sanofi Announce First Patient Enrolled in Large European Clinical Study to Investigate Protection Against RSV, the Leading Cause of Infant Hospitalisation Worldwide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ NIHR","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Approved in the US as the First HER2-directed Therapy for Patients With Previously Treated HER2-mutant Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MPS Clinical Program Update and Paradigm to Present at the International Conference on Lysosomal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGF2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Gets Priority Review for PNH Med Crovalimab in China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Crovalimab","moa":"Completent C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte\u2122 on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trodelvy\u00ae Significantly Improves Overall Survival in Pre-Treated HR+\/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's OmicronContaining Bivalent Booster in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on Phase III Canopy-a Study Evaluating Canakinumab as Adjuvant Treatment in Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 20-valent Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolebrutinib Clinical Trial Program Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolebrutinib","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Significantly Delayed Disease Progression in DESTINY-breast02 Phase Iii Trial Vs. Physician\u2019s Choice of Treatment in Patients With HER2-positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients With High Levels of MET Overexpression and\/or Amplification in SAVANNAH Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Additional Indication of Darolutamide in Combination With Docetaxel for the Treatment of Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoclonal Antibody Mitchga for the Treatment of Itching Associated with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ C.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Versus Physician\u2019s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Taltz\u00ae (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"Il-17 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC42","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gannex Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pha.."},{"orgOrder":0,"company":"Crestone","sponsor":"Praedicare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crestone, Inc. and Praedicare Inc. Announce the Publication of Data on the Novel Antibiotic CRS0540 in the Hollow Fiber System Model of the Orphan Disease Disseminated Listeriosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CRS0540","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crestone \/ Praedicare","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Survival with RADICAVA\u00ae (edaravone)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alternative Pathway Blocker Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Efficacy Trial in C3 Glomerulopathy (C3G) Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NM8074","moa":"C3\/ C5 convertase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class Irreversible Oral Dual Acting inhibitor for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"DWP213388","moa":"ITK\/BTK","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Positive Topline Results for CNM-Au8\u00ae in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Completes Clinical Development for Phase III Trials and Booster Doses For BBV154 Intranasal Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Nuvaxovid\u2122 COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"Gluten","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ Mayo Clinic","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics\u2019 Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Medicine Publishes Interim Results from Gritstone bio\u2019s Phase 1\/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GRT-C901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VTX958","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1\/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology and Quantum Leap Healthcare Collaborative\u2122 Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu\u00ae in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial o","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CF-296","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Research Evaluating VASCEPA\u00ae\/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT\u00ae Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Acyl-CoA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Plant Extract","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Announces Presentation of the EMPATHY Study of Ensovibep for the Treatment of COVID-19 at ECCMID 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensovibep","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$75.0 million","newsHeadline":"Ultragenyx Exercises Option to Acquire GeneTx","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children's Hospital Medical Center for S&P Vaccine Platform Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health Update on Abaloparatide Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Affinivax","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$3,300.0 million","upfrontCash":"$2,100.0 million","newsHeadline":"GSK Completes Acquisition of Affinivax, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"AFX3772","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":3.2999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":3.2999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Affinivax \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medison Pharma \/ Albireo","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"Senda Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$123.0 million","upfrontCash":"Undisclosed","newsHeadline":"Senda Biosciences Announces Close of $123 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series C Financing","leadProduct":"SendRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senda Biosciences","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Senda Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"4","companyTruncated":"Senda Bios.."},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Arkin Bio Ventures","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bluejay Therapeutics Raises $41 Million In Series B Round to Drive Clinical Trials in Chronic Hepatitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series B Financing","leadProduct":"BJT-778","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bluejay Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bluejay Therapeutics \/ Arkin Bio Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Bluejay Th.."},{"orgOrder":0,"company":"Vici Health Sciences","sponsor":"Psycheceutical","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"$10.5 million","newsHeadline":"Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vici Health Sciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vici Health Sciences \/ Psycheceutical Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Vici Healt.."},{"orgOrder":0,"company":"Medicinova","sponsor":"University Health Network","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Ibudilast","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ University Health Network","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Intellipharmaceutics Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Desvenlafaxine Succinate","moa":"SNRI","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Taro Pharmaceutical Industries \/ Intellipharmaceutics","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharm.."},{"orgOrder":0,"company":"X-Chem","sponsor":"BioDuro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioDuro-Sundia and X\u2011Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ BioDuro-Sundia","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ B.."},{"orgOrder":0,"company":"GSK","sponsor":"UNICEF","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"Millions More Children to Benefit from Malaria Vaccine As UNICEF Secures Supply","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"RTS, S\/AS01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ UNICEF","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ UNIC.."},{"orgOrder":0,"company":"AUM LifeTech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI\/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Antisense Oligonucleotides","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM LifeTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM LifeTech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"AUM LifeTe.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4,100.0 million","upfrontCash":"$4,100.0 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":4.0999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":4.0999999999999996,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"CH Trading Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido\u00ae Across Certain Designated Territories Including Middle East and North Africa","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ CH Trading Group","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Tenmile","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Carina Biotech Raises $7.5 Million at First Close with Tenmile as The Cornerstone Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Financing","leadProduct":"LGR5 CAR-T Cell Therapy","moa":"LGR5","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Carina Biotech \/ Tenmile","highestDevelopmentStatusID":"5","companyTruncated":"Carina Bio.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Announces $150 Million Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Private Placement","leadProduct":"KT-413","moa":"IRAK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$19.9 million","upfrontCash":"Undisclosed","newsHeadline":"Emtora Biosciences Receives $16.9M Grant from the Cancer Prevention & Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Bio.."},{"orgOrder":0,"company":"Bill & Melinda Gates Foundation","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"OPC-167832","moa":"DprE1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bill & Melinda Gates Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Foundation \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bill & Mel.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$21.8 million","upfrontCash":"Undisclosed","newsHeadline":"EIB to Support Ryvu Therapeutics\u2019 Discovery, Research and Development of New Cancer Treatments with \u20ac22 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Financing","leadProduct":"RVU120","moa":"CDK8\/CDK19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innoviva Completes Acquisition of La Jolla Pharmaceutical","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Angiotensin II","moa":"Angiotensin II receptor type 1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"La Jolla Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"La Jolla Pharmaceutical \/ Innoviva","highestDevelopmentStatusID":"12","companyTruncated":"La Jolla P.."},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Funding","leadProduct":"PTM-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"PanTher Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Th.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Noile-Immune Biotech Inc","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"$146.2 million","upfrontCash":"Undisclosed","newsHeadline":"Chugai and Noile-Immune Biotech Enter into a License Agreement for Noile-Immune\u2019s PRIME CAR-T Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"NIB102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Noile-Immune Biotech Inc","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Noile-Immune Biotech Inc \/ Chugai","highestDevelopmentStatusID":"4","companyTruncated":"Noile-Immu.."},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calyptus Pharmaceuticals Announces Partnership with Provepharm to Accelerate Development of an Acute Care Injectable Product","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Cetrorelix Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Provepharm","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus P.."},{"orgOrder":0,"company":"Valneva","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Provides Update on IXIARO\u00ae Supply Contract with U.S. Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Inactivated Japanese Encephalitis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ART26.12","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Arm Gets Final US FDA Nod for Vasopressin injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akorn Announces FDA-Approved Generic Cetrorelix Acetate for Injection 0.25 mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Phar.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Daratumumab","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PL9643","moa":"MCR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Index Pharmaceuticals Announces Successful Interactions With the PMDA for the Clinical Development of Cobitolimod in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Neumifil","moa":"Sialic acid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pneumagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STP135G","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"XMT-1660","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Adelaide Begins Human Trial of Omicron COVID Vaccine Booster Using PharmaJet Needle-free System","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"DNA-based COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaJet \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aytu BioPharma Announces Issuance of Its First Patent for AR101\/Enzastaurin","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPh.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO\u00ae, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI311","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Garadacimab","moa":"Factor XIIa","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Novavax","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Nuvaxovid\u2122 COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Department of Health and Human Services","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore IPF Interim Data Selected as an Oral \"Late-breaker\" at the ERS Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavneos\u00ae (avacopan) Recommended by England\u2019s NICE for the Treatment of AAV (GPA\/MPA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Cybin","sponsor":"Clinilabs","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1\/2a First-In-Human Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Clinilabs","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Cl.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA\u00ae Biosimilar HADLIMA\u2122 (adalimumab-bwwd)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Initiate Phase 1\/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-MMP7","moa":"MMP7","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Trethera","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Mabwell Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Yale Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I\/II Trial Evaluating Allocetra\u2122 Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Yale Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed\/Refractory Classical Hodgkin Lymphoma (cHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous CD30.CAR-T Cell Therapy","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3\/PDE4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Nuance Pharma \/ Verona Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ReCOV","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tarcocimab Tedromer","moa":"VEGF receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase level","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Piramal Critical Care Launches First to Market Generic Zinc Sulfate Injection in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Zinc Sulphate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Piramal Pharma Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Piramal Pharma Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Piramal Ph.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Doses the First Patient in Phase I\/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"COX-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall's Klisyri\u00ae (tirbanibulin) Receives Strong Recommendation in American Academy of Dermatology AK Guideline Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Valo Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 Study of An Oral ROCK1\/2 Inhibitor for The Treatment of Non-Proliferative Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"OPL-0401","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Healt.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex\u00ae\/Epidyolex\u00ae (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER\u00ae Patents; Rules Teva Infringes Tris Patents","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Tris Pharma Inc \/ Teva","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gr\u00fcnenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Grunenthal \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients With Relapsed Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet Receives FDA Approval for Phase II Study of RIPK1 Inhibitor (GFH312)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH312","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s QDENGA\u00ae (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"9vHPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives US FDA Approval for Rufinamide Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rufinamide","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CV0501","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND\u00ae (mitapivat) for Adults with Pyruvate Kinase Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen\u00ae for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company\u2019s Phase I Trial of GCC19CART for Relapsed\/Refractory Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GCC19CART","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AUM601","moa":"TRKA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Innovation1 Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabivarin Prodrug","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Innovation1 Biotech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovation1 Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO\u00ae (berotralstat) in Saudi Arabia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Celltrion Healthcare\u2019s Vegzelma\u2122 (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermaliq Therapeutics Announces First Patient Dosed in Phase 1b\/2 Trial Evaluating DLQ02 for Treatment of Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"DLQ02","moa":"Calcineurin","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Dermaliq Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq T.."},{"orgOrder":0,"company":"Genuv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication in Nature Molecular Psychiatry Supports Genuv\u2019s Alternate Theory for Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Trametinib","moa":"MEK 1\/2","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ No.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants Marketing Authorisation for Novartis\u2019 Radioligand Therapy Pluvicto\u00ae (Lutetium (\u00b9\u2077\u2077lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Advanced Accelerator Applications","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanced Accelerator Applications \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanced A.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces FDA Approval of AUVELITY\u2122, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calyptus Pharmaceuticals Announces FDA Approval of Cetrorelix Acetate for Injection, 0.25 mg\/vial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calyptus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus P.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World's First CAR-T for NMOSD Treatment, IASO Biotherapeutics' Equecabtagene Autoleucel, Receives IND Approval by NMPA","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+\/HER2- Advanced or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Radius","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Evidence of Data Manipulation in Science Publication on Simufilam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Simufilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Update on IMM-124E SARS-CoV-2 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Senaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT The.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kapruvia\u00ae Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AC0176","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA\u00ae (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Burosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA\u2019s Human Medicines Committee Begins Review of Conditional MAA for Skycovion Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SARS-CoV-2 Surface Spike Protein","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Chemicals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Chemicals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Chemica.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Nuance Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuance Pharma Receives Clearance to Begin Pivotal Clinical Trials With Ensifentrine for COPD in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3\/PDE4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Verona Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Krystal Biotech\u2019s Biologics License Application for Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"Splicing","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces First Global Regulatory Approval of Sunlenca\u00ae (lenacapavir), the Only Twice-Yearly HIV Treatment Option","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Vifor Fresenius Medical Care Renal Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VFMCRP Announces U.S. Court Upholds Validity of Velphoro\u00ae Patent","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Vifor Fresenius Medical Care Renal Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Vifor Fresenius Medical Care Renal Pharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Vifor Fres.."},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VAD044 L-Tartrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vaderis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vaderis Therapeutics \/ Medicxi","highestDevelopmentStatusID":"6","companyTruncated":"Vaderis Th.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics to Hold Webinar on a New Approach to Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verismo Therapeutics Seeks US FDA Approval to Begin Phase 1 trial of SynKIR-110 in Patients With Mesothelin-Expressing Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SynKIR-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verismo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Th.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PHA121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"VERVE-201","moa":"ANGPTL3 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainVectis, a subsidiary of AskBio, Receives Clearance to Conduct Phase I\/II clinical trial in France for Its Novel Gene Therapy for Early-stage Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BV-101","moa":"CYP46A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Bayer","highestDevelopmentStatusID":"4","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present New Data at ESC Congress 2022 Highlighting Up to 8.5 Years of Repatha\u00ae (Evolocumab) Safety and Tolerability Data in High-risk ASCVD Patient Populations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix\u00ae in Highly Sensitized Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IC 100","moa":"ASC","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Imetelstat","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"AChE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"OCE-205","moa":"V1R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocelot Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE\u2011AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"CSL","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Vifor and Travere Therapeutics Announce EMA Has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL \/ Travere Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Trav.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 At the European Respiratory Society International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Nippon Kayaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solasia Announces Launch of Darvias\u00ae in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Darinaparsin","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Solasia Pharma KK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Solasia Pharma KK \/ Nippon Kayaku","highestDevelopmentStatusID":"12","companyTruncated":"Solasia Ph.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Indivior","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Drinabant","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Indivior \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1\/2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"DynamiCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"DCBY02","moa":"CD93","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"DynamiCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DynamiCure \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"DynamiCure.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia\u2019s Therapeutic Goods Administration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1\/2 Trial of Seclidemstat as a Treatment for Ewing\u2019s Sarcoma and FET-Rearranged Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ NIHR","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC Provides Oncology Pipeline Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Grifola Frondosa Extract","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms\u2019 Tumor 1 (WT1) - Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-102","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces First Patient Dosed in Phase 1b\/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Receives Notice of Allowance For U.S. Patent Application Covering Use of ANJESO\u00ae For the Treatment of Moderate to Severe Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Publishes New Data Highlighting Apabetalone\u2019s Benefit in Non-alcoholic Fatty Liver Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Attralus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Attralus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirena\u00ae from Bayer Approved in the US For Extended Duration of Use in Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Insert","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present Data From CV- Portfolio, Including a Late-breaking Presentation From Fidelity (Kerendia\u2122) and New Phase Ib Data From Pacific Trial Program for the Oral Factor Xia Inhibitor Asundexian","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Supplemental Biologics License Application for Roche\u2019s Polivy Combination for People With Previously Untreated Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts New Drug Application for GSK\u2019s Momelotinib for the Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Successfully Completes Phase 2 Trial With Cagrisema in People With Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Commences Review of Oral Fixed-dose Combination of Decitabine and Cedazuridine for the Treatment of Adults With Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion (containing benzyl alcohol), Due To The Potential Presence of Visible Particulates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Propofol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hospira, Inc.","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hospira, I.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Provides Update on Amcenestrant Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"SER","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Completes Trial Design for Tollovid\u2122 Long COVID Clinical Study in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Plant Extracts","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Privo Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Privo Technologies Receives U.S. FDA Orphan Drug Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Privo Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Privo Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Privo Tech.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$800.0 million","newsHeadline":"Gyroscope Therapeutics Acquisition is Complete","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"GT005","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":1.5,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.5,"dosageForm":"","sponsorNew":"Gyroscope Therapeutics \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives FDA Fast Track Designation for Branaplam (LMI070) For the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Branaplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Anti-PD-1 Tislelizumab Accepted By EMA For Regulatory Review in Esophageal and Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BieGene","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Branaplam : VIBRANT-HD Study Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Branaplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee Pharmaceutical","pharmaFlowCategory":"D","amount":"$78.9 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces KL4 Surfactant and AEROSURF\u00ae Global License Agreement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Lucinactant","moa":"SERCA2a","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Powder for Inhalation","sponsorNew":"Windtree Therapeutics \/ Lee Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Actinium-225 Conjugated Therapy","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aktis Oncology \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Onco.."},{"orgOrder":0,"company":"Zerion Pharma","sponsor":"Hovione","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zerion Pharma and Hovione Extend Partnership to Cover Use of The Dispersome\u00ae Technology Platform in Nutraceuticals","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Beta-lactoglobulin","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Zerion Pharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zerion Pharma \/ Hovione","highestDevelopmentStatusID":"4","companyTruncated":"Zerion Pha.."},{"orgOrder":0,"company":"DoubleRainbow Biosciences","sponsor":"Kelai Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kelai Pharmaceuticals & DoubleRainbow Biosciences Collaborate on Novel Natural Compound Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Kavalactone Therapeutic","moa":"GABA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"DoubleRainbow Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DoubleRainbow Biosciences \/ Kelai Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"DoubleRain.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Announces Closing of Private Placement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Private Placement","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"AdvanCell","sponsor":"Morningside","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"AdvanCell Closes A $18M Series B Funding Led by Morningside","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series B Financing","leadProduct":"212Pb-ADVC001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AdvanCell","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"AdvanCell \/ Morningside","highestDevelopmentStatusID":"6","companyTruncated":"AdvanCell .."},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Bi.."},{"orgOrder":0,"company":"Lacerta Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lacerta and Prevail, A Wholly Owned Subsidiary of Lilly, Sign Agreement to Develop Novel AAV Capsids for CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"AAV Capsid-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Lacerta Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lacerta Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lacerta Th.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Horizon Technology","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Financing","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Horizon Technology","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"BioCardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock\u2019s Cell Therapy to Treat Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Expands Partnership with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"SaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Series B Financing","leadProduct":"Nitric Oxide","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Horizons Ventures","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Cowen Healthcare","pharmaFlowCategory":"D","amount":"$161.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aktis Oncology Raises $84 Million to Advance Novel Targeted Alpha Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Series A Financing","leadProduct":"Radiopharmaceutical Therapy","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aktis Oncology","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Aktis Oncology \/ Cowen Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Aktis Onco.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$40.5 million","upfrontCash":"Undisclosed","newsHeadline":"Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters\u2019 Option to Purchase Additional Shares in Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"U.S. Government Exercises Option to Purchase Additional RAPIVAB\u00ae (peramivir injection) from BioCryst for Pandemic Influenza Preparedness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Acuitas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"LNP-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Arbor Biotechnologies, Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Acuitas Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Lantu Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VectorBuilder Supports First Gene Therapy Trial for Menkes Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"LTGT06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"VectorBuilder","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectorBuilder \/ Lantu Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"VectorBuil.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"PhysIQ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III Study in Patients with Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Flecainide","moa":"Sodium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"InCarda Therapeutics \/ physIQ","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Th.."},{"orgOrder":0,"company":"iVeena","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Glaukos Licenses Iveena\u2019s Investigational Keratoconus Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Copper Sulphate Pentahydrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"iVeena \/ Glaukos","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ G.."},{"orgOrder":0,"company":"Chimerix","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$374.5 million","upfrontCash":"$238.0 million","newsHeadline":"Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.37,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.37,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$92.3 million","newsHeadline":"Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Gicell","sponsor":"HK inno.N","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GICELL Announces Research Collaboration with HK inno.N For Next-Generation CAR-NK Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Allogeneic CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Gicell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gicell \/ HK inno.N","highestDevelopmentStatusID":"2","companyTruncated":"Gicell \/ H.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$0.5 million","newsHeadline":"Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Nepicastat","moa":"DBH","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Acorda Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Acorda Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Revision Skincare","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revision Skincare\u00ae Announces Strategic Partnership with RVL Pharmaceuticals, Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Revision Skincare","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Revision Skincare \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Revision S.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Pricing of $6.2 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris Set to Regain Full Rights to Macrilen\u2122 (Macimorelin) in U.S. and Canada from Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Termination","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Eight Capital","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bright Minds Biosciences Announces Closing of $4 Million Unit Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"BMB-101","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Eight Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alladapt Announces Loan Agreement with Hercules Capital","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Bactolife","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bactolife Receives USD 5 Million in New Funding to Address Gastrointestinal Infections Worldwide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bactolife","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bactolife \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bactolife .."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Suzhou Royaltech Med Co., Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced and Royaltech Announce Strategic Collaboration to Accelerate the Development of Bacterial Drugs and mRNA Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"MV-based mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Suzhou Royaltech Med Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Second Sight Medical Products","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Merger","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Second Sight Medical Products","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Med.."},{"orgOrder":0,"company":"iQure Pharma","sponsor":"Keiretsu Mid-Atlantic","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"iQure Pharma Secures $600K in Early Closing to Research Neuropathic Pain Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Series A Financing","leadProduct":"iQ-007","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"iQure Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"iQure Pharma \/ Keiretsu Mid-Atlantic","highestDevelopmentStatusID":"4","companyTruncated":"iQure Phar.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger with Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"CHI3L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes Second Tranche of Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ U.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"Nafamostat Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ensysce Biosciences \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Mymetics","sponsor":"PCI Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mymetics and PCI Biotech Sign a Preclinical Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Nucleic Acid Therapeutic","moa":"CD4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mymetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mymetics \/ PCI Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Mymetics \/.."},{"orgOrder":0,"company":"GNS healthcare","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"GNS healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GNS healthcare \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"GNS health.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Funding","leadProduct":"SLS-004","moa":"SNCA gene","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"OmniAb","sponsor":"Avista Public Acquisition Corp. II","pharmaFlowCategory":"D","amount":"$396.0 million","upfrontCash":"$130.0 million","newsHeadline":"Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0.40000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"OmniAb \/ Avista Public Acquisition Corp. II","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ A.."},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"LifeMine Therapeutics Announces $175 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine T.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"GTB-3650","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Cytovance Biologics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using Medincell\u2019s Technology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Olanzapine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Selecxine","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SLC-3010","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Selecxine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecxine \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"Selecxine .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Top-line Results From Phase 3 Study of ABP959, Biosimilar Candidate to Soliris\u00ae (Eculizumab)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord Healthcare Launches Generic Drug for Treating Brain Tumors & Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Carmustine","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Texas Biomedical Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Modified Bladder Cancer Treatment Shows Promise in Animal Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-Guerin vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Texas Biomedical Research Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Texas Biomedical Research Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Texas Biom.."},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"KTX-1001","moa":"Methyltransferase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"K36 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therap.."},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase 3 Pivotal Study in Patients Undergoing Head and Neck Surgery","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ALM-488","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Alume Biosciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alume Bios.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir to Present at the Erik Penser Bank Company Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Crofelemer","moa":"Chloride channel","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1\/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Abivertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE 327","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air Affiliate Beyond Cancer Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Ro\ufb02umilast Cream in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine\u00ae TCR-T Candidate IMA203CD8 Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"CD8 alpha beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Present Data from ReSPECT-GBM\u2122 Clinical Trial at the European Society for Medical Oncology Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AF710B","moa":"SIGMAR1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Publication of Phase 2 Data Showing Topical Eye Drops Anti-tnf\u03b1 Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Licaminlimab","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hutchmed Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CM369","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Keymed Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Biopharma to Present New Data on Trends in Varicella Incidence Cases with Complications Among Korean Children at the 2022 ICPE","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"MG1111","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Segal Trials","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Segal Trials Participation in Study Shows Positive Results From Phase 3 EMERGENT-2 KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic M1\/M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Segal Trials","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Immunome","sponsor":"University of Vermont Larner College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ University of Vermont Larner College of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"iECURE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GTP-506A","moa":"PCSK9 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"iECURE","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iECURE \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ N.."},{"orgOrder":0,"company":"GeneCentric Therapeutics","sponsor":"Atrium Health Levine Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Therapy","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"GeneCentric Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneCentric Therapeutics \/ Atrium Health Levine Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"GeneCentri.."},{"orgOrder":0,"company":"VectorY","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectorY to Present Poster on Huntington\u2019s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV Vector","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite\u2019s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Namodenoson","moa":"A3AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Biopharma Announces Completion of its EVEREST Phase II\/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Zorifertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biop.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"APL-1702","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Megalabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Megalabs USA Announces Launch of Two New Products in North American Market: Abintra and Glutapak R","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Abintra","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Megalabs","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Megalabs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Megalabs \/.."},{"orgOrder":0,"company":"Calyptus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calyptus Pharmaceuticals Announces Approval of Arformoterol Tartrate Inhalation Solution, EQ 0.015 mg Base\/2 ml","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Arformoterol Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Calyptus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Calyptus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calyptus P.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Expands anti-PVRIG COM701 Patent Portfolio with New Composition of Matter and Use Patent in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ No.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Provides Regulatory Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Erythrocytes Encapsulating L-asparaginase","moa":"Asparagine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ab Science Announces that It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"CSF1R","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"SciSparc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ SciSparc Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Aviv Clinics","sponsor":"Sagol Center for Hyperbaric Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviv Clinics and Sagol Center for Hyperbaric Medicine and Research Present Webinar on Research Findings from the First Long COVID Clinical Trial to Show Symptom Relief","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyperbaric Oxygen Therapy","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aviv Clinics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aviv Clinics \/ Sagol Center for Hyperbaric Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Aviv Clini.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces TAVNEOS\u00ae (avacopan) Presentations at Upcoming Medical Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences\u2019 Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Macrophage homeostasis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Tachyon Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TACH101","moa":"KDM4 histone demethylase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tachyon Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tachyon Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tachyon Te.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant to Present New Data from Phase 3 Trial Program of VTAMA\u00ae (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau\u00ae in Adult Males Compared to BOTOX\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA-Xvfs","moa":"SNAP-25","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RNK05047","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ranok Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Ther.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Incyte\u2019s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"TK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Aims to Transform Cancer Outcomes With New Data Across Industry-leading Portfolio at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"PT199","moa":"C73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SYNB1353","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Hempstreet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarpagandha Ghan Vati to Treat High Blood Pressure!","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Jatamansi","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hempstreet","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hempstreet \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hempstreet.."},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regen BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioP.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"B.More","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"B.More","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"B.More \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"B.More \/ N.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethylamide","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BYON3521","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announced Further Strengthening of its IP Position for Improved Treatment for Women Suffering From FSIAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin's Arm Gets UK Regulator Nod for COPD Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pressurised Metered Dose Inhaler","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"JS110","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"FIN-524","moa":"Microbiome","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegtibatinase","moa":"PEGylated enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B\u2122 Cell Therapy Through Levels of Vascular Biomarker","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Abelacimab","moa":"Factor XI\/XIa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CNTY-101","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tilray Medical Launches New Products and \u2018CannaPoints\u2019 Program to Support Patients Across Canada","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tilray","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ N.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"VEGFR 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Announces Positive Phase 2\/3 Results in Adolescents for its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quince Therapeutics to Present at Upcoming Scientific Meetings","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NOV004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Files with FDA to Expand Ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals\u2019 Phase 3 ultraVIOLET Study Evaluating the Efficacy and Safety of VIVJOA\u2122 (oteseconazole) in Women with Recurrent Vulvovaginal Candidiasis (RVVC) Published in the American Journal of Obstetrics and Gynecology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP451","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson\u2019s Disease and Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-458","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Pharma to Present New Data in Moderate-to-severe Atopic Dermatitis and Chronic Hand Eczema at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Genexine","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA\u00ae (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GX-188E","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoinvent Initiates Radspherin\u00ae Phase 2A Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Radspherin","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1\/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI363","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients With Early Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STP144G","moa":"Complement factor B","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Approval of Cadonilimab (PD-1\/CTLA-4 Bispecific) Published in Drugs, a Peer-reviewed Medical Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Perelman School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"KP104","moa":"Complement system","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Perelman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharm.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics to Present at the Retina Forum 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"vMCO-010","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces 2022 Interim Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-001Pro","moa":"Abl kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Higher Dose Flu Vaccines Preferentially Recommended for Adults 65+ in CDC Morbidity and Mortality Weekly Report","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Scemblix\u00ae, With Novel Mechanism of Action, Approved by the European Commission for Adult Patients With Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Asciminib","moa":"STAMP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pozelimab","moa":"Completent C5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes\u2122 Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric Auto Antibody Receptor T Cells","moa":"DSG3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocytogen \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Ludwig-Maximilians-University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Live Virus Assays at Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen Confirm PolyTope\u2019s Efficacy Against SARS-CoV-2 Variants Including BA.5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TATX-03","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmunoPrecise \/ Ludwig-Maximilians-University","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Showcases Leadership in Cardiometabolic Disease Treatment in Multiple Presentations at ESC Congress 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Lifesciences Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir\u00ae Digihaler\u00ae (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis ALS Therapy Sotuletinib Gets FDA Orphan Drug Status","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotuletinib","moa":"CSF1R","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Sabatolimab Receives Orphan Drug Designation From the European Commission for Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"TIM-3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TQS-168","moa":"PGC-1a","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis T.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONK Therapeutics Presents Promising In-Vivo Data of its Optimized Affinity CD38 CAR-NK Candidate, Being Developed for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ONKT102","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ONK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ONK Therap.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Announces 2022 Interim Results and Recent Business Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ IQVIA Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1\/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225-Vofatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Amgen Data at ESC 2022 Show Long-term LDL-C Lowering With Repatha\u00ae (Evolocumab) Was Well-tolerated for More Than 8 Years","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Evolocumab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Gradalis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gradalis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to Conduct a Phase II Clinical Trial of Sovateltide (PMZ-1620) in Hypoxic-Ischemic Encephalopathy in Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Macrophage homeostasis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"REN001","moa":"PARP delta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics Initiates KIN001 Phase II KINFAST Clinical Trial in COVID-19 Outpatients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"p38\/Mapk","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"StemCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Umbilical Cord Blood Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"StemCyte","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"StemCyte \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"StemCyte \/.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Announces Presentations at the 22nd Euretina Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"vMCO-010","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NP-300","moa":"Chloride channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Goods Administration Provisionally Approves Moderna\u2019s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido\u00ae, for the Treatment of Acute Low Back Pain (LBP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy\u2019s Laboratories Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-174","moa":"H3R","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Collegium Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Collegium .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen\u00ae (rintatolimod) in Primary PD-1\/PD-L1 Resistant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to Treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"ChemR23","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ AmbioPharma","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NOV004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Paragon Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Castle Creek Biosciences Announces Publication of Preclinical Study for Potential In Vivo Gene Therapy in Nature Communications","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"LV-FAH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Castle Creek Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Castle Creek Biosciences \/ Paragon Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forge Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1\/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10-hGALC","moa":"GALC gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forge Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces Updated Preliminary Phase 1\/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated \u03b1-gal A Enzyme Activity in Five Longest Treated Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics Announces Early Completion of Enrollment in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Berberine Ursodeoxycholate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Inc. Announces First Participants Dosed in its Phase 1\/2a Trial of CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer is Advancing in the Fight Against Cancer Showcasing New Study Data at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD\u2122 Compound","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"SkinMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SkinMedica\u00ae Launches Firm & Tone Lotion for Body","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Caffeine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SkinMedica","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"SkinMedica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SkinMedica.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present New, Positive Clinical and Real-World Data Across Inflammation Portfolio At EADV 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-Acting Antibody Combination Approved for Prevention and Treatment of Covid-19 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Farxiga Significantly Lowers the Risk of Cardiovascular Death in Patients With Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients With Mildly Reduced or Preserved Ejection Fraction in Deliver Phase III Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in Japan for the Treatment of Adults With Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in Japan for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved in Japan as Adjuvant Treatment for Patients With BRCA-mutated HER2-Negative High-risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Indicate Positive Effects of Kerendia\u2122 (Finerenone) on Mortality in Patients With Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4\/BA.5 Adapted Bivalent Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Milvexian","moa":"FXIa","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for POLIVY for Additional Indication of Previously Untreated Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"CD79b","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"Tsukuba Research Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supplementary New Drug Application Submitted in Japan for Antiepileptic Drug Fycompa\u00ae Injection Formulation as A New Route of Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Tsukuba Research Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ts.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenpozyme TM (Olipudase Alfa-rpcp) Approved by FDA as First Disease-specific Treatment for ASMD (Non-CNS Manifestations)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olipudase Alfa-rpcp","moa":"Acid sphingomyelinase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RIST4721","moa":"CXCR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Th.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Launches Ryaltris\u2122 Seasonal Allergic Rhinitis Nasal Spray in The US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Rafa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Rafa","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rafa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rafa \/ Not.."},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyftor\u2122 (Sirolimus Topical Gel) 0.2%, the First FDA-approved Topical Treatment for Facial Angiofibroma Associated With Tuberous Sclerosis, is Now Available in the US","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Nobelpharma America","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nobelpharm.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"MZE001","moa":"GYS1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Commencement of LPS Challenge Trial for Lead Candidate EP395","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"EP395","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"EpiEndo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EpiEndo Ph.."},{"orgOrder":0,"company":"Futura Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highly Positive FM71 Phase 3 Study Results With All Primary and Secondary Endpoints Achieved, MED3000 Remains on Track to Submit for FDA Marketing Authorization","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Futura Medical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Futura Med.."},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa\u00ae (Osilodrostat) in Patients With Cushing\u2019s Disease in the European Journal of Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pivekimab Sunirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Presents Additional Positive Interim Data from the Phase I\/II\/III CAMPSIITE\u2122 Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RGX-121","moa":"IDS gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"HEC Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ HEC Group","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emactuzumab Designated as an Orphan Medicinal Product in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Emactuzumab","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SynOx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID\/NIH Recognizes the Potency of Ub-421 Against Multi-drug Resistant HIV and Receives the FDA Approval to Conduct a Phase 2 Clinical Trial With Ub-421","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Chidamide","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces New Interim Data from Phase 1\/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Idursulfase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Forcefield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Three Proteins Which Have the Potential to Prevent Heart Failure After Heart Attack","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Chrdl1","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Forcefield Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forcefield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Forcefield.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Announces Multiple Abstracts Highlighting ILUVIEN\u00ae Real World Data at EURETINA Annual Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"PLA2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron\u2019s Lomecel-B\u2122 Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Bone Marrow-derived Medicinal Signaling Cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Submits TransCon\u2122 PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Initiation of Phase 2b \u2018ASCEND-NASH\u2019 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"SNS-101","moa":"VISTA checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HilleVax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib Supplemental New Drug Application Submitted in Japan for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Emavusertib","moa":"IRAK4 kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's Ilb\u00ae Mobilizes and Modulates Key Growth Factors That Trigger a Cascade of Neuroprotective Mechanisms Able to Target All Neuroinflammation-driven Diseases Including ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"ILB","moa":"TGF beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tikomed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tikomed \/ .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Non-tryptamine Psychedelic Derivatives","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX\u00ae (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves IMBRUVICA\u00ae (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics LLC","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Marks First Approval Worldwide for TECVAYLI\u00ae (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Teclistamab","moa":"BCMA\/CD3","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"MK-2060","moa":"Factor XI","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Authorizes Moderna\u2019s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid19 Booster Vaccine, mRNA-1273.222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents New Data in Breast and Prostate Cancer at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Efanesoctocog Alfa for People With Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"VWF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Dupixent\u00ae (Dupilumab) Data at ERS Adds to Body of Safety and Efficacy Data in Chronic Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$53.0 million","newsHeadline":"Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi\u00ae (solriamfetol) to Axsome Therapeutics","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Divestment","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Closing of $6.2 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Sernova","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Human Donor Islets Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0.27000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"Implant","sponsorNew":"Sernova \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"Juniper Biologics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Healthcare SA Signs Exclusive License Agreement with Juniper Biologics Pte. Ltd. for LEDAGA\u00ae (chlormethine) in Australia, Asia and the Middle East*","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Juniper Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Juniper Biologics \/ Helsinn","highestDevelopmentStatusID":"12","companyTruncated":"Juniper Bi.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"MyPharma2Go Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen\u00ae and Tru Niagen\u00ae PRO into Brazil","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ MyPharma2Go Corporation","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerveau Technologies Inc. and Alnylam\u00ae Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"ALN-APP","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Cerveau Technologies \/ Alnylam","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Te.."},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$49.2 million","upfrontCash":"Undisclosed","newsHeadline":"Abivax Announces Successful Oversubscribed EUR 49.2M Cross-Over Financing with Top-Tier US and European Biotech Investors","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0.050000000000000003,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ T.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"THR-149","moa":"PKal","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"XPhyto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"XPhyto Closes Final Tranche of Fully Subscribed Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"XPhyto \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"XPhyto \/ U.."},{"orgOrder":0,"company":"Synairgen","sponsor":"University of Southampton","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synairgen Announces Its Collaboration on The UNIVERSAL Trial, an Observational Study of Patients Hospitalised Due to A Range of Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Interferon Beta-1A","moa":"IFN beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Synairgen \/ University of Southampton","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$360.0 million","newsHeadline":"Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Emergence","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Softbank Vision Fund 2","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series B Financing","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ArsenalBio","amount2":0.22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"ArsenalBio \/ Softbank Vision Fund 2","highestDevelopmentStatusID":"5","companyTruncated":"ArsenalBio.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Equillium","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"Equillium to Acquire Metacrine in All-Stock Transaction","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"MET642","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Metacrine","amount2":0.059999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Metacrine \/ Equillium","highestDevelopmentStatusID":"8","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"NaNotics","sponsor":"Mass General Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NaNotics to Collaborate with Mass General Cancer Center (MGCC) on Novel Nanomedicine for Treating Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"TNF alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NaNotics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NaNotics \/ Mass General Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"NaNotics \/.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Knott Partners","pharmaFlowCategory":"D","amount":"$42.8 million","upfrontCash":"Undisclosed","newsHeadline":"ILiAD Biotechnologies Announces $42.8M Financing Round to Advance BPZE1 Pertussis Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series D Financing","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"ILiAD Biotechnologies \/ Knott Partners","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Cure AP-4","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Cure AP-4","highestDevelopmentStatusID":"4","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Beactica","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Dong-A ST","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/.."},{"orgOrder":0,"company":"Pleco Therapeutics","sponsor":"Oost NL","pharmaFlowCategory":"D","amount":"$17.4 million","upfrontCash":"Undisclosed","newsHeadline":"Pleco Therapeutics Announces Final Close of its Series A Financing Raising \u20ac17.3m to Progress its Novel Plecoid\u2122 Product in Acute Myeloid Leukaemia to Regulatory Filing in USA and EU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"PTX-061","moa":"Metal","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pleco Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Pleco Therapeutics \/ Oost NL","highestDevelopmentStatusID":"4","companyTruncated":"Pleco Ther.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Shuttle Pharmaceuticals Announces Closing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Soligenix","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte\u2122 in the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"Multivalent Gonorrhea Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"IsoPlexis","sponsor":"MediMergent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention of COVID-19 Infection in Immuno-Compromised Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"IsoPlexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IsoPlexis \/ MediMergent","highestDevelopmentStatusID":"12","companyTruncated":"IsoPlexis .."},{"orgOrder":0,"company":"Pluri","sponsor":"European Union\u2019s Horizon Europe","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"\u20ac7.5 Million Granted to Collaborative PROTO Project led by Charit\u00e9 to Study Pluri\u2019s PLX-PAD Cells for Osteoarthritis Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Pluri","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Pluri \/ European Union\u2019s Horizon Europe","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Eu.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$39.2 million","upfrontCash":"$3.4 million","newsHeadline":"Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE\u00ae (dasiglucagon)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"CUREator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"AZR-MD-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ CUREator","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"OncoResponse","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo\u00ae (cemiplimab) in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"CD163","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoResponse","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoResponse \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"OncoRespon.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupin Ltd \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$16.0 million","newsHeadline":"Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis B.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces $225 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$625.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0.63,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.63,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Neovii","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neovii and Fosun Pharma Enter Into an Exclusive Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Rabbit Anti-human T-lymphocyte Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Neovii","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neovii \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Neovii \/ F.."},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Launches, Founded by Cumulus Oncology and In Partnership with The Lead Discovery Center, to Focus on Developing First and Best-In-Class Molecules Inhibiting Novel DNA Damage Response Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nodus Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nodus Oncology \/ Cumulus Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Nodus Onco.."},{"orgOrder":0,"company":"Vernalis","sponsor":"Unison Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vernalis Research, a Fully Owned Subsidiary of HitGen Inc., and Unison Medicines Inc. Announce a Research Collaboration in The Field of Anti-Infectives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vernalis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ Unison Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/.."},{"orgOrder":0,"company":"Lonza Capsugel","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza and Touchlight Collaborate on End-To-End mRNA Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Capsugel","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Capsugel \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Caps.."},{"orgOrder":0,"company":"Monteloeder","sponsor":"Suanfarma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Suanfarma Strengthens Positioning in Clinically Proven Active Nutraceuticals with The Acquisition of Monteloeder","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Lemon Verbena Extract","moa":"GABA A receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Monteloeder","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Monteloeder \/ Suanfarma","highestDevelopmentStatusID":"12","companyTruncated":"Monteloede.."},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in The First-To-File ANDA For the Private Label Version of Lumify\u00ae in The U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback P.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"DNDi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services and DNDi To Explore Joint Opportunities to Develop Affordable and Life-Saving New Drugs for Neglected Tropical Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ DNDi","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Orbital Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beam Therapeutics \/ Orbital","highestDevelopmentStatusID":"1","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Immutep","sponsor":"Maria Sk\u0142odowska-Curie National Research Institute","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Maria Sk\u0142odowska-Curie National Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kerendia\u2122 (finerenone) Receives Updated Label in the U.S. To Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTherapeutix Announces Initiation of Global Phase 2 Clinical Trial of ATX01 for the Relief of Pain in Chemotherapy-induced Peripheral Neuropathy in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Amitriptyline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immusoft Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immusoft Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immusoft C.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Highlights Depth of Immunology Pipeline With Novel Data at Key Upcoming International Congresses","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"COYA 101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Nevakar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Atropine","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ N.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1\/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL2-IL2R beta\/IL2R gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology \u2013 Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Synagile","sponsor":"Clintrex Research Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SynAgile Completes Enrollment of its Phase 2 Clinical Trial of its DopaFuse Delivery System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Clintrex Research Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BE's Pediatric Pneumonia Jab Gets CDSCO Expert Panel Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"14-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Adapted COVID-19 Booster Vaccines Recommended for Approval in the EU","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-MMP7","moa":"MMP7","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"OVX836","moa":"Nucleoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BBT-301","moa":"KCa 3.1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves First Treatment Option for Generalized Pustular Psoriasis Flares in Adults","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Spesolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir To Present at the Pareto Securities\u00b4Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Breakthrough Discovery With the Potential to Help Millions of People Suffering From Urea Associated Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"MC2-25","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patent Issued in Europe for Orexo's Adrenaline Product OX640","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces U.S. FDA Approval for ORKAMBI\u00ae (lumacaftor\/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lumacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep\u2122 (Omeprazole and Sodium Bicarbonate for Oral Suspension)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole","moa":"ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Ph.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-Omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CT053","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases Announces Presentations on Lysosomal Storage Diseases at the Society for the Study of Inborn Errors of Metabolism Annual Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Aston Sci","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+\/2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aston Sci","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aston Sci \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aston Sci .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Announces Submission of IND Application to the FDA for Phase 1\/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"MEK","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New TROPiCS-02 Data in HR+\/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy\u00ae Regardless of Their HER2 Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cudetaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Linperlisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Y.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in China for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients With Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Boehringer Ingelheim Support the Potential Use of Nintedanib in Children and Adolescents With Fibrosing Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"FAP Activated Doxorubicin Prodrug","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET\u2122 Platform at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TYRA-300","moa":"FGFR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent\/ Metastatic Squamous Cell Carcinoma of the Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Phase 2b Study Results of Obefazimod (ABX464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IR.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Reports Update on Initial AVT02 Biologics License Application","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Highlights Progress in its DNA-based Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 DNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Authorizes Novavax Nuvaxovid\u2122 COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESMO Presentations of Libtayo\u00ae (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"CD223","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Positive Topline Data from Zimura\u00ae GATHER2 Phase 3 Clinical Trial in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"CB2 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"iECURE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GTP-506A","moa":"PCSK9 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"iECURE","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iECURE \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ N.."},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1\/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"TAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira .."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS\u00ae (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"JAB-21822","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Darovasertib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome to Present Updates on EO2401, its First-in-Class OncoMimics\u2122 Therapeutic Cancer Vaccine Targeting Solid Tumors, at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EO2401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"SARS-CoV-2 viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Biovaxys","sponsor":"Merck Millipore","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biovaxys Announces Completed Synthesis of Its Pan-sarbecovirus Vaccine Candidate and Launch of in Vivo Animal Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BVX-0320","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ Millipore-Sigma","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"QOL Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QOL Medical, LLC Receives FDA Approval of Sucraid\u00ae (sacrosidase) Oral Solution Single-Use Containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacrosidase","moa":"Sucrase enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"QOL Medical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"QOL Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"QOL Medica.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD154","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate\u2019s PNV-6005 as a Potential Treatment for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PNV-6005","moa":"ADORA2A","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Attralus","sponsor":"University of Tennessee Graduate School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attralus Announces New Preclinical Data Demonstrating Novel Human Chimeric Antigen Receptor-Macrophages (CAR-M) for Potential Amyloid Removal at 18th International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AT-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Attralus \/ University of Tennessee Graduate School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italian Medicines Agency Approves Reimbursed Access to Bylvay\u00ae (odevixibat) For Patients with All PFIC Types","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Arcutis\u2019 Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-301","moa":"HDAC6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Macrophage homeostasis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Basimglurant","moa":"mGluR5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Announces Initiation of Phase 1\/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-101","moa":"DMPK gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-1500","moa":"CD154","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Attralus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attralus Presents In Vivo Preclinical Data for AT-02 Demonstrating Significant Amyloid Reduction at 18th International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Attralus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Announces First Patient Dosed in Phase 1\/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-251","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Yale University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant VSV-vectored Lassa Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Clofazimine","moa":"ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Publication and Presentation of Phase 2 Data Showing Topical OCS-01 Improves Macular Thickness and Visual Acuity in Patients With Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177-edotreotide","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trodelvy\u00ae Significantly Improved Overall Survival in Pre-Treated HR+\/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Xevinapant","moa":"IAP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"EMD Serono \/ Merck KgaA","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032\/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson\u2019s or Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CST-107","moa":"ADRB2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CuraSen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Th.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir\u00ae Digihaler\u00ae (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Alzheimer's Memory Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMC Research Enrolling Patients near Charlotte, NC for Clinical Trial of Promising New Investigational Treatment for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ACU193","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alzheimer\\'s Memory Center","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzheimer\\'s Memory Center \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzheimer\\.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"2Seventy Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Announces Positive Findings From Analysis of Lung Samples From the SG015 trial of SNG001 in Virally Infected COPD patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"IFN alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BT5528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SER-109","moa":"Intestinal gut microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation to Pfizer\u2019s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"6-valent Polysaccharide Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Orbital Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Orbital Th.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces Notice Of Opportunity For An Fda Hearing On The Snda For Hetlioz\u00ae In Jet Lag Disorder","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Details of Presentations at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax to Participate in Upcoming September Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Brand Institute","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer and Reduction of Risk of Upper Gastrointestinal Bleeding in Critically Ill Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole","moa":"KATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Brand Institute","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Brand Institute \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Brand Inst.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published In Epilepsia Shows Significant Prolongation Of Time Intervals Between Seizure Clusters Treated With Neurelis' Valtoco\u00ae (Diazepam Nasal Spray) Civ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SB-01","moa":"TGF beta-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioP.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives USFDA Approval for Generic Version of Revlimid\u00ae (Lenalidomide capsules)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"TNF alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezpegaldesleukin","moa":"IL-2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nektar Therapeutics \/ Eli lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's Drug Candidate ILB\u00ae Inhibited Infection of Human Cells by Dengue, Zika and Yellow Fever Viruses in Vitro, Providing Further Support for Its Broad Spectrum Mechanism of Action","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LMW-dextran Sulfate","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tikomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ .."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Presents Positive Results From Phase 3 NEURO-TTransform Study at International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eplontersen","moa":"TTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Dizlin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizlin Pharmaceuticals Publishes Data from Pharmacokinetic Study (PK) (IPO-001) with Infudopa SubC (DIZ102) and Infudopa IntraV (DIZ101) in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dizlin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizlin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Dizlin Pha.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol Reports Data from the AGENT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Flugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Live Attenuated Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ N.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASI Pharmaceuticals And Bioinvent Announce Dosing Of First Patient In BI-1206 Phase 1 Clinical Trial For The Treatment Of Relapsed\/Refractory Non-Hodgkin's Lymphoma In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BI1206","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Bioinvent","highestDevelopmentStatusID":"7","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CX-2051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui P","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Camrelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevar Therapeutics \/ Hengrui Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen\u2019s Litifilimab (BIIB059) in Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC\/NCI\/AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"MCLA-129","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Presents Promising Preliminary Phase 1\/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"Polykinase","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"22nd Century Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"22nd Century Group (Nasdaq: XXII) Launches VLN\u00ae Reduced Nicotine Content Cigarettes in Colorado with Circle K, Smoker Friendly and New Distribution Points","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"22nd Century Group","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"22nd Century Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"22nd Centu.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-005","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AMB-05X","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 2 Study of D-4517.2 for the Treatment of Wet AMD and DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxyl Dendrimer","moa":"VEGFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present at Two September 2022 Scientific Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-401","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Potential Hypoparathyroidism Treatment, AZP-3601, on Monday, September 12th at 1:30pm CT\/2:30pm ET in Austin, Texas","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PRAX-222","moa":"SCN2A gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"LTS LOHMANN Therapie-Systeme AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX\u2122 Ketamine Patch","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG","highestDevelopmentStatusID":"5","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi\u00ae Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa\u00ae (oral octreotide) at ENEA 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Two New Development Programs for Batoclimab","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"George Medicines Provides Single-pill Triple Combination Candidate for Hypertension to VERONICA-Nigeria trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Telmisartan","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"George Med.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"SCN10A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RBN-3143","moa":"PARP14","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bispecific Antibody Therapeutic","moa":"CHI3L1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s CAR T-cell Therapy Tecartus\u00ae Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r\/r ALL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Update on US FDA Regulatory Review of Daprodustat in Anaemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK to Highlight the Latest Advances in Cancer Research From Across Its Portfolio and Pipeline at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"PATH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Grants Prequalification to GSK\u2019s Mosquirix \u2013 the First and Only Approved Malaria Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RTS,S\/AS01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ PATH","highestDevelopmentStatusID":"12","companyTruncated":""},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Dupixent\u00ae (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend\u00ae (pegfilgrastim-fpgk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Dupixent\u00ae (dupilumab) Data at EADV 2022 Adds to Body of Evidence Across Multiple Inflammatory Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's First Intra-Nasal COVID Vaccine by Bharat Biotech gets DCGI Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ChAd36-SARS-CoV-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Three-Year BIMZELX\u00ae (bimekizumab) Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL17A\/IL17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL17A\/IL17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"Cereblon","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NVL-520","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN\u2122 (valoctocogene roxaparvovec), Approved by European Commission (EC)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE\u2122 (roflumilast) Cream 0.3% for Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Nodus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Announces Acquisition of Basilea Pharmaceutica\u2019s PARG Inhibitor Programme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"PARG","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Nodus Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Valneva","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ VBI Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"NexImmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"HLA IgG4 Fusion Proteins","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KBI Biopharma \/ NexImmune","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopha.."},{"orgOrder":0,"company":"Innervace","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"Tissue-engineered Nigrostriatal Pathway Cell Therapy","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innervace","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intracerebral Injection","sponsorNew":"Innervace \/ Deerfield Management","highestDevelopmentStatusID":"4","companyTruncated":"Innervace .."},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"$16.0 million","newsHeadline":"LifeArc Portfolio Company Ducentis Bio Therapeutics Acquired by Arcutis Biotherapeutics for Up to $400 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis B.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Nodus Oncology","pharmaFlowCategory":"D","amount":"$251.0 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Sale of Preclinical Oncology Program to Nodus Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Divestment","leadProduct":"Undisclosed","moa":"PARG","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Nodus Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Love Pharma\u2019s Investment in US Biotech Offers Strategic Industry Advantages and Enhanced Shareholder Value","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Psychedelic-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starton Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction with White Lion Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"OCX-253","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Jantibody","sponsor":"H-CYTE","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"H-CYTE Completes Acquisition of Jantibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Jantibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jantibody","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jantibody \/ H-CYTE","highestDevelopmentStatusID":"4","companyTruncated":"Jantibody .."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"BAMF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Radioisotopes-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ BAMF","highestDevelopmentStatusID":"3","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Pharmacosmos AS","sponsor":"Zydus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus Buys Rights from Pharmacosmos to Sell Drug to Treat Anemia in India, Nepal","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Ferric Derisomaltose","moa":"Iron","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Pharmacosmos AS","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pharmacosmos AS \/ Zydus","highestDevelopmentStatusID":"12","companyTruncated":"Pharmacosm.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"ACh release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Kovina Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kovina Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kovina Therapeutics \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Kovina The.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0.69999999999999996,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"Injectable Solution","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$12.7 million","upfrontCash":"Undisclosed","newsHeadline":"Akari Therapeutics Announces $12.75 Million Registered Direct Offering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0.01,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$35.0 million","newsHeadline":"AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Divestment","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"AnaptysBio \/ DRI Healthcare Trust","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Fludarabine","moa":"HA-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Gatehouse Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"GHB-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Gatehouse Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gatehouse Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Gatehouse .."},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"VG201","moa":"IL-12 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Virogin Biotech \/ MD Anderson","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Bi.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Series C Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0.089999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Forge Biologics \/ Drive Capital","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"MedinCell","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Medicines Patent Pool","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series D Financing","leadProduct":"RYZ101","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Voronoi","sponsor":"METiS Therapeutics","pharmaFlowCategory":"D","amount":"$482.2 million","upfrontCash":"$1.7 million","newsHeadline":"METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Pan-RAF","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Voronoi","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Voronoi \/ METiS Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Voronoi \/ .."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series C Financing","leadProduct":"Izokibep","moa":"IL-17A receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0.29999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.29999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Access Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SparingVision Raises \u20ac75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series B Financing","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"SparingVision \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Prices Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Cannabinol","moa":"CB2\/CB1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"InMed Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Arctic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"N-acetylcysteine Amide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Nacuity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Arctic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nacuity Ph.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Betaine","moa":"Methylation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Undisclosed \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Tencent","pharmaFlowCategory":"D","amount":"$43.5 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series B Financing","leadProduct":"NB1000S","moa":"Oxalate","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ Tencent","highestDevelopmentStatusID":"7","companyTruncated":"Novome Bio.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"U.S. FDA","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker\u2019s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"Zelenoleucel","moa":"MultiTAA targeted T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ U.S. FDA","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akero Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Starry Syndicate Powers $165M Bet on In Vivo CAR-T Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"tLNP-medicated In-vivo CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Capstan Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Th.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Guangzhou FineImmune Biotechnology Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"TCR-mimic Antibody-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Guangzhou FineImmune Biotechnology Co","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Blue Ocean (\u201cABO\u201d) Announces a CAD 10M Financing Arrangement with Tetra Bio-Pharma (\u201cTBP\u201d or the \u201cCompany\u201d)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Institute of Neurodegenerative Diseases of Bordeaux","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"CTx-TFEB","moa":"TFEB","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coave Therapeutics \/ Institute of Neurodegenerative Diseases of Bordeaux","highestDevelopmentStatusID":"4","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$10.9 million","upfrontCash":"Undisclosed","newsHeadline":"Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"THB001","moa":"KIT","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Third Harmonic Bio \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Third Harm.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with Caris Life Sciences\u00ae to Expand Patient Outreach and Molecular Profiling","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Caris Life Science","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Larimar Therapeutics Announces $70 Million Underwritten Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$21.8 million","upfrontCash":"Undisclosed","newsHeadline":"Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"cAd3-Marburg","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sabin Vaccine Institute","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Sabin Vaccine Institute \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Sabin Vacc.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Whitelab Genomics","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Debiopharm","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Debiopharm \/ Whitelab Genomics","highestDevelopmentStatusID":"2","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Metabolon\u202f","sponsor":"BioFINDER","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metabolon Partners with the Swedish BioFINDER 2 Study to Develop Biomarkers and Increase Insight into Alzheimer's and other Dementia Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Metabolon\u202f","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metabolon\u202f \/ BioFINDER","highestDevelopmentStatusID":"2","companyTruncated":"Metabolon\u202f.."},{"orgOrder":0,"company":"KBio","sponsor":"ZabBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KBio Announces Strategic Partnership with ZabBio to Discover and Develop Antibody Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Monoclonal Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"KBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KBio \/ ZabBio","highestDevelopmentStatusID":"2","companyTruncated":"KBio \/ Zab.."},{"orgOrder":0,"company":"Allermi","sponsor":"Lucas Venture Group","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Allermi Launches First and Only Customized, Multi-Ingredient Nasal Spray to Offer Relief to Millions of Allergy Sufferers","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Allermi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Allermi \/ Lucas Venture Group","highestDevelopmentStatusID":"12","companyTruncated":"Allermi \/ .."},{"orgOrder":0,"company":"Cellusion","sponsor":"Hangzhou Celregen Therapeutics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CLS001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Cellusion \/ Hangzhou Celregen Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion .."},{"orgOrder":0,"company":"Biogen","sponsor":"Envisagenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Envisagenics","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA\u00ae (pembrolizumab) in ABILITY Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"tLNP-medicated In-vivo CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Capstan Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Th.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent's Sintilimab Plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder Following Interim Analysis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Initiates Advance-2 Phase 3 Trial of AXS-05 in Alzheimer\u2019s Disease Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"InnoCare Pharma \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Studies Show Effectiveness of AJOVY\u00ae (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab-vfrm","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Present at World Anti-Microbial Resistance Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents New Adtralza\u00ae Safety Data in Moderate-to-Severe Atopic Dermatitis at the 31st EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab-ldrm","moa":"IL-13 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Allermi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allermi Launches First and Only Customized, Multi-Ingredient Nasal Spray to Offer Relief to Millions of Allergy Sufferers","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Allermi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Allermi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allermi \/ .."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YishengBio Received Approvals From Philippines and UAE For Phase 2 \/ 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ubrogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir to Present Data on Additive Efficacy of Fostrox in Combination With Anti-PD1 in Nonclinical Tumor Models at the SITC 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Neuroplast","sponsor":"Lumana Invest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuroplast Receives Second Orphan Medicinal Product Designation for Neuro-Cells\u00ae, Paving the Way for Application to Both Chronic and Trauma-induced Neurodegenerative Diseases","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous Fresh Stem Cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuroplast \/ Lumana Invest","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Sustained-Release Depot","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"MCO-020","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Collaborators\u2019 Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PL8177","moa":"MC1R","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive New Data At EADV 2022 For Otezla\u00ae (Apremilast)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-3139","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Receives US Patent for NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceptance in Major Peer-Reviewed Journals of Two Landmark Pre-Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Radium-224","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Cream","sponsorNew":"InMed Pharmaceuticals \/ BayMedica","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Navicixizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncXerna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna T.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"APX3330","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propella Therapeutics Announces Presentation of Phase 1\/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Decanoate","moa":"CYP17","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Researchers Develop Gene Therapy for Rare Ciliopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based NPHP5 Gene Thearapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Mast cell","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA and EMA Accept Regulatory Submission for Pfizer\u2019s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritlecitinib","moa":"JAK3\/TEC","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Sotyktu\u2122 (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON\u2122 (eflapegrastim-xnst) Injection","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"KIF18A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Volastra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Volastra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Volastra T.."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced\/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenalisib","moa":"PI3K delta\/gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rhizen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Prednisolone","moa":"HSD-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Alvogen","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Alvogen","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Alvogen \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Late-Breaking Phase 3 Data at The EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Presents Updated Data From the Phase I\/II study of ANV419 during the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ANV419","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Shows Clinically Meaningful Symptom Improvements in Patients With Hidradenitis Suppurativa in Pivotal Phase III Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Presents Promising Initial Phase 1 data for First off-the-shelf TCR Therapy Targeting PRAME at the ESMO 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMC-F106C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Selects Additional Vitargus\u00ae Phase II Study Site","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Arcutis\u2019 STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HANBEITAI in Patients with Advanced Hepatocellular Carcinoma Published in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Henlius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Henlius \/ .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zejula (Niraparib) Shows Durable and Sustained Long-term Progression-free Survival Benefit in the PRIMA Study of First-line Platinum-responsive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"University of Michigan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cereno Scientific Broadens Patent Protection for Drug Candidate CS585 and Strengthens Its Future Commercial Position in the US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CS585","moa":"Prostacyclin receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cereno Scientific","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cereno Scientific \/ University of Michigan","highestDevelopmentStatusID":"4","companyTruncated":"Cereno Sci.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Union Therapeutics Presents New Data on Orismilast at the 31st EADV Congress Supporting Orismilast\u2019s Potential as a First-in-class or Best-in-class Treatment for Certain Immunological Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Orismilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Muvon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence Using a Novel Regenerative Cell Therapy","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous Muscle Precursor Cell Therapy","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase I","graph3":"Muvon Therapeutics","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Muvon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Muvon Ther.."},{"orgOrder":0,"company":"Biosergen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosergen Moves into the MAD (Multiple Ascending Dose) Part of its Phase I Study After 4 Cohorts Tested in the SAD (Single Ascending Dose) Part of the Study.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BSG005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Biosergen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosergen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosergen .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces New Sotyktu\u2122 (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"Tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"IG-like receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DCC-3116","moa":"ULK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five-Year Data for Merck's KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent\/Metastatic Cervical Cancer at the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1\/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients With EGFR-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology\u2019s Rubraca\u00ae (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumakras\u00ae\/Lumykras\u00ae (Sotorasib) Demonstrates Superior Progression-Free Survival Over Docetaxel In First Positive Phase 3 Trial Of A Kras G12C Inhibitor In Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate (HALAVEN\u00ae) at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eribulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elev","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Camrelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiangsu Hengrui Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu He.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Late-Breaking Results from Phase 3 Trials of SKYRIZI\u00ae (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Seeks DCGI Nod for Phase-3 Study of Intranasal Covid Vaccine in 5-18 Age Group","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces FDA Approval of DAXXIFY\u2122 (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"ACh release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Tislelizumab Demonstrated Efficacy and Tolerability in First-line Advanced Liver Cancer in Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ICT01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Presents New Interim Data from the DesCAARTes\u2122 Phase 1 Trial at the 31st EADV Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric Auto Antibody Receptor T-cell Therapy","moa":"DSG3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody\u00ae ADG126 in Patients with Advanced Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG126","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LYL797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"XMT-1660","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Provides an Enrollment Update on the Phase 2\/3 Study of Tempol in COVID-19 Positive High-Risk Subjects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Presents Encouraging Phase 1\/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CLDN6 CAR-T Cell Therapy","moa":"CLDN6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Military Health System Research Symposium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Presents Latest Research Showing Benefits of Needle-free at Military Health System Research Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DNA-based Venezuelan Equine Encephalitis Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaJet \/ Military Health System Research Symposium","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) Plus Chemotherapy Further Improved Overall Survival Benefit in Advanced Biliary Tract Cancer in The TOPAZ-1 Phase III Trial, Reducing the Risk of Death by 24% in Additional Follow-Up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI\u2019s Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"NewG Lab Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ NewG Lab Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidubicel","moa":"CD34","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NOV004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sj\u00f6gren\u2019s Syndrome Meets Primary Endpoint","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dazodalibep","moa":"CD40","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Trofinetide","moa":"IGF-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Trifluridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fore Biotherapeutics Presents Positive Interim Data From Phase 1\/2a Trial Evaluating FORE8394 in Patients With Advanced Tumors With Activating BRAF Alterations at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"FORE8394","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Bioth.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIMEDX EPIFIX\u00ae Receives Reimbursement Approval in Japan","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Amnion Membrane Allograft","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ N.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE\u00ae Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GTB-5550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Updated Data from Investigator-Sponsored Phase 1\/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rigosertib","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"CTLA4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of \u20181104 in Eosinophilic Esophagitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio Announces Presentation of Phase 2 PK\/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ABM-05X","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b\/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-612","moa":"SARS-CoV-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"HepQuant","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 \u2018ALTITUDE-NASH\u2019 Liver Function Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ HepQuant","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2\/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma\u2019s TransCon\u2122 PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody\u00ae Therapeutic BMS-986249","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BMS-986249","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CF-296","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Mast cell","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraventricular Catheter","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GRT-C903","moa":"CD8 positve cytotoxic T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gritstone bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of Phase 2 D-PLEX\u2081\u2080\u2080 Clinical Data at the European Society for Coloproctology Scientific Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Royal Marsden NHS Foundation Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncXerna Therapeutics Announces New Xerna\u2122 TME Panel Biomarker Data from Retrospective Analysis of Results from a Randomized Phase 2 Trial Evaluating Anti-PD-1 Maintenance Therapy in Esophagogastric Adenocarcinoma at the ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncXerna Therapeutics \/ Royal Marsden NHS Foundation Trust","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna T.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LB101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-012","moa":"SMAD 2\/3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b \u2018FASCINATE-2\u2019 Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Denifanstat","moa":"FASN","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma Announces Completion of its Pivotal Study Comparing UTULY\u2122 Epinephrine Intranasal Spray vs. 0.3 mg Epinephrine Autoinjector for the Treatment of Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RYZ101","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Nura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nura Bio Reports Preclinical Data Validating a Conserved Mechanism of Inhibition of NAD Hydrolases Implicated in Neurodegeneration in Neuron","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SARM1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/.."},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"National Health Research Institutes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib\/II Protocol Amendment for ABT-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DBPR112","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anbogen Therapeutics \/ National Health Research Institutes","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Th.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium to Present Positive Data on ADHD Medication AZSTARYS\u00ae (serdexmethylphenidate and dexmethylphenidate) and Alzheimer's Disease Medication ADLARITY\u00ae (donepezil transdermal system) at Psych Congress 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First and Only TIGIT\/TGF-\u03b2 Dual-targeting Antibody Fusion Protein of Akeso Demonstrated Promise in Preclinical Results Published at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AK130","moa":"TIGIT\/TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CD388","moa":"Neuraminidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company\u2019s Drug Candidate for the Treatment of Ataxia Telangiectasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-313","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PBI-0451","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pardes Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2\/3 Trial of LBP-EC01 for Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Locus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dehydrated Human Amniotic Membrane","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Te.."},{"orgOrder":0,"company":"Akouos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akouos \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ N.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Agent in Hypovolemic Shock Patients at Upcoming Military Health System Research Symposium","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants GENFIT\u2019s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces New Patent for Mycapssa\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pritumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nascent Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharnext: Findings From 'Real-World' Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed\/Refractory Multiple Myeloma in Nature\u2019s Blood Cancer Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Iopofosine I 131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"vMCO-010","moa":"MCO gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich\u2019s Ataxia Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosomal protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astrocyte Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1\/2 Gene Therapy Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-05","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Receives U.S. FDA Approval for Terlivaz\u00ae (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research From the University of Birmingham, U.K., Identifies New Treatment Target for CNS Injury and Neurological Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Chk-1\/Chk-2","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Birmingham \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Psilera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psilera Receives First Patent Allowance for Transdermal Patch Formulations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Psilera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ .."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Initiation of a Phase 2 Clinical Trial in CKD-aP","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"MC2-25","moa":"Carbamylation","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TST003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Presents Data on QN-302 at AACR\u2019s Pancreatic Cancer Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science - Positive Recommendation of the Data and Safety Monitoring Board to Continue the Phase 2 Study Evaluating the Antiviral Activity of Masitinib in Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"ApcinteX","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SerpinPC","moa":"APC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ ApcinteX","highestDevelopmentStatusID":"8","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Provides Research and Development Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TT-10","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Tarus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zotatifin","moa":"SARS-CoV-2 helicase eIF4A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"IL-27 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+\/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4\/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Sermonix Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix P.."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Secures Funding Ahead of Phase 2 Study of Golexanolone in Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+\/HER2- Breast Cancer and an ESR1 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Sermonix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix P.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"FRTX-02","moa":"DYRK1A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN\u2122 (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Submits Applications for Rubraca\u00ae Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"PDE4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those With Aggressive HR+\/HER2- Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Translational Research in Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical Announces Positive Results of Phase III Trial in Japan for Brexpiprazole in the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Syringe","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Neoadjuvant Libtayo\u00ae (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fianlimab (LAG-3 Inhibitor) Combined with Libtayo\u00ae (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Na\u00efve to PD-1 or PD-L1 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASBMR 2022: 3D Modelling of Hip DXA Scans in Postmenopausal Women With Osteoporosis Reveals Superior Improvements in Bone Density of Romosozumab Versus Controls","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Romosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Amgen Inc","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Aesthetics and BOTOX\u00ae Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"ACh release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumakras\u00ae (Sotorasib) Combined With Vectibix\u00ae (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients With KRAS G12C-mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Further Improved Overall Survival Benefit in Advanced Biliary Tract Cancer in the TOPAZ-1 Phase III trial, Reducing the Risk of Death by 24% in Additional Follow-up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and Tremelimumab With Chemotherapy Demonstrated Sustained Survival Benefit in Metastatic Non-small Cell Lung Cancer, Nearly Doubling the Number of Patients Alive After Three Years Vs. Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Continues to Demonstrate Clinically Meaningful Tumour Response in Patients With HER2-Mutant Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza in Combination With Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-line Advanced Ovarian Cancer Across Two Phase III Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New ARASENS Data Reinforce Strong Tolerability Profile of Darolutamide Plus ADT and Docetaxel Without Compromising Quality of Life for Patients With mHSPC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aflibercept 8 mg First to Achieve Extended Injection Intervals of 16 Weeks in Up to 89% of Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA\u00ae (lenvatinib) Plus KEYTRUDA\u00ae (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Late-Breaking Phase 3 Data at EADV 2022 Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"In Akero Therapeutics\u2019 Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ovarian Cancer Vaccine","moa":"ED-AMHR2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Cleveland Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"NIHR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial to Test Treatment for Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NIHR","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NIHR \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NIHR \/ Not.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-012","moa":"SMAD 2\/3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Closing of Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"ACh","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Financing","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ K2 HealthVentures","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Cartexell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Cell Therapy","moa":"CLND18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Integral Molecular","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Cartexell","highestDevelopmentStatusID":"2","companyTruncated":"Integral M.."},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Louisville","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"INB-400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ University of Louisville","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ U.."},{"orgOrder":0,"company":"RIGImmune","sponsor":"RIGImmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"RIG-101","moa":"RIG-I","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RIGImmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RIGImmune \/ RIGImmune","highestDevelopmentStatusID":"5","companyTruncated":"RIGImmune .."},{"orgOrder":0,"company":"Celularity","sponsor":"YA II PN","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Celularity \/ YA II PN","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Recombinant Human Polyclonal Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Merger","leadProduct":"Gemcitabine","moa":"Alpha V integrin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ Caladrius Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Avicanna","sponsor":"University of Toronto","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"AVCN319302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ University of Toronto","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Tyme Technologies \/ Syros","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$138.0 million","upfrontCash":"Undisclosed","newsHeadline":"Edgewise Therapeutics Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"EDG-5506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Edgewise Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Announces Pricing of $20.0 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Plasmid DNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Aditxt \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ H.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"BB-301","moa":"PABPN1 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"$39.9 million","upfrontCash":"$35.5 million","newsHeadline":"Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Termination","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"IDT Biologika GmbH","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"IDT Biologika GmbH \/ Valneva","highestDevelopmentStatusID":"12","companyTruncated":"IDT Biolog.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$13.9 million","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"$22.0 million","newsHeadline":"NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"GPR119","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Dong-A ST Co.","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Versantis","sponsor":"Genfit","pharmaFlowCategory":"D","amount":"$107.6 million","upfrontCash":"Undisclosed","newsHeadline":"GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, Expanding its Portfolio in Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"VS-01","moa":"Ammonia clearance","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Versantis","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Versantis \/ GENFIT","highestDevelopmentStatusID":"6","companyTruncated":"Versantis .."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics, Inc. Announces Pricing of Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical Isotope","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"n.c.a Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiopharm Theranostics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ SHINE Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Radiopharm.."},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"GIBF2","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"TRPV3","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kamari Pharma","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Kamari Pharma \/ GIBF2","highestDevelopmentStatusID":"4","companyTruncated":"Kamari Pha.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$176.6 million","upfrontCash":"Undisclosed","newsHeadline":"Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"VTX958","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.17999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Redmile Group","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","amount":"$334.0 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Acquisition of Rights for Oncology Asset BAL0891 by SillaJen And Updates Financial Guidance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"BAL0891","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ SillaJen","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$124.8 million","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","amount":"$294.3 million","upfrontCash":"$7.0 million","newsHeadline":"Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Alisertib","moa":"Aurora kinase A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Puma Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$20.0 million","newsHeadline":"Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Cytoreason","amount2":0.11,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Cytoreason \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason.."},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"Undisclosed","newsHeadline":"Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem\u00ae in China to Treat Antimicrobial Resistant Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Menarini","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"Injectable\/Injection","sponsorNew":"Menarini \/ SciClone","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces Pricing of $100 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"ALPN-303","moa":"BAFF\/APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"China International Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ China International Capital","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"MiroBio","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$405.0 million","upfrontCash":"$405.0 million","newsHeadline":"Gilead Sciences Completes Acquisition of MiroBio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"MB272","moa":"BTLA","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"MiroBio","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"MiroBio \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MiroBio \/ .."},{"orgOrder":0,"company":"Neuron23","sponsor":"Qiagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuron23","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuron23 \/ Qiagen","highestDevelopmentStatusID":"4","companyTruncated":"Neuron23 \/.."},{"orgOrder":0,"company":"Bugworks","sponsor":"Cytecare Cancer Hospitals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bugworks Research Inc. and Cytecare Cancer Hospitals Announce Collaboration to Accelerate the Development of Cutting-Edge Immuno-Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bugworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bugworks \/ Cytecare Cancer Hospitals","highestDevelopmentStatusID":"2","companyTruncated":"Bugworks \/.."},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Anzu Partners","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"TCR-T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ImmunoScape \/ Anzu Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScap.."},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Orano","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NETRIS Pharma, Orano and Centre Leon Berard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"NP137","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NETRIS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NETRIS Pharma \/ Orano","highestDevelopmentStatusID":"8","companyTruncated":"NETRIS Pha.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Altasciences","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"TCG GreenChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ TCG GreenChem","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiondVax\u2019s Strategic Research Collaboration: Significant Progress Towards Development Of Innovative Nanosized Antibodies (NanoAbs) for Therapeutic Indications in Addition to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Alpaca\u2011derived Nanosized Antibody","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Nuvisan GmbH","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"NUVISAN Receives US$9.6M Grant for A Multi-Target Drug Discovery Program on Novel Non-Hormonal Contraceptive Medicines","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Nuvisan GmbH","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nuvisan Gm.."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Rejoy Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jupiter Wellness Signs Exclusive License Agreement With Rejoy Corporation","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"JW-500","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Safety Shot \/ Rejoy Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"Cevec","sponsor":"Rokote Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rokote Laboratories Licenses Cevec\u2019s Cap\u00ae Ad Technology For Vaccine Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"FINCoVac 2.1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cevec","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ ROKOTE Laboratories Finland","highestDevelopmentStatusID":"4","companyTruncated":"Cevec \/ RO.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Gastro-Intestinal Research Foundation","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"ELI-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Gastro-Intestinal Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytoreason \/ Pfizer","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason.."},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuneSensor Awarded $16 Million Grant from the Cancer Prevention and Research Institute of Texas (CPRIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"IMSA101","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmuneSensor Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"ImmuneSens.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Vanderbilt University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neumora therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Vanderbilt University","highestDevelopmentStatusID":"4","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$49.9 million","upfrontCash":"Undisclosed","newsHeadline":"Just \u2013 Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Just \u2013 Evotec Biologics","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Just \u2013 Evotec Biologics \/ Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Just \u2013 Evo.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"GHS Investments","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ GHS Investments","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"jCyte","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Center for Breakthrough Medicines and jCyte Announce Strategic Partnership to Manufacture jCyte\u2019s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Human Retinal Progenitor Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"jCyte \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Ce.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Tamibarotene","moa":"RAR alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Syros Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"NMS-293","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nerviano Medical Sciences \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano M.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Isotopia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clovis Oncology \/ Isotopia","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Collaborates in The Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign.."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a \"Multi-Antigen\" CAR T Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"SNAP-CAR T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Th.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Sino Biopharm","pharmaFlowCategory":"D","amount":"$307.0 million","upfrontCash":"$12.0 million","newsHeadline":"Inventiva and Sino Biopharm Announce Licensing and Collaboration Agreement to Develop and Commercialize Lanifibranor in Greater China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Lanifibranor","moa":"PPAR alpha","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0.31,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Sino Biopharm","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Altay Therapeutics","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOLVE FSHD Invests US$3 Million in Altay Therapeutics","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Altay Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altay Therapeutics \/ SOLVE FSHD","highestDevelopmentStatusID":"2","companyTruncated":"Altay Ther.."},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"LCTG-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lactiga \/ 1517 Fund","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ .."},{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"iBio","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"$1.0 million","newsHeadline":"iBio Acquires RubrYc Therapeutics\u2019 AI Drug Discovery Platform and Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"RTX-003","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"RubrYc Therapeutics \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc The.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics, Inc. Announces Closing of Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series B Financing","leadProduct":"HU6","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Phar.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I\/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-In","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Denileukin Diftitox","moa":"Protein synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ University of Pittsburgh","highestDevelopmentStatusID":"7","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$115.0 million","newsHeadline":"Albireo Announces $115 Million Royalty Monetization Agreement with Sagard","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Sagard","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$17.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Roca Therapeutics","sponsor":"3B Future Health Fund II","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roca Therapeutics Completes Seed Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"RCT001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Roca Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Roca Therapeutics \/ 3B Future Health Fund II","highestDevelopmentStatusID":"5","companyTruncated":"Roca Thera.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Beauty Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeautyHealth\u2019s Hydrafacial Announces Partnership With Organicell To Develop Breakthrough Exosome Booster","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Exosome Based Therapeutic","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Beauty Health","highestDevelopmentStatusID":"1","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Omeros","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"MASP-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Q.."},{"orgOrder":0,"company":"Onco360","sponsor":"Servier","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIBSOVO\u00ae (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-Mutant Acute Myeloid Leukemia or Previously Treated, IDH1-Mutant Metastatic Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Servier","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ALN-HSD","moa":"HSD17B13","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Dupixent\u00ae (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis Published in The Lancet","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Treatment for Rare Cancer Cholangiocarcinoma Approved in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Specialised Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Servier","sponsor":"Mission Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Leverages Mission Bio's Tapestri\u00ae Platform to Uncover AML Resistance Mechanisms in Pivotal TIBSOVO\u00ae (ivosidenib) Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Mission Bio","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Beyfortus\u00ae (Nirsevimab) For Prevention of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA\u00ae (calcipotriene and betamethasone dipropionate) Cream, 0.005%\/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"EPI Health \/ MC2 therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health.."},{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anima Research Center Participating In A Trial For An Investigational RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anima Medical Centre","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anima Medical Centre \/ Moderna","highestDevelopmentStatusID":"4","companyTruncated":"Anima Medi.."},{"orgOrder":0,"company":"Biogen","sponsor":"Feinstein Institutes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Experimental Lupus Therapy Shows Promise In Feinstein-led Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Feinstein Institutes for Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ F.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics and Sobi Announce ZYNLONTA\u00ae (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY\u00ae Conditional Marketing Authorization to Full Marketing Authorization in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybin-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Akome Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akome Biotech \/ Core One Labs","highestDevelopmentStatusID":"4","companyTruncated":"Akome Biot.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Campbell Neurosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Campbell Neurosciences","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Hoag","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoag Enrolling Patients for Clinical Trial of Promising New Investigational Treatment for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ACU193","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Hoag","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas' Partner Stada Launches The First Medicine Authorized In The EU For Treating Primary Iga Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"STADA Arzneimittel \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lys-MDA","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Emerson Urology Associates","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mycobacterium Bovis Bacille Calmette-guerin Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ludwig Enterprises","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ludwig Enterprises \/ Emerson Urology Associates","highestDevelopmentStatusID":"1","companyTruncated":"Ludwig Ent.."},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Invitae","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invitae\u2019s Real-World Ciitizen Data Utilized in Praxis Precision Medicines\u2019 PRAX-222 IND Filing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PRAX-222","moa":"SCN2A gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Praxis Bioresearch","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Bioresearch \/ Invitae","highestDevelopmentStatusID":"5","companyTruncated":"Praxis Bio.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY\u00ae (fosdenopterin) for the Treatment of MoCD Type A","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Otoferlin","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Omeros","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"MASP-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quantum Leap Healthcare \/ Omeros","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Genelux","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant\/Refractory Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ GOG Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved In China As 1st-line Maintenance Treatment With Bevacizumab For HRD-positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Approved In The Eu For The Treatment Of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus (nirsevimab) Recommended for Approval in the EU by CHMP for the Prevention of RSV Lower Respiratory Tract Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danicopan (ALXN2040) Add-On to Ultomiris or Soliris Met Primary Endpoint In Alpha Phase III Trial For Patients With Paroxysmal Nocturnal Haemoglobinuria Who Experience Clinically Significant Extravascular Haemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Sage Therapeutics Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s CAR T-cell Therapy Yescarta\u00ae First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-Grade B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ALN-HSD","moa":"HSD17B13","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Ketamine Wellness Center","sponsor":"Delic Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ketamine Wellness Centers (KWC) Launches SPRAVATO\u00ae Nasal Spray Therapy in Minneapolis, Salt Lake City and Dallas","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Ketamine Wellness Center","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ketamine Wellness Center \/ Delic Corp","highestDevelopmentStatusID":"12","companyTruncated":"Ketamine W.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acadia Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"University of Florida","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces Results of First Patient Dosed in Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Yale School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Ceruvia Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceruvia Lifesciences \/ Yale School of Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Ceruvia Li.."},{"orgOrder":0,"company":"SpectrumX","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpectrumX Reaches Partnership Agreement on Human Volunteer Study for Ground-breaking Respiratory Infection Drug Candidate SPX-001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"SPX-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpectrumX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SpectrumX .."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase\u00ae Closes $2.5M Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB\/C Melanoma in the CheckMate -76K Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Expands Recommendation for Veklury\u00ae (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ABX1100","moa":"Glycogen synthase 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Launches NativusWell\u00ae, a Novel Nutraceutical for Menopause, in Hong Kong","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dioscorea Polystachya","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Receives IND Clearance for Phase 2 Trial of INV-202 in Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Confo Therapeutics Announces Poster Presentations on CFTX-1554 Preclinical Profiling and Mechanism of Action at the IASP 2022 World Congress on Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CRV\u2011101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Curevo Vaccine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vac.."},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J INTS BIO, Poster Presentation of Further Preclinical Data of Its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"JIN-A02","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn\u00ae Phase 2 Progressive MS Trial in Multiple Sclerosis Journal BrainStorm Logo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"MSC-NTF Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS\u00ae (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, In the Treatment of Patients With Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Humanized Anti-CD117 Monoclonal Antibody","moa":"CD117","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Completes Enrollment of the Phase I\/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson's Disease and Movement Disorders\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharma Two B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-333","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Di-deuterated Linoleic Acid Ester","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1\/2 Trial Evaluating EBT-101 as a Potential Cure for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EBT-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fc-modified Anti-CD154mAb","moa":"CD154","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure's Alzheimer\u2019s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Announces Positive Data for CRISPR Candidate","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Receives FDA Accelerated Approval for SKYSONA\u00ae Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"LAG3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Receives Positive CHMP Opinion of Adtralza\u00ae (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SRK-181","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-Transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Maribavir","moa":"CMV pUL97 kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-Targeting Platform for Traumatic Bone Injury","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NOV004","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive CHMP Opinion for VAXNEUVANCE\u2122 (pneumococcal 15-valent conjugate vaccine) in Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danicopan (ALXN2040) Add-On to ULTOMIRIS\u00ae (ravulizumab-cwvz) or SOLIRIS\u00ae (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion to Extend Indication of Veklury\u00ae (Remdesivir) for the Treatment of Pediatric Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces U.S. FDA Approval of APONVIE\u2122 (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte\u00ae","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CellResearch Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CellResear.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Large Commercial Payer Adds Phexxi\u00ae to Formulary for Standard Plans Nationwide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat\u2019s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion for Mycapssa\u00ae for the Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1\/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease at the MDS International Congress of Parkinson's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Receives Positive CHMP Opinion for PYRUKYND\u00ae (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PHVS416","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Media Update: CHMP Recommends Approval Of Enjaymo\u2122 (Sutimlimab), First And Only Approved Treatment For Hemolytic Anemia In Adult Patients With Cold Agglutinin Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"Complement C1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Further Progress on its Biosimilar Pipeline, With Release of Positive Results For Denosumab Integrated Phase I\/III Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Roche\u2019s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGF A\/Ang-2 inhibitor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"20vPnC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Recommends BeiGene\u2019s BRUKINSA\u00ae (zanubrutinib) for Patients with Waldenstrom\u2019s Macroglobulinemia Who have had at Least One Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, Featuring Peter Houghton, Ph.D.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Announces Peer-Reviewed Publication of PrimeC Phase IIa ALS Study in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemosensory receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY\u2122 (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"ACh","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives Positive CHMP Opinion for BRUKINSA\u00ae (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Interleukin-2","moa":"TNF-13","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents INGREZZA\u00ae (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"HMBD-002","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium Announces Publication of ADLARITY\u00ae (donepezil transdermal system) Clinical Trial Data: Drug Exposure Equivalent to Oral Donepezil With Favorable GI Side Effect Profile","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"ACh","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1 inhibitor\/4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TCX \u2013 101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"MC4R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Bilayer tablet","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybin-assisted Psychotherapy","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psyence \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX\u2081\u2080\u2080 in the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Treosulfan","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nelonemdaz","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GNT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces European Commission Approval of LUPKYNIS\u00ae (voclosporin) for the Treatment of Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus to Launch CIMERLI (ranibizumab-eqrn) in the United States on October 3, 2022","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover\u2019s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"SARS-CoV-2 S-trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Invenra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"INV322","moa":"CTLA-4\/CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Invenra","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invenra \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Invenra \/ .."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-NK Cell Therapy","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1\u00ae as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Achieves Research and Development Milestones Ahead of Projected Timelines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) Exclusivity","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tazarotene","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial Under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GLY-200","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glyscend Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend T.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"IFN beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Receives Approval in Europe for AMVUTTRA\u00ae (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vutrisiran Sodium","moa":"TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Cellevolve","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-Controlled Study of CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CE-VST01-JC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cellevolve","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellevolve \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellevolve.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Results From Clinical Trial With Diamyd\u00ae Presented Today At Diabetes Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GAD65-Alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110\u2122, a KIR-CAR T Cell Immunotherapy Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SynKIR-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verismo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Th.."},{"orgOrder":0,"company":"Xpira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xpira Pharmaceuticals Inc. Receives FDA Approval For Psilocybin Trial IND Application","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybin-based Therapeutic","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Xpira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xpira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Xpira Phar.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMU-856","moa":"Intestinal barrier function","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIMEDX Announces Launch of AXIOFILL\u2122","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Acellular Human Extracellular Matrix","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ N.."},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector\u2122 Compositions","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Ring Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Ring Thera.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219\u2019s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Positive Update from Phase 1b\/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"WVE-003","moa":"SNP3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Completes Drug Production for Phase 1 Clinical Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LPCN 1154","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Receives FDA Accelerated Approval for SKYSONA\u00ae Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Elivaldogene Autotemcel","moa":"ALDP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces TUKYSA\u00ae (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 TK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Lilly's Retevmo\u00ae (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"VEGFR 1\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Provides Update on the Phase 2\/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SON-1010","moa":"IL-12-FHAB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Regorafenib","moa":"Tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Coalition for Adaptive Research \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"p38 alpha kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RVM-V001","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RVAC Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medic.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"IMT-009","moa":"CD161","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunitas Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas .."},{"orgOrder":0,"company":"NodThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-0796","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NodThera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NodThera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio\u00ae Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-Reviewed Journal PLOS ONE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-001","moa":"MCM","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Phase I\/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"Biocodex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antiseizure Drug DIACOMIT Now Approved for Children as Young as 6 Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Stiripentol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biocodex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocodex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocodex \/.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Presents Data on RADICAVA ORS\u00ae (edaravone) at 2022 AANEM Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AC-0027838","moa":"TrkA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"APR-TD011","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spexis Announces Positive Renal Impairment Clinical Trial Results With Balixafortide","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCR4","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ N.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Pan-RAF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SNS-101","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"KIRS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"GABA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX\u2122, an Oral Testosterone Replacement Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Presents Novel Data On Chlormethine Gel At EORTC Cutaneous Lymphomas Tumors Group Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1\/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BI 456906","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing Forms of Multiple Sclerosis (RMS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present at Informa Connect\u2019s Next Generation Protein Therapeutics Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ADC-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"FT-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Frontera Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frontera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontera T.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"HSF-1 pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX\u00ae2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"SIR","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Proton Boron Capture-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life S.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-323","moa":"L-protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T Cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ATRN-W1051","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"mTOR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Doses First Patient in Phase 1\/1b Clinical Trial of RMC-6291, Company\u2019s First Mutant-Selective RAS(ON) Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"RMC-6291","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterium Stabilized (R)\u2010Pioglitazone","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"SCN10A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Charsire Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Charsire's New Drug Aims to Capture Multi-Billion-Dollar Dementia Treatment Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Multiglycan Complex","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Charsire Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Charsire Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Charsire B.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4\/IL-13 Super-Antagonist at Cytokines 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bi-functional SuperKines ImmunoTherapy","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI\u00ae) for the Treatment of Adults with Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-acting Antibody Combination Recommended for Approval in the EU For the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer To Present New Cardiorenal Data For Kerendia\u2122 (Finerenone) Across A Broad Range Of Patients With Early To Late-stage Chronic Kidney Disease And Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncologic Drugs Advisory Committee To Review Zejula Overall Survival Data from the NOVA Phase III Trial in Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Plans To Petition The U.S. Supreme Court To Uphold Validity Of The Gilenya\u00ae (Fingolimod) Dosing Regimen Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"More People With Type 2 Diabetes Achieved Blood Sugar Target With Once-weekly Insulin Icodec Compared With Once-daily Insulin Degludec","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces EC Approval Of Lupkynis\u00ae (Voclosporin) As First Oral Treatment For Active Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentavalent Meningococcal Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval Of Enjaymo\u2122 (Sutimlimab), First And Only Approved Treatment For Hemolytic Anemia In Adult Patients With Cold Agglutinin Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"Complement C1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Presents Latest Data From Generalized Myasthenia Gravis Portfolio At AANEM Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Rozanolixizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces Pricing of $55 Million Public Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Narcotic","amount2New":0.059999999999999998,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$70.0 million","newsHeadline":"Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"T-cell Based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ArsenalBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"ArsenalBio.."},{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TargEDys and Inoliva Announce They Have Entered a Distribution Partnership to Bring Satylia\u00ae to Turkey","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"TargEDys","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TargEDys \/ Inoliva","highestDevelopmentStatusID":"12","companyTruncated":"TargEDys \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"2-deoxy-D-glucose Prodrug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"$9.5 million","upfrontCash":"$0.5 million","newsHeadline":"Mindset Pharma Provides Strategic Intellectual Property License to Cybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Cybin","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Announces Signing of Multiple Agreements With New and Existing Customers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"LAPAM","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"NeuShen Therapeutics Closes Pre-A Financing with ~$20M","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"NeuShen Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"NeuShen Therapeutics \/ LAPAM","highestDevelopmentStatusID":"2","companyTruncated":"NeuShen Th.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Pricing of Approximately $6 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Ivospemin","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"KBio","sponsor":"Leaf Expression Systems","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KBio Announces Strategic Collaboration with Leaf Expression Systems to Enhance Development and Production of Novel Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"KBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KBio \/ Leaf Expression Systems","highestDevelopmentStatusID":"4","companyTruncated":"KBio \/ Lea.."},{"orgOrder":0,"company":"Aceragen","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Idera Pharmaceuticals Acquires Aceragen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Sodium Fusidate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aceragen \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/.."},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"Brandon Capital","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brandon Capital Co-Leads USD 68M Series A Financing of London-Based ADC Company Pheon Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"PHN-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pheon Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Pheon Therapeutics \/ Brandon Capital","highestDevelopmentStatusID":"5","companyTruncated":"Pheon Ther.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"OliPass","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"mRNA","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ OliPass","highestDevelopmentStatusID":"4","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"AmerisourceBergen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics\u00ae and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ AmerisourceBergen","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$365.0 million","upfrontCash":"$45.0 million","newsHeadline":"Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel\u00ae) Commercialization Agreement with Pierre Fabre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0.37,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant\u2122 (diazepam) Buccal Film for European and MENA Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ocugen \/ Washington University","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ W.."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Synthonics","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Secures $3 Million Seed II Round of Funding","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Cannabidiolic Acid Complex","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Synthonics","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTher.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ NIH","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$250.0 million","newsHeadline":"Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"PD-1-targeted IL-2 Therapy","moa":"PD-1 inhibitor\/IL-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bonum Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Ther.."},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$56.3 million","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (\u201cIM\u201d) Formulation of ENA-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"ENA-001","moa":"Potassium channel","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Enalare Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Th.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR\/Cas9-Based Gene-Editing Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1\/2 Trial Evaluating EBT-101 as a Potential Cure for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"EBT-101","moa":"CRISPR-Cas9 gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Excision BioTherapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$17.8 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Funding","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"EMERCell","sponsor":"Cell-Easy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-Up and Manufacturing of NK-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"NK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EMERCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EMERCell \/ Cell-Easy","highestDevelopmentStatusID":"4","companyTruncated":"EMERCell \/.."},{"orgOrder":0,"company":"PhoreMost","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PhoreMost Enters Multi-Project Drug Target Discovery Collaboration with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost .."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio and Carisma Therapeutics Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Merger","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Rohto Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese Company Bloomage Biotech Forges Partnership with Japanese Firms on Regenerative Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"Mesenchymal Stem Cells-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ ROHTO Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Medytox","sponsor":"Bloomage Biotechnology Corp., Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medytox\u2019s Chinese Partner Terminates BTX Deal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Medytox","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medytox \/ Bloomage BioTechnology","highestDevelopmentStatusID":"12","companyTruncated":"Medytox \/ .."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health and Glenmark Announce the Approval of RYALTRIS\u00ae in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch Health \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"Ach","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Announces Issuance of U.S. Patent Covering Phexxi\u00ae Composition of Matter","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185\u2019s Effectiveness Against Multiple COVID-19 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel\u2122 to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"Vascular Cell","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in Europe for the Treatment of Adults With Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eylea\u00ae Approved in Japan for Treatment of Preterm Infants With Retinopathy of Prematurity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine to Participate in BIO-Europe 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"LPCN 1154","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD117","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1\/1b Clinical Trial of Mupadolimab (Anti-CD73) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mupadolimab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TCX \u2013 101","moa":"miHA-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate\u2019s PNV-5030 as a Potential Treatment for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PNV-5030","moa":"Adenosine A1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"QBECO-SSI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SZN-413","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio Provides Update on AMB-05X Program for Tenosynovial Giant Cell Tumor (TGCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AMB-05X","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dystrogen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"DT-DEC01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dystrogen Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dystrogen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dystrogen .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1\/2 MARINA\u2122 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AOC 1001","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"HLB Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"RegeneRx Biopharmaceuticals \/ HLB Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator\u00ae at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"iNexin","moa":"CX43","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Xequel Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Re-Launches Bentrio in Europe for Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse\u00ae for Treatment of Fibrotic Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"EmpathBio","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"EmpathBio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EmpathBio \/ atai Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"EmpathBio .."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b\/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribaxamase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT\u2122 Study of Efzofitimod in Patients with Pulmonary Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"Neuropilin-2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor\u2019s Broad Potential in Chronic Neutropenia (CN)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Selonabant","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xnk Therapeutics to Use Generic Name Evencaleucel for Lead Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Evencaleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"XNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XNK Therapeutics \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"XNK Therap.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Regulatory Filing for DANYELZA\u00ae (naxitamab-gqgk) in Brazil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"UBE Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen and UBE Received FDA Approval for OMLONTI\u00ae (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidenepag Isopropyl","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ UBE Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Positive Results from the Phase 1\/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"VB10.2210","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Announces Achievement of the Primary Endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 Part of the Phase 2\/3 Clinical Trial in Asia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Aurohealth","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Healthcare Brand Launches Nationwide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aurohealth","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Insert","sponsorNew":"Aurohealth \/ Aurobindo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aurohealth.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AXA1125","moa":"PPAR alpha","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Serine protease","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GB2064","moa":"LOXL2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"FORE8394","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Bioth.."},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Gavocabtagene Autoleucel","moa":"CD3E subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Thera.."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents Positive Results From a Preclinical Study of Golexanolone","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi\u00ae (tafasitamab-cxix) for Patients with R\/R DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASTRUM-005: The First Immunotherapy Clinical Study of SCLC Published in JAMA, One of the Top Medical Journals in the World","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ISB 1442","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"Evommune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"EVO101","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Evommune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gas","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Istaroxime","moa":"Sodium\/potassium-transporting ATPase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Gradalis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company\u2019s Immuno-Oncology Treatment, Vigil\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gradalis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking e-Posters at the 51st Annual European Society for Dermatological Research Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613\u00ae (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Announces Notice of Allowance for Minoxidil Adjuvant Therapies U.S. Patent","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Minoxidil","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Safety Shot \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4\/BA.5 Targeting Bivalent COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO\u2122 for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Kling Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of KBA1412 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"KBA1412","moa":"CD9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kling Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kling Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kling Biot.."},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces Publication of Results from the CHELATE Trial in The Lancet Gastroenterology & Hepatology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/.."},{"orgOrder":0,"company":"TearClear","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (Latanoprost Ophthalmic Solution 0.005%)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Latanoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"TearClear \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1\/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC\u2122 Degrader, in BRAF-V600 Mutant Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CFT1946","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE\u00ae Expanding Patient Population to Include Pediatric Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Amifampridine","moa":"KCNQ channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Maxwell Biosciences","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER Platform\u2019s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Antimicrobial Peptides","moa":"SARS-CoV-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Maxwell Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Maxwell Biosciences \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Maxwell Bi.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV9 Capsid","moa":"AAV9.LAMP2B gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-Blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"SNS-101","moa":"VISTA checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Topotecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Approved in Japan for the Treatment of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Koselugo Approved in Japan for Paediatric Patients With Plexiform Neurofibromas in Neurofibromatosis Type 1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MEK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA\u00ae (tocilizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files New Drug Application in Japan for Fixed-Dose Subcutaneous Combination of Pertuzumab and Trastuzumab for HER2-Positive Breast and Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EZHARMIA\u00ae Approved in Japan as First Dual EZH1 and EZH2 Inhibitor Therapy for Patients with Adult T-Cell Leukemia\/ Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Medac","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metoject\u00ae Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medac","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medac \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Ei.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aflibercept 8 Mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FINTEPLA (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Announce Global Exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"Exon 51 skipping oligonucleotide","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis Due to NASH Did Not Meet its Primary Endpoint","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Receives Manufacturing and Marketing Authorization in Japan for \u201cBerinert S.C. Injection 2000,\u201d as a Medicine for Prevention of Acute Hereditary Angioedema (HAE) Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2022 FIC Exhibition | Bloomage Biotech Launches AbateHP\u2122- the New Anti-Helicobacter Pylori Solution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Helicobacter Pylori","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Completed the Phase 1 Clinical Trial of HLX22 for the Treatment of HER2 Overexpressing Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"HLX22","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius Received IND Approval from US FDA for HLX07 in CSCC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"HLX07","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$11,600.0 million","upfrontCash":"$11,600.0 million","newsHeadline":"Pfizer Completes Acquisition of Biohaven Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":11.6,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":11.6,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"TradeUP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Estrella Biopharma, Inc., a Biopharmaceutical Company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Merger","leadProduct":"EB103","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Estrella Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Estrella Biopharma \/ TradeUP","highestDevelopmentStatusID":"4","companyTruncated":"Estrella B.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"BTIG","pharmaFlowCategory":"D","amount":"$100.3 million","upfrontCash":"Undisclosed","newsHeadline":"Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"H.I.G. Capital Acquires Morningside Healthcare and Morningside Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Gestodene","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Morningside Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Morningside Pharmaceuticals \/ Aspire Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Morningsid.."},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"8VC","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series D Financing","leadProduct":"In-vivo Human Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ 8VC","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Ther.."},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"mRNA-based Regenerative Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Pantherna Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pantherna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Pantherna .."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics Enters into Commercial License Agreement with Genmab","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"OBT700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"5","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Omeros","sponsor":"DRI Healthcare Acquisitions","pharmaFlowCategory":"D","amount":"$188.4 million","upfrontCash":"Undisclosed","newsHeadline":"Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Omeros","amount2":0.19,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.19,"dosageForm":"Solution","sponsorNew":"Omeros \/ DRI Healthcare Acquisitions","highestDevelopmentStatusID":"12","companyTruncated":"Omeros \/ D.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Neovacs","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharnext Executes a Financing Agreement with N\u00e9ovacs for EUR 20.7 Million Net to Further Develop PXT3003 for Charcot-Marie-Tooth Disease Type 1A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Neovacs","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Mazindol","moa":"MAT","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Laidlaw & Company","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase\u00ae Commences $CAN 2.5 M Follow-On Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Myrtelle","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"AAV-based TMPRSS3 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forge Biologics \/ Myrtelle","highestDevelopmentStatusID":"5","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"$30.0 million","newsHeadline":"Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0.33000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"miRecule","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"$30.0 million","newsHeadline":"miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"MC-DX4","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"miRecule","amount2":0.42999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"miRecule \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"miRecule \/.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus\u2019 Proprietary Safety Switch System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech Closes $24 Million Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Araris Biotech \/ 4BIO Capital","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"SyntheX labs","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$550.0 million","upfrontCash":"Undisclosed","newsHeadline":"SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SyntheX labs","amount2":0.55000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"SyntheX labs \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"SyntheX la.."},{"orgOrder":0,"company":"Personalis","sponsor":"Olink Proteomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PDL1\/PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Personalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Personalis \/ Olink Proteomics","highestDevelopmentStatusID":"12","companyTruncated":"Personalis.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Cellarity","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$274.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellarity Announces Close of $121 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cellarity","amount2":0.27000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Cellarity \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Cellarity .."},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"V-Bio Ventures","pharmaFlowCategory":"D","amount":"$22.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sibylla Biotech Raises \u20ac23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline and Expand Technology Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ V-Bio Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Bi.."},{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Series A Financing","leadProduct":"Nicotine","moa":"ACh receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Qnovia","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Qnovia \/ Blue Ledge Capital","highestDevelopmentStatusID":"4","companyTruncated":"Qnovia \/ B.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank A\/S","pharmaFlowCategory":"D","amount":"$102.5 million","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Completion of a Directed Issue and Private Placement of 4,975,000 New Ordinary Shares Raising Gross Proceeds Of Approx. DKK 786 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Danske Bank A\/S","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$99.9 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Closing of Upsized \u20ac102.9 Million Global Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"OspA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Directed Issue And Private Placement Of Approximately 4.5M New Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Glepaglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Batoclimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Immunovant","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunovant \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"XORTX Announces US$5 Million Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB\u00ae Hydrogel from the United States Department of Defense","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"DispersinB","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","amount":"$568.0 million","upfrontCash":"$30.0 million","newsHeadline":"Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.56999999999999995,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo\u2019s Global Footprint Grows With Middle East Expansion, Disrupting the Erectile Dysfunction Market With Oral Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Taiba Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Immuron","sponsor":"Pharmaron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Pharmaron","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical Development of its Long-Acting Stable Glucagon Analog for the Treatment of Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/.."},{"orgOrder":0,"company":"Circularis Biotechnologies","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Circular RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Circularis Biotechnologies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Circularis Biotechnologies \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Circularis.."},{"orgOrder":0,"company":"Valitor","sponsor":"Morningside","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series B Financing","leadProduct":"VLTR-557","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Valitor","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Valitor \/ Morningside","highestDevelopmentStatusID":"5","companyTruncated":"Valitor \/ .."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce Execution of a Second up to $40 Million Backstop Agreement, for a Total of up to $80 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Merger","leadProduct":"OCX-253","moa":"CHI3L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 Per H Share","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"LVRNA009","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AIM Vaccine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AIM Vaccine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AIM Vaccin.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$5,400.0 million","upfrontCash":"$5,400.0 million","newsHeadline":"Pfizer Completes Acquisition of Global Blood Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":5.4000000000000004,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":5.4000000000000004,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Applied BioMath","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ Applied BioMath","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"ST101","moa":"C\/EBP beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"AeroRx Therapeutics","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AeroRx Partners with HCmed to Develop a Nebulized LABA\/LAMA Combination Solution for the Treatment of Chronic Obstructive Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"AeroRx Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AeroRx Therapeutics \/ HCmed Innovations","highestDevelopmentStatusID":"1","companyTruncated":"AeroRx The.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Artemis Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Tobacco Leaf Protein","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Artemis Biotech","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Biolink LifeSciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce Contract For Developing a Novel Treatment of COVID Pneumonia And Prevention of Long COVID","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Ramatroban","moa":"Thromboxane A2\/TP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Biolink LifeSciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Biolink LifeSciences \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Biolink Li.."},{"orgOrder":0,"company":"Intravacc","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Partners With Intravacc To Develop An Intranasal, Broadly Protective Betacoronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Avacc 101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nested Therapeutics Launches With $125 Million Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"NEST-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nested Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Nested Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nested The.."},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Awarded US$14.6 Million NIH\/NIAID Contract To Develop Intranasal Gonorrhea Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Recombinant Human IL-12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Intravacc \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Tempus","sponsor":"Kartos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Navtemadlin","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tempus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tempus \/ Kartos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tempus \/ K.."},{"orgOrder":0,"company":"Phoenix Pharmalabs","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$8.7 million","upfrontCash":"Undisclosed","newsHeadline":"Phoenix PharmaLabs Awarded $8.7 Million Grant from NIDA to Study Compound for Treatment of Cocaine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"PPL-138","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Phoenix Pharmalabs","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Phoenix Pharmalabs \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Ph.."},{"orgOrder":0,"company":"Seqirus","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$30.1 million","upfrontCash":"Undisclosed","newsHeadline":"CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Seqirus \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Unitaid","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Rifapentine","moa":"DdRP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Unitaid","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$13.8 million","upfrontCash":"Undisclosed","newsHeadline":"Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Osanetant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NexImmune \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Platform and Diagnostic Companion Radiopharmaceuticals to Address Unmet Needs in Oncology; Michael Lee-Chin Appointed to The Board of The Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"212Pb-DOTAMTATE","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Portland Investment Counsel Inc.","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"XORTX Announces Closing of US$5 Million Public Offering","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0.01,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Replimune","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Pregene","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"$9.7 million","newsHeadline":"Bone Therapeutics to Regain Worldwide Rights to ALLOB","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alexion, AstraZeneca Rare Disease to Acquire LogicBio\u00ae Therapeutics to Accelerate Growth in Genomic Medicine","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$20.0 million","newsHeadline":"Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces $110 Million Underwritten Offering of Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"IMA203","moa":"TCR-T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"siRNA Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ochre Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ochre Bio \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ochre Bio .."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"RTx-015","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ray Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ray Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Ray Therap.."},{"orgOrder":0,"company":"Synergys Biotherapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synergys Receives Third NIH SBIR Grant from National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"SYN-001","moa":"Vasculogenic Mimicry","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synergys Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synergys Biotherapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Synergys B.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"$8.0 million","newsHeadline":"SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Bi.."},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives FDA Approval for VENTANA MMR RxDx Panel to Identify dMMR Solid Tumour Patients and pMMR Endometrial Cancer Patients Eligible for KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PDL1\/PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Roche Diagnostics GmbH \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diag.."},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's VENTANA PD-L1 (SP263) Assay Receives CE IVD Approval To Identify Patients With Locally Advanced And Metastatic Non-small Cell Lung Cancer Eligible For Libtayo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roche Diagnostics GmbH \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diag.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"TNFR1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"University of Michigan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin\u2019s Effect on Reducing Recurrent Heart Failure Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1\/2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ University of Michigan","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Aficamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b\/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Botaretigene Sparoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Patisiran","moa":"Mutated-TTR mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches First Biosimilar with ALYMSYS\u00ae (bevacizumab-maly) in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SVV-001","moa":"TEM8","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seneca Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seneca Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Seneca The.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ\u00ae AAC Platform\u2019s Potential as an Effective Red Blood Cell-Derived Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SQZ-AAC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-938","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"THE-349","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KP104","moa":"Complement system","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharm.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval from U.S. FDA for Darunavir Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Darunavir","moa":"HIV protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"NICE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Review Does Not Recommend Routine Funding For Duchenne Muscular Dystrophy Gene Therapy Ataluren In Draft Guidance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ataluren","moa":"80s ribosome","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ NICE","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka And Lundbeck Generate Exploratory Data In Major Depressive Disorder Based On Patient Feedback","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sapanisertib","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Phase 1\/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Botaretigene Sparoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MeiraGTx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8\u00ae in Healey ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"HSF-1 pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Baiya Phytopharm","sponsor":"3M Company","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"25 Baiya SARS-CoV-2 Vax 2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baiya Phytopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baiya Phytopharm \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"Baiya Phyt.."},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives FDA Approval For First Companion Diagnostic To Identify Patients With HER2 Low Metastatic Breast Cancer Eligible For ENHERTU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Roche Diagnostics GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Roche Diagnostics GmbH \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Roche Diag.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Receives IND Clearance for ONCT-808, its Autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ONCT-808","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Announces Review of Strategic Alternatives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Receives Positive CHMP Opinion For Jyseleca\u00ae European Label Update Based On Testicular Function Safety Data From MANTA\/RAy Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK 1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies\u2019 Trogarzo\u00ae Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibalizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Pivotal Data for Omburtamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA052","moa":"CD30","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-Weekly Insulin Icodec Demonstrates Superior Reduction In HbA1c In Combination With A Dosing Guide App Versus Once-daily Basal Insulin In People With Type 2 Diabetes In ONWARDS 5 Phase 3a Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson\u2019s Disease Associated with LRRK2 Pathogenic Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BIIB122","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ D.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imunon Reports Partial Results from Ongoing Non-Human Primate Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 DNA Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces Positive Results from Phase I\/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATSN-101","moa":"LCA1 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air\u00ae Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"113 Anti-tau Antibody","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Enalare Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Sunosi\u00ae (solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Launches A Non-Profit Patent Licensing Program To Enable The Field of CRISPR Editing in Prokaryotes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KVD824","moa":"Protease","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"Tregs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"BostonGene","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BostonGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BostonGene \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BostonGene.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Broadens Its International Presence with Nuceiva\u00ae Launch in Great Britain","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Commences Phase 2b Study of Trappsol\u00ae Cyclo\u2122 for the Treatment of Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcuro Initiates Phase 1\/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ABC008","moa":"KLRG1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abcuro, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Abcuro, Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Announces Positive Data From The US NIH-led ACTIV-2 Phase 2 Trial For SNG001 In Home-based Participants With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"IFN beta 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Talazoparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche To Present New Data From Its Expanding Neuromuscular Disease Portfolio At World Muscle Society 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"NextCure","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Announces Initiation of Phase 1b\/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Immune Checkpoint Refractory or Na\u00efve Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-201","moa":"MYBPC3 Gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ELI-005","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-101","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL\u2122 Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EB-101","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilacidin","moa":"HSPGs","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT\u2122 Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical\u2019s Proprietary Suprachoroidal Space Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clearside Biomedical \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poolbeg Pharma PLC Announces POLB 001 US Patent Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"POLB 001","moa":"p38","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Ph.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Supported Clinical Trial Of Phage Therapy For Cystic Fibrosis Begins","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"WRAIR_EPa11","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"National I.."},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1\/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Additional Indication For NUBEQA\u00ae (darolutamide) For The Treatment Of Metastatic Castration-sensitive Prostate Cancer (mCSPC) In Combination With Docetaxel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domain Therapeutics To Present New Data On Its EP4R and CCR8 Antagonists at 2022 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DT-9081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Century Therapeutics to Present at the SITC 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CNTY-101","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DEINOVE To Present Data On DNV3837 At The ESCMID\/ASM Conference in Dublin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxaquin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Deinove SAS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SA.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MiNK-413","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MiNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Osanetant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CCX559","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Announces Vitargus\u00ae Phase II Study Plan Approved by HREC in Australia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Showcase New Data at AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer\u2019s (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"23ME-00610","moa":"CD200R1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NC762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TNG260","moa":"CoREST-HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX130","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SNS-102","moa":"PSGL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IO102","moa":"IDO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-6-415","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LYL845","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-401","moa":"VSIG2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"STAT6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-101","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Six Poster Presentations at the Upcoming Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-1607","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer\u2019s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LX1001","moa":"APOE2 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eliem Therapeutics Provides Update on Pipeline Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ETX-155","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eliem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis to Present Pre-Clinical Data on TALEN-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic MUC-1 CAR T-cell Therapy","moa":"MUC1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Prokarium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Salmonella Typhi","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime\/Enmetazobactam Met Criteria for Superiority","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Enmetazobactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allecra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Th.."},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ICVB-1042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IconOVir Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir B.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer\u2019s Subjects","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"Neurotrophic factor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-101","moa":"ADCC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CMTX-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB248","moa":"IL-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Catamaran Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR\u2011NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CAT-248","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catamaran Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catamaran Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catamaran .."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Vudalimab","moa":"PD-1\/CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Repertoire\u00ae Immune Medicines Demonstrate Effectiveness of Its DECODE\u2122 Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals to Present LIVMARLI\u00ae (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Medikine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting (SITC 2022)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MDK-703","moa":"IL-7 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medikine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Navidea Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CD206 Activated Macrophage-payload Paclitaxel","moa":"CD206 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Navidea Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Navidea Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Navidea Bi.."},{"orgOrder":0,"company":"Regen BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Na\u00efve T Cells to Kill Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regen BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regen BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Regen BioP.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"sa-mRNA Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunitas Therapeutics to Present Preclinical Data on IMT-009 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMT-009","moa":"CD161","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THR\u03b2 Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC41","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TST004","moa":"MASP2","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VILTEPSO\u00ae (viltolarsen) Injection Four-Year Clinical Trial Data to be Presented at the World Muscle Society 2022 Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Achieves Primary Endpoint in PARA_OA_008 Synovial Fluid Biomarker Phase 2 Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGF2","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Model Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Model Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Model Medicines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Model Medi.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HL161ANS","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Bio.."},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dichloroacetic Acid","moa":"PDK","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Saol therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Saol therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Saol thera.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"CD103","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology to Present Initial Phase 1a\/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-175","moa":"AHR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Acetaminophen Analog","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Japan Announces Positive Results With Daridorexant In A Phase 3 Study Of Japanese Patients With Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"WVE-004","moa":"C9orf72 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes The First Pharmaceutical Company To Launch Lobeglitazone In India For Uncontrolled Type 2 Diabetes In Adults","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lobeglitazone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ENA-001","moa":"Potassium ion channel","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Enalare Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enalare Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enalare Th.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Announces Results from Phase 3 Alzheimer\u2019s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Initiates Industry\u2019s First Allogeneic CAR T Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-501A","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO\u00ae (lumasiran) in Advanced Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO\u2122 (molnupiravir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic M1\/M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProDERM Study Results of Octagam\u00ae 10% Treatment in Patients With Dermatomyositis Published in the New England Journal of Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"IgG","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces Peer-Reviewed Publication of Thykamine\u2122 Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Non-viral Gamma Delta T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Imvax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 SITC Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imvax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ No.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe Conferences in October 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Wellbeing Digital Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science Corp","highestDevelopmentStatusID":"6","companyTruncated":"Wellbeing .."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE\u2122 Platform at Next Generation Undruggable Conference","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VENT-01","moa":"NLRP3","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Announces Health Canada Approval for Cationorm\u00ae Plus to Relieve the Symptoms of Dry Eye and Ocular Allergy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Glycerine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Provides Update on its Intellectual Property Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Present Data from the Phase 1 DRAGON Trial at the SITC 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SRK-181","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ICON Selected By BARDA To Conduct Anthrax Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AV7909","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/.."},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caraway Therapeutics to Present at The Michael J. Fox Foundation\u2019s Parkinson\u2019s Disease Therapeutics Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"TRPML1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Caraway Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caraway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Caraway Th.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"C21","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Compugen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen to Present New Clinical and Research Data in Two Oral Presentations at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Compugen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces FDA Authorization to Proceed with Phase 2\/3 Trial for Buntanetap in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Approval of Phexxi in Nigeria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1\/2 Clinical Trial of MB-106, a First-in-Class CD20-Targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Applied Biology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Initiates Clinical Trial for Potential New Treatment for Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimozide","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Safety Shot \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Upifitamab Rilsodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LYL845","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Provides Further Insights Into The Treatment Of Ulcerative Colitis At The Upcoming United European Gastroenterology (UEG) Week 2022 Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK 1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines to Participate at Upcoming Conferences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-103","moa":"Phenylalanine ammonia lyase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"GTB-3550","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Bharat biotech","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ B.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paladin Phase 4 Study Confirms ILUVIEN\u00ae Patients' Reduced Need for Multiple Treatments","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CRN04777","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric Auto Antibody Receptor T Cells","moa":"EC 1\/2\/3\/4","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Toragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toragen, Inc. Announces Chief Medical Officer to Drive the Company\u2019s Clinical Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TGN-S11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Toragen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toragen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Toragen \/ .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM\/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Approval of XERAVA\u00ae in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Eravacycline","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Galderma's Aesthetics Portfolio To Be Presented At 2022 ASDS Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"ACh","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MSC-NTF Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated In Clarity's Therapeutic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SAR-bisPSMA","moa":"Ionising radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Triple Antigen VLP Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Presents New Qwo\u00ae (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum-aaes","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Theolytics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theolytics Presents CAF-Targeting Therapy For Stromal Rich Tumours, And Strengthens Leadership Team","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"THEO-260","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theolytics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1\/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LAVA-051","moa":"CD1d","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"ProLynx","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProLynx Announces Initiation Of Phase II Clinical Trial Of Its DNA-Damaging Agent PLX038 in Patients With Platinum-resistant Ovarian Cancer at the Mayo Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Oncorus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA\/LNP Platform for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ONCR-788","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncorus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncorus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncorus \/ .."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PHA121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BBP-454","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"NeoTCR-P1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PACT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"AnaptysBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Headline Results From PERLA, The Phase II Trial Of Jemperli (dostarlimab) Plus Chemotherapy In Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ AnaptysBio","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Anap.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech\u2019s Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"CNS","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPh.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts Takeda\u2019s Supplemental Biologics License Application for Use of TAKHZYRO (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-Driven Lung and Thyroid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The China NMPA Approved CYRAMZA\u00ae (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ramucirumab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an Oral Small Molecule GLP-1 Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"XW014","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Announces U.S. Launch of PKU GOLIKE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Amino Acids Mixture","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data Update on ACTengine\u00ae IMA203 TCR-T Monotherapy Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"TCR-T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene\u00ae, an Investigational Hormone-Free Monthly Intravaginal Contraceptive","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ferrous Gluconate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Aravive","sponsor":"3D Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Receives Third Development Milestone from 3D Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ 3D Medicines","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Receives First Agencies Authorizations To Initiate Confirmatory Phase 3 Clinical Study With Masitinib In The Treatment Of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Levosimendan","moa":"K-ATP channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Provides Regulatory Update on SPN-830","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SPN-830","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart to Present at World Vaccine Congress Europe 2022 on October 13","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1.1-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FDA Approval of FUROSCIX\u00ae (furosemide injection), the First and Only Self-Administered, Subcutaneous Loop Diuretic for the At-Home Treatment of Congestion in Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SZN-043","moa":"Wnt signalling pathway","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"TIL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Pace Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Pace Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"ARSA gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Phase II\/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"Syk","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Renovacor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-based Gene Therapy","moa":"BAG3 Gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor .."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces First Patient Dosed in Pivotal Study of Litifilimab in Cutaneous Lupus Erythematosus, an Autoimmune Disease Affecting Skin","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Litifilimab","moa":"BDCA2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves BOOSTRIX For Immunisation During Pregnancy For The Prevention Of Whooping Cough In Newborn Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetanus Toxoid Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STELARA\u00ae (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Top-Line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotatercept","moa":"ActRIIA-Fc","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"PellePharm","sponsor":"Phyton Biotech LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Patidegib","moa":"Hedgehog pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"PellePharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"PellePharm \/ Phyton Biotech","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Immune-Onc Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immune-Onc Therapeutics Enters into Clinical Collaboration with BeiGene in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"IO-108","moa":"LILRB","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Immune-Onc","highestDevelopmentStatusID":"4","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Illumina","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Illumina \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","amount":"$138.6 million","upfrontCash":"$20.8 million","newsHeadline":"HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ CSPC NBP Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aadi Bioscience \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$496.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"AMPK","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0.5,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Dualsystems Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Dualsystems Biotech","highestDevelopmentStatusID":"2","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Abu Dhabi Growth Fund","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neumora Therapeutics Announces $112 Million Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series B Financing","leadProduct":"Navacaprant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0.11,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Abu Dhabi Growth Fund","highestDevelopmentStatusID":"8","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$246.3 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"PsychoGenics","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"KAR-501","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PsychoGenics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PsychoGeni.."},{"orgOrder":0,"company":"Omniose","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines Against Klebsiella Pneumoniae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Bioconjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Omniose","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omniose \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Omniose \/ .."},{"orgOrder":0,"company":"ONI","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONI and the University of Pennsylvania Start Research Collaboration to Identify Unique Biomarkers and Characteristics to Guide Next Generation CAR-T Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ONI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ONI \/ University of Pennsylvania","highestDevelopmentStatusID":"1","companyTruncated":"ONI \/ Univ.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and IASO Biotherapeutics Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CABA-201","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.16,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"IASO Bio \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"VolitionRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xenetic Biosciences \/ VolitionRx","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Bi.."},{"orgOrder":0,"company":"Eyam Vaccines and Immunotherapeutics","sponsor":"Mitacs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyam Announces Partnership with Mitacs to Fund Next Generation COVID-19 Vaccine Technologies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Self-amplifying mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eyam Vaccines and Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eyam Vaccines and Immunotherapeutics \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Eyam Vacci.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Exercises Option To License Proprietary Targeting Technology From Autolus","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Moderna","highestDevelopmentStatusID":"1","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Inceptor Bio","sponsor":"Avectas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inceptor Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inceptor Bio \/ Avectas","highestDevelopmentStatusID":"4","companyTruncated":"Inceptor B.."},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"OmniAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IPA\u2019s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"OmniChicken-derived Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Talem Therapeutics \/ OmniAb","highestDevelopmentStatusID":"3","companyTruncated":"Talem Ther.."},{"orgOrder":0,"company":"Agenus","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Balstilimab","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ VBI Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Agenus \/ V.."},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Cambrian BioPharma","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series B Financing","leadProduct":"VTA-100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vita Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vita Therapeutics \/ Cambrian BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"Vita Thera.."},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuron Strategic Investment in Leading Gut Health Biotech Ateria Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ateria Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"12","companyTruncated":"Ateria Hea.."},{"orgOrder":0,"company":"Enterin","sponsor":"Parkinson\u2019s Virtual Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enterin and Parkinson\u2019s UK Announce Research Collaboration in Parkinson\u2019s Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"ENT-01","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Parkinson\u2019s Virtual Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ .."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"DICE Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","amount":"$448.0 million","upfrontCash":"$17.5 million","newsHeadline":"Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros The.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Trabedersen","moa":"TGF beta-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"CD8+ T-cell Adaptive Vaccine","moa":"CD8+","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Bone Biologics","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"NELL-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bone Biologics \/ WallachBeth Capital","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biolo.."},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","amount":"$168.0 million","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Th.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.13,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Allergy Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA\u00ae [Peanut (arachis hypogaea) Allergen Powder-dnfp] Directly to Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Arachis Hypogaea","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Allergy Partners","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Allomek","sponsor":"Camac Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Acquires AlloMek Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"CIP-137401","moa":"MEK1\/2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allomek \/ Camac Partners","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Good Works II Acquisition Corp.","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"$75.0 million","newsHeadline":"Good Works II Acquisition Corp. and Direct Biologics, LLC Announce a Definitive Agreement for a Business Combination","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"ExoFlo","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0.080000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Good Works II Acquisition Corp.","highestDevelopmentStatusID":"10","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Toregem BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"TRG035","moa":"USAG1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Toregem BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Oculis","sponsor":"European Biotech Acquisition Corp","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oculis SA and European Biotech Acquisition Corp Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Driving Breakthrough Innovations in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Merger","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.080000000000000002,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ European Biotech Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ E.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gavi, Moderna Update COVAX Supply Agreement; Agree on Access to Variant-Containing Vaccines for Lower-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Gavi","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferring Pharmaceuticals and Blackstone Life Sciences Restructure Novel Gene Therapy Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Nadofaragene Firadonavec","moa":"INF alpha 2b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ferring Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Camford Capital","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"SURGE Therapeutics Raises $26M Series A Financing to Accelerate Development of Intraoperative Immunotherapy to Improve Survival Outcomes Post-Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SURGE Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"SURGE Therapeutics \/ Camford Capital","highestDevelopmentStatusID":"4","companyTruncated":"SURGE Ther.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"LILRB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inversago Pharma Raises $95 million CAD in Series C Financing","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series C Financing","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ New Enterprise Associates","highestDevelopmentStatusID":"8","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Exacis Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exacis Biotherapeutics Grants Eterna Therapeutics An Option To License Up To Four Allogeneic Ipsc-Derived Nk And T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ExaNK","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Exacis Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Eterna The.."},{"orgOrder":0,"company":"ASEP Medical","sponsor":"Bohai Biomedical Technology Development Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility of Peptide-based Oral Rinse for the Chinese Market","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"ASEP Medical \/ Bohai Biomedical Technology Development Co.","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medic.."},{"orgOrder":0,"company":"Mendus","sponsor":"Minaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mendus AB: Mendus Secures Manufacturing Partner For Establishing Potential Pivotal Trial-stage And Commercial Production Of DCP-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Minaris","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ M.."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0.34999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Tovorafenib","moa":"Type II Pan-RAF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Day One Biopharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Verona Pharma \/ Oxford Finance LLC","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Cancer Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"KVA12123","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ M.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$566.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Tivozanib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.56999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.56999999999999995,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ LG Chem","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Naltrexone Therapeutics","sponsor":"Love Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Love Pharma Signs Letter of Intent to Acquire Naltrexone Therapeutics Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Naltrexone Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Naltrexone Therapeutics \/ Love Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Naltrexone.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anokion Announces $35 Million Equity Investment from Pfizer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0.040000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS\u00ae T Cell Therapy for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ARTEMIS T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Nanoscope Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"vMCO-010","moa":"MCO gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Empyrean Neuroscience","sponsor":"Veteran biotech","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"Psilocybin Derivative","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Empyrean Neuroscience","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Empyrean Neuroscience \/ Veteran biotech","highestDevelopmentStatusID":"5","companyTruncated":"Empyrean N.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.13,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sebela Pharmaceuticals\u00ae Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Tegoprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"BRAINTREE LABS","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BRAINTREE LABS \/ SEBELA PHARMACEUTICALS INC","highestDevelopmentStatusID":"10","companyTruncated":"BRAINTREE .."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Arformoterol Tartrate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Inhalation Solution","sponsorNew":"Sunovion Pharmaceuticals \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Merger","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Nucleome Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$43.2 million","upfrontCash":"Undisclosed","newsHeadline":"Nucleome Therapeutics Raises Oversubscribed \u00a337.5 Million Series A Financing to Decode the Dark Matter of The Human Genome and Deliver First-In-Class Precision Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nucleome Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Nucleome Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nucleome T.."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"PIC Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PIC Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"PIC Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"2","companyTruncated":"PIC Therap.."},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Engineered Cytokines","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Orionis Biosciences \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Bi.."},{"orgOrder":0,"company":"Hemispherian","sponsor":"EIC fund","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Hemispherian Secures EUR 10M in Financing from the European Innovation Council (EIC) Accelerator Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"GLIX1","moa":"TET2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Hemispherian \/ EIC fund","highestDevelopmentStatusID":"4","companyTruncated":"Hemispheri.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Mountain Crest Acquisition Corp. V","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Merger","leadProduct":"AUM001","moa":"MNK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Recombinant Iduronate 2 Sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"Denali Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Trethera","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ITM-31","moa":"CA XII","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Isotope Technologies Munich","highestDevelopmentStatusID":"4","companyTruncated":"Helmholtz .."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Syncromune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"YH002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"QBKPN SSI","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Tempus","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK Announces Expanded Collaboration With Tempus In Precision Medicine To Accelerate R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Tempus \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ G.."},{"orgOrder":0,"company":"DJS Antibodies","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$255.0 million","newsHeadline":"AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"DJS-002","moa":"LPAR1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"DJS Antibodies","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DJS Antibodies \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"DJS Antibo.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen Successfully Completes Acquisition of Chemocentryx","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Signs Grant Agreement to Advance Innovation in Non-Hormonal Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Yoshindo","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Yoshindo","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Yoshindo \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Yoshindo \/.."},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$487.0 million","upfrontCash":"$487.0 million","newsHeadline":"Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.48999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ E.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$214.2 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.20999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"IMU-935","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Refuge Biotechnologies","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Refuge Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Refuge Biotechnologies \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Refuge Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"MK-7762","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Novo Nordisk Announces the Completion of The Forma Therapeutics Acquisition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":1.1000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Zedira","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"TAK-227","moa":"TG2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Zedira","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zedira \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"Zedira \/ T.."},{"orgOrder":0,"company":"Galecto","sponsor":"Providence Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galecto\u2019s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"GB1211","moa":"Galectin-3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ Providence Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NMD670","moa":"CIC-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Gets US & European Patents Covering Processes For Manufacturing Allogeneic Oligodendrocyte Progenitor & Retinal Pigmented Epithelium Cells","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Therapy-1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay\u00ae (odevixibat) in Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Announces Pre-IND Meeting Request Granted by FDA for Its New Chemical Entity Triptax\u2122 Targeting Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Triptax","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AC0682","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1\/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon to Present on Phase 1\/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"E-602","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-ANG3","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venatorx Pharmaceuticals to Present at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cefepime","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces Details of Poster Presentation of a Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta at Vaccine Summit 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BAT2022","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1\/2 Gene Therapy Trial for Patients with Krabbe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10-hGALC","moa":"GALC gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forge Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Announces Phase 1\/2 EXPLORE44\u2122 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AOC 1044","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Discogenic Progenitor Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics.."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noven To Present Poster Data At The American Academy Of Child And Adolescent Psychiatry (Aacap) And Canadian Academy Of Child And Adolescent Psychiatry (Cacap) Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Phar.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Over-the-Counter Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application (NDA) to U.S. Food and Drug Administration for RiVive\u2122 (3.0 mg intranasal naloxone) for Emergency Treatment of Opioid Overd","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Announces Data Highlighting Pravibismane's Effect on Bacterial Energetics Presented at ASM Microbe 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"For Suspension","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Totus Medicines CEO to Present at Next-Generation Undruggable Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TOS-358","moa":"PI3K alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Totus Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medi.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna\u2122 at the Annual Congress of the World Muscle Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic Uremic Syndrome with First-in-class CRISPR-based medicine","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EB003","moa":"STEC bacteria","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eligo Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bios.."},{"orgOrder":0,"company":"Caring Cross","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caring Cross Announces Dosing of First Participant in Anti-HIV DuoCAR-T Cell Therapy Phase 1\/2a Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"duoCAR-T Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Caring Cross","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caring Cross \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"Caring Cro.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Announces Positive Data From Phase 1 Clinical Study For OX640 - A Nasal Epinephrine Rescue Medication For Allergic Reactions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Vaxart","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syngene Set For Phase-2 Trial Of Covid Oral Tablet Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VXA-CoV2-1.1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syngene International Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syngene International Limited \/ Vaxart","highestDevelopmentStatusID":"8","companyTruncated":"Syngene In.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma to Present Full Phase 2a Data on AZP-3601 at Upcoming Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive New Data For Roche\u2019s Evrysdi In Largest Trial Ever Undertaken In Patients With Previously-treated Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Presents Data on Two TALEN\u00ae-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis Type I at ESGCT 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"IDUA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-251","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Pan-RAF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates DAZALS \u2013 A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dazucorilant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody\u2122, ADG116, at Upcoming Society for Immunotherapy of Cancer\u2019s (SITC) Annual Meeting in November","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ADG116","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"VEGFR 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BWV-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blue Water Vaccines \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences\u2019 Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Launches CAR T Together\u2122, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for \u201cOff-The-Shelf\u201d Allogeneic Cell Therapy Investigational Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SEL-302","moa":"AAV gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"TeraImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TeraImmune Receives FDA IND Clearance to Initiate Phase 1\/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TI-168","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Niclosamide","moa":"mTOR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Engineered Hematopoietic Stem Cell","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1\/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen\u2019s LUMAKRAS\u00ae (sotorasib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BBP-398","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT\u2011240","moa":"AOPE gene","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Headline Results From Phase I Clinical Trial Of Ultra-rapid Acting Insulin Candidate AT247 Demonstrate Significantly Accelerated Insulin Absorption And Early Exposure Compared To Gold Standard Insulins NovoLog\u00ae And Fiasp\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ultra Rapid Acting Prandial Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DC-806","moa":"IL-17","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DICE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER\u2122 Generated Capsid Families","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"113 Anti-tau Antibody","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Chameleon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chameleon Biosciences Presents Poster on AAV Gene Therapy Redosing Success at ESGCT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"AAV8 IgG","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Chameleon Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chameleon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chameleon .."},{"orgOrder":0,"company":"Amniotics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amniotics Announces First Patient Dosed In Phase Ib Study With PulmoStem To Treat Severe Viral Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PulmoStem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Amniotics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amniotics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amniotics .."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"JANX007","moa":"PSMA\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma\u2019s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Chymotrypsinogen","moa":"Chymotrypsinogen enzyme","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian to Present Thykamine\u2122 Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Presents Long-Term LIVMARLI\u00ae (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bendamustine","moa":"MCT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"STX-721","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces New UPLIZNA\u00ae (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EVM201","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FX-322","moa":"Stem Cell","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Aims To Advance NMOSD Treatment Landscape With Exceptional ULTOMIRIS\u00ae (ravulizumab-cwvz) Efficacy Data at ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Provides Development Update for Otenaproxesul","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterium Stabilized (R)\u2010Pioglitazone","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Presentation Of Analysis Of Time Between Seizure Clusters With Valtoco\u00ae (Diazepam Nasal Spray) Civ At The 2022 Annual Meeting Of The Academy Of Managed Care Pharmacy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics to Present Research on PT-112 in Prostate Cancer at the 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces Poster Presentation on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/ binding protein beta inhibitor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2101","moa":"c-Myc cell proliferation","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Maiden Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Govt Forms Panel To Study WHO Report On Deaths Of 66 Gambian Children Linked To 4 Indian Syrups","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Promethazine","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Maiden Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Maiden Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Maiden Pha.."},{"orgOrder":0,"company":"Love Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Love Pharma - Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Love Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Love Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Love Pharm.."},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clairvoyant's Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyan.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4\/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CD27","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-103","moa":"AAV5 vectors gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Late Breaking Presentation On The Successfully Completed ERADICATE Phase 3 Study With Ceftobiprole In Staphylococcus Aureus Bacteremia (SAB) at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces IND Approval for Yuyuan Bioscience\u2019s Phase 1 Clinical Trial of Nolasiban in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nolasiban","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Yuyuan Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Y.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen\u00ae in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Completion of Dosing in OCU400 Phase 1\/2 Cohort 2","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX \u00ae (tecovirimat) for Treatment of Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Patent & Trademark Office Allows AVEO Oncology\u2019s Patent Application Covering Use of FOTIVDA\u00ae for the Treatment of Refractory Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adintrevimab","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Preclinical Data In Melanoma And Squamous Cell Carcinoma, Initiates A Program Aimed At Advancing Topical Therapies For Skin Cancer To The Clinic","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Crisaborole","moa":"Nrf2","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Acinetobacter baumannii enzyme","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"exoVACC","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Onc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OP-1250","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ University of Minnesota","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC\/NCI\/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MCLA-129","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KUR-101","moa":"MOR","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KB-0742","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/CDK19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Presentation Of Analysis Of Time Between Seizure Clusters With VALTOCO (Diazepam Nasal Spray) CIV At The 2022 Annual Meeting Of The Academy Of Managed Care Pharmacy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"SiSaf","sponsor":"CSSi LifeSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SiSaf's Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SIS-101-ADO","moa":"CLCN7 gene mutation","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ CSSi LifeSciences","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ CS.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Aims To Advance NMOSD Treatment Landscape With Exceptional ULTOMIRIS (ravulizumab-cwvz) Efficacy Data At ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Older Adult Respiratory Syncytial Virus (RSV) Vaccine Candidate Shows 94.1% Reduction In Severe RSV Disease And Overall Vaccine Efficacy Of 82.6% In Pivotal Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AS01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstrating Efficacy of Nangibotide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nangibotide","moa":"TREM-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OTO-413","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Biopharma Submitted Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV9-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Lucy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lucy Therapeutics Debuts Novel Therapeutic Agents for Parkinson\u2019s Disease at Michael J. Fox Foundation Annual Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LucyTx-1209","moa":"F1F0-ATPase","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Lucy Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lucy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lucy Thera.."},{"orgOrder":0,"company":"Epic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epic Bio Presents Proprietary Gene Expression Modulation System (GEMS) Demonstrating Precise Engineering of DUX4 Gene in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EPI-321","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant to Present Data from Multiple Clinical Trials of VTAMA\u00ae (tapinarof) Cream, 1% at the 2022 Fall Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc to Present New Data on TEPEZZA\u00ae (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Namodenoson","moa":"A3AR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"4P-004","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Bi.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Presents Novel, Investigational Analysis Of Valtoco\u00ae (diazepam nasal spray) Civ Demonstrating Increased Time Between Seizure Clusters At The 51St Child Neurology Society Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNBX Patent Application \"Composition and Method for Treating Cancer with Cannabinoids\" Enters National Phase in US and Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CNBX RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Reports Positive Interim Phase 1\/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INO-3107","moa":"HPV6\/HPV11","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HBM7008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR\u00ae in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive New Data for Genentech\u2019s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumoni","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CAL02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Atara Biotherapeutics\u2019 Ebvallo\u2122 (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan\u00ae\/Reeqonus\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Novan","sponsor":"EPI Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ EPI Health","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ EP.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics to Present in Upcoming Conferences","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-125755","moa":"siRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BBP-418","moa":"Alpha-dystroglycan","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion for Pluvicto\u00ae for Patients with Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Dr. Rick Strassman Author of \u201cDMT: The Spirit Molecule\u201d to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-9167","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Advances Tollovir\u2122: 3CL Clinical Trials to Phase 2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NLC-V-01","moa":"3CL protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology\u2019s Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Eravacycline","moa":"30S Ribosomal subunit","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"La Jolla Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"La Jolla Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"La Jolla P.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Conditional Marketing Authorization For Spesolimab As First In Class Treatment Option For Generalized Pustular Psoriasis Flares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Spesolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"NeoPharm Co., Ltd.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI\u00ae (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ NeoPharm","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"9vHPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology\u2019s Kidney Week 2022 Annual Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives Positive CHMP Opinion for BRUKINSA\u00ae (zanubrutinib) for the Treatment of Adults With CLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Platelet aggregation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala\u00ae (mepolizumab)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"2-deoxy-d-glucose Prodrug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CRB-601","moa":"AlphaVbeta8 integrin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Announces FDA IND Clearance for PT217, an Anti-DLL3\/Anti-CD47 Bispecific Antibody Being Developed For Patients With Small Cell Lung Cancer And Other Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PT217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reaches Recruitment Milestone And Focuses Nadunolimab Development On Upcoming Randomized Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"IL1RAP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Is Developing Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1\/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Drebuxelimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso's Cadonilimab (PD-1\/CTLA-4 Bi-specific) Included in the 2022 CSCO Guidelines as the Top Recommendation for Cervical Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Acne Vulgaris in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute to Produce Ebola Vaccine for Use in Uganda Outbreak","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1 biEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ University of Oxford","highestDevelopmentStatusID":"6","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Medpace","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"YH008","moa":"CTL4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS\u00ae T cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ET140203","moa":"Alpha fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Xeruborbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qpex Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Bioph.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-323","moa":"L-protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noven To Present Data For: Extrapolating Pediatric Transdermal ADHD Treatment Efficacy Data To Adult Populations And Correlating Treatment Effect Duration With Patch Wear Times At American Psychiatric Nurses Association Annual Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Phar.."},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum Toxin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eirion Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eirion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eirion The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces Publication of Vyleesi\u00ae (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"MCR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Crofelemer","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SNK02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3K\u03b1:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BBO-8520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 Without the Need for a Ritonavir Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM\u2019s Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 \/ 2 Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-SLB101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces FDA\u2019s 3-Month Extension of Review Period for the New Drug Application for Tofersen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta\u00ae (metreleptin)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Metreleptin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Attralus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic\u2019s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus To Report Positive Clinical And Preclinical Data In Ovarian Cancer At The European Society Of Gynaecological Oncology 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Dicot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicot Has Submitted A New Patent Application","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LIB-01","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dicot","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicot \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dicot \/ No.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Menveo in a New Single-vial Presentation To Help Prevent Disease Caused By Meningococcal Bacteria Serogroups A, C, Y, and W","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Meningococcal Groups A, C, Y, and W-135 Diphtheria Vaccine","moa":"Capsular polysaccharides","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ENOB-DC-11","moa":"Treg","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1\/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Submits Response to CRL from FDA for RIZAPORT\u00ae VersaFilm\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals\u2019 LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol\u00ae Cyclo\u2122 for the Treatment of Niemann-Pick Disease Type C1 (NPC1)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an ongoing Phase 2 Trial of Lerapolturev in Anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lerapolturev","moa":"CD155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Istari Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Istari Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Istari Onc.."},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO\u00ae (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington\u2019s Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Assia Chemical Industries Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assia Chemical Industries Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Assia Chem.."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"ACh receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"LENZ Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avilar Therapeutics to Present New In Vivo Proof-of-Concept Data for ATAC Extracellular Protein Degraders at Upcoming Drug Discovery Conferences","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Avilar Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avilar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avilar The.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KYV-101","moa":"CD19","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase 2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-101a","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alphyn Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Bio.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PTC518","moa":"HD protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CNBX RCC-33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SK10","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Zhiyi Biotech","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhiyi Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zhiyi Biot.."},{"orgOrder":0,"company":"Origin Therapeutics","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Origin Therapeutics\u2019 Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Origin Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Origin Therapeutics \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Origin The.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO\u00ae and Selection of Tolmar, Inc. as Successful Bidder","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"Serine protease","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP800","moa":"HSF1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"Polykinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma Receives FDA Fast Track Designation for Basimglurant (NOE-101) in Trigeminal Neuralgia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Basimglurant","moa":"mGluR5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present the AURELIO-04 Phase 2 Study Design and Findings from BOXR Research at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CLS-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Publishes New Data Evaluating Chlormethine Gel\u2019s Mode Of Action In Dermatology And Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Mechlorethamine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PRT3789","moa":"SMARCA2 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-930","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Invios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"invIOs To Present Data From Clinical Stage Cbl-b Program At SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"siRNA-transfected Peripheral Blood Mononuclear Cells","moa":"Cbl-b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invios \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ N.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LX1004","moa":"TPP1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Present Data on Pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute\u2019s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-097558","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EV104","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmu.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound's EscharEx\u00ae Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FR\u03b1), in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ITIL-306","moa":"FOLR1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Providence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark becomes the First Company in India to Launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, having Comorbidities","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teneligliptin Hydrobromide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura\u2122) in Vitiligo Published in New England Journal of Medicine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AZR-MD-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics\u2019 ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Tvardi Therapeutics\u2019 TTI-101 for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja\u00ae (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek\u2122 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-235","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Longhorn Vaccines & Diagnostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longhorn Vaccines and Diagnostics to Present at Infectious Disease Week 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AddaVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Longhorn Vaccines & Diagnostics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longhorn Vaccines & Diagnostics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Longhorn V.."},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OTT166","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra T.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO\u00ae (budesonide) in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA-Approved Biologic Medication for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Benztropine","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Islatravir Prodrug","moa":"NRTI","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals to Present New Data Highlighting Future Assisted Reproductive Technology Market Trends at ASRM 2022 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Merotocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"APG-1387","moa":"IAP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Reports Excellent Rotigotine In-Vitro\/Ex-Vivo Results for Parkinson's Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"XPhyto \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY\u00ae in Children 6 Months to Less than 5 Years in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"F3-8-60","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SP-3164","moa":"Cereblon","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-VV200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Epetraborole","moa":"Leucyl-tRNA synthetase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MNPR-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second United States Patent Granted for Small Pharma\u2019s Psychedelics Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL\u2122 Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TNG908","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"VIB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ VIB","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie\u2019s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domain Therapeutics To Progress Into Clinical Trials With Its EP4R Antagonist DT-9081 In Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DT-9081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche To Present New OCREVUS (ocrelizumab) Data In Multiple Sclerosis And Continued Research Into Neuromyelitis Optica Spectrum Disorder At ECTRIMS 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO and Selection of Tolmar, Inc. as Successful Bidder","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-pharma Provides Business Update And Outcome Of Pre-planned Interim Futility Analysis Of Phase 3 Revival Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"A2AR","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDWeek Data Reinforces AstraZeneca\u2019s Commitment To Advance Science In Vaccines And Immune Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Aims To Advance NMOSD Treatment Landscape With Exceptional Ultomiris Efficacy Data At ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Expands Development Program For Elinzanetant With Phase III Study In Breast Cancer Patients With Vasomotor Symptoms Caused By Endocrine Therapy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirena\u00ae Approved In Europe For Extended Duration Of Use In Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Insert","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Sage Therapeutics Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead\u2019s Trodelvy\u00ae for Pre-Treated HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Regulatory Submission Accepted By Japanese Regulator For Respiratory Syncytial Virus Older Adult Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Shingrix Can Provide At Least 10 Years Of Protection Against Shingles In Adults Aged 50 Years And Over","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Zoster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK To Present Updates On Its Industry-leading Infectious Disease Portfolio At IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ema Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European\nUnion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Elasomeran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"90-Day Analysis Shows Moderna\u2019s Omicron BA.1- Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-634","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data Update on ACTengine\u00ae IMA203 TCR-T Monotherapy Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Esmethadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Reldesemtiv","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA\u00ae (zanubrutinib) Compared to IMBRUVICA\u00ae (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"Exon 51","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EYLEA\u00ae (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat at the Upcoming 29th International Society of Hypertension 2022 Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Preliminary Results For Major Brivaracetam (Briviact[\u00ae]) Study In Asia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Duchesnay","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA Approved Treatment for the Chronic Management of Urea Cycle Disorders (UCDs)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Duchesnay","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granule","sponsorNew":"Duchesnay \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay .."},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for Treatment of Relapsed or Refractor Peripheral T-Cell Lymphoma Now Approved by Ministry of Health, Labour and Welfare (Japan)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Darinaparsin","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Solasia Pharma KK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Solasia Pharma KK \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"Solasia Ph.."},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"NeuBase Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuBase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"NeuBase Th.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"$27.0 million","newsHeadline":"Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Divestment","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Undisclosed","amount2":0.080000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Undisclosed \/ Altamira Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Agtc","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syncona to Acquire Applied Genetic Technologies Corporation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"AGTC-501","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Syncona","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Syn.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"USAID","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"On World Polio Day 2022, PharmaJet Announces $1.5 Million Grant From USAID to Evaluate Use of Needle-Free Delivery in Routine Polio Immunization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Fractional Inactivated Poliovirus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaJet \/ USAID","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Griffith University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LimmaTech Enters Exclusive License and Collaboration Agreement with Griffith University to Expand its Vaccine Technology Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Gonococcal Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LimmaTech Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Griffith University","highestDevelopmentStatusID":"4","companyTruncated":"LimmaTech .."},{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eleusis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"6","companyTruncated":"Eleusis \/ .."},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"LUT017","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Lutris Pharma","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Lutris Pha.."},{"orgOrder":0,"company":"Rutgers University","sponsor":"Sauvie Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sauvie Inc. Enters into an Exclusive Worldwide License Agreement to Develop and Commercialize a Nanobody-based NK Cell Engager","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Nanobody-based NK Cell Engager","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rutgers University \/ Sauvie Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers Un.."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Closing of Upsized Initial Public Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$316.0 million","upfrontCash":"Undisclosed","newsHeadline":"Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"Recombinant Iduronate 2 Sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0.32000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Infusion","sponsorNew":"Denali Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","amount":"$56.1 million","upfrontCash":"Undisclosed","newsHeadline":"VectorBuilder Secures CNY410M in Series C Round","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0.059999999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuil.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Announces $150 Million Private Placement to New and Existing Investors, Led by Kinnevik AB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Kinnevik AB","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces $35 Million Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series B Financing","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Lightswitch Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Normunity","sponsor":"Canaan Ventures","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Normunity Announces $65 Million Series A Financing to Expand the Frontier of Precision Immuno-Oncology With Immune Normalizer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series A Financing","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Normunity","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Normunity \/ Canaan Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Normunity .."},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$24.5 million","upfrontCash":"Undisclosed","newsHeadline":"Micreos\u2019 Alternative to Antibiotics Secures Next \u20ac25 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"XZ.700","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Hu.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Bioscience and CEPI Sign Agreement to Develop mRNA Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","amount":"$13.7 million","upfrontCash":"Undisclosed","newsHeadline":"Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"ATX-01","moa":"MBNL protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ARTHEx Biotech","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ARTHEx Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"5","companyTruncated":"ARTHEx Bio.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Meteva AS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BerGenBio ASA Secures NOK 100 Million Shareholder Loan Facility from Meteva AS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Meteva AS","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Modifi Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"MGMT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Modifi Bio \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio.."},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ .."},{"orgOrder":0,"company":"Aravive","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$41.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aravive Announces Approximately $41.5 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Aravive \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone Bio Announces Private Placement of $45.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Private Placement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha\u2019s AAV-based Gene Therapy Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"TSHA-102","moa":"MECP2 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.050000000000000003,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ Astellas","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"AVANIR PHARMS","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avanir Pharmaceuticals, Inc. Business Will Be Integrated Into Otsuka America Pharmaceuticals, Inc. as of January 1, 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Merger","leadProduct":"Deudextromethorphan Hydrobromide","moa":"MAO","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AVANIR PHARMS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"AVANIR PHA.."},{"orgOrder":0,"company":"Proteros","sponsor":"Adrestia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Proteros and Adrestia Initiate Multi-Target Partnership to Discover First-In-Class Drugs for Intractable Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Proteros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteros \/ Adrestia Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Proteros \/.."},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Epoetin Alfa","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"JSR Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"JSR Life Sciences \/ Blau Farmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"JSR Life S.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Ataluren","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Granules for Oral Suspension","sponsorNew":"PTC Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$9.0 million","newsHeadline":"Aquestive Therapeutics Licenses Sympazan\u00ae (clobazam) Oral Film to Assertio Holdings, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clobazam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Emergent BioSolutions","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"TSHA-102","moa":"MECP2 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Taysha Gene Therapies","amount2":0.029999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Clarus Therapeutics","sponsor":"Tolmar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tolmar Announces Acquisition of JATENZO\u00ae (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Clarus Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clarus Therapeutics \/ Tolmar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Clarus The.."},{"orgOrder":0,"company":"XtalPi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XtalPi Announces Research Collaboration with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ J.."},{"orgOrder":0,"company":"ImmVira","sponsor":"China Merchants China Direct Investments","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Imm Vira Announced Its Signing of Series C+ Financing and Negotiation with Further Investors for The Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmVira \/ China Merchants China Direct Investments","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"2seventy Bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"TCR T-cell Therapy","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"2Seventy Bio \/ JW Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","amount":"$131.8 million","upfrontCash":"Undisclosed","newsHeadline":"Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO\u00ae Royalty","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Candel Therapeutics Partners with the University of Pennsylvania\u2019s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ University of Pennsylvania","highestDevelopmentStatusID":"3","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$32.5 million","newsHeadline":"Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Felzartamab","moa":"CD38","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0.12,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ A.."},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant Polyclonal Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic .."},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvalent Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"NVL-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$520.5 million","upfrontCash":"$10.5 million","newsHeadline":"Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.52000000000000002,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.52000000000000002,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$284.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA\u00ae (omadacycline) Under BARDA Project BioShield Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0.28000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Evorpacept","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ALX Oncology \/ Oxford Finance","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"IL12-FHAB","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies Using YH003 Antibody Sequence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Toripalimab","moa":"IgG2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ ISU ABXIS","highestDevelopmentStatusID":"8","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Enters Into Strategic Option and License Agreement with Translational Sciences","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Tran.."},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces that Janssen Has Received Approval from U.S. FDA for Tecvayli\u2122 (teclistamab) for The Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Teclistamab-cqyv","moa":"CD3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"OmniAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OmniAb \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"OmniAb \/ J.."},{"orgOrder":0,"company":"OmniAb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces that Janssen Has Received Approval from European Commission for Tecvayli\u00ae (teclistamab) for The Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Teclistamab-cqyv","moa":"CD3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"OmniAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OmniAb \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"OmniAb \/ J.."},{"orgOrder":0,"company":"IAVI","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"rVSV\u2206G-LASV-GPC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IAVI \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Mer.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$63000.0 million","upfrontCash":"$63000.0 million","newsHeadline":"AbbVie Completes Transformative Acquisition of Allergan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"OnabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":63,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":63,"dosageForm":"Injectable\/Injection","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Receives Six Months of U.S. Pediatric Exclusivity for Eylea\u00ae (aflibercept) Injection","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF-A\/PlGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMU-935","moa":"ROR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aditxt\u2019s (Nasdaq: ADTX) Adimune\u2122 Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI\u2122-100 in Preparation for Planned Psoriasis First-in-Human Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-100","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aditxt \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ N.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB359","moa":"IL-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"IL-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ES005","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS\u00ae (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VPO-227","moa":"CFTR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"6","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA\u00ae (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIRONA Completes Enrollment - A Leap in the DCB Treatment of Femoropopliteal Arterial Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces Presentation at Arrowhead's 16th Annual Pain Therapeutics Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethylamide","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Receives Fda Approval To Manufacture Numbrino\u00ae At Seymour Plant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cocaine Hydrochloride","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Olorofim","moa":"Pyrimidine biosynthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD\u2019s The Liver Meeting\u00ae 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three-dose Hepatitis B Vaccine Regimen Protects People With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HEPLISAV-B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imjudo (tremelimumab) in Combination with Imfinzi Approved in the US for Patients With Unresectable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tremelimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New TREMFYA\u00ae (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. to Present at the Virtual Investor Pioneering Regenerative Medicine Without Immunosuppression Roundtable Event","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"iTOL-101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Will Present XIFAXAN(R) (rifaximin), TRULANCE(R) (plecanatide) and RELISTOR(R) (methylnaltrexone bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NM-136","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"ClearB Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClearB Therapeutics Announces Upcoming Poster Presentations of Pre-Clinical Hepatitis B Data at AASLD 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CLB-3000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ClearB Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ClearB Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ClearB The.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"CD103","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Data Announced from Mirum\u2019s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Rebiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CG Oncology \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting\u00ae","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OCE-205","moa":"V1R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ocelot Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocelot Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocelot Bio.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol\u00ae for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive Data Showing Vocabria (cabotegravir) and Rekambys (rilpivirine) Can Be Successfully Implemented Across a Range of European Healthcare Settings","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy\u00ae for the Treatment of People Living With HIV With a Range of Comorbidities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval to Initiate Amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS\u00ae (opicapone) Open-Label Study at ANA2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enosi Therapeutics to Present at the ENA 2022 Symposium on Molecular Targets and Cancer Therapeutics in Barcelona","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EN-2642","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Enosi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enosi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Enosi Ther.."},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seal Rock Therapeutics Announces Upcoming Oral and Poster Presentations at AASLD's The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SRT-015","moa":"ASK1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seal Rock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock .."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt to Present Data on TERLIVAZ\u00ae (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pancrelipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PL8177","moa":"MC1R","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Timbetasin Acetate","moa":"Thymosin beta 4 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMP Pharma, Inc Announces that Tadliq\u00ae, the First and Only FDA-approved Liquid Suspension of Tadalafil, is Now Available","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tadalafil","moa":"PDE5","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma Reports on Results of VILTEPSO\u00ae (viltolarsen) Injection After Four Years of Treatment in Open-Label Extension Trial in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"DMD dystrophin pre-mRNA exon 53","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces Upcoming Presentations at ASN\u2019s Kidney Week 2022 and NEALS","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"APX3330","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent\/ Metastatic Squamous Cel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Tumor stroma barrier","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Assembly Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Assembly Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"K-ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Air\u00ae Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit\u00ae PRO in a Poster Presentation at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Beyond Air \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EV104","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"EvolveImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EvolveImmu.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Present New ORLADEYO\u00ae (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces First Patient Dosed in Phase 1\/1b Study of BP1002 in Refractory\/Relapsed Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BP1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY\u00ae 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Reports Positive Topline Data from Phase 1\/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Step Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Step Pharma Announces First Patient Dosed with STP938, the World\u2019s Most Advanced CTPS1 Inhibitor, in a Phase 1\/2 Trial for T Cell and B Cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"STP938","moa":"CTPS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Step Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Step Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Step Pharm.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERADICATE Phase 3 Study Results Highlight The Potential Role Of Ceftobiprole In The Treatment Of Staphylococcus Aureus Bacteremia (SAB)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"PBP2a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Teclistamab-cqyv For Relapsed Or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teclistamab-cqyv","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces FDA Acceptance of NDA for Neffy\u00ae (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem Announces That Its ESSENTIAL Phase II Study For The Treatment Of Critically Ill COVID-19 Patients Meets Its Primary And Key Secondary Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nangibotide","moa":"TREM-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Approves Zydus Lifesciences to Market Generic Micafungin Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Micafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"TLR4","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"PTK","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics Announces Presentations at The Liver Meeting\u00ae 2022","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Berberine Ursodeoxycholate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Inipharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inipharm to Present Data on Anti-Fibrotic Effects of Its Development Candidate Targeting HSD17B13 at AASLD\u2019s The Liver Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INI-822","moa":"HSD17B13","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Inipharm","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inipharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inipharm \/.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"CTNS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Namodenoson","moa":"A3AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CNP-106","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cour Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharm.."},{"orgOrder":0,"company":"Cellevolve","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CE-VST01-JC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cellevolve","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellevolve \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellevolve.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Doses First Patient in a Registrational Phase II\/III study of SLS-005 in Spinocerebellar Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Trehalose API","moa":"TFEB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RZNOMICS Inc. Received FDA Approval To Initiate Clinical Development Of Trans-splicing Ribozyme-based RNA Editing Technology In Liver Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"RZ-001","moa":"hTERT expression","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/.."},{"orgOrder":0,"company":"Oblato","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oblato Announces That It Has Completed Enrollment Of Patients For The Phase 2 Recurrent Glioblastoma Multiforme Clinical Trial In The US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OKN-007","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oblato","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oblato \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oblato \/ N.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"Alpha4beta7 integrin","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Announces Initiation of Phase 1b\/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Covis Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Covis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Covis Phar.."},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhittya Genesis Medicine - Parkinson\u2019s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FGF-1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zhittya Genesis Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Ge.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"GABA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"PTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Istaroxime","moa":"Sodium\/potassium-transporting ATPase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"NEXGEL Advanced Hydrogel Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac","moa":"COX","url1":"","url2":"","graph1":"Rheumatology","graph2":"Undisclosed","graph3":"NEXGEL Advanced Hydrogel Solutions","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"NEXGEL Advanced Hydrogel Solutions \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NEXGEL Adv.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Nephrology Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek\u00ae 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Perception Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Perception.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The British Journal of Dermatology Publishes Results from Amryt\u2019s EASE Phase 3 Trial in Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Oleogel-S10","moa":"Transient receptor potential channel","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CLN-619","moa":"MICA\/MICB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"samRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives Including Opportunities to Better Leverage TSC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall PROSES Study Demonstrates Appropriate Acne Treatment Decreases The Burden Of Impact On Acne Sufferers\u2019 Social And Emotional Wellbeing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sarecycline","moa":"DNA\/Protein synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational Oral Monotherapy Iptacopan Demonstrates Clinically Meaningful Superiority Over Anti-C5 Treatment in Phase III APPLY-PNH Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive Proof-of-concept Findings For N6LS, An Investigational, Broadly Neutralising Antibody (bNAb) Offering A Potential New Approach For The Treatment Of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"GSK3810109A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u00ae (Upadacitinib) Receives Its Sixth U.S. FDA Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the MESSINA Phase III Trial for Fasenra in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves TECVAYLI\u2122 (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teclistamab-cqyv","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Expands Merck\u2019s VAXNEUVANCE\u2122 (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"AL002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alector \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves JUV\u00c9DERM\u00ae VOLUMA\u2122 XC for Enhancement of the Chin Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Hyaluronic acid","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"MTBhsp70-Avidin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Voltron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capivasertib Plus Faslodex Significantly Improved Progression-free Survival Vs. Faslodex In CAPItello-291 Phase III Trial In Advanced HR-positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Capivasertib","moa":"AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca\u2122 in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Angiotensin II type-1 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis of UPLIZNA\u00ae (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Reports Preliminary Data From Its Phase 1\/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2\/CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO\u2122 (celiprolol)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Celiprolol Hydrochloride","moa":"ADRB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Publication of Phase 2a \u2018AMBITION\u2019 Clinical Trial Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Zotatifin","moa":"SARS-CoV-2 helicase eIF4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma\u2019s Oral Antiviral Candidate CC-42344","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1\/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"4D-710","moa":"microCFTR transgene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TERN-101","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Announces a Poster Presentation at the 34th EORTC\/AACR\/NCI Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"MDM2-p53 complex","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1\/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INT301","moa":"Allergen Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-930","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1\/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Genomic Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dante Genomics Creates Separate Drug Discovery And Development Company Genomic Biopharma Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dellera","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Genomic Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genomic Biopharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Genomic Bi.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"miR-10b","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-609","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at ECTRIMS 2022 Highlight Biogen\u2019s Commitment to Advancing Individualized Disease Management for People Living with MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Peginterferon Beta-1a","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"RVU120","moa":"CDK8\/CDK19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OP-1250","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Crofelemer","moa":"CFTR","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Confere","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EPI-8207","moa":"ANITAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enteris BioPharma Presents Study of Ovarest\u00ae Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Bi.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY\u00ae Annual Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill\u00ae Daily Oral Contraceptive for Over-The-Counter (OTC) Use","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"Androgen receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Enrolls First Patient In Phase III trial of BI 1015550 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BI 1015550","moa":"PDE4B","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Live-attenuated Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"THE-349","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Results from the Phase 1\/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Phase 3 LIGHTHOUSE Study Further Confirms Clinical Benefit Of Melflufen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Encouraging Development in Maralixibat\/LIVMARLI in Rare Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ALPN-303","moa":"BAFF\/APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces British Journal of Dermatology Publication of Adbry\u2122 (tralokinumab-ldrm) Pooled Safety Data in Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab-ldrm","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"GTAEXS-617","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"4","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"IL-2\/IL-9\/IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FTX-6746","moa":"PPARG","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Flare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flare Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX\u00ae (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Camizestrant","moa":"SERD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic EBV T-cell","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"Intestinal gut microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer To Present New Cardiorenal Data From Comprehensive Kerendia\u2122 (finerenone) Clinical Trial Program Across A Broad Range Of Patients With Chronic Kidney Disease And Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Treatment with Roche's OCREVUS Leads To Reduced Disease Progression And Healthcare Costs; Nine-year Safety Data Reinforce Favourable Benefit-risk Profile","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$40.0 million","newsHeadline":"Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRP\u03b1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"ADU-1805","moa":"SIRP alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ .."},{"orgOrder":0,"company":"OmniAb","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Completion of OmniAb Spin-Off","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Demerger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OmniAb \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ L.."},{"orgOrder":0,"company":"Applied BioMath","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied BioMath \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"iPSC-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Eterna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Eterna The.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0.29999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Case Western Reserve University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Case Western Reserve University","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Mitobridge","sponsor":"OrsoBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"TLC-065","moa":"ACMSD","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Mitobridge","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mitobridge \/ OrsoBio","highestDevelopmentStatusID":"4","companyTruncated":"Mitobridge.."},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$9.1 million","upfrontCash":"Undisclosed","newsHeadline":"Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Cerus Corporation \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corp.."},{"orgOrder":0,"company":"Simulations Plus","sponsor":"Food and Drug Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Simulations Plus","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Simulations Plus \/ Food and Drug Administration","highestDevelopmentStatusID":"4","companyTruncated":"Simulation.."},{"orgOrder":0,"company":"Shionogi","sponsor":"OrsoBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"TLC-3595","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Phenex Pharmaceuticals","sponsor":"OrsoBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"TLC-2716","moa":"Liver X receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Phenex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phenex Pharmaceuticals \/ OrsoBio","highestDevelopmentStatusID":"6","companyTruncated":"Phenex Pha.."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"ENS-002","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Concerto Biosciences","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Concerto Biosciences \/ Safar Partners","highestDevelopmentStatusID":"2","companyTruncated":"Concerto B.."},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alterome Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alterome Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Alterome T.."},{"orgOrder":0,"company":"Lusaris Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lusaris Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Lusaris Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Lusaris Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$498.1 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes Deal To Acquire Testosterone Therapy Nebido\u2122 From Bayer For \u20ac495 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Bayer AG","amount2":0.5,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.5,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Aptar Pharma","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"American Society of Ophthalmic Administrator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol\u00ae and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$30.0 million","newsHeadline":"Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Science Ventures","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series B Financing","leadProduct":"NVD-X3","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Novadip Biosciences","amount2":0.089999999999999997,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Science Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Novadip Bi.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.6 million","upfrontCash":"Undisclosed","newsHeadline":"Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"NYX-783","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Aptinyx","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capita","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Peak Bio, Inc. Announces Closing of up to $100 Million Common Stock Purchase Transaction with White Lion Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"PHP-303","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Peak Bio \/ White Lion Capita","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Parkinson\u2019s Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NKGen Biotech Announces Collaboration with the Parkinson\u2019s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Parkinson\u2019s Foundation","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"hC Bioscience Announces Extension of Series A to $40 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Engineered tRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"hC Bioscience","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"hC Bioscience \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"hC Bioscie.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioAtla Announces $65 Million Underwritten Offering of its Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"AXL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"BioAtla \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rain Therapeutics Announces $50 Million Registered Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Milademetan","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"EpiVax Joins Intravacc, CEPI On Project To Develop Universal Betacoronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Avacc 101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ I.."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Tri-specific Antibody","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Eucure Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ ISU ABXIS Co.","highestDevelopmentStatusID":"2","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Provides An Update On The Development Of Cedirogant By AbbVie","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Termination","leadProduct":"Cedirogant","moa":"ROR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Kovina Therapeutics","sponsor":"National Institute of Dental and Craniofacial Research","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Kovina Therapeutics Receives NIH Grant to Develop Human Papillomavirus E6 Inhibitors to Treat Oropharyngeal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"HPV E6","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kovina Therapeutics \/ National Institute of Dental and Craniofacial Research","highestDevelopmentStatusID":"4","companyTruncated":"Kovina The.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Twentyeight-Seven Therapeutics","pharmaFlowCategory":"D","amount":"$357.9 million","upfrontCash":"$1.0 million","newsHeadline":"Basilea Announces Sale Of Preclinical Oncology Program To Twentyeight-Seven Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"CLK kinases","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Twentyeight-Seven Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Res Nova Bio","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Demerger","leadProduct":"ValloVax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Res Nova Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Res Nova Bio \/ Therapeutic Solutions International","highestDevelopmentStatusID":"5","companyTruncated":"Res Nova B.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera\u2019s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA\u00ae (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"IO102-IO103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Affimed","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE\u00ae) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"AB-101","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"Eclipse","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eclipse and Mayo Clinic Create Nucleus RadioPharma to Better Serve Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Financing","leadProduct":"Radiopharmaceutical Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nucleus RadioPharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Nucleus RadioPharma \/ Eclipse","highestDevelopmentStatusID":"1","companyTruncated":"Nucleus Ra.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amid Low Vaccine Demand, Novavax Pulls Out Of Fujifilm Manufacturing Deal And Inks $185M Settlement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2022","year":"2022","type":"Termination","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0.19,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.19,"dosageForm":"Injectable\/Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Advanced Bioscience laboratories","sponsor":"DAIDS","pharmaFlowCategory":"D","amount":"$364.5 million","upfrontCash":"Undisclosed","newsHeadline":"ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"HIV-1 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Advanced Bioscience laboratories","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Advanced Bioscience laboratories \/ DAIDS","highestDevelopmentStatusID":"4","companyTruncated":"Advanced B.."},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi ATU Announces Licensing Agreement with Janssen for TESSA\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAV Vectors","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Advanced Therapies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Advanced Therapies \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Advan.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FUJIFILM Diosynth Biotechnologies Enters into an Agreement with Argenx to Manufacture Efgartigimod, a Monoclonal Antibody (mAb) for the Treatment of Severe Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Argenx","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grand River Aseptic Manufacturing to Fill and Finish Smallpox\/Monkeypox Vaccines and Accelerate Domestic Supply","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Live Nonreplicating Smallpox And Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Grand River Aseptic Manufacturing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Grand River Aseptic Manufacturing \/ Bavarian Nordic","highestDevelopmentStatusID":"12","companyTruncated":"Grand Rive.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Awakn Life Sciences Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"MK-4464","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dragonfly Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Reports Outcome From US FDA Advisory Committee Meeting On Daprodustat For Anaemia Of CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Otilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Lo.Li. Pharma International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pervistop\u00ae, The Once-daily Supplement Specifically Designed To Manage Persistent HPV, Is Now Available For Exclusive Distribution Rights Worldwide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Green Tea Extract","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lo.Li. Pharma International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lo.Li. Pharma International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lo.Li. Pha.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Phase III Results Show Roche's Vabysmo Improved Vision For People Living With Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Showed Zero Relapses In Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) With Median Treatment Duration Of 73 Weeks","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmazeb\u00ae (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Atoltivimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Reports Outcome From US FDA Advisory Committee Meeting on Daprodustat for Anaemia of CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Daprodustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NBI-1117568","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u2122 (ciltacabtagene autoleucel) Receives Approval from Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Janssen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX-914","moa":"IL-7 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Vyant Bio","sponsor":"The Loulou Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Vyant Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyant Bio \/ The Loulou Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Vyant Bio .."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma To Present at Upcoming Investor and Scientific Conferences","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Atropine","moa":"ACh receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Laboratories Thea","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ L.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DYAI-100","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HMI-103","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Glucose","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pha.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Avadomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"Covalent menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates a Phase II\/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AAVrh.10hFXN","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi to Present Data from REAL-HLH Study at the ACR Convergence 2022 Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Emapalumab-lzsg","moa":"INF gamma","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta to Present Pre-clinical Data on VISTA and CD27 Programs at SITC 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KVA12123","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177-edotreotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ReveraGen BioPharma \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Presents Preliminary Results from Phase 1\/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tulmimetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pha.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for Leniolisib \nPharming Group N.V. Logo","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NVL-520","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Quadrivalent HPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (ecnoglutide) in Patients with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"XW003","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Totus Medicines Announces Poster Presentation for TOS-358, the First Highly Selective Covalent Molecule Targeting PI3K\u03b1, at the 34th EORTC-NCI-AACR Symposium in Barcelona","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TOS-358","moa":"PI3K alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Totus Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medi.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics To Present New Data on CD38 Flex-NK\u2122 Cell Engager Bispecific Antibodies for Multiple Myeloma at 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CYT-338","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (axicabtagene ciloleucel injection) Approved for CDE Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Kite Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Kite Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Kite.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SIM0237","moa":"PD-L1\/IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"GT20029","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akorn Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Phar.."},{"orgOrder":0,"company":"Vivera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TABMELT Granted Patent Allowance in Israel, Expanding Vivera's Global Licensing Reach","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Vivera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivera Pha.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"AllerPops","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Clinical Trial Confirms Safety and Effectiveness of AllerPops","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AllerPops","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AllerPops","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Lollipop","sponsorNew":"AllerPops \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AllerPops .."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO\u2122 I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2002","moa":"Myc expression","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene to Host Research and Development Day on November 15th and 17th, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FX-909","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Ther.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca\u00ae (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Sporos BioDiscovery","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SPR1","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sporos BioDiscovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sporos BioDiscovery \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sporos Bio.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s KERENDIA\u00ae (finerenone) Recommended as Part of Comprehensive Treatment Strategy for Chronic Kidney Disease Associated With Type 2 Diabetes in Newly Published Clinical Recommendations","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA\u00ae (Vibegron 75mg) Administered as an Intact or Crushed Tablet","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"TAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira .."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Leadership Team Expansion to Support Advancement of Clinical-Stage Autoimmune Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC\/NCI\/AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EDG-5506","moa":"Myosin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Oregon State University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oregon State Researchers Take Key Step Toward Improving Treatment Of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA Loaded Lipid Nanoparticle","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oregon State University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oregon Sta.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Remedy For Diamedica As FDA Maintains Hold On Stroke Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets USFDA Nod For Generic Injection To Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase III Study, FRESH And Is Redirecting To New Developments","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Firibastat","moa":"Glutamyl aminopeptidase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody\u00ae-CD3xCD20) for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD3\/CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"CBX-12","moa":"Topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR0602","moa":"TCR-V beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Th.."},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavanta Therapeutics to Present Preclinical Data for TAVT-135 at the North American Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TAVT-135","moa":"Chloride ion","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tavanta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tavanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tavanta Th.."},{"orgOrder":0,"company":"Nuevocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Adeno-associated Virus Based Gene Therapy","moa":"LMNA Gene","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuevocor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-P8","moa":"TGF beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Hinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HP518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ N.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announces Oral Presentation of Ivonescimab (PD-1\/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI343","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"Lysosomal alpha-glucosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Provides an Update on its Clinical Collaboration with Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Janssen","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Gives Final Approval To Zydus\u2019s Acetaminophen Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Paracetamol","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences Begins Patient Dosing In Second Human Abuse Potential Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ORM-5029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orum Thera.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"VRG50635","moa":"PIKFYVE protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"Epic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EPI-321","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TIDAL-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Turnstone Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turnstone Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Vasodilation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ICP-723","moa":"pan-TRK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1\/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Pidnarulex","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces New Data to be Presented in PBC, Liver Fibrosis Due to NASH and Pipeline at AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INT-787","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting\u00ae 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-101","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1\/2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide\u2019s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Kt-3000","moa":"PARP\/HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD\u2019s The Liver Meeting\u00ae 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review Ascendis Pharma\u2019s NDA for TransCon\u2122 PTH in Adult Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I\/II (COVALENT-111) Study of BMF-219","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"5-HT1A\/2A\/2B\/7 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1\/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"DYNE-251","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase Alfa","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ITIL-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Instil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"sGC","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ainos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ainos \/ No.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini Group","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves RINVOQ\u00ae (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets USFDA Nod For Generic Version Of Glycopyrrolate Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"ACh receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Article Based on Infant Bacterial Therapeutics\u2019 (IBT) Connection Study published in the British Journal of Gastroenterology Demonstrates That One Day Shift In Sustained Feeding Tolerance (SFT) Correlates To Clinically Meaningful Outcomes.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IBP-9414","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Provides an Update on the Phase II Clinical Trial with Ensereptide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensereptide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Promore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Noramco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Noramco","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Noramco \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noramco \/ .."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akston Biosciences Announces Positive Interim Phase II Results from COVID \u201cUniversal\u201d Booster Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting\u00ae 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teon Therapeutics Announces First Patient Treated in Phase 1\/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TT-816","moa":"CB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Teon Thera.."},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avilar Therapeutics to Present In Vivo Non-Human Primate Data on ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Avilar Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avilar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avilar The.."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TLC-2716","moa":"Liver X receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev\u00ae (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"BitNile Holdings","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BitNile Holdings Announces That Alzamend Neuro Receives FDA \u201cStudy May Proceed\u201d Letter for Phase I\/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ALZN002","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ BitNile Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306, a Proposed Biosimilar of Cosentyx\u00ae (Secukinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC11","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 37th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Data at 21st Annual NEALS Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces Topline Results from Phase 2 Proof-Of-Concept Study Evaluating Pitolisant For Excessive Daytime Sleepiness in Patients with Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Crossject","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crossject - Clinical Demonstration Of Zeneo\u00ae Efficiency For Intramuscular Injection Of Midazolam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Crossject \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: New Patent Application Associating NFL-101 With Other Smoking Cessation Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tobacco Leaf Protein","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Completes Fed\/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Present Late Breaking Bylvay\u00ae (odevixibat) Data at AASLD 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anika\u2019s Cingal\u00ae Successfully Achieves Primary Endpoint in Third Phase III Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"Hyaluronic acid","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Anika Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Ther.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting\u2122 2022, Hosted by the AASLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"PDE5","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ACU193","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Phase 1\/2 Study Single Dose Healthy Volunteer Data with TAK-594\/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TAK-594","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Denali Therapeutics \/ Takeda","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Vemlidy\u00ae (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma And Partner Sarepta Therapeutics Plan To Initiate A Clinical Study With Imlifidase As A Pre-treatment To Sarepta\u2019s SRP-9001 Gene Therapy In DMD In 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PACT Pharma to Present New Data Highlighting First-of-its-Kind Personalized Neoantigen TCR T Cell Therapy Platform at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NeoTCR-P1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PACT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharm.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OTX-2002","moa":"Myc expression","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"INF gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Access to Advanced Health Institute Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AAHI-SC2 Self-amplifying RNA Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Access to Advanced Health Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Access to Advanced Health Institute \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Access to .."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of Non-CF Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Initiation of Phase 1 Study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EQ102","moa":"IL15\/IL-21","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TLC-6740","moa":"AMPK","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OrsoBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Samsara BioCapital","highestDevelopmentStatusID":"5","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives FDA Approval for Leuprolide Acetate Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciliary Neurotrophic Factor","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Neurotech Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Neurotech Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurotech .."},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pathios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Th.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt to Present Data on TERLIVAZ\u00ae (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE\u00ae Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis B.."},{"orgOrder":0,"company":"Brexogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BRE-AD01","moa":"IL-31","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Brexogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brexogen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Brexogen \/.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Cisplatin During Radiation Therapy With And Without Triapine\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanopharmaceutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanopharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanopharma.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Dosing of First Patient in Europe\/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thryv Therapeutics Inc. Announces the Presentation of Scientific Data for Its Novel SGK1 Inhibitors at American Heart Association and San Antonio Breast Cancer Symposium","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SGK1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Thryv Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Thryv Ther.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Receives FDA Fast Track Designation for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax\u2122-RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CodaVax-RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b\/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribaxamase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"A197","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Dompe farmaceutici","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Bio.."},{"orgOrder":0,"company":"Sernova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1\/2 Trial with Cell Pouch System\u2122 for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Donor Islets Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sernova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AT-752","moa":"Dengue viral polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Announces Publication Of Phase 2b Study Of COMP360 Psilocybin Therapy For Treatment-resistant Depression In The New England Journal Of Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona\u2019s Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 is Ready for Clinical Studies","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SAN903","moa":"KCa3.1","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Alunacedase Alfa","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"HC-7366","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ALA-002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"PharmAla Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAla Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmAla B.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma\u2019s Medication for Treating Depression in Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting\u00ae Providing Update on the Phase 1b\/2a Study of VTP-300","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals to Present Two Posters at Upcoming AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek\u00ae and Plans to Initiate Phase 3 Trial in Early 2023","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel\u2122 for the Treatment of 22q11.2 Deletion Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3\/TCR complex","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics to Provide Update on ReSPECT\u2122 Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EAGLE-2 and EAGLE-3 Phase III Trials for Gepotidacin Stopped Early for Efficacy Following Pre-Planned Interim Analysis by Independent Data Monitoring Committee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gepotidacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave Signs Rho For Phase 2 Trial Of Gastrointestinal Drug","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"UniCAR CD123","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AvenCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants First Approval Worldwide Of Beyfortus\u00ae (Nirsevimab) For Prevention Of RSV Disease In Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Presents New Proof of Concept Data at American Society of Nephrology","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine Oxidase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"NovalGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovalGen Announces One Oral And Two Poster Presentations At The American Society Of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NVG-111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NovalGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovalGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovalGen \/.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NC525","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"HPN217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Announces Poster Presentation on CTX110\u00ae at the American Society of Hematology (ASH) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX110","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OTL-201","moa":"SGSH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"VIP943","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics to Present Updated Interim Phase 1\/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NL-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"KIT D816V","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Presentation of Phase 1\/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"CD123\/CD16A","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ALLO-647","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SerpinPC","moa":"Protein C","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ bluebird bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TT11X","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche To Present Data At ASH 2022 Showcasing Strength Of Haematology Portfolio And Expanding Into New Areas To Address More Patient Needs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ORIC-533","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-047","moa":"ALK-2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"FT819","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Presents Overview of DiversitAb\u2122 Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 64th ASH Annual Meeting and Exposition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AG-946","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Fate Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAR NK Cell Therapy","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Fate Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL\u2122 Study of EB-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET\u2122 Platform at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IPH6101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ALPN-303","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN\u2019s Kidney Week 2022 Annual Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Presents Results from Phase 2 Clinical Study of LAU-7b in Cystic Fibrosis at the NACFC 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenretinide","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Schr\u00f6dinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SGR-2921","moa":"CDC7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Birtamimab","moa":"Light chain aggregates","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"RAR alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin\u2019s Lymphoma at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asher Bio to Present New Preclinical Data for Selective Support of CAR-T Cell Therapies by Cis-Targeted IL-2 and IL-21 Cytokines at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AB821","moa":"IL-21","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ajax Therapeutics Announces Oral and Poster Presentations on Next\u2011Generation JAK2 Inhibitors at American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AJ1-10502","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ajax Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ajax Thera.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Denifanstat","moa":"FASN","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Glofitamab","moa":"CD20\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio to Present Four Abstracts at the 64th American Society of Hematology Annual Meeting, Including Updated Relapse-Free Survival Data with Orca-T and the First Clinical Data for Orca-Q","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Orca-Q","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BGB-11417","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"ATCC (American Type Culture Collection)","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATCC Announces New Immuno-oncology CAR-T Target Luciferase Reporter Cell Lines to Enable Discovery and Development of Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ATCC (American Type Culture Collection)","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATCC (American Type Culture Collection) \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ATCC (Amer.."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces Presentation of Five Abstracts at AASLD\u2019s The Liver Meeting\u00ae 2022 Highlighting Programs for Severe Metabolic Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TLC-3595","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grid Therapeutics Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GT103","moa":"CFH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Thera.."},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ENB003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ENB Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therap.."},{"orgOrder":0,"company":"Mercator MedSystems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mercator MedSystems Announces Publication of Results from TANGO Phase 2 Clinical Trial to Improve Outcomes after Below-Knee Arterial Revascularization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Temsirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mercator MedSystems","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Mercator MedSystems \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mercator M.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3\/CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Positive Results From Fesomersen Development Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fesomersen","moa":"Factor XI","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T Tisagenlecleucel, at 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"Human IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"CellCentric","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CellCentric To Present Inobrodib Phase I Multiple Myeloma Efficacy And Safety Data At The American Society Of Haematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Inobrodib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CellCentri.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Announces Poster Highlighting Pravibismane Activity Against Common Cystic Fibrosis Pulmonary Pathogens to be Presented at the North American Cystic Fibrosis Conference 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax to Present at Recent Advances in Fermentation Technology (RAFT) 14 Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TP-3654","moa":"PIM kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH\u00ae (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cladribine","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Selinexor","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rusfertide Analog","moa":"Hepcidin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protagonist Therapeutics \/ Janssen","highestDevelopmentStatusID":"4","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Theradex Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Theradex Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yuyu Pharma Attendance at European Pharmaceutical Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"YP-P10","moa":"Cytokines\/Cheokines","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharm.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"linvoseltamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA\u00ae (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at ASH 2022 Bolster Servier's Leadership in Hematology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacritinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"VMAT2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoGenesis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4\/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landmark EMPA-KIDNEY Trial Showed Significant Benefit Of Jardiance\u00ae In Reducing Kidney Disease Progression Or Cardiovascular Death By 28% Vs. Placebo In People With Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MZ-301","moa":"APOL1","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Announces Positive Initial Results From Its Phase II Trial on Its BMND01 Candidate for Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Gates Biomanufacturing Facility","sponsor":"Institute for Molecular Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AV-1980R","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Gates Biomanufacturing Facility","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gates Biomanufacturing Facility \/ Institute for Molecular Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Gates Biom.."},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Certa Therapeutics' Investigational Drug Ft011 Delivers Breakthrough Results As A Potential Novel Treatment For Serious Inflammatory And Fibrotic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"FT011","moa":"TGF beta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Ther.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-8421","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Cell wall synthesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal The.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Presents New Data at AASLD The Liver Meeting\u00ae Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ABI-4334","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR delta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM936","moa":"ILT\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TYA-11631","moa":"HDAC6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SLN360","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazindol","moa":"Sodium-dependent dopamine transporter","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Aesthetics Celebrates Fourth Annual BOTOX\u00ae Cosmetic (onabotulinumtoxinA) Day","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Presents New Phase 2 Data That Show Olpasiran Delivers Significant Reduction in Lipoprotein(a) Levels","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olpasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus Approved In The EU For The Prevention Of RSV Lower Respiratory Tract Disease In Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Detailed Data From Pivotal Studies With Aflibercept 8 Mg Demonstrate Sustained Improvements In Visual Acuity And Anatomic Measures With Large Majority Of Patients Maintaining Treatment Intervals Of 16","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF A\/PlGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Satisfies All-case Study Requirement For Antiepileptic Agent Inovelon\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rufinamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Respiratory Syncytial Virus Older Adult Vaccine Candidate Granted Priority Review By US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AS01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants First Approval Worldwide Of Beyfortus\u00ae (nirsevimab) For Prevention Of RSV Disease In Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"Sanofi \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio\u2019s OXL001 Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxilio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxilio \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Oxilio \/ Q.."},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Drug ABBV-CLS-7262 Initiates Design Phase For Entry Into The HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ABBV-CLS-7262","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Receives FDA Approval for DURYSTA\u2122 (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to Lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Famy Life Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life .."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"ACh receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.41999999999999998,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Microtubules","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Ph.."},{"orgOrder":0,"company":"Res Nova Bio","sponsor":"Veltmeyer MD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"ValloVax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Res Nova Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Res Nova Bio \/ Veltmeyer MD","highestDevelopmentStatusID":"5","companyTruncated":"Res Nova B.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Adagrasib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAVrh.10hAPOE2","moa":"APOE4 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cerveau Technologies \/ LEXEO Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Te.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Streeterville Capital","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Streeterville Capital","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"ONO-8250","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ ONO Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"ES Therapeutics","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"AVTX-007","moa":"LIGHT","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Avalo Therapeutics \/ ES Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Eisai","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai To Divest Rights For Muscle Relaxant Myonal\u00ae And Vertigo And Equilibrium Disturbance Treatment Merislon\u00ae In Asia To DKSH","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Eperisone Hydrochloride","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ DKSH","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ DK.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"FamyGen Life Sciences","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$35.0 million","newsHeadline":"Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ FamyGen Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series B Financing","leadProduct":"Obexelimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Enavate Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioP.."},{"orgOrder":0,"company":"FibroGen","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$50.0 million","newsHeadline":"FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0.050000000000000003,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ NovaQuest Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to \u2018Off-the-Shelf\u2019 CAR-T Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"CD30.CAR-EBVST Cells","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Sensorium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sensorium Raises $30M in Series A Round To Probe Plants, Fungi For Psychoactive Natural Products","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"SENS-01","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sensorium Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Sensorium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sensorium .."},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech Enters Into Collaboration And License Agreement With Sanofi To Advance Discovery Programs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Bi.."},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition Corp.","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"Conduit Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"AZD5904","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Ph.."},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Announces Closing Of $32.3 Million Underwritten Public Offering Including Full Exercise Of Overallotment Option And Concurrent Private Placement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Dong-A ST Co., Ltd.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dong-A ST Co., Ltd. \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dong-A ST .."},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"Undisclosed","newsHeadline":"Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"JUV-161","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Juvena Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Juvena Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"5","companyTruncated":"Juvena The.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"TP ICAP Midcap","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Totum\u2022070","moa":"Lipid metabolism","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ TP ICAP Midcap","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARS Pharmaceuticals Closes Merger with Silverback Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Merger","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"Silverback Therapeutics \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Baergic Bio","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A \u03b12\/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"BAER-101","moa":"GABA-A alpha 2\/3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Baergic Bio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baergic Bio \/ Avenue Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Baergic Bi.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$591.0 million","upfrontCash":"$66.0 million","newsHeadline":"Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.58999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.81999999999999995,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"IMM60","moa":"iNKT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"NRG Therapeutics Announces \u00a316 Million Series A to Advance Mitochondrial Therapeutics for Parkinson's and ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"mPTP","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"NRG Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therap.."},{"orgOrder":0,"company":"Spanios","sponsor":"Unravel Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Unravel Biosciences Partners with Spanios to Discover Therapeutic Targets for Rare Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Spanios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spanios \/ Unravel Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Spanios \/ .."},{"orgOrder":0,"company":"MGFB","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MGFB Announces Agreement With Mayo Clinic For Development Of Novel Therapeutic Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MGFB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MGFB \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"MGFB \/ May.."},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Sun Pharma and SPARC Enter Into A License Agreement For Commercialization Of Phenobarbital For Injection In The US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Phenobarbital Sodium","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"SPARC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SPARC \/ Sun Pharma","highestDevelopmentStatusID":"10","companyTruncated":"SPARC \/ Su.."},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Polifarma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dong-A ST Signs License-out Deal with Polifarma of T\u00fcrkiye for NESP\u00ae Biosimilar DA-3880","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Darbepoetin alfa","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Dong-A ST Co., Ltd.","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Polifarma","highestDevelopmentStatusID":"12","companyTruncated":"Dong-A ST .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$250.0 million","newsHeadline":"Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"Lipoprotein","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0.40999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Alethea Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"GDD3898","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Lipidio Pharmaceuticals \/ Alethea Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Ph.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"International Centre for Genetic Engineering and Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Antiviral Therapeutics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"Parthenon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies\u2019 Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"PRTH-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Parthenon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"T-Cell Protect","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Todos Medical Terminates Tollovid\u2122 Products License & Distribution Agreement with T-Cell Protect Hellas S.A.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Termination","leadProduct":"Plant Extracts","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Todos Medical \/ T-Cell Protect","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"APIM Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nordic Nanovector and APIM Therapeutics Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Merger","leadProduct":"Sodium Deoxycholate","moa":"PCNA\/APIM PPI","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nordic Nanovector \/ APIM Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National C.."},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"HDX Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TAE Life Sciences Announces Partnership with HDX Corporation for Launch of Boron Neutron Capture Therapy in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"BNCT","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ HDX Corporation","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life S.."},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Imperial College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EnteroBiotix Partners With Imperial College London To Develop Microbiome Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"EBX-102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiot.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Enters into a License and Collaboration Agreement with Moderna","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Moderna","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for NY-ESO-1\u30fbsiTCR\u00ae Gene Therapy Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Termination","leadProduct":"NY-ESO-1.siTCR","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takara Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Takara Bio.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$80.0 million","newsHeadline":"Ionis Partners with Metagenomi to Add Gene Editing to Its Broad Technology Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"Recipharm AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Selects Recipharm as Product Characterization Partner","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"RSBT-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ Recipharm AB","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTher.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"CUE-101","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Piper Sandler & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Wellington Management","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series B Financing","leadProduct":"MBX 2109","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0.12,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Wellington Management","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$204.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Captor Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Captor Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Captor The.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"NM-102","moa":"Intestinal microbiome","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"9 Meters Biopharma \/ Gustave Roussy","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Hamden Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Naltrexone Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Halberd Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Halberd Corporation \/ Hamden Group","highestDevelopmentStatusID":"1","companyTruncated":"Halberd Co.."},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$213.0 million","upfrontCash":"$145.0 million","newsHeadline":"Indivior To Acquire Opiant Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"CB receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.20999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics and The Institute of Cancer Research Enter Into Collaboration For Cancer Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ The Institute of Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Apollo The.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Mannin Research","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Q Biomed Announces Addition Of Multi-Million Dollar Asset Value With Equity Stake In Maniin Research Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"MAN-01","moa":"IOP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Q BioMed","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Q BioMed \/ Mannin Research","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HCR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RedHill Biopharma \/ HCR","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TauRx Announces Additional Investment of USD119 Million Following Announcement Of Phase 3 LUCIDITY Topline Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VPAC1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"CDMRP","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Alhydrogel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergent BioSolutions \/ CDMRP","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Zhejiang Medicine Co Ltd","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ambrx Announces NovoCodex\u2019s Dosing of First Patient with ARX305, Ambrx\u2019s Investigational Antibody Drug Conjugate Targeting CD70","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"ARX305","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ambrx Inc \/ NovoCodex","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Breathe Biologics","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Demerger","leadProduct":"Umbilical Cord Derived Monocyte","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Breathe Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Breathe Biologics \/ Therapeutic Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Breathe Bi.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves QULIPTA\u2122 (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"50 Million Doses Of Covaxin Set To Expire Early 2023 Due To Poor Off Take","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV152","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab\uff08IBI306\uff09in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC41","moa":"THR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"c-Abl kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Salmeterol Xinafoate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"APOC3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor\u2019s IL2-Fc Cytokine, XmAb\u00ae564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"XmAb564","moa":"IL-2 beta","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outside the US Bayer Extends Development Program for Investigational Product Elinzanetant With Phase III Study in Breast Cancer Patients With Vasomotor Symptoms Caused by Endocrine Therapy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Announces Positive Interim Clinical Data for Its Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine Candidate for Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Live Attenuated RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"A2B530","moa":"HLA A2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AFNT-111","moa":"KRAS G12V","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affini-T Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affini-T Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affini-T T.."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BCA356","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bicara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-925","moa":"Tumor stress ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From Incyte\u2019s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"INCAGN01876","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pionyr Immunotherapeutics\u2019 MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PY265","moa":"MARCO receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pionyr Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pionyr Imm.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase 3 Efficacy and Safety Data for Ferring\u2019s RBX2660 Published in Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Positive Preclinical Data in NASH Non-human Primate Models","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX702A","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Apros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apros Therapeutics to Present Interim Clinical Data from a Phase 1 Study Evaluating APR003 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting and World Vaccine & Immunotherapy Congress (WVIC) West Coast","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"APR003","moa":"TLR-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Apros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apros Ther.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RLYB116","moa":"Completent C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL\u00ae in Systematic Literature Review of 138 Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant HPV Quadrivalent Types 6, 11, 16, and 18 Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Regimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 American Society of Hematology Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RGI-2001","moa":"Tregs","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune .."},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Cyanvac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Lake Biotechnology Announces Positive Interim Phase 1 Data for BLB201 Intranasal RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CPI-RSV-F Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Blue Lake Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blue Lake Biotechnology \/ CyanVac","highestDevelopmentStatusID":"6","companyTruncated":"Blue Lake .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aprocitentan","moa":"ET receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"COX-2","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Brand Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Congestion Due to Fluid Overload in Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Presents Positive Phase 2 Data In Patients With IgA Nephropathy at American Society of Nephrology's Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IONIS-FB-LRx","moa":"Complement factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MSC-nTF Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"US Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Biologic\u00ae to Present Development of a Chewable Flu Vaccine: Offers New Tool to Increase Vaccine Equity, Avoid Needles, and Reduce Pandemics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Flu Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"US Biologic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"US Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"US Biologi.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"VERVE-101","moa":"PCSK9 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (mazindol ER) in the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazindol","moa":"MAT","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (aviptadil)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIPR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic SA Provides Update On Its Autoimmune Disease Platform Based On ATO (arsenic trioxide)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"T\/B Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-term Leqvio\u00ae (inclisiran) Data From Novartis Show Sustained Efficacy And Safety Over Four Years","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Provides EU Regulatory Update for AT-GAA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"Lysosomal alpha-glucosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Presents Additional Efficacy Analysis In Phase 2 Study Of VB10.16 In Combination With Atezolizumab In Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"APC receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer\u2019s Disease Patients with Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Polygala Tenuifolia Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elixirgen Therapeutics to Present New Data Showing Successful Ex Vivo Telomere Elongation with EXG-34217 in a Phase 1\/2 Clinical Trial at the 64th ASH Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EXG-001","moa":"ZSCAN4 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech Provides Update on Ongoing VTP-300 Phase 1b\/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"FS118","moa":"PD-L1\/LAG-3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD\u2019s The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Alpha1-proteinase","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"sGC Inhibitor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin\u2019s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"SGLT1\/2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"HBsAg expression","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting\u00ae 2022","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney W","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"Nicotinic receptor alpha4\/beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allysta Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2b\/3 Clinical Trial (OASIS-1) Evaluating the Efficacy and Safety of ALY688 Ophthalmic Solution in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ALY688","moa":"Adiponectin signaling pathway","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allysta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Ph.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia's CAN10 Demonstrates Positive Activity In Systemic Sclerosis Models In New Data Presented At ACR Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"HexaPro","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ N.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"BiomeBank","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomeBank Announces World First Regulatory Approval for Donor Derived Microbiome Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Microbiome-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BiomeBank","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BiomeBank \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BiomeBank .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA\u00ae (tapinarof) cream, 1% in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPrint\u2122 Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"PGF2 alpha receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint .."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics to Present Multiple Posters at SFN 2022 Neuroscience Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PIPE-791","moa":"LPA1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-01","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qnovia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ N.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sustained Patient Response to KRYSTEXXA\u00ae (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegloticase","moa":"Uric acid oxidative enzyme","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"DynamiCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"DCBY02","moa":"CD93","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"DynamiCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DynamiCure \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"DynamiCure.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanraplenib","moa":"Syk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"ExCellThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExCellThera Announces 100th Patient Treated With UM171-expanded Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"UM171-expanded Cord Blood Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ExCellThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE\u00ae (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"POMC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Neuronascent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NNI-362","moa":"S6K1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neuronascent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuronasce.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin 3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy - including in Difficult-to-Treat Manifestations - Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Funct","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17A receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"INT-787","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Pharmaceuticals Announces the Enrollment of the First Patient in Part 2 of the NOVA-II Phase 2 Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OQL011","moa":"VEGF","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Announces IND Approval for Second Phase 2 Clinical Trial of AC101 (HLX22) in Gastric Cancer developed by Shanghai Henlius Biotech in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"HLX22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Inventprise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Inventprise Pneumococcal Vaccine Enters Phase 1\/2 Clinical Evaluation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"25-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Inventprise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inventprise \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inventpris.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 \u2013 14, in Philadelphia, PA","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ABP-671","moa":"URAT1","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eikonoklastes Therapeutics Receives FDA Orphan Drug Designation for 1st-in-class Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ET-101","moa":"Caveolin-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eikonoklastes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklas.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing Chronic Obstructive Pulmonary Disease (COPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"CD103","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EDP-235","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants Approval of Beyfortus\u00ae\u25bc(nirsevimab) for Prevention of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK\u2019s Next-generation COVID-19 Booster Vaccine VidPrevtyn\u00ae Beta Approved By The European Commission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Monovalent Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL\u00ae System for Soft Tissue Repair","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Regenerative Epidermal Cell","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medi.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"ChemR23","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"JKB-122","moa":"TLR4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Immune Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immune The.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R\/R Patients with Neuroendocrine Carcinomas (NECs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Publication of Positive Data from Phase 1b\/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"MHC class II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of \u20181104 in Eosinophilic Esophagitis has Completed the Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"INF904","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1\/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Axitinib","moa":"Tyrosine kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA\u00ae (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Gu\u00e9rin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Engineered Oncolytic Adenovirus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Medikine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medikine Presents Preliminary Results of a Single-Dose Phase 1 Healthy Subject Study of MDK-703, a Peptide-Based Mimetic of Interleukin-7 (IL-7)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MDK-703","moa":"IL-7R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medikine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repertoire\u00ae Immune Medicines Presents New Data From Its DECODE\u2122 Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RPTR-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"PicnicHealth","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PicnicHealth Announces Engagement with Bristol Myers Squibb to Leverage Real-World Evidence to Study Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PicnicHealth","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PicnicHealth \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"PicnicHeal.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IO-202","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Provides Progress Update on its CYB004-E Phase 1 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EQ101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PYRUKYND\u00ae (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer\u2019s 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AK007","moa":"Siglec-10","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE\u2122 Molecule, at the Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"WTX-330","moa":"recombinant IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B\u2122 for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Bone Marrow-derived Medicinal Signaling Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ bioRASI","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1\/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda\u00ae (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sellas Life Sciences Group \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PHA121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting Neffy\u00ae (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics to Present New Preclinical Data for BRG1\/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"PD-1\/PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New TREMFYA\u00ae (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ATG-101","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineret\u00ae Authorised For Emergency Use By Fda For The Treatment Of COVID-19 Related Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA\u00ae (motixafortide) in Stem Cell Mobilization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"APL-1401","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"APG-5918","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc\/GSPT1 Degrader GT19715","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GT19715","moa":"c-Myc\/GSPT1 Degrader","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Resolve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RSLV-132","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Resolve Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resolve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Resolve Th.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NKTR-255","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Announces Efficacy and Safety Data for its I\/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Flugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Published in the Journal of Infectious Diseases Demonstrate FluGen's M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Live Attenuated Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Flugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flugen \/ N.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer\u2019s (SITC) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"23ME-00610","moa":"CD200R1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-rhPSMA-10.1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Blue Earth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission (EC) Approves LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And\/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Maribavir","moa":"CMV pUL97 kinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and Imjudo With Chemotherapy Approved in the US for Patients With Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KYV-101","moa":"CD19","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Tallac Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TAC-001","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tallac Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tallac Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tallac The.."},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Ph.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy In Combination With Pembrolizumab In Relapsed\/Refractory (R\/R) Gastrointestinal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CV8102","moa":"TLR7\/8\/RIG-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dose Escalation Data From TranscendIT-101, Ascendis Pharma\u2019s Phase 1\/2 Trial of TransCon\u2122 TLR7\/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Resiquimod","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"STAT3\/NF-kB\/poly-tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces New Data from a Phase 1\/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces CHMP Adoption of PRAC\u2019s Recommendation For Jyseleca\u00ae Following Extensive Safety Review Of All JAK Inhibitors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Presents Positive Phase 2 Data From Open Label Extension Study Of Donidalorsen At 2022 ACAAI Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Donidalorsen","moa":"Prekallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS\u00ae (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MSC-nTF Cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Expands Global Footprint In Rare Disease With Availability Of First Alexion Rare Disease Therapy For Patients In China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Presents New Biomarker Analysis For KIMMTRAK (tebentafusp-tebn) In Metastatic Uveal Melanoma At The SITC 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tebentafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen To Present New Research Across Serious Inflammatory And Bone Diseases At ACR 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Improved Symptom Burden And Health-related Quality Of Life In Patients With Mildly Reduced Or Preserved Ejection Fraction In DELIVER Phase III Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives Positive CHMP Opinion For Eylea\u2122 In The EU For Treatment Of Preterm Infants With Retinopathy Of Prematurity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Fosun Pharma Receive Emergency Use Authorization for Omicron-BA.4\/BA.5 Adapted Bivalent Vaccine in Hong Kong and Special Import Authorization for Macau","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Omicron BA.4\/BA.5-adapted Bivalent Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Provides An Update On Zejula (niraparib) US Prescribing Information","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK\u2019s Next-generation COVID-19 Booster Vaccine VidPrevtyn Beta Approved by the European Commission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant-protein Monovalent COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data For Bepirovirsen From B-clear Phase IIb Trial Presented At American Association For The Study Of Liver Diseases\u2019 Meeting With Simultaneous Publication In The New England Journal Of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bepirovirsen","moa":"HBsAg","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Provides Update on DREAMM-3 Phase III Trial For Blenrep in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Belantamab Mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New TREMFYA\u00ae (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful LongTerm Improvement in Health-Related Quality of Life","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Reinforces Commitment to Rheumatology with 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D Alpha\/5HT1D Beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon\u2019s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Lanier Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Molecules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LNR 125","moa":"IL-25","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lanier Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lanier Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lanier Bio.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"kt-3283","moa":"PARP-HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Receives Health Canada \u201cNo Objection Letter\u201d to Commence Clinical Trial of XPro1595 in Mild Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"TNF alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab \/ Balstilimab Combination in Nine Different Treatment-Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ABI-4334","moa":"cccDNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1\/2 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamoxifen Citrate","moa":"17-Beta estradiol","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PGN-EDO53","moa":"Exon 53 skipping oligonucleotide","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1\/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease at Neuroscience 2022 by the Society for Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-s","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1\/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"4D-150","moa":"VEGF A\/B\/C","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MSP-1014","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen\u00ae as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D Alpha\/5HT1D Beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Announces Positive Data from Ongoing Phase 1\/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-Weekly TransCon\u2122 CNP Achieved Primary Efficacy Objective, with Superiority at 100 \u00b5g\/kg\/week, in Ascendis Pharma\u2019s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Natriuretic Peptide, C-Type","moa":"C-type natriuretic peptide","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna's BA.4\/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Midatech Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Midatech P.."},{"orgOrder":0,"company":"Aerogen","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen and CanSinoBIO, First Public Booster Immunization in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Homologous Inactivated Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aerogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aerogen \/ CanSinoBIO","highestDevelopmentStatusID":"12","companyTruncated":"Aerogen \/ .."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Announces FDA Accelerated Approval of ELAHERE\u2122 (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine-gynx","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Formulation Of 5-MeO-DMT","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orionis Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Bi.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO\u00ae was Used in Patients with Upper Tract Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA synthesis","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Announces Publication of Phase 1 Data for Oral TNF-alpha Inhibitor MYMD-1\u00ae in Peer-Reviewed Journal Drug Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpiEndo Commences Phase 2a Trial For EP395 in COPD Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EP395","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Ph.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SPI-62","moa":"HSD-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Everest Medicines \/ Calliditas","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Medicines360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Medicines360's LILETTA\u00ae (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Medicines360","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Medicines360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medicines3.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces U.S. FDA Acceptance Of New Drug Application And EMA MAA Validation For Zilucoplan For The Treatment Of Generalized Myasthenia Gravis In Adult Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer'S Association Statement On Gantenerumab Phase 3 Topline Data Release","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioArctic Receives New Patent In The US For Blood-brain Barrier Transport Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QUVIVIQ (daridorexant) \u2013 Europe\u2019s First Dual Orexin Receptor Antagonist \u2013 Is Now Available For Patients With Chronic Insomnia Disorder In Italy And Germany","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAL02","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys\u2019 Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MorphoSys \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Global Rare Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Late-Breaking Phase 3 Data Presented At UEG Week 2022 Showed Significant Histological Remission Of Eosinophilic Esophagitis (EoE) In Children 1 To 11 Years Old","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"MedTech","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$110.0 million","newsHeadline":"TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Merger","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ MedTech","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"Casma Therapeutics","sponsor":"Amgen Ventures","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Casma Therapeutics Raises $46.0 M in Series C Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Casma Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Casma Therapeutics \/ Amgen Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Casma Ther.."},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","amount":"$93.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"PDL1 Dependent INF-alpha Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bonum Therapeutics \/ Roche Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Ther.."},{"orgOrder":0,"company":"Soligenix","sponsor":"NJEDA","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ NJEDA","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$30.0 million","newsHeadline":"Simcere and Idorsia Enter Into a Licensing Agreement for Daridorexant in China","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series C Financing","leadProduct":"JNT-517","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"DynamiCure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"DCBY02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ DynamiCure","highestDevelopmentStatusID":"6","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"Affini-T Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T's T Cell Therapy Programs Targeting Core Oncogenic Drivers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"TCR-engineered T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Affini-T Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affini-T Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"4","companyTruncated":"Affini-T T.."},{"orgOrder":0,"company":"Curatis","sponsor":"Great Health Companion Group Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Pamapimod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Great Health Companion Group Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"NextCure","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"NC762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NextCure \/ LegoChem Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$99.4 million","upfrontCash":"Undisclosed","newsHeadline":"Acrivon Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Prexasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Acrivon Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Th.."},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Redpin Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Redpin Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Redpin The.."},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"CRV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable, Suspension","sponsorNew":"Curevo Vaccine \/ Janus Henderson Investors","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vac.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio\u00ae Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Afrigen Biologics and Vaccines","sponsor":"Curapath","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curapath Announces Collaboration with Afrigen Biologics to Advance Development of African-owned mRNA SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA based SARS-CoV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Afrigen Biologics and Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Afrigen Biologics and Vaccines \/ Curapath","highestDevelopmentStatusID":"4","companyTruncated":"Afrigen Bi.."},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1\/TIGIT Bispecific","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AZD2936","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Hilma","sponsor":"Biocodex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocodex Group Strengthens Its Position in the US Market With the Acquisition of Hilma, a Fast-Growing Natural Remedies Start-Up","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Hilma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Hilma \/ Biocodex","highestDevelopmentStatusID":"12","companyTruncated":"Hilma \/ Bi.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","amount":"$266.0 million","upfrontCash":"$10.0 million","newsHeadline":"Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0.27000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0.27000000000000002,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Normunity","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Normunity","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Normunity \/ Alloy Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Normunity .."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Myeloma Investment Fund","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Financing","leadProduct":"DSP107","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kahr Medical","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Myeloma Investment Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"Theragent","sponsor":"CellVax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"FK-PC101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theragent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theragent \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Theragent .."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenaya Therapeutics Announces Pricing of Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"TN-301","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"RAPT Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Zelnecirnon","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"$395.0 million","upfrontCash":"Undisclosed","newsHeadline":"MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"MacroGenics","amount2":0.40000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Provention Bio","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase \u00ae Closes Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"HERA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ HERA","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Rezo Therapeutics","sponsor":"SR One","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rezo Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Rezo Therapeutics \/ SR One","highestDevelopmentStatusID":"2","companyTruncated":"Rezo Thera.."},{"orgOrder":0,"company":"Ossianix","sponsor":"Attralus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AT-04","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ossianix \/ Attralus","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/.."},{"orgOrder":0,"company":"FundaMental Pharma","sponsor":"BGV","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"FundaMental Pharma Launches With EUR 10 Million in Seed Financing Led By BGV and Thuja Capital to Advance A First-in-Class Neuroprotectant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"FundaMental Pharma","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"FundaMental Pharma \/ BGV","highestDevelopmentStatusID":"4","companyTruncated":"FundaMenta.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenaya Therapeutics Announces Proposed Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"K1.1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"PharmAla Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ PharmAla Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"NSERC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (\"NSERC\") Alliance Grant Funding","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"INM-900","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InMed Pharmaceuticals \/ NSERC","highestDevelopmentStatusID":"4","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Ateria Health","sponsor":"Immuron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.8 million","newsHeadline":"Immuron Completes Strategic Investment in Leading Gut Health Biotech Ateria Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ateria Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ateria Health \/ Immuron","highestDevelopmentStatusID":"12","companyTruncated":"Ateria Hea.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Noventia Pharma","sponsor":"Delbert Lab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DELBERT Laboratories Are Proud to Announce the Acquisition From Noventia Pharma Srl of the European Marketing Authorisation of CEPLENE\u00ae 0.5mg\/0.5ml","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Histamine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Noventia Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Noventia Pharma \/ Delbert Lab","highestDevelopmentStatusID":"12","companyTruncated":"Noventia P.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS\u2122 Selected Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"HFB200603","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Novartis","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix Announces $15 Million Private Placement with Existing Investors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Population Health Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"NVD200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invivyd \/ Population Health Partners","highestDevelopmentStatusID":"5","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monrol and FutureChem Announced a Clinical Supply Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"[177Lu]Ludotadipep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem","highestDevelopmentStatusID":"6","companyTruncated":"Eczac\u0131ba\u015f\u0131.."},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$100.0 million","newsHeadline":"Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004\/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"NNC6019","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Prothena","amount2":1.2,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Opna Bio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Opna Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Opna Bio \/ Longitude Capital","highestDevelopmentStatusID":"2","companyTruncated":"Opna Bio \/.."},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Healiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healiva\u00ae Acquires Critical Cell Therapy Manufacturing Assets From B. Braun","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocytes","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"B. Braun Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"B. Braun Medical \/ Healiva","highestDevelopmentStatusID":"12","companyTruncated":"B. Braun M.."},{"orgOrder":0,"company":"FogPharma","sponsor":"ARCH Venture","pharmaFlowCategory":"D","amount":"$178.0 million","upfrontCash":"Undisclosed","newsHeadline":"FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series D Financing","leadProduct":"FOG-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"FogPharma \/ ARCH Venture","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma .."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"scPharmaceuticals Announces Pricing of $50 Million Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenaya Therapeutics Announces Closing of Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"CalciMedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Graybug and CalciMedica Enter into Definitive Merger Agreement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Merger","leadProduct":"Auxora","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ CalciMedica","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"ObsEva","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$490.0 million","upfrontCash":"$15.0 million","newsHeadline":"XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Ebopiprant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0.48999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"ObsEva \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ X.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Raises \u20ac10 Million in Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Optinose","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces Pricing of Public Offering of Common Stock and Warrants","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.050000000000000003,"dosageForm":"Spray","sponsorNew":"Optinose \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"3","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Texas Health San Antonio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Agreement for Chlamydia Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Live Attenuated Chlamydia Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ University of Texas Health San Antonio","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Washington University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"SNS-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Enters Agreement with Dragonfly Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Dragonfly Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Reakiro","sponsor":"A2W Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A2W Pharma Ltd Announces Commercial Partnership with Reakiro","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Reakiro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Reakiro \/ A2W Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Reakiro \/ .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Dare Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"DARE-LBT","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,940.0 million","upfrontCash":"$180.0 million","newsHeadline":"I-Mab Provides Updates on Its Global Strategic Partnership with AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Termination","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":1.9399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.9399999999999999,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Enterome","sponsor":"BIOASTER Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enterome Collaborates With BIOASTER Institute to Provide New Insights Into Mechanisms of Potential Microbiome-Derived Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ BIOASTER Institute","highestDevelopmentStatusID":"4","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Pharmaceuticals Reaches Settlement Agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Iktos","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Iktos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Me.."},{"orgOrder":0,"company":"Turbine","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","amount":"$20.7 million","upfrontCash":"Undisclosed","newsHeadline":"Turbine Raises \u20ac20 Million in Series A Financing to Advance Programs & Partnerships Towards the Clinic with World\u2019s First Cancer Cell Simulation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Turbine \/ MSD Global Health Innovation","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company\u2019s Ophthalmic Pharmaceutical Business","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"ImaginAb","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"G1 Therapeutics Announces Closing of Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces Closing of $50 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Brandon Capital","pharmaFlowCategory":"D","amount":"$51.8 million","upfrontCash":"Undisclosed","newsHeadline":"CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series C Financing","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"CatalYm \/ Brandon Capital","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"SNAP CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ IQVIA","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Th.."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"University of Birmingham","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acticor Biotech: World\u2019s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acticor Biotech SAS \/ University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"G1 Therapeutics Announces Pricing of Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Ablexis","sponsor":"AlivaMab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Antibody-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ablexis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ablexis \/ AlivaMab","highestDevelopmentStatusID":"2","companyTruncated":"Ablexis \/ .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas' Partner Everest Medicine's New Drug Application for Nefecon is Accepted by the China NMPA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Phase IIa Study Results for a New First-in-class Candidate Medicine for Patients With Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GSK3036656","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Reports Positive TCMCB07 Data from Single Ascending Dose Portion of Phase 1 Clinical Trial in Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica B.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Publishes Phase 1 Trial Results for BIO 300 Oral Powder","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Trichomylin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"CVS Pharmacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmacist Prescribing of COVID-19 Antiviral Treatment Now Available at CVS Pharmacy\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CVS Pharmacy","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CVS Pharmacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CVS Pharma.."},{"orgOrder":0,"company":"ZielBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ZielBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZielBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ZielBio \/ .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR\/MSI-High Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GAd-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Highlights New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren\u2019s Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"ExCellThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExCellThera Announces Completion of Phase 2 Clinical Trials for UM171-Expanded Cell Therapy in High-Risk Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"UM171-expanded Cord Blood Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ExCellThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Dosing of the First Patient in Phase I\/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AUM001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"C101248","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inycte","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell CEO Discusses Positive Clinical Results of its Breast Cancer Immunotherapy Treatment in an Audio Interview with SmallCapVoice.com","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Inycte","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel\u2122 in 22q11.2 Deletion Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Announces VAZKEPA\u00ae (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Temelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeNeuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA\u00ae (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Announces Acceptance of their Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis to the UK Medicines and Healthcare Products Regulatory Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Trimethoprim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MLS-101","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coagulant Therapeutics Announces Upcoming Oral and Poster Presentations at the 2022 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CT-001","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant .."},{"orgOrder":0,"company":"Biovaxys","sponsor":"The Ohio State University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BVX-0320","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biovaxys \/ The Ohio State University","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces Presentation of Data From Ongoing Phase 1\/2 trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma (ROSALIE study) at SNO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EO2401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC61","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1\/2 BRILLIANCE Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EDIT-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Leucovorin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IM156","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoMet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoMet \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMet .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP\u00ae Therapy Platform for Targeted Treatment of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EP547","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Announces Upcoming Presentation of Late-Breaking Data for MYMD-1\u00ae at the 2022 British Society for Immunology (BSI) Congress","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AZR-MD-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Afrin\u00ae WOWs Parents with Launch of Children\u2019s Acute Medicated Nasal Sprays \u2013 Because One Sick Kid Can Throw Everything Off in An Instant","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Trial of ICLUSIG\u00ae (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ponatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Kinevant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Namilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Kinevant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kinevant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kinevant S.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives European Commission Approval for BRUKINSA\u00ae (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Publication in Cells Demonstrating AV-101\u2019s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"4-Chlorokynurenine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Opaganib","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Ascendis Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Ascendis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Provides an Update on Lassa Fever and MERS Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"INO-4500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax\u00ae-L for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dendritic Cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Endari\u00ae Marketing Authorization from the Qatar Ministry of Public Health","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA\/LABA as the Preferred Treatment for the Majority of Patients with COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Enjaymo\u00ae (Sutimlimab) for Treatment of Hemolytic Anemia in Adult Patients With Cold Agglutinin Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides Vitargus\u00ae Update - Phase II Vitargus\u00ae Study Protocol Received Thai FDA Approval","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab \/ Balstilimab Combination in Advanced Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces First Subjects Dosed in Phase 1a\/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"Sernova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sernova Announces First Two Patients Implanted with Cell Pouch\u2122 in the Second Cohort of its US Phase 1\/2 Clinical Trial for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Donor Islets Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sernova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Jeune Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KB301","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Jeune Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jeune Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jeune Aest.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Announces Promising Results From Phase 1\/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EVX-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT162b4","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNtech","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Vyant Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vyant Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyant Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vyant Bio .."},{"orgOrder":0,"company":"DepYmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DepYmed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ .."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF\/MET Platform at Neuroscience 2022 Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"INBRX-109","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sezaby\u2122 (Phenobarbital Sodium Powder for Injection) Approved By USFDA for the Treatment of Neonatal Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Phenobarbital Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Starts Enrolling Long COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin\u2019s Lymphoma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Updates and Topline Results from Phase 2\/3 AAVance Gene Therapy Clinical Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces Interim Analysis for KALAHARI Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA\u2019s Orange Book","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"TrueBinding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrueBinding Announces Results of TB006 Phase 1b\/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TB006","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"TrueBinding \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBindin.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at the 2022 CTOS Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AMB-05X","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Oncorus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR\/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ONCR-719","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncorus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oncorus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncorus \/ .."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN-3110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Report New Data on Omicron BA.4\/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene to Provide Updates and Topline Results from Phase 2\/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday\/Wednesday\/Friday Intramuscular Dosing Schedule for Rylaze\u00ae (asparaginase erwinia chrysanthemi (recombinant)-rywn)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides Update on Its REDUVO\u2122 New Drug Submission","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Prasco Laboratories","sponsor":"Thea Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prasco Launches Authorized Generic of ZIOPTAN\u00ae Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Prasco Laboratories","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"Prasco Laboratories \/ Thea Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Prasco Lab.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)","therapeuticArea":"Sleep","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioarctic Expands Portfolio With Alpha-synuclein Brain Transporter Project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PD-BT2238","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody\u00ae-CD3xCD20) for the Treatment of Relapsed\/Refractory Large B-Cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz\u00ae-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3K\u03b1 Inhibitor at San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"STX-478","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Provides Regulatory Update on Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LB2102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology\u2122 (PERIO\u2122) 01 and 02 Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer\u00e2\u20ac\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replay Launches Big DNA HSV Gene Therapy Company, Telaria, Focused on Rare Skin Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SynHSV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RP1208","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics\u00ae Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Onapristone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Pluripotent Stem Cell Derived Neuronal Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Dosing Of First Patient In Phase 1\/2 Trial Of YH001 In Combination With Envafolimab And Doxorubicin In Front Line Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai To Present Full Findings From Lecanemab Confirmatory Phase 3 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in PII 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"4-L-[131I] Iodo-phenylalanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND Approval From FDA For Theranostic SAR-Bombesin Trial in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SAR-bombesin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triastek Receives FDA IND Clearance for 3D Printed Medicine","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"T21","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Triastek","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Recommended for Approval in the EU by CHMP For Patients With Previously Treated HER2-positive Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Recommended for Approval in the EU by CHMP as First Immunotherapy Regimen for Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza in Combination With Abiraterone Recommended for Approval in the EU by CHMP As 1st-line Treatment for Patients With Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Results of Booster Vaccination Trial of Its mRNA COVID-19 Vaccine (DS-5670) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac Co.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metoject\u00ae Subcutaneous Injection Syringe (Methotrexate) Launched in Japan for Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eisai \/ Nippon Medac Co.","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ni.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Imlunestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY\u00ae Subcutaneous Injection 225mg for Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces European Commission Approval of SKYRIZI\u00ae (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Risankizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome\u2019s OncoMimics\u2122 Peptide-based Immunotherapy EO2401 Generates and Maintains Elevated Anti-tumor T Cell Responses for More Than 10 Months in Patients With Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces First Patient Dosed in a Phase 1\/2 trial with Second OncoMimics\u2122 vaccine, EO2463, in Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"EO2463","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome\u2019s Innovative OncoMimics\u2122-Based Immunotherapy EO2401 distinguished with \u201cBest Clinical Research Award\u201d at EANO Meeting 2022 for Promising Results in Recurrent Gliobastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Highlights Microbiome Publication Describing Sibofimloc\u2019s Novel Mechanism of Action for the Treatment of Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sibofimloc","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome to Present Significant Progress With Its Oncomimics\u2122 Pipeline at Jefferies London Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Significant Progress with OncoMimics\u2122 and EndoMimics\u2122 pipelines of transformational medicines for cancer and immune diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in a Phase 1\/2 Trial With EO2401, an Innovative \u2018oncomimic\u2019 Based Immunotherapy Candidate Targeting Adrenal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EO2401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Initiates First Clinical Trial With EO2401 \u2013 an Innovative Microbiome-antigen (\u2018oncomimic\u2019) Based Cancer Immunotherapy Candidate Targeting Aggressive Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion Announces Sonlicromanol Phase IIb Progress Supporting Phase III Development in Melas Spectrum Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spravato\u00ae (Esketamine Nasal Spray) Data From the Phase 3b ESCAPE-TRD Study Demonstrate Superior Efficacy Compared to Quetiapine Extended-release in Treatment-resistant Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Launches First Commercial for VTAMA\u00ae (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Second Biosimilar with RELEUKO\u00ae (filgrastim-ayow) in the United States","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Filgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C\u2019s Potential as an Effective Treatment for Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX104C","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presents Additional Phase 1\/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA\u00ae Versus IMBRUVICA\u00ae in Late-Breaking Oral Session at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer\u2019s Disease Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"University of Michigan School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SOD2 mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ University of Michigan School","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Reaches Target Enrollment for IB1001 NPC Pivotal Clinical Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granules for Oral Suspension","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune\u00ae, in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosight Launches a Phase 1\/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MT-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Publication of Positive Phase 2 data in Translational Vision Science & Technology (TVST) Investigating Topical Anti-TNF\u03b1 Agent Licaminlimab (OCS-02) in Acute Anterior Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Licaminlimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MORF-057","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ARV-471","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT\u00ae (avapritinib) for the Treatment of Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Avoro Capital","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"Nab-sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.070000000000000007,"dosageForm":"Suspension for Injection","sponsorNew":"Aadi Bioscience \/ Avoro Capital","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sirona Biochem Corp \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Evive Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurobindo Unit, Evive Biotech Ink Licensing Pact to Commercialise CIN Treatment Product in US","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurobindo Pharma Limited \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Biocon \/ Z.."},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"International Vaccine Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Cholera Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Biovac Institute \/ International Vaccine Institute","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac.."},{"orgOrder":0,"company":"MedinCell","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$41.8 million","upfrontCash":"Undisclosed","newsHeadline":"France : EIB and MedinCell Sign a New \u20ac40 Million Loan Agreement to Support Development of Innovative Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0.040000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ European Investment Bank","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect\u2122 Formulation of Teprotumumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xeris Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"AcuCort","sponsor":"Kamada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AcuCort Signs Its First Commercial Agreement for The Company's Drug Zeqmelit\u2122","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AcuCort","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Film","sponsorNew":"AcuCort \/ Kamada","highestDevelopmentStatusID":"12","companyTruncated":"AcuCort \/ .."},{"orgOrder":0,"company":"InfoRLife SA","sponsor":"Navamedic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Navamedic ASA Acquires Innovative Antibiotic Product for Hospital Use in The Nordic Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Clindamycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InfoRLife SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InfoRLife SA \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"InfoRLife .."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$82.7 million","newsHeadline":"Grunenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Kirin \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"XtalPi","sponsor":"CK Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XtalPi and CK Life Sciences to Collaborate in AI-empowered Tumour Vaccine Research And Development, Opening A New Paradigm For Scientific Innovation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ CK Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ C.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.23999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Hemispherian","sponsor":"Meneldor","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Hemispherian Raises the First Tranche of A Series A To Fund the Development of Its Novel Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"GLIX1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemispherian \/ Meneldor","highestDevelopmentStatusID":"4","companyTruncated":"Hemispheri.."},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"Biovac Signs Deal With IVI to Develop and Manufacture Oral Cholera Vaccine for African and Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Cholera Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The Biovac Institute","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"The Biovac Institute \/ Wellcome","highestDevelopmentStatusID":"4","companyTruncated":"The Biovac.."},{"orgOrder":0,"company":"NICE","sponsor":"Healthcare Improvement Scotland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NICE and SMC\/HIS Collaboration on Health Technology Appraisal of Therapeutics for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Cilgavimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NICE","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NICE \/ Healthcare Improvement Scotland","highestDevelopmentStatusID":"12","companyTruncated":"NICE \/ Hea.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides Enters Into a Renewed Loan Facility Agreement of Up To \u20ac30 Million with The European Investment Bank","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Melphalan Flufenamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ European Investment Bank","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs License Agreement With Voyager for Use of Touchlight\u2019s DNA Technology in Voyager\u2019s Capsid Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Voyager Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Antibody Agreement with ADC Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ ADC Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Lyvgen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"LVGN7409","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lyvgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lyvgen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Lyvgen \/ B.."},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$200.0 million","newsHeadline":"AstraZeneca To Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"TCR Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$41.4 million","upfrontCash":"$20.7 million","newsHeadline":"BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Funding","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"MediPharm Labs \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Aurigene","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership With EQRX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aurigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aurigene \/ EQRx","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene \/.."},{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The French Specialty Pharmaceutical Company Juvis\u00e9 Pharmaceuticals Has Successfully Completed a \u20ac400M Refinancing Following the Acquisition of The Worldwide Rights of Pylera\u00ae, An Antimicrobial Tri-Therapy Indicated for Gastro-Intestinal Helicobacter Pylor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"Bismuth Potassium Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Juvise Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Juvise Pharmaceuticals \/ AbbVie","highestDevelopmentStatusID":"12","companyTruncated":"Juvise Pha.."},{"orgOrder":0,"company":"Evonik","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evonik \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Evonik \/ P.."},{"orgOrder":0,"company":"Evonik","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evonik Invests US$220 Million in Partnership with The U.S. Government to Build New Lipid Production Facility For mRNA-Based Therapies in The U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evonik","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"Evonik \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Evonik \/ B.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vaccines for Africa","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"10 Valent Pneumococcal Polysaccharide Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Serum Institute of India","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Treeway","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Signs License Agreement To Develop An Oral Formulation Treatment For Patients With ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ferrer Internacional \/ Treeway","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Int.."},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"TaiRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora Pharmaceuticals Partners with TaiRx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bora Pharmaceuticals \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"Bora Pharm.."},{"orgOrder":0,"company":"C4X Discovery","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$402.0 million","upfrontCash":"$2.0 million","newsHeadline":"C4XD Agreement with AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"C4X_6665","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.40000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"C4X Discovery \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discov.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$15.7 million","upfrontCash":"Undisclosed","newsHeadline":"Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Alaunos Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"KPI-012","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kala Pharmaceuticals \/ ","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Withdrawal of Marketed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces $3.8 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ ","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Replay Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Replay Receives $1.5 Million Grant For Its Hypoimmunogenic Technology Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"iPSC-derived Immune Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bright Minds Biosciences Announces Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ ","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Farma Mondo Group and Helsinn Sign Exclusive Partnership To Commercialize AKYNZEO\u00ae In The Baltic Region","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Netupitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"FarmaMondo","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"FarmaMondo \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"FarmaMondo.."},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"ICR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ICR Announces New Strategic Collaboration With Apollo Therapeutics To Develop Novel Cancer Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ ICR","highestDevelopmentStatusID":"2","companyTruncated":"Apollo The.."},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"FPV","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Strand Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ FPV","highestDevelopmentStatusID":"4","companyTruncated":"Strand The.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"NEA","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Escient Pharmaceuticals Announces $120 Million Series C Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series C Financing","leadProduct":"EP547","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ NEA","highestDevelopmentStatusID":"8","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Focus-X Therapeutics","sponsor":"Full-Life Technologies","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"NTSR1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Focus-X Therapeutics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Focus-X Therapeutics \/ Full-Life Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Focus-X Th.."},{"orgOrder":0,"company":"Cajal Neuroscience","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Cajal Neuroscience","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cajal Neuroscience \/ The Column Group","highestDevelopmentStatusID":"2","companyTruncated":"Cajal Neur.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin's Brazil Subsidiary Acquires 9 Brands From Bausch Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Chlordiazepoxide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaJet Receives NIH Grant to Evaluate Use of Needle-free Intradermal Delivery for HPV Immunization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Funding","leadProduct":"HPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaJet \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ribon Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Oncolytic Viral Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turnstone Biologics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Minapharm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Minapharm Pharmaceuticals \/ Bioventure","highestDevelopmentStatusID":"1","companyTruncated":"Minapharm .."},{"orgOrder":0,"company":"EpicentRx","sponsor":"FightMND","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"EpicentRx Awarded Funding from FightMND to Evaluate Therapeutic Potential of RRx-001 in Motor Neuron Disease (aka ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Argenx","sponsor":"USFDA","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"argenx Enters Into Agreement To Acquire Priority Review Voucher","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ USFDA","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ U.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Voriconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Sotio","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"SOT106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sotio \/ Le.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"$5.0 million","newsHeadline":"Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-1777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Beacon Discovery","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Beacon Discovery","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Discovery \/ Eurofins","highestDevelopmentStatusID":"2","companyTruncated":"Beacon Dis.."},{"orgOrder":0,"company":"Intract Pharma","sponsor":"SGS Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SGS\u2019s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Infliximab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Intract Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intract Pharma \/ SGS Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Intract Ph.."},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"ET-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eikonoklastes Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklas.."},{"orgOrder":0,"company":"Scynexis","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"SCY-247","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Progesterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"MedinCell","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"UTMB","sponsor":"HDT Bio","pharmaFlowCategory":"D","amount":"$87.4 million","upfrontCash":"Undisclosed","newsHeadline":"UTMB and HDT Bio Awarded Prototype Project Funding Worth Up To $87.4M From the U.S. Government to Develop saRNA Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"saRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"UTMB","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"UTMB \/ HDT Bio","highestDevelopmentStatusID":"4","companyTruncated":"UTMB \/ HDT.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bluebird Bio Sells Priority Review Voucher for $102 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Divestment","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Suspension For Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$80.4 million","upfrontCash":"Undisclosed","newsHeadline":"Aura Biosciences Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Public Offering","leadProduct":"Belzupacap Sarotalocan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Advancements in FDA Review of ROCTAVIAN\u2122 (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Further Improves THR-149 Patent Position","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune to Present Progress of Alzheimer\u00e2\u20ac\u2122s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai To Present Latest Data On Fycompa\u00ae (perampanel) Ciii At The 76Th American Epilepsy Society (Aes) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STORM Therapeutics Doses First Patient With Oral METTL3 Targeting Drug Candidate In A Solid Tumor Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"STC-15","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Storm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Group Announces Presentation Of New Leniolisib Data At 2022 ASH Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"SpectrumX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpectrumX Confirms Next Step in Clinical Development of Respiratory Drug Candidate SPX-001 After MHRA Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypochlorous Acid Based SPX-069","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpectrumX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpectrumX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SpectrumX .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LetibotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Hugel","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hugel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hugel \/ No.."},{"orgOrder":0,"company":"Synletis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sylentis, a PharmaMar Group Company, Begins A New Phase II Trial With SYL1801 For Patients With Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SYL1801","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Synletis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Synletis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synletis \/.."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Pharmaceutical Obtains Additional Indication of \"Postoperative Adjuvant Chemotherapy for Hormone Receptor-Positive and HER2-Negative Breast Cancer at High Risk of Recurrence\" for Oral Anticancer Agent TS-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Tegafur","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"Acousia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hearing Loss Company Acousia Therapeutics to Present Data for Lead Candidates ACOU085 & ACOU082 at ARO 2023 Mid Winter Meeting February 11-15","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ACOU085","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Acousia Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acousia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acousia Th.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MAPT N279K","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"9vHPV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyderabad's Biophore To Manufacture Ingredients of Pfizer's Covid Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophore I.."},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophore Applies For DCGI Approval for Emergency Use of Aviptadil to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biophore I.."},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenara Pharma, a Biophore Subsidiary, Gets DCGI Nod for Favipiravir Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zenara Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenara Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zenara Pha.."},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyderabad Based Biophore India Gets DCGI Nod To Manufacture COVID Drug Favipiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophore I.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemotherapy May Be Completed Within 8 Days with Two Doses of Polytaxel, an Innovative Anticancer Drug from South Korea's Biotech Firm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hyundai Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hyundai Bi.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Data From The AGENT Study Confirms Topline Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Partial Clinical Hold on Diamyd\u00ae Phase III Trial Lifted by the FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"GAD65-Alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Successful Tests in Animal Models Pave Way for Strategy for Universal Flu Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Flu Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"University of Pennsylvania \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Taisho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibandronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Taisho Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves CSL\u2019s HEMGENIX\u00ae (etranacogene dezaparvovec-drlb), The First Gene Therapy For Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eleven Experts From Leading Medical Institutions And Eight Experts From Eisai* Publish Full Results Of Lecanemab Phase 3 Confirmatory Clarity Ad Study For Early Alzheimer\u2019s Disease In The New England Journal Of Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer\u2019s Disease At Clinical Trials On Alzheimer\u2019s Disease (Ctad) Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants Expanded Marketing Authorization for Gilead\u2019s Biktarvy\u00ae for the Treatment of HIV in Pediatric Populations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Etrumadenant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Arcus Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Provides An Update On Blenrep (belantamab mafodotin-blmf) US Marketing Authorization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Belantamab Mafodotin-blmf","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sanofi","sponsor":"DNDi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acoziborole: Investigational Single-dose Oral Treatment Raises Hope For Elimination Of Sleeping Sickness In Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Acoziborole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ DNDi","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ D.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Submits Response to FDA Complete Response Letter for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in Japan for Patients with Previously Treated HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data on Perampanel at The 76th American Epilepsy Society (AES) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept\u00ae for Treatment of Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Donepezil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Prostate Cancer Medicines Abiraterone and Abiraterone\/prednisolone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces 3 Major Product Launches","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the FDA Approval and Launch of an AB Rated Generic Version of Tobradex\u00ae Ophthalmic Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tobramycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspirin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ferrer Internacional","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"12","companyTruncated":"Ferrer Int.."},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled In Ferrer's FNP122 ADORE Phase III Clinical Trial For Amyotrophic Lateral Sclerosis (ALS) Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ferrer Internacional","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferrer Internacional \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferrer Int.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Approves FYB201\/CIMERLITM* (ranibizumab-eqrn), The First and Only Biosimilar Interchangeable with Lucentis\u00ae**","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics Announces FDA File Acceptance For Review Of Natalizumab, First Proposed Biosimilar To Tysabri\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA\u2019s Authorization for BIOEQ\u2019s Biosimilar in the United Kingdom","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Formycon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics Group Announces That Its Joint Venture Company Bioeq Has Submitted A Biologics License Application (BLA) to the FDA For The Ranibizumab Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bioeq IP AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioeq IP AG \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Bioeq IP A.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Approved In Chinafor The Treatment Of Iron Deficiency In Adult Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Speedy Review To Sarepta\u2019s Duchenne Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KPI-012","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Secures A New Patent Expanding The IP Protection Of Its Lead Product Candidate Lanifibranor In The US","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TN-401","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PTX-COVID19-B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Providence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PRAX-562","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IK-595","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Provides Update on CRN04777 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CRN04777","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8\u00ae Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel in the Journal of Neurodevelopmental Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA\u00c2\u00ae (lefamulin) in Adult Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO\u00ae (berotralstat) by the Israeli Ministry of Health","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ATH-1105","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"T Cell Adaptive Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Announces First Patient Dosed in its Phase 1\/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer\u2019s Disease Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO (berotralstat) by the Israeli Ministry of Health","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Hugel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma Australia, a Subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LetibotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Hugel","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hugel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hugel \/ No.."},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NP137","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NETRIS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NETRIS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NETRIS Pha.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Granted Broad Patent on Treatment of Neurodegenerative Conditions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Broccoli Extract","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen\u00ae) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"RG6501","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec SE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1\/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"EXS-21546","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Exscientia \/ Evotec SE","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluoxetine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech\u2019s Intranasal Vaccine \u2018iNCOVACC\u2019 Eeceives CDSCO Approval Under Restricted Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Apimostinel","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gate Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gate Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gate Neuro.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Provides Development Program Updates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Volixibat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Announces Launch Of Leuprolide Acetate Injection Depot (22.5Mg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents Full Results Of Lecanemab Phase 3 Confirmatory Clarity Ad Study For Early Alzheimer'S Disease At Clinical Trials On Alzheimer'S Disease (CTAD) Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Sanzyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Probiotic Strain SNZ 1969\u00ae Helps Manage IBS-D & IBS-C Symptoms Effectively, Latest Clinical Study Shows","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Probiotic Strain SNZ 1969","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanzyme","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanzyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanzyme \/ .."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyra Biosciences Initiates SURF301 Phase 1\/2 Clinical Study and Doses First Patient with TYRA-300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TYRA-300","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyra Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yuyu Pharma Plans to Enter the U.S. and European Markets for Hair Loss Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dutasteride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuyu Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharm.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"International Vaccine Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover\u2019s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SCB-2019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ International Vaccine Institute","highestDevelopmentStatusID":"10","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"MedGene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedGene Therapeutics Publishes Preclinical Data Demonstrating RIV-8\u2019s Ability to Overcome T Cell Exhaustion in the Journal Science Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MedGene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MedGene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MedGene Th.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-1558","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-260","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Data from Ambrx\u2019s Study of ARX788 Selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ARX788","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Announces Presentation On CINV Trial at European Society for Medical Oncology (ESMO) Asia","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Netupitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie\u2019s Phase 3 Trial Assessing NE3107 in Alzheimer\u2019s Disease Has Fully Enrolled the Targeted 316 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer\u2019s Disease Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Diazepam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Integral Molecular","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics\u00ae Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Integral Molecular","highestDevelopmentStatusID":"4","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-PNT6555","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AK006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Reports Successful Results In Preclinical In Vivo Study Of Its Innovative Inhaled COVID-19 NanoAb Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"COVID-19 NanoAb","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of Phase 2 D-PLEX\u2081\u2080\u2080 Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune\u2019s Alzheimer\u2019s Disease Vaccine-candidate ACI-35.030 Selected for Further Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta\u2019s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merakris Announces Review in Biomedicines Medical Journal Highlighting Therapeutic Potential of Cell-Free Amniotic Fluid","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Merakris Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merakris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Merakris T.."},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenara Launches Generic Version Of Pfizer Covid Drug Paxlovid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophore I.."},{"orgOrder":0,"company":"Erasca","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erasca \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ P.."},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow and iOR Partners Expand National Product Supply Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ i.."},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Integrated Sciences\u2019 Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Torsemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sarfez Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Sarfez Pha.."},{"orgOrder":0,"company":"Liminatus Pharma","sponsor":"Iris Acquisition Corp","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Liminatus Pharma LLC and Iris Acquisition Corp to Combine to Incorporate and Accelerate Much-Needed Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Financing","leadProduct":"Adenovirus 5\/F35-human Guanylyl Cyclase C-pADRE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Liminatus Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Liminatus Pharma \/ Iris Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Liminatus .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Canadian Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche Canada Announces Purchase Agreement with the Government of Canada for ACTEMRA\u00ae IV (tocilizumab for injection) for Treatment of Adult Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Canadian Government","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Akouos","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,097.0 million","upfrontCash":"$1,097.0 million","newsHeadline":"Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":1.1000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Akouos \/ Eli Lilly","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ E.."},{"orgOrder":0,"company":"Renovacor","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rocket Pharmaceuticals Completes Acquisition of Renovacor","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"REN-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Renovacor","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Renovacor \/ Rocket Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Renovacor .."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Minotaur Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies(TM) (HSB-1940) Against PD-1, By Combining Quatramers(TM) with OmniAb's Picobodies(TM), via a Collaboration Agreement, Against Novel, Unreachable and Undruggabl","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"HSB-1940","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Minotaur Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carrick Therapeutics Closes Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series C Financing","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carrick Therapeutics Announces $35 Million Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma and Pediatrix Therapeutics Announce Expansion of Partnership to Commercialize Tris's ADHD Portfolio and Pipeline Products in China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Gadeta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (\u03b3\u03b4) TCR ImmTAC for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"GDT201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunocore \/ Gadeta","highestDevelopmentStatusID":"4","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neuro-inflammation Biotech Jupiter Neurosciences Revises Terms Ahead Of $15 million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Ne.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Focus-X Therapeutics","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Radiopharmaceutical Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Full-Life Technologies","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Focus-X Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Pricing of $5 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"CMS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ CMS","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","amount":"$225.7 million","upfrontCash":"$140.0 million","newsHeadline":"TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mayne Pharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.23000000000000001,"dosageForm":"Insert","sponsorNew":"Mayne Pharma \/ TherapeuticsMD","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Curamys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Curamys","highestDevelopmentStatusID":"1","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"AbCellera","sponsor":"Rallybio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Rallybio","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Vaxart","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Norovirus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ B.."},{"orgOrder":0,"company":"AavantiBio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Merger","leadProduct":"AVB-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AavantiBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AavantiBio \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AavantiBio.."},{"orgOrder":0,"company":"AavantiBio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Merger","leadProduct":"AVB-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AavantiBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AavantiBio \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AavantiBio.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Private Placement","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100\u00ae Disc Program to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Regenexx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenexx \/ BioRestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Collaboration with Boston Children\u2019s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"TNX-1500","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"MBP134","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mapp Biopharmaceutical \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Bioph.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Mainbridge Health Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Mainbridge Health Partners","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$60.7 million","upfrontCash":"Undisclosed","newsHeadline":"SonoThera Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"SonoThera","amount2":0.059999999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SonoThera \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"SonoThera .."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$40.0 million","newsHeadline":"AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Clear Creek Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clear Creek Bio \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Clear Cree.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"National Institute for Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"KRM-II-81","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ National Institute for Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"ExpreS2ion Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evaxion and ExpreS\u00b2ion Initiate Research Collaboration On A Novel Cytomegalovirus (CMV) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"EVX-V1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ ExpreS2ion Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Re-vana Therapeutics Raises $11.9 Million In Series A Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Th.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"OneVentures","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Raises US$23 Million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"HexaPro","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ OneVentures","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ O.."},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","amount":"$136.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Closing of $5 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Meloxicam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Entactbio","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entact Bio Launch with $81M Series A to Develop Precision Medicines for Targeted Protein Enhancement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Entactbio","amount2":0.080000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Entactbio \/ 4BIO Capital","highestDevelopmentStatusID":"2","companyTruncated":"Entactbio .."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Enzyvant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzyvant Announces Merger with Altavant","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Merger","leadProduct":"Allogeneic Processed Thymus Tissue-agdc","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altavant Sciences \/ Enzyvant Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Eunice Kennedy Shriver National Institute Of Child Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem\u00ae Targeting Polycystic Ovary Syndrome as an Indication","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Brown Adipose-derived Stem Cells","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Eunice Kennedy Shriver National Institute Of Child Health","highestDevelopmentStatusID":"1","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Pictet Alternative Advisors","pharmaFlowCategory":"D","amount":"$147.5 million","upfrontCash":"Undisclosed","newsHeadline":"Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series C Financing","leadProduct":"Opelconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Suspension","sponsorNew":"Pulmocide \/ Pictet Alternative Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide .."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syndax Announces Pricing of $150 Million Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Axatilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA\u00ae (pembrolizumab) in Patients with HPV16-Positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.25,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Prices $65.0 Million Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","amount":"$136.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Merger","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic .."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$550.0 million","upfrontCash":"$50.0 million","newsHeadline":"Sanofi Terminated the Collaboration with Revolution Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"Vociprotafib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Revolution Medicines","amount2":0.55000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"NJ Biopharmaceuticals","sponsor":"Aarvik","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aarvik Therapeutics Announces a Global Novel Payload Agreement with NJ Bio, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NJ Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NJ Biopharmaceuticals \/ Aarvik","highestDevelopmentStatusID":"4","companyTruncated":"NJ Biophar.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$50.0 million","newsHeadline":"Kite and Daiichi Sankyo Announce Changes to YESCARTA\u00ae CAR T-Cell Therapy Licensing Agreement in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"infusion","sponsorNew":"Kite Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"KCNC1 Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Metrion Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metrion Biosciences \/ KCNC1 Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Metrion Bi.."},{"orgOrder":0,"company":"Touchlight","sponsor":"Odimma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Odimma Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Boosts \u2018Coronavirus X\u2019 Vaccine Search With Expanded VBI Vaccines Deal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"VBI-2900","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"VBI Vaccines","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"VBI Vaccines \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Infinimmune Raises $12 Million in Seed Funding to Pioneer Novel Approach to Antibody Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Infinimmune","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Infinimmune \/ Playground Global","highestDevelopmentStatusID":"2","companyTruncated":"Infinimmun.."},{"orgOrder":0,"company":"Equillium","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$164.5 million","upfrontCash":"$26.0 million","newsHeadline":"Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Itolizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0.16,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Universitat Aut\u00f2noma de Barcelona","sponsor":"ANEW MEDICAL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANEW MEDICAL, INC. Acquires World Wide License to Treat Neurodegenerative Diseases Using a Longevity Protein and Gene Therapy Programs.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Alpha Klotho Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Universitat Aut\u00f2noma de Barcelona","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Universitat Aut\u00f2noma de Barcelona \/ ANEW MEDICAL","highestDevelopmentStatusID":"4","companyTruncated":"Universita.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma Announces Acquisition of New, Late-Stage Drug Candidate for Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"TRN-261","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ Tris Pharma Inc","highestDevelopmentStatusID":"1","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Berkshire Biomedical","sponsor":"National Institute of Drug Abuse","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Berkshire Biomedical Awarded Phase II Funding for NIH Research Grant to Support Continued Development of the COPA\u2122 System for Automated at Home Methadone Administration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Methadone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Berkshire Biomedical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Berkshire Biomedical \/ National Institute of Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Berkshire .."},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"QVC Skincare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pressure BioSciences Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening and Wrinkle Reduction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Vitamin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pressure BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pressure BioSciences \/ QVC Skincare","highestDevelopmentStatusID":"1","companyTruncated":"Pressure B.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"BVF Partners L.P.","pharmaFlowCategory":"D","amount":"$70.6 million","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ BVF Partners L.P.","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","amount":"$7.9 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"SAB-195","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Brookline Capital Markets","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Replimune Announces Proposed Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Negev Capital","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Announces Closing of Private Placement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Negev Capital","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Evercore Group L.L.C.","pharmaFlowCategory":"D","amount":"$65.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Gemtuzumab Ozogamicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Evercore Group L.L.C.","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Replimune","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replimune \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Announces the Acquisition of HALDOL\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Haloperidol Decanoate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Gemtuzumab Ozogamicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics to Present FLX475 Phase 1\/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tivumecirnon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b\/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ATL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reimbursed Access to Bylvay\u00ae (odevixibat) Approved in France for Patients with PFIC 1 & 2","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"AUM302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases - Biology and Therapeutics Conference and Publication in Neuropharmacology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"C101248","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces New Patent for Mycapssa\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-3600","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Memgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"MEM-288","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Memgen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Memgen \/ N.."},{"orgOrder":0,"company":"Spirita Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Combination with Dabrafenib in Patients with Central Nervous System Metastases from BRAF V600 Mutated Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"E6201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spirita Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spirita Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spirita On.."},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing .."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer's Disease (CTAD) and Neuroscience 2022 Meetings","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX-07010","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Receives FDA \u201cStudy May Proceed\u201d Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"PH10","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant\u2019s PFS Increases with Duration of Prior CDK4\/6i in ER+, HER2- in Metastatic Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ NYU Langone Health","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Sci.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Announces Strategic Prioritization of SQZ\u00ae Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS\u00ae (voclosporin) for the Treatment of Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856 Presented at Alzheimer's Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Initiates Phase 1 Study of Immune-enabling Antibody Therapy CMTX-101 Against Community-acquired Bacterial Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CMTX-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LUCIDITY Phase 3 Topline Data Presented At CTAD For HMTM - The Only Oral Anti-Tau Therapy In Late-stage Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dianthus Therapeutics Announces First Participant Dosed in Phase 1 Trial of DNTH103, a Selective Inhibitor of the Classical Complement Pathway","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"DNTH103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dianthus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus T.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Kira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"KP104","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Kira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kira Pharm.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 Induced Oropharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Launches Phase I Clinical Trial Of Avacc 10\u00ae, An Intranasal Subunit Booster Vaccine For SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacc 10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Jemperli RUBY Phase III Trial Met Its Primary Endpoint For Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces U.S. FDA Approval of REZLIDHIA\u2122 (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Results Show Roche's Subcutaneous Formulation Of Tecentriq Is Comparable To Intravenous Tecentriq And Delivered In Minutes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qurient Announces Dosing of First Patient in Q901 Phase 1\/2 Clinical Study for the Treatment of Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Q901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ .."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VENT-02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Sunovion Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Presents at 4th Inflammasome Therapeutics Summit","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HT-6184","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Ther.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO\u00ae, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Pyelocalyceal Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"T Cell Therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Otsuka America Pharmaceutical, Inc.","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical & Lundbeck Present Positive Data From Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms of Agitation in Patients With Alzheimer\u2019s Dementia at the 2022 Clinical Trials for Alzheimer\u2019s Disease Congress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka America Pharmaceutical, Inc.","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka America Pharmaceutical, Inc. \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Ame.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANAVEX\u00ae2\u201373 (blarcamesine) Phase 2B\/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces Update from Ongoing TH1902 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TH1902","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VTX958","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B and Chronic Hepatitis D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BJT-778","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bluejay Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluejay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bluejay Th.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-471","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV8.hLCA5","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Opus Genetics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NXP800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Announces Interim Results from Phase 1\/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PF-06480605","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Roivant Sciences \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME\u00ae (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"SparingVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparingVision's Lead Asset SPVN06 Clears IND Application in the US for the Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SparingVision \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA (TM) Abuse Deterrent Transdermal Technology Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented at Alzheimer's Conference CTAD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AC-0027875","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanford Burnham Prebys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanford Burnham Prebys Announces Start Of Phase 2 Clinical Trial Of DS-1211 In Individuals With PseudoXanthoma Elasticum","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"N-Acetyl-D-Leucine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Sanford Burnham Prebys","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Medera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medera\u2019s Sardocor Announces FDA Clearance of IND for First-in-Human Gene Therapy Clinical Trial for DMD Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SRD-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Medera","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medera \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Medera \/ N.."},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aucta Announces FDA Approval Of A Generic Version Of Perforomist\u00ae (formoterol fumarate) Inhalation Solution","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Aucta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Phar.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuvivo's NP001 for Treatment of ALS Slows Disease Progression Through Regulation of Microbial Translocation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NP001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Eribulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazilian Regulatory Authority Grants Approval for Waylivra\u2122 for Familial Partial Lipodystrophy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Volanesorsen","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compelling Preclinical Data For Kazia's EVT801 Published In Peer-Reviewed Cancer Research Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"EVT801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaxSwab\u2122 OTC Novel Naloxone Nasal Swab Demonstrates Faster Absorption And Higher Early Exposures Against Other Naloxone Products In Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Pocket Naloxone","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"Pocket Naloxone \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pocket Nal.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces U.S. FDA Approval of REZLIDHIA\u2122 (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1\/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma (NHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-\u03b1-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BAT8006","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VQW-765","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Presents Design of Newly Initiated Phase 1\/2a Trial of Vosilasarm (EP0062) at SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Vosilasarm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Union Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Orismilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ UNION therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Pluvicto\u2122 Shows Statistically Significant and Clinically Meaningful Radiographic Progression-Free Survival Benefit in Patients With PSMA\u2013Positive Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Istesso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istesso Announces FDA Fast Track and Orphan Drug Designation for MBS2320","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MBS2320","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Istesso","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Istesso \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Istesso \/ .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences\u2019 CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Approves QUVIVIQ (daridorexant) \u2013 A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio- And GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) Meets Primary Endpoint In Phase 3 RUBY Trial in Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Zandelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEI Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Positive Results for NE3107 in Parkinson\u2019s and Alzheimer\u2019s Phase 2 Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMC-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NYMOX Announces New Marketing Submission for NYMOZARFEX for BPH","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ALTITUDE-NASH\u2122 Liver Function Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CPI-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma to Initiate TransCon PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and\u00c2 Entry into the HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DNL343","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Mycapssa\u00ae For the Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HilleVax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Submits IND Application To FDA for Travelan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Initiates Clinical Trial with SpagoPix in Endometriosis and Concludes SPAGOPIX-01","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SN132D","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma to Present New Clinical Data and Studies at ASH 2022 to Demonstrate Its Continued Mission to Meet the Challenges Faced by People with Bleeding Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Von Willebrand Factor\/Coagulation Factor VIII Complex","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fractyl Health Announced Positive Proof-of-Concept Data of Pancreatic GLP-1 Gene Therapy in a Type 2 Diabetes Animal Model at the 20th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pancreatic GLP-1 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl He.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II\/III Study for Registration in Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMC-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmuneOncia Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmuneOncia Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneOnci.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BGE-105","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primates","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1\/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Axatilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces First Patient Dosed in Phase \u2161 Clinical Study of LNK01003 in Patients with Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LNK01003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Presents New AMG 133 Phase 1 Clinical Data AT WCIRDC 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AMG 133","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Trial Demonstrated Jardiance\u00ae Is the First SGLT2 Inhibitor to Show Statistically Significant Reduction in Blood Sugar Levels in Children and Adolescents with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Marketing Authorisation Application for Momelotinib for The Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Prolonged PFS Benefit for Pre- and Perimenopausal Patients with Aggressive HR+\/HER2\u2212 Metastatic Breast Cancer Compared to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evkeeza\u00ae (Evinacumab-dgnb) SBLA For Children with Ultra-Rare Inherited Form of High Cholesterol Accepted for FDA Priority Review","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Evinacumab-dgnb","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Showcase New Data from Oncology Portfolio Spanning Marketed Products and Investigational Compounds at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SAR443579","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brivaracetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Reports Combination Therapy with INB03\u2122 Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer\u00e2\u20ac\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STI-1557","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences\u2019 CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMP761","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PAS-003","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Busulfan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol\u00c2\u00ae Eye Drops for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN\u00c2\u00ae (naloxone HCl) Nasal Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Presents Clinical Data on FS222, a CD137\/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"FS222","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics\u2019 KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Additional Findings from Phase 2 Alzheimer\u00e2\u20ac\u2122s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NBI-827104","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NBI-921352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PRA023","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PERLA Phase II Trial of Jemperli (dostarlimab) Plus Chemotherapy Shows Positive Results In First-line Metastatic Non-squamous Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Gets Regulatory Nod To Launch Shingles Vaccine In India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Zoster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate (ONTOZRY\u00ae), for the Treatment of Uncontrolled Focal-onset Seizures in Adults, Is Now Available in France and Belgium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Angelini P.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, a First-In-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KSQ-4279","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"SpineThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Supporting the Potential for Best-In-Class Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SpineThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera.."},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delta-Fly Pharma, Inc. is Granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DFP-10917","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly .."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kurome Therapeutics Announces Oral and Poster Presentations on Dual IRAK1\/4 Inhibitors at American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kurome Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kurome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kurome The.."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Announces the Launch of Griseofulvin Oral Suspension, 125 mg\/5 mL.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Griseofulvin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cosette Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PH10","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Acacia Catechu","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Scienc.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Seralutinib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Human Mesenchymal Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (valiltramiprosate) in APOE4\/4 Homozygotes with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Esmethadone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endari\u00ae Receives Kuwaiti Marketing Authorization","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamond Therapeutics Completes Phase I Clinical Study Of Low-dose Psilocybin In Healthy Human Subjects","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Th.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Provides Update On Pepaxto US Marketing Authorization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SION-638","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna The.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Presents Two Posters On Phase 2 Data Of Its Lead Immunotherapy, EO2401, In Recurrent Glioblastoma (ROSALIE study) at ESMO IO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces Publication Of Data From Phase 3 Study Of Leniolisib In Patients With APDS in ASH's Blood","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET\u00ae DF1001 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Df1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Announces Patent Issued for Radiation Protection with RRx-001 in Combination Regimens","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BMS-986207","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+\/HER2- Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NGM707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pacmilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"GB2064","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DT-216","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Design Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Design The.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4\/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"OP-1250","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI\u00ae To Treat Moderate to Severe Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Announces VAZKEPA\u00ae (icosapent ethyl) Receives Regulatory Approval in Switzerland","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Update on OCU400 Phase 1\/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CK-136","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First AML Patient Successfully Transplanted with Vor Bio\u2019s Investigational Trem-cel (VOR33) and Tolerated Mylotarg\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY\u00c2\u00ae on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annu","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Replimune","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2\/3 Program Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces First Patient Dosed in Phase 1\/1b Clinical Trial of BP1001-A in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Liposomal Grb2 Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and STADA Broaden Access to Hukyndra\u00ae Adalimumab Biosimilar in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer\u2019s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"LabGenius","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"LabGenius Wins Government Innovation Grant to Support the Development of ML-driven Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Funding","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LabGenius \/ Innovate UK","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius .."},{"orgOrder":0,"company":"Eigen Therapeutics","sponsor":"Josh Kopelman","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eigen Therapeutics Emerges From Stealth With $7M in Funding to Develop Therapies That Address Cancer Heterogeneity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eigen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Eigen Therapeutics \/ Josh Kopelman","highestDevelopmentStatusID":"3","companyTruncated":"Eigen Ther.."},{"orgOrder":0,"company":"Replimune","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Replimune Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"PRA023","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0.5,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Cowen and Company","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio Announces $35 Million Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Desmoglein 3 Chimeric Auto Antibody Receptor T Cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Cowen and Company","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$336.0 million","upfrontCash":"$5.0 million","newsHeadline":"Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Crown Bioscience","sponsor":"ERS Genomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crown Bioscience and ERS Genomics Announce Global CRISPR\/Cas9 Licensing Agreement for Genome Editing Patents","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crown Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crown Bioscience \/ ERS Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Crown Bios.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in Combination with Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"PT199","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 Negative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Erasca","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"$300.0 million","newsHeadline":"Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Erasca","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autolus Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Obecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Novartis Innovative Therapies","pharmaFlowCategory":"D","amount":"$680.7 million","upfrontCash":"$50.0 million","newsHeadline":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Divestment","leadProduct":"177Lu-FAP-2286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Clovis Oncology \/ Novartis Innovative Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Magrolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Gates Foundation","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccines In Africa","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Pneumococcal Polysaccharide Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"BCG","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"ImmunityBio \/ Piper Sandler & Co.","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Optieum Biotechnologies","sponsor":"GI CELL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Announcement of Research License and Option Agreement with GI CELL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Optieum Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optieum Biotechnologies \/ GI CELL","highestDevelopmentStatusID":"3","companyTruncated":"Optieum Bi.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces Closing of $25 Million Financing With Highbridge","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Highbridge Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$4,500.0 million","upfrontCash":"$200.0 million","newsHeadline":"CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"ARCT-154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":4.5,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":4.5,"dosageForm":"Injectable\/Injection","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Frontage Partners with Eisai and Biogen to Complete the Clarity AD Study for the Alzheimer's Drug, Lecanemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage L.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Invests Up to $4.85 Million in Aridis Pharmaceuticals for Testing of Anti-Infective","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Ocular Therapeutix","highestDevelopmentStatusID":"4","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Genomic Biopharma","sponsor":"POIC e dintorni","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genomic Biopharma and Patient Advocacy Organization POIC e Dintorni APS Partner To Offer Whole Genome Sequencing To Bring Better Treatments And Cures To Those Living With Gastrointestinal Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Genomic Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genomic Biopharma \/ POIC e dintorni","highestDevelopmentStatusID":"2","companyTruncated":"Genomic Bi.."},{"orgOrder":0,"company":"Curia","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Murine Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curia \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ To.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$26.4 million","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Draws Down \u20ac25 Million Tranche Under Finance Contract With The European Investment Bank","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Arecor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetris Pharma Signs Service Agreement With Syneos Health","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tetris Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Arecor","highestDevelopmentStatusID":"12","companyTruncated":"Tetris Pha.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Optime Care","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia\u2122 Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Optime Care","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble The.."},{"orgOrder":0,"company":"Tellus Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tellus Therapeutics Announces $35 Million Series A Financing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"TT-20","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Tellus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Tellus Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Tellus The.."},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"PIP-2","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Peroxitech Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Peroxitech Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Peroxitech.."},{"orgOrder":0,"company":"Prothena","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prothena Announces Proposed Public Offering of Ordinary Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Birtamimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"MRM Health","sponsor":"IFF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"M008","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ IFF","highestDevelopmentStatusID":"4","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"Isotopia","sponsor":"Philochem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Philochem AG, Seibersdorf Labor GmbH and Isotopia Announce Supply, Development, And Manufacturing Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"177Lu-OncoFAP-23","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotopia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isotopia \/ Philochem","highestDevelopmentStatusID":"4","companyTruncated":"Isotopia \/.."},{"orgOrder":0,"company":"Biosion","sponsor":"Immunogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Biosion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biosion \/ ImmunoGen","highestDevelopmentStatusID":"2","companyTruncated":"Biosion \/ .."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$20.0 million","newsHeadline":"Calliditas Therapeutics Announces License Agreement With Viatris To Register And Commercialize Specialty Therapy For IgA Nephropathy In Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"GRI Bio","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$15.0 million","newsHeadline":"Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Merger","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Vallon Pharmaceuticals \/ GRI Bio","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"PRAX-020","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Praxis Precision Medicines \/ UCB","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Maxim Group","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Maxim Group","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","amount":"$475.5 million","upfrontCash":"$276.0 million","newsHeadline":"AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.47999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Zelenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Bio Farma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio Farma And Msd Signed A Framework Agreement Related To Technology Transfer Cooperation To Produce The Human Papillomavirus (HPV) Vaccine Locally In Indonesia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"4-valent HPV vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bio Farma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio Farma \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Bio Farma .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to Ilevro\u00ae, Nevanac\u00ae, Vigamox\u00ae, Maxidex\u00ae, And Triesence\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Nepafenac","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.17999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Suspension\/Drops","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,045.0 million","upfrontCash":"$45.0 million","newsHeadline":"Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"SNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":1.05,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.05,"dosageForm":"","sponsorNew":"Exicure \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"JB Pharma","pharmaFlowCategory":"D","amount":"$37.9 million","upfrontCash":"$37.9 million","newsHeadline":"JB Pharma To Acquire The Entire Razel (rousvastatin) Franchise From Glenmark Pharmaceuticals Ltd","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Divestment","leadProduct":"Rosuvastatin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ JB Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID\u2122 to Help Combat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Ritonavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Alternative Bio","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alternative Bio","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Alternative Bio \/ F-Prime Capital","highestDevelopmentStatusID":"3","companyTruncated":"Alternativ.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$95.5 million","upfrontCash":"$10.0 million","newsHeadline":"Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Tigulixostat","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"LG Chem","amount2":0.10000000000000001,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"LG Chem \/ Innovent Biologics","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Eisai","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai And Washington University School Of Medicine In St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming To Create New Therapies For Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ Wa.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Alpha-9 Theranostics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series B Financing","leadProduct":"Radiopharmaceutical","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha-9 Theranostics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Alpha-9 Theranostics \/ Nextech Invest","highestDevelopmentStatusID":"2","companyTruncated":"Alpha-9 Th.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0.01,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"PrecisionLife","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"PrecisionLife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PrecisionLife \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"PrecisionL.."},{"orgOrder":0,"company":"Psyence","sponsor":"Brandon Kerzner","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psyence \/ Brandon Kerzner","highestDevelopmentStatusID":"1","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Solutions Forms New Partnerships With Three Biotechnology Companies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosc.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s QDENGA\u00ae\u25bc (dengue tetravalent vaccine [Live, Attenuated]) Approved for Use in European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Live Attenuated Tetravalent Dengue Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capivasertib Plus Faslodex Reduced the Risk of Disease Progression or Death by 40% Versus Faslodex in Advanced HR-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Receives USFDA Final Approval for Desonide Cream, 0.05%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Desonide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"CanaQuest Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"CanaQuest Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CanaQuest Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CanaQuest .."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Completes Recruitment for IB1001 NPC Pivotal Clinical Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granules for Oral Suspension","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ONC201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs\u2019 DANYELZA\u00ae (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences\u2019 Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen\u00ae (rintatolimod) in Healthy Subjects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Provides Miricorilant Clinical Development Update","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Miricorilant","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Provides Update on Strategic Priorities","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SNS-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics\u00ae Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Onapristone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS\/MND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Reldesemtiv","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"INB-400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PHA121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Presents Update from its Phase 1\/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tivumecirnon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Presents Ovarian Cancer Expansion Data For ImmTAC\u00ae Candidate IMC-C103C Targeting MAGE-A4","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMC-C103C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen Notes Results from The MIROCALS Trial Investigating Low Dose Proleukin\u00ae (aldesleukin) In Patients with Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Initiates Phase Ib Pancreatic Cancer Trial of Next-Generation Autotaxin Inhibitor IOA-289","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences SA Announces Positive Results from Phase 1\/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NVD-003","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Met in The CLEAR Outcomes Trial of Bempedoic Acid Showing Statistically Significant Relative Risk Reduction in Major Adverse CV Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDC*line Pharma Presents First Immunological Results From Phase I\/II Trial With PDC*lung01 at ESMO-IO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PDC*lung01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDC*line Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line P.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3K\u03b1 Inhibitor at San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STX-478","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MTTI Obtains FDA Allowance of Investigational New Drug (IND) for H\u00fcrthle Cell Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-EB-TATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Molecular Targeting Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Health Canada Approval for PreHevbrio\u2122 for the Prevention of Hepatitis B in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"3-antigen Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HZN-457","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pralatrexate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO\u00ae (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IBI110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI\u2122 (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LB-P8","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Federation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Federation Bio Administers First Dose in Phase 1 Clinical Trial Evaluating Investigational Bacterial Cell Therapy","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"FB-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Federation Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Federation Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Federation.."},{"orgOrder":0,"company":"Visiox Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visiox Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Visiox Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visiox Pha.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics Presents Safety and Efficacy Data of PT-112 in Combination with PD-L1 Inhibition in Treatment of Advanced Non-Small Cell Lung Cancer at ESMO I-O 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Df1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Completion of Dosing in the Phase I\/II Trial of RGX-111 for the Treatment of Severe MPS I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RGX-111","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Positive Reimbursement Decision in Italy For Idefirix\u00ae (imlifidase) As Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Createrna Science and Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"QR052107B","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Createrna Science and Technology","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Createrna Science and Technology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Createrna .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ARX788","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Announces Pivotal Phase 2 FELIX Clinical Trial Has Met Primary Endpoint at Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of PENNSAID\u00ae 2% w\/w in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SX-682","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syntrix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Syntrix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syntrix Ph.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"EVT801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Receives Approval from Health Canada for Empaveli\u2122 (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT162b2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odronextamab (CD20XCD3) Demonstrates High and Durable Complete Response Rate Among Patients with Relapsed\/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Odronextamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AJ1-10502","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ajax Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ajax Thera.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma (NHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced S\u00e9zary Syndrome at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacutamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ORM-6151","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orum Thera.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SG295","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Imvotamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-253","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tuspetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SerpinPC","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI\u00ae\u25bc (teclistamab) in Combination with DARZALEX\u00ae (daratumumab) Subcutaneous (SC) Formulation and Lenalidomide in Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA\u00ae (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Pharmacyclics","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents New Data for Talquetamab, a GPRC5DxCD3 Bispecific Antibody, Showing Durable Responses in Patients with Heavily Pretreated Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Talquetamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART\u00ae (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"FT819","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL's Novel Gene Therapy HEMGENIX\u00ae (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimivalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Talquetamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA\u00ae (tocilizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed\/Refractory Large B-cell Lymphoma in New CIBMTR Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Starts The First Phase 3 Study With A Long-acting Anti-IL-5 Treatment For Patients With Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Depemokimab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI\u2122 (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Seeks Nod For Adult TB Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Plamotamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS\u00ae (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Onchilles Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"N17350","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Onchilles Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onchilles Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Onchilles .."},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphera Announces Clinical Updates of MesoPher Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous DCs Loaded With PheraLys","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Amphera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amphera \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amphera \/ .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-522","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Schr\u00f6dinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SGR-2921","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RC118","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T\u00ae Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PRGN-3006","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real-World Study Shows Patients Treated with IMBRUVICA\u00ae (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Properdin Antibody (NM3086) Reduced Hemolysis, LDH, and Free Hemoglobin in an Animal Model of Paroxysmal Nocturnal Hemoglobinuria (PNH) -- a Rare Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NM3086","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Linvoseltamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Has Completed A Successful Pre-IND Meeting With The FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 Inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"APL-1202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Enterome","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Completes Patient Enrollment Of Phase 2 ROSALIE Study Evaluating Its Lead Immunotherapy, EO2401, In Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enterome \/ Covance, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Na\u00efve Patients with Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"APVO436","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poolbeg Pharma PLC - POLB 001 LPS Human Challenge Trial Completed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"POLB 001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Ph.."},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carina Biotech Submits an Investigational New Drug (IND) Application to US FDA for LGR5-Targeted CAR-T Cell Therapy Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CNA3103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carina Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Bio.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bendamustine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Announces Publication of Results of Phase 1b\/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NEO-TRA1","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spark Therapeutics Announces Updated Phase 1\/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SPK-8011","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spark Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents New Data Demonstrating the Potential Benefit of Glofitamab and Lunsumio as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX\u00ae (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KER-047","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data from Kymera Therapeutics\u2122 Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-333","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON Trial of CTX110\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MGTA-117","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1\/2 Study Evaluating RECCE\u00ae 327 in Patients with Diabetic Foot Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics\u2122 STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KOL Review of Lumos Pharma\u2122s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"OTL-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"INB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TSC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives European Commission Approval for Pluvicto\u00ae as The First Targeted Radioligand Therapy for Treatment of Progressive Psma\u2013positive Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Outcome Of FDA Advisory Committee Vote On Omecamtiv Mecarbil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Evonik","sponsor":"Allay Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pain Therapy Implants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evonik \/ Allay Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Evonik \/ A.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics\u2019 Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves SPEVIGO\u00ae (spesolimab) For Generalized Pustular Psoriasis Flares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Qiagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qiagen Receives FDA Approval for Companion Diagnostic to Mirati Therapeutics\u2019 KRAZATI in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ QIAGEN","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"AOP Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOP Health Presents Latest Updates On BESREMi\u00ae (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AOP Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"AOP Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AOP Health.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals\u2019 LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Responds to Ruling in HETLIOZ\u00ae ANDA Litigation","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-Selective Inhibitor NVL-520","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NVL-520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cebranopadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Receives Notice of Deficiency (NOD) from Health Canada For Masitinib In The Treatment Of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its \u03b1V\u03b23 Small Molecule-Drug Conjugate (SMDC) VIP236","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VIP236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Cancer\u00ae Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Beyond Cancer \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Can.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed\/Refractory Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b\/2a IMX-110 Monotherapy Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi\u2122 for In-Office Pupil Dilation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Plinabulin","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-3490","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ORIC-533","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin\u2019s Potential for Treating Fungal Keratitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilacidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV\u2122 & BIVIGAM\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Expands Global Presence as NexoBrid\u00ae Gains Approval in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Therabest","sponsor":"Glycotope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therabest and Glycotope to Assess Therabest\u2019s iPSC-derived NK Cell Product TB-100 in Combination with Glycotope\u2019s GT-00AxIL15 Immuno-cytokine For Development In Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"GT-00AxIL15","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therabest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therabest \/ Glycotope","highestDevelopmentStatusID":"4","companyTruncated":"Therabest .."},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spexis Announces Promising Pre-clinical Data With Balixafortide In Combination With Various Therapies On The Market For Treating B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ N.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences Reports Data From Non-hodgkin Lymphoma Therapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Idacio\u00ae (adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol\u2122 (formerly VRP324)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NEO-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BGE-105","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermaliq Therapeutics Announces First Participant Randomized in Phase 1b\/2 Trial Evaluating DLQ01 Solution for Treatment of Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DLQ01","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dermaliq Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq T.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Data from Phase 1 Study Evaluating Brain Effects of Novel Drug Combinations","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ALTO-102","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"EP0031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinogen Announces First Patient Treated In Depression And Cognitive Impairment Phase 2 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanamem","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen .."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in the Randomized Phase 2 ROCKET Trial in Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA\u00ae in Combination with Tagrisso\u00ae in Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Announces Positive AOC 1001 Phase 1\/2 MARINA\u2122 Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AOC 1001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"SpliSense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpliSense Initiates Phase 1\/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SPL84","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliSense","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"SpliSense \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Etcembly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Etcembly Announces Breakthrough in Optimising TCR Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Etcembly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Etcembly \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Etcembly \/.."},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arthex Announces Regulatory Milestones Met in Its Program to Develop ATX-01 in Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ATX-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ARTHEx Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARTHEx Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARTHEx Bio.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB reports Last Patient Last Visit (\u201cLPLV\u201d) Achieved in Phase IIb Clinical Study of Mesdopetam in PD-LIDs with Top-Line Results Anticipated Mid-January 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi\u2019s Decision to Advance KT-474 into Phase 2 Clinical Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b\/3 Alzheimer\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tendu","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NMD670","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Miromatrix Announces FDA Clinical Hold on IND Application for miroliverELAP","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"miroliverELAP","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"United The.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ALG-125755","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Upifitamab Rilsodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody\u00ae sonelokimab in active psoriatic arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Safety and Tolerability Results with Daridorexant in Patients with Insomnia Disorder Published in CNS Drugs","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film-Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MNPR-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BLINCYTO\u00ae (BLINATUMOMAB) Added to Consolidation Chemotherapy Significantly Improves Survival in Adult Patients with Measurable Residual Disease-Negative B-Lineage Acute Lymphoblastic Leukemia (B-ALL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camizestrant Significantly Delayed Disease Progression in Advanced Er-Positive Breast Cancer, Adding at Least 3.5 Months Benefit versus Faslodex","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Camizestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL\u2019s Novel Gene Therapy HEMGENIX\u00ae (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Supplemental New Drug Application Submitted in Japan for Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1\/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Kite's Tecartus\u00ae CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three-Year Follow-Up Analysis of Kite\u2019s Yescarta\u00ae CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna and Merck Announce mRNA-4157\/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA\u00ae (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives FDA Emergency Use Authorization For Omicron-targeting Bivalent Covid-19 Booster Vaccine In Children 6 Months Through 5 Years Of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Pivotal Phase III APPLY-PNH Data at ASH Demonstrating Investigational Oral Monotherapy Iptacopan Superiority Over Anti-C5","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Subcutaneous Crovalimab Given Every Four Weeks Achieves Disease Control In People With PNH, a Life-threatening Blood Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational Iptacopan Provides Clinically Meaningful Increases In Hemoglobin Levels In Complement-inhibitor-na\u00efve Patients With PNH","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Population Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anji Pharmaceutical \/ Population Health","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharm.."},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Urica Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Urica Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuh.."},{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Third Pole Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Third Pole Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Third Pole.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics\u2122 First-in-Class Immunotherapy Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"QBECO-SSI","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Qu Biologics Inc \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series A Financing","leadProduct":"BDTX-1535","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$3.1 million","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"AD-MSC-based Oncolytic Virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ CIRM","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$735.0 million","upfrontCash":"$224.0 million","newsHeadline":"Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"EEV-conjugated Phosphorodiamidate Morpholino Oligomer","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.73999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"SNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":1.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.02,"dosageForm":"","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"HighTide Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Berberine Ursodeoxycholate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quotient Sciences \/ HighTide Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"Avalon Ventures","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enlaza Therapeutics Launches with $61 Million Financing to Advance the First Covalent Biologic Therapeutic Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Protein-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlaza Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Enlaza Therapeutics \/ Avalon Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Enlaza The.."},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Series B Financing","leadProduct":"GM-1020","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gilgamesh Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Gilgamesh Pharmaceuticals \/ Prime Movers Lab","highestDevelopmentStatusID":"4","companyTruncated":"Gilgamesh .."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine Announces Closing of Investment from Goldman Sachs Asset Management","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Pricing of $65 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$207.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"AOC 1001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0.20999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$731.0 million","upfrontCash":"$37.0 million","newsHeadline":"Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0.72999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Filament Health","sponsor":"Psyence","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Filament Health \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Filament H.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"EMD Financial","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Ltd. Expands Life Offering to Quebec","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ EMD Financial","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"BioCardia Announces $3.6 Million Private Placement of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Matrix-M1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia Launches Preclinical Collaboration With Qimr Berghofer Medical Research Institute And Announces Patent Filing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Paxalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"MinervaX","sponsor":"REPAIR Impact Fund","pharmaFlowCategory":"D","amount":"$23.4 million","upfrontCash":"Undisclosed","newsHeadline":"MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"GBS-NN\/NN2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"MinervaX \/ REPAIR Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/.."},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"DR30303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zhejiang Doer Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Zhejiang D.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Aenco Technologies Limited","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Announces Completion of $3 Million Convertible Note due 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Rilpivirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Aenco Technologies Limited","highestDevelopmentStatusID":"6","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C..."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Pricing of $8 Million Underwritten Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Eurostars","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"EDP1815","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"EVT8683","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evotec","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,466.5 million","upfrontCash":"$26.6 million","newsHeadline":"Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Innate Pharma","amount2":1.47,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Biogen","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ G.."},{"orgOrder":0,"company":"XtalPi","sponsor":"EDDC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XtalPi and EDDC Collaborate In AI-Empowered Drug Discovery Program for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"XtalPi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ EDDC","highestDevelopmentStatusID":"2","companyTruncated":"XtalPi \/ E.."},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Angiocrine Bioscience Announces it Has Been Awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"E-CEL Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Angiocrine Bioscience \/ CIRM","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine.."},{"orgOrder":0,"company":"ProCare Health","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral Immunocaps","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ProCare Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"ProCare Health \/ Biovaxys","highestDevelopmentStatusID":"12","companyTruncated":"ProCare He.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenFleet Therapeutics and Merck Enter into Trial Collaboration to Initiate Study Investigating Combination Therapy of GFH925 (KRAS G12C inhibitor) and ERBITUX\u00ae (cetuximab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Terns Announces Proposed Public Offering","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"TERN-501","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$160.0 million","newsHeadline":"Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA\u00c2\u00ae (Perampanel) CIII From Eisai Co., Ltd","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ca.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Financing Commitment for up to $60 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children\u2122s Research Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"RECCE 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"LianBio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"$20.0 million","newsHeadline":"Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Sisunatovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"LianBio","amount2":0.16,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"LianBio \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Starbloom Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences Investors Increase Investment in LIfT and Johnson and Johnson Welcomes LIfT into JLABS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Neutrophil based Leukocyte Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LIfT Biosciences \/ Starbloom Capital","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosc.."},{"orgOrder":0,"company":"Kineta","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kineta Completes Reverse Merger with Yumanity Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Merger","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Yumanity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ Y.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"$10.0 million","newsHeadline":"Basilea Announces Transition Milestone for Oncology Asset BAL0891, Triggering Milestone Payment of USD 4 Million by SillaJen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"BAL0891","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ SillaJen","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Jalon Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Jalon Therapeutics Raises Nearly 2 Million Euros To Develop A Disruptive Approach In Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"JRT39","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jalon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jalon Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"Jalon Ther.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"TmXX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kite Pharma \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C..."},{"orgOrder":0,"company":"Parallel Bio","sponsor":"Refactor Capital","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Parallel Bio Secures $4.3 Million Seed Round to Accelerate Drug Discovery through Human Immune System in a Dish","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Parallel Bio","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parallel Bio \/ Refactor Capital","highestDevelopmentStatusID":"2","companyTruncated":"Parallel B.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$673.5 million","upfrontCash":"$35.0 million","newsHeadline":"Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Olpasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0.67000000000000004,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"$31.0 million","newsHeadline":"Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Atara Biotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected by CSL Behring as a Limited Distribution Partner for HEMGENIX\u00ae, the First and Only Gene Therapy for Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Ionctura","sponsor":"European Investment Council","pharmaFlowCategory":"D","amount":"$18.5 million","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Awarded EUR17.5 Million Funding from The EIC Accelerator For Clinical Development of Novel Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ European Investment Council","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Binnopharm Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Binnopharm Group \/ Mabwell Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Binnopharm.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","amount":"$157.5 million","upfrontCash":"$157.5 million","newsHeadline":"Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.16,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.16,"dosageForm":"Injectable\/Injection","sponsorNew":"Sutro Biopharma \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Closing of $8 Million Underwritten Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holdings","pharmaFlowCategory":"D","amount":"$2,115.0 million","upfrontCash":"$260.0 million","newsHeadline":"POINT Biopharma Announces Closing of Agreements with Lantheus Holdings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.1200000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Point Biopharma \/ Lantheus Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vistagen to Acquire Pherin Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pha.."},{"orgOrder":0,"company":"Ethris","sponsor":"DIOSynVax","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ethris","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Ethris \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"Ethris \/ D.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Hercules Credit Facility","pharmaFlowCategory":"D","amount":"$255.0 million","upfrontCash":"Undisclosed","newsHeadline":"Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0.26000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Hercules Credit Facility","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"WEP Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ WEP Clinical","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$5.0 million","newsHeadline":"EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE\u00ae in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"EPI Health \/ Sato Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Staidson Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"BDB-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Staidson Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$830.0 million","upfrontCash":"$30.0 million","newsHeadline":"Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Mersana Therapeutics","amount2":0.82999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.82999999999999996,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"InSitu Biologics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InSitu Biologics Announces License Agreement With Mayo Clinic For Co-Development of Anti-Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"INSB400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"InSitu Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InSitu Biologics \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"InSitu Bio.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Finalizes Strategic Partnership with UK Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Elasomeran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ UK Government","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$57.2 million","upfrontCash":"Undisclosed","newsHeadline":"Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"RVU120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Ordaos Bio","sponsor":"Yatiri Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orda\u014ds Announces a Joint Development Agreement to Create Novel Therapeutics for AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ordaos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ordaos Bio \/ Yatiri Bio","highestDevelopmentStatusID":"2","companyTruncated":"Ordaos Bio.."},{"orgOrder":0,"company":"Anocca","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anocca Secures EUR 25 Million from The European Investment Bank (EIB) To Support Clinical Development of Next-Generation T-cell Therapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Financing","leadProduct":"TCR-modified T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Anocca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anocca \/ European Investment Bank","highestDevelopmentStatusID":"4","companyTruncated":"Anocca \/ E.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer\u2122s Disease","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody\u00ae ADG126 in Combination with Roche\u2019s Standard-of-Care for First-Line Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"ADG126","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Roche","highestDevelopmentStatusID":"4","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Limited Initiates Clinical Study of Itolizumab for Ulcerative Colitis in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Targets Treatment of Certain Seizures with Launch of Generic Lacosamide Injection, USP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company\u2019s Second Therapeutic Candidate for Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"FX-345","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Safusidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STAR-0215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thea Pharma Announces FDA Approval of IYUZEH\u2122 for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-angle Glaucoma or Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharm.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r\/r DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SBT101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Th.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LP-284","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology\u2122 (PERIO\u2122) Clinical Trial Progress and Pre-clinical Research Developments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"R289","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"China Pharma Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Pharma Holdings, Inc. Announced That Several Products Are Included in The Catalogue of Medicines for People Infected With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"China Pharma Holdings","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"China Pharma Holdings \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"China Phar.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SLS-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Submission of New Drug Application to the FDA for HyBryte\u2122 in the Treatment of Cutaneous T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Casi Pharmaceuticals' Partner Juventas Announces New Drug Application For Cnct19 Accepted By China National Medical Products Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Cells Collected in XNK's Preclinical Bladder Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"XNK03","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"XNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XNK Therap.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation at The 64th American Society of Hematology (ASH) Annual Meeting and Exposition English","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Avirmax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Avirmax","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avirmax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avirmax \/ .."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Gets Late-Breaking Abstract on New Data with Its Alzheimer Project Alzstatin Accepted At AD\/PD 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AC-0027875","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Emraclidine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NX-5948","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CTX-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Providence Therapeutics Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Providence.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Small Pharma\u2019s Drug Interaction Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion to Present a Full Clinical Readout on Two Personalized Cancer Immunotherapies In Q2 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"EVX-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Marketing Authorisations for IOPIDINE\u00ae (apraclonidine) Fully Transferred to Essential Pharma as Change in UK NICE Guidelines for Glaucoma Treatment Expected to Lead to Increase in Patients\u2019 Need for Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Essential .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RZ402","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"THB001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Harm.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Initiates OPUS a Phase 3 Program to Investigate Cenerimod for The Treatment of Patients with Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cenerimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Updates Older Genentech Cancer Drug Label","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Announces Publication of a Retrospective Cohort Review of 15 LEUKINE\u00ae Treated Patients with Pediatric Malignancies and Invasive Fungal Disease Refractory to Antifungal Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Sargramostim","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Ferring Pharma'S First Gene Therapy For Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nadofaragene Firadenovec-vncg","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Provides Update on FDA Appeal for XPHOZAH\u00ae (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves VRAYLAR\u00ae (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS\/LM Metastasis from Neuroblastoma in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Positive CHMP Opinion for Etranacogene Dezaparvovec \u2013 Gene Therapy for Adults with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS\u00ae (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on PEARL Phase III Trial of Imfinzi Monotherapy In Stage IV Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Etrumadenant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Submits a New Drug Application to the US FDA For Aprocitentan for The Treatment of Patients with Difficult-To-Control Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Aprocitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Successfully Completes Phase 1 Study Of DRL_TC, a Proposed Biosimilar of Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson\u2019s Disease or Mild Cognitive Impairment (MCI) with CST-103\/CST-107 Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CST-103","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CuraSen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Th.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics\u2019 Ebvallo\u2122 (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech\u2019s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Levocarnitine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NUV-868","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Phase 3 AURORA Study Provides Evidence of Maribavir\u2019s Clinically Meaningful and Durable Effect in Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Maribavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LPCN 1148","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2-ND1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fanapt\u00ae Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Iloperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Shingles Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Invectys","sponsor":"CTMA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HLA-G\/CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ CTMA","highestDevelopmentStatusID":"5","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ABI-H3733","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Presents Clinical Data of Confirming TGF-\u00ce\u00b22 as the appropriate target for gliomas at JCA-AACR Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabedersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Submits Supplemental New Drug Application for ZORYVE\u00ae (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"WVE-N531","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA\u00ae (omadacycline) under BARDA Project BioShield","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMP Adopts Positive Opinion on Orphan Designation for Mycapssa\u00ae for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results in U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RMC-5552","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RL-007","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY\u00ae in Combination with Pembrolizumab and Platinum Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Emraclidine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olorofim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Expansion Of EU Label For Hemlibra To Include People With Moderate Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Emicizumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Obefazimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Vaxess","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxess Announces Interim Results from Phase I Clinical Trial of MIMIX-Flu Vaccine Patch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MIMIX-flu Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxess","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxess \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxess \/ N.."},{"orgOrder":0,"company":"Immuneel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneel's CAR-T Cell Therapy Reports Positive In Early Phase-2 Trials In India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMN-003A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immuneel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immuneel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immuneel T.."},{"orgOrder":0,"company":"Regimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RGI-2001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune .."},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMB-150","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Th.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UPLIZNA\u00ae (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ A.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Qure Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QureBio Ltd. to Present its Q-1802 Clinical Phase \u2160 Data at 2023 ASCO-GI Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Q-1802","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Qure Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qure Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qure Biote.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis' NASH Drug ASC41(THR\u03b2) Phase II Enrollment is Progressing as Planned","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ASC41","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ACTUS-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STP707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma Announces Receipt of Orphan Drug Designation from the U.S. FDA for NS-018, an Investigational Treatment for Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ilginatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ruxolitinib And Methylprednisolone For Treatment Of Patients With Relapsed\/refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ONCOtherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherap.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Results from Phase 1\/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AGI-134","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II\/III Clinical Trial of Simcere's 3CL-Targeting Anti-SARS-COV-2 Drug Candidate Complete All Patients Enrollment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ritonavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Eurocine Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outstanding Results for Eurocine Vaccines\u00b4 mRNA Based HSV-2 Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-based HSV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eurocine Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eurocine Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eurocine V.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Provides Update for MGTA-117 Phase 1\/2 Dose Escalation Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MGTA-117","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Invectys","sponsor":"CTMC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HLA-G\/CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ CTMC","highestDevelopmentStatusID":"5","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Athenex","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ Athenex","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b\/2a IMX-110 Monotherapy Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS\/MAPK Pathway-Altered Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cemiplimab To Replace Pembrolizumab In UV1 Phase II LUNGVAC Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen Initiates A Managed Access Program For Relugolix In Europe For The Treatment Of Advanced Hormone-sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Announces Expanded Clinical Development Plan For Its Lead Cancer Vaccine VB10.16 in HPV16-positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxycodone Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Approved In The EU As First Immunotherapy Regimen For Patients With Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV9 Capsid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Actemra for the Treatment of COVID-19 in Hospitalized Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharmaceuticals\u2019 MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ALN-KHK","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fazirsiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX\u20112191 for the Treatment of Primary Vitreoretinal Lymphoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"OVX836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA\u00ae (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Submits CTA for BEN-8744, an Oral PDE10 Inhibitor, As A First-in-class Treatment For Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BEN-8744","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Dupixent\u00ae (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Nuevocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant AAV\u2011based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nuevocor","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuevocor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuevocor \/.."},{"orgOrder":0,"company":"Gradalis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil\u00ae (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Gemogenovatucel-t","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gradalis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RGX-181","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CM-101","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"RQ Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AZD3152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RQ Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RQ Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RQ Bio \/ N.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynlonta\u00ae (loncastuximab tesirine) Approved in the EU For The Treatment Of Relapsed Or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AFM28","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT162b2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MVA-BN RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on U.S. Regulatory Status of AVT02, Alvotech\u2122s Proposed High-Concentration, Interchangeable Biosimilar to Humira\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"LX9211","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"MNV-BLD","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Minovia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Minovia Th.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on First BioNTainer for African-based mRNA Manufacturing Facility","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT165","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Critical Milestone Toward the Planned Initiation of a Phase 2 Trial in Pulmonary Arterial Hypertension (PAH) During the First Half of 2023","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami The.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"STRO-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Completes Enrollment in Phase 2 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Announces First Patient Enrolled in the \u2018THRIVE\u2019 Phase 3 Trial in Patients With Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody\u00ae-CD3xCD20) for the Treatment of Relapsed\/Refractory Large B-Cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-\u03b2 Bispecific Antibody for Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ES014","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta\u00ae Now Approved in Japan for Initial Treatment of Relapsed\/Refractory Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"UNC School of Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNC Health Provider Ushers in First FDA-Approved Medication for Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"UNC School of Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UNC School of Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"UNC School.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Initiates BLA Submission of Data for Lecanemab in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves New HIV Drug for Adults with Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Availability of REZLIDHIA\u2122 (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Announces Completion of its Phase 1b\/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REDUVO\u2122 Marketing Approval on the Right Path","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Further Strengthens CRISPR\/Cas IP Portfolio With Patent Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the Treatment of r\/r B-cell ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"UCART22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1\/2a Human Clinical Trial Assessing Avenanthramide Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avenanthramide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ceapro \/ N.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company\u2019s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Encaleret","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Etrasimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT163","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Announces Submission of the Biologics License Application (BLA) of Novel Subcutaneous Formulation of CT-P13 to U.S. Food and Drug Administration","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Infliximab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA agrees to Actinogen Six-month Phase 2b Alzheimer's Disease trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanamem","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart\u00ae","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous Cartilagenous Tissue","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braeburn Receives Complete Response Letter for the NDA for BRIXADI\u2122 (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"Equillium","sponsor":"Metacrine","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"MET642","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Equillium","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Equillium \/ Metacrine","highestDevelopmentStatusID":"8","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$86.3 million","upfrontCash":"Undisclosed","newsHeadline":"Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"TERN-501","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Brookline Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics\u00ae Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Brookline Capital","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"M.S. Howells & Co.","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ M.S. Howells & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"MVA-BN-WEV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and Junshi Biosciences Sign Exclusive Licensing Agreement For Cancer Treatment Drug Toripalimab For The Middle East And North Africa Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Yonghe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ablaze Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ablaze Pharma \/ Yonghe Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Ablaze Pha.."},{"orgOrder":0,"company":"Antengene","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kineta Completes Reverse Merger with Yumanity Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ U.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$227.0 million","upfrontCash":"$120.0 million","newsHeadline":"Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"GS-1811","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$143.6 million","newsHeadline":"Henlius and Fosun Pharma Entered into an Exclusive License Agreement for HANSIZHUANG in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"GNI Group","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Biosciences Completes First Steps in Reverse Merger Plan","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Hydronidone","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GNI Group","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GNI Group \/ Catalyst Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"GNI Group .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Ethris","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla EU to Invest EUR 15 Million In Ethris, Initiating A Strategic Collaboration","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"ETH45","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ethris","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Cipla","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ C.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Merger","leadProduct":"Oportuzumab Monatox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Carisma Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","amount":"$15.2 million","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Coya 301","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Coya Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Coya Therapeutics \/ Chardan","highestDevelopmentStatusID":"5","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Gemini Therapeutics","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces Completion of Merger with Gemini Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Merger","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.17999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Disc medicine \/ Gemini Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Opus Genetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.5 million","newsHeadline":"Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"AAv-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IVERIC bio \/ Opus Genetics","highestDevelopmentStatusID":"4","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$160.0 million","newsHeadline":"Eisai to Divest Rights for Anti-Epileptic Drug Fycompa\u00ae (perampanel) CIII In United States to Catalyst Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Divestment","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ca.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$3,750.0 million","upfrontCash":"$75.0 million","newsHeadline":"Lilly and ProQR to Expand RNA Editing Collaboration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Expanded Collaboration","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"ProQR Therapeutics","amount2":3.75,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":3.75,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Stand Up Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stand Up Therapeutics Signed with VectorBuilder for World's First Gene Therapy Supply for Paraplegia Patient","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"AAV-Based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"VectorBuilder","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorBuilder \/ Stand Up Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"VectorBuil.."},{"orgOrder":0,"company":"Ping An-Shionogi","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Notice Regarding a License Agreement for the Promotion of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19, in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ping An-Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ping An-Shionogi \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Ping An-Sh.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$1.0 million","newsHeadline":"Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi\u00ae in Southeast Asia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyphens Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunlenca\u00ae (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives Complete Response Letter for Palovarotene, an Investigational Treatment for Fibrodysplasia Ossificans Progressiva","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza\u00ae (tralokinumab) in Japan for Adults with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Lunsumio, a First-In-Class Bispecific Antibody, To Treat People with Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Expands NexoBrid\u2019s Global Presence with Marketing Approval in Japan","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KUR-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Receives FDA Approval for Travelan IND Application","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Regulatory Approval of Antifungal Cresemba\u00ae (isavuconazole) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Receives USFDA Final Approval for Fulvestrant Injection, 250 mg\/5 mL (50 mg\/mL) per Single-Dose Prefilled Syringe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNCOVACC\u00ae is Now Available On CoWin, Priced At INR 800+GST for Private Markets and INR 325+GST for Governments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BBV154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Seeks Drug Regulator's Approval for Market Authorisation of Its Covid Vaccine as Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harm Reduction Therapeutics' New Drug Application for RiVive\u2122 Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Hetero","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero\u2019s \u2018NIRMACOM\u2019 is World\u2019s First Generic Version Of COVID-19 Oral Drug \u2018PAXLOVID\u2019 To Receive WHO Prequalification","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hetero","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hetero \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hetero \/ N.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"KPI-012","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CNM-ZnAg","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Masitinib Receives Orphan Drug Status for The Treatment of Amyotrophic Lateral Sclerosis in Switzerland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"DK210","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Deka Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosc.."},{"orgOrder":0,"company":"ZielBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ZB131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ZielBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZielBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ZielBio \/ .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Tafasitamab in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"JANX008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Tergene Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tergene Biotech Gets Recommendation From CDSCO Subject Expert Committee for Pneumococcal 15-Valent Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pneumococcal 15-valent Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tergene Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tergene Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tergene Bi.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"VV116","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fidanacogene Elaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces FDA Approval of BRIUMVI\u2122 (ublituximab-xiiy)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Has Received Approval From The U.S. Food and Drug Administration (FDA) To Initiate The Confirmatory Phase 3 Study With Masitinib In The Treatment Of Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces FDA Approval of NexoBrid\u00ae for the Treatment of Severe Thermal Burns in Adults","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Silo Pharma \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Further Heterologous Booster Data For Its Inactivated COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"OncoC4","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Onc-392","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoC4","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"OncoC4 \/ M.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Provides Business and Clinical Development Program Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Vericel Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vericel Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vericel Co.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China CDE\/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen Launches RenNano\u2122 Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"RenNano","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer\u2019s Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Review the Biologics License Application for Pfizer\u2019s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pentavalent Meningococcal Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Approved in Japan for Adults with Treatment-Na\u00efve Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Imjudo Approved in Japan for Advanced Liver and Non-Small Cell Lung Cancers, and Imfinzi Approved for Unresectable Biliary Tract and Liver Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza in Combination with Abiraterone Approved in The EU as 1st-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Recommended for Approval in The EU by CHMP For Patients With HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Imjudo Recommended for Approval in The EU by CHMP For the Treatment of Advanced Liver and Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Recommended for Approval in The EU by CHMP for Symptomatic Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Priority Review of Lynparza in Combination with Abiraterone in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finerenone Receives Positive CHMP Opinion For EU-Label Extension for Broad Range of Patients with Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT165","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Fosun Pharma Announce Full Regulatory Approval of their Mono- and Bivalent COVID-19 Vaccine COMIRNATY\u00ae in Individuals 12 Years and Older in Hong Kong","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Announces Plans for a Clinical Trial Hub in Taiwan for mRNA-based Cancer Immunotherapies as Part of Asia-Pacific Expansion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BNT113","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAR T Cell Therapy Breyanzi\u00ae Approved as Relapsed or Refractory Large B-cell Lymphoma Second-Line Therapy in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanized Anti-CD20 Monoclonal Antibody Gazyva Approved for Additional Indication of Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Obinutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Receives Positive CHMP Opinion for Etranacogene Dezaparvovec \u2013 Gene Therapy for Adults with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EZHARMIA\u00ae Launched in Japan as First Dual EZH1 and EZH2 Inhibitor Therapy for Patients with Adult T-Cell LeukemiaLymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VidPrevtyn Beta COVID-19 Booster Vaccine, Developed by Sanofi and GSK, Approved for Use in Great Britain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant Monovalent Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Uro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna\u2019s BA.1 Targeting Bivalent Covid-19 Booster in Children (6-11 YEARS) In the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna and Merck Announce MRNA-4157\/V940, An Investigational Personalized Mrna Cancer Vaccine, in Combination with Keytruda (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2B KEYNOTE-942 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Approved by European Commission as The First and Only Targeted Medicine Indicated for Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Actemra for The Treatment of Covid-19 in Hospitalised Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FINTEPLA (fenfluramine) Oral Solution Recommended for Approval in The EU For Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF\u00ae and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Initiates First Human Clinical Trial of A New Molecule, PM534, For Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"PM534","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella, Inc., a Subsidiary of Immix Biopharma, Announces Poster Presentation at The European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-Cell Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company\u2019s Drug Candidate for the Treatment of Ataxia Telangiectasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Betamethasone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Leads to Atezolizumab Approval for Advanced Alveolar Soft Part Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National I.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Life Receives Final USFDA Approval for Insomnia Drug","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Triazolam","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acquisition of A Majority Participation of Medsenic Valued at EUR 40 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"T\/B Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Phase 1\/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA\u00ae (pegfilgrastim-pbbk)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA\u00ae (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Febuxostat Tablets in the U.S. Market","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Febuxostat","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Henlius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Henlius \/ .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Presentation of D-PLEX\u201a\u0081Phase 2 Clinical Data at ASM Microbe 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs\u2019 UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"hTERT specific CD4-helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"SIFI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Announces Approval and Pricing Granted for ILUVIEN for Uveitis in Italy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ SIFI","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Todos Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid\u00ae Treatment Followed by Tollovid\u2122 Dietary Supplementation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Todos Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Todos Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Todos Medi.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT\u00ae (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves FYB201\/Ranivisio\u00ae1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis\u00ae2","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Bioeq","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Topline Data from Lumakras\u00ae (sotorasib) Phase 3 Trial in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces IMCIVREE\u00ae (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"MC4R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Readouts for Transgene\u2019s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vorolanib","moa":"TYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio CEO Ryan Saadi and CSO Neal Flomenberg Share White House Concerns About Emerging COVID-19 Variants And Impact On Immunocompromised Patients, And Express Commitment To Accelerate Development Of Company\u2019s Investigational COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation of MRI Data at Clinical Trials and Alzheimer's Disease (CTAD) Conference Demonstrates Potential of Neflamapimod to Positively Impact the Cholinergic Degenerative Process in Early Alzheimer's Disease (AD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"$3,335.0 million","upfrontCash":"$2,225.0 million","newsHeadline":"Biocon Biologics Completes Acquisition of Viatris\u2019 Global Biosimilars Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":3.3399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.3399999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Forge Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blacksmith Medicines Announces Merger with Forge Therapeutics to Create Leading Company Developing Medicines Targeting Metalloenzymes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blacksmith Medicines \/ Forge Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith.."},{"orgOrder":0,"company":"Alteogen","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen\u2019s Hybrozyme\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alteogen \/ Sandoz","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","amount":"$15.2 million","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Coya 301","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Coya Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Coya Therapeutics \/ Chardan","highestDevelopmentStatusID":"5","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","amount":"$225.7 million","upfrontCash":"$140.0 million","newsHeadline":"TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"TherapeuticsMD","amount2":0.23000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.23000000000000001,"dosageForm":"Insert","sponsorNew":"TherapeuticsMD \/ Mayne Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","amount":"$79.7 million","upfrontCash":"Undisclosed","newsHeadline":"Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series C Financing","leadProduct":"Atomoxetin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0.080000000000000002,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Alpha Wave Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"AJU Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ST-100","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stuart Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Stuart Therapeutics \/ AJU Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Stuart The.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$415.0 million","newsHeadline":"Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Varenicline Tartrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0.41999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.41999999999999998,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0.28000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Famy Life Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life .."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","amount":"$121.0 million","upfrontCash":"$5.0 million","newsHeadline":"PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"NHS-IL12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ PDS Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$658.5 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.66000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Thera.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Primera Therapeutics","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"mtDNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cellectis","amount2":0.75,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.75,"dosageForm":"","sponsorNew":"Cellectis \/ Primera Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NeoImmuneTech \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"OriCiro Genomics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna to Acquire OriCiro Genomics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"OriCiro Genomics","amount2":0.089999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"OriCiro Genomics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"OriCiro Ge.."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"4","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"Sanegene Bio","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and SanegeneBio Collaborate to Identify Targeting Peptides for RNAi Drugs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"RNAi-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanegene Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanegene Bio \/ Orbit Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Sanegene B.."},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Alpha Healthcare Acquisition Corp.","pharmaFlowCategory":"D","amount":"$154.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Merger","leadProduct":"Allogeneic Plasma-based Biomaterial","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Alpha Healthcare Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Th.."},{"orgOrder":0,"company":"Geron","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geron Corporation Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Go.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$2,080.0 million","upfrontCash":"$80.0 million","newsHeadline":"Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Belharra Therapeutics","amount2":2.0800000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0800000000000001,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Belharra T.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Announces Strategic European Partnership with Orion Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Abiraterone Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Inhibrx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Actinium-225 Conjugated Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Inhibrx","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Belharra Therapeutics Debuts With $130 Million in Funding","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra T.."},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIMEDX Announces Commercial Launch of EPIFIX\u00c2\u00ae in Japan with Exclusive Distribution Agreement with Gunze Medical Limited","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Human Amnion Membrane Allograft","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Gunze Medical Limited","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ G.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kane Biotech Announces First Distribution Agreement for its Coactiv+\u2122 Antimicrobial Hydrogel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Salud Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"$10.0 million","newsHeadline":"Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Nusinersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alcyone Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Alcyone Th.."},{"orgOrder":0,"company":"Oncorus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oncorus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oncorus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Oncorus \/ .."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$10.0 million","newsHeadline":"HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"HB-400","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.40999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$138.4 million","upfrontCash":"$10.6 million","newsHeadline":"Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (govorestat) in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"$187.0 million","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb\u00ae Antibody Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Caris Life Sciences","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Xencor","highestDevelopmentStatusID":"2","companyTruncated":"Caris Life.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA\u00ae (pembrolizumab) in a Phase 2 Randomized Trials in dMMR\/MSI-High Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"GAd20-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"TCM Healthcare","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"HighTide Therapeutics Raises $107 Million in Series C\/C+ Financing to Advance Innovative Pipeline and Business Collaborations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series C Financing","leadProduct":"Berberine Ursodeoxycholate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0.11,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ TCM Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":2,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Synaffix \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntoCell Enters into Development and License Option Agreement with ADC Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"IntoCell","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IntoCell \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IntoCell \/.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA's Novel Immunotherapy ISA103 in Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"ISA103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ISA Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Cancer Focus Fund","highestDevelopmentStatusID":"4","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Hadassah Medical Organization","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"HBI0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Hadassah Medical Organization","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Successfully Closes Second Tranche Of \u00a310m Seed Financing To Progress Pipeline For Treatment Of Cancer Cachexia And Other Muscle Wasting Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"Turbine","sponsor":"Cancer Research Horizons","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine\u2019s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK\u2019s Latest Biotech Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"CRT\u20192199","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Turbine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turbine \/ Cancer Research Horizons","highestDevelopmentStatusID":"4","companyTruncated":"Turbine \/ .."},{"orgOrder":0,"company":"Capsida","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"$55.0 million","newsHeadline":"Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Capsida","amount2":0.73999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Capsida \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Biorasi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I\/IIA Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Medable","sponsor":"Every Cure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medable Partners with Every Cure to Accelerate Discovery of Treatments for Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Approved","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Medable","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medable \/ Every Cure","highestDevelopmentStatusID":"1","companyTruncated":"Medable \/ .."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"ENGOT","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ ENGOT","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$40.0 million","newsHeadline":"WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"T-cell Engaging Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":1.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5,"dosageForm":"","sponsorNew":"WuXi Biologics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$1,235.0 million","upfrontCash":"$35.0 million","newsHeadline":"CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"CytomX Therapeutics","amount2":1.24,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.24,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Janssen","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Termination","leadProduct":"Allogenic CAR NK Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":3.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.1000000000000001,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Janssen","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,120.0 million","upfrontCash":"$20.0 million","newsHeadline":"Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":1.1200000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.1200000000000001,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Nimble The.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.14999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Novo Hold\u00adings","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.28000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Metagenomi \/ Novo Hold\u00adings","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Triwise Capital","pharmaFlowCategory":"D","amount":"$131.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"IO-108","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ Triwise Capital","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Ophirex","sponsor":"AXA IM Prime Impact Master Fund","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Varespladib Methyl","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0.040000000000000001,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Ophirex \/ AXA IM Prime Impact Master Fund","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ .."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.0 million","newsHeadline":"Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Catalent Pharma Solutions \/ Sarepta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Sironax","sponsor":"X-Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Sironax","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sironax \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"Sironax \/ .."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Petrichor","pharmaFlowCategory":"D","amount":"$37.7 million","upfrontCash":"Undisclosed","newsHeadline":"Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Series D Financing","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Petrichor","highestDevelopmentStatusID":"10","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Baylor BioSciences","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse\u00c2\u00ae in Greater China with Baylor BioSciences","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Baylor BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Imunon","sponsor":"The Wistar Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMUNON Enters into Collaborative Research Agreement with The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ The Wistar Institute","highestDevelopmentStatusID":"2","companyTruncated":"Imunon \/ T.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"World Orphan Drug Alliance Announces Agreement with Theratechnologies for the Distribution of EGRIFTA SV","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$304.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA\u00ae (omadacycline) under BARDA Project BioShield Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Funding","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0.29999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1\/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo\u00ae (cemiplimab) in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.7 million","upfrontCash":"Undisclosed","newsHeadline":"Landos Biopharma Announces $16.7 Million Private Placement Financing","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"NX-13","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Frontier Medicine","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Frontier Medicine \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"Immunome","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$30.0 million","newsHeadline":"AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":1.3,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3,"dosageForm":"","sponsorNew":"Immunome \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"GERO.AI","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"GERO.AI","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GERO.AI \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"GERO.AI \/ .."},{"orgOrder":0,"company":"Esperovax","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Circular RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Esperovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Esperovax \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Esperovax .."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"BWX Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"[225Ac]-FPI-1434","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fusion Pharma \/ BWX Technologies","highestDevelopmentStatusID":"7","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"Carmot Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Demerger","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kimia Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kimia Therapeutics \/ Carmot Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kimia Ther.."},{"orgOrder":0,"company":"TeraImmune","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Talquetamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hutchmed Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix\u00ae (imlifidase) in the Czech Republic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Engineered Stem Cell Antibody Paired Evasion","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharmaceutical Launches Generic Drug for Treating Prostate Cancer in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Apalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Conference Call for Top-Line Results from IMerge Phase 3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK\u00ae in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17\/18 Only","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Yaral Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Yaral Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yaral Phar.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson\u2019s Disease Psychosis Patients Treated with NUPLAZID\u00ae (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor, in Combination With Dabrafenib for Advanced Solid Tumors With BRAF V600E\/K mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JS InnoPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPha.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Announces Striking Six-Month Interim Results from its Exploratory Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients with Treatment-Resistant Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wex Pharmaceuticals Inc. Enrolls the First Patient in the Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharma.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TST003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Mobius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mobius Therapeutics\u2122 Granted New US Patent for Injected Ophthalmic Mitomycin-C","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Mobius","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mobius \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mobius \/ N.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CM-101","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA \"Study May Proceed\" Letter for PRO1160, a CD70-Directed ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PRO1184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Upamostat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Positive Clinical Data from a Phase I\/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphalyse and Bavarian Nordic A\/S Significantly Shorten the Time Necessary to Document HCP Impurities In COVID-19 Vaccine Candidate for Phase 3 clinical trial \u2013 Through World\u2019s First MS-based HCP Analysis Under GMP Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Receives Approval From FDA To Proceed With The Clinical Phase 2b Study For EVX-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX-100 in the Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Announces Health Canada Approval of Citrate-Free High-Concentration of HUMIRA\u00ae Biosimilar (adalimumab; SB5)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Unicycive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Lanthanum Carbonate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Unicycive Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Unicycive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Unicycive .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis and Medicines for Malaria Venture Announce Decision to Move to Phase 3 Study for Novel Ganaplacide\/lumefantrine-Sdf Combination in Adults and Children with Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ganaplacide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"HT-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Posi","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06480605","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Publishes Novel Data with Respect to Obefazimod\u2019s Anti-Inflammatory Mechanism of Action","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obefazimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sonoma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pha.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Receives FDA\u2019s IND Clearance and Fast Track Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Gunagratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Suono Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SUO-2002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Suono Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Suono Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Suono Bio .."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol\u2122 (formerly VRP324)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RYZ101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VENT-03","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juno Pharmaceuticals Receives Approval From Health Canada To Import Amoxicillin Amidst Nationwide Shortage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Amoxicillin Trihydrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharm.."},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SURGE Therapeutics Receives FDA Clearance of IND Application to Initiate Phase 1\/2a Study of Intraoperative Immunotherapy in Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Resiquimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"SURGE Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SURGE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SURGE Ther.."},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SIG001","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Arugula Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arugula Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arugula Sc.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Oranomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"\u00b2\u00b9\u00b2Pb-DOTAM-GRPR1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oranomed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oranomed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oranomed \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Completes Patient Recruitment for Stage 1 of Phase 3 Diamond Study Evaluating the Efficacy and Safety of Ocs-01 in Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TMP-301","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domain Therapeutics Announces First Patient Dosed With DT-9081 In Phase I Clinical Study In Patients With Advanced, Recurrent Or Metastatic Solid Tumors: The EPRAD Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DT-9081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Domain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"Diaccurate","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diaccurate Receives Support From Bpifrance To Conduct Its DIACC2020 Program On The Development Of New Payloads For Antibody-drug Conjugates (ADCs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DIACC2010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Diaccurate","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diaccurate \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Diaccurate.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HMI-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces Changes To The Clinical Development Of Lanifibranor, Including Plans For A New Phase III Trial In Patients With NASH And Compensated Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I\/II (COVALENT-111) Study of BMF-219","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CBO-212","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma\u2019s TransCon\u2122 PTH for Eligible U.S. Adult Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Netupitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Milciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM\u00ae at the Company's Facility in Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Cytomegalovirus Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caris Life Sciences Announces the Expansion of Caris Discovery to Accelerate Development of Novel Precision Therapeutics to Combat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life.."},{"orgOrder":0,"company":"MinervaX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MinervaX Appoints Lidia Oostvogels As Chief Medical Officer And Provides Clinical And Regulatory Update On Its Novel GBS Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GBS-NN\/NN2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MinervaX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IBI351","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse\u2122 Immunotherapy in Recurrent Respiratory Papillomatosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Tempero Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempero Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TMP-301 for the Treatment of Alcohol and Other Substance Use Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TMP-301","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Tempero Bio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempero Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tempero Bi.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Reports Results From The Open-label Part Of The ARMOR Study Showing Improvements In Histology, Imaging, And Biomarkers With Aramchol","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Aramchol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Immunitas Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunitas Therapeutics Announces First Patient Dosed in Phase 1\/2a Study of IMT-009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IMT-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunitas Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunitas Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunitas .."},{"orgOrder":0,"company":"Genprex","sponsor":"University of Pittsburgh","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab US Regulatory Submission Accepted For The Prevention Of RSV Lower Respiratory Tract Disease In Infants And Children Up To Age 24 Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review To Roche\u2019s Bispecific Antibody Glofitamab For People With Relapsed Or Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSinoBIO Announces Encouraging Clinical Progress of its COVID-19 mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TG6050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen Launches RenNano\u00ae Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RenNano","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Announces Positive Results For The SAIVE Clinical Study In Prevention Of Covid-19 Infection In A Contact-based Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA\u2122 as a New Class of DNA-Based Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DNA-based Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-1015","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ArsenalBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ArsenalBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ArsenalBio.."},{"orgOrder":0,"company":"Inspirna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inspirna Announces Interim Data from Phase 1b\/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inspirna \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosabutate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Enrolled in the AriBio USA Phase 3 Registration Trial to Evaluate AR1001 in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ N.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MTX652","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mission Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TAK-755","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ATAI Life Sciences \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rosnilimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Cellf BIO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellf BIO Begins Phase 1 Clinical Trial of BioSphincter Implant for Fecal Incontinence","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Autologous Bioengineered Internal Anal Sphincter","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cellf BIO","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cellf BIO \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellf BIO .."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKIT Programs with Issuance of U.S. Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte\u2019s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BIOKEY","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BLEX 404","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABVC BioPharma \/ BioKey","highestDevelopmentStatusID":"5","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"OV329","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-195","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-\u00df Drug Candidate for NASH, ALG-055009","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AUM302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3204","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b\/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Belapectin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of 1104 in Allergic Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces First Patient Dosed in a Phase 1\/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SRF114","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FMC-376","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Frontier Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Frontier Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"01-2023-InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lomitapide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Marketing Authorization Application For Trodelvy\u00ae (sacituzumab govitecan-hziy) For Pre-treated HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer\u2019s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI\u2122 (lecanemab-irmb) for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Nirsevimab Application As First Protective Option Against RSV Disease For All Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Rozanolixizumab BLA For The Treatment Of Generalized Myasthenia Gravis Filed With U.S. FDA And Designated For Priority Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rozanolixizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves LEQEMBI\u2122 (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Alvotech \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,762.5 million","upfrontCash":"$50.0 million","newsHeadline":"Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":1.76,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.76,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Medicox Co.","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Medicox Co.","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Harbor Discoveries","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cold Spring Harbor Laboratory and Deerfield Management Launch Harbor Discoveries to Advance New Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Harbor Discoveries","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbor Discoveries \/ Deerfield Management","highestDevelopmentStatusID":"2","companyTruncated":"Harbor Dis.."},{"orgOrder":0,"company":"VivaVision","sponsor":"Everads Therapy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"VivaVision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VivaVision \/ Everads Therapy","highestDevelopmentStatusID":"2","companyTruncated":"VivaVision.."},{"orgOrder":0,"company":"Perceive Biotherapeutics","sponsor":"Johnson & Johnson Innovation","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Perceive Biotherapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Perceive Biotherapeutics \/ Johnson & Johnson Innovation","highestDevelopmentStatusID":"5","companyTruncated":"Perceive B.."},{"orgOrder":0,"company":"Genprex","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AMR Action Fund Announces Investment in BioVersys AG","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Rifabutin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ AMR Action Fund","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys .."},{"orgOrder":0,"company":"Synthekine","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Synthekine \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bluebird Bio Sells Second Priority Review Voucher for $95 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Suspension For Infusion","sponsorNew":"Bluebird Bio \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"METiS Therapeutics","sponsor":"Evopoint Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"METiS Announces License Agreement with Evopoint Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"METiS Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"METiS Therapeutics \/ Evopoint Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"METiS Ther.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$138.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series C Financing","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Sofinnova Partners","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"NG-350A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Akamis Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio.."},{"orgOrder":0,"company":"Novavax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$74.7 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Psyence","sponsor":"Newcourt Acquisition Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Merger","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Newcourt Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Soroka Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Soroka Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$32.5 million","newsHeadline":"Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea\u00ae Biosimilar FYB203 from Klinge Biopharma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Klinge Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Klinge Pharma \/ Coherus BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Klinge Pha.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"INNA-051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"ENA Respiratory \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"AmMax Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evopoint Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evopoint Biosciences \/ AmMax Bio","highestDevelopmentStatusID":"4","companyTruncated":"Evopoint B.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Alberta Innovation Employment Grant","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Alberta Innovation Employment Grant","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Lonza Inc & Lonza America Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Lonza Inc","highestDevelopmentStatusID":"4","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"GreenLight Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ EpiVax","highestDevelopmentStatusID":"2","companyTruncated":"GreenLight.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$574.0 million","upfrontCash":"$20.0 million","newsHeadline":"Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kronos Bio","amount2":0.56999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"","sponsorNew":"Kronos Bio \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Signs Exclusive In-Licensing Agreement for Late-Stage Clinical Neuropsychiatric and Neurodevelopmental Disorder Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Mavoglurant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0.27000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.27000000000000002,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio Secures EUR 25 Million Venture Debt Financing from The European Investment Bank","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"XVR012","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeVir Bio \/ European Investment Bank","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$511.6 million","upfrontCash":"$69.3 million","newsHeadline":"Continued Strong Cresemba (isavuconazole) Sales by Astellas in the U.S. Trigger CHF 20 Million Sales Milestone Payment to Basilea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0.51000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.51000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Farmaceutici","pharmaFlowCategory":"D","amount":"$1,480.0 million","upfrontCash":"$1,250.0 million","newsHeadline":"Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Oleogel-S10","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":1.48,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.48,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Chiesi Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"$162.4 million","upfrontCash":"$34.0 million","newsHeadline":"CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0.16,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"LinKinVax","sponsor":"Andre-Jacques Auberton-Herve","pharmaFlowCategory":"D","amount":"$7.9 million","upfrontCash":"Undisclosed","newsHeadline":"LinKinVax Just Completed a New Round of Financing, Initiated in 2022, for a Total of \u20ac7,3 M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Protein-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"LinKinVax \/ Andre-Jacques Auberton-Herve","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax .."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,300.0 million","newsHeadline":"AstraZeneca to Acquire Cin Cor Pharma to Strengthen Cardiorenal Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$1,675.0 million","upfrontCash":"$175.0 million","newsHeadline":"Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager\u2019s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"GBA1-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.6799999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$952.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.94999999999999996,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$500.0 million","newsHeadline":"Ionis and Royalty Pharma Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis' Genetic Medicines and Commercial Readiness","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Nusinersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ionis Pharmaceuticals","amount2":1.1299999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.1299999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Aqemia","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqemia \/ Servier","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ S.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Adalvo","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ Z.."},{"orgOrder":0,"company":"AskBio","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"AskBio \/ R.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$10.0 million","newsHeadline":"Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AT845","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prokarium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,155.0 million","upfrontCash":"$55.0 million","newsHeadline":"TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"TRB-051","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ .."},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$268.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"T-cell based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"3T Biosciences","amount2":0.27000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"3T Bioscie.."},{"orgOrder":0,"company":"Gensaic","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"CFTR-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Gensaic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gensaic \/ CF Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Gensaic \/ .."},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Receives Funding From the Crohn\u2019s & Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"eGenesis","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"eGenesis \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Pikralida biopharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Polpharma Partners with Pikralida Biopharmaceutical Start-Up","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"PKL-021","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polpharma \/ Pikralida biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Michigan State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Orbus Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Orbus Therapeutics \/ Michigan State University","highestDevelopmentStatusID":"1","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Closes Financing Agreement with Oberland Capital","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Anamorelin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$688.0 million","upfrontCash":"$443.3 million","newsHeadline":"BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.68999999999999995,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep .."},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"SIFI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sifi Announces License Agreement with Avanzanite Bioscience for Akantior\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Avanzanite Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Avanzanite Bioscience \/ SIFI","highestDevelopmentStatusID":"10","companyTruncated":"Avanzanite.."},{"orgOrder":0,"company":"Anima Biotech","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$582.0 million","upfrontCash":"$42.0 million","newsHeadline":"AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators Against Oncology and Immunology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Anima Biotech","amount2":0.57999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"","sponsorNew":"Anima Biotech \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Anima Biot.."},{"orgOrder":0,"company":"Soin Therapeutics","sponsor":"JanOne","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Soin Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Soin Therapeutics \/ JanOne","highestDevelopmentStatusID":"4","companyTruncated":"Soin Thera.."},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ajinomoto Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Company \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva Strategic Opportunities","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva Strategic Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Geron","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$227.8 million","upfrontCash":"Undisclosed","newsHeadline":"Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ Go.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne\u00aeCDx as a Companion Diagnostic for XPOVIO\u00ae (selinexor)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foundation Medicine \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"NextPoint","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NextPoint","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"NextPoint \/ Leaps by Bayer","highestDevelopmentStatusID":"1","companyTruncated":"NextPoint .."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Aerosol (PMDI)","sponsorNew":"ReCode Therapeutics \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Spiral Therapeutics","sponsor":"Savoir Capital","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"SPT-2101","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Spiral Therapeutics","amount2":0.01,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Spiral Therapeutics \/ Savoir Capital","highestDevelopmentStatusID":"6","companyTruncated":"Spiral The.."},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aethon Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Aethon Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Aethon The.."},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Plex Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atavistik Bio \/ Plex Research","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Indiana University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ Indiana University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Phlox Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Phlox Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":1.2,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pheno Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Pheno Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"French Government","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Receives a Joint Grant from The French Government and The Occitanie Region for its PRECESTO Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"Tobacco Leaf Protein","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ French Government","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Schrodinger","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otsuka and Schr\u00f6dinger Announce Single-Target, Drug Discovery Collaboration in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Otsuka Pharmaceutical \/ Schrodinger","highestDevelopmentStatusID":"2","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Exothera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics Selects Exothera to Develop Large-Scale Oncolytic Adenovirus Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"VALO-D102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Exothera","highestDevelopmentStatusID":"2","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"cAd3-EBO-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sabin Vaccine Institute","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Sabin Vaccine Institute \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Sabin Vacc.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ National Resilience","highestDevelopmentStatusID":"1","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Ltd. Closes $4.3 Million Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Infant Bacterial Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IBT Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Medical College of Wisconsin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medical College of Wisconsin \/ Infant Bacterial Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Medical Co.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enliven Therapeutics and Imara Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Merger","leadProduct":"ELVN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Th.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Osanetant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legacy Healthcare Announces Positive Top-Line Results from Phase 2\/3 Trial of Coacillium Cutaneous Solution, the First Drug for Children and Adolescents with Moderate and Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Coacillium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Hea.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"JNT-517","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jnana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Cleave Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Casi Pharmaceuticals and Cleave Therapeutics Announce Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CB-5339","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CASI Pharmaceuticals \/ Cleave Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Double-Blind Period Completes! Primary Endpoint Analysis of Phase 3 Clinical Trial to Be Conducted for China's First Hormone Replacement Treatment Targeting Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3K\u03b4 inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Integral Molecular","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Integral M.."},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavanta Therapeutics Announces Positive Top-line Results from Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Tavanta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tavanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tavanta Th.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc. Receives Orphan Drug Designation for Jbi-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"JBI-802","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"OQL011","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"QurAlis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"QRL-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS PBC Announces Positive Results from Confirmatory Phase 3 \"MAPP2\" Trial of MDMA-Assisted Therapy for Treatment of PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Lykos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Ther.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Provides Development Update on First-In-Class Semi-Allosteric PI3K\u03b4 Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HFB200603","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Novan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand\u2019s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Novan","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company\u2019s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FT-001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Frontera Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frontera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Frontera T.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CTX-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularitya Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohns Disease in Phase 1, Phase 1b\/2a and Phase 1b Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"APPL-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed\/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NanoAb COVID-19 Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graphite Bio Announces Voluntary Pause of Phase 1\/2 CEDAR Study of Nulabeglogene Autogedtemcel (nula-Cel) for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist\u00ae (Bicycle TICA\u00ae) Programs at the SITC 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BT7480","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati announces Adagrasib (Krazati\u2122) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b\/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23\/WCC)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Publication Showing Bucillamine's Potential Impact on COVID-19 Omicron Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tipelukast","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan\u00ae Oral Film Patent","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Clobazam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"Assertio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a\/b Clinical Trial of Novel BET Inhibitor VYN201","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals\u2122 Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 Trials With OVYDSO (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 Without the Need for Ritonavir Boosting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"STI-1558","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen\u00ae and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SRF114","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CVN766","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 \/ 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for Both Vasomotor and Vaginal Symptoms of Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients With Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VCN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces FDAs 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients With Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Small Pharma's Phase I Study Exploring Intramuscular Administration of SPL026","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BCX10013","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TRV045","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-45","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody\u00ae ADG126 up to 10 mg\/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b\/2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ADG126","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol\u00ae in Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"TELA Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivis Fibrillar Collagen Pack","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"TELA Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TELA Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TELA Bio \/.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Etifoxine Deuterated","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AFM13","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) in Phase 2\/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ANX005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Announces Positive Data from Ongoing Phase 1\/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"rAAV9 Capsid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Acticor Biotech's Clinical Developments with Glenzocimab in The Treatment of Cardiovascular Emergencies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"huMNC2-CAR22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Minerva Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Bi.."},{"orgOrder":0,"company":"Rejuvenate Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Bio Announces New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RJB-01","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Rejuvenate Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rejuvenate Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rejuvenate.."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Selonabant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Provides MultiStem Clinical Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Provides an Update on DAXXIFY\u00ae Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol\u00ae Cyclo\u2122 for the Treatment of Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Glycomine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GLM101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Glycomine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Glycomine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine .."},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myrtelle Announces Positive Interim Data in Phase 1\/2 Clinical Trial of Its Proprietary Investigational Gene Therapy rAAV-Olig001-ASPA in Canavan Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"rAAV-Olig001-ASPA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN\u2122 in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fazirsiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GX-188E","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Maveropepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALE.F02","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer\u2019s Dementia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spanish, Italian and French Health Authorities Expand Recommendations for Use of Novavax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo initiates exploratory feasibility studies of amorphOX\u00ae with two leading biopharmaceutical and vaccine companies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"NeuroDerm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"NeuroDerm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeuroDerm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NeuroDerm .."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Attenuated Varicella Virus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Azeliragon for The Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Immorna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"JCXH-105","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immorna","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immorna \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immorna \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Therapeutics Announces Positive Topline Results from The IASOS Phase 2b Study of Oral Orismilast in Patients with Moderate to Severe Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Orismilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Secura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Peripheral T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Duvelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Secura Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Secura Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Secura Bio.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Filing of Its Investigational New Drug Application for NRL-1049, a Rho Kinase (ROCK) Inhibitor with Potential to Treat Cerebral Cavernous Malformations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NRL-1049","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Launches Generic Version of Diuretic Bumetanide Injection","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bumetanide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tipelukast","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces New Patent Issuance, Bria-OTS IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Sernova","sponsor":"Evotec","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Donor Islets Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sernova \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PL8177","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CFI-402257","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Naronapride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Renexxion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Renexxion .."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XELSTRYM\u2122 (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professional Society of ADHD and Related Disorders (APSARD) Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Results for ALTO-100 in Phase 2 Study Supporting Advancement of First-in-Class Mechanism for Treating Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Genethon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GNT-003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Genethon","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genethon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genethon \/.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer\u2019s Disease in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Provides Update for KETARX (Racemic Ketamine) Development Programs and Expected Milestones for 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE\u00ae Anti-Infectives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"R529","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ATRN-119","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FRTX-02","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn's and Colitis Organization","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NX-13","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Landos Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obexelimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioP.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ethanol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi\u00ae and Simponi Aria\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airsupra (PT027) Approved in the US for Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Exkivity\u00ae (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of the First Post-Commercial Utilization Review of Jelmyto\u00ae Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics\u2019 Phase I MAD Study of ATI-2138","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ATI-2138","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I\/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ecopipam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bio.."},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SFA Therapeutics Announces FDA Clearance for Amendment to Extend Phase 1b Trial of SFA-002 for Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Magnesium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therap.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"INFEX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Partner Infex Therapeutics Receives FDA QIDP Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MET-X","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"INFEX Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INFEX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INFEX Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Approved for Self-Administration in The EU In a New Pre-Filled Pen","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits Application for Marketing Approval of mRNA COVID-19 Vaccine (DS-5670) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Issues CRL for Proposed Biosimilar Insulin-R: Biocon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"STX-N","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Oximes-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ADXS-504","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Reveals Positive Evidence That Optejet\u00ae Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medlab Announces Favourable Interim Readout of Nanabis Real-World Evidence (RWE) Medcare Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medlab Clinical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Cli.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SLN360","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"WRAIR_EPa11","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptive Phage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant to Present Data from Multiple Studies of Vtama\u00ae (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Announces FDA Approval of Label Update for Rybelsus\u00ae (semaglutide) Allowing Use as A First-Line Option for Adults with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 Antibody by the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM1020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Applies Extended-Release Formulation Expertise to Reduce Treatment Frequency Burden for Acromegaly & Gep-Net Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b\/2 Trial to be Conducted at the Pomeranian Medical University in Poland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Canada Royal Enoch Phytomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canada Royal Enoch Phytomedicine Launches Clinical Trial of its Ginseng-Derived Redsenol-1 Plus Noble Ginsenoside Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ginsenoside","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Canada Royal Enoch Phytomedicine","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Canada Royal Enoch Phytomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Canada Roy.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Govt Panel Recommends Market Authorisation for Covovax Jab as Heterologous Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Isterian Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cambrian BioPharma Unveils New Pipeline Company - Isterian Biotech","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IST-01","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Isterian Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Isterian Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Isterian B.."},{"orgOrder":0,"company":"MicrofluidX","sponsor":"CCRM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microfluidx And CCRM Partner On End-to-end Bioprocessing Of CAR-T Cell Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Partnership","leadProduct":"mRNA-based CART-cell Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"MicrofluidX","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MicrofluidX \/ CCRM","highestDevelopmentStatusID":"2","companyTruncated":"Microfluid.."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuance Pharma Announces Partnership With DKSH To Launch Bentrio\u2122 Nasal Spray In Hong Kong And Macau","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Bentonite","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nuance Pharma \/ DKSH","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Neogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$320.0 million","newsHeadline":"Acquisition of Neogene Therapeutics Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Neogene \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Huadong Medicine","pharmaFlowCategory":"D","amount":"$181.3 million","upfrontCash":"$29.6 million","newsHeadline":"CARsgen, Huadong Medicine Ink Deal To Sell CAR T-cell Product In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Zevorcabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Huadong Medicine","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"RODAN & FIELDS LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Termination","leadProduct":"Difluorocyclohexyloxyphenol","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ RODAN & FIELDS LLC","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based Neopharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amylyx Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Monash University","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Pharmaceutical Enters Research Deal With Monash University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Monash University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monash University \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Monash Uni.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0.13,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Angion Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics and Angion Enter into Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Elicio Therapeutics \/ Angion Biomedica","highestDevelopmentStatusID":"6","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Leap Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leap Therapeutics Acquires Flame Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"FL-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Leap Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","amount":"$41.6 million","upfrontCash":"Undisclosed","newsHeadline":"Eris Lifesciences To Buy Some Dermatology Brands From Glenmark Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Divestment","leadProduct":"Sertaconzole Nitrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Eris Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Shanghai Guoxin Investment & Development","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"IASO Bio Raises Nearly $75 Million in Series C1 Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series C Financing","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"IASO Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Shanghai Guoxin Investment & Development","highestDevelopmentStatusID":"12","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Cristal Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Cristal Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Bentracimab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"LGS Foundation","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Clobazam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"Assertio Therapeutics \/ LGS Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"Medigene","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene Receives $3 Million Milestone Payment from 2seventy Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ 2seventy bio","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS\u00ae in the National Reimbursement Drug List in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Savolitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$16.8 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Termination","leadProduct":"Human Polyclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"CIP-137401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ WuXi AppTec Inc.","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Hypersomnia Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Hypersomnia Foundation","highestDevelopmentStatusID":"8","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Upacicalcet Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ Launch Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys P.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"Suspension for Infusion","sponsorNew":"Bluebird Bio \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Cryoport Systems Inc","sponsor":"Syneos Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cryoport Systems Inc","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cryoport Systems Inc \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Cryoport S.."},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"EVOQ Therapeutics and Amgen Expanding Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Thera.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advaxis and Ayala Pharmaceuticals Complete Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Merger","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Advaxis Immunotherapies","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Shoreline Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas iNK Cell Franchise and Related Gene Editing Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"EDIT-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Editas Medicine \/ Shoreline Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"VectorY","sponsor":"Annogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ Annogen","highestDevelopmentStatusID":"2","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"$15.0 million","newsHeadline":"Repare Therapeutics Receives $1.5 Million (\u00a5200 million) Payment from Ono Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"RP-2119","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"D","amount":"$412.5 million","upfrontCash":"$10.0 million","newsHeadline":"Mabwell Announces Exclusive Licensing Agreement with Disc Medicine, Inc. for Innovative Drug Candidates of Hematologic Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-001","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0.40999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Mabwell \/ DISC MEDICINE","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$576.0 million","upfrontCash":"$576.0 million","newsHeadline":"Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.57999999999999996,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Strata Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Strata Oncology \/ Gilead","highestDevelopmentStatusID":"8","companyTruncated":"Strata Onc.."},{"orgOrder":0,"company":"LinKinVax","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LinKinVax and Gustave Roussy Collaborate on a Phase I\/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"CD40HVac","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LinKinVax \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax .."},{"orgOrder":0,"company":"Neochromosome","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neochromosome and Sumitovant Biopharma Announce Successful Collaboration to Accelerate Protein Drug Discovery and Improve Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Neochromosome","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neochromosome \/ Sumitovant Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Neochromos.."},{"orgOrder":0,"company":"Teon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Teon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teon Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Teon Thera.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"SAB-195","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Upacicalcet Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ Abingworth","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys P.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mineralys Polishes $100M IPO Ahead of Phase 3 Hypertension Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Mineralys Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"NeoPhore","sponsor":"CRT Pioneer Fund","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Completes Extension To Series B Financing To Further Advance Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"NeoPhore \/ CRT Pioneer Fund","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"McSAF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Collaborates Cristal Therapeutics And McSAF to Expand Bioconjugates Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ McSAF","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"$20.0 million","newsHeadline":"Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Gene-edited iPSC-derived NK Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0.82999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.82999999999999996,"dosageForm":"","sponsorNew":"Cellectis \/ Cytovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"QliniQ","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Expands Its Pipeline with A Product Candidate for A Mineral Deficiency in The Blood (hypophosphatemia)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"QliniQ","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QliniQ \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"QliniQ \/ H.."},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"siRNA Duplex Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"ADARx Pharmaceuticals \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Phar.."},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","amount":"$5,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":5,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Su.."},{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rznomics \/ Charles River","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinuvel Trial Results Show Drug Reduces DNA Damage","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Afamelanotide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel P.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Doses Additional Patients in Ongoing Phase 1b\/2a IMX-110 Monotherapy Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Successfully Concludes Toxicity Study with CAN10 Antibody Ahead of Phase I Clinical Trial Application","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CAN10","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Febuxostat Tablets","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Febuxostat","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Confirms Benefit of Rivaroxaban for Prevention of Recurrence of Venous Thromboembolism in Cancer Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCGI Approves Market Authorisation for Covovax as COVID Booster Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Tentative Approval from The USFDA For Levomilnacipran Extended-Release Capsules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Levomilnacipran","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir to present at the Redeye Fight Cancer Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Gonorrhea Vaccine Avacc 11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Bio-Thera Solutions\u2019 BAT1806, A Biosimilar to Actemra\u00ae (Tocilizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abionyx Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CER-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Ph.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IPH6101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research Between Meiji Seika Pharma and The Foundation for Biomedical Research and Innovation at Kobe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ASC11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Luye Pharma\u2019s Rykindo\u00ae for the Treatment of Schizophrenia and Bipolar 1 Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lucid-Psych","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Selects IRL1117 As Drug Candidate to Develop a New Treatment for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL1117","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Selects CD and Enters Next Development Phase with Alzstatin ACD680 Against Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ACD680","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Launches Palbociclib, a Novel Targeted Therapy for Advanced Breast Cancer with A Unique Patient Assistance Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palbociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter Narcan\u00ae (naloxone HCl) Nasal Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CV0501","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of NDA for VV116 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuremdesivir Hydrobromide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"KIN-3248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Doses First Patient in Phase I\/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Polyclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1\/2 MYCHELANGELO\u2122 I Study at\nthe American Society of Clinical Oncology Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"OTX-2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IGM-7354","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA\u2019s Approval of TASCENSO ODT\u00ae (fingolimod)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST .."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Submits Its Phase-1 Clinical Trial Application for Lucid-Ms (lucid-21-302) for First-In-Human Safety and Tolerability Investigation","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184\u2019s Phase 1 Clinical Trial in Q2 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asher Bio Announces Dosing of First Patient in Phase 1a\/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AB248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asher Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphagen Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for OR-449 for the Treatment of Pediatric Adrenocortical Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"OR-449","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orphagen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen P.."},{"orgOrder":0,"company":"Servier","sponsor":"Taiho Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier and Taiho Oncology Present Overall Survival Data for Trifluridine\/Tipiracil (Lonsurf\u00ae) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Trifluridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Taiho Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CMG901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Bi.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta to Present \"Trial in Progress\" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G\/GEJ Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Polymyxin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics' Anti-Claudin 18.2 Antibody Patent Granted in The US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PT886","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceruvia Lifesciences Announces First Participant Dosed in BOL-148 Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceruvia Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Li.."},{"orgOrder":0,"company":"Henlius","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Henlius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Henlius \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Henlius \/ .."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation of a Phase1\/2\/3 Clinical Trial (Part 2) and Phase 3 Additional Dose Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-based Vaccine, S-268019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"S-268019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for The Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MP0533","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse in Fibrotic Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company\u2019s AIM Platform to Treat Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NEXI-004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces First Patient In in NET, A Collaborative Phase II Basket Study with Iadademstat in R\/R Patients with Neuroendocrine Carcinomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Hinge Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hinge Bio Expands Senior Management Team to Drive GEM-DIMER\u2122 Programs to Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Hinge Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hinge Bio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Hinge Bio .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants Orphan Drug Designation for aTyr Pharma\u2019s Efzofitimod for Treatment of Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg\/m2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"KB407","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology Announces Publication in The New England Journal of Medicine of Pivotal Data for Futibatinib in Previously Treated Patients With Metastatic Intrahepatic Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Labs Doses First Patient in Take Home Psilocybin Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1020","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Comprehensive Cancer Network\u00ae Adds Newly Approved Rezlidhia\u2122 (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CAN103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sj\u00f6gren\u2019s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dazodalibep","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"EXG102-031","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Exegenesis Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Exegenesis Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Exegenesis.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem\u2122 Supports Potential for RenovoTAMP\u00ae Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TTHX1114","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Nalmefene Prefilled Syringe for the Treatment of Known or Suspected Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Purdue Pharmaceuticals L.P \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII Seeks Inclusion of Covid Jab Covovax in CoWin Portal as Heterologous Booster Dose for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx\u2122 for the Treatment of Recurrent Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ad26.Mos4.HIV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Nuvaxovid Approved in South Korea as an Adult Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breast Cancer Treatment Made More Affordable & Accessible with Launch of World\u2019s First Branded Generic Palbociclib Tablets (Palborest) 75\/100\/125mg by MSN Group","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palbociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MSN Labora.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CTX-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio\u2019s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AMB-05X","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Pulmobiotics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pulmobiotics Engineered Live Biotherapeutic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pulmobiotics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pulmobiotics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pulmobioti.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn\u2019s & Colitis Congress 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem\u2019s Tech Transfer Company, Yissum","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Bone Marrow-derived Medicinal Signaling Cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ABV-1505","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FLT190","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sotio Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ARC-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen Announces New Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, at ASCO Gastrointestinal Cancers Symposium 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Intercept\u2019s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Tecentriq plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People with Certain Types of Early-Stage Liver Cancer in A Phase III Trial.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stemedica Initiating Phase IIb\/III Clinical Trial for Patients with Chronic Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Adult Mesenchymal Bone Marrow Stem Cell","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemedica Cell Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemedica .."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Differentiated Capabilities of Surmodics\u2019 Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil\u2122 Drug-Coated Balloon","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Donepezil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Zymeworks","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Zymeworks","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Initiates Enrollment in The Phase 2 Bremelanotide Breakout Study in Patients with Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MRTX1133","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Vial","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vial Announces Enrollment of First Patient in Phase II Clinical Trial TLL018-205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll Pharmaceutical","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TLL-018","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Vial","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vial \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vial \/ Not.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Leucovorin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brukinsa\u00ae (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces Inclusion of Nuzyra\u00ae (omadacycline) in China's National Reimbursement Drug List (NRDL)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sellas Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Essential Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"French Marketing Authorization for Iopidine\u00ae 1% (Apraclodinin) Transferred to Essential Pharma in Line with The Company's Medical Needs and Expansion Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Essential Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Essential Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Essential .."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinopharm Unit Gets Ok For Clinical Trials Of mRNA Covid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Successfully Completes Full Set Of Clinical Studies Of Its Rituximab Biosimilar For Filing In The U.S., Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rituximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CYR-064","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Recommends All-oral Treatment For Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ixazomib Citrate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProBioGen\u2019s Vaccine Production Cell Line AGE1.CR.pIX\u00ae Used for Clinical Production","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProBioGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: CESTO II Trial Progressing On Schedule","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tobacco Leaf Protein","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Supplemental New Drug Application for Jardiance\u00ae For Adults with Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third\/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gast","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Humanized Claudin18.2 Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DB-1303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADARx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Phar.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde\u00ae Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JUV\u00c9DERM\u00ae VOLUX\u2122 XC For Improvement Of Jawline Definition Now Available Nationwide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SkinMedica\u00ae Launches Even & Correct","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Caffeine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AT845","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Files Marketing Authorization Application For Anti-amyloid-beta Protofibril Antibody Lecanemab For Early Alzheimer\u2019s Disease In Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Aims To Advance Gastrointestinal Cancer Treatment With Research Across Multiple Tumor Types At ASCO GI 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints In Phase 3 Trial In Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Announces The European Commission Approval Of Xofluza For The Treatment And Prevention Of Influenza In Children Aged One Year And Above","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"D","amount":"$422.5 million","upfrontCash":"$10.0 million","newsHeadline":"Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"MWTX-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Disc medicine","amount2":0.41999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"5","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Ingenza","sponsor":"Amplifica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ingenza Collaborates with Amplifica to Advance Novel Alopecia Treatments","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ingenza","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ingenza \/ Amplifica","highestDevelopmentStatusID":"1","companyTruncated":"Ingenza \/ .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Announces Agreement to Acquire Leading Antifungal Agent Mycamine\u00ae From Astellas, Reinforcing Hospital Offering and Leading Anti-Infectives Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Bioasis","sponsor":"Midatech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioasis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioasis \/ Midatech Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bioasis \/ .."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University of Illinois","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ University of Illinois","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"$206.3 million","upfrontCash":"$206.3 million","newsHeadline":"Clinigen Divests Proleukin\u00ae to Iovance Biotherapeutics for \u00a3166.7 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Divestment","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Cytoreason","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Cytoreason","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytoreason \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO\u00ae (berotralstat) in Central and Eastern Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Swixx BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Hemostemix","sponsor":"McGill University Health Centre","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"ACP-01","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hemostemix","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hemostemix \/ McGill University Health Centre","highestDevelopmentStatusID":"8","companyTruncated":"Hemostemix.."},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharm.."},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harrow Closes Acquisition of U.S. Rights to ILEVRO\u00ae, NEVANAC\u00ae, VIGAMOX\u00ae, MAXIDEX\u00ae, and TRIESENCE\u00ae and Will Begin Receiving Net Profit Payments for Acquired Products","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Nepafenac","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Suspension\/Drops","sponsorNew":"Harrow \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ N.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$400.0 million","newsHeadline":"HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":1.1299999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Tillomed Laboratories Ltd","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Completes Major Product Acquisition from Tillomed Spain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tillomed Laboratories Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tillomed Laboratories Ltd \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Tillomed L.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentiva Continues Its Expansion in Oncology with The Launch of Alymsys\u00ae (Bevacizumab) in 21 Countries Across Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Collaboration","leadProduct":"5-Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mabxience \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan Ebolavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"MBP134","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mapp Biopharmaceutical \/ KBI Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Bioph.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.25,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Stanford School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beyond Cancer\u00ae Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beyond Cancer","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beyond Cancer \/ Stanford School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Beyond Can.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Apexigen Announces Approximately $2.8 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pyxis Oncology \/ Brookline Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"XOMA","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"AZP-40XX","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Amolyt Pharma","highestDevelopmentStatusID":"4","companyTruncated":"XOMA \/ Amo.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Immedica Enter Exclusive Partnership for Commercialisation of Cancer Supportive Care Products in Core European Markets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Immedica Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Announces Commercial Partnership for Maxigesic IV in 9 European Countries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Salus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salus Pharmaceuticals \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Salus Phar.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Truist Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Private Placement","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Truist Securities","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$143.7 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Vimseltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Boustead Securities","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Boustead Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"Eisai","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$160.0 million","newsHeadline":"Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA\u00ae (Perampanel) CIII","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ca.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"IkT-148009","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,495.5 million","upfrontCash":"$27.1 million","newsHeadline":"Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Innate Pharma","amount2":1.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Children\u2019s Hospital Los Angeles","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"Children\u2019s Hospital Los Angeles to Launch $5.3 Million NIH Study for First Clinical Trial for Down Syndrome Regression Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Funding","leadProduct":"Lorazepam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Children\u2019s Hospital Los Angeles","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"","sponsorNew":"Children\u2019s Hospital Los Angeles \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"Children\u2019s.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ\u2019s CRISPRomics\u00ae Platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"John Ballantyne","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myosana Therapeutics Raises $5 Million in Seed Funding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Myosana Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Myosana Therapeutics \/ John Ballantyne","highestDevelopmentStatusID":"2","companyTruncated":"Myosana Th.."},{"orgOrder":0,"company":"Atomic AI","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"RNA-based Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomic AI","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Atomic AI \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Atomic AI .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Pricing of Approximately $15 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$1,680.0 million","upfrontCash":"$80.0 million","newsHeadline":"CytomX Therapeutics Announces Milestone Achievement in Probody\u00ae T-Cell Engaging Bispecific (TCB) Collaboration with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":1.6799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Astellas","highestDevelopmentStatusID":"4","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Nogra Pharma","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Torii Has Entered Into a License Agreement with Nogra Pharma Limited to Develop & Commercialize NAC-GED-0507 in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Nogra Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nogra Pharma \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nogra Phar.."},{"orgOrder":0,"company":"Herophilus","sponsor":"Rett Syndrome Research Trust","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Rett Syndrome Research Trust Funds Herophilus\u2019 Rett Syndrome Lead Candidate Studies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"HRP-12975","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Herophilus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Herophilus \/ Rett Syndrome Research Trust","highestDevelopmentStatusID":"4","companyTruncated":"Herophilus.."},{"orgOrder":0,"company":"Fzata","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fzata Raising Series A For New Oral Biologics Platform Modality","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"FZ002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Fzata","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fzata \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Fzata \/ Un.."},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.7 million","upfrontCash":"Undisclosed","newsHeadline":"Tetra Pharm Technologies Secures \u20ac9 Million In Series A Round to Expand R&D Operations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Tetra Pharm Technologies","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra Phar.."},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Grey Wolf Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Grey Wolf Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Grey Wolf .."},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScie.."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Hitachi Global Life Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"EXG34217","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Boustead Securities","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ Boustead Securities","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Evotec","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ J.."},{"orgOrder":0,"company":"GenKOre","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"GenKOre","amount2":0.29999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"GenKOre \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"GenKOre \/ .."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$287.5 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.28999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Neurochase","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spark Therapeutics, Inc \/ Neurochase","highestDevelopmentStatusID":"2","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$12.8 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Patidegib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Sol-Gel Technologies \/ Raymond James & Associates","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"PellePharm","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","amount":"$74.7 million","upfrontCash":"$4.7 million","newsHeadline":"Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Patidegib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"PellePharm","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Gel","sponsorNew":"PellePharm \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"PellePharm.."},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Funding","leadProduct":"Iduronicrin Genleukocel-T","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Immusoft Corporation \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft C.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"IkT-148009","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$125.0 million","newsHeadline":"Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"SAR443820","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":1.1299999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":1.1299999999999999,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Launches iNCOVACC\u00ae: World\u2019s 1st Intranasal COVID Vaccine for Primary Series and Heterologous Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Chad SARS-COV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Xbrane Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stada and Xbrane Obtain British Approval for Ximluci\u00ae (ranibizumab) Biosimilar Referencing Lucentis\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"STADA Arzneimittel \/ Xbrane Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IOS-1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunOs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunOs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunOs Th.."},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poolbeg Pharma PLC Announces Strategic Expansion of POLB 001 into Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"POLB 001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Ph.."},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carina Biotech Receives FDA \u201cSafe to Proceed\u201d Letter for IND Application for Phase 1\/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment of Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CNA3103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carina Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Bio.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab\/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"1st Leukemia Patient Dosed With SMART101 at MSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SMART101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LAVA-1207","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncXerna Therapeutics Announces Final Results and New Xerna\u2122 TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bavituximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OncXerna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna T.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TSC-204-A0201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax\u2019s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind\u2019s Inhaled Clofazimine Will Advance to an Adaptive Phase 2\/3 Study For Potential Treatment of Rare Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Clofazimine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VMT-\u03b1-NET","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Viewpoint Molecular Targeting","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viewpoint Molecular Targeting \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viewpoint .."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Receives Regulatory Approval for Nuceiva\u00ae in Australia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus to Present Phase 2 Interim Data from Jeuveau\u00ae \u201cExtra-Strength\u201d Dose for Extended Duration Study at 2023 IMCAS World Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PUR1800","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for Ayvakit\u00ae (avapritinib) for the Treatment of Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Illuminare Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Illuminare Biotechnologies Announces First Participant Dosed in Phase I Study of Novel Nerve Visualization Investigational Fluorophore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Illuminare-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Illuminare Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Illuminare Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Illuminare.."},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera Announces First Patients Enrolled in Pivotal MO-TRANS gLobal Phase 2b\/3 Study with Mocravimod as An Adjunctive and Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mocravimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Priothera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Arpraziquantel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Sci.."},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Will Be the First Offering EU Dossier for Finasteride \/ Tadalafil 5 Mg \/ 5 Mg Fixed-Dose Combination","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Finasteride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Sci.."},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Announces Successful Pivotal BE Trial on Sacubitril + Valsartan Development","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Sci.."},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U announces Completion of Bioequivalence Trials on Sertraline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Sertraline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Prague Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prague Sci.."},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zent2U Announces Successful Pivotal Bioequivalence Study Results on Omeprazole Immediate Release Capsules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Sci.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"TheracosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TheracosBio Announces FDA Approval of Brenzavvy\u2122 (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"TheracosBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TheracosBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TheracosBi.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Shares Update on FDA Advisory Committee Meeting for Tofersen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marksans Pharma Announces UK MHRA Approval for Fluoxetine 20mg\/5ml Oral Solution","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluoxetine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans P.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Reports Positive Top-Line Results From Phase IIa Trial of SPL026 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics\u2019 (IBT) Publishes Clinical Findings in The British Journal of Gastroenterology on The Convincing Association of Clinical Events to The Feeding Primary Endpoint of The \u2018Connection Study\u2019","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALLO-647","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Provides Update on Clinical Trials with Bentrio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Publication in the Journal of Vascular Surgery \u2013 Vascular Science Reports the Human Acellular Vessel\u2122 (HAV\u2122) Remains Durable at Six Years in Patients with Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-978","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Center for Medicare Services Established National Pricing of Vendaje\u2122 in All MAC regions","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dehydrated Human Amniotic Membrane","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Te.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"KO-2806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Company\u2019s Development of Monoclonal Antibody Therapeutics for Monkeypox and Smallpox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TNX-3400","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Provides Positive Regulatory Update for D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BKV Neutralising Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for Lupkynis\u00ae in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vitrac Therapeutics Initiates a Phase 1 Clinical Trial with the Aurora Kinase A Inhibitor VIC-1911 and G12C Inhibitor Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VITRAC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC The.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation Of the Phase 3 Study for The Second Long-Acting Injectable Antipsychotic Using Medin Cell\u2019s Technology (Program mdc-TJK)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aculys Pharma Initiates Phase 3 Trial of Pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aculys Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pha.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PH10","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"ClostraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClostraBio Announces Breakthrough Publication Describing Targeted Delivery of Metabolite to Gastrointestinal Tract via Oral Nanoparticles; Appoints CEO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Butyrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ClostraBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ClostraBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ClostraBio.."},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunis Recruits Individuals with Muscle Atrophy for Phase 1\/2a Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies\u2014A Patent Has Been Filed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"ENB Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENB Therapeutics to present at the 2023 BIO CEO & Investor and Immuno-Oncology 360 degree Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ENB003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ENB Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ENB Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ENB Therap.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IMPT-314","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmPACT Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bi.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCGI Approves Keytruda for Treatment of Cervical Cancer: MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Of India Launches the First Made-In-India qHPV Vaccine 'CERVAVAC'","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Capsid L1 Virus-like Particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Herophilus","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Herophilus Announces Results from Research Collaboration with Cerevel Therapeutics to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Herophilus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Herophilus \/ Cerevel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Herophilus.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Once-Weekly Efanesoctocog Alfa Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1\/2 Dose-Escalation Clinical Trial to Investigate Drug Safety","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MGTA-117","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"APX3330","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren\u2019s Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I\/II Trial of Allocetra in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T\u2122 Target for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ALLO-213","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hebrew University Yissum and Clearmind Medicine\u2019s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"XMT-2056","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"OT-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Announces Updated Nccn Clinical Practice Guidelines Recommend Pedmark\u00ae (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG462","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase\u00ae Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Submitted NDA For Its Global New Drug Fexuclue in 11 Countries, only 1 Year After Approval in Korea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Fexuprazan","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix to Host Key Opinion Leader Webinar \"PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment\"","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves ALK's Odactra\u00ae (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Patient Enrollment Update for Phase 3 Study of Buntanetap for The Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Storm Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"STC-15","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Storm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PXL770","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces KEYNOTE-991 Trial Evaluating Keytruda\u00ae (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Launches Sezaby\u2122 (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Phenobarbital Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"KT-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer\u2019s Disease Accepted by European Medicines Agency","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & \u03b2-catenin Targeted Drug Development Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Announces FDA Clearance of IND for its \u2018Inflammation Regulator Protein,\u2019 Gelsolin, for the Treatment of ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Plasma Gelsolin Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1\/2a Clinical Trial of LB101, First LockBody\u00ae Candidate, for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LB101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lapix Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"LPX-TI641","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LAPIX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Ther.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo\u00ae (berotralstat) in Pediatric Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune\u2019s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer\u2019s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b\/2 ABATE Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Commercial Launch of Briumvi\u2122 (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro to Present at Sequire Biotechnology Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer\u2019s Disease (AD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Coya 302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"XC001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi\u00ae (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeGi Pharma Announces Clearance of Investigational New Drug (IND) Application for EXE-346 a Live Biotherapeutic Biologic Drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"EXE-346","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ No.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Data Demonstrating Clinically Meaningful Prevention of Bleeds and Superior Bleed Protection for Efanesoctocog Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbsen Therapeutics Announces Encouraging Interim Results from The NEPHSTROM Proof of Concept Clinical Study Evaluating Orbcel\u2122 Cell Therapy in Patients with Diabetes and Advanced Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stromal Cell","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Orbsen Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orbsen The.."},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CD.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Food and Drug Administration Emergency Use Authorisation of Evusheld","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Recommended for Expanded EU Approval by The CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Netris Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NETRIS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NETRIS Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NETRIS Pha.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brukinsa\u00ae Approved in the U.S. for Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces FDA Accelerated Approval of Tukysa\u00ae (tucatinib) in Combination with Trastuzumab for People with Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ideaya Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crispr Therapeutics and Vertex Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Announces Vazkepa (Icosapent Ethyl) Approved By Medsafe In New Zealand","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for The Treatment of Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in The U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Difluprednate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl\u00ae (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huida Gene's First Gene Therapy Drug Approved By IND in the United States, And International Multi-Center Clinical Trials Will Be Carried Out","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HG004","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"HuidaGene Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HuidaGene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HuidaGene .."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Updates the Timeline of The Phase Iii Study CONCLUDE With Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Jaypirca\u2122 (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VidPrevtyn Beta COVID-19 Booster Vaccine, Developed by Sanofi And GSK, Approved for Use in Great Britain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Monovalent Recombinant-protein COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of Carvykti\u00ae (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Keytruda\u00ae (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a \u22654 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s Keytruda\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$84.9 million","upfrontCash":"Undisclosed","newsHeadline":"CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters\u00e2\u20ac\u2122 Option to Purchase Additional Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"RBN-2397","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ribon Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ribon Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces $60 Million in Additional Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$225.0 million","newsHeadline":"Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Termination","leadProduct":"CART-ddBCMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"iTolerance","sponsor":"Diabetes Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. Enters into Master Services Agreement with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine to Advance iTOL-100 Platform Technology for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Allogenic Pancreatic Islets","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Diabetes Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Launches a Round of Fundraising for Approximately 2.5 Million Euros","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Financing","leadProduct":"NFL-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Divestment","leadProduct":"COR588","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Lighthouse Pharmaceuticals \/ Cortexyme","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Aeolian","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeolian Biotech Corp. Formed to Create an Improved Pneumococcal Vaccine with Experienced Vaccine Development Leadership Team","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ Aeolian","highestDevelopmentStatusID":"4","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Apic Bio","sponsor":"Uniqure","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$10.0 million","newsHeadline":"uniQure and Apic Bio Enter Into Global Licensing Agreement For APB-102, a Clinical Stage Gene Therapy for Patients With ALS Caused by Mutations in SOD1","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"APB-102","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Apic Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Apic Bio \/ uniQure","highestDevelopmentStatusID":"5","companyTruncated":"Apic Bio \/.."},{"orgOrder":0,"company":"Ypsomed","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ypsomed","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ypsomed \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Ypsomed \/ .."},{"orgOrder":0,"company":"X-Chem","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem and Kymera Expand Existing Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ K.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Nagoya University","sponsor":"Ymmunobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"YB-800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nagoya University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nagoya University \/ Ymmunobio","highestDevelopmentStatusID":"4","companyTruncated":"Nagoya Uni.."},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pha.."},{"orgOrder":0,"company":"COTA","sponsor":"Clinical Research Data Sharing Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"COTA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"COTA \/ Clinical Research Data Sharing Alliance","highestDevelopmentStatusID":"2","companyTruncated":"COTA \/ Cli.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on Phase III Stand Trial Assessing Crizanlizumab","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Crizanlizumab-tmca","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023\/2024 Vaccination Season at VRBPAC Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC\u2122 Degrader, in BRAF V600 Mutant Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CFT1946","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive Chmp Opinion for Citrate-Free High Concentration Formulation of Adalimumab Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Approved by European Commission as The First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\"Extra-Strength\" Formulation of Jeuveau\u00ae Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA-xvfs","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lecanemab Receives Priority Review Status in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Alpha Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDE Accepted Alpha Biopharma's New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-Mutated NSCLC Patients with CNS Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Zorifertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Alpha Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Alpha Biop.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tuspetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NM8074","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Approval for Marketing of VV116 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuremidevir Hydrobromide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Provides Furoscix (furosemide injection) Commercial Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"AmMax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AMB-05X","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AmMax Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmMax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AmMax Bio .."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity\u2019s ATH434 Prevents Loss of Brain Cells in Parkinson\u2019s Disease Animal Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qurient Announces Dosing of First Patient in Q702 in Combination with Keytruda\u00ae in a Phase 1b\/2 Clinical Study for the Treatment of Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Qurient","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Qurient \/ .."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM\u2022854 Clinical Study, Against High Blood Pressure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TOTUM\u2022854","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for Orserdu\u2122 (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stemline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruiting Underway in FSD Pharma\u2019s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spesolimab Meets Primary and Key Secondary Endpoint for Prevention of Generalized Pustular Psoriasis Flares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GPRC5D-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"DK210","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Deka Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosc.."},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Help Therapeutics Announces IND Approval of First Universal iPSC-derived Cardiomyocyte Therapy for End-stage Heart Failure in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HiCM-188","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Help Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Help Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Help Thera.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"CV0501","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Expansion of Coverage on China\u2019s National Reimbursement Drug List","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Applies for the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti\u00ae (brexpiprazole) in Japan","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approved (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces the NMPA Approval Of 9MW3011 (FIC) for IND","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW3011","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Tentative Approval From U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Kelso Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kelso Pharma Announces First Product Launch","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Kelso Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"Kelso Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kelso Phar.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-RIGA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnGeneIC Publishes The COVID-EDV Vaccine\u2019s Novel Mechanism of Action in A Leading Immunology Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"COVID-EDV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"EnGeneIC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnGeneIC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnGeneIC \/.."},{"orgOrder":0,"company":"Flag Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FLAG-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Flag Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flag Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flag Thera.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"2-Fluorodeschloroketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavodelpar","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Announces Pedmark\u00ae (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Submits European Marketing Authorisation Application for Aprocitentan for The Treatment of Patients with Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Aprocitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arugula Sciences Announces FDA Approval to Proceed with Phase 1 Study of SIG002, a Perinatal-derived Secretome Product, for the Treatment of Big Toe Osteoarthritis (Hallux Rigidus)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SIG002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arugula Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arugula Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arugula Sc.."},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"PRX005","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ARCT-032","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"BB-031","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basking Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Bi.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Provides Update on Rolvedon\u2122 (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Istari Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lerapolturev","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Istari Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Istari Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Istari Onc.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ASC10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"ACD440","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amjevita\u2122 (adalimumab-atto), First Biosimilar to Humira\u00ae, Now Available in The United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkem Becomes First Indian Company to Launch Novel Antibiotic for Multiple Drug Resistance (MDR) Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ceftazidime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alkem Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alkem Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkem Labo.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jesduvroq (daprodustat) Approved By US FDA For Anaemia of Chronic Kidney Disease in Adults on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Daprodustat","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benlysta Granted Orphan Drug Designation by US FDA For the Potential Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Belimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Bayer\u2019s Darolutamide for The Treatment of Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Label Expansion of Roche\u2019s Hemlibra to Include People with Moderate Haemophilia A In The EU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Emicizumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu\u00ae Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$50.0 million","newsHeadline":"Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Engineered Protein-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.8999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Generate B.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$5,300.0 million","upfrontCash":"$100.0 million","newsHeadline":"Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-engineered Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":5.2999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":5.2999999999999998,"dosageForm":"","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$3,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"CNTY-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Century Therapeutics","amount2":3.1499999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.1499999999999999,"dosageForm":"","sponsorNew":"Century Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$967.0 million","upfrontCash":"$60.0 million","newsHeadline":"Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0.96999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.96999999999999997,"dosageForm":"","sponsorNew":"Stoke Therapeutics \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$790.0 million","upfrontCash":"$40.0 million","newsHeadline":"BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Crescendo Biologics Ltd","amount2":0.79000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.79000000000000004,"dosageForm":"","sponsorNew":"Crescendo Biologics Ltd \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Crescendo .."},{"orgOrder":0,"company":"ABL Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,060.0 million","upfrontCash":"$75.0 million","newsHeadline":"ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"ABL301","moa":"IGF-1R","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ABL Bio","amount2":1.0600000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.0600000000000001,"dosageForm":"","sponsorNew":"ABL Bio \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ .."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,350.0 million","upfrontCash":"$300.0 million","newsHeadline":"Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Precision Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Beam Therapeutics","amount2":1.3500000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.3500000000000001,"dosageForm":"","sponsorNew":"Beam Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$760.0 million","upfrontCash":"$30.0 million","newsHeadline":"AstraZeneca and Neurimmune Sign Exclusive Global Collaboration and Licence Agreement to Develop and Commercialise NI006","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin amyloid","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0.76000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"Evotec","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Lilly Enter Into Drug Discovery Collaboration in Metabolic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Evotec","amount2":1,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":1,"dosageForm":"Oral","sponsorNew":"Evotec \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ E.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","amount":"$735.0 million","upfrontCash":"$30.0 million","newsHeadline":"Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Allogeneic Cardiac-derived Cell Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.73999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"UCB to Acquire Zogenix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine Hydrochloride","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":1.8999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB Pharma S.A","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$40.0 million","newsHeadline":"Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Mersana Therapeutics","amount2":1.04,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"$2,350.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Divestment","leadProduct":"Etanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":2.2999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Samsung Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,045.0 million","upfrontCash":"$45.0 million","newsHeadline":"Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.05,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.05,"dosageForm":"","sponsorNew":"Remix Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Remix Ther.."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"$604.0 million","newsHeadline":"Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,745.5 million","upfrontCash":"$13.0 million","newsHeadline":"ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Camptothecin-based Antibody Conjugate","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immunogen","amount2":1.75,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Immunogen \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$40.0 million","newsHeadline":"Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"In Vivo Gene Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Mammoth Biosciences","amount2":1.04,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Mammoth Biosciences \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Mammoth Bi.."},{"orgOrder":0,"company":"Code Bio","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Code Bio","amount2":2,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Code Bio \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Code Bio \/.."},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"$3,335.0 million","upfrontCash":"$2,335.0 million","newsHeadline":"Biocon Biologics to Acquire Viatris\u2019 Biosimilars Assets for up to USD 3.335 billion in Stock and Cash","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Biosimilar","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Viatris","amount2":3.3399999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":3.3399999999999999,"dosageForm":"Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Curve Therapeutics","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.7,"dosageForm":"","sponsorNew":"Curve Therapeutics \/ MSD","highestDevelopmentStatusID":"3","companyTruncated":"Curve Ther.."},{"orgOrder":0,"company":"Syndesi Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$130.0 million","newsHeadline":"AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"SDI-118","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Syndesi Therapeutics","amount2":1,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1,"dosageForm":"Capsule","sponsorNew":"Syndesi Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Syndesi Th.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,517.5 million","upfrontCash":"$17.5 million","newsHeadline":"Adagene Announces SAFEbody\u00ae Multi-Target Collaboration with Sanofi for Novel Masked ImmunoOncology Antibody Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adagene Suzhou Limited","amount2":2.52,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.52,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,754.0 million","upfrontCash":"$54.0 million","newsHeadline":"Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER AAV Capsids for Gene Therapy Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Voyager Therapeutics, Inc","amount2":1.75,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$30.0 million","newsHeadline":"Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Volastra Therapeutics","amount2":1.1299999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Volastra Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Volastra T.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$6,165.0 million","upfrontCash":"$150.0 million","newsHeadline":"Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Engineered IgM Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1699999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,275.0 million","upfrontCash":"$15.0 million","newsHeadline":"Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFN\u03b1 INDUKINE\u2122 Molecule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"WTX-613","moa":"INF alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Werewolf Therapeutics","amount2":1.28,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.28,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology for $1.9bn","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Momelotinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":1.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":""},{"orgOrder":0,"company":"Channel BioSciences","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,237.5 million","upfrontCash":"$100.0 million","newsHeadline":"Biohaven Acquires KV7 Ion Channel Platform for The Treatment of Epilepsy and Other Neurologic Disorders from Channel Biosciences, A Subsidiary of Knopp Biosciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Acquisition","leadProduct":"BHV-7000","moa":"Kv7 channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Channel BioSciences","amount2":1.24,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.24,"dosageForm":"","sponsorNew":"Channel BioSciences \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Channel Bi.."},{"orgOrder":0,"company":"Athos","sponsor":"Formycon","pharmaFlowCategory":"D","amount":"$720.7 million","upfrontCash":"Undisclosed","newsHeadline":"Formycon is Acquiring the Biosimilar Assets FYB201 and FYB202 and Strengthening Its Position in The Global Growth Market of Biosimilars Through Long-Term Partnership with Athos KG","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Athos","amount2":0.71999999999999997,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athos \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Athos \/ Fo.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"$960.0 million","newsHeadline":"Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Antares Pharma","amount2":0.95999999999999996,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.95999999999999996,"dosageForm":"Capsule","sponsorNew":"Antares Pharma \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"$20.0 million","newsHeadline":"Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.67000000000000004,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Th.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,140.0 million","upfrontCash":"$50.0 million","newsHeadline":"Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"DSP-0187","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Sumitomo","amount2":1.1399999999999999,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":1.1399999999999999,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$11,600.0 million","upfrontCash":"$11,600.0 million","newsHeadline":"Pfizer to Acquire Biohaven Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":11.6,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":11.6,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$30.0 million","newsHeadline":"Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1.28,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.28,"dosageForm":"Inhalation","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1,"dosageForm":"Inhalation","sponsorNew":"Amphista Therapeutics \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$905.0 million","upfrontCash":"$90.0 million","newsHeadline":"BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"BBP-398","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0.91000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.91000000000000003,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"GO Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"$783.5 million","upfrontCash":"$20.5 million","newsHeadline":"Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"GO Therapeutics","amount2":0.78000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"GO Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GO Therape.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,460.0 million","upfrontCash":"$60.0 million","newsHeadline":"Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":1.46,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.46,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$554.0 million","upfrontCash":"Undisclosed","newsHeadline":"Proxygen announces strategic collaboration with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"AUSTRIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":0.55000000000000004,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Proxygen \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/.."},{"orgOrder":0,"company":"Alectos Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$722.5 million","upfrontCash":"$15.0 million","newsHeadline":"Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"AL01811","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alectos Therapeutics","amount2":0.71999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"Oral","sponsorNew":"Alectos Therapeutics \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Alectos Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$900.0 million","newsHeadline":"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo\u00ae (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"Cemiplimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":1.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","amount":"$1,015.0 million","upfrontCash":"$15.0 million","newsHeadline":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Felzartamab","moa":"CD38","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"MorphoSys","amount2":1.02,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":1.02,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ HIBio","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,475.0 million","upfrontCash":"$75.0 million","newsHeadline":"Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Discovery","graph3":"Precision BioSciences","amount2":1.48,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.48,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"TeneoTwo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,265.0 million","upfrontCash":"$100.0 million","newsHeadline":"AstraZeneca to Acquire TeneoTwo and Its Clinical-Stage T-Cell Engager, Strengthening Haematological Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD19\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TeneoTwo","amount2":1.27,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.27,"dosageForm":"Injectable\/Injection","sponsorNew":"TeneoTwo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"TeneoTwo \/.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Theravance Biopharma","amount2":1.55,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":1.55,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Theravance Biopharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Avista Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,007.5 million","upfrontCash":"$7.5 million","newsHeadline":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Avista Therapeutics","amount2":1.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.01,"dosageForm":"","sponsorNew":"Avista Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Avista The.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$1,061.5 million","upfrontCash":"$121.0 million","newsHeadline":"NewAmsterdam Pharma and The Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Obicetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":1.0600000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.0600000000000001,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Kelun-Biotech","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$936.0 million","upfrontCash":"$35.0 million","newsHeadline":"Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kelun-Biotech","amount2":0.93999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.93999999999999995,"dosageForm":"","sponsorNew":"Kelun-Biotech \/ MSD","highestDevelopmentStatusID":"4","companyTruncated":"Kelun-Biot.."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","amount":"$1,175.0 million","upfrontCash":"$27.0 million","newsHeadline":"Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"SYSA1801","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":1.1799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1799999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"CSPC Pharmaceutical Group \/ Elevation Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharm.."},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,592.0 million","upfrontCash":"$45.0 million","newsHeadline":"Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo\u2019s STAR Platform Into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"STAR002","moa":"TCR-V beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Marengo Therapeutics","amount2":1.5900000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5900000000000001,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Marengo Th.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$40.0 million","newsHeadline":"Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":1.28,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.28,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$6,220.0 million","upfrontCash":"$110.0 million","newsHeadline":"Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"P-BCMA-ALLO1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":6.2199999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6.2199999999999998,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kiniksa Pharmaceuticals","amount2":0.69999999999999996,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$3,700.0 million","upfrontCash":"$3,700.0 million","newsHeadline":"Amgen to Acquire Chemocentryx for $4 Billion in Cash","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":3.7000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":3.7000000000000002,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Amgen Inc","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal to License Osteoarthritis Pain Treatment to Shionogi in Japan in Deal of up to > $ 500 Million","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Grunenthal","amount2":0.67000000000000004,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Grunenthal \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,460.0 million","upfrontCash":"$100.0 million","newsHeadline":"Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"XMT-2056","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":1.46,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.46,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Egineered Treg Cell Therapy","moa":"Treg Cell","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"GentiBio","amount2":1.8999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"GentiBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"GentiBio \/.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$5,400.0 million","upfrontCash":"$5,400.0 million","newsHeadline":"Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":5.4000000000000004,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":5.4000000000000004,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"$55.0 million","newsHeadline":"Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"ADX-914","moa":"IL-7 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.69999999999999996,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$25.0 million","newsHeadline":"Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevance","amount2":1.1299999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co. Inc.","highestDevelopmentStatusID":"3","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$3,650.0 million","upfrontCash":"$150.0 million","newsHeadline":"Merck and Orna Therapeutics Collaborate to Advance Orna\u2019s Next Generation of RNA Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Circular RNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Orna Therapeutics","amount2":3.6499999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":3.6499999999999999,"dosageForm":"","sponsorNew":"Orna Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"3","companyTruncated":"Orna Thera.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":1.02,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.02,"dosageForm":"","sponsorNew":"Atomwise \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$60.0 million","newsHeadline":"Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Licensing Agreement","leadProduct":"JMKX002992","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0.65000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Jemincare \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Novo Nordisk to Acquire Forma Therapeutics and Expand Presence in Sickle Cell Disease and Rare Blood Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"PKR","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":1.1000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":1.1000000000000001,"dosageForm":"Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Abpro","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"$1,750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"ABP-102","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abpro","amount2":1.75,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Abpro \/ Celltrion","highestDevelopmentStatusID":"4","companyTruncated":"Abpro \/ Ce.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$816.0 million","upfrontCash":"$66.0 million","newsHeadline":"GSK and Spero Therapeutics Announce Exclusive Licence Agreement for Tebipenem HBr, a Late-Stage Antibiotic that May Treat Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.81999999999999995,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.81999999999999995,"dosageForm":"Tablet","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Seagen","sponsor":"Lava Therapeutics","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"$50.0 million","newsHeadline":"Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"LAVA-1223","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Seagen \/ LAVA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ L.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$703.0 million","upfrontCash":"$70.0 million","newsHeadline":"Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"VENT-01","moa":"NLRP3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0.69999999999999996,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$25.0 million","newsHeadline":"Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-Based Cell Therapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Villaris Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$1,430.0 million","upfrontCash":"$70.0 million","newsHeadline":"Incyte Announces Agreement to Acquire Medicxi-Backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15R\u03b2 Monoclonal Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Auremolimab","moa":"CD122","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Villaris Therapeutics","amount2":1.4299999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.4299999999999999,"dosageForm":"","sponsorNew":"Villaris Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Villaris T.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Funding","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$599.0 million","upfrontCash":"$12.5 million","newsHeadline":"Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"SZN-413","moa":"Wnt Signalling","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Surrozen","amount2":0.59999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Surrozen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,760.0 million","upfrontCash":"$60.0 million","newsHeadline":"Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"MGD024","moa":"CD123\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":1.76,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.76,"dosageForm":"","sponsorNew":"MacroGenics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"MedAlliance","sponsor":"Cordis","pharmaFlowCategory":"D","amount":"$1,135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cordis Announces Acquisition of MedAlliance","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MedAlliance","amount2":1.1399999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":1.1399999999999999,"dosageForm":"","sponsorNew":"MedAlliance \/ Cordis","highestDevelopmentStatusID":"12","companyTruncated":"MedAllianc.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,762.5 million","upfrontCash":"$50.0 million","newsHeadline":"Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Zanidatamab","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":1.76,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.76,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","amount":"$2,115.0 million","upfrontCash":"$260.0 million","newsHeadline":"Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":2.1200000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":2.1200000000000001,"dosageForm":"","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,030.0 million","upfrontCash":"$30.0 million","newsHeadline":"Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"CytomX Therapeutics","amount2":2.0299999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0299999999999998,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,350.0 million","upfrontCash":"$1,350.0 million","newsHeadline":"Merck to Acquire Imago BioSciences, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Bomedemstat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":1.3500000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$2,050.0 million","upfrontCash":"$50.0 million","newsHeadline":"Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":2.0499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$4225.0 million","upfrontCash":"$225.0 million","newsHeadline":"Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"CART-ddBCMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":4.2300000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":4.2300000000000004,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$3,335.0 million","upfrontCash":"$170.0 million","newsHeadline":"GSK and Wave Life Sciences Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Wave Life Sciences","amount2":3.3399999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":3.3399999999999999,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$27,800.0 million","upfrontCash":"$27,800.0 million","newsHeadline":"Amgen Inc to Acquire Horizon Therapeutics plc","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":27.800000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":27.800000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$4,000.0 million","newsHeadline":"Takeda to Acquire Nimbus Therapeutics\u2019 Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"NDI-034858","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":1.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.25,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","amount":"$5,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1\/VEGF)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":5,"dosageForm":"","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Su.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,235.0 million","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream Announces New Research and Collaboration Agreement with Lilly for the Discovery of Novel Peptide Drug Conjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":1.24,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.24,"dosageForm":"","sponsorNew":"PeptiDream \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Kelun-Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$9,475.0 million","upfrontCash":"$175.0 million","newsHeadline":"Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kelun-Biotech","amount2":9.4800000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":9.4800000000000004,"dosageForm":"","sponsorNew":"Kelun-Biotech \/ Merck & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Kelun-Biot.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"$1,700.0 million","newsHeadline":"Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.7,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,054 million","upfrontCash":"$54.0 million","newsHeadline":"Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":2.0499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","amount":"$930.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.93000000000000005,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.93000000000000005,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Global Cord Blood Corporation","pharmaFlowCategory":"D","amount":"$664.0 million","upfrontCash":"$664.0 million","newsHeadline":"Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"CK0802","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0.66000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Global Cord Blood Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,221.5 million","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"HONG KONG","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Insilico Medicine","amount2":1.22,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.22,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Peptide Drug Conjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.1000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"PeptiDream \/ MSD","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Adenomed","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Divestment","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Adenomed","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara's CD73 Oncology DFC Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"CD421","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Cidara Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Maryland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in Animals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"TNX-1500","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"BioCardia","sponsor":"CellProthera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes\u2122 for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Protheracytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioCardia \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Duquesne Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ratio Therapeutics","amount2":0.02,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ratio Therapeutics \/ Duquesne Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ratio Ther.."},{"orgOrder":0,"company":"Federation Bio","sponsor":"MD Anderson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Microbiome-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Federation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Federation Bio \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Federation.."},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeutics","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Disc.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"MiroliverELAP","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United Therapeutics \/ Baxter International","highestDevelopmentStatusID":"5","companyTruncated":"United The.."},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"NICHD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Scenic Biotech","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ NICHD","highestDevelopmentStatusID":"2","companyTruncated":"Scenic Bio.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"AbVacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ AbVacc","highestDevelopmentStatusID":"2","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"AVTX-002","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Avalo Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"RVT-3101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0.20000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Roivant Sciences \/ Goldman Sachs","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"CEA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tobacco Addiction: NFL Biosciences Collaborates with The CEA To Study the Mechanism of Action of Its Drug Candidate NFL-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"NFL-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ CEA","highestDevelopmentStatusID":"9","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Healion Bio","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"TNX-3900","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Healion Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Healion Bio \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Healion Bi.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Teplizumab-mzwv","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Guardant Health","sponsor":"AnHeart Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360\u00ae CDx and Guardant360 TissueNext\u2122 as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Guardant Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Guardant Health \/ AnHeart Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Guardant H.."},{"orgOrder":0,"company":"Pherin Pharmaceuticals","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Pherin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pherin Pharmaceuticals \/ VistaGen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pherin Pha.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cellectis Announces Launch of Follow-On Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"UCART123v1.2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Cellectis \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.6 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Enteric Capsule","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Lind Global Partners","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PaxMedica \/ Lind Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Revive Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Durect Corporation \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Qurient","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Telacebec","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Qurient","highestDevelopmentStatusID":"8","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"Personalis","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Personalis \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"Personalis.."},{"orgOrder":0,"company":"Recurv Pharma","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"TVM Capital Life Science Announces Up To USD 24 Million Investment in Oncology Company, Recurv Pharma, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"RP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Recurv Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Emulsion","sponsorNew":"Recurv Pharma \/ TVM Capital Life Science","highestDevelopmentStatusID":"4","companyTruncated":"Recurv Pha.."},{"orgOrder":0,"company":"Athena Pharmaceutiques","sponsor":"NFL Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NFL BIOSCIENCES: Co-development Agreement For A Drug Candidate to Reduce Alcohol Consumption","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"NFL-301","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Athena Pharmaceutiques","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athena Pharmaceutiques \/ NFL Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Athena Pha.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters\u2122 Option to Purchase Additional Shares in Public Offering of Class A Common Stock","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.12,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair\u00ae (Omalizumab)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","amount":"$1,326 million","upfrontCash":"$126.0 million","newsHeadline":"Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Omeros","amount2":1.3300000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"12","companyTruncated":"Omeros \/ R.."},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Isoray","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"VMT01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viewpoint Molecular Targeting","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viewpoint Molecular Targeting \/ Isoray","highestDevelopmentStatusID":"7","companyTruncated":"Viewpoint .."},{"orgOrder":0,"company":"IgGenix","sponsor":"Alexandria Venture","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"IgGenix \/ Alexandria Venture","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ .."},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"RBO-0618","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Rubedo Life Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Rubedo Lif.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Lintuzumab-ac225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Synaffix \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","amount":"$1,325 million","upfrontCash":"$125.0 million","newsHeadline":"Omeros Announces Agreement to Sell OMIDRIA\u00ae Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Omeros","amount2":1.3300000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"12","companyTruncated":"Omeros \/ R.."},{"orgOrder":0,"company":"Omeros","sponsor":"Rayner","pharmaFlowCategory":"D","amount":"$1,326 million","upfrontCash":"$126.0 million","newsHeadline":"Omeros Completes Sale of OMIDRIA\u00ae Franchise to Rayner Surgical","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Omeros","amount2":1.3300000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Omeros \/ Rayner","highestDevelopmentStatusID":"12","companyTruncated":"Omeros \/ R.."},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","amount":"$586.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.58999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Canadian Institute of Health Resources","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Canadian Institute of Health Resources","highestDevelopmentStatusID":"1","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Nodus Oncology","sponsor":"KHAN Technology Transfer Fund I","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Secures \u00a32.4m ($2.9m) Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nodus Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nodus Oncology \/ KHAN Technology Transfer Fund I","highestDevelopmentStatusID":"4","companyTruncated":"Nodus Onco.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,068.5 million","upfrontCash":"$72.3 million","newsHeadline":"Continued Strong Cresemba\u00ae (isavuconazole) Sales Performance in Asia Pacific and China Triggers Second Sales Milestone Payment to Basilea from Pfizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":1.0700000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":1.0700000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$24.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cellectis Announces Closing of Global Offering and Exercise of Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"UCART123v1.2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$185.3 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters\u2122 Option to Purchase Additional American Depositary Shares","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0.19,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Structure Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Finland\u2019s Lifeline Ventures","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Proposed Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"mRNA-based Prophylactic Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0.20000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Lung Cancer Initiative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ankyra Therapeutics \/ Lung Cancer Initiative","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"NTX-1088","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nectin Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Nectin The.."},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wellmarker Bio Announces Clinical Trial Collaboration With MSD To Evaluate WM-A1-3389 In Combination With KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Wellmarker Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wellmarker Bio \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Wellmarker.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$16.1 million","newsHeadline":"Orion and Jemincare Enter Into an Exclusive Agreement Regarding a Non-Opioid Drug Candidate for The Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Agreement","leadProduct":"JMKX000623","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jemincare \/ Orion","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"Veripalvelu","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion and Veripalvelu To Cooperate for The Development of A New CAR T Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FINLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Veripalvelu","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veripalvelu \/ Orion","highestDevelopmentStatusID":"1","companyTruncated":"Veripalvel.."},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fly Like an Eagle: Garuda Brings in A $62M Series B","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"Blood Stem cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Garuda Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Garuda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Garuda The.."},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"LX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Lirum Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Ther.."},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"DOD","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"EuMentis Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EuMentis Therapeutics \/ DOD","highestDevelopmentStatusID":"2","companyTruncated":"EuMentis T.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces $6.8 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$4,000.0 million","newsHeadline":"Takeda Completes Acquisition of Nimbus Therapeutics\u2019 TYK2 Program Subsidiary","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"NDI-034858","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":6,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Takeda","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"The Mark Foundation for Cancer Research","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"The Mark Foundation for Cancer Research Announces More Than $2 Million in Funding for Two New Drug Discovery Awards for Pancreatic Cancer and Anticancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Undisclosed \/ The Mark Foundation for Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ReviR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReviR Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"ReviR Ther.."},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generian Achieves First Milestones in Mitobridge Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generian Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generian Pharmaceuticals \/ Mitobridge","highestDevelopmentStatusID":"3","companyTruncated":"Generian P.."},{"orgOrder":0,"company":"Bio Immunitas","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A Joint Collaboration Between Bio Immunitas and GenScript ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bio Immunitas","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio Immunitas \/ GenScript ProBio","highestDevelopmentStatusID":"3","companyTruncated":"Bio Immuni.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"SON-080","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ S.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm for the Treatment of Parkinsona's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"aTyr Pharma Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ RBC Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$735.0 million","upfrontCash":"$224.0 million","newsHeadline":"Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"EEV-conjugated Phosphorodiamidate Morpholino Oligomer","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.73999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5am Ventures","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"Undisclosed","newsHeadline":"Spruce Biosciences Announces $53.6 Million Private Placement Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ 5am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Adimab","sponsor":"Ablexis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablexis Announces License Agreement with Adimab","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Adimab","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ablexis","highestDevelopmentStatusID":"3","companyTruncated":"Adimab \/ A.."},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prokarium","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.6 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"REVTx-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"STAR-0215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mythic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mythic Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Napo Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$58.8 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Napo Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"6","companyTruncated":"Napo Thera.."},{"orgOrder":0,"company":"Evotec","sponsor":"Related Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ R.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Completes Full Acquisition of Samsung Bioepis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2022","year":"2022","type":"Acquisition","leadProduct":"Etanercept","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Samsung Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"$960.0 million","newsHeadline":"Halozyme Completes Antares Pharma Acquisition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Antares Pharma","amount2":0.95999999999999996,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.95999999999999996,"dosageForm":"Capsule","sponsorNew":"Antares Pharma \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","amount":"$5,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":5,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Su.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,350.0 million","upfrontCash":"$1,350.0 million","newsHeadline":"Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Bomedemstat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":1.3500000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":1.3500000000000001,"dosageForm":"Capsule","sponsorNew":"Imago BioSciences \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","amount":"$930.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company\u2019s Ophthalmic Pharmaceutical Business","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.93000000000000005,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.93000000000000005,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Formycon","sponsor":"Athos Therapeutics","pharmaFlowCategory":"D","amount":"$720.7 million","upfrontCash":"Undisclosed","newsHeadline":"Formycon AG And Athos KG Announce Closing of Transaction to Acquire Biosimilar Assets FYB201 And FYB202 As Well as Bioeq Gmbh","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0.71999999999999997,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"Formycon \/ Athos Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"$553.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Completes Majority Stake Acquisition Of mAbxience Holding S.L., Significantly Enhancing Presence in High-Growth Biopharmaceuticals Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mabxience","amount2":0.55000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Twelve Bio","sponsor":"Ensoma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ensoma Announces Closing of Twelve Bio Acquisition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twelve Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twelve Bio \/ Ensoma","highestDevelopmentStatusID":"3","companyTruncated":"Twelve Bio.."},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Jewish General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Adva-27a","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunshine Biopharma \/ Jewish General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine B.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares in Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Receives FDA Fast Track Designation in The United States","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Presents Data on Dagger a Next Generation AlloCAR Platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ALLO-316","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX\u2122 (Ketamine) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Patch","sponsorNew":"Agile Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agile Ther.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present at Two February 2023 Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Miromatrix Provides Update on miroliverELAP","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MiroliverELAP","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"United The.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GreenLight Biosciences Receives Approval to Initiate Phase I\/II Clinical Trial of Covid-19 mRNA Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GLB-COV2-043","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GreenLight Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GreenLight Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GreenLight.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (\u00b9\u2078\u2076Re) Obisbemeda for the Treatment of Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romeg Therapeutics Announces Issuance of U.S. Patent for Pilocarpine Oral Solution","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Preclinical","graph3":"RxOMEG Therapeutics","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"RxOMEG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RxOMEG The.."},{"orgOrder":0,"company":"Beactica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beactica Therapeutics Receives FDA Orphan Drug Designation for BEA-17 For the Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BEA-17","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"STP705","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First U.S. Patient Dosed in Aulos Bioscience\u2019s Phase 1\/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology\u2019s Nerlynx\u00ae Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaypirca\u2122 (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EP0042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces GSK Has Advanced Bepirovirsen Into Phase 3 Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bepirovirsen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psycheceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceut.."},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FT-003","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Frontera Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frontera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Frontera T.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PLN-101095","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Immunotherapeutics Completes Patient Enrollment and Randomization Ahead of Schedule in A Phase 2 Trial of The Nanobody\u00ae Sonelokimab in Moderate-To-Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Technologies Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MSP-1014","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX\u00ae2-73 (blarcamesine) EXCELLENCE Phase 2\/3 Rett Syndrome Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Doses First Patient in A Phase I\/II Study of ANV419 as Monotherapy or In Combination with Check Point Inhibitors in Patients with Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ANV419","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anaveon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Publication of REZLIDHIA\u2122 (olutasidenib) Phase 2 Clinical Results in Blood Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Rosalind Franklin University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RFU Startup Preparing For Pivotal Clinical Trial On Novel Therapy For Sudden Cardiac Arrest","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Losartan Potassium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Rosalind Franklin University","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rosalind Franklin University \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rosalind F.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire\u00ae Approved for Self-Administration in The U.S. with A New Pre-Filled Pen","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo\u00ae)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"INO-4201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics to Present Clinical Trial for PT-112 in Prostate Cancer at the ASCO 2023 Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Appoints Nicole Hijnen as President of The Board, Overseeing the Company's Upcoming Clinical Development Program With Lybrido\u2122 Against FSIAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Sonire therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Announcement of First Patient Enrolled in a Randomized Phase 2 study of SONIRE\u2019s Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sonire therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Sonire therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonire the.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Authorities Approve Lyophilized S\/D Treated Plasma OctaplasLG\u00ae for Pre-Hospital Transfusion","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Pooled Plasma","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ORG-129","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1\/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-MMP7","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Coya 301","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase IIb Clinical Study of Investigational Compound Elinzanetant Evaluated Efficacy and Safety in Postmenopausal Patients with Vasomotor Symptoms Study Findings Published in Menopause: The Journal of The North American Menopause Society","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Review of Ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORSERDU\u2122 Now Available from Onco360 for the Treatment of Postmenopausal Women or Adult Men, with ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer with Disease Progression Following at Least One Line of Endocrine Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"SABI Mind","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Alberta Clinical Site for Study of Psychedelic-Assisted Treatment for Alcohol Use Disorder Approved","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SABI Mind","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SABI Mind \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SABI Mind .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"SENS-501","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BIO101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EB06","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX\u2122 (Ketamine) for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EXS4318","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patients with Hidradenitis Suppurativa Experienced Sustained Efficacy and Symptom Improvement at One Year when Treated with Novartis Cosentyx\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Announces Publication of New Data Evaluating Impact Of NEPA (netupitant\/palonosetron) On Hospital Costs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Netupitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Present New ORLADEYO\u00ae (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Filing for House Dust Mite Allergy Tablet Accepted for Review in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmAla Biotech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmAla B.."},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terran Biosciences Announces Publication Of PCT Patent Applications Covering Orally Active Forms Of DMT and 5-MeO-DMT And Long-Acting MDMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Terran Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terran Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Terran Bio.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AC0676","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Takeda\u2019s TAKHZYRO\u00ae (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Trodelvy\u00ae in Pre-treated HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Egret Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EGT 101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Egret Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Egret Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Egret Ther.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b\/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Aflibercept 8 mg for Regulatory Approval in Two Major Retinal Eye Diseases in The EU","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Biologics License Application For Proposed Biosimilar Denosumab Accepted By US FDA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Hemlibra Approved by the European Commission to Treat People with Moderate Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Emicizumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavneos\u00ae (avacopan) Approved In Australia For the Treatment Of ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacopan","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CNA3103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carina Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carina Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carina Bio.."},{"orgOrder":0,"company":"Aceragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Fusidate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aceragen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Receives Approval to Initiate Trials with ProLectin-I","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ProLectin-I","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of \u20181104 in Food Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"SerpinPC","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"APN-346958","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"4","companyTruncated":"Atreca \/ X.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Onapristone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVENTION\u2122 Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EA-2353","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endogena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena T.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Addex Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX71149","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Addex Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Announces the Results Of REACT a Phase 3 Study of Clazosentan in Patients Following Aneurysmal Subarachnoid Hemorrhage","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Study of Orelabrutinib in Patients with R\/R CLL\/SLL Published by American Journal of Hematology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"DF6002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Hinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"HP518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hinova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ N.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Begins the First Administration of The Bersiporocin, New Treatment for Idiopathic Pulmonary Fibrosis, as Phase II Clinical Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bersiposocin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ground-breaking Results in Phase 2 Scleroderma Study by Certa Therapeutics Demonstrates Improvement in More than 60% of Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FT011","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Ther.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Receives IND Clearance For IMG-008, A Long-Acting IL-36R mAb","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IMG-008","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Lake Biotechnology To Highlight Preliminary COVID Phase 1 data at BIO CEO Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CVXGA1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Blue Lake Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Lake Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Blue Lake .."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX\u2122 (Ketamine) On-Body Pump System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Roche Diagnostics GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Announces Positive Data from Global Phase III Programme for Crovalimab In PNH, A Rare Life-Threatening Blood Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Roche Diagnostics GmbH","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roche Diagnostics GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Roche Diag.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology Holdings, Inc. Reports that Its Lead Clinical Compound, LB-100, Can Kill Cancer Cells Through Hyper-Stimulation of Cell Proliferation Signals in Pre-Clinical Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal The.."},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optimi Health Submits Clinical Trial Application After Developing Proprietary MDMA Drug: Mugglehead Magazine","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Hea.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib\u2019s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rigosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene\/Novartis anti-PD-1 Tislelizumab Phase 1b\/2a Combination Clinical Trial in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"LUCID-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Hims","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hims Launches Hard Mints \u2013 A Highly Personalized Treatment For Erectile Dysfunction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Hims","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hims \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hims \/ Not.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RNAimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RNAimmune .."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The FDA Approves the Use of Darolutamide in Combination with Docetaxel as An Additional Indication in The Treatment of Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion Plans to Focus Research and Product Development - In The Future on Cancer and Pain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and Bayer Are Expanding the Darolutamide Development Program in The Area of \u200b\u200bprostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in The EU For the Treatment of Symptomatic Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"NEOGAP Therapeutics","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neogap Receives CTA Approval for A Phase I\/IIa Clinical Trial with Its Advanced Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Personalised Tumor Trained Lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NEOGAP Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NEOGAP Therapeutics \/ Karolinska University Hospital","highestDevelopmentStatusID":"5","companyTruncated":"NEOGAP The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EYLEA\u00ae (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2\/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Publication of Preclinical Infectimune\u2122 Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem\u00ae Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Brown Adipose-derived Stem Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I\/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ATSN-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CNTY-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company's Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion and Pantherna Announce Promising Preclinical mRNA Vaccine Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BLU-5937","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"SER-155","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Initiates ALPHA-STAR Phase 1b\/2 Clinical Trial of STAR-0215 in People with HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"STAR-0215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Plans to File a Markting Authorisation Application for CyclASol\u00ae in the E.U. for the Treatment of Dry Eye Disease in July 2023","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Announces that FDA Accepts The ATI-1501 NDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO\u2122 (tabelecleucel)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pierre Fabre \/ Atara Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MVR-T3011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halucenex Life Sciences Inc. Targets Australian Market Following Landmark TGA Decision","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Halucenex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-ALZ","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Announces Issuance of New Composition of Matter Patent for Aramchol Meglumine Salt","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aramchol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Posiphen tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces Topline Results From Phase 3 DIVERSITY Trial of Filgotinib In Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Filgotinib","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Fails to Recommend Boehringer Ingelheim and Lilly Alliance\u2019s Empagliflozin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Launches In-House Palbociclib (PRIMCYV\u00ae) To Widen Access to High-Quality Breast Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palbociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Announces Positive Data from Global Phase III Program for Crovalimab in PNH, a Rare Life-Threatening Blood Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s Tecartus\u00ae CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Advisory Committee Votes in Support of Trials Designed to Evaluate Jemperli (dostarlimab-gxly) As a Potential Treatment for Mismatch Repair-Deficient\/microsatellite Instability-High Locally Advanced Rectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab-gxly","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FINTEPLA (fenfluramine) Oral Solution Approved in The EU for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut syndrome (LGS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Presented Encouraging Initial Safety and Efficacy Data at 2023 EBMT-EHA For Point-Of-Care Manufactured CAR-T candidate, GLPG5201, in rrCLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GLPG5201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse in Fibrotic Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Artios Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ART0380","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artios Pharma Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artios Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artios Pha.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company's Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tnx-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Oncology Announces the Publication of Data from Its Phase 1 THINK Study Of CYAD-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CYAD-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium\u2122 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Announces the Approval and Launch of Metronidazole Gel USP, 1%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosette Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"Vivacelle Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivacelle Bio\u2019s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VBI-S","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vivacelle Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vivacelle Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivacelle .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TDM-180935","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerm.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Aesther Healthcare Acquisition Corp.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce the Award of New Patents for Novel Monospecific and Bispecific Antibodies that Suppress Multiple Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Aesther Healthcare Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prolong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PP-007","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Prolong Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prolong Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prolong Ph.."},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BB-031","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Basking Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basking Bi.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tirofiban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent (IIV4) Delivered Using High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Inactivated Seasonal Influenza Vaccine Quadrivalent","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ N.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Provides Progress Update on RXC007 Clinical Programm","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RXC007","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Regular Approval for Jemperli for The Treatment of Patients with Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Heartseed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heartseed and Novo Nordisk Announce First Patient Dosed in Clinical Study With HS-001 A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"HS-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Heartseed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase III Data Show Roch Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People with Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO\u00ae (abrocitinib)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 2 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE), Confirming the Positive Results of the Recent DELTA 1 Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Silver Creek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silver Creek Presents ARPEGGIO, a Phase 2 Clinical Trial Evaluating Scp776 -- a First-in-Class Cell Rescue Drug -- for the Treatment of Acute Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Scp776","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Silver Creek","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Silver Creek \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silver Cre.."},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allegro Ophthalmics Announces Presentation of Key Data Surrounding Dry AMD Pipeline Candidates, Treatment Considerations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Risuteganib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allegro Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Op.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"SLS-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Partial Clinical Hold for Phase 1\/2 VELA Trial of BLU-222","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BLU-222","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Phase III Trial Results Demonstrating Sovateltide's Efficacy to Treat Acute Cerebral Ischemic Stroke Presented at The International Stroke Conference 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anokion Announces $35 Million Equity Investment from Pfizer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carrick Therapeutics Announces $35 Million Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Antibody Agreement with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$955.0 million","upfrontCash":"$25.0 million","newsHeadline":"HOOKIPA Announces Strategic Collaboration And License Agreement With Roche To Develop Novel Arenaviral Immunotherapy For KRAS-mutated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"HB-700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.95999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Dren Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$25.0 million","newsHeadline":"Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dren Bio","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Dren Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Dren Bio \/.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"Undisclosed","newsHeadline":"Schr\u00f6dinger Hosts Platform Day","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Schrodinger","amount2":0.42999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Schrodinger \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Kyttaro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyttaro Announces Worldwide Exclusive Licensing Agreement With Lilly for Antibody Therapeutic Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"LY3561774","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Kyttaro","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$258.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Abbisko Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Abbisko Th.."},{"orgOrder":0,"company":"Evozyne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Evozyne","amount2":0.40000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Evozyne \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CBC Group-backed Hasten Biopharma Successfully Completes Acquisition Of Five Cardiovascular And Metabolism Drugs From Takeda","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.5 million","upfrontCash":"Undisclosed","newsHeadline":"Luxna Announces Technology License Agreement With Takeda","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Luxna Biotech","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Luxna Biot.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adge Pharmaceuticals Secures License To Evaluate Two New Programs In Rare Pediatric Diseases","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Elocalcitol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Aquinnah Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aquinnah Pharmaceuticals Announces Collaboration With Roche To Advance New Therapies for ALS and Other Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Aquinnah Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aquinnah Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Aquinnah P.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$5.0 million","newsHeadline":"Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Telix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$192.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.19,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Scilex Holding Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company, A Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Acquires Rights To FDA-Approved ELYXYB\u2122 in the U.S. and Canada For the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Celecoxib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Undisclosed \/ Scilex Holding Company","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Announces Amended Collaboration Agreement with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Sotrovimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0.25,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.25,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Gates Frontier","pharmaFlowCategory":"D","amount":"$116.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevance Expands Series B Financing with Additional $51 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"CVN424","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"","sponsorNew":"Cerevance \/ Gates Frontier","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied Biomedical Science Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$955.0 million","upfrontCash":"$25.0 million","newsHeadline":"HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"HB-700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0.95999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TNX-3600","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"4","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Cardiff University","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Cardiff University","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff University \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Cardiff Un.."},{"orgOrder":0,"company":"Austin Biosciences","sponsor":"Financial Strategies Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Financial Strategies Acquisition Corp. Announces Merger with Austin Biosciences Corp, A Texas Biotechnology Platform Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Austin Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Austin Biosciences \/ Financial Strategies Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Austin Bio.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Teplizumab-mzwv","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Bigfoot Biomedical","sponsor":"Insulet Corporation","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Bigfoot Biomedical","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Bigfoot Biomedical \/ Insulet Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bigfoot Bi.."},{"orgOrder":0,"company":"Elthera","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Elthera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elthera \/ LegoChem Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Elthera \/ .."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.6 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"REVTx-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","amount":"$588.0 million","upfrontCash":"$25.0 million","newsHeadline":"Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HBM7008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Cullinan Oncology, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"CureVac","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"mRNA-based Prophylactic Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0.25,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.25,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Corbus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$692.5 million","upfrontCash":"$7.5 million","newsHeadline":"Corbus Pharmaceuticals Expands Oncology Pipeline with The Addition of A Clinical Stage Nectin-4 Targeting Antibody Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":0.68999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Megalith P.."},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sentia Medical Science","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Sentia Med.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$220.8 million","upfrontCash":"Undisclosed","newsHeadline":"Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.22,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gritstone bio \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$62.5 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Disc medicine \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Ryne Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ryne Biotechnology Awarded $4 Million from the California Institute for Regenerative Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"RNDP-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ryne Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryne Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ryne Biote.."},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Invasight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eurofins Discovery Collaborating with Invasight on Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eurofins Discovery \/ Invasight","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins D.."},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Similis Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs Targeting Cancer and Autoimmune Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"JSR Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JSR Life Sciences \/ Similis Bio","highestDevelopmentStatusID":"4","companyTruncated":"JSR Life S.."},{"orgOrder":0,"company":"Cellectricon","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cellectricon","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectricon \/ Delix Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectric.."},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$77.3 million","upfrontCash":"Undisclosed","newsHeadline":"Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Hexagon Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bi.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$270.0 million","newsHeadline":"Bavarian Nordic To Acquire Portfolio of Travel Vaccines From Emergent Biosolutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Typhoid Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0.38,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.38,"dosageForm":"Capsule","sponsorNew":"Emergent BioSolutions \/ Bavarian Nordic","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"Defense Innovation Unit","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"The Access to Advanced Health Institute Announces $3M Award to Develop an Intranasal Pan-Viral Countermeasure against Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Access to Advanced Health Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Access to Advanced Health Institute \/ Defense Innovation Unit","highestDevelopmentStatusID":"4","companyTruncated":"Access to .."},{"orgOrder":0,"company":"ARScience Bio","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya\u2019s Low-Dose Interleukin 2 (IL-2) Product Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Coya 301","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"ARScience Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ARScience Bio \/ Coya Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARScience .."},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories International","highestDevelopmentStatusID":"4","companyTruncated":"Purespring.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Codagenix Announces Close of $25 million Extension of Series B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"CodaVax-RSV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Scripps Research","sponsor":"Gates MRI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calibr and Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Candidate Tuberculosis Treatment Compound","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CLB073","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Gates MRI","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"GAIA BioMedicine","sponsor":"TreeFrog Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GAIA BioMedicine and TreeFrog Therapeutics Announce Collaboration for the Expansion of Allogeneic NK-like Cells Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Allogeneic NK-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GAIA BioMedicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GAIA BioMedicine \/ TreeFrog Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"GAIA BioMe.."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b\/2 Clinical Trial to the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"ATRN-119","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"EM-113","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"EuMentis Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"EuMentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EuMentis T.."},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen, Universite de Montreal and IRICoR Broaden Existing Oncology Partnership, with An Exclusive License Agreement and Two New Discovery-Stage Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Universit\u00e9.."},{"orgOrder":0,"company":"Maxion Therapeutics","sponsor":"LifeArc Ventures","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"LifeArc Ventures Invests in Maxion Therapeutics to Drive Antibody Development for Previously Untreatable Ion Channel And GPCR-Driven Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series A Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Maxion Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Maxion Therapeutics \/ LifeArc Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Maxion The.."},{"orgOrder":0,"company":"Pherecydes Pharma","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"Anti-Staphylococcus Aureus Bacteriophage","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pherecydes Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pherecydes Pharma \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pherecydes.."},{"orgOrder":0,"company":"Xilis","sponsor":"MD Anderson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xilis and MD Anderson Announce Strategic Collaboration to Advance Novel Technology and Accelerate Therapeutic Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Xilis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilis \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Xilis \/ MD.."},{"orgOrder":0,"company":"Psycheceutical","sponsor":"iNGEN\u016b","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Psycheceutical \/ iNGEN\u016b","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceut.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"EmVenio Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"GEO-CM04S1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeoVax Labs \/ EmVenio Research","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"$12.0 million","newsHeadline":"Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","amount":"$16.1 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Securities LLC","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Closes First Tranche of Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Spartan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"M2Gen","sponsor":"Zephyr AI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M2GEN and Zephyr AI Announce Partnership to Better Identify Treatments and Cures for Patients with Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"M2Gen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"M2Gen \/ Zephyr AI","highestDevelopmentStatusID":"2","companyTruncated":"M2Gen \/ Ze.."},{"orgOrder":0,"company":"Avilar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Avilar Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Avilar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Avilar The.."},{"orgOrder":0,"company":"Aqilion","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$10.6 million","newsHeadline":"Aqilion Announces Pre-Clinical Licensing and Strategic Research Collaboration Agreement with Merck","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Aqilion","amount2":1.03,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Aqilion \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Aqilion \/ .."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval From USFDA For Glycopyrrolate Injection USP","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Glycopyrronium Bromide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Expands Gedeptin\u00ae Clinical Research for Advanced Head and Neck Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ad\/PNP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Receives FDA Orphan Drug Designation For Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ISM001-55","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT\u00ae (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RIST4721","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Th.."},{"orgOrder":0,"company":"Viatris","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Issues CRL for Bevacizumab License Application Moved By Viatris: Biocon","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab-maly","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Viatris \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kerendia Granted Expanded Indication in EU for Broad Range of Patients With CKD And Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Launches COVID-19 Booster Vaccine in the People\u2019s Republic of China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Lorigerlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabometyx\u00ae In Combination with Nivolumab Shows Durable Survival Benefits at Over Three-Years\u2019 Follow-Up in First-Line Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Osanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"INNA-051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic A\u03b2 Oligomers in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ACU193","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol\u00ae Eye Drops for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ONL Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8\u00ae Treatment Improved Brain Neuronal Structural Integrity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium\u2122 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis\u00ae for wet AMD Published in the Journal Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"OPT-302","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Angiocrine Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial Data during the Annual Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-205","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Angiocrine Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Angiocrine Bioscience \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Angiocrine.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc. Receives Orphan Drug Designation For The PRMT5 Inhibitor - JBI-778 For the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"JBI-778","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"REC610","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA\u00ae (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children as Young as 2 Years Old","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug, Tascenso ODT\u00ae (fingolimod), Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from Pioneer Phase I\/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GS030","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Onco360","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lytgobi\u00ae (futibatinib) Now Available from Onco360 for the Treatment of Adult Patients with Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Fusions or Other Rearrangements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onco360","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Onco360 \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology\u2019s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2\\'-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"BITT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BITT Provides Update on DOMab Platform and CD40 Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BITT-CD4D11","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"BITT","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BITT \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ Not.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for Linzess\u00ae (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Enkephalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ADU-1805","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sairopa","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Sairopa \/ .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo\u00ae (nivolumab) in Combination with Cabometyx\u00ae (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Exosome","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ALG.APV-527","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Aptevo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Bionxt Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Lif.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Announces Positive Response In COVIDITY Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Plasmid DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World\u2019s First Topical Use PROTAC Compound","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GT20029","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"KIN-3248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology Holdings Reports Newly Published Independent Pre-Clinical Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Publication of OLINVYK Respiratory Physiology Study In Anesthesiology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I\/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"NRTX-1001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VXA-GI.1.NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propella Therapeutics Announces Presentation of Updated Phase 1\/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Abiraterone Decanoate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI\u2122 (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"SNS-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex, mRNA-DegradaBALL Vaccine LEM-mR203 Clinical Phase 1 Trial IND Submission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"LEM-mR203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lemonex Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bi.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Halda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halda Therapeutics Unveils Its First Pipeline Data For RIPTAC\u2122 therapeutics, A New Drug Modality, at ASCO GU Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Regulated Induced Proximity Targeting Chimeras Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Halda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Halda Ther.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech to Advance LYT-300 (Oral allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived VHH Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics\u2019 Investigational SER-109 ECOSPOR IV Study Data Published in Jama Network Open","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Firmicute Species Bacterial Spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Scienc.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I\/II Study of BT8009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Announces Availability of REBYOTA\u2122 (fecal microbiota, live \u2013 jslm) \u2013 the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Fecal Microbiota-jslm","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare To Present First Head-To-Head Data for Long-Acting Hiv Treatment Cabenuva Against Daily Oral Biktarvy At CROI 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"enGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"enGene Announces Positive Preliminary Phase 1\/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EG-70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"enGene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ N.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1020","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rilvegostomig","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Provides Complementary Information on The Phase III Program CONCLUDE With Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IBI311","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Accelagen","sponsor":"Kiora Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Groundbreaking Clinical Trial Underway to Improve Vision in Individuals with Advanced Retinitis Pigmentosa (RP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"KIO-301","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Accelagen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accelagen \/ Kiora Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Accelagen .."},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KKR-backed Replay and MD Anderson Form New Product Company Syena to Pioneer First-In-Class TCR-NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TCR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"BioMed X","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMed X Launches New T Cell Immunology Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioMed X","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioMed X \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"BioMed X \/.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax to Present Blood and Rectal Tissue Data from UC Patients Treated with Obefazimod at the 18th Congress of ECCO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Obefazimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'Helping End Addiction Long-Term' (HEAL) Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RLF-TD011","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate Phase 1\/2 Study of First mRNA-based Shingles Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-07915234","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Provides Regulatory Update on Tedopi\u00ae, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"OSE2101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR\u00ae, with Product Development Roadmap for the Development of Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-PNPLA3","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BRII-179","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IBI311","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. and Dr Falk Pharma GmbH Announce the Start of The Phase II Study of Naronapride in Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ATI 7505","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion .."},{"orgOrder":0,"company":"Unravel Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unravel Biosciences Announces Positive Feedback from FDA Pre-IND Meeting on RVL001 Rett Syndrome Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RVL001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Unravel Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Unravel Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Unravel Bi.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Opaganib","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces FDA\u2019s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ABI-5366","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in Small Pharma\u2019s First-in-Human Phase I Clinical Trial with SPL028","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Cytovation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovation Announces First Patient Dosed in Phase 2a Study Investigating CyPep-1 Monotherapy in Advanced Melanoma Refractory to Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cytovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cytovation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Reports FDA Advisory Committees\u2019 Unanimous Vote in Favor of NARCAN\u00ae (naloxone HCI) Nasal Spray for Over-the-Counter Use","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives USFDA Tentative Approval For Canagliflozin Tablet","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VERVE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Th.."},{"orgOrder":0,"company":"Purple Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CM-24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Purple Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purple Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Purple Bio.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT to Present Interim Clinical Data from INGLAXA Phase 1\/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b\/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ribaxamase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First AML Patient Transplanted with Vor Bio Trem-cel Demonstrated Durable Engraftment Through Multiple Mylotarg Cycles at Initial Dose Level","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemtuzumab Ozogamicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Initiates a Phase 1b\/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces Path to Resume TH1902 Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TH1902","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1\/2 Trials of INZ-701","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Enfortumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MZE001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive TALZENNA\u00ae and XTANDI\u00ae Combination Data from Phase 3 TALAPRO-2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Talazoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio to Present \u2018Quality Of Life In QUILT 3.032 Study: Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Receiving IL-15R\u237aFc Superagonist N-803 Plus BCG\u2019 at ASCO GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat the Macula Society 46th Annu","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AceLink Therapeutics To Present Two Posters on Fabry Disease and Gaucher Disease at 2023 WORLD Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AL01211","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AceLink Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Th.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARX517, Ambrx\u2019s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ARX517","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology\u2122-01 and -02 Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX\u2011629 Into New Phase 2 Systemic Disease Trials","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX\u2011629","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Sarcoma Therapy Now Approved for New Zealand Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Announces Positive Preliminary Results from Second Cohort of Phase 1\/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Provides Update on EMA Regulatory Review of Leniolisib For APDS in Europe","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA\u00ae) for Oncology Support","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RHB-102","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1010","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives 2nd ANDA Tentative Approval For Saxagliptin Tablets, 2.5 mg and 5 mg","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Saxagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces FDA Approval of AUSTEDO\u00ae XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO\u00ae (deutetrabenazine) Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate -274 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E\/R4","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck\u2019s PREVYMIS\u2122 for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Letermovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma Announces First Patient Enrolled in Phase 2 Study to Assess Efficacy and Safety of NS-018 Compared to Best Available Therapy (BAT) in Patients With Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ilginatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI\u2122 (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves SYFOVRE\u2122 (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trodelvy\u00ae Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Authorizes Moderna's Omicron-Targeting Bivalent Covid-19 Vaccine in Children & Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1273.214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Heartseed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heartseed and Novo Nordisk Announce First Patient Dosed in Clinical Study With HS-001 \u2013 A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"HS-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Heartseed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Gets CDSCO Nod for Drug to Treat Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FT-002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Frontera Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Frontera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Frontera T.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AC0176","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence tablet Formulation Approved in The EU for Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren Disease Treatment and Application","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkem Subsidiary Enzene Launches Adalimumab Biosimilar in India","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Enzene Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enzene Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Enzene Bio.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX-246","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea\u00ae Biosimilar in Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Altos Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altos Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Altos Biol.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AceLink Presents Preclinical Data on AL00804 at WORLD Symposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AL00804","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AceLink Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AceLink Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AceLink Th.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Optimizes Statistical Analysis for Its Ongoing ALLOB Phase IIb Study for High-Risk Tibial Fractures, Requiring Fewer Patients and Completes Patient Recruitment","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Anti-IL-8 Recycling Antibody AMY109, Improves Inflammation and Fibrosis in Endometriosis in an Industry-Government-Academia Non-Clinical Study Published in Science Translational Medicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AMY109","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"AbCheck","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"AbCheck","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"AbCheck \/ .."},{"orgOrder":0,"company":"Nanite","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMT Research Foundation and Nanite Inc. Announce Partnership to Enhance Therapeutic Efficacy of Antisense Oligonucleotides in CMT1A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nanite","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanite \/ CMT Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nanite \/ C.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium 2023","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Asceneuron","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ASN90","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asceneuron \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AT845","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data Presented At WORLD Symposium\u2122 Reinforce Nexviazyme\u00ae (avalglucosidase alfa) As Potential New Standard of Care for All People Living with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avalglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BA3182","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,300.0 million","newsHeadline":"Acquisition of CinCor Pharma Complete","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":1.8,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BBT-401","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FAMAR and Medicom Healthcare Announce The Acquisition By Medicom Of The Pharmaceutical Dossier Of BIMATOPROST","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Medicom Healthcare","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Medicom Healthcare \/ Famar","highestDevelopmentStatusID":"12","companyTruncated":"Medicom He.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Celebrates Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bispecific Antibody Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"BiomX","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces $7.5 Million Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"BiomX \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Or.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Positive Results from Part 1 of the Phase 1b\/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals, Inc. Announces Publication of Pediatric Phase 1 (KOURAGE) Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"BXQ-350","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pha.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces Positive Data Demonstrating Long-Acting Injectable Cabenuva (cabotegravir, Rilpivirine) Is as Effective as Daily Oral Biktarvy (BIC\/FTC\/TAF) For the Treatment Of HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis and Nestl\u00e9 Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CM-101","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CM369","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Keymed Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"KYM Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,163.0 million","upfrontCash":"$63.0 million","newsHeadline":"Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KYM Biosciences","amount2":1.1599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"KYM Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"KYM Biosci.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818\u2019s (ITK Inhibitor) Potential to Block HIV Latency Reversal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CPI-818","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"CUE-401","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0.22,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, \u201cLong COVID: What Will it Take to Accelerate Therapeutic Progress?\u201d","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Sanders Morris Harris","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing Round","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series A Financing","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Olatec Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Olatec Therapeutics \/ Sanders Morris Harris","highestDevelopmentStatusID":"9","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"Eversana","sponsor":"Xspray Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Dasatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eversana \/ Xspray Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Present New Data on DAXXIFY\u00ae (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Announces Positive Top-Line Results from Fed\/Fast Study of Lead Asset CTx-1301 for ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Imjudo Approved in The EU for Patients with Advanced Liver and Non-Small Cell Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Once-Weekly ALTUVIIIO A New Class of Factor VIII Therapy for Hemophilia a That Offers Significant Bleed Protection","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Once-Weekly Efanesoctocog Alfa, a New Class of High-Sustained Factor VIII Therapy for Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"MEI Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"Eganelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Infinity Pharmaceuticals \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGA Grants Provisional Approval To Moderna\u2019s COVID-19 Bivalent (SPIKEVAX Bivalent Original\/Omicron BA.4-5) Booster Dose Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Elasomeran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Elranatamab Receives FDA and EMA Filing Acceptance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"ELVN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Th.."},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"ELVN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Enliven Therapeutics \/ Fairmount","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Th.."},{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARS Pharmaceuticals Reacquires European Marketing Rights to Neffy\u00ae (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma\u2019s UTULY\u2122 13.2mg Intranasal Epinephrine Spray Provides Higher and More Sustained PK Compared to Standard Reference Product, the 0.3mg Epinephrine Autoinjector and Inpatient Standard of Care, the 0.5mg Manual Injection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bryn Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"TVM Capital Life Science","sponsor":"TVM Capital Life Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarit\u00c3\u00a9 FTQ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"ESP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TVM Capital Life Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"TVM Capital Life Science \/ TVM Capital Life Science","highestDevelopmentStatusID":"8","companyTruncated":"TVM Capita.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Gene Therapy for Hemophilia B, CSL's HEMGENIX\u00ae, Approved by the European Commission","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Exarafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Exarafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Provides Update on Fezolinetant New Drug Application in U.S.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Bioth.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Has Determined the Recommended Phase 2 Dose for Fostrox in Combination with Lenvima In HCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Fapon Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FP002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fapon Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fapon Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fapon Biot.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"FTX-6058","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX\u00ae (furosemide injection)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Approves Zydus Gabapentin Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Gabapentin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Galinpepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Sellas Life Sciences Group \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"IPS Heart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants IPS HEART Orphan Drug Designation for GIVI-MPC for Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GIVI-MPC","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IPS Heart","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IPS Heart \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IPS Heart .."},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grid Therapeutics Initiates a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck\u2019s Pembrolizumab in Patients with Advanced Stage Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"GT103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Thera.."},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"HMB-001","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Hemab Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Ther.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma USA Requests FDA Approval For Wilate\u00ae VWD Prophylaxis Supplement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Von Willebrand Factor\/Coagulation Factor VIII Complex","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Hypoimmune Pluripotent Stem Cell","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eterna The.."},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami The.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Announces Initial Phase 1 Safety and Pharmacodynamic Activity Data with First Soluble TCR Therapy for People Living With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IMC-M113V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1\/2 STAAR Study in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Isaralgagene Civaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ISM3312","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Granted FDA Fast Track Designation for IVX-A12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"10-1074","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces First Patient Enrolled in Pediatric Clinical Trial of Leniolisib","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Loxapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MDG1011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Receives FDA Investigational New Drug (IND) Approval for Phase IIb Study Of BPL-003, A Novel Synthetic Formulation of 5-MeO-DMT (Mebufotenin)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celltrion and LISCure Biosciences Announce Strategic Collaboration to Develop Novel Microbiome Treatment for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Microbiome-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Celltrion","highestDevelopmentStatusID":"2","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data for Sotatercept and MK-0616 at ACC.23\/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MK-0616","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Early Efficacy Data from Monotherapy Part Of ModiFY Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Modi-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO\u2122 (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO\u2122 (Molnupiravir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna and Merck Announce mRNA-4157\/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna And Life Edit Therapeutics Enter Strategic Collaboration To Accelerate The Development Of Novel In Vivo Gene Editing Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Life Edit Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Life Edit Therapeutics \/ Moderna","highestDevelopmentStatusID":"3","companyTruncated":"Life Edit .."},{"orgOrder":0,"company":"Exelead","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$780.0 million","upfrontCash":"$780.0 million","newsHeadline":"Definitive Agreement to Acquire Exelead will Strengthen Merck\u2019s CDMO Offering for mRNA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exelead","amount2":0.78000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.78000000000000003,"dosageForm":"","sponsorNew":"Exelead \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Exelead \/ .."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"MyMD Announces $15 Million Offering with Existing Investors","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"MYMD-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Advances TRIFOUR Trial to Randomized Stage Following Promising Early Safety and Efficacy of Nadunolimab in Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Receives \u20ac 1.7 Million In \u00ab Avance Innovation \u00bb Funding From Bpifrance","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"NFL-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Bpifrance","highestDevelopmentStatusID":"9","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for AKEEGA\u00ae (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1\/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Claris Ventures","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Resalis Therapeutics Announces Seed Financing of \u20ac10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Non-Coding RNA-Based Therapy","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Resalis Therapeutics","amount2":0.01,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Claris Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Resalis Th.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"NR082","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$137.7 million","upfrontCash":"Undisclosed","newsHeadline":"Abivax Announces Successful Oversubscribed EUR 130M Cross-Over Financing at Market Price with Top-Tier US and European Biotech Investors","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0.14000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ T.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"OTX-2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Curatis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pamapimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curatis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PAS-002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO\u00ae (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pilocarpine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Orasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pozelimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn\u2019s and Colitis Organisation (ECCO)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PRA023","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,702.0 million","upfrontCash":"$775.0 million","newsHeadline":"Blueprint Medicines to Regain Global Rights to GAVRETO\u00ae (pralsetinib) from Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Termination","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"Blueprint Medicines \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Aural Analytics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aural Analytics Speech Technology Signaled Slowing of Decline in ALS Patients\u2019 Speech and Bulbar Function in Platform Trial Evaluating Pridopidine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Aural Analytics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aural Analytics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aural Anal.."},{"orgOrder":0,"company":"Adimmune","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Adimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adimmune \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Adimmune \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceutical Selects CMAX Research Facility For Phase III Urinary Tract Infection Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"The Lind Partners","pharmaFlowCategory":"D","amount":"$3.1 million","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ The Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palvella Therapeutics Announces Pipeline Update on QTORIN\u2122 3.9% Rapamycin Anhydrous Gel (QTORIN\u2122 Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces New Interim Data from DNL310 Phase 1\/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2 Sulfatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veklury\u00ae (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezpegaldesleukin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaEssentia Initiates Phase 2b Trial of Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) in North America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Biologics License Application for Pfizer\u2019s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landmark New England Journal of Medicine Publication Reinforces Potential Of GSK\u2019s Respiratory Syncytial Virus Older Adult Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3 OA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura\u2122) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"RVAC Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"RVM-V001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GenScript ProBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GenScript ProBio \/ RVAC Medicines","highestDevelopmentStatusID":"6","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"RVAC Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RVM-V001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"RVAC Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RVAC Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RVAC Medic.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Redx and Jounce Announce Recommended Business Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"RXC007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO\u00ae (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT\u2122 and Virtue\u00ae SAB at CRT 2023","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchestra Biomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra .."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","amount":"$167.0 million","upfrontCash":"$66.0 million","newsHeadline":"Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi\u00ae (solriamfetol) in Europe","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Solriamfetol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK\u2019s National Institute for Health and Care Excellence (NICE)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotrovimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Taldefgrobep-alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite Completes Acquisition of Tmunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"TmXX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kite Pharma \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Inclusion Of the First Volunteer in The PRECESTO Study, Which Aims to Demonstrate the Complementarity Of NFL-101 With Other Smoking Cessation Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tobacco Leaf Protein","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in China for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior AntiHER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TTI-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic A\/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Typhoid Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bavarian Nordic \/ Danske Bank","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial (\"FUEL-2\") in Fontan Subjects","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Udenafil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"NRG Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson\u2019s Programme","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NRG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NRG Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"NRG Therap.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"BRAIN Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics and BRAIN Biotech Join Forces To Develop a CRISPR-derived Technology Platform For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ BRAIN Biotech","highestDevelopmentStatusID":"2","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Cvergenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology and Cvergenx Announce Partnership To Develop The First-ever Genomics-based Approach To Precision Radiation Therapy And Drug Discovery Using Artificial Intelligence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Predictive Oncology \/ Cvergenx","highestDevelopmentStatusID":"4","companyTruncated":"Predictive.."},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$665.0 million","upfrontCash":"$70.0 million","newsHeadline":"AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Capsida","amount2":0.67000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Capsida \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen Launches \u201cNano 100 Project\u201d to Develop Fully Human Nanobody Therapeutics for Over 100 Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nanobody Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Receives Positive CHMP Opinion in Europe for Vafseo\u2122 (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Valneva\u2019s Chikungunya Vaccine License Application for Priority Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Notable Labs","sponsor":"VBL Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"Volasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ VBL Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"Builders VC","pharmaFlowCategory":"D","amount":"$10.3 million","upfrontCash":"Undisclosed","newsHeadline":"VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Volasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Notable Labs \/ Builders VC","highestDevelopmentStatusID":"8","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Center for Breakthrough Medicines","sponsor":"Virion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Center for Breakthrough Medicines and Virion Therapeutics Announce Strategic Partnership to Manufacture Virion's Proprietary CD8+ T cell-based Clinical Development Programs for Infectious Diseases and Cancers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Center for Breakthrough Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Center for Breakthrough Medicines \/ Virion Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Center for.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"WTX-330","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$402.5 million","upfrontCash":"Undisclosed","newsHeadline":"Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0.40000000000000002,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ J.P. Morgan Securities","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharma.."},{"orgOrder":0,"company":"Xinvento","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","amount":"$211.0 million","upfrontCash":"$5.0 million","newsHeadline":"Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Xinvento","amount2":0.20999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Xinvento \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xinvento \/.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"New Therapies Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ New Therapies Council","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Rallybio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio's Inhibitor of Complement Component 5 (C5) and EyePoint's Proprietary Durasert\u00ae Technology for Sustained Intraocular Delivery in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"RLYB114","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Chipscreen NewWay Biosciences","pharmaFlowCategory":"D","amount":"$85.9 million","upfrontCash":"$5.7 million","newsHeadline":"Biocytogen\u2019s Subsidiary Eucure Biopharma and Chipscreen Biosciences\u2019 Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"YH008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eucure Biopharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ Chipscreen NewWay Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Eucure Bio.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Marzeptacog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Catalyst Biosciences \/ GC Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$1.0 million","newsHeadline":"Agreement with Sebela Pharmaceuticals for NTCD-M3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"NTCD-M3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0.56999999999999995,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Liquid","sponsorNew":"Destiny Pharma \/ Sebela Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"TTC Oncology","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ Lantern Pharma","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncolo.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"finnCap Limited","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"Destiny Pharma Announces Fundraising Upto \u00a38 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Financing","leadProduct":"NTCD-M3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Destiny Pharma \/ finnCap Limited","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Summit Pharmaceuticals International Corporation Invests in Luxna Biotech Co., Ltd. Possessing the Nucleic Acid Pharmaceutical Element Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Financing","leadProduct":"Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biot.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Culls Pliant-Partnered NASH Program in Pipeline Sweep","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Termination","leadProduct":"PLN-1474","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Amarin","sponsor":"Seqirus","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA (icosapent ethyl) in Australia and New Zealand","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ S.."},{"orgOrder":0,"company":"University of Arizona","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arizona","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Arizona \/ Sunshine Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","amount":"$23.5 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Private Placement","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"2Seventy Bio Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"2Seventy Bio","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Tempus","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tempus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempus \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Tempus \/ P.."},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal\u00ae For the Treatment of Rare Kidney Disease in Germany, Austria, Switzerland and Greece","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Potassium Citrate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Avanzanite Bioscience","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-Release Granule","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"12","companyTruncated":"Avanzanite.."},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undislcosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voltron Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Th.."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oricell Closes $45M Series B1 Financing to Expand Development of Key Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OriCell Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OriCell Therapeutics \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo\u2122 (Enavogliflozin) for Brazil and Mexico","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"ATRN-119","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aprea Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"PF-07081532","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":1.8899999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.8899999999999999,"dosageForm":"Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.5,"dosageForm":"Injectable\/Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$7.1 million","upfrontCash":"Undisclosed","newsHeadline":"Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"TACH101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Tachyon Therapeutics \/ CIRM","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Th.."},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Veblen Ventures","pharmaFlowCategory":"D","amount":"$11.6 million","upfrontCash":"Undisclosed","newsHeadline":"Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"TACH101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Tachyon Therapeutics \/ Veblen Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Th.."},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"CRG-022","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"CARGO Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Ther.."},{"orgOrder":0,"company":"Inspirevax","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"BDX301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Inspirevax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inspirevax \/ Oragenics","highestDevelopmentStatusID":"4","companyTruncated":"Inspirevax.."},{"orgOrder":0,"company":"Alessa Therapeutics","sponsor":"Celanese","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celanese Announces Collaboration with Alessa Therapeutics for the Advancement of Oncology Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alessa Therapeutics \/ Celanese","highestDevelopmentStatusID":"1","companyTruncated":"Alessa The.."},{"orgOrder":0,"company":"TandemAI","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"TandemAI","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"TandemAI \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"TandemAI \/.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$352.0 million","upfrontCash":"$15.0 million","newsHeadline":"ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Immunogen","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"Pillar VC","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"THY-100","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Thymmune Therapeutics \/ Pillar VC","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune T.."},{"orgOrder":0,"company":"Praetego","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Praetego","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praetego \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"Praetego \/.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Chroma Medicine","amount2":0.14000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Chroma Medicine \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Chroma Med.."},{"orgOrder":0,"company":"SiSaf","sponsor":"University of Leipzig","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"miR24-3p","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SiSaf","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ University of Leipzig","highestDevelopmentStatusID":"4","companyTruncated":"SiSaf \/ Un.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$952.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Completes Acquisition of Albireo, Expanding the Scope of Its Rare Disease Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.94999999999999996,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Phar.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$630.0 million","upfrontCash":"$40.0 million","newsHeadline":"Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CFTX-1554","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0.63,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.63,"dosageForm":"Liquid","sponsorNew":"Confo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$213.0 million","upfrontCash":"$145.0 million","newsHeadline":"Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.20999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"CureLab Oncology","sponsor":"Dr. John Ballantyne","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Plasmid-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CureLab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureLab Oncology \/ Dr. John Ballantyne","highestDevelopmentStatusID":"4","companyTruncated":"CureLab On.."},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"IAVI and BARDA Expand Partnership to Advance IAVI's Filovirus Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"rVSV\u0394G-MARV-GP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BAR.."},{"orgOrder":0,"company":"Intsel Chimos","sponsor":"Biophytis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Intsel Chimos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intsel Chimos \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Intsel Chi.."},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"Dynacure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"Antisence Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Flamingo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Flamingo Therapeutics \/ Dynacure","highestDevelopmentStatusID":"8","companyTruncated":"Flamingo T.."},{"orgOrder":0,"company":"Axplora","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep And Paratek Enhance Collaboration to Manufacture Omadacycline (NUZYRA\u00ae), A Novel Tetracycline-Class Antibiotic for The Treatment of Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Collaboration","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Axplora","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axplora \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Axplora \/ .."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"McSAF","sponsor":"Axplora","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"McSAF and Novasep Announce Their Successful Collaboration To Produce A Next-generation Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Monomethyl Auristatin E-Conjugated Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"McSAF","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McSAF \/ Novasep","highestDevelopmentStatusID":"4","companyTruncated":"McSAF \/ No.."},{"orgOrder":0,"company":"Pharma15","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"$2.0 million","newsHeadline":"Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pharma15","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharma15 \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"Pharma15 \/.."},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Shanghai Allist Pharmaceuticals","pharmaFlowCategory":"D","amount":"$187.9 million","upfrontCash":"Undisclosed","newsHeadline":"Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ABK3376","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abbisko Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Abbisko Therapeutics \/ Shanghai Allist Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Abbisko Th.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters Option to Purchase Additional Shares","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.5,"dosageForm":"Injectable\/Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"FT-3171","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biogen Japan And Eisai Provide Update On Co-promotion Of Multiple Sclerosis Treatments In Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Termination","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in China for Patients With HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan-nxki","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo\u00ae Intravenous Infusion Approved for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Combination with Chemotherapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ .."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Receives a Positive CHMP Opinion For Tibsovo\u00ae in IDH1-Mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU200","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos To Present New Data from Long-Term Extension Study of Filgotinib in Ulcerative Colitis at Annual ECCO congress 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Filgotinib","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces the Commercial Launch Of ELYXYBTM (celecoxib oral solution) in the U.S., Strengthening Its Leadership Position in Non-Opioid Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Receives Antiviral Testing Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Imunon","sponsor":"Break Through Cancer","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON and Break Through Cancer Commence Enrollment in a Phase 1\/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Break Through Cancer","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ B.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8\u00ae Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP2939","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Amdizalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera Cleared to Begin Japanese Arm of Pivotal Phase 3 Study with Mocravimod in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Mocravimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Priothera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Receives Approval for Additional Prostate Cancer Indication in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"NYX-458","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Initiates Nuceiva\u00ae Launch in Germany and Austria","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CEL383","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Celsius Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MZE001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Submits New Drug Application to U.S. FDA for iDose TR","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-\u03b2 Bispecific Antibody ES014","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ES014","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A\/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IBI333","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-1003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces 48-Week Results from Global, Open-Label, Phase 3 Trial of RADICAVA ORS\u00ae (edaravone) in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ\u00ae) for the Treatment of Adults with Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensereptide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Promore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Ph.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Envlo' of Daewoong Pharmaceutical, To Be Launched in The Global Markets Entering the 1.54 Billion USD Market in Brazil and Mexico","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Positive Interim Data from Phase I\/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-111","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Levation Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levation Pharma Initiates Phase I\/II Clinical Trial of LEV102 for Acquired Blepharoptosis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Levation Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Levation Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Levation P.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces China\u2019s NMPA has Accepted the Supplementary New Drug Application of Sugemalimab as First-Line Treatment for Patients with Locally Advanced or Metastatic Gastric\/gastroesophageal Junction Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Sugemalimab in Metastatic Squamous and Non-squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces Precision Medicine Avapritinib (ayvakit\u00ae) Recommended in China\u2019s First \u201cchinese Guidelines for The Diagnosis and Treatment of Systemic Mastocytosis in Adult Patients\u201d","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces the NDA Approval of GAVRETO\u00ae (pralsetinib) for the Treatment of Advanced RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Altered Thyroid Cancer in Taiwan, China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces the Registrational Clinical Trial of Sugemalimab as First-Line Treatment in Patients with Esophageal Squamous Cell Carcinoma Met Primary Endpoints and Plans to Submit a Supplemental NDA to NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases Announces FDA Approval of Lamzede\u00ae(velmanase alfa-tycv) for Alpha-Mannosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Velmanase Alfa-tycv","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Gets USFDA Nod to Market Generic Medication to Treat High Blood Pressure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Losartan Potassium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"LinKinVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CD40.HIVRI.Env","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"LinKinVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"LinKinVax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LinKinVax .."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"HC-7366","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spexis Reports Solid Safety and Pharmacokinetics Results from First-In-Human Study with Inhaled Murepavadin, a Novel Macrocycle Compound","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Murepavadin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ N.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimagrumab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis B.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FBX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forge Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"GX-188E","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Phase I\/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Sernova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sernova Announces Advancements with its Novel Cell Pouch System to Preserve Thyroid Function Following Total Thyroidectomy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Donor Islets Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sernova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes Researcher Discovers Potential Therapeutic Target for Lethal Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"HSB-510","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Positive Interim Data From Phase I\/II\/III CAMPSIITE\u2122 Trial Of REGENXBIO's RGX-121 For The Treatment Of MPS II (Hunter Syndrome) Presented At 19th Annual WORLDSymposium","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kevzara (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sarilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Phase 2 Study of Ampligen for the Treatment of Pancreatic Cancer is Open and Recruiting Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Incyclix Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"INX-315","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyclix Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Incyclix Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Incyclix B.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1\/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"23ME-00610","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Ongericimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS\u2122 (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod to Market Generic Drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Apixaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Toragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"TGN-S11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Toragen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toragen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Toragen \/ .."},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA","therapeuticArea":"Technology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Announces Interim Results from Ongoing Phase 1\/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-C3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cessation Therapeutics\u2019 Anti-Fentanyl Monoclonal Antibody Treatment Shows Promise in Protecting Against Fentanyl-Induced Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CSX-1004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cessation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation .."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Reports Favorable Deltacel\u2122 Preclinical Pharmacology Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"EDG-7500","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-\u03b1 Inhibitor MYMD-1\u00ae at the Society of Toxicology 2023 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MYMD-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW3811","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Ymmunobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Ymmunobio's CEACAM Antibody for the Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"YB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ymmunobio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ymmunobio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ymmunobio .."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B\u00ae, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"JWATM214","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"IQ-AI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IQ-AI Announces Orphan Drug Designation Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Gallium Maltolate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medical College of Wisconsin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medical College of Wisconsin \/ IQ-AI","highestDevelopmentStatusID":"6","companyTruncated":"Medical Co.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb\u2019s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Aflibercept 8 Mg for Marketing Authorization in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06928316","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Treatment in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Garadacimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Tolebrutinib, Sanofi\u2019s Investigational Brain-Penetrant BTK Inhibitor, Showed Significant Effect On CNS Immune Mediators that Drive MS Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tolebrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical Announces Positive Results From CHIHUAHUA, Phase 1 Clinical Trial of Second-Generation DSR Product for Congestive Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"DSR 2.0","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Me.."},{"orgOrder":0,"company":"Organogenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Organogenesis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogene.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BSB-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Plinabulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Receives EU Approval for Additional Indication in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals, Inc. Receives FDA Approval for EMERPHED\u00ae (ephedrine sulfate injection) Pre-Filled Syringe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ephedrine Sulfate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACE-Breast-02 Pivotal Phase 3 Study of Ambrx\u2019s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ARX788","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ABP-671","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"ERP Biomarker Qualification Consortium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Industry Consortium Completes Brain Wave Study of Ketamine Effects on Healthy Volunteers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ERP Biomarker Qualification Consortium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ERP Biomarker Qualification Consortium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ERP Biomar.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil\u00ae Dual Action Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ecopipam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bio.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present New Repatha\u00ae (evolocumab) and Olpasiran Data at ACC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Evolocumab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Dosing of First Subject in Italy for Phase 1\/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant P","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TYRA-300","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet Receives EMA Approval for Phase Ib\/II Study Of GFH925 (KRAS G12C inhibitor) in Combination with Erbitux\u00ae (cetuximab) Treating Patients with Advanced Nsclc in First-Line Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Stem Cell-derived Pancreatic Islets","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IMCY-0098","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Imcyse","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imcyse \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imcyse \/ N.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Final Approval for Docetaxel Injection USP, 20 mg\/2 mL (10 mg\/mL) Single-Dose Vial, and 80 mg\/8 mL (10 mg\/mL) and 160 mg\/16 mL (10 mg\/mL) Multiple-Dose Vials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b\/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Belapectin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ\u2122 (sodium oxybate) Extended Release Oral Suspension","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Temferon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Results from Pivotal XTEND-Kids Phase 3 Study of Efanesoctocog Alfa in Children Under 12 Years of Age with Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Launches NativusWell\u00ae, a Novel Nutraceutical for Menopause, in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NativusWell","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane\u00ae (Betaine Anhydrous for Oral Solution)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Betaine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosette Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Lynparza in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Milvexian","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Tentative Approval from The USFDA for Bosentan Tablets for Oral Suspension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Bosentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Sirolimus Tablets, 1 mg and 2 mg","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Tentative Approval from The USFDA for Canagliflozin and Metformin Hydrochloride Tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2\/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO \u201923 Congress","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AMT-101","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Kinimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinimmune Publishes Results from A Phase I \u201cWindow of Opportunity\u201d Trial in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kinimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinimmune .."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ALS-4","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Broadens Indication for Verzenio\u00ae (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IYUZEH\u2122 (Latanoprost Ophthalmic Solution) 0.005%, The First and Only Preservative-Free Latanoprost Ophthalmic Solution, Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatan\u00ae in Patients with Primary Open-Angl","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Advisory Committee Votes to Support Effectiveness and Safety of GSK\u2019s Respiratory Syncytial Virus Older Adult Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3 OA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval of Reblozyl\u00ae (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Charles River Laboratories International","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Flagship\u2019s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Charles River Laboratories International","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories International \/ Pioneering Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellerophon Therapeutics Announces $5 Million Registered Direct Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,754.0 million","upfrontCash":"$54.0 million","newsHeadline":"Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AAV-based Capsid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":1.75,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$188.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"OTL-200","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0.19,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Red Tree Venture Capital","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"BCA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Bicara Therapeutics \/ Red Tree Venture Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$576.0 million","upfrontCash":"$576.0 million","newsHeadline":"Sun Pharma Completes Acquisition of Concert Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.57999999999999996,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Selagine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Selagine \/.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phanes Therapeutics Entered Into A Research Collaboration With Xyphos Biosciences, Inc., An Astellas Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptimmune and TCR\u00b2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ TCR\u00b2 Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Partnership","leadProduct":"Human Cellular Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kytopen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kytopen \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kytopen \/ .."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"BI 907828","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Boehringer Ingelheim","highestDevelopmentStatusID":"8","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affamed Therapeutics To Commercialize Galcanezumab For Migraine Prevention In Mainland China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ AffaMed Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Antiverse","sponsor":"InnoSpark","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antiverse Raises Funding and Demonstrates Therapeutic Antibody Identification With AI-driven Drug Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antiverse \/ InnoSpark","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse .."},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Funding Program Between Oxurion and Negma Ends","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Termination","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection, Extended Release","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Kyorin Pharmaceutical","sponsor":"Sumitomo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyorin And Sumitomo Pharma Enter Into License Agreement Of Vibegron In Taiwan And Other Asian Countries","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Kyorin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyorin Pharmaceutical \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Kyorin Pha.."},{"orgOrder":0,"company":"Gubra","sponsor":"Skandinaviska Enskilda Banken","pharmaFlowCategory":"D","amount":"$71.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gubra Announces Intention To Launch An Initial Public Offering On Nasdaq Copenhagen And Raise Capital To Support Its Growth Strategy","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Amylin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Gubra","amount2":0.070000000000000007,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Gubra \/ Skandinaviska Enskilda Banken","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Sk.."},{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affibody And Chiesi Group Collaborate To Develop And Commercialize Innovative Treatments For Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Affibody","amount2":0.20999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Affibody \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Affibody \/.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Sovilnesib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Volastra Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Sovilnesib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"6","companyTruncated":"Volastra T.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OPKO Health's ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"MDX-2201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OPKO Health \/ Merck & Co. Inc.","highestDevelopmentStatusID":"5","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series C Financing","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Signs Cooperative Research And Development Agreement (CRADA) With Us National Institute On Drug Abuse (NIDA) To Cover Phase 3 Development Of Mavoglurant In Cocaine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"TT11X","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Noema Pharma","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"","sponsorNew":"Noema Pharma \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Announces RenLite\u00ae Licensing Agreement with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Janssen Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"invoX Pharma Limited","pharmaFlowCategory":"D","amount":"$161.0 million","upfrontCash":"$161.0 million","newsHeadline":"invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"FS118","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F-star Therapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ invoX Pharma Limited","highestDevelopmentStatusID":"7","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Stelis Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Termination","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akston Biosciences \/ Stelis Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Akston Bio.."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Sectoral Asset Management","pharmaFlowCategory":"D","amount":"$83.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Sectoral Asset Management","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Korro Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Korro Bio \/ Genevant Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"RApport","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rapport Therapeutics Launches with $100 Million to Transform the Treatment of Neurological Disease Through the Discovery and Development of Precision Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"RApport","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"RApport \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"RApport \/ .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridGene Biosciences Achieves Milestone in Takeda Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0.5,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"BridGene Biosciences \/ Takeda","highestDevelopmentStatusID":"3","companyTruncated":"BridGene B.."},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IBSA Pharma and Mark Cuban Cost Plus Drug Company Team Up to Make Tirosint More Affordable","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"IBSA Institut Biochimique","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"12","companyTruncated":"IBSA Insti.."},{"orgOrder":0,"company":"Alpha Fusion","sponsor":"Sumitomo Heavy Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sumitomo Heavy Industries, Ltd. Invests in Alpha Fusion Inc., Developer of Astatine Based Radiopharmaceuticals for Targeted Alpha Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Astatine-211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alpha Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpha Fusion \/ Sumitomo Heavy Industries","highestDevelopmentStatusID":"2","companyTruncated":"Alpha Fusi.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cediprof","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for U.S. FDA Approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Dextroamphetamine Saccharate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","amount":"$86.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series C Financing","leadProduct":"Anellovirus-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Ring Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Alexandria Venture Investments","highestDevelopmentStatusID":"4","companyTruncated":"Ring Thera.."},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"INCE Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"A Next-generation Precision Medicine Company Focusing On Oncology And Autoimmune Diseases, Raises $50 Million Series B Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"ARTS-011","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Allorion Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Allorion Therapeutics \/ INCE Capital","highestDevelopmentStatusID":"5","companyTruncated":"Allorion T.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Givosiran Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"QurAlis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"QRL-201","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"QurAlis \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"University of Iowa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"AbCheck","sponsor":"Czech Republic","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Czech Republic","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ .."},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Creative Medical Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 \/ 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"CELZ-201","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syneos Health \/ Creative Medical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"Cancer Research UK","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK Signs Multi-Project Collaboration With UCB To Advance Oncology Antibody Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Tipiracil Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research UK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research UK \/ UCB Pharma S.A","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Res.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$11.2 million","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","amount":"$253.0 million","upfrontCash":"$3.0 million","newsHeadline":"AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0.25,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Phar.."},{"orgOrder":0,"company":"Simris Group","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its ADC Payload Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Simris Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Simris Group \/ Lonza Group","highestDevelopmentStatusID":"2","companyTruncated":"Simris Gro.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"$1,700.0 million","newsHeadline":"Sumitovant Biopharma Completes Acquisition of Myovant Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.7,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Olatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson\u2019s Disease Progression","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olatec Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides Update on FDA Review of ROCTAVIAN\u2122 (valoctocogene roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Eisai\u2019s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI\u2122 (lecanemab-irmb) for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology\u2019s 72nd Annual Scientific Session Together With World Heart Federation\u2019s World Congress of Cardiology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New STELARA\u00ae (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO\u00ae (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Properdin Antibody (NM3086) Demonstrates Efficacy in a Primate Model of Wet-AMD and Dry-AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NM3086","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Additional Findings From Phase 2 Parkinson\u2019s Disease Trial: More Patients Treated With NE3107 Experienced Morning \u201con State\u201d with Levodopa Withheld Overnight Compared to Those Treated with Placebo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves UDENYCA\u00ae Autoinjector","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IK-175","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23\/WCC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYD222 is a mAb Which Was Engineered from Adintrevimab, Which Provided Neutralizing Protection Against SARS-CoV-2 For All Variants of Concern until The Emergence of The Omicron BA.2 Strain and Its Sublineages.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm\/year with No Treatment-related Adverse Events","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show CNM-Au8\u00ae Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Zunsemetinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using FloraStilbene\u2122 Immune Stimulator Through Res Nova Bio Subsidiary","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"FloraStilbene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BAT8010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotatercept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MK-0616","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumor Types in DESTINYPanTumor02 Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"The Access to Advanced Health Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Access to Advanced Health Institute Reports Encouraging Results of First-In-Human Trial of Its Temperature-Stable Tuberculosis Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"GLA-SE","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"The Access to Advanced Health Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"The Access to Advanced Health Institute \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"The Access.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics to Present Preclinical Poster on PIPE-791 at the Glial Biology: Functional Interactions Among Glia Neurons, a Gordon Research Conference (GRC)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PIPE-791","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Dicyclomine Hydrochloride Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dicyclomine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Miami Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Cantex Pharmaceuticals \/ Miami Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HMBD-001 Is a Clinical-Stage IgG1 Antibody Designed to Target HER3. It Has Superior Affinity and More Potent Tumor Growth Inhibition Compared to Existing Anti-HER3 Antibodies.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"HMBD-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"COM701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b\/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hanall Biopharma \/ Harbour BioMed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Intramuscular Administration for Merck\u2019s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Measles, Mumps, Rubella and Varicella Virus Live Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Coagulant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coagulant Therapeutics Announces Publication in Blood Advances Describing Novel Nanobody Library to Activated Protein C (APC) and Initial Leads for Treatment of Trauma and Hemophilia","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CT-001","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Coagulant Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coagulant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coagulant .."},{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"LR 09","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Laevoroc Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laevoroc Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Laevoroc O.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA2001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ractigen Therapeutics Receives FDA Orphan Drug Designation For the Novel Oligonucleotide Conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RAG-17","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets USFDA nod for Fluorouracil Injection USP, 2.5 g\/50 mL Pharmacy Bulk Vial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Engages Catalent to Develop and Manufacture cGMP-Grade Psilocybin Drug Products for Clinical Trials and Potential Commercial Use","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Incannex Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Mesoblast\u2019s Resubmission of The Biologic License Application for Remestemcel-L in Children with Steroid-Refractory Acute Graft versus Host Disease as A Complete Response and Sets Goal Date of August 2, 2023","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-l","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"ViaDerma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Minoxidil","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ViaDerma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"ViaDerma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViaDerma \/.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Sernova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1\/2 Clinical Trial for Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Donor Islets Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sernova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Antev","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antev Receives US FDA Guidance on Teverelix\u00ae Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Teverelix Trifluoroacetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Antev","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Antev \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antev \/ No.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 -7 Years Old","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSyent Announces Launch of New FeraMAX Pd Maintenance 45","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Polydextrose Iron Complex","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BIOSYENT PHARMA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT P.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"FRTX-02","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Novan\u2019s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TRV045","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX1700 Presented in a Poster at the Keystone Symposia, \u201cCancer Immunotherapy: Mechanisms of Response Versus Resistance\u201d","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TNX-1700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of Tadekinig alfa to Treat Primary Monogenic IL-18 Driven HLH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tadekinig Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AB2 Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Itruvone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGem as a Treatment Option for Locally Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Prednisolone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"SonALAsense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Aminolevulinic Acid HCl","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SonALAsense","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SonALAsense \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SonALAsens.."},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BAT8008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Esteve Quimica","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESTEVE Launches INBRIJA\u00ae in Spain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Esteve Quimica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Esteve Quimica \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Esteve Qui.."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaBay Pharmaceuticals Launches Avenova\u00ae Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfort Dry Eyes and Promote Overall Eye Health","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Maqui Berry Extract","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Enthera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enthera Ph.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Blood and Marrow Transplant Clinical Trials Network","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Blood and Marrow Transplant Clinical Trials Network","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EBC-129","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Experimental Drug Development Centre \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Experiment.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Solanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Estrella Biopharma Announces FDA Clearance of IND Application for Phase I\/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS\u00ae T Cell Therapy, to Patients with B-Cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EB103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Estrella Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Estrella Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Estrella B.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts Supplemental New Drug Application for Jardiance\u00ae for Children 10 Years and Older with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces Initiation of Clinical Study of Carteyva\u00ae in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO\u00ae (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vosoritide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Study Provides Evidence that Recombinant Endolysin XZ.700* Is a Promising Novel Non-Antibiotic Treatment Strategy Aimed at Controlling Staphylococcus Aureus (S. Aureus) Colonization of Lesional Skin in Cutaneous T-Cell Lymphoma (CTCL).","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"XZ.700","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Micreos Human Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Micreos Human Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Micreos Hu.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces FDA Acceptance of New Drug Application for Eplontersen for The Treatment of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PN-235","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Gets Approval Of Zepzelca For Treatment Of Metastatic Small Cell Lung Cancer In Switzerland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Final Approval for Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Prazosin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-8421","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Thera","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Receives Approval to Conduct Its Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNM-Au8 Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ICP-248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Irofulven","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Areteia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Areteia Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Areteia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Areteia Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Significantly Improved Event-Free Survival In AEGEAN Phase III Trial for Patients with Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VX-264","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and Natco Announce Launch of Additional Strengths for The Generic Version of Revlimid\u00ae (Lenalidomide Capsules), in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Natco Pharma \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AHB-137","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte\u2122 New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Announces First Patient Dosed in Phase 1b\/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Demonstrated Strong Overall Survival Benefit in The ADAURA Phase III Trial for Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RBN-3143","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Announce China\u2019s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ A.."},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marksans Pharma Limited Announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Famotidine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Macitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s ZAVZPRET\u2122 (zavegepant) Migraine Nasal Spray Receives FDA Approval","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nubeqa\u2122 (darolutamide) Receives EU Approval for Additional Indication in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First Generic Version of Pylera\u00ae (Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride) Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bismuth Potassium Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE\u2122 (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aucta Announced FDA Approval of A Generic Version of Trileptal\u00ae(oxcarbazepine) Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Oxcarbazepine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aucta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Phar.."},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$30.0 million","newsHeadline":"Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Teijin Pharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Teijin Pharma \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Teijin Pha.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.3 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Prices $5.3 Million Offering of ADSs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Indegene","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Indegene","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indegene \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Indegene \/.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,900.0 million","upfrontCash":"$2,900.0 million","newsHeadline":"Sanofi To Acquire Provention Bio, Adding To Portfolio Tzield, The First Disease-modifying Treatment For The Delay Of Stage 3 Type 1 Diabetes (T1D)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":2.8999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.8999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$43,000.0 million","upfrontCash":"$43,000.0 million","newsHeadline":"Pfizer Invests $43 Billion to Battle Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":43,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":43,"dosageForm":"Injectable\/Injection","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ P.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Cowen and Company LLC","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ambrx Raises $78 Million and Completes its ATM Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Cowen and Company LLC","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Nagasaki University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Drugs with Nagasaki University and MMV, Supported by the GHIT Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Nagasaki University","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Shionogi","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Bennu Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Bennu Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$400.0 million","newsHeadline":"HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":1.1299999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Announces $6.0 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H..."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Professor Colin Masters","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"PBT2","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Professor Colin Masters","highestDevelopmentStatusID":"4","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"T-cell based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Eureka Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National C.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals Announces Divestment of DSUVIA\u00ae to Alora Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Divestment","leadProduct":"Sufentanil Citrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"PharmaLogic","sponsor":"Viewpoint Molecular Targeting","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Perspective Therapeutics And Pharmalogic Announce Collaboration For The Development And Production Of Theranostics For Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"VMT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaLogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaLogic \/ Viewpoint Molecular Targeting","highestDevelopmentStatusID":"4","companyTruncated":"PharmaLogi.."},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of ADC Collaboration with MacroGenics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Synaffix","amount2":2.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"2","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Ainos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merdury Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Merdury Pharmaceutical \/ Ainos","highestDevelopmentStatusID":"8","companyTruncated":"Merdury Ph.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA\u00ae (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Merck & Co. Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Myosin Therapeutics","sponsor":"Mint12 Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"MT-125","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Myosin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myosin Therapeutics \/ Mint12 Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Myosin The.."},{"orgOrder":0,"company":"OmniaBio","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catamaran Bio Selects Omniabio As Partner To Develop And Manufacture Allogeneic CAR-NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"CAR-NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OmniaBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OmniaBio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"OmniaBio \/.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Relyens Innovation Sant\u00e9","pharmaFlowCategory":"D","amount":"$21.2 million","upfrontCash":"Undisclosed","newsHeadline":"AlgoTx Raises \u20ac20M to Conduct ATX01\u2019s Phase 2 Program in Peripheral Neuropathic Pain","therapeuticArea":"","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Amitriptyline Hydrochloride","moa":"","url1":"","url2":"","graph1":"","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0.02,"therapeuticAreaNew":"","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","productSubType":"","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"AlgoTherapeutix \/ Relyens Innovation Sant\u00e9","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Switch Therapeutics","sponsor":"Insight Partners","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"RNAi-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Switch Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Switch Therapeutics \/ Insight Partners","highestDevelopmentStatusID":"4","companyTruncated":"Switch The.."},{"orgOrder":0,"company":"Tulex Pharmaceutical","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"ET-600","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Tulex Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tulex Pharmaceutical \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Tulex Phar.."},{"orgOrder":0,"company":"Libera Bio","sponsor":"Talem Therapeutics","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise Antibodies\u2019 Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Libera Bio","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Libera Bio \/ Talem Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Libera Bio.."},{"orgOrder":0,"company":"Nanite","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"m-RNA Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nanite","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanite \/ CF Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Nanite \/ C.."},{"orgOrder":0,"company":"Aitia","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Aitia","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aitia \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Aitia \/ UC.."},{"orgOrder":0,"company":"Protai","sponsor":"Grove Ventures","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protai Adds $12 Million to Seed Round - Bringing the Total to $20 Million - to Build an Oncology Drug Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Protai","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Protai \/ Grove Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Protai \/ G.."},{"orgOrder":0,"company":"DelSiTech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DelSiTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"DelSiTech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"DelSiTech .."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Vurolenatide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lantern Pharma \/ TTC Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"PRT2527","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem to Supply UNICEF with $200 Million Worth of Essential Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"LG Chem","amount2":0.20000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"LG Chem \/ UNICEF","highestDevelopmentStatusID":"12","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mediar Therapeutics","amount2":0.11,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Mediar The.."},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Announces Closing of $6.0 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H..."},{"orgOrder":0,"company":"Allermi","sponsor":"Nelstone Ventures","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Allermi Secures $3.5M in Seed Funding to Meet Growing Demand for Customized Approach to Allergy Symptoms","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Allermi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Allermi \/ Nelstone Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Allermi \/ .."},{"orgOrder":0,"company":"Seamless Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Seamless Therapeutics","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Seamless Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seamless T.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Closes Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Great Ormond Street Hospital","sponsor":"Leucid Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leucid Bio And Great Ormond Street Hospital Enter Commercial Agreement At New Gene Therapy Manufacturing Centre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Autologous CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Great Ormond Street Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Great Ormond Street Hospital \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"Great Ormo.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$5,200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"Undisclosed","newsHeadline":"Royalty Pharma Nabs $475M Milestone from Pfizer upon Migraine Nasal Spray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Royalty Pharma","amount2":0.47999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Royalty Ph.."},{"orgOrder":0,"company":"Aldena Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aldena Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Aldena Therapeutics \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Aldena The.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"RARE-X","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ RARE-X","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Cancer Research Horizons","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology And Cancer Research Horizons Have Partnered To Pursue Development Of Cancer Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Predictive Oncology \/ Cancer Research Horizons","highestDevelopmentStatusID":"4","companyTruncated":"Predictive.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon\u00ae in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus receives final approval from the USFDA for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Reports a First Complete Bone Marrow Response in A Relapsed Refractory Acute Myeloid Leukemia Patient from The Very Low Dose Arm of Its AB8939 Phase I\/II Clinical Trial (AB18001)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AB8939","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ORY-4001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"XMT-2056","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology and Quantum Leap Healthcare Collaborative\u2122 Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"University Hospital Muenster","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM, Helmholtz Munich and University Hospital M\u00fcnster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ITM-31","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Isotope Technologies Munich \/ University Hospital Muenster","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"VIB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"XVR013","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeVir Bio \/ VIB","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Advances Chronic Obstructive Pulmonary Disease Program by Identifying Novel B Regulatory Cell Mechanism of Action for JadiCell Universal Donor Adult Stem Cell","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle\u00ae (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Follitropin Delta","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BAT8007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Gatehouse Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gatehouse Bio Announces Upcoming Presentation at RNA Leaders Europe Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"GHB1589M","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Gatehouse Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gatehouse Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gatehouse .."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ\u00ae Injections at 3-Year Follow-Up of REFLECT Phase III Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenadogene Nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Phase 3 China ARCHES Study of XTANDI\u00ae Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"89Zr-DFO-girentuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord Healthcare Adds Generic Drug Approved for the Treatment of Relapsing MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Achieves Last Patient Last Visit (LPLV) in its Phase II Clinical Trial of the Non-Opioid ACD440 in Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ACD440","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Forays Into Dermatological Space with Launch of Psoriasis Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG908","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CTX112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody\u00ae, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ADG126","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Mablink Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MBK-103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mablink Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mablink Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mablink Bi.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Announces Poster Presentation on TALEN-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic MUC-1 CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-617","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annual AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"QTX3034","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Quanta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Quanta The.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"SNS-103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VIP236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Discontinues Phase 1\/2 Trials and Initiates Evaluation of Strategic Alternatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-343","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Initiation of Phase II\/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Proteovant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PVTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Proteovant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteovant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteovant.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Update on AAV Ophthalmology Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ABO-504","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavodelpar","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TSC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Type D Meeting with FDA to be held May 1, 2023","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Announces QINLOCK\u00ae Included in NCCN Guidelines\u00ae for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17\/18","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo\u2122 in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ExoFlo","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP-235","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Nebraska Medical Center and ANANDA Scientific Announce First Patient Enrolled in FDA-Approved Clinical Trial For Post-Traumatic Stress Disorder (PTSD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska Medical Center","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Nebraska Medical Center \/ ANANDA Scientific","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EP0042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ST316","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier's Pivotal Phase 3 INDIGO Trial Investigating Vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 2 Data from Atrial Fibrillation Clinical Trial \u2013 Primary Endpoint Met","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AP30663","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acesion Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Ph.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in The Phase 2a Part of Medivir's Study with Fostrox in Combination with Lenvima\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Launched First In Human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW3011","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cambrian Bio Launches Amplifier Therapeutics to Develop Clinical-Stage AMPK Activator","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ATX-304","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Amplifier Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplifier Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amplifier .."},{"orgOrder":0,"company":"TrueBinding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TB006","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TrueBinding \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBindin.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suven Life Sciences Breathes New Life Into Drug Discovery Plans","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Masupirdine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PBT2","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Announces Expansion of its Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EXS74539","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rare Disease Treatment, HYFTOR\u00ae (sirolimus topical gel) 0.2% Coverage Expanded by Medicaid, Including in Key U.S. States","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Nobelpharma America","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nobelpharm.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo's Generic Ibuprofen, Pseudoephedrine Hydrochloride Receives Approval in U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun's Generic Empagliflozin Receives Approval in U.S.","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo's Generic Lurasidone Hydrochloride Receives Approval in U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Pivotal Phase III Data for 5-in-1 Meningococcal ABCWY Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MenACWY","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Emzahh (Norethindrone Tablets USP), 0.35mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Norethisterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Lacosamide Tablets 50mg, 100mg, 150mg, & 200mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Lacosamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Dimethyl Fumarate Delayed-Release Capsules, 120mg and 240mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Sildenafil for Oral Suspension, 10mg\/mL","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Ranolazine ER Tablets 500mg and 1000m","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ranolazine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Solifenacin Succinate Tablets, 5mg and 10mg","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage .."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed\/Refractory FLT3-mutant Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RCT1100","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety\/Tolerability\/PK\/PD Trial of EVX-301","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-301","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1\/2a MONARCH Study of Children and Adolescents with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo\u00ae [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VT3989","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vivace Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivace Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivace The.."},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IG-002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intergalactic Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Intergalactic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Intergalac.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Announces Positive Results from A Pharmacokinetic (PK) Study with Cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioprojet: WAKIX\u00ae (pitolisant) Receives Approval for The Treatment of Narcolepsy in Children Over 6 Years of Age, a Rare, Under-Diagnosed Condition","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Bioprojet Pharma","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioprojet Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioprojet .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics\u2019 SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"DNA-methyltransferase 3 Beta mRNA","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rusfertide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH\/NIAID-Affiliated and Other Academic Researchers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Brilacidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Inspire Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inspire Biotherapeutics Launches with Pre-seed Investment to Target Monogenic and Acquired Lung Diseases with Proprietary AAVenger Gene Therapy Platform","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AAVenger Gene Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Inspire Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inspire Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inspire Bi.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Filament Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Filament Health Announces FDA Approval Of Phase II Clinical Trial Studying Psilocybin For Methamphetamine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Filament Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Filament Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Filament H.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA\u00ae (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos\u00ae for Treatment of Adults with Newly Diagnosed Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Daunorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China National Medical Products Administration Accepts Regulatory Submission for Nucala (Mepolizumab) in Severe Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Tafinlar + Mekinist Approved by FDA for Pediatric Patients With BRAF V600E Low-Grade Glioma, the Most Common Pediatric Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"JTX-8064","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CTS-2090","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"CancerVAX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CancerVAX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CancerVAX \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CancerVAX .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives New FDA PDUFA Date for Investigational Palovarotene for The Treatment of People With FOP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b\/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Belapectin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"ViaDerma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Minoxidil","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"ViaDerma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"ViaDerma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViaDerma \/.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-161","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA\u00ae (dimethyl fumarate) Regulatory Data and Marketing Protection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease Is Now Listed on The ClinicalTrials.gov Public Website","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon Announces First Patient Dosed With ANV419 In a Phase I\/II Study of ANV419 In Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ANV419","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anaveon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Delivers a New Post-Hoc Analysis of Its Phase III JTA-004 trial on Knee Osteo-Arthritis with Positive Action on The Most Severely Affected Patient Population","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"JTA-004","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1\/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Asunercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Matrivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MVX01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Matrivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Matrivax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Matrivax \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Inaxaplin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Modra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006\/r","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Modra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Modra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Modra Phar.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX\u20112191 in Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Study Shows XTANDI\u00ae (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Announces Publication of Pioneering Research Describing the Unique Biological Features of Roginolisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives Acceptance from U.S. FDA on Its IND Application for GRC 54276 To Proceed with A Phase 1\/2, First-In-Human Clinical Study of The Molecule for The Treatment of Patients with Advanced Solid Tumors and Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"GRC 54276","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Approval of Xerava in China for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Indication for Telix's Illuccix\u00ae to Include Patient Selection for PSMA-Directed Radioligand Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gallium Ga 68 Gozetotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in Phase 2 \u2018UPLIFT\u2019 Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"JAB-2485","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer\u2019s PAXLOVID\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Osanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CBP-201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Kuria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"KTX-1161","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kuria Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kuria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kuria Ther.."},{"orgOrder":0,"company":"Likang Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First Personalized Neoantigen-Targeted Cancer Vaccine Receives NMPA's Clinical Trial Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"LK101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Likang Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Likang Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Likang Lif.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rosuvastatin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rocatinlimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files Two IND's For Its Botulinum Toxin With FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Ph.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Veterans\u2019 Health Administration (VHA) Provides Coverage of Leqembi\u2122 (lecanemab-Irmb) Two Months After Leqembi\u2019s FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Updates on Nemolizumab Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Real World Study Data on Reduced Risk of Adverse Kidney Outcomes for Xarelto\u2122 Compared to Vka","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Canadian Filing of NDS for Preservative - Free Glaucoma Medication","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aequus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Civica Rx","sponsor":"CalRx Biosimilar Insulin Initiative","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"California Selects Civica Rx as Its Insulin Manufacturing Partner","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Civica Rx","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Civica Rx \/ CalRx Biosimilar Insulin Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Civica Rx .."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Graybug Vision Inc","sponsor":"CalciMedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Graybug Vision Inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Graybug Vision Inc \/ CalciMedica","highestDevelopmentStatusID":"8","companyTruncated":"Graybug Vi.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.3 million","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy\u2019s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS\u00ae \u25bcin the European Economic Area, the United Kingdom, Australia and Brazil","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dermata Therapeutics Announces Closing of $5.0 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$484.7 million","upfrontCash":"$18.0 million","newsHeadline":"Daiichi and Zymeworks End Antibody Pact After Seven Years","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Termination","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Zymeworks \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$445.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"NX\u20110479","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Nurix Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"OncoC4","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$200.0 million","newsHeadline":"BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OncoC4","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"OncoC4 \/ B.."},{"orgOrder":0,"company":"Gladstone Institutes","sponsor":"InvisiShield","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InvisiShield Technologies Collaborates with Gladstone Institutes to Accelerate Development of Intranasal Preventatives against SARS-CoV-2, Influenza, and RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"IS101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gladstone Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Gladstone Institutes \/ InvisiShield","highestDevelopmentStatusID":"4","companyTruncated":"Gladstone .."},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CHARM Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Ther.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","amount":"$535.0 million","upfrontCash":"$15.0 million","newsHeadline":"Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio\u2019s Investigational TRPC4\/5 Product Candidates","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GFB-887","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Goldfinch Bio, Inc","amount2":0.54000000000000004,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Karuna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cantone Research","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx Announces Closing of Notes Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Rizatriptan Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Cantone Research","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Hea.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"YA II PN","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ YA II PN","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Karuna Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Zura Bio","sponsor":"JATT Acquisition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"ZB-168","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zura Bio \/ JATT Acquisition","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/.."},{"orgOrder":0,"company":"Diabeloop","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Insulin Pens","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Diabeloop","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Diabeloop \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Diabeloop .."},{"orgOrder":0,"company":"Ingenu","sponsor":"Psyence","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psyence Partners with iNGEN\u016b for Palliative Care Clinical Trial in Australia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ingenu","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ingenu \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Ingenu \/ P.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Disc medicine \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","amount":"$29.9 million","upfrontCash":"Undisclosed","newsHeadline":"Harm Reduction Therapeutics to Receive Additional Funding for its Low-Cost Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Minaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences and Minaris Regenerative Medicine Enter into a Manufacturing Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Partnership","leadProduct":"Neutrophil Progenitor-based Leukocyte Infusion Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LIfT Biosciences \/ Minaris","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosc.."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carisma Therapeutics Closes Merger with Sesen Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sesen Bio \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ethicann Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"$150.0 million","newsHeadline":"MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ\u2122 (retifanlimab-dlwr)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Retifanlimab-dlwr","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MacroGenics","amount2":0.90000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Bifunctional Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"EpiBiologics \/ Mubadala Capital","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologi.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InvoX Pharma\u2019s F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Georgetown University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"SP-2-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Andira Pharmaceuticals","sponsor":"University of British Columbia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Andira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Andira Pharmaceuticals \/ University of British Columbia","highestDevelopmentStatusID":"4","companyTruncated":"Andira Pha.."},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"$970.0 million","upfrontCash":"$10.0 million","newsHeadline":"Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2\/JAK1 Inhibitor for Immune-Mediated Brain Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"BHV-8000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0.96999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.96999999999999997,"dosageForm":"","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hangzhou H.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$745.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Therapeutics Partners With Novo Nordisk To Explore The Field Of Biomolecular Condensates To Treat Insulin Resistance And Diabetes Progression","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Dewpoint Therapeutics","amount2":0.75,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.75,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","amount":"$123.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"FX-909","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Flare Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"5","companyTruncated":"Flare Ther.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.9 million","newsHeadline":"TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Jiaozuo Joincare Biotechnological","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and Gr\u00fcnenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Grunenthal","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobio Announces Clinical Collaboration To Evaluate CD73 Monoclonal Antibody JAB-BX102 In Combination With KEYTRUDA\u00ae (pembrolizumab) For Patients With Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"JAB-BX102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jacobio Pharma \/ Merck & Co. Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"AbCellera","sponsor":"RQ Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ RQ Bio","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"NeoGenomics","sponsor":"Massive Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"NeoGenomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoGenomics \/ Massive Bio","highestDevelopmentStatusID":"2","companyTruncated":"NeoGenomic.."},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arzeda, the Protein Design Company\u2122, Announces Collaboration with Takeda to Accelerate Protein Biologics Optimization","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Arzeda","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arzeda \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Arzeda \/ T.."},{"orgOrder":0,"company":"Exothera","sponsor":"Remedium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium and Exothera Partner On Scale-up And Demonstration Runs For AAV2-FGF18","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"RMD 1101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Exothera","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Exothera \/ Remedium","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/.."},{"orgOrder":0,"company":"Pangea Biomed","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Rigosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pangea Biomed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pangea Biomed \/ Onconova Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pangea Bio.."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"$40.0 million","newsHeadline":"Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Generation Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Generation Bio \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"Generation.."},{"orgOrder":0,"company":"Psyence","sponsor":"Cantheon Capital","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence Group Announces Cantheon Capital Private Placement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Cantheon Capital","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Yonsei University Health System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orange Grove Bio Expands Academic Collaboration Activities Internationally Through New Strategic Partnerships","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orange Grove Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Yonsei University Health System","highestDevelopmentStatusID":"2","companyTruncated":"Orange Gro.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","amount":"$72.3 million","upfrontCash":"$7.5 million","newsHeadline":"Basilea Announces CHF 5 Million Milestone Payment From Asahi Kasei Pharma For Antifungal Cresemba\u00ae (isavuconazole) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$100.0 million","newsHeadline":"PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.5,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Pragma Bio","sponsor":"Viking Global","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Pragma Bio","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Pragma Bio \/ Viking Global","highestDevelopmentStatusID":"2","companyTruncated":"Pragma Bio.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Guangdong Academy of Medical Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Guangdong Academy of Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ NRC IRAP","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Macomics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Macomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Macomics \/.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Avance Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"EB-373","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure\u2019s First Clinical Pharmacokinetic Study for EMPLI03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Imm.."},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0.28000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Bo.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"Undisclosed","newsHeadline":"Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Shares Zolgensma Long-Term Data Demonstrating Sustained Durability up To 7.5 Years Post-Dosing; 100% Achievement of All Assessed Milestones in Children Treated Prior To SMA Symptom Onse","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-To-Severe Atopic Hand and Foot Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI\u00ae (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"KPG-818","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Kangpu Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kangpu Bio.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"LEO 138559","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"JNJ-1802","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VXX-401","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Elutia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aziyo Biologics Provides Update on FDA Submission for CanGaroo\u00ae RM Antibacterial Envelope","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rifampicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ N.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I\/II Trial of Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech\u2019s VTP-200 Ph 1b\/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VTP-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Exosome","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dovitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide Approved for Additional Prostate Cancer Indication in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Four-Year Data for Roche Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of The Most Severely Affected People with Types 2 and 3 Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Receives FDA Fast Track Designation for ARO-APOC3","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fore Bioth.."},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Lif.."},{"orgOrder":0,"company":"Athenex","sponsor":"Alter Pharma group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Magnesium Sulfate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Athenex \/ Alter Pharma Group","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TLC-3595","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Announces Successful Submission of an Investigational New Drug (IND) and Fast Track Designation (FTD) Application for AVD-104 for the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration (AMD)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Techdow USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Techdow USA Announces FDA Approval of Generic Lovenox\u00ae, (Enoxaparin Sodium \u2013 Preservative Free) In Prefilled Syringes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Techdow USA","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Techdow USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Techdow US.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"FPI-2058","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PT886","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data by AKL Therapeutics Suggests Investigational Oral Osteoarthritis Drug APPA May Have a Promising Senotherapeutic Effect with Potential in Other Diseases of Ageing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"APPA","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AKL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therap.."},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Europe in Clairvoyant\u2019s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyan.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gennova Biopharma Seeks DCGI Nod for Its Omicron Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect\u2122 Ketamine Topical Cream in Treating PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Psycheceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceut.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives US FDA Approval for Biosimilar Hyrimoz\u00ae (adalimumab-adaz) High-Concentration Formulation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-adaz","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"SEL-037","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIfT BioSciences Announces Breakthrough Preclinical Data Demonstrating the Dual Mode of Action Commonly Believed Necessary for Curing Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Immunomodulatory Alpha Neutrophil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosc.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib\/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ATYR0101","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"SNS-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ExoFlo","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Coya 302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Scancell","sponsor":"PharmaJet","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Announces Clinical Results from Scancell\u2019s COVID-19 DNA Vaccine Study Exclusively Administered with Their Needle-free Precision Delivery Systems","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"SCOV1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Scancell \/ PharmaJet","highestDevelopmentStatusID":"6","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Yale Study Evaluates Paxlovid's Use in Long COVID Recovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Yale School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Yale School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Yale Schoo.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) antibody Innate Cell Modulator, ISB 1442","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ISB 1442","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"University of Alabama","sponsor":"Diamond Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"University of Alabama","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Alabama \/ Diamond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Shanghai Yingli Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TEB-17231","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Yingli Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Yingli Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Y.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PRX-115","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"(Z)-endoxifen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenScript ProBio Congratulates Eutilex\u2019s IND Clearance from MFDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EU307","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eutilex Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eutilex Inc \/ GenScript ProBio","highestDevelopmentStatusID":"6","companyTruncated":"Eutilex In.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s Yescarta\u00ae CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed\/Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Approves Lupin's Brexpiprazole Tablets for Schizophrenia and Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Approves Prostate Cancer Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ Ahead of Anticipated Final Approval Decision","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Initiates Cohort 3 in Phase 1\/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio\u2019s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Evinacumab-dgnb","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infant Bacterial Therapeutics\u2019 (IBT) Opening of A Final Infant Cohort Will Accelerate Patient Recruitment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO\u2122 (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces FDA Approval of Zynyz\u2122 (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab-dlwr","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lucid-Psych","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL\u2122 PF for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbachol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces Successful Type B Meeting with the FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Announces New Clinical Data Supporting MZE001 as a Potential Treatment for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MZE001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQZ Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"NImmune Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Omilancor","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Accounces FDA Advisory Committee Voted Unanimously for A Potential Accelerated Approval of Tofersen For SOD1-ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta to Present Two Preclinical Studies at AACR 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TST010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TST003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"L-Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"NEXT Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEXT Life Sciences Announces Launch of Plan A\u2122 Birth Control for Men","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vasalgel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"NEXT Life Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NEXT Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NEXT Life .."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Announces Launch of The Phase 1\/2 GaLuCi\u2122 Study for Its CA IX-Targeted Radiopharmaceutical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"[177Lu]Lu-DPI-4452","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus granted Orphan Drug Designation By the USFDA for ZYIL1 In Treatment of Patients with Cryopyrin Associated Periodic Syndrome (CAPS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Usnoflast","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Prochlorperazine Maleate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval for Naloxone HCl Injection Prefilled Syringe 2 mg\/2 mL","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces First-to-Market Launch of Naloxone Hydrochloride Injection USP, 2 mg\/2 mL (1 mg\/mL) Single-dose Prefilled Syringe in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa\/Foslevodopa) New Drug Application","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Launch of First-to-Market Generic Version of Narcan\u00ae (Naloxone Hydrochloride Nasal Spray), in the U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and Bayer Expand Clinical Development Program for Darolutamide in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"DYNE-251","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridgebio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for Shp2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb\u2019s Opdivo\u00ae (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BBP-398","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OLX72021","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Radiprodil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GRIN Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"GRIN Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GRIN Thera.."},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurion Biotech Receives Approval from Japan\u2019s PMDA for New Drug Application","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Corneal Endothelial Cell Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aurion Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurion Bio.."},{"orgOrder":0,"company":"CV Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"CV Science","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CV Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CV Science.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Advances Upadacitinib (RINVOQ\u00ae) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Enrollment Completion for Global, Phase 3b Study of RADICAVA ORS\u00ae (edaravone) in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Risankizumab (SKYRIZI\u00ae) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NVL-655","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO PHARMA USA's Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Receives Forerunner Designation for Enspryng in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune Encephalitis (AIE)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Granted First Regulatory Approval in China for Adults with Previously Treated Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxilio Announces Start of Its First Clinical Trial With OXL001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves First Treatment Option for Generalized Pustular Psoriasis Flares in Adults","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Semaglutide 25 mg and 50 mg Demonstrate Superior Reductions in Hb A1c and Body Weight versus 14 mg in People with Type 2 Diabetes in The PIONEER PLUS Phase 3 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces US FDA Approval of Joenja\u00ae (leniolisib) as The First and Only Treatment Indicated for APDS","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces First Healthy Subjects Dosed in Investigational Study of NRL-1049, a RHO Kinase (rock) Inhibitor with Potential to Treat Cerebral Cavernous Malformations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NRL-1049","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-na\u00efve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s QDENGA\u00ae (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Brazil for Use Regardless of Prior Dengue Exposure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Attenuated Tetravalent Dengue Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$2,850.0 million","upfrontCash":"$850.0 million","newsHeadline":"Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to PD-L1 antibody BAVENCIO\u00ae (avelumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Termination","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":2.8500000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.8500000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Merck KGaA","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Biorchestra","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$861.0 million","upfrontCash":"Undisclosed","newsHeadline":"BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"BMD-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0.85999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.85999999999999999,"dosageForm":"","sponsorNew":"Biorchestra \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestr.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"$455.0 million","upfrontCash":"$280.0 million","newsHeadline":"Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Everest Medicines","amount2":0.46000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Immunomedics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"$100.0 million","newsHeadline":"Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex\u2019s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Insulin-producing Hypoimmune Islet Cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0.33000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,750.0 million","upfrontCash":"$50.0 million","newsHeadline":"Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle\u00ae Radio-Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":1.75,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$5,200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Evotec And Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":5.2000000000000002,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Covant Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$481.0 million","upfrontCash":"$10.0 million","newsHeadline":"Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Covant Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Covant Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Covant The.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"$218.9 million","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Completion Of A Directed Issue And Private Placement Of 6,578,948 Million New Ordinary Shares Raising Gross Proceeds Of DKK 1.5 Billion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.22,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0.22,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Yunfeng Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Etana Has Secured Financing From Deg, East Ventures And Other Global Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Etana Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Etana Biotechnologies \/ Yunfeng Capital","highestDevelopmentStatusID":"12","companyTruncated":"Etana Biot.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics to Commercial Manufacture Provention Bio Diabetes Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Agreement","leadProduct":"Teplizumab-mzwv","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Provention Bio","highestDevelopmentStatusID":"12","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"New Leaf","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics Announces Closing of $25 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"HPN217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Harpoon Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ New Leaf","highestDevelopmentStatusID":"6","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","amount":"$96.4 million","upfrontCash":"$96.4 million","newsHeadline":"Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"JTX-4014","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Concentra Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STALICLA and Firefly Neuroscience Enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stalicla \/ Firefly Neuroscience","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"","sponsorNew":"Arrivent \/ Sofinnova","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/.."},{"orgOrder":0,"company":"Argenx","sponsor":"OncoVerity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief Executive Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cusatuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Argenx \/ OncoVerity","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ O.."},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief Executive Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"Cusatuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"OncoVerity \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity.."},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"French Blood Establishment","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"French Blood Establishment (EFS) & Brenus Pharma Partner for the GMP Production of STC-1010, an Innovative Therapy Against Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"STC-1010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brenus Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brenus Pharma \/ French Blood Establishment","highestDevelopmentStatusID":"4","companyTruncated":"Brenus Pha.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Closes First Tranche of Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"SciNeuro Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals and SciNeuro Pharmaceuticals Enter into Research and Option Agreement in the Field of CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ SciNeuro Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"BJ Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"BJ-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BJ Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BJ Bioscience \/ Merck & Co. Inc.","highestDevelopmentStatusID":"6","companyTruncated":"BJ Bioscie.."},{"orgOrder":0,"company":"BPGbio","sponsor":"Debra of America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BPGbio Announces Expanded Partnership with debra of America for BPM 31510 for Epidermolysis Bullosa Phase II\/III Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"BPM31510","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BPGbio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BPGbio \/ Debra of America","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ D.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Harm Reduction Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"T\u03c5HURA Biopharma","sponsor":"Morphogenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Morphogenesis Inc. Acquires T\u03c5HURA Biopharma\u2019s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"T\u03c5HURA Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"T\u03c5HURA Biopharma \/ Morphogenesis","highestDevelopmentStatusID":"2","companyTruncated":"T\u03c5HURA Bio.."},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$75.0 million","newsHeadline":"Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Treg-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0.12,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Bio.."},{"orgOrder":0,"company":"Simulations Plus","sponsor":"SACF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Simulations Plus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Simulations Plus \/ SACF","highestDevelopmentStatusID":"2","companyTruncated":"Simulation.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silence Therapeutics to Buyback siRNA Complement Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"siRNA-based Drug","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Silence Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Osivax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osivax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ B.."},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"JK07","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Salubris Biotherapeutics \/ Shenzhen Salubris Pharmaceuticals Co.Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Salubris B.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"","sponsorNew":"Milestone Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Shenzhen Hepalink Pharmaceutical","sponsor":"Orient EuroPharma","pharmaFlowCategory":"D","amount":"$11.2 million","upfrontCash":"Undisclosed","newsHeadline":"OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Hepalink Pharmaceutical","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Shenzhen Hepalink Pharmaceutical \/ Orient EuroPharma","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen H.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Atnahs Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant\u2122 (diazepam) Buccal Film to Additional Global Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Diazepam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Aquestive Therapeutics \/ Atnahs Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"bitBiome","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bitBiome and Kaken Pharmaceuticals Sign Joint Research Agreement on The Discovery of Drugs for Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"bitBiome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"bitBiome \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"bitBiome \/.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Rxilient Biotech","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Rxilient Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Th\u00e9a Open Innovation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Th\u00e9a Open Innovation and Galimedix Announce Strategic Partnership to Develop and Commercialize GAL-101, a Phase 2\/3-ready Small Molecule, to Treat Ophthalmic Indications with High Unmet Medical Need","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GAL-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Galimedix Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galimedix Therapeutics \/ Th\u00e9a Open Innovation","highestDevelopmentStatusID":"6","companyTruncated":"Galimedix .."},{"orgOrder":0,"company":"Eisai","sponsor":"GHIT","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Fosravuconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ GHIT","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GH.."},{"orgOrder":0,"company":"Ehime University","sponsor":"GHIT","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ehime University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ehime University \/ GHIT","highestDevelopmentStatusID":"1","companyTruncated":"Ehime Univ.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"BDC-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Galapagos","sponsor":"NovAliX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galapagos and NovAliX Enter Into An Integrated Drug Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galapagos \/ NovAliX","highestDevelopmentStatusID":"2","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank A\/S","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Directed Issue And Private Placement Of Approximately 6.5 Million New Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Danske Bank A\/S","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Predictive Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Predictive Oncology \/ Integra Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Predictive.."},{"orgOrder":0,"company":"BioAdaptives","sponsor":"LY Research Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAdaptives Inc. Announced Today the Signing of a License for Eye Health due to Myopia and Presbyopia; a Patent Valued at US$ 570,000,000","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lutein","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"BioAdaptives","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAdaptives \/ LY Research Corporation","highestDevelopmentStatusID":"4","companyTruncated":"BioAdaptiv.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Maxpro Capital Acquisition Corp.","pharmaFlowCategory":"D","amount":"$23.6 million","upfrontCash":"Undisclosed","newsHeadline":"Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Private Placement","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apollomics Inc","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Apollomics Inc \/ Maxpro Capital Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Coagulation Factor IX (recombinant)","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"CervoMed","sponsor":"CervoMed","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"CervoMed \/ EIP Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Smart Immune Receives \u20ac2.5m Grant and \u20ac15m Equity Investment Commitment from the European Innovation Council (EIC) via the EIC Accelerator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Funding","leadProduct":"Allogeneic T-cell Progenitor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Smart Immune \/ European Innovation Council","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Group","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Series A Financing","leadProduct":"TBX201","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trobix Bio \/ Chartered Group","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio.."},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise\u2019s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Talem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Talem Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Talem Ther.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect\u2122","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"CSI Pharmacy","sponsor":"Bio Products Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSI Pharmacy Announces Limited Distribution Agreement for Gammaplex","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Human Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSI Pharmacy","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSI Pharmacy \/ Bio Products Laboratory","highestDevelopmentStatusID":"12","companyTruncated":"CSI Pharma.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces $6 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Co.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Crinetics Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quotient Sciences Supports Crinetics Pharmaceuticals with Fully Integrated Pediatric Development and Clinical Testing Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"CRN04894","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Crinetics Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$7.1 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.1 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"$11.0 million","newsHeadline":"AstraZeneca Pulls Pneumonia Collab With Aridis Over Allegations Of A Missed Payment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Termination","leadProduct":"Suvratoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Aridis Pharmaceuticals \/ MedImmune","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"PathAI, inc","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"GSK4532990","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"PathAI, inc","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PathAI, inc \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"PathAI, in.."},{"orgOrder":0,"company":"KYM Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,163.0 million","upfrontCash":"$63.0 million","newsHeadline":"License Agreement with KYM Biosciences for CMG901, a Claudin-18.2 Antibody Drug Conjugate, Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KYM Biosciences","amount2":1.1599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"KYM Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"KYM Biosci.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicines Patent Pool Signs Sublicences With Aurobindo, Cipla and Viatris to Produce Generic Versions of ViiV Healthcare\u2019s Innovative Long-acting HIV Prevention Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ The Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lubiprostone","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaptys Bio- and GSK-Partnered Immuno-Oncology Agent Jemperli (dostarlimab-gxly) Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for The Treatment of Primary Advanced or Recurrent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Result of Interim Analysis of Phase 2b\/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Clonidine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"AIDS Clinical Trials Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sofosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AIDS Clinical Trials Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AIDS Clinical Trials Group \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"AIDS Clini.."},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Phase III NATALEE Trial Meets Primary Endpoint at Interim Analysis Demonstrating Clinically Meaningful Benefit in Broad Population of Patients with Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ribociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Translational Research In Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Translational Research In Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Translatio.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces Completion of Phase 2a Trial of \u20181104 in Allergic Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"KPI-012","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1\/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Entourage Health","sponsor":"NordicCan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entourage Health Continues to Expand Medical Offerings with Launch of CBD Chewing Gum and Signs New Union Group to the Starseed Medicinal Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Entourage Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Entourage Health \/ NordicCan","highestDevelopmentStatusID":"12","companyTruncated":"Entourage .."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces European Commission Approval for Pombiliti\u2122 in Patients with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-617","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Zagociguat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO\u00ae\u25bc(Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Asunercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AVA3996","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OLX10212","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Imvax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imvax Announces First Patient Dosed in Phase 2b Trial of IGV-001 for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imvax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ No.."},{"orgOrder":0,"company":"Neuraly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuraly \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Japanese Approval of Pemazyre\u00ae (pemigatinib) for the Treatment of Patients with Myeloid\/Lymphoid Neoplasms (MLNs)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavneos\u00ae (avacopan) Included in Updated EULAR Recommendations for The Management Of AAV","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, An Off-The-Shelf EGFR-Targeting \u03b3\u03b42 T cell Therapy Against EGFR-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ACE2016","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HaemaLogiX To Present Final Data from Anti-KMA CAR-T Preclinical Studies At AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Anti-KMA CAR-T Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"HaemaLogiX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HaemaLogiX \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HaemaLogiX.."},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sintetica US Launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SINTETICA SA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SINTETICA SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SINTETICA .."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"PIKA COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Reports Positive Topline 66-Week Results of Eplontersen Phase 3 Study for Patients With ATTRv-PN","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn\u00ae for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives final Approval from the USFDA for Doxepin Hydrochloride Capsules USP, 150 mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxepin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from the USFDA for Levothyroxine Sodium for Injection","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from the USFDA for Doxepin Hydrochloride Capsules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxepin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Launches New Long-Acting Insulin Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Indian Immunologicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IIL Gets Regulatory Nod for Measles-Rubella Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Measles-rubella Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Indian Immunologicals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Immunologicals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indian Imm.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Gets Tentative USFDA Approval to Market Generic Valbenazine Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ZKN-013","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces FDA Advisory Committee for neffy\u00ae for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1\/2a Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Nanoliposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ZP8396","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnteroBiotix Initiates Phase 2 Study of Microbiome Drug EBX-102 In Liver Cirrhosis and Hepatic Encephalopathy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"EBX-102","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteroBiotix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiot.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil\u2122 Drug-Coated Balloon","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surmodics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic\u2122, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ananda Scientific \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Sci.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1\/2 VELA Trial of BLU-222","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BLU-222","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PANTHERx\u00ae Rare Launches Drug for APDS","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PANTHERx Rare Pharmacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill\u00ae Daily Oral Contraceptive for OTC Use","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"TrueBinding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open-Label Extension Study for Alzheimer's Treatment Showed Disease Reversal in Nearly Half of Study Participants in Just Three Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"TB006","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TrueBinding \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBindin.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1\/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grey Wolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III RUBY Clinical Trial Demonstrates Potential of Jemperli (dostarlimab) Plus Chemotherapy to Redefine the Treatment of Primary Advanced or Recurrent Endometrial Cancer versus Chemotherapy Alone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"BDC-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Zelnecirnon","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poland and U.K. Regulatory Authorities \u2013 URPL and MHRA \u2013 Approve Use of New, Higher-Yielding Manu","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX\u2122 (Ketamine) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Libtayo\u00ae (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed \/ Refractory CD123-Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AFM28","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Converts to Full Approval Indication for KEYTRUDA\u00ae (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with Shortages of Critical Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eptifibatide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharm.."},{"orgOrder":0,"company":"PathoVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PathoVax's Licensed HPV Vaccine Receives FDA Clearance of HPV16 RG1-VLP Investigational New Drug Application","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"HPV16 RG1-VLP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"PathoVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PathoVax \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PathoVax \/.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"Vella Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vella Bioscience Inc. Granted First Patent For Use of Cannabinoids in Treating Antidepressant-Induced Female Sexual Dysfunction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Vella Bioscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vella Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vella Bios.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Announces Further Advancement of UltraCAR-T\u00ae Platform with First Patient Dosed in Phase 1\/1b Dose Escalation\/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces Accelerated Timeline for Phase 3 Intune Study in Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent\/Attenuate Chemotherapy and Radiation Treatment Induced Severe Oral Mucositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira's Oncolytic Product MVR-C5252 Targeting Malignant Glioma Obtained NMPA's Approval for Clinical Trial in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"C5252","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson's Disease at AD\/PDTM 2023 International Conference on Alzheimer's and Parkinson's Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-1005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH-063","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athos Ther.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions\u2019 NARCAN\u00ae Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Develco Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Develco Pharma \/ HMNC Brain Health","highestDevelopmentStatusID":"8","companyTruncated":"Develco Ph.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1\/GIP Receptor Agonist VK2735","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1\/GIP Receptor Agonist VK2735","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Awarded UK's MHRA Innovation Passport for Entry Into Innovative Licensing and Access Pathway (ILAP)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Gabapentin Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gabapentin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Avalyn Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1\/2 ABILITY Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANAVEX\u00ae2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMWC 2023: Data From Sculptra\u00ae Cheek Wrinkle and Alluzience\u00ae Star Studies Reinforce Strength of Galderma\u2019s Broad Aesthetic Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Introduces FDA-Approved Epinephrine Injection, USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"Sustained Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sustained Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sustained Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sustained .."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I\/ONTAK, into a Standalone Public Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Combined Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Combined Therapeutics to Present its Next-Generation mRNA-Based Vaccine Platform at the World Vaccine Congress 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Combined Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Combined Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Combined T.."},{"orgOrder":0,"company":"Cannabotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoRix's Breast Cancer Integrative Solution Demonstrated Enhanced Efficacy when Combined with Chemotherapy in An Ex-Vivo Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid Extract","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cannabotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cannabotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cannabotec.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ThirtyFiveBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFive.."},{"orgOrder":0,"company":"Oxford Vacmedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DxVx Co., Ltd.'s Affiliated Company, Oxford Vacmedix (OVM) Successfully Completed Phase 1a in Clinical Trial of Novel Cancer Vaccine OVM-200","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OVM-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Vacmedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Vacmedix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Vac.."},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CBP-4888","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Comanche Biopharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Comanche Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Comanche B.."},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HIPRA's Vaccine Against COVID-19, BIMERVAX\u00ae, Receives EMA's Positive Opinion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Protein Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Laboratorios HIPRA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laboratorios HIPRA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"VGL101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval from USFDA for Tenofovir Alafenamide Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases Announces Approval of FERRIPROX\u2122 MR Deferiprone Extended-Release Tablets in Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Deferiprone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Glo.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Entresto Receives Positive CHMP Opinion for Pediatric Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi\u2122 (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar, EPYSQLI\u2122","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI\u2122 (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMP Pharma's Potassium Phosphates Injection Receives FDA Shelf Life Extension for Specific Lots","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Potassium Phosphate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma.."},{"orgOrder":0,"company":"Ablaze Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ablaze Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ablaze Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ablaze Pha.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Brensocatib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New RYBREVANT\u00ae (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Approval to Manufacture and Market Entyvio\u00ae Subcutaneous Injection in Japan for the Maintenance Treatment of Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in Japan as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan-nxki","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Recommended for Approval in The EU By CHMP For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eplontersen Demonstrated Sustained Benefit in Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) Through 66 Weeks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Accelerated Approval for PADCEV\u00ae (enfortumab vedotin-ejfv) with KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genenta Science \/ Ospedale San Raffaele","highestDevelopmentStatusID":"5","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and Evergreen Discovery Collaborate to Discover Peptides for Targeting Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Evergreen Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Disc.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Completes $5.0 Million Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"ADX71149","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,030.0 million","upfrontCash":"$120.0 million","newsHeadline":"Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GSK4532990","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":1.03,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":1.03,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"Enzyme-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Anagram Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Th.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$618.0 million","upfrontCash":"$65.0 million","newsHeadline":"Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"STX-721","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Scorpion Therapeutics","amount2":0.62,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.62,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","amount":"$178.0 million","upfrontCash":"Undisclosed","newsHeadline":"Beactica Therapeutics and Oscotec Mutually Agree to Conclude Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Termination","leadProduct":"BEA-17","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$5.0 million","newsHeadline":"Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0.41999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Innate Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"National Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Enters Into Agreement With National Cancer Center To Collaborate On Investigator-initiated Clinical Research For Anticancer Agent Tazemetostat Based On \u201cPatient-proposed Healthcare Services\u201d System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ National Cancer Center","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Na.."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$1,670.0 million","upfrontCash":"$170.0 million","newsHeadline":"BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"DB-1303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6699999999999999,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"Regimmune","sponsor":"San Fu Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"RGI-2001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Regimmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regimmune \/ San Fu Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Regimmune .."},{"orgOrder":0,"company":"Histogen","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Emricasan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Johns Hopkins University","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence Group Announces Closing of Fourth Round Tranche of Private Placement and Conversion of Convertible Debt Note","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Medigene","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene Enters Cooperative Research and Development Agreement with the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"T cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces Private Placement with Commitments of $5.0 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Johns Hopkins University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Johns Hopkins University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN\u00ae in the Nordic Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Horus Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Horus Pharma \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Horus Phar.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"The Jikei University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ The Jikei University","highestDevelopmentStatusID":"2","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain Cargo\u24c7 for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eckert & Ziegler to Supply POINT Biopharma with Actinium-225","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eckert & Ziegler Strahlen \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Z.."},{"orgOrder":0,"company":"Forcefield Therapeutics","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Forcefield Therapeutics Signs Exclusive Patent And Know-how License Agreement With Freeline Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Forcefield Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forcefield Therapeutics \/ Freeline Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Forcefield.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$300.0 million","newsHeadline":"First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Fazirsiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.04,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Diamyd Medical Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Recombinant Human Glutamic Acid Decarboxylase","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Diamyd Medical AB \/ JDRF","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jounce Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Termination","leadProduct":"RXC007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Redx Pharma \/ Jounce Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Precigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Autologous CAR-T Cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Precigen","highestDevelopmentStatusID":"6","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"PureIMS","sponsor":"Boost-UP Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PureIMS Secures New Investment Round To Develop Lead Inhalation Product And Facilitate Partnering Activities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"PureIMS \/ Boost-UP Foundation","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ .."},{"orgOrder":0,"company":"Diamond Therapeutics","sponsor":"FAV LS Fund I","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamond Therapeutics \/ FAV LS Fund I","highestDevelopmentStatusID":"6","companyTruncated":"Diamond Th.."},{"orgOrder":0,"company":"Adcendo","sponsor":"Pontifax Venture Capital","pharmaFlowCategory":"D","amount":"$89.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Adcendo \/ Pontifax Venture Capital","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ .."},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectis Enters Into Warrant Agreement with The European Investment Bank Related to Credit Facility Agreement and Announces the Drawdown of The First Tranche of 20 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Alemtuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Mosaic Therapeutics","sponsor":"Syncona Investment Management","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mosaic Therapeutics Closes $28m Series A Funding and Appoints Brian Gladsden as CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mosaic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Mosaic Therapeutics \/ Syncona Investment Management","highestDevelopmentStatusID":"4","companyTruncated":"Mosaic The.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Rusfertide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Protagonist Therapeutics \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Karveer Meditech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"NV-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Karveer Meditech","highestDevelopmentStatusID":"7","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Peter Hecht","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Zagociguat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cyclerion Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Cyclerion Therapeutics \/ Peter Hecht","highestDevelopmentStatusID":"4","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Dalmore Group","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Dalmore Group","highestDevelopmentStatusID":"6","companyTruncated":"Algernon N.."},{"orgOrder":0,"company":"Celanese","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Celanese","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Celanese \/ Glaukos","highestDevelopmentStatusID":"10","companyTruncated":"Celanese \/.."},{"orgOrder":0,"company":"StrideBio","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"StrideBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"StrideBio \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"StrideBio .."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$360.0 million","upfrontCash":"$7.0 million","newsHeadline":"Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioTheryX","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"BioTheryX \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Longboard Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Societal CDMO \/ Longboard Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":2.5499999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":2.5499999999999998,"dosageForm":"","sponsorNew":"Proxygen \/ Merck & Co. Inc.","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd. Related to BENDEKA (bendamustine hydrochloride)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA\u00ae to Alora Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Divestment","leadProduct":"Sufentanil Citrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Alora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Various Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Simcha Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"University College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Ampakine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Closes US$3.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evopoint Biosciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint B.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Mirvetuximab Soravtansine-gynx","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Pharmakon Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"KRM-II-81","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"D-4517.2","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pomotrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pardes Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Halts Work on BTK Inhibitor After 2 Patient Deaths","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"GB5121","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"CPI-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH\u2122 in Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Fluphenazine Hydrochloride Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluphenazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraGin\u00ae, Developed by NuLiv Science, Demonstrates Improvements in Gut Health in Human Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AstraGin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NuLiv Science \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Scie.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Attralus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD\/PD 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AT-04","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Attralus","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Attralus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG260","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Precision Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"NEO-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scioto Biosciences Announces Publication of Phase 1b Study in Autism","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SB-121","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scioto Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Bio.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"STX-241","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AISA Pharma Announces NIH-NINDS Award To Investigate Profervia\u00ae as A Non-Opioid Analgesic for Acute and Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cilnidipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aisa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharm.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"DA-1241","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERLEADA\u00ae (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option Now Available in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Apalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vico Therapeutics Announces First Patient Dosed in Phase 1\/2a Clinical Trial of VO659 in Huntington's Disease and Spinocerebellar Ataxia Types 1 and 3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"VO659","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vico Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Thera.."},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami The.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune\u2122 to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"KRM-II-81","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Initiation of a Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces the Initiation of a Phase I\/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer\u2019s Type","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ALZN002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcuro Initiates Registrational Phase 2\/3 Study of ABC008 for the Treatment of Inclusion Body Myositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ABC008","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Abcuro, Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Authorized Generic Version of Noxafil\u00ae (posaconazole) Oral Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm.."},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HuidaGene Receives Orphan Drug Designation for Gene Therapy of Blindness","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HG004","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"HuidaGene Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HuidaGene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HuidaGene .."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte\u2122 New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"KSI-501","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives EC Approval For Hyrimoz High-concentration Formulation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Seeks Inclusion of Covovax on CoWIN As Heterologous Booster Dose for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Shares New Timeline for The High-Dose Rescue Medication for Opioid Overdose, OX124","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The World's Second Approved Biosimilars of Denosumab (MAILISHU)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HMPL-453","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dipraglurant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone Bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"GRT-R910","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of Emapalumab in Patients with Secondary HLH\/Macrophage Activation Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Emapalumab-lzsg","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen for the Treatment of Post-COVID Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-2004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Repairon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1\/2 Trial in Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Engineered Heart Muscle","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Repairon","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Repairon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repairon \/.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Announces VAZKEPA (Icosapent Ethyl) Approved by Israel's Ministry of Health","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"IgGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgGenix Announces Patent Granted by USPTO Covering the Generation of Allergen-specific Antibodies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Allergen-specific Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IgGenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ .."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baxter Launches Zosyn Premix in US","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Piperacillin Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Baxter Healthcare Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baxter Healthcare Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baxter Hea.."},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MYTX-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mythic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic The.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Pfizer\u2019s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1\/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"PER-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Perfuse Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Perfuse Th.."},{"orgOrder":0,"company":"RxOMEG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romeg Therapeutics Announces Publication of RMG-03 Phase 2 Study Results in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"RMG-03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RxOMEG Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RxOMEG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RxOMEG The.."},{"orgOrder":0,"company":"Biosion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BSI-045B","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biosion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ .."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Aurigene","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Au.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SLS-005","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for Exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: Two Fitusiran Phase 3 Studies Published in The Lancet and The Lancet Haematology Highlight Potential to Address Unmet Needs Across All Types of Hemophilia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Givosiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope Ongoing Phase 1b Clinical Trial in Evaluating Lixte Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces That It Has Submitted Its Response to The Day 120 Questions in The EMA Regulatory Review of Masitinib in Amyotrophic Lateral Sclerosis and Clarifies the New Timeline for Responding to Health Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Colestipol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"4","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae and IMFINZI\u00ae Combination Improved Progression-Free Survival in Newly Diagnosed Patients with Advanced Ovarian Cancer without Tumor BRCA Mutations In DUO-O Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verismo Therapeutics Secures Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SynKIR-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Th.."},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"DK210","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Deka Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosc.."},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AST-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Initiates Phase IIa Study of 5-MeO-DMT Candidate BPL-003 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Camlipixant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BEN2293","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"NM-136","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-DOTA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04 for Phase 2b Trial in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Newsoara Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Newsoara Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces New Coverage for ZORYVE\u00ae (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Macimorelin Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endogena Therapeutics Completes Dose Escalation in the Phase 1\/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"EA-2353","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endogena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena T.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives USAN Approval for \"Hypericin Sodium\" as Nonproprietary Name for Novel Active Ingredient in HyBryte\u2122 and SGX302","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Diaccurate","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"DIACC3010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Diaccurate","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diaccurate \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Diaccurate.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Receives New European Patent for AV-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"4-Chlorokynurenine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP-323","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First\u2011in\u2011Class Antibody Therapy for von Willebrand Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"VGA039","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Thera.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB211","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease (\"COPD\")","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Nuance Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Torrent Pharma launches First and Only Generic Version of Keveyis\u00ae (dichlorphenamide) Tablets in the United States","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dichlorphenamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Torrent Ph.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydroxyprogesterone Caproate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"B244","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Th.."},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Accent The.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRNA-4157\/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III\/IV Melan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MRNA-4157\/V940","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-0169","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on IMBRUVICA\u00ae (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Janssen Ortho LLC","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","amount":"$33.2 million","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Divests Certain Non-Core Brands in Dermatology in India to Eris Lifesciences to Focus on Strengthening Core","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Phillip Frost","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Phillip Frost","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Queen\u2019s University Belfast","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aviceda Therapeutics Announces Strategic Partnership with Queen\u2019s University Belfast (QUB)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aviceda Therapeutics \/ Queen\u2019s University Belfast","highestDevelopmentStatusID":"2","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Omeros","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Omeros","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Omeros \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Has Entered Into a Joint Research Agreement with Astellas Pharma Inc.","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Tec.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"ABL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza and ABL Bio Collaborate in the Development and Manufacture of Bispecific Antibody Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Stanford Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Effector Therapeutics \/ Stanford Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna The.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Samsung Venture Investment Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Announces Strategic Investment with Samsung Ventures","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Samsung Venture Investment Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"ImmuneBridge","sponsor":"Insight Partners","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"NK cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImmuneBridge","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ImmuneBridge \/ Insight Partners","highestDevelopmentStatusID":"4","companyTruncated":"ImmuneBrid.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.0 million","newsHeadline":"Sobi to Streamline Nirsevimab Contractual Arrangements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Termination","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"One-Two Therapeutics Assets Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Termination","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited","highestDevelopmentStatusID":"12","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Treventis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$372.5 million","upfrontCash":"Undisclosed","newsHeadline":"Treventis Partners its Preclinical Program in Alzheimer's Disease with Takeda","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Treventis","amount2":0.37,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.37,"dosageForm":"","sponsorNew":"Treventis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Treventis .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$674.9 million","upfrontCash":"$131.7 million","newsHeadline":"Nirsevimab: Sanofi, AstraZeneca and Sobi Simplify Contractual Agreements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.67000000000000004,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sobi To Streamline Nirsevimab Contractual Arrangements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Center for iPS Cell Research and Application","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"iPS cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Center for iPS Cell Research and Application","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Center for iPS Cell Research and Application \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Center for.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"University of Texas Health Science Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"BWV-401","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ University of Texas Health Science Center","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ Assay Across Its Hematologic Malignancy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adaptive Biotechnologies \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive B.."},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"3B Future Health Fund","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geneos Therapeutics Secures $5 Million in Series A3 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Geneos Therapeutics \/ 3B Future Health Fund","highestDevelopmentStatusID":"7","companyTruncated":"Geneos The.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Abiraterone Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Essa Pharma \/ Janssen Ortho LLC","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Westar Capital Limited","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Announces Private Placement of Secured Convertible Debentures for Gross Proceeds of a Minimum of AUD$2,000,000","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Westar Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic One Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Rubic One Health","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$1,480.0 million","upfrontCash":"$1,250.0 million","newsHeadline":"Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Oleogel-S10","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amryt Pharma","amount2":1.48,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.48,"dosageForm":"Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"Leucid Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"89Zr-crefmirlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"Lygenesis","sponsor":"Imagine Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lygenesis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lygenesis \/ Imagine Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lygenesis .."},{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$2,675.0 million","upfrontCash":"$75.0 million","newsHeadline":"Aspect Biosystems And Novo Nordisk Enter Partnership To Develop Bioprinted Tissue Therapeutics For Diabetes And Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Bioprinted-based Tissue Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Aspect Biosystems","amount2":2.6800000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.6800000000000002,"dosageForm":"","sponsorNew":"Aspect Biosystems \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Aspect Bio.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series C Financing","leadProduct":"ALE.F02","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Benchmark Company","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"CTM-N2D","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ Benchmark Company","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Th.."},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","amount":"$158.0 million","upfrontCash":"Undisclosed","newsHeadline":"TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"TORL BioTherapeutics \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTh.."},{"orgOrder":0,"company":"Walgreens","sponsor":"Prothena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer\u2019s Disease Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"PRX012","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Walgreens","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Walgreens \/ Prothena","highestDevelopmentStatusID":"6","companyTruncated":"Walgreens .."},{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Cl.."},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GQ1010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pyramid Bio","amount2":1.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Pyramid Bio \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Pyramid Bi.."},{"orgOrder":0,"company":"Aer Therapeutics","sponsor":"Canaan","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"AER-01","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Aer Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Inhalation","sponsorNew":"Aer Therapeutics \/ Canaan","highestDevelopmentStatusID":"4","companyTruncated":"Aer Therap.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp. IV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Merger","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp. IV","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"ProBioGen","sponsor":"ImmunOs Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"IOS-1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProBioGen \/ ImmunOs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"ANGLE plc","sponsor":"Crescendo Biologics Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Angle PLC, Crescendo Biologics Ink Clinical Services Contract","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"CB307","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ANGLE plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ANGLE plc \/ Crescendo Biologics Ltd","highestDevelopmentStatusID":"6","companyTruncated":"ANGLE plc .."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"White Lion Capital","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ White Lion Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Two Cells","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai and TWOCELLS Announce the Decision of the Termination of License Agreement on Investigational Regenerative Cellular Medicine for Knee Chondrogenesis (gMSC\u00ae1)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Termination","leadProduct":"gMSC1","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Two Cells","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Two Cells \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Two Cells .."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces U.S. FDA Approval of YUSIMRY\u2122 (adalimumab-aqvh)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Polygala Tenuifolia Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"DNL343","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"NXP800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuance Pharma Announces Dosing of First Patient in ENHANCE China Phase 3 Trial for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Nuance Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pha.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA\u00ae (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic\/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Instillation","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TP-1287","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Relmacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"JW Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Over 100 Patients Now Enrolled in CNS Pharmaceuticals\u2019 (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Olmesartan Medoxomil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Vigabatrin for Oral Solution USP, 500 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Lenalidomide Capsules, 2.5 mg and 20 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Erythromycin Tablets USP, 250 mg and 500 mg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Erythromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Loperamide Hydrochloride Capsules USP, 2 mg","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Loperamide Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Acetazolamide Tablets USP, 125 mg and 250 mg","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Acetazolamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Carbidopa and Levodopa Tablets USP, 10 mg\/100 mg, 25 mg\/100 mg, and 25 mg\/250 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Azithromycin Tablets USP, 500 mg","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Acyclovir Cream","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Aciclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE Anti-Infectives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell\u2122, an Immunotherapeutic for Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Peptide-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MVA-mBN294B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia's Paradigm Biopharmaceuticals Says Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification at 6-Month Follow-Up","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"IMPACT Therapeutics, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Senaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Junshi Biosciences \/ IMPACT Therapeutics, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel\u2122 (HAV\u2122) for Hemodialysis Access in End-Stage Renal Disease Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS\u00ae in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives FDA Approval to Expand the Use of HYQVIA\u00ae to Treat Primary Immunodeficiency in Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quadriga BioSciences Announces Dosing of First Subject in Phase 2 Study Evaluating QBS72S For Brain Metastases of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"QBS72S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Quadriga BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Quadriga BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quadriga B.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ N.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"CHK-336","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid Jab Covovax as Heterologous Booster to Be Available on CoWIN Soon; to Cost Rs 225 per Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HST-1011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HotSpot Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Approves Bivalent Pfizer Ltd. Covid-19 Original \/ Omicron BA4-5 Booster Dose for Adults Aged 12 and Over","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Tavaborole Topical Solution, 5%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tavaborole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress\u2122 Manufacturing Platform Process","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-314","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"JDRF","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ JDRF","highestDevelopmentStatusID":"8","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"KPI-012","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Announces First Patient Dosed in Phase 1\/2 Clinical Study of KVA12123 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BBT-877","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"[225-Actinium]-FPI-2068","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SNP318","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SciNeuro Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciNeuro Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciNeuro P.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1\u00ae as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Merck Group","sponsor":"EMD Serono Research & Development Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Continue","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck Group \/ EMD Serono Research & Development Institute","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tildrakizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allegro Ophthalmics Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 2b\/3 Clinical Trial of Risuteganib for the Treatment of Intermediate Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Risuteganib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allegro Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Op.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae and Charles River Present Positive Data for Next Generation, Oral TNF-\u03b1 Inhibitor MYMD-1\u00ae in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MYMD-1","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Penn Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Penn Medicine Researchers Take Step Toward Development of Personalized, CAR T-like Treatment for Rare Form of Autoimmune Disease Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"MuSK-CAART","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Penn Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Penn Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Penn Medic.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Provides Regulatory Update on AVT02 Biologics License Application","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1\/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegtarviliase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"JBI-589","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TOS-358","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Totus Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medi.."},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ZX-7101A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine P.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaxSwab\u2122 OTC Novel Naloxone Nasal Swab Successfully Administered by Children and Adults to Potentially Rescue Someone from An Opioid Overdose in Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Pocket Naloxone","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Swab","sponsorNew":"Pocket Naloxone \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pocket Nal.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"PCSK9-specific ARCUS Nuclease Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Celmatix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celmatix Launches Novel PCOS Drug Program","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/.."},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in a Phase 3 Clinical Study of ZX-7101A for the Treatment of Uncomplicated Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"ZX-7101A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine P.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Announces Phase 1 Results from the First-in-Human Phase 1\/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"23ME-00610","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1\/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA\u00ae (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089\/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"NCNP-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MH004","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rozanolixizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Araris Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Acquires ARS Pharmaceutical's Nectin-4 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARS Pharmaceuticals \/ Araris Biotech","highestDevelopmentStatusID":"4","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"RAD602","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TerThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TerThera \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"TerThera \/.."},{"orgOrder":0,"company":"Genmab","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Argenx","highestDevelopmentStatusID":"2","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Smart Immune Receives $5 Million Investment To Further Its Thymus-empowered Protcell Therapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Allogeneic T-cell Progenitor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Smart Immune \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"PIPE-307","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":1.1000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Contineum Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Complement Therapeutics","sponsor":"Gimv","pharmaFlowCategory":"D","amount":"$78.9 million","upfrontCash":"Undisclosed","newsHeadline":"Complement Therapeutics Secures \u20ac72 Million in Series A Financing to Advance Novel Therapies Targeting Complement-Mediated Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Complement Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Complement Therapeutics \/ Gimv","highestDevelopmentStatusID":"4","companyTruncated":"Complement.."},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSi.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"SNBL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SNBL to Acquire Satsuma Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Satsuma Pharmaceuticals \/ SNBL","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Reachbio Research Labs","sponsor":"Discovery Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Discovery Life Sciences Acquires ReachBio Research Labs","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Discovery","graph3":"Reachbio Research Labs","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reachbio Research Labs \/ Discovery Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Reachbio R.."},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Flare Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare's Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"FX-909","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Caris Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Flare Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Caris Life.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company BELLUS Health","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Camlipixant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":2,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":2,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Private Placement","leadProduct":"QLS-215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Catabasis Pharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Vildagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Epic Bio","sponsor":"Solve FSHD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOLVE FSHD Invests in Epic Bio for The Development of A Novel Treatment for Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"EPI-321","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Solve FSHD","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Brigham and Women\u2019s Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Brigham and Women\u2019s Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuneering Announces $30 Million Underwritten Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"IMM-1-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spexis Announces Closing of Capital Commitment of USD 4.5 Million From SPRIM Global Investments (sgi) to Enable Initiation of ColiFin\u00ae Phase 3 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ S.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"DTRA","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaJet Announces U.S. Government Award Expansion to Clinically Assess a DNA Vaccine Combined with its Systems","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Venezuelan Equine Encephalitis Virus DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaJet \/ DTRA","highestDevelopmentStatusID":"4","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Sygnature Discovery","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sygnature Discovery","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sygnature Discovery \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sygnature .."},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Announces Joint Research Agreement with Sumitomo Pharma Co. Ltd.","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Tec.."},{"orgOrder":0,"company":"NeoPhore","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoPhore \/ The Institute of Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/.."},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shanghai Pharma Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai P.."},{"orgOrder":0,"company":"Senisca","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"SENISCA Awarded Innovate UK Grant to Develop Oligonucleotide Therapeutics for The Treatment of Idiopathic Pulmonary Fibrosis (IPF).","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"Oligonucleotide-based Thearpy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Senisca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senisca \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Senisca \/ .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Pricing of $500 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.5,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"GORTEC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics Announces Phase 1b Trial in Collaboration With GORTEC To Investigate OBT076 In Adenoid Cystic Carcinoma (ACC) of The Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"MEN1309","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ GORTEC","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"30 Technology","sponsor":"ConvaTec","pharmaFlowCategory":"D","amount":"$218.0 million","upfrontCash":"$55.9 million","newsHeadline":"30 Technology's Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Divestment","leadProduct":"RESP301","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"30 Technology","amount2":0.22,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Inhalation Solution","sponsorNew":"30 Technology \/ ConvaTec","highestDevelopmentStatusID":"8","companyTruncated":"30 Technol.."},{"orgOrder":0,"company":"Tubulis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,022.7 million","upfrontCash":"$22.7 million","newsHeadline":"Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":1.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.02,"dosageForm":"","sponsorNew":"Tubulis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"NINDS","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sinopia Biosciences Selects Lead Clinical Candidate, Secures Funding to Advance into the Clinic for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ NINDS","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Bi.."},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"MJFF","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sinopia Biosciences Selects Lead Clinical Candidate, Secures Funding to Advance into the Clinic for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"SB-0110","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sinopia Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ MJFF","highestDevelopmentStatusID":"4","companyTruncated":"Sinopia Bi.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler & Co.","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces Pricing of $23 Million Public Offering of Securities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Omidubicel-onlv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gamida Cell","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Piper Sandler & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co. Inc.","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"ProgenaCare Global","sponsor":"Kane Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.5 million","newsHeadline":"Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"ProgenaCare Global","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"ProgenaCare Global \/ Kane Biotech","highestDevelopmentStatusID":"12","companyTruncated":"ProgenaCar.."},{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$20.0 million","newsHeadline":"Blue Water Announces Acquisition of ENTADFI\u00ae, an FDA-Approved Benign Prostatic Hyperplasia Asset","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Veru","amount2":0.10000000000000001,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Veru \/ Blu.."},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","amount":"$315.0 million","upfrontCash":"Undisclosed","newsHeadline":"CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hasten Biopharmaceutic","amount2":0.32000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"12","companyTruncated":"Hasten Bio.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"MJFF","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Therapeutics Awarded Grant by The Michael J. Fox Foundation to Support Development of a NLRP3 PET Tracer","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"VENT-02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ MJFF","highestDevelopmentStatusID":"6","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Aditxt","sponsor":"Cellvera","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$10.0 million","newsHeadline":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aditxt","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aditxt \/ Cellvera","highestDevelopmentStatusID":"12","companyTruncated":"Aditxt \/ C.."},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$142.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"ABD-147","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Abdera The.."},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Kinnevik","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Enveda Bioscience","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Enveda Bioscience \/ Kinnevik","highestDevelopmentStatusID":"2","companyTruncated":"Enveda Bio.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$575.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.57999999999999996,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"GRI Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Merger","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Vallon Pharmaceuticals \/ GRI Bio","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$462.7 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0.46000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Achilles Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InSilicoTrials and AchilleS Vaccines Join Forces to Create Next-Generation Vaccines and Monoclonal Antibodies Against Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"InSilicoTrials","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InSilicoTrials \/ AchilleS Vaccines","highestDevelopmentStatusID":"2","companyTruncated":"InSilicoTr.."},{"orgOrder":0,"company":"Deverra Therapeutics","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"DVX201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deverra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Deverra Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Deverra Th.."},{"orgOrder":0,"company":"GRI Bio","sponsor":"Altium Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"GRI Bio \/ Altium Capital","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veklury\u00ae (remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gepotidacin\u2019s Positive Phase III Data Shows Potential to Be the First in A New Class of Oral Antibiotics for Uncomplicated Urinary Tract Infections in Over 20 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Gepotidacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA\u00ae (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III\/IV Melanoma Following Com","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi-Based Treatment Before and After Surgery Reduced the Risk of Disease Recurrence, Progression Events or Death by 32% in Resectable Non-Small Cell Lung Cancer in The AEGEAN Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Tecentriq plus Avastin Reduced the Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in A Phase III Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Alhemo, the First Subcutaneous Prophylactic Treatment for People Living with Hemophilia B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Concizumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Announces FDA Approval of RIZAFILM\u00ae for the Treatment of Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Exarafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus\u2019 Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Petosemtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Hutrukin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1\/2 and Phase 2 Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell\u2019s Allogeneic Cell Therapy Omisirge\u00ae (omidubicel-onlv) Receives FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Omidubicel-onlv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces DAYBUE\u2122 (trofinetide) is Now Available for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves QULIPTA\u00ae (atogepant) for Adults With Chronic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Atogepant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA\u00ae for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Insert","sponsorNew":"AffaMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Announces Launch of Argatroban Injection Through Premier's ProRx\u00ae Private-Label Program","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Argatroban","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Obefazimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nigeria Regulator Grants Approval to Oxford's Malaria Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"R21 Malaria Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"University.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Panel May Review Gennova's mrna Omicron Booster Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces Masitinib Patent Granted in Japan for The Treatment of Amyotrophic Lateral Sclerosis, Strengthening the Company\u2019s Intellectual Property Position until 2037","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nykode Therapeutics Announces Positive Final Results from Its Phase 2 Trial Of VB10.16 in Combination with PD-L1 Inhibitor Atezolizumab in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3K\u03b1 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ABI-4334","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH\u00ae (tenapanor)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Announces Promising Clinical Data For DNA-Based Personalized Cancer Immunotherapy EVX-02: Phase 1\/2a Trial Met Both Primary and Secondary Endpoints","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable, Suspension","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Phase 1\/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Further Strengthens IP Protection for Lead Product Neumifil with Granting of US Composition of Matter Patent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Neumifil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pneumagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Provides Update on New Drug Application to The US Food and Drug Administration for Antibiotic Ceftobiprole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces Submission of Maxigesic\u00ae IV Packaging Data Requested by The US FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Receives Key European Patent From EPO, For Further Therapeutic Development in Cancer, Infectious and Immune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon Pharmaceuticals Presents Initial Phase 1 Results from the GLIMMER-01 Clinical Trial for E-602, the First Ever Glyco-Immune Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Scienc.."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ABX-002","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Autobahn Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"Genexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexa Receives Its First Patent for Agave-Based Medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genexa","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Genexa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genexa \/ N.."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Completes Clinical Portion of Alzamend Neuro\u2019s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Altasciences Company Inc \/ Altasciences Company Inc","highestDevelopmentStatusID":"10","companyTruncated":"Altascienc.."},{"orgOrder":0,"company":"Cali Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cali Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cali Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cali Biosc.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Taiho Oncology's Supplemental New Drug Application for the Use of Trifluridine\/Tipiracil (LONSURF\u00ae) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer (mCRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Trifluridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Receives FDA Approval for Hizentra\u00ae (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin G","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TDM-105795","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerm.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Completes Pre-IND Meeting with FDA on Jan123","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huida Genomics HG004 IND Was Approved By NMPA, And China's First International Multi-Regional, Multi-Center Gene Therapy Drug Clinical Trial with The Same Master Plan Will Be Carried Out","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HG004","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"HuidaGene Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HuidaGene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HuidaGene .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets Final Approval from The US FDA to Market Estradiol Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Patch","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Polivy in Combination With R-CHP For People with Certain Types of Previously Untreated Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BXT-25","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B\u2122 for Aging-Related Frailty in Japan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of \u20181104 in Adults with Active Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra in Patients Receiving CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1\/2a Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Roflumilast Tablets, 250 mcg","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 \u2013 3 Years After Receiving Pre-BLA Responses from FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X Pro1595 Improves Outcomes in A Mouse Model of TBI-Induced Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R\/R MZL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Reports Compelling Data as ExoFlo\u2122 Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ExoFlo","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Wins Patent Appeal on Otezla\u00ae (apremilast)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Apremilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C\u2019Dot Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ELU001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida On.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OCF-203","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm\u2122 for Lead Candidate AQST-109 (Epinephrine Sublingual Film)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SNS-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces US Commercial Launch of Cuvrior\u2122 for the Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences to File Alzheimer\u2019s IND for Intranasal Foralumab in Q2 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"JANX008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Janux Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces European Commission Approval of Opzelura\u00ae (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF\u2122 for the Treatment of Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbachol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Visus Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Visus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Visus Ther.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"CT041","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2\/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"iTolerance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. Announces Issuance of U.S. Patent Covering Proprietary Regenerative SA-FasL Microgel Technology, iTOL-100","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"iTOL-100","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensereptide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Promore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promore Ph.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Polycystic Kidney Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaBay Pharmaceuticals Launches DERMAdoctor\u2019s New Comfort + Joy Psoriasis Therapeutic Moisturizing Cream on the QVC\u00ae Network","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Salicylic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Marks First Approval Worldwide for AKEEGA\u00ae (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1\/2 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and\/or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ 2seventy bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Gives Green Light to Ibrutinib Plus Venetoclax as First-Line Treatment Option for Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Oblato","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients in the USA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OKN-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oblato","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oblato \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oblato \/ N.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"$7.2 million","newsHeadline":"Navamedic ASA: Recommended Cash Offer to Acquire Sensidose for Approximately SEK 75 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sensidose","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"Sensidose .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$10,800.0 million","upfrontCash":"$10,800.0 million","newsHeadline":"Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"PRA023","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":10.800000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Adare Biome","sponsor":"Royal DSM","pharmaFlowCategory":"D","amount":"$302.8 million","upfrontCash":"Undisclosed","newsHeadline":"DSM Agrees Terms To Acquire Postbiotics Pioneer Adare Biome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Lactobacillus LB","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Adare Biome","amount2":0.29999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Adare Biome \/ Royal DSM","highestDevelopmentStatusID":"12","companyTruncated":"Adare Biom.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co. Inc.","pharmaFlowCategory":"D","amount":"$12.4 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.4 million","upfrontCash":"Undisclosed","newsHeadline":"AB Science Announces the Success of Its Capital Increase by Private Placement for An Amount Of 15 Million Euros","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Aevitas Therapeutics","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$140.0 million","newsHeadline":"Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas\u2019 Short-Form Human Complement Factor H","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"4D-175","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Aevitas Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Aevitas Therapeutics \/ 4D Molecular Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aevitas Th.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"$30.0 million","newsHeadline":"Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of Rezzayo\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Sensidose","sponsor":"Navamedic","pharmaFlowCategory":"D","amount":"$9.3 million","upfrontCash":"$9.3 million","newsHeadline":"Navamedic ASA: Amended Cash Offer to Acquire Sensidose AB And Acquisition of Shares in Sensidose AB","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sensidose","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet, Dispersible","sponsorNew":"Sensidose \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"Sensidose .."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology, Inc. Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,075.0 million","upfrontCash":"$625.0 million","newsHeadline":"Lilly to Divest BAQSIMI to Amphastar","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.0800000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Completes Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Remestemcel-l","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Radiant Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Bi.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"$757.0 million","upfrontCash":"$291.0 million","newsHeadline":"Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim-xnst","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0.76000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","amount":"$106.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ AXA IM Alts","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Albatroz Therapeutics","sponsor":"Outram Bio","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Albatroz Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Albatroz Therapeutics \/ Outram Bio","highestDevelopmentStatusID":"4","companyTruncated":"Albatroz T.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"OMERS Life Sciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET\u00ae (U.S.)\/MAVIRET\u00ae (ex-U.S.) (Glecaprevir\/Pibrentasvir) to OMERS Life Sciences for $200 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Divestment","leadProduct":"Glecaprevir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Enanta Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ OMERS Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"BRV Capital Management","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Udenafil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ BRV Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$465.0 million","upfrontCash":"$40.0 million","newsHeadline":"3B Pharmaceuticals Enters Into a Global Exclusive Licensing Agreement for Its FAP-Targeting Peptide Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"FAP-2286","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"3B Pharmaceuticals","amount2":0.46999999999999997,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"3B Pharmac.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Pricing of $4 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Meloxicam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Eos Angel Investment Syndicate","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Human Alpha Interferon","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ILC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILC Therapeutics \/ Eos Angel Investment Syndicate","highestDevelopmentStatusID":"6","companyTruncated":"ILC Therap.."},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"RNA-based therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbital Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Orbital Th.."},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate B.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"HSB-1216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$22.8 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 2.0 Million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,900.0 million","upfrontCash":"$2,900.0 million","newsHeadline":"Sanofi Completes Acquisition of Provention Bio, Inc.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Provention Bio","amount2":2.8999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.8999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Provention Bio \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Provention.."},{"orgOrder":0,"company":"OpenBench","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"OpenBench","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OpenBench \/ Tavros Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"OpenBench .."},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Prime Capital Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"HCW9218","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HCW Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HCW Biologics \/ Prime Capital Ventures","highestDevelopmentStatusID":"7","companyTruncated":"HCW Biolog.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Paul Scherrer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Terbium-161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Paul Scherrer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology, Inc. Announces Closing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zura Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$4.2 million","newsHeadline":"Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"$80.0 million","newsHeadline":"Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Oaktree Capital Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seres Therapeutics Announces $250 Million Debt Financing with Oaktree","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Oaktree Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Therini Bio","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series A Financing","leadProduct":"THN391","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Therini Bio \/ Dementia Discovery Fund","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bi.."},{"orgOrder":0,"company":"Biomica","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Biomica \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Aksigen Hospital Care","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Acquires Disperzyme\u00ae and Phlogam\u00ae Brands to Strengthen Its Anti-Inflammatory Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aksigen Hospital Care","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Aksigen Ho.."},{"orgOrder":0,"company":"Cartherics","sponsor":"Shunxi Holding Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cartherics Grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CTH-004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cartherics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartherics \/ Shunxi Holding Group","highestDevelopmentStatusID":"5","companyTruncated":"Cartherics.."},{"orgOrder":0,"company":"Arix Bioscience Plc","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Series B Financing","leadProduct":"EVO101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arix Bioscience Plc","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Cream","sponsorNew":"Arix Bioscience Plc \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arix Biosc.."},{"orgOrder":0,"company":"BullFrog","sponsor":"Sage Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BullFrog AI Partners With The Sage Group to Explore JV Opportunities to Advance its Oncology Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"BF-222","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BullFrog","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BullFrog \/ Sage Group","highestDevelopmentStatusID":"6","companyTruncated":"BullFrog \/.."},{"orgOrder":0,"company":"Plasticell","sponsor":"LambdaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plasticell and LambdaGen Form Collaboration to Develop iPSC-Derived CAR-NK Allogeneic Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"iPSC-derived Allogenic Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Plasticell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plasticell \/ LambdaGen","highestDevelopmentStatusID":"2","companyTruncated":"Plasticell.."},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$825.9 million","upfrontCash":"Undisclosed","newsHeadline":"Cheplapharm Places Notes in A Volume of \u20ac750m in Challenging Market Environment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0.82999999999999996,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Cheplaphar.."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma & Perceptive Advisors","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinRx Pharma Announces First Participant Dosed in CinDome\u2019s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Private Placement","leadProduct":"Deudomperidone","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ CinRx Pharma & Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Rezpegaldesleukin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Vitalli Bio","pharmaFlowCategory":"D","amount":"$477.0 million","upfrontCash":"$10.0 million","newsHeadline":"Daewoong Pharmaceutical Announces A Global License Agreement For DWP213388, A New Drug Candidate For Autoimmune Disease With Vitalli Bio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Licensing Agreement","leadProduct":"DWP213388","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0.47999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Vitalli Bio","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Ossium Health","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Ossium Health Awarded $3.46M in Funding From The California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Funding","leadProduct":"OSSM-007","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ossium Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ossium Health \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ossium Hea.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi's Alemtuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Alemtuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Launch Of Mounjaro 2.5mg\/5mg Ateos The World's First Sustained Release GIP\/GLP-1 Receptor Agonist","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Launches Nefecon in China\u2019s Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mydecine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mydecine \/.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b\/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Lantheus Holding","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Lantheus Holding","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Beremagene Geperpavec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE\u00ae (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Provides an Update on FHD-609","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-609","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1044","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte\u2122 in the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belief BioMed Announces a Key Milestone of Dosing Completion for All Subjects in its Registrational Clinical Trial of BBM-H901","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BBM-H901","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belief BioMed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Belief BioMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belief Bio.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitrofurantoin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Announces Launch of AVAXIM\u00ae Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Hepatitis A Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves BEYFORTUS\u2122 (nirsevimab) For the Prevention Of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Submits Biologics License Application (BLA) to FDA for Lovotibeglogene Autotemcel (lovo-Cel) for Patients with Sickle Cell Disease (SCD) 12 Years and Older with A History of Vaso-Occlusive Events","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals\u2019 Proprietary Pulmonary TRiM\u2122 Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-RAGE","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces FDA Clinical Hold on IND Application for AB-101, An Oral PD-L1 Inhibitor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I\/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ATSN-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"MORF-057","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HilleVax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Provides Updated Guidance on Timeline for Readout Of INITIUM Phase II Clinical Trial Of UV1 In Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vamorolone NDA Mid-Cycle Review Meeting by FDA Completed","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Pan-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pan-Biome Pharmaceuticals, A Startup Focused on Age-Related Diseases and Increasing Human Healthspan, Reports Positive Results in A Preclinical Trial of Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Pan-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pan-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pan-Biome .."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ART27.13","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Glucose","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pha.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Completes Enrollment in Phase 1b\/2 SIGNAL-AD (Alzheimer\u2019s Disease) Study of Pepinemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Receives FDA Orphan Drug Designation for INB-400\/410 for the Treatment of Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"INB-400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer\u2019s Disease With a Proprietary Formulation Based On 5-MeO-DMT","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OMS906","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX\u00ae COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Protein Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Laboratorios HIPRA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Laboratorios HIPRA \/ Veristat","highestDevelopmentStatusID":"12","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Parthenon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IgG1 Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Parthenon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parthenon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Parthenon .."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Receives Authorization to Initiate a Phase 1\/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"STK-002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Multicenter Trial Opens to Study ImmunityBio\u2019s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nogapendekin alfa Inbakicept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmunityBio \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bioved Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioved Pharmaceuticals Granted a US Patent for Its Oral, Natural Plant-Based Product, Artovid-20\u00ae for The Treatment Of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ashwagandha Root Extract","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bioved Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioved Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioved Pha.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Receives European Commission Approval for Vafseo\u2122 (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Bloom Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BL-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bloom Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Scie.."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Amino Acid Mixture","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Ludwig Enterprises","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ludwig Enterprises \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ludwig Ent.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Accelerated Approval for QALSODY\u2122 (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Marketing Authorisation Application for Jemperli (dostarlimab) Plus Chemotherapy for The Treatment Of dMMR\/MSI-H Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ALN-APP","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Initiates Phase 3 Program with Filgotinib in Patients with Active Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Filgotinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda\u00ae (miglustat) for Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Roche\u2019s Fixed-Duration Columvi (glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Gains Positive CHMP Opinion for Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rumi Scientific Announces Data Demonstrating Disease Modifying Effect of BRD9 Inhibition in a Huntington\u2019s Disease Animal Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumi Scientific","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rumi Scientific \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rumi Scien.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Phase III APPOINT-PNH Trial Shows Investigational Oral Monotherapy Iptacopan Improves Hemoglobin to Near-Normal Levels, Leading to Transfusion Independence in All Treatment-Na\u00efve PNH Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces First Patient Dosed in the Phase 1b\/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics and Nestl\u00e9 Health Science Announce FDA Approval of Vowst\u2122 (fecal Microbiota Spores, Live-Brpk) for Prevention of Recurrence of C. Difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces U.S. FDA Approval for TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ALE.F02","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Receives FDA Clearance to Initiate Phase 1b\/2a Clinical Trial of ExoFlo\u2122 in Patients with Medically Refractory Perianal Fistulizing Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ExoFlo","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS\u00ae (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"9","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bendamustine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apotex Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc.."},{"orgOrder":0,"company":"Galactosemia Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galactosemia Foundation Urges FDA to Incorporate Voice of the Patient in Review of Potential First Treatment for Children with Life-Altering Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Galactosemia Foundation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galactosemia Foundation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galactosem.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fosun Pharma Develops Innovative Artemisinin-Based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Artemisinin-based Antimalarial Drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1\/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IkT-148009","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ABBV-CLS-7262","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calico Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calico Lif.."},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1\/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AVB-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avenge Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TCB-008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest to Report Early Results from Global Randomized Phase 1b\/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Busulfan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bispecific Antibody Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces First Patient Dosed in Phase 1\/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS\/NRAS Mutated Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU410ST","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Otsuka and Lundbeck\u2019s ABILIFY ASIMTUFII\u00ae (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Brenus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"STC-1010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brenus Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brenus Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Brenus Pha.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in the US in Avacta\u2019s AVA6000 Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinRx Pharma Announces First Participant Dosed in CinDome\u2019s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Deudomperidone","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio\u00ae (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1\/2 MARINA\u2122 Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"RV-1730","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune .."},{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Enterade Clinical Study Demonstrates Fewer Stopped Treatments and Lower GI Side Effects for Cancer Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Entrinsic bioscience","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution","sponsorNew":"Entrinsic bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Entrinsic .."},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yuyu Pharma Unveiled the Results of Its Mechanism of Action and Head-To- Head Studies for Its Dry Eye Treatment Peptide","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"YP-P10","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharm.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion for Futibatinib for The Treatment of Adults with Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Drogsan Pharmaceuticals","sponsor":"Rockwell Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rockwell Medical's Partner Drogsan Pharmaceuticals Submits Marketing Authorization Application in Turkey for Triferic AVNU","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Drogsan Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Drogsan Pharmaceuticals \/ Rockwell Medical","highestDevelopmentStatusID":"12","companyTruncated":"Drogsan Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Tirzepatide Achieved up To 15.7% Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes In SURMOUNT-2","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves PREVNAR 20\u00ae, Pfizer\u2019s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pneumococcal 20-valent Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Launches CEQUA, A Novel Therapy for Dry Eye Disease in India","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MM-II","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox's Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and MedinCell Announce FDA Approval of UZEDY\u2122 (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on FDA Advisory Committee Vote on LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OLX10010","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX\u2011101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces FDA Approval and Launch of A-Rated Generic Version of Uceris\u00ae (budesonide 2 Mg Rectal Foam)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Foam","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Announces FDA Clearance of IND Application for OQL036","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"OQL036","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquavit Files Investigational New Drug Application for its Flagship Intradermal Injection of Botulinum Toxin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"AqubotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Ph.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMG-004 Demonstrated Extended Half-Life and Durable Pharmacodynamic Characteristics in A Phase 1 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"IMG-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Announces Positive Early Results from Global Randomized Phase 1b\/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Adagene Suzhou Limited","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Vitalli Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aditum Bio Announces Formation of Vitalli Bio, Focused on Immunological Disorders","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"VIT-801","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vitalli Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vitalli Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vitalli Bi.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indication of Vabysmo for Macular Edema Associated with Retinal Vein Occlusion in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Respiratory Syncytial Virus Older Adult Vaccine Candidate Gains Positive European Medicines Agency CHMP Opinion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3 OA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Actemra Approved in Taiwan For the Treatment Of COVID-19 in Hospitalized Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and Axial Spondyloarthritis in the European Union","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$5,900.0 million","upfrontCash":"$5,900.0 million","newsHeadline":"Astellas Enters Into Definitive Agreement to Acquire Iveric Bio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":5.9000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":5.9000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"OBiO Technology","sponsor":"Chinagene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OBiO and Chinagene Reached A Strategic Agreement Of Commercial Manufacturing Services For Gene Therapy Products","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"ZVS101e","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"OBiO Technology","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OBiO Technology \/ Chinagene","highestDevelopmentStatusID":"7","companyTruncated":"OBiO Techn.."},{"orgOrder":0,"company":"CellReady","sponsor":"Marker Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"MT-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CellReady","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CellReady \/ Marker Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CellReady .."},{"orgOrder":0,"company":"Initial Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Initial Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Initial Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"3","companyTruncated":"Initial Th.."},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Soligenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Beh\u00e7et's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Pentoxifylline","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Silk Road Therapies \/ Soligenix","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road .."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"$150.0 million","newsHeadline":"Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"MZE001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0.75,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.75,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$35.0 million","newsHeadline":"Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.19,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Morgan Stanley Tactical Value","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Pamrevlumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Morgan Stanley Tactical Value","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$505.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"$10.0 million","newsHeadline":"Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"GV101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Graviton Bioscience \/ Ovid Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Graviton B.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Closing of $4 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","amount":"$30.9 million","upfrontCash":"Undisclosed","newsHeadline":"Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Anavo Therapeutics \/ MRL Ventures Fund","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Ther.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0.23999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Announces Closing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Salinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ ThinkEquity","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"VIR-1388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"IMP Clinical Supply Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ IMP Clinical Supply Services","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Exacis Biotherapeutics","sponsor":"Eterna Therapeutics","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"iPSC-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Exacis Biotherapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Exacis Biotherapeutics \/ Eterna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Exacis Bio.."},{"orgOrder":0,"company":"Ten63 Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","amount":"$15.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ten63 Therapeutics Raises $15.9 Million in Oversubscribed Series A Financing to Drug the Undruggables by Combining the Power of AI and Physics-based Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ten63 Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ten63 Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ten63 Ther.."},{"orgOrder":0,"company":"Helmholtz Zentrum M\u00fcnchen","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene Acquires Worldwide, Exclusive License Of CD40L-CD28 Costimulatory Switch Receptor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TCR-T-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Helmholtz Zentrum M\u00fcnchen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helmholtz Zentrum M\u00fcnchen \/ Medigene","highestDevelopmentStatusID":"2","companyTruncated":"Helmholtz .."},{"orgOrder":0,"company":"Odimma Therapeutics","sponsor":"Capital Grand Est","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Odimma Therapeutics Secures \u20ac2 Million to Complete the Preparation of Its First-in-Man Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"ODI-2001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Odimma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Odimma Therapeutics \/ Capital Grand Est","highestDevelopmentStatusID":"4","companyTruncated":"Odimma The.."},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Rhenium Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Piramal Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Piramal Pharma Solutions \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Piramal Ph.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Prizloncabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cellular Biomedicine Group","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Cellular Biomedicine Group \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Maxim Group","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Chromocell Therapeutics Announce IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"CC8464","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Chromocell Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chromocell Corporation \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"Chromocell.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Tipelukast","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and AntiPD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu\u00e9rin-Unresponsive Non-Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XTANDI\u00ae (enzalutamide) Plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer Versus Placebo Plus Leuprolide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for ORKAMBI\u00ae (lumacaftor\/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years Old","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Lumacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb\u2019s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl\u00ae (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Pari","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Cyclosporine A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Pari","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's RHB-102 (BEKINDA\u00ae) and Opaganib Granted New Patents in Oncology Setting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CAS 103639-04-9","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concept Medical Received IDE Approval to Investigate Safety and Efficacy of Its MagicTouch Sirolimus Coated Balloon Catheter for The Treatment of Small Coronary Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura\u00ae (ruxolitinib) Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M\u2122 Autologous SIRP\u03b1low Activated Macrophage Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Autologous SIRP\u03b1low Activated Macrophage Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIRPant Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Im.."},{"orgOrder":0,"company":"VasoSome Vascular","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Launches VasoSome Vascular Inc Based on Successful Treatment of Aortic Aneurysms using Patent Pending Exosome Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Stem Cell Derived Exosomes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"VasoSome Vascular","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VasoSome Vascular \/ Therapeutic Solutions","highestDevelopmentStatusID":"5","companyTruncated":"VasoSome V.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA\u00ae (teprotumumab-trbw) in Adults with Chronic\/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food & Drug Administration Issues Complete Response Letter for TransCon\u2122 PTH in Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Fast Track Designation for CABA-201","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ\u2122 (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces Olpruva\u2122 Commercial Launch Progressing Ahead of Schedule","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-500","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN202","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ERAS-801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX\u00ae2-73 (blarcamesine)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roluperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"The International Vaccine Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVI Begins Clinical Development Of DuoChol Oral Cholera Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"DuoChol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"The International Vaccine Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The International Vaccine Institute \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"The Intern.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BKV Neutralising Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Derm.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Quviviq (daridorexant) for The Management of Adult Patients with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat Achieved in Four Weeks Treating NAFLD Patients with DD01, a Novel Long-Acting GLP-1\/Glucagon Receptor Agonist","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DD01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"D&D Pharmatech","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"D&D Pharmatech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"D&D Pharma.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS\u00ae (voclosporin)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SPEVIGO\u00ae Granted Breakthrough Therapy Designation In The U.S. For the Prevention of Generalized Pustular Psoriasis Flares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial of STX-478, Its Mutant-Selective PI3K\u03b1 Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Defence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defence\u2019s Succesfull Accutoxtm Pre-Clinical Efficacy Study Complete Ready for Phase I IND Filing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AccuTOX","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Defence Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Defence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Defence Th.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ZKN-013","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism Following Positive End of Phase 2 Meeting with FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Holdings Submits Fast Track Application to FDA for KETARX\u2122 (ketamine) for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine\u00ae IMA203 TCR-T Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience Announced Positive Phase 2 Clinical Study Results of The Global Blockbuster Candidate for The Covid-19 Antiviral Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bi.."},{"orgOrder":0,"company":"EirGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EirGenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EirGenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EirGenix \/.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX With or Without Nivolumab as First-line Treatment of Gastric\/Gastro-Esophageal Junction Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent\u00ae Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Successfully Completes First Cohort in Phase 1b\/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellenkos Announces First Patient Dosed with CK0803 Cell Therapy for Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CK0803","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma and SporeGen\u00ae Announce Update from Research Collaboration Under Innovate UK Grant Award to Develop a Biotherapeutic Treatment (SPOR-COV\u00ae) for COVID-19 and Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bacillus Bacteria","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"NIMML Institute","sponsor":"NImmune Biopharma","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Omilancor","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NIMML Institute","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"NIMML Institute \/ NImmune Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"NIMML Inst.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Reprocell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Selects Reprocell USA to Provide Support for the Phase 2 Harmonic\u2122 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Clavius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iOnctura and Clavius Exercise Option for TGF-\u03b2 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"IOA-359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Clavius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Health Holland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Expands Pipeline And Receives Development Grant From Health Holland And KWF","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"IOA-359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Health Holland","highestDevelopmentStatusID":"4","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reneo Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Mavodelpar","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Dianthus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Merger","leadProduct":"DNTH103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Magenta Therapeutics \/ Dianthus Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Sernova","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sernova","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sernova \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Sernova \/ .."},{"orgOrder":0,"company":"SHL Medical AG","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics and SHL Medical Collaborate To Jointly Develop An Autoinjector For Sonelokimab Supply","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"SHL Medical AG","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SHL Medical AG \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SHL Medica.."},{"orgOrder":0,"company":"Multiomic Health","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","amount":"$8.6 million","upfrontCash":"Undisclosed","newsHeadline":"MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Multiomic Health","amount2":0.01,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Multiomic Health \/ Hoxton Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Multiomic .."},{"orgOrder":0,"company":"Convergent Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Actinium-J591","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Convergent Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Convergent Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Convergent.."},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","amount":"$46.4 million","upfrontCash":"Undisclosed","newsHeadline":"ARTHEx Biotech Announces Closing of \u20ac42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series B Financing","leadProduct":"ATX-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ARTHEx Biotech","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"ARTHEx Biotech \/ Columbus Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"ARTHEx Bio.."},{"orgOrder":0,"company":"Adalvo","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz To Exclusively Commercialize Six Products In The Us, Reinforcing Global Leadership Position In Off-patent Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ S.."},{"orgOrder":0,"company":"Artisan Bio","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BrightPath and Artisan Bio Sign Agreement To Expedite Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Allogeneic iNKT Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artisan Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artisan Bio \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Artisan Bi.."},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Fidelity Management & Research","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"DNTH103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Dianthus Therapeutics \/ Fidelity Management & Research","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus T.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Angiogenesis Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Oat Beta Glucan","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Angiogenesis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ A.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene \/ Novartis Anti-PD-1 Antibody Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"IND Enabling","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM\u00ae at the Company\u2019s Facility in Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytomegalovirus Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"PPC Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EZC Pak Declares Remarkable Results in Double-Blind Study, Including a 1.39-Day Reduction in Illness Duration for Patients with Upper Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Echinacea","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"PPC Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PPC Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PPC Group .."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"KGK Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Aloe Vera","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KGK Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Scienc.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS\u00ae (Voclosporin) For Adults with Active Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ELAHERE\u00ae Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FR\u03b1-Positive Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharma Completes Enrollment in Pivotal Phase 3 Clinical Trial Of SPI-1005 For the Treatment of Meniere's Disease Involving Hearing Loss, Tinnitus, and Dizziness","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Pharm Technologies Launches First Product in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Tetra Pharm Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tetra Pharm Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tetra Phar.."},{"orgOrder":0,"company":"Bloomsbury Genetic Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bloomsbury Genetic Therapies Receives Rare Paediatric Disease Designation from the U.S. FDA for BGT-DTDS for the Treatment of Dopamine Transporter Deficiency Syndrome (DTDS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BGT-DTDS","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloomsbury Genetic Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bloomsbury Genetic Therapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bloomsbury.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"C21","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces U.S. FDA Approval for KALYDECO\u00ae (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves GSK\u2019s Arexvy, the World\u2019s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Receives Approval in India to Import and Market Trastuzumab Deruxtecan for The Treatment of Select HER-2 Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verismo Therapeutics Announces the Activation of its STAR-101 Clinical Trial at the University of Pennsylvania","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SynKIR-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Th.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurobo Pharmaceuticals Announces FDA Clearance of IND for A Phase 2A Clinical Trial Of DA-1241 For The Treatment of Nash","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DA-1241","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trialof PRF-110 in Patients Undergoing Bunionectomy Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"PainReform \/ Lotus Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"PainReform.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$4,080.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"siRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Silence Therapeutics","amount2":4.0800000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":4.0800000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"German Cancer Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle\u00ae Radio Conjugates for a Range of Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Bicyclic Peptide-based Radio Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ German Cancer Research Center","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"Undisclosed","newsHeadline":"ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0.54000000000000004,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.62,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Nevakar","sponsor":"Long Grove Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Long Grove Pharmaceuticals Secures Commercial Rights to an Essential Critical Care Medication","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Norepinephrine Bitartrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nevakar","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nevakar \/ Long Grove Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class \u03b2-catenin Antagonist","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"ST316","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$30.0 million","newsHeadline":"Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Amphista Therapeutics","amount2":1.28,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.28,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces $15 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XNK Therapeutics Enters into Research Agreement with Global Pharma Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"XNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XNK Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"XNK Therap.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hasten Acquires Commercial Rights In China For Roche\u2019s Antibiotic Rocephin\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Ceftriaxone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.12,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$12.1 million","newsHeadline":"Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody\u00ae Novel Masked Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"ADG126","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Exelixis","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Walking Fish Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"B Cell-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Walking Fish Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"National Institute of Environmental Health Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Hyaluronan","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol, Powder","sponsorNew":"TFF Pharmaceuticals \/ National Institute of Environmental Health Sciences","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"George Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"George Clinical to Support Hummingbird\u2019s Phase 1 Oncology Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"HMBD-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hummingbird Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ George Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte\u2019s Human Acellular Vessel\u2122 (HAV\u2122) Receives FDA\u2019s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entod Pharmaceuticals Launches CYCLOTEARS Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Entod Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Entod Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Entod Phar.."},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juno Pharmaceuticals Approved to Import Ketamine, Providing Immediate Relief for Hospitals Across Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharm.."},{"orgOrder":0,"company":"FoundationOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FoundationOne\u00aeLiquid CDx Receives FDA-Approval as a Companion Diagnostic for EXKIVITY\u00ae (mobocertinib) to Identify Patients with EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"FoundationOne","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FoundationOne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion Recommending Hepcludex\u00ae (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Beckley Psytech\u2019s Phase IIa Study of BPL-003 for Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ABM-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IMU-856","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido\u00ae, for the Treatment of Acute Low Back Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ABV-1504","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies\u2019 Trogarzo\u00ae (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Iibalizumab-uiyk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Confirms Eligibility of XORLO\u2122 for Accelerated Approval","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TNX-1500","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIfT Biosciences Announces Data Demonstrating Potent Killing of Pancreatic Cancer Tumouroids","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpha Neutrophil-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosc.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi\u00ae and Simponi Aria\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1\/2a Trial of EA-2353 for Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"EA-2353","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endogena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena T.."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Innosuisse","highestDevelopmentStatusID":"4","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"Medisol","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$20.1 million","upfrontCash":"$16.2 million","newsHeadline":"Lupin Announces Acquisition of French Pharmaceutical Company Medisol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Medisol","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Medisol \/ Lupin Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Medisol \/ .."},{"orgOrder":0,"company":"Transgene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Scraps Transgene Pact in Blow to Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$276.0 million","upfrontCash":"Undisclosed","newsHeadline":"Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"MORF-057","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0.28000000000000003,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"BiomX","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Second Closing of $7.5 Million Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"BiomX \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Or.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sareum Announces Approval to Initiate Phase 1 Clinical Trial of Its Lead Product SDC-1801","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SDC-1801","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060\/AZD1402)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Elarekibep","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"ProBioGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Reaches Clinical Phase II Using ProBioGen\u2019s AGE1.CR.pIX\u00ae Production Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GAd20-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nouscom AG \/ ProBioGen","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roxadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Global Rare Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Announces FDA Acceptance of NDA Submission for iDose TR","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AB011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeting RAS: Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$728.3 million","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0.72999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bliss Biopharmaceutical Enters Into A Clinical Trial Collaboration Agreement With An Option Of Strategic Collaboration With Eisai For BB-1701","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"BB-1701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Bliss Bio \/ Eisai","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix to Supply Bayer with Illuccix\u00ae for Global Phase III Prostate Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval for Azacitidine for Injection, 100 mg Single-Dose Vial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Phar.."},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval for Lenalidomide Capsules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Phar.."},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval for Diltiazem Hydrochloride Injection, 25 mg\/5 mL (5 mg\/mL), 50 mg\/10 mL (5 mg\/mL), and 125 mg\/25 mL (5 mg\/mL), Single-Dose Vials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Diltiazem Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Phar.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives New Approvals for BRUKINSA\u00ae (zanubrutinib) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IBI311","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Therapy for Rare Gastrointestinal Stromal Tumours Approved in Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suzhou GenAssist Therapeutic Co.,Ltd Recently Announced that Its First Base Editing Product, GEN6050, Has Submitted a Pre-IND Application to The FDA and Has Been Accepted","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GEN6050","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Suzhou GenAssist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou Gen.."},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval for Hydralazine Hydrochloride Injection USP, 20 mg\/mL Single-Dose Vials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydralazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Phar.."},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval for Voriconazole for Injection, 200 mg\/Vial Single-Dose Vial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Koselugo Approved in China for Paediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Selumetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Neuro3 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"H. Lundbeck AS \/ Neuro3 Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Life Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forge Biologics \/ Life Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cyclica \/ Recursion Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ .."},{"orgOrder":0,"company":"Cullgen","sponsor":"AZ-CICC","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cullgen \/ AZ-CICC","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"U.S. Air Force Academy","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ U.S. Air Force Academy","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Chance Pharmaceuticals","pharmaFlowCategory":"D","amount":"$144.0 million","upfrontCash":"$2.5 million","newsHeadline":"Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA\u00ae in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Acorda Therapeutics \/ Chance Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Interius BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"INT-2104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Advanced Therapies \/ Interius BioTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advan.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Fortis Therapeutics","sponsor":"FibroGen","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"FOR46","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fortis Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Fortis Therapeutics \/ FibroGen","highestDevelopmentStatusID":"7","companyTruncated":"Fortis The.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Northwell Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company\u2019s Phase 2 Clinical Trial","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Northwell Health","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$406.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.40999999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Societal CDMO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin\u2122","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"iNexin","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Xequel Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Xequel Bio \/ Societal CDMO","highestDevelopmentStatusID":"6","companyTruncated":"Xequel Bio.."},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Everest Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wholly-Owned Psychedelics Subsidiary, Halucenex Life Sciences Inc. \u2013 Phase II Clinical Trial Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Halucenex Life Sciences \/ Everest Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex .."},{"orgOrder":0,"company":"GSK","sponsor":"CureVac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Dosing of First Participant in Combined Phase 1\/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GSK4382276A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ CureVac","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Cure.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ASC10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Roche\u2019s Vabysmo for The Treatment of Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE\u00ae Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune\u2122, a Natural Killer Therapy, for a Phase I\/II Trial in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Announces FDA Approval of Mydcombi\u2122, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company\u2019s Proprietary Optejet\u00ae Device Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Approval of OLINVYK in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Naval Medical Research Center","sponsor":"Immuron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Naval Medical Research Center","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Naval Medical Research Center \/ Immuron","highestDevelopmentStatusID":"5","companyTruncated":"Naval Medi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Extended in The US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to A Broader Range of Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Just \u2013 Evotec Biologics","amount2":0.64000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"Just \u2013 Evotec Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Just \u2013 Evo.."},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"DyNAbind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ DyNAbind","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Bi.."},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces an Additional $10 Million Award from BARDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0.17999999999999999,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$530.0 million","upfrontCash":"$30.0 million","newsHeadline":"Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$138.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$373.8 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0.37,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"XinThera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"XIN5104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"XinThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XinThera \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"XinThera \/.."},{"orgOrder":0,"company":"Zion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$680.0 million","upfrontCash":"$70.0 million","newsHeadline":"Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"ZN-A-1041","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"Enteric Capsule","sponsorNew":"Zion Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharm.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$621.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acelyrin, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0.62,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.62,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Closing of $8.5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Gamma Delta T Cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytoMed Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CytoMed Th.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"$1,700.0 million","newsHeadline":"Sobi to Acquire CTI BioPharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE\u00ae From 80 mg Per Day To 100 mg Per Day","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Amifampridine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals\u2019 Phase 1\/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptive Biotechnologies Announces FDA Acceptance of Genentech\u2019s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TCR based T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adaptive Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Biotechnologies \/ Genentech","highestDevelopmentStatusID":"5","companyTruncated":"Adaptive B.."},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"68Ga-Trivehexin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Announces First Person Dosed in Phase 1a\/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GS-2829","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces that Health Canada Has Resumed Its Review of The New Drug Submission for Masitinib in Amyotrophic Lateral Sclerosis, Following Issuance of A Screening Acceptance Letter","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Recruitment Completed for The PRECESTO Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tobacco Leaf Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NFL Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosci.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy\u00ae for the Treatment of Type I Allergic Reactions Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B\u2122 for Hypoplastic Left Heart Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Enleofen Bio Pte","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 765423","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Enleofen Bio Pte","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"RP-A601","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1\/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BBI-355","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The China NMPA Approves TYVYT\u00ae (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ampreloxetine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DLX-001","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Aramchol Meglumine","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Virginia Commonwealth University","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announces Advice from the FDA on its US Clinical Development Program of Lybrido\u2122 for the treatment of Female Sexual Interest\/Arousal Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Theranexus","sponsor":"Beyond Batten Disease Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Miglustat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Theranexus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theranexus \/ Beyond Batten Disease Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Theranexus.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Submission of IND for HEMO-CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"HEMO-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"Safety Shot","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Secures Foundational Patent Marking Milestone in Pursuit of Global Hair Loss Market","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Minoxidil","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Safety Shot \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Safety Sho.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP-235","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Gets Marketing Authorisation from UK for Chemotherapy Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Gets Marketing Authorisation for Generic Cancer Drugs from Uzbekistan, Palestine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in The EU for Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1,745.0 million","upfrontCash":"$45.0 million","newsHeadline":"Bayer, Bicycle Therapeutics Partner on Targeted Radionuclide Therapies in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Bicyclic Peptide-based Radio Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Bicycle Therapeutics","amount2":1.75,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"DiogenX","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiogenX Raises \u20ac27.5M Series A Financing To Advance its First-in-class Regenerative Treatment For Type 1 Diabetes into Clinical Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"DiogenX","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"DiogenX \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"DiogenX \/ .."},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ariceum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Ariceum Th.."},{"orgOrder":0,"company":"Curatis","sponsor":"ChaoDian","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kinarus Therapeutics Signed CHF1.5 Million Convertible Loan Agreement With ChaoDian (Hangzhou) Investment Management","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Pamapimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Curatis","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curatis \/ ChaoDian","highestDevelopmentStatusID":"6","companyTruncated":"Curatis \/ .."},{"orgOrder":0,"company":"Polifarma","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Enters Into Commercialization Agreement With Polifarma For Proposed Biosimilar to Eylea\u00ae (aflibercept)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polifarma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polifarma \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Polifarma .."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"DynamiCure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital\u00b7BioHealth Business Forum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"RNA-based Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ DynamiCure","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TG6050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First-In-Class Migraine Treatment Vydura Approved for NHS Scotland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Pfizer Inc \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SYNB1934","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI\u00ae (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer\u2019s Disease","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"OC514","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross .."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and Zealand Pharma Announce Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 456906","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill\u00ae Daily Oral Contraceptive for OTC Use","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Pharmaceuticals Announces Support for a Clinical Trial being Conducted by the U.S. Department of Defense Evaluating QUVIVIQ (daridorexant) as Potential Therapy for Treatment of Posttraumatic Stress Disorder (PTSD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Receives European Commission Approval of Tibsovo\u00ae (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Initiates Dosing in Phase 1 Study of Intranasal, Live-Attenuated RSV Vaccine, CodaVax\u2122- RSV, in a Pediatric Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Live-Attenuated RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Global Rare Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO\u00ae (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa-iwxj","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"LHP588","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lighthouse Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Drospirenone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roluperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane\u00ae (betaine anhydrous for oral solution)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Betaine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study\u2019s Independent Interim Review Committee Recommends Continuing Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"JNJ-40411813","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces Phase III Study Results of bardoxolone methyl (RTA 402) in Japan and Discontinuation of Development","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kyowa Kirin \/ Reata Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$8.8 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Awarded $8.8 Million From U.S. Department of Defense to Develop Fast-Acting, Intranasal Countermeasure Against Respiratory Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Powder for Inhalation","sponsorNew":"Lumen Bioscience \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Successful Capital Increase For Biophytis With \u20ac2.3 Million Raised","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"$8.0 million","newsHeadline":"Cyclerion Announces Definitive Agreement for Zagociguat and CY3018","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"McMaster University","sponsor":"Brain Cancer Canada","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Brain Cancer Canada Awards CAD 80,000 Grant to Fund Innovative Glioblastoma Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"CAR-T Cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"McMaster University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McMaster University \/ Brain Cancer Canada","highestDevelopmentStatusID":"2","companyTruncated":"McMaster U.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"$505.5 million","upfrontCash":"Undisclosed","newsHeadline":"Angelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercialization of Novel Biologic Therapies in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0.51000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Angelini Pharma","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Matinas End Oral mRNA Delivery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Termination","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SERB Pharmaceuticals and SFJ Pharmaceuticals Announce a U.S. Partnership for Bentracimab, a Ticagrelor","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Bentracimab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SFJ Pharmaceuticals \/ SERB","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharma.."},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Latvia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latvia Can! A New Remedy for Respiratory Diseases Created and Researched!","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Olea Europea","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Silvanols","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Silvanols \/ University of Latvia","highestDevelopmentStatusID":"12","companyTruncated":"Silvanols .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Neffy\u00ae (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pyrilutamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte\u2122 in the Treatment of Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Phase 2 Clinical Trial Has Received Ethics Approval for World First Take-Home LSD-Microdosing Trials in Cancer Patients Experiencing Emotional Distress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Announces Positive Topline Results From PRAX-628 Phase 1 Study Enabling Best-In-Class Profile","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PRAX-628","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4\/6 Inhibitor Palbociclib in Phase 1b\/2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"OP-1250","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse\u00ae in Fibrotic Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFN\u03b1 and an NRTI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Doses First Patient in Phase 1\/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CK-586","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Marketing Approval of CAMZYOS\u00ae (mavacamten) in the Macau Special Administrative Region (SAR) of China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CTO1681","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Extend Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Extend Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Extend Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Extend Bio.."},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deerfield Management-Founded Aviko Radiopharmaceuticals to Advance Precision Boron Neutron Capture Therapy to Treat Cancer and Other Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Boron Neutron Capture Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aviko Radiopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radi.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ PharmaEssentia","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos\u2019 Oligonucleotide Platform for the Treatment of Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Aligos Therapeutics","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"2","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$593.0 million","upfrontCash":"$90.0 million","newsHeadline":"SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME\u00ae (Ibrexafungerp Tablets)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0.58999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Oberland Capital","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"$40.0 million","newsHeadline":"Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0.16,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.16,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Oberland Capital","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$55.0 million","newsHeadline":"LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LaNova Medicines","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"LaNova Medicines \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"LaNova Med.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Delivers 83% Reduction in RSV Infant Hospitalizations in A Real-World Clinical Trial Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocentrx Provides Update on Clinical Progress of Lead Programme, Keticap\u00ae, an Oral Ketamine Formulation for the Treatment of Mood Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Neurocentrx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentr.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' VEOZAH\u2122 (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Poxel","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"$299.0 million","upfrontCash":"$42.0 million","newsHeadline":"Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG\u00ae (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0.29999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ Su.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP-235","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Convenient Treatment Option for Thromboembolic Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Prague Scientific","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Prague Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prague Sci.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$12.0 million","newsHeadline":"F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ikena Oncology Announces $40 Million Underwritten Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"IK-930","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"$384.0 million","upfrontCash":"$274.0 million","newsHeadline":"Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Typhoid Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0.38,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.38,"dosageForm":"Capsule","sponsorNew":"Emergent BioSolutions \/ Bavarian Nordic","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Uniqure","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"$400.0 million","newsHeadline":"uniQure Announces Sale of Royalty Interest in HEMGENIX for Up To $400 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Divestment","leadProduct":"Etranacogene Dezaparvovec-drbl","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Uniqure","amount2":0.40000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ HealthCare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genelux Corporation Announces $33 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0.11,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"OMass Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"2","companyTruncated":"OMass Ther.."},{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ F.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Cure Stat Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Mifepristone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Cure Stat Rx","highestDevelopmentStatusID":"6","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"NVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CHARM Therapeutics Receives Investment for Deep Learning-Enabled Drug Discovery Research from NVIDIA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CHARM Therapeutics \/ NVentures","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Ther.."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Delafloxacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Nusano","sponsor":"PharmaLogic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nusano and PharmaLogic Announce Collaboration to Enable Next Generation Radiotherapeutics Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nusano","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nusano \/ PharmaLogic","highestDevelopmentStatusID":"1","companyTruncated":"Nusano \/ P.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,715.0 million","upfrontCash":"$35.0 million","newsHeadline":"Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Arcus Biosciences","amount2":1.72,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.72,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"NIDO-361","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nido Biosciences","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Nido Biosciences \/ 5AM Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Nido Biosc.."},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophore, Its Subsidiary Zenara Pharma, Receive First Approval for Cannabidiol in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zenara Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zenara Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zenara Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces FDA Clearance of NXP900 IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NXP900","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"SiSaf","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants SiSaf\u2019s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SIS-101-ADO","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ No.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Immunai","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed\/Refractory Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunai \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immunai \/ .."},{"orgOrder":0,"company":"Exscientia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DSP-2342","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Therini Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"THN391","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therini Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bi.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Methsuximide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Study of DFP-10917 in the R\/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DFP-10917","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly .."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Hefei Tianmai Biotechnology Development","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hefei Tianmai Biotechnology Development","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hefei Tianmai Biotechnology Development \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hefei Tian.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caldolor\u00ae Now FDA Approved for Treatment of Fever & Pain in Infants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IMPT-314","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmPACT Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmPACT Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmPACT Bi.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acesion Pharma Announces Positive Pre-Clinical Data for AP31969","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AP31969","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acesion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Ph.."},{"orgOrder":0,"company":"ForCast Orthopedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ForCast Orthopedics Receives QIDP Designation From FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"FC001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ForCast Orthopedics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ForCast Orthopedics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ForCast Or.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial\u2019s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich\u2019s Ataxia and First Quarter 2023 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CTI-1601","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SKINVIVE\u2122 by JUV\u00c9DERM\u00ae Receives U.S. FDA Approval","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sony Corporation","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sony Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sony Corporation \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sony Corpo.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Chinook Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"$1,575.0 million","upfrontCash":"$75.0 million","newsHeadline":"Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"CRISPR-based Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.5800000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.5800000000000001,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"OCX-253","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ocean Biomedical","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Microbix Biosystems","sponsor":"Sequel Pharma","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Microbix Secures Funded Drug Commercialization Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Urokinase","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Microbix Biosystems","amount2":0.040000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Microbix Biosystems \/ Sequel Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Microbix B.."},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Myeloma Investment Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin\u2019s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"NTX1088","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nectin Therapeutics \/ Myeloma Investment Fund","highestDevelopmentStatusID":"6","companyTruncated":"Nectin The.."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Novo Holdings A\/S","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"RTx-015","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ray Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ray Therapeutics \/ Novo Holdings A\/S","highestDevelopmentStatusID":"5","companyTruncated":"Ray Therap.."},{"orgOrder":0,"company":"Ensoma","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ensoma Closes Series B Extension, Bringing Total Round to $135 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series B Financing","leadProduct":"Genomic Medicine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ensoma","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Ensoma \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ K.."},{"orgOrder":0,"company":"Personalis","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Personalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Personalis \/ Ono Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Personalis.."},{"orgOrder":0,"company":"Drug Farm","sponsor":"YD Capital","pharmaFlowCategory":"D","amount":"$27.0 million","upfrontCash":"Undisclosed","newsHeadline":"Drug Farm Raises $27M USD Financing for Advancement of First-In-Class Hepatitis B and Cardiovascular-Renal Drugs into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series C Financing","leadProduct":"DF-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Liquid","sponsorNew":"Drug Farm \/ YD Capital","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"InflaRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WuXi Biologics \/ InflaRx","highestDevelopmentStatusID":"12","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRLAB Therapeutics and the McQuade Center for Strategic Research and Development Enter into Agreement to Evaluate IRLAB\u2019s Neuropsychiatric Programs IRL757 and IRL942","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"IRL757","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRLAB \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"5","companyTruncated":"IRLAB \/ Mc.."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boundless Bio Announces $100 Million Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance First ecDNA-Directed Therapies for Patients with Oncogene Amplified Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series C Financing","leadProduct":"ecDNA-directed Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Boundless Bio \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Metaphore Biotechnologies","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Metaphore Biotechnologies \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Metaphore .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives U.S. FDA Fast Track Designation for Asundexian Atrial Fibrillation Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, Designed for Treating Acute Spinal Cord Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces Receipt of Marketing Authorization for Glassia\u00ae for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Apadamtase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"HiST Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiST Pharma Announces U.S. FDA Approval to Initiate Phase III Clinical Study With TC Cream \u2013 World\u2019s First Botanical Small-Molecule Drug That Treats Psoriasis Vulgaris","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Plant-based Medicine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"HiST Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"HiST Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HiST Pharm.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Third Biosimilar with FYLNETRA\u2122 (pegfilgrastim-pbbk) in the United States","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim-pbbk","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Kashiv Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec\u2019s NLRP3 Inhibitor Dapansutrile and Merck\u2019s Keytruda\u00ae in Patients with Advanced Refractory Melanoma at Duke Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olatec Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA\u00ae (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Alphamedix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex Pharmaceuticals Announces Issuance of A Patent for Azeliragon as A Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kimera\u00ae Labs Receives FDA Phase I\/IIa IND Approval For Its MSC Exosomes Human Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Placental Cell Derived Mesenchymal Stem Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kimera Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kimera Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kimera Lab.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Eversana","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Treatment of T-cell Leukemia Across the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nelarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shorla Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shorla Oncology \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PIKA Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iterion Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dusquetide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of mRNA Universal Influenza Vaccine Candidate Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"H1ssF-3928 mRNA-LNP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SBI-100","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"SRI International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SRI\u2019s Radioactive Contamination Treatment Is Now in Its First-In-Human Trial","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"3,4,3-Li(1,2-hopo)","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SRI Intern.."},{"orgOrder":0,"company":"JAMP PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMP Pharma Group Receives Health Canada Approval For Pr JAMP Dapagliflozin, A New Generic Alternative for The Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"JAMP PHARMA","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JAMP PHARMA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"JAMP PHARM.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Blosozumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoBrain Checkpoint Doses First Patients in Phase 1b Clinical Trial of IBC-Ab002 for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IBC-Ab002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoBrain Checkpoint \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrai.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lysergic Acid Diethylamide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"MTBVAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1\/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GTX-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia\u2122","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Lobe Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"12","companyTruncated":"Lobe Scien.."},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Pharmanovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Closed Loop Medicine and Pharmanovia Enter a Co-Development Partnership for Precision Medicine Combination Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Closed Loop Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Closed Loop Medicine \/ Pharmanovia","highestDevelopmentStatusID":"4","companyTruncated":"Closed Loo.."},{"orgOrder":0,"company":"BeiGene","sponsor":"The Max Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Max Foundation, BeiGene, and The BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA\u00ae for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ The Max Foundation","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$510.0 million","upfrontCash":"Undisclosed","newsHeadline":"KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Servier","sponsor":"Aitia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Servier \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prelude Therapeutics Announces Launch of Proposed Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"enGene","sponsor":"Forbion Growth","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"enGene, Inc. and Forbion European Acquisition Corp. (\u201cFEAC\u201d, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Forbion Growth","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ F.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Leaps by Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Etrasimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Everest Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Chemotherapy Demonstrated Strong Improvement in Progression-Free Survival for Patients with EGFR-Mutated Advanced Lung Cancer in FLAURA2 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People with Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fenebrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH (tenapanor)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIVUS QSIVA in Combination with a Digital Lifestyle Intervention Leads to Significant Weight Loss and Decreased Cardiovascular Risk in Patients with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Phentermine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Ma.."},{"orgOrder":0,"company":"NImmune Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Omilancor","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"NImmune Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NImmune Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NImmune Bi.."},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b\/2a US\/EU Clinical Trial","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NVD-003","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Bi.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sepiapterin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Launches Phase 1\/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Debio 0123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emcure Pharmaceuticals to Launch The 750 Mg Injectable Variant of Ferric Carboxymaltose","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pha.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Reacquires Global IP Rights and Provides Update On JTA-004 Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Clonidine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAPIX Therapeutics Inc. Announces the Issuance of U.S. Patent for LPX-TI641, Its First-in-Class, Orally Administered Tim3\/4 Agonist for Treg Expansion to Treat Autoimmune Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"LPX-TI641","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LAPIX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Ther.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kerendia\u2122 (finerenone) Granted Expanded Indication in China for Broad Range of Patients with Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","amount":"$82.5 million","upfrontCash":"$75.0 million","newsHeadline":"EyePoint Pharmaceuticals Announces Sale of YUTIQ\u00ae to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Divestment","leadProduct":"Fluocinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prelude Therapeutics Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"Tubepharma","sponsor":"Oncomatryx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncomatryx Acquires Tube Pharmaceuticals GmbH to Consolidate its Pioneering Pipeline of ADCs Targeting the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"OMTX705","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tubepharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tubepharma \/ Oncomatryx","highestDevelopmentStatusID":"6","companyTruncated":"Tubepharma.."},{"orgOrder":0,"company":"HitGen","sponsor":"ARase Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ ARase Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ A.."},{"orgOrder":0,"company":"Immunoforge","sponsor":"Duke University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoForge Expands Drug Development Licensing Agreement with Duke University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immunoforge","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunoforge \/ Duke University","highestDevelopmentStatusID":"2","companyTruncated":"Immunoforg.."},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"SiteOne Therapeutics Awarded up to $15M Grant to Develop NaV1.8 Inhibitor as Non-Opioid Therapeutic for Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SiteOne Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"SiteOne Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"SiteOne Th.."},{"orgOrder":0,"company":"OncoResponse","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"OR502","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"OncoResponse \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"OncoRespon.."},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"iTolerance","sponsor":"BIRD Foundation","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. Receive US $1.0 Million Grant from the BIRD Foundation","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Allogenic Pancreatic Islet Cell","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iTolerance \/ BIRD Foundation","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Hatteras Investment Partners","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Myeloid Therapeutics \/ Hatteras Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Th.."},{"orgOrder":0,"company":"OncoResponse","sponsor":"RiverVest Venture Partners","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoResponse Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"OR502","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"OncoResponse \/ RiverVest Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"OncoRespon.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ATG-031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces NDA Submission for XPOVIO\u00ae in Indonesia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Na\u00efve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rucosopasem","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Roxadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma\/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Adminis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant COVID-19 Bivalent Protein Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"WestVac Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"WestVac Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"WestVac Bi.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CT041","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IAB56","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kapruvia\u00ae (difelikefalin) Recommended By England's NICE For the Treatment of Adults with Moderate-To-Severe CKD-Associated Pruritus","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Study Suggests the Use of OraPharma\u2019s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"ORAPHARMA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves RINVOQ\u00ae (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO\u2122 (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Support of Approval for Pfizer\u2019s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06928316","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"VTX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"NIDCR","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Collagen","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cayman Chemical Company Inc \/ NIDCR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Che.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Devonian Announces Private Placement of up to $5 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ TSX Venture Exchange","highestDevelopmentStatusID":"9","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"SBIR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cayman Receives SBIR Grant for Alzheimer\u2019s Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cayman Chemical Company Inc \/ SBIR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Che.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Phase 3 Clinical Trial of Mutant Strain COVID-19 Vaccine (DS-5670) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Beremagene Geperpavec-svdt","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"KT-253","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPKINLY\u2122 (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R\/R) Diffuse Large B-cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Interim Analysis of 'GEN-001' Plus Avelumab (Bavencio\u00ae) Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll Biopharma Announces Results from Phase III Randomized, Double-Masked Active Treatment-Controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Bio.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rucosopasem Manganese","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Imugene IND To Commence onCARlytics First-In-Class Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as A Treatment for Pre-Cirrhotic Fibrosis Due To NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ulcerative Colitis Phase II Study of GSK2831781 Discontinued","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immutep","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer\u2019s Disease in Great Britain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute of Harvard","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-810","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Trueline Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trueline Therapeutics \/ Broad Institute of Harvard","highestDevelopmentStatusID":"5","companyTruncated":"Trueline T.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"Undisclosed","newsHeadline":"7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Alintegimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$22.4 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","amount":"$50.7 million","upfrontCash":"Undisclosed","newsHeadline":"Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series D Financing","leadProduct":"QTX3034","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"5","companyTruncated":"Quanta The.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE (setmelanotide) to Patients in Gulf Cooperation Council Countries","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Avoro Capital Advisors","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Krystal Biotech Announces $160 Million Private Placement Equity Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Beremagene Geperpavec-svdt","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Krystal Biotech","amount2":0.16,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.16,"dosageForm":"Suspension","sponsorNew":"Krystal Biotech \/ Avoro Capital Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"PharmEnable","sponsor":"MP Healthcare Venture Management","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmEnable","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"PharmEnable \/ MP Healthcare Venture Management","highestDevelopmentStatusID":"2","companyTruncated":"PharmEnabl.."},{"orgOrder":0,"company":"Eversana","sponsor":"Yaral Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Eversana \/ Yaral Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$87.5 million","upfrontCash":"$87.5 million","newsHeadline":"AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Divestment","leadProduct":"CTNS-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Avrobio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Thousand Oaks Biologics","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"Undisclosed","newsHeadline":"Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Thousand Oaks Biologics","amount2":0.029999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Thousand Oaks Biologics \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"Thousand O.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":1,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":1,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I\/II Program in STK11 Mutant Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CDX-1140","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HiberCell \/ Celldex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Semaglutide 50 mg Achieved 15.1% Weight Loss (17.4% if all People Adhered to Treatment) in Adults with Obesity or Overweight in the OASIS 1 Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Human IgG4 Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene AG Expands Patent Portfolio for its End-to-End Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TCR-T-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces First US Site for its Phase I\/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Adipic Acid Dihydrazide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces U.S. Launch of UDENYCA Autoinjector","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"FLT201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Phase 2 Altitude-NashTrial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Pint Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Pint Pharma","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Bio.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II\/III Clinical Study on TOTUM\u202263: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TOTUM\u202263","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb\u2019s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BMS-986278","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Isaralgagene Civaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanX Biopharmaceuticals Announces HX009 IND Approval from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"HX009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HanX Bioph.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"FSH Receptor CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces UK MHRA Approval of Vafseo\u00ae (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium's Novel ADHD Medication AZSTARYS\u00ae (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth Rate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves the Cyltezo Pen, a New Autoinjector Option, Ahead Of July 1 Commercial Launch","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Provides R&D Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces IND Clearance Enabling Phase 1\/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AMG 193","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves AYVAKIT\u00ae (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure is Granted European Patent for NeuroRestore ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ACD856","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX\u2081\u2080\u2080 for Prevention of Abdominal Colorectal Surgical Site Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Smartbax","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"smartbax Announces Seed Financing of \u20ac1.2 Million to Develop Next-generation Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Smartbax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Smartbax \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Smartbax \/.."},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"CSIRO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amplia Receives Grant to Collaborate with CSIRO \u2013 Supplementary Announcement","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"AMP945","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Amplia Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplia Therapeutics \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Amplia The.."},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Polaris Innovation Fund","pharmaFlowCategory":"D","amount":"$35.5 million","upfrontCash":"Undisclosed","newsHeadline":"Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Larkspur Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Larkspur Biosciences \/ Polaris Innovation Fund","highestDevelopmentStatusID":"2","companyTruncated":"Larkspur B.."},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"CohBar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TuHURA Biosciences \/ CohBar","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Bio.."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Z-endoxifen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Societal CDMO \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Societal C.."},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"OnKure Therapeutics Announces $54 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series C Financing","leadProduct":"OKI-219","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"5","companyTruncated":"OnKure The.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$130.7 million","upfrontCash":"Undisclosed","newsHeadline":"Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$5.0 million","newsHeadline":"2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"2Seventy Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"CohBar","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"IFx-Hu2.0","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CohBar","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"CohBar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ U.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Keyuan Xinhai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Influenza A virus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Keyuan Xinhai","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP\/p300 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"P-300","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novo Nordisk \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,920.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Life Edit Therapeutics","amount2":1.9199999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Life Edit Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Life Edit .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$343.4 million","upfrontCash":"$60.1 million","newsHeadline":"Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0.34000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Gene-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ClearPoint Neuro","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ClearPoint Neuro \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"ClearPoint.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Pyxis Oncology","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pyxis Oncology to Acquire Apexigen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Pyxis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Israeli Phage Therapy Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Bacteriophage-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","amount":"$401.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0.40000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"Endo International","sponsor":"MAIA Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Bivalirudin","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ MAIA Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"InProTher","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"IPT001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InProTher","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"InProTher \/ European Innovation Council","highestDevelopmentStatusID":"5","companyTruncated":"InProTher .."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Announces U.S. Food and Drug Administration Approval of OPVEE\u00ae (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"AnaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AM1476","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ N.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates Phase I Safety, Tolerability and Pharmacokinetics Study of NMD1343","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"NMD1343","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"MRT-6160","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Estianeptine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Affimed","sponsor":"Artiva Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Artiva Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces Start of Phase 2 study with Selective TYK2 inhibitor, GLPG3667, in Patients with Dermatomyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GLPG3667","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Olitigaltin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO\u00ae (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Innoviva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innoviva \/.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bempedoic Acid Significantly Reduces the risk of Major Adverse Cardiovascular Events, and Increased Combination Therapies can help More Patients Achieve LDL-C Goals \u2014 late breaking EAS Data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VGA039","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Thera.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi\u00ae (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exo Announces Lead Program, Targeting TANK Binding Kinase 1 (TBK1), for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Exo Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Exo Therap.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Voruciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"RP-L301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces FDA Approval of Brixadi\u2122 for the Treatment of Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AG-73305","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allgenesis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis.."},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Innoviva","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innoviva \/.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vatiquinone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"TrialSpark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrialSpark Announces First Patient Dosed in Phase 2 Clinical Trial for ASN008-201 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ASN008","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TrialSpark","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"TrialSpark \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TrialSpark.."},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allos Pharma Inc. Receives FDA Guidance for the Design of a Phase 3 Trial to Support a New Drug Application for Treatment of Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Baclofen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Allos Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allos Phar.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orsini Specialty Pharmacy Selected as part of the Limited Specialty Pharmacy Network For VYJUVEK\u2122, the First Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Beremagene Geperpavec-svdt","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillhurst Biopharmaceuticals Announces Completion Of Last Patient Last Visit In Phase 1 Clinical Trial Of HBI-002","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbon Monoxide","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst .."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cumberland Pharmaceuticals Announces FDA Clearance Of IND For New Treatment Of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ifetroban Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PMC-403","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"MHB018A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ATG-022","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical has Submitted Application to Start Tumorad(R) Clinical Phase I\/IIa Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Topline Results from Phase 1b\/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"WVE-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic CAR-T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Ceapro","sponsor":"McMaster University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PGX-processed Yeast Beta Glucan","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ McMaster University","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ M.."},{"orgOrder":0,"company":"Chulalongkorn University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thailand Develops Nasal Spray with Highly Effective Antibodies Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"THAILAND","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Human IgG1 anti-SARS-CoV-2 Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chulalongkorn University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Chulalongkorn University \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chulalongk.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ANX007","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami The.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Completes Recruitment for its Landmark NEW DAY Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Sydney","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Announces U.S. FDA Approval of Yuflyma\u00ae (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira\u00ae (adalimumab) Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aaty","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYK2\/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AC-201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Accro Bioscience","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Accro Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Accro Bios.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BRY812","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioRay Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pha.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-opioid ACD440","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ACD440","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase Ia Healthy Volunteer Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"MHB018A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VANFLYTA\u00ae First FLT3 Inhibitor Approved in Japan for Patients with Newly Diagnosed FLT3-ITD Positive AML","therapeuticArea":"","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GHIT Fund","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"$11.6 million","upfrontCash":"Undisclosed","newsHeadline":"Eisai\u2019s Initiatives For Developing New Medicines For Neglected Tropical Diseases And Malaria And Commitment For Funding To The 3rd Phase Of Global Health Innovative Technology Fund Activities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Fosravuconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GHIT Fund","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"GHIT Fund \/ Eisai","highestDevelopmentStatusID":"8","companyTruncated":"GHIT Fund .."},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaPro Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaPro Therapeutics \/ BriaCell","highestDevelopmentStatusID":"4","companyTruncated":"BriaPro Th.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Multiple Sclerosis Society","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8\u00ae in Non-Active Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ National Multiple Sclerosis Society","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharma.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series E Financing","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Carmot Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"OBT620","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Medice Arzneimittel P\u00fctter GmbH&Co.KG","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$10.0 million","newsHeadline":"Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel P\u00fctter GmbH&Co.KG For the Commercialization of Vafseo\u00ae for The Treatment of Anemia Associated With CKD in Europe and Australia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0.11,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Sino Biopharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces that its Partner Sino Biopharm Received IND Approval from the NMPA to initiate Clinical Trial with Lanifibranor in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Inventiva Pharma \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech Announces FDA 510(k) Clearance for its coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Citric Acid","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rigosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Doses First Patient in AIPAC-003 Phase II\/III Trial for Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Linvoseltamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Structure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ANT3310","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Antabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antabio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antabio \/ .."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Marketing Authorization Applications For Proposed Biosimilar Denosumab Accepted By EMA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI\u00ae (ciltacabtagene autoleucel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Publishes Report by Leading FDA Experts Validating MindMed\u2019s MM-120 Drug Development Strategy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lysergic Acid Diethylamide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral\u00ae Birch","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Stallergenes Greer","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stallergen.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Milvexian","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s PAXLOVID\u2122 Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1\/2 Trial of THE-630 in Patients with Advanced GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"THE-630","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Psilera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PSIL-006","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Psilera","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psilera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Psilera \/ .."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Allgenesis Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AG-73305","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Completes Enrollment Of Phase 3 Registrational Intune Study In Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01004","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ N.."},{"orgOrder":0,"company":"Bial","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson's Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BIA 28-6156","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Bial","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bial \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Not.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tradipitant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Publishes New Data on A Fibromun-Based Treatment Combination in Science Translational Medicine in Collaboration with The University Hospital Zurich","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Fibromun","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent and Transgene Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion to Extend the Use of Veklury\u00ae (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Hauck Aufh\u00e4user Lampe Privatbank AG","pharmaFlowCategory":"D","amount":"$26.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Hauck Aufh\u00e4user Lampe Privatbank AG","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"FivepHusion","sponsor":"Syneos Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusio.."},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosenic Provides Update Regarding Current License Agreement With Phebra","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Announces FDA Approval of INPEFA\u2122 (sotagliflozin) for Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives CHMP Negative Opinion, Following Re-examination of Potential First FOP Treatment In The E.U.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY\u00ae (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Condoliase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) Plus LYNPARZA\u00ae (olaparib) and IMFINZI Alone Both Significantly Improved Progression-free Survival in Advanced Endometrial Cancer When Added to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Nuvaxovid\u2122 Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Intsel Chimos","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"20-hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Intsel Chimos","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Revoking the Conditional Marketing Authorization for Adakveo\u00ae (crizanlizumab)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Crizanlizumab-tmca","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Approval of COVID-19 Vaccine SKYCovion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AS03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SK Chemicals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Chemicals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Chemica.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-weekly Sogroya\u00ae (somapacitan) Receives CHMP Positive Opinion for Expanded use in Children and Adolescents With Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Somapacitan","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in Japan for the Prevention of Relapses in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENVIMA\u00ae (lenvatinib) Plus KEYTRUDA\u00ae (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"NurrOn Pharmaceuticals","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"ATH-399A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NurrOn Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurrOn Pharmaceuticals \/ HanAll Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"NurrOn Pha.."},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abiogen Pharma Completes the Acquisition of EffRx Pharmaceuticals","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Phar.."},{"orgOrder":0,"company":"AstriVax","sponsor":"VLAIO","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"AstriVax Awarded \u20ac2.5 Million Grant to Advance Innovative Vaccine Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AstriVax","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstriVax \/ VLAIO","highestDevelopmentStatusID":"3","companyTruncated":"AstriVax \/.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"kt-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Cyteph","sponsor":"CUREator","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Australian Startup Cyteph Secures $1.5 M for Brain Cancer Immunotherapy Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"Allogeneic Cytomegalovirus-specific T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cyteph","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyteph \/ CUREator","highestDevelopmentStatusID":"4","companyTruncated":"Cyteph \/ C.."},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Selects Charles River Laboratories for IMP761\u2019s GLP Toxicology Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"IMP761","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Charles River Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concept Medical's Fourth IDE Approval for the MagicTouch Sirolimus Coated Balloon is Granted for the Treatment of Superficial Femoral Artery Disease (SFA)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in Model of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amplia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amplia The.."},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma and Philogen Sign Licence Agreement for Anti-Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bifikafusp Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Amplo Biotechnology","sponsor":"NIH-NIAMS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"AAV-ColQ-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Amplo Biotechnology","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplo Biotechnology \/ NIH-NIAMS","highestDevelopmentStatusID":"4","companyTruncated":"Amplo Biot.."},{"orgOrder":0,"company":"BNS Ophthalmics","sponsor":"BioNanoSim","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BNS and RAFARM Create BNS Ophthalmics to Leverage Nanotechnology in The Development of Novel Ophthalmic Products","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"BNS Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BNS Ophthalmics \/ BioNanoSim","highestDevelopmentStatusID":"4","companyTruncated":"BNS Ophtha.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Elamipretide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stealth Biotherapeutics \/ Pharmanovia","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"XtalPi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$250 million","upfrontCash":"Undisclosed","newsHeadline":"XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0.25,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"XtalPi \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ E.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$525 million","upfrontCash":"$175 million","newsHeadline":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Launches $6.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Prodrug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"SVB Securities LLC","pharmaFlowCategory":"D","amount":"$30 million","upfrontCash":"Undisclosed","newsHeadline":"Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Tinlarebant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Belite Bio \/ SVB Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Trethera","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$2 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","amount":"$392 million","upfrontCash":"$10 million","newsHeadline":"C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC\u2122 Degrader of EGFR L858R for NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CFT8919","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.39000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"FAR Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ FAR Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"Anocca","sponsor":"AMF","pharmaFlowCategory":"D","amount":"$36.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anocca Raises SEK 400 Million for Large-Scale Development of Cancer Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"TCR-T-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Anocca","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Anocca \/ AMF","highestDevelopmentStatusID":"2","companyTruncated":"Anocca \/ A.."},{"orgOrder":0,"company":"Anew Medical","sponsor":"Redwoods Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anew Medical, Inc. Enters Into Definitive Merger Agreement with Redwoods Acquisition Corp.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Merger","leadProduct":"Alpha Klotho-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Anew Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anew Medical \/ Redwoods Acquisition Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Anew Medic.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR and Sumitomo Dainippon Pharma Enter into Marketing Alliance for Agalsidase Beta BS I.V. Infusion, for Treatment of Fabry Disease in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Biosimilar","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Announces the Launch of Cetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Enzene Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enzene Biosciences \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Enzene Bio.."},{"orgOrder":0,"company":"Trevena","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"$2.5 million","newsHeadline":"Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$40.2 million","upfrontCash":"Undisclosed","newsHeadline":"Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0.040000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.040000000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ B.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Announces Proposed Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Farouk, Maamoun Tamer & Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (\u201cCHT\u201d or \u201cTerritories Distributor\u201d) and Farouk, Maamoun Tamer & Co. (\u201cMaster Distributor\u201d) For the Distribution of ZTlido\u00ae in the Kingdom of Saudi Arabia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ Farouk, Maamoun Tamer & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$10 million","upfrontCash":"Undisclosed","newsHeadline":"LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"LTZ-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"LTZ Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"LTZ Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"LTZ Therap.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4 million","upfrontCash":"Undisclosed","newsHeadline":"Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$50 million","upfrontCash":"$10 million","newsHeadline":"InDex Pharmaceuticals Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cobitolimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Enema","sponsorNew":"InDex Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Yuhan Corporation","pharmaFlowCategory":"D","amount":"$325 million","upfrontCash":"$1.9 million","newsHeadline":"Yuhan Corporation and J INTS BIO Inked a Licensing Agreement for A New Drug Candidate Targeting HER2 NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"JIN-A04","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"J Ints Bio","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"J Ints Bio \/ Yuhan Corporation","highestDevelopmentStatusID":"4","companyTruncated":"J Ints Bio.."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Nucleai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Buparlisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Nucleai","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","amount":"$28.1 million","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Seal Rock Therapeutics","sponsor":"Genfit","pharmaFlowCategory":"D","amount":"$106.8 million","upfrontCash":"Undisclosed","newsHeadline":"GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SRT-015","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Seal Rock Therapeutics","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Seal Rock Therapeutics \/ GENFIT","highestDevelopmentStatusID":"6","companyTruncated":"Seal Rock .."},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer to Acquire Exclusive License from Cedilla Therapeutics on Selective Inhibitors in Pre-Clinical Precision Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cedilla Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Th.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$62.2 million","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$50 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics Announces Closing of $50.0 Million Private Placement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mark Cuban Cost Plus Drug Company Joins Forces with Coherus to Make Yusimry, a Humira Biosimilar, Available to Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Adalimumab-aqvh","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Angion Biomedica \/ Elicio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7\/8 Dual Agonists","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"BDB018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Eikon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Seven and .."},{"orgOrder":0,"company":"Theragnostics","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","amount":"$44 million","upfrontCash":"$2.5 million","newsHeadline":"Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"ATD-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theragnostics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Theragnostics \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theragnost.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Johnson & Johnson Enterprise Innovation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shasqi Announces Research Collaboration to Transform Targeted Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shasqi \/ Johnson & Johnson Enterprise Innovation","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ J.."},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Pharming Announces Sale of Priority Review Voucher","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Divestment","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0.02,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rentschler Biopharma Joins Forces with Ikarovec to Accelerate Novel Gene Therapies for Treatment of Ophthalmic Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/.."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"Adcendo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Duality Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duality Biologics \/ Adcendo","highestDevelopmentStatusID":"2","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Advanced Bioscience laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"MVA-based SARS-CoV-2 Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GeoVax Labs \/ Advanced Bioscience Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","amount":"$10 million","upfrontCash":"Undisclosed","newsHeadline":"Pneumagen Raises \u00a38m to Accelerate Phase 2 Clinical Development of Neumifil for The Prevention & Treatment of Viral Respiratory Tract Infections","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Sialic Acid Binding Protein","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Liquid","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Philogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Philogen Announces Clinical Trial Collaboration with MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Bifikafusp Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Philogen \/ Merck & Co. Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the next trial in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nykode Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"pHion Therapeutics","sponsor":"Invox Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"RALA-mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"pHion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"pHion Therapeutics \/ invoX Pharma","highestDevelopmentStatusID":"4","companyTruncated":"pHion Ther.."},{"orgOrder":0,"company":"Modulo Bio","sponsor":"Initialized Capital","pharmaFlowCategory":"D","amount":"$8 million","upfrontCash":"Undisclosed","newsHeadline":"Modulo Bio Launches to Map the Neuroimmune System and Develop Treatments for Neurodegenerative Diseases, Starting With ALS and FTD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Modulo Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Modulo Bio \/ Initialized Capital","highestDevelopmentStatusID":"2","companyTruncated":"Modulo Bio.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX\u00ae)for KRASG12C-mutated NSCLC in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Levolta Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Zoledronic Acid Derivative","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Levolta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Levolta Ph.."},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights to Intellectual Property from Georgetown University for Azeliragon as A Potential Treatment of Cancer-Related Cognitive Decline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown.."},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"IMP1734","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IMPACT Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMPACT Therapeutics, Inc \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IMPACT The.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Tillotts Pharma AG","pharmaFlowCategory":"D","amount":"$130.3 million","upfrontCash":"Undisclosed","newsHeadline":"Astellas Transfers Dificlir in Europe, Middle East, Africa and selected CIS to Tillotts Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Fidaxomicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Tillotts Pharma AG","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Cytovation","sponsor":"Sandwater","pharmaFlowCategory":"D","amount":"$8 million","upfrontCash":"Undisclosed","newsHeadline":"Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement Of CyPep-1, A First-In-Class Targeted Tumor Membrane Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Cytovation \/ Sandwater","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Pint Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi\u00ae (ropeginterferon alfa-2b-njft) in Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaEssentia \/ Pint Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4 million","upfrontCash":"Undisclosed","newsHeadline":"Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Ianalumab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupus Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Ther.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Terran Biosciences Announces Exclusive Licensing Deal with Pierre Fabre for Idazoxan; Terran Completes Key Development Milestones","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Evotec","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ O.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"University Health Network","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ University Health Network","highestDevelopmentStatusID":"2","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with Wee1 Inhibitor Debio 0123 to Outsmart DDR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Announces First Patient Dosed with Imlifidase in A Global Pivotal Phase 3 Trial in Anti-Glomerular Basement Membrane (anti-GBM) Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Addresses COVID-19 Mutations with Broad-spectrum Neutralizing Antibody Products: SA55 Injection and Nasal Spray Approved for Clinical Trial in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SA55","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Files for Chikungunya Vaccine Authorization with Health Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Novel Drug Olverembatinib Recommended for a Breakthrough Therapy Designation in China for the Treatment of SDH-Deficient GIST, the Second BTD for the Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brand Institute Partners on Brand Name Development for FDA-Approved Nasal Spray to Reverse Fentanyl and Other Opioid Overdoses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"INBRX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Macitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA in Combination with Tagrisso in Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI\u00ae (CAN108) EMBARK Phase 2 Study in Biliary Atresia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat Chloride","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"A2B530","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"A2 Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches RFID-Enabled Rocuronium Bromide Injection, its First Product Compatible with Bluesight's KitCheck System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Rocuronium Bromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi USA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"DermBiont","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigos and Normalizing Pigmentation of the Skin with 0.8% SM-030 Topical Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruboxistaurin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb\u2019s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Marstacimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algiax Pharmaceuticals Announces Positive Interim Analysis of Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AP-325","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pha.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB has Activated all 38 Study Sites in the Phase IIb Study of Pirepemat Aiming to Improve Balance and Reduce Falls in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirepemat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vurolenatide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anika Completes Enrollment in Hyalofast\u00ae U.S. Pivotal Phase III Study Achieving Key Milestone","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Anika Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Ther.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CSTI-500","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ConSynance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rain Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"PYX-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AUM001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosci.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Initiates Recruitment of Travelan\u00ae Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Provides Akebia Therapeutics a Path Forward for Vadadustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Gets China NMPA Approval For ILUMETRI To Treat Moderate-To-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tildrakizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CDI-988","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Repirinast","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1\/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegtibatinase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Analog Pharma","sponsor":"Dipharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analog Pharma and Dipharma Announce US FDA Approval of Abbreviated New Drug Application (ANDA) of 20 mg Generic Nitisinone Capsules (temperature stable)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitisinone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Analog Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Analog Pharma \/ Dipharma","highestDevelopmentStatusID":"12","companyTruncated":"Analog Pha.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Imvotamab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I\/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AAV2\/5-hPDE6B","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coave Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"HB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterin Announces FDA Acceptance of An Investigator Sponsored IND To Treat a Patient with Prodromal Multisystem Atrophy (MSA) with ENT-01","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Squalamine Phosphate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enterin \/ .."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1\/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"N-acetylcysteine Amide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Ph.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Biosion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CDX-585","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celldex Therapeutics \/ Biosion","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist\u00ae Prefilled Syringe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Diazepam","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcuro Completes Enrollment of Sentinel Cohort in Phase 2\/3 Study of ABC008 for the Treatment of Inclusion Body Myositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"ABC008","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Abcuro, Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225 Dotatate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"GLY-200","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glyscend Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend T.."},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighField Biopharmaceuticals\u2019 HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"All-trans Retinoic Acid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField .."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Cataract Surgery Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"11","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BT051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adiso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Ther.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Launch Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving Hemodialysis","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pathalys Pharma \/ Launch Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys P.."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Study of Upadacitinib (RINVOQ\u00ae) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Elsubrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces XPOVIO\u00ae plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and\/or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"BRII-297","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"selectION","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SelectION Reports Safety Results from SAD Stage of SI-544 Phase Ib trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"si-544","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"selectION \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"selectION .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza plus Abiraterone Approved in the US for the Treatment of BRCA-mutated Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Brazikumab Development Programme","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Brazikumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AbbVie Inc","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves ABRYSVO\u2122, Pfizer\u2019s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Study Suggests the Use of OraPharma\u2019s ARESTIN\u00ae (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Approved","graph3":"ORAPHARMA","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"","amount2New":0,"dosageForm":"Microspheres, Sustained Release","sponsorNew":"ORAPHARMA \/ Bausch Health","highestDevelopmentStatusID":"12","companyTruncated":"ORAPHARMA .."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-0169","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Announces First Patient Dosed in Phase 1\/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa (Icosapent Ethyl) in Mainland China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ E.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces European Commission Approval for BRIUMVI (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ublituximab-xiiy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"T-knife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TK-8001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-knife \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Completes HAT-301 Registrational Trial for PAX-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BJT-778","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bluejay Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluejay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bluejay Th.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"S1p receptor agonist 1","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces Issuance of A Canadian Patent for Masitinib in The Treatment Of ALS With Protection Until 2037","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RenovoRx \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CMTX-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Athersys","sponsor":"The University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys\u2019 MultiStem\u00ae Following Hemorrhagic Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ The University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Studies of Pfizer\u2019s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aztreonam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Akeso","sponsor":"AD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Accepted Akeso's Ebronucimab (PCSK9) Marketing Application in two Cardiovascular Indications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ebronucimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ AD Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ AD.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VCA-894A","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"STP122G","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"PIKA Adjuvanted Inactivated Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company's First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Coated Pellets","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"NeuroTrauma Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NTS-105 Prodrug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTrauma Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NeuroTrauma Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTraum.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Positive Donidalorsen Late-stage Clinical Progress in HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Donidalorsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix (imlifidase) in Belgium as Desensitization Treatment for Highly Sensitized Patients in kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minoryx Gains FDA Approval to Initiate a Phase 3 Clinical Trial in Patients with Cerebral Adrenoleukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Leriglitazone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Minoryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Starts Phase II\/III Study with Vericiguat in Children with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Vericiguat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives European Approval for Cosentyx as First and Only IL-17A Inhibitor for Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 2 Data of Novel Investigational Anti-CD40L Antibody Frexalimab Show Significantly Reduced Disease Activity in Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Frexalimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Fidaxomicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tillotts Pharma AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tillotts P.."},{"orgOrder":0,"company":"Valensa International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valensa\u2019s Chief Science Officer Presents New Research on Efficacy of a Lipidosterolic Extract of Saw Palmetto","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Serenoa Repens Extract","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical","graph3":"Valensa International","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valensa International \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Valensa In.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Marketing Approval of CAN108 (LIVMARLI\u00ae) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat Chloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotec.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Windtree Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s DIFICID\u00ae (fidaxomicin) to Treat Clostridioides Difficile in Children Aged Six Months and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fidaxomicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Tillotts Pharma AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tillotts Pharma AG Announces That Dificlirtm (fidaxomicin) Is Recommended For The Treatment Of Clostridioides Difficile Infection (CDI) By Escmid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Fidaxomicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tillotts Pharma AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tillotts Pharma AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tillotts P.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$71.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lexicon pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Max Planck","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biondvax Signs Exclusive License Agreement for Development and Commercialization of a Novel Anti-IL-17 Antibody for Treatment of Autoimmune and Inflammatory Diseases Including Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"VHH-Antibody","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Max Planck","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Max Planck \/ BiondVax Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck.."},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for Gildeuretinol (ALK-001) in the Treatment of Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"Gildeuretinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pha.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$272.7 million","upfrontCash":"Undisclosed","newsHeadline":"ITM Announces \u20ac255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Everolimus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.27000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ Temasek","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Rafael Holdings","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Rafael Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"MEDIC Life Sciences","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"MEDIC Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MEDIC Life Sciences \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"MEDIC Life.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Neurogastrx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada Upon Termination of License Agreement With Neurogastrx","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Termination","leadProduct":"Fexuprazan","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Neurogastrx","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Medical Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M\u2122 Adjuvant as Potential Component in Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Bill & Melinda Gates Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Selvita S.A","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Oxford and Selvita Collaborate to Advance Potential Therapeutics for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Selvita S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selvita S.A \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Selvita S..."},{"orgOrder":0,"company":"VaxEquity","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"saRNA Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxEquity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VaxEquity \/ Innovate UK","highestDevelopmentStatusID":"1","companyTruncated":"VaxEquity .."},{"orgOrder":0,"company":"Oragenics","sponsor":"CQDM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"NT-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ CQDM","highestDevelopmentStatusID":"5","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Solve Therapeutics","sponsor":"Nerviano Medical Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Solve Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Solve Therapeutics \/ Nerviano Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Solve Ther.."},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimeric Announces Launch of New Phase 1B Glioblastoma Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Chlorotoxin CAR T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Chimeric Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chimeric Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chimeric T.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"The Sheffield Institute for Translational Neuroscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BEN-34712","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ The Sheffield Institute for Translational Neuroscience","highestDevelopmentStatusID":"5","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s Keytruda (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM1020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Harbour Bi.."},{"orgOrder":0,"company":"VivaVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VVN539 Met Primary Study Endpoints in US Phase IIa Clinical Study for The Treatment of Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VVN539","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"VivaVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2\/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM-1-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"PeptiDream","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AZP-3813","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amolyt Pharma \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ENT-03","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterin \/ .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1\/2 Trial Under Investigation for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway and Preservation of the Classical Pathway A Long-Acting Anti-Properdin Monoclonal Antibody NM3086 for PNH Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NM3086","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"WAL0921","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walden Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RAG-17","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANeuroTech Receives IND Approval from the FDA for Pivotal Phase IIIB Trial of Adjunctive Anti-Depression Drug, ANT-01","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pipamperone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ANeuroTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics\u2122 Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and\/or Refractory AML\/MDS Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse\u00ae for Treatment of Fibrotic Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics and Nestl\u00e9 Health Science Announce U.S. Commercial Availability of VOWST\u2122, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Andexanet Alfa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"FogPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FogPharma Announces First Patient Dosed in Phase 1\/2 Clinical Trial of First-in-class TCF-blocking \u03b2-catenin Inhibitor, FOG-001, in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FOG-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FogPharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma .."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"EVM301","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TLC-6740","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"HexaPro","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxas \/ N.."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Kelun-Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following \u2018Encouraging\u2019 Data on Next Generation Selective RET Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"A400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Kelun-Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INJECTAFER Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"STP705","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ABM-168","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Shanghai Escugen Biotechnology","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Escugen Biotechnology Co., Ltd., a Partner of Levena Biopharma, a Sorrento Company, Releases Positive Results From a First-in-Human Study of ESG401, a TROP2 Antibody Drug Conjugate in Patients with Locally Advanced\/metastatic Solid Tumors at the ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TROP2 Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Escugen Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Escugen Biotechnology \/ Levena Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai E.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR\/MSI-H Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"aVaxziPen","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Needle-free Vaccine Delivery Platform Aims To End Frozen Storage Needs And Improve Access","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Protein-based Vaccine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"aVaxziPen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aVaxziPen \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"aVaxziPen .."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Bezuclastinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Pricing of $7 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$287.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0.28999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.28999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"BIOKEY","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undislcosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merdury Pharmaceutical","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merdury Pharmaceutical \/ BioKey","highestDevelopmentStatusID":"3","companyTruncated":"Merdury Ph.."},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$65.2 million","upfrontCash":"Undisclosed","newsHeadline":"AAVantgarde Closes \u20ac61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"Usher1B-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AAVantgarde Bio","amount2":0.070000000000000007,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"AAVantgarde Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"AAVantgard.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Devonian Announces Closing of a Private Placement of $1.2 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Peter MacCallum Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propanc Biopharma Announces Strategic Pharma Partnering Initiative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Pancreatic Proenzyme","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Peter MacCallum Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS\u00ae T-Cell Therapy in Pediatric Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Autologous T Cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO\u00ae and EPSOLAY\u00ae in Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/.."},{"orgOrder":0,"company":"Thor Medical","sponsor":"Nordic Nanovector","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nordic Nanovector Announces Agreement to Acquire Thor Medical, an Emerging Producer of Alpha-emitters for Radiopharmaceuticals to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Radioimmunoconjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Thor Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thor Medical \/ Nordic Nanovector","highestDevelopmentStatusID":"1","companyTruncated":"Thor Medic.."},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Qu\u00e9bec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Islasertib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Thryv Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Thryv Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"6","companyTruncated":"Thryv Ther.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series D Financing","leadProduct":"Allogenic Gamma Delta T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"LianBio","sponsor":"QED Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ QED Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces First Patient Dosed in Phase 1\/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ONCT-808","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"University of Lausanne Hospitals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Announces Positive Phase I Trial Data for DengueTcP\u2122, Its Novel T Cell-Priming Immune Set-Point Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergex Vaccines Holding \/ University of Lausanne Hospitals","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VXA-G1.1-NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CM5480","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Completion of ANAVEX2-73 (blarcamesine) EXCELLENCE Phase 2\/3 Rett Syndrome Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Nevakar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyluma Announces FDA Acceptance of New Drug Application for NVK002, Its Novel Investigational Treatment for Pediatric Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ N.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TSC-200-A0201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Azenosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITabMed Announces The IND Approval From NMPA for A-337, a CD3-Activating Bispecific Antibody Targeting EpCAM To Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"A-337","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tianweiyuanhe Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tianweiyuanhe Biomedical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tianweiyua.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI\u00ae (ciltacabtagene autoleucel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Receives Notice of Allowance for Patent on Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphera Announces a Positive Opinion of the European Medicines Agency on the Granting of Orphan Medicinal Product Designation for MesoPher in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Autologous Dendritic Cells Loaded PheraLys","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amphera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amphera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amphera \/ .."},{"orgOrder":0,"company":"BPGbio","sponsor":"Berg Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Berg Health","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ B.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves New Indication for Merck\u2019s PREVYMIS (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Letermovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ Treatment for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-ALZ","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"QRL-201","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"QurAlis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Announces FDA Clearance of IND Application for OQL051, for the Prophylaxis of Chemotherapy-Induced Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"OQL051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn\u00ae Biologics License Application Scheduled for September 27, 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MSC-NTF Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Major Life Saving Drugs Program Funding for Rare Genetic Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Eliglustat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Authorises GSK\u2019s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives New European Commission Approvals for BIMZELX (bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isu Abxis, Ranked First for Two Consecutive Years in the Algerian Gaucher Disease Treatment Bidding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Imiglucerase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"ISU ABXIS","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ISU ABXIS .."},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isu Abxis Expects 100% Exclusive Treatment for Gaucher Disease in Algeria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Imiglucerase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"ISU ABXIS","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ISU ABXIS .."},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bitterroot Bio Launches Out of Stealth with $145 Million Series A Financing to Develop Transformative Medicines in Cardio-immunology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0.14999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Bitterroot Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"AMRMC","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Receives Army Medical Research Grant for Study on Mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Galantamine Prodrug","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Cognition \/ AMRMC","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Aegis Life","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"DNA-encoded Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aegis Life","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aegis Life \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aegis Life.."},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"MTX-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Mozart Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Mozart Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mozart The.."},{"orgOrder":0,"company":"Hopewell Therapeutics","sponsor":"Mass Ave Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hopewell Therapeutics Announces $25 Million Seed Financing to Advance Next Generation Lipid Nanoparticles for Targeted Delivery of Genomic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"LNPmRNA-based Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hopewell Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Hopewell Therapeutics \/ Mass Ave Capital","highestDevelopmentStatusID":"3","companyTruncated":"Hopewell T.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Lotus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"$10.0 million","newsHeadline":"NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration for the Development and Commercialization of NRX-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Lotus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VTX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Deflazacort","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-line Patients with Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Additional, Positive Top-Line Results from Phase 2 Randomized Clinical Trial of BX1000","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b\/2 Randomized Trial of Doxorubicin +\/- LIXTE Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAR\u2019579 \/ IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IPH6101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lunresertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Repare Therapeutics \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Epoxyestrenolone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"DTx-1252","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DTx Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Curasight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curasight A\/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Peptide-based Radioligand Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Curasight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Curasight \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Curasight .."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Files Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer\u2019s Disease in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Walloon Region","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris has been Granted EUR 1 Million in Non-Dilutive Funding from the Walloon Region","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"HY-083","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hyloris Pharmaceuticals \/ Walloon Region","highestDevelopmentStatusID":"4","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"PoloMar Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PaxMedica Enters Research Collaboration Agreement with PoloMar Health for Phase II Study in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Emodin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PaxMedica \/ PoloMar Health","highestDevelopmentStatusID":"4","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,094.2 million","upfrontCash":"$72.3 million","newsHeadline":"Continued Strong Cresemba\u00ae (isavuconazole) Sales by Pfizer Trigger USD 26 Million Sales Milestone Payments to Basilea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":1.0900000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":1.1000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Mendus","sponsor":"Flerie","pharmaFlowCategory":"D","amount":"$29.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mendus Announces a Directed Share Issue and a Fully Secured Rights Issue of Units Totaling Approximately SEK 317 Million in Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Vididencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Flerie","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ F.."},{"orgOrder":0,"company":"Endoceutics","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cosette Pharmaceuticals Acquires Intrarosa\u00ae from Endoceutics, Inc.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Prasterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Endoceutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Insert","sponsorNew":"Endoceutics \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Endoceutic.."},{"orgOrder":0,"company":"Acrobat Genomics","sponsor":"Stanford Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acrobat Genomics, NanoString, and Illumina Accelerator Collaborate with Stanford Medicine to Discover New Drug Targets for Gene Editing-Based Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"Acrobat Genomics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acrobat Genomics \/ Stanford Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Acrobat Ge.."},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Neutron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aviko Radiopharmaceuticals and Neutron Therapeutics Form Strategic Partnership to Advance Boron Neutron Capture Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Boron Neutron Capture Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aviko Radiopharmaceuticals \/ Neutron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radi.."},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"UPB-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream Bio","amount2":0.20000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Upstream Bio \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Upstream B.."},{"orgOrder":0,"company":"Iktos","sponsor":"Curreio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curreio and Iktos Announce Collaboration in New Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Iktos","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Curreio","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Cu.."},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kate Therapeutics Debuts with $51 Million Series A to Develop Next-generation Genetic Medicines to Treat Muscle and Heart Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Kate Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Kate Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"2","companyTruncated":"Kate Thera.."},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kate Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kate Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kate Thera.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$411.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and Pfizer Announce Strategic Collaboration for Long-Term Manufacturing of Biosimilars Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,085.0 million","upfrontCash":"$85.0 million","newsHeadline":"Astra Zeneca Announces Agreement with Quell Therapeutics to Develop, Manufacture and Commercialise Engineered T-Regulatory Cell Therapies for Autoimmune Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Treg-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Quell Therapeutics","amount2":2.0899999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.0899999999999999,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Quell Ther.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Bielefeld University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Leverages AI Platform, RADR\u00ae, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Cryptophycin Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Bielefeld University","highestDevelopmentStatusID":"2","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Itreas","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics' Dual-Acting Factor XI\/XIa Inhibitor Abelacimab","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Itreas","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Large Phase 3 Clinical Trial Successfully Meets Primary Endpoint, Confirming the Potential of ALKs House Dust Mite Tablet in Young Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dendritic-Cell Therapeutic Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Announces Interim Data from the ARV-766 Phase 1\/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ARV-766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"LianBio","sponsor":"Tarsus Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LianBio \/ Tarsus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaliq Announces FDA Approval of Vevye (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"PIPE-791","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Techdow USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Techdow USA Announces Launch of its Generic Lovenox, (Enoxaparin Sodium \u2013 Preservative Free) in Prefilled Syringes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Techdow USA","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Techdow USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Techdow US.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RP-A601","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Merck\u2019s Keytruda (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Unanimously Recommended by FDA Advisory Committee for the Prevention of RSV Lower Respiratory Tract Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Submits New Drug Application for Zolbetuximab in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"NRx Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Chongqing Zhifei Biological Products","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$14,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"MSD and Zhifei Renew Collaboration on Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Recombinant Human Papillomavirus Quadrivalent Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chongqing Zhifei Biological Products","amount2":14.800000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":14.800000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Chongqing Zhifei Biological Products \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Chongqing .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Roches Subcutaneously Administered Crovalimab Achieved Disease Control and was Well-Tolerated in People with Paroxysmal Nocturnal Haemoglobinuria (PNH)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Yet Another \u201cFirst Cycle\u201d FDA Approval for an Abbreviated New Drug Application (ANDA), Dexmedetomidine Hydrochloride Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Milla Phar.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Approves FoundationOneLiquid CDx as a Companion Diagnostic for Pfizer\u2019s BRAFTOVI\u00ae (encorafenib) in Combination with Cetuximab to Identify Patients with BRAF V600E Alterations in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Starts Trial to Generate Data on Effect of Saroglitazar Mg in NAFLD Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Saroglitazar magnesium","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renhui Bio Announced that the Application for the Marketing of Benaglutide Injection for Weight Loss Indications has been Accepted in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Beinaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Shanghai Renhui Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Renhui Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai R.."},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Clinical Application for the New Pump Administration Method of Benaglutide for Weight Loss Indications was Approved","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Beinaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Shanghai Renhui Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Renhui Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai R.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danicopan as Add-on to Ultomiris or Soliris Improved Haemoglobin Levels and Maintained Disease Control in Patients with PNH Experiencing Signs or Symptoms of Clinically Significant Extravascular Haemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$3,500.0 million","upfrontCash":"$3,500.0 million","newsHeadline":"Novartis Bolsters Innovative Medicines Strategy and Renal Pipeline with Agreement to Acquire Chinook Therapeutics for USD 3.2bn Upfront (USD 40 \/ share)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":3.5,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":3.5,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.10000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Galactomannan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Ray Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AAV.7m8","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adverum Biotechnologies \/ Ray Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Genelux","sponsor":"Benchmark Company","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genelux Corporation Announces $18 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Beacon Therapeutics Launches with \u00a396 Million ($120 million) to Develop a New Generation of Gene Therapies for Retinal Diseases Resulting in Blindness","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Recombinant Adeno-associated Virus Vector","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Beacon Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Beacon The.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Curigin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Curigin Collaborate to Produce Oncolytic RNAi Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Genetically Engineered Adenovirus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Curigin","highestDevelopmentStatusID":"4","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Vincere Biosciences","sponsor":"Hanall Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vincere Biosciences Announces Strategic Investment From Daewoong Pharmaceutical and HanAll Biopharma to Foster Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Vincere Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincere Biosciences \/ HanAll Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Vincere Bi.."},{"orgOrder":0,"company":"Eccogene","sponsor":"New Alliance Capital","pharmaFlowCategory":"D","amount":"$25.1 million","upfrontCash":"Undisclosed","newsHeadline":"Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"ECC5004","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Eccogene","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ New Alliance Capital","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/.."},{"orgOrder":0,"company":"CancerVAX","sponsor":"UCLA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CancerVAX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CancerVAX \/ UCLA","highestDevelopmentStatusID":"2","companyTruncated":"CancerVAX .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1\/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1\/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ChAdOx1-PCAQ","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Launches Quviviq (Daridorexant) In Switzerland \u201c A First-In-Class Treatment For Chronic Insomnia Disorder To Improve Both Nighttime Symptoms And Daytime Functioning","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Announces FDA Approval Of New Indication For Linzess (Linaclotide) For The Treatment Of Functional Constipation In Pediatric Patients Ages 6-17 Years-Old","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironwood Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Receives U.S. FDA Approval of Drug Substance Manufacturing Scale-up Process for Gene Therapy ADSTILADRIN (nadofaragene firadenovec-vncg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nadofaragene Firadenovec-vncg","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capivasertib In Combination With Faslodex (Fulvestrant) Granted Priority Review In The Us For Patients With Advanced Hr-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Futura Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MED3000","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Futura Medical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Futura Med.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aardvark Therapeutics Reports Positive Phase II Clinical Data for ARD-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Denatonium Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark T.."},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Utidelone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Bi.."},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma-Pharma Announces Enrollment of First Patient in Hyaluronic Acid Dermal Filler Clinical Trial in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Croma-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Phar.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches PREVDUO (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Neostigmine Methylsulfate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved In China For The Treatment Of Adults With Refractory Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Biotech Announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"ALA-002","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla B.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"$96.0 million","newsHeadline":"Advanz Pharma Corp. Limited Closes Acquisition of the Rights to a Portfolio of Alprostadil Products from UCB S.A. for $83 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$137.2 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.14000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"vitaCare Prescription Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agile Therapeutics Announces New Agreement with vitaCare\u00ae Prescription Services to Improve Access to Twirla\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ vitaCare Prescription Services","highestDevelopmentStatusID":"12","companyTruncated":"Agile Ther.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces $8 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna and Langara College Announce Cannabinoid-based Translational Research Collaboration and NSERC Grant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Applied Research Centre at Langara College","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"$12.0 million","newsHeadline":"Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"Bacteriophage-based Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Future Fields","sponsor":"Jenthera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Future Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"CRISPR Based Ribonucleoprotein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Future Fields","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Future Fields \/ Jenthera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Future Fie.."},{"orgOrder":0,"company":"Novaliq","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Senju Pharmaceutical and Novaliq Enter into License Agreement for NOV03 (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of Dry Eye Disease in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Perfluorohexyloctane","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Novaliq \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Moat Biotechnology","sponsor":"Cortado Ventures","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Moat Biotechnology Raises $6.5M in First Close for Intranasal\/Inhaled Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moat Biotechnology","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Moat Biotechnology \/ Cortado Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Moat Biote.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Turnstone Biologics Files for $86M IPO Amid Financial Difficulties","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Texcell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valo Therapeutics \/ Texcell","highestDevelopmentStatusID":"6","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Nod for Alembic\u2019S Generic Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces European Commission Approval for Expanded Use of Erleada\u00ae\u25bc (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis\u2019 Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) in Combination with OPDIVO\u00ae (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces Positive Topline Results From The Investigator-Initiated Phase II Clinical Trial Evaluating Lanifibranor In Patients With T2D And NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1\/2 Clinical Trial of LX2006 for the Treatment of Friedreich\u2122s Ataxia Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Zunsemetinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed\/Refractory AML or Higher Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"OLX72021","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Announces ADCETRIS (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces First Patient Dosed in Phase 1-2 Clinical Study of its First-in-Class \u03b2-catenin Antagonist, ST316, in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ST316","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Breakthrough Discovery in Microdosing Clinical Trial Reveals Significant Positive Effects on Quality Of Sleep","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ \/ HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Z-endoxifen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Bylvay For Patients Living With Cholestatic Pruritus Due To Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files New Drug Application in Japan for Crovalimab for Paroxysmal Nocturnal Hemoglobinuria","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$11,700.0 million","upfrontCash":"$11,700.0 million","newsHeadline":"Finalization of Vifor Pharma Acquisition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":11.699999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":11.699999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Bridgewest Group","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Immix Biopharma \/ Bridgewest Group","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmu.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"CancerVAX","sponsor":"StartEngine","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CancerVAX Launches $10 Million Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Cancer Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CancerVAX","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"CancerVAX \/ StartEngine","highestDevelopmentStatusID":"2","companyTruncated":"CancerVAX .."},{"orgOrder":0,"company":"Invirsa","sponsor":"CincyTech","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"Undisclosed","newsHeadline":"Invirsa Completes $7.7M Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"INV-102","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution\/Drops","sponsorNew":"Invirsa \/ CincyTech","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen Lines up Potential Deal for ALS Drug, Doubling Down on Neurofilament Biomarker","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Cullgen","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$35.0 million","newsHeadline":"Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Cullgen \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives USFDA\u2019s Final Nod for Varenicline Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Exaluren Sulfate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA\u00ae in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CAL02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Seagen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS\u00ae (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ T.."},{"orgOrder":0,"company":"EyeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeBio Announces First Patients Dosed in Phase 1b\/2 Trial of Restoret\u2122 in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"EYE103","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyeBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ N.."},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Arginine Vasopressin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Fresenius Kabi USA","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU\u00ae, a Ready-to-Use Oncology Injectable","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"SC-DARIC33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"MindRank","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MDR-001","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MindRank","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindRank \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MindRank \/.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Statement Regarding Submission of Application Seeking Approval for a Generic to Tyrvaya\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Vyriad","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vyriad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vyriad \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vyriad \/ R.."},{"orgOrder":0,"company":"TearClear","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TearClear Announces the Successful Initiation of Its TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"TearClear \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear .."},{"orgOrder":0,"company":"TearClear","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"TearClear","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"TearClear \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TearClear .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Late-Breaking Data from Phase III COMBI-i Trial of Spartalizumab (PDR001) with Tafinlar\u00ae and Mekinist\u00ae in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Long-Term, Relapse-Free Survival Benefit for High-Risk, Stage III Melanoma Patients Treated with Tafinlar\u00ae + Mekinist\u00ae Following Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clene Announces Launch of Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$59.1 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Beyond Air","sponsor":"Avenue Capital Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beyond Air\u00ae Secures up to $40 Million Debt Financing","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Beyond Air","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Beyond Air \/ Avenue Capital Group","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Air.."},{"orgOrder":0,"company":"Hebrew University","sponsor":"Beyond Air","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beyond Air\u00ae Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"7-Nitroindazole","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hebrew University","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hebrew University \/ Beyond Air","highestDevelopmentStatusID":"4","companyTruncated":"Hebrew Uni.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$22.7 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Helocyte","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"CMV-MVA Triplex Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Helocyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Helocyte \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Helocyte \/.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Verastem Oncology \/ RBC Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"GPCR Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Pricing of Initial Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Strain of Staphylococcus Epidermidis","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ T.."},{"orgOrder":0,"company":"Flamingo Therapeutics","sponsor":"VLAIO","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Flamingo Therapeutics Receives \u20ac1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Danvatirsen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Flamingo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Flamingo Therapeutics \/ VLAIO","highestDevelopmentStatusID":"8","companyTruncated":"Flamingo T.."},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neuvivo Raises $11M in Venture Financing to Develop Treatment for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"NP001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ .."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"$60.0 million","newsHeadline":"Verve Establishes Global Collaboration with Lilly to Advance Verve\u2019s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Lipoprotein","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene's CNM-Au8 Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1\/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ASCEND-NASH Trial of Rencofilstat","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANAVEX\u00ae2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Upifitamab Rilsodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"BCI Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Announces New Positive Preclinical Data from CSF-1R Inhibitor Program","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ BCI Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS\u00ae (mavacamten) Label","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS (Omaveloxlone) NDA Prior Approval Supplement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VRG50635","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Exceeds 150 Injectable Medicines in The US with Launch of Dobutamine Injection, USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dobutamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces the U.S. FDA Approval of 9MW3811 for IND","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW3811","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma Announces FDA Clearance to Initiate a Phase I\/II Study for NS-050\/NCNP-03, an Exon 50 Skipping Candidate for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NS-050\/NCNP-03","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AVB-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avenge Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avenge Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avenge Bio.."},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approved Utidelone Injectable (UTD1) Phase 2\/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Utidelone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Bi.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Risankizumab (SKYRIZI) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Confirms Taflotan\u2019S Efficacy in Reducing Intraocular Pressure, Inhibiting Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paliperidone Extended-Release Tablets Obtains Drug Registration Approval","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"CSPC Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"CSPC Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSPC Pharm.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Paliperidone Extended-Release Tablets in The United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval From U.S. FDA for Paliperidone Extended-Release Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Paliperidone Palmitate 6-Month (P6M) Supplemental New Drug Application to U.S. FDA for Treatment Of Schizophrenia in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Extension to the European Medicines Agency to Register Paliperidone Palmitate 6-Monthly (Pp6M) For Treatment of Schizophrenia in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces U.S. Fda Approval of Invega Hafyera\u2122 (6-Month Paliperidone Palmitate), First and Only Twice-Yearly Treatment For Adults With Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for Byannli\u00ae (6-Monthly Paliperidone Palmitate) for the Maintenance Treatment of Schizophrenia in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Application For Luye Pharma'S Paliperidone Palmitate Injection (LY03010) Accepted In China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019S Innovative Formulation LY03010 Begins Pivotal Study in the U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019S Innovative Formulation LY03010 Meets Endpoints in Pivotal U.S. Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma Receives Clinical Trial Approval in Europe For Its Innovative Formulation Paliperidone Palmitate Long-Acting Injection LY03010","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Approval For Byannli","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Achievement of Statistical Significance For Primary Endpoint And All Secondary Endpoints In Phase 3 Invigorate\u20112 Trial Of Reproxalap in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Extension Of Fda Review Period For Momelotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda and Hutchmed Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Pricing of Approximately $8.5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clene Announces Pricing of $40 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"$25.0 million","newsHeadline":"Coherus to Acquire Surface Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Coherus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$10,800.0 million","upfrontCash":"$10,800.0 million","newsHeadline":"Merck Completes Acquisition of Prometheus Biosciences, Inc.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Tulisokibart","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Prometheus Biosciences","amount2":10.800000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":10.800000000000001,"dosageForm":"Infusion","sponsorNew":"Prometheus Biosciences \/ Merck & Co. Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Mandos Health","sponsor":"INPDR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"International Niemann-Pick Disease Registry and Mandos Health Announce New Research Collaboration Using Real-World Data to Evaluate the Treatment Effects of VTS-270 To Manage Niemann-Pick type C1","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Adrabetadex","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Mandos Health","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mandos Health \/ INPDR","highestDevelopmentStatusID":"9","companyTruncated":"Mandos Hea.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biomm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara\u00ae Biosimilar","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bio-Thera Solutions \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Cholesgen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cholesgen to Enter into a Drug Discovery Collaboration and Licensing Option Agreement in Hypercholesterolemia with AstraZeneca","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cholesgen","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cholesgen \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Cholesgen .."},{"orgOrder":0,"company":"Lucis Pharma","sponsor":"Rosemont","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rosemont Expands its Offering with Portfolio Acquisition from Lucis Pharma Ltd","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Alimemazine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Lucis Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lucis Pharma \/ Rosemont","highestDevelopmentStatusID":"12","companyTruncated":"Lucis Phar.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd Line Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche's Columvi, the First and Only Bispecific Antibody with a Fixed-Duration Treatment for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Glofitamab-gxbm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Galcanezumab-gnlm","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The U.S. FDA Approved the Phase I\/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16\/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LBL-033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biol.."},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TGI-6","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TG ImmunoPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoP.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval From USFDA For Pimavanserin Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval From USFDA For Pimavanserin Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Gets SEC Nod For Phase III Clinical Trial For Antipsychotic Drug Pimavanserin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID\u00ae (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer\u2019s Disease Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID\u00ae (pimavanserin) for the Treatment of Alzheimer\u2019s Disease Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Plan for a Resubmission of Its Supplemental New Drug Application to U.S. FDA for NUPLAZID\u00ae (pimavanserin)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IASO-782","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves EPIDIOLEX (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Greenwich Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Greenwich Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Gets NICE Backing for Its Cannabinoid-Based Medicine","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx\u2122 for the Treatment of Recurrent Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx\u2122 in a Model of Acute Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx\u2122 for Treatment of Acute Myocarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx\u2122 for Recurrent Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx\u2122 for Acute Myocarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx\u2122 for Acute Myocarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Receptor Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Receptor Life Sciences Announces Initiation of IND-Opening Clinical PK Study of RLS102 for Irritability in Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Receptor Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Receptor Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Receptor L.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Department of Health - Abu Dhabi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Department of Health - Abu Dhabi, M42 and AbbVie Enter a Strategic Partnership to Advance Personalised Medicine and Genomics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Precision Medicine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Department of Health - Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"$231.0 million","upfrontCash":"$90.0 million","newsHeadline":"Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.23000000000000001,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Adaptive Clinical Trial of P140 (Lupuzor) in Lupus to Commence Following FDA Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Forigerimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ImmuPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir's Patent Application for Fostrox Approved in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AG-80308","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allgenesis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Allgenesis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allgenesis.."},{"orgOrder":0,"company":"TG ImmunoPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG ImmunoPharma Announces FDA Approval for Clinical Trial of TGI-6 Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TGI-6","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TG ImmunoPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TG ImmunoPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TG ImmunoP.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"STP705","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Coacillium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Hea.."},{"orgOrder":0,"company":"Freya Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Pharma Solutions Announces Response from the FDA on its US Clinical Development Program of LybridoTM for the treatment of Female Sexual Interest\/Arousal Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Freya Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Immediate Release","sponsorNew":"Freya Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Freya Phar.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Empasiprubart","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Invios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"invIOs Presents Exciting Preclinical Data Showing that Immune-Activating Small Molecule INV501 Induces Strong Cytotoxic Activity Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"INV501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invios \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ N.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Olorofim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Puts Phase IIb ALLOB Trial on Hold","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Bone Cell Therapy","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod for Generic Acne-treating Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharma Major Lupin Launches Injection to Cure Thiamine Deficiency in US","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Thiamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Welton Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lubrizol Licenses Award-Winning Apisolex\u2122 Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lubrizol Life Science Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lubrizol Life Science Health \/ Welton Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lubrizol L.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Vitruvias Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher and Vitruvias Enter into Collaboration Agreement for Commercialization of KETARX\u2122 (racemic ketamine) in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Vitruvias Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pharvaris Announces $70 Million Private Placement Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Deucrictibant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Immediate Release Capsule","sponsorNew":"Pharvaris \/ General Atlantic","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed\/Refractory B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AC0676","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AccutarBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AL1211","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AceLink Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Th.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"FSHD Society","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ FSHD Society","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Allopregnanolone Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Surmodics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"$25.0 million","newsHeadline":"Surmodics Receives FDA Approval for the SurVeil\u2122 Drug-Coated Balloon","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Surmodics","amount2":0.089999999999999997,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Surmodics \/ Abbott Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Surmodics .."},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nelivaptan","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"HMNC Brain Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain.."},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Frazier","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Attovia Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Attovia Therapeutics \/ Frazier","highestDevelopmentStatusID":"3","companyTruncated":"Attovia Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s TALZENNA in Combination with XTANDI Receives U.S. FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Talazoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ TFS Trial Form Support","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson\u2019s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"AGEPHA Pharma US","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AGEPHA Pharma US","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AGEPHA Pharma US \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AGEPHA Pha.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 has Enrolled 29 Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Closing of Initial Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ T.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"AX-5006","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axial Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Arcellx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcellx Announces Clinical Hold for Its IMMagine-1 Phase 2 Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CART-ddBCMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults 65 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CHIKV VLP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Vivo Capital","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Swissmedic Approval of Vafseo (vadadustat)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Commences COMBAT Theranostic Prostate Cancer Trial in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Copper-64 SAR Bombesin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CVGBM","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,400.0 million","newsHeadline":"Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":2.3999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Jadeite Medicines","sponsor":"Albireo Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Jadeite Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jadeite Medicines \/ Albireo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Jadeite Me.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Closing of Approximately $8.5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"DLX-001","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04 in Alzheimer\u2019s Disease Treatment in Poland, Bulgaria, and Slovakia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Alphamab Oncology","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"DNL310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP-323","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Halozyme Therapeutics \/ argenx","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"IBMP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex and Brazil's IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"EMX-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergex Vaccines Holding \/ IBMP","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-In-Class Oral Mrgprx2 Antagonist for Mast Cell Mediated Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Announces the First Patient has Received FDA-Approved HEMGENIX\u00ae (etranacogene dezaparvovec-drlb) for Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"$2,050.0 million","upfrontCash":"$450.0 million","newsHeadline":"uniQure Announces Achievement of $100 Million Milestone Related to Hemophilia B Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Uniqure","amount2":2.0499999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"12","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$593.0 million","upfrontCash":"$90.0 million","newsHeadline":"SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0.58999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (SCD) 12 Years and Older with a History of Vaso-Occlusive Events","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MHB036C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulator Approves First Omicron-Specific MRNA Vaccine from India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replay and MD Anderson Announce FDA Clearance of IND Application for First-in-class T-Cell Receptor Natural Killer (TCR-NK) Cell Therapy for Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NY-ESO-1 TCR\/IL-15 NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Receives \u20ac1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi\u00ae in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"OSE2101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"University of Tennessee Health Science Center","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Veru Inc.'s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"University of Tennessee Health Science Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Tennessee Health Science Center \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"12","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"AlloVir Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse\u2122 Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"PTC518","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Update on U.S. Phase I\/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"PharmaLogic","sponsor":"UPMC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UPMC and PharmaLogic Partner to Develop Novel Radiopharmaceuticals at New Facility in Pittsburgh","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Radiopharmaceutical","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PharmaLogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaLogic \/ UPMC","highestDevelopmentStatusID":"2","companyTruncated":"PharmaLogi.."},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AISA Pharma Announces Start of Phase 2b Profervia Study for Raynaud's Phenomenon in Systemic Sclerosis (SSc)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cilnidipine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Aisa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharm.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Full Approval for Blincyto (Blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMP Pharma, Inc Announces that Liqrev, the First and Only Ready-made FDA-approved Liquid Suspension of Sildenafil is Now Available","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma.."},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teikoku Pharma Granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Teikoku Pharma USA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Teikoku Pharma USA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Ph.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","amount":"$37.5 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Therapeutics Announces $37.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Therapeutics Announces that the FDA has Removed the Clinical Hold on DM199 Phase 2\/3 Trial for Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Provides Regulatory Update on ADX-2191","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Itruvone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Shares Positive Data for Arexvy, its Respiratory Syncytial Virus (RSV) Older Adult Vaccine, Indicating Protection Over Two RSV Seasons","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Centers for Disease Control and Prevention\u2019s Advisory Committee on Immunization Practices Votes to Recommend Arexvy for the Prevention of RSV Disease in Adults Aged 60 and Older with Shared Clinical Decision Making","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"SC0062","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients with Hypothyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"TGW101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tagworks Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Tagworks Pharmaceuticals \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tagworks P.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Vaneltix Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Hyloris Pharmaceuticals \/ Vaneltix Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Announces Vascepa (icosapent ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Empress Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Empress Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Empress Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"2","companyTruncated":"Empress Th.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IBT Continues to Recruit Prematurely Born Infants to the Connection Study Following a Planned Safety Analysis.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Ozette Technologies","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ozette Technologies Announces New Collaboration with Umoja Biopharma to Accelerate Biomarker Discovery in Preclinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ozette Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ozette Technologies \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Ozette Tec.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Start Phase III Study with Finerenone in Adults with Chronic Kidney Disease and Type 1 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Jardiance (Empagliflozin) for the Treatment of Type 2 Diabetes in Children 10 Years and Older","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Zenyaku Kogyo","pharmaFlowCategory":"D","amount":"$138.5 million","upfrontCash":"$12.0 million","newsHeadline":"ASLAN Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0.14000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Aeglea BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"SPY001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Spyre Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spyre Therapeutics \/ Aeglea BioTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Spyre Ther.."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Talaris Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tourmaline Bio \/ Talaris Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"212Pb-NG001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ARTBIO \/ F-Prime Capital","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ F.."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cimeio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs\u2122 for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"CD117-shielded Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Cimeio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"University of Maryland","sponsor":"NICO Corporation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"New ENRICH-PLUS Study Builds on World's First Positive Clinical Trial for Hemorrhagic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Pioglitazone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"University of Maryland","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Maryland \/ NICO Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Cereius","sponsor":"Solve Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solve Therapeutics, Inc. Acquires Cereius, Inc., a Duke University Spin-Out","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Radionuclide Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cereius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cereius \/ Solve Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cereius \/ .."},{"orgOrder":0,"company":"Psylo","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psylo Announces Sponsored Research Agreement with Daiichi Sankyo to Develop Non-hallucinogenic Psychiatric Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Psychiatric Medicine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Psylo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psylo \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Psylo \/ Da.."},{"orgOrder":0,"company":"Tagworks Pharmaceuticals","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"TGW101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tagworks Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Tagworks Pharmaceuticals \/ Ysios Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tagworks P.."},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NephroDI Therapeutics Enters Agreement to Develop a First-in-Class Treatment for a Genetic, Rare Disease of the Kidneys","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"NDI-5001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NephroDI Therapeutics \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI T.."},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"LadRx","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"LadRx \/ XO.."},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Peptide Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"IRBM","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRBM \/ Merck & Co. Inc.","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Mer.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$157.8 million","upfrontCash":"Undisclosed","newsHeadline":"Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.16,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"MAPS","sponsor":"Steven & Alexandra Cohen Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MAPS","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"","sponsorNew":"MAPS \/ Steven & Alexandra Cohen Foundation","highestDevelopmentStatusID":"10","companyTruncated":"MAPS \/ Ste.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"IGM Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$63.3 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$50.0 million","newsHeadline":"Kite Announces Completion of Marketing Authorization Transfer for Yescarta\u00ae CAR T-cell Therapy in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"WraSer Pharmaceuticals","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"$8.5 million","newsHeadline":"Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Levoamlodipine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"WraSer Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"WraSer Pharmaceuticals \/ Blue Water Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"WraSer Pha.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Fairmount Funds Management","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"SPY001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Aeglea BioTherapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Fairmount Funds Management","highestDevelopmentStatusID":"4","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Nilotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"The Medici.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apogee Takes Aim at Regeneron, Lilly as it Readies IPO","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Jackson Investment Group","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"NSC-CRAd-S-pk7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Calidi Biotherapeutics \/ Jackson Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psychedelics Company Silo Pharma Working on Time-Release and Dosage Ketamine Implant and Topical, Hoping to Deliver Steady Pain Relief for Four Million Fibromyalgia Sufferers","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Silo Pharma \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"ASEP Medical","sponsor":"NMIN","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Asep Inc. Receives Grant from NanoMedicines Innovation Network (NMIN), Funded by the Government of Canada","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Nanoparticle-formulated Peptide Solution","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"ASEP Medical","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"ASEP Medical \/ NMIN","highestDevelopmentStatusID":"4","companyTruncated":"ASEP Medic.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announced the Global Multi-Regional Registration Trial of Anti-PD-1 Antibody Nofazinlimab in Combination with Lenvatinib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma Successfully Reached the Prespecified Enrollment Ta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharma Launches Generic Lenvatinib for Cancer Patients in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"COM701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec-rokl","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TTI-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Palleon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Palleon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Cocrystal","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA\u00ae (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Updates on a Phase 1b\/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Rilpivirine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Start Phase III Study with Finerenone in Adults with Chronic Kidney Disease and Type 1 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for \u2018B-Cell Lymphomas\u2019","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Starts U.S. Pivotal Phase II\/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BKV Neutralising Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1273.815","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ERAS-801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneration and Reinnervation of Spinal Cord in Rats Treated with NurExone's Intranasal ExoPTEN","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Exosome","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"UB-312","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX-100 for Prevention of Abdominal Colorectal Surgical Site Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060\/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Elarekibep","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pieris Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Union Therapeutics Announces Positive Topline Results from the Osiris Investigator-Initiated Proof-of-Concept Study of Oral Orismilast In Patients With Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Orismilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepcludex (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zejula (Niraparib) is the First and Only Once-Daily PARP inhibitor FDA-Approved as a First-Line Monotherapy Maintenance Treatment for Women With Advanced Ovarian Cancer Regardless of Biomarker Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Submission of GSK\u2019s Marketing Authorisation Application for Zejula (niraparib) in First-line Maintenance Treatment for Women with Platinum-responsive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Zejula (niraparib) as the Only once-daily PARP inhibitor in First-line Monotherapy Maintenance Treatment for Women With Platinum-responsive Advanced Ovarian Cancer Regardless of Biomarker Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atogepant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance Recommended for the Treatment of Adults With Chronic Kidney Disease in the EU","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Pfizer's Hair Loss Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ritlecitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Receives CHMP Positive Opinion for Trodelvy in Pre-Treated HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Receives CHMP Negative Opinion on Its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyltezo, First Interchangeable Biosimilar to Humira, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"CMP Pharma, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CMP Pharma, Inc Announces that Atorvaliq, the First and Only FDA-approved Liquid Suspension of Atorvastatin is Now Available","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atorvastatin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CMP Pharma, Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CMP Pharma, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CMP Pharma.."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orsini Specialty Pharmacy Now Dispensing VOWST (fecal microbiota spores, live - brpk) Capsules for Oral Administration for the Prevention of Recurrence of C. Difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orsini Specialty Pharmacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LX9211","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Anti-chitinase 1","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Molecure","sponsor":"Galapagos","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"OATD-01","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Molecure \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS\u00ae Selected Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"HFB200301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Receives Positive CHMP Opinion for New Adtralza (tralokinumab) Injection Device","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Qpex Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$24.0 million","newsHeadline":"Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"BRII-693","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brii Biosciences \/ Qpex Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"Qpex Biopharma","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$100.0 million","newsHeadline":"Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"QPX2015","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Qpex Biopharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Qpex Biopharma \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Qpex Bioph.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT\u00ae (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"CARE Pharma Shanghai Ltd.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Omoprubart","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ CARE Pharma Shanghai Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Immunotherapeutics Achieves Landmark Milestone with Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan\u2019s Ministry of Health, Labour and Welfare Approves Shingrix for the Prevention of Shingles in at-risk Adults Aged 18 and Over","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Zoster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives Positive CHMP Opinion Recommending Authorisation of Daprodustat for Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Daprodustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Recommended for Approval in the EU by CHMP for Children and Adolescents with Refractory Generalised Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Fiocruz","sponsor":"Nortec Quimica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fiocruz and Nortec Quimica Launch Partnership Against Chagas Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Partnership","leadProduct":"Benznidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fiocruz","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fiocruz \/ Nortec Quimica","highestDevelopmentStatusID":"8","companyTruncated":"Fiocruz \/ .."},{"orgOrder":0,"company":"Pendulum Therapeutics","sponsor":"Fonterra Co-operative Group","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pendulum Therapeutics Announces Strategic Partnership and $10M Investment from Global Nutrition Science Leader, Fonterra","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Akkermansia Muciniphila","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Pendulum Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Pendulum Therapeutics \/ Fonterra Co-operative Group","highestDevelopmentStatusID":"12","companyTruncated":"Pendulum T.."},{"orgOrder":0,"company":"Xentria","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","amount":"$680.0 million","upfrontCash":"$45.0 million","newsHeadline":"Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"XTMAB-16","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Xentria","amount2":0.68000000000000005,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Xentria \/ .."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"IMGS-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoGenesis \/ Cancer Focus Fund","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Leuprolide Mesylate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axsome Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Enters into a Warrant Exercise Transaction for Proceeds of $9.6 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ContraFect Corporation","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Charioteer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seven Manufacturers Sign Sublicence Agreements with the Medicines Patent Pool to Produce Generic Versions of Shionogi's COVID-19 Oral Antiviral Ensitrelvir to Increase Access in Low- and Middle-Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Charioteer","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Nucleus RadioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Actinium-225 Conjugated Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Nucleus RadioPharma","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Piramal Critical Care","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Piramal Critical Care","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Piramal Critical Care \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Piramal Cr.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Issues Complete Response Letter (CRL) for Aflibercept 8 Mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces U.S. FDA Approval of Rystiggo (Rozanolixizumab-Noli) for the Treatment of Adults with Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Rozanolixizumab-noli","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums gets DCGI Approval for Perampanel Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Akums Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Akums Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Life.."},{"orgOrder":0,"company":"ForCast Orthopedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ForCast Orthopedics Receives Orphan Drug Designation From FDA for the Treatment of Periprosthetic Joint Infection (PJI)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FC001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ForCast Orthopedics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ForCast Orthopedics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ForCast Or.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"IAVI","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAVI Starts First-in-Human Phase I Clinical Trial of Single-Dose Sudan Virus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"rVSV\u2206G-SEBOV-GP Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IAVI \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"IAVI \/ Bio.."},{"orgOrder":0,"company":"Microba Life Sciences","sponsor":"Bacthera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microba Commences Phase I Clinical Trial for IBD Therapeutic","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"MAP 315","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Microba Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"Microba Life Sciences \/ Bacthera","highestDevelopmentStatusID":"6","companyTruncated":"Microba Li.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS\u00ae (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and AbbVie Announce Positive Topline Results from Phase 1\/2 EPCORE\u2122 NHL-1 Trial Evaluating Epcoritamab (DuoBody CD3xCD20) in Patients with Relapsed\/Refractory Follicular Lymphoma (FL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FB101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Freya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Freya Bios.."},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lobe Sciences Initiates Phase 1 Clinical Trial of L-130","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Analogue","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lobe Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Scien.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-SOD1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX\u2011629 in Patients with Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX\u2011629","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Pfizer\u2019s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fidanacogene Elaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP for the Treatment of Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Allecra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allecra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allecra Th.."},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Anaprozole Sodium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sihuan Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sihuan Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lymphoma Therapy Now Approved for Australian Patients with Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Aurisco Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurisco Gets Auxiton (Dydrogesterone) as First Generic Approval in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dydrogesterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Aurisco Pharmaceutical","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurisco Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurisco Ph.."},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"AcuteBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel that Received IND Approval","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Clopidogrel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Ascendia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendia Pharmaceuticals \/ AcuteBio","highestDevelopmentStatusID":"5","companyTruncated":"Ascendia P.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA (tivozanib) in Combination with OPDIVO\u00ae (nivolumab) in Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA (nusinersen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alcyone Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Alcyone Th.."},{"orgOrder":0,"company":"MinervaX","sponsor":"European and Developing Countries Clinical Trials Partnership","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MinervaX Announces Completion of Enrolment in Phase I Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"GBS-NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MinervaX \/ European and Developing Countries Clinical Trials Partnership","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b\/2 Study Evaluating Ampligen\u00c2 (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Canc","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves BriaCells Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"HPN217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX\u2122 (racemic ketamine) to the FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluerock\u2019s Neuronal Stem Cell Therapy for Parkinson\u2019s Disease is First to Show Positive Results in Phase I Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ BlueRock Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"GSK","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate that could be the First in 100 Years if Proven Effective","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"AS01E","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0.55000000000000004,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Bill.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"GSK Completes Acquisition of BELLUS Health","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Camlipixant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"BELLUS Health","amount2":2,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":2,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Pharmosa Biopharm","sponsor":"Liquidia Corporation","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"$10.0 million","newsHeadline":"Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmosa Biopharm","amount2":0.23000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pharmosa Biopharm \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Pharmosa B.."},{"orgOrder":0,"company":"Kineta","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kineta to Receive $5 Million Milestone Payment from Merck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kineta","amount2":0.5,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Kineta \/ Merck & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ M.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly to Acquire Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sigilon Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amphastar Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,075.0 million","upfrontCash":"$625.0 million","newsHeadline":"Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Divestment","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":1.0800000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":1.0800000000000001,"dosageForm":"Powder","sponsorNew":"Eli Lilly \/ Amphastar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"$1,750.0 million","newsHeadline":"Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":2.5,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$351.3 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"BAY401016","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Evotec","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$977.0 million","upfrontCash":"$30.0 million","newsHeadline":"Lupin Announces Achievement of Key Milestone for its Phase 1 Clinical Stage MALT 1 Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"ABBV-525","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lupin Ltd","amount2":0.97999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.97999999999999998,"dosageForm":"","sponsorNew":"Lupin Ltd \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"$60.0 million","newsHeadline":"Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Forms Partnership with Hangzhou Zhongmei Huadong Pharmaceutical, Catalyzing Innovative Drug Research and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Biological Product","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Bio.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Capital Markets","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"SON-1010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"REM-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kintara Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Caeregen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caeregen Therapeutics and Wacker Biotech Announce Collaboration Agreement to Produce the Regenerative Medicine Clinical Candidate CTR-107 (Noregen\u2122) for Retinal Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"CTR-107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Wacker Chemie AG","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Wacker Chemie AG \/ Caeregen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Wacker Che.."},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0.040000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","productSubType":"Antibiotic","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ambrx Announces Closing of $75 Million Market Priced Registered Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Roluperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"XVR021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeVir Bio \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Nextech Invest","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series B Financing","leadProduct":"KTX-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"K36 Therapeutics \/ Nextech Invest","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therap.."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strategic Partnership with Pfizer to Launch Local Brand of Oral Antiviral Treatment for Covid-19 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CSPC Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"CSPC Pharmaceutical Group \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"CSPC Pharm.."},{"orgOrder":0,"company":"Sanofi","sponsor":"CORONA remedies","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CORONA Remedies Buys India's Ortho Brand Myoril","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Thiocolchicoside","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sanofi","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ CORONA remedies","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ C.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Gustave Roussy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA\u2122 for Treatment of Relapsed Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onxeo \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ Gu.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Announces Distribution Agreement with United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated with Interstitial Lung Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Ferrer Internacional","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Liquidia Enters into a Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Financing","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Liquidia Corporation \/ HealthCare Royalty","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"RareGen","sponsor":"Liquidia Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"RareGen","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RareGen \/ Liquidia Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RareGen \/ .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics Announces Agreement to Acquire Priority Review Voucher","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Undisclosed","amount2":0.11,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.11,"dosageForm":"Powder for Inhalation","sponsorNew":"Undisclosed \/ United Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$55.2 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$48.0 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Public Offering","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$51.1 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Morphimmune","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Morphimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Morphimmune \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Morphimmun.."},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"IMM-ONC-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Leads Biolabs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"LBL-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chime Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Leads Biolabs","highestDevelopmentStatusID":"7","companyTruncated":"Chime Biol.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes Non-Brokered Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"TeraImmune","sponsor":"Baudax Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Acquires TeraImmune, Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"TI-168","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ Baudax Bio","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"BVF Partners L.P.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"CX-2029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ BVF Partners L.P.","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"ZYMEDI","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zymedi Announced their Collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to Develop ZMA001 mAb, a Potential Treatment for Pulmonary Arterial Hypertension (PAH), a Rare, Female Predominant Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"ZMA001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ZYMEDI","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ZYMEDI \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"ZYMEDI \/ N.."},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ .."},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","amount":"$13.1 million","upfrontCash":"$13.1 million","newsHeadline":"Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Isoprocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Reunion Neuroscience","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Reunion Ne.."},{"orgOrder":0,"company":"Immunorizon","sponsor":"Purple Biotech","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"$3.5 million","newsHeadline":"Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Tri-specific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunorizon","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Immunorizon \/ Purple Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Immunorizo.."},{"orgOrder":0,"company":"4SR Biosciences","sponsor":"hC Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"hC Bioscience and 4SR Biosciences Join Forces to Expand Platform Development of tRNA-Based Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"tRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"4SR Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4SR Biosciences \/ hC Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"4SR Biosci.."},{"orgOrder":0,"company":"Eisai","sponsor":"DRI Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$85.0 million","newsHeadline":"Eisai Transfers all Future Economic Rights for Elacestrant, a Selective Estrogen Receptor Degrader, to DRI Healthcare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ DRI Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ DR.."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"This Women's Healthcare Company Raised $7.5 Million in a Public Offering and Says it's Targeting $25 to $30 Million Net Revenue by End of 2023","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Agile Ther.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"EB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$22.0 million","newsHeadline":"Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"2-hydroxybenzoyl Amino Octanoate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Intensity Therapeutics \/ The Benchmark Company","highestDevelopmentStatusID":"8","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Pfizer\u2019s NGENLA, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Somatrogon-ghla","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ OPKO Health","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China\u2019s NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Napo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Jaguar Health \/ Napo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AMTX-100 CF3","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx The.."},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AusperBio Announces IND Approval from China CDE for HBV ASO AHB-137","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AHB-137","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Z-endoxifen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Amplifica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplifica Announces First-in-Human Study Initiated","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"AMP-303","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplifica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Na\u00efve Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alloy Therapeutics Launches Proprietary AntiClastic Antisense Oligonucleotide Platform to Make Potent Genetic Medicines","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Ther.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics\u2019 Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R\/R EBV+ PTCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VLP Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Blue Water Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Water.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX\u00c22-73 (blarcamesine) for Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dehydrated Alcohol","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aflibercept 8 Mg in Diabetic Macular Edema First to Achieve Sustained Vision Gains with up to 83% of Patients Extended to 16-24 Weeks at Two Years","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aqvh","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration to Treat PAH Patients in US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ United Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Palmitil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Gets CDSCO Panel Nod to Manufacture & Market Treprostinil Solution for Infusion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Provides an Update on the Progress of the Tyvaso DPI New Drug Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces FDA Acceptance of Tyvaso DPI New Drug Application For Priority Review","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"DEKA Research & Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ DEKA Research & Development","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces Commercial Launch Of The Remunity Pump For Remodulin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Launches Drug to Treat Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Enzene Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzene Biosciences Launches Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Enzene Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enzene Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Enzene Bio.."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio NPC Phase III Successful Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granules for Oral Suspension","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Drug Farm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral ALPK1 Selective Kinase Inhibitor, DF-003","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Drug Farm","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Drug Farm \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX\u20112191 in Patients with Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Receives U.S. FDA\u2019s Go Ahead for Piclidenoson Psoriasis Registration Plan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression \u22651%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Syneos Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrophy and Receives Priority Review","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Givinostat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"The Italfarmaco Group \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"The Italfa.."},{"orgOrder":0,"company":"CellTrans","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Donislecel-jujn","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"CellTrans","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CellTrans \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CellTrans .."},{"orgOrder":0,"company":"DelSiTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelSiTech Announces Positive Topline Clinical Data from Phase 1 Trial with its Sustained Release Eye Drop Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"DST-2105","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"DelSiTech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"DelSiTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"DelSiTech .."},{"orgOrder":0,"company":"HaemaLogiX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HaemaLogiX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HaemaLogiX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HaemaLogiX.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Announces Approval of XCOPRI (cenobamate tablets) in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Vatiquinone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First Generic Version of Noxafil (posaconazole) Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, a Rare Cholestatic Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Genfit","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ge.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenocutuzumab (Zeno) Granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the Treatment of NRG1+ Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dotinurad","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"Urica Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Urica Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Urica Ther.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Successfully Manufactures Clinical Supply \u2013 Initiation of Pediatric Phase 3 Studies to Commence in July and August","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Temferon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer\u2019s Disease-Related Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tifcemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harbour Bi.."},{"orgOrder":0,"company":"BioNTech","sponsor":"OncoC4","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316\/ONC-392 Program in Metastatic NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Gotistobart","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ OncoC4","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx Announces Positive Results in Phase 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mizagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Vogenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ N.."},{"orgOrder":0,"company":"Toragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toragen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva\u2019s 3rd Interim Analysis of PEARL Real-world Study on AJOVY (fremanezumab) Reveals Sustained Long-term Effectiveness in Reducing Frequency, Duration and Severity of Attacks in Patients with Chronic and Episodic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fremanezumab-vfrm","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Rad51-IN-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz to launch Hyrimoz (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-adaz","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx and Zai Lab Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Hannover Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Hannover Medical School","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces First Patient Dosed in a Phase 1\/2 Trial with Third Oncomimics Immunotherapy, EO4010, in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"EO4010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Launches Lenvatinib Capsules in India Under the Brand Name Lenshil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Med.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Submits Regulatory Application to the European Medicines Agency for its Updated Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Elasomeran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Four-Year Follow up Data for Roche\u2019s Evrysdi Show Continued Increase in Number of Children with A Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Launches Yuflyma (adalimumab-aaty), a Humira (adalimumab) Biosimilar, in the United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aaty","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and\/or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"SystImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SystImmune, Inc. Announces FDA Clearance of IND Application for BL-B01D1, a Bi-specific Antibody Drug Conjugate Targeting EGFR and HER3, Enabling Initiation of Phase 1 Clinical Trials in the U.S. for Metastatic or Unresectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BL-B01D1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SystImmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyltezo, First and Only FDA-Approved Interchangeable Biosimilar to Humira, Now Commercially Available in The U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-adbm","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Organon","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA (adalimumab-bwwd) in Multiple Presentations Consistent with Originator","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-bwwd","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Organon","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Organon \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HTL\u2019149","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Hamlet Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clearance of IND Application for Alpha1H for the Treatment of Non-muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpha1H","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hamlet Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamlet Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hamlet Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer in Tropion-Lung01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Asunercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"After Five Years of Successful Experience Internationally, Biocon Biologics' Hulio Biosimilar To Humira, Now Available in the United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-fkjp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"SKG0106","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Skyline Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Skyline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Skyline Th.."},{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Infant Bacterial Therapeutics Product Receives FDA Orphan Drug Designation","therapeuticArea":"Pediatrics\/Neonatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","url1":"","url2":"","graph1":"Pediatrics\/Neonatology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"therapeuticAreaNew":"Pediatrics\/Neonatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Pediatrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bac.."},{"orgOrder":0,"company":"Nevakar Injectables","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nevakar Injectables Announces FDA Approval of Cyclophosphamide RTD Solution","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Nevakar Injectables","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nevakar Injectables \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nevakar In.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"KB407","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Positive Results From Part 1 Of Multiple Ascending Dose Trial with Amylin Analog ZP8396","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ZP8396","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches its Citrate-free Biosimilar Ldacio (adalimumab-aacf) in the United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aacf","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus BioSciences Launches Biosimilar Version of AbbVie's Blockbuster Humira","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-aqvh","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives U.S. FDA Complete Response Letter for IPX203","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Avra","sponsor":"Springs Rejuvenation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Merger","leadProduct":"Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Avra","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avra \/ Springs Rejuvenation","highestDevelopmentStatusID":"1","companyTruncated":"Avra \/ Spr.."},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erytech and Pherecydes Announce Merger and Name Change to Phaxiam Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Merger","leadProduct":"Anti Staphylococcus aureus Bacteriophage","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Phaxiam Therapeutics \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Th.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0.25,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.25,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Christopher Schelling","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acer Therapeutics \/ Christopher Schelling","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Nextech","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORIC Pharmaceuticals Announces $85 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"ORIC-114","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$390.0 million","upfrontCash":"$140.0 million","newsHeadline":"Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.39000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Sutro Biopharma \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"AdvanCell","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"212Pb-ADVC001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AdvanCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AdvanCell \/ POINT Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"AdvanCell .."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$22.0 million","newsHeadline":"Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Sumatriptan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Upsher-Smith Laboratories \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"$188.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0.19,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Universal Influenza Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Craig-Hallum Capital Group LLC","pharmaFlowCategory":"D","amount":"$37.5 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Recombinant Human Tissue Kallikrein","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"DiaMedica Therapeutics \/ Craig-Hallum Capital Group LLC","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"$1,700.0 million","newsHeadline":"Sobi Completes Acquisition of CTI BioPharma Corp.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Pacritinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.7,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"STx-02","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Lonza Group","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of \u00a35 Million to Advance Clinical Development of Lead Programme for Cancer Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Series A Financing","leadProduct":"S-pindolol Benzoate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Funding","leadProduct":"Zedenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Daehwa Pharmaceutical Co. Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daehwa Pharm Applies for Approval of Anti-Dementia Patch in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Daehwa Pharmaceutical Co. Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Daehwa Pharmaceutical Co. Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daehwa Pha.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Knight Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Comera Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comera Life Sciences Announces Favorable Preclinical Topline Safety Results of Lead SQore Excipient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Caffeine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Comera Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comera Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Comera Lif.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives One ANDA Approval and Two Tentative ANDA Approvals - Tadalafil Gabapentin Enacarbil and Apremilast","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Finasteride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval From USFDA For Tadalafil Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Macitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Provides Update on Lotiglipron Development","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lotiglipron","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sosei Heptares \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Olgotrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"TT-10","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Marketing Approval of CAMZYOS (mavacamten) in Singapore","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Announces First Patient Dosed with its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FLT201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Quisovalimab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Eli Lilly","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Deucrictibant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitapivat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval of CAMZYOS\u00ae (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin\u2019s Lymphoma (NHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"ADI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TEPEZZA\u00ae (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Files for Orphan Drug Designation Using JadiCell Adult Universal Donor Stem Cells for Treatment of Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Cystetic Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"cystetic Medicines Initiates Phase 1 Clinical Trial of a Molecular Prosthetic for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"CM001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystetic Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Cystetic Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cystetic M.."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives US FDA Fast Track Designation for Investigational Vaccine Against Gonorrhoea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Neisseria Gonorrhoeae Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical Announces Positive Results of Phase III Trial in Japan Showing Reduced Agitation in Patients With Alzheimer's Dementia Treated With Brexpiprazole","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Phase 2B Data in Atopic Dermatitis Support Amlitelimab as A Potential First and Best-in-Class Novel Investigational Anti-Ox40-Ligand Monoclonal Antibody","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xigduo XR Approved in China for Adults with Type-2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Bi.."},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"LongeVC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LongeVC Joins Freedom Biosciences\u2019 Funding Round for Psychedelic-Powered Mental Health Care","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Freedom Biosciences \/ LongeVC","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SPRAVATO\u00ae\u25bc (esketamine nasal spray) Data from the Phase 3b ESCAPE-TRD Study Demonstrate Superior Efficacy Compared to Quetiapine Extended-Release in Treatment-Resistant Major Depressive Disorder1","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces U.S. FDA Approval of SPRAVATO\u00ae (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"(n)SPRAVATO\u00ae (esketamine)* Nasal Spray is Available for Canadian Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Phar.."},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Somalab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pressure BioSciences Announces Agreement with Somalab Int\u2019l for Development & Distribution of UltraShear-Enabled Nanoemulsified Health and Wellness Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pressure BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pressure BioSciences \/ Somalab","highestDevelopmentStatusID":"12","companyTruncated":"Pressure B.."},{"orgOrder":0,"company":"Avicanna","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna\u2019s Proprietary SEDDS Technology Capsules for Canadian and International Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avicanna \/ Medipharm Labs","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"HempMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medical Marijuana, Inc. Subsidiary HempMeds\u00ae Brasil Launches Two New Full Spectrum Concentrations in Brazil With Competitive Price Point","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"HempMeds","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HempMeds \/.."},{"orgOrder":0,"company":"Elixinol Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GLOBAL CBD BRAND ELIXINOL WELLNESS INTRODUCES TWO INNOVATIVE SLEEP* PRODUCTS","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Elixinol Wellness","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Elixinol Wellness \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elixinol W.."},{"orgOrder":0,"company":"HempMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"HempMeds","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"HempMeds \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HempMeds \/.."},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMC Pharmaceuticals Awarded Sequential Phase II SBIR Grant to Continue Pharmaceutical Development of a Medical Countermeasure to Nerve Agents","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CMC Pharmaceuticals \/ U.S. Defense Department","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharma.."},{"orgOrder":0,"company":"Sydnexis","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Santen and Sydnexis Execute an Exclusive Licensing Agreement for SYD-101, a Novel Investigational Treatment for Progressive Childhood Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sydnexis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Sydnexis \/ Santen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sydnexis \/.."},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMC Pharmaceuticals Awarded SBIR Grant for Concentrated Atropine Formulation","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"IND Enabling","graph3":"CMC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CMC Pharmaceuticals \/ U.S. Defense Department","highestDevelopmentStatusID":"5","companyTruncated":"CMC Pharma.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Pheon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Pharmaceuticals Enters into License Agreement with Pheon Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Pheon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","amount":"$437.0 million","upfrontCash":"$15.0 million","newsHeadline":"VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership to Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"BRII-179","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0.44,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.44,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2023","year":"2023","type":"Divestment","leadProduct":"Delandistrogene Moxeparvovec-rokl","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sarepta Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"$0.4 million","newsHeadline":"Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Hea.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"COMPASS Pathways Secures Term Loan Facility for up to $50 Million from Hercules Capital","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Compass Pathways \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Heqet Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"EDIRNA","sponsor":"Sirnaomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"RNA-editing Therapeutic","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"EDIRNA","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EDIRNA \/ Sirnaomics","highestDevelopmentStatusID":"3","companyTruncated":"EDIRNA \/ S.."},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Signs IHAT Sales and Marketing Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Nemysis","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nemysis \/ Bruno Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Nemysis \/ .."},{"orgOrder":0,"company":"Evotec","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"Undisclosed","newsHeadline":"Just \u2013 Evotec Biologics Awarded Second Contract from U.S. Department of Defense under Accelerated Antibodies Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Evotec \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ U.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobio Regains Global Rights to SHP2 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Termination","leadProduct":"JAB-3312","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jacobio Pharma \/ Abbvie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Avrio Health","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bansk Group-Backed Arcadia Consumer Health Acquires Avrio Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Sennosides","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Avrio Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avrio Health \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Avrio Heal.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phil and RedHill Biopharma Partner to Increase Access to Talicia\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"PIP-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Undisclosed \/ Shorla Oncology","highestDevelopmentStatusID":"10","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Announces a $3 Million Private Placement of its Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"$106.5 million","upfrontCash":"$106.5 million","newsHeadline":"Bausch + Lomb Expands OTC Product Line with Acquisition of Blink\u00ae Eye Drops","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Macrogol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0.11,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Solution\/Drops","sponsorNew":"Johnson & Johnson \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"AM-401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Curis","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$15.1 million","upfrontCash":"Undisclosed","newsHeadline":"Curis Announces $15.1 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Emavusertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Curis \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Ca.."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio Collaborate to Develop Five Innovative ADC Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Vox Nova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PaxMedica \/ Vox Nova","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences Announces $25 Million Equity Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Allogeneic CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"IAVI","sponsor":"German government","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Germany Issues Award to IAVI to Support Development of the MTBVAC Tuberculosis Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"MTBVAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IAVI \/ German government","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ Ger.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced at-the-Market under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"EB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Applied Biomedical Science Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Applied Biomedical Science Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biomedical Science Institute \/ Hillstream BioPharma","highestDevelopmentStatusID":"2","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea (paclitaxel micellar)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Generic of Abraxane in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fer.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ICP-488","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Glecirasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"RareStone Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves RareStone's Pitolisant (Wakix) for the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"RareStone Group","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"RareStone Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RareStone .."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants Conditional Marketing Authorization for Taiho's LYTGOBI\u00ae Tablets for the Treatment of Adults With Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"PN-235","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aspen Pharmacare Holdings \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entod Pharma Gets DCGI Nod to Conduct Phase III Study of 0.05% Atropine","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Entod Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Entod Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Entod Phar.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Launches FDA-Approved Atropine Sulfate Injection, USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Global Multi-center Phase III Clinical trials of Okvision's Low-concentration Atropine OT-101 Have Completed the Enrollment of Global Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Another City! Okuvision's Low-Concentration Atropine OT-101 Obtained Approval for Phase I Clinical Trials in the UK","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okuvision Low-Concentration Atropine OT-101 was Approved by CDE to Carry Out Phase III Clinical Trials in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okuvision's Low-Concentration Atropine OT-101 Application for Phase III Clinical Trial in the Uk has been Accepted","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okuvision'S Low-Concentration Atropine OT-101 Submitted a Phase III Clinical Trial Application in China and was Accepted by CDE","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okuvision's Low-Concentration Atropine OT-101 has been Approved by the US FDA to Carry out The Pediatric Research Program (IPSP)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okvision Low Concentration Atropine Sulfate Eye Drops OT-101 Completed the First Subject Enrollment and Plans to Carry out Real-World Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Okuvision Low Concentration Atropine Sulfate Eye Drops Ot-101 was Approved by the US FDA For Phase III Clinical Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyluma Inc Launches With Robust Ophthalmic Portfolio, Leading With a Pharmaceutical Treatment In Phase III for Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ N.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Completes Three Year Enrollment In Nevakar\u2019S Phase III Champ Study of NVK002 Evaluating Low-Dose Atropine Ophthalmic Solution for the Treatment of Myopia In Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ N.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Gets US FDA Tentative Approval for Dolutegravir Tablets for Oral Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Gives Final Nod to Zydus\u2019 Tablets for Treatment of Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxcarbazepine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair (omalizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves ORKAMBI (lumacaftor\/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Lumacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Aggregate Safety Data From Vafidemstat\u2019s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC\u2122 Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CFT8919","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan\u2019s Pharmaceutical Medical Device Agency","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"MEN1309","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenocutuzumab (Zeno) Granted Second Breakthrough Therapy Designation by the U.S. Food & Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed\/Refractory Marginal Zone Lymphoma (R\/R MZL) and Its Plan for a Pivotal Phase III Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Abivertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO\u2122 (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Shenzhen Second People's Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Shenzhen Second People's Hospital","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Tiumbio","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518\/TU2670' from NMPA in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HS-10518","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiumbio \/ Hansoh Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ .."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"P-CD19CD20-ALLO1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Poseida Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants Marketing Authorisation for Opzelura\u00ae (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Padeliporfin VTP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"Avrio Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Purdue Pharma\u2019s Avrio Health Launches Two Senokot\u00ae Dietary Supplement Products","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Sennosides","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Avrio Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avrio Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avrio Heal.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmascience Introduces Myinfla(TM) (Colchicine 0.5 Mg Extended-Release Tablets), a New Repurposed Treatment Now Available in Canada to Reduce the Risk of Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pharmascience Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmascie.."},{"orgOrder":0,"company":"Avion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avion Pharmaceuticals' New Gout Prophylaxis Product, GLOPERBA\u00ae, is the First and Only Liquid form of Colchicine","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Avion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avion Phar.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Colchicine Tablets USP, 0.6mg","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announces Tentative Approval of Colchicine Capsules, 0.6 mg, Generic Equivalent of Mitigare\u00ae Capsules, 0.6mg of Hikma International Pharmaceuticals LLC.","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Receives Approval from US Food & Drug Administration (US FDA) of Colchicine Tablets used for the treatment of Familial Mediterranean Fever (FMF).","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montreal Heart Institute Announces COLCORONA Trial in Patients with COVID-19 Passes Futility Test in Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Colchicine Reduces the Risk of COVID-19-related Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Colchicine Shows Promise as a Treatment for at-home COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives US FDA Approval for Colchicine Tablets","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Gets FDA Nod for Digoxin Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Digoxin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocumension and the Three Parties Signed a Real-World Research Strategic Cooperation Agreement and Officially Launched the Real-World Research on Low-Concentration Atropine OT-101","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Gets Marketing Authorization from Saudi Arabia for Chemotherapy Drug Docetaxel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Receives USFDA Approval for Docetaxel Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boryung Launches Alcohol-free Breast Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boryung Ph.."},{"orgOrder":0,"company":"Eisai","sponsor":"C2N Diagnostics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C2N Diagnostics, Used in Clinical Trials for LEQEMBI\u2122 for Alzheimer\u2019s Disease Treatment1,2, Is Poised to Support Medical Community in Next Steps","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ C2N Diagnostics","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ C2.."},{"orgOrder":0,"company":"IPS Heart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ISX9-CPC","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IPS Heart","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IPS Heart \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IPS Heart .."},{"orgOrder":0,"company":"EpicentRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting \"nibrozetone\" as New Generic Name for EpicentRx's Lead Small Molecule NLRP3 Inhibitor, RRx-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"RRx-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EpicentRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EpicentRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia's Paxalisib Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Traditional Approval for LEQEMBI\u00ae (lecanemab-irmb) for the Treatment of Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"VXA-G1.1-NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces Positive Phase 2 Signal Detection Study Evaluating Pitolisant for Excessive Daytime Sleepiness in Prader-Willi Syndrome At Sleep 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences to Present New Wakix\u00ae (Pitolisant) Safety And Efficacy Data at Sleep 2023 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioprojet: European Marketing Authorisation for OZAWADE\u2122","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Bioprojet Pharma","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bioprojet Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioprojet .."},{"orgOrder":0,"company":"RareStone Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RareStone Inc. Announces Submission of New Drug Application (NDA) of Wakix\u00ae (pitolisant) for narcolepsy with and without cataplexy in China","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"RareStone Group","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"RareStone Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RareStone .."},{"orgOrder":0,"company":"TheiaLife","sponsor":"LifeSci Consulting","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TheiaLife Signs Agreement with LifeSci Consulting for Transaction Advisory Services for Strategic Partnering Initiatives","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"7-Methylxanthine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TheiaLife","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TheiaLife \/ LifeSci Consulting","highestDevelopmentStatusID":"8","companyTruncated":"TheiaLife .."},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Organon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Announces Completion of Organon & Co. Spinoff","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Demerger","leadProduct":"Etonogestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"PINOTBIO","sponsor":"Lotte Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LOTTE BIOLOGICS Announces Investment in PINOT BIO, ADC Platform Development Pioneer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Sacituzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PINOTBIO","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PINOTBIO \/ Lotte Biologics","highestDevelopmentStatusID":"4","companyTruncated":"PINOTBIO \/.."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$141.9 million","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Delafloxacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Oligonucleotide Drug","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biot.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$304.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0.29999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Duality Biologics","amount2":1.3,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3,"dosageForm":"","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Sapienza University of Rome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Sapienza University of Rome","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Cr\u00e8me de Canna","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pressure BioSciences Announces UltraShear Processed Nano-CBD Topical Spray Distribution Agreement with Premier CA Cannabis Partner Cr\u00e8me de Canna","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pressure BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pressure BioSciences \/ Cr\u00e8me de Canna","highestDevelopmentStatusID":"12","companyTruncated":"Pressure B.."},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Doer Biologics Announces License Agreement with BioNTech","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Zhejiang Doer Biologics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Zhejiang D.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$962.5 million","upfrontCash":"$20.0 million","newsHeadline":"Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Adeno-associated Virus Vector","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"4D Molecular Therapeutics","amount2":0.95999999999999996,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Race Oncology Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Race Executes Global License Agreement with City of Hope to Access FTO IP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bisantrene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Race Oncology Limited","highestDevelopmentStatusID":"9","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics, Inc. Announces Pricing of its Public Offering of $150 Million of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vittoria Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Viper 101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Vittoria Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces $25.5 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ BMO Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Fulcrum Therapeutics","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"CAMP4 Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"CAMP4 Therapeutics \/ Fulcrum Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"CAMP4 Ther.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$3,610.0 million","upfrontCash":"$60.0 million","newsHeadline":"NANOBIOTIX Announces License Agreement for Worldwide Co-Development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":3.6099999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":3.6099999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Receives Orphan Drug Designation for First-in-class Trispecific Antibody, ISB 2001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ISB 2001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ichnos Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"280Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"280 Bio Receives IND Approval from the FDA for YL-17231","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"YL-17231","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"280Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"280Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"280Bio \/ N.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to NS-089\/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Brogidirsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Phase I Study of its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HMPL-415S1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in The UK","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Nuvaxovid\u2122 Receives Full Marketing Authorization in the EU for the Prevention of COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Announces its Insomnia Medication, QUVIVIQ (daridorexant), is Now Covered by CVS","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Daridorexant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicines and Healthcare Products Regulatory Agency Authorises GSK\u2019s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in SAR\u2019514 \/ IPH6401 Phase 1\/2 Clinical Trial in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"IPH6401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Announces Positive Data from Ongoing Phase 1\/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cytokine Induced Memory-Like Natural Killer Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA\u00ae) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eganelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Infinity Pharmaceuticals \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expanding Access to Women\u2019s Health Fresenius Kabi Launches Generic Fertility Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ganirelix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"MyoPax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoPax Receives Rare Pediatric Disease Designation from FDA for Breakthrough Regenerative Cell Product in Exstrophy-Epispadias Complex","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Muscle Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"MyoPax","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MyoPax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoPax \/ N.."},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 1\/2 \u201cELUCIDATE\u201d Trial Assessing GTAEXS617 in Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"GTAEXS617","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ GT Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Full FDA Review for HEMO-CAR-T IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HEMO-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Roches Fixed-duration Columvi (glofitamab) for People with Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces Preliminary Safety Analysis for ASPIRE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Luca Szalontay","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Luca Szalontay","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results in Its U.S. Phase I\/II Study of MW005 for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus for the Treatment of Uveitic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Arctic Vision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":"12","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"LN-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Zedenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 POWER Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1\/2 Trial in Patients With MTAP-deleted Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG462","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Expanded Indication for Novartis Leqvio (inclisiran) to Include Treatment of Adults with High LDL-C and who are at Increased Risk of Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Inclisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","amount":"$276.0 million","upfrontCash":"$276.0 million","newsHeadline":"Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE upon Completion of Business Combination with AEON Biopharma, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.28000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Septerna","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Septerna","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Septerna \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Septerna \/.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$5,900.0 million","upfrontCash":"$5,900.0 million","newsHeadline":"Astellas Completes Acquisition of Iveric Bio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":5.9000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":5.9000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4,000.0 million","upfrontCash":"$50.0 million","newsHeadline":"Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evotec","amount2":4,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":4,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Announces $2.1 Million Registered Direct Offering","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Crossbow Therapeutics","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies that Mimic T-Cell Receptors to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"TCR-mimetic Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Crossbow Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Crossbow Therapeutics \/ MPM BioImpact","highestDevelopmentStatusID":"2","companyTruncated":"Crossbow T.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Cancer Science Institute of Singapore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Cancer Science Institute of Singapore","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Na.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$263.1 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics to Raise up to $263.1M in IPO","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Science 37 Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Labafenogene Marselecobac","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Synlogic \/ Science 37 Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"Solve FSHD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOLVE FSHD Announces New Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nationwide Children\u2019s Hospital \/ Solve FSHD","highestDevelopmentStatusID":"4","companyTruncated":"Nationwide.."},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","amount":"$820.0 million","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Announces Closing of Fertin Pharma Acquisition; Advances PMI\u2019s Goal of Becoming a Majority Smoke-Free Business by 2025 and Creates Growth Opportunities Beyond Nicotine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Fertin Pharma AS","amount2":0.81999999999999995,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.81999999999999995,"dosageForm":"Gum, Chewing","sponsorNew":"Fertin Pharma AS \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Fertin Pha.."},{"orgOrder":0,"company":"Fertin Pharma AS","sponsor":"Philip Morris International","pharmaFlowCategory":"D","amount":"$820.0 million","upfrontCash":"Undisclosed","newsHeadline":"Philip Morris International Announces Agreement to Acquire Fertin Pharma","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Fertin Pharma AS","amount2":0.81999999999999995,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.81999999999999995,"dosageForm":"Gum, Chewing","sponsorNew":"Fertin Pharma AS \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"Fertin Pha.."},{"orgOrder":0,"company":"Burjeel Holdings","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burjeel Holdings to Launch Rare Disease Research & Development Project 'NADER' in Partnership with US-based BridgeBio Pharma","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"U.A.E","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Burjeel Holdings","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Burjeel Holdings \/ BridgeBio Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Burjeel Ho.."},{"orgOrder":0,"company":"IRBM","sponsor":"Rainwater Charitable Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"IRBM","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRBM \/ Rainwater Charitable Foundation","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Rai.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"ObsEva Recovers Full Worldwide Rights on Nolasiban","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Termination","leadProduct":"Nolasiban","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0.13,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Yuyuan","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Y.."},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"BBP-398","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Closes $25.5 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Tenpoint Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SparingVision Sells Ex Vivo GIRK Technology to Tenpoint Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Divestment","leadProduct":"SPVN20","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SparingVision \/ Tenpoint Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB\u00ae Distribution Agreement in the U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Human Rabies Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ K.."},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Raya Therapeutic Announces Early-Stage R&D Collaboration with Argenx","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Raya Therapeutic","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Raya Therapeutic \/ argenx","highestDevelopmentStatusID":"1","companyTruncated":"Raya Thera.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$300.0 million","newsHeadline":"Novartis Retreats from TIGIT, Handing $300M Drug Back to BeiGene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Termination","leadProduct":"Ociperlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"Injectable\/Injection","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"PRX005","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Prothena","amount2":2.2000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"CellCentric","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"CellCentric Announces $25m Strategic Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Inobrodib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"CellCentri.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences Announces $25 Million Equity Investment from Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Guangrun Health Industry","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arthrosi Secures $75M in Series D Financing","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series D Financing","leadProduct":"AR882","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II","graph3":"Arthrosi Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Immediate Release Capsule","sponsorNew":"Arthrosi Therapeutics \/ Guangrun Health Industry","highestDevelopmentStatusID":"8","companyTruncated":"Arthrosi T.."},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Tenpoint Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Tenpoint Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"3","companyTruncated":"Tenpoint T.."},{"orgOrder":0,"company":"Ardena","sponsor":"Race Oncology","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Bisantrene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ardena","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ardena \/ Race Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Ardena \/ R.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InnoCare and ArriVent Announce Clinical Development Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"$12.0 million","newsHeadline":"Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.13,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Superior Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Adalimumab-aqvh","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Superior Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Superior Biologics \/ Coherus Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Superior B.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Molecular Templates Announces up to $40 Million Private Placement Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"MT-6402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Stifel","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"EG 427","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.2 million","upfrontCash":"Undisclosed","newsHeadline":"EG 427 Announces Final Series a Closing, Achieving \u20ac18 Million in Total Funds Raised","therapeuticArea":"Urology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"EG110A","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0.02,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EG 427 \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ U.."},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$463.0 million","upfrontCash":"$100.0 million","newsHeadline":"Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren\u2019s NNZ-2591 in Rett Syndrome and Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cyclo-Glycyl-proline Analog","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0.46000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.46000000000000002,"dosageForm":"Solution","sponsorNew":"Neuren Pharmaceuticals \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pha.."},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Savara","amount2":0.080000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Solution for Nebulizer","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ J.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"KSQ-4279","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KSQ Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"CHAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Emtricitabine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ CHAI","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Korro Bio and Frequency Therapeutics Announce Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,925.0 million","upfrontCash":"$1,925.0 million","newsHeadline":"Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis B.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Synthetic Hypericin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Seeks US FDA Approval to Initiate SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura) in Children with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ICVB-1042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IconOVir Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir B.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orsini Selected by BioMarin to Dispense ROCTAVIAN, the First Gene Therapy for the Treatment of Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec-rvox","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HI-Bio Initiates Healthy Volunteer Study of HIB210 for Immune-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HIB210","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"HI-Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HI-Bio \/ N.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Risk of Post-Operative Complications in Patients Undergoing Cardiothoracic Surgery","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Company\u2019s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nacuity Pharmaceuticals Advances Phase 1\/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"NPI-002","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Ph.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed\/Refractory Non-Hodgkin Lymphoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"SP-3164","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies, LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces First Cohort Dosed in RECCE 327 Rapid Infusion Phase I\/II Urinary Tract Infection (UTI) Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces First Patient Dosed in Phase 2 Trial with OncoMimics Immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EO2040","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy\u2019s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rituximab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA Indication","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bit.bio Launches Two New Human Cell Disease Models to Advance Discovery and Development of Treatments for Duchenne Muscular Dystrophy (DMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase III Results for Roches OCREVUS (ocrelizumab) Twice a year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAs Qualified Infectious Diseases Product (QIDP) Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"George Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"George Medicines Completes Recruitment of First Phase III Hypertension Trial Investigating Novel Single-pill Triple Combination Xandidate GMRx2","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Telmisartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"George Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"George Med.."},{"orgOrder":0,"company":"Velico Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Velico Medical Begins Clinical Trial on Spray Dried Plasma","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Plasma","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Velico Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Velico Med.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Approved in China as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Labafenogene Marselecobac","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Arm Gets USFDA Nod for Sevelamer Hydrochloride Tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Invectys","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invectys Announces Initiation of Phase 1\/2a Clinical Trial in Solid Tumors and Change in Leadership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin\u00ae-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atea Pharmaceuticals Highlights Strategic Priorities for 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ruzasvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"argenx Announces Launch of Proposed Global Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0.75,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.75,"dosageForm":"Infusion","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ J.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"ACU193","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"NysnoBio","sponsor":"MJFF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NysnoBio Awarded Michael J. Fox Foundation Grant for Advancement of Parkin Gene Therapy to IND","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"NB001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NysnoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NysnoBio \/ MJFF","highestDevelopmentStatusID":"5","companyTruncated":"NysnoBio \/.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"$445.0 million","upfrontCash":"$210.0 million","newsHeadline":"Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Divestment","leadProduct":"Cholic Acid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.45000000000000001,"dosageForm":"Capsule","sponsorNew":"Travere Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"MediPacific","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"$125.0 million","newsHeadline":"Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Pomotrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Pardes Biosciences \/ MediPacific","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Washington","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"leadXpro","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules Against Novel Cancer-Focused GPCR Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"leadXpro","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"leadXpro \/ Cumulus Oncology","highestDevelopmentStatusID":"2","companyTruncated":"leadXpro \/.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,240.0 million","upfrontCash":"$40.0 million","newsHeadline":"Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Ex-vivo NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.24,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scipher Medicine Signs Multi-Target Partnership with Ionis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Oligonucleotide Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Scipher Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scipher Medicine \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Scipher Me.."},{"orgOrder":0,"company":"Caeregen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH\/NEI to Advance Development of Regenerative Medicine Clinical Candidate CTR-107 (Noregen\u2122) for Retinal Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"CTR-107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"Caeregen Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caeregen Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Caeregen T.."},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$15.0 million","newsHeadline":"Ligand Offers $15 Million to Acquire Assets of Novan, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Li.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"$1,190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sangamo Therapeutics Announces Research Evaluation and Option Agreement with Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Adeno-associated Virus Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":1.1899999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.1899999999999999,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Endo International","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo and Premier, Inc. Collaborate to Address Pitocin\u00ae (oxytocin injection, USP) Shortage","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Endo International \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"InxMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeneQuantum and InxMed have Reached a Technology Licensing Collaboration, Providing Strong Support for Innovative ADC Drug Research and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ InxMed","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"Seqens","sponsor":"Biophytis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Seqens","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seqens \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Seqens \/ B.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"CB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"DTx Pharma Announces Acquisition by Novartis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"DTx-1252","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":1,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"DTx Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Turnstone Charts $75M IPO for TIL Cell Therapies in Drumroll of Biotech IPOs this Month","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Oncolytic Viral Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"$231.0 million","upfrontCash":"$75.0 million","newsHeadline":"Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.23000000000000001,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Announces Pricing of Upsized $130 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"ACU193","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0.34999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaTher Announces Positive Research Results for PharmaPatch\u2122 with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Sairiyo Therapeutics \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Th.."},{"orgOrder":0,"company":"Advent","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Funding","leadProduct":"Vitamin A Palmitate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Advent","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Advent \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Advent \/ N.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Neurogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurogene and Neoleukin Announce Definitive Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Merger","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neoleukin Therapeutics \/ Neurogene","highestDevelopmentStatusID":"7","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Visiox Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Omidenepag Isopropyl","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Visiox Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Acquires Santen\u2019s Branded Ophthalmic Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE\u00ae (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Novaliq \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Actinium-225 Conjugated Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"BT5528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Genprex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Genprex","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"KayoThera","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KayoThera","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"KayoThera \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"2","companyTruncated":"KayoThera .."},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"SURGE Therapeutics Raises $32M Series B Financing to Advance Intraoperative Immunotherapy to Improve Cancer Patient Survival Outcomes Post-Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series B Financing","leadProduct":"STM-416","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SURGE Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"SURGE Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"7","companyTruncated":"SURGE Ther.."},{"orgOrder":0,"company":"VitriVax","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"VitriVax Awarded $29M DoD Contract to Fund Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"Thermostable Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VitriVax","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"VitriVax \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"2","companyTruncated":"VitriVax \/.."},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Riparian Pharmaceuticals Announces Agreements with Pfizer for Novel Cardiovascular Programs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Riparian Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Riparian P.."},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biotheus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Biotheus \/.."},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"ELGAN Pharma Awarded $2.5 Million EU Grant to Support Phase III Registrational Study of ELGN-GI for the Treatment of Intestinal Malabsorption in Preterm Infants","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Funding","leadProduct":"Recombinant Human Insulin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Elgan Pharma \/ European Innovation Council","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Phar.."},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces $3.8 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Erkim","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO\u00ae (berotralstat) in Turkey","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Erkim","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Erkim \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Erkim \/ Bi.."},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$1,270.0 million","upfrontCash":"Undisclosed","newsHeadline":"argenx Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":1.27,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.27,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ J.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"$9.5 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Divestment","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Pioneering Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"$100.0 million","newsHeadline":"Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Pioneering Medicines","amount2":0.80000000000000004,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Pioneering Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Pioneering.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series B Financing","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Synaptogenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Bryostatin-1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Synaptogenix","highestDevelopmentStatusID":"4","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"Neurogene","sponsor":"Great Point Partners","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurogene and Neoleukin Announce Definitive Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurogene \/ Great Point Partners","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Crossject","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Crossject Signs New Licensing Agreement on ZENEO\u00ae Midazolam Epilepsy Rescue Therapy with AFT Pharmaceuticals for Australia & New Zealand","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Crossject \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"Pharma Nordic","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Bentonite","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pharma Nordic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pharma Nordic \/ Altamira Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pharma Nor.."},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,325.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":1.3300000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix P.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Acquires Idorsia\u2019s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Clazosentan Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idorsia Pharmaceuticals \/ Sosei Heptares","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces Closing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Chroma Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Epigenetic Medicine","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Chroma Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Imugene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP\u2122) Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Oncolytic Virus Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP\/P97 Inhibitor CB-5339","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"CB-5339","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave The.."},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleave Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleave Therapeutics \/ Eikon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cleave The.."},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Digitalis Ventures","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"EpiBiologics \/ Digitalis Ventures","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologi.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","amount":"$212.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gossamer Bio Announces $212 Million Private Placement Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Seralutinib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0.20999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Gossamer Bio \/ New Enterprise Associates","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Riparian Pharmaceuticals","sponsor":"Viva Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Riparian Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Riparian Pharmaceuticals \/ Viva Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Riparian P.."},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"University of Sydney","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"ALA-002","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAla Biotech \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla B.."},{"orgOrder":0,"company":"KayoThera","sponsor":"NIH NIDDK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"KayoThera","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KayoThera \/ NIH NIDDK","highestDevelopmentStatusID":"1","companyTruncated":"KayoThera .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ALN-APP","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r\/r B-NHL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcepts Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Miricorilant","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Beyfortus (nirsevimab-alip) to Protect Infants Against RSV Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed\/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b\/2a IMX-110 IMMINENT-01 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"IMX-110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AG10 (Acoramidis) is an Investigational, Orally-Administered Small Molecule Designed to Potently Stabilize Tetrameric Transthyretin (TTR)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1\/1b Clinical Trial of BP1001-A in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"EXO Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EXO Biologics Pioneers with EVENEW Clinical Trial in Broncho Pulmonary Dysplasia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EXOB-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"EXO Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EXO Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EXO Biolog.."},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST .."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray\u2019s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Itruvone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"JANX007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Janux Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1\/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-DUX4","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b\/2 Trial of HF1K16 for Recurrent and Refractory Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"All-trans Retinoic Acid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField .."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1\/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment with RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces New Phase 3 Data Reinforcing Long-Term Safety and Efficacy of Octreotide SC Depot (CAM2029) in Patients with Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\u2019s Phase IIb Study with Pirepemat Passes DSMB Safety Review with Unanimous Recommendation to Continue the Ongoing Phase IIb Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirepemat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Pellet","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of \u20181104 in Adults with Active Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein\u00ae (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Albumin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"OTT166","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra T.."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ENX-102","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"NSC.CRAd-S-pk7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"BlackThorn Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Navacaprant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ BlackThorn Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Kite Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fosun Kite Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Kite.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Bivalirudin Injection in Ready-to-Use Vials","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bivalirudin","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW2921","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"APVO436","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bond Biosciences Announces Positive Phase Ia\/b Pharmacodynamic and Safety Data for BBI-001, a Novel, Non-Absorbed, Oral Therapy for Iron Overload","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BBI-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Bond Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosc.."},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CID-078","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Circle Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Circle Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Circle Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ARM210","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARMGO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Phar.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"SENS-501","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces the First Patient Dosed with Its First-In-Class CDH3-targeting ADC BC3195 in a Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BC3195","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ASC42","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gannex Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pha.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the First Generic Over-the-Counter Approval of a Naloxone Nasal Spray Product","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 study in ANCA-associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics World First Phase 2 Take-Home LSD-Microdosing Clinical Trial in Patients with Major Depressive Disorder Begins Pre-Screening Participants","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Updates Positive Clinical Data from Phase I\/II BEXMAB Study of Bexmarilimab in Relapsed\/Refractory AML and MDS BEXMAB Study Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces First Patient Injected in New Phase 1\/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Palovarotene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for Ambrx\u2122s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ARX517","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Emergex Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP\u2122, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"PepGNP-COVID19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergex Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergex Vaccines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements\/Milestones for NASH Drug Candidate, ALG-055009","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS(Anthrax Vaccine Adsorbed, Adjuvanted), Previously Known As AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Anthrax Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Elucida Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ELU001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elucida Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elucida Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elucida On.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN\u2122 3.9% Rapamycin Anhydrous Gel (QTORIN\u2122 rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN\u2122 3.9% Rapamycin Anhydrous Gel (QTORIN\u2122 rapamycin) for the Treatment of Pachyonychia Congenita","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE\u00ae 327 as an Intravenous Infusion Formulation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EBT-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T21 is Triastek\u2019s third 3D printed oral colon-targeted delivery drug product, which is investigated for the treatment of for moderate to severe ulcerative colitis (UC)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"T21","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Triastek","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triastek \/.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BMB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VANFLYTA\u00ae First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"STAR-0215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScie.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces Plans to Initiate Phase 3 Registrational Study of Pitolisant in Prader-willi Syndrome Following Positive End-of-Phase 2 Meeting With the U.S. Food And Drug Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perfuse Therapeutics Announces Initiation of Enrollment to Ph2a portion of the Phase 1\/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"PER-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Perfuse Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Perfuse Th.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Regorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin\u00ae-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adrulipase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone 5%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapsone","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"TheracosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TheracosBio Announces Commercial Availability of Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"TheracosBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TheracosBi.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1\/2 Study and Terminate Development of THE-630 in Patients with GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"THE-630","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Marketing Authorization for Endari in Oman","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vigeo Therapeutics Provides Clinical Update on VT1021 Treatment of GBM Expansion Patient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"VT1021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Vigeo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vigeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Vigeo Ther.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Supportive Interim Data From Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Imaging Biometrics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IQ-AI Announces Orphan Drug Designation for GaM in Pediatric GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Gallium Maltolate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Imaging Biometrics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imaging Biometrics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Imaging Bi.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS at Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Astellas\u2019 Marketing Authorization Application for Zolbetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Nonprescription Daily Oral Contraceptive","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Lynparza in Combination with Abiraterone and Prednisone or Prednisolone for Patients with BRCA Mutated Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent is Now Approved in India for the Treatment of Adults with Moderate-to-severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Negev Autism Center Soroka University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc to Commence its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Negev Autism Center Soroka University Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Concludes Positive Meeting with U.S. FDA Concerning Multikine\u2019s Approval for Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Veklury (remdesivir) for COVID-19 Treatment in Patients with Severe Renal Impairment, Including those on Dialysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101a","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Bio.."},{"orgOrder":0,"company":"POP Biotechnologies","sponsor":"EuBiologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EuCorVac-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"POP Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"POP Biotechnologies \/ EuBiologics","highestDevelopmentStatusID":"10","companyTruncated":"POP Biotec.."},{"orgOrder":0,"company":"OnKai","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galmed to Employ OnKai's Disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Aramchol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"OnKai","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnKai \/ Galmed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"OnKai \/ Ga.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Merger","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$26.3 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Nafamostat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AcelRx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Botanix Pharma","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"$8.2 million","newsHeadline":"Fresh Tracks Announces $8.25 Million Buyout of its Right to Receive Future Sofpironium Bromide Payments from Botanix","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Sofpironium Bromide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Fresh Tracks Therapeutics \/ Botanix Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$310.0 million","newsHeadline":"Roche Enters Partnership with Alnylam to Co-Develop and Co-Commercialise RNAi Therapeutic Zilebesiran to Treat Hypertension in Patients with High Cardiovascular Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Lyrus Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akums, Lyrus Life Sciences Collaborate for Patented Technologies and Formulations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Lyrus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drug.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arvinas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ Arvinas","highestDevelopmentStatusID":"4","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY\u00ae) for the Treatment of Adults with Relapsed\/Refractory (R\/R) Diffuse Large B-cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Daxdilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU\u00ae (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive European Union CHMP Opinion for Gefapixant","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"7MW3711","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"SunHo BioPharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SunHo Announces First Patient Dosed in Phase I\/II Clinical Trial of a Potential First-in-class Immunocytokine IBB0979","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"IBB0979","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SunHo BioPharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SunHo BioPharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SunHo BioP.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Asparaginase Erwinia Chrysanthemi-rywn","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01004","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces U.S. Availability of RYSTIGGO\u00ae (rozanolixizumab-noli) for the Treatment of Generalized Myasthenia Gravis (gMG) In Adult Patients who are Anti-Acetylcholine Receptor (AChR) or Anti-Muscle-Specific Tyrosine Kinase (MuSK) Antibody Positive","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rozanolixizumab-noli","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gc Biopharma'S \"GC Flu\" Obtains Vaccine Approval in Egypt: First-Ever Approval of the Company's Quadrivalent Flu Vaccine on the African Continent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces FDA Approval of YCANTH (cantharidin) Topical Solution as the First FDA Approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analysis from Phase 3 ATTR-ACT and its Long-Term Extension Study Demonstrates VYNDAQEL\u00ae 80 mg\/VYNDAMAX\u00ae 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafamidis","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ritlecitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Provides Update on RSV Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"MVA-BN-RSV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Roche\u2019s Evrysdi for Babies Under Two Months Old with Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare\u2019s Cabotegravir for HIV Prevention Receives Positive CHMP Opinion From European Medicines Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums Receives DCGI Approval for Type 2 Diabetes Drug to Improve Insulin Resistance","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Lobeglitazone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drug.."},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","amount":"$32.4 million","upfrontCash":"$0.4 million","newsHeadline":"Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$1,270.0 million","upfrontCash":"Undisclosed","newsHeadline":"argenx Announces Closing of Global Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":1.27,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.27,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ J.."},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"MEI Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Termination","leadProduct":"Eganelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Infinity Pharmaceuticals \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Closing of Underwriters\u2019 Partial Exercise of Option to Purchase Additional Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crescendo Biologics Secures $32M and Announces Expansion of CB307 Phase 1b Trial in PSMA+ Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"CB307","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Crescendo Biologics Ltd","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Crescendo Biologics Ltd \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Crescendo .."},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","amount":"$485.0 million","upfrontCash":"$485.0 million","newsHeadline":"Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0.48999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.48999999999999999,"dosageForm":"Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Q.."},{"orgOrder":0,"company":"ImmunoBiochem","sponsor":"Immunogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ImmunoBiochem","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoBiochem \/ ImmunoGen","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoBioc.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$749.9 million","upfrontCash":"$21.2 million","newsHeadline":"Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Protein Degrader Drug","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0.75,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.75,"dosageForm":"","sponsorNew":"PeptiDream \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ\u00ae) in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Overland Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA\u00ae for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Overland Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The U.S. Food and Drug Administration Gives the Green Light to Molecure's Flagship Program Phase II Clinical Testing of OATD-01 is Ready for Launch","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"OATD-01","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, all Countries\/Regions in the Aspire Trial are Now Open and Actively Enrolling","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Replay Bio","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replay and MD Anderson Announce FDA Clearance of IND Application for First-in-Class T-Cell Receptor Natural Killer (TCR-NK) Cell Therapy for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"NY-ESO-1 TCR\/IL-15 NK Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1\/2 Trial in Patients with STK11-Mutant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive CHMP Opinion for Multiple Sclerosis Biosimilar Natalizumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Natalizumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results with VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Isotretinoin Capsules, USP","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tarcocimab Tedromer","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CAL02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics Announces Positive CHMP Opinion for YESAFILI, Biosimilar Aflibercept","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,375.0 million","upfrontCash":"$125.0 million","newsHeadline":"SQZ Biotechnologies Provides Update on Collaboration with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":1.3799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3799999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"SQZ Biotechnologies \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Breye Therapeutics","sponsor":"Golgi Neurosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Golgi Neurosciences and Breye Therapeutics Announce Successful Closing of P2X7 Receptor Antagonist Program Transfer","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Breye Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Breye Therapeutics \/ Golgi Neurosciences","highestDevelopmentStatusID":"4","companyTruncated":"Breye Ther.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm\u00ae for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"COOPER PHARMA","pharmaFlowCategory":"D","amount":"$20.3 million","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical's Fexuprazan Takes its First Step into Africa Entering into a Partnership with Cooper Pharma, the No. 1 Pharmaceutical Company in Morocco in the Field of Digestive Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Fexuprazan","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Cooper Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Swiss TPH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Swiss TPH to Develop Treatment Against Soil-Transmitted Helminths","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Emodepside","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Swiss TPH","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Peking University","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Extends Partnership with Peking University to Foster Pharmaceutical Innovation in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Peking University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peking University \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Peking Uni.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Availability of CAPLYTA\u2122 (lumateperone) for Adult Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA\u2122 (lumateperone) for the Treatment of Schizophrenia in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA\u00ae (lumateperone) sNDAs for the Treatment of Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA\u00ae (lumateperone) for the Treatment of Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Zurletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae (empagliflozin) Approved in the EU for the Treatment of Adults with Chronic kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1\/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Supplemental New Drug Application for OFEV\u00ae (nintedanib) for Children and Adolescents Aged 6-17 Years Old with Fibrosing Interstitial Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and\/or Established Atherosclerotic Cardiovascular Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Completes Patient Randomization Ahead of Schedule for its Phase 2 Trial in Active Psoriatic Arthritis (PsA) and Provides Calendar of Next Readouts","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601\u2019s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves XDEMVY\u2122 (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Provides Regulatory Update on Galactosemia Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Announces First Patients Enrolled in Travelan\u00ae Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves AbbVie's RINVOQ\u00ae (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis Fran\u00e7ais","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series C Financing","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Partners with Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Worldwide Clinical Trials \/ Cybin","highestDevelopmentStatusID":"7","companyTruncated":"Worldwide .."},{"orgOrder":0,"company":"Nexo Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nexo Therapeutics Launches with $60 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nexo Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Nexo Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nexo Thera.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"KB707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Vantage Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALSA Ventures Launches Vantage Biosciences to Treat Diabetic Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"VX-01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ Vantage Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Viage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viage Therapeutics Announces Data from a Phase 1 Study with DGX-001, a First-In-Class Oral Neurotherapeutic Targeting Cognitive Impairment in Patients with Alzheimer's Disease and Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"DGX-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Viage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viage Ther.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I\/II UTI Clinical Trial of RECCE 327 at Scientia Clinical Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SKYRIZI\u00ae (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sahmyook University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sahmyook University Study Repurposes Meclofenamate to Treat Abnormal Respiratory Mucus","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Meclofenamic Acid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Sahmyook University","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sahmyook University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sahmyook U.."},{"orgOrder":0,"company":"MyoPax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoPax Receives FDA Orphan Drug Designation for its Innovative Regenerative Cell Therapy for Exstrophy-Epispadias Complex","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Muscle Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"MyoPax","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MyoPax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoPax \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA\u00ae (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceptance of Clinical Trial Application for the Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Shingles Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of Vafidemstat in Borderline Personality Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Announces Submission of New Drug Application to FDA with Intranasal Scopolamine for Prevention of Nausea and Vomiting Induced by Motion in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Financing","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ OrbiMed","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Completes Enrollment in Phase 2\/3 Trial of Human Acellular Vessel (HAV) for Vascular Trauma Repair","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Announces \u201cSozinibercept\u201d as the Nonproprietary Drug Name for OPT-302","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"AsclepiX Therapeutics Raises $10 Million to Advance Phase 1\/2a Clinical Study of AXT107","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"Gersizangitide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX T.."},{"orgOrder":0,"company":"Calibr","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Switchable CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calibr","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calibr \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Calibr \/ A.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion, AstraZeneca Rare Disease, Enters Agreement with Pfizer to Acquire a Portfolio of Preclinical Rare Disease Gene Therapies","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Pfizer Inc","amount2":1,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas\u2122 Manufacturing Capabilities for Advancing the EDIT-301 Program through Approval to Commercialization","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"EDIT-301","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Grou.."},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi to Acquire Qunol\u00ae, a Fast-Growing U.S. Brand in the Healthy Aging Segment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Qunol","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Qunol \/ Sa.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"rhENPP1-Fc","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Wilmington Capital Securities","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Grifola frondosa Maitake Mushroom Extract","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABVC BioPharma \/ Wilmington Capital Securities","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Merger","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"UroGen Announces $120 Million Private Placement of Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.12,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Axolotl Biologix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Axolotl Bi.."},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Axoltis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"NX210c","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"InSilicoTrials","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InSilicoTrials \/ Axoltis Pharma","highestDevelopmentStatusID":"6","companyTruncated":"InSilicoTr.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"$15.0 million","newsHeadline":"Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Pegzilarginase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Fortrea","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incannex Engages Fortrea to Manage its FDA IND Opening Phase 2\/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Acetazolamide","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Fortrea","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fortrea \/ Incannex Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Fortrea \/ .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","amount":"$41.1 million","upfrontCash":"$13.7 million","newsHeadline":"Ipsen Ends Neurotoxin Pact with Galderma after Arbitration Cases Filed in International Court","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Ga.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Gets CDSCO Panel Nod to Study Lumateperone Capsules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"HMI-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Announces First Patient Enrolled in Phase 1\/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"AnnJi Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces First Patient Dosed in Phase 1b\/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avenue Therapeutics \/ AnnJi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn\u2122s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06480605","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roivant Sciences \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nomacopan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Upifitamab Rilsodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm (epinephrine) Sublingual Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand\u2019s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Gilead\u2019s Trodelvy\u00ae For Pre-Treated HR+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal\u00ae 0.75%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"STK-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cessation Therapeutics Announces Food and Drug Administration Authorization for First-in-Human Clinical Trial of Antibody for Prevention of Fentanyl Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"CSX-1004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cessation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BHV-7000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"LPCN 1148","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tirzepatide Demonstrated Significant and Superior Weight Loss Compared to Placebo in two Pivotal Studies","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved in the EU for Children and Adolescents with Refractory Generalised Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Demonstrated Clinically Meaningful Progression-free Survival and Overall Survival Across Multiple HER2-expressing Advanced Solid Tumours in DESTINY-PanTumor02 Phase II trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$104.0 million","upfrontCash":"$49.2 million","newsHeadline":"Santhera Completes Divestment of Raxone\u00ae\/Idebenone Business to Chiesi Group","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Divestment","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Santhera Pharmaceuticals \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Proposed Public Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$7,300.0 million","upfrontCash":"$7,300.0 million","newsHeadline":"Biogen to Acquire Reata Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":7.2999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":7.2999999999999998,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Tufts Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (\u201cNCP\u201d) Following Announcement of Clinical Trial Agreement with Tufts Medical Center","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Tufts Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$3,800.0 million","upfrontCash":"$200.0 million","newsHeadline":"Ionis Expands Eplontersen Agreement with AstraZeneca to Include Exclusive Rights in Latin America","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":3.7999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":3.7999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums Gets DCGI Nod for Triple Combination Diabetes Medication","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drug.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Zigakibart","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Temferon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Blosozumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR\u2122 (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Denileukin Diftitox-cxdl","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Ajinomoto Company","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ulotaront","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"FivepHusion","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol\u2122 with DRP\u00ae Companion Diagnostics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Allarity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusio.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim-xnst","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$704.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga\u2122 Treatment for Ebola","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Ansuvimab-zykl","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0.69999999999999996,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"Injectable\/Injection","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"USAMMDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Defender Pharmaceuticals Announces Exclusive License Agreement with the U.S. Army for the Development of Products to Treat Tropical Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Defender Pharmaceuticals \/ USAMMDA","highestDevelopmentStatusID":"5","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Solve GNE","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Solve GNE Raises $2.5 Million, Secures Leading Researchers to Help Develop Cure for HIBM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Financing","leadProduct":"GA-002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Solve GNE","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Solve GNE \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Solve GNE .."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Isotope Technologies Munich \/ POINT Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"uBriGene","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"$6.0 million","newsHeadline":"Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ uBriGene","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$548.6 million","upfrontCash":"$548.6 million","newsHeadline":"BioNTech Completes Acquisition of InstaDeep","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.55000000000000004,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep .."},{"orgOrder":0,"company":"Amarin","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa\u00ae (Icosapent Ethyl) in Southeast Asia and South Korea","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Partnership","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ L.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institute of Child Health and Human Development","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ National Institute of Child Health and Human Development","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Invus","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"Zagociguat","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Tisento Therapeutics \/ Invus","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Th.."},{"orgOrder":0,"company":"Alvotech","sponsor":"ATP Holdings","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Completes $100 Million Convertible Bond Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","year":"2023","type":"Private Placement","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ ATP Holdings","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Withdrawal of Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","amount":"$18.7 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra and Searchlight Pharma Announce Donesta\u00ae Licensing Agreement for Canada","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Overnight Marketed Public Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"CYB003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Ca.."},{"orgOrder":0,"company":"Replimune","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"INCB99280","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replimune \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Celloram","sponsor":"Genfit","pharmaFlowCategory":"D","amount":"$175.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cleveland-based Biotech Celloram Inc. Strikes Landmark Licensing Deal with French Biotech GENFIT to Propel its Lead Asset CLM-022 in Liver Disease Treatment","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CLM-022","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Celloram","amount2":0.17999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Celloram \/ Genfit","highestDevelopmentStatusID":"4","companyTruncated":"Celloram \/.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncolytics Biotech\u00ae Announces US$15 Million Bought Deal Offering of Units","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Public Offering","leadProduct":"Pelareorep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Leede Jones Gable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for \u00a315.95m","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Divestment","leadProduct":"C4X_3256","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"C4X Discovery","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"C4X Discovery \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"C4X Discov.."},{"orgOrder":0,"company":"Medomie","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Medomie","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Medomie \/ Aytu BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Medomie \/ .."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Tisento Therapeutics","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"$8.0 million","newsHeadline":"Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Tisento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China\u2019s National Medical Products Administration Accepts Astellas\u2019 Biologics License Application for Zolbetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Provides Update on REZZAYO\u2122 (rezafungin for injection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR\/MSI-H Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Dosing of First Patient Under The Amended Protocol of Its Phase II trial Evaluating Allocetra\u2122 in Patients With Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1\/2 Trial in Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1\/2\/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"UX701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I\/R9) Based on Glycosylated Alpha-dystroglycan (lgmd2i\/r9) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 \u2018STROBE\u2019 Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Marinus Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approval of Ztalmy (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Orion Corporation \/ Marinus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Presents Promising Results on EVX-B1, an AI-designed Vaccine Against Staphylococcus Aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-B1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Invectys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-\u03b1 Inhibitor MYMD-1 in Sarcopenia\/Age-Related Frailty","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harrow Launches VIGAMOX in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Moxifloxacin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Harrow","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ N.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Completion of Patient Enrollment in Nefecon China Open Label Extension Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Taldefgrobep-alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Completes Enrollment in Landmark Phase 3 CARDIO-TTRansform Study in Patients with TTR-mediated Amyloid Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Upamostat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Biosion","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"BSI-045B","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biosion \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ .."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Announces Launch of Breyna\u2122 (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort\u00ae for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC\u00ae ER degrader being developed in ER+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Vepdegestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infec","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"St. Jude Children\u2019s Research Hospital","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renaissance Pharma Launches Today and Announces the In-Licensing of Hu14.18K322A (Hu14.18) from St. Jude Children\u2122s Research Hospital for the Treatment of High-Risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children\u2019s Research Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"St. Jude Children\u2019s Research Hospital \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude C.."},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More than $1 Billion in Additional Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Rev.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"$13.7 million","newsHeadline":"ProQR Therapeutics and Laboratoires Th\u00e9a Announce Agreement for Th\u00e9a to Acquire ProQR\u2019s Sepofarsen and Ultevursen Ophthalmic Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0.16,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.19,"dosageForm":"Injectable\/Injection","sponsorNew":"ProQR Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Negma Group","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Announces Financing Commitments Totaling up to USD 20 Million with Negma Group","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Evaxion Biotech \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"$645.0 million","upfrontCash":"$140.0 million","newsHeadline":"TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI\u00ae (ublituximab-xiiy)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ublituximab-xiiy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0.65000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Xinnovation Therapeutics","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ABV-1504","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Xinnovation Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Prime Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Genetic Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Prime Medicine","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$64.5 million","upfrontCash":"Undisclosed","newsHeadline":"Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"rhENPP1-Fc","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Inozyme Pharma \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"FB-102","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Forte Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Forte Biosciences \/ Alger","highestDevelopmentStatusID":"4","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Aulos","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aulos Bioscience Raises $20 Million in Series A Extension Financing from Apple Tree Partners","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series A Financing","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Aulos \/ Apple Tree Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Ap.."},{"orgOrder":0,"company":"Solu Therapeutics","sponsor":"Longwood","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Solu Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Solu Therapeutics \/ Longwood","highestDevelopmentStatusID":"3","companyTruncated":"Solu Thera.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor\/Ataxia Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Funding","leadProduct":"Allopregnanolone Prodrug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"PureTech Health","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"PureTech Health \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amygdala Neurosciences Awarded $2.0 Million NIH Grant to Conduct IND Enabling Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"ANS-858","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amygdala Neurosciences \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala N.."},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Phoenixus","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Vyera Pharmaceuticals, LLC and Phoenixus AG Sign Asset Purchase Agreement to Sell Rights to Daraprim and Vecamyl","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Pyrimethamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vyera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vyera Pharmaceuticals \/ Phoenixus","highestDevelopmentStatusID":"12","companyTruncated":"Vyera Phar.."},{"orgOrder":0,"company":"Remedium Bio","sponsor":"National Science Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium Awarded National Science Foundation (NSF) Innovation Grant","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"RMD1202","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Remedium Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Remedium Bio \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Remedium B.."},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN\u00ae (Pralatrexate) in China to CASI Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Pralatrexate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Acrotech Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acrotech Biopharma \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acrotech B.."},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"iTolerance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for the Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"iTOL-102","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ iTolerance","highestDevelopmentStatusID":"4","companyTruncated":"Northway B.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-bwwd","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-302","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Actuate Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Elraglusib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Actuate Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actuate Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actuate Th.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Completes Enrollment for \u2018BUENA\u2019 Montelukast VersaFilm\u00ae Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Positive Scientific Advice from European Medicines Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Laboratories, Inc. Announces Filing of its Investigational New Drug Application for Sildenafil Oral Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Completes First Cohort Dosing of Phase l\/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AAVrh10-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Commercial Launch of NexoBrid in Japan","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BAER-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunis\u2019 Phase 1\/2a Clinical Trial Approved by Data Safety and Monitoring Board to Proceed with Dose Escalation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ .."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients Have Been Treated with Immunomodulatory AVM0703 Through Expanded Access\/Compassionate Use Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Harm Reduction Therapeutics\u2019 Over-the-Counter Opioid Overdose Reversal Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071 for Hypoxic Ischemic Encephalopathy in Newborns","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Phase 1 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"PIPE-791","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval from NMPA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"DR10624","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zhejiang Doer Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang D.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DAICHIRONA for Intramuscular Injection (Monovalent: Original Strain), mRNA COVID-19 Vaccine, Approved for Manufacturing and Marketing as Booster Vaccination in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"DS-5670","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CV0601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"3-Methylmethcathinone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Rafael Holdings","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Rafael Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Grunenthal Meds","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$83.2 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal, Kyowa Kirin International Enter Joint Venture Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Grunenthal Meds","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Grunenthal Meds \/ Grunenthal","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Synthetic Tetrahydrocannabinol Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharm.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"$335.0 million","upfrontCash":"$5.0 million","newsHeadline":"Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Indivior","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Closing of Non-Brokered Private Placement of Debenture Units","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$487.7 million","upfrontCash":"Undisclosed","newsHeadline":"CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"CDR202","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0.48999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for Clinical Trial Authorization for EBTATE in Nasopharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-DOTA-EB-TATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Targeting Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Arbele","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbele Announces Early Safety Data for Novel CDH17xCD3 Bispecific T-cell Engager at American Society of Clinical Oncology Breakthrough Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arbele \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ N.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves LONSURF\u00ae (trifluridine\/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Trifluridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Inimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"INI-2004","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Inimmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inimmune \/.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Batiraxcept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","amount":"$147.5 million","upfrontCash":"$17.5 million","newsHeadline":"Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alnylam Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"$45.4 million","upfrontCash":"$29.0 million","newsHeadline":"Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma Under Estelle\u00ae Licensing Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Amber Bio","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amber Bio Raises $26 Million Seed Financing Co-Led by Playground Global and Andreessen Horowitz to Advance New RNA-Based Gene Editing Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Genetic Medicine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Amber Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Amber Bio \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Amber Bio .."},{"orgOrder":0,"company":"Access to Advanced Health Institute","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine through a Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Access to Advanced Health Institute","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Access to Advanced Health Institute \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Access to .."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Announces Exclusive License Agreement with Catalent for its Patented Zydis\u00ae Fast-Dissolve Technology for Use with MM-120","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BlueRock Therapeutics and Bit.Bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) Based Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"iPSC-derived T-cell Based Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ BlueRock Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$60.0 million","newsHeadline":"Ionis Enters Collaboration to Advance Next Generation Program Targeting Lp(a) for Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Pelacarsen","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bill & Melinda Gates Foundation, Children\u2019s Investment Fund Foundation, Pfizer and Becton, Dickinson & Company Expand Partnership for Greater Access to Injectable Contraceptive for Women in Low- and Lower-Middle-Income Countries","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Medroxyprogesterone Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BBP-398","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Astrazeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren\u2019s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request with the US FDA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients with HER2-Positive Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BDC-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Genixus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GENIXUS Announces Launch of KinetiXTM Rocuronium Bromide Injection 5mL & 10mL Ready-to-Administer Syringes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Rocuronium Bromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genixus","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genixus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genixus \/ .."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CEL383","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aardvark Therapeutics Announces Receipt of FDA Rare Pediatric Disease Designation for Prader-Willi Syndrome and Expands the Ongoing Phase 2 Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Denatonium Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Aardvark Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark T.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Announces First Patient Dosed in Phase 1 \/ Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I\/R9 (LGMD2I\/R9)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-1003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perfuse Therapeutics Announces Initiation of Enrollment to the Phase 2A Clinical Trial of PER001 Intravitreal Implant in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"PER-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Perfuse Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Perfuse Th.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Merck\u2019s ERVEBO\u00ae (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ebola Zaire Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. CDC Advisory Committee Unanimously Recommends Routine Use of Beyfortus\u2122 (nirsevimab-alip) to Protect Infants Against RSV Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evox Therapeutics Enters into Agreement to Advance Next Generation Exosome-Delivered AAV Gene Therapy for the Treatment of Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Exosome-encapsulated AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"Cybin","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Closing of Overnight Marketed Public Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Ca.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Laboratorios HIPRA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ACCORD and HIPRA Enter into Exclusive Distribution Agreement to Commercialise HIPRA's COVID-19 vaccine (BIMERVAX\u00ae) in the United Kingdom","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Recombinant, Adjuvanted Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accord healthcare \/ Laboratorios HIPRA","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"APVO436","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod for Generic Rheumatoid Arthritis Treatment Drug","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Indomethacin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImPact Biotech Receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Padeliporfin VTP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Submission of a New Drug Application to The US Food and Drug Administration for its Antibiotic Ceftobiprole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Receives U.S. FDA Approval for IZERVAY\u2122 (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Enzolytics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ITV-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enzolytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Enzolytics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enzolytics.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Retevmo\u00ae (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission (EC) Adopts Decision Endorsing CHMP Recommendation to Revoke the Conditional Marketing Authorization for Adakveo\u00ae (crizanlizumab)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Crizanlizumab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CHIKV VLP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$1,670.0 million","upfrontCash":"$170.0 million","newsHeadline":"DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"DB-1303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Duality Biologics","amount2":1.6699999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6699999999999999,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Hebrew University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"180 Life Sciences \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Lundbeckfonden BioCapital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"IO Biotech, Inc. Announces $75 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"IO Biotech \/ Lundbeckfonden BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","amount":"$43.0 million","upfrontCash":"$43.0 million","newsHeadline":"Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction, New Capital will Expand Ikena's Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"IK-930","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Ikena Oncology \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mira Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Kingswood Investments","highestDevelopmentStatusID":"5","companyTruncated":"Mira Pharm.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gracell Biotechnologies Announces up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"P-MUC1C-ALLO1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Ikena Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Imm.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MBX 1416","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Zedenoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"PRAX-628","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Temozolomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to NS-089\/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Brogidirsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huidagene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HG004","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"HuidaGene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene .."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Glecirasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Announces Completion of Enrollment for Phase I Clinical Trial of HT-6184","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-6184","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Ther.."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces FDA Clearance of Investigational New Drug Application for its First-in-Class CD3\/EGFR Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BC3448","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Viatris \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves ZURZUVAE\u2122 (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Neopharm","sponsor":"Amarin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amarin and Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA\u00ae (Icosapent Ethyl) in Israel","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Neopharm","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neopharm \/ Amarin","highestDevelopmentStatusID":"12","companyTruncated":"Neopharm \/.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$535.0 million","upfrontCash":"$35.0 million","newsHeadline":"Astex Expands Drug Discovery Collaboration with MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Astex Pharmaceuticals","amount2":0.54000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sparian Biosciences Awarded $19 Million Five-Year NIH\/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"SBS-518","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Sparian Biosciences","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sparian Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Sparian Bi.."},{"orgOrder":0,"company":"Celmatix","sponsor":"Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celmatix and Ach\u00e9 Laborat\u00f3rios Announce Collaboration to Investigate a Novel Melatonin Receptor Agonists for Women\u2019s Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Celmatix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celmatix \/ Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"4","companyTruncated":"Celmatix \/.."},{"orgOrder":0,"company":"Novavax","sponsor":"SK Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Matrix-m1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ SK bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$213.0 million","upfrontCash":"$213.0 million","newsHeadline":"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Georgiamune","sponsor":"General Catalyst","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Georgiamune Inc. Achieves US FDA Clearance for Investigational New Drug (IND) Application and Secures $75 Million in Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series A Financing","leadProduct":"GIM-122","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Georgiamune","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Georgiamune \/ General Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"Georgiamun.."},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADARx Pharmaceuticals, a Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series C Financing","leadProduct":"siRNA Duplex Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Phar.."},{"orgOrder":0,"company":"Alltrna","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"tRNA Medicine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alltrna","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Alltrna \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Alltrna \/ .."},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merus Announces Pricing of Public Offering of Common Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Petosemtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Je.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"ResolutionRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mangoceuticals Partners with Greater NY Chamber of Commerce for Mass Marketing & Sales of Flagship Mango Product","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuti.."},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Axolotl Biologix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Axolotl Bi.."},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,400.0 million","newsHeadline":"Lilly Completes Acquisition of DICE Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":2.3999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"DICE Thera.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stealth BioTherapeutics Awarded Grant from The Michael J. Fox Foundation to Support Development of SBT-272 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"SBT-272","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Stealth Biotherapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-\u00ce\u00b2 Agonist TERN-501 in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TERN-101","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"R-Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Perception Neuroscience \/ atai Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Perception.."},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSyent Launches Inofolic\u00ae for Women with Polycystic Ovary Syndrome (PCOS)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Inositol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIOSYENT PHARMA INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT P.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Alke Research Private Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bioxytran \/ Alke Research Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Algernon NeuroScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Algernon NeuroScience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Algernon NeuroScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon N.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Provides Encouraging Camsirubicin Clinical Data Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BMB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bright Minds Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Min.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Semaglutide 2.4 mg Reduces the Risk of Major Adverse Cardiovascular Events by 20% in Adults with Overweight or Obesity in the SELECT Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilamakitug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchestra BioMed\u2122 Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue\u00ae Sirolimus AngioInfusion Balloon\u2122 in Patients with Coronary In-Stent Restenosis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen\u00ae for the Treatment of Post-COVID Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LSTA1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Announces Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants and Toddlers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MV-012-968","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Alisertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ALETA-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aleta Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aleta Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aleta Biot.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the First Launch of an Over-the-counter Naloxone Nasal Spray in The United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS-018, an Investigational Treatment for Myelofibrosis, Receives Orphan Drug Designation from the European Commission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ilginatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ANPD001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aspen Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aspen Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aspen Neur.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin's Vyleesi\u00ae Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Formycon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Formycon","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora in Acute Pancreatitis (AP)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1\/2 ABILITY Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-978","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Remibrutinib Phase III trials Met Their Primary Endpoints and Showed Rapid Symptom Control in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Remibrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VANFLYTA\u00ae Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Plerixafor Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lemonex Announces Approval of IND Application for mRNA-DegradaBALL Vaccine, LEM-mR203, Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LEM-mR203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lemonex Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bi.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Delamanid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Otsuka Pharmaceutical \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-ALZ","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Announces FDA Confirmation that the Ongoing Phase 1\/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces First Patient Enrolled in Phase III Clinical Trial of Leniolisib for the Treatment of APDS in Japan","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences Announces IRB Approval of Key Study Protocol","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxycodone Prodrug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"SYSNAV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pheburane (sodium phenylbutyrate) Coverage Rapidly Expands to the Benefit of Americans with Certain Urea Cycle Disorders (UCDs)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"SYSNAV Healthcare","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pellet","sponsorNew":"SYSNAV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SYSNAV Hea.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Divestment","leadProduct":"Dexrazoxane","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinigen Group \/ CNX Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Smartway Pharmaceuticals","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marius Pharmaceuticals Partners with Smartway to Design and Manage the Global Early Access Program for KYZATREX\u2122 (testosterone undecanoate)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Smartway Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Smartway Pharmaceuticals \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Smartway P.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"GeneFab","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"$38.0 million","newsHeadline":"Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Senti Biosciences \/ GeneFab","highestDevelopmentStatusID":"5","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Huadong Medicine","pharmaFlowCategory":"D","amount":"$94.2 million","upfrontCash":"$30.0 million","newsHeadline":"Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Huadong Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tango Therapeutics Announces $80 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"TNG908","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Spectral Medical Inc. Announces C$5 Million Bought Deal Convertible Note Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,075.0 million","upfrontCash":"$1,075.0 million","newsHeadline":"Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and Other Serious Metabolic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"INV-202","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":1.0800000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox\u2122 Platform Cancer Treatment in the Middle East and North Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rakuten Medical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Corium","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY\u00ae in Multiple Markets Across Asia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Donepezil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ L.."},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eugia Pharma Receives USFDA Approval For Plerixafor Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Phar.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval From The USFDA For Plerixafor Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Initiates Phase 1\/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I\/IIa Trial with Cancer Immunotherapy Drug HTL0039732","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"GPRC5D-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok\u00ae Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Astellas' sNDA for CRESEMBA\u00ae (isavuconazonium sulfate) in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA\u00ae Immunogene Therapy for the Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HyBryte\u2122 Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"AffaMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Saxagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves TALVEY\u2122 (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Talquetamab-tgvs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial Data Suggests Major Breakthrough in Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CD.."},{"orgOrder":0,"company":"Rising Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address Lead Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Rising Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rising Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rising Pha.."},{"orgOrder":0,"company":"AceLink Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AL01211","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AceLink Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Th.."},{"orgOrder":0,"company":"CAS","sponsor":"Molecule.one","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CAS and Molecule.one Announce a Strategic Collaboration to Accelerate Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"CAS","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CAS \/ Molecule.one","highestDevelopmentStatusID":"2","companyTruncated":"CAS \/ Mole.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Benitec Biopharma \/ JMP Securities","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$3,500.0 million","upfrontCash":"$3,500.0 million","newsHeadline":"Novartis Completes Acquisition of Chinook Therapeutics","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":3.5,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":3.5,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Zetagen Therapeutics","sponsor":"New York Ventures","pharmaFlowCategory":"D","amount":"$9.7 million","upfrontCash":"Undisclosed","newsHeadline":"Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet\u2122 and ZetaMAST\u2122 for Treatment of Metastatic Bone and Soft Tissue Lesions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"ZetaMAST","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zetagen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Zetagen Therapeutics \/ New York Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Zetagen Th.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyanutra\u2122 RH Hair Nourishing Shield-Innovation Hyaluronic Acid Hair Care Solution","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bloomage Biotech Presents Nourishing Anti-Frizz Repairing Hairspray at in-cosmetics Global 2023 The Formulation Lab\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B\u2122 in Hypoplastic Left Heart Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves AKEEGA\u2122 (Niraparib and Abiraterone Acetate), the First-and-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Designates PYC'S Lead as a Fast Track Development Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"VP-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"PYC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PYC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PYC Therap.."},{"orgOrder":0,"company":"Zumutor Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zumutor Biologics Inc Announces FDA Clearance of IND Application of ZM008, a Novel Monoclonal Antibody Drug Against Multiple Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ZM008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zumutor Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zumutor Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zumutor Bi.."},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Signals of Effect in Annexin's RVO-Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Annexin A5","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Ph.."},{"orgOrder":0,"company":"Antengene","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$101.5 million","upfrontCash":"$27.6 million","newsHeadline":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First\/Only-in-Class XPO1 Inhibitor XPOVIO\u00ae(selinexor) in the Mainland of China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Antengene \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Follows Gilead in Axing Cancer Trials as Data Disappoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$189.0 million","upfrontCash":"$10.0 million","newsHeadline":"Incyte Drops Syros Blood Cancer Partnership, Following Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Syros Pharmaceuticals","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.20000000000000001,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with M\u00f6lnlycke on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke .."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Gritstone bio","pharmaFlowCategory":"D","amount":"$136.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone bio and Genevant Sciences Announce Option and License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"samRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Genevant Sciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Genevant Sciences \/ Gritstone bio","highestDevelopmentStatusID":"1","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Spexis Announces USD $2.5 Million Capital Commitment to Support the Upcoming Phase 3 ColiFin\u00ae Studies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ S.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Closing of $3 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Genosera","sponsor":"Solve GNE","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"GA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Genosera","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genosera \/ Solve GNE","highestDevelopmentStatusID":"4","companyTruncated":"Genosera \/.."},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$306.0 million","upfrontCash":"$66.0 million","newsHeadline":"Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Tentarix Biotherapeutics","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Tentarix B.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Announces $150 Million Private Placement Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.14999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","amount":"$662.0 million","upfrontCash":"$29.0 million","newsHeadline":"Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0.66000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Searchlight Pharma Announces Suvexx\u00ae Launch in Europe, Along with Deal Expansion to all E.U. Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Naproxen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Nuvo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvo Pharmaceuticals \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Nuvo Pharm.."},{"orgOrder":0,"company":"Biddle Sawyer Corporation","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TAE Life Sciences Signs Biddle Sawyer to Manufacture Boronated TC220 Drug for BNCT Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"TC220","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Biddle Sawyer Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biddle Sawyer Corporation \/ TAE Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Biddle Saw.."},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,925.0 million","upfrontCash":"$1,925.0 million","newsHeadline":"Lilly Completes Acquisition of Versanis Bio","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis B.."},{"orgOrder":0,"company":"Remington Pharmaceuticals","sponsor":"TB Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Pretomanid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Remington Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Remington Pharmaceuticals \/ TB Alliance","highestDevelopmentStatusID":"12","companyTruncated":"Remington .."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly Completes Acquisition of Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"SIG-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sigilon Therapeutics","amount2":0.34000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s ELREXFIO\u2122 Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Elranatamab-bcmm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves First Therapeutic Indication for Revance\u2019s DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"JKB-122","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Immune Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immune The.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Olitigaltin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive Results from Mylight Phase lll Study for Biosimilar Aflibercept","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"DT-216","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Design Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Design The.."},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Prolonged-release Formulation","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain.."},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SFA Therapeutics Announces Results for SFA-002 from Phase 1b Cohort 1 Clinical Trial for Treatment of Mild-to-Moderate Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Magnesium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therap.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Exaluren Sulfate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride for Injection Concentrate, USP","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Polaris Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegargiminase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Global Coalition for Adaptive Research \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venatorx Pharmaceuticals Announces FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Wugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R\/R) Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"WU-NK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Wugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wugen \/ No.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO\u00ae (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R\/R) Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene's OX40 mAb, with an Extended Half-life and Silenced ADCC, Enters POC Study in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMG-007","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1044","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Impilo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Nucleic Acid-based Medicine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Impilo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Impilo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Impilo The.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CUSP06","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnCusp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp The.."},{"orgOrder":0,"company":"MedAlliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedAlliance Announces the Completion of Enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MedAlliance","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"MedAlliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MedAllianc.."},{"orgOrder":0,"company":"Arcellx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CART-ddBCMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcellx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcellx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Tumor Control for Fostrox in Combination with Lenvima in Ongoing Phase 2a Study in HCC, 15th Patient Included","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Radius Health","sponsor":"DRI Healthcare","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$130.0 million","newsHeadline":"Radius Announces Royalty Purchase Agreement with DRI Healthcare to Sell a Portion of its Royalty and Commercial Milestone Interest in Elacestrant for up to $140 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Radius Health","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Radius Health \/ DRI Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Yangtze River-CMB International Industry Fund","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series C Financing","leadProduct":"Esonadogene Imvoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"$125.0 million","newsHeadline":"COMPASS Pathways Announces up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0.28999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.28999999999999998,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS\u2122 Immunotherapy for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$316.0 million","upfrontCash":"$3.0 million","newsHeadline":"Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Sprint Bioscience \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bio.."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"CervoMed","sponsor":"EIP Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CervoMed Announces Completion of Merger with EIP Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ EIP Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces First Data from Ongoing Multicenter Phase 1\/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mangoceuticals Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuti.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TNX-1500","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK\u00ae Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Artiva Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Announces First Patient Rolled-Over to Open-Label Extension of RESCUE, a Phase 2 Clinical Trial of SPI-62 for ACTH-Dependent Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN\u00ae) in Patients with Previously Treated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bluebird bio Confirms that FDA has Communicated that Advisory Committee Meeting will not be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the NMPA Approval of SINTBILO\u00ae (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Tiotropium Dry Powder for Inhaler for the Treatment of COPD in the United States","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tiotropium Bromide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"EO-3021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seagen Phase 3 Trial of TUKYSA (tucatinib) in Combination with Antibody-Drug Conjugate Ado-trastuzumab Emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Magenta Therapeutics and Bluebird Bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta\u2019s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"MGTA-145","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ bluebird bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"4Living Biotech and Sanofi Enter into a Collaboration Agreement to Demonstrate Potential Clinical Efficacy of Mozobil\u00ae as a Treatment for Acute and Chronic Complications of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"4P-Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4P-Pharma \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma .."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces $1.9 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"BX1000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Baudax Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Extension of Existing Loan Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"ABC008","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.16,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.16,"dosageForm":"Injectable\/Injection","sponsorNew":"Abcuro, Inc \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, In.."},{"orgOrder":0,"company":"TFC Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFC Therapeutics Launches to Advance Novel Platform and Technologies in Cancer Biology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"TFC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFC Therapeutics \/ Columbia University","highestDevelopmentStatusID":"2","companyTruncated":"TFC Therap.."},{"orgOrder":0,"company":"TheracosBio","sponsor":"SmithRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy\u2122 (bexagliflozin) to Members with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Bexagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"TheracosBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ SmithRx","highestDevelopmentStatusID":"12","companyTruncated":"TheracosBi.."},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altruix Approved to Dispense Brixadi\u00ae for Moderate to Severe Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/.."},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meitheal Pharmaceuticals has Plerixafor Injection Now Available","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal P.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Announces Positive Preliminary Results From Phase 2 Clinical Trial of Mgta-145 in Multiple Myeloma and Provides An Update on Its Anticipated Clinical Study with MGTA-117","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"MGTA-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Nanjing Jianyou Biochemical Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. About the Subsidiary Product Plerixafor Injection Announcement of US FDA approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Plerixafor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Nanjing Jianyou Biochemical Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nanjing Jianyou Biochemical Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nanjing Ji.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpha Tau Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed\/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Odronextamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NXP800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextPoint Therapeutics Announces First Patient Dosed in Phase 1a\/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NPX267","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"RDX-002","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Response P.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Announces First Patient Dosed in Phase I\/II Clinical Trial of Second Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NFS-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IKT-001PRO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Bloom Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BL-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bloom Science \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Scie.."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MH004","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces European Commission Approval of AQUIPTA\u00ae (atogepant) for the Preventive Treatment of Migraine in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atogepant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Clinical Trial Data Confirm its Updated Covid-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1273.815","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"3Z","sponsor":"biotx.ai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"3Z","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3Z \/ biotx.ai","highestDevelopmentStatusID":"2","companyTruncated":"3Z \/ biotx.."},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Alzheimer's Drug Discovery Foundation","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals\u2019 $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"AST-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Astrocyte Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Alzheimer's Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Astrocyte .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"$28.3 million","newsHeadline":"Lupin Acquires Brands ONDERO\u00ae and ONDERO MET\u00ae to Expand Diabetes Portfolio in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Linagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets U.S. FDA nod for Generic Icatibant Injection","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives USFDA Final Approval for Solifenacin Succinate Tablets","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDSCO Panel Gives Nod for FDC Tamsulosin + Solifenacin","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Tamsulosin","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MSN Laboratories Gets CDSCO Panel Nod For FDCs Solifenacin, Mirabegron Capsules","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"MSN Laboratories","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"MSN Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MSN Labora.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veopoz\u2122 (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Pozelimab-bbfg","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Reduced Dosing Frequency for Janssen\u2019s Bispecific Antibody TECVAYLI\u00ae (teclistamab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Teclistamab-cqyv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BITT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BITT Announces FDA Acceptance of IND for TNFR2 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BITT2101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BITT","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BITT \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BITT \/ Not.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Su.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene's anti-OX40 mAb Demonstrated an Extended Half-life And a Favorable Safety Profile in a Phase I study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMG-007","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Full Approval of TARPEYO for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces FDA Approval of INGREZZA\u00ae (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim to Advance Survodutide into Three Global Phase III Studies in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Survodutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in China to Reduce the Risk of Cardiovascular Death And Hospitalisation in Adult Patients With Symptomatic Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"IVERIC bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Iveric Bio\u2019s Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Astellas Pharma \/ Iveric Bio","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces WELIREG\u00ae (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Belzutifan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-\/-) Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AMG 193","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Announces $20.4 Million Private Placement Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Affinity Asset Advisors","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"$14.0 million","newsHeadline":"LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ LEO Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2023","year":"2023","type":"Divestment","leadProduct":"Beremagene Geperpavec-svdt","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Krystal Biotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"GordonMD\u00ae Invests in Private Placement for Taysha Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.14999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ GordonMD Global Investments","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genesis Therapeutics Closes Oversubscribed $200 Million Series B","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Th.."},{"orgOrder":0,"company":"Abivax","sponsor":"Kreos Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ K.."},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Mysthera Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mysthera Therapeutics \/ Forty51 Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mysthera T.."},{"orgOrder":0,"company":"Bird Rock Bio","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Skye Acquires Bird Rock Bio","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Nimacimab","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Bird Rock Bio","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Bird Rock Bio \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Bird Rock .."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"SBI-100","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Skye Bioscience","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ 5AM Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Korea's SK Biopharma Enters MENA Through Strategic Partnership with Hikma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SK Biopharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Claudin18.2 mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IR.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tnx-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pottsville Residents with Non-Alcoholic Steatohepatitis (NASH) Liver Disease Can Now Join New Research Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Selonabant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Anebulo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Expands Generics Portfolio with Launch of Mesalamine Extended-Release Capsules, USP","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesalazine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Jiangsu Hengrui Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Doses First Patient with ZE46-0134, A Selective FLT3WT-Sparing, Pan FLT3Mut Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ZE46-0134","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean The.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Initiates Development of Second Generation c-Abl Inhibitors and Names IkT-148009 as Risvodetinib","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib Succinate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"CanariaBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MAb-AR20.5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CanariaBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CanariaBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CanariaBio.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE705","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon\u00ae for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Discuss Application For Lumakras (Sotorasib) for the Treatment of KRAS G12C-positive NSCLC at FDA Advisory Committee Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves ABRYSVO\u2122, Pfizer\u2019s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa\u00ae (darolutamide) for Planned Phase 1b\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$326.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Monoclonal Antibody Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0.33000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WuXi Advanced Therapies \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advan.."},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exavir Therapeutics Receives $3M Award from NIH \/ NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"XVIR-110","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Exavir Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Exavir Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"Exavir The.."},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Techdow USA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Fosaprepitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA","highestDevelopmentStatusID":"12","companyTruncated":"Chia Tai T.."},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating De Novo Coronary Artery Disease (CAD)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced N.."},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sinorda Biomedicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Biopharmaceuticals and Sinorda Biomedicine Signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanyou Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine","highestDevelopmentStatusID":"4","companyTruncated":"Sanyou Bio.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Provides Update on Mesdopetam's Phase IIb Study Data and the Plans Toward Phase III","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Phase 1a\/1b Human Clinical Trial of NV-CoV-2, the Company\u2019s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celcuity Announces Plan to Conduct Phase 1b\/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces FDA Clearance of IND for VIP943","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"VIP943","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"AKAVA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AKV9","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AKAVA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AKAVA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AKAVA Ther.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"VENT-02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Retevmo\u00ae (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"GT20029","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Shingrix Data Demonstrate 100% Vaccine Efficacy in the Prevention of Shingles in Adults Aged 50 and Over in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Zoster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"APRINOIA Therapeutics","sponsor":"ROSS Acquisition Corp II","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Termination","leadProduct":"APNmAb005","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"APRINOIA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II","highestDevelopmentStatusID":"6","companyTruncated":"APRINOIA T.."},{"orgOrder":0,"company":"GRI Bio","sponsor":"Aardvark Therapeutics","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GRI Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Immediate-Release Tablet","sponsorNew":"GRI Bio \/ Aardvark Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Apexigen","sponsor":"Pyxis Oncology","pharmaFlowCategory":"D","amount":"$10.7 million","upfrontCash":"Undisclosed","newsHeadline":"Pyxis Oncology Successfully Completes Acquisition of Apexigen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Apexigen","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Apexigen \/ Pyxis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Apexigen \/.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$300.0 million","newsHeadline":"Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin\u00ae (nadofaragene firadenovec-vncg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Nadofaragene Firadenovec-vncg","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.5,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Awarded US$3.67 Million (AU$5.4 million) from Global Charitable Foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination Using Needle-Free Vaccine Patch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"Typhoid Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ Wellcome","highestDevelopmentStatusID":"5","companyTruncated":"Vaxxas \/ W.."},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"SR One","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series D Financing","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fore Biotherapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Fore Biotherapeutics \/ SR One","highestDevelopmentStatusID":"7","companyTruncated":"Fore Bioth.."},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rapport Therapeutics Raises $150 Million in Series B Funding Round and Announces Key Board Appointments to Further Advance Precision Neuromedicine Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Rapport Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rapport Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Rapport Th.."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ\u2122 (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Pozelimab-bbfg","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"FXR314","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Organovo Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo H.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Completes Stage 1 Data Analysis of Phase I\/II Clinical Trial for the Treatment of Burn Wound Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Sapu Bioscience","sponsor":"Cromos Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapu BioScience and Cromos Pharma initiating P201 \u201c A Registrational trial for OT-101 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Trabedersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sapu Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sapu Bioscience \/ Cromos Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sapu Biosc.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Completes Enrollment of Phase 1b\/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LP352","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT\/BAL Program in Multiple Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 Mediated Pre-Term Preeclampsia","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"siRNA-2283","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Comanche Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche B.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Results from a Phase 3 Clinical Trial in Subjects with Noninfectious Anterior Uveitis Including Subjects with Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for XTANDI\u00ae in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in Japan as First HER2 Directed Therapy for Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan\u00ae Approved for Lupus Nephritis that has Not Responded Sufficiently to Existing Therapies","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Rituximab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Zenyaku Kogyo","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Zenyaku Ko.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Plus Abiraterone Approved in Japan for the Treatment of BRCA-mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved in Japan for Paediatric Patients with Generalised Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marksans Receives USFDA Approval for Guaifenesin Extended-Release Tablets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Guaifenesin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans P.."},{"orgOrder":0,"company":"Imunon","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"DNA-based Lassa Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Announces $12 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Suspension","sponsorNew":"Eyenovia \/ William Blair","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"PHP-303","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/.."},{"orgOrder":0,"company":"Celyad Oncology","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments from Historical Shareholders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"B7-H6 Specific CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Celyad Oncology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Celyad Oncology \/ Fortress Investment Group","highestDevelopmentStatusID":"4","companyTruncated":"Celyad Onc.."},{"orgOrder":0,"company":"TerThera","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radiopharm Theranostics Expands Supply Agreement with TerThera for Terbium-161 Isotope Use in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"RAD 402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TerThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TerThera \/ Radiopharm Theranostics","highestDevelopmentStatusID":"4","companyTruncated":"TerThera \/.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$70.1 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra Prices Private Placement to Raise EUR 20 Million in Equity","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Mithra Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Fondazione Telethon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of a Fondazione Telethon and Naples University Researcher Showing Piclidenoson is Efficacious in Treating Lowe Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Fondazione Telethon","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves CYSTADROPS\u00ae (Cysteamine Ophthalmic Solution) 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cysteamine Bitartrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Scientis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyspera\u00ae Launches New Three-Step System with Novel Pigment Corrector to Treat Hyperpigmentation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Cysteamine Bitartrate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Scientis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scientis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scientis \/.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics Plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI\u00ae (Cysteamine Bitartrate) Delayed-Release Oral Granules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cysteamine Bitartrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics Plc Announces Availability of PROCYSBI\u00ae (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cysteamine Bitartrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camber Pharmaceuticals Launches Generic Vesicare\u00ae","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Camber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Camber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camber Pha.."},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Modified Release Tablet","sponsorNew":"Adalvo \/ Adamed Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ A.."},{"orgOrder":0,"company":"Sawai Pharmaceutical Co., Ltd.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Sawai Pharmaceutical Co., Ltd.","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sawai Pharmaceutical Co., Ltd. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sawai Phar.."},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JB Chemicals Gets USFDA Nod to Market Generic Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxepin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"J.B.Chemic.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives FDA Approval for Tyruko (natalizumab-sztn), First and Only FDA-Approved Biosimilar for Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Natalizumab-sztn","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Polpharma","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Doses Patients in Phase I\/II Clinical Trial of RECCE 327 for Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"SNK02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ITI-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s ABRYSVO\u2122 to Help Protect Infants through Maternal Immunization and Older Adults from RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Veklury\u00ae (Remdesivir) to Treat COVID-19 in People with Mild to Severe Hepatic Impairment With No Dose Adjustment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ALE.C04","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ABA-201","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Abata Ther.."},{"orgOrder":0,"company":"Novaliq","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Novaliq\u2019s Marketing Authorization Application for CyclASol\u00ae (ciclosporin ophthalmic solution) 0.1% for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novaliq","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Novaliq \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novaliq \/ .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon\u00ae for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maplight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of The Novel Muscarinic Receptor Agonist ML-007","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ML-007","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight T.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Development of Novel Formulation of Risvodetinib","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced NDA Acceptance of IL-12\/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ebdarokimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"CPC Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Studies with Finerenone Across a Wide Range of Heart Failure Patients Initiated","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ CPC Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Announces Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Nura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NB-4746","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nura Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/.."},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"AHB-137","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio .."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Treated at the Highest Dose Level in Clarity's Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"64Cu SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Supplemental Biologics License Application to the U.S. Food and Drug Administration Seeking Approval of RYBREVANT (amivantamab-vmjw) in Combination with Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metasta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"HanX Biopharmaceuticals","sponsor":"Crown Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HX009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HanX Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HanX Biopharmaceuticals \/ Crown Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"HanX Bioph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"MK-0616","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Semaglutide 2.4 mg Shows Large Reductions in Heart Failure-Related Symptoms and Physical Limitations in People with Heart Failure with Preserved Ejection Fraction and Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$62.5 million","newsHeadline":"Sandoz Completes Acquisition of Leading Antifungal Agent Mycamine\u00ae from Astellas, Reinforcing Leading Global Anti-Infectives Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Micafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong\u2019s Botulinum Toxin Wins 'World\u2019s 1st' Nod to Treat Square Jaw","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Secondary Analysis of Clear Outcomes Data for Bempedoic Acid Show Significant Risk Reduction of Total Cardiovascular Events and No Increase of New-Onset Diabetes in Patients at High-Risk of Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER\u00ae","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Receives Green Light for Higher Dose in Rapid Infusion Phase I\/II UTI Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Alloksys Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alloksys Reports Interim Results of Its Clinical Phase IIb Trial with Alkaline Phosphatase Therapy RESCAP\u00ae in Critical Care Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Alkaline Phosphatase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alloksys Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alloksys Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alloksys L.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin to Acquire Small Pharma Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$16.6 million","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Tris Pharma Inc","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","amount":"$637.0 million","upfrontCash":"$11.5 million","newsHeadline":"Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Verastem Oncology","amount2":0.64000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$34.0 million","newsHeadline":"ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE\u00ae in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"CSL","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"CSL \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ BARD.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0.029999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Superluminal Medicines \/ RA Capital","highestDevelopmentStatusID":"2","companyTruncated":"Superlumin.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO's Cardiovascular Gene Therapies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"LX2021","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS\u00ae (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Treated Using NorthStar Medical Radioisotopes\u2019 Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals\u2019 Phase I\/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"67Cu-Sartate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Bristol Myers Squibb\u2019s Reblozyl\u00ae (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA\u00ae (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Grow","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"NeuroDerm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease at 2023 International Congress of Parkinson's Disease and Movement Disorders Society (MDS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ NeuroDerm","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents New Long-Term Leqvio\u00ae (inclisiran) Data Demonstrating Consistent Efficacy and Safety Beyond Six Years","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Inclisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM9033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour Bi.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Savolitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces First Patient Dosed in Phase I\/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ONL1204","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ONL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therap.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Gel","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","amount":"$56.5 million","upfrontCash":"$11.5 million","newsHeadline":"Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA\u2122 from Relief Therapeutics, Excluding the Geographical Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Relief Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Merger","leadProduct":"POZ-apomorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AgeX Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission approves Roches Evrysdi for babies under two months old with spinal muscular atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexmarilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Genexine","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine\u2019s long-acting growth hormone meets Phase 3 primary endpoint","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftansomatropin Alfa","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ I-Mab Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Omicron XBB.1.5-adapted Monovalent COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Menarini","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Menarini Group Announces ELZONRIS\u00ae (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tagraxofusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Menarini \/ Nippon Shinyaku","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"STP707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"APL-1401","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions\u2019 NARCAN\u00ae Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRxs Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"SparingVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I\/II Gene Therapy Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SparingVision \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Qatar Holding","pharmaFlowCategory":"D","amount":"$38.6 million","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Announces a Financing of Approximately \u20ac35.7 Million from New and Existing Investors, Consisting of a \u20ac30.6 Million Reserved Capital Increase and a \u20ac5.1 Million Issuance of Royalty Certificates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inventiva Pharma \/ Qatar Holding","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience Announces $7.0 Million Registered Direct Offering Priced at-the-Market under Nasdaq Rules","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$57.6 million","upfrontCash":"Undisclosed","newsHeadline":"Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0M (US$57.6 million\u00b9)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ U.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"EuBiologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Euvichol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GC Biopharma \/ Eubiologics","highestDevelopmentStatusID":"12","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Treeway","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Treeway Licensing Deal with Specialised Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Treeway","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Treeway \/ Specialised Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Treeway \/ .."},{"orgOrder":0,"company":"Vaxxas","sponsor":"SK Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Typhoid Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Vaxxas \/ SK bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ S.."},{"orgOrder":0,"company":"Phost'in Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho Pharmaceutical and Phost\u2019in Therapeutics Announce an Option and License Agreement on the First-in-Class GnT-V Inhibitor PhOx430","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Licensing Agreement","leadProduct":"PhOx430","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phost\\'in Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phost\\'in Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Phost\\'in .."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$59.2 million","upfrontCash":"$59.2 million","newsHeadline":"Otsuka Pharmaceutical to Acquire Mindset Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mindset Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"BITT","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BITT Announces NIH Award for Advancement of Anti-CD40 Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"BITT-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BITT \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ Nat.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"BriaPro Therapeutics","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Demerger","leadProduct":"Bria-TILsRx","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaPro Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaPro Therapeutics \/ BriaCell Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"BriaPro Th.."},{"orgOrder":0,"company":"Pardes Biosciences","sponsor":"MediPacific","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pardes Biosciences Announces Closing of Tender Offer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Pomotrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pardes Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Pardes Biosciences \/ MediPacific","highestDevelopmentStatusID":"8","companyTruncated":"Pardes Bio.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Expands AI Capabilities of RADR\u00ae Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Provides Update on Phase 3 ENGOT-ov50 \/ GOG-3029 \/ INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NovoTTF-100L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces Start of Phase 2 Study with Selective TYK2 Inhibitor, GLPG3667, in Patients With Active Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"GLPG3667","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an Anti-IL-6 Antibody With a Differentiated Profile for the Treatment of Thyroid Eye Disease (TED)","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Tourmaline Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BEN-8744","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Povetacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (mdc-CWM), a First-in-Class Therapy for Localized Pain Relief After Total Knee Replacement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces all U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to Treat Dry Eye Disease (\u201cDED\u201d)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Accepts Valneva\u2019s Chikungunya Vaccine License Application for Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TTI-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Expands Clinical Development Program Investigating Finerenone for Potential Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTIMIS Post-hoc Results on Imaging Stroke Data Using Artificial Intelligence Reinforces Glenzocimab Mode of Action in Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE\u2122 Commercial Launch and Pipeline Advancement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit\/Hyperactivity Disorder (ADHD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ISA104","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"ABNCoV2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and\/or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-010 Trial Evaluating LENVIMA\u00ae (lenvatinib) Plus KEYTRUDA\u00ae (pembrolizumab) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Alecensa Delivers Positive Phase III Results for People with ALK-Positive Early-Stage Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union\n30 August 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cadrenal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"OMTX705","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Propranolol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dendritic Cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Curadh","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"Actinium-225 Conjugated Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Curadh","highestDevelopmentStatusID":"4","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Cannabidiolic Acid Complex","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"RS BioTherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"4","companyTruncated":"RS BioTher.."},{"orgOrder":0,"company":"Immgenuity","sponsor":"Biostax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"IMTVO14","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immgenuity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immgenuity \/ Biostax","highestDevelopmentStatusID":"4","companyTruncated":"Immgenuity.."},{"orgOrder":0,"company":"Celularity","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celularity Announces Multi-Year Research Collaboration Services Agreement with Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Allogeneic Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$8.1 million","upfrontCash":"Undisclosed","newsHeadline":"ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Funding","leadProduct":"INNA-051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Embark Biotech","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$511.1 million","upfrontCash":"$16.2 million","newsHeadline":"Novo Nordisk Acquires Embark Biotech, Including its Lead Asset Targeting Obesity and Other Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Embark Biotech","amount2":0.51000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Embark Biotech \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Embark Bio.."},{"orgOrder":0,"company":"Intarcia Therapeutics","sponsor":"i2o Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intarcia, a Former Biotech Unicorn, Gets New Life with Startup Deal","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"i2o-105","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Intarcia Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intarcia Therapeutics \/ i2o Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Intarcia T.."},{"orgOrder":0,"company":"Elastin Biosciences","sponsor":"Longaevus Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration: Paving the Way for Treatment of Elastin-Deficiency Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Demerger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Elastin Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elastin Biosciences \/ Longaevus Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Elastin Bi.."},{"orgOrder":0,"company":"Epigenic Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Epigenic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Epigenic Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Epigenic T.."},{"orgOrder":0,"company":"Emergence Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Enfortumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Emergence Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergence Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Emergence .."},{"orgOrder":0,"company":"Akeso","sponsor":"Summit Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1\/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Summit Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Su.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Receives Health Canada\u2019s Approval to Initiate Phase 2\/3 Clinical Trial in Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deflazacort","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE 327 at 3,000mg in Phase I\/II UTI\/Urosepsis Rapid Infusion Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"TSC-203-A0201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Roche's Evrysdi For Babies Under Two Months Old with Spinal Muscular Atrophy (SMA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Pharma Arm Gets USFDA Nod for Generic Mycophenolate Mofetil Oral Suspension","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated Advanced Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ABM-1310","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Provides Additional Positive Update on Patients Treated Under \u201cSpecial Access Scheme\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Regulatory Submission Accepted for Review by Japanese Regulator for Use of Nucala (Mepolizumab) in Adults with Chronic Rhinosinusitis with Nasal Polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"CCM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CCM Biosciences Launches from Stealth to Advance Portfolio of Proprietary, First-in-Class Therapies and Companion Diagnostic Tests Across Multiple Therapeutic Areas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"KRAS Gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CCM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CCM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"CCM Biosci.."},{"orgOrder":0,"company":"Oncorena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncorena's First Patient Treated with ONC175 (Orellanine) in Clinical Phase I\/II Trial in Patients with Metastatic Renal Cancer and Dialysis at Karolinska University Hospital in Stockholm, Sweden","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Orellanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncorena","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncorena \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncorena \/.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Reports Promising Interim Data, Including a First Complete Response in Phase 1B\/2A HCC Study with Fostrox in Combination with Lenvima","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Actor Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"$48.6 million","upfrontCash":"$48.6 million","newsHeadline":"Cipla to Acquire South Africa-based Actor Pharma","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Glycine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Actor Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Gel","sponsorNew":"Actor Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Actor Phar.."},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"U.S. Army DEVCOM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON Signs Bacteriophage Development Project with U.S. Army DEVCOM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"iNtRON Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iNtRON Biotechnology \/ U.S. Army DEVCOM","highestDevelopmentStatusID":"3","companyTruncated":"iNtRON Bio.."},{"orgOrder":0,"company":"Nestle","sponsor":"Stallergenes Greer","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stallergenes Greer Announces Global Agreement with Nestl\u00e9 Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Divestment","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Nestle","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle \/ Stallergenes Greer","highestDevelopmentStatusID":"12","companyTruncated":"Nestle \/ S.."},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Receives UKMHRA Approval for Mouth-dissolving Strips to Treat Illnesses","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Med.."},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab and Seagen Announce that TIVDAK\u00ae (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ S.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Approved in China for Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$343.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Reacquires the World-Wide Rights to Aprocitentan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Aprocitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0.34000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34000000000000002,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Axolotl Biologix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Axolotl Bi.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Financing","leadProduct":"lonapegsomatropin-tcgd","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendis Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"TT-10","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Portage Biotech \/ Merck & co","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Douglas Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience Completes Previously Announced Equity Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Douglas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Paradigm BioCapital","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces Combined Financing for up to $180 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Palazestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Olema Oncology \/ Paradigm BioCapital","highestDevelopmentStatusID":"6","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"PsychoGenics","sponsor":"SBIR Grant","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"PsychoGenics and Collaborations Pharmaceuticals Awarded a $1 M Grant to Use AI Platforms to Design New Drugs for Mental Health Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"PsychoGenics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PsychoGenics \/ SBIR Grant","highestDevelopmentStatusID":"2","companyTruncated":"PsychoGeni.."},{"orgOrder":0,"company":"Star Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Star Therapeutics Raises $90 Million Financing to Accelerate its Pipeline of Novel Antibody Therapies and Growth of its Portfolio Companies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series C Financing","leadProduct":"VGA039","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Star Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Star Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"6","companyTruncated":"Star Thera.."},{"orgOrder":0,"company":"XtalPi","sponsor":"Parthenon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XtalPi and Parthenon Enter into AI-Powered Antibody Discovery Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"XtalPi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ Parthenon Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"XtalPi \/ P.."},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Synthetic Tetrahydrocannabinol Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ MZ Group","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharm.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Queen Mary University of London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Queen Mary University of London","highestDevelopmentStatusID":"2","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$50.0 million","newsHeadline":"Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Obexelimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenas BioPharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioP.."},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"GT-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Giiant pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Giiant pharma \/ Palisade Bio","highestDevelopmentStatusID":"5","companyTruncated":"Giiant pha.."},{"orgOrder":0,"company":"Tramontane Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Tramontane Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tramontane Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Tramontane.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$780.0 million","upfrontCash":"$27.0 million","newsHeadline":"Cidara Therapeutics Announces Janssen's Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0.78000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.78000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"Cidara Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Tuspetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Trevena","sponsor":"CBC Group","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$15.0 million","newsHeadline":"Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Trevena \/ CBC Group","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Anova Enterprises","sponsor":"Dizal Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anova Partners with Dizal (Jiangsu) Pharmaceuticals to Accelerate Development of DZD9008 for Patients with Advanced or Metastatic NSCLC with EGFR Exon20 Insertion Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Anova Enterprises","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anova Enterprises \/ Dizal Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Anova Ente.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Awarded Contract from Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"CTMC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL\u00ae) Therapies for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"KSQ-001EX","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ CTMC","highestDevelopmentStatusID":"5","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"IMIDomics","sponsor":"TNAX Biopharma Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TNAX101A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMIDomics \/ TNAX Biopharma Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics .."},{"orgOrder":0,"company":"Rejuvenation Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Rejuvenation Technologies Raises $10.6M Seed Financing Led by Khosla Ventures to Develop mRNA Therapeutics to Reverse Aging","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"RTI-LNG1","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Rejuvenation Technologies","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rejuvenation Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Rejuvenati.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo\u00ae (cemiplimab) in ONM-501 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OncoNano Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix B.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"NDI-101150","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$226.5 million","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics Closes $226.5 Million Series C Financing Led by Patient Square Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Apollo The.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to Expand Access to Medication for COPD Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Tiotropium Bromide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Lupin Ltd \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Johns Hopkins University","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"invIOs Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"APN401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invios \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ A.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Laboratories Announces IND Clearance by U.S. FDA, Enabling Launch of Bioequivalence and Food-Effect Studies for Sildenafil Oral Spray","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual \u201cR&D Day\u201d","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"WVE-006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AMT-260","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1\/2a Trial for Leptomeningeal Metastase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KB408","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"EsoCap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EsoCap Completes Patient Recruitment in ACESO Phase II Trial in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ N.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX71149","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Genentech\u2019s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Registrational Phase III Trial in Type 1 Diabetes with Diamyd\u00ae Expands to the US","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Human Glutamic Acid Decarboxylase","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"MedAlliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedAlliance Announces Enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MedAlliance","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"MedAlliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MedAllianc.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BHV-7000","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Zidesamtinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)\/Dolutegravir (DTG)\/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Abacavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Soquelitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VXA-G1.1-NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbus Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Study in Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Lineage Cell Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IPSC-derived Cell Ttransplant Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eterna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lineage Cell Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Eterna The.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX\u2122 (Ketamine) to the FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TRV045","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1\/2-mutant and Other HRD+ Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall Survival in Patients Undergoing Hematopoietic Stem Cell Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"SpineThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpineThera Announces Breakthrough Market Research Results for SX600 in the Management of Sciatica Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"SpineThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Calcium Gluconate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Dr. Vince Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics\u2019 CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ Dr. Vince Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives First Product Approval in China","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFN\u03b1 for the Treatment of Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BRII-179","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Taladegib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I\/R9 (LGMD2I\/R9), Cleared to Proceed By FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"GNT0006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Atamyo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atamyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atamyo The.."},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DifGen Pharmaceuticals Completes Successful USFDA Audit of Its US Manufacturing Site Aveva Drug Delivery Systems; Also Launches its First Oral Thin Film Product, a Generic to Suboxone (Buprenorphine\/ Naloxone) in the US Laying a Solid Platform of Manufact","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenoprhine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Difgen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Difgen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Difgen \/ N.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Gentamicin Sulfate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT\u00ae (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemother","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1\/GIP Receptor Agonist VK2735 in Patients with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"SpliSense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpliSense Successfully Completed Phase 1 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"SPL84","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliSense","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SpliSense \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Gloria Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Zimberelimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gloria Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gloria Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gloria Bio.."},{"orgOrder":0,"company":"EOM Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"EOM613","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"EOM Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EOM Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EOM Pharma.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omicron XBB.1.5-adapted COVID-19 Vaccine (DS-5670) Supplemental New Drug Application Submitted in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DS-5670","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Results of Booster Vaccination Trial of mRNA COVID-19 Vaccine DS-5670 (Bivalent: Original Strain and Omicron Strain) in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DS-5670","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ARCT-154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Clinical Trial Data Confirm its Updated Covid-19 Vaccine Generates Strong Immune Response In Humans Against Ba.2.86","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1273.815","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Ultomiris in NMOSD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Otsuka Collaborates with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":1.5,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.5,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shape Ther.."},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Icahn School of Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icahn School of Medicine \/ Cell BioEngines","highestDevelopmentStatusID":"3","companyTruncated":"Icahn Scho.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"GI Research Foundation","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"ELI-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ GI Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","amount":"$3,460.0 million","upfrontCash":"$60.0 million","newsHeadline":"Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nurix Therapeutics","amount2":3.46,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.46,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Seagen","highestDevelopmentStatusID":"4","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Myricx Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myricx Enters into Antibody License Agreement with Biocytogen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Myricx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Procaps Group","sponsor":"BDR Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Procaps Group Announces the Expansion of its Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Procaps Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Procaps Group \/ BDR Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Procaps Gr.."},{"orgOrder":0,"company":"Mariana Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mariana Oncology Announces $175 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"MC-339","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mariana Oncology","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Mariana Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"4","companyTruncated":"Mariana On.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Oberon Capital","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"MGC Pharma Launches Share Purchase Plan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"MGC Pharmaceuticals \/ Oberon Capital","highestDevelopmentStatusID":"12","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruna Bio Announces Preclinical Results from Pilot Study Evaluating AB126 for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Exaluren Sulfate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opus Genetics Announces First Patient Dosed in Phase 1\/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OPGx-LCA5","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Opus Genetics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12\/13","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CT7439","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ART26.12","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Risk of Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Zilebesiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"F. Hoffmann-La Roche \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Announces FDA Approval of its Investigational New Drug Application for Phase 2b\/3 IMPACT Clinical Trials of S-Pindolol Benzoate to Treat Cancer Cachexia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"S-pindolol Benzoate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actimed Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Actimed Th.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-07307405","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"The University of Birmingham","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acticor Biotech SAS \/ The University of Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib for IDH1-Mutant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Safusidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DS-3939","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PL9643","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces US Food & Drug Administration Orphan Drug Designation for Pitolisant for Treatment of Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Expands Merck\u2019s ERVEBO\u00ae [Ebola Zaire Vaccine, (rVSV\u0394G-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ebola Zaire Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$66.9 million","upfrontCash":"$26.9 million","newsHeadline":"Coherus Completes Surface Oncology Acquisition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injectable\/Injection","sponsorNew":"Surface Oncology \/ Coherus BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$882.0 million","upfrontCash":"$42.0 million","newsHeadline":"Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0.88,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Verge Genomics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","amount":"$20.4 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Closes $20.4 Million Private Placement Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ BTIG, LLC","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"CICC","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grit Biotechnology Announces Closing of $60 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"GT101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"GRIT Biotechnology \/ CICC","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biote.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Neuroplast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuroplast Successfully Completes Patient Inclusion of Phase II Clinical Trial for Traumatic Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Neuro-Cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Neuroplast","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neuroplast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neuroplast.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PT217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics Doses First Patient with Its First-in-class Targeted Radiopharmaceutical Drug Satoreotide in Its Phase Ib Study in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-satoreotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ariceum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Th.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to Treat Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus Receives U.S. FDA Fast Track Designation for Vididencel in Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vididencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) Regarding the Planned Resubmission of the BLA for LYMPHIR\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Denileukin Diftitox-cxdl","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gsk Regulatory Submission for Momelotinib for the Treatment of Myelofibrosis Accepted for Review by Japanese Regulator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Samsung Bioepis","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Avior Bio","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Avior Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Avior Bio \/ Hillstream BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Avior Bio .."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cingulate Announces Pricing of $4.0 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$17.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"6","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Immatics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$1,820.0 million","upfrontCash":"$120.0 million","newsHeadline":"Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":1.8200000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8200000000000001,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Announces Key Amendments to Atlas and Kreos\/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"NovaBay Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova\u00ae Allograft","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Amniotic Tissue Allograft","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ NovaBay Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Te.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Nant Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunityBio Announces $470 Million Equity and Debt Financing from Founder, Dr. Patrick Soon-Shiong and Nant Entities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"BCG Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Nant Capital","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orano Med and Orbit Discovery Enter Collaboration to Discover Novel Targeted Radioligand Therapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Oranomed","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Disc.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0.29999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.29999999999999999,"dosageForm":"Powder","sponsorNew":"Amphastar Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ADVANZ PHARMA Further Strengthens its Specialty and Hospital Business by Acquiring an Anti-Infective Portfolio from Sanofi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"Aztreonam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Quadrivalent Seasonal Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed\/Refractory Follicular Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NBI-1117570","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte to Announce Top Line Data from Phase 2\/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel\u2122 (HAV\u2122) Tuesday, September 12, 2023 at 8:00 AM ET","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a\/1b Clinical Trial with AB-101; Cash Runway Extended","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen\u00ae as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Bre","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ATRN-1051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant\u2122 (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Diazepam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MBX 2109","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"MBX Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Veru","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Eli.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"INF904","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"INNA-051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FASENRA Met the Primary Endpoint in the MANDARA Phase III Trial in Eosinophilic Granulomatosis with Polyangiitis (EGPA)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Benralizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ABX-002","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Autobahn Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"225Ac-rhPSMA-10.1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Earth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BT8009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NDI-034858","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"SA55","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-KIT","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces FDA Approval of APHEXDA\u2122 (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Medivir","sponsor":"Tango Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir's Partner Tango Therapeutics Received FDA Clearance to Start the TNG348 Phase 1\/2 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TNG348","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medivir \/ Tango Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosyngen Received FDA approval for Phase I\/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BRL03","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Elasomeran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADVANZ PHARMA Launches Palmeux\u00ae\/Paliperidone 1-month Long-acting Injection Across Various European countries","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Advanz Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Advanz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pha.."},{"orgOrder":0,"company":"Chemify","sponsor":"Dewpoint Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Therapeutics Partners with Chemify to Apply Groundbreaking Chemistry AI to Radically Accelerate the Discovery of Molecules Targeting Cancer and Neurodegeneration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Chemify","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chemify \/ Dewpoint Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Chemify \/ .."},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sumitomo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech enters into research collaboration with Sumitomo Pharma to advance a drug discovery program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Salipro Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Sumitomo","highestDevelopmentStatusID":"3","companyTruncated":"Salipro Bi.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"National Institute of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spinogenix \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","amount":"$45.1 million","upfrontCash":"$0.1 million","newsHeadline":"Avalo Enters into Agreement to Divest AVTX-800 Series","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Divestment","leadProduct":"Alpha-D-Galactose","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Avalo Therapeutics \/ AUG Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Teduglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Biologics","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"RP-A501","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0.17999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ISM3091","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Exelixis","highestDevelopmentStatusID":"5","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$20.0 million","newsHeadline":"LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lerodalcibep","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0.33000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therap.."},{"orgOrder":0,"company":"Septerna","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$47.5 million","newsHeadline":"Septerna Announces Novel GPCR-targeted Program Acquired by Vertex","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Septerna","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Septerna \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Septerna \/.."},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$149.0 million","upfrontCash":"Undisclosed","newsHeadline":"ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"RPT-2950","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Rome Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Rome Thera.."},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Canaan","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actio Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Actio Biosciences \/ Canaan","highestDevelopmentStatusID":"4","companyTruncated":"Actio Bios.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf\u00ae in Taiwan and select South-East Asian markets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Peficitinib Hydrobromide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Axolotl Biologix","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Axolotl Bi.."},{"orgOrder":0,"company":"Vertical bio","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"VERT-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vertical bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vertical bio \/ Pierre Fabre","highestDevelopmentStatusID":"5","companyTruncated":"Vertical b.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Juniper Point","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Juniper Point","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","amount":"$665.0 million","upfrontCash":"$7.0 million","newsHeadline":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0.67000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Avalon BioVentures","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"ART5803","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arialys Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Arialys Therapeutics \/ Avalon BioVentures","highestDevelopmentStatusID":"4","companyTruncated":"Arialys Th.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Amitriptyline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NC318","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NXP900","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Announces Positive Top Line Results from Phase 2\/3 Trial of Human Acellular Vessel\u2122 (HAV\u2122) in Treatment of Patients with Vascular Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK\u00ae for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"CancerVAX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"CancerVAX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CancerVAX \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"CancerVAX .."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Olgotrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RP-A501","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Pherin Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PH80","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Pherin Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Nadofaragene Firadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Prednisolone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Clinical Progress with KAN-101 and ANK-700","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Launches MIEBO\u2122 (Perfluorohexyloctane Ophthalmic Solution) in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Type II Variation for Astellas' XTANDI\u00ae (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's SKYRIZI\u00ae (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara\u00ae (ustekinumab) in Head-to-Head Study in Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Risankizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corium Announces Publication of Favorable ADLARITY\u00ae (donepezil transdermal system) Skin Irritation Clinical Trial Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Donepezil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Corium","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ N.."},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RBI-4000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replicate Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Replicate .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"CyGenica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CyGenica Limited Secures USFDA Approval for Orphan Drug Designation for Novel Drug Conjugate in Glioblastoma Multiforme Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Nucleotide-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CyGenica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CyGenica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CyGenica \/.."},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Modified Vaccinia Ankara","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Bavarian Nordic \/ European Union","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Qu\u00e9bec government","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"DalCor Pharmaceuticals Announces Dal-GenE-2 Confirmatory Trial and Closing of Series D Financing Round","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series D Financing","leadProduct":"Dalcetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"DalCor Pharmaceuticals \/ Qu\u00e9bec government","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pha.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmazz Inc. and Sun Pharma Enter into Licensing Agreement for Introducing Tyvalzi\u2122 (sovateltide) in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cingulate Announces Closing of $4.0 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"HPN217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Public Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Synaffix","sponsor":"ABL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ ABL Bio","highestDevelopmentStatusID":"3","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Granted Upgraded Recommendations in 2023 ESC Heart Failure Guidelines","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Canadian Approval of ZORYVE\u2122 (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Curia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RBI-4000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replicate Bioscience \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Replicate .."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Exosome","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Positive Clinical Study Update from the Phase 1\/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Integrated Sciences\u2019 IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey\u2019s Ministry of Health","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Iodine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Integrated Sciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Novo Integrated Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Integ.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Bempikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RG6501 (OpRegen\u00ae) Phase 1\/2a Additional Results to be Featured at 23rd EURETINA Congress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RG6501","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO\u00ae (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AN2 Therapeutics Commences Phase 3 Part of Phase 2\/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezpegaldesleukin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna Therapeutics Announces Achievement of 28-Day Post-Infusion Milestone for First U.S. Patient Dosed in Phase 1 Clinical Trial of CD19 CAR T-Cell Therapy for Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zuberitamab (Anruixi\u00ae), the First Domestically Developed Anti-CD20 Antibody as a Class I Innovative Drug from BioRay Pharmaceutical, has been Approved for Marketing in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Zuberitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioRay Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioRay Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioRay Pha.."},{"orgOrder":0,"company":"Imcyse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IMCY-0141","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Imcyse","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Imcyse \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imcyse \/ N.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"AlveoGene","sponsor":"Oxford Science Enterprises","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"AVG-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AlveoGene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AlveoGene \/ Oxford Science Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"AlveoGene .."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$258.7 million","upfrontCash":"Undisclosed","newsHeadline":"CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Limited Announces Withdrawal of Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"KU Leuven","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"NX-13","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ KU Leuven","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ F.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$526.0 million","upfrontCash":"$20.0 million","newsHeadline":"Bionomics Announces Update on the \u03b17 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Donepepzil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bionomics","amount2":0.53000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Bionomics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Related Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Aclipse Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to Develop Potential Disease-Modifying Treatment for Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lobeglitazone","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Aclipse Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun .."},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$273.0 million","upfrontCash":"Undisclosed","newsHeadline":"Generate:Biomedicines Announces Close of $273M Series C Financing to Advance its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series C Financing","leadProduct":"GB-0669","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0.27000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Generate B.."},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Frametact","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cure Genetics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cure Genetics \/ Frametact","highestDevelopmentStatusID":"3","companyTruncated":"Cure Genet.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tulmimetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Optimi Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Optimi Hea.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Receives Positive CHMP Opinion for TransCon\u2122 PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido\u00ae, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to S","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex\u2019s Phase 2b\/3 Trial of Blarcamesine (ANAVEX\u00ae2-73) in Patients with Alzheimer\u2019s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VIP943","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTICOR Adapts Its ACTISAVE Clinical Study to Prepare the Registration of Glenzocimab for the Treatment of Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"EDG-7500","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaBay Pharmaceuticals Announces Commercial Launch of Avenova\u00ae Allograft","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Amniotic Tissue Allograft","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics' Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MEN1703","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA\u00ae (valbenazine) Oral Granules Sprinkle Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oscotec\/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ADEL-Y01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oscotec \/ ADEL Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ .."},{"orgOrder":0,"company":"MedAlliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"MedAlliance","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"MedAlliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MedAllianc.."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed\/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DVX201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Coeptis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coeptis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Coeptis Th.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Taldefgrobep-alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Golidocitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna\u2019s Updated Covid-19 Vaccine in The European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Elasomeran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Launches SKYTROFA\u00ae (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lonapegsomatropin-tcgd","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EBGLYSS\u00ae (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for KAFTRIO\u00ae (ivacaftor\/tezacaftor\/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Sumitomo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO\u00ae for Treatment of Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Sumitomo","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Ric.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ojjaara (Momelotinib) Approved in the US as the First And Only Treatment Indicated for Myelofibrosis Patients with Anaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives CHMP Positive Opinion of Zilucoplan for the Treatment of Adults with Generalized Myasthenia Gravis in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive CHMP Opinion for Breast and Gastric Cancer Biosimilar Trastuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ EirGenix, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"ResVita Bio","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"RVB-101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ResVita Bio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Lotion","sponsorNew":"ResVita Bio \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"ResVita Bi.."},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$35.0 million","newsHeadline":"Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ B.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Closes US$2.25 Million Public Offering","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Aegis Capital Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Kineta","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ F.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Biocure Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"zapnometinib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atriva Therapeutics \/ Biocure Technology","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Announces Termination of at-the-Market Sales Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Termination","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI\u00ae (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ P.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail InfoWorks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail InfoWorks","highestDevelopmentStatusID":"4","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"Athebio","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"DARPin-targeted Radioligand","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Athebio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athebio \/ POINT Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Athebio \/ .."},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI\u2019s 100 Days Mission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"BNT166","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioNTech","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"BioNTech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Withdraws COVID Phase IIB IND, will Resubmit Pending Assessment of Ability to Meet FDA Requirements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Provides an Update on the EMA Timetable for Examination of the Masitinib Marketing Authorization Application in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3\/4 Agonist LPX-TI641 to Treat Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"LPX-TI641","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LAPIX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Ther.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-B3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill\u00ae Containing Ustekinumab Biosimilar, CT-P43)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MDG2011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed\/Refractory Cutaneous T-Cell Lymphoma and Relapsed\/Refractory Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KT-333","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK\/JAK3 Inhibitor","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ATI-2138","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Exaluren Sulfate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin\u2019s Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"KayoThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KAYO-1609","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KayoThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KayoThera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"KayoThera .."},{"orgOrder":0,"company":"LinKinVax","sponsor":"Gustave Roussy","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I\/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CD40HVac","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LinKinVax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"LinKinVax \/ Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"LinKinVax .."},{"orgOrder":0,"company":"Osmol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May Proceed","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OSM-0205","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Osmol Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osmol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Osmol Ther.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY\u2122 (avacincaptad pegol intravitreal solution) for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IVERIC bio \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Lenox Hill Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex Pharmaceuticals and Lenox Hill Hospital Announce Initiation of a Phase 2 Study of RAGE Inhibitor Azeliragon as a Front-Line Treatment For Unmethylated Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Lenox Hill Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Endosane Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"PreveCeutical Medical \/ Endosane Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeuti.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Masofaniten","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces FDA sNDA Approval for Talicia\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Omeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ainos\u2019 VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ainos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ No.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INESSS Recommends Public Reimbursement for BioCryst\u2019s ORLADEYO\u00ae (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Qu\u00e9bec","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XACDURO\u00ae, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Innoviva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innoviva \/.."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid Tumors with KEAP1 Activator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VVD-130037","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vividion Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX\u00ae Cosmetic) for the Treatment of Platysma Prominence","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"HilleVax Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","amount":"$26.2 million","upfrontCash":"Undisclosed","newsHeadline":"Elutia Announces Private Placement for Proceeds up to $26 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ H.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Exaluren Sulfate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Peptide-radioisotope Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$358.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Actinium-225 Dotatate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0.35999999999999999,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Bioluminescence Ventures","pharmaFlowCategory":"D","amount":"$260.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReCode Therapeutics Announces Closing of Extension to Series B Financing","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"RCT1100","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Bioluminescence Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharmaceuticals Signs Exclusive Licensing Agreement with Radius Health to Commercialize BINOSTO\u00ae in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Phar.."},{"orgOrder":0,"company":"BioLoomics","sponsor":"Innovation Endeavors","pharmaFlowCategory":"D","amount":"$8.7 million","upfrontCash":"Undisclosed","newsHeadline":"BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"BioLoomics","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"BioLoomics \/ Innovation Endeavors","highestDevelopmentStatusID":"2","companyTruncated":"BioLoomics.."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO\u00ae (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Abemaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"Magnet Biomedicine","sponsor":"Newpath Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Magnet Biomedicine Emerges from Stealth with $50 Million to Advance Rational Approach to Molecular Glues with TrueGlue\u2122 Discovery Platform","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Magnet Biomedicine","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Magnet Biomedicine \/ Newpath Partners","highestDevelopmentStatusID":"3","companyTruncated":"Magnet Bio.."},{"orgOrder":0,"company":"Hyku Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hyku Biosciences Launches with $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Hyku Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Hyku Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Hyku Biosc.."},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"ALSA Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALSA Ventures Launches Novel Gene Therapy Portfolio Company Axovia Therapeutics to Treat Ciliopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"AXV101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axovia Therapeutics \/ ALSA Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Axovia The.."},{"orgOrder":0,"company":"Syndesis Health","sponsor":"InSyBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syndesis Health and InSyBio Partner in Predictive Modelling and Biomarker Discovery","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Syndesis Health","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syndesis Health \/ InSyBio","highestDevelopmentStatusID":"3","companyTruncated":"Syndesis H.."},{"orgOrder":0,"company":"Airna","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"RNA Editing Therapeutic","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Airna","amount2":0.029999999999999999,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Airna \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Airna \/ AR.."},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$8.6 million","upfrontCash":"Undisclosed","newsHeadline":"ATA-200, Atamyo Therapeutics\u2019 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C\/R5, Reaches Key Milestones with the Filing of a Clinical Trial Application in Europe and a Non-Dilutive Financing from France 2030 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Financing","leadProduct":"ATA-200","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Atamyo Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo The.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"EVX-B2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Hepalys Pharma","pharmaFlowCategory":"D","amount":"$241.0 million","upfrontCash":"$10.0 million","newsHeadline":"Inventiva and Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor in Japan and South Korea","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0.23999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inventiva Pharma \/ Hepalys Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Corsair Pharma","sponsor":"Junson Capital","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Treprostinil Prodrug","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsair Pharma","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Patch","sponsorNew":"Corsair Pharma \/ Junson Capital","highestDevelopmentStatusID":"6","companyTruncated":"Corsair Ph.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Naason Science","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Addex mGlu2 NAM Cognition Program Receives \u20ac4 Million Grant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Naason Science","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"$132.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and Other Potential Indications in Greater China, South Korea and Southeast Asia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Zetomipzomib","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.13,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Sarcomatrix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Sarcomatrix Therapeutics Corp.\u2019s Exclusive Research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to Advance Small Molecules Promoting Muscle Regeneration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"S-969","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sarcomatrix","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarcomatrix \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Sarcomatri.."},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"RXM-4768","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"3B Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ RefleXion Medical","highestDevelopmentStatusID":"4","companyTruncated":"3B Pharmac.."},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$2,047.0 million","upfrontCash":"$47.0 million","newsHeadline":"Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":2.0499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Orionis Biosciences \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Bi.."},{"orgOrder":0,"company":"Tolremo therapeutics","sponsor":"Pierre Fabre Invest","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"TOLREMO Therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series A Financing","leadProduct":"TT125-802","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tolremo therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Tolremo therapeutics \/ Pierre Fabre Invest","highestDevelopmentStatusID":"4","companyTruncated":"Tolremo th.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$694.0 million","upfrontCash":"$20.0 million","newsHeadline":"Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0.68999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"Exscientia \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$594.0 million","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Signs Strategic Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BenevolentAI","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"BenevolentAI \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hillhurst Biopharmaceuticals Receives $3 Million in NIH SBIR Funding for Phase 2a Clinical Study in Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Carbon Monoxide","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector\u00ae Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Kyverna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion Completes Purchase and Licence Agreement for Early-Stage Rare Disease Gene Therapy Portfolio from Pfizer","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Pfizer Inc","amount2":1,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabxience \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Expands Access of KYZATREX\u2122 (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX\u2081\u2080\u2080","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Plans to Submit Tab-cel\u00ae BLA in Q2 2024 Following FDA Agreement on Comparability","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for ADCETRIS\u00ae (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Issues Complete Response Letter for Neffy\u00ae (epinephrine nasal spray) New Drug Application with Request for Additional Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-120","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CVN293","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Laboratories Inc. Announces Initial Dosing of All Subjects in Bioavailability Study for Sildenafil Oral Suspension","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Doses First Patient in Phase 1\/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RMC-9805","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion to Extend the Use of Veklury\u00ae (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review Merck\u2019s Supplemental New Drug Application for WELIREG\u00ae (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Belzutifan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Drug Farm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Farm Doses First Patient in Phase 1 Trial for ALPK1 Inhibitor, DF-003","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"8-Bromo-pet-cyclic gmps","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATA-200, Atamyo Therapeutics\u2019 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C\/R5, Reaches Key Milestones with the Filing of a Clinical Trial Application in Europe and a Non-Dilutive Financing from France 2030 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ATA-200","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atamyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo The.."},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Astex Announce that the European Commission Has Approved INAQOVI\u00ae (oral decitabine and cedazuridine) for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Otsuka Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Otsuka Holdings \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Hol.."},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MH002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s LITFULO\u2122 for Adolescents and Adults With Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ritlecitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS Function in Mouse Models of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"SL-1002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Saol therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Saol therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saol thera.."},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyenne\u00ae*, Fresenius Kabi\u2019s Tocilizumab Biosimilar, Receives European Commission Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite\u2019s Car T-cell Therapy Yescarta\u00ae Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed\/Refractory Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Provides Update on U.S. Regulatory Review of Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission authorises ViiV Healthcare\u2019s Apretude (cabotegravir long-acting and tablets) for HIV prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"GSK \/ ViiV Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ ViiV.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China\u2019s National Medical Products Administration Accepts New Drug Application for XTANDI\u00ae (enzalutamide) in Metastatic Hormone-Sensitive Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics\u2019 Once-Daily Oral Paltusotine Achieved The Primary and All Secondary Endpoints in The Phase 3 Pathfndr-1 Study Evaluating Treatment of Patients With Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vigil Neuroscience Announces Update on Its Small Molecule Trem2 Agonist Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VG-3927","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vigil Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beam Therapeutics Announces First Patient Dosed in Phase 1\/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL\/T-LL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BEAM-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Label Update for NUPLAZID\u00ae (pimavanserin)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DISC-3405","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"6","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vericel Announces U.S. Commercial Availability of NexoBrid (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Vericel Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vericel Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vericel Co.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Dosing of First Patient in Phase 1b\/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0202","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VIR-1388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira (adalimumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Menarini Group\u2019s ORSERDU\u00ae (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memphis Seniors with a History of Atrial Fibrillation Joining New Research Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Photocure","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"APL-1702","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Photocure","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Hepagene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"HPG7233","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Hepagene Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hepagene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hepagene T.."},{"orgOrder":0,"company":"CCM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CCM Biosciences Announces Launch of Protein Upregulation Business Unit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CCM Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CCM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CCM Biosci.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA\u00ae for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Insert","sponsorNew":"AffaMed Therapeutics \/ Ocular Therapeutix","highestDevelopmentStatusID":"12","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"NICHD","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0.050000000000000003,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ NICHD","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Jura Bio","sponsor":"Replay Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replay Announces Partnership Between Product Company Syena and JURA Bio to Advance T Cell Receptor NK Therapies in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"T-cell Receptor Based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Jura Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jura Bio \/ Replay Bio","highestDevelopmentStatusID":"3","companyTruncated":"Jura Bio \/.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$462.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gurnet Point Capital and Novo Holdings A\/S Complete Acquisition of Paratek Pharmaceuticals, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Paratek Pharmaceuticals","amount2":0.46000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Gurnet Point Capital","highestDevelopmentStatusID":"6","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Asteroid Partners","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osteal Therapeutics Closes $23M Series C Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Series C Financing","leadProduct":"Vancomycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Asteroid Partners","highestDevelopmentStatusID":"8","companyTruncated":"Osteal The.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Applied Molecular Transport \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Nanjing Ki.."},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SRB21","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SunRock Biopharma \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Bi.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institute of Health","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"China Grand Prosperity Investment","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series C Financing","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Lynk Pharmaceuticals \/ China Grand Prosperity Investment","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IL12-FHAB","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Initiates AFFIRM, a Phase 3b\/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis Due to Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Announces IND Clearance for NASH Lead, ALG-055009","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI\u00ae Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint Versus Active Control, Irbesartan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces U.S. Commercial Availability of NexoBrid\u00ae for the Treatment of Severe Thermal Burns in Adults","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Atomoxetin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"KB408","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Inc. Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of '1104","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Gensco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Provides RIZAFILM\u00ae U.S. Commercialization Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Gensco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Alisertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Quaternary Ammonium Palmitoyl Glycol Chitosan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altascienc.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to 9MW3011","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW3011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze\u00ae (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Erwinia Asparaginase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD\/MAD Clinical Trials of GM-1020","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"GM-1020","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilgamesh Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh .."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Golidocitinib Granted Priority Review by China NMPA for the Treatment of r\/r PTCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Golidocitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ATG-031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Merger","leadProduct":"AZD5904","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Ph.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,940.0 million","upfrontCash":"$180.0 million","newsHeadline":"AbbVie Terminates Deal with I-Mab to Develop Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Termination","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":1.9399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.9399999999999999,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"FS120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients With HR-Positive, HER2-Low or Negative Breast Cancer in Tropion-Breast01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 KEYNOTE-A39\/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Jardiance\u00ae for the Treatment of Adults with Chronic Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Two Phase 3 Trials Evaluating LENVIMA\u00ae (lenvatinib) Plus KEYTRUDA\u00ae (pembrolizumab) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO\u2122 for RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Otsuka and Lundbeck's ABILIFY MAINTENA\u00ae (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Aripiprazole Monohydrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Menarini","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Lupin Inks Pact to Acquire 5 Drug Brands from Menarini for Rs 101 Crore","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Sodium Picosulfate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Menarini","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Menarini \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces New IXIARO\u00ae Supply Contract with the U.S. Government Worth a Minimum of $32 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Inactivated Adsorbed Japanese Encephalitis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Valneva \/ United States Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Radioligand Therapy Lutathera\u00ae Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEQEMBI\u00ae Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer\u2019s Disease in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces European Commission Approval of TEPKINLY\u00ae (epcoritamab) for Adults with Relapsed or Refractory (R\/R) Diffuse Large B-cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Approval of KORSUVA\u00ae IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARA Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenapanor for Hyperphosphatemia Approved in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-weekly ALTUVIIIO\u00ae Approved in Japan as a New Class of Factor VIII Therapy for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Launches Evkeeza\u00ae (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Evinacumab-dgnb","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Approval of CUVITRU\u2122 Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis pharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ\u2122 (ATI-1501) Metronidazole Oral Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis pharm","highestDevelopmentStatusID":"12","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ASC40","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Senores Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senores Pharmaceuticals, Inc. Announces the Launch of Nicardipine Hydrochloride Capsules USP, 20 mg and 30 mg in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Nicardipine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Senores Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senores Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Senores Ph.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Approval of RYSTIGGO[\u00ae] (rozanolixizumab) and ZILBRYSQ[\u00ae] (zilucoplan) for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rozanolixizumab-noli","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (Dupilumab) SBLA for Treatment of Eosinophilic Esophagitis (EOE) in Children Aged 1 To 11 Accepted For FDA Priority Review","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan\u2019s Ministry of Health, Labour and Welfare Approves GSK\u2019s Arexvy, the Country\u2019s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Issues Complete Response Letter (CRL) for UDENYCA\u00ae ONBODY\u201e\u00a2 Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Evommune","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Evommune \/ Maruho","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Pricing of $450 Million Common Stock Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.45000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Proposed Public Offering of Common Stock and\/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and\/or Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$433.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"GRT-R910","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0.42999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina\u2019s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Dis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Everads Therapy","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Everads Therapy","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everads Therapy \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Everads Th.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Avalyn Pharma","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Series C Financing","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Inhalation","sponsorNew":"Avalyn Pharma \/ Avalyn Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a Monoclonal Antibody Targeting Anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"BC3402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geneos Therapeutics Closes its Series A3 Financing with Investment of $5 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series A Financing","leadProduct":"GNOS-PV02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Geneos The.."},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"UK government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pathios Therapeutics \/ UK government","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Th.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosenic Performs Further Analysis of its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for its Next Late-Stage Trial of Arsenic Trioxide In Cgvhd","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Medicinova","sponsor":"BARDA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sagimet Biosciences \/ Ascletis Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI\u2122 (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tro","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1\/2 Clinical Study of SNS-101 with Regeneron\u2019s Libtayo\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensei Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces FDA Acceptance, as a Priority Original Abbreviated New Drug Application, for KETARX\u2122 (Ketamine)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Two Leukemia Patients Received Smart Immune's SMART101 Therapy in Phase I\/II ReSET-02 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"SMART101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO\u00ae (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Announces Results of Probudur\u2122 Dose Escalation Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Zatolmilast","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tetra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Kallyope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kallyope Enters Phase 2 with First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"K-757","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kallyope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MSC-NTF Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Approval of XERAVA\u00ae in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Therapeutics Granted Orphan Drug Designation by the FDA for the Treatment of Alport Syndrome with Setanaxib","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Pivotal Clinical Trial To Evaluate The Safety and Efficacy of Azeliragon in The Treatment Of Patients Hospitalized For Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canadian Veteran Receives Approval for APEX's Psilocybin Therapy Through Health Canada's Special Access Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1\/2 mutant Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Canada Launches Prwinlevi for Treatment for Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Glycotope","sponsor":"Max Delbr\u00fcck Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycotope and Max Delbr\u00fcck Center Enter into Research Collaboration to Explore Combination of GlycoTargets and CAR Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycotope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ Max Delbr\u00fcck Center","highestDevelopmentStatusID":"4","companyTruncated":"Glycotope .."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Pricing of $8 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$213.0 million","upfrontCash":"$213.0 million","newsHeadline":"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Decibel Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Decibel Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$2,760.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Valo Health","amount2":2.7599999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.7599999999999998,"dosageForm":"","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Valo Healt.."},{"orgOrder":0,"company":"Vernalis","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pierre Fabre Laboratories and Vernalis Announce a Drug Discovery Collaboration in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vernalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Vernalis \/.."},{"orgOrder":0,"company":"AcuraStem","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$580.0 million","upfrontCash":"Undisclosed","newsHeadline":"AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AS-202","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AcuraStem","amount2":0.57999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.57999999999999996,"dosageForm":"Injection","sponsorNew":"AcuraStem \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"AcuraStem .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Qatar Investment Authority","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces $250 Million Private Placement Equity Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.25,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Qatar Investment Authority","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Proposed Offering of $300 Million of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.29999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$7,300.0 million","upfrontCash":"$7,300.0 million","newsHeadline":"Biogen Completes Acquisition of Reata Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":7.2999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":7.2999999999999998,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Acasti Announces $7.5 Million Private Placement Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Acasti Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$794.0 million","upfrontCash":"$794.0 million","newsHeadline":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.79000000000000004,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Spinogenix","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for its Zydis\u00ae Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Melt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Fluence","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Fluence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fluence \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Fluence \/ .."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arcturus Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Partillion Bioscience","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Partillion Bioscience","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Partillion Bioscience \/ Alloy Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Partillion.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk and Evotec Collaborate to Launch LAB eN\u00b2, a Translational Drug Discovery Accelerator, to Address Innovation Gap in Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Beactica","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beactica Therapeutics Announces Collaboration with the National Center for Advancing Translational Sciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"YAP\u2013TEAD","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/.."},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Canaan","pharmaFlowCategory":"D","amount":"$47.6 million","upfrontCash":"Undisclosed","newsHeadline":"Acesion Pharma Closes Oversubscribed \u20ac45M Series B Financing Round to Advance Development of Novel Therapy for Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"AP31969","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Acesion Pharma \/ Canaan","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Ph.."},{"orgOrder":0,"company":"Evozyne","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Evozyne","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Evozyne \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"2","companyTruncated":"Evozyne \/ .."},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Acquires Assets of Novan, Inc. for $12.2 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Divestment","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Li.."},{"orgOrder":0,"company":"Omniose","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omniose Awarded NIH Grant of up to $3.0 Million to Develop Vaccines Against Group B Streptococcus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"GBS Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Omniose","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omniose \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"2","companyTruncated":"Omniose \/ .."},{"orgOrder":0,"company":"Starpax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Starpax Biopharma Announces Launch of $24 Million Regulation A+ Capital Raise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Starpax Biopharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Starpax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Starpax Bi.."},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Azurity Pharmaceuticals Acquires Slayback Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Slayback Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Slayback P.."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$331.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.33000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$60.0 million","newsHeadline":"Ionis Enters Agreement with Roche for Two Novel RNA-targeted Programs for Alzheimer's Disease and Huntington's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Adimab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adimab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Adimab \/ O.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Cosmo and Glenmark Announce the Signing of Distribution and License Agreements for Winlevi\u00ae in Europe and South Africa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Cellular Biomedicine Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"C-TIL051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nektar Therapeutics \/ Cellular Biomedicine Group","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"MediWound","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid\u00ae Development for the U.S. Army","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ModeX Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"ModeX Ther.."},{"orgOrder":0,"company":"Quris","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Quris","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quris \/ Merck group","highestDevelopmentStatusID":"4","companyTruncated":"Quris \/ Me.."},{"orgOrder":0,"company":"GigaGen","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ National Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0.5,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.59999999999999998,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces Pricing of $9.6 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Closing of $8.5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and\/or Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Adage Capital Partners LP","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Agreement","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Amicus Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","amount":"$41.5 million","upfrontCash":"Undisclosed","newsHeadline":"Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Deka Biosciences \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosc.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Viralgen","sponsor":"Elpida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viralgen & Elpida Partner for SPG50 & CMT4J Trials","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"Serotype 9 AAV Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viralgen \/ Elpida","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Cipla Medpro Exclusive Distribution and Marketing Rights for Seroquel\u00ae and Seroquel XR\u00ae in South Africa and Certain Neighbouring Countries","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Local Seroquel\u00ae Distribution and Marketing Partnership with ICI Pakistan Limited","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"$1,750.0 million","newsHeadline":"Novartis Completes Divestment of \u2018Front of Eye\u2019 Ophthalmology Assets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":2.5,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"GEDiCube","sponsor":"Renovaro Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Merger","leadProduct":"Dendritic Cell Therapeutic Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GEDiCube","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEDiCube \/ Renovaro Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"GEDiCube \/.."},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces $6.0 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"TT-10","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Portage Biotech","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Portage Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Portage Bi.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced at-the-Market under Nasdaq Rules","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Capricor Therapeutics Announces $23 Million Registered Direct Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Announces $300 Million Private Placement Equity Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Private Placement","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Capsule","sponsorNew":"Structure Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$106.1 million","upfrontCash":"Undisclosed","newsHeadline":"Adlai Nortye Ltd. Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Thymmune Therapeutics Receives $37M in Funding from the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Thymmune Therapeutics \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune T.."},{"orgOrder":0,"company":"Estrella Biopharma","sponsor":"TradeUP Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Merger","leadProduct":"EB103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Estrella Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Estrella Biopharma \/ TradeUP Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Estrella B.."},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Completes Acquisition of Qunol\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Qunol","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Qunol \/ Sa.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the \"We Care About Mental Health\" Initiative","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Doses First Patient in Phase 1b\/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Defender Pharmaceuticals\u2122 New Drug Application for Intranasal Scopolamine Gel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-2004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1\/2 Adult Trial for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Completes Dosing in Phase I\/II Clinical Trial of RECCE\u00ae 327 for Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIMEDX Announces Launch of EPIEFFECT","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lyophilized Human Placental-based Allograft","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MiMedx \/ N.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"EB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1\/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO\u201e\u00a2 I Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OTX-2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Omega Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IMVT-1402","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives European Commission Approval for Tyruko\u00ae (natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Natalizumab-sztn","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"NMD670","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"MYTX-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mythic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic The.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ES009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elpiscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"OST31-164","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Drug Farm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Farm Doses First Patient in Part 3 of Phase 1 Chronic Hepatitis B Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"DF-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Drug Farm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Updated Clinical Development Strategy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-100 in Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin\u2122 (TP508)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rusalatide Acetate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Chrysalis BioTherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chrysalis BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chrysalis .."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"ABM-1310","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Thea Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thea Pharma Inc. Launches IYUZEH\u2122 (latanoprost ophthalmic solution) 0.005% in the U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Thea Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution","sponsorNew":"Thea Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Thea Pharm.."},{"orgOrder":0,"company":"Gensco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gensco\u00ae Pharma Announces RizaFilm Commercialization Update in the United States","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Gensco Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film","sponsorNew":"Gensco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gensco Pha.."},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinogen Optimizes XanaMIA Phase 2b Alzheimer's Disease Trial Design and Provides General Business Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanamem","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen .."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PIKA Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex and Allegheny Health Network Announce Initiation of a Phase 1\/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b\/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"AP-SA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Approval of Vafseo (vadadustat) in Australia and Provides Commercial Update","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1\/2 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Statement on the Discontinuation of Magrolimab Study in AML with TP53 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CDI-988","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"TI-168","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRAS\u1d33\u00b9\u00b2\u1d9c Inhibitors in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BDC-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cipaglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1\/2 OVATION 2 Study in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Partial Clinical Hold Lifted on IND for EryDel\u2019s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Scancell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ Scancell","highestDevelopmentStatusID":"8","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase 1b Clinical Trial of Synthekine\u2019s \u03b1\/\u03b2 Biased IL-2, STK-012, for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Karuna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Receives Approval to Initiate PK\/PD Study of Otenaproxesul","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ELAHERE\u00ae Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FR\u03b1-Positive Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Fabre-Kramer Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA\u2122, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Gepirone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Fabre-Kramer Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Fabre-Kramer Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fabre-Kram.."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGenesis Doses First Patient in Phase 1a\/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"IMGS-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoGenesis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces First Patient Dosed in Phase Ib\/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT\u00ae (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mut","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tozinameran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotatercept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"GH Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GH Researc.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Biogen\u2019s TOFIDENCE\u2122 (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odronextamab BLA for Treatment of Relapsed\/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Odronextamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Requests Type A Meeting With FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Structure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I\/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Lepunafusp Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed\/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Gets ANDA Approval for Generic Quetiapine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense Ends its at-the-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Skyepharma","sponsor":"Biophytis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophytis and Skyepharma Sign a Partnership Agreement for The Production of Sarconeos (BIO101)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Skyepharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Skyepharma \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Skyepharma.."},{"orgOrder":0,"company":"Aviko Radiopharmaceuticals","sponsor":"Leo Cancer Care","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aviko Radiopharmaceuticals and Neutron Therapeutics Form Exclusive, Strategic Partnership with Leo Cancer Care to Expand Development of Boron Neutron Capture Therapy for Treating Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Boron Neutron Capture Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aviko Radiopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aviko Radiopharmaceuticals \/ Leo Cancer Care","highestDevelopmentStatusID":"1","companyTruncated":"Aviko Radi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$175.0 million","newsHeadline":"Sanofi Announces Agreement for Potential First-In-Class Vaccine Against Extraintestinal Pathogenic E. Coli","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"ExPEC9V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Immunovant","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$492.1 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"IMVT-1402","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0.48999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Gadeta","sponsor":"Clade Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clade Therapeutics Announces the Acquisition of Gadeta B.V.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"TEG002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gadeta \/ Clade Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ C.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Amicus Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Graf Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NKGen Biotech, Inc. Announces Closing of Business Combination","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Graf Acquisition Corp.","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.13,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vistagen Announces Pricing of $100 Million Underwritten Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"IAMA-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Evotec","highestDevelopmentStatusID":"4","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Venture Management","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mogrify Extends Series A Financing to $46 Million USD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Mogrify","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Mogrify \/ Astellas Venture Management","highestDevelopmentStatusID":"4","companyTruncated":"Mogrify \/ .."},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"$3,370.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Viatris","amount2":3.3700000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":3.3700000000000001,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT005 (PPY988): Development Program in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"PPY988","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of AlSP","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"VGL101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vigil Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neur.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarin Receives Positive CHMP Opinion in Europe to Expand Use of Voxzogo\u00ae (Vosoritide) to treat Children Aged 4 Months and Older with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Vosoritide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms Of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 764532","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ABI-6250","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces U.S. FDA Approval of the EMPAVELI\u00ae Injector, a Device to Streamline Self-Administration","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin\u00ae Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Corticotropin","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HEX17","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pneumagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces FDA Acceptance of New Drug Application for Antibiotic Ceftobiprole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabis-derived Therapy","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabis-derived Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oil","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on EXKIVITY\u00ae (mobocertinib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR\u00ae (omalizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Chenodeoxycholic Acid","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Receives FDA \u201cStudy May Proceed\u201d Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"AntiCancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AntiCancer\u2019s PDOX Mouse Model Has Demonstrated High Clinical Concordance Which Will Enable Precise Individualized Chemotherapy of Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AntiCancer","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AntiCancer \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AntiCancer.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-KIT","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Avenge Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte\u2122 Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AVB-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenge Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenge Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenge Bio.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Enspryng Launched in Taiwan as First Indication for Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide for The Treatment of Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO\u2122 (rezafungin for injection)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Marnetegragene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Scleroderma Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Scleroderma Research Foundation (SRF) Announces Second Partnership for Conquest Trial Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Vetophage","sponsor":"PHAXIAM Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vetophage","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vetophage \/ PHAXIAM Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vetophage .."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adlai Nortye Ltd. Announces Closing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"VIR-7229","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vir Biotechnology","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-in-Class Pan-Coronavirus Protease Inhibitor, ALG-097558","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"ALG-097558","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aligos Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Resilience","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"BBP-812","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Resilience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Resilience \/ BridgeBio Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Resilience.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"CRISPR-based Gene Editing Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair\u00ae (omalizumab)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kashiv BioSciences \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"OncoHost","sponsor":"Hengenix Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoHost's PROphet\u00ae Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OncoHost","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoHost \/ Hengenix Biotech","highestDevelopmentStatusID":"10","companyTruncated":"OncoHost \/.."},{"orgOrder":0,"company":"Morphimmune","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Morphimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Morphimmune \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Morphimmun.."},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"IMM20320","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaEssentia Enters into Exclusive Global License Agreement with WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Myeloid Immune Checkpoint Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ PharmaEssentia","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Esperovax","sponsor":"Blue Knight","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Covid-19 RNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Esperovax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Esperovax \/ Blue Knight","highestDevelopmentStatusID":"4","companyTruncated":"Esperovax .."},{"orgOrder":0,"company":"Neurodon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurodon Awarded Nearly $3 Million from NIH to Advance its Drug for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Neurodon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurodon \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"Neurodon \/.."},{"orgOrder":0,"company":"Capsida","sponsor":"Kate Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx's Next-Generation Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Capsida","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capsida \/ Kate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$1,400.0 million","newsHeadline":"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Executes Sandoz Spin-off, Completing Strategic Transformation into a Leading, Focused Innovative Medicines Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Updates on QM-1114 Regulatory Process","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT\u2122 in Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SV-BR-1-GM","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1\/2 VISTA-101 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"DISC-3405","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b\/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Live","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Belapectin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ATI-1777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Na\u00efve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric\/Gastroesophageal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"SciTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciTech Readies for First-in-Human Trial with Clinical Supply of ST-001 nanoFenretinide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Cu-67 SAR-Bombesin in Theranostic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-BBN","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nafamostat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"United States Army Medical Research Institute of Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Opaganib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ United States Army Medical Research Institute of Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Sunstone Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunstone Therapies Announces Expansion of Innovative Dyad Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sunstone Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunstone Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sunstone T.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Attenuated Tetravalent Dengue Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Confirms Sandoz Spin-off for October 4, 2023","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Institute of Cardiovascular and Metabolic Diseases","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Seven New CSL Global Research Acceleration Initiative Awardees Announced to Fast-Track Therapeutics Innovation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"EUROPE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Institute of Cardiovascular and Metabolic Diseases","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institute of Cardiovascular and Metabolic Diseases \/ CSL","highestDevelopmentStatusID":"2","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediciNova Receives Gene Therapy Milestone Payment","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Medicinova \/ Sanofi Genzyme","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Announces Proposed Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"NYCBS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT\u201e\u00a2 in Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Retifanlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ NYCBS","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Oakrum Pharma, LLC","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Nitisinone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Oakrum Pharma, LLC","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Oakrum Pha.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$500.0 million","newsHeadline":"Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"TEV-48574","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":1.5,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.5,"dosageForm":"Infusion","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"St. Jude Children\u2019s Research Hospital","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"n-Lorem Foundation Collaborates to Support Children With Extremely Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"St. Jude Children\u2019s Research Hospital","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"St. Jude Children\u2019s Research Hospital \/ n-Lorem Foundation","highestDevelopmentStatusID":"2","companyTruncated":"St. Jude C.."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"ANK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ankyra Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"TNAX101A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ IMIDomics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Atum Bio","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"ANG003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Atum Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atum Bio \/ Anagram Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Atum Bio \/.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Kurma Partners\u2019 Growth Opportunities Fund","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series B Financing","leadProduct":"SH-105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Shorla Oncology \/ Kurma Partners\u2019 Growth Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shasqi to Expand Existing Research Collaboration to Advance Targeted Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shasqi \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ J.."},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic The.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Advancement of XIPERE\u00ae in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic\u00ae, Wegovy\u00ae, or Mounjaro\u00ae, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CIMERLI\u00ae (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab-eqrn","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI\u201e\u00a2 (dexmedetomidine) Sublingual Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1\/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"FLT201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b\/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SBT101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Th.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech\u2019s Evrysdi Able to Sit Independently After 1 Year of Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Biomed Announces Positive Results from Phase 1b Clinical Trial with RJx-01 in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Galantamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rejuvenate Biomed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim to Start Phase 1 Development of BI 771716 \u2013 a Potential New Treatment for Geographic Atrophy, a Leading Cause of Blindness Worldwide","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 771716","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Met Primary Endpoint in T2NOW Phase III trial, One of the Largest Paediatric Type 2 Diabetes Studies Performed to Date","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Positive Phase 1\/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1083","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"$45.1 million","upfrontCash":"Undisclosed","newsHeadline":"National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8\u00ae Study in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.050000000000000003,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Vaccine and Immunotherapy Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic\u2019s C1 Platform Selected by the Vaccine and Immunotherapy Center (\u201cVIC\u201d) at Massachusetts General Hospital as Part of VIC\u2019s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Prophylactic Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Vaccine and Immunotherapy Center","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"Dyadic\u2019s C1 Platform Selected by the Vaccine and Immunotherapy Center (\u201cVIC\u201d) at Massachusetts General Hospital as Part of VIC\u2019s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Prophylactic Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaccine and Immunotherapy Center","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaccine and Immunotherapy Center \/ U.S. Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"Vaccine an.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$387.4 million","upfrontCash":"$387.4 million","newsHeadline":"Kyowa Kirin to Acquire Orchard Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0.39000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$188.0 million","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics to Acquire Odyssey Health\u2019s Neurological Drug Technology Pipeline Including Concussion Drug Candidate","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$654.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"MTK-458","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0.65000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Mitokinin \/ Abbvie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin .."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Vaccine Industrial Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex and Saudi Arabia\u2019s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Infectious Disease Solutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"CD8+ T-cell Adaptive Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergex Vaccines Holding \/ Vaccine Industrial Company","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Ampio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"OA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ascendia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Ampio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ascendia P.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,780.0 million","upfrontCash":"$2,780.0 million","newsHeadline":"Amgen Completes Acquisition of Horizon Therapeutics Plc","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":2.7799999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.7799999999999998,"dosageForm":"infusion","sponsorNew":"Horizon Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA\u00ae ONBODY\u2122","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Efavirenz","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces First Patient Dosed in Phase 1\/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ONCT-534","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Doses First Patient in the MyPeak-1\u2122 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TN-201","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"BioAdaptives","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAdaptives, Inc. Commences Development of a New Supplement for Womens Health","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vitamin D","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"BioAdaptives","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAdaptives \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioAdaptiv.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Positive Top-Line Results for Lomecel-B\u2122 in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (\"DED\")","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and Without Diabetes, Cardiovascular Disease and Chronic Kidney Disease","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Survodutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Provides Update on Acc\u00e8s Compassionnel for AMX0035 in France","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AHF: Newly Approved Malaria Vaccine Is a Win for Global Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"R21\/Matrix-M Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ecopipam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bio.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Files Request With the UK\u2019s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RG6501 (OpRegen\u00ae) Phase 1\/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RG6501","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn\u2019s Disease and Starts STENOVA Phase 2a Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AGMB-129","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Provides Update on Lacutamab Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lacutamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fostrox + Lenvima Continues to Show Promising Tumor Control in HCC, all Patients Have now Dosed at Least two Treatment Cycles","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Committee for Orphan Medicinal Products Provides Positive Opinion On Calliditas' Application for Setanaxib in Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to GC Biopharma's Drug Candidate for Thrombotic Thrombocytopenic Purpura","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GC1126A","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"K\u00fcleon Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"K\u00fcleon Bioscience Announces Scientific Breakthrough with First Known ''Trifunctional'' 5-HT2C Receptor Agonist that is also a Full Antagonist of the 5-HT2A and 5-HT2B Receptors, Creating an Exciting Lead for Multiple Neuropsychiatric Illnesses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-128","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"K\u00fcleon Bioscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"K\u00fcleon Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"K\u00fcleon Bio.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2\/N1 Inhibitor in Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ABBV-CLS-484","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Icosapent Ethyl Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for Neffy\u00ae (epinephrine nasal spray)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Marizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Glutathione","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Marizyme","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marizyme \/.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Arcutis'S ZORYVE\u00ae (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Application to the European Medicines Agency for RYBREVANT\u00ae\u25bc (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Muta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab-vmjw","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"AIDS Healthcare Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AHF Praises Colombia's Stand for Accessible HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ AIDS Healthcare Foundation","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma has Completed Enrollment to the Phase 3 Study for MOB-015 in North America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Terbinafine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces US FDA Filing Acceptance of New Drug Application (NDA) For Deuruxolitinib","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Novartis Cosentyx\u00ae as First Intravenous (IV) Formulation Interleukin-17A Antagonist for Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$5,800.0 million","upfrontCash":"$5,800.0 million","newsHeadline":"Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":5.7999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":5.7999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"GSK","sponsor":"Chongqing Zhifei Biological Products","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK and Zhifei Announce Exclusive Strategic Vaccine Partnership in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Adjuvanted Recombinant Zoster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Chongqing Zhifei Biological Products","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Chon.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct its Phase IIA Study in Patients with Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Announces it has Contracted with Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer\u2019s Disease in September 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Safety Data Suggests SPRAVATO\u00ae (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Marketing Approval of CAN108 (\/LIVMARLI\u00ae) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat Chloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Efdamrofusp Alfa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves TOFIDENCE\u2122 (tocilizumab-bavi) a Biosimilar of ACTEMRA\u00ae Developed by Bio-Thera Solutions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"CuraSen Therapeutics Announces Strategic Investment from the Alzheimer\u2019s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"CST-3056","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CuraSen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"CuraSen Therapeutics \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"CuraSen Th.."},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"LimmaTech Biologics Raises $37 Million Series A to Advance its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"LMTB Gonococcal Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"LimmaTech Biologics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Adjuvant Capital","highestDevelopmentStatusID":"4","companyTruncated":"LimmaTech .."},{"orgOrder":0,"company":"AstronauTx","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstronauTx Closes \u00a348 Million ($61 Million) Series A Financing to Create New Treatments for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AstronauTx","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"AstronauTx \/ Novartis Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"AstronauTx.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Deploys NexoBrid\u00ae for Emergency Supply","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VTX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces IND Clearance for Phase 1b\/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBX Biosciences Doses First Participant in Phase 1\/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MBX 1416","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"MBX Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MBX Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavodelpar","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAD Receives Approval for Phase 1 Therapeutic Study of PDL1-nanobody in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RAD204","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiopharm Theranostics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Radiopharm.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (\u0153NCP\u009d)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RJB-0402","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rejuvenate Biomed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rejuvenate Biomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rejuvenate.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer\u2019s Disease (AD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Coya 301","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Doses First Patient in Phase 2b\/3 Clinical Trial of a New Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ABP-671","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HNSA-5487","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Sigrid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigrid Therapeutics Announces First Patient Treated with SiPore21\u00ae Medical Device for Sustained Diabetes and Obesity Control","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Synthetic Amorphous Silicon Dioxide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sigrid Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Sigrid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sigrid The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Vabysmo Maintained Vision Improvements with Extended Treatment Intervals up To Four Months for People with Retinal Vein Occlusion (RVO) in Phase III Studies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$63.2 million","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"ALX Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Piper Sandler","highestDevelopmentStatusID":"9","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Stem Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Stem Pharm","highestDevelopmentStatusID":"2","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces Expansion of Collaboration Agreement with Novartis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Palazestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Icosagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Icosagen","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Bi.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"PharmEnable","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ PharmEnable","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$167.0 million","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Ceftibuten-ledaborbactam Etzadroxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"VenatoRx Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"VenatoRx Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Viatris","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Announces Agreement to Acquire the European Rights to Duphaston\u00ae and Femoston\u00ae from Viatris, Inc.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Divestment","leadProduct":"Dydrogesterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Viatris \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Y.S.P. Industries M Sdn Bhd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Enters Exclusive License Agreement with YSP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Y.S.P. Industries M Sdn Bhd","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Arovella Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"SPX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SparX Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SparX Biopharmaceutical \/ Arovella Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparX Biop.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"CanariaBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CanariaBio and Hikma Announce the Signing of Distribution and License Agreement for Oregovomab in MENA Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hikma Pharmaceuticals \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"BioMap","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$10.0 million","newsHeadline":"BioMap Establishes a Strategic Collaboration with Sanofi to Co-Develop AI Modules to Accelerate Drug Discovery for Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"BioMap","amount2":1,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"BioMap \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"BioMap \/ S.."},{"orgOrder":0,"company":"Athersys","sponsor":"Healios K.K.","pharmaFlowCategory":"D","amount":"$151.5 million","upfrontCash":"Undisclosed","newsHeadline":"Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Invimestrocel","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Athersys","amount2":0.14999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Athersys \/ Healios K.K.","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Will Stop the Once-weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CT-996","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carmot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"rhENPP1-Fc","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (\u00b9\u2078\u2076Re) Obisbemeda in Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH\/NIAID Project NextGen for Inclusion in Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ocugen \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr\u00e9 Syndrome (GBS)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ANX005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GPCR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Thera.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Toragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toragen, Inc. Announced Full Enrollment of Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toragen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ .."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab\/Balstilimab in Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio Announces Initiation of Phase 1\/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AVB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Transgene","sponsor":"BioInvent","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ BioInvent","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Introduces Levocarnitine Injection, USP; FDA-Approved, \"AP\" Rated, and Therapeutically Equivalent to Carnitor\u00ae\u00b9","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Levocarnitine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B\/ABL503","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TJ-L14B","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Receives FDA Feedback that Data from Completed Phase 1\/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet Starts Phase Ib\/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed\/Refractory Peripheral T-cell Lymphomas (PTCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1\/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"STX-721","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scorpion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"7","companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Signs Phase III Regulatory US Consultants to Support Preparation for Mesdopetam\u2019s End-of-Phase 2 Meeting with the US FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"ClinConnect","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ClinConnect Partners with Conduit Pharmaceuticals on Cocrystal Development Program for AZD1656","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"AZD1656","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"ClinConnect","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ClinConnect \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"ClinConnec.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Israeli Shekels","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"ExoTherapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Israeli Shekels","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with 3M on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"3M Health Care","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"3M Health Care \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"3M Health .."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities LLC","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Apitegromab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$15.0 million","newsHeadline":"Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"STAR-0310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ichnos Sciences","amount2":0.32000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Astria Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"Federation Bio","sponsor":"Kanvas Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kanvas Biosciences Acquires Federation Bio Assets to Scale the Discovery, Development and Manufacturing of Microbiome-Based Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Federation Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Federation Bio \/ Kanvas Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Federation.."},{"orgOrder":0,"company":"IMIDomics","sponsor":"University of Barcelona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"IMB-1003","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMIDomics \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics .."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series C Financing","leadProduct":"ORG-129","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"AgomAb Therapeutics N.V \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SNAP CAR T-cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ Coeptis Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"University.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Virion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"VRON-0200-AdC6","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocean Biomedical \/ Virion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"MinervaX","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$56.8 million","upfrontCash":"Undisclosed","newsHeadline":"MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Aluminium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MinervaX","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"MinervaX \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"MinervaX \/.."},{"orgOrder":0,"company":"Ab Initio Pharma","sponsor":"ResolutionRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc.\u2019s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Ab Initio Pharma","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ab Initio Pharma \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"Ab Initio .."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immetas Therapeutics and GC Biopharma Announce Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immetas Therapeutics \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Th.."},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"EpimAb Biotherapeutics \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Bio.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"CanariaBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Specialised Therapeutics Signs Exclusive License Agreement with CanariaBio For New Ovarian Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Specialised Therapeutics \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"Biocon","sponsor":"Juno Pharmaceuticals Pty Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Limited Signs Commercialization Agreement with Juno Pharmaceuticals in Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Juno Pharmaceuticals Pty Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ J.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Large Phase 3 Clinical Trial Successfully Meets Primary Endpoint, Confirming the Potential of ALK's Tree Tablet in Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces First Patient Dosed in Phase Ib\/II Trial of SLS009 (GFH009) in Relapsed\/Refractory Peripheral T-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1\/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed\/Refractory AML and HMA-Refractory MDS Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyluma Announces Positive Results From Second Stage of Phase III CHAMP Study of NVK002 for the Treatment of Myopia in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Vyluma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ N.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Cytovation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovation Reports Promising Interim Results from Phase 1\/2a CICILIA Study with CyPep-1 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CyPep-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cytovation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cytovation.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deucravacitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SRK-439","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety in the Treatment of Geographic Atrophy Secondary to Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Positive Clinical Data From Phase 1b Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog\/SMO Inhibitor GT1708F for Treatment of IPF in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GT1708F","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Announces that all Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program CONCLUDE","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces Closing of $4 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ INGENIA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"The Mark Foundation for Cancer Research","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Mark Foundation for Cancer Research Teams up with Takeda to Fund Groundbreaking Research to Uncover and Target Novel Cancer Vulnerabilities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"The Mark Foundation for Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Mark Foundation for Cancer Research \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"The Mark F.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Na\u00efve Patients with First-Line CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$1,070.0 million","upfrontCash":"$70.0 million","newsHeadline":"MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to Develop Next-Generation Anti-Cancer Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MediLink Therapeutics","amount2":1.0700000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.0700000000000001,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"MediLink T.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$960.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0.95999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.95999999999999996,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"CastleVax","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"NDV-HXP-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CastleVax","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"CastleVax \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"7","companyTruncated":"CastleVax .."},{"orgOrder":0,"company":"Codagenix","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Live-attenuated Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Codagenix \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Project NextGen Selects Initial Vaccine Candidates and Awards Over $500 Million to Advance Development of Vaccines and Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"GRT-R910","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gritstone bio","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Argenx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Temtokibart Achieves First Subject First Treatment (FSFT) Milestone in Phase 2b trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Temtokibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ argenx","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RLY-4008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in its Alzheimer's Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"INB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"REVTx-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"ClearB Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClearB Therapeutics Announces First Patient Dosed in a Phase 1b","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CLB-405","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ClearB Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ClearB Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ClearB The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Pfizer\u2019s BRAFTOVI\u00ae + MEKTOVI\u00ae for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Marketing Approval of CAN108 (\u9081\u82ae\u500d\u00ae\/LIVMARLI\u00ae) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat Chloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Launches 'Oraal\u2019 for Treatment of Oral Mucositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Curcuma Longa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Med.."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genevant Sciences LNP Technology Used in samRNA Covid-19 Vaccine Candidate Behind Gritstone bio's BARDA Award","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GRT-R910","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Genevant Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genevant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CYR-064","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano The.."},{"orgOrder":0,"company":"MimiVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Montanide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"MimiVax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ .."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HL192","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Bio.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis\u00ae (cyclosporine ophthalmic emulsion) 0.05%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"SystImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SystImmune, Inc. Announces First Patient Dosed in U.S. Phase 1 Clinical Trial of BL-B01D1 for the Treatment of Metastatic or Unresectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BL-B01D1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SystImmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Data for Roche's BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fenebrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (na-SPMS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces Results from Trogarzo\u00ae (Ibalizumab-uiyk) Intramuscular Administration Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Iibalizumab-uiyk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE\u00ae (vamorolone) for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Opdivo\u00ae (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives Positive CHMP Opinion for BRUKINSA\u00ae (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma and Cidara Therapeutics Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Pfizer\u2019s VELSIPITY\u2122 for Adults with Moderately to Severely Active Ulcerative Colitis (UC)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Etrasimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS \u22651)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Padagis Announces the Launch of Brinzolamide Ophthalmic Suspension with CGT Exclusivity","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Brinzolamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Provides Update on Near Term Plans for Submission of Marketing Authorization Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dendritic Cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for VEOZA\u2122 (fezolinetant)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"IMG-007","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces Topline Data from Phase 3 Intune Study Evaluating Pitolisant in Patients with Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience Announces that \"Xafty is the only Antiviral that can be Immediately Used for the Treatment of Dengue Fever\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyundai Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hyundai Bi.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"ImmunoACT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India\u2019s First Cell Therapy for Cancer Treatment Receives Regulatory Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Actalycabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ImmunoACT","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoACT \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ImmunoACT .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Upadacitinib (RINVOQ\u00ae) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Approves FoundationOne\u00aeCDx as a Companion Diagnostic for Janssen\u2019s AKEEGA\u2122 (niraparib and abiraterone acetate Dual Action Tablet) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CanariaBio","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CanariaBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CanariaBio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CanariaBio.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s ELREXFIO\u2122 Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Elranatamab-bcmm","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Expands Reach with the Launch of Elores in Ecuador","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ceftriaxone","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injection","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NVL-655","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed\/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Immunotherapeutics Announces the Full Dataset from its 24-week MIRA Clinical Trial, Establishing the Nanobody\u00ae Sonelokimab as a Highly Promising and Differentiated Therapeutic Solution for Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2\/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives Positive CHMP Opinion Recommending Approval of Jemperli (dostarlimab) Plus Chemotherapy as a New Frontline Treatment for dMMR\/MSI-H Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-mutated Advanced Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Recombinant Human Gelsolin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Notable Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Notable Labs Closes Merger Transaction with VBL Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"Volasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"VBL Therapeutics \/ Notable Labs","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Helocyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV\/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CMV-MVA Triplex","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"City of Hope \/ Helocyte","highestDevelopmentStatusID":"8","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Organon","pharmaFlowCategory":"D","amount":"$192.8 million","upfrontCash":"$10.0 million","newsHeadline":"Dar\u00e9 Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO\u2122 (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.19,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.19,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vaxcyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Group \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Ocedurenone for Uncontrolled Hypertension from KBP Biosciences","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Ocedurenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":1.3,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Modifi Bio","sponsor":"Connecticut Innovation","pharmaFlowCategory":"D","amount":"$10.7 million","upfrontCash":"Undisclosed","newsHeadline":"Modifi Bio Raises Additional $4.3 Million in Seed Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Modifi Bio","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Modifi Bio \/ Connecticut Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Modifi Bio.."},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Glycotope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ LegoChem Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Glycotope .."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$97.8 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Apitegromab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Kaitai Capital","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series D Financing","leadProduct":"ABP-671","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0.080000000000000002,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"Antiverse","sponsor":"GlobalBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antiverse \/ GlobalBio","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse .."},{"orgOrder":0,"company":"Synaffix","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix\u2019s ADC Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synaffix","amount2":0.73999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ SOTIO","highestDevelopmentStatusID":"3","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvalent Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Zidesamtinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"Notable stockholders Builders VC","pharmaFlowCategory":"D","amount":"$10.3 million","upfrontCash":"Undisclosed","newsHeadline":"Notable Labs Closes Merger Transaction with VBL Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Volasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Notable Labs \/ Notable stockholders Builders VC","highestDevelopmentStatusID":"8","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nidlegy\u2122 Phase III PIVOTAL Trial Meets the Study\u2019s Primary Objective in Patients with Locally Advanced Fully Resectable Melanoma (Price Sensitive)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bifikafusp Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TERN-701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Busulfan","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elixirgen Therapeutics Announces Promising Phase 1\/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"EXG-5003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixirgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Opelconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Pulmocide \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide .."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-RIGA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed with Phase 1 Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Risvodetinib Succinate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TRV045","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves KEYTRUDA\u00ae (pembrolizumab) for Treatment of Patients with Resectable (T\u22654 cm or N+) NSCLC in Combination with Chemotherapy as Neoadjuvant Treatment, then Continued as a Single Agent as Adjuvant Treatment After Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GDA-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KEYTRUDA\u00ae (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TMB-365","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"TaiMed Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TaiMed Bio.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ\/11 Metastatic Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Glucocerebrosidase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat Chloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase(R) Provides Update on Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Gets Marketing Approval for Six Chemotherapy Drugs from Philippines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Ardelyx","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ SLR Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ultragenyx Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jiangsu Hengrui Pharma and Elevar Therapeutics Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Camrelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Elevar Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu He.."},{"orgOrder":0,"company":"GRI Bio","sponsor":"NIHR Respiratory TRC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"GRI Bio \/ NIHR Respiratory TRC","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$2,050.0 million","upfrontCash":"$50.0 million","newsHeadline":"Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Monte Rosa Therapeutics","amount2":2.0499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Defence R&D Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Defence R&D Canada","highestDevelopmentStatusID":"1","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Tessellate BIO","sponsor":"BioGeneration Ventures","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Tessellate BIO Emerges from Stealth","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tessellate BIO","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Tessellate BIO \/ BioGeneration Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Tessellate.."},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GordonMD\u00ae Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Radionetics Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radionetics Oncology \/ GordonMD Global Investments","highestDevelopmentStatusID":"2","companyTruncated":"Radionetic.."},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poolbeg Partners with a Nasdaq-Listed Biopharma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Poolbeg Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poolbeg Pharma \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Poolbeg Ph.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"ABI-4334","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.29999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Mablink Bioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mablink Bioscience Enters an Agreement to be Acquired by Lilly","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mablink Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mablink Bioscience \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mablink Bi.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid\u2019s Cash Runway into 2026","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Soticlestat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"University of Georgia Research Foundation","sponsor":"AN2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AN15368","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Georgia Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia Research Foundation \/ AN2 Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$14.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Cessation Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Cessation Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Cessation .."},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avanzanite Bioscience Expands Partnership with Advicenne in Additional European Countries","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Potassium Citrate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Avanzanite Bioscience","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"12","companyTruncated":"Avanzanite.."},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ST-113","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Stuart Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stuart Therapeutics \/ Glaukos","highestDevelopmentStatusID":"5","companyTruncated":"Stuart The.."},{"orgOrder":0,"company":"Traverse Biotech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Traverse Biotech has been Awarded a Phase I SBIR Grant from the National Cancer Institute to Develop Targeted Immunotherapy for Selected Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Traverse Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Traverse Biotech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Traverse B.."},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$59.5 million","upfrontCash":"Undisclosed","newsHeadline":"Actym Closes $59.5 Million Series A with New $25.5 Million Extension","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"ACTM-838","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Actym Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"5","companyTruncated":"Actym Ther.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Awarded $16.2 Million in DoD Funding to Advance LMN-201 through Late-Stage Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"LMN-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ U.S. Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"SpliceBio","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","amount":"$216.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SpliceBio","amount2":0.22,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"SpliceBio \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"2","companyTruncated":"SpliceBio .."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock\u2019s Phase I Study with Bemdaneprocel in Patients with Parkinson\u2019s Disease Meets Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves XPHOZAH\u00ae (tenapanor), a First-in-Class Phosphate Absorption Inhibitor","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-DOTA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-500","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Announces First Patient Dosed in Phase 1\/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VRON-0200-AdC6","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NKX019","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Announces Interim PK\/PD and Clinical Data for MRT-2359 in Phase 1\/2 Trial for MYC-Driven Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Announces First Patient Dosed in Phase 1\/2 Study of BDC-3042 in Patients with Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BDC-3042","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"EDP2939","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel\u00ae (darvadstrocel) in Complex Crohn\u2019s Perianal Fistulas","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Darvadstrocel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Empaveli is the First Treatment for PNH that Binds to the Complement Protein C3","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pint Pharma \/ OrphanDC","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharm.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoAgents Announces Initiation of Patient Enrollment in Phase 1b\/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CTO1681","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SEFA-6179","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for PREVYMIS\u00ae for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Letermovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Phase IV UNITE Study Shows AJOVY\u00ae (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fremanezumab-vfrm","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Bio4t2","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio4t2 Announces Trial Evaluating Repeat Infusions of CAR-T Targeting Solid Tumors without Lymphodepletion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"B4T2-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio4t2","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio4t2 \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio4t2 \/ N.."},{"orgOrder":0,"company":"Amplifier Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplifier Therapeutics, a Cambrian Bio Pipeline Company, Doses First Patients in Phase 1B Clinical Trial and Closes New Financing from Future Ventures and RA Capital Management","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ATX-304","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Amplifier Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplifier Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amplifier .."},{"orgOrder":0,"company":"Immunoforge","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide for Dermatomyositis\/Polymyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Froniglutide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunoforge","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunoforge \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunoforg.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Na\u00efve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces U.S. FDA Approval of ZILBRYSQ\u00ae (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Gears up for Weight Loss Drug Study","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"DOC1021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos O.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIMZELX[\u00ae] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved in China for the Ttreatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Teneligliptin Hydrobromide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Amniotic Membrane","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON Announces First Patient Enrolled in Phase 1\/2 Clinical Trial of IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Allowance by FDA for at-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel \u201cImmune-Quiet\u201d DNA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"iqDNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Generation Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation.."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Announces Travelan\u00ae Clinical Study Cohort 2 Commences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People with ALK-positive Early-Stage Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces U.S. FDA Approval of Maxigesic\u00ae IV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1\/2a study of DSR\u00ae 2.0 for Treatment of Heart Failure Through Breaking Vicious Cycle of Cardiorenal Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dextrose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Me.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves ADCETRIS\u00ae (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Initiates First Clinical Study of Otenaproxesul\u2019s New Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lutetium-177 Rosopatamab Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Brise Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brise Pharma Announces First Patient Dosed with BR01T in Phase I Study in Patients with Chronic Low Back Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BR01T","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Brise Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brise Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Brise Phar.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MSC-NTF Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Aculys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aculys Pharma Delivers Positive Phase 3 Clinical Study Interim Analysis Result of a Diazepam Nasal Spray: an Antiepileptic Drug for the Treatment of Epileptic Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Diazepam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Aculys Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aculys Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aculys Pha.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcutis Announces Pricing of $100 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Tourmaline Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Talaris Therapeutics \/ Tourmaline Bio","highestDevelopmentStatusID":"8","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"Biosight","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ayala Pharmaceuticals Announces Closing of Merger with Biosight","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Biosight \/ Ayala Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Gravitas Therapeutics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$70.7 million","upfrontCash":"$2.0 million","newsHeadline":"Basilea Announces Acquisition of Novel Clinical-Stage Antifungal for Treatment of Aspergillus Mold Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"BAL2062","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gravitas Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Gravitas Therapeutics \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Gravitas T.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$22,000.0 million","upfrontCash":"$5,500.0 million","newsHeadline":"Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Patritumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":22,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Qnovia","sponsor":"University of Virginia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"QN-05","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Qnovia","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ University of Virginia","highestDevelopmentStatusID":"4","companyTruncated":"Qnovia \/ U.."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Endeavor Biomedicines","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HMBD-501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.42999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ Endeavor BioMedicines","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"PTC Therapeutics Announces Evrysdi\u00ae Royalty Agreement with Royalty Pharma for Up To $1.5 Billion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":1.5,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":1.5,"dosageForm":"Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"cAd3-Marburg Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sabin Vaccine Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sabin Vaccine Institute \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Sabin Vacc.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I\/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NRTX-1001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibalizumab-uiyk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD\u2122, Reduced Acute Inflammatory Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol Analog","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Bi.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Receives Approval to Initiate the Clinical Phase I\/IIa study with Tumorad(R) in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Introduces Potassium Phosphates, USP; FDA-Approved and \"AP\" Rated\u00b9","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Potassium Phosphate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"Menarini","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Rise Therapeutics' IND Application to Initiate a Phase 1 Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"R-2487","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rise Thera.."},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Flare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Flare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Flare Ther.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Sumitomo","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Sumitomo","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo \/.."},{"orgOrder":0,"company":"Skyline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skyline Therapeutics Receives China NMPA's Approval of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SKG0106","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Skyline Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skyline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Skyline Th.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Announces IND Submission to US FDA for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Rivfloza\u2122 for Children \u22659 Years Old and Adults Living with Primary Hyperoxaluria Type 1 (PH1), a Rare Genetic Condition","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nedosiran","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Larotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"AB Institut de Neuroci\u00e8ncies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Gives Cannabidiol Orphan Drug Designation for the Treatment of Leigh syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AB Institut de Neuroci\u00e8ncies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Institut de Neuroci\u00e8ncies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AB Institu.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces NAV\u00ae Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Public-private Consortium will Fund three Gene Therapy Clinical Trials at UT Southwestern and Children\u2019s Health","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"UT Southwestern Medical Center","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"UT Southwe.."},{"orgOrder":0,"company":"Myto Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYT-109, a Promising Treatment for Leigh Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Monomethyl Fumarate Prodrug","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Myto Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myto Therapeutics \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"Myto Thera.."},{"orgOrder":0,"company":"EA Pharma","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All-case Surveillance Condition for Approval of \u201cActonel\u00ae 17.5 mg tablets\u201d for Treatment of Paget\u2019s Disease of Bone Cleared in Japan","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Risedronate Sodium","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"EA Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EA Pharma \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"EA Pharma .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","amount":"$207.0 million","upfrontCash":"$7.0 million","newsHeadline":"ABVC BioPharma Entered into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Radix Polygalae Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.20999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Harmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals and Expands Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.20000000000000001,"dosageForm":"Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,570.0 million","upfrontCash":"$85.0 million","newsHeadline":"GSK Enters Exclusive License Agreement with Hansoh for HS-20089","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20089","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":1.5700000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5700000000000001,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pha.."},{"orgOrder":0,"company":"LianBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Mavacamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"LianBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Elektrofi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$20.0 million","newsHeadline":"Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Elektrofi","amount2":0.46999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Elektrofi \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Elektrofi .."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$326.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.33000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$7,250.0 million","upfrontCash":"$7,100.0 million","newsHeadline":"Roche Enters into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease from Roivant","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"PF-06480605","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Telavant","amount2":7.25,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":7.25,"dosageForm":"Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/.."},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"AIO-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":0.25,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Aiolos Bio \/ Atlas Venture","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio.."},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","amount":"$485.0 million","upfrontCash":"$485.0 million","newsHeadline":"Quince Therapeutics Completes Acquisition of EryDel S.p.A.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0.48999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.48999999999999999,"dosageForm":"Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Q.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"SAR444656","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,482.0 million","upfrontCash":"$169.3 million","newsHeadline":"Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HRS-1167","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":1.48,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.48,"dosageForm":"","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu He.."},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series C Financing","leadProduct":"ML-007C-MA","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"MapLight Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"MapLight T.."},{"orgOrder":0,"company":"Verve","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"$60.0 million","newsHeadline":"Verve and Lilly Relationship Expands to Include Verve\u2019s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"VERVE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve","amount2":0.53000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Infusion","sponsorNew":"Verve \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Verve \/ El.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Ixaka","sponsor":"Alaya.bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alaya.bio Acquires Key Assets from Ixaka France, Accelerating the Progress of its Novel In Vivo CAR-T Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ixaka","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ixaka \/ Alaya.bio","highestDevelopmentStatusID":"4","companyTruncated":"Ixaka \/ Al.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Innocan Pharma Announces Closing of Second and Final Tranche of Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Northwestern University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Tomivosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Falk Medical Research Trust","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Artemisinin-based Medicine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocean Biomedical \/ Falk Medical Research Trust","highestDevelopmentStatusID":"4","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Armistice Capital","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Announces $92 Million Private Placement Financing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Armistice Capital","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Soleus Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harpoon Therapeutics Announces up to $150 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Soleus Capital","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"$45.4 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra to Receive EUR 2.5 Million Milestone Payment from Fuji Pharma under ESTELLE\u00ae Licensing Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.050000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Fuji Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"DermBiont","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","amount":"$35.2 million","upfrontCash":"Undisclosed","newsHeadline":"DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series B Financing","leadProduct":"SM-020","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont .."},{"orgOrder":0,"company":"Rampart Bioscience","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rampart Bioscience","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Rampart Bioscience \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"Rampart Bi.."},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turbine \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ .."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Beverly Hills Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiromic BioPharma \/ Beverly Hills Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Phar.."},{"orgOrder":0,"company":"Inimmune","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inimmune Collaborates with Boston Children's Hospital to Develop Novel Adjuvants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Inimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inimmune \/ Boston Children's Hospital","highestDevelopmentStatusID":"2","companyTruncated":"Inimmune \/.."},{"orgOrder":0,"company":"Codagenix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"Codagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"CodaVax-DENV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codagenix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Codagenix \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ideaya Biosciences","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"OBiO Technology","sponsor":"Refreshgene Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"RRG-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OBiO Technology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OBiO Technology \/ Refreshgene Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"OBiO Techn.."},{"orgOrder":0,"company":"Naya Biosciences","sponsor":"INVO Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"CYT-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Naya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Naya Biosciences \/ INVO Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Naya Biosc.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Ensysce Biosciences Secures $1.7 Million Convertible Note Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Oxycodone Prodrug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ensysce Biosciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Announces Brokered LIFE Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"RevBio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"RevBio Awarded a $2 Million Follow-on NIH Grant to Reduce Opioid Use and Addiction with TETRANITE\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"TN-ADBS","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"RevBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RevBio \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"RevBio \/ N.."},{"orgOrder":0,"company":"Flashpoint Therapeutics","sponsor":"Beta Lab","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flashpoint Therapeutics Announces $10M Seed Financing Led by Beta Lab to Pioneer Nanotechnology-Enabled Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Flashpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Flashpoint Therapeutics \/ Beta Lab","highestDevelopmentStatusID":"4","companyTruncated":"Flashpoint.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"USAFA","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics\u2019 Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ USAFA","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene\u2019s New Cell Therapy Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"MDG1015","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Medigene","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Chardan","highestDevelopmentStatusID":"7","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced at- the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"MRT-2359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Monte Rosa Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Monte Rosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"SEARCHLIGHT PHARMA INC","pharmaFlowCategory":"D","amount":"$17.9 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra and Searchlight Pharma Sign DONESTA\u00ae Licensing Agreement for Canada","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105\/Azelaprag Co-Administered with Tirzepatide for Treatment of Obesity, in Collaboration with Lilly\u2019s Chorus Organization","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"Ypsomed","sponsor":"Viridian Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"VRDN-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ypsomed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ypsomed \/ Viridian Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ypsomed \/ .."},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"iVeena Awarded NEI-SBIR Grant for Progressive Myopia Drug Candidate IVMED-85","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"IVMED-85","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ N.."},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hope Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"HMI-115","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Chime Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chime Biologics \/ Hope Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Chime Biol.."},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"Undisclosed","newsHeadline":"Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"TRIV-509","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Triveni Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Triveni Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Triveni Bi.."},{"orgOrder":0,"company":"L2P Research","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"L2P Research Labs Awarded NIH SBIR Grant for Arthritis, Musculoskeletal and Skin Diseases Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"L2P Research","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"L2P Research \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"L2P Resear.."},{"orgOrder":0,"company":"Henlius","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"$195.5 million","upfrontCash":"$44.4 million","newsHeadline":"Henlius Deepens Collaboration with Intas to Bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Henlius","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Henlius \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Henlius \/ .."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"Rotigotine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupus Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Ther.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Completes Transfer of NDAs and Launches FLAREX\u00ae, NATACYN\u00ae, TOBRADEX\u00ae ST, VERKAZIA\u00ae, and ZERVIATE\u00ae in the U.S.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"$15.0 million","newsHeadline":"Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Acquisition","leadProduct":"Zastaprazan","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Onconic Therapeutics","amount2":0.13,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Onconic Therapeutics \/ Livzon Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Onconic Th.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"VYNE Therapeutics Announces Private Placement of $88 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics to Acquire Miromatrix Medical","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United The.."},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Brigimadlin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Burning Rock Dx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Burning Rock Dx \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Burning Ro.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nippon Kayaku","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.0 million","newsHeadline":"AnHeart Therapeutics Announces Exclusive License Agreement with Nippon Kayaku for Taletrectinib in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Nippon Kayaku","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Perigon Pharmacy 360","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL\u00ae XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Perigon Pharmacy 360","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Fairmount Funds","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"VRDN-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.19,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Fairmount Funds","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$CHECK CHECK","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Bio.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","amount":"$202.0 million","upfrontCash":"$7.5 million","newsHeadline":"SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ 3D Medicines Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iNtRON, Executes Evaluation License and Option Agreement for SAL200","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Bio.."},{"orgOrder":0,"company":"Rational Vaccines","sponsor":"Shenzhen Mellow Hope Pharm Industrial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"RVx-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Rational Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rational Vaccines \/ Shenzhen Mellow Hope Pharm Industry","highestDevelopmentStatusID":"5","companyTruncated":"Rational V.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRAS\u1d33\u00b9\u00b2\u1d9c-Mutated NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Terremoto Biosciences Closes $175 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Terremoto Biosciences","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Terremoto Biosciences \/ EcoR1 Capital","highestDevelopmentStatusID":"2","companyTruncated":"Terremoto .."},{"orgOrder":0,"company":"Napo EU","sponsor":"Quadri Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Quadri Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Siren Biotechnology","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"AAV Immuno-gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Siren Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siren Biotechnology \/ CIRM","highestDevelopmentStatusID":"4","companyTruncated":"Siren Biot.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"$30.0 million","newsHeadline":"Atara Biotherapeutics Announces Expanded Global Tab-cel\u00ae Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atara Biotherapeutics","amount2":0.64000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.64000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Tolerance Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$20.0 million","newsHeadline":"Ligand Acquires Royalty on Sanofi\u2019s TZIELD\u00ae for $20 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Teplizumab-mzwv","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tolerance Therapeutics","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Tolerance Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tolerance .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$501.0 million","upfrontCash":"$100.0 million","newsHeadline":"Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0.5,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Solution","sponsorNew":"Aldeyra Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$990.0 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"PN-235","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.98999999999999999,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacterial Agent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Bio.."},{"orgOrder":0,"company":"Engine Biosciences","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engine Biosciences Secures $27 Million Series A Extension to Advance Development of Precision Oncology Medicines and Novel Biomarkers for Patient Selection","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"ENB-812","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Engine Biosciences","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Engine Biosciences \/ Polaris Partners","highestDevelopmentStatusID":"5","companyTruncated":"Engine Bio.."},{"orgOrder":0,"company":"Epic Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Kite Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Epic Bio \/.."},{"orgOrder":0,"company":"Therakind","sponsor":"Shorla Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Therakind","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Solution","sponsorNew":"Therakind \/ Shorla Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Therakind .."},{"orgOrder":0,"company":"Lung Therapeutics","sponsor":"Aileron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Acquisition of Lung Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"LTI-03","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Lung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lung Therapeutics \/ Aileron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lung Thera.."},{"orgOrder":0,"company":"Imagine Pharma","sponsor":"IP Investors LLC","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"Imagine Pharma Secures $32.5M Series A for Continued Development of its Novel IMG-1 Polypeptide and Associated Programs","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"IMG-1","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Imagine Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imagine Pharma \/ IP Investors LLC","highestDevelopmentStatusID":"6","companyTruncated":"Imagine Ph.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Undisclosed \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"$91.0 million","newsHeadline":"United Therapeutics to Acquire Miromatrix Medical","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United The.."},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Financing","leadProduct":"AAV-AQP1","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0.029999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MeiraGTx \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/.."},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"One Small Planet","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Magdalena Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magdalena Biosciences \/ One Small Planet","highestDevelopmentStatusID":"1","companyTruncated":"Magdalena .."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Genevant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genevant Sciences \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE\u00ae Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"ACU193","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Halozyme Therapeutics \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$200.5 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"OMERS Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xencor Sells Portion of Royalties and Milestones from Ultomiris\u00ae and Monjuvi\u00ae to OMERS Life Sciences for $215 Million","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Divestment","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"OMERS Life Sciences","amount2":0.22,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.22,"dosageForm":"Infusion","sponsorNew":"OMERS Life Sciences \/ Xencor","highestDevelopmentStatusID":"12","companyTruncated":"OMERS Life.."},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU\u00ae (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Menarini \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"OrsoBio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"TLC-3595","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"OrsoBio","amount2":0.059999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"OrsoBio \/ Longitude Capital","highestDevelopmentStatusID":"8","companyTruncated":"OrsoBio \/ .."},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$1,055.0 million","upfrontCash":"$55.0 million","newsHeadline":"Biotheus Enters into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"PM8002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":1.0600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.0600000000000001,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"DiaUnion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diamyd Medical Partners with DiaUnion to Recruit Participants for Type 1 Diabetes Prevention Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Recombinant Human Glutamic Acid Decarboxylase","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ DiaUnion","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$794.0 million","upfrontCash":"$794.0 million","newsHeadline":"Alfasigma Completes Acquisition of Intercept Pharmaceuticals, Inc.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0.79000000000000004,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.79000000000000004,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Invios","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"invIOs and Dana-Farber Cancer Institute Start Collaboration to Study Novel Small Molecule INV501 for Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invios \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ D.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$80.0 million","newsHeadline":"Bayer and Recursion Focus Research Collaboration on Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Recursion Pharma","amount2":1.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Melinta Therapeutics \/ Venatorx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Th.."},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,010.0 million","upfrontCash":"$185.0 million","newsHeadline":"Eccogene Enters Exclusive License Agreement with AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eccogene","amount2":2.0099999999999998,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"NMD Pharma Raises \u20ac75 Million (~$80 million) in a Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series B Financing","leadProduct":"NMD670","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Novo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology Announces $4 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"USAMRDC","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"Regdanvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inhalon Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Inhalon Biopharma \/ USAMRDC","highestDevelopmentStatusID":"6","companyTruncated":"Inhalon Bi.."},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reverb Therapeutics Debuts Its Amplifier\u2122 Platform for Redirecting Endogenous Cytokines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Reverb Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Reverb The.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and Graphite Bio Announce Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ LENZ Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$53.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics and Graphite Bio Announce Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astellas to Acquire Propella Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"$85.0 million","newsHeadline":"Arcellx and Kite Announce Expansion in Strategic Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"ACLX-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ .."},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Mississippi State University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halberd Corporation Plans to Extend Research Partnership with Mississippi State University","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Halberd Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Halberd Corporation \/ Mississippi State University","highestDevelopmentStatusID":"4","companyTruncated":"Halberd Co.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Pierre Fabre","highestDevelopmentStatusID":"10","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"DyDo Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE\u00ae (amifampridine) in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Amifampridine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ DyDo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Gets USFDA Nod for Generic Drug Used for Short-term Treatment of Heartburn","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Esomeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn\u00ae (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Shows ZORYVE\u00ae (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRUKINSA\u00ae Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves BioMarin's VOXZOGO\u00ae (vosoritide) for Children Under 5 Years with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vosoritide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives USFDA Approval for ZITUVIO\u2122 to Treat Adult Patients with Type 2 Diabetes Mellitus","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces TREMFYA\u00ae (guselkumab) Demonstrates Significant Skin Clearance in First-of-its-Kind Prospective, Large-Scale Study Dedicated to People of Color Living with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA - A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CB03","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RVU120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Regeneron Provide Update on Dupixent\u00ae (dupilumab) sBLA for Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Genmab","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIVDAK\u00ae (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ S.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ORIC-114","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics\u2019 Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Na\u00efve in Global Pivotal TRUST-II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA\u00ae (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Infliximab-dyyb","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Adiso Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BT051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Adiso Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adiso Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adiso Ther.."},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PHAXIAM Therapeutics Obtains Authorizations to Launch its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Phage Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Phaxiam Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phaxiam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Phaxiam Th.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 764532","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Therini Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"THN391","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therini Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bi.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Actinium-225 Dotatate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138-NODAGA-Cu64","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-386\u2122s Ability to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer\u2122s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine\u00ae IMA203 TCR-T Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ANX007","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"EA 2351","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Endogena Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endogena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Endogena T.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics to Submit Updated IND Application for BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Pluvicto\u2122 Shows Clinically Meaningful and Highly Statistically Significant rPFS Benefit in Patients with PSMA-positive Metastatic Castration-resistant Prostate Cancer in the Pre-taxane Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lutetium Lu 177 Vipivotide Tetraxetan)","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Updates on E.U. Marketing Authorisation Application for Odevixibat in Alagille syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer\u2122s Disease to Proceed at Highest Investigated Dose","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Clear Street LLC","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Acquisition of Lung Therapeutics","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Private Placement","leadProduct":"LTI-03","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Aileron Therapeutics \/ Clear Street LLC","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Broad Institute Extend Cancer Therapy Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Broad Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Cellectis","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$105.0 million","newsHeadline":"Astrazeneca Announces Collaboration and Investment Agreement with Cellectis to Accelerate Cell Therapy and Genomic Medicine Ambitions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cellectis","amount2":0.94999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cellectis \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Earns $5 Million Milestone upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"XOMA","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Immediate-Release Tablet","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"XOMA \/ Day.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,026.0 million","upfrontCash":"$26.0 million","newsHeadline":"Sosei Heptares will Receive US$3.75 Million Payment in Multi-Target Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":1.03,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Gloria Biosciences","pharmaFlowCategory":"D","amount":"$279.6 million","upfrontCash":"$29.6 million","newsHeadline":"BioLineRx Entered Exclusive License Agreement with Motixafortide in Asia, Advised by MSQ Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Gloria Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gsk Enters Agreement to Obtain Exclusive License for JNJ-3989 to Expand the Development of Bepirovirsen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bepirovirsen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$250.0 million","newsHeadline":"Beam Announces Agreement for Lilly to Acquire Beam\u2019s Opt-In Rights to Verve Therapeutics\u2019 Base Editing Programs for Cardiovascular Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"VERVE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Beam Therapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"Infusion","sponsorNew":"Beam Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"$100.0 million","newsHeadline":"Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"ORM-6151","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Orum Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Orum Thera.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Nephron Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"BioCina","sponsor":"GPN Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCina Expands Partnership with GPN Vaccines","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Gamma-PN3","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioCina","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCina \/ GPN Vaccines","highestDevelopmentStatusID":"6","companyTruncated":"BioCina \/ .."},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$770.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Autifony Therapeutics","amount2":0.77000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.77000000000000002,"dosageForm":"","sponsorNew":"Autifony Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Autifony T.."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,305.0 million","upfrontCash":"$80.0 million","newsHeadline":"Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CKD-510","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":1.3100000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.3100000000000001,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun .."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Aitia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Aitia","highestDevelopmentStatusID":"2","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revolution Medicines Completes Acquisition of EQRx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Rev.."},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$35.0 million","newsHeadline":"Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ B.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Cartesian Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Merger with Cartesian Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Merger","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Cartesian Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$60.2 million","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Merger with Cartesian Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"ViaNautis Bio","sponsor":"SomaServe","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"ViaNautis Bio Announces $25 Million Series A Financing to Drive the Next Generation of Genetic Nanomedicines","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ViaNautis Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"ViaNautis Bio \/ SomaServe","highestDevelopmentStatusID":"3","companyTruncated":"ViaNautis .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$147.0 million","upfrontCash":"$37.0 million","newsHeadline":"Basilea Announces Acquisition of Fosmanogepix, a Phase-3-Ready Broad-Spectrum Antifungal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Fosmanogepix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"VectorY","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","amount":"$138.0 million","upfrontCash":"Undisclosed","newsHeadline":"VectorY Raises \u20ac129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"OPL-002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"VectorY","amount2":0.14000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"VectorY \/ MRL Ventures Fund","highestDevelopmentStatusID":"8","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,110.0 million","upfrontCash":"$100.0 million","newsHeadline":"Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"LB2102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":1.1100000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1100000000000001,"dosageForm":"","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo\u00ae (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ankyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ankyra Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"Ethris","sponsor":"Heqet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"ETH51","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ethris \/ Heqet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ H.."},{"orgOrder":0,"company":"Miralogx","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ketamine Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Miralogx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miralogx \/ MIRA Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Miralogx \/.."},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group Signed a License Agreement with Haisco Pharmaceutical to Develop, Manufacture, and Commercialise a Novel, Reversible Dipeptidyl Peptidase 1 Inhibitor for Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HSK31858","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Haisco Pharmaceutical \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pha.."},{"orgOrder":0,"company":"Medicovestor","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicovestor, Inc Announces the Completion of an Oversubscribed Seed Financing Round to Advance its Novel Antibody Drug-conjugate (ADC) Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medicovestor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicovestor \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Medicovest.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"$5.0 million","newsHeadline":"Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astex Pharmaceuticals","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.28000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"$141.0 million","upfrontCash":"$21.0 million","newsHeadline":"Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Rademikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Myricx Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Myricx Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Caraway Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$610.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck to Acquire Caraway Therapeutics, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Caraway Therapeutics","amount2":0.60999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.60999999999999999,"dosageForm":"","sponsorNew":"Caraway Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Caraway Th.."},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$1,330.0 million","upfrontCash":"Undisclosed","newsHeadline":"BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ETX-197","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ensem Therapeutics","amount2":1.3300000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Ensem Therapeutics \/ BeiGene","highestDevelopmentStatusID":"5","companyTruncated":"Ensem Ther.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma and Zydus Sign Licensing Agreement for Co-Marketing of Desidustat, a Critical Treatment Option for Chronic Kidney Disease Patients in India","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$143.8 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Darovasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"JM17","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Galinpepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Pritzker Neuropsychiatric Disorders Research Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Pritzker Neuropsychiatric Disorders Research Consortium","highestDevelopmentStatusID":"3","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"$5.8 million","newsHeadline":"OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Annovis Bio Announces Pricing of $7.5 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"T-Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"T-Therapeutics Raises \u00a348 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"TCR Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"T-Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"T-Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"3","companyTruncated":"T-Therapeu.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"$28.3 million","newsHeadline":"Syncona to Acquire Freeline Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"FLT201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Syncona","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$509.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Expands Immuno-Oncology Portfolio with the Acquisition of Bacterial Cancer Therapy Specialist T3 Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"T3 Pharma","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"T3 Pharma .."},{"orgOrder":0,"company":"PaxMedica","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PaxMedica Announces Closing of $7.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PaxMedica","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Humanetics","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Humanetics \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lexeo Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Yousen Jianheng Biopharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$419.0 million","upfrontCash":"$24.0 million","newsHeadline":"Uson Health Announces an Exclusive Global Licensing Agreement with AstraZeneca for UA022, a New Small Molecule Drug Candidate Targeting the KRAS G12D Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"UA022","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Yousen Jianheng Biopharmaceutical","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Yousen Jianheng Biopharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Yousen Jia.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Oxford Vacmedix","sponsor":"DxVx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DxVx, Plans to Make a License-in Agreement of OVM-200 and Conduct Clinical Trials in Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"OVM-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Vacmedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Vacmedix \/ DxVx","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Vac.."},{"orgOrder":0,"company":"Glycologix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GLX-100","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase I","graph3":"Glycologix","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycologix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycologix.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SPI-62","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Ph.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ANK-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 \/ 2 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Bio.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit\/Hyperactivity Disorder (ADHD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Programme","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Neurocentrx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentr.."},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"UPB-101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Upstream B.."},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ASP1012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KaliVir Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KaliVir Im.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BMS-986278","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Beckley Psytech\u2019s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next\u2011Generation Lithium Therapeutic Drug Candidate AL001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2\/3 U.S. Clinical Trial; Initiation of Part 2 Imminent","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"All-trans Retinoic Acid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"HighField Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HighField .."},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iksuda Therapeutics Announces First Patient Dosed in Phase 1 trial of IKS014 in Patients with Advanced Solid Tumours That Express HER2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"IKS014","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iksuda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iksuda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iksuda The.."},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine and KGbio Received the First Market Approval for Novel Long-acting Erythropoietin, Efepoetin Alfa, from The Indonesian Food and Drug Authority (BPOM)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Efepoetin Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRP\u03b1 Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 770371","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax to Initiate NDA Submission of Revumenib in Relapsed\/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Servier Announces FDA Approval of TIBSOVO\u00ae (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R\/R) Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Application (IND) for BioRay Pharmaceutical's BR105 Injection Receives U.S. FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BR105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioRay Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioRay Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioRay Pha.."},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"FT011","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Ther.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse\/Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TCB-008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces Authorization in Canada of ORGOVYX\u00ae (relugolix) for the Treatment of Men with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Vaxcyte","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"$135.0 million","newsHeadline":"Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Sutro Biopharma \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","amount":"$667.0 million","upfrontCash":"$7.0 million","newsHeadline":"ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties up to $200M","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ABV-1504","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.67000000000000004,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Healthwell Acquisition Corp. I","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Termination","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starton Therapeutics \/ Healthwell Acquisition Corp. I","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ABX1100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aro Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer\u2019s Disease and Cerebral Amyloid Angiopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ALN-APP","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"PolyMedics Innovations","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid\u00ae Distribution in Europe","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"PolyMedics Innovations","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"PolyMedics Innovations \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"PolyMedics.."},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in the Second Dose Group in Annexin's RVO study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Annexin A5","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Ph.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BCX10013","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Q32 Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio and Homology Medicines Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Merger","leadProduct":"Bempikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Homology Medicines \/ Q32 Bio","highestDevelopmentStatusID":"8","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio and Homology Medicines Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Bempikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Q32 Bio \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Bioconjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"myNEO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"myNEO Evolves into myNEO Therapeutics to Reflect its New Strategy to Develop off-the-shelf Cancer Vaccine Immunotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CAMYO-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"myNEO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"myNEO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"myNEO Ther.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Cannabinoid-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Cannasoul","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cannasoul \/ Synaptogenix","highestDevelopmentStatusID":"1","companyTruncated":"Cannasoul .."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Safety Committee Approves Faster Infusion Rate in Phase I\/II Trial of RECCE\u00ae 327 for Urinary Tract Infections and Urosepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Zagociguat","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tisento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Th.."},{"orgOrder":0,"company":"Landmark Bio","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Landmark Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Landmark Bio \/ Galapagos","highestDevelopmentStatusID":"1","companyTruncated":"Landmark B.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"AnaptysBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.0 million","newsHeadline":"Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche's Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab-svoa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qilu Pharmaceutical Announces the Latest Results from its Clinical Study on QL1706, in Combination with Chemotherapy, as a First-Line Treatment for Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Iparomlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharm.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Announces Data from Study of \u20181104 in Atopic Adults","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BBT-877","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Meiji Pharmaceutical","sponsor":"Zhejiang Hengkang Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zhejiang Hengkang Pharmaceutical Acquires Meiji Pharmaceutical (Shandong) to Enter the Field of Green Synthetic Biology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"KD-370","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Meiji Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Pharmaceutical \/ Zhejiang Hengkang Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Accepts for Review AstraZeneca\u2019s Supplemental Biologics License Application for Self-administration of FLUMIST\u00ae QUADRIVALENT (Influenza Vaccine Live, Intranasal)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Intranasal Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic\u2019s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Nonreplicating Smallpox and Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R\u00ce\u00b12\u0090targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MB-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-1083","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"BWX Technologies","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BWXT Medical Expands Collaboration with Fusion Pharmaceuticals through Strengthened Actinium Supply and Access to Generator Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BWX Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BWX Technologies \/ Fusion Pharma","highestDevelopmentStatusID":"1","companyTruncated":"BWX Techno.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ONCT-534","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Signs Definitive Agreement for 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"Undisclosed \/ BioNxt Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750\u2019s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders","therapeuticArea":"Sleep","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ORX750","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Michigan Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Pancreatic Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ Michigan Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Fractyl He.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Magdalena Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Plant Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Magdalena Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for AREXVY, GSK\u2019s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"ReHeva Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reheva Biosciences Successfully Completes RH324 Phase I Clinical Trial for Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"RH324","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ReHeva Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReHeva Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReHeva Bio.."},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"RNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Serina Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Serina The.."},{"orgOrder":0,"company":"FDC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDC Launches Two Variants of COVID-19 Drug Favipiravir in India at \u20b955 Per Tablet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"FDC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FDC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"FDC \/ Not .."},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"$125.1 million","upfrontCash":"$2.0 million","newsHeadline":"Telix Announces Proposed Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Samarium-153-DOTMP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosc.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of its Q3 Report on Friday","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Gets USFDA Nod to Market Generic Antifungal Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces Authorization in Canada of Orgovyx for Treatment Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SAR444836","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicinova \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Receives U.S. FDA Approval of AGAMREE\u00ae (vamorolone) for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Initiates MONARCH \u2013 A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Miricorilant","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at \u0153Targeted Protein Degradation Think Tank\u009d Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"ST-00937","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Seed Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Seed Thera.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Reports New NYMOZARFEX Marketing Application is Accepted for Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TN-401","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris\u2019 Proprietary Linker-Conjugation Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Araris Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Araris Bio.."},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akums Drugs Enters into a Joint Association with Leiutis and Biophore for First-of-its-kind Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Biophore India Pharmaceuticals Pvt Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Akums Drug.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1\/GIP Receptor Agonist VK2735 in Patients with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Phase 3 Results Show Sustained Efficacy for up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for this Serious Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biodexa Enters into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tolimidone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adhera Therapeutics \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Adhera The.."},{"orgOrder":0,"company":"Arvinas","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arvinas Announces Oversubscribed $350 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Vepdegestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Arvinas \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avenue Therapeutics Announces Closing of $5.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"JM17","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Avenue Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","amount":"$88.2 million","upfrontCash":"Undisclosed","newsHeadline":"VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioStem Technologies Closes Oversubscribed $2M Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Amniotic Tissue Allograft","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Te.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$99.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aura Biosciences Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Belzupacap Sarotalocan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Ready-to-use Injection","sponsorNew":"Aura Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces Pricing of $150 Million Public Offering","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0.14999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces Proposed Public Offering","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0.14999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Alto Capital","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ascidian Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian T.."},{"orgOrder":0,"company":"NuclixBio","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio Partners with NuclixBio to Pave the Way for South Korea\u2019s First Large-scale Production Process for \u201cCircular RNA Therapeutics\u201d","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Circular RNA-based Drug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"NuclixBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NuclixBio \/ GenScript ProBio","highestDevelopmentStatusID":"2","companyTruncated":"NuclixBio .."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Pricing of $10.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Cybin","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces up to US$64 Million Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cybin \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Al.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Closing of $10.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"VIPER-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vittoria Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Vittoria B.."},{"orgOrder":0,"company":"BioCardia","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced at-the-Market under Nasdaq Rules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reviva Announces $30 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MAIA Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reviva Announces Closing of $30 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Gain Therapeutics Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Alto Capital","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Accelerating Clinical Trial","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"QBECO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qu Biologics Inc \/ Accelerating Clinical Trial","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BNT-161","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Virion Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VRON-0200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocean Biomedical \/ Virion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts ImmunityBio\u2019s BLA Resubmission as Complete and Sets New PDUFA Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Expands Proprietary Technology Platforms with Development of a Novel mRNA-Launched eVLP Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-Based eVLP Vaccine Platform","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-Naive Muscle Invasive Bladder Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPh.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon\u00ae for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Lilly's Omvoh\u2122 (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirikizumab-mrkz","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Metabolexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biolexis Therapeutics Launches Subsidiary Metabolexis to Develop Novel Oral Medicines for Obesity and Type 2 Diabetes to Improve Human Longevity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"MLX7000","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biolexis Therapeutics \/ Metabolexis","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis T.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BST02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioSyngen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioSyngen .."},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDP Pharma Announces First Patient Dosed in a Phase 1\/2 Clinical Trial of IDP-121, a Direct cMyc Protein Inhibitor and Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"IDP-121","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IDP Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IDP Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IDP Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Receives Approval from China\u2019s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) Used in Combination with Rekambys (rilpivirine), the First and Only Complete Long-acting HIV-1 Injectable Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Authorizes CSL's HEMGENIX\u00ae (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec-drlb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tecentriq plus Chemotherapy and Avastin Reduced the Risk of Disease Worsening or Death in Phase III study in People with Extensive-stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT\/E) for the Treatment of Glabellar Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"TrenibotulinumtoxinE","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"AccutarBio","sponsor":"Evommune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AccutarBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AccutarBio \/ Evommune","highestDevelopmentStatusID":"3","companyTruncated":"AccutarBio.."},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$660.0 million","upfrontCash":"Undisclosed","newsHeadline":"PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0.66000000000000003,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Prism Biolab \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biol.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,275.0 million","upfrontCash":"$100.0 million","newsHeadline":"Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC\u2122 Platform Technology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"RNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Avidity Biosciences","amount2":2.2799999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.2799999999999998,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"AbSci","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"Undisclosed","newsHeadline":"Almirall and Absci Announce AI Drug Discovery Partnership to Rapidly Develop Novel Treatments for Dermatological Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"De novo Therapeutic Antibody","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0.65000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"AbSci \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ Al.."},{"orgOrder":0,"company":"Glox Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Glox Therapeutics Secures \u00a34.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Engineered Protein Bacteriocin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Glox Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Glox Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Glox Thera.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0.13,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.29999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.23000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"$70.0 million","newsHeadline":"Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0.25,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Teijin Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$509.0 million","upfrontCash":"$9.0 million","newsHeadline":"Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Phenomic AI","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Phenomic AI \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Phenomic A.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$500.0 million","newsHeadline":"Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":1.5,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":1.5,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$10,100.0 million","upfrontCash":"$10,100.0 million","newsHeadline":"AbbVie to Acquire ImmunoGen, Including its Flagship Cancer Therapy ELAHERE\u00ae (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine-gynx","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":10.1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":10.1,"dosageForm":"Injection","sponsorNew":"Immunogen \/ Abbvie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"CARGO Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$281.3 million","upfrontCash":"Undisclosed","newsHeadline":"CARGO Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"CRG-022","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CARGO Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"CARGO Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"CARGO Ther.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,095.4 million","upfrontCash":"$72.3 million","newsHeadline":"Continued Strong Cresemba (isavuconazole) Sales Performance in Asia Pacific and China Triggers Third Sales Milestone Payment for the Region from Pfizer this Year","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":1.1000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit\/Hyperactivity Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Centanafadine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves PENBRAYA\u2122, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Meningococcal Group B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enarodustat (ONNARO\u00ae) Approved by NMPA for Treatment of Renal Anemia (Abstract) NMPA approved Enarodustat (ONNARO\u00ae)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Enarodustat","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SHENZHEN S.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA\u201e\u00a2 (adalimumab-bwwd), a Biosimilar to Humira\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab-bwwd","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPHOZAH\u00ae (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Autologous SIRP\u03b1low Activated Macrophage Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Im.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer\u2122s Disease in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1\/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CT-868","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Carmot Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Resubmits NDA for TransCon\u201e\u00a2 PTH to the U.S. FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Augtyro\u2122 (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ORB-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orionis Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Bi.."},{"orgOrder":0,"company":"Xentria","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xentria\u2019s XTMAB-16 Receives Orphan Drug Designation From European Medicines Agency as First Patient is Enrolled in Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"XTMAB-16","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Xentria","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xentria \/ .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol\u03b8 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RP-1664","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a\/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"MidAmerica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MidAmerica Pharmaceuticals Launches KOURZEQ\u2122 Oral Paste - an FDA Approved Prescription Medication that Helps Canker Sores Heal Faster","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"MidAmerica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Paste","sponsorNew":"MidAmerica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MidAmerica.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives Approval to Conduct MONTPARK\u2122 Montelukast VersaFilm\u00ae Phase 2 Clinical Trial in Patients with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ATSN-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX71149","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Kesin Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kesin Pharma Announces FDA Approval and U.S. Availability of LIKMEZ\u2122 (metronidazole) Oral Suspension","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kesin Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Kesin Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kesin Phar.."},{"orgOrder":0,"company":"TRexBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"TRB-061","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"TRexBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TRexBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TRexBio \/ .."},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Lerodalcibep","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"LIB Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therap.."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AV-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Satellos Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Satellos B.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Allopregnanolone Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Gamma Delta T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-KIT","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces U.S. Availability of BIMZELX\u00ae for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT\u00ae) for Diabetic CKD and Provides Corporate Updates","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CVN424","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Ketabon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral Treatment, at doses used for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ketabon","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Prolonged-release Formulation","sponsorNew":"Ketabon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ketabon \/ .."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid\u00ae to Treat Pediatric Patients","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Zunsemetinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Terbinafine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blueberry Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Presents ODOMZO\u00ae and LEVULAN\u00ae KERASTICK\u00ae + BLU-U\u00ae Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonidegib Phosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Transpose RT Cell Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"InGeneron","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InGeneron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"InGeneron .."},{"orgOrder":0,"company":"RoslinCT","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roslinct to Manufacture Exagamglogene Autotemcel (Exa-cel) for Vertex Pharmaceuticals Inc Following an Extensive Development Collaboration","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"RoslinCT","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RoslinCT \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"RoslinCT \/.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS\u2122 (Anthrax Vaccine Adsorbed, Adjuvanted)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Harness Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harness Therapeutics Secures Additional \u00a34 Million Funding to Pursue Physiological Upregulation Approach to Treat Neurodegenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Harness Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Harness Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Harness Th.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$41.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aro Biotherapeutics Secures $41.5M Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series B Financing","leadProduct":"ABX1100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Aro Biotherapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Genetic Cures for Kids","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Genetic Cures for Kids","highestDevelopmentStatusID":"2","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Orlance","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orlance Inc. Awarded Pivotal $3M NIH SBIR Grant for Advancing MACH-1\u2122 Needle-Free, Powdered Universal Influenza Vaccine to the Clinic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orlance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orlance \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Orlance \/ .."},{"orgOrder":0,"company":"One Biosciences","sponsor":"AP-HP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"One Biosciences Partners with AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"One Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"One Biosciences \/ AP-HP","highestDevelopmentStatusID":"2","companyTruncated":"One Biosci.."},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Camallergy and OnDosis Announce a Groundbreaking Partnership to Revolutionize Food Allergy Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Camallergy","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Camallergy \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Camallergy.."},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Clarke Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"MLX0800","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0.01,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Biolexis Therapeutics \/ Clarke Capital","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis T.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Research Capital Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"IBM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ IBM","highestDevelopmentStatusID":"2","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Orlando Health Ventures","pharmaFlowCategory":"D","amount":"$45.2 million","upfrontCash":"Undisclosed","newsHeadline":"ArrivoBio Raises $45M in Series B Financing to Advance Pipeline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series B Financing","leadProduct":"SP-624","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0.050000000000000003,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Orlando Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo Bio.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"VERVE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Receives EU Horizon Grant Funding for E40","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"Endoprotease 40 Glutenase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Nemysis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nemysis \/ European Union","highestDevelopmentStatusID":"6","companyTruncated":"Nemysis \/ .."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"ACU193","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics Receives $4M in Funding from The California Institute for Regenerative Medicine (CIRM)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"RTx-021","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Ray Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ray Therapeutics \/ CIRM","highestDevelopmentStatusID":"2","companyTruncated":"Ray Therap.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Sessa Capital","pharmaFlowCategory":"D","amount":"$67.1 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Sessa Capital","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$72.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nouscom Raises \u20ac67.5 million ($72 million) in Oversubscribed Series C Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series C Financing","leadProduct":"GAd20-209-FSP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nouscom AG","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Andera Partners","highestDevelopmentStatusID":"8","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"TPG Life Sciences Innovations","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series B Financing","leadProduct":"MBRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"MBrace Therapeutics \/ TPG Life Sciences Innovations","highestDevelopmentStatusID":"6","companyTruncated":"MBrace The.."},{"orgOrder":0,"company":"EyeBio","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"EYE103","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"EyeBio \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ B.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Announces a New Financing Through a Convertible Bond Program for a Total Amount of up to \u20ac45 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.050000000000000003,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series C Financing","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.050000000000000003,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ InVivium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Fujifilm Cellular Dynamics","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"iPSC-derived Cell Therpay","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Fujifilm Cellular Dynamics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Cellular Dynamics \/ Century Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Fujifilm C.."},{"orgOrder":0,"company":"RetinalGeniX Technologies","sponsor":"Avania","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RetinalGeniX Contracts with Avania CRO to Provide Guidance for Interactions with FDA on Development of Two Drug Therapies and the RetinalCam\u2122 Image Visualization Device","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"RTG-2023","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"RetinalGeniX Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RetinalGeniX Technologies \/ Avania","highestDevelopmentStatusID":"4","companyTruncated":"RetinalGen.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced at-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Shape Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Shape Ther.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Chengwei Capital","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Chengwei Capital","highestDevelopmentStatusID":"2","companyTruncated":"Shape Ther.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"$5.0 million","newsHeadline":"Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration \n- AstraZeneca's Truqap\u2122 for the treatment of metastatic breast cancer approved in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astex Pharmaceuticals","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.28000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Provides Update on Aliqopa\u00ae (copanlisib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Copanlisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next\u2011Generation Lithium Therapeutic Drug Candidate AL001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anthos Therapeutics' Novel Dual-Acting Factor XI\/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFlection Therapeutics Announces Positive Results from Phase 2b Study of NFX\u2011179 Topical Gel in the Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NFX-179","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"NFlection Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NFlection .."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101, a Fully Human CD19 CAR T-Cell Therapy to Treat Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI\u00ae (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Revefenacin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay\u2122 (odevixibat) for the Treatment of Pruritus Due to Progressive Familial Intrahepatic Cholestasis (PFIC)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Odevixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Imbria Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ninerafaxstat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Imbria Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Modified Release Tablet","sponsorNew":"Imbria Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imbria Pha.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Shares Positive Clinical Update from Ongoing Trial of ION582 for Angelman syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ION582","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Aims to Change Tourette Syndrome Treatments; will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Group Provides Updates on EMA Regulatory Review of Leniolisib MAA and Plans to File For UK Regulatory Approval","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces First Patient Dosed in Phase 1\/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST Modifier Gene Therapy for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU410ST","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension, Liposomal","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Gut-brain Axis Based Drug","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule, Delayed Release","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phenomic AI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phenomic AI \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Phenomic A.."},{"orgOrder":0,"company":"Buck Institute for Research on Aging","sponsor":"Hevolution Foundation","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hevolution Foundation Announces Multi-Million Dollar Research Grants at Global Healthspan Summit and Convenes Changemakers to Tackle World's Aging Crisis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Buck Institute for Research on Aging","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Buck Institute for Research on Aging \/ Hevolution Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Buck Insti.."},{"orgOrder":0,"company":"Peptone","sponsor":"The Institute of Oncology Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Peptone","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peptone \/ The Institute of Oncology Research","highestDevelopmentStatusID":"2","companyTruncated":"Peptone \/ .."},{"orgOrder":0,"company":"Tharimmune","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tharimmune, Inc. Announces Closing of $11 Million Public Offering","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Tharimmune","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Tharimmune \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Tharimmune.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Gate Bioscience","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"Molecular Gates","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Gate Bioscience","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Pill","sponsorNew":"Gate Bioscience \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Gate Biosc.."},{"orgOrder":0,"company":"Forward Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Forward Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Forward Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Forward Th.."},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$62.1 million","upfrontCash":"Undisclosed","newsHeadline":"Kynexis Launched to Advance Precision Therapeutics for Brain Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kynexis Therapeutics \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Th.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"UBX1325","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meridian Medical Technologies, Kindeva Drug Delivery\u2019s Global Health Security Division, Awarded Contract to Supply DuoDote\u00ae","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Meridian Medical Technologies","amount2":0.01,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"12","companyTruncated":"Meridian M.."},{"orgOrder":0,"company":"Gradalis","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Gradalis Awarded $9.9 Million Grant from the Cancer Prevention and Research Institute of Texas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"FANG vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Gradalis \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced at-the-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Private Placement","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$175.0 million","newsHeadline":"Media Update: Sanofi Completes Closing for Potential First-in-Class Vaccine Against Extraintestinal Pathogenic E.coli (ExPEC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"ExPEC9V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","amount":"$43.8 million","upfrontCash":"Undisclosed","newsHeadline":"Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Divestment","leadProduct":"Everolimus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Biocon Biologics \/ Eris Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Bio.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Obesity and Diabetes Biotech Carmot Therapeutics Files for IPO","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"BostonGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Anti-PD-1 Ab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"LegoChem Biosciences \/ BostonGene","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"IPGaia","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Duke-NUS and Japan-based IPGaia Announce Partnership to Accelerate Innovation in Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"IPGaia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IPGaia \/ Duke-NUS Medical School","highestDevelopmentStatusID":"2","companyTruncated":"IPGaia \/ D.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celest Therapeutics","pharmaFlowCategory":"D","amount":"$156.0 million","upfrontCash":"Undisclosed","newsHeadline":"Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"SENTI-301A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Celest Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tilray","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm\u00ae Products with Tilray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Tilray","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Inotrem","sponsor":"Crohn\u2019s & Colitis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Receives Milestone Funding from the Crohn\u2019s & Colitis Foundation IBD Ventures Program to Advance its Inflammatory Bowel Disease Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"INO-02","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Crohn\u2019s & Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"ResoTher Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"ResoTher Pharma Receives a \u20ac2.5 Million Grant from European Innovation Council (EIC) to Support a Phase 2a Clinical Study of their Lead Candidate RTP-026 for Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"RTP-026","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ResoTher Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ResoTher Pharma \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"ResoTher P.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","amount":"$82.5 million","upfrontCash":"$5.0 million","newsHeadline":"BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside\u2019s Proprietary SCS Microinjector\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Avoralstat","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Clearside Biomedical","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PsychoGenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"RO7117997","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ PsychoGenics","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Announces Closing of Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Aexon Labs","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Roswell Park Comprehensive Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"CAR T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Generate Biomedicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Generate B.."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN\u2122 Rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and Other Sleep Disorders","therapeuticArea":"Sleep","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Discovery","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apnimed \/ Shionogi","highestDevelopmentStatusID":"2","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Abliva","sponsor":"Owl Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Owl Therapeutics Enters a Strategic Clinical Collaboration with Abliva to Advance NeuroSTAT\u00ae (OWL-1410) for Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"OWL-1410","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Abliva","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abliva \/ Owl Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Abliva \/ O.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD\u2122 Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Mezigdomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"PaxMedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rediscovery Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rediscovery Life Sciences \/ PaxMedica","highestDevelopmentStatusID":"10","companyTruncated":"Rediscover.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Cadisegliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Reneo Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Closing of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.34999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$287.5 million","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.32000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced at-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$201.2 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Premier","sponsor":"Trevena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trevena Awarded OLINVYK Agreement with Premier, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Premier","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Premier \/ Trevena","highestDevelopmentStatusID":"12","companyTruncated":"Premier \/ .."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Lycia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Curis","sponsor":"University of Florida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curis Enters into Agreement for Emavusertib \/ Pembrolizumab Combination Study in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Emavusertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ University of Florida","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ Un.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Proposed Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company LLC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Therapeutics Announces $101 Million Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Odyssey Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey Th.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics, Inc. and Dr. Reddy\u2019s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Interleukin 2","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$8,700.0 million","upfrontCash":"$8,700.0 million","newsHeadline":"AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Emraclidine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":8.6999999999999993,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Arup Laboratories","sponsor":"Medicover","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"Valoctocogene Roxaparvovec-rvox","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Arup Laboratories","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arup Laboratories \/ Medicover","highestDevelopmentStatusID":"12","companyTruncated":"Arup Labor.."},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0.14999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Bo.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"SAR444656","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Bial","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS\u00ae (opicapone)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Opicapone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bial","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bial \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Bial \/ Amn.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kedrion Announces an Eight-Year Extension of the Distribution Agreement with Kamada in the US for Kedrab\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Kedrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kedrion \/ Kamada","highestDevelopmentStatusID":"12","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Camino Pharma Receives $1.97M Small Business Innovation Research (SBIR) Grant from the National Institute of Alcohol Abuse and Alcoholism","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Camino Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Camino Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Camino Pha.."},{"orgOrder":0,"company":"ARTBIO","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"212Pb-NG001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"ARTBIO \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ T.."},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Tilde Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tilde Sciences Acquires Daraprim\u00ae and Vecamyl\u00ae from Vyera Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Pyrimethamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vyera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vyera Pharmaceuticals \/ Tilde Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Vyera Phar.."},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY\u00ae (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Ponesimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Actelion Pharmaceuticals Ltd","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Actelion P.."},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Beijing Continent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Biosciences Announces Completion of Business Combination with Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Merger","leadProduct":"Hydronidone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Gyre Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gyre Therapeutics \/ Beijing Continent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gyre Thera.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$316.2 million","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.32000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$186.3 million","upfrontCash":"$8.6 million","newsHeadline":"ProQR Therapeutics Announces Transaction Completed for Th\u00e9a to Acquire Sepofarsen and Ultevursen Ophthalmic Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Divestment","leadProduct":"Sepofarsen","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0.19,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.19,"dosageForm":"Injection","sponsorNew":"ProQR Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Closing of $1.265 Million Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISU ABXIS has Signed a License Agreement for \u201cfabagal\u201d a Therapeutic for Fabry Disease, with NPO Petrovax Pharm Located in Russia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Agalsidase Beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"ISU ABXIS","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Petrovax","highestDevelopmentStatusID":"12","companyTruncated":"ISU ABXIS .."},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$355.0 million","upfrontCash":"$30.0 million","newsHeadline":"AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"BigHat Biosciences \/ Abbvie Inc","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Bio.."},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biot.."},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the Manufacture of Clexane\u00ae","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Minapharm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Minapharm .."},{"orgOrder":0,"company":"PostEra","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PostEra","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PostEra \/ Amgen Inc","highestDevelopmentStatusID":"2","companyTruncated":"PostEra \/ .."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prelude Therapeutics Announces $25 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"PRT3789","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$46.9 million","upfrontCash":"Undisclosed","newsHeadline":"IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"INB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"IN8bio \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ C.."},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycotope and Evotec Enter Licensing Agreement to Combine Glycotope Antibodies and Evotec\u2019s Immune Cell Engager Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Glycotope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ Evotec","highestDevelopmentStatusID":"2","companyTruncated":"Glycotope .."},{"orgOrder":0,"company":"SystImmune","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$8,400.0 million","upfrontCash":"$800.0 million","newsHeadline":"SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"BL-B01D1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":8.4000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":8.4000000000000004,"dosageForm":"Infusion","sponsorNew":"SystImmune \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune.."},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,560.0 million","upfrontCash":"$200.0 million","newsHeadline":"Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Agenus","amount2":1.5600000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5600000000000001,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"PharmaBiome","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferring and PharmaBiome Enter into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Microbiome-based Therapy","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"PharmaBiome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaBiome \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"PharmaBiom.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Imugene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech and Imugene Enter into Strategic Research Collaboration to Improve Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Imugene","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Hoba Therapeutics","sponsor":"Indaco Venture Partners","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hoba Therapeutics Raises EUR 23 Million in a Series A to Advance New Drug Candidate Against Chronic Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"Recombinant Human Meteorin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hoba Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Hoba Therapeutics \/ Indaco Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Hoba Thera.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Asundexian Phase III Study to Include Patients with Atrial Fibrillation Ineligible for Oral Anticoagulant Treatment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I\/II Clinical Trial of JR-441 for the Treatment of MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"JR-441","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines' AYVAKYT\u00ae (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RZ-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin Peanut in Toddlers","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Viaskin Peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LYL845","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Show Potential of Remibrutinib as an Oral Treatment for Chronic Spontaneous Urticaria Providing Significant Symptom Improvement as Early as Week 2","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Remibrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Doses First Participants in Phase 1\/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA\u00ae in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Na\u00efve Patients at 36 Months","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I\/II Trial of RECCE\u00ae 327 for Urinary Tract Infections and Urosepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets \u03b15\u03b21 Integrin for the Treatment of both Sporadic and Familial ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PAS-003","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SRSD107","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirius The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ADAMTS13 Recombinant-krhn","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb\u2019s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Announces Deltacel\u2122 Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Reports PK Results of First Clinical Study of Otenaproxesul\u2019s New Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) plus Bevacizumab Met Primary Endpoint for Progression-Free Survival in Liver Cancer Eligible for Embolization in EMERALD-1 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VANFLYTA\u00ae Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Quizartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"MVR-T3011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration Following Dose Level 1 Safety Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PMC-403","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives U.S. FDA Approval of FRUZAQLA\u2122 (fruquintinib) for Previously Treated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Lilly's Zepbound\u2122 (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Reports Interim Clinical Data from ACTengine\u00ae IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Induced Hepatocyte-like Cell","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Levetiracetam Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3\/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and other Autoimmune Conditions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LPX-TI641","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LAPIX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Ther.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe Rheumatoid Arthritis, Supporting its Progression into a Combination Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso's Cadonilimab (PD-1\/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC\/GE","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"iTolerance","sponsor":"Kadimastem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Stem Cell-derived Pancreatic Islets","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"iTolerance","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"iTolerance \/ Kadimastem","highestDevelopmentStatusID":"4","companyTruncated":"iTolerance.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VTX958","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Sunstone Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunstone Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunstone Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sunstone T.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AVB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Toragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toragen, Inc. Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toragen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ .."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Pitavastatin Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitavastatin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Results in Phase 3 Diabetic Retinopathy Glow Study and Following Dialogue with US Regulatory Authorities on A Regulatory Pathway for BLA Submission","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tarcocimab Tedromer","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The World's First \"Recombinant Anthrax Vaccine\": GC Biopharma applies for MFDS Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"GC1109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T3D Therapeutics Announces Positive Top-Line Results from the Phase 2 PIONEER Trial of T3D-959 in Mild-To-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"T3D-959","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therap.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-8421","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1\/2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"TERN-601","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Angiex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angiex Announces FDA Clearance of IND Application for AGX101, a novel, First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AGX 101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Angiex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Angiex \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Angiex \/ N.."},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve\u2122 Antimicrobial Wound Gel at Advanced Wound Care Fall Forum","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved","graph3":"Kane Biotech","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kane Biote.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Provides Update on Type A Meetings with FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canadian Veteran Dosed with First Cycle of APEX-90 Macrodose Psilocybin in Apex Labs' Early Access Program.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio\u2122 for Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Colchicine Capsules, Generic Version of MITIGARE\u00ae","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Pierre Fabre Laboratories' Marketing Authorisation Application for Combination Braftovi\u00ae (encorafenib) and Mektovi\u00ae (binimetinib) for Patients with BRAFv600-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Regulator Approves Pfizer's Hair Loss Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ritlecitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Reset Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Reset Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reset Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Reset Phar.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"D-4517.2","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SPARC Completes Enrolment in PROSEEK, Phase 2 Study of Vodobatinib in Early Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vodobatinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharma Advanced Research Company \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Submits Updated IND Application for BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LianBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-Term Data on Fabrazyme\u00ae (agalsidase Beta) for People with Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Agalsidase Beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Biologically-guided Exosome Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed\/Refractory Peripheral T-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BMS-984923","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Ther.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA\u00ae TRIPLE PAK\u00ae (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA\u00ae DUAL PAK\u00ae (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1\/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN202","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Arrivent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Receives Positive Recommendation to Continue Phase 2\/3 Trial of Buntanetap for Alzheimer\u2019s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Porosome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Porosome Therapeutics Announces Groundbreaking Approach to Advance Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"T1D-PT101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Porosome Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porosome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Porosome T.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1\/2 Study of Vimseltinib in TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics Announces First Patient Dosed in Phase I\/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"VLS-1488","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Volastra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Volastra T.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces Initiation of Phase 1\/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BBT-207","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2\/PD-L1 Antibody Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"SPX-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SparX Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biop.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Pharma's Schizophrenia Drug Succeeds in Late-Stage Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$34.7 million","upfrontCash":"Undisclosed","newsHeadline":"NANOBIOTIX Announces Closing of Global Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Public Offering","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$2,700.0 million","newsHeadline":"Carmot Therapeutics Enters into Definitive Merger Agreement with Roche","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Awarded with a Grant for ORY-4001 from the ALS Association in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"ORY-4001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$70.0 million","newsHeadline":"Merck Strengthens Oncology Portfolio Through Commercialization Agreement with Abbisko for Phase III Asset, Pimicotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Pimicotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Th.."},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"S-1117","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Seismic Therapeutic \/ Bessemer Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Th.."},{"orgOrder":0,"company":"X-Chem","sponsor":"Relay Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem Announces Achievement of Collaboration Milestone","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Relay Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ R.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eligo Bioscience Raises $30 Million to Write a Novel Chapter for Genetic Medicines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"EB005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Eligo Bioscience \/ Sanofi Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bios.."},{"orgOrder":0,"company":"Aqemia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"AQEMIA Announces a Major Multi-year Collaboration of $140 Million with Sanofi","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Aqemia","amount2":0.14000000000000001,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Aqemia \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Aqemia \/ S.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"LifeArc","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"LifeArc Announces \u00a35 million Drug Repurposing Programme for Motor Neuron Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Undisclosed","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Undisclosed \/ LifeArc","highestDevelopmentStatusID":"4","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.0 million","newsHeadline":"Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Petrichor","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fennec Announces Incremental $5 Million Investment from Petrichor","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Petrichor","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.32000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"VitriVax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"VitriVax Receives $5M Grant for Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VitriVax","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"VitriVax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"VitriVax \/.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Pricing of $1.1 Million Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$705.0 million","upfrontCash":"$75.0 million","newsHeadline":"Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0.70999999999999996,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"Infusion","sponsorNew":"Selecta Biosciences \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus Inks Licensing Agreement with Daewoong Pharmaceutical for Leuprolide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daewoong Pharmaceutical \/ Zydus Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Tome Biosciences","amount2":0.12,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Tome Biosciences \/ Andreessen Horowitz","highestDevelopmentStatusID":"2","companyTruncated":"Tome Biosc.."},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"89bio","amount2":0.17000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ Bo.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$610.0 million","upfrontCash":"$10.0 million","newsHeadline":"C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Degrader-antibody Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"C4 Therapeutics","amount2":0.60999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.60999999999999999,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"IVX-A12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstriVax","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"AstriVax Awarded \u20ac3 Million Grant to Advance therapeutic Hepatitis B Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstriVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstriVax \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"4","companyTruncated":"AstriVax \/.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Announces Closing of $26.5 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"COYA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ BTIG, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Freya Biosciences","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"Undisclosed","newsHeadline":"Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women\u2019s Reproductive Immunotherapies","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"FB101","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Freya Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Freya Biosciences \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Freya Bios.."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series C Financing","leadProduct":"BCA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Infusion","sponsorNew":"Bicara Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"6","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"Depixus","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Depixus Announces Strategic Collaboration with Daiichi Sankyo to Use MAGNA\u2122 Technology to Accelerate RNA-targeted Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Depixus","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Depixus \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Depixus \/ .."},{"orgOrder":0,"company":"Etherna","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$327.0 million","upfrontCash":"Undisclosed","newsHeadline":"Almirall and etherna Enter into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Etherna","amount2":0.33000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Etherna \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"Etherna \/ .."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Therapeutics Announces Interim Data from Pivotal Trial Showing Cell Therapy Technology Could Eliminate Life-Long Need for Immunosuppressant Drugs Following Kidney Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE\u00ae (setmelanotide)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH\/NIAID Project NextGen for Inclusion in Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Horsepox Virus, Live Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ad5 Norovirus GI.1 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Novartis Cosentyx\u00ae as The First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyGlass Pharma Initiates Phase I\/II Clinical Trial of its Intraocular Drug Delivery Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass P.."},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"AL01211","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AceLink Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Th.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Approves Treatment for Rare Haematological Disorder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CLN-617","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Mavodelpar","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SLS009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectral Medical Provides Tigris Trial Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectral Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Incretin-based Triagonist","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegtibatinase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"George Clinical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"2-hydroxypropyl-beta-cyclodextrin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ George Clinical","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1\/1b Clinical Trial of BP1002 in Refractory\/Relapsed Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BP1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZURZUVAE (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Modalis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Modalis and JCR Pharmaceuticals Enter into Joint Research Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Modalis Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Ironwood Announces the Completion of Squeeze-Out Merger with VectivBio","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":1,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":1,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"Seagen","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$43,000.0 million","upfrontCash":"$43,000.0 million","newsHeadline":"Pfizer Completes Acquisition of Seagen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":43,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":43,"dosageForm":"Infusion","sponsorNew":"Seagen \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ P.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"K2bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Partners with K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Rhenium-186 NanoLiposome","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ K2bio","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"The Sage Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Cadrenal Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ The Sage Group","highestDevelopmentStatusID":"9","companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi\u00ae, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Aditxt","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Shinobi Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"NJA-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shinobi Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Shinobi Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Shinobi Th.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ocular Therapeutix Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Receives Grant to Develop Innovative Live Cell Delivery Platform of Antibody Therapeutics for Treating HIV and Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Rutgers Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD\u2122 in Clinical Study of Early-Stage Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Doxorubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Haystack Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Haystack Oncology \/ Rutgers Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Haystack O.."},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veru Announces Proposed Public Offering of Common Stock","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Ray.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Editas Medicine \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Bio-identical Progesterone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"EV-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EvolveImmune Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"EvolveImmune Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"EvolveImmu.."},{"orgOrder":0,"company":"MitoRx Therapeutics","sponsor":"Wren Capital","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"MitoRx Therapeutics Announces Close of Seed Extension Financing Round to Advance its Mitochondrial-Protective Therapeutics to Treat Degenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MitoRx Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MitoRx Therapeutics \/ Wren Capital","highestDevelopmentStatusID":"4","companyTruncated":"MitoRx The.."},{"orgOrder":0,"company":"Miromatrix Medical","sponsor":"United Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Miromatrix Medical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Miromatrix Medical \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Miromatrix.."},{"orgOrder":0,"company":"Encellin","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"ENC-201","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Encellin","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Encellin \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Encellin \/.."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"DLX-007","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Inhibitor Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Itraconazole","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Johns Hopkins University \/ Inhibitor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","amount":"$987.5 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"JNJ-2113","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.98999999999999999,"dosageForm":"Tablet","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for a New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Eisai","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Investment of Approximately USD 8.8 Million for New Drug Development Against Malaria to Partners Including Marubeni and Eisai","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"SJ733","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eisai","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Eisai \/ GHIT Fund","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ GH.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ITM-52","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Isotope Technologies Munich","highestDevelopmentStatusID":"4","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Veru Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0.029999999999999999,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Veru \/ Raymond James & Associates","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Ray.."},{"orgOrder":0,"company":"Telavant","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$7,250.0 million","upfrontCash":"$7,100.0 million","newsHeadline":"Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"RVT-3101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Telavant","amount2":7.25,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":7.25,"dosageForm":"Injection","sponsorNew":"Telavant \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Telavant \/.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Phathom Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Merger","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ A.."},{"orgOrder":0,"company":"GPCR Therapeutics","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.5 million","newsHeadline":"GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"GPCR Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GPCR Therapeutics \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GPCR Thera.."},{"orgOrder":0,"company":"Vandria","sponsor":"ND Capital","pharmaFlowCategory":"D","amount":"$20.6 million","upfrontCash":"Undisclosed","newsHeadline":"Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"VNA-318","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vandria","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Vandria \/ ND Capital","highestDevelopmentStatusID":"5","companyTruncated":"Vandria \/ .."},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic D.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Neochromosome","sponsor":"University of Edinburgh","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neochromosome Announces Collaboration with University of Edinburgh Creating Defined Variant Libraries for Designer Enzymes","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Neochromosome","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neochromosome \/ University of Edinburgh","highestDevelopmentStatusID":"3","companyTruncated":"Neochromos.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"CAR-M-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syndax Announces Pricing of $200 Million Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,103.0 million","upfrontCash":"$53.0 million","newsHeadline":"Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":1.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nerviano Medical Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nerviano Medical Sciences \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"2","companyTruncated":"Nerviano M.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"IBI-343","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Deep Apple Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Deep Apple Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Deep Apple.."},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuti.."},{"orgOrder":0,"company":"ONK Therapeutics","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies and FLEX-NK\u2122 Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"NY-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ONK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ONK Therapeutics \/ NAYA Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"ONK Therap.."},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"X-Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rumi Scientific Announces Partnership with X-Chem for Development of Lead Candidate in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"iBRD9","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rumi Scientific \/ X-Chem","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scien.."},{"orgOrder":0,"company":"AbSci","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbSci \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ As.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Mr. Doug Janzen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Financing to Support Launch of Zimed\u00ae Preservative - Free (Bimatoprost 0.03%) and Board Update","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Mr. Doug Janzen","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed\u00ae PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Series C Financing","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass P.."},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediPrint\u2122 Ophthalmics Announces Initial Series A Funding Success","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Series A Financing","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$115.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ocular Therapeutix Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0.12,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syena and Miltenyi Biotec Enter into Exclusive Licensing and GMP Manufacturing Agreement for PRAME TCR-NK Cell Therapy Based on CliniMACS Prodigy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi B.."},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Onconetix","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"12","companyTruncated":"Onconetix .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Syena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replay and its Engineered NK Cell Therapy Company Syena Announce Exclusive Licensing Agreement with National Institutes of Health for TCRs Targeting Cancer Neoantigens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SY-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Syena","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Ther.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio, Inc. Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Betibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Anagenex","sponsor":"Nimbus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anagenex \/ Nimbus Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/.."},{"orgOrder":0,"company":"Organon","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Galcanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Organon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Organon \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","amount":"$625.5 million","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375\/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"VS-7375","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0.63,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.63,"dosageForm":"","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ona Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Ona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$65.0 million","newsHeadline":"Ionis Announces European Licensing Agreement with Otsuka for Donidalorsen in Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Donidalorsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Fareva","sponsor":"CureVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac and Fareva Sign Agreement for Filling and Packaging of CureVac COVID19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fareva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fareva \/ CureVac","highestDevelopmentStatusID":"8","companyTruncated":"Fareva \/ C.."},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi B.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Tiumbio","sponsor":"SK Chemicals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"Merigolix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tiumbio \/ SK Chemicals","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ .."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"$171.0 million","upfrontCash":"$12.0 million","newsHeadline":"Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma to Acquire 16.7% Stake in Lyndra Therapeutics for $30 mn","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Edity Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"$2.0 million","newsHeadline":"Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Edity Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edity Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Edity Ther.."},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Pharmavite","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmavite, a U.S. Subsidiary of Otsuka Pharmaceutical, Acquires Bonafide Health, a Provider of Women's Health Products","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Bonafide Pollen","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bonafide Health","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bonafide Health \/ Pharmavite","highestDevelopmentStatusID":"12","companyTruncated":"Bonafide H.."},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","amount":"$133.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Copper Histidine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyprium Therapeutics","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Cyprium Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cyprium Th.."},{"orgOrder":0,"company":"OpenEye","sponsor":"ASAP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cadence Partners with Antiviral Discovery Consortium to Spearhead Rapid Development of Treatments for Viral Pandemics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"OpenEye","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OpenEye \/ ASAP","highestDevelopmentStatusID":"3","companyTruncated":"OpenEye \/ .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"BMT CTN","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Partners with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults with SR-aGVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ BMT CTN","highestDevelopmentStatusID":"12","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Genentech","sponsor":"NVIDIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ NVIDIA","highestDevelopmentStatusID":"3","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Fractyl Health","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoping its GLP-1 gene therapy can beat Wegovy, Fractyl plans IPO","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"AAV-based Pancreatic Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ BofA Securities","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl He.."},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$66.0 million","upfrontCash":"Undisclosed","newsHeadline":"Totus Medicines Closes $66M Series B to Fund Early-Stage PI3Ka Inhibitor, Names New CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"TOS-358","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medi.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Vezocolmitide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stuart Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stuart Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Stuart The.."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Secures Marketing Approval from Israel, Colombia for Two Oncology Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Announces Closing of Convertible Debentures for Further Development of BETR-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$100.0 million","newsHeadline":"Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.3,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.3,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Sagard Healthcare","sponsor":"Mannkind","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for up to $200 Million","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sagard Healthcare","amount2":0.20000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Sagard Healthcare \/ MannKind","highestDevelopmentStatusID":"12","companyTruncated":"Sagard Hea.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Verona Pharma \/ Oxford Finance","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$229.7 million","upfrontCash":"$54.7 million","newsHeadline":"Galapagos Signs Agreement to Transfer Jyseleca\u00ae Business to Alfasigma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Filgotinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Galapagos","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"SWK Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ SWK Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healis Therapeutics Announces Supply Agreement with CKD Bio to Develop CKDB-501 for Neuropsychiatric Indications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"CKDB-501","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"CKD Bio Corporation","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CKD Bio Co.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Completes Acquisition of Odyssey Health\u2019s Neurological Assets","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Odyssey Health \/ Oragenics","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Oberland Capital","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"BCG Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunityBio","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"ImmunityBio \/ Oberland Capital","highestDevelopmentStatusID":"10","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$260.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics Announces Second Close of Series C Financing Bringing Total Raised in Round to $260 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apollo Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Apollo The.."},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$40.0 million","newsHeadline":"Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allorion Therapeutics","amount2":0.54000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"Allorion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Allorion T.."},{"orgOrder":0,"company":"MediLink Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$50.0 million","newsHeadline":"MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-Generation Antibody Drug Conjugate in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"YL211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MediLink Therapeutics","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"MediLink Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"MediLink T.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability\u2013High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2seventy bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces First Patient Dosed in a Phase 1\/2 Study of INKmune\u201e\u00a2 in Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Provides an Update on Rett Syndrome Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Submits sBLA for Trogarzo\u00ae Intramuscular (IM) Method of Administration to FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibalizumab-uiyk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Umoja Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ IASO BIO","highestDevelopmentStatusID":"2","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Announces Proposed Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Fortress Biotech \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$727.0 million","upfrontCash":"Undisclosed","newsHeadline":"Galapagos Establishes Strategic Collaboration with BridGene Biosciences to Expand Small Molecule Drug Discovery in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0.72999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"BridGene B.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Lion TCR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Lion TCR","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Elektrofi","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","amount":"$793.0 million","upfrontCash":"$18.0 million","newsHeadline":"Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi's Formulation Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elektrofi","amount2":0.79000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.79000000000000004,"dosageForm":"Injection","sponsorNew":"Elektrofi \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Elektrofi .."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","amount":"$667.0 million","upfrontCash":"$7.0 million","newsHeadline":"ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1504","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.67000000000000004,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.67000000000000004,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CIP-137401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Completion of Enrollment in Phase 1b\/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces U.S. Launch of LOQTORZI\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b\/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Turning Point Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diakonos Oncology Completes Phase 1 Glioblastoma Trial Recruitment; Receives FDA Orphan Drug Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DOC1021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos O.."},{"orgOrder":0,"company":"Inventprise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"25-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Inventprise","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventprise \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inventpris.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ABP-745","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok\u00ae Therapeutic to Salvage Catheters","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Ramp.."},{"orgOrder":0,"company":"Gannex Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ASC41","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gannex Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gannex Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gannex Pha.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB is Granted an End-of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP\u00e2\u201e\u00a2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PepGNP-COVID19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergex Vaccines Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigator-initiated Phase 1\/2 Clinical Trial Using Salarius Pharmaceuticals\u2122 Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Completion of Enrollment in Global Phase 1\/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"GTX-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for\u00c2 VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised\u00c2 Adults and Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Verekitug","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream B.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna's KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"ChemDiv","sponsor":"Orionis Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ORB-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemDiv \/ Orionis Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ .."},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maplight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M1\/m4 Muscarinic Agonist in Development for Schizophrenia and Alzheimer's Disease Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ML-007","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"MapLight Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"MapLight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MapLight T.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Genascence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Genascence","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genascence.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZILBRYSQ\u00ae (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CM-101","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI\u00ae (olanzapine and samidorphan)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BBM-H803","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belief BioMed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Belief Bio.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.20999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,110.0 million","upfrontCash":"$100.0 million","newsHeadline":"Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"LB2102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":1.1100000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1100000000000001,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"LCB84","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"LegoChem Biosciences","amount2":1.7,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.7,"dosageForm":"Infusion","sponsorNew":"LegoChem Biosciences \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4,100.0 million","upfrontCash":"$4,100.0 million","newsHeadline":"Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Actinium-225 Dotatate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":4.0999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":4.0999999999999996,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Axatilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Gracell Biotechnologies to be Acquired by AstraZeneca, Furthering Cell Therapy Ambition Across Oncology and Autoimmune Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":1.2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Ribocure Pharmaceuticals","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ribo Partners with Boehringer Ingelheim to Develop New Treatments for People with Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Ribocure Pharmaceuticals","amount2":2,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Ribocure Pharmaceuticals \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Ribocure P.."},{"orgOrder":0,"company":"CuradhMTR","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Ac-225-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"CuradhMTR","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CuradhMTR \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"CuradhMTR .."},{"orgOrder":0,"company":"TRexBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"TRexBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TRexBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"TRexBio \/ .."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"$171.0 million","upfrontCash":"$12.0 million","newsHeadline":"Cosette Pharmaceuticals Acquires Vyleesi\u00ae (Bremelanotide Injection) from Palatin Technologies Inc.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"MenoLabs","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Announces the Acquisition of MenoLabs\u00ae, a Leading Women\u2019s Health and Dietary Supplements Portfolio of Brands","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Bifidobacterium Animalis","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"MenoLabs","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MenoLabs \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"MenoLabs \/.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics to Develop KER-065 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KER-065","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Announces FDA Clearance of IND Application for BBO-8520, a First-in-Class Direct Inhibitor of KRASG12C (ON)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BBO-8520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tango Therapeutics Announces First Patient Dosed in Phase 1\/2 Trial of TNG348 in Patients with BRCA1\/2-Mutant and Other HRD+ Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Completes Enrollment of Phase 2\/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitapivat","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE\u2122 Platform in Developing Therapeutics for Rare Muscle Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"GPN Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Gamma-PN3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GPN Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GPN Vaccines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GPN Vaccin.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Pfizer Canada's Gene Therapy in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Fidanacogene Elaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ALLO-647","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Iodide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Faraday Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Faraday Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Faraday Ph.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare\u0301 Bioscience\u2019s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women\u2019s Health as well as in Treating a Broad Range of Diseases","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,483.0 million","upfrontCash":"$26.6 million","newsHeadline":"Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-based NK Cell Engager Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":1.48,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.48,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$848.0 million","upfrontCash":"$60.0 million","newsHeadline":"Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"COM503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Compugen","amount2":0.84999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,710.0 million","upfrontCash":"$185.0 million","newsHeadline":"GSK Enters Exclusive License Agreement with Hansoh for HS-20093","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20093","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":1.71,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.71,"dosageForm":"Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pha.."},{"orgOrder":0,"company":"Elpiscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$1,737.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"ES019","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpiscience","amount2":1.74,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.74,"dosageForm":"","sponsorNew":"Elpiscience \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Elpiscienc.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$1,400.0 million","newsHeadline":"Lilly Completes Acquisition of POINT Biopharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"177Lu-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":1.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":1.3999999999999999,"dosageForm":"Infusion","sponsorNew":"Point Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"Base4 Biotechnology","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Base4 Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Base4 Biotechnology \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Base4 Biot.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Institut Pasteur","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders has been Extended for Five Years","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"SENS-501","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Institut Pasteur","highestDevelopmentStatusID":"4","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","amount":"$279.0 million","upfrontCash":"$15.0 million","newsHeadline":"Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.28000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Tenacia Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Greenbrook TMS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Compass Pathways and Greenbrook TMS Enter into Three-Year Research Collaboration Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Greenbrook TMS","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Rett Syndrome Research Trust","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProQR and Rett Syndrome Research Trust Join Forces with Axiomer\u2122 RNA Editing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Rett Syndrome Research Trust","highestDevelopmentStatusID":"3","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Caficrestat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3K\u00ce\u00b1 inhibitor, OKI-219","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OKI-219","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnKure The.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza\u00ae \u2013\u00bc (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Evinacumab-dgnb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO\u00ae in Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Completes Recruitment for the Synchronicity Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"QTX3034","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Quanta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Quanta The.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OQL025","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"OnQuality Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Hypericin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Gradalis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gradalis\u2122 GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"GRAD1405","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Gradalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gradalis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gradalis \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer WITH Fgfr2 Gene Fusion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tasurgratinib Succinate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Data from the BRUIN Phase 1\/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio\u00ae (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rivus Pharmaceuticals Announces Completion of Enrollment in Phase 2a HuMAIN Trial of HU6","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"HU6","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rivus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Phar.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supplemental New Drug Application for Akeso's Cadonilimab (PD-1\/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Announces Results from the Phase 4 YUPELRI\u00ae PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Revefenacin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$14,000.0 million","upfrontCash":"$14,000.0 million","newsHeadline":"Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":14,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$350.0 million","newsHeadline":"MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Botaretigene Sparoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MeiraGTx","amount2":0.41999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"Injection","sponsorNew":"MeiraGTx \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"MeiraGTx \/.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Ryvu Therapeutics","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ryvu Therapeutics Enters into Two Agreements with Zak\u0142ady Farmaceutyczne Polpharma S.A. in the Area of RVU120 Active Substance (API) Production for Phase II Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"RVU120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Polpharma \/ Ryvu Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SC262","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces Pricing of $275 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Ohio Innovation Fund","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"CMTX-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Clarametyx Biosciences \/ Ohio Innovation Fund","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$52.5 million","upfrontCash":"Undisclosed","newsHeadline":"Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Radionetics Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Radionetics Oncology \/ Frazier Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Radionetic.."},{"orgOrder":0,"company":"Omniose","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Omniose","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omniose \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Omniose \/ .."},{"orgOrder":0,"company":"Turbine","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turbine \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ .."},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AOB Pharma and Maruho Enter into an Exclusive License Agreement for AOB Pharma's Topical Biologic B244 for the Treatment of Inflammatory Indications Including Atopic Dermatitis in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"B244","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Th.."},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Kexing Biopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding its Overseas Product Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Eribulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Xiling Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiling Lab \/ Kexing Biopharm","highestDevelopmentStatusID":"12","companyTruncated":"Xiling Lab.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"$80.0 million","newsHeadline":"Immunic, Inc. Announces Private Placement of up to $240 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"SanReno Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"SanReno Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"SanReno Th.."},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Dr.."},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$401.0 million","upfrontCash":"$90.0 million","newsHeadline":"GSK Amends Deal with Scynexis Amid Brexafemme Manufacturing Woes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0.40000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"Tablet, Film Coated","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Prosperity7 Ventures","pharmaFlowCategory":"D","amount":"$47.3 million","upfrontCash":"Undisclosed","newsHeadline":"Global Radiotherapeutics Company Full-Life Technologies Announces USD $47.3 Million Series B Financing, Prosperity7 Ventures Jointly Leads the Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"225Ac-FL-020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Prosperity7 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"Heranova Lifesciences","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"Undisclosed","newsHeadline":"Heranova Lifesciences Debuts with $13.5 Million Seed and Seed+ Round Funding to Offer Integrated Clinical Solutions to Women's Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Heranova Lifesciences","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Heranova Lifesciences \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Heranova L.."},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Helena","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAPS Public Benefit Corporation Announces Oversubscribed Series A Financing and Renames to Lykos Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Helena","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Ther.."},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$4,165.0 million","upfrontCash":"$185.0 million","newsHeadline":"Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"BW-02","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Argo Biopharma","amount2":4.1699999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":4.1699999999999999,"dosageForm":"","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Argo Bioph.."},{"orgOrder":0,"company":"CrossLink Life Sciences","sponsor":"Heron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF\u00ae, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"CrossLink Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"CrossLink Life Sciences \/ Heron Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CrossLink .."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Specialised Therapeutics Signs Exclusive Agreement with Ascendis Pharma A\/s for Distribution and Commercialisation of Three Endocrinology Therapies in Australia and Select South-East Asia Countries","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Specialised Therapeutics \/ Ascendis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,237.5 million","upfrontCash":"$37.5 million","newsHeadline":"Isomorphic Labs Announces Strategic Multi-target Research Collaboration with Novartis","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.24,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.24,"dosageForm":"","sponsorNew":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic.."},{"orgOrder":0,"company":"Moonwalk Biosciences","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moonwalk Biosciences Launches with $57 Million in Financing to Advance a New Class of Precision Epigenetic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Moonwalk Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Moonwalk Biosciences \/ Alpha Wave Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Moonwalk B.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NDI-101150","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CV0701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Expands Production of Pluvicto\u2122 with Addition of its Largest and Most Advanced Radioligand Therapy Manufacturing Facility in Indianapolis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Phase Ib trial of AB-1005 Gene Therapy in Patients with Parkinson\u2019s Disease Meets Primary Endpoint","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV2-GDNF","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Enitociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Amezosvatein","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curevo Vaccine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vac.."},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva\u00ae GLP-1 Gene Therapy Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV-Delivered Pancreatic Gene Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl He.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,240.0 million","upfrontCash":"$40.0 million","newsHeadline":"Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"CRISPR-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":1.24,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.24,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$1,255.0 million","upfrontCash":"$30.0 million","newsHeadline":"Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":1.26,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.26,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"Undisclosed","newsHeadline":"ENYO Pharma Announces a \u20ac39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series C Financing","leadProduct":"Vonafexor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enyo Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Enyo Pharma \/ OrbiMed","highestDevelopmentStatusID":"5","companyTruncated":"Enyo Pharm.."},{"orgOrder":0,"company":"Sail Biomedicines","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sail Biomedicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sail Biomedicines \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Sail Biome.."},{"orgOrder":0,"company":"EG 427","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)","therapeuticArea":"Urology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"EG110A","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EG 427 \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ N.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH\u2122 for the Treatment of Common Warts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Film-Forming Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"INF904","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KYN-5356","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kynexis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kynexis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynexis Th.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indication of Alecensa for Postoperative Adjuvant Therapy for ALK Fusion Gene-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Launches Phesgo Subcutaneous Combination for the Treatment of HER2-Positive Breast and Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transfer and Future Marketing of Anti-Cancer Agent \u201cXeloda\u00ae Tablets 300\u201d in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s DONQ52, a Multispecific Antibody under Development for Celiac Disease, Non-Clinical Research Results Published in Nature Communications","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"DONQ52","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-CD20 Monoclonal Antibody Rituxan\u00ae Approved for Suppression and Treatment of Antibody-mediated Rejection in Organ Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Rituximab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mural Oncology Announces Enhancements to Late-Stage Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mural Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mural Oncology \/ Alkermes Plc","highestDevelopmentStatusID":"10","companyTruncated":"Mural Onco.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NUV-1511","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s TALZENNA\u00ae in Combination with XTANDI\u00ae for Adult Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Talazoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField .."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Topline Results from its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USAN Approves Generic Name \u201cRuxoprubart\u201d for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ruxoprubart","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ORIC-944","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Aurigene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OP-3136","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olema Oncology \/ Aurigene","highestDevelopmentStatusID":"4","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 \/ ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"FT825","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of its Tumor-Activated Immuno-Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"XTX301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1\/2 Study of ONCT-534 for the Treatment of R\/R Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ONCT-534","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gsk Filing Accepted by European Medicines Agency for Trelegy Ellipta Use in Adult Patients with Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gsk Confirms Therapeutic Efficacy of COPD Triple-Therapy Inhaler","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gsk Launches Once Daily, Single Inhaler-Triple Therapy for COPD Patients for the First Time in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces Significant Milestone in its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Thera.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed\/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed\/Refractory Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SLS009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its Anti-\u03b1v\u03b28 Monoclonal Antibody (CRB-601)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CRB-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NGM707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"VRG50635","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside Information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as Part of Phase 2 of BEXMAB Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A.forall Announces Launch of a Generic Version of Sodium Acetate Injection 4 mEq\/mL","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Acetate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Woodward Pharma Services","highestDevelopmentStatusID":"12","companyTruncated":"Milla Phar.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SH-105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shorla Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Focal Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focal Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Focal Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Focal Medi.."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Ischemic Stroke Recovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Talfirastide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Constant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Intrommune Therapeutics","sponsor":"Inimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inimmune Corporation and Intrommune Therapeutics Announce a Collaboration to Advance a Revolutionary Rapid, Long-acting Oral Mucosal Allergy Immunotherapy for the Treatment of Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Intrommune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Paste","sponsorNew":"Intrommune Therapeutics \/ Inimmune","highestDevelopmentStatusID":"6","companyTruncated":"Intrommune.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$680.0 million","upfrontCash":"$680.0 million","newsHeadline":"Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,900.0 million","newsHeadline":"Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$151.3 million","upfrontCash":"Undisclosed","newsHeadline":"Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Elritercept","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$315.5 million","upfrontCash":"$7.5 million","newsHeadline":"TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.32000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"GSK Enters Agreement to Acquire Aiolos Bio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":1.3999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines, Inc. Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inventiva Draws Down the Second Tranche of \u20ac25 Million under Existing Finance Contract with the European Investment Bank","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Expands Research Collaboration with the University of Michigan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"WAL0921","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"6","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject\u00ae Formulation of Teprotumumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of its Oral Testosterone Therapy, KYZATREX\u00ae (CIII testosterone undecanoate capsules), on Male Fertility","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leqembi\u00ae Approved for the Treatment of Alzheimer's Disease in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioArctic AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Launches PRODUODOPA\u00ae (foslevodopa\/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports Phase I Clinical Progress in the CAN10 Project","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIVDAK\u00ae (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breo Ellipta Approval Expanded to Pediatric Patients with Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilanterol Trifenatate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches World\u2019s First Fixed-dose Triple Combination Drug, Vilfuro-G\u00ae for COPD Management in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilanterol Trifenatate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Gets CDSCO Panel Nod to Market Asthma COPD Drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Vilanterol Trifenatate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation in Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell\u2019s Partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK \/ Olanzapine Long-Acting Injectable (LAI)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Approval of First CRISPR\/Cas9 Gene-Edited Therapy, CASGEVY\u2122, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sialic Acid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Mitochon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency (EMA) Greenlights Mitochon Pharmaceuticals to Initiate Phase I\/IIa Biomarker Study in Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"MP101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Mitochon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mitochon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mitochon P.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$345.1 million","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nangibotide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbisko Therapeutic Announces that EMA has Granted Orphan Drug Designation for its CSF-1R Inhibitor Pimicotinib (ABSK021)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Th.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"GC Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ .."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lutikizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JBI-802 Initial Phase I Data Suggests Therapeutic Potential in Sensitizing Immunotherapy Resistant Tumors and in Myeloproliferative Neoplasms with Thrombocytosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"JBI-802","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Soligenix \"Fast Track\" Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dusquetide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Biosion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosion's Partner OBI Pharma Announces FDA Clearance of IND Application for a Phase 1\/2 Study of OBI-992 (TROP2 ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OBI-992","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OBI Pharma \/ Biosion","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Completes Enrollment of Adult Patients in Phase 2 CLIMB Study in Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Receives Approval for AGAMREE\u00ae (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RC88","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA\u00ae (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bond Biosciences Announces Successful Pre-IND Meeting with the FDA to Advance the Development of BBI-001 for Treatment of Iron Overload Associated with Hereditary Hemochromatosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BBI-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bond Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosc.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R\/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SLS009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval from U.S. FDA for Varenicline Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Linagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"USV Private Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"USV Private Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"USV Privat.."},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Rosuvastatin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"USV Private Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"USV Private Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"USV Privat.."},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Jalra Trio for Management of Type 2 Diabetes in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Vildagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"USV Private Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"USV Private Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"USV Privat.."},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Pioz-V for Uncontrolled Diabetic Patients with Fatty Liver","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Vildagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"USV Private Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"USV Private Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"USV Privat.."},{"orgOrder":0,"company":"Zydus Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Healthcare Gets CDSCO Panel Nod to Market Vilanterol, Glycopyrrolate, Fluticasone Metered Dose Inhaler","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Vilanterol Trifenatate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Healthcare","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Zydus Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Heal.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Majority of Individuals with Atopic Dermatitis Improved with Arcutis\u2019 Roflumilast Cream 0.15% According to New Data from Phase 3 Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Drug Farm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Farm Receives Rare Pediatric Disease Designation from the U.S. FDA for DF-003 to Treat ROSAH Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DF-003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Drug Farm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"HMI-115","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hope Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medic.."},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Biogenomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"USV, Biogenomics Launch Biosimilar Insulin Aspart INSUQUICK","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Insulin aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"USV Private Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"USV Private Limited \/ Biogenomics","highestDevelopmentStatusID":"12","companyTruncated":"USV Privat.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"USV Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supplier can only Seek Advance Ruling under GST, Rules MAAR","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"Vildagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ USV Private Limited","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"D","amount":"$512.0 million","upfrontCash":"$12.0 million","newsHeadline":"Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Insilico Medicine","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Stemline Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avistone Biotechnology Announces Closing of Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital","highestDevelopmentStatusID":"12","companyTruncated":"Beijing Av.."},{"orgOrder":0,"company":"Inspirna","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$45.0 million","newsHeadline":"Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inspirna","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inspirna \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Inspirna \/.."},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$2,066.0 million","upfrontCash":"$66.0 million","newsHeadline":"MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MOMA Therapeutics","amount2":2.0699999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.0699999999999998,"dosageForm":"","sponsorNew":"MOMA Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"MOMA Thera.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"CUSP06","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnCusp Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"OnCusp Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"OnCusp The.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"CONNECT","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Olutasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rigel Pharmaceuticals \/ CONNECT","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Alpha Wave Global","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Alpha Wave Global","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ A.."},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$538.5 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and 3T Biosciences Enter into a Second Partnership to Develop Next-Generation Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"3T Biosciences","amount2":0.54000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"3T Bioscie.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI\u2122 (toripalimab-tpzi)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"INO-3112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coherus Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allorion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Allorion T.."},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Resalis Therapeutics Raises \u20ac10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"RES-010","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Resalis Therapeutics","amount2":0.01,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Resalis Therapeutics \/ Sunstone Life Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Resalis Th.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ atai Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Licenses Multiple Dark Antigens\u00ae from Enara Bio to Develop off-the-shelf Immunotherapies for Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enara Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio .."},{"orgOrder":0,"company":"Claris Bio","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Claris Bio Emerges from Stealth with a New Investor and Prepares for Next Development Stage with Late-Stage Data Expected in 1H24","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Oremepermin Alfa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Claris Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Solution\/Drops","sponsorNew":"Claris Bio \/ Novo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Claris Bio.."},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with MIMEDX on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"MiMedx \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ M.."},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A\/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vector Pharma \/ Ascendis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pha.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Carnegie Investment Bank","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Directed Issue and Private Placement for Gross Proceeds of DKK 1.45 Billion","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Survodutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.20999999999999999,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Carnegie Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Signs a New Subscription Agreement for a Maximum of EUR 1.2M in Convertible Bonds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abeona Therapeutics Announces $50 Million Credit Facility","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Prademagene Zamikeracel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$108.9 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences Announces $109 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Solid Biosciences \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Relay Therapeutics Announces $30 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Chengdu Kanghua Biological Products","sponsor":"HilleVax","pharmaFlowCategory":"D","amount":"$270.5 million","upfrontCash":"$15.0 million","newsHeadline":"HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"HIL-216","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chengdu Kanghua Biological Products","amount2":0.27000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Chengdu Kanghua Biological Products \/ HilleVax","highestDevelopmentStatusID":"4","companyTruncated":"Chengdu Ka.."},{"orgOrder":0,"company":"Cumulus Oncology","sponsor":"Eos Advisory","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Cumulus Oncology Raises \u00a39m in Seed Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cumulus Oncology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Cumulus Oncology \/ Eos Advisory","highestDevelopmentStatusID":"4","companyTruncated":"Cumulus On.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Acquires European Rights to Colobreathe\u00ae(colistimethate sodium) from Teva","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Colistimethate Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Glykos","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion and Glykos Announce Research Collaboration and Licensing Agreement to Develop Next-Generation ADCs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glykos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glykos \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Glykos \/ O.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$241.5 million","upfrontCash":"Undisclosed","newsHeadline":"Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.23999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"YH012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Radiance Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"CAR T-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"$310.0 million","upfrontCash":"$35.0 million","newsHeadline":"Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ZPC-21","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zentalis Pharmaceuticals","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Oak Hill Bio Announce License and Development Agreement to Develop, Manufacture, and Commercialise OHB-607, a Potentially Transformative Neonatal Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Mecasermin Rinfabate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill B.."},{"orgOrder":0,"company":"Georgetown University","sponsor":"KeifeRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KeifeRx Expands Exclusive Licensing Agreement with Georgetown University to Include Multiple Disease Indications for Portfolio of Novel Tyrosine Kinase Inhibitors","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"KFRX03","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Georgetown University","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Georgetown University \/ KeifeRx","highestDevelopmentStatusID":"5","companyTruncated":"Georgetown.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo\u00ae (cemiplimab) in Multiple Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medison Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Myrobalan Therapeutics","sponsor":"Co-win Ventures","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Myrobalan Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Myrobalan Therapeutics \/ Co-win Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Myrobalan .."},{"orgOrder":0,"company":"Kolinpharma","sponsor":"Nemysis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Signs with Kolinpharma SpA an IHAT Sales and Marketing Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Kolinpharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kolinpharma \/ Nemysis","highestDevelopmentStatusID":"12","companyTruncated":"Kolinpharm.."},{"orgOrder":0,"company":"Calypso Biotech SA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$250.0 million","newsHeadline":"Calypso Enters into Agreement to be Acquired by Novartis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"CALY-002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Calypso Biotech SA","amount2":0.42999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"Calypso Biotech SA \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Calypso Bi.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$22.0 million","newsHeadline":"Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement with Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Itraconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Pulmatrix \/ Cipla","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"MimiVax","sponsor":"Brain Tumor Investment Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Montanide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MimiVax \/ Brain Tumor Investment Fund","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ .."},{"orgOrder":0,"company":"SpectronRx","sponsor":"ARTBIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"212Pb-NG001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SpectronRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpectronRx \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"SpectronRx.."},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$58.6 million","upfrontCash":"$5.0 million","newsHeadline":"FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LadRx","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"9","companyTruncated":"LadRx \/ XO.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$235.8 million","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax\u00ae (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Anthrax Vaccine Adsorbed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0.23999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"ElevateBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xcell Biosciences Announces Collaboration with ElevateBio to Advance Technology Development for Cell and Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Bios.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$510.0 million","upfrontCash":"$110.0 million","newsHeadline":"Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA\u00ae by January 2025","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.51000000000000001,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Acorda Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GENESIS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GENESIS Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GENESIS Ph.."},{"orgOrder":0,"company":"PharmaLogic","sponsor":"ARTBIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"212Pb-NG001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaLogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaLogic \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"PharmaLogi.."},{"orgOrder":0,"company":"AbCheck","sponsor":"Ampersand Biomedicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Ampersand Biomedicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ .."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Arbor Biotechnologies, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Arbor Biotechnologies, Inc","highestDevelopmentStatusID":"4","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"NuFund Venture Group","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"VS-041","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vasa Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vasa Therapeutics \/ NuFund Venture Group","highestDevelopmentStatusID":"5","companyTruncated":"Vasa Thera.."},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,042.0 million","upfrontCash":"$30.0 million","newsHeadline":"Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.04,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Remix Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Remix Ther.."},{"orgOrder":0,"company":"PolyPid","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Private Placement for $16 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Paste","sponsorNew":"PolyPid \/ JMP Securities","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Voyager Therapeutics Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"VY-TAU01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Citigroup","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$287.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces Proposed Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.28999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galapagos Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific to Further Expand its Decentralized CAR-T Manufacturing Network in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"GLPG-5101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Galapagos","highestDevelopmentStatusID":"8","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-s","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","amount":"$305.0 million","upfrontCash":"$100.0 million","newsHeadline":"Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"LB54640","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$532.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Cellarity","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$532.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Cellarity","amount2":0.53000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Cellarity \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Cellarity .."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA\u00ae [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus Approved in China for The Prevention of Rsv Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nirsevimab-alip","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Is the First to Launch Biosimilar of Popular Anti\u2010diabetic Drug, \nLiraglutide, in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Spexis","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Acquisition of Preclinical Antibiotics Program from Spexis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Spexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spexis \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"4","companyTruncated":"Spexis \/ B.."},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Reaches Agreement on a Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ B.."},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Armatus Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Andelyn Biosciences and Armatus Bio Partner to Manufacture Suspension-Based AAV Gene Therapy for Rare Neurological Disease Charcot-Marie-Tooth Type 1A (CMT1A)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Andelyn Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Andelyn Biosciences \/ Armatus Bio","highestDevelopmentStatusID":"4","companyTruncated":"Andelyn Bi.."},{"orgOrder":0,"company":"Prota Therapeutics","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"PRT120","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Prota Therapeutics","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Prota Therapeutics \/ SPRIM Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Prota Ther.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1\/2 Study of OBI-992","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OBI-992","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea\u00ae (aflibercept)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lacutamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OcuTerra Therapeutics Announces Last Patient Completes Final Visit in Nesvategrast (OTT166) Eye Drop Phase 2 DR:EAM Clinical Trial in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nesvategrast","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra T.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"EB-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"VENT-03","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Ventus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RCT1100","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Reports Exceptional One-year Results of Study 014\/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"GMI-1687","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Vicagrel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JIANGSU VC.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208\/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves ZELSUVMI\u2122 as a First-in-Class Medication for the Treatment of Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ligand Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Sail Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"eRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Sail Biomedicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sail Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sail Biome.."},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara\u00ae (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Accord BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accord BioPharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Accord Bio.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"COYA 302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"XVR013m","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeVir Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Launches AGAMREE\u00ae (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen's CT011 Achieves IND Clearance from the NMPA for the GPC3-positive Stage \u2162a Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CT011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"XNK Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XNK Therapeutics Receives EMA Scientific Recommendation for Evencaleucel as An Advanced Therapy Medicinal Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Evencaleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"XNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XNK Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"XNK Therap.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Gets USFDA Nod for Generic Hypertension Drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Propranolol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Open Enrollment for Phase 1b\/2 Study Evaluating Ampligen\u00ae (rintatolimod) in Combination with AstraZeneca's Imfinzi\u00ae (durvalumab) for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"VYN201","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1\/2 Pediatric Trial in Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Provides Update for Expected FDA Approval of Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Completed Type A Meeting with the FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ATI-1777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory\/Relapsed Lymphoma and Refractory\/Relapsed Chronic Lymphocytic Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"L-Bcl-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces Roche Receives European Commission Approval of Tecentriq\u00ae SC with ENHANZE\u00ae Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Muzastotug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY\u2122 (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NX-5948","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Pleco Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PTX-252","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hyloris Pharmaceuticals \/ Pleco Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Carotuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kairos Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kairos Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kairos Pha.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Aruna Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AB126","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aruna Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruna Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aruna Bio .."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ATSN-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX\u00ae3-71 in Schizophrenia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AF710B","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria did not Meet their Primary Endpoints","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Indomethacin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2\/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Positive Interim Data from Phase II AAVIATE\u00ae Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-314","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presage Announces FDA Study May Proceed to Evaluate Pre-GMP Drug Candidate in CIVO Phase 0 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PBA-0405","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Pure Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Presage Bi.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Melphalan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Delcath Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Epitomee","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epitomee\u00ae Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Biopolymer","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Epitomee","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Epitomee \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epitomee \/.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Gildeuretinol Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pha.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar to Stelara","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluorometholone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Condensate Modifying Drug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Compass Pathways Enters Into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational COMP360 Psilocybin Treatment, if FDA-Approved","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Hackensack Meridian Health","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Tome Biosciences","pharmaFlowCategory":"D","amount":"$114.3 million","upfrontCash":"Undisclosed","newsHeadline":"Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Genevant Sciences","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Genevant Sciences \/ Tome Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Genevant S.."},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex\u2122s Immunotherapeutic Candidates with DEKA\u2122s Intradermal Therapeutic Applicator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"DengueTcP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DEKA Research & Development","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"DEKA Research & Development \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"6","companyTruncated":"DEKA Resea.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Eyenovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bausch & Lomb Incorporated \/ Eyenovia","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Intravacc","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Avacc 11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Intravacc \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$17.4 million","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"Ibudilast","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stalicla","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Stalicla \/ SPRIM Global Investments","highestDevelopmentStatusID":"6","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"DISCO Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$21.7 million","upfrontCash":"Undisclosed","newsHeadline":"DISCO Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DISCO Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"DISCO Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"3","companyTruncated":"DISCO Phar.."},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Entecavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DelSiTech","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"DelSiTech \/ DRW Venture Capital LLC","highestDevelopmentStatusID":"1","companyTruncated":"DelSiTech .."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience preps IPO to Push CNS Therapies Through Clinic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"$410.9 million","upfrontCash":"Undisclosed","newsHeadline":"LegoChemBio Joins Hands with Orion to Become a Global Top ADC Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"LCB14","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"LegoChem Biosciences","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Infusion","sponsorNew":"LegoChem Biosciences \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Advanced Medicine Partners","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advanced Medicine Partners Launches to Set New Standard for Manufacturing and Testing Advanced Medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"JAG201","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Advanced Medicine Partners","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Advanced Medicine Partners \/ Deerfield Management","highestDevelopmentStatusID":"4","companyTruncated":"Advanced M.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"VCAR33","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vor Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vor Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Provides Update on its Ongoing Phase 1\/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I\/II Trial Evaluating Allocetra in up to 160 Patients with Moderate to Severe Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"IPL344","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunity Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity P.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clearance of Amplia's IND for Pancreatic Cancer Trial in US","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AMP945","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amplia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amplia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amplia The.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream with Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Zurletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Apitegromab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"JUV-161","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Juvena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Juvena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Juvena The.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"2\\'-O-methoxyethyl Phosphorothioate Oligonucleotide Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"AGEPHA Pharma US","sponsor":"Caristo Diagnostics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agepha Pharma and Caristo Diagnostics Team up to Fight Coronary Inflammation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AGEPHA Pharma US","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AGEPHA Pharma US \/ Caristo Diagnostics","highestDevelopmentStatusID":"12","companyTruncated":"AGEPHA Pha.."},{"orgOrder":0,"company":"Cyrano Therapeutics","sponsor":"DeepWork Capital","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"Theophylline","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Cyrano Therapeutics","amount2":0.01,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"Cyrano Therapeutics \/ DeepWork Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cyrano The.."},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces Pricing of $175 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Inteligex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Exosome-based Therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery Platform","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Inteligex","highestDevelopmentStatusID":"3","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee\u2019s Pharmaceutical","pharmaFlowCategory":"D","amount":"$138.1 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces License Agreement with Lee\u2019s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China \/ Asia Pacific Region","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Lee\u2019s Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"CBP-4888","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Comanche Biopharma \/ Google Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Comanche B.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"VRDN-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Viridian Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"BioWin","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*line Pharma and Partners Receive \u20ac8.1M from Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Dendritic Cell-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PDC*line Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"PDC*line Pharma \/ BioWin","highestDevelopmentStatusID":"4","companyTruncated":"PDC*line P.."},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"PagsGroup","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"FAP-targeted Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ratio Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Ratio Therapeutics \/ PagsGroup","highestDevelopmentStatusID":"4","companyTruncated":"Ratio Ther.."},{"orgOrder":0,"company":"Medac","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medac \/ UroGen Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Medac \/ Ur.."},{"orgOrder":0,"company":"ReiThera","sponsor":"The Ragon Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"GRAd-HIV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ The Ragon Institute","highestDevelopmentStatusID":"4","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Vivtex","sponsor":"AI Proteins","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Vivtex","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivtex \/ AI Proteins","highestDevelopmentStatusID":"3","companyTruncated":"Vivtex \/ A.."},{"orgOrder":0,"company":"Talphera","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA\u00ae Acquisition","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Sufentanil Citrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Talphera","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Talphera \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"Talphera \/.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$500.0 million","newsHeadline":"BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.5,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Blue Owl Capital","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Alaya.bio","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alaya.Bio Announces Significant Collaboration with Leading Global Cancer Center to Advance in Situ CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alaya.bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alaya.bio \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Alaya.bio .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"$2.5 million","newsHeadline":"Lipocine and Verity Pharma Enter into License Agreement for TLANDO\u00ae Franchise in the U.S. and Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0.27000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.27000000000000002,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,196.0 million","upfrontCash":"$2,196.0 million","newsHeadline":"Inhibrx Announces Sale of INBRX-101 to Sanofi for an Aggregate Value of up to $2.2 B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$200.0 million","newsHeadline":"Inhibrx Announces Sale of INBRX-101 to Sanofi for an Aggregate Value of up to $2.2 B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Demerger","leadProduct":"INBRX-105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NAYA Biosciences to Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"AAV-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INVO Bioscience \/ NAYA Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Biosc.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DA-1241","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Evommune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evommune Announces Initiation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"EVO756","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evommune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/.."},{"orgOrder":0,"company":"PureIMS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureIMS Gears up for Abbreviated Registration of Levodopa Cyclops\u00ae DPI Against OFF Episodes in Parkinson's Disease with the Successful Completion of a Comparative Pharmacokinetic Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PureIMS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"PureIMS \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PureIMS \/ .."},{"orgOrder":0,"company":"Synendos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System Modulator, SYT-510","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SYT-510","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Synendos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synendos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Synendos T.."},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323\/DB-1303 in Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DB-1303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Duality Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Duality Biologics \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Duality Bi.."},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quotient Sciences Supports YourChoice Therapeutics with Phase I Trial of Novel Hormone-Free Male Birth Control Pill","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"YCT-529","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"YourChoice Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice.."},{"orgOrder":0,"company":"Medivir","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quotient Sciences Supports Medivir with Updated Formulation of Fostrox","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Gubra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gubra Announces First Subject Dosed in Phase 1 Clinical Trial of Amylin Agonist (GUBamy) for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"GUB014295","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gubra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ No.."},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports Favorable Data from a Phase 1 SAD\/MAD Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"HSDB 4295","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Evecxia Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Evecxia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evecxia Th.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Launches First Trial of Hormone-Free Male Birth Control Pill","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"YCT-529","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quotient Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2\/F3 NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Positive Topline Results from Phase 3 OASIS-HAE Study of Investigational Donidalorsen in Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Donidalorsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Announces Acceptance of Biologics License Application For Obecabtagene Autoleucel (Obe-Cel) as a Potential Treatment For Relapsed\/Refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Indian Immunologicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IIL Launches First Indigenous Hepatitis A Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Havisure","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Indian Immunologicals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indian Immunologicals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indian Imm.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Reports Positive Phase I\/II Trial Results of RECCE\u00ae 327 for the Treatment of Diabetic Foot Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$23.9 million","upfrontCash":"Undisclosed","newsHeadline":"Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Locus Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$5,800.0 million","upfrontCash":"$5,800.0 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":5.7999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":5.7999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mirati Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LEO Pharma Finalizes Acquisition of Key Assets from Timber Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Isotretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ LEO Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Fujifilm Cellular Dynamics","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BlueRock Therapeutics Exercises Exclusive Option to License IPSC Cell Therapy Candidate OpCT-001 for Treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"OpCT-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Fujifilm Cellular Dynamics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Cellular Dynamics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm C.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen\u00ae for the Treatment of Locally Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody\u00ae Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CX-2051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Refines Timeline for Parkinsons Phase III Study Data Announcement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SparingVision \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Amphista Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OT-A201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onward Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Onward Therapeutics \/ Biomunex Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Onward The.."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Taladegib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 4 Study Evaluating Use of ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg) in Real-World Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nadofaragene Firadenovec-vncg","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B\/3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sionna Therapeutics Announces Phase 1 Initiation for SION-109 in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"SION-109","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna The.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area\u2019s Early Access Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2\/F3 NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"4","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo's Paladin Labs Announces Launch of XCOPRI\u00ae (cenobamate tablets) in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Biological E","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORBEVAX\u00ae, A Covid 19 Vaccine Developed by Bio E-India Based on The RBD Protein Antigen Technology from Texas Children's Hospital Center for Vaccine Development, Receives World Health Organization Emergency Use Listing Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biological E \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Great Point Partners","pharmaFlowCategory":"D","amount":"$172.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics\u00ae Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Great Point Partners","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gate Neurosciences Announces Clinical Collaboration with Beacon Biosignals to Advance Precision EEG Biomarkers in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Zelquistinel","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gate Neurosciences \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neuro.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Ltd. Announces Offering of up to $3 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology Announces Oversubscribed $150 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Kura Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$477.6 million","upfrontCash":"$387.4 million","newsHeadline":"Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"IMU Biosciences","sponsor":"Molten Ventures","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"IMU Biosciences Secures \u00a311.5 Million in Series A Funding to Revolutionise Immune Powered Precision Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"IMU Biosciences","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"IMU Biosciences \/ Molten Ventures","highestDevelopmentStatusID":"3","companyTruncated":"IMU Biosci.."},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"SNV1521","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Synnovation Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Synnovatio.."},{"orgOrder":0,"company":"Ainos","sponsor":"Lind Partners","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Ainos Announces $1.75 Million Follow-On Funding","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Li.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Exosome-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Aptose Biosciences \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"ArriVent Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Renalys Pharma","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.12,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Renalys Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Tomivosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Receives up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE\u2122 Prime Editors for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Prime Medicine \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Beneluxa Initiative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Beneluxa Initiative","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tourmaline Bio Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"LAVA-1207","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lava Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Pathos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pathos AI Completes Acquisition of Rain Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Milademetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rain Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Rain Oncology \/ Pathos","highestDevelopmentStatusID":"10","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces an Update in The Marketing Authorization Application of Masitinib in Amyotrophic Lateral Sclerosis at The European Medicines Agency","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1\/2\/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"UX701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALKs European Registration Application for House Dust Mite SLIT-tablet in Young Children Accepted for Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dermatophagoides Farinae Extract","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Networks Phase 2\/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Type II Variation Application for PADCEV\u00ae (enfortumab vedotin) with KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase 2 Portion of Aulos Bioscience\u2019s Phase 1\/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renalys Pharma is Launched to Bring New Innovative Medicines to Patients in Japan and Other Countries in Asia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Ph.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna\u2122 (ataluren) Following Re-examination Procedure","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI\u2122 in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NS-229","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae (guselkumab) Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Color in New Large Phase 3b Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Positive Topline Results from Phase 3 OASIS-HAE Study of Investigational Donidalorsen in Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Donidalorsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b\/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"4D-710","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pentoxifylline","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIRSUPRA\u00ae (albuterol\/budesonide) Now Available as The First and Only FDA-Approved Anti-Inflammatory Rescue Option for Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CDR404","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CDR Life","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CDR Life \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical Announces DSMB Approval to Start Randomized MOJAVE Cohort US Phase 1\/2a Study of DSR\u00ae 2.0 for Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DSR 2.0","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Me.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b\/2 Study Evaluating Ampligen\u00ae in Combination with AstraZeneca's Imfinzi\u00ae for the Treatment of Late-Stage Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZORYVE\u00ae (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Neldaleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PMN400","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Deucrictibant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Provides Update on Phase 3 EVOKE-01 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.25 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Closing of $7.25 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORIC Pharmaceuticals Announces $125 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"ORIC-533","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ORIC Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"8","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$85.2 million","upfrontCash":"Undisclosed","newsHeadline":"Adicet Bio, Inc. Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Medivir","sponsor":"Hallberg Management AB","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Medivir Carries Out a Directed Share Issue of Approx. SEK 20 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Hallberg Management AB","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$20.4 million","newsHeadline":"CalciMedica Announces Private Placement of up to Approximately $55 Million","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0.059999999999999998,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ Deerfield Management","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Initiates First in Human Trial with Eiletoclax, a Selective Bcl2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax and Venetoclax-Like Molecules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Eiletoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean The.."},{"orgOrder":0,"company":"CellVax Therapeutics","sponsor":"Society of Urologic Oncology Clinical Trials Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"FK-PC101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CellVax Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CellVax Therapeutics \/ Society of Urologic Oncology Clinical Trials Consortium","highestDevelopmentStatusID":"8","companyTruncated":"CellVax Th.."},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Completes Single Dose Studies AND Initiates Multiple Dosing of Healthy Volunteers WITH Lomonitinib, a Selective Pan-FLT3\/IRAK4 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lomonitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean The.."},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Rise Therapeutics' Rheumatoid Arthritis Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"R-2487","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rise Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rise Thera.."},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"GPRC5D-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OriCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OriCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OriCell Th.."},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ACDN-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascidian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian T.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Angany","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ANG-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Angany \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ N.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s GAMMAGARD LIQUID\u00ae Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Fresenius Kabi USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fresenius Kabi USA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"FBX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Forge Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bivalirudin","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Vesleteplirsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Reports a Groundbreaking Discovery Regarding Its LPD Platform and Global CBD Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna Launches RHO Phyto\u2122 Topical Gels in Canada and Initiates Clinical Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapient Therapeutics Announce Positive Results From Phase 1 Part A Trial for Its Solid Dose Prescription CBD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avata Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Bios.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Receives Health Canada Approval for Epidiolex\u00ae (Cannabidiol Oral Solution) for the Treatment of Seizures Associated with Three Rare Forms of Epilepsy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avata Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Bios.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325\/DB-1305","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"BNT325","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Completes Enrollment of Phase 1\/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Submits Supplemental New Drug Application in Japan for PADCEV\u2122 (enfortumab vedotin (genetical recombination)) with KEYTRUDA\u00ae (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Enfortumab Vedotin-ejfv","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of DARZALEX FASPRO\u00ae (Daratumumab and Hyaluronidase-Fihj)-Based Regimen for the Treatment of Patients with Transplant-Eligible, Newly Diagnosed Multiple Myelo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Bilayer Tablet","sponsorNew":"Iterum Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for Advanced Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DWN12088","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Magdalena Biosciences","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Plant Extract","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Magdalena Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magdalena Biosciences \/ Jaguar Health","highestDevelopmentStatusID":"4","companyTruncated":"Magdalena .."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Apalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kairos Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kairos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kairos Pha.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL201104","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Suzetrigine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz launches First and Only Biosimilar for Multiple Sclerosis, Tyruko\u00ae (Natalizumab), in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Natalizumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Mediforum","sponsor":"Vision Sensing Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Merger","leadProduct":"PM012","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Mediforum","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mediforum \/ Vision Sensing Acquisition Corp.","highestDevelopmentStatusID":"9","companyTruncated":"Mediforum .."},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectis Announces the Drawdown of the Second Tranche of \u201a\u20ac15 Million Under the Credit Facility Agreement Entered with the European Investment Bank (EIB)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"UCART22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ European Investment Bank","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"EicOsis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EicOsis Initiates Phase 1b Clinical Trial of EC5026","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"EC5026","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EicOsis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ .."},{"orgOrder":0,"company":"DP Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"DPT0218","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DP Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"DP Technol.."},{"orgOrder":0,"company":"Uvax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"UVAX-1107","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Uvax Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uvax Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Uvax Bio \/.."},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"JAG201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Jaguar Gene Therapy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaguar Gene Therapy \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jaguar Gen.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed\/Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RVU120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Trichostatin A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH\u00ae Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Doses First Subject in NORSE EIGHT","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dare Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"23ME-01473","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Granted Priority Review in The US for Patients with Metastatic HER2-positive Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Transarterial Chemoembolisation (TACE) and Bevacizumab Reduced the Risk of Disease Progression or Death by 23% vs. TACE in Liver Cancer Eligible for Embolisation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Application for Regulatory Approval of Aflibercept 8 mg Accepted in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Eylea\u2122 8 mg Approved in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s RSV Vaccine, Arexvy, Accepted for Regulatory Review by The European Medicines Agency for The Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda\u2019s HYQVIA\u00ae Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronidase","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA\u00ae (Lutetium Lu 177 Dotatate)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus H.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Na\u00efve Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Quemliclustat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its Anti-\u03b1v\u03b28 Monoclonal Antibody (CRB-601)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CRB-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$287.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.28999999999999998,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Biotech Announces Pricing of $15 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Triastek","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triastek's 3D Printed Gastric Retention Product T22 Receives FDA Clearance of IND Application","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"T22","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Triastek","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Triastek \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Triastek \/.."},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akumentis Healthcare Launches Clasepi, First Synthetic Cannabidiol for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Akumentis Healthcare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Akumentis Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akumentis .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health Sciences Authority","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Leronlimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"HEPHAISTOS-Pharma","sponsor":"Xista Science Ventures","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"HEPHAISTOS-Pharma Secures a \u20ac2 Million Seed Round with Xista Science Ventures, Foundation Fournier-Majoie and Noshaq","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"ONCO-Boost","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HEPHAISTOS-Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HEPHAISTOS-Pharma \/ Xista Science Ventures","highestDevelopmentStatusID":"5","companyTruncated":"HEPHAISTOS.."},{"orgOrder":0,"company":"GenEdit","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$644.0 million","upfrontCash":"$15.0 million","newsHeadline":"GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"GenEdit","amount2":0.64000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"GenEdit \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"GenEdit \/ .."},{"orgOrder":0,"company":"Deerfield Management","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Termination","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Deerfield Management","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Deerfield Management \/ Windtree Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Deerfield .."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Crist\u00e1lia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Formosa Pharmaceuticals Announces Licensing Agreement with Crist\u00e1lia, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Crist\u00e1lia","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines Announce the Signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Al.."},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$135.7 million","upfrontCash":"Undisclosed","newsHeadline":"Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/.."},{"orgOrder":0,"company":"Calluna Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$81.1 million","upfrontCash":"Undisclosed","newsHeadline":"Two biotechs Merge to Form Calluna, with \u20ac75M in Hand to Focus on Immunotherapy Antibodies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"CAL101","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Calluna Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Calluna Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Calluna Ph.."},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dianthus Therapeutics Announces $230 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"DNTH103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus T.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Pricing of Approximately $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma AG","pharmaFlowCategory":"D","amount":"$42.7 million","upfrontCash":"$2.2 million","newsHeadline":"Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Can-Fite BioPharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Ewopharma AG","highestDevelopmentStatusID":"6","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"UB-311","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Sipp Industries","sponsor":"SinuSave","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sipp Industries Announces Distribution Agreement for Patented SinuSave\u00ae CBD Nasal Spray","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sipp Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sipp Industries \/ SinuSave","highestDevelopmentStatusID":"12","companyTruncated":"Sipp Indus.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$300.0 million","newsHeadline":"Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Rusfertide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Semper Paratus Acquisition Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tevogen Bio is Looking Forward to Closing its Transaction with Semper Paratus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Merger","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Semper Paratus Acquisition Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Canaccord Genuity Corp","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Ltd. Announces Closing of the First Tranche of its Private Placement for Gross Proceeds of $913,500","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Canaccord Genuity Corp","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"D","amount":"$13.7 million","upfrontCash":"Undisclosed","newsHeadline":"Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Tuspetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptose Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptose Biosciences \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Alfasigma","pharmaFlowCategory":"D","amount":"$184.9 million","upfrontCash":"$54.3 million","newsHeadline":"Galapagos Completes Transaction to Transfer Jyseleca\u00ae Business to Alfasigma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Filgotinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Galapagos","amount2":0.17999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Alfasigma","highestDevelopmentStatusID":"12","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$82.2 million","upfrontCash":"Undisclosed","newsHeadline":"Corbus Pharmaceuticals Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"CRB-701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor\u00ae (Rexlemestrocel-L) in Children With Congenital Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALK Completes First Part of Phase 1 Trial with Peanut SLIT-tablet","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Peanut Sublingual Immunotherapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KRRO-110","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Korro Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OBT076","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces China NMPA's Approval of Its Trientine Tetrahydrochloride Product for The Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Trientine Tetrahydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orphalan","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Orphalan \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orphalan \/.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Announces Approval of VYVDURA\u00ae (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Kamuvudine-8","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Inflammasome Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inflammasome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflammaso.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"AnGes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger and Partner, AnGes, Receive Approval for Zokinvy\u00ae (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ AnGes","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 Against Severe Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ACD137","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Purna Female Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Miconazole Nitrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Hyloris Pharmaceuticals \/ Purna Female Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ubenimex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Delta-Fly Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Delta-Fly .."},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"LT-3001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lumosa Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lumosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumosa The.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$418.0 million","upfrontCash":"Undisclosed","newsHeadline":"AC Immune to Regain Global Rights to Crenezumab and Semorinemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Termination","leadProduct":"Crenezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0.41999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"Infusion","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.25,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$2,730.0 million","upfrontCash":"$60.0 million","newsHeadline":"Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":2.73,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2.73,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Eyconis","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","amount":"$248.0 million","upfrontCash":"Undisclosed","newsHeadline":"New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyconis","amount2":0.25,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Eyconis \/ Ascendis Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Eyconis \/ .."},{"orgOrder":0,"company":"H3D Foundation","sponsor":"LifeArc","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"LifeArc Makes Multi-million Pound Investment to Support Drug Discovery in Sub-Saharan Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"H3D Foundation","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"H3D Foundation \/ LifeArc","highestDevelopmentStatusID":"2","companyTruncated":"H3D Founda.."},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"French Government","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Vivet Therapeutics Receives EUR 4.9 Million to Advance Development of a Gene Therapy for the Treatment of Cerebrotendinous Xanthomatosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"VTX-806","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ French Government","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Ther.."},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"GV101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Graviton Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Graviton B.."},{"orgOrder":0,"company":"NeoPhore","sponsor":"Sixth element capital","pharmaFlowCategory":"D","amount":"$39.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Raises an Additional \u00a39.6m (USD $12.2m) Series B Financing Extension to Further Progress Drug Discovery Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"NP1867","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"NeoPhore \/ Sixth Element Capital","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$862.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.85999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.85999999999999999,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$94.5 million","upfrontCash":"Undisclosed","newsHeadline":"Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"CRB-701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$255.0 million","upfrontCash":"Undisclosed","newsHeadline":"EraCal Therapeutics Enters into a Collaboration and License Agreement with Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal The.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,338.6 million","upfrontCash":"$125.0 million","newsHeadline":"Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Camonsertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":1.3400000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.3400000000000001,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$437.0 million","upfrontCash":"Undisclosed","newsHeadline":"CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Pricing of $750 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.75,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.85999999999999999,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.85999999999999999,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurimmune to Regain Global Rights to Brain Amyloid Depleter for the Treatment of Alzheimer\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Termination","leadProduct":"Aducanumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurimmune","amount2":0.38,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.38,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GB2064","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Aroxybutynin","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Tomivosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0.17000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Tourmaline Bio \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$2,700.0 million","newsHeadline":"Carmot Therapeutics Announces Completion of Acquisition by Roche","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Pricing of Approximately $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"saRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ University Medical Center Utrecht","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant\/Adjuvant Solid Tumor Basket Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SLS009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Last Subject Dosed in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VXA-GI.1.NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$2,897.9 million","upfrontCash":"$2,897.9 million","newsHeadline":"Novartis to Strengthen Oncology Pipeline with Agreement to Acquire MorphoSys AG for EUR 68 per Share or an Aggregate of EUR 2.7bn in Cash","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":2.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.8999999999999999,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.25,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Cream","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Sale of Priority Review Voucher for $103 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Divestment","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"San Raffaele-Telethon Institute for Gene Therapy","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"AnaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AM1476","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AnaMar","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnaMar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaMar \/ N.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ\u00ae in the Treatment of Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ACE2016","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Cancer Vaccine Trial Begins in UK, Scientists Hopeful of 'Dawn of A New Age of Treatments'","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-4359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Launches Rexigo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"GTX-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"ProLynx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProLynx Announces Initiation of Phase I\/II Clinical Trial of its DNA-Damaging Agent PLX038 in Patients with Rare CNS Tumors at the National Cancer Institute (NCI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PLX038","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA\u2122 (metreleptin for injection) for the Treatment of Patients with Lipodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Metreleptin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Glo.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12\/23 Antibody (RT-111)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProfoundBio Announces First Patient Dosed in Phase 1\/2 Clinical Trial of PRO1107, a Protein Tyrosine Kinase 7 (PTK7)-Targeted Antibody-Drug Conjugate Incorporating a Novel, Proprietary Hydrophilic MMAE-Based Linker-Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PRO1107","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"FZ007-119","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Guangzhou Fermion Technology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Guangzhou Fermion Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Guangzhou .."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TDM-105795","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerm.."},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hikma Announces US Launch of COMBOGESIC\u00ae IV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Phar.."},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ainos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ainos \/ No.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DREAMM-7 Phase III Trial Shows Blenrep Combination Nearly Tripled Median Progression-Free Survival versus Standard of Care Combination in Patients with Relapsed\/refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Belantamab Mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Tafasitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Exicure","sponsor":"Bluejay","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cavrotolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exicure \/ Bluejay","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Silence Therapeutics Announces Oversubscribed $120 Million Private Placement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Zerlasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0.12,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"HOPE Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend\/Royalty Coupon","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Merger","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HOPE Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HOPE Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"HOPE Thera.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"STAR-0215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Astria Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO and Tectonic Therapeutic Announce Merger","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ AVROBIO","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","amount":"$130.7 million","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO and Tectonic Therapeutic Announce Merger","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0.13,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Panakes Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enterprise Therapeutics Closes \u00a326 million ($33.1 million) Series B Follow-on Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series B Financing","leadProduct":"ETD001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Solution for Nebulizer","sponsorNew":"Enterprise Therapeutics \/ Panakes Partners","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital LLC","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ WallachBeth Capital LLC","highestDevelopmentStatusID":"12","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Acquisition","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"2Seventy Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"2Seventy Bio \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Umira Ventures","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"CNP-106","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Umira Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharm.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Wugen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"WU-CART-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ Wugen","highestDevelopmentStatusID":"7","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Aqemia","sponsor":"Wendel Growth","pharmaFlowCategory":"D","amount":"$64.5 million","upfrontCash":"Undisclosed","newsHeadline":"AQEMIA Boosts Series A Funding to \u20ac60M to Accelerate on its Proprietary Therapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aqemia","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Aqemia \/ Wendel Growth","highestDevelopmentStatusID":"4","companyTruncated":"Aqemia \/ W.."},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ichnos and Glenmark Take a Collaborative Leap to Accelerate Innovation in Cancer Treatment with their alliance -'Ichnos Glenmark Innovation'","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"GRC 54276","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sci.."},{"orgOrder":0,"company":"Rznomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rznomics Inc. Secures Orphan Drug Designation from FDA for RZ-001 in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RZ-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rznomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/.."},{"orgOrder":0,"company":"Canary Speech","sponsor":"Halia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI-Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"HT-4253","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Canary Speech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Canary Speech \/ Halia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Canary Spe.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$86.9 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Editing Biotech Metagenomi Plans Modest $87M IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evaxion Announces Closing of $15 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"$87.5 million","upfrontCash":"$20.0 million","newsHeadline":"Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, from Ayala Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Launches XOSPATA (Gilteritinib) in Singapore to Treat Adult Leukaemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kotobuki Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Astellas' XOSPATA\u00ae (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Kotobuki Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-in-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"ERAS-007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SUN Pharma Gets CDSCO Nod to Manufacture, Market FDC Silodosin JP Plus Tadalafil","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Silodosin","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums Introduces Tamsulosin + Tadalafil Capsule \u2014 to the Indian Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tamsulosin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drug.."},{"orgOrder":0,"company":"CTCBIO INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTC Bio's Film-type Erectile Dysfunction Treatment OKed in 3 Countries","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"CTCBIO INC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CTCBIO INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTCBIO INC.."},{"orgOrder":0,"company":"Dongkook Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Will Dongkook Pharm Present New Combo Therapy for BPH?","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dutasteride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Dongkook Pharmaceutical","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Steroid ","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dongkook Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dongkook P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Demonstrate Clinical Safety, Benefit and Durability of Nexviazyme\u00ae Across a Wide-Range of Pompe Disease Patient Groups","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Avalglucosidase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Paulson Investment Company","pharmaFlowCategory":"D","amount":"$6.1 million","upfrontCash":"Undisclosed","newsHeadline":"RenovoRx Closes $6.1 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RenovoRx \/ Paulson Investment Company","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.0 million","newsHeadline":"Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synthekine \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"BIRAD","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BIRAD","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BIRAD \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"BIRAD \/ Cl.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Chang Gung University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Chang Gung University","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Announces Closing of Approximately $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$128.6 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.13,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Proniras","sponsor":"Accelerator Life Science Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"Tezampanel","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Proniras","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Proniras \/ Accelerator Life Science Partners","highestDevelopmentStatusID":"7","companyTruncated":"Proniras \/.."},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"LBT-SA7","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"LimmaTech Biologics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Adjuvant Capital","highestDevelopmentStatusID":"5","companyTruncated":"LimmaTech .."},{"orgOrder":0,"company":"TheracosBio","sponsor":"Independent Pharmacy Cooperative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY\u00ae (bexagliflozin) with TheracosBio Partnership","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"TheracosBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Independent Pharmacy Cooperative","highestDevelopmentStatusID":"12","companyTruncated":"TheracosBi.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NWY001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"HEMO-CAR-T","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"Currax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Contrave\u00ae\/Mysimba\u00ae Demonstrates No Increased Risk in Major Adverse Cardiac Events in A Large, Long-Term Real-World Evidence Study","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Currax","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Currax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Currax \/ N.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harm Reduction Therapeutics Introduces RiVive, Over-the-Counter Opioid Overdose Reversal Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventage Lab Introduces \u2018One-Month Long-Acting\u2019 Drug Addiction Injection on the International Stage","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Inventage Lab","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventage Lab \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inventage .."},{"orgOrder":0,"company":"NK CellTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NK CellTech Announces FDA Clearance for Clinical Trial of NK010","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NK010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NK CellTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NK CellTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NK CellTec.."},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Naronapride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion .."},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Reports Positive Interim Phase 2a Data in Orphan Disease Cutaneous T-cell lymphoma (CTCL) with Lead Asset VDA-1102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tuvatexib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Vidac Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Phar.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces Updated Phase 1\/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Isaralgagene Civaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"APR-1051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Prokarium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ZH9","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prokarium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BC-NKA-20008","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ZYMEDI","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZYMEDI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYMEDI \/ N.."},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Mycovia Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA\u00ae (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Mycovia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu He.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Phase 2 Results Published in the New England Journal of Medicine Show Orforglipron, a Once-Daily Oral Nonpeptide GLP-1 Receptor Agonist, Achieved up to 14.7% Mean Weight Reduction at 36 Weeks in Adults with Obesity or Overweight","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly to Present New Research in the Treatment of Diabetes and Obesity at the American Diabetes Association's 83rd Scientific Sessions","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Gets CDSCO Panel Nod to Supply Antidiabetic Drug Orforglipron","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas and Pfizers Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+\/HER2- Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Vepdegestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stemson Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Th.."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ETX101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RSVPreF3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid and Hematologic Tumors with Oral STAT3 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vividion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zuellig Pharma Acquires Cialis\u00ae (Tadalafil) and Alimta\u00ae (Pemetrexed) from Lilly in Select ASEAN Markets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Awarded EU Seal of Excellence and Public Financing of 2 M USD to Develop Ladademstat in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Funding","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ European Commission","highestDevelopmentStatusID":"5","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Myung in Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Myung In Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"$123.1 million","upfrontCash":"$33.1 million","newsHeadline":"Telix Signs Agreement to Acquire QSAM Biosciences and its Bone Cancer Targeting Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Samarium-153-DOTMP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosc.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$93.7 million","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi Announces Pricing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$880.0 million","upfrontCash":"$10.0 million","newsHeadline":"Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.88,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TAK-861","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II\/ Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Pharm Technologies Advances CB1 Antagonist, TPT0701, for Appetite Suppression into Preclinical Testing","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TPT0701","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tetra Pharm Technologies","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra Phar.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces Proposed Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mineralys Therapeutics Announces $120 Million Private Placement Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Lorundrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mineralys Therapeutics","amount2":0.12,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Mineralys .."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"NRTX-1001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Neurona Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$50.0 million","newsHeadline":"BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"BNT211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Vandria","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Vandria Awarded \u20ac3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"VNA-318","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Vandria","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vandria \/ Innosuisse","highestDevelopmentStatusID":"5","companyTruncated":"Vandria \/ .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","amount":"$32.8 million","upfrontCash":"$3.2 million","newsHeadline":"Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Kowa Company","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Pricing of Upsized Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Vandria","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Vandria Awarded \u20ac3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"VNA-052","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Vandria","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vandria \/ Eurostars","highestDevelopmentStatusID":"5","companyTruncated":"Vandria \/ .."},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SWEET REMEDY Gummies with Libido-Boosting Drug Being Hailed as Bedroom Flop Stoppers \u2013 with Effects in Just Minutes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Seattle Gummy \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gu.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-121","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Ther.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DISC-3405","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.75 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$54.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sensorion Announces a \u20ac50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Pharmaseed","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals Announces Collaboration with Pharmaseed","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Ketamine Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pharmaseed","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmaseed \/ MIRA Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaseed.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with KEYTRUDA\u00ae (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Muzastotug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adagene Suzhou Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adagene Suzhou Limited \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson's Nipocalimab Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"FHD-909","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-01","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$99.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Two Significant Agreements with Sandoz for China and Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0.10000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Aspen pharmacare holdings","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CTO1681","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"CSL","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics\u2019 ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ARCT-154","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arcturus Therapeutics \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+\/HER2- Advanced Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Labafenogene Marselecobac","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"IMVT-1402","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Gets Tentative Approval for Yondelis Generic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo\u00ae (nivolumab) in Combination with CABOMETYX\u00ae (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Received European Commission Approval for SKYCLARYS\u00ae (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Jaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaya Biosciences Presents Promising Preclinical Data in Alzheimer\u2122s Disease at the 20th Annual WORLDSymposium\u2122 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"JB111","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Jaya Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaya Biosc.."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ruxoprubart","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MDG1015","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$189.7 million","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$319.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.32000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$4,300.0 million","upfrontCash":"$4,300.0 million","newsHeadline":"Gilead Sciences Expands Liver Portfolio with Acquisition of CymaBay Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":4.2999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":4.2999999999999998,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$10,100.0 million","upfrontCash":"$10,100.0 million","newsHeadline":"AbbVie Completes Acquisition of ImmunoGen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":10.1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":10.1,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$366.9 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.37,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nectero Medical Announces Initiation of Phase II\/III Clinical Trial of the Nectero EAST\u00ae System for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pentagalloyl Glucose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Nectero Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nectero Medical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nectero Me.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia Due to Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Deudextromethorphan Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PAS-004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN-3110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Ends License Agreement for Cancer Drug with Allarity Therapeutics for Lack of Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Termination","leadProduct":"Dovitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Allarity Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon Biologics \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Bio.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","amount":"$568.0 million","upfrontCash":"$39.0 million","newsHeadline":"Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0.56999999999999995,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.56999999999999995,"dosageForm":"Infusion","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"KB707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Alvogen","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"$10.0 million","newsHeadline":"NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Alvogen","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Zambon Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Zambon Group Spa","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"D","amount":"$33.9 million","upfrontCash":"$10.9 million","newsHeadline":"Luye Pharma Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal Patches on China\u2019s Mainland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Gensci","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Exeltis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Exeltis Exclusive Commercialization Rights to its Innovative Alzheimer\u2019s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$64.2 million","upfrontCash":"$48.1 million","newsHeadline":"Almirall Acquires Rights for an Alzheimer\u2019s Product in Spain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Patch","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"Erasca","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cogent Biosciences Announces Oversubscribed $225 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Bezuclastinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cogent Biosciences","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"NM49","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"Igrelimogene Litadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TILT Biotherapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"NextPoint","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","amount":"$122.5 million","upfrontCash":"Undisclosed","newsHeadline":"NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"NPX267","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Catalio Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Gensci","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Application for Luye Pharma's Rivastigmine Multi-Day Transdermal Patch Product Rivalif\u00ae under Review at EU Competent Authorities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Transdermal Patch Launches in China Bringing Benefits to the Country\u2019s 9 Million Alzheimer\u2019s Patients and Their Families","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019s Innovative Alzheimer\u2019s Disease Therapy Rivastigmine Multi-Day Transdermal Patch Now Eligible for Marketing Authorization in Several EU Countries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019s Innovative Alzheimer\u2019s Disease Therapy Rivastigmine Multi-Day Transdermal Patch Receives Marketing Approval in the UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Gensci","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marketing Authorization Application for Luye Pharma\u2019s Rivastigmine Twice Weekly Transdermal Patch Accepted in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Patch","sponsorNew":"Luye Pharma \/ Gensci","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine Tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivastigmine Tartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor\/Tezacaftor\/Deutivacaftor, Next-in-Class Triple Combination Treatment for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Vanzacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR\u2122 (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI\u2122 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Marnetegragene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Eicos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Medication to Treat Severe Frostbite","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Iloprost","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Eicos Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"HPAPI","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eicos Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eicos Scie.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b\/2 Study Evaluating Ampligen\u00ae (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics Announces First Patient Dosed in Phase 1b\/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus Botensilimab and Balstilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AgenT-797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MiNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Last Patient Last Visit in the Phase II\/III Study of Buntanetap in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen's Onivyde\u00ae Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"KRM-II-81","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize to Evaluate Nitric Oxide Nasal Spray for the Treatment of Sinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Alisertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Enteric Coated Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"OLX75016","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Satellos Bioscience","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Satellos B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA\u00ae (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"enGene","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"enGene Announces Oversubscribed $200 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Detalimogene Voraplasmid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Adage Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ A.."},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"LTG-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Latigo Biotherapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Bio.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Biosidus S.A.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabxience \/ Biosidus S.A.","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Population Health Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Population Health Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET\u00ae with Gilead's Trodelvy\u00ae in two Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Df1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"CRISPR-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Harrow","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Harrow \/ Apotex Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ A.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\u2019s Pioneering Phase IIb Study with Pirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pirepemat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Petrovax","sponsor":"ISU ABXIS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fabagal\u00ae for Fabry Disease Management is Now Available in Russia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Agalsidase Beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Petrovax","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Petrovax \/ ISU ABXIS","highestDevelopmentStatusID":"12","companyTruncated":"Petrovax \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u200b\u200bBoehringer's Jardiance Now Gets CDSCO Nod for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in US","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bromfenac","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$173.5 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0.17000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$93.7 million","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi Announces Closing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Larimar Therapeutics Announces Proposed Underwritten Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"IM-1021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Pricing of Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ T.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$147.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"SUDO-550","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sudo Biosciences","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Sudo Biosc.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0.17000000000000001,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"Areteia Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"Undisclosed","newsHeadline":"Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Areteia Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.42999999999999999,"dosageForm":"Tablet","sponsorNew":"Areteia Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"10","companyTruncated":"Areteia Th.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"$10.0 million","newsHeadline":"Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"BRII-179","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"VBI Vaccines \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate (ADC) Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"Rinatabart Sesutecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Ally Bridge Group","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK Exercises Option to License Elsie Biotechnologies\u2019 Discovery Platform to Find and Develop Novel Oligonucleotides","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biot.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$160.1 million","upfrontCash":"Undisclosed","newsHeadline":"KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"$840.0 million","upfrontCash":"$40.0 million","newsHeadline":"Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kelonia Therapeutics","amount2":0.83999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.83999999999999997,"dosageForm":"","sponsorNew":"Kelonia Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Kelonia Th.."},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alector Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"7","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$227.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Shattuck Labs","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca\u00ae (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma\u2019s Innovative Drug Lurbinectedin Approved for Urgent Clinical Use in Hainan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Luye Pharma \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca\u2122 (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca\u2122 (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ PharmaMar","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis\u00ae in Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Receives US$10 Million Milestone Payment from Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Receives US$10 Million Milestone Payment from Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,325.0 million","upfrontCash":"$125.0 million","newsHeadline":"Repare Therapeutics to Regain Global Rights to Camonsertib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Termination","leadProduct":"Camonsertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Repare Therapeutics","amount2":1.3300000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$305.5 million","upfrontCash":"$17.5 million","newsHeadline":"Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.31,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alys Pharmaceuticals Launches with $100M Financing from Medicxi to Advance Immuno-Dermatology Focused Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"siRNA Lipid Conjugate-based Therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Alys Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Gel","sponsorNew":"Alys Pharmaceuticals \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alys Pharm.."},{"orgOrder":0,"company":"Immunovaccine Technologies","sponsor":"Biovaxys","pharmaFlowCategory":"D","amount":"$25.7 million","upfrontCash":"$25.7 million","newsHeadline":"BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Maveropepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunovaccine Technologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovaccine Technologies \/ BioVaxys","highestDevelopmentStatusID":"8","companyTruncated":"Immunovacc.."},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Pivmecillinam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"UTILITY therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ AMR Action Fund","highestDevelopmentStatusID":"12","companyTruncated":"UTILITY th.."},{"orgOrder":0,"company":"Chemify","sponsor":"Prepaire Labs","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chemify Partners with Prepaire Labs to Apply Ground-breaking Chemistry AI-Robotics to Radically Accelerate the Discovery of Non-Addictive Opioids","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Chemify","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Chemify \/ Prepaire Labs","highestDevelopmentStatusID":"3","companyTruncated":"Chemify \/ .."},{"orgOrder":0,"company":"Cellectar","sponsor":"Meaningful Insights-BioTech Analytics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"Iopofosine I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Meaningful Insights-BioTech Analytics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmascience Canada is Thrilled to Launch (PR)pms-Teriflunomide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmascience Inc.","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmascience Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmascie.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Rejects Aubagio sNDA for Pediatric Relapsing MS Indication","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Famar","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of Laquinimod","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Laquinimod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Famar","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Famar \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Famar \/ Ac.."},{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Collaboration Between FAMAR and Lavipharm: Joining Forces in the Production of Pharmaceutical Products","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Famar","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ Lavipharm","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ La.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall Licenses an Anti-IL-21 Monoclonal Antibody from Novo Nordisk to Develop it as a First-in-Class Agent in Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Jixing Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bayer and RTW Investments Lead Series D Financing in Chinese Biotech Ji Xing Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series D Financing","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Jixing Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Jixing Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Jixing Pha.."},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alector Announces Closing of Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen and Gilead Enter into a Multi-Target Antibody Collaboration Agreement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Demonstrated Overwhelming Efficacy Benefit for Patients with Unresectable, Stage III EGFR-Mutated Lung Cancer In LAURA Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indication of Evrysdi for Pre-Symptomatic Spinal Muscular Atrophy and Additional Dosage for Infants up to 2 Months of Age","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Risdiplam","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Updates on Nemolizumab Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"Nippon Medac","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metoject\u00ae Subcutaneous Injection Pen (methotrexate) Pen-Type Autoinjector Approved in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Nippon Medac","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ni.."},{"orgOrder":0,"company":"IsomAb","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"IsomAb Announces Close of \u00a37.5 Million Financing to Accelerate Lead Candidate for Treatment of Peripheral Arterial Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"ISM-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"IsomAb","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"IsomAb \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"IsomAb \/ B.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Digital Offering, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Digital Offering, LLC","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b\/2 Study for First-Line Treatment of Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immune-Onc Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"5","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$161.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0.16,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"$28.3 million","newsHeadline":"Acquisition of Freeline by Syncona Becomes Effective","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"FLT201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Spur Therapeutics \/ Syncona","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$211.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"InveniAI","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InveniAI \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/.."},{"orgOrder":0,"company":"Vernalis","sponsor":"HOX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hox Therapeutics and Vernalis Announce a Drug Discovery Collaboration in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vernalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ HOX Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vernalis \/.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Certa Therapeutics' FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"FT011","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Certa Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Certa Ther.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of Neffy\u00ae (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ayala Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zelnecirnon","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC\u00ae Protein Degrader for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ARV-102","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"VY-TAU01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Provides Update on Pre-Planned Interim Analysis of the Phase III Fibrosarc Trial Investigating Onfekafusp Alfa (L19TNF) in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"CC8464","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Chromocell Corporation","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chromocell.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectral Medical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces Multiple New Agreements for Access to ActivMAb\u00ae Antigen Virus Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibiotic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"FG-2101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Blacksmith Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blacksmith Medicines \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Blacksmith.."},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Acquisition of Icosavax Completed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"IVX-A12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Remsima\u2122 SC for the Treatment of Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Infliximab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Glecirasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod for Generic Drug to Prevent Chest Pain in Heart Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Isosorbide Mononitrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Launches ORLADEYO\u00ae (berotralstat) in Italy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Presents High Efficacy in Multiple Solid Tumor Models for its Next-Generation Cancer Drug Candidate and Synergy with Standard-of-Care Treatment in Liver Cancer Organoids","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vidac Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vidac Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vidac Phar.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s VELSIPITY\u00ae for Patients with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Etrasimod Arginine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI311","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA\u00ae for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Insert","sponsorNew":"AffaMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Announces Completion of Patient Enrollment for Opvika\u00ae Phase I\/II Clinical Trial in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Esonadogene Imvoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CK0803","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CFI-400945","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson\u2019s Disease with its NLRP3 Inhibitor, Dapansutrile","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Olatec Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Initiates Phase II Study with First-in-Class Anti-Alpha2 Antiplasmin Antibody in Patients with Deep Vein Thrombosis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BAY3018250","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"177Lu-rhPSMA-10.1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TECVAYLI\u00ae (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA For the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Teclistamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AOC 1044","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"7MW3711","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Mabwell","sponsor":"Disc medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to 9MW3011","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW3011","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ DISC Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Receives U.S. Food and Drug Administration Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-Mutant Diffuse Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Announces First Patient Dosed in Phase 1b\/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RCT2100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Orziloben","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"NorthSea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TVGN 489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Aleta Biotherapeutics","sponsor":"Cancer Research UK\u2019s Centre for Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleta Biotherapeutics and Cancer Research UK\u2019s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1\/2 Clinical Trial in Patients with Relapsed\/Refractory B-Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ALETA-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aleta Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aleta Biotherapeutics \/ Cancer Research UK\u2019s Centre for Drug Development","highestDevelopmentStatusID":"7","companyTruncated":"Aleta Biot.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the Journal JAMA Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Polpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics' Investigational Biosimilar Shows PK\/PD Comparability to Inflammatory Bowel Disease Blockbuster Entyvio\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Polpharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Completes Enrollment of All 120 Patients in Phase 2 Trial Of Allocetra in Patients with Sepsis, Third-Leading Cause of Mortality in US Hospitals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT\u2122 Clinical Trial Participants","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Galactomannan","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linvoseltamab BLA for Treatment of Relapsed\/Refractory Multiple Myeloma Accepted for FDA Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Linvoseltamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"jCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell\u00ae for Retinitis Pigmentosa in the Second Half of 2024","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"jCell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"jCyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ No.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"FMC-376","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Frontier Medicine \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Gracell Biotechnologies Acquisition Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":1.2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0.33000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.33000000000000002,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Immunocore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunocore Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate IMC-F106C (PRAME HLA-A02) in Combination with Nivolumab in its Registrational Phase 3 First-Line Advanced Cutaneous Melanoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"IMC-F106C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Immunocore","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Dream CIS","sponsor":"Curi Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Clostridium Botulinum Toxin Type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dream CIS","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dream CIS \/ Curi Bio","highestDevelopmentStatusID":"12","companyTruncated":"Dream CIS .."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting\u00ae 2023","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celcuity Announces First Patient Dosed in Phase 1b\/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celcuity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1\/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV5-hRORA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept \u201cTick-Kill\u201d Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"CinPhloro Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 Enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Phloroglucinol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinPhloro Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CinPhloro Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinPhloro .."},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV\u00ae (nitroglycerin) Ointment, 0.4%, with 180 Days Competitive Generic Therapy (CGT) Exclusivity","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nitroglycerin","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cosette Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Cosette Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosette Ph.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ARCT-032","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","amount":"$117.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"Blueprint Medicines \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK\u00ae in Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LimmaTech Biologics Reports Positive Interim Phase I\/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"S4V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LimmaTech Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"LimmaTech Biologics \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"LimmaTech .."},{"orgOrder":0,"company":"Immunofoco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IMC001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunofoco","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunofoco \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunofoco.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TCB008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"EO-3021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Storm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voydeya Recommended for Approval in the EU by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with Pnh Who Have Residual Haemolytic Anaemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BAY2927088","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease Due to MASH, with Significant Improvements in Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Survodutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Expanded Indication for Gilead\u2019s Biktarvy\u00ae to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransThera Initiates IND-Enabling Studies for TT-02332, a Novel, Highly Potent and CNS-Penetrating NLRP3 Inhibitor","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TT-02332","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TransThera.."},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aucta Pharmaceuticals, Inc. (\"Aucta Pharmaceuticals\") Launches MOTPOLY XR\u2122 (lacosamide) Extended-Release Capsules C-V, the First, and Only Once-Daily Formulation of Lacosamide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Lacosamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aucta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Aucta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aucta Phar.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CYP-006TK","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial for Gepotidacin in Uncomplicated Urogenital Gonorrhoea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Gepotidacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY\u00ae) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Xyra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Budiodarone","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Xyra","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xyra \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xyra \/ Not.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces Neffy\u00ae Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody\u00ae sonelokimab (SLK) in Hidradenitis Suppurativa (HS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate\/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DNTH103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Dianthus Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dianthus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dianthus T.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Kezar Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Kezar Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ETX101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"PK MED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"PK MED","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection, Prolonged Release","sponsorNew":"PK MED \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PK MED \/ N.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Announces Study Findings that LPT-CBD Maintains its Prolonged Release in Rabbits","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Expansion of Phase I\/II Trial of RECCE\u00ae 327 for the Treatment of Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Gets Europe Approval for Varenicline Tablets, 0.5mg and 1mg","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Med.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Gelsolin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces Launch of Maxigesic\u00ae IV in the U.S. and Approval in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals Prepares to Begin Ind-Enabling Studies for Db-007-4, a Potential Best-In-Class Treatment for Inflammatory Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DB-007-4","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1\/2 Clinical Trial of IMUNON\u2122s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene\u2019s Biologics License Application for TEVIMBRA\u00ae (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Idorsia and Viatris Enter Into a Significant Global Research and Development Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Selatogrel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Denali Therapeutics Announces $500 million Private Placement Equity Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Tividenofusp Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0.5,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Denali Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pyxis Oncology Announces $50 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"PYX-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Pyxis Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Chromocell Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Diclofenac","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Benuvia Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Benuvia Therapeutics \/ Chromocell Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Benuvia Th.."},{"orgOrder":0,"company":"Crossject","sponsor":"Heights Capital Management","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crossject Obtains a Financing up To \u201a\u00ac12 Million, in Two Tranches","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Crossject \/ Heights Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Announces Pricing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janux Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Carbidopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viking Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0.34999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.63,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Pelage Pharmaceuticals","sponsor":"Main Street Advisors","pharmaFlowCategory":"D","amount":"$16.7 million","upfrontCash":"Undisclosed","newsHeadline":"Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"PP405","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Pelage Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Pelage Pharmaceuticals \/ Main Street Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Pelage Pha.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$455.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"IMG-007","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0.46000000000000002,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"$2.5 million","newsHeadline":"Lipocine Announces Continued Commercialization of TLANDO\u00ae Through Verity Pharmaceuticals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0.27000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.27000000000000002,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"VantAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$674.0 million","upfrontCash":"Undisclosed","newsHeadline":"VantAI Enters Collaboration with Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0.67000000000000004,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"VantAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ B.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"Undisclosed","newsHeadline":"CRISPR Therapeutics Announces $280 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"CTX112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome Announces Closing of Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"IM-1021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Aiolos Bio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"GSK Completes Acquisition of Aiolos Bio for Up to $1.4 Bln","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"AIO-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aiolos Bio","amount2":1.3999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"Injection","sponsorNew":"Aiolos Bio \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Aiolos Bio.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"TYRA-300","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0.20000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Roluperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healis Therapeutics' Asset CKDB-501A Shares Phase III Topline Results for Glabellar Injections from CKD Bio in South Korea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Serotype A Botulinum Toxin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"CKD Bio Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CKD Bio Co.."},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanqua Bio to Present Pre-Clinical Data on VQ-101, a Novel GCase Activator For The Treatment of GBA-Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"VQ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanqua Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Receives Refusal to File Letter for Trogarzo\u00ae Intramuscular Method of Administration sBLA from FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Iibalizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Has Pre-IND Meeting with FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cilastatin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"North Star Processing, LLC.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ North Star Processing, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"GP2 Peptide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment of EGFRI-Induced Acneiform Rash","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"LUT014","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pha.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR\u2122 Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATX-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ARTHEx Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARTHEx Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARTHEx Bio.."},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces Expansion of IMBRUVICA\u00ae (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pharmacyclics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Pharmacycl.."},{"orgOrder":0,"company":"PharmAust","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND \/ ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Monepantel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"PharmAust","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PharmAust \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmAust .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Axatilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Altius Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant\u00ae) in Canada","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexlansoprazole","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Altius Healthcare","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Altius Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Altius Hea.."},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP\u00ae for the Treatment of Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Allecra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allecra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allecra Th.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to 9MW2821","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1a\/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI in Patients with Advanced Cancer at Memorial Sloan Kettering Cancer Center in New York","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CRD3874-SI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curadev Pharma Private Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Curadev Pharma Private Limited \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curadev Ph.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zidesamtinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$1,865.0 million","upfrontCash":"$165.0 million","newsHeadline":"Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"VY-FXN01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.8700000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.8700000000000001,"dosageForm":"Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Neomorph","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,460.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.46,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":1.46,"dosageForm":"","sponsorNew":"Neomorph \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"$645.0 million","upfrontCash":"$152.5 million","newsHeadline":"TG Therapeutics Announces European Launch of BRIUMVI\u00ae (ublituximab-xiiy)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Ublituximab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0.65000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"TG Therapeutics \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.25,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0.55000000000000004,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.63,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Data in CLL With Ibrutinib\/Venetoclax Doublet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pharmacyclics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Pharmacycl.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Evaluates Triple-Drug Regimen for Patients Newly Diagnosed with FLT3-Mutated AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Basking Biosciences","sponsor":"Longview Ventures","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Basking Biosciences Announces Close of $55 Million Financing to Accelerate Clinical Development for First Reversible Thrombolytic for Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"BB-031","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Basking Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Basking Biosciences \/ Longview Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Basking Bi.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"DeGregorio Family Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"Dendritic Cell-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israe.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$296.5 million","upfrontCash":"Undisclosed","newsHeadline":"Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Ther.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Announces Oversubscribed $400 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"AOC 1001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0.40000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Adage Capital Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Secures $210M from Abingworth to Fund Trodelvy Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Financing","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Abingworth","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SYMPATICO Trial of Ibrutinib Plus Venetoclax Boosts PFS in MCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacycl.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS\/CMML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astex Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R\/R AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Enasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Celgene Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Co.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: Phase 2 Results Demonstrate Rilzabrutinib Rapidly Reduced Itch Severity and Significantly Improved Disease Activity in Adults with Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix B.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$713.0 million","upfrontCash":"$48.0 million","newsHeadline":"AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"OSE-230","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: Japan First in the World to Approve Dupixent\u00ae for Chronic Spontaneous Urticaria (CSU)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Medicines Patent Pool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strides and its African Subsidiary Universal Corporation Partner with Medicines Patent Pool (MPP) to Commercialize Molnupiravir for The Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Molnupiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Medicines Patent Pool","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eli Lilly Japan, Daiichi Sankyo Ink Pact to Commercialise Migraine Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Senisca","sponsor":"Emerging Longevity Ventures","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Senisca Secures Additional \u00a33.7 Million Financing to Support Rapid Development of Senotherapeutic Platform to Treat Age-Related Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Senotherapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Senisca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senisca \/ Emerging Longevity Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Senisca \/ .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$1,680.0 million","upfrontCash":"$80.0 million","newsHeadline":"CytomX Therapeutics Announces Milestone Achievement in PROBODY\u00ae T-Cell Engaging Bispecific (TCB) Collaboration with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":1.6799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"BiomX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Adaptive Phage Therapeutics \/ BiomX","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ De.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$350.0 million","newsHeadline":"Idorsia and Viatris Successfully Close the Transaction for The Global Research and Development Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Selatogrel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0.59999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.59999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Madrigal Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$159.0 million","upfrontCash":"$60.0 million","newsHeadline":"Outlook Therapeutics Announces Closing of Private Placement of up to $159 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.16,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"TaiMed Biologics","sponsor":"AcedrA BioPharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo\u00ae (Ibalizumab-uiyk) in the Middle East and North Africa Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ibalisumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TaiMed Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TaiMed Biologics \/ AcedrA BioPharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"TaiMed Bio.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Announces $6.0 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS\u00ae T-cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ECT204","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"AliveGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-801","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"AliveGen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AliveGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AliveGen \/.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces New Product Launches and Participation in DCAT Week 2024","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosaprepitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF\/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Efdamrofusp alfa","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR\u2122 (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase II Clinical Trial (CGZ203 study) of Chiglitazar Monotherapy for Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Chiglitazar Sodium","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1\/PD-L1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tunlametinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Kechow Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai K.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Sanegene Bio","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"SGB-3908","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Sanegene Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanegene Bio \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Sanegene B.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astellas completes acquisition of Propella Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Abiraterone Decanoate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Propella Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$5.0 million","newsHeadline":"Codexis Announces Purchase Agreement with Nestl\u00e9 Health Science for CDX-7108","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0.050000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Codexis","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Hea.."},{"orgOrder":0,"company":"Opthea","sponsor":"Carlyle Group","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opthea to Receive US$35M Commitment and Additional US$50M Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Opthea \/ Carlyle Group","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ C.."},{"orgOrder":0,"company":"WuXi XDC","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"WuXi XDC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi XDC \/ Multitude Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"WuXi XDC \/.."},{"orgOrder":0,"company":"Firefly Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$94.0 million","upfrontCash":"Undisclosed","newsHeadline":"Firefly Bio Debuts with $94 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Firefly Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Firefly Bio \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Firefly Bi.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG\u00ae (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Belzutifan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Seattle Children\u2019s","sponsor":"BrainChild Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seattle Children's Launches Brainchild Bio to Accelerate Car T-Cell Therapies for Children with Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"SC-CAR4BRAIN","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seattle Children\u2019s","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seattle Children\u2019s \/ BrainChild Bio","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Ch.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Arcus Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tarsus Announces Pricing of $100.0 Million Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tarsus Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"12","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$40.2 million","upfrontCash":"Undisclosed","newsHeadline":"Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Humacyte","amount2":0.040000000000000001,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Propel Bio Partners LLC","pharmaFlowCategory":"D","amount":"$124.2 million","upfrontCash":"$60.0 million","newsHeadline":"Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.12,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Propel Bio Partners LLC","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Murdoch Children\u2019s Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children's Research Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Murdoch Children\u2019s Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"CTx-TFEB","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coave Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coave Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Piper Sandler & Co","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"BlossomHill Therapeutics","sponsor":"Colt Ventures","pharmaFlowCategory":"D","amount":"$173.0 million","upfrontCash":"Undisclosed","newsHeadline":"BlossomHill Therapeutics Closes $100 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"BlossomHill Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"BlossomHill Therapeutics \/ Colt Ventures","highestDevelopmentStatusID":"2","companyTruncated":"BlossomHil.."},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Genson Capital","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"NEU-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Neurenati Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurenati Therapeutics \/ Genson Capital","highestDevelopmentStatusID":"4","companyTruncated":"Neurenati .."},{"orgOrder":0,"company":"Kenai Therapeutics","sponsor":"Alaska Permanent Fund Corporation","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"RNDP-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kenai Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Kenai Therapeutics \/ Alaska Permanent Fund Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Kenai Ther.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Oragenics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Announces Closing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GENESIS Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GENESIS Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GENESIS Ph.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$1.0 million","newsHeadline":"NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akero Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0.25,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Cyprium Therapeutics","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"$4.1 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"AAV-ATP7A","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cyprium Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyprium Therapeutics \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"4","companyTruncated":"Cyprium Th.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$756.0 million","upfrontCash":"$16.0 million","newsHeadline":"C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"C4 Therapeutics","amount2":0.76000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Mesenchymal Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"CytoMed Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ Sengkang General Hospital","highestDevelopmentStatusID":"2","companyTruncated":"CytoMed Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$310.0 million","newsHeadline":"BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$170.0 million","newsHeadline":"Sandoz Acquires Cimerli\u00ae Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Institut Curie","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"BMX-500","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Institut Curie","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institut Curie \/ Biomunex Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Institut C.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Pricing of $100.0 Million Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Barclays","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Arkin Bio Capital","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nocion Therapeutics Announces $62 Million Series B Financing to Advance Lead Program in Cough into Later Stage Development","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series B Financing","leadProduct":"Taplucanium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Nocion Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Nocion Therapeutics \/ Arkin Bio Capital","highestDevelopmentStatusID":"6","companyTruncated":"Nocion The.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$632.5 million","upfrontCash":"Undisclosed","newsHeadline":"Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0.63,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.63,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"AP\u2010PA02","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Rezpegaldesleukin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ TCGX","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$319.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akero Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.32000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Daridorexant HCl","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Sosei Heptares","amount2":0.44,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.44,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sosei Heptares \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Lykos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Ther.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Announces FDA Approval of iDose\u00ae TR (travoprost intracameral implant)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextPoint Therapeutics Announces First Patient Dosed in Phase 1a\/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NPX887","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI\u00ae (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck's Application for KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Neurodawn Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Findings of a Phase III Clinical Study of Sanbexin\u00ae Sublingual Tablets Published in JAMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Neurodawn Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Stumbles In HIMALAYA Trial, Chalking up Phase 2 ALS Fail","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DNL788","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIb Trial with Nadunolimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oil","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galimedix Therapeutics presents New Scientific Data Showing Promising Neuroprotective Effects of GAL-201 for the Treatment of Alzheimers Disease at AD\/PD\u2122 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"GAL-201","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Galimedix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galimedix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Galimedix .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1\/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ARO-DM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIMZELX\u00ae 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"RGT-075","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Regor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Ther.."},{"orgOrder":0,"company":"Promontory Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Promontory Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promontory Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promontory.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"APR-1051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ranibizumab Launch - Midas Pharma is the Marketing Authorisation Holder (MAH) of a Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Midas Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Midas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Midas Phar.."},{"orgOrder":0,"company":"Pharmacare Premium","sponsor":"Midas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Midas Pharma\u2019s Partner, the Malta-based Generics Developer Pharmacare Premium, Has Successfully Conducted BE-Studies for Both Strengths of a Generic Version of Norvatis\u2019 Vorient\u00ae.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Pazopanib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacare Premium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmacare Premium \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacare.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ANAVEX 3-71","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Deucrictibant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH\/NASH and T2D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives FDA Approval of Lenmeldy\u2122 (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r\/r AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Me.."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Launches Baclofen Injection, USP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Baclofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Phar.."},{"orgOrder":0,"company":"Shaperon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"HY209","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts the New Drug Application for Review of Idorsia\u2019s Daridorexant for the Treatment of Adult Patients with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Daridorexant HCl","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia submits European Marketing Authorisation Application for Daridorexant for the Treatment of Adult Patients with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Daridorexant HCl","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Europe\u2019s first Dual Orexin Receptor Antagonist \u2013 QUVIVIQ (daridorexant) \u2013 Granted Approval to Improve Both Nighttime Symptoms and Daytime Functioning in Adults with Chronic Insomnia Disorder","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant HCl","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia\u2019s new Treatment QUVIVIQ (daridorexant) is now Available in the us for Adults Living with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Daridorexant HCl","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Fibrocor Therapeutics","sponsor":"McQuade Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fibrocor Therapeutics Enters into Research and Development Collaboration with McQuade Center for Strategic Research and Development to Advance Alport Syndrome Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"FIB918","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Fibrocor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fibrocor Therapeutics \/ McQuade Center","highestDevelopmentStatusID":"5","companyTruncated":"Fibrocor T.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0.41999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Nanna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ubiquigent Enters Agreement with Astellas Subsidiary, Nanna Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ubiquigent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Nanna Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ubiquigent.."},{"orgOrder":0,"company":"Expert Systems","sponsor":"Eilean Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Expert Systems Expands Partnership with Eilean Therapeutics and Joins its Best-in-Class PTPN2 Inhibitor Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Expert Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Expert Systems \/ Eilean Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Expert Sys.."},{"orgOrder":0,"company":"Biotheus","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR\/cMET Bispecific Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotheus \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/.."},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"Latiglutenase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX.."},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilgamesh Pharmaceuticals \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Gilgamesh .."},{"orgOrder":0,"company":"Tubulis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"$138.8 million","upfrontCash":"Undisclosed","newsHeadline":"Tubulis Rides Wave of ADC Interest to $138M Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series B Financing","leadProduct":"TUB-040","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Tubulis \/ EQT Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$32.7 million","upfrontCash":"Undisclosed","newsHeadline":"Swedish Biotech Raises \u20ac30M Series A to Develop Off-the-shelf Gene Therapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series A Financing","leadProduct":"AT-108","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Asgard Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Asgard Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Asgard The.."},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.14999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Bio.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James Ltd","pharmaFlowCategory":"D","amount":"$33.9 million","upfrontCash":"Undisclosed","newsHeadline":"Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia P.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Jeffrey C. Thacker","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Contineum Therapeutics Files for IPO with MS Drug in Phase II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"PIPE-307","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Contineum Therapeutics \/ Jeffrey C. Thacker","highestDevelopmentStatusID":"8","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and Stelis Biopharma Partner to Supply 200 million Doses of the Sputnik V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Covid Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strides Pharma Science \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TLC and Strides partner to launch Liposomal Amphotericin B in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Partnership","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TLC BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC BioSciences \/ Strides Pharma Science","highestDevelopmentStatusID":"12","companyTruncated":"TLC BioSci.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$14,000.0 million","upfrontCash":"$14,000.0 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":14,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","amount":"$271.6 million","upfrontCash":"$43.4 million","newsHeadline":"Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Thiosulfate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Fennec Pharmaceuticals","amount2":0.27000000000000002,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.27000000000000002,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Norgine","highestDevelopmentStatusID":"12","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$300.0 million","newsHeadline":"Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Rusfertide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"AstraZeneca to Acquire Fusion to Accelerate the Development of Next-generation Radioconjugates to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":2.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":2.3999999999999999,"dosageForm":"","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Aegis Life","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aegis Life","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aegis Life \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Aegis Life.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0.080000000000000002,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"FT576","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"ELVN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Enliven Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Th.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya, for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almac Group \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Capstan Therapeutics Announces $175M Oversubscribed Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Th.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"PRTX007","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Primmune Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Primmune Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Agreement with SERB Pharmaceuticals to Bring Voraxaze\u00ae (glucarpidase) to Latin America","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Ph.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"GEN","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Jaguar Health \/ GEN","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"DepYmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"DPM-1003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DepYmed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces First Patient Dosed in Phase 1b\/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Completes Dosing Cohort in Phase I\/II Trial of RECCE\u00ae 327 for Urinary Tract Infections and Urosepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spevigo\u00ae Approved for Expanded Indications in China and The US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics\u2019 Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG\u00ae (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ponatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"LIB Therapeutics","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical Products Administration in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lerodalcibep","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"LIB Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"LIB Therapeutics \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"LIB Therap.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Topline Results from Phase III Long-Term Study OASIS 3 Support Submissions for Marketing Authorization for Bayer\u2019s Elinzanetant","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma\u2019s Deltacel-01 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Launches Versavo\u00ae (bevacizumab) in The UK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN\u00ae for the Treatment of Primary IgA Nephropathy in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Trehalose API","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Approved by Health Canada for The Treatment of Iron Deficiency Anemia in Adult and Pediatric Patients and Iron Deficiency in Adult Patients with Heart Failure","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza\u2122 as a Treatment for AADC Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PTC Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"HTL0033744","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba\u00ae Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PDA-002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Provides Data Announcement Update for the Phase II\/III Study of Buntanetap in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"23ME-01473","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Announces Positive Phase 1\/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lonigutamab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb\u2019s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer\u2019s Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IGC-AD1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Schr\u00f6dinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"SGR-1505","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Schrodinger \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Usona Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Usona Institute Announces Launch of uAspire Phase 3 Clinical Trial Investigating Psilocybin for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Usona Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Inst.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Alisertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Enteric Coated Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Furosemide for Injection in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ\u00ae Injections Four Years After One-Time Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenadogene Nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics' PT886 Granted Fast Track Designation for TheTreatment of Patients with Metastatic Claudin 18.2-positive Pancreatic Adenocarcinoma by The FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ATG-022","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Idorsia's Once-Daily TRYVIO (aprocitentan) - the First and Only Endothelin Receptor Antagonist for the Treatment of High Blood Pressure Not Adequately Controlled in Combination with Other Antihypertensives","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Aprocitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II\/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Awiqli\u00ae (once-weekly basal insulin icodec) Recommended for Approval for The Treatment of Diabetes by The European Regulatory Authorities","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CMP-CPS-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CAMP4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Ther.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Receives FDA Approval for Duvyzat\u2122 (givinostat) in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Givinostat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Italfarmaco S.p.A","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Italfarmaco S.p.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Italfarmac.."},{"orgOrder":0,"company":"Blue Lake Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blue Lake Biotechnology Reports Positive Interim Clinical Data in Children for Its RSV Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BLB201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Blue Lake Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Blue Lake Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Lake .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VX-407","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Maintenance LYNPARZA\u00ae (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Utidelone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Bi.."},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Cevidoplenib for ITP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ .."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ N.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"I-Mab Hangzhou Company","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Signs Agreement to Divest its Assets and Business Operations in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Divestment","leadProduct":"Eftansomatropin Alfa","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ I-Mab Hangzhou Company","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Natural Sciences and Engineering Council of Canada","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"QBSAU","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Natural Sciences and Engineering Council of Canada","highestDevelopmentStatusID":"4","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"IMIDomics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB announces Strategic Investment in IMIDomics, Inc to Advance Breakthrough Solutions for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"IMB1001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMIDomics \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics .."},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apontis Pharma and Midas Pharma Agree on Further Development Partnership for The Market Launch of A Single Pill with Pan-European Intellectual Property Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"Bisoprolol Fumarate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Apontis Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Apontis Ph.."},{"orgOrder":0,"company":"Sycamore BioPharma","sponsor":"Branded Legacy, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sycamore BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Sycamore BioPharma \/ Branded Legacy, Inc","highestDevelopmentStatusID":"12","companyTruncated":"Sycamore B.."},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lamassu Awarded NIH Grant For Breakthrough Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"SA53","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Ph.."},{"orgOrder":0,"company":"Alcresta Therapeutics","sponsor":"Linden Capital Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linden Capital Partners Acquires Alcresta Therapeutics, Inc.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"ALC-079","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Alcresta Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alcresta Therapeutics \/ Linden Capital Partners","highestDevelopmentStatusID":"1","companyTruncated":"Alcresta T.."},{"orgOrder":0,"company":"GenBio","sponsor":"Strainsforpains","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"GenBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenBio \/ Strainsforpains","highestDevelopmentStatusID":"5","companyTruncated":"GenBio \/ S.."},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"DCVC","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Relation Therapeutics Secures $35 million of New Seed Financing Led by DCVC and Co-Lead NVentures, NVIDIA's Venture Arm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Relation Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ DCVC","highestDevelopmentStatusID":"2","companyTruncated":"Relation T.."},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"Anocca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"TCR-T Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Emendo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emendo Biotherapeutics \/ Anocca","highestDevelopmentStatusID":"5","companyTruncated":"Emendo Bio.."},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sibylla Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Sibylla Bi.."},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precisio Biotix Therapeutics Announces Collaboration with Mayo Clinic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precisio Biotix Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precisio Biotix Therapeutics \/ MAYO CLINIC","highestDevelopmentStatusID":"1","companyTruncated":"Precisio B.."},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ennaid Therapeutics Partners Exclusively with Strides to Manufacture Life-Saving Oral COVID-19 Tablet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ennaid Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ennaid Therapeutics \/ Strides Pharma Science","highestDevelopmentStatusID":"2","companyTruncated":"Ennaid The.."},{"orgOrder":0,"company":"Parvus Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"PVT-401","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Parvus Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parvus Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Parvus The.."},{"orgOrder":0,"company":"Celanese","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Celanese","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Celanese \/ Secarna Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Celanese \/.."},{"orgOrder":0,"company":"Clasp Therapeutics","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clasp Therapeutics Launches with $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"T Cell Engagers","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Clasp Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Clasp Therapeutics \/ Catalio Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"Clasp Ther.."},{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AEX-2","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Aexon Labs","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aexon Labs \/ NLS Pharmaceutics","highestDevelopmentStatusID":"4","companyTruncated":"Aexon Labs.."},{"orgOrder":0,"company":"Cybin","sponsor":"Bloom Burton Securities Inc","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.14999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Cybin \/ Bloom Burton Securities Inc","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ Bl.."},{"orgOrder":0,"company":"Geron","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Geron \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ TD.."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series B Financing","leadProduct":"ENX-102","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ F-Prime Capital","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo\u00ae Technology for Neurodegenerative Disease in Research Collaboration with Alexion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"HypoSpray Pharma","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nascent Biotech & HypoSpray Pharma Collaborate on Proprietary Transdermal Delivery System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Pritumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HypoSpray Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HypoSpray Pharma \/ Nascent Biotech","highestDevelopmentStatusID":"6","companyTruncated":"HypoSpray .."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$53.5 million","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Graphite Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Graphite Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"LENZ Therapeutics \/ Graphite Bio","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Angelini Ventures","pharmaFlowCategory":"D","amount":"$82.1 million","upfrontCash":"Undisclosed","newsHeadline":"Angelini Ventures Invests into Extended \u20ac75.8 million ($82 million) Series C financing Round for Nouscom, a Clinical Stage Immuno-Oncology Company Developing Off-The-Shelf and Personalized Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series C Financing","leadProduct":"NOUS-209","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nouscom AG","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Nouscom AG \/ Angelini Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Nouscom AG.."},{"orgOrder":0,"company":"Mirador Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Mirador Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Mirador Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Mirador Th.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmazz Inc. and Dr. Reddy's Laboratories have Entered into a Licensing Agreement to Market Centhaquine (Lyfaquin) as a Resuscitative Agent for Hypovolemic Shock in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Univercells","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Univercells","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Landos Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$212.5 million","upfrontCash":"$137.5 million","newsHeadline":"AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"NX-13","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Landos Biopharma","amount2":0.20999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Landos Biopharma \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Landos Bio.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0.080000000000000002,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces $25 Million Registered Direct Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nkarta Announces Pricing of $240 Million Underwritten Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"NKX019","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Nkarta Therapeutics \/ Adage Capital Partners LP","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"CDR132L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":1.1100000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":1.1100000000000001,"dosageForm":"Injection","sponsorNew":"Cardior Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"Vivox","sponsor":"NurExone Biologic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for its Spinal Cord Injury Therapy, ExoPTEN","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vivox","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivox \/ NurExone Biologic","highestDevelopmentStatusID":"4","companyTruncated":"Vivox \/ Nu.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"ABL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Nuvation Bio","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"VRG50635","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"AriBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$770.0 million","upfrontCash":"$90.0 million","newsHeadline":"AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer\u2019s Disease in China for $770 Million USD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Mirodenafil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0.77000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.77000000000000002,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ U.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$4,300.0 million","upfrontCash":"$4,300.0 million","newsHeadline":"Gilead Sciences Announces Completion of Acquisition of CymaBay","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":4.2999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":4.2999999999999998,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Barclays","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Q32 Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"Bempikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Homology Medicines \/ Q32 Bio","highestDevelopmentStatusID":"8","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Bempikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Grace Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Andelyn Biosciences and Grace Science, LLC Partner to Tech Transfer Phase I\/II\/III Manufacturing of a Suspension Process Adeno-Associated Virus (AAV) Gene Therapy for NGLY1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"GS-100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Andelyn Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Andelyn Biosciences \/ Grace Science","highestDevelopmentStatusID":"7","companyTruncated":"Andelyn Bi.."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Australian Government","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"Linezolid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Australian Government","highestDevelopmentStatusID":"8","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Hebrew University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innocan Pharma Paves its Way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), Key Milestones for FDA Approval","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Hebrew University","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Naval Medical Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Naval Medical Research Center","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Batavia and Candel Partner to Accelerate Development of CAN-3110","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"CAN-3110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Batavia Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Batavia Bioscience \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Batavia Bi.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"$100.0 million","newsHeadline":"Intellia Exits Hemophilia B Pact with Regeneron","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Termination","leadProduct":"CRISPR-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0.41999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Healis Therapeutics Announces Collaboration with Massachusetts General Hospital (MGH) and Affiliates of Harvard Medical School to Advance Clinical-Stage Neuroscience Research","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"CKDB-501A","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Healis Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Healis The.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"POZ-Apomorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AgeX Therapeutics \/ Serina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"ForSeeCon Eye Corporation","pharmaFlowCategory":"D","amount":"$93.5 million","upfrontCash":"$33.5 million","newsHeadline":"ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Hyaluronic Acid-derived Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ ForSeeCon Eye Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stoke Therapeutics Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Zorevunersen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Stoke Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Juvis\u00e9 Pharmaceuticals Acquires Multiple Sclerosis Drug PONVORY\u00ae (ex-US\/Canada) and Opens its Capital to Bpifrance and Pemberton","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Ponesimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Actelion P.."},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo The.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"$87.5 million","upfrontCash":"$20.0 million","newsHeadline":"Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"AL102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ayala Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Function Oncology","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"VLS-1488","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Function Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Function Oncology \/ Volastra Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Function O.."},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"Amlodipine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Closed Loop Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Closed Loop Medicine \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Closed Loo.."},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Debio-0432","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ubiquigent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Ubiquigent.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"University of Colorado School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ University of Colorado School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Erasca","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Erasca Announces $45 Million Oversubscribed Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Erasca \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ B.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines, Inc. Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"PRAX-628","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"AlmataBio","sponsor":"Avalo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avalo Acquires Anti-IL-1\u03b2 mAb and Announces Private Placement Financing of up to $185 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"AVTX-009","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"AlmataBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlmataBio \/ Avalo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"AlmataBio .."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$115.6 million","newsHeadline":"Avalo Acquires Anti-IL-1\u03b2 mAb and Announces Private Placement Financing of up to $185 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"AVTX-009","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0.19,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Avalo Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Seyltx","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"$2.0 million","newsHeadline":"Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Seyltx","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Vector Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ Vector Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"University of Miami","sponsor":"Provectus Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Miami","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Provectus Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"$8.0 million","newsHeadline":"Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Brolucizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Pyxis Oncology","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Pyxis Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Zorevunersen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Stoke Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boundless Bio Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"BBI-355","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Boundless Bio \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"Merrimack Pharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$575.0 million","newsHeadline":"Merrimack Receives $225 Million Milestone Payment from Ipsen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merrimack Pharmaceuticals","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Merrimack Pharmaceuticals \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Merrimack .."},{"orgOrder":0,"company":"The University of New Mexico","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"The University of New Mexico","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"The University of New Mexico \/ Purdue Pharma","highestDevelopmentStatusID":"12","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone Life Sciences Announces Collaboration to Support Moderna\u2019s Influenza Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"mRNA-1010","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0.75,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"iNGENu","sponsor":"FSD Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"iNGENu","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iNGENu \/ FSD Pharma","highestDevelopmentStatusID":"6","companyTruncated":"iNGENu \/ F.."},{"orgOrder":0,"company":"University of Central florida","sponsor":"Ludwig Enterprises","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Temozolomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Central florida","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Central florida \/ Ludwig Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strides Partners with Medicines Patent Pool (MPP) to Commercialize the Generic Version of Pfizer\u2019s COVID-19 Oral Treatment Across 95 Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Medicines Patent Pool","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"The Medicines Patent Pool \/ Strides Pharma Science","highestDevelopmentStatusID":"12","companyTruncated":"The Medici.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Thermo Fisher Scientific \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Omexa Formulary","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"lpca Laboratories Enters into Technology Transfer Agreement with Omexa Formulary","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ipca Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ipca Laboratories \/ Omexa Formulary","highestDevelopmentStatusID":"1","companyTruncated":"Ipca Labor.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"DIOSynVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen Partners with DIOSynVax to Manufacture Trivalent Hemorrhagic Fever Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"DIOS-HFVac3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ DIOSynVax","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$647.5 million","upfrontCash":"$43.5 million","newsHeadline":"Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"XTX301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xilio Therapeutics","amount2":0.65000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Otsuka and Sumitomo Revise License Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ulotaront","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"PRAX-628","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.20000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"CervoMed","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$149.4 million","upfrontCash":"$50.0 million","newsHeadline":"CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Capsule","sponsorNew":"CervoMed \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$9.5 million","upfrontCash":"Undisclosed","newsHeadline":"Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"MT-6402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Molecular Templates \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReAlta Life Sciences Announces New Research Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate RLS-0071 as a Medical Countermeasure for Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"RLS-0071","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Emory University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS\/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"BBT-877","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bridge Biotherapeutics \/ Emory University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Hevolution","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aeovian Pharmaceuticals Doses First Participants in Phase 1 Clinical Trial, Strengthens Leadership Team and Raises Additional $50 Million Financing","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"AV078","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Aeovian Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution","sponsorNew":"Aeovian Pharmaceuticals \/ Hevolution","highestDevelopmentStatusID":"6","companyTruncated":"Aeovian Ph.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ Flanders Innovation & Entrepreneurship","highestDevelopmentStatusID":"2","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Enters into Exclusive Distribution Partnership with Sanofi Healthcare India Private Limited for Their Vaccine Brands in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"DTaP-IPV-HB-Hib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Wockhardt","sponsor":"ICICI Prudential","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt Raises Rs 480 Crore to Pare Debt, Fund Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Wockhardt \/ ICICI Prudential","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Receives Permanent J-Code for DAXXIFY\u00ae and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delta-Fly Pharma Inc.: FDA Submission of the Protocol of the Phase I\/II study of DFP-10917 Combined with Venetoclax (VTX) in the AML Patients Pretreated by VTX Involved One Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly .."},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MangoRx Officially Launches \u2018PRIME\u2019 by MangoRx, Powered by Kyzatrex\u00ae\ufe0f FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuti.."},{"orgOrder":0,"company":"Evonik","sponsor":"JeNaCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evonik Company JenaCell Launches Wound Dressing Epicite\u00ae Balance for Chronic Wounds","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cellulose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Evonik \/ JeNaCell","highestDevelopmentStatusID":"12","companyTruncated":"Evonik \/ J.."},{"orgOrder":0,"company":"Evonik","sponsor":"JeNaCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evonik Company JeNaCell Launches Wound Dressing Epicite\u00ae Balance for Chronic Wounds","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Cellulose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Evonik","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Evonik \/ JeNaCell","highestDevelopmentStatusID":"12","companyTruncated":"Evonik \/ J.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"STAC-BBB","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL\u00ae9","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Multi-Valent Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Madrigal Mental Care","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Announces Groundbreaking Ketamine Research for PTSD Treatment and Upcoming In-Human Clinical Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Madrigal Mental Care","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Madrigal Mental Care \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Madrigal M.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CB-012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"University of Calgary","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ University of Calgary","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Favor of Bristol Myers Squibb\u2019s and 2seventy bio\u2019s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LP-284","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Oncologic Drugs Advisory Committee Recommends CARVYKTI\u00ae (ciltacabtagene autoleucel) for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ImmVira","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmVira's Oncolytic Product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"MVR-T3011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmVira","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmVira \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive RUBY Phase III Data Show Potential for Jemperli (dostarlimab-gxly) Combinations in More Patients with Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files New Drug Application in Japan for Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indication of Tecentriq for the Treatment of Alveolar Soft Part Sarcoma, an Ultra-rare Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan New Drug Application Submitted in Japan for Patients with Previously Treated Advanced HR Positive, HER2 Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Loratadine OTC Softgel Capsules","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Loratadine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Tentative Approval for Triamcinolone Acetonide Ointment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Tetracycline Hydrochloride Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetracycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA Approval for Flucytosine Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluocytosine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Develops and Commences Export of Favipiravir Antiviral Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Triamcinolone Acetonide Ointment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums Launches Lasmiditan Tablet to Alleviate Symptoms Associated with Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Akums Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akums Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Life.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's REYVOW\u2122 (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REYVOW\u00ae (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Ursodiol Tablets","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ursodeoxycholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives DCGI Approval Under EUA to Commercialize Molnupiravir, An Oral Medication for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Potassium Chloride Oral Solution","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Ibuprofen Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Ibuprofen OTC Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II\/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stelis Receives a Positive Recommendation From European Medicines Agency (EMA) granting Market Authorization for KaulivTM, a Recombinant Human Teriparatide Biosimilar to Treat Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Amantadine Hydrochloride Softgel Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Levetiracetam Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Pregabalin Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Gabapentin Tablets USP, 600 mg and 800 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Gabapentin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA Approval for Sevelamer Carbonate for Oral Suspension","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives Tentative USFDA Approval for Dolutegravir Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives Tentative USFDA Approval for Dolutegravir\/ Lamivudine\/Tenofovir Disproxil Fumurate Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator\u2122 VAR 200 in Patients with Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG\u00ae (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ponatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Receives USFDA Approval for Mometasone Furoate Monohydrate Nasal Spray 50 mcg\/spray","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharmaceuticals Receives Approval for Winlevi in Australia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Venus Remedies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venus Remedies Secures Regulatory Approvals for Three Key Oncology Drugs in Ukraine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Venus Remedies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Venus Remedies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Venus Reme.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers' Opdivo-Yervoy Combo Meets Main Goal in Liver Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Inhalon Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IN-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inhalon Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Inhalon Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhalon Bi.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Reports its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Antennova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ATN-031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antennova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antennova \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antennova .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Phase III Study of Enspryng in Patients with Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Satralizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Stemirna Halts mRNA Cancer Vaccine Trial, Researchers Say","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"SW1115C3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stemirna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna T.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves EDURANT\u00ae PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Rilpivirine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Gears Up for Neffy US Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (I","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"ProLynx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PLX038","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Magnesium Potentiated Oxytocin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BJT-778","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluejay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Th.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"RM-718","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LNC-docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4RR\u03b1 Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"APG808","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide\/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Plinabulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical Announces Three Month Follow-Up Data From MOJAVE Non-randomized Cohort Confirming Dramatic Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR\u00ae Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"DSR 2.0","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Me.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemivibart","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemivibart","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate\/Expanded Use Access Program Achieve Complete Clinical Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Fabhalta\u00ae (iptacopan) Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Receives FDA IND Clearance to Initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NMD670","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease Including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in the UK is Dosed in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"OATD-01","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zorevunersen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Plozasiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b\/2 Trial of STAR-0215 for HAE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"STAR-0215","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astria Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria The.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab-cwvz) Approved in the US for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BEN-8744","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Broad New Labels for Esperion\u2019s NEXLETOL\u00ae and NEXLIZET\u00ae to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinions for Both Bempedoic Acid and The Bempedoic Acid \/ Ezetimibe Fixed-Dose Combination Tablet as Treatments for Hypercholesterolaemia and Significantly Reducing Cardiovascular Events","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Aptamer Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"AST-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptamer Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptamer Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptamer Gr.."},{"orgOrder":0,"company":"Brain Trust Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brain Trust Bio Receives Approval for Patient Trials Targeting ALS and Other CNS Diseases with Continuous Intrathecal Drug Delivery Method","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Riluzole","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Brain Trust Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brain Trust Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Brain Trus.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B\/2 AML Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor \u03b1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BAT8006","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirabrutinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves OPSYNVI\u00ae (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Macitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE\u00ae (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for XTANDI\u2122 in Additional Recurrent Early Prostate Cancer Treatment Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"ProteinQure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be Presented at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ProteinQure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProteinQure \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProteinQur.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Provides Update on Biologics License Application for Odronextamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma to Report Topline Data from Ongoing Phase 1\/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opus Genetics Announces Completion of Dosing in First Cohort of Phase 1\/2 Trial of Gene Therapy OPGx-LCA5 in Patients with Rare Inherited Retinal Disease LCA5","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"OPGx-LCA5","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Opus Genetics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r\/r AML and Provides Steering Committee Update on Phase 3 REGAL Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces that YCANTH\u2122 Receives New Chemical Entity Status and Orange Book Listing from the FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PRAX-628","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Announces Positive Data of First in Human Intranasal OMV Based Vaccine for SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Avacc 10","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VLA1601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s WINREVAIR\u2122 (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotatercept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"DT-9045","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Domain Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Approval of ADZYNMA\u00ae Intravenous Injection 1500 (apadamtase alfa \/cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Apadamtase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Voruciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"STK-009","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Synthekine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthekine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Relaxin-2 protein, human","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Inactivated quadrivalent influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C\/R5","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ATA-200","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atamyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo The.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H\/dMMR Colon Cancer Neoadjuvant Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed\/Refractory KMT2Ar Acute Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Norgine Receives Positive ChMP Opinion Recommending Approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the Treatment of Malignant Hyperthermia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Dantrolene","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' VYLOY\u2122 (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Folinic Acid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"TU7710","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tiumbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiumbio \/ .."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1\/GIP Receptor Agonist VK2735","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VK2735","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Announces U.S. FDA Accepts New Drug Application for IB1001 for the Treatment of Niemann-Pick Disease Type C","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granules for Oral Suspension","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Rusfertide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protagonist Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"After Terminating 1 of 2 Late-Stage Sickle Cell Disease Trials, Pfizer Still Expects FDA Approval in 2026","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Inclacumab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Biofabri","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Begins Clinical Trials of TB Vaccine on Adults in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mtbvac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Biofabri","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanoscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Na\u00efve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Savolitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Rezatapopt","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PMV Pharma \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Announces First Patient Dosed in its Phase 1\/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IMM-6-415","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemnifosbuvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Levofloxacin","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China's NMPA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, .."},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beckley Psytech Announces Positive Initial Data from Phase IIa Study of Novel 5-MeO-DMT Formulation BPL-003 for Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Beckley Psytech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Ps.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Receives FDA Approval of Vafseo\u00ae (vadadustat) Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports Progress Towards Start of DOD-Sponsored Clinical Trial of Nadunolimab in Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nadunolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Renexxion","sponsor":"Dr. Falk Pharma GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Naronapride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Renexxion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Renexxion \/ Dr. Falk Pharma GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Renexxion .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus Approved in Japan for the Prevention of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso with the Addition of Chemotherapy Showed Favourable Trend in Overall Survival in EGFR-mutated Advanced Lung Cancer with Further Follow Up in FLAURA2 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza and Imfinzi Demonstrated Strong Clinical Benefit and More than Doubled Median Duration of Response vs. Chemotherapy in Patients with Mismatch Repair Proficient Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA, AKT1 or PTEN Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ C.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for \u201cPiasky 340mg\u201d for Paroxysmal Nocturnal Hemoglobinuria in Japan","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson's Nipocalimab Granted U.S. FDA Fast Track Designation to Reduce the Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) in Alloimmunized Pregnant Adults","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces Interim Data from Phase 2b\/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"OPC-167832","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Approval in Japan for Entresto\u00ae Granular Tablets for Pediatric Use, a Formulation Dedicated for Pediatric Patients with Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abilify Maintena\u00ae 960mg (aripiprazole) Approved in the EU as the First Once-Every-two-months Long-acting Injectable for The Maintenance Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB receives Positive CHMP Opinion for BIMZELX[\u00ae]\u25bc(bimekizumab) for the Treatment of Adults with Moderate to Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tenofovir Alafenamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Dodecanoate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Says Weight Loss Drug Minimized Muscle Loss in Trial Results, Which May Set it Apart","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Biocon","sponsor":"Zentiva","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon to Obtain Approval for Diabetes Drug, Liraglutide in UK","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Z.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Ocean Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VRON-0200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ocean Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocean Biomedical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocean Biom.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"4D-710","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Larkspur Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LRK-A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Larkspur Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Larkspur Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Larkspur B.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung\u2026","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IAM1363","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Iambic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Iambic The.."},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 \/ 2 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Bio.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NBI-1065890","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sepiapterin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF\/MEK Molecular Glue","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NST-628","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nested Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nested Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nested The.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed\/Refractory mNPM1 Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHLW Approves Lilly\u2019s Migrane Drug Reyvow, Amgen\u2019s KRAS Inhibitor and More","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ildong\u2019s Migraine Drug Patent Blocks Latecomer\u2019s Market Entry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Ildong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Ildong Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China\u2019s National Medical Products Administration Accepts Astellas and Pfizer\u2019s Supplemental Biologics License Application for Enfortumab Vedotin with KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Enfortumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Truqap Plus Faslodex Approved in Japan for Patients with Advanced HR-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upsher-Smith Launches Methimazole Tablets, USP","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Methimazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LB-P8","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Bi.."},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PassPort Technologies, Inc. Announces Positive Interim Phase I Results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"PassPort Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort T.."},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"AP303","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alebund Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alebund Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alebund Ph.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"ProJenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Prosetin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"ProJenX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ .."},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kimia Therapeutics Raises $55 Million Series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kimia Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kimia Therapeutics \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Kimia Ther.."},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Neurocrine Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Broad Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"LASN01","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Lassen Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Lassen Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Lassen The.."},{"orgOrder":0,"company":"Escugen","sponsor":"InxMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Escugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escugen \/ InxMed","highestDevelopmentStatusID":"3","companyTruncated":"Escugen \/ .."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Mayo Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$116.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"SUDO-550","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sudo Biosciences","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Sudo Biosc.."},{"orgOrder":0,"company":"Trutag Technologies","sponsor":"Spinnaker Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TruTag Technologies and Spinnaker Biosciences Partner on a New Targeted, Controlled Release Therapy for Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"Silicon Oxide Loaded Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Trutag Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trutag Technologies \/ Spinnaker Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Trutag Tec.."},{"orgOrder":0,"company":"Infinimmune","sponsor":"Infinimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infinimmune \/ Infinimmune","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmun.."},{"orgOrder":0,"company":"IAVI","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Zendal Announce Funding for Efficacy Trial of Promising TB Vaccine Candidate in Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"MTBVAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"IAVI \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ Bil.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Attwill Medical Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Attwill Medical Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"$171.0 million","upfrontCash":"$12.0 million","newsHeadline":"Palatin Completes Sale of Vyleesi\u00ae to Cosette Pharmaceuticals for up to $171 Million","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.17000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Cosette Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Cosmos Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Sitagliptin Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Undisclosed \/ Cosmos Health","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"$60.0 million","newsHeadline":"Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Acazicolcept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Termination","leadProduct":"AAV-mediated Gene Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"EVQLV","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV's AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"EVQLV","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EVQLV \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"EVQLV \/ On.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$34.8 million","upfrontCash":"Undisclosed","newsHeadline":"New Partnership Aims to Advance Vaccine Against MERS Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"VTP-500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ CEPI","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$144.0 million","upfrontCash":"$30.0 million","newsHeadline":"Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0.14000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"enGene","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"enGene Announces Expanded $50 Million Debt Facility with Hercules Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"enGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"enGene \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"enGene \/ H.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Formue Nord Fokus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million that Extends Financial Runway and Increases Business Opportunities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Formue Nord Fokus","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ Fo.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Atlantis Holdings to Acquire Accretive Established Products in Europe and Canada from Sanofi","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Levalbuterol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ L.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sarissa Capital","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lyndra Therapeutics Raises US$101 Million in Series E Funding","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Series E Financing","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Lyndra Therapeutics \/ Sarissa Capital","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"THE-349","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Crossject signs ZEPIZURE\u00ae Commercialization Agreement for Northern Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"GKCC, LLC","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Announces $7.0 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ GKCC, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience Secures $12 million in Royalty-backed Investment Structure","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces $50 Million Private Placement to EcoR1 Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"ZW171","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Zymeworks \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Applied Molecular Transport \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"Vaxart","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$9.2 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"VXA-CoV2-1.1-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ B.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$170.0 million","newsHeadline":"Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Divestment","leadProduct":"Ranibizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Public Offering","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","amount":"$1,225.0 million","upfrontCash":"$375.0 million","newsHeadline":"Gilead and Arcus Announce Amended Collaboration and Equity Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":1.23,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.23,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Alpha-9 Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9's Clinical Radiopharmaceutical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Alpha-9 Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Invitae","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Invitae","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invitae \/ BridgeBio Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Invitae \/ .."},{"orgOrder":0,"company":"Avicanna","sponsor":"Bryden Stokes Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Bryden Stokes Limited","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plans scrapped for Xadago Trial for Levodopa-induced Dyskinesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Safinamide Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Newron Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Raises \u20ac500,000 in Private Placement of New Shares with Established New Investors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ Gestys Sant\u00e9 Biotech","highestDevelopmentStatusID":"8","companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cingulate Announces Pricing of $7.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Pluri","sponsor":"Bar-Ilan University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Emiplacel","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Bar-Ilan University","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ Ba.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cingulate Announces Closing of $7.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Cingulate Therapeutics, LLC \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ RBC Capital Markets","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Attralus","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Attralus Closes $56 Million Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Attralus \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$147.9 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.14999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Scripps Research","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calibr-Skaggs Announces Expansion of Option and License Agreement with Abbvie to Develop Novel Cell Therapies for Solid Tumors and Autoimmune Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"CAR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"Camino Pharma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"$9 Million NIH Grant Advances Drug to Treat Nicotine Addiction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Camino Pharma","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Camino Pharma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Camino Pha.."},{"orgOrder":0,"company":"Jeeva clinical Trials","sponsor":"Redwood Scientific Technologies Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Redwood Scientific Enters into Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips for Smoking and E-cigarette Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Jeeva clinical Trials","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Strip","sponsorNew":"Jeeva clinical Trials \/ Redwood Scientific Technologies Inc","highestDevelopmentStatusID":"11","companyTruncated":"Jeeva clin.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"PT Etana Biotechnologies Indonesia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ PT Etana Biotechnologies Indonesia","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pacira BioSciences Awarded Brand Pharmaceuticals Agreement with Premier, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces Pricing of $3.7 Million PIPE Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$80.1 million","upfrontCash":"Undisclosed","newsHeadline":"PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ R.."},{"orgOrder":0,"company":"Myrobalan Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Myrobalan Therapeutics Receives a Grant from the ALS Association to Advance its CSF1R Inhibitor Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Myrobalan Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myrobalan Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Myrobalan .."},{"orgOrder":0,"company":"Arkuda Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arkuda Therapeutics Announces Option and Asset Purchase Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Agreement","leadProduct":"ARKD-104","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Arkuda Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arkuda Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Arkuda The.."},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Tr1X Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Tr1X Bio \/.."},{"orgOrder":0,"company":"Cellogen Therapeutics","sponsor":"Natco Pharma","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NATCO Invests US$ 2 Million in Cellogen Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellogen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellogen Therapeutics \/ NATCO Pharma Limited","highestDevelopmentStatusID":"1","companyTruncated":"Cellogen T.."},{"orgOrder":0,"company":"UNeMed","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"UNeMed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UNeMed \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"UNeMed \/ C.."},{"orgOrder":0,"company":"Rho","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Rho","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rho \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Rho \/ Toni.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces Termination of Proposed Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Theseus Pharmaceuticals","sponsor":"Concentra Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theseus Pharmaceuticals Announces Closing of Tender Offer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"THE-349","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Theseus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theseus Pharmaceuticals \/ Concentra Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Theseus Ph.."},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Experimental Drug Development Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoScape Partners with Singapore\u2019s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Partnership","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ImmunoScape","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoScape \/ Experimental Drug Development Centre","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoScap.."},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Bi.."},{"orgOrder":0,"company":"Central Drug Research Institute","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Partners with CSIR-CDRI to Develop Formulation for Fungal Keratitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Central Drug Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Central Drug Research Institute \/ Cipla","highestDevelopmentStatusID":"4","companyTruncated":"Central Dr.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$172.5 million","upfrontCash":"Undisclosed","newsHeadline":"Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"CC8464","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Chromocell Corporation","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Alliance Global Partners","highestDevelopmentStatusID":"4","companyTruncated":"Chromocell.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Exarafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ XOMA","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Closing of Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0.01,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Azitra \/ ThinkEquity","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ T.."},{"orgOrder":0,"company":"Heidelberg University","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Heidelberg University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Heidelberg University \/ Fusion Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Heidelberg.."},{"orgOrder":0,"company":"Athos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athos, an Autoimmune and Cancer Biotech, is Raising $35M for Clinical Trials","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series B Financing","leadProduct":"ATH-063","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Athos Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Athos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Athos Ther.."},{"orgOrder":0,"company":"Reservoir Neuroscience","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kizoo Leads Financing Round in Reservoir Neuroscience to Restore Health to the Aging Brain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Reservoir Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reservoir Neuroscience \/ Kizoo Technology Capital","highestDevelopmentStatusID":"3","companyTruncated":"Reservoir .."},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Revatis SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ Revatis SA","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Bi.."},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"EXO Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"GF-3001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Genflow Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ EXO Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Genflow Bi.."},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series C Financing","leadProduct":"ATX968","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent The.."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"LB Pharmaceuticals Closes $75M Series C as it Begins Ph II Schizophrenia Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series C Financing","leadProduct":"N-Methyl Amisulpride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"Cellectar","sponsor":"Rosalind Advisors","pharmaFlowCategory":"D","amount":"$44.1 million","upfrontCash":"Undisclosed","newsHeadline":"Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Iopofosine I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Rosalind Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"$28.0 million","newsHeadline":"Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"212Pb-VMT-alpha-NET","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Holding","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Lantheus Holding \/ Perspective Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus H.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Recursion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,440.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"UB-VV111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Umoja Biopharma","amount2":1.4399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.4399999999999999,"dosageForm":"","sponsorNew":"Umoja Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Umoja Biop.."},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"CDIB","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Series A Financing","leadProduct":"ABT-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Anbogen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Anbogen Therapeutics \/ CDIB","highestDevelopmentStatusID":"7","companyTruncated":"Anbogen Th.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Announces Termination of Collaboration Agreements with Providence","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Termination","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ Everest Medicines","highestDevelopmentStatusID":"4","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Osivax","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Osivax \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"Mendus","sponsor":"Australasian Leukaemia & Lymphoma Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mendus and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Australasian Leukaemia & Lymphoma Group","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ A.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"Upamostat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"PhorMed","sponsor":"WeFunder","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"PhorMed Inc Launches New Regulation CF Equity Crowdfunding Campaign on WeFunder","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Funding","leadProduct":"RP-323","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"PhorMed","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"PhorMed \/ WeFunder","highestDevelopmentStatusID":"6","companyTruncated":"PhorMed \/ .."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"mRNAi-based Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0.56999999999999995,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Leukemia & Lymphoma Society","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kura Oncology\u2019s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society\u2019s Pediatric Acute Leukemia (PedAL) Master Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Leukemia & Lymphoma Society","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio-Immunology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Bitterroot Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bitterroot Bio \/ Biotheus","highestDevelopmentStatusID":"2","companyTruncated":"Bitterroot.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Hampton Securities Limited","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Hampton Securities Limited","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Merger","leadProduct":"NGM707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ The Column Group","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"LB-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lixte Biotechnology \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"7","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4.1 million","upfrontCash":"$4.1 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"Actinium-225 Dotatate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RayzeBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RayzeBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Baseimmune","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","amount":"$11.3 million","upfrontCash":"Undisclosed","newsHeadline":"Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"BSI002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baseimmune","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Baseimmune \/ MSD Global Health Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Baseimmune.."},{"orgOrder":0,"company":"Jiangsu Nhwa Pharmaceutical","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO\u00ae in China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Deutetrabenazine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Jiangsu Nhwa Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Nh.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Boostimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Boostimmune","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Metaba","sponsor":"MAX BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Oxysterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Metaba","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metaba \/ MAX BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Metaba \/ M.."},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","amount":"$43.8 million","upfrontCash":"Undisclosed","newsHeadline":"Curve Therapeutics raises \u00a340.5 million to Turbocharge Discovery Platform and Advance Breakthrough Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Curve Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Curve Therapeutics \/ Columbus Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Curve Ther.."},{"orgOrder":0,"company":"Biological E","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Live Attenuated Tetravalent Dengue Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Biological E \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcutis Announces Pricing of $150 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$25.0 million","newsHeadline":"Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Pellet","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Rabian BV","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rabian BV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rabian BV \/ Dyadic International, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Rabian BV .."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Applied Therapeutics Announces $100 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Suspension","sponsorNew":"Applied Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Samsara BioCapital, LLC","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"Cadisegliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Samsara BioCapital, LLC","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company Announces $10 Million Bought Deal Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Engineering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Bennu Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Engineering Development for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Bennu Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"BRL Medicine Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of CGT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Partnership","leadProduct":"BRL-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Porton Advanced Solutions \/ BRL Medicine Inc","highestDevelopmentStatusID":"6","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"Ascle Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Advanced and Ascle Therapeutics Reached a Strategic Partnership to Promote the Application of NK Cells in Cancer Prevention, Beauty, and Anti-aging","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Porton Advanced Solutions \/ Ascle Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Porton Adv.."},{"orgOrder":0,"company":"FogPharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series E Financing","leadProduct":"FOG-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FogPharma","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"FogPharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"FogPharma .."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Expiration of Marketing Alliance Agreement for TENELIA\u00ae Tablets, TENELIA\u00ae OD Tablets and CANAGLU\u00ae Tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Termination","leadProduct":"Teneligliptin Hydrobromide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mitsubishi Tanabe Pharma \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Scilex Pharmaceuticals \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$460.5 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Peak Bio","sponsor":"Akari Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Peak Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peak Bio \/ Akari Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Peak Bio \/.."},{"orgOrder":0,"company":"Bit Bio","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ .."},{"orgOrder":0,"company":"Sonata Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonata Therapeutics and the Champalimaud Foundation Announce Research Collaboration for SNT-3012 in Pancreatic and Colorectal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"SNT-3012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonata Therapeutics \/ Champalimaud Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Sonata The.."},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$259.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series C Financing","leadProduct":"ESK-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Alumis","amount2":0.26000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alumis \/ F.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"BiomX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Merger","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Adaptive Phage Therapeutics \/ BiomX","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Sosei Group Corporation \/ Formosa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Merus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,581.0 million","upfrontCash":"$56.0 million","newsHeadline":"Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merus","amount2":1.5800000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.5800000000000001,"dosageForm":"","sponsorNew":"Merus \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Merus \/ Gi.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"REGENXBIO Announces Proposed Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"RGX-314","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Regenxbio","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","amount":"$182.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series C Financing","leadProduct":"SION-638","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Sionna Therapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sionna The.."},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ De.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventyx Biosciences Announces $100 Million Private Placement of Common Stock","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"VTX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Armatus Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to Treat FSHD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Armatus Bio","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Completes Acquisition of Ambrx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"ARX517","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals, Inc. Secures $2.4 Million through New Jersey Economic Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Funding","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"$50.0 million","newsHeadline":"LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2\/LAVA-1223)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"PF-08046052","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transgene, NEC, and BostonGene Expand Collaboration for Phase I\/II Clinical Trial of Neoantigen Cancer Vaccine TG4050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$366.9 million","upfrontCash":"Undisclosed","newsHeadline":"Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.37,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Roskamp Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"SM07883","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biosplice \/ Roskamp Institute","highestDevelopmentStatusID":"4","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101\/ABBV-303 Dragonfly Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"ABBV-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dragonfly Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Immuron","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immuron Announces Positive Results Support Travelan\u00ae progress to Phase 3 Clinical Trials in the US","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Funding","leadProduct":"Bovine Colostrum","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immuron \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Strengthens Pharma Portfolio with New Cardiology Drug Acoramidis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$732.5 million","upfrontCash":"$27.3 million","newsHeadline":"Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"HTL0039732","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":0.72999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.72999999999999998,"dosageForm":"Capsule","sponsorNew":"Sosei Heptares \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Ability Pharma","sponsor":"CTI Life Sciences","pharmaFlowCategory":"D","amount":"$7.6 million","upfrontCash":"Undisclosed","newsHeadline":"AbilityPharma Announces \u20ac 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"ABTL0812","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ CTI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ability Ph.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James Ltd","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0.029999999999999999,"dosageForm":"Sustained-Release","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia P.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"APR-1051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"LX9211","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.25,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of Harpoon Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0.65000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.65000000000000002,"dosageForm":"Infusion","sponsorNew":"Harpoon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Medicaid","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bluebird Bio \/ Medicaid","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Evolus","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"PrabotulinumtoxinA-xvfs","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0.050000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Evolus \/ Leerink Partners","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ L.."},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Candesartan Cilexetil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Apontis Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Apontis Ph.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA\u00ae (pembrolizumab) in Patients with Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"IDE161","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Coripharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coripharma and Midas Have Entered into an Exclusive Licensing Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Raltegravir Potassium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Coripharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Coripharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Coripharma.."},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$483.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters\u2122 Option to Purchase Additional Shares for Gross Proceeds of $483 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Apogee The.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ALLO-329","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Arbor Biotechnologies, Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"Arecor","sponsor":"TRx BIOSCIENCES","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arecor and TRX Biosciences Establish Research Collaboration to Develop Oral Glp-1 with Enhanced Bioavailability","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arecor \/ TRx BIOSCIENCES","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ T.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"GEICAM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"GLSI-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Greenwich LifeSciences \/ GEICAM","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Pearl Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pearl Bio Inks Collaboration with Merck to Discover Novel Engineered Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pearl Bio","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Pearl Bio \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Pearl Bio .."},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"SymBiosis and Khosla Ventures","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Series C Financing","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Siolta The.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Hyphens Pharma licenses Wynzora\u00ae Cream for ASEAN countries from MC2 Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Hyphens Pharma","highestDevelopmentStatusID":"12","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Domain Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domain Therapeutics and Chime Biologics Announce Manufacturing Agreement to Advance Novel Anti-Ccr8 Antibody for Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"DT-7012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Chime Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chime Biologics \/ Domain Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chime Biol.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma Enters Exclusive Pact to Distribute Astrazeneca's Anti-Asthma Drug Symbicort in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$473.0 million","upfrontCash":"$3.0 million","newsHeadline":"Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ZKN-013","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0.46999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"NovaBay Pharmaceuticals \/ Eyenovia","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"BioCardia","sponsor":"StemCardia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"SCM-102","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ StemCardia","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Cybin","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Announces Oversubscribed Private Placement of U.S. $150 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Private Placement","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0.14999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Cybin \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ De.."},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$835.0 million","upfrontCash":"$90.0 million","newsHeadline":"Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IFM Therapeutics","amount2":0.83999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.83999999999999997,"dosageForm":"","sponsorNew":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IFM Therap.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$200.0 million","newsHeadline":"BMS Exits Next-gen Yervoy Pact, Taking $300M in Biobucks with it","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"BMS-986288","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,050.0 million","upfrontCash":"$800.0 million","newsHeadline":"Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":1.05,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.05,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Navega Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"NT-Z001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Navega Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1\/2 Study of Pelareorep and Atezolizumab has Met the Success Criteria for Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Prokarium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ZH9","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"PolyActiva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyActiva Reports Promising Clinical Trial Results For its 6-month Sustained Drug Delivery, Biodegradable Ocular Implant in Glaucoma Patients.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"PolyActiva","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PolyActiva.."},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine Transdermal System From Its US Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing US Made Transdermal Patches And Sublingual Fi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Difgen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Patch","sponsorNew":"Difgen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Difgen \/ N.."},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves the Commercialisation of RYEQO\u00ae for the Symptomatic Treatment of Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Gedeon Richter","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gedeon Richter \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gedeon Ric.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"INBRX-109","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CS32582","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00a9 Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Zerlasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Completes First Clinical Study of Otenaproxesul\u2019s New Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Huidagene Therapeutics Announces First Patient Dosed in Multinational Phase 1\/2 Trial of HG004 for Inherited Blindness","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"HG004","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"HuidaGene Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HuidaGene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"HuidaGene .."},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soterios Pharma completes Phase II Enrolment for STS-01 in Mild \/ Moderate (patchy) Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"STS-01","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Soterios Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Soterios P.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Tianeptine Oxalate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin\u00ae in Ovarian Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpha-emitting Radionuclide Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Announces that Envelta\u2122 Remains on Track for Trial in Humans Following FDA Review","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Enkephalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Cessation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004 for Prevention of Fentanyl and Fentanyl Analog Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CSX-1004","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cessation Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cessation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cessation .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Novartis Cosentyx\u00ae as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Secukinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Updated COVID-19 Vaccine Now Approved in the EU","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy (PMN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ N.."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"PIKA Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimeric Therapeutics Announces FDA Clearance of IND Application For CHM 2101, a Novel CDH17 CAR T Cell Therapy for Advanced Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"CHM 2101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chimeric Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chimeric Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chimeric T.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Announces FDA Clearance of IND Application for Roginolisib, a First-in-class Allosteric Modulator of PI3K\u03b4","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Roginolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Panel Says Vertex\/CRISPR to Assess Safety Risks of Gene Therapy in Follow-up Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK's Jemperli Shows Survival Benefits in Phase III Trial for Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin\u00ae in Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpha-emitting Radionuclide Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon\u00ae for the Treatment of Primary IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares\u2019 Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PF-06954522","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS\u00ae (Voclosporin) in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Received US FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Polaris Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Polaris Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Polaris Gr.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Precision Medicines Receives PRIME Designation from the EMA for Elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Elsunersen","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Praxis Precision Medicines","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Praxis Precision Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN\u2122 3.9% Rapamycin Anhydrous Gel (QTORIN\u2122rapamycin) for the Treatment of Microcystic Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palvella T.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Announces European Commission Approval of Subcutaneous VYVGART\u00ae (efgartigimod alfa) for Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirdametinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Gritgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China\u2019s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"GS1191","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Gritgen Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gritgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritgen Th.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR\/Cas9 Gene-Edited Therapy, CASGEVY\u2122 (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Human Clinical Study to Assess U.S. Department of Defense DNA Vaccine Candidate against Venezuelan Equine Encephalitis Delivered with PharmaJet Precision Delivery Systems.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VEE DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Needle-free Injection","sponsorNew":"PharmaJet \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alentis Therapeutics Doses First Patient in Phase 1\/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ALE.C04","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Kanna Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical trial for the development of KH-001 as first FDA-approved treatment for premature ejaculation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KH-001 Besylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Kanna Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kanna Health \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kanna Heal.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Once-Weekly TransCon\u2122 CNP Achieved Primary Efficacy Objective in Accomplish China Phase 2 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"C-type Natriuretic Peptide Prodrug","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lighthouse Pharmaceuticals Announces FDA Approval To Proceed With Phase 2 Spring Trial Of LHP588, A Next-Generation Treatment For P. Gingivalis-positive Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LHP588","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lighthouse Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Astellas' XTANDI\u00ae Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Delpor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delpor's Investigational Risperidone Implant Product Provides Schizophrenia Therapy for up to One Year after a Single Administration in Phase 1b\/2a Patient Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Delpor","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Delpor \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Delpor \/ N.."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Linezolid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"UP421","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Buparlisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bizaxofusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Approval of a Generic Version of Forteo\u00ae (teriparatide injection), in the U.S.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRUQAP\u2122 (capivasertib) Plus Fulvestrant Approved in The Us for Patients with Advanced HR-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Receives European Commission Approval of EBGLYSS\u00ae (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives European Commission Approval for BRUKINSA\u00ae (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Pharmaceuticals Announces the Commencement of Phase 2 Study for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CG200745","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CrystalGenomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGen.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Commission Approves Label Update for TAKHZYRO\u00ae (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio announces First Patient Randomized in Phase 1 Trial of AB-1005","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AB-1005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys\u2019 Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pelabresib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves FoundationOne\u00aeCDx as a Companion Diagnostic for AstraZeneca\u2019s Truqap\u2122 (capivasertib) in Combination with Faslodex\u00ae (fulvestrant) to Identify Patients with HR-Positive, HER2-Negative Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzamend Neuro Receives FDA \u201cStudy May Proceed\u201d Notification for a Phase IIA Clinical Trial of AL001, a Next\u2011Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharm.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Announces European Commission Approval of YORVIPATH (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimers Disease to European Medicines Agency (EMA)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"HB-500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AG-946","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bios INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Autologous Genetically Modified Gamma-delta T Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccine Partner Valneva Receives FDA Approval for the World's First Chikungunya Vaccine Using Albumedix' Recombumin\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Prademagene Zamikeracel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia\u00ae with IP Protection Running to 2034","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Amoxicillin Trihydrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae Significantly Reduced COPD Exacerbations in Second Positive Phase 3 trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIBTAYO\u00ae (CEMIPLIMAB) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO\u00ae in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"IBI351","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon\u00ae for the treatment of primary IgA nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces FDA Approval of OGSIVEO (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"HC-5404","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ N.."},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04 for Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AD04","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage .."},{"orgOrder":0,"company":"GRI Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (\u201ciNKT\u201d) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"GRI Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Brepocitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1\/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Full Enrollment of Its Phase II\/III Alzheimer's Disease Trial, Exceeding Original Projections","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Genelux","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant\/Refractory Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Olvimulogene Nanivacirepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genelux \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NMRA-266","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"XEN1101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY\u00ae\/TEPKINLY\u00ae) for the Treatment of Relapsed\/Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Beremagene Geperpavec-svdt","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Priothera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priothera \u201c US FDA grants Orphan Drug Designation to Mocravimod to Improve the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) in Patients with Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Mocravimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Priothera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer\u2019s Disease Psychosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ACP-204","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ONM-501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OncoNano Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano M.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ARCT-032","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"OmnImmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Racemic Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY\u00ae\/TEPKINLY\u00ae) for the Treatment of Relapsed\/Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Announces Updated Formulation of Fostrox, Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PN-235","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Tharimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"TH104","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Tharimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Tharimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tharimmune.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambrx Provides Update On APEX-01, an On-Going Phase 1 \/ 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ARX517","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ambrx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ambrx Inc .."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-in-class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR\/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL\u00ae) Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KSQ-001EX","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ASC618","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ASC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therap.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Acceptance of Nefecon\u00ae New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity's Theranostic Prostate Cancer Trial Progresses at The Highest Dose Level Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Telisotuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"OncoResponse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoResponse Announces Initiation of Phase 1\/2 Clinical Trial of OR502, Anti-LILRB2 Antibody, in Subjects with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoResponse","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoResponse \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OncoRespon.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyan.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces FDA Clearance of IND Application for Drug\/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pemvidutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LP-284","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Etrasimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio Co., Ltd. Announces Global Expansion of POLARIS-AD, A Phase 3 Early Alzheimer\u2019s Disease Registration Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Mirodenafil dihydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ N.."},{"orgOrder":0,"company":"Servier","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Servier","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Servier \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Servier \/ .."},{"orgOrder":0,"company":"TAE Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAE Life Sciences' Research on Boronotyrosine (BTS) Drug Shows Promise in Advancing Cancer-Fighting Potential of BNCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TAE Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TAE Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TAE Life S.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Results From DREAMM-7 Head-to-Head Phase Iii Trial for Blenrep in Relapsed\/refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Belantamab Mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK rEceives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III RUBY Trial of Jemperli (dostarlimab) Plus Chemotherapy Meets Endpoint of Overall Survival in Patients with Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Application to the European Medicines Agency for RYBREVANT\u00ae\u25bc (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 MARIPOSA-2 Study Shows RYBREVANT\u00ae (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56% and 52% in Patients with EGFR-Mutated NSCLC who Progressed on or After Osimertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 TREMFYA\u00ae (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Phase 3 PAPILLON Study Show RYBREVANT\u00ae (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GT-00513","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Ambio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambio Announces US FDA Approval of a Generic Version of Forteo\u00ae (Teriparatide Injection) for Its Partner Apotex","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ambio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ambio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ambio \/ No.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Danuglipron","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaypirca\u00ae (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pirtobrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Asundexian Phase III Study to Include Patients with Atrial Fibrillation Ineligible for Oral Anticoagulant Treatment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Asundexian","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Kerendia\u2122 (finerenone) Data Show Impact of Early Albuminuria Reduction in Patients with Chronic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Phase 3 Study Data to the European Medicines Agency and U.S. Food and Drug Administration for SIRTURO\u00ae (bedaquiline)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bedaquiline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VERVE-101","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s ELREXFIO\u00ae for Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Kadcyla","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Positive Recommendation of The Third DMC of the Phase III Clinical Trial with Lanifibranor in Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GTB-3650","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Interim Data from Phase 1b\/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy\u2019s Labs Gets Nod to Study Popular Weight Loss Medication","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Odronextamab Data from Relapsed\/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B\u200b","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SC-2882","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Scenic Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scenic Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Reinforce the Benefit of Early Preventative Treatment With Genentech\u2019s Hemlibra (emicizumab-kxwh) for Babies With Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Emicizumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ATG-031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' VEOZA\u2122 (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data for Bispecific Antibody Epcoritamab (DuoBody\u00ae CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Epcoritamab-bysp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarclisa\u00ae (isatuximab) Phase 3 Trial Met Primary Endpoint of Progression Free Survival in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Third Pole Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Third Pole Therapeutics Announces First Patient Dosed in Feasibility Study with eNOfit\u2122 Portable Inhaled Nitric Oxide Delivery System","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Third Pole Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Third Pole Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Pole.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed\/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ORIC-533","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI\u201e\u00a2 (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CIP-137401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lotilaner","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Completes Phase 1\/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Bio.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Atidarsagene Autotemcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nimacimab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"MT-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Affimed","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Updated Phase 1\/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Acimtamig","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis investigational iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients With C3 Glomerulopathy (C3G)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros\u2122 Phase 2 RAINBOW study, Evaluating Nizubaglustat in GM2 and NPC Patients, is Now Fully Enrolled","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nizubaglustat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Marstacimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Mogamulizumab-kpkc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Glycomine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GLM101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Glycomine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Glycomine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine .."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies (PIDs)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Announces that it has Completed Enrollment of a Phase II\/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CFT7455","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Foselutoclax","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ceapro \/ N.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RZ402","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces First Patient Dosed in Phase 1\/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 \u201dModifier Gene Therapy\u201d for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU410","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces FDA Approval of Trogarzo\u00ae 90-Second Intravenous (IV) Push Loading Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Iibalizumab-uiyk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BDTX-1535","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A\/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Levicept","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"LEVI-04","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Levicept","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Levicept \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Levicept \/.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ECUR-506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Suzetrigine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pimicotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Abbisko Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abbisko Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abbisko Th.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tarlatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Alebund Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"EOS789","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Alebund Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"HT-6184","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Halia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Halia Ther.."},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DeFloria LLC Commences Phase 1 Clinical Program for Innovative Full Spectrum Hemp Botanical Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabinoid-based Drug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/.."},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CV6 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therap.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s WELIREG\u00ae (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Belzutifan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US WorldMeds Announces FDA Approval of IWILFIN\u2122 (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"US WorldMeds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel\u2122 for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AGMB-447","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Announces US FDA Approval to Initiate Phase II Clinical Trial of its Lead Asset MTX652 in Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"MTX652","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imlifidase met Primary Endpoint in 16-HMedIdes-12 Phase 2 Trial in Patients with AMR Following Kidney Transplantation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Garadacimab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Eflornithine for Adult and Pediatric Patients with High-Risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"US WorldMeds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Arcutis' ZORYVE\u00ae (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion for Biogen's SKYCLARYS\u00ae (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia, a Rare Neurodegenerative Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"WVE-N531","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Samuraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Carrick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Carrick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carrick Th.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Film-Forming Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: EMA Gives Positive Opinion to Fexinidazole Winthrop as First Oral Treatment of Acute Form of Sleeping Sickness (rhodesiense) Found in East and Southern Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fexinidazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Indication for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Inc. Announces U.S. FDA approval of Adbry\u00ae (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tralokinumab-ldrm","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Submits New Drug Application in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti\u00ae (brexpiprazole)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: Sarclisa\u00ae (isatuximab) Plus KRd Significantly Improved Rate of Minimal Residual Disease Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma versus KRd Alone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Delivers First Medicines from Global Health Unit\u2019s Impact Brand Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest Odronextamab Data in Relapsed\/Refractory Follicular Lymphoma Showed Compelling Responses AND Overall Maintenance of Patient-Reported Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Odronextamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Kadcyla is the First Targeted Therapy to Show Significant Overall Survival Benefit in People with Her2-Positive Early-Stage Breast Cancer with Residual Invasive Disease After Neoadjuvant Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Emtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Subcutaneous Injection of Tecentriq Recommended by The EU\u2019s CHMP for Multiple Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for HYQVIA\u00ae as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for the First CRISPR\/Cas9 Gene-Edited Therapy, CASGEVY\u2122 (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY\u2122 (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves KAFTRIO\u00ae in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"L-praziquantel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Dispersible","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Receives European Commission Decision for Evkeeza\u00ae (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Evinacumab-dgnb","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix\u2122) for Imaging of Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"89Zr-DFO-girentuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-term ALPHA Phase III Trial Data Showed Danicopan as Add-on to Ultomiris or Soliris Sustained Clinical Improvements in Subset of Patients with Pnh Experiencing Clinically Significant Extravascular Haemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on CRYSTALIZE Evidence Trials","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on PACIFIC-2 Phase III Trial of Imfinzi Concurrently Administered with Platinum-Based Chemoradiotherapy in Unresectable, Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi plus Chemotherapy Approved in China as First Immunotherapy Regimen for Patients with Locally Advanced or Metastatic Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zibotentan\/dapagliflozin combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Zibotentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZORA Real-World Evidence Demonstrates that Lokelma Substantially Increases Cardiorenal Patients\u2019 Chances of Maintaining Lifesaving RAASi Therapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Demonstrated Clinically Meaningful Survival Across Multiple HER2-expressing Advanced Solid Tumours in DESTINY-PanTumor02 Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Improved Progression-Free Survival vs. Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Significantly Extended Progression-Free Survival vs. Chemotherapy in Patients with HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in the EU as the first HER2-directed Therapy for Patients with HER2-mutant Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Plus Imfinzi Demonstrated Robust and Durable Tumour Responses in 1st-line Treatment of Patients with Metastatic Triple-negative Breast Cancer in BEGONIA Phase Ib\/II trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi plus Lynparza Reduced the Risk of Disease Progression or Death by 45% vs. Chemotherapy in Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Chemotherapy Reduced the Risk of Disease Progression in the Brain by 42% in Patients with EGFR-mutated Advanced Lung Cancer and Brain Metastases at Baseline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Aflibercept 8 mg Recommended for Approval in EU","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis' Zoryve Has Snagged a 2nd Dermatology Nod From FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus gets USFDA Nod for Antiviral Drug used in HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Darunavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-A12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Weight Loss Treatment: SciSparc's Obesity Drug Showed Positive Results in a Pre-Clinical Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ICP-332","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for the First CRISPR\/Cas9 Gene-Edited Therapy, CASGEVY\u2122 (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immusoft Administers the First Engineered B Cell in a Human Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immusoft Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft C.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"JR-441","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Biopharma Announces US FDA Approval for ALYGLO\u2122 (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human-stwk","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Launches EasyFourPol in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Hib DTP Poliovirus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Jemperli (dostarlimab) plus Chemotherapy Approved as The First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR\/MSI-H primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Abecma\u00ae Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for HYQVIA\u00ae as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carina Biotech Doses First Patient in Phase 1\/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CNA3103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Carina Bio.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"KB-9558","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Panbela Therapeutics \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Istaroxime","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"PGN-EDODM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fosciclopirox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"8","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE\u00ae 327 Against Gonorrhea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RECCE-327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"[Lu-177]-PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantheus Holding \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus H.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CardiAMP Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"LX2020","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VYD222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"DyDo Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces FIRDAPSE\u00ae New Drug Application Submitted in Japan by Partner DyDo Pharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ DyDo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Ethris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-induced Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ETH47","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ N.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Receives Positive DSMB Opinion on DONESTA\u00ae European Phase 3 Trial","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tendu","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera\u2122s AGAMREE\u00ae (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol\u00ae Cyclo\u2122 Clinical Program for the Treatment of Niemann-Pick Disease Type C1","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics and Innovent Announce China\u2019s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Aulos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1\/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aulos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ No.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Therapy-1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VRDN-003","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Selenium Sulfide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS \u22651) and Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"HF158K1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RV-1770","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RNAimmune \/ Sirnaomics","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune .."},{"orgOrder":0,"company":"Avstera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AVS100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avstera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avstera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avstera Th.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NXL-004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuExcell therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Berubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB Submits Request for an End-of-Phase 2 Meeting with the FDA for the Phase III-ready Mesdopetam Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemperli (dostarlimab) plus Zejula (niraparib) Combination Significantly Improved Progression-Free Survival in Primary Advanced or Recurrent Endometrial Cancer in Ruby Part 2 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Structure's Diabetes Pill Misses Weight-Loss Expectations in Mid-stage Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Structure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Declines to Approve Checkpoint Therapeutics' Skin Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Scraps Opdualag Trial in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Pathways Announces Investigational COMP360 Psilocybin Treatment was Well-tolerated in Phase 2 Study of Post-traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Receives European Commission Approval\u00a0for Catiolanze\u00ae\u00a0(cationic emulsion of latanoprost 50\u03bcg\/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets US FDA Approval for Generic Latisse Ophthalmic Solution","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces Start of PAPILIO-1 Phase 1\/2 Multiple Myeloma Study of Point-of-Care Manufactured BCMA CAR-T candidate, GLPG5301","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GLPG5301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ\u00ae (birch triterpenes) Topical Gel for the Treatment of Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Birch Triterpenes","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Global Rare Diseases","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Chiesi Global Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Glo.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults with Food Allergies Based on Positive National Institutes of Health phase III Study Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCon\u2122 hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"23andMe","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"23andMe Announces Further Expansion of 23ME-00610 Phase 1\/2a Clinical Trial in Advanced Neuroendocrine and Ovarian Cancer Patient Cohorts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"23ME-00610","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"23andMe \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Update on Phase I\/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AMT-130","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Beremagene Geperpavec-svdt","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Doses First Patient in CardiALLO Phase I\/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma to Conduct Phase 2b Study for Actinic Keratosis Therapeutic Candidate VDA-1102 with CentroDerm","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tuvatexib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Vidac Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Phar.."},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigational Antibody-Drug Conjugate MBRC-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Monomethyl Auristatin E","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MBrace Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MBrace The.."},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avata Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Bios.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ANX007","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Diclofenac","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B in the Treatment of Mild Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX\u00ae2-73 from AVATAR Study in Patients with Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Promising Initial Data From Phase 1\/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"PBFT02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harm Reduction Therapeutics Introduces RiVive\u2122, Over-the-Counter Opioid Overdose Reversal Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduc.."},{"orgOrder":0,"company":"Ocelot Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"OCE-205","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Ocelot Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocelot Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocelot Bio.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB116","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IAMA-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"IAMA Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAMA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IAMA Thera.."},{"orgOrder":0,"company":"Theragent","sponsor":"CellVax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"FK-PC101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theragent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theragent \/ CellVax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Theragent .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"EQ302","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ALM223","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wainua (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"JZP150","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS-089\/NCNP-02 Receives Orphan Drug Designation from the European Commission for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Brogidirsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces European Approval of REZZAYO\u00ae (rezafungin) for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"TYRA-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces FDA Approval of UDENYCA ONBODY, a Novel and Proprietary State-of-the-Art Delivery System for Pegfilgrastim-cbqv","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces New Drug Application Acceptance of Nefecon\u00ae in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NTX1088","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nectin The.."},{"orgOrder":0,"company":"Jemincare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"JMKX003801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Jemincare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jemincare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jemincare .."},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Elite Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elite Phar.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Provides Regulatory Update on Status of Lumakras\u00ae (sotorasib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Sotorasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centralized Marketing Authorizations of Generic Versions of TECFIDERA\u00ae are Revoked by the European Commission","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion for Biogen\u2019s SKYCLARYS\u00ae (omaveloxolone), the First Therapy to Treat Friedreich\u2019s Ataxia, a Rare Neurodegenerative Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u201cLEQEMBI\u00ae Intravenous Infusion\u201d (Lecanemab) for the Treatment of Alzheimer\u2019s Disease to be Launched in Japan on December 20","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Biogen\u2019s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"BIIB080","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen EMEA Announces RWD on Taptiqom","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo\u00ae in Advanced Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Oligonucleotide-based Therapy","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyond Cancer\u201e\u00a2 Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Can.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets USFDA Nod for Generic Antifungal Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1\/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Shingles Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Jiangsu Recbio Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Recbio Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Re.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Announces Positive Phase \u2160 Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SCB-219M","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Achieves Major Milestone in Chronic Kidney Disease: Aldosterone Synthase Inhibitor on Top of Empagliflozin Delivers Promising Results in Phase II trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 690517","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in Combination with RYBREVANT\u00ae (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lazertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson\u2019s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna and Merck Announce mRNA-4157 (V940) in Combination with KEYTRUDA\u00ae (pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III\/IV Melanoma Following Comple","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Obtains the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti\u00ae in Japan","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tusamitamab Ravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Announces Positive Phase III Results for Inavolisib Combination in People with Advanced Hormone Receptor-Positive, HER2-negative Breast Cancer with a PIK3CA Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Duality Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323\/DB-1303 in Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"DB-1303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Duality Biologics","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EZHARMIA\u00ae Showed Clinically Meaningful and Durable Responses in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma in VALENTINE-PTCL01 Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DAICHIRONA\u00ae FOR INTRAMUSCULAR INJECTION for Booster Vaccination Approved in Japan as Omicron XBB.1.5-adapted Monovalent mRNA Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Omicron XBB.1.5-adapted Monovalent mRNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Raludotatug Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b\/2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ifinatamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8\u00ae Treatment in VISIONARY-MS Trial Long-Term Open Label Extension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Organon","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organon\u2019s XACIATO (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Organon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Organon \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"12","companyTruncated":"Organon \/ .."},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to Test its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ATT001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Th.."},{"orgOrder":0,"company":"Fermion Oy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fermion Announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by China NMPA","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"FZ008-145","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Fermion Oy","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fermion Oy \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fermion Oy.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Proceeds to the Next Dose Level in the Phase I\/IIa Study Tumorad-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"[177Lu]Lu-SN201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces European Commission Approval of RYSTIGGO\u00ae (rozanolixizumab) for the tReatment of Adults with Generalized Myasthenia Gravis in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rozanolixizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nucala (mepolizumab) Approved in China for Use in Severe Asthma with An Eosinophilic Phenotype","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharma Marks In-House Radiopharma Manufacturing Success, Details PhII\/III Trial Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Akumentis Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akumentis Healthcare Launches Drug for Treatment of Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Akumentis Healthcare","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Akumentis Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akumentis .."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ELI-002 7P","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results Expected in March 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson\u2019s Disease in Addition to Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"COYA 302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution for the Treatment of Non-infectious Uveitis including Uveitic Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TOXINS 2024: Galderma\u2019s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow\u2019s Feet Simultaneously","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Na\u00efve Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Quemliclustat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E\/R4","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Takeda\u2019s HYQVIA\u00ae as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Melphalan Hydrochloride for Injection in the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"POLB001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poolbeg Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Ligelizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Declines to Approve Shin Nippon Biomedical's Migraine Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1\/2 Clinical Trial in some European Countries","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Grants Full Approval for BALVERSA\u00ae to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ's Newest PNH med Voydeya Approved in Japan","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna Accelerates into Another FDA Fast Track","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1 B\/2 A Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEES)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s AskBio Initiates Phase II GenePHIT Trial in Congestive Heart Failure (CHF)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-1002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Eylea' 8 mg Approved in EU","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Marketing Authorization Application for Lecanemab in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab-irmb","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PRX123","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Soligenix \"Fast Track\" Designation for Dusquetide in the Treatment of Oral Lesions of Beh\u00e7et's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dusquetide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-CLR 121225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Iopofosine I-131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Nanoform","sponsor":"ONConcept\u00ae Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Nanoform \/ ONConcept\u00ae Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Completes Submission of Biologics License Application for CT-P47, a Biosimilar Candidate of ACTEMRA\u00ae (tocilizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data for Genentech\u2019s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"RS Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Thiostrepton","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RS Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RS Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RS Oncolog.."},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2\/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AVD-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aviceda Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aviceda Th.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Prademagene Zamikeracel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TYRA-300","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Tyra Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces Initiation of Phase IB \/ IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Chloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BST-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"NurExone Biologic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ExoPTEN","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NurExone Biologic","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NurExone Biologic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NurExone B.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Genmab","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genmab \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Linvoseltamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Announces Authorisation Of REZZAYO\u00ae (Rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency For the Treatment of Invasive Candidiasis in Adults1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Napp Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharm.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"UX111","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"FundaMental Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FundaMental Pharma GmbH Announces Publication of a Groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"FP802","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"FundaMental Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FundaMental Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FundaMenta.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MOB-015 is Launched in Sweden under the Brand Name Terclara- pharmacies Report Major Demand for the New Medication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Terbinafine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Reports Successful Results From ODF Cladribine Toxicity Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"PF614","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Statement on Discontinuation of Phase 3 ENHANCE-3 Study in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Soquelitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen\u00ae for the Treatment of Post-COVID Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AUTX-703","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Auron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Auron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Auron Ther.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Announces Complete Response Resubmission for IPX203 New Drug Application","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Carbidopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Human Acellular Vessel (HAV) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb\u2019s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Phase I Study for Relapsed and Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mosunetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for PARP Inhibitor, Talazoparib, Which is Approved for BRCA Gene Mutation-Positive Castration-Resistant Prostate Cancer with Distant Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Talazoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CSL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissmedic Authorises CSL's HEMGENIX\u00ae (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Etranacogene Dezaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CSL \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL \/ Not .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for The Indication of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Methylcobalamin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antiepileptic Drug Fycompa\u00ae Injection Formulation Approved in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Authorises GSK\u2019s Omjjara (momelotinib)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Reports Positive Topline Results for Nipocalimab from a Phase 3 Pivotal Study in Generalized Myasthenia Gravis (gMG) and a Phase 2 Study in Sj\u00f6gren\u2019s Disease (SjD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Lutathera\u00ae Significantly Reduced Risk of Disease Progression or Death by 72% as First-Line Treatment for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Scemblix\u00ae Shows Superior Major Molecular Response (MMR) Rates vs. Standard\u2010of\u2010care TKIs in Phase III trial for newly Diagnosed Patients with Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Asciminib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIVDAK\u00ae Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EZHARMIA\u00ae Supplemental New Drug Application Submitted in Japan for Patients with Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New long-term data for Roche\u2019s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission approves Roche\u2019s Tecentriq SC, the EU's first PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma Commences Yondelis\u00ae Commercialization in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NVG-2089","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Nuvig Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvig Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvig Ther.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Isaralgagene Civaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sangamo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Takeda\u2019s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Xspray Pharma\u2019s NDA-resubmission for Dasynoc\u00ae \u2013 PDUFA Date set to 31 July 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dasatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Xspray Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xspray Pha.."},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2\/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Epetraborole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therap.."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RadioMedix and Orano Med Receive FDA Breakthrough Therapy Designation for AlphaMedixTM in Gastroenteropancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"212Pb-DOTAMTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix.."},{"orgOrder":0,"company":"Oranomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NVL-655","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oranomed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oranomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oranomed \/.."},{"orgOrder":0,"company":"Trawsfynydd Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trawsfynydd Therapeutics Receives Approval for the First Patient Trial of TRX01, a Once-Daily Protease Inhibitor for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Travatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trawsfynydd Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trawsfynydd Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trawsfynyd.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma receives USFDA Approval for Deflazacort Tablets, 6 mg, 18 mg, 30 mg, and 36 mg","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Deflazacort","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Oligodendrocyte Progenitor Cell Therapy-1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"EDG-5506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves First CRISPR\/Cas9 Gene-Edited Therapy, CASGEVY\u2122 (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora for the Treatment of Severe Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyo","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TPN-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Transposon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor\u00ae (Rexlemestrocel-L) in Children With Congenital Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"ACTG","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ACTG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ACTG \/ ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"ACTG \/ Vii.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"BT524","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATA3219","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from First Patient in Kiromic BioPharma\u2019s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb\u2019s Application for Augtyro\u2122 (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iNtRON, Development of PHAGERIA\u00ae Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"P18-BE3CRC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"iNtRON Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iNtRON Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"iNtRON Bio.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Received U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Provides Update on Results from Pre-IND Enabling Studies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"OA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed\/Refractory AML and HR-MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RVU120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AusperBio Announces Major Progress in AHB-137 Clinical Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"AHB-137","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AusperBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AusperBio .."},{"orgOrder":0,"company":"ProJenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Prosetin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"ProJenX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ .."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RBI-4000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Replicate Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Replicate .."},{"orgOrder":0,"company":"SKINVISIBLE PHARMACEUTICALS INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"SKINVISIBLE PHARMACEUTICALS INC","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"SKINVISIBLE PHARMACEUTICALS INC \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SKINVISIBL.."},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101\/GSK4527226 in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"GSK4527226","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Latozinemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis in the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OrphAI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI The.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sudocetaxel Zendusortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Basal Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Kurome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORRECTING and REPLACING Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"KME-0584","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kurome Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kurome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kurome The.."},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyros Pharmaceuticals Announces Positive Outcome of the European Decentralised Procedure for Approval of VIGZIP\u2122 (vigabatrin oral solution)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pyros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Phar.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RP-1664","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"OVX033","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PADCEV\u2122 (Enfortumab Vedotin (Genetical Recombination)) with KEYTRUDA\u00ae (Pembrolizumab (Genetical Recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Enfortumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"HealthBioAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HealthBioAI Announces the Acceptance by the Food and Drug Administration (FDA) to Proceed with a Randomized Clinical Trial for the Treatment of Long COVID\/Post Acute Sequelae of COVID (PASC) with Selzentry\u00ae (maraviroc) in Combination with Lipitor (atorvas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Maraviroc","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HealthBioAI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HealthBioAI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"HealthBioA.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olezarsen Receives Orphan Drug designation from U.S. FDA for Familial Chylomicronemia Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Olezarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin for Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mizagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Vogenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ N.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin launches Ganirelix Acetate Injection in US","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ganirelix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eplontersen granted U.S. FDA Fast Track Designation for Patients with Transthyretin-mediated Amyloid Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Eplontersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DA-1726","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto\u00ae Tablet","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE\u00ae Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Regulatory Application for Shingrix for the Prevention of Shingles in at-risk Adults Aged 18 and Over Accepted for Review by China National Medical Products Administration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Zoster Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Receives US FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Bepirovirsen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance\u2019s AMTAGVI\u2122 (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAGRISSO\u00ae (osimertinib) with the Addition of Chemotherapy Approved in the US for Patients with EGFR-mutated Advanced Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NAN-101","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sibeprenlimab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves Xolair\u00ae (omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT (amivantamab), in combination with Lazertinib, for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"NMDP","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMDP Announces Enrollment of First Patient in OPTIMIZE Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NMDP","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NMDP \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NMDP \/ Not.."},{"orgOrder":0,"company":"Mestag Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"M300","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mestag Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mestag Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mestag The.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Sairiyo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cepharanthine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sairiyo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sairiyo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sairiyo Th.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Announces U.S. Launch of UDENYCA ONBODY\u2122 a Novel and Proprietary State-of-the-Art Delivery System for Pegfilgrastim-cbqv","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"NOVOS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longevity Company, NOVOS, Launches Daily Chew That Optimizes and Maintains Essential Organ Function","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Trehalose API","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"NOVOS","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"NOVOS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NOVOS \/ No.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ad5 CEA\/MUC1\/Brachyury Vaccine Tri-Ad5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Expert Systems","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Eiletoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Expert Systems","highestDevelopmentStatusID":"6","companyTruncated":"Eilean The.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Initiates Phase 1 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Volasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable La.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Significant Survival Benefit With CNM-Au8\u00ae Treatment in ALS EAP Compassionate Use Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"IgGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgGenix Presents Groundbreaking Research Using its SEQ SIFTER Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IGNX001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IgGenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ .."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB has Completed a Successful End-of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"OncoC4","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1\/2 Trial of BioNTech-partnered BNT316\/ONC-392 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Gotistobart","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoC4","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"OncoC4 \/ B.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and Teva Announce U.S. Approval of SIMLANDI\u00ae (adalimumab-ryvk) Injection, the First Interchangeable High-concentration, Citrate-Free Biosimilar to Humira\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Receives Approval to Commence its Phase I\/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen's QALSODY\u00ae (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CHIKV VLP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legend Biotech Announces Positive CHMP Opinion for CARVYKTI\u00ae (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Receives CHMP Positive Opinion for KALYDECO\u00ae for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl\u00ae (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia Due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PassPort Technologies, Inc. Initiated US Phase I Clinical Trial of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"PassPort Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort T.."},{"orgOrder":0,"company":"Oscotec","sponsor":"ADEL Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oscotec\/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ADEL-Y01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Oscotec","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oscotec \/ ADEL Inc","highestDevelopmentStatusID":"6","companyTruncated":"Oscotec \/ .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn\u00ae in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MSC-NTF Cell Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer\u2019s Disease Trial Sponsored by AriBio Co., Ltd.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirodenafil dihydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ N.."},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Ph.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Launches Icosapent Ethyl Acid Soft Gel Capsules in Partnership with Amneal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Strides Pharma Science \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PST-809","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"PulseSight Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PulseSight Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"PulseSight.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Aims to Launch First New Drug in US by Early 2026","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Saroglitazar magnesium","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TNX-1500","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Govorestat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic\u00ae\/Wegovy\u00ae and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Med.."},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fresenius SE & Co. KGaA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"SKY-0515","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Skyhawk Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"PL9643","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FETROJA\u00ae (cefiderocol) Approved by TFDA in Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"SciSparc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"SciSparc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva\u00ae (obeticholic acid) for the Treatment of PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces FDA Has Lifted Clinical Hold","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Leronlimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DONESTA\u00ae Safety Study for Menopause Completes Treatment Phase and Advances to Data Management & Reporting Phase","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces New Efficacy Analysis Comparing BRUKINSA\u00ae vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATA3219","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Celanese","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celanese Announces Commercial Launch of Glaukos' iDose\u00ae TR (Travoprost Intracameral Implant) Using Celanese's VitalDose\u00ae Ethylene Vinyl Acetate (EVA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Celanese","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO\u00ae for RSV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin\u2019s Lymphoma and Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"5-MeO-DMT","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biomind Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind La.."},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Co.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an Anti-IL-4R\u03b1\/TSLP Bispecific Antibody) in Australia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI3002","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"LISCure Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LISCure Biosciences Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of LB-P8 for Primary Sclerosing Cholangitis (PSC)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"LB-P8","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"LISCure Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LISCure Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LISCure Bi.."},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SN BioScience Received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScie.."},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"ATT001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ariceum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ariceum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ariceum Th.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IMNN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Launches Obesity Treatment Wegovy in Japan","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Alumis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"A-005","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alumis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ N.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA\/B Antibody, CLN-619, for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-619","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar\u00ae Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect\u2122 Injector","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Corticotropin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zevorcabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"JAB-30300","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Reports Completion of ODF Cladribine PK Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RYBREVANT\u00ae (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK MHRA Approves New Formulation of Amgen\u2019s XGEVA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Boston Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boston Scientific","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Boston Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boston Sci.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incannex H.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019s Protein-based Non-mRNA COVID-19 Vaccine Available Now as Additional Dose for Individuals Aged 65 and Older Following U.S. CDC Advisory Committee Recommendation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NVX-CoV2601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Fezolinetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hugel Receives U.S. FDA Approval for Its Botulinum Toxin Letybo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Botulinum Toxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Hugel","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hugel \/ Si.."},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CBL-514","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR-Positive, HER2-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"GRI Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"GRI Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VAX-24","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxcyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ .."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invitation to Participate in STOP-PC Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Oncotelic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncotelic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"QRX003","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Quoin Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial Designed to Support Potential Accelerated Approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirdametinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LN-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents New Data on Safety and Efficacy of Zolgensma, Including Maintained and Improved Motor Milestones in Older and Heavier Children with SMA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimers Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics and Innovent Announce China\u2019s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Phase I Clinical Trial Findings of a Cabotegravir Long-acting Injectable Investigational Formulation Allowing at Least Four Months Between Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Glycomine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"GLM101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Glycomine","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Glycomine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glycomine .."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Phase 2 GvHD Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CYP-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ AimMax Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"Valo Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"OPL-0401","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valo Healt.."},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BC 007","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berlin Cures \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cur.."},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Landmark Clinical Approval for YOLT-201 Obtained by the NMPA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"YOLT-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"YolTech Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Th.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR\u2122 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Del-desiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-01","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b\/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Crossbow Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CBX-250","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Crossbow Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crossbow Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Crossbow T.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives FDA Approval for First and Only Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Reports Significant EEG Improvement in Alzheimers Patients Treated with XPro","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LP-410","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified Humanized Anti-CD40L mAb) Supports Monthly I.V. Dosing in Humans","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"TNX-1500","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH\/MASH with Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces First Clinical Data from 90mg Dosing of Efti","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allyx Therapeutics Announces Expansion into Parkinsons Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ALX-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Allyx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Allyx Ther.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Alnylam Report Positive Topline Results from The Phase II Kardia-2 Study in People with Hypertension, Demonstrating Clinically Significant Blood Pressure Reductions with Zilebesiran when Added to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zilebesiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA\u00ae as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk A\/S: Semaglutide 1.0 mg Demonstrates 24% Reduction in the Risk of Kidney Disease-related Events in People with Type 2 Diabetes and Chronic Kidney Disease in the FLOW trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Grace Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grace Science, LLC Announces First Patient Treated in Phase 1\/2\/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"GS-100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grace Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Scie.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Elebsiran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Nielsen BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Candida albicans Skin Test Antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nielsen BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nielsen BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nielsen Bi.."},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Aluminum Hydroxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ankyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra The.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Indicates Completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhotonPharma, Inc. Receives FDA Clearance for a First in Human Clinical Study for Stage III\/IV Ovarian Cancer Treatment with the Investigational Autologous Vaccine Therapy, Innocell\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Personalized Vaccine Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PhotonPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PhotonPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PhotonPhar.."},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laminar Pharmaceuticals S.A. Receives Recommendation from The Independent Data Monitoring Committee to Advance to the Next Stage of CLINGLIO, the Phase 2b\/3 Clinical Trial of LAM561 in Combination with RT and TMZ for Adults with Newly Diagnosed Glioblasto","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"2-Hydroxyoleic Acid (2-Ohoa); Idroxioleic Acid, Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laminar Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Ph.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Rezpegaldesleukin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elysium Therapeutics Announces Compelling Human Proof-of-Concept Data for its SMART\u2122 Opioid, O2P Hydrocodone Prodrug for Acute Pain that Could Disrupt the Industry by Establishing New Standards for Opioid Safety","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"O2P Hydrocodone Prodrug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Elysium Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elysium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Th.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Announces New Positive Initial Efficacy Data from Affinity Duchenne\u00ae Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed\/Refractory Indolent Non-Hodgkin's Lymphoma In China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"BI-1206","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports New Preclinical Data on Antitumor Effects of Nadunolimab in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Lexaria Bioscience","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexaria Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Lexaria Bi.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Submits Application to the European Medicines Agency for DARZALEX\u00ae (daratumumab)-based Quadruplet Therapy for the Treatment of Patients with Transplant-Eligible, Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"MiNK-215","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MiNK Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MiNK Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Selects EVERSANA\u00ae to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA\u00ae (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ersodetug","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psyence Biomedical's Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psyence \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPrint\u00ae Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1\/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ECUR-506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma: First Patient Dosed in Phase 1\/2 study of IPH6501 in Relapsed \/Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IPH6501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IPH45","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1\/CTLA-4) Combined with Chemotherapy Versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 Negative NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO\u00ae","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Naltrexone Methobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Injection","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces that Screening in the NATiV3, Phase III, Clinical Trial Evaluating lanifibranor in NASH has Resumed","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer\u2122s and Parkinson's Diseases and Related Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Persica Pharmaceuticals Completes Recruitment into Modic Trial Assessing Efficacy of PP353, to Treat Chronic Lower Back Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PP353","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Persica Ph.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Opdivo\u00ae (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Debio 0123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association\u2019s Adopted Name Council for \u201cNelitolimod\u201d as the Nonproprietary Drug Name for SD-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nelitolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"CERo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CER-1236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CERo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CERo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CERo Thera.."},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Verekitug","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream B.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphyn Announces Positive Results from Second Cohort of Phase 2a Clinical Trial in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zabalafin Hydrogel","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alphyn Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Bio.."},{"orgOrder":0,"company":"Gabather","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gabather reports Initial Positive Results from the EEG\/fMRI Target Engagement Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"GT-002","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gabather \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation for iOnctura's First-in-class Autotaxin Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cambritaxestat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG.APV-527","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s Obesity Pill Bests Wegovy in Early Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Amycretin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Visen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Visen Phar.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"KT-621","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"TT-00420","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TransThera.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wegovy\u00ae Receives FDA approval for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antion Biosciences Announces Latest Data and Validation of Its Technology Platform Through Important Milestone Achievements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"miCAR7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antion Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Bio.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Completes Submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an Interchangeable Biosimilar Candidate of XOLAIR\u00ae (omalizumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura\u00ae) in Patients with Mild-to-Moderate Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces Acceptance of VELSIPITY\u00ae New Drug Application in Macau","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Etrasimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Phase I Clinical Trial for Parkinson\u2019s Disease Continues to Show Positive Trends at 18 Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"More Than Two-Thirds of People with Atopic Dermatitis and Skin of Color Experienced Skin Improvement in a First-Of-Its-Kind Lebrikizumab Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"TERN-701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ .."},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ALX-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Ther.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b\/3 Clinical Trial of Izokibep in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Acelyrin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Izokibep","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI\u00ae (sparsentan) for the Treatment of IgA Nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praluent\u00ae (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Alirocumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NX-2127","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Rhenium (186 Re) Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"VTX3232","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Replay Bio","sponsor":"Syena","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replay's Cell Therapy Product Company Syena Announces First Patient Dosed in Phase 1\/2 study of TCR-NK Cell Therapy for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Replay Bio \/ Syena","highestDevelopmentStatusID":"7","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3\/IL-1\u03b2 Pathway Inhibitor","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"MRT-8102","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Press Release: New Phase 2b rEsults for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Ranok Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ranok Therapeutics Expands Clinical Testing of CHAMP\u00ae BRD4 Protein Degrader RNK05047 to China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"RNK05047","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ranok Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ranok Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ranok Ther.."},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"SNV1521","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Synnovation Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synnovatio.."},{"orgOrder":0,"company":"Ribometrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ribometrix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ribometrix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ribometrix.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Approved to Initiate First Patient Trial with Balamenib (ze63-0302), a Selective Best-In-Class Menin Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Balamenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eilean Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eilean The.."},{"orgOrder":0,"company":"10xbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Polidocanol","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ N.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA\u00ae (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Empowerpharm Awaits Phase Ii Clinical Trial on Groundbreaking Treatment to Manage Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPha.."},{"orgOrder":0,"company":"ImmunAbs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IM-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ImmunAbs","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunAbs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunAbs \/.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon\u00ae","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Submits Supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA\u00ae (guselkumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Announces Early Safety Data from the Company\u2019s Phase 1b\/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study\u2019s Initial Pre-Specified Objective","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Interleukin-6","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biktarvy\u00ae Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces Positive Results from DREAMM-8 phase III trial for Blenrep Versus Standard of Care Combination in Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Belantamab Mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Shows JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PN-235","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS\u00ae Regimen in Patients with Relapsed\/\u200bRefractory Diffuse Large B-cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UPDATE -- Fractyl Health Announces New Results From Its Rejuva\u00ae Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db\/db Mouse Model of Diabetes and Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"RJVA-001","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fractyl Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl He.."},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"AST-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astrocyte Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte .."},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Arctic Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"AT-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Nacuity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Arctic Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Nacuity Ph.."},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"SIRPant-M","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Im.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and\/or ASCVD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1\/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus Provides Business Update and Outlook for Vididencel Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Vididencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tuvatexib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Vidac Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Phar.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Announces Completion of 12-week Phase 2 RAINBOW Study Evaluating Lead Asset Nizubaglustat in Rare Disease Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nizubaglustat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Pridopidine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NTX-470","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nutcracker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker.."},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Ph.."},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroGenesis Reports Positive Results from Phase 2 Extension Study in Progressive Multiple Sclerosis Treated with NG-01 Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NG-01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroGenesis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenes.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces Availability of ORGOVYX\u00ae (relugolix) in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Relugolix","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1\/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU410","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I\/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Enekinragene Inzadenovec","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ZL-1310","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals\u2019 LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"SPN-820","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Xcovery","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ensartinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Xcovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xcovery \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xcovery \/ .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Mezagitamab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LYT-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Zerlasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s PREVENAR 20\u00ae to Help Protect Infants and Children Against Pneumococcal Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Alzprotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Feedback From the EMA and FDA on Alzprotect's Phase 2b\/3 Development Strategy for PSP","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ezeprogind","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alzprotect","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alzprotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzprotect.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"P-BCMA-ALLO1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Announces Positive Results from Phase 2 Study of ION224, An Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH\/MASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ION224","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNxt Reports Successful Results From ODF Cladribine PK Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Bionxt Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Launches Anti-Cancer Generic Drug Olaparib in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Announces Pivotal Study for Anaphylm\u2122 (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Resmetirom","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HepaRegeniX Publishes Data for Its First-In-Class MKK4 inhibitor HRX-215 for the treatment of Acute and Chronic Liver Diseases in Cell","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"HRX-215","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"HepaRegeniX","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HepaRegeniX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HepaRegeni.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NXP800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Doses Next Cohort in Phase I\/II Trial of RECCE\u00ae 327 for Urinary Tract Infections and Urosepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers, Accepted for Presentation at the 2024 ESMO Sarcoma and Rare Cancers Congres","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"LX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lirum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Ther.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Elritercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1\/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Atrogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ATR-258","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Atrogi","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atrogi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atrogi \/ N.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE\u00ae (Vamorolone) in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Bristol Myers Squibb\u2019s Breyanzi\u00ae as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives FDA Approval for TEVIMBRA\u00ae for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Doses First Patient in Phase 1\/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"NUV-1511","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nesvategrast","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OcuTerra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra T.."},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ETX-19477","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"858 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"858 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"858 Therap.."},{"orgOrder":0,"company":"Gynica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gynica Announces First-in-Human Clinical Trial of Novel IntraVag\u00a9 Treatment for Endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabinoid-based Drug","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Gynica","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gynica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gynica \/ N.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Presents New Human Data Further Supporting CAN10 in the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Submission of Leqembi\u00ae (lecanemab-irmb) sBLA for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA Completed","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Cayman Pharma s.r.o","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cayman Update on its Dental Implant candidate KMN-159 for Osseointegration","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"KMN-159","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Pharma s.r.o","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cayman Pharma s.r.o \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Pha.."},{"orgOrder":0,"company":"Eisai","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Eisai","amount2":0.029999999999999999,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Ka.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Vector Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides, Vector partner to distribute Oncopeptides\u2019 Pepaxti in MENA region to treat multiple myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncopeptides \/ Vector Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"XOMA","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO\u00ae Royalties","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Financing","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"XOMA","amount2":0.14000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"XOMA \/ Blue Owl Capital","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ Blu.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"TC BioPharm Announces Closing of $3.5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syros Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Syros Pharmaceuticals \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Neurogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Merger","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neoleukin Therapeutics \/ Neurogene","highestDevelopmentStatusID":"7","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"TC BioPharm Announces Pricing of $3.5 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"ImmunogenX","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Merger","leadProduct":"Latiglutenase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunogenX \/ First Wave BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"ANX007","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0.13,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Annexon Biosciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Indian firm Intas Pharma Inks New Licensing Agreement for Treating Autoimmune Diseases in 150+ Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Tolimidone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Evercore ISI","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"SL-172154","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Shattuck Labs \/ Evercore ISI","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$21.2 million","upfrontCash":"Undisclosed","newsHeadline":"HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Financing","leadProduct":"HB-500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"LianBio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanobiotix Partner LianBio Assigns its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"LianBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"LianBio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Atreca","sponsor":"Immunome","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"$5.5 million","newsHeadline":"Immunome to Acquire Antibody-Related Assets and Materials from Atreca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"APN-497444","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Atreca \/ Immunome","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ I.."},{"orgOrder":0,"company":"Hemispherian","sponsor":"Research Council of Norway","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Hemispherian Awarded NOK 16M Grant from the Research Council of Norway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"GLIX5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemispherian \/ Research Council of Norway","highestDevelopmentStatusID":"4","companyTruncated":"Hemispheri.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Xuanzhu Biopharma","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"KM-501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xuanzhu Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xuanzhu Biopharma \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Xuanzhu Bi.."},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Crohn\u2019s and Colitis Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Funding","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Giiant pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Giiant pharma \/ Crohn\u2019s and Colitis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Giiant pha.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"SunRock Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SRB19","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ SunRock biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taro Announces Merger Agreement with Sun Pharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharm.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$11.2 million","newsHeadline":"Cresemba\u00ae Sales in Latin America Trigger First Sales Milestone Payment to Basilea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TransCode Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Mass General Brigham","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Announces Strategic Collaboration with Mass General Brigham","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Mass General Brigham","highestDevelopmentStatusID":"2","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Partners with Pfizer to Launch Abrocitinib in India to Treat Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"Abrocitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Inoviv","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inoviv Secures Investment to Expand Quantitative Proteomics Product Offerings to Accelerate Drug Development Pipelines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Financing","leadProduct":"HER-096","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Inoviv","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inoviv \/ Hoxton Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Inoviv \/ H.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Partners with Legochem Biosciences for ADC Development and Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"LCB73","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ LegoChem Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiwan Toyo Obtains Exclusive License for New Soft Tissue Sarcoma Drug Yondelis\u00ae in Taiwan, Hong Kong and Macau","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$441.8 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Licenses a New Compound as Part of its Commitment to People Living with Fibro-Inflammatory Diseases\u200b from Kyowa Kirin","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyowa Kirin","amount2":0.44,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"HDT Bio Receives $749,000 EZBAA Contract and Partners with BARDA Under Project NextGen's Enabler's Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Partnership","leadProduct":"HDT-521","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HDT Biotech \/ BARDA","highestDevelopmentStatusID":"5","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vesper Bio Awarded Grant by The Michael J. Fox Foundation to Assess Sortilin Inhibitors in the Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"VES001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Vesper Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vesper Bio \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Vesper Bio.."},{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ .."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Alberta Cancer Foundation Announces Initial Investment of its Novel Philanthropic Breakthrough Fund to Support Early-Stage Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Alberta Cancer Foundation Announces Initial Investment of its Novel Philanthropic Breakthrough Fund to Support Early-Stage Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"48Hour Discovery \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Dis.."},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Agence Nationale de la Recherche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress its Proprietary CCR8 Antibody Candidate to the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Funding","leadProduct":"DT-7012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Domain Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domain Therapeutics \/ Agence Nationale de la Recherche","highestDevelopmentStatusID":"4","companyTruncated":"Domain The.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Divestment","leadProduct":"EB-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Zolmitriptan","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harrow Completes Transfer of the TRIESENCE\u00ae New Drug Application","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.13,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Steroid","amount2New":0.13,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"$225.0 million","newsHeadline":"GSK, Vir End Flu Drug Alliance, Removing Key Piece of $345M Pact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Termination","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0.34999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Kamau Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"Nulabeglogene Autogedtemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Graphite Bio \/ Kamau Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Novo Holding","pharmaFlowCategory":"D","amount":"$28.1 million","upfrontCash":"Undisclosed","newsHeadline":"Orbis Medicines Launches with \u20ac26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable \u2018nCycles\u2019","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbis Medicines","amount2":0.029999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Orbis Medicines \/ Novo Holding","highestDevelopmentStatusID":"3","companyTruncated":"Orbis Medi.."},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Private Placement","leadProduct":"IC 100-08","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Th.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$30.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kinnate Biopharma Inc. Sells its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Exarafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Turbine","sponsor":"Harmonic Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turbine \/ Harmonic Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA\/TEV-\u2019248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Launch Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA\/TEV-\u2019248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0.14999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Powder for Inhalation","sponsorNew":"Teva Pharmaceutical Industries \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ TD Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Meridian Medical Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meridian Medical Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"12","companyTruncated":"Meridian M.."},{"orgOrder":0,"company":"Surrozen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$192.5 million","upfrontCash":"Undisclosed","newsHeadline":"Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"SZN-043","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0.19,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Surrozen \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Perceptive Advisors LLC","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Perceptive Advisors LLC","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merz Enters Asset Purchase Agreement With a US-based Biotech Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.19,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.19,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Cipla","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, Cipla Enters into Exclusive Distribution Partnership to Expand Reach of CNS Portfolio in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"Clobazam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cipla \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Sa.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$41.2 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Onconova Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-class Virology and Oncology Company","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Merger","leadProduct":"Viroksavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Traws Pharma \/ Onconova Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Traws Phar.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Be Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"B Cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Be Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora Pharmaceuticals Completes Acquisition of Upsher-Smith","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Amantadine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Bora Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smi.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,903.5 million","upfrontCash":"$45.0 million","newsHeadline":"Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"NX-0479","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nurix Therapeutics","amount2":1.8999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Luveltamab Tazevibulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Sutro Biopharma \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen and Sutro Biopharma announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"STRO-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Traws Pharma","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Viroksavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Traws Pharma \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"Traws Phar.."},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SEARCHLIGHT PHARMA INC","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"SEARCHLIGH.."},{"orgOrder":0,"company":"Modulus Therapeutics","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Acquires Modulus Cell Therapy Platform Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Modulus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Modulus Therapeutics \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Modulus Th.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARCA biopharma and Oruka Therapeutics Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA biopharma and Oruka Therapeutics Announce Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Oruka Therapeutics \/ Fairmount","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Ther.."},{"orgOrder":0,"company":"Diagonal Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$128.0 million","upfrontCash":"Undisclosed","newsHeadline":"Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Diagonal Therapeutics","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Diagonal Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"4","companyTruncated":"Diagonal T.."},{"orgOrder":0,"company":"CancerVAX","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CancerVax Launches $5 Million Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CancerVAX","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"CancerVAX \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"CancerVAX .."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,800.0 million","newsHeadline":"Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":1.8,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"SpliSense","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"SPL84","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliSense","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ CF Foundation","highestDevelopmentStatusID":"7","companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Conformation-X Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"Undisclosed","newsHeadline":"Conformation-X Therapeutics Bolts Out of Stealth, Securing Over $13.5M in Funding to Propel its Innovative Immune-Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Conformation-X Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Conformation-X Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Conformati.."},{"orgOrder":0,"company":"Neurosterix","sponsor":"Perceptive Xontogeny Venture Fund II","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurosterix Launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Neurosterix","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Neurosterix \/ Perceptive Xontogeny Venture Fund II","highestDevelopmentStatusID":"4","companyTruncated":"Neurosteri.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Merger","leadProduct":"IFx-2.0","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kintara Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Human Biome Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to Validate it","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"HBI-06","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Human Biome Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Human Biome Institute \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Human Biom.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Announces a Delay in the Initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Aramchol Meglumine","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galmed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Chengdu Origen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2201 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"KH631","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Chengdu Origen Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu Origen Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Or.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT\u00ae (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Enrolled in Phase 1 Study of MRX-5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Benzodiazepine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MicuRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pha.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen\u00ae for the Treatment of Post-COVID Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Launches ORLADEYO\u00ae (berotralstat) in Spain","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces First Patient Dosed in Pediatric Clinical Trial for Children Aged 1 to 6 Years for Leniolisib","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Hyrimoz\u00ae (adalimumab) High-Concentration Formulation in Europe, Aiming to Improve Patient Care","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight\u2019s Enzymatic Doggybone DNA used in the Manufacture of Versameb\u2019s VMB-100 for First-in-human Clinical Study","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VMB-100","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin\u00ae Softgels","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Ambio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Fermentation Inc. \/ Ambio","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fer.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals dIscontinues Cobitolimod Phase III Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Ainos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ainos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ No.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CM-101","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB\u00ae with Potential Advantages Compared to Cal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alladapt Immunotherapeutics Receives FDA Fast Track Designation for ADP101 for the Treatment of Mono- and Multi-Food Allergies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Alladapt Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Angany","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Favorable Safety Results From First Subjects of ANGANY\u2019s New Biologic Against Allergy to Cats, Clinical Study to Move Ahead","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ANG-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Angany","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Angany \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Angany \/ N.."},{"orgOrder":0,"company":"EirGenix","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EirGenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"EirGenix \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"EirGenix \/.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dendritic Cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Macrophage-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NBI-921352","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Voltron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VTX-0P4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voltron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voltron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voltron Th.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"MC2-25 VLS","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pyridoxal Phosphate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Medicure","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rexlemestrocel-L","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SBI-100","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Ethris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ETH47","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Ethris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ethris \/ N.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"CT-0525","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Announces FDA Acceptance of New Drug Application Filing for OX124, a High-dose Rescue Medication for Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Phase 1a\/1b Human Clinical Trial of NV-CoV-2, the Company\u2019s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets USFDA Nod for HIV drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Darunavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Polaris Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20\/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pegargiminase","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Polaris Group","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Polaris Gr.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 764532","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"DYAI-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dyadic International, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dyadic Int.."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NE3107","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1\/2 Adult Trial to Include Adolescent Rett Syndrome Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Arcutis\u2122 Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"PAS-004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"AMT-191","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Approval of ORLADEYO\u00ae (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verge Genomics Will Use Modality.AI in its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VRG50635","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verge Genomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Geno.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Positive Topline Results from Part 2 of the Phase 1b\/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"BX004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi\u00ae and Simponi Aria\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sequana Medical announces Positive Data from Non-Randomized Cohort in US Phase 1\/2a MOJAVE Study of DSR\u00ae 2.0 for Treatment of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Me.."},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vidac Pharma Reports in Vitro Results Showing VDA-1275 Compatible with Classical Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"VDA-1275","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vidac Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vidac Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vidac Phar.."},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qnovia, Inc. Announces Positive Results from First-In-Human Pharmacokinetic and Safety Study of Lead Asset QN-01, a Prescription Inhaled Smoking Cessation Therapy","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"QN-01","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ N.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LP659","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"OLX10212","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Group Announces New PDUFA Date for Givinostat DMD NDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Givinostat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"The Italfarmaco Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfa.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Announces First Patient Dosed in Phase 1b\/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"LX9211","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Patidegib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Biopharma Announces First Subject Dosed in Phase 1b\/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Receives Guidance From the FDA for the DONESTA\u00ae NDA Marketing Authorization Filing in The United States","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Galderma\u2019s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow\u2019s Feet and Frown Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s Application for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Inipharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inipharm Initiates Dosing in Phase 1 Study of its Small Molecule Inhibitor of HSD17B13","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"INI-822","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Inipharm","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inipharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inipharm \/.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Doses First Patients in Phase 1\/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Cybin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Deuterated Psilocybin Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Cybin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cybin \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybin \/ No.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Registrational Phase III CLARIFY Trial in Prostate Cancer Commences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Beh\u00e7et's Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dusquetide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciNeuro Completes Dosing in its Phase 1 Clinical Trial of SNP318, an Oral Therapeutic for Alzheimer's Disease and Other Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"SNP318","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"SciNeuro Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciNeuro Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciNeuro P.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Initiates Clinical Study to Evaluate Setanaxib in Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE\u00ae Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces argenx Receives European Commission Approval of VYVGART\u00ae SC with ENHANZE\u00ae for Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Halozyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASGEVY Gets Bahrain Approval for Treatment, Marking it Second Country in The World","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Exagamglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Ivabradine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Use of CRESEMBA\u00ae (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"DARA BIOSCIENCES","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tamoxifen Citrate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I\/ Phase II","graph3":"DARA BIOSCIENCES","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"DARA BIOSCIENCES \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DARA BIOSC.."},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VIPER-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Vittoria Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vittoria Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vittoria B.."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"KRRO-110","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Korro Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Korro Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTB-268","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Xilio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Linvoseltamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"MC2-25 CKD","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF\u03b1 Licaminlimab (OCS-02) in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Licaminlimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suspension\/Drops","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Group Announces Marketing Approval for PIVLAZ\u2122 (clazosentan sodium) 150 mg in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Clazosentan Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"NextPoint","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NPX887","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NextPoint","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextPoint \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NextPoint .."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Belzupacap Sarotalocan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lobe Sciences Provides Update on L-130 Clinical Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocin Mucate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lobe Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lobe Scien.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability\u2013High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LYNPARZA\u00ae (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+\/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4\/6 Inhibitors And Endocrine Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RGT-419B","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Regor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Regor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regor Ther.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces FDA Clearance of the INOmax\u00ae EVOLVE\u2122 DS Delivery System and Approval of the INOmax\u00ae (nitric oxide) Mini-Cylinder","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Bio-Thera Solutions' Avzivi\u00ae (bevacizumab-tnjn), a Biosimilar Referencing Avastin\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Announces Positive Topline Data from Phase 2 Signal Detection Study Evaluating Pitolisant in Adult Patients with Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vesper Bio doses First Volunteer in Phase I Study of First-In-Class Oral Treatment for Frontotemporal Dementia (FTD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VES001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vesper Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imlifidase Demonstrated Positive Safety, Tolerability, and Early Efficacy Outcomes in 15-HMedIdeS-09 Phase 2 Trial in Guillain-Barr\u00e9 Syndrome (GBS)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Spago Nanomedical's Clinical Phase I\/IIa Study within the Tumorad(R) Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Bluebird Bio","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExeGi Pharma Announces First Patient Enrollment in the PROF Trial of EXE-346","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"EXE-346","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ No.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VLA15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces Positive 12-month Safety and Efficacy Data from Ongoing Phase I\/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ATSN-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"Polaris Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20\/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polaris Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polaris Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polaris Gr.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Oxytocin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Immuron","sponsor":"US Naval Medical Research Command","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CampETEC","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ US Naval Medical Research Command","highestDevelopmentStatusID":"6","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces US FDA Approval for Podofilox Gel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Podophyllotoxin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Medefil","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medefil Announces Availability of FDA-Approved Emergency Syringes, Atropine Sulfate Injection, USP, and 10% Calcium Chloride Injection, USP","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Medefil","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medefil \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medefil \/ .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initiation of the STELLAR-305 Phase 2\/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed\/Refractory Multiple Myeloma or Relapsed\/Refractory Primary Plasma Cell Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CT071","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"TDM-180935","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerm.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"89Zr-DFO-girentuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Merck Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Provides Updates on Translarna Regulatory Activities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax's Updated COVID-19 Vaccine Now Authorized in Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NVX-CoV2601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Initiates Phase 1\/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"DF6215","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma USA: FDA Grants Expanded Approval to wilate\u00ae as the First VWF Concentrate for Prophylaxis in All Types of VWD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Denifanstat","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mission Therapeutics Granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"MTX325","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tradipitant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"EVM301","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GlucoCorticoid","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb\u2019s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic\u2026","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ALTO-300","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives FDA Approval for Fabhalta\u00ae (iptacopan), offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"FutuRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2\/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BSEN760","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"FutuRx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FutuRx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FutuRx \/ N.."},{"orgOrder":0,"company":"GRI Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (\u201cIPF\u201d)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GRI-0621","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"GRI Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Laboratories Inc. Announces Completion of Dosing of All Subjects in Sildenafil Oral Suspension Bioavailability Study and Initiation of Dosing in Companion Food-Effect Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm\u2122 (epinephrine) Sublingual Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity\u2019s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP\u00ae Companion Diagnostic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteal Therapeutics\u2019 VT-X7 Receives FDA\u2019s Breakthrough Therapy Designation for the Treatment of Periprosthetic Joint Infection of The Hip and Knee and Completes Enrollment of The Pivotal APEX-2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal The.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BDC-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte\u00ae Liquid Clinical Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris T.."},{"orgOrder":0,"company":"EsoCap","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EsoCap Reports Positive Topline Results from ACESO Phase II Trial Investigating ESO-101 in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EsoCap","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EsoCap \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EsoCap \/ N.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for The Treatment of Rare Cholestatic Liver Disease, PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"WVE-006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA\u00ae (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CNTY-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Century Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SOD1-ALS","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescendo Biologics Announces first U.S. Patients Dosed in Expanded Phase 1b Clinical Trial of CB307 for Patients with mCRPC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CB307","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Crescendo Biologics Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Crescendo Biologics Ltd \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crescendo .."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"RAG-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Deucrictibant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BI 771716","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CDR Life","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CDR Life \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"NBI-1117569","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TUKYSA\u00ae (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA\u00ae (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed\/Refractory Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"PDC*lung01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDC*line Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line P.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Initiates GlycoProteMim Trademark for Anti-Aging Molecule TFC-1326","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Alisertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA\u00ae (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Acella Pharmaceuticals","sponsor":"Milla Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A.forall Announces Launch of a Generic Version of Pyridostigmine Bromide Syrup","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pyridostigmine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Acella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Acella Pharmaceuticals \/ Milla Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acella Pha.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Data Monitoring Committee Recommends Continuing the Trial Evaluating Temelimab in Long COVID Without Any Modifications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Temelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GeNeuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Ropidoxuridine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shuttle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Ph.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY\u2122 in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Talquetamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"HMB-001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemab Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Ther.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers\u2019 Sensory Perceptions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharma.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Announces FDA Clearance of IND Application for Phase 1\/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM-6-415","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Receives FDA Clearance of IND to Begin Phase 1 Trial of Oncology Drug Candidate, GIGA-564, in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GIGA-564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"PrabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SI-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"SIRPant Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIRPant Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SIRPant Im.."},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel\u2122 (HAV\u2122) for the Treatment of Vascular Trauma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Humacyte","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"VQ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Vanqua Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanqua Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vanqua Bio.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADMA Biologics Announces FDA Approval for BIVIGAM\u00ae in the Pediatric Patient Setting for Those 2 Years of Age and Older","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADMA Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Suzhou OSAI Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suzhou OSAI Biopharma Announces Positive Phase III Clinical Trial Results for Lactobacillus Crispatus Live Bacteria Capsule, Significantly Reducing Recurrence of Gynecological Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Vaginal L. Crispatus Live Bacteria","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Suzhou OSAI Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Suzhou OSAI Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou OSA.."},{"orgOrder":0,"company":"Toragen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Toragen, Inc. Announced Positive Safety Data Update from Cohort 2 and the Initiation of its Dose Expansion of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toragen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ .."},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Obsidian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian T.."},{"orgOrder":0,"company":"SolasCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"SolasCure","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SolasCure .."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Initiates Phase \u2160 Clinical Trial for RSV Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SCB-1019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Plexium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plexium Initiates Dosing in Phase 1 Study of PLX-4545, a Potent and Selective Degrader of the Transcription Factor IKZF2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"PLX-4545","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Plexium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Plexium \/ .."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Reports Highlights of Randomized Phase 2 Cancer Vaccine Trial in Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISA Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Serplulimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Emavusertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Lykos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Ther.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scinai Announces Promising Results in a Psoriatic Human Skin Model","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan\u2019s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) Regulatory Application to Prevent RSV Disease in Adults aged 50-59 at Increased Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Jemperli (dostarlimab) Plus Chemotherapy Approved as The First and Only Frontline Immuno-oncology Treatment in the European Union for dMMR\/MSI-H Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)-based quadruplet Therapy Regimen Shows Significant Improvement in Outcomes for Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA\u00ae (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences gets USFDA Nod for Generic Cancer Treatment Capsules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB announces European Commission Approval of ZILBRYSQ[\u00ae]\u25bc (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives CHMP Positive Opinion for Rozanolixizumab for Treatment of Adults with Generalized Myasthenia Gravis in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rozanolixizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy More than Doubled Pathologic Complete Response Rate in Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers versus Chemotherapy Alone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Uvax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"UVAX-1107","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Uvax Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uvax Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Uvax Bio \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ablative Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ablative Solutions, Inc. Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine System\u2122 Kit for Patients with Uncontrolled Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Ethanol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ablative Solutions","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ablative Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ablative S.."},{"orgOrder":0,"company":"Scleroderma Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Scleroderma Research Foundation Announces the Launch of the CONQUEST Trial Platform and IND Clearance","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amlitelimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Scleroderma Research Foundation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scleroderma Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Scleroderm.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology & EVERSANA Announce U.S. Commercial Launch of FDA-Approved JYLAMVO, the First and Only Oral Methotrexate Solution Approved in the U.S. for Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shorla Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Solution","sponsorNew":"Shorla Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"ChemDiv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Trials Completion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AV5124","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"ChemDiv \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ .."},{"orgOrder":0,"company":"Alora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alora Pharmaceuticals, LLC Announces the Availability of Once-Daily Relexxii\u00ae for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Alora Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alora Phar.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"8MW0511","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Update on Phase I\/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AMT-130","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ANX1502","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Renexxion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Naronapride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Renexxion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renexxion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Renexxion .."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Completes Pediatric Study of ESTELLE\u00ae in Adolescent Patients","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Padeliporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Therapeutics Announces Full FDA Approval of TARPEYO\u00ae, the Only FDA-approved Treatment for Iga Nephropathy to Significantly Reduce the Loss of Kidney Function","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"CellOrigin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CellOrigin Announced Treatment of the First Patient with CAR-M in China and Reported the Second Generation of CAR-M for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SY001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CellOrigin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CellOrigin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CellOrigin.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Upamostat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"SciTech Development","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciTech Development Announces First Patient Dosed in Phase 1 Clinical Trial of ST-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech De.."},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase \u2162 Clinical Study of LNK01001","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"LNK01001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharm.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\u2019s Drug Candidate IRL757 is Phase I Ready","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IRL757","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1\/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CELZ-201-DDT","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Declines to Approve Merck's Chronic Cough Drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8\u00ae Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1\/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Gains FDA Alignment on Key Aspects of OCU400\u2014Modifier Gene Therapy\u2014Pivotal Phase 3 Study Design","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Label Update for Kite\u2019s Yescarta\u00ae CAR T-Cell Therapy to Include Overall Survival Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces China NMPA Approval of LIVTENCITY\u00ae (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Maribavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1\/2a Study of ARO-CFB for Complement Mediated Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-CFB","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed\/Refractory Patients with Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"TT-00420","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TransThera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TransThera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TransThera.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT\u00ae (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Amiselimod HCl","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma Announces European Approval of REZZAYO\u00ae (rezafungin) for the Treatment of Invasive Candidiasis in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APL-2301, a Compound Developed by Asieris for the Treatment of Acinetobacter Baumannii Infection, was Approved for Phase I Clinical trials in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"APL-2301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Declines to Approve Zealand Pharma's Drug for Low Blood Sugar in Infants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"OLX75016","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Cellusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"CLS001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Cellusion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellusion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellusion .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Glepaglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hyloris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB\u00ae for Acute Treatment of Migraine With or Without","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Celecoxib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Updates the Status of its Phase 1\/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"ONCT-808","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Biocytogen","sponsor":"CtM Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1\/HLA-A02","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ CtM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Live Nonreplicating Smallpox and Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON Files IND Application to Begin Human Testing of IMNN-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"IMNN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma Gets Tentative USFDA Nod for Breast Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ribociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"FG-3246","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telomir Pharmaceuticals\u2019 Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Ph.."},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass P.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SYS6002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Abiprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Live Nonreplicating Smallpox and Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Expands Approval of Bristol Myers Squibb\u2019s Reblozyl\u00ae (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Luspatercept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL\u00ae Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cross-linked Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nordic Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nordic Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nordic Pha.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"D&D Pharmatech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH\/MASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"DD01","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"D&D Pharmatech","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"D&D Pharmatech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"D&D Pharma.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sj\u00f6gren's Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals' Fanapt\u00ae (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Iloperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Infinant Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinant Health Announces Submission of Orphan Drug Designation Application","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"INF108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infinant Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Infinant H.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NPRL2 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"YOLT-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"YolTech Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Th.."},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharm.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concept Medical Receives US FDA IDE Approval for Magictouch AVF Indication, Their Fifth Us Clinical Study Approval for the Magictouch Portfolio","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx Completes Dosing of Last Patient in Phase 2 Clinical Study of Mizagliflozin for the Treatment of Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Mizagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Vogenx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Vogenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vogenx \/ N.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Brepocitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EVX-B1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-positive, HER2-negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VERVE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Eyestem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyestem to Begin Human Trials for its Pioneering Dry AMD Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"iPSC-derived Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eyestem","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eyestem \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eyestem \/ .."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Vobramitamab Duocarmazine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EBX-102-02","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiot.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ALTO-203","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REJOICE-Ovarian01 Phase 2\/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Raludotatug Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos Receives Permanent J-code for iDose\u00ae TR (travoprost intracameral implant)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"LENZ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Aceclidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"LENZ Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"LENZ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LENZ Thera.."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Partner Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics' Leukine\u00ae (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sargramostim","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Nobelpharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nobelpharma \/ Partner Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Nobelpharm.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces US FDA Approval of Antibiotic ZEVTERA\u00ae (ceftobiprole medocaril) for Three Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ceftobiprole Medocaril","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NBI-1070770","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Initiates Global Phase 3 Registrational Trial (TEMPO Study) of Pitolisant in Patients with Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denovo Biopharma Announces a Major Breakthrough in Treatment-Resistant Depression with Precision Medicine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Liafensine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"SpliSense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SPL84","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliSense","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"SpliSense \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1\/2 Interim Data on Moderna\u2019s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-3927","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ACD137","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Hangzhou Jiuyuan Gene Engineering","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First Biosimilar Ozempic Drug Applies for Approval","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hangzhou Jiuyuan Gene Engineering","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Jiuyuan Gene Engineering \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou J.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST a Modifier Gene Therapy in GARDian Study for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV5-hRORA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Gritstone bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2\/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Gritstone bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gritstone bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gritstone .."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SZN-043","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Disc medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bitopertin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Disc medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Disc medic.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SGT-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"AudioCure Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sudden Hearing Loss: AudioCure's Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AC102","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AudioCure Pharma","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"AudioCure Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AudioCure .."},{"orgOrder":0,"company":"Asha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ASHA-624","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Asha Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Asha Thera.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2\/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Inaxaplin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VOYDEYA\u2122 Approved in the US as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viatris Announces the Launch of RYZUMVl\u2122 (Phentolamine Ophthalmic Solution) 0.75% in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Padagis","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve\u00ae Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Padagis \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ .."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Zai Lab \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Povorcitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioLineRx Announces $6 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$1,680.0 million","upfrontCash":"$80.0 million","newsHeadline":"CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY\u00ae T-Cell Engaging Bispecific (TCB) Collaboration with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":1.6799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Mabxience","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabxience \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience .."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"RNAa-based Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"3","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Odyssey Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Odyssey Th.."},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aethon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aethon Therapeutics \/ Revolution Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Aethon The.."},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"EnteroBiotix Completes \u00a327m Financing Round to Advance Clinical Trials","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"EBX-102-02","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"EnteroBiotix","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"8","companyTruncated":"EnteroBiot.."},{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","amount":"$61.3 million","upfrontCash":"Undisclosed","newsHeadline":"French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac\u00ae and Parkinane\u00ae LP to CNX Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Divestment","leadProduct":"Loxapine Succinate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eisai","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eisai \/ CNX Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ CN.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Bilthoven Biologicals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech, Bilthoven Biologicals Collaborate for Oral Polio Vaccines Production, Supply","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Live, Attenuated Polio Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bharat Biotech \/ Bilthoven Biologicals","highestDevelopmentStatusID":"12","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Wellington Management","pharmaFlowCategory":"D","amount":"$160.5 million","upfrontCash":"Undisclosed","newsHeadline":"Obsidian Therapeutics Rakes in $160M for Solid Tumor Cell Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series C Financing","leadProduct":"OBX-115","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Obsidian Therapeutics \/ Wellington Management","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian T.."},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$132.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alterome Raises $132M to Take Next-Gen Cancer Drugs Aimed at The 'Undruggable' into Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Alterome Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Alterome Therapeutics \/ Goldman Sachs","highestDevelopmentStatusID":"5","companyTruncated":"Alterome T.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Contineum Prices $110M IPO as IPF and Neuro Drugs Advance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"PIPE-307","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Contineum Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Spanios","sponsor":"Rare Cancer Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rare Cancer Research Foundation Partners with Spanios to Advance Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Spanios","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spanios \/ Rare Cancer Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Spanios \/ .."},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-in-Class Antibody Drug Conjugate Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":1.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Caris Life Sciences \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life.."},{"orgOrder":0,"company":"Predicine","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predicine Announces Collaboration with Apollomics to Develop PredicineCARE\u2122 as a Companion Diagnostic Assay in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Predicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Predicine \/ Apollomics Inc","highestDevelopmentStatusID":"8","companyTruncated":"Predicine .."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Dr. Reddy\u2019s sign a marketing and distribution agreement for second brand of Vericiguat\u2122 in India","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Vericiguat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Significantly Improved Overall Survival and Progression-Free Survival for Patients with Limited-Stage Small Cell Lung Cancer in ADRIATIC Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Gets Nod for Injectable Polio Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Inactivated Poliomyelitis Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Initiates Phase 3 Clinical Trial of Investigational Oral KRAS G12C Inhibitor MK-1084","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MK-1084","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Confirms Plans to File for Pluvicto\u00ae Pre-taxane Label Expansion in H2 2024 Based on Latest Data from Phase III PSMAfore Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Approved in the US as First Tumor-Agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"2Seventy Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Bristol Myers Squibb and 2seventy bio\u2019s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Idecabtagene Vicleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ 2Seventy Bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunome to Present Preclinical Data for IM-3050, its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"IM-3050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Announces Launch of Verorab\u00ae (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rabies Vaccine, Inactivated","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u00ae is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eilean Therapeutics Receives Clearance to Initiate R\/R AML Trial with Lomonitinib, a Selective Pan-FLT3\/IRAK4 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Lomonitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eilean Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean The.."},{"orgOrder":0,"company":"IRBM","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AM E3-SG3249","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"IRBM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRBM \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IRBM \/ Not.."},{"orgOrder":0,"company":"HJF Medical Research International","sponsor":"IAVI","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"NIGERIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"HJF Medical Research International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HJF Medical Research International \/ IAVI","highestDevelopmentStatusID":"8","companyTruncated":"HJF Medica.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Supplemental Biologics License Applications for BIMZELX\u00ae (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx to Pull Failed ALS Drug Relyvrio From Market, cut 70% of Staffers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CDR Life \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Choline Chloride","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Updates Status of Buprenorphine Buccal Film ANDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410\u2014a Modifier Gene Therapy\u2014in Phase 1\/2 ArMaDa Study for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU410","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolTREG Identifies Promising Efficacy Biomarker for Type-1 Diabetes in Patients Treated with its Treg Therapy in Combination with Rituximab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"PolTREG","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PolTREG \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA\u00ae (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MK-1084","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK MHRA Approves Advanz Pharma Antibiotic for Complex Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Enmetazobactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Advanz Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Advanz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pha.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EOS-984","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Positive Phase 2 PAXTRAVA\u2122 Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Travoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewood Oncology Announces Positive Efficacy Data From Investigator-sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-A51","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Edgewood Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Edgewood Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Edgewood O.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Zilebesiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geneos Therapeutics Announces Positive Phase 1\/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GNOS-PV02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Geneos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Olezarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Liverpool","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Joins Forces with University of Liverpool for NSCLC Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Touchlight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ University of Liverpool","highestDevelopmentStatusID":"3","companyTruncated":"Touchlight.."},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"Pantherna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wacker and Pantherna Intensify Collaboration in the Development and Production of mRNA Biopharmaceuticals","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"PAN004","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Wacker Chemie AG","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wacker Chemie AG \/ Pantherna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Wacker Che.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three-year Phase 1 Follow-up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results Announced from EMPACT-MI Phase III Trial Investigating the Effect of Jardiance\u00ae (empagliflozin) on Risk of Heart Failure Hospitalization and Death in Adults Following a Heart Attack","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Leash Biosciences","sponsor":"Springtide Ventures","pharmaFlowCategory":"D","amount":"$9.3 million","upfrontCash":"Undisclosed","newsHeadline":"Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Leash Biosciences","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Leash Biosciences \/ Springtide Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Leash Bios.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Galen Patient Recruitment","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Galen Patient Recruitment","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Varian Biopharmaceutical","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"VAR-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Varian Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Varian Biopharmaceutical \/ Windtree Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Varian Bio.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.25 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces Pricing of $5.25 Million Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"CorMedix","sponsor":"ARC Dialysis, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ ARC Dialysis, LLC","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"RenovoRx Announces $11.1 Million at Market Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"Sensorion Announces a \u20ac15 Million Financing, Extending Cash Runway Until the End of 2025","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0.02,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Sensorion \/ Redmile Group","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"D3 Bio","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Medicxi Announces $40M Investment in D3 Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"D3S-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"D3 Bio \/ Medicxi","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ M.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Agilent Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Agilent Technology Inc","highestDevelopmentStatusID":"10","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Abceutics Inc","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$208.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck & Co. Signs $208M Deal to Acquire Startup in Bid to Improve ADC Safety","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"ADC-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Abceutics Inc","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Abceutics Inc \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Abceutics .."},{"orgOrder":0,"company":"Renaissance Pharma","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Acquires Renaissance Pharma Ltd with its Clinical Stage Immunotherapy for The Treatment of High-risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Hu14.18K322A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Renaissance Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renaissance Pharma \/ Essential Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renaissanc.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Awarded CARB-X Grant to Develop Recently Acquired Novel Class of Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,577.0 million","upfrontCash":"$55.0 million","newsHeadline":"Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Nurix Therapeutics","amount2":2.5800000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":2.5800000000000001,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Optimi Health","sponsor":"M\u0101tai Medical Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based M\u0101tai Medical Research Institute","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Optimi Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Optimi Health \/ M\u0101tai Medical Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Optimi Hea.."},{"orgOrder":0,"company":"ALMATICA PHARMA INC","sponsor":"TWi Pharmaceuticals","pharmaFlowCategory":"D","amount":"$38.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bora Acquires Six US Brand Product Licenses, Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Acquisition","leadProduct":"Lisinopril","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ALMATICA PHARMA INC","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"ALMATICA PHARMA INC \/ TWi Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"ALMATICA P.."},{"orgOrder":0,"company":"Bora Pharmaceuticals","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Partnership","leadProduct":"CT-G20","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bora Pharmaceuticals \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Bora Pharm.."},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SunWay Biotech and Gnosis by Lesaffre Form Alliance to Launch MenaQ7\u00ae Metabolic, featuring the ANKASCIN\u00ae 568-R ingredient","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"SunWay Biotech","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SunWay Biotech \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"12","companyTruncated":"SunWay Bio.."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Axovia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River & Axovia Partner to Support Development of Gene Therapies for Ciliopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"AXV101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zevra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"12","companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Komodo Health","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MoonLake Immunotherapeutics Inks Three-year Technology Partnership with Komodo Health to Advance Research on Inflammatory Skin and Joint Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Komodo Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Komodo Health \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Komodo Hea.."},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Announces Private Placement and Concurrent Debt Settlement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PharmAla Biotech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmAla B.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX BioPharma","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$100.0 million","newsHeadline":"ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology\/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Liquid","sponsorNew":"ABVC BioPharma \/ OncoX BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK-Tech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Revolutionary Anti-Inflammatory Injectable","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"SJP-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK-Tech","highestDevelopmentStatusID":"4","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ BlackRock","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Nuvation Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio Completes Acquisition of AnHeart Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AnHeart Therapeutics \/ Nuvation Bio","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$4,900.0 million","upfrontCash":"$4,900.0 million","newsHeadline":"Vertex Enters Into Agreement to Acquire Alpine Immune Sciences","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Povetacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":4.9000000000000004,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":4.9000000000000004,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"NorthStar Medical Radioisotopes","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"67SAR-bisPSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NorthStar Medical Radioisotopes","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NorthStar Medical Radioisotopes \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"NorthStar .."},{"orgOrder":0,"company":"Invenra","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invenra \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ .."},{"orgOrder":0,"company":"Rallybio","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"Undisclosed","newsHeadline":"Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"RLYB212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rallybio","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rallybio \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Gabather","sponsor":"Centre for Neuropsychiatric Schizophrenia Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"GT-002","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Receives 8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi\u00ae in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"OSE2101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$158.0 million","upfrontCash":"Undisclosed","newsHeadline":"TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"TORL BioTherapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTh.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces Closing of $5.2 Million Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ U.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing its Clinical Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,160.0 million","upfrontCash":"$150.0 million","newsHeadline":"Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC\u00ae Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Luxdegalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arvinas","amount2":1.1599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Budoprutug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Eliem Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"CNTY-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Century Th.."},{"orgOrder":0,"company":"DeepCure","sponsor":"IAG Capital Partners","pharmaFlowCategory":"D","amount":"$24.6 million","upfrontCash":"Undisclosed","newsHeadline":"DeepCure Closes $24M Funding Round Led by IAG Capital Partners","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"Brd4","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"DeepCure","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"DeepCure \/ IAG Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"DeepCure \/.."},{"orgOrder":0,"company":"Nectero Medical","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","amount":"$96.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nectero Medical Announces Completion of $96M Series D Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series D Financing","leadProduct":"Pentagalloyl Glucose","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Nectero Medical","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nectero Medical \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Nectero Me.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leap Therapeutics Announces $40 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Fluorouracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Leap Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","amount":"$393.0 million","upfrontCash":"$25.5 million","newsHeadline":"Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"TPM-1116","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Preclinical","graph3":"Bioprojet Pharma","amount2":0.39000000000000001,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"Bioprojet Pharma \/ Harmony Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Bioprojet .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Nanoform","sponsor":"PlusVitech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and PlusVitech Partner to Repurpose Aprepitant as a Treatment for Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Aprepitant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Nanoform \/ PlusVitech","highestDevelopmentStatusID":"8","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"APVO436","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Tenet Medicines","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Budoprutug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tenet Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenet Medicines \/ Eliem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tenet Medi.."},{"orgOrder":0,"company":"Clade Therapeutics","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$45.0 million","newsHeadline":"Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"iPSC-derived Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Clade Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Clade Therapeutics \/ Century Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Clade Ther.."},{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emifarma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emifarma \/ Mangoceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Emifarma \/.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"HANDOK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ\u2122 in South Korea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Clazosentan Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sosei Group Corporation \/ Handok","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of Sparsentan for IgA Nephropathy in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Ph.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SCB-1019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1\/2 GATEWAY Clinical Trial for Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VTX-801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Ther.."},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GV20-0251","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Thera.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"PT217","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edison Oncology Reports Promising Interim Data from Ongoing Orotecan\u00ae Clinical Trial for Recurrent Pediatric Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Edison Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Edison Onc.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS\u00ae (edaravone)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Wonderberlly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wonderbelly Expands its Suite of Digestive Health Medicines with Launch of Bloat + Gas Relief","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Simethicone","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Wonderberlly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Wonderberlly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Wonderberl.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-hydroxyecdysone)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1\/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (\u201cR\/R B-NHL\u201d)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Announces Initiation of Placebo-controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Soquelitinib","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NX-5948","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tivumecirnon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b\/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Belapectin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinsons Disease and Related Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VQ-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanqua Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Baclofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptar Pharma\u2019s Airless+ system Delivers China NMPA Approved Rosacea Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Metronidazole","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Aptar Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aptar Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aptar Phar.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra\u2122 in Patients With Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ELVN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enliven Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Th.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Confirms Efficacy and Safety of AJOVY\u00ae (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1\/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BBI-825","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Boundless Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boundless Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Boundless .."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin\u00ae) in Relapsed Metastatic Colorectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FASENRA Approved for Treatment of Children Aged 6 to 11 with Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Benralizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allay Therapeutics\u2019 Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Ther.."},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2\/PD-L1 Bispecific Antibody Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SPX-303","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SparX Biopharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biop.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XCOPRI\u00ae (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cenobamate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Stamford Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stamford Pharmaceuticals Inc Announces the First Patient to Be Treated with SP-002 in Combination with Erivedge\u00ae in a Phase 2 Study in Locally Advanced BCC Subjects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SP-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Stamford Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stamford Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stamford P.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu's Groundbreaking Cancer Treatment Protocol","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SA53-OS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lamassu Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lamassu Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Lamassu Ph.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sudan Ebola Virus Glycoprotein","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algiax Pharmaceuticals Expands Phase 2a Study with Lead Candidate AP-325 in Chronic Neuropathic Pain with 12 New Clinical Sites in Belgium and France","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AP-325","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pha.."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-in-Class Antibody Drug Conjugate Targeting Glypican 3","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BC2027","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Avicanna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CBD-based Trunerox OK\u2019d as Add-on Dravet Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avicanna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UBC Researchers Launch Clinical Trial Exploring CBD for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"The University of British Columbia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"The University of British Columbia \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Quolet Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quolet Announces Completion of Phase 1 Healthy Volunteer Study Evaluating the Safety and Bioavailability of Cannabidiol in a Novel Formulation Intended for Treatment of Various Neurological and Psychiatric Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quolet Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quolet Industries \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quolet Ind.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alligator Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Provides Pipeline Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG.APV-527","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Alligator Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Norepinephrine Bitartrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Baxter Healthcare Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baxter Hea.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ALKS 2680","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSyent Announces Extension of RepaGyn\u00ae and Proktis-M\u00ae Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"BIOSYENT PHARMA INC","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suppository","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BIOSYENT P.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics\u00ae Announces Closing of Private Placement of $5.0 Million","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Nika Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Vinpocetine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Undisclosed \/ Nika Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"RenovoRx \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"APVO436","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","amount":"$555.0 million","upfrontCash":"$100.0 million","newsHeadline":"Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.56000000000000005,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series C Financing","leadProduct":"AB248","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Asher Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biot.."},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Petrichor","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"177Lu-EVG-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Evergreen Theragnostics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Petrichor","highestDevelopmentStatusID":"4","companyTruncated":"Evergreen .."},{"orgOrder":0,"company":"CureVac","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0.5,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sentia Medical Science","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Sentia Med.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Announces Strategic Decisions on FXR Agonist ASC42","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ASC42","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCa Platform Development","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Liquid-filled Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA\u00ae in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics Provides Interim Phase I\/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ATL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Egle Therapeutics to Present Novel Immunocytokine Preclinical Data for EGL-001 with Poster Presentation at the 2024 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EGL-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Egle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Egle Thera.."},{"orgOrder":0,"company":"iECURE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ECUR-506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iECURE \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ N.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GSK4382276A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PROSEEK Study Shows No Treatment Benefit of Vodobatinib in Patients with Early Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Vodobatinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sun Pharma Advanced Research Company","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharma Advanced Research Company \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Therapeutics Completes Patient Enrolment in Phase 1 Trial of CYP-006TK in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CYP-006TK","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO\u00ae in Adults Aged 18 to 59 at Increased Risk for RSV Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"RSVpreF","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rabies Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Enibarcimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400\u2014Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectral Medical Provides Tigris Trial Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectral Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimers Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"ViGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VG901","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ViGeneron","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ViGeneron \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ViGeneron .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Kexing Biopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Bio.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Povetacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Neuboron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuboron Medical Group Advances Cancer Treatment: Introducing Next-Generation Boron Neutron Capture Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"P-Borono-L-Phenylalanine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neuboron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuboron \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuboron \/.."},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpiEndo reports Phase 2A Results for Lead Asset, EP395, in COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EP395","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EpiEndo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EpiEndo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EpiEndo Ph.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination as Potential Treatment for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Novartis Fabhalta\u00ae (iptacopan) Data Show Clinically Meaningful and Statistically Significant Proteinuria Reduction of 38.3% Versus Placebo for Patients with IgA nephropathy (IgAN)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1\/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"FXR314","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Organovo Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Organovo H.."},{"orgOrder":0,"company":"London Research & Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"London Research & Pharmaceuticals presents the Advancement of LRP-661, their oral Cannabidiol Sulphate Drug Candidate at The Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol Sulphate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"London Research & Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"London Research & Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"London Res.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients with Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Dazucorilant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG601","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Opelconazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Pulmocide \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide .."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"WAL0921","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Walden Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Positive Interim Phase 1\/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GTX-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NMRA-266","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PHAXIAM Therapeutics Announces Enrolment of the First Patient in The Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Phaxiam Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phaxiam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phaxiam Th.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne\u00ae, its Third Approved Biosimilar in the U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Desmopressin Acetate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NiKang Therapeutics Doses First Patient in a Phase 1\/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NKT3447","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AVB-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AviadoBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Columvi Meets Primary Endpoint of Overall Survival in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 \/ IPH6101 Progressing to Phase 2 for Blood Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SAR443579","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Norgine B.V. Submits Marketing Authorisation Application via Project Orbis for Eflornithine (difluoromethylornithine [DFMO]) in High-risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Norgine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ .."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Actinogen's XanaMIA Phase 2b Alzheimer's Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Dr. Axel Lehrer","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Marburg Marburgvirus Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Dr. Axel Lehrer","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NM5072","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"TheracosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Head-to-Head Study Finds TheracosBio's BRENZAVVY\u00ae (bexagliflozin) Non-Inferior to Dapagliflozin in Chinese Patients with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"TheracosBio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TheracosBi.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces Updated Phase 1 Data and Progress on BOT\/BAL Development in Metastatic MSS Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruitment Milestone Reached in Diamyd\u00ae Phase 3 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suven Life Sciences to Present phase-2 Results on Samelisant at AAN 2024","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Samelisant","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Nadofaragene Firadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches PEMRYDI RTU\u00ae, the First Ready-to-Use Version of Important Oncology Injectable Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SP-624","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo Bio.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC-AD1\u2019s Interim Phase 2 Data Show a Reduction in Alzheimer\u2019s Agitation at Week Two","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Solution","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sovilnesib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Volastra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Volastra T.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) plus Chemotherapy Doubled Overall Survival Rate at Three Years for Patients with Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Exaluren Sulfate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Provides SAB-142 Trial Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-978","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan Approves Japan-Based Shionogi's Influenza Drug for Paediatric Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tirzepatide Reduced Sleep Apnea Severity by Up to Nearly Two-Thirds in Adults with Obstructive Sleep Apnea (OSA) and Obesity","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals\u2122 Topical Therapy Shows Positive Results in Preclinical Skin Cancer Trial: Drug Prevents the Development of Precancerous Skin Conditions and Treats Existing Skin Cancers with No Observable Side Effects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Evaxion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EVX-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Evaxion Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evaxion Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evaxion Bi.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Subcutaneous OCREVUS One-Year Data Demonstrates Near-complete Suppression of Clinical Relapses and Brain Lesions in Patients with Progressive and Relapsing Forms of MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Joincare Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Successfully Completes TG-1000 Phase III Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"TG-1000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Joincare Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxyntomodulin Analog","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kesimpta\u00ae six-Year Efficacy Data Show Substantial Benefits in Recently Diagnosed Treatment-Na\u00efve People with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EAGLE-1 Phase III data Show Potential for Gepotidacin as A New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea (GC) Amid Growing Resistance to Existing Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Gepotidacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s 5-in-1 Meningococcal ABCWY Vaccine Candidate Accepted for Regulatory Review by US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MenABCWY","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gland Pharma Receives USFDA Approval for Eribulin Mesylate Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Eribulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHAR.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Provides Regulatory Update for SPN-830","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I\/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CX-2051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm\u00ae in Phase 2 \u02dcMONTPARK\u2122 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial \u201d First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1\/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Leniolisib","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces U.S. FDA Approval of Dovato (dolutegravir\/lamivudine) for Adolescents Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Purdue Pharmaceuticals L.P \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SH-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shorla Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Shorla Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I\/II Study of DFP-10917 Combined with Venetoclax","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Pharma Gets USFDA Nod for Antidepressant Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluoxetine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SAGE-718","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai's Antiepileptic Drug Fycompa Injection Formulation Launches in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Subcutaneous Administration of Takeda\u2019s ENTYVIO\u00ae (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Barinthus Bio Announces Topline Data from Phase 1b\/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VTP-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nexcella","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1\/2 Study of ONCT-534 for the Treatment of R\/R Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ONCT-534","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"IMNN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b\/2a Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1\/1b Clinical Trial of BP1002 in Refractory\/Relapsed Acute Myeloid Leukemia (AML) Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BP1002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Positive Topline Phase 1 Data for AXPAXLI\u2122 in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tavapadon","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ\u00ae) Showed Positive Results in Patients With Giant Cell Arteritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"YS-HBV-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Yisheng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Yisheng Bi.."},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$188.6 million","upfrontCash":"Undisclosed","newsHeadline":"Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Ther.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Announces the Acquisition of Reminyl\u00ae (galantamine hydrobromide) Oral Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Galantamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Biocon","sponsor":"Biomm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Partners Biomm to Commercialise Diabetes Drug in Brazil","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Biomm","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ B.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma and Vectura Announce Plans to Reformulate flutiform\u00ae (fluticasone propionate\/formoterol fumarate) Pressurised Metered-dose Inhaler (pMDI) as a Commitment to Reducing the Product\u2019s Carbon Footprint","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Evotec","sponsor":"Variant Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Variant Bio","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ V.."},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"GV20-0251","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Thera.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Korro Announces $70 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"KRRO-110","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Korro Bio","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Korro Bio \/ Deep Track Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"Pathios Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-class Immunotherapy Approach into Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"PTT-4256","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pathios Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Pathios Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Pathios Th.."},{"orgOrder":0,"company":"Outrun Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outrun Therapeutics Launches with a $10m Seed Financing from M Ventures and MP Healthcare Venture Management to Develop a Protein Stabilisation Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outrun Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Outrun Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Outrun The.."},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MH002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"MRM Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sentynl Therapeutics Receives MHRA Authorization of NULIBRY\u00ae (fosdenopterin) for Treatment of MoCD Type A in Great Britain","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sentynl Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sentynl Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sentynl Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New 48-week Frexalimab Phase 2 Data Support Potential for High Sustained Efficacy in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Frexalimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and Teva Announce U.S. FDA Approval of SELARSDI\u2122 (ustekinumab-aekn), Biosimilar to Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients\u2019 Stool","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CTX-8371","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I\/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$1,675.0 million","upfrontCash":"$175.0 million","newsHeadline":"Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"GBA1 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.6799999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.6799999999999999,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"CLN-978","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Cullinan Therapeutics","amount2":0.28000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"Cullinan Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"5","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Venture Life","sponsor":"Jaguar Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Licenses FDA-approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Maltodextrin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Venture Life","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Venture Life \/ Jaguar Health","highestDevelopmentStatusID":"12","companyTruncated":"Venture Li.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"$100.0 million","newsHeadline":"Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NBI-1117568","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sosei Group Corporation","amount2":2.7000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":2.7000000000000002,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$713.0 million","upfrontCash":"$48.0 million","newsHeadline":"OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"OSE-230","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Citizens JMP","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Benitec Biopharma \/ Citizens JMP","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-1002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SEC Recommends Approval to Dr Reddy's to Import and Market Anti-cancer Drug Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b \u2018ASCEND-NASH\u2019 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"ACTG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ChAdOx1.HIVconsv62","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ACTG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ACTG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ACTG \/ Not.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1\/2 ArMaDa Clinical Trial of OCU410\u201dA Modifier Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU410","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,330.0 million","upfrontCash":"$130.0 million","newsHeadline":"Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Kumquat Biosciences","amount2":1.3300000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Kumquat Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Kumquat Bi.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intra-Cellular Therapies Prices Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0.5,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"OncoX","pharmaFlowCategory":"D","amount":"$26.2 million","upfrontCash":"$13.7 million","newsHeadline":"ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1519","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABVC BioPharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Liquid","sponsorNew":"ABVC BioPharma \/ OncoX","highestDevelopmentStatusID":"7","companyTruncated":"ABVC BioPh.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$6,165.0 million","upfrontCash":"$150.0 million","newsHeadline":"IGM Biosciences Announces Refocusing of Sanofi Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":6.1699999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Theolytics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","amount":"$24.5 million","upfrontCash":"Undisclosed","newsHeadline":"Theolytics Successfully Closes Latest Financing Raising Total of \u00a319M ($24.5M) and Welcomes Sound Bioventures as New Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"THEO-260","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Sound Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics.."},{"orgOrder":0,"company":"RevolKa","sponsor":"La Jolla Institute for Immunology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"La Jolla Institute for Immunology and RevolKa Started a Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"RK009","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"RevolKa","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ La Jolla Institute for Immunology","highestDevelopmentStatusID":"2","companyTruncated":"RevolKa \/ .."},{"orgOrder":0,"company":"Zura Bio","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$112.5 million","upfrontCash":"Undisclosed","newsHeadline":"Zura Bio Announces Oversubscribed $112.5 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Tibulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.11,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/.."},{"orgOrder":0,"company":"Neurenati Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ with the Support of Impulsion PME","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"NEU-001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Neurenati Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Neurenati Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"4","companyTruncated":"Neurenati .."},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Closing of Non-brokered Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Pricing of $4.75 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Hypericin Sodium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Kincell Bio","sponsor":"Imugene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kincell Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kincell Bio \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Kincell Bi.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Suzetrigine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concept Medical Announces Enrollment of First Patient In \"MAGICAL-ISR\" IDE Study in the US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI351","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Nora Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nora Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nora Pharm.."},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Nadofaragene Firadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SK Pharmteco","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"SK Pharmteco \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"SK Pharmte.."},{"orgOrder":0,"company":"Corner Therapeutics","sponsor":"Ziff Capital Partners","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Corner Therapeutics Announces $54 Million Series a Funding to Pioneer Novel Vaccines that Provide Lifelong Immunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Corner Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Corner Therapeutics \/ Ziff Capital Partners","highestDevelopmentStatusID":"4","companyTruncated":"Corner The.."},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"PharmAla Closes Private Placement and Concurrent Debt Settlement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PharmAla Biotech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PharmAla B.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-concentration Interchangeable Biosimilar to Humira\u00ae (adalimumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Regeneration Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneration Biomedical Doses First Patient in a First-in-Human Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brain of Patients with Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"RB-ADSC","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Regeneration Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneration Biomedical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regenerati.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Averoa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Averoa","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Averoa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Averoa \/ N.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Launches Mirabegron Extended-release Tablets in the US","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirabegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Receives Regulatory Approval to Expand Harmonic\u2122 Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s EMBLAVEO\u00ae for Patients with Multidrug-Resistant Infections and Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Aztreonam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"Actinogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Xanamem","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AMG 193","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Screening Completed: Berlin Cures Achieves Key Milestone in BC 007 Phase II Trial for Treatment of Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rovunaptabin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berlin Cures \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cur.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA\u00ae) for Preventive Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Atogepant","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Askbio Presents 18-month Phase Ib Trial Results of AB-1005 Gene Therapy for Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV2-GDNF","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Present TEZSPIRE\u00ae Phase 2a Copd Data at ATS 2024","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Radioligand Therapy Lutathera\u00ae FDA Approved as First Medicine Specifically for Pediatric Patients with Gastroenteropancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Response Pharmaceuticals\u2019 Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"RDX-002","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Response P.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ALTO-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sevasemten","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"hC Bioscience Announces Lead Program in Hemophilia and Reports Positive Preclinical Data on Novel Protein Editing Approach Using Anticodon Engineered tRNA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"HCB-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"hC Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"hC Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"hC Bioscie.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rilzabrutinib LUNA 3 Phase 3 Study Met Primary Endpoint in Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pint Pharma Announces the Approval of ORLADEYO (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharm.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","amount":"$6.1 million","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Inc. Announces $8.4M Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"Metsera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$290 million","upfrontCash":"Undisclosed","newsHeadline":"Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0.28999999999999998,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Metsera \/ ARCH Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ .."},{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/.."},{"orgOrder":0,"company":"Ochre Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,035.0 million","upfrontCash":"$35.0 million","newsHeadline":"Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Ochre Bio","amount2":1.04,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Ochre Bio \/ Boehringer Ingelheim Gmbh","highestDevelopmentStatusID":"2","companyTruncated":"Ochre Bio .."},{"orgOrder":0,"company":"Cornell University","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cornell University","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cornell University \/ Lexeo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cornell Un.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai In-Licenses RNAi Therapeutic Zilebesiran for Hypertension with High Cardiovascular Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Zilebesiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$49.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"IND Enabling","graph3":"Dar\u00e9 Bioscience","amount2":0.050000000000000003,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioArctic and Eisai Sign Research Evaluation Agreement Regarding BAN2802","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"BAN2802","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai Inc","highestDevelopmentStatusID":"4","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Oculis","sponsor":"BBA\/\/Fjeldco","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Oculis \/ BBA\/\/Fjeldco","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ B.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"LifeSci Capital","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ LifeSci Capital","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"United States Department of Defense","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Plus Therapeutics \/ United States Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"RLS-1496","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Lif.."},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"JK07","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Salubris Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Salubris Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Salubris B.."},{"orgOrder":0,"company":"Brise Pharma","sponsor":"Shunxi Fund","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brise Pharmaceuticals Raises Nearly $20M in Series Pre-A and Pre-A+ Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"BR01T","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Brise Pharma","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Brise Pharma \/ Shunxi Fund","highestDevelopmentStatusID":"6","companyTruncated":"Brise Phar.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"SynOx Therapeutics \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":1.8,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1.8,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Beiersdorf AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rubedo Pulls in $40M Series A to Advance Atopic Dermatitis Candidate Targeting Aging Cells","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"RLS-1496","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Beiersdorf AG","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Lif.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"SerpinPC","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Centessa Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"8","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$3,312.0 million","upfrontCash":"$12.0 million","newsHeadline":"Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":3.3100000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":3.3100000000000001,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"MAIA Biotechnology Announces $1.00 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"BH3120","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-class Oral MRGPR Antagonists","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.75,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.75,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biolojic Design Announces that Nektar Therapeutics has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic D.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Cidara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"CD388","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cidara Therapeutics","amount2":0.23999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$575.0 million","upfrontCash":"Undisclosed","newsHeadline":"Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters\u2122 Option to Purchase Additional Shares","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0.57999999999999996,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.57999999999999996,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BigHat Biosciences Enters Into Strategic Collaboration to Leverage Machine Learning in Antibody Discovery & Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BigHat Biosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Bio.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"AyurMaya","pharmaFlowCategory":"D","amount":"$132.5 million","upfrontCash":"Undisclosed","newsHeadline":"Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Series C Financing","leadProduct":"Taladegib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0.13,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Belite Bio Announces $25 Million Registered Direct Offering","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Tinlarebant","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Belite Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Belite Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"VIP236","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vincerx Pharma \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Maxim Group","pharmaFlowCategory":"D","amount":"$9.7 million","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Maxim Group","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Agent Capital","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"CVN424","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Agent Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"XOMA","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"XOMA","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Immediate-Release Tablet","sponsorNew":"XOMA \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ Day.."},{"orgOrder":0,"company":"HRA Pharma","sponsor":"Esteve Healthcare","pharmaFlowCategory":"D","amount":"$294.2 million","upfrontCash":"$203.3 million","newsHeadline":"Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to \u20ac275 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Divestment","leadProduct":"Metyrapone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"HRA Pharma","amount2":0.28999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0.28999999999999998,"dosageForm":"Soft gel Capsule","sponsorNew":"HRA Pharma \/ Esteve Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"HRA Pharma.."},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prism Biolab \/ ONO Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biol.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces ODF Cladribine Update and Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film, Dispersible","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","amount":"$41.5 million","upfrontCash":"Undisclosed","newsHeadline":"Biodexa Enters Into Exclusive License to eRapa\u2122, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Bio.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"ALLO-316","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Public Offering","leadProduct":"VIP924","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vincerx Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Vincerx Pharma \/ Leerink Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vincerx Ph.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces $15 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$69.7 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Modified Vaccinia Ankara","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ European Union","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta\u00ae and Nucynta\u00ae ER","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Collegium Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Collegium Pharmaceutical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Collegium .."},{"orgOrder":0,"company":"BioVie","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$13.1 million","upfrontCash":"Undisclosed","newsHeadline":"BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Bezisterim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVie","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"BioVie \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"BioVie \/ U.."},{"orgOrder":0,"company":"Oncotelic Therapeutics","sponsor":"Mosaic ImmunoEngineering","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncotelic Therapeutics, Inc. to Sell its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Trabedersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncotelic Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Oncotelic Therapeutics \/ Mosaic ImmunoEngineering","highestDevelopmentStatusID":"8","companyTruncated":"Oncotelic .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Journey Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, if approved for Treatment-resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Journey Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,400.0 million","newsHeadline":"Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":2.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ ONO Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"4P-Pharma Announces Total Capital of \u20ac15 Million Successfully Secured in Second Closing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4P-Pharma","amount2":0.02,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"4P-Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma .."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1865 million","upfrontCash":"$65.0 million","newsHeadline":"Repertoire\u00ae Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":1.8700000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.8700000000000001,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx\u00ae Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI\u2122 (mavorixafor), the First FDA-approved Therapy Indicated for Use in Patients with WHIM Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PANTHERx Rare Pharmacy \/ X4 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Ventures","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Locate Bio Raises \u00a39.2 Million to Progress LDGraft Clinical Study for Anterior Lumbar Interbody Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"rhBMP-2","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Locate Bio","amount2":0.01,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Locate Bio \/ Mercia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Locate Bio.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Shilpa Medicare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shilpa Medicare Launches Pemetrexed Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amneal Pharmaceuticals \/ Shilpa Medicare","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Manufacturing and Marketing Approval for Three Ingredients and Eight Items","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Zonisamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Towa Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Towa Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Towa Pharm.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Zortress\u00ae)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 5 mg Strength (generic for Saphris\u00ae)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 2.5 and 10mg Strengths (generic for Saphris\u00ae)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Penicillamine Capsules, USP (generic for Cuprimine\u00ae)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Penicillamine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Norepinephrine Bitartrate Injection, USP (generic for Levophed\u00ae)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Norepinephrine Bitartrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANDA Approval for Teriflunomide Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apixaban Tablets (generic for Eliquis\u00ae) Approved","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder (generic for Kyprolis\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien\u00ae CR)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Zolpidem Tartrate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenrid.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT20029 China Phase II Trial For AGA Reached Primary Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GT20029","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Receives Approval for Tacrolimus Capsules from SAHPRA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves New Indication for Merck\u2019s PREVYMIS\u00ae (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Letermovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EBT-104","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EBT-107","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Provides Regulatory Update on Pz-cel","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Prademagene Zamikeracel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I\/II Trial Evaluating Allocetra\u2122 in Patients with Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"KB707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024","therapeuticArea":"Sleep","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ORX750","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"IND Enabling","graph3":"Centessa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centessa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Centessa P.."},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kynos Therapeutics Announces Positive Top-Line Results from The First-in-human Phase I Study of its KMO Inhibitor, KNS366, Demonstrating Safety, Tolerability and Target Engagement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"KNS366","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kynos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Ther.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Gains European Commission Approval For PYZCHIVA\u2122 a Biosimilar to Stelara (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces FDA Approval of ANKTIVA\u00ae, First-in-class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bacillus Calmette Guerin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u00ae (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voydeya Approved in the EU as Add-on Treatment to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH who have Residual Haemolytic Anaemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Novartis Data Show Early Addition of Twice-yearly* Leqvio\u00ae (inclisiran) Following Maximally Tolerated Statin Therapy Significantly Reduces LDL-C in ASCVD Patients in Real-world Setting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Inclisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Receives European Commission Approval for BIMZELX[\u00ae]\u25bc(bimekizumab) as the first IL-17A and IL-17F Biologic for Moderate to Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Kynos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kynos Therapeutics Announces Positive Top Line Results from the First-in-human Phase I study of its KMO inhibitor, KNS366, Demonstrating Safety, Tolerability and Target Engagement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"KNS366","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Kynos Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kynos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kynos Ther.."},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hyundai Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hyundai Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies <5 kg with Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Artemether","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Day One's OJEMDA\u201e (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Day One Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Foselutoclax","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc. Announces 24-Month Stability Validation of XPro\u2122 for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"OncoC4","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ONC-841","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoC4 \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ N.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Qilu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VCN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITM, Helmholtz Munich and University Hospital M\u00fcnster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Lu-177 labeled 6A10-Fab-fragments","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"Genethon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy Presented at International Myology 2024 Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GNT0004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genethon \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas' XTANDI\u2122 (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Bio Drug Candidate Shows Success in Weight Loss in New Study","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"A07D","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Endevica Bio","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Endevica B.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NBI-1065845","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pyridoxal Phosphate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's Phase 3 Select -GCA study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Padeliporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Kingdom's MHRA Approves YORVIPATH\u00ae (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg\/mL) Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"PAS-004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"HB-700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Mebufotenin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi\u00ae (golimumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Nogapendekin Alfa Inbakicept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Announces U.S. FDA Approval of Over-the-counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1\/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ARO-CFB","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Innoviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innoviva Specialty Therapeutics\u2019 Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Zoliflodacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Innoviva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/.."},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b\/3 Clinical Trial of a New Investigational Treatment for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ABP-671","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu At.."},{"orgOrder":0,"company":"UTILITY therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves New Treatment for Uncomplicated Urinary Tract Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pivmecillinam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"UTILITY therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UTILITY therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UTILITY th.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora\u2122 in Acute Pancreatitis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ALKS 2680","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Upamostat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI\u00ae (sparsentan) for the treatment of IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Patient-friendly Oral Drug Against Visceral Leishmaniasis Enters Phase II Clinical trial in Ethiopia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"LXE408","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Receives Positive CHMP Opinion for TOFIDENCE\u2122 (tocilizumab), a Biosimilar Referencing ROACTEMRA\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-in Cohort","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-02","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Dextrose","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pha.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CTX-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Announces Pivotal Phase 2\/3 Trial Design for HB-200 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"HB-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi\u2122 and Clobetasol Propionate Ophthalmic Suspension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tropicamide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EO2463","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eyeDNA Therapeutics to Present 2-year Follow-up Phase I\/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV2\/5-hPDE6B","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coave Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Ther.."},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PEP-Therapy \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therap.."},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exegenesis Bio to Present 9-Patient Data from a Phase 1\/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without External Assistance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EXG001-307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Exegenesis Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exegenesis Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exegenesis.."},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beijing Av.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"PH15","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Kinevant Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Namilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roivant Sciences \/ Kinevant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Onconic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Zastaprazan Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Onconic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Onconic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Onconic Th.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Medivir\u00b4s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Legg-Calv\u00e9-Perthes Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"MIV-711","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Announces Start of Combined Phase 1\/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"H5N1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Receives Positive CHMP opinion for RYBREVANT\u00ae\u2013\u00bc (amivantamab) in Combination with Chemotherapy for The First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon 20 Insertion Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JERAYGO (aprocitentan) Recommended for Approval in Europe for The Treatment of Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Aprocitentan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces European Commission Approval for KALYDECO\u00ae to Treat Infants with Cystic Fibrosis Ages 1 Month and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Biktarvy\u00ae Label Update With Data for Pregnant Adults With HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bictegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb\u2019s Opdivo\u00ae (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Pfizer\u2019s BEQVEZ\u2122 (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fidanacogene elaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre Laboratories Receive Positive CHMP Opinion for OBGEMSA\u2122(vibegron) in Overactive Bladder Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen to Submit Teprotumumab Marketing Authorization Application to The European Medicines Agency","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi\u00ae Receives Positive CHMP Opinion Recommending Approval of Efanesoctocog Alfa for Once-weekly Treatment of Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer\u2019s Disease (POLARIS-AD)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharma gets USFDA Nod for Generic Anti-inflammatory Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"TERN-701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Statistically Significant Phase II\/III Data in Patients With Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CHIKV VLP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b\/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-stage Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Completes Enrollment in Phase 4 CATALYST Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Mifepristone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1\/2 Study of INKmune\u2122 Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Bitterroot Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BRB-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Bitterroot Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bitterroot Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bitterroot.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant\u2122 (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual Film","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Diazepam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"PM359","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medi.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces FDA Approval of Xolremdi (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Clofazimine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"INNA-051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Provides Update on ADX71149 Phase 2 Epilepsy Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ADX71149","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Addex Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Full Approval for TIVDAK\u00ae to Treat Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Genmab","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Eptifibatide for Injection in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Eptifibatide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries below the Knee","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Everolimus","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of HERCESSI\u2122 (trastuzumab-strf), a biosimilar to Herceptin\u00ae (trastuzumab) for the Treatment of Several Forms of HER2-overexpressing Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Accord BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord Bio.."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"TDM-180935","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerm.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate\u00ae, the First VWF Concentrate for Prophylaxis in all Types of VWD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Human Von Willebrand Factor\/Coagulation Factor VIII Complex","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Labcorp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Fidanacogene elaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Labcorp","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Labcorp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Labcorp \/ .."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"MedinCell","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,935.0 million","upfrontCash":"$35.0 million","newsHeadline":"Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"MedinCell","amount2":1.9399999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.9399999999999999,"dosageForm":"Injection","sponsorNew":"MedinCell \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"SNIPR Biome Receives Funding from CARB-X to Support Advancement of CRISPR-medicine SNIPR001 into Clinical Trials in Haematological Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"SNIPR001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SNIPR Biome","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SNIPR Biome \/ CARB-X","highestDevelopmentStatusID":"6","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"TreeFrog Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$780.0 million","upfrontCash":"$25.0 million","newsHeadline":"Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex\u2019s Cell Therapies for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"VX-880","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"TreeFrog Therapeutics","amount2":0.78000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.78000000000000003,"dosageForm":"Infusion","sponsorNew":"TreeFrog Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"TreeFrog T.."},{"orgOrder":0,"company":"Immedica Pharma","sponsor":"KKR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KKR and Impilo Announce Strategic Partnership Together with Management in Rare Disease Platform Immedica Pharma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Pegzilarginase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Immedica Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immedica Pharma \/ KKR","highestDevelopmentStatusID":"12","companyTruncated":"Immedica P.."},{"orgOrder":0,"company":"Hongene Biotech","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"ASO-based Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Hongene Biotech","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hongene Biotech \/ n-Lorem Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Hongene Bi.."},{"orgOrder":0,"company":"Glysious","sponsor":"Tetra Pharm Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"TPT0201","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Glysious","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glysious \/ Tetra Pharm Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Glysious \/.."},{"orgOrder":0,"company":"Flindr Therapeutics","sponsor":"V-Bio Ventures","pharmaFlowCategory":"D","amount":"$21.3 million","upfrontCash":"Undisclosed","newsHeadline":"Precision Oncology Company Flindr Therapeutics Announces \u20ac20 million Series A Financing to Advance First-in-class Small Molecule Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Flindr Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Flindr Therapeutics \/ V-Bio Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Flindr The.."},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$100.0 million","newsHeadline":"Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"CRISPR-based Therapy","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Mammoth Biosciences","amount2":0.46999999999999997,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Mammoth Biosciences \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Mammoth Bi.."},{"orgOrder":0,"company":"RevOpsis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"RevOpsis Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"RevOpsis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"RevOpsis T.."},{"orgOrder":0,"company":"Acrivon Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acrivon Therapeutics Announces $130 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Prexasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Acrivon Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Acrivon Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Acrivon Th.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$14.5 million","upfrontCash":"Undisclosed","newsHeadline":"Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Financing","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Seqirus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARS Pharmaceuticals Submits Response for Neffy\u00ae (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00a9 Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Ferrous Gluconate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.02,"dosageForm":"Ring","sponsorNew":"Dar\u00e9 Bioscience \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Surf Bio","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Surf Bio Announces $1.6 Million Non-Dilutive Grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Surf Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surf Bio \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Surf Bio \/.."},{"orgOrder":0,"company":"Wellbeam Consumer Health","sponsor":"Carlin Consumer Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carlin Consumer Health Acquires Penetrex from Wellbeam Consumer Health","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Arnica Montana","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Wellbeam Consumer Health","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Wellbeam Consumer Health \/ Carlin Consumer Health","highestDevelopmentStatusID":"12","companyTruncated":"Wellbeam C.."},{"orgOrder":0,"company":"PeptiDream","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$2,890.0 million","upfrontCash":"$180.0 million","newsHeadline":"PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.8900000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.8900000000000001,"dosageForm":"","sponsorNew":"PeptiDream \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream.."},{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enlaza Therapeutics Raises $100 Million through its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enlaza Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Enlaza Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"3","companyTruncated":"Enlaza The.."},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Bio.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7\u2122 Genetic Biomarker-Guided Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Funding","leadProduct":"5-Fluorocytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Denovo Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Denovo Biopharma \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","amount":"$680.0 million","upfrontCash":"$35.0 million","newsHeadline":"Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Clemizole hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0.68000000000000005,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.68000000000000005,"dosageForm":"Solution","sponsorNew":"Epygenix Therapeutics \/ Harmony Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional LATAM and APAC Markets Including Australia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics Secures up to $35m Debt Financing with Hercules Capital to Progress Development and Commercialisation of Emactuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SynOx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"SynOx Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"SynOx Ther.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Evotec Collaborate to Advance Precision Cardiology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"iPSC-based Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"LTI-03","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$3,892.3 million","upfrontCash":"$25.0 million","newsHeadline":"Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Alpha-beta T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":3.8900000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.8900000000000001,"dosageForm":"","sponsorNew":"Editas Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pepper Bio","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"G1 Therapeutics, Inc","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Pepper Bio","highestDevelopmentStatusID":"6","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Remepy","sponsor":"NFX","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Remepy Launches with $15 Million in Funding to Bring First Hybrid Drug to Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Remepy","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Remepy \/ NFX","highestDevelopmentStatusID":"2","companyTruncated":"Remepy \/ N.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"ABCL575","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Viking Global Investors","highestDevelopmentStatusID":"5","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"RPESC-RPE-4W","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luxa Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biote.."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$50.0 million","newsHeadline":"Astellas and Poseida Therapeutics Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Poseida Therapeutics, Inc","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi to Regain Full Development Rights to its Wholly-owned Base Editing and RIGS Systems","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Creyon Bio","sponsor":"Cajal Neuroscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creyon Bio \/ Cajal Neuroscience","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$138.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crossject Signs a Geographic Extension of ZEPIZURE\u00ae Commercialization Agreement in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Zenyaku Kogyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASLAN Pharmaceuticals Announces Expansion of its Collaboration with Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Eblasakimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$25.0 million","newsHeadline":"Cerevance Achieves First Milestone in Research Collaboration with Merck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevance","amount2":1.1299999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Context Therapeutics Announces $100 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Nextech","highestDevelopmentStatusID":"4","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Launches BridgeBio Oncology Therapeutics (BBOT) with $200M of Private External Capital to Accelerate the Development of its Novel Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"BBO-8520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Mindful Health Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Compass Pathways Establishes Research Collaboration with Mindful Health Solutions to Inform the Development of a Scalable and Cost-effective Delivery Model for Investigational COMP360 Psilocybin Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Mindful Health Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"RE104","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Ne.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across all Cancer Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alfa Inbakicept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"ImmunityBio \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$250.0 million","newsHeadline":"Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0.40999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Latus Bio","sponsor":"8VC","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Latus Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Latus Bio \/ 8VC","highestDevelopmentStatusID":"4","companyTruncated":"Latus Bio .."},{"orgOrder":0,"company":"Novocure","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novocure \/ Pharmakon Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Mariana Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,750.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"MC-339","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mariana Oncology","amount2":1.75,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Mariana Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Mariana On.."},{"orgOrder":0,"company":"Delphia Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Delphia Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Delphia Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Delphia Th.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Announces Intent to Complete Private Placement of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"LTI-03","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Prademagene Zamikeracel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Stifel","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentynl Therapeutics Announces Global Acquisition of Zokinvy\u00ae (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Lonafarnib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Sentynl Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Oregon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-in-Class Drug Candidate XCE853 \u2013 A Potent Inhibitor of Cancer Metabolism","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"XCE853","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Oregon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1\/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-DM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"TX000045","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"V116","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed \u00ae Preservative Free (Bimatoprost 0.03%)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Zimed\u00ae PF Now Available in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPrint\u00ae Ophthalmics Announces Promising Results from its SIGHT-2 Phase 2b Group 1 Clinical Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint .."},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimatoprost by Laboratoires Thea for Open-Angle Glaucoma: Likelihood of Approval","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Laboratoires Thea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoir.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces VYZULTA\u00ae (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in Brazil","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Nicox SA \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Announces Additional Expanded Public Coverage for (Pr)VYZULTA\u00ae (Latanoprostene Bunod Ophthalmic Solution 0.024% w\/w) in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Licensee Bausch + Lomb Secures Approval of VYZULTA\u00ae in Colombia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces Vyzulta\u00ae (latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved in South Korea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Latanoprostene Bunod","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Submits IND Application to US Food & Drug Administration for AUR 200","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"AUR200","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon\u00ae the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces the First Patient Dosed with its Anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib\/II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BC3402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Inc. Receives Orphan Drug Designation for its Lead Development Asset","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Notice of Acquisition of Approval for Application for Partial Change of Manufacturing and Marketing Approval for Esomeprazole Capsules Concerning the Addition of a Manufacturing Plant","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Esomeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Towa Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Towa Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Towa Pharm.."},{"orgOrder":0,"company":"Evexta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evexta Bio Reports Progress Towards Clinical Development of Rupitasertib in Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rupitasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Evexta Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evexta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Evexta Bio.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA\u00ae (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Truqap Plus Faslodex Recommended for Approval in the EU by CHMP for Patients with Advanced ER-positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Alecensa as an Adjuvant Treatment for Resected ALK-Positive Early-Stage Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts for Priority Review GSK\u2019s Application for An Expanded Indication of Jemperli (dostarlimab) Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Submit sNDA for FDA Review of Brexpiprazole and Sertraline Combination as Potential Treatment for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1\/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NPI-002","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Nacuity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Ph.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"WVE-006","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Alumis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"A-005","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alumis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ N.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"VXA-GI.1.NN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XProTM Under Compassionate Use for Over Three Years","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegipanermin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFR\u03b1ME-O1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Luveltamab Tazevibulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I\/II Trial of RECCE\u00ae 327 for Urinary Tract Infections and Urosepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX\u2081\u2080\u2080 for the Prevention of Abdominal Colorectal Surgical Site Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Replay Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replay and MD Anderson announce FDA Clearance of IND Application for First-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) Cell Therapy for Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Replay Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replay Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Replay Bio.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"INB-400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IN8bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 771716","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"CDR Life","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CDR Life \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arsenal Biosciences Announces First Patient Dosed in Phase 1\/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-2100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ArsenalBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ArsenalBio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ArsenalBio.."},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurion Biotech Announces Completion of Enrollment in Phase 1 \/ 2 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Bio.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Announces Results of Maximum Tolerated Dose Study for Probudur\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1\/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Lunresertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Announces Positive Top-line Results From Potentially Pivotal Phase II\/III Study 008A With Evenamide in Schizophrenia Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS\u00ae (voclosporin) Label to Include Long-Term Data from the AURORA Clinical Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801\/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Glecirasib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jacobio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jacobio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jacobio Ph.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA\u00ae SPRINKLE (valbenazine) Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Valbenazine Tosylate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Chidamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b\/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Leads Biolabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1\/4-1BB Bispecific Antibody Developed by Leads Biolabs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"LBL-024","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leads Biolabs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leads Biolabs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Leads Biol.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"FP-020","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gummies","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG\u00ae (belzutifan) in Patients with Advanced ccRCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"HC-7366","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"GB1211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r\/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"LTI-03","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2\/3 HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DNL343","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I\/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ATSN-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atsena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena The.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-02","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"GM-1020","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gilgamesh Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Reports Successful Stage 1 Completion of The EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EVT801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves High-Concentration, Citrate-Free Formulation of Cyltezo\u00ae (adalimumab-adbm) Injection, Boehringer Ingelheim's interchangeable Biosimilar to Humira\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Submits Regulatory Applications to European Medicines Agency for TREMFYA\u00ae (guselkumab) For Treatment of Patients with Ulcerative Colitis and Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellipses' Next Generation Selective RET Inhibitor EP0031\/A400 Cleared to Start Phase 2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EP0031","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses P.."},{"orgOrder":0,"company":"Stalicla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STALICLA Initiates U.S. Phase 3 Enabling DDI Study of STP7 (Mavoglurant) To Treat Cocaine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mavoglurant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Amolyt Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics\u2122 Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CTIM-76","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BG1805","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Guangzhou Bio-gene Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou .."},{"orgOrder":0,"company":"Organogenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu\u00ae for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Amniotic Suspension Allograft","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organogenesis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogene.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Smart Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Smart Immune Treats Adult Acute Leukemia Patient at Final Dose Level in Phase I\/II ReSET-02 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic T-cell Progenitors","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Smart Immune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Smart Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Smart Immu.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Combination Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-line Mantle Cell Lymphoma in ECHO Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"University of Florida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RNA Glioblastoma Vaccine Shows Promise in First Human Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RNA-LNP Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"University of Florida","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Florida \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AAVantgarde Announces its Innovative Clinical Study Design for its Lead Program in Usher 1 B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AAVB-081","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AAVantgarde Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgard.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAR-200 Monotherapy Shows Greater than 80 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NNC6022-0001","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 Data for ERLEADA\u00ae (apalutamide) Plus Androgen Deprivation Therapy Following Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer Show 100% Biochemical Free Recurrence Rate More than Two Years Post-Surgery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Apalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hanall Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Bio.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Rymti Biosimilar Etanercept in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Etanercept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAR-210 Results Show 90 Percent Recurrence-Free Survival and 90 Percent Complete Response in Patients with High-Risk and Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Respectively","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Erdafitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Real-World Study on Retrograde Instillation of JELMYTO\u00ae for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL757","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Shares Positive Results from the First Study Worldwide in Diabetic Macular Ischemia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 764524","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cycloserine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VYN202","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Clofazimine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Verve-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verve Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DB-OTO","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Metaphore Biotechnologies","amount2":0.59999999999999998,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Metaphore Biotechnologies \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Metaphore .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Oaktree Capital Management, L.P","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0.65000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.65000000000000002,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Verona Pharma \/ Oaktree Capital Management, L.P","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Novasep","sponsor":"Sensorion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion and Novasep Sign Agreement","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Novasep","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novasep \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Novasep \/ .."},{"orgOrder":0,"company":"Novasep","sponsor":"Celladon","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Novasep Signs \u20ac4.7m Biomanufacturing Deal with Biotech","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"AAV1-based Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Novasep","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Novasep \/ Celladon","highestDevelopmentStatusID":"8","companyTruncated":"Novasep \/ .."},{"orgOrder":0,"company":"Novasep","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novasep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novasep \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Novasep \/ .."},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Res.."},{"orgOrder":0,"company":"Quallent Pharmaceuticals","sponsor":"Alvotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira\u00ae (adalimumab)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Quallent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Quallent Pharmaceuticals \/ Alvotech","highestDevelopmentStatusID":"12","companyTruncated":"Quallent P.."},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Poolbeg Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Pentoxifylline","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Silk Road Therapies \/ Poolbeg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road .."},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Canaan","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS\u2011111, a First-in-class IOP-lowering Drug Candidate for Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Series B Financing","leadProduct":"QLS-111","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Canaan","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio.."},{"orgOrder":0,"company":"Nestl\u00e9 India Limited","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 India and Dr. Reddy\u2019s to Form Joint Venture to Take Health Science Nutraceutical Portfolio to Consumers Across India and Other Agreed Territories","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Agreement","leadProduct":"Biotin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Nestl\u00e9 India Limited","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestl\u00e9 India Limited \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Nestl\u00e9 Ind.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"AIGH Capital Management LLC","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"$6.5 million","newsHeadline":"Plus Therapeutics Announces Private Placement Financing of up to $18 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ AIGH Capital Management LLC","highestDevelopmentStatusID":"6","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"MMCAP Infuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Purdue Pharma L.P. Enters Agreement to Provide Low-cost Opioid use Disorder Treatment to Correctional Facilities for Incarcerated Individuals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharma \/ MMCAP Infuse","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pha.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"BioCopy AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Evaluation and Potential Licensing Agreement with BioCopy For TCR-mimic Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ BioCopy AG","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$326.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Seralutinib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Gossamer Bio","amount2":0.33000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.33000000000000002,"dosageForm":"Powder In Capsule","sponsorNew":"Gossamer Bio \/ Chiesi Group","highestDevelopmentStatusID":"10","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"TC BioPharm Announces Exercise of Warrants for \u00a33.1 Million Gross Proceeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPhar.."},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Guangzhou-Israel Biotechnology Fund","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"GIBF Invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-class Immunotherapies and Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"NTX-1088","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Nectin Therapeutics \/ Guangzhou-Israel Biotechnology Fund","highestDevelopmentStatusID":"6","companyTruncated":"Nectin The.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Cancer Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI\u00ae (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"ENB003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Cancer Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Ladenburg Thalmann","highestDevelopmentStatusID":"5","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Zenas BioPharma","sponsor":"SR One","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"Obexelimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Zenas BioPharma","amount2":0.20000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Zenas BioPharma \/ SR One","highestDevelopmentStatusID":"10","companyTruncated":"Zenas BioP.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$49.4 million","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics Increases Series C Financing to CHF 45 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"BKV Neutralising Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"9","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$49.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys .."},{"orgOrder":0,"company":"Agenus","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand and Agenus Enter into $100 Million Royalty Financing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Agenus \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ L.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M8 Pharmaceuticals, an Acino company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree\u00ae (Viloxazine XR) in Latin America","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"$3.0 million","newsHeadline":"IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"IRLAB","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"5","companyTruncated":"IRLAB \/ Mc.."},{"orgOrder":0,"company":"Ainos","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ainos Raises $9 Million in Growth Capital with Existing Shareholder","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Interferon Alfa","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Ainos","amount2":0.01,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.01,"dosageForm":"Troche\/Lozenge","sponsorNew":"Ainos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ainos \/ Un.."},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.01,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Organovo Holdings \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo H.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apollomics Announces Private Placement Financing and Addition to Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Vebreltinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Apollomics Inc \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Siren Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"AAV-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Siren Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"B. Dyson Capital Advisors","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ B. Dyson Capital Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Natural Sciences and Engineering Council","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Derm-Biome Pharmaceuticals and TransBIOtech Awarded $450,000 Applied Research and Development (ARD) Grant Funding","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"DB-007-4","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Pharma Inventor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Pharma Inventor","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"PBGENE-HBV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"ARTBIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"212Pb-NG001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nucleus RadioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nucleus RadioPharma \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"Nucleus Ra.."},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Yissum Research Development Company","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Yissum Res.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"CX-801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Avance Clinical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oragenics \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroTherapia Receives Grant from Alzheimer's Association for Development of First-in-class Drug for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"NTRX-07","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroTherapia \/ Alzheimer's Association","highestDevelopmentStatusID":"6","companyTruncated":"NeuroThera.."},{"orgOrder":0,"company":"Shionogi","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-based Institutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an Anti-PD-L1 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"ImmunoACT","sponsor":"Caring Cross","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caring Cross, ImmunoACT Ink Agreement to Commercialize TriCAR-T Cell Immunotherapy for Leukaemia and Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Actalycabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"ImmunoACT","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoACT \/ Caring Cross","highestDevelopmentStatusID":"12","companyTruncated":"ImmunoACT .."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Formosa Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$50.0 million","newsHeadline":"Anaptys to Receive $50 Million in a Capped Non-recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"Undisclosed","newsHeadline":"Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$182.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"BJT-778","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bluejay Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Bluejay Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Bluejay Th.."},{"orgOrder":0,"company":"Arecor","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arecor and Medtronic Diabetes Establish Collaboration to Develop a Novel Thermostable Insulin for Implantable Pump Delivery","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Arecor \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ M.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Divestment","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Royalty Pharma to Acquire Royalty Interest in Sanofi\u2019s Frexalimab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Frexalimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"ImmuNext Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmuNext Inc \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"ImmuNext I.."},{"orgOrder":0,"company":"Novavax","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$500.0 million","newsHeadline":"Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NVX-CoV2601","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Novavax","amount2":1.2,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.2,"dosageForm":"Injection","sponsorNew":"Novavax \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Alpha-lactalbumin-based Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tevogen Bio Announces up to $50 Million in Financing to Further Advance Operational Objectives","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"TVGN 489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"iTeos Therapeutics Announces $120 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Belrestotug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$150.0 million","newsHeadline":"Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"MZE001","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Maze Thera.."},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-based Institutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ Th.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-based Institutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Medix","sponsor":"Biocon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Limited Signs Semi-Exclusive Distribution and Supply Deal for The Commercialization of Generic Saxenda\u00ae (Liraglutide) in Mexico with Medix","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Medix","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medix \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Medix \/ Bi.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reneo Pharmaceuticals and OnKure Announce Proposed Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"GKCC","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"MiNK-215","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MiNK Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MiNK Therapeutics \/ GKCC","highestDevelopmentStatusID":"4","companyTruncated":"MiNK Thera.."},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","amount":"$106.6 million","upfrontCash":"Undisclosed","newsHeadline":"Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"Lysosomal-targeted Chimeras","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Lycia Therapeutics","amount2":0.11,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Lycia Ther.."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Primula Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"WAL0921","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Walden Biosciences \/ Primula Group","highestDevelopmentStatusID":"6","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"$100.0 million","newsHeadline":"AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-24.060","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":2.2000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,055.0 million","upfrontCash":"$80.0 million","newsHeadline":"Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":1.0600000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":1.0600000000000001,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Macomics","sponsor":"IFOM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Macrophage-targeted Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ IFOM","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/.."},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-class Type II JAK2 Inhibitor, AJ1-11095, into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"AJ1-11095","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ajax Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Thera.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Quallent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Expands Access to Adalimumab-Adbm Injection, the Company's Biosimilar to Humira\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Quallent Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$2,015.0 million","upfrontCash":"$65.0 million","newsHeadline":"AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-license Agreement to Develop Next-Generation Therapies for Psychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Gilgamesh Pharmaceuticals","amount2":2.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":2.02,"dosageForm":"","sponsorNew":"Gilgamesh Pharmaceuticals \/ Abbvie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Gilgamesh .."},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"ABMRF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"ANS-858","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Amygdala Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amygdala Neurosciences \/ ABMRF","highestDevelopmentStatusID":"4","companyTruncated":"Amygdala N.."},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to Initiate a Phase 3 Clinical Trial of Intralesional rhEGF for the Treatment of Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Discovery Therapeutics","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Discovery Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Discovery .."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"JSKN003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluri Launches Immunotherapy Platform for Solid Tumour Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cell-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK MHRA Grants Marketing Approval for ViiV Healthcare\u2019s Cabotegravir Formulations to Help Prevent Hiv-1 Infection in Adults and Adolescents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Reports Positive Interim Results from Phase 2a Trial of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"IMG-007","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BA3361","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Implant","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU\u2122 in Non-Proliferative Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Vorolanib","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA\u00ae in Patients with Relapsed\/Refractory Marginal Zone Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Gersizangitide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AsclepiX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX T.."},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EDG-7500","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Edgewise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise T.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Receives NMPA Breakthrough Therapy Designation for IBI343\uff08Anti-Claudin18.2 ADC\uff09as Monotherapy for Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI343","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ADRX-0706","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adcentrx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adcentrx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcentrx T.."},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azurity Pharmaceuticals, Inc. Announces FDA Approval of Myhibbin\u2122 (mycophenolate mofetil oral suspension)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Ph.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Eisbach Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisbach Bio Announces FDA Clearance of IND Application for EIS-12656, a First-in-class Allosteric Inhibitor of ALC1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EIS-12656","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eisbach Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisbach Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eisbach Bi.."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Padeliporfin VTP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"PaxMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Suramin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica .."},{"orgOrder":0,"company":"Invivyd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pemivibart","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Invivyd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"iECURE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ECUR-506","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iECURE \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ N.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth Biotherapeutics' Barth Syndrome NDA Receives Priority Review Designation","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to 9MW2821","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotheryx Announces U.S. FDA Clearance of Investigational New Drug Application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4\/6","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-9341","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioTheryX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer reports patient death in Duchenne gene therapy study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mediar Advances First-in-class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 and Establishes Clinical Advisory Board","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"MTX-463","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Mediar Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mediar The.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Prepares the Launch of The Anticoagulant Rivaroxaban.","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches the Anticoagulant Rivaroxaban on Day One in Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches the Generic Version of Teriflunomide in more than 20 European Countries","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches the Antihistamine Bilastine for A Market Entry as Over-the-counter (OTC) Medicine in Germany","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Bilastine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Psoriasis Medication Apremilast in Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Anticoagulant Medicine Apixaban in Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Apixaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Diabetes Medicine Vildagliptin and Vildagliptin \/metformin in Africa","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Vildagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Expands the Launch of The Anticoagulant Medicine Rivaroxaban to Central America and Further International Markets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sclerosis Medicine Teriflunomide in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbach.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY\u00ae T-Cell Engager)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CX-904","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"OCS-05","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Atumelnant","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Therini Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"THN391","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Therini Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therini Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Therini Bi.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer\u2122 RNA Editing Program Targeting NTCP for Cholestatic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AX-0810","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sabirnetug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CK-586","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Exosome-based Therapy","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestora.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Pathways Announces Durable Improvement in Symptoms Through 12 Weeks in Open-label Phase 2 study of COMP360 Psilocybin in Post-Traumatic Stress Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New US Product, ORMALVI\u2122 (dichlorphenamide) Tablets, Launches for Primary Periodic Paralysis (PPP) Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dichlorphenamide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-\u2018749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Medincell","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"NeuShen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NS-136","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"NeuShen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeuShen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuShen Th.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NBI-1117567","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Tiumbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-associated Pain","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Merigolix","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Tiumbio","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tiumbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiumbio \/ .."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical to Present the Phase I\/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"MHB088C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Delpacibart Etedesiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspaveli\u00ae (pegcetacoplan) Approved in Europe for use Among Treatment Na\u00efve Adult Patients with PNH","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Approval for MOB-015 in All 13 Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Terbinafine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScie.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NBI-1076986","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Jaguar Health","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent\/Metastatic HPV16-positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate Prodrug","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY\u00ae for the Treatment of Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA\u00ae (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Update on Investigational RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Sevelamer Carbonate Tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharma to Present phase I\/II study Results of MHB088C to Treat Patients with Recurrent or Metastatic Solid Tumors at ASCO meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"MHB088C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minghui Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Minghui Ph.."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sabirnetug","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces Approval of AUGTYRO\u2122 (repotrectinib) for Patients with ROS1-positive NSCLC by China\u2019s NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Photocure Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Cevira in China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to unveil Late-breaking Data from Phase III OASIS 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts Bristol Myers Squibb\u2019s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antiepileptic Drug Fycompa\u00ae Approved in China for Adjunctive Treatment of Primary Generalized Tonic-clonic Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Perampanel","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Statement on FDA Advisory Committee Meeting on Donanemab for Early Symptomatic Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk A\/S: Once-weekly and Once-monthly Mim8 Demonstrate Superior Reduction of Treated Bleeding Episodes Compared to On-Demand and Prior Prophylaxis Treatment in People with Haemophilia a In the Frontier 2 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics\u00ae Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Briquilimab Development Program in Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Briquilimab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Excision BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excision BioTherapeutics Announces Data from the Phase 1\/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EBT-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Excision BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Excision BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Excision B.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE\u00ae 327 in Lung Infection Pilot Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pint Pharma Announces the Approval of ORLADEYO\u00ae (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Mexico","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pint Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pint Pharm.."},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lipid-based Therapy","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Baxter Healthcare Corporation","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baxter Hea.."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DLX-001","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ajax Therapeutics Announces FDA Clearance of IND Application for AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AJ1-11095","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Thera.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-risk Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tarcocimab Tedromer","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"OSR Holdings","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSR Holdings and SillaJen have Entered into a Memorandum of Understanding to Collaboratively Pursue the Development of Innovative Therapeutics and Enter the U.S. Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"BAL0891","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSR Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OSR Holdings \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"OSR Holdin.."},{"orgOrder":0,"company":"OverT Bio","sponsor":"Artis Ventures","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"OverT Bio Raises $16 Million, Tapping Innovative Reprogramming of Immune Cells to Deliver Next-generation Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"OverT Bio","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"OverT Bio \/ Artis Ventures","highestDevelopmentStatusID":"3","companyTruncated":"OverT Bio .."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Beta Bionics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Beta Bionics","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"HK inno.N","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sciwind Biosciences & HK inno.N ink $56 M Deal to Treat Metabolic Diseases in Korea","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Sciwind Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ HK inno.N","highestDevelopmentStatusID":"10","companyTruncated":"Sciwind Bi.."},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"ATTO-1310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Attovia Therapeutics","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Attovia Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"5","companyTruncated":"Attovia Th.."},{"orgOrder":0,"company":"Commit Biologics","sponsor":"Bioqube Ventures","pharmaFlowCategory":"D","amount":"$17.2 million","upfrontCash":"Undisclosed","newsHeadline":"Commit Biologics Launches with \u20ac16M Seed Financing to Pioneer Complement System Activation to Treat Cancer and Autoimmune Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Commit Biologics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Commit Biologics \/ Bioqube Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Commit Bio.."},{"orgOrder":0,"company":"5 Prime Sciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"5 Prime Sciences Announces Strategic Collaboration with Lilly in Cardio-Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"5 Prime Sciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"5 Prime Sciences \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"5 Prime Sc.."},{"orgOrder":0,"company":"Eluminex Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"EB-105","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eluminex Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eluminex Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Eluminex B.."},{"orgOrder":0,"company":"Traws Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Travatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Traws Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Traws Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Traws Phar.."},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telios Pharma Announces Successful Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TL-925","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pha.."},{"orgOrder":0,"company":"TerSera Canada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves ZOLADEX\u00ae LA for the Management of Estrogen Receptor-Positive (ER+) Early Breast Cancer with a High Risk of Recurrence or Advanced Breast Cancer in Pre- and Perimenopausal Women","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Goserelin Acetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TerSera Canada","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"TerSera Canada \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TerSera Ca.."},{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product\u2122 for Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Purified Exosome-based Therapy","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Rion","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rion \/ Not.."},{"orgOrder":0,"company":"Chengdu Weisijin Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"WGc-043","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Chengdu Weisijin Biomedical Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chengdu Weisijin Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chengdu We.."},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Glyph Allopregnanolone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seaport Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Th.."},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avata Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Bios.."},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of its Series C Round by CHF 12.3 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Alpibectir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys .."},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series C Financing","leadProduct":"Denatonium Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark T.."},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-based Institutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Corallopyronin A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Eisai \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Th.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"SAKK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics, SAKK ink Agreement to Conduct Phase 2 Trial in Early-stage Breast Cancer in Europe for INT230-6","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Vinblastine Sulfate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ SAKK","highestDevelopmentStatusID":"8","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-stage Stargardt Disease Patients Treated with Gildeuretinol","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Gildeuretinol Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pha.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"$667.0 million","upfrontCash":"$27.0 million","newsHeadline":"Atara Biotherapeutics Submits Tabelecleucel (Tab-cel\u00ae) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Atara Biotherapeutics","amount2":0.67000000000000004,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Injection","sponsorNew":"Atara Biotherapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"12","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0.5,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","amount":"$448.0 million","upfrontCash":"$17.5 million","newsHeadline":"Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros The.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$325.5 million","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.33000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone Unsheathes Uniquity Bio with $300M","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Solrikitug","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Uniquity Bio","amount2":0.29999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Uniquity Bio \/ Blackstone Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Uniquity B.."},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,800.0 million","newsHeadline":"Genmab Completes Acquisition of ProfoundBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":1.8,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBi.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,150.0 million","newsHeadline":"Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":1.8,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ B.."},{"orgOrder":0,"company":"Aktis Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,160.0 million","upfrontCash":"$60.0 million","newsHeadline":"Aktis Oncology Enters Into Strategic Collaboration with Lilly to Discover and Develop Novel Anticancer Radiopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Radiopharmaceutical-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aktis Oncology","amount2":1.1599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"Aktis Oncology \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Aktis Onco.."},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$850.0 million","newsHeadline":"Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologi.."},{"orgOrder":0,"company":"Hercules CM NewCo","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Investors put $400M into Biotech Licensing Obesity Drugs from China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"HRS-7535","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Hercules CM NewCo","amount2":0.40000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"Hercules CM NewCo \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Hercules C.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"AltruBio","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"AltruBio Secures $225m for Immune Checkpoint Programme Development","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"Leiolizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AltruBio","amount2":0.23000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"AltruBio \/ BVF Partners LP","highestDevelopmentStatusID":"8","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$374.3 million","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.37,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$555.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bicycle Therapeutics","amount2":0.56000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"Infusion","sponsorNew":"Bicycle Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"9","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$1,250.0 million","newsHeadline":"Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"NM26","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":1.25,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.25,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics Announces Closing of Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0.5,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Tablet","sponsorNew":"Cytokinetics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$905.0 million","upfrontCash":"$905.0 million","newsHeadline":"Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0.91000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.91000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Prothena","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"$150.0 million","newsHeadline":"Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"PRX019","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Prothena","amount2":2.2000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"","sponsorNew":"Prothena \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"Undisclosed","newsHeadline":"Insmed Announces Pricing of $650 Million Public Offering of Common Stock","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0.65000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.65000000000000002,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ G.."},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Turn Biotechnologies","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Hanall Biopharma","amount2":0.29999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Turn Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"Hanall Bio.."},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$400.2 million","upfrontCash":"Undisclosed","newsHeadline":"Merus Announces Pricing of Upsized Public Offering of Common Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0.40000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Infusion","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Je.."},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$3,000.0 million","upfrontCash":"$1,300.0 million","newsHeadline":"Merck to Acquire EyeBio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"EyeBio","amount2":3,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":3,"dosageForm":"Injection","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"EyeBio \/ M.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$565.0 million","upfrontCash":"$70.0 million","newsHeadline":"Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0.56999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Galapagos","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,196.0 million","upfrontCash":"$2,196.0 million","newsHeadline":"Sanofi Completes Acquisition of Inhibrx, Inc.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"SAR447537","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ .."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$750.0 million","upfrontCash":"Undisclosed","newsHeadline":"Incyte Completes Acquisition of Escient Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.75,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.75,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Rilvegostomig","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech, Dr. Reddy's Collaborate on Denosumab Biosimilar in US, EU, UK","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Degron Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda & Degron Deal Announced: Multi-Target Molecular Glue Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Degron Therapeutics","amount2":1.2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Degron Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Degron The.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie: Starts Phase 3 Trial of ABBV-383 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ABBV-383","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen: Positive Uplizna Phase 3 Trial in Immunoglobulin G4-Related Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myrtelle: FDA Selects rAAV-Olig001-ASPA for Canavan START Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MYR-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/.."},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision Bio: PBGENE-HBV Preclinical Safety Data at EASL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Abiraterone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Bio.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lykos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lykos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lykos Ther.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"VK2809","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efineptakin Alfa","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Vaccinated in IMUNON\u2019s IMNN-101 Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"IMNN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon Announces Proposed Public Offering of Common Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"QUANTRO Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$544.0 million","upfrontCash":"Undisclosed","newsHeadline":"QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"QUANTRO Therapeutics","amount2":0.54000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"QUANTRO Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"QUANTRO Th.."},{"orgOrder":0,"company":"Crossject","sponsor":"Gemmes Venture","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"Crossject announces highly successful closing of its \u20ac8 million rights offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crossject","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Crossject \/ Gemmes Venture","highestDevelopmentStatusID":"12","companyTruncated":"Crossject .."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BlueSphere Bio Establishes Strategic Collaboration with the National Cancer Institute to Advance Treatments for Rare Respiratory Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"TCR T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ National Cancer Institute","highestDevelopmentStatusID":"2","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Vilya","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"Macrocycle-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Vilya","amount2":0.070000000000000007,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Vilya \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Vilya \/ AR.."},{"orgOrder":0,"company":"BioVersys AG","sponsor":"CF AMR Syndicate","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"BV500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BioVersys AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioVersys AG \/ CF AMR Syndicate","highestDevelopmentStatusID":"2","companyTruncated":"BioVersys .."},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Delix Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Delix Ther.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"HMNC Brain Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ HMNC Brain Health","highestDevelopmentStatusID":"6","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"Acquisition of Fusion Pharmaceuticals Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":2.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":2.3999999999999999,"dosageForm":"Injection","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"SciTech Development","sponsor":"Storm Lake Capital","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"SciTech Development Raises Additional $3.2M to Expand Clinical Trials for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciTech Development \/ Storm Lake Capital","highestDevelopmentStatusID":"6","companyTruncated":"SciTech De.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission approves Roche\u2019s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"EUROAPI","sponsor":"Priothera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EUROAPI and Priothera enter into CDMO collaboration to advance oncology project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Mocravimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EUROAPI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"EUROAPI \/ Priothera","highestDevelopmentStatusID":"10","companyTruncated":"EUROAPI \/ .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s and Novartis sign distribution agreement for anti-diabetes products","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Vildagliptin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Bal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bal Pharma Launches Antiviral Drug Favipiravir at Rs 85\/Tablet","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bal Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bal Pharma.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Suvecaltamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Announces Initial Closing of Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alzamend Neuro","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$376.3 million","upfrontCash":"Undisclosed","newsHeadline":"Biolojic, Merck KGaA Multi-Target Drug Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Biolojic Design \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic D.."},{"orgOrder":0,"company":"LadRx","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Termination","leadProduct":"Aldoxorubicin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"LadRx","amount2":0.35999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.35999999999999999,"dosageForm":"Infusion","sponsorNew":"LadRx \/ ImmunityBio","highestDevelopmentStatusID":"10","companyTruncated":"LadRx \/ Im.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Raises $200 Million; Also Expands License Territories for Ivonescimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$400.9 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.40000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nxera Receives US$10 Million from AbbVie for Neurological Diseases Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Group Corporation","amount2":1.2,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FibroGen, Regeneron Evaluate FG-3165, FG-3175 Plus LIBTAYO Combos","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"VGXI","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VGXI, Sutro Partner to Support Sutro's Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Luveltamab Tazevibulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"VGXI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VGXI \/ Sutro Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"VGXI \/ Sut.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces Positive Lanifibranor DMC Recommendation in NATiV3","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue's AJ201 Muscle Atrophy Trial Completes Last Patient Visit","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Doses First Alzheimer's Participants in VY-TAU01 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VY-TAU01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Vepdegestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Endeavor Biomedicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENV-101 Phase 2a Shows Lung Function, Fibrosis Reversal in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Taladegib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Endeavor Biomedicines","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endeavor Biomedicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor B.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seladelpar Shows Liver, Itch Improvements in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Seladelpar","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Doses First CT-0525 HER2 CAR-Monocyte Patient","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CT-0525","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis, Biogen Announce ALS Drug Topline Phase 1\/2 Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ION541","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar: FDA Removes Partial Hold on Nomlabofusp Friedreich's Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor: Positive 3-Year CAP-1002 Efficacy in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre: IND for PFL-002\/VERT-002 in Solid Tumors with MET Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PFL-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olaparib Tablets Obtains Drug Registration Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CSPC Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSPC Pharm.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves EPKINLY\u00ae for Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai and Biogen Launch Alzheimer's Drug Leqembi in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epcoritamab (TEPKINLY\u00ae) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed\/ Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for WINREVAIR\u2122 (sotatercept) in Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotatercept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alumis Announces Pricing of Initial Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Alumis","amount2":0.25,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Alumis \/ M.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Completion of an Upsized Equity Offering of 8.35 Million New Ordinary Shares Raising Gross Proceeds of USD 1 billion \/ DKK 7 Billion","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":1,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Launches Equity Offering Raising USD 900 Million \/ DKK 6.257 Billion","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0.90000000000000002,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$381.0 million","upfrontCash":"$381.0 million","newsHeadline":"ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0.38,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.38,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sc.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$461.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Closes Upsized Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.46000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,842.0 million","upfrontCash":"$42.0 million","newsHeadline":"Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ascidian Therapeutics","amount2":1.8400000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8400000000000001,"dosageForm":"","sponsorNew":"Ascidian Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Ascidian T.."},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$850.0 million","upfrontCash":"$850.0 million","newsHeadline":"Johnson & Johnson Completes Acquisition of Proteologix, Inc.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0.84999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologi.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"siRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Haleon","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"$632.9 million","upfrontCash":"$579.8 million","newsHeadline":"Dr. Reddy's Acquire Nicotinell and Related Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Haleon","amount2":0.63,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.63,"dosageForm":"Troche\/Lozenge","sponsorNew":"Haleon \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"2","companyTruncated":"Haleon \/ D.."},{"orgOrder":0,"company":"TRexBio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,155.0 million","upfrontCash":"$55.0 million","newsHeadline":"TRexBio Announces Lilly has Initiated Phase 1 Study for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"TRB-051","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TRexBio","amount2":1.1599999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"TRexBio \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ .."},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$622.0 million","upfrontCash":"$45.0 million","newsHeadline":"QurAlis Grants Lilly Exclusive Global License For QRL-204 In ALS, FTD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"QRL-204","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0.62,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.62,"dosageForm":"","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Arrivent","pharmaFlowCategory":"D","amount":"$615.5 million","upfrontCash":"Undisclosed","newsHeadline":"ArriVent Announces a Multi-Target ADC Collaboration with Alphamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alphamab Oncology","amount2":0.62,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.62,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ ArriVent","highestDevelopmentStatusID":"2","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Cilcare","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"$16.0 million","newsHeadline":"Japan's Shionogi Inks \u20ac400 M Deal with French Firm Cilcare","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"CIL001","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Cilcare","amount2":0.02,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Cilcare \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Cilcare \/ .."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ultragenyx Prices Public Offering Of Common Stock, Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Vaxart","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$453.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxart Gets BARDA Award Up To $453M For COVID-19 Oral Pill Vaccine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0.45000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ B.."},{"orgOrder":0,"company":"FutureGen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,710.0 million","upfrontCash":"$150.0 million","newsHeadline":"AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"FG-M701","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"FutureGen","amount2":1.71,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.71,"dosageForm":"","sponsorNew":"FutureGen \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"FutureGen .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":1.3,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.3,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"MabCare Therapeutics","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$1,207.0 million","upfrontCash":"$55.0 million","newsHeadline":"Day One Inks $1.2B Biobucks Pact for MabCare\u2019s Solid Tumor ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"MTX-13","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MabCare Therapeutics","amount2":1.21,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.21,"dosageForm":"","sponsorNew":"MabCare Therapeutics \/ Day One Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MabCare Th.."},{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Melodia and Alivexis Sign Exclusive License for Cathepsin C Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"MDI-0151","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alivexis","amount2":0.28000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Alivexis \/ Melodia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Alivexis \/.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$547.4 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Closes Upsized Offering, Fully Exercised Underwriter Option","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0.55000000000000004,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.55000000000000004,"dosageForm":"Capsule","sponsorNew":"Structure Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep, Merck Collaborate On Efti Plus KEYTRUDA In Pivotal Phase III","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Biophta","sponsor":"UI Investissement","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"BIOPHTA Raises \u20ac6.5M For Eye Disease Therapy Clinical Transition","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Insert","sponsorNew":"Biophta \/ UI Investissement","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities, Inc","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gain Therapeutics Announces Pricing of $11.0 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"6","companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$740.0 million","upfrontCash":"$40.0 million","newsHeadline":"Belharra & Sanofi Partner to Discover New Small Molecules for Immunological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Belharra Therapeutics","amount2":0.73999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.73999999999999999,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Belharra T.."},{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$372.0 million","upfrontCash":"Undisclosed","newsHeadline":"Formation Bio Raises $372M Series D to Expand Drug Pipeline and AI-Driven Development Platform","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Formation Bio","amount2":0.37,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Formation .."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$250.0 million","newsHeadline":"AbbVie Acquires Celsius Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"CEL383","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Celsius Therapeutics","amount2":0.25,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Celsius Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bionomics Limited Announces Private Placement of up to $70.0 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.070000000000000007,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Bionomics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"$174.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rapport Therapeutics Closes $174M IPO, Including Underwriters\u2019 Option and Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rezolute Announces $60M Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Replimune","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Replimune Announces $100 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Replimune \/ Redmile Group","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marea Therapeutics Launches with $190M to Develop Medicines for Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"MAR001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Marea Therapeutics","amount2":0.19,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Marea Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Marea Ther.."},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iambic Therapeutics Closes $50M Series B Extension to Broaden AI-Discovered Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"IAM1363","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Iambic Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Iambic The.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Frontier Medicines Appoints Gerardo Ubaghs as CFO, Announces $20M Series C Extension","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series C Financing","leadProduct":"FMC-376","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Frontier Medicine","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Frontier Medicine \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$20.0 million","newsHeadline":"NeuroBo Pharmaceuticals Closes $70M Private Placement and Direct Offering Priced At-the-Market","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"DA-1726","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"$154.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rapport Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Th.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Submits NDA to FDA for DCCR Tablets for Prader-Willi Syndrome Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Vabysmo gets CHMP Recommendation for Third Indication Retinal Vein Occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends EU Approval of Roche\u2019s PiaSky for PNH Treatment","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Crovalimab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odronextamab Recommended for EU Approval to Treat Relapsed\/Refractory Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis to Seek Re-Examination After Negative CHMP Opinion for Pegcetacoplan in EU","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Doses First Person in Phase 1b Trial of HB-500 for HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"HB-500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Positive Clinical Trial Results for BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharma Reports Positive Data from Phase I\/II Trial of RECCE\u00ae 327 for UTI\/Urosepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Menten AI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Menten AI Announces Completion of Research Collaboration with Bristol Myers Squibb","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Peptide-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Menten AI","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Menten AI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Menten AI .."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reviva Closes $3M Registered Direct Offering Priced At-the-Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"ExpressionEdits","sponsor":"Octopus Ventures","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"ExpressionEdits Raises $13M Seed Funding to Advance AI-Driven Intronization Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Protein-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ExpressionEdits","amount2":0.01,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ExpressionEdits \/ Octopus Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Expression.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Live Modified Vaccinia Virus Ankara","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sinopia Secures Grant from NIGMS to Advance Metabolomics Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sinopia Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopia Biosciences \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Sinopia Bi.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children's Research Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioLineRx, St. Jude to Evaluate Motixafortide for CD34+ HSC Mobilization in Sickle Cell Gene Therapy","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioLineRx \/ St. Jude Children's Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Jones","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics Announces Proposed Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Jones","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eliem Announces Closing of Acquisition of Tenet Medicines & $120 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"Budoprutug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eliem Therapeutics","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eliem Ther.."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0.13,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Altos Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altos Biologics Files for Approval of Aflibercept Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Altos Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altos Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Altos Biol.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharma Receives Breakthrough Therapy Designation for Bexicaserin (LP352)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Cohance Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avra Laboratories Gets Regulatory Approval for Covid-19 Drug Favipiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cohance Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cohance Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cohance Li.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati: Isturisa\u00ae (Osilodrostat) Approved In The U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Ingenus Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr Reddy's Signs In-Licensing Pact with Ingenus for Cancer Treatment Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ingenus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Ingenus Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Ingenus Ph.."},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Kalinga Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supriya Lifescience Signs Agreement with KIT for Further Development of Wound Healing Gel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Protein-based Crosslinked Hydrogel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Supriya Lifescience","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supriya Lifescience \/ Kalinga Institute of Technology","highestDevelopmentStatusID":"4","companyTruncated":"Supriya Li.."},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terran Announces Develop of TerXT, Xanomeline &Trospium Prodrugs for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Trospium Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Terran Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terran Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Terran Bio.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces New Clinical Data of KAN-101 for the Treatment of Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Precigen","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Reports Positive PRGN-2012 Data For Recurrent Respiratory Papillomatosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Elastin BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elastin Reports Positive Data For Aneurysm And Williams Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Elastin BioSciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elastin BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elastin Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Riliprubart Shows Promise in CIDP Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Riliprubart","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre Overactive Bladder Med Wins Approval","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Vibegron","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpringWorks Submits NDA For Mirdametinib in NF1-PN Treatment For Children And Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirdametinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Adalvo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo Announces Successful DCP Approval of Pregabalin Prolonged Release Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ N.."},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Launch of AFD-NP Product for Neuropathic Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Anglo-French Drugs and industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Anglo-French Drugs and industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Anglo-Fren.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frexalimab Ph 2 Data Showed Red of Key Biomarker of Nerve Cell Damage in Relapsing MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Frexalimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camber Launches Generic Lyrica\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Camber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Camber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camber Pha.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Two Final Approvals from The USFDA for Silodosin and Pregabalin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indoco Remedies Receives Final ANDA Approval from USFDA for Pregabalin Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Rem.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Receives FDA Approval for Pregabalin Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Xgene Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NDA Application of XG005 will Follows a Regulatory Pathway Bosed on FDA\u2019s Feedback","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xgene Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xgene Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xgene Phar.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Announces its First Product Approval from its Formulation Division IV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Anew Medical","sponsor":"Japan\u2019s Okinawa Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANEW MEDICAL Partners with Okinawa Research Center to Study Klotho Gene","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Klotho Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Anew Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anew Medical \/ Japan\u2019s Okinawa Research Center","highestDevelopmentStatusID":"4","companyTruncated":"Anew Medic.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Gets EU Orphan Designation for RP-A601 in Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RP-A601","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Multiply Labs","sponsor":"Retro Biosciences","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Multiply Labs and Retro Biosciences Announce $85 Million Partnership for Cell Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Multiply Labs","amount2":0.089999999999999997,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Multiply Labs \/ Retro Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Multiply L.."},{"orgOrder":0,"company":"Tourmaline Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tourmaline Bio Begins Phase 2 TRANQUILITY Trial of TOUR006 for Cardiovascular Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TOUR006","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tourmaline Bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tourmaline Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tourmaline.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive HELIOS-B Phase 3 Results for Vutrisiran in Both Populations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence's Zerlasiran Shows Positive 48-week Phase 2 Data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Zerlasiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Completes Taro Merger","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharm.."},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taro Shareholders Approve Merger with Sun Pharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Merger","leadProduct":"Acetazolamide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharm.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics and Royalty Pharma Announce $575 Million Funding Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences gets tentative approval from USFDA for BP lowering drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Gets FDA Tentative Approval for Hypertension Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NILEMDO\u00ae and NUSTENDI\u00ae Approved in Europe for Lowering LDL Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST\u201e","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Etripamil","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyre Pharmaceuticals Gets IND Approval from NMPA for F230 in Pulmonary Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"F230","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Gyre Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gyre Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Gyre Thera.."},{"orgOrder":0,"company":"Amarin","sponsor":"Vianex S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amarin Receives National Reimbursement for VAZKEPA\u00ae in Greece and Signs Marketing Deal","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Vianex S.A","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ V.."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerovate: 24-Week Results from Phase 2b IMPAHCT for Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Isoproterenol Hydrochloride Injection, USP in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Isoproterenol HCl","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Losartan and Hydrochlorothiazide Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Losartan Potassium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Metoprolol Succinate ER Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Metoprolol Succinate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuLiv's Verbasnol Reduces Acne And Improves Skin Quality in Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Norepinephrine","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"NuLiv Science","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NuLiv Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NuLiv Scie.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Pharmaceuticals Inc., Receives ANDA Approval for Prazosin Hydrochloride Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Prazosin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Sildenafil for Oral Suspension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faraday Completes Enrollment in Phase 3 Iocyte AMI-3 Trial of FDY-5301","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Iodide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Faraday Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Faraday Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Faraday Ph.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analysis Shows INPEFA Reduced Heart Failure Risk in Preserved Ejection Fraction Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Announces Further Success with AstraZeneca Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN10","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concerto Receives FDA IND Clearance for Live Biotherapeutic for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ENS-002","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Concerto Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Concerto Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Concerto B.."},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maruho Launches Mitchga SC Injection for Pruritus in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Maruho","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Maruho \/ C.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Achieves Primary Endpoints for Picankibart in Psoriasis Phase 3 Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Picankibart","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evolus Launches Nuceiva in Spain for Botulinum Toxin Type A","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Santa Ana Bio","sponsor":"GV","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Santa Ana Bio Launches With $168 Million for Precision Medicines in Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"SAB01","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Santa Ana Bio","amount2":0.13,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Santa Ana Bio \/ GV","highestDevelopmentStatusID":"5","companyTruncated":"Santa Ana .."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Initiates Phase 3 VELA Program of sonelokimab for Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDSCO Approves Boehringer Ingelheim\u2019s Spevigo for Generalized Pustular Psoriasis Flare","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Spesolimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Adbry Autoinjector for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves biosimilar Pyzchiva\u00ae (ustekinumab-ttwe), to be commercialized by Sandoz in US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Starts Phase 2 Trial for Zl-1102 in Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ZL-1102","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics: Outcome of KOURAGE-1 Study on Oral Difelikefalin in Notalgia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"EQ101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dermata Announces $2.66 Million Warrant Exercise Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"DMT310","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-332","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Completes Patient Enrollment in Phase II Trial of ICP-488 for Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-488","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Gets Positive FDA Feedback And Updates Expansion Strategy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"MC2-32","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Toray Industries","sponsor":"Immunis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toray Industries \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Toray Indu.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Completes Phase 2b Study of ADESOS, Data Presented at RAVE 2024","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Orismilast","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No sweat for dermatology specialist Botanix as hyperhidrosis gel Sofdra gains FDA approval","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Botanix Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Botanix Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Botanix Ph.."},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soterios Pharma Reports Positive Phase II Results for STS-01 in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"STS-01","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soterios Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Soterios P.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tapinarof","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Almirall\u2019s Klisyri\u00ae for Actinic Keratosis on Expanded Facial Areas","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apotex Acquires Searchlight, a Canadian Specialty Innovative Branded Pharma Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SEARCHLIGHT PHARMA INC","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"SEARCHLIGH.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Beimei Pharma","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$10.0 million","newsHeadline":"Sol-Gel and Beimei Pharma Announce Asset Purchase Agreement for TWYNEO\u00ae in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.02,"dosageForm":"","sponsorNew":"Sol-Gel Technologies \/ Beimei Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"Undisclosed","newsHeadline":"Enveda Biosciences Announces $55M in New Funding to Advance Candidates to Clinical Trials","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0.12,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bio.."},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lindus Health Launches Acne Trial with Acinonyx Bio Evaluating Alternative Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"ACX","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Hea.."},{"orgOrder":0,"company":"Topix Skin Health","sponsor":"University of Minnesota","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TOPIX Partners with University of Minnesota for ProteXidine Molecule Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"ProteXidine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Topix Skin Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Topix Skin Health \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Topix Skin.."},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turn Therapeutics Invites Investment for Wound Formula Expansion into Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Turn Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Turn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Turn Thera.."},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Develops iPSCelz\u00ae to Produce Human Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Producing Islet Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"PolTREG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolTREG\u2019s PTG-007 Shows Long-Term Safety in Type-1 Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PTG-007","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"PolTREG","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolTREG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PolTREG \/ .."},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kexing Gets Approval for Trial of Long-Acting Growth Hormone Drug","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"GB08","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Kexing Biopharm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kexing Biopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kexing Bio.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Bio","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SAB-142","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$35.1 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Reports Positive Phase I Results For CT-388 In Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Reports Positive Phase Ib Results For CT-388 In Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CT-388","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Gets Positive CHMP Opinion for Dasiglucagon in Severe Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Vivani's IND for NPM-119 Drug Implant","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Med.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"At278 Insulin Shows Superiority in Phase I Trial for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Aspart","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction and Safety","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Efsitora Alfa","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA panel votes against Novo Nordisk's weekly insulin in type 1 diabetes patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Gets Approval for Generic Somatuline\u00ae Depot Injection (Lanreotide)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Launches Authorized Generic of Victoza (liraglutide) in the U.S.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Adalvo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ N.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis must wait 3 more months for FDA verdict on TransCon PTH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Announces Extension of FDA Review for TransCon PTH in Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Palopegteriparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA places clinical hold on Biomea's diabetes trials","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indoco's ANDA for Canagliflozin, Metformin Gets Tentative Approval","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Rem.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga approved in the US for the treatment of paediatric type-2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphaia's Lead Drug Shows Positive Phase 2 Results for Prediabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dextrose","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pha.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Closes Upsized Public Offering with Additional Shares Option","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Structure Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUADONG MEDICINE Reports Positive Phase I Results for GLP-1 Agonist HDM1002","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"HDM1002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Huadong Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Huadong Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Huadong Me.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Biopharma Reports Positive Phase 2 Data for Once-Weekly Levothyroxine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Laxxon Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laxxon Medical Develops Non-Invasive 3D Printed Oral GLP-1 Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"LXM.2","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Laxxon Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laxxon Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Laxxon Med.."},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NephroDI Secures Investment to Develop NDI-5001 for Pediatric Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"NDI-5001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NephroDI Therapeutics \/ Sound Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI T.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases to Present Data in Cushing\u2019s Disease at ENDO 2024","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Meets Primary Endpoint in Phase 3 GRACE Trial of Relacorilant in Cushing's","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Biosplice","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosplice, Novo Nordisk Partner to Develop Drug Candidates for Treatment of Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biosplice \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Biosplice .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSyent In-Licenses Endocrinology Product for Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ BIOSYENT PHARMA INC","highestDevelopmentStatusID":"1","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"SNIPR Biome","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"SNIPR Biome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SNIPR Biome \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SNIPR Biom.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae QUASAR Study in UC Meets Primary and Major Secondary Endpoints","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA Outperforms STELARA In Phase 3 Crohn's Disease Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYMFENTRA\u2122 Shows Long-Term Efficacy for Crohn's Disease and Ulcerative Colitis Treatment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Infliximab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"More than Half of Crohn's Patients Achieve Remission with Lilly's mirikizumab","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Mozart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mozart Therapeutics Doses First Cohort in Phase 1a\/b Trial of MTX-101","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MTX-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Mozart Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mozart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mozart The.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio's PALI-2108 Shows Efficacy in Preclinical Models","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Strand Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palisade Provides Update on Advancement of its Collaboration with Strand Life Sciences","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Strand Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Spyre Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spyre Doses First Patients in Phase 1 Trial, SPY001 for the Treatment of IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SPY001","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Spyre Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spyre Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spyre Ther.."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"CinRx Pharma","pharmaFlowCategory":"D","amount":"$59.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinDome Pharma Announces $40 Million Series B Extension","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"Deudomperidone","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"CinRx Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"CinRx Pharma \/ CinRx Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark gets USFDA nod to market generic drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Esomeprazole Magnesium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Trial of EP-104GI","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia P.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chugai Pharma Europe","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn, Chugai renew partnership to sell AKYNZEO\u00ae in UK and Ireland","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Fosnetupitant Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Group launches Akynzeo injection in US market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosnetupitant Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Loperamide HCl and Simethicone Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Loperamide Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Anbison","sponsor":"Ethypharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethypharm expands its Mesalazine (Etiasa\u00ae) Portfolio in China","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Mesalazine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Anbison","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Anbison \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Anbison \/ .."},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurogastrx Secures $60 Million Series B Financing to Advance Gastrointestinal Therapies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series B Financing","leadProduct":"Metopimazine Mesylate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Neurogastrx \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastr.."},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ensho Therapeutics Launches with Phase 2-Ready Oral \u03b14\u03b27 Inhibitor for IBD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma .."},{"orgOrder":0,"company":"EA Pharma","sponsor":"Ensho Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EA Pharma and Ensho Sign License Agreement for EA1080, \u03b14\u03b27 Integrin Antagonist","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NSHO-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"EA Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EA Pharma \/ Ensho Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"EA Pharma .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Pantoprazole Sod Delayed-Release Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Pantoprazole Sodium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums Launches Rabeprazole + Levosulpiride SR Capsules for GERD in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rabeprazole","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drug.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm\/10 mL","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sucralfate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Signs Agreement With Takeda To Commercialize Vonoprazan in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Signs Patent License with Takeda for Voltapraz in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen: Enrollment Approved for High Dose Cohort 3 in GARDian Study for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV5-hRORA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Completes Dosing for Stargardt Disease in Phase 1\/2 GARDian Trial of OCU410ST","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV5-hRORA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbor Biotechnologies Presents ABO-101 Data at ASGCT Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ABO-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arbor Biotechnologies, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Reports Positive Interim Data for AMT-130 in Huntington Disease Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AMT-130","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Receives FDA RMAT Designation for AMT-130 in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AMT-130","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Be Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Be Bio\u2019s haemophilia B treatment gains FDA orphan drug status","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Be Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Be Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Reports Positive Results from Phase 3 DTX401 Gene Therapy Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DTX401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Grace Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grace Science Selected by FDA for START Pilot Program for GS-100 Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GS-100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grace Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Scie.."},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beacon Therapeutics treats first patient with AGTC-501 in pivotal VISTA trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon The.."},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":"9","companyTruncated":"Beacon The.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Provides Regulatory Update on Kresladi","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Marnetegragene Autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA Pilot Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NGN-401","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Reports Positive Long-Term Data on NTLA-2002 for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NTLA-2002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Doses First Patient in Phase 3 Trial for OCU400 in RP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Opus Genetics Announces $1.7 Million in Funding for Preclinical Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"OPGx-RHO","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Opus Genetics \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genet.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Plans Accelerated Approval for UX111 in Sanfilippo Syndrome A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rebisufligene Etisparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Expands AFFINITY DUCHENNE\u00ae Trial to Younger Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Proposes Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Prices Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha's TSHA-102 Shows Positive Data Ongoing REVEAL Ph 1\/2 Trials in Rett Syndrome Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"TSHA-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"2seventy bio Sells Hemophilia A Candidate and MegaTAL Technology to Novo Nordisk for $40M","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Divestment","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy B.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ARCT-032","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali\u2019s DNL126 Selected for Pilot Program to Accelerate Rare Disease Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"DNL126","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"Ionis Expands Licensing Agreement with Otsuka for Donidalorsen in Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Donidalorsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Reports Data from ACHIEVE and DELIVER Trials on Biomarkers and Function","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DYNE-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi's ALTUVOCT\u2122 Gets EU Approval for Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efanesoctocog Alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entrada Therapeutics Announces $100 Million Registered Direct Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Entrada Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Janus Henderson Investors","highestDevelopmentStatusID":"6","companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis announces positive results from Phase 1\/2a trial of ION582 for Angelman syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ION582","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna's mRNA-3705 for Methylmalonic Acidemia Chosen for FDA START Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-3705","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Generium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia registers domestic generic of Spinraza","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Generium","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Generium \/.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis\u2019 Olezarsen FCS NDA Accepted for Priority Review; Phase 3 sHTG Enrollment Completed","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Olezarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Reports Topline Results for Plozasiran in Familial Chylomicronemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Plozasiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Advances RNAi-based Plozasiran into Phase 3 CAPITAN Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Plozasiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Biopharma\/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Recombinant Human Heparan N-sulfatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"5","companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mereo BioPharma Prices $50 Million Direct Offering of American Depository Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx & Mereo BioPharma: New Phase 2 Data on Setrusumab in Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma Shares Preliminary Results Of Viltolarsen Phase 3 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Seroba","pharmaFlowCategory":"D","amount":"$70.7 million","upfrontCash":"Undisclosed","newsHeadline":"Seroba and Kurma Announce \u20ac65.8 Million Funding for Vico Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"VO659","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Seroba","highestDevelopmentStatusID":"7","companyTruncated":"Vico Thera.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences Reports Positive SELECT-HD Trial Results in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"WVE-003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma gets USFDA nod for generic injection to treat hereditary angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives NICE Recommendation for IMCIVREE\u00ae in Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE\u00ae in Obesity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Cranbury Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cranbury Receives FDA Approval for First Generic Emflaza Oral Suspension","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Deflazacort","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cranbury Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Cranbury Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cranbury P.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva\u2019s AUSTEDO\u00ae XR Approved as Once-Daily Treatment for Tardive Dyskinesia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"EV\u014cQ Nano","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EV\u014cQ Bio Completes Pre-IND Meeting with FDA for Inhaled Therapeutic for Lung Infections","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EVQ-218","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"EV\u014cQ Nano","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EV\u014cQ Nano \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EV\u014cQ Nano .."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera's Raxone\u00ae Meets Phase 4 Endpoint in Optic Neuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio: Positive Phase 2 Results for Infigratinib in Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios\u2019 Mitapivat Meets All Key Endpoints in Phase 3 ENERGIZE-T Study for Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitapivat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuren Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pha.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Secures Approval for Penicillamine Capsules, Generic of Cuprimine\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Penicillamine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim PIVOT-HD Results Show Favorable Effects in Huntington's Disease Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PTC518","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Forms Clinical Advisory Board for SAT-3247 in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Satellos Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Satellos B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Submits NDA for Sebetralstat for Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Initiates KONFIDENT-KID Trial for Sebetralstat in Children with Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sebetralstat","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Status To Spinogenix's SPG601 For Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG601","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rege Nephro Enrolls Patients For Phase II Tamibarotene ADPKD Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rege Nephro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephr.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Tranexamic Acid Injection, USP in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMT Research Partners with ReviR to Advance Small Molecule Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReviR Therapeutics \/ CMT Research Foundation","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Ther.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"R-Bridge","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"$30.0 million","newsHeadline":"Santhera Secures CHF 69 Million in Royalty and Debt Financing for Cash Flow Break-Even","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ R-Bridge","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Launches AGAMREE\u00ae Early Access in China by its Partner Sperogenix","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Sperogenix Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sperogenix.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Ethypharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acquisition of Argatroban Business in Europe","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Argatroban Monohydrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mitsubishi Tanabe Pharma \/ Ethypharm","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Reports Positive Interim Data in Chronic Neutropenia Trial","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"SMC Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Leronlimab","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ SMC Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Launches Phase 3 Trial of Pegozafermin in MASH Patients with Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegozafermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Surrozen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surrozen Begins Phase 1b Trial of SZN-043 for Severe Alcohol-Associated Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SZN-043","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer's Survodutide Shows Improvement in Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Survodutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen's Iqirvo\u00ae Gets FDA Approval for Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Status To DURECT's Larsucosterol For Hepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Larsucosterol","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum\u2019s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Volixibat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Reports Positive Data from Phase 2 CARPO Trial of Auxora in Acute Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Ochre Bio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$37.5 million","upfrontCash":"Undisclosed","newsHeadline":"GSK Enters Multi-Year Data Licence Agreement with Ochre Bio for Liver Disease Research","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Ochre Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ochre Bio \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Ochre Bio .."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Receives RMAT Designation for Descartes-08 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antion Develops Safety-Enhanced Off-The-Shelf CAR T-Cells For Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"miCAR19","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antion Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Bio.."},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quell's QEL-001 CAR-Treg Therapy Moves to Phase 1\/2 Trial for Liver Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"QEL-001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Quell Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Quell Ther.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Hong Kong King-Friend Industrial Co. Ltd","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$40.0 million","newsHeadline":"Coherus BioSciences Divests YUSIMRY in $40 Million All Cash Transaction","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Divestment","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Coherus Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Hong Kong King-Friend Industrial Co. Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Reports Positive Phase 1 Results for AK006 with Favorable Safety Profile","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AK006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces First Patient Dosed in Phase 1 of AK006 in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AK006","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Announces First Patient Dosed in Ph 2 Study of Barzolvolimab in Prurigo Nodularis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Resubmits Batoclimab BLA to NMPA for Myasthenia Gravis Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harbour Bi.."},{"orgOrder":0,"company":"Tenet Medicines","sponsor":"Eliem Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eliem Announces Closing of Acquisition of Tenet Medicines & $120 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Budoprutug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Tenet Medicines","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenet Medicines \/ Eliem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Tenet Medi.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASI Pharmaceuticals Plans IND Submission for CID-103 and Receives Acquisition Proposal","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CID-103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CASI Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASI Pharmaceuticals Receives FDA IND Clearance for CID-103 in Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CID-103","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CASI Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Reports Second Positive DSMB Review For Efzofitimod In Sarcoidosis Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi's Emapalumab-lzsg Gets FDA Fast Track For Macrophage Activation Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Emapalumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HI-Bio Reports Positive Phase 2 Results of Felzartamab in Kidney Transplant Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ N.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes University Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE: Positive Phase 1\/2 Results for FR104\/VEL-101 in Renal Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"FR104","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"$157.5 million","upfrontCash":"$10.0 million","newsHeadline":"Bio-Thera and STADA Reach Agreement for BAT2506 Biosimilar in the EU and UK","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Gollmumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.16,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces IBI311 New Drug Application Accepted by NMPA for Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI311","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Biotest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols\u2019 Biotest: FDA Approves Yimmugo for Primary Immunodeficiencies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin Intravenous, Human - Dira","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biotest","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biotest \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biotest \/ .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen\u2019s trial brings new hope for IgG4-RD patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Hits Interim Enrollment in Phase 3 Itolizumab Study for Acute GVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"JJP Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JJP Biologics to Execute First-in-Human Trial of mAb JJP-1212 for Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"JJP-1212","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"JJP Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JJP Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"JJP Biolog.."},{"orgOrder":0,"company":"Radar Therapeutics","sponsor":"NfX Bio","pharmaFlowCategory":"D","amount":"$13.4 million","upfrontCash":"Undisclosed","newsHeadline":"Radar Therapeutics Raises $13.4M in Seed Funding for Programmable Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Radar Therapeutics","amount2":0.01,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Radar Therapeutics \/ NfX Bio","highestDevelopmentStatusID":"2","companyTruncated":"Radar Ther.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late Results Show Nipocalimab Improves Sj\u00f6gren's Disease Activity in Phase 2 Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kashiv BioSciences Licenses Proposed Biosimilar to XOLAIR\u00ae (Omalizumab) from Amneal","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv BioSciences \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives EU Approval for Omlyclo\u00ae (CT-P39), Omalizumab Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Ruxoprubart Phase II Trial for ANCA Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ruxoprubart","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"NovelMed Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NovelMed T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kevzara Approved for Active Polyarticular Juvenile Idiopathic Arthritis by FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sarilumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Completes Enrollment in Phase III Trials of Telitacicept for IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TOFIDENCE (tocilizumab) Approved as Biosimilar to ROACTEMRA in EU","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics: Phase 3 Program for VRDN-003 in Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"VRDN-003","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Holoclara","sponsor":"BOLD Capital Partners","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Holoclara Announces $16 Million Series A for Worm-Derived Therapies for Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"Worm-derived Drug","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Holoclara","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Holoclara \/ BOLD Capital Partners","highestDevelopmentStatusID":"3","companyTruncated":"Holoclara .."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"7 Hills Pharma Receives $4.7MM Grant for Cell\/Gene Therapy Technology in the Clinic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"7HP935","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Cogent Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cogent's SUMMIT Trial Data Shows Promise for Bezuclastinib in Patients with NonAdvSM","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bezuclastinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cogent Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cogent Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cogent Bio.."},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celon Pharma Reports Phase II Results for CPL\u2019 116 in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CPL\u2019 116","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celon Phar.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Reports Positive Anaphylm\u2122 Study Data for Epinephrine Sublingual Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Announces Positive Results from IMG-004 Multiple Ascending Dose Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"IMG-004","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene B.."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Advances Lead Candidate to Phase 2b Following FDA Type-C Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monte Rosa Therapeutics Proposes Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"MRT-6160","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ TD Cowen","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"NodThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NodThera's NT-0796 Meets Primary Endpoint in Inflammation Reversal in Obese Subjects","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NT-0796","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NodThera","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NodThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NodThera \/.."},{"orgOrder":0,"company":"Molecure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecure Receives Approval for Phase II Trial of OATD-01 for Pulmonary Sarcoidosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"OATD-01","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Molecure","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Molecure \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Confirms Long-term Safety of Remibrutinib in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Remibrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Updates on Tacrolimus Inhalation Powder Phase 2 Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI and AstraZeneca Collaboration Yields Further Novel Target Progress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"LogiX Biosciences","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Logix Biosciences Partners with Mayo Clinic for Allergy Relief and Infectious Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"LogiX Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogiX Biosciences \/ Mayo Clinic","highestDevelopmentStatusID":"2","companyTruncated":"LogiX Bios.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"PrecisionLife","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ PrecisionLife","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio: TVGN 489 Shows Efficacy Against FLiRT Strains of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"TVGN 489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tevogen Bio Enters Agreement for Up to $50 Million in Financing for R&D Efforts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"TVGN 489","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"ACTG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Announces Launch of its First HIV Cure Clinical Trial in Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"10-1074-LS-J","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"ACTG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ACTG \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ACTG \/ Not.."},{"orgOrder":0,"company":"Bluejay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluejay Receives EMA Orphan Designation for BJT-778 in Chronic Hepatitis D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BJT-778","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Bluejay Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluejay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluejay Th.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 Agrees to Acquire Global Rights to VOWST\u00ae, Product it Launched in June 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores Live","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sipavibart Meets Primary Endpoints In Phase III COVID-19 Prevention Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sipavibart","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeNeuro Announces Results of the GNC-501 Study in post-Covid-19 Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Temelimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeNeuro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeNeuro \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tobevibart + Elebsiran Show High Response in Hepatitis Delta Virus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Elebsiran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Bio Receives IND Clearance & Fast Track for Tobevibart & Elebsiran for CHD Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Elebsiran","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedanta Biosciences Enrolls First Patient in Phase 3 RESTORATiVE303 Study of VE303","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vedanta Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Elion Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elion Therapeutics Closes $81 Million Series B Funding Led by Deerfield & AMR Action Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"Amphotericin B Analog","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Elion Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Elion Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Elion Ther.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verrica Amends Collaboration with Torii to Fund Phase 3 Trial for YCANTH\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Broad-spectrum Antiviral May Work Against H5N1 in Humans","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Acino Pharma","sponsor":"Allecra Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allecra and Acino sign deal for Exblifep antibiotic in GCC, South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Acino Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Acino Pharma \/ Allecra Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acino Phar.."},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Orchid Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Orchid Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Orchid Pha.."},{"orgOrder":0,"company":"Orchid Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchid Pharma Receives DCGI Approval for Cefepime & Enmetazobactam Antibiotic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cefepime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Orchid Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Orchid Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchid Pha.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J seeks expanded approvals for paediatric HIV-1 therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Darunavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Shionogi","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Updates SCORPIO-HR Study of Ensitrelvir for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India gets ANDA Approval for Guaifenesin and Pseudoephedrine Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Guaifenesin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Gets Tentative Approval for Guaifenesin ER Tablets, Generic of Mucinex\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Guaifenesin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Successfully Completes FDA End-of-Phase 2 Meeting for Ibezapolstat in C. difficile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets Approval for LIVTENCITY\u00ae in Japan for CMV Infection Post-Transplant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Maribavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Reports Positive Phase 2 Results for Masitinib in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharma Hits Key Goals in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Hyundai Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hyundai Develops Multi-Treatment for Mosquito-Borne Viral Infections, Including Dengue","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Niclosamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Hyundai Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hyundai Bioscience \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hyundai Bi.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Receives Licences from MPP to Market Nirmatrelvir; Ritonavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirmatrelvir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NV-387 Achieves Ideal Blood Concentration for Sustained Antiviral Effect","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NV-387 Broad-Spectrum Antiviral Effective Against Influenza A in Animal Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NV-387","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avanzanite\u2019s AKANTIOR\u00ae Gets Positive CHMP Opinion and Expands into 26 European Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SIFI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MicuRx Completes Phase I Trial for MRX-8 Antibacterial Drug in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Polymyxin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MicuRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pha.."},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Spectral Medical Inc. Announces Closing of C$8.5 Million Convertible Notes Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectral Medical","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"12","companyTruncated":"Spectral M.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Doses First Participants in UTI and Urosepsis Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Completes Dosing in Phase I\/II UTI\/Urosepsis Rapid Infusion Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sen-Jam Pharmaceutical Nears Completion of SJP-002C Trial for Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SJP-002C","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sen-Jam Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Ph.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Tafenoquine Clinical Trial for Babesiosis at Tufts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"CorMedix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ CorMedix","highestDevelopmentStatusID":"12","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"ASEAN","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Agreement to Sell TPOXX\u00ae to ASEAN Member States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Divestment","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ ASEAN","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Awarded Up to $34 Million DOD Contract for Antiviral Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"TNX-4200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Announces Closing of $1.7 Million Public Offering for IMC-2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Osteal Therapeutics Raises $50M To Support Lead Candidate Launch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Series D Financing","leadProduct":"Vancomycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Osteal The.."},{"orgOrder":0,"company":"Exavir Therapeutics","sponsor":"ViiV Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exavir Enters Settlement and License Agreement for HIV Compounds with ViiV Healthcare","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"XVIR-110","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exavir Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exavir Therapeutics \/ ViiV Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Exavir The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Gets FDA Approval for CAPVAXIVE Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA declines expanded use of Dynavax's hepatitis B vaccine on insufficient data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynavax Updates On HEPLISAV-B sBLA For Hemodialysis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Adjuvanted Recombinant Hepatitis B Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"AstriVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstriVax enters clinical phase with its novel vaccine platform technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AVX70120","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstriVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstriVax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstriVax \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Get Positive CHMP Opinion for Omicron COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BNT162b2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"BioNTech","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"BNT165e","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"BioNTech \/ CEPI","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Emmes Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ILiAD Plans Collaboration with Emmes for Phase III Trials of Next-Gen Pertussis Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILiAD Biotechnologies \/ Emmes Group","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Reports Positive Results in Phase 2b Trial of BPZE1 Pertussis Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Health Canada Approval of the World\u2019s First Chikungunya Vaccine, IXCHIQ\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine, Live","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Receives Marketing Authorization for IXCHIQ\u00ae, the First Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine, Live","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Receives EMA's Positive CHMP Opinion for its Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Chikungunya Vaccine, Live","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CHIKV VLP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entos Gets Approval to Begin Clinical Trial for COVID-19 Vaccine Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Covigenix VAX-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Cyanvac","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CyanVac wins BARDA award for Phase 2b study of intranasal COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"CVXGA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cyanvac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyanvac \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Cyanvac \/ .."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpyBiotech And Oxford Collaborate On Epstein-Barr Virus Research And Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"EBV Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"National Institutes of Biomedical Innovation, Health and nutrition","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo and Japan National Institute's universal influenza vaccine enters clinical trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DSP-0546LP","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Doses First Participant in Phase 2 Seasonal Influenza Study with GSK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"GSK4382276A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SEC recommends approval for Zydus Lifesciences' trivalent influenza vaccine in children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Inactivated Trivalent Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Submits Updated COVID-19 Vaccine to U.S. FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"JN.1 Subvariant SARS CoV-2 rS Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDSCO panel gives nod for continuation of phase-II clinical trial of SII's dengue vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Live Attenuated Tetravalent Dengue Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Seeks FDA Approval for Freeze-Dried Smallpox and Mpox Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Modified Vaccinia Ankara-Bavarian Nordic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Reports Positive Phase 3 Data for mRNA-1283 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-1283","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-1345","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Osivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osivax Completes Enrollment for Phase 1 Sarbecovirus Vaccine Candidate OVX033","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"OVX033","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Osivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osivax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Osivax \/ N.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Age Indication for GSK\u2019s Arexvy RSV Vaccine for Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Respiratory Syncytial Virus Vaccine, Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"RocketVax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rocketvax Collaborates with NIH for Clinical Trial of RVX-sCPD9 Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"RVX-sCPD9","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RocketVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RocketVax \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"RocketVax .."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynavax Initiates Phase 1\/2 Study of Novel Shingles Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Z-1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$5.0 million","newsHeadline":"Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0.02,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex: Positive Interim Data from Phase I\/II Allocetra in Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Authorized for Phase I\/II Trial of Allocetra in Thumb Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Doses First Patient in Phase I\/II Trial of AllocetraTM for Thumb Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio: Positive Data from Phase 1\/2 RESET-Myositis and RESET-SLE Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna's KYV-101 Receives IND Clearance for Stiff-Person Syndrome Phase 2 Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Government of Wallonia","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences PLC Announces Receipt of Grant Funding","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Muscle Progenitor Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ Government of Wallonia","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Bi.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Henlius and Organon Biosimilar Filings for Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and STADA Add to Strategic Alliance Through Denosumab Partnership","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix's Tonmya\u2122 for Fibromyalgia Gets Positive Pre-NDA FDA Review","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"PharmaCyte Biotech","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Makes $7 Million Investment in MyMD for Inflammatory Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ PharmaCyte Biotech","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharm.."},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telomir Pharma Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Ph.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma-Moebius Injection Shows Pain Relief in Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MM-II","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Initiates NKX019 Trial in Lupus Nephritis, Expands Pipeline to Autoimmune Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NKX019","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProKidney Proposes $125 Million Public Offering of Class A Ordinary Shares","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0.13,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProKidney Prices Upsized $130 Million Public Offering of Class A Shares","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProKidney Closes $140 Million Public Offering of Class A Shares with Underwriters\u2019 Option","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0.14000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney .."},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vera's Atacicept gets FDA Breakthrough Therapy for IgA nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Thera.."},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,150.0 million","newsHeadline":"Biogen Completes Acquisition of Human Immunology Biosciences","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":1.8,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":1.8,"dosageForm":"","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ B.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Completes Dosing in Phase 1 Gemini Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the Launch of Kionex\u00ae Suspension","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Polystyrene Sulfonate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Shows Proteinuria Reduction Data from Atrasentan Phase III Trial in IgAN","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas's STADA Receives Positive CHMP Opinion for Kinpeygo\u00ae in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Gets Approval for Potassium Chloride ER Capsules, Generic of Micro-K","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Gets ANDA Approval For Potassium Chloride Oral Solution","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Approves Potassium Chloride Oral Solution, Generic of Genus Lifesciences","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India gets USFDA nod for potassium chloride tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences' Gemini Phase 1 Study Meets Safety Endpoint","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RVL-HV02","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity\u2019s SC0062 Meets Primary Endpoint in IgA Nephropathy in 2-SUCCEED Phase 2 Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Bi.."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Tiopronin Delayed-Release Tablets Launch For Cystinuria Treatment","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"EG 427","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants IND Clearance for EG 427 Gene Therapy in Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"EG110A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EG 427 \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ N.."},{"orgOrder":0,"company":"EpilepsyGTx","sponsor":"UCL Technology Fund","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpilepsyGTx Raises $10 Million for CTA-Enabling Nonclinical Package for EPY201","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"EPY201","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"EpilepsyGTx","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"EpilepsyGTx \/ UCL Technology Fund","highestDevelopmentStatusID":"4","companyTruncated":"EpilepsyGT.."},{"orgOrder":0,"company":"Neurona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurona's NRTX-1001 Gets FDA RMAT Designation for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NRTX-1001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Neurona Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurona Th.."},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"NKGen Biotech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NKGen Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKGen Biot.."},{"orgOrder":0,"company":"Alchemab","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Alchemab Advances Novel Antibody for Parkinson's Disease with Michael J. Fox Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Houston Methodist Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Expands Research Collaboration for T Cell Exosome Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"COYA 301","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Houston Methodist Research Institute","highestDevelopmentStatusID":"5","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Alzheimer\u2019s Drug Discovery Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Announces $5 Million Investment by Alzheimer\u2019s Drug Discovery Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"COYA 302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Alzheimer\u2019s Drug Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coya Therapeutics Completes Phase 2 Study of Low Dose IL-2 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"COYA 302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Thera.."},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dianthus Therapeutics Gets FDA Clearance for Phase 2 Trial of DNTH103 in MMN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"DNTH103","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dianthus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus T.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Accepts Priority Review for Efgartigimod Alfa Injection in CIDP in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Doses First Patient with Moderate Alzheimer\u2019s Disease with Foralumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Seeks ALS Association Grant for Intranasal Foralumab Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Fast Track Submission for Tiziana Life Sciences\u2019 MS Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New AJOVY\u00ae (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Eisai\u2019s LEQEMBI\u00ae Supplemental Application for Early Alzheimer\u2019s Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Initiates Rolling BLA for LEQEMBI\u00ae for Alzheimer\u2019s Disease Maintenance Dosing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s OCREVUS Subcutaneous Admin Approved as Twice-a-Year Injection for MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Therapeutics Announces $11.8 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"Rinvecalinase Alfa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DiaMedica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen's QALSODY\u00ae gets EU approval for rare ALS therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofersen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"VectorY","sponsor":"UMC Utrecht","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ UMC Utrecht","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"VectorY","sponsor":"University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UMC Utrecht and VectorY collaborate to identify biomarkers of ALS in new study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"VTx-002","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VectorY \/ University Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Granules' Extended-Release Acetaminophen Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Reports Preclinical Results for Parkinson's Disease Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AEX-2","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$18.5 million","upfrontCash":"Undisclosed","newsHeadline":"Augustine Therapeutics Raises \u20ac17 Million in Series A for Neurological Lead Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"AGT100216","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Augustine Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Augustine Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Augustine .."},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio gets IND approval for Phase 3 Alzheimer\u2019s trial in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ N.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Completes First Cohort in Phase 1 Trial of ATH-1105 for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ATH-1105","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longboard Pharmaceuticals: Positive Interim Results from PACIFIC Study on Bexicaserin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allay Therapeutics: IND Accepted for Pivotal Phase 2B Trial of ATX101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Ther.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Submits ZYNRELEF\u00ae Vial Access Needle for FDA Approval","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announces Approval of Butalbital, Acetaminophen and Caffeine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innocan Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Ph.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"PhaseV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroSense And PhaseV Partner To Optimize ALS Phase 3 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ PhaseV","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Bionxt Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bionxt Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Bionxt Solutions \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bionxt Sol.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"NIH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Provides Update on its NIH-Funded Expanded Access Program for CNM-Au8\u00ae in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ NIH","highestDevelopmentStatusID":"9","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Merry Life Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MLB's TML-6 Gets FDA IND Nod for Alzheimer's Phase 1 Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Curcumin Analog","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Merry Life Biomedical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merry Life Biomedical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Merry Life.."},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka to Terminate Development of AVP-786","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Deudextromethorphan Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Otsuka Holdings \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Hol.."},{"orgOrder":0,"company":"Mannkind","sponsor":"Pulmatrix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Dihydroergotamine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Mannkind","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mannkind \/ Pulmatrix","highestDevelopmentStatusID":"6","companyTruncated":"Mannkind \/.."},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fasudil","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Raya Therapeutic","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Raya Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Raya Thera.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa\/Foslevodopa)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Foslevodopa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remedy Pharmaceuticals Reclaims Stroke Drug Rights; Reports Phase 3 Study Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pha.."},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halia Therapeutics to Launch LRRK2 Program for Alzheimer's at Discovery Europe 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"HT-4253","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Halia Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Halia Ther.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Reports Promising Interim Data From SPN-817 Epilepsy Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fordine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Submits UK Marketing Application for HMTM as Alzheimer\u2019s Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Granules' OTC Equivalent Of Advil Dual Action Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Announces Patient Enrollment at Neurostudies in Ph 2 Trial Investigating IGC-AD1","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"IGC-AD1","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Fenja Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRLAB Strengthens its Liquidity by Drawing SEK 25M on a Previously Secured Loan Facility","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"IRL757","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRLAB \/ Fenja Capital","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Fe.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB has Administered the First Dose in a Phase I Trial with the Drug Candidate IRL757","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"IRL757","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Kannalife","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kannalife Secures $1.49 Million from Michael J. Fox Foundation for Parkinson\u2019s Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"KLS-13019","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kannalife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kannalife \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Kannalife .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Receives ANDA Approval for Levetiracetam Tablets in record 9 months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"B. Braun Launches Levetiracetam in Sodium Chloride Injection Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"B. Braun Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"B. Braun Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"B. Braun M.."},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Link Healthcare Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm\u00ae in China on May 8, 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teikoku Pharma USA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teikoku Pharma USA \/ Link Healthcare Group","highestDevelopmentStatusID":"12","companyTruncated":"Teikoku Ph.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives Approval for Phase-1 Multiple Ascending Doses Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives HERC Approval for Phase 1 Trial of Lucid-21-302 in Australia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Lucy Therapeutics","sponsor":"Engine Ventures","pharmaFlowCategory":"D","amount":"$36.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lucy Therapeutics Secures Funding to Advance Alzheimer\u2019s and Parkinson\u2019s Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"LucyTx-1209","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Lucy Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Lucy Therapeutics \/ Engine Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Lucy Thera.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris and Ceapro Complete Merger Transaction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Merger","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ A.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Magnesium Sulfate in Water for Injection in the U.S. Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Magnesium Sulfate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharma Doses First Patient in Phase 3 Trial of MELT-300 for Opioid-Free Sedation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"$5.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Therapeutics Awarded $5.2M from Michael J. Fox Foundation and Parkinson's UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"MTX325","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Receives FDA Approval for Naproxen Sodium\/Diphenhydramine Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Naproxen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CervoMed Completes Enrollment in Phase 2b Trial of Neflamapimod for Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn and Angelini Renew Partnership for AULIN\u00ae and MESULID\u00ae in Central Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Nimesulide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumora Starts Phase 1b Study of NMRA-511 for Alzheimer's Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NMRA-511","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ensysce Advances Overdose Protection Platform in Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Nafamostat HCl","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Ensysce Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Announces Completion of Transfer of FDA Marketing Authorization for PONVORY\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ponesimod","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Enable Injections","sponsor":"Serina Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enable Injections and Serina to Develop SER-252 for Advanced Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"POZ-Apomorphine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Enable Injections","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enable Injections \/ Serina Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Enable Inj.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Reports Takeda\u2019s Phase 3 Study Results for Soticlestat","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Soticlestat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Zelira's HOPE\u00ae SPV receives US$819,000 second tranche of funding","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira The.."},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Zelira Initiates HOPE\u00ae Trial After Closing First Round of HOPE SPV Fundraise","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zelira Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":"1","companyTruncated":"Zelira The.."},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transposon Receives US FDA Fast Track Designation for TPN-101 for Supranuclear Palsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TPN-101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transposon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon.."},{"orgOrder":0,"company":"Progentos Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Progentos Therapeutics Closes $65 Million Series A Financing for Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Progentos Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Progentos Therapeutics \/ Forbion","highestDevelopmentStatusID":"5","companyTruncated":"Progentos .."},{"orgOrder":0,"company":"Iktos","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Italfarmaco Partners with Iktos to Speed Drug Discovery with AI","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Iktos","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"3","companyTruncated":"Iktos \/ It.."},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Kvantify","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Pharm and Kvantify Announce Partnership for Endocannabinoid Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Tetra Pharm Technologies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra Pharm Technologies \/ Kvantify","highestDevelopmentStatusID":"2","companyTruncated":"Tetra Phar.."},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"National Institutes of Mental Health","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"RUMI Scientific Receives Two-Year Phase II SBIR Award of $1.9 Million for Autism","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rumi Scientific \/ National Institutes of Mental Health","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scien.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Usnoflast","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Alerce Medical Technology Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzheon Raises $100 Million Series E Financing for ALZ-801\/Valiltramiprosate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series E Financing","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alzheon \/ Alerce Medical Technology Partners","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Vesper Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vesper Bio Completes Single Ascending Dose Stage for VES001 in Dementia Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VES001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vesper Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vesper Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vesper Bio.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited announces approval of Vigabatrin for Oral Solution USP, 500 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Pyros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pyros Pharmaceuticals: FDA Approves VIGAFYDE as Ready-to-Use Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Vigabatrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pyros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pyros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pyros Phar.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4,000.0 million","upfrontCash":"$50.0 million","newsHeadline":"Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Evotec","amount2":4,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":4,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Starts Phase 2 EMBRAZE Trial of Apitegromab in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Apitegromab","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glyscend Doses First Patient in Phase 2 Obesity Trial of GLY-200","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GLY-200","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glyscend Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend T.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"ProGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics Announces Partnership with ProGen on Development of Obesity Treatment","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"RT-114","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rani Therapeutics \/ ProGen","highestDevelopmentStatusID":"4","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"SixPeaks Bio AG Debuts With $110 Million in Funding","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0.080000000000000002,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SixPeaks Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks B.."},{"orgOrder":0,"company":"ProFound Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flagship Pioneering and ProFound Collaborate on First-in-Class Therapeutics for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"ProFound Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProFound Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"ProFound T.."},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"SixPeaks Bio AG Debuts With $110 Million in Funding","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"SixPeaks Bio \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks B.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$20.0 million","newsHeadline":"NeuroBo Pharmaceuticals Secures Up to $70 Million Placement Priced At-the-Market","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"DA-1726","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Shares Results from DREAM Trial of Dapiglutide in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapiglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Updates on Mazdutide GLORY-1 Study and Biomedicine Pipeline","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand's Petrelintide Shows Positive Phase 1b Results","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Petrelintide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Atlas","pharmaFlowCategory":"D","amount":"$17.1 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biophytis","amount2":0.02,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Biophytis \/ Atlas","highestDevelopmentStatusID":"6","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinRx Pharma Announces Additional $73 Million Financing","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dextrose","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aphaia Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pha.."},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Structure Therapeutics Reports Positive Data from Phase 2a Obesity Study","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GSBR-1290","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Structure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure .."},{"orgOrder":0,"company":"Evotec","sponsor":"Inserm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec, Inserm, Lille University Hospital Collaborate on Therapeutic Targets in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Inserm","highestDevelopmentStatusID":"4","companyTruncated":"Evotec \/ I.."},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix\u00ae in the US","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cetrorelix Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fer.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"OLIC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin partners with Fuji to strengthen women's health portfolio in Vietnam and Philippines","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Drospirenone","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ OLIC","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elinzanetant Reduces Hot Flashes In Menopausal Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Insud Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Merger","leadProduct":"Levonorgestrel","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Agile Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Agile Therapeutics \/ Insud Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Agile Ther.."},{"orgOrder":0,"company":"Noema Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noema Pharma Doses First Patient in Phase 2a Study of NOE-115 for Menopause Symptoms","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NOE-115","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Noema Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noema Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noema Phar.."},{"orgOrder":0,"company":"YourChoice Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YourChoice Completes Phase 1a Study Of First Hormone-Free Male Birth Control Pill","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"YCT529","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"YourChoice Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"YourChoice Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"YourChoice.."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A2 Bio Doses First Patient In EVEREST-2 Trial Of Mesothelin CAR T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"A2B694","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"A2 Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Afamitresgene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Candel Reports Positive Data from Phase 2 Trial of CAN-2409 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Aglatimagene Besadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio Completes Enrollment for Precision-T Phase 3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic T-Cell Immunotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Presents Overview of DUET-01 Phase 1\/2 Study at ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BOXR1030","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"NMDP BioTherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BlueSphere Bio Partners with NMDP BioTherapies for TCR-based Product Candidate Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"BSB-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ NMDP BioTherapies","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"BlueSphere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueSphere Bio Gets IND Clearance for First in Human Candidate in Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BSB-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BlueSphere Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueSphere Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BlueSphere.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carisma Therapeutics Nominates First CAR-M Candidate for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"CAR-M-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Announces CAR T-cell Therapies Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"CAR-T Based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Starts Phase 2 Trial for CAR T Therapy in B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cemacabtagene Ansegedleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u00ae Shows Improved PFS vs. Standard Therapies for High-Risk Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calidi Collaborates with SIGA to Advance RTNova Virotherapy for Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"CLD-400","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carisma Granted FDA Fast Track for CT-0525 in HER2-Overexpressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CT-0525","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carisma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Th.."},{"orgOrder":0,"company":"ExCellThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ExCellThera: EMA Accepts MAA for UM171 Cell Therapy in Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExCellThera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Follicle Stimulating Hormone Receptor T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"ERS Genomics","sponsor":"IRBM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ERS Genomics and IRBM Sign CRISPR\/Cas9 License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ERS Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ERS Genomics \/ IRBM","highestDevelopmentStatusID":"3","companyTruncated":"ERS Genomi.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Indapta Therapeutics Awarded $4.5 Million by CPRIT for Allogenic Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Shinobi Therapeutics","sponsor":"Anocca AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anocca and Shinobi Partner to Develop TCR-T Cell Therapies for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"iPS-T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Shinobi Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shinobi Therapeutics \/ Anocca AB","highestDevelopmentStatusID":"2","companyTruncated":"Shinobi Th.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics Doses First Patient in KSQ-001EX eTIL Therapy Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb\u2019s Breyanzi CAR T Therapy Approved for Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves BMS\u2019s Breyanzi as New CAR T Therapy for Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lisocabtagene Maraleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyell Reports Dose-dependent Activity from Phase 1 of LYL797, ROR1-targeted CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LYL797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lyell Immunopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immu.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutch Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio: Positive Data from Waldenstrom Macroglobulinemia CAR-T Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MB-106","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Fred Hutch Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene Announces Lead Selection for KRAS-targeting TCR-T in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MDG2021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First mRNA LNP Based CAR-T Cell Injection (SYS6020) Obtains Clinical Trial Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-Lipid Nanoparticles","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CSPC Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSPC Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CSPC Pharm.."},{"orgOrder":0,"company":"LIfT Biosciences","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LIfT BioSciences Gets UK Grant For IMAN Cell Therapy Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Neutrophil-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LIfT Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LIfT Biosciences \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"LIfT Biosc.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Doses First Patient in Acclaim-3 Study of Reqorsa\u00ae for Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"IASO Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IASO Bio\u2019s RD118 CAR-T for Multiple Myeloma Receives IND Approval from NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RD118","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"IASO Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IASO Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"IASO Bio \/.."},{"orgOrder":0,"company":"SCG Cell Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCG Cell Therapy Gets FDA IND Clearance for SCG142 HPV-specific TCR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SCG142","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"SCG Cell Therapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SCG Cell Therapy \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SCG Cell T.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Bio Doses First Patient in Phase 1 Trial of SENTI-202 for Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene-BioNTech Collaboration Agreement Extended Beyond Initial Term","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"T-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Yellowstone Bioscience","sponsor":"Syncona Limited","pharmaFlowCategory":"D","amount":"$17.7 million","upfrontCash":"Undisclosed","newsHeadline":"Yellowstone Biosciences Launches with \u00a316.5 Million for TCR-based Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Yellowstone Bioscience","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Yellowstone Bioscience \/ Syncona Limited","highestDevelopmentStatusID":"4","companyTruncated":"Yellowston.."},{"orgOrder":0,"company":"AmplifyBio","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AmplifyBio And Xcell Partner To Manufacture TCR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AmplifyBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AmplifyBio \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AmplifyBio.."},{"orgOrder":0,"company":"Captain T Cell","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River, Captain T Cell Sign Plasmid DNA & Viral Vector Production Program Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"TCR-T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Captain T Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Captain T Cell \/ Charles River Laboratories, inc","highestDevelopmentStatusID":"4","companyTruncated":"Captain T .."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Receives FDA RMAT Designation for TCR-T Therapy Candidates in Heme Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TSC-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Announces First Patient Dosed in Phase 1 TCR-T Therapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TSC-203-A0201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Gets Orphan Drug Status for UCART22 in Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"UCART22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Shandong Quangang Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"125SER","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GRIT Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GRIT Biotechnology \/ Shandong Quangang Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"GRIT Biote.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-PSMA-RADmAb","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Completes TLX250-CDx (Zircaix\u2122) BLA Submission for Kidney Cancer Imaging","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"89Zr-DFO-girentuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Genmab","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasunlimab with Pembrolizumab Shows Activity in Metastatic NSCLC Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Acasunlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ B.."},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abdera Therapeutics Gets FDA Fast Track Designation for ABD-147 in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera The.."},{"orgOrder":0,"company":"Abdera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Abdera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abdera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Abdera The.."},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actym Therapeutics Gets IND Clearance for ACTM-838 in Solid Tumors Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ACTM-838","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Actym Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actym Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Actym Ther.."},{"orgOrder":0,"company":"Adcytherix","sponsor":"Pontifax","pharmaFlowCategory":"D","amount":"$32.2 million","upfrontCash":"Undisclosed","newsHeadline":"Adcytherix Launches with \u20ac30 Million in Seed Funding for Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"ADC-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adcytherix","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Adcytherix \/ Pontifax","highestDevelopmentStatusID":"2","companyTruncated":"Adcytherix.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFM24 Plus Atezolizumab Shows Durable Responses in Heavily Pretreated NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Receives Fast Track for AFM24 and Atezolizumab in NSCLC Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AFM24","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Aummune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aummune's Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AM003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aummune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aummune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aummune Th.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 PALOMA-3 Shows Five-Fold Reduction in Reactions with Amivantamab Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amivantamab BLA Submitted to FDA for EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RYBREVANT\u00ae Plus Lazertinib Shows Longer PFS vs. Osimertinib in High-Risk NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PALOMA-2 Shows Positive Results for Subcutaneous RYBREVANT\u00ae in EGFR-Mutated NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RYBREVANT\u00ae Approved by EU for First-line Treatment in Advanced NSCLC with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ability Biologics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ability Biologics Closes $18 Million Seed Funding Extension for Immunomodulators","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ability Biologics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ability Biologics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"3","companyTruncated":"Ability Bi.."},{"orgOrder":0,"company":"LabGenius","sponsor":"M Ventures","pharmaFlowCategory":"D","amount":"$44.5 million","upfrontCash":"Undisclosed","newsHeadline":"UK biotech raises \u00a335M to develop solid tumor drugs based on machine learning","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"LabGenius \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius .."},{"orgOrder":0,"company":"Adcendo","sponsor":"Dawn Biopharma","pharmaFlowCategory":"D","amount":"$106.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adcendo ApS Extends Series A Financing to EUR 98M for First-in-Class ADC Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adcendo","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Adcendo \/ Dawn Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Adcendo \/ .."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm And Genome & Company Partner On Novel Oncology ADC Family","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genome & Company \/ Debiopharm","highestDevelopmentStatusID":"3","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Anaveon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I\/II clinical study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ANV600","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Anaveon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anaveon \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Anaveon \/ .."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"APVO436","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Aulos","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aulos Bioscience Partners with Merck KGaA to Study Bavencio\u00ae with AU-007","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Aldesleukin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aulos \/ Merck KGaA","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Me.."},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicara Reports Updated Data for Ficerafusp Alfa in HPV-negative Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BCA101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara The.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belantamab Mafodotin Cuts Disease Progression Risk by Nearly 50% in Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Belantamab Mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos and GSK Launch Phase 3 Study on Belrestotug and Dostarlimab in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Belrestotug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Gets Positive CHMP Opinion For Avzivi, A Biosimilar To Avastin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Doses First Patient with BHV-1510 ADC in Advanced Epithelial Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BHV-1510","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics and Boehringer Ingelheim Expand Cancer and Disease Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"BI 754091","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmBH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves BLINCYTO for B-ALL in Consolidation Phase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BND-35","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biond Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biol.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Agenus Type B Meeting for BOT\/BAL Therapy in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bright Peak Therapeutics Announces $90 Million in Series C Financing for PD1-IL18","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series C Financing","leadProduct":"BPT567","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Bright Pea.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Begins Phase 3 Trial of Brenetafusp for Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Brenetafusp","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADCETRIS\u00ae Shows Improvement in Overall Survival in Relapsed DLBCL Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants ODD for CAN-3110 for the Treatment of Recurrent High-Grade Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"CAN-3110","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life Announces Pipeline Expansion of Highly Tumor-Targeted T Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CDR813","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CDR Life","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CDR Life \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jiangsu Si.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DARZALEX\u00ae Regimens Improve Outcomes in Newly Diagnosed Multiple Myeloma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Shows Survival Benefit Over Chemo in Phase 3 TROPION-Lung01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"BioNTech","sponsor":"DualityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and DualityBio Receive FDA Fast Track for BNT324\/DB-1311 in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"DB-1311","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ DualityBio","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Gets EU Approval for Wyost\u00ae and Jubbonti\u00ae Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Therapeutics Collaborates to Evaluate DF9001 with KEYTRUDA\u00ae in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"DF9001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential .."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Reports Positive Results from Divesiran Phase 1 in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Divesiran","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Silence Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Arcus Report Anti-TIGIT Combo Exceeds One Year of PFS in Upper GI Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcus Biosciences Completes Enrollment in Phase 3 Trial for Upper GI Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jemperli Shows 100% No Evidence of Disease in dMMR Rectal Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi approved in the US for endometrial cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae Shows Survival Benefit in Limited-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae Shows Significant Improvement in Survival for Bladder Cancer in NIAGARA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer's Elrexfio Shows Positive Results in Phase 2 RRMM Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Elranatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Terminates ENVASARC Trial and Will Explore Strategic Alternatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Envafolimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology Plans Combination Strategy for EO-3021 in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"EO-3021","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epcoritamab Combo Shows 95% Response Rate in Untreated Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAtla Presents Evalstotug Data at the 2024 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Evalstotug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Receives FDA Clearance for FG-3165 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"FG-3165","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Doses First Patient In Phase 1 Trial Of GIGA-564 For Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"GIGA-564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Columvi Extends Survival in Phase 3 Lymphoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Glofitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Receives FDA IND Clearance for GTB-3650 NK Cell Engager in CD33+ Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GTB-3650","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Gets Fast Track for IBI343 in Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"IBI343","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Imvax","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Imvax Completes IGV-001 Phase 2b Trial Enrollment And Secures Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imvax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ Un.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron's RYTELO Approved by FDA for Low-Risk MDS with Transfusion-Dependent Anemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarclisa Accepted for FDA Priority Review in Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ivonescimab Approved in China for EGFRm NSCLC Based on HARMONi-A Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ivonescimab Shows Superiority Over Pembrolizumab in NSCLC First-Line Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Philogen","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen and Sun Pharma seek EMA approval for melanoma therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"L19IL2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem and AVEO Start Phase 1 Anti-Cancer Compound Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LB-LR1109","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ AVEO Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Announces Positive ProstACT SELECT Trial Data For Prostate Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lutetium-177 Rosopatamab Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Telix Phar.."},{"orgOrder":0,"company":"Macomics","sponsor":"Institute of Oncology Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Macomics and IOR Announce Macrophage Collaboration in Prostate Cancer Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Macrophage-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ Institute of Oncology Research","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Receives EMA Approval to Expand Phase 1\/2 ABILITY-1 Study to Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MDNA11","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Amend & Extend Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"MNPR-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pre-Surgery Bristol Myers Combination Therapy Improves Skin Cancer Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS: Opdivo + Yervoy Improve Survival in Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS Receives EU Approval for Opdivo\u00ae with Cisplatin and Gemcitabine in Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Updates on Subcutaneous Nivolumab with ENHANZE\u00ae from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Initiates Phase 1\/2 Study for OBI-992, a TROP2-Targeted ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"OBI-992","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"Genelux","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$27.5 million","upfrontCash":"Undisclosed","newsHeadline":"Genelux Corporation Announces Pricing of $27.5 Million Underwritten Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Genelux \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patritumab Deruxtecan BLA Submission Gets Complete Response Letter from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eisai","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Efficacy Data for KEYNOTE-B61 Added to LENVIMA\u00ae US Label for Advanced RCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Me.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYNOTE-522 Trial Meets Survival Endpoint in High-Risk TNBC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus and Dr. Reddy\u2019s License Agreement for Co-Marketing Pertuzumab Biosimilar in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Merus","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merus N.V. Announces Proposed Public Offering of Common Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0.40000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Merus \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ Je.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus' Petosemtamab and Pembrolizumab Show Strong Response in 1L r\/m HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Pheon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pheon Therapeutics Announces $120M Series B Financing for ADC Pipeline Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"PHN-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pheon Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Pheon Therapeutics \/ TCGX","highestDevelopmentStatusID":"4","companyTruncated":"Pheon Ther.."},{"orgOrder":0,"company":"Pheast Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pheast Unveils Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"PHST001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Pheast Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pheast Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pheast The.."},{"orgOrder":0,"company":"Xencor","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,313.0 million","upfrontCash":"$100.0 million","newsHeadline":"Xencor To Regain Global Rights To Bispecific T-Cell Engager Plamotamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Termination","leadProduct":"Plamotamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":1.3100000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3100000000000001,"dosageForm":"","sponsorNew":"Xencor \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ J.."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ractigen Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RAG-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGN7075 Shows Promising Activity in Combination with Libtayo\u00ae at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaEssentia Completes Enrollment for Phase 2b and Phase 3 Trials in Blood Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune: Positive IGNYTE Data for RP1 + Nivolumab in Anti-PD1 Failed Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Provides Update on Phase 3 TROPiCS-04 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Receives Orphan Drug Designation for SL-172154 in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Reports Positive Data for SL-172154 in HR-MDS and AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Sotio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO Doses First Patient In Phase 1 Study Of SOT201 For Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SOT201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ No.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Completes STP707 Phase I Study with Strong Safety Profile in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"STP707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Strand Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strand doses first patient with mRNA Therapy STX-001 in Phase 1 solid tumor trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strand Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Strand Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Strand The.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone\u2019s Cejemly\u00ae Recommended for NSCLC First-Line Treatment by EMA CHMP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ipsen and Marengo Announce Partnership for Precision T Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"T Cell Engager","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Marengo Therapeutics","amount2":1.2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.2,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Marengo Th.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare's BLA for Tafasitamab Accepted in China for B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves IMDELLTRA\u2122 (TARLATAMAB-DLLE) for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tarlatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Tacalyx","sponsor":"Thuja Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tacalyx extends seed funding round to raise over \u20ac14m","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"TCX-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tacalyx","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Tacalyx \/ Thuja Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tacalyx \/ .."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Converts TEBE-AM Trial to Registrational Phase 3 for KIMMTRAK in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Updates on Phase II\/III SKYSCRAPER-06 Study in Metastatic NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark unit ties up with BeiGene to market cancer drugs in India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Tislelizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ BeiGene","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tisotumab Vedotin Phase 2 Shows Antitumor Activity in Recurrent Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coherus Presents Results from Phase I Study of CCR8 Antibody CHS-114 at ASCO 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripaliamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Coherus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coherus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Coherus Bi.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences' Phase 3 Toripalimab Study Meets Primary Endpoint in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi's Toripalimab sNDA Approved for Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces sNDA Approval for Toripalimab in Advanced TNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Shows 13.2-Month PFS in HER2-Low Metastatic Breast Cancer After Endocrine Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Natera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natera Announces DECIPHER: Phase II Trial in Gastroesophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Natera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ N.."},{"orgOrder":0,"company":"Tubulis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tubulis Begins Phase I\/IIa Trial of TUB-040 in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"TUB-040","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tubulis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Tubulis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tubulis Receives FDA Fast Track for TUB-040 in Platinum-resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"TUB-040","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tubulis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tubulis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Shaperon","sponsor":"Dong-A ST","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shaperon and Dong-A ST Sign MOU for Nanobody-Based New Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shaperon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shaperon \/ Dong-A ST","highestDevelopmentStatusID":"3","companyTruncated":"Shaperon \/.."},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"Cartography Announces Collaboration with Gilead for Oncology Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cartography Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartography Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Cartograph.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva Biologics Gets Fast Track Designation for VCN-01 in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech's Phase 1\/2 Study Shows Promise for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CatalYm Reports Lasting Responses in Late-Line NSCLC and Other Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks: NMPA Accepts BLA for Zanidatamab in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Zanidatamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Acknowledges Astellas' Zolbetuximab resubmission, Sets New Action Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks: FDA Clears IND for ZW171 Bispecific Antibody for Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ZW171","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Completes Enrollment for CENDIFOX Pancreatic Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Greenwich LifeSciences Announces $2.5 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"GP2 Peptide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Greenwich LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$204.0 million","upfrontCash":"Undisclosed","newsHeadline":"ITM Raises \u20ac188M to Enhance Radiopharmaceutical Pipeline and Strengthen Position","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Lutetium-177-edotreotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Temasek","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Te.."},{"orgOrder":0,"company":"RS Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RS Oncology Reports Positive Phase 1 Data for RSO-021 in Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Thiostrepton","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RS Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RS Oncolog.."},{"orgOrder":0,"company":"Rapafusyn Pharmaceuticals","sponsor":"3E Bioventures Capital","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rapafusyn Pharmaceuticals Secures $28 Million Series A for Molecular Glue Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rapafusyn Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Rapafusyn Pharmaceuticals \/ 3E Bioventures Capital","highestDevelopmentStatusID":"2","companyTruncated":"Rapafusyn .."},{"orgOrder":0,"company":"TwoStep Therapeutics","sponsor":"NFX Bio","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"TwoStep Therapeutics Launches to Advance Targeting Platform for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TwoStep Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"TwoStep Therapeutics \/ NFX Bio","highestDevelopmentStatusID":"3","companyTruncated":"TwoStep Th.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"177Lu-SN201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"ARTBIO","sponsor":"FogPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FogPharma and ARTBIO Collaborate on Alpha-Particle Radioligand Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"212Pb Alpha Radioligand Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ARTBIO","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARTBIO \/ FogPharma","highestDevelopmentStatusID":"3","companyTruncated":"ARTBIO \/ F.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Full-Life Technologies Gets FDA IND Clearance for 225Ac-FL-020 in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Full-Life Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laminar Completes Recruitment for LAM561 in Glioblastoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"2-Hydroxyoleic Acid","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Laminar Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Ph.."},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Northwestern University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanopharmaceutics and Northwestern Start Phase I Study of Oral Triapine\u00ae for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanopharmaceutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanopharmaceutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Nanopharma.."},{"orgOrder":0,"company":"GUERBET","sponsor":"NUCLIDIUM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NUCLIDIUM and Guerbet Form Strategic Partnership for Copper-based Radiotheranostics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"67Cu-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GUERBET","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GUERBET \/ NUCLIDIUM","highestDevelopmentStatusID":"4","companyTruncated":"GUERBET \/ .."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA: THIO Shows Strong Efficacy in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"KGI Venture Capital","pharmaFlowCategory":"D","amount":"$19.8 million","upfrontCash":"Undisclosed","newsHeadline":"Anbogen Therapeutics Completes A+ Round Financing for ABT-301 Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"ABT-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Anbogen Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Anbogen Therapeutics \/ KGI Venture Capital","highestDevelopmentStatusID":"6","companyTruncated":"Anbogen Th.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharma doses first patient in FPI-2265 prostate cancer trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Plus Chemoimmunotherapy Reduces Progression Risk in Lymphoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Acerta Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Avelos Therapeutics","sponsor":"Stassets Investment","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Avelos Therapeutics Announces KRW 17 Billion Series B Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"AD1208","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avelos Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Avelos Therapeutics \/ Stassets Investment","highestDevelopmentStatusID":"5","companyTruncated":"Avelos The.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alectinib Deemed \u201cHighly Promising\u201d for Pediatric ALK Fusion-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoinvent Receives FDA Fast Track for Radspherin\u00ae in Ovarian Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Alpha-emitting Radionuclide Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncoinvent \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest's Amezalpat Shows 6-month Survival Gain in HCC Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Amezalpat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics: First Patient Dosed in Phase 1 WEE1 Inhibitor Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"APR-1051","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Scemblix\u00ae Shows Superior Efficacy vs. TKIs in Newly Diagnosed CML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Asciminib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Reports Interim Results from RAMP 205 Trial of Avutometinib Plus Gemcitabine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Begins Rolling NDA Submission to FDA for Avutometinib & Defactinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Azenosertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio: First Patient Dosed in ONKORAS-101 Trial for KRASG12C NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BBO-8520","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Ensem Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensem Therapeutics: Milestone Achieved with CDK2 Inhibitor for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BG-68501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Ensem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Doses First Patients in Phase 1 Trial for BG-68501 to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BG-68501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewood Doses First Patients In Phase 2a Study Of BTX-A51 For Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-A51","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Edgewood Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edgewood Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewood O.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Expands Agreement for Cabometyx\u00ae in Neuroendocrine Tumors After CABINET Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ex.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Doses First Patient in Camonsertib NSCLC Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Camonsertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAPItello-290 Phase III: Truqap Plus Chemo in Advanced Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MEDSIR & Debiopharm Explore Synergy of Debio 0123 & Sacituzumab in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MEDSIR","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MEDSIR \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"MEDSIR \/ D.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Reports Positive Phase 1b Results with NGC-Cap in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn Therapeutics Raises $110 Million Through Direct Offering to Advance Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Initiates Phase II\/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Hengrui","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets EU Approval for FRUZAQLA in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Celcuity","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celcuity Plans Phase 3 Trial for Gedatolisib in Advanced Breast Cancer with Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Gedatolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Celcuity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Celcuity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celcuity \/.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNMC Launches Enrollment for RenovoRx\u2019s Phase III TIGeR-PaC Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Golidocitinib Approved in China for T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Golidocitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Grey Wolf Therapeutics","sponsor":"ICG\u2019s Life Sciences","pharmaFlowCategory":"D","amount":"$99.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"GRWD5769","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grey Wolf Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Grey Wolf Therapeutics \/ ICG\u2019s Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Grey Wolf .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Receives FDA Protocol Acceptance for NBTXR3 in Stage Three Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"HiberCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiberCell Doses First Patient in Phase 1b Trial of HC-7366 in AML Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"HC-7366","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiberCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell .."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Launches RAPHAEL Phase III Trial of HMPL-306 for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"HMPL-306","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Starts Phase I Trial of Menin Inhibitor HMPL-506 in Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"HMPL-506","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Hinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hinova Pharmaceuticals Receives FDA Fast Track for HP518 in AR+ TNBC Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"HP518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hinova \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hinova \/ N.."},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 CAPTIVATE Study Shows IMBRUVICA-Venetoclax Benefit in CLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacycl.."},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RESONATE-2 Study Shows Long-term Benefit of IMBRUVICA in CLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacycl.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Updates on IDE397, a Phase 2 MAT2A Inhibitor for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"IDE397","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces First Patient in Phase 1 Trial of IDE397 and Trodelvy\u00ae in Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"IDE397","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"IDRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDRx Updates Phase 1 Data Supporting IDRX-42 in GIST Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"IDRX-42","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Not.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifebemtinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Genentech\u2019s Inavolisib in PIK3CA-mutated Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Inavolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation to Inavolisib for Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Reports Third Safety Review Recommending Continuation of ASPIRE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivospemin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Panbela Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Panbela Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Panbela Th.."},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JIN-A02 Shows Tumor Reductions in Ongoing Phase 1 Study with Brain Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"JIN-A02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio.."},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sermonix Pharma receives Chinese approval of IND application for lasofoxifene","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sermonix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Sermonix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sermonix P.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Deimos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"G1 Therapeutics and Deimos Sign License for Lerociclib for Radioprotective Uses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Deimos Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Glioblastoma Foundation Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Lisavanbulin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Glioblastoma Foundation Inc","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare's Lunresertib Gets FDA Fast Track for Platinum-Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lunresertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine Partners with Repare for Genomic Profiling and Companion Diagnostic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Lunresertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Repare Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Elite Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elite Phar.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen's UGN-102 Shows 82.3% Response in ENVISION Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"UroGen Pharma Announces Public Offering of Ordinary Shares and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$107.5 million","upfrontCash":"Undisclosed","newsHeadline":"UroGen Pharma Prices Public Offering of Ordinary Shares and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Mitomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"","sponsorNew":"UroGen Pharma \/ TD Cowen","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK\u2019s Omjjara receives Japanese approval for treatment of myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Momelotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Receives IRB Approval for Namodenoson in Pancreatic Cancer Phase IIa Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$184.0 million","upfrontCash":"Undisclosed","newsHeadline":"Erasca Announces Closing of Underwritten Offering of Common Stock and Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ J.."},{"orgOrder":0,"company":"Erasca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Erasca Starts Phase 3 Trial for Naporafenib in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Naporafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Erasca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ N.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"NVL-655","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvectis' NXP900 Shows Strong Activity in Non-Small Lung Cancer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis P.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reneo Pharmaceuticals and OnKure Announce Proposed Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Owkin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Owkin Unveils AI-Driven Oncology & Immunology Pipeline, In-Licenses Best-in-Class OKN4395","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"OKN4395","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Owkin","highestDevelopmentStatusID":"4","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China CDE Approves Olverembatinib Phase III Study for SDH-Deficient GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Received US$100 Million Option Payment from Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":1.3,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.3,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Completes Enrollment for ONCT-534 in Metastatic Prostate Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ONCT-534","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,920.0 million","upfrontCash":"$290.0 million","newsHeadline":"Merck and Orion Mutual Option Exercise for Opevesostat in Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Opevesostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":1.9199999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.9199999999999999,"dosageForm":"","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Granted Priority Review for Unresectable Stage III Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAGRISSO\u00ae Reduces Disease Progression Risk by 84% in Stage III EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec introduces generic version of cancer drug in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Launches Paclitaxel Protein-Bound Particles Injectable Suspension","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American R.."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImPact Biotech Presents Interim Data on Padeliporfin VTP in Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Padeliporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"ImPact Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adlai Nortye Doses First Patient in Phase II Trial of Palupiprant for Rectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Palupiprant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adlai Nortye \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pasithea Completes Enrollment for PAS-004 in Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PAS-004","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea T.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 per Share","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Optime Care","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optime Care Announces Enhanced Partnership with Rigel for GAVRETO\u00ae Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Optime Care","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Optime Care \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Optime Car.."},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quanta Doses First Patient in Phase 1\/1b Trial of QTX3046 and Other Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quanta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quanta The.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biodexa Reports Positive Phase 2 Results of eRapa\u2122 in Familial Adenomatous Polyposis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Augtyro for NTRK-Positive Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax to Advance Revumenib into Phase 1b Trial for Metastatic MSS CRC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine and PMV Pharma Collaborate on Diagnostic for Rezatapopt","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Rezatapopt","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PMV Pharma \/ Foundation Medicine","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$17.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Rhenium-186 Obisbemeda","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ CPRIT","highestDevelopmentStatusID":"6","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,400.0 million","newsHeadline":"Ono Acquires Deciphera Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":2.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2.3999999999999999,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relay Therapeutics, Pfizer to Collaborate on Atirmociclib and RLY-2608 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"RLY-2608","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Syncona Limited","pharmaFlowCategory":"D","amount":"$85.9 million","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Announces \u20ac80 Million Series B Financing to Progress Pipeline Through Phase II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Series B Financing","leadProduct":"Roginolisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ionctura","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ionctura \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rutherrin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Retevmo lands new accelerated approval for pediatric cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Receives Rare Pediatric Disease Designation for SLS009 in ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SLS009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Completes Enrollment and Reports Positive Data in Phase 2a AML Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity\u2019s Stenoparib Continues to Show Benefit in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Stenoparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dizal Highlights Sunvozertinib's Efficacy for Lung Cancer with EGFR Exon 20 Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunvozertinib Meets Primary Endpoint in NSCLC with EGFR Exon 20 Insertions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sunvozertinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dizal Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dizal Phar.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Initiates Phase II\/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Hengrui","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Wistar Institute of Anatomy and Biology","sponsor":"Active Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Wistar Institute of Anatomy and Biology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wistar Institute of Anatomy and Biology \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Wistar Ins.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Thiotepa","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shorla Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shorla Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir\u00b4s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TNG348","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tango Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Onco360","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BrightSpring Health Announces Onco360 was Selected as National Pharmacy Partner for OJEMDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Partnership","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Onco360","highestDevelopmentStatusID":"12","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces Sale of Priority Review Voucher for $108 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Divestment","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Day One Biopharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"XOMA","sponsor":"Viracta Therapeutics","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Receives $8.1 Million Milestone for Day One Biopharmaceuticals\u2019 Priority Voucher","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"XOMA","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"","sponsorNew":"XOMA \/ Viracta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"XOMA \/ Vir.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trilaciclib Combined with ADC Shows Improved Survival and Tolerability in Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyligand Doses First Patient in Phase 1\/2 Trial of KRAS G12D Inhibitor TSN1611","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TSN1611","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tyligand Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyligand Bioscience \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tyligand B.."},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReviR Therapeutics Reaches Milestone in Splicing Therapy Development with Asieris","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReviR Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Ther.."},{"orgOrder":0,"company":"NeoPhore","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Closes Oversubscribed Series B Round with Funding from Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NeoPhore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoPhore \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"NeoPhore \/.."},{"orgOrder":0,"company":"Cardiff University","sponsor":"Immutep","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Signs License Agreement with Cardiff University for Anti-LAG-3 Molecules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cardiff University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff University \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Cardiff Un.."},{"orgOrder":0,"company":"Cypris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cypris Therapeutics Launches, Secures Over $500k in Pre-Seed Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cypris Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cypris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Cypris The.."},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sibylla Biotech and MD Anderson Collaborate on Small-Molecule Protein Degraders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo\u2019s Ezharmia Approved for Relapsed Peripheral T-Cell Lymphoma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Valemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenFleet's GFH375 IND Approved in China for KRAS G12D Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-7375","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenFleet Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Starts NIH-Funded Phase 2 Trial of STAT3 Inhibitor for Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"WP1066","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BeiGene","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeiGene and NewBridge Conclude BRUKINSA\u00ae Partnership in MENA Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Zanubrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Completes Enrollment in Reg-Directed Trial of Ziftomenib in NPM1-Mutant AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Announces Positive Data From Phase 2b Study Of Zipalertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CLN-081","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eFFECTOR and Dana-Farber to Evaluate Zotatifin in ER+ Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Zotatifin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"The University of British Columbia","sponsor":"Brain Cancer Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brain Cancer Canada Awards $80,000 Grant for Immune Therapies in Glioblastomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of British Columbia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of British Columbia \/ Brain Cancer Canada","highestDevelopmentStatusID":"1","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Oncocross","sponsor":"JW Pharmaceutical Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncocross Expands Collaboration with JW Pharmaceutical on AI Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncocross","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ JW Pharmaceutical Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Oncocross .."},{"orgOrder":0,"company":"Merck Group","sponsor":"The Department of Health, Abu Dhabi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DoH & MSD expand long-standing partnership to advance clinical research on lung cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck Group \/ The Department of Health, Abu Dhabi","highestDevelopmentStatusID":"1","companyTruncated":"Merck Grou.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Reports Preliminary Disease-Free Survival from AMPLIFY-7P Phase 1a Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ELI-002 7P","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Shows High Response Rate for EO2463 in Lymphoma Study at ASCO 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"EO2463","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Life Sciences: Positive Phase 3 REGAL Trial in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sellas to Continue Phase 3 REGAL Trial for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Precision-Panc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision-Panc Launches PRIMUS-006 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immodulon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immodulon Therapeutics \/ Precision-Panc","highestDevelopmentStatusID":"6","companyTruncated":"Immodulon .."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Achilles and Arcturus Collaborate on Second-Generation mRNA Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"mRNA Based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Therapeutics \/ Arcturus Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna & Merck: 3-Year Data for mRNA-4157 & KEYTRUDA Shows Improved Survival in Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"mRNA-4157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OS Therapies Gives Positive Update on Phase 2b trial in Recurrent Osteosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"OST31-154","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech: Data Update from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qu Biologics And Foundation Medicine Partner For Colorectal Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"QBECO SSI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Foundation Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"MimiVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Supplemental Orphan Drug Designation To SurVaxM For Malignant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Montanide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MimiVax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MimiVax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MimiVax \/ .."},{"orgOrder":0,"company":"Syncromune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syncromune Receives FDA IND Clearance for SYNC-T SV-102 in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SV-102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syncromune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"YGION Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"Undisclosed","newsHeadline":"YGION Biomedical Announces \u20ac15 Million Series A Financing for Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"YG-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"YGION Biomedical","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"YGION Biomedical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"YGION Biom.."},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"KALA BIO Announces $12,500,000 Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"KALA Bio \/ SR One","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/.."},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurion's AURN001 Gets Breakthrough and RMAT Designations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Neltependocel","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Aurion Biotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aurion Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aurion Bio.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DSMB Approves Enrollment in Cohort 3 of OCU410 ArMaDa Study for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU410","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech And Advanz Sign Agreement For Eylea Biosimilar In Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"MS Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MS Pharma Partners for FYB203 Biosimilar Commercialization in MENA Region","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Klinge Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Klinge Pharma \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Klinge Pha.."},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics gets FDA nod for Yesafili\u2122, enters U.S. ophthalmology market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Bio.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis' Licaminlimab Shows Positive Results for Dry Eye with a Precision Medicine Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Licaminlimab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Kemwell Biopharma Private Limited","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"RO-104","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kemwell Biopharma Private Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kemwell Biopharma Private Limited \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Kemwell Bi.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Enrollment in Pivotal Ph 3 Clinical Program with Sozinibercept in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opthea Announces Entitlement Offer to Raise A$227.3 Million (US$150 Million)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"Aflibercept","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ U.."},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harrow Announces 52-Week Data from VEVYE\u00ae ESSENCE-2 Open-Label Extension Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ N.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SYFOVRE Preserves Visual Function at 36 Months in GALE Extension Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Expands Global Portfolio with Ocular and Postpartum Acquisitions","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Apraclonidine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Vyluma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyluma Meets FDA on Atropine Solution for Pediatric Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Vyluma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vyluma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vyluma \/ N.."},{"orgOrder":0,"company":"Drug Farm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Farm Gets IND Clearance for Phase 1b of DF-003 in ROSAH Syndrome Patients","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"DF-003","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Drug Farm","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Drug Farm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Drug Farm .."},{"orgOrder":0,"company":"Teva Pharma (Thailand)","sponsor":"Lotus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiwan's Lotus Pharma acquires Teva Pharma Thailand, expanding footprint in Southeast Asia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Hydroxypropyl Methylcellulose","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharma (Thailand)","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharma (Thailand) \/ Lotus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Launches Blink NutriTears Supplement For Dry Eyes In US","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lutein","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bausch & Lomb Incorporated \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Reports Topline Results from Phase 2 Study of RZ402 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RZ402","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azura Enrolls First Patient in Phase 3 Trial for MGD Treatment AZR-MD-001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Selenium Sulfide","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Azura Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Timolol Maleate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharmaceuticals\u2019 IND Involving Cochlear Implantation Allowed by the FDA","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Expands RECCE\u00ae 327 Gel Trials for Skin Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I\/ Phase II","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Initiates Phase 2 Study of Bremelanotide for Erectile Dysfunction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Magdalena Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Executes Out-License Deal for Botanical Drug Candidate for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Botanical Drug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Magdalena Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RevolKa enters master service agreement with Daiichi Sankyo","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"RevolKa","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"RevolKa \/ .."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reviva Announces $3 Million Direct Offering Priced Under Nasdaq Rules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reviva Updates Enrollment For Brilaroxazine Schizophrenia Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Brilaroxazine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reviva Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Receives ANDA Approval For Bupropion HCl Extended-Release Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bupropion Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EmpowerPharm: Positive Phase 2 Results for CBD in Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EmpowerPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPha.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Gets FDA Approval for ONYDA XR, First Liquid ADHD Medication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Clonidine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Cingulate Therapeutics, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cingulate Achieves Milestone in ADHD Drug CTx-1301 for FDA Marketing Clearance","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Cingulate Therapeutics, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Cingulate Therapeutics, LLC \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cingulate .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Receives USFDA approval for complex, ADHD Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules Pharmaceuticals Receives ANDA Approval for Amphetamine Mixed Salts (IR Tablets)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Dextroamphetamine Saccharate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Elevates EB-003 to Lead Candidate in Pipeline Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"EB-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MangoRx to Launch \"MOJO\" for Low Testosterone & Hormone Imbalances","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Clomiphene Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuti.."},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indivior Doses First Subject in Phase 2 INDV-2000 Study for Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"INDV-2000","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIRA Pharmaceuticals\u2019 Ketamir-2 Shows Promising Safety in Preclinical Testing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Analog","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharm.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Seelos Therapeutics Announces Pricing of $1.1 Million Direct Offering and Placement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Reports Phase 2A Trial: Improved Outcomes in Depressed Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed's FDA End-of-Phase 2 Meeting Positive for MM120 in GAD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"ZMI Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZMI Management Acquires ZIMHI\u2122 from DMK Pharmaceuticals, Partners with FFF","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"DMK Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"","sponsorNew":"DMK Pharmaceuticals \/ ZMI Pharma","highestDevelopmentStatusID":"12","companyTruncated":"DMK Pharma.."},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumora Announces Initiation of Ph 2 Study of Navacaprant in Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Navacaprant","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neumora therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumora th.."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Prochlorperazine Edisylate Injection, USP in the U.S. Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Prochlorperazine Edisylate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Avenacy","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai's ELE-101 Phase 1\/2a Trial Update for Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocin","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"MindBio Therapeutics","pharmaFlowCategory":"D","amount":"$66.5 million","upfrontCash":"Undisclosed","newsHeadline":"Enveric Biosciences Signs $66.5 Million Term Sheet with MindBio for Psilocin Prodrug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocin Prodrug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Enveric Biosciences","amount2":0.070000000000000007,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ MindBio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"Psylo","sponsor":"University of Sydney","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psylo and University of Sydney to Develop Psychedelic Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Psylo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Psylo \/ University of Sydney","highestDevelopmentStatusID":"1","companyTruncated":"Psylo \/ Un.."},{"orgOrder":0,"company":"Yissum Research Development Company","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Secures Global Rights To Psychedelic Compounds For PTSD Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Psychedelic-based Therapy","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Yissum Research Development Company","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yissum Research Development Company \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Yissum Res.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Received ANDA Approval for Venlafaxine ER Capsules","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Venlafaxine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"SpineThera","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpineThera Collaborates with Mayo Clinic for Substance Abuse Disorder Solutions","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"SpineThera","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpineThera \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"SpineThera.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK announces positive results from ph III severe asthma trials of depemokimab","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Depemokimab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Priority Review Update For Dupixent In COPD With Type 2 Inflammation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Ethris","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"ETH47","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ethris \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ B.."},{"orgOrder":0,"company":"Ethris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethris Announces Positive Initial Phase 1 Data for ETH47 mRNA Nasal Delivery","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ETH47","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Ethris","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ethris \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ethris \/ N.."},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alentis Receives FDA ODD for Lixudebart to Treat Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lixudebart","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Th.."},{"orgOrder":0,"company":"Oak Hill Bio","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oak Hill Bio & Chiesi Group Resume Phase 2 Study of OHB-607 for Bronchopulmonary Dysplasia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mecasermin Rinfabate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oak Hill Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oak Hill Bio \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"Oak Hill B.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa\u2019s Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Paridiprubart","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Uniquity Bio","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blackstone Launches Uniquity Bio For Novel Immunology And Inflammation Medicines","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Solrikitug","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Uniquity Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniquity Bio \/ Blackstone Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Uniquity B.."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Avrobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tectonic Therapeutic Closes Merger with AVROBIO and Private Placement of $130.7 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Merger","leadProduct":"TX000045","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Avrobio","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"TAS Partners","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tectonic Therapeutic Closes Merger with AVROBIO and Private Placement of $130.7 Million","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"TX000045","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Tectonic Therapeutic","amount2":0.17999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ TAS Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track To Vasomune's AV-001 Novel Investigational Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"AV-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"AgomAb Therapeutics N.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AGMB-447","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AgomAb Therapeutics N.V","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgomAb Therapeutics N.V \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AgomAb The.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Reports Positive Data from Bexotegrast Imaging Trial in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Insmed","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Insmed Announces Proposed $500 Million Public Offering of Common Stock","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"Brensocatib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0.5,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"","sponsorNew":"Insmed \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ G.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Announces Positive Results from ASPEN Study of Brensocatib in Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Brensocatib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Reports Positive Results from Phase 2a AIR Trial of Buloxibutid in IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Buloxibutid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus receives final approval from USFDA for Dexamethasone Tablets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces US FDA Approval of Ohtuvayre\u2122 (ensifentrine)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinaset Therapeutics Shares Positive Data from Phase 1b KN-002 Study at ATS 2024","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"KN-002","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Kinaset Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinaset Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinaset Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Atlantis Holdings completes acquisition of two brands from Sanofi in Europe & Canada","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Sodium Cromoglicate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Lupin Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ L.."},{"orgOrder":0,"company":"GRI Bio","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"GRI Bio Announces Pricing of $4 Million Public Offering","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Tazarotene","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"GRI Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GRI Bio \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"GRI Bio \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences gets USFDA nod for asthma treatment drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Theophylline","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Begins Patient Recruitment for AB-1005 in Phase 2 Parkinson\u2019s Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-1005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Modalis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Modalis Reports Data on MDL-101 Epigenome Editing for LAMA2-CMD Treatment","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"MDL-101","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Modalis Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Modalis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Modalis Th.."},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotech Receives Priority Review for NT-501 as Treatment for MacTel Type 2","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Revakinagene Taroretcel","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Neurotech Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurotech Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurotech .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas Announces Sponsored Research Agreement with UMass Chan Medical School","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ UMass Chan Medical School","highestDevelopmentStatusID":"2","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon Announces Pricing of $125 Million Underwritten Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ANX005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0.13,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon: Positive Phase 3 Results for ANX005 in Guillain-Barr\u00e9 Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ANX005","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for rADAMTS13 in Congenital TTP","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Apadamtase Alfa","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"AprilBio","sponsor":"Evommune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evommune Secures Rights to Develop Phase 2-ready IL-18 Fusion Protein From AprilBio","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"APB-R3","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"AprilBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AprilBio \/ Evommune","highestDevelopmentStatusID":"6","companyTruncated":"AprilBio \/.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Interchangeable Biosimilar for Two Rare Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"KORU Medical Systems","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KORU Signs Supply Agreement For Phase III Trial Of Endocrinological Biologic","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"Enzyme Replacement Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"KORU Medical Systems","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KORU Medical Systems \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"KORU Medic.."},{"orgOrder":0,"company":"KBio","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBio Gets FDA IND Clearance for EV68-228-N in Acute Flaccid Myelitis Phase 1","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"EV68-228-N","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"KBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KBio \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"KBio \/ Nat.."},{"orgOrder":0,"company":"Savara","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0.10000000000000001,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Savara \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ J.."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara Reports Molgramostim Achieved Significance in Phase 3 IMPALA-2 Trial for aPAP","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReCode Receives FDA Orphan Drug Designation for RCT1100 in Primary Ciliary Dyskinesia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RCT1100","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ReCode Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Chenodeoxycholic Acid","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Completes Enrollment in Phase 3 TransportNPC\u2122 Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex's NRC Gets FDA ODD and RPD for Ataxia Telangiectasia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"University College Cork","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quoin Signs Research Agreement With University College Cork, Ireland","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Quoin Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quoin Pharmaceuticals \/ University College Cork","highestDevelopmentStatusID":"4","companyTruncated":"Quoin Phar.."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited Announced ANDA Approval for Colchicine Capsules","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex: FDA Approves Gloperba sNDA for Commercial Manufacturing","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ORX750","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HARMONY BIOSCIENCES Receives FDA Approval for WAKIX\u00ae in Pediatric Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Immunocan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocan Launches Alpaca-Derived Nanobody Discovery Platform: ImmuAlpaca\u00ae Mouse","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Alpaca-derived Nanobody Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Immunocan","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunocan \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Immunocan .."},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics Announces Platform License Agreement with Lilly","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Ther.."},{"orgOrder":0,"company":"Nabla Bio","sponsor":"Radical Ventures","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nabla Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Nabla Bio \/ Radical Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nabla Bio .."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna and Orbit Discovery Collaborate on Targeted Antisense Oligonucleotide Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK Accelerates Oligonucleotide Platform with Acquisition of Elsie Biotechnologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Oligonucleotide-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0.050000000000000003,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biot.."},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RevolKa Signed Master Service Agreement with Daiichi Sankyo","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Agreement","leadProduct":"RK007","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"RevolKa","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"1","companyTruncated":"RevolKa \/ .."},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,745.0 million","upfrontCash":"$45.0 million","newsHeadline":"Isomorphic Labs Announces Strategic Multi-Target Research Collaboration with Lilly","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.75,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":1.75,"dosageForm":"","sponsorNew":"Isomorphic Labs \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic.."},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Totus Medicines","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Totus Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Totus Medi.."},{"orgOrder":0,"company":"NEOsphere Biotechnologies","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NEOsphere, Kymera Therapeutics Collaborate on Novel Molecular Glue Target Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"NEOsphere Biotechnologies","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NEOsphere Biotechnologies \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"NEOsphere .."},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Microsoft","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enveda Biosciences Announces Microsoft Collaboration for Chemistry Translation","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Microsoft","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bio.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Oxford Nanopore Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Nanopore Collaborates with Twist Bioscience to Launch Pharmacogenomics Program","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Oxford Nanopore Technologies","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Pluri","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Exercises Option to Fund $1.4 Million for Pluri\u2019s Acute Radiation Syndrome Contract","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Funding","leadProduct":"Avoplacel","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ Na.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Receives DOD Award for Phase 2 Study on CX1739 in Spinal Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Ampakine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics, Inc. Announces Proposed Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Oragenics, Inc. Announces Pricing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics, Inc. Announces Closing of Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Dawson James Securities","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ONP-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Granules India Limited announces approval of Trospium Chloride ER Capsules, 60 mg","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trospium Chloride","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules I.."},{"orgOrder":0,"company":"Eisai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$650.0 million","newsHeadline":"Japan's Eisai Terminates ADC Manufacturing Pact with BMS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Termination","leadProduct":"Farletuzumab Ecteribulin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eisai","amount2":3.1000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Bristol Myers Squibb","highestDevelopmentStatusID":null,"companyTruncated":"Eisai \/ Br.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Received US$100 Million Option Payment from Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ascentage Pharma","amount2":1.3,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Takeda Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$2,075.0 million","upfrontCash":"$625.0 million","newsHeadline":"iTeos Doses First Patient in GALAXIES Lung-301 Phase 3, Earns $35M from GSK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Belrestotug","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Iteos Therapeutics","amount2":2.0800000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":null,"companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$263.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"IDE397","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ideaya Biosciences","amount2":0.26000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":null,"companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Yellow Jersey Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$1,250.0 million","newsHeadline":"J&J Completes Acquisition of Yellow Jersey Therapeutics, Gains NM26 for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"NM26","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Yellow Jersey Therapeutics","amount2":1.25,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yellow Jersey Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":null,"companyTruncated":"Yellow Jer.."},{"orgOrder":0,"company":"Foreseen Biotechnology","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,030.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ipsen and Foreseen Announce Global Licensing Agreement for Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"FS001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Foreseen Biotechnology","amount2":1.03,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foreseen Biotechnology \/ Ipsen","highestDevelopmentStatusID":null,"companyTruncated":"Foreseen B.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$302.4 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Closing of Public Offering and Full Exercise of Underwriters' Option","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"IDE397","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ideaya Biosciences","amount2":0.29999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":null,"companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"EyeBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$3,000.0 million","upfrontCash":"$1,300.0 million","newsHeadline":"Merck Completes Acquisition of EyeBio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"EYE103","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"EyeBio","amount2":3,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EyeBio \/ Merck & Co","highestDevelopmentStatusID":null,"companyTruncated":"EyeBio \/ M.."},{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,050.0 million","upfrontCash":"$800.0 million","newsHeadline":"AstraZeneca Closes Acquisition of Amolyt Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Amolyt Pharma","amount2":1.05,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amolyt Pharma \/ AstraZeneca","highestDevelopmentStatusID":null,"companyTruncated":"Amolyt Pha.."},{"orgOrder":0,"company":"Nerio Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nerio Therapeutics","amount2":1.3,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nerio Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":null,"companyTruncated":"Nerio Ther.."},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$550.0 million","upfrontCash":"$525.0 million","newsHeadline":"Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ironshore Pharmaceuticals","amount2":0.55000000000000004,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"Ironshore .."},{"orgOrder":0,"company":"OPKO Health","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"OPKO and HealthCare Royalty Enter $250M Note Purchase Agreement Secured by NGENLA Payments","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"OPKO Health","amount2":0.25,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OPKO Health \/ HealthCare Royalty","highestDevelopmentStatusID":null,"companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$571.5 million","upfrontCash":"Undisclosed","newsHeadline":"Full-Life Technologies, SK Biopharma Enter $571.5M License Agreement for FL-091","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"225Ac-FL-091","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Full-Life Technologies","amount2":0.56999999999999995,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ SK Biopharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","amount":"$260.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cardurion Raises $260M Series B Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cardurion Pharmaceutical","amount2":0.26000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":null,"companyTruncated":"Cardurion .."},{"orgOrder":0,"company":"Valinor Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Continues US Growth Push with $250M Acquisition of Valinor Pharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Naloxegol Oxalate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Valinor Pharma","amount2":0.25,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valinor Pharma \/ Grunenthal","highestDevelopmentStatusID":null,"companyTruncated":"Valinor Ph.."},{"orgOrder":0,"company":"Frontier Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Frontier Announces Milestone Payment in AbbVie Partnership for Advancing Lead Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Frontier Medicine","amount2":1,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Frontier Medicine \/ AbbVie Inc","highestDevelopmentStatusID":null,"companyTruncated":"Frontier M.."},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$593.0 million","upfrontCash":"$90.0 million","newsHeadline":"SCYNEXIS to Receive $10M from GSK for Completed FURI, CARES and NATURE Study Reports","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Scynexis","amount2":0.58999999999999997,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":null,"companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$45.0 million","newsHeadline":"Pinetree Announces Option and Global License Agreement with AstraZeneca for EGFR Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pinetree Therapeutics","amount2":0.5,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pinetree Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":null,"companyTruncated":"Pinetree T.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$461.0 million","upfrontCash":"$111.0 million","newsHeadline":"Ipsen and Day One Announce Exclusive Ex-U.S. Licensing Agreement for Tovorafenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Day One Biopharmaceuticals","amount2":0.46000000000000002,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Ipsen","highestDevelopmentStatusID":null,"companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$848.0 million","upfrontCash":"$60.0 million","newsHeadline":"Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"COM503","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Compugen","amount2":0.84999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":null,"companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"$1,640.0 million","upfrontCash":"Undisclosed","newsHeadline":"India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bharat Serums & Vaccines ltd","amount2":1.6399999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Serums & Vaccines ltd \/ Mankind Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Bharat Ser.."},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Forman Investment Trust","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Zelira\u2019s HOPE\u00ae SPV Receives US$681,000 Third Tranche of Funding","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zelira Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Forman Investment Trust","highestDevelopmentStatusID":null,"companyTruncated":"Zelira The.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Receives IND Clearance from FDA to Start Phase 2 Trial of NMD670 for CMT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NMD670","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Announces Updated Results from Ph 1\/2 Blood Cancer Trial SAR443579\/IPH6101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexatamig","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":null,"companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABIONYX Completes Successful Pre-IND Meeting with FDA for CER-001 Trial for Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CER-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Abionyx Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Abionyx Ph.."},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inhibikase Completes Enrollment of Ph 2 Evaluating Risvodetinib in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Risvodetinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inhibikase Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inhibikase Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Inhibikase.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck's KEYTRUDA Plus Carboplatin and Paclitaxel for Endometrial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Provides Update on FDA Type C Meeting for Bucillamine Study to Treat Long COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Revive The.."},{"orgOrder":0,"company":"IN8bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IN8bio Present Positive Data Showing 1-year Complete Remission in Phase 1 Trial of INB-100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"INB-100","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IN8bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IN8bio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"IN8bio \/ N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Ascentage's Phase III Study of Olverembatinib for SDH-deficient GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Completion of Investigator Meeting for Ph 2b Trial for HLHS","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Longeveron","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Announces Ph 3 SYNCHRONY Trial of Efruxifermin for Compensated Cirrhosis Due to MASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Provide Update from Ph I Study Showing Strong Survival with UV1 & Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health to Report Phase 3 Trial Results for Crofelemer on or Before July 23, 2024","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Apex Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apex Labs Files IND with FDA for Microdose Psilocybin Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Apex Labs","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apex Labs \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Apex Labs .."},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindBio Reports Sustained Antidepressant Response from MB22001 in Depression Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LSD","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MindBio Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MindBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"MindBio Th.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approval of VYVGART Hytrulo for Inflammatory Demyelinating Polyneuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod Alfa","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Argenx","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starton Announces 100% Partial Response or Better in Myeloma Patients in Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Starton Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starton Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Starton Th.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces FDA Approval of KRAZATI with Cetuximab for CRC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Adagrasib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Announces Screening of First Patient in CATT1 Trial for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cadisegliatin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Imfinzi Fails in Late-Stage Trial to Treat Certain Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGC Pharma's TGR-63 Preclinical Results Show Reduction in Amyloid Plaque in Alzheimer's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"Vogenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vogenx's Positive Results from Ph 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mizagliflozin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vogenx","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vogenx \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vogenx \/ N.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Announces Oversubscribed Private Placement and 2024 Annual Meeting Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"KT-2000","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Signs a New Subscription Agreement for a Maximum of EUR 2.1M in Convertible Bonds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioSenic","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ ABO Securities","highestDevelopmentStatusID":null,"companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"ALK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALK's European Reg Application for ITULAZAX\u00ae for Paediatric Indication Accepted for Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Birch Pollen Extract","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ALK","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALK \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ALK \/ Not .."},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SFA Thera Announces Completion of Enrollment in Phase 1b Trial of SFA-002 for Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Calcium","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SFA Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SFA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"SFA Therap.."},{"orgOrder":0,"company":"SpliSense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpliSense Receives FDA Fast Track Designation for SPL84 for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SPL84","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SpliSense","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpliSense \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"SpliSense .."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Completes Site Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Liposomal Tacrolimus","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Announces Positive CHMP Opinion for LIVMARLI Oral Solution for PFIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"SN BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Drug Designation for SNB-101 for Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SN BioScience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SN BioScience \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"SN BioScie.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Announces Positive Phase 2 Results of KP1077 for Hypersomnia at SLEEP 2024","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Reports Completion of Last Patient in SIGNAL-AD Study for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Anthos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anthos Announces 84% Transition to Abelacimab in AZALEA-TIMI 71 Study for AFib at a Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Abelacimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Anthos Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anthos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Anthos The.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calico Announces Fosigotifator Selected for FDA Pilot Program for White Matter Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosigotifator","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Calico Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calico Life Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Calico Lif.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Announces Expanded FDA Approval of ELEVIDYS for DMD Patients Ages 4 & Above","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J Submits FDA Application for TREMFYA for Moderately to Severely Active Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Guselkumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CG Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CG Oncology \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Doses First Participant in Phase 1b Trial of ABI-4334 for Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ABI-4334","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Announces Ethics Approval for Phase II Trial of LSALT Peptide for CS-AKI","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Surpasses Enrollment Target and Receives FDA Designation for BBP-418","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"NMD670","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mim8 Show Superior Reduction in Bleeding Rate Compared to Prior Treatment in Haemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Mim8","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Highlights Data on Solriamfetol Showing Cognitive Improvement in Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Completes Enrollment in Phase 3 Trial of Reproxalap in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Reproxalap","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Initiation of Ph 1 Study of Aficamten in Japanese Participants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Aficamten","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Announces Topline Results from Ph 3 Trial of IV Ganaxolone in Status Epilepticus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Announces Positive FDA Meeting for CAP-1002 Program for DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allyx Announces First Alzheimer\u2019s Disease Patient Treated with Lead Compound ALX-001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"BMS-984923","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Allyx Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allyx Therapeutics \/ Yale University","highestDevelopmentStatusID":null,"companyTruncated":"Allyx Ther.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Receives FDA ODD for Tafenoquine for Acute Babesiosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Nutriband","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutriband Provides Product Development Update for its Lead Product Aversa Fentanyl","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Fentanyl","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nutriband","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nutriband \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Nutriband .."},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4Moving Biotech Announces Success in Phase I Trial of Liraglutide for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"4Moving Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"4Moving Bi.."},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MoonLake Announces Positive FDA and EMA Feedback for Ph 3 of Sonelokimab in Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Sonelokimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MoonLake Immunotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MoonLake Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"MoonLake I.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Bio Doses First Participant in Phase 1a\/b Trial of ABI-5366 for Herpes Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ABI-5366","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON Announces Database Lock for Phase 2 Study with IMNN-001 in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Imunon","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx's GOHIBIC Selected for First BARDA-Sponsored Trial for ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"InflaRx","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in mTNBC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entrada Reports Preliminary Data from Phase 1 ENTR-601-44-101 Trial for DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"ENTR-601-44","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Entrada Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entrada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Entrada Th.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Data Showing Lean Mass Preservation After GLP-1 Agonist Withdrawal","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SRK-439","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Announces Positive Data from Phase 1b Trial of RGLS8429 for ADPKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RGLS8429","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Announces Results for IGALMI for Agitation Associated with Bipolar Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Werewolf Highlights Data from Phase 1 Trial of WTX-330 for Tumors or Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"WTX-330","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Werewolf Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Werewolf Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Werewolf T.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quince Announces First Patient Dosed in Phase 3 Trial of EryDex for Ataxia-Telangiectasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synaptogenix Announces FDA IND Authorization for Bryostatin-1 Trial in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Synaptogenix","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaptogenix \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Synaptogen.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Announces Expansion of DM199 (Rinvecalinase Alfa) Program into Preeclampsia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Rinvecalinase Alfa","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas Bio Reports Successful Treatment of Limb-Threatening Mucor Infection with MAT2203","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MRT-2359","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Monte Rosa Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Monte Rosa.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Announces Long-Term Benefit of Deramiocel in HOPE-2 OLE Study for DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Deramiocel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine's Phase 1 Trial of PMC-403 for Macular Degeneration Advances to 4mg and 3mg","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PMC-403","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Announces FDA Acceptance and Priority Review for Crinecerfont for CAH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic Reports Favorable Six-Week Results from Fourth Patient in Deltacel-01 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Announces New Tumor Response Data from Phase 2b Study of VBI-1901 in Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s KEYTRUDA Plus Chemotherapy for Advanced Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Selected by FDA for START Program for Nomlabofusp in Friedreich's Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Nomlabofusp","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomea Completes Enrollment of First 3 Arms in Phase 2 COVALENT-111 Study for BMF-219","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"BMF-219","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biomea Fusion","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomea Fusion \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Biomea Fus.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Initiates Enrollment in First Study of Bria-OTS in Advanced Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Radiopharm Receives Strategic Investment for up to A$18 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Private Placement","leadProduct":"[68Ga]-Trivehexin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Radiopharm Theranostics","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":null,"companyTruncated":"Radiopharm.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medsenic Subsidiary Signs Licensing Agreement with Phebra PTY Ltd","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioSenic","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ Phebra","highestDevelopmentStatusID":null,"companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Codexis","sponsor":"Crosswalk Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"AAV Gene Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Codexis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Crosswalk Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Senti Bio Awarded CIRM Grant for Logic Gated CAR-NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Cytarabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Senti Biosciences","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":null,"companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$140.0 million","newsHeadline":"Radionetics Oncology Enters Into Strategic Agreement With Lilly","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Radionetics Oncology","amount2":1,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radionetics Oncology \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"Radionetic.."},{"orgOrder":0,"company":"CureVac","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$1,556.0 million","upfrontCash":"$429.2 million","newsHeadline":"GSK buys full rights to make COVID, influenza vaccines from CureVac","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"GSK4382276A","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CureVac","amount2":1.5600000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Biogen","highestDevelopmentStatusID":null,"companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"ThirtyFiveBio Wins Grant to Advance GPR35 Inhibitor for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ThirtyFiveBio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ThirtyFiveBio \/ Innovate UK","highestDevelopmentStatusID":null,"companyTruncated":"ThirtyFive.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bird flu concern prompts US to award Moderna $176 million for vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"mRNA-1010","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Moderna Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":null,"companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Glycotope","sponsor":"PentixaPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pentixapharm Acquires Target Discovery Business of Glycotope","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Glycotope","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycotope \/ Pentixapharm","highestDevelopmentStatusID":null,"companyTruncated":"Glycotope .."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"$0.9 million","newsHeadline":"Cosmo and Infectopharm Sign License for Winlevi\u00ae in Germany, Italy, and Austria","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":null,"companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi\u00ae in Korea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":null,"companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.7 million","newsHeadline":"Cosmo and Hikma Sign License for Winlevi\u00ae in 17 Middle East and North Africa Countries","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cosmo Pharmaceuticals N.V. Launches Public Exchange Offer to Acquire Cassiopea S.p.A.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Med Patent Pool Signs with Aurobindo, Cipla & Viatris for Generic HIV Prevention Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"The Medicines Patent Pool","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Medicines Patent Pool \/ Aurobindo Pharma Limited","highestDevelopmentStatusID":null,"companyTruncated":"The Medici.."},{"orgOrder":0,"company":"Kanvas Biosciences","sponsor":"DCVC","pharmaFlowCategory":"D","amount":"$29.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kanvas Biosciences Raises $12.5M in Additional Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"KAN-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kanvas Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kanvas Biosciences \/ DCVC","highestDevelopmentStatusID":null,"companyTruncated":"Kanvas Bio.."},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Beacon Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":null,"companyTruncated":"Beacon The.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Celltrion","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":null,"companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus and Dr Reddy's Co-Market Pertuzumab Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":null,"companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Canada","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"McGill, industry, CQDM and Brain Canada collaborate for drug discovery","therapeuticArea":"Sleep","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"McGill University","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McGill University \/ Brain Canada","highestDevelopmentStatusID":null,"companyTruncated":"McGill Uni.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":null,"companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Genexine","sponsor":"EPD Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Genexine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ EPD Biotherapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"SmartCella","sponsor":"Fj\u00e4rde AP-fonden","pharmaFlowCategory":"D","amount":"$54.1 million","upfrontCash":"Undisclosed","newsHeadline":"SmartCella raises EUR 50 million to accelerate growth and commercialization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"PROC-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SmartCella","amount2":0.050000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SmartCella \/ Fj\u00e4rde AP-fonden","highestDevelopmentStatusID":null,"companyTruncated":"SmartCella.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics & IASO Bio enter strategic collaboration in cell therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Equecabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":null,"companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Myricx Bio","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$114.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings Leads \u00a390M Financing for Myricx Bio ADC Payload Class","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"MYX2468","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Myricx Bio","amount2":0.11,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myricx Bio \/ Novo Holdings","highestDevelopmentStatusID":null,"companyTruncated":"Myricx Bio.."},{"orgOrder":0,"company":"Synsight","sponsor":"Iktos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iktos Acquires Synsight for Protein and RNA-Protein Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Synsight","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synsight \/ Iktos","highestDevelopmentStatusID":null,"companyTruncated":"Synsight \/.."},{"orgOrder":0,"company":"RS BioTherapeutics","sponsor":"University of Colorado School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RS BioTherapeutics Announces Research Collaboration with University of Colorado","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"RSBT-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"RS BioTherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RS BioTherapeutics \/ University of Colorado School of Medicine","highestDevelopmentStatusID":null,"companyTruncated":"RS BioTher.."},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trevena Secures $2M Financing and Reduces Liabilities for ex-US Royalty Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Oliceridine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Trevena","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":null,"companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"CellProthera","sponsor":"BioCardia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CellProthera and BioCardia Collaborate on Phase II ProtheraCytes\u2122 Trial for AMI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"ProtheraCytes","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CellProthera","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CellProthera \/ BioCardia","highestDevelopmentStatusID":null,"companyTruncated":"CellProthe.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"TuHURA Biosciences","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kineta Signs Exclusivity Agreement for VISTA Blocking Antibody with TuHURA Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"KVA12123","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kintara Therapeutics","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintara Therapeutics \/ TuHURA Biosciences","highestDevelopmentStatusID":null,"companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiho Exercises License Option for Quemliclustat in Japan and Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Quemliclustat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$128.0 million","upfrontCash":"$100.0 million","newsHeadline":"Ligand to Acquire APEIRON Biologics AG for $100 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Apeiron Biologics","amount2":0.13,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Bionxt Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNxt Signs Agreement with Contract Research and Manufacturing Organization","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Cladribine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ BioNxt Solutions","highestDevelopmentStatusID":null,"companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Mitsubishi Tanabe Sign Agreement for mRNA Vaccines in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Covid-19 Vaccine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":null,"companyTruncated":"Theralase .."},{"orgOrder":0,"company":"SciRhom","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"SciRhom Secures \u20ac63M Financing to Advance iRhom2 Therapies in Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"SR-878","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SciRhom","amount2":0.070000000000000007,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciRhom \/ Andera Partners","highestDevelopmentStatusID":null,"companyTruncated":"SciRhom \/ .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"$36.3 million","upfrontCash":"$12.0 million","newsHeadline":"RedHill Biopharma Terminates License Agreement for Aemcolo\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Termination","leadProduct":"Rifamycin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"RedHill Biopharma","amount2":0.040000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ RedHill Biopharma","highestDevelopmentStatusID":null,"companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Endomimetics","sponsor":"Innovate Alabama","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Endomimetics Wins $100K Grant to Develop Bionanomatrix for Knee Arthroplasty Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Endomimetics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Endomimetics \/ Innovate Alabama","highestDevelopmentStatusID":null,"companyTruncated":"Endomimeti.."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prelude and Merck to Evaluate PRT3789 with KEYTRUDA\u00ae for SMARCA4-Mutated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Docetaxel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Merck & Co","highestDevelopmentStatusID":null,"companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"Crossject","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"Crossject Wins \u20ac69M French Government Funding to Develop ZENEO\u00ae Epinephrine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Crossject","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crossject \/ Bpifrance","highestDevelopmentStatusID":null,"companyTruncated":"Crossject .."},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Vesalius Biocapital IV","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"HepaRegeniX Raises \u20ac15M to Advance HRX-215 for Liver Regeneration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"HRX-215","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"HepaRegeniX","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HepaRegeniX \/ Vesalius Biocapital IV","highestDevelopmentStatusID":null,"companyTruncated":"HepaRegeni.."},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Acorda Therapeutics","amount2":0.19,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acorda Therapeutics \/ Merz Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Acorda The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cosette Acquires Ambien\u00ae and Ambien CR\u00ae from Sanofi US","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Zolpidem Tartrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sanofi","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Cosette Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Sanofi \/ C.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$35.1 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Acquires Phase 3-Ready GLP-1 Receptor Antagonist (Avexitide)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eiger BioPharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Ensol BioSciences","sponsor":"Spine BioPharma","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spine BioPharma Signs with Ensol BioSciences to Expand Indications for SB-01 Injection","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"SB-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ensol BioSciences","amount2":0.16,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ensol BioSciences \/ Spine BioPharma","highestDevelopmentStatusID":null,"companyTruncated":"Ensol BioS.."},{"orgOrder":0,"company":"Link Immunotherapeutics","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"CT-95","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Link Immunotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Link Immunotherapeutics \/ Context Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Link Immun.."},{"orgOrder":0,"company":"Evotec","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Pfizer Collaborate to Advance Drug Discovery in France","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Evotec","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Pfizer Inc","highestDevelopmentStatusID":null,"companyTruncated":"Evotec \/ P.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Beacon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abeona and Beacon Sign Non-Exclusive Deal for AAV204 Capsid for Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"AAV204","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Beacon Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Announces Closing of Private Debt Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alvotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Pan Cancer T","sponsor":"InnovationQuarter","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Pan Cancer T Raises \u20ac425M to Advance Next-Gen T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"PCT-1","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pan Cancer T","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pan Cancer T \/ InnovationQuarter","highestDevelopmentStatusID":null,"companyTruncated":"Pan Cancer.."},{"orgOrder":0,"company":"Onco360","sponsor":"Geron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Onco360 Chosen as Specialty Pharmacy Partner for Rytelo\u2122 (Imetelstat)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Onco360","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onco360 \/ Geron","highestDevelopmentStatusID":null,"companyTruncated":"Onco360 \/ .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Verastem Doses First Patient with GFH375\/VS-7375 in Phase 1\/2 Trial in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"VS-7375","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ GenFleet Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Tiba Biotech","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA Partners with Tiba Biotech to Develop Innovative Therapeutics Against Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tiba Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiba Biotech \/ BARDA","highestDevelopmentStatusID":null,"companyTruncated":"Tiba Biote.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Evofem Biosciences","pharmaFlowCategory":"D","amount":"$84.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lupin divests women\u2019s health specialty business in US to Evofem for $84 million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Divestment","leadProduct":"Secnidazole","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lupin Ltd","amount2":0.080000000000000002,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Evofem Biosciences","highestDevelopmentStatusID":null,"companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Akos Biosciences","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"EV102","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Enveric Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Akos Biosciences","highestDevelopmentStatusID":null,"companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces $25 Million Strategic Private Placement Financing","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MediWound","amount2":0.029999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":null,"companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Trethera","sponsor":"Small Business Innovation Research","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Wins $2M NIH Grant for Pediatric Neurologic Disease Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"TRE-515","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Trethera","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trethera \/ Small Business Innovation Research","highestDevelopmentStatusID":null,"companyTruncated":"Trethera \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recce Receives $2M US Defense Grant for RECCE\u00ae 327 Gel","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"R327","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":null,"companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"MediWound","sponsor":"EIC","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Secures $1625M from European Innovation Council Program","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MediWound","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ EIC","highestDevelopmentStatusID":null,"companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SPC-14","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Willett Advisors","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scorpion Wins $150M Financing to Advance Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"STX-478","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Scorpion Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scorpion Therapeutics \/ Willett Advisors","highestDevelopmentStatusID":null,"companyTruncated":"Scorpion T.."},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleo Health Selected as Specialty Pharmacy for ALYGLO\u2122 for Adults with PI","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Soleo Health","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":null,"companyTruncated":"Soleo Heal.."},{"orgOrder":0,"company":"Genomics plc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genomics and Vertex Extend Drug Discovery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Genomics plc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genomics plc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Genomics p.."},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","amount":"$38.8 million","upfrontCash":"Undisclosed","newsHeadline":"Renalys Pharma Closes \u00a560Bn Financing to Advance Kidney Disease Treatments in Asia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Renalys Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Renalys Pharma \/ Catalys Pacific","highestDevelopmentStatusID":null,"companyTruncated":"Renalys Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sionna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sionna Expands CF Pipeline with AbbVie License Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Sionna Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Mankind Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"CatalYm","sponsor":"Canaan Partners","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"CatalYm cashes in on early-stage cancer data with $150M series D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series D Financing","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CatalYm","amount2":0.14999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Canaan Partners","highestDevelopmentStatusID":null,"companyTruncated":"CatalYm \/ .."},{"orgOrder":0,"company":"Asceneuron","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asceneuron raises $100M series C for ph. 2 Alzheimer's trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ASN51","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Asceneuron","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asceneuron \/ EQT Life Sciences","highestDevelopmentStatusID":null,"companyTruncated":"Asceneuron.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ORIC Announces Collaborations to Evaluate ORIC-944 for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"ORIC-944","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":null,"companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$31.5 million","upfrontCash":"$26.5 million","newsHeadline":"Aclaris Sells OLUMIANT\u00ae Royalties to OMERS for Up to $315M","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aclaris Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"TCG","pharmaFlowCategory":"D","amount":"$122.0 million","upfrontCash":"Undisclosed","newsHeadline":"3 months after taking NGM Bio private, VC firm oversees biotech\u2019s $122M series A","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Aldafermin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NGM Biopharmaceuticals","amount2":0.12,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ TCG","highestDevelopmentStatusID":null,"companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"ACEA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scilex and ACEA Collaborate to Expand ZTlido\u00ae in ex-US and Far East Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ ACEA Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"SciSparc Signs Letter of Intent for Global Out-Licensing of Pain Treatment for $6M","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SciSparc","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"SciSparc \/.."},{"orgOrder":0,"company":"Ancilia Bioscience","sponsor":"Safar Partners","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Ancilia Biosciences Announces Closing of $4.2 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Bacteria-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ancilia Bioscience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ancilia Bioscience \/ Safar Partners","highestDevelopmentStatusID":null,"companyTruncated":"Ancilia Bi.."},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sanyou Biopharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"Sanyou Bio.."},{"orgOrder":0,"company":"Draupnir Bio","sponsor":"MP Healthcare","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"Draupnir Bio Completes 12M Seed Round to Advance Oral Small Molecule Degraders","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Draupnir Bio","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Draupnir Bio \/ MP Healthcare","highestDevelopmentStatusID":null,"companyTruncated":"Draupnir B.."},{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"ITV-1 - ImmunH","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nika Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nika Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Nika Pharm.."},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Longeveron Announces $9M Registered Direct Offering Under Nasdaq Rules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Longeveron","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":null,"companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Haystack Oncology","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Haystack Oncology and Lisata Therapeutics Start Collaboration to Use MRD\u2122 Tech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Haystack Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Haystack Oncology \/ Lisata Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Haystack O.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","amount":"$21.8 million","upfrontCash":"Undisclosed","newsHeadline":"Inventiva announces a \u20ac20.1 million issuance of royalty certificates","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Lanifibranor","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inventiva Pharma","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inventiva Pharma \/ Samsara BioCapital","highestDevelopmentStatusID":null,"companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Meitheal Pharmaceuticals Expands Portfolio with Acquisition of CONTEPO\u2122 from Nabriva","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"GT Apeiron","sponsor":"Exscientia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exscientia Acquires Rights to Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"GTAEXS617","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GT Apeiron","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Apeiron \/ Exscientia","highestDevelopmentStatusID":null,"companyTruncated":"GT Apeiron.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna Receives Award from BARDA to Accelerate mRNA-based Influenza Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"mRNA-1018","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Moderna Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":null,"companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Resyca BV Partner","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma and Resyca BV Partner on Device and CMC Development for PTSD Drug SPC-15","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"SPC-15","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silo Pharma \/ Resyca BV Partner","highestDevelopmentStatusID":null,"companyTruncated":"Silo Pharm.."},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rona Therapeutics Raises $35M Series A+ to Advance Innovative Metabolic siRNA Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rona Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":null,"companyTruncated":"Rona Thera.."},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Andelyn Biosciences, UMass Partner on Cockayne Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Andelyn Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Andelyn Biosciences \/ UMass Chan Medical School","highestDevelopmentStatusID":null,"companyTruncated":"Andelyn Bi.."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$167.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Artiva Biotherapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Jefferies","highestDevelopmentStatusID":null,"companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"GRO Biosciences","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GRO Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GRO Biosciences \/ Atlas Venture","highestDevelopmentStatusID":null,"companyTruncated":"GRO Biosci.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus signs patent licensing agreement with Takeda for 'VaultA\u2019 in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Zydus Lifesciences","highestDevelopmentStatusID":null,"companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Signs Patent Licensing Agreement with Takeda to Commercialize Vonoprazan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":null,"companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Announces Pricing of $5M Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biodexa Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":null,"companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Signs Clinical Trial Agreements for Tafenoquine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Yale University","highestDevelopmentStatusID":null,"companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics, Inc. Announces Pricing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":null,"companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Pharma Two B","sponsor":"Hepion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharma Two B Announces Merger with Hepion and $11.5M Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Merger","leadProduct":"Pramipexole Dihydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pharma Two B","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharma Two B \/ Hepion Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Pharma Two.."},{"orgOrder":0,"company":"Valneva","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$41.3 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Expands Partnership with Valneva with $41.3M Grant for Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Chikungunya Vaccine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Valneva","amount2":0.040000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ CEPI","highestDevelopmentStatusID":null,"companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Cell BioEngine","sponsor":"SOSV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cell BioEngines Secures $2M Funding from SOSV and New York Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"CBE-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cell BioEngine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cell BioEngine \/ SOSV","highestDevelopmentStatusID":null,"companyTruncated":"Cell BioEn.."},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"Anebulo Pharmaceuticals Awarded NIDA Grant for Acute Cannabis-Induced Toxic Effects","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Selonabant","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Anebulo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anebulo Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":null,"companyTruncated":"Anebulo Ph.."},{"orgOrder":0,"company":"Lario Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lario Therapeutics Awarded $6M Grant from Michael Fox Foundation for Parkinson\u2019s Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lario Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lario Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":null,"companyTruncated":"Lario Ther.."},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics and Oxford Collaborate on Drug Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Apollo Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ University of Oxford","highestDevelopmentStatusID":null,"companyTruncated":"Apollo The.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Inks Contracts in Asia to Expand Presence in the Region","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biophytis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Eisai","sponsor":"Sato Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Partners with Sato Pharma to Commercialize Fosravuconazole in Asia, Oceania","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Fosravuconazole","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eisai","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Sato Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Eisai \/ Sa.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"SENJU PHARMACEUTICAL CO LTD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":null,"companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology Announces Pricing of $55M Public Offering of Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Verastem Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":null,"companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"J&J vets burst into biotech with $165M Third Arc series A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"ADC-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Third Arc Bio","amount2":0.17000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Third Arc Bio \/ Vida Ventures","highestDevelopmentStatusID":null,"companyTruncated":"Third Arc .."},{"orgOrder":0,"company":"Abiologics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Flagship\u2019s Abiologics sets sail with $50M for synthetic protein R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Synteins-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Abiologics","amount2":0.050000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abiologics \/ Flagship Pioneering","highestDevelopmentStatusID":null,"companyTruncated":"Abiologics.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"TransCode Therapeutics, Inc. Announces Closing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":null,"companyTruncated":"TransCode .."},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"EIC","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"ImPact Biotech Receives \u20ac13.5M Investment from European Innovation Council","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Padeliporfin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ImPact Biotech","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImPact Biotech \/ EIC","highestDevelopmentStatusID":null,"companyTruncated":"ImPact Bio.."},{"orgOrder":0,"company":"Beacon Biosignals","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beacon Biosignals Collaborates with Skye Bioscience to Integrate Sleep Quality Endpoints","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Beacon Biosignals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Biosignals \/ Skye Bioscience","highestDevelopmentStatusID":null,"companyTruncated":"Beacon Bio.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Canaan Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Completes $100M Series C Financing to Advance Depression Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ABX-002","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ Canaan Partners","highestDevelopmentStatusID":null,"companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fortress Bio Announces First Patient Dosed in Phase 2 CMV Study for Liver Transplantation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"CMV Vaccine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Fortress Biotech","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fortress Biotech \/ NIAID","highestDevelopmentStatusID":null,"companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"DIMERx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DIMERx Secures Global Rights to Novel Amino Acid Prodrug Developed at MGH","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ DIMERx","highestDevelopmentStatusID":null,"companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Medical University of Innsbruck","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evergreen Theragnostics Licenses EVG321 from Innsbruck for Radioligand Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"177Lu-EVG-321","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Evergreen Theragnostics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evergreen Theragnostics \/ Medical University of Innsbruck","highestDevelopmentStatusID":null,"companyTruncated":"Evergreen .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals and Cleveland Clinic to Advance Influenza Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Cleveland Clinic","highestDevelopmentStatusID":null,"companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"University College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Earth Therapeutics Announces Collaboration with UCL for Prostate Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"225Ac-rhPSMA-10.1","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Blue Earth Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blue Earth Therapeutics \/ University College London","highestDevelopmentStatusID":null,"companyTruncated":"Blue Earth.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Pharmaceuticals Enters License Agreement with Kye for AGAMREE\u00ae in Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalyst Pharmaceuticals \/ Kye Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beacon Biosignals Collaborates with Skye Bioscience to Integrate Sleep Quality Endpoints","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":null,"companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Completes $100M Series C Financing to Advance Depression Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series C Financing","leadProduct":"ABX-002","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":null,"companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"Nexcella","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"California Institute Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nexcella","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ CIRM","highestDevelopmentStatusID":null,"companyTruncated":"Nexcella \/.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chemomab Therapeutics Announces $10 Million Private Placement","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"CM-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ChemomAb","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChemomAb \/ HBM Healthcare Investments","highestDevelopmentStatusID":null,"companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Signs Licenses to Commercialize TWYNEO\u00ae and EPSOLAY\u00ae in Europe and South Africa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":null,"companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Aditxt","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Signs Amendment with Appili Therapeutics for September 30 Acquisition Close","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Aditxt","highestDevelopmentStatusID":null,"companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Marvel Biosciences","sponsor":"iBraiN Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marvel Biosciences Extends Collaboration with iBraiN Institute on Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Istradefylline","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Marvel Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marvel Biosciences \/ iBraiN Institute","highestDevelopmentStatusID":null,"companyTruncated":"Marvel Bio.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"University of Texas MD Anderson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Summit Therapeutics and MD Anderson Collaborate to Accelerate Ivonescimab Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ University of Texas MD Anderson","highestDevelopmentStatusID":null,"companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Immunis","sponsor":"Springbok","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunis Partners with Springbok Analytics to Assess IMMUNA for Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Immunis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunis \/ Springbok","highestDevelopmentStatusID":null,"companyTruncated":"Immunis \/ .."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Driehaus Capital Management","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Secures EUR 60M Series B for GPCR-Modulating Therapies","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Confo Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ Driehaus Capital Management","highestDevelopmentStatusID":null,"companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","amount":"$11.7 million","upfrontCash":"Undisclosed","newsHeadline":"Alto Neuroscience Gets Trust Funding for ALTO-100 in Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alto Neuroscience","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":null,"companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"KT-2000","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rakovina Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Rakovina T.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Great Point Partners","pharmaFlowCategory":"D","amount":"$122.7 million","upfrontCash":"Undisclosed","newsHeadline":"ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ProMIS Neurosciences","amount2":0.12,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Great Point Partners","highestDevelopmentStatusID":null,"companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Announces Pricing of $10.8 Million Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":null,"companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReviR Therapeutics Raises $30M Series A to Oral Genetic Medicines for CNS Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ReviR Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReviR Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":null,"companyTruncated":"ReviR Ther.."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Genomma Lab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genomma Lab Announces Strategic Bolt-On Acquisition of Four Brands","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Ibuprofen","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ Genomma Lab","highestDevelopmentStatusID":null,"companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"ITF Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx\u00aeRare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Givinostat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PANTHERx Rare Pharmacy \/ ITF Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Gets FDA Clearance for Iomab-ACT IND Targeting Sickle Cell Disease Conditioning","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":null,"companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"PK MED","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"PK MED Receives \u20ac1.5M DeepTech Financing from Bpifrance for Cell-Homing Implant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"PKM-02","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PK MED","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PK MED \/ Bpifrance","highestDevelopmentStatusID":null,"companyTruncated":"PK MED \/ B.."},{"orgOrder":0,"company":"Versatope Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versatope Receives Grants to Support Malaria Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Versatope Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Versatope Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":null,"companyTruncated":"Versatope .."},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Health2Sync","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merdury Signs MOU with Health2Sync for StackDose Trial in GLP-1 Medication","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merdury Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merdury Pharmaceutical \/ Health2Sync","highestDevelopmentStatusID":null,"companyTruncated":"Merdury Ph.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"WeComput","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent and WeComput Announce Partnership to Advance AI-Driven Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ WeComput","highestDevelopmentStatusID":null,"companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Silicon Valley Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Silicon Valley Bank","highestDevelopmentStatusID":null,"companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcutis Announces ZORYVE\u00ae U.S. Co-promote Agreement with Kowa Pharmaceuticals America","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":null,"companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$905.0 million","upfrontCash":"$150.0 million","newsHeadline":"MacroGenics Achieves $100M in Milestones from Retifanlimab Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MacroGenics","amount2":0.91000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Incyte Corporation","highestDevelopmentStatusID":null,"companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KabaFusion Selected by GC Biopharma USA as Limited Distribution Partner for ALYGLO\u2122","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GC Biopharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":null,"companyTruncated":"GC Biophar.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia and SGN Nanopharma Announce Collaboration for Chronic Dry Eye Disease Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":null,"companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Announces Oversubscribed $175.0 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Private Placement","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Day One Biopharmaceuticals","amount2":0.17999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Day One Biopharmaceuticals \/ Fairmount","highestDevelopmentStatusID":null,"companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"CastleVax","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"CastleVax Receives $34M from BARDA to Advance Intranasal NDV-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"CVAX-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CastleVax","amount2":0.029999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CastleVax \/ BARDA","highestDevelopmentStatusID":null,"companyTruncated":"CastleVax .."},{"orgOrder":0,"company":"Immuneel Therapeutics","sponsor":"taiba Healthcare Group","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taiba Makes Strategic Investment in Immuneel Therapeutics to Advance CAR T-cell Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Financing","leadProduct":"Varnimcabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Immuneel Therapeutics","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneel Therapeutics \/ taiba Healthcare Group","highestDevelopmentStatusID":null,"companyTruncated":"Immuneel T.."},{"orgOrder":0,"company":"LTZ Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"LTZ Therapeutics Announces $20M Series A for Myeloid Engager-Based Immunotherapy Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"LTZ-301","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"LTZ Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LTZ Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":null,"companyTruncated":"LTZ Therap.."},{"orgOrder":0,"company":"Leveragen","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leveragen Announces Collaboration with Moderna to Advance Antibody Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Leveragen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leveragen \/ Moderna Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Leveragen .."},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FOXG1 Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River Partners with FOXG1 Research Foundation to Advance CGT for Rare Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ FOXG1 Research Foundation","highestDevelopmentStatusID":null,"companyTruncated":"Charles Ri.."},{"orgOrder":0,"company":"Pinetree Therapeutics","sponsor":"STIC Investments","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pinetree Closes $17M Series A to Advance AbReptor\u2122 Protein Degradation Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pinetree Therapeutics","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pinetree Therapeutics \/ STIC Investments","highestDevelopmentStatusID":null,"companyTruncated":"Pinetree T.."},{"orgOrder":0,"company":"Cortice Biosciences","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals Expands Pipeline with Abeotaxane for Brain Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Abeotaxane","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cortice Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cortice Biosciences \/ CNS Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Cortice Bi.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Signs Exclusive License Agreement with MTHERA for NB-01","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NB-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":null,"companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"CORTx","sponsor":"MRFF","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australia Injects $4M into National Centre for Biopharma Optimisation of mRNA Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Funding","leadProduct":"mRNA-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CORTx","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CORTx \/ MRFF","highestDevelopmentStatusID":null,"companyTruncated":"CORTx \/ MR.."},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$7,200.0 million","upfrontCash":"$150.0 million","newsHeadline":"GSK becomes Flagship's latest partner in $7B biobucks respiratory, immunology pact","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Flagship Pioneering","amount2":7.2000000000000002,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flagship Pioneering \/ GSK","highestDevelopmentStatusID":null,"companyTruncated":"Flagship P.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Expanded Collaboration","leadProduct":"ADC-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AbCellera","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Market","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"OS Therapies Announces Pricing of IPO on NYSE American under Symbol \u201cOSTX\u201d","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Public Offering","leadProduct":"OST31-164","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"OS Therapies","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Brookline Capital Market","highestDevelopmentStatusID":null,"companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,125.0 million","upfrontCash":"$800.0 million","newsHeadline":"Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"JNT-517","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Jnana Therapeutics","amount2":1.1299999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Sagesse Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics Partners with Gore Range to Establish JV Sagesse Bio for RNAi Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Lixadesiran","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Sagesse Bio","highestDevelopmentStatusID":null,"companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Medicilon","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicilon & Hengrui Pharma Deepen Collaboration on ADCs, Small Nucleic Acids, & CGT Drugs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Medicilon","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicilon \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":null,"companyTruncated":"Medicilon .."},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KVK Tech\u2019s Lomaira Completes Registration in Mexico Through Partner Medix","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"KVK.Tech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":null,"companyTruncated":"KVK.Tech \/.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"$406.5 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Biosciences Announces License Agreement for B7H3\/PTK7 ADC Program with Biocytogen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biocytogen","amount2":0.40999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ IDEAYA Biosciences","highestDevelopmentStatusID":null,"companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Avicenna Pharmaceutical","sponsor":"Molecure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicenna Biosciences & Molecure S.A. Sign Collaboration for Small Molecule Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Avicenna Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avicenna Pharmaceutical \/ Molecure","highestDevelopmentStatusID":null,"companyTruncated":"Avicenna P.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PolyPid","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":null,"companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Outpace Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outpace Bio Announces $144M Series B to Advance AI-powered Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"OPB-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Outpace Bio","amount2":0.20000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Outpace Bio \/ RA Capital Management","highestDevelopmentStatusID":null,"companyTruncated":"Outpace Bi.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"GEMMA Biotherapeutics","pharmaFlowCategory":"D","amount":"$134.0 million","upfrontCash":"Undisclosed","newsHeadline":"Passage Bio Out-licenses Pediatric Gene Therapy Programs to GEMMA Biotherapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Passage Bio","amount2":0.13,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Passage Bio \/ GEMMA Biotherapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Instil Bio","pharmaFlowCategory":"D","amount":"$2,050.0 million","upfrontCash":"$50.0 million","newsHeadline":"Instil Bio and ImmuneOnco Announce License Agreement for IMM2510 and IMM27M Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"SYN-2510","moa":"PD-L1\/VEGF","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ImmuneOnco","amount2":2.0499999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmuneOnco \/ Instil Bio","highestDevelopmentStatusID":null,"companyTruncated":"ImmuneOnco.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Expands with Worldwide License Agreement with Sanofi for T-cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sanofi","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Vir Biotechnology","highestDevelopmentStatusID":null,"companyTruncated":"Sanofi \/ V.."},{"orgOrder":0,"company":"Healx","sponsor":"R42 Group","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Healx Announces $47M Series C and FDA Clearance for Neurofibromatosis Type 1 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Series C Financing","leadProduct":"HLX-1502","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Healx","amount2":0.050000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Healx \/ R42 Group","highestDevelopmentStatusID":null,"companyTruncated":"Healx \/ R4.."},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$159.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridGene Biosciences Expands Collaboration with Galapagos for SMARCA2 PROTAC Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BridGene Biosciences","amount2":0.16,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":null,"companyTruncated":"BridGene B.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$8,700.0 million","upfrontCash":"$8,700.0 million","newsHeadline":"AbbVie Completes Acquisition of Cerevel Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ Abbvie Inc","highestDevelopmentStatusID":null,"companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Jade Biosciences","sponsor":"Fairmount","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jade Biosciences Launches with $80M to Develop Therapies for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Jade Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jade Biosciences \/ Fairmount","highestDevelopmentStatusID":null,"companyTruncated":"Jade Biosc.."},{"orgOrder":0,"company":"LimmaTech Biologics","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.8 million","newsHeadline":"Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"S4V","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"LimmaTech Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LimmaTech Biologics \/ Valneva","highestDevelopmentStatusID":null,"companyTruncated":"LimmaTech .."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lundbeck Partners with Takeda in the US, Opts for Royalties, Focuses on Rexulti","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Vortioxetine Hydrobromide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"BioSyngen","sponsor":"A STAR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosyngen partners with Singapore's A*STAR to advance autoimmune therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioSyngen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSyngen \/ A STAR","highestDevelopmentStatusID":null,"companyTruncated":"BioSyngen .."},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Formosa Pharmaceuticals Announce Licensing Agreement with Apotex for Clobetasol Propionate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Formosa Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Formosa Pharmaceuticals \/ Apotex Inc","highestDevelopmentStatusID":null,"companyTruncated":"Formosa Ph.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"SWK Funding LLC","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Relief Therapeutics Secures up to $11 Million from Royalty Sales","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Relief Therapeutics","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relief Therapeutics \/ SWK Funding LLC","highestDevelopmentStatusID":null,"companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Senti Bio Announces Grant Award from CIRM for SENTI-202 Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Funding","leadProduct":"SENTI-202","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Senti Biosciences","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":null,"companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$63.5 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Biosciences Raises $63.5M in Series C to Advance Precision Endocrine Peptide\u2122 Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Series C Financing","leadProduct":"MBX 2109","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MBX Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Deep Track Capital","highestDevelopmentStatusID":null,"companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Rznomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK pharmteco and Rznomics Explore Collaboration for RNA-based Gene Therapy Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SK Pharmteco","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Pharmteco \/ Rznomics","highestDevelopmentStatusID":null,"companyTruncated":"SK Pharmte.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"CVC Capital Partners","pharmaFlowCategory":"D","amount":"$925.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mallinckrodt Reaches Agreement to Sell Therakos\u00ae Business to CVC for $925 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Methoxsalen","moa":"DNA synthesis Inhibitor","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mallinckrodt Pharmaceuticals","amount2":0.93000000000000005,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ CVC Capital Partners","highestDevelopmentStatusID":null,"companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$905.0 million","upfrontCash":"$905.0 million","newsHeadline":"Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Agios Pharmaceuticals","amount2":0.91000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"BVF Partners LP","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Private Placement","leadProduct":"Levosimendan","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tenax Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ BVF Partners LP","highestDevelopmentStatusID":null,"companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Seed Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$1,500.0 million","newsHeadline":"SEED Therapeutics Enters Collaboration with Eisai for Novel Molecular Glue Degraders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Seed Therapeutics","amount2":1.5,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seed Therapeutics \/ Eisai","highestDevelopmentStatusID":null,"companyTruncated":"Seed Thera.."},{"orgOrder":0,"company":"Release Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"Release Therapeutics Secures CHF 3.3 Million in Seed Funding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Release Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Release Therapeutics \/ Undisclosed","highestDevelopmentStatusID":null,"companyTruncated":"Release Th.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,950.0 million","upfrontCash":"$50.0 million","newsHeadline":"Sangamo Therapeutics Announces License Agreement with Genentech for Genomic Medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ST-501","moa":"Tau protein production Reducer","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sangamo Therapeutics","amount2":1.8999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Genentech","highestDevelopmentStatusID":null,"companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$170.0 million","newsHeadline":"Daiichi Sankyo and Merck Enter Global Development Agreement for MK-6070","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Daiichi Sankyo","highestDevelopmentStatusID":null,"companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Financing","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Artax Biopharma","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"NeuroTherapia Raises $12.3M in the First Close of its Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NeuroTherapia","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":null,"companyTruncated":"NeuroThera.."},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Silo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Announces Partnership with Global CRO for CNS Homing Peptide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"SPU-16","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"WuXi AppTec","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Silo Pharma","highestDevelopmentStatusID":null,"companyTruncated":"WuXi AppTe.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pharmacosmos AS","pharmaFlowCategory":"D","amount":"$405.0 million","upfrontCash":"$405.0 million","newsHeadline":"Pharmacosmos Group to Acquire G1 Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"G1 Therapeutics, Inc","amount2":0.40999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"G1 Therapeutics, Inc \/ Pharmacosmos AS","highestDevelopmentStatusID":null,"companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"IDRx","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDRx Announces $120M Series B to Advance New Treatment for Gastrointestinal Stromal Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Series B Financing","leadProduct":"IDRX-42","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IDRx","amount2":0.12,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDRx \/ RA Capital Management","highestDevelopmentStatusID":null,"companyTruncated":"IDRx \/ RA .."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyowa Kirin and NewBridge Enter Agreement to Improve Rare Disease Access in MENA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Burosumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Precigen","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"PRGN-2012","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Precigen","amount2":0.029999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Stifel","highestDevelopmentStatusID":null,"companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$3,200.0 million","upfrontCash":"$3,200.0 million","newsHeadline":"Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Morphic Therapeutic","amount2":3.2000000000000002,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Exscientia","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AI biotechs Exscientia and Recursion agree $688m merger \nNews","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Merger","leadProduct":"GTAEXS617","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Exscientia","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Recursion Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Exscientia.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Can-Fite BioPharma","amount2":0.01,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":null,"companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zevra Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Cantor","highestDevelopmentStatusID":null,"companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Conduit Pharmaceuticals Signs Exclusive License with AstraZeneca for Novel Treatments","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AZD1656","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Conduit Pharma","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene and WuXi Biologics Collaborate on Off-the-Shelf TCR-Guided T Cell Engagers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Gene-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Medigene","highestDevelopmentStatusID":null,"companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$156.8 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Receives $156.8M from U.S. for Smallpox\/Mpox Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Live Nonreplicating Smallpox and Monkeypox Vaccine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bavarian Nordic","amount2":0.16,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ BARDA","highestDevelopmentStatusID":null,"companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Pharmaceuticals Announces $500M Financing Facility with Sixth Street","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Financing","leadProduct":"Plozasiran","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":null,"companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Humanetics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Uniformed Services University Grants Support for Humanetics Radiation Countermeasure","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Funding","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Humanetics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humanetics \/ U.S. Department of Defense","highestDevelopmentStatusID":null,"companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"NEC Corporation","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NEC Bio Therapeutics and AGC Biologics Collaborate on Personalized Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"NECVAX-NEO1","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NEC Corporation","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NEC Corporation \/ AGC Biologics","highestDevelopmentStatusID":null,"companyTruncated":"NEC Corpor.."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4,000.0 million","upfrontCash":"$50.0 million","newsHeadline":"Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"BMS-986419","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Evotec","amount2":4,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":null,"companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab Takes Full Control of Acasunlimab Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Termination","leadProduct":"Acasunlimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioNTech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Genmab","highestDevelopmentStatusID":null,"companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Devart Middle East","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Signs Master Distributor Agreement for ZTlido\u00ae Distribution in MENA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Lidocaine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scilex Pharmaceuticals \/ Devart Middle East","highestDevelopmentStatusID":null,"companyTruncated":"Scilex Pha.."},{"orgOrder":0,"company":"Curon Biopharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$700.0 million","newsHeadline":"Merck Puts Up Potential $1.3B to Acquire Curon\u2019s B Cell Depletion Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"CN201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Curon Biopharmaceutical","amount2":1.3,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curon Biopharmaceutical \/ Merck & Co","highestDevelopmentStatusID":null,"companyTruncated":"Curon Biop.."},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alzamend Neuro Partners with MGH for Phase II Trial of AL001 in Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Partnership","leadProduct":"Lithium Salicylate Proline","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alzamend Neuro","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":null,"companyTruncated":"Alzamend N.."},{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cadrenal and Abbott Collaborate on Novel Anticoagulant Tecarfarin for LVAD Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Tecarfarin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cadrenal Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cadrenal Therapeutics \/ Abbott Laboratories","highestDevelopmentStatusID":null,"companyTruncated":"Cadrenal T.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Lysergide D-tartrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Leerink Partners","highestDevelopmentStatusID":null,"companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Development Center for Biotechnology","sponsor":"HoneyBear Biosciences","pharmaFlowCategory":"D","amount":"$22.4 million","upfrontCash":"Undisclosed","newsHeadline":"MOEA Announces Global First Dual-Function Anti-Cancer ADC Drug with DCB Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ADC-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Development Center for Biotechnology","amount2":0.02,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Development Center for Biotechnology \/ HoneyBear Biosciences","highestDevelopmentStatusID":null,"companyTruncated":"Developmen.."},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaBay Pharmaceuticals Launches Avenova Bundles for Multifactorial Dry Eye Relief","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Omega-3","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NovaBay Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NovaBay Ph.."},{"orgOrder":0,"company":"Inimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INIMMUNE Reports Phase 1 Results for INI-2004 Allergy Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"INI-2004","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inimmune","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inimmune \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Inimmune \/.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Reports Positive Phase III Result for Tradipitant in Motion Sickness","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tradipitant","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ractigen Therapeutics Receives IND Approval for Phase 1 Trials of RAG-17 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"RAG-17","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ractigen Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ractigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ractigen T.."},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantex Pharmaceuticals Gets FDA Orphan Drug Status for Azeliragon in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Azeliragon","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cantex Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cantex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cantex Pha.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet BioTherapeutics Updates Data for SON-1010 Monotherapy and Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Completes Enrollment in ALG-055009 Phase 2a Study for MASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-055009","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indaptus Therapeutics Completes First Patient Dosing of Decoy20 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Decoy20","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Indaptus Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Indaptus T.."},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laekna Gets FDA Approval for Phase III Protocol of LAE002 Plus LAE001 in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"LAE001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Laekna Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laekna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Laekna The.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai's LEQEMBI receives approval in South Korea for treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eisai","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Begins NDA Submission for Avutometinib & Defactinib Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics SRC Endorses ATRN-119 Dosing at 800 mg Daily in ABOYA-119 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"ATRN-119","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Receives EC Marketing Authorization for LYTENAVA\u2122 in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab Gamma","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health\u2019s Crofelemer Trial Shows Positive Results for Functional Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NLS Pharmaceutics Reports Positive KO-874 Study on Mazindol for Narcoleptic-like Model","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazindol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NLS Pharmaceutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NLS Pharmaceutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NLS Pharma.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Updates on Masitinib\u2019s Conditional Marketing Authorization for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AB Science","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AB Science.."},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TransCode Reports Positive Data from First-in-Human Study of TTX-MC138","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"TTX-MC138","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TransCode Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TransCode Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"TransCode .."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Starts ORCA-OL Trial for Cytisinicline in Nicotine Users","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Receives FDA IND Clearance for SPG302 for ALS Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlueRock Therapeutics Gets FDA RMAT Designation for Parkinson\u2019s Disease Cell Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Bemdaneprocel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BlueRock Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BlueRock Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BlueRock T.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Gets Ethics Approval for Phase 2 Trial of SPG302 for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Reports Positive Phase 3 Results for Lumateperone in Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder for Lung Transplant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Ayrtons Saunders","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayrton Announces UK MHRA Approval of Next Gen Nicotine Inhaler for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nicotine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ayrtons Saunders","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayrtons Saunders \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ayrtons Sa.."},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeno Biosciences Starts Phase 1b Proof-of-Concept Study in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"XEN-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Xeno Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xeno Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Xeno Biosc.."},{"orgOrder":0,"company":"GenVivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenVivo Begins Patient Dosing in Phase I\/Ib Trial for GEN2 Gene Vector Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"GVO-1102","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GenVivo","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenVivo \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"GenVivo \/ .."},{"orgOrder":0,"company":"Bioxodes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxodes Meets Enrollment Milestone for BIOX-101 in Intracerebral Hemorrhagic Stroke","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Ir-CPI","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bioxodes","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioxodes \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bioxodes \/.."},{"orgOrder":0,"company":"Resolution Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resolution Therapeutics Gets MHRA Approval for Phase I\/II EMERALD Study RTX001","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"RTX001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Resolution Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resolution Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Resolution.."},{"orgOrder":0,"company":"Syncromune","sponsor":"Williams Cancer Foundation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syncromune Granted FDA Fast-Track for SYNC-T SV-102 for Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SV-102","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Syncromune","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syncromune \/ Williams Cancer Foundation","highestDevelopmentStatusID":null,"companyTruncated":"Syncromune.."},{"orgOrder":0,"company":"Humacyte","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humacyte\u2019s ATEV\u2122 Receives FDA RMAT Designation for Advanced Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Humacyte","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humacyte \/ FGK Clinical Research","highestDevelopmentStatusID":null,"companyTruncated":"Humacyte \/.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Graviton Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid and Graviton Announce Data for OV888\/GV101 in Cerebral Cavernous Malformations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GV101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ Graviton Bioscience","highestDevelopmentStatusID":null,"companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Signet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Signet Therapeutics Receives IND Approval for Targeted Therapy for Diffuse Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"sigx1094","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Signet","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Signet \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Signet \/ N.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Provides Updates on OTC Deficiency and CF Programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KaliVir Immunotherapeutics Gets FDA Clearance for VET3-TGI Oncolytic Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"KaliVir Immunotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KaliVir Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"KaliVir Im.."},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Circle Pharma Files IND for First-in-Class Oral Cyclin A\/B RxL Inhibitor for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CID-078","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Circle Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Circle Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Circle Pha.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves FoundationOne\u00aeLiquid CDx as Companion Diagnostic for AKEEGA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Janssen Biotech","highestDevelopmentStatusID":null,"companyTruncated":"Foundation.."},{"orgOrder":0,"company":"AviadoBio","sponsor":"The Ohio State University Wexner Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASPIRE-FTD Phase 1\/2 Trial Opens at Ohio State University Wexner Medical Center","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AAV-PGRN","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AviadoBio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AviadoBio \/ The Ohio State University Wexner Medical Center","highestDevelopmentStatusID":null,"companyTruncated":"AviadoBio .."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"NeuraLight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Shows Significant Efficacy and Survival in ALS from 12-Month PARADIGM Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ NeuraLight","highestDevelopmentStatusID":null,"companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Kisunla\u2122 Approved by FDA for Early Symptomatic Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Donanemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"IRLAB","sponsor":"Integrative Research Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\u2019s Phase IIb Study of Pirepemat Continues After Positive Safety Review","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pirepemat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IRLAB","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRLAB \/ Integrative Research Laboratories","highestDevelopmentStatusID":null,"companyTruncated":"IRLAB \/ In.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Full-Life Technologies Receives FDA Fast Track for 225Ac-FL-020 in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Full-Life Technologies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyra Biosciences Announces Proof-of-Concept Results for TYRA-300 in Hypochondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TYRA-300","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tyra Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and \"AP\" Rated\u00b9","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Disodium Hydrogen Phosphate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"American Regent","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"American R.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Accepts Prior Approval Supplement for ZYNRELEF\u00ae Vial Access Needle","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heron Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":null,"companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARVYKTI\u00ae Achieves Significant Survival Improvement in CARTITUDE-4 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Legend Biotech","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae Approved in EU as First Targeted Therapy for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dupilumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":null,"companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Nanjing Healthnice Pharmaceutical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyre Therapeutics Gets NMPA Approval for Avatrombopag in CLD-Associated Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Gyre Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gyre Therapeutics \/ Nanjing Healthnice Pharmaceutical Technology","highestDevelopmentStatusID":null,"companyTruncated":"Gyre Thera.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Suffield Research Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Updates on Bucillamine Study for Nerve Agent Exposure","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Suffield Research Centre","highestDevelopmentStatusID":null,"companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Reports Positive Results for AVT03, a Proposed Biosimilar for Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alvotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Reports Phase III Parkinson\u2019s Data Showing Improved UPDRS and Cognition","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":null,"companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Launches FDA-Approved Naproxen Delayed-Release Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Naproxen","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Doses First Patient in Phase 2 Trial of Descartes-08 for Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Descartes-08","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delta-Fly Pharma Begins Phase III Trial of DFP-14323","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ubenimex","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Delta-Fly Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Delta-Fly .."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Gets Positive DSMB Review for Phase 2 Trial of MaaT033 in Allo-HSCT Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Gets FDA Acceptance for Vanzacaftor\/Tezacaftor\/Deutivacaftor for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vanzacaftor","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Launches Subcutaneous Formulation of Tyenne\u00ae in U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Fresenius SE & Co. KGaA","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fresenius SE & Co. KGaA \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEDIPAL and JCR Complete CTN for Phase I\/II Study of JR-446 in Mucopolysaccharidosis IIIB","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"JR-446","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":null,"companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Presents Data Showing Muscle Repair from SAT-3247 in Canine Model of DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Satellos Bioscience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Satellos B.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Yifan Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem enters Chinese osteoarthritis treatment market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"LG Chem","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LG Chem \/ Yifan Pharmaceutical","highestDevelopmentStatusID":null,"companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Gubra","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and Gubra Start Clinical Development of Obesity Triple Agonist","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 3034701","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Gubra","highestDevelopmentStatusID":null,"companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Receives NDA Acceptance & Priority Review for Tazemetostat in Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Hutchmed","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Hutchmed \/.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim and OSE Immunotherapeutics Advance SIRP Cancer Immunology Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BI 770371","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":null,"companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Reports Preliminary Results for Montelukast VersaFilm\u00ae in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Roche\u2019s Vabysmo Prefilled Syringe for Vision Loss Causes","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma gets tentative nod from USFDA for Ivosidenib tablets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track to Full-Life Technologies\u2019 225Ac-FL-020 for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"225Ac-FL-020","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Full-Life Technologies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Full-Life Technologies \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Full-Life .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Approves AstraZeneca\u2019s Tagrisso with Chemotherapy for EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas\u2019 Partner Viatris Pharma Starts Phase III Trial with Nefecon in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Viatris","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhejiang Doer Completes Phase 1b\/2a Trial Enrollment for DR10624 in Obese Subjects","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"DR10624","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zhejiang Doer Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zhejiang D.."},{"orgOrder":0,"company":"GSK","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GSK","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Medicines for Malaria Venture","highestDevelopmentStatusID":null,"companyTruncated":"GSK \/ Medi.."},{"orgOrder":0,"company":"Oxolife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxolife\u2019s Oral Drug Increases IVF and ICSI Success Rates, Data Presented at ESHRE","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Tungstate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Oxolife","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxolife \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Oxolife \/ .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Reports Positive Results for GalNAc-Based RNAi Therapeutic STP122G","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"STP122G","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPOVIO\u00ae Approved for DLBCL in China, Offering New Treatment Option","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Antengene","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhiyi Biotech Completes Phase I Trial of SK10 for Chemotherapy-Induced Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SK10","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zhiyi Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhiyi Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zhiyi Biot.."},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostar Pharma Gets FDA Clearance for Phase 2 Study of Utidelone in HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Beijing Bi.."},{"orgOrder":0,"company":"HilleVax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HilleVax\u2019s Norovirus Vaccine Fails Phase 2 Trial, Stock Falls 80%","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"HIL-214","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"HilleVax","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HilleVax \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"HilleVax \/.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J\u2019s Sirturo for Tuberculosis Receives Full US, EU Approvals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bedaquiline","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interius BioTherapeutics Receives HREC Approval for Phase 1 CAR Therapeutic Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INT2104","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Interius BioTherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Interius BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Interius B.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Resubmits BLA for Ryoncil\u00ae in Children with Steroid-Refractory aGVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Expands KT-474 (SAR444656) HS and AD Phase 2 Studies After Safety Review","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines to Update RMC-6236 Pancreatic Cancer Program on July 15, 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RMC-6236","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Receives EMA Orphan Drug Designation for SLS009 in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Gets UK MHRA Approval for LYTENAVA\u2122 (bevacizumab gamma)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Merus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merus","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merus \/ Merck & Co","highestDevelopmentStatusID":null,"companyTruncated":"Merus \/ Me.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Reports Positive Pre-NDA Meeting for Tonmya\u2122 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Completes Enrollment in Phase 3 TANDEM Trial for Obicetrapib","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NewAmsterdam Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NewAmsterdam Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NewAmsterd.."},{"orgOrder":0,"company":"Edding Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Partner EddingPharm Gets Approval for VASCEPA\u00ae in China for CVRR","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Edding Pharm","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edding Pharm \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Edding Pha.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spur Therapeutics Completes Phase 1\/2 GALILEO-1 Trial for FLT201 in Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"FLT201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals\u2019 LIVMARLI Approved in the European Union for Patients with PFIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Bio Receives FDA Fast Track for ADI-270 in Advanced Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"E2086","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eisai","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Woolsey Pharmaceuticals Treats First ALS Patient with Higher-Dose BRAVYL in REAL Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fasudil","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Woolsey Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Woolsey Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Woolsey Ph.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Enrolls First Patient in Phase 2 KOURAGE Trial of Auxora\u2122 in AKI","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio Completes Enrollment in Phase 2 Trial of Bempikibart for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bempikibart","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Q32 Bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution in Canine Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Belhaven Biopharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":null,"companyTruncated":"Belhaven B.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Io Therapeutics Presents IRX4204 Data for Aging, Parkinson\u2019s, and Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Arcutis\u2122 ZORYVE\u00ae for Atopic Dermatitis in Adults and Children 6 Years and Up","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"CURIUM US LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dotatate Lutenium Lu-177","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CURIUM US LLC","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CURIUM US LLC \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"CURIUM US .."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zevra Announces FDA Advisory Committee Meeting for Arimoclomol in Niemann-Pick Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Begins Enrollment in Abiprubart Phase 2b Trial for Sjogren Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Abiprubart","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"PPD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEON Biopharma Shifts Focus to Biosimilar Pathway for ABP-450","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AEON Biopharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AEON Biopharma \/ PPD","highestDevelopmentStatusID":null,"companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Jiangsu Hengrui Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strong Data from Phase 2 Trial of PDE10A Inhibitor CPL\u212236 as Novel Oral Antipsychotic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CPL500036","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Celon Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celon Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Celon Phar.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Completes LIFT-AD Trial of Fosgonimeton in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosgonimeton","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Enrolls First Patient in Phase 1 Trial of MNPR-101-Zr Radiopharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"MNPR-101-Zr","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gain Therapeutics Completes Dosing in Phase 1 Study of GT-02287 for Parkinson Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GT-02287","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Gain Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gain Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Gain Thera.."},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalo Therapeutics Gets Active IND for AVTX-009 in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AVTX-009","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Avalo Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avalo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Avalo Ther.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Announces IRB Approval for Tafenoquine Study in Babesiosis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tafenoquine Succinate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abata Therapeutics Gets FDA Clearance for ABA-101 in Progressive Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ABA-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Abata Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Abata Ther.."},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pint Pharma Approves ORLADEYO\u00ae for HAE Prevention in Peru","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Berotralstat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pint Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pint Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pint Pharm.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches FOCINVEZ\u2122, the First Ready-to-Use Version of Fosaprepitant","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fosaprepitant","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xspray Pharma\u2019s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Nilotinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Xspray Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xspray Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Xspray Pha.."},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Analyses Show TGR-63's Blood-Brain Barrier Permeability and Safety","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TGR-63","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IGC Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGC Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"IGC Pharma.."},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio\u00ae Antisense Strand","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Inclisiran","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"EnPlusOne Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnPlusOne Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"EnPlusOne .."},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Gene Therapy to Start Pediatric Trial for ASD and Phelan-McDermid Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"JAG201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Jaguar Gene Therapy","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Gene Therapy \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Jaguar Gen.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Positive Data for AMT-130 in Huntington Disease Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AMT-130","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Uniqure","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin receives US FDA tentative marketing approval for generic Trijardy XR tablets","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Completes Enrollment of TETON 2 Study for Inhaled Treprostinil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"United The.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leqembi approved for the treatment of Alzheimer's disease in Hong Kong","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eisai","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"AusperBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AusperBio Receives Breakthrough Designation for AHB-137 in Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AHB-137","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AusperBio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AusperBio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AusperBio .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rgenta Therapeutics Gets IND Clearance for RGT-61159 in ACC and CRC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RGT-61159","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rgenta Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rgenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Rgenta The.."},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Pharmass\u00eatX Orphan Drug Designation for Green Tea-Based IBD Treatment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Green Tea Extract","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pharmass\u00eatX","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmass\u00eatX \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pharmass\u00eat.."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Skyhawk Therapeutics Reports Positive Phase 1 Results for SKY-0515 in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SKY-0515","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Skyhawk Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics\u2019 Certepetide Shows Promise in Cholangiocarcinoma in Preclinical Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tr1X Doses First Patient in GvHD Trial with TRX103, a Type 1 Treg Cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TRX103","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tr1X Bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tr1X Bio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tr1X Bio \/.."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron\u00ae Receives RMAT Designation for Lomecel-B\u2122 in Mild Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Longeveron","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Reports Positive Data from OK-101 Phase 2 Trial in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Therapeutics Announces Phase II\/III Results for Paxalisib in Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Paxalisib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biophytis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA declines to approve Novo Nordisk's weekly insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Insulin Icodec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivani Medical Updates on NPM-115 GLP-1 Obesity Implant Program Development","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vivani Medical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivani Medical \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vivani Med.."},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Submits Filing for Phase 1 Trial with SAT-3247","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Satellos Bioscience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Satellos B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Advances Once-Daily Oral GLP-1 Agonist Danuglipron Development","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Danuglipron","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Positive Results in Head and Neck SCC Patients with Negative PD-L1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Eftilagimod Alfa","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Immutep","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Applies for FDA Orphan Drug Status for Namodenoson in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biodexa Reports 12-Month Data from Phase 2 eRapa Trial for GI Tract Polyps","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leqembi approved for the treatment of Alzheimer's disease in Israel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":null,"companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 2 Study of Dapansutrile for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Olatec Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase I Clinical Trial of YOLT-201","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"YOLT-201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"YolTech Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"YolTech Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"YolTech Th.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Completes Enrollment in Phase 2 Tailwind Study of AP-PA02 in Bronchiectasis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AP\u2010PA02","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Provides Update on Vafseo\u00ae (vadadustat) Commercial Launch","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OKYO Pharma Announces Data from OK-101 Phase 2 Dry Eye Disease Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OK-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"OKYO Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OKYO Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"OKYO Pharm.."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants fast track designation to AskBio\u2019s AB-1005 for PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AB-1005","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AskBio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg\/vial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Selexipag","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences gets USFDA nod to market chronic heart failure treatment drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sacubitril Sodium","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Grants Priority Review for ViiV's Cabotegravir for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare's Apretude Approved by US FDA for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV\u2019s Cabotegravir for HIV Prevention Receives Positive CHMP Opinion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Announces Health Canada Approval for APRETUDE for HIV Pre-Exposure Prophylaxis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LATITUDE Phase III Data Shows Cabenuva Superior to Daily Therapy for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosmo Begins Phase III Trials for Androgenetic Alopecia in Males","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosmo Announces Submission of Winlevi\u00ae to the European Medicines Agency (EMA)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces Health Canada Approval for PRWINLEVI\u00ae in Acne Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nipocalimab Phase 3 Trial Shows Longest Disease Control in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INO-3107 Awarded Innovation Passport in UK for Innovative Licensing Pathway","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Resubmits BLA for Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azafaros Announces Positive Phase 2 Data with Nizubaglustat in GM2 and Niemann-Pick","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Nizubaglustat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Azafaros","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azafaros \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Argenx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab and argenx Approve Efgartigimod Alfa for Generalized Myasthenia Gravis in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ argenx","highestDevelopmentStatusID":null,"companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrivo Gets FDA Fast Track for RABI-767 in Acute Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RABI-767","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arrivo BioVentures","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrivo BioVentures \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Arrivo Bio.."},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diakonos Oncology Receives FDA Fast Track for Pancreatic Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dendritic Cell Vaccine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Diakonos Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diakonos Oncology \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Diakonos O.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Positive Secondary Efficacy Data from SENS-401 Phase 2a Trial","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sensorion","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals\u2019 ET-400 NDA Accepted by FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Sabin Vaccine Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"cAD3-Sudan Ebolavirus Vaccine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sabin Vaccine Institute","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sabin Vaccine Institute \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sabin Vacc.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Receives FDA Nod for ART26.12 as Fatty Acid Binding Protein 5 Inhibitor","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ART26.12","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Reports Positive Data from INTEGRIS-PSC Phase 2a Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bexotegrast","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexeo Therapeutics Reports Positive Interim Phase 1\/2 Data of LX2006 for Friedreich Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"LX2006","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lexeo Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexeo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lexeo Ther.."},{"orgOrder":0,"company":"Cytonics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytonics Initiates Phase 1 Study of CYT-108 for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CYT-108","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cytonics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytonics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cytonics \/.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"9MW2821","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mabwell","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma\u2019s DSP-5336 Receives FDA Fast Track for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Enzomenib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC\u00ae","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Endo Pharm","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Endo Pharm.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scinai Immunotherapeutics Reports Promising Results in Psoriatic Skin Model","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NanoAb-based Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Reports Positive Phase 3 Results for CAM2029 in Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Camurus","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Io Therapeutics Presents IRX4204 Results for ALS Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IRX4204","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Receives FDA Rare Pediatric Disease Designation for SLS009 in Pediatric AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearmind Medicine Gets FDA IND Approval for Phase I\/IIa Trial in Alcoholism","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Clearmind Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Clearmind .."},{"orgOrder":0,"company":"Flag Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FLAG Therapeutics Announces Positive Preclinical Data for FLAG-003 in DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"FLAG-003","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Flag Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flag Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Flag Thera.."},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biodexa Announces Health Canada Approval for Phase 2a Tolimidone in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tolimidone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biodexa Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biodexa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Biodexa Ph.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Initiate Global Phase 3 Program for Barzolvolimab in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Reports 93% Cough Suppression with Ifenprodil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Receives PDUFA Goal Date for Sotagliflozin NDA Resubmission","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lisata Therapeutics Completes Enrollment in Phase 2a BOLSTER Trial of Certepetide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Certepetide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"NexThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexThera Files IND for Phase 1\/2a Trial of NT-101 Eye Drop for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NT-101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NexThera","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexThera \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NexThera \/.."},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alto Neuroscience Completes Enrollment in Phase 2b Study of ALTO-100 for Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ALTO-100","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alto Neuroscience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alto Neuroscience \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alto Neuro.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA declines to approve Orexo's opioid overdose drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Orexo","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to 7MW3711","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"7MW3711","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mabwell","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mabwell \/ .."},{"orgOrder":0,"company":"Evommune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evommune Announces Positive Results for MRGPRX2 Antagonist EVO756","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"EVO756","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Evommune","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evommune \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Evommune \/.."},{"orgOrder":0,"company":"BioSyngen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosyngen\u2019s BRG01 Enters Phase II Trial as First Autologous EBV-Specific CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BRG01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioSyngen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSyngen \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioSyngen .."},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiscGenics Gets FDA Nod for Phase III Trial of Injectable Disc Progenitor Cells","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Rebonuputemcel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"DiscGenics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"DiscGenics.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharma gets USFDA nod for seizure treatment drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Topiramate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences\u2019 Toripalimab and Bevacizumab NDA Accepted for Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Reports Successful End-of-Phase 2 Meeting for GTX-102 in Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GTX-102","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALOR Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VLA15","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Valneva","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":null,"companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Receives Clearance for Phase I Study of LAG-3 Agonist Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"IMP761","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Immutep","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron\u00ae Receives Fast Track Designation for Lomecel-B\u2122 in Mild Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Allogeneic Medicinal Signaling Cell Therapy","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Longeveron","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Reports Positive ATH434-202 Phase 2 Data in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ATH434","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4DMT Reports Positive Phase 2 PRISM Interim Results for 4D-150 in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"4D-150","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Reports Positive Phase III Results for NUBEQA\u00ae in Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Darolutamide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces Positive Phase I Results of Oral GLP-1 Agonist CT-996 for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CT-996","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Genentech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Plans NDA for Tonmya for Fibromyalgia Management","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Receives Second FDA Fast Track Designation for Diamyd\u00ae in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renalys Pharma Doses First Patient in Phase III Trial of Sparsentan for IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Renalys Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Renalys Ph.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotheryx Doses First Patient in Phase 1 Trial of BTX-9341 for HR+\/HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BTX-9341","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioTheryX","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits NDA to FDA for Expanded Pediatric Indication for EDURANT\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Rilpivirine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Health Canada Approval of CABENUVA\u2122 for HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Announces European Decision for Vocabria and Rekambys Injections for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Announces FDA Acceptance and Priority Review of Tabelecleucel for EBV Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics Initiates Phase 3 AFFIRM-1 Trial with BNC210 for Social Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BNC210","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bionomics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Abliva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abliva Report Positive Interim Analysis of FALCON Study of KL1333 in Mitochondrial Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KL1333","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Abliva","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abliva \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Abliva \/ N.."},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkeus Pharmaceuticals Shows Progress in Stargardt Disease with TEASE-3 Study Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Gildeuretinol Acetate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alkeus Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkeus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alkeus Pha.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA\u00ae for Non-Erosive GERD","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Reports Results from Phase 1 Study with CDI-988 for Norovirus\/Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CDI-988","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Announces Supplemental Data from Phase 1 Trial of BT-600","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Biora Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Biora Ther.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Reports Unique Effects of Varoglutamstat on Kidney Function in Diabetes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Releases New Analysis of Phase 2 Data for Arsenic Trioxide in cGvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioSenic","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioSenic \/.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Deciphera\u2019s MAA for Vimseltinib for Tenosynovial Giant Cell Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Vimseltinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Phase 3 Evidence of AJOVY\u00ae for Migraine Prevention in Children","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Updates on Zatolmilast for Fragile X Syndrome, Including Study Protocol Changes","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Zatolmilast","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Shionogi","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Announces Ganaxolone Approved in China for CDKL5 Deficiency Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marinus Pharmaceuticals \/ Tenacia Biotechnology","highestDevelopmentStatusID":null,"companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces End-of-Phase-2 Meeting Outcomes for BOT\/BAL in MSS Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Agenus","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Phase 3 Results for TiNivo-2 in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tivozanib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Receives Positive Feedback from FDA on Tonmya\u2122 for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's weight loss drug tirzepatide gets approval in China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Announces Top-line Data from NUZYRA\u00ae for Severe Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Completes Phase 3 Enrollment for EFZO-FIT\u2122 Study in Pulmonary Sarcoidosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Efzofitimod","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Samsung Bioepis\u2019 EPYSQLI\u00ae as Biosimilar to Soliris","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STADA and Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar to Stelara in Europe","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":null,"companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces FDA Clearance of IND for ZW191, Novel Folate Receptor-\u237a ADC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ZW191","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Certa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Certa Therapeutics Receives EU Orphan Designation for FT011 in Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"FT011","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Certa Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Certa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Certa Ther.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex\u2019s Partner Discontinues ADX71149 development in Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ADX71149","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Commences in Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Positive DSMB Recommendation for Phase 2a NOTOXIS Trial","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"R-Azasetron Besylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sensorion","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Palonosetron Hydrochloride Injection, USP in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Palonosetron","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Avenacy","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Avenacy \/ .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TME Pharma Announces Plan to Externalize and Monetize NOX-E36","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Eli lilly","highestDevelopmentStatusID":null,"companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytoki Pharma Announces Positive Phase 1 Data for CK-0045 in Cardiometabolic Risk Factors","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CK-0045","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cytoki Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytoki Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cytoki Pha.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J seeks expanded approval for antidepressant Spravato","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences gets Mexican regulatory nod for cancer treatment biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Zentiva","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generic HIV raltegravir medicines approved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Raltegravir Potassium","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Zentiva","highestDevelopmentStatusID":null,"companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Receives Positive Opinion for Orphan Drug Designation for Polihexanide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Polyhexanide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SIFI","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIFI \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"SIFI \/ Not.."},{"orgOrder":0,"company":"Nuvalent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a\/1b Trial of NVL-330","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NVL-330","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nuvalent","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvalent \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Nuvalent \/.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces First Patient Dosed with KB-0742 in Ovarian Cancer Expansion Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Completes Enrollment in IMC-2 Phase 2 Long-COVID Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Valacyclovir","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Advances to Second Cohort in AD04 Study for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ondansetron","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Submits sNDA for ZORYVE\u00ae Foam for Scalp and Body Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAtla Receives FDA Fast Track Designation for Ozuriftamab Vedotin in Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ozuriftamab Vedotin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioAtla","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives Authorization to Start Phase I Trial of Allocetra in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharma Announces First Patients Dosed in Phase 2 Trial of LB54640 for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"LB54640","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Opens Enrollment for Phase 2 Trial of SPG601 in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG601","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reunion Neuroscience Doses 1st Patient in Phase 2 Trial of RE104 for Postpartum Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RE104","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Reunion Neuroscience","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reunion Neuroscience \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Reunion Ne.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InnoCare Doses First Subject in Clinical Trial of TYK2 Inhibitor ICP-332","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ICP-332","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"InnoCare Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AffyImmune Receives FDA RMAT Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AIC100","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AffyImmune Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AffyImmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AffyImmune.."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpyBiotech Completes Enrollment in Phase I Trial of SPYVLP01 for HCMV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SPYVLP01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Topline Results from Phase 2b\/3 Trial of Clesrovimab for RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Clesrovimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon to Present Phase 2 Biomarker Results for ALZ-801 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alzheon","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial of ETD001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ETD001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brii Biosciences Presents Data on Novel HIV Therapeutics at IDWeek 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Rilpivirine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ConSynance Receives Rare Pediatric Disease Designation for CSTI-500 in PW Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CSTI-500","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ConSynance Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ConSynance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ConSynance.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Granted FDA Fast Track Designation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Foralumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Doses First Patient in Phase 3 LiGeR-HN2 Trial of Petosemtamab in HNSCC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Petosemtamab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merus","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nkarta Announces Investigator-Sponsored Trial of NKX019 for Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nkarta Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OS Therapies Announces Safety Data from Phase 1 Trial of OST-HER2 in HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"OST31-154","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Topline Results from Phase 3 Hemophilia A Gene Therapy Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Giroctocogene Fitelparovec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan and Rare Pediatric Designation to Cellectis\u2019 UCART22 for ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"UCART22","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cellectis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Authority Adopts Update to Wegovy\u00ae Label for Cardiovascular Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Publishes Data Supporting INZ-701 for Rare Bone and Blood Vessel Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces sNDA Filing to Expand FUROSCIX to Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Reports Positive Data for Anaphylm\u2122 Sublingual Film","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya\u2122 for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission for Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Commenced in Phase 3 Trial of CardiAMP Cell Therapy for Ischemic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BCDA-02","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioCardia","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Biosimilar Pyzchiva\u00ae (ustekinumab) Across Europe for Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Pfizer\u2019s DURVEQTIX\u00ae Gene Therapy for Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Fidanacogene elaparvovec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum\u2019s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Maralixibat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viridian Therapeutics Completes Enrollment for VRDN-001 in Chronic Thyroid Eye Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VRDN-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viridian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kashiv BioSciences Completes Enrollment in Phase III Trial of ADL018 Biosimilar to XOLAIR\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kashiv BioSciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kashiv BioSciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kashiv Bio.."},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Announces Preclinical Results for EB-003 Oral Administration Potential","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"EB-003","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Enveric Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enveric Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Enveric Bi.."},{"orgOrder":0,"company":"A.forall","sponsor":"Sagent Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A.forall Launches Fifth ANDA and Second \u201cFirst Cycle\u201d FDA Approval","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"A.forall","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"A.forall \/ Sagent Pharmaceuticals","highestDevelopmentStatusID":null,"companyTruncated":"A.forall \/.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma's drug to treat alopecia areata gets USFDA nod","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Deuruxolitinib phosphate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Menarini","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma to Announce Phase 3 Data for Obicetrapib in Hypercholesterolemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Menarini","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Menarini \/ NewAmsterdam Pharma","highestDevelopmentStatusID":null,"companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Receives Positive EMA CHMP Opinion for Toripalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Toripalimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PMN310","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends RYBREVANT\u00ae in Combo with Chemo for Advanced NSCLC After Prior Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J Receives Positive CHMP Opinion for Yuvanci\u00ae in Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Macitentan","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives CHMP Opinions for Iqirvo\u00ae and Kayfanda\u00ae in Rare Cholestatic Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ipsen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives CHMP Opinion for Mpox Vaccine Real-World Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Modified Vaccinia Ankara","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI\u2019s Phase 3 Analysis Demonstrates Balanced Patient Population for Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae Plus Padcev\u00ae in Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Pfizer Inc","highestDevelopmentStatusID":null,"companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Receives Positive CHMP Opinion for Zolbetuximab in Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces EC Approval of SKYRIZI for Moderate to Severe Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Risankizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas\u2019 STADA Receives EC Decision for Full Approval of Kinpeygo\u00ae in IgA Nephropathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces EC Approval of Sugemalimab as First-Line Treatment for NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP has adopted a negative opinion on lecanemab for the EU","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArctic AB \/ Eisai","highestDevelopmentStatusID":null,"companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Positive TRANSFORM Phase 2b Data in Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma Announces FDA Approval of ERZOFRI for Schizophrenia & Schizoaffective Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission approves Roche\u2019s Vabysmo for treatment of retinal vein occlusion (RVO)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Faricimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Clearside Biomedical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical\u2019s Partner Reports Positive Phase 3 Results for ARCATUS\u00ae in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arctic Vision","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arctic Vision \/ Clearside Biomedical","highestDevelopmentStatusID":null,"companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Reports Positive Results from Barzolvolimab Phase 2 Study in Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Barzolvolimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palisade Bio Completes Microbiome Study Confirming Bacterial Enzymes for PALI-2108","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PALI-2108","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventyx Biosciences Announces Results from Phase 2 Trial of VTX958 in Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VTX958","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ventyx Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ventyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ventyx Bio.."},{"orgOrder":0,"company":"Alumis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alumis Initiates ONWARD Phase 3 Program for ESK-001 in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"ESK-001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alumis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alumis \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alumis \/ N.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Launches ZORYVE\u00ae (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Roflumilast","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics\u2019 Phase 2 SHINE Trial Shows Improvement with CT1812 in Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Doses First Subject in Phase 1 Study of Sabirnetug for Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sabirnetug","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Acumen Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acumen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Acumen Pha.."},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eledon Provides Enrollment Update for Phase 2 Trial of Tegoprubart for Organ Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eledon Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eledon Pha.."},{"orgOrder":0,"company":"Attralus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attralus Receives EMA COMP Positive Opinions for AT-02 in ATTR and AL Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Attralus","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Attralus \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma\u2019s Relfydess\u2122 (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Galderma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition\u2019s Oral Therapy ZUNVEYL\u00ae Receives FDA Approval to Treat Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Doses First Patient in Phase 2 Trial of Azelaprag for Obesity with Tirzepatide","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Azelaprag","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE\u00ae Plus Venetoclax Improves Survival in 1st-line CLL in AMPLIFY Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Completes Enrollment in Phase 2a Study of BBT-877 for IPF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BBT-877","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOPE Therapeutics and NRx Align with FDA on Pediatric Study Plan for NRX-100","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Receives Positive IDMC Recommendation for Bersiporocin","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"DWN12088","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Completes Mid-Cycle Review for Elamipretide in Barth Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Elamipretide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Announces PDUFA Action Date Extension for Revumenib NDA in KMT2Ar Acute Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Revumenib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"COM503","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Compugen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":null,"companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ivonescimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Akeso","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces Topline Results from Pamrevlumab Pancreatic Cancer Studies and Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"FibroGen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Tectonic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"TX000045","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Tectonic Therapeutic","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tectonic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Tectonic T.."},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADvantage Therapeutics Announces Breakthrough Findings for AD04TM in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Aluminium Hydroxide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ADvantage Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ADvantage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ADvantage .."},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marius Pharmaceuticals Submits KYZATREX\u00ae for Approval to Health Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Marius Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Marius Pha.."},{"orgOrder":0,"company":"Georgiamune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Georgiamune Doses First Patient in Phase 1 Trial of GIM-531 for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"GIM-531","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Georgiamune","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Georgiamune \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Georgiamun.."},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yamo Pharmaceuticals Reports Positive Data from Phase 2 Study of L1-79 in Autism","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Racemetirosine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Yamo Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yamo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Yamo Pharm.."},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Reports Positive Data on New CBD Formulation with Enhanced Uptake","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"180 Life S.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Announces FDA Clearance of NGC-Cap Phase 2 Trial in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Gets Authorization for NTLA-3001 Phase 1\/2 for Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"NTLA-3001","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Axitinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"PepGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepGen Reports Positive Data from Low-Dose Cohort of PGN-EDO51 in DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"PGN-EDO51","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PepGen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PepGen \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"PepGen \/ N.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Suzetrigine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinFina Pharma Begins Phase 1 MAD Trial of CIN-110 for Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"CinRx Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"CinRx Phar.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Labs Data Shows ASP-001 Oral Spray Absorbs Faster than Viagra\u00ae Tablets","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Life Sciences Receives NOC from Health Canada for Proof-of-Concept Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Pediatric Indication Extension for Palforzia\u00ae Oral Immunotherapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Stallergenes Greer","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stallergenes Greer \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Stallergen.."},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"BC-NKA-20008","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ZYMEDI","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYMEDI \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ZYMEDI \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DARZALEX FASPRO\u00ae Quadruplet Regimen Approved for Newly Diagnosed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-term lecanemab data show increased patient benefit with maintained safety profile","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eisai","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ BioArctic AB","highestDevelopmentStatusID":null,"companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"Connext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"CNT201","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Connext","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Connext \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Connext \/ .."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin receives US FDA tentative marketing approval for generic Descovy tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Immuneering Corporation","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Announces First Patient Dosed in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Reports Phase 2 Data Showing Evorpacept Improves HER2-Positive Gastric Cancer Response","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Evorpacept","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Reports Positive Data from SIGNAL-AD Phase 1b\/2 Trial of Pepinemab in Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Pepinemab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theriva\u2122 Biologics Receives Rare Pediatric Drug Designation for VCN-01 in Retinoblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"VCN-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACHV's Cytisinicline Gets FDA Breakthrough Therapy in Nicotine Dependence","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Cytisine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Completes Five-Year Study of NUZYRA\u00ae Showing No Change in In Vitro Potency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharma Announces Phase 3 Study Completion of SPI-1005 for Meniere\u2019s Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA Acceptance of Mazdutide NDA for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mazdutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Biopharma's Herceptin Biosimilar Tuznue\u00ae Receives Positive CHMP Opinion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants Priority Review for Tab-cel\u00ae in EBV-Positive Lymphoproliferative Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tabelecleucel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts BLA for Mesoblast\u2019s Ryoncil\u00ae in Pediatric Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves expanded dosing for Grifols' XEMBIFY","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin, Human","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Grifols International","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Expansion of Open-Label Extension Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Simufilam","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMUNON Reports 11.1-Month Survival Increase in Ovarian Cancer Treated with IMNN-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Imunon","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces EC Expands IMCIVREE\u00ae Authorization for Young Children","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Cellectis\u2019 CLLS52 (alemtuzumab) For ALL Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Alemtuzumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cellectis","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevar Therapeutics Receives EMA Orphan Designation for Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Rivoceranib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib in PTCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Soquelitinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Receives FDA RMAT Designation for Ixo-vec in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ixoberogene Soroparvovec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spinogenix Announces Enrollment for Phase 2 Study of SPG302 in Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"SPG302","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Spinogenix","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spinogenix \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Spinogenix.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Phase 3 ACTIVATE-KidsT Results for Mitapivat in PK Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Mitapivat","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Receives FDA Accelerated Approval for TECELRA\u00ae in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Afamitresgene Autoleucel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Expands Jemperli Plus Chemo Approval to All Adult Endometrial Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GSK","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits NDA for Elinzanetant for Menopause Symptoms to U.S. FDA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Elinzanetant","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Celltrion\u2019s Steqeyma\u00ae Biosimilar to Stelara\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Celltrion","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in Deltacel-01 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"KB-GDT-01","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kiromic BioPharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiromic BioPharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Kiromic Bi.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Starts for Relapsed SCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ifinatamab Deruxtecan","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Annamycin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE\u00ae TRIAL OF RGX-202","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"RGX-202","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly\u2019s Tirzepatide Shows Benefit in Phase 3 Study for Heart Failure and Obesity","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk launches weight-loss drug Wegovy in Australia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Supports Arimoclomol as Effective for Niemann-Pick Disease Type C","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zevra Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zevra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zevra Ther.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Receives Orphan Drug Designation for AMX0035 in Wolfram Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan FDA approves Chugai\u2019s Alecensa for the treatment of early stage ALK-positive NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Alectinib Hydrochloride","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":null,"companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Nelarabine injection gets FDA final approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nelarabine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Data from Phase II of UV1 and Pembrolizumab in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"ANX007","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Annexon Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Annexon Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces FDA Clearance for Phase 3 Study of RZ358 in Tumor Hyperinsulinism","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Ersodetug","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Rezolute","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Reports Positive Results from U.S. NexoBrid\u00ae Expanded Access Protocol","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"MediWound","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces FDA Approval of Expanded Access Program for Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"OCU400","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ocugen","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concentric Analgesics Data Shows Durable Pain Relief and Earlier Opioid Cessation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Vocacapsaicin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Concentric Analgesics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Concentric Analgesics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Concentric.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Provides Update from Phase 2 HARMONIC\u2122 Trial for NSCLC in Never Smokers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Submits IND Application to Evaluate Sunobinop for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Sunobinop","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Imbrium Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Imbrium Th.."},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salubris Biotherapeutics Gets EMA Approval to Begin Phase 1 Trial of JK06 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"JK06","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Salubris Biotherapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Salubris Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Salubris B.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso\u2019s Ligufalimab with Azacitidine Enters US Phase 2 for Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Akeso","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces XPOVIO\u00ae (selinexor) Approved for Commercialization in Malaysia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Selinexor","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Antengene","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Antengene .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces Updated Strategy for ROCTAVIAN\u00ae to Focus on U.S., Germany and Italy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Meta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"META Receives Rare Pediatric Disease Designation for META-001-PH","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"META-001-PH","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Meta Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Meta Pharm.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Provides Update on BLA Filing and Future Plans for Iomab-B in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finerenone Meets Endpoint in Phase III FINEARTS-HF Study for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Finerenone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Gets EMA Orphan Drug Designation for SLS009 in Peripheral T-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Reports Positive Phase 2 Data for Tacrolimus Powder in Lung Transplant Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Submits New Biomarker and Clinical Efficacy Data for CNM-Au8\u00ae in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Completes Enrollment in COMPANION-002 Study of CTX-009 in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"CTX-009","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Positive Interim Data from Phase 3 EQUATOR Study of Itolizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Equillium","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences Gets FDA Study May Proceed Letter for Silmitasertib in Young Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","amount":"$63.5 million","upfrontCash":"$6.5 million","newsHeadline":"Cosmo and 3SBio Announce Signing of License Agreement for Winlevi\u00ae in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Cosmo Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":null,"companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bloomecto\u2122 Ectoine -- Nasal Spray New Solution","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ectoine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lumenis and Bloomage Biotech jointly released a new product - M22 medical wound dressing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":null,"companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hybloom Zinc Hyaluronate and Hyanutra-RH Hair Nourishing Shield won Fountain Awards","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Zinc Hyaluronate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCC77: Bloomage Bloomsurfact EncapCare RP Ensures 99% Dispersion of Anti-aging Ingredient","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Bloomage B.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma Gained EU-Approval of Testosterone Enantate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Enanthate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma gained EU-Approval for Advanced Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Eribulin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma Announces Approval of Testosterone Undecanoate in the EU","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma gains EU Marketing Authorization for Trabectedin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma receives EU marketing authorization for Azacitidine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma gains EU marketing authorization for value-added Pemetrexed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma gains EU marketing authorization for value-added Cabazitaxel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestl\u00e9 Health Science","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"$250.0 million","newsHeadline":"Seres Announces Signing of VOWST\u2122 Asset Purchase Agreement with Nestl\u00e9 Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Seres Therapeutics","amount2":0.53000000000000003,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seres Therapeutics \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":null,"companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Gilead","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead shells out $320M to J&J to buy out rare liver disease drug royalties","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Seladelpar Lysine","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Johnson & Johnson","amount2":0.32000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Gilead","highestDevelopmentStatusID":null,"companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Avidity Biosciences","amount2":0.25,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":null,"companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$3,200.0 million","upfrontCash":"$3,200.0 million","newsHeadline":"Lilly Completes Acquisition of Morphic to Improve Outcomes for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Acquisition","leadProduct":"MORF-057","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Morphic Therapeutic","amount2":3.2000000000000002,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Morphic Therapeutic \/ Eli Lilly","highestDevelopmentStatusID":null,"companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Multitude Therapeutics","sponsor":"Adcendo","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adcendo & Multitude Announce Agreement on First-in-class ADC Targeting Tissue Factor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"ADCE-T02","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Multitude Therapeutics","amount2":1,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Multitude Therapeutics \/ Adcendo","highestDevelopmentStatusID":null,"companyTruncated":"Multitude .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces Pricing of $225 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kymera Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":null,"companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$345.1 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Avidity Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":null,"companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$258.7 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Kymera Therapeutics","amount2":0.26000000000000001,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":null,"companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"GondolaBio","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio launches another offshoot with $300M and early genetic disease programs","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Demerger","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"GondolaBio","amount2":0.29999999999999999,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GondolaBio \/ BridgeBio Pharma","highestDevelopmentStatusID":null,"companyTruncated":"GondolaBio.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"CBC Group","pharmaFlowCategory":"D","amount":"$680.0 million","upfrontCash":"Undisclosed","newsHeadline":"Belgium's UCB to sell China neurology, allergy business for $680 mln","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Divestment","leadProduct":"Levetiracetam","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"UCB Pharma S.A","amount2":0.68000000000000005,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ CBC Group","highestDevelopmentStatusID":null,"companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Lindy Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$954.0 million","upfrontCash":"$20.0 million","newsHeadline":"Lindy Bio Enters Collaboration Agreement with Novartis for Drug Delivery Innovation","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Lindy Biosciences","amount2":0.94999999999999996,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":null,"companyTruncated":"Lindy Bios.."}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Testosterone Enanthate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.

                          Product Name : Testosterone Enantate Ever Pharma

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 19, 2024

                          Lead Product(s) : Testosterone Enanthate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Ever Pharma CB

                          02

                          Lead Product(s) : Eribulin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.

                          Product Name : Eribulin EVER Pharma

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 16, 2024

                          Lead Product(s) : Eribulin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Ever Pharma CB

                          03

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Testosterone undecanoate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in males for conditions associated with a deficiency of endogenous testosterone.

                          Product Name : Testosterone Undecanoate EVER Pharma

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 13, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Ever Pharma CB

                          04

                          Lead Product(s) : Trabectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.

                          Product Name : Trabectedin EVER Pharma

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 22, 2024

                          Lead Product(s) : Trabectedin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Ever Pharma CB

                          05

                          Lead Product(s) : Sodium Cromoglicate,Bronchodil

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Details : Lupin has completed the acquisition of two well-known brands, Aarane (sodium cromoglicate) in Germany and Nalcrom (cromoglicic acid) in Canada and the Netherlands, from Sanofi.

                          Product Name : Aarane

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : Sodium Cromoglicate,Bronchodil

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Sanofi Company Banner

                          06

                          Lead Product(s) : ABBV-383

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : ABBV-383 is an investigational distinctive BCMA x CD3 bispecific antibody T-cell engager being investigated for relapsed or refractory multiple myeloma.

                          Product Name : ABBV-383

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 05, 2024

                          Lead Product(s) : ABBV-383

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Abbvie Company Banner

                          07

                          Lead Product(s) : Isatuximab,Bortezomib,Lenalidomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Sarclisa (isatuximab) will be the first anti-CD38 therapy in combination with Bortezomib and Dexamethasone soc treatment for patients with newly diagnosed transplant-ineligible multiple myeloma.

                          Product Name : Sarclisa

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 27, 2024

                          Lead Product(s) : Isatuximab,Bortezomib,Lenalidomide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Sanofi Company Banner

                          08

                          Lead Product(s) : Upadacitinib,Corticosteroid

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Rinvoq (upadacitinib) is a janus kinase inhibitor, small molecule drug candidate which is being evaluated for the treatment of giant cell arteritis.

                          Product Name : Rinvoq

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 18, 2024

                          Lead Product(s) : Upadacitinib,Corticosteroid

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Abbvie Company Banner

                          09

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Fluoxetine hydrochloride, generic of Prozac, is an antidepressant of the selective serotonin reuptake inhibitor class. It is used for the treatment of major depressive disorder, obsessive–compulsive dis...

                          Product Name : Prozac-Generic

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Strides Pharma Science

                          10

                          Lead Product(s) : Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Versavo (bevacizumab) is a VEGF A inhibitor indicated for the treatment of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metasta...

                          Product Name : Versavo

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 19, 2024

                          Lead Product(s) : Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner